19-norandrostenedione	DDI-DrugBank.d436.s0	NO_SECTION	NO_SETID	14
No drug, nutritional supplement, food or herb interactions have yet been reported.
1	0	1	O	No
2	3	6	O	drug
3	7	7	O	,
4	9	19	O	nutritional
5	21	30	O	supplement
6	31	31	O	,
7	33	36	O	food
8	38	39	O	or
9	41	44	O	herb
10	46	57	O	interactions
11	59	62	O	have
12	64	66	O	yet
13	68	71	O	been
14	73	80	O	reported
NULL

Abarelix	DDI-DrugBank.d519.s0	NO_SECTION	NO_SETID	11
No formal drug/drug interaction studies with Plenaxis were performed.
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	14	14	O	/
5	15	18	O	drug
6	20	30	O	interaction
7	32	38	O	studies
8	40	43	O	with
9	45	52	O	XXXXXXXX
10	54	57	O	were
11	59	67	O	performed
NULL

Abarelix	DDI-DrugBank.d519.s1	NO_SECTION	NO_SETID	14
Cytochrome P-450 is not known to be involved in the metabolism of Plenaxis.
1	0	9	O	Cytochrome
2	11	11	O	P
3	13	15	O	450
4	17	18	O	is
5	20	22	O	not
6	24	28	O	known
7	30	31	O	to
8	33	34	O	be
9	36	43	O	involved
10	45	46	O	in
11	48	50	O	the
12	52	61	O	metabolism
13	63	64	O	of
14	66	73	O	XXXXXXXX
NULL

Abarelix	DDI-DrugBank.d519.s2	NO_SECTION	NO_SETID	10
Plenaxis is highly bound to plasma proteins (96 to 99%).
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	17	O	highly
4	19	23	O	bound
5	25	26	O	to
6	28	33	O	plasma
7	35	42	O	proteins
8	45	46	O	96
9	48	49	O	to
10	51	53	O	99%
NULL

Abarelix	DDI-DrugBank.d519.s3	NO_SECTION	NO_SETID	26
Laboratory Tests Response to Plenaxis should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter.
1	0	9	O	Laboratory
2	11	15	O	Tests
3	17	24	O	Response
4	26	27	O	to
5	29	36	O	XXXXXXXX
6	38	43	O	should
7	45	46	O	be
8	48	56	O	monitored
9	58	59	O	by
10	61	69	O	measuring
11	71	75	O	serum
12	77	81	O	total
13	83	94	U-UNK	testosterone
14	96	109	O	concentrations
15	111	114	O	just
16	116	120	O	prior
17	122	123	O	to
18	125	138	O	administration
19	140	141	O	on
20	143	145	O	Day
21	147	148	O	29
22	150	152	O	and
23	154	158	O	every
24	160	160	O	8
25	162	166	O	weeks
26	168	177	O	thereafter
NULL

Abarelix	DDI-DrugBank.d519.s4	NO_SECTION	NO_SETID	15
Serum transaminase levels should be obtained before starting treatment with Plenaxis and periodically during treatment.
1	0	4	O	Serum
2	6	17	O	transaminase
3	19	24	O	levels
4	26	31	O	should
5	33	34	O	be
6	36	43	O	obtained
7	45	50	O	before
8	52	59	O	starting
9	61	69	O	treatment
10	71	74	O	with
11	76	83	O	XXXXXXXX
12	85	87	O	and
13	89	100	O	periodically
14	102	107	O	during
15	109	117	O	treatment
NULL

Abarelix	DDI-DrugBank.d519.s5	NO_SECTION	NO_SETID	10
Periodic measurement of serum PSA levels may also be considered.
1	0	7	O	Periodic
2	9	19	O	measurement
3	21	22	O	of
4	24	28	O	serum
5	30	32	O	PSA
6	34	39	O	levels
7	41	43	O	may
8	45	48	O	also
9	50	51	O	be
10	53	62	O	considered
NULL

Abatacept	DDI-DrugBank.d297.s0	NO_SECTION	NO_SETID	10
Formal drug interaction studies have not been conducted with ORENCIA.
1	0	5	O	Formal
2	7	10	O	drug
3	12	22	O	interaction
4	24	30	O	studies
5	32	35	O	have
6	37	39	O	not
7	41	44	O	been
8	46	54	O	conducted
9	56	59	O	with
10	61	67	O	XXXXXXXX
NULL

Abatacept	DDI-DrugBank.d297.s1	NO_SECTION	NO_SETID	20
Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and TNF blocking agents did not influence abatacept clearance.
1	0	9	O	Population
2	11	25	O	pharmacokinetic
3	27	34	O	analyses
4	36	43	O	revealed
5	45	48	O	that
6	50	52	U-UNK	MTX
7	53	53	O	,
8	55	60	U-UNK	NSAIDs
9	61	61	O	,
10	63	77	U-UNK	corticosteroids
11	78	78	O	,
12	80	82	O	and
13	84	86	B-UNK	TNF
14	88	95	I-UNK	blocking
15	97	102	L-UNK	agents
16	104	106	O	did
17	108	110	O	not
18	112	120	O	influence
19	122	130	O	XXXXXXXX
20	132	140	O	clearance
NULL

Abatacept	DDI-DrugBank.d297.s2	NO_SECTION	NO_SETID	44
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.
1	0	2	O	The
2	4	11	O	majority
3	13	14	O	of
4	16	23	O	patients
5	25	26	O	in
6	28	29	O	RA
7	31	38	O	clinical
8	40	46	O	studies
9	48	55	O	received
10	57	59	O	one
11	61	62	O	or
12	64	67	O	more
13	69	70	O	of
14	72	74	O	the
15	76	84	O	following
16	86	96	O	concomitant
17	98	108	O	medications
18	110	113	O	with
19	115	121	O	XXXXXXXX
20	122	122	O	:
21	124	126	U-UNK	MTX
22	127	127	O	,
23	129	134	U-UNK	NSAIDs
24	135	135	O	,
25	137	151	U-UNK	corticosteroids
26	152	152	O	,
27	154	156	B-UNK	TNF
28	158	165	I-UNK	blocking
29	167	172	L-UNK	agents
30	173	173	O	,
31	175	186	U-UNK	azathioprine
32	187	187	O	,
33	189	199	U-UNK	chloroquine
34	200	200	O	,
35	202	205	U-UNK	gold
36	206	206	O	,
37	208	225	U-UNK	hydroxychloroquine
38	226	226	O	,
39	228	238	U-UNK	leflunomide
40	239	239	O	,
41	241	253	U-UNK	sulfasalazine
42	254	254	O	,
43	256	258	O	and
44	260	267	U-UNK	anakinra
NULL

Abatacept	DDI-DrugBank.d297.s3	NO_SECTION	NO_SETID	30
Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	29	O	a
5	31	33	B-DYN	TNF
6	35	44	L-DYN	antagonist
7	46	49	O	with
8	51	57	O	XXXXXXXX
9	59	61	O	has
10	63	66	O	been
11	68	77	O	associated
12	79	82	O	with
13	84	85	O	an
14	87	95	O	increased
15	97	100	O	risk
16	102	103	O	of
17	105	111	O	serious
18	113	122	O	infections
19	124	126	O	and
20	128	129	O	no
21	131	141	O	significant
22	143	152	O	additional
23	154	161	O	efficacy
24	163	166	O	over
25	168	170	O	use
26	172	173	O	of
27	175	177	O	the
28	179	181	B-UNK	TNF
29	183	193	L-UNK	antagonists
30	195	199	O	alone
NULL

Abatacept	DDI-DrugBank.d297.s4	NO_SECTION	NO_SETID	10
Concurrent therapy with ORENCIA and TNF antagonists is not recommended.
1	0	9	O	Concurrent
2	11	17	O	therapy
3	19	22	O	with
4	24	30	O	XXXXXXXX
5	32	34	O	and
6	36	38	B-DYN	TNF
7	40	50	L-DYN	antagonists
8	52	53	O	is
9	55	57	O	not
10	59	69	O	recommended
NULL

Abatacept	DDI-DrugBank.d297.s5	NO_SECTION	NO_SETID	24
There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.
1	0	4	O	There
2	6	7	O	is
3	9	20	O	insufficient
4	22	31	O	experience
5	33	34	O	to
6	36	41	O	assess
7	43	45	O	the
8	47	52	O	safety
9	54	56	O	and
10	58	65	O	efficacy
11	67	68	O	of
12	70	76	O	XXXXXXXX
13	78	89	O	administered
14	91	102	O	concurrently
15	104	107	O	with
16	109	116	U-DYN	anakinra
17	117	117	O	,
18	119	121	O	and
19	123	131	O	therefore
20	133	136	O	such
21	138	140	O	use
22	142	143	O	is
23	145	147	O	not
24	149	159	O	recommended
NULL

Abciximab	DDI-DrugBank.d532.s0	NO_SECTION	NO_SETID	10
Formal drug interaction studies with Abciximab have not been conducted.
1	0	5	O	Formal
2	7	10	O	drug
3	12	22	O	interaction
4	24	30	O	studies
5	32	35	O	with
6	37	45	O	XXXXXXXX
7	47	50	O	have
8	52	54	O	not
9	56	59	O	been
10	61	69	O	conducted
NULL

Abciximab	DDI-DrugBank.d532.s1	NO_SECTION	NO_SETID	28
Abciximab has been administered to patients with ischemic heart disease treated concomitantly with a broad range of medications used in the treatment of angina myocardial infarction and hypertension.
1	0	8	O	XXXXXXXX
2	10	12	O	has
3	14	17	O	been
4	19	30	O	administered
5	32	33	O	to
6	35	42	O	patients
7	44	47	O	with
8	49	56	O	ischemic
9	58	62	O	heart
10	64	70	O	disease
11	72	78	O	treated
12	80	92	O	concomitantly
13	94	97	O	with
14	99	99	O	a
15	101	105	O	broad
16	107	111	O	range
17	113	114	O	of
18	116	126	O	medications
19	128	131	O	used
20	133	134	O	in
21	136	138	O	the
22	140	148	O	treatment
23	150	151	O	of
24	153	158	O	angina
25	160	169	O	myocardial
26	171	180	O	infarction
27	182	184	O	and
28	186	197	O	hypertension
NULL

Abciximab	DDI-DrugBank.d532.s2	NO_SECTION	NO_SETID	31
These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.
1	0	4	O	These
2	6	16	O	medications
3	18	21	O	have
4	23	30	O	included
5	32	38	U-UNK	heparin
6	39	39	O	,
7	41	48	U-UNK	warfarin
8	49	49	O	,
9	51	54	B-UNK	beta
10	56	65	I-UNK	adrenergic
11	67	74	I-UNK	receptor
12	76	83	L-UNK	blockers
13	84	84	O	,
14	86	92	B-UNK	calcium
15	94	100	I-UNK	channel
16	102	112	L-UNK	antagonists
17	113	113	O	,
18	115	125	B-UNK	angiotensin
19	127	136	I-UNK	converting
20	138	143	I-UNK	enzyme
21	145	154	L-UNK	inhibitors
22	155	155	O	,
23	157	167	O	intravenous
24	169	171	O	and
25	173	176	O	oral
26	178	185	U-UNK	nitrates
27	186	186	O	,
28	188	198	U-UNK	ticlopidine
29	199	199	O	,
30	201	203	O	and
31	205	211	O	XXXXXXXX
NULL

Abciximab	DDI-DrugBank.d532.s3	NO_SECTION	NO_SETID	18
Heparin, other anticoagulants, thrombolytics, and anti platelet agents are associated with an increase in bleeding.
1	0	6	U-UNK	Heparin
2	7	7	O	,
3	9	13	O	other
4	15	28	U-UNK	anticoagulants
5	29	29	O	,
6	31	43	U-UNK	thrombolytics
7	44	44	O	,
8	46	48	O	and
9	50	53	B-UNK	anti
10	55	62	I-UNK	platelet
11	64	69	L-UNK	agents
12	71	73	O	are
13	75	84	O	associated
14	86	89	O	with
15	91	92	O	an
16	94	101	O	increase
17	103	104	O	in
18	106	113	O	bleeding
NULL

Abciximab	DDI-DrugBank.d532.s4	NO_SECTION	NO_SETID	19
Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
1	0	7	O	Patients
2	9	12	O	with
3	14	17	O	HACA
4	19	24	O	titers
5	26	28	O	may
6	30	33	O	have
7	35	42	O	allergic
8	44	45	O	or
9	47	62	O	hypersensitivity
10	64	72	O	reactions
11	74	77	O	when
12	79	85	O	treated
13	87	90	O	with
14	92	96	O	other
15	98	107	B-UNK	diagnostic
16	109	110	I-UNK	or
17	112	122	I-UNK	therapeutic
18	124	133	I-UNK	monoclonal
19	135	144	L-UNK	antibodies
NULL

Acamprosate	DDI-DrugBank.d0.s0	NO_SECTION	NO_SETID	17
The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate.
1	0	2	O	The
2	4	14	O	concomitant
3	16	21	O	intake
4	23	24	O	of
5	26	32	U-UNK	alcohol
6	34	36	O	and
7	38	48	O	XXXXXXXX
8	50	53	O	does
9	55	57	O	not
10	59	64	O	affect
11	66	68	O	the
12	70	85	O	pharmacokinetics
13	87	88	O	of
14	90	95	O	either
15	97	103	U-UNK	alcohol
16	105	106	O	or
17	108	118	O	XXXXXXXX
NULL

Acamprosate	DDI-DrugBank.d0.s1	NO_SECTION	NO_SETID	16
Pharmacokinetic studies indicate that administration of disulfiram or diazepam does not affect the pharmacokinetics of acamprosate.
1	0	14	O	Pharmacokinetic
2	16	22	O	studies
3	24	31	O	indicate
4	33	36	O	that
5	38	51	O	administration
6	53	54	O	of
7	56	65	U-UNK	disulfiram
8	67	68	O	or
9	70	77	U-UNK	diazepam
10	79	82	O	does
11	84	86	O	not
12	88	93	O	affect
13	95	97	O	the
14	99	114	O	pharmacokinetics
15	116	117	O	of
16	119	129	O	XXXXXXXX
NULL

Acamprosate	DDI-DrugBank.d0.s2	NO_SECTION	NO_SETID	21
Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	30	U-KIN	naltrexone
5	32	35	O	with
6	37	47	O	XXXXXXXX
7	49	56	O	produced
8	58	58	O	a
9	60	62	O	25%
10	64	71	O	increase
11	73	74	O	in
12	76	78	O	AUC
13	80	82	O	and
14	84	84	O	a
15	86	88	O	33%
16	90	97	O	increase
17	99	100	O	in
18	102	104	O	the
19	106	109	O	Cmax
20	111	112	O	of
21	114	124	O	XXXXXXXX
NULL

Acamprosate	DDI-DrugBank.d0.s3	NO_SECTION	NO_SETID	9
No adjustment of dosage is recommended in such patients.
1	0	1	O	No
2	3	12	O	adjustment
3	14	15	O	of
4	17	22	O	dosage
5	24	25	O	is
6	27	37	O	recommended
7	39	40	O	in
8	42	45	O	such
9	47	54	O	patients
NULL

Acamprosate	DDI-DrugBank.d0.s4	NO_SECTION	NO_SETID	18
The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected following co-administration with Acamprosate.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	33	U-UNK	naltrexone
5	35	37	O	and
6	39	41	O	its
7	43	47	O	major
8	49	58	O	metabolite
9	60	60	B-UNK	6
10	62	65	I-UNK	beta
11	67	75	L-UNK	naltrexol
12	77	80	O	were
13	82	91	O	unaffected
14	93	101	O	following
15	103	104	O	co
16	106	119	O	administration
17	121	124	O	with
18	126	136	O	XXXXXXXX
NULL

Acamprosate	DDI-DrugBank.d0.s5	NO_SECTION	NO_SETID	42
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.
1	0	4	O	Other
2	6	16	O	concomitant
3	18	26	O	therapies
4	27	27	O	:
5	29	30	O	In
6	32	39	O	clinical
7	41	46	O	trials
8	47	47	O	,
9	49	51	O	the
10	53	58	O	safety
11	60	66	O	profile
12	68	69	O	in
13	71	78	O	subjects
14	80	86	O	treated
15	88	91	O	with
16	93	103	O	XXXXXXXX
17	105	117	O	concomitantly
18	119	122	O	with
19	124	134	U-UNK	anxiolytics
20	135	135	O	,
21	137	145	U-UNK	hypnotics
22	147	149	O	and
23	151	159	U-UNK	sedatives
24	162	170	O	including
25	172	186	U-UNK	benzodiazepines
26	188	188	O	,
27	190	191	O	or
28	193	195	B-UNK	non
29	197	202	I-UNK	opioid
30	204	213	L-UNK	analgesics
31	215	217	O	was
32	219	225	O	similar
33	227	228	O	to
34	230	233	O	that
35	235	236	O	of
36	238	245	O	subjects
37	247	252	O	taking
38	254	260	O	placebo
39	262	265	O	with
40	267	271	O	these
41	273	283	O	concomitant
42	285	295	O	medications
NULL

Acamprosate	DDI-DrugBank.d0.s6	NO_SECTION	NO_SETID	23
Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.
1	0	7	O	Patients
2	9	14	O	taking
3	16	26	O	XXXXXXXX
4	28	40	O	concomitantly
5	42	45	O	with
6	47	61	U-DYN	antidepressants
7	63	66	O	more
8	68	75	O	commonly
9	77	84	O	reported
10	86	89	O	both
11	91	96	O	weight
12	98	101	O	gain
13	103	105	O	and
14	107	112	O	weight
15	114	117	O	loss
16	118	118	O	,
17	120	127	O	compared
18	129	132	O	with
19	134	141	O	patients
20	143	148	O	taking
21	150	155	O	either
22	157	166	O	medication
23	168	172	O	alone
NULL

Acarbose	DDI-DrugBank.d536.s0	NO_SECTION	NO_SETID	15
Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control.
1	0	6	O	Certain
2	8	12	O	drugs
3	14	17	O	tend
4	19	20	O	to
5	22	28	O	produce
6	30	42	O	hyperglycemia
7	44	46	O	and
8	48	50	O	may
9	52	55	O	lead
10	57	58	O	to
11	60	63	O	loss
12	65	66	O	of
13	68	72	O	blood
14	74	80	O	glucose
15	82	88	O	control
NULL

Acarbose	DDI-DrugBank.d536.s1	NO_SECTION	NO_SETID	35
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
1	0	4	O	These
2	6	10	O	drugs
3	12	18	O	include
4	20	22	O	the
5	24	32	U-UNK	thiazides
6	34	36	O	and
7	38	42	O	other
8	44	52	U-UNK	diuretics
9	53	53	O	,
10	55	69	U-UNK	corticosteroids
11	70	70	O	,
12	72	85	U-UNK	phenothiazines
13	86	86	O	,
14	88	94	B-UNK	thyroid
15	96	103	L-UNK	products
16	104	104	O	,
17	106	114	U-UNK	estrogens
18	115	115	O	,
19	117	120	O	oral
20	122	135	U-UNK	contraceptives
21	136	136	O	,
22	138	146	U-UNK	phenytoin
23	147	147	O	,
24	149	157	B-UNK	nicotinic
25	159	162	L-UNK	acid
26	163	163	O	,
27	165	180	U-UNK	sympathomimetics
28	181	181	O	,
29	183	189	B-UNK	calcium
30	191	197	I-UNK	channel
31	199	206	I-UNK	blocking
32	208	212	L-UNK	drugs
33	213	213	O	,
34	215	217	O	and
35	219	227	U-UNK	isoniazid
NULL

Acarbose	DDI-DrugBank.d536.s2	NO_SECTION	NO_SETID	23
When such drugs are administered to a patient receiving Acarbose, the patient should be closely observed for loss of blood glucose control.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	31	O	administered
6	33	34	O	to
7	36	36	O	a
8	38	44	O	patient
9	46	54	O	receiving
10	56	63	O	XXXXXXXX
11	64	64	O	,
12	66	68	O	the
13	70	76	O	patient
14	78	83	O	should
15	85	86	O	be
16	88	94	O	closely
17	96	103	O	observed
18	105	107	O	for
19	109	112	O	loss
20	114	115	O	of
21	117	121	O	blood
22	123	129	O	glucose
23	131	137	O	control
NULL

Acarbose	DDI-DrugBank.d536.s3	NO_SECTION	NO_SETID	26
When such drugs are withdrawn from patients receiving Acarbose in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	28	O	withdrawn
6	30	33	O	from
7	35	42	O	patients
8	44	52	O	receiving
9	54	61	O	XXXXXXXX
10	63	64	O	in
11	66	76	O	combination
12	78	81	O	with
13	83	95	U-UNK	sulfonylureas
14	97	98	O	or
15	100	106	U-UNK	insulin
16	107	107	O	,
17	109	116	O	patients
18	118	123	O	should
19	125	126	O	be
20	128	135	O	observed
21	137	143	O	closely
22	145	147	O	for
23	149	151	O	any
24	153	160	O	evidence
25	162	163	O	of
26	165	176	O	hypoglycemia
NULL

Acarbose	DDI-DrugBank.d536.s4	NO_SECTION	NO_SETID	32
Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.
1	0	9	B-KIN	Intestinal
2	11	20	L-KIN	adsorbents
3	23	23	O	e
4	26	26	O	g
5	28	28	O	,
6	30	37	U-KIN	charcoal
7	40	42	O	and
8	44	52	B-UNK	digestive
9	54	59	I-UNK	enzyme
10	61	72	L-UNK	preparations
11	74	83	O	containing
12	85	96	O	carbohydrate
13	98	106	O	splitting
14	108	114	O	enzymes
15	117	117	O	e
16	120	120	O	g
17	122	122	O	,
18	124	130	U-KIN	amylase
19	131	131	O	,
20	133	142	U-KIN	pancreatin
21	145	147	O	may
22	149	154	O	reduce
23	156	158	O	the
24	160	165	O	effect
25	167	168	O	of
26	170	177	O	XXXXXXXX
27	179	181	O	and
28	183	188	O	should
29	190	192	O	not
30	194	195	O	be
31	197	201	O	taken
32	203	215	O	concomitantly
NULL

Acarbose	DDI-DrugBank.d536.s5	NO_SECTION	NO_SETID	21
Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	16	O	been
4	18	22	O	shown
5	24	25	O	to
6	27	32	O	change
7	34	36	O	the
8	38	52	O	bioavailabillty
9	54	60	U-KIN	digoxin
10	62	65	O	when
11	67	70	O	they
12	72	74	O	are
13	76	77	O	co
14	79	90	O	administered
15	91	91	O	,
16	93	97	O	which
17	99	101	O	may
18	103	109	O	require
19	111	117	U-UNK	digoxin
20	119	122	O	dose
21	124	133	O	adjustment
NULL

Acarbose	DDI-DrugBank.d536.s6	NO_SECTION	NO_SETID	26
Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or ranitidine.
1	0	6	O	Studies
2	8	9	O	in
3	11	17	O	healthy
4	19	28	O	volunteers
5	30	33	O	have
6	35	39	O	shown
7	41	44	O	that
8	46	53	O	XXXXXXXX
9	55	57	O	has
10	59	60	O	no
11	62	67	O	effect
12	69	70	O	on
13	72	77	O	either
14	79	81	O	the
15	83	98	O	pharmacokinetics
16	100	101	O	or
17	103	118	O	pharmacodynamics
18	120	121	O	of
19	123	129	U-UNK	digoxin
20	130	130	O	,
21	132	141	U-UNK	nifedipine
22	142	142	O	,
23	144	154	U-UNK	propranolol
24	155	155	O	,
25	157	158	O	or
26	160	169	U-UNK	ranitidine
NULL

Acarbose	DDI-DrugBank.d536.s7	NO_SECTION	NO_SETID	16
Acarbose did not interfere with the absorption or disposition of the sulfonylurea glyburide in diabetic patients.
1	0	7	O	XXXXXXXX
2	9	11	O	did
3	13	15	O	not
4	17	25	O	interfere
5	27	30	O	with
6	32	34	O	the
7	36	45	O	absorption
8	47	48	O	or
9	50	60	O	disposition
10	62	63	O	of
11	65	67	O	the
12	69	80	U-UNK	sulfonylurea
13	82	90	U-UNK	glyburide
14	92	93	O	in
15	95	102	O	diabetic
16	104	111	O	patients
NULL

Acarbose	DDI-DrugBank.d536.s8	NO_SECTION	NO_SETID	52
Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
1	0	7	O	XXXXXXXX
2	9	11	O	may
3	13	18	O	affect
4	20	26	U-UNK	digoxin
5	28	42	O	bioavailabillty
6	44	46	O	and
7	48	50	O	may
8	52	58	O	require
9	60	63	O	dose
10	65	74	O	adjustment
11	76	77	O	of
12	79	85	U-UNK	digoxin
13	87	88	O	by
14	90	92	O	16%
15	95	97	O	90%
16	99	108	O	confidence
17	110	117	O	interval
18	118	118	O	:
19	120	120	O	8
20	122	124	O	23%
21	126	126	O	,
22	128	135	O	decrease
23	137	140	O	mean
24	142	142	O	C
25	144	146	O	max
26	148	154	U-UNK	digoxin
27	156	157	O	by
28	159	161	O	26%
29	164	166	O	90%
30	168	177	O	confidence
31	179	186	O	interval
32	187	187	O	:
33	189	190	O	16
34	192	194	O	34%
35	197	199	O	and
36	201	208	O	decrease
37	210	213	O	mean
38	215	220	O	trough
39	222	235	O	concentrations
40	237	238	O	of
41	240	246	U-UNK	digoxin
42	248	249	O	by
43	251	252	O	9%
44	255	257	O	90%
45	259	268	O	confidence
46	270	274	O	limit
47	275	275	O	:
48	277	279	O	19%
49	281	288	O	decrease
50	290	291	O	to
51	293	294	O	2%
52	296	303	O	increase
NULL

Acarbose	DDI-DrugBank.d536.s9	NO_SECTION	NO_SETID	25
The amount of metformin absorbed while taking Acarbose was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values.
1	0	2	O	The
2	4	9	O	amount
3	11	12	O	of
4	14	22	U-UNK	metformin
5	24	31	O	absorbed
6	33	37	O	while
7	39	44	O	taking
8	46	53	O	XXXXXXXX
9	55	57	O	was
10	59	71	O	bioequivalent
11	73	74	O	to
12	76	78	O	the
13	80	85	O	amount
14	87	94	O	absorbed
15	96	99	O	when
16	101	106	O	taking
17	108	114	O	placebo
18	115	115	O	,
19	117	118	O	as
20	120	128	O	indicated
21	130	131	O	by
22	133	135	O	the
23	137	142	O	plasma
24	144	146	O	AUC
25	148	153	O	values
NULL

Acarbose	DDI-DrugBank.d536.s10	NO_SECTION	NO_SETID	26
However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	16	O	peak
5	18	23	O	plasma
6	25	29	O	level
7	31	32	O	of
8	34	42	U-KIN	metformin
9	44	46	O	was
10	48	54	O	reduced
11	56	57	O	by
12	59	71	O	approximately
13	73	75	O	20%
14	77	80	O	when
15	82	87	O	taking
16	89	96	O	XXXXXXXX
17	98	100	O	due
18	102	103	O	to
19	105	105	O	a
20	107	112	O	slight
21	114	118	O	delay
22	120	121	O	in
23	123	125	O	the
24	127	136	O	absorption
25	138	139	O	of
26	141	149	U-KIN	metformin
NULL

Acarbose	DDI-DrugBank.d536.s11	NO_SECTION	NO_SETID	12
There is little if any clinically significant interaction between Acarbose and metformin.
1	0	4	O	There
2	6	7	O	is
3	9	14	O	little
4	16	17	O	if
5	19	21	O	any
6	23	32	O	clinically
7	34	44	O	significant
8	46	56	O	interaction
9	58	64	O	between
10	66	73	O	XXXXXXXX
11	75	77	O	and
12	79	87	U-UNK	metformin
NULL

Acebutolol	DDI-DrugBank.d388.s0	NO_SECTION	NO_SETID	19
Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.
1	0	12	B-UNK	Catecholamine
2	14	22	I-UNK	depleting
3	24	28	L-UNK	drugs
4	29	29	O	,
5	31	34	O	such
6	36	37	O	as
7	39	47	U-UNK	reserpine
8	48	48	O	,
9	50	52	O	may
10	54	57	O	have
11	59	60	O	an
12	62	69	O	additive
13	71	76	O	effect
14	78	81	O	when
15	83	87	O	given
16	89	92	O	with
17	94	97	B-UNK	beta
18	99	106	I-UNK	blocking
19	108	113	L-UNK	agents
NULL

Acebutolol	DDI-DrugBank.d388.s1	NO_SECTION	NO_SETID	40
Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.
1	0	7	O	Patients
2	9	15	O	treated
3	17	20	O	with
4	22	31	O	XXXXXXXX
5	33	36	O	plus
6	38	50	B-DYN	catecholamine
7	52	60	L-DYN	depletors
8	62	67	O	should
9	68	68	O	,
10	70	78	O	therefore
11	79	79	O	,
12	81	82	O	be
13	84	91	O	observed
14	93	99	O	closely
15	101	103	O	for
16	105	112	O	evidence
17	114	115	O	of
18	117	122	O	marked
19	124	134	O	bradycardia
20	136	137	O	or
21	139	149	O	hypotension
22	151	155	O	which
23	157	159	O	may
24	161	167	O	present
25	169	170	O	as
26	172	178	O	vertigo
27	179	179	O	,
28	181	187	O	syncope
29	188	188	O	/
30	189	198	O	presyncope
31	199	199	O	,
32	201	202	O	or
33	204	214	O	orthostatic
34	216	222	O	changes
35	224	225	O	in
36	227	231	O	blood
37	233	240	O	pressure
38	242	248	O	without
39	250	261	O	compensatory
40	263	273	O	tachycardia
NULL

Acebutolol	DDI-DrugBank.d388.s2	NO_SECTION	NO_SETID	30
Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.
1	0	10	O	Exaggerated
2	12	23	O	hypertensive
3	25	33	O	responses
4	35	38	O	have
5	40	43	O	been
6	45	52	O	reported
7	54	57	O	from
8	59	61	O	the
9	63	70	O	combined
10	72	74	O	use
11	76	77	O	of
12	79	82	B-UNK	beta
13	84	93	I-UNK	adrenergic
14	95	105	L-UNK	antagonists
15	107	109	O	and
16	111	115	B-UNK	alpha
17	117	126	I-UNK	adrenergic
18	128	137	L-UNK	stimulants
19	138	138	O	,
20	140	148	O	including
21	150	154	O	those
22	156	164	O	contained
23	166	167	O	in
24	169	179	O	proprietary
25	181	184	O	cold
26	186	193	O	remedies
27	195	197	O	and
28	199	214	O	vasoconstrictive
29	216	220	O	nasal
30	222	226	O	drops
NULL

Acebutolol	DDI-DrugBank.d388.s3	NO_SECTION	NO_SETID	11
Patients receiving beta-blockers should be warned of this potential hazard.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	22	B-UNK	beta
4	24	31	L-UNK	blockers
5	33	38	O	should
6	40	41	O	be
7	43	48	O	warned
8	50	51	O	of
9	53	56	O	this
10	58	66	O	potential
11	68	73	O	hazard
NULL

Acebutolol	DDI-DrugBank.d388.s4	NO_SECTION	NO_SETID	18
Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.
1	0	7	O	Blunting
2	9	10	O	of
3	12	14	O	the
4	16	31	O	antihypertensive
5	33	38	O	effect
6	40	41	O	of
7	43	46	B-UNK	beta
8	48	59	I-UNK	adrenoceptor
9	61	68	I-UNK	blocking
10	70	75	L-UNK	agents
11	77	78	O	by
12	80	91	B-UNK	nonsteroidal
13	93	96	I-UNK	anti
14	98	109	I-UNK	inflammatory
15	111	115	L-UNK	drugs
16	117	119	O	has
17	121	124	O	been
18	126	133	O	reported
NULL

Acebutolol	DDI-DrugBank.d388.s5	NO_SECTION	NO_SETID	22
No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.
1	0	1	O	No
2	3	13	O	significant
3	15	26	O	interactions
4	28	31	O	with
5	33	39	U-UNK	digoxin
6	40	40	O	,
7	42	60	U-UNK	hydrochlorothiazide
8	61	61	O	,
9	63	73	U-UNK	hydralazine
10	74	74	O	,
11	76	89	U-UNK	sulfinpyrazone
12	90	90	O	,
13	92	95	O	oral
14	97	110	U-UNK	contraceptives
15	111	111	O	,
16	113	123	U-UNK	tolbutamide
17	124	124	O	,
18	126	127	O	or
19	129	136	U-UNK	warfarin
20	138	141	O	have
21	143	146	O	been
22	148	155	O	observed
NULL

Acetazolamide	DDI-DrugBank.d368.s0	NO_SECTION	NO_SETID	10
DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.
1	0	5	O	XXXXXXXX
2	7	14	O	modifies
3	16	24	U-KIN	phenytoin
4	26	35	O	metabolism
5	37	40	O	with
6	42	50	O	increased
7	52	56	O	serum
8	58	63	O	levels
9	65	66	O	of
10	68	76	U-KIN	phenytoin
NULL

Acetazolamide	DDI-DrugBank.d368.s1	NO_SECTION	NO_SETID	16
This may increase or enhance the occurrence of osteomalacia in some patients receiving chronic phenytoin therapy.
1	0	3	O	This
2	5	7	O	may
3	9	16	O	increase
4	18	19	O	or
5	21	27	O	enhance
6	29	31	O	the
7	33	42	O	occurrence
8	44	45	O	of
9	47	58	O	osteomalacia
10	60	61	O	in
11	63	66	O	some
12	68	75	O	patients
13	77	85	O	receiving
14	87	93	O	chronic
15	95	103	U-UNK	phenytoin
16	105	111	O	therapy
NULL

Acetazolamide	DDI-DrugBank.d368.s2	NO_SECTION	NO_SETID	9
Caution is advised in patients receiving chronic concomitant therapy.
1	0	6	O	Caution
2	8	9	O	is
3	11	17	O	advised
4	19	20	O	in
5	22	29	O	patients
6	31	39	O	receiving
7	41	47	O	chronic
8	49	59	O	concomitant
9	61	67	O	therapy
NULL

Acetazolamide	DDI-DrugBank.d368.s3	NO_SECTION	NO_SETID	27
By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.
1	0	1	O	By
2	3	12	O	decreasing
3	14	16	O	the
4	18	33	O	gastrointestinal
5	35	44	O	absorption
6	46	47	O	of
7	49	57	U-UNK	primidone
8	58	58	O	,
9	60	65	O	XXXXXXXX
10	67	69	O	may
11	71	78	O	decrease
12	80	84	O	serum
13	86	99	O	concentrations
14	101	102	O	of
15	104	112	U-KIN	primidone
16	114	116	O	and
17	118	120	O	its
18	122	132	O	metabolites
19	133	133	O	,
20	135	138	O	with
21	140	140	O	a
22	142	151	O	consequent
23	153	160	O	possible
24	162	169	O	decrease
25	171	172	O	in
26	174	187	O	anticonvulsant
27	189	194	O	effect
NULL

Acetazolamide	DDI-DrugBank.d368.s4	NO_SECTION	NO_SETID	18
Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.
1	0	6	O	Caution
2	8	9	O	is
3	11	17	O	advised
4	19	22	O	when
5	24	32	O	beginning
6	33	33	O	,
7	35	47	O	discontinuing
8	48	48	O	,
9	50	51	O	or
10	53	60	O	changing
11	62	64	O	the
12	66	69	O	dose
13	71	72	O	of
14	74	79	O	XXXXXXXX
15	81	82	O	in
16	84	91	O	patients
17	93	101	O	receiving
18	103	111	U-DYN	primidone
NULL

Acetazolamide	DDI-DrugBank.d368.s5	NO_SECTION	NO_SETID	16
Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable.
1	0	6	O	Because
2	8	9	O	of
3	11	18	O	possible
4	20	27	O	additive
5	29	35	O	effects
6	37	40	O	with
7	42	46	O	other
8	48	55	B-UNK	carbonic
9	57	65	I-UNK	anhydrase
10	67	76	L-UNK	inhibitors
11	77	77	O	,
12	79	89	O	concomitant
13	91	93	O	use
14	95	96	O	is
15	98	100	O	not
16	102	110	O	advisable
NULL

Acetazolamide	DDI-DrugBank.d368.s6	NO_SECTION	NO_SETID	10
Acetazolamide may increase the effects of other folic acid antagonists.
1	0	12	O	XXXXXXXX
2	14	16	O	may
3	18	25	O	increase
4	27	29	O	the
5	31	37	O	effects
6	39	40	O	of
7	42	46	O	other
8	48	52	B-DYN	folic
9	54	57	I-DYN	acid
10	59	69	L-DYN	antagonists
NULL

Acetazolamide	DDI-DrugBank.d368.s7	NO_SECTION	NO_SETID	8
Acetazolamide may increase or decrease blood glucose levels.
1	0	12	O	XXXXXXXX
2	14	16	O	may
3	18	25	O	increase
4	27	28	O	or
5	30	37	O	decrease
6	39	43	O	blood
7	45	51	O	glucose
8	53	58	O	levels
NULL

Acetazolamide	DDI-DrugBank.d368.s8	NO_SECTION	NO_SETID	11
Consideration should be taken in patients being treated with antidiabetic agents.
1	0	12	O	Consideration
2	14	19	O	should
3	21	22	O	be
4	24	28	O	taken
5	30	31	O	in
6	33	40	O	patients
7	42	46	O	being
8	48	54	O	treated
9	56	59	O	with
10	61	72	U-UNK	antidiabetic
11	74	79	O	agents
NULL

Acetazolamide	DDI-DrugBank.d368.s9	NO_SECTION	NO_SETID	16
Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.
1	0	12	O	XXXXXXXX
2	14	22	O	decreases
3	24	30	O	urinary
4	32	40	O	excretion
5	42	43	O	of
6	45	55	U-KIN	amphetamine
7	57	59	O	and
8	61	63	O	may
9	65	71	O	enhance
10	73	75	O	the
11	77	85	O	magnitude
12	87	89	O	and
13	91	98	O	duration
14	100	101	O	of
15	103	107	O	their
16	109	114	O	effect
NULL

Acetazolamide	DDI-DrugBank.d368.s10	NO_SECTION	NO_SETID	11
Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.
1	0	12	O	XXXXXXXX
2	14	20	O	reduces
3	22	28	O	urinary
4	30	38	O	excretion
5	40	41	O	of
6	43	51	U-KIN	quinidine
7	53	55	O	and
8	57	59	O	may
9	61	67	O	enhance
10	69	71	O	its
11	73	78	O	effect
NULL

Acetazolamide	DDI-DrugBank.d368.s11	NO_SECTION	NO_SETID	9
Acetazolamide may prevent the urinary antiseptic effect of methenamine.
1	0	12	O	XXXXXXXX
2	14	16	O	may
3	18	24	O	prevent
4	26	28	O	the
5	30	36	O	urinary
6	38	47	O	antiseptic
7	49	54	O	effect
8	56	57	O	of
9	59	69	U-DYN	methenamine
NULL

Acetazolamide	DDI-DrugBank.d368.s12	NO_SECTION	NO_SETID	10
Acetazolamide increases lithium excretion and the lithium may be decreased.
1	0	12	O	XXXXXXXX
2	14	22	O	increases
3	24	30	U-KIN	lithium
4	32	40	O	excretion
5	42	44	O	and
6	46	48	O	the
7	50	56	U-UNK	lithium
8	58	60	O	may
9	62	63	O	be
10	65	73	O	decreased
NULL

Acetazolamide	DDI-DrugBank.d368.s13	NO_SECTION	NO_SETID	13
Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.
1	0	12	O	XXXXXXXX
2	14	16	O	and
3	18	23	B-DYN	sodium
4	25	35	L-DYN	bicarbonate
5	37	40	O	used
6	42	53	O	concurrently
7	55	63	O	increases
8	65	67	O	the
9	69	72	O	risk
10	74	75	O	of
11	77	81	O	renal
12	83	90	O	calculus
13	92	100	O	formation
NULL

Acetazolamide	DDI-DrugBank.d368.s14	NO_SECTION	NO_SETID	5
Acetazolamide may elevate cyclosporine levels.
1	0	12	O	XXXXXXXX
2	14	16	O	may
3	18	24	O	elevate
4	26	37	U-KIN	cyclosporine
5	39	44	O	levels
NULL

Acetohydroxamic Acid	DDI-DrugBank.d117.s0	NO_SECTION	NO_SETID	13
Concomitant use with iron supplements may result in the reduced absorption of iron.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	19	O	with
4	21	24	U-UNK	iron
5	26	36	O	supplements
6	38	40	O	may
7	42	47	O	result
8	49	50	O	in
9	52	54	O	the
10	56	62	O	reduced
11	64	73	O	absorption
12	75	76	O	of
13	78	81	U-UNK	iron
NULL

Aciclovir	DDI-DrugBank.d200.s0	NO_SECTION	NO_SETID	23
Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	30	U-UNK	probenecid
5	32	35	O	with
6	37	45	U-UNK	acyclovir
7	47	49	O	has
8	51	54	O	been
9	56	60	O	shown
10	62	63	O	to
11	65	72	O	increase
12	74	76	O	the
13	78	81	O	mean
14	83	86	O	half
15	88	91	O	life
16	93	95	O	and
17	97	99	O	the
18	101	104	O	area
19	106	110	O	under
20	112	114	O	the
21	116	128	O	concentration
22	130	133	O	time
23	135	139	O	curve
NULL

Aciclovir	DDI-DrugBank.d200.s1	NO_SECTION	NO_SETID	8
Urinary excretion and renal clearance were correspondingly reduced.
1	0	6	O	Urinary
2	8	16	O	excretion
3	18	20	O	and
4	22	26	O	renal
5	28	36	O	clearance
6	38	41	O	were
7	43	57	O	correspondingly
8	59	65	O	reduced
NULL

Aciclovir	DDI-DrugBank.d200.s2	NO_SECTION	NO_SETID	10
The clinical effects of this combination have not been studied.
1	0	2	O	The
2	4	11	O	clinical
3	13	19	O	effects
4	21	22	O	of
5	24	27	O	this
6	29	39	O	combination
7	41	44	O	have
8	46	48	O	not
9	50	53	O	been
10	55	61	O	studied
NULL

Acitretin	DDI-DrugBank.d353.s0	NO_SECTION	NO_SETID	16
Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.
1	0	15	O	Ethanol:Clinical
2	17	24	O	evidence
3	26	28	O	has
4	30	34	O	shown
5	36	39	O	that
6	41	50	U-UNK	etretinate
7	52	54	O	can
8	56	57	O	be
9	59	64	O	formed
10	66	69	O	with
11	71	80	O	concurrent
12	82	90	O	ingestion
13	92	93	O	of
14	95	103	O	XXXXXXXX
15	105	107	O	and
16	109	115	U-KIN	ethanol
NULL

Acitretin	DDI-DrugBank.d353.s1	NO_SECTION	NO_SETID	32
Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.
1	0	12	U-UNK	Glibenclamide
2	13	13	O	:
3	15	16	O	In
4	18	18	O	a
5	20	24	O	study
6	26	27	O	of
7	29	29	O	7
8	31	37	O	healthy
9	39	42	O	male
10	44	53	O	volunteers
11	54	54	O	,
12	56	64	O	XXXXXXXX
13	66	74	O	treatment
14	76	86	O	potentiated
15	88	90	O	the
16	92	96	O	blood
17	98	104	O	glucose
18	106	113	O	lowering
19	115	120	O	effect
20	122	123	O	of
21	125	137	U-DYN	glibenclamide
22	140	140	O	a
23	142	153	U-UNK	sulfonylurea
24	155	161	O	similar
25	163	164	O	to
26	166	179	U-UNK	chlorpropamide
27	182	183	O	in
28	185	185	O	3
29	187	188	O	of
30	190	192	O	the
31	194	194	O	7
32	196	203	O	subjects
NULL

Acitretin	DDI-DrugBank.d353.s2	NO_SECTION	NO_SETID	23
Repeating the study with 6 healthy male volunteers in the absence of glibenclamide did not detect an effect of acitretin on glucose tolerance.
1	0	8	O	Repeating
2	10	12	O	the
3	14	18	O	study
4	20	23	O	with
5	25	25	O	6
6	27	33	O	healthy
7	35	38	O	male
8	40	49	O	volunteers
9	51	52	O	in
10	54	56	O	the
11	58	64	O	absence
12	66	67	O	of
13	69	81	U-UNK	glibenclamide
14	83	85	O	did
15	87	89	O	not
16	91	96	O	detect
17	98	99	O	an
18	101	106	O	effect
19	108	109	O	of
20	111	119	O	XXXXXXXX
21	121	122	O	on
22	124	130	O	glucose
23	132	140	O	tolerance
NULL

Acitretin	DDI-DrugBank.d353.s3	NO_SECTION	NO_SETID	11
Careful supervision of diabetic patients under treatment with Soriatane is recommended.
1	0	6	O	Careful
2	8	18	O	supervision
3	20	21	O	of
4	23	30	O	diabetic
5	32	39	O	patients
6	41	45	O	under
7	47	55	O	treatment
8	57	60	O	with
9	62	70	O	XXXXXXXX
10	72	73	O	is
11	75	85	O	recommended
NULL

Acitretin	DDI-DrugBank.d353.s4	NO_SECTION	NO_SETID	20
Hormonal Contraceptives: It has not been established if there is a pharmacokinetic interaction between acitretin and combined oral contraceptives.
1	0	7	B-UNK	Hormonal
2	9	22	L-UNK	Contraceptives
3	23	23	O	:
4	25	26	O	It
5	28	30	O	has
6	32	34	O	not
7	36	39	O	been
8	41	51	O	established
9	53	54	O	if
10	56	60	O	there
11	62	63	O	is
12	65	65	O	a
13	67	81	O	pharmacokinetic
14	83	93	O	interaction
15	95	101	O	between
16	103	111	O	XXXXXXXX
17	113	115	O	and
18	117	124	B-UNK	combined
19	126	129	I-UNK	oral
20	131	144	L-UNK	contraceptives
NULL

Acitretin	DDI-DrugBank.d353.s5	NO_SECTION	NO_SETID	18
However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	it
4	12	14	O	has
5	16	19	O	been
6	21	31	O	established
7	33	36	O	that
8	38	46	O	XXXXXXXX
9	48	57	O	interferes
10	59	62	O	with
11	64	66	O	the
12	68	80	O	contraceptive
13	82	87	O	effect
14	89	90	O	of
15	92	101	O	microdosed
16	103	111	U-DYN	progestin
17	113	120	O	minipill
18	122	133	O	preparations
NULL

Acitretin	DDI-DrugBank.d353.s6	NO_SECTION	NO_SETID	11
Microdosed minipill progestin preparations are not recommended for use with Soriatane.
1	0	9	O	Microdosed
2	11	18	O	minipill
3	20	28	U-UNK	progestin
4	30	41	O	preparations
5	43	45	O	are
6	47	49	O	not
7	51	61	O	recommended
8	63	65	O	for
9	67	69	O	use
10	71	74	O	with
11	76	84	U-UNK	Soriatane
NULL

Acitretin	DDI-DrugBank.d353.s7	NO_SECTION	NO_SETID	23
It is not known whether other progestational contraceptives, such as implants and injectables, are adequate methods of contraception during acitretin therapy.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	known
5	16	22	O	whether
6	24	28	O	other
7	30	43	B-UNK	progestational
8	45	58	L-UNK	contraceptives
9	59	59	O	,
10	61	64	O	such
11	66	67	O	as
12	69	76	O	implants
13	78	80	O	and
14	82	92	O	injectables
15	93	93	O	,
16	95	97	O	are
17	99	106	O	adequate
18	108	114	O	methods
19	116	117	O	of
20	119	131	O	contraception
21	133	138	O	during
22	140	148	O	XXXXXXXX
23	150	156	O	therapy
NULL

Acitretin	DDI-DrugBank.d353.s8	NO_SECTION	NO_SETID	19
Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.
1	0	11	U-UNK	Methotrexate
2	12	12	O	:
3	14	15	O	An
4	17	25	O	increased
5	27	30	O	risk
6	32	33	O	of
7	35	43	O	hepatitis
8	45	47	O	has
9	49	52	O	been
10	54	61	O	reported
11	63	64	O	to
12	66	71	O	result
13	73	76	O	from
14	78	85	O	combined
15	87	89	O	use
16	91	92	O	of
17	94	105	U-UNK	methotrexate
18	107	109	O	and
19	111	120	U-UNK	etretinate
NULL

Acitretin	DDI-DrugBank.d353.s9	NO_SECTION	NO_SETID	11
Consequently, the combination of methotrexate with acitretin is also contraindicated.
1	0	11	O	Consequently
2	12	12	O	,
3	14	16	O	the
4	18	28	O	combination
5	30	31	O	of
6	33	44	U-DYN	methotrexate
7	46	49	O	with
8	51	59	O	XXXXXXXX
9	61	62	O	is
10	64	67	O	also
11	69	83	O	contraindicated
NULL

Acitretin	DDI-DrugBank.d353.s10	NO_SECTION	NO_SETID	18
Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.
1	0	8	U-UNK	Phenytoin
2	9	9	O	:
3	11	12	O	If
4	14	22	O	XXXXXXXX
5	24	25	O	is
6	27	31	O	given
7	33	44	O	concurrently
8	46	49	O	with
9	51	59	U-KIN	phenytoin
10	60	60	O	,
11	62	64	O	the
12	66	72	O	protein
13	74	80	O	binding
14	82	83	O	of
15	85	93	U-UNK	phenytoin
16	95	97	O	may
17	99	100	O	be
18	102	108	O	reduced
NULL

Acitretin	DDI-DrugBank.d353.s11	NO_SECTION	NO_SETID	18
Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.
1	0	12	U-UNK	Tetracyclines
2	13	13	O	:
3	15	19	O	Since
4	21	24	O	both
5	26	34	O	XXXXXXXX
6	36	38	O	and
7	40	52	U-DYN	tetracyclines
8	54	56	O	can
9	58	62	O	cause
10	64	72	O	increased
11	74	85	O	intracranial
12	87	94	O	pressure
13	95	95	O	,
14	97	101	O	their
15	103	110	O	combined
16	112	114	O	use
17	116	117	O	is
18	119	133	O	contraindicated
NULL

Acitretin	DDI-DrugBank.d353.s12	NO_SECTION	NO_SETID	29
Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.
1	0	6	B-UNK	Vitamin
2	8	8	L-UNK	A
3	10	12	O	and
4	14	17	O	oral
5	19	27	U-UNK	retinoids
6	28	28	O	:
7	30	40	O	Concomitant
8	42	55	O	administration
9	57	58	O	of
10	60	66	B-DYN	vitamin
11	68	68	L-DYN	A
12	70	72	O	and
13	73	73	O	/
14	74	75	O	or
15	77	81	O	other
16	83	86	O	oral
17	88	96	U-DYN	retinoids
18	98	101	O	with
19	103	111	O	XXXXXXXX
20	113	116	O	must
21	118	119	O	be
22	121	127	O	avoided
23	129	135	O	because
24	137	138	O	of
25	140	142	O	the
26	144	147	O	risk
27	149	150	O	of
28	152	167	O	hypervitaminosis
29	169	169	O	A
NULL

Acitretin	DDI-DrugBank.d353.s13	NO_SECTION	NO_SETID	18
Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine, digoxin, or glyburide.
1	0	4	O	Other
2	5	5	O	:
3	7	11	O	There
4	13	19	O	appears
5	21	22	O	to
6	24	25	O	be
7	27	28	O	no
8	30	44	O	pharmacokinetic
9	46	56	O	interaction
10	58	64	O	between
11	66	74	O	XXXXXXXX
12	76	78	O	and
13	80	89	U-UNK	cimetidine
14	90	90	O	,
15	92	98	U-UNK	digoxin
16	99	99	O	,
17	101	102	O	or
18	104	112	U-UNK	glyburide
NULL

Acitretin	DDI-DrugBank.d353.s14	NO_SECTION	NO_SETID	20
Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed no interaction.
1	0	13	O	Investigations
2	15	18	O	into
3	20	22	O	the
4	24	29	O	effect
5	31	32	O	of
6	34	42	O	XXXXXXXX
7	44	45	O	on
8	47	49	O	the
9	51	57	O	protein
10	59	65	O	binding
11	67	68	O	of
12	70	83	B-UNK	anticoagulants
13	85	86	I-UNK	of
14	88	90	I-UNK	the
15	92	99	I-UNK	coumarin
16	101	104	L-UNK	type
17	107	114	U-UNK	warfarin
18	117	124	O	revealed
19	126	127	O	no
20	129	139	O	interaction
NULL

Acitretin	DDI-DrugBank.d353.s15	NO_SECTION	NO_SETID	26
Laboratory Tests If significant abnormal laboratory results are obtained, either dosage reduction with careful monitoring or treatment discontinuation is recommended, depending on clinical judgement.
1	0	9	O	Laboratory
2	11	15	O	Tests
3	17	18	O	If
4	20	30	O	significant
5	32	39	O	abnormal
6	41	50	O	laboratory
7	52	58	O	results
8	60	62	O	are
9	64	71	O	obtained
10	72	72	O	,
11	74	79	O	either
12	81	86	O	dosage
13	88	96	O	reduction
14	98	101	O	with
15	103	109	O	careful
16	111	120	O	monitoring
17	122	123	O	or
18	125	133	O	treatment
19	135	149	O	discontinuation
20	151	152	O	is
21	154	164	O	recommended
22	165	165	O	,
23	167	175	O	depending
24	177	178	O	on
25	180	187	O	clinical
26	189	197	O	judgement
NULL

Acitretin	DDI-DrugBank.d353.s16	NO_SECTION	NO_SETID	14
Blood Sugar: Some patients receiving retinoids have experienced problems with blood sugar control.
1	0	4	O	Blood
2	6	10	O	Sugar
3	11	11	O	:
4	13	16	O	Some
5	18	25	O	patients
6	27	35	O	receiving
7	37	45	U-UNK	retinoids
8	47	50	O	have
9	52	62	O	experienced
10	64	71	O	problems
11	73	76	O	with
12	78	82	O	blood
13	84	88	O	sugar
14	90	96	O	control
NULL

Acitretin	DDI-DrugBank.d353.s17	NO_SECTION	NO_SETID	17
In addition, new cases of diabetes have been diagnosed during retinoid therapy, including diabetic ketoacidosis.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	15	O	new
5	17	21	O	cases
6	23	24	O	of
7	26	33	O	diabetes
8	35	38	O	have
9	40	43	O	been
10	45	53	O	diagnosed
11	55	60	O	during
12	62	69	U-UNK	retinoid
13	71	77	O	therapy
14	78	78	O	,
15	80	88	O	including
16	90	97	O	diabetic
17	99	110	O	ketoacidosis
NULL

Acitretin	DDI-DrugBank.d353.s18	NO_SECTION	NO_SETID	11
In diabetics, blood-sugar levels should be monitored very carefully.
1	0	1	O	In
2	3	11	O	diabetics
3	12	12	O	,
4	14	18	O	blood
5	20	24	O	sugar
6	26	31	O	levels
7	33	38	O	should
8	40	41	O	be
9	43	51	O	monitored
10	53	56	O	very
11	58	66	O	carefully
NULL

Acitretin	DDI-DrugBank.d353.s19	NO_SECTION	NO_SETID	23
Lipids: In clinical studies, the incidence of hypertriglyceridemia was 66%, hypercholesterolemia was 33% and that of decreased HDL was 40%.
1	0	5	O	Lipids
2	6	6	O	:
3	8	9	O	In
4	11	18	O	clinical
5	20	26	O	studies
6	27	27	O	,
7	29	31	O	the
8	33	41	O	incidence
9	43	44	O	of
10	46	65	O	hypertriglyceridemia
11	67	69	O	was
12	71	73	O	66%
13	74	74	O	,
14	76	95	O	hypercholesterolemia
15	97	99	O	was
16	101	103	O	33%
17	105	107	O	and
18	109	112	O	that
19	114	115	O	of
20	117	125	O	decreased
21	127	129	O	HDL
22	131	133	O	was
23	135	137	O	40%
NULL

Acitretin	DDI-DrugBank.d353.s20	NO_SECTION	NO_SETID	11
Pretreatment and follow-up measurements should be obtained under fasting conditions.
1	0	11	O	Pretreatment
2	13	15	O	and
3	17	22	O	follow
4	24	25	O	up
5	27	38	O	measurements
6	40	45	O	should
7	47	48	O	be
8	50	57	O	obtained
9	59	63	O	under
10	65	71	O	fasting
11	73	82	O	conditions
NULL

Acitretin	DDI-DrugBank.d353.s21	NO_SECTION	NO_SETID	21
It is recommended that these tests be performed weekly or every other week until the lipid response to Soriatane has stabilized.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	27	O	these
6	29	33	O	tests
7	35	36	O	be
8	38	46	O	performed
9	48	53	O	weekly
10	55	56	O	or
11	58	62	O	every
12	64	68	O	other
13	70	73	O	week
14	75	79	O	until
15	81	83	O	the
16	85	89	O	lipid
17	91	98	O	response
18	100	101	O	to
19	103	111	O	XXXXXXXX
20	113	115	O	has
21	117	126	O	stabilized
NULL

Acitretin	DDI-DrugBank.d353.s22	NO_SECTION	NO_SETID	24
Liver Function Tests: Elevations of AST (SGOT), ALT (SGPT) or LDH were experienced by approximately 1 in 3 patients treated with Soriatane.
1	0	4	O	Liver
2	6	13	O	Function
3	15	19	O	Tests
4	20	20	O	:
5	22	31	O	Elevations
6	33	34	O	of
7	36	38	O	AST
8	41	44	O	SGOT
9	46	46	O	,
10	48	50	O	ALT
11	53	56	O	SGPT
12	59	60	O	or
13	62	64	O	LDH
14	66	69	O	were
15	71	81	O	experienced
16	83	84	O	by
17	86	98	O	approximately
18	100	100	O	1
19	102	103	O	in
20	105	105	O	3
21	107	114	O	patients
22	116	122	O	treated
23	124	127	O	with
24	129	137	O	XXXXXXXX
NULL

Acitretin	DDI-DrugBank.d353.s23	NO_SECTION	NO_SETID	30
It is recommended that these tests be performed prior to initiation of Soriatane therapy, at 1- to 2-week intervals until stable and thereafter at intervals as clinically indicated.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	27	O	these
6	29	33	O	tests
7	35	36	O	be
8	38	46	O	performed
9	48	52	O	prior
10	54	55	O	to
11	57	66	O	initiation
12	68	69	O	of
13	71	79	O	XXXXXXXX
14	81	87	O	therapy
15	88	88	O	,
16	90	91	O	at
17	93	93	O	1
18	96	97	O	to
19	99	99	O	2
20	101	104	O	week
21	106	114	O	intervals
22	116	120	O	until
23	122	127	O	stable
24	129	131	O	and
25	133	142	O	thereafter
26	144	145	O	at
27	147	155	O	intervals
28	157	158	O	as
29	160	169	O	clinically
30	171	179	O	indicated
NULL

Adalimumab	DDI-DrugBank.d493.s0	NO_SECTION	NO_SETID	13
Methotrexate: HUMIRA has been studied in rheumatoid arthritis patients taking concomitant MTX.
1	0	11	U-UNK	Methotrexate
2	12	12	O	:
3	14	19	O	XXXXXXXX
4	21	23	O	has
5	25	28	O	been
6	30	36	O	studied
7	38	39	O	in
8	41	50	O	rheumatoid
9	52	60	O	arthritis
10	62	69	O	patients
11	71	76	O	taking
12	78	88	O	concomitant
13	90	92	U-UNK	MTX
NULL

Adalimumab	DDI-DrugBank.d493.s1	NO_SECTION	NO_SETID	15
The data do not suggest the need for dose adjustment of either HUMIRA or MTX.
1	0	2	O	The
2	4	7	O	data
3	9	10	O	do
4	12	14	O	not
5	16	22	O	suggest
6	24	26	O	the
7	28	31	O	need
8	33	35	O	for
9	37	40	O	dose
10	42	51	O	adjustment
11	53	54	O	of
12	56	61	O	either
13	63	68	O	XXXXXXXX
14	70	71	O	or
15	73	75	U-UNK	MTX
NULL

Adalimumab	DDI-DrugBank.d493.s2	NO_SECTION	NO_SETID	41
Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
1	0	7	U-UNK	Anakinra
2	8	8	O	:
3	10	19	O	Concurrent
4	21	34	O	administration
5	36	37	O	of
6	39	46	U-UNK	anakinra
7	49	50	O	an
8	52	62	B-UNK	interleukin
9	64	64	I-UNK	1
10	66	75	L-UNK	antagonist
11	78	80	O	and
12	82	88	O	another
13	90	92	B-UNK	TNF
14	94	101	I-UNK	blocking
15	103	107	L-UNK	agent
16	109	111	O	has
17	113	116	O	been
18	118	127	O	associated
19	129	132	O	with
20	134	135	O	an
21	137	145	O	increased
22	147	150	O	risk
23	152	153	O	of
24	155	161	O	serious
25	163	172	O	infections
26	173	173	O	,
27	175	176	O	an
28	178	186	O	increased
29	188	191	O	risk
30	193	194	O	of
31	196	206	O	neutropenia
32	208	210	O	and
33	212	213	O	no
34	215	224	O	additional
35	226	232	O	benefit
36	234	241	O	compared
37	243	244	O	to
38	246	250	O	these
39	252	260	O	medicinal
40	262	269	O	products
41	271	275	O	alone
NULL

Adalimumab	DDI-DrugBank.d493.s3	NO_SECTION	NO_SETID	15
The safety and efficacy of anakinra used in combination with HUMIRA has not been studied.
1	0	2	O	The
2	4	9	O	safety
3	11	13	O	and
4	15	22	O	efficacy
5	24	25	O	of
6	27	34	U-UNK	anakinra
7	36	39	O	used
8	41	42	O	in
9	44	54	O	combination
10	56	59	O	with
11	61	66	O	XXXXXXXX
12	68	70	O	has
13	72	74	O	not
14	76	79	O	been
15	81	87	O	studied
NULL

Adalimumab	DDI-DrugBank.d493.s4	NO_SECTION	NO_SETID	22
Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.
1	0	8	O	Therefore
2	10	12	O	the
3	13	13	O	,
4	15	25	O	combination
5	27	28	O	of
6	30	37	U-DYN	anakinra
7	39	42	O	with
8	44	48	O	other
9	50	52	B-UNK	TNF
10	54	61	I-UNK	blocking
11	63	68	L-UNK	agents
12	69	69	O	,
13	71	79	O	including
14	81	86	O	XXXXXXXX
15	87	87	O	,
16	89	91	O	may
17	93	96	O	also
18	98	103	O	result
19	105	105	O	i
20	107	107	O	n
21	109	115	O	similar
22	117	126	O	toxicities
NULL

Adapalene	DDI-DrugBank.d370.s0	NO_SECTION	NO_SETID	57
As DIFFERIN Gel has the potential to produce local irritation in some patients, concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime) should be approached with caution.
1	0	1	O	As
2	3	10	O	XXXXXXXX
3	12	14	O	Gel
4	16	18	O	has
5	20	22	O	the
6	24	32	O	potential
7	34	35	O	to
8	37	43	O	produce
9	45	49	O	local
10	51	60	O	irritation
11	62	63	O	in
12	65	68	O	some
13	70	77	O	patients
14	78	78	O	,
15	80	90	O	concomitant
16	92	94	O	use
17	96	97	O	of
18	99	103	O	other
19	105	115	O	potentially
20	117	126	O	irritating
21	128	134	O	topical
22	136	143	O	products
23	146	154	O	medicated
24	156	157	O	or
25	159	166	O	abrasive
26	168	172	O	soaps
27	174	176	O	and
28	178	186	O	cleansers
29	187	187	O	,
30	189	193	O	soaps
31	195	197	O	and
32	199	207	O	cosmetics
33	209	212	O	that
34	214	217	O	have
35	219	219	O	a
36	221	226	O	strong
37	228	233	O	drying
38	235	240	O	effect
39	241	241	O	,
40	243	245	O	and
41	247	254	O	products
42	256	259	O	with
43	261	264	O	high
44	266	279	O	concentrations
45	281	282	O	of
46	284	290	O	alcohol
47	291	291	O	,
48	293	303	O	astringents
49	304	304	O	,
50	306	311	O	spices
51	313	314	O	or
52	316	319	O	lime
53	322	327	O	should
54	329	330	O	be
55	332	341	O	approached
56	343	346	O	with
57	348	354	O	caution
NULL

Adapalene	DDI-DrugBank.d370.s1	NO_SECTION	NO_SETID	21
Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with DIFFERIN Gel.
1	0	9	O	Particular
2	11	17	O	caution
3	19	24	O	should
4	26	27	O	be
5	29	37	O	exercised
6	39	40	O	in
7	42	46	O	using
8	48	59	O	preparations
9	61	70	O	containing
10	72	77	U-UNK	sulfur
11	78	78	O	,
12	80	89	U-UNK	resorcinol
13	90	90	O	,
14	92	93	O	or
15	95	103	B-UNK	salicylic
16	105	108	L-UNK	acid
17	110	111	O	in
18	113	123	O	combination
19	125	128	O	with
20	130	137	O	XXXXXXXX
21	139	141	O	Gel
NULL

Adapalene	DDI-DrugBank.d370.s2	NO_SECTION	NO_SETID	27
If these preparations have been used it is advisable not to start therapy with DIFFERIN Gel until the effects of such preparations in the skin have subsided.
1	0	1	O	If
2	3	7	O	these
3	9	20	O	preparations
4	22	25	O	have
5	27	30	O	been
6	32	35	O	used
7	37	38	O	it
8	40	41	O	is
9	43	51	O	advisable
10	53	55	O	not
11	57	58	O	to
12	60	64	O	start
13	66	72	O	therapy
14	74	77	O	with
15	79	86	O	XXXXXXXX
16	88	90	O	Gel
17	92	96	O	until
18	98	100	O	the
19	102	108	O	effects
20	110	111	O	of
21	113	116	O	such
22	118	129	O	preparations
23	131	132	O	in
24	134	136	O	the
25	138	141	O	skin
26	143	146	O	have
27	148	155	O	subsided
NULL

Adefovir Dipivoxil	DDI-DrugBank.d244.s0	NO_SECTION	NO_SETID	47
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.
1	0	5	O	Before
2	7	11	O	using
3	13	16	O	this
4	18	27	O	medication
5	28	28	O	,
6	30	33	O	tell
7	35	38	O	your
8	40	45	O	doctor
9	47	48	O	or
10	50	59	O	pharmacist
11	61	62	O	of
12	64	66	O	all
13	68	79	O	prescription
14	81	83	O	and
15	85	99	O	nonprescription
16	101	108	O	products
17	110	112	O	you
18	114	116	O	may
19	118	120	O	use
20	121	121	O	,
21	123	132	O	especially
22	134	135	O	of
23	136	136	O	:
24	138	152	U-UNK	aminoglycosides
25	155	157	O	e.g
26	159	159	O	,
27	161	170	U-UNK	gentamicin
28	171	171	O	,
29	173	180	U-UNK	amikacin
30	182	182	O	,
31	184	195	B-UNK	amphotericin
32	197	197	L-UNK	B
33	198	198	O	,
34	200	211	U-UNK	cyclosporine
35	212	212	O	,
36	214	216	B-UNK	non
37	218	226	I-UNK	steroidal
38	228	231	I-UNK	anti
39	233	244	L-UNK	inflammatory
40	246	250	O	drugs
41	253	255	O	e.g
42	257	257	O	,
43	259	267	U-UNK	ibuprofen
44	269	269	O	,
45	271	280	U-UNK	tacrolimus
46	281	281	O	,
47	283	292	U-UNK	vancomycin
NULL

Adefovir Dipivoxil	DDI-DrugBank.d244.s1	NO_SECTION	NO_SETID	12
Do not start or stop any medicine without doctor or pharmacist approval.
1	0	1	O	Do
2	3	5	O	not
3	7	11	O	start
4	13	14	O	or
5	16	19	O	stop
6	21	23	O	any
7	25	32	O	medicine
8	34	40	O	without
9	42	47	O	doctor
10	49	50	O	or
11	52	61	O	pharmacist
12	63	70	O	approval
NULL

Adenosine	DDI-DrugBank.d226.s0	NO_SECTION	NO_SETID	43
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.
1	0	10	O	Intravenous
2	12	20	O	XXXXXXXX
3	23	31	U-UNK	adenosine
4	34	36	O	has
5	38	41	O	been
6	43	53	O	effectively
7	55	66	O	administered
8	68	69	O	in
9	71	73	O	the
10	75	82	O	presence
11	84	85	O	of
12	87	91	O	other
13	93	104	O	cardioactive
14	106	110	O	drugs
15	111	111	O	,
16	113	116	O	such
17	118	119	O	as
18	121	129	U-UNK	quinidine
19	130	130	O	,
20	132	135	B-UNK	beta
21	137	146	I-UNK	adrenergic
22	148	155	I-UNK	blocking
23	157	162	L-UNK	agents
24	163	163	O	,
25	165	171	B-UNK	calcium
26	173	179	I-UNK	channel
27	181	188	I-UNK	blocking
28	190	195	L-UNK	agents
29	196	196	O	,
30	198	200	O	and
31	202	212	B-UNK	angiotensin
32	214	223	I-UNK	converting
33	225	230	I-UNK	enzyme
34	232	241	L-UNK	inhibitors
35	242	242	O	,
36	244	250	O	without
37	252	254	O	any
38	256	261	O	change
39	263	264	O	in
40	266	268	O	the
41	270	276	O	adverse
42	278	285	O	reaction
43	287	293	O	profile
NULL

Adenosine	DDI-DrugBank.d226.s1	NO_SECTION	NO_SETID	15
Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.
1	0	6	U-DYN	Digoxin
2	8	10	O	and
3	12	20	U-DYN	verapamil
4	22	24	O	use
5	26	28	O	may
6	30	31	O	be
7	33	38	O	rarely
8	40	49	O	associated
9	51	54	O	with
10	56	66	O	ventricular
11	68	79	O	fibrillation
12	81	84	O	when
13	86	93	O	combined
14	95	98	O	with
15	100	108	O	XXXXXXXX
NULL

Adenosine	DDI-DrugBank.d226.s2	NO_SECTION	NO_SETID	31
Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, Adenocard should be used with caution in the presence of these agents.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	23	O	potential
5	25	27	O	for
6	29	36	O	additive
7	38	39	O	or
8	41	51	O	synergistic
9	53	62	O	depressant
10	64	70	O	effects
11	72	73	O	on
12	75	77	O	the
13	79	80	O	SA
14	82	84	O	and
15	86	87	O	AV
16	89	93	O	nodes
17	94	94	O	,
18	96	102	O	however
19	103	103	O	,
20	105	113	O	XXXXXXXX
21	115	120	O	should
22	122	123	O	be
23	125	128	O	used
24	130	133	O	with
25	135	141	O	caution
26	143	144	O	in
27	146	148	O	the
28	150	157	O	presence
29	159	160	O	of
30	162	166	O	these
31	168	173	O	agents
NULL

Adenosine	DDI-DrugBank.d226.s3	NO_SECTION	NO_SETID	15
The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	19	O	XXXXXXXX
5	21	22	O	in
6	24	31	O	patients
7	33	41	O	receiving
8	43	51	U-DYN	digitalis
9	53	55	O	may
10	57	58	O	be
11	60	65	O	rarely
12	67	76	O	associated
13	78	81	O	with
14	83	93	O	ventricular
15	95	106	O	fibrillation
NULL

Adenosine	DDI-DrugBank.d226.s4	NO_SECTION	NO_SETID	13
The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	23	O	XXXXXXXX
5	25	27	O	are
6	29	39	O	antagonized
7	41	42	O	by
8	44	58	U-DYN	methylxanthines
9	60	63	O	such
10	65	66	O	as
11	68	75	U-DYN	caffeine
12	77	79	O	and
13	81	92	U-DYN	theophylline
NULL

Adenosine	DDI-DrugBank.d226.s5	NO_SECTION	NO_SETID	20
In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.
1	0	1	O	In
2	3	5	O	the
3	7	14	O	presence
4	16	17	O	of
5	19	23	O	these
6	25	39	U-DYN	methylxanthines
7	40	40	O	,
8	42	47	O	larger
9	49	53	O	doses
10	55	56	O	of
11	58	66	O	XXXXXXXX
12	68	70	O	may
13	72	73	O	be
14	75	82	O	required
15	84	85	O	or
16	87	95	O	XXXXXXXX
17	97	99	O	may
18	101	103	O	not
19	105	106	O	be
20	108	116	O	effective
NULL

Adenosine	DDI-DrugBank.d226.s6	NO_SECTION	NO_SETID	6
Adenosine effects are potentiated by dipyridamole.
1	0	8	O	XXXXXXXX
2	10	16	O	effects
3	18	20	O	are
4	22	32	O	potentiated
5	34	35	O	by
6	37	48	U-DYN	dipyridamole
NULL

Adenosine	DDI-DrugBank.d226.s7	NO_SECTION	NO_SETID	14
Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.
1	0	3	O	Thus
2	4	4	O	,
3	6	12	O	smaller
4	14	18	O	doses
5	20	21	O	of
6	23	31	O	XXXXXXXX
7	33	35	O	may
8	37	38	O	be
9	40	48	O	effective
10	50	51	O	in
11	53	55	O	the
12	57	64	O	presence
13	66	67	O	of
14	69	80	U-DYN	dipyridamole
NULL

Adenosine	DDI-DrugBank.d226.s8	NO_SECTION	NO_SETID	15
Carbamazepine has been reported to increase the degree of heart block produced by other agents.
1	0	12	U-UNK	Carbamazepine
2	14	16	O	has
3	18	21	O	been
4	23	30	O	reported
5	32	33	O	to
6	35	42	O	increase
7	44	46	O	the
8	48	53	O	degree
9	55	56	O	of
10	58	62	O	heart
11	64	68	O	block
12	70	77	O	produced
13	79	80	O	by
14	82	86	O	other
15	88	93	O	agents
NULL

Adenosine	DDI-DrugBank.d226.s9	NO_SECTION	NO_SETID	29
As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.
1	0	1	O	As
2	3	5	O	the
3	7	13	O	primary
4	15	20	O	effect
5	22	23	O	of
6	25	33	O	XXXXXXXX
7	35	36	O	is
8	38	39	O	to
9	41	48	O	decrease
10	50	59	O	conduction
11	61	67	O	through
12	69	71	O	the
13	73	73	O	A
14	75	75	O	V
15	77	80	O	node
16	81	81	O	,
17	83	88	O	higher
18	90	96	O	degrees
19	98	99	O	of
20	101	105	O	heart
21	107	111	O	block
22	113	115	O	may
23	117	118	O	be
24	120	127	O	produced
25	129	130	O	in
26	132	134	O	the
27	136	143	O	presence
28	145	146	O	of
29	148	160	U-DYN	carbamazepine
NULL

Adinazolam	DDI-DrugBank.d449.s0	NO_SECTION	NO_SETID	13
Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended.
1	0	1	O	Co
2	3	16	O	administration
3	18	21	O	with
4	23	32	B-UNK	antifungal
5	34	39	L-UNK	agents
6	41	44	O	such
7	46	47	O	as
8	49	60	U-UNK	ketoconazole
9	62	63	O	or
10	65	76	U-UNK	itraconazole
11	78	79	O	is
12	81	83	O	not
13	85	95	O	recommended
NULL

Adinazolam	DDI-DrugBank.d449.s1	NO_SECTION	NO_SETID	9
Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).
1	0	9	U-DYN	Nafazodone
2	10	10	O	,
3	12	22	U-DYN	fluvoxamine
4	23	23	O	,
5	25	34	U-DYN	cimetidine
6	37	44	O	consider
7	46	50	O	XXXXXXXX
8	52	55	O	dose
9	57	65	O	reduction
NULL

Adinazolam	DDI-DrugBank.d449.s2	NO_SECTION	NO_SETID	12
Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).
1	0	9	U-UNK	Fluoxetine
2	10	10	O	,
3	12	14	U-UNK	OCs
4	15	15	O	,
5	17	26	U-UNK	sertraline
6	27	27	O	,
7	29	37	U-UNK	diltiazem
8	38	38	O	,
9	40	48	B-UNK	macrolide
10	50	60	L-UNK	antibiotics
11	63	70	O	exercise
12	72	78	O	caution
NULL

Agalsidase beta	DDI-DrugBank.d164.s0	NO_SECTION	NO_SETID	6
No drug interaction studies were performed.
1	0	1	O	No
2	3	6	O	drug
3	8	18	O	interaction
4	20	26	O	studies
5	28	31	O	were
6	33	41	O	performed
NULL

Agalsidase beta	DDI-DrugBank.d164.s1	NO_SECTION	NO_SETID	7
No in vitro metabolism studies were performed.
1	0	1	O	No
2	3	4	O	in
3	6	10	O	vitro
4	12	21	O	metabolism
5	23	29	O	studies
6	31	34	O	were
7	36	44	O	performed
NULL

Albendazole	DDI-DrugBank.d321.s0	NO_SECTION	NO_SETID	34
Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.
1	0	12	U-UNK	Dexamethasone
2	13	13	O	:
3	15	20	O	Steady
4	22	26	O	state
5	28	33	O	trough
6	35	48	O	concentrations
7	50	51	O	of
8	53	63	O	XXXXXXXX
9	65	73	O	sulfoxide
10	75	78	O	were
11	80	84	O	about
12	86	88	O	56%
13	90	95	O	higher
14	97	100	O	when
15	102	102	O	8
16	104	105	O	mg
17	107	119	U-KIN	dexamethasone
18	121	123	O	was
19	125	138	O	coadministered
20	140	143	O	with
21	145	148	O	each
22	150	153	O	dose
23	155	156	O	of
24	158	168	O	XXXXXXXX
25	171	172	O	15
26	174	175	O	mg
27	176	176	O	/
28	177	178	O	kg
29	179	179	O	/
30	180	182	O	day
31	185	186	O	in
32	188	192	O	eight
33	194	211	O	neurocysticercosis
34	213	220	O	patients
NULL

Albendazole	DDI-DrugBank.d321.s1	NO_SECTION	NO_SETID	43
Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.
1	0	11	U-UNK	Praziquantel
2	12	12	O	:
3	14	15	O	In
4	17	19	O	the
5	21	23	O	fed
6	25	29	O	state
7	30	30	O	,
8	32	43	U-KIN	praziquantel
9	46	47	O	40
10	49	50	O	mg
11	51	51	O	/
12	52	53	O	kg
13	56	64	O	increased
14	66	69	O	mean
15	71	77	O	maximum
16	79	84	O	plasma
17	86	98	O	concentration
18	100	102	O	and
19	104	107	O	area
20	109	113	O	under
21	115	117	O	the
22	119	123	O	curve
23	125	126	O	of
24	128	138	O	XXXXXXXX
25	140	148	O	sulfoxide
26	150	151	O	by
27	153	157	O	about
28	159	161	O	50%
29	163	164	O	in
30	166	172	O	healthy
31	174	181	O	subjects
32	184	187	O	n=10
33	190	197	O	compared
34	199	202	O	with
35	204	204	O	a
36	206	213	O	separate
37	215	219	O	group
38	221	222	O	of
39	224	231	O	subjects
40	234	236	O	n=6
41	239	243	O	given
42	245	255	O	XXXXXXXX
43	257	261	O	alone
NULL

Albendazole	DDI-DrugBank.d321.s2	NO_SECTION	NO_SETID	14
Mean T max and mean plasma elimination half-life of albendazole sulfoxide were unchanged.
1	0	3	O	Mean
2	5	5	O	T
3	7	9	O	max
4	11	13	O	and
5	15	18	O	mean
6	20	25	O	plasma
7	27	37	O	elimination
8	39	42	O	half
9	44	47	O	life
10	49	50	O	of
11	52	62	O	XXXXXXXX
12	64	72	O	sulfoxide
13	74	77	O	were
14	79	87	O	unchanged
NULL

Albendazole	DDI-DrugBank.d321.s3	NO_SECTION	NO_SETID	12
The pharmacokinetics of praziquantel were unchanged following coadministration with albendazole (400 mg).
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	35	U-UNK	praziquantel
5	37	40	O	were
6	42	50	O	unchanged
7	52	60	O	following
8	62	77	O	coadministration
9	79	82	O	with
10	84	94	O	XXXXXXXX
11	97	99	O	400
12	101	102	O	mg
NULL

Albendazole	DDI-DrugBank.d321.s4	NO_SECTION	NO_SETID	40
Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).
1	0	9	U-UNK	Cimetidine
2	10	10	O	:
3	12	22	O	XXXXXXXX
4	24	32	O	sulfoxide
5	34	47	O	concentrations
6	49	50	O	in
7	52	55	O	bile
8	57	59	O	and
9	61	66	O	cystic
10	68	72	O	fluid
11	74	77	O	were
12	79	87	O	increased
13	90	94	O	about
14	96	96	O	2
15	98	101	O	fold
16	104	105	O	in
17	107	113	O	hydatid
18	115	118	O	cyst
19	120	127	O	patients
20	129	135	O	treated
21	137	140	O	with
22	142	151	U-KIN	cimetidine
23	154	155	O	10
24	157	158	O	mg
25	159	159	O	/
26	160	161	O	kg
27	162	162	O	/
28	163	165	O	day
29	169	171	O	n=7
30	174	181	O	compared
31	183	186	O	with
32	188	198	O	XXXXXXXX
33	201	202	O	20
34	204	205	O	mg
35	206	206	O	/
36	207	208	O	kg
37	209	209	O	/
38	210	212	O	day
39	215	219	O	alone
40	222	225	O	n=12
NULL

Albendazole	DDI-DrugBank.d321.s5	NO_SECTION	NO_SETID	10
Albendazole sulfoxide plasma concentrations were unchanged 4 hours after dosing.
1	0	10	O	XXXXXXXX
2	12	20	O	sulfoxide
3	22	27	O	plasma
4	29	42	O	concentrations
5	44	47	O	were
6	49	57	O	unchanged
7	59	59	O	4
8	61	65	O	hours
9	67	71	O	after
10	73	78	O	dosing
NULL

Albendazole	DDI-DrugBank.d321.s6	NO_SECTION	NO_SETID	30
Theophylline: The pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.
1	0	11	U-UNK	Theophylline
2	12	12	O	:
3	14	16	O	The
4	18	33	O	pharmacokinetics
5	35	36	O	of
6	38	49	U-UNK	theophylline
7	52	64	U-UNK	aminophylline
8	66	68	O	5.8
9	70	71	O	mg
10	72	72	O	/
11	73	74	O	kg
12	76	82	O	infused
13	84	87	O	over
14	89	90	O	20
15	92	98	O	minutes
16	101	104	O	were
17	106	114	O	unchanged
18	116	124	O	following
19	126	126	O	a
20	128	133	O	single
21	135	138	O	oral
22	140	143	O	dose
23	145	146	O	of
24	148	158	O	XXXXXXXX
25	161	163	O	400
26	165	166	O	mg
27	169	170	O	in
28	172	172	O	6
29	174	180	O	healthy
30	182	189	O	subjects
NULL

Alclometasone	DDI-DrugBank.d102.s0	NO_SECTION	NO_SETID	3
No information provided
1	0	1	O	No
2	3	13	O	information
3	15	22	O	provided
NULL

Aldesleukin	DDI-DrugBank.d114.s0	NO_SECTION	NO_SETID	6
PROLEUKIN may affect central nervous function.
1	0	8	O	XXXXXXXX
2	10	12	O	may
3	14	19	O	affect
4	21	27	O	central
5	29	35	O	nervous
6	37	44	O	function
NULL

Aldesleukin	DDI-DrugBank.d114.s1	NO_SECTION	NO_SETID	22
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, sedatives, tranquilizers).
1	0	8	O	Therefore
2	9	9	O	,
3	11	22	O	interactions
4	24	28	O	could
5	30	34	O	occur
6	36	44	O	following
7	46	56	O	concomitant
8	58	71	O	administration
9	73	74	O	of
10	76	87	B-UNK	psychotropic
11	89	93	L-UNK	drugs
12	96	98	O	e.g
13	100	100	O	,
14	102	110	U-UNK	narcotics
15	111	111	O	,
16	113	122	U-UNK	analgesics
17	123	123	O	,
18	125	135	U-UNK	antiemetics
19	136	136	O	,
20	138	146	U-UNK	sedatives
21	147	147	O	,
22	149	161	U-UNK	tranquilizers
NULL

Aldesleukin	DDI-DrugBank.d114.s2	NO_SECTION	NO_SETID	39
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	33	O	drugs
5	35	44	O	possessing
6	46	56	O	nephrotoxic
7	59	61	O	e.g
8	63	63	O	,
9	65	79	U-DYN	aminoglycosides
10	80	80	O	,
11	82	93	U-DYN	indomethacin
12	95	95	O	,
13	97	106	O	myelotoxic
14	109	111	O	e.g
15	113	113	O	,
16	115	123	U-DYN	cytotoxic
17	125	136	O	chemotherapy
18	138	138	O	,
19	140	150	O	cardiotoxic
20	153	155	O	e.g
21	157	157	O	,
22	159	169	U-DYN	doxorubicin
23	172	173	O	or
24	175	185	O	hepatotoxic
25	188	190	O	e.g
26	192	192	O	,
27	194	205	U-DYN	methotrexate
28	206	206	O	,
29	208	219	U-DYN	asparaginase
30	222	228	O	effects
31	230	233	O	with
32	235	243	O	XXXXXXXX
33	245	247	O	may
34	249	256	O	increase
35	258	265	O	toxicity
36	267	268	O	in
37	270	274	O	these
38	276	280	O	organ
39	282	288	O	systems
NULL

Aldesleukin	DDI-DrugBank.d114.s3	NO_SECTION	NO_SETID	16
The safety and efficacy of PROLEUKIN in combination with any antineoplastic agents have not been established.
1	0	2	O	The
2	4	9	O	safety
3	11	13	O	and
4	15	22	O	efficacy
5	24	25	O	of
6	27	35	O	XXXXXXXX
7	37	38	O	in
8	40	50	O	combination
9	52	55	O	with
10	57	59	O	any
11	61	74	B-UNK	antineoplastic
12	76	81	L-UNK	agents
13	83	86	O	have
14	88	90	O	not
15	92	95	O	been
16	97	107	O	established
NULL

Aldesleukin	DDI-DrugBank.d114.s4	NO_SECTION	NO_SETID	28
In addition, reduced kidney and liver function secondary to PROLEUKIN treatment may delay elimination of concomitant medications and increase the risk of adverse events from those drugs.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	reduced
5	21	26	O	kidney
6	28	30	O	and
7	32	36	O	liver
8	38	45	O	function
9	47	55	O	secondary
10	57	58	O	to
11	60	68	O	XXXXXXXX
12	70	78	O	treatment
13	80	82	O	may
14	84	88	O	delay
15	90	100	O	elimination
16	102	103	O	of
17	105	115	O	concomitant
18	117	127	O	medications
19	129	131	O	and
20	133	140	O	increase
21	142	144	O	the
22	146	149	O	risk
23	151	152	O	of
24	154	160	O	adverse
25	162	167	O	events
26	169	172	O	from
27	174	178	O	those
28	180	184	O	drugs
NULL

Aldesleukin	DDI-DrugBank.d114.s5	NO_SECTION	NO_SETID	30
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
1	0	15	O	Hypersensitivity
2	17	25	O	reactions
3	27	30	O	have
4	32	35	O	been
5	37	44	O	reported
6	46	47	O	in
7	49	56	O	patients
8	58	66	O	receiving
9	68	78	O	combination
10	80	87	O	regimens
11	89	98	O	containing
12	100	109	O	sequential
13	111	114	O	high
14	116	119	O	dose
15	121	129	O	XXXXXXXX
16	131	133	O	and
17	135	148	B-DYN	antineoplastic
18	150	155	L-DYN	agents
19	156	156	O	,
20	158	169	O	specifically
21	170	170	O	,
22	172	182	U-DYN	dacarbazine
23	183	183	O	,
24	185	187	B-DYN	cis
25	189	196	L-DYN	platinum
26	197	197	O	,
27	199	207	U-DYN	tamoxifen
28	209	211	O	and
29	213	222	B-DYN	interferon
30	224	227	L-DYN	alfa
NULL

Aldesleukin	DDI-DrugBank.d114.s6	NO_SECTION	NO_SETID	18
These reactions consisted of erythema, pruritus, and hypotension and occurred within hours of administration of chemotherapy.
1	0	4	O	These
2	6	14	O	reactions
3	16	24	O	consisted
4	26	27	O	of
5	29	36	O	erythema
6	37	37	O	,
7	39	46	O	pruritus
8	47	47	O	,
9	49	51	O	and
10	53	63	O	hypotension
11	65	67	O	and
12	69	76	O	occurred
13	78	83	O	within
14	85	89	O	hours
15	91	92	O	of
16	94	107	O	administration
17	109	110	O	of
18	112	123	O	chemotherapy
NULL

Aldesleukin	DDI-DrugBank.d114.s7	NO_SECTION	NO_SETID	8
These events required medical intervention in some patients.
1	0	4	O	These
2	6	11	O	events
3	13	20	O	required
4	22	28	O	medical
5	30	41	O	intervention
6	43	44	O	in
7	46	49	O	some
8	51	58	O	patients
NULL

Aldesleukin	DDI-DrugBank.d114.s8	NO_SECTION	NO_SETID	27
Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.
1	0	9	O	Myocardial
2	11	16	O	injury
3	17	17	O	,
4	19	27	O	including
5	29	38	O	myocardial
6	40	49	O	infarction
7	50	50	O	,
8	52	62	O	myocarditis
9	63	63	O	,
10	65	75	O	ventricular
11	77	87	O	hypokinesia
12	88	88	O	,
13	90	92	O	and
14	94	99	O	severe
15	101	114	O	rhabdomyolysis
16	116	121	O	appear
17	123	124	O	to
18	126	127	O	be
19	129	137	O	increased
20	139	140	O	in
21	142	149	O	patients
22	151	159	O	receiving
23	161	169	O	XXXXXXXX
24	171	173	O	and
25	175	184	B-DYN	interferon
26	186	189	L-DYN	alfa
27	191	202	O	concurrently
NULL

Aldesleukin	DDI-DrugBank.d114.s9	NO_SECTION	NO_SETID	47
Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.
1	0	11	O	Exacerbation
2	13	14	O	or
3	16	18	O	the
4	20	26	O	initial
5	28	39	O	presentation
6	41	42	O	of
7	44	44	O	a
8	46	51	O	number
9	53	54	O	of
10	56	65	O	autoimmune
11	67	69	O	and
12	71	82	O	inflammatory
13	84	92	O	disorders
14	94	96	O	has
15	98	101	O	been
16	103	110	O	observed
17	112	120	O	following
18	122	131	O	concurrent
19	133	135	O	use
20	137	138	O	of
21	140	149	B-DYN	interferon
22	151	154	L-DYN	alfa
23	156	158	O	and
24	160	168	O	XXXXXXXX
25	169	169	O	,
26	171	179	O	including
27	181	190	O	crescentic
28	192	194	O	IgA
29	196	213	O	glomerulonephritis
30	214	214	O	,
31	216	220	O	oculo
32	222	227	O	bulbar
33	229	238	O	myasthenia
34	240	245	O	gravis
35	246	246	O	,
36	248	259	O	inflammatory
37	261	269	O	arthritis
38	270	270	O	,
39	272	282	O	thyroiditis
40	283	283	O	,
41	285	291	O	bullous
42	293	302	O	pemphigoid
43	303	303	O	,
44	305	307	O	and
45	309	315	O	Stevens
46	317	323	O	Johnson
47	325	332	O	syndrome
NULL

Aldesleukin	DDI-DrugBank.d114.s10	NO_SECTION	NO_SETID	56
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
1	0	7	O	Although
2	9	23	U-DYN	glucocorticoids
3	25	28	O	have
4	30	33	O	been
5	35	39	O	shown
6	41	42	O	to
7	44	49	O	reduce
8	51	59	O	XXXXXXXX
9	61	67	O	induced
10	69	72	O	side
11	74	80	O	effects
12	82	90	O	including
13	92	96	O	fever
14	97	97	O	,
15	99	103	O	renal
16	105	117	O	insufficiency
17	118	118	O	,
18	120	137	O	hyperbilirubinemia
19	138	138	O	,
20	140	148	O	confusion
21	149	149	O	,
22	151	153	O	and
23	155	161	O	dyspnea
24	162	162	O	,
25	164	174	O	concomitant
26	176	189	O	administration
27	191	192	O	of
28	194	198	O	these
29	200	205	O	agents
30	207	210	O	with
31	212	220	O	XXXXXXXX
32	222	224	O	may
33	226	231	O	reduce
34	233	235	O	the
35	237	245	O	antitumor
36	247	259	O	effectiveness
37	261	262	O	of
38	264	272	O	XXXXXXXX
39	274	276	O	and
40	278	281	O	thus
41	283	288	O	should
42	290	291	O	be
43	293	299	O	avoided
44	302	303	O	12
45	305	308	B-DYN	Beta
46	310	317	L-DYN	blockers
47	319	321	O	and
48	323	327	O	other
49	329	345	U-DYN	antihypertensives
50	347	349	O	may
51	351	360	O	potentiate
52	362	364	O	the
53	366	376	O	hypotension
54	378	381	O	seen
55	383	386	O	with
56	388	396	O	XXXXXXXX
NULL

Aldesleukin	DDI-DrugBank.d114.s11	NO_SECTION	NO_SETID	43
Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.
1	0	6	O	Delayed
2	8	14	O	Adverse
3	16	24	O	Reactions
4	26	27	O	to
5	29	37	B-UNK	Iodinated
6	39	46	I-UNK	Contrast
7	48	52	L-UNK	Media
8	53	53	O	:
9	55	55	O	A
10	57	62	O	review
11	64	65	O	of
12	67	69	O	the
13	71	80	O	literature
14	82	89	O	revealed
15	91	94	O	that
16	96	100	O	12.6%
17	103	107	O	range
18	109	110	O	11
19	112	114	O	28%
20	117	118	O	of
21	120	122	O	501
22	124	131	O	patients
23	133	139	O	treated
24	141	144	O	with
25	146	152	O	various
26	154	164	B-UNK	interleukin
27	166	166	L-UNK	2
28	168	177	O	containing
29	179	186	O	regimens
30	188	190	O	who
31	192	195	O	were
32	197	208	O	subsequently
33	210	221	O	administered
34	223	234	B-UNK	radiographic
35	236	244	I-UNK	iodinated
36	246	253	I-UNK	contrast
37	255	259	L-UNK	media
38	261	271	O	experienced
39	273	277	O	acute
40	278	278	O	,
41	280	287	O	atypical
42	289	295	O	adverse
43	297	305	O	reactions
NULL

Aldesleukin	DDI-DrugBank.d114.s12	NO_SECTION	NO_SETID	20
The onset of symptoms usually occurred within hours (most commonly 1 to 4 hours) following the administration of contrast media.
1	0	2	O	The
2	4	8	O	onset
3	10	11	O	of
4	13	20	O	symptoms
5	22	28	O	usually
6	30	37	O	occurred
7	39	44	O	within
8	46	50	O	hours
9	53	56	O	most
10	58	65	O	commonly
11	67	67	O	1
12	69	70	O	to
13	72	72	O	4
14	74	78	O	hours
15	81	89	O	following
16	91	93	O	the
17	95	108	O	administration
18	110	111	O	of
19	113	120	O	contrast
20	122	126	O	media
NULL

Aldesleukin	DDI-DrugBank.d114.s13	NO_SECTION	NO_SETID	23
These reactions include fever, chills, nausea, vomiting, pruritus, rash, diarrhea, hypotension, edema, and oliguria.
1	0	4	O	These
2	6	14	O	reactions
3	16	22	O	include
4	24	28	O	fever
5	29	29	O	,
6	31	36	O	chills
7	37	37	O	,
8	39	44	O	nausea
9	45	45	O	,
10	47	54	O	vomiting
11	55	55	O	,
12	57	64	O	pruritus
13	65	65	O	,
14	67	70	O	rash
15	71	71	O	,
16	73	80	O	diarrhea
17	81	81	O	,
18	83	93	O	hypotension
19	94	94	O	,
20	96	100	O	edema
21	101	101	O	,
22	103	105	O	and
23	107	114	O	oliguria
NULL

Aldesleukin	DDI-DrugBank.d114.s14	NO_SECTION	NO_SETID	30
Some clinicians have noted that these reactions resemble the immediate side effects caused by interleukin-2 administration, however the cause of contrast reactions after interleukin-2 therapy is unknown.
1	0	3	O	Some
2	5	14	O	clinicians
3	16	19	O	have
4	21	25	O	noted
5	27	30	O	that
6	32	36	O	these
7	38	46	O	reactions
8	48	55	O	resemble
9	57	59	O	the
10	61	69	O	immediate
11	71	74	O	side
12	76	82	O	effects
13	84	89	O	caused
14	91	92	O	by
15	94	104	B-UNK	interleukin
16	106	106	L-UNK	2
17	108	121	O	administration
18	122	122	O	,
19	124	130	O	however
20	132	134	O	the
21	136	140	O	cause
22	142	143	O	of
23	145	152	O	contrast
24	154	162	O	reactions
25	164	168	O	after
26	170	180	O	interleukin
27	182	182	O	2
28	184	190	O	therapy
29	192	193	O	is
30	195	201	O	unknown
NULL

Aldesleukin	DDI-DrugBank.d114.s15	NO_SECTION	NO_SETID	21
Most events were reported to occur when contrast media was given within 4 weeks after the last dose of interleukin-2.
1	0	3	O	Most
2	5	10	O	events
3	12	15	O	were
4	17	24	O	reported
5	26	27	O	to
6	29	33	O	occur
7	35	38	O	when
8	40	47	O	contrast
9	49	53	O	media
10	55	57	O	was
11	59	63	O	given
12	65	70	O	within
13	72	72	O	4
14	74	78	O	weeks
15	80	84	O	after
16	86	88	O	the
17	90	93	O	last
18	95	98	O	dose
19	100	101	O	of
20	103	113	B-UNK	interleukin
21	115	115	L-UNK	2
NULL

Aldesleukin	DDI-DrugBank.d114.s16	NO_SECTION	NO_SETID	18
These events were also reported to occur when contrast media was given several months after interleukin-2 treatment.
1	0	4	O	These
2	6	11	O	events
3	13	16	O	were
4	18	21	O	also
5	23	30	O	reported
6	32	33	O	to
7	35	39	O	occur
8	41	44	O	when
9	46	53	O	contrast
10	55	59	O	media
11	61	63	O	was
12	65	69	O	given
13	71	77	O	several
14	79	84	O	months
15	86	90	O	after
16	92	102	B-UNK	interleukin
17	104	104	L-UNK	2
18	106	114	O	treatment
NULL

Alefacept	DDI-DrugBank.d491.s0	NO_SECTION	NO_SETID	7
No formal interaction studies have been performed.
1	0	1	O	No
2	3	8	O	formal
3	10	20	O	interaction
4	22	28	O	studies
5	30	33	O	have
6	35	38	O	been
7	40	48	O	performed
NULL

Alefacept	DDI-DrugBank.d491.s1	NO_SECTION	NO_SETID	21
The duration of the period following treatment with AMEVIVE  before one should consider starting other immunosuppressive therapy has not been evaluated.
1	0	2	O	The
2	4	11	O	duration
3	13	14	O	of
4	16	18	O	the
5	20	25	O	period
6	27	35	O	following
7	37	45	O	treatment
8	47	50	O	with
9	52	58	O	XXXXXXXX
10	61	66	O	before
11	68	70	O	one
12	72	77	O	should
13	79	86	O	consider
14	88	95	O	starting
15	97	101	O	other
16	103	119	U-UNK	immunosuppressive
17	121	127	O	therapy
18	129	131	O	has
19	133	135	O	not
20	137	140	O	been
21	142	150	O	evaluated
NULL

Alefacept	DDI-DrugBank.d491.s2	NO_SECTION	NO_SETID	6
Carcinogenesis, Mutagenesis, and Fertility
1	0	13	O	Carcinogenesis
2	14	14	O	,
3	16	26	O	Mutagenesis
4	27	27	O	,
5	29	31	O	and
6	33	41	O	Fertility
NULL

Alefacept	DDI-DrugBank.d491.s3	NO_SECTION	NO_SETID	31
In a chronic toxicity study, cynomolgus monkeys were dosed weekly for 52 weeks with intravenous alefacept at 1 mg/kg/dose or 20 mg/kg/dose.
1	0	1	O	In
2	3	3	O	a
3	5	11	O	chronic
4	13	20	O	toxicity
5	22	26	O	study
6	27	27	O	,
7	29	38	O	cynomolgus
8	40	46	O	monkeys
9	48	51	O	were
10	53	57	O	dosed
11	59	64	O	weekly
12	66	68	O	for
13	70	71	O	52
14	73	77	O	weeks
15	79	82	O	with
16	84	94	O	intravenous
17	96	104	O	XXXXXXXX
18	106	107	O	at
19	109	109	O	1
20	111	112	O	mg
21	113	113	O	/
22	114	115	O	kg
23	116	116	O	/
24	117	120	O	dose
25	122	123	O	or
26	125	126	O	20
27	128	129	O	mg
28	130	130	O	/
29	131	132	O	kg
30	133	133	O	/
31	134	137	O	dose
NULL

Alefacept	DDI-DrugBank.d491.s4	NO_SECTION	NO_SETID	20
One animal in the high dose group developed a B-cell lymphoma that was detected after 28 weeks of dosing.
1	0	2	O	One
2	4	9	O	animal
3	11	12	O	in
4	14	16	O	the
5	18	21	O	high
6	23	26	O	dose
7	28	32	O	group
8	34	42	O	developed
9	44	44	O	a
10	46	46	O	B
11	48	51	O	cell
12	53	60	O	lymphoma
13	62	65	O	that
14	67	69	O	was
15	71	78	O	detected
16	80	84	O	after
17	86	87	O	28
18	89	93	O	weeks
19	95	96	O	of
20	98	103	O	dosing
NULL

Alefacept	DDI-DrugBank.d491.s5	NO_SECTION	NO_SETID	16
Additional animals in both dose groups developed B-cell hyperplasia of the spleen and lymph nodes.
1	0	9	O	Additional
2	11	17	O	animals
3	19	20	O	in
4	22	25	O	both
5	27	30	O	dose
6	32	37	O	groups
7	39	47	O	developed
8	49	49	O	B
9	51	54	O	cell
10	56	66	O	hyperplasia
11	68	69	O	of
12	71	73	O	the
13	75	80	O	spleen
14	82	84	O	and
15	86	90	O	lymph
16	92	96	O	nodes
NULL

Alefacept	DDI-DrugBank.d491.s6	NO_SECTION	NO_SETID	18
All animals in the study were positive for an endemic primate gammaherpes virus also known as lymphocryptovirus (LCV).
1	0	2	O	All
2	4	10	O	animals
3	12	13	O	in
4	15	17	O	the
5	19	23	O	study
6	25	28	O	were
7	30	37	O	positive
8	39	41	O	for
9	43	44	O	an
10	46	52	O	endemic
11	54	60	O	primate
12	62	72	O	gammaherpes
13	74	78	O	virus
14	80	83	O	also
15	85	89	O	known
16	91	92	O	as
17	94	110	O	lymphocryptovirus
18	113	115	O	LCV
NULL

Alefacept	DDI-DrugBank.d491.s7	NO_SECTION	NO_SETID	19
Latent LCV infection is generally asymptomatic, but can lead to B-cell lymphomas when animals are immune suppressed.
1	0	5	O	Latent
2	7	9	O	LCV
3	11	19	O	infection
4	21	22	O	is
5	24	32	O	generally
6	34	45	O	asymptomatic
7	46	46	O	,
8	48	50	O	but
9	52	54	O	can
10	56	59	O	lead
11	61	62	O	to
12	64	64	O	B
13	66	69	O	cell
14	71	79	O	lymphomas
15	81	84	O	when
16	86	92	O	animals
17	94	96	O	are
18	98	103	O	immune
19	105	114	O	suppressed
NULL

Alefacept	DDI-DrugBank.d491.s8	NO_SECTION	NO_SETID	43
In a separate study, baboons given 3 doses of alefacept at 1 mg/kg every 8 weeks were found to have centroblast proliferation in B-cell dependent areas in the germinal centers of the spleen following a 116-day washout period.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	separate
4	14	18	O	study
5	19	19	O	,
6	21	27	O	baboons
7	29	33	O	given
8	35	35	O	3
9	37	41	O	doses
10	43	44	O	of
11	46	54	O	XXXXXXXX
12	56	57	O	at
13	59	59	O	1
14	61	62	O	mg
15	63	63	O	/
16	64	65	O	kg
17	67	71	O	every
18	73	73	O	8
19	75	79	O	weeks
20	81	84	O	were
21	86	90	O	found
22	92	93	O	to
23	95	98	O	have
24	100	110	O	centroblast
25	112	124	O	proliferation
26	126	127	O	in
27	129	129	O	B
28	131	134	O	cell
29	136	144	O	dependent
30	146	150	O	areas
31	152	153	O	in
32	155	157	O	the
33	159	166	O	germinal
34	168	174	O	centers
35	176	177	O	of
36	179	181	O	the
37	183	188	O	spleen
38	190	198	O	following
39	200	200	O	a
40	202	204	O	116
41	206	208	O	day
42	210	216	O	washout
43	218	223	O	period
NULL

Alefacept	DDI-DrugBank.d491.s9	NO_SECTION	NO_SETID	26
The role of AMEVIVE in the development of the lymphoid malignancy and the hyperplasia observed in non-human primates and the relevance to humans is unknown.
1	0	2	O	The
2	4	7	O	role
3	9	10	O	of
4	12	18	O	XXXXXXXX
5	20	21	O	in
6	23	25	O	the
7	27	37	O	development
8	39	40	O	of
9	42	44	O	the
10	46	53	O	lymphoid
11	55	64	O	malignancy
12	66	68	O	and
13	70	72	O	the
14	74	84	O	hyperplasia
15	86	93	O	observed
16	95	96	O	in
17	98	100	O	non
18	102	106	O	human
19	108	115	O	primates
20	117	119	O	and
21	121	123	O	the
22	125	133	O	relevance
23	135	136	O	to
24	138	143	O	humans
25	145	146	O	is
26	148	154	O	unknown
NULL

Alefacept	DDI-DrugBank.d491.s10	NO_SECTION	NO_SETID	29
Immunodeficiency-associated lymphocyte disorders (plasmacytic hyperplasia, polymorphic proliferation, and B-cell lymphomas) occur in patients who have congenital or acquired immunodeficiencies including those resulting from immunosuppressive therapy.
1	0	15	O	Immunodeficiency
2	17	26	O	associated
3	28	37	O	lymphocyte
4	39	47	O	disorders
5	50	60	O	plasmacytic
6	62	72	O	hyperplasia
7	73	73	O	,
8	75	85	O	polymorphic
9	87	99	O	proliferation
10	100	100	O	,
11	102	104	O	and
12	106	106	O	B
13	108	111	O	cell
14	113	121	O	lymphomas
15	124	128	O	occur
16	130	131	O	in
17	133	140	O	patients
18	142	144	O	who
19	146	149	O	have
20	151	160	O	congenital
21	162	163	O	or
22	165	172	O	acquired
23	174	191	O	immunodeficiencies
24	193	201	O	including
25	203	207	O	those
26	209	217	O	resulting
27	219	222	O	from
28	224	240	U-UNK	immunosuppressive
29	242	248	O	therapy
NULL

Alefacept	DDI-DrugBank.d491.s11	NO_SECTION	NO_SETID	7
No carcinogenicity or fertility studies were conducted.
1	0	1	O	No
2	3	17	O	carcinogenicity
3	19	20	O	or
4	22	30	O	fertility
5	32	38	O	studies
6	40	43	O	were
7	45	53	O	conducted
NULL

Alefacept	DDI-DrugBank.d491.s12	NO_SECTION	NO_SETID	9
Mutagenicity studies were conducted in vitro and in vivo;
1	0	11	O	Mutagenicity
2	13	19	O	studies
3	21	24	O	were
4	26	34	O	conducted
5	36	37	O	in
6	39	43	O	vitro
7	45	47	O	and
8	49	50	O	in
9	52	55	O	vivo
NULL

Alefacept	DDI-DrugBank.d491.s13	NO_SECTION	NO_SETID	6
no evidence of mutagenicity was observed.
1	0	1	O	no
2	3	10	O	evidence
3	12	13	O	of
4	15	26	O	mutagenicity
5	28	30	O	was
6	32	39	O	observed
NULL

Alefacept	DDI-DrugBank.d491.s14	NO_SECTION	NO_SETID	3
Pregnancy (Category B)
1	0	8	O	Pregnancy
2	11	18	O	Category
3	20	20	O	B
NULL

Alefacept	DDI-DrugBank.d491.s15	NO_SECTION	NO_SETID	16
Women of childbearing potential make up a considerable segment of the patient population affected by psoriasis.
1	0	4	O	Women
2	6	7	O	of
3	9	20	O	childbearing
4	22	30	O	potential
5	32	35	O	make
6	37	38	O	up
7	40	40	O	a
8	42	53	O	considerable
9	55	61	O	segment
10	63	64	O	of
11	66	68	O	the
12	70	76	O	patient
13	78	87	O	population
14	89	96	O	affected
15	98	99	O	by
16	101	109	O	psoriasis
NULL

Alefacept	DDI-DrugBank.d491.s16	NO_SECTION	NO_SETID	48
Since the effect of AMEVIVE on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking AMEVIVE who become pregnant into the Biogen Pregnancy Registry by calling 1-866-AMEVIVE (1-866-263-8483).
1	0	4	O	Since
2	6	8	O	the
3	10	15	O	effect
4	17	18	O	of
5	20	26	O	XXXXXXXX
6	28	29	O	on
7	31	39	O	pregnancy
8	41	43	O	and
9	45	49	O	fetal
10	51	61	O	development
11	62	62	O	,
12	64	72	O	including
13	74	79	O	immune
14	81	86	O	system
15	88	98	O	development
16	99	99	O	,
17	101	102	O	is
18	104	106	O	not
19	108	112	O	known
20	113	113	O	,
21	115	120	O	health
22	122	125	O	care
23	127	135	O	providers
24	137	139	O	are
25	141	150	O	encouraged
26	152	153	O	to
27	155	160	O	enroll
28	162	169	O	patients
29	171	179	O	currently
30	181	186	O	taking
31	188	194	O	XXXXXXXX
32	196	198	O	who
33	200	205	O	become
34	207	214	O	pregnant
35	216	219	O	into
36	221	223	O	the
37	225	230	O	Biogen
38	232	240	O	Pregnancy
39	242	249	O	Registry
40	251	252	O	by
41	254	260	O	calling
42	262	262	O	1
43	264	266	O	866
44	268	274	O	XXXXXXXX
45	277	277	O	1
46	279	281	O	866
47	283	285	O	263
48	287	290	O	8483
NULL

Alefacept	DDI-DrugBank.d491.s17	NO_SECTION	NO_SETID	45
Reproductive toxicology studies have been performed in cynomolgus monkeys at doses up to 5 mg/kg/week (about 62 times the human dose based on body weight) and have revealed no evidence of impaired fertility or harm to the fetus due to AMEVIVE.
1	0	11	O	Reproductive
2	13	22	O	toxicology
3	24	30	O	studies
4	32	35	O	have
5	37	40	O	been
6	42	50	O	performed
7	52	53	O	in
8	55	64	O	cynomolgus
9	66	72	O	monkeys
10	74	75	O	at
11	77	81	O	doses
12	83	84	O	up
13	86	87	O	to
14	89	89	O	5
15	91	92	O	mg
16	93	93	O	/
17	94	95	O	kg
18	96	96	O	/
19	97	100	O	week
20	103	107	O	about
21	109	110	O	62
22	112	116	O	times
23	118	120	O	the
24	122	126	O	human
25	128	131	O	dose
26	133	137	O	based
27	139	140	O	on
28	142	145	O	body
29	147	152	O	weight
30	155	157	O	and
31	159	162	O	have
32	164	171	O	revealed
33	173	174	O	no
34	176	183	O	evidence
35	185	186	O	of
36	188	195	O	impaired
37	197	205	O	fertility
38	207	208	O	or
39	210	213	O	harm
40	215	216	O	to
41	218	220	O	the
42	222	226	O	fetus
43	228	230	O	due
44	232	233	O	to
45	235	241	O	XXXXXXXX
NULL

Alefacept	DDI-DrugBank.d491.s18	NO_SECTION	NO_SETID	25
No abortifacient or teratogenic effects were observed in cynomolgus monkeys following intravenous bolus injections of AMEVIVE administered weekly during the period of organogenesis to gestation.
1	0	1	O	No
2	3	15	O	abortifacient
3	17	18	O	or
4	20	30	O	teratogenic
5	32	38	O	effects
6	40	43	O	were
7	45	52	O	observed
8	54	55	O	in
9	57	66	O	cynomolgus
10	68	74	O	monkeys
11	76	84	O	following
12	86	96	O	intravenous
13	98	102	O	bolus
14	104	113	O	injections
15	115	116	O	of
16	118	124	O	XXXXXXXX
17	126	137	O	administered
18	139	144	O	weekly
19	146	151	O	during
20	153	155	O	the
21	157	162	O	period
22	164	165	O	of
23	167	179	O	organogenesis
24	181	182	O	to
25	184	192	O	gestation
NULL

Alefacept	DDI-DrugBank.d491.s19	NO_SECTION	NO_SETID	14
AMEVIVE underwent trans-placental passage and produced in utero exposure in the developing monkeys.
1	0	6	O	XXXXXXXX
2	8	16	O	underwent
3	18	22	O	trans
4	24	32	O	placental
5	34	40	O	passage
6	42	44	O	and
7	46	53	O	produced
8	55	56	O	in
9	58	62	O	utero
10	64	71	O	exposure
11	73	74	O	in
12	76	78	O	the
13	80	89	O	developing
14	91	97	O	monkeys
NULL

Alefacept	DDI-DrugBank.d491.s20	NO_SECTION	NO_SETID	16
In utero, serum levels of exposure in these monkeys were 23% of maternal serum levels.
1	0	1	O	In
2	3	7	O	utero
3	8	8	O	,
4	10	14	O	serum
5	16	21	O	levels
6	23	24	O	of
7	26	33	O	exposure
8	35	36	O	in
9	38	42	O	these
10	44	50	O	monkeys
11	52	55	O	were
12	57	59	O	23%
13	61	62	O	of
14	64	71	O	maternal
15	73	77	O	serum
16	79	84	O	levels
NULL

Alefacept	DDI-DrugBank.d491.s21	NO_SECTION	NO_SETID	19
No evidence of fetal toxicity including adverse effects on immune system development was observed in any of these animals.
1	0	1	O	No
2	3	10	O	evidence
3	12	13	O	of
4	15	19	O	fetal
5	21	28	O	toxicity
6	30	38	O	including
7	40	46	O	adverse
8	48	54	O	effects
9	56	57	O	on
10	59	64	O	immune
11	66	71	O	system
12	73	83	O	development
13	85	87	O	was
14	89	96	O	observed
15	98	99	O	in
16	101	103	O	any
17	105	106	O	of
18	108	112	O	these
19	114	120	O	animals
NULL

Alefacept	DDI-DrugBank.d491.s22	NO_SECTION	NO_SETID	25
Animal reproduction studies, however, are not always predictive of human response and there are no adequate and well-controlled studies in pregnant women.
1	0	5	O	Animal
2	7	18	O	reproduction
3	20	26	O	studies
4	27	27	O	,
5	29	35	O	however
6	36	36	O	,
7	38	40	O	are
8	42	44	O	not
9	46	51	O	always
10	53	62	O	predictive
11	64	65	O	of
12	67	71	O	human
13	73	80	O	response
14	82	84	O	and
15	86	90	O	there
16	92	94	O	are
17	96	97	O	no
18	99	106	O	adequate
19	108	110	O	and
20	112	115	O	well
21	117	126	O	controlled
22	128	134	O	studies
23	136	137	O	in
24	139	146	O	pregnant
25	148	152	O	women
NULL

Alefacept	DDI-DrugBank.d491.s23	NO_SECTION	NO_SETID	30
Because the risk to the development of the fetal immune system and postnatal immune function in humans is unknown, AMEVIVE  should be used during pregnancy only if clearly needed.
1	0	6	O	Because
2	8	10	O	the
3	12	15	O	risk
4	17	18	O	to
5	20	22	O	the
6	24	34	O	development
7	36	37	O	of
8	39	41	O	the
9	43	47	O	fetal
10	49	54	O	immune
11	56	61	O	system
12	63	65	O	and
13	67	75	O	postnatal
14	77	82	O	immune
15	84	91	O	function
16	93	94	O	in
17	96	101	O	humans
18	103	104	O	is
19	106	112	O	unknown
20	113	113	O	,
21	115	121	O	XXXXXXXX
22	124	129	O	should
23	131	132	O	be
24	134	137	O	used
25	139	144	O	during
26	146	154	O	pregnancy
27	156	159	O	only
28	161	162	O	if
29	164	170	O	clearly
30	172	177	O	needed
NULL

Alefacept	DDI-DrugBank.d491.s24	NO_SECTION	NO_SETID	15
If pregnancy occurs while taking AMEVIVE, continued use of the drug should be assessed.
1	0	1	O	If
2	3	11	O	pregnancy
3	13	18	O	occurs
4	20	24	O	while
5	26	31	O	taking
6	33	39	O	XXXXXXXX
7	40	40	O	,
8	42	50	O	continued
9	52	54	O	use
10	56	57	O	of
11	59	61	O	the
12	63	66	O	drug
13	68	73	O	should
14	75	76	O	be
15	78	85	O	assessed
NULL

Alefacept	DDI-DrugBank.d491.s26	NO_SECTION	NO_SETID	11
It is not known whether AMEVIVE is excreted in human milk.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	known
5	16	22	O	whether
6	24	30	O	XXXXXXXX
7	32	33	O	is
8	35	42	O	excreted
9	44	45	O	in
10	47	51	O	human
11	53	56	O	milk
NULL

Alefacept	DDI-DrugBank.d491.s27	NO_SECTION	NO_SETID	58
Because many drugs are excreted in human milk, and because there exists the potential for serious adverse reactions in nursing infants from AMEVIVE, a decision should be made whether to discontinue nursing while taking the drug or to discontinue the use of the drug, taking into account the importance of the drug to the mother.
1	0	6	O	Because
2	8	11	O	many
3	13	17	O	drugs
4	19	21	O	are
5	23	30	O	excreted
6	32	33	O	in
7	35	39	O	human
8	41	44	O	milk
9	45	45	O	,
10	47	49	O	and
11	51	57	O	because
12	59	63	O	there
13	65	70	O	exists
14	72	74	O	the
15	76	84	O	potential
16	86	88	O	for
17	90	96	O	serious
18	98	104	O	adverse
19	106	114	O	reactions
20	116	117	O	in
21	119	125	O	nursing
22	127	133	O	infants
23	135	138	O	from
24	140	146	O	XXXXXXXX
25	147	147	O	,
26	149	149	O	a
27	151	158	O	decision
28	160	165	O	should
29	167	168	O	be
30	170	173	O	made
31	175	181	O	whether
32	183	184	O	to
33	186	196	O	discontinue
34	198	204	O	nursing
35	206	210	O	while
36	212	217	O	taking
37	219	221	O	the
38	223	226	O	drug
39	228	229	O	or
40	231	232	O	to
41	234	244	O	discontinue
42	246	248	O	the
43	250	252	O	use
44	254	255	O	of
45	257	259	O	the
46	261	264	O	drug
47	265	265	O	,
48	267	272	O	taking
49	274	277	O	into
50	279	285	O	account
51	287	289	O	the
52	291	300	O	importance
53	302	303	O	of
54	305	307	O	the
55	309	312	O	drug
56	314	315	O	to
57	317	319	O	the
58	321	326	O	mother
NULL

Alefacept	DDI-DrugBank.d491.s29	NO_SECTION	NO_SETID	17
Of the 1357 patients who received AMEVIVE in clinical trials, a total of 100 patients were
1	0	1	O	Of
2	3	5	O	the
3	7	10	O	1357
4	12	19	O	patients
5	21	23	O	who
6	25	32	O	received
7	34	40	O	XXXXXXXX
8	42	43	O	in
9	45	52	O	clinical
10	54	59	O	trials
11	60	60	O	,
12	62	62	O	a
13	64	68	O	total
14	70	71	O	of
15	73	75	O	100
16	77	84	O	patients
17	86	89	O	were
NULL

Alefacept	DDI-DrugBank.d491.s30	NO_SECTION	NO_SETID	8
65 years of age and 13 patients were
1	0	1	O	65
2	3	7	O	years
3	9	10	O	of
4	12	14	O	age
5	16	18	O	and
6	20	21	O	13
7	23	30	O	patients
8	32	35	O	were
NULL

Alefacept	DDI-DrugBank.d491.s32	NO_SECTION	NO_SETID	24
No differences in safety or efficacy were observed between older and younger patients, but there were not sufficient data to exclude important differences.
1	0	1	O	No
2	3	13	O	differences
3	15	16	O	in
4	18	23	O	safety
5	25	26	O	or
6	28	35	O	efficacy
7	37	40	O	were
8	42	49	O	observed
9	51	57	O	between
10	59	63	O	older
11	65	67	O	and
12	69	75	O	younger
13	77	84	O	patients
14	85	85	O	,
15	87	89	O	but
16	91	95	O	there
17	97	100	O	were
18	102	104	O	not
19	106	115	O	sufficient
20	117	120	O	data
21	122	123	O	to
22	125	131	O	exclude
23	133	141	O	important
24	143	153	O	differences
NULL

Alefacept	DDI-DrugBank.d491.s33	NO_SECTION	NO_SETID	26
Because the incidence of infections and certain malignancies is higher in the elderly population, in general, caution should be used in treating the elderly.
1	0	6	O	Because
2	8	10	O	the
3	12	20	O	incidence
4	22	23	O	of
5	25	34	O	infections
6	36	38	O	and
7	40	46	O	certain
8	48	59	O	malignancies
9	61	62	O	is
10	64	69	O	higher
11	71	72	O	in
12	74	76	O	the
13	78	84	O	elderly
14	86	95	O	population
15	96	96	O	,
16	98	99	O	in
17	101	107	O	general
18	108	108	O	,
19	110	116	O	caution
20	118	123	O	should
21	125	126	O	be
22	128	131	O	used
23	133	134	O	in
24	136	143	O	treating
25	145	147	O	the
26	149	155	O	elderly
NULL

Alefacept	DDI-DrugBank.d491.s35	NO_SECTION	NO_SETID	13
The safety and efficacy of AMEVIVE in pediatric patients have not been studied.
1	0	2	O	The
2	4	9	O	safety
3	11	13	O	and
4	15	22	O	efficacy
5	24	25	O	of
6	27	33	O	XXXXXXXX
7	35	36	O	in
8	38	46	O	pediatric
9	48	55	O	patients
10	57	60	O	have
11	62	64	O	not
12	66	69	O	been
13	71	77	O	studied
NULL

Alefacept	DDI-DrugBank.d491.s36	NO_SECTION	NO_SETID	7
AMEVIVE is not indicated for pediatric patients.
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	13	O	not
4	15	23	O	indicated
5	25	27	O	for
6	29	37	O	pediatric
7	39	46	O	patients
NULL

Alemtuzumab	DDI-DrugBank.d407.s0	NO_SECTION	NO_SETID	14
Drug/Laboratory Interactions No formal drug interaction studies have been performed with Campath.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	27	O	Interactions
5	29	30	O	No
6	32	37	O	formal
7	39	42	O	drug
8	44	54	O	interaction
9	56	62	O	studies
10	64	67	O	have
11	69	72	O	been
12	74	82	O	performed
13	84	87	O	with
14	89	95	O	XXXXXXXX
NULL

Alemtuzumab	DDI-DrugBank.d407.s1	NO_SECTION	NO_SETID	15
An immune response to Campath may interfere with subsequent diagnostic serum tests that utilize antibodies
1	0	1	O	An
2	3	8	O	immune
3	10	17	O	response
4	19	20	O	to
5	22	28	O	XXXXXXXX
6	30	32	O	may
7	34	42	O	interfere
8	44	47	O	with
9	49	58	O	subsequent
10	60	69	O	diagnostic
11	71	75	O	serum
12	77	81	O	tests
13	83	86	O	that
14	88	94	O	utilize
15	96	105	U-UNK	antibodies
NULL

Alendronate	DDI-DrugBank.d430.s0	NO_SECTION	NO_SETID	11
Intravenous ranitidine was shown to double the bioavailability of oral alendronate.
1	0	10	O	Intravenous
2	12	21	U-KIN	ranitidine
3	23	25	O	was
4	27	31	O	shown
5	33	34	O	to
6	36	41	O	double
7	43	45	O	the
8	47	61	O	bioavailability
9	63	64	O	of
10	66	69	O	oral
11	71	81	O	XXXXXXXX
NULL

Alendronate	DDI-DrugBank.d430.s1	NO_SECTION	NO_SETID	21
The clinical significance of this increased bioavailability and whether similar increases will occur in patients given oral H2-antagonists is unknown;
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	42	O	increased
7	44	58	O	bioavailability
8	60	62	O	and
9	64	70	O	whether
10	72	78	O	similar
11	80	88	O	increases
12	90	93	O	will
13	95	99	O	occur
14	101	102	O	in
15	104	111	O	patients
16	113	117	O	given
17	119	122	O	oral
18	124	125	B-UNK	H2
19	127	137	L-UNK	antagonists
20	139	140	O	is
21	142	148	O	unknown
NULL

Alendronate	DDI-DrugBank.d430.s2	NO_SECTION	NO_SETID	8
no other specific drug interaction studies were performed.
1	0	1	O	no
2	3	7	O	other
3	9	16	O	specific
4	18	21	O	drug
5	23	33	O	interaction
6	35	41	O	studies
7	43	46	O	were
8	48	56	O	performed
NULL

Alendronate	DDI-DrugBank.d430.s3	NO_SECTION	NO_SETID	14
Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.
1	0	7	O	Products
2	9	18	O	containing
3	20	26	U-KIN	calcium
4	28	30	O	and
5	32	36	O	other
6	38	48	B-KIN	multivalent
7	50	56	L-KIN	cations
8	58	63	O	likely
9	65	68	O	will
10	70	78	O	interfere
11	80	83	O	with
12	85	94	O	absorption
13	96	97	O	of
14	99	109	O	XXXXXXXX
NULL

Alfentanil	DDI-DrugBank.d8.s0	NO_SECTION	NO_SETID	37
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
1	0	3	O	Both
2	5	7	O	the
3	9	17	O	magnitude
4	19	21	O	and
5	23	30	O	duration
6	32	33	O	of
7	35	41	O	central
8	43	49	O	nervous
9	51	56	O	system
10	58	60	O	and
11	62	75	O	cardiovascular
12	77	83	O	effects
13	85	87	O	may
14	89	90	O	be
15	92	99	O	enhanced
16	101	104	O	when
17	106	112	O	XXXXXXXX
18	114	115	O	is
19	117	128	O	administered
20	130	131	O	in
21	133	143	O	combination
22	145	148	O	with
23	150	154	O	other
24	156	158	B-DYN	CNS
25	160	170	L-DYN	depressants
26	172	175	O	such
27	177	178	O	as
28	180	191	U-DYN	barbiturates
29	192	192	O	,
30	194	206	U-DYN	tranquilizers
31	207	207	O	,
32	209	215	U-DYN	opioids
33	216	216	O	,
34	218	219	O	or
35	221	230	O	inhalation
36	232	238	O	general
37	240	250	U-DYN	anesthetics
NULL

Alfentanil	DDI-DrugBank.d8.s1	NO_SECTION	NO_SETID	11
Postoperative respiratory depression may be enhanced or prolonged by these agents.
1	0	12	O	Postoperative
2	14	24	O	respiratory
3	26	35	O	depression
4	37	39	O	may
5	41	42	O	be
6	44	51	O	enhanced
7	53	54	O	or
8	56	64	O	prolonged
9	66	67	O	by
10	69	73	O	these
11	75	80	O	agents
NULL

Alfentanil	DDI-DrugBank.d8.s2	NO_SECTION	NO_SETID	17
In such cases of combined treatment, the dose of one or both agents should be reduced.
1	0	1	O	In
2	3	6	O	such
3	8	12	O	cases
4	14	15	O	of
5	17	24	O	combined
6	26	34	O	treatment
7	35	35	O	,
8	37	39	O	the
9	41	44	O	dose
10	46	47	O	of
11	49	51	O	one
12	53	54	O	or
13	56	59	O	both
14	61	66	O	agents
15	68	73	O	should
16	75	76	O	be
17	78	84	O	reduced
NULL

Alfentanil	DDI-DrugBank.d8.s3	NO_SECTION	NO_SETID	48
Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
1	0	6	O	Limited
2	8	15	O	clinical
3	17	26	O	experience
4	28	36	O	indicates
5	38	41	O	that
6	43	54	O	requirements
7	56	58	O	for
8	60	67	B-KIN	volatile
9	69	78	I-KIN	inhalation
10	80	90	L-KIN	anesthetics
11	92	94	O	are
12	96	102	O	reduced
13	104	105	O	by
14	107	108	O	30
15	110	111	O	to
16	113	115	O	50%
17	117	119	O	for
18	121	123	O	the
19	125	129	O	first
20	131	135	O	sixty
21	138	139	O	60
22	142	148	O	minutes
23	150	158	O	following
24	160	166	O	XXXXXXXX
25	168	176	O	induction
26	178	180	O	The
27	182	192	O	concomitant
28	194	196	O	use
29	198	199	O	of
30	201	212	U-KIN	erythromycin
31	214	217	O	with
32	219	225	O	XXXXXXXX
33	227	229	O	can
34	231	243	O	significantly
35	245	251	O	inhibit
36	253	259	O	XXXXXXXX
37	261	269	O	clearance
38	271	273	O	and
39	275	277	O	may
40	279	286	O	increase
41	288	290	O	the
42	292	295	O	risk
43	297	298	O	of
44	300	308	O	prolonged
45	310	311	O	or
46	313	319	O	delayed
47	321	331	O	respiratory
48	333	342	O	depression
NULL

Alfentanil	DDI-DrugBank.d8.s4	NO_SECTION	NO_SETID	6
Cimetidine reduces the clearance of ALFENTA.
1	0	9	U-KIN	Cimetidine
2	11	17	O	reduces
3	19	21	O	the
4	23	31	O	clearance
5	33	34	O	of
6	36	42	O	XXXXXXXX
NULL

Alfentanil	DDI-DrugBank.d8.s5	NO_SECTION	NO_SETID	20
Therefore smaller ALFENTA doses will be required with prolonged administration and the duration of action of ALFENTA my be extended.
1	0	8	O	Therefore
2	10	16	O	smaller
3	18	24	O	XXXXXXXX
4	26	30	O	doses
5	32	35	O	will
6	37	38	O	be
7	40	47	O	required
8	49	52	O	with
9	54	62	O	prolonged
10	64	77	O	administration
11	79	81	O	and
12	83	85	O	the
13	87	94	O	duration
14	96	97	O	of
15	99	104	O	action
16	106	107	O	of
17	109	115	O	XXXXXXXX
18	117	118	O	my
19	120	121	O	be
20	123	130	O	extended
NULL

Alfentanil	DDI-DrugBank.d8.s6	NO_SECTION	NO_SETID	18
Perioperative administration of drugs affecting hepatic blood flow or enzyme function may reduce plasma clearance and prolong recovery.
1	0	12	O	Perioperative
2	14	27	O	administration
3	29	30	O	of
4	32	36	O	drugs
5	38	46	O	affecting
6	48	54	O	hepatic
7	56	60	O	blood
8	62	65	O	flow
9	67	68	O	or
10	70	75	O	enzyme
11	77	84	O	function
12	86	88	O	may
13	90	95	O	reduce
14	97	102	O	plasma
15	104	112	O	clearance
16	114	116	O	and
17	118	124	O	prolong
18	126	133	O	recovery
NULL

Alfuzosin	DDI-DrugBank.d273.s0	NO_SECTION	NO_SETID	19
Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between UROXATRAL and other alpha-blockers have not been determined.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	21	O	Interactions
4	22	22	O	:
5	24	26	O	The
6	28	42	O	pharmacokinetic
7	44	46	O	and
8	48	62	O	pharmacodynamic
9	64	75	O	interactions
10	77	83	O	between
11	85	93	O	XXXXXXXX
12	95	97	O	and
13	99	103	O	other
14	105	109	B-UNK	alpha
15	111	118	L-UNK	blockers
16	120	123	O	have
17	125	127	O	not
18	129	132	O	been
19	134	143	O	determined
NULL

Alfuzosin	DDI-DrugBank.d273.s1	NO_SECTION	NO_SETID	19
However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.
1	0	6	O	However
2	7	7	O	,
3	9	20	O	interactions
4	22	24	O	may
5	26	27	O	be
6	29	36	O	expected
7	37	37	O	,
8	39	41	O	and
9	43	51	O	XXXXXXXX
10	53	58	O	should
11	60	62	O	NOT
12	64	65	O	be
13	67	70	O	used
14	72	73	O	in
15	75	85	O	combination
16	87	90	O	with
17	92	96	O	other
18	98	102	B-DYN	alpha
19	104	111	L-DYN	blockers
NULL

Alglucosidase alfa	DDI-DrugBank.d90.s0	NO_SECTION	NO_SETID	7
No drug interaction studies have been performed.
1	0	1	O	No
2	3	6	O	drug
3	8	18	O	interaction
4	20	26	O	studies
5	28	31	O	have
6	33	36	O	been
7	38	46	O	performed
NULL

Aliskiren	DDI-DrugBank.d533.s0	NO_SECTION	NO_SETID	18
Effects of Other Drugs on Aliskiren Based on in-vitro studies, aliskiren is metabolized by CYP 3A4.
1	0	6	O	Effects
2	8	9	O	of
3	11	15	O	Other
4	17	21	O	Drugs
5	23	24	O	on
6	26	34	O	XXXXXXXX
7	36	40	O	Based
8	42	43	O	on
9	45	46	O	in
10	48	52	O	vitro
11	54	60	O	studies
12	61	61	O	,
13	63	71	O	XXXXXXXX
14	73	74	O	is
15	76	86	O	metabolized
16	88	89	O	by
17	91	93	O	CYP
18	95	97	O	3A4
NULL

Aliskiren	DDI-DrugBank.d533.s1	NO_SECTION	NO_SETID	34
Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	30	U-UNK	lovastatin
5	31	31	O	,
6	33	40	U-UNK	atenolol
7	41	41	O	,
8	43	50	U-UNK	warfarin
9	51	51	O	,
10	53	62	U-UNK	furosemide
11	63	63	O	,
12	65	71	U-UNK	digoxin
13	72	72	O	,
14	74	82	U-UNK	celecoxib
15	83	83	O	,
16	85	103	U-UNK	hydrochlorothiazide
17	104	104	O	,
18	106	113	U-UNK	ramipril
19	114	114	O	,
20	116	124	U-UNK	valsartan
21	125	125	O	,
22	127	135	U-UNK	metformin
23	137	139	O	and
24	141	150	U-UNK	amlodipine
25	152	154	O	did
26	156	158	O	not
27	160	165	O	result
28	167	168	O	in
29	170	179	O	clinically
30	181	191	O	significant
31	193	201	O	increases
32	203	204	O	in
33	206	214	O	XXXXXXXX
34	216	223	O	exposure
NULL

Aliskiren	DDI-DrugBank.d533.s2	NO_SECTION	NO_SETID	13
Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	30	U-KIN	irbesartan
5	32	38	O	reduced
6	40	48	O	XXXXXXXX
7	50	53	O	Cmax
8	55	56	O	up
9	58	59	O	to
10	61	63	O	50%
11	65	69	O	after
12	71	78	O	multiple
13	80	85	O	dosing
NULL

Aliskiren	DDI-DrugBank.d533.s3	NO_SECTION	NO_SETID	18
Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	32	U-KIN	atorvastatin
5	34	41	O	resulted
6	43	44	O	in
7	46	50	O	about
8	52	52	O	a
9	54	56	O	50%
10	58	65	O	increase
11	67	68	O	in
12	70	78	O	XXXXXXXX
13	80	83	O	Cmax
14	85	87	O	and
15	89	91	O	AUC
16	93	97	O	after
17	99	106	O	multiple
18	108	113	O	dosing
NULL

Aliskiren	DDI-DrugBank.d533.s4	NO_SECTION	NO_SETID	23
Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	15	O	Co
4	17	30	O	administration
5	32	33	O	of
6	35	37	O	200
7	39	40	O	mg
8	42	46	O	twice
9	48	52	O	daily
10	54	65	U-KIN	ketoconazole
11	67	70	O	with
12	72	80	O	XXXXXXXX
13	82	89	O	resulted
14	91	92	O	in
15	94	95	O	an
16	97	107	O	approximate
17	109	111	O	80%
18	113	120	O	increase
19	122	123	O	in
20	125	130	O	plasma
21	132	137	O	levels
22	139	140	O	of
23	142	150	O	XXXXXXXX
NULL

Aliskiren	DDI-DrugBank.d533.s5	NO_SECTION	NO_SETID	19
A 400 mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further.
1	0	0	O	A
2	2	4	O	400
3	6	7	O	mg
4	9	12	O	once
5	14	18	O	daily
6	20	23	O	dose
7	25	27	O	was
8	29	31	O	not
9	33	39	O	studied
10	41	43	O	but
11	45	49	O	would
12	51	52	O	be
13	54	61	O	expected
14	63	64	O	to
15	66	73	O	increase
16	75	83	O	XXXXXXXX
17	85	89	O	blood
18	91	96	O	levels
19	98	104	O	further
NULL

Aliskiren	DDI-DrugBank.d533.s6	NO_SECTION	NO_SETID	32
Effects of Aliskiren on Other Drugs Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and CYP 3A) or induce CYP 3A4.
1	0	6	O	Effects
2	8	9	O	of
3	11	19	O	XXXXXXXX
4	21	22	O	on
5	24	28	O	Other
6	30	34	O	Drugs
7	36	44	O	XXXXXXXX
8	46	49	O	does
9	51	53	O	not
10	55	61	O	inhibit
11	63	65	O	the
12	67	72	O	CYP450
13	74	83	O	isoenzymes
14	86	91	O	CYP1A2
15	92	92	O	,
16	94	96	O	2C8
17	97	97	O	,
18	99	101	O	2C9
19	102	102	O	,
20	104	107	O	2C19
21	108	108	O	,
22	110	112	O	2D6
23	113	113	O	,
24	115	117	O	2E1
25	118	118	O	,
26	120	122	O	and
27	124	126	O	CYP
28	128	129	O	3A
29	132	133	O	or
30	135	140	O	induce
31	142	144	O	CYP
32	146	148	O	3A4
NULL

Aliskiren	DDI-DrugBank.d533.s7	NO_SECTION	NO_SETID	30
Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	29	O	XXXXXXXX
5	31	33	O	did
6	35	37	O	not
7	39	51	O	significantly
8	53	58	O	affect
9	60	62	O	the
10	64	79	O	pharmacokinetics
11	81	82	O	of
12	84	93	U-UNK	lovastatin
13	94	94	O	,
14	96	102	U-UNK	digoxin
15	103	103	O	,
16	105	113	U-UNK	valsartan
17	114	114	O	,
18	116	125	U-UNK	amlodipine
19	126	126	O	,
20	128	136	U-UNK	metformin
21	137	137	O	,
22	139	147	U-UNK	celecoxib
23	148	148	O	,
24	150	157	U-UNK	atenolol
25	158	158	O	,
26	160	171	U-UNK	atorvastatin
27	172	172	O	,
28	174	181	U-UNK	ramipril
29	183	184	O	or
30	186	204	U-UNK	hydrochlorothiazide
NULL

Aliskiren	DDI-DrugBank.d533.s8	NO_SECTION	NO_SETID	19
Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated in a well-controlled clinical trial.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	12	O	The
4	14	20	O	effects
5	22	23	O	of
6	25	33	O	XXXXXXXX
7	35	36	O	on
8	38	45	U-UNK	warfarin
9	47	62	O	pharmacokinetics
10	64	67	O	have
11	69	71	O	not
12	73	76	O	been
13	78	86	O	evaluated
14	88	89	O	in
15	91	91	O	a
16	93	96	O	well
17	98	107	O	controlled
18	109	116	O	clinical
19	118	122	O	trial
NULL

Aliskiren	DDI-DrugBank.d533.s9	NO_SECTION	NO_SETID	25
Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.
1	0	9	U-UNK	Furosemide
2	10	10	O	:
3	12	15	O	When
4	17	25	O	XXXXXXXX
5	27	29	O	was
6	31	32	O	co
7	34	45	O	administered
8	47	50	O	with
9	52	61	U-KIN	furosemide
10	62	62	O	,
11	64	66	O	the
12	68	70	O	AUC
13	72	74	O	and
14	76	79	O	Cmax
15	81	82	O	of
16	84	93	U-UNK	furosemide
17	95	98	O	were
18	100	106	O	reduced
19	108	109	O	by
20	111	115	O	about
21	117	119	O	30%
22	121	123	O	and
23	125	127	O	50%
24	128	128	O	,
25	130	141	O	respectively
NULL

Alitretinoin	DDI-DrugBank.d392.s0	NO_SECTION	NO_SETID	28
Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.
1	0	7	O	Patients
2	9	11	O	who
3	13	15	O	are
4	17	24	O	applying
5	26	33	O	XXXXXXXX
6	35	37	O	gel
7	39	44	O	should
8	46	48	O	not
9	50	61	O	concurrently
10	63	65	O	use
11	67	74	O	products
12	76	79	O	that
13	81	87	O	contain
14	89	92	U-DYN	DEET
15	95	95	O	N
16	96	96	O	,
17	98	98	B-DYN	N
18	100	106	I-DYN	diethyl
19	108	108	I-DYN	m
20	110	118	L-DYN	toluamide
21	120	120	O	,
22	122	122	O	a
23	124	129	O	common
24	131	139	O	component
25	141	142	O	of
26	144	149	O	insect
27	151	159	O	repellent
28	161	168	O	products
NULL

Alitretinoin	DDI-DrugBank.d392.s1	NO_SECTION	NO_SETID	16
Animal toxicology studies showed increased DEET toxicity when DEET was included as proof of the formulation.
1	0	5	O	Animal
2	7	16	O	toxicology
3	18	24	O	studies
4	26	31	O	showed
5	33	41	O	increased
6	43	46	U-UNK	DEET
7	48	55	O	toxicity
8	57	60	O	when
9	62	65	U-UNK	DEET
10	67	69	O	was
11	71	78	O	included
12	80	81	O	as
13	83	87	O	proof
14	89	90	O	of
15	92	94	O	the
16	96	106	O	formulation
NULL

Alitretinoin	DDI-DrugBank.d392.s2	NO_SECTION	NO_SETID	46
Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic antiretroviral agents, including protease inhibitors, macrolide antibiotics, and azole antifungals, the effect of Panretin gel on the steady-state concentrations of these drugs is not known.
1	0	7	O	Although
2	9	13	O	there
3	15	17	O	was
4	19	20	O	no
5	22	29	O	clinical
6	31	38	O	evidence
7	40	41	O	in
8	43	45	O	the
9	47	53	O	vehicle
10	55	64	O	controlled
11	66	72	O	studies
12	74	75	O	of
13	77	80	O	drug
14	82	93	O	interactions
15	95	98	O	with
16	100	107	O	systemic
17	109	122	B-UNK	antiretroviral
18	124	129	L-UNK	agents
19	130	130	O	,
20	132	140	O	including
21	142	149	B-UNK	protease
22	151	160	L-UNK	inhibitors
23	161	161	O	,
24	163	171	B-UNK	macrolide
25	173	183	L-UNK	antibiotics
26	184	184	O	,
27	186	188	O	and
28	190	194	B-UNK	azole
29	196	206	L-UNK	antifungals
30	207	207	O	,
31	209	211	O	the
32	213	218	O	effect
33	220	221	O	of
34	223	230	O	XXXXXXXX
35	232	234	O	gel
36	236	237	O	on
37	239	241	O	the
38	243	248	O	steady
39	250	254	O	state
40	256	269	O	concentrations
41	271	272	O	of
42	274	278	O	these
43	280	284	O	drugs
44	286	287	O	is
45	289	291	O	not
46	293	297	O	known
NULL

Alitretinoin	DDI-DrugBank.d392.s3	NO_SECTION	NO_SETID	17
No drug interaction data are available on concomitant administration of Panretin gel and systemic anti-KS agents.
1	0	1	O	No
2	3	6	O	drug
3	8	18	O	interaction
4	20	23	O	data
5	25	27	O	are
6	29	37	O	available
7	39	40	O	on
8	42	52	O	concomitant
9	54	67	O	administration
10	69	70	O	of
11	72	79	O	XXXXXXXX
12	81	83	O	gel
13	85	87	O	and
14	89	96	O	systemic
15	98	101	O	anti
16	103	104	O	KS
17	106	111	O	agents
NULL

Allopurinol	DDI-DrugBank.d413.s0	NO_SECTION	NO_SETID	14
The following drug interactions were observed in some patients undergoing treatment with oral allopurinol.
1	0	2	O	The
2	4	12	O	following
3	14	17	O	drug
4	19	30	O	interactions
5	32	35	O	were
6	37	44	O	observed
7	46	47	O	in
8	49	52	O	some
9	54	61	O	patients
10	63	72	O	undergoing
11	74	82	O	treatment
12	84	87	O	with
13	89	92	O	oral
14	94	104	O	XXXXXXXX
NULL

Allopurinol	DDI-DrugBank.d413.s1	NO_SECTION	NO_SETID	26
Although the pattern of use for oral allopurinol includes longer term therapy, particularly for gout and renal calculi, the experience gained may be relevant.
1	0	7	O	Although
2	9	11	O	the
3	13	19	O	pattern
4	21	22	O	of
5	24	26	O	use
6	28	30	O	for
7	32	35	O	oral
8	37	47	O	XXXXXXXX
9	49	56	O	includes
10	58	63	O	longer
11	65	68	O	term
12	70	76	O	therapy
13	77	77	O	,
14	79	90	O	particularly
15	92	94	O	for
16	96	99	O	gout
17	101	103	O	and
18	105	109	O	renal
19	111	117	O	calculi
20	118	118	O	,
21	120	122	O	the
22	124	133	O	experience
23	135	140	O	gained
24	142	144	O	may
25	146	147	O	be
26	149	156	O	relevant
NULL

Allopurinol	DDI-DrugBank.d413.s2	NO_SECTION	NO_SETID	17
Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.
1	0	13	U-UNK	Mercaptopurine
2	14	14	O	/
3	15	26	U-UNK	Azathioprine
4	27	27	O	:
5	29	39	O	XXXXXXXX
6	41	48	O	inhibits
7	50	52	O	the
8	54	62	O	enzymatic
9	64	72	O	oxidation
10	74	75	O	of
11	77	90	U-KIN	mercaptopurine
12	92	94	O	and
13	96	107	U-KIN	azathioprine
14	109	110	O	to
15	112	112	B-UNK	6
16	114	121	I-UNK	thiouric
17	123	126	L-UNK	acid
NULL

Allopurinol	DDI-DrugBank.d413.s3	NO_SECTION	NO_SETID	12
This oxidation, which is catalyzed by xanthine oxidase, inactivates mercaptopurine.
1	0	3	O	This
2	5	13	O	oxidation
3	14	14	O	,
4	16	20	O	which
5	22	23	O	is
6	25	33	O	catalyzed
7	35	36	O	by
8	38	45	O	xanthine
9	47	53	O	oxidase
10	54	54	O	,
11	56	66	O	inactivates
12	68	81	U-UNK	mercaptopurine
NULL

Allopurinol	DDI-DrugBank.d413.s4	NO_SECTION	NO_SETID	41
In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.
1	0	1	O	In
2	3	10	O	patients
3	12	20	O	receiving
4	22	35	U-UNK	mercaptopurine
5	38	47	O	Purinethol
6	50	51	O	or
7	53	64	U-UNK	azathioprine
8	67	72	O	XXXXXXXX
9	74	74	O	,
10	76	78	O	the
11	80	90	O	concomitant
12	92	105	O	administration
13	107	108	O	of
14	110	112	O	300
15	114	116	O	600
16	118	119	O	mg
17	121	122	O	of
18	124	134	U-UNK	allopurinol
19	136	138	O	per
20	140	142	O	day
21	144	147	O	will
22	149	155	O	require
23	157	157	O	a
24	159	167	O	reduction
25	169	170	O	in
26	172	175	O	dose
27	177	178	O	to
28	180	192	O	approximately
29	194	196	O	one
30	198	202	O	third
31	204	205	O	to
32	207	209	O	one
33	211	216	O	fourth
34	218	219	O	of
35	221	223	O	the
36	225	229	O	usual
37	231	234	O	dose
38	236	237	O	of
39	239	252	U-UNK	mercaptopurine
40	254	255	O	or
41	257	268	U-UNK	azathioprine
NULL

Allopurinol	DDI-DrugBank.d413.s5	NO_SECTION	NO_SETID	23
Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects.
1	0	9	O	Subsequent
2	11	20	O	adjustment
3	22	23	O	of
4	25	29	O	doses
5	31	32	O	of
6	34	47	U-UNK	mercaptopurine
7	49	50	O	or
8	52	63	U-UNK	azathioprine
9	65	70	O	should
10	72	73	O	be
11	75	78	O	made
12	80	81	O	on
13	83	85	O	the
14	87	91	O	basis
15	93	94	O	of
16	96	106	O	therapeutic
17	108	115	O	response
18	117	119	O	and
19	121	123	O	the
20	125	134	O	appearance
21	136	137	O	of
22	139	143	O	toxic
23	145	151	O	effects
NULL

Allopurinol	DDI-DrugBank.d413.s6	NO_SECTION	NO_SETID	17
Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.
1	0	8	U-UNK	Dicumarol
2	9	9	O	:
3	11	12	O	It
4	14	16	O	has
5	18	21	O	been
6	23	30	O	reported
7	32	35	O	that
8	37	47	O	XXXXXXXX
9	49	56	O	prolongs
10	58	60	O	the
11	62	65	O	half
12	67	70	O	life
13	72	73	O	of
14	75	77	O	the
15	79	91	U-UNK	anticoagulant
16	92	92	O	,
17	94	102	U-KIN	dicumarol
NULL

Allopurinol	DDI-DrugBank.d413.s7	NO_SECTION	NO_SETID	25
The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.
1	0	2	O	The
2	4	11	O	clinical
3	13	17	O	basis
4	19	20	O	of
5	22	25	O	this
6	27	30	O	drug
7	32	42	O	interaction
8	44	46	O	has
9	48	50	O	not
10	52	55	O	been
11	57	67	O	established
12	69	71	O	but
13	73	78	O	should
14	80	81	O	be
15	83	87	O	noted
16	89	92	O	when
17	94	104	O	XXXXXXXX
18	106	107	O	is
19	109	113	O	given
20	115	116	O	to
21	118	125	O	patients
22	127	133	O	already
23	135	136	O	on
24	138	146	U-UNK	dicumarol
25	148	154	O	therapy
NULL

Allopurinol	DDI-DrugBank.d413.s8	NO_SECTION	NO_SETID	13
Consequently, prothrombin time should be reassessed periodically in patients receiving both drugs.
1	0	11	O	Consequently
2	12	12	O	,
3	14	24	O	prothrombin
4	26	29	O	time
5	31	36	O	should
6	38	39	O	be
7	41	50	O	reassessed
8	52	63	O	periodically
9	65	66	O	in
10	68	75	O	patients
11	77	85	O	receiving
12	87	90	O	both
13	92	96	O	drugs
NULL

Allopurinol	DDI-DrugBank.d413.s9	NO_SECTION	NO_SETID	44
Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.
1	0	9	B-UNK	Uricosuric
2	11	16	L-UNK	Agents
3	17	17	O	:
4	19	23	O	Since
5	25	27	O	the
6	29	37	O	excretion
7	39	40	O	of
8	42	51	U-UNK	oxipurinol
9	53	54	O	is
10	56	62	O	similar
11	64	65	O	to
12	67	70	O	that
13	72	73	O	of
14	75	79	O	urate
15	80	80	O	,
16	82	91	B-UNK	uricosuric
17	93	98	L-UNK	agents
18	99	99	O	,
19	101	105	O	which
20	107	114	O	increase
21	116	118	O	the
22	120	128	O	excretion
23	130	131	O	of
24	133	137	O	urate
25	138	138	O	,
26	140	142	O	are
27	144	147	O	also
28	149	154	O	likely
29	156	157	O	to
30	159	166	O	increase
31	168	170	O	the
32	172	180	O	excretion
33	182	183	O	of
34	185	194	U-UNK	oxipurinol
35	196	198	O	and
36	200	203	O	thus
37	205	209	O	lower
38	211	213	O	the
39	215	220	O	degree
40	222	223	O	of
41	225	234	O	inhibition
42	236	237	O	of
43	239	246	O	xanthine
44	248	254	O	oxidase
NULL

Allopurinol	DDI-DrugBank.d413.s10	NO_SECTION	NO_SETID	37
The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.
1	0	2	O	The
2	4	14	O	concomitant
3	16	29	O	administration
4	31	32	O	of
5	34	43	B-KIN	uricosuric
6	45	50	L-KIN	agents
7	52	54	O	and
8	56	66	O	XXXXXXXX
9	68	70	O	has
10	72	75	O	been
11	77	86	O	associated
12	88	91	O	with
13	93	93	O	a
14	95	102	O	decrease
15	104	105	O	in
16	107	109	O	the
17	111	119	O	excretion
18	121	122	O	of
19	124	133	O	oxypurines
20	136	147	O	hypoxanthine
21	149	151	O	and
22	153	160	O	xanthine
23	163	165	O	and
24	167	168	O	an
25	170	177	O	increase
26	179	180	O	in
27	182	188	O	urinary
28	190	193	O	uric
29	195	198	O	acid
30	200	208	O	excretion
31	210	217	O	compared
32	219	222	O	with
33	224	227	O	that
34	229	236	O	observed
35	238	241	O	with
36	243	253	O	XXXXXXXX
37	255	259	O	alone
NULL

Allopurinol	DDI-DrugBank.d413.s11	NO_SECTION	NO_SETID	32
Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on allopurinol alone or in combination with uricosuric agents, the possibility should be kept in mind.
1	0	7	O	Although
2	9	16	O	clinical
3	18	25	O	evidence
4	27	28	O	to
5	30	33	O	date
6	35	37	O	has
7	39	41	O	not
8	43	54	O	demonstrated
9	56	60	O	renal
10	62	74	O	precipitation
11	76	77	O	of
12	79	88	O	oxypurines
13	90	91	O	in
14	93	100	O	patients
15	102	107	O	either
16	109	110	O	on
17	112	122	O	XXXXXXXX
18	124	128	O	alone
19	130	131	O	or
20	133	134	O	in
21	136	146	O	combination
22	148	151	O	with
23	153	162	B-UNK	uricosuric
24	164	169	L-UNK	agents
25	170	170	O	,
26	172	174	O	the
27	176	186	O	possibility
28	188	193	O	should
29	195	196	O	be
30	198	201	O	kept
31	203	204	O	in
32	206	209	O	mind
NULL

Allopurinol	DDI-DrugBank.d413.s12	NO_SECTION	NO_SETID	43
Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
1	0	7	B-UNK	Thiazide
2	9	17	L-UNK	Diuretics
3	18	18	O	:
4	20	22	O	The
5	24	30	O	reports
6	32	35	O	that
7	37	39	O	the
8	41	51	O	concomitant
9	53	55	O	use
10	57	58	O	of
11	60	70	O	XXXXXXXX
12	72	74	O	and
13	76	83	B-DYN	thiazide
14	85	93	L-DYN	diuretics
15	95	97	O	may
16	99	108	O	contribute
17	110	111	O	to
18	113	115	O	the
19	117	127	O	enhancement
20	129	130	O	of
21	132	142	O	XXXXXXXX
22	144	151	O	toxicity
23	153	154	O	in
24	156	159	O	some
25	161	168	O	patients
26	170	173	O	have
27	175	178	O	been
28	180	187	O	reviewed
29	189	190	O	in
30	192	193	O	an
31	195	201	O	attempt
32	203	204	O	to
33	206	214	O	establish
34	216	216	O	a
35	218	222	O	cause
36	224	226	O	and
37	228	233	O	effect
38	235	246	O	relationship
39	248	250	O	and
40	252	252	O	a
41	254	262	O	mechanism
42	264	265	O	of
43	267	275	O	causation
NULL

Allopurinol	DDI-DrugBank.d413.s13	NO_SECTION	NO_SETID	33
Review of these case reports indicates that the patients were mainly receiving thiazide diuretics for hypertension and that tests to rule out decreased renal function secondary to hypertensive nephropathy were not often performed.
1	0	5	O	Review
2	7	8	O	of
3	10	14	O	these
4	16	19	O	case
5	21	27	O	reports
6	29	37	O	indicates
7	39	42	O	that
8	44	46	O	the
9	48	55	O	patients
10	57	60	O	were
11	62	67	O	mainly
12	69	77	O	receiving
13	79	86	B-UNK	thiazide
14	88	96	L-UNK	diuretics
15	98	100	O	for
16	102	113	O	hypertension
17	115	117	O	and
18	119	122	O	that
19	124	128	O	tests
20	130	131	O	to
21	133	136	O	rule
22	138	140	O	out
23	142	150	O	decreased
24	152	156	O	renal
25	158	165	O	function
26	167	175	O	secondary
27	177	178	O	to
28	180	191	O	hypertensive
29	193	203	O	nephropathy
30	205	208	O	were
31	210	212	O	not
32	214	218	O	often
33	220	228	O	performed
NULL

Allopurinol	DDI-DrugBank.d413.s14	NO_SECTION	NO_SETID	23
In those patients in whom renal insufficiency was documented, however, the recommendation to lower the dose of allopurinol was not followed.
1	0	1	O	In
2	3	7	O	those
3	9	16	O	patients
4	18	19	O	in
5	21	24	O	whom
6	26	30	O	renal
7	32	44	O	insufficiency
8	46	48	O	was
9	50	59	O	documented
10	60	60	O	,
11	62	68	O	however
12	69	69	O	,
13	71	73	O	the
14	75	88	O	recommendation
15	90	91	O	to
16	93	97	O	lower
17	99	101	O	the
18	103	106	O	dose
19	108	109	O	of
20	111	121	O	XXXXXXXX
21	123	125	O	was
22	127	129	O	not
23	131	138	O	followed
NULL

Allopurinol	DDI-DrugBank.d413.s15	NO_SECTION	NO_SETID	61
Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..
1	0	7	O	Although
2	9	9	O	a
3	11	16	O	causal
4	18	26	O	mechanism
5	28	30	O	and
6	32	32	O	a
7	34	38	O	cause
8	40	42	O	and
9	44	49	O	effect
10	51	62	O	relationship
11	64	67	O	have
12	69	71	O	not
13	73	76	O	been
14	78	88	O	established
15	89	89	O	,
16	91	97	O	current
17	99	106	O	evidence
18	108	115	O	suggests
19	117	120	O	that
20	122	126	O	renal
21	128	135	O	function
22	137	142	O	should
23	144	145	O	be
24	147	155	O	monitored
25	157	158	O	in
26	160	167	O	patients
27	169	170	O	on
28	172	179	B-DYN	thiazide
29	181	189	L-DYN	diuretics
30	191	193	O	and
31	195	205	O	XXXXXXXX
32	207	210	O	even
33	212	213	O	in
34	215	217	O	the
35	219	225	O	absence
36	227	228	O	of
37	230	234	O	renal
38	236	242	O	failure
39	243	243	O	,
40	245	247	O	and
41	249	254	O	dosage
42	256	261	O	levels
43	263	268	O	should
44	270	271	O	be
45	273	276	O	even
46	278	281	O	more
47	283	296	O	conservatively
48	298	305	O	adjusted
49	307	308	O	in
50	310	314	O	those
51	316	323	O	patients
52	325	326	O	on
53	328	331	O	such
54	333	340	O	combined
55	342	348	O	therapy
56	350	351	O	if
57	353	362	O	diminished
58	364	368	O	renal
59	370	377	O	function
60	379	380	O	is
61	382	389	O	detected
NULL

Allopurinol	DDI-DrugBank.d413.s16	NO_SECTION	NO_SETID	33
Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.
1	0	9	U-UNK	Ampicillin
2	10	10	O	/
3	11	21	U-UNK	Amoxicillin
4	22	22	O	:
5	24	25	O	An
6	27	34	O	increase
7	36	37	O	in
8	39	41	O	the
9	43	51	O	frequency
10	53	54	O	of
11	56	59	O	skin
12	61	64	O	rash
13	66	68	O	has
14	70	73	O	been
15	75	82	O	reported
16	84	88	O	among
17	90	97	O	patients
18	99	107	O	receiving
19	109	118	U-DYN	ampicillin
20	120	121	O	or
21	123	133	U-DYN	amoxicillin
22	135	146	O	concurrently
23	148	151	O	with
24	153	163	O	XXXXXXXX
25	165	172	O	compared
26	174	175	O	to
27	177	184	O	patients
28	186	188	O	who
29	190	192	O	are
30	194	196	O	not
31	198	206	O	receiving
32	208	211	O	both
33	213	217	O	drugs
NULL

Allopurinol	DDI-DrugBank.d413.s17	NO_SECTION	NO_SETID	10
The cause of the reported association has not been established.
1	0	2	O	The
2	4	8	O	cause
3	10	11	O	of
4	13	15	O	the
5	17	24	O	reported
6	26	36	O	association
7	38	40	O	has
8	42	44	O	not
9	46	49	O	been
10	51	61	O	established
NULL

Allopurinol	DDI-DrugBank.d413.s18	NO_SECTION	NO_SETID	30
Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.
1	0	8	B-UNK	Cytotoxic
2	10	15	L-UNK	Agents
3	16	16	O	:
4	18	25	O	Enhanced
5	27	30	O	bone
6	32	37	O	marrow
7	39	49	O	suppression
8	51	52	O	by
9	54	69	U-DYN	cyclophosphamide
10	71	73	O	and
11	75	79	O	other
12	81	89	B-DYN	cytotoxic
13	91	96	L-DYN	agents
14	98	100	O	has
15	102	105	O	been
16	107	114	O	reported
17	116	120	O	among
18	122	129	O	patients
19	131	134	O	with
20	136	145	O	neoplastic
21	147	153	O	disease
22	154	154	O	,
23	156	161	O	except
24	163	170	O	leukemia
25	171	171	O	,
26	173	174	O	in
27	176	178	O	the
28	180	187	O	presence
29	189	190	O	of
30	192	202	O	XXXXXXXX
NULL

Allopurinol	DDI-DrugBank.d413.s19	NO_SECTION	NO_SETID	37
However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or mechlorethamine.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	12	O	a
5	14	17	O	well
6	19	28	O	controlled
7	30	34	O	study
8	36	37	O	of
9	39	46	O	patients
10	48	51	O	with
11	53	60	O	lymphoma
12	62	63	O	on
13	65	75	O	combination
14	77	83	O	therapy
15	84	84	O	,
16	86	96	O	XXXXXXXX
17	98	100	O	did
18	102	104	O	not
19	106	113	O	increase
20	115	117	O	the
21	119	124	O	marrow
22	126	133	O	toxicity
23	135	136	O	of
24	138	145	O	patients
25	147	153	O	treated
26	155	158	O	with
27	160	175	U-UNK	cyclophosphamide
28	176	176	O	,
29	178	188	U-UNK	doxorubicin
30	189	189	O	,
31	191	199	U-UNK	bleomycin
32	200	200	O	,
33	202	213	U-UNK	procarbazine
34	215	217	O	and
35	218	218	O	/
36	219	220	O	or
37	222	236	U-UNK	mechlorethamine
NULL

Allopurinol	DDI-DrugBank.d413.s20	NO_SECTION	NO_SETID	24
Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.
1	0	13	U-UNK	Chlorpropamide
2	14	14	O	:
3	16	30	O	Chlorpropamides
4	32	37	O	plasma
5	39	42	O	half
6	44	47	O	life
7	49	51	O	may
8	53	54	O	be
9	56	64	O	prolonged
10	66	67	O	by
11	69	79	O	XXXXXXXX
12	80	80	O	,
13	82	86	O	since
14	88	98	O	XXXXXXXX
15	100	102	O	and
16	104	117	U-KIN	chlorpropamide
17	119	121	O	may
18	123	129	O	compete
19	131	133	O	for
20	135	143	O	excretion
21	145	146	O	in
22	148	150	O	the
23	152	156	O	renal
24	158	163	O	tubule
NULL

Allopurinol	DDI-DrugBank.d413.s21	NO_SECTION	NO_SETID	24
The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	23	O	hypoglycemia
5	25	33	O	secondary
6	35	36	O	to
7	38	41	O	this
8	43	51	O	mechanism
9	53	55	O	may
10	57	58	O	be
11	60	68	O	increased
12	70	71	O	if
13	73	83	O	XXXXXXXX
14	85	87	O	and
15	89	102	U-DYN	chlorpropamide
16	104	106	O	are
17	108	112	O	given
18	114	126	O	concomitantly
19	128	129	O	in
20	131	133	O	the
21	135	142	O	presence
22	144	145	O	of
23	147	151	O	renal
24	153	165	O	insufficiency
NULL

Allopurinol	DDI-DrugBank.d413.s22	NO_SECTION	NO_SETID	18
Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.
1	0	10	U-UNK	Cyclosporin
2	11	11	O	:
3	13	19	O	Reports
4	21	28	O	indicate
5	30	33	O	that
6	35	46	U-KIN	cyclosporine
7	48	53	O	levels
8	55	57	O	may
9	59	60	O	be
10	62	70	O	increased
11	72	77	O	during
12	79	89	O	concomitant
13	91	99	O	treatment
14	101	104	O	with
15	106	116	O	XXXXXXXX
16	118	123	O	sodium
17	125	127	O	for
18	129	137	O	injection
NULL

Allopurinol	DDI-DrugBank.d413.s23	NO_SECTION	NO_SETID	19
Monitoring of cyclosporine levels and possible adjustment of cyclosporine dosage should be considered when these drugs are co-administered.
1	0	9	O	Monitoring
2	11	12	O	of
3	14	25	U-UNK	cyclosporine
4	27	32	O	levels
5	34	36	O	and
6	38	45	O	possible
7	47	56	O	adjustment
8	58	59	O	of
9	61	72	U-UNK	cyclosporine
10	74	79	O	dosage
11	81	86	O	should
12	88	89	O	be
13	91	100	O	considered
14	102	105	O	when
15	107	111	O	these
16	113	117	O	drugs
17	119	121	O	are
18	123	124	O	co
19	126	137	O	administered
NULL

Allopurinol	DDI-DrugBank.d413.s24	NO_SECTION	NO_SETID	17
Tolbutamides conversion to inactive metabolites has been shown to be catalyzed by xanthine oxidase from rat liver.
1	0	11	O	Tolbutamides
2	13	22	O	conversion
3	24	25	O	to
4	27	34	O	inactive
5	36	46	O	metabolites
6	48	50	O	has
7	52	55	O	been
8	57	61	O	shown
9	63	64	O	to
10	66	67	O	be
11	69	77	O	catalyzed
12	79	80	O	by
13	82	89	O	xanthine
14	91	97	O	oxidase
15	99	102	O	from
16	104	106	O	rat
17	108	112	O	liver
NULL

Allopurinol	DDI-DrugBank.d413.s25	NO_SECTION	NO_SETID	12
The clinical significance, if any, of these observations is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	25	25	O	,
5	27	28	O	if
6	30	32	O	any
7	33	33	O	,
8	35	36	O	of
9	38	42	O	these
10	44	55	O	observations
11	57	58	O	is
12	60	66	O	unknown
NULL

Almotriptan	DDI-DrugBank.d299.s0	NO_SECTION	NO_SETID	14
Ergot-Containing Drugs: These drugs have been reported to cause prolonged vasospastic reactions.
1	0	4	B-UNK	Ergot
2	6	15	I-UNK	Containing
3	17	21	L-UNK	Drugs
4	22	22	O	:
5	24	28	O	These
6	30	34	O	drugs
7	36	39	O	have
8	41	44	O	been
9	46	53	O	reported
10	55	56	O	to
11	58	62	O	cause
12	64	72	O	prolonged
13	74	84	O	vasospastic
14	86	94	O	reactions
NULL

Almotriptan	DDI-DrugBank.d299.s1	NO_SECTION	NO_SETID	36
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
1	0	6	O	Because
2	8	12	O	there
3	14	15	O	is
4	17	17	O	a
5	19	29	O	theoretical
6	31	35	O	basis
7	37	40	O	that
8	42	46	O	these
9	48	54	O	effects
10	56	58	O	may
11	60	61	O	be
12	63	70	O	additive
13	71	71	O	,
14	73	75	O	use
15	77	78	O	of
16	80	89	U-DYN	ergotamine
17	91	100	O	containing
18	102	103	O	or
19	105	109	B-DYN	ergot
20	111	114	I-DYN	type
21	116	126	L-DYN	medications
22	129	132	O	like
23	134	150	U-DYN	dihydroergotamine
24	152	153	O	or
25	155	166	U-DYN	methysergide
26	169	171	O	and
27	173	177	O	XXXXXXXX
28	179	184	O	within
29	186	187	O	24
30	189	193	O	hours
31	195	196	O	of
32	198	201	O	each
33	203	207	O	other
34	209	214	O	should
35	216	217	O	be
36	219	225	O	avoided
NULL

Almotriptan	DDI-DrugBank.d299.s2	NO_SECTION	NO_SETID	23
Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.
1	0	8	B-UNK	Monoamine
2	10	16	I-UNK	Oxidase
3	18	27	L-UNK	Inhibitors
4	28	28	O	:
5	30	45	O	Coadministration
6	47	48	O	of
7	50	60	U-KIN	moclobemide
8	62	69	O	resulted
9	71	72	O	in
10	74	74	O	a
11	76	78	O	27%
12	80	87	O	decrease
13	89	90	O	in
14	92	102	O	XXXXXXXX
15	104	112	O	clearance
16	114	116	O	and
17	118	119	O	an
18	121	128	O	increase
19	130	131	O	in
20	133	136	O	Cmax
21	138	139	O	of
22	141	153	O	approximately
23	155	156	O	6%
NULL

Almotriptan	DDI-DrugBank.d299.s3	NO_SECTION	NO_SETID	5
No dose adjustment is necessary.
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	is
5	22	30	O	necessary
NULL

Almotriptan	DDI-DrugBank.d299.s4	NO_SECTION	NO_SETID	24
Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.
1	0	4	O	Other
2	6	6	B-UNK	5
3	8	11	I-UNK	HT1B
4	12	12	I-UNK	/
5	13	14	I-UNK	1D
6	16	23	L-UNK	Agonists
7	25	35	O	Concomitant
8	37	39	O	use
9	41	42	O	of
10	44	48	O	other
11	50	50	B-DYN	5
12	52	55	I-DYN	HT1B
13	56	56	I-DYN	/
14	57	58	I-DYN	1D
15	60	67	L-DYN	agonists
16	69	74	O	within
17	76	77	O	24
18	79	83	O	hours
19	85	86	O	of
20	88	96	O	treatment
21	98	101	O	with
22	103	107	O	XXXXXXXX
23	109	110	O	is
24	112	126	O	contraindicated
NULL

Almotriptan	DDI-DrugBank.d299.s5	NO_SECTION	NO_SETID	13
Propanolol: The pharmacokinetics of almotriptan were not affected by coadministration of propranolol.
1	0	9	U-UNK	Propanolol
2	10	10	O	:
3	12	14	O	The
4	16	31	O	pharmacokinetics
5	33	34	O	of
6	36	46	O	XXXXXXXX
7	48	51	O	were
8	53	55	O	not
9	57	64	O	affected
10	66	67	O	by
11	69	84	O	coadministration
12	86	87	O	of
13	89	99	U-UNK	propranolol
NULL

Almotriptan	DDI-DrugBank.d299.s6	NO_SECTION	NO_SETID	34
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
1	0	8	B-UNK	Selective
2	10	18	I-UNK	Serotonin
3	20	27	I-UNK	Reuptake
4	29	38	L-UNK	Inhibitors
5	41	45	U-UNK	SSRIs
6	47	47	O	:
7	49	53	U-UNK	SSRIs
8	56	58	O	e.g
9	60	60	O	,
10	62	71	U-UNK	fluoxetine
11	72	72	O	,
12	74	84	U-UNK	fluvoxamine
13	85	85	O	,
14	87	96	U-UNK	paroxetine
15	97	97	O	,
16	99	108	U-UNK	sertraline
17	111	114	O	have
18	116	119	O	been
19	121	126	O	rarely
20	128	135	O	reported
21	137	138	O	to
22	140	144	O	cause
23	146	153	O	weakness
24	154	154	O	,
25	156	168	O	hyperreflexia
26	169	169	O	,
27	171	173	O	and
28	175	188	O	incoordination
29	190	193	O	when
30	195	208	O	coadministered
31	210	213	O	with
32	215	215	B-UNK	5
33	217	219	I-UNK	HT1
34	221	228	L-UNK	agonists
NULL

Almotriptan	DDI-DrugBank.d299.s7	NO_SECTION	NO_SETID	19
If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.
1	0	1	O	If
2	3	13	O	concomitant
3	15	23	O	treatment
4	25	28	O	with
5	30	34	O	XXXXXXXX
6	36	38	O	and
7	40	41	O	an
8	43	46	U-DYN	SSRI
9	48	49	O	is
10	51	60	O	clinically
11	62	70	O	warranted
12	71	71	O	,
13	73	83	O	appropriate
14	85	95	O	observation
15	97	98	O	of
16	100	102	O	the
17	104	110	O	patient
18	112	113	O	is
19	115	121	O	advised
NULL

Almotriptan	DDI-DrugBank.d299.s8	NO_SECTION	NO_SETID	17
Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.
1	0	8	U-UNK	Verapamil
2	9	9	O	:
3	11	26	O	Coadministration
4	28	29	O	of
5	31	41	O	XXXXXXXX
6	43	45	O	and
7	47	55	U-KIN	verapamil
8	57	64	O	resulted
9	66	67	O	in
10	69	69	O	a
11	71	73	O	24%
12	75	82	O	increase
13	84	85	O	in
14	87	92	O	plasma
15	94	107	O	concentrations
16	109	110	O	of
17	112	122	O	XXXXXXXX
NULL

Almotriptan	DDI-DrugBank.d299.s9	NO_SECTION	NO_SETID	5
No dose adjustment is necessary.
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	is
5	22	30	O	necessary
NULL

Almotriptan	DDI-DrugBank.d299.s10	NO_SECTION	NO_SETID	36
Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	30	O	XXXXXXXX
4	32	34	O	and
5	36	38	O	the
6	40	45	O	potent
7	47	52	O	CYP3A4
8	54	62	O	inhibitor
9	64	75	U-KIN	ketoconazole
10	78	80	O	400
11	82	83	O	mg
12	85	87	O	q.d
13	90	92	O	for
14	94	94	O	3
15	96	99	O	days
16	102	109	O	resulted
17	111	112	O	in
18	114	115	O	an
19	117	129	O	approximately
20	131	133	O	60%
21	135	142	O	increase
22	144	145	O	in
23	147	149	O	the
24	151	154	O	area
25	156	160	O	under
26	162	164	O	the
27	166	171	O	plasma
28	173	185	O	concentration
29	187	190	O	time
30	192	196	O	curve
31	198	200	O	and
32	202	208	O	maximal
33	210	215	O	plasma
34	217	230	O	concentrations
35	232	233	O	of
36	235	245	O	XXXXXXXX
NULL

Almotriptan	DDI-DrugBank.d299.s11	NO_SECTION	NO_SETID	38
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
1	0	7	O	Although
2	9	11	O	the
3	13	23	O	interaction
4	25	31	O	between
5	33	43	O	XXXXXXXX
6	45	47	O	and
7	49	53	O	other
8	55	60	O	potent
9	62	67	O	CYP3A4
10	69	78	O	inhibitors
11	81	83	O	e.g
12	85	85	O	,
13	87	98	U-DYN	itraconazole
14	99	99	O	,
15	101	109	U-DYN	ritonavir
16	110	110	O	,
17	112	114	O	and
18	116	127	U-DYN	erythromycin
19	130	132	O	has
20	134	136	O	not
21	138	141	O	been
22	143	149	O	studied
23	150	150	O	,
24	152	160	O	increased
25	162	170	O	exposures
26	172	173	O	to
27	175	185	O	XXXXXXXX
28	187	189	O	may
29	191	192	O	be
30	194	201	O	expected
31	203	206	O	when
32	208	218	O	XXXXXXXX
33	220	221	O	is
34	223	226	O	used
35	228	240	O	concomitantly
36	242	245	O	with
37	247	251	O	these
38	253	263	O	medications
NULL

Almotriptan	DDI-DrugBank.d299.s12	NO_SECTION	NO_SETID	12
AXERT is not known to interfere with commonly employed clinical laboratory tests.
1	0	4	O	XXXXXXXX
2	6	7	O	is
3	9	11	O	not
4	13	17	O	known
5	19	20	O	to
6	22	30	O	interfere
7	32	35	O	with
8	37	44	O	commonly
9	46	53	O	employed
10	55	62	O	clinical
11	64	73	O	laboratory
12	75	79	O	tests
NULL

Alosetron	DDI-DrugBank.d364.s0	NO_SECTION	NO_SETID	26
Because alosetron is metabolized by a variety of hepatic CYP drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of alosetron.
1	0	6	O	Because
2	8	16	O	XXXXXXXX
3	18	19	O	is
4	21	31	O	metabolized
5	33	34	O	by
6	36	36	O	a
7	38	44	O	variety
8	46	47	O	of
9	49	55	O	hepatic
10	57	59	O	CYP
11	61	64	O	drug
12	66	77	O	metabolizing
13	79	85	O	enzymes
14	86	86	O	,
15	88	95	O	inducers
16	97	98	O	or
17	100	109	O	inhibitors
18	111	112	O	of
19	114	118	O	these
20	120	126	O	enzymes
21	128	130	O	may
22	132	137	O	change
23	139	141	O	the
24	143	151	O	clearance
25	153	154	O	of
26	156	164	O	XXXXXXXX
NULL

Alosetron	DDI-DrugBank.d364.s1	NO_SECTION	NO_SETID	17
Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9, and CYP2C19.
1	0	10	U-UNK	Fluvoxamine
2	12	13	O	is
3	15	15	O	a
4	17	21	O	known
5	23	28	O	strong
6	30	38	O	inhibitor
7	40	41	O	of
8	43	48	O	CYP1A2
9	50	52	O	and
10	54	57	O	also
11	59	66	O	inhibits
12	68	73	O	CYP3A4
13	74	74	O	,
14	76	81	O	CYP2C9
15	82	82	O	,
16	84	86	O	and
17	88	94	O	CYP2C19
NULL

Alosetron	DDI-DrugBank.d364.s2	NO_SECTION	NO_SETID	35
In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 to 200 mg per day for 16 days, with coadministration of alosetron 1 mg on the last day.
1	0	1	O	In
2	3	3	O	a
3	5	19	O	pharmacokinetic
4	21	25	O	study
5	26	26	O	,
6	28	29	O	40
7	31	37	O	healthy
8	39	44	O	female
9	46	53	O	subjects
10	55	62	O	received
11	64	74	U-UNK	fluvoxamine
12	76	77	O	in
13	79	88	O	escalating
14	90	94	O	doses
15	96	99	O	from
16	101	102	O	50
17	104	105	O	to
18	107	109	O	200
19	111	112	O	mg
20	114	116	O	per
21	118	120	O	day
22	122	124	O	for
23	126	127	O	16
24	129	132	O	days
25	133	133	O	,
26	135	138	O	with
27	140	155	O	coadministration
28	157	158	O	of
29	160	168	O	XXXXXXXX
30	170	170	O	1
31	172	173	O	mg
32	175	176	O	on
33	178	180	O	the
34	182	185	O	last
35	187	189	O	day
NULL

Alosetron	DDI-DrugBank.d364.s3	NO_SECTION	NO_SETID	19
Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.
1	0	10	U-KIN	Fluvoxamine
2	12	20	O	increased
3	22	25	O	mean
4	27	35	O	XXXXXXXX
5	37	42	O	plasma
6	44	57	O	concentrations
7	60	62	O	AUC
8	65	77	O	approximately
9	79	79	O	6
10	81	84	O	fold
11	86	88	O	and
12	90	98	O	prolonged
13	100	102	O	the
14	104	107	O	half
15	109	112	O	life
16	114	115	O	by
17	117	129	O	approximately
18	131	131	O	3
19	133	136	O	fold
NULL

Alosetron	DDI-DrugBank.d364.s4	NO_SECTION	NO_SETID	8
Concomitant administration of alosetron and fluvoxamine is contraindicated.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	38	O	XXXXXXXX
5	40	42	O	and
6	44	54	U-DYN	fluvoxamine
7	56	57	O	is
8	59	73	O	contraindicated
NULL

Alosetron	DDI-DrugBank.d364.s5	NO_SECTION	NO_SETID	33
Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	38	O	XXXXXXXX
5	40	42	O	and
6	44	51	O	moderate
7	53	58	O	CYP1A2
8	60	69	O	inhibitors
9	70	70	O	,
10	72	80	O	including
11	82	90	B-DYN	quinolone
12	92	102	L-DYN	antibiotics
13	104	106	O	and
14	108	117	U-DYN	cimetidine
15	118	118	O	,
16	120	122	O	has
17	124	126	O	not
18	128	131	O	been
19	133	141	O	evaluated
20	142	142	O	,
21	144	146	O	but
22	148	153	O	should
23	155	156	O	be
24	158	164	O	avoided
25	166	171	O	unless
26	173	182	O	clinically
27	184	192	O	necessary
28	194	200	O	because
29	202	203	O	of
30	205	211	O	similar
31	213	221	O	potential
32	223	226	O	drug
33	228	239	O	interactions
NULL

Alosetron	DDI-DrugBank.d364.s6	NO_SECTION	NO_SETID	8
Ketoconazole is a known strong inhibitor of CYP3A4.
1	0	11	U-UNK	Ketoconazole
2	13	14	O	is
3	16	16	O	a
4	18	22	O	known
5	24	29	O	strong
6	31	39	O	inhibitor
7	41	42	O	of
8	44	49	O	CYP3A4
NULL

Alosetron	DDI-DrugBank.d364.s7	NO_SECTION	NO_SETID	29
In a pharmacokinetic study, 38 healthy female subjects received ketoconazole 200 mg twice daily for 7 days, with coadministration of alosetron 1 mg on the last day.
1	0	1	O	In
2	3	3	O	a
3	5	19	O	pharmacokinetic
4	21	25	O	study
5	26	26	O	,
6	28	29	O	38
7	31	37	O	healthy
8	39	44	O	female
9	46	53	O	subjects
10	55	62	O	received
11	64	75	U-UNK	ketoconazole
12	77	79	O	200
13	81	82	O	mg
14	84	88	O	twice
15	90	94	O	daily
16	96	98	O	for
17	100	100	O	7
18	102	105	O	days
19	106	106	O	,
20	108	111	O	with
21	113	128	O	coadministration
22	130	131	O	of
23	133	141	O	XXXXXXXX
24	143	143	O	1
25	145	146	O	mg
26	148	149	O	on
27	151	153	O	the
28	155	158	O	last
29	160	162	O	day
NULL

Alosetron	DDI-DrugBank.d364.s8	NO_SECTION	NO_SETID	9
Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.
1	0	11	U-KIN	Ketoconazole
2	13	21	O	increased
3	23	26	O	mean
4	28	36	O	XXXXXXXX
5	38	43	O	plasma
6	45	58	O	concentrations
7	61	63	O	AUC
8	66	67	O	by
9	69	71	O	29%
NULL

Alosetron	DDI-DrugBank.d364.s9	NO_SECTION	NO_SETID	11
Caution should be used when alosetron and ketoconazole are administered concomitantly.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	26	O	when
6	28	36	O	XXXXXXXX
7	38	40	O	and
8	42	53	U-DYN	ketoconazole
9	55	57	O	are
10	59	70	O	administered
11	72	84	O	concomitantly
NULL

Alosetron	DDI-DrugBank.d364.s10	NO_SECTION	NO_SETID	37
Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	28	O	XXXXXXXX
4	30	32	O	and
5	34	39	O	strong
6	41	46	O	CYP3A4
7	48	57	O	inhibitors
8	58	58	O	,
9	60	63	O	such
10	65	66	O	as
11	68	81	U-DYN	clarithromycin
12	82	82	O	,
13	84	96	U-DYN	telithromycin
14	97	97	O	,
15	99	106	B-DYN	protease
16	108	117	L-DYN	inhibitors
17	118	118	O	,
18	120	131	U-DYN	voriconazole
19	132	132	O	,
20	134	136	O	and
21	138	149	U-DYN	itraconazole
22	151	153	O	has
23	155	157	O	not
24	159	162	O	been
25	164	172	O	evaluated
26	174	176	O	but
27	178	183	O	should
28	185	186	O	be
29	188	197	O	undertaken
30	199	202	O	with
31	204	210	O	caution
32	212	218	O	because
33	220	221	O	of
34	223	229	O	similar
35	231	239	O	potential
36	241	244	O	drug
37	246	257	O	interactions
NULL

Alosetron	DDI-DrugBank.d364.s11	NO_SECTION	NO_SETID	19
The effect of induction or inhibition of other pathways on exposure to alosetron and its metabolites is not known.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	22	O	induction
5	24	25	O	or
6	27	36	O	inhibition
7	38	39	O	of
8	41	45	O	other
9	47	54	O	pathways
10	56	57	O	on
11	59	66	O	exposure
12	68	69	O	to
13	71	79	O	XXXXXXXX
14	81	83	O	and
15	85	87	O	its
16	89	99	O	metabolites
17	101	102	O	is
18	104	106	O	not
19	108	112	O	known
NULL

Alosetron	DDI-DrugBank.d364.s12	NO_SECTION	NO_SETID	29
In vitro human liver microsome studies and an in vivo metabolic probe study demonstrated that alosetron did not inhibit CYP enzymes 2D6, 3A4, 2C9, or 2C19.
1	0	1	O	In
2	3	7	O	vitro
3	9	13	O	human
4	15	19	O	liver
5	21	29	O	microsome
6	31	37	O	studies
7	39	41	O	and
8	43	44	O	an
9	46	47	O	in
10	49	52	O	vivo
11	54	62	O	metabolic
12	64	68	O	probe
13	70	74	O	study
14	76	87	O	demonstrated
15	89	92	O	that
16	94	102	O	XXXXXXXX
17	104	106	O	did
18	108	110	O	not
19	112	118	O	inhibit
20	120	122	O	CYP
21	124	130	O	enzymes
22	132	134	O	2D6
23	135	135	O	,
24	137	139	O	3A4
25	140	140	O	,
26	142	144	O	2C9
27	145	145	O	,
28	147	148	O	or
29	150	153	O	2C19
NULL

Alosetron	DDI-DrugBank.d364.s13	NO_SECTION	NO_SETID	30
In vitro, at total drug concentrations 27-fold higher than peak plasma concentrations observed with the 1-mg dosage, alosetron inhibited CYP enzymes 1A2 (60%) and 2E1 (50%).
1	0	1	O	In
2	3	7	O	vitro
3	8	8	O	,
4	10	11	O	at
5	13	17	O	total
6	19	22	O	drug
7	24	37	O	concentrations
8	39	40	O	27
9	42	45	O	fold
10	47	52	O	higher
11	54	57	O	than
12	59	62	O	peak
13	64	69	O	plasma
14	71	84	O	concentrations
15	86	93	O	observed
16	95	98	O	with
17	100	102	O	the
18	104	104	O	1
19	106	107	O	mg
20	109	114	O	dosage
21	115	115	O	,
22	117	125	O	XXXXXXXX
23	127	135	O	inhibited
24	137	139	O	CYP
25	141	147	O	enzymes
26	149	151	O	1A2
27	154	156	O	60%
28	159	161	O	and
29	163	165	O	2E1
30	168	170	O	50%
NULL

Alosetron	DDI-DrugBank.d364.s14	NO_SECTION	NO_SETID	24
In an in vivo metabolic probe study, alosetron did not inhibit CYP2E1 but did produce 30% inhibition of both CYP1A2 and N-acetyltransferase.
1	0	1	O	In
2	3	4	O	an
3	6	7	O	in
4	9	12	O	vivo
5	14	22	O	metabolic
6	24	28	O	probe
7	30	34	O	study
8	35	35	O	,
9	37	45	O	XXXXXXXX
10	47	49	O	did
11	51	53	O	not
12	55	61	O	inhibit
13	63	68	O	CYP2E1
14	70	72	O	but
15	74	76	O	did
16	78	84	O	produce
17	86	88	O	30%
18	90	99	O	inhibition
19	101	102	O	of
20	104	107	O	both
21	109	114	O	CYP1A2
22	116	118	O	and
23	120	120	O	N
24	122	138	O	acetyltransferase
NULL

Alosetron	DDI-DrugBank.d364.s15	NO_SECTION	NO_SETID	25
Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.
1	0	7	O	Although
2	9	11	O	not
3	13	19	O	studied
4	21	24	O	with
5	26	34	O	XXXXXXXX
6	35	35	O	,
7	37	46	O	inhibition
8	48	49	O	of
9	51	51	O	N
10	53	69	O	acetyltransferase
11	71	73	O	may
12	75	78	O	have
13	80	89	O	clinically
14	91	98	O	relevant
15	100	111	O	consequences
16	113	115	O	for
17	117	121	O	drugs
18	123	126	O	such
19	128	129	O	as
20	131	139	U-DYN	isoniazid
21	140	140	O	,
22	142	153	U-DYN	procainamide
23	154	154	O	,
24	156	158	O	and
25	160	170	U-DYN	hydralazine
NULL

Alosetron	DDI-DrugBank.d364.s16	NO_SECTION	NO_SETID	21
The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	on
4	14	19	O	CYP1A2
5	21	23	O	was
6	25	32	O	explored
7	34	40	O	further
8	42	43	O	in
9	45	45	O	a
10	47	54	O	clinical
11	56	66	O	interaction
12	68	72	O	study
13	74	77	O	with
14	79	90	U-UNK	theophylline
15	92	94	O	and
16	96	97	O	no
17	99	104	O	effect
18	106	107	O	on
19	109	118	O	metabolism
20	120	122	O	was
21	124	131	O	observed
NULL

Alosetron	DDI-DrugBank.d364.s17	NO_SECTION	NO_SETID	24
Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates).
1	0	6	O	Another
2	8	12	O	study
3	14	19	O	showed
4	21	24	O	that
5	26	34	O	XXXXXXXX
6	36	38	O	had
7	40	41	O	no
8	43	52	O	clinically
9	54	64	O	significant
10	66	71	O	effect
11	73	74	O	on
12	76	81	O	plasma
13	83	96	O	concentrations
14	98	99	O	of
15	101	103	O	the
16	105	108	O	oral
17	110	122	B-UNK	contraceptive
18	124	129	L-UNK	agents
19	131	137	B-UNK	ethinyl
20	139	147	L-UNK	estradiol
21	149	151	O	and
22	153	166	U-UNK	levonorgestrel
23	169	174	O	CYP3A4
24	176	185	O	substrates
NULL

Alosetron	DDI-DrugBank.d364.s18	NO_SECTION	NO_SETID	14
A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride.
1	0	0	O	A
2	2	9	O	clinical
3	11	21	O	interaction
4	23	27	O	study
5	29	31	O	was
6	33	36	O	also
7	38	46	O	conducted
8	48	51	O	with
9	53	61	O	XXXXXXXX
10	63	65	O	and
11	67	69	O	the
12	71	76	O	CYP3A4
13	78	86	O	substrate
14	88	96	U-UNK	cisapride
NULL

Alosetron	DDI-DrugBank.d364.s19	NO_SECTION	NO_SETID	11
No significant effects on cisapride metabolism or QT interval were noted.
1	0	1	O	No
2	3	13	O	significant
3	15	21	O	effects
4	23	24	O	on
5	26	34	U-UNK	cisapride
6	36	45	O	metabolism
7	47	48	O	or
8	50	51	O	QT
9	53	60	O	interval
10	62	65	O	were
11	67	71	O	noted
NULL

Alosetron	DDI-DrugBank.d364.s20	NO_SECTION	NO_SETID	21
The effect of alosetron on monoamine oxidases and on intestinal first pass secondary to high intraluminal concentrations have not been examined.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	22	O	XXXXXXXX
5	24	25	O	on
6	27	35	O	monoamine
7	37	44	O	oxidases
8	46	48	O	and
9	50	51	O	on
10	53	62	O	intestinal
11	64	68	O	first
12	70	73	O	pass
13	75	83	O	secondary
14	85	86	O	to
15	88	91	O	high
16	93	104	O	intraluminal
17	106	119	O	concentrations
18	121	124	O	have
19	126	128	O	not
20	130	133	O	been
21	135	142	O	examined
NULL

Alosetron	DDI-DrugBank.d364.s21	NO_SECTION	NO_SETID	50
Based on the above data from in vitro and in vivo studies, it is unlikely that alosetron will inhibit the hepatic metabolic clearance of drugs metabolized by the major CYP enzyme 3A4, as well as the CYP enzymes 2D6, 2C9, 2C19, 2E1, or 1A2.
1	0	4	O	Based
2	6	7	O	on
3	9	11	O	the
4	13	17	O	above
5	19	22	O	data
6	24	27	O	from
7	29	30	O	in
8	32	36	O	vitro
9	38	40	O	and
10	42	43	O	in
11	45	48	O	vivo
12	50	56	O	studies
13	57	57	O	,
14	59	60	O	it
15	62	63	O	is
16	65	72	O	unlikely
17	74	77	O	that
18	79	87	O	XXXXXXXX
19	89	92	O	will
20	94	100	O	inhibit
21	102	104	O	the
22	106	112	O	hepatic
23	114	122	O	metabolic
24	124	132	O	clearance
25	134	135	O	of
26	137	141	O	drugs
27	143	153	O	metabolized
28	155	156	O	by
29	158	160	O	the
30	162	166	O	major
31	168	170	O	CYP
32	172	177	O	enzyme
33	179	181	O	3A4
34	182	182	O	,
35	184	185	O	as
36	187	190	O	well
37	192	193	O	as
38	195	197	O	the
39	199	201	O	CYP
40	203	209	O	enzymes
41	211	213	O	2D6
42	214	214	O	,
43	216	218	O	2C9
44	219	219	O	,
45	221	224	O	2C19
46	225	225	O	,
47	227	229	O	2E1
48	230	230	O	,
49	232	233	O	or
50	235	237	O	1A2
NULL

Alosetron	DDI-DrugBank.d364.s22	NO_SECTION	NO_SETID	15
Alosetron does not appear to induce the major cytochrome P450 (CYP) drug metabolizing enzyme 3A.
1	0	8	O	XXXXXXXX
2	10	13	O	does
3	15	17	O	not
4	19	24	O	appear
5	26	27	O	to
6	29	34	O	induce
7	36	38	O	the
8	40	44	O	major
9	46	55	O	cytochrome
10	57	60	O	P450
11	63	65	O	CYP
12	68	71	O	drug
13	73	84	O	metabolizing
14	86	91	O	enzyme
15	93	94	O	3A
NULL

Alosetron	DDI-DrugBank.d364.s23	NO_SECTION	NO_SETID	12
Alosetron also does not appear to induce CYP enzymes 2E1 or 2C19.
1	0	8	O	XXXXXXXX
2	10	13	O	also
3	15	18	O	does
4	20	22	O	not
5	24	29	O	appear
6	31	32	O	to
7	34	39	O	induce
8	41	43	O	CYP
9	45	51	O	enzymes
10	53	55	O	2E1
11	57	58	O	or
12	60	63	O	2C19
NULL

Alosetron	DDI-DrugBank.d364.s24	NO_SECTION	NO_SETID	10
It is not known whether alosetron might induce other enzymes.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	known
5	16	22	O	whether
6	24	32	O	XXXXXXXX
7	34	38	O	might
8	40	45	O	induce
9	47	51	O	other
10	53	59	O	enzymes
NULL

Alprazolam	DDI-DrugBank.d131.s0	NO_SECTION	NO_SETID	33
The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
1	0	2	O	The
2	4	18	U-UNK	benzodiazepines
3	19	19	O	,
4	21	29	O	including
5	31	40	O	XXXXXXXX
6	41	41	O	,
7	43	49	O	produce
8	51	58	O	additive
9	60	62	O	CNS
10	64	73	O	depressant
11	75	81	O	effects
12	83	86	O	when
13	88	89	O	co
14	91	102	O	administered
15	104	107	O	with
16	109	113	O	other
17	115	126	B-DYN	psychotropic
18	128	138	L-DYN	medications
19	139	139	O	,
20	141	155	U-DYN	anticonvulsants
21	156	156	O	,
22	158	172	U-DYN	antihistaminics
23	173	173	O	,
24	175	181	U-DYN	ethanol
25	182	182	O	,
26	184	186	O	and
27	188	192	O	other
28	194	198	O	drugs
29	200	204	O	which
30	206	215	O	themselves
31	217	223	O	produce
32	225	227	O	CNS
33	229	238	O	depression
NULL

Alprazolam	DDI-DrugBank.d131.s1	NO_SECTION	NO_SETID	39
The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
1	0	2	O	The
2	4	9	O	steady
3	11	15	O	state
4	17	22	O	plasma
5	24	37	O	concentrations
6	39	40	O	of
7	42	51	U-KIN	imipramine
8	53	55	O	and
9	57	67	U-KIN	desipramine
10	69	72	O	have
11	74	77	O	been
12	79	86	O	reported
13	88	89	O	to
14	91	92	O	be
15	94	102	O	increased
16	104	105	O	an
17	107	113	O	average
18	115	116	O	of
19	118	120	O	31%
20	122	124	O	and
21	126	128	O	20%
22	129	129	O	,
23	131	142	O	respectively
24	143	143	O	,
25	145	146	O	by
26	148	150	O	the
27	152	162	O	concomitant
28	164	177	O	administration
29	179	180	O	of
30	182	191	O	XXXXXXXX
31	193	199	O	tablets
32	201	202	O	in
33	204	208	O	doses
34	210	211	O	up
35	213	214	O	to
36	216	216	O	4
37	218	219	O	mg
38	220	220	O	/
39	221	223	O	day
NULL

Alprazolam	DDI-DrugBank.d131.s2	NO_SECTION	NO_SETID	8
The clinical significance of these changes is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	33	O	these
6	35	41	O	changes
7	43	44	O	is
8	46	52	O	unknown
NULL

Alprazolam	DDI-DrugBank.d131.s3	NO_SECTION	NO_SETID	25
Drugs That Inhibit Alprazolam Metabolism Via Cytochrome P450 3A: The initial step in alprazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).
1	0	4	O	Drugs
2	6	9	O	That
3	11	17	O	Inhibit
4	19	28	O	XXXXXXXX
5	30	39	O	Metabolism
6	41	43	O	Via
7	45	54	O	Cytochrome
8	56	59	O	P450
9	61	62	O	3A
10	63	63	O	:
11	65	67	O	The
12	69	75	O	initial
13	77	80	O	step
14	82	83	O	in
15	85	94	O	XXXXXXXX
16	96	105	O	metabolism
17	107	108	O	is
18	110	122	O	hydroxylation
19	124	132	O	catalyzed
20	134	135	O	by
21	137	146	O	cytochrome
22	148	151	O	P450
23	153	154	O	3A
24	157	159	O	CYP
25	161	162	O	3A
NULL

Alprazolam	DDI-DrugBank.d131.s4	NO_SECTION	NO_SETID	16
Drugs which inhibit this metabolic pathway may have a profound effect on the clearance of alprazolam .
1	0	4	O	Drugs
2	6	10	O	which
3	12	18	O	inhibit
4	20	23	O	this
5	25	33	O	metabolic
6	35	41	O	pathway
7	43	45	O	may
8	47	50	O	have
9	52	52	O	a
10	54	61	O	profound
11	63	68	O	effect
12	70	71	O	on
13	73	75	O	the
14	77	85	O	clearance
15	87	88	O	of
16	90	99	O	XXXXXXXX
NULL

Alprazolam	DDI-DrugBank.d131.s5	NO_SECTION	NO_SETID	58
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
1	0	4	O	Drugs
2	6	17	O	Demonstrated
3	19	20	O	to
4	22	23	O	be
5	25	27	O	CYP
6	29	30	O	3A
7	32	41	O	Inhibitors
8	43	44	O	of
9	46	53	O	Possible
10	55	62	O	Clinical
11	64	75	O	Significance
12	77	78	O	on
13	80	82	O	the
14	84	88	O	Basis
15	90	91	O	of
16	93	100	O	Clinical
17	102	108	O	Studies
18	110	118	O	Involving
19	120	129	O	XXXXXXXX
20	132	138	O	caution
21	140	141	O	is
22	143	153	O	recommended
23	155	160	O	during
24	162	177	O	coadministration
25	179	182	O	with
26	184	193	O	XXXXXXXX
27	195	195	O	:
28	197	212	O	Coadministration
29	214	215	O	of
30	217	226	U-KIN	fluoxetine
31	228	231	O	with
32	233	242	O	XXXXXXXX
33	244	252	O	increased
34	254	256	O	the
35	258	264	O	maximum
36	266	271	O	plasma
37	273	285	O	concentration
38	287	288	O	of
39	290	299	O	XXXXXXXX
40	301	302	O	by
41	304	306	O	46%
42	307	307	O	,
43	309	317	O	decreased
44	319	327	O	clearance
45	329	330	O	by
46	332	334	O	21%
47	335	335	O	,
48	337	345	O	increased
49	347	350	O	half
50	352	355	O	life
51	357	358	O	by
52	360	362	O	17%
53	363	363	O	,
54	365	367	O	and
55	369	377	O	decreased
56	379	386	O	measured
57	388	398	O	psychomotor
58	400	410	O	performance
NULL

Alprazolam	DDI-DrugBank.d131.s6	NO_SECTION	NO_SETID	24
Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	31	U-KIN	propoxyphene
4	33	41	O	decreased
5	43	45	O	the
6	47	53	O	maximum
7	55	60	O	plasma
8	62	74	O	concentration
9	76	77	O	of
10	79	88	O	XXXXXXXX
11	90	91	O	by
12	93	94	O	6%
13	95	95	O	,
14	97	105	O	decreased
15	107	115	O	clearance
16	117	118	O	by
17	120	122	O	38%
18	123	123	O	,
19	125	127	O	and
20	129	137	O	increased
21	139	142	O	half
22	144	147	O	life
23	149	150	O	by
24	152	154	O	58%
NULL

Alprazolam	DDI-DrugBank.d131.s7	NO_SECTION	NO_SETID	25
Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 29%.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	23	O	oral
4	25	38	U-KIN	contraceptives
5	40	48	O	increased
6	50	52	O	the
7	54	60	O	maximum
8	62	67	O	plasma
9	69	81	O	concentration
10	83	84	O	of
11	86	95	O	XXXXXXXX
12	97	98	O	by
13	100	102	O	18%
14	103	103	O	,
15	105	113	O	decreased
16	115	123	O	clearance
17	125	126	O	by
18	128	130	O	22%
19	131	131	O	,
20	133	135	O	and
21	137	145	O	increased
22	147	150	O	half
23	152	155	O	life
24	157	158	O	by
25	160	162	O	29%
NULL

Alprazolam	DDI-DrugBank.d131.s8	NO_SECTION	NO_SETID	79
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
1	0	4	O	Drugs
2	6	8	O	and
3	10	14	O	other
4	16	25	O	substances
5	27	38	O	demonstrated
6	40	41	O	to
7	43	44	O	be
8	46	48	O	CYP
9	50	51	O	3A
10	53	62	O	inhibitors
11	64	65	O	on
12	67	69	O	the
13	71	75	O	basis
14	77	78	O	of
15	80	87	O	clinical
16	89	95	O	studies
17	97	105	O	involving
18	107	121	U-UNK	benzodiazepines
19	123	133	O	metabolized
20	135	143	O	similarly
21	145	146	O	to
22	148	157	O	XXXXXXXX
23	159	160	O	or
24	162	163	O	on
25	165	167	O	the
26	169	173	O	basis
27	175	176	O	of
28	178	179	O	in
29	181	185	O	vitro
30	187	193	O	studies
31	195	198	O	with
32	200	209	O	XXXXXXXX
33	211	212	O	or
34	214	218	O	other
35	220	234	U-UNK	benzodiazepines
36	237	243	O	caution
37	245	246	O	is
38	248	258	O	recommended
39	260	265	O	during
40	267	282	O	coadministration
41	284	287	O	with
42	289	298	O	XXXXXXXX
43	300	300	O	:
44	302	310	O	Available
45	312	315	O	data
46	317	320	O	from
47	322	329	O	clinical
48	331	337	O	studies
49	339	340	O	of
50	342	356	U-UNK	benzodiazepines
51	358	362	O	other
52	364	367	O	than
53	369	378	O	XXXXXXXX
54	380	386	O	suggest
55	388	388	O	a
56	390	397	O	possible
57	399	402	O	drug
58	404	414	O	interaction
59	416	419	O	with
60	421	430	O	XXXXXXXX
61	432	434	O	for
62	436	438	O	the
63	440	448	O	following
64	449	449	O	:
65	451	459	U-UNK	diltiazem
66	460	460	O	,
67	462	470	U-UNK	isoniazid
68	471	471	O	,
69	473	481	B-UNK	macrolide
70	483	493	L-UNK	antibiotics
71	495	498	O	such
72	500	501	O	as
73	503	514	U-UNK	erythromycin
74	516	518	O	and
75	520	533	U-UNK	clarithromycin
76	534	534	O	,
77	536	538	O	and
78	540	549	O	grapefruit
79	551	555	O	juice
NULL

Alprazolam	DDI-DrugBank.d131.s9	NO_SECTION	NO_SETID	21
Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.
1	0	3	O	Data
2	5	8	O	from
3	10	11	O	in
4	13	17	O	vitro
5	19	25	O	studies
6	27	28	O	of
7	30	39	O	XXXXXXXX
8	41	47	O	suggest
9	49	49	O	a
10	51	58	O	possible
11	60	63	O	drug
12	65	75	O	interaction
13	77	80	O	with
14	82	91	O	XXXXXXXX
15	93	95	O	for
16	97	99	O	the
17	101	109	O	following
18	110	110	O	:
19	112	121	U-UNK	sertraline
20	123	125	O	and
21	127	136	U-UNK	paroxetine
NULL

Alprazolam	DDI-DrugBank.d131.s10	NO_SECTION	NO_SETID	29
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
1	0	3	O	Data
2	5	8	O	from
3	10	11	O	in
4	13	17	O	vitro
5	19	25	O	studies
6	27	28	O	of
7	30	44	U-UNK	benzodiazepines
8	46	50	O	other
9	52	55	O	than
10	57	66	O	XXXXXXXX
11	68	74	O	suggest
12	76	76	O	a
13	78	85	O	possible
14	87	90	O	drug
15	92	102	O	interaction
16	104	106	O	for
17	108	110	O	the
18	112	120	O	following
19	121	121	O	:
20	123	132	U-UNK	ergotamine
21	133	133	O	,
22	135	146	U-UNK	cyclosporine
23	147	147	O	,
24	149	158	U-UNK	amiodarone
25	159	159	O	,
26	161	171	U-UNK	nicardipine
27	172	172	O	,
28	174	176	O	and
29	178	187	U-UNK	nifedipine
NULL

Alprazolam	DDI-DrugBank.d131.s11	NO_SECTION	NO_SETID	12
Caution is recommended during the coadministration of any of these with alprazolam.
1	0	6	O	Caution
2	8	9	O	is
3	11	21	O	recommended
4	23	28	O	during
5	30	32	O	the
6	34	49	O	coadministration
7	51	52	O	of
8	54	56	O	any
9	58	59	O	of
10	61	65	O	these
11	67	70	O	with
12	72	81	O	XXXXXXXX
NULL

Alprostadil	DDI-DrugBank.d290.s0	NO_SECTION	NO_SETID	21
No drug interactions have been reported between Prostin VR Pediatric and the therapy standard in neonates with restricted pulmonary or systemic blood flow.
1	0	1	O	No
2	3	6	O	drug
3	8	19	O	interactions
4	21	24	O	have
5	26	29	O	been
6	31	38	O	reported
7	40	46	O	between
8	48	67	O	XXXXXXXX
9	69	71	O	and
10	73	75	O	the
11	77	83	O	therapy
12	85	92	O	standard
13	94	95	O	in
14	97	104	O	neonates
15	106	109	O	with
16	111	120	O	restricted
17	122	130	O	pulmonary
18	132	133	O	or
19	135	142	O	systemic
20	144	148	O	blood
21	150	153	O	flow
NULL

Alprostadil	DDI-DrugBank.d290.s1	NO_SECTION	NO_SETID	10
Standard therapy includes antibiotics, such as penicillin and gentamicin;
1	0	7	O	Standard
2	9	15	O	therapy
3	17	24	O	includes
4	26	36	U-UNK	antibiotics
5	37	37	O	,
6	39	42	O	such
7	44	45	O	as
8	47	56	U-UNK	penicillin
9	58	60	O	and
10	62	71	U-UNK	gentamicin
NULL

Alprostadil	DDI-DrugBank.d290.s2	NO_SECTION	NO_SETID	7
vasopressors, such as dopamine and isoproterenol;
1	0	11	U-UNK	vasopressors
2	12	12	O	,
3	14	17	O	such
4	19	20	O	as
5	22	29	U-UNK	dopamine
6	31	33	O	and
7	35	47	U-UNK	isoproterenol
NULL

Alprostadil	DDI-DrugBank.d290.s4	NO_SECTION	NO_SETID	6
and diuretics, such as furosemide.
1	0	2	O	and
2	4	12	U-UNK	diuretics
3	13	13	O	,
4	15	18	O	such
5	20	21	O	as
6	23	32	U-UNK	furosemide
NULL

Alprostadil	DDI-DrugBank.d290.s5	NO_SECTION	NO_SETID	19
Caverject: The potential for pharmacokinetic drug-drug interactions between alprostadil and other agents has not been formally studied.
1	0	8	O	XXXXXXXX
2	9	9	O	:
3	11	13	O	The
4	15	23	O	potential
5	25	27	O	for
6	29	43	O	pharmacokinetic
7	45	48	O	drug
8	50	53	O	drug
9	55	66	O	interactions
10	68	74	O	between
11	76	86	U-UNK	alprostadil
12	88	90	O	and
13	92	96	O	other
14	98	103	O	agents
15	105	107	O	has
16	109	111	O	not
17	113	116	O	been
18	118	125	O	formally
19	127	133	O	studied
NULL

Alteplase	DDI-DrugBank.d508.s0	NO_SECTION	NO_SETID	14
The interaction of Activase with other cardioactive or cerebroactive drugs has not been studied.
1	0	2	O	The
2	4	14	O	interaction
3	16	17	O	of
4	19	26	O	XXXXXXXX
5	28	31	O	with
6	33	37	O	other
7	39	50	O	cardioactive
8	52	53	O	or
9	55	67	O	cerebroactive
10	69	73	O	drugs
11	75	77	O	has
12	79	81	O	not
13	83	86	O	been
14	88	94	O	studied
NULL

Alteplase	DDI-DrugBank.d508.s1	NO_SECTION	NO_SETID	42
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
1	0	1	O	In
2	3	10	O	addition
3	12	13	O	to
4	15	22	O	bleeding
5	24	33	O	associated
6	35	38	O	with
7	40	46	U-DYN	heparin
8	48	50	O	and
9	52	58	B-DYN	vitamin
10	60	60	I-DYN	K
11	62	72	L-DYN	antagonists
12	73	73	O	,
13	75	79	O	drugs
14	81	84	O	that
15	86	90	O	alter
16	92	99	O	platelet
17	101	108	O	function
18	111	114	O	such
19	116	117	O	as
20	119	133	B-UNK	acetylsalicylic
21	135	138	L-UNK	acid
22	139	139	O	,
23	141	152	U-DYN	dipyridamole
24	154	156	O	and
25	158	166	U-DYN	Abciximab
26	169	171	O	may
27	173	180	O	increase
28	182	184	O	the
29	186	189	O	risk
30	191	192	O	of
31	194	201	O	bleeding
32	203	204	O	if
33	206	217	O	administered
34	219	223	O	prior
35	225	226	O	to
36	227	227	O	,
37	229	234	O	during
38	235	235	O	,
39	237	238	O	or
40	240	244	O	after
41	246	253	O	XXXXXXXX
42	255	261	O	therapy
NULL

Alteplase	DDI-DrugBank.d508.s2	NO_SECTION	NO_SETID	26
Use of Antithrombotics Aspirin and heparin have been administered concomitantly with and following infusions of Activase in the management of acute myocardial infarction or pulmonary embolism.
1	0	2	O	Use
2	4	5	O	of
3	7	21	U-UNK	Antithrombotics
4	23	29	O	Aspirin
5	31	33	O	and
6	35	41	U-UNK	heparin
7	43	46	O	have
8	48	51	O	been
9	53	64	O	administered
10	66	78	O	concomitantly
11	80	83	O	with
12	85	87	O	and
13	89	97	O	following
14	99	107	O	infusions
15	109	110	O	of
16	112	119	O	XXXXXXXX
17	121	122	O	in
18	124	126	O	the
19	128	137	O	management
20	139	140	O	of
21	142	146	O	acute
22	148	157	O	myocardial
23	159	168	O	infarction
24	170	171	O	or
25	173	181	O	pulmonary
26	183	190	O	embolism
NULL

Alteplase	DDI-DrugBank.d508.s3	NO_SECTION	NO_SETID	24
Because heparin, aspirin, or Activase may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.
1	0	6	O	Because
2	8	14	U-UNK	heparin
3	15	15	O	,
4	17	23	O	aspirin
5	24	24	O	,
6	26	27	O	or
7	29	36	O	XXXXXXXX
8	38	40	O	may
9	42	46	O	cause
10	48	55	O	bleeding
11	57	69	O	complications
12	70	70	O	,
13	72	78	O	careful
14	80	89	O	monitoring
15	91	93	O	for
16	95	102	O	bleeding
17	104	105	O	is
18	107	113	O	advised
19	114	114	O	,
20	116	125	O	especially
21	127	128	O	at
22	130	137	O	arterial
23	139	146	O	puncture
24	148	152	O	sites
NULL

Alteplase	DDI-DrugBank.d508.s4	NO_SECTION	NO_SETID	24
The concomitant use of heparin or aspirin during the first 24 hours following symptom onset were prohibited in The NINDS t-PA Stroke Trial.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	29	U-UNK	heparin
6	31	32	O	or
7	34	40	O	XXXXXXXX
8	42	47	O	during
9	49	51	O	the
10	53	57	O	first
11	59	60	O	24
12	62	66	O	hours
13	68	76	O	following
14	78	84	O	symptom
15	86	90	O	onset
16	92	95	O	were
17	97	106	O	prohibited
18	108	109	O	in
19	111	113	O	The
20	115	119	O	NINDS
21	121	121	O	t
22	123	124	O	PA
23	126	131	O	Stroke
24	133	137	O	Trial
NULL

Alteplase	DDI-DrugBank.d508.s5	NO_SECTION	NO_SETID	17
The safety of such concomitant use with Activase for the management of acute ischemic stroke is unknown.
1	0	2	O	The
2	4	9	O	safety
3	11	12	O	of
4	14	17	O	such
5	19	29	O	concomitant
6	31	33	O	use
7	35	38	O	with
8	40	47	O	XXXXXXXX
9	49	51	O	for
10	53	55	O	the
11	57	66	O	management
12	68	69	O	of
13	71	75	O	acute
14	77	84	O	ischemic
15	86	91	O	stroke
16	93	94	O	is
17	96	102	O	unknown
NULL

Altretamine	DDI-DrugBank.d188.s0	NO_SECTION	NO_SETID	34
Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	35	O	XXXXXXXX
5	37	39	O	and
6	41	55	B-DYN	antidepressants
7	57	58	I-DYN	of
8	60	62	I-DYN	the
9	64	66	I-DYN	MAO
10	68	76	I-DYN	inhibitor
11	78	82	L-DYN	class
12	84	86	O	may
13	88	92	O	cause
14	94	99	O	severe
15	101	111	O	orthostatic
16	113	134	O	hypotension.Cimetidine
17	135	135	O	,
18	137	138	O	an
19	140	148	O	inhibitor
20	150	151	O	of
21	153	162	O	microsomal
22	164	167	O	drug
23	169	178	O	metabolism
24	179	179	O	,
25	181	189	O	increased
26	191	202	O	altretamines
27	204	207	O	half
28	209	212	O	life
29	214	216	O	and
30	218	225	O	toxicity
31	227	228	O	in
32	230	230	O	a
33	232	234	O	rat
34	236	240	O	model
NULL

Altretamine	DDI-DrugBank.d188.s1	NO_SECTION	NO_SETID	22
Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;
1	0	3	O	Data
2	5	8	O	from
3	10	10	O	a
4	12	21	O	randomized
5	23	27	O	trial
6	29	30	O	of
7	32	38	O	XXXXXXXX
8	40	42	O	and
9	44	52	U-DYN	cisplatin
10	54	57	O	plus
11	59	60	O	or
12	62	66	O	minus
13	68	77	U-UNK	pyridoxine
14	79	80	O	in
15	82	88	O	ovarian
16	90	95	O	cancer
17	97	105	O	indicated
18	107	110	O	that
19	112	121	U-UNK	pyridoxine
20	123	135	O	significantly
21	137	143	O	reduced
22	145	157	O	neurotoxicity
NULL

Altretamine	DDI-DrugBank.d188.s2	NO_SECTION	NO_SETID	20
however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1
1	0	6	O	however
2	7	7	O	,
3	9	10	O	it
4	12	20	O	adversely
5	22	29	O	affected
6	31	38	O	response
7	40	47	O	duration
8	49	58	O	suggesting
9	60	63	O	that
10	65	74	U-DYN	pyridoxine
11	76	81	O	should
12	83	85	O	not
13	87	88	O	be
14	90	101	O	administered
15	103	106	O	with
16	108	114	O	XXXXXXXX
17	116	118	O	and
18	119	119	O	/
19	120	121	O	or
20	123	133	O	cisplatin.1
NULL

Amantadine	DDI-DrugBank.d116.s0	NO_SECTION	NO_SETID	14
Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.
1	0	6	O	Careful
2	8	18	O	observation
3	20	21	O	is
4	23	30	O	required
5	32	35	O	when
6	37	46	O	XXXXXXXX
7	48	49	O	is
8	51	62	O	administered
9	64	75	O	concurrently
10	77	80	O	with
11	82	88	B-DYN	central
12	90	96	I-DYN	nervous
13	98	103	I-DYN	system
14	105	114	L-DYN	stimulants
NULL

Amantadine	DDI-DrugBank.d116.s1	NO_SECTION	NO_SETID	16
Coadministration of thioridazine has been reported to worsen the tremor in elderly patients with Parkinsons disease;
1	0	15	O	Coadministration
2	17	18	O	of
3	20	31	U-UNK	thioridazine
4	33	35	O	has
5	37	40	O	been
6	42	49	O	reported
7	51	52	O	to
8	54	59	O	worsen
9	61	63	O	the
10	65	70	O	tremor
11	72	73	O	in
12	75	81	O	elderly
13	83	90	O	patients
14	92	95	O	with
15	97	106	O	Parkinsons
16	108	114	O	disease
NULL

Amantadine	DDI-DrugBank.d116.s2	NO_SECTION	NO_SETID	13
however, it is not known if other phenothiazines produce a similar response.
1	0	6	O	however
2	7	7	O	,
3	9	10	O	it
4	12	13	O	is
5	15	17	O	not
6	19	23	O	known
7	25	26	O	if
8	28	32	O	other
9	34	47	U-UNK	phenothiazines
10	49	55	O	produce
11	57	57	O	a
12	59	65	O	similar
13	67	74	O	response
NULL

Amifostine	DDI-DrugBank.d563.s0	NO_SECTION	NO_SETID	24
Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.
1	0	6	O	Special
2	8	20	O	consideration
3	22	27	O	should
4	29	30	O	be
5	32	36	O	given
6	38	39	O	to
7	41	43	O	the
8	45	58	O	administration
9	60	61	O	of
10	63	68	O	XXXXXXXX
11	70	71	O	in
12	73	80	O	patients
13	82	90	O	receiving
14	92	107	B-DYN	antihypertensive
15	109	119	L-DYN	medications
16	121	122	O	or
17	124	128	O	other
18	130	134	O	drugs
19	136	139	O	that
20	141	145	O	could
21	147	151	O	cause
22	153	154	O	or
23	156	165	O	potentiate
24	167	177	O	hypotension
NULL

Amiloride	DDI-DrugBank.d356.s0	NO_SECTION	NO_SETID	20
When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.
1	0	3	O	When
2	5	13	O	XXXXXXXX
3	15	17	O	HCl
4	19	20	O	is
5	22	33	O	administered
6	35	47	O	concomitantly
7	49	52	O	with
8	54	55	O	an
9	57	67	B-DYN	angiotensin
10	69	78	I-DYN	converting
11	80	85	I-DYN	enzyme
12	87	95	L-DYN	inhibitor
13	96	96	O	,
14	98	100	O	the
15	102	105	O	risk
16	107	108	O	of
17	110	121	O	hyperkalemia
18	123	125	O	may
19	127	128	O	be
20	130	138	O	increased
NULL

Amiloride	DDI-DrugBank.d356.s1	NO_SECTION	NO_SETID	28
Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	if
4	14	24	O	concomitant
5	26	28	O	use
6	30	31	O	of
7	33	37	O	these
8	39	44	O	agents
9	46	47	O	is
10	49	57	O	indicated
11	59	65	O	because
12	67	68	O	of
13	70	81	O	demonstrated
14	83	93	O	hypokalemia
15	94	94	O	,
16	96	99	O	they
17	101	106	O	should
18	108	109	O	be
19	111	114	O	used
20	116	119	O	with
21	121	127	O	caution
22	129	131	O	and
23	133	136	O	with
24	138	145	O	frequent
25	147	156	O	monitoring
26	158	159	O	of
27	161	165	O	serum
28	167	175	O	potassium
NULL

Amiloride	DDI-DrugBank.d356.s2	NO_SECTION	NO_SETID	22
Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
1	0	6	U-UNK	Lithium
2	8	16	O	generally
3	18	23	O	should
4	25	27	O	not
5	29	30	O	be
6	32	36	O	given
7	38	41	O	with
8	43	51	U-UNK	diuretics
9	53	59	O	because
10	61	64	O	they
11	66	71	O	reduce
12	73	75	O	its
13	77	81	O	renal
14	83	91	O	clearance
15	93	95	O	and
16	97	99	O	add
17	101	101	O	a
18	103	106	O	high
19	108	111	O	risk
20	113	114	O	of
21	116	122	O	lithium
22	124	131	O	toxicity
NULL

Amiloride	DDI-DrugBank.d356.s3	NO_SECTION	NO_SETID	11
Read circulars for lithium preparations before use of such concomitant therapy.
1	0	3	O	Read
2	5	13	O	circulars
3	15	17	O	for
4	19	25	U-UNK	lithium
5	27	38	O	preparations
6	40	45	O	before
7	47	49	O	use
8	51	52	O	of
9	54	57	O	such
10	59	69	O	concomitant
11	71	77	O	therapy
NULL

Amiloride	DDI-DrugBank.d356.s4	NO_SECTION	NO_SETID	31
In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
1	0	1	O	In
2	3	6	O	some
3	8	15	O	patients
4	16	16	O	,
5	18	20	O	the
6	22	35	O	administration
7	37	38	O	of
8	40	40	O	a
9	42	44	B-UNK	non
10	46	54	I-UNK	steroidal
11	56	59	I-UNK	anti
12	61	72	I-UNK	inflammatory
13	74	78	L-UNK	agent
14	80	82	O	can
15	84	89	O	reduce
16	91	93	O	the
17	95	102	O	diuretic
18	103	103	O	,
19	105	115	O	natriuretic
20	116	116	O	,
21	118	120	O	and
22	122	137	O	antihypertensive
23	139	145	O	effects
24	147	148	O	of
25	150	153	B-UNK	loop
26	154	154	I-UNK	,
27	156	164	I-UNK	potassium
28	166	172	I-UNK	sparing
29	174	176	I-UNK	and
30	178	185	I-UNK	thiazide
31	187	195	L-UNK	diuretics
NULL

Amiloride	DDI-DrugBank.d356.s5	NO_SECTION	NO_SETID	31
Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	22	O	XXXXXXXX
5	24	26	O	and
6	28	30	B-DYN	non
7	32	40	I-DYN	steroidal
8	42	45	I-DYN	anti
9	47	58	I-DYN	inflammatory
10	60	65	L-DYN	agents
11	67	69	O	are
12	71	74	O	used
13	76	88	O	concomitantly
14	89	89	O	,
15	91	93	O	the
16	95	101	O	patient
17	103	108	O	should
18	110	111	O	be
19	113	120	O	observed
20	122	128	O	closely
21	130	131	O	to
22	133	141	O	determine
23	143	144	O	if
24	146	148	O	the
25	150	156	O	desired
26	158	163	O	effect
27	165	166	O	of
28	168	170	O	the
29	172	179	U-UNK	diuretic
30	181	182	O	is
31	184	191	O	obtained
NULL

Amiloride	DDI-DrugBank.d356.s6	NO_SECTION	NO_SETID	38
Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
1	0	4	O	Since
2	6	17	U-DYN	indomethacin
3	19	21	O	and
4	23	31	B-UNK	potassium
5	33	39	I-UNK	sparing
6	41	49	L-UNK	diuretics
7	50	50	O	,
8	52	60	O	including
9	62	68	O	XXXXXXXX
10	69	69	O	,
11	71	73	O	may
12	75	78	O	each
13	80	81	O	be
14	83	92	O	associated
15	94	97	O	with
16	99	107	O	increased
17	109	113	O	serum
18	115	123	O	potassium
19	125	130	O	levels
20	131	131	O	,
21	133	135	O	the
22	137	145	O	potential
23	147	153	O	effects
24	155	156	O	on
25	158	166	O	potassium
26	168	175	O	kinetics
27	177	179	O	and
28	181	185	O	renal
29	187	194	O	function
30	196	201	O	should
31	203	204	O	be
32	206	215	O	considered
33	217	220	O	when
34	222	226	O	these
35	228	233	O	agents
36	235	237	O	are
37	239	250	O	administered
38	252	263	O	concurrently
NULL

Aminocaproic Acid	DDI-DrugBank.d553.s0	NO_SECTION	NO_SETID	27
Drug Laboratory Test Interactions: Prolongation of the template bleeding time has been reported during continuous intravenous infusion of AMICAR at dosages exceeding 24 g/day.
1	0	3	O	Drug
2	5	14	O	Laboratory
3	16	19	O	Test
4	21	32	O	Interactions
5	33	33	O	:
6	35	46	O	Prolongation
7	48	49	O	of
8	51	53	O	the
9	55	62	O	template
10	64	71	O	bleeding
11	73	76	O	time
12	78	80	O	has
13	82	85	O	been
14	87	94	O	reported
15	96	101	O	during
16	103	112	O	continuous
17	114	124	O	intravenous
18	126	133	O	infusion
19	135	136	O	of
20	138	143	O	XXXXXXXX
21	145	146	O	at
22	148	154	O	dosages
23	156	164	O	exceeding
24	166	167	O	24
25	169	169	O	g
26	170	170	O	/
27	171	173	O	day
NULL

Aminocaproic Acid	DDI-DrugBank.d553.s1	NO_SECTION	NO_SETID	13
Platelet function studies in these patients have not demonstrated any significant platelet dysfunction.
1	0	7	O	Platelet
2	9	16	O	function
3	18	24	O	studies
4	26	27	O	in
5	29	33	O	these
6	35	42	O	patients
7	44	47	O	have
8	49	51	O	not
9	53	64	O	demonstrated
10	66	68	O	any
11	70	80	O	significant
12	82	89	O	platelet
13	91	101	O	dysfunction
NULL

Aminocaproic Acid	DDI-DrugBank.d553.s2	NO_SECTION	NO_SETID	51
However, in vitro studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) EACA inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	16	O	vitro
5	18	24	O	studies
6	26	29	O	have
7	31	35	O	shown
8	37	40	O	that
9	42	43	O	at
10	45	48	O	high
11	50	63	O	concentrations
12	66	68	O	7.4
13	70	73	O	mMol
14	74	74	O	/
15	75	75	O	L
16	77	78	O	or
17	80	83	O	0.97
18	85	86	O	mg
19	87	87	O	/
20	88	89	O	mL
21	91	93	O	and
22	95	101	O	greater
23	104	107	U-UNK	EACA
24	109	116	O	inhibits
25	118	120	O	ADP
26	122	124	O	and
27	126	133	O	collagen
28	135	141	O	induced
29	143	150	O	platelet
30	152	162	O	aggregation
31	163	163	O	,
32	165	167	O	the
33	169	175	O	release
34	177	178	O	of
35	180	182	O	ATP
36	184	186	O	and
37	188	196	O	serotonin
38	197	197	O	,
39	199	201	O	and
40	203	205	O	the
41	207	213	O	binding
42	215	216	O	of
43	218	227	O	fibrinogen
44	229	230	O	to
45	232	234	O	the
46	236	244	O	platelets
47	246	247	O	in
48	249	249	O	a
49	251	263	O	concentration
50	265	272	O	response
51	274	279	O	manner
NULL

Aminocaproic Acid	DDI-DrugBank.d553.s3	NO_SECTION	NO_SETID	25
Following a 10 g bolus of AMICAR, transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained.
1	0	8	O	Following
2	10	10	O	a
3	12	13	O	10
4	15	15	O	g
5	17	21	O	bolus
6	23	24	O	of
7	26	31	O	XXXXXXXX
8	32	32	O	,
9	34	42	O	transient
10	44	47	O	peak
11	49	54	O	plasma
12	56	69	O	concentrations
13	71	72	O	of
14	74	76	O	4.6
15	78	81	O	mMol
16	82	82	O	/
17	83	83	O	L
18	85	86	O	or
19	88	91	O	0.60
20	93	94	O	mg
21	95	95	O	/
22	96	97	O	mL
23	99	102	O	have
24	104	107	O	been
25	109	116	O	obtained
NULL

Aminocaproic Acid	DDI-DrugBank.d553.s4	NO_SECTION	NO_SETID	20
The concentration of AMICAR necessary to maintain inhibition of fibrinolysis is 0.99 mMol/L or 0.13 mg/mL.
1	0	2	O	The
2	4	16	O	concentration
3	18	19	O	of
4	21	26	O	XXXXXXXX
5	28	36	O	necessary
6	38	39	O	to
7	41	48	O	maintain
8	50	59	O	inhibition
9	61	62	O	of
10	64	75	O	fibrinolysis
11	77	78	O	is
12	80	83	O	0.99
13	85	88	O	mMol
14	89	89	O	/
15	90	90	O	L
16	92	93	O	or
17	95	98	O	0.13
18	100	101	O	mg
19	102	102	O	/
20	103	104	O	mL
NULL

Aminocaproic Acid	DDI-DrugBank.d553.s5	NO_SECTION	NO_SETID	25
Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL.
1	0	13	O	Administration
2	15	16	O	of
3	18	18	O	a
4	20	20	O	5
5	22	22	O	g
6	24	28	O	bolus
7	30	37	O	followed
8	39	40	O	by
9	42	42	O	1
10	44	45	O	to
11	47	50	O	1.25
12	52	52	O	g
13	53	53	O	/
14	54	55	O	hr
15	57	62	O	should
16	64	70	O	achieve
17	72	74	O	and
18	76	82	O	sustain
19	84	89	O	plasma
20	91	96	O	levels
21	98	99	O	of
22	101	104	O	0.13
23	106	107	O	mg
24	108	108	O	/
25	109	110	O	mL
NULL

Aminocaproic Acid	DDI-DrugBank.d553.s6	NO_SECTION	NO_SETID	32
Thus, concentrations which have been obtained in vivo clinically in patients with normal renal function are considerably lower than the in vitro concentrations found to induce abnormalities in platelet function tests.
1	0	3	O	Thus
2	4	4	O	,
3	6	19	O	concentrations
4	21	25	O	which
5	27	30	O	have
6	32	35	O	been
7	37	44	O	obtained
8	46	47	O	in
9	49	52	O	vivo
10	54	63	O	clinically
11	65	66	O	in
12	68	75	O	patients
13	77	80	O	with
14	82	87	O	normal
15	89	93	O	renal
16	95	102	O	function
17	104	106	O	are
18	108	119	O	considerably
19	121	125	O	lower
20	127	130	O	than
21	132	134	O	the
22	136	137	O	in
23	139	143	O	vitro
24	145	158	O	concentrations
25	160	164	O	found
26	166	167	O	to
27	169	174	O	induce
28	176	188	O	abnormalities
29	190	191	O	in
30	193	200	O	platelet
31	202	209	O	function
32	211	215	O	tests
NULL

Aminocaproic Acid	DDI-DrugBank.d553.s7	NO_SECTION	NO_SETID	15
However, higher plasma concentrations of AMICAR may occur in patients with severe renal failure.
1	0	6	O	However
2	7	7	O	,
3	9	14	O	higher
4	16	21	O	plasma
5	23	36	O	concentrations
6	38	39	O	of
7	41	46	O	XXXXXXXX
8	48	50	O	may
9	52	56	O	occur
10	58	59	O	in
11	61	68	O	patients
12	70	73	O	with
13	75	80	O	severe
14	82	86	O	renal
15	88	94	O	failure
NULL

Aminoglutethimide	DDI-DrugBank.d372.s0	NO_SECTION	NO_SETID	6
Cytadren accelerates the metabolism of dexamethasone;
1	0	7	O	XXXXXXXX
2	9	19	O	accelerates
3	21	23	O	the
4	25	34	O	metabolism
5	36	37	O	of
6	39	51	U-KIN	dexamethasone
NULL

Aminoglutethimide	DDI-DrugBank.d372.s1	NO_SECTION	NO_SETID	12
therefore, if glucocorticoid replacement is needed, hydrocortisone should be prescribed.
1	0	8	O	therefore
2	9	9	O	,
3	11	12	O	if
4	14	27	U-UNK	glucocorticoid
5	29	39	O	replacement
6	41	42	O	is
7	44	49	O	needed
8	50	50	O	,
9	52	65	U-UNK	hydrocortisone
10	67	72	O	should
11	74	75	O	be
12	77	86	O	prescribed
NULL

Aminoglutethimide	DDI-DrugBank.d372.s2	NO_SECTION	NO_SETID	8
Aminoglutethimide diminishes the effect of coumarin and warfarin.
1	0	16	O	XXXXXXXX
2	18	27	O	diminishes
3	29	31	O	the
4	33	38	O	effect
5	40	41	O	of
6	43	50	U-DYN	coumarin
7	52	54	O	and
8	56	63	U-DYN	warfarin
NULL

Aminohippurate	DDI-DrugBank.d416.s0	NO_SECTION	NO_SETID	21
Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.
1	0	4	O	Renal
2	6	14	O	clearance
3	16	27	O	measurements
4	29	30	O	of
5	32	34	U-UNK	PAH
6	36	41	O	cannot
7	43	44	O	be
8	46	49	O	made
9	51	54	O	with
10	56	58	O	any
11	60	70	O	significant
12	72	79	O	accuracy
13	81	82	O	in
14	84	91	O	patients
15	93	101	O	receiving
16	103	114	U-UNK	sulfonamides
17	115	115	O	,
18	117	124	U-UNK	procaine
19	125	125	O	,
20	127	128	O	or
21	130	144	U-UNK	thiazolesulfone
NULL

Aminohippurate	DDI-DrugBank.d416.s1	NO_SECTION	NO_SETID	12
These compounds interfere with chemical color development essential to the analytical procedures.
1	0	4	O	These
2	6	14	O	compounds
3	16	24	O	interfere
4	26	29	O	with
5	31	38	O	chemical
6	40	44	O	color
7	46	56	O	development
8	58	66	O	essential
9	68	69	O	to
10	71	73	O	the
11	75	84	O	analytical
12	86	95	O	procedures
NULL

Aminohippurate	DDI-DrugBank.d416.s2	NO_SECTION	NO_SETID	11
Probenecid depresses tubular secretion of certain weak acids such as PAH.
1	0	9	U-UNK	Probenecid
2	11	19	O	depresses
3	21	27	O	tubular
4	29	37	O	secretion
5	39	40	O	of
6	42	48	O	certain
7	50	53	O	weak
8	55	59	O	acids
9	61	64	O	such
10	66	67	O	as
11	69	71	U-UNK	PAH
NULL

Aminohippurate	DDI-DrugBank.d416.s3	NO_SECTION	NO_SETID	14
Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	O	patients
4	20	28	O	receiving
5	30	39	U-UNK	probenecid
6	41	44	O	will
7	46	49	O	have
8	51	61	O	erroneously
9	63	65	O	low
10	67	70	O	ERPF
11	72	74	O	and
12	76	77	O	Tm
13	79	81	U-UNK	PAH
14	83	88	O	values
NULL

Aminolevulinic acid	DDI-DrugBank.d379.s0	NO_SECTION	NO_SETID	33
There have been no formal studies of the interaction of LEVULAN KERASTICK for Topical Solution with any other drugs, and no drug-specific interactions were noted during any of the controlled clinical trials.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	17	O	no
5	19	24	O	formal
6	26	32	O	studies
7	34	35	O	of
8	37	39	O	the
9	41	51	O	interaction
10	53	54	O	of
11	56	72	O	XXXXXXXX
12	74	76	O	for
13	78	84	O	Topical
14	86	93	O	Solution
15	95	98	O	with
16	100	102	O	any
17	104	108	O	other
18	110	114	O	drugs
19	115	115	O	,
20	117	119	O	and
21	121	122	O	no
22	124	127	O	drug
23	129	136	O	specific
24	138	149	O	interactions
25	151	154	O	were
26	156	160	O	noted
27	162	167	O	during
28	169	171	O	any
29	173	174	O	of
30	176	178	O	the
31	180	189	O	controlled
32	191	198	O	clinical
33	200	205	O	trials
NULL

Aminolevulinic acid	DDI-DrugBank.d379.s1	NO_SECTION	NO_SETID	43
It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
1	0	1	O	It
2	3	4	O	is
3	5	5	O	,
4	7	13	O	however
5	14	14	O	,
6	16	23	O	possible
7	25	28	O	that
8	30	40	O	concomitant
9	42	44	O	use
10	46	47	O	of
11	49	53	O	other
12	55	59	O	known
13	61	76	B-DYN	photosensitizing
14	78	83	L-DYN	agents
15	85	88	O	such
16	90	91	O	as
17	93	104	U-DYN	griseofulvin
18	105	105	O	,
19	107	114	B-DYN	thiazide
20	116	124	L-DYN	diuretics
21	125	125	O	,
22	127	139	U-DYN	sulfonylureas
23	140	140	O	,
24	142	155	U-DYN	phenothiazines
25	156	156	O	,
26	158	169	U-DYN	sulfonamides
27	171	173	O	and
28	175	187	U-DYN	tetracyclines
29	189	193	O	might
30	195	202	O	increase
31	204	206	O	the
32	208	223	O	photosensitivity
33	225	232	O	reaction
34	234	235	O	of
35	237	243	O	actinic
36	245	253	O	keratoses
37	255	261	O	treated
38	263	266	O	with
39	268	270	O	the
40	272	288	O	XXXXXXXX
41	290	292	O	for
42	294	300	O	Topical
43	302	309	O	Solution
NULL

Aminosalicylic Acid	DDI-DrugBank.d22.s0	NO_SECTION	NO_SETID	17
Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.
1	0	13	B-KIN	Aminosalicylic
2	15	18	L-KIN	acid
3	20	22	O	may
4	24	31	O	decrease
5	33	35	O	the
6	37	42	O	amount
7	44	45	O	of
8	47	53	U-UNK	digoxin
9	56	62	O	XXXXXXXX
10	63	63	O	,
11	65	74	U-UNK	Lanoxicaps
12	77	80	O	that
13	82	85	O	gets
14	87	94	O	absorbed
15	96	99	O	into
16	101	104	O	your
17	106	109	O	body
NULL

Aminosalicylic Acid	DDI-DrugBank.d22.s1	NO_SECTION	NO_SETID	19
In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.
1	0	1	O	In
2	3	5	O	the
3	7	10	O	case
4	12	15	O	that
5	17	19	O	you
6	21	23	O	are
7	25	30	O	taking
8	32	38	U-DYN	digoxin
9	40	44	O	while
10	46	51	O	taking
11	53	71	O	XXXXXXXX
12	72	72	O	,
13	74	79	O	higher
14	81	85	O	doses
15	87	88	O	of
16	90	96	U-UNK	digoxin
17	98	100	O	may
18	102	103	O	be
19	105	110	O	needed
NULL

Aminosalicylic Acid	DDI-DrugBank.d22.s2	NO_SECTION	NO_SETID	16
Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.
1	0	18	O	XXXXXXXX
2	20	22	O	may
3	24	27	O	also
4	29	36	O	decrease
5	38	40	O	the
6	42	51	O	absorption
7	53	54	O	of
8	56	62	B-KIN	vitamin
9	64	66	L-KIN	B12
10	67	67	O	,
11	69	73	O	which
12	75	77	O	can
13	79	82	O	lead
14	84	85	O	to
15	87	87	O	a
16	89	98	O	deficiency
NULL

Aminosalicylic Acid	DDI-DrugBank.d22.s3	NO_SECTION	NO_SETID	13
Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.
1	0	8	O	Therefore
2	10	12	O	you
3	14	16	O	may
4	18	21	O	need
5	23	24	O	to
6	26	29	O	take
7	31	31	O	a
8	33	39	B-DYN	vitamin
9	41	43	L-DYN	B12
10	45	54	O	supplement
11	56	60	O	while
12	62	67	O	taking
13	69	87	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s0	NO_SECTION	NO_SETID	21
Amiodarone is metabolized to desethylamiodarone by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	metabolized
4	26	27	O	to
5	29	36	O	desethyl
6	37	46	O	XXXXXXXX
7	48	49	O	by
8	51	53	O	the
9	55	64	O	cytochrome
10	66	69	O	P450
11	72	77	O	CYP450
12	80	85	O	enzyme
13	87	91	O	group
14	92	92	O	,
15	94	105	O	specifically
16	107	117	O	cytochromes
17	119	122	O	P450
18	124	126	O	3A4
19	129	134	O	CYP3A4
20	137	139	O	and
21	141	146	O	CYP2C8
NULL

Amiodarone	DDI-DrugBank.d143.s1	NO_SECTION	NO_SETID	11
The CYP3A4 isoenzyme is present in both the liver and intestines.
1	0	2	O	The
2	4	9	O	CYP3A4
3	11	19	O	isoenzyme
4	21	22	O	is
5	24	30	O	present
6	32	33	O	in
7	35	38	O	both
8	40	42	O	the
9	44	48	O	liver
10	50	52	O	and
11	54	63	O	intestines
NULL

Amiodarone	DDI-DrugBank.d143.s2	NO_SECTION	NO_SETID	10
Amiodarone is also known to be an inhibitor of CYP3A4.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	17	O	also
4	19	23	O	known
5	25	26	O	to
6	28	29	O	be
7	31	32	O	an
8	34	42	O	inhibitor
9	44	45	O	of
10	47	52	O	CYP3A4
NULL

Amiodarone	DDI-DrugBank.d143.s3	NO_SECTION	NO_SETID	22
Therefore, amiodarone has the potential for interactions with drugs or substances that may be substrates, inhibitors or inducers of CYP3A4.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	XXXXXXXX
4	22	24	O	has
5	26	28	O	the
6	30	38	O	potential
7	40	42	O	for
8	44	55	O	interactions
9	57	60	O	with
10	62	66	O	drugs
11	68	69	O	or
12	71	80	O	substances
13	82	85	O	that
14	87	89	O	may
15	91	92	O	be
16	94	103	O	substrates
17	104	104	O	,
18	106	115	O	inhibitors
19	117	118	O	or
20	120	127	O	inducers
21	129	130	O	of
22	132	137	O	CYP3A4
NULL

Amiodarone	DDI-DrugBank.d143.s4	NO_SECTION	NO_SETID	31
While only a limited number of in vivo drug-drug interactions with amiodarone have been reported, chiefly with the oral formulation, the potential for other interactions should be anticipated.
1	0	4	O	While
2	6	9	O	only
3	11	11	O	a
4	13	19	O	limited
5	21	26	O	number
6	28	29	O	of
7	31	32	O	in
8	34	37	O	vivo
9	39	42	O	drug
10	44	47	O	drug
11	49	60	O	interactions
12	62	65	O	with
13	67	76	O	XXXXXXXX
14	78	81	O	have
15	83	86	O	been
16	88	95	O	reported
17	96	96	O	,
18	98	104	O	chiefly
19	106	109	O	with
20	111	113	O	the
21	115	118	O	oral
22	120	130	O	formulation
23	131	131	O	,
24	133	135	O	the
25	137	145	O	potential
26	147	149	O	for
27	151	155	O	other
28	157	168	O	interactions
29	170	175	O	should
30	177	178	O	be
31	180	190	O	anticipated
NULL

Amiodarone	DDI-DrugBank.d143.s5	NO_SECTION	NO_SETID	15
This is especially important for drugs associated with serious toxicity, such as other antiarrhythmics.
1	0	3	O	This
2	5	6	O	is
3	8	17	O	especially
4	19	27	O	important
5	29	31	O	for
6	33	37	O	drugs
7	39	48	O	associated
8	50	53	O	with
9	55	61	O	serious
10	63	70	O	toxicity
11	71	71	O	,
12	73	76	O	such
13	78	79	O	as
14	81	85	O	other
15	87	101	U-UNK	antiarrhythmics
NULL

Amiodarone	DDI-DrugBank.d143.s6	NO_SECTION	NO_SETID	19
If such drugs are needed, their dose should be reassessed and, where appropriate, plasma concentration measured.
1	0	1	O	If
2	3	6	O	such
3	8	12	O	drugs
4	14	16	O	are
5	18	23	O	needed
6	24	24	O	,
7	26	30	O	their
8	32	35	O	dose
9	37	42	O	should
10	44	45	O	be
11	47	56	O	reassessed
12	58	60	O	and
13	61	61	O	,
14	63	67	O	where
15	69	79	O	appropriate
16	80	80	O	,
17	82	87	O	plasma
18	89	101	O	concentration
19	103	110	O	measured
NULL

Amiodarone	DDI-DrugBank.d143.s7	NO_SECTION	NO_SETID	31
In view of the long and variable half-life of amiodarone, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of amiodarone.
1	0	1	O	In
2	3	6	O	view
3	8	9	O	of
4	11	13	O	the
5	15	18	O	long
6	20	22	O	and
7	24	31	O	variable
8	33	36	O	half
9	38	41	O	life
10	43	44	O	of
11	46	55	O	XXXXXXXX
12	56	56	O	,
13	58	66	O	potential
14	68	70	O	for
15	72	75	O	drug
16	77	88	O	interactions
17	90	95	O	exists
18	97	99	O	not
19	101	104	O	only
20	106	109	O	with
21	111	121	O	concomitant
22	123	132	O	medication
23	134	136	O	but
24	138	141	O	also
25	143	146	O	with
26	148	152	O	drugs
27	154	165	O	administered
28	167	171	O	after
29	173	187	O	discontinuation
30	189	190	O	of
31	192	201	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s8	NO_SECTION	NO_SETID	27
Since amiodarone is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of amiodarone.
1	0	4	O	Since
2	6	15	O	XXXXXXXX
3	17	18	O	is
4	20	20	O	a
5	22	30	O	substrate
6	32	34	O	for
7	36	41	O	CYP3A4
8	43	45	O	and
9	47	52	O	CYP2C8
10	53	53	O	,
11	55	59	O	drugs
12	60	60	O	/
13	61	70	O	substances
14	72	75	O	that
15	77	83	O	inhibit
16	85	89	O	these
17	91	100	O	isoenzymes
18	102	104	O	may
19	106	113	O	decrease
20	115	117	O	the
21	119	128	O	metabolism
22	130	132	O	and
23	134	141	O	increase
24	143	147	O	serum
25	149	161	O	concentration
26	163	164	O	of
27	166	175	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s9	NO_SECTION	NO_SETID	19
Reported examples include the following: Protease Inhibitors: Protease inhibitors are known to inhibit CYP3A4 to varying degrees.
1	0	7	O	Reported
2	9	16	O	examples
3	18	24	O	include
4	26	28	O	the
5	30	38	O	following
6	39	39	O	:
7	41	48	B-UNK	Protease
8	50	59	L-UNK	Inhibitors
9	60	60	O	:
10	62	69	B-UNK	Protease
11	71	80	L-UNK	inhibitors
12	82	84	O	are
13	86	90	O	known
14	92	93	O	to
15	95	101	O	inhibit
16	103	108	O	CYP3A4
17	110	111	O	to
18	113	119	O	varying
19	121	127	O	degrees
NULL

Amiodarone	DDI-DrugBank.d143.s10	NO_SECTION	NO_SETID	34
A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.
1	0	0	O	A
2	2	5	O	case
3	7	12	O	report
4	14	15	O	of
5	17	19	O	one
6	21	27	O	patient
7	29	34	O	taking
8	36	45	O	XXXXXXXX
9	47	49	O	200
10	51	52	O	mg
11	54	56	O	and
12	58	66	U-KIN	indinavir
13	68	70	O	800
14	72	73	O	mg
15	75	79	O	three
16	81	85	O	times
17	87	87	O	a
18	89	91	O	day
19	93	100	O	resulted
20	102	103	O	in
21	105	113	O	increases
22	115	116	O	in
23	118	127	O	XXXXXXXX
24	129	142	O	concentrations
25	144	147	O	from
26	149	151	O	0.9
27	153	154	O	mg
28	155	155	O	/
29	156	156	O	L
30	158	159	O	to
31	161	163	O	1.3
32	165	166	O	mg
33	167	167	O	/
34	168	168	O	L
NULL

Amiodarone	DDI-DrugBank.d143.s11	NO_SECTION	NO_SETID	5
DEA concentrations were not affected.
1	0	2	O	DEA
2	4	17	O	concentrations
3	19	22	O	were
4	24	26	O	not
5	28	35	O	affected
NULL

Amiodarone	DDI-DrugBank.d143.s12	NO_SECTION	NO_SETID	6
There was no evidence of toxicity.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	20	O	evidence
5	22	23	O	of
6	25	32	O	toxicity
NULL

Amiodarone	DDI-DrugBank.d143.s13	NO_SECTION	NO_SETID	19
Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.
1	0	9	O	Monitoring
2	11	13	O	for
3	15	24	O	XXXXXXXX
4	26	33	O	toxicity
5	35	37	O	and
6	39	44	O	serial
7	46	56	O	measurement
8	58	59	O	of
9	61	70	O	XXXXXXXX
10	72	76	O	serum
11	78	90	O	concentration
12	92	97	O	during
13	99	109	O	concomitant
14	111	118	B-DYN	protease
15	120	128	L-DYN	inhibitor
16	130	136	O	therapy
17	138	143	O	should
18	145	146	O	be
19	148	157	O	considered
NULL

Amiodarone	DDI-DrugBank.d143.s14	NO_SECTION	NO_SETID	13
Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.
1	0	8	B-UNK	Histamine
2	10	11	I-UNK	H2
3	13	23	L-UNK	antagonists
4	24	24	O	:
5	26	35	U-UNK	Cimetidine
6	37	44	O	inhibits
7	46	51	O	CYP3A4
8	53	55	O	and
9	57	59	O	can
10	61	68	O	increase
11	70	74	O	serum
12	76	85	O	XXXXXXXX
13	87	92	O	levels
NULL

Amiodarone	DDI-DrugBank.d143.s15	NO_SECTION	NO_SETID	26
Other substances: Grapefruit juice given to healthy volunteers increased amiodarone AUC by 50% and Cmax by 84%, resulting in increased plasma levels of amiodarone.
1	0	4	O	Other
2	6	15	O	substances
3	16	16	O	:
4	18	27	O	Grapefruit
5	29	33	O	juice
6	35	39	O	given
7	41	42	O	to
8	44	50	O	healthy
9	52	61	O	volunteers
10	63	71	O	increased
11	73	82	O	XXXXXXXX
12	84	86	O	AUC
13	88	89	O	by
14	91	93	O	50%
15	95	97	O	and
16	99	102	O	Cmax
17	104	105	O	by
18	107	109	O	84%
19	110	110	O	,
20	112	120	O	resulting
21	122	123	O	in
22	125	133	O	increased
23	135	140	O	plasma
24	142	147	O	levels
25	149	150	O	of
26	152	161	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s16	NO_SECTION	NO_SETID	11
Grapefruit juice should not be taken during treatment with oral amiodarone.
1	0	9	O	Grapefruit
2	11	15	O	juice
3	17	22	O	should
4	24	26	O	not
5	28	29	O	be
6	31	35	O	taken
7	37	42	O	during
8	44	52	O	treatment
9	54	57	O	with
10	59	62	O	oral
11	64	73	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s17	NO_SECTION	NO_SETID	13
This information should be considered when changing from intravenous amiodarone to oral amiodarone .
1	0	3	O	This
2	5	15	O	information
3	17	22	O	should
4	24	25	O	be
5	27	36	O	considered
6	38	41	O	when
7	43	50	O	changing
8	52	55	O	from
9	57	67	O	intravenous
10	69	78	O	XXXXXXXX
11	80	81	O	to
12	83	86	O	oral
13	88	97	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s18	NO_SECTION	NO_SETID	16
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4.
1	0	9	O	XXXXXXXX
2	11	13	O	may
3	15	22	O	suppress
4	24	30	O	certain
5	32	37	O	CYP450
6	39	45	O	enzymes
7	46	46	O	,
8	48	56	O	including
9	58	63	U-UNK	CYP1A2
10	64	64	O	,
11	66	71	U-UNK	CYP2C9
12	72	72	O	,
13	74	79	U-UNK	CYP2D6
14	80	80	O	,
15	82	84	O	and
16	86	91	U-UNK	CYP3A4
NULL

Amiodarone	DDI-DrugBank.d143.s19	NO_SECTION	NO_SETID	19
This inhibition can result in unexpectedly high plasma levels of other drugs which are metabolized by those CYP450 enzymes.
1	0	3	O	This
2	5	14	O	inhibition
3	16	18	O	can
4	20	25	O	result
5	27	28	O	in
6	30	41	O	unexpectedly
7	43	46	O	high
8	48	53	O	plasma
9	55	60	O	levels
10	62	63	O	of
11	65	69	O	other
12	71	75	U-UNK	drugs
13	77	81	O	which
14	83	85	O	are
15	87	97	O	metabolized
16	99	100	O	by
17	102	106	O	those
18	108	113	O	CYP450
19	115	121	O	enzymes
NULL

Amiodarone	DDI-DrugBank.d143.s20	NO_SECTION	NO_SETID	42
Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.
1	0	7	O	Reported
2	9	16	O	examples
3	18	19	O	of
4	21	24	O	this
5	26	36	O	interaction
6	38	44	O	include
7	46	48	O	the
8	50	58	O	following
9	59	59	O	:
10	61	78	O	Immunosuppressives
11	79	79	O	:
12	81	92	U-UNK	Cyclosporine
13	95	100	U-UNK	CYP3A4
14	102	110	O	substrate
15	113	124	O	administered
16	126	127	O	in
17	129	139	O	combination
18	141	144	O	with
19	146	149	O	oral
20	151	160	O	XXXXXXXX
21	162	164	O	has
22	166	169	O	been
23	171	178	O	reported
24	180	181	O	to
25	183	189	O	produce
26	191	202	O	persistently
27	204	211	O	elevated
28	213	218	O	plasma
29	220	233	O	concentrations
30	235	236	O	of
31	238	249	U-UNK	cyclosporine
32	251	259	O	resulting
33	261	262	O	in
34	264	271	O	elevated
35	273	282	O	creatinine
36	283	283	O	,
37	285	291	O	despite
38	293	301	O	reduction
39	303	304	O	in
40	306	309	O	dose
41	311	312	O	of
42	314	325	U-UNK	cyclosporine
NULL

Amiodarone	DDI-DrugBank.d143.s21	NO_SECTION	NO_SETID	21
HMG-CoA Reductase Inhibitors: Simvastatin (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.
1	0	2	B-UNK	HMG
2	4	6	I-UNK	CoA
3	8	16	I-UNK	Reductase
4	18	27	L-UNK	Inhibitors
5	28	28	O	:
6	30	40	U-UNK	Simvastatin
7	43	48	U-UNK	CYP3A4
8	50	58	O	substrate
9	61	62	O	in
10	64	74	O	combination
11	76	79	O	with
12	81	90	O	XXXXXXXX
13	92	94	O	has
14	96	99	O	been
15	101	110	O	associated
16	112	115	O	with
17	117	123	O	reports
18	125	126	O	of
19	128	135	O	myopathy
20	136	136	O	/
21	137	150	O	rhabdomyolysis
NULL

Amiodarone	DDI-DrugBank.d143.s22	NO_SECTION	NO_SETID	33
Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.
1	0	14	O	Cardiovasculars
2	15	15	O	:
3	17	23	B-UNK	Cardiac
4	25	34	L-UNK	glycosides
5	35	35	O	:
6	37	38	O	In
7	40	47	O	patients
8	49	57	O	receiving
9	59	65	U-UNK	digoxin
10	67	73	O	therapy
11	74	74	O	,
12	76	89	O	administration
13	91	92	O	of
14	94	97	O	oral
15	99	108	O	XXXXXXXX
16	110	118	O	regularly
17	120	126	O	results
18	128	129	O	in
19	131	132	O	an
20	134	141	O	increase
21	143	144	O	in
22	146	150	O	serum
23	152	158	U-UNK	digoxin
24	160	172	O	concentration
25	174	177	O	that
26	179	181	O	may
27	183	187	O	reach
28	189	193	O	toxic
29	195	200	O	levels
30	202	205	O	with
31	207	215	O	resultant
32	217	224	O	clinical
33	226	233	O	toxicity
NULL

Amiodarone	DDI-DrugBank.d143.s23	NO_SECTION	NO_SETID	15
Amiodarone taken concomitantly with digoxin increases the serum digoxin concentration by 70% after one day.
1	0	9	O	XXXXXXXX
2	11	15	O	taken
3	17	29	O	concomitantly
4	31	34	O	with
5	36	42	U-UNK	digoxin
6	44	52	O	increases
7	54	56	O	the
8	58	62	O	serum
9	64	70	U-UNK	digoxin
10	72	84	O	concentration
11	86	87	O	by
12	89	91	O	70%
13	93	97	O	after
14	99	101	O	one
15	103	105	O	day
NULL

Amiodarone	DDI-DrugBank.d143.s24	NO_SECTION	NO_SETID	23
On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.
1	0	1	O	On
2	3	16	O	administration
3	18	19	O	of
4	21	24	O	oral
5	26	35	O	XXXXXXXX
6	36	36	O	,
7	38	40	O	the
8	42	45	O	need
9	47	49	O	for
10	51	59	U-DYN	digitalis
11	61	67	O	therapy
12	69	74	O	should
13	76	77	O	be
14	79	86	O	reviewed
15	88	90	O	and
16	92	94	O	the
17	96	99	O	dose
18	101	107	O	reduced
19	109	110	O	by
20	112	124	O	approximately
21	126	128	O	50%
22	130	131	O	or
23	133	144	O	discontinued
NULL

Amiodarone	DDI-DrugBank.d143.s25	NO_SECTION	NO_SETID	20
If digitalis treatment is continued, serum levels should be closely monitored and patients observed for clinical evidence of toxicity.
1	0	1	O	If
2	3	11	U-UNK	digitalis
3	13	21	O	treatment
4	23	24	O	is
5	26	34	O	continued
6	35	35	O	,
7	37	41	O	serum
8	43	48	O	levels
9	50	55	O	should
10	57	58	O	be
11	60	66	O	closely
12	68	76	O	monitored
13	78	80	O	and
14	82	89	O	patients
15	91	98	O	observed
16	100	102	O	for
17	104	111	O	clinical
18	113	120	O	evidence
19	122	123	O	of
20	125	132	O	toxicity
NULL

Amiodarone	DDI-DrugBank.d143.s26	NO_SECTION	NO_SETID	10
These precautions probably should apply to digitoxin administration as well.
1	0	4	O	These
2	6	16	O	precautions
3	18	25	O	probably
4	27	32	O	should
5	34	38	O	apply
6	40	41	O	to
7	43	51	U-UNK	digitoxin
8	53	66	O	administration
9	68	69	O	as
10	71	74	O	well
NULL

Amiodarone	DDI-DrugBank.d143.s27	NO_SECTION	NO_SETID	23
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.
1	0	14	U-UNK	Antiarrhythmics
2	15	15	O	:
3	17	21	O	Other
4	23	36	U-UNK	antiarrhythmic
5	38	42	O	drugs
6	43	43	O	,
7	45	48	O	such
8	50	51	O	as
9	53	61	U-UNK	quinidine
10	62	62	O	,
11	64	75	U-UNK	procainamide
12	76	76	O	,
13	78	89	U-UNK	disopyramide
14	90	90	O	,
15	92	94	O	and
16	96	104	U-UNK	phenytoin
17	105	105	O	,
18	107	110	O	have
19	112	115	O	been
20	117	120	O	used
21	122	133	O	concurrently
22	135	138	O	with
23	140	149	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s28	NO_SECTION	NO_SETID	22
There have been case reports of increased steady-state levels of quinidine, procainamide, and phenytoin during concomitant therapy with amiodarone.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	19	O	case
5	21	27	O	reports
6	29	30	O	of
7	32	40	O	increased
8	42	47	O	steady
9	49	53	O	state
10	55	60	O	levels
11	62	63	O	of
12	65	73	U-UNK	quinidine
13	74	74	O	,
14	76	87	U-UNK	procainamide
15	88	88	O	,
16	90	92	O	and
17	94	102	U-UNK	phenytoin
18	104	109	O	during
19	111	121	O	concomitant
20	123	129	O	therapy
21	131	134	O	with
22	136	145	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s29	NO_SECTION	NO_SETID	5
Phenytoin decreases serum amiodarone levels.
1	0	8	U-UNK	Phenytoin
2	10	18	O	decreases
3	20	24	O	serum
4	26	35	O	XXXXXXXX
5	37	42	O	levels
NULL

Amiodarone	DDI-DrugBank.d143.s30	NO_SECTION	NO_SETID	14
Amiodarone taken concomitantly with quinidine increases quinidine serum concentration by 33% after two days.
1	0	9	O	XXXXXXXX
2	11	15	O	taken
3	17	29	O	concomitantly
4	31	34	O	with
5	36	44	U-UNK	quinidine
6	46	54	O	increases
7	56	64	U-UNK	quinidine
8	66	70	O	serum
9	72	84	O	concentration
10	86	87	O	by
11	89	91	O	33%
12	93	97	O	after
13	99	101	O	two
14	103	106	O	days
NULL

Amiodarone	DDI-DrugBank.d143.s31	NO_SECTION	NO_SETID	25
Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.
1	0	9	O	XXXXXXXX
2	11	15	O	taken
3	17	29	O	concomitantly
4	31	34	O	with
5	36	47	U-UNK	procainamide
6	49	51	O	for
7	53	56	O	less
8	58	61	O	than
9	63	67	O	seven
10	69	72	O	days
11	74	82	O	increases
12	84	89	O	plasma
13	91	104	O	concentrations
14	106	107	O	of
15	109	120	U-UNK	procainamide
16	122	124	O	and
17	126	126	O	n
18	128	133	O	acetyl
19	135	146	U-UNK	procainamide
20	148	149	O	by
21	151	153	O	55%
22	155	157	O	and
23	159	161	O	33%
24	162	162	O	,
25	164	175	O	respectively
NULL

Amiodarone	DDI-DrugBank.d143.s32	NO_SECTION	NO_SETID	16
Quinidine and procainamide doses should be reduced by one-third when either is administered with amiodarone.
1	0	8	U-UNK	Quinidine
2	10	12	O	and
3	14	25	O	procainamide
4	27	31	O	doses
5	33	38	O	should
6	40	41	O	be
7	43	49	O	reduced
8	51	52	O	by
9	54	56	O	one
10	58	62	O	third
11	64	67	O	when
12	69	74	O	either
13	76	77	O	is
14	79	90	O	administered
15	92	95	O	with
16	97	106	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s33	NO_SECTION	NO_SETID	15
Plasma levels of flecainide have been reported to increase in the presence of oral amiodarone;
1	0	5	O	Plasma
2	7	12	O	levels
3	14	15	O	of
4	17	26	U-UNK	flecainide
5	28	31	O	have
6	33	36	O	been
7	38	45	O	reported
8	47	48	O	to
9	50	57	O	increase
10	59	60	O	in
11	62	64	O	the
12	66	73	O	presence
13	75	76	O	of
14	78	81	O	oral
15	83	92	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s34	NO_SECTION	NO_SETID	17
because of this, the dosage of flecainide should be adjusted when these drugs are administered concomitantly.
1	0	6	O	because
2	8	9	O	of
3	11	14	O	this
4	15	15	O	,
5	17	19	O	the
6	21	26	O	dosage
7	28	29	O	of
8	31	40	U-UNK	flecainide
9	42	47	O	should
10	49	50	O	be
11	52	59	O	adjusted
12	61	64	O	when
13	66	70	O	these
14	72	76	U-UNK	drugs
15	78	80	O	are
16	82	93	O	administered
17	95	107	O	concomitantly
NULL

Amiodarone	DDI-DrugBank.d143.s35	NO_SECTION	NO_SETID	19
In general, any added antiarrhythmic drug should be initiated at a lower than usual dose with careful monitoring.
1	0	1	O	In
2	3	9	O	general
3	10	10	O	,
4	12	14	O	any
5	16	20	O	added
6	22	35	B-UNK	antiarrhythmic
7	37	40	L-UNK	drug
8	42	47	O	should
9	49	50	O	be
10	52	60	O	initiated
11	62	63	O	at
12	65	65	O	a
13	67	71	O	lower
14	73	76	O	than
15	78	82	O	usual
16	84	87	O	dose
17	89	92	O	with
18	94	100	O	careful
19	102	111	O	monitoring
NULL

Amiodarone	DDI-DrugBank.d143.s36	NO_SECTION	NO_SETID	30
Combination of amiodarone with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.
1	0	10	O	Combination
2	12	13	O	of
3	15	24	O	XXXXXXXX
4	26	29	O	with
5	31	35	O	other
6	37	50	U-UNK	antiarrhythmic
7	52	58	O	therapy
8	60	65	O	should
9	67	68	O	be
10	70	77	O	reserved
11	79	81	O	for
12	83	90	O	patients
13	92	95	O	with
14	97	100	O	life
15	102	112	O	threatening
16	114	124	O	ventricular
17	126	136	O	arrhythmias
18	138	140	O	who
19	142	144	O	are
20	146	157	O	incompletely
21	159	168	O	responsive
22	170	171	O	to
23	173	173	O	a
24	175	180	O	single
25	182	186	O	agent
26	188	189	O	or
27	191	202	O	incompletely
28	204	213	O	responsive
29	215	216	O	to
30	218	227	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s37	NO_SECTION	NO_SETID	28
During transfer to oral amiodarone, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral amiodarone.
1	0	5	O	During
2	7	14	O	transfer
3	16	17	O	to
4	19	22	O	oral
5	24	33	O	XXXXXXXX
6	34	34	O	,
7	36	38	O	the
8	40	43	O	dose
9	45	50	O	levels
10	52	53	O	of
11	55	64	O	previously
12	66	77	O	administered
13	79	84	O	agents
14	86	91	O	should
15	93	94	O	be
16	96	102	O	reduced
17	104	105	O	by
18	107	108	O	30
19	110	111	O	to
20	113	115	O	50%
21	117	123	O	several
22	125	128	O	days
23	130	134	O	after
24	136	138	O	the
25	140	147	O	addition
26	149	150	O	of
27	152	155	O	oral
28	157	166	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s38	NO_SECTION	NO_SETID	26
The continued need for the other antiarrhythmic agent should be reviewed after the effects of amiodarone have been established, and discontinuation ordinarily should be attempted.
1	0	2	O	The
2	4	12	O	continued
3	14	17	O	need
4	19	21	O	for
5	23	25	O	the
6	27	31	O	other
7	33	46	U-UNK	antiarrhythmic
8	48	52	O	agent
9	54	59	O	should
10	61	62	O	be
11	64	71	O	reviewed
12	73	77	O	after
13	79	81	O	the
14	83	89	O	effects
15	91	92	O	of
16	94	103	O	XXXXXXXX
17	105	108	O	have
18	110	113	O	been
19	115	125	O	established
20	126	126	O	,
21	128	130	O	and
22	132	146	O	discontinuation
23	148	157	O	ordinarily
24	159	164	O	should
25	166	167	O	be
26	169	177	O	attempted
NULL

Amiodarone	DDI-DrugBank.d143.s39	NO_SECTION	NO_SETID	29
If the treatment is continued, these patients should be particularly carefully monitored for adverse effects, especially conduction disturbances and exacerbation of tachyarrhythmias, as amiodarone is continued.
1	0	1	O	If
2	3	5	O	the
3	7	15	O	treatment
4	17	18	O	is
5	20	28	O	continued
6	29	29	O	,
7	31	35	O	these
8	37	44	O	patients
9	46	51	O	should
10	53	54	O	be
11	56	67	O	particularly
12	69	77	O	carefully
13	79	87	O	monitored
14	89	91	O	for
15	93	99	O	adverse
16	101	107	O	effects
17	108	108	O	,
18	110	119	O	especially
19	121	130	O	conduction
20	132	143	O	disturbances
21	145	147	O	and
22	149	160	O	exacerbation
23	162	163	O	of
24	165	180	O	tachyarrhythmias
25	181	181	O	,
26	183	184	O	as
27	186	195	O	XXXXXXXX
28	197	198	O	is
29	200	208	O	continued
NULL

Amiodarone	DDI-DrugBank.d143.s40	NO_SECTION	NO_SETID	25
In amiodarone-treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose.
1	0	1	O	In
2	3	12	O	XXXXXXXX
3	14	20	O	treated
4	22	29	O	patients
5	31	33	O	who
6	35	41	O	require
7	43	52	O	additional
8	54	67	U-UNK	antiarrhythmic
9	69	75	O	therapy
10	76	76	O	,
11	78	80	O	the
12	82	88	O	initial
13	90	93	O	dose
14	95	96	O	of
15	98	101	O	such
16	103	108	O	agents
17	110	115	O	should
18	117	118	O	be
19	120	132	O	approximately
20	134	137	O	half
21	139	140	O	of
22	142	144	O	the
23	146	150	O	usual
24	152	162	O	recommended
25	164	167	O	dose
NULL

Amiodarone	DDI-DrugBank.d143.s41	NO_SECTION	NO_SETID	53
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
1	0	16	U-UNK	Antihypertensives
2	17	17	O	:
3	19	28	O	XXXXXXXX
4	30	35	O	should
5	37	38	O	be
6	40	43	O	used
7	45	48	O	with
8	50	56	O	caution
9	58	59	O	in
10	61	68	O	patients
11	70	78	O	receiving
12	82	89	U-UNK	receptor
13	91	98	O	blocking
14	100	105	O	agents
15	108	110	O	e.g
16	112	112	O	,
17	114	124	U-UNK	propranolol
18	125	125	O	,
19	127	127	O	a
20	129	134	U-UNK	CYP3A4
21	136	144	O	inhibitor
22	147	148	O	or
23	150	156	B-UNK	calcium
24	158	164	L-UNK	channel
25	166	176	O	antagonists
26	179	181	O	e.g
27	183	183	O	,
28	185	193	U-UNK	verapamil
29	194	194	O	,
30	196	196	O	a
31	198	203	U-UNK	CYP3A4
32	205	213	O	substrate
33	214	214	O	,
34	216	218	O	and
35	220	228	U-UNK	diltiazem
36	229	229	O	,
37	231	231	O	a
38	233	238	U-UNK	CYP3A4
39	240	248	O	inhibitor
40	251	257	O	because
41	259	260	O	of
42	262	264	O	the
43	266	273	O	possible
44	275	286	O	potentiation
45	288	289	O	of
46	291	301	O	bradycardia
47	302	302	O	,
48	304	308	O	sinus
49	310	315	O	arrest
50	316	316	O	,
51	318	320	O	and
52	322	323	O	AV
53	325	329	O	block
NULL

Amiodarone	DDI-DrugBank.d143.s42	NO_SECTION	NO_SETID	22
if necessary, amiodarone can continue to be used after insertion of a pacemaker in patients with severe bradycardia or sinus arrest.
1	0	1	O	if
2	3	11	O	necessary
3	12	12	O	,
4	14	23	O	XXXXXXXX
5	25	27	O	can
6	29	36	O	continue
7	38	39	O	to
8	41	42	O	be
9	44	47	O	used
10	49	53	O	after
11	55	63	O	insertion
12	65	66	O	of
13	68	68	O	a
14	70	78	O	pacemaker
15	80	81	O	in
16	83	90	O	patients
17	92	95	O	with
18	97	102	O	severe
19	104	114	O	bradycardia
20	116	117	O	or
21	119	123	O	sinus
22	125	130	O	arrest
NULL

Amiodarone	DDI-DrugBank.d143.s43	NO_SECTION	NO_SETID	28
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
1	0	13	U-UNK	Anticoagulants
2	14	14	O	:
3	16	27	O	Potentiation
4	29	30	O	of
5	32	39	U-UNK	warfarin
6	41	44	O	type
7	47	52	U-UNK	CYP2C9
8	54	56	O	and
9	58	63	U-UNK	CYP3A4
10	65	73	O	substrate
11	76	88	U-UNK	anticoagulant
12	90	97	O	response
13	99	100	O	is
14	102	107	O	almost
15	109	114	O	always
16	116	119	O	seen
17	121	122	O	in
18	124	131	O	patients
19	133	141	O	receiving
20	143	152	O	XXXXXXXX
21	154	156	O	and
22	158	160	O	can
23	162	167	O	result
24	169	170	O	in
25	172	178	O	serious
26	180	181	O	or
27	183	187	O	fatal
28	189	196	O	bleeding
NULL

Amiodarone	DDI-DrugBank.d143.s44	NO_SECTION	NO_SETID	42
Since the concomitant administration of warfarin with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.
1	0	4	O	Since
2	6	8	O	the
3	10	20	O	concomitant
4	22	35	O	administration
5	37	38	O	of
6	40	47	U-UNK	warfarin
7	49	52	O	with
8	54	63	O	XXXXXXXX
9	65	73	O	increases
10	75	77	O	the
11	79	89	O	prothrombin
12	91	94	O	time
13	96	97	O	by
14	99	102	O	100%
15	104	108	O	after
16	110	110	O	3
17	112	113	O	to
18	115	115	O	4
19	117	120	O	days
20	121	121	O	,
21	123	125	O	the
22	127	130	O	dose
23	132	133	O	of
24	135	137	O	the
25	139	151	U-UNK	anticoagulant
26	153	158	O	should
27	160	161	O	be
28	163	169	O	reduced
29	171	172	O	by
30	174	176	O	one
31	178	182	O	third
32	184	185	O	to
33	187	189	O	one
34	191	194	O	half
35	195	195	O	,
36	197	199	O	and
37	201	211	O	prothrombin
38	213	217	O	times
39	219	224	O	should
40	226	227	O	be
41	229	237	O	monitored
42	239	245	O	closely
NULL

Amiodarone	DDI-DrugBank.d143.s45	NO_SECTION	NO_SETID	20
Some drugs/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).
1	0	3	O	Some
2	5	9	U-UNK	drugs
3	10	10	O	/
4	11	20	O	substances
5	22	24	O	are
6	26	30	O	known
7	32	33	O	to
8	35	44	O	accelerate
9	46	48	O	the
10	50	59	O	metabolism
11	61	62	O	of
12	64	73	O	XXXXXXXX
13	75	76	O	by
14	78	88	O	stimulating
15	90	92	O	the
16	94	102	O	synthesis
17	104	105	O	of
18	107	112	U-UNK	CYP3A4
19	115	120	O	enzyme
20	122	130	O	induction
NULL

Amiodarone	DDI-DrugBank.d143.s46	NO_SECTION	NO_SETID	13
This may lead to low amiodarone serum levels and potential decrease in efficacy.
1	0	3	O	This
2	5	7	O	may
3	9	12	O	lead
4	14	15	O	to
5	17	19	O	low
6	21	30	O	XXXXXXXX
7	32	36	O	serum
8	38	43	O	levels
9	45	47	O	and
10	49	57	O	potential
11	59	66	O	decrease
12	68	69	O	in
13	71	78	O	efficacy
NULL

Amiodarone	DDI-DrugBank.d143.s47	NO_SECTION	NO_SETID	18
Reported examples of this interaction include the following: Antibiotics: Rifampin is a potent inducer of CYP3A4.
1	0	7	O	Reported
2	9	16	O	examples
3	18	19	O	of
4	21	24	O	this
5	26	36	O	interaction
6	38	44	O	include
7	46	48	O	the
8	50	58	O	following
9	59	59	O	:
10	61	71	U-UNK	Antibiotics
11	72	72	O	:
12	74	81	U-UNK	Rifampin
13	83	84	O	is
14	86	86	O	a
15	88	93	O	potent
16	95	101	O	inducer
17	103	104	O	of
18	106	111	U-UNK	CYP3A4
NULL

Amiodarone	DDI-DrugBank.d143.s48	NO_SECTION	NO_SETID	22
Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.
1	0	13	O	Administration
2	15	16	O	of
3	18	25	U-UNK	rifampin
4	27	39	O	concomitantly
5	41	44	O	with
6	46	49	O	oral
7	51	60	O	XXXXXXXX
8	62	64	O	has
9	66	69	O	been
10	71	75	O	shown
11	77	78	O	to
12	80	85	O	result
13	87	88	O	in
14	90	98	O	decreases
15	100	101	O	in
16	103	107	O	serum
17	109	122	O	concentrations
18	124	125	O	of
19	127	136	O	XXXXXXXX
20	138	140	O	and
21	142	149	O	desethyl
22	150	159	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s49	NO_SECTION	NO_SETID	15
Other substances, including herbal preparations: St. John s Wort (Hypericum perforatum) induces CYP3A4.
1	0	4	O	Other
2	6	15	O	substances
3	16	16	O	,
4	18	26	O	including
5	28	33	O	herbal
6	35	46	O	preparations
7	47	47	O	:
8	49	50	O	St
9	53	56	O	John
10	58	58	O	s
11	60	63	O	Wort
12	66	74	O	Hypericum
13	76	85	O	perforatum
14	88	94	O	induces
15	96	101	O	CYP3A4
NULL

Amiodarone	DDI-DrugBank.d143.s50	NO_SECTION	NO_SETID	30
Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.
1	0	4	O	Since
2	6	15	O	XXXXXXXX
3	17	18	O	is
4	20	20	O	a
5	22	30	O	substrate
6	32	34	O	for
7	36	41	U-UNK	CYP3A4
8	42	42	O	,
9	44	48	O	there
10	50	51	O	is
11	53	55	O	the
12	57	65	O	potential
13	67	70	O	that
14	72	74	O	the
15	76	78	O	use
16	80	81	O	of
17	83	84	O	St
18	87	90	O	John
19	92	92	O	s
20	94	97	O	Wort
21	99	100	O	in
22	102	109	O	patients
23	111	119	O	receiving
24	121	130	O	XXXXXXXX
25	132	136	O	could
26	138	143	O	result
27	145	146	O	in
28	148	154	O	reduced
29	156	165	O	XXXXXXXX
30	167	172	O	levels
NULL

Amiodarone	DDI-DrugBank.d143.s51	NO_SECTION	NO_SETID	23
Other reported interactions with amiodarone: Fentanyl (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.
1	0	4	O	Other
2	6	13	O	reported
3	15	26	O	interactions
4	28	31	O	with
5	33	42	O	XXXXXXXX
6	43	43	O	:
7	45	52	U-UNK	Fentanyl
8	55	60	U-UNK	CYP3A4
9	62	70	O	substrate
10	73	74	O	in
11	76	86	O	combination
12	88	91	O	with
13	93	102	O	XXXXXXXX
14	104	106	O	may
15	108	112	O	cause
16	114	124	O	hypotension
17	125	125	O	,
18	127	137	O	bradycardia
19	138	138	O	,
20	140	142	O	and
21	144	152	O	decreased
22	154	160	O	cardiac
23	162	167	O	output
NULL

Amiodarone	DDI-DrugBank.d143.s52	NO_SECTION	NO_SETID	18
Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (CYP3A4 substrate) given for local anesthesia.
1	0	4	O	Sinus
2	6	16	O	bradycardia
3	18	20	O	has
4	22	25	O	been
5	27	34	O	reported
6	36	39	O	with
7	41	44	O	oral
8	46	55	O	XXXXXXXX
9	57	58	O	in
10	60	70	O	combination
11	72	75	O	with
12	77	85	U-UNK	lidocaine
13	88	93	U-UNK	CYP3A4
14	95	103	O	substrate
15	106	110	O	given
16	112	114	O	for
17	116	120	O	local
18	122	131	U-UNK	anesthesia
NULL

Amiodarone	DDI-DrugBank.d143.s53	NO_SECTION	NO_SETID	17
Seizure, associated with increased lidocaine concentrations, has been reported with concomitant administration of intravenous amiodarone.
1	0	6	O	Seizure
2	7	7	O	,
3	9	18	O	associated
4	20	23	O	with
5	25	33	O	increased
6	35	43	U-UNK	lidocaine
7	45	58	O	concentrations
8	59	59	O	,
9	61	63	O	has
10	65	68	O	been
11	70	77	O	reported
12	79	82	O	with
13	84	94	O	concomitant
14	96	109	O	administration
15	111	112	O	of
16	114	124	O	intravenous
17	126	135	O	XXXXXXXX
NULL

Amiodarone	DDI-DrugBank.d143.s54	NO_SECTION	NO_SETID	9
Dextromethorphan is a substrate for both CYP2D6 and CYP3A4.
1	0	15	U-UNK	Dextromethorphan
2	17	18	O	is
3	20	20	O	a
4	22	30	O	substrate
5	32	34	O	for
6	36	39	O	both
7	41	46	U-UNK	CYP2D6
8	48	50	O	and
9	52	57	U-UNK	CYP3A4
NULL

Amiodarone	DDI-DrugBank.d143.s55	NO_SECTION	NO_SETID	3
Amiodarone inhibits CYP2D6.
1	0	9	O	XXXXXXXX
2	11	18	O	inhibits
3	20	25	U-UNK	CYP2D6
NULL

Amiodarone	DDI-DrugBank.d143.s56	NO_SECTION	NO_SETID	16
Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1/2.
1	0	13	U-UNK	Cholestyramine
2	15	23	O	increases
3	25	37	O	enterohepatic
4	39	49	O	elimination
5	51	52	O	of
6	54	63	O	XXXXXXXX
7	65	67	O	and
8	69	71	O	may
9	73	78	O	reduce
10	80	82	O	its
11	84	88	O	serum
12	90	95	O	levels
13	97	99	O	and
14	101	102	U-UNK	t1
15	103	103	O	/
16	104	104	O	2
NULL

Amiodarone	DDI-DrugBank.d143.s57	NO_SECTION	NO_SETID	8
Disopyramide increases QT prolongation which could cause arrhythmia.
1	0	11	U-UNK	Disopyramide
2	13	21	O	increases
3	23	24	O	QT
4	26	37	O	prolongation
5	39	43	O	which
6	45	49	O	could
7	51	55	O	cause
8	57	66	O	arrhythmia
NULL

Amiodarone	DDI-DrugBank.d143.s58	NO_SECTION	NO_SETID	13
Fluoroquinolones, macrolide antibiotics, and azoles are known to cause QTc prolongation.
1	0	15	U-UNK	Fluoroquinolones
2	16	16	O	,
3	18	26	B-UNK	macrolide
4	28	38	L-UNK	antibiotics
5	39	39	O	,
6	41	43	O	and
7	45	50	O	azoles
8	52	54	O	are
9	56	60	O	known
10	62	63	O	to
11	65	69	O	cause
12	71	73	O	QTc
13	75	86	O	prolongation
NULL

Amiodarone	DDI-DrugBank.d143.s59	NO_SECTION	NO_SETID	28
There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	22	O	reports
5	24	25	O	of
6	27	29	O	QTc
7	31	42	O	prolongation
8	43	43	O	,
9	45	48	O	with
10	50	51	O	or
11	53	59	O	without
12	61	63	O	TdP
13	64	64	O	,
14	66	67	O	in
15	69	76	O	patients
16	78	83	O	taking
17	85	94	O	XXXXXXXX
18	96	99	O	when
19	101	116	U-UNK	fluoroquinolones
20	117	117	O	,
21	119	127	B-UNK	macrolide
22	129	139	L-UNK	antibiotics
23	140	140	O	,
24	142	143	O	or
25	145	150	O	azoles
26	152	155	O	were
27	157	168	O	administered
28	170	182	O	concomitantly
NULL

Amiodarone	DDI-DrugBank.d143.s60	NO_SECTION	NO_SETID	18
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol, diltiazem, and verapamil.
1	0	10	O	Hemodynamic
2	12	14	O	and
3	16	33	O	electrophysiologic
4	35	46	O	interactions
5	48	51	O	have
6	53	56	O	also
7	58	61	O	been
8	63	70	O	observed
9	72	76	O	after
10	78	88	O	concomitant
11	90	103	O	administration
12	105	108	O	with
13	110	120	U-UNK	propranolol
14	121	121	O	,
15	123	131	U-UNK	diltiazem
16	132	132	O	,
17	134	136	O	and
18	138	146	U-UNK	verapamil
NULL

Amiodarone	DDI-DrugBank.d143.s61	NO_SECTION	NO_SETID	3
Volatile Anesthetic Agents:.
1	0	7	O	Volatile
2	9	18	U-UNK	Anesthetic
3	20	26	O	Agents:
NULL

Amiodarone	DDI-DrugBank.d143.s62	NO_SECTION	NO_SETID	23
In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of phenytoin, dextromethorphan, and methotrexate.
1	0	1	O	In
2	3	10	O	addition
3	12	13	O	to
4	15	17	O	the
5	19	30	O	interactions
6	32	36	O	noted
7	38	42	O	above
8	43	43	O	,
9	45	51	O	chronic
10	56	56	O	2
11	58	62	O	weeks
12	65	68	O	oral
13	70	78	U-UNK	Cordarone
14	80	93	O	administration
15	95	101	O	impairs
16	103	112	O	metabolism
17	114	115	O	of
18	117	125	U-UNK	phenytoin
19	126	126	O	,
20	128	143	U-UNK	dextromethorphan
21	144	144	O	,
22	146	148	O	and
23	150	161	U-UNK	methotrexate
NULL

Amiodarone	DDI-DrugBank.d143.s63	NO_SECTION	NO_SETID	37
Electrolyte Disturbances Patients with hypokalemia or hypomagnesemia should have the condition corrected whenever possible before being treated with Cordarone I.V., as these disorders can exaggerate the degree of QTc prolongation and increase the potential for TdP.
1	0	10	O	Electrolyte
2	12	23	O	Disturbances
3	25	32	O	Patients
4	34	37	O	with
5	39	49	O	hypokalemia
6	51	52	O	or
7	54	67	O	hypomagnesemia
8	69	74	O	should
9	76	79	O	have
10	81	83	O	the
11	85	93	O	condition
12	95	103	O	corrected
13	105	112	O	whenever
14	114	121	O	possible
15	123	128	O	before
16	130	134	O	being
17	136	142	O	treated
18	144	147	O	with
19	149	157	B-UNK	Cordarone
20	159	161	L-UNK	I.V
21	163	163	O	,
22	165	166	O	as
23	168	172	O	these
24	174	182	O	disorders
25	184	186	O	can
26	188	197	O	exaggerate
27	199	201	O	the
28	203	208	O	degree
29	210	211	O	of
30	213	215	O	QTc
31	217	228	O	prolongation
32	230	232	O	and
33	234	241	O	increase
34	243	245	O	the
35	247	255	O	potential
36	257	259	O	for
37	261	263	O	TdP
NULL

Amiodarone	DDI-DrugBank.d143.s64	NO_SECTION	NO_SETID	24
Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics.
1	0	6	O	Special
2	8	16	O	attention
3	18	23	O	should
4	25	26	O	be
5	28	32	O	given
6	34	35	O	to
7	37	47	O	electrolyte
8	49	51	O	and
9	53	56	O	acid
10	58	61	O	base
11	63	69	O	balance
12	71	72	O	in
13	74	81	O	patients
14	83	94	O	experiencing
15	96	101	O	severe
16	103	104	O	or
17	106	114	O	prolonged
18	116	123	O	diarrhea
19	125	126	O	or
20	128	129	O	in
21	131	138	O	patients
22	140	148	O	receiving
23	150	160	O	concomitant
24	162	170	U-UNK	diuretics
NULL

Amitriptyline	DDI-DrugBank.d99.s0	NO_SECTION	NO_SETID	37
Drugs Metabolized by P450 2D6 - The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called poor metabolizers);
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	24	O	P450
5	26	28	O	2D6
6	32	34	O	The
7	36	46	O	biochemical
8	48	55	O	activity
9	57	58	O	of
10	60	62	O	the
11	64	67	O	drug
12	69	80	O	metabolizing
13	82	88	O	isozyme
14	90	99	O	cytochrome
15	101	104	O	P450
16	106	108	O	2D6
17	111	121	O	debrisoquin
18	123	133	O	hydroxylase
19	136	137	O	is
20	139	145	O	reduced
21	147	148	O	in
22	150	150	O	a
23	152	157	O	subset
24	159	160	O	of
25	162	164	O	the
26	166	174	O	caucasian
27	176	185	O	population
28	188	192	O	about
29	194	194	O	7
30	196	198	O	10%
31	200	201	O	of
32	203	212	O	caucasians
33	214	216	O	are
34	218	219	O	so
35	221	226	O	called
36	228	231	O	poor
37	233	244	O	metabolizers
NULL

Amitriptyline	DDI-DrugBank.d99.s1	NO_SECTION	NO_SETID	22
reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
1	0	7	O	reliable
2	9	17	O	estimates
3	19	20	O	of
4	22	24	O	the
5	26	35	O	prevalence
6	37	38	O	of
7	40	46	O	reduced
8	48	51	O	P450
9	53	55	O	2D6
10	57	63	O	isozyme
11	65	72	O	activity
12	74	78	O	among
13	80	84	O	Asian
14	85	85	O	,
15	87	93	O	African
16	95	97	O	and
17	99	103	O	other
18	105	115	O	populations
19	117	119	O	are
20	121	123	O	not
21	125	127	O	yet
22	129	137	O	available
NULL

Amitriptyline	DDI-DrugBank.d99.s2	NO_SECTION	NO_SETID	16
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
1	0	3	O	Poor
2	5	16	O	metabolizers
3	18	21	O	have
4	23	28	O	higher
5	30	33	O	than
6	35	42	O	expected
7	44	49	O	plasma
8	51	64	O	concentrations
9	66	67	O	of
10	69	77	B-UNK	tricyclic
11	79	93	L-UNK	antidepressants
12	96	99	U-UNK	TCAs
13	102	105	O	when
14	107	111	O	given
15	113	117	O	usual
16	119	123	O	doses
NULL

Amitriptyline	DDI-DrugBank.d99.s3	NO_SECTION	NO_SETID	32
Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).
1	0	8	O	Depending
2	10	11	O	on
3	13	15	O	the
4	17	24	O	fraction
5	26	27	O	of
6	29	32	O	drug
7	34	44	O	metabolized
8	46	47	O	by
9	49	52	O	P450
10	54	56	O	2D6
11	57	57	O	,
12	59	61	O	the
13	63	70	O	increase
14	72	73	O	in
15	75	80	O	plasma
16	82	94	O	concentration
17	96	98	O	may
18	100	101	O	be
19	103	107	O	small
20	108	108	O	,
21	110	111	O	or
22	113	117	O	quite
23	119	123	O	large
24	126	126	O	8
25	128	131	O	fold
26	133	140	O	increase
27	142	143	O	in
28	145	150	O	plasma
29	152	154	O	AUC
30	156	157	O	of
31	159	161	O	the
32	163	165	U-UNK	TCA
NULL

Amitriptyline	DDI-DrugBank.d99.s4	NO_SECTION	NO_SETID	18
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	certain
5	21	25	O	drugs
6	27	33	O	inhibit
7	35	37	O	the
8	39	46	O	activity
9	48	49	O	of
10	51	54	O	this
11	56	62	O	isozyme
12	64	66	O	and
13	68	71	O	make
14	73	78	O	normal
15	80	91	O	metabolizers
16	93	100	O	resemble
17	102	105	O	poor
18	107	118	O	metabolizers
NULL

Amitriptyline	DDI-DrugBank.d99.s5	NO_SECTION	NO_SETID	25
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
1	0	1	O	An
2	3	12	O	individual
3	14	16	O	who
4	18	19	O	is
5	21	26	O	stable
6	28	29	O	on
7	31	31	O	a
8	33	37	O	given
9	39	42	O	dose
10	44	45	O	of
11	47	49	U-UNK	TCA
12	51	53	O	may
13	55	60	O	become
14	62	69	O	abruptly
15	71	75	O	toxic
16	77	80	O	when
17	82	86	O	given
18	88	90	O	one
19	92	93	O	of
20	95	99	O	these
21	101	110	O	inhibiting
22	112	116	O	drugs
23	118	119	O	as
24	121	131	O	concomitant
25	133	139	O	therapy
NULL

Amitriptyline	DDI-DrugBank.d99.s6	NO_SECTION	NO_SETID	17
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;
1	0	2	O	The
2	4	8	O	drugs
3	10	13	O	that
4	15	21	O	inhibit
5	23	32	O	cytochrome
6	34	37	O	P450
7	39	41	O	2D6
8	43	49	O	include
9	51	54	O	some
10	56	59	O	that
11	61	63	O	are
12	65	67	O	not
13	69	79	O	metabolized
14	81	82	O	by
15	84	86	O	the
16	88	93	O	enzyme
17	96	104	U-UNK	quinidine
NULL

Amitriptyline	DDI-DrugBank.d99.s7	NO_SECTION	NO_SETID	23
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
1	0	9	U-UNK	cimetidine
2	12	14	O	and
3	16	19	O	many
4	21	24	O	that
5	26	28	O	are
6	30	39	O	substrates
7	41	43	O	for
8	45	48	O	P450
9	50	52	O	2D6
10	55	58	O	many
11	60	64	O	other
12	66	80	U-UNK	antidepressants
13	81	81	O	,
14	83	96	U-UNK	phenothiazines
15	97	97	O	,
16	99	101	O	and
17	103	105	O	the
18	107	110	B-UNK	Type
19	112	113	I-UNK	1C
20	115	129	L-UNK	antiarrhythmics
21	131	141	U-UNK	propafenone
22	143	145	O	and
23	147	156	U-UNK	flecainide
NULL

Amitriptyline	DDI-DrugBank.d99.s8	NO_SECTION	NO_SETID	30
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
1	0	4	O	While
2	6	8	O	all
3	10	12	O	the
4	14	22	O	selective
5	24	32	B-UNK	serotonin
6	34	41	I-UNK	reuptake
7	43	52	L-UNK	inhibitors
8	55	59	U-UNK	SSRIs
9	61	61	O	,
10	63	65	O	e.g
11	67	67	O	,
12	69	78	U-UNK	fluoxetine
13	79	79	O	,
14	81	90	U-UNK	sertraline
15	91	91	O	,
16	93	95	O	and
17	97	106	U-UNK	paroxetine
18	107	107	O	,
19	109	115	O	inhibit
20	117	120	O	P450
21	122	124	O	2D6
22	125	125	O	,
23	127	130	O	they
24	132	134	O	may
25	136	139	O	vary
26	141	142	O	in
27	144	146	O	the
28	148	153	O	extent
29	155	156	O	of
30	158	167	O	inhibition
NULL

Amitriptyline	DDI-DrugBank.d99.s9	NO_SECTION	NO_SETID	25
The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	to
4	14	18	O	which
5	20	23	U-UNK	SSRI
6	25	27	U-UNK	TCA
7	29	40	O	interactions
8	42	44	O	may
9	46	49	O	pose
10	51	58	O	clinical
11	60	67	O	problems
12	69	72	O	will
13	74	79	O	depend
14	81	82	O	on
15	84	86	O	the
16	88	93	O	degree
17	95	96	O	of
18	98	107	O	inhibition
19	109	111	O	and
20	113	115	O	the
21	117	132	O	pharmacokinetics
22	134	135	O	of
23	137	139	O	the
24	141	144	U-UNK	SSRI
25	146	153	O	involved
NULL

Amitriptyline	DDI-DrugBank.d99.s10	NO_SECTION	NO_SETID	25
Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	O	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	57	O	coadministration
9	59	60	O	of
10	62	65	U-UNK	TCAs
11	67	70	O	with
12	72	74	O	any
13	76	77	O	of
14	79	81	O	the
15	83	87	U-UNK	SSRIs
16	89	91	O	and
17	93	96	O	also
18	98	99	O	in
19	101	109	O	switching
20	111	114	O	from
21	116	118	O	one
22	120	124	O	class
23	126	127	O	to
24	129	131	O	the
25	133	137	O	other
NULL

Amitriptyline	DDI-DrugBank.d99.s11	NO_SECTION	NO_SETID	38
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
1	0	1	O	Of
2	3	12	O	particular
3	14	23	O	importance
4	24	24	O	,
5	26	35	O	sufficient
6	37	40	O	time
7	42	45	O	must
8	47	52	O	elapse
9	54	59	O	before
10	61	70	O	initiating
11	72	74	O	TCA
12	76	84	O	treatment
13	86	87	O	in
14	89	89	O	a
15	91	97	O	patient
16	99	103	O	being
17	105	113	O	withdrawn
18	115	118	O	from
19	120	129	U-UNK	fluoxetine
20	130	130	O	,
21	132	136	O	given
22	138	140	O	the
23	142	145	O	long
24	147	150	O	half
25	152	155	O	life
26	157	158	O	of
27	160	162	O	the
28	164	169	O	parent
29	171	173	O	and
30	175	180	O	active
31	182	191	O	metabolite
32	194	195	O	at
33	197	201	O	least
34	203	203	O	5
35	205	209	O	weeks
36	211	213	O	may
37	215	216	O	be
38	218	226	O	necessary
NULL

Amitriptyline	DDI-DrugBank.d99.s12	NO_SECTION	NO_SETID	29
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	27	B-UNK	tricyclic
5	29	43	L-UNK	antidepressants
6	45	48	O	with
7	50	54	O	drugs
8	56	59	O	that
9	61	63	O	can
10	65	71	O	inhibit
11	73	82	O	cytochrome
12	84	87	O	P450
13	89	91	O	2D6
14	93	95	O	may
15	97	103	O	require
16	105	109	O	lower
17	111	115	O	doses
18	117	120	O	than
19	122	128	O	usually
20	130	139	O	prescribed
21	141	143	O	for
22	145	150	O	either
23	152	154	O	the
24	156	164	B-UNK	tricyclic
25	166	179	L-UNK	antidepressant
26	181	182	O	or
27	184	186	O	the
28	188	192	O	other
29	194	197	O	drug
NULL

Amitriptyline	DDI-DrugBank.d99.s13	NO_SECTION	NO_SETID	23
Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	20	O	whenever
4	22	24	O	one
5	26	27	O	of
6	29	33	O	these
7	35	39	O	other
8	41	45	O	drugs
9	47	48	O	is
10	50	58	O	withdrawn
11	60	63	O	from
12	65	66	O	co
13	68	74	O	therapy
14	75	75	O	,
15	77	78	O	an
16	80	88	O	increased
17	90	93	O	dose
18	95	96	O	of
19	98	106	B-UNK	tricyclic
20	108	121	L-UNK	antidepressant
21	123	125	O	may
22	127	128	O	be
23	130	137	O	required
NULL

Amitriptyline	DDI-DrugBank.d99.s14	NO_SECTION	NO_SETID	27
It is desirable to monitor TCA plasma levels whenever a TCA is going to be coadministered with another drug known to be an inhibitor of P450 2D6.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	desirable
4	16	17	O	to
5	19	25	O	monitor
6	27	29	U-UNK	TCA
7	31	36	O	plasma
8	38	43	O	levels
9	45	52	O	whenever
10	54	54	O	a
11	56	58	U-UNK	TCA
12	60	61	O	is
13	63	67	O	going
14	69	70	O	to
15	72	73	O	be
16	75	88	O	coadministered
17	90	93	O	with
18	95	101	O	another
19	103	106	O	drug
20	108	112	O	known
21	114	115	O	to
22	117	118	O	be
23	120	121	O	an
24	123	131	O	inhibitor
25	133	134	O	of
26	136	139	O	P450
27	141	143	O	2D6
NULL

Amitriptyline	DDI-DrugBank.d99.s15	NO_SECTION	NO_SETID	9
Monoamine Oxidase Inhibitors: Guanethidine or similarly acting compounds;
1	0	8	B-UNK	Monoamine
2	10	16	I-UNK	Oxidase
3	18	27	L-UNK	Inhibitors
4	28	28	O	:
5	30	41	U-UNK	Guanethidine
6	43	44	O	or
7	46	54	O	similarly
8	56	61	O	acting
9	63	71	O	compounds
NULL

Amitriptyline	DDI-DrugBank.d99.s17	NO_SECTION	NO_SETID	7
alcohol, barbiturates and other CNS depressants;
1	0	6	U-UNK	alcohol
2	7	7	O	,
3	9	20	U-UNK	barbiturates
4	22	24	O	and
5	26	30	O	other
6	32	34	B-UNK	CNS
7	36	46	L-UNK	depressants
NULL

Amitriptyline	DDI-DrugBank.d99.s18	NO_SECTION	NO_SETID	30
and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.
1	0	2	O	and
2	4	13	U-UNK	disulfiram
3	15	18	O	When
4	20	32	O	XXXXXXXX
5	34	36	O	HCl
6	38	39	O	is
7	41	45	O	given
8	47	50	O	with
9	52	66	U-UNK	anticholinergic
10	68	73	O	agents
11	75	76	O	or
12	78	92	U-UNK	sympathomimetic
13	94	98	O	drugs
14	99	99	O	,
15	101	109	O	including
16	111	121	U-UNK	epinephrine
17	123	130	O	combined
18	132	135	O	with
19	137	141	O	local
20	143	153	U-UNK	anesthetics
21	154	154	O	,
22	156	160	O	close
23	162	172	O	supervision
24	174	176	O	and
25	178	184	O	careful
26	186	195	O	adjustment
27	197	198	O	of
28	200	206	O	dosages
29	208	210	O	are
30	212	219	O	required
NULL

Amitriptyline	DDI-DrugBank.d99.s19	NO_SECTION	NO_SETID	21
Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.
1	0	11	O	Hyperpyrexia
2	13	15	O	has
3	17	20	O	been
4	22	29	O	reported
5	31	34	O	when
6	36	48	O	XXXXXXXX
7	50	52	O	HCl
8	54	55	O	is
9	57	68	O	administered
10	70	73	O	with
11	75	89	U-DYN	anticholinergic
12	91	96	O	agents
13	98	99	O	or
14	101	104	O	with
15	106	116	U-UNK	neuroleptic
16	118	122	O	drugs
17	123	123	O	,
18	125	136	O	particularly
19	138	143	O	during
20	145	147	O	hot
21	149	155	O	weather
NULL

Amitriptyline	DDI-DrugBank.d99.s20	NO_SECTION	NO_SETID	15
Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.
1	0	8	O	Paralytic
2	10	14	O	ileus
3	16	18	O	may
4	20	24	O	occur
5	26	27	O	in
6	29	36	O	patients
7	38	43	O	taking
8	45	53	B-UNK	tricyclic
9	55	69	L-UNK	antidepressants
10	71	72	O	in
11	74	84	O	combination
12	86	89	O	with
13	91	105	U-UNK	anticholinergic
14	107	110	O	type
15	112	116	O	drugs
NULL

Amitriptyline	DDI-DrugBank.d99.s21	NO_SECTION	NO_SETID	23
Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.
1	0	9	U-UNK	Cimetidine
2	11	12	O	is
3	14	21	O	reported
4	23	24	O	to
5	26	31	O	reduce
6	33	39	O	hepatic
7	41	50	O	metabolism
8	52	53	O	of
9	55	61	O	certain
10	63	71	B-UNK	tricyclic
11	73	87	L-UNK	antidepressants
12	88	88	O	,
13	90	96	O	thereby
14	98	105	O	delaying
15	107	117	O	elimination
16	119	121	O	and
17	123	132	O	increasing
18	134	139	O	steady
19	141	145	O	state
20	147	160	O	concentrations
21	162	163	O	of
22	165	169	O	these
23	171	175	U-UNK	drugs
NULL

Amitriptyline	DDI-DrugBank.d99.s22	NO_SECTION	NO_SETID	15
Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.
1	0	9	O	Clinically
2	11	21	O	significant
3	23	29	O	effects
4	31	34	O	have
5	36	39	O	been
6	41	48	O	reported
7	50	53	O	with
8	55	57	O	the
9	59	67	B-UNK	tricyclic
10	69	83	L-UNK	antidepressants
11	85	88	O	when
12	90	93	O	used
13	95	107	O	concomitantly
14	109	112	O	with
15	114	123	U-UNK	cimetidine
NULL

Amitriptyline	DDI-DrugBank.d99.s23	NO_SECTION	NO_SETID	32
Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.
1	0	8	O	Increases
2	10	11	O	in
3	13	18	O	plasma
4	20	25	O	levels
5	27	28	O	of
6	30	38	B-UNK	tricyclic
7	40	54	L-UNK	antidepressants
8	55	55	O	,
9	57	59	O	and
10	61	62	O	in
11	64	66	O	the
12	68	76	O	frequency
13	78	80	O	and
14	82	89	O	severity
15	91	92	O	of
16	94	97	O	side
17	99	105	O	effects
18	106	106	O	,
19	108	119	O	particularly
20	121	135	U-UNK	anticholinergic
21	136	136	O	,
22	138	141	O	have
23	143	146	O	been
24	148	155	O	reported
25	157	160	O	when
26	162	171	U-UNK	cimetidine
27	173	175	O	was
28	177	181	O	added
29	183	184	O	to
30	186	188	O	the
31	190	193	U-UNK	drug
32	195	201	O	regimen
NULL

Amitriptyline	DDI-DrugBank.d99.s24	NO_SECTION	NO_SETID	22
Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.
1	0	14	O	Discontinuation
2	16	17	O	of
3	19	28	U-UNK	cimetidine
4	30	31	O	in
5	33	36	O	well
6	38	47	O	controlled
7	49	56	O	patients
8	58	66	O	receiving
9	68	76	B-UNK	tricyclic
10	78	92	L-UNK	antidepressants
11	94	96	O	and
12	98	107	U-UNK	cimetidine
13	109	111	O	may
14	113	120	O	decrease
15	122	124	O	the
16	126	131	O	plasma
17	133	138	O	levels
18	140	142	O	and
19	144	151	O	efficacy
20	153	154	O	of
21	156	158	O	the
22	160	174	U-UNK	antidepressants
NULL

Amitriptyline	DDI-DrugBank.d99.s25	NO_SECTION	NO_SETID	11
Caution is advised if patients receive large doses of ethchlorvynol concurrently.
1	0	6	O	Caution
2	8	9	O	is
3	11	17	O	advised
4	19	20	O	if
5	22	29	O	patients
6	31	37	O	receive
7	39	43	O	large
8	45	49	O	doses
9	51	52	O	of
10	54	66	U-UNK	ethchlorvynol
11	68	79	O	concurrently
NULL

Amitriptyline	DDI-DrugBank.d99.s26	NO_SECTION	NO_SETID	22
Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.
1	0	8	O	Transient
2	10	17	O	delirium
3	19	21	O	has
4	23	26	O	been
5	28	35	O	reported
6	37	38	O	in
7	40	47	O	patients
8	49	51	O	who
9	53	56	O	were
10	58	64	O	treated
11	66	69	O	with
12	71	73	O	one
13	75	78	O	gram
14	80	81	O	of
15	83	95	U-DYN	ethchlorvynol
16	97	99	O	and
17	101	102	O	75
18	106	108	O	150
19	110	111	O	mg
20	113	114	O	of
21	116	128	O	XXXXXXXX
22	130	132	O	HCl
NULL

Amphotericin B	DDI-DrugBank.d318.s0	NO_SECTION	NO_SETID	26
When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.
1	0	3	O	When
2	5	16	O	administered
3	18	29	O	concurrently
4	30	30	O	,
5	32	34	O	the
6	36	44	O	following
7	46	50	O	drugs
8	52	54	O	may
9	56	63	O	interact
10	65	68	O	with
11	70	83	O	XXXXXXXX
12	84	84	O	:
13	86	99	B-DYN	Antineoplastic
14	101	106	L-DYN	agents
15	107	107	O	:
16	109	111	O	may
17	113	119	O	enhance
18	121	123	O	the
19	125	133	O	potential
20	135	137	O	for
21	139	143	O	renal
22	145	152	O	toxicity
23	153	153	O	,
24	155	166	O	bronchospasm
25	168	170	O	and
26	172	182	O	hypotension
NULL

Amphotericin B	DDI-DrugBank.d318.s1	NO_SECTION	NO_SETID	17
Antineoplastic agents (e. g., nitrogen mustard, etc.) should be given concomitantly only with great caution.
1	0	13	B-UNK	Antineoplastic
2	15	20	L-UNK	agents
3	23	23	O	e
4	26	26	O	g
5	28	28	O	,
6	30	37	B-UNK	nitrogen
7	39	45	L-UNK	mustard
8	46	46	O	,
9	48	50	O	etc
10	54	59	O	should
11	61	62	O	be
12	64	68	O	given
13	70	82	O	concomitantly
14	84	87	O	only
15	89	92	O	with
16	94	98	O	great
17	100	106	O	caution
NULL

Amphotericin B	DDI-DrugBank.d318.s2	NO_SECTION	NO_SETID	18
Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
1	0	14	U-DYN	Corticosteroids
2	16	18	O	and
3	20	32	U-DYN	Corticotropin
4	35	38	U-DYN	ACTH
5	40	40	O	:
6	42	44	O	may
7	46	55	O	potentiate
8	57	70	O	XXXXXXXX
9	73	79	O	induced
10	81	91	O	hypokalemia
11	93	97	O	which
12	99	101	O	may
13	103	112	O	predispose
14	114	116	O	the
15	118	124	O	patient
16	126	127	O	to
17	129	135	O	cardiac
18	137	147	O	dysfunction
NULL

Amphotericin B	DDI-DrugBank.d318.s3	NO_SECTION	NO_SETID	11
Avoid concomitant use unless necessary to control side effects of amphotericin B.
1	0	4	O	Avoid
2	6	16	O	concomitant
3	18	20	O	use
4	22	27	O	unless
5	29	37	O	necessary
6	39	40	O	to
7	42	48	O	control
8	50	53	O	side
9	55	61	O	effects
10	63	64	O	of
11	66	79	O	XXXXXXXX
NULL

Amphotericin B	DDI-DrugBank.d318.s4	NO_SECTION	NO_SETID	11
If used concomitantly, closely monitor serum electrolytes and cardiac function.
1	0	1	O	If
2	3	6	O	used
3	8	20	O	concomitantly
4	21	21	O	,
5	23	29	O	closely
6	31	37	O	monitor
7	39	43	O	serum
8	45	56	O	electrolytes
9	58	60	O	and
10	62	68	O	cardiac
11	70	77	O	function
NULL

Amphotericin B	DDI-DrugBank.d318.s5	NO_SECTION	NO_SETID	10
Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.
1	0	8	B-UNK	Digitalis
2	10	19	L-UNK	glycosides
3	20	20	O	:
4	22	35	O	XXXXXXXX
5	37	43	O	induced
6	45	55	O	hypokalemia
7	57	59	O	may
8	61	70	O	potentiate
9	72	80	U-DYN	digitalis
10	82	89	O	toxicity
NULL

Amphotericin B	DDI-DrugBank.d318.s6	NO_SECTION	NO_SETID	15
Serum potassium levels and cardiac function should be closely monitored and any deficit promptly corrected.
1	0	4	O	Serum
2	6	14	O	potassium
3	16	21	O	levels
4	23	25	O	and
5	27	33	O	cardiac
6	35	42	O	function
7	44	49	O	should
8	51	52	O	be
9	54	60	O	closely
10	62	70	O	monitored
11	72	74	O	and
12	76	78	O	any
13	80	86	O	deficit
14	88	95	O	promptly
15	97	105	O	corrected
NULL

Amphotericin B	DDI-DrugBank.d318.s7	NO_SECTION	NO_SETID	33
Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.
1	0	10	U-UNK	Flucytosine
2	11	11	O	:
3	13	17	O	while
4	19	19	O	a
5	21	31	O	synergistic
6	33	44	O	relationship
7	46	49	O	with
8	51	64	O	XXXXXXXX
9	66	68	O	has
10	70	73	O	been
11	75	82	O	reported
12	83	83	O	,
13	85	95	O	concomitant
14	97	99	O	use
15	101	103	O	may
16	105	112	O	increase
17	114	116	O	the
18	118	125	O	toxicity
19	127	128	O	of
20	130	140	U-DYN	flucytosine
21	142	143	O	by
22	145	152	O	possibly
23	154	163	O	increasing
24	165	167	O	its
25	169	176	O	cellular
26	178	183	O	uptake
27	185	187	O	and
28	188	188	O	/
29	189	190	O	or
30	192	200	O	impairing
31	202	204	O	its
32	206	210	O	renal
33	212	220	O	excretion
NULL

Amphotericin B	DDI-DrugBank.d318.s8	NO_SECTION	NO_SETID	35
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.
1	0	9	U-UNK	Imidazoles
2	12	12	O	e
3	15	15	O	g
4	17	17	O	,
5	19	30	U-UNK	ketoconazole
6	31	31	O	,
7	33	42	U-UNK	miconazole
8	43	43	O	,
9	45	56	U-UNK	clotrimazole
10	57	57	O	,
11	59	69	U-UNK	fluconazole
12	70	70	O	,
13	72	74	O	etc
14	77	77	O	:
15	79	80	O	in
16	82	86	O	vitro
17	88	90	O	and
18	92	97	O	animal
19	99	105	O	studies
20	107	110	O	with
21	112	114	O	the
22	116	126	O	combination
23	128	129	O	of
24	131	144	O	XXXXXXXX
25	146	148	O	and
26	150	159	U-UNK	imidazoles
27	161	167	O	suggest
28	169	172	O	that
29	174	183	U-DYN	imidazoles
30	185	187	O	may
31	189	194	O	induce
32	196	201	O	fungal
33	203	212	O	resistance
34	214	215	O	to
35	217	230	O	XXXXXXXX
NULL

Amphotericin B	DDI-DrugBank.d318.s9	NO_SECTION	NO_SETID	12
Combination therapy should be administered with caution, especially in immunocompromised patients.
1	0	10	O	Combination
2	12	18	O	therapy
3	20	25	O	should
4	27	28	O	be
5	30	41	O	administered
6	43	46	O	with
7	48	54	O	caution
8	55	55	O	,
9	57	66	O	especially
10	68	69	O	in
11	71	87	O	immunocompromised
12	89	96	O	patients
NULL

Amphotericin B	DDI-DrugBank.d318.s10	NO_SECTION	NO_SETID	32
Other nephrotoxic medications: agents such as aminoglycosides, cyclosporine, and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.
1	0	4	O	Other
2	6	16	O	nephrotoxic
3	18	28	O	medications
4	29	29	O	:
5	31	36	O	agents
6	38	41	O	such
7	43	44	O	as
8	46	60	U-UNK	aminoglycosides
9	61	61	O	,
10	63	74	U-UNK	cyclosporine
11	75	75	O	,
12	77	79	O	and
13	81	91	U-UNK	pentamidine
14	93	95	O	may
15	97	103	O	enhance
16	105	107	O	the
17	109	117	O	potential
18	119	121	O	for
19	123	126	O	drug
20	128	134	O	induced
21	136	140	O	renal
22	142	149	O	toxicity
23	150	150	O	,
24	152	154	O	and
25	156	161	O	should
26	163	164	O	be
27	166	169	O	used
28	171	183	O	concomitantly
29	185	188	O	only
30	190	193	O	with
31	195	199	O	great
32	201	207	O	caution
NULL

Amphotericin B	DDI-DrugBank.d318.s11	NO_SECTION	NO_SETID	15
Intensive monitoring of renal function is recommended in patients requiring any combination of nephrotoxic medications .
1	0	8	O	Intensive
2	10	19	O	monitoring
3	21	22	O	of
4	24	28	O	renal
5	30	37	O	function
6	39	40	O	is
7	42	52	O	recommended
8	54	55	O	in
9	57	64	O	patients
10	66	74	O	requiring
11	76	78	O	any
12	80	90	O	combination
13	92	93	O	of
14	95	105	O	nephrotoxic
15	107	117	O	medications
NULL

Amphotericin B	DDI-DrugBank.d318.s12	NO_SECTION	NO_SETID	19
Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
1	0	7	B-UNK	Skeletal
2	9	14	I-UNK	muscle
3	16	24	L-UNK	relaxants
4	25	25	O	:
5	27	40	O	XXXXXXXX
6	42	48	O	induced
7	50	60	O	hypokalemia
8	62	64	O	may
9	66	72	O	enhance
10	74	76	O	the
11	78	87	O	curariform
12	89	94	O	effect
13	96	97	O	of
14	99	106	B-DYN	skeletal
15	108	113	I-DYN	muscle
16	115	123	L-DYN	relaxants
17	126	128	O	e.g
18	130	130	O	,
19	132	143	U-DYN	tubocurarine
NULL

Amphotericin B	DDI-DrugBank.d318.s13	NO_SECTION	NO_SETID	9
Serum potassium levels should be monitored and deficiencies corrected.
1	0	4	O	Serum
2	6	14	O	potassium
3	16	21	O	levels
4	23	28	O	should
5	30	31	O	be
6	33	41	O	monitored
7	43	45	O	and
8	47	58	O	deficiencies
9	60	68	O	corrected
NULL

Amphotericin B	DDI-DrugBank.d318.s14	NO_SECTION	NO_SETID	17
Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.
1	0	8	B-UNK	Leukocyte
2	10	21	L-UNK	transfusions
3	22	22	O	:
4	24	28	O	acute
5	30	38	O	pulmonary
6	40	47	O	toxicity
7	49	51	O	has
8	53	56	O	been
9	58	65	O	reported
10	67	68	O	in
11	70	77	O	patients
12	79	87	O	receiving
13	89	99	O	intravenous
14	101	114	O	XXXXXXXX
15	116	118	O	and
16	120	128	B-DYN	leukocyte
17	130	141	L-DYN	transfusions
NULL

Ampicillin	DDI-DrugBank.d211.s0	NO_SECTION	NO_SETID	11
When administered concurrently, the following drugs may interact with ampicillin.
1	0	3	O	When
2	5	16	O	administered
3	18	29	O	concurrently
4	30	30	O	,
5	32	34	O	the
6	36	44	O	following
7	46	50	O	drugs
8	52	54	O	may
9	56	63	O	interact
10	65	68	O	with
11	70	79	O	XXXXXXXX
NULL

Ampicillin	DDI-DrugBank.d211.s1	NO_SECTION	NO_SETID	14
Allopurinol: Increased possibility of skin rash, particularly in hyperuricemic patients may occur.
1	0	10	U-UNK	Allopurinol
2	11	11	O	:
3	13	21	O	Increased
4	23	33	O	possibility
5	35	36	O	of
6	38	41	O	skin
7	43	46	O	rash
8	47	47	O	,
9	49	60	O	particularly
10	62	63	O	in
11	65	77	O	hyperuricemic
12	79	86	O	patients
13	88	90	O	may
14	92	96	O	occur
NULL

Ampicillin	DDI-DrugBank.d211.s2	NO_SECTION	NO_SETID	19
Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.
1	0	13	B-UNK	Bacteriostatic
2	15	25	L-UNK	Antibiotics
3	26	26	O	:
4	28	42	U-UNK	Chloramphenicol
5	43	43	O	,
6	45	57	U-UNK	erythromycins
7	58	58	O	,
8	60	71	U-UNK	sulfonamides
9	72	72	O	,
10	74	75	O	or
11	77	89	U-UNK	tetracyclines
12	91	93	O	may
13	95	103	O	interfere
14	105	108	O	with
15	110	112	O	the
16	114	125	O	bactericidal
17	127	132	O	effect
18	134	135	O	of
19	137	147	U-UNK	penicillins
NULL

Ampicillin	DDI-DrugBank.d211.s3	NO_SECTION	NO_SETID	19
This has been demonstrated in view, however, the clinical significance of this interaction is not well documented.
1	0	3	O	This
2	5	7	O	has
3	9	12	O	been
4	14	25	O	demonstrated
5	27	28	O	in
6	30	33	O	view
7	34	34	O	,
8	36	42	O	however
9	43	43	O	,
10	45	47	O	the
11	49	56	O	clinical
12	58	69	O	significance
13	71	72	O	of
14	74	77	O	this
15	79	89	O	interaction
16	91	92	O	is
17	94	96	O	not
18	98	101	O	well
19	103	112	O	documented
NULL

Ampicillin	DDI-DrugBank.d211.s4	NO_SECTION	NO_SETID	13
Oral Contraceptives: May be less effective and increased breakthrough bleeding may occur.
1	0	3	O	Oral
2	5	18	U-UNK	Contraceptives
3	19	19	O	:
4	21	23	O	May
5	25	26	O	be
6	28	31	O	less
7	33	41	O	effective
8	43	45	O	and
9	47	55	O	increased
10	57	68	O	breakthrough
11	70	77	O	bleeding
12	79	81	O	may
13	83	87	O	occur
NULL

Ampicillin	DDI-DrugBank.d211.s5	NO_SECTION	NO_SETID	19
Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.
1	0	9	U-KIN	Probenecid
2	10	10	O	:
3	12	14	O	May
4	16	23	O	decrease
5	25	29	O	renal
6	31	37	O	tubular
7	39	47	O	secretion
8	49	50	O	of
9	52	61	O	XXXXXXXX
10	63	71	O	resulting
11	73	74	O	in
12	76	84	O	increased
13	86	90	O	blood
14	92	97	O	levels
15	99	101	O	and
16	102	102	O	/
17	103	104	O	or
18	106	115	O	XXXXXXXX
19	117	124	O	toxicity
NULL

Ampicillin	DDI-DrugBank.d211.s6	NO_SECTION	NO_SETID	49
Drug/Laboratory Test Interaction After treatment with ampicillin, a false-positive reaction for glucose in the urine may occur with copper sulfate tests (Benedicts solution, Fehlings solution, or Clinitest tablets) but not with enzyme based tests such as Clinistix and Glucose Enzymatic Test Strip USP.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	31	O	Interaction
6	33	37	O	After
7	39	47	O	treatment
8	49	52	O	with
9	54	63	O	XXXXXXXX
10	64	64	O	,
11	66	66	O	a
12	68	72	O	false
13	74	81	O	positive
14	83	90	O	reaction
15	92	94	O	for
16	96	102	O	glucose
17	104	105	O	in
18	107	109	O	the
19	111	115	O	urine
20	117	119	O	may
21	121	125	O	occur
22	127	130	O	with
23	132	137	B-UNK	copper
24	139	145	L-UNK	sulfate
25	147	151	O	tests
26	154	162	O	Benedicts
27	164	171	O	solution
28	172	172	O	,
29	174	181	O	Fehlings
30	183	190	O	solution
31	191	191	O	,
32	193	194	O	or
33	196	204	O	Clinitest
34	206	212	O	tablets
35	215	217	O	but
36	219	221	O	not
37	223	226	O	with
38	228	233	O	enzyme
39	235	239	O	based
40	241	245	O	tests
41	247	250	O	such
42	252	253	O	as
43	255	263	O	Clinistix
44	265	267	O	and
45	269	275	O	Glucose
46	277	285	O	Enzymatic
47	287	290	O	Test
48	292	296	O	Strip
49	298	300	O	USP
NULL

Amprenavir	DDI-DrugBank.d437.s0	NO_SECTION	NO_SETID	12
Amprenavir is metabolized in the liver by the cytochrome P450 enzyme system.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	metabolized
4	26	27	O	in
5	29	31	O	the
6	33	37	O	liver
7	39	40	O	by
8	42	44	O	the
9	46	55	O	cytochrome
10	57	60	O	P450
11	62	67	O	enzyme
12	69	74	O	system
NULL

Amprenavir	DDI-DrugBank.d437.s1	NO_SECTION	NO_SETID	3
Amprenavir inhibits CYP3A4.
1	0	9	O	XXXXXXXX
2	11	18	O	inhibits
3	20	25	O	CYP3A4
NULL

Amprenavir	DDI-DrugBank.d437.s2	NO_SECTION	NO_SETID	27
Caution should be used when coadministering medications that are substrates, inhibitors, or inducers of CYP3A4, or potentially toxic medications that are metabolized by CYP3A4.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	26	O	when
6	28	42	O	coadministering
7	44	54	O	medications
8	56	59	O	that
9	61	63	O	are
10	65	74	O	substrates
11	75	75	O	,
12	77	86	O	inhibitors
13	87	87	O	,
14	89	90	O	or
15	92	99	O	inducers
16	101	102	O	of
17	104	109	O	CYP3A4
18	110	110	O	,
19	112	113	O	or
20	115	125	O	potentially
21	127	131	O	toxic
22	133	143	O	medications
23	145	148	O	that
24	150	152	O	are
25	154	164	O	metabolized
26	166	167	O	by
27	169	174	O	CYP3A4
NULL

Amprenavir	DDI-DrugBank.d437.s3	NO_SECTION	NO_SETID	18
Amprenavir does not inhibit CYP2D6, CYP1A2, CYP2C9, CYP2C19, CYP2E1, or uridine glucuronosyltransferase (UDPGT).
1	0	9	O	XXXXXXXX
2	11	14	O	does
3	16	18	O	not
4	20	26	O	inhibit
5	28	33	O	CYP2D6
6	34	34	O	,
7	36	41	O	CYP1A2
8	42	42	O	,
9	44	49	O	CYP2C9
10	50	50	O	,
11	52	58	O	CYP2C19
12	59	59	O	,
13	61	66	O	CYP2E1
14	67	67	O	,
15	69	70	O	or
16	72	78	O	uridine
17	80	102	O	glucuronosyltransferase
18	105	109	O	UDPGT
NULL

Amprenavir	DDI-DrugBank.d437.s4	NO_SECTION	NO_SETID	29
HIV Protease Inhibitors: The effect of amprenavir on total drug concentrations of other HIV protease inhibitors in subjects receiving both agents was evaluated using comparisons to historical data.
1	0	2	B-UNK	HIV
2	4	11	I-UNK	Protease
3	13	22	L-UNK	Inhibitors
4	23	23	O	:
5	25	27	O	The
6	29	34	O	effect
7	36	37	O	of
8	39	48	O	XXXXXXXX
9	50	51	O	on
10	53	57	O	total
11	59	62	O	drug
12	64	77	O	concentrations
13	79	80	O	of
14	82	86	O	other
15	88	90	B-UNK	HIV
16	92	99	I-UNK	protease
17	101	110	L-UNK	inhibitors
18	112	113	O	in
19	115	122	O	subjects
20	124	132	O	receiving
21	134	137	O	both
22	139	144	O	agents
23	146	148	O	was
24	150	158	O	evaluated
25	160	164	O	using
26	166	176	O	comparisons
27	178	179	O	to
28	181	190	O	historical
29	192	195	O	data
NULL

Amprenavir	DDI-DrugBank.d437.s5	NO_SECTION	NO_SETID	23
Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.
1	0	8	U-KIN	Indinavir
2	10	15	O	steady
3	17	21	O	state
4	23	26	O	Cmax
5	27	27	O	,
6	29	31	O	A.C
7	34	36	O	and
8	38	41	O	Cmin
9	43	46	O	were
10	48	56	O	decreased
11	58	59	O	by
12	61	63	O	22%
13	64	64	O	,
14	66	68	O	38%
15	69	69	O	,
16	71	73	O	and
17	75	77	O	27%
18	78	78	O	,
19	80	91	O	respectively
20	92	92	O	,
21	94	95	O	by
22	97	107	O	concomitant
23	109	118	O	XXXXXXXX
NULL

Amprenavir	DDI-DrugBank.d437.s6	NO_SECTION	NO_SETID	12
Similar decreases in Cmax and AUC were seen after the first dose.
1	0	6	O	Similar
2	8	16	O	decreases
3	18	19	O	in
4	21	24	O	Cmax
5	26	28	O	and
6	30	32	O	AUC
7	34	37	O	were
8	39	42	O	seen
9	44	48	O	after
10	50	52	O	the
11	54	58	O	first
12	60	63	O	dose
NULL

Amprenavir	DDI-DrugBank.d437.s7	NO_SECTION	NO_SETID	24
Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.
1	0	9	U-KIN	Saquinavir
2	11	16	O	steady
3	18	22	O	state
4	24	27	O	Cmax
5	28	28	O	,
6	30	32	O	A.C
7	35	37	O	and
8	39	42	O	Cmin
9	44	47	O	were
10	49	57	O	increased
11	59	61	O	21%
12	62	62	O	,
13	64	72	O	decreased
14	74	76	O	19%
15	77	77	O	,
16	79	81	O	and
17	83	91	O	decreased
18	93	95	O	48%
19	96	96	O	,
20	98	109	O	respectively
21	110	110	O	,
22	112	113	O	by
23	115	125	O	concomitant
24	127	136	O	XXXXXXXX
NULL

Amprenavir	DDI-DrugBank.d437.s8	NO_SECTION	NO_SETID	23
Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.
1	0	9	U-KIN	Nelfinavir
2	11	16	O	steady
3	18	22	O	state
4	24	27	O	Cmax
5	28	28	O	,
6	30	32	O	A.C
7	35	37	O	and
8	39	42	O	Cmin
9	44	47	O	were
10	49	57	O	increased
11	59	60	O	by
12	62	64	O	12%
13	65	65	O	,
14	67	69	O	15%
15	70	70	O	,
16	72	74	O	and
17	76	78	O	14%
18	79	79	O	,
19	81	92	O	respectively
20	93	93	O	,
21	95	96	O	by
22	98	108	O	concomitant
23	110	119	O	XXXXXXXX
NULL

Amprenavir	DDI-DrugBank.d437.s9	NO_SECTION	NO_SETID	13
Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.
1	0	8	U-UNK	Methadone
2	9	9	O	:
3	11	26	O	Coadministration
4	28	29	O	of
5	31	40	O	XXXXXXXX
6	42	44	O	and
7	46	54	U-DYN	methadone
8	56	58	O	can
9	60	67	O	decrease
10	69	74	O	plasma
11	76	81	O	levels
12	83	84	O	of
13	86	94	U-UNK	methadone
NULL

Amprenavir	DDI-DrugBank.d437.s10	NO_SECTION	NO_SETID	33
Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	O	XXXXXXXX
4	31	33	O	and
5	35	43	U-KIN	methadone
6	45	46	O	as
7	48	55	O	compared
8	57	58	O	to
9	60	60	O	a
10	62	64	O	non
11	66	72	O	matched
12	74	90	O	historicalcontrol
13	92	96	O	group
14	98	105	O	resulted
15	107	108	O	in
16	110	110	O	a
17	112	114	O	30%
18	115	115	O	,
19	117	119	O	27%
20	120	120	O	,
21	122	124	O	and
22	126	128	O	25%
23	130	137	O	decrease
24	139	140	O	in
25	142	146	O	serum
26	148	157	O	XXXXXXXX
27	159	161	O	AUC
28	162	162	O	,
29	164	167	O	Cmax
30	168	168	O	,
31	170	176	O	andCmin
32	177	177	O	,
33	179	190	O	respectively
NULL

Amprenavir	DDI-DrugBank.d437.s11	NO_SECTION	NO_SETID	27
Amprenavir is an inhibitor of cytochrome P450 C.P.A. metabolism and therefore should not be administered concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	15	O	an
4	17	25	O	inhibitor
5	27	28	O	of
6	30	39	O	cytochrome
7	41	44	O	P450
8	46	50	O	C.P.A
9	53	62	O	metabolism
10	64	66	O	and
11	68	76	O	therefore
12	78	83	O	should
13	85	87	O	not
14	89	90	O	be
15	92	103	O	administered
16	105	116	O	concurrently
17	118	121	O	with
18	123	133	O	medications
19	135	138	O	with
20	140	145	O	narrow
21	147	157	O	therapeutic
22	159	165	O	windows
23	167	170	O	that
24	172	174	O	are
25	176	185	O	substrates
26	187	188	O	of
27	190	195	O	CYP3A4
NULL

Amprenavir	DDI-DrugBank.d437.s12	NO_SECTION	NO_SETID	16
There are other agents that may result in serious and/or life-threatening drug interactions.
1	0	4	O	There
2	6	8	O	are
3	10	14	O	other
4	16	21	O	agents
5	23	26	O	that
6	28	30	O	may
7	32	37	O	result
8	39	40	O	in
9	42	48	O	serious
10	50	52	O	and
11	53	53	O	/
12	54	55	O	or
13	57	60	O	life
14	62	72	O	threatening
15	74	77	O	drug
16	79	90	O	interactions
NULL

Amprenavir	DDI-DrugBank.d437.s13	NO_SECTION	NO_SETID	30
Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.
1	0	9	O	Laboratory
2	11	15	O	Tests
3	16	16	O	:
4	18	20	O	The
5	22	32	O	combination
6	34	35	O	of
7	37	46	O	XXXXXXXX
8	48	50	O	and
9	52	54	O	low
10	56	59	O	dose
11	61	69	U-DYN	ritonavir
12	71	73	O	has
13	75	78	O	been
14	80	89	O	associated
15	91	94	O	with
16	96	105	O	elevations
17	107	108	O	of
18	110	120	O	cholesterol
19	122	124	O	and
20	126	138	O	triglycerides
21	139	139	O	,
22	141	144	O	SGOT
23	147	149	O	AST
24	151	151	O	,
25	153	155	O	and
26	157	160	O	SGPT
27	163	165	O	ALT
28	168	169	O	in
29	171	174	O	some
30	176	183	O	patients
NULL

Amprenavir	DDI-DrugBank.d437.s14	NO_SECTION	NO_SETID	36
Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.
1	0	10	O	Appropriate
2	12	21	O	laboratory
3	23	29	O	testing
4	31	36	O	should
5	38	39	O	be
6	41	50	O	considered
7	52	56	O	prior
8	58	59	O	to
9	61	70	O	initiating
10	72	82	O	combination
11	84	90	O	therapy
12	92	95	O	with
13	97	106	O	XXXXXXXX
14	108	110	O	and
15	112	120	U-DYN	ritonavir
16	122	124	O	and
17	126	127	O	at
18	129	136	O	periodic
19	138	146	O	intervals
20	148	149	O	or
21	151	152	O	if
22	154	156	O	any
23	158	165	O	clinical
24	167	171	O	signs
25	173	174	O	or
26	176	183	O	symptoms
27	185	186	O	of
28	188	201	O	hyperlipidemia
29	203	204	O	or
30	206	213	O	elevated
31	215	219	O	liver
32	221	228	O	function
33	230	234	O	tests
34	236	240	O	occur
35	242	247	O	during
36	249	255	O	therapy
NULL

Amprenavir	DDI-DrugBank.d437.s15	NO_SECTION	NO_SETID	22
For comprehensive information concerning laboratory test alterations associated with ritonavir, physicians should refer to the complete prescribing information for NORVIR (ritonavir).
1	0	2	O	For
2	4	16	O	comprehensive
3	18	28	O	information
4	30	39	O	concerning
5	41	50	O	laboratory
6	52	55	O	test
7	57	67	O	alterations
8	69	78	O	associated
9	80	83	O	with
10	85	93	U-UNK	ritonavir
11	94	94	O	,
12	96	105	O	physicians
13	107	112	O	should
14	114	118	O	refer
15	120	121	O	to
16	123	125	O	the
17	127	134	O	complete
18	136	146	O	prescribing
19	148	158	O	information
20	160	162	O	for
21	164	169	O	XXXXXXXX
22	172	180	U-UNK	ritonavir
NULL

Amyl Nitrite	DDI-DrugBank.d56.s0	NO_SECTION	NO_SETID	17
Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.
1	0	5	O	Taking
2	7	18	O	XXXXXXXX
3	20	24	O	after
4	26	33	O	drinking
5	35	41	U-DYN	alcohol
6	43	45	O	may
7	47	52	O	worsen
8	54	57	O	side
9	59	65	O	effects
10	67	69	O	and
11	71	73	O	may
12	75	79	O	cause
13	81	86	O	severe
14	88	98	O	hypotension
15	100	102	O	and
16	104	117	O	cardiovascular
17	119	126	O	collapse
NULL

Anagrelide	DDI-DrugBank.d75.s0	NO_SECTION	NO_SETID	19
Limited PK and/or PD studies investigating possible interactions between anagrelide and other medicinal products have been conducted.
1	0	6	O	Limited
2	8	9	O	PK
3	11	13	O	and
4	14	14	O	/
5	15	16	O	or
6	18	19	O	PD
7	21	27	O	studies
8	29	41	O	investigating
9	43	50	O	possible
10	52	63	O	interactions
11	65	71	O	between
12	73	82	O	XXXXXXXX
13	84	86	O	and
14	88	92	O	other
15	94	102	O	medicinal
16	104	111	O	products
17	113	116	O	have
18	118	121	O	been
19	123	131	O	conducted
NULL

Anagrelide	DDI-DrugBank.d75.s1	NO_SECTION	NO_SETID	32
In vivo interaction studies in humans have demonstrated that digoxin and warfarin do not affect the PK properties of anagrelide, nor does anagrelide affect the PK properties of digoxin or warfarin.
1	0	1	O	In
2	3	6	O	vivo
3	8	18	O	interaction
4	20	26	O	studies
5	28	29	O	in
6	31	36	O	humans
7	38	41	O	have
8	43	54	O	demonstrated
9	56	59	O	that
10	61	67	U-UNK	digoxin
11	69	71	O	and
12	73	80	U-UNK	warfarin
13	82	83	O	do
14	85	87	O	not
15	89	94	O	affect
16	96	98	O	the
17	100	101	O	PK
18	103	112	O	properties
19	114	115	O	of
20	117	126	O	XXXXXXXX
21	127	127	O	,
22	129	131	O	nor
23	133	136	O	does
24	138	147	O	XXXXXXXX
25	149	154	O	affect
26	156	158	O	the
27	160	161	O	PK
28	163	172	O	properties
29	174	175	O	of
30	177	183	U-UNK	digoxin
31	185	186	O	or
32	188	195	U-UNK	warfarin
NULL

Anagrelide	DDI-DrugBank.d75.s2	NO_SECTION	NO_SETID	36
Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
1	0	7	O	Although
2	9	18	O	additional
3	20	23	O	drug
4	25	35	O	interaction
5	37	43	O	studies
6	45	48	O	have
7	50	52	O	not
8	54	57	O	been
9	59	67	O	conducted
10	68	68	O	,
11	70	72	O	the
12	74	77	O	most
13	79	84	O	common
14	86	96	O	medications
15	98	101	O	used
16	103	115	O	concomitantly
17	117	120	O	with
18	122	131	U-UNK	anagrelide
19	133	134	O	in
20	136	143	O	clinical
21	145	150	O	trials
22	152	155	O	were
23	157	163	O	XXXXXXXX
24	164	164	O	,
25	166	178	U-UNK	acetaminophen
26	179	179	O	,
27	181	190	U-UNK	furosemide
28	191	191	O	,
29	193	196	U-UNK	iron
30	197	197	O	,
31	199	208	U-UNK	ranitidine
32	209	209	O	,
33	211	221	U-UNK	hydroxyurea
34	222	222	O	,
35	224	226	O	and
36	228	238	U-UNK	allopurinol
NULL

Anagrelide	DDI-DrugBank.d75.s3	NO_SECTION	NO_SETID	15
There is no clinical evidence to suggest that anagrelide interacts with any of these compounds.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	19	O	clinical
5	21	28	O	evidence
6	30	31	O	to
7	33	39	O	suggest
8	41	44	O	that
9	46	55	O	XXXXXXXX
10	57	65	O	interacts
11	67	70	O	with
12	72	74	O	any
13	76	77	O	of
14	79	83	O	these
15	85	93	O	compounds
NULL

Anagrelide	DDI-DrugBank.d75.s4	NO_SECTION	NO_SETID	29
An in vivo interaction study in humans demonstrated that a single 1mg dose of anagrelide administered concomitantly with a single 900 mg dose of aspirin was generally well tolerated.
1	0	1	O	An
2	3	4	O	in
3	6	9	O	vivo
4	11	21	O	interaction
5	23	27	O	study
6	29	30	O	in
7	32	37	O	humans
8	39	50	O	demonstrated
9	52	55	O	that
10	57	57	O	a
11	59	64	O	single
12	66	68	O	1mg
13	70	73	O	dose
14	75	76	O	of
15	78	87	U-UNK	anagrelide
16	89	100	O	administered
17	102	114	O	concomitantly
18	116	119	O	with
19	121	121	O	a
20	123	128	O	single
21	130	132	O	900
22	134	135	O	mg
23	137	140	O	dose
24	142	143	O	of
25	145	151	O	XXXXXXXX
26	153	155	O	was
27	157	165	O	generally
28	167	170	O	well
29	172	180	O	tolerated
NULL

Anagrelide	DDI-DrugBank.d75.s5	NO_SECTION	NO_SETID	11
There was no effect on bleeding time, PT or aPTT.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	18	O	effect
5	20	21	O	on
6	23	30	O	bleeding
7	32	35	O	time
8	36	36	O	,
9	38	39	O	PT
10	41	42	O	or
11	44	47	O	aPTT
NULL

Anagrelide	DDI-DrugBank.d75.s6	NO_SECTION	NO_SETID	12
No clinically relevant pharmacokinetic interactions between anagrelide and acetylsalicylic acid were observed.
1	0	1	O	No
2	3	12	O	clinically
3	14	21	O	relevant
4	23	37	O	pharmacokinetic
5	39	50	O	interactions
6	52	58	O	between
7	60	69	O	XXXXXXXX
8	71	73	O	and
9	75	89	B-UNK	acetylsalicylic
10	91	94	L-UNK	acid
11	96	99	O	were
12	101	108	O	observed
NULL

Anagrelide	DDI-DrugBank.d75.s7	NO_SECTION	NO_SETID	16
In that same study, aspirin alone produced a marked inhibition in platelet aggregation ex vivo.
1	0	1	O	In
2	3	6	O	that
3	8	11	O	same
4	13	17	O	study
5	18	18	O	,
6	20	26	O	XXXXXXXX
7	28	32	O	alone
8	34	41	O	produced
9	43	43	O	a
10	45	50	O	marked
11	52	61	O	inhibition
12	63	64	O	in
13	66	73	O	platelet
14	75	85	O	aggregation
15	87	88	O	ex
16	90	93	O	vivo
NULL

Anagrelide	DDI-DrugBank.d75.s8	NO_SECTION	NO_SETID	20
Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.
1	0	9	U-DYN	Anagrelide
2	11	15	O	alone
3	17	19	O	had
4	21	22	O	no
5	24	29	O	effect
6	31	32	O	on
7	34	41	O	platelet
8	43	53	O	aggregation
9	54	54	O	,
10	56	58	O	but
11	60	62	O	did
12	64	71	O	slightly
13	73	79	O	enhance
14	81	83	O	the
15	85	94	O	inhibition
16	96	97	O	of
17	99	106	O	platelet
18	108	118	O	aggregation
19	120	121	O	by
20	123	129	O	XXXXXXXX
NULL

Anagrelide	DDI-DrugBank.d75.s9	NO_SECTION	NO_SETID	9
Anagrelide is metabolized at least in part by CYP1A2.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	metabolized
4	26	27	O	at
5	29	33	O	least
6	35	36	O	in
7	38	41	O	part
8	43	44	O	by
9	46	51	O	CYP1A2
NULL

Anagrelide	DDI-DrugBank.d75.s10	NO_SECTION	NO_SETID	27
It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.
1	0	1	O	It
2	3	4	O	is
3	6	10	O	known
4	12	15	O	that
5	17	22	O	CYP1A2
6	24	25	O	is
7	27	35	O	inhibited
8	37	38	O	by
9	40	46	O	several
10	48	56	O	medicinal
11	58	65	O	products
12	66	66	O	,
13	68	76	O	including
14	78	88	U-KIN	fluvoxamine
15	89	89	O	,
16	91	93	O	and
17	95	98	O	such
18	100	108	O	medicinal
19	110	117	O	products
20	119	123	O	could
21	125	137	O	theoretically
22	139	147	O	adversely
23	149	157	O	influence
24	159	161	O	the
25	163	171	O	clearance
26	173	174	O	of
27	176	185	O	XXXXXXXX
NULL

Anagrelide	DDI-DrugBank.d75.s11	NO_SECTION	NO_SETID	26
Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g.
1	0	9	O	XXXXXXXX
2	11	22	O	demonstrates
3	24	27	O	some
4	29	35	O	limited
5	37	46	O	inhibitory
6	48	55	O	activity
7	57	63	O	towards
8	65	70	O	CYP1A2
9	72	76	O	which
10	78	80	O	may
11	82	88	O	present
12	90	90	O	a
13	92	102	O	theoretical
14	104	112	O	potential
15	114	116	O	for
16	118	128	O	interaction
17	130	133	O	with
18	135	139	O	other
19	141	154	O	coadministered
20	156	164	O	medicinal
21	166	173	O	products
22	175	181	O	sharing
23	183	186	O	that
24	188	196	O	clearance
25	198	206	O	mechanism
26	208	210	O	e.g
NULL

Anagrelide	DDI-DrugBank.d75.s12	NO_SECTION	NO_SETID	27
Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.
1	0	9	O	XXXXXXXX
2	11	22	O	demonstrates
3	24	27	O	some
4	29	35	O	limited
5	37	46	O	inhibitory
6	48	55	O	activity
7	57	63	O	towards
8	65	70	O	CYP1A2
9	72	76	O	which
10	78	80	O	may
11	82	88	O	present
12	90	90	O	a
13	92	102	O	theoretical
14	104	112	O	potential
15	114	116	O	for
16	118	128	O	interaction
17	130	133	O	with
18	135	139	O	other
19	141	154	O	coadministered
20	156	164	O	medicinal
21	166	173	O	products
22	175	181	O	sharing
23	183	186	O	that
24	188	196	O	clearance
25	198	206	O	mechanism
26	208	210	O	e.g
27	213	224	U-KIN	theophylline
NULL

Anagrelide	DDI-DrugBank.d75.s13	NO_SECTION	NO_SETID	9
Anagrelide is an inhibitor of cyclic AMP PDE III.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	15	O	an
4	17	25	O	inhibitor
5	27	28	O	of
6	30	35	O	cyclic
7	37	39	O	AMP
8	41	43	O	PDE
9	45	47	O	III
NULL

Anagrelide	DDI-DrugBank.d75.s14	NO_SECTION	NO_SETID	25
The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	23	O	medicinal
5	25	32	O	products
6	34	37	O	with
7	39	45	O	similar
8	47	56	O	properties
9	58	61	O	such
10	63	64	O	as
11	66	74	O	inotropes
12	76	84	U-DYN	milrinone
13	85	85	O	,
14	87	95	U-DYN	enoximone
15	96	96	O	,
16	98	105	U-DYN	amrinone
17	106	106	O	,
18	108	116	U-DYN	olprinone
19	118	120	O	and
20	122	131	U-DYN	cilostazol
21	133	135	O	may
22	137	138	O	be
23	140	150	O	exacerbated
24	152	153	O	by
25	155	164	O	XXXXXXXX
NULL

Anagrelide	DDI-DrugBank.d75.s15	NO_SECTION	NO_SETID	16
There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.
1	0	4	O	There
2	6	7	O	is
3	9	9	O	a
4	11	16	O	single
5	18	21	O	case
6	23	28	O	report
7	29	29	O	,
8	31	35	O	which
9	37	44	O	suggests
10	46	49	O	that
11	51	60	U-KIN	sucralfate
12	62	64	O	may
13	66	74	O	interfere
14	76	79	O	with
15	81	90	O	XXXXXXXX
16	92	101	O	absorption
NULL

Anagrelide	DDI-DrugBank.d75.s16	NO_SECTION	NO_SETID	11
Food has no clinically significant effect on the bioavailability of anagrelide.
1	0	3	O	Food
2	5	7	O	has
3	9	10	O	no
4	12	21	O	clinically
5	23	33	O	significant
6	35	40	O	effect
7	42	43	O	on
8	45	47	O	the
9	49	63	O	bioavailability
10	65	66	O	of
11	68	77	O	XXXXXXXX
NULL

Anakinra	DDI-DrugBank.d275.s0	NO_SECTION	NO_SETID	11
No drug-drug interaction studies in human subjects have been conducted.
1	0	1	O	No
2	3	6	O	drug
3	8	11	O	drug
4	13	23	O	interaction
5	25	31	O	studies
6	33	34	O	in
7	36	40	O	human
8	42	49	O	subjects
9	51	54	O	have
10	56	59	O	been
11	61	69	O	conducted
NULL

Anakinra	DDI-DrugBank.d275.s1	NO_SECTION	NO_SETID	29
Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret when the two agents were administered together.
1	0	10	O	Toxicologic
2	12	14	O	and
3	16	28	O	toxicokinetic
4	30	36	O	studies
5	38	39	O	in
6	41	44	O	rats
7	46	48	O	did
8	50	52	O	not
9	54	64	O	demonstrate
10	66	68	O	any
11	70	80	O	alterations
12	82	83	O	in
13	85	87	O	the
14	89	97	O	clearance
15	99	100	O	or
16	102	112	O	toxicologic
17	114	120	O	profile
18	122	123	O	of
19	125	130	O	either
20	132	143	U-UNK	methotrexate
21	145	146	O	or
22	148	154	O	XXXXXXXX
23	156	159	O	when
24	161	163	O	the
25	165	167	O	two
26	169	174	O	agents
27	176	179	O	were
28	181	192	O	administered
29	194	201	O	together
NULL

Anakinra	DDI-DrugBank.d275.s2	NO_SECTION	NO_SETID	42
In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	in
5	14	18	O	which
6	20	27	O	patients
7	29	32	O	with
8	34	39	O	active
9	41	42	O	RA
10	44	47	O	were
11	49	55	O	treated
12	57	59	O	for
13	61	62	O	up
14	64	65	O	to
15	67	68	O	24
16	70	74	O	weeks
17	76	79	O	with
18	81	90	O	concurrent
19	92	98	O	XXXXXXXX
20	100	102	O	and
21	104	113	U-DYN	etanercept
22	115	121	O	therapy
23	122	122	O	,
24	124	124	O	a
25	126	127	O	7%
26	129	132	O	rate
27	134	135	O	of
28	137	143	O	serious
29	145	154	O	infections
30	156	158	O	was
31	160	167	O	observed
32	168	168	O	,
33	170	174	O	which
34	176	178	O	was
35	180	185	O	higher
36	187	190	O	than
37	192	195	O	that
38	197	204	O	observed
39	206	209	O	with
40	211	220	U-UNK	etanercept
41	222	226	O	alone
42	229	230	O	0%
NULL

Anakinra	DDI-DrugBank.d275.s3	NO_SECTION	NO_SETID	18
Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).
1	0	2	O	Two
2	4	10	O	percent
3	12	13	O	of
4	15	22	O	patients
5	24	30	O	treated
6	32	43	O	concurrently
7	45	48	O	with
8	50	56	O	XXXXXXXX
9	58	60	O	and
10	62	71	U-DYN	etanercept
11	73	81	O	developed
12	83	93	O	neutropenia
13	96	98	O	ANC
14	101	101	O	1
15	103	103	O	x
16	105	107	O	109
17	108	108	O	/
18	109	109	O	L
NULL

Anastrozole	DDI-DrugBank.d195.s0	NO_SECTION	NO_SETID	24
Anastrozole inhibited in vitro metabolic reactions catalyzed by cytochromes P450 1A2, 2C8/9, and 3A4 but only at relatively high concentrations.
1	0	10	O	XXXXXXXX
2	12	20	O	inhibited
3	22	23	O	in
4	25	29	O	vitro
5	31	39	O	metabolic
6	41	49	O	reactions
7	51	59	O	catalyzed
8	61	62	O	by
9	64	74	O	cytochromes
10	76	79	O	P450
11	81	83	O	1A2
12	84	84	O	,
13	86	88	O	2C8
14	89	89	O	/
15	90	90	O	9
16	91	91	O	,
17	93	95	O	and
18	97	99	O	3A4
19	101	103	O	but
20	105	108	O	only
21	110	111	O	at
22	113	122	O	relatively
23	124	127	O	high
24	129	142	O	concentrations
NULL

Anastrozole	DDI-DrugBank.d195.s1	NO_SECTION	NO_SETID	15
Anastrozole did not inhibit P450 2A6 or the polymorphic P450 2D6 in human liver microsomes.
1	0	10	O	XXXXXXXX
2	12	14	O	did
3	16	18	O	not
4	20	26	O	inhibit
5	28	31	O	P450
6	33	35	O	2A6
7	37	38	O	or
8	40	42	O	the
9	44	54	O	polymorphic
10	56	59	O	P450
11	61	63	O	2D6
12	65	66	O	in
13	68	72	O	human
14	74	78	O	liver
15	80	89	O	microsomes
NULL

Anastrozole	DDI-DrugBank.d195.s2	NO_SECTION	NO_SETID	8
Anastrozole did not alter the pharmacokinetics of antipyrine.
1	0	10	O	XXXXXXXX
2	12	14	O	did
3	16	18	O	not
4	20	24	O	alter
5	26	28	O	the
6	30	45	O	pharmacokinetics
7	47	48	O	of
8	50	59	U-UNK	antipyrine
NULL

Anastrozole	DDI-DrugBank.d195.s3	NO_SECTION	NO_SETID	55
Although there have been no formal interaction studies other than with antipyrine, based on these in vivo and in vitro studies, it is unlikely that co-administration of a 1 mg dose of ARIMIDEX with other drugs will result in clinically significant drug inhibition of cytochrome P450-mediated metabolism of the other drugs.
1	0	7	O	Although
2	9	13	O	there
3	15	18	O	have
4	20	23	O	been
5	25	26	O	no
6	28	33	O	formal
7	35	45	O	interaction
8	47	53	O	studies
9	55	59	O	other
10	61	64	O	than
11	66	69	O	with
12	71	80	U-UNK	antipyrine
13	81	81	O	,
14	83	87	O	based
15	89	90	O	on
16	92	96	O	these
17	98	99	O	in
18	101	104	O	vivo
19	106	108	O	and
20	110	111	O	in
21	113	117	O	vitro
22	119	125	O	studies
23	126	126	O	,
24	128	129	O	it
25	131	132	O	is
26	134	141	O	unlikely
27	143	146	O	that
28	148	149	O	co
29	151	164	O	administration
30	166	167	O	of
31	169	169	O	a
32	171	171	O	1
33	173	174	O	mg
34	176	179	O	dose
35	181	182	O	of
36	184	191	O	XXXXXXXX
37	193	196	O	with
38	198	202	O	other
39	204	208	O	drugs
40	210	213	O	will
41	215	220	O	result
42	222	223	O	in
43	225	234	O	clinically
44	236	246	O	significant
45	248	251	O	drug
46	253	262	O	inhibition
47	264	265	O	of
48	267	276	O	cytochrome
49	278	281	O	P450
50	283	290	O	mediated
51	292	301	O	metabolism
52	303	304	O	of
53	306	308	O	the
54	310	314	O	other
55	316	320	O	drugs
NULL

Anastrozole	DDI-DrugBank.d195.s4	NO_SECTION	NO_SETID	18
An interaction study with warfarin showed no clinically significant effect of anastrozole on warfarin pharmacokinetics or anticoagulant activity.
1	0	1	O	An
2	3	13	O	interaction
3	15	19	O	study
4	21	24	O	with
5	26	33	U-UNK	warfarin
6	35	40	O	showed
7	42	43	O	no
8	45	54	O	clinically
9	56	66	O	significant
10	68	73	O	effect
11	75	76	O	of
12	78	88	O	XXXXXXXX
13	90	91	O	on
14	93	100	U-UNK	warfarin
15	102	117	O	pharmacokinetics
16	119	120	O	or
17	122	134	O	anticoagulant
18	136	143	O	activity
NULL

Anastrozole	DDI-DrugBank.d195.s5	NO_SECTION	NO_SETID	37
At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation.
1	0	1	O	At
2	3	3	O	a
3	5	10	O	median
4	12	17	O	follow
5	19	20	O	up
6	22	23	O	of
7	25	26	O	33
8	28	33	O	months
9	34	34	O	,
10	36	38	O	the
11	40	50	O	combination
12	52	53	O	of
13	55	62	O	XXXXXXXX
14	64	66	O	and
15	68	76	U-UNK	tamoxifen
16	78	80	O	did
17	82	84	O	not
18	86	96	O	demonstrate
19	98	100	O	any
20	102	109	O	efficacy
21	111	117	O	benefit
22	119	122	O	when
23	124	131	O	compared
24	133	136	O	with
25	138	146	U-UNK	tamoxifen
26	148	149	O	in
27	151	153	O	all
28	155	162	O	patients
29	164	165	O	as
30	167	170	O	well
31	172	173	O	as
32	175	176	O	in
33	178	180	O	the
34	182	188	O	hormone
35	190	197	O	receptor
36	199	206	O	positive
37	208	220	O	subpopulation
NULL

Anastrozole	DDI-DrugBank.d195.s6	NO_SECTION	NO_SETID	8
This treatment arm was discontinued from the trial.
1	0	3	O	This
2	5	13	O	treatment
3	15	17	O	arm
4	19	21	O	was
5	23	34	O	discontinued
6	36	39	O	from
7	41	43	O	the
8	45	49	O	trial
NULL

Anastrozole	DDI-DrugBank.d195.s7	NO_SECTION	NO_SETID	37
Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).
1	0	4	O	Based
2	6	7	O	on
3	9	16	O	clinical
4	18	20	O	and
5	22	36	O	pharmacokinetic
6	38	44	O	results
7	46	49	O	from
8	51	53	O	the
9	55	58	O	ATAC
10	60	64	O	trial
11	65	65	O	,
12	67	75	U-DYN	tamoxifen
13	77	82	O	should
14	84	86	O	not
15	88	89	O	be
16	91	102	O	administered
17	104	107	O	with
18	109	119	O	XXXXXXXX
19	122	124	O	see
20	126	133	O	CLINICAL
21	135	146	O	PHARMACOLOGY
22	150	153	O	Drug
23	155	166	O	Interactions
24	168	170	O	and
25	172	179	O	CLINICAL
26	181	192	O	PHARMACOLOGY
27	196	203	O	Clinical
28	205	211	O	Studies
29	215	222	O	Adjuvant
30	224	232	O	Treatment
31	234	235	O	of
32	237	242	O	Breast
33	244	249	O	Cancer
34	251	252	O	in
35	254	267	O	Postmenopausal
36	269	273	O	Women
37	275	285	O	subsections
NULL

Anastrozole	DDI-DrugBank.d195.s8	NO_SECTION	NO_SETID	23
Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	31	O	XXXXXXXX
5	33	35	O	and
6	37	45	U-KIN	tamoxifen
7	47	54	O	resulted
8	56	57	O	in
9	59	59	O	a
10	61	69	O	reduction
11	71	72	O	of
12	74	84	O	XXXXXXXX
13	86	91	O	plasma
14	93	98	O	levels
15	100	101	O	by
16	103	105	O	27%
17	107	114	O	compared
18	116	119	O	with
19	121	125	O	those
20	127	134	O	achieved
21	136	139	O	with
22	141	151	O	XXXXXXXX
23	153	157	O	alone
NULL

Anastrozole	DDI-DrugBank.d195.s9	NO_SECTION	NO_SETID	16
Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.
1	0	7	U-DYN	Estrogen
2	9	18	O	containing
3	20	28	O	therapies
4	30	35	O	should
5	37	39	O	not
6	41	42	O	be
7	44	47	O	used
8	49	52	O	with
9	54	61	O	XXXXXXXX
10	63	64	O	as
11	66	69	O	they
12	71	73	O	may
13	75	82	O	diminish
14	84	86	O	its
15	88	100	O	pharmacologic
16	102	107	O	action
NULL

Anastrozole	DDI-DrugBank.d195.s10	NO_SECTION	NO_SETID	19
Drug/Laboratory Test Interactions No clinically significant changes in the results of clinical laboratory tests have been observed
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	35	O	No
7	37	46	O	clinically
8	48	58	O	significant
9	60	66	O	changes
10	68	69	O	in
11	71	73	O	the
12	75	81	O	results
13	83	84	O	of
14	86	93	O	clinical
15	95	104	O	laboratory
16	106	110	O	tests
17	112	115	O	have
18	117	120	O	been
19	122	129	O	observed
NULL

Anidulafungin	DDI-DrugBank.d445.s0	NO_SECTION	NO_SETID	18
No clinically relevant drug-drug interactions have been observed with drugs likely to be co-administered with anidulafungin.
1	0	1	O	No
2	3	12	O	clinically
3	14	21	O	relevant
4	23	26	O	drug
5	28	31	O	drug
6	33	44	O	interactions
7	46	49	O	have
8	51	54	O	been
9	56	63	O	observed
10	65	68	O	with
11	70	74	O	drugs
12	76	81	O	likely
13	83	84	O	to
14	86	87	O	be
15	89	90	O	co
16	92	103	O	administered
17	105	108	O	with
18	110	122	O	XXXXXXXX
NULL

Anileridine	DDI-DrugBank.d215.s0	NO_SECTION	NO_SETID	28
Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	25	O	observed
5	27	30	O	when
6	32	42	O	XXXXXXXX
7	44	45	O	is
8	47	60	O	coadministered
9	62	65	O	with
10	67	71	O	other
11	73	79	U-DYN	opioids
12	80	80	O	,
13	82	90	U-DYN	sedatives
14	91	91	O	,
15	93	106	U-DYN	phenothiazines
16	107	107	O	,
17	109	110	O	or
18	112	122	U-DYN	anesthetics
19	123	123	O	,
20	125	126	O	as
21	128	132	O	these
22	134	139	O	agents
23	141	143	O	may
24	145	152	O	increase
25	154	164	O	respiratory
26	166	168	O	and
27	170	180	O	circulatory
28	182	191	O	depression
NULL

Anisindione	DDI-DrugBank.d64.s0	NO_SECTION	NO_SETID	22
Addition or deletion of any drug from the therapeutic regimen of patients receiving oral anticoagulants may affect patient response to the anticoagulant.
1	0	7	O	Addition
2	9	10	O	or
3	12	19	O	deletion
4	21	22	O	of
5	24	26	O	any
6	28	31	O	drug
7	33	36	O	from
8	38	40	O	the
9	42	52	O	therapeutic
10	54	60	O	regimen
11	62	63	O	of
12	65	72	O	patients
13	74	82	O	receiving
14	84	87	O	oral
15	89	102	U-UNK	anticoagulants
16	104	106	O	may
17	108	113	O	affect
18	115	121	O	patient
19	123	130	O	response
20	132	133	O	to
21	135	137	O	the
22	139	151	U-UNK	anticoagulant
NULL

Anisindione	DDI-DrugBank.d64.s1	NO_SECTION	NO_SETID	24
Frequent determination of prothrombin time and close monitoring of the patient is essential to ascertain when adjustment of dosage of anticoagulant may be needed.
1	0	7	O	Frequent
2	9	21	O	determination
3	23	24	O	of
4	26	36	O	prothrombin
5	38	41	O	time
6	43	45	O	and
7	47	51	O	close
8	53	62	O	monitoring
9	64	65	O	of
10	67	69	O	the
11	71	77	O	patient
12	79	80	O	is
13	82	90	O	essential
14	92	93	O	to
15	95	103	O	ascertain
16	105	108	O	when
17	110	119	O	adjustment
18	121	122	O	of
19	124	129	O	dosage
20	131	132	O	of
21	134	146	U-UNK	anticoagulant
22	148	150	O	may
23	152	153	O	be
24	155	160	O	needed
NULL

Anisindione	DDI-DrugBank.d64.s2	NO_SECTION	NO_SETID	61
Because of the variability of individual patient response, multiple interacting mechanisms with some drugs, the dependency of the extent of the interaction on the dosage and duration of therapy, and the possible administration of several interacting drugs simultaneously, it is difficult to predict the direction and degree of the ultimate effect of concomitant medications on anticoagulant response.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	25	O	variability
5	27	28	O	of
6	30	39	O	individual
7	41	47	O	patient
8	49	56	O	response
9	57	57	O	,
10	59	66	O	multiple
11	68	78	O	interacting
12	80	89	O	mechanisms
13	91	94	O	with
14	96	99	O	some
15	101	105	O	drugs
16	106	106	O	,
17	108	110	O	the
18	112	121	O	dependency
19	123	124	O	of
20	126	128	O	the
21	130	135	O	extent
22	137	138	O	of
23	140	142	O	the
24	144	154	O	interaction
25	156	157	O	on
26	159	161	O	the
27	163	168	O	dosage
28	170	172	O	and
29	174	181	O	duration
30	183	184	O	of
31	186	192	O	therapy
32	193	193	O	,
33	195	197	O	and
34	199	201	O	the
35	203	210	O	possible
36	212	225	O	administration
37	227	228	O	of
38	230	236	O	several
39	238	248	O	interacting
40	250	254	O	drugs
41	256	269	O	simultaneously
42	270	270	O	,
43	272	273	O	it
44	275	276	O	is
45	278	286	O	difficult
46	288	289	O	to
47	291	297	O	predict
48	299	301	O	the
49	303	311	O	direction
50	313	315	O	and
51	317	322	O	degree
52	324	325	O	of
53	327	329	O	the
54	331	338	O	ultimate
55	340	345	O	effect
56	347	348	O	of
57	350	360	O	concomitant
58	362	372	O	medications
59	374	375	O	on
60	377	389	U-UNK	anticoagulant
61	391	398	O	response
NULL

Anisindione	DDI-DrugBank.d64.s3	NO_SECTION	NO_SETID	24
For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.
1	0	2	O	For
2	4	10	O	example
3	11	11	O	,
4	13	17	O	since
5	19	32	U-UNK	cholestyramine
6	34	36	O	may
7	38	43	O	reduce
8	45	47	O	the
9	49	64	O	gastrointestinal
10	66	75	O	absorption
11	77	78	O	of
12	80	83	O	both
13	85	87	O	the
14	89	92	O	oral
15	94	107	U-UNK	anticoagulants
16	109	111	O	and
17	113	119	B-UNK	vitamin
18	121	121	L-UNK	K
19	122	122	O	,
20	124	126	O	the
21	128	130	O	net
22	132	138	O	effects
23	140	142	O	are
24	144	156	O	unpredictable
NULL

Anisindione	DDI-DrugBank.d64.s4	NO_SECTION	NO_SETID	43
Chloral hydrate may cause an increased prothrombin response by displacing the anticoagulant from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction, thus leading to inter-patient variation in ultimate prothrombin effect.
1	0	6	B-UNK	Chloral
2	8	14	L-UNK	hydrate
3	16	18	O	may
4	20	24	O	cause
5	26	27	O	an
6	29	37	O	increased
7	39	49	O	prothrombin
8	51	58	O	response
9	60	61	O	by
10	63	72	O	displacing
11	74	76	O	the
12	78	90	U-UNK	anticoagulant
13	92	95	O	from
14	97	103	O	protein
15	105	111	O	binding
16	113	117	O	sites
17	119	120	O	or
18	122	122	O	a
19	124	133	O	diminished
20	135	145	O	prothrombin
21	147	154	O	response
22	156	162	O	through
23	164	172	O	increased
24	174	183	O	metabolism
25	185	186	O	of
26	188	190	O	the
27	192	198	O	unbound
28	200	203	O	drug
29	205	206	O	by
30	208	214	O	hepatic
31	216	221	O	enzyme
32	223	231	O	induction
33	232	232	O	,
34	234	237	O	thus
35	239	245	O	leading
36	247	248	O	to
37	250	254	O	inter
38	256	262	O	patient
39	264	272	O	variation
40	274	275	O	in
41	277	284	O	ultimate
42	286	296	O	prothrombin
43	298	303	O	effect
NULL

Anisindione	DDI-DrugBank.d64.s5	NO_SECTION	NO_SETID	37
An interacting drug which leads to a decrease in prothrombin time necessitating an increased dose of oral anticoagulant to maintain an adequate degree of anticoagulation may, if abruptly discontinued, increase the risk of subsequent bleeding.
1	0	1	O	An
2	3	13	O	interacting
3	15	18	O	drug
4	20	24	O	which
5	26	30	O	leads
6	32	33	O	to
7	35	35	O	a
8	37	44	O	decrease
9	46	47	O	in
10	49	59	O	prothrombin
11	61	64	O	time
12	66	78	O	necessitating
13	80	81	O	an
14	83	91	O	increased
15	93	96	O	dose
16	98	99	O	of
17	101	104	O	oral
18	106	118	U-UNK	anticoagulant
19	120	121	O	to
20	123	130	O	maintain
21	132	133	O	an
22	135	142	O	adequate
23	144	149	O	degree
24	151	152	O	of
25	154	168	O	anticoagulation
26	170	172	O	may
27	173	173	O	,
28	175	176	O	if
29	178	185	O	abruptly
30	187	198	O	discontinued
31	199	199	O	,
32	201	208	O	increase
33	210	212	O	the
34	214	217	O	risk
35	219	220	O	of
36	222	231	O	subsequent
37	233	240	O	bleeding
NULL

Anisindione	DDI-DrugBank.d64.s6	NO_SECTION	NO_SETID	26
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;
1	0	4	O	Drugs
2	6	9	O	that
3	11	14	O	have
4	16	19	O	been
5	21	28	O	reported
6	30	31	O	to
7	33	40	O	diminish
8	42	45	O	oral
9	47	59	U-UNK	anticoagulant
10	61	68	O	response
11	69	69	O	,
12	71	72	O	ie
13	73	73	O	,
14	75	83	O	decreased
15	85	92	O	prothrom
16	94	96	O	bin
17	98	101	O	time
18	103	110	O	response
19	111	111	O	,
20	113	114	O	in
21	116	118	O	man
22	120	132	O	significantly
23	134	140	O	include
24	141	141	O	:
25	143	156	B-UNK	adrenocortical
26	158	165	L-UNK	steroids
NULL

Anisindione	DDI-DrugBank.d64.s15	NO_SECTION	NO_SETID	5
diet high in vitamin K;
1	0	3	O	diet
2	5	8	O	high
3	10	11	O	in
4	13	19	B-UNK	vitamin
5	21	21	L-UNK	K
NULL

Anisindione	DDI-DrugBank.d64.s22	NO_SECTION	NO_SETID	2
oral contraceptives;
1	0	3	O	oral
2	5	18	U-UNK	contraceptives
NULL

Anisindione	DDI-DrugBank.d64.s27	NO_SECTION	NO_SETID	4
unreliable prothrombin time determinations;
1	0	9	O	unreliable
2	11	21	O	prothrombin
3	23	26	O	time
4	28	41	O	determinations
NULL

Anisindione	DDI-DrugBank.d64.s29	NO_SECTION	NO_SETID	39
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
1	0	4	O	Drugs
2	6	9	O	that
3	11	14	O	have
4	16	19	O	been
5	21	28	O	reported
6	30	31	O	to
7	33	40	O	diminish
8	42	45	O	oral
9	47	59	U-UNK	anticoagulant
10	61	68	O	response
11	69	69	O	,
12	71	72	O	ie
13	73	73	O	,
14	75	83	O	decreased
15	85	92	O	prothrom
16	94	96	O	bin
17	98	101	O	time
18	103	110	O	response
19	111	111	O	,
20	113	114	O	in
21	116	118	O	man
22	120	132	O	significantly
23	134	140	O	include
24	141	141	O	:
25	143	156	U-UNK	adrenocortical
26	158	233	O	steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral
27	235	279	O	hydrate*;chlordiazepoxide;cholestyramine;diet
28	281	284	O	high
29	286	287	O	in
30	289	295	U-UNK	vitamin
31	297	377	O	K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral
32	379	446	O	contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable
33	448	458	O	prothrombin
34	460	463	O	time
35	465	486	O	determinations;vitamin
36	488	497	O	C;warfarin
37	499	504	U-UNK	sodium
38	506	510	O	under
39	512	517	O	dosage
NULL

Anisindione	DDI-DrugBank.d64.s30	NO_SECTION	NO_SETID	18
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;
1	0	4	O	Drugs
2	6	9	O	that
3	11	20	O	reportedly
4	22	24	O	may
5	26	33	O	increase
6	35	38	O	oral
7	40	52	U-UNK	anticoagulant
8	54	61	O	response
9	62	62	O	,
10	64	65	O	ie
11	66	66	O	,
12	68	76	O	increased
13	78	88	O	prothrombin
14	90	97	O	response
15	98	98	O	,
16	100	101	O	in
17	103	105	O	man
18	107	122	O	include:alcohol*
NULL

Anisindione	DDI-DrugBank.d64.s32	NO_SECTION	NO_SETID	2
aminosalicylic acid;
1	0	13	B-UNK	aminosalicylic
2	15	18	L-UNK	acid
NULL

Anisindione	DDI-DrugBank.d64.s46	NO_SECTION	NO_SETID	2
dietary deficiencies;
1	0	6	O	dietary
2	8	19	O	deficiencies
NULL

Anisindione	DDI-DrugBank.d64.s50	NO_SECTION	NO_SETID	4
drugs affecting blood elements;
1	0	4	O	drugs
2	6	14	O	affecting
3	16	20	O	blood
4	22	29	O	elements
NULL

Anisindione	DDI-DrugBank.d64.s57	NO_SECTION	NO_SETID	3
influenza virus vaccine;
1	0	8	B-UNK	influenza
2	10	14	I-UNK	virus
3	16	22	L-UNK	vaccine
NULL

Anisindione	DDI-DrugBank.d64.s58	NO_SECTION	NO_SETID	2
inhalation anesthetics;
1	0	9	O	inhalation
2	11	21	U-UNK	anesthetics
NULL

Anisindione	DDI-DrugBank.d64.s64	NO_SECTION	NO_SETID	3
monoamine oxidase inhibitors;
1	0	8	B-UNK	monoamine
2	10	16	I-UNK	oxidase
3	18	27	L-UNK	inhibitors
NULL

Anisindione	DDI-DrugBank.d64.s73	NO_SECTION	NO_SETID	3
prolonged hot weather;
1	0	8	O	prolonged
2	10	12	O	hot
3	14	20	O	weather
NULL

Anisindione	DDI-DrugBank.d64.s74	NO_SECTION	NO_SETID	2
prolonged narcotics;
1	0	8	B-UNK	prolonged
2	10	18	L-UNK	narcotics
NULL

Anisindione	DDI-DrugBank.d64.s79	NO_SECTION	NO_SETID	1
salicylates;sulfinpyrazone;
1	0	25	O	salicylates;sulfinpyrazone
NULL

Anisindione	DDI-DrugBank.d64.s80	NO_SECTION	NO_SETID	4
sulfonamides, long acting;
1	0	11	U-UNK	sulfonamides
2	12	12	O	,
3	14	17	O	long
4	19	24	O	acting
NULL

Anisindione	DDI-DrugBank.d64.s85	NO_SECTION	NO_SETID	3
trimethoprim/sulfamethoxazole;
1	0	11	U-UNK	trimethoprim
2	12	12	O	/
3	13	28	U-UNK	sulfamethoxazole
NULL

Anisindione	DDI-DrugBank.d64.s86	NO_SECTION	NO_SETID	4
unreliable prothrombin time determinations;
1	0	9	O	unreliable
2	11	21	O	prothrombin
3	23	26	O	time
4	28	41	O	determinations
NULL

Anisindione	DDI-DrugBank.d64.s87	NO_SECTION	NO_SETID	50
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
1	0	4	O	Drugs
2	6	9	O	that
3	11	20	O	reportedly
4	22	24	O	may
5	26	33	O	increase
6	35	38	O	oral
7	40	52	U-UNK	anticoagulant
8	54	61	O	response
9	62	62	O	,
10	64	65	O	ie
11	66	66	O	,
12	68	76	O	increased
13	78	88	O	prothrombin
14	90	97	O	response
15	98	98	O	,
16	100	101	O	in
17	103	105	O	man
18	107	149	O	include:alcohol*;allopurinol;aminosalicylic
19	151	174	O	acid;amiodarone;anabolic
20	176	214	O	steroids;antibiotics;bromelains;chloral
21	216	326	O	hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary
22	328	367	O	deficiencies;diflunisal;disulfiram;drugs
23	369	377	O	affecting
24	379	383	O	blood
25	385	403	O	elements;ethacrynic
26	405	440	O	acid;fenoprofen;glucagon;hepatotoxic
27	442	479	O	drugs;ibuprofen;indomethacin;influenza
28	481	485	U-UNK	virus
29	487	504	O	vaccine;inhalation
30	506	526	O	anesthetics;mefenamic
31	528	593	O	acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine
32	595	601	U-UNK	oxidase
33	603	622	O	inhibitors;nalidixic
34	624	645	O	acid;naproxen;oxolinic
35	647	729	O	acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged
36	731	733	O	hot
37	735	751	O	weather;prolonged
38	753	843	O	narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides
39	844	844	O	,
40	846	849	O	long
41	851	873	O	acting;sulindac;thyroid
42	875	901	O	drugs;tolbutamide;triclofos
43	903	921	O	sodium;trimethoprim
44	922	922	O	/
45	923	949	O	sulfamethoxazole;unreliable
46	951	961	O	prothrombin
47	963	966	O	time
48	968	990	O	determinations;warfarin
49	992	997	U-UNK	sodium
50	999	1008	O	overdosage
NULL

Anisindione	DDI-DrugBank.d64.s88	NO_SECTION	NO_SETID	24
Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.
1	0	3	O	Oral
2	5	18	U-UNK	anticoagulants
3	20	22	O	may
4	24	33	O	potentiate
5	35	37	O	the
6	39	50	O	hypoglycemic
7	52	57	O	action
8	59	60	O	of
9	62	73	B-UNK	hypoglycemic
10	75	80	L-UNK	agents
11	81	81	O	,
12	83	84	O	eg
13	85	85	O	,
14	87	97	U-UNK	tolbutamide
15	99	101	O	and
16	103	116	U-UNK	chlorpropamide
17	117	117	O	,
18	119	120	O	by
19	122	131	O	inhibiting
20	133	137	O	their
21	139	148	O	metabolism
22	150	151	O	in
23	153	155	O	the
24	157	161	O	liver
NULL

Anisindione	DDI-DrugBank.d64.s89	NO_SECTION	NO_SETID	28
Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.
1	0	6	O	Because
2	8	11	O	oral
3	13	26	U-UNK	anticoagulants
4	28	30	O	may
5	32	40	O	interfere
6	42	45	O	with
7	47	49	O	the
8	51	57	O	hepatic
9	59	68	O	metabolism
10	70	71	O	of
11	73	81	U-UNK	phenytoin
12	82	82	O	,
13	84	88	O	toxic
14	90	95	O	levels
15	97	98	O	of
16	100	102	O	the
17	104	117	U-UNK	anticonvulsant
18	119	121	O	may
19	123	127	O	occur
20	129	132	O	when
21	134	135	O	an
22	137	140	O	oral
23	142	154	U-UNK	anticoagulant
24	156	158	O	and
25	160	168	U-UNK	phenytoin
26	170	172	O	are
27	174	185	O	administered
28	187	198	O	concurrently
NULL

Anisindione	DDI-DrugBank.d64.s90	NO_SECTION	NO_SETID	54
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
1	0	4	O	Drugs
2	6	9	O	that
3	11	16	O	reduce
4	18	20	O	the
5	22	27	O	number
6	29	30	O	of
7	32	36	O	blood
8	38	46	O	platelets
9	48	49	O	by
10	51	57	O	causing
11	59	62	O	bone
12	64	69	O	marrow
13	71	80	O	depression
14	83	86	O	such
15	88	89	O	as
16	91	104	B-UNK	antineoplastic
17	106	111	L-UNK	agents
18	114	115	O	or
19	117	121	O	drugs
20	123	127	O	which
21	129	135	O	inhibit
22	137	144	O	platelet
23	146	153	O	function
24	156	157	O	eg
25	158	158	O	,
26	160	166	O	XXXXXXXX
27	168	170	O	and
28	172	176	O	other
29	178	180	B-UNK	non
30	182	190	I-UNK	steroidal
31	192	195	I-UNK	anti
32	197	208	I-UNK	inflammatory
33	210	214	L-UNK	drugs
34	215	215	O	,
35	217	228	U-UNK	dipyridamole
36	229	229	O	,
37	231	246	U-UNK	hydrochloroquine
38	247	247	O	,
39	249	258	U-UNK	clofibrate
40	259	259	O	,
41	261	267	U-UNK	dextran
42	270	272	O	may
43	274	281	O	increase
44	283	285	O	the
45	287	294	O	bleeding
46	296	303	O	tendency
47	305	312	O	produced
48	314	315	O	by
49	317	330	U-DYN	anticoagulants
50	332	338	O	without
51	340	347	O	altering
52	349	359	O	prothrombin
53	361	364	O	time
54	366	379	O	determinations
NULL

Anisindione	DDI-DrugBank.d64.s91	NO_SECTION	NO_SETID	25
The beneficial effects on arterial thrombus formation from combined therapy with antiplatelet and anticoagulant medication must be weighed against an increased risk of inducing hemorrhage.
1	0	2	O	The
2	4	13	O	beneficial
3	15	21	O	effects
4	23	24	O	on
5	26	33	O	arterial
6	35	42	O	thrombus
7	44	52	O	formation
8	54	57	O	from
9	59	66	O	combined
10	68	74	O	therapy
11	76	79	O	with
12	81	92	B-UNK	antiplatelet
13	94	96	I-UNK	and
14	98	110	I-UNK	anticoagulant
15	112	121	L-UNK	medication
16	123	126	O	must
17	128	129	O	be
18	131	137	O	weighed
19	139	145	O	against
20	147	148	O	an
21	150	158	O	increased
22	160	163	O	risk
23	165	166	O	of
24	168	175	O	inducing
25	177	186	O	hemorrhage
NULL

Anisindione	DDI-DrugBank.d64.s92	NO_SECTION	NO_SETID	9
*Increased and decreased prothrombin time responses have been reported.
1	0	9	O	Increased
2	11	13	O	and
3	15	23	O	decreased
4	25	35	O	prothrombin
5	37	40	O	time
6	42	50	O	responses
7	52	55	O	have
8	57	60	O	been
9	62	69	O	reported
NULL

Anisindione	DDI-DrugBank.d64.s93	NO_SECTION	NO_SETID	33
Drug/Laboratory Test Interferences: Dicumarol and indanedione anticoagulants, including anisindione, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	33	O	Interferences
6	34	34	O	:
7	36	44	U-UNK	Dicumarol
8	46	48	O	and
9	50	60	B-UNK	indanedione
10	62	75	L-UNK	anticoagulants
11	76	76	O	,
12	78	86	O	including
13	88	98	O	XXXXXXXX
14	99	99	O	,
15	101	102	O	or
16	104	108	O	their
17	110	120	O	metabolites
18	122	124	O	may
19	126	130	O	color
20	132	139	O	alkaline
21	141	145	O	urine
22	147	149	O	red
23	151	156	O	orange
24	157	157	O	,
25	159	163	O	which
26	165	167	O	may
27	169	177	O	interfere
28	179	182	O	with
29	184	205	O	spectrophotometrically
30	207	216	O	determined
31	218	224	O	urinary
32	226	235	O	laboratory
33	237	241	O	tests
NULL

Anisindione	DDI-DrugBank.d64.s94	NO_SECTION	NO_SETID	16
The color reverses when the test sample is acidified in vitro to a pH below 4.
1	0	2	O	The
2	4	8	O	color
3	10	17	O	reverses
4	19	22	O	when
5	24	26	O	the
6	28	31	O	test
7	33	38	O	sample
8	40	41	O	is
9	43	51	O	acidified
10	53	54	O	in
11	56	60	O	vitro
12	62	63	O	to
13	65	65	O	a
14	67	68	O	pH
15	70	74	O	below
16	76	76	O	4
NULL

Apomorphine	DDI-DrugBank.d357.s0	NO_SECTION	NO_SETID	49
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
1	0	3	B-UNK	5HT3
2	5	15	L-UNK	Antagonists
3	16	16	O	:
4	18	22	O	Based
5	24	25	O	on
6	27	33	O	reports
7	35	36	O	of
8	38	45	O	profound
9	47	57	O	hypotension
10	59	61	O	and
11	63	66	O	loss
12	68	69	O	of
13	71	83	O	consciousness
14	85	88	O	when
15	90	100	O	XXXXXXXX
16	102	104	O	was
17	106	117	O	administered
18	119	122	O	with
19	124	134	U-DYN	ondansetron
20	135	135	O	,
21	137	139	O	the
22	141	151	O	concomitant
23	153	155	O	use
24	157	158	O	of
25	160	170	O	XXXXXXXX
26	172	175	O	with
27	177	181	O	drugs
28	183	184	O	of
29	186	188	O	the
30	190	193	B-DYN	5HT3
31	195	204	I-DYN	antagonist
32	206	210	L-DYN	class
33	213	221	O	including
34	222	222	O	,
35	224	226	O	for
36	228	234	O	example
37	235	235	O	,
38	237	247	U-DYN	ondansetron
39	248	248	O	,
40	250	260	U-DYN	granisetron
41	261	261	O	,
42	263	272	U-DYN	dolasetron
43	273	273	O	,
44	275	286	U-DYN	palonosetron
45	287	287	O	,
46	289	291	O	and
47	293	301	U-DYN	alosetron
48	304	305	O	is
49	307	321	O	contraindicated
NULL

Apomorphine	DDI-DrugBank.d357.s1	NO_SECTION	NO_SETID	67
Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
1	0	15	U-UNK	Antihypertensive
2	17	27	O	Medications
3	29	31	O	and
4	33	44	U-UNK	Vasodilators
5	45	45	O	:
6	47	49	O	The
7	51	59	O	following
8	61	67	O	adverse
9	69	74	O	events
10	76	79	O	were
11	81	91	O	experienced
12	93	96	O	more
13	98	105	O	commonly
14	107	108	O	in
15	110	117	O	patients
16	119	127	O	receiving
17	129	139	O	concomitant
18	141	156	B-UNK	antihypertensive
19	158	168	L-UNK	medications
20	170	171	O	or
21	173	184	U-UNK	vasodilators
22	187	187	O	n
23	189	189	O	=
24	191	192	O	94
25	195	202	O	compared
26	204	205	O	to
27	207	214	O	patients
28	216	218	O	not
29	220	228	O	receiving
30	230	234	O	these
31	236	246	O	concomitant
32	248	252	O	drugs
33	255	255	O	n
34	257	257	O	=
35	259	261	O	456
36	263	263	O	:
37	265	275	O	hypotension
38	277	279	O	10%
39	281	282	O	vs
40	284	285	O	4%
41	286	286	O	,
42	288	297	O	myocardial
43	299	308	O	infarction
44	310	311	O	3%
45	313	314	O	vs
46	316	317	O	1%
47	318	318	O	,
48	320	326	O	serious
49	328	336	O	pneumonia
50	338	339	O	5%
51	341	342	O	vs
52	344	345	O	3%
53	346	346	O	,
54	348	354	O	serious
55	356	360	O	falls
56	362	363	O	9%
57	365	366	O	vs
58	368	369	O	3%
59	370	370	O	,
60	372	374	O	and
61	376	379	O	bone
62	381	383	O	and
63	385	389	O	joint
64	391	398	O	injuries
65	400	401	O	6%
66	403	404	O	vs
67	406	407	O	2%
NULL

Apomorphine	DDI-DrugBank.d357.s2	NO_SECTION	NO_SETID	15
The mechanism underlying many of these events is unknown, but may represent increased hypotension .
1	0	2	O	The
2	4	12	O	mechanism
3	14	23	O	underlying
4	25	28	O	many
5	30	31	O	of
6	33	37	O	these
7	39	44	O	events
8	46	47	O	is
9	49	55	O	unknown
10	56	56	O	,
11	58	60	O	but
12	62	64	O	may
13	66	74	O	represent
14	76	84	O	increased
15	86	96	O	hypotension
NULL

Apomorphine	DDI-DrugBank.d357.s3	NO_SECTION	NO_SETID	35
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
1	0	7	B-UNK	Dopamine
2	9	19	L-UNK	Antagonists
3	20	20	O	:
4	22	26	O	Since
5	28	38	U-UNK	apomorphine
6	40	41	O	is
7	43	43	O	a
8	45	52	B-UNK	dopamine
9	54	60	L-UNK	agonist
10	61	61	O	,
11	63	64	O	it
12	66	67	O	is
13	69	76	O	possible
14	78	81	O	that
15	83	90	B-UNK	dopamine
16	92	102	L-UNK	antagonists
17	103	103	O	,
18	105	108	O	such
19	110	111	O	as
20	113	115	O	the
21	117	128	U-UNK	neuroleptics
22	131	144	U-DYN	phenothiazines
23	145	145	O	,
24	147	160	U-DYN	butyrophenones
25	161	161	O	,
26	163	175	U-DYN	thioxanthenes
27	178	179	O	or
28	181	194	U-DYN	metoclopramide
29	195	195	O	,
30	197	199	O	may
31	201	208	O	diminish
32	210	212	O	the
33	214	226	O	effectiveness
34	228	229	O	of
35	231	236	O	XXXXXXXX
NULL

Apomorphine	DDI-DrugBank.d357.s4	NO_SECTION	NO_SETID	24
Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.
1	0	7	O	Patients
2	9	12	O	with
3	14	18	O	major
4	20	28	O	psychotic
5	30	38	O	disorders
6	39	39	O	,
7	41	47	O	treated
8	49	52	O	with
9	54	65	U-UNK	neuroleptics
10	66	66	O	,
11	68	73	O	should
12	75	76	O	be
13	78	84	O	treated
14	86	89	O	with
15	91	98	B-UNK	dopamine
16	100	107	L-UNK	agonists
17	109	112	O	only
18	114	115	O	if
19	117	119	O	the
20	121	129	O	potential
21	131	138	O	benefits
22	140	147	O	outweigh
23	149	151	O	the
24	153	157	O	risks
NULL

Apomorphine	DDI-DrugBank.d357.s5	NO_SECTION	NO_SETID	24
Drugs Prolonging the QT/QTc Interval Caution should be exercised when prescribing apomorphine concomitantly with drugs that prolong the QT/QTc interval.
1	0	4	O	Drugs
2	6	15	O	Prolonging
3	17	19	O	the
4	21	22	O	QT
5	23	23	O	/
6	24	26	O	QTc
7	28	35	O	Interval
8	37	43	O	Caution
9	45	50	O	should
10	52	53	O	be
11	55	63	O	exercised
12	65	68	O	when
13	70	80	O	prescribing
14	82	92	O	XXXXXXXX
15	94	106	O	concomitantly
16	108	111	O	with
17	113	117	O	drugs
18	119	122	O	that
19	124	130	O	prolong
20	132	134	O	the
21	136	137	O	QT
22	138	138	O	/
23	139	141	O	QTc
24	143	150	O	interval
NULL

Apomorphine	DDI-DrugBank.d357.s6	NO_SECTION	NO_SETID	15
Drug/Laboratory Test Interactions There are no known interactions between APOKYN and laboratory tests.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	38	O	There
7	40	42	O	are
8	44	45	O	no
9	47	51	O	known
10	53	64	O	interactions
11	66	72	O	between
12	74	79	O	XXXXXXXX
13	81	83	O	and
14	85	94	O	laboratory
15	96	100	O	tests
NULL

Apraclonidine	DDI-DrugBank.d224.s0	NO_SECTION	NO_SETID	10
Apraclonidine should not be used in patients receiving MAO inhibitors..
1	0	12	O	XXXXXXXX
2	14	19	O	should
3	21	23	O	not
4	25	26	O	be
5	28	31	O	used
6	33	34	O	in
7	36	43	O	patients
8	45	53	O	receiving
9	55	57	B-DYN	MAO
10	59	68	L-DYN	inhibitors
NULL

Apraclonidine	DDI-DrugBank.d224.s1	NO_SECTION	NO_SETID	46
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
1	0	7	O	Although
2	9	10	O	no
3	12	19	O	specific
4	21	24	O	drug
5	26	37	O	interactions
6	39	42	O	with
7	44	50	O	topical
8	52	59	O	glaucoma
9	61	65	O	drugs
10	67	68	O	or
11	70	77	O	systemic
12	79	89	O	medications
13	91	94	O	were
14	96	105	O	identified
15	107	108	O	in
16	110	117	O	clinical
17	119	125	O	studies
18	127	128	O	of
19	130	137	O	XXXXXXXX
20	139	142	O	0.5%
21	144	153	O	Ophthalmic
22	155	162	O	Solution
23	163	163	O	,
24	165	167	O	the
25	169	179	O	possibility
26	181	182	O	of
27	184	185	O	an
28	187	194	O	additive
29	196	197	O	or
30	199	210	O	potentiating
31	212	217	O	effect
32	219	222	O	with
33	224	226	B-DYN	CNS
34	228	238	L-DYN	depressants
35	241	247	U-DYN	alcohol
36	248	248	O	,
37	250	261	U-DYN	barbiturates
38	262	262	O	,
39	264	270	U-DYN	opiates
40	271	271	O	,
41	273	281	U-DYN	sedatives
42	282	282	O	,
43	284	294	U-DYN	anesthetics
44	297	302	O	should
45	304	305	O	be
46	307	316	O	considered
NULL

Apraclonidine	DDI-DrugBank.d224.s2	NO_SECTION	NO_SETID	13
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.
1	0	8	B-UNK	Tricyclic
2	10	24	L-UNK	antidepressants
3	26	29	O	have
4	31	34	O	been
5	36	43	O	reported
6	45	46	O	to
7	48	52	O	blunt
8	54	56	O	the
9	58	68	O	hypotensive
10	70	75	O	effect
11	77	78	O	of
12	80	87	O	systemic
13	89	97	U-UNK	clonidine
NULL

Apraclonidine	DDI-DrugBank.d224.s3	NO_SECTION	NO_SETID	22
It is not known whether the concurrent use of these agents with apraclonidine can lead to a reduction in IOP lowering effect.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	known
5	16	22	O	whether
6	24	26	O	the
7	28	37	O	concurrent
8	39	41	O	use
9	43	44	O	of
10	46	50	O	these
11	52	57	O	agents
12	59	62	O	with
13	64	76	O	XXXXXXXX
14	78	80	O	can
15	82	85	O	lead
16	87	88	O	to
17	90	90	O	a
18	92	100	O	reduction
19	102	103	O	in
20	105	107	O	IOP
21	109	116	O	lowering
22	118	123	O	effect
NULL

Apraclonidine	DDI-DrugBank.d224.s4	NO_SECTION	NO_SETID	13
No data on the level of circulating catecholamines after apraclonidine withdrawal are available.
1	0	1	O	No
2	3	6	O	data
3	8	9	O	on
4	11	13	O	the
5	15	19	O	level
6	21	22	O	of
7	24	34	O	circulating
8	36	49	O	catecholamines
9	51	55	O	after
10	57	69	O	XXXXXXXX
11	71	80	O	withdrawal
12	82	84	O	are
13	86	94	O	available
NULL

Apraclonidine	DDI-DrugBank.d224.s5	NO_SECTION	NO_SETID	21
Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.
1	0	6	O	Caution
2	7	7	O	,
3	9	15	O	however
4	16	16	O	,
5	18	19	O	is
6	21	27	O	advised
7	29	30	O	in
8	32	39	O	patients
9	41	46	O	taking
10	48	56	B-UNK	tricyclic
11	58	72	L-UNK	antidepressants
12	74	78	O	which
13	80	82	O	can
14	84	89	O	affect
15	91	93	O	the
16	95	104	O	metabolism
17	106	108	O	and
18	110	115	O	uptake
19	117	118	O	of
20	120	130	O	circulating
21	132	137	O	amines
NULL

Apraclonidine	DDI-DrugBank.d224.s6	NO_SECTION	NO_SETID	16
An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.
1	0	1	O	An
2	3	10	O	additive
3	12	22	O	hypotensive
4	24	29	O	effect
5	31	33	O	has
6	35	38	O	been
7	40	47	O	reported
8	49	52	O	with
9	54	56	O	the
10	58	68	O	combination
11	70	71	O	of
12	73	80	O	systemic
13	82	90	U-UNK	clonidine
14	92	94	O	and
15	96	106	U-UNK	neuroleptic
16	108	114	O	therapy
NULL

Apraclonidine	DDI-DrugBank.d224.s7	NO_SECTION	NO_SETID	22
Systemic clonidine may inhibit the production of catecholamines in response to insulin-induced hypoglycemia and mask the signs and symptoms of hypoglycemia.
1	0	7	O	Systemic
2	9	17	U-UNK	clonidine
3	19	21	O	may
4	23	29	O	inhibit
5	31	33	O	the
6	35	44	O	production
7	46	47	O	of
8	49	62	O	catecholamines
9	64	65	O	in
10	67	74	O	response
11	76	77	O	to
12	79	85	O	insulin
13	87	93	O	induced
14	95	106	O	hypoglycemia
15	108	110	O	and
16	112	115	O	mask
17	117	119	O	the
18	121	125	O	signs
19	127	129	O	and
20	131	138	O	symptoms
21	140	141	O	of
22	143	154	O	hypoglycemia
NULL

Apraclonidine	DDI-DrugBank.d224.s8	NO_SECTION	NO_SETID	28
Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.
1	0	4	O	Since
2	6	18	O	XXXXXXXX
3	20	22	O	may
4	24	29	O	reduce
5	31	35	O	pulse
6	37	39	O	and
7	41	45	O	blood
8	47	54	O	pressure
9	55	55	O	,
10	57	63	O	caution
11	65	66	O	in
12	68	72	O	using
13	74	78	O	drugs
14	80	83	O	such
15	85	86	O	as
16	88	91	B-DYN	beta
17	93	100	L-DYN	blockers
18	103	112	O	ophthalmic
19	114	116	O	and
20	118	125	O	systemic
21	127	127	O	,
22	129	145	U-DYN	antihypertensives
23	146	146	O	,
24	148	150	O	and
25	152	158	B-DYN	cardiac
26	160	169	L-DYN	glycosides
27	171	172	O	is
28	174	180	O	advised
NULL

Apraclonidine	DDI-DrugBank.d224.s9	NO_SECTION	NO_SETID	18
Patients using cardiovascular drugs concurrently with IOPIDINE 0.5% Ophthalmic Solution should have pulse and blood pressures frequently monitored.
1	0	7	O	Patients
2	9	13	O	using
3	15	28	O	cardiovascular
4	30	34	O	drugs
5	36	47	O	concurrently
6	49	52	O	with
7	54	61	O	XXXXXXXX
8	63	66	O	0.5%
9	68	77	O	Ophthalmic
10	79	86	O	Solution
11	88	93	O	should
12	95	98	O	have
13	100	104	O	pulse
14	106	108	O	and
15	110	114	O	blood
16	116	124	O	pressures
17	126	135	O	frequently
18	137	145	O	monitored
NULL

Apraclonidine	DDI-DrugBank.d224.s10	NO_SECTION	NO_SETID	14
Caution should be exercised with simultaneous use of clonidine and other similar pharmacologic agents
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	with
6	33	44	O	simultaneous
7	46	48	O	use
8	50	51	O	of
9	53	61	U-UNK	clonidine
10	63	65	O	and
11	67	71	O	other
12	73	79	O	similar
13	81	93	O	pharmacologic
14	95	100	O	agents
NULL

Aprepitant	DDI-DrugBank.d382.s0	NO_SECTION	NO_SETID	14
Aprepitant is a substrate, a moderate inhibitor, and an inducer of CYP3A4.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	14	O	a
4	16	24	O	substrate
5	25	25	O	,
6	27	27	O	a
7	29	36	O	moderate
8	38	46	O	inhibitor
9	47	47	O	,
10	49	51	O	and
11	53	54	O	an
12	56	62	O	inducer
13	64	65	O	of
14	67	72	O	CYP3A4
NULL

Aprepitant	DDI-DrugBank.d382.s1	NO_SECTION	NO_SETID	7
Aprepitant is also an inducer of CYP2C9.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	17	O	also
4	19	20	O	an
5	22	28	O	inducer
6	30	31	O	of
7	33	38	O	CYP2C9
NULL

Aprepitant	DDI-DrugBank.d382.s2	NO_SECTION	NO_SETID	9
Effect of aprepitant on the pharmacokinetics of other agents
1	0	5	O	Effect
2	7	8	O	of
3	10	19	O	XXXXXXXX
4	21	22	O	on
5	24	26	O	the
6	28	43	O	pharmacokinetics
7	45	46	O	of
8	48	52	O	other
9	54	59	O	agents
NULL

Aprepitant	DDI-DrugBank.d382.s3	NO_SECTION	NO_SETID	21
As a moderate inhibitor of CYP3A4, aprepitant can increase plasma concentrations of coadministered medicinal products that are metabolized through CYP3A4.
1	0	1	O	As
2	3	3	O	a
3	5	12	O	moderate
4	14	22	O	inhibitor
5	24	25	O	of
6	27	32	O	CYP3A4
7	33	33	O	,
8	35	44	O	XXXXXXXX
9	46	48	O	can
10	50	57	O	increase
11	59	64	O	plasma
12	66	79	O	concentrations
13	81	82	O	of
14	84	97	O	coadministered
15	99	107	O	medicinal
16	109	116	O	products
17	118	121	O	that
18	123	125	O	are
19	127	137	O	metabolized
20	139	145	O	through
21	147	152	O	CYP3A4
NULL

Aprepitant	DDI-DrugBank.d382.s4	NO_SECTION	NO_SETID	19
Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.
1	0	9	O	XXXXXXXX
2	11	13	O	has
3	15	18	O	been
4	20	24	O	shown
5	26	27	O	to
6	29	34	O	induce
7	36	38	O	the
8	40	49	O	metabolism
9	51	52	O	of
10	54	54	B-KIN	S
11	59	66	L-KIN	warfarin
12	68	70	O	and
13	72	82	U-KIN	tolbutamide
14	83	83	O	,
15	85	89	O	which
16	91	93	O	are
17	95	105	O	metabolized
18	107	113	O	through
19	115	120	O	CYP2C9
NULL

Aprepitant	DDI-DrugBank.d382.s5	NO_SECTION	NO_SETID	31
Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	O	XXXXXXXX
4	31	34	O	with
5	36	40	O	these
6	42	46	O	drugs
7	48	49	O	or
8	51	55	O	other
9	57	61	O	drugs
10	63	66	O	that
11	68	70	O	are
12	72	76	O	known
13	78	79	O	to
14	81	82	O	be
15	84	94	O	metabolized
16	96	97	O	by
17	99	104	O	CYP2C9
18	105	105	O	,
19	107	110	O	such
20	112	113	O	as
21	115	123	U-KIN	phenytoin
22	124	124	O	,
23	126	128	O	may
24	130	135	O	result
25	137	138	O	in
26	140	144	O	lower
27	146	151	O	plasma
28	153	166	O	concentrations
29	168	169	O	of
30	171	175	O	these
31	177	181	O	drugs
NULL

Aprepitant	DDI-DrugBank.d382.s6	NO_SECTION	NO_SETID	33
Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with digoxin in a clinical drug interaction study.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	21	O	unlikely
4	23	24	O	to
5	26	33	O	interact
6	35	38	O	with
7	40	44	O	drugs
8	46	49	O	that
9	51	53	O	are
10	55	64	O	substrates
11	66	68	O	for
12	70	72	O	the
13	74	74	O	P
14	76	87	O	glycoprotein
15	89	99	O	transporter
16	100	100	O	,
17	102	103	O	as
18	105	116	O	demonstrated
19	118	119	O	by
20	121	123	O	the
21	125	128	O	lack
22	130	131	O	of
23	133	143	O	interaction
24	145	146	O	of
25	148	157	O	XXXXXXXX
26	159	162	O	with
27	164	170	U-UNK	digoxin
28	172	173	O	in
29	175	175	O	a
30	177	184	O	clinical
31	186	189	O	drug
32	191	201	O	interaction
33	203	207	O	study
NULL

Aprepitant	DDI-DrugBank.d382.s7	NO_SECTION	NO_SETID	24
5-HT3 antagonists: In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron.
1	0	0	B-UNK	5
2	2	4	I-UNK	HT3
3	6	16	L-UNK	antagonists
4	17	17	O	:
5	19	20	O	In
6	22	29	O	clinical
7	31	34	O	drug
8	36	46	O	interaction
9	48	54	O	studies
10	55	55	O	,
11	57	66	O	XXXXXXXX
12	68	70	O	did
13	72	74	O	not
14	76	79	O	have
15	81	90	O	clinically
16	92	100	O	important
17	102	108	O	effects
18	110	111	O	on
19	113	115	O	the
20	117	132	O	pharmacokinetics
21	134	135	O	of
22	137	147	U-UNK	ondansetron
23	149	150	O	or
24	152	162	U-UNK	granisetron
NULL

Aprepitant	DDI-DrugBank.d382.s8	NO_SECTION	NO_SETID	10
No clinical or drug interaction study was conducted with dolasetron.
1	0	1	O	No
2	3	10	O	clinical
3	12	13	O	or
4	15	18	O	drug
5	20	30	O	interaction
6	32	36	O	study
7	38	40	O	was
8	42	50	O	conducted
9	52	55	O	with
10	57	66	U-UNK	dolasetron
NULL

Aprepitant	DDI-DrugBank.d382.s9	NO_SECTION	NO_SETID	64
Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
1	0	14	U-UNK	Corticosteroids
2	15	15	O	:
3	17	29	U-UNK	Dexamethasone
4	30	30	O	:
5	32	41	O	XXXXXXXX
6	42	42	O	,
7	44	47	O	when
8	49	53	O	given
9	55	56	O	as
10	58	58	O	a
11	60	66	O	regimen
12	68	69	O	of
13	71	75	O	125mg
14	77	80	O	with
15	82	94	U-KIN	dexamethasone
16	96	109	O	coadministered
17	111	116	O	orally
18	118	119	O	as
19	121	122	O	20
20	124	125	O	mg
21	127	128	O	on
22	130	132	O	Day
23	134	134	O	1
24	135	135	O	,
25	137	139	O	and
26	141	150	O	XXXXXXXX
27	152	155	O	when
28	157	161	O	given
29	163	164	O	as
30	166	167	O	80
31	169	170	O	mg
32	171	171	O	/
33	172	174	O	day
34	176	179	O	with
35	181	193	U-KIN	dexamethasone
36	195	208	O	coadministered
37	210	215	O	orally
38	217	218	O	as
39	220	220	O	8
40	222	223	O	mg
41	225	226	O	on
42	228	231	O	Days
43	233	233	O	2
44	235	241	O	through
45	243	243	O	5
46	244	244	O	,
47	246	254	O	increased
48	256	258	O	the
49	260	262	O	AUC
50	264	265	O	of
51	267	279	U-UNK	dexamethasone
52	280	280	O	,
53	282	282	O	a
54	284	289	O	CYP3A4
55	291	299	O	substrate
56	301	302	O	by
57	304	306	O	2.2
58	308	311	O	fold
59	312	312	O	,
60	314	315	O	on
61	317	320	O	Days
62	322	322	O	1
63	324	326	O	and
64	328	328	O	5
NULL

Aprepitant	DDI-DrugBank.d382.s10	NO_SECTION	NO_SETID	30
The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.
1	0	2	O	The
2	4	7	O	oral
3	9	21	U-DYN	dexamethasone
4	23	27	O	doses
5	29	34	O	should
6	36	37	O	be
7	39	45	O	reduced
8	47	48	O	by
9	50	62	O	approximately
10	64	66	O	50%
11	68	71	O	when
12	73	86	O	coadministered
13	88	91	O	with
14	93	102	O	XXXXXXXX
15	103	103	O	,
16	105	106	O	to
17	108	114	O	achieve
18	116	124	O	exposures
19	126	127	O	of
20	129	141	U-UNK	dexamethasone
21	143	149	O	similar
22	151	152	O	to
23	154	158	O	those
24	160	167	O	obtained
25	169	172	O	when
26	174	175	O	it
27	177	178	O	is
28	180	184	O	given
29	186	192	O	without
30	194	203	O	XXXXXXXX
NULL

Aprepitant	DDI-DrugBank.d382.s11	NO_SECTION	NO_SETID	21
The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.
1	0	2	O	The
2	4	8	O	daily
3	10	13	O	dose
4	15	16	O	of
5	18	30	U-KIN	dexamethasone
6	32	43	O	administered
7	45	46	O	in
8	48	55	O	clinical
9	57	63	O	studies
10	65	68	O	with
11	70	79	O	XXXXXXXX
12	81	88	O	reflects
13	90	91	O	an
14	93	103	O	approximate
15	105	107	O	50%
16	109	117	O	reduction
17	119	120	O	of
18	122	124	O	the
19	126	129	O	dose
20	131	132	O	of
21	134	146	U-UNK	dexamethasone
NULL

Aprepitant	DDI-DrugBank.d382.s13	NO_SECTION	NO_SETID	69
Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.
1	0	9	O	XXXXXXXX
2	10	10	O	,
3	12	15	O	when
4	17	21	O	given
5	23	24	O	as
6	26	26	O	a
7	28	34	O	regimen
8	36	37	O	of
9	39	41	O	125
10	43	44	O	mg
11	46	47	O	on
12	49	51	O	Day
13	53	53	O	1
14	55	57	O	and
15	59	60	O	80
16	62	63	O	mg
17	64	64	O	/
18	65	67	O	day
19	69	70	O	on
20	72	75	O	Days
21	77	77	O	2
22	79	81	O	and
23	83	83	O	3
24	84	84	O	,
25	86	94	O	increased
26	96	98	O	the
27	100	102	O	AUC
28	104	105	O	of
29	107	124	U-KIN	methylprednisolone
30	125	125	O	,
31	127	127	O	a
32	129	134	O	CYP3A4
33	136	144	O	substrate
34	145	145	O	,
35	147	148	O	by
36	150	153	O	1.34
37	155	158	O	fold
38	160	161	O	on
39	163	165	O	Day
40	167	167	O	1
41	169	171	O	and
42	173	174	O	by
43	176	178	O	2.5
44	180	183	O	fold
45	185	186	O	on
46	188	190	O	Day
47	192	192	O	3
48	193	193	O	,
49	195	198	O	when
50	200	217	U-UNK	methylprednisolone
51	219	221	O	was
52	223	236	O	coadministered
53	238	250	O	intravenously
54	252	253	O	as
55	255	257	O	125
56	259	260	O	mg
57	262	263	O	on
58	265	267	O	Day
59	269	269	O	1
60	271	273	O	and
61	275	280	O	orally
62	282	283	O	as
63	285	286	O	40
64	288	289	O	mg
65	291	292	O	on
66	294	297	O	Days
67	299	299	O	2
68	301	303	O	and
69	305	305	O	3
NULL

Aprepitant	DDI-DrugBank.d382.s14	NO_SECTION	NO_SETID	41
The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.
1	0	2	O	The
2	4	5	O	IV
3	7	24	U-DYN	methylprednisolone
4	26	29	O	dose
5	31	36	O	should
6	38	39	O	be
7	41	47	O	reduced
8	49	50	O	by
9	52	64	O	approximately
10	66	68	O	25%
11	69	69	O	,
12	71	73	O	and
13	75	77	O	the
14	79	82	O	oral
15	84	101	U-DYN	methylprednisolone
16	103	106	O	dose
17	108	113	O	should
18	115	116	O	be
19	118	124	O	reduced
20	126	127	O	by
21	129	141	O	approximately
22	143	145	O	50%
23	147	150	O	when
24	152	165	O	coadministered
25	167	170	O	with
26	172	181	O	XXXXXXXX
27	183	184	O	to
28	186	192	O	achieve
29	194	202	O	exposures
30	204	205	O	of
31	207	224	U-UNK	methylprednisolone
32	226	232	O	similar
33	234	235	O	to
34	237	241	O	those
35	243	250	O	obtained
36	252	255	O	when
37	257	258	O	it
38	260	261	O	is
39	263	267	O	given
40	269	275	O	without
41	277	286	O	XXXXXXXX
NULL

Aprepitant	DDI-DrugBank.d382.s15	NO_SECTION	NO_SETID	34
Warfarin: A single 125-mg dose of Aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	10	O	A
4	12	17	O	single
5	19	21	O	125
6	23	24	O	mg
7	26	29	O	dose
8	31	32	O	of
9	34	43	O	XXXXXXXX
10	45	47	O	was
11	49	60	O	administered
12	62	63	O	on
13	65	67	O	Day
14	69	69	O	1
15	71	73	O	and
16	75	76	O	80
17	78	79	O	mg
18	80	80	O	/
19	81	83	O	day
20	85	86	O	on
21	88	91	O	Days
22	93	93	O	2
23	95	97	O	and
24	99	99	O	3
25	101	102	O	to
26	104	110	O	healthy
27	112	119	O	subjects
28	121	123	O	who
29	125	128	O	were
30	130	139	O	stabilized
31	141	142	O	on
32	144	150	O	chronic
33	152	159	U-UNK	warfarin
34	161	167	O	therapy
NULL

Aprepitant	DDI-DrugBank.d382.s16	NO_SECTION	NO_SETID	58
Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.
1	0	7	O	Although
2	9	13	O	there
3	15	17	O	was
4	19	20	O	no
5	22	27	O	effect
6	29	30	O	of
7	32	41	O	XXXXXXXX
8	43	44	O	on
9	46	48	O	the
10	50	55	O	plasma
11	57	59	O	AUC
12	61	62	O	of
13	64	66	B-UNK	R(+
14	69	70	I-UNK	or
15	72	72	I-UNK	S
16	77	84	L-UNK	warfarin
17	86	95	O	determined
18	97	98	O	on
19	100	102	O	Day
20	104	104	O	3
21	105	105	O	,
22	107	111	O	there
23	113	115	O	was
24	117	117	O	a
25	119	121	O	34%
26	123	130	O	decrease
27	132	133	O	in
28	135	135	B-KIN	S
29	139	146	L-KIN	warfarin
30	149	149	O	a
31	151	156	O	CYP2C9
32	158	166	O	substrate
33	169	174	O	trough
34	176	188	O	concentration
35	190	200	O	accompanied
36	202	203	O	by
37	205	205	O	a
38	207	209	O	14%
39	211	218	O	decrease
40	220	221	O	in
41	223	225	O	the
42	227	237	O	prothrombin
43	239	242	O	time
44	245	252	O	reported
45	254	255	O	as
46	257	269	O	International
47	271	280	O	Normalized
48	282	286	O	Ratio
49	288	289	O	or
50	291	293	O	INR
51	296	296	O	5
52	298	301	O	days
53	303	307	O	after
54	309	318	O	completion
55	320	321	O	of
56	323	328	O	dosing
57	330	333	O	with
58	335	344	O	XXXXXXXX
NULL

Aprepitant	DDI-DrugBank.d382.s17	NO_SECTION	NO_SETID	41
In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.
1	0	1	O	In
2	3	10	O	patients
3	12	13	O	on
4	15	21	O	chronic
5	23	30	U-DYN	warfarin
6	32	38	O	therapy
7	39	39	O	,
8	41	43	O	the
9	45	55	O	prothrombin
10	57	60	O	time
11	63	65	O	INR
12	68	73	O	should
13	75	76	O	be
14	78	84	O	closely
15	86	94	O	monitored
16	96	97	O	in
17	99	101	O	the
18	103	103	O	2
19	105	108	O	week
20	110	115	O	period
21	116	116	O	,
22	118	129	O	particularly
23	131	132	O	at
24	134	134	O	7
25	136	137	O	to
26	139	140	O	10
27	142	145	O	days
28	146	146	O	,
29	148	156	O	following
30	158	167	O	initiation
31	169	170	O	of
32	172	174	O	the
33	176	176	O	3
34	178	180	O	day
35	182	188	O	regimen
36	190	191	O	of
37	193	202	O	XXXXXXXX
38	204	207	O	with
39	209	212	O	each
40	214	225	O	chemotherapy
41	227	231	O	cycle
NULL

Aprepitant	DDI-DrugBank.d382.s18	NO_SECTION	NO_SETID	77
Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
1	0	10	U-UNK	Tolbutamide
2	11	11	O	:
3	13	22	O	XXXXXXXX
4	23	23	O	,
5	25	28	O	when
6	30	34	O	given
7	36	37	O	as
8	39	41	O	125
9	43	44	O	mg
10	46	47	O	on
11	49	51	O	Day
12	53	53	O	1
13	55	57	O	and
14	59	60	O	80
15	62	63	O	mg
16	64	64	O	/
17	65	67	O	day
18	69	70	O	on
19	72	75	O	Days
20	77	77	O	2
21	79	81	O	and
22	83	83	O	3
23	84	84	O	,
24	86	94	O	decreased
25	96	98	O	the
26	100	102	O	AUC
27	104	105	O	of
28	107	117	U-UNK	tolbutamide
29	120	120	O	a
30	122	127	O	CYP2C9
31	129	137	O	substrate
32	140	141	O	by
33	143	145	O	23%
34	147	148	O	on
35	150	152	O	Day
36	154	154	O	4
37	155	155	O	,
38	157	159	O	28%
39	161	162	O	on
40	164	166	O	Day
41	168	168	O	8
42	169	169	O	,
43	171	173	O	and
44	175	177	O	15%
45	179	180	O	on
46	182	184	O	Day
47	186	187	O	15
48	188	188	O	,
49	190	193	O	when
50	195	195	O	a
51	197	202	O	single
52	204	207	O	dose
53	209	210	O	of
54	212	222	U-KIN	tolbutamide
55	224	226	O	500
56	228	229	O	mg
57	231	233	O	was
58	235	247	O	admini,stered
59	249	254	O	orally
60	256	260	O	prior
61	262	263	O	to
62	265	267	O	the
63	269	282	O	administration
64	284	285	O	of
65	287	289	O	the
66	291	291	O	3
67	293	295	O	day
68	297	303	O	regimen
69	305	306	O	of
70	308	317	O	XXXXXXXX
71	319	321	O	and
72	323	324	O	on
73	326	329	O	Days
74	331	333	O	4,8
75	334	334	O	,
76	336	338	O	and
77	340	341	O	15
NULL

Aprepitant	DDI-DrugBank.d382.s19	NO_SECTION	NO_SETID	50
Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
1	0	3	O	Oral
2	5	18	U-UNK	contraceptives
3	19	19	O	:
4	21	30	O	XXXXXXXX
5	31	31	O	,
6	33	36	O	when
7	38	42	O	given
8	44	47	O	once
9	49	53	O	daily
10	55	57	O	for
11	59	60	O	14
12	62	65	O	days
13	67	68	O	as
14	70	70	O	a
15	72	74	O	100
16	76	77	O	mg
17	79	85	O	capsule
18	87	90	O	with
19	92	93	O	an
20	95	98	O	oral
21	100	112	U-UNK	contraceptive
22	114	123	O	containing
23	125	126	O	35
24	128	130	O	mcg
25	132	133	O	of
26	135	141	B-KIN	ethinyl
27	143	151	L-KIN	estradiol
28	153	155	O	and
29	157	157	O	1
30	159	160	O	mg
31	162	163	O	of
32	165	177	U-KIN	norethindrone
33	178	178	O	,
34	180	188	O	decreased
35	190	192	O	the
36	194	196	O	AUC
37	198	199	O	of
38	201	207	B-UNK	ethinyl
39	209	217	L-UNK	estradiol
40	219	220	O	by
41	222	224	O	43%
42	225	225	O	,
43	227	229	O	and
44	231	239	O	decreased
45	241	243	O	the
46	245	247	O	AUC
47	249	250	O	of
48	252	264	U-UNK	norethindrone
49	266	267	O	by
50	269	270	O	8%
NULL

Aprepitant	DDI-DrugBank.d382.s20	NO_SECTION	NO_SETID	14
therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.
1	0	8	O	therefore
2	9	9	O	,
3	11	13	O	the
4	15	22	O	efficacy
5	24	25	O	of
6	27	30	O	oral
7	32	45	U-DYN	contraceptives
8	47	52	O	during
9	54	67	O	administration
10	69	70	O	of
11	72	81	O	XXXXXXXX
12	83	85	O	may
13	87	88	O	be
14	90	96	O	reduced
NULL

Aprepitant	DDI-DrugBank.d382.s21	NO_SECTION	NO_SETID	27
Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.
1	0	7	O	Although
2	9	9	O	a
3	11	11	O	3
4	13	15	O	day
5	17	23	O	regimen
6	25	26	O	of
7	28	37	O	XXXXXXXX
8	39	43	O	given
9	45	57	O	concomitantly
10	59	62	O	with
11	64	67	O	oral
12	69	82	U-DYN	contraceptives
13	84	86	O	has
14	88	90	O	not
15	92	95	O	been
16	97	103	O	studied
17	104	104	O	,
18	106	116	O	alternative
19	118	119	O	or
20	121	124	O	back
21	126	127	O	up
22	129	135	O	methods
23	137	138	O	of
24	140	152	O	contraception
25	154	159	O	should
26	161	162	O	be
27	164	167	O	used
NULL

Aprepitant	DDI-DrugBank.d382.s22	NO_SECTION	NO_SETID	64
Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.
1	0	8	U-UNK	Midazolam
2	9	9	O	:
3	11	20	O	XXXXXXXX
4	22	30	O	increased
5	32	34	O	the
6	36	38	O	AUC
7	40	41	O	of
8	43	51	U-KIN	midazolam
9	52	52	O	,
10	54	54	O	a
11	56	64	O	sensitive
12	66	71	O	CYP3A4
13	73	81	O	substrate
14	82	82	O	,
15	84	85	O	by
16	87	89	O	2.3
17	91	94	O	fold
18	96	97	O	on
19	99	101	O	Day
20	103	103	O	1
21	105	107	O	and
22	109	111	O	3.3
23	113	116	O	fold
24	118	119	O	on
25	121	123	O	Day
26	125	125	O	5
27	126	126	O	,
28	128	131	O	when
29	133	133	O	a
30	135	140	O	single
31	142	145	O	oral
32	147	150	O	dose
33	152	153	O	of
34	155	163	U-UNK	midazolam
35	165	165	O	2
36	167	168	O	mg
37	170	172	O	was
38	174	187	O	coadministered
39	189	190	O	on
40	192	194	O	Day
41	196	196	O	1
42	198	200	O	and
43	202	204	O	Day
44	206	206	O	5
45	208	209	O	of
46	211	211	O	a
47	213	219	O	regimen
48	221	222	O	of
49	224	233	O	XXXXXXXX
50	235	237	O	125
51	239	240	O	mg
52	242	243	O	on
53	245	247	O	Day
54	249	249	O	1
55	251	253	O	and
56	255	256	O	80
57	258	259	O	mg
58	260	260	O	/
59	261	263	O	day
60	265	266	O	on
61	268	271	O	Days
62	273	273	O	2
63	275	281	O	through
64	283	283	O	5
NULL

Aprepitant	DDI-DrugBank.d382.s23	NO_SECTION	NO_SETID	27
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
1	0	2	O	The
2	4	12	O	potential
3	14	20	O	effects
4	22	23	O	of
5	25	33	O	increased
6	35	40	O	plasma
7	42	55	O	concentrations
8	57	58	O	of
9	60	68	U-DYN	midazolam
10	70	71	O	or
11	73	77	O	other
12	79	93	U-DYN	benzodiazepines
13	95	105	O	metabolized
14	107	109	O	via
15	111	116	O	CYP3A4
16	119	128	U-DYN	alprazolam
17	129	129	O	,
18	131	139	U-DYN	triazolam
19	142	147	O	should
20	149	150	O	be
21	152	161	O	considered
22	163	166	O	when
23	168	182	O	coadministering
24	184	188	O	these
25	190	195	O	agents
26	197	200	O	with
27	202	211	O	XXXXXXXX
NULL

Aprepitant	DDI-DrugBank.d382.s24	NO_SECTION	NO_SETID	56
In another study with intravenous administration of midazolam, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15.
1	0	1	O	In
2	3	9	O	another
3	11	15	O	study
4	17	20	O	with
5	22	32	O	intravenous
6	34	47	O	administration
7	49	50	O	of
8	52	60	U-UNK	midazolam
9	61	61	O	,
10	63	72	O	XXXXXXXX
11	74	76	O	was
12	78	82	O	given
13	84	85	O	as
14	87	89	O	125
15	91	92	O	mg
16	94	95	O	on
17	97	99	O	Day
18	101	101	O	1
19	103	105	O	and
20	107	108	O	80
21	110	111	O	mg
22	112	112	O	/
23	113	115	O	day
24	117	118	O	on
25	120	123	O	Days
26	125	125	O	2
27	127	129	O	and
28	131	131	O	3
29	132	132	O	,
30	134	136	O	and
31	138	146	U-UNK	midazolam
32	148	148	O	2
33	150	151	O	mg
34	153	154	O	IV
35	156	158	O	was
36	160	164	O	given
37	166	170	O	prior
38	172	173	O	to
39	175	177	O	the
40	179	192	O	administration
41	194	195	O	of
42	197	199	O	the
43	201	201	O	3
44	203	205	O	day
45	207	213	O	regimen
46	215	216	O	of
47	218	227	O	XXXXXXXX
48	229	231	O	and
49	233	234	O	on
50	236	239	O	Days
51	241	241	O	4
52	242	242	O	,
53	244	244	O	8
54	245	245	O	,
55	247	249	O	and
56	251	252	O	15
NULL

Aprepitant	DDI-DrugBank.d382.s25	NO_SECTION	NO_SETID	33
Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
1	0	9	O	XXXXXXXX
2	11	19	O	increased
3	21	23	O	the
4	25	27	O	AUC
5	29	30	O	of
6	32	40	U-KIN	midazolam
7	42	43	O	by
8	45	47	O	25%
9	49	50	O	on
10	52	54	O	Day
11	56	56	O	4
12	58	60	O	and
13	62	70	O	decreased
14	72	74	O	the
15	76	78	O	AUC
16	80	81	O	of
17	83	91	U-KIN	midazolam
18	93	94	O	by
19	96	98	O	19%
20	100	101	O	on
21	103	105	O	Day
22	107	107	O	8
23	109	116	O	relative
24	118	119	O	to
25	121	123	O	the
26	125	130	O	dosing
27	132	133	O	of
28	135	144	O	XXXXXXXX
29	146	147	O	on
30	149	152	O	Days
31	154	154	O	1
32	156	162	O	through
33	164	164	O	3
NULL

Aprepitant	DDI-DrugBank.d382.s26	NO_SECTION	NO_SETID	7
These effects were not considered clinically important.
1	0	4	O	These
2	6	12	O	effects
3	14	17	O	were
4	19	21	O	not
5	23	32	O	considered
6	34	43	O	clinically
7	45	53	O	important
NULL

Aprepitant	DDI-DrugBank.d382.s27	NO_SECTION	NO_SETID	14
The AUC of midazolam on Day 15 was similar to that observed at baseline.
1	0	2	O	The
2	4	6	O	AUC
3	8	9	O	of
4	11	19	U-UNK	midazolam
5	21	22	O	on
6	24	26	O	Day
7	28	29	O	15
8	31	33	O	was
9	35	41	O	similar
10	43	44	O	to
11	46	49	O	that
12	51	58	O	observed
13	60	61	O	at
14	63	70	O	baseline
NULL

Aprepitant	DDI-DrugBank.d382.s28	NO_SECTION	NO_SETID	9
Effect of other agents on the pharmacokinefics of aprepitant
1	0	5	O	Effect
2	7	8	O	of
3	10	14	O	other
4	16	21	O	agents
5	23	24	O	on
6	26	28	O	the
7	30	45	O	pharmacokinefics
8	47	48	O	of
9	50	59	O	XXXXXXXX
NULL

Aprepitant	DDI-DrugBank.d382.s29	NO_SECTION	NO_SETID	6
Aprepitant is a substrate for CYP3A4;
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	14	O	a
4	16	24	O	substrate
5	26	28	O	for
6	30	35	O	CYP3A4
NULL

Aprepitant	DDI-DrugBank.d382.s30	NO_SECTION	NO_SETID	19
therefore, coadministration of Aprepitant with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of aprepitant.
1	0	8	O	therefore
2	9	9	O	,
3	11	26	O	coadministration
4	28	29	O	of
5	31	40	O	XXXXXXXX
6	42	45	O	with
7	47	51	O	drugs
8	53	56	O	that
9	58	64	O	inhibit
10	66	71	O	CYP3A4
11	73	80	O	activity
12	82	84	O	may
13	86	91	O	result
14	93	94	O	in
15	96	104	O	increased
16	106	111	O	plasma
17	113	126	O	concentrations
18	128	129	O	of
19	131	140	O	XXXXXXXX
NULL

Aprepitant	DDI-DrugBank.d382.s31	NO_SECTION	NO_SETID	30
Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
1	0	11	O	Consequently
2	12	12	O	,
3	14	24	O	concomitant
4	26	39	O	administration
5	41	42	O	of
6	44	53	O	XXXXXXXX
7	55	58	O	with
8	60	65	O	strong
9	67	72	O	CYP3A4
10	74	83	O	inhibitors
11	86	88	O	e.g
12	90	90	O	,
13	92	103	U-DYN	ketoconazole
14	104	104	O	,
15	106	117	U-DYN	itraconazole
16	118	118	O	,
17	120	129	U-DYN	nefazodone
18	130	130	O	,
19	132	145	U-DYN	troleandomycin
20	146	146	O	,
21	148	161	U-DYN	clarithromycin
22	162	162	O	,
23	164	172	U-DYN	ritonavir
24	173	173	O	,
25	175	184	U-DYN	nelfinavir
26	187	192	O	should
27	194	195	O	be
28	197	206	O	approached
29	208	211	O	with
30	213	219	O	caution
NULL

Aprepitant	DDI-DrugBank.d382.s32	NO_SECTION	NO_SETID	26
Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.
1	0	6	O	Because
2	8	15	O	moderate
3	17	22	O	CYP3A4
4	24	33	O	inhibitors
5	36	38	O	e.g
6	40	40	O	,
7	42	50	U-DYN	diltiazem
8	53	58	O	result
9	60	61	O	in
10	63	63	O	2
11	65	68	O	fold
12	70	77	O	increase
13	79	80	O	in
14	82	87	O	plasma
15	89	102	O	concentrations
16	104	105	O	of
17	107	116	O	XXXXXXXX
18	117	117	O	,
19	119	129	O	concomitant
20	131	144	O	administration
21	146	151	O	should
22	153	156	O	also
23	158	159	O	be
24	161	170	O	approached
25	172	175	O	with
26	177	183	O	caution
NULL

Aprepitant	DDI-DrugBank.d382.s33	NO_SECTION	NO_SETID	6
Aprepitant is a substrate for CYP3A4;
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	14	O	a
4	16	24	O	substrate
5	26	28	O	for
6	30	35	O	CYP3A4
NULL

Aprepitant	DDI-DrugBank.d382.s34	NO_SECTION	NO_SETID	35
therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.
1	0	8	O	therefore
2	9	9	O	,
3	11	26	O	coadministration
4	28	29	O	of
5	31	40	O	XXXXXXXX
6	42	45	O	with
7	47	51	O	drugs
8	53	56	O	that
9	58	65	O	strongly
10	67	72	O	induce
11	74	79	O	CYP3A4
12	81	88	O	activity
13	91	93	O	e.g
14	95	95	O	,
15	97	104	U-KIN	rifampin
16	105	105	O	,
17	107	119	U-UNK	carbamazepine
18	120	120	O	,
19	122	130	U-KIN	phenytoin
20	133	135	O	may
21	137	142	O	result
22	144	145	O	in
23	147	153	O	reduced
24	155	160	O	plasma
25	162	175	O	concentrations
26	177	178	O	of
27	180	189	U-KIN	XXXXXXXX
28	191	194	O	that
29	196	198	O	may
30	200	205	O	result
31	207	208	O	in
32	210	218	O	decreased
33	220	227	O	efficacy
34	229	230	O	of
35	232	241	O	XXXXXXXX
NULL

Aprepitant	DDI-DrugBank.d382.s35	NO_SECTION	NO_SETID	16
Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	17	O	When
4	19	19	O	a
5	21	26	O	single
6	28	30	O	125
7	32	33	O	mg
8	35	38	O	dose
9	40	41	O	of
10	43	52	O	XXXXXXXX
11	54	56	O	was
12	58	69	O	administered
13	71	72	O	on
14	74	77	O	Day5
15	79	80	O	of
16	82	82	O	a
NULL

Aprepitant	DDI-DrugBank.d382.s36	NO_SECTION	NO_SETID	52
Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	17	O	When
4	19	19	O	a
5	21	26	O	single
6	28	30	O	125
7	32	33	O	mg
8	35	38	O	dose
9	40	41	O	of
10	43	52	O	XXXXXXXX
11	54	56	O	was
12	58	69	O	administered
13	71	72	O	on
14	74	77	O	Day5
15	79	80	O	of
16	82	82	O	a
17	84	85	O	10
18	87	89	O	day
19	91	97	O	regimen
20	99	100	O	of
21	102	104	O	400
22	106	107	O	mg
23	108	108	O	/
24	109	111	O	day
25	113	114	O	of
26	116	127	U-KIN	ketoconazole
27	128	128	O	,
28	130	130	O	a
29	132	137	O	strong
30	139	144	O	CYP3A4
31	146	154	O	inhibitor
32	155	155	O	,
33	157	159	O	the
34	161	163	O	AUC
35	165	166	O	of
36	168	177	O	XXXXXXXX
37	179	187	O	increased
38	189	201	O	approximately
39	203	203	O	5
40	205	208	O	fold
41	210	212	O	and
42	214	216	O	the
43	218	221	O	mean
44	223	230	O	terminal
45	232	235	O	half
46	237	240	O	life
47	242	243	O	of
48	245	254	O	XXXXXXXX
49	256	264	O	increased
50	266	278	O	approximately
51	280	280	O	3
52	282	285	O	fold
NULL

Aprepitant	DDI-DrugBank.d382.s37	NO_SECTION	NO_SETID	12
Concomitant administration of Aprepitant with strong CYP3A4 inhibitors should be approached cautiously.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	39	O	XXXXXXXX
5	41	44	O	with
6	46	51	O	strong
7	53	58	O	CYP3A4
8	60	69	O	inhibitors
9	71	76	O	should
10	78	79	O	be
11	81	90	O	approached
12	92	101	O	cautiously
NULL

Aprepitant	DDI-DrugBank.d382.s38	NO_SECTION	NO_SETID	50
Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.
1	0	7	U-UNK	Rifampin
2	8	8	O	:
3	10	13	O	When
4	15	15	O	a
5	17	22	O	single
6	24	26	O	375
7	28	29	O	mg
8	31	34	O	dose
9	36	37	O	of
10	39	48	O	XXXXXXXX
11	50	52	O	was
12	54	65	O	administered
13	67	68	O	on
14	70	73	O	Day9
15	75	76	O	of
16	78	78	O	a
17	80	81	O	14
18	83	85	O	day
19	87	93	O	regimen
20	95	96	O	of
21	98	100	O	600
22	102	103	O	mg
23	104	104	O	/
24	105	107	O	day
25	109	110	O	of
26	112	119	U-KIN	rifampin
27	120	120	O	,
28	122	122	O	a
29	124	129	O	strong
30	131	136	O	CYP3A4
31	138	144	O	inducer
32	145	145	O	,
33	147	149	O	the
34	151	153	O	AUC
35	155	156	O	of
36	158	167	O	XXXXXXXX
37	169	177	O	decreased
38	179	191	O	approximately
39	193	194	O	11
40	196	199	O	fold
41	201	203	O	and
42	205	207	O	the
43	209	212	O	mean
44	214	221	O	terminal
45	223	226	O	half
46	228	231	O	life
47	233	241	O	decreased
48	243	255	O	approximately
49	257	257	O	3
50	259	262	O	fold
NULL

Aprepitant	DDI-DrugBank.d382.s39	NO_SECTION	NO_SETID	20
Coadministration of Aprepitant with drugs that induce CYP3A4 activity may result in reduced plasma concentrations and decreased efficacy of Aprepitant.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	O	XXXXXXXX
4	31	34	O	with
5	36	40	O	drugs
6	42	45	O	that
7	47	52	O	induce
8	54	59	O	CYP3A4
9	61	68	O	activity
10	70	72	O	may
11	74	79	O	result
12	81	82	O	in
13	84	90	O	reduced
14	92	97	O	plasma
15	99	112	O	concentrations
16	114	116	O	and
17	118	126	O	decreased
18	128	135	O	efficacy
19	137	138	O	of
20	140	149	O	XXXXXXXX
NULL

Aprepitant	DDI-DrugBank.d382.s40	NO_SECTION	NO_SETID	2
Additional interactions
1	0	9	O	Additional
2	11	22	O	interactions
NULL

Aprepitant	DDI-DrugBank.d382.s41	NO_SECTION	NO_SETID	58
Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.
1	0	8	U-UNK	Diltiazem
2	9	9	O	:
3	11	12	O	In
4	14	21	O	patients
5	23	26	O	with
6	28	31	O	mild
7	33	34	O	to
8	36	43	O	moderate
9	45	56	O	hypertension
10	57	57	O	,
11	59	72	O	administration
12	74	75	O	of
13	77	86	O	XXXXXXXX
14	88	91	O	once
15	93	97	O	daily
16	98	98	O	,
17	100	101	O	as
18	103	103	O	a
19	105	110	O	tablet
20	112	122	O	formulation
21	124	133	O	comparable
22	135	136	O	to
23	138	140	O	230
24	142	143	O	mg
25	145	146	O	of
26	148	150	O	the
27	152	158	O	capsule
28	160	170	O	formulation
29	171	171	O	,
30	173	176	O	with
31	178	186	U-KIN	diltiazem
32	188	190	O	120
33	192	193	O	mg
34	195	195	O	3
35	197	201	O	times
36	203	207	O	daily
37	209	211	O	for
38	213	213	O	5
39	215	218	O	days
40	219	219	O	,
41	221	228	O	resulted
42	230	231	O	in
43	233	233	O	a
44	235	235	O	2
45	237	240	O	fold
46	242	249	O	increase
47	251	252	O	of
48	254	263	O	XXXXXXXX
49	265	267	O	AUC
50	269	271	O	and
51	273	273	O	a
52	275	286	O	simultaneous
53	288	290	O	1.7
54	292	295	O	fold
55	297	304	O	increase
56	306	307	O	of
57	309	317	U-UNK	diltiazem
58	319	321	O	AUC
NULL

Aprepitant	DDI-DrugBank.d382.s42	NO_SECTION	NO_SETID	25
These pharmacokinetic effects did not result in clinically meaningful changes in ECG, heart rate or blood pressure beyond those changes induced by diltiazem alone.
1	0	4	O	These
2	6	20	O	pharmacokinetic
3	22	28	O	effects
4	30	32	O	did
5	34	36	O	not
6	38	43	O	result
7	45	46	O	in
8	48	57	O	clinically
9	59	68	O	meaningful
10	70	76	O	changes
11	78	79	O	in
12	81	83	O	ECG
13	84	84	O	,
14	86	90	O	heart
15	92	95	O	rate
16	97	98	O	or
17	100	104	O	blood
18	106	113	O	pressure
19	115	120	O	beyond
20	122	126	O	those
21	128	134	O	changes
22	136	142	O	induced
23	144	145	O	by
24	147	155	U-UNK	diltiazem
25	157	161	O	alone
NULL

Aprepitant	DDI-DrugBank.d382.s43	NO_SECTION	NO_SETID	53
Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.
1	0	9	U-UNK	Paroxetine
2	10	10	O	:
3	12	27	O	Coadministration
4	29	30	O	of
5	32	35	O	once
6	37	41	O	daily
7	43	47	O	doses
8	49	50	O	of
9	52	61	O	XXXXXXXX
10	62	62	O	,
11	64	65	O	as
12	67	67	O	a
13	69	74	O	tablet
14	76	86	O	formulation
15	88	97	O	comparable
16	99	100	O	to
17	102	103	O	85
18	105	106	O	mg
19	108	109	O	or
20	111	113	O	170
21	115	116	O	mg
22	118	119	O	of
23	121	123	O	the
24	125	131	O	capsule
25	133	143	O	formulation
26	144	144	O	,
27	146	149	O	with
28	151	160	U-KIN	paroxetine
29	162	163	O	20
30	165	166	O	mg
31	168	171	O	once
32	173	177	O	daily
33	178	178	O	,
34	180	187	O	resulted
35	189	190	O	in
36	192	192	O	a
37	194	201	O	decrease
38	203	204	O	in
39	206	208	O	AUC
40	210	211	O	by
41	213	225	O	approximately
42	227	229	O	25%
43	231	233	O	and
44	235	238	O	Cmax
45	239	239	O	,
46	241	242	O	by
47	244	256	O	approximately
48	258	260	O	20%
49	262	263	O	of
50	265	268	O	both
51	270	279	O	XXXXXXXX
52	281	283	O	and
53	285	294	U-UNK	paroxetine
NULL

Arbutamine	DDI-DrugBank.d253.s0	NO_SECTION	NO_SETID	13
Beta-adrenergic blocking agents: concurrent use may blunt the response to arbutamine.
1	0	3	B-UNK	Beta
2	5	14	I-UNK	adrenergic
3	16	23	I-UNK	blocking
4	25	30	L-UNK	agents
5	31	31	O	:
6	33	42	O	concurrent
7	44	46	O	use
8	48	50	O	may
9	52	56	O	blunt
10	58	60	O	the
11	62	69	O	response
12	71	72	O	to
13	74	83	O	XXXXXXXX
NULL

Arbutamine	DDI-DrugBank.d253.s1	NO_SECTION	NO_SETID	18
Beta-adrenergic blocking agents should be withdrawn at least 48 hours before conducting an arbutamine-mediated stress test.
1	0	3	B-DYN	Beta
2	5	14	I-DYN	adrenergic
3	16	23	I-DYN	blocking
4	25	30	L-DYN	agents
5	32	37	O	should
6	39	40	O	be
7	42	50	O	withdrawn
8	52	53	O	at
9	55	59	O	least
10	61	62	O	48
11	64	68	O	hours
12	70	75	O	before
13	77	86	O	conducting
14	88	89	O	an
15	91	100	O	XXXXXXXX
16	102	109	O	mediated
17	111	116	O	stress
18	118	121	O	test
NULL

Arbutamine	DDI-DrugBank.d253.s2	NO_SECTION	NO_SETID	23
Antiarrhythmic agents, class I (such as flecainide, lidocaine, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.
1	0	13	B-UNK	Antiarrhythmic
2	15	20	I-UNK	agents
3	21	21	I-UNK	,
4	23	27	I-UNK	class
5	29	29	L-UNK	I
6	32	35	O	such
7	37	38	O	as
8	40	49	U-UNK	flecainide
9	50	50	O	,
10	52	60	U-UNK	lidocaine
11	61	61	O	,
12	63	64	O	or
13	66	74	U-UNK	quinidine
14	76	76	O	:
15	78	87	O	concurrent
16	89	91	O	use
17	93	96	O	with
18	98	107	O	XXXXXXXX
19	109	111	O	may
20	113	116	O	have
21	118	118	O	a
22	120	132	O	proarrhythmic
23	134	139	O	effect
NULL

Arbutamine	DDI-DrugBank.d253.s3	NO_SECTION	NO_SETID	26
Antidepressants (tricyclic), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
1	0	14	U-UNK	Antidepressants
2	17	25	U-UNK	tricyclic
3	27	27	O	,
4	29	36	U-UNK	atropine
5	38	39	O	or
6	41	45	O	other
7	47	61	B-UNK	anticholinergic
8	63	68	L-UNK	agents
9	69	69	O	,
10	71	72	O	or
11	74	82	B-UNK	digitalis
12	84	93	L-UNK	glycosides
13	94	94	O	:
14	96	105	O	concurrent
15	107	109	O	use
16	111	114	O	with
17	116	125	O	XXXXXXXX
18	127	129	O	may
19	131	137	O	produce
20	139	146	O	additive
21	148	156	O	inotropic
22	158	160	O	and
23	161	161	O	/
24	162	163	O	or
25	165	176	O	chronotropic
26	178	184	O	effects
NULL

Ardeparin	DDI-DrugBank.d105.s0	NO_SECTION	NO_SETID	33
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
1	0	13	U-UNK	Anticoagulants
2	15	23	O	including
3	25	32	O	coumarin
4	34	44	O	derivatives
5	45	45	O	,
6	47	56	O	indandione
7	58	68	O	derivatives
8	69	69	O	,
9	71	73	O	and
10	75	82	B-UNK	platelet
11	84	94	I-UNK	aggregation
12	96	105	L-UNK	inhibitors
13	107	110	O	such
14	112	113	O	as
15	115	126	B-UNK	nonsteroidal
16	128	131	I-UNK	anti
17	133	144	I-UNK	inflammatory
18	146	150	L-UNK	drugs
19	153	158	U-UNK	NSAIDs
20	160	160	O	,
21	162	164	O	and
22	166	172	O	XXXXXXXX
23	174	176	O	may
24	178	185	O	increase
25	187	189	O	the
26	191	194	O	risk
27	196	197	O	of
28	199	206	O	bleeding
29	208	211	O	when
30	213	224	O	administered
31	226	238	O	concomitantly
32	240	243	O	with
33	245	253	U-DYN	ardeparin
NULL

Arformoterol	DDI-DrugBank.d284.s0	NO_SECTION	NO_SETID	29
If additional adrenergic drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of BROVANA may be potentiated.
1	0	1	O	If
2	3	12	O	additional
3	14	23	B-DYN	adrenergic
4	25	29	L-DYN	drugs
5	31	33	O	are
6	35	36	O	to
7	38	39	O	be
8	41	52	O	administered
9	54	55	O	by
10	57	59	O	any
11	61	65	O	route
12	66	66	O	,
13	68	71	O	they
14	73	78	O	should
15	80	81	O	be
16	83	86	O	used
17	88	91	O	with
18	93	99	O	caution
19	101	107	O	because
20	109	111	O	the
21	113	129	O	pharmacologically
22	131	141	O	predictable
23	143	153	O	sympathetic
24	155	161	O	effects
25	163	164	O	of
26	166	172	O	XXXXXXXX
27	174	176	O	may
28	178	179	O	be
29	181	191	O	potentiated
NULL

Arformoterol	DDI-DrugBank.d284.s1	NO_SECTION	NO_SETID	25
When paroxetine, a potent inhibitor of CYP2D6, was co-administered with BROVANA at steady-state, exposure to either drug was not altered.
1	0	3	O	When
2	5	14	U-UNK	paroxetine
3	15	15	O	,
4	17	17	O	a
5	19	24	O	potent
6	26	34	O	inhibitor
7	36	37	O	of
8	39	44	O	CYP2D6
9	45	45	O	,
10	47	49	O	was
11	51	52	O	co
12	54	65	O	administered
13	67	70	O	with
14	72	78	O	XXXXXXXX
15	80	81	O	at
16	83	88	O	steady
17	90	94	O	state
18	95	95	O	,
19	97	104	O	exposure
20	106	107	O	to
21	109	114	O	either
22	116	119	O	drug
23	121	123	O	was
24	125	127	O	not
25	129	135	O	altered
NULL

Arformoterol	DDI-DrugBank.d284.s2	NO_SECTION	NO_SETID	17
Dosage adjustments of BROVANA are not necessary when the drug is given concomitantly with potent CYP2D6 inhibitors.
1	0	5	O	Dosage
2	7	17	O	adjustments
3	19	20	O	of
4	22	28	O	XXXXXXXX
5	30	32	O	are
6	34	36	O	not
7	38	46	O	necessary
8	48	51	O	when
9	53	55	O	the
10	57	60	O	drug
11	62	63	O	is
12	65	69	O	given
13	71	83	O	concomitantly
14	85	88	O	with
15	90	95	O	potent
16	97	102	O	CYP2D6
17	104	113	O	inhibitors
NULL

Arformoterol	DDI-DrugBank.d284.s3	NO_SECTION	NO_SETID	20
Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
1	0	10	O	Concomitant
2	12	20	O	treatment
3	22	25	O	with
4	27	41	U-UNK	methylxanthines
5	44	56	U-UNK	aminophylline
6	57	57	O	,
7	59	70	U-UNK	theophylline
8	72	72	O	,
9	74	81	U-UNK	steroids
10	82	82	O	,
11	84	85	O	or
12	87	95	U-UNK	diuretics
13	97	99	O	may
14	101	110	O	potentiate
15	112	114	O	any
16	116	126	O	hypokalemic
17	128	133	O	effect
18	135	136	O	of
19	138	147	B-UNK	adrenergic
20	149	156	L-UNK	agonists
NULL

Arformoterol	DDI-DrugBank.d284.s4	NO_SECTION	NO_SETID	43
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
1	0	2	O	The
2	4	6	O	ECG
3	8	14	O	changes
4	16	18	O	and
5	19	19	O	/
6	20	21	O	or
7	23	33	O	hypokalemia
8	35	38	O	that
9	40	42	O	may
10	44	49	O	result
11	51	54	O	from
12	56	58	O	the
13	60	73	O	administration
14	75	76	O	of
15	78	80	B-UNK	non
16	82	90	I-UNK	potassium
17	92	98	I-UNK	sparing
18	100	108	L-UNK	diuretics
19	111	114	O	such
20	116	117	O	as
21	119	122	B-UNK	loop
22	124	125	I-UNK	or
23	127	134	I-UNK	thiazide
24	136	144	L-UNK	diuretics
25	147	149	O	can
26	151	152	O	be
27	154	160	O	acutely
28	162	169	O	worsened
29	171	172	O	by
30	174	177	B-UNK	beta
31	179	186	L-UNK	agonists
32	187	187	O	,
33	189	198	O	especially
34	200	203	O	when
35	205	207	O	the
36	209	219	O	recommended
37	221	224	O	dose
38	226	227	O	of
39	229	231	O	the
40	233	236	B-UNK	beta
41	238	244	L-UNK	agonist
42	246	247	O	is
43	249	256	O	exceeded
NULL

Arformoterol	DDI-DrugBank.d284.s5	NO_SECTION	NO_SETID	26
Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics.
1	0	7	O	Although
2	9	11	O	the
3	13	20	O	clinical
4	22	33	O	significance
5	35	36	O	of
6	38	42	O	these
7	44	50	O	effects
8	52	53	O	is
9	55	57	O	not
10	59	63	O	known
11	64	64	O	,
12	66	72	O	caution
13	74	75	O	is
14	77	83	O	advised
15	85	86	O	in
16	88	90	O	the
17	92	93	O	co
18	95	108	O	administration
19	110	111	O	of
20	113	116	B-UNK	beta
21	118	125	L-UNK	agonists
22	127	130	O	with
23	132	134	B-UNK	non
24	136	144	I-UNK	potassium
25	146	152	I-UNK	sparing
26	154	162	L-UNK	diuretics
NULL

Arformoterol	DDI-DrugBank.d284.s6	NO_SECTION	NO_SETID	50
BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
1	0	6	O	XXXXXXXX
2	7	7	O	,
3	9	10	O	as
4	12	15	O	with
5	17	21	O	other
6	23	27	B-UNK	beta2
7	29	36	L-UNK	agonists
8	37	37	O	,
9	39	44	O	should
10	46	47	O	be
11	49	60	O	administered
12	62	65	O	with
13	67	73	O	extreme
14	75	81	O	caution
15	83	84	O	to
16	86	93	O	patients
17	95	99	O	being
18	101	107	O	treated
19	109	112	O	with
20	114	122	B-DYN	monoamine
21	124	130	I-DYN	oxidase
22	132	141	L-DYN	inhibitors
23	142	142	O	,
24	144	152	B-DYN	tricyclic
25	154	168	L-DYN	antidepressants
26	169	169	O	,
27	171	172	O	or
28	174	178	O	drugs
29	180	184	O	known
30	186	187	O	to
31	189	195	O	prolong
32	197	199	O	the
33	201	203	O	QTc
34	205	212	O	interval
35	214	220	O	because
36	222	224	O	the
37	226	231	O	action
38	233	234	O	of
39	236	245	B-UNK	adrenergic
40	247	254	L-UNK	agonists
41	256	257	O	on
42	259	261	O	the
43	263	276	O	cardiovascular
44	278	283	O	system
45	285	287	O	may
46	289	290	O	be
47	292	302	O	potentiated
48	304	305	O	by
49	307	311	O	these
50	313	318	O	agents
NULL

Arformoterol	DDI-DrugBank.d284.s7	NO_SECTION	NO_SETID	16
Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias.
1	0	4	O	Drugs
2	6	9	O	that
3	11	13	O	are
4	15	19	O	known
5	21	22	O	to
6	24	30	O	prolong
7	32	34	O	the
8	36	38	O	QTc
9	40	47	O	interval
10	49	52	O	have
11	54	55	O	an
12	57	65	O	increased
13	67	70	O	risk
14	72	73	O	of
15	75	85	O	ventricular
16	87	97	O	arrhythmias
NULL

Arformoterol	DDI-DrugBank.d284.s8	NO_SECTION	NO_SETID	23
The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, theophylline) by patients receiving BROVANA has not been completely evaluated.
1	0	2	O	The
2	4	13	O	concurrent
3	15	17	O	use
4	19	20	O	of
5	22	34	O	intravenously
6	36	37	O	or
7	39	44	O	orally
8	46	57	O	administered
9	59	73	U-UNK	methylxanthines
10	76	78	O	e.g
11	80	80	O	,
12	82	94	U-UNK	aminophylline
13	95	95	O	,
14	97	108	U-UNK	theophylline
15	111	112	O	by
16	114	121	O	patients
17	123	131	O	receiving
18	133	139	O	XXXXXXXX
19	141	143	O	has
20	145	147	O	not
21	149	152	O	been
22	154	163	O	completely
23	165	173	O	evaluated
NULL

Arformoterol	DDI-DrugBank.d284.s9	NO_SECTION	NO_SETID	41
In two combined 12-week placebo controlled trials that included BROVANA doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA -treated subjects received concomitant theophylline at study entry.
1	0	1	O	In
2	3	5	O	two
3	7	14	O	combined
4	16	17	O	12
5	19	22	O	week
6	24	30	O	placebo
7	32	41	O	controlled
8	43	48	O	trials
9	50	53	O	that
10	55	62	O	included
11	64	70	O	XXXXXXXX
12	72	76	O	doses
13	78	79	O	of
14	81	82	O	15
15	84	86	O	mcg
16	88	92	O	twice
17	94	98	O	daily
18	99	99	O	,
19	101	102	O	25
20	104	106	O	mcg
21	108	112	O	twice
22	114	118	O	daily
23	119	119	O	,
24	121	123	O	and
25	125	126	O	50
26	128	130	O	mcg
27	132	135	O	once
28	137	141	O	daily
29	142	142	O	,
30	144	145	O	54
31	147	148	O	of
32	150	152	O	873
33	154	160	O	XXXXXXXX
34	163	169	O	treated
35	171	178	O	subjects
36	180	187	O	received
37	189	199	O	concomitant
38	201	212	U-UNK	theophylline
39	214	215	O	at
40	217	221	O	study
41	223	227	O	entry
NULL

Arformoterol	DDI-DrugBank.d284.s10	NO_SECTION	NO_SETID	29
In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose, 30 of the 528 BROVANA -treated subjects received concomitant theophylline at study entry.
1	0	1	O	In
2	3	3	O	a
3	5	6	O	12
4	8	12	O	month
5	14	23	O	controlled
6	25	29	O	trial
7	31	34	O	that
8	36	43	O	included
9	45	45	O	a
10	47	48	O	50
11	50	52	O	mcg
12	54	57	O	once
13	59	63	O	daily
14	65	71	O	XXXXXXXX
15	73	76	O	dose
16	77	77	O	,
17	79	80	O	30
18	82	83	O	of
19	85	87	O	the
20	89	91	O	528
21	93	99	O	XXXXXXXX
22	102	108	O	treated
23	110	117	O	subjects
24	119	126	O	received
25	128	138	O	concomitant
26	140	151	U-UNK	theophylline
27	153	154	O	at
28	156	160	O	study
29	162	166	O	entry
NULL

Arformoterol	DDI-DrugBank.d284.s11	NO_SECTION	NO_SETID	34
In these trials, heart rate and systolic blood pressure were approximately 2-3 bpm and 6-8 mm Hg higher, respectively, in subjects on concomitant theophylline compared with the overall population.
1	0	1	O	In
2	3	7	O	these
3	9	14	O	trials
4	15	15	O	,
5	17	21	O	heart
6	23	26	O	rate
7	28	30	O	and
8	32	39	O	systolic
9	41	45	O	blood
10	47	54	O	pressure
11	56	59	O	were
12	61	73	O	approximately
13	75	75	O	2
14	77	77	O	3
15	79	81	O	bpm
16	83	85	O	and
17	87	87	O	6
18	89	89	O	8
19	91	92	O	mm
20	94	95	O	Hg
21	97	102	O	higher
22	103	103	O	,
23	105	116	O	respectively
24	117	117	O	,
25	119	120	O	in
26	122	129	O	subjects
27	131	132	O	on
28	134	144	O	concomitant
29	146	157	U-UNK	theophylline
30	159	166	O	compared
31	168	171	O	with
32	173	175	O	the
33	177	183	O	overall
34	185	194	O	population
NULL

Arformoterol	DDI-DrugBank.d284.s12	NO_SECTION	NO_SETID	19
Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently.
1	0	3	B-DYN	Beta
2	5	14	I-DYN	adrenergic
3	16	23	I-DYN	receptor
4	25	35	L-DYN	antagonists
5	38	41	B-DYN	beta
6	43	50	L-DYN	blockers
7	53	55	O	and
8	57	63	O	XXXXXXXX
9	65	67	O	may
10	69	77	O	interfere
11	79	82	O	with
12	84	86	O	the
13	88	93	O	effect
14	95	96	O	of
15	98	101	O	each
16	103	107	O	other
17	109	112	O	when
18	114	125	O	administered
19	127	138	O	concurrently
NULL

Arformoterol	DDI-DrugBank.d284.s13	NO_SECTION	NO_SETID	20
Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients.
1	0	3	B-UNK	Beta
2	5	12	L-UNK	blockers
3	14	16	O	not
4	18	21	O	only
5	23	27	O	block
6	29	31	O	the
7	33	43	O	therapeutic
8	45	51	O	effects
9	53	54	O	of
10	56	59	B-UNK	beta
11	61	68	L-UNK	agonists
12	69	69	O	,
13	71	73	O	but
14	75	77	O	may
15	79	85	O	produce
16	87	92	O	severe
17	94	105	O	bronchospasm
18	107	108	O	in
19	110	113	O	COPD
20	115	122	O	patients
NULL

Arformoterol	DDI-DrugBank.d284.s14	NO_SECTION	NO_SETID	13
Therefore, patients with COPD should not normally be treated with beta-blockers.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	O	patients
4	20	23	O	with
5	25	28	O	COPD
6	30	35	O	should
7	37	39	O	not
8	41	48	O	normally
9	50	51	O	be
10	53	59	O	treated
11	61	64	O	with
12	66	69	B-UNK	beta
13	71	78	L-UNK	blockers
NULL

Arformoterol	DDI-DrugBank.d284.s15	NO_SECTION	NO_SETID	30
However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	under
4	15	21	O	certain
5	23	35	O	circumstances
6	36	36	O	,
7	38	40	O	e.g
8	42	42	O	,
9	44	45	O	as
10	47	57	O	prophylaxis
11	59	63	O	after
12	65	74	O	myocardial
13	76	85	O	infarction
14	86	86	O	,
15	88	92	O	there
16	94	96	O	may
17	98	99	O	be
18	101	102	O	no
19	104	113	O	acceptable
20	115	126	O	alternatives
21	128	129	O	to
22	131	133	O	the
23	135	137	O	use
24	139	140	O	of
25	142	145	B-UNK	beta
26	147	154	L-UNK	blockers
27	156	157	O	in
28	159	166	O	patients
29	168	171	O	with
30	173	176	O	COPD
NULL

Arformoterol	DDI-DrugBank.d284.s16	NO_SECTION	NO_SETID	18
In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.
1	0	1	O	In
2	3	6	O	this
3	8	14	O	setting
4	15	15	O	,
5	17	31	B-UNK	cardioselective
6	33	36	I-UNK	beta
7	38	45	L-UNK	blockers
8	47	51	O	could
9	53	54	O	be
10	56	65	O	considered
11	66	66	O	,
12	68	75	O	although
13	77	80	O	they
14	82	87	O	should
15	89	90	O	be
16	92	103	O	administered
17	105	108	O	with
18	110	116	O	caution
NULL

Argatroban	DDI-DrugBank.d148.s0	NO_SECTION	NO_SETID	25
Heparin: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.
1	0	6	U-UNK	Heparin
2	7	7	O	:
3	9	13	O	Since
4	15	21	U-UNK	heparin
5	23	24	O	is
6	26	40	O	contraindicated
7	42	43	O	in
8	45	52	O	patients
9	54	57	O	with
10	59	65	U-UNK	heparin
11	67	73	O	induced
12	75	90	O	thrombocytopenia
13	91	91	O	,
14	93	95	O	the
15	97	98	O	co
16	100	113	O	administration
17	115	116	O	of
18	118	127	O	XXXXXXXX
19	129	131	O	and
20	133	139	U-UNK	heparin
21	141	142	O	is
22	144	151	O	unlikely
23	153	155	O	for
24	157	160	O	this
25	162	171	O	indication
NULL

Argatroban	DDI-DrugBank.d148.s1	NO_SECTION	NO_SETID	31
However, if Argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	if
4	12	21	O	XXXXXXXX
5	23	24	O	is
6	26	27	O	to
7	29	30	O	be
8	32	40	O	initiated
9	42	46	O	after
10	48	56	O	cessation
11	58	59	O	of
12	61	67	U-UNK	heparin
13	69	75	O	therapy
14	76	76	O	,
15	78	82	O	allow
16	84	93	O	sufficient
17	95	98	O	time
18	100	102	O	for
19	104	111	O	heparins
20	113	118	O	effect
21	120	121	O	on
22	123	125	O	the
23	127	130	O	aPTT
24	132	133	O	to
25	135	142	O	decrease
26	144	148	O	prior
27	150	151	O	to
28	153	162	O	initiation
29	164	165	O	of
30	167	176	O	XXXXXXXX
31	178	184	O	therapy
NULL

Argatroban	DDI-DrugBank.d148.s2	NO_SECTION	NO_SETID	77
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).
1	0	6	O	XXXXXXXX
2	7	7	O	/
3	8	20	U-UNK	Acetaminophen
4	21	21	O	:
5	23	37	O	Pharmacokinetic
6	39	40	O	or
7	42	56	O	pharmacodynamic
8	58	61	O	drug
9	63	66	O	drug
10	68	79	O	interactions
11	81	84	O	have
12	86	88	O	not
13	90	93	O	been
14	95	106	O	demonstrated
15	108	114	O	between
16	116	125	U-UNK	Argatroban
17	127	129	O	and
18	131	143	O	concomitantly
19	145	156	O	administered
20	158	164	O	XXXXXXXX
21	167	171	O	162.5
22	173	174	O	mg
23	176	181	O	orally
24	183	187	O	given
25	189	190	O	26
26	192	194	O	and
27	196	196	O	2
28	198	202	O	hours
29	204	208	O	prior
30	210	211	O	to
31	213	222	O	initiation
32	224	225	O	of
33	227	236	U-UNK	Argatroban
34	238	238	O	1
35	241	241	O	g
36	242	242	O	/
37	243	244	O	kg
38	245	245	O	/
39	246	248	O	min
40	251	254	O	over
41	256	256	O	4
42	258	262	O	hours
43	265	266	O	or
44	268	280	U-UNK	acetaminophen
45	283	286	O	1000
46	288	289	O	mg
47	291	296	O	orally
48	298	302	O	given
49	304	305	O	12
50	306	306	O	,
51	308	308	O	6
52	310	312	O	and
53	314	314	O	0
54	316	320	O	hours
55	322	326	O	prior
56	328	329	O	to
57	330	330	O	,
58	332	334	O	and
59	336	336	O	6
60	338	340	O	and
61	342	343	O	12
62	345	349	O	hours
63	351	360	O	subsequent
64	362	363	O	to
65	364	364	O	,
66	366	375	O	initiation
67	377	378	O	of
68	380	389	U-UNK	Argatroban
69	391	393	O	1.5
70	396	396	O	g
71	397	397	O	/
72	398	399	O	kg
73	400	400	O	/
74	401	403	O	min
75	406	409	O	over
76	411	412	O	18
77	414	418	O	hours
NULL

Argatroban	DDI-DrugBank.d148.s3	NO_SECTION	NO_SETID	21
Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between Argatroban and warfarin (7.5 mg single oral dose) have not been demonstrated.
1	0	3	O	Oral
2	5	17	B-UNK	anticoagulant
3	19	24	L-UNK	agents
4	25	25	O	:
5	27	41	O	Pharmacokinetic
6	43	46	O	drug
7	48	51	O	drug
8	53	64	O	interactions
9	66	72	O	between
10	74	83	O	XXXXXXXX
11	85	87	O	and
12	89	96	U-UNK	warfarin
13	99	101	O	7.5
14	103	104	O	mg
15	106	111	O	single
16	113	116	O	oral
17	118	121	O	dose
18	124	127	O	have
19	129	131	O	not
20	133	136	O	been
21	138	149	O	demonstrated
NULL

Argatroban	DDI-DrugBank.d148.s4	NO_SECTION	NO_SETID	40
However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	23	O	concomitant
5	25	27	O	use
6	29	30	O	of
7	32	41	O	XXXXXXXX
8	43	45	O	and
9	47	54	U-DYN	warfarin
10	57	57	O	5
11	59	61	O	7.5
12	63	64	O	mg
13	66	72	O	initial
14	74	77	O	oral
15	79	82	O	dose
16	84	91	O	followed
17	93	94	O	by
18	96	98	O	2.5
19	100	100	O	6
20	102	103	O	mg
21	104	104	O	/
22	105	107	O	day
23	109	114	O	orally
24	116	118	O	for
25	120	120	O	6
26	122	123	O	10
27	125	128	O	days
28	131	137	O	results
29	139	140	O	in
30	142	153	O	prolongation
31	155	156	O	of
32	158	160	O	the
33	162	172	O	prothrombin
34	174	177	O	time
35	180	181	O	PT
36	184	186	O	and
37	188	200	O	International
38	202	211	O	Normalized
39	213	217	O	Ratio
40	220	222	O	INR
NULL

Argatroban	DDI-DrugBank.d148.s5	NO_SECTION	NO_SETID	16
Thrombolytic agents: The safety and effectiveness of Argatroban with thrombolytic agents have not been established.
1	0	11	B-UNK	Thrombolytic
2	13	18	L-UNK	agents
3	19	19	O	:
4	21	23	O	The
5	25	30	O	safety
6	32	34	O	and
7	36	48	O	effectiveness
8	50	51	O	of
9	53	62	O	XXXXXXXX
10	64	67	O	with
11	69	80	B-UNK	thrombolytic
12	82	87	L-UNK	agents
13	89	92	O	have
14	94	96	O	not
15	98	101	O	been
16	103	113	O	established
NULL

Argatroban	DDI-DrugBank.d148.s6	NO_SECTION	NO_SETID	22
Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.
1	0	1	O	Co
2	3	16	O	administration
3	17	17	O	:
4	19	29	O	Concomitant
5	31	33	O	use
6	35	36	O	of
7	38	47	O	XXXXXXXX
8	49	52	O	with
9	54	65	B-DYN	antiplatelet
10	67	72	L-DYN	agents
11	73	73	O	,
12	75	87	U-DYN	thrombolytics
13	88	88	O	,
14	90	92	O	and
15	94	98	O	other
16	100	113	U-DYN	anticoagulants
17	115	117	O	may
18	119	126	O	increase
19	128	130	O	the
20	132	135	O	risk
21	137	138	O	of
22	140	147	O	bleeding
NULL

Argatroban	DDI-DrugBank.d148.s7	NO_SECTION	NO_SETID	13
Drug-drug interactions have not been observed between Argatroban and digoxin or erythromycin.
1	0	3	O	Drug
2	5	8	O	drug
3	10	21	O	interactions
4	23	26	O	have
5	28	30	O	not
6	32	35	O	been
7	37	44	O	observed
8	46	52	O	between
9	54	63	O	XXXXXXXX
10	65	67	O	and
11	69	75	U-UNK	digoxin
12	77	78	O	or
13	80	91	U-UNK	erythromycin
NULL

Aripiprazole	DDI-DrugBank.d509.s0	NO_SECTION	NO_SETID	28
Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	21	O	Interactions
4	23	27	O	Given
5	29	31	O	the
6	33	39	O	primary
7	41	43	O	CNS
8	45	51	O	effects
9	53	54	O	of
10	56	67	U-UNK	aripiprazole
11	68	68	O	,
12	70	76	O	caution
13	78	83	O	should
14	85	86	O	be
15	88	91	O	used
16	93	96	O	when
17	98	104	O	XXXXXXXX
18	106	107	O	is
19	109	113	O	taken
20	115	116	O	in
21	118	128	O	combination
22	130	133	O	with
23	135	139	O	other
24	141	149	B-DYN	centrally
25	151	156	I-DYN	acting
26	158	162	L-DYN	drugs
27	164	166	O	and
28	168	174	U-DYN	alcohol
NULL

Aripiprazole	DDI-DrugBank.d509.s2	NO_SECTION	NO_SETID	17
1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.
1	0	0	O	1
2	3	12	O	adrenergic
3	14	21	O	receptor
4	23	32	O	antagonism
5	33	33	O	,
6	35	46	O	XXXXXXXX
7	48	50	O	has
8	52	54	O	the
9	56	64	O	potential
10	66	67	O	to
11	69	75	O	enhance
12	77	79	O	the
13	81	86	O	effect
14	88	89	O	of
15	91	97	O	certain
16	99	114	B-DYN	antihypertensive
17	116	121	L-DYN	agents
NULL

Aripiprazole	DDI-DrugBank.d509.s3	NO_SECTION	NO_SETID	30
Potential for Other Drugs to Affect ABILIFY Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes.
1	0	8	O	Potential
2	10	12	O	for
3	14	18	O	Other
4	20	24	O	Drugs
5	26	27	O	to
6	29	34	O	Affect
7	36	42	O	ABILIFY
8	44	55	O	XXXXXXXX
9	57	58	O	is
10	60	62	O	not
11	64	64	O	a
12	66	74	O	substrate
13	76	77	O	of
14	79	84	O	CYP1A1
15	85	85	O	,
16	87	92	O	CYP1A2
17	93	93	O	,
18	95	100	O	CYP2A6
19	101	101	O	,
20	103	108	O	CYP2B6
21	109	109	O	,
22	111	116	O	CYP2C8
23	117	117	O	,
24	119	124	O	CYP2C9
25	125	125	O	,
26	127	133	O	CYP2C19
27	134	134	O	,
28	136	137	O	or
29	139	144	O	CYP2E1
30	146	152	O	enzymes
NULL

Aripiprazole	DDI-DrugBank.d509.s4	NO_SECTION	NO_SETID	7
Aripiprazole also does not undergo direct glucuronidation.
1	0	11	O	XXXXXXXX
2	13	16	O	also
3	18	21	O	does
4	23	25	O	not
5	27	33	O	undergo
6	35	40	O	direct
7	42	56	O	glucuronidation
NULL

Aripiprazole	DDI-DrugBank.d509.s5	NO_SECTION	NO_SETID	24
This suggests that an interaction of aripiprazole with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
1	0	3	O	This
2	5	12	O	suggests
3	14	17	O	that
4	19	20	O	an
5	22	32	O	interaction
6	34	35	O	of
7	37	48	O	XXXXXXXX
8	50	53	O	with
9	55	64	O	inhibitors
10	66	67	O	or
11	69	76	O	inducers
12	78	79	O	of
13	81	85	O	these
14	87	93	O	enzymes
15	94	94	O	,
16	96	97	O	or
17	99	103	O	other
18	105	111	O	factors
19	112	112	O	,
20	114	117	O	like
21	119	125	O	smoking
22	126	126	O	,
23	128	129	O	is
24	131	138	O	unlikely
NULL

Aripiprazole	DDI-DrugBank.d509.s6	NO_SECTION	NO_SETID	9
Both CYP3A4 and CYP2D6 are responsible for aripiprazole metabolism.
1	0	3	O	Both
2	5	10	O	CYP3A4
3	12	14	O	and
4	16	21	O	CYP2D6
5	23	25	O	are
6	27	37	O	responsible
7	39	41	O	for
8	43	54	O	XXXXXXXX
9	56	65	O	metabolism
NULL

Aripiprazole	DDI-DrugBank.d509.s7	NO_SECTION	NO_SETID	18
Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.
1	0	5	O	Agents
2	7	10	O	that
3	12	17	O	induce
4	19	24	O	CYP3A4
5	27	28	O	eg
6	29	29	O	,
7	31	43	U-KIN	carbamazepine
8	46	50	O	could
9	52	56	O	cause
10	58	59	O	an
11	61	68	O	increase
12	70	71	O	in
13	73	84	O	XXXXXXXX
14	86	94	O	clearance
15	96	98	O	and
16	100	104	O	lower
17	106	110	O	blood
18	112	117	O	levels
NULL

Aripiprazole	DDI-DrugBank.d509.s8	NO_SECTION	NO_SETID	25
Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
1	0	9	O	Inhibitors
2	11	12	O	of
3	14	19	O	CYP3A4
4	22	23	O	eg
5	24	24	O	,
6	26	37	U-KIN	ketoconazole
7	40	41	O	or
8	43	48	O	CYP2D6
9	51	52	O	eg
10	53	53	O	,
11	55	63	U-KIN	quinidine
12	64	64	O	,
13	66	75	U-KIN	fluoxetine
14	76	76	O	,
15	78	79	O	or
16	81	90	U-KIN	paroxetine
17	93	95	O	can
18	97	103	O	inhibit
19	105	116	O	XXXXXXXX
20	118	128	O	elimination
21	130	132	O	and
22	134	138	O	cause
23	140	148	O	increased
24	150	154	O	blood
25	156	161	O	levels
NULL

Aripiprazole	DDI-DrugBank.d509.s9	NO_SECTION	NO_SETID	35
Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	29	O	Coadministration
4	31	32	O	of
5	34	45	U-KIN	ketoconazole
6	48	50	O	200
7	52	53	O	mg
8	54	54	O	/
9	55	57	O	day
10	59	61	O	for
11	63	64	O	14
12	66	69	O	days
13	72	75	O	with
14	77	77	O	a
15	79	80	O	15
16	82	83	O	mg
17	85	90	O	single
18	92	95	O	dose
19	97	98	O	of
20	100	111	O	XXXXXXXX
21	113	121	O	increased
22	123	125	O	the
23	127	129	O	AUC
24	131	132	O	of
25	134	145	O	XXXXXXXX
26	147	149	O	and
27	151	153	O	its
28	155	160	O	active
29	162	171	O	metabolite
30	173	174	O	by
31	176	178	O	63%
32	180	182	O	and
33	184	186	O	77%
34	187	187	O	,
35	189	200	O	respectively
NULL

Aripiprazole	DDI-DrugBank.d509.s10	NO_SECTION	NO_SETID	15
The effect of a higher ketoconazole dose (400 mg/day) has not been studied.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	14	O	a
5	16	21	O	higher
6	23	34	U-UNK	ketoconazole
7	36	39	O	dose
8	42	44	O	400
9	46	47	O	mg
10	48	48	O	/
11	49	51	O	day
12	54	56	O	has
13	58	60	O	not
14	62	65	O	been
15	67	73	O	studied
NULL

Aripiprazole	DDI-DrugBank.d509.s11	NO_SECTION	NO_SETID	21
When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.
1	0	3	O	When
2	5	15	O	concomitant
3	17	30	O	administration
4	32	33	O	of
5	35	46	U-DYN	ketoconazole
6	48	51	O	with
7	53	64	O	XXXXXXXX
8	66	71	O	occurs
9	72	72	O	,
10	74	85	O	XXXXXXXX
11	87	90	O	dose
12	92	97	O	should
13	99	100	O	be
14	102	108	O	reduced
15	110	111	O	to
16	113	115	O	one
17	117	120	O	half
18	122	123	O	of
19	125	127	O	its
20	129	134	O	normal
21	136	139	O	dose
NULL

Aripiprazole	DDI-DrugBank.d509.s12	NO_SECTION	NO_SETID	18
Other strong inhibitors of CYP3A4 (itraconazole) would be expected to have similar effects and need similar dose reductions;
1	0	4	O	Other
2	6	11	O	strong
3	13	22	O	inhibitors
4	24	25	O	of
5	27	32	O	CYP3A4
6	35	46	U-UNK	itraconazole
7	49	53	O	would
8	55	56	O	be
9	58	65	O	expected
10	67	68	O	to
11	70	73	O	have
12	75	81	O	similar
13	83	89	O	effects
14	91	93	O	and
15	95	98	O	need
16	100	106	O	similar
17	108	111	O	dose
18	113	122	O	reductions
NULL

Aripiprazole	DDI-DrugBank.d509.s13	NO_SECTION	NO_SETID	10
weaker inhibitors (erythromycin, grapefruit juice) have not been studied.
1	0	5	O	weaker
2	7	16	O	inhibitors
3	19	30	U-UNK	erythromycin
4	31	31	O	,
5	33	42	O	grapefruit
6	44	48	O	juice
7	51	54	O	have
8	56	58	O	not
9	60	63	O	been
10	65	71	O	studied
NULL

Aripiprazole	DDI-DrugBank.d509.s14	NO_SECTION	NO_SETID	17
When the CYP3A4 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased.
1	0	3	O	When
2	5	7	O	the
3	9	14	O	CYP3A4
4	16	24	O	inhibitor
5	26	27	O	is
6	29	37	O	withdrawn
7	39	42	O	from
8	44	46	O	the
9	48	58	O	combination
10	60	66	O	therapy
11	67	67	O	,
12	69	80	O	XXXXXXXX
13	82	85	O	dose
14	87	92	O	should
15	94	97	O	then
16	99	100	O	be
17	102	110	O	increased
NULL

Aripiprazole	DDI-DrugBank.d509.s15	NO_SECTION	NO_SETID	48
Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.
1	0	8	U-UNK	Quinidine
2	9	9	O	:
3	11	26	O	Coadministration
4	28	29	O	of
5	31	31	O	a
6	33	34	O	10
7	36	37	O	mg
8	39	44	O	single
9	46	49	O	dose
10	51	52	O	of
11	54	65	O	XXXXXXXX
12	67	70	O	with
13	72	80	U-KIN	quinidine
14	83	85	O	166
15	87	88	O	mg
16	89	89	O	/
17	90	92	O	day
18	94	96	O	for
19	98	99	O	13
20	101	104	O	days
21	106	106	O	,
22	108	108	O	a
23	110	115	O	potent
24	117	125	O	inhibitor
25	127	128	O	of
26	130	135	O	CYP2D6
27	136	136	O	,
28	138	146	O	increased
29	148	150	O	the
30	152	154	O	AUC
31	156	157	O	of
32	159	170	O	XXXXXXXX
33	172	173	O	by
34	175	178	O	112%
35	180	182	O	but
36	184	192	O	decreased
37	194	196	O	the
38	198	200	O	AUC
39	202	203	O	of
40	205	207	O	its
41	209	214	O	active
42	216	225	O	metabolite
43	226	226	O	,
44	228	234	O	dehydro
45	235	246	O	XXXXXXXX
46	247	247	O	,
47	249	250	O	by
48	252	254	O	35%
NULL

Aripiprazole	DDI-DrugBank.d509.s16	NO_SECTION	NO_SETID	20
Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.
1	0	11	O	XXXXXXXX
2	13	16	O	dose
3	18	23	O	should
4	25	26	O	be
5	28	34	O	reduced
6	36	37	O	to
7	39	41	O	one
8	43	46	O	half
9	48	49	O	of
10	51	53	O	its
11	55	60	O	normal
12	62	65	O	dose
13	67	70	O	when
14	72	82	O	concomitant
15	84	97	O	administration
16	99	100	O	of
17	102	110	U-DYN	quinidine
18	112	115	O	with
19	117	128	O	XXXXXXXX
20	130	135	O	occurs
NULL

Aripiprazole	DDI-DrugBank.d509.s17	NO_SECTION	NO_SETID	30
Other significant inhibitors of CYP2D6, such as fluoxetine or paroxetine, would be expected to have similar effects and, therefore, should be accompanied by similar dose reductions.
1	0	4	O	Other
2	6	16	O	significant
3	18	27	O	inhibitors
4	29	30	O	of
5	32	37	O	CYP2D6
6	38	38	O	,
7	40	43	O	such
8	45	46	O	as
9	48	57	U-UNK	fluoxetine
10	59	60	O	or
11	62	71	U-UNK	paroxetine
12	72	72	O	,
13	74	78	O	would
14	80	81	O	be
15	83	90	O	expected
16	92	93	O	to
17	95	98	O	have
18	100	106	O	similar
19	108	114	O	effects
20	116	118	O	and
21	119	119	O	,
22	121	129	O	therefore
23	130	130	O	,
24	132	137	O	should
25	139	140	O	be
26	142	152	O	accompanied
27	154	155	O	by
28	157	163	O	similar
29	165	168	O	dose
30	170	179	O	reductions
NULL

Aripiprazole	DDI-DrugBank.d509.s18	NO_SECTION	NO_SETID	17
When the CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased.
1	0	3	O	When
2	5	7	O	the
3	9	14	O	CYP2D6
4	16	24	O	inhibitor
5	26	27	O	is
6	29	37	O	withdrawn
7	39	42	O	from
8	44	46	O	the
9	48	58	O	combination
10	60	66	O	therapy
11	67	67	O	,
12	69	80	O	XXXXXXXX
13	82	85	O	dose
14	87	92	O	should
15	94	97	O	then
16	99	100	O	be
17	102	110	O	increased
NULL

Aripiprazole	DDI-DrugBank.d509.s19	NO_SECTION	NO_SETID	40
Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.
1	0	12	U-UNK	Carbamazepine
2	13	13	O	:
3	15	30	O	Coadministration
4	32	33	O	of
5	35	47	U-KIN	carbamazepine
6	50	52	O	200
7	54	55	O	mg
8	57	59	O	BID
9	61	61	O	,
10	63	63	O	a
11	65	70	O	potent
12	72	77	O	CYP3A4
13	79	85	O	inducer
14	86	86	O	,
15	88	91	O	with
16	93	104	O	XXXXXXXX
17	107	108	O	30
18	110	111	O	mg
19	113	114	O	QD
20	117	124	O	resulted
21	126	127	O	in
22	129	130	O	an
23	132	142	O	approximate
24	144	146	O	70%
25	148	155	O	decrease
26	157	158	O	in
27	160	163	O	Cmax
28	165	167	O	and
29	169	171	O	AUC
30	173	178	O	values
31	180	181	O	of
32	183	186	O	both
33	188	199	O	XXXXXXXX
34	201	203	O	and
35	205	207	O	its
36	209	214	O	active
37	216	225	O	metabolite
38	226	226	O	,
39	228	234	O	dehydro
40	236	247	O	XXXXXXXX
NULL

Aripiprazole	DDI-DrugBank.d509.s20	NO_SECTION	NO_SETID	13
When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.
1	0	3	O	When
2	5	17	U-DYN	carbamazepine
3	19	20	O	is
4	22	26	O	added
5	28	29	O	to
6	31	42	O	XXXXXXXX
7	44	50	O	therapy
8	51	51	O	,
9	53	64	O	XXXXXXXX
10	66	69	O	dose
11	71	76	O	should
12	78	79	O	be
13	81	87	O	doubled
NULL

Aripiprazole	DDI-DrugBank.d509.s21	NO_SECTION	NO_SETID	9
Additional dose increases should be based on clinical evaluation.
1	0	9	O	Additional
2	11	14	O	dose
3	16	24	O	increases
4	26	31	O	should
5	33	34	O	be
6	36	40	O	based
7	42	43	O	on
8	45	52	O	clinical
9	54	63	O	evaluation
NULL

Aripiprazole	DDI-DrugBank.d509.s22	NO_SECTION	NO_SETID	15
When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.
1	0	3	O	When
2	5	17	U-DYN	carbamazepine
3	19	20	O	is
4	22	30	O	withdrawn
5	32	35	O	from
6	37	39	O	the
7	41	51	O	combination
8	53	59	O	therapy
9	60	60	O	,
10	62	73	O	XXXXXXXX
11	75	78	O	dose
12	80	85	O	should
13	87	90	O	then
14	92	93	O	be
15	95	101	O	reduced
NULL

Aripiprazole	DDI-DrugBank.d509.s23	NO_SECTION	NO_SETID	25
No clinically significant effect of famotidine, valproate, or lithium was seen on the pharmacokinetics of aripiprazole (see CLINICAL PHARMACOLOGY: Drug- Drug Interactions).
1	0	1	O	No
2	3	12	O	clinically
3	14	24	O	significant
4	26	31	O	effect
5	33	34	O	of
6	36	45	U-UNK	famotidine
7	46	46	O	,
8	48	56	U-UNK	valproate
9	57	57	O	,
10	59	60	O	or
11	62	68	U-UNK	lithium
12	70	72	O	was
13	74	77	O	seen
14	79	80	O	on
15	82	84	O	the
16	86	101	O	pharmacokinetics
17	103	104	O	of
18	106	117	O	XXXXXXXX
19	120	122	O	see
20	124	131	O	CLINICAL
21	133	144	O	PHARMACOLOGY
22	145	145	O	:
23	147	150	O	Drug
24	153	156	O	Drug
25	158	169	O	Interactions
NULL

Aripiprazole	DDI-DrugBank.d509.s24	NO_SECTION	NO_SETID	23
Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.
1	0	8	O	Potential
2	10	12	O	for
3	14	20	O	XXXXXXXX
4	22	23	O	to
5	25	30	O	Affect
6	32	36	O	Other
7	38	42	O	Drugs
8	44	55	U-UNK	Aripiprazole
9	57	58	O	is
10	60	67	O	unlikely
11	69	70	O	to
12	72	76	O	cause
13	78	87	O	clinically
14	89	97	O	important
15	99	113	O	pharmacokinetic
16	115	126	O	interactions
17	128	131	O	with
18	133	137	O	drugs
19	139	149	O	metabolized
20	151	152	O	by
21	154	163	O	cytochrome
22	165	168	O	P450
23	170	176	O	enzymes
NULL

Aripiprazole	DDI-DrugBank.d509.s25	NO_SECTION	NO_SETID	36
In in vivo studies, 10- to 30-mg/day doses of aripiprazole had no significant effect on metabolism by CYP2D6 (dextromethorphan), CYP2C9 (warfarin), CYP2C19 (omeprazole, warfarin), and CYP3A4 (dextromethorphan) substrates.
1	0	1	O	In
2	3	4	O	in
3	6	9	O	vivo
4	11	17	O	studies
5	18	18	O	,
6	20	21	O	10
7	24	25	O	to
8	27	28	O	30
9	30	31	O	mg
10	32	32	O	/
11	33	35	O	day
12	37	41	O	doses
13	43	44	O	of
14	46	57	O	XXXXXXXX
15	59	61	O	had
16	63	64	O	no
17	66	76	O	significant
18	78	83	O	effect
19	85	86	O	on
20	88	97	O	metabolism
21	99	100	O	by
22	102	107	O	CYP2D6
23	110	125	U-UNK	dextromethorphan
24	127	127	O	,
25	129	134	O	CYP2C9
26	137	144	U-UNK	warfarin
27	146	146	O	,
28	148	154	O	CYP2C19
29	157	166	U-UNK	omeprazole
30	167	167	O	,
31	169	176	U-UNK	warfarin
32	178	178	O	,
33	180	182	O	and
34	184	189	O	CYP3A4
35	192	207	U-UNK	dextromethorphan
36	210	219	O	substrates
NULL

Aripiprazole	DDI-DrugBank.d509.s26	NO_SECTION	NO_SETID	17
Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro.
1	0	11	O	Additionally
2	12	12	O	,
3	14	25	O	XXXXXXXX
4	27	29	O	and
5	31	37	O	dehydro
6	38	49	O	XXXXXXXX
7	51	53	O	did
8	55	57	O	not
9	59	62	O	show
10	64	72	O	potential
11	74	76	O	for
12	78	85	O	altering
13	87	92	O	CYP1A2
14	94	101	O	mediated
15	103	112	O	metabolism
16	114	115	O	in
17	117	121	O	vitro
NULL

Aripiprazole	DDI-DrugBank.d509.s27	NO_SECTION	NO_SETID	29
Alcohol: There was no significant difference between aripiprazole coadministered with ethanol and placebo coadministered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.
1	0	6	U-UNK	Alcohol
2	7	7	O	:
3	9	13	O	There
4	15	17	O	was
5	19	20	O	no
6	22	32	O	significant
7	34	43	O	difference
8	45	51	O	between
9	53	64	O	XXXXXXXX
10	66	79	O	coadministered
11	81	84	O	with
12	86	92	U-UNK	ethanol
13	94	96	O	and
14	98	104	O	placebo
15	106	119	O	coadministered
16	121	124	O	with
17	126	132	U-UNK	ethanol
18	134	135	O	on
19	137	147	O	performance
20	149	150	O	of
21	152	156	O	gross
22	158	162	O	motor
23	164	169	O	skills
24	171	172	O	or
25	174	181	O	stimulus
26	183	190	O	response
27	192	193	O	in
28	195	201	O	healthy
29	203	210	O	subjects
NULL

Aripiprazole	DDI-DrugBank.d509.s28	NO_SECTION	NO_SETID	16
As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY
1	0	1	O	As
2	3	6	O	with
3	8	11	O	most
4	13	24	O	psychoactive
5	26	36	O	medications
6	37	37	O	,
7	39	46	O	patients
8	48	53	O	should
9	55	56	O	be
10	58	64	O	advised
11	66	67	O	to
12	69	73	O	avoid
13	75	81	U-DYN	alcohol
14	83	87	O	while
15	89	94	O	taking
16	96	102	O	XXXXXXXX
NULL

Arsenic trioxide	DDI-DrugBank.d470.s0	NO_SECTION	NO_SETID	16
No formal assessments of pharmacokinetic drug-drug interactions between TRISENOX and other agents have been conducted.
1	0	1	O	No
2	3	8	O	formal
3	10	20	O	assessments
4	22	23	O	of
5	25	39	O	pharmacokinetic
6	41	44	O	drug
7	46	49	O	drug
8	51	62	O	interactions
9	64	70	O	between
10	72	79	O	XXXXXXXX
11	81	83	O	and
12	85	89	O	other
13	91	96	O	agents
14	98	101	O	have
15	103	106	O	been
16	108	116	O	conducted
NULL

Arsenic trioxide	DDI-DrugBank.d470.s1	NO_SECTION	NO_SETID	32
Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).
1	0	6	O	Caution
2	8	9	O	is
3	11	17	O	advised
4	19	22	O	when
5	24	31	O	XXXXXXXX
6	33	34	O	is
7	36	49	O	coadministered
8	51	54	O	with
9	56	60	O	other
10	62	72	O	medications
11	74	77	O	that
12	79	81	O	can
13	83	89	O	prolong
14	91	93	O	the
15	95	96	O	QT
16	98	105	O	interval
17	108	110	O	e.g
18	113	119	O	certain
19	121	135	U-DYN	antiarrhythmics
20	137	138	O	or
21	140	151	U-DYN	thioridazine
22	154	155	O	or
23	157	160	O	lead
24	162	163	O	to
25	165	175	O	electrolyte
26	177	189	O	abnormalities
27	192	195	O	such
28	197	198	O	as
29	200	208	U-DYN	diuretics
30	210	211	O	or
31	213	224	B-DYN	amphotericin
32	226	226	L-DYN	B
NULL

Asparaginase	DDI-DrugBank.d21.s0	NO_SECTION	NO_SETID	33
Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.
1	0	5	O	Tissue
2	7	13	O	culture
3	15	17	O	and
4	19	24	O	animal
5	26	32	O	studies
6	34	41	O	indicate
7	43	46	O	that
8	48	53	O	XXXXXXXX
9	55	57	O	can
10	59	66	O	diminish
11	68	69	O	or
12	71	77	O	abolish
13	79	81	O	the
14	83	88	O	effect
15	90	91	O	of
16	93	104	U-DYN	methotrexate
17	106	107	O	on
18	109	117	O	malignant
19	119	126	O	cells.14
20	128	131	O	This
21	133	138	O	effect
22	140	141	O	on
23	143	154	U-UNK	methotrexate
24	156	163	O	activity
25	165	172	O	persists
26	174	175	O	as
27	177	180	O	long
28	182	183	O	as
29	185	190	O	plasma
30	192	201	O	asparagine
31	203	208	O	levels
32	210	212	O	are
33	214	223	O	suppressed
NULL

Asparaginase	DDI-DrugBank.d21.s1	NO_SECTION	NO_SETID	29
These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.
1	0	4	O	These
2	6	12	O	results
3	14	18	O	would
4	20	23	O	seem
5	25	26	O	to
6	28	34	O	dictate
7	36	42	O	against
8	44	46	O	the
9	48	55	O	clinical
10	57	59	O	use
11	61	62	O	of
12	64	75	U-DYN	methotrexate
13	77	80	O	with
14	82	87	O	XXXXXXXX
15	88	88	O	,
16	90	91	O	or
17	93	98	O	during
18	100	102	O	the
19	104	109	O	period
20	111	119	O	following
21	121	126	O	XXXXXXXX
22	128	134	O	therapy
23	136	139	O	when
24	141	146	O	plasma
25	148	157	O	asparagine
26	159	164	O	levels
27	166	168	O	are
28	170	174	O	below
29	176	181	O	normal
NULL

Aspirin	DDI-DrugBank.d443.s0	NO_SECTION	NO_SETID	15
Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.
1	0	9	B-UNK	Uricosuric
2	11	16	L-UNK	Agents
3	17	17	O	:
4	19	25	O	XXXXXXXX
5	27	29	O	may
6	31	38	O	decrease
7	40	42	O	the
8	44	50	O	effects
9	52	53	O	of
10	55	64	U-DYN	probenecid
11	65	65	O	,
12	67	80	U-DYN	sulfinpyrazone
13	81	81	O	,
14	83	85	O	and
15	87	100	U-DYN	phenylbutazone
NULL

Aspirin	DDI-DrugBank.d443.s1	NO_SECTION	NO_SETID	12
Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.
1	0	6	U-DYN	Alcohol
2	7	7	O	:
3	9	11	O	Has
4	13	13	O	a
5	15	25	O	synergistic
6	27	32	O	effect
7	34	37	O	with
8	39	45	O	XXXXXXXX
9	47	48	O	in
10	50	56	O	causing
11	58	73	O	gastrointestinal
12	75	82	O	bleeding
NULL

Aspirin	DDI-DrugBank.d443.s2	NO_SECTION	NO_SETID	19
Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.
1	0	14	U-DYN	Corticosteroids
2	15	15	O	:
3	17	27	O	Concomitant
4	29	42	O	administration
5	44	47	O	with
6	49	55	O	XXXXXXXX
7	57	59	O	may
8	61	68	O	increase
9	70	72	O	the
10	74	77	O	risk
11	79	80	O	of
12	82	97	O	gastrointestinal
13	99	108	O	ulceration
14	110	112	O	and
15	114	116	O	may
16	118	123	O	reduce
17	125	129	O	serum
18	131	140	O	salicylate
19	142	147	O	levels
NULL

Aspirin	DDI-DrugBank.d443.s3	NO_SECTION	NO_SETID	21
Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.
1	0	9	B-DYN	Pyrazolone
2	11	21	L-DYN	Derivatives
3	24	37	U-DYN	phenylbutazone
4	38	38	O	,
5	40	54	U-DYN	oxyphenbutazone
6	55	55	O	,
7	57	59	O	and
8	61	68	O	possibly
9	70	77	U-DYN	dipyrone
10	79	79	O	:
11	81	91	O	Concomitant
12	93	106	O	administration
13	108	111	O	with
14	113	119	O	XXXXXXXX
15	121	123	O	may
16	125	132	O	increase
17	134	136	O	the
18	138	141	O	risk
19	143	144	O	of
20	146	161	O	gastrointestinal
21	163	172	O	ulceration
NULL

Aspirin	DDI-DrugBank.d443.s4	NO_SECTION	NO_SETID	17
Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.
1	0	11	B-UNK	Nonsteroidal
2	13	28	L-UNK	Antiinflammatory
3	30	35	O	Agents
4	36	36	O	:
5	38	44	O	XXXXXXXX
6	46	47	O	is
7	49	63	O	contraindicated
8	65	66	O	in
9	68	75	O	patients
10	77	79	O	who
11	81	83	O	are
12	85	98	O	hypersensitive
13	100	101	O	to
14	103	114	B-DYN	nonsteroidal
15	116	119	I-DYN	anti
16	121	132	L-DYN	inflammatory
17	134	139	O	agents
NULL

Aspirin	DDI-DrugBank.d443.s5	NO_SECTION	NO_SETID	14
Urinary Alkalinizers: Decrease aspirin effectiveness by increasing the rate of salicylate renal excretion.
1	0	6	O	Urinary
2	8	19	O	Alkalinizers
3	20	20	O	:
4	22	29	O	Decrease
5	31	37	O	XXXXXXXX
6	39	51	O	effectiveness
7	53	54	O	by
8	56	65	O	increasing
9	67	69	O	the
10	71	74	O	rate
11	76	77	O	of
12	79	88	U-UNK	salicylate
13	90	94	O	renal
14	96	104	O	excretion
NULL

Aspirin	DDI-DrugBank.d443.s6	NO_SECTION	NO_SETID	8
Phenobarbital: Decreases aspirin effectiveness by enzyme induction.
1	0	12	U-KIN	Phenobarbital
2	13	13	O	:
3	15	23	O	Decreases
4	25	31	O	XXXXXXXX
5	33	45	O	effectiveness
6	47	48	O	by
7	50	55	O	enzyme
8	57	65	O	induction
NULL

Aspirin	DDI-DrugBank.d443.s7	NO_SECTION	NO_SETID	10
Phenytoin: Serum phenytoin levels may be increased by aspirin.
1	0	8	U-UNK	Phenytoin
2	9	9	O	:
3	11	15	O	Serum
4	17	25	U-DYN	phenytoin
5	27	32	O	levels
6	34	36	O	may
7	38	39	O	be
8	41	49	O	increased
9	51	52	O	by
10	54	60	O	XXXXXXXX
NULL

Aspirin	DDI-DrugBank.d443.s8	NO_SECTION	NO_SETID	14
Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.
1	0	10	U-DYN	Propranolol
2	11	11	O	:
3	13	15	O	May
4	17	24	O	decrease
5	26	33	O	XXXXXXXX
6	35	38	O	anti
7	40	51	O	inflammatory
8	53	58	O	action
9	60	61	O	by
10	63	71	O	competing
11	73	75	O	for
12	77	79	O	the
13	81	84	O	same
14	86	94	O	receptors
NULL

Aspirin	DDI-DrugBank.d443.s9	NO_SECTION	NO_SETID	30
Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.
1	0	7	U-UNK	Antacids
2	8	8	O	:
3	10	16	O	Enteric
4	18	23	O	Coated
5	25	31	O	XXXXXXXX
6	33	38	O	should
7	40	42	O	not
8	44	45	O	be
9	47	51	O	given
10	53	64	O	concurrently
11	66	69	O	with
12	71	78	U-DYN	antacids
13	79	79	O	,
14	81	85	O	since
15	87	88	O	an
16	90	97	O	increase
17	99	100	O	in
18	102	104	O	the
19	106	107	O	pH
20	109	110	O	of
21	112	114	O	the
22	116	122	O	stomach
23	124	126	O	may
24	128	133	O	effect
25	135	137	O	the
26	139	145	O	enteric
27	147	153	O	coating
28	155	156	O	of
29	158	160	O	the
30	162	168	O	tablets
NULL

Astemizole	DDI-DrugBank.d109.s0	NO_SECTION	NO_SETID	8
Ketoconazole/Itraconazole, Macrolides, Including Erythromycin
1	0	11	U-UNK	Ketoconazole
2	12	12	O	/
3	13	24	U-UNK	Itraconazole
4	25	25	O	,
5	27	36	U-UNK	Macrolides
6	37	37	O	,
7	39	47	O	Including
8	49	60	U-UNK	Erythromycin
NULL

Atenolol	DDI-DrugBank.d73.s0	NO_SECTION	NO_SETID	17
Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.
1	0	12	O	Catecholamine
2	14	22	O	depleting
3	24	28	O	drugs
4	31	32	O	eg
5	33	33	O	,
6	35	43	U-UNK	reserpine
7	46	48	O	may
8	50	53	O	have
9	55	56	O	an
10	58	65	O	additive
11	67	72	O	effect
12	74	77	O	when
13	79	83	O	given
14	85	88	O	with
15	90	93	B-UNK	beta
16	95	102	L-UNK	blocking
17	104	109	O	agents
NULL

Atenolol	DDI-DrugBank.d73.s1	NO_SECTION	NO_SETID	32
Patients treated with TENORMIN plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension.
1	0	7	O	Patients
2	9	15	O	treated
3	17	20	O	with
4	22	29	O	XXXXXXXX
5	31	34	O	plus
6	36	36	O	a
7	38	50	O	catecholamine
8	52	59	O	depletor
9	61	66	O	should
10	68	76	O	therefore
11	78	79	O	be
12	81	87	O	closely
13	89	96	O	observed
14	98	100	O	for
15	102	109	O	evidence
16	111	112	O	of
17	114	124	O	hypotension
18	126	128	O	and
19	129	129	O	/
20	130	131	O	or
21	133	138	O	marked
22	140	150	O	bradycardia
23	152	156	O	which
24	158	160	O	may
25	162	168	O	produce
26	170	176	O	vertigo
27	177	177	O	,
28	179	185	O	syncope
29	186	186	O	,
30	188	189	O	or
31	191	198	O	postural
32	200	210	O	hypotension
NULL

Atenolol	DDI-DrugBank.d73.s2	NO_SECTION	NO_SETID	13
Calcium channel blockers may also have an additive effect when given with TENORMIN .
1	0	6	B-DYN	Calcium
2	8	14	I-DYN	channel
3	16	23	L-DYN	blockers
4	25	27	O	may
5	29	32	O	also
6	34	37	O	have
7	39	40	O	an
8	42	49	O	additive
9	51	56	O	effect
10	58	61	O	when
11	63	67	O	given
12	69	72	O	with
13	74	81	O	XXXXXXXX
NULL

Atenolol	DDI-DrugBank.d73.s3	NO_SECTION	NO_SETID	14
Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.
1	0	3	B-UNK	Beta
2	5	12	L-UNK	blockers
3	14	16	O	may
4	18	27	O	exacerbate
5	29	31	O	the
6	33	39	O	rebound
7	41	52	O	hypertension
8	54	58	O	which
9	60	62	O	can
10	64	69	O	follow
11	71	73	O	the
12	75	84	O	withdrawal
13	86	87	O	of
14	89	97	U-UNK	clonidine
NULL

Atenolol	DDI-DrugBank.d73.s4	NO_SECTION	NO_SETID	21
If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.
1	0	1	O	If
2	3	5	O	the
3	7	9	O	two
4	11	15	O	drugs
5	17	19	O	are
6	21	34	O	coadministered
7	35	35	O	,
8	37	39	O	the
9	41	44	B-UNK	beta
10	46	52	L-UNK	blocker
11	54	59	O	should
12	61	62	O	be
13	64	72	O	withdrawn
14	74	80	O	several
15	82	85	O	days
16	87	92	O	before
17	94	96	O	the
18	98	104	O	gradual
19	106	115	O	withdrawal
20	117	118	O	of
21	120	128	U-UNK	clonidine
NULL

Atenolol	DDI-DrugBank.d73.s5	NO_SECTION	NO_SETID	24
If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.
1	0	1	O	If
2	3	11	O	replacing
3	13	21	U-UNK	clonidine
4	23	24	O	by
5	26	29	B-UNK	beta
6	31	37	L-UNK	blocker
7	39	45	O	therapy
8	46	46	O	,
9	48	50	O	the
10	52	63	O	introduction
11	65	66	O	of
12	68	71	B-UNK	beta
13	73	80	L-UNK	blockers
14	82	87	O	should
15	89	90	O	be
16	92	98	O	delayed
17	100	102	O	for
18	104	110	O	several
19	112	115	O	days
20	117	121	O	after
21	123	131	U-UNK	clonidine
22	133	146	O	administration
23	148	150	O	has
24	152	158	O	stopped
NULL

Atenolol	DDI-DrugBank.d73.s6	NO_SECTION	NO_SETID	20
Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	31	O	prostaglandin
5	33	40	O	synthase
6	42	51	O	inhibiting
7	53	57	O	drugs
8	58	58	O	,
9	60	61	O	eg
10	62	62	O	,
11	64	75	U-UNK	indomethacin
12	76	76	O	,
13	78	80	O	may
14	82	89	O	decrease
15	91	93	O	the
16	95	105	O	hypotensive
17	107	113	O	effects
18	115	116	O	of
19	118	121	B-UNK	beta
20	123	130	L-UNK	blockers
NULL

Atenolol	DDI-DrugBank.d73.s7	NO_SECTION	NO_SETID	10
Information on concurrent usage of atenolol and aspirin is limited.
1	0	10	O	Information
2	12	13	O	on
3	15	24	O	concurrent
4	26	30	O	usage
5	32	33	O	of
6	35	42	U-UNK	atenolol
7	44	46	O	and
8	48	54	O	XXXXXXXX
9	56	57	O	is
10	59	65	O	limited
NULL

Atenolol	DDI-DrugBank.d73.s8	NO_SECTION	NO_SETID	31
Data from several studies, ie, TIMI-II, ISIS-2, currently do not suggest any clinical interaction between aspirin and beta blockers in the acute myocardial infarction setting.
1	0	3	O	Data
2	5	8	O	from
3	10	16	O	several
4	18	24	O	studies
5	25	25	O	,
6	27	28	O	ie
7	29	29	O	,
8	31	34	O	TIMI
9	36	37	O	II
10	38	38	O	,
11	40	43	O	ISIS
12	45	45	O	2
13	46	46	O	,
14	48	56	O	currently
15	58	59	O	do
16	61	63	O	not
17	65	71	O	suggest
18	73	75	O	any
19	77	84	O	clinical
20	86	96	O	interaction
21	98	104	O	between
22	106	112	O	XXXXXXXX
23	114	116	O	and
24	118	121	B-UNK	beta
25	123	130	L-UNK	blockers
26	132	133	O	in
27	135	137	O	the
28	139	143	O	acute
29	145	154	O	myocardial
30	156	165	O	infarction
31	167	173	O	setting
NULL

Atenolol	DDI-DrugBank.d73.s9	NO_SECTION	NO_SETID	33
While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge, either accidental, diagnostic or therapeutic.
1	0	4	O	While
2	6	11	O	taking
3	13	16	B-UNK	beta
4	18	25	L-UNK	blockers
5	26	26	O	,
6	28	35	O	patients
7	37	40	O	with
8	42	42	O	a
9	44	50	O	history
10	52	53	O	of
11	55	66	O	anaphylactic
12	68	75	O	reaction
13	77	78	O	to
14	80	80	O	a
15	82	88	O	variety
16	90	91	O	of
17	93	101	O	allergens
18	103	105	O	may
19	107	110	O	have
20	112	112	O	a
21	114	117	O	more
22	119	124	O	severe
23	126	133	O	reaction
24	135	136	O	on
25	138	145	O	repeated
26	147	155	O	challenge
27	156	156	O	,
28	158	163	O	either
29	165	174	O	accidental
30	175	175	O	,
31	177	186	O	diagnostic
32	188	189	O	or
33	191	201	O	therapeutic
NULL

Atenolol	DDI-DrugBank.d73.s10	NO_SECTION	NO_SETID	17
Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction.
1	0	3	O	Such
2	5	12	O	patients
3	14	16	O	may
4	18	19	O	be
5	21	32	O	unresponsive
6	34	35	O	to
7	37	39	O	the
8	41	45	O	usual
9	47	51	O	doses
10	53	54	O	of
11	56	66	U-UNK	epinephrine
12	68	71	O	used
13	73	74	O	to
14	76	80	O	treat
15	82	84	O	the
16	86	93	O	allergic
17	95	102	O	reaction
NULL

Atomoxetine	DDI-DrugBank.d11.s0	NO_SECTION	NO_SETID	46
Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	21	O	Interactions
4	23	31	U-UNK	Albuterol
5	35	43	O	XXXXXXXX
6	45	50	O	should
7	52	53	O	be
8	55	66	O	administered
9	68	71	O	with
10	73	79	O	caution
11	81	82	O	to
12	84	91	O	patients
13	93	97	O	being
14	99	105	O	treated
15	107	110	O	with
16	112	123	O	systemically
17	125	136	O	administered
18	139	142	O	oral
19	144	145	O	or
20	147	157	O	intravenous
21	160	168	U-DYN	albuterol
22	171	172	O	or
23	174	178	O	other
24	180	184	B-UNK	beta2
25	186	193	L-UNK	agonists
26	196	202	O	because
27	204	206	O	the
28	208	213	O	action
29	215	216	O	of
30	218	226	U-UNK	albuterol
31	228	229	O	on
32	231	233	O	the
33	235	248	O	cardiovascular
34	250	255	O	system
35	257	259	O	can
36	261	262	O	be
37	264	274	O	potentiated
38	276	284	O	resulting
39	286	287	O	in
40	289	297	O	increases
41	299	300	O	in
42	302	306	O	heart
43	308	311	O	rate
44	313	315	O	and
45	317	321	O	blood
46	323	330	O	pressure
NULL

Atomoxetine	DDI-DrugBank.d11.s1	NO_SECTION	NO_SETID	14
CYP2D6 inhibitors - Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine.
1	0	5	O	CYP2D6
2	7	16	O	inhibitors
3	20	30	O	XXXXXXXX
4	32	33	O	is
5	35	43	O	primarily
6	45	55	O	metabolized
7	57	58	O	by
8	60	62	O	the
9	64	69	O	CYP2D6
10	71	77	O	pathway
11	79	80	O	to
12	82	82	O	4
13	84	90	O	hydroxy
14	91	101	O	XXXXXXXX
NULL

Atomoxetine	DDI-DrugBank.d11.s2	NO_SECTION	NO_SETID	21
In EMs, selective inhibitors of CYP2D6 increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in PMs.
1	0	1	O	In
2	3	5	O	EMs
3	6	6	O	,
4	8	16	O	selective
5	18	27	O	inhibitors
6	29	30	O	of
7	32	37	O	CYP2D6
8	39	46	O	increase
9	48	58	O	XXXXXXXX
10	60	65	O	steady
11	67	71	O	state
12	73	78	O	plasma
13	80	93	O	concentrations
14	95	96	O	to
15	98	106	O	exposures
16	108	114	O	similar
17	116	117	O	to
18	119	123	O	those
19	125	132	O	observed
20	134	135	O	in
21	137	139	O	PMs
NULL

Atomoxetine	DDI-DrugBank.d11.s3	NO_SECTION	NO_SETID	21
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.
1	0	5	O	Dosage
2	7	16	O	adjustment
3	18	19	O	of
4	21	29	O	XXXXXXXX
5	31	33	O	may
6	35	36	O	be
7	38	46	O	necessary
8	48	51	O	when
9	53	66	O	coadministered
10	68	71	O	with
11	73	78	O	CYP2D6
12	80	89	O	inhibitors
13	90	90	O	,
14	92	94	O	e.g
15	96	96	O	,
16	98	107	U-DYN	paroxetine
17	108	108	O	,
18	110	119	U-DYN	fluoxetine
19	120	120	O	,
20	122	124	O	and
21	126	134	U-DYN	quinidine
NULL

Atomoxetine	DDI-DrugBank.d11.s4	NO_SECTION	NO_SETID	31
In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
1	0	1	O	In
2	3	4	O	EM
3	6	16	O	individuals
4	18	24	O	treated
5	26	29	O	with
6	31	40	U-KIN	paroxetine
7	42	43	O	or
8	45	54	U-KIN	fluoxetine
9	55	55	O	,
10	57	59	O	the
11	61	63	O	AUC
12	65	66	O	of
13	68	78	O	XXXXXXXX
14	80	81	O	is
15	83	95	O	approximately
16	97	97	O	6
17	100	101	O	to
18	103	103	O	8
19	105	108	O	fold
20	110	112	O	and
21	114	120	O	Css,max
22	122	123	O	is
23	125	129	O	about
24	131	131	O	3
25	134	135	O	to
26	137	137	O	4
27	139	142	O	fold
28	144	150	O	greater
29	152	155	O	than
30	157	167	O	XXXXXXXX
31	169	173	O	alone
NULL

Atomoxetine	DDI-DrugBank.d11.s5	NO_SECTION	NO_SETID	20
In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	23	O	suggest
5	25	28	O	that
6	30	45	O	coadministration
7	47	48	O	of
8	50	59	O	cytochrome
9	61	64	O	P450
10	66	75	O	inhibitors
11	77	78	O	to
12	80	82	O	PMs
13	84	87	O	will
14	89	91	O	not
15	93	100	O	increase
16	102	104	O	the
17	106	111	O	plasma
18	113	126	O	concentrations
19	128	129	O	of
20	131	141	O	XXXXXXXX
NULL

Atomoxetine	DDI-DrugBank.d11.s6	NO_SECTION	NO_SETID	18
Pressor agents - Because of possible effects on blood pressure, STRATTERA should be used cautiously with pressor agents.
1	0	6	O	Pressor
2	8	13	O	agents
3	17	23	O	Because
4	25	26	O	of
5	28	35	O	possible
6	37	43	O	effects
7	45	46	O	on
8	48	52	O	blood
9	54	61	O	pressure
10	62	62	O	,
11	64	72	O	XXXXXXXX
12	74	79	O	should
13	81	82	O	be
14	84	87	O	used
15	89	98	O	cautiously
16	100	103	O	with
17	105	111	O	pressor
18	113	118	O	agents
NULL

Atorvastatin	DDI-DrugBank.d140.s0	NO_SECTION	NO_SETID	31
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic acid), erythromycin, azole antifungals.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	O	myopathy
5	21	26	O	during
6	28	36	O	treatment
7	38	41	O	with
8	43	47	O	drugs
9	49	50	O	of
10	52	55	O	this
11	57	61	O	class
12	63	64	O	is
13	66	74	O	increased
14	76	79	O	with
15	81	90	O	concurrent
16	92	105	O	administration
17	107	108	O	of
18	110	121	U-UNK	cyclosporine
19	122	122	O	,
20	124	129	B-UNK	fibric
21	131	134	I-UNK	acid
22	136	146	L-UNK	derivatives
23	147	147	O	,
24	149	154	U-UNK	niacin
25	157	165	B-UNK	nicotinic
26	167	170	L-UNK	acid
27	172	172	O	,
28	174	185	U-UNK	erythromycin
29	186	186	O	,
30	188	192	B-UNK	azole
31	194	204	L-UNK	antifungals
NULL

Atorvastatin	DDI-DrugBank.d140.s1	NO_SECTION	NO_SETID	17
Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.
1	0	6	U-UNK	Antacid
2	7	7	O	:
3	9	12	O	When
4	14	25	U-KIN	atorvastatin
5	27	29	O	and
6	31	39	O	XXXXXXXX
7	41	50	O	suspension
8	52	55	O	were
9	57	70	O	coadministered
10	71	71	O	,
11	73	78	O	plasma
12	80	93	O	concentrations
13	95	96	O	of
14	98	109	U-UNK	atorvastatin
15	111	119	O	decreased
16	121	133	O	approximately
17	135	137	O	35%
NULL

Atorvastatin	DDI-DrugBank.d140.s2	NO_SECTION	NO_SETID	8
However, LDL-C reduction was not altered.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	LDL
4	13	13	O	C
5	15	23	O	reduction
6	25	27	O	was
7	29	31	O	not
8	33	39	O	altered
NULL

Atorvastatin	DDI-DrugBank.d140.s3	NO_SECTION	NO_SETID	25
Antipyrine: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.
1	0	9	U-UNK	Antipyrine
2	10	10	O	:
3	12	18	O	Because
4	20	31	O	XXXXXXXX
5	33	36	O	does
6	38	40	O	not
7	42	47	O	affect
8	49	51	O	the
9	53	68	O	pharmacokinetics
10	70	71	O	of
11	73	82	U-UNK	antipyrine
12	83	83	O	,
13	85	96	O	interactions
14	98	101	O	with
15	103	107	O	other
16	109	113	U-UNK	drugs
17	115	125	O	metabolized
18	127	129	O	via
19	131	133	O	the
20	135	138	O	same
21	140	149	O	cytochrome
22	151	158	O	isozymes
23	160	162	O	are
24	164	166	O	not
25	168	175	O	expected
NULL

Atorvastatin	DDI-DrugBank.d140.s4	NO_SECTION	NO_SETID	15
Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered.
1	0	9	U-UNK	Colestipol
2	10	10	O	:
3	12	17	O	Plasma
4	19	32	O	concentrations
5	34	35	O	of
6	37	48	O	XXXXXXXX
7	50	58	O	decreased
8	60	72	O	approximately
9	74	76	O	25%
10	78	81	O	when
11	83	92	U-KIN	colestipol
12	94	96	O	and
13	98	109	O	XXXXXXXX
14	111	114	O	were
15	116	129	O	coadministered
NULL

Atorvastatin	DDI-DrugBank.d140.s5	NO_SECTION	NO_SETID	20
However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	LDL
4	13	13	O	C
5	15	23	O	reduction
6	25	27	O	was
7	29	35	O	greater
8	37	40	O	when
9	42	53	O	XXXXXXXX
10	55	57	O	and
11	59	68	U-DYN	colestipol
12	70	73	O	were
13	75	88	O	coadministered
14	90	93	O	than
15	95	98	O	when
16	100	105	O	either
17	107	110	O	drug
18	112	114	O	was
19	116	120	O	given
20	122	126	O	alone
NULL

Atorvastatin	DDI-DrugBank.d140.s6	NO_SECTION	NO_SETID	16
Cimetidine: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.
1	0	9	U-UNK	Cimetidine
2	10	10	O	:
3	12	23	O	XXXXXXXX
4	25	30	O	plasma
5	32	45	O	concentrations
6	47	49	O	and
7	51	53	O	LDL
8	55	55	O	C
9	57	65	O	reduction
10	67	70	O	were
11	72	74	O	not
12	76	82	O	altered
13	84	85	O	by
14	87	102	O	coadministration
15	104	105	O	of
16	107	116	U-UNK	cimetidine
NULL

Atorvastatin	DDI-DrugBank.d140.s7	NO_SECTION	NO_SETID	21
Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	12	O	When
4	14	21	O	multiple
5	23	27	O	doses
6	29	30	O	of
7	32	43	O	XXXXXXXX
8	45	47	O	and
9	49	55	U-KIN	digoxin
10	57	60	O	were
11	62	75	O	coadministered
12	76	76	O	,
13	78	83	O	steady
14	85	89	O	state
15	91	96	O	plasma
16	98	104	U-UNK	digoxin
17	106	119	O	concentrations
18	121	129	O	increased
19	131	132	O	by
20	134	146	O	approximately
21	148	150	O	20%
NULL

Atorvastatin	DDI-DrugBank.d140.s8	NO_SECTION	NO_SETID	7
Patients taking digoxin should be monitored appropriately.
1	0	7	O	Patients
2	9	14	O	taking
3	16	22	U-UNK	digoxin
4	24	29	O	should
5	31	32	O	be
6	34	42	O	monitored
7	44	56	O	appropriately
NULL

Atorvastatin	DDI-DrugBank.d140.s9	NO_SECTION	NO_SETID	27
Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
1	0	11	U-UNK	Erythromycin
2	12	12	O	:
3	14	15	O	In
4	17	23	O	healthy
5	25	35	O	individuals
6	36	36	O	,
7	38	43	O	plasma
8	45	58	O	concentrations
9	60	61	O	of
10	63	74	O	XXXXXXXX
11	76	84	O	increased
12	86	98	O	approximately
13	100	102	O	40%
14	104	107	O	with
15	109	124	O	coadministration
16	126	127	O	of
17	129	140	O	XXXXXXXX
18	142	144	O	and
19	146	157	U-KIN	erythromycin
20	158	158	O	,
21	160	160	O	a
22	162	166	O	known
23	168	176	O	inhibitor
24	178	179	O	of
25	181	190	O	cytochrome
26	192	195	O	P450
27	197	199	O	3A4
NULL

Atorvastatin	DDI-DrugBank.d140.s10	NO_SECTION	NO_SETID	23
Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.
1	0	3	O	Oral
2	5	18	U-UNK	Contraceptives
3	19	19	O	:
4	21	36	O	Coadministration
5	38	39	O	of
6	41	52	O	XXXXXXXX
7	54	56	O	and
8	58	59	O	an
9	61	64	O	oral
10	66	78	U-KIN	contraceptive
11	80	88	O	increased
12	90	92	O	AUC
13	94	99	O	values
14	101	103	O	for
15	105	117	U-KIN	norethindrone
16	119	121	O	and
17	123	129	B-KIN	ethinyl
18	131	139	L-KIN	estradiol
19	141	142	O	by
20	144	156	O	approximately
21	158	160	O	30%
22	162	164	O	and
23	166	168	O	20%
NULL

Atorvastatin	DDI-DrugBank.d140.s11	NO_SECTION	NO_SETID	15
These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin.
1	0	4	O	These
2	6	14	O	increases
3	16	21	O	should
4	23	24	O	be
5	26	35	O	considered
6	37	40	O	when
7	42	50	O	selecting
8	52	53	O	an
9	55	58	O	oral
10	60	72	U-DYN	contraceptive
11	74	76	O	for
12	78	78	O	a
13	80	84	O	woman
14	86	91	O	taking
15	93	104	O	XXXXXXXX
NULL

Atorvastatin	DDI-DrugBank.d140.s12	NO_SECTION	NO_SETID	19
Warfarin: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	21	O	XXXXXXXX
4	23	25	O	had
5	27	28	O	no
6	30	39	O	clinically
7	41	51	O	significant
8	53	58	O	effect
9	60	61	O	on
10	63	73	O	prothrombin
11	75	78	O	time
12	80	83	O	when
13	85	96	O	administered
14	98	99	O	to
15	101	108	O	patients
16	110	118	O	receiving
17	120	126	O	chronic
18	128	135	U-UNK	warfarin
19	137	145	O	treatment
NULL

Atorvastatin	DDI-DrugBank.d140.s13	NO_SECTION	NO_SETID	21
Endocrine Function HMG-CoA reductase inhibitors interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production.
1	0	8	O	Endocrine
2	10	17	O	Function
3	19	21	B-UNK	HMG
4	23	25	I-UNK	CoA
5	27	35	I-UNK	reductase
6	37	46	L-UNK	inhibitors
7	48	56	O	interfere
8	58	61	O	with
9	63	73	O	cholesterol
10	75	83	O	synthesis
11	85	87	O	and
12	89	101	O	theoretically
13	103	107	O	might
14	109	113	O	blunt
15	115	121	O	adrenal
16	123	125	O	and
17	126	126	O	/
18	127	128	O	or
19	130	136	O	gonadal
20	138	144	O	steroid
21	146	155	O	production
NULL

Atorvastatin	DDI-DrugBank.d140.s14	NO_SECTION	NO_SETID	17
Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve.
1	0	7	O	Clinical
2	9	15	O	studies
3	17	20	O	have
4	22	26	O	shown
5	28	31	O	that
6	33	44	O	XXXXXXXX
7	46	49	O	does
8	51	53	O	not
9	55	60	O	reduce
10	62	66	O	basal
11	68	73	O	plasma
12	75	82	O	cortisol
13	84	96	O	concentration
14	98	99	O	or
15	101	106	O	impair
16	108	114	O	adrenal
17	116	122	O	reserve
NULL

Atorvastatin	DDI-DrugBank.d140.s15	NO_SECTION	NO_SETID	19
The effects of HMG-CoA reductase inhibitors on male fertility have not been studied in adequate numbers of patients.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	17	B-UNK	HMG
5	19	21	I-UNK	CoA
6	23	31	I-UNK	reductase
7	33	42	L-UNK	inhibitors
8	44	45	O	on
9	47	50	O	male
10	52	60	O	fertility
11	62	65	O	have
12	67	69	O	not
13	71	74	O	been
14	76	82	O	studied
15	84	85	O	in
16	87	94	O	adequate
17	96	102	O	numbers
18	104	105	O	of
19	107	114	O	patients
NULL

Atorvastatin	DDI-DrugBank.d140.s16	NO_SECTION	NO_SETID	16
The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown.
1	0	2	O	The
2	4	10	O	effects
3	11	11	O	,
4	13	14	O	if
5	16	18	O	any
6	19	19	O	,
7	21	22	O	on
8	24	26	O	the
9	28	36	O	pituitary
10	38	44	O	gonadal
11	46	49	O	axis
12	51	52	O	in
13	54	66	O	premenopausal
14	68	72	O	women
15	74	76	O	are
16	78	84	O	unknown
NULL

Atorvastatin	DDI-DrugBank.d140.s17	NO_SECTION	NO_SETID	35
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	29	O	if
6	31	32	O	an
7	34	36	B-UNK	HMG
8	38	40	I-UNK	CoA
9	42	50	I-UNK	reductase
10	52	60	L-UNK	inhibitor
11	62	63	O	is
12	65	76	O	administered
13	78	90	O	concomitantly
14	92	95	O	with
15	97	101	O	drugs
16	103	106	O	that
17	108	110	O	may
18	112	119	O	decrease
19	121	123	O	the
20	125	130	O	levels
21	132	133	O	or
22	135	142	O	activity
23	144	145	O	of
24	147	156	O	endogenous
25	158	164	O	steroid
26	166	173	O	hormones
27	174	174	O	,
28	176	179	O	such
29	181	182	O	as
30	184	195	U-UNK	ketoconazole
31	196	196	O	,
32	198	211	U-UNK	spironolactone
33	212	212	O	,
34	214	216	O	and
35	218	227	U-UNK	cimetidine
NULL

Atorvastatin	DDI-DrugBank.d140.s18	NO_SECTION	NO_SETID	21
CNS Toxicity Brain hemorrhage was seen in a female dog treated for 3 months at 120 mg/kg/day.
1	0	2	O	CNS
2	4	11	O	Toxicity
3	13	17	O	Brain
4	19	28	O	hemorrhage
5	30	32	O	was
6	34	37	O	seen
7	39	40	O	in
8	42	42	O	a
9	44	49	O	female
10	51	53	O	dog
11	55	61	O	treated
12	63	65	O	for
13	67	67	O	3
14	69	74	O	months
15	76	77	O	at
16	79	81	O	120
17	83	84	O	mg
18	85	85	O	/
19	86	87	O	kg
20	88	88	O	/
21	89	91	O	day
NULL

Atorvastatin	DDI-DrugBank.d140.s19	NO_SECTION	NO_SETID	32
Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day.
1	0	4	O	Brain
2	6	15	O	hemorrhage
3	17	19	O	and
4	21	25	O	optic
5	27	31	O	nerve
6	33	43	O	vacuolation
7	45	48	O	were
8	50	53	O	seen
9	55	56	O	in
10	58	64	O	another
11	66	71	O	female
12	73	75	O	dog
13	77	80	O	that
14	82	84	O	was
15	86	95	O	sacrificed
16	97	98	O	in
17	100	107	O	moribund
18	109	117	O	condition
19	119	123	O	after
20	125	126	O	11
21	128	132	O	weeks
22	134	135	O	of
23	137	146	O	escalating
24	148	152	O	doses
25	154	155	O	up
26	157	158	O	to
27	160	162	O	280
28	164	165	O	mg
29	166	166	O	/
30	167	168	O	kg
31	169	169	O	/
32	170	172	O	day
NULL

Atorvastatin	DDI-DrugBank.d140.s20	NO_SECTION	NO_SETID	37
The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0-24 hours) based on the maximum human dose of 80 mg/day.
1	0	2	O	The
2	4	6	O	120
3	8	9	O	mg
4	10	10	O	/
5	11	12	O	kg
6	14	17	O	dose
7	19	26	O	resulted
8	28	29	O	in
9	31	31	O	a
10	33	40	O	systemic
11	42	49	O	exposure
12	51	63	O	approximately
13	65	66	O	16
14	68	72	O	times
15	74	76	O	the
16	78	82	O	human
17	84	89	O	plasma
18	91	94	O	area
19	96	100	O	under
20	102	104	O	the
21	106	110	O	curve
22	113	115	O	AUC
23	116	116	O	,
24	118	118	O	0
25	120	121	O	24
26	123	127	O	hours
27	130	134	O	based
28	136	137	O	on
29	139	141	O	the
30	143	149	O	maximum
31	151	155	O	human
32	157	160	O	dose
33	162	163	O	of
34	165	166	O	80
35	168	169	O	mg
36	170	170	O	/
37	171	173	O	day
NULL

Atorvastatin	DDI-DrugBank.d140.s21	NO_SECTION	NO_SETID	35
A single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study.
1	0	0	O	A
2	2	7	O	single
3	9	13	O	tonic
4	15	24	O	convulsion
5	26	28	O	was
6	30	33	O	seen
7	35	36	O	in
8	38	41	O	each
9	43	44	O	of
10	46	46	O	2
11	48	51	O	male
12	53	56	O	dogs
13	59	61	O	one
14	63	69	O	treated
15	71	72	O	at
16	74	75	O	10
17	77	78	O	mg
18	79	79	O	/
19	80	81	O	kg
20	82	82	O	/
21	83	85	O	day
22	87	89	O	and
23	91	93	O	one
24	95	96	O	at
25	98	100	O	120
26	102	103	O	mg
27	104	104	O	/
28	105	106	O	kg
29	107	107	O	/
30	108	110	O	day
31	113	114	O	in
32	116	116	O	a
33	118	118	O	2
34	120	123	O	year
35	125	129	O	study
NULL

Atorvastatin	DDI-DrugBank.d140.s22	NO_SECTION	NO_SETID	39
No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day.
1	0	1	O	No
2	3	5	O	CNS
3	7	13	O	lesions
4	15	18	O	have
5	20	23	O	been
6	25	32	O	observed
7	34	35	O	in
8	37	40	O	mice
9	42	46	O	after
10	48	54	O	chronic
11	56	64	O	treatment
12	66	68	O	for
13	70	71	O	up
14	73	74	O	to
15	76	76	O	2
16	78	82	O	years
17	84	85	O	at
18	87	91	O	doses
19	93	94	O	up
20	96	97	O	to
21	99	101	O	400
22	103	104	O	mg
23	105	105	O	/
24	106	107	O	kg
25	108	108	O	/
26	109	111	O	day
27	113	114	O	or
28	116	117	O	in
29	119	122	O	rats
30	124	125	O	at
31	127	131	O	doses
32	133	134	O	up
33	136	137	O	to
34	139	141	O	100
35	143	144	O	mg
36	145	145	O	/
37	146	147	O	kg
38	148	148	O	/
39	149	151	O	day
NULL

Atorvastatin	DDI-DrugBank.d140.s23	NO_SECTION	NO_SETID	31
These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0-24) based on the maximum recommended human dose of 80 mg/day.
1	0	4	O	These
2	6	10	O	doses
3	12	15	O	were
4	17	17	O	6
5	19	20	O	to
6	22	23	O	11
7	25	29	O	times
8	32	36	O	mouse
9	39	41	O	and
10	43	43	O	8
11	45	46	O	to
12	48	49	O	16
13	51	55	O	times
14	58	60	O	rat
15	63	65	O	the
16	67	71	O	human
17	73	75	O	AUC
18	78	78	O	0
19	80	81	O	24
20	84	88	O	based
21	90	91	O	on
22	93	95	O	the
23	97	103	O	maximum
24	105	115	O	recommended
25	117	121	O	human
26	123	126	O	dose
27	128	129	O	of
28	131	132	O	80
29	134	135	O	mg
30	136	136	O	/
31	137	139	O	day
NULL

Atorvastatin	DDI-DrugBank.d140.s24	NO_SECTION	NO_SETID	31
CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this class.
1	0	2	O	CNS
2	4	11	O	vascular
3	13	19	O	lesions
4	20	20	O	,
5	22	34	O	characterized
6	36	37	O	by
7	39	50	O	perivascular
8	52	62	O	hemorrhages
9	63	63	O	,
10	65	69	O	edema
11	70	70	O	,
12	72	74	O	and
13	76	86	O	mononuclear
14	88	91	O	cell
15	93	104	O	infiltration
16	106	107	O	of
17	109	120	O	perivascular
18	122	127	O	spaces
19	128	128	O	,
20	130	133	O	have
21	135	138	O	been
22	140	147	O	observed
23	149	150	O	in
24	152	155	O	dogs
25	157	163	O	treated
26	165	168	O	with
27	170	174	O	other
28	176	182	O	members
29	184	185	O	of
30	187	190	O	this
31	192	196	O	class
NULL

Atorvastatin	DDI-DrugBank.d140.s25	NO_SECTION	NO_SETID	49
A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose.
1	0	0	O	A
2	2	11	O	chemically
3	13	19	O	similar
4	21	24	O	drug
5	26	27	O	in
6	29	32	O	this
7	34	38	O	class
8	40	47	O	produced
9	49	53	O	optic
10	55	59	O	nerve
11	61	72	O	degeneration
12	75	83	O	Wallerian
13	85	96	O	degeneration
14	98	99	O	of
15	101	116	O	retinogeniculate
16	118	123	O	fibers
17	126	127	O	in
18	129	138	O	clinically
19	140	145	O	normal
20	147	150	O	dogs
21	152	153	O	in
22	155	155	O	a
23	157	160	O	dose
24	162	170	O	dependent
25	172	178	O	fashion
26	180	181	O	at
27	183	183	O	a
28	185	188	O	dose
29	190	193	O	that
30	195	202	O	produced
31	204	209	O	plasma
32	211	214	O	drug
33	216	221	O	levels
34	223	227	O	about
35	229	230	O	30
36	232	236	O	times
37	238	243	O	higher
38	245	248	O	than
39	250	252	O	the
40	254	257	O	mean
41	259	262	O	drug
42	264	268	O	level
43	270	271	O	in
44	273	278	O	humans
45	280	285	O	taking
46	287	289	O	the
47	291	297	O	highest
48	299	309	O	recommended
49	311	314	O	dose
NULL

Atovaquone	DDI-DrugBank.d424.s0	NO_SECTION	NO_SETID	8
Atovaquone is highly bound to plasma protein (99.9%).
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	19	O	highly
4	21	25	O	bound
5	27	28	O	to
6	30	35	O	plasma
7	37	43	O	protein
8	46	50	O	99.9%
NULL

Atovaquone	DDI-DrugBank.d424.s1	NO_SECTION	NO_SETID	29
Therefore, caution should be used when administering MEPRON concurrently with other highly plasma protein- bound drugs with narrow therapeutic indices, as competition for binding sites may occur.
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	O	caution
4	19	24	O	should
5	26	27	O	be
6	29	32	O	used
7	34	37	O	when
8	39	51	O	administering
9	53	58	O	XXXXXXXX
10	60	71	O	concurrently
11	73	76	O	with
12	78	82	O	other
13	84	89	O	highly
14	91	96	O	plasma
15	98	104	O	protein
16	107	111	O	bound
17	113	117	O	drugs
18	119	122	O	with
19	124	129	O	narrow
20	131	141	O	therapeutic
21	143	149	O	indices
22	150	150	O	,
23	152	153	O	as
24	155	165	O	competition
25	167	169	O	for
26	171	177	O	binding
27	179	183	O	sites
28	185	187	O	may
29	189	193	O	occur
NULL

Atovaquone	DDI-DrugBank.d424.s2	NO_SECTION	NO_SETID	39
The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of phenytoin (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of atovaquone.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	of
4	14	19	O	plasma
5	21	27	O	protein
6	29	35	O	binding
7	37	38	O	of
8	40	49	O	XXXXXXXX
9	51	52	O	in
10	54	58	O	human
11	60	65	O	plasma
12	67	68	O	is
13	70	72	O	not
14	74	81	O	affected
15	83	84	O	by
16	86	88	O	the
17	90	97	O	presence
18	99	100	O	of
19	102	112	O	therapeutic
20	114	127	O	concentrations
21	129	130	O	of
22	132	140	U-UNK	phenytoin
23	143	144	O	15
24	146	148	O	mcg
25	149	149	O	/
26	151	152	O	mL
27	154	154	O	,
28	156	158	O	nor
29	160	161	O	is
30	163	165	O	the
31	167	173	O	binding
32	175	176	O	of
33	178	186	U-UNK	phenytoin
34	188	195	O	affected
35	197	198	O	by
36	200	202	O	the
37	204	211	O	presence
38	213	214	O	of
39	216	225	O	XXXXXXXX
NULL

Atovaquone	DDI-DrugBank.d424.s3	NO_SECTION	NO_SETID	20
Rifampin: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.
1	0	7	U-UNK	Rifampin
2	8	8	O	:
3	10	25	O	Coadministration
4	27	28	O	of
5	30	37	U-KIN	rifampin
6	39	41	O	and
7	43	48	O	XXXXXXXX
8	50	59	O	Suspension
9	61	67	O	results
10	69	70	O	in
11	72	72	O	a
12	74	84	O	significant
13	86	93	O	decrease
14	95	96	O	in
15	98	104	O	average
16	106	111	O	steady
17	114	118	O	state
18	120	125	O	plasma
19	127	136	U-UNK	atovaquone
20	138	151	O	concentrations
NULL

Atovaquone	DDI-DrugBank.d424.s4	NO_SECTION	NO_SETID	14
Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON.
1	0	11	O	Alternatives
2	13	14	O	to
3	16	23	U-DYN	rifampin
4	25	30	O	should
5	32	33	O	be
6	35	44	O	considered
7	46	51	O	during
8	53	55	O	the
9	57	62	O	course
10	64	65	O	of
11	67	69	O	PCP
12	71	79	O	treatment
13	81	84	O	with
14	86	91	O	XXXXXXXX
NULL

Atovaquone	DDI-DrugBank.d424.s5	NO_SECTION	NO_SETID	22
Rifabutin, another rifamycin, is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin.
1	0	8	U-UNK	Rifabutin
2	9	9	O	,
3	11	17	O	another
4	19	27	U-UNK	rifamycin
5	28	28	O	,
6	30	31	O	is
7	33	44	O	structurally
8	46	52	O	similar
9	54	55	O	to
10	57	64	U-UNK	rifampin
11	66	68	O	and
12	70	72	O	may
13	74	81	O	possibly
14	83	86	O	have
15	88	91	O	some
16	93	94	O	of
17	96	98	O	the
18	100	103	O	same
19	105	108	O	drug
20	110	121	O	interactions
21	123	124	O	as
22	126	133	U-UNK	rifampin
NULL

Atovaquone	DDI-DrugBank.d424.s6	NO_SECTION	NO_SETID	10
No interaction trials have been conducted with MEPRON and rifabutin.
1	0	1	O	No
2	3	13	O	interaction
3	15	20	O	trials
4	22	25	O	have
5	27	30	O	been
6	32	40	O	conducted
7	42	45	O	with
8	47	52	O	XXXXXXXX
9	54	56	O	and
10	58	66	U-UNK	rifabutin
NULL

Atovaquone	DDI-DrugBank.d424.s7	NO_SECTION	NO_SETID	20
Drug/ Laboratory Test Interactions: It is not known if MEPRON interferes with clinical laboratory test or assay results.
1	0	3	O	Drug
2	4	4	O	/
3	6	15	O	Laboratory
4	17	20	O	Test
5	22	33	O	Interactions
6	34	34	O	:
7	36	37	O	It
8	39	40	O	is
9	42	44	O	not
10	46	50	O	known
11	52	53	O	if
12	55	60	O	XXXXXXXX
13	62	71	O	interferes
14	73	76	O	with
15	78	85	O	clinical
16	87	96	O	laboratory
17	98	101	O	test
18	103	104	O	or
19	106	110	O	assay
20	112	118	O	results
NULL

Atracurium	DDI-DrugBank.d469.s0	NO_SECTION	NO_SETID	13
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;
1	0	4	O	Drugs
2	6	10	O	which
3	12	14	O	may
4	16	22	O	enhance
5	24	26	O	the
6	28	40	O	neuromuscular
7	42	49	O	blocking
8	51	56	O	action
9	58	59	O	of
10	61	68	O	XXXXXXXX
11	70	76	O	include
12	77	77	O	:
13	79	87	U-DYN	enflurane
NULL

Atracurium	DDI-DrugBank.d469.s3	NO_SECTION	NO_SETID	8
certain antibiotics, especially the aminoglycosides and polymyxins;
1	0	6	O	certain
2	8	18	U-UNK	antibiotics
3	19	19	O	,
4	21	30	O	especially
5	32	34	O	the
6	36	50	U-UNK	aminoglycosides
7	52	54	O	and
8	56	65	U-UNK	polymyxins
NULL

Atracurium	DDI-DrugBank.d469.s7	NO_SECTION	NO_SETID	22
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
1	0	4	O	Drugs
2	6	10	O	which
3	12	14	O	may
4	16	22	O	enhance
5	24	26	O	the
6	28	40	O	neuromuscular
7	42	49	O	blocking
8	51	56	O	action
9	58	59	O	of
10	61	68	O	XXXXXXXX
11	70	76	O	include
12	77	77	O	:
13	79	116	O	enflurane;isoflurane;halothane;certain
14	118	128	U-DYN	antibiotics
15	129	129	O	,
16	131	140	O	especially
17	142	144	O	the
18	146	160	U-DYN	aminoglycosides
19	162	164	O	and
20	166	193	O	polymyxins;lithium;magnesium
21	195	216	O	salts;procainamide;and
22	218	226	U-DYN	quinidine
NULL

Atracurium	DDI-DrugBank.d469.s8	NO_SECTION	NO_SETID	22
If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered.
1	0	1	O	If
2	3	7	O	other
3	9	14	B-UNK	muscle
4	16	24	L-UNK	relaxants
5	26	28	O	are
6	30	33	O	used
7	35	40	O	during
8	42	44	O	the
9	46	49	O	same
10	51	59	O	procedure
11	60	60	O	,
12	62	64	O	the
13	66	76	O	possibility
14	78	79	O	of
15	81	81	O	a
16	83	93	O	synergistic
17	95	96	O	or
18	98	107	O	antagonist
19	109	114	O	effect
20	116	121	O	should
21	123	124	O	be
22	126	135	O	considered
NULL

Atracurium	DDI-DrugBank.d469.s9	NO_SECTION	NO_SETID	27
The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by TRACRIUM.
1	0	2	O	The
2	4	8	O	prior
3	10	23	O	administration
4	25	26	O	of
5	28	42	U-DYN	succinylcholine
6	44	47	O	does
7	49	51	O	not
8	53	59	O	enhance
9	61	63	O	the
10	65	72	O	duration
11	73	73	O	,
12	75	77	O	but
13	79	86	O	quickens
14	88	90	O	the
15	92	96	O	onset
16	98	100	O	and
17	102	104	O	may
18	106	113	O	increase
19	115	117	O	the
20	119	123	O	depth
21	124	124	O	,
22	126	127	O	of
23	129	141	O	neuromuscular
24	143	147	O	block
25	149	155	O	induced
26	157	158	O	by
27	160	167	O	XXXXXXXX
NULL

Atracurium	DDI-DrugBank.d469.s10	NO_SECTION	NO_SETID	15
TRACRIUM should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block.
1	0	7	O	XXXXXXXX
2	9	14	O	should
3	16	18	O	not
4	20	21	O	be
5	23	34	O	administered
6	36	40	O	until
7	42	42	O	a
8	44	50	O	patient
9	52	54	O	has
10	56	64	O	recovered
11	66	69	O	from
12	71	85	U-DYN	succinylcholine
13	87	93	O	induced
14	95	107	O	neuromuscular
15	109	113	O	block
NULL

Atropine	DDI-DrugBank.d222.s0	NO_SECTION	NO_SETID	45
When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.
1	0	3	O	When
2	5	12	O	XXXXXXXX
3	14	16	O	and
4	18	28	U-DYN	pralidoxime
5	30	32	O	are
6	34	37	O	used
7	39	46	O	together
8	47	47	O	,
9	49	51	O	the
10	53	57	O	signs
11	59	60	O	of
12	62	75	O	atropinization
13	78	85	O	flushing
14	86	86	O	,
15	88	96	O	mydriasis
16	97	97	O	,
17	99	109	O	tachycardia
18	110	110	O	,
19	112	118	O	dryness
20	120	121	O	of
21	123	125	O	the
22	127	131	O	mouth
23	133	135	O	and
24	137	140	O	nose
25	143	145	O	may
26	147	151	O	occur
27	153	159	O	earlier
28	161	164	O	than
29	166	170	O	might
30	172	173	O	be
31	175	182	O	expected
32	184	187	O	than
33	189	192	O	when
34	194	201	O	XXXXXXXX
35	203	204	O	is
36	206	209	O	used
37	211	215	O	alone
38	217	223	O	because
39	225	235	U-DYN	pralidoxime
40	237	239	O	may
41	241	250	O	potentiate
42	252	254	O	the
43	256	261	O	effect
44	263	264	O	of
45	266	273	O	XXXXXXXX
NULL

Atropine	DDI-DrugBank.d222.s1	NO_SECTION	NO_SETID	27
The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.
1	0	2	O	The
2	4	12	O	following
3	14	24	O	precautions
4	26	31	O	should
5	33	34	O	be
6	36	39	O	kept
7	41	42	O	in
8	44	47	O	mind
9	49	50	O	in
10	52	54	O	the
11	56	64	O	treatment
12	66	67	O	of
13	69	86	O	anticholinesterase
14	88	96	O	poisoning
15	98	105	O	although
16	107	110	O	they
17	112	113	O	do
18	115	117	O	not
19	119	122	O	bear
20	124	131	O	directly
21	133	134	O	on
22	136	138	O	the
23	140	142	O	use
24	144	145	O	of
25	147	154	O	XXXXXXXX
26	156	158	O	and
27	160	170	U-DYN	pralidoxime
NULL

Atropine	DDI-DrugBank.d222.s2	NO_SECTION	NO_SETID	18
Since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions.
1	0	4	O	Since
2	6	17	U-UNK	barbiturates
3	19	21	O	are
4	23	33	O	potentiated
5	35	36	O	by
6	38	40	O	the
7	42	60	U-UNK	anticholinesterases
8	61	61	O	,
9	63	66	O	they
10	68	73	O	should
11	75	76	O	be
12	78	81	O	used
13	83	92	O	cautiously
14	94	95	O	in
15	97	99	O	the
16	101	109	O	treatment
17	111	112	O	of
18	114	124	O	convulsions
NULL

Auranofin	DDI-DrugBank.d374.s0	NO_SECTION	NO_SETID	21
Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.
1	0	8	U-DYN	Auranofin
2	10	15	O	should
3	17	18	O	be
4	20	26	O	avoided
5	28	29	O	by
6	31	38	O	patients
7	40	43	O	with
8	45	45	O	a
9	47	53	O	history
10	55	56	O	of
11	58	64	O	serious
12	66	73	O	reaction
13	75	76	O	to
14	78	80	O	any
15	82	85	B-UNK	gold
16	87	96	L-UNK	medication
17	97	97	O	,
18	99	107	O	including
19	109	116	O	Solganal
20	118	120	O	and
21	122	132	O	XXXXXXXX
NULL

Auranofin	DDI-DrugBank.d374.s1	NO_SECTION	NO_SETID	15
Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.
1	0	8	U-DYN	Auranofin
2	10	15	O	should
3	17	19	O	not
4	21	22	O	be
5	24	27	O	used
6	29	36	O	together
7	38	41	O	with
8	43	55	U-UNK	penicillamine
9	58	62	O	Depen
10	63	63	O	,
11	65	73	O	XXXXXXXX
12	75	75	O	,
13	77	83	O	another
14	85	93	O	arthritis
15	95	104	O	medication
NULL

Auranofin	DDI-DrugBank.d374.s2	NO_SECTION	NO_SETID	22
It should also be avoided in patients with blood, liver or kidney diseases, recent radiation treatment, or uncontrolled diabetes.
1	0	1	O	It
2	3	8	O	should
3	10	13	O	also
4	15	16	O	be
5	18	24	O	avoided
6	26	27	O	in
7	29	36	O	patients
8	38	41	O	with
9	43	47	O	blood
10	48	48	O	,
11	50	54	O	liver
12	56	57	O	or
13	59	64	O	kidney
14	66	73	O	diseases
15	74	74	O	,
16	76	81	O	recent
17	83	91	O	radiation
18	93	101	O	treatment
19	102	102	O	,
20	104	105	O	or
21	107	118	O	uncontrolled
22	120	127	O	diabetes
NULL

Auranofin	DDI-DrugBank.d374.s3	NO_SECTION	NO_SETID	21
Patients should report to their practitioners any new rashes, itching, mouth sores, or unusual taste while taking auranofin.
1	0	7	O	Patients
2	9	14	O	should
3	16	21	O	report
4	23	24	O	to
5	26	30	O	their
6	32	44	O	practitioners
7	46	48	O	any
8	50	52	O	new
9	54	59	O	rashes
10	60	60	O	,
11	62	68	O	itching
12	69	69	O	,
13	71	75	O	mouth
14	77	81	O	sores
15	82	82	O	,
16	84	85	O	or
17	87	93	O	unusual
18	95	99	O	taste
19	101	105	O	while
20	107	112	O	taking
21	114	122	O	XXXXXXXX
NULL

Auranofin	DDI-DrugBank.d374.s4	NO_SECTION	NO_SETID	7
Gold is excreted slowly from the body.
1	0	3	U-UNK	Gold
2	5	6	O	is
3	8	15	O	excreted
4	17	22	O	slowly
5	24	27	O	from
6	29	31	O	the
7	33	36	O	body
NULL

Auranofin	DDI-DrugBank.d374.s5	NO_SECTION	NO_SETID	9
Safety and effectiveness in children has not been established.
1	0	5	O	Safety
2	7	9	O	and
3	11	23	O	effectiveness
4	25	26	O	in
5	28	35	O	children
6	37	39	O	has
7	41	43	O	not
8	45	48	O	been
9	50	60	O	established
NULL

Azacitidine	DDI-DrugBank.d147.s0	NO_SECTION	NO_SETID	15
No formal assessments of drug-drug interactions between Vidaza and other agents have been conducted
1	0	1	O	No
2	3	8	O	formal
3	10	20	O	assessments
4	22	23	O	of
5	25	28	O	drug
6	30	33	O	drug
7	35	46	O	interactions
8	48	54	O	between
9	56	61	O	XXXXXXXX
10	63	65	O	and
11	67	71	O	other
12	73	78	O	agents
13	80	83	O	have
14	85	88	O	been
15	90	98	O	conducted
NULL

Azatadine	DDI-DrugBank.d448.s0	NO_SECTION	NO_SETID	9
MAO inhibitors prolong and intensify the effects of antihistamines.
1	0	2	B-UNK	MAO
2	4	13	L-UNK	inhibitors
3	15	21	O	prolong
4	23	25	O	and
5	27	35	O	intensify
6	37	39	O	the
7	41	47	O	effects
8	49	50	O	of
9	52	65	U-UNK	antihistamines
NULL

Azatadine	DDI-DrugBank.d448.s1	NO_SECTION	NO_SETID	23
Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	32	U-UNK	antihistamines
5	34	37	O	with
6	39	45	U-UNK	alcohol
7	46	46	O	,
8	48	56	B-UNK	tricyclic
9	58	72	L-UNK	antidepressants
10	73	73	O	,
11	75	86	U-UNK	barbiturates
12	87	87	O	,
13	89	90	O	or
14	92	96	O	other
15	98	104	B-UNK	central
16	106	112	I-UNK	nervous
17	114	119	I-UNK	system
18	121	131	L-UNK	depressants
19	133	135	O	may
20	137	140	O	have
21	142	143	O	an
22	145	152	O	additive
23	154	159	O	effect
NULL

Azatadine	DDI-DrugBank.d448.s2	NO_SECTION	NO_SETID	21
When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.
1	0	3	O	When
2	5	19	B-UNK	sympathomimetic
3	21	25	L-UNK	drugs
4	27	29	O	are
5	31	35	O	given
6	37	38	O	to
7	40	47	O	patients
8	49	57	O	receiving
9	59	67	B-UNK	monoamine
10	69	75	I-UNK	oxidase
11	77	86	L-UNK	inhibitors
12	87	87	O	,
13	89	100	O	hypertensive
14	102	110	O	reactions
15	111	111	O	,
16	113	121	O	including
17	123	134	O	hypertensive
18	136	141	O	crises
19	142	142	O	,
20	144	146	O	may
21	148	152	O	occur
NULL

Azatadine	DDI-DrugBank.d448.s3	NO_SECTION	NO_SETID	18
The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.
1	0	2	O	The
2	4	19	O	antihypertensive
3	21	27	O	effects
4	29	30	O	of
5	32	41	U-UNK	methyldopa
6	42	42	O	,
7	44	55	U-UNK	mecamylamine
8	56	56	O	,
9	58	66	U-UNK	reserpine
10	67	67	O	,
11	69	71	O	and
12	73	80	B-UNK	veratrum
13	82	90	L-UNK	alkaloids
14	92	94	O	may
15	96	97	O	be
16	99	105	O	reduced
17	107	108	O	by
18	110	125	U-UNK	sympathomimetics
NULL

Azatadine	DDI-DrugBank.d448.s4	NO_SECTION	NO_SETID	9
Beta-adrenergic blocking agents may also interact with sympathomimetics.
1	0	3	B-UNK	Beta
2	5	14	I-UNK	adrenergic
3	16	23	I-UNK	blocking
4	25	30	L-UNK	agents
5	32	34	O	may
6	36	39	O	also
7	41	48	O	interact
8	50	53	O	with
9	55	70	U-UNK	sympathomimetics
NULL

Azatadine	DDI-DrugBank.d448.s5	NO_SECTION	NO_SETID	13
Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.
1	0	8	O	Increased
2	10	16	O	ectopic
3	18	26	O	pacemaker
4	28	35	O	activity
5	37	39	O	can
6	41	45	O	occur
7	47	50	O	when
8	52	66	U-UNK	pseudoephedrine
9	68	69	O	is
10	71	74	O	used
11	76	88	O	concomitantly
12	90	93	O	with
13	95	103	U-UNK	digitalis
NULL

Azatadine	DDI-DrugBank.d448.s6	NO_SECTION	NO_SETID	13
Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.
1	0	7	U-UNK	Antacids
2	9	16	O	increase
3	18	20	O	the
4	22	25	O	rate
5	27	28	O	of
6	30	39	O	absorption
7	41	42	O	of
8	44	58	U-UNK	pseudoephedrine
9	59	59	O	,
10	61	65	O	while
11	67	72	U-UNK	kaolin
12	74	82	O	decreases
13	84	85	O	it
NULL

Azathioprine	DDI-DrugBank.d233.s0	NO_SECTION	NO_SETID	15
Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.
1	0	2	O	Use
2	4	7	O	with
3	9	19	U-UNK	Allopurinol
4	20	20	O	:
5	22	24	O	The
6	26	34	O	principal
7	36	42	O	pathway
8	44	46	O	for
9	48	61	O	detoxification
10	63	64	O	of
11	66	77	O	XXXXXXXX
12	79	80	O	is
13	82	90	O	inhibited
14	92	93	O	by
15	95	105	U-KIN	allopurinol
NULL

Azathioprine	DDI-DrugBank.d233.s1	NO_SECTION	NO_SETID	26
Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	30	O	XXXXXXXX
4	32	34	O	and
5	36	46	U-DYN	allopurinol
6	48	60	O	concomitantly
7	62	67	O	should
8	69	72	O	have
9	74	74	O	a
10	76	79	O	dose
11	81	89	O	reduction
12	91	92	O	of
13	94	105	O	XXXXXXXX
14	106	106	O	,
15	108	109	O	to
16	111	123	O	approximately
17	125	125	O	1
18	126	126	O	/
19	127	127	O	3
20	129	130	O	to
21	132	132	O	1
22	133	133	O	/
23	134	134	O	4
24	136	138	O	the
25	140	144	O	usual
26	146	149	O	dose
NULL

Azathioprine	DDI-DrugBank.d233.s2	NO_SECTION	NO_SETID	28
Use with Other Agents Affecting Myelopoesis: Drugs which may affect leukocyte production, including co-trimoxazole, may lead to exaggerated leukopenia, especially in renal transplant recipients.
1	0	2	O	Use
2	4	7	O	with
3	9	13	O	Other
4	15	20	O	Agents
5	22	30	O	Affecting
6	32	42	O	Myelopoesis
7	43	43	O	:
8	45	49	O	Drugs
9	51	55	O	which
10	57	59	O	may
11	61	66	O	affect
12	68	76	O	leukocyte
13	78	87	O	production
14	88	88	O	,
15	90	98	O	including
16	100	113	O	XXXXXXXX
17	114	114	O	,
18	116	118	O	may
19	120	123	O	lead
20	125	126	O	to
21	128	138	O	exaggerated
22	140	149	O	leukopenia
23	150	150	O	,
24	152	161	O	especially
25	163	164	O	in
26	166	170	O	renal
27	172	181	O	transplant
28	183	192	O	recipients
NULL

Azathioprine	DDI-DrugBank.d233.s3	NO_SECTION	NO_SETID	28
Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.
1	0	2	O	Use
2	4	7	O	with
3	9	19	B-UNK	Angiotensln
4	21	30	I-UNK	Converting
5	32	37	I-UNK	Enzyme
6	39	48	L-UNK	Inhibitors
7	49	49	O	:
8	51	53	O	The
9	55	57	O	use
10	59	60	O	of
11	62	72	B-DYN	angiotensin
12	74	83	I-DYN	converting
13	85	90	I-DYN	enzyme
14	92	101	L-DYN	inhibitors
15	103	104	O	to
16	106	112	O	control
17	114	125	O	hypertension
18	127	128	O	in
19	130	137	O	patients
20	139	140	O	on
21	142	153	O	XXXXXXXX
22	155	157	O	has
23	159	162	O	been
24	164	171	O	reported
25	173	174	O	to
26	176	181	O	induce
27	183	188	O	severe
28	190	199	O	leukopenia
NULL

Azelaic Acid	DDI-DrugBank.d383.s0	NO_SECTION	NO_SETID	3
No information provided
1	0	1	O	No
2	3	13	O	information
3	15	22	O	provided
NULL

Azithromycin	DDI-DrugBank.d53.s0	NO_SECTION	NO_SETID	13
Co-administration of nelfinavir at steady-state with a single dose of azithromycin.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	30	U-UNK	nelfinavir
5	32	33	O	at
6	35	40	O	steady
7	42	46	O	state
8	48	51	O	with
9	53	53	O	a
10	55	60	O	single
11	62	65	O	dose
12	67	68	O	of
13	70	81	O	XXXXXXXX
NULL

Azithromycin	DDI-DrugBank.d53.s1	NO_SECTION	NO_SETID	24
Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	30	U-DYN	nelfinavir
5	32	33	O	at
6	35	40	O	steady
7	42	46	O	state
8	48	51	O	with
9	53	53	O	a
10	55	60	O	single
11	62	65	O	dose
12	67	68	O	of
13	70	81	O	XXXXXXXX
14	84	84	O	2
15	86	86	O	x
16	88	90	O	600
17	92	93	O	mg
18	95	101	O	tablets
19	104	110	O	results
20	112	113	O	in
21	115	123	O	increased
22	125	136	O	XXXXXXXX
23	138	142	O	serum
24	144	157	O	concentrations
NULL

Azithromycin	DDI-DrugBank.d53.s2	NO_SECTION	NO_SETID	36
Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.
1	0	7	O	Although
2	9	9	O	a
3	11	14	O	dose
4	16	25	O	adjustment
5	27	28	O	of
6	30	41	O	XXXXXXXX
7	43	44	O	is
8	46	48	O	not
9	50	60	O	recommended
10	62	65	O	when
11	67	78	O	administered
12	80	81	O	in
13	83	93	O	combination
14	95	98	O	with
15	100	109	U-DYN	nelfinavir
16	110	110	O	,
17	112	116	O	close
18	118	127	O	monitoring
19	129	131	O	for
20	133	137	O	known
21	139	142	O	side
22	144	150	O	effects
23	152	153	O	of
24	155	166	O	XXXXXXXX
25	167	167	O	,
26	169	172	O	such
27	174	175	O	as
28	177	181	O	liver
29	183	188	O	enzyme
30	190	202	O	abnormalities
31	204	206	O	and
32	208	214	O	hearing
33	216	225	O	impairment
34	226	226	O	,
35	228	229	O	is
36	231	239	O	warranted
NULL

Azithromycin	DDI-DrugBank.d53.s3	NO_SECTION	NO_SETID	14
Azithromycin did not affect the prothrombin time response to a single dose of warfarin.
1	0	11	O	XXXXXXXX
2	13	15	O	did
3	17	19	O	not
4	21	26	O	affect
5	28	30	O	the
6	32	42	O	prothrombin
7	44	47	O	time
8	49	56	O	response
9	58	59	O	to
10	61	61	O	a
11	63	68	O	single
12	70	73	O	dose
13	75	76	O	of
14	78	85	U-UNK	warfarin
NULL

Azithromycin	DDI-DrugBank.d53.s4	NO_SECTION	NO_SETID	20
However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	prudent
4	17	23	O	medical
5	25	32	O	practice
6	34	41	O	dictates
7	43	49	O	careful
8	51	60	O	monitoring
9	62	63	O	of
10	65	75	O	prothrombin
11	77	80	O	time
12	82	83	O	in
13	85	87	O	all
14	89	96	O	patients
15	98	104	O	treated
16	106	109	O	with
17	111	122	O	XXXXXXXX
18	124	126	O	and
19	128	135	U-DYN	warfarin
20	137	149	O	concomitantly
NULL

Azithromycin	DDI-DrugBank.d53.s5	NO_SECTION	NO_SETID	16
Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	16	O	of
4	18	27	U-UNK	macrolides
5	29	31	O	and
6	33	40	U-UNK	warfarin
7	42	43	O	in
8	45	52	O	clinical
9	54	61	O	practice
10	63	65	O	has
11	67	70	O	been
12	72	81	O	associated
13	83	86	O	with
14	88	96	O	increased
15	98	110	O	anticoagulant
16	112	118	O	effects
NULL

Azithromycin	DDI-DrugBank.d53.s6	NO_SECTION	NO_SETID	15
Drug interaction studies were performed with azithromycin and other drugs likely to be co-administered.
1	0	3	O	Drug
2	5	15	O	interaction
3	17	23	O	studies
4	25	28	O	were
5	30	38	O	performed
6	40	43	O	with
7	45	56	O	XXXXXXXX
8	58	60	O	and
9	62	66	O	other
10	68	72	O	drugs
11	74	79	O	likely
12	81	82	O	to
13	84	85	O	be
14	87	88	O	co
15	90	101	O	administered
NULL

Azithromycin	DDI-DrugBank.d53.s7	NO_SECTION	NO_SETID	47
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
1	0	3	O	When
2	5	8	O	used
3	10	11	O	in
4	13	23	O	therapeutic
5	25	29	O	doses
6	30	30	O	,
7	32	43	O	XXXXXXXX
8	45	47	O	had
9	49	49	O	a
10	51	56	O	modest
11	58	63	O	effect
12	65	66	O	on
13	68	70	O	the
14	72	87	O	pharmacokinetics
15	89	90	O	of
16	92	103	U-KIN	atorvastatin
17	104	104	O	,
18	106	118	U-KIN	carbamazepine
19	119	119	O	,
20	121	130	U-KIN	cetirizine
21	131	131	O	,
22	133	142	U-KIN	didanosine
23	143	143	O	,
24	145	153	U-KIN	efavirenz
25	154	154	O	,
26	156	166	U-KIN	fluconazole
27	167	167	O	,
28	169	177	U-KIN	indinavir
29	178	178	O	,
30	180	188	U-KIN	midazolam
31	189	189	O	,
32	191	199	U-KIN	rifabutin
33	200	200	O	,
34	202	211	U-KIN	sildenafil
35	212	212	O	,
36	214	225	U-KIN	theophylline
37	228	238	O	intravenous
38	240	242	O	and
39	244	247	O	oral
40	249	249	O	,
41	251	259	U-KIN	triazolam
42	260	260	O	,
43	262	273	U-KIN	trimethoprim
44	274	274	O	/
45	275	290	U-KIN	sulfamethoxazole
46	292	293	O	or
47	295	304	U-KIN	zidovudine
NULL

Azithromycin	DDI-DrugBank.d53.s8	NO_SECTION	NO_SETID	15
Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.
1	0	1	O	Co
2	3	16	O	administration
3	18	21	O	with
4	23	31	U-KIN	efavirenz
5	33	34	O	or
6	36	46	U-KIN	fluconazole
7	48	50	O	had
8	52	52	O	a
9	54	59	O	modest
10	61	66	O	effect
11	68	69	O	on
12	71	73	O	the
13	75	90	O	pharmacokinetics
14	92	93	O	of
15	95	106	O	XXXXXXXX
NULL

Azithromycin	DDI-DrugBank.d53.s9	NO_SECTION	NO_SETID	19
No dosage adjustment of either drug is recommended when azithromycin is co administered with any of the above agents.
1	0	1	O	No
2	3	8	O	dosage
3	10	19	O	adjustment
4	21	22	O	of
5	24	29	O	either
6	31	34	O	drug
7	36	37	O	is
8	39	49	O	recommended
9	51	54	O	when
10	56	67	O	XXXXXXXX
11	69	70	O	is
12	72	73	O	co
13	75	86	O	administered
14	88	91	O	with
15	93	95	O	any
16	97	98	O	of
17	100	102	O	the
18	104	108	O	above
19	110	115	O	agents
NULL

Azithromycin	DDI-DrugBank.d53.s10	NO_SECTION	NO_SETID	15
Interactions with the drugs listed below have not been reported in clinical trials with azithromycin;
1	0	11	O	Interactions
2	13	16	O	with
3	18	20	O	the
4	22	26	O	drugs
5	28	33	O	listed
6	35	39	O	below
7	41	44	O	have
8	46	48	O	not
9	50	53	O	been
10	55	62	O	reported
11	64	65	O	in
12	67	74	O	clinical
13	76	81	O	trials
14	83	86	O	with
15	88	99	O	XXXXXXXX
NULL

Azithromycin	DDI-DrugBank.d53.s11	NO_SECTION	NO_SETID	16
however, no specific drug interaction studies have been performed to evaluate potential drug-drug interaction.
1	0	6	O	however
2	7	7	O	,
3	9	10	O	no
4	12	19	O	specific
5	21	24	O	drug
6	26	36	O	interaction
7	38	44	O	studies
8	46	49	O	have
9	51	54	O	been
10	56	64	O	performed
11	66	67	O	to
12	69	76	O	evaluate
13	78	86	O	potential
14	88	91	O	drug
15	93	96	O	drug
16	98	108	O	interaction
NULL

Azithromycin	DDI-DrugBank.d53.s12	NO_SECTION	NO_SETID	9
Nonetheless, they have been observed with macrolide products.
1	0	10	O	Nonetheless
2	11	11	O	,
3	13	16	O	they
4	18	21	O	have
5	23	26	O	been
6	28	35	O	observed
7	37	40	O	with
8	42	50	B-UNK	macrolide
9	52	59	L-UNK	products
NULL

Azithromycin	DDI-DrugBank.d53.s13	NO_SECTION	NO_SETID	28
Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated digoxin concentrations.
1	0	4	O	Until
2	6	12	O	further
3	14	17	O	data
4	19	21	O	are
5	23	31	O	developed
6	33	41	O	regarding
7	43	46	O	drug
8	48	59	O	interactions
9	61	64	O	when
10	66	77	O	XXXXXXXX
11	79	81	O	and
12	83	87	O	these
13	89	93	O	drugs
14	95	97	O	are
15	99	102	O	used
16	104	116	O	concomitantly
17	117	117	O	,
18	119	125	O	careful
19	127	136	O	monitoring
20	138	139	O	of
21	141	148	O	patients
22	150	151	O	is
23	153	159	O	advised
24	160	160	O	:
25	162	168	U-UNK	Digoxin
26	170	177	O	elevated
27	179	185	U-UNK	digoxin
28	187	200	O	concentrations
NULL

Azithromycin	DDI-DrugBank.d53.s14	NO_SECTION	NO_SETID	13
Ergotamine or dihydroergotamine acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
1	0	9	U-UNK	Ergotamine
2	11	12	O	or
3	14	30	U-UNK	dihydroergotamine
4	32	36	O	acute
5	38	42	O	ergot
6	44	51	O	toxicity
7	53	65	O	characterized
8	67	68	O	by
9	70	75	O	severe
10	77	86	O	peripheral
11	88	96	O	vasospasm
12	98	100	O	and
13	102	112	O	dysesthesia
NULL

Azithromycin	DDI-DrugBank.d53.s15	NO_SECTION	NO_SETID	6
Cyclosporine, hexobarbital and phenytoin concentrations.
1	0	11	U-UNK	Cyclosporine
2	12	12	O	,
3	14	25	U-UNK	hexobarbital
4	27	29	O	and
5	31	39	U-UNK	phenytoin
6	41	54	O	concentrations
NULL

Azithromycin	DDI-DrugBank.d53.s16	NO_SECTION	NO_SETID	10
Laboratory Test Interactions There are no reported laboratory test interactions.
1	0	9	O	Laboratory
2	11	14	O	Test
3	16	27	O	Interactions
4	29	33	O	There
5	35	37	O	are
6	39	40	O	no
7	42	49	O	reported
8	51	60	O	laboratory
9	62	65	O	test
10	67	78	O	interactions
NULL

Azithromycin	DDI-DrugBank.d53.s17	NO_SECTION	NO_SETID	15
Repeat Treatment Studies evaluating the use of repeated courses of Zmax have not been conducted.
1	0	5	O	Repeat
2	7	15	O	Treatment
3	17	23	O	Studies
4	25	34	O	evaluating
5	36	38	O	the
6	40	42	O	use
7	44	45	O	of
8	47	54	O	repeated
9	56	62	O	courses
10	64	65	O	of
11	67	70	O	XXXXXXXX
12	72	75	O	have
13	77	79	O	not
14	81	84	O	been
15	86	94	O	conducted
NULL

Azlocillin	DDI-DrugBank.d9.s0	NO_SECTION	NO_SETID	17
Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
1	0	9	O	XXXXXXXX
2	11	16	O	should
3	18	20	O	not
4	22	23	O	be
5	25	36	O	administered
6	38	50	O	concomitantly
7	52	55	O	with
8	57	64	U-DYN	amikacin
9	65	65	O	,
10	67	79	U-DYN	ciprofloxacin
11	80	80	O	,
12	82	91	U-DYN	gentamicin
13	92	92	O	,
14	94	103	U-DYN	netilmicin
15	104	104	O	,
16	106	107	O	or
17	109	118	U-DYN	tobramycin
NULL

Baclofen	DDI-DrugBank.d523.s0	NO_SECTION	NO_SETID	23
Injection There is inadequate systematic experience with the use of baclofen injection in combination with other medications to predict specific drug-drug interactions.
1	0	8	O	Injection
2	10	14	O	There
3	16	17	O	is
4	19	28	O	inadequate
5	30	39	O	systematic
6	41	50	O	experience
7	52	55	O	with
8	57	59	O	the
9	61	63	O	use
10	65	66	O	of
11	68	75	O	XXXXXXXX
12	77	85	O	injection
13	87	88	O	in
14	90	100	O	combination
15	102	105	O	with
16	107	111	O	other
17	113	123	O	medications
18	125	126	O	to
19	128	134	O	predict
20	136	143	O	specific
21	145	148	O	drug
22	150	153	O	drug
23	155	166	O	interactions
NULL

Baclofen	DDI-DrugBank.d523.s1	NO_SECTION	NO_SETID	16
Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.
1	0	11	O	Interactions
2	13	22	O	attributed
3	24	25	O	to
4	27	29	O	the
5	31	38	O	combined
6	40	42	O	use
7	44	45	O	of
8	47	54	O	XXXXXXXX
9	56	64	O	injection
10	66	68	O	and
11	70	77	O	epidural
12	79	86	U-DYN	morphine
13	88	94	O	include
14	96	106	O	hypotension
15	108	110	O	and
16	112	118	O	dyspnea
NULL

Baclofen	DDI-DrugBank.d523.s2	NO_SECTION	NO_SETID	17
SIDE EFFECTS (KEMSTRO) The most common adverse reaction during treatment with baclofen is transient drowsiness (10-63%).
1	0	3	O	SIDE
2	5	11	O	EFFECTS
3	14	20	O	XXXXXXXX
4	23	25	O	The
5	27	30	O	most
6	32	37	O	common
7	39	45	O	adverse
8	47	54	O	reaction
9	56	61	O	during
10	63	71	O	treatment
11	73	76	O	with
12	78	85	U-UNK	baclofen
13	87	88	O	is
14	90	98	O	transient
15	100	109	O	drowsiness
16	112	113	O	10
17	115	117	O	63%
NULL

Baclofen	DDI-DrugBank.d523.s3	NO_SECTION	NO_SETID	28
In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen tablets compared to 36% of those in the placebo group.
1	0	1	O	In
2	3	5	O	one
3	7	16	O	controlled
4	18	22	O	study
5	24	25	O	of
6	27	29	O	175
7	31	38	O	patients
8	39	39	O	,
9	41	49	O	transient
10	51	60	O	drowsiness
11	62	64	O	was
12	66	73	O	observed
13	75	76	O	in
14	78	80	O	63%
15	82	83	O	of
16	85	89	O	those
17	91	99	O	receiving
18	101	108	O	XXXXXXXX
19	110	116	O	tablets
20	118	125	O	compared
21	127	128	O	to
22	130	132	O	36%
23	134	135	O	of
24	137	141	O	those
25	143	144	O	in
26	146	148	O	the
27	150	156	O	placebo
28	158	162	O	group
NULL

Baclofen	DDI-DrugBank.d523.s4	NO_SECTION	NO_SETID	16
Other common adverse reactions are dizziness (5-15%), weakness (5-15%) and fatigue (2-4%).
1	0	4	O	Other
2	6	11	O	common
3	13	19	O	adverse
4	21	29	O	reactions
5	31	33	O	are
6	35	43	O	dizziness
7	46	46	O	5
8	48	50	O	15%
9	52	52	O	,
10	54	61	O	weakness
11	64	64	O	5
12	66	68	O	15%
13	71	73	O	and
14	75	81	O	fatigue
15	84	84	O	2
16	86	87	O	4%
NULL

Baclofen	DDI-DrugBank.d523.s5	NO_SECTION	NO_SETID	16
Others reported: Neuropsychiatric: Confusion (1-11%), headache (4-8%), insomnia (2-7%);
1	0	5	O	Others
2	7	14	O	reported
3	15	15	O	:
4	17	32	O	Neuropsychiatric
5	33	33	O	:
6	35	43	O	Confusion
7	46	46	O	1
8	48	50	O	11%
9	52	52	O	,
10	54	61	O	headache
11	64	64	O	4
12	66	67	O	8%
13	69	69	O	,
14	71	78	O	insomnia
15	81	81	O	2
16	83	84	O	7%
NULL

Baclofen	DDI-DrugBank.d523.s6	NO_SECTION	NO_SETID	50
and, rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure.
1	0	2	O	and
2	3	3	O	,
3	5	10	O	rarely
4	11	11	O	,
5	13	20	O	euphoria
6	21	21	O	,
7	23	32	O	excitement
8	33	33	O	,
9	35	44	O	depression
10	45	45	O	,
11	47	60	O	hallucinations
12	61	61	O	,
13	63	73	O	paresthesia
14	74	74	O	,
15	76	81	O	muscle
16	83	86	O	pain
17	87	87	O	,
18	89	96	O	tinnitus
19	97	97	O	,
20	99	105	O	slurred
21	107	112	O	speech
22	113	113	O	,
23	115	126	O	coordination
24	128	135	O	disorder
25	136	136	O	,
26	138	143	O	tremor
27	144	144	O	,
28	146	153	O	rigidity
29	154	154	O	,
30	156	163	O	dystonia
31	164	164	O	,
32	166	171	O	ataxia
33	172	172	O	,
34	174	180	O	blurred
35	182	187	O	vision
36	188	188	O	,
37	190	198	O	nystagmus
38	199	199	O	,
39	201	210	O	strabismus
40	211	211	O	,
41	213	218	O	miosis
42	219	219	O	,
43	221	229	O	mydriasis
44	230	230	O	,
45	232	239	O	diplopia
46	240	240	O	,
47	242	251	O	dysarthria
48	252	252	O	,
49	254	262	O	epileptic
50	264	270	O	seizure
NULL

Baclofen	DDI-DrugBank.d523.s7	NO_SECTION	NO_SETID	5
Cardiovascular: Hypotension (0-9%).
1	0	13	O	Cardiovascular
2	14	14	O	:
3	16	26	O	Hypotension
4	29	29	O	0
5	31	32	O	9%
NULL

Baclofen	DDI-DrugBank.d523.s8	NO_SECTION	NO_SETID	11
Rare instances of dyspnea, palpitation, chest pain, syncope.
1	0	3	O	Rare
2	5	13	O	instances
3	15	16	O	of
4	18	24	O	dyspnea
5	25	25	O	,
6	27	37	O	palpitation
7	38	38	O	,
8	40	44	O	chest
9	46	49	O	pain
10	50	50	O	,
11	52	58	O	syncope
NULL

Baclofen	DDI-DrugBank.d523.s9	NO_SECTION	NO_SETID	9
Gastrointestinal: Nausea (4-12%), constipation (2-6%);
1	0	15	O	Gastrointestinal
2	16	16	O	:
3	18	23	O	Nausea
4	26	26	O	4
5	28	30	O	12%
6	32	32	O	,
7	34	45	O	constipation
8	48	48	O	2
9	50	51	O	6%
NULL

Baclofen	DDI-DrugBank.d523.s10	NO_SECTION	NO_SETID	27
and, rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool.
1	0	2	O	and
2	3	3	O	,
3	5	10	O	rarely
4	11	11	O	,
5	13	15	O	dry
6	17	21	O	mouth
7	22	22	O	,
8	24	31	O	anorexia
9	32	32	O	,
10	34	38	O	taste
11	40	47	O	disorder
12	48	48	O	,
13	50	58	O	abdominal
14	60	63	O	pain
15	64	64	O	,
16	66	73	O	vomiting
17	74	74	O	,
18	76	83	O	diarrhea
19	84	84	O	,
20	86	88	O	and
21	90	97	O	positive
22	99	102	O	test
23	104	106	O	for
24	108	113	O	occult
25	115	119	O	blood
26	121	122	O	in
27	124	128	O	stool
NULL

Baclofen	DDI-DrugBank.d523.s11	NO_SECTION	NO_SETID	6
Genitourinary: Urinary frequency (2-6%);
1	0	12	O	Genitourinary
2	13	13	O	:
3	15	21	O	Urinary
4	23	31	O	frequency
5	34	34	O	2
6	36	37	O	6%
NULL

Baclofen	DDI-DrugBank.d523.s12	NO_SECTION	NO_SETID	20
and, rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria.
1	0	2	O	and
2	3	3	O	,
3	5	10	O	rarely
4	11	11	O	,
5	13	20	O	enuresis
6	21	21	O	,
7	23	29	O	urinary
8	31	39	O	retention
9	40	40	O	,
10	42	48	O	dysuria
11	49	49	O	,
12	51	59	O	impotence
13	60	60	O	,
14	62	70	O	inability
15	72	73	O	to
16	75	83	O	ejaculate
17	84	84	O	,
18	86	93	O	nocturia
19	94	94	O	,
20	96	104	O	hematuria
NULL

Baclofen	DDI-DrugBank.d523.s13	NO_SECTION	NO_SETID	19
Other: Instances of rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion.
1	0	4	O	Other
2	5	5	O	:
3	7	15	O	Instances
4	17	18	O	of
5	20	23	O	rash
6	24	24	O	,
7	26	33	O	pruritus
8	34	34	O	,
9	36	40	O	ankle
10	42	46	O	edema
11	47	47	O	,
12	49	57	O	excessive
13	59	70	O	perspiration
14	71	71	O	,
15	73	78	O	weight
16	80	83	O	gain
17	84	84	O	,
18	86	90	O	nasal
19	92	101	O	congestion
NULL

Baclofen	DDI-DrugBank.d523.s14	NO_SECTION	NO_SETID	19
Some of the CNS and genitourinary symptoms may be related to the underlying disease rather than to drug therapy.
1	0	3	O	Some
2	5	6	O	of
3	8	10	O	the
4	12	14	O	CNS
5	16	18	O	and
6	20	32	O	genitourinary
7	34	41	O	symptoms
8	43	45	O	may
9	47	48	O	be
10	50	56	O	related
11	58	59	O	to
12	61	63	O	the
13	65	74	O	underlying
14	76	82	O	disease
15	84	89	O	rather
16	91	94	O	than
17	96	97	O	to
18	99	102	O	drug
19	104	110	O	therapy
NULL

Baclofen	DDI-DrugBank.d523.s15	NO_SECTION	NO_SETID	29
The following laboratory tests have been found to be abnormal in a few patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar.
1	0	2	O	The
2	4	12	O	following
3	14	23	O	laboratory
4	25	29	O	tests
5	31	34	O	have
6	36	39	O	been
7	41	45	O	found
8	47	48	O	to
9	50	51	O	be
10	53	60	O	abnormal
11	62	63	O	in
12	65	65	O	a
13	67	69	O	few
14	71	78	O	patients
15	80	88	O	receiving
16	90	97	O	XXXXXXXX
17	98	98	O	:
18	100	108	O	increased
19	110	113	O	SGOT
20	114	114	O	,
21	116	123	O	elevated
22	125	132	O	alkaline
23	134	144	O	phosphatase
24	145	145	O	,
25	147	149	O	and
26	151	159	O	elevation
27	161	162	O	of
28	164	168	O	blood
29	170	174	O	sugar
NULL

Baclofen	DDI-DrugBank.d523.s16	NO_SECTION	NO_SETID	15
The adverse experience profile seen with KEMSTROTM was similar to that seen with baclofen tablets.
1	0	2	O	The
2	4	10	O	adverse
3	12	21	O	experience
4	23	29	O	profile
5	31	34	O	seen
6	36	39	O	with
7	41	49	O	XXXXXXXX
8	51	53	O	was
9	55	61	O	similar
10	63	64	O	to
11	66	69	O	that
12	71	74	O	seen
13	76	79	O	with
14	81	88	U-UNK	baclofen
15	90	96	O	tablets
NULL

Balsalazide	DDI-DrugBank.d486.s0	NO_SECTION	NO_SETID	30
No drug interaction studies have been conducted for COLAZAL, however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon.
1	0	1	O	No
2	3	6	O	drug
3	8	18	O	interaction
4	20	26	O	studies
5	28	31	O	have
6	33	36	O	been
7	38	46	O	conducted
8	48	50	O	for
9	52	58	O	XXXXXXXX
10	59	59	O	,
11	61	67	O	however
12	69	71	O	the
13	73	75	O	use
14	77	78	O	of
15	80	85	O	orally
16	87	98	O	administered
17	100	110	U-UNK	antibiotics
18	112	116	O	could
19	117	117	O	,
20	119	131	O	theoretically
21	132	132	O	,
22	134	142	O	interfere
23	144	147	O	with
24	149	151	O	the
25	153	159	O	release
26	161	162	O	of
27	164	173	U-UNK	mesalamine
28	175	176	O	in
29	178	180	O	the
30	182	186	O	colon
NULL

Basiliximab	DDI-DrugBank.d544.s0	NO_SECTION	NO_SETID	24
No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil.
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	is
5	22	30	O	necessary
6	32	35	O	when
7	37	44	O	XXXXXXXX
8	46	47	O	is
9	49	53	O	added
10	55	56	O	to
11	58	63	O	triple
12	65	81	O	immunosuppression
13	83	90	O	regimens
14	92	100	O	including
15	102	113	U-UNK	cyclosporine
16	114	114	O	,
17	116	130	U-UNK	corticosteroids
18	131	131	O	,
19	133	135	O	and
20	137	142	O	either
21	144	155	U-UNK	azathioprine
22	157	158	O	or
23	160	172	B-UNK	mycophenolate
24	174	180	L-UNK	mofetil
NULL

Basiliximab	DDI-DrugBank.d544.s1	NO_SECTION	NO_SETID	13
Three clinical trials have investigated Simulect use in combination with triple-therapy regimens.
1	0	4	O	Three
2	6	13	O	clinical
3	15	20	O	trials
4	22	25	O	have
5	27	38	O	investigated
6	40	47	O	XXXXXXXX
7	49	51	O	use
8	53	54	O	in
9	56	66	O	combination
10	68	71	O	with
11	73	78	O	triple
12	80	86	O	therapy
13	88	95	O	regimens
NULL

Basiliximab	DDI-DrugBank.d544.s2	NO_SECTION	NO_SETID	8
Pharmacokinetics were assessed in two of these trials.
1	0	15	O	Pharmacokinetics
2	17	20	O	were
3	22	29	O	assessed
4	31	32	O	in
5	34	36	O	two
6	38	39	O	of
7	41	45	O	these
8	47	52	O	trials
NULL

Basiliximab	DDI-DrugBank.d544.s3	NO_SECTION	NO_SETID	34
Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.
1	0	4	O	Total
2	6	9	O	body
3	11	19	O	clearance
4	21	22	O	of
5	24	31	O	XXXXXXXX
6	33	35	O	was
7	37	43	O	reduced
8	45	46	O	by
9	48	49	O	an
10	51	57	O	average
11	59	61	O	22%
12	63	65	O	and
13	67	69	O	51%
14	71	74	O	when
15	76	87	U-KIN	azathioprine
16	89	91	O	and
17	93	105	B-KIN	mycophenolate
18	107	113	L-KIN	mofetil
19	114	114	O	,
20	116	127	O	respectively
21	128	128	O	,
22	130	133	O	were
23	135	139	O	added
24	141	142	O	to
25	144	144	O	a
26	146	152	O	regimen
27	154	163	O	consisting
28	165	166	O	of
29	168	179	U-UNK	cyclosporine
30	180	180	O	,
31	182	184	O	USP
32	187	194	O	MODIFIED
33	197	199	O	and
34	201	215	U-UNK	corticosteroids
NULL

Basiliximab	DDI-DrugBank.d544.s4	NO_SECTION	NO_SETID	42
Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).
1	0	10	O	Nonetheless
2	11	11	O	,
3	13	15	O	the
4	17	21	O	range
5	23	24	O	of
6	26	35	O	individual
7	37	44	O	XXXXXXXX
8	46	54	O	clearance
9	56	61	O	values
10	63	64	O	in
11	66	68	O	the
12	70	77	O	presence
13	79	80	O	of
14	82	93	U-UNK	azathioprine
15	96	97	O	12
16	99	100	O	57
17	102	103	O	mL
18	104	104	O	/
19	105	105	O	h
20	108	109	O	or
21	111	123	B-UNK	mycophenolate
22	125	131	L-UNK	mofetil
23	134	134	O	7
24	136	137	O	54
25	139	140	O	mL
26	141	141	O	/
27	142	142	O	h
28	145	147	O	did
29	149	151	O	not
30	153	158	O	extend
31	160	166	O	outside
32	168	170	O	the
33	172	176	O	range
34	178	185	O	observed
35	187	190	O	with
36	192	195	O	dual
37	197	203	O	therapy
38	206	207	O	10
39	209	210	O	78
40	212	213	O	mL
41	214	214	O	/
42	215	215	O	h
NULL

Basiliximab	DDI-DrugBank.d544.s5	NO_SECTION	NO_SETID	34
The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromonab-CD3.
1	0	2	O	The
2	4	12	O	following
3	14	24	O	medications
4	26	29	O	have
5	31	34	O	been
6	36	47	O	administered
7	49	50	O	in
8	52	59	O	clinical
9	61	66	O	trials
10	68	71	O	with
11	73	80	O	XXXXXXXX
12	82	85	O	with
13	87	88	O	no
14	90	97	O	increase
15	99	100	O	in
16	102	108	O	adverse
17	110	118	O	reactions
18	119	119	O	:
19	121	123	O	ATG
20	124	124	O	/
21	125	127	O	ALG
22	128	128	O	,
23	130	141	U-UNK	azathioprine
24	142	142	O	,
25	144	158	U-UNK	corticosteroids
26	159	159	O	,
27	161	172	U-UNK	cyclosporine
28	173	173	O	,
29	175	187	B-UNK	mycophenolate
30	189	195	L-UNK	mofetil
31	196	196	O	,
32	198	200	O	and
33	202	210	B-UNK	muromonab
34	212	214	L-UNK	CD3
NULL

Becaplermin	DDI-DrugBank.d385.s0	NO_SECTION	NO_SETID	17
It is not known if REGRANEX Gel interacts with other topical medications applied to the ulcer site.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	known
5	16	17	O	if
6	19	26	O	XXXXXXXX
7	28	30	O	Gel
8	32	40	O	interacts
9	42	45	O	with
10	47	51	O	other
11	53	59	O	topical
12	61	71	O	medications
13	73	79	O	applied
14	81	82	O	to
15	84	86	O	the
16	88	92	O	ulcer
17	94	97	O	site
NULL

Becaplermin	DDI-DrugBank.d385.s1	NO_SECTION	NO_SETID	13
The use of REGRANEX Gel with other topical drugs has not been studied.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	18	O	XXXXXXXX
5	20	22	O	Gel
6	24	27	O	with
7	29	33	O	other
8	35	41	O	topical
9	43	47	O	drugs
10	49	51	O	has
11	53	55	O	not
12	57	60	O	been
13	62	68	O	studied
NULL

Beclomethasone	DDI-DrugBank.d524.s0	NO_SECTION	NO_SETID	10
Albuterol, Antihistamines, antidiabetic drugs, diuretics, digitalis.
1	0	8	U-UNK	Albuterol
2	9	9	O	,
3	11	24	U-UNK	Antihistamines
4	25	25	O	,
5	27	38	B-UNK	antidiabetic
6	40	44	L-UNK	drugs
7	45	45	O	,
8	47	55	U-UNK	diuretics
9	56	56	O	,
10	58	66	U-UNK	digitalis
NULL

Benazepril	DDI-DrugBank.d561.s0	NO_SECTION	NO_SETID	31
Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.
1	0	8	U-UNK	Diuretics
2	9	9	O	:
3	11	18	O	Patients
4	20	21	O	on
5	23	31	U-DYN	diuretics
6	32	32	O	,
7	34	43	O	especially
8	45	49	O	those
9	51	52	O	in
10	54	57	O	whom
11	59	66	O	diuretic
12	68	74	O	therapy
13	76	78	O	was
14	80	87	O	recently
15	89	98	O	instituted
16	99	99	O	,
17	101	103	O	may
18	105	116	O	occasionally
19	118	127	O	experience
20	129	130	O	an
21	132	140	O	excessive
22	142	150	O	reduction
23	152	153	O	of
24	155	159	O	blood
25	161	168	O	pressure
26	170	174	O	after
27	176	185	O	initiation
28	187	188	O	of
29	190	196	O	therapy
30	198	201	O	with
31	203	210	O	XXXXXXXX
NULL

Benazepril	DDI-DrugBank.d561.s1	NO_SECTION	NO_SETID	27
The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.
1	0	2	O	The
2	4	14	O	possibility
3	16	17	O	of
4	19	29	O	hypotensive
5	31	37	O	effects
6	39	42	O	with
7	44	51	O	XXXXXXXX
8	53	55	O	can
9	57	58	O	be
10	60	68	O	minimized
11	70	71	O	by
12	73	78	O	either
13	80	92	O	discontinuing
14	94	96	O	the
15	98	105	U-DYN	diuretic
16	107	108	O	or
17	110	119	O	increasing
18	121	123	O	the
19	125	128	O	salt
20	130	135	O	intake
21	137	141	O	prior
22	143	144	O	to
23	146	155	O	initiation
24	157	158	O	of
25	160	168	O	treatment
26	170	173	O	with
27	175	182	O	XXXXXXXX
NULL

Benazepril	DDI-DrugBank.d561.s2	NO_SECTION	NO_SETID	12
If this is not possible, the starting dose should be reduced.
1	0	1	O	If
2	3	6	O	this
3	8	9	O	is
4	11	13	O	not
5	15	22	O	possible
6	23	23	O	,
7	25	27	O	the
8	29	36	O	starting
9	38	41	O	dose
10	43	48	O	should
11	50	51	O	be
12	53	59	O	reduced
NULL

Benazepril	DDI-DrugBank.d561.s3	NO_SECTION	NO_SETID	15
Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.
1	0	8	U-UNK	Potassium
2	10	20	O	Supplements
3	22	24	O	and
4	26	34	B-UNK	Potassium
5	36	42	I-UNK	Sparing
6	44	52	L-UNK	Diuretics
7	54	61	O	Lotensin
8	63	65	O	can
9	67	75	O	attenuate
10	77	85	O	potassium
11	87	90	O	loss
12	92	97	O	caused
13	99	100	O	by
14	102	109	B-UNK	thiazide
15	111	119	L-UNK	diuretics
NULL

Benazepril	DDI-DrugBank.d561.s4	NO_SECTION	NO_SETID	20
Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.
1	0	8	B-UNK	Potassium
2	10	16	I-UNK	sparing
3	18	26	L-UNK	diuretics
4	29	42	U-UNK	spironolactone
5	43	43	O	,
6	45	53	U-UNK	amiloride
7	54	54	O	,
8	56	66	U-UNK	triamterene
9	67	67	O	,
10	69	71	O	and
11	73	78	O	others
12	81	82	O	or
13	84	92	U-UNK	potassium
14	94	104	O	supplements
15	106	108	O	can
16	110	117	O	increase
17	119	121	O	the
18	123	126	O	risk
19	128	129	O	of
20	131	142	O	hyperkalemia
NULL

Benazepril	DDI-DrugBank.d561.s5	NO_SECTION	NO_SETID	27
Therefore, if concomitant use of such agents is indicated, they should be given with caution, and the patient's serum potassium should be monitored frequently.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	if
4	14	24	O	concomitant
5	26	28	O	use
6	30	31	O	of
7	33	36	O	such
8	38	43	O	agents
9	45	46	O	is
10	48	56	O	indicated
11	57	57	O	,
12	59	62	O	they
13	64	69	O	should
14	71	72	O	be
15	74	78	O	given
16	80	83	O	with
17	85	91	O	caution
18	92	92	O	,
19	94	96	O	and
20	98	100	O	the
21	102	110	O	patient's
22	112	116	O	serum
23	118	126	O	potassium
24	128	133	O	should
25	135	136	O	be
26	138	146	O	monitored
27	148	157	O	frequently
NULL

Benazepril	DDI-DrugBank.d561.s6	NO_SECTION	NO_SETID	25
Oral Anticoagulants Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.
1	0	3	O	Oral
2	5	18	U-UNK	Anticoagulants
3	20	30	O	Interaction
4	32	38	O	studies
5	40	43	O	with
6	45	52	U-UNK	warfarin
7	54	56	O	and
8	58	70	U-UNK	acenocoumarol
9	72	77	O	failed
10	79	80	O	to
11	82	89	O	identify
12	91	93	O	any
13	95	104	O	clinically
14	106	114	O	important
15	116	122	O	effects
16	124	125	O	on
17	127	129	O	the
18	131	135	O	serum
19	137	150	O	concentrations
20	152	153	O	or
21	155	162	O	clinical
22	164	170	O	effects
23	172	173	O	of
24	175	179	O	these
25	181	194	U-UNK	anticoagulants
NULL

Benazepril	DDI-DrugBank.d561.s7	NO_SECTION	NO_SETID	23
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	17	O	Increased
4	19	23	O	serum
5	25	31	U-UNK	lithium
6	33	38	O	levels
7	40	42	O	and
8	44	51	O	symptoms
9	53	54	O	of
10	56	62	U-UNK	lithium
11	64	71	O	toxicity
12	73	76	O	have
13	78	81	O	been
14	83	90	O	reported
15	92	93	O	in
16	95	102	O	patients
17	104	112	O	receiving
18	114	116	B-UNK	ACE
19	118	127	L-UNK	inhibitors
20	129	134	O	during
21	136	142	O	therapy
22	144	147	O	with
23	149	155	U-UNK	lithium
NULL

Benazepril	DDI-DrugBank.d561.s8	NO_SECTION	NO_SETID	17
These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.
1	0	4	O	These
2	6	10	O	drugs
3	12	17	O	should
4	19	20	O	be
5	22	35	O	coadministered
6	37	40	O	with
7	42	48	O	caution
8	49	49	O	,
9	51	53	O	and
10	55	62	O	frequent
11	64	73	O	monitoring
12	75	76	O	of
13	78	82	O	serum
14	84	90	U-UNK	lithium
15	92	97	O	levels
16	99	100	O	is
17	102	112	O	recommended
NULL

Benazepril	DDI-DrugBank.d561.s9	NO_SECTION	NO_SETID	15
If a diuretic is also used, the risk of lithium toxicity may be increased.
1	0	1	O	If
2	3	3	O	a
3	5	12	U-UNK	diuretic
4	14	15	O	is
5	17	20	O	also
6	22	25	O	used
7	26	26	O	,
8	28	30	O	the
9	32	35	O	risk
10	37	38	O	of
11	40	46	U-UNK	lithium
12	48	55	O	toxicity
13	57	59	O	may
14	61	62	O	be
15	64	72	O	increased
NULL

Benazepril	DDI-DrugBank.d561.s10	NO_SECTION	NO_SETID	29
Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone, furosemide, digoxin, propranolol, atenolol, naproxen, or cimetidine.
1	0	4	O	Other
2	6	7	O	No
3	9	18	O	clinically
4	20	28	O	important
5	30	44	O	pharmacokinetic
6	46	57	O	interactions
7	59	66	O	occurred
8	68	71	O	when
9	73	80	O	XXXXXXXX
10	82	84	O	was
11	86	97	O	administered
12	99	111	O	concomitantly
13	113	116	O	with
14	118	136	U-UNK	hydrochlorothiazide
15	137	137	O	,
16	139	152	U-UNK	chlorthalidone
17	153	153	O	,
18	155	164	U-UNK	furosemide
19	165	165	O	,
20	167	173	U-UNK	digoxin
21	174	174	O	,
22	176	186	U-UNK	propranolol
23	187	187	O	,
24	189	196	U-UNK	atenolol
25	197	197	O	,
26	199	206	U-UNK	naproxen
27	207	207	O	,
28	209	210	O	or
29	212	221	U-UNK	cimetidine
NULL

Benazepril	DDI-DrugBank.d561.s11	NO_SECTION	NO_SETID	30
Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	16	O	been
4	18	21	O	used
5	23	35	O	concomitantly
6	37	40	O	with
7	42	45	B-UNK	beta
8	47	56	I-UNK	adrenergic
9	58	65	I-UNK	blocking
10	67	72	L-UNK	agents
11	73	73	O	,
12	75	81	B-UNK	calcium
13	83	89	I-UNK	channel
14	91	98	I-UNK	blocking
15	100	105	L-UNK	agents
16	106	106	O	,
17	108	116	U-UNK	diuretics
18	117	117	O	,
19	119	125	U-UNK	digoxin
20	126	126	O	,
21	128	130	O	and
22	132	142	U-UNK	hydralazine
23	143	143	O	,
24	145	151	O	without
25	153	160	O	evidence
26	162	163	O	of
27	165	174	O	clinically
28	176	184	O	important
29	186	192	O	adverse
30	194	205	O	interactions
NULL

Benazepril	DDI-DrugBank.d561.s12	NO_SECTION	NO_SETID	33
Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
1	0	9	O	XXXXXXXX
2	10	10	O	,
3	12	15	O	like
4	17	21	O	other
5	23	25	B-UNK	ACE
6	27	36	L-UNK	inhibitors
7	37	37	O	,
8	39	41	O	has
9	43	45	O	had
10	47	50	O	less
11	52	55	O	than
12	57	64	O	additive
13	66	72	O	effects
14	74	77	O	with
15	79	82	B-DYN	beta
16	84	93	I-DYN	adrenergic
17	95	102	L-DYN	blockers
18	103	103	O	,
19	105	114	O	presumably
20	116	122	O	because
21	124	127	O	both
22	129	133	O	drugs
23	135	139	O	lower
24	141	145	O	blood
25	147	154	O	pressure
26	156	157	O	by
27	159	168	O	inhibiting
28	170	174	O	parts
29	176	177	O	of
30	179	181	O	the
31	183	187	O	renin
32	189	199	O	angiotensin
33	201	206	O	system
NULL

Bendroflumethiazide	DDI-DrugBank.d304.s0	NO_SECTION	NO_SETID	20
May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;
1	0	2	O	May
2	4	11	O	interact
3	13	16	O	with
4	18	20	O	the
5	22	30	O	following
6	31	31	O	:
7	33	46	U-UNK	cholestyramine
8	47	47	O	,
9	49	58	U-UNK	colestipol
10	61	63	O	use
11	65	68	O	with
12	70	77	B-UNK	thiazide
13	79	87	L-UNK	diuretics
14	89	91	O	may
15	93	99	O	prevent
16	101	103	O	the
17	105	112	U-UNK	diuretic
18	114	117	O	from
19	119	125	O	working
20	127	134	O	properly
NULL

Bentiromide	DDI-DrugBank.d537.s0	NO_SECTION	NO_SETID	72
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
1	0	10	U-UNK	Bentiromide
2	12	14	O	may
3	16	23	O	interact
4	25	28	O	with
5	30	42	U-UNK	acetaminophen
6	45	47	O	e.g
7	49	49	O	,
8	51	57	O	Tylenol
9	59	59	O	,
10	61	75	U-UNK	chloramphenicol
11	78	80	O	e.g
12	82	82	O	,
13	84	96	O	Chloromycetin
14	98	98	O	,
15	100	104	O	local
16	106	116	U-UNK	anesthetics
17	119	121	O	e.g
18	123	123	O	,
19	125	134	U-UNK	benzocaine
20	136	138	O	and
21	140	148	U-UNK	lidocaine
22	150	150	O	,
23	152	155	B-UNK	para
24	157	168	I-UNK	aminobenzoic
25	170	173	L-UNK	acid
26	176	179	U-UNK	PABA
27	182	191	O	containing
28	193	204	O	preparations
29	207	209	O	e.g
30	211	211	O	,
31	213	222	O	sunscreens
32	224	226	O	and
33	228	231	O	some
34	233	245	U-UNK	multivitamins
35	247	247	O	,
36	249	260	U-UNK	procainamide
37	263	265	O	e.g
38	267	267	O	,
39	269	277	O	XXXXXXXX
40	279	279	O	,
41	281	292	U-UNK	sulfonamides
42	295	299	O	sulfa
43	301	309	O	medicines
44	311	311	O	,
45	313	320	B-UNK	thiazide
46	322	330	L-UNK	diuretics
47	333	335	O	use
48	337	338	O	of
49	340	344	O	these
50	346	354	O	medicines
51	356	361	O	during
52	363	365	O	the
53	367	370	O	test
54	372	377	O	period
55	379	382	O	will
56	384	389	O	affect
57	391	393	O	the
58	395	398	O	test
59	400	406	O	results
60	408	408	O	,
61	410	412	O	and
62	414	423	O	pancreatic
63	425	435	O	supplements
64	438	440	O	use
65	442	443	O	of
66	445	454	O	pancreatic
67	456	466	O	supplements
68	468	470	O	may
69	472	475	O	give
70	477	481	O	false
71	483	486	O	test
72	488	494	O	results
NULL

Bentoquatam	DDI-DrugBank.d173.s0	NO_SECTION	NO_SETID	25
May interact with other creams, lotions, or skin medicines when placed on the same areas of your skin that you are using bentoquatam.
1	0	2	O	May
2	4	11	O	interact
3	13	16	O	with
4	18	22	O	other
5	24	29	O	creams
6	30	30	O	,
7	32	38	O	lotions
8	39	39	O	,
9	41	42	O	or
10	44	47	O	skin
11	49	57	O	medicines
12	59	62	O	when
13	64	69	O	placed
14	71	72	O	on
15	74	76	O	the
16	78	81	O	same
17	83	87	O	areas
18	89	90	O	of
19	92	95	O	your
20	97	100	O	skin
21	102	105	O	that
22	107	109	O	you
23	111	113	O	are
24	115	119	O	using
25	121	131	O	XXXXXXXX
NULL

Benzocaine	DDI-DrugBank.d24.s0	NO_SECTION	NO_SETID	4
No information is available.
1	0	1	O	No
2	3	13	O	information
3	15	16	O	is
4	18	26	O	available
NULL

Benzphetamine	DDI-DrugBank.d477.s0	NO_SECTION	NO_SETID	19
Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.
1	0	11	O	Hypertensive
2	13	18	O	crises
3	20	23	O	have
4	25	32	O	resulted
5	34	37	O	when
6	39	53	B-UNK	sympathomimetic
7	55	60	L-UNK	amines
8	62	65	O	have
9	67	70	O	been
10	72	75	O	used
11	77	89	O	concomitantly
12	91	98	O	within14
13	100	103	O	days
14	105	113	O	following
15	115	117	O	use
16	119	120	O	of
17	122	130	B-UNK	monoamine
18	132	138	I-UNK	oxidase
19	140	149	L-UNK	inhibitors
NULL

Benzphetamine	DDI-DrugBank.d477.s1	NO_SECTION	NO_SETID	10
DIDREX should not be used concomitantly with other CNS stimulants.
1	0	5	O	XXXXXXXX
2	7	12	O	should
3	14	16	O	not
4	18	19	O	be
5	21	24	O	used
6	26	38	O	concomitantly
7	40	43	O	with
8	45	49	O	other
9	51	53	B-DYN	CNS
10	55	64	L-DYN	stimulants
NULL

Benzphetamine	DDI-DrugBank.d477.s2	NO_SECTION	NO_SETID	8
Amphetamines may decrease the hypotensive effect of antihypertensives.
1	0	11	U-UNK	Amphetamines
2	13	15	O	may
3	17	24	O	decrease
4	26	28	O	the
5	30	40	O	hypotensive
6	42	47	O	effect
7	49	50	O	of
8	52	68	U-UNK	antihypertensives
NULL

Benzphetamine	DDI-DrugBank.d477.s3	NO_SECTION	NO_SETID	8
Amphetamines may enhance the effects of tricyclic antidepressants.
1	0	11	U-UNK	Amphetamines
2	13	15	O	may
3	17	23	O	enhance
4	25	27	O	the
5	29	35	O	effects
6	37	38	O	of
7	40	48	B-UNK	tricyclic
8	50	64	L-UNK	antidepressants
NULL

Benzphetamine	DDI-DrugBank.d477.s4	NO_SECTION	NO_SETID	11
Urinary alkalinizing agents increase blood levels and decrease excretion of amphetamines.
1	0	6	O	Urinary
2	8	19	O	alkalinizing
3	21	26	O	agents
4	28	35	O	increase
5	37	41	O	blood
6	43	48	O	levels
7	50	52	O	and
8	54	61	O	decrease
9	63	71	O	excretion
10	73	74	O	of
11	76	87	U-UNK	amphetamines
NULL

Benzphetamine	DDI-DrugBank.d477.s5	NO_SECTION	NO_SETID	11
Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.
1	0	6	B-UNK	Urinary
2	8	17	L-UNK	acidifying
3	19	24	O	agents
4	26	33	O	decrease
5	35	39	O	blood
6	41	46	O	levels
7	48	50	O	and
8	52	59	O	increase
9	61	69	O	excretion
10	71	72	O	of
11	74	85	U-UNK	amphetamines
NULL

Benzthiazide	DDI-DrugBank.d208.s0	NO_SECTION	NO_SETID	37
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
1	0	11	U-UNK	Benzthiazide
2	13	15	O	may
3	17	24	O	interact
4	26	29	O	with
5	31	37	U-UNK	alcohol
6	38	38	O	,
7	40	44	U-UNK	blood
8	46	53	O	thinners
9	54	54	O	,
10	56	67	B-UNK	decongestant
11	69	73	L-UNK	drugs
12	76	82	O	allergy
13	83	83	O	,
14	85	88	O	cold
15	89	89	O	,
16	91	93	O	and
17	95	99	O	sinus
18	101	109	O	medicines
19	111	111	O	,
20	113	120	O	diabetic
21	122	126	O	drugs
22	127	127	O	,
23	129	135	U-UNK	lithium
24	136	136	O	,
25	138	151	U-UNK	norepinephrine
26	152	152	O	,
27	154	159	U-UNK	NSAIDs
28	161	164	O	like
29	166	170	O	XXXXXXXX
30	172	173	O	or
31	175	183	U-UNK	Ibuprofen
32	184	184	O	,
33	186	188	O	and
34	190	193	O	high
35	195	199	O	blood
36	201	208	O	pressure
37	210	220	O	medications
NULL

Benztropine	DDI-DrugBank.d390.s0	NO_SECTION	NO_SETID	7
Antipsychotic drugs such as phenothiazines or haloperidol;
1	0	12	B-UNK	Antipsychotic
2	14	18	L-UNK	drugs
3	20	23	O	such
4	25	26	O	as
5	28	41	U-UNK	phenothiazines
6	43	44	O	or
7	46	56	U-UNK	haloperidol
NULL

Benztropine	DDI-DrugBank.d390.s1	NO_SECTION	NO_SETID	2
tricyclic antidepressants.
1	0	8	B-UNK	tricyclic
2	10	24	L-UNK	antidepressants
NULL

Bepridil	DDI-DrugBank.d137.s0	NO_SECTION	NO_SETID	23
Nitrates: The concomitant use of Bepridil with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.
1	0	7	U-UNK	Nitrates
2	8	8	O	:
3	10	12	O	The
4	14	24	O	concomitant
5	26	28	O	use
6	30	31	O	of
7	33	40	O	XXXXXXXX
8	42	45	O	with
9	47	50	O	long
10	53	55	O	and
11	57	61	O	short
12	63	68	O	acting
13	70	77	U-UNK	nitrates
14	79	81	O	has
15	83	86	O	been
16	88	93	O	safely
17	95	103	O	tolerated
18	105	106	O	in
19	108	115	O	patients
20	117	120	O	with
21	122	127	O	stable
22	129	134	O	angina
23	136	143	O	pectoris
NULL

Bepridil	DDI-DrugBank.d137.s1	NO_SECTION	NO_SETID	17
Sublingual nitroglycerin may be taken if necessary for the control of acute angina attacks during Bepridil therapy.
1	0	9	O	Sublingual
2	11	23	U-UNK	nitroglycerin
3	25	27	O	may
4	29	30	O	be
5	32	36	O	taken
6	38	39	O	if
7	41	49	O	necessary
8	51	53	O	for
9	55	57	O	the
10	59	65	O	control
11	67	68	O	of
12	70	74	O	acute
13	76	81	O	angina
14	83	89	O	attacks
15	91	96	O	during
16	98	105	O	XXXXXXXX
17	107	113	O	therapy
NULL

Bepridil	DDI-DrugBank.d137.s2	NO_SECTION	NO_SETID	22
Beta-blocking Agents: The concomitant use of Bepridil and beta-blocking agents has been well tolerated in patients with stable angina.
1	0	3	B-UNK	Beta
2	5	12	I-UNK	blocking
3	14	19	L-UNK	Agents
4	20	20	O	:
5	22	24	O	The
6	26	36	O	concomitant
7	38	40	O	use
8	42	43	O	of
9	45	52	O	XXXXXXXX
10	54	56	O	and
11	58	61	B-UNK	beta
12	63	70	I-UNK	blocking
13	72	77	L-UNK	agents
14	79	81	O	has
15	83	86	O	been
16	88	91	O	well
17	93	101	O	tolerated
18	103	104	O	in
19	106	113	O	patients
20	115	118	O	with
21	120	125	O	stable
22	127	132	O	angina
NULL

Bepridil	DDI-DrugBank.d137.s3	NO_SECTION	NO_SETID	25
Available data are not sufficient, however, to predict the effects of concomitant medication on patients with impaired ventricular function or cardiac conduction abnormalities.
1	0	8	O	Available
2	10	13	O	data
3	15	17	O	are
4	19	21	O	not
5	23	32	O	sufficient
6	33	33	O	,
7	35	41	O	however
8	42	42	O	,
9	44	45	O	to
10	47	53	O	predict
11	55	57	O	the
12	59	65	O	effects
13	67	68	O	of
14	70	80	O	concomitant
15	82	91	O	medication
16	93	94	O	on
17	96	103	O	patients
18	105	108	O	with
19	110	117	O	impaired
20	119	129	O	ventricular
21	131	138	O	function
22	140	141	O	or
23	143	149	O	cardiac
24	151	160	O	conduction
25	162	174	O	abnormalities
NULL

Bepridil	DDI-DrugBank.d137.s4	NO_SECTION	NO_SETID	34
Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	10	O	In
4	12	21	O	controlled
5	23	29	O	studies
6	31	32	O	in
7	34	40	O	healthy
8	42	51	O	volunteers
9	52	52	O	,
10	54	61	O	XXXXXXXX
11	63	75	O	hydrochloride
12	77	82	O	either
13	84	86	O	had
14	88	89	O	no
15	91	96	O	effect
16	99	101	O	one
17	103	107	O	study
18	110	111	O	or
19	113	115	O	was
20	117	126	O	associated
21	128	131	O	with
22	133	138	O	modest
23	140	148	O	increases
24	149	149	O	,
25	151	155	O	about
26	157	159	O	30%
27	162	164	O	two
28	166	172	O	studies
29	175	176	O	in
30	178	183	O	steady
31	185	189	O	state
32	191	195	O	serum
33	197	203	U-KIN	digoxin
34	205	218	O	concentrations
NULL

Bepridil	DDI-DrugBank.d137.s5	NO_SECTION	NO_SETID	21
Limited clinical data in angina patients receiving concomitant bepridil hydrochloride and digoxin therapy indicate no discernible changes in serum digoxin levels.
1	0	6	O	Limited
2	8	15	O	clinical
3	17	20	O	data
4	22	23	O	in
5	25	30	O	angina
6	32	39	O	patients
7	41	49	O	receiving
8	51	61	O	concomitant
9	63	70	O	XXXXXXXX
10	72	84	O	hydrochloride
11	86	88	O	and
12	90	96	U-UNK	digoxin
13	98	104	O	therapy
14	106	113	O	indicate
15	115	116	O	no
16	118	128	O	discernible
17	130	136	O	changes
18	138	139	O	in
19	141	145	O	serum
20	147	153	O	digoxin
21	155	160	O	levels
NULL

Bepridil	DDI-DrugBank.d137.s6	NO_SECTION	NO_SETID	38
Available data are neither sufficient to rule out possible increases in serum digoxin with concomitant treatment in some patients, nor other possible interactions, particularly in patients with cardiac conduction abnormalities (Also see WARNINGS Congestive Heart Failure).
1	0	8	O	Available
2	10	13	O	data
3	15	17	O	are
4	19	25	O	neither
5	27	36	O	sufficient
6	38	39	O	to
7	41	44	O	rule
8	46	48	O	out
9	50	57	O	possible
10	59	67	O	increases
11	69	70	O	in
12	72	76	O	serum
13	78	84	U-UNK	digoxin
14	86	89	O	with
15	91	101	O	concomitant
16	103	111	O	treatment
17	113	114	O	in
18	116	119	O	some
19	121	128	O	patients
20	129	129	O	,
21	131	133	O	nor
22	135	139	O	other
23	141	148	O	possible
24	150	161	O	interactions
25	162	162	O	,
26	164	175	O	particularly
27	177	178	O	in
28	180	187	O	patients
29	189	192	O	with
30	194	200	O	cardiac
31	202	211	O	conduction
32	213	225	O	abnormalities
33	228	231	O	Also
34	233	235	O	see
35	237	244	O	WARNINGS
36	246	255	O	Congestive
37	257	261	O	Heart
38	263	269	O	Failure
NULL

Bepridil	DDI-DrugBank.d137.s7	NO_SECTION	NO_SETID	28
Oral Hypoglycemics: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic agents.
1	0	3	O	Oral
2	5	17	U-UNK	Hypoglycemics
3	18	18	O	:
4	20	27	O	XXXXXXXX
5	29	31	O	has
6	33	36	O	been
7	38	43	O	safely
8	45	48	O	used
9	50	51	O	in
10	53	60	O	diabetic
11	62	69	O	patients
12	71	77	O	without
13	79	91	O	significantly
14	93	100	O	lowering
15	102	106	O	their
16	108	112	O	blood
17	114	120	O	glucose
18	122	127	O	levels
19	129	130	O	or
20	132	139	O	altering
21	141	145	O	their
22	147	150	O	need
23	152	154	O	for
24	156	162	U-UNK	insulin
25	164	165	O	or
26	167	170	O	oral
27	172	183	B-UNK	hypoglycemic
28	185	190	L-UNK	agents
NULL

Bepridil	DDI-DrugBank.d137.s8	NO_SECTION	NO_SETID	17
General Interactions: Certain drugs could increase the likelihood of potentially serious adverse effects with bepridil hydrochloride.
1	0	6	O	General
2	8	19	O	Interactions
3	20	20	O	:
4	22	28	O	Certain
5	30	34	O	drugs
6	36	40	O	could
7	42	49	O	increase
8	51	53	O	the
9	55	64	O	likelihood
10	66	67	O	of
11	69	79	O	potentially
12	81	87	O	serious
13	89	95	O	adverse
14	97	103	O	effects
15	105	108	O	with
16	110	117	O	XXXXXXXX
17	119	131	O	hydrochloride
NULL

Bepridil	DDI-DrugBank.d137.s9	NO_SECTION	NO_SETID	34
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.
1	0	1	O	In
2	3	9	O	general
3	10	10	O	,
4	12	16	O	these
5	18	20	O	are
6	22	26	O	drugs
7	28	31	O	that
8	33	36	O	have
9	38	40	O	one
10	42	43	O	or
11	45	48	O	more
12	50	62	O	pharmacologic
13	64	73	O	activities
14	75	81	O	similar
15	83	84	O	to
16	86	93	O	XXXXXXXX
17	95	107	O	hydrochloride
18	108	108	O	,
19	110	118	O	including
20	120	123	B-UNK	anti
21	125	134	I-UNK	arrhythmic
22	136	141	L-UNK	agents
23	143	146	O	such
24	148	149	O	as
25	151	159	U-UNK	quinidine
26	161	163	O	and
27	165	176	U-UNK	procainamide
28	177	177	O	,
29	179	185	B-UNK	cardiac
30	187	196	L-UNK	glycosides
31	198	200	O	and
32	202	210	B-UNK	tricyclic
33	212	215	I-UNK	anti
34	217	227	L-UNK	depressants
NULL

Bepridil	DDI-DrugBank.d137.s10	NO_SECTION	NO_SETID	18
Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.
1	0	3	B-DYN	Anti
2	5	15	L-DYN	arrhythmics
3	17	19	O	and
4	21	29	B-DYN	tricyclic
5	31	34	I-DYN	anti
6	36	46	L-DYN	depressants
7	48	52	O	could
8	54	63	O	exaggerate
9	65	67	O	the
10	69	80	O	prolongation
11	82	83	O	of
12	85	87	O	the
13	89	90	O	QT
14	92	99	O	interval
15	101	108	O	observed
16	110	113	O	with
17	115	122	O	XXXXXXXX
18	124	136	O	hydrochloride
NULL

Bepridil	DDI-DrugBank.d137.s11	NO_SECTION	NO_SETID	14
Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.
1	0	6	B-DYN	Cardiac
2	8	17	L-DYN	glycosides
3	19	23	O	could
4	25	34	O	exaggerate
5	36	38	O	the
6	40	49	O	depression
7	51	52	O	of
8	54	55	O	AV
9	57	61	O	nodal
10	63	72	O	conduction
11	74	81	O	observed
12	83	86	O	with
13	88	95	O	XXXXXXXX
14	97	109	O	hydrochloride
NULL

Betaxolol	DDI-DrugBank.d489.s0	NO_SECTION	NO_SETID	23
The following drugs have been coadministered with Kerlone and have not altered its pharmacokinetics: cimetidine, nifedipine, chlorthalidone, and hydrochlorothiazide.
1	0	2	O	The
2	4	12	O	following
3	14	18	O	drugs
4	20	23	O	have
5	25	28	O	been
6	30	43	O	coadministered
7	45	48	O	with
8	50	56	O	XXXXXXXX
9	58	60	O	and
10	62	65	O	have
11	67	69	O	not
12	71	77	O	altered
13	79	81	O	its
14	83	98	O	pharmacokinetics
15	99	99	O	:
16	101	110	U-UNK	cimetidine
17	111	111	O	,
18	113	122	U-UNK	nifedipine
19	123	123	O	,
20	125	138	U-UNK	chlorthalidone
21	139	139	O	,
22	141	143	O	and
23	145	163	U-UNK	hydrochlorothiazide
NULL

Betaxolol	DDI-DrugBank.d489.s1	NO_SECTION	NO_SETID	20
Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	36	O	XXXXXXXX
5	38	41	O	with
6	43	45	O	the
7	47	50	O	oral
8	52	64	U-UNK	anticoagulant
9	66	73	U-UNK	warfarin
10	75	77	O	has
11	79	82	O	been
12	84	88	O	shown
13	90	92	O	not
14	94	95	O	to
15	97	106	O	potentiate
16	108	110	O	the
17	112	124	O	anticoagulant
18	126	131	O	effect
19	133	134	O	of
20	136	143	U-UNK	warfarin
NULL

Betaxolol	DDI-DrugBank.d489.s2	NO_SECTION	NO_SETID	17
Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
1	0	12	O	Catecholamine
2	14	22	O	depleting
3	24	28	O	drugs
4	31	33	O	e.g
5	35	35	O	,
6	37	45	U-UNK	reserpine
7	48	50	O	may
8	52	55	O	have
9	57	58	O	an
10	60	67	O	additive
11	69	74	O	effect
12	76	79	O	when
13	81	85	O	given
14	87	90	O	with
15	92	95	B-UNK	beta
16	97	104	L-UNK	blocking
17	106	111	O	agents
NULL

Betaxolol	DDI-DrugBank.d489.s3	NO_SECTION	NO_SETID	36
Patients treated with a beta-adrenergic receptor blocking agent plus a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
1	0	7	O	Patients
2	9	15	O	treated
3	17	20	O	with
4	22	22	O	a
5	24	27	B-UNK	beta
6	29	38	I-UNK	adrenergic
7	40	47	I-UNK	receptor
8	49	56	I-UNK	blocking
9	58	62	L-UNK	agent
10	64	67	O	plus
11	69	69	O	a
12	71	83	O	catecholamine
13	85	92	O	depletor
14	94	99	O	should
15	101	109	O	therefore
16	111	112	O	be
17	114	120	O	closely
18	122	129	O	observed
19	131	133	O	for
20	135	142	O	evidence
21	144	145	O	of
22	147	157	O	hypotension
23	159	160	O	or
24	162	167	O	marked
25	169	179	O	bradycardia
26	180	180	O	,
27	182	186	O	which
28	188	190	O	may
29	192	198	O	produce
30	200	206	O	vertigo
31	207	207	O	,
32	209	215	O	syncope
33	216	216	O	,
34	218	219	O	or
35	221	228	O	postural
36	230	240	O	hypotension
NULL

Betaxolol	DDI-DrugBank.d489.s4	NO_SECTION	NO_SETID	32
Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.
1	0	5	O	Should
2	7	8	O	it
3	10	11	O	be
4	13	19	O	decided
5	21	22	O	to
6	24	34	O	discontinue
7	36	42	O	therapy
8	44	45	O	in
9	47	54	O	patients
10	56	64	O	receiving
11	66	69	B-UNK	beta
12	71	78	L-UNK	blockers
13	80	82	O	and
14	84	92	U-UNK	clonidine
15	94	105	O	concurrently
16	106	106	O	,
17	108	110	O	the
18	112	115	B-UNK	beta
19	117	123	L-UNK	blocker
20	125	130	O	should
21	132	133	O	be
22	135	146	O	discontinued
23	148	153	O	slowly
24	155	158	O	over
25	160	166	O	several
26	168	171	O	days
27	173	178	O	before
28	180	182	O	the
29	184	190	O	gradual
30	192	201	O	withdrawal
31	203	204	O	of
32	206	214	U-UNK	clonidine
NULL

Betaxolol	DDI-DrugBank.d489.s5	NO_SECTION	NO_SETID	33
Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.
1	0	9	O	Literature
2	11	17	O	reports
3	19	25	O	suggest
4	27	30	O	that
5	32	35	O	oral
6	37	43	B-UNK	calcium
7	45	55	L-UNK	antagonists
8	57	59	O	may
9	61	62	O	be
10	64	67	O	used
11	69	70	O	in
12	72	82	O	combination
13	84	87	O	with
14	89	92	B-UNK	beta
15	94	103	I-UNK	adrenergic
16	105	112	I-UNK	blocking
17	114	119	L-UNK	agents
18	121	124	O	when
19	126	130	O	heart
20	132	139	O	function
21	141	142	O	is
22	144	149	O	normal
23	150	150	O	,
24	152	154	O	but
25	156	161	O	should
26	163	164	O	be
27	166	172	O	avoided
28	174	175	O	in
29	177	184	O	patients
30	186	189	O	with
31	191	198	O	impaired
32	200	206	O	cardiac
33	208	215	O	function
NULL

Betaxolol	DDI-DrugBank.d489.s6	NO_SECTION	NO_SETID	32
Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.
1	0	10	O	Hypotension
2	11	11	O	,
3	13	14	O	AV
4	16	25	O	conduction
5	27	38	O	disturbances
6	39	39	O	,
7	41	43	O	and
8	45	48	O	left
9	50	60	O	ventricular
10	62	68	O	failure
11	70	73	O	have
12	75	78	O	been
13	80	87	O	reported
14	89	90	O	in
15	92	95	O	some
16	97	104	O	patients
17	106	114	O	receiving
18	116	119	B-UNK	beta
19	121	130	I-UNK	adrenergic
20	132	139	I-UNK	blocking
21	141	146	L-UNK	agents
22	148	151	O	when
23	153	154	O	an
24	156	159	O	oral
25	161	167	B-UNK	calcium
26	169	178	L-UNK	antagonist
27	180	182	O	was
28	184	188	O	added
29	190	191	O	to
30	193	195	O	the
31	197	205	O	treatment
32	207	213	O	regimen
NULL

Betaxolol	DDI-DrugBank.d489.s7	NO_SECTION	NO_SETID	43
Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.
1	0	10	O	Hypotension
2	12	14	O	was
3	16	19	O	more
4	21	26	O	likely
5	28	29	O	to
6	31	35	O	occur
7	37	38	O	if
8	40	42	O	the
9	44	50	B-UNK	calcium
10	52	61	L-UNK	antagonist
11	63	66	O	were
12	68	68	O	a
13	70	84	B-UNK	dihydropyridine
14	86	95	L-UNK	derivative
15	96	96	O	,
16	98	100	O	e.g
17	102	102	O	,
18	104	113	U-UNK	nifedipine
19	114	114	O	,
20	116	120	O	while
21	122	125	O	left
22	127	137	O	ventricular
23	139	145	O	failure
24	147	149	O	and
25	151	152	O	AV
26	154	163	O	conduction
27	165	176	O	disturbances
28	177	177	O	,
29	179	187	O	including
30	189	196	O	complete
31	198	202	O	heart
32	204	208	O	block
33	209	209	O	,
34	211	214	O	were
35	216	219	O	more
36	221	226	O	likely
37	228	229	O	to
38	231	235	O	occur
39	237	240	O	with
40	242	247	O	either
41	249	257	U-UNK	verapamil
42	259	260	O	or
43	262	270	U-UNK	diltiazem
NULL

Betaxolol	DDI-DrugBank.d489.s8	NO_SECTION	NO_SETID	52
Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
1	0	3	O	Risk
2	5	6	O	of
3	8	19	O	Anaphylactic
4	21	28	O	Reaction
5	29	29	O	:
6	31	38	O	Although
7	40	41	O	it
8	43	44	O	is
9	46	50	O	known
10	52	55	O	that
11	57	64	O	patients
12	66	67	O	on
13	69	72	B-UNK	beta
14	74	81	L-UNK	blockers
15	83	85	O	may
16	87	88	O	be
17	90	99	O	refractory
18	101	102	O	to
19	104	114	U-UNK	epinephrine
20	116	117	O	in
21	119	121	O	the
22	123	131	O	treatment
23	133	134	O	of
24	136	147	O	anaphylactic
25	149	153	O	shock
26	154	154	O	,
27	156	159	B-UNK	beta
28	161	168	L-UNK	blockers
29	170	172	O	can
30	173	173	O	,
31	175	176	O	in
32	178	185	O	addition
33	186	186	O	,
34	188	196	O	interfere
35	198	201	O	with
36	203	205	O	the
37	207	216	O	modulation
38	218	219	O	of
39	221	228	O	allergic
40	230	237	O	reaction
41	239	241	O	and
42	243	246	O	lead
43	248	249	O	to
44	251	252	O	an
45	254	262	O	increased
46	264	271	O	severity
47	273	275	O	and
48	276	276	O	/
49	277	278	O	or
50	280	288	O	frequency
51	290	291	O	of
52	293	299	O	attacks
NULL

Betaxolol	DDI-DrugBank.d489.s9	NO_SECTION	NO_SETID	35
Severe allergic reactions including anaphylaxis have been reported in patients exposed to a variety of allergens either by repeated challenge, or accidental contact, and with diagnostic or therapeutic agents while receiving beta-blockers.
1	0	5	O	Severe
2	7	14	O	allergic
3	16	24	O	reactions
4	26	34	O	including
5	36	46	O	anaphylaxis
6	48	51	O	have
7	53	56	O	been
8	58	65	O	reported
9	67	68	O	in
10	70	77	O	patients
11	79	85	O	exposed
12	87	88	O	to
13	90	90	O	a
14	92	98	O	variety
15	100	101	O	of
16	103	111	O	allergens
17	113	118	O	either
18	120	121	O	by
19	123	130	O	repeated
20	132	140	O	challenge
21	141	141	O	,
22	143	144	O	or
23	146	155	O	accidental
24	157	163	O	contact
25	164	164	O	,
26	166	168	O	and
27	170	173	O	with
28	175	184	O	diagnostic
29	186	187	O	or
30	189	199	O	therapeutic
31	201	206	O	agents
32	208	212	O	while
33	214	222	O	receiving
34	224	227	B-UNK	beta
35	229	236	L-UNK	blockers
NULL

Betaxolol	DDI-DrugBank.d489.s10	NO_SECTION	NO_SETID	16
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
1	0	3	O	Such
2	5	12	O	patients
3	14	16	O	may
4	18	19	O	be
5	21	32	O	unresponsive
6	34	35	O	to
7	37	39	O	the
8	41	45	O	usual
9	47	51	O	doses
10	53	54	O	of
11	56	66	U-UNK	epinephrine
12	68	71	O	used
13	73	74	O	to
14	76	80	O	treat
15	82	89	O	allergic
16	91	98	O	reaction
NULL

Bethanechol	DDI-DrugBank.d513.s0	NO_SECTION	NO_SETID	24
Special care is required if this drug is given to patients receiving ganglion blocking compounds because a critical fall in blood pressure may occur.
1	0	6	O	Special
2	8	11	O	care
3	13	14	O	is
4	16	23	O	required
5	25	26	O	if
6	28	31	O	this
7	33	36	O	drug
8	38	39	O	is
9	41	45	O	given
10	47	48	O	to
11	50	57	O	patients
12	59	67	O	receiving
13	69	76	B-UNK	ganglion
14	78	85	I-UNK	blocking
15	87	95	L-UNK	compounds
16	97	103	O	because
17	105	105	O	a
18	107	114	O	critical
19	116	119	O	fall
20	121	122	O	in
21	124	128	O	blood
22	130	137	O	pressure
23	139	141	O	may
24	143	147	O	occur
NULL

Bethanechol	DDI-DrugBank.d513.s1	NO_SECTION	NO_SETID	16
Usually, severe abdominal symptoms appear before there is such a fall in the blood pressure.
1	0	6	O	Usually
2	7	7	O	,
3	9	14	O	severe
4	16	24	O	abdominal
5	26	33	O	symptoms
6	35	40	O	appear
7	42	47	O	before
8	49	53	O	there
9	55	56	O	is
10	58	61	O	such
11	63	63	O	a
12	65	68	O	fall
13	70	71	O	in
14	73	75	O	the
15	77	81	O	blood
16	83	90	O	pressure
NULL

Bevacizumab	DDI-DrugBank.d312.s0	NO_SECTION	NO_SETID	12
No formal drug interaction studies with anti-neoplastic agents have been conducted.
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	25	O	interaction
5	27	33	O	studies
6	35	38	O	with
7	40	43	B-UNK	anti
8	45	54	I-UNK	neoplastic
9	56	61	L-UNK	agents
10	63	66	O	have
11	68	71	O	been
12	73	81	O	conducted
NULL

Bevacizumab	DDI-DrugBank.d312.s1	NO_SECTION	NO_SETID	22
In Study 1, patients with colorectal cancer were given irinotecan/5-FU/leucovorin (bolus-IFL) with or without AVASTIN.
1	0	1	O	In
2	3	7	O	Study
3	9	9	O	1
4	10	10	O	,
5	12	19	O	patients
6	21	24	O	with
7	26	35	O	colorectal
8	37	42	O	cancer
9	44	47	O	were
10	49	53	O	given
11	55	64	U-UNK	irinotecan
12	65	65	O	/
13	66	66	B-UNK	5
14	68	69	L-UNK	FU
15	70	70	O	/
16	71	80	U-UNK	leucovorin
17	83	87	O	bolus
18	89	91	O	IFL
19	94	97	O	with
20	99	100	O	or
21	102	108	O	without
22	110	116	O	XXXXXXXX
NULL

Bevacizumab	DDI-DrugBank.d312.s2	NO_SECTION	NO_SETID	15
Irinotecan concentrations were similar in patients receiving bolus-IFL alone and in combination with AVASTIN.
1	0	9	U-UNK	Irinotecan
2	11	24	O	concentrations
3	26	29	O	were
4	31	37	O	similar
5	39	40	O	in
6	42	49	O	patients
7	51	59	O	receiving
8	61	65	O	bolus
9	67	69	O	IFL
10	71	75	O	alone
11	77	79	O	and
12	81	82	O	in
13	84	94	O	combination
14	96	99	O	with
15	101	107	O	XXXXXXXX
NULL

Bevacizumab	DDI-DrugBank.d312.s3	NO_SECTION	NO_SETID	31
The concentrations of SN38, the active metabolite of irinotecan, were on average 33% higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone.
1	0	2	O	The
2	4	17	O	concentrations
3	19	20	O	of
4	22	25	U-UNK	SN38
5	26	26	O	,
6	28	30	O	the
7	32	37	O	active
8	39	48	O	metabolite
9	50	51	O	of
10	53	62	U-UNK	irinotecan
11	63	63	O	,
12	65	68	O	were
13	70	71	O	on
14	73	79	O	average
15	81	83	O	33%
16	85	90	O	higher
17	92	93	O	in
18	95	102	O	patients
19	104	112	O	receiving
20	114	118	O	bolus
21	120	122	O	IFL
22	124	125	O	in
23	127	137	O	combination
24	139	142	O	with
25	144	150	O	XXXXXXXX
26	152	155	O	when
27	157	164	O	compared
28	166	169	O	with
29	171	175	O	bolus
30	177	179	O	IFL
31	181	185	O	alone
NULL

Bevacizumab	DDI-DrugBank.d312.s4	NO_SECTION	NO_SETID	21
In Study 1, patients receiving bolus-IFL plus AVASTIN had a higher incidence of Grade 3-4 diarrhea and neutropenia.
1	0	1	O	In
2	3	7	O	Study
3	9	9	O	1
4	10	10	O	,
5	12	19	O	patients
6	21	29	O	receiving
7	31	35	O	bolus
8	37	39	O	IFL
9	41	44	O	plus
10	46	52	O	XXXXXXXX
11	54	56	O	had
12	58	58	O	a
13	60	65	O	higher
14	67	75	O	incidence
15	77	78	O	of
16	80	84	O	Grade
17	86	86	O	3
18	88	88	O	4
19	90	97	O	diarrhea
20	99	101	O	and
21	103	113	O	neutropenia
NULL

Bevacizumab	DDI-DrugBank.d312.s5	NO_SECTION	NO_SETID	27
Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain.
1	0	2	O	Due
2	4	5	O	to
3	7	10	O	high
4	12	16	O	inter
5	18	24	O	patient
6	26	36	O	variability
7	38	40	O	and
8	42	48	O	limited
9	50	57	O	sampling
10	58	58	O	,
11	60	62	O	the
12	64	69	O	extent
13	71	72	O	of
14	74	76	O	the
15	78	85	O	increase
16	87	88	O	in
17	90	93	U-UNK	SN38
18	95	100	O	levels
19	102	103	O	in
20	105	112	O	patients
21	114	122	O	receiving
22	124	133	O	concurrent
23	135	144	U-UNK	irinotecan
24	146	148	O	and
25	150	156	O	XXXXXXXX
26	158	159	O	is
27	161	169	O	uncertain
NULL

Bexarotene	DDI-DrugBank.d467.s0	NO_SECTION	NO_SETID	12
No formal studies to evaluate drug interactions with bexarotene have been conducted.
1	0	1	O	No
2	3	8	O	formal
3	10	16	O	studies
4	18	19	O	to
5	21	28	O	evaluate
6	30	33	O	drug
7	35	46	O	interactions
8	48	51	O	with
9	53	62	O	XXXXXXXX
10	64	67	O	have
11	69	72	O	been
12	74	82	O	conducted
NULL

Bexarotene	DDI-DrugBank.d467.s1	NO_SECTION	NO_SETID	11
Bexarotene oxidative metabolites appear to be formed by cytochrome P450 3A4.
1	0	9	O	XXXXXXXX
2	11	19	O	oxidative
3	21	31	O	metabolites
4	33	38	O	appear
5	40	41	O	to
6	43	44	O	be
7	46	51	O	formed
8	53	54	O	by
9	56	65	O	cytochrome
10	67	70	O	P450
11	72	74	O	3A4
NULL

Bexarotene	DDI-DrugBank.d467.s2	NO_SECTION	NO_SETID	43
On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
1	0	1	O	On
2	3	5	O	the
3	7	11	O	basis
4	13	14	O	of
5	16	18	O	the
6	20	29	O	metabolism
7	31	32	O	of
8	34	43	O	XXXXXXXX
9	45	46	O	by
10	48	57	O	cytochrome
11	59	62	O	P450
12	64	66	O	3A4
13	67	67	O	,
14	69	80	U-KIN	ketoconazole
15	81	81	O	,
16	83	94	U-KIN	itraconazole
17	95	95	O	,
18	97	108	U-KIN	erythromycin
19	109	109	O	,
20	111	121	U-KIN	gemfibrozil
21	122	122	O	,
22	124	133	O	grapefruit
23	135	139	O	juice
24	140	140	O	,
25	142	144	O	and
26	146	150	O	other
27	152	161	O	inhibitors
28	163	164	O	of
29	166	175	O	cytochrome
30	177	180	O	P450
31	182	184	O	3A4
32	186	190	O	would
33	192	193	O	be
34	195	202	O	expected
35	204	205	O	to
36	207	210	O	lead
37	212	213	O	to
38	215	216	O	an
39	218	225	O	increase
40	227	228	O	in
41	230	235	O	plasma
42	237	246	O	XXXXXXXX
43	248	261	O	concentrations
NULL

Bexarotene	DDI-DrugBank.d467.s3	NO_SECTION	NO_SETID	23
Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	20	U-KIN	rifampin
4	21	21	O	,
5	23	31	U-KIN	phenytoin
6	32	32	O	,
7	34	46	U-KIN	phenobarbital
8	47	47	O	,
9	49	51	O	and
10	53	57	O	other
11	59	66	O	inducers
12	68	69	O	of
13	71	80	O	cytochrome
14	82	85	O	P450
15	87	89	O	3A4
16	91	93	O	may
17	95	99	O	cause
18	101	101	O	a
19	103	111	O	reduction
20	113	114	O	in
21	116	121	O	plasma
22	123	132	O	XXXXXXXX
23	134	147	O	concentrations
NULL

Bexarotene	DDI-DrugBank.d467.s4	NO_SECTION	NO_SETID	29
Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	38	O	XXXXXXXX
5	40	47	O	capsules
6	49	51	O	and
7	53	63	U-KIN	gemfibrozil
8	65	72	O	resulted
9	74	75	O	in
10	77	87	O	substantial
11	89	97	O	increases
12	99	100	O	in
13	102	107	O	plasma
14	109	122	O	concentrations
15	124	125	O	of
16	127	136	U-UNK	bexarotene
17	137	137	O	,
18	139	146	O	probably
19	148	149	O	at
20	151	155	O	least
21	157	165	O	partially
22	167	173	O	related
23	175	176	O	to
24	178	187	O	cytochrome
25	189	192	O	P450
26	194	196	O	3A4
27	198	207	O	inhibition
28	209	210	O	by
29	212	222	U-UNK	gemfibrozil
NULL

Bexarotene	DDI-DrugBank.d467.s5	NO_SECTION	NO_SETID	13
Under similar conditions, bexarotene concentrations were not affected by concomitant atorvastatin administration.
1	0	4	O	Under
2	6	12	O	similar
3	14	23	O	conditions
4	24	24	O	,
5	26	35	O	XXXXXXXX
6	37	50	O	concentrations
7	52	55	O	were
8	57	59	O	not
9	61	68	O	affected
10	70	71	O	by
11	73	83	O	concomitant
12	85	96	U-UNK	atorvastatin
13	98	111	O	administration
NULL

Bexarotene	DDI-DrugBank.d467.s6	NO_SECTION	NO_SETID	10
Concomitant administration of gemfibrozil with Targretin capsules is not recommended.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	40	U-DYN	gemfibrozil
5	42	45	O	with
6	47	55	O	XXXXXXXX
7	57	64	O	capsules
8	66	67	O	is
9	69	71	O	not
10	73	83	O	recommended
NULL

Bezafibrate	DDI-DrugBank.d291.s0	NO_SECTION	NO_SETID	37
When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.
1	0	3	O	When
2	5	11	O	Bezalip
3	13	14	O	or
4	16	29	O	XXXXXXXX
5	31	32	O	is
6	34	37	O	used
7	39	40	O	at
8	42	44	O	the
9	46	49	O	same
10	51	54	O	time
11	56	57	O	as
12	59	63	O	other
13	65	73	O	medicines
14	75	76	O	or
15	78	87	O	substances
16	89	91	O	the
17	93	101	O	following
18	103	114	O	interactions
19	116	119	O	must
20	121	122	O	be
21	124	128	O	taken
22	130	133	O	into
23	135	141	O	account
24	142	142	O	:
25	146	152	O	Bezalip
26	154	156	O	and
27	158	171	O	XXXXXXXX
28	173	175	O	may
29	177	183	O	enhance
30	185	187	O	the
31	189	194	O	action
32	196	197	O	of
33	199	212	B-DYN	anticoagulants
34	214	215	I-DYN	of
35	217	219	I-DYN	the
36	221	228	I-DYN	coumarin
37	230	233	L-DYN	type
NULL

Bezafibrate	DDI-DrugBank.d291.s1	NO_SECTION	NO_SETID	34
For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters
1	0	2	O	For
2	4	7	O	this
3	9	14	O	reason
4	15	15	O	,
5	17	19	O	the
6	21	24	O	dose
7	26	27	O	of
8	29	31	O	the
9	33	45	U-DYN	anticoagulant
10	47	52	O	should
11	54	55	O	be
12	57	63	O	reduced
13	65	66	O	by
14	68	69	O	30
15	73	75	O	50%
16	77	78	O	at
17	80	82	O	the
18	84	88	O	start
19	90	91	O	of
20	93	101	O	treatment
21	103	106	O	with
22	108	114	O	XXXXXXXX
23	116	117	O	or
24	119	125	O	XXXXXXXX
25	127	132	O	retard
26	134	136	O	and
27	138	141	O	then
28	143	150	O	titrated
29	152	160	O	according
30	162	163	O	to
31	165	167	O	the
32	169	173	O	blood
33	175	182	O	clotting
34	184	193	O	parameters
NULL

Bezafibrate	DDI-DrugBank.d291.s3	NO_SECTION	NO_SETID	13
- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
1	2	4	O	The
2	6	11	O	action
3	13	14	O	of
4	16	29	U-DYN	sulphonylureas
5	31	33	O	and
6	35	41	U-DYN	insulin
7	43	45	O	may
8	47	48	O	be
9	50	57	O	enhanced
10	59	60	O	by
11	62	68	O	Bezalip
12	70	71	O	or
13	73	86	O	XXXXXXXX
NULL

Bezafibrate	DDI-DrugBank.d291.s4	NO_SECTION	NO_SETID	15
This may be due to an improved glucose utilization with simultaneous reduction in insulin requirement
1	0	3	O	This
2	5	7	O	may
3	9	10	O	be
4	12	14	O	due
5	16	17	O	to
6	19	20	O	an
7	22	29	O	improved
8	31	37	O	glucose
9	39	49	O	utilization
10	51	54	O	with
11	56	67	O	simultaneous
12	69	77	O	reduction
13	79	80	O	in
14	82	88	U-UNK	insulin
15	90	100	O	requirement
NULL

Bezafibrate	DDI-DrugBank.d291.s6	NO_SECTION	NO_SETID	37
- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.
1	2	3	O	In
2	5	12	O	isolated
3	14	18	O	cases
4	19	19	O	,
5	21	21	O	a
6	23	32	O	pronounced
7	34	39	O	though
8	41	50	O	reversible
9	51	51	O	,
10	53	62	O	impairment
11	64	65	O	of
12	67	71	O	renal
13	73	80	O	function
14	83	93	O	accompanied
15	95	96	O	by
16	98	98	O	a
17	100	112	O	corresponding
18	114	121	O	increase
19	123	124	O	in
20	126	128	O	the
21	130	134	O	serum
22	136	145	O	creatinine
23	147	151	O	level
24	154	156	O	has
25	158	161	O	been
26	163	170	O	reported
27	172	173	O	in
28	175	179	O	organ
29	181	190	O	transplant
30	192	199	O	patients
31	201	209	O	receiving
32	211	216	B-DYN	immuno
33	218	228	L-DYN	suppressant
34	230	236	O	therapy
35	238	240	O	and
36	242	252	O	concomitant
37	254	264	O	XXXXXXXX
NULL

Bezafibrate	DDI-DrugBank.d291.s7	NO_SECTION	NO_SETID	32
Accordingly, renal function should be closely monitored in these patients and, in the event of relevant significant changes in laboratory parameters, bezafibrate should, if necessary, be discontinued
1	0	10	O	Accordingly
2	11	11	O	,
3	13	17	O	renal
4	19	26	O	function
5	28	33	O	should
6	35	36	O	be
7	38	44	O	closely
8	46	54	O	monitored
9	56	57	O	in
10	59	63	O	these
11	65	72	O	patients
12	74	76	O	and
13	77	77	O	,
14	79	80	O	in
15	82	84	O	the
16	86	90	O	event
17	92	93	O	of
18	95	102	O	relevant
19	104	114	O	significant
20	116	122	O	changes
21	124	125	O	in
22	127	136	O	laboratory
23	138	147	O	parameters
24	148	148	O	,
25	150	160	O	XXXXXXXX
26	162	167	O	should
27	168	168	O	,
28	170	171	O	if
29	173	181	O	necessary
30	182	182	O	,
31	184	185	O	be
32	187	198	O	discontinued
NULL

Bezafibrate	DDI-DrugBank.d291.s9	NO_SECTION	NO_SETID	38
- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
1	2	5	O	When
2	7	13	O	Bezalip
3	15	16	O	or
4	18	31	O	XXXXXXXX
5	33	34	O	is
6	36	39	O	used
7	41	52	O	concurrently
8	54	57	O	with
9	59	63	B-DYN	anion
10	65	72	I-DYN	exchange
11	74	79	L-DYN	resins
12	82	84	O	e.g
13	87	101	U-DYN	cholestryramine
14	103	103	O	,
15	105	106	O	an
16	108	115	O	interval
17	117	118	O	of
18	120	121	O	at
19	123	127	O	least
20	129	129	O	2
21	131	135	O	hours
22	137	142	O	should
23	144	145	O	be
24	147	156	O	maintained
25	158	164	O	between
26	166	168	O	the
27	170	172	O	two
28	174	182	O	medicines
29	183	183	O	,
30	185	189	O	since
31	191	193	O	the
32	195	204	O	absorption
33	206	207	O	of
34	209	215	O	Bezalip
35	217	218	O	or
36	220	233	O	XXXXXXXX
37	235	236	O	is
38	238	245	O	impaired
NULL

Bezafibrate	DDI-DrugBank.d291.s11	NO_SECTION	NO_SETID	18
- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
1	2	12	B-DYN	Perhexiline
2	14	21	I-DYN	hydrogen
3	23	29	L-DYN	maleate
4	31	32	O	or
5	34	36	B-DYN	MAO
6	38	47	L-DYN	inhibitors
7	50	53	O	with
8	55	65	O	hepatotoxic
9	67	75	O	potential
10	78	81	O	must
11	83	85	O	not
12	87	88	O	be
13	90	101	O	administered
14	103	110	O	together
15	112	115	O	with
16	117	123	O	Bezalip
17	125	126	O	or
18	128	141	O	XXXXXXXX
NULL

Bicalutamide	DDI-DrugBank.d266.s0	NO_SECTION	NO_SETID	20
In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	26	O	shown
6	28	34	O	XXXXXXXX
7	36	38	O	can
8	40	47	O	displace
9	49	56	U-KIN	coumarin
10	58	71	O	anticoagulants
11	72	72	O	,
12	74	77	O	such
13	79	80	O	as
14	82	89	U-UNK	warfarin
15	90	90	O	,
16	92	95	O	from
17	97	101	O	their
18	103	109	O	protein
19	111	117	O	binding
20	119	123	O	sites
NULL

Bicalutamide	DDI-DrugBank.d266.s1	NO_SECTION	NO_SETID	30
It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	24	O	if
6	26	32	O	XXXXXXXX
7	34	35	O	is
8	37	43	O	started
9	45	46	O	in
10	48	55	O	patients
11	57	63	O	already
12	65	73	O	receiving
13	75	82	B-DYN	coumarin
14	84	97	L-DYN	anticoagulants
15	98	98	O	,
16	100	110	O	prothrombin
17	112	116	O	times
18	118	123	O	should
19	125	126	O	be
20	128	134	O	closely
21	136	144	O	monitored
22	146	148	O	and
23	150	159	O	adjustment
24	161	162	O	of
25	164	166	O	the
26	168	180	U-DYN	anticoagulant
27	182	185	O	dose
28	187	189	O	may
29	191	192	O	be
30	194	202	O	necessary
NULL

Bimatoprost	DDI-DrugBank.d264.s0	NO_SECTION	NO_SETID	3
No Information Provided
1	0	1	O	No
2	3	13	O	Information
3	15	22	O	Provided
NULL

Biperiden	DDI-DrugBank.d401.s0	NO_SECTION	NO_SETID	54
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
1	0	3	O	Drug
2	5	16	O	Interactions
3	17	17	O	:
4	19	21	O	The
5	23	29	O	central
6	31	45	U-UNK	anticholinergic
7	47	54	O	syndrome
8	56	58	O	can
9	60	64	O	occur
10	66	69	O	when
11	71	85	O	anticholinergic
12	87	92	O	agents
13	94	97	O	such
14	99	100	O	as
15	102	109	O	XXXXXXXX
16	111	113	O	are
17	115	126	O	administered
18	128	140	O	concomitantly
19	142	145	O	with
20	147	151	O	drugs
21	153	156	O	that
22	158	161	O	have
23	163	171	O	secondary
24	173	187	O	anticholinergic
25	189	195	O	actions
26	196	196	O	,
27	198	200	O	e.g
28	202	202	O	,
29	204	210	O	certain
30	212	219	B-DYN	narcotic
31	221	230	L-DYN	analgesics
32	232	235	O	such
33	237	238	O	as
34	240	249	U-DYN	meperidine
35	250	250	O	,
36	252	254	O	the
37	256	269	U-DYN	phenothiazines
38	271	273	O	and
39	275	279	O	other
40	281	294	U-DYN	antipsychotics
41	295	295	O	,
42	297	305	B-DYN	tricyclic
43	307	321	L-DYN	antidepressants
44	322	322	O	,
45	324	330	O	certain
46	332	346	U-DYN	antiarrhythmics
47	348	351	O	such
48	353	354	O	as
49	356	358	O	the
50	360	368	U-DYN	quinidine
51	370	374	O	salts
52	375	375	O	,
53	377	379	O	and
54	381	394	U-DYN	antihistamines
NULL

Bisoprolol	DDI-DrugBank.d476.s0	NO_SECTION	NO_SETID	10
ZEBETA should not be combined with other beta-blocking agents.
1	0	5	O	XXXXXXXX
2	7	12	O	should
3	14	16	O	not
4	18	19	O	be
5	21	28	O	combined
6	30	33	O	with
7	35	39	O	other
8	41	44	B-DYN	beta
9	46	53	I-DYN	blocking
10	55	60	L-DYN	agents
NULL

Bisoprolol	DDI-DrugBank.d476.s1	NO_SECTION	NO_SETID	33
Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	31	O	catecholamine
4	33	41	O	depleting
5	43	47	O	drugs
6	48	48	O	,
7	50	53	O	such
8	55	56	O	as
9	58	66	U-DYN	reserpine
10	68	69	O	or
11	71	82	U-DYN	guanethidine
12	83	83	O	,
13	85	90	O	should
14	92	93	O	be
15	95	101	O	closely
16	103	111	O	monitored
17	112	112	O	,
18	114	120	O	because
19	122	124	O	the
20	126	130	O	added
21	132	135	O	beta
22	137	146	O	adrenergic
23	148	155	O	blocking
24	157	162	O	action
25	164	165	O	of
26	167	172	O	XXXXXXXX
27	174	176	O	may
28	178	184	O	produce
29	186	194	O	excessive
30	196	204	O	reduction
31	206	207	O	of
32	209	219	O	sympathetic
33	221	228	O	activity
NULL

Bisoprolol	DDI-DrugBank.d476.s2	NO_SECTION	NO_SETID	30
In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.
1	0	1	O	In
2	3	10	O	patients
3	12	20	O	receiving
4	22	31	O	concurrent
5	33	39	O	therapy
6	41	44	O	with
7	46	54	U-UNK	clonidine
8	55	55	O	,
9	57	58	O	if
10	60	66	O	therapy
11	68	69	O	is
12	71	72	O	to
13	74	75	O	be
14	77	88	O	discontinued
15	89	89	O	,
16	91	92	O	it
17	94	95	O	is
18	97	105	O	suggested
19	107	110	O	that
20	112	117	O	XXXXXXXX
21	119	120	O	be
22	122	133	O	discontinued
23	135	137	O	for
24	139	145	O	several
25	147	150	O	days
26	152	157	O	before
27	159	161	O	the
28	163	172	O	withdrawal
29	174	175	O	of
30	177	185	U-DYN	clonidine
NULL

Bisoprolol	DDI-DrugBank.d476.s3	NO_SECTION	NO_SETID	41
ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
1	0	5	O	XXXXXXXX
2	7	12	O	should
3	14	15	O	be
4	17	20	O	used
5	22	25	O	with
6	27	30	O	care
7	32	35	O	when
8	37	46	B-DYN	myocardial
9	48	58	L-DYN	depressants
10	60	61	O	or
11	63	72	O	inhibitors
12	74	75	O	of
13	77	78	O	AV
14	80	89	O	conduction
15	90	90	O	,
16	92	95	O	such
17	97	98	O	as
18	100	106	O	certain
19	108	114	B-DYN	calcium
20	116	126	L-DYN	antagonists
21	129	140	O	particularly
22	142	143	O	of
23	145	147	O	the
24	149	164	U-DYN	phenylalkylamine
25	167	175	U-DYN	verapamil
26	178	180	O	and
27	182	196	U-DYN	benzothiazepine
28	199	207	U-DYN	diltiazem
29	210	216	O	classes
30	218	218	O	,
31	220	221	O	or
32	223	236	B-DYN	antiarrhythmic
33	238	243	L-DYN	agents
34	244	244	O	,
35	246	249	O	such
36	251	252	O	as
37	254	265	U-DYN	disopyramide
38	266	266	O	,
39	268	270	O	are
40	272	275	O	used
41	277	288	O	concurrently
NULL

Bisoprolol	DDI-DrugBank.d476.s4	NO_SECTION	NO_SETID	20
Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	16	O	of
4	18	25	U-KIN	rifampin
5	27	35	O	increases
6	37	39	O	the
7	41	49	O	metabolic
8	51	59	O	clearance
9	61	62	O	of
10	64	69	O	XXXXXXXX
11	70	70	O	,
12	72	80	O	resulting
13	82	83	O	in
14	85	85	O	a
15	87	95	O	shortened
16	97	107	O	elimination
17	109	112	O	half
18	114	117	O	life
19	119	120	O	of
20	122	127	O	XXXXXXXX
NULL

Bisoprolol	DDI-DrugBank.d476.s5	NO_SECTION	NO_SETID	9
However, initial dose modification is generally not necessary.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	initial
4	17	20	O	dose
5	22	33	O	modification
6	35	36	O	is
7	38	46	O	generally
8	48	50	O	not
9	52	60	O	necessary
NULL

Bisoprolol	DDI-DrugBank.d476.s6	NO_SECTION	NO_SETID	21
Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics, digoxin, and cimetidine.
1	0	14	O	Pharmacokinetic
2	16	22	O	studies
3	24	31	O	document
4	33	34	O	no
5	36	45	O	clinically
6	47	54	O	relevant
7	56	67	O	interactions
8	69	72	O	with
9	74	78	O	other
10	80	85	O	agents
11	87	91	O	given
12	93	105	O	concomitantly
13	106	106	O	,
14	108	116	O	including
15	118	125	B-UNK	thiazide
16	127	135	L-UNK	diuretics
17	136	136	O	,
18	138	144	U-UNK	digoxin
19	145	145	O	,
20	147	149	O	and
21	151	160	U-UNK	cimetidine
NULL

Bisoprolol	DDI-DrugBank.d476.s7	NO_SECTION	NO_SETID	16
There was no effect of ZEBETA on prothrombin time in patients on stable doses of warfarin.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	18	O	effect
5	20	21	O	of
6	23	28	O	XXXXXXXX
7	30	31	O	on
8	33	43	O	prothrombin
9	45	48	O	time
10	50	51	O	in
11	53	60	O	patients
12	62	63	O	on
13	65	70	O	stable
14	72	76	O	doses
15	78	79	O	of
16	81	88	U-UNK	warfarin
NULL

Bisoprolol	DDI-DrugBank.d476.s8	NO_SECTION	NO_SETID	38
Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.
1	0	3	O	Risk
2	5	6	O	of
3	8	19	O	Anaphylactic
4	21	28	O	Reaction
5	29	29	O	:
6	31	35	O	While
7	37	42	O	taking
8	44	47	B-UNK	beta
9	49	56	L-UNK	blockers
10	57	57	O	,
11	59	66	O	patients
12	68	71	O	with
13	73	73	O	a
14	75	81	O	history
15	83	84	O	of
16	86	91	O	severe
17	93	104	O	anaphylactic
18	106	113	O	reaction
19	115	116	O	to
20	118	118	O	a
21	120	126	O	variety
22	128	129	O	of
23	131	139	O	allergens
24	141	143	O	may
25	145	146	O	be
26	148	151	O	more
27	153	160	O	reactive
28	162	163	O	to
29	165	172	O	repeated
30	174	182	O	challenge
31	183	183	O	,
32	185	190	O	either
33	192	201	O	accidental
34	202	202	O	,
35	204	213	O	diagnostic
36	214	214	O	,
37	216	217	O	or
38	219	229	O	therapeutic
NULL

Bisoprolol	DDI-DrugBank.d476.s9	NO_SECTION	NO_SETID	16
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.
1	0	3	O	Such
2	5	12	O	patients
3	14	16	O	may
4	18	19	O	be
5	21	32	O	unresponsive
6	34	35	O	to
7	37	39	O	the
8	41	45	O	usual
9	47	51	O	doses
10	53	54	O	of
11	56	66	U-UNK	epinephrine
12	68	71	O	used
13	73	74	O	to
14	76	80	O	treat
15	82	89	O	allergic
16	91	99	O	reactions
NULL

Bitolterol	DDI-DrugBank.d560.s0	NO_SECTION	NO_SETID	15
Use of MAO inhibitors may cause an excessive increase in blood pressure and heart stimulation.
1	0	2	O	Use
2	4	5	O	of
3	7	9	B-UNK	MAO
4	11	20	L-UNK	inhibitors
5	22	24	O	may
6	26	30	O	cause
7	32	33	O	an
8	35	43	O	excessive
9	45	52	O	increase
10	54	55	O	in
11	57	61	O	blood
12	63	70	O	pressure
13	72	74	O	and
14	76	80	O	heart
15	82	92	O	stimulation
NULL

Bitolterol	DDI-DrugBank.d560.s1	NO_SECTION	NO_SETID	23
If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.
1	0	1	O	If
2	3	5	O	you
3	7	9	O	are
4	11	14	O	also
5	16	20	O	using
6	22	22	O	a
7	24	30	U-DYN	steroid
8	32	38	O	inhaler
9	39	39	O	,
10	41	44	O	take
11	46	55	O	XXXXXXXX
12	57	61	O	first
13	63	65	O	and
14	67	70	O	then
15	72	75	O	wait
16	77	81	O	about
17	83	84	O	15
18	86	92	O	minutes
19	94	99	O	before
20	101	105	O	using
21	107	109	O	the
22	111	117	U-DYN	steroid
23	119	125	O	inhaler
NULL

Bitolterol	DDI-DrugBank.d560.s2	NO_SECTION	NO_SETID	14
This allows bitolterol to open air passages, increasing the effectiveness of the steroid.
1	0	3	O	This
2	5	10	O	allows
3	12	21	O	XXXXXXXX
4	23	24	O	to
5	26	29	O	open
6	31	33	O	air
7	35	42	O	passages
8	43	43	O	,
9	45	54	O	increasing
10	56	58	O	the
11	60	72	O	effectiveness
12	74	75	O	of
13	77	79	O	the
14	81	87	U-DYN	steroid
NULL

Bivalirudin	DDI-DrugBank.d569.s0	NO_SECTION	NO_SETID	15
Angiomax does not exhibit binding to plasma proteins (other than thrombin) or red blood cells.
1	0	7	O	XXXXXXXX
2	9	12	O	does
3	14	16	O	not
4	18	24	O	exhibit
5	26	32	O	binding
6	34	35	O	to
7	37	42	O	plasma
8	44	51	O	proteins
9	54	58	O	other
10	60	63	O	than
11	65	72	O	thrombin
12	75	76	O	or
13	78	80	O	red
14	82	86	O	blood
15	88	92	O	cells
NULL

Bivalirudin	DDI-DrugBank.d569.s1	NO_SECTION	NO_SETID	43
In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
1	0	1	O	In
2	3	10	O	clinical
3	12	17	O	trials
4	19	20	O	in
5	22	29	O	patients
6	31	40	O	undergoing
7	42	45	O	PTCA
8	46	46	O	/
9	47	49	O	PCI
10	50	50	O	,
11	52	53	O	co
12	55	68	O	administration
13	70	71	O	of
14	73	80	O	XXXXXXXX
15	82	85	O	with
16	87	93	U-DYN	heparin
17	94	94	O	,
18	96	103	U-DYN	warfarin
19	104	104	O	,
20	106	118	U-DYN	thrombolytics
21	120	121	O	or
22	123	134	O	glycoprotein
23	136	138	O	IIb
24	139	139	O	/
25	140	143	O	IIIa
26	145	154	O	inhibitors
27	156	158	O	was
28	160	169	O	associated
29	171	174	O	with
30	176	184	O	increased
31	186	190	O	risks
32	192	193	O	of
33	195	199	O	major
34	201	208	O	bleeding
35	210	215	O	events
36	217	224	O	compared
37	226	227	O	to
38	229	236	O	patients
39	238	240	O	not
40	242	250	O	receiving
41	252	256	O	these
42	258	268	O	concomitant
43	270	280	O	medications
NULL

Bivalirudin	DDI-DrugBank.d569.s2	NO_SECTION	NO_SETID	15
There is no experience with co-administration of Angiomax and plasma expanders such as dextran.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	21	O	experience
5	23	26	O	with
6	28	29	O	co
7	31	44	O	administration
8	46	47	O	of
9	49	56	O	XXXXXXXX
10	58	60	O	and
11	62	67	O	plasma
12	69	77	O	expanders
13	79	82	O	such
14	84	85	O	as
15	87	93	U-UNK	dextran
NULL

Bivalirudin	DDI-DrugBank.d569.s3	NO_SECTION	NO_SETID	18
Angiomax should be used with caution in patients with disease states associated with an increased risk of bleeding.
1	0	7	O	XXXXXXXX
2	9	14	O	should
3	16	17	O	be
4	19	22	O	used
5	24	27	O	with
6	29	35	O	caution
7	37	38	O	in
8	40	47	O	patients
9	49	52	O	with
10	54	60	O	disease
11	62	67	O	states
12	69	78	O	associated
13	80	83	O	with
14	85	86	O	an
15	88	96	O	increased
16	98	101	O	risk
17	103	104	O	of
18	106	113	O	bleeding
NULL

Bivalirudin	DDI-DrugBank.d569.s4	NO_SECTION	NO_SETID	27
Immunogenicity/Re-exposure: In in vitro studies, Angiomax exhibited no platelet aggregation response against sera from patients with a history of HIT/HITTS.
1	0	13	O	Immunogenicity
2	14	14	O	/
3	15	16	O	Re
4	18	25	O	exposure
5	26	26	O	:
6	28	29	O	In
7	31	32	O	in
8	34	38	O	vitro
9	40	46	O	studies
10	47	47	O	,
11	49	56	O	XXXXXXXX
12	58	66	O	exhibited
13	68	69	O	no
14	71	78	O	platelet
15	80	90	O	aggregation
16	92	99	O	response
17	101	107	O	against
18	109	112	O	sera
19	114	117	O	from
20	119	126	O	patients
21	128	131	O	with
22	133	133	O	a
23	135	141	O	history
24	143	144	O	of
25	146	148	O	HIT
26	149	149	O	/
27	150	154	O	HITTS
NULL

Bivalirudin	DDI-DrugBank.d569.s5	NO_SECTION	NO_SETID	24
Among 494 subjects who received Angiomax in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests.
1	0	4	O	Among
2	6	8	O	494
3	10	17	O	subjects
4	19	21	O	who
5	23	30	O	received
6	32	39	O	XXXXXXXX
7	41	42	O	in
8	44	51	O	clinical
9	53	58	O	trials
10	60	62	O	and
11	64	67	O	were
12	69	74	O	tested
13	76	78	O	for
14	80	89	O	antibodies
15	90	90	O	,
16	92	92	O	2
17	94	101	O	subjects
18	103	105	O	had
19	107	115	O	treatment
20	117	124	O	emergent
21	126	133	O	positive
22	135	145	U-UNK	bivalirudin
23	147	154	O	antibody
24	156	160	O	tests
NULL

Bivalirudin	DDI-DrugBank.d569.s6	NO_SECTION	NO_SETID	16
Neither subject demonstrated clinical evidence of allergic or anaphylactic reactions and repeat testing was not performed.
1	0	6	O	Neither
2	8	14	O	subject
3	16	27	O	demonstrated
4	29	36	O	clinical
5	38	45	O	evidence
6	47	48	O	of
7	50	57	O	allergic
8	59	60	O	or
9	62	73	O	anaphylactic
10	75	83	O	reactions
11	85	87	O	and
12	89	94	O	repeat
13	96	102	O	testing
14	104	106	O	was
15	108	110	O	not
16	112	120	O	performed
NULL

Bivalirudin	DDI-DrugBank.d569.s7	NO_SECTION	NO_SETID	13
Nine additional patients who had initial positive tests were negative on repeat testing.
1	0	3	O	Nine
2	5	14	O	additional
3	16	23	O	patients
4	25	27	O	who
5	29	31	O	had
6	33	39	O	initial
7	41	48	O	positive
8	50	54	O	tests
9	56	59	O	were
10	61	68	O	negative
11	70	71	O	on
12	73	78	O	repeat
13	80	86	O	testing
NULL

Bleomycin	DDI-DrugBank.d554.s0	NO_SECTION	NO_SETID	13
Certain antibiotic, cisplatin, cyclosporine, diuretic, foscarnet, and vaccines.
1	0	6	O	Certain
2	8	17	U-UNK	antibiotic
3	18	18	O	,
4	20	28	U-UNK	cisplatin
5	29	29	O	,
6	31	42	U-UNK	cyclosporine
7	43	43	O	,
8	45	52	U-UNK	diuretic
9	53	53	O	,
10	55	63	U-UNK	foscarnet
11	64	64	O	,
12	66	68	O	and
13	70	77	U-UNK	vaccines
NULL

Bortezomib	DDI-DrugBank.d571.s0	NO_SECTION	NO_SETID	10
No formal drug interaction studies have been conducted with VELCADE.
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	25	O	interaction
5	27	33	O	studies
6	35	38	O	have
7	40	43	O	been
8	45	53	O	conducted
9	55	58	O	with
10	60	66	O	XXXXXXXX
NULL

Bortezomib	DDI-DrugBank.d571.s1	NO_SECTION	NO_SETID	23
In vitro studies with human liver microsomes indicate that bortezomib is primarily a substrate for cytochrome P450 3A4, 2C19, and 1A2.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	with
5	22	26	O	human
6	28	32	O	liver
7	34	43	O	microsomes
8	45	52	O	indicate
9	54	57	O	that
10	59	68	O	XXXXXXXX
11	70	71	O	is
12	73	81	O	primarily
13	83	83	O	a
14	85	93	O	substrate
15	95	97	O	for
16	99	108	O	cytochrome
17	110	113	O	P450
18	115	117	O	3A4
19	118	118	O	,
20	120	123	O	2C19
21	124	124	O	,
22	126	128	O	and
23	130	132	O	1A2
NULL

Bortezomib	DDI-DrugBank.d571.s2	NO_SECTION	NO_SETID	27
Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy .
1	0	7	O	Patients
2	9	11	O	who
3	13	15	O	are
4	17	29	O	concomitantly
5	31	39	O	receiving
6	41	47	O	XXXXXXXX
7	49	51	O	and
8	53	57	O	drugs
9	59	62	O	that
10	64	66	O	are
11	68	77	O	inhibitors
12	79	80	O	or
13	82	89	O	inducers
14	91	92	O	of
15	94	103	O	cytochrome
16	105	108	O	P450
17	110	112	O	3A4
18	114	119	O	should
19	121	122	O	be
20	124	130	O	closely
21	132	140	O	monitored
22	142	144	O	for
23	146	151	O	either
24	153	162	O	toxicities
25	164	165	O	or
26	167	173	O	reduced
27	175	182	O	efficacy
NULL

Bortezomib	DDI-DrugBank.d571.s3	NO_SECTION	NO_SETID	15
During clinical trials, hypoglycemia and hyperglycemia were reported in diabetic patients receiving oral hypoglycemics.
1	0	5	O	During
2	7	14	O	clinical
3	16	21	O	trials
4	22	22	O	,
5	24	35	O	hypoglycemia
6	37	39	O	and
7	41	53	O	hyperglycemia
8	55	58	O	were
9	60	67	O	reported
10	69	70	O	in
11	72	79	O	diabetic
12	81	88	O	patients
13	90	98	O	receiving
14	100	103	O	oral
15	105	117	U-UNK	hypoglycemics
NULL

Bortezomib	DDI-DrugBank.d571.s4	NO_SECTION	NO_SETID	26
Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.
1	0	7	O	Patients
2	9	10	O	on
3	12	15	O	oral
4	17	28	B-DYN	antidiabetic
5	30	35	L-DYN	agents
6	37	45	O	receiving
7	47	53	O	XXXXXXXX
8	55	63	O	treatment
9	65	67	O	may
10	69	75	O	require
11	77	81	O	close
12	83	92	O	monitoring
13	94	95	O	of
14	97	101	O	their
15	103	107	O	blood
16	109	115	O	glucose
17	117	122	O	levels
18	124	126	O	and
19	128	137	O	adjustment
20	139	140	O	of
21	142	144	O	the
22	146	149	O	dose
23	151	152	O	of
24	154	158	O	their
25	160	171	B-UNK	antidiabetic
26	173	182	L-UNK	medication
NULL

Bortezomib	DDI-DrugBank.d571.s5	NO_SECTION	NO_SETID	6
Drug Laboratory Test Interactions None known.
1	0	3	O	Drug
2	5	14	O	Laboratory
3	16	19	O	Test
4	21	32	O	Interactions
5	34	37	O	None
6	39	43	O	known
NULL

Bosentan	DDI-DrugBank.d289.s0	NO_SECTION	NO_SETID	7
Bosentan is metabolized by CYP2C9 and CYP3A4.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	22	O	metabolized
4	24	25	O	by
5	27	32	O	CYP2C9
6	34	36	O	and
7	38	43	O	CYP3A4
NULL

Bosentan	DDI-DrugBank.d289.s1	NO_SECTION	NO_SETID	11
Inhibition of these isoenzymes may increase the plasma concentration of bosentan.
1	0	9	O	Inhibition
2	11	12	O	of
3	14	18	O	these
4	20	29	O	isoenzymes
5	31	33	O	may
6	35	42	O	increase
7	44	46	O	the
8	48	53	O	plasma
9	55	67	O	concentration
10	69	70	O	of
11	72	79	O	XXXXXXXX
NULL

Bosentan	DDI-DrugBank.d289.s2	NO_SECTION	NO_SETID	8
Bosentan is an inducer of CYP3A4 and CYP2C9.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	13	O	an
4	15	21	O	inducer
5	23	24	O	of
6	26	31	O	CYP3A4
7	33	35	O	and
8	37	42	O	CYP2C9
NULL

Bosentan	DDI-DrugBank.d289.s3	NO_SECTION	NO_SETID	19
Consequently, plasma concentrations of drugs metabolized by these two isoenzymes will be decreased when TRACLEER is co-administered.
1	0	11	O	Consequently
2	12	12	O	,
3	14	19	O	plasma
4	21	34	O	concentrations
5	36	37	O	of
6	39	43	O	drugs
7	45	55	O	metabolized
8	57	58	O	by
9	60	64	O	these
10	66	68	O	two
11	70	79	O	isoenzymes
12	81	84	O	will
13	86	87	O	be
14	89	97	O	decreased
15	99	102	O	when
16	104	111	O	XXXXXXXX
17	113	114	O	is
18	116	117	O	co
19	119	130	O	administered
NULL

Bosentan	DDI-DrugBank.d289.s4	NO_SECTION	NO_SETID	20
Bosentan had no relevant inhibitory effect on any CYP isoenzymes tested (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4).
1	0	7	O	XXXXXXXX
2	9	11	O	had
3	13	14	O	no
4	16	23	O	relevant
5	25	34	O	inhibitory
6	36	41	O	effect
7	43	44	O	on
8	46	48	O	any
9	50	52	O	CYP
10	54	63	O	isoenzymes
11	65	70	O	tested
12	73	78	O	CYP1A2
13	79	79	O	,
14	81	86	O	CYP2C9
15	87	87	O	,
16	89	95	O	CYP2C19
17	96	96	O	,
18	98	103	O	CYP2D6
19	104	104	O	,
20	106	111	O	CYP3A4
NULL

Bosentan	DDI-DrugBank.d289.s5	NO_SECTION	NO_SETID	17
Consequently, TRACLEER is not expected to increase the plasma concentrations of drugs metabolized by these enzymes.
1	0	11	O	Consequently
2	12	12	O	,
3	14	21	O	XXXXXXXX
4	23	24	O	is
5	26	28	O	not
6	30	37	O	expected
7	39	40	O	to
8	42	49	O	increase
9	51	53	O	the
10	55	60	O	plasma
11	62	75	O	concentrations
12	77	78	O	of
13	80	84	O	drugs
14	86	96	O	metabolized
15	98	99	O	by
16	101	105	O	these
17	107	113	O	enzymes
NULL

Bosentan	DDI-DrugBank.d289.s6	NO_SECTION	NO_SETID	44
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.
1	0	7	B-UNK	Hormonal
2	9	22	L-UNK	Contraceptives
3	23	23	O	,
4	25	33	O	Including
5	35	38	O	Oral
6	39	39	O	,
7	41	50	O	Injectable
8	51	51	O	,
9	53	63	O	Transdermal
10	64	64	O	,
11	66	68	O	and
12	70	80	O	Implantable
13	82	95	U-UNK	Contraceptives
14	96	96	O	:
15	98	99	O	An
16	101	111	O	interaction
17	113	117	O	study
18	119	130	O	demonstrated
19	132	135	O	that
20	137	138	O	co
21	140	153	O	administration
22	155	156	O	of
23	158	165	U-KIN	bosentan
24	167	169	O	and
25	171	173	O	the
26	175	178	O	oral
27	180	187	B-UNK	hormonal
28	189	201	L-UNK	contraceptive
29	203	213	O	XXXXXXXX
30	215	222	O	produced
31	224	230	O	average
32	232	240	O	decreases
33	242	243	O	of
34	245	257	U-UNK	norethindrone
35	259	261	O	and
36	263	269	B-UNK	ethinyl
37	271	279	L-UNK	estradiol
38	281	286	O	levels
39	288	289	O	of
40	291	293	O	14%
41	295	297	O	and
42	299	301	O	31%
43	302	302	O	,
44	304	315	O	respectively
NULL

Bosentan	DDI-DrugBank.d289.s7	NO_SECTION	NO_SETID	18
However, decreases in exposure were as much as 56% and 66%, respectively, in individual subjects.
1	0	6	O	However
2	7	7	O	,
3	9	17	O	decreases
4	19	20	O	in
5	22	29	O	exposure
6	31	34	O	were
7	36	37	O	as
8	39	42	O	much
9	44	45	O	as
10	47	49	O	56%
11	51	53	O	and
12	55	57	O	66%
13	58	58	O	,
14	60	71	O	respectively
15	72	72	O	,
16	74	75	O	in
17	77	86	O	individual
18	88	95	O	subjects
NULL

Bosentan	DDI-DrugBank.d289.s8	NO_SECTION	NO_SETID	25
Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	B-DYN	hormonal
4	20	33	L-DYN	contraceptives
5	34	34	O	,
6	36	44	O	including
7	46	49	O	oral
8	50	50	O	,
9	52	61	O	injectable
10	62	62	O	,
11	64	74	O	transdermal
12	75	75	O	,
13	77	79	O	and
14	81	91	O	implantable
15	93	97	O	forms
16	98	98	O	,
17	100	102	O	may
18	104	106	O	not
19	108	109	O	be
20	111	118	O	reliable
21	120	123	O	when
22	125	132	O	XXXXXXXX
23	134	135	O	is
24	137	138	O	co
25	140	151	O	administered
NULL

Bosentan	DDI-DrugBank.d289.s9	NO_SECTION	NO_SETID	17
Women should practice additional methods of contraception and not rely on hormonal contraception alone when taking TRACLEER.
1	0	4	O	Women
2	6	11	O	should
3	13	20	O	practice
4	22	31	O	additional
5	33	39	O	methods
6	41	42	O	of
7	44	56	O	contraception
8	58	60	O	and
9	62	64	O	not
10	66	69	O	rely
11	71	72	O	on
12	74	81	O	hormonal
13	83	95	O	contraception
14	97	101	O	alone
15	103	106	O	when
16	108	113	O	taking
17	115	122	O	XXXXXXXX
NULL

Bosentan	DDI-DrugBank.d289.s10	NO_SECTION	NO_SETID	29
Specific interaction studies have demonstrated the following: Cyclosporine A: During the first day of concomitant administration, trough concentrations of bosentan were increased by about 30-fold.
1	0	7	O	Specific
2	9	19	O	interaction
3	21	27	O	studies
4	29	32	O	have
5	34	45	O	demonstrated
6	47	49	O	the
7	51	59	O	following
8	60	60	O	:
9	62	73	B-UNK	Cyclosporine
10	75	75	L-UNK	A
11	76	76	O	:
12	78	83	O	During
13	85	87	O	the
14	89	93	O	first
15	95	97	O	day
16	99	100	O	of
17	102	112	O	concomitant
18	114	127	O	administration
19	128	128	O	,
20	130	135	O	trough
21	137	150	O	concentrations
22	152	153	O	of
23	155	162	O	XXXXXXXX
24	164	167	O	were
25	169	177	O	increased
26	179	180	O	by
27	182	186	O	about
28	188	189	O	30
29	191	194	O	fold
NULL

Bosentan	DDI-DrugBank.d289.s11	NO_SECTION	NO_SETID	18
Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.
1	0	5	O	Steady
2	7	11	O	state
3	13	20	O	XXXXXXXX
4	22	27	O	plasma
5	29	42	O	concentrations
6	44	47	O	were
7	49	49	O	3
8	52	53	O	to
9	55	55	O	4
10	57	60	O	fold
11	62	67	O	higher
12	69	72	O	than
13	74	75	O	in
14	77	79	O	the
15	81	87	O	absence
16	89	90	O	of
17	92	103	B-KIN	cyclosporine
18	105	105	L-KIN	A
NULL

Bosentan	DDI-DrugBank.d289.s12	NO_SECTION	NO_SETID	10
The concomitant administration of bosentan and cyclosporine A is contraindicated.
1	0	2	O	The
2	4	14	O	concomitant
3	16	29	O	administration
4	31	32	O	of
5	34	41	O	XXXXXXXX
6	43	45	O	and
7	47	58	B-DYN	cyclosporine
8	60	60	L-DYN	A
9	62	63	O	is
10	65	79	O	contraindicated
NULL

Bosentan	DDI-DrugBank.d289.s13	NO_SECTION	NO_SETID	17
Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	28	O	XXXXXXXX
5	30	38	O	decreased
6	40	42	O	the
7	44	49	O	plasma
8	51	64	O	concentrations
9	66	67	O	of
10	69	80	B-KIN	cyclosporine
11	82	82	L-KIN	A
12	85	85	O	a
13	87	92	O	CYP3A4
14	94	102	O	substrate
15	105	106	O	by
16	108	120	O	approximately
17	122	124	O	50%
NULL

Bosentan	DDI-DrugBank.d289.s14	NO_SECTION	NO_SETID	14
Tacrolimus: Co-administration of tacrolimus and bosentan has not been studied in man.
1	0	9	U-UNK	Tacrolimus
2	10	10	O	:
3	12	13	O	Co
4	15	28	O	administration
5	30	31	O	of
6	33	42	U-UNK	tacrolimus
7	44	46	O	and
8	48	55	O	XXXXXXXX
9	57	59	O	has
10	61	63	O	not
11	65	68	O	been
12	70	76	O	studied
13	78	79	O	in
14	81	83	O	man
NULL

Bosentan	DDI-DrugBank.d289.s15	NO_SECTION	NO_SETID	16
Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	30	U-KIN	tacrolimus
5	32	34	O	and
6	36	43	O	XXXXXXXX
7	45	52	O	resulted
8	54	55	O	in
9	57	64	O	markedly
10	66	74	O	increased
11	76	81	O	plasma
12	83	96	O	concentrations
13	98	99	O	of
14	101	108	O	XXXXXXXX
15	110	111	O	in
16	113	119	O	animals
NULL

Bosentan	DDI-DrugBank.d289.s16	NO_SECTION	NO_SETID	11
Caution should be exercised if tacrolimus and bosentan are used together.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	29	O	if
6	31	40	U-DYN	tacrolimus
7	42	44	O	and
8	46	53	O	XXXXXXXX
9	55	57	O	are
10	59	62	O	used
11	64	71	O	together
NULL

Bosentan	DDI-DrugBank.d289.s17	NO_SECTION	NO_SETID	18
Glyburide: An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with glyburide.
1	0	8	U-UNK	Glyburide
2	9	9	O	:
3	11	12	O	An
4	14	22	O	increased
5	24	27	O	risk
6	29	30	O	of
7	32	39	O	elevated
8	41	45	O	liver
9	47	63	O	aminotransferases
10	65	67	O	was
11	69	76	O	observed
12	78	79	O	in
13	81	88	O	patients
14	90	98	O	receiving
15	100	110	O	concomitant
16	112	118	O	therapy
17	120	123	O	with
18	125	133	U-UNK	glyburide
NULL

Bosentan	DDI-DrugBank.d289.s18	NO_SECTION	NO_SETID	19
Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	25	O	concomitant
5	27	40	O	administration
6	42	43	O	of
7	45	52	O	XXXXXXXX
8	54	56	O	and
9	58	66	U-DYN	glyburide
10	68	69	O	is
11	71	85	O	contraindicated
12	86	86	O	,
13	88	90	O	and
14	92	102	O	alternative
15	104	115	B-UNK	hypoglycemic
16	117	122	L-UNK	agents
17	124	129	O	should
18	131	132	O	be
19	134	143	O	considered
NULL

Bosentan	DDI-DrugBank.d289.s19	NO_SECTION	NO_SETID	13
Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	28	O	XXXXXXXX
5	30	38	O	decreased
6	40	42	O	the
7	44	49	O	plasma
8	51	64	O	concentrations
9	66	67	O	of
10	69	77	U-KIN	glyburide
11	79	80	O	by
12	82	94	O	approximately
13	96	98	O	40%
NULL

Bosentan	DDI-DrugBank.d289.s20	NO_SECTION	NO_SETID	11
The plasma concentrations of bosentan were also decreased by approximately 30%.
1	0	2	O	The
2	4	9	O	plasma
3	11	24	O	concentrations
4	26	27	O	of
5	29	36	O	XXXXXXXX
6	38	41	O	were
7	43	46	O	also
8	48	56	O	decreased
9	58	59	O	by
10	61	73	O	approximately
11	75	77	O	30%
NULL

Bosentan	DDI-DrugBank.d289.s21	NO_SECTION	NO_SETID	21
Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	15	O	also
4	17	24	O	expected
5	26	27	O	to
6	29	34	O	reduce
7	36	41	O	plasma
8	43	56	O	concentrations
9	58	59	O	of
10	61	65	O	other
11	67	70	O	oral
12	72	83	B-KIN	hypoglycemic
13	85	90	L-KIN	agents
14	92	95	O	that
15	97	99	O	are
16	101	113	O	predominantly
17	115	125	O	metabolized
18	127	128	O	by
19	130	135	O	CYP2C9
20	137	138	O	or
21	140	145	O	CYP3A4
NULL

Bosentan	DDI-DrugBank.d289.s22	NO_SECTION	NO_SETID	14
The possibility of worsened glucose control in patients using these agents should be considered.
1	0	2	O	The
2	4	14	O	possibility
3	16	17	O	of
4	19	26	O	worsened
5	28	34	O	glucose
6	36	42	O	control
7	44	45	O	in
8	47	54	O	patients
9	56	60	O	using
10	62	66	O	these
11	68	73	O	agents
12	75	80	O	should
13	82	83	O	be
14	85	94	O	considered
NULL

Bosentan	DDI-DrugBank.d289.s23	NO_SECTION	NO_SETID	27
Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	15	O	Co
4	17	30	O	administration
5	32	33	O	of
6	35	42	O	XXXXXXXX
7	44	46	O	125
8	48	49	O	mg
9	51	55	O	b.i.d
10	58	60	O	and
11	62	73	U-KIN	ketoconazole
12	74	74	O	,
13	76	76	O	a
14	78	83	O	potent
15	85	90	O	CYP3A4
16	92	100	O	inhibitor
17	101	101	O	,
18	103	111	O	increased
19	113	115	O	the
20	117	122	O	plasma
21	124	137	O	concentrations
22	139	140	O	of
23	142	149	O	XXXXXXXX
24	151	152	O	by
25	154	166	O	approximately
26	168	168	O	2
27	170	173	O	fold
NULL

Bosentan	DDI-DrugBank.d289.s24	NO_SECTION	NO_SETID	16
No dose adjustment of bosentan is necessary, but increased effects of bosentan should be considered.
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	of
5	22	29	O	XXXXXXXX
6	31	32	O	is
7	34	42	O	necessary
8	43	43	O	,
9	45	47	O	but
10	49	57	O	increased
11	59	65	O	effects
12	67	68	O	of
13	70	77	O	XXXXXXXX
14	79	84	O	should
15	86	87	O	be
16	89	98	O	considered
NULL

Bosentan	DDI-DrugBank.d289.s25	NO_SECTION	NO_SETID	29
Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.
1	0	10	U-UNK	Simvastatin
2	12	14	O	and
3	16	20	O	Other
4	22	28	U-UNK	Statins
5	29	29	O	:
6	31	32	O	Co
7	34	47	O	administration
8	49	50	O	of
9	52	59	O	XXXXXXXX
10	61	69	O	decreased
11	71	73	O	the
12	75	80	O	plasma
13	82	95	O	concentrations
14	97	98	O	of
15	100	110	U-KIN	simvastatin
16	113	113	O	a
17	115	120	O	CYP3A4
18	122	130	O	substrate
19	132	132	O	,
20	134	136	O	and
21	138	140	O	its
22	142	147	O	active
23	151	157	O	hydroxy
24	159	162	O	acid
25	164	173	O	metabolite
26	174	174	O	,
27	176	177	O	by
28	179	191	O	approximately
29	193	195	O	50%
NULL

Bosentan	DDI-DrugBank.d289.s26	NO_SECTION	NO_SETID	8
The plasma concentrations of bosentan were not affected.
1	0	2	O	The
2	4	9	O	plasma
3	11	24	O	concentrations
4	26	27	O	of
5	29	36	O	XXXXXXXX
6	38	41	O	were
7	43	45	O	not
8	47	54	O	affected
NULL

Bosentan	DDI-DrugBank.d289.s27	NO_SECTION	NO_SETID	23
Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	15	O	also
4	17	24	O	expected
5	26	27	O	to
6	29	34	O	reduce
7	36	41	O	plasma
8	43	56	O	concentrations
9	58	59	O	of
10	61	65	O	other
11	67	73	U-KIN	statins
12	75	78	O	that
13	80	83	O	have
14	85	95	O	significant
15	97	106	O	metabolism
16	108	109	O	by
17	111	116	O	CYP3A4
18	117	117	O	,
19	119	122	O	such
20	124	125	O	as
21	127	136	U-KIN	lovastatin
22	138	140	O	and
23	142	153	U-KIN	atorvastatin
NULL

Bosentan	DDI-DrugBank.d289.s28	NO_SECTION	NO_SETID	9
The possibility of reduced statin efficacy should be considered.
1	0	2	O	The
2	4	14	O	possibility
3	16	17	O	of
4	19	25	O	reduced
5	27	32	U-UNK	statin
6	34	41	O	efficacy
7	43	48	O	should
8	50	51	O	be
9	53	62	O	considered
NULL

Bosentan	DDI-DrugBank.d289.s29	NO_SECTION	NO_SETID	22
Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.
1	0	7	O	Patients
2	9	13	O	using
3	15	20	O	CYP3A4
4	22	32	O	metabolized
5	34	40	U-DYN	statins
6	42	47	O	should
7	49	52	O	have
8	54	64	O	cholesterol
9	66	71	O	levels
10	73	81	O	monitored
11	83	87	O	after
12	89	96	O	XXXXXXXX
13	98	99	O	is
14	101	109	O	initiated
15	111	112	O	to
16	114	116	O	see
17	118	124	O	whether
18	126	128	O	the
19	130	135	U-UNK	statin
20	137	140	O	dose
21	142	146	O	needs
22	148	157	O	adjustment
NULL

Bosentan	DDI-DrugBank.d289.s30	NO_SECTION	NO_SETID	35
Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	11	O	Co
4	13	26	O	administration
5	28	29	O	of
6	31	38	O	XXXXXXXX
7	40	42	O	500
8	44	45	O	mg
9	47	51	O	b.i.d
10	54	56	O	for
11	58	58	O	6
12	60	63	O	days
13	65	73	O	decreased
14	75	77	O	the
15	79	84	O	plasma
16	86	99	O	concentrations
17	101	102	O	of
18	104	107	O	both
19	109	109	B-KIN	S
20	111	118	L-KIN	warfarin
21	121	121	O	a
22	123	128	O	CYP2C9
23	130	138	O	substrate
24	141	143	O	and
25	145	145	B-KIN	R
26	147	154	L-KIN	warfarin
27	157	157	O	a
28	159	164	O	CYP3A4
29	166	174	O	substrate
30	177	178	O	by
31	180	181	O	29
32	183	185	O	and
33	187	189	O	38%
34	190	190	O	,
35	192	203	O	respectively
NULL

Bosentan	DDI-DrugBank.d289.s31	NO_SECTION	NO_SETID	63
Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.
1	0	7	O	Clinical
2	9	18	O	experience
3	20	23	O	with
4	25	35	O	concomitant
5	37	50	O	administration
6	52	53	O	of
7	55	62	O	XXXXXXXX
8	64	66	O	and
9	68	75	U-UNK	warfarin
10	77	78	O	in
11	80	87	O	patients
12	89	92	O	with
13	94	102	O	pulmonary
14	104	111	O	arterial
15	113	124	O	hypertension
16	126	128	O	did
17	130	132	O	not
18	134	137	O	show
19	139	148	O	clinically
20	150	157	O	relevant
21	159	165	O	changes
22	167	168	O	in
23	170	172	O	INR
24	174	175	O	or
25	177	184	U-UNK	warfarin
26	186	189	O	dose
27	192	199	O	baseline
28	201	202	O	vs
29	205	207	O	end
30	209	210	O	of
31	212	214	O	the
32	216	223	O	clinical
33	225	231	O	studies
34	233	233	O	,
35	235	237	O	and
36	239	241	O	the
37	243	246	O	need
38	248	249	O	to
39	251	256	O	change
40	258	260	O	the
41	262	269	U-UNK	warfarin
42	271	274	O	dose
43	276	281	O	during
44	283	285	O	the
45	287	292	O	trials
46	294	296	O	due
47	298	299	O	to
48	301	307	O	changes
49	309	310	O	in
50	312	314	O	INR
51	316	317	O	or
52	319	321	O	due
53	323	324	O	to
54	326	332	O	adverse
55	334	339	O	events
56	341	343	O	was
57	345	351	O	similar
58	353	357	O	among
59	359	366	O	XXXXXXXX
60	369	371	O	and
61	373	379	O	placebo
62	381	387	O	treated
63	389	396	O	patients
NULL

Bosentan	DDI-DrugBank.d289.s32	NO_SECTION	NO_SETID	28
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.
1	0	6	U-UNK	Digoxin
2	7	7	O	,
3	9	18	U-UNK	Nimodipine
4	20	22	O	and
5	24	31	U-UNK	Losartan
6	32	32	O	:
7	34	41	O	XXXXXXXX
8	43	45	O	has
9	47	48	O	no
10	50	60	O	significant
11	62	76	O	pharmacokinetic
12	78	89	O	interactions
13	91	94	O	with
14	96	102	U-UNK	digoxin
15	104	106	O	and
16	108	117	U-UNK	nimodipine
17	118	118	O	,
18	120	122	O	and
19	124	131	U-UNK	losartan
20	133	135	O	has
21	137	138	O	no
22	140	150	O	significant
23	152	157	O	effect
24	159	160	O	on
25	162	167	O	plasma
26	169	174	O	levels
27	176	177	O	of
28	179	186	O	XXXXXXXX
NULL

Botulinum Toxin Type A	DDI-DrugBank.d133.s0	NO_SECTION	NO_SETID	33
Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	25	O	XXXXXXXX
5	27	29	O	and
6	31	45	U-DYN	aminoglycosides
7	47	48	O	or
8	50	54	O	other
9	56	61	O	agents
10	63	73	O	interfering
11	75	78	O	with
12	80	92	O	neuromuscular
13	94	105	O	transmission
14	108	110	O	e.g
15	112	112	O	,
16	114	119	B-DYN	curare
17	121	124	I-DYN	like
18	126	134	L-DYN	compounds
19	137	142	O	should
20	144	147	O	only
21	149	150	O	be
22	152	160	O	performed
23	162	165	O	with
24	167	173	O	caution
25	175	176	O	as
26	178	180	O	the
27	182	187	O	effect
28	189	190	O	of
29	192	194	O	the
30	196	200	U-UNK	toxin
31	202	204	O	may
32	206	207	O	be
33	209	219	O	potentiated
NULL

Botulinum Toxin Type A	DDI-DrugBank.d133.s1	NO_SECTION	NO_SETID	21
The effect of administering different botulinum neurotoxin serotypes at the same time or within several months of each other is unknown.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	26	O	administering
5	28	36	O	different
6	38	46	B-UNK	botulinum
7	48	57	L-UNK	neurotoxin
8	59	67	O	serotypes
9	69	70	O	at
10	72	74	O	the
11	76	79	O	same
12	81	84	O	time
13	86	87	O	or
14	89	94	O	within
15	96	102	O	several
16	104	109	O	months
17	111	112	O	of
18	114	117	O	each
19	119	123	O	other
20	125	126	O	is
21	128	134	O	unknown
NULL

Botulinum Toxin Type A	DDI-DrugBank.d133.s2	NO_SECTION	NO_SETID	25
Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
1	0	8	O	Excessive
2	10	22	O	neuromuscular
3	24	31	O	weakness
4	33	35	O	may
5	37	38	O	be
6	40	50	O	exacerbated
7	52	53	O	by
8	55	68	O	administration
9	70	71	O	of
10	73	79	O	another
11	81	89	B-UNK	botulinum
12	91	95	L-UNK	toxin
13	97	101	O	prior
14	103	104	O	to
15	106	108	O	the
16	110	119	O	resolution
17	121	122	O	of
18	124	126	O	the
19	128	134	O	effects
20	136	137	O	of
21	139	139	O	a
22	141	150	O	previously
23	152	163	O	administered
24	165	173	B-UNK	botulinum
25	175	179	L-UNK	toxin
NULL

Botulinum Toxin Type B	DDI-DrugBank.d323.s0	NO_SECTION	NO_SETID	33
Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	27	O	XXXXXXXX
5	29	31	O	and
6	33	47	U-DYN	aminoglycosides
7	49	50	O	or
8	52	56	O	other
9	58	63	O	agents
10	65	75	O	interfering
11	77	80	O	with
12	82	94	O	neuromuscular
13	96	107	O	transmission
14	110	112	O	e.g
15	114	114	O	,
16	116	121	B-DYN	curare
17	123	126	I-DYN	like
18	128	136	L-DYN	compounds
19	139	144	O	should
20	146	149	O	only
21	151	152	O	be
22	154	162	O	performed
23	164	167	O	with
24	169	175	O	caution
25	177	178	O	as
26	180	182	O	the
27	184	189	O	effect
28	191	192	O	of
29	194	196	O	the
30	198	202	U-UNK	toxin
31	204	206	O	may
32	208	209	O	be
33	211	221	O	potentiated
NULL

Botulinum Toxin Type B	DDI-DrugBank.d323.s1	NO_SECTION	NO_SETID	23
The effect of administering different botulinum neurotoxin serotypes at the same time or within less than 4 months of each other is unknown.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	26	O	administering
5	28	36	O	different
6	38	46	B-UNK	botulinum
7	48	57	L-UNK	neurotoxin
8	59	67	O	serotypes
9	69	70	O	at
10	72	74	O	the
11	76	79	O	same
12	81	84	O	time
13	86	87	O	or
14	89	94	O	within
15	96	99	O	less
16	101	104	O	than
17	106	106	O	4
18	108	113	O	months
19	115	116	O	of
20	118	121	O	each
21	123	127	O	other
22	129	130	O	is
23	132	138	O	unknown
NULL

Botulinum Toxin Type B	DDI-DrugBank.d323.s2	NO_SECTION	NO_SETID	18
However, neuromuscular paralysis may be potentiated by co-administration or overlapping administration of different botulinum toxin serotypes.
1	0	6	O	However
2	7	7	O	,
3	9	21	O	neuromuscular
4	23	31	O	paralysis
5	33	35	O	may
6	37	38	O	be
7	40	50	O	potentiated
8	52	53	O	by
9	55	56	O	co
10	58	71	O	administration
11	73	74	O	or
12	76	86	O	overlapping
13	88	101	O	administration
14	103	104	O	of
15	106	114	O	different
16	116	124	B-UNK	botulinum
17	126	130	L-UNK	toxin
18	132	140	O	serotypes
NULL

Bretylium	DDI-DrugBank.d180.s0	NO_SECTION	NO_SETID	16
Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.
1	0	8	U-DYN	Digitalis
2	10	17	O	toxicity
3	19	21	O	may
4	23	24	O	be
5	26	35	O	aggravated
6	37	38	O	by
7	40	42	O	the
8	44	50	O	initial
9	52	58	O	release
10	60	61	O	of
11	63	76	O	norepinephrine
12	78	83	O	caused
13	85	86	O	by
14	88	96	O	XXXXXXXX
15	98	105	O	Tosylate
16	107	115	O	Injection
NULL

Bretylium	DDI-DrugBank.d180.s1	NO_SECTION	NO_SETID	15
The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.
1	0	2	O	The
2	4	10	O	pressor
3	12	18	O	effects
4	20	21	O	of
5	23	36	U-DYN	catecholamines
6	38	41	O	such
7	43	44	O	as
8	46	53	U-DYN	dopamine
9	55	56	O	or
10	58	71	U-DYN	norepinephrine
11	73	75	O	are
12	77	84	O	enhanced
13	86	87	O	by
14	89	97	O	XXXXXXXX
15	99	106	O	Tosylate
NULL

Bretylium	DDI-DrugBank.d180.s2	NO_SECTION	NO_SETID	17
When catecholamines are administered, dilute solutions should be used and blood pressure should be monitored closely.
1	0	3	O	When
2	5	18	U-UNK	catecholamines
3	20	22	O	are
4	24	35	O	administered
5	36	36	O	,
6	38	43	O	dilute
7	45	53	O	solutions
8	55	60	O	should
9	62	63	O	be
10	65	68	O	used
11	70	72	O	and
12	74	78	O	blood
13	80	87	O	pressure
14	89	94	O	should
15	96	97	O	be
16	99	107	O	monitored
17	109	115	O	closely
NULL

Bretylium	DDI-DrugBank.d180.s3	NO_SECTION	NO_SETID	33
Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.
1	0	7	O	Although
2	9	13	O	there
3	15	16	O	is
4	18	23	O	little
5	25	33	O	published
6	35	45	O	information
7	47	48	O	on
8	50	60	O	concomitant
9	62	75	O	administration
10	77	78	O	of
11	80	88	U-UNK	lidocaine
12	90	92	O	and
13	94	102	O	XXXXXXXX
14	104	111	O	Tosylate
15	112	112	O	,
16	114	118	O	these
17	120	124	O	drugs
18	126	128	O	are
19	130	134	O	often
20	136	147	O	administered
21	149	160	O	concurrently
22	162	168	O	without
23	170	172	O	any
24	174	181	O	evidence
25	183	184	O	of
26	186	197	O	interactions
27	199	207	O	resulting
28	209	210	O	in
29	212	218	O	adverse
30	220	226	O	effects
31	228	229	O	or
32	231	240	O	diminished
33	242	249	O	efficacy
NULL

Brimonidine	DDI-DrugBank.d138.s0	NO_SECTION	NO_SETID	36
Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
1	0	7	O	Although
2	9	16	O	specific
3	18	21	O	drug
4	23	33	O	interaction
5	35	41	O	studies
6	43	46	O	have
7	48	50	O	not
8	52	55	O	been
9	57	65	O	conducted
10	67	70	O	with
11	72	81	O	XXXXXXXX
12	82	82	O	,
13	84	86	O	the
14	88	98	O	possibility
15	100	101	O	of
16	103	104	O	an
17	106	113	O	additive
18	115	116	O	or
19	118	129	O	potentiating
20	131	136	O	effect
21	138	141	O	with
22	143	145	B-DYN	CNS
23	147	157	L-DYN	depressants
24	160	166	U-DYN	alcohol
25	167	167	O	,
26	169	180	U-DYN	barbiturates
27	181	181	O	,
28	183	189	U-DYN	opiates
29	190	190	O	,
30	192	200	U-DYN	sedatives
31	201	201	O	,
32	203	204	O	or
33	206	216	U-DYN	anesthetics
34	219	224	O	should
35	226	227	O	be
36	229	238	O	considered
NULL

Brimonidine	DDI-DrugBank.d138.s1	NO_SECTION	NO_SETID	13
Alpha-agonists, as a class, may reduce pulse and blood pressure.
1	0	4	B-UNK	Alpha
2	6	13	L-UNK	agonists
3	14	14	O	,
4	16	17	O	as
5	19	19	O	a
6	21	25	O	class
7	26	26	O	,
8	28	30	O	may
9	32	37	O	reduce
10	39	43	O	pulse
11	45	47	O	and
12	49	53	O	blood
13	55	62	O	pressure
NULL

Brimonidine	DDI-DrugBank.d138.s2	NO_SECTION	NO_SETID	22
Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.
1	0	6	O	Caution
2	8	9	O	in
3	11	15	O	using
4	17	27	O	concomitant
5	29	33	O	drugs
6	35	38	O	such
7	40	41	O	as
8	43	46	B-UNK	beta
9	48	55	L-UNK	blockers
10	58	67	O	ophthalmic
11	69	71	O	and
12	73	80	O	systemic
13	82	82	O	,
14	84	87	B-UNK	anti
15	89	101	L-UNK	hypertensives
16	103	105	O	and
17	106	106	O	/
18	107	108	O	or
19	110	116	B-UNK	cardiac
20	118	127	L-UNK	glycosides
21	129	130	O	is
22	132	138	O	advised
NULL

Brimonidine	DDI-DrugBank.d138.s3	NO_SECTION	NO_SETID	37
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.
1	0	8	B-UNK	Tricyclic
2	10	24	L-UNK	antidepressants
3	26	29	O	have
4	31	34	O	been
5	36	43	O	reported
6	45	46	O	to
7	48	52	O	blunt
8	54	56	O	the
9	58	68	O	hypotensive
10	70	75	O	effect
11	77	78	O	of
12	80	87	O	systemic
13	89	100	O	clonidine.It
14	102	103	O	is
15	105	107	O	not
16	109	113	O	known
17	115	121	O	whether
18	123	125	O	the
19	127	136	O	concurrent
20	138	140	O	use
21	142	143	O	of
22	145	149	O	these
23	151	156	O	agents
24	158	161	O	with
25	163	172	O	XXXXXXXX
26	174	175	O	in
27	177	182	O	humans
28	184	186	O	can
29	188	191	O	lead
30	193	194	O	to
31	196	204	O	resulting
32	206	217	O	interference
33	219	222	O	with
34	224	226	O	the
35	228	230	O	IOP
36	232	239	O	lowering
37	241	246	O	effect
NULL

Brimonidine	DDI-DrugBank.d138.s4	NO_SECTION	NO_SETID	13
No data on the level of circulating catecholamines after ALPHAGAN P administration are available.
1	0	1	O	No
2	3	6	O	data
3	8	9	O	on
4	11	13	O	the
5	15	19	O	level
6	21	22	O	of
7	24	34	O	circulating
8	36	49	O	catecholamines
9	51	55	O	after
10	57	66	O	XXXXXXXX
11	68	81	O	administration
12	83	85	O	are
13	87	95	O	available
NULL

Brimonidine	DDI-DrugBank.d138.s5	NO_SECTION	NO_SETID	21
Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.
1	0	6	O	Caution
2	7	7	O	,
3	9	15	O	however
4	16	16	O	,
5	18	19	O	is
6	21	27	O	advised
7	29	30	O	in
8	32	39	O	patients
9	41	46	O	taking
10	48	56	B-UNK	tricyclic
11	58	72	L-UNK	antidepressants
12	74	78	O	which
13	80	82	O	can
14	84	89	O	affect
15	91	93	O	the
16	95	104	O	metabolism
17	106	108	O	and
18	110	115	O	uptake
19	117	118	O	of
20	120	130	O	circulating
21	132	137	O	amines
NULL

Brinzolamide	DDI-DrugBank.d497.s0	NO_SECTION	NO_SETID	10
AZOPT (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor.
1	0	4	O	XXXXXXXX
2	7	18	U-UNK	brinzolamide
3	20	29	O	ophthalmic
4	31	40	O	suspension
5	43	44	O	1%
6	46	53	O	contains
7	55	55	O	a
8	57	64	B-UNK	carbonic
9	66	74	I-UNK	anhydrase
10	76	84	L-UNK	inhibitor
NULL

Brinzolamide	DDI-DrugBank.d497.s1	NO_SECTION	NO_SETID	14
Acid-base and electrolyte alterations were not reported in the clinical trials with brinzolamide.
1	0	3	O	Acid
2	5	8	O	base
3	10	12	O	and
4	14	24	O	electrolyte
5	26	36	O	alterations
6	38	41	O	were
7	43	45	O	not
8	47	54	O	reported
9	56	57	O	in
10	59	61	O	the
11	63	70	O	clinical
12	72	77	O	trials
13	79	82	O	with
14	84	95	O	XXXXXXXX
NULL

Brinzolamide	DDI-DrugBank.d497.s2	NO_SECTION	NO_SETID	23
However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	19	O	patients
5	21	27	O	treated
6	29	32	O	with
7	34	37	O	oral
8	39	46	B-UNK	carbonic
9	48	56	I-UNK	anhydrase
10	58	67	L-UNK	inhibitors
11	68	68	O	,
12	70	73	O	rare
13	75	83	O	instances
14	85	86	O	of
15	88	91	O	drug
16	93	104	O	interactions
17	106	109	O	have
18	111	118	O	occurred
19	120	123	O	with
20	125	128	O	high
21	130	133	O	dose
22	135	144	U-UNK	salicylate
23	146	152	O	therapy
NULL

Brinzolamide	DDI-DrugBank.d497.s3	NO_SECTION	NO_SETID	19
Therefore, the potential for such drug interaction should be considered in patients receiving AZOPT (brinzolamide ophthalmic suspension) 1%.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	23	O	potential
5	25	27	O	for
6	29	32	O	such
7	34	37	O	drug
8	39	49	O	interaction
9	51	56	O	should
10	58	59	O	be
11	61	70	O	considered
12	72	73	O	in
13	75	82	O	patients
14	84	92	O	receiving
15	94	98	O	XXXXXXXX
16	101	112	U-UNK	brinzolamide
17	114	123	O	ophthalmic
18	125	134	O	suspension
19	137	138	O	1%
NULL

Bromocriptine	DDI-DrugBank.d272.s0	NO_SECTION	NO_SETID	27
The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	16	O	using
5	18	30	O	XXXXXXXX
6	32	39	O	mesylate
7	41	42	O	in
8	44	54	O	combination
9	56	59	O	with
10	61	65	O	other
11	67	71	O	drugs
12	73	75	O	has
13	77	79	O	not
14	81	84	O	been
15	86	99	O	systematically
16	101	109	O	evaluated
17	110	110	O	,
18	112	114	O	but
19	116	122	U-DYN	alcohol
20	124	126	O	may
21	128	137	O	potentiate
22	139	141	O	the
23	143	146	O	side
24	148	154	O	effects
25	156	157	O	of
26	159	171	O	XXXXXXXX
27	173	180	O	mesylate
NULL

Bromocriptine	DDI-DrugBank.d272.s1	NO_SECTION	NO_SETID	14
Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.
1	0	12	O	XXXXXXXX
2	14	21	O	mesylate
3	23	25	O	may
4	27	34	O	interact
5	36	39	O	with
6	41	48	B-UNK	dopamine
7	50	60	L-UNK	antagonists
8	61	61	O	,
9	63	76	U-UNK	butyrophenones
10	77	77	O	,
11	79	81	O	and
12	83	89	O	certain
13	91	95	O	other
14	97	102	O	agents
NULL

Bromocriptine	DDI-DrugBank.d272.s2	NO_SECTION	NO_SETID	20
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
1	0	8	O	Compounds
2	10	11	O	in
3	13	17	O	these
4	19	28	O	categories
5	30	35	O	result
6	37	38	O	in
7	40	40	O	a
8	42	50	O	decreased
9	52	59	O	efficacy
10	61	62	O	of
11	64	76	O	XXXXXXXX
12	78	85	O	mesylate
13	86	86	O	:
14	88	101	U-DYN	phenothiazines
15	102	102	O	,
16	104	114	U-DYN	haloperidol
17	115	115	O	,
18	117	130	U-DYN	metoclopramide
19	131	131	O	,
20	133	140	U-DYN	pimozide
NULL

Bromocriptine	DDI-DrugBank.d272.s3	NO_SECTION	NO_SETID	12
Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	31	O	XXXXXXXX
5	33	40	O	mesylate
6	42	45	O	with
7	47	51	O	other
8	53	57	B-DYN	ergot
9	59	67	L-DYN	alkaloids
10	69	70	O	is
11	72	74	O	not
12	76	86	O	recommended
NULL

Brompheniramine	DDI-DrugBank.d192.s0	NO_SECTION	NO_SETID	65
Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
1	0	2	O	Dex
2	3	17	O	XXXXXXXX
3	19	21	O	can
4	23	30	O	interact
5	32	35	O	with
6	37	43	U-DYN	alcohol
7	45	46	O	or
8	48	52	O	other
9	54	56	B-DYN	CNS
10	58	68	L-DYN	depressants
11	71	73	O	may
12	75	84	O	potentiate
13	86	88	O	the
14	90	92	O	CNS
15	94	103	O	depressant
16	105	111	O	effects
17	113	114	O	of
18	116	121	O	either
19	123	127	O	these
20	129	139	O	medications
21	141	142	O	or
22	144	157	U-UNK	antihistamines
23	159	159	O	,
24	161	176	U-DYN	anticholinergics
25	178	179	O	or
26	181	185	O	other
27	187	197	O	medications
28	199	202	O	with
29	204	218	O	anticholinergic
30	220	227	O	activity
31	230	244	O	anticholinergic
32	246	252	O	effects
33	254	256	O	may
34	258	259	O	be
35	261	271	O	potentiated
36	273	276	O	when
37	278	282	O	these
38	284	294	O	medications
39	296	298	O	are
40	300	303	O	used
41	305	316	O	concurrently
42	318	321	O	with
43	323	336	U-UNK	antihistamines
44	338	338	O	,
45	340	342	O	and
46	344	352	B-DYN	monoamine
47	354	360	I-DYN	oxidase
48	363	365	I-DYN	MAO
49	368	377	L-DYN	inhibitors
50	380	389	O	concurrent
51	391	393	O	use
52	395	398	O	with
53	400	413	U-UNK	antihistamines
54	415	417	O	may
55	419	425	O	prolong
56	427	429	O	and
57	431	439	O	intensify
58	441	443	O	the
59	445	459	O	anticholinergic
60	461	463	O	and
61	465	467	O	CNS
62	469	478	O	depressant
63	480	486	O	effects
64	488	489	O	of
65	491	504	U-UNK	antihistamines
NULL

Buclizine	DDI-DrugBank.d342.s0	NO_SECTION	NO_SETID	65
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
1	0	3	O	This
2	5	8	O	drug
3	10	12	O	may
4	14	21	O	interact
5	23	26	O	with
6	28	34	U-UNK	alcohol
7	36	37	O	or
8	39	43	O	other
9	45	47	B-UNK	CNS
10	49	59	L-UNK	depressants
11	62	64	O	may
12	66	75	O	potentiate
13	77	79	O	the
14	81	83	O	CNS
15	85	94	O	depressant
16	96	102	O	effects
17	104	105	O	of
18	107	112	O	either
19	114	118	O	these
20	120	130	O	medications
21	132	133	O	or
22	135	148	U-UNK	antihistamines
23	150	150	O	,
24	152	167	U-UNK	anticholinergics
25	169	170	O	or
26	172	176	O	other
27	178	188	O	medications
28	190	193	O	with
29	195	209	O	anticholinergic
30	211	218	O	activity
31	221	235	O	anticholinergic
32	237	243	O	effects
33	245	247	O	may
34	249	250	O	be
35	252	262	O	potentiated
36	264	267	O	when
37	269	273	O	these
38	275	285	O	medications
39	287	289	O	are
40	291	294	O	used
41	296	307	O	concurrently
42	309	312	O	with
43	314	327	U-UNK	antihistamines
44	329	329	O	,
45	331	333	O	and
46	335	343	B-UNK	monoamine
47	345	351	I-UNK	oxidase
48	354	356	I-UNK	MAO
49	359	368	L-UNK	inhibitors
50	371	380	O	concurrent
51	382	384	O	use
52	386	389	O	with
53	391	404	U-UNK	antihistamines
54	406	408	O	may
55	410	416	O	prolong
56	418	420	O	and
57	422	430	O	intensify
58	432	434	O	the
59	436	450	O	anticholinergic
60	452	454	O	and
61	456	458	O	CNS
62	460	469	O	depressant
63	471	477	O	effects
64	479	480	O	of
65	482	495	U-UNK	antihistamines
NULL

Budesonide	DDI-DrugBank.d144.s0	NO_SECTION	NO_SETID	31
Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.
1	0	10	O	Concomitant
2	12	15	O	oral
3	17	30	O	administration
4	32	33	O	of
5	35	46	U-KIN	ketoconazole
6	49	49	O	a
7	51	55	O	known
8	57	65	O	inhibitor
9	67	68	O	of
10	70	75	O	CYP3A4
11	77	84	O	activity
12	86	87	O	in
13	89	91	O	the
14	93	97	O	liver
15	99	101	O	and
16	103	104	O	in
17	106	108	O	the
18	110	119	O	intestinal
19	121	126	O	mucosa
20	129	134	O	caused
21	136	137	O	an
22	139	143	O	eight
23	145	148	O	fold
24	150	157	O	increase
25	159	160	O	of
26	162	164	O	the
27	166	173	O	systemic
28	175	182	O	exposure
29	184	185	O	to
30	187	190	O	oral
31	192	201	O	XXXXXXXX
NULL

Budesonide	DDI-DrugBank.d144.s1	NO_SECTION	NO_SETID	33
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
1	0	1	O	If
2	3	11	O	treatment
3	13	16	O	with
4	18	27	O	inhibitors
5	29	30	O	of
6	32	37	O	CYP3A4
7	39	46	O	activity
8	49	52	O	such
9	54	55	O	as
10	57	68	U-DYN	ketoconazole
11	69	69	O	,
12	71	83	U-DYN	intraconazole
13	84	84	O	,
14	86	94	U-DYN	ritonavir
15	95	95	O	,
16	97	105	U-DYN	indinavir
17	106	106	O	,
18	108	117	U-DYN	saquinavir
19	118	118	O	,
20	120	131	U-DYN	erythromycin
21	132	132	O	,
22	134	136	O	etc
23	140	141	O	is
24	143	151	O	indicated
25	152	152	O	,
26	154	162	O	reduction
27	164	165	O	of
28	167	169	O	the
29	171	180	O	XXXXXXXX
30	182	185	O	dose
31	187	192	O	should
32	194	195	O	be
33	197	206	O	considered
NULL

Budesonide	DDI-DrugBank.d144.s2	NO_SECTION	NO_SETID	26
After extensive intake of grapefruit juice (which inhibits CYP3A4 activity predominantly in the intestinal mucosa), the systemic exposure for oral budesonide increased about two times.
1	0	4	O	After
2	6	14	O	extensive
3	16	21	O	intake
4	23	24	O	of
5	26	35	O	grapefruit
6	37	41	O	juice
7	44	48	O	which
8	50	57	O	inhibits
9	59	64	O	CYP3A4
10	66	73	O	activity
11	75	87	O	predominantly
12	89	90	O	in
13	92	94	O	the
14	96	105	O	intestinal
15	107	112	O	mucosa
16	114	114	O	,
17	116	118	O	the
18	120	127	O	systemic
19	129	136	O	exposure
20	138	140	O	for
21	142	145	O	oral
22	147	156	O	XXXXXXXX
23	158	166	O	increased
24	168	172	O	about
25	174	176	O	two
26	178	182	O	times
NULL

Budesonide	DDI-DrugBank.d144.s3	NO_SECTION	NO_SETID	24
As with other drugs primarily being metabolized through CYP3A4, ingestion of grapefruit or grapefruit juice should be avoided in connection with budesonide administration.
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	18	O	drugs
5	20	28	O	primarily
6	30	34	O	being
7	36	46	O	metabolized
8	48	54	O	through
9	56	61	O	CYP3A4
10	62	62	O	,
11	64	72	O	ingestion
12	74	75	O	of
13	77	86	O	grapefruit
14	88	89	O	or
15	91	100	O	grapefruit
16	102	106	O	juice
17	108	113	O	should
18	115	116	O	be
19	118	124	O	avoided
20	126	127	O	in
21	129	138	O	connection
22	140	143	O	with
23	145	154	O	XXXXXXXX
24	156	169	O	administration
NULL

Bumetanide	DDI-DrugBank.d331.s0	NO_SECTION	NO_SETID	39
- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.
1	2	6	O	Drugs
2	8	11	O	with
3	13	20	O	ototoxic
4	22	30	O	potential
5	31	31	O	:
6	33	42	O	Especially
7	44	45	O	in
8	47	49	O	the
9	51	58	O	presence
10	60	61	O	of
11	63	70	O	impaired
12	72	76	O	renal
13	78	85	O	function
14	86	86	O	,
15	88	90	O	the
16	92	94	O	use
17	96	97	O	of
18	99	110	O	parenterally
19	112	123	O	administered
20	125	134	O	XXXXXXXX
21	136	137	O	in
22	139	146	O	patients
23	148	149	O	to
24	151	154	O	whom
25	156	169	B-DYN	aminoglycoside
26	171	181	L-DYN	antibiotics
27	183	185	O	are
28	187	190	O	also
29	192	196	O	being
30	198	202	O	given
31	204	209	O	should
32	211	212	O	be
33	214	220	O	avoided
34	221	221	O	,
35	223	228	O	except
36	230	231	O	in
37	233	236	O	life
38	238	248	O	threatening
39	250	259	O	conditions
NULL

Bumetanide	DDI-DrugBank.d331.s1	NO_SECTION	NO_SETID	24
- Drugs with nephrotoxic potential: There has been no experience on the concurrent use of bumetanide with drugs known to have a nephrotoxic potential.
1	2	6	O	Drugs
2	8	11	O	with
3	13	23	O	nephrotoxic
4	25	33	O	potential
5	34	34	O	:
6	36	40	O	There
7	42	44	O	has
8	46	49	O	been
9	51	52	O	no
10	54	63	O	experience
11	65	66	O	on
12	68	70	O	the
13	72	81	O	concurrent
14	83	85	O	use
15	87	88	O	of
16	90	99	O	XXXXXXXX
17	101	104	O	with
18	106	110	O	drugs
19	112	116	O	known
20	118	119	O	to
21	121	124	O	have
22	126	126	O	a
23	128	138	O	nephrotoxic
24	140	148	O	potential
NULL

Bumetanide	DDI-DrugBank.d331.s2	NO_SECTION	NO_SETID	11
Therefore, the simultaneous administration of these drugs should be avoided.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	26	O	simultaneous
5	28	41	O	administration
6	43	44	O	of
7	46	50	O	these
8	52	56	O	drugs
9	58	63	O	should
10	65	66	O	be
11	68	74	O	avoided
NULL

Bumetanide	DDI-DrugBank.d331.s3	NO_SECTION	NO_SETID	27
- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.
1	2	8	U-UNK	Lithium
2	9	9	O	:
3	11	17	U-DYN	Lithium
4	19	24	O	should
5	26	34	O	generally
6	36	38	O	not
7	40	41	O	be
8	43	47	O	given
9	49	52	O	with
10	54	62	U-UNK	diuretics
11	65	68	O	such
12	70	71	O	as
13	73	82	O	XXXXXXXX
14	85	91	O	because
15	93	96	O	they
16	98	103	O	reduce
17	105	107	O	its
18	109	113	O	renal
19	115	123	O	clearance
20	125	127	O	and
21	129	131	O	add
22	133	133	O	a
23	135	138	O	high
24	140	143	O	risk
25	145	146	O	of
26	148	154	U-UNK	lithium
27	156	163	O	toxicity
NULL

Bumetanide	DDI-DrugBank.d331.s4	NO_SECTION	NO_SETID	14
- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.
1	2	11	U-UNK	Probenecid
2	12	12	O	:
3	14	25	O	Pretreatment
4	27	30	O	with
5	32	41	U-DYN	probenecid
6	43	49	O	reduces
7	51	54	O	both
8	56	58	O	the
9	60	70	O	natriuresis
10	72	74	O	and
11	76	89	O	hyperreninemia
12	91	98	O	produced
13	100	101	O	by
14	103	112	O	XXXXXXXX
NULL

Bumetanide	DDI-DrugBank.d331.s5	NO_SECTION	NO_SETID	32
This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.
1	0	3	O	This
2	5	16	O	antagonistic
3	18	23	O	effect
4	25	26	O	of
5	28	37	U-KIN	probenecid
6	39	40	O	on
7	42	51	O	XXXXXXXX
8	53	63	O	natriuresis
9	65	66	O	is
10	68	70	O	not
11	72	74	O	due
12	76	77	O	to
13	79	79	O	a
14	81	86	O	direct
15	88	93	O	action
16	95	96	O	on
17	98	103	O	sodium
18	105	113	O	excretion
19	115	117	O	but
20	119	120	O	is
21	122	129	O	probably
22	131	139	O	secondary
23	141	142	O	to
24	144	146	O	its
25	148	157	O	inhibitory
26	159	164	O	effect
27	166	167	O	on
28	169	173	O	renal
29	175	181	O	tubular
30	183	191	O	secretion
31	193	194	O	of
32	196	205	O	XXXXXXXX
NULL

Bumetanide	DDI-DrugBank.d331.s6	NO_SECTION	NO_SETID	10
Thus, probenecid should not be administered concurrently with bumetanide.
1	0	3	O	Thus
2	4	4	O	,
3	6	15	U-DYN	probenecid
4	17	22	O	should
5	24	26	O	not
6	28	29	O	be
7	31	42	O	administered
8	44	55	O	concurrently
9	57	60	O	with
10	62	71	O	XXXXXXXX
NULL

Bumetanide	DDI-DrugBank.d331.s7	NO_SECTION	NO_SETID	26
- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.
1	2	13	U-UNK	Indomethacin
2	14	14	O	:
3	16	27	U-DYN	Indomethacin
4	29	34	O	blunts
5	36	38	O	the
6	40	48	O	increases
7	50	51	O	in
8	53	57	O	urine
9	59	64	O	volume
10	66	68	O	and
11	70	75	O	sodium
12	77	85	O	excretion
13	87	90	O	seen
14	92	97	O	during
15	99	108	O	XXXXXXXX
16	110	118	O	treatment
17	120	122	O	and
18	124	131	O	inhibits
19	133	135	O	the
20	137	146	O	XXXXXXXX
21	148	154	O	induced
22	156	163	O	increase
23	165	166	O	in
24	168	173	O	plasma
25	175	179	O	renin
26	181	188	O	activity
NULL

Bumetanide	DDI-DrugBank.d331.s8	NO_SECTION	NO_SETID	8
Concurrent therapy with bumetanide is thus not recommended.
1	0	9	O	Concurrent
2	11	17	O	therapy
3	19	22	O	with
4	24	33	O	XXXXXXXX
5	35	36	O	is
6	38	41	O	thus
7	43	45	O	not
8	47	57	O	recommended
NULL

Bumetanide	DDI-DrugBank.d331.s9	NO_SECTION	NO_SETID	21
- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.
1	2	18	U-UNK	Antihypertensives
2	19	19	O	:
3	21	30	O	XXXXXXXX
4	32	34	O	may
5	36	45	O	potentiate
6	47	49	O	the
7	51	56	O	effect
8	58	59	O	of
9	61	67	O	various
10	69	84	B-DYN	antihypertensive
11	86	90	L-DYN	drugs
12	91	91	O	,
13	93	105	O	necessitating
14	107	107	O	a
15	109	117	O	reduction
16	119	120	O	in
17	122	124	O	the
18	126	131	O	dosage
19	133	134	O	of
20	136	140	O	these
21	142	146	O	drugs
NULL

Bumetanide	DDI-DrugBank.d331.s10	NO_SECTION	NO_SETID	14
- Digoxin: Interaction studies in humans have shown no effect on digoxin blood levels.
1	2	8	U-UNK	Digoxin
2	9	9	O	:
3	11	21	O	Interaction
4	23	29	O	studies
5	31	32	O	in
6	34	39	O	humans
7	41	44	O	have
8	46	50	O	shown
9	52	53	O	no
10	55	60	O	effect
11	62	63	O	on
12	65	71	U-UNK	digoxin
13	73	77	O	blood
14	79	84	O	levels
NULL

Bumetanide	DDI-DrugBank.d331.s11	NO_SECTION	NO_SETID	21
- Anticoagulants: Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity.
1	2	15	U-UNK	Anticoagulants
2	16	16	O	:
3	18	28	O	Interaction
4	30	36	O	studies
5	38	39	O	in
6	41	46	O	humans
7	48	51	O	have
8	53	57	O	shown
9	59	68	O	XXXXXXXX
10	70	71	O	to
11	73	76	O	have
12	78	79	O	no
13	81	86	O	effect
14	88	89	O	on
15	91	98	U-UNK	warfarin
16	100	109	O	metabolism
17	111	112	O	or
18	114	115	O	on
19	117	122	O	plasma
20	124	134	O	prothrombin
21	136	143	O	activity
NULL

Bupivacaine	DDI-DrugBank.d153.s0	NO_SECTION	NO_SETID	25
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
1	0	2	O	The
2	4	17	O	administration
3	19	20	O	of
4	22	26	O	local
5	28	37	B-UNK	anesthetic
6	39	47	L-UNK	solutions
7	49	58	O	containing
8	60	70	U-UNK	epinephrine
9	72	73	O	or
10	75	88	U-UNK	norepinephrine
11	90	91	O	to
12	93	100	O	patients
13	102	110	O	receiving
14	112	120	B-UNK	monoamine
15	122	128	I-UNK	oxidase
16	130	139	L-UNK	inhibitors
17	141	142	O	or
18	144	152	B-UNK	tricyclic
19	154	168	L-UNK	antidepressants
20	170	172	O	may
21	174	180	O	produce
22	182	187	O	severe
23	188	188	O	,
24	190	198	O	prolonged
25	200	211	O	hypertension
NULL

Bupivacaine	DDI-DrugBank.d153.s1	NO_SECTION	NO_SETID	9
Concurrent use of these agents should generally be avoided.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	16	O	of
4	18	22	O	these
5	24	29	O	agents
6	31	36	O	should
7	38	46	O	generally
8	48	49	O	be
9	51	57	O	avoided
NULL

Bupivacaine	DDI-DrugBank.d153.s2	NO_SECTION	NO_SETID	14
In situations in which concurrent therapy is necessary, careful patient monitoring is essential.
1	0	1	O	In
2	3	12	O	situations
3	14	15	O	in
4	17	21	O	which
5	23	32	O	concurrent
6	34	40	O	therapy
7	42	43	O	is
8	45	53	O	necessary
9	54	54	O	,
10	56	62	O	careful
11	64	70	O	patient
12	72	81	O	monitoring
13	83	84	O	is
14	86	94	O	essential
NULL

Bupivacaine	DDI-DrugBank.d153.s3	NO_SECTION	NO_SETID	20
Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	39	B-UNK	vasopressor
5	41	45	L-UNK	drugs
6	47	49	O	and
7	51	52	O	of
8	54	58	B-UNK	ergot
9	60	63	I-UNK	type
10	65	72	I-UNK	oxytocic
11	74	78	L-UNK	drugs
12	80	82	O	may
13	84	88	O	cause
14	90	95	O	severe
15	96	96	O	,
16	98	107	O	persistent
17	109	120	O	hypertension
18	122	123	O	or
19	125	139	O	cerebrovascular
20	141	149	O	accidents
NULL

Bupivacaine	DDI-DrugBank.d153.s4	NO_SECTION	NO_SETID	12
Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
1	0	13	U-UNK	Phenothiazines
2	15	17	O	and
3	19	32	U-UNK	butyrophenones
4	34	36	O	may
5	38	43	O	reduce
6	45	46	O	or
7	48	54	O	reverse
8	56	58	O	the
9	60	66	O	pressor
10	68	73	O	effect
11	75	76	O	of
12	78	88	U-UNK	epinephrine
NULL

Buprenorphine	DDI-DrugBank.d380.s0	NO_SECTION	NO_SETID	10
Buprenorphine is metabolized to norbuprenorphine by cytochrome CYP 3A4.
1	0	12	O	XXXXXXXX
2	14	15	O	is
3	17	27	O	metabolized
4	29	30	O	to
5	32	34	O	nor
6	35	47	O	XXXXXXXX
7	49	50	O	by
8	52	61	O	cytochrome
9	63	65	O	CYP
10	67	69	O	3A4
NULL

Buprenorphine	DDI-DrugBank.d380.s1	NO_SECTION	NO_SETID	22
Because CYP 3A4 inhibitors may increase plasma concentrations of buprenorphine, patients already on CYP 3A4 inhibitors such as azole antifungals (e.g.
1	0	6	O	Because
2	8	10	O	CYP
3	12	14	O	3A4
4	16	25	O	inhibitors
5	27	29	O	may
6	31	38	O	increase
7	40	45	O	plasma
8	47	60	O	concentrations
9	62	63	O	of
10	65	77	O	XXXXXXXX
11	78	78	O	,
12	80	87	O	patients
13	89	95	O	already
14	97	98	O	on
15	100	102	O	CYP
16	104	106	O	3A4
17	108	117	O	inhibitors
18	119	122	O	such
19	124	125	O	as
20	127	131	B-UNK	azole
21	133	143	L-UNK	antifungals
22	146	148	O	e.g
NULL

Buprenorphine	DDI-DrugBank.d380.s2	NO_SECTION	NO_SETID	26
ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
1	0	11	U-UNK	ketoconazole
2	13	13	O	,
3	15	23	B-UNK	macrolide
4	25	35	L-UNK	antibiotics
5	38	40	O	e.g
6	43	54	U-UNK	erythromycin
7	56	56	O	,
8	58	60	O	and
9	62	64	B-UNK	HIV
10	66	73	I-UNK	protease
11	75	84	L-UNK	inhibitors
12	87	89	O	e.g
13	92	100	U-UNK	ritonavir
14	101	101	O	,
15	103	111	U-UNK	indinavir
16	113	115	O	and
17	117	126	U-UNK	saquinavir
18	129	134	O	should
19	136	139	O	have
20	141	145	O	their
21	147	150	O	dose
22	152	153	O	of
23	155	161	O	SUBUTEX
24	163	164	O	or
25	166	173	O	XXXXXXXX
26	175	182	O	adjusted
NULL

Buprenorphine	DDI-DrugBank.d380.s3	NO_SECTION	NO_SETID	14
Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.
1	0	4	O	Based
2	6	7	O	on
3	9	17	O	anecdotal
4	19	25	O	reports
5	26	26	O	,
6	28	32	O	there
7	34	36	O	may
8	38	39	O	be
9	41	42	O	an
10	44	54	O	interaction
11	56	62	O	between
12	64	76	O	XXXXXXXX
13	78	80	O	and
14	82	96	U-UNK	benzodiazepines
NULL

Buprenorphine	DDI-DrugBank.d380.s4	NO_SECTION	NO_SETID	28
There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	16	O	a
5	18	23	O	number
6	25	26	O	of
7	28	34	O	reports
8	36	37	O	in
9	39	41	O	the
10	43	46	O	post
11	48	56	O	marketing
12	58	67	O	experience
13	69	70	O	of
14	72	75	O	coma
15	77	79	O	and
16	81	85	O	death
17	87	96	O	associated
18	98	101	O	with
19	103	105	O	the
20	107	117	O	concomitant
21	119	129	O	intravenous
22	131	136	O	misuse
23	138	139	O	of
24	141	153	O	XXXXXXXX
25	155	157	O	and
26	159	173	U-DYN	benzodiazepines
27	175	176	O	by
28	178	184	O	addicts
NULL

Buprenorphine	DDI-DrugBank.d380.s5	NO_SECTION	NO_SETID	16
In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.
1	0	1	O	In
2	3	6	O	many
3	8	9	O	of
4	11	15	O	these
5	17	21	O	cases
6	22	22	O	,
7	24	36	U-UNK	buprenorphine
8	38	40	O	was
9	42	48	O	misused
10	50	51	O	by
11	53	56	O	self
12	58	66	O	injection
13	68	69	O	of
14	71	77	O	crushed
15	79	85	O	XXXXXXXX
16	87	93	O	tablets
NULL

Buprenorphine	DDI-DrugBank.d380.s6	NO_SECTION	NO_SETID	43
SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.
1	0	6	O	SUBUTEX
2	8	10	O	and
3	12	19	O	XXXXXXXX
4	21	26	O	should
5	28	29	O	be
6	31	40	O	prescribed
7	42	45	O	with
8	47	53	O	caution
9	55	56	O	to
10	58	65	O	patients
11	67	68	O	on
12	70	84	U-DYN	benzodiazepines
13	86	87	O	or
14	89	93	O	other
15	95	99	O	drugs
16	101	104	O	that
17	106	108	O	act
18	110	111	O	on
19	113	115	O	the
20	117	123	O	central
21	125	131	O	nervous
22	133	138	O	system
23	139	139	O	,
24	141	150	O	regardless
25	152	153	O	of
26	155	161	O	whether
27	163	167	O	these
28	169	173	O	drugs
29	175	177	O	are
30	179	183	O	taken
31	185	186	O	on
32	188	190	O	the
33	192	197	O	advice
34	199	200	O	of
35	202	202	O	a
36	204	212	O	physician
37	214	215	O	or
38	217	219	O	are
39	221	225	O	taken
40	227	228	O	as
41	230	234	O	drugs
42	236	237	O	of
43	239	243	O	abuse
NULL

Buprenorphine	DDI-DrugBank.d380.s7	NO_SECTION	NO_SETID	22
Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.
1	0	7	O	Patients
2	9	14	O	should
3	16	17	O	be
4	19	24	O	warned
5	26	27	O	of
6	29	31	O	the
7	33	41	O	potential
8	43	48	O	danger
9	50	51	O	of
10	53	55	O	the
11	57	67	O	intravenous
12	69	72	O	self
13	74	87	O	administration
14	89	90	O	of
15	92	106	U-DYN	benzodiazepines
16	108	112	O	while
17	114	118	O	under
18	120	128	O	treatment
19	130	133	O	with
20	135	142	O	SUBOXONE
21	144	145	O	or
22	147	153	O	XXXXXXXX
NULL

Bupropion	DDI-DrugBank.d5.s0	NO_SECTION	NO_SETID	34
Few systemic data have been collected on the metabolism of WELLBUTRIN following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of WELLBUTRIN on the metabolism of other drugs.
1	0	2	O	Few
2	4	11	O	systemic
3	13	16	O	data
4	18	21	O	have
5	23	26	O	been
6	28	36	O	collected
7	38	39	O	on
8	41	43	O	the
9	45	54	O	metabolism
10	56	57	O	of
11	59	68	O	XXXXXXXX
12	70	78	O	following
13	80	90	O	concomitant
14	92	105	O	administration
15	107	110	O	with
16	112	116	O	other
17	118	122	O	drugs
18	124	125	O	or
19	126	126	O	,
20	128	140	O	alternatively
21	141	141	O	,
22	143	145	O	the
23	147	152	O	effect
24	154	155	O	of
25	157	167	O	concomitant
26	169	182	O	administration
27	184	185	O	of
28	187	196	O	XXXXXXXX
29	198	199	O	on
30	201	203	O	the
31	205	214	O	metabolism
32	216	217	O	of
33	219	223	O	other
34	225	229	O	drugs
NULL

Bupropion	DDI-DrugBank.d5.s1	NO_SECTION	NO_SETID	16
Because bupropion is extensively metabolized, the coadministration of other drugs may affect its clinical activity.
1	0	6	O	Because
2	8	16	O	XXXXXXXX
3	18	19	O	is
4	21	31	O	extensively
5	33	43	O	metabolized
6	44	44	O	,
7	46	48	O	the
8	50	65	O	coadministration
9	67	68	O	of
10	70	74	O	other
11	76	80	O	drugs
12	82	84	O	may
13	86	91	O	affect
14	93	95	O	its
15	97	104	O	clinical
16	106	113	O	activity
NULL

Bupropion	DDI-DrugBank.d5.s2	NO_SECTION	NO_SETID	16
In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	24	O	indicate
5	26	29	O	that
6	31	39	O	XXXXXXXX
7	41	42	O	is
8	44	52	O	primarily
9	54	64	O	metabolized
10	66	67	O	to
11	69	75	O	hydroxy
12	76	84	O	XXXXXXXX
13	86	87	O	by
14	89	91	O	the
15	93	98	O	CYP2B6
16	100	108	O	isoenzyme
NULL

Bupropion	DDI-DrugBank.d5.s3	NO_SECTION	NO_SETID	23
Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	23	O	potential
5	25	30	O	exists
6	32	34	O	for
7	36	36	O	a
8	38	41	O	drug
9	43	53	O	interaction
10	55	61	O	between
11	63	72	O	XXXXXXXX
12	74	76	O	and
13	78	82	O	drugs
14	84	87	O	that
15	89	94	O	affect
16	96	98	O	the
17	100	105	O	CYP2B6
18	107	115	O	isoenzyme
19	118	120	O	e.g
20	122	122	O	,
21	124	135	U-UNK	orphenadrine
22	137	139	O	and
23	141	156	U-UNK	cyclophosphamide
NULL

Bupropion	DDI-DrugBank.d5.s4	NO_SECTION	NO_SETID	17
The threohydrobupropion metabolite of bupropion does not appear to be produced by the cytochrome P450 isoenzymes.
1	0	2	O	The
2	4	13	O	threohydro
3	14	22	O	XXXXXXXX
4	24	33	O	metabolite
5	35	36	O	of
6	38	46	O	XXXXXXXX
7	48	51	O	does
8	53	55	O	not
9	57	62	O	appear
10	64	65	O	to
11	67	68	O	be
12	70	77	O	produced
13	79	80	O	by
14	82	84	O	the
15	86	95	O	cytochrome
16	97	100	O	P450
17	102	111	O	isoenzymes
NULL

Bupropion	DDI-DrugBank.d5.s5	NO_SECTION	NO_SETID	24
The effects of concomitant administration of cimetidine on the pharmacokinetics of bupropion and its active metabolites were studied in 24 healthy young male volunteers.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	25	O	concomitant
5	27	40	O	administration
6	42	43	O	of
7	45	54	U-UNK	cimetidine
8	56	57	O	on
9	59	61	O	the
10	63	78	O	pharmacokinetics
11	80	81	O	of
12	83	91	O	XXXXXXXX
13	93	95	O	and
14	97	99	O	its
15	101	106	O	active
16	108	118	O	metabolites
17	120	123	O	were
18	125	131	O	studied
19	133	134	O	in
20	136	137	O	24
21	139	145	O	healthy
22	147	151	O	young
23	153	156	O	male
24	158	167	O	volunteers
NULL

Bupropion	DDI-DrugBank.d5.s6	NO_SECTION	NO_SETID	27
Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and hydroxybupropion were unaffected.
1	0	8	O	Following
2	10	13	O	oral
3	15	28	O	administration
4	30	31	O	of
5	33	35	O	two
6	37	39	O	150
7	41	42	O	mg
8	44	52	O	sustained
9	54	60	O	release
10	62	68	O	tablets
11	70	73	O	with
12	75	77	O	and
13	79	85	O	without
14	87	89	O	800
15	91	92	O	mg
16	94	95	O	of
17	97	106	U-UNK	cimetidine
18	107	107	O	,
19	109	111	O	the
20	113	128	O	pharmacokinetics
21	130	131	O	of
22	133	141	O	XXXXXXXX
23	143	145	O	and
24	147	153	O	hydroxy
25	154	162	O	XXXXXXXX
26	164	167	O	were
27	169	178	O	unaffected
NULL

Bupropion	DDI-DrugBank.d5.s7	NO_SECTION	NO_SETID	26
However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	there
4	15	18	O	were
5	20	22	O	16%
6	24	26	O	and
7	28	30	O	32%
8	32	40	O	increases
9	42	43	O	in
10	45	47	O	the
11	49	51	O	AUC
12	53	55	O	and
13	57	60	O	Cmax
14	61	61	O	,
15	63	74	O	respectively
16	75	75	O	,
17	77	78	O	of
18	80	82	O	the
19	84	91	O	combined
20	93	100	O	moieties
21	102	103	O	of
22	105	114	O	threohydro
23	115	123	O	XXXXXXXX
24	125	127	O	and
25	129	140	O	erythrohydro
26	141	149	O	XXXXXXXX
NULL

Bupropion	DDI-DrugBank.d5.s8	NO_SECTION	NO_SETID	20
While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).
1	0	4	O	While
2	6	8	O	not
3	10	23	O	systematically
4	25	31	O	studied
5	32	32	O	,
6	34	40	O	certain
7	42	46	O	drugs
8	48	50	O	may
9	52	57	O	induce
10	59	61	O	the
11	63	72	O	metabolism
12	74	75	O	of
13	77	85	O	XXXXXXXX
14	88	90	O	e.g
15	92	92	O	,
16	94	106	U-KIN	carbamazepine
17	107	107	O	,
18	109	121	U-KIN	phenobarbital
19	122	122	O	,
20	124	132	U-KIN	phenytoin
NULL

Bupropion	DDI-DrugBank.d5.s9	NO_SECTION	NO_SETID	15
Animal data indicated that bupropion may be an inducer of drug-metabolizing enzymes in humans.
1	0	5	O	Animal
2	7	10	O	data
3	12	20	O	indicated
4	22	25	O	that
5	27	35	O	XXXXXXXX
6	37	39	O	may
7	41	42	O	be
8	44	45	O	an
9	47	53	O	inducer
10	55	56	O	of
11	58	61	O	drug
12	63	74	O	metabolizing
13	76	82	O	enzymes
14	84	85	O	in
15	87	92	O	humans
NULL

Bupropion	DDI-DrugBank.d5.s10	NO_SECTION	NO_SETID	34
In one study, following chronic administration of bupropion, 100 mg 3 times daily to 8 healthy male volunteers for 14 days, there was no evidence of induction of its own metabolism.
1	0	1	O	In
2	3	5	O	one
3	7	11	O	study
4	12	12	O	,
5	14	22	O	following
6	24	30	O	chronic
7	32	45	O	administration
8	47	48	O	of
9	50	58	O	XXXXXXXX
10	59	59	O	,
11	61	63	O	100
12	65	66	O	mg
13	68	68	O	3
14	70	74	O	times
15	76	80	O	daily
16	82	83	O	to
17	85	85	O	8
18	87	93	O	healthy
19	95	98	O	male
20	100	109	O	volunteers
21	111	113	O	for
22	115	116	O	14
23	118	121	O	days
24	122	122	O	,
25	124	128	O	there
26	130	132	O	was
27	134	135	O	no
28	137	144	O	evidence
29	146	147	O	of
30	149	157	O	induction
31	159	160	O	of
32	162	164	O	its
33	166	168	O	own
34	170	179	O	metabolism
NULL

Bupropion	DDI-DrugBank.d5.s11	NO_SECTION	NO_SETID	17
Nevertheless, there may be the potential for clinically important alterations of blood levels of coadministered drugs.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	18	O	there
4	20	22	O	may
5	24	25	O	be
6	27	29	O	the
7	31	39	O	potential
8	41	43	O	for
9	45	54	O	clinically
10	56	64	O	important
11	66	76	O	alterations
12	78	79	O	of
13	81	85	O	blood
14	87	92	O	levels
15	94	95	O	of
16	97	110	O	coadministered
17	112	116	O	drugs
NULL

Bupropion	DDI-DrugBank.d5.s12	NO_SECTION	NO_SETID	31
Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	30	O	Cytochrome
5	32	39	O	P450IID6
6	42	47	O	CYP2D6
7	49	49	O	:
8	51	54	O	Many
9	56	60	O	drugs
10	61	61	O	,
11	63	71	O	including
12	73	76	O	most
13	78	92	U-UNK	antidepressants
14	95	99	O	SSRIs
15	100	100	O	,
16	102	105	O	many
17	107	116	U-UNK	tricyclics
18	118	118	O	,
19	120	123	B-UNK	beta
20	125	132	L-UNK	blockers
21	133	133	O	,
22	135	149	U-UNK	antiarrhythmics
23	150	150	O	,
24	152	154	O	and
25	156	169	U-UNK	antipsychotics
26	171	173	O	are
27	175	185	O	metabolized
28	187	188	O	by
29	190	192	O	the
30	194	199	O	CYP2D6
31	201	209	O	isoenzyme
NULL

Bupropion	DDI-DrugBank.d5.s13	NO_SECTION	NO_SETID	21
Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.
1	0	7	O	Although
2	9	17	O	XXXXXXXX
3	19	20	O	is
4	22	24	O	not
5	26	36	O	metabolized
6	38	39	O	by
7	41	44	O	this
8	46	54	O	isoenzyme
9	55	55	O	,
10	57	65	O	XXXXXXXX
11	67	69	O	and
12	71	77	O	hydroxy
13	78	86	O	XXXXXXXX
14	88	90	O	are
15	92	101	O	inhibitors
16	103	104	O	of
17	106	108	O	the
18	110	115	O	CYP2D6
19	117	125	O	isoenzyme
20	127	128	O	in
21	130	134	O	vitro
NULL

Bupropion	DDI-DrugBank.d5.s14	NO_SECTION	NO_SETID	65
In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	15	O	15
6	17	20	O	male
7	22	29	O	subjects
8	32	35	O	ages
9	37	38	O	19
10	40	41	O	to
11	43	44	O	35
12	46	50	O	years
13	53	55	O	who
14	57	60	O	were
15	62	70	O	extensive
16	72	83	O	metabolizers
17	85	86	O	of
18	88	90	O	the
19	92	97	O	CYP2D6
20	99	107	O	isoenzyme
21	108	108	O	,
22	110	114	O	daily
23	116	120	O	doses
24	122	123	O	of
25	125	133	O	XXXXXXXX
26	135	139	O	given
27	141	142	O	as
28	144	146	O	150
29	148	149	O	mg
30	151	155	O	twice
31	157	161	O	daily
32	163	170	O	followed
33	172	173	O	by
34	175	175	O	a
35	177	182	O	single
36	184	187	O	dose
37	189	190	O	of
38	192	193	O	50
39	195	196	O	mg
40	198	208	U-KIN	desipramine
41	210	218	O	increased
42	220	222	O	the
43	224	227	O	Cmax
44	228	228	O	,
45	230	232	O	AUC
46	233	233	O	,
47	235	237	O	and
48	239	240	O	t1
49	241	241	O	/
50	242	242	O	2
51	244	245	O	of
52	247	257	U-UNK	desipramine
53	259	260	O	by
54	262	263	O	an
55	265	271	O	average
56	273	274	O	of
57	276	288	O	approximately
58	290	290	O	2
59	292	292	O	,
60	294	294	O	5
61	297	299	O	and
62	301	301	O	2
63	303	306	O	fold
64	307	307	O	,
65	309	320	O	respectively
NULL

Bupropion	DDI-DrugBank.d5.s15	NO_SECTION	NO_SETID	15
The effect was present for at least 7 days after the last dose of bupropion.
1	0	2	O	The
2	4	9	O	effect
3	11	13	O	was
4	15	21	O	present
5	23	25	O	for
6	27	28	O	at
7	30	34	O	least
8	36	36	O	7
9	38	41	O	days
10	43	47	O	after
11	49	51	O	the
12	53	56	O	last
13	58	61	O	dose
14	63	64	O	of
15	66	74	O	XXXXXXXX
NULL

Bupropion	DDI-DrugBank.d5.s16	NO_SECTION	NO_SETID	15
Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	27	O	XXXXXXXX
5	29	32	O	with
6	34	38	O	other
7	40	44	O	drugs
8	46	56	O	metabolized
9	58	59	O	by
10	61	66	O	CYP2D6
11	68	70	O	has
12	72	74	O	not
13	76	79	O	been
14	81	88	O	formally
15	90	96	O	studied
NULL

Bupropion	DDI-DrugBank.d5.s17	NO_SECTION	NO_SETID	77
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	co
4	14	27	O	administration
5	29	30	O	of
6	32	40	O	XXXXXXXX
7	42	45	O	with
8	47	51	O	drugs
9	53	56	O	that
10	58	60	O	are
11	62	72	O	metabolized
12	74	75	O	by
13	77	82	O	CYP2D6
14	84	92	O	isoenzyme
15	94	102	O	including
16	104	110	O	certain
17	112	126	U-DYN	antidepressants
18	129	131	O	e.g
19	133	133	O	,
20	135	147	U-DYN	nortriptyline
21	148	148	O	,
22	150	159	U-DYN	imipramine
23	160	160	O	,
24	162	172	U-DYN	desipramine
25	173	173	O	,
26	175	184	U-DYN	paroxetine
27	185	185	O	,
28	187	196	U-DYN	fluoxetine
29	197	197	O	,
30	199	208	U-DYN	sertraline
31	210	210	O	,
32	212	225	U-DYN	antipsychotics
33	228	230	O	e.g
34	232	232	O	,
35	234	244	U-DYN	haloperidol
36	245	245	O	,
37	247	257	U-DYN	risperidone
38	258	258	O	,
39	260	271	U-DYN	thioridazine
40	273	273	O	,
41	275	278	B-DYN	beta
42	280	287	L-DYN	blockers
43	290	292	O	e.g
44	294	294	O	,
45	296	305	U-DYN	metoprolol
46	307	307	O	,
47	309	311	O	and
48	313	316	B-DYN	Type
49	318	319	I-DYN	1C
50	321	335	L-DYN	antiarrhythmics
51	338	340	O	e.g
52	342	342	O	,
53	344	354	U-DYN	propafenone
54	355	355	O	,
55	357	366	U-DYN	flecainide
56	368	368	O	,
57	370	375	O	should
58	377	378	O	be
59	380	389	O	approached
60	391	394	O	with
61	396	402	O	caution
62	404	406	O	and
63	408	413	O	should
64	415	416	O	be
65	418	426	O	initiated
66	428	429	O	at
67	431	433	O	the
68	435	439	O	lower
69	441	443	O	end
70	445	446	O	of
71	448	450	O	the
72	452	455	O	dose
73	457	461	O	range
74	463	464	O	of
75	466	468	O	the
76	470	480	O	concomitant
77	482	491	O	medication
NULL

Bupropion	DDI-DrugBank.d5.s18	NO_SECTION	NO_SETID	43
If bupropion is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need to decrease the dose of the original medication should be considered, particularly for those concomitant medications with a narrow therapeutic index.
1	0	1	O	If
2	3	11	O	XXXXXXXX
3	13	14	O	is
4	16	20	O	added
5	22	23	O	to
6	25	27	O	the
7	29	37	O	treatment
8	39	45	O	regimen
9	47	48	O	of
10	50	50	O	a
11	52	58	O	patient
12	60	66	O	already
13	68	76	O	receiving
14	78	78	O	a
15	80	83	O	drug
16	85	95	O	metabolized
17	97	98	O	by
18	100	105	O	CYP2D6
19	106	106	O	,
20	108	110	O	the
21	112	115	O	need
22	117	118	O	to
23	120	127	O	decrease
24	129	131	O	the
25	133	136	O	dose
26	138	139	O	of
27	141	143	O	the
28	145	152	O	original
29	154	163	O	medication
30	165	170	O	should
31	172	173	O	be
32	175	184	O	considered
33	185	185	O	,
34	187	198	O	particularly
35	200	202	O	for
36	204	208	O	those
37	210	220	O	concomitant
38	222	232	O	medications
39	234	237	O	with
40	239	239	O	a
41	241	246	O	narrow
42	248	258	O	therapeutic
43	260	264	O	index
NULL

Bupropion	DDI-DrugBank.d5.s19	NO_SECTION	NO_SETID	20
MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .
1	0	2	B-UNK	MAO
2	4	13	L-UNK	Inhibitors
3	14	14	O	:
4	16	22	O	Studies
5	24	25	O	in
6	27	33	O	animals
7	35	45	O	demonstrate
8	47	50	O	that
9	52	54	O	the
10	56	60	O	acute
11	62	69	O	toxicity
12	71	72	O	of
13	74	82	O	XXXXXXXX
14	84	85	O	is
15	87	94	O	enhanced
16	96	97	O	by
17	99	101	O	the
18	103	105	B-UNK	MAO
19	107	115	L-UNK	inhibitor
20	117	126	U-DYN	phenelzine
NULL

Bupropion	DDI-DrugBank.d5.s20	NO_SECTION	NO_SETID	24
Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.
1	0	7	U-UNK	Levodopa
2	9	11	O	and
3	13	22	U-UNK	Amantadine
4	23	23	O	:
5	25	31	O	Limited
6	33	40	O	clinical
7	42	45	O	data
8	47	53	O	suggest
9	55	55	O	a
10	57	62	O	higher
11	64	72	O	incidence
12	74	75	O	of
13	77	83	O	adverse
14	85	95	O	experiences
15	97	98	O	in
16	100	107	O	patients
17	109	117	O	receiving
18	119	127	O	XXXXXXXX
19	129	140	O	concurrently
20	142	145	O	with
21	147	152	O	either
22	154	161	U-DYN	levodopa
23	163	164	O	or
24	166	175	U-DYN	amantadine
NULL

Bupropion	DDI-DrugBank.d5.s21	NO_SECTION	NO_SETID	27
Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.
1	0	13	O	Administration
2	15	16	O	of
3	18	27	O	XXXXXXXX
4	29	35	O	Tablets
5	37	38	O	to
6	40	47	O	patients
7	49	57	O	receiving
8	59	64	O	either
9	66	73	U-DYN	levodopa
10	75	76	O	or
11	78	87	U-DYN	amantadine
12	89	100	O	concurrently
13	102	107	O	should
14	109	110	O	be
15	112	121	O	undertaken
16	123	126	O	with
17	128	134	O	caution
18	135	135	O	,
19	137	141	O	using
20	143	147	O	small
21	149	155	O	initial
22	157	161	O	doses
23	163	165	O	and
24	167	171	O	small
25	173	179	O	gradual
26	181	184	O	dose
27	186	194	O	increases
NULL

Bupropion	DDI-DrugBank.d5.s22	NO_SECTION	NO_SETID	36
Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.
1	0	4	O	Drugs
2	6	9	O	that
3	11	15	O	Lower
4	17	23	O	Seizure
5	25	33	O	Threshold
6	34	34	O	:
7	36	45	O	Concurrent
8	47	60	O	administration
9	62	63	O	of
10	65	74	O	XXXXXXXX
11	76	78	O	and
12	80	85	O	agents
13	88	90	O	e.g
14	92	92	O	,
15	94	107	U-DYN	antipsychotics
16	108	108	O	,
17	110	114	O	other
18	116	130	U-DYN	antidepressants
19	131	131	O	,
20	133	144	U-DYN	theophylline
21	145	145	O	,
22	147	154	O	systemic
23	156	163	U-DYN	steroids
24	164	164	O	,
25	166	168	O	etc
26	172	175	O	that
27	177	181	O	lower
28	183	189	O	seizure
29	191	199	O	threshold
30	201	206	O	should
31	208	209	O	be
32	211	220	O	undertaken
33	222	225	O	only
34	227	230	O	with
35	232	238	O	extreme
36	240	246	O	caution
NULL

Bupropion	DDI-DrugBank.d5.s23	NO_SECTION	NO_SETID	11
Low initial dosing and small gradual dose increases should be employed.
1	0	2	O	Low
2	4	10	O	initial
3	12	17	O	dosing
4	19	21	O	and
5	23	27	O	small
6	29	35	O	gradual
7	37	40	O	dose
8	42	50	O	increases
9	52	57	O	should
10	59	60	O	be
11	62	69	O	employed
NULL

Bupropion	DDI-DrugBank.d5.s24	NO_SECTION	NO_SETID	4
Nicotine Transdermal System: .
1	0	7	U-UNK	Nicotine
2	9	19	O	Transdermal
3	21	26	O	System
4	27	27	O	:
NULL

Bupropion	DDI-DrugBank.d5.s25	NO_SECTION	NO_SETID	30
Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.
1	0	6	U-UNK	Alcohol
2	7	7	O	:
3	9	10	O	In
4	12	15	O	post
5	17	25	O	marketing
6	27	36	O	experience
7	37	37	O	,
8	39	43	O	there
9	45	48	O	have
10	50	53	O	been
11	55	58	O	rare
12	60	66	O	reports
13	68	69	O	of
14	71	77	O	adverse
15	79	94	O	neuropsychiatric
16	96	101	O	events
17	103	104	O	or
18	106	112	O	reduced
19	114	120	U-UNK	alcohol
20	122	130	O	tolerance
21	132	133	O	in
22	135	142	O	patients
23	144	146	O	who
24	148	151	O	were
25	153	160	O	drinking
26	162	168	U-DYN	alcohol
27	170	175	O	during
28	177	185	O	treatment
29	187	190	O	with
30	192	201	O	XXXXXXXX
NULL

Bupropion	DDI-DrugBank.d5.s26	NO_SECTION	NO_SETID	19
The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)
1	0	2	O	The
2	4	14	O	consumption
3	16	17	O	of
4	19	25	U-DYN	alcohol
5	27	32	O	during
6	34	42	O	treatment
7	44	47	O	with
8	49	58	O	XXXXXXXX
9	60	65	O	should
10	67	68	O	be
11	70	78	O	minimized
12	80	81	O	or
13	83	89	O	avoided
14	92	95	O	also
15	97	99	O	see
16	102	102	O	a
17	104	108	O	href=
18	110	126	O	bupropz_od.htm#CI
19	128	144	O	CONTRAINDICATIONS
NULL

Buspirone	DDI-DrugBank.d463.s0	NO_SECTION	NO_SETID	48
It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	31	O	XXXXXXXX
6	33	45	O	hydrochloride
7	47	49	O	not
8	51	52	O	be
9	54	57	O	used
10	59	71	O	concomitantly
11	73	76	O	with
12	78	80	B-DYN	MAO
13	82	91	L-DYN	inhibitors
14	93	99	O	Because
15	101	103	O	the
16	105	111	O	effects
17	113	114	O	of
18	116	126	O	concomitant
19	128	141	O	administration
20	143	144	O	of
21	146	154	O	XXXXXXXX
22	156	158	O	HCl
23	160	163	O	with
24	165	168	O	most
25	170	174	O	other
26	176	187	B-UNK	psychotropic
27	189	193	L-UNK	drugs
28	195	198	O	have
29	200	202	O	not
30	204	207	O	been
31	209	215	O	studied
32	216	216	O	,
33	218	220	O	the
34	222	232	O	concomitant
35	234	236	O	use
36	238	239	O	of
37	241	249	O	XXXXXXXX
38	251	253	O	HCl
39	255	258	O	with
40	260	264	O	other
41	266	268	O	CNS
42	270	275	O	active
43	277	281	O	drugs
44	283	288	O	should
45	290	291	O	be
46	293	302	O	approached
47	304	307	O	with
48	309	315	O	caution
NULL

Buspirone	DDI-DrugBank.d463.s1	NO_SECTION	NO_SETID	31
There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
1	0	4	O	There
2	6	7	O	is
3	9	11	O	one
4	13	18	O	report
5	20	29	O	suggesting
6	31	34	O	that
7	36	38	O	the
8	40	50	O	concomitant
9	52	54	O	use
10	56	57	O	of
11	59	67	B-UNK	trazodone
12	69	81	L-UNK	hydrochloride
13	84	90	O	XXXXXXXX
14	93	95	O	and
15	97	105	B-DYN	buspirone
16	107	109	L-DYN	HCl
17	111	113	O	may
18	115	118	O	have
19	120	125	O	caused
20	127	127	O	3
21	130	131	O	to
22	133	133	O	6
23	135	138	O	fold
24	140	149	O	elevations
25	151	152	O	on
26	154	157	O	SGPT
27	160	162	O	ALT
28	165	166	O	in
29	168	168	O	a
30	170	172	O	few
31	174	181	O	patients
NULL

Buspirone	DDI-DrugBank.d463.s2	NO_SECTION	NO_SETID	19
In a similar study, attempting to replicate this finding, no interactive effect on hepatic transaminases was identified.
1	0	1	O	In
2	3	3	O	a
3	5	11	O	similar
4	13	17	O	study
5	18	18	O	,
6	20	29	O	attempting
7	31	32	O	to
8	34	42	O	replicate
9	44	47	O	this
10	49	55	O	finding
11	56	56	O	,
12	58	59	O	no
13	61	71	O	interactive
14	73	78	O	effect
15	80	81	O	on
16	83	89	O	hepatic
17	91	103	O	transaminases
18	105	107	O	was
19	109	118	O	identified
NULL

Buspirone	DDI-DrugBank.d463.s3	NO_SECTION	NO_SETID	20
In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	in
5	14	19	O	normal
6	21	30	O	volunteers
7	31	31	O	,
8	33	43	O	concomitant
9	45	58	O	administration
10	60	61	O	of
11	63	71	O	XXXXXXXX
12	73	75	O	HCl
13	77	79	O	and
14	81	91	U-KIN	haloperidol
15	93	100	O	resulted
16	102	103	O	in
17	105	113	O	increased
18	115	119	O	serum
19	121	131	U-UNK	haloperidol
20	133	146	O	concentrations
NULL

Buspirone	DDI-DrugBank.d463.s4	NO_SECTION	NO_SETID	9
The clinical significance of this finding is not clear.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	40	O	finding
7	42	43	O	is
8	45	47	O	not
9	49	53	O	clear
NULL

Buspirone	DDI-DrugBank.d463.s5	NO_SECTION	NO_SETID	20
In vitro, buspirone does not displace tightly bound drugs like phenytoin, propranolol, and warfarin from serum proteins.
1	0	1	O	In
2	3	7	O	vitro
3	8	8	O	,
4	10	18	O	XXXXXXXX
5	20	23	O	does
6	25	27	O	not
7	29	36	O	displace
8	38	44	O	tightly
9	46	50	O	bound
10	52	56	O	drugs
11	58	61	O	like
12	63	71	U-UNK	phenytoin
13	72	72	O	,
14	74	84	U-UNK	propranolol
15	85	85	O	,
16	87	89	O	and
17	91	98	U-UNK	warfarin
18	100	103	O	from
19	105	109	O	serum
20	111	118	O	proteins
NULL

Buspirone	DDI-DrugBank.d463.s6	NO_SECTION	NO_SETID	24
However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	there
4	15	17	O	has
5	19	22	O	been
6	24	26	O	one
7	28	33	O	report
8	35	36	O	of
9	38	46	O	prolonged
10	48	58	O	prothrombin
11	60	63	O	time
12	65	68	O	when
13	70	78	O	XXXXXXXX
14	80	82	O	was
15	84	88	O	added
16	90	91	O	to
17	93	95	O	the
18	97	103	O	regimen
19	105	106	O	of
20	108	108	O	a
21	110	116	O	patient
22	118	124	O	treated
23	126	129	O	with
24	131	138	U-DYN	warfarin
NULL

Buspirone	DDI-DrugBank.d463.s7	NO_SECTION	NO_SETID	15
The patient was also chronically receiving phenytoin, phenobarbital, digoxin, and levothyroxine sodium.
1	0	2	O	The
2	4	10	O	patient
3	12	14	O	was
4	16	19	O	also
5	21	31	O	chronically
6	33	41	O	receiving
7	43	51	U-UNK	phenytoin
8	52	52	O	,
9	54	66	U-UNK	phenobarbital
10	67	67	O	,
11	69	75	U-UNK	digoxin
12	76	76	O	,
13	78	80	O	and
14	82	94	B-UNK	levothyroxine
15	96	101	L-UNK	sodium
NULL

Buspirone	DDI-DrugBank.d463.s8	NO_SECTION	NO_SETID	12
In vitro, buspirone may displace less firmly bound drugs like digoxin.
1	0	1	O	In
2	3	7	O	vitro
3	8	8	O	,
4	10	18	O	XXXXXXXX
5	20	22	O	may
6	24	31	O	displace
7	33	36	O	less
8	38	43	O	firmly
9	45	49	O	bound
10	51	55	O	drugs
11	57	60	O	like
12	62	68	U-KIN	digoxin
NULL

Buspirone	DDI-DrugBank.d463.s9	NO_SECTION	NO_SETID	8
The clinical significance of this property is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	41	O	property
7	43	44	O	is
8	46	52	O	unknown
NULL

Busulfan	DDI-DrugBank.d72.s0	NO_SECTION	NO_SETID	19
Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500  M min in some patients.
1	0	11	U-KIN	Itraconazole
2	13	21	O	decreases
3	23	30	O	XXXXXXXX
4	32	40	O	clearance
5	42	43	O	by
6	45	46	O	up
7	48	49	O	to
8	51	53	O	25%
9	54	54	O	,
10	56	58	O	and
11	60	62	O	may
12	64	70	O	produce
13	72	75	O	AUCs
14	79	82	O	1500
15	85	85	O	M
16	87	89	O	min
17	91	92	O	in
18	94	97	O	some
19	99	106	O	patients
NULL

Busulfan	DDI-DrugBank.d72.s1	NO_SECTION	NO_SETID	18
Fluconazole, and the 5-HT3 antiemetics ondansetron (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.
1	0	10	U-UNK	Fluconazole
2	11	11	O	,
3	13	15	O	and
4	17	19	O	the
5	21	21	B-UNK	5
6	23	25	I-UNK	HT3
7	27	37	L-UNK	antiemetics
8	39	49	U-UNK	ondansetron
9	52	57	O	Zofran
10	60	62	O	and
11	64	74	U-UNK	granisetron
12	77	82	O	Kytril
13	85	88	O	have
14	90	92	O	all
15	94	97	O	been
16	99	102	O	used
17	104	107	O	with
18	109	116	O	XXXXXXXX
NULL

Busulfan	DDI-DrugBank.d72.s2	NO_SECTION	NO_SETID	20
Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.
1	0	8	U-KIN	Phenytoin
2	10	18	O	increases
3	20	22	O	the
4	24	32	O	clearance
5	34	35	O	of
6	37	44	O	XXXXXXXX
7	46	47	O	by
8	49	51	O	15%
9	53	54	O	or
10	56	59	O	more
11	60	60	O	,
12	62	69	O	possibly
13	71	73	O	due
14	75	76	O	to
15	78	80	O	the
16	82	90	O	induction
17	92	93	O	of
18	95	105	O	glutathione
19	107	107	O	S
20	109	119	O	transferase
NULL

Busulfan	DDI-DrugBank.d72.s3	NO_SECTION	NO_SETID	34
Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.
1	0	4	O	Since
2	6	8	O	the
3	10	25	O	pharmacokinetics
4	27	28	O	of
5	30	37	O	XXXXXXXX
6	39	42	O	were
7	44	50	O	studied
8	52	53	O	in
9	55	62	O	patients
10	64	70	O	treated
11	72	75	O	with
12	77	85	U-KIN	phenytoin
13	86	86	O	,
14	88	90	O	the
15	92	100	O	clearance
16	102	103	O	of
17	105	112	O	XXXXXXXX
18	114	115	O	at
19	117	119	O	the
20	121	131	O	recommended
21	133	136	O	dose
22	138	140	O	may
23	142	143	O	be
24	145	149	O	lower
25	151	153	O	and
26	155	162	O	exposure
27	165	167	O	AUC
28	170	175	O	higher
29	177	178	O	in
30	180	187	O	patients
31	189	191	O	not
32	193	199	O	treated
33	201	204	O	with
34	206	214	U-UNK	phenytoin
NULL

Busulfan	DDI-DrugBank.d72.s4	NO_SECTION	NO_SETID	45
Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.
1	0	6	O	Because
2	8	15	U-UNK	busulfan
3	17	18	O	is
4	20	29	O	eliminated
5	31	34	O	from
6	36	38	O	the
7	40	43	O	body
8	45	47	O	via
9	49	59	O	conjugation
10	61	64	O	with
11	66	76	O	glutathione
12	77	77	O	,
13	79	81	O	use
14	83	84	O	of
15	86	98	U-KIN	acetaminophen
16	100	104	O	prior
17	106	107	O	to
18	111	112	O	72
19	114	118	O	hours
20	121	122	O	or
21	124	133	O	concurrent
22	135	138	O	with
23	140	147	O	XXXXXXXX
24	149	151	O	may
25	153	158	O	result
26	160	161	O	in
27	163	169	O	reduced
28	171	178	U-UNK	busulfan
29	180	188	O	clearance
30	190	194	O	based
31	196	199	O	upon
32	201	203	O	the
33	205	209	O	known
34	211	218	O	property
35	220	221	O	of
36	223	235	U-UNK	acetaminophen
37	237	238	O	to
38	240	247	O	decrease
39	249	259	O	glutathione
40	261	266	O	levels
41	268	269	O	in
42	271	273	O	the
43	275	279	O	blood
44	281	283	O	and
45	285	291	O	tissues
NULL

Butabarbital	DDI-DrugBank.d184.s0	NO_SECTION	NO_SETID	97
Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
1	0	11	O	Interactions
2	13	15	O	may
3	17	21	O	occur
4	23	26	O	with
5	28	30	O	the
6	32	40	O	following
7	41	41	O	:
8	43	58	O	adrenocorticoids
9	61	69	O	cortisone
10	71	74	O	like
11	76	83	O	medicine
12	85	85	O	,
13	87	100	U-UNK	anticoagulants
14	103	107	U-UNK	blood
15	109	116	O	thinners
16	118	118	O	,
17	120	132	U-UNK	carbamazepine
18	133	133	O	,
19	135	147	U-UNK	corticotropin
20	150	161	U-UNK	barbiturates
21	163	165	O	may
22	167	174	O	decrease
23	176	178	O	the
24	180	186	O	effects
25	188	189	O	of
26	191	195	O	these
27	197	205	O	medicines
28	207	207	O	,
29	209	215	B-UNK	central
30	217	223	I-UNK	nervous
31	225	230	I-UNK	system
32	233	235	I-UNK	CNS
33	238	248	L-UNK	depressants
34	251	255	O	using
35	257	261	O	these
36	263	271	O	medicines
37	273	276	O	with
38	278	289	U-UNK	barbiturates
39	291	293	O	may
40	295	300	O	result
41	302	303	O	in
42	305	313	O	increased
43	315	317	O	CNS
44	319	328	O	depressant
45	330	336	O	effects
46	338	338	O	,
47	340	349	B-UNK	divalproex
48	351	356	L-UNK	sodium
49	357	357	O	,
50	359	366	B-UNK	valproic
51	368	371	L-UNK	acid
52	374	378	O	using
53	380	384	O	these
54	386	394	O	medicines
55	396	399	O	with
56	401	412	U-UNK	barbiturates
57	414	416	O	may
58	418	423	O	change
59	425	427	O	the
60	429	434	O	amount
61	436	437	O	of
62	439	444	O	either
63	446	453	O	medicine
64	455	458	O	that
65	460	462	O	you
66	464	467	O	need
67	469	470	O	to
68	472	475	O	take
69	477	477	O	,
70	479	481	O	and
71	483	486	O	oral
72	488	501	U-UNK	contraceptives
73	503	512	O	containing
74	514	522	U-UNK	estrogens
75	525	536	U-UNK	barbiturates
76	538	540	O	may
77	542	549	O	decrease
78	551	553	O	the
79	555	567	O	effectiveness
80	569	570	O	of
81	572	576	O	these
82	578	581	O	oral
83	583	596	U-UNK	contraceptives
84	597	597	O	,
85	599	601	O	and
86	603	605	O	you
87	607	609	O	may
88	611	614	O	need
89	616	617	O	to
90	619	624	O	change
91	626	627	O	to
92	629	629	O	a
93	631	639	O	different
94	641	644	O	type
95	646	647	O	of
96	649	653	O	birth
97	655	661	O	control
NULL

Butalbital	DDI-DrugBank.d559.s0	NO_SECTION	NO_SETID	13
The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.
1	0	2	O	The
2	4	6	O	CNS
3	8	14	O	effects
4	16	17	O	of
5	19	28	O	XXXXXXXX
6	30	32	O	may
7	34	35	O	be
8	37	44	O	enhanced
9	46	47	O	by
10	49	57	B-DYN	monoamine
11	59	65	I-DYN	oxidase
12	68	70	I-DYN	MAO
13	73	82	L-DYN	inhibitors
NULL

Butalbital	DDI-DrugBank.d559.s1	NO_SECTION	NO_SETID	37
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
1	0	9	O	XXXXXXXX
2	10	10	O	,
3	12	24	U-UNK	acetaminophen
4	26	28	O	and
5	30	37	U-UNK	caffeine
6	39	41	O	may
7	43	49	O	enhance
8	51	53	O	the
9	55	61	O	effects
10	63	64	O	of
11	65	65	O	:
12	67	71	O	other
13	73	80	U-DYN	narcotic
14	82	91	O	analgesics
15	92	92	O	,
16	94	100	U-DYN	alcohol
17	101	101	O	,
18	103	109	O	general
19	111	121	U-DYN	anesthetics
20	122	122	O	,
21	124	136	U-DYN	tranquilizers
22	138	141	O	such
23	143	144	O	as
24	146	161	U-DYN	chlordiazepoxide
25	162	162	O	,
26	164	171	B-DYN	sedative
27	173	181	L-DYN	hypnotics
28	182	182	O	,
29	184	185	O	or
30	187	191	O	other
31	193	195	B-DYN	CNS
32	197	207	L-DYN	depressants
33	208	208	O	,
34	210	216	O	causing
35	218	226	O	increased
36	228	230	O	CNS
37	232	241	O	depression
NULL

Butalbital	DDI-DrugBank.d559.s2	NO_SECTION	NO_SETID	17
Drug/Laboratory Test Interactions Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	46	U-UNK	Acetaminophen
7	48	50	O	may
8	52	58	O	produce
9	60	64	O	false
10	66	73	O	positive
11	75	78	O	test
12	80	86	O	results
13	88	90	O	for
14	92	98	O	urinary
15	100	100	O	5
16	102	120	O	hydroxyindoleacetic
17	122	125	O	acid
NULL

Butenafine	DDI-DrugBank.d80.s0	NO_SECTION	NO_SETID	20
Potential drug interactions between Mentax (butenafine HCl cream) Cream, 1%, and other drugs have not been systematically evaluated.
1	0	8	O	Potential
2	10	13	O	drug
3	15	26	O	interactions
4	28	34	O	between
5	36	41	O	XXXXXXXX
6	44	53	B-UNK	butenafine
7	55	57	L-UNK	HCl
8	59	63	O	cream
9	66	70	O	Cream
10	71	71	O	,
11	73	74	O	1%
12	75	75	O	,
13	77	79	O	and
14	81	85	O	other
15	87	91	O	drugs
16	93	96	O	have
17	98	100	O	not
18	102	105	O	been
19	107	120	O	systematically
20	122	130	O	evaluated
NULL

Butorphanol	DDI-DrugBank.d246.s0	NO_SECTION	NO_SETID	28
Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	16	O	of
4	18	28	O	XXXXXXXX
5	30	33	O	with
6	35	41	B-DYN	central
7	43	49	I-DYN	nervous
8	51	56	I-DYN	system
9	58	68	L-DYN	depressants
10	71	73	O	e.g
11	75	75	O	,
12	77	83	U-DYN	alcohol
13	84	84	O	,
14	86	97	U-DYN	barbiturates
15	98	98	O	,
16	100	112	U-DYN	tranquilizers
17	113	113	O	,
18	115	117	O	and
19	119	132	U-DYN	antihistamines
20	135	137	O	may
21	139	144	O	result
22	146	147	O	in
23	149	157	O	increased
24	159	165	B-UNK	central
25	167	173	I-UNK	nervous
26	175	180	I-UNK	system
27	182	191	L-UNK	depressant
28	193	199	O	effects
NULL

Butorphanol	DDI-DrugBank.d246.s1	NO_SECTION	NO_SETID	38
When used concurrently with such drugs, the dose of butorphanol should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of opioids.
1	0	3	O	When
2	5	8	O	used
3	10	21	O	concurrently
4	23	26	O	with
5	28	31	O	such
6	33	37	O	drugs
7	38	38	O	,
8	40	42	O	the
9	44	47	O	dose
10	49	50	O	of
11	52	62	O	XXXXXXXX
12	64	69	O	should
13	71	72	O	be
14	74	76	O	the
15	78	85	O	smallest
16	87	95	O	effective
17	97	100	O	dose
18	102	104	O	and
19	106	108	O	the
20	110	118	O	frequency
21	120	121	O	of
22	123	128	O	dosing
23	130	136	O	reduced
24	138	139	O	as
25	141	144	O	much
26	146	147	O	as
27	149	156	O	possible
28	158	161	O	when
29	163	174	O	administered
30	176	188	O	concomitantly
31	190	193	O	with
32	195	199	O	drugs
33	201	204	O	that
34	206	215	O	potentiate
35	217	219	O	the
36	221	226	O	action
37	228	229	O	of
38	231	237	U-UNK	opioids
NULL

Butorphanol	DDI-DrugBank.d246.s2	NO_SECTION	NO_SETID	31
In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan.
1	0	1	O	In
2	3	9	O	healthy
3	11	20	O	volunteers
4	21	21	O	,
5	23	25	O	the
6	27	42	O	pharmacokinetics
7	44	45	O	of
8	47	47	O	a
9	49	49	O	1
10	51	52	O	mg
11	54	57	O	dose
12	59	60	O	of
13	62	72	U-UNK	butorphanol
14	74	85	O	administered
15	87	88	O	as
16	90	98	O	XXXXXXXX
17	100	103	O	were
18	105	107	O	not
19	109	116	O	affected
20	118	119	O	by
21	121	123	O	the
22	125	140	O	coadministration
23	142	143	O	of
24	145	145	O	a
25	147	152	O	single
26	154	154	O	6
27	156	157	O	mg
28	159	170	O	subcutaneous
29	172	175	O	dose
30	177	178	O	of
31	180	190	U-UNK	sumatriptan
NULL

Butorphanol	DDI-DrugBank.d246.s3	NO_SECTION	NO_SETID	45
However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	18	O	another
5	20	24	O	study
6	26	27	O	in
7	29	35	O	healthy
8	37	46	O	volunteers
9	47	47	O	,
10	49	51	O	the
11	53	68	O	pharmacokinetics
12	70	71	O	of
13	73	83	U-UNK	butorphanol
14	85	88	O	were
15	90	102	O	significantly
16	104	110	O	altered
17	113	115	O	29%
18	117	124	O	decrease
19	126	127	O	in
20	129	131	O	AUC
21	133	135	O	and
22	137	139	O	38%
23	141	148	O	decrease
24	150	151	O	in
25	153	156	O	Cmax
26	159	162	O	when
27	164	164	O	a
28	166	166	O	1
29	168	169	O	mg
30	171	174	O	dose
31	176	177	O	of
32	179	187	O	XXXXXXXX
33	189	191	O	was
34	193	204	O	administered
35	206	206	O	1
36	208	213	O	minute
37	215	219	O	after
38	221	221	O	a
39	223	224	O	20
40	226	227	O	mg
41	229	232	O	dose
42	234	235	O	of
43	237	247	U-KIN	sumatriptan
44	249	253	O	nasal
45	255	259	O	spray
NULL

Butorphanol	DDI-DrugBank.d246.s4	NO_SECTION	NO_SETID	8
(The two drugs were administered in opposite nostrils.)
1	1	3	O	The
2	5	7	O	two
3	9	13	O	drugs
4	15	18	O	were
5	20	31	O	administered
6	33	34	O	in
7	36	43	O	opposite
8	45	52	O	nostrils
NULL

Butorphanol	DDI-DrugBank.d246.s5	NO_SECTION	NO_SETID	23
When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.
1	0	3	O	When
2	5	7	O	the
3	9	17	O	XXXXXXXX
4	19	21	O	was
5	23	34	O	administered
6	36	37	O	30
7	39	45	O	minutes
8	47	51	O	after
9	53	55	O	the
10	57	67	U-KIN	sumatriptan
11	69	73	O	nasal
12	75	79	O	spray
13	80	80	O	,
14	82	84	O	the
15	86	88	O	AUC
16	90	91	O	of
17	93	103	U-UNK	butorphanol
18	105	113	O	increased
19	115	117	O	11%
20	119	121	O	and
21	123	126	O	Cmax
22	128	136	O	decreased
23	138	140	O	18%
NULL

Butorphanol	DDI-DrugBank.d246.s6	NO_SECTION	NO_SETID	13
In neither case were the pharmacokinetics of sumatriptan affected by coadministration with STADOL NS.
1	0	1	O	In
2	3	9	O	neither
3	11	14	O	case
4	16	19	O	were
5	21	23	O	the
6	25	40	O	pharmacokinetics
7	42	43	O	of
8	45	55	U-UNK	sumatriptan
9	57	64	O	affected
10	66	67	O	by
11	69	84	O	coadministration
12	86	89	O	with
13	91	99	O	XXXXXXXX
NULL

Butorphanol	DDI-DrugBank.d246.s7	NO_SECTION	NO_SETID	34
These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.
1	0	4	O	These
2	6	12	O	results
3	14	20	O	suggest
4	22	25	O	that
5	27	29	O	the
6	31	39	O	analgesic
7	41	46	O	effect
8	48	49	O	of
9	51	59	O	XXXXXXXX
10	61	63	O	may
11	65	66	O	be
12	68	77	O	diminished
13	79	82	O	when
14	84	85	O	it
15	87	88	O	is
16	90	101	O	administered
17	103	109	O	shortly
18	111	115	O	after
19	117	127	U-DYN	sumatriptan
20	129	133	O	nasal
21	135	139	O	spray
22	140	140	O	,
23	142	144	O	but
24	146	147	O	by
25	149	150	O	30
26	152	158	O	minutes
27	160	162	O	any
28	164	167	O	such
29	169	177	O	reduction
30	179	180	O	in
31	182	187	O	effect
32	189	194	O	should
33	196	197	O	be
34	199	205	O	minimal
NULL

Butorphanol	DDI-DrugBank.d246.s8	NO_SECTION	NO_SETID	21
The safety of using STADOL NS and IMITREX (sumatriptan) Nasal Spray during the same episode of migraine has not been established.
1	0	2	O	The
2	4	9	O	safety
3	11	12	O	of
4	14	18	O	using
5	20	25	O	STADOL
6	27	28	O	NS
7	30	32	O	and
8	34	40	O	XXXXXXXX
9	43	53	U-UNK	sumatriptan
10	56	60	O	Nasal
11	62	66	O	Spray
12	68	73	O	during
13	75	77	O	the
14	79	82	O	same
15	84	90	O	episode
16	92	93	O	of
17	95	102	O	migraine
18	104	106	O	has
19	108	110	O	not
20	112	115	O	been
21	117	127	O	established
NULL

Butorphanol	DDI-DrugBank.d246.s9	NO_SECTION	NO_SETID	18
However, it should be noted that both products are capable of producing transient increases in blood pressure.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	it
4	12	17	O	should
5	19	20	O	be
6	22	26	O	noted
7	28	31	O	that
8	33	36	O	both
9	38	45	O	products
10	47	49	O	are
11	51	57	O	capable
12	59	60	O	of
13	62	70	O	producing
14	72	80	O	transient
15	82	90	O	increases
16	92	93	O	in
17	95	99	O	blood
18	101	108	O	pressure
NULL

Butorphanol	DDI-DrugBank.d246.s10	NO_SECTION	NO_SETID	23
The pharmacokinetics of a 1-mg dose of butorphanol administered as STADOL NS were not affected by the coadministration of cimetidine (300 mg QID).
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	24	O	a
5	26	26	O	1
6	28	29	O	mg
7	31	34	O	dose
8	36	37	O	of
9	39	49	U-UNK	butorphanol
10	51	62	O	administered
11	64	65	O	as
12	67	75	O	XXXXXXXX
13	77	80	O	were
14	82	84	O	not
15	86	93	O	affected
16	95	96	O	by
17	98	100	O	the
18	102	117	O	coadministration
19	119	120	O	of
20	122	131	U-UNK	cimetidine
21	134	136	O	300
22	138	139	O	mg
23	141	143	O	QID
NULL

Butorphanol	DDI-DrugBank.d246.s11	NO_SECTION	NO_SETID	22
Conversely, the administration of STADOL NS (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine.
1	0	9	O	Conversely
2	10	10	O	,
3	12	14	O	the
4	16	29	O	administration
5	31	32	O	of
6	34	42	O	XXXXXXXX
7	45	45	O	1
8	47	48	O	mg
9	50	60	U-UNK	butorphanol
10	62	64	O	QID
11	67	69	O	did
12	71	73	O	not
13	75	79	O	alter
14	81	83	O	the
15	85	100	O	pharmacokinetics
16	102	103	O	of
17	105	105	O	a
18	107	109	O	300
19	111	112	O	mg
20	114	117	O	dose
21	119	120	O	of
22	122	131	U-UNK	cimetidine
NULL

Butorphanol	DDI-DrugBank.d246.s12	NO_SECTION	NO_SETID	45
It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	known
5	16	17	O	if
6	19	21	O	the
7	23	29	O	effects
8	31	32	O	of
9	34	44	O	XXXXXXXX
10	46	48	O	are
11	50	56	O	altered
12	58	59	O	by
13	61	71	O	concomitant
14	73	83	O	medications
15	85	88	O	that
16	90	95	O	affect
17	97	103	O	hepatic
18	105	114	O	metabolism
19	116	117	O	of
20	119	123	O	drugs
21	126	137	U-DYN	erythromycin
22	138	138	O	,
23	140	142	O	etc
24	145	145	O	,
25	147	149	O	but
26	151	160	O	physicians
27	162	167	O	should
28	169	170	O	be
29	172	176	O	alert
30	178	179	O	to
31	181	183	O	the
32	185	195	O	possibility
33	197	200	O	that
34	202	202	O	a
35	204	210	O	smaller
36	212	218	O	initial
37	220	223	O	dose
38	225	227	O	and
39	229	234	O	longer
40	236	244	O	intervals
41	246	252	O	between
42	254	258	O	doses
43	260	262	O	may
44	264	265	O	be
45	267	272	O	needed
NULL

Butorphanol	DDI-DrugBank.d246.s13	NO_SECTION	NO_SETID	24
The fraction of STADOL NS absorbed is unaffected by the concomitant administration of a nasal vasoconstrictor (oxymetazoline), but the rate of absorption is decreased.
1	0	2	O	The
2	4	11	O	fraction
3	13	14	O	of
4	16	24	O	XXXXXXXX
5	26	33	O	absorbed
6	35	36	O	is
7	38	47	O	unaffected
8	49	50	O	by
9	52	54	O	the
10	56	66	O	concomitant
11	68	81	O	administration
12	83	84	O	of
13	86	86	O	a
14	88	92	B-UNK	nasal
15	94	108	L-UNK	vasoconstrictor
16	111	123	U-UNK	oxymetazoline
17	125	125	O	,
18	127	129	O	but
19	131	133	O	the
20	135	138	O	rate
21	140	141	O	of
22	143	152	O	absorption
23	154	155	O	is
24	157	165	O	decreased
NULL

Butorphanol	DDI-DrugBank.d246.s14	NO_SECTION	NO_SETID	22
Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.
1	0	8	O	Therefore
2	9	9	O	,
3	11	11	O	a
4	13	18	O	slower
5	20	24	O	onset
6	26	28	O	can
7	30	31	O	be
8	33	43	O	anticipated
9	45	46	O	if
10	48	56	O	XXXXXXXX
11	58	59	O	is
12	61	72	O	administered
13	74	86	O	concomitantly
14	88	91	O	with
15	92	92	O	,
16	94	95	O	or
17	97	107	O	immediately
18	109	117	O	following
19	118	118	O	,
20	120	120	O	a
21	122	126	B-DYN	nasal
22	128	142	L-DYN	vasoconstrictor
NULL

Butorphanol	DDI-DrugBank.d246.s15	NO_SECTION	NO_SETID	13
No information is available about the use of butorphanol concurrently with MAO inhibitors.
1	0	1	O	No
2	3	13	O	information
3	15	16	O	is
4	18	26	O	available
5	28	32	O	about
6	34	36	O	the
7	38	40	O	use
8	42	43	O	of
9	45	55	O	XXXXXXXX
10	57	68	O	concurrently
11	70	73	O	with
12	75	77	B-UNK	MAO
13	79	88	L-UNK	inhibitors
NULL

Cabergoline	DDI-DrugBank.d282.s0	NO_SECTION	NO_SETID	20
DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.
1	0	7	O	XXXXXXXX
2	9	14	O	should
3	16	18	O	not
4	20	21	O	be
5	23	34	O	administered
6	36	47	O	concurrently
7	49	52	O	with
8	54	55	O	D2
9	57	67	O	antagonists
10	68	68	O	,
11	70	73	O	such
12	75	76	O	as
13	78	91	U-DYN	phenothiazines
14	92	92	O	,
15	94	107	U-DYN	butyrophenones
16	108	108	O	,
17	110	122	U-DYN	thioxanthines
18	123	123	O	,
19	125	126	O	or
20	128	141	U-DYN	metoclopramide
NULL

Caffeine	DDI-DrugBank.d89.s0	NO_SECTION	NO_SETID	17
Cytochrome P450 1A2 (CYP1A2) is known to be the major enzyme involved in the metabolism of caffeine.
1	0	9	O	Cytochrome
2	11	14	O	P450
3	16	18	O	1A2
4	21	26	O	CYP1A2
5	29	30	O	is
6	32	36	O	known
7	38	39	O	to
8	41	42	O	be
9	44	46	O	the
10	48	52	O	major
11	54	59	O	enzyme
12	61	68	O	involved
13	70	71	O	in
14	73	75	O	the
15	77	86	O	metabolism
16	88	89	O	of
17	91	98	O	XXXXXXXX
NULL

Caffeine	DDI-DrugBank.d89.s1	NO_SECTION	NO_SETID	22
Therefore, caffeine has the potential to interact with drugs that are substrates for CYP1A2, inhibit CYP1A2, or induce CYP1A2.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	O	XXXXXXXX
4	20	22	O	has
5	24	26	O	the
6	28	36	O	potential
7	38	39	O	to
8	41	48	O	interact
9	50	53	O	with
10	55	59	O	drugs
11	61	64	O	that
12	66	68	O	are
13	70	79	O	substrates
14	81	83	O	for
15	85	90	O	CYP1A2
16	91	91	O	,
17	93	99	O	inhibit
18	101	106	O	CYP1A2
19	107	107	O	,
20	109	110	O	or
21	112	117	O	induce
22	119	124	O	CYP1A2
NULL

Caffeine	DDI-DrugBank.d89.s2	NO_SECTION	NO_SETID	11
Few data exist on drug interactions with caffeine in preterm neonates.
1	0	2	O	Few
2	4	7	O	data
3	9	13	O	exist
4	15	16	O	on
5	18	21	O	drug
6	23	34	O	interactions
7	36	39	O	with
8	41	48	O	XXXXXXXX
9	50	51	O	in
10	53	59	O	preterm
11	61	68	O	neonates
NULL

Caffeine	DDI-DrugBank.d89.s3	NO_SECTION	NO_SETID	48
Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
1	0	4	O	Based
2	6	7	O	on
3	9	13	O	adult
4	15	18	O	data
5	19	19	O	,
6	21	25	O	lower
7	27	31	O	doses
8	33	34	O	of
9	36	43	O	XXXXXXXX
10	45	47	O	may
11	49	50	O	be
12	52	57	O	needed
13	59	67	O	following
14	69	84	O	coadministration
15	86	87	O	of
16	89	93	O	drugs
17	95	99	O	which
18	101	103	O	are
19	105	112	O	reported
20	114	115	O	to
21	117	124	O	decrease
22	126	133	O	XXXXXXXX
23	135	145	O	elimination
24	148	150	O	e.g
25	152	152	O	,
26	154	163	U-DYN	cimetidine
27	165	167	O	and
28	169	180	U-DYN	ketoconazole
29	183	185	O	and
30	187	192	O	higher
31	194	201	O	XXXXXXXX
32	203	207	O	doses
33	209	211	O	may
34	213	214	O	be
35	216	221	O	needed
36	223	231	O	following
37	233	248	O	coadministration
38	250	251	O	of
39	253	257	O	drugs
40	259	262	O	that
41	264	271	O	increase
42	273	280	O	XXXXXXXX
43	282	292	O	elimination
44	295	297	O	e.g
45	299	299	O	,
46	301	313	U-DYN	phenobarbital
47	315	317	O	and
48	319	327	U-DYN	phenytoin
NULL

Caffeine	DDI-DrugBank.d89.s4	NO_SECTION	NO_SETID	13
Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.
1	0	7	O	XXXXXXXX
2	9	20	O	administered
3	22	33	O	concurrently
4	35	38	O	with
5	40	49	U-DYN	ketoprofen
6	51	57	O	reduced
7	59	61	O	the
8	63	67	O	urine
9	69	74	O	volume
10	76	77	O	in
11	79	79	O	4
12	81	87	O	healthy
13	89	98	O	volunteers
NULL

Caffeine	DDI-DrugBank.d89.s5	NO_SECTION	NO_SETID	12
The clinical significance of this interaction in preterm neonates is not known.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	44	O	interaction
7	46	47	O	in
8	49	55	O	preterm
9	57	64	O	neonates
10	66	67	O	is
11	69	71	O	not
12	73	77	O	known
NULL

Caffeine	DDI-DrugBank.d89.s6	NO_SECTION	NO_SETID	11
Interconversion between caffeine and theophylline has been reported in preterm neonates.
1	0	14	O	Interconversion
2	16	22	O	between
3	24	31	O	XXXXXXXX
4	33	35	O	and
5	37	48	U-UNK	theophylline
6	50	52	O	has
7	54	57	O	been
8	59	66	O	reported
9	68	69	O	in
10	71	77	O	preterm
11	79	86	O	neonates
NULL

Caffeine	DDI-DrugBank.d89.s7	NO_SECTION	NO_SETID	9
The concurrent use of these drugs is not recommended.
1	0	2	O	The
2	4	13	O	concurrent
3	15	17	O	use
4	19	20	O	of
5	22	26	O	these
6	28	32	O	drugs
7	34	35	O	is
8	37	39	O	not
9	41	51	O	recommended
NULL

Calcidiol	DDI-DrugBank.d98.s0	NO_SECTION	NO_SETID	30
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
1	0	11	O	Interactions
2	13	15	O	for
3	17	23	B-UNK	vitamin
4	25	25	I-UNK	D
5	27	35	L-UNK	analogues
6	38	44	B-UNK	Vitamin
7	46	47	L-UNK	D2
8	48	48	O	,
9	50	56	B-UNK	Vitamin
10	58	59	L-UNK	D3
11	60	60	O	,
12	62	71	U-UNK	Calcitriol
13	72	72	O	,
14	74	76	O	and
15	78	86	O	XXXXXXXX
16	88	88	O	:
17	90	103	U-UNK	Cholestyramine
18	104	104	O	:
19	106	119	U-UNK	Cholestyramine
20	121	123	O	has
21	125	128	O	been
22	130	137	O	reported
23	139	140	O	to
24	142	147	O	reduce
25	149	158	O	intestinal
26	160	169	O	absorption
27	171	172	O	of
28	174	176	B-UNK	fat
29	178	184	I-UNK	soluble
30	186	193	L-UNK	vitamins
NULL

Calcidiol	DDI-DrugBank.d98.s1	NO_SECTION	NO_SETID	12
as such it may impair intestinal absorption of any of vitamin D.
1	0	1	O	as
2	3	6	O	such
3	8	9	O	it
4	11	13	O	may
5	15	20	O	impair
6	22	31	O	intestinal
7	33	42	O	absorption
8	44	45	O	of
9	47	49	O	any
10	51	52	O	of
11	54	60	B-UNK	vitamin
12	62	62	L-UNK	D
NULL

Calcidiol	DDI-DrugBank.d98.s2	NO_SECTION	NO_SETID	32
Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
1	0	8	U-UNK	Phenytoin
2	9	9	O	/
3	10	22	U-UNK	Phenobarbital
4	23	23	O	:
5	25	27	O	The
6	29	44	O	coadministration
7	46	47	O	of
8	49	57	U-UNK	phenytoin
9	59	60	O	or
10	62	74	U-UNK	phenobarbital
11	76	79	O	will
12	81	83	O	not
13	85	90	O	affect
14	92	97	O	plasma
15	99	112	O	concentrations
16	114	115	O	of
17	117	123	B-UNK	vitamin
18	125	125	L-UNK	D
19	126	126	O	,
20	128	130	O	but
21	132	134	O	may
22	136	141	O	reduce
23	143	152	O	endogenous
24	154	159	O	plasma
25	161	166	O	levels
26	168	169	O	of
27	171	180	U-UNK	calcitriol
28	181	181	O	/
29	182	195	O	ergocalcitriol
30	197	198	O	by
31	200	211	O	accelerating
32	213	222	O	metabolism
NULL

Calcidiol	DDI-DrugBank.d98.s3	NO_SECTION	NO_SETID	24
Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
1	0	4	O	Since
2	6	10	O	blood
3	12	16	O	level
4	18	19	O	of
5	21	30	U-UNK	calcitriol
6	31	31	O	/
7	32	45	O	ergocalcitriol
8	47	50	O	will
9	52	53	O	be
10	55	61	O	reduced
11	62	62	O	,
12	64	69	O	higher
13	71	75	O	doses
14	77	78	O	of
15	80	88	O	XXXXXXXX
16	90	92	O	may
17	94	95	O	be
18	97	105	O	necessary
19	107	108	O	if
20	110	114	O	these
21	116	120	O	drugs
22	122	124	O	are
23	126	137	O	administered
24	139	152	O	simultaneously
NULL

Calcidiol	DDI-DrugBank.d98.s4	NO_SECTION	NO_SETID	16
Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
1	0	8	U-UNK	Thiazides
2	9	9	O	:
3	11	19	U-UNK	Thiazides
4	21	23	O	are
5	25	29	O	known
6	31	32	O	to
7	34	39	O	induce
8	41	53	O	hypercalcemia
9	55	56	O	by
10	58	60	O	the
11	62	70	O	reduction
12	72	73	O	of
13	75	81	O	calcium
14	83	91	O	excretion
15	93	94	O	in
16	96	100	O	urine
NULL

Calcidiol	DDI-DrugBank.d98.s5	NO_SECTION	NO_SETID	15
Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
1	0	3	O	Some
2	5	11	O	reports
3	13	16	O	have
4	18	22	O	shown
5	24	27	O	that
6	29	31	O	the
7	33	43	O	concomitant
8	45	58	O	administration
9	60	61	O	of
10	63	71	U-UNK	thiazides
11	73	76	O	with
12	78	84	B-UNK	vitamin
13	86	86	L-UNK	D
14	88	93	O	causes
15	95	107	O	hypercalcemia
NULL

Calcidiol	DDI-DrugBank.d98.s6	NO_SECTION	NO_SETID	10
Therefore, precaution should be taken when coadministration is necessary.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	precaution
4	22	27	O	should
5	29	30	O	be
6	32	36	O	taken
7	38	41	O	when
8	43	58	O	coadministration
9	60	61	O	is
10	63	71	O	necessary
NULL

Calcidiol	DDI-DrugBank.d98.s7	NO_SECTION	NO_SETID	26
Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
1	0	8	U-UNK	Digitalis
2	9	9	O	:
3	11	17	B-UNK	Vitamin
4	19	19	L-UNK	D
5	21	26	O	dosage
6	28	31	O	must
7	33	34	O	be
8	36	45	O	determined
9	47	50	O	with
10	52	55	O	care
11	57	58	O	in
12	60	67	O	patients
13	69	78	O	undergoing
14	80	88	O	treatment
15	90	93	O	with
16	95	103	U-UNK	digitalis
17	104	104	O	,
18	106	107	O	as
19	109	121	O	hypercalcemia
20	123	124	O	in
21	126	129	O	such
22	131	138	O	patients
23	140	142	O	may
24	144	154	O	precipitate
25	156	162	O	cardiac
26	164	174	O	arrhythmias
NULL

Calcidiol	DDI-DrugBank.d98.s8	NO_SECTION	NO_SETID	13
Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	25	U-UNK	Ketoconazole
4	27	29	O	may
5	31	37	O	inhibit
6	39	42	O	both
7	44	52	O	synthetic
8	54	56	O	and
9	58	66	O	catabolic
10	68	74	O	enzymes
11	76	77	O	of
12	79	85	B-UNK	vitamin
13	87	87	L-UNK	D
NULL

Calcidiol	DDI-DrugBank.d98.s9	NO_SECTION	NO_SETID	30
Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.
1	0	9	O	Reductions
2	11	12	O	in
3	14	18	O	serum
4	20	29	O	endogenous
5	31	37	O	vitamin
6	39	39	O	D
7	41	54	O	concentrations
8	56	59	O	have
9	61	64	O	been
10	66	73	O	observed
11	75	83	O	following
12	85	87	O	the
13	89	102	O	administration
14	104	105	O	of
15	107	109	O	300
16	111	112	O	mg
17	113	113	O	/
18	114	116	O	day
19	118	119	O	to
20	121	124	O	1200
21	126	127	O	mg
22	128	128	O	/
23	129	131	O	day
24	133	144	U-UNK	ketoconazole
25	146	148	O	for
26	150	150	O	a
27	152	155	O	week
28	157	158	O	to
29	160	166	O	healthy
30	168	170	O	men
NULL

Calcidiol	DDI-DrugBank.d98.s10	NO_SECTION	NO_SETID	16
However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	15	O	vivo
5	17	20	O	drug
6	22	32	O	interaction
7	34	40	O	studies
8	42	43	O	of
9	45	56	U-UNK	ketoconazole
10	58	61	O	with
11	63	69	B-UNK	vitamin
12	71	71	L-UNK	D
13	73	76	O	have
14	78	80	O	not
15	82	85	O	been
16	87	98	O	investigated
NULL

Calcidiol	DDI-DrugBank.d98.s11	NO_SECTION	NO_SETID	25
Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
1	0	14	U-UNK	Corticosteroids
2	15	15	O	:
3	17	17	O	A
4	19	30	O	relationship
5	32	33	O	of
6	35	44	O	functional
7	46	55	O	antagonism
8	57	62	O	exists
9	64	70	O	between
10	72	78	B-UNK	vitamin
11	80	80	I-UNK	D
12	82	90	L-UNK	analogues
13	91	91	O	,
14	93	97	O	which
15	99	105	O	promote
16	107	113	O	calcium
17	115	124	O	absorption
18	125	125	O	,
19	127	129	O	and
20	131	145	U-UNK	corticosteroids
21	146	146	O	,
22	148	152	O	which
23	154	160	O	inhibit
24	162	168	O	calcium
25	170	179	O	absorption
NULL

Calcidiol	DDI-DrugBank.d98.s12	NO_SECTION	NO_SETID	38
Phosphate-Binding Agents: Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.
1	0	8	O	Phosphate
2	10	16	O	Binding
3	18	23	O	Agents
4	24	24	O	:
5	26	30	O	Since
6	32	38	B-UNK	vitamin
7	40	40	L-UNK	D
8	42	45	O	also
9	47	49	O	has
10	51	52	O	an
11	54	59	O	effect
12	61	62	O	on
13	64	72	O	phosphate
14	74	82	O	transport
15	84	85	O	in
16	87	89	O	the
17	91	99	O	intestine
18	100	100	O	,
19	102	108	O	kidneys
20	110	112	O	and
21	114	118	O	bones
22	119	119	O	,
23	121	123	O	the
24	125	130	O	dosage
25	132	133	O	of
26	135	143	O	phosphate
27	145	151	O	binding
28	153	158	O	agents
29	160	163	O	must
30	165	166	O	be
31	168	175	O	adjusted
32	177	178	O	in
33	180	189	O	accordance
34	191	194	O	with
35	196	198	O	the
36	200	204	O	serum
37	206	214	O	phosphate
38	216	228	O	concentration
NULL

Calcidiol	DDI-DrugBank.d98.s13	NO_SECTION	NO_SETID	24
Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
1	0	6	B-UNK	Vitamin
2	8	8	L-UNK	D
3	9	9	O	:
4	11	13	O	The
5	15	30	O	coadministration
6	32	33	O	of
7	35	37	O	any
8	39	40	O	of
9	42	44	O	the
10	46	52	B-UNK	vitamin
11	54	54	I-UNK	D
12	56	64	L-UNK	analogues
13	66	71	O	should
14	73	74	O	be
15	76	82	O	avoided
16	84	85	O	as
17	87	90	O	this
18	92	96	O	could
19	98	103	O	create
20	105	112	O	possible
21	114	121	O	additive
22	123	129	O	effects
23	131	133	O	and
24	135	147	O	hypercalcemia
NULL

Calcidiol	DDI-DrugBank.d98.s14	NO_SECTION	NO_SETID	13
Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.
1	0	6	U-UNK	Calcium
2	8	18	O	Supplements
3	19	19	O	:
4	21	32	O	Uncontrolled
5	34	39	O	intake
6	41	42	O	of
7	44	53	O	additional
8	55	61	U-UNK	calcium
9	63	72	O	containing
10	74	85	O	preparations
11	87	92	O	should
12	94	95	O	be
13	97	103	O	avoided
NULL

Calcidiol	DDI-DrugBank.d98.s15	NO_SECTION	NO_SETID	28
Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
1	0	8	U-UNK	Magnesium
2	9	9	O	:
3	11	19	U-UNK	Magnesium
4	21	30	O	containing
5	32	43	O	preparations
6	46	47	O	eg
7	48	48	O	,
8	50	57	U-UNK	antacids
9	60	62	O	may
10	64	68	O	cause
11	70	84	O	hypermagnesemia
12	86	88	O	and
13	90	95	O	should
14	97	105	O	therefore
15	107	109	O	not
16	111	112	O	be
17	114	118	O	taken
18	120	125	O	during
19	127	133	O	therapy
20	135	138	O	with
21	140	146	B-UNK	vitamin
22	148	148	L-UNK	D
23	150	151	O	by
24	153	160	O	patients
25	162	163	O	on
26	165	171	O	chronic
27	173	177	O	renal
28	179	186	O	dialysis
NULL

Calcitriol	DDI-DrugBank.d384.s0	NO_SECTION	NO_SETID	30
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
1	0	11	O	Interactions
2	13	15	O	for
3	17	23	B-UNK	vitamin
4	25	25	I-UNK	D
5	27	35	L-UNK	analogues
6	38	44	B-UNK	Vitamin
7	46	47	L-UNK	D2
8	48	48	O	,
9	50	56	B-UNK	Vitamin
10	58	59	L-UNK	D3
11	60	60	O	,
12	62	71	O	XXXXXXXX
13	72	72	O	,
14	74	76	O	and
15	78	86	U-UNK	Calcidiol
16	88	88	O	:
17	90	103	U-UNK	Cholestyramine
18	104	104	O	:
19	106	119	U-UNK	Cholestyramine
20	121	123	O	has
21	125	128	O	been
22	130	137	O	reported
23	139	140	O	to
24	142	147	O	reduce
25	149	158	O	intestinal
26	160	169	O	absorption
27	171	172	O	of
28	174	176	B-UNK	fat
29	178	184	I-UNK	soluble
30	186	193	L-UNK	vitamins
NULL

Calcitriol	DDI-DrugBank.d384.s1	NO_SECTION	NO_SETID	12
as such it may impair intestinal absorption of any of vitamin D.
1	0	1	O	as
2	3	6	O	such
3	8	9	O	it
4	11	13	O	may
5	15	20	O	impair
6	22	31	O	intestinal
7	33	42	O	absorption
8	44	45	O	of
9	47	49	O	any
10	51	52	O	of
11	54	60	B-UNK	vitamin
12	62	62	L-UNK	D
NULL

Calcitriol	DDI-DrugBank.d384.s2	NO_SECTION	NO_SETID	33
Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
1	0	8	U-UNK	Phenytoin
2	9	9	O	/
3	10	22	U-UNK	Phenobarbital
4	23	23	O	:
5	25	27	O	The
6	29	44	O	coadministration
7	46	47	O	of
8	49	57	U-KIN	phenytoin
9	59	60	O	or
10	62	74	U-KIN	phenobarbital
11	76	79	O	will
12	81	83	O	not
13	85	90	O	affect
14	92	97	O	plasma
15	99	112	O	concentrations
16	114	115	O	of
17	117	123	B-UNK	vitamin
18	125	125	L-UNK	D
19	126	126	O	,
20	128	130	O	but
21	132	134	O	may
22	136	141	O	reduce
23	143	152	O	endogenous
24	154	159	O	plasma
25	161	166	O	levels
26	168	169	O	of
27	171	180	O	XXXXXXXX
28	181	181	O	/
29	182	185	O	ergo
30	186	195	O	XXXXXXXX
31	197	198	O	by
32	200	211	O	accelerating
33	213	222	O	metabolism
NULL

Calcitriol	DDI-DrugBank.d384.s3	NO_SECTION	NO_SETID	24
Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
1	0	4	O	Since
2	6	10	O	blood
3	12	16	O	level
4	18	19	O	of
5	21	30	U-UNK	calcitriol
6	31	31	O	/
7	32	45	O	ergocalcitriol
8	47	50	O	will
9	52	53	O	be
10	55	61	O	reduced
11	62	62	O	,
12	64	69	O	higher
13	71	75	O	doses
14	77	78	O	of
15	80	88	O	XXXXXXXX
16	90	92	O	may
17	94	95	O	be
18	97	105	O	necessary
19	107	108	O	if
20	110	114	O	these
21	116	120	O	drugs
22	122	124	O	are
23	126	137	O	administered
24	139	152	O	simultaneously
NULL

Calcitriol	DDI-DrugBank.d384.s4	NO_SECTION	NO_SETID	16
Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
1	0	8	U-UNK	Thiazides
2	9	9	O	:
3	11	19	U-UNK	Thiazides
4	21	23	O	are
5	25	29	O	known
6	31	32	O	to
7	34	39	O	induce
8	41	53	O	hypercalcemia
9	55	56	O	by
10	58	60	O	the
11	62	70	O	reduction
12	72	73	O	of
13	75	81	U-UNK	calcium
14	83	91	O	excretion
15	93	94	O	in
16	96	100	O	urine
NULL

Calcitriol	DDI-DrugBank.d384.s5	NO_SECTION	NO_SETID	15
Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
1	0	3	O	Some
2	5	11	O	reports
3	13	16	O	have
4	18	22	O	shown
5	24	27	O	that
6	29	31	O	the
7	33	43	O	concomitant
8	45	58	O	administration
9	60	61	O	of
10	63	71	U-UNK	thiazides
11	73	76	O	with
12	78	84	B-UNK	vitamin
13	86	86	L-UNK	D
14	88	93	O	causes
15	95	107	O	hypercalcemia
NULL

Calcitriol	DDI-DrugBank.d384.s6	NO_SECTION	NO_SETID	10
Therefore, precaution should be taken when coadministration is necessary.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	precaution
4	22	27	O	should
5	29	30	O	be
6	32	36	O	taken
7	38	41	O	when
8	43	58	O	coadministration
9	60	61	O	is
10	63	71	O	necessary
NULL

Calcitriol	DDI-DrugBank.d384.s7	NO_SECTION	NO_SETID	26
Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
1	0	8	U-UNK	Digitalis
2	9	9	O	:
3	11	17	B-UNK	Vitamin
4	19	19	L-UNK	D
5	21	26	O	dosage
6	28	31	O	must
7	33	34	O	be
8	36	45	O	determined
9	47	50	O	with
10	52	55	O	care
11	57	58	O	in
12	60	67	O	patients
13	69	78	O	undergoing
14	80	88	O	treatment
15	90	93	O	with
16	95	103	U-UNK	digitalis
17	104	104	O	,
18	106	107	O	as
19	109	121	O	hypercalcemia
20	123	124	O	in
21	126	129	O	such
22	131	138	O	patients
23	140	142	O	may
24	144	154	O	precipitate
25	156	162	O	cardiac
26	164	174	O	arrhythmias
NULL

Calcitriol	DDI-DrugBank.d384.s8	NO_SECTION	NO_SETID	13
Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	25	U-UNK	Ketoconazole
4	27	29	O	may
5	31	37	O	inhibit
6	39	42	O	both
7	44	52	O	synthetic
8	54	56	O	and
9	58	66	O	catabolic
10	68	74	O	enzymes
11	76	77	O	of
12	79	85	B-UNK	vitamin
13	87	87	L-UNK	D
NULL

Calcitriol	DDI-DrugBank.d384.s9	NO_SECTION	NO_SETID	30
Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.
1	0	9	O	Reductions
2	11	12	O	in
3	14	18	O	serum
4	20	29	O	endogenous
5	31	37	O	vitamin
6	39	39	O	D
7	41	54	O	concentrations
8	56	59	O	have
9	61	64	O	been
10	66	73	O	observed
11	75	83	O	following
12	85	87	O	the
13	89	102	O	administration
14	104	105	O	of
15	107	109	O	300
16	111	112	O	mg
17	113	113	O	/
18	114	116	O	day
19	118	119	O	to
20	121	124	O	1200
21	126	127	O	mg
22	128	128	O	/
23	129	131	O	day
24	133	144	U-UNK	ketoconazole
25	146	148	O	for
26	150	150	O	a
27	152	155	O	week
28	157	158	O	to
29	160	166	O	healthy
30	168	170	O	men
NULL

Calcitriol	DDI-DrugBank.d384.s10	NO_SECTION	NO_SETID	16
However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	15	O	vivo
5	17	20	O	drug
6	22	32	O	interaction
7	34	40	O	studies
8	42	43	O	of
9	45	56	U-UNK	ketoconazole
10	58	61	O	with
11	63	69	B-UNK	vitamin
12	71	71	L-UNK	D
13	73	76	O	have
14	78	80	O	not
15	82	85	O	been
16	87	98	O	investigated
NULL

Calcitriol	DDI-DrugBank.d384.s11	NO_SECTION	NO_SETID	25
Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
1	0	14	U-UNK	Corticosteroids
2	15	15	O	:
3	17	17	O	A
4	19	30	O	relationship
5	32	33	O	of
6	35	44	O	functional
7	46	55	O	antagonism
8	57	62	O	exists
9	64	70	O	between
10	72	78	B-UNK	vitamin
11	80	80	I-UNK	D
12	82	90	L-UNK	analogues
13	91	91	O	,
14	93	97	O	which
15	99	105	O	promote
16	107	113	O	calcium
17	115	124	O	absorption
18	125	125	O	,
19	127	129	O	and
20	131	145	U-UNK	corticosteroids
21	146	146	O	,
22	148	152	O	which
23	154	160	O	inhibit
24	162	168	O	calcium
25	170	179	O	absorption
NULL

Calcitriol	DDI-DrugBank.d384.s12	NO_SECTION	NO_SETID	38
Phosphate-Binding Agents: Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.
1	0	8	O	Phosphate
2	10	16	O	Binding
3	18	23	O	Agents
4	24	24	O	:
5	26	30	O	Since
6	32	38	B-UNK	vitamin
7	40	40	L-UNK	D
8	42	45	O	also
9	47	49	O	has
10	51	52	O	an
11	54	59	O	effect
12	61	62	O	on
13	64	72	O	phosphate
14	74	82	O	transport
15	84	85	O	in
16	87	89	O	the
17	91	99	O	intestine
18	100	100	O	,
19	102	108	O	kidneys
20	110	112	O	and
21	114	118	O	bones
22	119	119	O	,
23	121	123	O	the
24	125	130	O	dosage
25	132	133	O	of
26	135	143	O	phosphate
27	145	151	O	binding
28	153	158	O	agents
29	160	163	O	must
30	165	166	O	be
31	168	175	O	adjusted
32	177	178	O	in
33	180	189	O	accordance
34	191	194	O	with
35	196	198	O	the
36	200	204	O	serum
37	206	214	O	phosphate
38	216	228	O	concentration
NULL

Calcitriol	DDI-DrugBank.d384.s13	NO_SECTION	NO_SETID	24
Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
1	0	6	B-UNK	Vitamin
2	8	8	L-UNK	D
3	9	9	O	:
4	11	13	O	The
5	15	30	O	coadministration
6	32	33	O	of
7	35	37	O	any
8	39	40	O	of
9	42	44	O	the
10	46	52	B-UNK	vitamin
11	54	54	I-UNK	D
12	56	64	L-UNK	analogues
13	66	71	O	should
14	73	74	O	be
15	76	82	O	avoided
16	84	85	O	as
17	87	90	O	this
18	92	96	O	could
19	98	103	O	create
20	105	112	O	possible
21	114	121	O	additive
22	123	129	O	effects
23	131	133	O	and
24	135	147	O	hypercalcemia
NULL

Calcitriol	DDI-DrugBank.d384.s14	NO_SECTION	NO_SETID	13
Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.
1	0	6	U-UNK	Calcium
2	8	18	O	Supplements
3	19	19	O	:
4	21	32	O	Uncontrolled
5	34	39	O	intake
6	41	42	O	of
7	44	53	O	additional
8	55	61	U-UNK	calcium
9	63	72	O	containing
10	74	85	O	preparations
11	87	92	O	should
12	94	95	O	be
13	97	103	O	avoided
NULL

Calcitriol	DDI-DrugBank.d384.s15	NO_SECTION	NO_SETID	28
Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
1	0	8	U-UNK	Magnesium
2	9	9	O	:
3	11	19	U-UNK	Magnesium
4	21	30	O	containing
5	32	43	O	preparations
6	46	47	O	eg
7	48	48	O	,
8	50	57	U-UNK	antacids
9	60	62	O	may
10	64	68	O	cause
11	70	84	O	hypermagnesemia
12	86	88	O	and
13	90	95	O	should
14	97	105	O	therefore
15	107	109	O	not
16	111	112	O	be
17	114	118	O	taken
18	120	125	O	during
19	127	133	O	therapy
20	135	138	O	with
21	140	146	B-UNK	vitamin
22	148	148	L-UNK	D
23	150	151	O	by
24	153	160	O	patients
25	162	163	O	on
26	165	171	O	chronic
27	173	177	O	renal
28	179	186	O	dialysis
NULL

Calcium Acetate	DDI-DrugBank.d494.s0	NO_SECTION	NO_SETID	28
Concomitant use with other calcium-containing medicines (including antacids) may cause too much calcium in the blood or urine, which may increase the chance of side effects.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	19	O	with
4	21	25	O	other
5	27	33	U-UNK	calcium
6	35	44	O	containing
7	46	54	O	medicines
8	57	65	O	including
9	67	74	U-UNK	antacids
10	77	79	O	may
11	81	85	O	cause
12	87	89	O	too
13	91	94	O	much
14	96	102	U-UNK	calcium
15	104	105	O	in
16	107	109	O	the
17	111	115	O	blood
18	117	118	O	or
19	120	124	O	urine
20	125	125	O	,
21	127	131	O	which
22	133	135	O	may
23	137	144	O	increase
24	146	148	O	the
25	150	155	O	chance
26	157	158	O	of
27	160	163	O	side
28	165	171	O	effects
NULL

Calcium Acetate	DDI-DrugBank.d494.s1	NO_SECTION	NO_SETID	27
Using calcium acetate with digitalis glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.
1	0	4	O	Using
2	6	20	O	XXXXXXXX
3	22	25	O	with
4	27	35	B-DYN	digitalis
5	37	46	L-DYN	glycosides
6	49	53	O	heart
7	55	62	O	medicine
8	65	67	O	may
9	69	73	O	cause
10	75	87	O	hypercalcemia
11	90	92	O	too
12	94	97	O	much
13	99	105	U-UNK	calcium
14	107	108	O	in
15	110	112	O	the
16	114	118	O	blood
17	120	120	O	,
18	122	126	O	which
19	128	132	O	could
20	134	141	O	increase
21	143	145	O	the
22	147	152	O	chance
23	154	155	O	of
24	157	166	O	developing
25	168	169	O	an
26	171	179	O	irregular
27	181	189	O	heartbeat
NULL

Calcium Gluceptate	DDI-DrugBank.d406.s0	NO_SECTION	NO_SETID	19
May interact with cefamandole naftate, cephalothin sodium, magnesium sulfate, prednisolone sodium succinate, and prochlorperazine edisylate.
1	0	2	O	May
2	4	11	O	interact
3	13	16	O	with
4	18	28	B-UNK	cefamandole
5	30	36	L-UNK	naftate
6	37	37	O	,
7	39	49	B-UNK	cephalothin
8	51	56	L-UNK	sodium
9	57	57	O	,
10	59	67	B-UNK	magnesium
11	69	75	L-UNK	sulfate
12	76	76	O	,
13	78	89	B-UNK	prednisolone
14	91	96	I-UNK	sodium
15	98	106	L-UNK	succinate
16	107	107	O	,
17	109	111	O	and
18	113	128	B-UNK	prochlorperazine
19	130	138	L-UNK	edisylate
NULL

Candesartan	DDI-DrugBank.d547.s0	NO_SECTION	NO_SETID	49
No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
1	0	1	O	No
2	3	13	O	significant
3	15	18	O	drug
4	20	31	O	interactions
5	33	36	O	have
6	38	41	O	been
7	43	50	O	reported
8	52	53	O	in
9	55	61	O	studies
10	63	64	O	of
11	66	76	O	XXXXXXXX
12	78	86	O	cilexetil
13	88	92	O	given
14	94	97	O	with
15	99	103	O	other
16	105	109	O	drugs
17	111	114	O	such
18	116	117	O	as
19	119	127	U-UNK	glyburide
20	128	128	O	,
21	130	139	U-UNK	nifedipine
22	140	140	O	,
23	142	148	U-UNK	digoxin
24	149	149	O	,
25	151	158	U-UNK	warfarin
26	159	159	O	,
27	161	179	U-UNK	hydrochlorothiazide
28	180	180	O	,
29	182	184	O	and
30	186	189	O	oral
31	191	204	U-UNK	contraceptives
32	206	207	O	in
33	209	215	O	healthy
34	217	226	O	volunteers
35	227	227	O	,
36	229	230	O	or
37	232	236	O	given
38	238	241	O	with
39	243	251	U-UNK	enalapril
40	253	254	O	to
41	256	263	O	patients
42	265	268	O	with
43	270	274	O	heart
44	276	282	O	failure
45	285	288	O	NYHA
46	290	294	O	class
47	296	297	O	II
48	299	301	O	and
49	303	305	O	III
NULL

Candesartan	DDI-DrugBank.d547.s1	NO_SECTION	NO_SETID	37
Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.
1	0	6	O	Because
2	8	18	O	XXXXXXXX
3	20	21	O	is
4	23	25	O	not
5	27	39	O	significantly
6	41	51	O	metabolized
7	53	54	O	by
8	56	58	O	the
9	60	69	O	cytochrome
10	71	74	O	P450
11	76	81	O	system
12	83	85	O	and
13	87	88	O	at
14	90	100	O	therapeutic
15	102	115	O	concentrations
16	117	119	O	has
17	121	122	O	no
18	124	130	O	effects
19	132	133	O	on
20	135	138	O	P450
21	140	146	O	enzymes
22	147	147	O	,
23	149	160	O	interactions
24	162	165	O	with
25	167	171	O	drugs
26	173	176	O	that
27	178	184	O	inhibit
28	186	187	O	or
29	189	191	O	are
30	193	203	O	metabolized
31	205	206	O	by
32	208	212	O	those
33	214	220	O	enzymes
34	222	226	O	would
35	228	230	O	not
36	232	233	O	be
37	235	242	O	expected
NULL

Candesartan	DDI-DrugBank.d547.s2	NO_SECTION	NO_SETID	28
Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.
1	0	6	U-UNK	Lithium
2	8	17	O	Reversible
3	19	27	O	increases
4	29	30	O	in
5	32	36	O	serum
6	38	44	U-UNK	lithium
7	46	59	O	concentrations
8	61	63	O	and
9	65	72	O	toxicity
10	74	77	O	have
11	79	82	O	been
12	84	91	O	reported
13	93	98	O	during
14	100	110	O	concomitant
15	112	125	O	administration
16	127	128	O	of
17	130	136	U-UNK	lithium
18	138	141	O	with
19	143	145	B-UNK	ACE
20	147	156	L-UNK	inhibitors
21	157	157	O	,
22	159	161	O	and
23	163	166	O	with
24	168	171	O	some
25	173	183	B-UNK	angiotensin
26	185	186	I-UNK	II
27	188	195	I-UNK	receptor
28	197	207	L-UNK	antagonists
NULL

Candesartan	DDI-DrugBank.d547.s3	NO_SECTION	NO_SETID	29
An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.
1	0	1	O	An
2	3	10	O	increase
3	12	13	O	in
4	15	19	O	serum
5	21	27	U-UNK	lithium
6	29	41	O	concentration
7	43	45	O	has
8	47	50	O	been
9	52	59	O	reported
10	61	66	O	during
11	68	78	O	concomitant
12	80	93	O	administration
13	95	96	O	of
14	98	104	U-KIN	lithium
15	106	109	O	with
16	111	117	O	XXXXXXXX
17	118	118	O	,
18	120	121	O	so
19	123	129	O	careful
20	131	140	O	monitoring
21	142	143	O	of
22	145	149	O	serum
23	151	157	U-UNK	lithium
24	159	164	O	levels
25	166	167	O	is
26	169	179	O	recommended
27	181	186	O	during
28	188	198	O	concomitant
29	200	202	O	use
NULL

Capecitabine	DDI-DrugBank.d88.s0	NO_SECTION	NO_SETID	26
Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.
1	0	6	U-UNK	Antacid
2	7	7	O	:
3	9	11	O	The
4	13	18	O	effect
5	20	21	O	of
6	23	24	O	an
7	26	33	B-UNK	aluminum
8	35	43	L-UNK	hydroxide
9	46	48	O	and
10	50	58	B-UNK	magnesium
11	60	68	L-UNK	hydroxide
12	70	79	O	containing
13	81	87	U-UNK	antacid
14	90	95	O	XXXXXXXX
15	97	97	O	*
16	99	100	O	on
17	102	104	O	the
18	106	121	O	pharmacokinetics
19	123	124	O	of
20	126	137	U-UNK	capecitabine
21	139	141	O	was
22	143	154	O	investigated
23	156	157	O	in
24	159	160	O	12
25	162	167	O	cancer
26	169	176	O	patients
NULL

Capecitabine	DDI-DrugBank.d88.s1	NO_SECTION	NO_SETID	15
There was a small increase in plasma concentrations of capecitabine and one metabolite (5-DFCR);
1	0	4	O	There
2	6	8	O	was
3	10	10	O	a
4	12	16	O	small
5	18	25	O	increase
6	27	28	O	in
7	30	35	O	plasma
8	37	50	O	concentrations
9	52	53	O	of
10	55	66	O	XXXXXXXX
11	68	70	O	and
12	72	74	O	one
13	76	85	O	metabolite
14	88	88	B-UNK	5
15	90	93	L-UNK	DFCR
NULL

Capecitabine	DDI-DrugBank.d88.s2	NO_SECTION	NO_SETID	16
there was no effect on the 3 major metabolites (5-DFUR, 5-FU and FBAL).
1	0	4	O	there
2	6	8	O	was
3	10	11	O	no
4	13	18	O	effect
5	20	21	O	on
6	23	25	O	the
7	27	27	O	3
8	29	33	O	major
9	35	45	O	metabolites
10	48	48	B-UNK	5
11	50	53	L-UNK	DFUR
12	54	54	O	,
13	56	56	B-UNK	5
14	58	59	L-UNK	FU
15	61	63	O	and
16	65	68	U-UNK	FBAL
NULL

Capecitabine	DDI-DrugBank.d88.s3	NO_SECTION	NO_SETID	26
Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.
1	0	7	B-UNK	Coumarin
2	9	22	L-UNK	Anticoagulants
3	24	30	O	Altered
4	32	42	O	coagulation
5	44	53	O	parameters
6	55	57	O	and
7	58	58	O	/
8	59	60	O	or
9	62	69	O	bleeding
10	71	74	O	have
11	76	79	O	been
12	81	88	O	reported
13	90	91	O	in
14	93	100	O	patients
15	102	107	O	taking
16	109	120	O	XXXXXXXX
17	122	134	O	concomitantly
18	136	139	O	with
19	141	148	B-DYN	coumarin
20	150	159	I-DYN	derivative
21	161	174	L-DYN	anticoagulants
22	176	179	O	such
23	181	182	O	as
24	184	191	U-UNK	warfarin
25	193	195	O	and
26	197	209	U-DYN	phenprocoumon
NULL

Capecitabine	DDI-DrugBank.d88.s4	NO_SECTION	NO_SETID	21
Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).
1	0	7	O	Patients
2	9	14	O	taking
3	16	23	B-DYN	coumarin
4	25	34	I-DYN	derivative
5	36	49	L-DYN	anticoagulants
6	51	63	O	concomitantly
7	65	68	O	with
8	70	81	O	XXXXXXXX
9	83	88	O	should
10	90	91	O	be
11	93	101	O	monitored
12	103	111	O	regularly
13	113	115	O	for
14	117	127	O	alterations
15	129	130	O	in
16	132	136	O	their
17	138	148	O	coagulation
18	150	159	O	parameters
19	162	163	O	PT
20	165	166	O	or
21	168	170	O	INR
NULL

Capecitabine	DDI-DrugBank.d88.s5	NO_SECTION	NO_SETID	17
Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.
1	0	9	U-UNK	Leucovorin
2	10	10	O	:
3	12	14	O	The
4	16	28	O	concentration
5	30	31	O	of
6	33	33	B-UNK	5
7	35	46	L-UNK	fluorouracil
8	48	49	O	is
9	51	59	O	increased
10	61	63	O	and
11	65	67	O	its
12	69	76	O	toxicity
13	78	80	O	may
14	82	83	O	be
15	85	92	O	enhanced
16	94	95	O	by
17	97	106	U-UNK	leucovorin
NULL

Capecitabine	DDI-DrugBank.d88.s6	NO_SECTION	NO_SETID	20
Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.
1	0	5	O	Deaths
2	7	10	O	from
3	12	17	O	severe
4	19	31	O	enterocolitis
5	32	32	O	,
6	34	41	O	diarrhea
7	42	42	O	,
8	44	46	O	and
9	48	58	O	dehydration
10	60	63	O	have
11	65	68	O	been
12	70	77	O	reported
13	79	80	O	in
14	82	88	O	elderly
15	90	97	O	patients
16	99	107	O	receiving
17	109	114	O	weekly
18	116	125	U-UNK	leucovorin
19	127	129	O	and
20	131	142	U-UNK	fluorouracil
NULL

Captopril	DDI-DrugBank.d175.s0	NO_SECTION	NO_SETID	53
Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.
1	0	10	O	Hypotension
2	14	21	O	Patients
3	23	24	O	on
4	26	33	U-UNK	Diuretic
5	35	41	O	Therapy
6	42	42	O	:
7	44	51	O	Patients
8	53	54	O	on
9	56	64	U-DYN	diuretics
10	66	68	O	and
11	70	79	O	especially
12	81	85	O	those
13	87	88	O	in
14	90	93	O	whom
15	95	102	U-UNK	diuretic
16	104	110	O	therapy
17	112	114	O	was
18	116	123	O	recently
19	125	134	O	instituted
20	135	135	O	,
21	137	138	O	as
22	140	143	O	well
23	145	146	O	as
24	148	152	O	those
25	154	155	O	on
26	157	162	O	severe
27	164	170	O	dietary
28	172	175	O	salt
29	177	187	O	restriction
30	189	190	O	or
31	192	199	O	dialysis
32	200	200	O	,
33	202	204	O	may
34	206	217	O	occasionally
35	219	228	O	experience
36	230	230	O	a
37	232	242	O	precipitous
38	244	252	O	reduction
39	254	255	O	of
40	257	261	O	blood
41	263	270	O	pressure
42	272	278	O	usually
43	280	285	O	within
44	287	289	O	the
45	291	295	O	first
46	297	300	O	hour
47	302	306	O	after
48	308	316	O	receiving
49	318	320	O	the
50	322	328	O	initial
51	330	333	O	dose
52	335	336	O	of
53	338	346	O	XXXXXXXX
NULL

Captopril	DDI-DrugBank.d175.s1	NO_SECTION	NO_SETID	44
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).
1	0	2	O	The
2	4	14	O	possibility
3	16	17	O	of
4	19	29	O	hypotensive
5	31	37	O	effects
6	39	42	O	with
7	44	52	O	XXXXXXXX
8	54	56	O	can
9	58	59	O	be
10	61	69	O	minimized
11	71	72	O	by
12	74	79	O	either
13	81	93	O	discontinuing
14	95	97	O	the
15	99	106	U-DYN	diuretic
16	108	109	O	or
17	111	120	O	increasing
18	122	124	O	the
19	126	129	O	salt
20	131	136	O	intake
21	138	150	O	approximately
22	152	154	O	one
23	156	159	O	week
24	161	165	O	prior
25	167	168	O	to
26	170	179	O	initiation
27	181	182	O	of
28	184	192	O	treatment
29	194	197	O	with
30	199	207	O	XXXXXXXX
31	210	218	O	XXXXXXXX
32	220	226	O	tablets
33	227	227	O	,
34	229	231	O	USP
35	234	235	O	or
36	237	246	O	initiating
37	248	254	O	therapy
38	256	259	O	with
39	261	265	O	small
40	267	271	O	doses
41	274	277	O	6.25
42	279	280	O	or
43	282	285	O	12.5
44	287	288	O	mg
NULL

Captopril	DDI-DrugBank.d175.s2	NO_SECTION	NO_SETID	14
Alternatively, provide medical supervision for at least one hour after the initial dose.
1	0	12	O	Alternatively
2	13	13	O	,
3	15	21	O	provide
4	23	29	O	medical
5	31	41	O	supervision
6	43	45	O	for
7	47	48	O	at
8	50	54	O	least
9	56	58	O	one
10	60	63	O	hour
11	65	69	O	after
12	71	73	O	the
13	75	81	O	initial
14	83	86	O	dose
NULL

Captopril	DDI-DrugBank.d175.s3	NO_SECTION	NO_SETID	25
If hypotension occurs, the patient should be placed in a supine position and, if necessary, receive an intravenous infusion of normal saline.
1	0	1	O	If
2	3	13	O	hypotension
3	15	20	O	occurs
4	21	21	O	,
5	23	25	O	the
6	27	33	O	patient
7	35	40	O	should
8	42	43	O	be
9	45	50	O	placed
10	52	53	O	in
11	55	55	O	a
12	57	62	O	supine
13	64	71	O	position
14	73	75	O	and
15	76	76	O	,
16	78	79	O	if
17	81	89	O	necessary
18	90	90	O	,
19	92	98	O	receive
20	100	101	O	an
21	103	113	O	intravenous
22	115	122	O	infusion
23	124	125	O	of
24	127	132	O	normal
25	134	139	O	saline
NULL

Captopril	DDI-DrugBank.d175.s4	NO_SECTION	NO_SETID	26
This transient hypotensive response is not a contraindication to further doses which can be given without difficulty once the blood pressure has increased after volume expansion.
1	0	3	O	This
2	5	13	O	transient
3	15	25	O	hypotensive
4	27	34	O	response
5	36	37	O	is
6	39	41	O	not
7	43	43	O	a
8	45	60	O	contraindication
9	62	63	O	to
10	65	71	O	further
11	73	77	O	doses
12	79	83	O	which
13	85	87	O	can
14	89	90	O	be
15	92	96	O	given
16	98	104	O	without
17	106	115	O	difficulty
18	117	120	O	once
19	122	124	O	the
20	126	130	O	blood
21	132	139	O	pressure
22	141	143	O	has
23	145	153	O	increased
24	155	159	O	after
25	161	166	O	volume
26	168	176	O	expansion
NULL

Captopril	DDI-DrugBank.d175.s5	NO_SECTION	NO_SETID	25
Agents Having Vasodilator Activity: Data on the effect of concomitant use of other vasodilators in patients receiving captopril for heart failure are not available;
1	0	5	O	Agents
2	7	12	O	Having
3	14	24	O	Vasodilator
4	26	33	O	Activity
5	34	34	O	:
6	36	39	O	Data
7	41	42	O	on
8	44	46	O	the
9	48	53	O	effect
10	55	56	O	of
11	58	68	O	concomitant
12	70	72	O	use
13	74	75	O	of
14	77	81	O	other
15	83	94	U-UNK	vasodilators
16	96	97	O	in
17	99	106	O	patients
18	108	116	O	receiving
19	118	126	O	XXXXXXXX
20	128	130	O	for
21	132	136	O	heart
22	138	144	O	failure
23	146	148	O	are
24	150	152	O	not
25	154	162	O	available
NULL

Captopril	DDI-DrugBank.d175.s6	NO_SECTION	NO_SETID	28
therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.
1	0	8	O	therefore
2	9	9	O	,
3	11	23	U-DYN	nitroglycerin
4	25	26	O	or
5	28	32	O	other
6	34	41	U-DYN	nitrates
7	44	45	O	as
8	47	50	O	used
9	52	54	O	for
10	56	65	O	management
11	67	68	O	of
12	70	75	O	angina
13	78	79	O	or
14	81	85	O	other
15	87	91	O	drugs
16	93	98	O	having
17	100	110	O	vasodilator
18	112	119	O	activity
19	121	126	O	should
20	127	127	O	,
21	129	130	O	if
22	132	139	O	possible
23	140	140	O	,
24	142	143	O	be
25	145	156	O	discontinued
26	158	163	O	before
27	165	172	O	starting
28	174	182	O	XXXXXXXX
NULL

Captopril	DDI-DrugBank.d175.s7	NO_SECTION	NO_SETID	18
If resumed during captopril therapy, such agents should be administered cautiously, and perhaps at lower dosage.
1	0	1	O	If
2	3	9	O	resumed
3	11	16	O	during
4	18	26	O	XXXXXXXX
5	28	34	O	therapy
6	35	35	O	,
7	37	40	O	such
8	42	47	O	agents
9	49	54	O	should
10	56	57	O	be
11	59	70	O	administered
12	72	81	O	cautiously
13	82	82	O	,
14	84	86	O	and
15	88	94	O	perhaps
16	96	97	O	at
17	99	103	O	lower
18	105	110	O	dosage
NULL

Captopril	DDI-DrugBank.d175.s8	NO_SECTION	NO_SETID	17
Agents Causing Renin Release Captopril's effect will be augmented by antihypertensive agents that cause renin release.
1	0	5	O	Agents
2	7	13	O	Causing
3	15	19	O	Renin
4	21	27	O	Release
5	29	37	O	XXXXXXXX
6	38	39	O	's
7	41	46	O	effect
8	48	51	O	will
9	53	54	O	be
10	56	64	O	augmented
11	66	67	O	by
12	69	84	B-DYN	antihypertensive
13	86	91	L-DYN	agents
14	93	96	O	that
15	98	102	O	cause
16	104	108	O	renin
17	110	116	O	release
NULL

Captopril	DDI-DrugBank.d175.s9	NO_SECTION	NO_SETID	14
For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system.
1	0	2	O	For
2	4	10	O	example
3	11	11	O	,
4	13	21	U-UNK	diuretics
5	24	26	O	e.g
6	28	28	O	,
7	30	38	U-UNK	thiazides
8	41	43	O	may
9	45	52	O	activate
10	54	56	O	the
11	58	62	O	renin
12	64	74	O	angiotensin
13	76	86	O	aldosterone
14	88	93	O	system
NULL

Captopril	DDI-DrugBank.d175.s10	NO_SECTION	NO_SETID	24
Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics.
1	0	5	O	Agents
2	7	15	O	Affecting
3	17	27	O	Sympathetic
4	29	36	O	Activity
5	38	40	O	The
6	42	52	O	sympathetic
7	54	60	O	nervous
8	62	67	O	system
9	69	71	O	may
10	73	74	O	be
11	76	85	O	especially
12	87	95	O	important
13	97	98	O	in
14	100	109	O	supporting
15	111	115	O	blood
16	117	124	O	pressure
17	126	127	O	in
18	129	136	O	patients
19	138	146	O	receiving
20	148	156	O	XXXXXXXX
21	158	162	O	alone
22	164	165	O	or
23	167	170	O	with
24	172	180	U-UNK	diuretics
NULL

Captopril	DDI-DrugBank.d175.s11	NO_SECTION	NO_SETID	21
Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution.
1	0	8	O	Therefore
2	9	9	O	,
3	11	16	O	agents
4	18	26	O	affecting
5	28	38	O	sympathetic
6	40	47	O	activity
7	50	52	O	e.g
8	54	54	O	,
9	56	65	B-UNK	ganglionic
10	67	74	I-UNK	blocking
11	76	81	L-UNK	agents
12	83	84	O	or
13	86	95	B-UNK	adrenergic
14	97	102	I-UNK	neuron
15	104	111	I-UNK	blocking
16	113	118	L-UNK	agents
17	121	126	O	should
18	128	129	O	be
19	131	134	O	used
20	136	139	O	with
21	141	147	O	caution
NULL

Captopril	DDI-DrugBank.d175.s12	NO_SECTION	NO_SETID	20
Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive.
1	0	3	B-DYN	Beta
2	5	14	I-DYN	adrenergic
3	16	23	I-DYN	blocking
4	25	29	L-DYN	drugs
5	31	33	O	add
6	35	38	O	some
7	40	46	O	further
8	48	63	O	antihypertensive
9	65	70	O	effect
10	72	73	O	to
11	75	83	O	XXXXXXXX
12	84	84	O	,
13	86	88	O	but
14	90	92	O	the
15	94	100	O	overall
16	102	109	O	response
17	111	112	O	is
18	114	117	O	less
19	119	122	O	than
20	124	131	O	additive
NULL

Captopril	DDI-DrugBank.d175.s13	NO_SECTION	NO_SETID	16
Agents Increasing Serum Potassium Since captopril decreases aldosterone production, elevation of serum potassium may occur.
1	0	5	O	Agents
2	7	16	O	Increasing
3	18	22	O	Serum
4	24	32	O	Potassium
5	34	38	O	Since
6	40	48	O	XXXXXXXX
7	50	58	O	decreases
8	60	70	O	aldosterone
9	72	81	O	production
10	82	82	O	,
11	84	92	O	elevation
12	94	95	O	of
13	97	101	O	serum
14	103	111	O	potassium
15	113	115	O	may
16	117	121	O	occur
NULL

Captopril	DDI-DrugBank.d175.s14	NO_SECTION	NO_SETID	39
Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.
1	0	8	B-UNK	Potassium
2	10	16	I-UNK	sparing
3	18	26	L-UNK	diuretics
4	28	31	O	such
5	33	34	O	as
6	36	49	U-UNK	spironolactone
7	50	50	O	,
8	52	62	U-UNK	triamterene
9	63	63	O	,
10	65	66	O	or
11	68	76	U-UNK	amiloride
12	77	77	O	,
13	79	80	O	or
14	82	90	U-UNK	potassium
15	92	102	O	supplements
16	104	109	O	should
17	111	112	O	be
18	114	118	O	given
19	120	123	O	only
20	125	127	O	for
21	129	138	O	documented
22	140	150	O	hypokalemia
23	151	151	O	,
24	153	155	O	and
25	157	160	O	then
26	162	165	O	with
27	167	173	O	caution
28	174	174	O	,
29	176	180	O	since
30	182	185	O	they
31	187	189	O	may
32	191	194	O	lead
33	196	197	O	to
34	199	199	O	a
35	201	211	O	significant
36	213	220	O	increase
37	222	223	O	of
38	225	229	O	serum
39	231	239	O	potassium
NULL

Captopril	DDI-DrugBank.d175.s15	NO_SECTION	NO_SETID	10
Salt substitutes containing potassium should also be used with caution.
1	0	3	O	Salt
2	5	15	O	substitutes
3	17	26	O	containing
4	28	36	U-UNK	potassium
5	38	43	O	should
6	45	48	O	also
7	50	51	O	be
8	53	56	O	used
9	58	61	O	with
10	63	69	O	caution
NULL

Captopril	DDI-DrugBank.d175.s16	NO_SECTION	NO_SETID	26
Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.
1	0	9	O	Inhibitors
2	11	12	O	Of
3	14	23	O	Endogenous
4	25	37	O	Prostaglandin
5	39	47	O	Synthesis
6	49	50	O	It
7	52	54	O	has
8	56	59	O	been
9	61	68	O	reported
10	70	73	O	that
11	75	86	U-DYN	indomethacin
12	88	90	O	may
13	92	97	O	reduce
14	99	101	O	the
15	103	118	O	antihypertensive
16	120	125	O	effect
17	127	128	O	of
18	130	138	O	XXXXXXXX
19	139	139	O	,
20	141	150	O	especially
21	152	153	O	in
22	155	159	O	cases
23	161	162	O	of
24	164	166	O	low
25	168	172	O	renin
26	174	185	O	hypertension
NULL

Captopril	DDI-DrugBank.d175.s17	NO_SECTION	NO_SETID	13
Other nonsteroidal anti-inflammatory agents (e.g., aspirin) may also have this effect.
1	0	4	O	Other
2	6	17	B-UNK	nonsteroidal
3	19	22	I-UNK	anti
4	24	35	I-UNK	inflammatory
5	37	42	L-UNK	agents
6	45	47	O	e.g
7	49	49	O	,
8	51	57	O	XXXXXXXX
9	60	62	O	may
10	64	67	O	also
11	69	72	O	have
12	74	77	O	this
13	79	84	O	effect
NULL

Captopril	DDI-DrugBank.d175.s18	NO_SECTION	NO_SETID	23
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	17	O	Increased
4	19	23	O	serum
5	25	31	U-UNK	lithium
6	33	38	O	levels
7	40	42	O	and
8	44	51	O	symptoms
9	53	54	O	of
10	56	62	U-UNK	lithium
11	64	71	O	toxicity
12	73	76	O	have
13	78	81	O	been
14	83	90	O	reported
15	92	93	O	in
16	95	102	O	patients
17	104	112	O	receiving
18	114	124	O	concomitant
19	126	132	U-UNK	lithium
20	134	136	O	and
21	138	140	B-UNK	ACE
22	142	150	L-UNK	inhibitor
23	152	158	O	therapy
NULL

Captopril	DDI-DrugBank.d175.s19	NO_SECTION	NO_SETID	17
These drugs should be coad-ministered with caution and frequent monitoring of serum lithium levels is recommended.
1	0	4	O	These
2	6	10	O	drugs
3	12	17	O	should
4	19	20	O	be
5	22	25	O	coad
6	27	36	O	ministered
7	38	41	O	with
8	43	49	O	caution
9	51	53	O	and
10	55	62	O	frequent
11	64	73	O	monitoring
12	75	76	O	of
13	78	82	O	serum
14	84	90	U-UNK	lithium
15	92	97	O	levels
16	99	100	O	is
17	102	112	O	recommended
NULL

Captopril	DDI-DrugBank.d175.s20	NO_SECTION	NO_SETID	15
If a diuretic is also used, it may increase the risk of lithium toxicity.
1	0	1	O	If
2	3	3	O	a
3	5	12	U-UNK	diuretic
4	14	15	O	is
5	17	20	O	also
6	22	25	O	used
7	26	26	O	,
8	28	29	O	it
9	31	33	O	may
10	35	42	O	increase
11	44	46	O	the
12	48	51	O	risk
13	53	54	O	of
14	56	62	U-UNK	lithium
15	64	71	O	toxicity
NULL

Captopril	DDI-DrugBank.d175.s21	NO_SECTION	NO_SETID	23
Cardiac Glycosides: In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found.
1	0	6	B-UNK	Cardiac
2	8	17	L-UNK	Glycosides
3	18	18	O	:
4	20	21	O	In
5	23	23	O	a
6	25	29	O	study
7	31	32	O	of
8	34	38	O	young
9	40	46	O	healthy
10	48	51	O	male
11	53	60	O	subjects
12	62	63	O	no
13	65	72	O	evidence
14	74	75	O	of
15	77	77	O	a
16	79	84	O	direct
17	86	100	O	pharmacokinetic
18	102	110	O	XXXXXXXX
19	112	118	U-UNK	digoxin
20	120	130	O	interaction
21	132	136	O	could
22	138	139	O	be
23	141	145	O	found
NULL

Captopril	DDI-DrugBank.d175.s22	NO_SECTION	NO_SETID	20
Loop Diuretics: Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.
1	0	3	B-UNK	Loop
2	5	13	L-UNK	Diuretics
3	14	14	O	:
4	16	25	U-UNK	Furosemide
5	27	38	O	administered
6	40	51	O	concurrently
7	53	56	O	with
8	58	66	O	XXXXXXXX
9	68	71	O	does
10	73	75	O	not
11	77	81	O	alter
12	83	85	O	the
13	87	102	O	pharmacokinetics
14	104	105	O	of
15	107	115	O	XXXXXXXX
16	117	118	O	in
17	120	126	O	renally
18	128	135	O	impaired
19	137	148	O	hypertensive
20	150	157	O	patients
NULL

Captopril	DDI-DrugBank.d175.s23	NO_SECTION	NO_SETID	24
Allopurinol: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and allopurinol were administered concomitantly for 6 days.
1	0	10	U-UNK	Allopurinol
2	11	11	O	:
3	13	14	O	In
4	16	16	O	a
5	18	22	O	study
6	24	25	O	of
7	27	33	O	healthy
8	35	38	O	male
9	40	49	O	volunteers
10	51	52	O	no
11	54	64	O	significant
12	66	80	O	pharmacokinetic
13	82	92	O	interaction
14	94	101	O	occurred
15	103	106	O	when
16	108	116	O	XXXXXXXX
17	118	120	O	and
18	122	132	U-UNK	allopurinol
19	134	137	O	were
20	139	150	O	administered
21	152	164	O	concomitantly
22	166	168	O	for
23	170	170	O	6
24	172	175	O	days
NULL

Captopril	DDI-DrugBank.d175.s24	NO_SECTION	NO_SETID	15
Drug/Laboratory Test Interaction Captopril may cause a false-positive urine test for acetone.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	31	O	Interaction
6	33	41	O	XXXXXXXX
7	43	45	O	may
8	47	51	O	cause
9	53	53	O	a
10	55	59	O	false
11	61	68	O	positive
12	70	74	O	urine
13	76	79	O	test
14	81	83	O	for
15	85	91	O	acetone
NULL

Carbamazepine	DDI-DrugBank.d94.s0	NO_SECTION	NO_SETID	34
Clinically meaningful drug interactions have occurred with concomitant medications and include, but are not limited to the following: Agents Highly Bound to Plasma Protein Carbamazepine is not highly bound to plasma proteins;
1	0	9	O	Clinically
2	11	20	O	meaningful
3	22	25	O	drug
4	27	38	O	interactions
5	40	43	O	have
6	45	52	O	occurred
7	54	57	O	with
8	59	69	O	concomitant
9	71	81	O	medications
10	83	85	O	and
11	87	93	O	include
12	94	94	O	,
13	96	98	O	but
14	100	102	O	are
15	104	106	O	not
16	108	114	O	limited
17	116	117	O	to
18	119	121	O	the
19	123	131	O	following
20	132	132	O	:
21	134	139	O	Agents
22	141	146	O	Highly
23	148	152	O	Bound
24	154	155	O	to
25	157	162	O	Plasma
26	164	170	O	Protein
27	172	184	O	XXXXXXXX
28	186	187	O	is
29	189	191	O	not
30	193	198	O	highly
31	200	204	O	bound
32	206	207	O	to
33	209	214	O	plasma
34	216	223	O	proteins
NULL

Carbamazepine	DDI-DrugBank.d94.s1	NO_SECTION	NO_SETID	26
therefore, administration of EQUETROTM to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.
1	0	8	O	therefore
2	9	9	O	,
3	11	24	O	administration
4	26	27	O	of
5	29	37	O	XXXXXXXX
6	39	40	O	to
7	42	42	O	a
8	44	50	O	patient
9	52	57	O	taking
10	59	65	O	another
11	67	70	O	drug
12	72	75	O	that
13	77	78	O	is
14	80	85	O	highly
15	87	93	O	protein
16	95	99	O	bound
17	101	106	O	should
18	108	110	O	not
19	112	116	O	cause
20	118	126	O	increased
21	128	131	O	free
22	133	146	O	concentrations
23	148	149	O	of
24	151	153	O	the
25	155	159	O	other
26	161	164	O	drug
NULL

Carbamazepine	DDI-DrugBank.d94.s2	NO_SECTION	NO_SETID	38
Agents that Inhibit Cytochrome P450 Isoenzymes and/or Epoxide Hydrolase Carbamazepine is metabolized mainly by cytochrome P450 (CYP) 3A4 to the active carbamazepine 10,11-epoxide, which is further metabolized to the trans-diol by epoxide hydrolase.
1	0	5	O	Agents
2	7	10	O	that
3	12	18	O	Inhibit
4	20	29	O	Cytochrome
5	31	34	O	P450
6	36	45	O	Isoenzymes
7	47	49	O	and
8	50	50	O	/
9	51	52	O	or
10	54	60	O	Epoxide
11	62	70	O	Hydrolase
12	72	84	O	XXXXXXXX
13	86	87	O	is
14	89	99	O	metabolized
15	101	106	O	mainly
16	108	109	O	by
17	111	120	O	cytochrome
18	122	125	O	P450
19	128	130	O	CYP
20	133	135	O	3A4
21	137	138	O	to
22	140	142	O	the
23	144	149	O	active
24	151	163	O	XXXXXXXX
25	165	169	O	10,11
26	171	177	O	epoxide
27	178	178	O	,
28	180	184	O	which
29	186	187	O	is
30	189	195	O	further
31	197	207	O	metabolized
32	209	210	O	to
33	212	214	O	the
34	216	220	O	trans
35	222	225	O	diol
36	227	228	O	by
37	230	236	O	epoxide
38	238	246	O	hydrolase
NULL

Carbamazepine	DDI-DrugBank.d94.s3	NO_SECTION	NO_SETID	20
Therefore, the potential exists for interaction between carbamazepine and any agent that inhibits CYP3A4 and/or epoxide hydrolase.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	23	O	potential
5	25	30	O	exists
6	32	34	O	for
7	36	46	O	interaction
8	48	54	O	between
9	56	68	O	XXXXXXXX
10	70	72	O	and
11	74	76	O	any
12	78	82	O	agent
13	84	87	O	that
14	89	96	O	inhibits
15	98	103	O	CYP3A4
16	105	107	O	and
17	108	108	O	/
18	109	110	O	or
19	112	118	O	epoxide
20	120	128	O	hydrolase
NULL

Carbamazepine	DDI-DrugBank.d94.s4	NO_SECTION	NO_SETID	80
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
1	0	5	O	Agents
2	7	10	O	that
3	12	14	O	are
4	16	21	O	CYP3A4
5	23	32	O	inhibitors
6	34	37	O	that
7	39	42	O	have
8	44	47	O	been
9	49	53	O	found
10	54	54	O	,
11	56	57	O	or
12	59	61	O	are
13	63	70	O	expected
14	71	71	O	,
15	73	74	O	to
16	76	83	O	increase
17	85	90	O	plasma
18	92	97	O	levels
19	99	100	O	of
20	102	110	O	XXXXXXXX
21	112	114	O	are
22	116	118	O	the
23	120	128	O	following
24	129	129	O	:
25	131	143	U-KIN	Acetazolamide
26	144	144	O	,
27	146	150	B-KIN	azole
28	152	162	L-KIN	antifungals
29	163	163	O	,
30	165	174	U-KIN	cimetidine
31	175	175	O	,
32	177	192	O	clarithromycin(1
33	194	194	O	,
34	196	207	U-KIN	dalfopristin
35	208	208	O	,
36	210	216	U-KIN	danazol
37	217	217	O	,
38	219	229	U-KIN	delavirdine
39	230	230	O	,
40	232	240	U-KIN	diltiazem
41	241	241	O	,
42	243	256	O	erythromycin(1
43	258	258	O	,
44	260	269	U-KIN	fluoxetine
45	270	270	O	,
46	272	282	U-KIN	fluvoxamine
47	283	283	O	,
48	285	294	O	grapefruit
49	296	300	O	juice
50	301	301	O	,
51	303	311	U-KIN	isoniazid
52	312	312	O	,
53	314	325	U-KIN	itraconazole
54	326	326	O	,
55	328	339	U-KIN	ketoconazole
56	340	340	O	,
57	342	351	U-KIN	loratadine
58	352	352	O	,
59	354	363	U-KIN	nefazodone
60	364	364	O	,
61	366	376	U-KIN	niacinamide
62	377	377	O	,
63	379	390	U-KIN	nicotinamide
64	391	391	O	,
65	393	400	B-KIN	protease
66	402	411	L-KIN	inhibitors
67	412	412	O	,
68	414	425	U-KIN	propoxyphene
69	426	426	O	,
70	428	434	U-KIN	quinine
71	435	435	O	,
72	437	448	U-KIN	quinupristin
73	449	449	O	,
74	451	464	U-KIN	troleandomycin
75	465	465	O	,
76	467	477	O	valproate(1
77	479	479	O	,
78	481	489	U-KIN	verapamil
79	490	490	O	,
80	492	499	U-KIN	zileuton
NULL

Carbamazepine	DDI-DrugBank.d94.s5	NO_SECTION	NO_SETID	46
Thus, if a patient has been titrated to a stable dosage of EQUETROTM, and then begins a course of treatment with one of these CYP3A4 or epoxide hydrolase inhibitors, it is reasonable to expect that a dose reduction for EQUETROTM may be necessary.
1	0	3	O	Thus
2	4	4	O	,
3	6	7	O	if
4	9	9	O	a
5	11	17	O	patient
6	19	21	O	has
7	23	26	O	been
8	28	35	O	titrated
9	37	38	O	to
10	40	40	O	a
11	42	47	O	stable
12	49	54	O	dosage
13	56	57	O	of
14	59	67	O	XXXXXXXX
15	68	68	O	,
16	70	72	O	and
17	74	77	O	then
18	79	84	O	begins
19	86	86	O	a
20	88	93	O	course
21	95	96	O	of
22	98	106	O	treatment
23	108	111	O	with
24	113	115	O	one
25	117	118	O	of
26	120	124	O	these
27	126	131	O	CYP3A4
28	133	134	O	or
29	136	142	O	epoxide
30	144	152	O	hydrolase
31	154	163	O	inhibitors
32	164	164	O	,
33	166	167	O	it
34	169	170	O	is
35	172	181	O	reasonable
36	183	184	O	to
37	186	191	O	expect
38	193	196	O	that
39	198	198	O	a
40	200	203	O	dose
41	205	213	O	reduction
42	215	217	O	for
43	219	227	O	XXXXXXXX
44	229	231	O	may
45	233	234	O	be
46	236	244	O	necessary
NULL

Carbamazepine	DDI-DrugBank.d94.s6	NO_SECTION	NO_SETID	11
Agents that Induce Cytochrome P450 Isoenzymes Carbamazepine is metabolized by CYP3A4.
1	0	5	O	Agents
2	7	10	O	that
3	12	17	O	Induce
4	19	28	O	Cytochrome
5	30	33	O	P450
6	35	44	O	Isoenzymes
7	46	58	O	XXXXXXXX
8	60	61	O	is
9	63	73	O	metabolized
10	75	76	O	by
11	78	83	O	CYP3A4
NULL

Carbamazepine	DDI-DrugBank.d94.s7	NO_SECTION	NO_SETID	15
Therefore, the potential exists for interaction between carbamazepine and any agent that induces CYP3A4.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	23	O	potential
5	25	30	O	exists
6	32	34	O	for
7	36	46	O	interaction
8	48	54	O	between
9	56	68	O	XXXXXXXX
10	70	72	O	and
11	74	76	O	any
12	78	82	O	agent
13	84	87	O	that
14	89	95	O	induces
15	97	102	O	CYP3A4
NULL

Carbamazepine	DDI-DrugBank.d94.s8	NO_SECTION	NO_SETID	86
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
1	0	5	O	Agents
2	7	10	O	that
3	12	14	O	are
4	16	18	O	CYP
5	20	27	O	inducers
6	29	32	O	that
7	34	37	O	have
8	39	42	O	been
9	44	48	O	found
10	49	49	O	,
11	51	52	O	or
12	54	56	O	are
13	58	65	O	expected
14	66	66	O	,
15	68	69	O	to
16	71	78	O	decrease
17	80	85	O	plasma
18	87	92	O	levels
19	94	95	O	of
20	97	105	O	XXXXXXXX
21	107	109	O	are
22	111	113	O	the
23	115	123	O	following
24	124	124	O	:
25	126	134	U-KIN	Cisplatin
26	135	135	O	,
27	137	147	B-KIN	doxorubicin
28	149	151	L-KIN	HCL
29	152	152	O	,
30	154	162	U-KIN	felbamate
31	163	163	O	,
32	165	172	U-KIN	rifampin
33	173	173	O	,
34	175	187	U-KIN	phenobarbital
35	188	188	O	,
36	190	200	O	Phenytoin(2
37	202	202	O	,
38	204	212	U-KIN	primidone
39	213	213	O	,
40	215	226	U-KIN	methsuximide
41	227	227	O	,
42	229	231	O	and
43	233	244	U-KIN	theophylline
44	246	249	O	Thus
45	250	250	O	,
46	252	253	O	if
47	255	255	O	a
48	257	263	O	patient
49	265	267	O	has
50	269	272	O	been
51	274	281	O	titrated
52	283	284	O	to
53	286	286	O	a
54	288	293	O	stable
55	295	300	O	dosage
56	302	303	O	on
57	305	313	O	XXXXXXXX
58	314	314	O	,
59	316	318	O	and
60	320	323	O	then
61	325	330	O	begins
62	332	332	O	a
63	334	339	O	course
64	341	342	O	of
65	344	352	O	treatment
66	354	357	O	with
67	359	361	O	one
68	363	364	O	of
69	366	370	O	these
70	372	377	O	CYP3A4
71	379	386	O	inducers
72	387	387	O	,
73	389	390	O	it
74	392	393	O	is
75	395	404	O	reasonable
76	406	407	O	to
77	409	414	O	expect
78	416	419	O	that
79	421	421	O	a
80	423	426	O	dose
81	428	435	O	increase
82	437	439	O	for
83	441	449	O	XXXXXXXX
84	451	453	O	may
85	455	456	O	be
86	458	466	O	necessary
NULL

Carbamazepine	DDI-DrugBank.d94.s9	NO_SECTION	NO_SETID	24
Agents with Decreased Levels in the Presence of Carbamazepine due to Induction of Cytochrome P450 Enzymes Carbamazepine is known to induce CYP1A2 and CYP3A4.
1	0	5	O	Agents
2	7	10	O	with
3	12	20	O	Decreased
4	22	27	O	Levels
5	29	30	O	in
6	32	34	O	the
7	36	43	O	Presence
8	45	46	O	of
9	48	60	O	XXXXXXXX
10	62	64	O	due
11	66	67	O	to
12	69	77	O	Induction
13	79	80	O	of
14	82	91	O	Cytochrome
15	93	96	O	P450
16	98	104	O	Enzymes
17	106	118	O	XXXXXXXX
18	120	121	O	is
19	123	127	O	known
20	129	130	O	to
21	132	137	O	induce
22	139	144	O	CYP1A2
23	146	148	O	and
24	150	155	O	CYP3A4
NULL

Carbamazepine	DDI-DrugBank.d94.s10	NO_SECTION	NO_SETID	20
Therefore, the potential exists for interaction between carbamazepine and any agent metabolized by one (or more) of these enzymes.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	23	O	potential
5	25	30	O	exists
6	32	34	O	for
7	36	46	O	interaction
8	48	54	O	between
9	56	68	O	XXXXXXXX
10	70	72	O	and
11	74	76	O	any
12	78	82	O	agent
13	84	94	O	metabolized
14	96	97	O	by
15	99	101	O	one
16	104	105	O	or
17	107	110	O	more
18	113	114	O	of
19	116	120	O	these
20	122	128	O	enzymes
NULL

Carbamazepine	DDI-DrugBank.d94.s11	NO_SECTION	NO_SETID	121
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
1	0	5	O	Agents
2	7	10	O	that
3	12	15	O	have
4	17	20	O	been
5	22	26	O	found
6	27	27	O	,
7	29	30	O	or
8	32	34	O	are
9	36	43	O	expected
10	45	46	O	to
11	48	51	O	have
12	53	61	O	decreased
13	63	68	O	plasma
14	70	75	O	levels
15	77	78	O	in
16	80	82	O	the
17	84	91	O	presence
18	93	94	O	of
19	96	104	O	XXXXXXXX
20	106	108	O	due
21	110	111	O	to
22	113	121	O	induction
23	123	124	O	of
24	126	128	O	CYP
25	130	136	O	enzymes
26	138	140	O	are
27	142	144	O	the
28	146	154	O	following
29	155	155	O	:
30	157	169	U-KIN	Acetaminophen
31	170	170	O	,
32	172	181	U-KIN	alprazolam
33	182	182	O	,
34	184	196	U-KIN	amitriptyline
35	197	197	O	,
36	199	207	U-KIN	bupropion
37	208	208	O	,
38	210	218	U-KIN	buspirone
39	219	219	O	,
40	221	230	U-KIN	citalopram
41	231	231	O	,
42	233	240	U-KIN	clobazam
43	241	241	O	,
44	243	252	U-KIN	clonazepam
45	253	253	O	,
46	255	263	U-KIN	clozapine
47	264	264	O	,
48	266	276	U-KIN	cyclosporin
49	277	277	O	,
50	279	289	U-KIN	delavirdine
51	290	290	O	,
52	292	302	U-KIN	desipramine
53	303	303	O	,
54	305	312	U-KIN	diazepam
55	313	313	O	,
56	315	323	U-KIN	dicumarol
57	324	324	O	,
58	326	336	U-KIN	doxycycline
59	337	337	O	,
60	339	350	U-KIN	ethosuximide
61	351	351	O	,
62	353	361	U-KIN	felbamate
63	362	362	O	,
64	364	373	U-KIN	felodipine
65	374	374	O	,
66	376	390	U-KIN	glucocorticoids
67	391	391	O	,
68	393	403	U-KIN	haloperidol
69	404	404	O	,
70	406	417	U-KIN	itraconazole
71	418	418	O	,
72	420	430	U-KIN	lamotrigine
73	431	431	O	,
74	433	445	U-KIN	levothyroxine
75	446	446	O	,
76	448	456	U-KIN	lorazepam
77	457	457	O	,
78	459	467	U-KIN	methadone
79	468	468	O	,
80	470	478	U-KIN	midazolam
81	479	479	O	,
82	481	491	U-KIN	mirtazapine
83	492	492	O	,
84	494	506	U-KIN	nortriptyline
85	507	507	O	,
86	509	518	U-KIN	olanzapine
87	519	519	O	,
88	521	524	O	oral
89	526	541	O	contraceptives(3
90	543	543	O	,
91	545	557	U-KIN	oxcarbazepine
92	558	558	O	,
93	560	570	O	Phenytoin(4
94	572	572	O	,
95	574	585	U-KIN	praziquantel
96	586	586	O	,
97	588	595	B-KIN	protease
98	597	606	L-KIN	inhibitors
99	607	607	O	,
100	609	618	U-KIN	quetiapine
101	619	619	O	,
102	621	631	U-KIN	risperidone
103	632	632	O	,
104	634	645	U-KIN	theophylline
105	646	646	O	,
106	648	657	U-KIN	topiramate
107	658	658	O	,
108	660	668	U-KIN	tiagabine
109	669	669	O	,
110	671	678	U-KIN	tramadol
111	679	679	O	,
112	681	689	U-KIN	triazolam
113	690	690	O	,
114	692	700	U-KIN	valproate
115	701	701	O	,
116	703	712	O	warfarin(5
117	715	715	O	,
118	717	727	U-KIN	ziprasidone
119	728	728	O	,
120	730	732	O	and
121	734	743	U-KIN	zonisamide
NULL

Carbamazepine	DDI-DrugBank.d94.s12	NO_SECTION	NO_SETID	47
Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with EQUETROTM, it is reasonable to expect that a dose increase for the concomitant agent may be necessary.
1	0	3	O	Thus
2	4	4	O	,
3	6	7	O	if
4	9	9	O	a
5	11	17	O	patient
6	19	21	O	has
7	23	26	O	been
8	28	35	O	titrated
9	37	38	O	to
10	40	40	O	a
11	42	47	O	stable
12	49	54	O	dosage
13	56	57	O	on
14	59	61	O	one
15	63	64	O	of
16	66	68	O	the
17	70	75	O	agents
18	77	78	O	in
19	80	83	O	this
20	85	92	O	category
21	93	93	O	,
22	95	97	O	and
23	99	102	O	then
24	104	109	O	begins
25	111	111	O	a
26	113	118	O	course
27	120	121	O	of
28	123	131	O	treatment
29	133	136	O	with
30	138	146	O	XXXXXXXX
31	147	147	O	,
32	149	150	O	it
33	152	153	O	is
34	155	164	O	reasonable
35	166	167	O	to
36	169	174	O	expect
37	176	179	O	that
38	181	181	O	a
39	183	186	O	dose
40	188	195	O	increase
41	197	199	O	for
42	201	203	O	the
43	205	215	O	concomitant
44	217	221	O	agent
45	223	225	O	may
46	227	228	O	be
47	230	238	O	necessary
NULL

Carbamazepine	DDI-DrugBank.d94.s13	NO_SECTION	NO_SETID	75
Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
1	0	5	O	Agents
2	7	10	O	with
3	12	20	O	Increased
4	22	27	O	Levels
5	29	30	O	in
6	32	34	O	the
7	36	43	O	Presence
8	45	46	O	of
9	48	60	U-UNK	Carbamazepine
10	61	61	O	:
11	63	71	O	XXXXXXXX
12	73	81	O	increases
13	83	85	O	the
14	87	92	O	plasma
15	94	99	O	levels
16	101	102	O	of
17	104	106	O	the
18	108	116	O	following
19	118	123	O	agents
20	124	124	O	:
21	126	137	B-KIN	Clomipramine
22	139	141	L-KIN	HCl
23	142	142	O	,
24	144	154	O	Phenytoin(6
25	156	156	O	,
26	158	160	O	and
27	162	170	U-KIN	primidone
28	172	175	O	Thus
29	176	176	O	,
30	178	179	O	if
31	181	181	O	a
32	183	189	O	patient
33	191	193	O	has
34	195	198	O	been
35	200	207	O	titrated
36	209	210	O	to
37	212	212	O	a
38	214	219	O	stable
39	221	226	O	dosage
40	228	229	O	on
41	231	233	O	one
42	235	236	O	of
43	238	240	O	the
44	242	247	O	agents
45	249	250	O	in
46	252	255	O	this
47	257	264	O	category
48	265	265	O	,
49	267	269	O	and
50	271	274	O	then
51	276	281	O	begins
52	283	283	O	a
53	285	290	O	course
54	292	293	O	of
55	295	297	O	the
56	299	307	O	treatment
57	309	312	O	with
58	314	322	O	XXXXXXXX
59	323	323	O	,
60	325	326	O	it
61	328	329	O	is
62	331	340	O	reasonable
63	342	343	O	to
64	345	350	O	expect
65	352	355	O	that
66	357	357	O	a
67	359	362	O	dose
68	364	371	O	decrease
69	373	375	O	for
70	377	379	O	the
71	381	391	O	concomitant
72	393	397	O	agent
73	399	401	O	may
74	403	404	O	be
75	406	414	O	necessary
NULL

Carbamazepine	DDI-DrugBank.d94.s14	NO_SECTION	NO_SETID	20
Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.
1	0	14	O	Pharmacological
2	15	15	O	/
3	16	30	O	Pharmacodynamic
4	32	43	O	Interactions
5	45	48	O	with
6	50	62	O	XXXXXXXX
7	64	74	O	Concomitant
8	76	89	O	administration
9	91	92	O	of
10	94	106	O	XXXXXXXX
11	108	110	O	and
12	112	118	U-DYN	lithium
13	120	122	O	may
14	124	131	O	increase
15	133	135	O	the
16	137	140	O	risk
17	142	143	O	of
18	145	154	O	neurotoxic
19	156	159	O	side
20	161	167	O	effects
NULL

Carbamazepine	DDI-DrugBank.d94.s15	NO_SECTION	NO_SETID	20
Given the anticonvulsant properties of carbamazepine, EQUETROTM may reduce the thyroid function as has been reported with other anticonvulsants.
1	0	4	O	Given
2	6	8	O	the
3	10	23	O	anticonvulsant
4	25	34	O	properties
5	36	37	O	of
6	39	51	U-UNK	carbamazepine
7	52	52	O	,
8	54	62	O	XXXXXXXX
9	64	66	O	may
10	68	73	O	reduce
11	75	77	O	the
12	79	85	O	thyroid
13	87	94	O	function
14	96	97	O	as
15	99	101	O	has
16	103	106	O	been
17	108	115	O	reported
18	117	120	O	with
19	122	126	O	other
20	128	142	U-UNK	anticonvulsants
NULL

Carbamazepine	DDI-DrugBank.d94.s16	NO_SECTION	NO_SETID	18
Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.
1	0	11	O	Additionally
2	12	12	O	,
3	14	17	B-DYN	anti
4	19	26	I-DYN	malarial
5	28	32	L-DYN	drugs
6	33	33	O	,
7	35	38	O	such
8	40	41	O	as
9	43	53	U-DYN	chloroquine
10	55	57	O	and
11	59	68	U-DYN	mefloquine
12	69	69	O	,
13	71	73	O	may
14	75	84	O	antagonize
15	86	88	O	the
16	90	97	O	activity
17	99	100	O	of
18	102	114	O	XXXXXXXX
NULL

Carbamazepine	DDI-DrugBank.d94.s17	NO_SECTION	NO_SETID	42
Thus if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with EQUETROTM, it is reasonable to expect that a dose adjustment may be necessary.
1	0	3	O	Thus
2	5	6	O	if
3	8	8	O	a
4	10	16	O	patient
5	18	20	O	has
6	22	25	O	been
7	27	34	O	titrated
8	36	37	O	to
9	39	39	O	a
10	41	46	O	stable
11	48	53	O	dosage
12	55	56	O	on
13	58	60	O	one
14	62	63	O	of
15	65	67	O	the
16	69	74	O	agents
17	76	77	O	in
18	79	82	O	this
19	84	91	O	category
20	92	92	O	,
21	94	96	O	and
22	98	101	O	then
23	103	108	O	begins
24	110	110	O	a
25	112	117	O	course
26	119	120	O	of
27	122	130	O	treatment
28	132	135	O	with
29	137	145	O	XXXXXXXX
30	146	146	O	,
31	148	149	O	it
32	151	152	O	is
33	154	163	O	reasonable
34	165	166	O	to
35	168	173	O	expect
36	175	178	O	that
37	180	180	O	a
38	182	185	O	dose
39	187	196	O	adjustment
40	198	200	O	may
41	202	203	O	be
42	205	213	O	necessary
NULL

Carbamazepine	DDI-DrugBank.d94.s18	NO_SECTION	NO_SETID	22
Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	its
4	15	21	O	primary
5	23	25	O	CNS
6	27	32	O	effect
7	33	33	O	,
8	35	41	O	caution
9	43	48	O	should
10	50	51	O	be
11	53	56	O	used
12	58	61	O	when
13	63	71	O	XXXXXXXX
14	73	74	O	is
15	76	80	O	taken
16	82	85	O	with
17	87	91	O	other
18	93	101	B-DYN	centrally
19	103	108	I-DYN	acting
20	110	114	L-DYN	drugs
21	116	118	O	and
22	120	126	U-DYN	alcohol
NULL

Carbenicillin	DDI-DrugBank.d545.s0	NO_SECTION	NO_SETID	16
Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.
1	0	8	O	XXXXXXXX
2	11	23	B-UNK	carbenicillin
3	25	31	I-UNK	indanyl
4	33	38	L-UNK	sodium
5	41	45	O	blood
6	47	52	O	levels
7	54	56	O	may
8	58	59	O	be
9	61	69	O	increased
10	71	73	O	and
11	75	83	O	prolonged
12	85	86	O	by
13	88	97	O	concurrent
14	99	112	O	administration
15	114	115	O	of
16	117	126	U-KIN	probenecid
NULL

Carbidopa	DDI-DrugBank.d47.s0	NO_SECTION	NO_SETID	22
Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with levodopa or carbidopa-levodopa combination products.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	35	O	the
7	37	45	O	following
8	47	51	O	drugs
9	53	55	O	are
10	57	68	O	administered
11	70	82	O	concomitantly
12	84	87	O	with
13	89	95	O	XXXXXXXX
14	98	106	U-UNK	Carbidopa
15	109	113	O	given
16	115	118	O	with
17	120	127	U-UNK	levodopa
18	129	130	O	or
19	132	140	U-UNK	carbidopa
20	142	149	U-UNK	levodopa
21	151	161	O	combination
22	163	170	O	products
NULL

Carbidopa	DDI-DrugBank.d47.s1	NO_SECTION	NO_SETID	9
For patients receiving monoamine oxidase inhibitors, see CONTRAINDICATIONS.
1	0	2	O	For
2	4	11	O	patients
3	13	21	O	receiving
4	23	31	B-UNK	monoamine
5	33	39	I-UNK	oxidase
6	41	50	L-UNK	inhibitors
7	51	51	O	,
8	53	55	O	see
9	57	73	O	CONTRAINDICATIONS
NULL

Carbidopa	DDI-DrugBank.d47.s2	NO_SECTION	NO_SETID	20
Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
1	0	7	B-UNK	Dopamine
2	9	10	I-UNK	D2
3	12	19	I-UNK	receptor
4	21	31	L-UNK	antagonists
5	34	36	O	e.g
6	38	38	O	,
7	40	53	U-UNK	phenothiazines
8	54	54	O	,
9	56	69	U-UNK	butyrophenones
10	70	70	O	,
11	72	82	U-UNK	risperidone
12	85	87	O	and
13	89	97	U-UNK	isoniazid
14	99	101	O	may
15	103	108	O	reduce
16	110	112	O	the
17	114	124	O	therapeutic
18	126	132	O	effects
19	134	135	O	of
20	137	144	U-UNK	levodopa
NULL

Carbidopa	DDI-DrugBank.d47.s3	NO_SECTION	NO_SETID	21
In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	15	O	the
5	17	26	O	beneficial
6	28	34	O	effects
7	36	37	O	of
8	39	46	U-UNK	levodopa
9	48	49	O	in
10	51	60	O	Parkinsons
11	62	68	O	disease
12	70	73	O	have
13	75	78	O	been
14	80	87	O	reported
15	89	90	O	to
16	92	93	O	be
17	95	102	O	reversed
18	104	105	O	by
19	107	115	U-UNK	phenytoin
20	117	119	O	and
21	121	130	U-UNK	papaverine
NULL

Carbidopa	DDI-DrugBank.d47.s4	NO_SECTION	NO_SETID	22
Patients taking these drugs with LODOSYN and levodopa or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.
1	0	7	O	Patients
2	9	14	O	taking
3	16	20	O	these
4	22	26	O	drugs
5	28	31	O	with
6	33	39	O	XXXXXXXX
7	41	43	O	and
8	45	52	U-UNK	levodopa
9	54	55	O	or
10	57	65	U-UNK	carbidopa
11	67	74	U-UNK	levodopa
12	76	86	O	combination
13	88	95	O	products
14	97	102	O	should
15	104	105	O	be
16	107	115	O	carefully
17	117	124	O	observed
18	126	128	O	for
19	130	133	O	loss
20	135	136	O	of
21	138	148	O	therapeutic
22	150	157	O	response
NULL

Carbidopa	DDI-DrugBank.d47.s5	NO_SECTION	NO_SETID	10
Iron salts may reduce the bioavailability of carbidopa and levodopa.
1	0	3	U-KIN	Iron
2	5	9	O	salts
3	11	13	O	may
4	15	20	O	reduce
5	22	24	O	the
6	26	40	O	bioavailability
7	42	43	O	of
8	45	53	O	XXXXXXXX
9	55	57	O	and
10	59	66	U-UNK	levodopa
NULL

Carbidopa	DDI-DrugBank.d47.s6	NO_SECTION	NO_SETID	5
The clinical relevance is unclear.
1	0	2	O	The
2	4	11	O	clinical
3	13	21	O	relevance
4	23	24	O	is
5	26	32	O	unclear
NULL

Carbidopa	DDI-DrugBank.d47.s7	NO_SECTION	NO_SETID	26
Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
1	0	7	O	Although
2	9	22	U-UNK	metoclopramide
3	24	26	O	may
4	28	35	O	increase
5	37	39	O	the
6	41	55	O	bioavailability
7	57	58	O	of
8	60	67	U-UNK	levodopa
9	69	70	O	by
10	72	81	O	increasing
11	83	89	O	gastric
12	91	98	O	emptying
13	99	99	O	,
14	101	114	U-UNK	metoclopramide
15	116	118	O	may
16	120	123	O	also
17	125	133	O	adversely
18	135	140	O	affect
19	142	148	O	disease
20	150	156	O	control
21	158	159	O	by
22	161	163	O	its
23	165	172	O	dopamine
24	174	181	O	receptor
25	183	194	O	antagonistic
26	196	205	O	properties
NULL

Carbimazole	DDI-DrugBank.d213.s0	NO_SECTION	NO_SETID	21
Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
1	0	5	U-DYN	Iodine
2	7	8	O	or
3	10	15	U-UNK	iodine
4	17	22	O	excess
5	24	26	O	may
6	28	35	O	decrease
7	37	39	O	the
8	41	46	O	effect
9	48	49	O	of
10	51	61	O	XXXXXXXX
11	62	62	O	,
12	64	66	O	and
13	68	69	O	an
14	71	76	U-DYN	iodine
15	78	87	O	deficiency
16	89	91	O	can
17	93	100	O	increase
18	102	104	O	the
19	106	111	O	effect
20	113	114	O	of
21	116	126	O	XXXXXXXX
NULL

Carbimazole	DDI-DrugBank.d213.s1	NO_SECTION	NO_SETID	13
Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.
1	0	4	O	Serum
2	6	18	O	concentration
3	20	21	O	of
4	23	29	U-UNK	digoxin
5	31	33	O	and
6	35	43	U-UNK	digitoxin
7	45	47	O	may
8	49	56	O	increase
9	58	61	O	when
10	63	70	O	patients
11	72	75	O	take
12	77	87	B-UNK	antithyroid
13	89	94	L-UNK	agents
NULL

Carbimazole	DDI-DrugBank.d213.s2	NO_SECTION	NO_SETID	12
A decrease of the dosage may be necessary when patient becomes euthyroid.
1	0	0	O	A
2	2	9	O	decrease
3	11	12	O	of
4	14	16	O	the
5	18	23	O	dosage
6	25	27	O	may
7	29	30	O	be
8	32	40	O	necessary
9	42	45	O	when
10	47	53	O	patient
11	55	61	O	becomes
12	63	71	O	euthyroid
NULL

Carbimazole	DDI-DrugBank.d213.s3	NO_SECTION	NO_SETID	26
Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.
1	0	10	B-UNK	Antithyroid
2	12	17	L-UNK	agents
3	19	21	O	may
4	23	30	O	decrease
5	32	40	O	thyroidal
6	42	47	O	uptake
7	49	50	O	of
8	52	57	B-UNK	sodium
9	59	64	I-UNK	iodide
10	66	69	L-UNK	I131
11	70	70	O	,
12	72	72	O	a
13	74	80	O	rebound
14	82	83	O	in
15	85	90	O	uptake
16	92	94	O	may
17	96	100	O	occur
18	102	103	O	up
19	105	106	O	to
20	108	108	O	5
21	110	113	O	days
22	115	119	O	after
23	121	126	O	sudden
24	128	137	O	withdrawal
25	139	140	O	of
26	142	152	O	XXXXXXXX
NULL

Carbimazole	DDI-DrugBank.d213.s4	NO_SECTION	NO_SETID	16
Patients response to oral anticoagulants may be affected by his/her thyroid and metabolic status.
1	0	7	O	Patients
2	9	16	O	response
3	18	19	O	to
4	21	24	O	oral
5	26	39	U-UNK	anticoagulants
6	41	43	O	may
7	45	46	O	be
8	48	55	O	affected
9	57	58	O	by
10	60	62	O	his
11	63	63	O	/
12	64	66	O	her
13	68	74	O	thyroid
14	76	78	O	and
15	80	88	O	metabolic
16	90	95	O	status
NULL

Carbimazole	DDI-DrugBank.d213.s5	NO_SECTION	NO_SETID	13
An evaluation of prothrombin time and an adjustment of anticoagulant dosage are recommended
1	0	1	O	An
2	3	12	O	evaluation
3	14	15	O	of
4	17	27	O	prothrombin
5	29	32	O	time
6	34	36	O	and
7	38	39	O	an
8	41	50	O	adjustment
9	52	53	O	of
10	55	67	U-UNK	anticoagulant
11	69	74	O	dosage
12	76	78	O	are
13	80	90	O	recommended
NULL

Carbinoxamine	DDI-DrugBank.d389.s0	NO_SECTION	NO_SETID	17
Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
1	0	13	U-UNK	Antihistamines
2	15	17	O	may
3	19	25	O	enhance
4	27	29	O	the
5	31	37	O	effects
6	39	40	O	of
7	42	50	B-UNK	tricyclic
8	52	66	L-UNK	antidepressants
9	67	67	O	,
10	69	80	U-UNK	barbiturates
11	81	81	O	,
12	83	89	U-UNK	alcohol
13	90	90	O	,
14	92	94	O	and
15	96	100	O	other
16	102	104	B-UNK	CNS
17	106	116	L-UNK	depressants
NULL

Carbinoxamine	DDI-DrugBank.d389.s1	NO_SECTION	NO_SETID	10
MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
1	0	2	B-UNK	MAO
2	4	13	L-UNK	inhibitors
3	15	21	O	prolong
4	23	25	O	and
5	27	35	O	intensify
6	37	39	O	the
7	41	55	O	anticholinergic
8	57	63	O	effects
9	65	66	O	of
10	68	81	U-UNK	antihistamines
NULL

Carbinoxamine	DDI-DrugBank.d389.s2	NO_SECTION	NO_SETID	16
Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.
1	0	14	B-UNK	Sympathomimetic
2	16	21	L-UNK	amines
3	23	25	O	may
4	27	32	O	reduce
5	34	36	O	the
6	38	53	O	antihypertensive
7	55	61	O	effects
8	63	64	O	of
9	66	74	U-UNK	reserpine
10	75	75	O	,
11	77	84	B-UNK	veratrum
12	86	94	L-UNK	alkaloids
13	95	95	O	,
14	97	106	U-UNK	methyldopa
15	108	110	O	and
16	112	123	U-UNK	mecamylamine
NULL

Carbinoxamine	DDI-DrugBank.d389.s3	NO_SECTION	NO_SETID	12
Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.
1	0	6	O	Effects
2	8	9	O	of
3	11	26	U-UNK	sympathomimetics
4	28	30	O	are
5	32	40	O	increased
6	42	45	O	with
7	47	49	B-UNK	MAO
8	51	60	L-UNK	inhibitors
9	62	64	O	and
10	66	69	B-UNK	beta
11	71	80	I-UNK	adrenergic
12	82	89	L-UNK	blockers
NULL

Carboplatin	DDI-DrugBank.d520.s0	NO_SECTION	NO_SETID	11
The renal effects of nephrotoxic compounds may be potentiated by Carboplatin.
1	0	2	O	The
2	4	8	O	renal
3	10	16	O	effects
4	18	19	O	of
5	21	31	O	nephrotoxic
6	33	41	O	compounds
7	43	45	O	may
8	47	48	O	be
9	50	60	O	potentiated
10	62	63	O	by
11	65	75	O	XXXXXXXX
NULL

Carboprost Tromethamine	DDI-DrugBank.d23.s0	NO_SECTION	NO_SETID	9
HEMABATE may augment the activity of other oxytocic agents.
1	0	7	O	XXXXXXXX
2	9	11	O	may
3	13	19	O	augment
4	21	23	O	the
5	25	32	O	activity
6	34	35	O	of
7	37	41	O	other
8	43	50	B-DYN	oxytocic
9	52	57	L-DYN	agents
NULL

Carboprost Tromethamine	DDI-DrugBank.d23.s1	NO_SECTION	NO_SETID	9
Concomitant use with other oxytocic agents is not recommended
1	0	10	O	Concomitant
2	12	14	O	use
3	16	19	O	with
4	21	25	O	other
5	27	34	B-UNK	oxytocic
6	36	41	L-UNK	agents
7	43	44	O	is
8	46	48	O	not
9	50	60	O	recommended
NULL

Carteolol	DDI-DrugBank.d502.s0	NO_SECTION	NO_SETID	28
Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.
1	0	7	O	XXXXXXXX
2	9	14	O	should
3	16	17	O	be
4	19	22	O	used
5	24	27	O	with
6	29	35	O	caution
7	37	38	O	in
8	40	47	O	patients
9	49	51	O	who
10	53	55	O	are
11	57	65	O	receiving
12	67	67	O	a
13	69	72	B-DYN	beta
14	74	83	I-DYN	adrenergic
15	85	92	I-DYN	blocking
16	94	98	L-DYN	agent
17	100	105	O	orally
18	107	113	O	because
19	115	116	O	of
20	118	120	O	the
21	122	130	O	potential
22	132	134	O	for
23	136	143	O	additive
24	145	151	O	effects
25	153	154	O	on
26	156	163	O	systemic
27	165	168	O	beta
28	170	177	O	blockade
NULL

Carteolol	DDI-DrugBank.d502.s1	NO_SECTION	NO_SETID	49
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
1	0	4	O	Close
2	6	16	O	observation
3	18	19	O	of
4	21	23	O	the
5	25	31	O	patient
6	33	34	O	is
7	36	46	O	recommended
8	48	51	O	when
9	53	53	O	a
10	55	58	B-UNK	beta
11	60	66	L-UNK	blocker
12	68	69	O	is
13	71	82	O	administered
14	84	85	O	to
15	87	94	O	patients
16	96	104	O	receiving
17	106	118	O	catecholamine
18	120	128	O	depleting
19	130	134	O	drugs
20	136	139	O	such
21	141	142	O	as
22	144	152	U-UNK	reserpine
23	153	153	O	,
24	155	161	O	because
25	163	164	O	of
26	166	173	O	possible
27	175	182	O	additive
28	184	190	O	effects
29	192	194	O	and
30	196	198	O	the
31	200	209	O	production
32	211	212	O	of
33	214	224	O	hypotension
34	226	228	O	and
35	229	229	O	/
36	230	231	O	or
37	233	238	O	marked
38	240	250	O	bradycardia
39	251	251	O	,
40	253	257	O	which
41	259	261	O	may
42	263	269	O	produce
43	271	277	O	vertigo
44	278	278	O	,
45	280	286	O	syncope
46	287	287	O	,
47	289	290	O	or
48	292	299	O	postural
49	301	311	O	hypotension
NULL

Carvedilol	DDI-DrugBank.d269.s0	NO_SECTION	NO_SETID	3
Inhibitors of CYP2D6;
1	0	9	O	Inhibitors
2	11	12	O	of
3	14	19	O	CYP2D6
NULL

Carvedilol	DDI-DrugBank.d269.s1	NO_SECTION	NO_SETID	44
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
1	0	3	O	poor
2	5	16	O	metabolizers
3	18	19	O	of
4	21	31	U-UNK	debrisoquin
5	32	32	O	:
6	34	45	O	Interactions
7	47	48	O	of
8	50	59	O	XXXXXXXX
9	61	64	O	with
10	66	71	O	strong
11	73	82	O	inhibitors
12	84	85	O	of
13	87	92	O	CYP2D6
14	95	98	O	such
15	100	101	O	as
16	103	111	U-DYN	quinidine
17	112	112	O	,
18	114	123	U-DYN	fluoxetine
19	124	124	O	,
20	126	135	U-DYN	paroxetine
21	136	136	O	,
22	138	140	O	and
23	142	152	U-DYN	propafenone
24	155	158	O	have
25	160	162	O	not
26	164	167	O	been
27	169	175	O	studied
28	176	176	O	,
29	178	180	O	but
30	182	186	O	these
31	188	192	O	drugs
32	194	198	O	would
33	200	201	O	be
34	203	210	O	expected
35	212	213	O	to
36	215	222	O	increase
37	224	228	O	blood
38	230	235	O	levels
39	237	238	O	of
40	240	242	O	the
41	244	246	O	R(+
42	249	258	O	enantiomer
43	260	261	O	of
44	263	272	O	XXXXXXXX
NULL

Carvedilol	DDI-DrugBank.d269.s2	NO_SECTION	NO_SETID	38
Retrospective analysis of side effects in clinical trials showed that poor 2D6 metabolizers had a higher rate of dizziness during up-titration, presumably resulting from vasodilating effects of the higher concentrations of the a-blocking R(+) enantiomer.
1	0	12	O	Retrospective
2	14	21	O	analysis
3	23	24	O	of
4	26	29	O	side
5	31	37	O	effects
6	39	40	O	in
7	42	49	O	clinical
8	51	56	O	trials
9	58	63	O	showed
10	65	68	O	that
11	70	73	O	poor
12	75	77	O	2D6
13	79	90	O	metabolizers
14	92	94	O	had
15	96	96	O	a
16	98	103	O	higher
17	105	108	O	rate
18	110	111	O	of
19	113	121	O	dizziness
20	123	128	O	during
21	130	131	O	up
22	133	141	O	titration
23	142	142	O	,
24	144	153	O	presumably
25	155	163	O	resulting
26	165	168	O	from
27	170	181	O	vasodilating
28	183	189	O	effects
29	191	192	O	of
30	194	196	O	the
31	198	203	O	higher
32	205	218	O	concentrations
33	220	221	O	of
34	223	225	O	the
35	227	227	O	a
36	229	236	O	blocking
37	238	240	O	R(+
38	243	252	O	enantiomer
NULL

Carvedilol	DDI-DrugBank.d269.s3	NO_SECTION	NO_SETID	39
Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.
1	0	12	O	Catecholamine
2	14	22	O	depleting
3	24	29	O	Agents
4	30	30	O	:
5	32	39	O	Patients
6	41	46	O	taking
7	48	51	O	both
8	53	58	B-UNK	agents
9	60	63	I-UNK	with
10	65	65	I-UNK	b
11	67	74	I-UNK	blocking
12	76	85	L-UNK	properties
13	87	89	O	and
14	91	91	O	a
15	93	96	O	drug
16	98	101	O	that
17	103	105	O	can
18	107	113	O	deplete
19	115	128	O	catecholamines
20	131	133	O	e.g
21	135	135	O	,
22	137	145	U-UNK	reserpine
23	147	149	O	and
24	151	159	B-UNK	monoamine
25	161	167	I-UNK	oxidase
26	169	178	L-UNK	inhibitors
27	181	186	O	should
28	188	189	O	be
29	191	198	O	observed
30	200	206	O	closely
31	208	210	O	for
32	212	216	O	signs
33	218	219	O	of
34	221	231	O	hypotension
35	233	235	O	and
36	236	236	O	/
37	237	238	O	or
38	240	245	O	severe
39	247	257	O	bradycardia
NULL

Carvedilol	DDI-DrugBank.d269.s4	NO_SECTION	NO_SETID	21
Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.
1	0	8	U-UNK	Clonidine
2	9	9	O	:
3	11	21	O	Concomitant
4	23	36	O	administration
5	38	39	O	of
6	41	49	U-UNK	clonidine
7	51	54	O	with
8	56	61	B-UNK	agents
9	63	66	I-UNK	with
10	68	68	I-UNK	b
11	70	77	I-UNK	blocking
12	79	88	L-UNK	properties
13	90	92	O	may
14	94	103	O	potentiate
15	105	109	O	blood
16	111	118	O	pressure
17	121	123	O	and
18	125	129	O	heart
19	131	134	O	rate
20	136	143	O	lowering
21	145	151	O	effects
NULL

Carvedilol	DDI-DrugBank.d269.s5	NO_SECTION	NO_SETID	24
When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.
1	0	3	O	When
2	5	15	O	concomitant
3	17	25	O	treatment
4	27	30	O	with
5	32	37	B-UNK	agents
6	39	42	I-UNK	with
7	44	44	I-UNK	b
8	46	53	I-UNK	blocking
9	55	64	L-UNK	properties
10	66	68	O	and
11	70	78	U-UNK	clonidine
12	80	81	O	is
13	83	84	O	to
14	86	87	O	be
15	89	98	O	terminated
16	99	99	O	,
17	101	103	O	the
18	105	105	B-UNK	b
19	107	114	I-UNK	blocking
20	116	120	L-UNK	agent
21	122	127	O	should
22	129	130	O	be
23	132	143	O	discontinued
24	145	149	O	first
NULL

Carvedilol	DDI-DrugBank.d269.s6	NO_SECTION	NO_SETID	14
Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage.
1	0	8	U-UNK	Clonidine
2	10	16	O	therapy
3	18	20	O	can
4	22	25	O	then
5	27	28	O	be
6	30	41	O	discontinued
7	43	49	O	several
8	51	54	O	days
9	56	60	O	later
10	62	63	O	by
11	65	73	O	gradually
12	75	84	O	decreasing
13	86	88	O	the
14	90	95	O	dosage
NULL

Carvedilol	DDI-DrugBank.d269.s7	NO_SECTION	NO_SETID	26
Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.
1	0	11	U-UNK	Cyclosporine
2	12	12	O	:
3	14	19	O	Modest
4	21	29	O	increases
5	31	32	O	in
6	34	37	O	mean
7	39	44	O	trough
8	46	57	U-KIN	cyclosporine
9	59	72	O	concentrations
10	74	77	O	were
11	79	86	O	observed
12	88	96	O	following
13	98	107	O	initiation
14	109	110	O	of
15	112	121	O	XXXXXXXX
16	123	131	O	treatment
17	133	134	O	in
18	136	137	O	21
19	139	143	O	renal
20	145	154	O	transplant
21	156	163	O	patients
22	165	173	O	suffering
23	175	178	O	from
24	180	186	O	chronic
25	188	195	O	vascular
26	197	205	O	rejection
NULL

Carvedilol	DDI-DrugBank.d269.s8	NO_SECTION	NO_SETID	33
In about 30% of patients, the dose of cyclosporine had to be reduced in order to maintain cyclosporine concentrations within the therapeutic range, while in the remainder no adjustment was needed.
1	0	1	O	In
2	3	7	O	about
3	9	11	O	30%
4	13	14	O	of
5	16	23	O	patients
6	24	24	O	,
7	26	28	O	the
8	30	33	O	dose
9	35	36	O	of
10	38	49	U-UNK	cyclosporine
11	51	53	O	had
12	55	56	O	to
13	58	59	O	be
14	61	67	O	reduced
15	69	70	O	in
16	72	76	O	order
17	78	79	O	to
18	81	88	O	maintain
19	90	101	U-UNK	cyclosporine
20	103	116	O	concentrations
21	118	123	O	within
22	125	127	O	the
23	129	139	O	therapeutic
24	141	145	O	range
25	146	146	O	,
26	148	152	O	while
27	154	155	O	in
28	157	159	O	the
29	161	169	O	remainder
30	171	172	O	no
31	174	183	O	adjustment
32	185	187	O	was
33	189	194	O	needed
NULL

Carvedilol	DDI-DrugBank.d269.s9	NO_SECTION	NO_SETID	18
On the average for the group, the dose of cyclosporine was reduced about 20% in these patients.
1	0	1	O	On
2	3	5	O	the
3	7	13	O	average
4	15	17	O	for
5	19	21	O	the
6	23	27	O	group
7	28	28	O	,
8	30	32	O	the
9	34	37	O	dose
10	39	40	O	of
11	42	53	U-UNK	cyclosporine
12	55	57	O	was
13	59	65	O	reduced
14	67	71	O	about
15	73	75	O	20%
16	77	78	O	in
17	80	84	O	these
18	86	93	O	patients
NULL

Carvedilol	DDI-DrugBank.d269.s10	NO_SECTION	NO_SETID	35
Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.
1	0	2	O	Due
2	4	5	O	to
3	7	10	O	wide
4	12	26	O	interindividual
5	28	38	O	variability
6	40	41	O	in
7	43	45	O	the
8	47	50	O	dose
9	52	61	O	adjustment
10	63	70	O	required
11	71	71	O	,
12	73	74	O	it
13	76	77	O	is
14	79	89	O	recommended
15	91	94	O	that
16	96	107	U-DYN	cyclosporine
17	109	122	O	concentrations
18	124	125	O	be
19	127	135	O	monitored
20	137	143	O	closely
21	145	149	O	after
22	151	160	O	initiation
23	162	163	O	of
24	165	174	O	XXXXXXXX
25	176	182	O	therapy
26	184	186	O	and
27	188	191	O	that
28	193	195	O	the
29	197	200	O	dose
30	202	203	O	of
31	205	216	U-DYN	cyclosporine
32	218	219	O	be
33	221	228	O	adjusted
34	230	231	O	as
35	233	243	O	appropriate
NULL

Carvedilol	DDI-DrugBank.d269.s11	NO_SECTION	NO_SETID	16
Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	15	U-UNK	Digoxin
4	17	30	O	concentrations
5	32	34	O	are
6	36	44	O	increased
7	46	47	O	by
8	49	53	O	about
9	55	57	O	15%
10	59	62	O	when
11	64	70	U-KIN	digoxin
12	72	74	O	and
13	76	85	O	XXXXXXXX
14	87	89	O	are
15	91	102	O	administered
16	104	116	O	concomitantly
NULL

Carvedilol	DDI-DrugBank.d269.s12	NO_SECTION	NO_SETID	7
Both digoxin and COREG slow AV conduction.
1	0	3	O	Both
2	5	11	U-DYN	digoxin
3	13	15	O	and
4	17	21	O	XXXXXXXX
5	23	26	O	slow
6	28	29	O	AV
7	31	40	O	conduction
NULL

Carvedilol	DDI-DrugBank.d269.s13	NO_SECTION	NO_SETID	16
Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.
1	0	8	O	Therefore
2	9	9	O	,
3	11	19	O	increased
4	21	30	O	monitoring
5	32	33	O	of
6	35	41	U-DYN	digoxin
7	43	44	O	is
8	46	56	O	recommended
9	58	61	O	when
10	63	72	O	initiating
11	73	73	O	,
12	75	83	O	adjusting
13	84	84	O	,
14	86	87	O	or
15	89	101	O	discontinuing
16	103	107	O	XXXXXXXX
NULL

Carvedilol	DDI-DrugBank.d269.s14	NO_SECTION	NO_SETID	16
Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.
1	0	7	O	Inducers
2	9	11	O	and
3	13	22	O	Inhibitors
4	24	25	O	of
5	27	33	O	Hepatic
6	35	44	O	Metabolism
7	45	45	O	:
8	47	54	U-KIN	Rifampin
9	56	62	O	reduced
10	64	69	O	plasma
11	71	84	O	concentrations
12	86	87	O	of
13	89	98	O	XXXXXXXX
14	100	101	O	by
15	103	107	O	about
16	109	111	O	70%
NULL

Carvedilol	DDI-DrugBank.d269.s15	NO_SECTION	NO_SETID	12
Cimetidine increased AUC by about 30% but caused no change in Cmax.
1	0	9	U-UNK	Cimetidine
2	11	19	O	increased
3	21	23	O	AUC
4	25	26	O	by
5	28	32	O	about
6	34	36	O	30%
7	38	40	O	but
8	42	47	O	caused
9	49	50	O	no
10	52	57	O	change
11	59	60	O	in
12	62	65	O	Cmax
NULL

Carvedilol	DDI-DrugBank.d269.s16	NO_SECTION	NO_SETID	23
Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.
1	0	6	B-UNK	Calcium
2	8	14	I-UNK	Channel
3	16	23	L-UNK	Blockers
4	24	24	O	:
5	26	33	O	Isolated
6	35	39	O	cases
7	41	42	O	of
8	44	53	O	conduction
9	55	65	O	disturbance
10	68	73	O	rarely
11	75	78	O	with
12	80	90	O	hemodynamic
13	92	101	O	compromise
14	104	107	O	have
15	109	112	O	been
16	114	121	O	observed
17	123	126	O	when
18	128	132	O	XXXXXXXX
19	134	135	O	is
20	137	138	O	co
21	140	151	O	administered
22	153	156	O	with
23	158	166	U-DYN	diltiazem
NULL

Carvedilol	DDI-DrugBank.d269.s17	NO_SECTION	NO_SETID	37
As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	19	B-UNK	agents
5	21	24	I-UNK	with
6	26	26	I-UNK	b
7	28	35	I-UNK	blocking
8	37	46	L-UNK	properties
9	47	47	O	,
10	49	50	O	if
11	52	56	O	XXXXXXXX
12	58	59	O	is
13	61	62	O	to
14	64	65	O	be
15	67	78	O	administered
16	80	85	O	orally
17	87	90	O	with
18	92	98	B-UNK	calcium
19	100	106	I-UNK	channel
20	108	115	L-UNK	blockers
21	117	118	O	of
22	120	122	O	the
23	124	132	U-DYN	verapamil
24	134	135	O	or
25	137	145	U-DYN	diltiazem
26	147	150	O	type
27	151	151	O	,
28	153	154	O	it
29	156	157	O	is
30	159	169	O	recommended
31	171	174	O	that
32	176	178	O	ECG
33	180	182	O	and
34	184	188	O	blood
35	190	197	O	pressure
36	199	200	O	be
37	202	210	O	monitored
NULL

Carvedilol	DDI-DrugBank.d269.s18	NO_SECTION	NO_SETID	22
Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.
1	0	6	U-UNK	Insulin
2	8	9	O	or
3	11	14	O	Oral
4	16	28	U-UNK	Hypoglycemics
5	29	29	O	:
6	31	36	B-UNK	Agents
7	38	41	I-UNK	with
8	43	43	I-UNK	b
9	45	52	I-UNK	blocking
10	54	63	L-UNK	properties
11	65	67	O	may
12	69	75	O	enhance
13	77	79	O	the
14	81	85	O	blood
15	87	91	O	sugar
16	93	100	O	reducing
17	102	107	O	effect
18	109	110	O	of
19	112	118	U-UNK	insulin
20	120	122	O	and
21	124	127	O	oral
22	129	141	U-UNK	hypoglycemics
NULL

Carvedilol	DDI-DrugBank.d269.s19	NO_SECTION	NO_SETID	17
Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring of blood glucose is recommended.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	in
4	14	21	O	patients
5	23	28	O	taking
6	30	36	U-UNK	insulin
7	38	39	O	or
8	41	44	O	oral
9	46	58	U-UNK	hypoglycemics
10	59	59	O	,
11	61	67	O	regular
12	69	78	O	monitoring
13	80	81	O	of
14	83	87	O	blood
15	89	95	O	glucose
16	97	98	O	is
17	100	110	O	recommended
NULL

Caspofungin	DDI-DrugBank.d350.s0	NO_SECTION	NO_SETID	20
Studies in vitro show that caspofungin acetate is not an inhibitor of any enzyme in the cytochrome P450 (CYP) system.
1	0	6	O	Studies
2	8	9	O	in
3	11	15	O	vitro
4	17	20	O	show
5	22	25	O	that
6	27	37	O	XXXXXXXX
7	39	45	O	acetate
8	47	48	O	is
9	50	52	O	not
10	54	55	O	an
11	57	65	O	inhibitor
12	67	68	O	of
13	70	72	O	any
14	74	79	O	enzyme
15	81	82	O	in
16	84	86	O	the
17	88	97	O	cytochrome
18	99	102	O	P450
19	105	107	O	CYP
20	110	115	O	system
NULL

Caspofungin	DDI-DrugBank.d350.s1	NO_SECTION	NO_SETID	14
In clinical studies, caspofungin did not induce the CYP3A4 metabolism of other drugs.
1	0	1	O	In
2	3	10	O	clinical
3	12	18	O	studies
4	19	19	O	,
5	21	31	O	XXXXXXXX
6	33	35	O	did
7	37	39	O	not
8	41	46	O	induce
9	48	50	O	the
10	52	57	O	CYP3A4
11	59	68	O	metabolism
12	70	71	O	of
13	73	77	O	other
14	79	83	O	drugs
NULL

Caspofungin	DDI-DrugBank.d350.s2	NO_SECTION	NO_SETID	17
Caspofungin is not a substrate for P-glycoprotein and is a poor substrate for cytochrome P450 enzymes.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	17	O	not
4	19	19	O	a
5	21	29	O	substrate
6	31	33	O	for
7	35	35	O	P
8	37	48	O	glycoprotein
9	50	52	O	and
10	54	55	O	is
11	57	57	O	a
12	59	62	O	poor
13	64	72	O	substrate
14	74	76	O	for
15	78	87	O	cytochrome
16	89	92	O	P450
17	94	100	O	enzymes
NULL

Caspofungin	DDI-DrugBank.d350.s3	NO_SECTION	NO_SETID	26
Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.
1	0	7	O	Clinical
2	9	15	O	studies
3	17	18	O	in
4	20	26	O	healthy
5	28	37	O	volunteers
6	39	42	O	show
7	44	47	O	that
8	49	51	O	the
9	53	68	O	pharmacokinetics
10	70	71	O	of
11	73	80	O	XXXXXXXX
12	82	84	O	are
13	86	88	O	not
14	90	96	O	altered
15	98	99	O	by
16	101	112	U-UNK	itraconazole
17	113	113	O	,
18	115	126	B-UNK	amphotericin
19	128	128	L-UNK	B
20	129	129	O	,
21	131	143	U-UNK	mycophenolate
22	144	144	O	,
23	146	155	U-UNK	nelfinavir
24	156	156	O	,
25	158	159	O	or
26	161	170	U-UNK	tacrolimus
NULL

Caspofungin	DDI-DrugBank.d350.s4	NO_SECTION	NO_SETID	19
CANCIDAS has no effect on the pharmacokinetics of itraconazole, amphotericin B, or the active metabolite of mycophenolate.
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	14	O	no
4	16	21	O	effect
5	23	24	O	on
6	26	28	O	the
7	30	45	O	pharmacokinetics
8	47	48	O	of
9	50	61	U-UNK	itraconazole
10	62	62	O	,
11	64	75	B-UNK	amphotericin
12	77	77	L-UNK	B
13	78	78	O	,
14	80	81	O	or
15	83	85	O	the
16	87	92	O	active
17	94	103	O	metabolite
18	105	106	O	of
19	108	120	O	mycophenolate
NULL

Caspofungin	DDI-DrugBank.d350.s5	NO_SECTION	NO_SETID	68
CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
1	0	7	O	XXXXXXXX
2	9	15	O	reduced
3	17	19	O	the
4	21	25	O	blood
5	27	30	O	AUC0
6	32	33	O	12
7	35	36	O	of
8	38	47	U-KIN	tacrolimus
9	49	50	O	by
10	52	64	O	approximately
11	66	68	O	20%
12	69	69	O	,
13	71	74	O	peak
14	76	80	O	blood
15	82	94	O	concentration
16	97	100	O	Cmax
17	103	104	O	by
18	106	108	O	16%
19	109	109	O	,
20	111	113	O	and
21	115	116	O	12
22	118	121	O	hour
23	123	127	O	blood
24	129	141	O	concentration
25	144	148	O	C12hr
26	151	152	O	by
27	154	156	O	26%
28	158	159	O	in
29	161	167	O	healthy
30	169	176	O	subjects
31	178	181	O	when
32	183	192	U-UNK	tacrolimus
33	195	195	O	2
34	197	201	O	doses
35	203	204	O	of
36	206	208	O	0.1
37	210	211	O	mg
38	212	212	O	/
39	213	214	O	kg
40	216	217	O	12
41	219	223	O	hours
42	225	229	O	apart
43	232	234	O	was
44	236	247	O	administered
45	249	250	O	on
46	252	254	O	the
47	256	259	O	10th
48	261	263	O	day
49	265	266	O	of
50	268	275	O	XXXXXXXX
51	277	278	O	70
52	280	281	O	mg
53	283	287	O	daily
54	288	288	O	,
55	290	291	O	as
56	293	300	O	compared
57	302	303	O	to
58	305	311	O	results
59	313	316	O	from
60	318	318	O	a
61	320	326	O	control
62	328	333	O	period
63	335	336	O	in
64	338	342	O	which
65	344	353	U-UNK	tacrolimus
66	355	357	O	was
67	359	370	O	administered
68	372	376	O	alone
NULL

Caspofungin	DDI-DrugBank.d350.s6	NO_SECTION	NO_SETID	19
For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.
1	0	2	O	For
2	4	11	O	patients
3	13	21	O	receiving
4	23	26	O	both
5	28	36	O	therapies
6	37	37	O	,
7	39	46	O	standard
8	48	57	O	monitoring
9	59	60	O	of
10	62	71	U-UNK	tacrolimus
11	73	77	O	blood
12	79	92	O	concentrations
13	94	96	O	and
14	98	108	O	appropriate
15	110	119	U-UNK	tacrolimus
16	121	126	O	dosage
17	128	138	O	adjustments
18	140	142	O	are
19	144	154	O	recommended
NULL

Caspofungin	DDI-DrugBank.d350.s7	NO_SECTION	NO_SETID	27
In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.
1	0	1	O	In
2	3	5	O	two
3	7	14	O	clinical
4	16	22	O	studies
5	23	23	O	,
6	25	36	U-KIN	cyclosporine
7	39	41	O	one
8	43	43	O	4
9	45	46	O	mg
10	47	47	O	/
11	48	49	O	kg
12	51	54	O	dose
13	56	57	O	or
14	59	61	O	two
15	63	63	O	3
16	65	66	O	mg
17	67	67	O	/
18	68	69	O	kg
19	71	75	O	doses
20	78	86	O	increased
21	88	90	O	the
22	92	94	O	AUC
23	96	97	O	of
24	99	109	O	XXXXXXXX
25	111	112	O	by
26	114	126	O	approximately
27	128	130	O	35%
NULL

Caspofungin	DDI-DrugBank.d350.s8	NO_SECTION	NO_SETID	9
CANCIDAS did not increase the plasma levels of cyclosporine.
1	0	7	O	XXXXXXXX
2	9	11	O	did
3	13	15	O	not
4	17	24	O	increase
5	26	28	O	the
6	30	35	O	plasma
7	37	42	O	levels
8	44	45	O	of
9	47	58	U-UNK	cyclosporine
NULL

Caspofungin	DDI-DrugBank.d350.s9	NO_SECTION	NO_SETID	16
There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.
1	0	4	O	There
2	6	9	O	were
3	11	19	O	transient
4	21	29	O	increases
5	31	32	O	in
6	34	38	O	liver
7	40	42	O	ALT
8	44	46	O	and
9	48	50	O	AST
10	52	55	O	when
11	57	64	O	XXXXXXXX
12	66	68	O	and
13	70	81	U-DYN	cyclosporine
14	83	86	O	were
15	88	89	O	co
16	91	102	O	administered
NULL

Caspofungin	DDI-DrugBank.d350.s10	NO_SECTION	NO_SETID	19
A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.
1	0	0	O	A
2	2	5	O	drug
3	7	10	O	drug
4	12	22	O	interaction
5	24	28	O	study
6	30	33	O	with
7	35	42	U-KIN	rifampin
8	44	45	O	in
9	47	53	O	healthy
10	55	64	O	volunteers
11	66	68	O	has
12	70	74	O	shown
13	76	76	O	a
14	78	80	O	30%
15	82	89	O	decrease
16	91	92	O	in
17	94	104	O	XXXXXXXX
18	106	111	O	trough
19	113	126	O	concentrations
NULL

Caspofungin	DDI-DrugBank.d350.s11	NO_SECTION	NO_SETID	10
Patients on rifampin should receive 70 mg of CANCIDAS daily.
1	0	7	O	Patients
2	9	10	O	on
3	12	19	U-DYN	rifampin
4	21	26	O	should
5	28	34	O	receive
6	36	37	O	70
7	39	40	O	mg
8	42	43	O	of
9	45	52	O	XXXXXXXX
10	54	58	O	daily
NULL

Caspofungin	DDI-DrugBank.d350.s12	NO_SECTION	NO_SETID	42
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	results
5	21	24	O	from
6	26	35	O	regression
7	37	44	O	analyses
8	46	47	O	of
9	49	55	O	patient
10	57	71	O	pharmacokinetic
11	73	76	O	data
12	78	84	O	suggest
13	86	89	O	that
14	91	92	O	co
15	94	107	O	administration
16	109	110	O	of
17	112	116	O	other
18	118	125	O	inducers
19	127	128	O	of
20	130	133	O	drug
21	135	143	O	clearance
22	146	154	U-KIN	efavirenz
23	155	155	O	,
24	157	166	U-KIN	nevirapine
25	167	167	O	,
26	169	177	U-KIN	phenytoin
27	178	178	O	,
28	180	192	U-KIN	dexamethasone
29	193	193	O	,
30	195	196	O	or
31	198	210	U-KIN	carbamazepine
32	213	216	O	with
33	218	225	O	XXXXXXXX
34	227	229	O	may
35	231	236	O	result
36	238	239	O	in
37	241	250	O	clinically
38	252	261	O	meaningful
39	263	272	O	reductions
40	274	275	O	in
41	277	287	U-UNK	caspofungin
42	289	302	O	concentrations
NULL

Caspofungin	DDI-DrugBank.d350.s13	NO_SECTION	NO_SETID	15
It is not known which drug clearance mechanism involved in caspofungin disposition may be inducible.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	known
5	16	20	O	which
6	22	25	O	drug
7	27	35	O	clearance
8	37	45	O	mechanism
9	47	54	O	involved
10	56	57	O	in
11	59	69	O	XXXXXXXX
12	71	81	O	disposition
13	83	85	O	may
14	87	88	O	be
15	90	98	O	inducible
NULL

Caspofungin	DDI-DrugBank.d350.s14	NO_SECTION	NO_SETID	37
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered
1	0	3	O	When
2	5	12	O	XXXXXXXX
3	14	15	O	is
4	17	18	O	co
5	20	31	O	administered
6	33	36	O	with
7	38	45	O	inducers
8	47	48	O	of
9	50	53	O	drug
10	55	63	O	clearance
11	64	64	O	,
12	66	69	O	such
13	71	72	O	as
14	74	82	U-DYN	efavirenz
15	83	83	O	,
16	85	94	U-DYN	nevirapine
17	95	95	O	,
18	97	105	U-DYN	phenytoin
19	106	106	O	,
20	108	120	U-DYN	dexamethasone
21	121	121	O	,
22	123	124	O	or
23	126	138	U-DYN	carbamazepine
24	139	139	O	,
25	141	143	O	use
26	145	146	O	of
27	148	148	O	a
28	150	154	O	daily
29	156	159	O	dose
30	161	162	O	of
31	164	165	O	70
32	167	168	O	mg
33	170	171	O	of
34	173	180	O	XXXXXXXX
35	182	187	O	should
36	189	190	O	be
37	192	201	O	considered
NULL

Cefadroxil	DDI-DrugBank.d557.s0	NO_SECTION	NO_SETID	18
Drug/Laboratory Test Interactions Positive direct Coombs  tests have been reported during treatment with the cephalosporin antibiotics.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	41	O	Positive
7	43	48	O	direct
8	50	55	O	Coombs
9	58	62	O	tests
10	64	67	O	have
11	69	72	O	been
12	74	81	O	reported
13	83	88	O	during
14	90	98	O	treatment
15	100	103	O	with
16	105	107	O	the
17	109	121	B-UNK	cephalosporin
18	123	133	L-UNK	antibiotics
NULL

Cefadroxil	DDI-DrugBank.d557.s1	NO_SECTION	NO_SETID	49
In hematologic studies or in transfusion cross-matching procedures when anti-globulin tests are performed on the minor side or in Coombs  testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombs  test may be due to the drug.
1	0	1	O	In
2	3	13	O	hematologic
3	15	21	O	studies
4	23	24	O	or
5	26	27	O	in
6	29	39	O	transfusion
7	41	45	O	cross
8	47	54	O	matching
9	56	65	O	procedures
10	67	70	O	when
11	72	75	O	anti
12	77	84	O	globulin
13	86	90	O	tests
14	92	94	O	are
15	96	104	O	performed
16	106	107	O	on
17	109	111	O	the
18	113	117	O	minor
19	119	122	O	side
20	124	125	O	or
21	127	128	O	in
22	130	135	O	Coombs
23	138	144	O	testing
24	146	147	O	of
25	149	156	O	newborns
26	158	162	O	whose
27	164	170	O	mothers
28	172	175	O	have
29	177	184	O	received
30	186	198	B-UNK	cephalosporin
31	200	210	L-UNK	antibiotics
32	212	217	O	before
33	219	229	O	parturition
34	230	230	O	,
35	232	233	O	it
36	235	240	O	should
37	242	243	O	be
38	245	254	O	recognized
39	256	259	O	that
40	261	261	O	a
41	263	270	O	positive
42	272	277	O	Coombs
43	280	283	O	test
44	285	287	O	may
45	289	290	O	be
46	292	294	O	due
47	296	297	O	to
48	299	301	O	the
49	303	306	O	drug
NULL

Cefazolin	DDI-DrugBank.d281.s0	NO_SECTION	NO_SETID	21
Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.
1	0	9	U-UNK	Probenecid
2	11	13	O	may
3	15	22	O	decrease
4	24	28	O	renal
5	30	36	O	tubular
6	38	46	O	secretion
7	48	49	O	of
8	51	64	U-UNK	cephalosporins
9	66	69	O	when
10	71	74	O	used
11	76	87	O	concurrently
12	88	88	O	,
13	90	98	O	resulting
14	100	101	O	in
15	103	111	O	increased
16	113	115	O	and
17	117	120	O	more
18	122	130	O	prolonged
19	132	144	U-UNK	cephalosporin
20	146	150	O	blood
21	152	157	O	levels
NULL

Cefazolin	DDI-DrugBank.d281.s1	NO_SECTION	NO_SETID	36
Drug/Laboratory Test Interactions A false positive reaction for glucose in the urine may occur with Benedicts solution, Fehlings solution or with CLINITEST  tablets, but not with enzyme-based tests such as CLINISTIX .
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	34	O	A
7	36	40	O	false
8	42	49	O	positive
9	51	58	O	reaction
10	60	62	O	for
11	64	70	O	glucose
12	72	73	O	in
13	75	77	O	the
14	79	83	O	urine
15	85	87	O	may
16	89	93	O	occur
17	95	98	O	with
18	100	108	O	Benedicts
19	110	117	O	solution
20	118	118	O	,
21	120	127	O	Fehlings
22	129	136	O	solution
23	138	139	O	or
24	141	144	O	with
25	146	154	O	CLINITEST
26	157	163	O	tablets
27	164	164	O	,
28	166	168	O	but
29	170	172	O	not
30	174	177	O	with
31	179	184	O	enzyme
32	186	190	O	based
33	192	196	O	tests
34	198	201	O	such
35	203	204	O	as
36	206	214	O	CLINISTIX
NULL

Cefazolin	DDI-DrugBank.d281.s2	NO_SECTION	NO_SETID	9
Positive direct and indirect antiglobulin (Coombs) tests have occurred;
1	0	7	O	Positive
2	9	14	O	direct
3	16	18	O	and
4	20	27	O	indirect
5	29	40	O	antiglobulin
6	43	48	O	Coombs
7	51	55	O	tests
8	57	60	O	have
9	62	69	O	occurred
NULL

Cefazolin	DDI-DrugBank.d281.s3	NO_SECTION	NO_SETID	12
these may also occur in neonates whose mothers received cephalosporins before delivery.
1	0	4	O	these
2	6	8	O	may
3	10	13	O	also
4	15	19	O	occur
5	21	22	O	in
6	24	31	O	neonates
7	33	37	O	whose
8	39	45	O	mothers
9	47	54	O	received
10	56	69	U-UNK	cephalosporins
11	71	76	O	before
12	78	85	O	delivery
NULL

Cefdinir	DDI-DrugBank.d420.s0	NO_SECTION	NO_SETID	30
Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.
1	0	7	U-UNK	Antacids
2	10	17	U-UNK	aluminum
3	20	21	O	or
4	23	31	U-UNK	magnesium
5	33	42	O	containing
6	44	44	O	:
7	46	56	O	Concomitant
8	58	71	O	administration
9	73	74	O	of
10	76	78	O	300
11	80	81	O	mg
12	83	90	U-KIN	cefdinir
13	92	99	O	capsules
14	101	104	O	with
15	106	107	O	30
16	109	110	O	mL
17	112	120	O	XXXXXXXX
18	122	131	O	suspension
19	133	139	O	reduces
20	141	143	O	the
21	145	148	O	rate
22	151	154	O	Cmax
23	157	159	O	and
24	161	166	O	extent
25	169	171	O	AUC
26	174	175	O	of
27	177	186	O	absorption
28	188	189	O	by
29	191	203	O	approximately
30	205	207	O	40%
NULL

Cefdinir	DDI-DrugBank.d420.s1	NO_SECTION	NO_SETID	10
Time to reach Cmax is also prolonged by 1 hour.
1	0	3	O	Time
2	5	6	O	to
3	8	12	O	reach
4	14	17	O	Cmax
5	19	20	O	is
6	22	25	O	also
7	27	35	O	prolonged
8	37	38	O	by
9	40	40	O	1
10	42	45	O	hour
NULL

Cefdinir	DDI-DrugBank.d420.s2	NO_SECTION	NO_SETID	21
There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	23	O	significant
5	25	31	O	effects
6	33	34	O	on
7	36	43	O	XXXXXXXX
8	45	60	O	pharmacokinetics
9	62	63	O	if
10	65	67	O	the
11	69	75	U-UNK	antacid
12	77	78	O	is
13	80	91	O	administered
14	93	93	O	2
15	95	99	O	hours
16	101	106	O	before
17	108	109	O	or
18	111	111	O	2
19	113	117	O	hours
20	119	123	O	after
21	125	132	O	XXXXXXXX
NULL

Cefdinir	DDI-DrugBank.d420.s3	NO_SECTION	NO_SETID	21
If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.
1	0	1	O	If
2	3	10	U-UNK	antacids
3	12	14	O	are
4	16	23	O	required
5	25	30	O	during
6	32	38	O	XXXXXXXX
7	40	46	O	therapy
8	47	47	O	,
9	49	55	O	XXXXXXXX
10	57	62	O	should
11	64	65	O	be
12	67	71	O	taken
13	73	74	O	at
14	76	80	O	least
15	82	82	O	2
16	84	88	O	hours
17	90	95	O	before
18	97	98	O	or
19	100	104	O	after
20	106	108	O	the
21	110	116	U-DYN	antacid
NULL

Cefdinir	DDI-DrugBank.d420.s4	NO_SECTION	NO_SETID	43
Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
1	0	9	U-UNK	Probenecid
2	10	10	O	:
3	12	13	O	As
4	15	18	O	with
5	20	24	O	other
6	26	26	B-KIN	b
7	28	33	I-KIN	lactam
8	35	45	L-KIN	antibiotics
9	46	46	O	,
10	48	57	U-KIN	probenecid
11	59	66	O	inhibits
12	68	70	O	the
13	72	76	O	renal
14	78	86	O	excretion
15	88	89	O	of
16	91	98	O	XXXXXXXX
17	99	99	O	,
18	101	109	O	resulting
19	111	112	O	in
20	114	115	O	an
21	117	127	O	approximate
22	129	136	O	doubling
23	138	139	O	in
24	141	143	O	A.C
25	146	146	O	a
26	148	150	O	54%
27	152	159	O	increase
28	161	162	O	in
29	164	167	O	peak
30	169	176	O	XXXXXXXX
31	178	183	O	plasma
32	185	190	O	levels
33	191	191	O	,
34	193	195	O	and
35	197	197	O	a
36	199	201	O	50%
37	203	214	O	prolongation
38	216	217	O	in
39	219	221	O	the
40	223	230	O	apparent
41	232	242	O	elimination
42	244	247	O	half
43	249	252	O	life
NULL

Cefdinir	DDI-DrugBank.d420.s5	NO_SECTION	NO_SETID	43
Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
1	0	3	B-UNK	Iron
2	5	15	L-UNK	Supplements
3	17	19	O	and
4	21	25	O	Foods
5	27	35	O	Fortified
6	37	40	O	With
7	42	45	U-UNK	Iron
8	47	57	O	Concomitant
9	59	72	O	administration
10	74	75	O	of
11	77	84	O	XXXXXXXX
12	86	89	O	with
13	91	91	O	a
14	93	103	O	therapeutic
15	105	108	B-UNK	iron
16	110	119	L-UNK	supplement
17	121	130	O	containing
18	132	133	O	60
19	135	136	O	mg
20	138	139	O	of
21	141	149	O	elemental
22	151	154	U-KIN	iron
23	157	158	O	as
24	160	164	O	FeSO4
25	167	168	O	or
26	170	177	U-UNK	vitamins
27	179	190	O	supplemented
28	192	195	O	with
29	197	198	O	10
30	200	201	O	mg
31	203	204	O	of
32	206	214	O	elemental
33	216	219	U-KIN	iron
34	221	227	O	reduced
35	229	234	O	extent
36	236	237	O	of
37	239	248	O	absorption
38	250	251	O	by
39	253	255	O	80%
40	257	259	O	and
41	261	263	O	31%
42	264	264	O	,
43	266	277	O	respectively
NULL

Cefdinir	DDI-DrugBank.d420.s6	NO_SECTION	NO_SETID	22
If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.
1	0	1	O	If
2	3	6	B-DYN	iron
3	8	18	L-DYN	supplements
4	20	22	O	are
5	24	31	O	required
6	33	38	O	during
7	40	46	O	XXXXXXXX
8	48	54	O	therapy
9	55	55	O	,
10	57	63	O	XXXXXXXX
11	65	70	O	should
12	72	73	O	be
13	75	79	O	taken
14	81	82	O	at
15	84	88	O	least
16	90	90	O	2
17	92	96	O	hours
18	98	103	O	before
19	105	106	O	or
20	108	112	O	after
21	114	116	O	the
22	118	127	O	supplement
NULL

Cefdinir	DDI-DrugBank.d420.s7	NO_SECTION	NO_SETID	21
The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	18	O	foods
5	20	25	O	highly
6	27	35	O	fortified
7	37	40	O	with
8	42	50	O	elemental
9	52	55	U-UNK	iron
10	58	66	O	primarily
11	68	71	U-UNK	iron
12	73	81	O	fortified
13	83	91	O	breakfast
14	93	99	O	cereals
15	102	103	O	on
16	105	112	O	XXXXXXXX
17	114	123	O	absorption
18	125	127	O	has
19	129	131	O	not
20	133	136	O	been
21	138	144	O	studied
NULL

Cefdinir	DDI-DrugBank.d420.s8	NO_SECTION	NO_SETID	20
Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics.
1	0	12	O	Concomitantly
2	14	25	O	administered
3	27	30	U-UNK	iron
4	32	40	O	fortified
5	42	47	O	infant
6	49	55	O	formula
7	58	60	O	2.2
8	62	63	O	mg
9	65	73	O	elemental
10	75	78	U-UNK	iron
11	79	79	O	/
12	80	80	O	6
13	82	83	O	oz
14	86	88	O	has
15	90	91	O	no
16	93	103	O	significant
17	105	110	O	effect
18	112	113	O	on
19	115	122	O	XXXXXXXX
20	124	139	O	pharmacokinetics
NULL

Cefdinir	DDI-DrugBank.d420.s9	NO_SECTION	NO_SETID	14
Therefore, OMNICEF for Oral Suspension can be administered with iron-fortified infant formula.
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	O	XXXXXXXX
4	19	21	O	for
5	23	26	O	Oral
6	28	37	O	Suspension
7	39	41	O	can
8	43	44	O	be
9	46	57	O	administered
10	59	62	O	with
11	64	67	U-UNK	iron
12	69	77	O	fortified
13	79	84	O	infant
14	86	92	O	formula
NULL

Cefdinir	DDI-DrugBank.d420.s10	NO_SECTION	NO_SETID	16
There have been rare reports of reddish stools in patients who have received cefdinir in Japan.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	19	O	rare
5	21	27	O	reports
6	29	30	O	of
7	32	38	O	reddish
8	40	45	O	stools
9	47	48	O	in
10	50	57	O	patients
11	59	61	O	who
12	63	66	O	have
13	68	75	O	received
14	77	84	O	XXXXXXXX
15	86	87	O	in
16	89	93	O	Japan
NULL

Cefdinir	DDI-DrugBank.d420.s11	NO_SECTION	NO_SETID	24
The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.
1	0	2	O	The
2	4	10	O	reddish
3	12	16	O	color
4	18	19	O	is
5	21	23	O	due
6	25	26	O	to
7	28	30	O	the
8	32	40	O	formation
9	42	43	O	of
10	45	45	O	a
11	47	59	O	nonabsorbable
12	61	67	O	complex
13	69	75	O	between
14	77	84	O	XXXXXXXX
15	86	87	O	or
16	89	91	O	its
17	93	101	O	breakdown
18	103	110	O	products
19	112	114	O	and
20	116	119	U-KIN	iron
21	121	122	O	in
22	124	126	O	the
23	128	143	O	gastrointestinal
24	145	149	O	tract
NULL

Cefdinir	DDI-DrugBank.d420.s12	NO_SECTION	NO_SETID	27
Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	34	O	A
7	36	40	O	false
8	42	49	O	positive
9	51	58	O	reaction
10	60	62	O	for
11	64	70	O	ketones
12	72	73	O	in
13	75	77	O	the
14	79	83	O	urine
15	85	87	O	may
16	89	93	O	occur
17	95	98	O	with
18	100	104	O	tests
19	106	110	O	using
20	112	124	U-UNK	nitroprusside
21	125	125	O	,
22	127	129	O	but
23	131	133	O	not
24	135	138	O	with
25	140	144	O	those
26	146	150	O	using
27	152	168	U-UNK	nitroferricyanide
NULL

Cefdinir	DDI-DrugBank.d420.s13	NO_SECTION	NO_SETID	25
The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest , Benedict s solution, or Fehlings solution.
1	0	2	O	The
2	4	17	O	administration
3	19	20	O	of
4	22	29	O	XXXXXXXX
5	31	33	O	may
6	35	40	O	result
7	42	43	O	in
8	45	45	O	a
9	47	51	O	false
10	53	60	O	positive
11	62	69	O	reaction
12	71	73	O	for
13	75	81	O	glucose
14	83	84	O	in
15	86	90	O	urine
16	92	96	O	using
17	98	106	O	Clinitest
18	108	108	O	,
19	110	117	O	Benedict
20	119	119	O	s
21	121	128	O	solution
22	129	129	O	,
23	131	132	O	or
24	134	141	O	Fehlings
25	143	150	O	solution
NULL

Cefdinir	DDI-DrugBank.d420.s14	NO_SECTION	NO_SETID	20
It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix  or Tes-Tape ) be used.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	29	O	glucose
6	31	35	O	tests
7	37	41	O	based
8	43	44	O	on
9	46	54	O	enzymatic
10	56	62	O	glucose
11	64	70	O	oxidase
12	72	80	O	reactions
13	83	86	O	such
14	88	89	O	as
15	91	99	O	Clinistix
16	102	103	O	or
17	105	107	O	Tes
18	109	112	O	Tape
19	116	117	O	be
20	119	122	O	used
NULL

Cefdinir	DDI-DrugBank.d420.s15	NO_SECTION	NO_SETID	11
Cephalosporins are known to occasionally induce a positive direct Coombs  test.
1	0	13	U-UNK	Cephalosporins
2	15	17	O	are
3	19	23	O	known
4	25	26	O	to
5	28	39	O	occasionally
6	41	46	O	induce
7	48	48	O	a
8	50	57	O	positive
9	59	64	O	direct
10	66	71	O	Coombs
11	74	77	O	test
NULL

Cefditoren	DDI-DrugBank.d550.s0	NO_SECTION	NO_SETID	24
Oral Contraceptives Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.
1	0	3	O	Oral
2	5	18	U-UNK	Contraceptives
3	20	27	O	Multiple
4	29	33	O	doses
5	35	36	O	of
6	38	47	O	XXXXXXXX
7	49	55	O	pivoxil
8	57	59	O	had
9	61	62	O	no
10	64	69	O	effect
11	71	72	O	on
12	74	76	O	the
13	78	93	O	pharmacokinetics
14	95	96	O	of
15	98	104	B-UNK	ethinyl
16	106	114	L-UNK	estradiol
17	115	115	O	,
18	117	119	O	the
19	121	130	O	estrogenic
20	132	140	O	component
21	142	143	O	in
22	145	148	O	most
23	150	153	O	oral
24	155	168	U-UNK	contraceptives
NULL

Cefditoren	DDI-DrugBank.d550.s1	NO_SECTION	NO_SETID	20
Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.
1	0	7	O	Although
2	9	11	O	the
3	13	20	O	clinical
4	22	33	O	significance
5	35	36	O	is
6	38	40	O	not
7	42	46	O	known
8	47	47	O	,
9	49	50	O	it
10	52	53	O	is
11	55	57	O	not
12	59	69	O	recommended
13	71	74	O	that
14	76	85	O	XXXXXXXX
15	87	93	O	pivoxil
16	95	96	O	be
17	98	102	O	taken
18	104	116	O	concomitantly
19	118	121	O	with
20	123	130	U-DYN	antacids
NULL

Cefditoren	DDI-DrugBank.d550.s2	NO_SECTION	NO_SETID	50
H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.
1	0	1	B-UNK	H2
2	3	10	I-UNK	Receptor
3	12	22	L-UNK	Antagonists
4	23	23	O	:
5	25	26	O	Co
6	28	41	O	administration
7	43	44	O	of
8	46	46	O	a
9	48	53	O	single
10	55	58	O	dose
11	60	61	O	of
12	63	75	O	intravenously
13	77	88	O	administered
14	90	99	U-KIN	famotidine
15	102	103	O	20
16	105	106	O	mg
17	109	115	O	reduced
18	117	119	O	the
19	121	124	O	oral
20	126	135	O	absorption
21	137	138	O	of
22	140	140	O	a
23	142	147	O	single
24	149	151	O	400
25	153	154	O	mg
26	156	159	O	dose
27	161	162	O	of
28	164	173	O	XXXXXXXX
29	175	181	O	pivoxil
30	183	194	O	administered
31	196	204	O	following
32	206	206	O	a
33	208	211	O	meal
34	212	212	O	,
35	214	215	O	as
36	217	225	O	evidenced
37	227	228	O	by
38	230	230	O	a
39	232	234	O	27%
40	236	243	O	decrease
41	245	246	O	in
42	248	251	O	mean
43	253	256	O	Cmax
44	258	260	O	and
45	262	262	O	a
46	264	266	O	22%
47	268	275	O	decrease
48	277	278	O	in
49	280	283	O	mean
50	285	287	O	AUC
NULL

Cefditoren	DDI-DrugBank.d550.s3	NO_SECTION	NO_SETID	22
Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with H2 receptor antagonists.
1	0	7	O	Although
2	9	11	O	the
3	13	20	O	clinical
4	22	33	O	significance
5	35	36	O	is
6	38	40	O	not
7	42	46	O	known
8	47	47	O	,
9	49	50	O	it
10	52	53	O	is
11	55	57	O	not
12	59	69	O	recommended
13	71	74	O	that
14	76	85	O	XXXXXXXX
15	87	93	O	pivoxil
16	95	96	O	be
17	98	102	O	taken
18	104	116	O	concomitantly
19	118	121	O	with
20	123	124	B-UNK	H2
21	126	133	I-UNK	receptor
22	135	145	L-UNK	antagonists
NULL

Cefditoren	DDI-DrugBank.d550.s4	NO_SECTION	NO_SETID	49
Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
1	0	9	U-UNK	Probenecid
2	10	10	O	:
3	12	13	O	As
4	15	18	O	with
5	20	24	O	other
6	26	26	B-KIN	b
7	28	33	I-KIN	lactam
8	35	45	L-KIN	antibiotics
9	46	46	O	,
10	48	49	O	co
11	51	64	O	administration
12	66	67	O	of
13	69	78	U-KIN	probenecid
14	80	83	O	with
15	85	94	O	XXXXXXXX
16	96	102	O	pivoxil
17	104	111	O	resulted
18	113	114	O	in
19	116	117	O	an
20	119	126	O	increase
21	128	129	O	in
22	131	133	O	the
23	135	140	O	plasma
24	142	149	O	exposure
25	151	152	O	of
26	154	163	O	XXXXXXXX
27	164	164	O	,
28	166	169	O	with
29	171	171	O	a
30	173	175	O	49%
31	177	184	O	increase
32	186	187	O	in
33	189	192	O	mean
34	194	197	O	Cmax
35	198	198	O	,
36	200	200	O	a
37	202	205	O	122%
38	207	214	O	increase
39	216	217	O	in
40	219	222	O	mean
41	224	226	O	AUC
42	227	227	O	,
43	229	231	O	and
44	233	233	O	a
45	235	237	O	53%
46	239	246	O	increase
47	248	249	O	in
48	251	254	O	half
49	256	259	O	life
NULL

Cefditoren	DDI-DrugBank.d550.s5	NO_SECTION	NO_SETID	16
Drug/Laboratory Test Interactions Cephalosporins are known to occasionally induce a positive direct Coombs test.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	47	U-UNK	Cephalosporins
7	49	51	O	are
8	53	57	O	known
9	59	60	O	to
10	62	73	O	occasionally
11	75	80	O	induce
12	82	82	O	a
13	84	91	O	positive
14	93	98	O	direct
15	100	105	O	Coombs
16	107	110	O	test
NULL

Cefditoren	DDI-DrugBank.d550.s6	NO_SECTION	NO_SETID	38
A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedicts or Fehlings solution or with CLINITEST tablets), but not with enzyme-based tests for glycosuria (e.g., CLINISTIX, TES-TAPE).
1	0	0	O	A
2	2	6	O	false
3	8	15	O	positive
4	17	24	O	reaction
5	26	28	O	for
6	30	36	O	glucose
7	38	39	O	in
8	41	43	O	the
9	45	49	O	urine
10	51	53	O	may
11	55	59	O	occur
12	61	64	O	with
13	66	71	O	copper
14	73	81	O	reduction
15	83	87	O	tests
16	90	98	O	Benedicts
17	100	101	O	or
18	103	110	O	Fehlings
19	112	119	O	solution
20	121	122	O	or
21	124	127	O	with
22	129	137	O	CLINITEST
23	139	145	O	tablets
24	147	147	O	,
25	149	151	O	but
26	153	155	O	not
27	157	160	O	with
28	162	167	O	enzyme
29	169	173	O	based
30	175	179	O	tests
31	181	183	O	for
32	185	194	O	glycosuria
33	197	199	O	e.g
34	201	201	O	,
35	203	211	O	CLINISTIX
36	212	212	O	,
37	214	216	O	TES
38	218	221	O	TAPE
NULL

Cefditoren	DDI-DrugBank.d550.s7	NO_SECTION	NO_SETID	37
As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood/plasma glucose levels in patients receiving cefditoren pivoxil.
1	0	1	O	As
2	3	3	O	a
3	5	9	O	false
4	11	18	O	negative
5	20	25	O	result
6	27	29	O	may
7	31	35	O	occur
8	37	38	O	in
9	40	42	O	the
10	44	55	O	ferricyanide
11	57	60	O	test
12	61	61	O	,
13	63	64	O	it
14	66	67	O	is
15	69	79	O	recommended
16	81	84	O	that
17	86	91	O	either
18	93	95	O	the
19	97	103	O	glucose
20	105	111	O	oxidase
21	113	114	O	or
22	116	125	O	hexokinase
23	127	132	O	method
24	134	135	O	be
25	137	140	O	used
26	142	143	O	to
27	145	153	O	determine
28	155	159	O	blood
29	160	160	O	/
30	161	166	O	plasma
31	168	174	O	glucose
32	176	181	O	levels
33	183	184	O	in
34	186	193	O	patients
35	195	203	O	receiving
36	205	214	O	XXXXXXXX
37	216	222	O	pivoxil
NULL

Cefepime	DDI-DrugBank.d378.s0	NO_SECTION	NO_SETID	29
Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.
1	0	4	O	Renal
2	6	13	O	function
3	15	20	O	should
4	22	23	O	be
5	25	33	O	monitored
6	35	43	O	carefully
7	45	46	O	if
8	48	51	O	high
9	53	57	O	doses
10	59	60	O	of
11	62	76	U-DYN	aminoglycosides
12	78	80	O	are
13	82	83	O	to
14	85	86	O	be
15	88	99	O	administered
16	101	104	O	with
17	106	113	O	XXXXXXXX
18	115	121	O	because
19	123	124	O	of
20	126	128	O	the
21	130	138	O	increased
22	140	148	O	potential
23	150	151	O	of
24	153	166	O	nephrotoxicity
25	168	170	O	and
26	172	182	O	ototoxicity
27	184	185	O	of
28	187	200	B-UNK	aminoglycoside
29	202	212	L-UNK	antibiotics
NULL

Cefepime	DDI-DrugBank.d378.s1	NO_SECTION	NO_SETID	16
Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
1	0	13	O	Nephrotoxicity
2	15	17	O	has
3	19	22	O	been
4	24	31	O	reported
5	33	41	O	following
6	43	53	O	concomitant
7	55	68	O	administration
8	70	71	O	of
9	73	77	O	other
10	79	92	U-UNK	cephalosporins
11	94	97	O	with
12	99	104	O	potent
13	106	114	U-UNK	diuretics
14	116	119	O	such
15	121	122	O	as
16	124	133	U-UNK	furosemide
NULL

Cefepime	DDI-DrugBank.d378.s2	NO_SECTION	NO_SETID	25
Drug/Laboratory Test Interactions The administration of cefepime may result in a false-positive reaction for glucose in the urine when using Clinitest  tablets.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	36	O	The
7	38	51	O	administration
8	53	54	O	of
9	56	63	O	XXXXXXXX
10	65	67	O	may
11	69	74	O	result
12	76	77	O	in
13	79	79	O	a
14	81	85	O	false
15	87	94	O	positive
16	96	103	O	reaction
17	105	107	O	for
18	109	115	O	glucose
19	117	118	O	in
20	120	122	O	the
21	124	128	O	urine
22	130	133	O	when
23	135	139	O	using
24	141	149	O	Clinitest
25	152	158	O	tablets
NULL

Cefepime	DDI-DrugBank.d378.s3	NO_SECTION	NO_SETID	20
It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix  or Tes-Tape  ) be used.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	29	O	glucose
6	31	35	O	tests
7	37	41	O	based
8	43	44	O	on
9	46	54	O	enzymatic
10	56	62	O	glucose
11	64	70	O	oxidase
12	72	80	O	reactions
13	83	86	O	such
14	88	89	O	as
15	91	99	O	Clinistix
16	102	103	O	or
17	105	107	O	Tes
18	109	112	O	Tape
19	117	118	O	be
20	120	123	O	used
NULL

Cefixime	DDI-DrugBank.d339.s0	NO_SECTION	NO_SETID	16
Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.
1	0	12	U-UNK	Carbamazepine
2	13	13	O	:
3	15	22	O	Elevated
4	24	36	U-KIN	carbamazepine
5	38	43	O	levels
6	45	48	O	have
7	50	53	O	been
8	55	62	O	reported
9	64	65	O	in
10	67	79	O	postmarketing
11	81	90	O	experience
12	92	95	O	when
13	97	102	O	XXXXXXXX
14	104	105	O	is
15	107	118	O	administered
16	120	132	O	concomitantly
NULL

Cefixime	DDI-DrugBank.d339.s1	NO_SECTION	NO_SETID	13
Drug monitoring may be of assistance in detecting alterations in carbamazepine plasma concentrations.
1	0	3	O	Drug
2	5	14	O	monitoring
3	16	18	O	may
4	20	21	O	be
5	23	24	O	of
6	26	35	O	assistance
7	37	38	O	in
8	40	48	O	detecting
9	50	60	O	alterations
10	62	63	O	in
11	65	77	U-UNK	carbamazepine
12	79	84	O	plasma
13	86	99	O	concentrations
NULL

Cefixime	DDI-DrugBank.d339.s2	NO_SECTION	NO_SETID	22
Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.
1	0	7	U-DYN	Warfarin
2	9	11	O	and
3	13	26	U-DYN	Anticoagulants
4	27	27	O	:
5	29	37	O	Increased
6	39	49	O	prothrombin
7	51	54	O	time
8	55	55	O	,
9	57	60	O	with
10	62	63	O	or
11	65	71	O	without
12	73	80	O	clinical
13	82	89	O	bleeding
14	90	90	O	,
15	92	94	O	has
16	96	99	O	been
17	101	108	O	reported
18	110	113	O	when
19	115	122	O	XXXXXXXX
20	124	125	O	is
21	127	138	O	administered
22	140	152	O	concomitantly
NULL

Cefixime	DDI-DrugBank.d339.s3	NO_SECTION	NO_SETID	26
Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	34	O	A
7	36	40	O	false
8	42	49	O	positive
9	51	58	O	reaction
10	60	62	O	for
11	64	70	O	ketones
12	72	73	O	in
13	75	77	O	the
14	79	83	O	urine
15	85	87	O	may
16	89	93	O	occur
17	95	98	O	with
18	100	104	O	tests
19	106	110	O	using
20	112	124	U-UNK	nitroprusside
21	126	128	O	but
22	130	132	O	not
23	134	137	O	with
24	139	143	O	those
25	145	149	O	using
26	151	167	U-UNK	nitroferricyanide
NULL

Cefixime	DDI-DrugBank.d339.s4	NO_SECTION	NO_SETID	28
The administration of SUPRAX may result in a false-positive reaction for glucose in the urine using Clinitest **, Benedict s solution, or Fehling s solution.
1	0	2	O	The
2	4	17	O	administration
3	19	20	O	of
4	22	27	O	XXXXXXXX
5	29	31	O	may
6	33	38	O	result
7	40	41	O	in
8	43	43	O	a
9	45	49	O	false
10	51	58	O	positive
11	60	67	O	reaction
12	69	71	O	for
13	73	79	O	glucose
14	81	82	O	in
15	84	86	O	the
16	88	92	O	urine
17	94	98	O	using
18	100	108	O	Clinitest
19	110	111	O	**
20	112	112	O	,
21	114	121	O	Benedict
22	123	123	O	s
23	125	132	O	solution
24	133	133	O	,
25	135	136	O	or
26	138	144	O	Fehling
27	146	146	O	s
28	148	155	O	solution
NULL

Cefixime	DDI-DrugBank.d339.s5	NO_SECTION	NO_SETID	22
It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix ** or Tes-Tape **) be used.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	29	O	glucose
6	31	35	O	tests
7	37	41	O	based
8	43	44	O	on
9	46	54	O	enzymatic
10	56	62	O	glucose
11	64	70	O	oxidase
12	72	80	O	reactions
13	83	86	O	such
14	88	89	O	as
15	91	99	O	Clinistix
16	101	102	O	**
17	104	105	O	or
18	107	109	O	Tes
19	111	114	O	Tape
20	116	117	O	**
21	120	121	O	be
22	123	126	O	used
NULL

Cefixime	DDI-DrugBank.d339.s6	NO_SECTION	NO_SETID	15
A false-positive direct Coombs test has been reported during treatment with other cephalosporin antibiotics;
1	0	0	O	A
2	2	6	O	false
3	8	15	O	positive
4	17	22	O	direct
5	24	29	O	Coombs
6	31	34	O	test
7	36	38	O	has
8	40	43	O	been
9	45	52	O	reported
10	54	59	O	during
11	61	69	O	treatment
12	71	74	O	with
13	76	80	O	other
14	82	94	B-UNK	cephalosporin
15	96	106	L-UNK	antibiotics
NULL

Cefixime	DDI-DrugBank.d339.s7	NO_SECTION	NO_SETID	17
therefore, it should be recognized that a positive Coombs test may be due to the drug.
1	0	8	O	therefore
2	9	9	O	,
3	11	12	O	it
4	14	19	O	should
5	21	22	O	be
6	24	33	O	recognized
7	35	38	O	that
8	40	40	O	a
9	42	49	O	positive
10	51	56	O	Coombs
11	58	61	O	test
12	63	65	O	may
13	67	68	O	be
14	70	72	O	due
15	74	75	O	to
16	77	79	O	the
17	81	84	O	drug
NULL

Cefotaxime	DDI-DrugBank.d100.s0	NO_SECTION	NO_SETID	13
Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
1	0	8	O	Increased
2	10	23	O	nephrotoxicity
3	25	27	O	has
4	29	32	O	been
5	34	41	O	reported
6	43	51	O	following
7	53	63	O	concomitant
8	65	78	O	administration
9	80	81	O	of
10	83	96	U-UNK	cephalosporins
11	98	100	O	and
12	102	115	B-UNK	aminoglycoside
13	117	127	L-UNK	antibiotics
NULL

Cefotaxime	DDI-DrugBank.d100.s1	NO_SECTION	NO_SETID	21
Drug/Laboratory Test Interactions Cephalosporins, including cefotaxime sodium, are known to occasionally induce a positive direct Coombs test.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	47	U-UNK	Cephalosporins
7	48	48	O	,
8	50	58	O	including
9	60	69	O	XXXXXXXX
10	71	76	O	sodium
11	77	77	O	,
12	79	81	O	are
13	83	87	O	known
14	89	90	O	to
15	92	103	O	occasionally
16	105	110	O	induce
17	112	112	O	a
18	114	121	O	positive
19	123	128	O	direct
20	130	135	O	Coombs
21	137	140	O	test
NULL

Cefotetan	DDI-DrugBank.d483.s0	NO_SECTION	NO_SETID	11
Increases in serum creatinine have occurred when CEFOTAN was given alone.
1	0	8	O	Increases
2	10	11	O	in
3	13	17	O	serum
4	19	28	O	creatinine
5	30	33	O	have
6	35	42	O	occurred
7	44	47	O	when
8	49	55	O	XXXXXXXX
9	57	59	O	was
10	61	65	O	given
11	67	71	O	alone
NULL

Cefotetan	DDI-DrugBank.d483.s1	NO_SECTION	NO_SETID	21
If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.
1	0	1	O	If
2	3	9	O	XXXXXXXX
3	11	13	O	and
4	15	16	O	an
5	18	31	U-DYN	aminoglycoside
6	33	35	O	are
7	37	40	O	used
8	42	54	O	concomitantly
9	55	55	O	,
10	57	61	O	renal
11	63	70	O	function
12	72	77	O	should
13	79	80	O	be
14	82	90	O	carefully
15	92	100	O	monitored
16	101	101	O	,
17	103	109	O	because
18	111	124	O	nephrotoxicity
19	126	128	O	may
20	130	131	O	be
21	133	143	O	potentiated
NULL

Cefotetan	DDI-DrugBank.d483.s2	NO_SECTION	NO_SETID	31
Drug/Laboratory Test Interactions: The administration of CEFOTAN may result in a false positive reaction for glucose in the urine using Clinitest  , Benedicts solution, or Fehlings solution.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	33	33	O	:
7	35	37	O	The
8	39	52	O	administration
9	54	55	O	of
10	57	63	O	XXXXXXXX
11	65	67	O	may
12	69	74	O	result
13	76	77	O	in
14	79	79	O	a
15	81	85	O	false
16	87	94	O	positive
17	96	103	O	reaction
18	105	107	O	for
19	109	115	O	glucose
20	117	118	O	in
21	120	122	O	the
22	124	128	O	urine
23	130	134	O	using
24	136	144	O	Clinitest
25	147	147	O	,
26	149	157	O	Benedicts
27	159	166	O	solution
28	167	167	O	,
29	169	170	O	or
30	172	179	O	Fehlings
31	181	188	O	solution
NULL

Cefotetan	DDI-DrugBank.d483.s3	NO_SECTION	NO_SETID	13
It is recommended that glucose tests based on enzymatic glucose oxidase be used.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	29	O	glucose
6	31	35	O	tests
7	37	41	O	based
8	43	44	O	on
9	46	54	O	enzymatic
10	56	62	O	glucose
11	64	70	O	oxidase
12	72	73	O	be
13	75	78	O	used
NULL

Cefotetan	DDI-DrugBank.d483.s4	NO_SECTION	NO_SETID	32
As with other cephalosporins, high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels by Jaffe  reaction and produce false increases in the levels of creatinine reported.
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	27	U-UNK	cephalosporins
5	28	28	O	,
6	30	33	O	high
7	35	48	O	concentrations
8	50	51	O	of
9	53	61	O	XXXXXXXX
10	63	65	O	may
11	67	75	O	interfere
12	77	80	O	with
13	82	92	O	measurement
14	94	95	O	of
15	97	101	O	serum
16	103	105	O	and
17	107	111	O	urine
18	113	122	O	creatinine
19	124	129	O	levels
20	131	132	O	by
21	134	138	O	Jaffe
22	141	148	O	reaction
23	150	152	O	and
24	154	160	O	produce
25	162	166	O	false
26	168	176	O	increases
27	178	179	O	in
28	181	183	O	the
29	185	190	O	levels
30	192	193	O	of
31	195	204	O	creatinine
32	206	213	O	reported
NULL

Cefoxitin	DDI-DrugBank.d556.s0	NO_SECTION	NO_SETID	13
Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
1	0	8	O	Increased
2	10	23	O	nephrotoxicity
3	25	27	O	has
4	29	32	O	been
5	34	41	O	reported
6	43	51	O	following
7	53	63	O	concomitant
8	65	78	O	administration
9	80	81	O	of
10	83	96	U-UNK	cephalosporins
11	98	100	O	and
12	102	115	B-UNK	aminoglycoside
13	117	127	L-UNK	antibiotics
NULL

Cefoxitin	DDI-DrugBank.d556.s1	NO_SECTION	NO_SETID	45
Drug/Laboratory Test Interactions As with cephalothin, high concentrations of cefoxitin ( 100 micrograms/mL) may interfere with measurement of serum and urine creatinine levels by the Jaff  reaction, and produce false increases of modest degree in the levels of creatinine reported.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	35	O	As
7	37	40	O	with
8	42	52	U-UNK	cephalothin
9	53	53	O	,
10	55	58	O	high
11	60	73	O	concentrations
12	75	76	O	of
13	78	86	O	XXXXXXXX
14	90	92	O	100
15	94	103	O	micrograms
16	104	104	O	/
17	105	106	O	mL
18	109	111	O	may
19	113	121	O	interfere
20	123	126	O	with
21	128	138	O	measurement
22	140	141	O	of
23	143	147	O	serum
24	149	151	O	and
25	153	157	O	urine
26	159	168	O	creatinine
27	170	175	O	levels
28	177	178	O	by
29	180	182	O	the
30	184	187	O	Jaff
31	190	197	O	reaction
32	198	198	O	,
33	200	202	O	and
34	204	210	O	produce
35	212	216	O	false
36	218	226	O	increases
37	228	229	O	of
38	231	236	O	modest
39	238	243	O	degree
40	245	246	O	in
41	248	250	O	the
42	252	257	O	levels
43	259	260	O	of
44	262	271	O	creatinine
45	273	280	O	reported
NULL

Cefoxitin	DDI-DrugBank.d556.s2	NO_SECTION	NO_SETID	21
Serum samples from patients treated with cefoxitin should not be analyzed for creatinine if withdrawn within 2 hours of drug administration.
1	0	4	O	Serum
2	6	12	O	samples
3	14	17	O	from
4	19	26	O	patients
5	28	34	O	treated
6	36	39	O	with
7	41	49	O	XXXXXXXX
8	51	56	O	should
9	58	60	O	not
10	62	63	O	be
11	65	72	O	analyzed
12	74	76	O	for
13	78	87	O	creatinine
14	89	90	O	if
15	92	100	O	withdrawn
16	102	107	O	within
17	109	109	O	2
18	111	115	O	hours
19	117	118	O	of
20	120	123	O	drug
21	125	138	O	administration
NULL

Cefoxitin	DDI-DrugBank.d556.s3	NO_SECTION	NO_SETID	33
High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported.
1	0	3	O	High
2	5	18	O	concentrations
3	20	21	O	of
4	23	31	O	XXXXXXXX
5	33	34	O	in
6	36	38	O	the
7	40	44	O	urine
8	46	48	O	may
9	50	58	O	interfere
10	60	63	O	with
11	65	75	O	measurement
12	77	78	O	of
13	80	86	O	urinary
14	88	89	O	17
15	91	97	O	hydroxy
16	99	113	O	corticosteroids
17	115	116	O	by
18	118	120	O	the
19	122	127	O	Porter
20	129	134	O	Silber
21	136	143	O	reaction
22	144	144	O	,
23	146	148	O	and
24	150	156	O	produce
25	158	162	O	false
26	164	172	O	increases
27	174	175	O	of
28	177	182	O	modest
29	184	189	O	degree
30	191	192	O	in
31	194	196	O	the
32	198	203	O	levels
33	205	212	O	reported
NULL

Cefoxitin	DDI-DrugBank.d556.s4	NO_SECTION	NO_SETID	11
A false-positive reaction for glucose in the urine may occur.
1	0	0	O	A
2	2	6	O	false
3	8	15	O	positive
4	17	24	O	reaction
5	26	28	O	for
6	30	36	O	glucose
7	38	39	O	in
8	41	43	O	the
9	45	49	O	urine
10	51	53	O	may
11	55	59	O	occur
NULL

Cefoxitin	DDI-DrugBank.d556.s5	NO_SECTION	NO_SETID	8
This has been observed with CLINITEST  reagent tablets
1	0	3	O	This
2	5	7	O	has
3	9	12	O	been
4	14	21	O	observed
5	23	26	O	with
6	28	36	O	CLINITEST
7	39	45	O	reagent
8	47	53	O	tablets
NULL

Cefoxitin	DDI-DrugBank.d556.s7	NO_SECTION	NO_SETID	12
Registered trademark of Ames Company, Division of Miles Laboratories, Inc.
1	0	9	O	Registered
2	11	19	O	trademark
3	21	22	O	of
4	24	27	O	Ames
5	29	35	O	Company
6	36	36	O	,
7	38	45	O	Division
8	47	48	O	of
9	50	54	O	Miles
10	56	67	O	Laboratories
11	68	68	O	,
12	70	72	O	Inc
NULL

Cefprozil	DDI-DrugBank.d121.s0	NO_SECTION	NO_SETID	13
Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.
1	0	13	O	Nephrotoxicity
2	15	17	O	has
3	19	22	O	been
4	24	31	O	reported
5	33	41	O	following
6	43	53	O	concomitant
7	55	68	O	administration
8	70	71	O	of
9	73	86	B-UNK	aminoglycoside
10	88	98	L-UNK	antibiotics
11	100	102	O	and
12	104	116	B-UNK	cephalosporin
13	118	128	L-UNK	antibiotics
NULL

Cefprozil	DDI-DrugBank.d121.s1	NO_SECTION	NO_SETID	9
Concomitant administration of probenecid doubled the AUC for cefprozil.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	39	U-KIN	probenecid
5	41	47	O	doubled
6	49	51	O	the
7	53	55	O	AUC
8	57	59	O	for
9	61	69	O	XXXXXXXX
NULL

Cefprozil	DDI-DrugBank.d121.s2	NO_SECTION	NO_SETID	18
The bioavailability of the capsule formulation of cefprozil was not affected when administered 5 minutes following an antacid.
1	0	2	O	The
2	4	18	O	bioavailability
3	20	21	O	of
4	23	25	O	the
5	27	33	O	capsule
6	35	45	O	formulation
7	47	48	O	of
8	50	58	O	XXXXXXXX
9	60	62	O	was
10	64	66	O	not
11	68	75	O	affected
12	77	80	O	when
13	82	93	O	administered
14	95	95	O	5
15	97	103	O	minutes
16	105	113	O	following
17	115	116	O	an
18	118	124	U-UNK	antacid
NULL

Ceftazidime	DDI-DrugBank.d122.s0	NO_SECTION	NO_SETID	18
Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.
1	0	13	O	Nephrotoxicity
2	15	17	O	has
3	19	22	O	been
4	24	31	O	reported
5	33	41	O	following
6	43	53	O	concomitant
7	55	68	O	administration
8	70	71	O	of
9	73	86	U-UNK	cephalosporins
10	88	91	O	with
11	93	106	B-UNK	aminoglycoside
12	108	118	L-UNK	antibiotics
13	120	121	O	or
14	123	128	O	potent
15	130	138	U-UNK	diuretics
16	140	143	O	such
17	145	146	O	as
18	148	157	U-UNK	furosemide
NULL

Ceftazidime	DDI-DrugBank.d122.s1	NO_SECTION	NO_SETID	34
Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics.
1	0	4	O	Renal
2	6	13	O	function
3	15	20	O	should
4	22	23	O	be
5	25	33	O	carefully
6	35	43	O	monitored
7	44	44	O	,
8	46	55	O	especially
9	57	58	O	if
10	60	65	O	higher
11	67	73	O	dosages
12	75	76	O	of
13	78	80	O	the
14	82	96	U-UNK	aminoglycosides
15	98	100	O	are
16	102	103	O	to
17	105	106	O	be
18	108	119	O	administered
19	121	122	O	or
20	124	125	O	if
21	127	133	O	therapy
22	135	136	O	is
23	138	146	O	prolonged
24	147	147	O	,
25	149	155	O	because
26	157	158	O	of
27	160	162	O	the
28	164	172	O	potential
29	174	187	O	nephrotoxicity
30	189	191	O	and
31	193	203	O	ototoxicity
32	205	206	O	of
33	208	222	B-UNK	aminoglycosidic
34	224	234	L-UNK	antibiotics
NULL

Ceftazidime	DDI-DrugBank.d122.s2	NO_SECTION	NO_SETID	14
Nephrotoxicity and ototoxicity were not noted when ceftazidime was given alone in clinical trials.
1	0	13	O	Nephrotoxicity
2	15	17	O	and
3	19	29	O	ototoxicity
4	31	34	O	were
5	36	38	O	not
6	40	44	O	noted
7	46	49	O	when
8	51	61	O	XXXXXXXX
9	63	65	O	was
10	67	71	O	given
11	73	77	O	alone
12	79	80	O	in
13	82	89	O	clinical
14	91	96	O	trials
NULL

Ceftazidime	DDI-DrugBank.d122.s3	NO_SECTION	NO_SETID	29
Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
1	0	14	U-DYN	Chloramphenicol
2	16	18	O	has
3	20	23	O	been
4	25	29	O	shown
5	31	32	O	to
6	34	35	O	be
7	37	48	O	antagonistic
8	50	51	O	to
9	53	56	B-UNK	beta
10	58	63	I-UNK	lactam
11	65	75	L-UNK	antibiotics
12	76	76	O	,
13	78	86	O	including
14	88	98	O	XXXXXXXX
15	99	99	O	,
16	101	105	O	based
17	107	108	O	on
18	110	111	O	in
19	113	117	O	vitro
20	119	125	O	studies
21	127	129	O	and
22	131	134	O	time
23	136	139	O	kill
24	141	146	O	curves
25	148	151	O	with
26	153	159	O	enteric
27	161	164	O	gram
28	166	173	O	negative
29	175	181	O	bacilli
NULL

Ceftazidime	DDI-DrugBank.d122.s4	NO_SECTION	NO_SETID	22
Due to the possibility of antagonism in vivo, particularly when bactericidal activity is desired, this drug combination should be avoided.
1	0	2	O	Due
2	4	5	O	to
3	7	9	O	the
4	11	21	O	possibility
5	23	24	O	of
6	26	35	O	antagonism
7	37	38	O	in
8	40	43	O	vivo
9	44	44	O	,
10	46	57	O	particularly
11	59	62	O	when
12	64	75	O	bactericidal
13	77	84	O	activity
14	86	87	O	is
15	89	95	O	desired
16	96	96	O	,
17	98	101	O	this
18	103	106	O	drug
19	108	118	O	combination
20	120	125	O	should
21	127	128	O	be
22	130	136	O	avoided
NULL

Ceftazidime	DDI-DrugBank.d122.s5	NO_SECTION	NO_SETID	32
Drug/Laboratory Test Interactions The administration of ceftazidime may result in a false-positive reaction for glucose in the urine when using CLINITEST  tablets, Benedicts solution, or Fehlings solution.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	36	O	The
7	38	51	O	administration
8	53	54	O	of
9	56	66	O	XXXXXXXX
10	68	70	O	may
11	72	77	O	result
12	79	80	O	in
13	82	82	O	a
14	84	88	O	false
15	90	97	O	positive
16	99	106	O	reaction
17	108	110	O	for
18	112	118	O	glucose
19	120	121	O	in
20	123	125	O	the
21	127	131	O	urine
22	133	136	O	when
23	138	142	O	using
24	144	152	O	CLINITEST
25	155	161	O	tablets
26	162	162	O	,
27	164	172	O	Benedicts
28	174	181	O	solution
29	182	182	O	,
30	184	185	O	or
31	187	194	O	Fehlings
32	196	203	O	solution
NULL

Ceftazidime	DDI-DrugBank.d122.s6	NO_SECTION	NO_SETID	20
It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX  or TES-TAPE ) be used.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	29	O	glucose
6	31	35	O	tests
7	37	41	O	based
8	43	44	O	on
9	46	54	O	enzymatic
10	56	62	O	glucose
11	64	70	O	oxidase
12	72	80	O	reactions
13	83	86	O	such
14	88	89	O	as
15	91	99	O	CLINISTIX
16	102	103	O	or
17	105	107	O	TES
18	109	112	O	TAPE
19	116	117	O	be
20	119	122	O	used
NULL

Ceftibuten	DDI-DrugBank.d32.s0	NO_SECTION	NO_SETID	18
Theophylline: Twelve healthy male volunteers were administered one 200-mg ceftibuten capsule twice daily for 6 days.
1	0	11	U-UNK	Theophylline
2	12	12	O	:
3	14	19	O	Twelve
4	21	27	O	healthy
5	29	32	O	male
6	34	43	O	volunteers
7	45	48	O	were
8	50	61	O	administered
9	63	65	O	one
10	67	69	O	200
11	71	72	O	mg
12	74	83	O	XXXXXXXX
13	85	91	O	capsule
14	93	97	O	twice
15	99	103	O	daily
16	105	107	O	for
17	109	109	O	6
18	111	114	O	days
NULL

Ceftibuten	DDI-DrugBank.d32.s1	NO_SECTION	NO_SETID	23
With the morning dose of ceftibuten on day 6, each volunteer received a single intravenous infusion of theophylline (4 mg/kg).
1	0	3	O	With
2	5	7	O	the
3	9	15	O	morning
4	17	20	O	dose
5	22	23	O	of
6	25	34	O	XXXXXXXX
7	36	37	O	on
8	39	41	O	day
9	43	43	O	6
10	44	44	O	,
11	46	49	O	each
12	51	59	O	volunteer
13	61	68	O	received
14	70	70	O	a
15	72	77	O	single
16	79	89	O	intravenous
17	91	98	O	infusion
18	100	101	O	of
19	103	114	U-UNK	theophylline
20	117	117	O	4
21	119	120	O	mg
22	121	121	O	/
23	122	123	O	kg
NULL

Ceftibuten	DDI-DrugBank.d32.s2	NO_SECTION	NO_SETID	7
The pharmacokinetics of theophylline were not altered.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	35	U-UNK	theophylline
5	37	40	O	were
6	42	44	O	not
7	46	52	O	altered
NULL

Ceftibuten	DDI-DrugBank.d32.s3	NO_SECTION	NO_SETID	15
The effect of ceftibuten on the pharmacokinetics of theophylline administered orally has not been investigated.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	26	O	on
6	28	30	O	the
7	32	47	O	pharmacokinetics
8	49	50	O	of
9	52	63	U-UNK	theophylline
10	65	76	O	administered
11	78	83	O	orally
12	85	87	O	has
13	89	91	O	not
14	93	96	O	been
15	98	109	O	investigated
NULL

Ceftibuten	DDI-DrugBank.d32.s4	NO_SECTION	NO_SETID	25
Antacids or H 2 -receptor antagonists: The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers.
1	0	7	U-UNK	Antacids
2	9	10	O	or
3	12	12	B-UNK	H
4	14	14	I-UNK	2
5	17	24	I-UNK	receptor
6	26	36	L-UNK	antagonists
7	37	37	O	:
8	39	41	O	The
9	43	48	O	effect
10	50	51	O	of
11	53	61	O	increased
12	63	69	O	gastric
13	71	72	O	pH
14	74	75	O	on
15	77	79	O	the
16	81	95	O	bioavailability
17	97	98	O	of
18	100	109	O	XXXXXXXX
19	111	113	O	was
20	115	123	O	evaluated
21	125	126	O	in
22	128	129	O	18
23	131	137	O	healthy
24	139	143	O	adult
25	145	154	O	volunteers
NULL

Ceftibuten	DDI-DrugBank.d32.s5	NO_SECTION	NO_SETID	9
Each volunteer was administered one 400-mg ceftibuten capsule.
1	0	3	O	Each
2	5	13	O	volunteer
3	15	17	O	was
4	19	30	O	administered
5	32	34	O	one
6	36	38	O	400
7	40	41	O	mg
8	43	52	O	XXXXXXXX
9	54	60	O	capsule
NULL

Ceftibuten	DDI-DrugBank.d32.s6	NO_SECTION	NO_SETID	16
A single dose of liquid antacid did not affect the C max or AUC of ceftibuten;
1	0	0	O	A
2	2	7	O	single
3	9	12	O	dose
4	14	15	O	of
5	17	22	O	liquid
6	24	30	U-UNK	antacid
7	32	34	O	did
8	36	38	O	not
9	40	45	O	affect
10	47	49	O	the
11	51	51	O	C
12	53	55	O	max
13	57	58	O	or
14	60	62	O	AUC
15	64	65	O	of
16	67	76	O	XXXXXXXX
NULL

Ceftibuten	DDI-DrugBank.d32.s7	NO_SECTION	NO_SETID	22
however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.
1	0	6	O	however
2	7	7	O	,
3	9	11	O	150
4	13	14	O	mg
5	16	17	O	of
6	19	28	U-KIN	ranitidine
7	30	33	O	q12h
8	35	37	O	for
9	39	39	O	3
10	41	44	O	days
11	46	54	O	increased
12	56	58	O	the
13	60	69	O	XXXXXXXX
14	71	71	O	C
15	73	75	O	max
16	77	78	O	by
17	80	82	O	23%
18	84	86	O	and
19	88	97	O	XXXXXXXX
20	99	101	O	AUC
21	103	104	O	by
22	106	108	O	16%
NULL

Ceftibuten	DDI-DrugBank.d32.s8	NO_SECTION	NO_SETID	9
The clinical relevance of these increases is not known.
1	0	2	O	The
2	4	11	O	clinical
3	13	21	O	relevance
4	23	24	O	of
5	26	30	O	these
6	32	40	O	increases
7	42	43	O	is
8	45	47	O	not
9	49	53	O	known
NULL

Ceftibuten	DDI-DrugBank.d32.s9	NO_SECTION	NO_SETID	20
Drug/Laboratory Test Interactions: There have been no chemical or laboratory test interactions with ceftibuten noted to date.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	33	33	O	:
7	35	39	O	There
8	41	44	O	have
9	46	49	O	been
10	51	52	O	no
11	54	61	O	chemical
12	63	64	O	or
13	66	75	O	laboratory
14	77	80	O	test
15	82	93	O	interactions
16	95	98	O	with
17	100	109	O	XXXXXXXX
18	111	115	O	noted
19	117	118	O	to
20	120	123	O	date
NULL

Ceftibuten	DDI-DrugBank.d32.s10	NO_SECTION	NO_SETID	13
False-positive direct Coombs tests have been reported during treatment with other cephalosporins.
1	0	4	O	False
2	6	13	O	positive
3	15	20	O	direct
4	22	27	O	Coombs
5	29	33	O	tests
6	35	38	O	have
7	40	43	O	been
8	45	52	O	reported
9	54	59	O	during
10	61	69	O	treatment
11	71	74	O	with
12	76	80	O	other
13	82	95	U-UNK	cephalosporins
NULL

Ceftibuten	DDI-DrugBank.d32.s11	NO_SECTION	NO_SETID	17
Therefore, it should be recognized that a positive Coombs test could be due to the drug.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	it
4	14	19	O	should
5	21	22	O	be
6	24	33	O	recognized
7	35	38	O	that
8	40	40	O	a
9	42	49	O	positive
10	51	56	O	Coombs
11	58	61	O	test
12	63	67	O	could
13	69	70	O	be
14	72	74	O	due
15	76	77	O	to
16	79	81	O	the
17	83	86	O	drug
NULL

Ceftibuten	DDI-DrugBank.d32.s12	NO_SECTION	NO_SETID	35
The results of assays using red cells from healthy subjects to determine whether ceftibuten would cause direct Coombs reactions in vitro showed no positive reaction at ceftibuten concentrations as high as 40  g/mL.
1	0	2	O	The
2	4	10	O	results
3	12	13	O	of
4	15	20	O	assays
5	22	26	O	using
6	28	30	O	red
7	32	36	O	cells
8	38	41	O	from
9	43	49	O	healthy
10	51	58	O	subjects
11	60	61	O	to
12	63	71	O	determine
13	73	79	O	whether
14	81	90	O	XXXXXXXX
15	92	96	O	would
16	98	102	O	cause
17	104	109	O	direct
18	111	116	O	Coombs
19	118	126	O	reactions
20	128	129	O	in
21	131	135	O	vitro
22	137	142	O	showed
23	144	145	O	no
24	147	154	O	positive
25	156	163	O	reaction
26	165	166	O	at
27	168	177	O	XXXXXXXX
28	179	192	O	concentrations
29	194	195	O	as
30	197	200	O	high
31	202	203	O	as
32	205	206	O	40
33	209	209	O	g
34	210	210	O	/
35	211	212	O	mL
NULL

Ceftizoxime	DDI-DrugBank.d33.s0	NO_SECTION	NO_SETID	22
Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.
1	0	7	O	Although
2	9	11	O	the
3	13	22	O	occurrence
4	24	26	O	has
5	28	30	O	not
6	32	35	O	been
7	37	44	O	reported
8	46	49	O	with
9	51	57	O	XXXXXXXX
10	58	58	O	,
11	60	73	O	nephrotoxicity
12	75	77	O	has
13	79	82	O	been
14	84	91	O	reported
15	93	101	O	following
16	103	113	O	concomitant
17	115	128	O	administration
18	130	131	O	of
19	133	137	O	other
20	139	152	U-UNK	cephalosporins
21	154	156	O	and
22	158	172	U-UNK	aminoglycosides
NULL

Cefuroxime	DDI-DrugBank.d447.s0	NO_SECTION	NO_SETID	39
Drug/Laboratory Test Interactions: A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedict s or Fehling s solution or with Clinitest  tablets) but not with enzyme-based tests for glycosuria.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	33	33	O	:
7	35	35	O	A
8	37	41	O	false
9	43	50	O	positive
10	52	59	O	reaction
11	61	63	O	for
12	65	71	O	glucose
13	73	74	O	in
14	76	78	O	the
15	80	84	O	urine
16	86	88	O	may
17	90	94	O	occur
18	96	99	O	with
19	101	106	O	copper
20	108	116	O	reduction
21	118	122	O	tests
22	125	132	O	Benedict
23	134	134	O	s
24	136	137	O	or
25	139	145	O	Fehling
26	147	147	O	s
27	149	156	O	solution
28	158	159	O	or
29	161	164	O	with
30	166	174	O	Clinitest
31	177	183	O	tablets
32	186	188	O	but
33	190	192	O	not
34	194	197	O	with
35	199	204	O	enzyme
36	206	210	O	based
37	212	216	O	tests
38	218	220	O	for
39	222	231	O	glycosuria
NULL

Cefuroxime	DDI-DrugBank.d447.s1	NO_SECTION	NO_SETID	35
As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving cefuroxime.
1	0	1	O	As
2	3	3	O	a
3	5	9	O	false
4	11	18	O	negative
5	20	25	O	result
6	27	29	O	may
7	31	35	O	occur
8	37	38	O	in
9	40	42	O	the
10	44	55	O	ferricyanide
11	57	60	O	test
12	61	61	O	,
13	63	64	O	it
14	66	67	O	is
15	69	79	O	recommended
16	81	84	O	that
17	86	91	O	either
18	93	95	O	the
19	97	103	O	glucose
20	105	111	O	oxidase
21	113	114	O	or
22	116	125	O	hexokinase
23	127	132	O	method
24	134	135	O	be
25	137	140	O	used
26	142	143	O	to
27	145	153	O	determine
28	155	159	O	blood
29	161	166	O	plasma
30	168	174	O	glucose
31	176	181	O	levels
32	183	184	O	in
33	186	193	O	patients
34	195	203	O	receiving
35	205	214	O	XXXXXXXX
NULL

Cefuroxime	DDI-DrugBank.d447.s2	NO_SECTION	NO_SETID	17
Cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method.
1	0	9	O	XXXXXXXX
2	11	14	O	does
3	16	18	O	not
4	20	28	O	interfere
5	30	33	O	with
6	35	37	O	the
7	39	43	O	assay
8	45	46	O	of
9	48	52	O	serum
10	54	56	O	and
11	58	62	O	urine
12	64	73	O	creatinine
13	75	76	O	by
14	78	80	O	the
15	82	89	O	alkaline
16	91	97	O	picrate
17	99	104	O	method
NULL

Celecoxib	DDI-DrugBank.d172.s0	NO_SECTION	NO_SETID	17
General: Significant interactions may occur when celecoxib is administered together with drugs that inhibit P450 2C9.
1	0	6	O	General
2	7	7	O	:
3	9	19	O	Significant
4	21	32	O	interactions
5	34	36	O	may
6	38	42	O	occur
7	44	47	O	when
8	49	57	O	XXXXXXXX
9	59	60	O	is
10	62	73	O	administered
11	75	82	O	together
12	84	87	O	with
13	89	93	O	drugs
14	95	98	O	that
15	100	106	O	inhibit
16	108	111	O	P450
17	113	115	O	2C9
NULL

Celecoxib	DDI-DrugBank.d172.s1	NO_SECTION	NO_SETID	12
Celecoxib metabolism is predominantly mediated via cytochrome P450 2C9 in the liver.
1	0	8	O	XXXXXXXX
2	10	19	O	metabolism
3	21	22	O	is
4	24	36	O	predominantly
5	38	45	O	mediated
6	47	49	O	via
7	51	60	O	cytochrome
8	62	65	O	P450
9	67	69	O	2C9
10	71	72	O	in
11	74	76	O	the
12	78	82	O	liver
NULL

Celecoxib	DDI-DrugBank.d172.s2	NO_SECTION	NO_SETID	17
Co-administration of celecoxib with drugs that are known to inhibit 2C9 should be done with caution.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	29	O	XXXXXXXX
5	31	34	O	with
6	36	40	O	drugs
7	42	45	O	that
8	47	49	O	are
9	51	55	O	known
10	57	58	O	to
11	60	66	O	inhibit
12	68	70	O	2C9
13	72	77	O	should
14	79	80	O	be
15	82	85	O	done
16	87	90	O	with
17	92	98	O	caution
NULL

Celecoxib	DDI-DrugBank.d172.s3	NO_SECTION	NO_SETID	18
In vitro studies indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	24	O	indicate
5	26	29	O	that
6	31	39	O	XXXXXXXX
7	41	42	O	is
8	44	46	O	not
9	48	49	O	an
10	51	59	O	inhibitor
11	61	62	O	of
12	64	73	O	cytochrome
13	75	78	O	P450
14	80	82	O	2C9
15	83	83	O	,
16	85	88	O	2C19
17	90	91	O	or
18	93	95	O	3A4
NULL

Celecoxib	DDI-DrugBank.d172.s4	NO_SECTION	NO_SETID	20
In vitro studies also indicate that celecoxib, although not a substrate, is an inhibitor of cytochrome P450 2D6.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	also
5	22	29	O	indicate
6	31	34	O	that
7	36	44	O	XXXXXXXX
8	45	45	O	,
9	47	54	O	although
10	56	58	O	not
11	60	60	O	a
12	62	70	O	substrate
13	71	71	O	,
14	73	74	O	is
15	76	77	O	an
16	79	87	O	inhibitor
17	89	90	O	of
18	92	101	O	cytochrome
19	103	106	O	P450
20	108	110	O	2D6
NULL

Celecoxib	DDI-DrugBank.d172.s5	NO_SECTION	NO_SETID	20
Therefore, there is a potential for an in vivo drug interaction with drugs that are metabolized by P450 2D6.
1	0	8	O	Therefore
2	9	9	O	,
3	11	15	O	there
4	17	18	O	is
5	20	20	O	a
6	22	30	O	potential
7	32	34	O	for
8	36	37	O	an
9	39	40	O	in
10	42	45	O	vivo
11	47	50	O	drug
12	52	62	O	interaction
13	64	67	O	with
14	69	73	O	drugs
15	75	78	O	that
16	80	82	O	are
17	84	94	O	metabolized
18	96	97	O	by
19	99	102	O	P450
20	104	106	O	2D6
NULL

Celecoxib	DDI-DrugBank.d172.s6	NO_SECTION	NO_SETID	13
Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.
1	0	7	O	Clinical
2	9	15	O	studies
3	17	20	O	with
4	22	30	O	XXXXXXXX
5	32	35	O	have
6	37	46	O	identified
7	48	58	O	potentially
8	60	70	O	significant
9	72	83	O	interactions
10	85	88	O	with
11	90	100	U-UNK	fluconazole
12	102	104	O	and
13	106	112	U-UNK	lithium
NULL

Celecoxib	DDI-DrugBank.d172.s7	NO_SECTION	NO_SETID	17
Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.
1	0	9	O	Experience
2	11	14	O	with
3	16	27	B-UNK	nonsteroidal
4	29	32	I-UNK	anti
5	34	45	I-UNK	inflammatory
6	47	51	L-UNK	drugs
7	54	59	U-UNK	NSAIDs
8	62	69	O	suggests
9	71	73	O	the
10	75	83	O	potential
11	85	87	O	for
12	89	100	O	interactions
13	102	105	O	with
14	107	116	U-UNK	furosemide
15	118	120	O	and
16	122	124	B-UNK	ACE
17	126	135	L-UNK	inhibitors
NULL

Celecoxib	DDI-DrugBank.d172.s8	NO_SECTION	NO_SETID	36
The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.
1	0	2	O	The
2	4	10	O	effects
3	12	20	O	XXXXXXXX
4	22	23	O	on
5	25	27	O	the
6	29	44	O	pharmacokinetics
7	46	48	O	and
8	49	49	O	/
9	50	51	O	or
10	53	68	O	pharmacodynamics
11	70	71	O	of
12	73	81	U-UNK	glyburide
13	82	82	O	,
14	84	95	U-UNK	ketoconazole
15	96	96	O	,
16	98	109	U-UNK	methotrexate
17	110	110	O	,
18	112	120	U-UNK	phenytoin
19	121	121	O	,
20	123	133	U-UNK	tolbutamide
21	134	134	O	,
22	136	138	O	and
23	140	147	U-UNK	warfarin
24	149	152	O	have
25	154	157	O	been
26	159	165	O	studied
27	167	168	O	in
28	170	173	O	vivo
29	175	177	O	and
30	179	188	O	clinically
31	190	198	O	important
32	200	211	O	interactions
33	213	216	O	have
34	218	220	O	not
35	222	225	O	been
36	227	231	O	found
NULL

Celecoxib	DDI-DrugBank.d172.s9	NO_SECTION	NO_SETID	18
ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
1	0	2	B-UNK	ACE
2	4	13	L-UNK	inhibitors
3	14	14	O	:
4	16	22	O	Reports
5	24	30	O	suggest
6	32	35	O	that
7	37	42	U-UNK	NSAIDs
8	44	46	O	may
9	48	55	O	diminish
10	57	59	O	the
11	61	76	O	antihypertensive
12	78	83	O	effect
13	85	86	O	of
14	88	98	B-UNK	Angiotensin
15	100	109	I-UNK	Converting
16	111	116	I-UNK	Enzyme
17	119	121	I-UNK	ACE
18	124	133	L-UNK	inhibitors
NULL

Celecoxib	DDI-DrugBank.d172.s10	NO_SECTION	NO_SETID	14
This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.
1	0	3	O	This
2	5	15	O	interaction
3	17	22	O	should
4	24	25	O	be
5	27	31	O	given
6	33	45	O	consideration
7	47	48	O	in
8	50	57	O	patients
9	59	64	O	taking
10	66	73	O	XXXXXXXX
11	75	87	O	concomitantly
12	89	92	O	with
13	94	96	B-DYN	ACE
14	98	107	L-DYN	inhibitors
NULL

Celecoxib	DDI-DrugBank.d172.s11	NO_SECTION	NO_SETID	28
Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
1	0	9	U-UNK	Furosemide
2	10	10	O	:
3	12	19	O	Clinical
4	21	27	O	studies
5	28	28	O	,
6	30	31	O	as
7	33	36	O	well
8	38	39	O	as
9	41	44	O	post
10	46	54	O	marketing
11	56	67	O	observations
12	68	68	O	,
13	70	73	O	have
14	75	79	O	shown
15	81	84	O	that
16	86	91	U-UNK	NSAIDs
17	93	95	O	can
18	97	102	O	reduce
19	104	106	O	the
20	108	118	O	natriuretic
21	120	125	O	effect
22	127	128	O	of
23	130	139	U-UNK	furosemide
24	141	143	O	and
25	145	153	U-UNK	thiazides
26	155	156	O	in
27	158	161	O	some
28	163	170	O	patients
NULL

Celecoxib	DDI-DrugBank.d172.s12	NO_SECTION	NO_SETID	11
This response has been attributed to inhibition of renal prostaglandin synthesis.
1	0	3	O	This
2	5	12	O	response
3	14	16	O	has
4	18	21	O	been
5	23	32	O	attributed
6	34	35	O	to
7	37	46	O	inhibition
8	48	49	O	of
9	51	55	O	renal
10	57	69	O	prostaglandin
11	71	79	O	synthesis
NULL

Celecoxib	DDI-DrugBank.d172.s13	NO_SECTION	NO_SETID	10
Aspirin: CELEBREX can be used with low dose aspirin.
1	0	6	O	XXXXXXXX
2	7	7	O	:
3	9	16	O	CELEBREX
4	18	20	O	can
5	22	23	O	be
6	25	28	O	used
7	30	33	O	with
8	35	37	O	low
9	39	42	O	dose
10	44	50	U-DYN	XXXXXXXX
NULL

Celecoxib	DDI-DrugBank.d172.s14	NO_SECTION	NO_SETID	27
However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.
1	0	6	O	However
2	7	7	O	,
3	9	19	O	concomitant
4	21	34	O	administration
5	36	37	O	of
6	39	45	O	aspirin
7	47	50	O	with
8	52	59	U-DYN	XXXXXXXX
9	61	63	O	may
10	65	70	O	result
11	72	73	O	in
12	75	76	O	an
13	78	86	O	increased
14	88	91	O	rate
15	93	94	O	of
16	96	97	O	GI
17	99	108	O	ulceration
18	110	111	O	or
19	113	117	O	other
20	119	131	O	complications
21	132	132	O	,
22	134	141	O	compared
23	143	144	O	to
24	146	148	O	use
25	150	151	O	of
26	153	160	O	XXXXXXXX
27	162	166	O	alone
NULL

Celecoxib	DDI-DrugBank.d172.s15	NO_SECTION	NO_SETID	18
Because of its lack of platelet effects, CELEBREX is not a substitute for aspirin for cardiovascular prophylaxis.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	its
4	15	18	O	lack
5	20	21	O	of
6	23	30	O	platelet
7	32	38	O	effects
8	39	39	O	,
9	41	48	O	CELEBREX
10	50	51	O	is
11	53	55	O	not
12	57	57	O	a
13	59	68	O	substitute
14	70	72	O	for
15	74	80	O	XXXXXXXX
16	82	84	O	for
17	86	99	O	cardiovascular
18	101	111	O	prophylaxis
NULL

Celecoxib	DDI-DrugBank.d172.s16	NO_SECTION	NO_SETID	20
Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.
1	0	10	U-UNK	Fluconazole
2	11	11	O	:
3	13	23	O	Concomitant
4	25	38	O	administration
5	40	41	O	of
6	43	53	U-KIN	fluconazole
7	55	56	O	at
8	58	60	O	200
9	62	63	O	mg
10	65	66	O	QD
11	68	75	O	resulted
12	77	78	O	in
13	80	80	O	a
14	82	84	O	two
15	86	89	O	fold
16	91	98	O	increase
17	100	101	O	in
18	103	111	O	XXXXXXXX
19	113	118	O	plasma
20	120	132	O	concentration
NULL

Celecoxib	DDI-DrugBank.d172.s17	NO_SECTION	NO_SETID	21
This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).
1	0	3	O	This
2	5	12	O	increase
3	14	15	O	is
4	17	19	O	due
5	21	22	O	to
6	24	26	O	the
7	28	37	O	inhibition
8	39	40	O	of
9	42	50	O	XXXXXXXX
10	52	61	O	metabolism
11	63	65	O	via
12	67	70	O	P450
13	72	74	O	2C9
14	76	77	O	by
15	79	89	U-KIN	fluconazole
16	92	94	O	see
17	96	103	O	CLINICAL
18	105	116	O	PHARMACOLOGY
19	120	135	O	Pharmacokinetics
20	136	136	O	:
21	138	147	O	Metabolism
NULL

Celecoxib	DDI-DrugBank.d172.s18	NO_SECTION	NO_SETID	13
CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.
1	0	7	O	XXXXXXXX
2	9	14	O	should
3	16	17	O	be
4	19	28	O	introduced
5	30	31	O	at
6	33	35	O	the
7	37	42	O	lowest
8	44	54	O	recommended
9	56	59	O	dose
10	61	62	O	in
11	64	71	O	patients
12	73	81	O	receiving
13	83	93	U-DYN	fluconazole
NULL

Celecoxib	DDI-DrugBank.d172.s19	NO_SECTION	NO_SETID	38
Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	10	O	In
4	12	12	O	a
5	14	18	O	study
6	20	28	O	conducted
7	30	31	O	in
8	33	39	O	healthy
9	41	48	O	subjects
10	49	49	O	,
11	51	54	O	mean
12	56	61	O	steady
13	63	67	O	state
14	69	75	U-UNK	lithium
15	77	82	O	plasma
16	84	89	O	levels
17	91	99	O	increased
18	101	113	O	approximately
19	115	117	O	17%
20	119	120	O	in
21	122	129	O	subjects
22	131	139	O	receiving
23	141	147	U-KIN	lithium
24	149	151	O	450
25	153	154	O	mg
26	156	158	O	BID
27	160	163	O	with
28	165	172	O	XXXXXXXX
29	174	176	O	200
30	178	179	O	mg
31	181	183	O	BID
32	185	186	O	as
33	188	195	O	compared
34	197	198	O	to
35	200	207	O	subjects
36	209	217	O	receiving
37	219	225	U-UNK	lithium
38	227	231	O	alone
NULL

Celecoxib	DDI-DrugBank.d172.s20	NO_SECTION	NO_SETID	14
Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.
1	0	7	O	Patients
2	9	10	O	on
3	12	18	U-DYN	lithium
4	20	28	O	treatment
5	30	35	O	should
6	37	38	O	be
7	40	46	O	closely
8	48	56	O	monitored
9	58	61	O	when
10	63	70	O	XXXXXXXX
11	72	73	O	is
12	75	84	O	introduced
13	86	87	O	or
14	89	97	O	withdrawn
NULL

Celecoxib	DDI-DrugBank.d172.s21	NO_SECTION	NO_SETID	25
Methotrexate: In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of methotrexate.
1	0	11	U-UNK	Methotrexate
2	12	12	O	:
3	14	15	O	In
4	17	18	O	an
5	20	30	O	interaction
6	32	36	O	study
7	38	39	O	of
8	41	50	O	rheumatoid
9	52	60	O	arthritis
10	62	69	O	patients
11	71	76	O	taking
12	78	89	U-UNK	methotrexate
13	90	90	O	,
14	92	99	O	XXXXXXXX
15	101	103	O	did
16	105	107	O	not
17	109	112	O	have
18	114	114	O	a
19	116	126	O	significant
20	128	133	O	effect
21	135	136	O	on
22	138	140	O	the
23	142	157	O	pharmacokinetics
24	159	160	O	of
25	162	173	U-UNK	methotrexate
NULL

Celecoxib	DDI-DrugBank.d172.s22	NO_SECTION	NO_SETID	30
Warfarin: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	12	O	The
4	14	19	O	effect
5	21	22	O	of
6	24	32	O	XXXXXXXX
7	34	35	O	on
8	37	39	O	the
9	41	44	O	anti
10	46	54	O	coagulant
11	56	61	O	effect
12	63	64	O	of
13	66	73	U-UNK	warfarin
14	75	77	O	was
15	79	85	O	studied
16	87	88	O	in
17	90	90	O	a
18	92	96	O	group
19	98	99	O	of
20	101	107	O	healthy
21	109	116	O	subjects
22	118	126	O	receiving
23	128	132	O	daily
24	134	138	O	doses
25	140	141	O	of
26	143	143	O	2
27	145	145	O	5
28	147	148	O	mg
29	150	151	O	of
30	153	160	U-UNK	warfarin
NULL

Celecoxib	DDI-DrugBank.d172.s23	NO_SECTION	NO_SETID	18
In these subjects, celecoxib did not alter the anticoagulant effect of warfarin as determined by prothrombin time.
1	0	1	O	In
2	3	7	O	these
3	9	16	O	subjects
4	17	17	O	,
5	19	27	O	XXXXXXXX
6	29	31	O	did
7	33	35	O	not
8	37	41	O	alter
9	43	45	O	the
10	47	59	O	anticoagulant
11	61	66	O	effect
12	68	69	O	of
13	71	78	U-UNK	warfarin
14	80	81	O	as
15	83	92	O	determined
16	94	95	O	by
17	97	107	O	prothrombin
18	109	112	O	time
NULL

Celecoxib	DDI-DrugBank.d172.s24	NO_SECTION	NO_SETID	21
However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	caution
4	17	22	O	should
5	24	25	O	be
6	27	30	O	used
7	32	35	O	when
8	37	49	O	administering
9	51	58	O	XXXXXXXX
10	60	63	O	with
11	65	72	U-DYN	warfarin
12	74	78	O	since
13	80	84	O	these
14	86	93	O	patients
15	95	97	O	are
16	99	100	O	at
17	102	110	O	increased
18	112	115	O	risk
19	117	118	O	of
20	120	127	O	bleeding
21	129	141	O	complications
NULL

Cephalexin	DDI-DrugBank.d303.s0	NO_SECTION	NO_SETID	40
Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.
1	0	8	U-UNK	Metformin
2	9	9	O	:
3	11	12	O	In
4	14	20	O	healthy
5	22	29	O	subjects
6	31	35	O	given
7	37	42	O	single
8	44	46	O	500
9	48	49	O	mg
10	51	55	O	doses
11	57	58	O	of
12	60	69	O	XXXXXXXX
13	71	73	O	and
14	75	83	U-KIN	metformin
15	84	84	O	,
16	86	91	O	plasma
17	93	101	U-UNK	metformin
18	103	106	O	mean
19	108	111	O	cmax
20	113	115	O	and
21	117	119	O	AUC
22	121	129	O	increased
23	131	132	O	by
24	134	135	O	an
25	137	143	O	average
26	145	146	O	of
27	148	150	O	34%
28	152	154	O	and
29	156	158	O	24%
30	159	159	O	,
31	161	172	O	respectively
32	173	173	O	,
33	175	177	O	and
34	179	187	U-UNK	metformin
35	189	192	O	mean
36	194	198	O	renal
37	200	208	O	clearance
38	210	218	O	decreased
39	220	221	O	by
40	223	225	O	14%
NULL

Cephalexin	DDI-DrugBank.d303.s1	NO_SECTION	NO_SETID	17
No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.
1	0	1	O	No
2	3	13	O	information
3	15	16	O	is
4	18	26	O	available
5	28	32	O	about
6	34	36	O	the
7	38	48	O	interaction
8	50	51	O	of
9	53	62	O	XXXXXXXX
10	64	66	O	and
11	68	76	U-UNK	metformin
12	78	86	O	following
13	88	95	O	multiple
14	97	101	O	doses
15	103	104	O	of
16	106	111	O	either
17	113	116	O	drug
NULL

Cephalexin	DDI-DrugBank.d303.s2	NO_SECTION	NO_SETID	29
Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.
1	0	7	O	Although
2	9	11	O	not
3	13	20	O	observed
4	22	23	O	in
5	25	28	O	this
6	30	34	O	study
7	35	35	O	,
8	37	43	O	adverse
9	45	51	O	effects
10	53	57	O	could
11	59	69	O	potentially
12	71	75	O	arise
13	77	80	O	from
14	82	83	O	co
15	85	98	O	administration
16	100	101	O	of
17	103	112	O	XXXXXXXX
18	114	116	O	and
19	118	126	U-KIN	metformin
20	128	129	O	by
21	131	140	O	inhibition
22	142	143	O	of
23	145	151	O	tubular
24	153	161	O	secretion
25	163	165	O	via
26	167	173	O	organic
27	175	182	O	cationic
28	184	194	O	transporter
29	196	202	O	systems
NULL

Cephalexin	DDI-DrugBank.d303.s3	NO_SECTION	NO_SETID	19
Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.
1	0	10	O	Accordingly
2	11	11	O	,
3	13	19	O	careful
4	21	27	O	patient
5	29	38	O	monitoring
6	40	42	O	and
7	44	47	O	dose
8	49	58	O	adjustment
9	60	61	O	of
10	63	71	U-UNK	metformin
11	73	74	O	is
12	76	86	O	recommended
13	88	89	O	in
14	91	98	O	patients
15	100	112	O	concomitantly
16	114	119	O	taking
17	121	130	O	XXXXXXXX
18	132	134	O	and
19	136	144	U-DYN	metformin
NULL

Cephalexin	DDI-DrugBank.d303.s4	NO_SECTION	NO_SETID	17
Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.
1	0	9	U-UNK	Probenecid
2	10	10	O	:
3	12	13	O	As
4	15	18	O	with
5	20	24	O	other
6	26	26	B-UNK	b
7	28	34	L-UNK	lactams
8	35	35	O	,
9	37	39	O	the
10	41	45	O	renal
11	47	55	O	excretion
12	57	58	O	of
13	60	69	O	XXXXXXXX
14	71	72	O	is
15	74	82	O	inhibited
16	84	85	O	by
17	87	96	U-KIN	probenecid
NULL

Cephalexin	DDI-DrugBank.d303.s5	NO_SECTION	NO_SETID	24
Drug / Laboratory Test Interactions As a result of administration of Keflex, a false-positive reaction for glucose in the urine may occur.
1	0	3	O	Drug
2	5	5	O	/
3	7	16	O	Laboratory
4	18	21	O	Test
5	23	34	O	Interactions
6	36	37	O	As
7	39	39	O	a
8	41	46	O	result
9	48	49	O	of
10	51	64	O	administration
11	66	67	O	of
12	69	74	O	XXXXXXXX
13	75	75	O	,
14	77	77	O	a
15	79	83	O	false
16	85	92	O	positive
17	94	101	O	reaction
18	103	105	O	for
19	107	113	O	glucose
20	115	116	O	in
21	118	120	O	the
22	122	126	O	urine
23	128	130	O	may
24	132	136	O	occur
NULL

Cephalexin	DDI-DrugBank.d303.s6	NO_SECTION	NO_SETID	16
This has been observed with Benedict s and Fehling s solutions and also with Clinitest  tablets.
1	0	3	O	This
2	5	7	O	has
3	9	12	O	been
4	14	21	O	observed
5	23	26	O	with
6	28	35	O	Benedict
7	37	37	O	s
8	39	41	O	and
9	43	49	O	Fehling
10	51	51	O	s
11	53	61	O	solutions
12	63	65	O	and
13	67	70	O	also
14	72	75	O	with
15	77	85	O	Clinitest
16	88	94	O	tablets
NULL

Cerivastatin	DDI-DrugBank.d141.s0	NO_SECTION	NO_SETID	18
Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.
1	0	16	B-UNK	Immunosuppressive
2	18	22	L-UNK	Drugs
3	23	23	O	,
4	25	30	B-UNK	Fibric
5	32	35	I-UNK	Acid
6	37	47	L-UNK	Derivatives
7	48	48	O	,
8	50	55	U-UNK	Niacin
9	58	66	B-UNK	Nicotinic
10	68	71	L-UNK	Acid
11	72	72	O	,
12	74	85	U-UNK	Erythromycin
13	86	86	O	,
14	88	92	B-UNK	Azole
15	94	104	L-UNK	Antifungals
16	105	105	O	:
17	107	114	O	Skeletal
18	116	121	O	Muscle
NULL

Cerivastatin	DDI-DrugBank.d141.s1	NO_SECTION	NO_SETID	16
ANTACID (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of antacid.
1	0	6	U-UNK	ANTACID
2	9	17	B-UNK	Magnesium
3	19	26	I-UNK	Aluminum
4	28	36	L-UNK	Hydroxide
5	38	38	O	:
6	40	51	O	XXXXXXXX
7	53	58	O	plasma
8	60	73	O	concentrations
9	75	78	O	were
10	80	82	O	not
11	84	91	O	affected
12	93	94	O	by
13	96	97	O	co
14	99	112	O	administration
15	114	115	O	of
16	117	123	U-UNK	antacid
NULL

Cerivastatin	DDI-DrugBank.d141.s2	NO_SECTION	NO_SETID	13
CIMETlDINE: Cerivastatin plasma concentrations were not affected by co-administration of cimetidine.
1	0	9	U-UNK	CIMETlDINE
2	10	10	O	:
3	12	23	O	XXXXXXXX
4	25	30	O	plasma
5	32	45	O	concentrations
6	47	50	O	were
7	52	54	O	not
8	56	63	O	affected
9	65	66	O	by
10	68	69	O	co
11	71	84	O	administration
12	86	87	O	of
13	89	98	U-UNK	cimetidine
NULL

Cerivastatin	DDI-DrugBank.d141.s3	NO_SECTION	NO_SETID	28
CHOLESTYRAMINE: The influence of the bile-acidsequestering agent cholestyramine on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies.
1	0	13	U-UNK	CHOLESTYRAMINE
2	14	14	O	:
3	16	18	O	The
4	20	28	O	influence
5	30	31	O	of
6	33	35	O	the
7	37	40	O	bile
8	42	57	O	acidsequestering
9	59	63	O	agent
10	65	78	U-UNK	cholestyramine
11	80	81	O	on
12	83	85	O	the
13	87	102	O	pharmacokinetits
14	104	105	O	of
15	107	118	O	XXXXXXXX
16	120	125	O	sodium
17	127	129	O	was
18	131	139	O	evaluated
19	141	142	O	in
20	144	145	O	12
21	147	153	O	healthy
22	155	159	O	males
23	161	162	O	in
24	164	164	O	2
25	166	173	O	separate
26	175	184	O	randomized
27	186	194	O	crossover
28	196	202	O	studies
NULL

Cerivastatin	DDI-DrugBank.d141.s4	NO_SECTION	NO_SETID	36
In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.
1	0	1	O	In
2	3	5	O	the
3	7	11	O	first
4	13	17	O	study
5	18	18	O	,
6	20	30	O	concomitant
7	32	45	O	administration
8	47	48	O	of
9	50	52	O	0.2
10	54	55	O	mg
11	57	68	O	XXXXXXXX
12	70	75	O	sodium
13	77	79	O	and
14	81	82	O	12
15	84	84	O	g
16	86	99	U-KIN	cholestyramine
17	101	108	O	resulted
18	110	111	O	in
19	113	121	O	decreases
20	123	124	O	of
21	126	129	O	more
22	131	134	O	than
23	136	138	O	22%
24	140	142	O	for
25	144	146	O	AUC
26	148	150	O	and
27	152	154	O	40%
28	156	158	O	for
29	160	163	O	Cmax
30	165	168	O	when
31	170	177	O	compared
32	179	180	O	to
33	182	187	O	dosing
34	189	200	O	XXXXXXXX
35	202	207	O	sodium
36	209	213	O	alone
NULL

Cerivastatin	DDI-DrugBank.d141.s5	NO_SECTION	NO_SETID	59
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	14	O	the
5	16	21	O	second
6	23	27	O	study
7	28	28	O	,
8	30	43	O	administration
9	45	46	O	of
10	48	49	O	12
11	51	51	O	g
12	53	66	U-KIN	cholestyramine
13	68	68	O	1
14	70	73	O	hour
15	75	80	O	before
16	82	84	O	the
17	86	92	O	evening
18	94	97	O	meal
19	99	101	O	and
20	103	105	O	0.3
21	107	108	O	mg
22	110	121	O	XXXXXXXX
23	123	128	O	sodium
24	130	142	O	approximately
25	144	144	O	4
26	146	150	O	hours
27	152	156	O	after
28	158	160	O	the
29	162	165	O	same
30	167	173	O	evening
31	175	178	O	meal
32	180	187	O	resulted
33	189	190	O	in
34	192	192	O	a
35	194	201	O	decrease
36	203	204	O	in
37	206	208	O	the
38	210	221	O	XXXXXXXX
39	223	225	O	AUC
40	227	228	O	of
41	230	233	O	less
42	235	238	O	than
43	240	241	O	8%
44	242	242	O	,
45	244	246	O	and
46	248	248	O	a
47	250	257	O	decrease
48	259	260	O	in
49	262	265	O	Cmax
50	267	268	O	of
51	270	274	O	about
52	276	278	O	30%
53	280	283	O	when
54	285	292	O	compared
55	294	295	O	to
56	297	302	O	dosing
57	304	315	O	XXXXXXXX
58	317	322	O	sodium
59	324	328	O	alone
NULL

Cerivastatin	DDI-DrugBank.d141.s6	NO_SECTION	NO_SETID	37
Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	it
4	14	18	O	would
5	20	21	O	be
6	23	30	O	expected
7	32	35	O	that
8	37	37	O	a
9	39	44	O	dosing
10	46	53	O	schedule
11	55	56	O	of
12	58	69	O	XXXXXXXX
13	71	76	O	sodium
14	78	82	O	given
15	84	85	O	at
16	87	93	O	bedtime
17	95	97	O	and
18	99	112	U-UNK	cholestyramine
19	114	118	O	given
20	120	125	O	before
21	127	129	O	the
22	131	137	O	evening
23	139	142	O	meal
24	144	148	O	would
25	150	152	O	not
26	154	159	O	result
27	161	162	O	in
28	164	164	O	a
29	166	176	O	significant
30	178	185	O	decrease
31	187	188	O	in
32	190	192	O	the
33	194	201	O	clinical
34	203	208	O	effect
35	210	211	O	of
36	213	224	O	XXXXXXXX
37	226	231	O	sodium
NULL

Cerivastatin	DDI-DrugBank.d141.s7	NO_SECTION	NO_SETID	22
DIGOXIN: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.
1	0	6	U-UNK	DIGOXIN
2	7	7	O	:
3	9	14	O	Plasma
4	16	22	U-UNK	digoxin
5	24	29	O	levels
6	31	33	O	and
7	35	41	U-UNK	digoxin
8	43	51	O	clearance
9	53	54	O	at
10	56	61	O	steady
11	63	67	O	state
12	69	72	O	were
13	74	76	O	not
14	78	85	O	affected
15	87	88	O	by
16	90	91	O	co
17	93	106	O	administration
18	108	109	O	of
19	111	113	O	0.2
20	115	116	O	mg
21	118	129	O	XXXXXXXX
22	131	136	O	sodium
NULL

Cerivastatin	DDI-DrugBank.d141.s8	NO_SECTION	NO_SETID	12
Cerivastatin plasma concentrations were also not affected by co-administration of digoxin.
1	0	11	O	XXXXXXXX
2	13	18	O	plasma
3	20	33	O	concentrations
4	35	38	O	were
5	40	43	O	also
6	45	47	O	not
7	49	56	O	affected
8	58	59	O	by
9	61	62	O	co
10	64	77	O	administration
11	79	80	O	of
12	82	88	U-UNK	digoxin
NULL

Cerivastatin	DDI-DrugBank.d141.s9	NO_SECTION	NO_SETID	33
WARFARIN: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.
1	0	7	U-UNK	WARFARIN
2	8	8	O	:
3	10	11	O	Co
4	14	27	O	administration
5	29	30	O	of
6	32	39	U-UNK	warfarin
7	41	43	O	and
8	45	56	O	XXXXXXXX
9	58	59	O	to
10	61	67	O	healthy
11	69	78	O	volunteers
12	80	82	O	did
13	84	86	O	not
14	88	93	O	result
15	95	96	O	in
16	98	100	O	any
17	102	108	O	changes
18	110	111	O	in
19	113	123	O	prothrombin
20	125	128	O	time
21	130	131	O	or
22	133	140	O	clotting
23	142	147	O	factor
24	149	151	O	VII
25	153	156	O	when
26	158	165	O	compared
27	167	168	O	to
28	170	171	O	co
29	173	186	O	administration
30	188	189	O	of
31	191	198	U-UNK	warfarin
32	200	202	O	and
33	204	210	O	placebo
NULL

Cerivastatin	DDI-DrugBank.d141.s10	NO_SECTION	NO_SETID	23
The AUC and Cmax of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of 0.3 mg cerivastatin sodium.
1	0	2	O	The
2	4	6	O	AUC
3	8	10	O	and
4	12	15	O	Cmax
5	17	18	O	of
6	20	23	O	both
7	25	27	O	the
8	30	30	O	R
9	33	35	O	and
10	38	38	O	S
11	41	47	O	isomers
12	49	50	O	of
13	52	59	U-UNK	warfarin
14	61	64	O	were
15	66	75	O	unaffected
16	77	78	O	by
17	80	89	O	concurrent
18	91	96	O	dosing
19	98	99	O	of
20	101	103	O	0.3
21	105	106	O	mg
22	108	119	O	XXXXXXXX
23	121	126	O	sodium
NULL

Cerivastatin	DDI-DrugBank.d141.s11	NO_SECTION	NO_SETID	14
Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin sodium.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	28	U-UNK	warfarin
5	30	32	O	and
6	34	45	O	XXXXXXXX
7	47	49	O	did
8	51	53	O	not
9	55	59	O	alter
10	61	63	O	the
11	65	80	O	pharmacokinetics
12	82	83	O	of
13	85	96	O	XXXXXXXX
14	98	103	O	sodium
NULL

Cerivastatin	DDI-DrugBank.d141.s12	NO_SECTION	NO_SETID	34
ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.
1	0	11	U-UNK	ERYTHROMYCIN
2	12	12	O	:
3	14	15	O	In
4	17	36	O	hypercholesterolemic
5	38	45	O	patients
6	46	46	O	,
7	48	53	O	steady
8	55	59	O	state
9	61	72	O	XXXXXXXX
10	74	76	O	AUC
11	78	80	O	and
12	82	85	O	Cmax
13	87	95	O	increased
14	97	109	O	approximately
15	111	113	O	50%
16	115	117	O	and
17	119	121	O	24%
18	123	134	O	respectively
19	136	140	O	after
20	142	143	O	10
21	145	148	O	days
22	150	153	O	with
23	155	156	O	co
24	158	171	O	administration
25	173	174	O	of
26	176	187	U-KIN	erythromycin
27	188	188	O	,
28	190	190	O	a
29	192	196	O	known
30	198	206	O	inhibitor
31	208	209	O	of
32	211	220	O	cytochrome
33	222	225	O	P450
34	227	229	O	3A4
NULL

Cerivastatin	DDI-DrugBank.d141.s13	NO_SECTION	NO_SETID	49
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.
1	0	4	O	OTHER
2	6	16	O	CONCOMITANT
3	18	24	O	THERAPY
4	25	25	O	:
5	27	34	O	Although
6	36	43	O	specific
7	45	55	O	interaction
8	57	63	O	studies
9	65	68	O	were
10	70	72	O	not
11	74	82	O	performed
12	83	83	O	,
13	85	86	O	in
14	88	95	O	clinical
15	97	103	O	studies
16	104	104	O	,
17	106	117	O	XXXXXXXX
18	119	124	O	sodium
19	126	128	O	was
20	130	133	O	used
21	135	147	O	concomitantly
22	149	152	O	with
23	154	164	B-UNK	angiotensin
24	167	176	I-UNK	converting
25	178	183	I-UNK	enzyme
26	186	188	I-UNK	ACE
27	191	200	L-UNK	inhibitors
28	201	201	O	,
29	203	214	U-UNK	betablockers
30	215	215	O	,
31	217	223	B-UNK	calcium
32	225	231	I-UNK	channel
33	233	240	L-UNK	blockers
34	241	241	O	,
35	243	251	U-UNK	diuretics
36	252	252	O	,
37	254	256	O	and
38	258	269	B-UNK	nonsteroidal
39	271	274	I-UNK	anti
40	276	287	I-UNK	inflammatory
41	289	293	L-UNK	drugs
42	296	301	U-UNK	NSAIDs
43	304	310	O	without
44	312	319	O	evidence
45	321	322	O	of
46	324	333	O	clinically
47	335	345	O	significant
48	347	353	O	adverse
49	355	366	O	interactions
NULL

Cetirizine	DDI-DrugBank.d393.s0	NO_SECTION	NO_SETID	19
Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin.
1	0	14	O	Pharmacokinetic
2	16	26	O	interaction
3	28	34	O	studies
4	36	39	O	with
5	41	50	O	XXXXXXXX
6	52	53	O	in
7	55	60	O	adults
8	62	65	O	were
9	67	75	O	conducted
10	77	80	O	with
11	82	96	U-UNK	pseudoephedrine
12	97	97	O	,
13	99	108	U-UNK	antipyrine
14	109	109	O	,
15	111	122	U-UNK	ketoconazole
16	123	123	O	,
17	125	136	U-UNK	erythromycin
18	138	140	O	and
19	142	153	U-UNK	azithromycin
NULL

Cetirizine	DDI-DrugBank.d393.s1	NO_SECTION	NO_SETID	4
No interactions were observed.
1	0	1	O	No
2	3	14	O	interactions
3	16	19	O	were
4	21	28	O	observed
NULL

Cetirizine	DDI-DrugBank.d393.s2	NO_SECTION	NO_SETID	34
In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	multiple
4	14	17	O	dose
5	19	23	O	study
6	25	26	O	of
7	28	39	U-KIN	theophylline
8	42	44	O	400
9	46	47	O	mg
10	49	52	O	once
11	54	58	O	daily
12	60	62	O	for
13	64	64	O	3
14	66	69	O	days
15	72	74	O	and
16	76	85	O	XXXXXXXX
17	88	89	O	20
18	91	92	O	mg
19	94	97	O	once
20	99	103	O	daily
21	105	107	O	for
22	109	109	O	3
23	111	114	O	days
24	116	116	O	,
25	118	118	O	a
26	120	122	O	16%
27	124	131	O	decrease
28	133	134	O	in
29	136	138	O	the
30	140	148	O	clearance
31	150	151	O	of
32	153	162	O	XXXXXXXX
33	164	166	O	was
34	168	175	O	observed
NULL

Cetirizine	DDI-DrugBank.d393.s3	NO_SECTION	NO_SETID	11
The disposition of theophylline was not altered by concomitant cetirizine administration.
1	0	2	O	The
2	4	14	O	disposition
3	16	17	O	of
4	19	30	U-UNK	theophylline
5	32	34	O	was
6	36	38	O	not
7	40	46	O	altered
8	48	49	O	by
9	51	61	O	concomitant
10	63	72	O	XXXXXXXX
11	74	87	O	administration
NULL

Cetirizine	DDI-DrugBank.d393.s4	NO_SECTION	NO_SETID	27
Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	21	O	Interactions
4	22	22	O	:
5	24	25	O	No
6	27	36	O	clinically
7	38	48	O	significant
8	50	53	O	drug
9	55	66	O	interactions
10	68	71	O	have
11	73	76	O	been
12	78	82	O	found
13	84	87	O	with
14	89	100	U-UNK	theophylline
15	102	103	O	at
16	105	105	O	a
17	107	109	O	low
18	111	114	O	dose
19	115	115	O	,
20	117	128	U-UNK	azithromycin
21	129	129	O	,
22	131	145	U-UNK	pseudoephedrine
23	146	146	O	,
24	148	159	U-UNK	ketoconazole
25	160	160	O	,
26	162	163	O	or
27	165	176	U-UNK	erythromycin
NULL

Cetirizine	DDI-DrugBank.d393.s5	NO_SECTION	NO_SETID	18
There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;
1	0	4	O	There
2	6	8	O	was
3	10	10	O	a
4	12	16	O	small
5	18	25	O	decrease
6	27	28	O	in
7	30	32	O	the
8	34	42	O	clearance
9	44	45	O	of
10	47	56	O	XXXXXXXX
11	58	63	O	caused
12	65	66	O	by
13	68	68	O	a
14	70	72	O	400
15	74	75	O	mg
16	77	80	O	dose
17	82	83	O	of
18	85	96	U-KIN	theophylline
NULL

Cetirizine	DDI-DrugBank.d393.s6	NO_SECTION	NO_SETID	12
it is possible that larger theophylline doses could have a greater effect.
1	0	1	O	it
2	3	4	O	is
3	6	13	O	possible
4	15	18	O	that
5	20	25	O	larger
6	27	38	U-UNK	theophylline
7	40	44	O	doses
8	46	50	O	could
9	52	55	O	have
10	57	57	O	a
11	59	65	O	greater
12	67	72	O	effect
NULL

Cetrorelix	DDI-DrugBank.d540.s0	NO_SECTION	NO_SETID	10
No formal drug interaction studies have been performed with Cetrotide .
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	25	O	interaction
5	27	33	O	studies
6	35	38	O	have
7	40	43	O	been
8	45	53	O	performed
9	55	58	O	with
10	60	68	O	XXXXXXXX
NULL

Cetuximab	DDI-DrugBank.d193.s0	NO_SECTION	NO_SETID	15
A drug interaction study was performed in which ERBITUX was administered in combination with irinotecan.
1	0	0	O	A
2	2	5	O	drug
3	7	17	O	interaction
4	19	23	O	study
5	25	27	O	was
6	29	37	O	performed
7	39	40	O	in
8	42	46	O	which
9	48	54	O	XXXXXXXX
10	56	58	O	was
11	60	71	O	administered
12	73	74	O	in
13	76	86	O	combination
14	88	91	O	with
15	93	102	U-UNK	irinotecan
NULL

Cetuximab	DDI-DrugBank.d193.s1	NO_SECTION	NO_SETID	12
There was no evidence of any pharmacokinetic interactions between ERBITUX and irinotecan.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	20	O	evidence
5	22	23	O	of
6	25	27	O	any
7	29	43	O	pharmacokinetic
8	45	56	O	interactions
9	58	64	O	between
10	66	72	O	XXXXXXXX
11	74	76	O	and
12	78	87	U-UNK	irinotecan
NULL

Cevimeline	DDI-DrugBank.d287.s0	NO_SECTION	NO_SETID	20
Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.
1	0	9	O	XXXXXXXX
2	11	16	O	should
3	18	19	O	be
4	21	32	O	administered
5	34	37	O	with
6	39	45	O	caution
7	47	48	O	to
8	50	57	O	patients
9	59	64	O	taking
10	66	69	B-DYN	beta
11	71	80	I-DYN	adrenergic
12	82	92	L-DYN	antagonists
13	93	93	O	,
14	95	101	O	because
15	103	104	O	of
16	106	108	O	the
17	110	120	O	possibility
18	122	123	O	of
19	125	134	O	conduction
20	136	147	O	disturbances
NULL

Cevimeline	DDI-DrugBank.d287.s1	NO_SECTION	NO_SETID	15
Drugs with parasympathomimetic effects administered concurrently with cevimeline can be expected to have additive effects.
1	0	4	O	Drugs
2	6	9	O	with
3	11	29	O	parasympathomimetic
4	31	37	O	effects
5	39	50	O	administered
6	52	63	O	concurrently
7	65	68	O	with
8	70	79	O	XXXXXXXX
9	81	83	O	can
10	85	86	O	be
11	88	95	O	expected
12	97	98	O	to
13	100	103	O	have
14	105	112	O	additive
15	114	120	O	effects
NULL

Cevimeline	DDI-DrugBank.d287.s2	NO_SECTION	NO_SETID	11
Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly.
1	0	9	O	XXXXXXXX
2	11	15	O	might
3	17	25	O	interfere
4	27	30	O	with
5	32	40	O	desirable
6	42	55	O	antimuscarinic
7	57	63	O	effects
8	65	66	O	of
9	68	72	O	drugs
10	74	77	O	used
11	79	91	O	concomitantly
NULL

Cevimeline	DDI-DrugBank.d287.s3	NO_SECTION	NO_SETID	14
Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline.
1	0	4	O	Drugs
2	6	10	O	which
3	12	18	O	inhibit
4	20	25	O	CYP2D6
5	27	29	O	and
6	31	36	O	CYP3A3
7	37	37	O	/
8	38	38	O	4
9	40	43	O	also
10	45	51	O	inhibit
11	53	55	O	the
12	57	66	O	metabolism
13	68	69	O	of
14	71	80	O	XXXXXXXX
NULL

Cevimeline	DDI-DrugBank.d287.s4	NO_SECTION	NO_SETID	34
Cevimeline should be used with caution in individuals known or suspected to be deficient in CYP2D6 activity, based on previous experience, as they may be at a higher risk of adverse events.
1	0	9	O	XXXXXXXX
2	11	16	O	should
3	18	19	O	be
4	21	24	O	used
5	26	29	O	with
6	31	37	O	caution
7	39	40	O	in
8	42	52	O	individuals
9	54	58	O	known
10	60	61	O	or
11	63	71	O	suspected
12	73	74	O	to
13	76	77	O	be
14	79	87	O	deficient
15	89	90	O	in
16	92	97	O	CYP2D6
17	99	106	O	activity
18	107	107	O	,
19	109	113	O	based
20	115	116	O	on
21	118	125	O	previous
22	127	136	O	experience
23	137	137	O	,
24	139	140	O	as
25	142	145	O	they
26	147	149	O	may
27	151	152	O	be
28	154	155	O	at
29	157	157	O	a
30	159	164	O	higher
31	166	169	O	risk
32	171	172	O	of
33	174	180	O	adverse
34	182	187	O	events
NULL

Cevimeline	DDI-DrugBank.d287.s5	NO_SECTION	NO_SETID	30
In an in vitro study, cytochrome P450 isozymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 were not inhibited by exposure to cevimeline.
1	0	1	O	In
2	3	4	O	an
3	6	7	O	in
4	9	13	O	vitro
5	15	19	O	study
6	20	20	O	,
7	22	31	O	cytochrome
8	33	36	O	P450
9	38	45	O	isozymes
10	47	49	O	1A2
11	50	50	O	,
12	52	54	O	2A6
13	55	55	O	,
14	57	59	O	2C9
15	60	60	O	,
16	62	65	O	2C19
17	66	66	O	,
18	68	70	O	2D6
19	71	71	O	,
20	73	75	O	2E1
21	76	76	O	,
22	78	80	O	and
23	82	84	O	3A4
24	86	89	O	were
25	91	93	O	not
26	95	103	O	inhibited
27	105	106	O	by
28	108	115	O	exposure
29	117	118	O	to
30	120	129	O	XXXXXXXX
NULL

Chlorambucil	DDI-DrugBank.d255.s0	NO_SECTION	NO_SETID	10
There are no known drug/drug interactions with chlorambucil.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	17	O	known
5	19	22	O	drug
6	23	23	O	/
7	24	27	O	drug
8	29	40	O	interactions
9	42	45	O	with
10	47	58	O	XXXXXXXX
NULL

Chlordiazepoxide	DDI-DrugBank.d336.s0	NO_SECTION	NO_SETID	34
Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.
1	0	7	O	Although
2	9	16	O	clinical
3	18	24	O	studies
4	26	29	O	have
5	31	33	O	not
6	35	45	O	established
7	47	47	O	a
8	49	53	O	cause
9	55	57	O	and
10	59	64	O	effect
11	66	77	O	relationship
12	78	78	O	,
13	80	89	O	physicians
14	91	96	O	should
15	98	99	O	be
16	101	105	O	aware
17	107	110	O	that
18	112	119	O	variable
19	121	127	O	effects
20	129	130	O	an
21	132	136	O	blood
22	138	148	O	coagulation
23	150	153	O	have
24	155	158	O	been
25	160	167	O	reported
26	169	172	O	very
27	174	179	O	rarely
28	181	182	O	in
29	184	191	O	patients
30	193	201	O	receiving
31	203	206	O	oral
32	208	221	U-DYN	anticoagulants
33	223	225	O	and
34	227	242	O	XXXXXXXX
NULL

Chlordiazepoxide	DDI-DrugBank.d336.s1	NO_SECTION	NO_SETID	16
The concomitant use of alcohol or other central nervous system depressants may have an additive effect.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	29	U-UNK	alcohol
6	31	32	O	or
7	34	38	O	other
8	40	46	B-UNK	central
9	48	54	I-UNK	nervous
10	56	61	I-UNK	system
11	63	73	L-UNK	depressants
12	75	77	O	may
13	79	82	O	have
14	84	85	O	an
15	87	94	O	additive
16	96	101	O	effect
NULL

Chloroprocaine	DDI-DrugBank.d110.s0	NO_SECTION	NO_SETID	29
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.
1	0	2	O	The
2	4	17	O	administration
3	19	20	O	of
4	22	26	O	local
5	28	37	B-UNK	anesthetic
6	39	47	L-UNK	solutions
7	49	58	O	containing
8	60	70	U-UNK	epinephrine
9	72	73	O	or
10	75	88	U-UNK	norepinephrine
11	90	91	O	to
12	93	100	O	patients
13	102	110	O	receiving
14	112	120	B-UNK	monoamine
15	122	128	I-UNK	oxidase
16	130	139	L-UNK	inhibitors
17	140	140	O	,
18	142	150	B-UNK	tricyclic
19	152	166	L-UNK	antidepressants
20	168	169	O	or
21	171	184	U-UNK	phenothiazines
22	186	188	O	may
23	190	196	O	produce
24	198	203	O	severe
25	204	204	O	,
26	206	214	O	prolonged
27	216	226	O	hypotension
28	228	229	O	or
29	231	242	O	hypertension
NULL

Chloroprocaine	DDI-DrugBank.d110.s1	NO_SECTION	NO_SETID	9
Concurrent use of these agents should generally be avoided.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	16	O	of
4	18	22	O	these
5	24	29	O	agents
6	31	36	O	should
7	38	46	O	generally
8	48	49	O	be
9	51	57	O	avoided
NULL

Chloroprocaine	DDI-DrugBank.d110.s2	NO_SECTION	NO_SETID	13
In situations when concurrent therapy is necessary, careful patient monitoring is essential.
1	0	1	O	In
2	3	12	O	situations
3	14	17	O	when
4	19	28	O	concurrent
5	30	36	O	therapy
6	38	39	O	is
7	41	49	O	necessary
8	50	50	O	,
9	52	58	O	careful
10	60	66	O	patient
11	68	77	O	monitoring
12	79	80	O	is
13	82	90	O	essential
NULL

Chloroprocaine	DDI-DrugBank.d110.s3	NO_SECTION	NO_SETID	28
Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	39	B-UNK	vasopressor
5	41	45	L-UNK	drugs
6	48	50	O	for
7	52	54	O	the
8	56	64	O	treatment
9	66	67	O	of
10	69	79	O	hypotension
11	81	87	O	related
12	89	90	O	to
13	92	100	O	obstetric
14	102	107	O	blocks
15	110	112	O	and
16	114	118	B-UNK	ergot
17	120	123	I-UNK	type
18	125	132	I-UNK	oxytocic
19	134	138	L-UNK	drugs
20	140	142	O	may
21	144	148	O	cause
22	150	155	O	severe
23	156	156	O	,
24	158	167	O	persistent
25	169	180	O	hypertension
26	182	183	O	or
27	185	199	O	cerebrovascular
28	201	209	O	accidents
NULL

Chloroprocaine	DDI-DrugBank.d110.s4	NO_SECTION	NO_SETID	12
The para-aminobenzoic acid metabolite of chloroprocaine inhibits the action of sulfonamides.
1	0	2	O	The
2	4	7	O	para
3	9	20	O	aminobenzoic
4	22	25	O	acid
5	27	36	O	metabolite
6	38	39	O	of
7	41	54	O	XXXXXXXX
8	56	63	O	inhibits
9	65	67	O	the
10	69	74	O	action
11	76	77	O	of
12	79	90	U-UNK	sulfonamides
NULL

Chloroprocaine	DDI-DrugBank.d110.s5	NO_SECTION	NO_SETID	18
Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.
1	0	8	O	Therefore
2	9	9	O	,
3	11	24	O	XXXXXXXX
4	26	31	O	should
5	33	35	O	not
6	37	38	O	be
7	40	43	O	used
8	45	46	O	in
9	48	50	O	any
10	52	60	O	condition
11	62	63	O	in
12	65	69	O	which
13	71	71	O	a
14	73	83	B-DYN	sulfonamide
15	85	88	L-DYN	drug
16	90	91	O	is
17	93	97	O	being
18	99	106	O	employed
NULL

Chloroquine	DDI-DrugBank.d429.s0	NO_SECTION	NO_SETID	12
Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;
1	0	7	U-UNK	Antacids
2	9	11	O	and
3	13	18	U-UNK	kaolin
4	19	19	O	:
5	21	28	U-KIN	Antacids
6	30	32	O	and
7	34	39	U-KIN	kaolin
8	41	43	O	can
9	45	50	O	reduce
10	52	61	O	absorption
11	63	64	O	of
12	66	76	O	XXXXXXXX
NULL

Chloroquine	DDI-DrugBank.d429.s1	NO_SECTION	NO_SETID	17
an interval of at least 4 hours between intake of these agents and chloroquine should be observed.
1	0	1	O	an
2	3	10	O	interval
3	12	13	O	of
4	15	16	O	at
5	18	22	O	least
6	24	24	O	4
7	26	30	O	hours
8	32	38	O	between
9	40	45	O	intake
10	47	48	O	of
11	50	54	O	these
12	56	61	O	agents
13	63	65	O	and
14	67	77	O	XXXXXXXX
15	79	84	O	should
16	86	87	O	be
17	89	96	O	observed
NULL

Chloroquine	DDI-DrugBank.d429.s2	NO_SECTION	NO_SETID	14
Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.
1	0	9	U-UNK	Cimetidine
2	10	10	O	:
3	12	21	U-KIN	Cimetidine
4	23	25	O	can
5	27	33	O	inhibit
6	35	37	O	the
7	39	48	O	metabolism
8	50	51	O	of
9	53	63	O	XXXXXXXX
10	64	64	O	,
11	66	75	O	increasing
12	77	79	O	its
13	81	86	O	plasma
14	88	92	O	level
NULL

Chloroquine	DDI-DrugBank.d429.s3	NO_SECTION	NO_SETID	7
Concomitant use of cimetidine should be avoided.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	28	U-UNK	cimetidine
5	30	35	O	should
6	37	38	O	be
7	40	46	O	avoided
NULL

Chloroquine	DDI-DrugBank.d429.s4	NO_SECTION	NO_SETID	16
Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.
1	0	9	U-UNK	Ampicillin
2	10	10	O	:
3	12	13	O	In
4	15	15	O	a
5	17	21	O	study
6	23	24	O	of
7	26	32	O	healthy
8	34	43	O	volunteers
9	44	44	O	,
10	46	56	O	XXXXXXXX
11	58	70	O	significantly
12	72	78	O	reduced
13	80	82	O	the
14	84	98	O	bioavailability
15	100	101	O	of
16	103	112	U-KIN	ampicillin
NULL

Chloroquine	DDI-DrugBank.d429.s5	NO_SECTION	NO_SETID	17
An interval of at least two hours between intake of this agent and chloroquine should be observed.
1	0	1	O	An
2	3	10	O	interval
3	12	13	O	of
4	15	16	O	at
5	18	22	O	least
6	24	26	O	two
7	28	32	O	hours
8	34	40	O	between
9	42	47	O	intake
10	49	50	O	of
11	52	55	O	this
12	57	61	O	agent
13	63	65	O	and
14	67	77	O	XXXXXXXX
15	79	84	O	should
16	86	87	O	be
17	89	96	O	observed
NULL

Chloroquine	DDI-DrugBank.d429.s6	NO_SECTION	NO_SETID	19
Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.
1	0	10	U-UNK	Cyclosporin
2	11	11	O	:
3	13	17	O	After
4	19	30	O	introduction
5	32	33	O	of
6	35	45	O	XXXXXXXX
7	48	51	O	oral
8	53	56	O	form
9	58	58	O	,
10	60	60	O	a
11	62	67	O	sudden
12	69	76	O	increase
13	78	79	O	in
14	81	85	O	serum
15	87	97	U-KIN	cyclosporin
16	99	103	O	level
17	105	107	O	has
18	109	112	O	been
19	114	121	O	reported
NULL

Chloroquine	DDI-DrugBank.d429.s7	NO_SECTION	NO_SETID	19
Therefore, close monitoring of serum cyclosporin level is recommended and, if necessary, chloroquine should be discontinued.
1	0	8	O	Therefore
2	9	9	O	,
3	11	15	O	close
4	17	26	O	monitoring
5	28	29	O	of
6	31	35	O	serum
7	37	47	U-UNK	cyclosporin
8	49	53	O	level
9	55	56	O	is
10	58	68	O	recommended
11	70	72	O	and
12	73	73	O	,
13	75	76	O	if
14	78	86	O	necessary
15	87	87	O	,
16	89	99	O	XXXXXXXX
17	101	106	O	should
18	108	109	O	be
19	111	122	O	discontinued
NULL

Chlorothiazide	DDI-DrugBank.d46.s0	NO_SECTION	NO_SETID	11
When given concurrently the following drugs may interact with thiazide diuretics.
1	0	3	O	When
2	5	9	O	given
3	11	22	O	concurrently
4	24	26	O	the
5	28	36	O	following
6	38	42	O	drugs
7	44	46	O	may
8	48	55	O	interact
9	57	60	O	with
10	62	69	B-UNK	thiazide
11	71	79	L-UNK	diuretics
NULL

Chlorothiazide	DDI-DrugBank.d46.s1	NO_SECTION	NO_SETID	13
- Alcohol, barbiturates, or narcotics: Potentiation of otthostatic hypotension may occur
1	2	8	U-UNK	Alcohol
2	9	9	O	,
3	11	22	U-UNK	barbiturates
4	23	23	O	,
5	25	26	O	or
6	28	36	U-UNK	narcotics
7	37	37	O	:
8	39	50	O	Potentiation
9	52	53	O	of
10	55	65	O	otthostatic
11	67	77	O	hypotension
12	79	81	O	may
13	83	87	O	occur
NULL

Chlorothiazide	DDI-DrugBank.d46.s3	NO_SECTION	NO_SETID	16
- Antidiabetic drugs: (Oral agents and insulin) Dosage adjustment of the antidiabetic drug may be required
1	2	13	B-UNK	Antidiabetic
2	15	19	L-UNK	drugs
3	20	20	O	:
4	23	26	O	Oral
5	28	33	O	agents
6	35	37	O	and
7	39	45	U-UNK	insulin
8	48	53	O	Dosage
9	55	64	O	adjustment
10	66	67	O	of
11	69	71	O	the
12	73	84	B-UNK	antidiabetic
13	86	89	L-UNK	drug
14	91	93	O	may
15	95	96	O	be
16	98	105	O	required
NULL

Chlorothiazide	DDI-DrugBank.d46.s5	NO_SECTION	NO_SETID	8
- Other antihypertensive drugs: Additive effect or potentiation
1	2	6	O	Other
2	8	23	B-UNK	antihypertensive
3	25	29	L-UNK	drugs
4	30	30	O	:
5	32	39	O	Additive
6	41	46	O	effect
7	48	49	O	or
8	51	62	O	potentiation
NULL

Chlorothiazide	DDI-DrugBank.d46.s7	NO_SECTION	NO_SETID	24
- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
1	2	15	U-UNK	Cholestyramine
2	17	19	O	and
3	21	30	U-UNK	colestipol
4	32	37	U-UNK	resins
5	38	38	O	:
6	40	53	U-UNK	Cholestytamine
7	55	57	O	and
8	59	68	U-UNK	colestipol
9	70	75	U-UNK	resins
10	77	80	O	have
11	82	84	O	the
12	86	94	O	potential
13	96	97	O	of
14	99	105	O	binding
15	107	114	B-UNK	thiazide
16	116	124	L-UNK	diuretics
17	126	128	O	and
18	130	137	O	reducing
19	139	146	U-UNK	diuretic
20	148	157	O	absorption
21	159	162	O	from
22	164	166	O	the
23	168	183	O	gastrointestinal
24	185	189	O	tract
NULL

Chlorothiazide	DDI-DrugBank.d46.s9	NO_SECTION	NO_SETID	10
- Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia
1	2	16	U-UNK	Corticosteroids
2	17	17	O	,
3	19	22	U-UNK	ACTH
4	23	23	O	:
5	25	35	O	Intensified
6	37	47	O	electrolyte
7	49	57	O	depletion
8	58	58	O	,
9	60	71	O	particularly
10	73	83	O	hypokalemia
NULL

Chlorothiazide	DDI-DrugBank.d46.s11	NO_SECTION	NO_SETID	19
- Pressor amines (e.g., norepinephrine): Possible decreased response to pressor amines but not sufficient to preclude their use
1	2	8	O	Pressor
2	10	15	O	amines
3	18	20	O	e.g
4	22	22	O	,
5	24	37	U-UNK	norepinephrine
6	39	39	O	:
7	41	48	O	Possible
8	50	58	O	decreased
9	60	67	O	response
10	69	70	O	to
11	72	78	O	pressor
12	80	85	O	amines
13	87	89	O	but
14	91	93	O	not
15	95	104	O	sufficient
16	106	107	O	to
17	109	116	O	preclude
18	118	122	O	their
19	124	126	O	use
NULL

Chlorothiazide	DDI-DrugBank.d46.s13	NO_SECTION	NO_SETID	16
- Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant
1	2	9	B-UNK	Skeletal
2	11	16	I-UNK	muscle
3	18	26	L-UNK	relaxants
4	27	27	O	,
5	29	43	O	nondepolarizing
6	46	48	O	e.g
7	50	50	O	,
8	52	63	U-UNK	tubocurarine
9	65	65	O	:
10	67	74	O	Possible
11	76	84	O	increased
12	86	99	O	responsiveness
13	101	102	O	to
14	104	106	O	the
15	108	113	B-UNK	muscle
16	115	122	L-UNK	relaxant
NULL

Chlorothiazide	DDI-DrugBank.d46.s15	NO_SECTION	NO_SETID	9
- Lithium: Generally should not be given with diuretics.
1	2	8	U-UNK	Lithium
2	9	9	O	:
3	11	19	O	Generally
4	21	26	O	should
5	28	30	O	not
6	32	33	O	be
7	35	39	O	given
8	41	44	O	with
9	46	54	U-UNK	diuretics
NULL

Chlorothiazide	DDI-DrugBank.d46.s16	NO_SECTION	NO_SETID	16
Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
1	0	7	B-UNK	Diuretic
2	9	14	L-UNK	agents
3	16	21	O	reduce
4	23	25	O	the
5	27	31	O	renal
6	33	41	O	clearance
7	43	44	O	of
8	46	52	U-UNK	lithium
9	54	56	O	and
10	58	60	O	add
11	62	62	O	a
12	64	67	O	high
13	69	72	O	risk
14	74	75	O	of
15	77	83	U-UNK	lithium
16	85	92	O	toxicity
NULL

Chlorothiazide	DDI-DrugBank.d46.s17	NO_SECTION	NO_SETID	15
Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide
1	0	4	O	Refer
2	6	7	O	to
3	9	11	O	the
4	13	19	O	package
5	21	26	O	insert
6	28	30	O	for
7	32	38	U-DYN	lithium
8	40	51	O	preparations
9	53	58	O	before
10	60	62	O	use
11	64	65	O	of
12	67	70	O	such
13	72	83	O	preparations
14	85	88	O	with
15	90	103	O	XXXXXXXX
NULL

Chlorothiazide	DDI-DrugBank.d46.s19	NO_SECTION	NO_SETID	37
- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
1	2	4	B-UNK	Non
2	6	14	I-UNK	steroidal
3	16	19	I-UNK	Anti
4	21	32	I-UNK	inflammatory
5	34	38	L-UNK	Drugs
6	39	39	O	:
7	41	42	O	In
8	44	47	O	some
9	49	56	O	patients
10	57	57	O	,
11	59	61	O	the
12	63	76	O	administration
13	78	79	O	of
14	81	81	O	a
15	83	85	B-UNK	non
16	87	95	I-UNK	steroidal
17	97	100	I-UNK	anti
18	102	113	I-UNK	inflammatory
19	115	119	L-UNK	agent
20	121	123	O	can
21	125	130	O	reduce
22	132	134	O	the
23	136	143	O	diuretic
24	144	144	O	,
25	146	156	O	natriuretic
26	157	157	O	,
27	159	161	O	and
28	163	178	O	antihypertensive
29	180	186	O	effects
30	188	189	O	of
31	191	194	B-UNK	loop
32	195	195	I-UNK	,
33	197	205	I-UNK	potassium
34	207	213	I-UNK	sparing
35	215	217	I-UNK	and
36	219	226	I-UNK	thiazide
37	228	236	L-UNK	diuretics
NULL

Chlorothiazide	DDI-DrugBank.d46.s20	NO_SECTION	NO_SETID	31
Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	29	O	XXXXXXXX
5	31	33	O	and
6	35	37	B-DYN	non
7	39	47	I-DYN	steroidal
8	49	52	I-DYN	anti
9	54	65	I-DYN	inflammatory
10	67	72	L-DYN	agents
11	74	76	O	are
12	78	81	O	used
13	83	95	O	concomitantly
14	96	96	O	,
15	98	100	O	the
16	102	108	O	patient
17	110	115	O	should
18	117	118	O	be
19	120	127	O	observed
20	129	135	O	closely
21	137	138	O	to
22	140	148	O	determine
23	150	151	O	if
24	153	155	O	the
25	157	163	O	desired
26	165	170	O	effect
27	172	173	O	of
28	175	177	O	the
29	179	186	U-UNK	diuretic
30	188	189	O	is
31	191	198	O	obtained
NULL

Chlorothiazide	DDI-DrugBank.d46.s22	NO_SECTION	NO_SETID	17
- Drug/Laboratory Test Interactions: Thiazides should be discontinued before carrying out tests for parathyroid function.
1	2	5	O	Drug
2	6	6	O	/
3	7	16	O	Laboratory
4	18	21	O	Test
5	23	34	O	Interactions
6	35	35	O	:
7	37	45	U-UNK	Thiazides
8	47	52	O	should
9	54	55	O	be
10	57	68	O	discontinued
11	70	75	O	before
12	77	84	O	carrying
13	86	88	O	out
14	90	94	O	tests
15	96	98	O	for
16	100	110	O	parathyroid
17	112	119	O	function
NULL

Chlorotrianisene	DDI-DrugBank.d446.s0	NO_SECTION	NO_SETID	31
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
1	0	15	U-UNK	Chlorotrianisene
2	17	19	O	may
3	21	28	O	interact
4	30	33	O	with
5	35	49	U-UNK	antidepressants
6	50	50	O	,
7	52	58	O	XXXXXXXX
8	59	59	O	,
9	61	72	U-UNK	barbiturates
10	73	73	O	,
11	75	87	U-UNK	bromocriptine
12	88	88	O	,
13	90	96	U-UNK	calcium
14	98	108	O	supplements
15	109	109	O	,
16	111	125	U-UNK	corticosteroids
17	126	126	O	,
18	128	140	U-UNK	corticotropin
19	141	141	O	,
20	143	154	U-UNK	cyclosporine
21	155	155	O	,
22	157	166	U-UNK	dantrolene
23	167	167	O	,
24	169	176	U-UNK	nicotine
25	177	177	O	,
26	179	188	U-UNK	somatropin
27	189	189	O	,
28	191	199	U-UNK	tamoxifen
29	200	200	O	,
30	202	204	O	and
31	206	213	U-UNK	warfarin
NULL

Chloroxine	DDI-DrugBank.d366.s0	NO_SECTION	NO_SETID	11
May interact with skin products or shampoos for dandruff or psoriasis.
1	0	2	O	May
2	4	11	O	interact
3	13	16	O	with
4	18	21	O	skin
5	23	30	O	products
6	32	33	O	or
7	35	42	O	shampoos
8	44	46	O	for
9	48	55	O	dandruff
10	57	58	O	or
11	60	68	O	psoriasis
NULL

Chlorpheniramine	DDI-DrugBank.d235.s0	NO_SECTION	NO_SETID	7
Substrate of CYP2D6 (minor), 3A4 (major);
1	0	8	O	Substrate
2	10	11	O	of
3	13	18	O	CYP2D6
4	21	25	O	minor
5	27	27	O	,
6	29	31	O	3A4
7	34	38	O	major
NULL

Chlorpheniramine	DDI-DrugBank.d235.s1	NO_SECTION	NO_SETID	3
Inhibits CYP2D6 (weak).
1	0	7	O	Inhibits
2	9	14	O	CYP2D6
3	17	20	O	weak
NULL

Chlorpheniramine	DDI-DrugBank.d235.s2	NO_SECTION	NO_SETID	15
Increased toxicity (CNS depression): CNS depressants, MAO inhibitors, tricyclic antidepressants, phenothiazines.
1	0	8	O	Increased
2	10	17	O	toxicity
3	20	22	O	CNS
4	24	33	O	depression
5	35	35	O	:
6	37	39	B-UNK	CNS
7	41	51	L-UNK	depressants
8	52	52	O	,
9	54	56	B-UNK	MAO
10	58	67	L-UNK	inhibitors
11	68	68	O	,
12	70	78	B-UNK	tricyclic
13	80	94	L-UNK	antidepressants
14	95	95	O	,
15	97	110	U-UNK	phenothiazines
NULL

Chlorpheniramine	DDI-DrugBank.d235.s3	NO_SECTION	NO_SETID	11
CYP3A4 inhibitors: May increase the levels/effects of chlorpheniramine.
1	0	5	O	CYP3A4
2	7	16	O	inhibitors
3	17	17	O	:
4	19	21	O	May
5	23	30	O	increase
6	32	34	O	the
7	36	41	O	levels
8	42	42	O	/
9	43	49	O	effects
10	51	52	O	of
11	54	69	O	XXXXXXXX
NULL

Chlorpheniramine	DDI-DrugBank.d235.s4	NO_SECTION	NO_SETID	33
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
1	0	6	O	Example
2	8	17	O	inhibitors
3	19	25	O	include
4	27	31	B-UNK	azole
5	33	43	L-UNK	antifungals
6	44	44	O	,
7	46	58	U-UNK	ciprofloxacin
8	59	59	O	,
9	61	74	U-UNK	clarithromycin
10	75	75	O	,
11	77	86	U-UNK	diclofenac
12	87	87	O	,
13	89	99	U-UNK	doxycycline
14	100	100	O	,
15	102	113	U-UNK	erythromycin
16	114	114	O	,
17	116	123	U-UNK	imatinib
18	124	124	O	,
19	126	134	U-UNK	isoniazid
20	135	135	O	,
21	137	146	U-UNK	nefazodone
22	147	147	O	,
23	149	159	U-UNK	nicardipine
24	160	160	O	,
25	162	169	U-UNK	propofol
26	170	170	O	,
27	172	179	B-UNK	protease
28	181	190	L-UNK	inhibitors
29	191	191	O	,
30	193	201	U-UNK	quinidine
31	202	202	O	,
32	204	206	O	and
33	208	216	U-UNK	verapamil
NULL

Chlorpromazine	DDI-DrugBank.d86.s0	NO_SECTION	NO_SETID	66
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
1	0	2	O	The
2	4	13	O	concurrent
3	15	17	O	use
4	19	20	O	of
5	22	24	O	two
6	26	27	O	or
7	29	32	O	more
8	34	38	O	drugs
9	40	43	O	with
10	45	59	O	anticholinergic
11	61	68	O	activity
12	71	74	O	such
13	76	77	O	as
14	79	80	O	an
15	82	94	B-UNK	antipsychotic
16	96	99	L-UNK	drug
17	102	103	O	eg
18	104	104	O	,
19	106	119	O	XXXXXXXX
20	121	121	O	,
21	123	124	O	an
22	126	141	B-DYN	antiparkinsonian
23	143	146	L-DYN	drug
24	149	150	O	eg
25	151	151	O	,
26	153	167	U-DYN	trihexyphenidyl
27	169	169	O	,
28	171	173	O	and
29	174	174	O	/
30	175	176	O	or
31	178	178	O	a
32	180	188	B-DYN	tricyclic
33	190	203	L-DYN	antidepressant
34	206	207	O	eg
35	208	208	O	,
36	210	222	U-DYN	amitriptyline
37	226	233	O	commonly
38	235	241	O	results
39	243	244	O	in
40	246	254	O	excessive
41	256	270	O	anticholinergic
42	272	278	O	effects
43	279	279	O	,
44	281	289	O	including
45	291	293	O	dry
46	295	299	O	mouth
47	301	303	O	and
48	305	314	O	associated
49	316	321	O	dental
50	323	335	O	complications
51	336	336	O	,
52	338	344	O	blurred
53	346	351	O	vision
54	352	352	O	,
55	354	356	O	and
56	357	357	O	,
57	359	360	O	in
58	362	369	O	patients
59	371	377	O	exposed
60	379	380	O	to
61	382	385	O	high
62	387	397	O	temperature
63	399	401	O	and
64	403	410	O	humidity
65	411	411	O	,
66	413	424	O	hyperpyrexia
NULL

Chlorpromazine	DDI-DrugBank.d86.s1	NO_SECTION	NO_SETID	71
Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
1	0	11	O	Interactions
2	13	15	O	may
3	17	20	O	also
4	22	26	O	occur
5	28	31	O	with
6	33	35	O	the
7	37	45	O	following
8	46	46	O	:
9	48	51	B-UNK	anti
10	53	63	L-UNK	depressants
11	64	64	O	/
12	65	68	B-UNK	anti
13	70	76	I-UNK	anxiety
14	78	82	L-UNK	drugs
15	83	83	O	,
16	85	89	O	drugs
17	91	94	O	used
18	96	97	O	to
19	99	103	O	treat
20	105	106	O	an
21	108	117	O	overactive
22	119	125	O	thyroid
23	126	126	O	,
24	128	131	B-UNK	beta
25	133	140	L-UNK	blockers
26	143	145	O	e.g
27	147	147	O	,
28	149	159	U-UNK	propranolol
29	161	161	O	,
30	163	174	U-UNK	sparfloxacin
31	175	175	O	,
32	177	189	U-UNK	grepafloxacin
33	190	190	O	,
34	192	203	U-UNK	guanethidine
35	204	204	O	,
36	206	214	U-UNK	guanadrel
37	215	215	O	,
38	217	227	U-UNK	metrizamide
39	228	228	O	,
40	230	240	U-UNK	cabergoline
41	241	241	O	,
42	243	249	U-UNK	lithium
43	250	250	O	,
44	252	259	U-UNK	narcotic
45	261	264	O	pain
46	266	275	O	medication
47	278	280	O	e.g
48	282	282	O	,
49	284	290	U-UNK	codeine
50	292	292	O	,
51	294	298	O	drugs
52	300	303	O	used
53	305	306	O	to
54	308	310	O	aid
55	312	316	O	sleep
56	317	317	O	,
57	319	328	O	drowsiness
58	330	336	O	causing
59	338	351	U-UNK	antihistamines
60	354	356	O	e.g
61	358	358	O	,
62	360	374	U-UNK	diphenhydramine
63	376	376	O	,
64	378	380	O	any
65	382	386	O	other
66	388	392	O	drugs
67	394	397	O	that
68	399	401	O	may
69	403	406	O	make
70	408	410	O	you
71	412	417	O	drowsy
NULL

Chlorpropamide	DDI-DrugBank.d245.s0	NO_SECTION	NO_SETID	44
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
1	0	2	O	The
2	4	15	O	hypoglycemic
3	17	22	O	action
4	24	25	O	of
5	27	38	U-UNK	sulfonylurea
6	40	42	O	may
7	44	45	O	be
8	47	57	O	potentiated
9	59	60	O	by
10	62	68	O	certain
11	70	74	O	drugs
12	76	84	O	including
13	86	97	B-UNK	nonsteroidal
14	99	102	I-UNK	anti
15	104	115	I-UNK	inflammatory
16	117	122	L-UNK	agents
17	124	126	O	and
18	128	132	O	other
19	134	138	O	drugs
20	140	143	O	that
21	145	147	O	are
22	149	154	O	highly
23	156	162	O	protein
24	164	168	O	bound
25	169	169	O	,
26	171	181	U-UNK	salicylates
27	182	182	O	,
28	184	195	U-UNK	sulfonamides
29	196	196	O	,
30	198	212	U-UNK	chloramphenicol
31	213	213	O	,
32	215	224	U-UNK	probenecid
33	225	225	O	,
34	227	235	U-UNK	coumarins
35	236	236	O	,
36	238	246	B-UNK	monoamine
37	248	254	I-UNK	oxidase
38	256	265	L-UNK	inhibitors
39	266	266	O	,
40	268	270	O	and
41	272	275	B-UNK	beta
42	277	286	I-UNK	adrenergic
43	288	295	I-UNK	blocking
44	297	302	L-UNK	agents
NULL

Chlorpropamide	DDI-DrugBank.d245.s1	NO_SECTION	NO_SETID	19
When such drugs are administered to a patient receiving DIABINESE, the patient should be observed closely for hypoglycemia.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	31	O	administered
6	33	34	O	to
7	36	36	O	a
8	38	44	O	patient
9	46	54	O	receiving
10	56	64	O	XXXXXXXX
11	65	65	O	,
12	67	69	O	the
13	71	77	O	patient
14	79	84	O	should
15	86	87	O	be
16	89	96	O	observed
17	98	104	O	closely
18	106	108	O	for
19	110	121	O	hypoglycemia
NULL

Chlorpropamide	DDI-DrugBank.d245.s2	NO_SECTION	NO_SETID	21
When such drugs are withdrawn from a patient receiving DIABINESE, the patient should be observed closely for loss of control.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	28	O	withdrawn
6	30	33	O	from
7	35	35	O	a
8	37	43	O	patient
9	45	53	O	receiving
10	55	63	O	XXXXXXXX
11	64	64	O	,
12	66	68	O	the
13	70	76	O	patient
14	78	83	O	should
15	85	86	O	be
16	88	95	O	observed
17	97	103	O	closely
18	105	107	O	for
19	109	112	O	loss
20	114	115	O	of
21	117	123	O	control
NULL

Chlorpropamide	DDI-DrugBank.d245.s3	NO_SECTION	NO_SETID	13
Certain drugs tend to produce hyperglycemia and may lead to loss of control.
1	0	6	O	Certain
2	8	12	O	drugs
3	14	17	O	tend
4	19	20	O	to
5	22	28	O	produce
6	30	42	O	hyperglycemia
7	44	46	O	and
8	48	50	O	may
9	52	55	O	lead
10	57	58	O	to
11	60	63	O	loss
12	65	66	O	of
13	68	74	O	control
NULL

Chlorpropamide	DDI-DrugBank.d245.s4	NO_SECTION	NO_SETID	35
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
1	0	4	O	These
2	6	10	O	drugs
3	12	18	O	include
4	20	22	O	the
5	24	32	U-UNK	thiazides
6	34	36	O	and
7	38	42	O	other
8	44	52	U-UNK	diuretics
9	53	53	O	,
10	55	69	U-UNK	corticosteroids
11	70	70	O	,
12	72	85	U-UNK	phenothiazines
13	86	86	O	,
14	88	94	O	thyroid
15	96	103	O	products
16	104	104	O	,
17	106	114	U-UNK	estrogens
18	115	115	O	,
19	117	120	O	oral
20	122	135	U-UNK	contraceptives
21	136	136	O	,
22	138	146	U-UNK	phenytoin
23	147	147	O	,
24	149	157	B-UNK	nicotinic
25	159	162	L-UNK	acid
26	163	163	O	,
27	165	180	U-UNK	sympathomimetics
28	181	181	O	,
29	183	189	B-UNK	calcium
30	191	197	I-UNK	channel
31	199	206	I-UNK	blocking
32	208	212	L-UNK	drugs
33	213	213	O	,
34	215	217	O	and
35	219	227	U-UNK	isoniazid
NULL

Chlorpropamide	DDI-DrugBank.d245.s5	NO_SECTION	NO_SETID	21
When such drugs are administered to a patient receiving DIABINESE, the patient should be closely observed for loss of control.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	31	O	administered
6	33	34	O	to
7	36	36	O	a
8	38	44	O	patient
9	46	54	O	receiving
10	56	64	O	XXXXXXXX
11	65	65	O	,
12	67	69	O	the
13	71	77	O	patient
14	79	84	O	should
15	86	87	O	be
16	89	95	O	closely
17	97	104	O	observed
18	106	108	O	for
19	110	113	O	loss
20	115	116	O	of
21	118	124	O	control
NULL

Chlorpropamide	DDI-DrugBank.d245.s6	NO_SECTION	NO_SETID	19
When such drugs are withdrawn from a patient receiving DIABINESE, the patient should be observed closely for hypoglycemia.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	28	O	withdrawn
6	30	33	O	from
7	35	35	O	a
8	37	43	O	patient
9	45	53	O	receiving
10	55	63	O	XXXXXXXX
11	64	64	O	,
12	66	68	O	the
13	70	76	O	patient
14	78	83	O	should
15	85	86	O	be
16	88	95	O	observed
17	97	103	O	closely
18	105	107	O	for
19	109	120	O	hypoglycemia
NULL

Chlorpropamide	DDI-DrugBank.d245.s7	NO_SECTION	NO_SETID	23
Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.
1	0	4	O	Since
2	6	11	O	animal
3	13	19	O	studies
4	21	27	O	suggest
5	29	32	O	that
6	34	36	O	the
7	38	43	O	action
8	45	46	O	of
9	48	59	U-DYN	barbiturates
10	61	63	O	may
11	65	66	O	be
12	68	76	O	prolonged
13	78	79	O	by
14	81	87	O	therapy
15	89	92	O	with
16	94	107	O	XXXXXXXX
17	108	108	O	,
18	110	121	U-UNK	barbiturates
19	123	128	O	should
20	130	131	O	be
21	133	140	O	employed
22	142	145	O	with
23	147	153	O	caution
NULL

Chlorpropamide	DDI-DrugBank.d245.s8	NO_SECTION	NO_SETID	16
In some patients, a disulfiram-like reaction may be produced by the ingestion of alcohol.
1	0	1	O	In
2	3	6	O	some
3	8	15	O	patients
4	16	16	O	,
5	18	18	O	a
6	20	29	U-UNK	disulfiram
7	31	34	O	like
8	36	43	O	reaction
9	45	47	O	may
10	49	50	O	be
11	52	59	O	produced
12	61	62	O	by
13	64	66	O	the
14	68	76	O	ingestion
15	78	79	O	of
16	81	87	U-UNK	alcohol
NULL

Chlorpropamide	DDI-DrugBank.d245.s9	NO_SECTION	NO_SETID	17
A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
1	0	0	O	A
2	2	10	O	potential
3	12	22	O	interaction
4	24	30	O	between
5	32	35	O	oral
6	37	46	U-UNK	miconazole
7	48	50	O	and
8	52	55	O	oral
9	57	68	B-UNK	hypoglycemic
10	70	75	L-UNK	agents
11	77	83	O	leading
12	85	86	O	to
13	88	93	O	severe
14	95	106	O	hypoglycemia
15	108	110	O	has
16	112	115	O	been
17	117	124	O	reported
NULL

Chlorpropamide	DDI-DrugBank.d245.s10	NO_SECTION	NO_SETID	19
Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.
1	0	6	O	Whether
2	8	11	O	this
3	13	23	O	interaction
4	25	28	O	also
5	30	35	O	occurs
6	37	40	O	with
7	42	44	O	the
8	46	56	O	intravenous
9	57	57	O	,
10	59	65	O	topical
11	66	66	O	,
12	68	69	O	or
13	71	77	O	vaginal
14	79	90	O	preparations
15	92	93	O	of
16	95	104	U-UNK	miconazole
17	106	107	O	is
18	109	111	O	not
19	113	117	O	known
NULL

Chlorprothixene	DDI-DrugBank.d503.s0	NO_SECTION	NO_SETID	10
Chlorprothixene may increase the plasma-level of concomitantly given lithium.
1	0	14	O	XXXXXXXX
2	16	18	O	may
3	20	27	O	increase
4	29	31	O	the
5	33	38	O	plasma
6	40	44	O	level
7	46	47	O	of
8	49	61	O	concomitantly
9	63	67	O	given
10	69	75	U-KIN	lithium
NULL

Chlorprothixene	DDI-DrugBank.d503.s1	NO_SECTION	NO_SETID	14
In order to avoid lithium intoxication, lithium plasma levels should be monitored closely.
1	0	1	O	In
2	3	7	O	order
3	9	10	O	to
4	12	16	O	avoid
5	18	24	U-UNK	lithium
6	26	37	O	intoxication
7	38	38	O	,
8	40	46	U-UNK	lithium
9	48	53	O	plasma
10	55	60	O	levels
11	62	67	O	should
12	69	70	O	be
13	72	80	O	monitored
14	82	88	O	closely
NULL

Chlorprothixene	DDI-DrugBank.d503.s2	NO_SECTION	NO_SETID	30
If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.
1	0	1	O	If
2	3	17	O	XXXXXXXX
3	19	20	O	is
4	22	26	O	given
5	28	40	O	concomitantly
6	42	45	O	with
7	47	53	U-DYN	opioids
8	54	54	O	,
9	56	58	O	the
10	60	65	U-UNK	opioid
11	67	70	O	dose
12	72	77	O	should
13	79	80	O	be
14	82	88	O	reduced
15	91	92	O	by
16	94	99	O	approx
17	102	104	O	50%
18	106	106	O	,
19	108	114	O	because
20	116	130	O	XXXXXXXX
21	132	140	O	amplifies
22	142	144	O	the
23	146	156	O	therapeutic
24	158	164	O	actions
25	166	168	O	and
26	170	173	O	side
27	175	181	O	effects
28	183	184	O	of
29	186	192	U-DYN	opioids
30	194	202	O	massively
NULL

Chlorprothixene	DDI-DrugBank.d503.s3	NO_SECTION	NO_SETID	9
Avoid the concomitant use of chlorprothixene and tramadol (Ultram).
1	0	4	O	Avoid
2	6	8	O	the
3	10	20	O	concomitant
4	22	24	O	use
5	26	27	O	of
6	29	43	U-DYN	chlorprothixene
7	45	47	O	and
8	49	56	U-UNK	tramadol
9	59	64	O	XXXXXXXX
NULL

Chlorprothixene	DDI-DrugBank.d503.s4	NO_SECTION	NO_SETID	8
Massive seizures may be encountered with this combination.
1	0	6	O	Massive
2	8	15	O	seizures
3	17	19	O	may
4	21	22	O	be
5	24	34	O	encountered
6	36	39	O	with
7	41	44	O	this
8	46	56	O	combination
NULL

Chlorprothixene	DDI-DrugBank.d503.s5	NO_SECTION	NO_SETID	18
Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.
1	0	7	O	Consider
2	9	16	O	additive
3	18	25	O	sedative
4	27	33	O	effects
5	35	37	O	and
6	39	49	O	confusional
7	51	56	O	states
8	58	59	O	to
9	61	66	O	emerge
10	67	67	O	,
11	69	70	O	if
12	72	86	O	XXXXXXXX
13	88	89	O	is
14	91	95	O	given
15	97	100	O	with
16	102	116	U-DYN	benzodiazepines
17	118	119	O	or
18	121	131	U-DYN	barbituates
NULL

Chlorprothixene	DDI-DrugBank.d503.s6	NO_SECTION	NO_SETID	7
Choose particular low doses of these drugs.
1	0	5	O	Choose
2	7	16	O	particular
3	18	20	O	low
4	22	26	O	doses
5	28	29	O	of
6	31	35	O	these
7	37	41	O	drugs
NULL

Chlorprothixene	DDI-DrugBank.d503.s7	NO_SECTION	NO_SETID	33
Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
1	0	4	O	Exert
2	6	15	O	particular
3	17	23	O	caution
4	25	26	O	in
5	28	36	O	combining
6	38	52	O	XXXXXXXX
7	54	57	O	with
8	59	63	O	other
9	65	79	B-DYN	anticholinergic
10	81	85	L-DYN	drugs
11	88	96	B-DYN	tricyclic
12	98	112	L-DYN	antidepressants
13	114	116	O	and
14	118	133	B-DYN	antiparkinsonian
15	135	140	L-DYN	agents
16	142	142	O	:
17	144	155	O	Particularly
18	157	159	O	the
19	161	167	O	elderly
20	169	171	O	may
21	173	179	O	develop
22	181	188	O	delirium
23	189	189	O	,
24	191	194	O	high
25	196	200	O	fever
26	201	201	O	,
27	203	208	O	severe
28	210	220	O	obstipation
29	221	221	O	,
30	223	226	O	even
31	228	232	O	ileus
32	234	236	O	and
33	238	245	O	glaucoma
NULL

Chlorthalidone	DDI-DrugBank.d265.s0	NO_SECTION	NO_SETID	12
Chlorthalidone may add to or potentiate the action of other antihypertensive drugs.
1	0	13	O	XXXXXXXX
2	15	17	O	may
3	19	21	O	add
4	23	24	O	to
5	26	27	O	or
6	29	38	O	potentiate
7	40	42	O	the
8	44	49	O	action
9	51	52	O	of
10	54	58	O	other
11	60	75	B-DYN	antihypertensive
12	77	81	L-DYN	drugs
NULL

Chlorthalidone	DDI-DrugBank.d265.s1	NO_SECTION	NO_SETID	8
Potentiation occurs with ganglionic peripheral adrenergic blocking drugs.
1	0	11	O	Potentiation
2	13	18	O	occurs
3	20	23	O	with
4	25	34	B-UNK	ganglionic
5	36	45	I-UNK	peripheral
6	47	56	I-UNK	adrenergic
7	58	65	I-UNK	blocking
8	67	71	L-UNK	drugs
NULL

Chlorthalidone	DDI-DrugBank.d265.s2	NO_SECTION	NO_SETID	9
Medication such as digitalis may also influence serum electrolytes.
1	0	9	O	Medication
2	11	14	O	such
3	16	17	O	as
4	19	27	U-UNK	digitalis
5	29	31	O	may
6	33	36	O	also
7	38	46	O	influence
8	48	52	O	serum
9	54	65	O	electrolytes
NULL

Chlorthalidone	DDI-DrugBank.d265.s3	NO_SECTION	NO_SETID	45
Warning signs, irrespective of cause, are: dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.
1	0	6	O	Warning
2	8	12	O	signs
3	13	13	O	,
4	15	26	O	irrespective
5	28	29	O	of
6	31	35	O	cause
7	36	36	O	,
8	38	40	O	are
9	41	41	O	:
10	43	49	O	dryness
11	51	52	O	of
12	54	58	O	mouth
13	59	59	O	,
14	61	66	O	thirst
15	67	67	O	,
16	69	76	O	weakness
17	77	77	O	,
18	79	86	O	lethargy
19	87	87	O	,
20	89	98	O	drowsiness
21	99	99	O	,
22	101	112	O	restlessness
23	113	113	O	,
24	115	120	O	muscle
25	122	126	O	pains
26	128	129	O	or
27	131	136	O	cramps
28	137	137	O	,
29	139	146	O	muscular
30	148	154	O	fatigue
31	155	155	O	,
32	157	167	O	hypotension
33	168	168	O	,
34	170	177	O	oliguria
35	178	178	O	,
36	180	190	O	tachycardia
37	191	191	O	,
38	193	195	O	and
39	197	212	O	gastrointestinal
40	214	225	O	disturbances
41	227	230	O	such
42	232	233	O	as
43	235	240	O	nausea
44	242	244	O	and
45	246	253	O	vomiting
NULL

Chlorthalidone	DDI-DrugBank.d265.s4	NO_SECTION	NO_SETID	13
Insulin requirements in diabetic patients may be increased, decreased, or unchanged.
1	0	6	U-UNK	Insulin
2	8	19	O	requirements
3	21	22	O	in
4	24	31	O	diabetic
5	33	40	O	patients
6	42	44	O	may
7	46	47	O	be
8	49	57	O	increased
9	58	58	O	,
10	60	68	O	decreased
11	69	69	O	,
12	71	72	O	or
13	74	82	O	unchanged
NULL

Chlorthalidone	DDI-DrugBank.d265.s5	NO_SECTION	NO_SETID	9
Higher dosage of oral hypoglycemic agents may be required.
1	0	5	O	Higher
2	7	12	O	dosage
3	14	15	O	of
4	17	20	O	oral
5	22	33	B-UNK	hypoglycemic
6	35	40	L-UNK	agents
7	42	44	O	may
8	46	47	O	be
9	49	56	O	required
NULL

Chlorthalidone	DDI-DrugBank.d265.s6	NO_SECTION	NO_SETID	9
Latent diabetes mellitus may become manifest during chlorthalidone administration.
1	0	5	O	Latent
2	7	14	O	diabetes
3	16	23	O	mellitus
4	25	27	O	may
5	29	34	O	become
6	36	43	O	manifest
7	45	50	O	during
8	52	65	O	XXXXXXXX
9	67	80	O	administration
NULL

Chlorthalidone	DDI-DrugBank.d265.s7	NO_SECTION	NO_SETID	10
Chlorthalidone and related drugs may increase the responsiveness to tubocurarine.
1	0	13	O	XXXXXXXX
2	15	17	O	and
3	19	25	O	related
4	27	31	O	drugs
5	33	35	O	may
6	37	44	O	increase
7	46	48	O	the
8	50	63	O	responsiveness
9	65	66	O	to
10	68	79	U-DYN	tubocurarine
NULL

Chlorthalidone	DDI-DrugBank.d265.s8	NO_SECTION	NO_SETID	10
Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine.
1	0	13	O	XXXXXXXX
2	15	17	O	and
3	19	25	O	related
4	27	31	O	drugs
5	33	35	O	may
6	37	44	O	decrease
7	46	53	O	arterial
8	55	68	O	responsiveness
9	70	71	O	to
10	73	86	U-DYN	norepinephrine
NULL

Chlorthalidone	DDI-DrugBank.d265.s9	NO_SECTION	NO_SETID	15
This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.
1	0	3	O	This
2	5	14	O	diminution
3	16	17	O	is
4	19	21	O	not
5	23	32	O	sufficient
6	34	35	O	to
7	37	44	O	preclude
8	46	58	O	effectiveness
9	60	61	O	of
10	63	65	O	the
11	67	73	O	pressor
12	75	79	O	agent
13	81	83	O	for
14	85	95	O	therapeutic
15	97	99	O	use
NULL

Chlorzoxazone	DDI-DrugBank.d262.s0	NO_SECTION	NO_SETID	16
The concomitant use of alcohol or other central nervous system depressants may have an additive effect.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	29	U-UNK	alcohol
6	31	32	O	or
7	34	38	O	other
8	40	46	B-UNK	central
9	48	54	I-UNK	nervous
10	56	61	I-UNK	system
11	63	73	L-UNK	depressants
12	75	77	O	may
13	79	82	O	have
14	84	85	O	an
15	87	94	O	additive
16	96	101	O	effect
NULL

Cholecalciferol	DDI-DrugBank.d404.s0	NO_SECTION	NO_SETID	30
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
1	0	11	O	Interactions
2	13	15	O	for
3	17	23	B-UNK	vitamin
4	25	25	L-UNK	D
5	27	35	O	analogues
6	38	44	B-UNK	Vitamin
7	46	47	L-UNK	D2
8	48	48	O	,
9	50	56	B-UNK	Vitamin
10	58	59	L-UNK	D3
11	60	60	O	,
12	62	71	U-UNK	Calcitriol
13	72	72	O	,
14	74	76	O	and
15	78	86	U-UNK	Calcidiol
16	88	88	O	:
17	90	103	U-UNK	Cholestyramine
18	104	104	O	:
19	106	119	U-UNK	Cholestyramine
20	121	123	O	has
21	125	128	O	been
22	130	137	O	reported
23	139	140	O	to
24	142	147	O	reduce
25	149	158	O	intestinal
26	160	169	O	absorption
27	171	172	O	of
28	174	176	B-UNK	fat
29	178	184	I-UNK	soluble
30	186	193	L-UNK	vitamins
NULL

Cholecalciferol	DDI-DrugBank.d404.s1	NO_SECTION	NO_SETID	12
as such it may impair intestinal absorption of any of vitamin D.
1	0	1	O	as
2	3	6	O	such
3	8	9	O	it
4	11	13	O	may
5	15	20	O	impair
6	22	31	O	intestinal
7	33	42	O	absorption
8	44	45	O	of
9	47	49	O	any
10	51	52	O	of
11	54	60	B-UNK	vitamin
12	62	62	L-UNK	D
NULL

Cholecalciferol	DDI-DrugBank.d404.s2	NO_SECTION	NO_SETID	32
Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
1	0	8	U-UNK	Phenytoin
2	9	9	O	/
3	10	22	U-UNK	Phenobarbital
4	23	23	O	:
5	25	27	O	The
6	29	44	O	coadministration
7	46	47	O	of
8	49	57	U-UNK	phenytoin
9	59	60	O	or
10	62	74	U-UNK	phenobarbital
11	76	79	O	will
12	81	83	O	not
13	85	90	O	affect
14	92	97	O	plasma
15	99	112	O	concentrations
16	114	115	O	of
17	117	123	B-UNK	vitamin
18	125	125	L-UNK	D
19	126	126	O	,
20	128	130	O	but
21	132	134	O	may
22	136	141	O	reduce
23	143	152	O	endogenous
24	154	159	O	plasma
25	161	166	O	levels
26	168	169	O	of
27	171	180	U-UNK	calcitriol
28	181	181	O	/
29	182	195	O	ergocalcitriol
30	197	198	O	by
31	200	211	O	accelerating
32	213	222	O	metabolism
NULL

Cholecalciferol	DDI-DrugBank.d404.s3	NO_SECTION	NO_SETID	24
Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.
1	0	4	O	Since
2	6	10	O	blood
3	12	16	O	level
4	18	19	O	of
5	21	30	U-UNK	calcitriol
6	31	31	O	/
7	32	45	O	ergocalcitriol
8	47	50	O	will
9	52	53	O	be
10	55	61	O	reduced
11	62	62	O	,
12	64	69	O	higher
13	71	75	O	doses
14	77	78	O	of
15	80	88	O	XXXXXXXX
16	90	92	O	may
17	94	95	O	be
18	97	105	O	necessary
19	107	108	O	if
20	110	114	O	these
21	116	120	O	drugs
22	122	124	O	are
23	126	137	O	administered
24	139	152	O	simultaneously
NULL

Cholecalciferol	DDI-DrugBank.d404.s4	NO_SECTION	NO_SETID	16
Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine.
1	0	8	U-UNK	Thiazides
2	9	9	O	:
3	11	19	U-UNK	Thiazides
4	21	23	O	are
5	25	29	O	known
6	31	32	O	to
7	34	39	O	induce
8	41	53	O	hypercalcemia
9	55	56	O	by
10	58	60	O	the
11	62	70	O	reduction
12	72	73	O	of
13	75	81	O	calcium
14	83	91	O	excretion
15	93	94	O	in
16	96	100	O	urine
NULL

Cholecalciferol	DDI-DrugBank.d404.s5	NO_SECTION	NO_SETID	15
Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
1	0	3	O	Some
2	5	11	O	reports
3	13	16	O	have
4	18	22	O	shown
5	24	27	O	that
6	29	31	O	the
7	33	43	O	concomitant
8	45	58	O	administration
9	60	61	O	of
10	63	71	U-UNK	thiazides
11	73	76	O	with
12	78	84	B-UNK	vitamin
13	86	86	L-UNK	D
14	88	93	O	causes
15	95	107	O	hypercalcemia
NULL

Cholecalciferol	DDI-DrugBank.d404.s6	NO_SECTION	NO_SETID	10
Therefore, precaution should be taken when coadministration is necessary.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	precaution
4	22	27	O	should
5	29	30	O	be
6	32	36	O	taken
7	38	41	O	when
8	43	58	O	coadministration
9	60	61	O	is
10	63	71	O	necessary
NULL

Cholecalciferol	DDI-DrugBank.d404.s7	NO_SECTION	NO_SETID	26
Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
1	0	8	U-UNK	Digitalis
2	9	9	O	:
3	11	17	B-UNK	Vitamin
4	19	19	L-UNK	D
5	21	26	O	dosage
6	28	31	O	must
7	33	34	O	be
8	36	45	O	determined
9	47	50	O	with
10	52	55	O	care
11	57	58	O	in
12	60	67	O	patients
13	69	78	O	undergoing
14	80	88	O	treatment
15	90	93	O	with
16	95	103	U-UNK	digitalis
17	104	104	O	,
18	106	107	O	as
19	109	121	O	hypercalcemia
20	123	124	O	in
21	126	129	O	such
22	131	138	O	patients
23	140	142	O	may
24	144	154	O	precipitate
25	156	162	O	cardiac
26	164	174	O	arrhythmias
NULL

Cholecalciferol	DDI-DrugBank.d404.s8	NO_SECTION	NO_SETID	13
Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	25	U-UNK	Ketoconazole
4	27	29	O	may
5	31	37	O	inhibit
6	39	42	O	both
7	44	52	O	synthetic
8	54	56	O	and
9	58	66	O	catabolic
10	68	74	O	enzymes
11	76	77	O	of
12	79	85	B-UNK	vitamin
13	87	87	L-UNK	D
NULL

Cholecalciferol	DDI-DrugBank.d404.s9	NO_SECTION	NO_SETID	30
Reductions in serum endogenous vitamin D concentrations have been observed following the administration of 300 mg/day to 1200 mg/day ketoconazole for a week to healthy men.
1	0	9	O	Reductions
2	11	12	O	in
3	14	18	O	serum
4	20	29	O	endogenous
5	31	37	O	vitamin
6	39	39	O	D
7	41	54	O	concentrations
8	56	59	O	have
9	61	64	O	been
10	66	73	O	observed
11	75	83	O	following
12	85	87	O	the
13	89	102	O	administration
14	104	105	O	of
15	107	109	O	300
16	111	112	O	mg
17	113	113	O	/
18	114	116	O	day
19	118	119	O	to
20	121	124	O	1200
21	126	127	O	mg
22	128	128	O	/
23	129	131	O	day
24	133	144	U-UNK	ketoconazole
25	146	148	O	for
26	150	150	O	a
27	152	155	O	week
28	157	158	O	to
29	160	166	O	healthy
30	168	170	O	men
NULL

Cholecalciferol	DDI-DrugBank.d404.s10	NO_SECTION	NO_SETID	16
However, in vivo drug interaction studies of ketoconazole with vitamin D have not been investigated.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	15	O	vivo
5	17	20	O	drug
6	22	32	O	interaction
7	34	40	O	studies
8	42	43	O	of
9	45	56	U-UNK	ketoconazole
10	58	61	O	with
11	63	69	B-UNK	vitamin
12	71	71	L-UNK	D
13	73	76	O	have
14	78	80	O	not
15	82	85	O	been
16	87	98	O	investigated
NULL

Cholecalciferol	DDI-DrugBank.d404.s11	NO_SECTION	NO_SETID	25
Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
1	0	14	U-UNK	Corticosteroids
2	15	15	O	:
3	17	17	O	A
4	19	30	O	relationship
5	32	33	O	of
6	35	44	O	functional
7	46	55	O	antagonism
8	57	62	O	exists
9	64	70	O	between
10	72	78	B-UNK	vitamin
11	80	80	L-UNK	D
12	82	90	O	analogues
13	91	91	O	,
14	93	97	O	which
15	99	105	O	promote
16	107	113	O	calcium
17	115	124	O	absorption
18	125	125	O	,
19	127	129	O	and
20	131	145	U-UNK	corticosteroids
21	146	146	O	,
22	148	152	O	which
23	154	160	O	inhibit
24	162	168	O	calcium
25	170	179	O	absorption
NULL

Cholecalciferol	DDI-DrugBank.d404.s12	NO_SECTION	NO_SETID	38
Phosphate-Binding Agents: Since vitamin D also has an effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate-binding agents must be adjusted in accordance with the serum phosphate concentration.
1	0	8	O	Phosphate
2	10	16	O	Binding
3	18	23	O	Agents
4	24	24	O	:
5	26	30	O	Since
6	32	38	B-UNK	vitamin
7	40	40	L-UNK	D
8	42	45	O	also
9	47	49	O	has
10	51	52	O	an
11	54	59	O	effect
12	61	62	O	on
13	64	72	O	phosphate
14	74	82	O	transport
15	84	85	O	in
16	87	89	O	the
17	91	99	O	intestine
18	100	100	O	,
19	102	108	O	kidneys
20	110	112	O	and
21	114	118	O	bones
22	119	119	O	,
23	121	123	O	the
24	125	130	O	dosage
25	132	133	O	of
26	135	143	O	phosphate
27	145	151	O	binding
28	153	158	O	agents
29	160	163	O	must
30	165	166	O	be
31	168	175	O	adjusted
32	177	178	O	in
33	180	189	O	accordance
34	191	194	O	with
35	196	198	O	the
36	200	204	O	serum
37	206	214	O	phosphate
38	216	228	O	concentration
NULL

Cholecalciferol	DDI-DrugBank.d404.s13	NO_SECTION	NO_SETID	24
Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.
1	0	6	B-UNK	Vitamin
2	8	8	L-UNK	D
3	9	9	O	:
4	11	13	O	The
5	15	30	O	coadministration
6	32	33	O	of
7	35	37	O	any
8	39	40	O	of
9	42	44	O	the
10	46	52	B-UNK	vitamin
11	54	54	L-UNK	D
12	56	64	O	analogues
13	66	71	O	should
14	73	74	O	be
15	76	82	O	avoided
16	84	85	O	as
17	87	90	O	this
18	92	96	O	could
19	98	103	O	create
20	105	112	O	possible
21	114	121	O	additive
22	123	129	O	effects
23	131	133	O	and
24	135	147	O	hypercalcemia
NULL

Cholecalciferol	DDI-DrugBank.d404.s14	NO_SECTION	NO_SETID	13
Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided.
1	0	6	U-UNK	Calcium
2	8	18	O	Supplements
3	19	19	O	:
4	21	32	O	Uncontrolled
5	34	39	O	intake
6	41	42	O	of
7	44	53	O	additional
8	55	61	U-UNK	calcium
9	63	72	O	containing
10	74	85	O	preparations
11	87	92	O	should
12	94	95	O	be
13	97	103	O	avoided
NULL

Cholecalciferol	DDI-DrugBank.d404.s15	NO_SECTION	NO_SETID	28
Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.
1	0	8	U-UNK	Magnesium
2	9	9	O	:
3	11	19	U-UNK	Magnesium
4	21	30	O	containing
5	32	43	O	preparations
6	46	47	O	eg
7	48	48	O	,
8	50	57	U-UNK	antacids
9	60	62	O	may
10	64	68	O	cause
11	70	84	O	hypermagnesemia
12	86	88	O	and
13	90	95	O	should
14	97	105	O	therefore
15	107	109	O	not
16	111	112	O	be
17	114	118	O	taken
18	120	125	O	during
19	127	133	O	therapy
20	135	138	O	with
21	140	146	B-UNK	vitamin
22	148	148	L-UNK	D
23	150	151	O	by
24	153	160	O	patients
25	162	163	O	on
26	165	171	O	chronic
27	173	177	O	renal
28	179	186	O	dialysis
NULL

Cholestyramine	DDI-DrugBank.d566.s0	NO_SECTION	NO_SETID	45
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
1	0	13	O	XXXXXXXX
2	15	19	U-UNK	resin
3	21	23	O	may
4	25	29	O	delay
5	31	32	O	or
6	34	39	O	reduce
7	41	43	O	the
8	45	54	O	absorption
9	56	57	O	of
10	59	69	O	concomitant
11	71	74	O	oral
12	76	85	O	medication
13	87	90	O	such
14	92	93	O	as
15	95	108	U-KIN	phenylbutazone
16	109	109	O	,
17	111	118	U-KIN	warfarin
18	119	119	O	,
19	121	128	B-KIN	thiazide
20	130	138	L-KIN	diuretics
21	141	146	O	acidic
22	149	150	O	or
23	152	162	U-KIN	propranolol
24	165	169	O	basic
25	171	171	O	,
26	173	174	O	as
27	176	179	O	well
28	181	182	O	as
29	184	195	U-KIN	tetracycline
30	197	206	B-KIN	penicillin
31	208	208	L-KIN	GGGGGGGG
32	209	209	O	,
33	211	223	U-KIN	phenobarbital
34	224	224	O	,
35	226	232	O	thyroid
36	234	236	O	and
37	238	246	U-KIN	thyroxine
38	248	259	O	preparations
39	260	260	O	,
40	262	270	U-KIN	estrogens
41	272	274	O	and
42	276	285	U-KIN	progestins
43	286	286	O	,
44	288	290	O	and
45	292	300	U-KIN	digitalis
NULL

Cholestyramine	DDI-DrugBank.d566.s1	NO_SECTION	NO_SETID	18
Interference with the absorption of oral phosphate supplements has been observed with another positively-charged bile acid sequestrant.
1	0	11	O	Interference
2	13	16	O	with
3	18	20	O	the
4	22	31	O	absorption
5	33	34	O	of
6	36	39	O	oral
7	41	49	U-UNK	phosphate
8	51	61	O	supplements
9	63	65	O	has
10	67	70	O	been
11	72	79	O	observed
12	81	84	O	with
13	86	92	O	another
14	94	103	O	positively
15	105	111	O	charged
16	113	116	O	bile
17	118	121	O	acid
18	123	133	O	sequestrant
NULL

Cholestyramine	DDI-DrugBank.d566.s2	NO_SECTION	NO_SETID	47
Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.
1	0	13	O	XXXXXXXX
2	15	19	U-UNK	resin
3	21	23	O	may
4	25	33	O	interfere
5	35	38	O	with
6	40	42	O	the
7	44	59	O	pharmacokinetics
8	61	62	O	of
9	64	68	O	drugs
10	70	73	O	that
11	75	81	O	undergo
12	83	95	O	enterohepatic
13	97	107	O	circulation
14	108	108	O	,
15	110	112	O	The
16	114	127	O	discontinuance
17	129	130	O	of
18	132	145	O	XXXXXXXX
19	147	151	U-UNK	resin
20	153	157	O	could
21	159	162	O	pose
22	164	164	O	a
23	166	171	O	hazard
24	173	174	O	to
25	176	181	O	health
26	183	184	O	if
27	186	186	O	a
28	188	198	O	potentially
29	200	204	O	toxic
30	206	209	O	drug
31	211	214	O	such
32	216	217	O	as
33	219	227	U-KIN	digitalis
34	229	231	O	has
35	233	236	O	been
36	238	246	O	filtrated
37	248	249	O	to
38	251	251	O	a
39	253	263	O	maintenance
40	265	269	O	level
41	271	275	O	while
42	277	279	O	the
43	281	287	O	patient
44	289	291	O	was
45	293	298	O	taking
46	300	313	O	XXXXXXXX
47	315	319	U-UNK	resin
NULL

Cholestyramine	DDI-DrugBank.d566.s3	NO_SECTION	NO_SETID	35
Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E, and K.
1	0	6	O	Because
2	8	21	O	XXXXXXXX
3	23	27	O	binds
4	29	32	O	bile
5	34	38	O	acids
6	39	39	O	,
7	41	54	O	XXXXXXXX
8	56	60	U-UNK	resin
9	62	64	O	may
10	66	74	O	interfere
11	76	79	O	with
12	81	86	O	normal
13	88	90	O	fat
14	92	100	O	digestion
15	102	104	O	and
16	106	115	O	absorption
17	117	119	O	and
18	121	124	O	thus
19	126	128	O	may
20	130	136	O	prevent
21	138	147	O	absorption
22	149	150	O	of
23	152	154	B-UNK	fat
24	156	162	I-UNK	soluble
25	164	171	L-UNK	vitamins
26	173	176	O	such
27	178	179	O	as
28	181	181	O	A
29	182	182	O	,
30	184	184	O	D
31	185	185	O	,
32	187	187	O	E
33	188	188	O	,
34	190	192	O	and
35	194	194	O	K
NULL

Cholestyramine	DDI-DrugBank.d566.s4	NO_SECTION	NO_SETID	26
When cholestyramine resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.
1	0	3	O	When
2	5	18	O	XXXXXXXX
3	20	24	U-UNK	resin
4	26	27	O	is
5	29	33	O	given
6	35	37	O	for
7	39	42	O	long
8	44	50	O	periods
9	52	53	O	of
10	55	58	O	time
11	59	59	O	,
12	61	71	O	concomitant
13	73	87	O	supplementation
14	89	92	O	with
15	94	98	O	water
16	100	107	O	miscible
17	110	111	O	or
18	113	122	O	parenteral
19	125	129	O	forms
20	131	132	O	of
21	134	136	B-UNK	fat
22	138	144	I-UNK	soluble
23	146	153	L-UNK	vitamins
24	155	160	O	should
25	162	163	O	be
26	165	174	O	considered
NULL

Cholestyramine	DDI-DrugBank.d566.s5	NO_SECTION	NO_SETID	44
SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.
1	0	4	O	SINCE
2	6	19	O	XXXXXXXX
3	21	25	U-UNK	RESIN
4	27	29	O	MAY
5	31	34	O	BIND
6	36	40	O	OTHER
7	42	46	O	DRUGS
8	48	52	O	GIVEN
9	54	65	O	CONCURRENTLY
10	66	66	O	,
11	68	69	O	IT
12	71	72	O	IS
13	74	84	O	RECOMMENDED
14	86	89	O	THAT
15	91	98	O	PATIENTS
16	100	103	O	TAKE
17	105	109	O	OTHER
18	111	115	O	DRUGS
19	117	118	O	AT
20	120	124	O	LEAST
21	126	126	O	1
22	128	131	O	HOUR
23	133	138	O	BEFORE
24	140	141	O	OR
25	143	143	O	4
26	145	146	O	TO
27	148	148	O	6
28	150	154	O	HOURS
29	156	160	O	AFTER
30	162	175	O	XXXXXXXX
31	177	181	U-UNK	RESIN
32	184	185	O	OR
33	187	188	O	AT
34	190	191	O	AS
35	193	197	O	GREAT
36	199	200	O	AN
37	202	209	O	INTERVAL
38	211	212	O	AS
39	214	221	O	POSSIBLE
40	224	225	O	TO
41	227	231	O	AVOID
42	233	240	O	IMPEDING
43	242	246	O	THEIR
44	248	257	O	ABSORPTION
NULL

Ciclesonide	DDI-DrugBank.d362.s0	NO_SECTION	NO_SETID	31
Based on in vitro studies in human liver microsomes, des-ciclesonide appears to have no inhibitory or induction potential on the metabolism of other drugs metabolized by CYP 450 enzymes.
1	0	4	O	Based
2	6	7	O	on
3	9	10	O	in
4	12	16	O	vitro
5	18	24	O	studies
6	26	27	O	in
7	29	33	O	human
8	35	39	O	liver
9	41	50	O	microsomes
10	51	51	O	,
11	53	55	O	des
12	57	67	O	XXXXXXXX
13	69	75	O	appears
14	77	78	O	to
15	80	83	O	have
16	85	86	O	no
17	88	97	O	inhibitory
18	99	100	O	or
19	102	110	O	induction
20	112	120	O	potential
21	122	123	O	on
22	125	127	O	the
23	129	138	O	metabolism
24	140	141	O	of
25	143	147	O	other
26	149	153	O	drugs
27	155	165	O	metabolized
28	167	168	O	by
29	170	172	O	CYP
30	174	176	O	450
31	178	184	O	enzymes
NULL

Ciclesonide	DDI-DrugBank.d362.s1	NO_SECTION	NO_SETID	12
The inhibitory potential of ciclesonide on CYP450 isoenzymes has not been studied.
1	0	2	O	The
2	4	13	O	inhibitory
3	15	23	O	potential
4	25	26	O	of
5	28	38	O	XXXXXXXX
6	40	41	O	on
7	43	48	O	CYP450
8	50	59	O	isoenzymes
9	61	63	O	has
10	65	67	O	not
11	69	72	O	been
12	74	80	O	studied
NULL

Ciclesonide	DDI-DrugBank.d362.s2	NO_SECTION	NO_SETID	30
In vitro studies demonstrated that the plasma protein binding of des-ciclesonide was not affected by warfarin or salicylic acid, indicating no potential for protein binding-based drug interactions.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	28	O	demonstrated
5	30	33	O	that
6	35	37	O	the
7	39	44	O	plasma
8	46	52	O	protein
9	54	60	O	binding
10	62	63	O	of
11	65	67	O	des
12	69	79	O	XXXXXXXX
13	81	83	O	was
14	85	87	O	not
15	89	96	O	affected
16	98	99	O	by
17	101	108	U-UNK	warfarin
18	110	111	O	or
19	113	121	B-UNK	salicylic
20	123	126	L-UNK	acid
21	127	127	O	,
22	129	138	O	indicating
23	140	141	O	no
24	143	151	O	potential
25	153	155	O	for
26	157	163	O	protein
27	165	171	O	binding
28	173	177	O	based
29	179	182	O	drug
30	184	195	O	interactions
NULL

Ciclesonide	DDI-DrugBank.d362.s3	NO_SECTION	NO_SETID	35
In a drug interaction study, co-administration of orally inhaled ciclesonide and oral erythromycin, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either des-ciclesonide or erythromycin.
1	0	1	O	In
2	3	3	O	a
3	5	8	O	drug
4	10	20	O	interaction
5	22	26	O	study
6	27	27	O	,
7	29	30	O	co
8	32	45	O	administration
9	47	48	O	of
10	50	55	O	orally
11	57	63	O	inhaled
12	65	75	O	XXXXXXXX
13	77	79	O	and
14	81	84	O	oral
15	86	97	U-UNK	erythromycin
16	98	98	O	,
17	100	101	O	an
18	103	111	O	inhibitor
19	113	114	O	of
20	116	125	O	cytochrome
21	127	130	O	P450
22	132	134	O	3A4
23	135	135	O	,
24	137	139	O	had
25	141	142	O	no
26	144	149	O	effect
27	151	152	O	on
28	154	156	O	the
29	158	173	O	pharmacokinetics
30	175	176	O	of
31	178	183	O	either
32	185	187	O	des
33	189	199	O	XXXXXXXX
34	201	202	O	or
35	204	215	U-UNK	erythromycin
NULL

Ciclesonide	DDI-DrugBank.d362.s4	NO_SECTION	NO_SETID	45
In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.
1	0	1	O	In
2	3	9	O	another
3	11	14	O	drug
4	16	26	O	interaction
5	28	32	O	study
6	33	33	O	,
7	35	36	O	co
8	38	51	O	administration
9	53	54	O	of
10	56	61	O	orally
11	63	69	O	inhaled
12	71	81	O	XXXXXXXX
13	83	85	O	and
14	87	90	O	oral
15	92	103	U-KIN	ketoconazole
16	104	104	O	,
17	106	106	O	a
18	108	113	O	potent
19	115	123	O	inhibitor
20	125	126	O	of
21	128	137	O	cytochrome
22	139	142	O	P450
23	144	146	O	3A4
24	147	147	O	,
25	149	157	O	increased
26	159	161	O	the
27	163	170	O	exposure
28	173	175	O	AUC
29	178	179	O	of
30	181	183	O	des
31	185	195	O	XXXXXXXX
32	197	198	O	by
33	200	212	O	approximately
34	214	216	O	3.6
35	218	221	O	fold
36	223	224	O	at
37	226	231	O	steady
38	233	237	O	state
39	238	238	O	,
40	240	244	O	while
41	246	251	O	levels
42	253	254	O	of
43	256	266	O	XXXXXXXX
44	268	275	O	remained
45	277	285	O	unchanged
NULL

Ciclesonide	DDI-DrugBank.d362.s5	NO_SECTION	NO_SETID	11
Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.
1	0	8	O	Therefore
2	9	9	O	,
3	11	22	U-DYN	ketoconazole
4	24	29	O	should
5	31	32	O	be
6	34	45	O	administered
7	47	50	O	with
8	52	58	O	caution
9	60	63	O	with
10	65	74	O	intranasal
11	76	86	O	XXXXXXXX
NULL

Cidofovir	DDI-DrugBank.d260.s0	NO_SECTION	NO_SETID	54
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
1	0	9	U-UNK	Probenecid
2	11	11	O	:
3	13	22	U-UNK	Probenecid
4	24	25	O	is
5	27	31	O	known
6	33	34	O	to
7	36	43	O	interact
8	45	48	O	with
9	50	52	O	the
10	54	63	O	metabolism
11	65	66	O	or
12	68	72	O	renal
13	74	80	O	tubular
14	82	90	O	excretion
15	92	93	O	of
16	95	98	O	many
17	100	104	O	drugs
18	107	109	O	e.g
19	111	111	O	,
20	113	125	U-UNK	acetaminophen
21	126	126	O	,
22	128	136	U-UNK	acyclovir
23	137	137	O	,
24	139	149	B-UNK	angiotensin
25	151	160	I-UNK	converting
26	162	167	I-UNK	enzyme
27	169	178	L-UNK	inhibitors
28	179	179	O	,
29	181	194	B-UNK	aminosalicylic
30	196	199	L-UNK	acid
31	200	200	O	,
32	202	213	U-UNK	barbiturates
33	214	214	O	,
34	216	230	U-UNK	benzodiazepines
35	231	231	O	,
36	233	242	U-UNK	bumetanide
37	243	243	O	,
38	245	254	U-UNK	clofibrate
39	255	255	O	,
40	257	268	U-UNK	methotrexate
41	269	269	O	,
42	271	280	U-UNK	famotidine
43	281	281	O	,
44	283	292	U-UNK	furosemide
45	293	293	O	,
46	295	306	B-UNK	nonsteroidal
47	308	311	I-UNK	anti
48	313	324	L-UNK	inflammatory
49	326	331	O	agents
50	332	332	O	,
51	334	345	U-UNK	theophylline
52	346	346	O	,
53	348	350	O	and
54	352	361	U-UNK	zidovudine
NULL

Cidofovir	DDI-DrugBank.d260.s1	NO_SECTION	NO_SETID	6
Concomitant medications should be carefully assessed.
1	0	10	O	Concomitant
2	12	22	O	medications
3	24	29	O	should
4	31	32	O	be
5	34	42	O	carefully
6	44	51	O	assessed
NULL

Cidofovir	DDI-DrugBank.d260.s2	NO_SECTION	NO_SETID	20
Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.
1	0	9	U-UNK	Zidovudine
2	11	16	O	should
3	18	23	O	either
4	25	26	O	be
5	28	38	O	temporarily
6	40	51	O	discontinued
7	53	54	O	or
8	56	64	O	decreased
9	66	67	O	by
10	69	71	O	50%
11	73	76	O	when
12	78	91	O	coadministered
13	93	96	O	with
14	98	107	U-UNK	probenecid
15	109	110	O	on
16	112	114	O	the
17	116	118	O	day
18	120	121	O	of
19	123	129	O	XXXXXXXX
20	131	138	O	infusion
NULL

Cidofovir	DDI-DrugBank.d260.s3	NO_SECTION	NO_SETID	43
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.
1	0	10	O	Nephrotoxic
2	12	17	O	agents
3	19	19	O	:
4	21	31	O	Concomitant
5	33	46	O	administration
6	48	49	O	of
7	51	57	O	XXXXXXXX
8	59	61	O	and
9	63	68	O	agents
10	70	73	O	with
11	75	85	O	nephrotoxic
12	87	95	O	potential
13	98	100	O	e.g
14	102	102	O	,
15	104	114	O	intravenous
16	116	130	U-DYN	aminoglycosides
17	133	135	O	e.g
18	137	137	O	,
19	139	148	U-DYN	tobramycin
20	149	149	O	,
21	151	160	U-DYN	gentamicin
22	161	161	O	,
23	163	165	O	and
24	167	174	U-DYN	amikacin
25	176	176	O	,
26	178	189	B-DYN	amphotericin
27	191	191	L-DYN	B
28	192	192	O	,
29	194	202	U-DYN	foscarnet
30	203	203	O	,
31	205	215	O	intravenous
32	217	227	U-DYN	pentamidine
33	228	228	O	,
34	230	239	U-DYN	vancomycin
35	240	240	O	,
36	242	244	O	and
37	246	248	B-DYN	non
38	250	258	I-DYN	steroidal
39	260	263	I-DYN	anti
40	265	276	I-DYN	inflammatory
41	278	283	L-DYN	agents
42	286	287	O	is
43	289	303	O	contraindicated
NULL

Cidofovir	DDI-DrugBank.d260.s4	NO_SECTION	NO_SETID	15
Such agents must be discontinued at least seven days prior to starting therapy with VISTIDE.
1	0	3	O	Such
2	5	10	O	agents
3	12	15	O	must
4	17	18	O	be
5	20	31	O	discontinued
6	33	34	O	at
7	36	40	O	least
8	42	46	O	seven
9	48	51	O	days
10	53	57	O	prior
11	59	60	O	to
12	62	69	O	starting
13	71	77	O	therapy
14	79	82	O	with
15	84	90	O	XXXXXXXX
NULL

Cilostazol	DDI-DrugBank.d358.s0	NO_SECTION	NO_SETID	35
Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
1	0	4	O	Since
2	6	11	O	XXXXXXXX
3	13	14	O	is
4	16	26	O	extensively
5	28	38	O	metabolized
6	40	41	O	by
7	43	52	O	cytochrome
8	54	54	O	P
9	56	58	O	450
10	60	69	O	isoenzymes
11	70	70	O	,
12	72	78	O	caution
13	80	85	O	should
14	87	88	O	be
15	90	98	O	exercised
16	100	103	O	when
17	105	110	O	XXXXXXXX
18	112	113	O	is
19	115	128	O	coadministered
20	130	133	O	with
21	135	144	O	inhibitors
22	146	147	O	of
23	149	153	O	C.P.A
24	156	159	O	such
25	161	162	O	as
26	164	175	U-DYN	ketoconazole
27	177	179	O	and
28	181	192	U-DYN	erythromycin
29	194	195	O	or
30	197	206	O	inhibitors
31	208	209	O	of
32	211	217	O	CYP2C19
33	219	222	O	such
34	224	225	O	as
35	227	236	U-DYN	omeprazole
NULL

Cilostazol	DDI-DrugBank.d358.s1	NO_SECTION	NO_SETID	21
Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
1	0	14	O	Pharmacokinetic
2	16	22	O	studies
3	24	27	O	have
4	29	40	O	demonstrated
5	42	45	O	that
6	47	56	U-KIN	omeprazole
7	58	60	O	and
8	62	73	U-KIN	erythromycin
9	75	87	O	significantly
10	89	97	O	increased
11	99	101	O	the
12	103	110	O	systemic
13	112	119	O	exposure
14	121	122	O	of
15	124	133	O	XXXXXXXX
16	135	137	O	and
17	138	138	O	/
18	139	140	O	or
19	142	144	O	its
20	146	150	O	major
21	152	162	O	metabolites
NULL

Cilostazol	DDI-DrugBank.d358.s2	NO_SECTION	NO_SETID	19
Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..
1	0	9	O	Population
2	11	25	O	pharmacokinetic
3	27	33	O	studies
4	35	40	O	showed
5	42	47	O	higher
6	49	62	O	concentrations
7	64	65	O	of
8	67	76	O	XXXXXXXX
9	78	82	O	among
10	84	91	O	patients
11	93	104	O	concurrently
12	106	112	O	treated
13	114	117	O	with
14	119	127	U-KIN	diltiazem
15	128	128	O	,
16	130	131	O	an
17	133	141	O	inhibitor
18	143	144	O	of
19	146	150	O	C.P.A
NULL

Cilostazol	DDI-DrugBank.d358.s3	NO_SECTION	NO_SETID	35
Pletal does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to C.P.A. inhibition.
1	0	5	O	XXXXXXXX
2	7	10	O	does
3	12	14	O	not
4	15	15	O	,
5	17	23	O	however
6	24	24	O	,
7	26	31	O	appear
8	33	34	O	to
9	36	40	O	cause
10	42	50	O	increased
11	52	56	O	blood
12	58	63	O	levels
13	65	66	O	of
14	68	72	O	drugs
15	74	84	O	metabolized
16	86	87	O	by
17	89	94	O	CYP3A4
18	95	95	O	,
19	97	98	O	as
20	100	101	O	it
21	103	105	O	had
22	107	108	O	no
23	110	115	O	effect
24	117	118	O	on
25	120	129	U-UNK	lovastatin
26	130	130	O	,
27	132	132	O	a
28	134	137	O	drug
29	139	142	O	with
30	144	153	O	metabolism
31	155	158	O	very
32	160	168	O	sensitive
33	170	171	O	to
34	173	177	O	C.P.A
35	180	189	O	inhibition
NULL

Cimetidine	DDI-DrugBank.d171.s0	NO_SECTION	NO_SETID	55
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.
1	0	6	O	XXXXXXXX
2	7	7	O	,
3	9	18	O	apparently
4	20	26	O	through
5	28	29	O	an
6	31	36	O	effect
7	38	39	O	on
8	41	47	O	certain
9	49	58	O	microsomal
10	60	65	O	enzyme
11	67	73	O	systems
12	74	74	O	,
13	76	78	O	has
14	80	83	O	been
15	85	92	O	reported
16	94	95	O	to
17	97	102	O	reduce
18	104	106	O	the
19	108	114	O	hepatic
20	116	125	O	metabolism
21	127	128	O	of
22	130	137	B-KIN	warfarin
23	139	142	I-KIN	type
24	144	157	L-KIN	anticoagulants
25	158	158	O	,
26	160	168	U-KIN	phenytoin
27	169	169	O	,
28	171	181	U-KIN	propranolol
29	182	182	O	,
30	184	193	U-KIN	nifedipine
31	194	194	O	,
32	196	211	U-KIN	chlordiazepoxide
33	212	212	O	,
34	214	221	U-KIN	diazepam
35	222	222	O	,
36	224	230	O	certain
37	232	240	B-KIN	tricyclic
38	242	256	L-KIN	antidepressants
39	257	257	O	,
40	259	267	U-KIN	lidocaine
41	268	268	O	,
42	270	281	U-KIN	theophylline
43	283	285	O	and
44	287	299	U-KIN	metronidazole
45	300	300	O	,
46	302	308	O	thereby
47	310	317	O	delaying
48	319	329	O	elimination
49	331	333	O	and
50	335	344	O	increasing
51	346	350	O	blood
52	352	357	O	levels
53	359	360	O	of
54	362	366	O	these
55	368	372	O	drugs
NULL

Cimetidine	DDI-DrugBank.d171.s1	NO_SECTION	NO_SETID	10
Clinically significant effects have been reported with the warfarin anticoagulants;
1	0	9	O	Clinically
2	11	21	O	significant
3	23	29	O	effects
4	31	34	O	have
5	36	39	O	been
6	41	48	O	reported
7	50	53	O	with
8	55	57	O	the
9	59	66	B-UNK	warfarin
10	68	81	L-UNK	anticoagulants
NULL

Cimetidine	DDI-DrugBank.d171.s2	NO_SECTION	NO_SETID	24
therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.
1	0	8	O	therefore
2	9	9	O	,
3	11	15	O	close
4	17	26	O	monitoring
5	28	29	O	of
6	31	41	O	prothrombin
7	43	46	O	time
8	48	49	O	is
9	51	61	O	recommended
10	62	62	O	,
11	64	66	O	and
12	68	77	O	adjustment
13	79	80	O	of
14	82	84	O	the
15	86	98	U-DYN	anticoagulant
16	100	103	O	dose
17	105	107	O	may
18	109	110	O	be
19	112	120	O	necessary
20	122	125	O	when
21	127	133	O	XXXXXXXX
22	135	136	O	is
23	138	149	O	administered
24	151	163	O	concomitantly
NULL

Cimetidine	DDI-DrugBank.d171.s3	NO_SECTION	NO_SETID	16
Interaction with phenytoin, lidocaine and theophylline has also been reported to produce adverse clinical effects.
1	0	10	O	Interaction
2	12	15	O	with
3	17	25	U-UNK	phenytoin
4	26	26	O	,
5	28	36	U-UNK	lidocaine
6	38	40	O	and
7	42	53	U-UNK	theophylline
8	55	57	O	has
9	59	62	O	also
10	64	67	O	been
11	69	76	O	reported
12	78	79	O	to
13	81	87	O	produce
14	89	95	O	adverse
15	97	104	O	clinical
16	106	112	O	effects
NULL

Cimetidine	DDI-DrugBank.d171.s4	NO_SECTION	NO_SETID	58
However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
1	0	6	O	However
2	7	7	O	,
3	9	9	O	a
4	11	19	O	crossover
5	21	25	O	study
6	27	28	O	in
7	30	36	O	healthy
8	38	45	O	subjects
9	47	55	O	receiving
10	57	62	O	either
11	64	70	O	Tagamet
12	72	74	O	300
13	76	77	O	mg
14	79	83	O	q.i.d
15	86	87	O	or
16	89	91	O	800
17	93	94	O	mg
18	96	98	O	h.s
19	101	113	O	concomitantly
20	115	118	O	with
21	120	120	O	a
22	122	124	O	300
23	126	127	O	mg
24	129	133	O	b.i.d
25	136	141	O	dosage
26	143	144	O	of
27	146	157	U-KIN	theophylline
28	160	167	U-KIN	XXXXXXXX
29	169	169	O	,
30	171	173	O	Key
31	175	189	O	Pharmaceuticals
32	190	190	O	,
33	192	194	O	Inc
34	198	209	O	demonstrated
35	211	214	O	less
36	216	225	O	alteration
37	227	228	O	in
38	230	235	O	steady
39	237	241	O	state
40	243	254	U-UNK	theophylline
41	256	259	O	peak
42	261	265	O	serum
43	267	272	O	levels
44	274	277	O	with
45	279	281	O	the
46	283	285	O	800
47	287	288	O	mg
48	290	292	O	h.s
49	295	301	O	regimen
50	302	302	O	,
51	304	315	O	particularly
52	317	318	O	in
53	320	327	O	subjects
54	329	332	O	aged
55	334	335	O	54
56	337	341	O	years
57	343	345	O	and
58	347	351	O	older
NULL

Cimetidine	DDI-DrugBank.d171.s5	NO_SECTION	NO_SETID	7
Data beyond 10 days are not available.
1	0	3	O	Data
2	5	10	O	beyond
3	12	13	O	10
4	15	18	O	days
5	20	22	O	are
6	24	26	O	not
7	28	36	O	available
NULL

Cimetidine	DDI-DrugBank.d171.s6	NO_SECTION	NO_SETID	16
(Note: All patients receiving theophylline should be monitored appropriately, regardless of concomitant drug therapy.)
1	1	4	O	Note
2	5	5	O	:
3	7	9	O	All
4	11	18	O	patients
5	20	28	O	receiving
6	30	41	U-UNK	theophylline
7	43	48	O	should
8	50	51	O	be
9	53	61	O	monitored
10	63	75	O	appropriately
11	76	76	O	,
12	78	87	O	regardless
13	89	90	O	of
14	92	102	O	concomitant
15	104	107	O	drug
16	109	115	O	therapy
NULL

Cimetidine	DDI-DrugBank.d171.s7	NO_SECTION	NO_SETID	45
Dosage of the drugs mentioned above and other similarly metabolized drugs, particularly those of low therapeutic ratio or in patients with renal and/or hepatic impairment, may require adjustment when starting or stopping concomitantly administered Tagamet to maintain optimum therapeutic blood levels.
1	0	5	O	Dosage
2	7	8	O	of
3	10	12	O	the
4	14	18	O	drugs
5	20	28	O	mentioned
6	30	34	O	above
7	36	38	O	and
8	40	44	O	other
9	46	54	O	similarly
10	56	66	O	metabolized
11	68	72	O	drugs
12	73	73	O	,
13	75	86	O	particularly
14	88	92	O	those
15	94	95	O	of
16	97	99	O	low
17	101	111	O	therapeutic
18	113	117	O	ratio
19	119	120	O	or
20	122	123	O	in
21	125	132	O	patients
22	134	137	O	with
23	139	143	O	renal
24	145	147	O	and
25	148	148	O	/
26	149	150	O	or
27	152	158	O	hepatic
28	160	169	O	impairment
29	170	170	O	,
30	172	174	O	may
31	176	182	O	require
32	184	193	O	adjustment
33	195	198	O	when
34	200	207	O	starting
35	209	210	O	or
36	212	219	O	stopping
37	221	233	O	concomitantly
38	235	246	O	administered
39	248	254	O	XXXXXXXX
40	256	257	O	to
41	259	266	O	maintain
42	268	274	O	optimum
43	276	286	O	therapeutic
44	288	292	O	blood
45	294	299	O	levels
NULL

Cimetidine	DDI-DrugBank.d171.s8	NO_SECTION	NO_SETID	12
Alteration of pH may affect absorption of certain drugs (e.g., ketoconazole).
1	0	9	O	Alteration
2	11	12	O	of
3	14	15	O	pH
4	17	19	O	may
5	21	26	O	affect
6	28	37	O	absorption
7	39	40	O	of
8	42	48	O	certain
9	50	54	O	drugs
10	57	59	O	e.g
11	61	61	O	,
12	63	74	U-UNK	ketoconazole
NULL

Cimetidine	DDI-DrugBank.d171.s9	NO_SECTION	NO_SETID	17
If these products are needed, they should be given at least 2 hours before cimetidine administration.
1	0	1	O	If
2	3	7	O	these
3	9	16	O	products
4	18	20	O	are
5	22	27	O	needed
6	28	28	O	,
7	30	33	O	they
8	35	40	O	should
9	42	43	O	be
10	45	49	O	given
11	51	52	O	at
12	54	58	O	least
13	60	60	O	2
14	62	66	O	hours
15	68	73	O	before
16	75	84	O	XXXXXXXX
17	86	99	O	administration
NULL

Cimetidine	DDI-DrugBank.d171.s10	NO_SECTION	NO_SETID	14
Additional clinical experience may reveal other drugs affected by the concomitant administration of Tagamet.
1	0	9	O	Additional
2	11	18	O	clinical
3	20	29	O	experience
4	31	33	O	may
5	35	40	O	reveal
6	42	46	O	other
7	48	52	O	drugs
8	54	61	O	affected
9	63	64	O	by
10	66	68	O	the
11	70	80	O	concomitant
12	82	95	O	administration
13	97	98	O	of
14	100	106	O	XXXXXXXX
NULL

Cinacalcet	DDI-DrugBank.d512.s0	NO_SECTION	NO_SETID	16
and/or Drug/Laboratory Test Interactions See CLINICAL PHARMACOLOGY, Pharmacokinetics and Drug Interactions.
1	0	2	O	and
2	3	3	O	/
3	4	5	O	or
4	7	10	O	Drug
5	11	11	O	/
6	12	21	O	Laboratory
7	23	26	O	Test
8	28	39	O	Interactions
9	41	43	O	See
10	45	52	O	CLINICAL
11	54	65	O	PHARMACOLOGY
12	66	66	O	,
13	68	83	O	Pharmacokinetics
14	85	87	O	and
15	89	92	O	Drug
16	94	105	O	Interactions
NULL

Cinacalcet	DDI-DrugBank.d512.s1	NO_SECTION	NO_SETID	24
Effect of Sensipar on other drugs: Drugs metabolized by cytochrome P450 2D6 (CYP2D6): Sensipar  is a strong in vitro inhibitor of CYP2D6.
1	0	5	O	Effect
2	7	8	O	of
3	10	17	O	XXXXXXXX
4	19	20	O	on
5	22	26	O	other
6	28	32	O	drugs
7	33	33	O	:
8	35	39	O	Drugs
9	41	51	O	metabolized
10	53	54	O	by
11	56	65	O	cytochrome
12	67	70	O	P450
13	72	74	O	2D6
14	77	82	O	CYP2D6
15	84	84	O	:
16	86	93	O	XXXXXXXX
17	96	97	O	is
18	99	99	O	a
19	101	106	O	strong
20	108	109	O	in
21	111	115	O	vitro
22	117	125	O	inhibitor
23	127	128	O	of
24	130	135	O	CYP2D6
NULL

Cinacalcet	DDI-DrugBank.d512.s2	NO_SECTION	NO_SETID	33
Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., flecainide, vinblastine, thioridazine and most tricyclic antidepressants) may be required.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	dose
4	16	26	O	adjustments
5	28	29	O	of
6	31	41	O	concomitant
7	43	53	O	medications
8	55	58	O	that
9	60	62	O	are
10	64	76	O	predominantly
11	78	88	O	metabolized
12	90	91	O	by
13	93	98	O	CYP2D6
14	100	102	O	and
15	104	107	O	have
16	109	109	O	a
17	111	116	O	narrow
18	118	128	O	therapeutic
19	130	134	O	index
20	137	139	O	e.g
21	141	141	O	,
22	143	152	U-UNK	flecainide
23	153	153	O	,
24	155	165	U-UNK	vinblastine
25	166	166	O	,
26	168	179	U-UNK	thioridazine
27	181	183	O	and
28	185	188	O	most
29	190	198	B-UNK	tricyclic
30	200	214	L-UNK	antidepressants
31	217	219	O	may
32	221	222	O	be
33	224	231	O	required
NULL

Cinacalcet	DDI-DrugBank.d512.s3	NO_SECTION	NO_SETID	30
Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
1	0	12	U-UNK	Amitriptyline
2	13	13	O	:
3	15	24	O	Concurrent
4	26	39	O	administration
5	41	42	O	of
6	44	45	O	25
7	47	48	O	mg
8	50	51	O	or
9	53	55	O	100
10	57	58	O	mg
11	60	69	O	XXXXXXXX
12	71	74	O	with
13	76	77	O	50
14	79	80	O	mg
15	82	94	U-KIN	amitriptyline
16	96	104	O	increased
17	106	118	U-UNK	amitriptyline
18	120	127	O	exposure
19	129	131	O	and
20	133	145	U-UNK	nortriptyline
21	148	153	O	active
22	155	164	O	metabolite
23	167	174	O	exposure
24	176	177	O	by
25	179	191	O	approximately
26	193	195	O	20%
27	197	198	O	in
28	200	205	O	CYP2D6
29	207	215	O	extensive
30	217	228	O	metabolizers
NULL

Cinacalcet	DDI-DrugBank.d512.s4	NO_SECTION	NO_SETID	23
Effect of other drugs on Sensipar : Sensipar  is metabolized by multiple cytochrome P450 enzymes, primarily CYP3A4, CYP2D6, and CYP1A2.
1	0	5	O	Effect
2	7	8	O	of
3	10	14	O	other
4	16	20	O	drugs
5	22	23	O	on
6	25	32	O	XXXXXXXX
7	34	34	O	:
8	36	43	O	XXXXXXXX
9	46	47	O	is
10	49	59	O	metabolized
11	61	62	O	by
12	64	71	O	multiple
13	73	82	O	cytochrome
14	84	87	O	P450
15	89	95	O	enzymes
16	96	96	O	,
17	98	106	O	primarily
18	108	113	O	CYP3A4
19	114	114	O	,
20	116	121	O	CYP2D6
21	122	122	O	,
22	124	126	O	and
23	128	133	O	CYP1A2
NULL

Cinacalcet	DDI-DrugBank.d512.s5	NO_SECTION	NO_SETID	9
Ketoconazole: Sensipar is metabolized in part by CYP3A4.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	21	O	XXXXXXXX
4	23	24	O	is
5	26	36	O	metabolized
6	38	39	O	in
7	41	44	O	part
8	46	47	O	by
9	49	54	O	CYP3A4
NULL

Cinacalcet	DDI-DrugBank.d512.s6	NO_SECTION	NO_SETID	25
Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	32	U-UNK	ketoconazole
5	33	33	O	,
6	35	35	O	a
7	37	42	O	strong
8	44	52	O	inhibitor
9	54	55	O	of
10	57	62	O	CYP3A4
11	63	63	O	,
12	65	73	O	increased
13	75	84	U-UNK	cinacalcet
14	86	93	O	exposure
15	95	103	O	following
16	105	105	O	a
17	107	112	O	single
18	114	115	O	90
19	117	118	O	mg
20	120	123	O	dose
21	125	126	O	of
22	128	135	O	XXXXXXXX
23	137	138	O	by
24	140	142	O	2.3
25	144	147	O	fold
NULL

Cinacalcet	DDI-DrugBank.d512.s7	NO_SECTION	NO_SETID	36
Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;
1	0	3	O	Dose
2	5	14	O	adjustment
3	16	17	O	of
4	19	26	O	XXXXXXXX
5	28	30	O	may
6	32	33	O	be
7	35	42	O	required
8	44	46	O	and
9	48	50	O	PTH
10	52	54	O	and
11	56	60	O	serum
12	62	68	O	calcium
13	70	83	O	concentrations
14	85	90	O	should
15	92	93	O	be
16	95	101	O	closely
17	103	111	O	monitored
18	113	114	O	if
19	116	116	O	a
20	118	124	O	patient
21	126	134	O	initiates
22	136	137	O	or
23	139	150	O	discontinues
24	152	158	O	therapy
25	160	163	O	with
26	165	165	O	a
27	167	172	O	strong
28	174	179	O	CYP3A4
29	181	189	O	inhibitor
30	192	194	O	e.g
31	196	196	O	,
32	198	209	U-DYN	ketoconazole
33	210	210	O	,
34	212	223	U-DYN	erythromycin
35	224	224	O	,
36	226	237	U-DYN	itraconazole
NULL

Cinacalcet	DDI-DrugBank.d512.s8	NO_SECTION	NO_SETID	4
see DOSAGE AND ADMINISTRATION).
1	0	2	O	see
2	4	9	O	DOSAGE
3	11	13	O	AND
4	15	28	O	ADMINISTRATION
NULL

Cinoxacin	DDI-DrugBank.d562.s0	NO_SECTION	NO_SETID	14
Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.
1	0	7	O	Elevated
2	9	14	O	plasma
3	16	21	O	levels
4	23	24	O	of
5	26	37	U-UNK	theophylline
6	39	42	O	have
7	44	47	O	been
8	49	56	O	reported
9	58	61	O	with
10	63	73	O	concomitant
11	75	77	O	use
12	79	80	O	of
13	82	85	O	some
14	87	96	U-UNK	quinolones
NULL

Cinoxacin	DDI-DrugBank.d562.s1	NO_SECTION	NO_SETID	16
There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	22	O	reports
5	24	25	O	of
6	27	38	U-UNK	theophylline
7	40	46	O	related
8	48	51	O	side
9	53	59	O	effects
10	61	62	O	in
11	64	71	O	patients
12	73	74	O	on
13	76	86	O	concomitant
14	88	99	U-UNK	theophylline
15	101	109	U-UNK	quinolone
16	111	117	O	therapy
NULL

Cinoxacin	DDI-DrugBank.d562.s2	NO_SECTION	NO_SETID	17
Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	monitoring
4	22	23	O	of
5	25	36	U-UNK	theophylline
6	38	43	O	plasma
7	45	50	O	levels
8	52	57	O	should
9	59	60	O	be
10	62	71	O	considered
11	73	75	O	and
12	77	82	O	dosage
13	84	85	O	of
14	87	98	U-UNK	theophylline
15	100	107	O	adjusted
16	109	110	O	as
17	112	119	O	required
NULL

Cinoxacin	DDI-DrugBank.d562.s3	NO_SECTION	NO_SETID	12
Quinolones have also been shown to interfere with the metabolism of caffeine.
1	0	9	U-UNK	Quinolones
2	11	14	O	have
3	16	19	O	also
4	21	24	O	been
5	26	30	O	shown
6	32	33	O	to
7	35	43	O	interfere
8	45	48	O	with
9	50	52	O	the
10	54	63	O	metabolism
11	65	66	O	of
12	68	75	U-UNK	caffeine
NULL

Cinoxacin	DDI-DrugBank.d562.s4	NO_SECTION	NO_SETID	16
This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life.
1	0	3	O	This
2	5	7	O	may
3	9	12	O	lead
4	14	15	O	to
5	17	23	O	reduced
6	25	33	O	clearance
7	35	36	O	of
8	38	45	U-UNK	caffeine
9	47	49	O	and
10	51	51	O	a
11	53	64	O	prolongation
12	66	67	O	of
13	69	71	O	its
14	73	78	O	plasma
15	80	83	O	half
16	85	88	O	life
NULL

Cinoxacin	DDI-DrugBank.d562.s5	NO_SECTION	NO_SETID	23
Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.
1	0	7	O	Although
2	9	12	O	this
3	14	24	O	interaction
4	26	28	O	has
5	30	32	O	not
6	34	37	O	been
7	39	46	O	reported
8	48	51	O	with
9	53	61	O	XXXXXXXX
10	62	62	O	,
11	64	70	O	caution
12	72	77	O	should
13	79	80	O	be
14	82	90	O	exercised
15	92	95	O	when
16	97	105	O	XXXXXXXX
17	107	108	O	is
18	110	114	O	given
19	116	128	O	concomitantly
20	130	133	O	with
21	135	142	U-DYN	caffeine
22	144	153	O	containing
23	155	162	O	products
NULL

Cinoxacin	DDI-DrugBank.d562.s6	NO_SECTION	NO_SETID	17
Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.
1	0	7	U-UNK	Antacids
2	9	10	O	or
3	12	21	U-UNK	sucralfate
4	23	35	O	substantially
5	37	45	O	interfere
6	47	50	O	with
7	52	54	O	the
8	56	65	O	absorption
9	67	68	O	of
10	70	73	O	some
11	75	84	U-UNK	quinolones
12	85	85	O	,
13	87	95	O	resulting
14	97	98	O	in
15	100	102	O	low
16	104	108	O	urine
17	110	115	O	levels
NULL

Cinoxacin	DDI-DrugBank.d562.s7	NO_SECTION	NO_SETID	35
Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
1	0	3	O	Also
2	4	4	O	,
3	6	16	O	concomitant
4	18	31	O	administration
5	33	34	O	of
6	36	45	U-KIN	quinolones
7	47	50	O	with
8	52	59	O	products
9	61	70	O	containing
10	72	75	U-UNK	iron
11	76	76	O	,
12	78	90	U-UNK	multivitamins
13	92	101	O	containing
14	103	106	U-UNK	zinc
15	107	107	O	,
16	109	110	O	or
17	112	116	O	XXXXXXXX
18	119	128	U-UNK	didanosine
19	131	138	O	chewable
20	139	139	O	/
21	140	147	O	buffered
22	149	155	O	tablets
23	157	158	O	or
24	160	162	O	the
25	164	172	O	pediatric
26	174	179	O	powder
27	181	183	O	for
28	185	188	O	oral
29	190	197	O	solution
30	199	201	O	may
31	203	208	O	result
32	210	211	O	in
33	213	215	O	low
34	217	221	O	urine
35	223	228	O	levels
NULL

Cinoxacin	DDI-DrugBank.d562.s8	NO_SECTION	NO_SETID	19
Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
1	0	9	U-UNK	Quinolones
2	10	10	O	,
3	12	20	O	including
4	22	30	O	XXXXXXXX
5	31	31	O	,
6	33	35	O	may
7	37	43	O	enhance
8	45	47	O	the
9	49	55	O	effects
10	57	58	O	of
11	60	63	O	oral
12	65	78	U-DYN	anticoagulants
13	79	79	O	,
14	81	84	O	such
15	86	87	O	as
16	89	96	U-DYN	warfarin
17	98	99	O	or
18	101	103	O	its
19	105	115	O	derivatives
NULL

Cinoxacin	DDI-DrugBank.d562.s9	NO_SECTION	NO_SETID	18
When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be closely monitored.
1	0	3	O	When
2	5	9	O	these
3	11	18	O	products
4	20	22	O	are
5	24	35	O	administered
6	37	49	O	concomitantly
7	50	50	O	,
8	52	62	O	prothrombin
9	64	67	O	time
10	69	70	O	or
11	72	76	O	other
12	78	85	O	suitable
13	87	97	O	coagulation
14	99	103	O	tests
15	105	110	O	should
16	112	113	O	be
17	115	121	O	closely
18	123	131	O	monitored
NULL

Cinoxacin	DDI-DrugBank.d562.s10	NO_SECTION	NO_SETID	19
Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.
1	0	7	O	Seizures
2	9	12	O	have
3	14	17	O	been
4	19	26	O	reported
5	28	29	O	in
6	31	38	O	patients
7	40	45	O	taking
8	47	53	O	another
9	55	63	B-UNK	quinolone
10	65	69	I-UNK	class
11	71	83	L-UNK	antimicrobial
12	85	87	O	and
13	89	91	O	the
14	93	104	B-UNK	nonsteroidal
15	106	109	I-UNK	anti
16	111	122	I-UNK	inflammatory
17	124	127	L-UNK	drug
18	129	136	U-UNK	fenbufen
19	138	149	O	concurrently
NULL

Cinoxacin	DDI-DrugBank.d562.s11	NO_SECTION	NO_SETID	16
Animal studies also suggest an increased potential for seizures when these 2 drugs are given concomitantly.
1	0	5	O	Animal
2	7	13	O	studies
3	15	18	O	also
4	20	26	O	suggest
5	28	29	O	an
6	31	39	O	increased
7	41	49	O	potential
8	51	53	O	for
9	55	62	O	seizures
10	64	67	O	when
11	69	73	O	these
12	75	75	O	2
13	77	81	O	drugs
14	83	85	O	are
15	87	91	O	given
16	93	105	O	concomitantly
NULL

Cinoxacin	DDI-DrugBank.d562.s12	NO_SECTION	NO_SETID	11
Fenbufen is not approved in the United States at this time.
1	0	7	U-UNK	Fenbufen
2	9	10	O	is
3	12	14	O	not
4	16	23	O	approved
5	25	26	O	in
6	28	30	O	the
7	32	37	O	United
8	39	44	O	States
9	46	47	O	at
10	49	52	O	this
11	54	57	O	time
NULL

Cinoxacin	DDI-DrugBank.d562.s13	NO_SECTION	NO_SETID	25
Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.
1	0	9	O	Physicians
2	11	13	O	are
3	15	22	O	provided
4	24	27	O	this
5	29	39	O	information
6	41	42	O	to
7	44	51	O	increase
8	53	61	O	awareness
9	63	64	O	of
10	66	68	O	the
11	70	78	O	potential
12	80	82	O	for
13	84	90	O	serious
14	92	103	O	interactions
15	105	108	O	when
16	110	118	O	XXXXXXXX
17	120	122	O	and
18	124	130	O	certain
19	132	143	B-DYN	nonsteroidal
20	145	148	I-DYN	anti
21	150	161	I-DYN	inflammatory
22	163	168	L-DYN	agents
23	170	172	O	are
24	174	185	O	administered
25	187	199	O	concomitantly
NULL

Cinoxacin	DDI-DrugBank.d562.s14	NO_SECTION	NO_SETID	15
Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.
1	0	7	O	Elevated
2	9	20	U-UNK	cyclosporine
3	22	26	O	serum
4	28	33	O	levels
5	35	38	O	have
6	40	43	O	been
7	45	52	O	reported
8	54	57	O	with
9	59	61	O	the
10	63	73	O	concomitant
11	75	77	O	use
12	79	80	O	of
13	82	91	U-UNK	quinolones
14	93	95	O	and
15	97	108	U-UNK	cyclosporine
NULL

Ciprofloxacin	DDI-DrugBank.d123.s0	NO_SECTION	NO_SETID	17
Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.
1	0	3	O	Some
2	5	14	U-UNK	quinolones
3	15	15	O	,
4	17	25	O	including
5	27	39	O	XXXXXXXX
6	40	40	O	,
7	42	45	O	have
8	47	50	O	also
9	52	55	O	been
10	57	61	O	shown
11	63	64	O	to
12	66	74	O	interfere
13	76	79	O	with
14	81	83	O	the
15	85	94	O	metabolism
16	96	97	O	of
17	99	106	U-KIN	caffeine
NULL

Ciprofloxacin	DDI-DrugBank.d123.s1	NO_SECTION	NO_SETID	16
This may lead to reduced clearance of caffeine and a prolongation of its serum half-life.
1	0	3	O	This
2	5	7	O	may
3	9	12	O	lead
4	14	15	O	to
5	17	23	O	reduced
6	25	33	O	clearance
7	35	36	O	of
8	38	45	U-UNK	caffeine
9	47	49	O	and
10	51	51	O	a
11	53	64	O	prolongation
12	66	67	O	of
13	69	71	O	its
14	73	77	O	serum
15	79	82	O	half
16	84	87	O	life
NULL

Ciprofloxacin	DDI-DrugBank.d123.s2	NO_SECTION	NO_SETID	20
Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
1	0	3	O	Some
2	5	14	U-UNK	quinolones
3	15	15	O	,
4	17	25	O	including
5	27	39	O	XXXXXXXX
6	40	40	O	,
7	42	45	O	have
8	47	50	O	been
9	52	61	O	associated
10	63	66	O	with
11	68	76	O	transient
12	78	87	O	elevations
13	89	90	O	in
14	92	96	O	serum
15	98	107	O	creatinine
16	109	110	O	in
17	112	119	O	patients
18	121	129	O	receiving
19	131	142	U-DYN	cyclosporine
20	144	156	O	concomitantly
NULL

Ciprofloxacin	DDI-DrugBank.d123.s3	NO_SECTION	NO_SETID	21
Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
1	0	8	U-UNK	Glyburide
2	9	9	O	:
3	11	13	O	The
4	15	25	O	concomitant
5	27	40	O	administration
6	42	43	O	of
7	45	57	O	XXXXXXXX
8	59	62	O	with
9	64	66	O	the
10	68	79	U-DYN	sulfonylurea
11	81	89	U-DYN	glyburide
12	91	93	O	has
13	94	94	O	,
14	96	97	O	on
15	99	102	O	rare
16	104	112	O	occasions
17	113	113	O	,
18	115	122	O	resulted
19	124	125	O	in
20	127	132	O	severe
21	134	145	O	hypoglycemia
NULL

Ciprofloxacin	DDI-DrugBank.d123.s4	NO_SECTION	NO_SETID	20
Histamine H2-receptor antagonists: Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of ciprofloxacin.
1	0	8	B-UNK	Histamine
2	10	11	I-UNK	H2
3	13	20	I-UNK	receptor
4	22	32	L-UNK	antagonists
5	33	33	O	:
6	35	43	B-UNK	Histamine
7	45	46	I-UNK	H2
8	48	55	I-UNK	receptor
9	57	67	L-UNK	antagonists
10	69	74	O	appear
11	76	77	O	to
12	79	82	O	have
13	84	85	O	no
14	87	97	O	significant
15	99	104	O	effect
16	106	107	O	on
17	109	111	O	the
18	113	127	O	bioavailability
19	129	130	O	of
20	132	144	O	XXXXXXXX
NULL

Ciprofloxacin	DDI-DrugBank.d123.s5	NO_SECTION	NO_SETID	23
Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.
1	0	11	U-UNK	Methotrexate
2	13	17	O	Renal
3	19	25	O	tubular
4	27	35	O	transport
5	37	38	O	of
6	40	51	U-KIN	methotrexate
7	53	55	O	may
8	57	58	O	be
9	60	68	O	inhibited
10	70	71	O	by
11	73	83	O	concomitant
12	85	98	O	administration
13	100	101	O	of
14	103	115	O	XXXXXXXX
15	116	116	O	,
16	118	128	O	potentially
17	130	136	O	leading
18	138	139	O	to
19	141	149	O	increased
20	151	156	O	plasma
21	158	163	O	levels
22	165	166	O	of
23	168	179	U-UNK	methotrexate
NULL

Ciprofloxacin	DDI-DrugBank.d123.s6	NO_SECTION	NO_SETID	9
This might increase the risk of methotrexate toxic reactions.
1	0	3	O	This
2	5	9	O	might
3	11	18	O	increase
4	20	22	O	the
5	24	27	O	risk
6	29	30	O	of
7	32	43	U-UNK	methotrexate
8	45	49	O	toxic
9	51	59	O	reactions
NULL

Ciprofloxacin	DDI-DrugBank.d123.s7	NO_SECTION	NO_SETID	16
Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	O	patients
4	20	24	O	under
5	26	37	U-DYN	methotrexate
6	39	45	O	therapy
7	47	52	O	should
8	54	55	O	be
9	57	65	O	carefully
10	67	75	O	monitored
11	77	80	O	when
12	82	92	O	concomitant
13	94	106	O	XXXXXXXX
14	108	114	O	therapy
15	116	117	O	is
16	119	127	O	indicated
NULL

Ciprofloxacin	DDI-DrugBank.d123.s8	NO_SECTION	NO_SETID	64
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
1	0	10	O	Multivalent
2	12	17	O	Cation
3	19	28	O	Containing
4	30	37	O	Products
5	38	38	O	:
6	40	49	O	Concurrent
7	51	64	O	administration
8	66	67	O	of
9	69	69	O	a
10	71	79	U-KIN	quinolone
11	80	80	O	,
12	82	90	O	including
13	92	104	U-KIN	ciprofloxacin
14	105	105	O	,
15	107	110	O	with
16	112	122	O	multivalent
17	124	129	O	cation
18	131	140	O	containing
19	142	149	O	products
20	151	154	O	such
21	156	157	O	as
22	159	167	U-UNK	magnesium
23	169	170	O	or
24	172	179	U-UNK	aluminum
25	181	188	U-UNK	antacids
26	189	189	O	,
27	191	200	U-UNK	sucralfate
28	201	201	O	,
29	203	207	O	XXXXXXXX
30	209	216	O	chewable
31	217	217	O	/
32	218	225	O	buffered
33	227	233	O	tablets
34	235	236	O	or
35	238	246	O	pediatric
36	248	253	O	powder
37	254	254	O	,
38	256	257	O	or
39	259	266	O	products
40	268	277	O	containing
41	279	285	U-UNK	calcium
42	286	286	O	,
43	288	291	U-UNK	iron
44	292	292	O	,
45	294	295	O	or
46	297	300	U-UNK	zinc
47	302	304	O	may
48	306	318	O	substantially
49	320	327	O	decrease
50	329	331	O	the
51	333	342	O	absorption
52	344	345	O	of
53	347	359	U-UNK	ciprofloxacin
54	360	360	O	,
55	362	370	O	resulting
56	372	373	O	in
57	375	379	O	serum
58	381	383	O	and
59	385	389	O	urine
60	391	396	O	levels
61	398	409	O	considerably
62	411	415	O	lower
63	417	420	O	than
64	422	428	O	desired
NULL

Ciprofloxacin	DDI-DrugBank.d123.s9	NO_SECTION	NO_SETID	15
Proquin XR should be administered at least 4 hours before or 2 hours after these products.
1	0	9	O	XXXXXXXX
2	11	16	O	should
3	18	19	O	be
4	21	32	O	administered
5	34	35	O	at
6	37	41	O	least
7	43	43	O	4
8	45	49	O	hours
9	51	56	O	before
10	58	59	O	or
11	61	61	O	2
12	63	67	O	hours
13	69	73	O	after
14	75	79	O	these
15	81	88	O	products
NULL

Ciprofloxacin	DDI-DrugBank.d123.s10	NO_SECTION	NO_SETID	25
This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.
1	0	3	O	This
2	5	8	O	time
3	10	15	O	window
4	17	18	O	is
5	20	28	O	different
6	30	33	O	than
7	35	37	O	for
8	39	43	O	other
9	45	48	O	oral
10	50	61	O	formulations
11	63	64	O	of
12	66	78	O	XXXXXXXX
13	79	79	O	,
14	81	85	O	which
15	87	89	O	are
16	91	97	O	usually
17	99	110	O	administered
18	112	112	O	2
19	114	118	O	hours
20	120	125	O	before
21	127	128	O	or
22	130	130	O	6
23	132	136	O	hours
24	138	142	O	after
25	144	151	U-DYN	antacids
NULL

Ciprofloxacin	DDI-DrugBank.d123.s11	NO_SECTION	NO_SETID	29
Non-steroidal anti-inflammatory drugs (but not aspirin): These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.
1	0	2	B-UNK	Non
2	4	12	I-UNK	steroidal
3	14	17	I-UNK	anti
4	19	30	I-UNK	inflammatory
5	32	36	L-UNK	drugs
6	39	41	O	but
7	43	45	O	not
8	47	53	O	XXXXXXXX
9	55	55	O	:
10	57	61	O	These
11	63	67	O	drugs
12	69	70	O	in
13	72	82	O	combination
14	84	87	O	with
15	89	92	O	very
16	94	97	O	high
17	99	103	O	doses
18	105	106	O	of
19	108	117	U-UNK	quinolones
20	119	122	O	have
21	124	127	O	been
22	129	133	O	shown
23	135	136	O	to
24	138	144	O	provoke
25	146	156	O	convulsions
26	158	159	O	in
27	161	163	O	pre
28	165	172	O	clinical
29	174	180	O	studies
NULL

Ciprofloxacin	DDI-DrugBank.d123.s12	NO_SECTION	NO_SETID	35
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.
1	0	9	U-UNK	Omeprazole
2	10	10	O	:
3	12	14	O	The
4	16	19	O	rate
5	21	23	O	and
6	25	30	O	extent
7	32	33	O	of
8	35	44	O	absorption
9	46	47	O	of
10	49	61	U-UNK	ciprofloxacin
11	63	65	O	was
12	67	79	O	bioequivalent
13	81	84	O	when
14	86	95	O	XXXXXXXX
15	97	99	O	was
16	101	105	O	given
17	107	111	O	alone
18	113	114	O	or
19	116	119	O	when
20	121	130	O	XXXXXXXX
21	132	134	O	was
22	136	140	O	given
23	142	142	O	2
24	144	148	O	hours
25	150	154	O	after
26	156	165	U-UNK	omeprazole
27	167	168	O	at
28	170	172	O	the
29	174	177	O	dose
30	179	182	O	that
31	184	192	O	maximally
32	194	203	O	suppresses
33	205	211	O	gastric
34	213	216	O	acid
35	218	226	O	secretion
NULL

Ciprofloxacin	DDI-DrugBank.d123.s13	NO_SECTION	NO_SETID	23
Omeprazole should be taken as directed and Proquin XR should be taken with a main meal of the day, preferably the evening meal..
1	0	9	U-UNK	Omeprazole
2	11	16	O	should
3	18	19	O	be
4	21	25	O	taken
5	27	28	O	as
6	30	37	O	directed
7	39	41	O	and
8	43	52	O	XXXXXXXX
9	54	59	O	should
10	61	62	O	be
11	64	68	O	taken
12	70	73	O	with
13	75	75	O	a
14	77	80	O	main
15	82	85	O	meal
16	87	88	O	of
17	90	92	O	the
18	94	96	O	day
19	97	97	O	,
20	99	108	O	preferably
21	110	112	O	the
22	114	120	O	evening
23	122	125	O	meal
NULL

Ciprofloxacin	DDI-DrugBank.d123.s14	NO_SECTION	NO_SETID	18
Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.
1	0	8	U-UNK	Phenytoin
2	9	9	O	:
3	11	17	O	Altered
4	19	23	O	serum
5	25	30	O	levels
6	32	33	O	of
7	35	43	U-KIN	phenytoin
8	46	54	O	increased
9	56	58	O	and
10	60	68	O	decreased
11	71	74	O	have
12	76	79	O	been
13	81	88	O	reported
14	90	91	O	in
15	93	100	O	patients
16	102	110	O	receiving
17	112	122	O	concomitant
18	124	136	O	XXXXXXXX
NULL

Ciprofloxacin	DDI-DrugBank.d123.s15	NO_SECTION	NO_SETID	21
Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.
1	0	9	U-UNK	Probenecid
2	10	10	O	:
3	12	21	U-KIN	Probenecid
4	23	32	O	interferes
5	34	37	O	with
6	39	43	O	renal
7	45	51	O	tubular
8	53	61	O	secretion
9	63	64	O	of
10	66	78	O	XXXXXXXX
11	80	82	O	and
12	84	91	O	produces
13	93	94	O	an
14	96	103	O	increase
15	105	106	O	in
16	108	110	O	the
17	112	116	O	level
18	118	119	O	of
19	121	133	O	XXXXXXXX
20	135	136	O	in
21	138	142	O	serum
NULL

Ciprofloxacin	DDI-DrugBank.d123.s16	NO_SECTION	NO_SETID	29
Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
1	0	11	U-UNK	Theophylline
2	12	12	O	:
3	14	15	O	As
4	17	20	O	with
5	22	25	O	some
6	27	31	O	other
7	33	42	U-UNK	quinolones
8	43	43	O	,
9	45	54	O	concurrent
10	56	69	O	administration
11	71	72	O	of
12	74	86	O	XXXXXXXX
13	88	91	O	with
14	93	104	U-KIN	theophylline
15	106	108	O	may
16	110	113	O	lead
17	115	116	O	to
18	118	125	O	elevated
19	127	131	O	serum
20	133	146	O	concentrations
21	148	149	O	of
22	151	162	U-UNK	theophylline
23	164	166	O	and
24	168	179	O	prolongation
25	181	182	O	of
26	184	186	O	its
27	188	198	O	elimination
28	200	203	O	half
29	205	208	O	life
NULL

Ciprofloxacin	DDI-DrugBank.d123.s17	NO_SECTION	NO_SETID	11
This may result in increased risk of theophylline-related adverse reactions.
1	0	3	O	This
2	5	7	O	may
3	9	14	O	result
4	16	17	O	in
5	19	27	O	increased
6	29	32	O	risk
7	34	35	O	of
8	37	48	U-UNK	theophylline
9	50	56	O	related
10	58	64	O	adverse
11	66	74	O	reactions
NULL

Ciprofloxacin	DDI-DrugBank.d123.s18	NO_SECTION	NO_SETID	20
If concomitant use cannot be avoided, serum levels of theophylline should be monitored and dosage adjustments made as appropriate.
1	0	1	O	If
2	3	13	O	concomitant
3	15	17	O	use
4	19	24	O	cannot
5	26	27	O	be
6	29	35	O	avoided
7	36	36	O	,
8	38	42	O	serum
9	44	49	O	levels
10	51	52	O	of
11	54	65	U-UNK	theophylline
12	67	72	O	should
13	74	75	O	be
14	77	85	O	monitored
15	87	89	O	and
16	91	96	O	dosage
17	98	108	O	adjustments
18	110	113	O	made
19	115	116	O	as
20	118	128	O	appropriate
NULL

Ciprofloxacin	DDI-DrugBank.d123.s19	NO_SECTION	NO_SETID	18
Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	19	U-UNK	Quinolones
4	21	24	O	have
5	26	29	O	been
6	31	38	O	reported
7	40	41	O	to
8	43	49	O	enhance
9	51	53	O	the
10	55	61	O	effects
11	63	64	O	of
12	66	68	O	the
13	70	73	O	oral
14	75	87	U-UNK	anticoagulant
15	89	96	U-UNK	warfarin
16	98	99	O	or
17	101	103	O	its
18	105	115	O	derivatives
NULL

Ciprofloxacin	DDI-DrugBank.d123.s20	NO_SECTION	NO_SETID	17
When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be monitored.
1	0	3	O	When
2	5	9	O	these
3	11	18	O	products
4	20	22	O	are
5	24	35	O	administered
6	37	49	O	concomitantly
7	50	50	O	,
8	52	62	O	prothrombin
9	64	67	O	time
10	69	70	O	or
11	72	76	O	other
12	78	85	O	suitable
13	87	97	O	coagulation
14	99	103	O	tests
15	105	110	O	should
16	112	113	O	be
17	115	123	O	monitored
NULL

Cisapride	DDI-DrugBank.d237.s0	NO_SECTION	NO_SETID	10
Cisapride is metabolized mainly via the cytochrome P450 3A4 enzyme.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	23	O	metabolized
4	25	30	O	mainly
5	32	34	O	via
6	36	38	O	the
7	40	49	O	cytochrome
8	51	54	O	P450
9	56	58	O	3A4
10	60	65	O	enzyme
NULL

Cisapride	DDI-DrugBank.d237.s1	NO_SECTION	NO_SETID	45
In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when cisapride was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood cisapride levels were noted at the time of the QT prolongation.
1	0	1	O	In
2	3	6	O	some
3	8	12	O	cases
4	14	18	O	where
5	20	26	O	serious
6	28	38	O	ventricular
7	40	50	O	arrhythmias
8	51	51	O	,
9	53	54	O	QT
10	56	67	O	prolongation
11	68	68	O	,
12	70	72	O	and
13	74	81	O	torsades
14	83	84	O	de
15	86	92	O	pointes
16	94	97	O	have
17	99	106	O	occurred
18	108	111	O	when
19	113	121	O	XXXXXXXX
20	123	125	O	was
21	127	131	O	taken
22	133	134	O	in
23	136	146	O	conjunction
24	148	151	O	with
25	153	155	O	one
26	157	158	O	of
27	160	162	O	the
28	164	173	O	cytochrome
29	175	178	O	P450
30	180	182	O	3A4
31	184	193	O	inhibitors
32	194	194	O	,
33	196	203	O	elevated
34	205	209	O	blood
35	211	219	O	XXXXXXXX
36	221	226	O	levels
37	228	231	O	were
38	233	237	O	noted
39	239	240	O	at
40	242	244	O	the
41	246	249	O	time
42	251	252	O	of
43	254	256	O	the
44	258	259	O	QT
45	261	272	O	prolongation
NULL

Cisapride	DDI-DrugBank.d237.s2	NO_SECTION	NO_SETID	44
Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
1	0	10	U-UNK	Antibiotics
2	11	11	O	:
3	13	14	O	In
4	16	20	O	vitro
5	22	24	O	and
6	25	25	O	/
7	26	27	O	or
8	29	30	O	in
9	32	35	O	vivo
10	37	40	O	data
11	42	45	O	show
12	47	50	O	that
13	52	65	U-KIN	clarithromycin
14	66	66	O	,
15	68	79	U-KIN	erythromycin
16	80	80	O	,
17	82	84	O	and
18	86	99	U-KIN	troleandomycin
19	101	108	O	markedly
20	110	116	O	inhibit
21	118	120	O	the
22	122	131	O	metabolism
23	133	134	O	of
24	136	144	O	XXXXXXXX
25	145	145	O	,
26	147	151	O	which
27	153	155	O	can
28	157	162	O	result
29	164	165	O	in
30	167	168	O	an
31	170	177	O	increase
32	179	180	O	in
33	182	187	O	plasma
34	189	197	O	XXXXXXXX
35	199	204	O	levels
36	206	208	O	and
37	210	221	O	prolongation
38	223	224	O	of
39	226	228	O	the
40	230	231	O	QT
41	233	240	O	interval
42	242	243	O	on
43	245	247	O	the
44	249	251	O	ECG
NULL

Cisapride	DDI-DrugBank.d237.s3	NO_SECTION	NO_SETID	26
Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.
1	0	15	U-UNK	Anticholinergics
2	16	16	O	:
3	18	27	O	Concurrent
4	29	42	O	administration
5	44	45	O	of
6	47	53	O	certain
7	55	69	B-DYN	anticholinergic
8	71	79	L-DYN	compounds
9	80	80	O	,
10	82	85	O	such
11	87	88	O	as
12	90	99	B-DYN	belladonna
13	101	109	L-DYN	alkaloids
14	111	113	O	and
15	115	125	U-DYN	dicyclomine
16	126	126	O	,
17	128	132	O	would
18	134	135	O	be
19	137	144	O	expected
20	146	147	O	to
21	149	158	O	compromise
22	160	162	O	the
23	164	173	O	beneficial
24	175	181	O	effects
25	183	184	O	of
26	186	194	O	XXXXXXXX
NULL

Cisapride	DDI-DrugBank.d237.s4	NO_SECTION	NO_SETID	17
Anticoagulants (Oral): In patients receiving oral anticoagulants, the coagulation times were increased in some cases.
1	0	13	U-UNK	Anticoagulants
2	16	19	O	Oral
3	21	21	O	:
4	23	24	O	In
5	26	33	O	patients
6	35	43	O	receiving
7	45	48	O	oral
8	50	63	U-UNK	anticoagulants
9	64	64	O	,
10	66	68	O	the
11	70	80	O	coagulation
12	82	86	O	times
13	88	91	O	were
14	93	101	O	increased
15	103	104	O	in
16	106	109	O	some
17	111	115	O	cases
NULL

Cisapride	DDI-DrugBank.d237.s5	NO_SECTION	NO_SETID	32
It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	advisable
4	16	17	O	to
5	19	23	O	check
6	25	35	O	coagulation
7	37	40	O	time
8	42	47	O	within
9	49	51	O	the
10	53	57	O	first
11	59	61	O	few
12	63	66	O	days
13	68	72	O	after
14	74	76	O	the
15	78	82	O	start
16	84	86	O	and
17	88	102	O	discontinuation
18	104	105	O	of
19	107	115	O	XXXXXXXX
20	117	123	O	therapy
21	124	124	O	,
22	126	129	O	with
23	131	132	O	an
24	134	144	O	appropriate
25	146	155	O	adjustment
26	157	158	O	of
27	160	162	O	the
28	164	176	U-DYN	anticoagulant
29	178	181	O	dose
30	182	182	O	,
31	184	185	O	if
32	187	195	O	necessary
NULL

Cisapride	DDI-DrugBank.d237.s6	NO_SECTION	NO_SETID	33
Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
1	0	14	U-UNK	Antidepressants
2	15	15	O	:
3	17	18	O	In
4	20	24	O	vitro
5	26	29	O	data
6	31	38	O	indicate
7	40	43	O	that
8	45	54	U-KIN	nefazodone
9	56	63	O	inhibits
10	65	67	O	the
11	69	78	O	metabolism
12	80	81	O	of
13	83	91	O	XXXXXXXX
14	92	92	O	,
15	94	98	O	which
16	100	102	O	can
17	104	109	O	result
18	111	112	O	in
19	114	115	O	an
20	117	124	O	increase
21	126	127	O	in
22	129	134	O	plasma
23	136	144	O	XXXXXXXX
24	146	151	O	levels
25	153	155	O	and
26	157	168	O	prolongation
27	170	171	O	of
28	173	175	O	the
29	177	178	O	QT
30	180	187	O	interval
31	189	190	O	on
32	192	194	O	the
33	196	198	O	ECG
NULL

Cisapride	DDI-DrugBank.d237.s7	NO_SECTION	NO_SETID	45
Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
1	0	10	U-UNK	Antifungals
2	11	11	O	:
3	13	14	O	In
4	16	20	O	vitro
5	22	24	O	and
6	25	25	O	/
7	26	27	O	or
8	29	30	O	in
9	32	35	O	vivo
10	37	40	O	data
11	42	49	O	indicate
12	51	54	O	that
13	56	66	U-KIN	fluconazole
14	67	67	O	,
15	69	80	U-KIN	itraconazole
16	81	81	O	,
17	83	85	O	and
18	87	90	O	oral
19	92	103	U-KIN	ketoconazole
20	105	112	O	markedly
21	114	120	O	inhibit
22	122	124	O	the
23	126	135	O	metabolism
24	137	138	O	of
25	140	148	O	XXXXXXXX
26	149	149	O	,
27	151	155	O	which
28	157	159	O	can
29	161	166	O	result
30	168	169	O	in
31	171	172	O	an
32	174	181	O	increase
33	183	184	O	in
34	186	191	O	plasma
35	193	201	O	XXXXXXXX
36	203	208	O	levels
37	210	212	O	and
38	214	225	O	prolongation
39	227	228	O	of
40	230	232	O	the
41	234	235	O	QT
42	237	244	O	interval
43	246	247	O	on
44	249	251	O	the
45	253	255	O	ECG
NULL

Cisapride	DDI-DrugBank.d237.s8	NO_SECTION	NO_SETID	25
Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.
1	0	4	O	Human
2	6	20	O	pharmacokinetic
3	22	25	O	data
4	27	34	O	indicate
5	36	39	O	that
6	41	44	O	oral
7	46	57	U-KIN	ketoconazole
8	59	66	O	markedly
9	68	75	O	inhibits
10	77	79	O	the
11	81	90	O	metabolism
12	92	93	O	of
13	95	103	O	XXXXXXXX
14	104	104	O	,
15	106	114	O	resulting
16	116	117	O	in
17	119	119	O	a
18	121	124	O	mean
19	126	130	O	eight
20	132	135	O	fold
21	137	144	O	increase
22	146	147	O	in
23	149	151	O	AUC
24	153	154	O	of
25	156	164	O	XXXXXXXX
NULL

Cisapride	DDI-DrugBank.d237.s9	NO_SECTION	NO_SETID	27
A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.
1	0	0	O	A
2	2	6	O	study
3	8	9	O	in
4	11	12	O	14
5	14	19	O	normal
6	21	24	O	male
7	26	28	O	and
8	30	35	O	female
9	37	46	O	volunteers
10	48	55	O	suggests
11	57	60	O	that
12	62	77	O	coadministration
13	79	80	O	of
14	82	90	O	XXXXXXXX
15	92	94	O	and
16	96	107	U-DYN	ketoconazole
17	109	111	O	can
18	113	118	O	result
19	120	121	O	in
20	123	134	O	prolongation
21	136	137	O	of
22	139	141	O	the
23	143	144	O	QT
24	146	153	O	interval
25	155	156	O	on
26	158	160	O	the
27	162	164	O	ECG
NULL

Cisapride	DDI-DrugBank.d237.s10	NO_SECTION	NO_SETID	31
H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.
1	0	1	B-UNK	H2
2	3	10	I-UNK	Receptor
3	12	22	L-UNK	Antagonists
4	23	23	O	:
5	25	34	U-KIN	Cimetidine
6	36	51	O	coadministration
7	53	57	O	leads
8	59	60	O	to
9	62	63	O	an
10	65	73	O	increased
11	75	78	O	peak
12	80	85	O	plasma
13	87	99	O	concentration
14	101	103	O	and
15	105	107	O	AUC
16	109	110	O	of
17	112	120	O	XXXXXXXX
18	121	121	O	,
19	123	127	O	there
20	129	130	O	is
21	132	133	O	no
22	135	140	O	effect
23	142	143	O	on
24	145	153	O	XXXXXXXX
25	155	164	O	absorption
26	166	169	O	when
27	171	172	O	it
28	174	175	O	is
29	177	190	O	coadministered
30	192	195	O	with
31	197	206	U-UNK	ranitidine
NULL

Cisapride	DDI-DrugBank.d237.s11	NO_SECTION	NO_SETID	15
The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
1	0	2	O	The
2	4	19	O	gastrointestinal
3	21	30	O	absorption
4	32	33	O	of
5	35	44	U-KIN	cimetidine
6	46	48	O	and
7	50	59	U-KIN	ranitidine
8	61	62	O	is
9	64	74	O	accelerated
10	76	79	O	when
11	81	84	O	they
12	86	88	O	are
13	90	103	O	coadministered
14	105	108	O	with
15	110	118	O	XXXXXXXX
NULL

Cisapride	DDI-DrugBank.d237.s12	NO_SECTION	NO_SETID	36
Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
1	0	7	B-UNK	Protease
2	9	18	L-UNK	Inhibitors
3	19	19	O	:
4	21	22	O	In
5	24	28	O	vitro
6	30	33	O	data
7	35	42	O	indicate
8	44	47	O	that
9	49	57	U-KIN	indinavir
10	59	61	O	and
11	63	71	U-KIN	ritonavir
12	73	80	O	markedly
13	82	88	O	inhibit
14	90	92	O	the
15	94	103	O	metabolism
16	105	106	O	of
17	108	116	O	XXXXXXXX
18	118	122	O	which
19	124	126	O	can
20	128	133	O	result
21	135	136	O	in
22	138	139	O	an
23	141	148	O	increase
24	150	151	O	in
25	153	158	O	plasma
26	160	168	O	XXXXXXXX
27	170	175	O	levels
28	177	179	O	and
29	181	192	O	prolongation
30	194	195	O	of
31	197	199	O	the
32	201	202	O	QT
33	204	211	O	interval
34	213	214	O	on
35	216	218	O	the
36	220	222	O	ECG
NULL

Cisapride	DDI-DrugBank.d237.s13	NO_SECTION	NO_SETID	19
Other: Coadministration of grapefruit juice with cisapride increases the bioavailability of cisapride and concomitant use should be avoided.
1	0	4	O	Other
2	5	5	O	:
3	7	22	O	Coadministration
4	24	25	O	of
5	27	36	O	grapefruit
6	38	42	O	juice
7	44	47	O	with
8	49	57	O	XXXXXXXX
9	59	67	O	increases
10	69	71	O	the
11	73	87	O	bioavailability
12	89	90	O	of
13	92	100	O	XXXXXXXX
14	102	104	O	and
15	106	116	O	concomitant
16	118	120	O	use
17	122	127	O	should
18	129	130	O	be
19	132	138	O	avoided
NULL

Cisapride	DDI-DrugBank.d237.s14	NO_SECTION	NO_SETID	35
Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);
1	0	8	O	XXXXXXXX
2	10	15	O	should
3	17	19	O	not
4	21	22	O	be
5	24	27	O	used
6	29	41	O	concomitantly
7	43	46	O	with
8	48	52	O	other
9	54	58	O	drugs
10	60	64	O	known
11	66	67	O	to
12	69	75	O	prolong
13	77	79	O	the
14	81	82	O	QT
15	84	91	O	interval
16	92	92	O	:
17	94	100	O	certain
18	102	116	U-DYN	antiarrhythmics
19	117	117	O	,
20	119	127	O	including
21	129	133	O	those
22	135	136	O	of
23	138	142	O	Class
24	144	145	O	IA
25	148	151	O	such
26	153	154	O	as
27	156	164	U-DYN	quinidine
28	166	168	O	and
29	170	181	U-DYN	procainamide
30	184	186	O	and
31	188	192	O	Class
32	194	196	O	III
33	199	202	O	such
34	204	205	O	as
35	207	213	U-DYN	sotalol
NULL

Cisapride	DDI-DrugBank.d237.s15	NO_SECTION	NO_SETID	5
tricyclic antidepressants (such as amitriptyline);
1	0	8	B-UNK	tricyclic
2	10	24	L-UNK	antidepressants
3	27	30	O	such
4	32	33	O	as
5	35	47	U-UNK	amitriptyline
NULL

Cisapride	DDI-DrugBank.d237.s16	NO_SECTION	NO_SETID	6
certain tetracyclic antidepressants (such as maprotiline);
1	0	6	O	certain
2	8	18	B-UNK	tetracyclic
3	20	34	L-UNK	antidepressants
4	37	40	O	such
5	42	43	O	as
6	45	55	U-UNK	maprotiline
NULL

Cisapride	DDI-DrugBank.d237.s17	NO_SECTION	NO_SETID	6
certain antipsychotic medications (such as sertindole);
1	0	6	O	certain
2	8	20	B-UNK	antipsychotic
3	22	32	L-UNK	medications
4	35	38	O	such
5	40	41	O	as
6	43	52	U-UNK	sertindole
NULL

Cisapride	DDI-DrugBank.d237.s18	NO_SECTION	NO_SETID	8
astemizole, bepridil, sparfloxacin, and terodiline.
1	0	9	U-UNK	astemizole
2	10	10	O	,
3	12	19	U-UNK	bepridil
4	20	20	O	,
5	22	33	U-UNK	sparfloxacin
6	34	34	O	,
7	36	38	O	and
8	40	49	U-UNK	terodiline
NULL

Cisapride	DDI-DrugBank.d237.s19	NO_SECTION	NO_SETID	8
The preceding lists of drugs are not comprehensive.
1	0	2	O	The
2	4	12	O	preceding
3	14	18	O	lists
4	20	21	O	of
5	23	27	O	drugs
6	29	31	O	are
7	33	35	O	not
8	37	49	O	comprehensive
NULL

Cisapride	DDI-DrugBank.d237.s20	NO_SECTION	NO_SETID	16
The acceleration of gastric emptying by cisapride could affect the rate of absorption of other drugs.
1	0	2	O	The
2	4	15	O	acceleration
3	17	18	O	of
4	20	26	O	gastric
5	28	35	O	emptying
6	37	38	O	by
7	40	48	O	XXXXXXXX
8	50	54	O	could
9	56	61	O	affect
10	63	65	O	the
11	67	70	O	rate
12	72	73	O	of
13	75	84	O	absorption
14	86	87	O	of
15	89	93	O	other
16	95	99	O	drugs
NULL

Cisapride	DDI-DrugBank.d237.s21	NO_SECTION	NO_SETID	17
Patients receiving narrow therapeutic ratio drugs or other drugs that require careful titration should be followed closely;
1	0	7	O	Patients
2	9	17	O	receiving
3	19	24	O	narrow
4	26	36	O	therapeutic
5	38	42	O	ratio
6	44	48	O	drugs
7	50	51	O	or
8	53	57	O	other
9	59	63	O	drugs
10	65	68	O	that
11	70	76	O	require
12	78	84	O	careful
13	86	94	O	titration
14	96	101	O	should
15	103	104	O	be
16	106	113	O	followed
17	115	121	O	closely
NULL

Cisapride	DDI-DrugBank.d237.s22	NO_SECTION	NO_SETID	11
if plasma levels are being monitored, they should be reassessed.
1	0	1	O	if
2	3	8	O	plasma
3	10	15	O	levels
4	17	19	O	are
5	21	25	O	being
6	27	35	O	monitored
7	36	36	O	,
8	38	41	O	they
9	43	48	O	should
10	50	51	O	be
11	53	62	O	reassessed
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s0	NO_SECTION	NO_SETID	29
Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.
1	0	13	O	Administration
2	15	16	O	of
3	18	20	O	0.1
4	22	23	O	mg
5	24	24	O	/
6	25	26	O	kg
7	29	29	O	2
8	31	31	O	x
9	33	36	O	ED95
10	39	44	O	XXXXXXXX
11	46	47	O	at
12	49	51	O	10%
13	53	54	O	or
14	56	58	O	95%
15	60	67	O	recovery
16	69	77	O	following
17	79	80	O	an
18	82	91	O	intubating
19	93	96	O	dose
20	98	99	O	of
21	101	115	U-DYN	succinylcholine
22	118	118	O	1
23	120	121	O	mg
24	122	122	O	/
25	123	124	O	kg
26	127	134	O	produced
27	137	139	O	95%
28	141	153	O	neuromuscular
29	155	159	O	block
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s1	NO_SECTION	NO_SETID	19
The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.
1	0	2	O	The
2	4	7	O	time
3	9	10	O	to
4	12	16	O	onset
5	18	19	O	of
6	21	27	O	maximum
7	29	33	O	block
8	35	43	O	following
9	45	50	O	XXXXXXXX
10	52	53	O	is
11	55	67	O	approximately
12	69	69	O	2
13	71	77	O	minutes
14	79	84	O	faster
15	86	89	O	with
16	91	95	O	prior
17	97	110	O	administration
18	112	113	O	of
19	115	129	U-DYN	succinylcholine
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s2	NO_SECTION	NO_SETID	21
Prior administration of succinylcholine had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of NIMBEX.
1	0	4	O	Prior
2	6	19	O	administration
3	21	22	O	of
4	24	38	U-UNK	succinylcholine
5	40	42	O	had
6	44	45	O	no
7	47	52	O	effect
8	54	55	O	on
9	57	59	O	the
10	61	68	O	duration
11	70	71	O	of
12	73	85	O	neuromuscular
13	87	91	O	block
14	93	101	O	following
15	103	109	O	initial
16	111	112	O	or
17	114	124	O	maintenance
18	126	130	O	bolus
19	132	136	O	doses
20	138	139	O	of
21	141	146	O	XXXXXXXX
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s3	NO_SECTION	NO_SETID	25
Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.
1	0	7	O	Infusion
2	9	20	O	requirements
3	22	23	O	of
4	25	30	O	XXXXXXXX
5	32	33	O	in
6	35	42	O	patients
7	44	55	O	administered
8	57	71	U-DYN	succinylcholine
9	73	77	O	prior
10	79	80	O	to
11	82	90	O	infusions
12	92	93	O	of
13	95	100	O	XXXXXXXX
14	102	105	O	were
15	107	116	O	comparable
16	118	119	O	to
17	121	122	O	or
18	124	131	O	slightly
19	133	139	O	greater
20	141	144	O	than
21	146	149	O	when
22	151	165	U-UNK	succinylcholine
23	167	169	O	was
24	171	173	O	not
25	175	186	O	administered
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s4	NO_SECTION	NO_SETID	19
The use of NIMBEX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	16	O	XXXXXXXX
5	18	23	O	before
6	25	39	U-UNK	succinylcholine
7	41	42	O	to
8	44	52	O	attenuate
9	54	57	O	some
10	59	60	O	of
11	62	64	O	the
12	66	69	O	side
13	71	77	O	effects
14	79	80	O	of
15	82	96	U-UNK	succinylcholine
16	98	100	O	has
17	102	104	O	not
18	106	109	O	been
19	111	117	O	studied
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s5	NO_SECTION	NO_SETID	34
Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium, pancuronium, or atracurium were administered following varying degrees of recovery from single doses or infusions of NIMBEX.
1	0	7	O	Although
2	9	11	O	not
3	13	19	O	studied
4	21	34	O	systematically
5	36	37	O	in
6	39	46	O	clinical
7	48	53	O	trials
8	54	54	O	,
9	56	57	O	no
10	59	62	O	drug
11	64	75	O	interactions
12	77	80	O	were
13	82	89	O	observed
14	91	94	O	when
15	96	105	U-UNK	vecuronium
16	106	106	O	,
17	108	118	U-UNK	pancuronium
18	119	119	O	,
19	121	122	O	or
20	124	133	U-UNK	atracurium
21	135	138	O	were
22	140	151	O	administered
23	153	161	O	following
24	163	169	O	varying
25	171	177	O	degrees
26	179	180	O	of
27	182	189	O	recovery
28	191	194	O	from
29	196	201	O	single
30	203	207	O	doses
31	209	210	O	or
32	212	220	O	infusions
33	222	223	O	of
34	225	230	O	XXXXXXXX
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s6	NO_SECTION	NO_SETID	39
Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
1	0	9	U-DYN	Isoflurane
2	11	12	O	or
3	14	22	U-DYN	enflurane
4	24	35	O	administered
5	37	40	O	with
6	42	48	B-DYN	nitrous
7	50	54	L-DYN	oxide
8	55	55	O	/
9	56	61	U-UNK	oxygen
10	63	64	O	to
11	66	72	O	achieve
12	74	77	O	1.25
13	79	81	O	MAC
14	84	90	O	Minimum
15	92	99	O	Alveolar
16	101	113	O	Concentration
17	116	118	O	may
18	120	126	O	prolong
19	128	130	O	the
20	132	141	O	clinically
21	143	151	O	effective
22	153	160	O	duration
23	162	163	O	of
24	165	170	O	action
25	172	173	O	of
26	175	181	O	initial
27	183	185	O	and
28	187	197	O	maintenance
29	199	203	O	doses
30	205	206	O	of
31	208	213	O	XXXXXXXX
32	215	217	O	and
33	219	226	O	decrease
34	228	230	O	the
35	232	239	O	required
36	241	248	O	infusion
37	250	253	O	rate
38	255	256	O	of
39	258	263	O	XXXXXXXX
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s7	NO_SECTION	NO_SETID	16
The magnitude of these effects may depend on the duration of administration of the volatile agents.
1	0	2	O	The
2	4	12	O	magnitude
3	14	15	O	of
4	17	21	O	these
5	23	29	O	effects
6	31	33	O	may
7	35	40	O	depend
8	42	43	O	on
9	45	47	O	the
10	49	56	O	duration
11	58	59	O	of
12	61	74	O	administration
13	76	77	O	of
14	79	81	O	the
15	83	90	O	volatile
16	92	97	O	agents
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s8	NO_SECTION	NO_SETID	47
Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.
1	0	6	O	Fifteen
2	8	9	O	to
3	11	12	O	30
4	14	20	O	minutes
5	22	23	O	of
6	25	32	O	exposure
7	34	35	O	to
8	37	40	O	1.25
9	42	44	O	MAC
10	46	55	U-UNK	isoflurane
11	57	58	O	or
12	60	68	U-UNK	enflurane
13	70	72	O	had
14	74	80	O	minimal
15	82	88	O	effects
16	90	91	O	on
17	93	95	O	the
18	97	104	O	duration
19	106	107	O	of
20	109	114	O	action
21	116	117	O	of
22	119	125	O	initial
23	127	131	O	doses
24	133	134	O	of
25	136	141	O	XXXXXXXX
26	143	145	O	and
27	147	155	O	therefore
28	156	156	O	,
29	158	159	O	no
30	161	170	O	adjustment
31	172	173	O	to
32	175	177	O	the
33	179	185	O	initial
34	187	190	O	dose
35	192	197	O	should
36	199	200	O	be
37	202	210	O	necessary
38	212	215	O	when
39	217	222	O	XXXXXXXX
40	224	225	O	is
41	227	238	O	administered
42	240	246	O	shortly
43	248	252	O	after
44	254	263	O	initiation
45	265	266	O	of
46	268	275	O	volatile
47	277	282	O	agents
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s9	NO_SECTION	NO_SETID	28
In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.
1	0	1	O	In
2	3	6	O	long
3	8	15	O	surgical
4	17	26	O	procedures
5	28	33	O	during
6	35	43	U-DYN	enflurane
7	45	46	O	or
8	48	57	U-DYN	isoflurane
9	59	68	O	anesthesia
10	69	69	O	,
11	71	74	O	less
12	76	83	O	frequent
13	85	95	O	maintenance
14	97	102	O	dosing
15	103	103	O	,
16	105	109	O	lower
17	111	121	O	maintenance
18	123	127	O	doses
19	128	128	O	,
20	130	131	O	or
21	133	139	O	reduced
22	141	148	O	infusion
23	150	154	O	rates
24	156	157	O	of
25	159	164	O	XXXXXXXX
26	166	168	O	may
27	170	171	O	be
28	173	181	O	necessary
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s10	NO_SECTION	NO_SETID	15
The average infusion rate requirement may be decreased by as much as 30% to 40%.
1	0	2	O	The
2	4	10	O	average
3	12	19	O	infusion
4	21	24	O	rate
5	26	36	O	requirement
6	38	40	O	may
7	42	43	O	be
8	45	53	O	decreased
9	55	56	O	by
10	58	59	O	as
11	61	64	O	much
12	66	67	O	as
13	69	71	O	30%
14	73	74	O	to
15	76	78	O	40%
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s11	NO_SECTION	NO_SETID	17
In clinical studies propofol had no effect on the duration of action or dosing requirements for NIMBEX.
1	0	1	O	In
2	3	10	O	clinical
3	12	18	O	studies
4	20	27	U-UNK	propofol
5	29	31	O	had
6	33	34	O	no
7	36	41	O	effect
8	43	44	O	on
9	46	48	O	the
10	50	57	O	duration
11	59	60	O	of
12	62	67	O	action
13	69	70	O	or
14	72	77	O	dosing
15	79	90	O	requirements
16	92	94	O	for
17	96	101	O	XXXXXXXX
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s12	NO_SECTION	NO_SETID	51
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
1	0	4	O	Other
2	6	10	O	drugs
3	12	16	O	which
4	18	20	O	may
5	22	28	O	enhance
6	30	32	O	the
7	34	46	O	neuromuscular
8	48	55	O	blocking
9	57	62	O	action
10	64	65	O	of
11	67	81	B-DYN	nondepolarizing
12	83	88	L-DYN	agents
13	90	93	O	such
14	95	96	O	as
15	98	103	O	XXXXXXXX
16	105	111	O	include
17	113	119	O	certain
18	121	131	U-DYN	antibiotics
19	134	134	O	e
20	137	137	O	g
21	139	139	O	,
22	141	155	U-DYN	aminoglycosides
23	156	156	O	,
24	158	170	U-DYN	tetracyclines
25	171	171	O	,
26	173	182	U-DYN	bacitracin
27	183	183	O	,
28	185	194	U-DYN	polymyxins
29	195	195	O	,
30	197	206	U-DYN	lincomycin
31	207	207	O	,
32	209	219	U-DYN	clindamycin
33	220	220	O	,
34	222	229	U-DYN	colistin
35	230	230	O	,
36	232	234	O	and
37	236	241	B-DYN	sodium
38	243	256	L-DYN	colistemethate
39	258	258	O	,
40	260	268	U-DYN	magnesium
41	270	274	O	salts
42	275	275	O	,
43	277	283	U-DYN	lithium
44	284	284	O	,
45	286	290	O	local
46	292	302	U-DYN	anesthetics
47	303	303	O	,
48	305	316	U-DYN	procainamide
49	317	317	O	,
50	319	321	O	and
51	323	331	U-DYN	quinidine
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s13	NO_SECTION	NO_SETID	21
Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
1	0	9	O	Resistance
2	11	12	O	to
3	14	16	O	the
4	18	30	O	neuromuscular
5	32	39	O	blocking
6	41	46	O	action
7	48	49	O	of
8	51	65	B-UNK	nondepolarizing
9	67	79	I-UNK	neuromuscular
10	81	88	I-UNK	blocking
11	90	95	L-UNK	agents
12	97	99	O	has
13	101	104	O	been
14	106	117	O	demonstrated
15	119	120	O	in
16	122	129	O	patients
17	131	141	O	chronically
18	143	154	O	administered
19	156	164	U-UNK	phenytoin
20	166	167	O	or
21	169	181	U-UNK	carbamazepine
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s14	NO_SECTION	NO_SETID	33
While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
1	0	4	O	While
2	6	8	O	the
3	10	16	O	effects
4	18	19	O	of
5	21	27	O	chronic
6	29	37	U-DYN	phenytoin
7	39	40	O	or
8	42	54	U-DYN	carbamazepine
9	56	62	O	therapy
10	64	65	O	on
11	67	69	O	the
12	71	76	O	action
13	78	79	O	of
14	81	86	O	XXXXXXXX
15	88	90	O	are
16	92	98	O	unknown
17	99	99	O	,
18	101	108	O	slightly
19	110	116	O	shorter
20	118	126	O	durations
21	128	129	O	of
22	131	143	O	neuromuscular
23	145	149	O	block
24	151	153	O	may
25	155	156	O	be
26	158	168	O	anticipated
27	170	172	O	and
28	174	181	O	infusion
29	183	186	O	rate
30	188	199	O	requirements
31	201	203	O	may
32	205	206	O	be
33	208	213	O	higher
NULL

Cisatracurium Besylate	DDI-DrugBank.d60.s15	NO_SECTION	NO_SETID	7
Drug/Laboratory Test Interactions None known.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	37	O	None
7	39	43	O	known
NULL

Cisplatin	DDI-DrugBank.d145.s0	NO_SECTION	NO_SETID	11
Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.
1	0	5	O	Plasma
2	7	12	O	levels
3	14	15	O	of
4	17	30	B-KIN	anticonvulsant
5	32	37	L-KIN	agents
6	39	41	O	may
7	43	48	O	become
8	50	63	O	subtherapeutic
9	65	70	O	during
10	72	80	O	XXXXXXXX
11	82	88	O	therapy
NULL

Citalopram	DDI-DrugBank.d472.s0	NO_SECTION	NO_SETID	40
Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
1	0	6	B-UNK	Central
2	8	14	I-UNK	nervous
3	16	21	I-UNK	system
4	23	32	L-UNK	depressant
5	35	37	O	CNS
6	40	44	O	drugs
7	46	54	O	including
8	56	62	U-UNK	alcohol
9	63	63	O	,
10	65	79	U-UNK	antidepressants
11	80	80	O	,
12	82	95	U-UNK	antihistamines
13	96	96	O	,
14	98	111	U-UNK	antipsychotics
15	112	112	O	,
16	114	118	O	blood
17	120	127	O	pressure
18	129	139	O	medications
19	142	150	U-UNK	reserpine
20	151	151	O	,
21	153	162	U-UNK	methyldopa
22	163	163	O	,
23	165	168	B-UNK	beta
24	170	177	L-UNK	blockers
25	179	179	O	,
26	181	186	O	motion
27	188	195	O	sickness
28	197	207	O	medications
29	208	208	O	,
30	210	215	B-UNK	muscle
31	217	225	L-UNK	relaxants
32	226	226	O	,
33	228	236	U-UNK	narcotics
34	237	237	O	,
35	239	247	U-UNK	sedatives
36	248	248	O	,
37	250	257	O	sleeping
38	259	263	O	pills
39	265	267	O	and
40	269	281	U-UNK	tranquilizers
NULL

Cladribine	DDI-DrugBank.d134.s0	NO_SECTION	NO_SETID	9
There are no known drug interactions with LEUSTATIN Injection.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	17	O	known
5	19	22	O	drug
6	24	35	O	interactions
7	37	40	O	with
8	42	50	O	XXXXXXXX
9	52	60	O	Injection
NULL

Cladribine	DDI-DrugBank.d134.s1	NO_SECTION	NO_SETID	25
Caution should be exercised if LEUSTATIN Injection is administered before, after, or in conjunction with other drugs known to cause immunosuppression or myelosuppression.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	29	O	if
6	31	39	O	XXXXXXXX
7	41	49	O	Injection
8	51	52	O	is
9	54	65	O	administered
10	67	72	O	before
11	73	73	O	,
12	75	79	O	after
13	80	80	O	,
14	82	83	O	or
15	85	86	O	in
16	88	98	O	conjunction
17	100	103	O	with
18	105	109	O	other
19	111	115	O	drugs
20	117	121	O	known
21	123	124	O	to
22	126	130	O	cause
23	132	148	O	immunosuppression
24	150	151	O	or
25	153	168	O	myelosuppression
NULL

Clavulanate	DDI-DrugBank.d419.s0	NO_SECTION	NO_SETID	25
The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.
1	0	2	O	The
2	4	13	O	concurrent
3	15	28	O	administration
4	30	31	O	of
5	33	43	U-UNK	allopurinol
6	45	47	O	and
7	49	58	U-UNK	ampicillin
8	60	68	O	increases
9	70	82	O	substantially
10	84	86	O	the
11	88	96	O	incidence
12	98	99	O	of
13	101	106	O	rashes
14	108	109	O	in
15	111	118	O	patients
16	120	128	O	receiving
17	130	133	O	both
18	135	139	O	drugs
19	141	142	O	as
20	144	151	O	compared
21	153	154	O	to
22	156	163	O	patients
23	165	173	O	receiving
24	175	184	U-UNK	ampicillin
25	186	190	O	alone
NULL

Clavulanate	DDI-DrugBank.d419.s1	NO_SECTION	NO_SETID	21
It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	known
5	16	22	O	whether
6	24	27	O	this
7	29	40	O	potentiation
8	42	43	O	of
9	45	54	U-UNK	ampicillin
10	56	61	O	rashes
11	63	64	O	is
12	66	68	O	due
13	70	71	O	to
14	73	83	U-UNK	allopurinol
15	85	86	O	or
16	88	90	O	the
17	92	104	O	hyperuricemia
18	106	112	O	present
19	114	115	O	in
20	117	121	O	these
21	123	130	O	patients
NULL

Clavulanate	DDI-DrugBank.d419.s2	NO_SECTION	NO_SETID	14
In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant allopurinol and AUGMENTIN XR.
1	0	1	O	In
2	3	12	O	controlled
3	14	21	O	clinical
4	23	28	O	trials
5	30	31	O	of
6	33	44	O	XXXXXXXX
7	45	45	O	,
8	47	48	O	22
9	50	57	O	patients
10	59	66	O	received
11	68	78	O	concomitant
12	80	90	U-UNK	allopurinol
13	92	94	O	and
14	96	107	O	XXXXXXXX
NULL

Clavulanate	DDI-DrugBank.d419.s3	NO_SECTION	NO_SETID	7
No rashes were reported in these patients.
1	0	1	O	No
2	3	8	O	rashes
3	10	13	O	were
4	15	22	O	reported
5	24	25	O	in
6	27	31	O	these
7	33	40	O	patients
NULL

Clavulanate	DDI-DrugBank.d419.s4	NO_SECTION	NO_SETID	27
However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant AUGMENTIN XR and allopurinol use.
1	0	6	O	However
2	7	7	O	,
3	9	12	O	this
4	14	19	O	sample
5	21	24	O	size
6	26	27	O	is
7	29	31	O	too
8	33	37	O	small
9	39	40	O	to
10	42	46	O	allow
11	48	50	O	for
12	52	54	O	any
13	56	66	O	conclusions
14	68	69	O	to
15	71	72	O	be
16	74	78	O	drawn
17	80	88	O	regarding
18	90	92	O	the
19	94	97	O	risk
20	99	100	O	of
21	102	107	O	rashes
22	109	112	O	with
23	114	124	O	concomitant
24	126	137	O	XXXXXXXX
25	139	141	O	and
26	143	153	U-UNK	allopurinol
27	155	157	O	use
NULL

Clavulanate	DDI-DrugBank.d419.s5	NO_SECTION	NO_SETID	16
In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives
1	0	1	O	In
2	3	8	O	common
3	10	13	O	with
4	15	19	O	other
5	21	25	B-UNK	broad
6	27	34	I-UNK	spectrum
7	36	46	L-UNK	antibiotics
8	47	47	O	,
9	49	60	O	XXXXXXXX
10	62	64	O	may
11	66	71	O	reduce
12	73	75	O	the
13	77	84	O	efficacy
14	86	87	O	of
15	89	92	O	oral
16	94	107	U-DYN	contraceptives
NULL

Clemastine	DDI-DrugBank.d309.s0	NO_SECTION	NO_SETID	21
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
1	0	7	O	Additive
2	9	11	O	CNS
3	13	22	O	depression
4	24	26	O	may
5	28	32	O	occur
6	34	37	O	when
7	39	52	U-UNK	antihistamines
8	54	56	O	are
9	58	69	O	administered
10	71	83	O	concomitantly
11	85	88	O	with
12	90	94	O	other
13	96	98	B-UNK	CNS
14	100	110	L-UNK	depressants
15	112	120	O	including
16	122	133	U-UNK	barbiturates
17	134	134	O	,
18	136	148	U-UNK	tranquilizers
19	149	149	O	,
20	151	153	O	and
21	155	161	U-UNK	alcohol
NULL

Clemastine	DDI-DrugBank.d309.s1	NO_SECTION	NO_SETID	15
Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	32	U-UNK	antihistamines
4	34	39	O	should
5	41	42	O	be
6	44	50	O	advised
7	52	58	O	against
8	60	62	O	the
9	64	73	O	concurrent
10	75	77	O	use
11	79	80	O	of
12	82	86	O	other
13	88	90	B-UNK	CNS
14	92	101	I-UNK	depressant
15	103	107	L-UNK	drugs
NULL

Clemastine	DDI-DrugBank.d309.s2	NO_SECTION	NO_SETID	12
Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.
1	0	8	B-UNK	Monoamine
2	10	16	I-UNK	oxidase
3	19	21	I-UNK	MAO
4	24	33	L-UNK	inhibitors
5	35	41	O	prolong
6	43	45	O	and
7	47	55	O	intensify
8	57	59	O	the
9	61	75	O	anticholinergic
10	77	83	O	effects
11	85	86	O	of
12	88	101	U-UNK	antihistamines
NULL

Clidinium	DDI-DrugBank.d322.s0	NO_SECTION	NO_SETID	13
Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.
1	0	9	U-DYN	Amantadine
2	10	10	O	,
3	12	20	B-DYN	tricyclic
4	22	36	L-DYN	antidepressants
5	37	37	O	,
6	39	41	O	and
7	43	47	U-DYN	MAOIs
8	49	51	O	may
9	53	60	O	increase
10	62	76	O	anticholinergic
11	78	83	O	effect
12	85	86	O	of
13	88	96	O	XXXXXXXX
NULL

Clidinium	DDI-DrugBank.d322.s1	NO_SECTION	NO_SETID	12
Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.
1	0	8	O	XXXXXXXX
2	10	12	O	may
3	14	21	O	decrease
4	23	25	O	the
5	27	32	O	effect
6	34	35	O	of
7	37	50	U-DYN	phenothiazines
8	51	51	O	,
9	53	60	U-DYN	levodopa
10	61	61	O	,
11	63	65	O	and
12	67	78	U-DYN	ketoconazole
NULL

Clindamycin	DDI-DrugBank.d256.s0	NO_SECTION	NO_SETID	19
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
1	0	10	O	XXXXXXXX
2	12	14	O	has
3	16	19	O	been
4	21	25	O	shown
5	27	28	O	to
6	30	33	O	have
7	35	47	O	neuromuscular
8	49	56	O	blocking
9	58	67	O	properties
10	69	72	O	that
11	74	76	O	may
12	78	84	O	enhance
13	86	88	O	the
14	90	95	O	action
15	97	98	O	of
16	100	104	O	other
17	106	118	B-DYN	neuromuscular
18	120	127	I-DYN	blocking
19	129	134	L-DYN	agents
NULL

Clindamycin	DDI-DrugBank.d256.s1	NO_SECTION	NO_SETID	13
Therefore, it should be used with caution in patients receiving such agents.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	it
4	14	19	O	should
5	21	22	O	be
6	24	27	O	used
7	29	32	O	with
8	34	40	O	caution
9	42	43	O	in
10	45	52	O	patients
11	54	62	O	receiving
12	64	67	O	such
13	69	74	O	agents
NULL

Clindamycin	DDI-DrugBank.d256.s2	NO_SECTION	NO_SETID	10
Antagonism has been demonstrated between clindamycin and erythromycin in vitro.
1	0	9	O	Antagonism
2	11	13	O	has
3	15	18	O	been
4	20	31	O	demonstrated
5	33	39	O	between
6	41	51	O	XXXXXXXX
7	53	55	O	and
8	57	68	U-DYN	erythromycin
9	70	71	O	in
10	73	77	O	vitro
NULL

Clindamycin	DDI-DrugBank.d256.s3	NO_SECTION	NO_SETID	14
Because of possible clinical significance, these two drugs should not be administered concurrently.
1	0	6	O	Because
2	8	9	O	of
3	11	18	O	possible
4	20	27	O	clinical
5	29	40	O	significance
6	41	41	O	,
7	43	47	O	these
8	49	51	O	two
9	53	57	O	drugs
10	59	64	O	should
11	66	68	O	not
12	70	71	O	be
13	73	84	O	administered
14	86	97	O	concurrently
NULL

Clobazam	DDI-DrugBank.d136.s0	NO_SECTION	NO_SETID	10
Alcohol (increases bioavailability by 50%), cimetidine, and valproates.
1	0	6	U-UNK	Alcohol
2	9	17	O	increases
3	19	33	O	bioavailability
4	35	36	O	by
5	38	40	O	50%
6	42	42	O	,
7	44	53	U-UNK	cimetidine
8	54	54	O	,
9	56	58	O	and
10	60	69	O	valproates
NULL

Clobetasol	DDI-DrugBank.d391.s0	NO_SECTION	NO_SETID	4
No separate information available
1	0	1	O	No
2	3	10	O	separate
3	12	22	O	information
4	24	32	O	available
NULL

Clofarabine	DDI-DrugBank.d473.s0	NO_SECTION	NO_SETID	35
Although no clinical drug-drug interaction studies have been conducted to date, on the basis of the in vitro studies, cytochrome p450 inhibitors and inducers are unlikely to affect the metabolism of clofarabine.
1	0	7	O	Although
2	9	10	O	no
3	12	19	O	clinical
4	21	24	O	drug
5	26	29	O	drug
6	31	41	O	interaction
7	43	49	O	studies
8	51	54	O	have
9	56	59	O	been
10	61	69	O	conducted
11	71	72	O	to
12	74	77	O	date
13	78	78	O	,
14	80	81	O	on
15	83	85	O	the
16	87	91	O	basis
17	93	94	O	of
18	96	98	O	the
19	100	101	O	in
20	103	107	O	vitro
21	109	115	O	studies
22	116	116	O	,
23	118	127	O	cytochrome
24	129	132	O	p450
25	134	143	O	inhibitors
26	145	147	O	and
27	149	156	O	inducers
28	158	160	O	are
29	162	169	O	unlikely
30	171	172	O	to
31	174	179	O	affect
32	181	183	O	the
33	185	194	O	metabolism
34	196	197	O	of
35	199	209	O	XXXXXXXX
NULL

Clofarabine	DDI-DrugBank.d473.s1	NO_SECTION	NO_SETID	15
The effect of clofarabine on the metabolism of cytochrome p450 substrates has not been studied.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	24	O	XXXXXXXX
5	26	27	O	on
6	29	31	O	the
7	33	42	O	metabolism
8	44	45	O	of
9	47	56	O	cytochrome
10	58	61	O	p450
11	63	72	O	substrates
12	74	76	O	has
13	78	80	O	not
14	82	85	O	been
15	87	93	O	studied
NULL

Clofarabine	DDI-DrugBank.d473.s2	NO_SECTION	NO_SETID	20
Drug/Laboratory Tests Interactions There are no known clinically significant interactions of CLOLAR  with other medications or laboratory tests.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	20	O	Tests
5	22	33	O	Interactions
6	35	39	O	There
7	41	43	O	are
8	45	46	O	no
9	48	52	O	known
10	54	63	O	clinically
11	65	75	O	significant
12	77	88	O	interactions
13	90	91	O	of
14	93	98	O	XXXXXXXX
15	101	104	O	with
16	106	110	O	other
17	112	122	O	medications
18	124	125	O	or
19	127	136	O	laboratory
20	138	142	O	tests
NULL

Clofarabine	DDI-DrugBank.d473.s3	NO_SECTION	NO_SETID	13
No formal drug/laboratory test interaction studies have been conducted with CLOLAR  .
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	14	14	O	/
5	15	24	O	laboratory
6	26	29	O	test
7	31	41	O	interaction
8	43	49	O	studies
9	51	54	O	have
10	56	59	O	been
11	61	69	O	conducted
12	71	74	O	with
13	76	81	O	XXXXXXXX
NULL

Clofazimine	DDI-DrugBank.d399.s0	NO_SECTION	NO_SETID	18
Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.
1	0	10	O	Preliminary
2	12	15	O	data
3	17	21	O	which
4	23	29	O	suggest
5	31	34	O	that
6	36	42	U-DYN	dapsone
7	44	46	O	may
8	48	54	O	inhibit
9	56	58	O	the
10	60	63	O	anti
11	65	76	O	inflammatory
12	78	85	O	activity
13	87	88	O	of
14	90	97	O	XXXXXXXX
15	99	102	O	have
16	104	106	O	not
17	108	111	O	been
18	113	121	O	confirmed
NULL

Clofazimine	DDI-DrugBank.d399.s1	NO_SECTION	NO_SETID	25
If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.
1	0	1	O	If
2	3	9	O	leprosy
3	11	20	O	associated
4	22	33	O	inflammatory
5	35	43	O	reactions
6	45	51	O	develop
7	53	54	O	in
8	56	63	O	patients
9	65	69	O	being
10	71	77	O	treated
11	79	82	O	with
12	84	90	U-DYN	dapsone
13	92	94	O	and
14	96	106	O	XXXXXXXX
15	107	107	O	,
16	109	110	O	it
17	112	113	O	is
18	115	119	O	still
19	121	129	O	advisable
20	131	132	O	to
21	134	141	O	continue
22	143	151	O	treatment
23	153	156	O	with
24	158	161	O	both
25	163	167	O	drugs
NULL

Clofibrate	DDI-DrugBank.d12.s0	NO_SECTION	NO_SETID	12
Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	46	U-DYN	anticoagulants
7	48	50	O	are
8	52	56	O	given
9	58	59	O	in
10	61	71	O	conjunction
11	73	76	O	with
12	78	86	O	XXXXXXXX
NULL

Clofibrate	DDI-DrugBank.d12.s1	NO_SECTION	NO_SETID	31
Usually, the dosage of the anticoagulant should be reduced by one-half (depending on the individual case) to maintain the prothrombin time at the desired level to prevent bleeding complications.
1	0	6	O	Usually
2	7	7	O	,
3	9	11	O	the
4	13	18	O	dosage
5	20	21	O	of
6	23	25	O	the
7	27	39	U-UNK	anticoagulant
8	41	46	O	should
9	48	49	O	be
10	51	57	O	reduced
11	59	60	O	by
12	62	64	O	one
13	66	69	O	half
14	72	80	O	depending
15	82	83	O	on
16	85	87	O	the
17	89	98	O	individual
18	100	103	O	case
19	106	107	O	to
20	109	116	O	maintain
21	118	120	O	the
22	122	132	O	prothrombin
23	134	137	O	time
24	139	140	O	at
25	142	144	O	the
26	146	152	O	desired
27	154	158	O	level
28	160	161	O	to
29	163	169	O	prevent
30	171	178	O	bleeding
31	180	192	O	complications
NULL

Clofibrate	DDI-DrugBank.d12.s2	NO_SECTION	NO_SETID	18
Frequent prothrombin determinations are advisable until it has been determined definitely that the prothrombin level has been stabilized.
1	0	7	O	Frequent
2	9	19	O	prothrombin
3	21	34	O	determinations
4	36	38	O	are
5	40	48	O	advisable
6	50	54	O	until
7	56	57	O	it
8	59	61	O	has
9	63	66	O	been
10	68	77	O	determined
11	79	88	O	definitely
12	90	93	O	that
13	95	97	O	the
14	99	109	O	prothrombin
15	111	115	O	level
16	117	119	O	has
17	121	124	O	been
18	126	135	O	stabilized
NULL

Clofibrate	DDI-DrugBank.d12.s3	NO_SECTION	NO_SETID	14
Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.
1	0	8	O	XXXXXXXX
2	10	12	O	may
3	14	21	O	displace
4	23	28	O	acidic
5	30	34	O	drugs
6	36	39	O	such
7	41	42	O	as
8	44	52	U-KIN	phenytoin
9	54	55	O	or
10	57	67	U-KIN	tolbutamide
11	69	72	O	from
12	74	78	O	their
13	80	86	O	binding
14	88	92	O	sites
NULL

Clofibrate	DDI-DrugBank.d12.s4	NO_SECTION	NO_SETID	20
Caution should be exercised when treating patients with either of these drugs or other highly protein-bound drugs and Atromid-S.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	40	O	treating
7	42	49	O	patients
8	51	54	O	with
9	56	61	O	either
10	63	64	O	of
11	66	70	O	these
12	72	76	O	drugs
13	78	79	O	or
14	81	85	O	other
15	87	92	O	highly
16	94	100	O	protein
17	102	106	O	bound
18	108	112	O	drugs
19	114	116	O	and
20	118	126	O	XXXXXXXX
NULL

Clofibrate	DDI-DrugBank.d12.s5	NO_SECTION	NO_SETID	15
The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.
1	0	2	O	The
2	4	15	O	hypoglycemic
3	17	22	O	effect
4	24	25	O	of
5	27	37	U-DYN	tolbutamide
6	39	41	O	has
7	43	46	O	been
8	48	55	O	reported
9	57	58	O	to
10	60	67	O	increase
11	69	72	O	when
12	74	82	O	XXXXXXXX
13	84	85	O	is
14	87	91	O	given
15	93	104	O	concurrently
NULL

Clofibrate	DDI-DrugBank.d12.s6	NO_SECTION	NO_SETID	27
Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.
1	0	8	O	Fulminant
2	10	23	O	rhabdomyolysis
3	25	27	O	has
4	29	32	O	been
5	34	37	O	seen
6	39	40	O	as
7	42	46	O	early
8	48	49	O	as
9	51	55	O	three
10	57	61	O	weeks
11	63	67	O	after
12	69	78	O	initiation
13	80	81	O	of
14	83	90	O	combined
15	92	98	O	therapy
16	100	103	O	with
17	105	111	O	another
18	113	119	U-UNK	fibrate
19	121	123	O	and
20	125	134	U-UNK	lovastatin
21	136	138	O	but
22	140	142	O	may
23	144	145	O	be
24	147	150	O	seen
25	152	156	O	after
26	158	164	O	several
27	166	171	O	months
NULL

Clofibrate	DDI-DrugBank.d12.s7	NO_SECTION	NO_SETID	50
For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.
1	0	2	O	For
2	4	8	O	these
3	10	16	O	reasons
4	17	17	O	,
5	19	20	O	it
6	22	23	O	is
7	25	28	O	felt
8	30	33	O	that
9	34	34	O	,
10	36	37	O	in
11	39	42	O	most
12	44	51	O	subjects
13	53	55	O	who
14	57	60	O	have
15	62	64	O	had
16	66	67	O	an
17	69	82	O	unsatisfactory
18	84	88	O	lipid
19	90	97	O	response
20	99	100	O	to
21	102	107	O	either
22	109	112	O	drug
23	114	118	O	alone
24	119	119	O	,
25	121	123	O	the
26	125	132	O	possible
27	134	141	O	benefits
28	143	144	O	of
29	146	153	O	combined
30	155	161	O	therapy
31	163	166	O	with
32	168	177	U-UNK	lovastatin
33	179	181	O	and
34	183	183	O	a
35	185	191	U-UNK	fibrate
36	193	194	O	do
37	196	198	O	not
38	200	207	O	outweigh
39	209	211	O	the
40	213	217	O	risks
41	219	220	O	of
42	222	227	O	severe
43	229	236	O	myopathy
44	237	237	O	,
45	239	252	O	rhabdomyolysis
46	253	253	O	,
47	255	257	O	and
48	259	263	O	acute
49	265	269	O	renal
50	271	277	O	failure
NULL

Clofibrate	DDI-DrugBank.d12.s8	NO_SECTION	NO_SETID	31
While it is not known whether this interaction occurs with fibrates other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate.
1	0	4	O	While
2	6	7	O	it
3	9	10	O	is
4	12	14	O	not
5	16	20	O	known
6	22	28	O	whether
7	30	33	O	this
8	35	45	O	interaction
9	47	52	O	occurs
10	54	57	O	with
11	59	66	U-UNK	fibrates
12	68	72	O	other
13	74	77	O	than
14	79	89	U-UNK	gemfibrozil
15	90	90	O	,
16	92	99	O	myopathy
17	101	103	O	and
18	105	118	O	rhabdomyolysis
19	120	123	O	have
20	125	136	O	occasionally
21	138	141	O	been
22	143	152	O	associated
23	154	157	O	with
24	159	161	O	the
25	163	165	O	use
26	167	168	O	of
27	170	177	U-UNK	fibrates
28	179	183	O	alone
29	184	184	O	,
30	186	194	O	including
31	196	205	O	XXXXXXXX
NULL

Clofibrate	DDI-DrugBank.d12.s9	NO_SECTION	NO_SETID	13
Therefore, the combined use of lovastatin with fibrates should generally be avoided.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	22	O	combined
5	24	26	O	use
6	28	29	O	of
7	31	40	U-UNK	lovastatin
8	42	45	O	with
9	47	54	U-UNK	fibrates
10	56	61	O	should
11	63	71	O	generally
12	73	74	O	be
13	76	82	O	avoided
NULL

Clomifene	DDI-DrugBank.d451.s0	NO_SECTION	NO_SETID	11
Drug interactions with clomiphene citrate tablets USP have not been documented.
1	0	3	O	Drug
2	5	16	O	interactions
3	18	21	O	with
4	23	32	B-UNK	clomiphene
5	34	40	L-UNK	citrate
6	42	48	O	tablets
7	50	52	O	USP
8	54	57	O	have
9	59	61	O	not
10	63	66	O	been
11	68	77	O	documented
NULL

Clomipramine	DDI-DrugBank.d238.s0	NO_SECTION	NO_SETID	15
The risks of using Anafranil in combination with other drugs have not been systematically evaluated.
1	0	2	O	The
2	4	8	O	risks
3	10	11	O	of
4	13	17	O	using
5	19	27	O	XXXXXXXX
6	29	30	O	in
7	32	42	O	combination
8	44	47	O	with
9	49	53	O	other
10	55	59	O	drugs
11	61	64	O	have
12	66	68	O	not
13	70	73	O	been
14	75	88	O	systematically
15	90	98	O	evaluated
NULL

Clomipramine	DDI-DrugBank.d238.s1	NO_SECTION	NO_SETID	20
Given the primary CNS effects of Anafranil, caution is advised in using it concomitantly with other CNS-active drugs.
1	0	4	O	Given
2	6	8	O	the
3	10	16	O	primary
4	18	20	O	CNS
5	22	28	O	effects
6	30	31	O	of
7	33	41	O	XXXXXXXX
8	42	42	O	,
9	44	50	O	caution
10	52	53	O	is
11	55	61	O	advised
12	63	64	O	in
13	66	70	O	using
14	72	73	O	it
15	75	87	O	concomitantly
16	89	92	O	with
17	94	98	O	other
18	100	102	O	CNS
19	104	109	O	active
20	111	115	O	drugs
NULL

Clomipramine	DDI-DrugBank.d238.s2	NO_SECTION	NO_SETID	8
Anafranil should not be used with MAO inhibitors.
1	0	8	O	XXXXXXXX
2	10	15	O	should
3	17	19	O	not
4	21	22	O	be
5	24	27	O	used
6	29	32	O	with
7	34	36	B-DYN	MAO
8	38	47	L-DYN	inhibitors
NULL

Clomipramine	DDI-DrugBank.d238.s3	NO_SECTION	NO_SETID	18
Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.
1	0	4	O	Close
2	6	16	O	supervision
3	18	20	O	and
4	22	28	O	careful
5	30	39	O	adjustment
6	41	42	O	of
7	44	49	O	dosage
8	51	53	O	are
9	55	62	O	required
10	64	67	O	when
11	69	77	O	XXXXXXXX
12	79	80	O	is
13	82	93	O	administered
14	95	98	O	with
15	100	114	U-DYN	anticholinergic
16	116	117	O	or
17	119	133	B-DYN	sympathomimetic
18	135	139	L-DYN	drugs
NULL

Clomipramine	DDI-DrugBank.d238.s4	NO_SECTION	NO_SETID	38
Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
1	0	6	O	Several
2	8	16	B-UNK	tricyclic
3	18	32	L-UNK	antidepressants
4	34	37	O	have
5	39	42	O	been
6	44	51	O	reported
7	53	54	O	to
8	56	60	O	block
9	62	64	O	the
10	66	78	O	pharmacologic
11	80	86	O	effects
12	88	89	O	of
13	91	102	U-UNK	guanethidine
14	103	103	O	,
15	105	113	U-UNK	clonidine
16	114	114	O	,
17	116	117	O	or
18	119	125	O	similar
19	127	132	O	agents
20	133	133	O	,
21	135	137	O	and
22	139	142	O	such
23	144	145	O	an
24	147	152	O	effect
25	154	156	O	may
26	158	159	O	be
27	161	171	O	anticipated
28	173	176	O	with
29	178	180	U-UNK	CMI
30	182	188	O	because
31	190	191	O	of
32	193	195	O	its
33	197	206	O	structural
34	208	217	O	similarity
35	219	220	O	to
36	222	226	O	other
37	228	236	B-UNK	tricyclic
38	238	252	L-UNK	antidepressants
NULL

Clomipramine	DDI-DrugBank.d238.s5	NO_SECTION	NO_SETID	17
The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol;
1	0	2	O	The
2	4	9	O	plasma
3	11	23	O	concentration
4	25	26	O	of
5	28	30	U-UNK	CMI
6	32	34	O	has
7	36	39	O	been
8	41	48	O	reported
9	50	51	O	to
10	53	54	O	be
11	56	64	O	increased
12	66	67	O	by
13	69	71	O	the
14	73	83	O	concomitant
15	85	98	O	administration
16	100	101	O	of
17	103	113	U-UNK	haloperidol
NULL

Clomipramine	DDI-DrugBank.d238.s6	NO_SECTION	NO_SETID	56
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
1	0	5	O	plasma
2	7	12	O	levels
3	14	15	O	of
4	17	23	O	several
5	25	31	O	closely
6	33	39	O	related
7	41	49	B-UNK	tricyclic
8	51	65	L-UNK	antidepressants
9	67	70	O	have
10	72	75	O	been
11	77	84	O	reported
12	86	87	O	to
13	89	90	O	be
14	92	100	O	increased
15	102	103	O	by
16	105	107	O	the
17	109	119	O	concomitant
18	121	134	O	administration
19	136	137	O	of
20	139	153	U-UNK	methylphenidate
21	155	156	O	or
22	158	164	O	hepatic
23	166	171	O	enzyme
24	173	182	O	inhibitors
25	185	187	O	e.g
26	189	189	O	,
27	191	200	U-UNK	cimetidine
28	201	201	O	,
29	203	212	U-UNK	fluoxetine
30	215	217	O	and
31	219	227	O	decreased
32	229	230	O	by
33	232	234	O	the
34	236	246	O	concomitant
35	248	261	O	administration
36	263	264	O	of
37	266	272	O	hepatic
38	274	279	O	enzyme
39	281	288	O	inducers
40	291	293	O	e.g
41	295	295	O	,
42	297	308	U-UNK	barbiturates
43	309	309	O	,
44	311	319	U-UNK	phenytoin
45	321	321	O	,
46	323	325	O	and
47	327	330	O	such
48	332	333	O	an
49	335	340	O	effect
50	342	344	O	may
51	346	347	O	be
52	349	359	O	anticipated
53	361	364	O	with
54	366	368	U-UNK	CMI
55	370	371	O	as
56	373	376	O	well
NULL

Clomipramine	DDI-DrugBank.d238.s7	NO_SECTION	NO_SETID	17
Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly.
1	0	13	O	Administration
2	15	16	O	of
3	18	20	U-UNK	CMI
4	22	24	O	has
5	26	29	O	been
6	31	38	O	reported
7	40	41	O	to
8	43	50	O	increase
9	52	54	O	the
10	56	61	O	plasma
11	63	68	O	levels
12	70	71	O	of
13	73	85	U-UNK	phenobarbital
14	86	86	O	,
15	88	89	O	if
16	91	95	O	given
17	97	109	O	concomitantly
NULL

Clomipramine	DDI-DrugBank.d238.s8	NO_SECTION	NO_SETID	38
Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the aucasian population (about 7%-10% of Caucasians are so-called poor metabolizers);
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	24	O	P450
5	26	28	O	2D6
6	29	29	O	:
7	31	33	O	The
8	35	45	O	biochemical
9	47	54	O	activity
10	56	57	O	of
11	59	61	O	the
12	63	66	O	drug
13	68	79	O	metabolizing
14	81	87	O	isozyme
15	89	98	O	cytochrome
16	100	103	O	P450
17	105	107	O	2D6
18	110	120	O	debrisoquin
19	122	132	O	hydroxylase
20	135	136	O	is
21	138	144	O	reduced
22	146	147	O	in
23	149	149	O	a
24	151	156	O	subset
25	158	159	O	of
26	161	163	O	the
27	165	172	O	aucasian
28	174	183	O	population
29	186	190	O	about
30	192	193	O	7%
31	195	197	O	10%
32	199	200	O	of
33	202	211	O	Caucasians
34	213	215	O	are
35	217	218	O	so
36	220	225	O	called
37	227	230	O	poor
38	232	243	O	metabolizers
NULL

Clomipramine	DDI-DrugBank.d238.s9	NO_SECTION	NO_SETID	22
reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
1	0	7	O	reliable
2	9	17	O	estimates
3	19	20	O	of
4	22	24	O	the
5	26	35	O	prevalence
6	37	38	O	of
7	40	46	O	reduced
8	48	51	O	P450
9	53	55	O	2D6
10	57	63	O	isozyme
11	65	72	O	activity
12	74	78	O	among
13	80	84	O	Asian
14	85	85	O	,
15	87	93	O	African
16	95	97	O	and
17	99	103	O	other
18	105	115	O	populations
19	117	119	O	are
20	121	123	O	not
21	125	127	O	yet
22	129	137	O	available
NULL

Clomipramine	DDI-DrugBank.d238.s10	NO_SECTION	NO_SETID	16
Poor metabolizers have higher than expected lasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
1	0	3	O	Poor
2	5	16	O	metabolizers
3	18	21	O	have
4	23	28	O	higher
5	30	33	O	than
6	35	42	O	expected
7	44	48	O	lasma
8	50	63	O	concentrations
9	65	66	O	of
10	68	76	B-UNK	tricyclic
11	78	92	L-UNK	antidepressants
12	95	98	U-UNK	TCAs
13	101	104	O	when
14	106	110	O	given
15	112	116	O	usual
16	118	122	O	doses
NULL

Clomipramine	DDI-DrugBank.d238.s11	NO_SECTION	NO_SETID	32
Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).
1	0	8	O	Depending
2	10	11	O	on
3	13	15	O	the
4	17	24	O	fraction
5	26	27	O	of
6	29	32	O	drug
7	34	44	O	metabolized
8	46	47	O	by
9	49	52	O	P450
10	54	56	O	2D6
11	57	57	O	,
12	59	61	O	the
13	63	70	O	increase
14	72	73	O	in
15	75	80	O	plasma
16	82	94	O	concentration
17	96	98	O	may
18	100	101	O	be
19	103	107	O	small
20	108	108	O	,
21	110	111	O	or
22	113	117	O	quite
23	119	123	O	large
24	126	126	O	8
25	128	131	O	fold
26	133	140	O	increase
27	142	143	O	in
28	145	150	O	plasma
29	152	154	O	AUC
30	156	157	O	of
31	159	161	O	the
32	163	165	U-UNK	TCA
NULL

Clomipramine	DDI-DrugBank.d238.s12	NO_SECTION	NO_SETID	18
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	certain
5	21	25	O	drugs
6	27	33	O	inhibit
7	35	37	O	the
8	39	46	O	activity
9	48	49	O	of
10	51	54	O	this
11	56	62	O	isozyme
12	64	66	O	and
13	68	71	O	make
14	73	78	O	normal
15	80	91	O	metabolizers
16	93	100	O	resemble
17	102	105	O	poor
18	107	118	O	metabolizers
NULL

Clomipramine	DDI-DrugBank.d238.s13	NO_SECTION	NO_SETID	24
An individual who is stable on a given dose of TCAmay become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
1	0	1	O	An
2	3	12	O	individual
3	14	16	O	who
4	18	19	O	is
5	21	26	O	stable
6	28	29	O	on
7	31	31	O	a
8	33	37	O	given
9	39	42	O	dose
10	44	45	O	of
11	47	52	O	TCAmay
12	54	59	O	become
13	61	68	O	abruptly
14	70	74	O	toxic
15	76	79	O	when
16	81	85	O	given
17	87	89	O	one
18	91	92	O	of
19	94	98	O	these
20	100	109	O	inhibiting
21	111	115	O	drugs
22	117	118	O	as
23	120	130	O	concomitant
24	132	138	O	therapy
NULL

Clomipramine	DDI-DrugBank.d238.s14	NO_SECTION	NO_SETID	17
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;
1	0	2	O	The
2	4	8	O	drugs
3	10	13	O	that
4	15	21	O	inhibit
5	23	32	O	cytochrome
6	34	37	O	P450
7	39	41	O	2D6
8	43	49	O	include
9	51	54	O	some
10	56	59	O	that
11	61	63	O	are
12	65	67	O	not
13	69	79	O	metabolized
14	81	82	O	by
15	84	86	O	the
16	88	93	O	enzyme
17	96	104	U-UNK	quinidine
NULL

Clomipramine	DDI-DrugBank.d238.s15	NO_SECTION	NO_SETID	23
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
1	0	9	U-UNK	cimetidine
2	12	14	O	and
3	16	19	O	many
4	21	24	O	that
5	26	28	O	are
6	30	39	O	substrates
7	41	43	O	for
8	45	48	O	P450
9	50	52	O	2D6
10	55	58	O	many
11	60	64	O	other
12	66	80	U-UNK	antidepressants
13	81	81	O	,
14	83	96	U-UNK	phenothiazines
15	97	97	O	,
16	99	101	O	and
17	103	105	O	the
18	107	110	B-UNK	Type
19	112	113	I-UNK	1C
20	115	129	L-UNK	antiarrhythmics
21	131	141	U-UNK	propafenone
22	143	145	O	and
23	147	156	U-UNK	flecainide
NULL

Clomipramine	DDI-DrugBank.d238.s16	NO_SECTION	NO_SETID	32
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
1	0	4	O	While
2	6	8	O	all
3	10	12	O	the
4	14	22	B-UNK	selective
5	24	32	I-UNK	serotonin
6	34	41	I-UNK	reuptake
7	43	52	L-UNK	inhibitors
8	55	59	U-UNK	SSRIs
9	61	61	O	,
10	63	65	O	e.g
11	67	67	O	,
12	69	78	U-UNK	fluoxetine
13	79	79	O	,
14	81	90	U-UNK	sertraline
15	91	91	O	,
16	93	102	U-UNK	paroxetine
17	103	103	O	,
18	105	107	O	and
19	109	119	U-UNK	fluvoxamine
20	120	120	O	,
21	122	128	O	inhibit
22	130	133	O	P450
23	135	137	O	2D6
24	138	138	O	,
25	140	143	O	they
26	145	147	O	may
27	149	152	O	vary
28	154	155	O	in
29	157	159	O	the
30	161	166	O	extent
31	168	169	O	of
32	171	180	O	inhibition
NULL

Clomipramine	DDI-DrugBank.d238.s17	NO_SECTION	NO_SETID	16
Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCAmetabolism.
1	0	10	U-UNK	Fluvoxamine
2	12	14	O	has
3	16	19	O	also
4	21	24	O	been
5	26	30	O	shown
6	32	33	O	to
7	35	41	O	inhibit
8	43	46	O	P450
9	48	50	O	1A2
10	51	51	O	,
11	53	54	O	an
12	56	62	O	isoform
13	64	67	O	also
14	69	76	O	involved
15	78	79	O	in
16	81	93	O	TCAmetabolism
NULL

Clomipramine	DDI-DrugBank.d238.s18	NO_SECTION	NO_SETID	24
The extent to which SSRI-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	to
4	14	18	O	which
5	20	23	U-UNK	SSRI
6	25	39	O	TCAinteractions
7	41	43	O	may
8	45	48	O	pose
9	50	57	O	clinical
10	59	66	O	problems
11	68	71	O	will
12	73	78	O	depend
13	80	81	O	on
14	83	85	O	the
15	87	92	O	degree
16	94	95	O	of
17	97	106	O	inhibition
18	108	110	O	and
19	112	114	O	the
20	116	131	O	pharmacokinetics
21	133	134	O	of
22	136	138	O	the
23	140	143	U-UNK	SSRI
24	145	152	O	involved
NULL

Clomipramine	DDI-DrugBank.d238.s19	NO_SECTION	NO_SETID	26
Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	O	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	43	O	co
9	45	58	O	administration
10	60	61	O	of
11	63	66	U-UNK	TCAs
12	68	71	O	with
13	73	75	O	any
14	77	78	O	of
15	80	82	O	the
16	84	88	U-UNK	SSRIs
17	90	92	O	and
18	94	97	O	also
19	99	100	O	in
20	102	110	O	switching
21	112	115	O	from
22	117	119	O	one
23	121	125	O	class
24	127	128	O	to
25	130	132	O	the
26	134	138	O	other
NULL

Clomipramine	DDI-DrugBank.d238.s20	NO_SECTION	NO_SETID	37
Of particular importance, sufficient time must elapse before initiating TCAtreatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
1	0	1	O	Of
2	3	12	O	particular
3	14	23	O	importance
4	24	24	O	,
5	26	35	O	sufficient
6	37	40	O	time
7	42	45	O	must
8	47	52	O	elapse
9	54	59	O	before
10	61	70	O	initiating
11	72	83	O	TCAtreatment
12	85	86	O	in
13	88	88	O	a
14	90	96	O	patient
15	98	102	O	being
16	104	112	O	withdrawn
17	114	117	O	from
18	119	128	U-UNK	fluoxetine
19	129	129	O	,
20	131	135	O	given
21	137	139	O	the
22	141	144	O	long
23	146	149	O	half
24	151	154	O	life
25	156	157	O	of
26	159	161	O	the
27	163	168	O	parent
28	170	172	O	and
29	174	179	O	active
30	181	190	O	metabolite
31	193	194	O	at
32	196	200	O	least
33	202	202	O	5
34	204	208	O	weeks
35	210	212	O	may
36	214	215	O	be
37	217	225	O	necessary
NULL

Clomipramine	DDI-DrugBank.d238.s21	NO_SECTION	NO_SETID	37
Concomitant use of agents in the tricyclic antidepressant class (which includes Anafranil) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	24	O	agents
5	26	27	O	in
6	29	31	O	the
7	33	41	B-UNK	tricyclic
8	43	56	I-UNK	antidepressant
9	58	62	L-UNK	class
10	65	69	O	which
11	71	78	O	includes
12	80	88	O	XXXXXXXX
13	91	94	O	with
14	96	100	O	drugs
15	102	105	O	that
16	107	109	O	can
17	111	117	O	inhibit
18	119	128	O	cytochrome
19	130	133	O	P450
20	135	137	O	2D6
21	139	141	O	may
22	143	149	O	require
23	151	155	O	lower
24	157	161	O	doses
25	163	166	O	than
26	168	174	O	usually
27	176	185	O	prescribed
28	187	189	O	for
29	191	196	O	either
30	198	200	O	the
31	202	210	B-UNK	tricyclic
32	212	225	I-UNK	antidepressant
33	227	231	L-UNK	agent
34	233	234	O	or
35	236	238	O	the
36	240	244	O	other
37	246	249	O	drug
NULL

Clomipramine	DDI-DrugBank.d238.s22	NO_SECTION	NO_SETID	23
Furthermore, whenever one of these drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant agent may be required.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	20	O	whenever
4	22	24	O	one
5	26	27	O	of
6	29	33	O	these
7	35	39	O	drugs
8	41	42	O	is
9	44	52	O	withdrawn
10	54	57	O	from
11	59	60	O	co
12	62	68	O	therapy
13	69	69	O	,
14	71	72	O	an
15	74	82	O	increased
16	84	87	O	dose
17	89	90	O	of
18	92	100	B-UNK	tricyclic
19	102	115	I-UNK	antidepressant
20	117	121	L-UNK	agent
21	123	125	O	may
22	127	128	O	be
23	130	137	O	required
NULL

Clomipramine	DDI-DrugBank.d238.s23	NO_SECTION	NO_SETID	39
It is desirable to monitor TCAplasma levels whenever an agent of the tricyclic antidepressant class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).
1	0	1	O	It
2	3	4	O	is
3	6	14	O	desirable
4	16	17	O	to
5	19	25	O	monitor
6	27	35	O	TCAplasma
7	37	42	O	levels
8	44	51	O	whenever
9	53	54	O	an
10	56	60	O	agent
11	62	63	O	of
12	65	67	O	the
13	69	77	B-UNK	tricyclic
14	79	92	I-UNK	antidepressant
15	94	98	L-UNK	class
16	100	108	O	including
17	110	118	O	XXXXXXXX
18	120	121	O	is
19	123	127	O	going
20	129	130	O	to
21	132	133	O	be
22	135	136	O	co
23	138	149	O	administered
24	151	154	O	with
25	156	162	O	another
26	164	167	O	drug
27	169	173	O	known
28	175	176	O	to
29	178	179	O	be
30	181	182	O	an
31	184	192	O	inhibitor
32	194	195	O	of
33	197	200	O	P450
34	202	204	O	2D6
35	207	209	O	and
36	210	210	O	/
37	211	212	O	or
38	214	217	O	P450
39	219	221	O	1A2
NULL

Clomipramine	DDI-DrugBank.d238.s24	NO_SECTION	NO_SETID	45
Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
1	0	6	O	Because
2	8	16	O	XXXXXXXX
3	18	19	O	is
4	21	26	O	highly
5	28	32	O	bound
6	34	35	O	to
7	37	41	O	serum
8	43	49	O	protein
9	50	50	O	,
10	52	54	O	the
11	56	69	O	administration
12	71	72	O	of
13	74	82	O	XXXXXXXX
14	84	85	O	to
15	87	94	O	patients
16	96	101	O	taking
17	103	107	O	other
18	109	113	O	drugs
19	115	118	O	that
20	120	122	O	are
21	124	129	O	highly
22	131	135	O	bound
23	137	138	O	to
24	140	146	O	protein
25	149	151	O	e.g
26	153	153	O	,
27	155	162	U-KIN	warfarin
28	163	163	O	,
29	165	171	U-KIN	digoxin
30	174	176	O	may
31	178	182	O	cause
32	184	185	O	an
33	187	194	O	increase
34	196	197	O	in
35	199	204	O	plasma
36	206	219	O	concentrations
37	221	222	O	of
38	224	228	O	these
39	230	234	O	drugs
40	235	235	O	,
41	237	247	O	potentially
42	249	257	O	resulting
43	259	260	O	in
44	262	268	O	adverse
45	270	276	O	effects
NULL

Clomipramine	DDI-DrugBank.d238.s25	NO_SECTION	NO_SETID	17
Conversely, adverse effects may result from displacement of protein-bound Anafranil by other highly bound drugs.
1	0	9	O	Conversely
2	10	10	O	,
3	12	18	O	adverse
4	20	26	O	effects
5	28	30	O	may
6	32	37	O	result
7	39	42	O	from
8	44	55	O	displacement
9	57	58	O	of
10	60	66	O	protein
11	68	72	O	bound
12	74	82	O	XXXXXXXX
13	84	85	O	by
14	87	91	O	other
15	93	98	O	highly
16	100	104	O	bound
17	106	110	O	drugs
NULL

Clonazepam	DDI-DrugBank.d333.s0	NO_SECTION	NO_SETID	25
Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital.
1	0	5	O	Effect
2	7	8	O	of
3	10	19	O	XXXXXXXX
4	21	22	O	on
5	24	26	O	the
6	28	43	O	Pharmacokinetics
7	45	46	O	of
8	48	52	O	Other
9	54	58	O	Drugs
10	59	59	O	:
11	61	70	O	XXXXXXXX
12	72	75	O	does
13	77	79	O	not
14	81	86	O	appear
15	88	89	O	to
16	91	95	O	alter
17	97	99	O	the
18	101	116	O	pharmacokinetics
19	118	119	O	of
20	121	129	U-UNK	phenytoin
21	130	130	O	,
22	132	144	U-UNK	carbamazepine
23	145	145	O	,
24	147	148	O	or
25	150	162	U-UNK	phenobarbital
NULL

Clonazepam	DDI-DrugBank.d333.s1	NO_SECTION	NO_SETID	14
The effect of clonazepam on the metabolism of other drugs has not been investigated.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	26	O	on
6	28	30	O	the
7	32	41	O	metabolism
8	43	44	O	of
9	46	50	O	other
10	52	56	O	drugs
11	58	60	O	has
12	62	64	O	not
13	66	69	O	been
14	71	82	O	investigated
NULL

Clonazepam	DDI-DrugBank.d333.s2	NO_SECTION	NO_SETID	29
Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.
1	0	5	O	Effect
2	7	8	O	of
3	10	14	O	Other
4	16	20	O	Drugs
5	22	23	O	on
6	25	27	O	the
7	29	44	O	Pharmacokinetics
8	46	47	O	of
9	49	58	O	XXXXXXXX
10	59	59	O	:
11	61	70	O	Literature
12	72	78	O	reports
13	80	86	O	suggest
14	88	91	O	that
15	93	102	U-UNK	ranitidine
16	103	103	O	,
17	105	106	O	an
18	108	112	O	agent
19	114	117	O	that
20	119	127	O	decreases
21	129	135	O	stomach
22	137	143	O	acidity
23	144	144	O	,
24	146	149	O	does
25	151	153	O	not
26	155	161	O	greatly
27	163	167	O	alter
28	169	178	O	XXXXXXXX
29	180	195	O	pharmacokinetics
NULL

Clonazepam	DDI-DrugBank.d333.s3	NO_SECTION	NO_SETID	63
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	in
5	14	18	O	which
6	20	22	O	the
7	24	24	O	2
8	26	27	O	mg
9	29	38	O	XXXXXXXX
10	40	45	O	orally
11	47	60	O	disintegrating
12	62	67	O	tablet
13	69	71	O	was
14	73	84	O	administered
15	86	89	O	with
16	91	93	O	and
17	95	101	O	without
18	103	115	U-KIN	propantheline
19	118	119	O	an
20	121	135	B-UNK	anticholinergic
21	137	141	L-UNK	agent
22	143	146	O	with
23	148	155	O	multiple
24	157	163	O	effects
25	165	166	O	on
26	168	170	O	the
27	172	173	O	GI
28	175	179	O	tract
29	182	183	O	to
30	185	191	O	healthy
31	193	202	O	volunteers
32	203	203	O	,
33	205	207	O	the
34	209	211	O	AUC
35	213	214	O	of
36	216	225	O	XXXXXXXX
37	227	229	O	was
38	231	233	O	10%
39	235	239	O	lower
40	241	243	O	and
41	245	247	O	the
42	249	252	O	Cmax
43	254	255	O	of
44	257	266	O	XXXXXXXX
45	268	270	O	was
46	272	274	O	20%
47	276	280	O	lower
48	282	285	O	when
49	287	289	O	the
50	291	296	O	orally
51	298	311	O	disintegrating
52	313	318	O	tablet
53	320	322	O	was
54	324	328	O	given
55	330	333	O	with
56	335	347	U-KIN	propantheline
57	349	356	O	compared
58	358	359	O	to
59	361	364	O	when
60	366	367	O	it
61	369	371	O	was
62	373	377	O	given
63	379	383	O	alone
NULL

Clonazepam	DDI-DrugBank.d333.s4	NO_SECTION	NO_SETID	8
Fluoxetine does not affect the pharmacokinetics of clonazepam.
1	0	9	U-UNK	Fluoxetine
2	11	14	O	does
3	16	18	O	not
4	20	25	O	affect
5	27	29	O	the
6	31	46	O	pharmacokinetics
7	48	49	O	of
8	51	60	O	XXXXXXXX
NULL

Clonazepam	DDI-DrugBank.d333.s5	NO_SECTION	NO_SETID	26
Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
1	0	9	O	Cytochrome
2	11	11	O	P
3	13	15	O	450
4	17	24	O	inducers
5	25	25	O	,
6	27	30	O	such
7	32	33	O	as
8	35	43	U-KIN	phenytoin
9	44	44	O	,
10	46	58	U-KIN	carbamazepine
11	60	62	O	and
12	64	76	U-KIN	phenobarbital
13	77	77	O	,
14	79	84	O	induce
15	86	95	O	XXXXXXXX
16	97	106	O	metabolism
17	107	107	O	,
18	109	115	O	causing
19	117	118	O	an
20	120	132	O	approximately
21	134	136	O	30%
22	138	145	O	decrease
23	147	148	O	in
24	150	155	O	plasma
25	157	166	O	XXXXXXXX
26	168	173	O	levels
NULL

Clonazepam	DDI-DrugBank.d333.s6	NO_SECTION	NO_SETID	42
Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving clonazepam.
1	0	7	O	Although
2	9	16	O	clinical
3	18	24	O	studies
4	26	29	O	have
5	31	33	O	not
6	35	38	O	been
7	40	48	O	performed
8	49	49	O	,
9	51	55	O	based
10	57	58	O	on
11	60	62	O	the
12	64	74	O	involvement
13	76	77	O	of
14	79	81	O	the
15	83	92	O	cytochrome
16	94	94	O	P
17	96	98	O	450
18	100	101	O	3A
19	103	108	O	family
20	110	111	O	in
21	113	122	O	XXXXXXXX
22	124	133	O	metabolism
23	134	134	O	,
24	136	145	O	inhibitors
25	147	148	O	of
26	150	153	O	this
27	155	160	O	enzyme
28	162	167	O	system
29	168	168	O	,
30	170	176	O	notably
31	178	181	O	oral
32	183	192	B-DYN	antifungal
33	194	199	L-DYN	agents
34	200	200	O	,
35	202	207	O	should
36	209	210	O	be
37	212	215	O	used
38	217	226	O	cautiously
39	228	229	O	in
40	231	238	O	patients
41	240	248	O	receiving
42	250	259	O	XXXXXXXX
NULL

Clonazepam	DDI-DrugBank.d333.s7	NO_SECTION	NO_SETID	53
Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
1	0	14	O	Pharmacodynamic
2	16	27	O	Interactions
3	28	28	O	:
4	30	32	O	The
5	34	36	O	CNS
6	38	47	O	depressant
7	49	54	O	action
8	56	57	O	of
9	59	61	O	the
10	63	76	B-UNK	benzodiazepine
11	78	82	L-UNK	class
12	84	85	O	of
13	87	91	O	drugs
14	93	95	O	may
15	97	98	O	be
16	100	110	O	potentiated
17	112	113	O	by
18	115	121	U-UNK	alcohol
19	122	122	O	,
20	124	132	U-UNK	narcotics
21	133	133	O	,
22	135	146	U-UNK	barbiturates
23	147	147	O	,
24	149	162	B-UNK	nonbarbiturate
25	164	172	L-UNK	hypnotics
26	173	173	O	,
27	175	185	B-UNK	antianxiety
28	187	192	L-UNK	agents
29	193	193	O	,
30	195	197	O	the
31	199	212	B-UNK	phenothiazines
32	213	213	I-UNK	,
33	215	226	I-UNK	thioxanthene
34	228	230	I-UNK	and
35	232	244	I-UNK	butyrophenone
36	246	252	I-UNK	classes
37	254	255	I-UNK	of
38	257	269	I-UNK	antipsychotic
39	271	276	L-UNK	agents
40	277	277	O	,
41	279	287	B-UNK	monoamine
42	289	295	I-UNK	oxidase
43	297	306	L-UNK	inhibitors
44	308	310	O	and
45	312	314	O	the
46	316	324	B-UNK	tricyclic
47	326	340	L-UNK	antidepressants
48	341	341	O	,
49	343	345	O	and
50	347	348	O	by
51	350	354	O	other
52	356	369	B-UNK	anticonvulsant
53	371	375	L-UNK	drugs
NULL

Clonidine	DDI-DrugBank.d495.s0	NO_SECTION	NO_SETID	27
Tablet If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the effect of clonidine may be reduced, thus necessitating an increase in dosage.
1	0	5	O	Tablet
2	7	8	O	If
3	10	10	O	a
4	12	18	O	patient
5	20	28	O	receiving
6	30	38	O	XXXXXXXX
7	40	52	O	hydrochloride
8	54	55	O	is
9	57	60	O	also
10	62	67	O	taking
11	69	77	B-DYN	tricyclic
12	79	93	L-DYN	antidepressants
13	94	94	O	,
14	96	98	O	the
15	100	105	O	effect
16	107	108	O	of
17	110	118	O	XXXXXXXX
18	120	122	O	may
19	124	125	O	be
20	127	133	O	reduced
21	134	134	O	,
22	136	139	O	thus
23	141	153	O	necessitating
24	155	156	O	an
25	158	165	O	increase
26	167	168	O	in
27	170	175	O	dosage
NULL

Clonidine	DDI-DrugBank.d495.s1	NO_SECTION	NO_SETID	15
Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.
1	0	8	O	XXXXXXXX
2	10	22	O	hydrochloride
3	24	26	O	may
4	28	34	O	enhance
5	36	38	O	the
6	40	42	O	CNS
7	44	53	O	depressive
8	55	61	O	effects
9	63	64	O	of
10	66	72	U-DYN	alcohol
11	73	73	O	,
12	75	86	U-DYN	barbiturates
13	88	89	O	or
14	91	95	O	other
15	97	105	U-DYN	sedatives
NULL

Clonidine	DDI-DrugBank.d495.s2	NO_SECTION	NO_SETID	30
Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
1	0	12	U-DYN	Amitriptyline
2	14	15	O	in
3	17	27	O	combination
4	29	32	O	with
5	34	42	O	XXXXXXXX
6	44	51	O	enhances
7	53	55	O	the
8	57	69	O	manifestation
9	71	72	O	of
10	74	80	O	corneal
11	82	88	O	lesions
12	90	91	O	in
13	93	96	O	rats
14	98	105	O	Epidural
15	107	115	O	Injection
16	117	125	O	XXXXXXXX
17	127	129	O	may
18	131	140	O	potentiate
19	142	144	O	the
20	146	148	O	CNS
21	150	159	O	depressive
22	161	166	O	effect
23	168	169	O	of
24	171	177	U-DYN	alcohol
25	178	178	O	,
26	180	191	U-DYN	barbiturates
27	193	194	O	or
28	196	200	O	other
29	202	209	B-DYN	sedating
30	211	215	L-DYN	drugs
NULL

Clonidine	DDI-DrugBank.d495.s3	NO_SECTION	NO_SETID	9
Narcotic analgesics may potentiate the hypotensive effects of clonidine.
1	0	7	B-DYN	Narcotic
2	9	18	L-DYN	analgesics
3	20	22	O	may
4	24	33	O	potentiate
5	35	37	O	the
6	39	49	O	hypotensive
7	51	57	O	effects
8	59	60	O	of
9	62	70	O	XXXXXXXX
NULL

Clonidine	DDI-DrugBank.d495.s4	NO_SECTION	NO_SETID	9
Tricyclic antidepressants may antagonize the hypotensive effects of clonidine.
1	0	8	B-DYN	Tricyclic
2	10	24	L-DYN	antidepressants
3	26	28	O	may
4	30	39	O	antagonize
5	41	43	O	the
6	45	55	O	hypotensive
7	57	63	O	effects
8	65	66	O	of
9	68	76	O	XXXXXXXX
NULL

Clonidine	DDI-DrugBank.d495.s5	NO_SECTION	NO_SETID	13
The effects of tricyclic antidepressants on clonidines analgesic actions are not known.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	23	B-UNK	tricyclic
5	25	39	L-UNK	antidepressants
6	41	42	O	on
7	44	52	O	XXXXXXXX
8	53	53	O	s
9	55	63	O	analgesic
10	65	71	O	actions
11	73	75	O	are
12	77	79	O	not
13	81	85	O	known
NULL

Clonidine	DDI-DrugBank.d495.s6	NO_SECTION	NO_SETID	11
Beta blockers may exacerbate the hypertensive response seen with clonidine withdrawl.
1	0	3	B-DYN	Beta
2	5	12	L-DYN	blockers
3	14	16	O	may
4	18	27	O	exacerbate
5	29	31	O	the
6	33	44	O	hypertensive
7	46	53	O	response
8	55	58	O	seen
9	60	63	O	with
10	65	73	O	XXXXXXXX
11	75	83	O	withdrawl
NULL

Clonidine	DDI-DrugBank.d495.s7	NO_SECTION	NO_SETID	46
Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)
1	0	3	O	Also
2	4	4	O	,
3	6	8	O	due
4	10	11	O	to
5	13	15	O	the
6	17	25	O	potential
7	27	29	O	for
8	31	38	O	additive
9	40	46	O	effects
10	48	51	O	such
11	53	54	O	as
12	56	66	O	bradycardia
13	68	70	O	and
14	72	73	O	AV
15	75	79	O	block
16	80	80	O	,
17	82	88	O	caution
18	90	91	O	is
19	93	101	O	warranted
20	103	104	O	in
21	106	113	O	patients
22	115	123	O	receiving
23	125	133	O	XXXXXXXX
24	135	138	O	with
25	140	145	O	agents
26	147	151	O	known
27	153	154	O	to
28	156	161	O	affect
29	163	167	O	sinus
30	169	172	O	node
31	174	181	O	function
32	183	184	O	or
33	186	187	O	AV
34	189	193	O	nodal
35	195	204	O	conduction
36	207	209	O	e.g
37	211	211	O	,
38	213	221	U-DYN	digitalis
39	222	222	O	,
40	224	230	B-DYN	calcium
41	232	238	I-DYN	channel
42	240	247	L-DYN	blockers
43	248	248	O	,
44	250	252	O	and
45	254	257	B-DYN	beta
46	259	266	L-DYN	blockers
NULL

Clonidine	DDI-DrugBank.d495.s8	NO_SECTION	NO_SETID	21
There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.
1	0	4	O	There
2	6	7	O	is
3	9	11	O	one
4	13	20	O	reported
5	22	25	O	case
6	27	28	O	of
7	30	30	O	a
8	32	38	O	patient
9	40	43	O	with
10	45	49	O	acute
11	51	58	O	delirium
12	60	69	O	associated
13	71	74	O	with
14	76	78	O	the
15	80	91	O	simultaneous
16	93	95	O	use
17	97	98	O	of
18	100	111	U-DYN	fluphenazine
19	113	115	O	and
20	117	120	O	oral
21	122	130	O	XXXXXXXX
NULL

Clonidine	DDI-DrugBank.d495.s9	NO_SECTION	NO_SETID	15
Symptoms resolved when clonidine was withdrawn and recurred when the patient was rechallenged with clonidine.
1	0	7	O	Symptoms
2	9	16	O	resolved
3	18	21	O	when
4	23	31	O	XXXXXXXX
5	33	35	O	was
6	37	45	O	withdrawn
7	47	49	O	and
8	51	58	O	recurred
9	60	63	O	when
10	65	67	O	the
11	69	75	O	patient
12	77	79	O	was
13	81	92	O	rechallenged
14	94	97	O	with
15	99	107	O	XXXXXXXX
NULL

Clonidine	DDI-DrugBank.d495.s10	NO_SECTION	NO_SETID	20
Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including both sensory and motor blockade.
1	0	7	O	Epidural
2	9	17	O	XXXXXXXX
3	19	21	O	may
4	23	29	O	prolong
5	31	33	O	the
6	35	42	O	duration
7	44	45	O	of
8	47	59	O	pharmacologic
9	61	67	O	effects
10	69	70	O	of
11	72	79	O	epidural
12	81	85	O	local
13	87	97	U-DYN	anesthetics
14	98	98	O	,
15	100	108	O	including
16	110	113	O	both
17	115	121	O	sensory
18	123	125	O	and
19	127	131	O	motor
20	133	140	O	blockade
NULL

Clopidogrel	DDI-DrugBank.d343.s0	NO_SECTION	NO_SETID	7
Aspirin, warfarin, heparin, NSAIDs
1	0	6	O	XXXXXXXX
2	7	7	O	,
3	9	16	U-UNK	warfarin
4	17	17	O	,
5	19	25	U-UNK	heparin
6	26	26	O	,
7	28	33	U-UNK	NSAIDs
NULL

Clorazepate	DDI-DrugBank.d335.s0	NO_SECTION	NO_SETID	30
If TRANXENE is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed.
1	0	1	O	If
2	3	10	O	XXXXXXXX
3	12	13	O	is
4	15	16	O	to
5	18	19	O	be
6	21	28	O	combined
7	30	33	O	with
8	35	39	O	other
9	41	45	O	drugs
10	47	52	O	acting
11	54	55	O	on
12	57	59	O	the
13	61	67	O	central
14	69	75	O	nervous
15	77	82	O	system
16	83	83	O	,
17	85	91	O	careful
18	93	105	O	consideration
19	107	112	O	should
20	114	115	O	be
21	117	121	O	given
22	123	124	O	to
23	126	128	O	the
24	130	141	O	pharmacology
25	143	144	O	of
26	146	148	O	the
27	150	155	O	agents
28	157	158	O	to
29	160	161	O	be
30	163	170	O	employed
NULL

Clorazepate	DDI-DrugBank.d335.s1	NO_SECTION	NO_SETID	31
Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.
1	0	5	O	Animal
2	7	16	O	experience
3	18	26	O	indicates
4	28	31	O	that
5	33	43	O	XXXXXXXX
6	45	55	O	dipotassium
7	57	64	O	prolongs
8	66	68	O	the
9	70	77	O	sleeping
10	79	82	O	time
11	84	88	O	after
12	90	101	U-DYN	hexobarbital
13	103	104	O	or
14	106	110	O	after
15	112	116	B-DYN	ethyl
16	118	124	L-DYN	alcohol
17	125	125	O	,
18	127	135	O	increases
19	137	139	O	the
20	141	150	O	inhibitory
21	152	158	O	effects
22	160	161	O	of
23	163	176	U-DYN	chlorpromazine
24	177	177	O	,
25	179	181	O	but
26	183	186	O	does
27	188	190	O	not
28	192	198	O	exhibit
29	200	208	O	monoamine
30	210	216	O	oxidase
31	218	227	O	inhibition
NULL

Clorazepate	DDI-DrugBank.d335.s2	NO_SECTION	NO_SETID	10
Clinical studies have shown increased sedation with concurrent hypnotic medications.
1	0	7	O	Clinical
2	9	15	O	studies
3	17	20	O	have
4	22	26	O	shown
5	28	36	O	increased
6	38	45	O	sedation
7	47	50	O	with
8	52	61	O	concurrent
9	63	70	B-UNK	hypnotic
10	72	82	L-UNK	medications
NULL

Clorazepate	DDI-DrugBank.d335.s3	NO_SECTION	NO_SETID	21
The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
1	0	2	O	The
2	4	10	O	actions
3	12	13	O	of
4	15	17	O	the
5	19	33	U-UNK	benzodiazepines
6	35	37	O	may
7	39	40	O	be
8	42	52	O	potentiated
9	54	55	O	by
10	57	68	U-UNK	barbiturates
11	69	69	O	,
12	71	79	U-UNK	narcotics
13	80	80	O	,
14	82	95	U-UNK	phenothiazines
15	96	96	O	,
16	98	106	B-UNK	monoamine
17	108	114	I-UNK	oxidase
18	116	125	L-UNK	inhibitors
19	127	128	O	or
20	130	134	O	other
21	136	150	U-UNK	antidepressants
NULL

Clorazepate	DDI-DrugBank.d335.s4	NO_SECTION	NO_SETID	26
If TRANXENE tablets are used to treat anxiety associated with somatic disease states, careful attention must be paid to possible drug interaction with concomitant medication.
1	0	1	O	If
2	3	10	O	XXXXXXXX
3	12	18	O	tablets
4	20	22	O	are
5	24	27	O	used
6	29	30	O	to
7	32	36	O	treat
8	38	44	O	anxiety
9	46	55	O	associated
10	57	60	O	with
11	62	68	O	somatic
12	70	76	O	disease
13	78	83	O	states
14	84	84	O	,
15	86	92	O	careful
16	94	102	O	attention
17	104	107	O	must
18	109	110	O	be
19	112	115	O	paid
20	117	118	O	to
21	120	127	O	possible
22	129	132	O	drug
23	134	144	O	interaction
24	146	149	O	with
25	151	161	O	concomitant
26	163	172	O	medication
NULL

Clorazepate	DDI-DrugBank.d335.s5	NO_SECTION	NO_SETID	24
In bioavailability studies with normal subjects, the concurrent administration of antacids at therapeutic levels did not significantly influence the bioavailability of TRANXENE tablets.
1	0	1	O	In
2	3	17	O	bioavailability
3	19	25	O	studies
4	27	30	O	with
5	32	37	O	normal
6	39	46	O	subjects
7	47	47	O	,
8	49	51	O	the
9	53	62	O	concurrent
10	64	77	O	administration
11	79	80	O	of
12	82	89	U-UNK	antacids
13	91	92	O	at
14	94	104	O	therapeutic
15	106	111	O	levels
16	113	115	O	did
17	117	119	O	not
18	121	133	O	significantly
19	135	143	O	influence
20	145	147	O	the
21	149	163	O	bioavailability
22	165	166	O	of
23	168	175	O	XXXXXXXX
24	177	183	O	tablets
NULL

Clozapine	DDI-DrugBank.d480.s0	NO_SECTION	NO_SETID	15
The risks of using Clozapine in combination with other drugs have not been systematically evaluated.
1	0	2	O	The
2	4	8	O	risks
3	10	11	O	of
4	13	17	O	using
5	19	27	O	XXXXXXXX
6	29	30	O	in
7	32	42	O	combination
8	44	47	O	with
9	49	53	O	other
10	55	59	O	drugs
11	61	64	O	have
12	66	68	O	not
13	70	73	O	been
14	75	88	O	systematically
15	90	98	O	evaluated
NULL

Clozapine	DDI-DrugBank.d480.s1	NO_SECTION	NO_SETID	12
Pharmacodynamic-related Interactions: The mechanism of Clozapine induced agranulocytosis is unknown;
1	0	14	O	Pharmacodynamic
2	16	22	O	related
3	24	35	O	Interactions
4	36	36	O	:
5	38	40	O	The
6	42	50	O	mechanism
7	52	53	O	of
8	55	63	O	XXXXXXXX
9	65	71	O	induced
10	73	87	O	agranulocytosis
11	89	90	O	is
12	92	98	O	unknown
NULL

Clozapine	DDI-DrugBank.d480.s2	NO_SECTION	NO_SETID	24
nonetheless, the possibility that causative factors may interact synergistically to increase the risk and/or severity of bone marrow suppression warrants consideration.
1	0	10	O	nonetheless
2	11	11	O	,
3	13	15	O	the
4	17	27	O	possibility
5	29	32	O	that
6	34	42	O	causative
7	44	50	O	factors
8	52	54	O	may
9	56	63	O	interact
10	65	79	O	synergistically
11	81	82	O	to
12	84	91	O	increase
13	93	95	O	the
14	97	100	O	risk
15	102	104	O	and
16	105	105	O	/
17	106	107	O	or
18	109	116	O	severity
19	118	119	O	of
20	121	124	O	bone
21	126	131	O	marrow
22	133	143	O	suppression
23	145	152	O	warrants
24	154	166	O	consideration
NULL

Clozapine	DDI-DrugBank.d480.s3	NO_SECTION	NO_SETID	20
Therefore, Clozapine should not be used with other agents having a well-known potential to suppress bone marrow function.
1	0	8	O	Therefore
2	9	9	O	,
3	11	19	O	XXXXXXXX
4	21	26	O	should
5	28	30	O	not
6	32	33	O	be
7	35	38	O	used
8	40	43	O	with
9	45	49	O	other
10	51	56	O	agents
11	58	63	O	having
12	65	65	O	a
13	67	70	O	well
14	72	76	O	known
15	78	86	O	potential
16	88	89	O	to
17	91	98	O	suppress
18	100	103	O	bone
19	105	110	O	marrow
20	112	119	O	function
NULL

Clozapine	DDI-DrugBank.d480.s4	NO_SECTION	NO_SETID	22
Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.
1	0	4	O	Given
2	6	8	O	the
3	10	16	O	primary
4	18	20	O	CNS
5	22	28	O	effects
6	30	31	O	of
7	33	41	O	XXXXXXXX
8	42	42	O	,
9	44	50	O	caution
10	52	53	O	is
11	55	61	O	advised
12	63	64	O	in
13	66	70	O	using
14	72	73	O	it
15	75	87	O	concomitantly
16	89	92	O	with
17	94	98	O	other
18	100	102	O	CNS
19	104	109	O	active
20	111	115	O	drugs
21	117	118	O	or
22	120	126	U-DYN	alcohol
NULL

Clozapine	DDI-DrugBank.d480.s5	NO_SECTION	NO_SETID	30
Orthostatic hypotension in patients taking clozapine can, in rare cases (approximately 1 case per 3,000 patients), be accompanied by profound collapse and respiratory and/or cardiac arrest.
1	0	10	O	Orthostatic
2	12	22	O	hypotension
3	24	25	O	in
4	27	34	O	patients
5	36	41	O	taking
6	43	51	O	XXXXXXXX
7	53	55	O	can
8	56	56	O	,
9	58	59	O	in
10	61	64	O	rare
11	66	70	O	cases
12	73	85	O	approximately
13	87	87	O	1
14	89	92	O	case
15	94	96	O	per
16	98	102	O	3,000
17	104	111	O	patients
18	113	113	O	,
19	115	116	O	be
20	118	128	O	accompanied
21	130	131	O	by
22	133	140	O	profound
23	142	149	O	collapse
24	151	153	O	and
25	155	165	O	respiratory
26	167	169	O	and
27	170	170	O	/
28	171	172	O	or
29	174	180	O	cardiac
30	182	187	O	arrest
NULL

Clozapine	DDI-DrugBank.d480.s6	NO_SECTION	NO_SETID	23
Some of the cases of collapse/respiratory arrest/cardiac arrest during initial treatment occurred in patients who were being administered benzodiazepines;
1	0	3	O	Some
2	5	6	O	of
3	8	10	O	the
4	12	16	O	cases
5	18	19	O	of
6	21	28	O	collapse
7	29	29	O	/
8	30	40	O	respiratory
9	42	47	O	arrest
10	48	48	O	/
11	49	55	O	cardiac
12	57	62	O	arrest
13	64	69	O	during
14	71	77	O	initial
15	79	87	O	treatment
16	89	96	O	occurred
17	98	99	O	in
18	101	108	O	patients
19	110	112	O	who
20	114	117	O	were
21	119	123	O	being
22	125	136	O	administered
23	138	152	U-UNK	benzodiazepines
NULL

Clozapine	DDI-DrugBank.d480.s7	NO_SECTION	NO_SETID	16
similar events have been reported in patients taking other psychotropic drugs or even Clozapine by itself.
1	0	6	O	similar
2	8	13	O	events
3	15	18	O	have
4	20	23	O	been
5	25	32	O	reported
6	34	35	O	in
7	37	44	O	patients
8	46	51	O	taking
9	53	57	O	other
10	59	70	B-UNK	psychotropic
11	72	76	L-UNK	drugs
12	78	79	O	or
13	81	84	O	even
14	86	94	O	XXXXXXXX
15	96	97	O	by
16	99	104	O	itself
NULL

Clozapine	DDI-DrugBank.d480.s8	NO_SECTION	NO_SETID	36
Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.
1	0	7	O	Although
2	9	10	O	it
3	12	14	O	has
4	16	18	O	not
5	20	23	O	been
6	25	35	O	established
7	37	40	O	that
8	42	46	O	there
9	48	49	O	is
10	51	52	O	an
11	54	64	O	interaction
12	66	72	O	between
13	74	82	O	XXXXXXXX
14	84	86	O	and
15	88	102	U-UNK	benzodiazepines
16	104	105	O	or
17	107	111	O	other
18	113	125	U-UNK	psychotropics
19	126	126	O	,
20	128	134	O	caution
21	136	137	O	is
22	139	145	O	advised
23	147	150	O	when
24	152	160	O	XXXXXXXX
25	162	163	O	is
26	165	173	O	initiated
27	175	176	O	in
28	178	185	O	patients
29	187	192	O	taking
30	194	194	O	a
31	196	209	U-DYN	benzodiazepine
32	211	212	O	or
33	214	216	O	any
34	218	222	O	other
35	224	235	B-DYN	psychotropic
36	237	240	L-DYN	drug
NULL

Clozapine	DDI-DrugBank.d480.s9	NO_SECTION	NO_SETID	17
Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.
1	0	8	O	XXXXXXXX
2	10	12	O	may
3	14	23	O	potentiate
4	25	27	O	the
5	29	39	O	hypotensive
6	41	47	O	effects
7	49	50	O	of
8	52	67	B-DYN	antihypertensive
9	69	73	L-DYN	drugs
10	75	77	O	and
11	79	81	O	the
12	83	97	O	anticholinergic
13	99	105	O	effects
14	107	108	O	of
15	110	117	U-DYN	atropine
16	119	122	O	type
17	124	128	O	drugs
NULL

Clozapine	DDI-DrugBank.d480.s10	NO_SECTION	NO_SETID	21
The administration of epinephrine should be avoided in the treatment of drug induced hypotension because of a possible reverse epinephrine effect.
1	0	2	O	The
2	4	17	O	administration
3	19	20	O	of
4	22	32	U-UNK	epinephrine
5	34	39	O	should
6	41	42	O	be
7	44	50	O	avoided
8	52	53	O	in
9	55	57	O	the
10	59	67	O	treatment
11	69	70	O	of
12	72	75	O	drug
13	77	83	O	induced
14	85	95	O	hypotension
15	97	103	O	because
16	105	106	O	of
17	108	108	O	a
18	110	117	O	possible
19	119	125	O	reverse
20	127	137	U-UNK	epinephrine
21	139	144	O	effect
NULL

Clozapine	DDI-DrugBank.d480.s11	NO_SECTION	NO_SETID	22
Pharmacokinetic-related Interactions: Clozapine is a substrate for many CYP 450 isozymes, in particular 1A2, 2D6, and 3A4.
1	0	14	O	Pharmacokinetic
2	16	22	O	related
3	24	35	O	Interactions
4	36	36	O	:
5	38	46	O	XXXXXXXX
6	48	49	O	is
7	51	51	O	a
8	53	61	O	substrate
9	63	65	O	for
10	67	70	O	many
11	72	74	O	CYP
12	76	78	O	450
13	80	87	O	isozymes
14	88	88	O	,
15	90	91	O	in
16	93	102	O	particular
17	104	106	O	1A2
18	107	107	O	,
19	109	111	O	2D6
20	112	112	O	,
21	114	116	O	and
22	118	120	O	3A4
NULL

Clozapine	DDI-DrugBank.d480.s12	NO_SECTION	NO_SETID	16
The risk of metabolic interactions caused by an effect on an individual isoform is therefore minimized.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	20	O	metabolic
5	22	33	O	interactions
6	35	40	O	caused
7	42	43	O	by
8	45	46	O	an
9	48	53	O	effect
10	55	56	O	on
11	58	59	O	an
12	61	70	O	individual
13	72	78	O	isoform
14	80	81	O	is
15	83	91	O	therefore
16	93	101	O	minimized
NULL

Clozapine	DDI-DrugBank.d480.s13	NO_SECTION	NO_SETID	23
Nevertheless, caution should be used in patients receiving concomitant treatment with other drugs that are either inhibitors or inducers of these enzymes.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	O	caution
4	22	27	O	should
5	29	30	O	be
6	32	35	O	used
7	37	38	O	in
8	40	47	O	patients
9	49	57	O	receiving
10	59	69	O	concomitant
11	71	79	O	treatment
12	81	84	O	with
13	86	90	O	other
14	92	96	O	drugs
15	98	101	O	that
16	103	105	O	are
17	107	112	O	either
18	114	123	O	inhibitors
19	125	126	O	or
20	128	135	O	inducers
21	137	138	O	of
22	140	144	O	these
23	146	152	O	enzymes
NULL

Clozapine	DDI-DrugBank.d480.s14	NO_SECTION	NO_SETID	17
Concomitant administration of drugs known to induce cytochrome P450 enzymes may decrease the plasma levels of clozapine.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	34	O	drugs
5	36	40	O	known
6	42	43	O	to
7	45	50	O	induce
8	52	61	O	cytochrome
9	63	66	O	P450
10	68	74	O	enzymes
11	76	78	O	may
12	80	87	O	decrease
13	89	91	O	the
14	93	98	O	plasma
15	100	105	O	levels
16	107	108	O	of
17	110	118	O	XXXXXXXX
NULL

Clozapine	DDI-DrugBank.d480.s15	NO_SECTION	NO_SETID	24
Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
1	0	8	U-KIN	Phenytoin
2	9	9	O	,
3	11	18	U-KIN	nicotine
4	19	19	O	,
5	21	23	O	and
6	25	32	U-KIN	rifampin
7	34	36	O	may
8	38	45	O	decrease
9	47	55	O	XXXXXXXX
10	57	62	O	plasma
11	64	69	O	levels
12	70	70	O	,
13	72	80	O	resulting
14	82	83	O	in
15	85	85	O	a
16	87	94	O	decrease
17	96	97	O	in
18	99	111	O	effectiveness
19	113	114	O	of
20	116	116	O	a
21	118	127	O	previously
22	129	137	O	effective
23	139	147	O	XXXXXXXX
24	149	152	O	dose
NULL

Clozapine	DDI-DrugBank.d480.s16	NO_SECTION	NO_SETID	20
Concomitant administration of drugs known to inhibit the activity of cytochrome P450 isozymes may increase the plasma levels of clozapine.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	34	O	drugs
5	36	40	O	known
6	42	43	O	to
7	45	51	O	inhibit
8	53	55	O	the
9	57	64	O	activity
10	66	67	O	of
11	69	78	O	cytochrome
12	80	83	O	P450
13	85	92	O	isozymes
14	94	96	O	may
15	98	105	O	increase
16	107	109	O	the
17	111	116	O	plasma
18	118	123	O	levels
19	125	126	O	of
20	128	136	O	XXXXXXXX
NULL

Clozapine	DDI-DrugBank.d480.s17	NO_SECTION	NO_SETID	18
Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.
1	0	9	U-KIN	Cimetidine
2	10	10	O	,
3	12	19	U-KIN	caffeine
4	20	20	O	,
5	22	24	O	and
6	26	37	U-KIN	erythromycin
7	39	41	O	may
8	43	50	O	increase
9	52	57	O	plasma
10	59	64	O	levels
11	66	67	O	of
12	69	77	O	XXXXXXXX
13	78	78	O	,
14	80	90	O	potentially
15	92	100	O	resulting
16	102	103	O	in
17	105	111	O	adverse
18	113	119	O	effects
NULL

Clozapine	DDI-DrugBank.d480.s18	NO_SECTION	NO_SETID	30
Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.
1	0	7	O	Although
2	9	19	O	concomitant
3	21	23	O	use
4	25	26	O	of
5	28	36	O	XXXXXXXX
6	38	40	O	and
7	42	54	U-DYN	carbamazepine
8	56	57	O	is
9	59	61	O	not
10	63	73	O	recommended
11	74	74	O	,
12	76	77	O	it
13	79	84	O	should
14	86	87	O	be
15	89	93	O	noted
16	95	98	O	that
17	100	114	O	discontinuation
18	116	117	O	of
19	119	129	O	concomitant
20	131	143	U-KIN	carbamazepine
21	145	158	O	administration
22	160	162	O	may
23	164	169	O	result
24	171	172	O	in
25	174	175	O	an
26	177	184	O	increase
27	186	187	O	in
28	189	197	O	XXXXXXXX
29	199	204	O	plasma
30	206	211	O	levels
NULL

Clozapine	DDI-DrugBank.d480.s19	NO_SECTION	NO_SETID	26
In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in 16 and 14 patients, respectively.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	26	O	schizophrenic
6	28	35	O	patients
7	37	39	O	who
8	41	48	O	received
9	50	58	O	XXXXXXXX
10	60	64	O	under
11	66	71	O	steady
12	73	77	O	state
13	79	88	O	conditions
14	89	89	O	,
15	91	101	U-UNK	fluvoxamine
16	103	104	O	or
17	106	115	U-UNK	paroxetine
18	117	119	O	was
19	121	125	O	added
20	127	128	O	in
21	130	131	O	16
22	133	135	O	and
23	137	138	O	14
24	140	147	O	patients
25	148	148	O	,
26	150	161	O	respectively
NULL

Clozapine	DDI-DrugBank.d480.s20	NO_SECTION	NO_SETID	36
After 14 days of co-administration, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated with fluvoxamine by about three-fold compared to baseline concentrations.
1	0	4	O	After
2	6	7	O	14
3	9	12	O	days
4	14	15	O	of
5	17	18	O	co
6	20	33	O	administration
7	34	34	O	,
8	36	39	O	mean
9	41	46	O	trough
10	48	61	O	concentrations
11	63	64	O	of
12	66	74	O	XXXXXXXX
13	76	78	O	and
14	80	82	O	its
15	84	94	O	metabolites
16	95	95	O	,
17	97	97	O	N
18	99	107	O	desmethyl
19	108	116	O	XXXXXXXX
20	118	120	O	and
21	122	130	O	XXXXXXXX
22	132	132	O	N
23	134	138	O	oxide
24	139	139	O	,
25	141	144	O	were
26	146	153	O	elevated
27	155	158	O	with
28	160	170	U-UNK	fluvoxamine
29	172	173	O	by
30	175	179	O	about
31	181	185	O	three
32	187	190	O	fold
33	192	199	O	compared
34	201	202	O	to
35	204	211	O	baseline
36	213	226	O	concentrations
NULL

Clozapine	DDI-DrugBank.d480.s21	NO_SECTION	NO_SETID	13
Paroxetine produced only minor changes in the levels of clozapine and its metabolites.
1	0	9	U-KIN	Paroxetine
2	11	18	O	produced
3	20	23	O	only
4	25	29	O	minor
5	31	37	O	changes
6	39	40	O	in
7	42	44	O	the
8	46	51	O	levels
9	53	54	O	of
10	56	64	O	XXXXXXXX
11	66	68	O	and
12	70	72	O	its
13	74	84	O	metabolites
NULL

Clozapine	DDI-DrugBank.d480.s22	NO_SECTION	NO_SETID	28
However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	other
4	15	23	O	published
5	25	31	O	reports
6	33	40	O	describe
7	42	47	O	modest
8	49	58	O	elevations
9	61	64	O	less
10	66	69	O	than
11	71	73	O	two
12	75	78	O	fold
13	81	82	O	of
14	84	92	O	XXXXXXXX
15	94	96	O	and
16	98	107	O	metabolite
17	109	122	O	concentrations
18	124	127	O	when
19	129	137	O	XXXXXXXX
20	139	141	O	was
21	143	147	O	taken
22	149	152	O	with
23	154	163	U-KIN	paroxetine
24	164	164	O	,
25	166	175	U-KIN	fluoxetine
26	176	176	O	,
27	178	180	O	and
28	182	191	U-KIN	sertraline
NULL

Clozapine	DDI-DrugBank.d480.s23	NO_SECTION	NO_SETID	27
Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	such
4	16	23	O	combined
5	25	33	O	treatment
6	35	40	O	should
7	42	43	O	be
8	45	54	O	approached
9	56	59	O	with
10	61	67	O	caution
11	69	71	O	and
12	73	80	O	patients
13	82	87	O	should
14	89	90	O	be
15	92	100	O	monitored
16	102	108	O	closely
17	110	113	O	when
18	115	123	O	XXXXXXXX
19	125	126	O	is
20	128	135	O	combined
21	137	140	O	with
22	142	146	O	these
23	148	152	O	drugs
24	153	153	O	,
25	155	166	O	particularly
26	168	171	O	with
27	173	183	U-DYN	fluvoxamine
NULL

Clozapine	DDI-DrugBank.d480.s24	NO_SECTION	NO_SETID	7
A reduced Clozapine dose should be considered.
1	0	0	O	A
2	2	8	O	reduced
3	10	18	O	XXXXXXXX
4	20	23	O	dose
5	25	30	O	should
6	32	33	O	be
7	35	44	O	considered
NULL

Clozapine	DDI-DrugBank.d480.s25	NO_SECTION	NO_SETID	23
A subset (3%-10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isozyme P450 2D6.
1	0	0	O	A
2	2	7	O	subset
3	10	11	O	3%
4	13	15	O	10%
5	18	19	O	of
6	21	23	O	the
7	25	34	O	population
8	36	38	O	has
9	40	46	O	reduced
10	48	55	O	activity
11	57	58	O	of
12	60	66	O	certain
13	68	71	O	drug
14	73	84	O	metabolizing
15	86	92	O	enzymes
16	94	97	O	such
17	99	100	O	as
18	102	104	O	the
19	106	115	O	cytochrome
20	117	120	O	P450
21	122	128	O	isozyme
22	130	133	O	P450
23	135	137	O	2D6
NULL

Clozapine	DDI-DrugBank.d480.s26	NO_SECTION	NO_SETID	22
Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, the tricyclic antidepressants, and clozapine.
1	0	3	O	Such
2	5	15	O	individuals
3	17	19	O	are
4	21	28	O	referred
5	30	31	O	to
6	33	34	O	as
7	36	39	O	poor
8	41	52	O	metabolizers
9	54	55	O	of
10	57	61	O	drugs
11	63	66	O	such
12	68	69	O	as
13	71	81	U-UNK	debrisoquin
14	82	82	O	,
15	84	99	U-UNK	dextromethorphan
16	100	100	O	,
17	102	104	O	the
18	106	114	B-UNK	tricyclic
19	116	130	L-UNK	antidepressants
20	131	131	O	,
21	133	135	O	and
22	137	145	O	XXXXXXXX
NULL

Clozapine	DDI-DrugBank.d480.s27	NO_SECTION	NO_SETID	15
These individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.
1	0	4	O	These
2	6	16	O	individuals
3	18	20	O	may
4	22	28	O	develop
5	30	35	O	higher
6	37	40	O	than
7	42	49	O	expected
8	51	56	O	plasma
9	58	71	O	concentrations
10	73	74	O	of
11	76	84	O	XXXXXXXX
12	86	89	O	when
13	91	95	O	given
14	97	101	O	usual
15	103	107	O	doses
NULL

Clozapine	DDI-DrugBank.d480.s28	NO_SECTION	NO_SETID	60
In addition, certain drugs that are metabolized by this isozyme, including many antidepressants (clozapine, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isozyme, and thus may make normal metabolizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interaction.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	certain
5	21	25	O	drugs
6	27	30	O	that
7	32	34	O	are
8	36	46	O	metabolized
9	48	49	O	by
10	51	54	O	this
11	56	62	O	isozyme
12	63	63	O	,
13	65	73	O	including
14	75	78	O	many
15	80	94	U-UNK	antidepressants
16	97	105	O	XXXXXXXX
17	106	106	O	,
18	108	116	B-UNK	selective
19	118	126	I-UNK	serotonin
20	128	135	I-UNK	reuptake
21	137	146	L-UNK	inhibitors
22	147	147	O	,
23	149	151	O	and
24	153	158	O	others
25	160	160	O	,
26	162	164	O	may
27	166	172	O	inhibit
28	174	176	O	the
29	178	185	O	activity
30	187	188	O	of
31	190	193	O	this
32	195	201	O	isozyme
33	202	202	O	,
34	204	206	O	and
35	208	211	O	thus
36	213	215	O	may
37	217	220	O	make
38	222	227	O	normal
39	229	240	O	metabolizers
40	242	249	O	resemble
41	251	254	O	poor
42	256	267	O	metabolizers
43	269	272	O	with
44	274	279	O	regard
45	281	282	O	to
46	284	294	O	concomitant
47	296	302	O	therapy
48	304	307	O	with
49	309	313	O	other
50	315	319	O	drugs
51	321	331	O	metabolized
52	333	334	O	by
53	336	339	O	this
54	341	346	O	enzyme
55	348	353	O	system
56	354	354	O	,
57	356	362	O	leading
58	364	365	O	to
59	367	370	O	drug
60	372	382	O	interaction
NULL

Clozapine	DDI-DrugBank.d480.s29	NO_SECTION	NO_SETID	26
Concomitant use of clozapine with other drugs metabolized by cytochrome P450 2D6 may require lower doses than usually prescribed for either clozapine or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	27	O	XXXXXXXX
5	29	32	O	with
6	34	38	O	other
7	40	44	O	drugs
8	46	56	O	metabolized
9	58	59	O	by
10	61	70	O	cytochrome
11	72	75	O	P450
12	77	79	O	2D6
13	81	83	O	may
14	85	91	O	require
15	93	97	O	lower
16	99	103	O	doses
17	105	108	O	than
18	110	116	O	usually
19	118	127	O	prescribed
20	129	131	O	for
21	133	138	O	either
22	140	148	O	XXXXXXXX
23	150	151	O	or
24	153	155	O	the
25	157	161	O	other
26	163	166	O	drug
NULL

Clozapine	DDI-DrugBank.d480.s30	NO_SECTION	NO_SETID	49
Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	co
4	14	27	O	administration
5	29	30	O	of
6	32	40	O	XXXXXXXX
7	42	45	O	with
8	47	51	O	other
9	53	57	O	drugs
10	59	62	O	that
11	64	66	O	are
12	68	78	O	metabolized
13	80	81	O	by
14	83	86	O	this
15	88	94	O	isozyme
16	95	95	O	,
17	97	105	O	including
18	107	121	U-DYN	antidepressants
19	122	122	O	,
20	124	137	U-DYN	phenothiazines
21	138	138	O	,
22	140	152	U-DYN	carbamazepine
23	153	153	O	,
24	155	157	O	and
25	159	162	B-DYN	Type
26	164	165	I-DYN	1C
27	167	181	L-DYN	antiarrhythmics
28	184	186	O	e.g
29	188	188	O	,
30	190	200	U-DYN	propafenone
31	201	201	O	,
32	203	212	U-DYN	flecainide
33	214	216	O	and
34	218	226	U-DYN	encainide
35	228	228	O	,
36	230	231	O	or
37	233	236	O	that
38	238	244	O	inhibit
39	246	249	O	this
40	251	256	O	enzyme
41	259	261	O	e.g
42	263	263	O	,
43	265	273	U-DYN	quinidine
44	275	275	O	,
45	277	282	O	should
46	284	285	O	be
47	287	296	O	approached
48	298	301	O	with
49	303	309	O	caution
NULL

Coagulation factor VIIa	DDI-DrugBank.d221.s0	NO_SECTION	NO_SETID	22
The risk of a potential interaction between NovoSeven and coagulation factor concentrates has not been adequately evaluated in preclinical or clinical studies.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	12	O	a
5	14	22	O	potential
6	24	34	O	interaction
7	36	42	O	between
8	44	52	O	XXXXXXXX
9	54	56	O	and
10	58	68	B-UNK	coagulation
11	70	75	L-UNK	factor
12	77	88	O	concentrates
13	90	92	O	has
14	94	96	O	not
15	98	101	O	been
16	103	112	O	adequately
17	114	122	O	evaluated
18	124	125	O	in
19	127	137	O	preclinical
20	139	140	O	or
21	142	149	O	clinical
22	151	157	O	studies
NULL

Coagulation factor VIIa	DDI-DrugBank.d221.s1	NO_SECTION	NO_SETID	14
Simultaneous use of activated prothrombin complex concentrates or prothrombin complex concentrates should be avoided.
1	0	11	O	Simultaneous
2	13	15	O	use
3	17	18	O	of
4	20	28	B-UNK	activated
5	30	40	I-UNK	prothrombin
6	42	48	I-UNK	complex
7	50	61	L-UNK	concentrates
8	63	64	O	or
9	66	76	B-UNK	prothrombin
10	78	84	I-UNK	complex
11	86	97	L-UNK	concentrates
12	99	104	O	should
13	106	107	O	be
14	109	115	O	avoided
NULL

Coagulation factor VIIa	DDI-DrugBank.d221.s2	NO_SECTION	NO_SETID	35
Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.
1	0	7	O	Although
2	9	11	O	the
3	13	20	O	specific
4	22	25	O	drug
5	27	37	O	interaction
6	39	41	O	was
7	43	45	O	not
8	47	53	O	studied
9	55	56	O	in
10	58	58	O	a
11	60	67	O	clinical
12	69	73	O	trial
13	74	74	O	,
14	76	80	O	there
15	82	85	O	have
16	87	90	O	been
17	92	95	O	more
18	97	100	O	than
19	102	103	O	50
20	105	112	O	episodes
21	114	115	O	of
22	117	127	O	concomitant
23	129	131	O	use
24	133	134	O	of
25	136	151	O	antifibrinolytic
26	153	161	O	therapies
27	164	166	O	i.e
28	168	168	O	,
29	170	179	B-UNK	tranexamic
30	181	184	L-UNK	acid
31	185	185	O	,
32	187	198	B-UNK	aminocaproic
33	200	203	L-UNK	acid
34	206	208	O	and
35	210	218	O	XXXXXXXX
NULL

Coagulation factor VIIa	DDI-DrugBank.d221.s3	NO_SECTION	NO_SETID	17
NovoSeven should not be mixed with infusion solutions until clinical data are available to direct this use.
1	0	8	O	XXXXXXXX
2	10	15	O	should
3	17	19	O	not
4	21	22	O	be
5	24	28	O	mixed
6	30	33	O	with
7	35	42	O	infusion
8	44	52	O	solutions
9	54	58	O	until
10	60	67	O	clinical
11	69	72	O	data
12	74	76	O	are
13	78	86	O	available
14	88	89	O	to
15	91	96	O	direct
16	98	101	O	this
17	103	105	O	use
NULL

Codeine	DDI-DrugBank.d464.s0	NO_SECTION	NO_SETID	28
Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
1	0	6	O	XXXXXXXX
2	8	9	O	in
3	11	21	O	combination
4	23	26	O	with
5	28	32	O	other
6	34	41	B-DYN	narcotic
7	43	52	L-DYN	analgesics
8	53	53	O	,
9	55	61	O	general
10	63	73	U-DYN	anesthetics
11	74	74	O	,
12	76	89	U-DYN	phenothiazines
13	90	90	O	,
14	92	104	U-DYN	tranquilizers
15	105	105	O	,
16	107	114	B-DYN	sedative
17	116	124	L-DYN	hypnotics
18	125	125	O	,
19	127	128	O	or
20	130	134	O	other
21	136	138	B-DYN	CNS
22	140	150	L-DYN	depressants
23	153	161	O	including
24	163	169	U-DYN	alcohol
25	172	174	O	has
26	176	183	O	additive
27	185	194	O	depressant
28	196	202	O	effects
NULL

Codeine	DDI-DrugBank.d464.s2	NO_SECTION	NO_SETID	15
combination therapy is contemplated, the dosage of one or both agents should be reduced.
1	0	10	O	combination
2	12	18	O	therapy
3	20	21	O	is
4	23	34	O	contemplated
5	35	35	O	,
6	37	39	O	the
7	41	46	O	dosage
8	48	49	O	of
9	51	53	O	one
10	55	56	O	or
11	58	61	O	both
12	63	68	O	agents
13	70	75	O	should
14	77	78	O	be
15	80	86	O	reduced
NULL

Colchicine	DDI-DrugBank.d146.s0	NO_SECTION	NO_SETID	6
Colchicine is inhibited by acidifying agents.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	22	O	inhibited
4	24	25	O	by
5	27	36	B-KIN	acidifying
6	38	43	L-KIN	agents
NULL

Colchicine	DDI-DrugBank.d146.s1	NO_SECTION	NO_SETID	9
The action of colchicine is potentiated by alkalinizing agents.
1	0	2	O	The
2	4	9	O	action
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	26	O	is
6	28	38	O	potentiated
7	40	41	O	by
8	43	54	B-KIN	alkalinizing
9	56	61	L-KIN	agents
NULL

Colchicine	DDI-DrugBank.d146.s2	NO_SECTION	NO_SETID	8
Colchicine may increase sensitivity to the CNS depressants.
1	0	9	O	XXXXXXXX
2	11	13	O	may
3	15	22	O	increase
4	24	34	O	sensitivity
5	36	37	O	to
6	39	41	O	the
7	43	45	B-DYN	CNS
8	47	57	L-DYN	depressants
NULL

Colchicine	DDI-DrugBank.d146.s3	NO_SECTION	NO_SETID	9
Response to sympathomimetic agents may be enhanced by colchicine.
1	0	7	O	Response
2	9	10	O	to
3	12	26	B-DYN	sympathomimetic
4	28	33	L-DYN	agents
5	35	37	O	may
6	39	40	O	be
7	42	49	O	enhanced
8	51	52	O	by
9	54	63	O	XXXXXXXX
NULL

Colesevelam	DDI-DrugBank.d551.s0	NO_SECTION	NO_SETID	22
WelChol  has been studied in several human drug interaction studies in which it was administered with a meal and the test drug.
1	0	6	O	XXXXXXXX
2	9	11	O	has
3	13	16	O	been
4	18	24	O	studied
5	26	27	O	in
6	29	35	O	several
7	37	41	O	human
8	43	46	O	drug
9	48	58	O	interaction
10	60	66	O	studies
11	68	69	O	in
12	71	75	O	which
13	77	78	O	it
14	80	82	O	was
15	84	95	O	administered
16	97	100	O	with
17	102	102	O	a
18	104	107	O	meal
19	109	111	O	and
20	113	115	O	the
21	117	120	O	test
22	122	125	O	drug
NULL

Colesevelam	DDI-DrugBank.d551.s1	NO_SECTION	NO_SETID	25
WelChol  was found to have no significant effect on the bioavailability of digoxin, lovastatin, metoprolol, quinidine, valproic acid, and warfarin.
1	0	6	O	XXXXXXXX
2	9	11	O	was
3	13	17	O	found
4	19	20	O	to
5	22	25	O	have
6	27	28	O	no
7	30	40	O	significant
8	42	47	O	effect
9	49	50	O	on
10	52	54	O	the
11	56	70	O	bioavailability
12	72	73	O	of
13	75	81	U-UNK	digoxin
14	82	82	O	,
15	84	93	U-UNK	lovastatin
16	94	94	O	,
17	96	105	U-UNK	metoprolol
18	106	106	O	,
19	108	116	U-UNK	quinidine
20	117	117	O	,
21	119	126	B-UNK	valproic
22	128	131	L-UNK	acid
23	132	132	O	,
24	134	136	O	and
25	138	145	U-UNK	warfarin
NULL

Colesevelam	DDI-DrugBank.d551.s2	NO_SECTION	NO_SETID	18
WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.
1	0	6	O	WelChol
2	9	17	O	decreased
3	19	21	O	the
4	23	26	O	Cmax
5	28	30	O	and
6	32	34	O	AUC
7	36	37	O	of
8	39	47	O	sustained
9	49	55	O	release
10	57	65	U-KIN	verapamil
11	68	75	U-KIN	XXXXXXXX
12	79	80	O	by
13	82	94	O	approximately
14	96	98	O	31%
15	100	102	O	and
16	104	106	O	11%
17	107	107	O	,
18	109	120	O	respectively
NULL

Colesevelam	DDI-DrugBank.d551.s3	NO_SECTION	NO_SETID	22
Since there is a high degree of variability in the bioavailability of verapamil, the clinical significance of this finding is unclear.
1	0	4	O	Since
2	6	10	O	there
3	12	13	O	is
4	15	15	O	a
5	17	20	O	high
6	22	27	O	degree
7	29	30	O	of
8	32	42	O	variability
9	44	45	O	in
10	47	49	O	the
11	51	65	O	bioavailability
12	67	68	O	of
13	70	78	U-UNK	verapamil
14	79	79	O	,
15	81	83	O	the
16	85	92	O	clinical
17	94	105	O	significance
18	107	108	O	of
19	110	113	O	this
20	115	121	O	finding
21	123	124	O	is
22	126	132	O	unclear
NULL

Colesevelam	DDI-DrugBank.d551.s4	NO_SECTION	NO_SETID	28
In clinical studies, coadministration of WelChol  with atorvastatin, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.
1	0	1	O	In
2	3	10	O	clinical
3	12	18	O	studies
4	19	19	O	,
5	21	36	O	coadministration
6	38	39	O	of
7	41	47	O	XXXXXXXX
8	50	53	O	with
9	55	66	U-UNK	atorvastatin
10	67	67	O	,
11	69	78	U-UNK	lovastatin
12	79	79	O	,
13	81	82	O	or
14	84	94	U-UNK	simvastatin
15	96	98	O	did
16	100	102	O	not
17	104	112	O	interfere
18	114	117	O	with
19	119	121	O	the
20	123	127	O	lipid
21	129	136	O	lowering
22	138	145	O	activity
23	147	148	O	of
24	150	152	O	the
25	154	156	B-UNK	HMG
26	158	160	I-UNK	CoA
27	162	170	I-UNK	reductase
28	172	180	L-UNK	inhibitor
NULL

Colesevelam	DDI-DrugBank.d551.s5	NO_SECTION	NO_SETID	6
Other drugs have not been studied.
1	0	4	O	Other
2	6	10	O	drugs
3	12	15	O	have
4	17	19	O	not
5	21	24	O	been
6	26	32	O	studied
NULL

Colesevelam	DDI-DrugBank.d551.s6	NO_SECTION	NO_SETID	29
When administering other drugs for which alterations in blood levels could have a clinically significant effect on safety or efficacy, physicians should consider monitoring drug levels or effects.
1	0	3	O	When
2	5	17	O	administering
3	19	23	O	other
4	25	29	O	drugs
5	31	33	O	for
6	35	39	O	which
7	41	51	O	alterations
8	53	54	O	in
9	56	60	O	blood
10	62	67	O	levels
11	69	73	O	could
12	75	78	O	have
13	80	80	O	a
14	82	91	O	clinically
15	93	103	O	significant
16	105	110	O	effect
17	112	113	O	on
18	115	120	O	safety
19	122	123	O	or
20	125	132	O	efficacy
21	133	133	O	,
22	135	144	O	physicians
23	146	151	O	should
24	153	160	O	consider
25	162	171	O	monitoring
26	173	176	O	drug
27	178	183	O	levels
28	185	186	O	or
29	188	194	O	effects
NULL

Colestipol	DDI-DrugBank.d345.s0	NO_SECTION	NO_SETID	22
Since colestipol hydrochloride is an anion exchange resin, it may have a strong affinity for anions other than the bile acids.
1	0	4	O	Since
2	6	15	O	XXXXXXXX
3	17	29	O	hydrochloride
4	31	32	O	is
5	34	35	O	an
6	37	41	B-UNK	anion
7	43	50	I-UNK	exchange
8	52	56	L-UNK	resin
9	57	57	O	,
10	59	60	O	it
11	62	64	O	may
12	66	69	O	have
13	71	71	O	a
14	73	78	O	strong
15	80	87	O	affinity
16	89	91	O	for
17	93	98	O	anions
18	100	104	O	other
19	106	109	O	than
20	111	113	O	the
21	115	118	O	bile
22	120	124	O	acids
NULL

Colestipol	DDI-DrugBank.d345.s1	NO_SECTION	NO_SETID	13
In vitro studies have indicated that colestipol hydrochloride binds a number of drugs.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	30	O	indicated
6	32	35	O	that
7	37	46	O	XXXXXXXX
8	48	60	O	hydrochloride
9	62	66	O	binds
10	68	68	O	a
11	70	75	O	number
12	77	78	O	of
13	80	84	O	drugs
NULL

Colestipol	DDI-DrugBank.d345.s2	NO_SECTION	NO_SETID	14
Therefore, COLESTlD Tablets may delay or reduce the absorption of concomitant oral medication.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	O	XXXXXXXX
4	20	26	O	Tablets
5	28	30	O	may
6	32	36	O	delay
7	38	39	O	or
8	41	46	O	reduce
9	48	50	O	the
10	52	61	O	absorption
11	63	64	O	of
12	66	76	O	concomitant
13	78	81	O	oral
14	83	92	O	medication
NULL

Colestipol	DDI-DrugBank.d345.s3	NO_SECTION	NO_SETID	18
The interval between the administration of COLESTID Tablets and any other medication should be as long as possible.
1	0	2	O	The
2	4	11	O	interval
3	13	19	O	between
4	21	23	O	the
5	25	38	O	administration
6	40	41	O	of
7	43	50	O	XXXXXXXX
8	52	58	O	Tablets
9	60	62	O	and
10	64	66	O	any
11	68	72	O	other
12	74	83	O	medication
13	85	90	O	should
14	92	93	O	be
15	95	96	O	as
16	98	101	O	long
17	103	104	O	as
18	106	113	O	possible
NULL

Colestipol	DDI-DrugBank.d345.s4	NO_SECTION	NO_SETID	21
Patients should take other drugs at least one hour before or four hours after COLESTID Tablets to avoid impeding their absorption.
1	0	7	O	Patients
2	9	14	O	should
3	16	19	O	take
4	21	25	O	other
5	27	31	O	drugs
6	33	34	O	at
7	36	40	O	least
8	42	44	O	one
9	46	49	O	hour
10	51	56	O	before
11	58	59	O	or
12	61	64	O	four
13	66	70	O	hours
14	72	76	O	after
15	78	85	O	XXXXXXXX
16	87	93	O	Tablets
17	95	96	O	to
18	98	102	O	avoid
19	104	111	O	impeding
20	113	117	O	their
21	119	128	O	absorption
NULL

Colestipol	DDI-DrugBank.d345.s5	NO_SECTION	NO_SETID	23
Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.
1	0	7	O	Repeated
2	9	13	O	doses
3	15	16	O	of
4	18	27	O	XXXXXXXX
5	29	41	O	hydrochloride
6	43	47	O	given
7	49	53	O	prior
8	55	56	O	to
9	58	58	O	a
10	60	65	O	single
11	67	70	O	dose
12	72	73	O	of
13	75	85	U-KIN	propranolol
14	87	88	O	in
15	90	94	O	human
16	96	101	O	trials
17	103	106	O	have
18	108	111	O	been
19	113	120	O	reported
20	122	123	O	to
21	125	132	O	decrease
22	134	144	U-UNK	propranolol
23	146	155	O	absorption
NULL

Colestipol	DDI-DrugBank.d345.s6	NO_SECTION	NO_SETID	52
However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption;
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	12	O	a
5	14	19	O	follow
6	21	22	O	up
7	24	28	O	study
8	30	31	O	in
9	33	38	O	normal
10	40	47	O	subjects
11	48	48	O	,
12	50	55	O	single
13	57	60	O	dose
14	62	75	O	administration
15	77	78	O	of
16	80	89	O	XXXXXXXX
17	91	103	O	hydrochloride
18	105	107	O	and
19	109	119	U-UNK	propranolol
20	121	123	O	and
21	125	129	O	twice
22	131	131	O	a
23	133	135	O	day
24	137	150	O	administration
25	152	154	O	for
26	156	156	O	5
27	158	161	O	days
28	163	164	O	of
29	166	169	O	both
30	171	176	O	agents
31	178	180	O	did
32	182	184	O	not
33	186	191	O	affect
34	193	195	O	the
35	197	202	O	extent
36	204	205	O	of
37	207	217	U-UNK	propranolol
38	219	228	O	absorption
39	229	229	O	,
40	231	233	O	but
41	235	237	O	had
42	239	239	O	a
43	241	245	O	small
44	247	249	O	yet
45	251	263	O	statistically
46	265	275	O	significant
47	277	282	O	effect
48	284	285	O	on
49	287	289	O	its
50	291	294	O	rate
51	296	297	O	of
52	299	308	O	absorption
NULL

Colestipol	DDI-DrugBank.d345.s7	NO_SECTION	NO_SETID	11
the time to reach maximum concentration was delayed approximately 30 minutes.
1	0	2	O	the
2	4	7	O	time
3	9	10	O	to
4	12	16	O	reach
5	18	24	O	maximum
6	26	38	O	concentration
7	40	42	O	was
8	44	50	O	delayed
9	52	64	O	approximately
10	66	67	O	30
11	69	75	O	minutes
NULL

Colestipol	DDI-DrugBank.d345.s8	NO_SECTION	NO_SETID	12
Effects on the absorption of other beta-blockers have not been determined.
1	0	6	O	Effects
2	8	9	O	on
3	11	13	O	the
4	15	24	O	absorption
5	26	27	O	of
6	29	33	O	other
7	35	38	B-UNK	beta
8	40	47	L-UNK	blockers
9	49	52	O	have
10	54	56	O	not
11	58	61	O	been
12	63	72	O	determined
NULL

Colestipol	DDI-DrugBank.d345.s9	NO_SECTION	NO_SETID	20
Therefore, patients on propranolol should be observed when COLESTID Tablets are either added or deleted from a therapeutic regimen.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	O	patients
4	20	21	O	on
5	23	33	U-DYN	propranolol
6	35	40	O	should
7	42	43	O	be
8	45	52	O	observed
9	54	57	O	when
10	59	66	O	XXXXXXXX
11	68	74	O	Tablets
12	76	78	O	are
13	80	85	O	either
14	87	91	O	added
15	93	94	O	or
16	96	102	O	deleted
17	104	107	O	from
18	109	109	O	a
19	111	121	O	therapeutic
20	123	129	O	regimen
NULL

Colestipol	DDI-DrugBank.d345.s10	NO_SECTION	NO_SETID	25
Studies in humans show that the absorption of chlorothiazide as reflected in urinary excretion is markedly decreased even when administered one hour before colestipol hydrochloride.
1	0	6	O	Studies
2	8	9	O	in
3	11	16	O	humans
4	18	21	O	show
5	23	26	O	that
6	28	30	O	the
7	32	41	O	absorption
8	43	44	O	of
9	46	59	U-KIN	chlorothiazide
10	61	62	O	as
11	64	72	O	reflected
12	74	75	O	in
13	77	83	O	urinary
14	85	93	O	excretion
15	95	96	O	is
16	98	105	O	markedly
17	107	115	O	decreased
18	117	120	O	even
19	122	125	O	when
20	127	138	O	administered
21	140	142	O	one
22	144	147	O	hour
23	149	154	O	before
24	156	165	O	XXXXXXXX
25	167	179	O	hydrochloride
NULL

Colestipol	DDI-DrugBank.d345.s11	NO_SECTION	NO_SETID	23
The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
1	0	2	O	The
2	4	13	O	absorption
3	15	16	O	of
4	18	29	U-KIN	tetracycline
5	30	30	O	,
6	32	41	U-KIN	furosemide
7	42	42	O	,
8	44	53	B-KIN	penicillin
9	55	55	L-KIN	GGGGGGGG
10	56	56	O	,
11	58	76	U-KIN	hydrochlorothiazide
12	77	77	O	,
13	79	81	O	and
14	83	93	U-KIN	gemfibrozil
15	95	97	O	was
16	99	111	O	significantly
17	113	121	O	decreased
18	123	126	O	when
19	128	132	O	given
20	134	147	O	simultaneously
21	149	152	O	with
22	154	163	O	XXXXXXXX
23	165	177	O	hydrochloride
NULL

Colestipol	DDI-DrugBank.d345.s12	NO_SECTION	NO_SETID	16
these drugs were not tested to determine the effect of administration one hour before colestipol hydrochloride.
1	0	4	O	these
2	6	10	O	drugs
3	12	15	O	were
4	17	19	O	not
5	21	26	O	tested
6	28	29	O	to
7	31	39	O	determine
8	41	43	O	the
9	45	50	O	effect
10	52	53	O	of
11	55	68	O	administration
12	70	72	O	one
13	74	77	O	hour
14	79	84	O	before
15	86	95	O	XXXXXXXX
16	97	109	O	hydrochloride
NULL

Colestipol	DDI-DrugBank.d345.s13	NO_SECTION	NO_SETID	39
No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.
1	0	1	O	No
2	3	12	O	depressant
3	14	19	O	effect
4	21	22	O	on
5	24	28	O	blood
6	30	35	O	levels
7	37	38	O	in
8	40	45	O	humans
9	47	49	O	was
10	51	55	O	noted
11	57	60	O	when
12	62	71	B-UNK	colestipol
13	73	85	L-UNK	hydrochloride
14	87	89	O	was
15	91	102	O	administered
16	104	107	O	with
17	109	111	O	any
18	113	114	O	of
19	116	118	O	the
20	120	128	O	following
21	130	134	O	drugs
22	135	135	O	:
23	137	143	O	aspirin
24	144	144	O	,
25	146	156	O	XXXXXXXX
26	157	157	O	,
27	159	168	U-UNK	clofibrate
28	169	169	O	,
29	171	180	U-UNK	methyldopa
30	181	181	O	,
31	183	191	B-UNK	nicotinic
32	193	196	L-UNK	acid
33	199	204	U-UNK	niacin
34	206	206	O	,
35	208	218	U-UNK	tolbutamide
36	219	219	O	,
37	221	229	U-UNK	phenytoin
38	231	232	O	or
39	234	241	U-UNK	warfarin
NULL

Colestipol	DDI-DrugBank.d345.s14	NO_SECTION	NO_SETID	26
Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.
1	0	9	O	Particular
2	11	17	O	caution
3	19	24	O	should
4	26	27	O	be
5	29	36	O	observed
6	38	41	O	with
7	43	51	B-DYN	digitalis
8	53	64	L-DYN	preparations
9	66	70	O	since
10	72	76	O	there
11	78	80	O	are
12	82	92	O	conflicting
13	94	100	O	results
14	102	104	O	for
15	106	108	O	the
16	110	115	O	effect
17	117	118	O	of
18	120	129	O	XXXXXXXX
19	131	143	O	hydrochloride
20	145	146	O	on
21	148	150	O	the
22	152	163	O	availability
23	165	166	O	of
24	168	174	U-KIN	digoxin
25	176	178	O	and
26	180	188	U-KIN	digitoxin
NULL

Colestipol	DDI-DrugBank.d345.s15	NO_SECTION	NO_SETID	12
The potential for binding of these drugs if given concomitantly is present.
1	0	2	O	The
2	4	12	O	potential
3	14	16	O	for
4	18	24	O	binding
5	26	27	O	of
6	29	33	O	these
7	35	39	O	drugs
8	41	42	O	if
9	44	48	O	given
10	50	62	O	concomitantly
11	64	65	O	is
12	67	73	O	present
NULL

Colestipol	DDI-DrugBank.d345.s16	NO_SECTION	NO_SETID	35
Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking colestipol hydrochloride.
1	0	12	O	Discontinuing
2	14	23	O	XXXXXXXX
3	25	37	O	hydrochloride
4	39	43	O	could
5	45	48	O	pose
6	50	50	O	a
7	52	57	O	hazard
8	59	60	O	to
9	62	67	O	health
10	69	70	O	if
11	72	72	O	a
12	74	84	O	potentially
13	86	90	O	toxic
14	92	95	O	drug
15	97	100	O	that
16	102	103	O	is
17	105	117	O	significantly
18	119	123	O	bound
19	125	126	O	to
20	128	130	O	the
21	132	136	U-UNK	resin
22	138	140	O	has
23	142	145	O	been
24	147	154	O	titrated
25	156	157	O	to
26	159	159	O	a
27	161	171	O	maintenance
28	173	177	O	level
29	179	183	O	while
30	185	187	O	the
31	189	195	O	patient
32	197	199	O	was
33	201	206	O	taking
34	208	217	O	XXXXXXXX
35	219	231	O	hydrochloride
NULL

Colestipol	DDI-DrugBank.d345.s17	NO_SECTION	NO_SETID	16
Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone.
1	0	3	B-UNK	Bile
2	5	8	I-UNK	acid
3	10	16	I-UNK	binding
4	18	23	L-UNK	resins
5	25	27	O	may
6	29	32	O	also
7	34	42	O	interfere
8	44	47	O	with
9	49	51	O	the
10	53	62	O	absorption
11	64	65	O	of
12	67	70	O	oral
13	72	80	U-UNK	phosphate
14	82	92	O	supplements
15	94	96	O	and
16	98	111	U-UNK	hydrocortisone
NULL

Colistimethate	DDI-DrugBank.d250.s0	NO_SECTION	NO_SETID	20
Certain other antibiotics (aminoglycosides and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction.
1	0	6	O	Certain
2	8	12	O	other
3	14	24	U-UNK	antibiotics
4	27	41	U-UNK	aminoglycosides
5	43	45	O	and
6	47	55	U-UNK	polymyxin
7	58	61	O	have
8	63	66	O	also
9	68	71	O	been
10	73	80	O	reported
11	82	83	O	to
12	85	93	O	interfere
13	95	98	O	with
14	100	102	O	the
15	104	108	O	nerve
16	110	121	O	transmission
17	123	124	O	at
18	126	128	O	the
19	130	142	O	neuromuscular
20	144	151	O	junction
NULL

Colistimethate	DDI-DrugBank.d250.s1	NO_SECTION	NO_SETID	20
Based on this reported activity, they should not be given concomitantly with Coly-Mycin M Parenteral except with the greatest caution.
1	0	4	O	Based
2	6	7	O	on
3	9	12	O	this
4	14	21	O	reported
5	23	30	O	activity
6	31	31	O	,
7	33	36	O	they
8	38	43	O	should
9	45	47	O	not
10	49	50	O	be
11	52	56	O	given
12	58	70	O	concomitantly
13	72	75	O	with
14	77	88	O	XXXXXXXX
15	90	99	O	Parenteral
16	101	106	O	except
17	108	111	O	with
18	113	115	O	the
19	117	124	O	greatest
20	126	132	O	caution
NULL

Colistimethate	DDI-DrugBank.d250.s2	NO_SECTION	NO_SETID	41
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
1	0	9	O	Curariform
2	11	16	O	muscle
3	18	26	O	relaxants
4	29	30	O	eg
5	31	31	O	,
6	33	44	U-DYN	tubocurarine
7	47	49	O	and
8	51	55	O	other
9	57	61	O	drugs
10	62	62	O	,
11	64	72	O	including
12	74	78	O	ether
13	79	79	O	,
14	81	95	U-DYN	succinylcholine
15	96	96	O	,
16	98	106	U-DYN	gallamine
17	107	107	O	,
18	109	121	U-DYN	decamethonium
19	123	125	O	and
20	127	132	B-DYN	sodium
21	134	140	L-DYN	citrate
22	141	141	O	,
23	143	152	O	potentiate
24	154	156	O	the
25	158	170	O	neuromuscular
26	172	179	O	blocking
27	181	186	O	effect
28	188	190	O	and
29	192	197	O	should
30	199	200	O	be
31	202	205	O	used
32	207	210	O	with
33	212	218	O	extreme
34	220	226	O	caution
35	228	229	O	in
36	231	238	O	patients
37	240	244	O	being
38	246	252	O	treated
39	254	257	O	with
40	259	270	U-DYN	XXXXXXXX
41	272	281	O	Parenteral
NULL

Colistimethate	DDI-DrugBank.d250.s3	NO_SECTION	NO_SETID	9
Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.
1	0	5	B-DYN	Sodium
2	7	17	L-DYN	cephalothin
3	19	21	O	may
4	23	29	O	enhance
5	31	33	O	the
6	35	48	O	nephrotoxicity
7	50	51	O	of
8	53	64	O	XXXXXXXX
9	66	75	O	Parenteral
NULL

Colistimethate	DDI-DrugBank.d250.s4	NO_SECTION	NO_SETID	12
The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	28	B-DYN	sodium
6	30	40	L-DYN	cephalothin
7	42	44	O	and
8	46	57	O	XXXXXXXX
9	59	68	O	Parenteral
10	70	75	O	should
11	77	78	O	be
12	80	86	O	avoided
NULL

Conivaptan	DDI-DrugBank.d315.s0	NO_SECTION	NO_SETID	29
Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	24	O	Coadministration
4	26	27	O	of
5	29	35	U-KIN	digoxin
6	36	36	O	,
7	38	38	O	a
8	40	40	O	P
9	42	53	O	glycoprotein
10	55	63	O	substrate
11	64	64	O	,
12	66	69	O	with
13	71	74	O	oral
14	76	85	O	XXXXXXXX
15	87	94	O	resulted
16	96	97	O	in
17	99	99	O	a
18	101	109	O	reduction
19	111	112	O	in
20	114	122	O	clearance
21	124	126	O	and
22	128	129	O	an
23	131	138	O	increase
24	140	141	O	in
25	143	149	U-UNK	digoxin
26	151	154	O	Cmax
27	156	158	O	and
28	160	162	O	AUC
29	164	169	O	values
NULL

Conivaptan	DDI-DrugBank.d315.s1	NO_SECTION	NO_SETID	22
Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	if
4	14	20	U-KIN	digoxin
5	22	23	O	is
6	25	36	O	administered
7	38	41	O	with
8	43	50	O	XXXXXXXX
9	51	51	O	,
10	53	55	O	the
11	57	65	O	clinician
12	67	72	O	should
13	74	75	O	be
14	77	81	O	alert
15	83	84	O	to
16	86	88	O	the
17	90	100	O	possibility
18	102	103	O	of
19	105	113	O	increases
20	115	116	O	in
21	118	124	U-UNK	digoxin
22	126	131	O	levels
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s0	NO_SECTION	NO_SETID	6
DRUG/LABORATORY TEST INTERACTIONS 1.
1	0	3	O	DRUG
2	4	4	O	/
3	5	14	O	LABORATORY
4	16	19	O	TEST
5	21	32	O	INTERACTIONS
6	34	34	O	1
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s1	NO_SECTION	NO_SETID	12
Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time;
1	0	10	O	Accelerated
2	12	22	O	prothrombin
3	24	27	O	time
4	28	28	O	,
5	30	36	O	partial
6	38	51	O	thromboplastin
7	53	56	O	time
8	57	57	O	,
9	59	61	O	and
10	63	70	O	platelet
11	72	82	O	aggregation
12	84	87	O	time
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s2	NO_SECTION	NO_SETID	3
increased platelet count;
1	0	8	O	increased
2	10	17	O	platelet
3	19	23	O	count
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s3	NO_SECTION	NO_SETID	32
increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin;
1	0	8	O	increased
2	10	16	O	factors
3	18	19	O	II
4	20	20	O	,
5	22	24	O	VII
6	26	32	O	antigen
7	33	33	O	,
8	35	38	O	VIII
9	40	46	O	antigen
10	47	47	O	,
11	49	52	O	VIII
12	54	62	O	coagulant
13	64	71	O	activity
14	72	72	O	,
15	74	75	O	IX
16	76	76	O	,
17	78	78	O	XXXXXXXX
18	79	79	O	,
19	81	83	O	XII
20	84	84	O	,
21	86	88	O	VII
22	90	90	O	XXXXXXXX
23	92	98	O	complex
24	99	99	O	,
25	101	102	O	II
26	104	106	O	VII
27	108	108	O	XXXXXXXX
28	110	116	O	complex
29	117	117	O	,
30	119	121	O	and
31	123	126	O	beta
32	128	142	O	thromboglobulin
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s4	NO_SECTION	NO_SETID	14
decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity;
1	0	8	O	decreased
2	10	15	O	levels
3	17	18	O	of
4	20	23	O	anti
5	25	30	O	factor
6	32	33	O	Xa
7	35	37	O	and
8	39	50	B-UNK	antithrombin
9	52	54	L-UNK	III
10	55	55	O	,
11	57	65	O	decreased
12	67	78	B-UNK	antithrombin
13	80	82	L-UNK	III
14	84	91	O	activity
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s5	NO_SECTION	NO_SETID	7
increased levels of fibrinogen and fibrinogen activity;
1	0	8	O	increased
2	10	15	O	levels
3	17	18	O	of
4	20	29	U-UNK	fibrinogen
5	31	33	O	and
6	35	44	U-UNK	fibrinogen
7	46	53	O	activity
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s6	NO_SECTION	NO_SETID	5
increased plasminogen antigen and activity.
1	0	8	O	increased
2	10	20	O	plasminogen
3	22	28	O	antigen
4	30	32	O	and
5	34	41	O	activity
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s8	NO_SECTION	NO_SETID	34
Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay.
1	0	8	O	Increased
2	10	16	O	thyroid
3	18	24	O	binding
4	26	33	O	globulin
5	36	38	O	TBG
6	41	46	O	levels
7	48	54	O	leading
8	56	57	O	to
9	59	67	O	increased
10	69	79	O	circulating
11	81	85	O	total
12	87	93	O	thyroid
13	95	101	O	hormone
14	103	108	O	levels
15	110	111	O	as
16	113	120	O	measured
17	122	123	O	by
18	125	131	O	protein
19	133	137	O	bound
20	139	144	U-UNK	iodine
21	147	149	O	PBI
22	151	151	O	,
23	153	154	O	T4
24	156	161	O	levels
25	164	165	O	by
26	167	172	O	column
27	174	175	O	or
28	177	178	O	by
29	180	195	O	radioimmunoassay
30	198	199	O	or
31	201	202	O	T3
32	204	209	O	levels
33	211	212	O	by
34	214	229	O	radioimmunoassay
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s9	NO_SECTION	NO_SETID	10
T3 resin uptake is decreased, reflecting the elevated TBG.
1	0	1	O	T3
2	3	7	O	resin
3	9	14	O	uptake
4	16	17	O	is
5	19	27	O	decreased
6	28	28	O	,
7	30	39	O	reflecting
8	41	43	O	the
9	45	52	O	elevated
10	54	56	O	TBG
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s10	NO_SECTION	NO_SETID	8
Free T4 and free T3 concentrations are unaltered.
1	0	3	O	Free
2	5	6	O	T4
3	8	10	O	and
4	12	15	O	free
5	17	18	O	T3
6	20	33	O	concentrations
7	35	37	O	are
8	39	47	O	unaltered
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s11	NO_SECTION	NO_SETID	12
Patients on thyroid replacement therapy may require higher doses of thyroid hormone.
1	0	7	O	Patients
2	9	10	O	on
3	12	18	O	thyroid
4	20	30	O	replacement
5	32	38	O	therapy
6	40	42	O	may
7	44	50	O	require
8	52	57	O	higher
9	59	63	O	doses
10	65	66	O	of
11	68	74	B-UNK	thyroid
12	76	82	L-UNK	hormone
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s13	NO_SECTION	NO_SETID	32
Other binding proteins may be elevated in serum, (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively.
1	0	4	O	Other
2	6	12	O	binding
3	14	21	O	proteins
4	23	25	O	may
5	27	28	O	be
6	30	37	O	elevated
7	39	40	O	in
8	42	46	O	serum
9	47	47	O	,
10	50	52	O	i.e
11	54	54	O	,
12	56	69	O	corticosteroid
13	71	77	O	binding
14	79	86	O	globulin
15	89	91	O	CBG
16	93	93	O	,
17	95	97	O	sex
18	99	105	O	hormone
19	107	113	O	binding
20	115	122	O	globulin
21	125	128	O	SHBG
22	132	138	O	leading
23	140	141	O	to
24	143	151	O	increased
25	153	157	O	total
26	159	169	O	circulating
27	171	185	U-UNK	corticosteroids
28	187	189	O	and
29	191	193	B-UNK	sex
30	195	202	L-UNK	steroids
31	203	203	O	,
32	205	216	O	respectively
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s14	NO_SECTION	NO_SETID	6
Free hormone concentrations may be decreased.
1	0	3	O	Free
2	5	11	O	hormone
3	13	26	O	concentrations
4	28	30	O	may
5	32	33	O	be
6	35	43	O	decreased
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s15	NO_SECTION	NO_SETID	16
Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).
1	0	4	O	Other
2	6	11	O	plasma
3	13	20	O	proteins
4	22	24	O	may
5	26	27	O	be
6	29	37	O	increased
7	40	54	O	angiotensinogen
8	55	55	O	/
9	56	60	O	renin
10	62	70	O	substrate
11	71	71	O	,
12	73	77	O	alpha
13	79	79	O	1
14	81	91	O	antitrypsin
15	92	92	O	,
16	94	106	O	ceruloplasmin
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s17	NO_SECTION	NO_SETID	17
Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels.
1	0	8	O	Increased
2	10	15	O	plasma
3	17	19	O	HDL
4	21	23	O	and
5	25	28	O	HDL2
6	30	40	O	cholesterol
7	42	52	O	subfraction
8	54	67	O	concentrations
9	68	68	O	,
10	70	76	O	reduced
11	78	80	O	LDL
12	82	92	O	cholesterol
13	94	106	O	concentration
14	107	107	O	,
15	109	117	O	increased
16	119	130	O	triglyceride
17	132	137	O	levels
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s19	NO_SECTION	NO_SETID	3
Impaired glucose tolerance.
1	0	7	O	Impaired
2	9	15	O	glucose
3	17	25	O	tolerance
NULL

Conjugated Estrogens	DDI-DrugBank.d317.s21	NO_SECTION	NO_SETID	5
Reduced response to metyrapone test.
1	0	6	O	Reduced
2	8	15	O	response
3	17	18	O	to
4	20	29	O	metyrapone
5	31	34	O	test
NULL

Corticotropin	DDI-DrugBank.d25.s0	NO_SECTION	NO_SETID	10
Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
1	0	12	O	XXXXXXXX
2	14	16	O	may
3	18	27	O	accentuate
4	29	31	O	the
5	33	43	O	electrolyte
6	45	48	O	loss
7	50	59	O	associated
8	61	64	O	with
9	66	73	U-DYN	diuretic
10	75	81	O	therapy
NULL

Cortisone acetate	DDI-DrugBank.d487.s0	NO_SECTION	NO_SETID	9
The pharmacokinetic interactions listed below are potentially clinically important.
1	0	2	O	The
2	4	18	O	pharmacokinetic
3	20	31	O	interactions
4	33	38	O	listed
5	40	44	O	below
6	46	48	O	are
7	50	60	O	potentially
8	62	71	O	clinically
9	73	81	O	important
NULL

Cortisone acetate	DDI-DrugBank.d487.s1	NO_SECTION	NO_SETID	30
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
1	0	4	O	Drugs
2	6	9	O	that
3	11	16	O	induce
4	18	24	O	hepatic
5	26	32	O	enzymes
6	34	37	O	such
7	39	40	O	as
8	42	54	U-UNK	phenobarbital
9	55	55	O	,
10	57	65	U-UNK	phenytoin
11	67	69	O	and
12	71	78	U-UNK	rifampin
13	80	82	O	may
14	84	91	O	increase
15	93	95	O	the
16	97	105	O	clearance
17	107	108	O	of
18	110	124	U-UNK	corticosteroids
19	126	128	O	and
20	130	132	O	may
21	134	140	O	require
22	142	150	O	increases
23	152	153	O	in
24	155	168	U-UNK	corticosteroid
25	170	173	O	dose
26	175	176	O	to
27	178	184	O	achieve
28	186	188	O	the
29	190	196	O	desired
30	198	205	O	response
NULL

Cortisone acetate	DDI-DrugBank.d487.s2	NO_SECTION	NO_SETID	17
Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
1	0	4	O	Drugs
2	6	9	O	such
3	11	12	O	as
4	14	27	U-UNK	troleandomycin
5	29	31	O	and
6	33	44	U-UNK	ketoconazole
7	46	48	O	may
8	50	56	O	inhibit
9	58	60	O	the
10	62	71	O	metabolism
11	73	74	O	of
12	76	90	U-UNK	corticosteroids
13	92	94	O	and
14	96	99	O	thus
15	101	108	O	decrease
16	110	114	O	their
17	116	124	O	clearance
NULL

Cortisone acetate	DDI-DrugBank.d487.s3	NO_SECTION	NO_SETID	13
Therefore, the dose of corticosteroid should be titrated to avoid steroid toxicity.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	18	O	dose
5	20	21	O	of
6	23	36	U-UNK	corticosteroid
7	38	43	O	should
8	45	46	O	be
9	48	55	O	titrated
10	57	58	O	to
11	60	64	O	avoid
12	66	72	O	steroid
13	74	81	O	toxicity
NULL

Cortisone acetate	DDI-DrugBank.d487.s4	NO_SECTION	NO_SETID	10
Corticosteroids may increase the clearance of chronic high dose aspirin.
1	0	14	U-DYN	Corticosteroids
2	16	18	O	may
3	20	27	O	increase
4	29	31	O	the
5	33	41	O	clearance
6	43	44	O	of
7	46	52	O	chronic
8	54	57	O	high
9	59	62	O	dose
10	64	70	O	XXXXXXXX
NULL

Cortisone acetate	DDI-DrugBank.d487.s5	NO_SECTION	NO_SETID	19
This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
1	0	3	O	This
2	5	9	O	could
3	11	14	O	lead
4	16	17	O	to
5	19	27	O	decreased
6	29	38	U-UNK	salicylate
7	40	44	O	serum
8	46	51	O	levels
9	53	54	O	or
10	56	63	O	increase
11	65	67	O	the
12	69	72	O	risk
13	74	75	O	of
14	77	86	U-UNK	salicylate
15	88	95	O	toxicity
16	97	100	O	when
17	102	115	U-UNK	corticosteroid
18	117	118	O	is
19	120	128	O	withdrawn
NULL

Cortisone acetate	DDI-DrugBank.d487.s6	NO_SECTION	NO_SETID	16
Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.
1	0	6	O	XXXXXXXX
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	32	O	cautiously
6	34	35	O	in
7	37	47	O	conjunction
8	49	52	O	with
9	54	60	B-DYN	cortico
10	62	69	L-DYN	steroids
11	71	72	O	in
12	74	81	O	patients
13	83	91	O	suffering
14	93	96	O	from
15	98	104	O	hypopro
16	106	117	O	thrombinemia
NULL

Cortisone acetate	DDI-DrugBank.d487.s7	NO_SECTION	NO_SETID	9
The effect of corticosteroids on oral anticoagulants is variable.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	28	U-UNK	corticosteroids
5	30	31	O	on
6	33	36	O	oral
7	38	51	U-UNK	anticoagulants
8	53	54	O	is
9	56	63	O	variable
NULL

Cortisone acetate	DDI-DrugBank.d487.s8	NO_SECTION	NO_SETID	17
There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.
1	0	4	O	There
2	6	8	O	are
3	10	16	O	reports
4	18	19	O	of
5	21	28	O	enhanced
6	30	31	O	as
7	33	36	O	well
8	38	39	O	as
9	41	50	O	diminished
10	52	58	O	effects
11	60	61	O	of
12	63	76	U-UNK	anticoagulants
13	78	81	O	when
14	83	87	O	given
15	89	100	O	concurrently
16	102	105	O	with
17	107	121	U-UNK	corticosteroids
NULL

Cortisone acetate	DDI-DrugBank.d487.s9	NO_SECTION	NO_SETID	13
Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.
1	0	8	O	Therefore
2	9	9	O	,
3	11	21	O	coagulation
4	23	29	O	indices
5	31	36	O	should
6	38	39	O	be
7	41	49	O	monitored
8	51	52	O	to
9	54	61	O	maintain
10	63	65	O	the
11	67	73	O	desired
12	75	87	O	anticoagulant
13	89	94	O	effect
NULL

Cosyntropin	DDI-DrugBank.d439.s0	NO_SECTION	NO_SETID	10
Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.
1	0	12	U-UNK	Corticotropin
2	14	16	O	may
3	18	27	O	accentuate
4	29	31	O	the
5	33	43	O	electrolyte
6	45	48	O	loss
7	50	59	O	associated
8	61	64	O	with
9	66	73	U-UNK	diuretic
10	75	81	O	therapy
NULL

Cromoglicate	DDI-DrugBank.d229.s0	NO_SECTION	NO_SETID	17
Drug Interaction During Pregnancy: Cromolyn sodium and isoproterenol were studied following subcutaneous injections in pregnant mice.
1	0	3	O	Drug
2	5	15	O	Interaction
3	17	22	O	During
4	24	32	O	Pregnancy
5	33	33	O	:
6	35	42	B-UNK	Cromolyn
7	44	49	L-UNK	sodium
8	51	53	O	and
9	55	67	U-UNK	isoproterenol
10	69	72	O	were
11	74	80	O	studied
12	82	90	O	following
13	92	103	O	subcutaneous
14	105	114	O	injections
15	116	117	O	in
16	119	126	O	pregnant
17	128	131	O	mice
NULL

Cromoglicate	DDI-DrugBank.d229.s1	NO_SECTION	NO_SETID	40
Cromolyn sodium alone in doses up to 540 mg/kg/day (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) did not cause significant increases in resorptions or major malformations.
1	0	7	B-UNK	Cromolyn
2	9	14	L-UNK	sodium
3	16	20	O	alone
4	22	23	O	in
5	25	29	O	doses
6	31	32	O	up
7	34	35	O	to
8	37	39	O	540
9	41	42	O	mg
10	43	43	O	/
11	44	45	O	kg
12	46	46	O	/
13	47	49	O	day
14	52	64	O	approximately
15	66	68	O	340
16	70	74	O	times
17	76	78	O	the
18	80	86	O	maximum
19	88	98	O	recommended
20	100	104	O	daily
21	106	115	O	inhalation
22	117	120	O	dose
23	122	123	O	in
24	125	130	O	adults
25	132	133	O	on
26	135	135	O	a
27	137	138	O	mg
28	139	139	O	/
29	140	141	O	m2
30	143	147	O	basis
31	150	152	O	did
32	154	156	O	not
33	158	162	O	cause
34	164	174	O	significant
35	176	184	O	increases
36	186	187	O	in
37	189	199	O	resorptions
38	201	202	O	or
39	204	208	O	major
40	210	222	O	malformations
NULL

Cromoglicate	DDI-DrugBank.d229.s2	NO_SECTION	NO_SETID	34
Isoproterenol alone at a dose of 2.7 mg/kg/day (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) increased both resorptions and malformations.
1	0	12	U-UNK	Isoproterenol
2	14	18	O	alone
3	20	21	O	at
4	23	23	O	a
5	25	28	O	dose
6	30	31	O	of
7	33	35	O	2.7
8	37	38	O	mg
9	39	39	O	/
10	40	41	O	kg
11	42	42	O	/
12	43	45	O	day
13	48	60	O	approximately
14	62	62	O	7
15	64	68	O	times
16	70	72	O	the
17	74	80	O	maximum
18	82	92	O	recommended
19	94	98	O	daily
20	100	109	O	inhalation
21	111	114	O	dose
22	116	117	O	in
23	119	124	O	adults
24	126	127	O	on
25	129	129	O	a
26	131	132	O	mg
27	133	133	O	/
28	134	135	O	m2
29	137	141	O	basis
30	144	152	O	increased
31	154	157	O	both
32	159	169	O	resorptions
33	171	173	O	and
34	175	187	O	malformations
NULL

Cromoglicate	DDI-DrugBank.d229.s3	NO_SECTION	NO_SETID	66
The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.
1	0	2	O	The
2	4	11	O	addition
3	13	14	O	of
4	16	18	O	540
5	20	21	O	mg
6	22	22	O	/
7	23	24	O	kg
8	25	25	O	/
9	26	28	O	day
10	30	31	O	of
11	33	40	B-UNK	cromolyn
12	42	47	L-UNK	sodium
13	50	62	O	approximately
14	64	66	O	340
15	68	72	O	times
16	74	76	O	the
17	78	84	O	maximum
18	86	96	O	recommended
19	98	102	O	daily
20	104	113	O	inhalation
21	115	118	O	dose
22	120	121	O	in
23	123	128	O	adults
24	130	131	O	on
25	133	133	O	a
26	135	136	O	mg
27	137	137	O	/
28	138	139	O	m2
29	141	145	O	basis
30	148	149	O	to
31	151	153	O	2.7
32	155	156	O	mg
33	157	157	O	/
34	158	159	O	kg
35	160	160	O	/
36	161	163	O	day
37	165	166	O	of
38	168	180	U-UNK	isoproterenol
39	183	195	O	approximately
40	197	197	O	7
41	199	203	O	times
42	205	207	O	the
43	209	215	O	maximum
44	217	227	O	recommended
45	229	233	O	daily
46	235	244	O	inhalation
47	246	249	O	dose
48	251	252	O	in
49	254	259	O	adults
50	261	262	O	on
51	264	264	O	a
52	266	267	O	mg
53	268	268	O	/
54	269	270	O	m2
55	272	276	O	basis
56	279	285	O	appears
57	287	288	O	to
58	290	293	O	have
59	295	303	O	increased
60	305	307	O	the
61	309	317	O	incidence
62	319	320	O	of
63	322	325	O	both
64	327	337	O	resorptions
65	339	341	O	and
66	343	355	O	malformations
NULL

Cyanocobalamin	DDI-DrugBank.d39.s0	NO_SECTION	NO_SETID	17
Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.
1	0	6	O	Persons
2	8	13	O	taking
3	15	18	O	most
4	20	30	U-UNK	antibiotics
5	31	31	O	,
6	33	44	U-UNK	methotrexate
7	46	48	O	and
8	50	62	U-UNK	pyrimethamine
9	64	73	O	invalidate
10	75	79	B-UNK	folic
11	81	84	L-UNK	acid
12	86	88	O	and
13	90	96	B-UNK	vitamin
14	98	100	L-UNK	B12
15	102	111	O	diagnostic
16	113	117	O	blood
17	119	124	O	assays
NULL

Cyanocobalamin	DDI-DrugBank.d39.s1	NO_SECTION	NO_SETID	19
Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.
1	0	9	U-UNK	Colchicine
2	11	14	B-UNK	para
3	16	29	I-UNK	aminosalicylic
4	31	34	L-UNK	acid
5	36	38	O	and
6	40	44	O	heavy
7	46	52	U-UNK	alcohol
8	54	59	O	intake
9	61	63	O	for
10	65	70	O	longer
11	72	75	O	than
12	77	77	O	2
13	79	83	O	weeks
14	85	87	O	may
15	89	95	O	produce
16	97	109	O	malabsorption
17	111	112	O	of
18	114	120	B-UNK	vitamin
19	122	124	L-UNK	B12
NULL

Cyclobenzaprine	DDI-DrugBank.d150.s0	NO_SECTION	NO_SETID	9
FLEXERIL may have life-threatening interactions with MAO inhibitors.
1	0	7	O	XXXXXXXX
2	9	11	O	may
3	13	16	O	have
4	18	21	O	life
5	23	33	O	threatening
6	35	46	O	interactions
7	48	51	O	with
8	53	55	B-UNK	MAO
9	57	66	L-UNK	inhibitors
NULL

Cyclobenzaprine	DDI-DrugBank.d150.s1	NO_SECTION	NO_SETID	14
FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
1	0	7	O	XXXXXXXX
2	9	11	O	may
3	13	19	O	enhance
4	21	23	O	the
5	25	31	O	effects
6	33	34	O	of
7	36	42	U-DYN	alcohol
8	43	43	O	,
9	45	56	U-DYN	barbiturates
10	57	57	O	,
11	59	61	O	and
12	63	67	O	other
13	69	71	B-DYN	CNS
14	73	83	L-DYN	depressants
NULL

Cyclobenzaprine	DDI-DrugBank.d150.s2	NO_SECTION	NO_SETID	13
Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.
1	0	8	B-UNK	Tricyclic
2	10	24	L-UNK	antidepressants
3	26	28	O	may
4	30	34	O	block
5	36	38	O	the
6	40	55	O	antihypertensive
7	57	62	O	action
8	64	65	O	of
9	67	78	U-UNK	guanethidine
10	80	82	O	and
11	84	92	O	similarly
12	94	99	O	acting
13	101	109	O	compounds
NULL

Cyclobenzaprine	DDI-DrugBank.d150.s3	NO_SECTION	NO_SETID	11
Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol
1	0	8	B-UNK	Tricyclic
2	10	24	L-UNK	antidepressants
3	26	28	O	may
4	30	36	O	enhance
5	38	40	O	the
6	42	48	O	seizure
7	50	53	O	risk
8	55	56	O	in
9	58	65	O	patients
10	67	72	O	taking
11	74	81	U-UNK	tramadol
NULL

Cyclopentolate	DDI-DrugBank.d298.s0	NO_SECTION	NO_SETID	12
Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;
1	0	13	O	XXXXXXXX
2	15	17	O	may
3	19	27	O	interfere
4	29	32	O	with
5	34	36	O	the
6	38	41	O	anti
7	43	50	O	glaucoma
8	52	57	O	action
9	59	60	O	of
10	62	70	U-DYN	carbachol
11	72	73	O	or
12	75	85	U-DYN	pilocarpine
NULL

Cyclopentolate	DDI-DrugBank.d298.s1	NO_SECTION	NO_SETID	19
also, concurrent use of this medication may antagonise the anti-glaucoma and miotic actions of ophthalmic cholinesterase inhibitors.
1	0	3	O	also
2	4	4	O	,
3	6	15	O	concurrent
4	17	19	O	use
5	21	22	O	of
6	24	27	O	this
7	29	38	O	medication
8	40	42	O	may
9	44	53	O	antagonise
10	55	57	O	the
11	59	62	O	anti
12	64	71	O	glaucoma
13	73	75	O	and
14	77	82	O	miotic
15	84	90	O	actions
16	92	93	O	of
17	95	104	O	ophthalmic
18	106	119	B-UNK	cholinesterase
19	121	130	L-UNK	inhibitors
NULL

Cyclophosphamide	DDI-DrugBank.d7.s0	NO_SECTION	NO_SETID	21
The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.
1	0	2	O	The
2	4	7	O	rate
3	9	10	O	of
4	12	21	O	metabolism
5	23	25	O	and
6	27	29	O	the
7	31	40	O	leukopenic
8	42	49	O	activity
9	51	52	O	of
10	54	69	O	XXXXXXXX
11	71	80	O	reportedly
12	82	84	O	are
13	86	94	O	increased
14	96	97	O	by
15	99	105	O	chronic
16	107	120	O	administration
17	122	123	O	of
18	125	128	O	high
19	130	134	O	doses
20	136	137	O	of
21	139	151	U-KIN	phenobarbital
NULL

Cyclophosphamide	DDI-DrugBank.d7.s1	NO_SECTION	NO_SETID	33
The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.
1	0	2	O	The
2	4	12	O	physician
3	14	19	O	should
4	21	22	O	be
5	24	28	O	alert
6	30	32	O	for
7	34	41	O	possible
8	43	50	O	combined
9	52	55	O	drug
10	57	63	O	actions
11	64	64	O	,
12	66	74	O	desirable
13	76	77	O	or
14	79	89	O	undesirable
15	90	90	O	,
16	92	100	O	involving
17	102	117	O	XXXXXXXX
18	119	122	O	even
19	124	129	O	though
20	131	146	O	XXXXXXXX
21	148	150	O	has
22	152	155	O	been
23	157	160	O	used
24	162	173	O	successfully
25	175	186	O	concurrently
26	188	191	O	with
27	193	197	O	other
28	199	203	O	drugs
29	204	204	O	,
30	206	214	O	including
31	216	220	O	other
32	222	230	O	cytotoxic
33	232	236	O	drugs
NULL

Cyclophosphamide	DDI-DrugBank.d7.s2	NO_SECTION	NO_SETID	20
Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride.
1	0	15	O	XXXXXXXX
2	17	25	O	treatment
3	26	26	O	,
4	28	32	O	which
5	34	39	O	causes
6	41	41	O	a
7	43	48	O	marked
8	50	52	O	and
9	54	63	O	persistent
10	65	74	O	inhibition
11	76	77	O	of
12	79	92	O	cholinesterase
13	94	101	O	activity
14	102	102	O	,
15	104	114	O	potentiates
16	116	118	O	the
17	120	125	O	effect
18	127	128	O	of
19	130	144	B-DYN	succinylcholine
20	146	153	L-DYN	chloride
NULL

Cyclophosphamide	DDI-DrugBank.d7.s3	NO_SECTION	NO_SETID	20
If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.
1	0	1	O	If
2	3	3	O	a
3	5	11	O	patient
4	13	15	O	has
5	17	20	O	been
6	22	28	O	treated
7	30	33	O	with
8	35	50	O	XXXXXXXX
9	52	57	O	within
10	59	60	O	10
11	62	65	O	days
12	67	68	O	of
13	70	76	O	general
14	78	87	O	anesthesia
15	88	88	O	,
16	90	92	O	the
17	94	109	O	anesthesiologist
18	111	116	O	should
19	118	119	O	be
20	121	127	O	alerted
NULL

Cycloserine	DDI-DrugBank.d128.s0	NO_SECTION	NO_SETID	9
May interact with wthionamide (Trecator-SC) and isoniazid (Nydrazid).
1	0	2	O	May
2	4	11	O	interact
3	13	16	O	with
4	18	28	O	wthionamide
5	31	38	O	Trecator
6	40	41	O	SC
7	44	46	O	and
8	48	56	U-UNK	isoniazid
9	59	66	O	XXXXXXXX
NULL

Cyproheptadine	DDI-DrugBank.d492.s0	NO_SECTION	NO_SETID	10
MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
1	0	2	B-UNK	MAO
2	4	13	L-UNK	inhibitors
3	15	21	O	prolong
4	23	25	O	and
5	27	35	O	intensify
6	37	39	O	the
7	41	55	O	anticholinergic
8	57	63	O	effects
9	65	66	O	of
10	68	81	U-UNK	antihistamines
NULL

Cyproheptadine	DDI-DrugBank.d492.s1	NO_SECTION	NO_SETID	22
Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
1	0	13	U-UNK	Antihistamines
2	15	17	O	may
3	19	22	O	have
4	24	31	O	additive
5	33	39	O	effects
6	41	44	O	with
7	46	52	U-UNK	alcohol
8	54	56	O	and
9	58	62	O	other
10	64	66	B-UNK	CNS
11	68	78	L-UNK	depressants
12	79	79	O	,
13	81	83	O	e.g
14	85	85	O	,
15	87	95	U-UNK	hypnotics
16	96	96	O	,
17	98	106	U-UNK	sedatives
18	107	107	O	,
19	109	121	U-UNK	tranquilizers
20	122	122	O	,
21	124	134	B-UNK	antianxiety
22	136	141	L-UNK	agents
NULL

Cysteamine	DDI-DrugBank.d259.s0	NO_SECTION	NO_SETID	6
No drug interactions have been reported.
1	0	1	O	No
2	3	6	O	drug
3	8	19	O	interactions
4	21	24	O	have
5	26	29	O	been
6	31	38	O	reported
NULL

Cytarabine	DDI-DrugBank.d101.s0	NO_SECTION	NO_SETID	10
Steady state plasma digitoxin concentrations did not appear to change.
1	0	5	O	Steady
2	7	11	O	state
3	13	18	O	plasma
4	20	28	U-UNK	digitoxin
5	30	43	O	concentrations
6	45	47	O	did
7	49	51	O	not
8	53	58	O	appear
9	60	61	O	to
10	63	68	O	change
NULL

Cytarabine	DDI-DrugBank.d101.s1	NO_SECTION	NO_SETID	17
Therefore, monitoring of plasma digoxin levels may be indicated in patients receiving similar combination chemotherapy regimens.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	monitoring
4	22	23	O	of
5	25	30	O	plasma
6	32	38	U-UNK	digoxin
7	40	45	O	levels
8	47	49	O	may
9	51	52	O	be
10	54	62	O	indicated
11	64	65	O	in
12	67	74	O	patients
13	76	84	O	receiving
14	86	92	O	similar
15	94	104	O	combination
16	106	117	O	chemotherapy
17	119	126	O	regimens
NULL

Cytarabine	DDI-DrugBank.d101.s2	NO_SECTION	NO_SETID	13
The utilization of digitoxin for such patients may be considered as an alternative.
1	0	2	O	The
2	4	14	O	utilization
3	16	17	O	of
4	19	27	U-UNK	digitoxin
5	29	31	O	for
6	33	36	O	such
7	38	45	O	patients
8	47	49	O	may
9	51	52	O	be
10	54	63	O	considered
11	65	66	O	as
12	68	69	O	an
13	71	81	O	alternative
NULL

Dactinomycin	DDI-DrugBank.d294.s0	NO_SECTION	NO_SETID	17
Drug/LaboratoryTest Interactions Dactinomycin may interfere with bioassay procedures for the determination of antibacterial drug levels.
1	0	3	O	Drug
2	4	4	O	/
3	5	18	O	LaboratoryTest
4	20	31	O	Interactions
5	33	44	O	XXXXXXXX
6	46	48	O	may
7	50	58	O	interfere
8	60	63	O	with
9	65	72	O	bioassay
10	74	83	O	procedures
11	85	87	O	for
12	89	91	O	the
13	93	105	O	determination
14	107	108	O	of
15	110	122	B-UNK	antibacterial
16	124	127	L-UNK	drug
17	129	134	O	levels
NULL

Dantrolene	DDI-DrugBank.d305.s0	NO_SECTION	NO_SETID	26
Dantrium is metabolized by the liver, and it is theoretically possible that its metabolism may be enhanced by drugs known to induce hepatic microsomal enzymes.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	22	O	metabolized
4	24	25	O	by
5	27	29	O	the
6	31	35	O	liver
7	36	36	O	,
8	38	40	O	and
9	42	43	O	it
10	45	46	O	is
11	48	60	O	theoretically
12	62	69	O	possible
13	71	74	O	that
14	76	78	O	its
15	80	89	O	metabolism
16	91	93	O	may
17	95	96	O	be
18	98	105	O	enhanced
19	107	108	O	by
20	110	114	O	drugs
21	116	120	O	known
22	122	123	O	to
23	125	130	O	induce
24	132	138	O	hepatic
25	140	149	O	microsomal
26	151	157	O	enzymes
NULL

Dantrolene	DDI-DrugBank.d305.s1	NO_SECTION	NO_SETID	11
However, neither phenobarbital nor diazepam appears to affect Dantrium metabolism.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	neither
4	17	29	U-UNK	phenobarbital
5	31	33	O	nor
6	35	42	U-UNK	diazepam
7	44	50	O	appears
8	52	53	O	to
9	55	60	O	affect
10	62	69	O	XXXXXXXX
11	71	80	O	metabolism
NULL

Dantrolene	DDI-DrugBank.d305.s2	NO_SECTION	NO_SETID	15
Binding to plasma protein is not significantly altered by diazepam, diphenylhydantoin, or phenylbutazone.
1	0	6	O	Binding
2	8	9	O	to
3	11	16	O	plasma
4	18	24	O	protein
5	26	27	O	is
6	29	31	O	not
7	33	45	O	significantly
8	47	53	O	altered
9	55	56	O	by
10	58	65	U-UNK	diazepam
11	66	66	O	,
12	68	84	U-UNK	diphenylhydantoin
13	85	85	O	,
14	87	88	O	or
15	90	103	U-UNK	phenylbutazone
NULL

Dantrolene	DDI-DrugBank.d305.s3	NO_SECTION	NO_SETID	14
Binding to plasma proteins is reduced by warfarin and clotibrate and increased by tolbutamide.
1	0	6	O	Binding
2	8	9	O	to
3	11	16	O	plasma
4	18	25	O	proteins
5	27	28	O	is
6	30	36	O	reduced
7	38	39	O	by
8	41	48	U-UNK	warfarin
9	50	52	O	and
10	54	63	O	clotibrate
11	65	67	O	and
12	69	77	O	increased
13	79	80	O	by
14	82	92	U-UNK	tolbutamide
NULL

Dantrolene	DDI-DrugBank.d305.s4	NO_SECTION	NO_SETID	13
Cardiovascular collapse in patients treated simultaneously with varapamil and dantrolene sodium is rare.
1	0	13	O	Cardiovascular
2	15	22	O	collapse
3	24	25	O	in
4	27	34	O	patients
5	36	42	O	treated
6	44	57	O	simultaneously
7	59	62	O	with
8	64	72	O	varapamil
9	74	76	O	and
10	78	87	O	XXXXXXXX
11	89	94	O	sodium
12	96	97	O	is
13	99	102	O	rare
NULL

Dantrolene	DDI-DrugBank.d305.s5	NO_SECTION	NO_SETID	30
The combination of therapeutic doses of intravenous dantrolene sodium and verapamil in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.
1	0	2	O	The
2	4	14	O	combination
3	16	17	O	of
4	19	29	O	therapeutic
5	31	35	O	doses
6	37	38	O	of
7	40	50	O	intravenous
8	52	61	O	XXXXXXXX
9	63	68	O	sodium
10	70	72	O	and
11	74	82	U-UNK	verapamil
12	84	85	O	in
13	87	95	U-UNK	halothane
14	97	97	O	a
15	99	108	O	chloralose
16	110	121	O	anesthetized
17	123	127	O	swine
18	129	131	O	has
19	133	140	O	resulted
20	142	143	O	in
21	145	155	O	ventricular
22	157	168	O	fibrillation
23	170	172	O	and
24	174	187	O	cardiovascular
25	189	196	O	collapse
26	198	199	O	in
27	201	211	O	association
28	213	216	O	with
29	218	223	O	marked
30	225	236	O	hyperkalemia
NULL

Dantrolene	DDI-DrugBank.d305.s6	NO_SECTION	NO_SETID	40
It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	25	O	the
6	27	37	O	combination
7	39	40	O	of
8	42	52	O	intravenous
9	54	63	O	XXXXXXXX
10	65	70	O	sodium
11	72	74	O	and
12	76	82	B-DYN	calcium
13	84	90	I-DYN	channel
14	92	99	L-DYN	blockers
15	100	100	O	,
16	102	105	O	such
17	107	108	O	as
18	110	118	U-DYN	verapamil
19	119	119	O	,
20	121	123	O	not
21	125	126	O	be
22	128	131	O	used
23	133	140	O	together
24	142	147	O	during
25	149	151	O	the
26	153	162	O	management
27	164	165	O	of
28	167	175	O	malignant
29	177	188	O	hyperthermia
30	190	195	O	crisis
31	197	201	O	until
32	203	205	O	the
33	207	215	O	relevance
34	217	218	O	of
35	220	224	O	these
36	226	233	O	findings
37	235	236	O	to
38	238	243	O	humans
39	245	246	O	is
40	248	258	O	established
NULL

Dantrolene	DDI-DrugBank.d305.s7	NO_SECTION	NO_SETID	9
Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.
1	0	13	O	Administration
2	15	16	O	of
3	18	27	O	XXXXXXXX
4	29	31	O	may
5	33	42	O	potentiate
6	44	53	U-DYN	vecuronium
7	55	61	O	induced
8	63	75	O	neuromuscular
9	77	81	O	block
NULL

Dapsone	DDI-DrugBank.d185.s0	NO_SECTION	NO_SETID	33
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/SMX).
1	0	0	O	A
2	2	5	O	drug
3	7	10	O	drug
4	12	22	O	interaction
5	24	28	O	study
6	30	38	O	evaluated
7	40	42	O	the
8	44	49	O	effect
9	51	52	O	of
10	54	56	O	the
11	58	60	O	use
12	62	63	O	of
13	65	70	O	XXXXXXXX
14	72	74	O	Gel
15	75	75	O	,
16	77	78	O	5%
17	79	79	O	,
18	81	82	O	in
19	84	94	O	combination
20	96	99	O	with
21	101	106	O	double
22	108	115	O	strength
23	118	120	O	160
24	122	123	O	mg
25	124	124	O	/
26	125	127	O	800
27	129	130	O	mg
28	133	144	U-UNK	trimethoprim
29	145	145	O	/
30	146	161	U-UNK	sulfamethoxazole
31	164	166	U-UNK	TMP
32	167	167	O	/
33	168	170	U-UNK	SMX
NULL

Dapsone	DDI-DrugBank.d185.s1	NO_SECTION	NO_SETID	13
During co-administration, systemic levels of TMP and SMX were essentially unchanged.
1	0	5	O	During
2	7	8	O	co
3	10	23	O	administration
4	24	24	O	,
5	26	33	O	systemic
6	35	40	O	levels
7	42	43	O	of
8	45	47	U-UNK	TMP
9	49	51	O	and
10	53	55	U-UNK	SMX
11	57	60	O	were
12	62	72	O	essentially
13	74	82	O	unchanged
NULL

Dapsone	DDI-DrugBank.d185.s2	NO_SECTION	NO_SETID	21
Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of TMP/SMX.
1	0	6	O	Notably
2	7	7	O	,
3	9	16	O	systemic
4	18	25	O	exposure
5	28	31	O	AUC0
6	33	34	O	12
7	37	38	O	of
8	40	46	O	XXXXXXXX
9	48	60	O	hydroxylamine
10	63	65	U-UNK	DHA
11	68	70	O	was
12	72	75	O	more
13	77	80	O	than
14	82	88	O	doubled
15	90	91	O	in
16	93	95	O	the
17	97	104	O	presence
18	106	107	O	of
19	109	111	U-UNK	TMP
20	112	112	O	/
21	113	115	U-UNK	SMX
NULL

Dapsone	DDI-DrugBank.d185.s3	NO_SECTION	NO_SETID	26
Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with TMP/SMX.
1	0	7	O	Exposure
2	9	12	O	from
3	14	16	O	the
4	18	25	O	proposed
5	27	33	O	topical
6	35	38	O	dose
7	40	41	O	is
8	43	47	O	about
9	49	50	O	1%
10	52	53	O	of
11	55	58	O	that
12	60	63	O	from
13	65	67	O	the
14	69	71	O	100
15	73	74	O	mg
16	76	79	O	oral
17	81	84	O	dose
18	85	85	O	,
19	87	90	O	even
20	92	95	O	when
21	97	98	O	co
22	100	111	O	administered
23	113	116	O	with
24	118	120	U-UNK	TMP
25	121	121	O	/
26	122	124	U-UNK	SMX
NULL

Dapsone	DDI-DrugBank.d185.s4	NO_SECTION	NO_SETID	10
Certain concomitant medications (such as rifampin, anticonvulsants, St.
1	0	6	O	Certain
2	8	18	O	concomitant
3	20	30	O	medications
4	33	36	O	such
5	38	39	O	as
6	41	48	U-UNK	rifampin
7	49	49	O	,
8	51	65	U-UNK	anticonvulsants
9	66	66	O	,
10	68	69	O	St
NULL

Dapsone	DDI-DrugBank.d185.s5	NO_SECTION	NO_SETID	18
John s wort) may increase the formation of dapsone hydroxylamine, a metabolite of dapsone associated with hemolysis.
1	0	3	O	John
2	5	5	O	s
3	7	10	O	wort
4	13	15	O	may
5	17	24	O	increase
6	26	28	O	the
7	30	38	O	formation
8	40	41	O	of
9	43	49	O	XXXXXXXX
10	51	63	O	hydroxylamine
11	64	64	O	,
12	66	66	O	a
13	68	77	O	metabolite
14	79	80	O	of
15	82	88	O	XXXXXXXX
16	90	99	O	associated
17	101	104	O	with
18	106	114	O	hemolysis
NULL

Dapsone	DDI-DrugBank.d185.s6	NO_SECTION	NO_SETID	22
With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
1	0	3	O	With
2	5	8	O	oral
3	10	16	O	XXXXXXXX
4	18	26	O	treatment
5	27	27	O	,
6	29	33	B-DYN	folic
7	35	38	I-DYN	acid
8	40	50	L-DYN	antagonists
9	52	55	O	such
10	57	58	O	as
11	60	72	U-DYN	pyrimethamine
12	74	77	O	have
13	79	82	O	been
14	84	88	O	noted
15	90	91	O	to
16	93	100	O	possibly
17	102	109	O	increase
18	111	113	O	the
19	115	124	O	likelihood
20	126	127	O	of
21	129	139	O	hematologic
22	141	149	O	reactions
NULL

Daptomycin	DDI-DrugBank.d337.s0	NO_SECTION	NO_SETID	42
Warfarin: Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	20	O	Concomitant
4	22	35	O	administration
5	37	38	O	of
6	40	49	O	XXXXXXXX
7	52	52	O	6
8	54	55	O	mg
9	56	56	O	/
10	57	58	O	kg
11	60	63	O	once
12	65	69	O	every
13	71	72	O	24
14	74	78	O	hours
15	80	82	O	for
16	84	84	O	5
17	86	89	O	days
18	92	94	O	and
19	96	103	U-UNK	warfarin
20	106	107	O	25
21	109	110	O	mg
22	112	117	O	single
23	119	122	O	oral
24	124	127	O	dose
25	130	132	O	had
26	134	135	O	no
27	137	147	O	significant
28	149	154	O	effect
29	156	157	O	on
30	159	161	O	the
31	163	178	O	pharmacokinetics
32	180	181	O	of
33	183	188	O	either
34	190	193	O	drug
35	194	194	O	,
36	196	198	O	and
37	200	202	O	the
38	204	206	O	INR
39	208	210	O	was
40	212	214	O	not
41	216	228	O	significantly
42	230	236	O	altered
NULL

Daptomycin	DDI-DrugBank.d337.s1	NO_SECTION	NO_SETID	28
HMG-CoA Reductase Inhibitors: Inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of CPK.
1	0	2	B-UNK	HMG
2	4	6	I-UNK	CoA
3	8	16	I-UNK	Reductase
4	18	27	L-UNK	Inhibitors
5	28	28	O	:
6	30	39	B-UNK	Inhibitors
7	41	42	I-UNK	of
8	44	46	I-UNK	HMG
9	48	50	I-UNK	CoA
10	52	60	L-UNK	reductase
11	62	64	O	may
12	66	70	O	cause
13	72	79	O	myopathy
14	80	80	O	,
15	82	86	O	which
16	88	89	O	is
17	91	100	O	manifested
18	102	103	O	as
19	105	110	O	muscle
20	112	115	O	pain
21	117	118	O	or
22	120	127	O	weakness
23	129	138	O	associated
24	140	143	O	with
25	145	152	O	elevated
26	154	159	O	levels
27	161	162	O	of
28	164	166	O	CPK
NULL

Daptomycin	DDI-DrugBank.d337.s2	NO_SECTION	NO_SETID	39
There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which 10 healthy subjects on stable simvastatin therapy were treated concurrently with daptomycin (4 mg/kg once every 24 hours) for 14 days.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	20	O	reports
5	22	23	O	of
6	25	32	O	skeletal
7	34	41	O	myopathy
8	43	44	O	in
9	46	46	O	a
10	48	54	O	placebo
11	56	65	O	controlled
12	67	71	O	Phase
13	73	73	O	I
14	75	79	O	trial
15	81	82	O	in
16	84	88	O	which
17	90	91	O	10
18	93	99	O	healthy
19	101	108	O	subjects
20	110	111	O	on
21	113	118	O	stable
22	120	130	U-UNK	simvastatin
23	132	138	O	therapy
24	140	143	O	were
25	145	151	O	treated
26	153	164	O	concurrently
27	166	169	O	with
28	171	180	O	XXXXXXXX
29	183	183	O	4
30	185	186	O	mg
31	187	187	O	/
32	188	189	O	kg
33	191	194	O	once
34	196	200	O	every
35	202	203	O	24
36	205	209	O	hours
37	212	214	O	for
38	216	217	O	14
39	219	222	O	days
NULL

Daptomycin	DDI-DrugBank.d337.s3	NO_SECTION	NO_SETID	31
Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.
1	0	9	O	Experience
2	11	14	O	with
3	16	17	O	co
4	19	32	O	administration
5	34	35	O	of
6	37	39	B-UNK	HMG
7	41	43	I-UNK	CoA
8	45	53	I-UNK	reductase
9	55	64	L-UNK	inhibitors
10	66	68	O	and
11	70	77	U-UNK	Fentanyl
12	79	80	O	in
13	82	89	O	patients
14	91	92	O	is
15	94	124	O	limited,therefore,consideration
16	126	131	O	should
17	133	134	O	be
18	136	140	O	given
19	142	143	O	to
20	145	155	O	temporarily
21	157	166	O	suspending
22	168	170	O	use
23	172	173	O	of
24	175	177	B-UNK	HMG
25	179	181	I-UNK	CoA
26	183	191	I-UNK	reductase
27	193	202	L-UNK	inhibitors
28	204	205	O	in
29	207	214	O	patients
30	216	224	O	receiving
31	226	233	U-UNK	Fentanyl
NULL

Daptomycin	DDI-DrugBank.d337.s4	NO_SECTION	NO_SETID	13
Drug-Laboratory Test Interactions: There are no reported drug-laboratory test interactions.
1	0	3	O	Drug
2	5	14	O	Laboratory
3	16	19	O	Test
4	21	32	O	Interactions
5	33	33	O	:
6	35	39	O	There
7	41	43	O	are
8	45	46	O	no
9	48	55	O	reported
10	57	60	O	drug
11	62	71	O	laboratory
12	73	76	O	test
13	78	89	O	interactions
NULL

Darbepoetin alfa	DDI-DrugBank.d534.s0	NO_SECTION	NO_SETID	10
No formal drug interaction studies of Aranesp  have been performed.
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	25	O	interaction
5	27	33	O	studies
6	35	36	O	of
7	38	44	O	XXXXXXXX
8	47	50	O	have
9	52	55	O	been
10	57	65	O	performed
NULL

Darifenacin	DDI-DrugBank.d459.s0	NO_SECTION	NO_SETID	29
The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
1	0	2	O	The
2	4	8	O	daily
3	10	13	O	dose
4	15	16	O	of
5	18	24	O	XXXXXXXX
6	26	31	O	should
7	33	35	O	not
8	37	42	O	exceed
9	44	46	O	7.5
10	48	49	O	mg
11	51	54	O	when
12	56	69	O	coadministered
13	71	74	O	with
14	76	81	O	potent
15	83	88	O	CYP3A4
16	90	99	O	inhibitors
17	102	104	O	e.g
18	106	106	O	,
19	108	119	U-DYN	ketoconazole
20	120	120	O	,
21	122	133	U-DYN	itraconazole
22	134	134	O	,
23	136	144	U-DYN	ritonavir
24	145	145	O	,
25	147	156	U-DYN	nelfinavir
26	157	157	O	,
27	159	172	U-DYN	clarithromycin
28	174	176	O	and
29	178	187	O	nefazadone
NULL

Darifenacin	DDI-DrugBank.d459.s1	NO_SECTION	NO_SETID	36
Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	22	O	taken
5	24	27	O	when
6	29	35	O	XXXXXXXX
7	37	38	O	is
8	40	43	O	used
9	45	57	O	concomitantly
10	59	62	O	with
11	64	74	O	medications
12	76	79	O	that
13	81	83	O	are
14	85	97	O	predominantly
15	99	109	O	metabolized
16	111	112	O	by
17	114	119	O	CYP2D6
18	121	123	O	and
19	125	129	O	which
20	131	134	O	have
21	136	136	O	a
22	138	143	O	narrow
23	145	155	O	therapeutic
24	157	162	O	window
25	163	163	O	,
26	165	168	O	such
27	170	171	O	as
28	173	182	U-DYN	flecainide
29	183	183	O	,
30	185	196	U-DYN	thioridazine
31	198	200	O	and
32	202	210	B-DYN	tricyclic
33	212	226	L-DYN	antidepressants
34	229	231	O	see
35	233	240	O	CLINICAL
36	242	253	O	PHARMACOLOGY
NULL

Darifenacin	DDI-DrugBank.d459.s2	NO_SECTION	NO_SETID	30
The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	29	O	XXXXXXXX
6	31	34	O	with
7	36	40	O	other
8	42	56	B-DYN	anticholinergic
9	58	63	L-DYN	agents
10	65	67	O	may
11	69	76	O	increase
12	78	80	O	the
13	82	90	O	frequency
14	92	94	O	and
15	95	95	O	/
16	96	97	O	or
17	99	106	O	severity
18	108	109	O	of
19	111	113	O	dry
20	115	119	O	mouth
21	120	120	O	,
22	122	133	O	constipation
23	134	134	O	,
24	136	142	O	blurred
25	144	149	O	vision
26	151	153	O	and
27	155	159	O	other
28	161	175	O	anticholinergic
29	177	191	O	pharmacological
30	193	199	O	effects
NULL

Darifenacin	DDI-DrugBank.d459.s3	NO_SECTION	NO_SETID	18
Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to effects on gastrointestinal motility.
1	0	14	B-UNK	Anticholinergic
2	16	21	L-UNK	agents
3	23	25	O	may
4	27	37	O	potentially
5	39	43	O	alter
6	45	47	O	the
7	49	58	O	absorption
8	60	61	O	of
9	63	66	O	some
10	68	80	O	concomitantly
11	82	93	O	administered
12	95	99	O	drugs
13	101	103	O	due
14	105	106	O	to
15	108	114	O	effects
16	116	117	O	on
17	119	134	O	gastrointestinal
18	136	143	O	motility
NULL

Darifenacin	DDI-DrugBank.d459.s4	NO_SECTION	NO_SETID	14
Drug Laboratory Test Interactions Interactions between darifenacin and laboratory tests have not been studied.
1	0	3	O	Drug
2	5	14	O	Laboratory
3	16	19	O	Test
4	21	32	O	Interactions
5	34	45	O	Interactions
6	47	53	O	between
7	55	65	O	XXXXXXXX
8	67	69	O	and
9	71	80	O	laboratory
10	82	86	O	tests
11	88	91	O	have
12	93	95	O	not
13	97	100	O	been
14	102	108	O	studied
NULL

Dasatinib	DDI-DrugBank.d48.s0	NO_SECTION	NO_SETID	15
Drugs that may increase dasatinib plasma concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate.
1	0	4	O	Drugs
2	6	9	O	that
3	11	13	O	may
4	15	22	O	increase
5	24	32	O	XXXXXXXX
6	34	39	O	plasma
7	41	54	O	concentrations
8	56	61	O	CYP3A4
9	63	72	O	Inhibitors
10	73	73	O	:
11	75	83	O	XXXXXXXX
12	85	86	O	is
13	88	88	O	a
14	90	95	O	CYP3A4
15	97	105	O	substrate
NULL

Dasatinib	DDI-DrugBank.d48.s1	NO_SECTION	NO_SETID	41
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	25	O	XXXXXXXX
5	27	29	O	and
6	31	35	O	drugs
7	37	40	O	that
8	42	48	O	inhibit
9	50	55	O	CYP3A4
10	58	59	O	eg
11	60	60	O	,
12	62	73	U-KIN	ketoconazole
13	74	74	O	,
14	76	87	U-KIN	itraconazole
15	88	88	O	,
16	90	101	U-KIN	erythromycin
17	102	102	O	,
18	104	117	U-KIN	clarithromycin
19	118	118	O	,
20	120	128	U-KIN	ritonavir
21	129	129	O	,
22	131	140	U-KIN	atazanavir
23	141	141	O	,
24	143	151	U-KIN	indinavir
25	152	152	O	,
26	154	163	U-KIN	nefazodone
27	164	164	O	,
28	166	175	U-KIN	nelfinavir
29	176	176	O	,
30	178	187	U-KIN	saquinavir
31	188	188	O	,
32	190	202	U-KIN	telithromycin
33	205	207	O	may
34	209	216	O	increase
35	218	225	O	exposure
36	227	228	O	to
37	230	238	U-UNK	dasatinib
38	240	242	O	and
39	244	249	O	should
40	251	252	O	be
41	254	260	O	avoided
NULL

Dasatinib	DDI-DrugBank.d48.s2	NO_SECTION	NO_SETID	30
In patients receiving treatment with SPRYCEL, close monitoring for toxicity and a SPRYCEL dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.
1	0	1	O	In
2	3	10	O	patients
3	12	20	O	receiving
4	22	30	O	treatment
5	32	35	O	with
6	37	43	O	XXXXXXXX
7	44	44	O	,
8	46	50	O	close
9	52	61	O	monitoring
10	63	65	O	for
11	67	74	O	toxicity
12	76	78	O	and
13	80	80	O	a
14	82	88	O	XXXXXXXX
15	90	93	O	dose
16	95	103	O	reduction
17	105	110	O	should
18	112	113	O	be
19	115	124	O	considered
20	126	127	O	if
21	129	136	O	systemic
22	138	151	O	administration
23	153	154	O	of
24	156	156	O	a
25	158	163	O	potent
26	165	170	O	CYP3A4
27	172	180	O	inhibitor
28	182	187	O	cannot
29	189	190	O	be
30	192	198	O	avoided
NULL

Dasatinib	DDI-DrugBank.d48.s3	NO_SECTION	NO_SETID	20
Drugs that may decrease dasatinib plasma concentrations CYP3A4 Inducers: Drugs that induce CYP3A4 activity may decrease dasatinib plasma concentrations.
1	0	4	O	Drugs
2	6	9	O	that
3	11	13	O	may
4	15	22	O	decrease
5	24	32	O	XXXXXXXX
6	34	39	O	plasma
7	41	54	O	concentrations
8	56	61	O	CYP3A4
9	63	70	O	Inducers
10	71	71	O	:
11	73	77	O	Drugs
12	79	82	O	that
13	84	89	O	induce
14	91	96	O	CYP3A4
15	98	105	O	activity
16	107	109	O	may
17	111	118	O	decrease
18	120	128	O	XXXXXXXX
19	130	135	O	plasma
20	137	150	O	concentrations
NULL

Dasatinib	DDI-DrugBank.d48.s4	NO_SECTION	NO_SETID	30
In patients in whom CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital) are indicated, alternative agents with less enzyme induction potential should be used.
1	0	1	O	In
2	3	10	O	patients
3	12	13	O	in
4	15	18	O	whom
5	20	25	O	CYP3A4
6	27	34	O	inducers
7	37	38	O	eg
8	39	39	O	,
9	41	53	U-UNK	dexamethasone
10	54	54	O	,
11	56	64	U-UNK	phenytoin
12	65	65	O	,
13	67	79	U-UNK	carbamazepine
14	80	80	O	,
15	82	91	U-UNK	rifampicin
16	92	92	O	,
17	94	106	U-UNK	phenobarbital
18	109	111	O	are
19	113	121	O	indicated
20	122	122	O	,
21	124	134	O	alternative
22	136	141	O	agents
23	143	146	O	with
24	148	151	O	less
25	153	158	O	enzyme
26	160	168	O	induction
27	170	178	O	potential
28	180	185	O	should
29	187	188	O	be
30	190	193	O	used
NULL

Dasatinib	DDI-DrugBank.d48.s5	NO_SECTION	NO_SETID	18
If SPRYCEL must be administered with a CYP3A4 inducer, a dose increase in SPRYCEL should be considered.
1	0	1	O	If
2	3	9	O	XXXXXXXX
3	11	14	O	must
4	16	17	O	be
5	19	30	O	administered
6	32	35	O	with
7	37	37	O	a
8	39	44	O	CYP3A4
9	46	52	O	inducer
10	53	53	O	,
11	55	55	O	a
12	57	60	O	dose
13	62	69	O	increase
14	71	72	O	in
15	74	80	O	XXXXXXXX
16	82	87	O	should
17	89	90	O	be
18	92	101	O	considered
NULL

Dasatinib	DDI-DrugBank.d48.s6	NO_SECTION	NO_SETID	11
St. Johns wort (Hypericum perforatum) may decrease SPRYCEL plasma concentrations unpredictably.
1	0	1	O	St
2	4	8	O	Johns
3	10	13	O	wort
4	16	24	O	Hypericum
5	26	35	O	perforatum
6	38	40	O	may
7	42	49	O	decrease
8	51	57	O	XXXXXXXX
9	59	64	O	plasma
10	66	79	O	concentrations
11	81	93	O	unpredictably
NULL

Dasatinib	DDI-DrugBank.d48.s7	NO_SECTION	NO_SETID	9
Patients receiving SPRYCEL should not take St. Johns wort.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	25	O	XXXXXXXX
4	27	32	O	should
5	34	36	O	not
6	38	41	O	take
7	43	44	O	St
8	47	51	O	Johns
9	53	56	O	wort
NULL

Dasatinib	DDI-DrugBank.d48.s8	NO_SECTION	NO_SETID	13
Antacids: Nonclinical data demonstrate that the solubility of dasatinib is pH dependent.
1	0	7	U-UNK	Antacids
2	8	8	O	:
3	10	20	O	Nonclinical
4	22	25	O	data
5	27	37	O	demonstrate
6	39	42	O	that
7	44	46	O	the
8	48	57	O	solubility
9	59	60	O	of
10	62	70	O	XXXXXXXX
11	72	73	O	is
12	75	76	O	pH
13	78	86	O	dependent
NULL

Dasatinib	DDI-DrugBank.d48.s9	NO_SECTION	NO_SETID	9
Simultaneous administration of SPRYCEL with antacids should be avoided.
1	0	11	O	Simultaneous
2	13	26	O	administration
3	28	29	O	of
4	31	37	O	XXXXXXXX
5	39	42	O	with
6	44	51	U-DYN	antacids
7	53	58	O	should
8	60	61	O	be
9	63	69	O	avoided
NULL

Dasatinib	DDI-DrugBank.d48.s10	NO_SECTION	NO_SETID	26
If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.
1	0	1	O	If
2	3	9	U-DYN	antacid
3	11	17	O	therapy
4	19	20	O	is
5	22	27	O	needed
6	28	28	O	,
7	30	32	O	the
8	34	40	O	antacid
9	42	45	O	dose
10	47	52	O	should
11	54	55	O	be
12	57	68	O	administered
13	70	71	O	at
14	73	77	O	least
15	79	79	O	2
16	81	85	O	hours
17	87	91	O	prior
18	93	94	O	to
19	96	97	O	or
20	99	99	O	2
21	101	105	O	hours
22	107	111	O	after
23	113	115	O	the
24	117	120	O	dose
25	122	123	O	of
26	125	131	O	XXXXXXXX
NULL

Dasatinib	DDI-DrugBank.d48.s11	NO_SECTION	NO_SETID	32
H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
1	0	1	B-UNK	H2
2	3	10	L-UNK	Blockers
3	11	11	O	/
4	12	17	B-UNK	Proton
5	19	22	I-UNK	Pump
6	24	33	L-UNK	Inhibitors
7	34	34	O	:
8	36	39	O	Long
9	41	44	O	term
10	46	56	O	suppression
11	58	59	O	of
12	61	67	O	gastric
13	69	72	O	acid
14	74	82	O	secretion
15	84	85	O	by
16	87	88	B-DYN	H2
17	90	97	L-DYN	blockers
18	99	100	O	or
19	102	107	B-DYN	proton
20	109	112	I-DYN	pump
21	114	123	L-DYN	inhibitors
22	126	127	O	eg
23	128	128	O	,
24	130	139	U-DYN	famotidine
25	141	143	O	and
26	145	154	U-DYN	omeprazole
27	157	158	O	is
28	160	165	O	likely
29	167	168	O	to
30	170	175	O	reduce
31	177	185	O	XXXXXXXX
32	187	194	O	exposure
NULL

Dasatinib	DDI-DrugBank.d48.s12	NO_SECTION	NO_SETID	15
The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	24	B-DYN	H2
6	26	33	L-DYN	blockers
7	35	36	O	or
8	38	43	B-DYN	proton
9	45	48	I-DYN	pump
10	50	59	L-DYN	inhibitors
11	61	64	O	with
12	66	72	O	XXXXXXXX
13	74	75	O	is
14	77	79	O	not
15	81	91	O	recommended
NULL

Dasatinib	DDI-DrugBank.d48.s13	NO_SECTION	NO_SETID	21
The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	18	U-UNK	antacids
5	20	25	O	should
6	27	28	O	be
7	30	39	O	considered
8	41	42	O	in
9	44	48	O	place
10	50	51	O	of
11	53	54	B-DYN	H2
12	56	63	L-DYN	blockers
13	65	66	O	or
14	68	73	B-DYN	proton
15	75	78	I-DYN	pump
16	80	89	L-DYN	inhibitors
17	91	92	O	in
18	94	101	O	patients
19	103	111	O	receiving
20	113	119	O	XXXXXXXX
21	121	127	O	therapy
NULL

Dasatinib	DDI-DrugBank.d48.s14	NO_SECTION	NO_SETID	21
Drugs that may have their plasma concentration altered by dasatinib CYP3A4 Substrates: Dasatinib is a time-dependent inhibitor of CYP3A4.
1	0	4	O	Drugs
2	6	9	O	that
3	11	13	O	may
4	15	18	O	have
5	20	24	O	their
6	26	31	O	plasma
7	33	45	O	concentration
8	47	53	O	altered
9	55	56	O	by
10	58	66	O	XXXXXXXX
11	68	73	O	CYP3A4
12	75	84	O	Substrates
13	85	85	O	:
14	87	95	O	XXXXXXXX
15	97	98	O	is
16	100	100	O	a
17	102	105	O	time
18	107	115	O	dependent
19	117	125	O	inhibitor
20	127	128	O	of
21	130	135	O	CYP3A4
NULL

Dasatinib	DDI-DrugBank.d48.s15	NO_SECTION	NO_SETID	48
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
1	0	8	O	Therefore
2	9	9	O	,
3	11	16	O	CYP3A4
4	18	27	O	substrates
5	29	33	O	known
6	35	36	O	to
7	38	41	O	have
8	43	43	O	a
9	45	50	O	narrow
10	52	62	O	therapeutic
11	64	68	O	index
12	70	73	O	such
13	75	76	O	as
14	78	87	U-DYN	alfentanil
15	88	88	O	,
16	90	99	U-DYN	astemizole
17	100	100	O	,
18	102	112	U-DYN	terfenadine
19	113	113	O	,
20	115	123	U-DYN	cisapride
21	124	124	O	,
22	126	137	U-DYN	cyclosporine
23	138	138	O	,
24	140	147	U-DYN	fentanyl
25	148	148	O	,
26	150	157	U-DYN	pimozide
27	158	158	O	,
28	160	168	U-DYN	quinidine
29	169	169	O	,
30	171	179	U-DYN	sirolimus
31	180	180	O	,
32	182	191	U-DYN	tacrolimus
33	192	192	O	,
34	194	195	O	or
35	197	201	B-DYN	ergot
36	203	211	L-DYN	alkaloids
37	214	223	U-DYN	ergotamine
38	224	224	O	,
39	226	242	U-DYN	dihydroergotamine
40	245	250	O	should
41	252	253	O	be
42	255	266	O	administered
43	268	271	O	with
44	273	279	O	caution
45	281	282	O	in
46	284	291	O	patients
47	293	301	O	receiving
48	303	309	O	XXXXXXXX
NULL

Dasatinib	DDI-DrugBank.d48.s16	NO_SECTION	NO_SETID	50
Hepatic Impairment There are currently no clinical studies with SPRYCEL in patients with impaired liver function (clinical studies have excluded patients with ALT and/or AST  2.5 times the upper limit of the normal range and/or total bilirubin  2 times the upper limit of the normal range).
1	0	6	O	Hepatic
2	8	17	O	Impairment
3	19	23	O	There
4	25	27	O	are
5	29	37	O	currently
6	39	40	O	no
7	42	49	O	clinical
8	51	57	O	studies
9	59	62	O	with
10	64	70	O	XXXXXXXX
11	72	73	O	in
12	75	82	O	patients
13	84	87	O	with
14	89	96	O	impaired
15	98	102	O	liver
16	104	111	O	function
17	114	121	O	clinical
18	123	129	O	studies
19	131	134	O	have
20	136	143	O	excluded
21	145	152	O	patients
22	154	157	O	with
23	159	161	O	ALT
24	163	165	O	and
25	166	166	O	/
26	167	168	O	or
27	170	172	O	AST
28	175	177	O	2.5
29	179	183	O	times
30	185	187	O	the
31	189	193	O	upper
32	195	199	O	limit
33	201	202	O	of
34	204	206	O	the
35	208	213	O	normal
36	215	219	O	range
37	221	223	O	and
38	224	224	O	/
39	225	226	O	or
40	228	232	O	total
41	234	242	O	bilirubin
42	245	245	O	2
43	247	251	O	times
44	253	255	O	the
45	257	261	O	upper
46	263	267	O	limit
47	269	270	O	of
48	272	274	O	the
49	276	281	O	normal
50	283	287	O	range
NULL

Dasatinib	DDI-DrugBank.d48.s17	NO_SECTION	NO_SETID	6
Metabolism of dasatinib is mainly hepatic.
1	0	9	O	Metabolism
2	11	12	O	of
3	14	22	O	XXXXXXXX
4	24	25	O	is
5	27	32	O	mainly
6	34	40	O	hepatic
NULL

Dasatinib	DDI-DrugBank.d48.s18	NO_SECTION	NO_SETID	8
Caution is recommended in patients with hepatic impairment.
1	0	6	O	Caution
2	8	9	O	is
3	11	21	O	recommended
4	23	24	O	in
5	26	33	O	patients
6	35	38	O	with
7	40	46	O	hepatic
8	48	57	O	impairment
NULL

Dasatinib	DDI-DrugBank.d48.s19	NO_SECTION	NO_SETID	34
Renal Impairment There are currently no clinical studies with SPRYCEL in patients with impaired renal function (clinical studies have excluded patients with serum creatinine concentration  1.5 times the upper limit of the normal range).
1	0	4	O	Renal
2	6	15	O	Impairment
3	17	21	O	There
4	23	25	O	are
5	27	35	O	currently
6	37	38	O	no
7	40	47	O	clinical
8	49	55	O	studies
9	57	60	O	with
10	62	68	O	XXXXXXXX
11	70	71	O	in
12	73	80	O	patients
13	82	85	O	with
14	87	94	O	impaired
15	96	100	O	renal
16	102	109	O	function
17	112	119	O	clinical
18	121	127	O	studies
19	129	132	O	have
20	134	141	O	excluded
21	143	150	O	patients
22	152	155	O	with
23	157	161	O	serum
24	163	172	O	creatinine
25	174	186	O	concentration
26	189	191	O	1.5
27	193	197	O	times
28	199	201	O	the
29	203	207	O	upper
30	209	213	O	limit
31	215	216	O	of
32	218	220	O	the
33	222	227	O	normal
34	229	233	O	range
NULL

Dasatinib	DDI-DrugBank.d48.s20	NO_SECTION	NO_SETID	10
Dasatinib and its metabolites are minimally excreted via the kidney.
1	0	8	O	XXXXXXXX
2	10	12	O	and
3	14	16	O	its
4	18	28	O	metabolites
5	30	32	O	are
6	34	42	O	minimally
7	44	51	O	excreted
8	53	55	O	via
9	57	59	O	the
10	61	66	O	kidney
NULL

Dasatinib	DDI-DrugBank.d48.s21	NO_SECTION	NO_SETID	27
Since the renal excretion of unchanged dasatinib and its metabolites is  4%, a decrease in total body clearance is not expected in patients with renal insufficiency.
1	0	4	O	Since
2	6	8	O	the
3	10	14	O	renal
4	16	24	O	excretion
5	26	27	O	of
6	29	37	O	unchanged
7	39	47	O	XXXXXXXX
8	49	51	O	and
9	53	55	O	its
10	57	67	O	metabolites
11	69	70	O	is
12	73	74	O	4%
13	75	75	O	,
14	77	77	O	a
15	79	86	O	decrease
16	88	89	O	in
17	91	95	O	total
18	97	100	O	body
19	102	110	O	clearance
20	112	113	O	is
21	115	117	O	not
22	119	126	O	expected
23	128	129	O	in
24	131	138	O	patients
25	140	143	O	with
26	145	149	O	renal
27	151	163	O	insufficiency
NULL

Daunorubicin	DDI-DrugBank.d69.s0	NO_SECTION	NO_SETID	16
Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.
1	0	2	O	Use
2	4	5	O	of
3	7	16	O	XXXXXXXX
4	18	19	O	in
5	21	21	O	a
6	23	29	O	patient
7	31	33	O	who
8	35	37	O	has
9	39	48	O	previously
10	50	57	O	received
11	59	69	U-DYN	doxorubicin
12	71	79	O	increases
13	81	83	O	the
14	85	88	O	risk
15	90	91	O	of
16	93	106	O	cardiotoxicity
NULL

Daunorubicin	DDI-DrugBank.d69.s1	NO_SECTION	NO_SETID	20
Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.
1	0	9	O	XXXXXXXX
2	11	16	O	should
3	18	20	O	not
4	22	23	O	be
5	25	28	O	used
6	30	31	O	in
7	33	40	O	patients
8	42	44	O	who
9	46	49	O	have
10	51	60	O	previously
11	62	69	O	received
12	71	73	O	the
13	75	85	O	recommended
14	87	93	O	maximum
15	95	104	O	cumulative
16	106	110	O	doses
17	112	113	O	of
18	115	125	U-DYN	doxorubicin
19	127	128	O	or
20	130	139	O	XXXXXXXX
NULL

Daunorubicin	DDI-DrugBank.d69.s2	NO_SECTION	NO_SETID	11
Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.
1	0	15	U-DYN	Cyclophosphamide
2	17	20	O	used
3	22	33	O	concurrently
4	35	38	O	with
5	40	49	O	XXXXXXXX
6	51	53	O	may
7	55	58	O	also
8	60	65	O	result
9	67	68	O	in
10	70	78	O	increased
11	80	93	O	cardiotoxicity
NULL

Daunorubicin	DDI-DrugBank.d69.s3	NO_SECTION	NO_SETID	14
Dosage reduction of Cerubidine may be required when used concurrently with other myelosuppressive agents.
1	0	5	O	Dosage
2	7	15	O	reduction
3	17	18	O	of
4	20	29	O	XXXXXXXX
5	31	33	O	may
6	35	36	O	be
7	38	45	O	required
8	47	50	O	when
9	52	55	O	used
10	57	68	O	concurrently
11	70	73	O	with
12	75	79	O	other
13	81	96	O	myelosuppressive
14	98	103	O	agents
NULL

Daunorubicin	DDI-DrugBank.d69.s4	NO_SECTION	NO_SETID	19
Hepatotoxic medications, such as high-dose methotrexate, may impair liver function and increase the risk of toxicity.
1	0	10	O	Hepatotoxic
2	12	22	O	medications
3	23	23	O	,
4	25	28	O	such
5	30	31	O	as
6	33	36	O	high
7	38	41	O	dose
8	43	54	U-UNK	methotrexate
9	55	55	O	,
10	57	59	O	may
11	61	66	O	impair
12	68	72	O	liver
13	74	81	O	function
14	83	85	O	and
15	87	94	O	increase
16	96	98	O	the
17	100	103	O	risk
18	105	106	O	of
19	108	115	O	toxicity
NULL

Decamethonium	DDI-DrugBank.d167.s0	NO_SECTION	NO_SETID	21
Potentially fatal drug interactions may occur when coadministered with digoxin, as this may enhance cardiovascular depression and bradyarrhythmias may occur.
1	0	10	O	Potentially
2	12	16	O	fatal
3	18	21	O	drug
4	23	34	O	interactions
5	36	38	O	may
6	40	44	O	occur
7	46	49	O	when
8	51	64	O	coadministered
9	66	69	O	with
10	71	77	U-UNK	digoxin
11	78	78	O	,
12	80	81	O	as
13	83	86	O	this
14	88	90	O	may
15	92	98	O	enhance
16	100	113	O	cardiovascular
17	115	124	O	depression
18	126	128	O	and
19	130	145	O	bradyarrhythmias
20	147	149	O	may
21	151	155	O	occur
NULL

Decamethonium	DDI-DrugBank.d167.s1	NO_SECTION	NO_SETID	18
Anticholinesterases (neostgmine, physostigmine), lignocaine, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.
1	0	18	U-UNK	Anticholinesterases
2	21	30	O	neostgmine
3	31	31	O	,
4	33	45	U-UNK	physostigmine
5	47	47	O	,
6	49	58	U-UNK	lignocaine
7	59	59	O	,
8	61	67	U-UNK	quinine
9	68	68	O	,
10	70	81	U-UNK	procainamide
11	83	85	O	can
12	87	93	O	enhance
13	95	102	O	toxicity
14	104	106	O	and
15	108	112	O	cause
16	114	119	O	cardio
17	121	131	O	respiratory
18	133	142	O	depression
NULL

Decamethonium	DDI-DrugBank.d167.s2	NO_SECTION	NO_SETID	29
In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	25	O	neuromuscular
5	27	34	O	blocking
6	36	41	O	action
7	43	44	O	is
8	46	53	O	enhanced
9	55	56	O	by
10	58	64	O	general
11	66	76	U-UNK	anesthetics
12	77	77	O	,
13	79	83	O	local
14	85	95	U-UNK	anesthetics
15	97	100	O	like
16	102	110	U-UNK	lidocaine
17	111	111	O	,
18	113	120	U-UNK	procaine
19	121	121	O	,
20	123	126	B-UNK	beta
21	128	135	L-UNK	blockers
22	136	136	O	,
23	138	151	U-UNK	metaclopramide
24	152	152	O	,
25	154	160	B-UNK	lithium
26	162	170	L-UNK	carbonate
27	171	171	O	,
28	173	175	O	and
29	177	187	U-UNK	terbutaline
NULL

Decitabine	DDI-DrugBank.d126.s0	NO_SECTION	NO_SETID	9
Drug interaction studies with decitabine have not been conducted.
1	0	3	O	Drug
2	5	15	O	interaction
3	17	23	O	studies
4	25	28	O	with
5	30	39	O	XXXXXXXX
6	41	44	O	have
7	46	48	O	not
8	50	53	O	been
9	55	63	O	conducted
NULL

Decitabine	DDI-DrugBank.d126.s1	NO_SECTION	NO_SETID	19
In vitro studies in human liver microsomes suggest that decitabine is unlikely to inhibit or induce cytochrome P450 enzymes.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	18	O	in
5	20	24	O	human
6	26	30	O	liver
7	32	41	O	microsomes
8	43	49	O	suggest
9	51	54	O	that
10	56	65	O	XXXXXXXX
11	67	68	O	is
12	70	77	O	unlikely
13	79	80	O	to
14	82	88	O	inhibit
15	90	91	O	or
16	93	98	O	induce
17	100	109	O	cytochrome
18	111	114	O	P450
19	116	122	O	enzymes
NULL

Decitabine	DDI-DrugBank.d126.s2	NO_SECTION	NO_SETID	19
In vitro metabolism studies have suggested that decitabine is not a substrate for the human liver cytochrome P450 enzymes.
1	0	1	O	In
2	3	7	O	vitro
3	9	18	O	metabolism
4	20	26	O	studies
5	28	31	O	have
6	33	41	O	suggested
7	43	46	O	that
8	48	57	O	XXXXXXXX
9	59	60	O	is
10	62	64	O	not
11	66	66	O	a
12	68	76	O	substrate
13	78	80	O	for
14	82	84	O	the
15	86	90	O	human
16	92	96	O	liver
17	98	107	O	cytochrome
18	109	112	O	P450
19	114	120	O	enzymes
NULL

Decitabine	DDI-DrugBank.d126.s3	NO_SECTION	NO_SETID	26
As plasma protein binding of decitabine is negligible ( 1%), interactions due to displacement of more highly protein bound drugs from plasma proteins are not expected.
1	0	1	O	As
2	3	8	O	plasma
3	10	16	O	protein
4	18	24	O	binding
5	26	27	O	of
6	29	38	O	XXXXXXXX
7	40	41	O	is
8	43	52	O	negligible
9	56	57	O	1%
10	59	59	O	,
11	61	72	O	interactions
12	74	76	O	due
13	78	79	O	to
14	81	92	O	displacement
15	94	95	O	of
16	97	100	O	more
17	102	107	O	highly
18	109	115	O	protein
19	117	121	O	bound
20	123	127	O	drugs
21	129	132	O	from
22	134	139	O	plasma
23	141	148	O	proteins
24	150	152	O	are
25	154	156	O	not
26	158	165	O	expected
NULL

Deferasirox	DDI-DrugBank.d84.s0	NO_SECTION	NO_SETID	15
The concomitant administration of Exjade and aluminum-containing antacid preparations has not been formally studied.
1	0	2	O	The
2	4	14	O	concomitant
3	16	29	O	administration
4	31	32	O	of
5	34	39	O	XXXXXXXX
6	41	43	O	and
7	45	52	U-UNK	aluminum
8	54	63	O	containing
9	65	71	B-UNK	antacid
10	73	84	L-UNK	preparations
11	86	88	O	has
12	90	92	O	not
13	94	97	O	been
14	99	106	O	formally
15	108	114	O	studied
NULL

Deferasirox	DDI-DrugBank.d84.s1	NO_SECTION	NO_SETID	22
Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.
1	0	7	O	Although
2	9	19	U-UNK	deferasirox
3	21	23	O	has
4	25	25	O	a
5	27	31	O	lower
6	33	40	O	affinity
7	42	44	O	for
8	46	53	U-UNK	aluminum
9	55	58	O	than
10	60	62	O	for
11	64	67	U-UNK	iron
12	68	68	O	,
13	70	75	O	XXXXXXXX
14	77	82	O	should
15	84	86	O	not
16	88	89	O	be
17	91	95	O	taken
18	97	100	O	with
19	102	109	U-DYN	aluminum
20	111	120	O	containing
21	122	128	B-UNK	antacid
22	130	141	L-UNK	preparations
NULL

Deferasirox	DDI-DrugBank.d84.s2	NO_SECTION	NO_SETID	13
In healthy volunteers, Exjade had no effect on the pharmacokinetics of digoxin.
1	0	1	O	In
2	3	9	O	healthy
3	11	20	O	volunteers
4	21	21	O	,
5	23	28	O	XXXXXXXX
6	30	32	O	had
7	34	35	O	no
8	37	42	O	effect
9	44	45	O	on
10	47	49	O	the
11	51	66	O	pharmacokinetics
12	68	69	O	of
13	71	77	U-UNK	digoxin
NULL

Deferasirox	DDI-DrugBank.d84.s3	NO_SECTION	NO_SETID	11
The effect of digoxin on Exjade pharmacokinetics has not been studied.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	20	U-UNK	digoxin
5	22	23	O	on
6	25	30	O	XXXXXXXX
7	32	47	O	pharmacokinetics
8	49	51	O	has
9	53	55	O	not
10	57	60	O	been
11	62	68	O	studied
NULL

Deferasirox	DDI-DrugBank.d84.s4	NO_SECTION	NO_SETID	13
The concomitant administration of Exjade and vitamin C has not been formally studied.
1	0	2	O	The
2	4	14	O	concomitant
3	16	29	O	administration
4	31	32	O	of
5	34	39	O	XXXXXXXX
6	41	43	O	and
7	45	51	B-UNK	vitamin
8	53	53	L-UNK	C
9	55	57	O	has
10	59	61	O	not
11	63	66	O	been
12	68	75	O	formally
13	77	83	O	studied
NULL

Deferasirox	DDI-DrugBank.d84.s5	NO_SECTION	NO_SETID	16
Doses of vitamin C up to 200 mg were allowed in clinical studies without negative consequences.
1	0	4	O	Doses
2	6	7	O	of
3	9	15	B-UNK	vitamin
4	17	17	L-UNK	C
5	19	20	O	up
6	22	23	O	to
7	25	27	O	200
8	29	30	O	mg
9	32	35	O	were
10	37	43	O	allowed
11	45	46	O	in
12	48	55	O	clinical
13	57	63	O	studies
14	65	71	O	without
15	73	80	O	negative
16	82	93	O	consequences
NULL

Deferasirox	DDI-DrugBank.d84.s6	NO_SECTION	NO_SETID	11
The interaction of Exjade with hydroxyurea has not been formally studied.
1	0	2	O	The
2	4	14	O	interaction
3	16	17	O	of
4	19	24	O	XXXXXXXX
5	26	29	O	with
6	31	41	U-UNK	hydroxyurea
7	43	45	O	has
8	47	49	O	not
9	51	54	O	been
10	56	63	O	formally
11	65	71	O	studied
NULL

Deferasirox	DDI-DrugBank.d84.s7	NO_SECTION	NO_SETID	18
No inhibition of deferasirox metabolism by hydroxyurea is expected based on the results of an in vitro study.
1	0	1	O	No
2	3	12	O	inhibition
3	14	15	O	of
4	17	27	O	XXXXXXXX
5	29	38	O	metabolism
6	40	41	O	by
7	43	53	U-UNK	hydroxyurea
8	55	56	O	is
9	58	65	O	expected
10	67	71	O	based
11	73	74	O	on
12	76	78	O	the
13	80	86	O	results
14	88	89	O	of
15	91	92	O	an
16	94	95	O	in
17	97	101	O	vitro
18	103	107	O	study
NULL

Deferasirox	DDI-DrugBank.d84.s8	NO_SECTION	NO_SETID	20
Exjade should not be combined with other iron chelator therapies, as safety of such combinations has not been established.
1	0	5	O	XXXXXXXX
2	7	12	O	should
3	14	16	O	not
4	18	19	O	be
5	21	28	O	combined
6	30	33	O	with
7	35	39	O	other
8	41	44	O	iron
9	46	53	O	chelator
10	55	63	O	therapies
11	64	64	O	,
12	66	67	O	as
13	69	74	O	safety
14	76	77	O	of
15	79	82	O	such
16	84	95	O	combinations
17	97	99	O	has
18	101	103	O	not
19	105	108	O	been
20	110	120	O	established
NULL

Deferasirox	DDI-DrugBank.d84.s9	NO_SECTION	NO_SETID	17
Drug/Food Interactions The bioavailability (AUC) of deferasirox was variably increased when taken with a meal.
1	0	3	O	Drug
2	4	4	O	/
3	5	8	O	Food
4	10	21	O	Interactions
5	23	25	O	The
6	27	41	O	bioavailability
7	44	46	O	AUC
8	49	50	O	of
9	52	62	O	XXXXXXXX
10	64	66	O	was
11	68	75	O	variably
12	77	85	O	increased
13	87	90	O	when
14	92	96	O	taken
15	98	101	O	with
16	103	103	O	a
17	105	108	O	meal
NULL

Deferasirox	DDI-DrugBank.d84.s10	NO_SECTION	NO_SETID	12
Deferasirox should be taken on an empty stomach 30 minutes before eating.
1	0	10	O	XXXXXXXX
2	12	17	O	should
3	19	20	O	be
4	22	26	O	taken
5	28	29	O	on
6	31	32	O	an
7	34	38	O	empty
8	40	46	O	stomach
9	48	49	O	30
10	51	57	O	minutes
11	59	64	O	before
12	66	71	O	eating
NULL

Deferasirox	DDI-DrugBank.d84.s11	NO_SECTION	NO_SETID	17
Exjade tablets for oral suspension can be dispersed in water, orange juice, or apple juice.
1	0	5	O	XXXXXXXX
2	7	13	O	tablets
3	15	17	O	for
4	19	22	O	oral
5	24	33	O	suspension
6	35	37	O	can
7	39	40	O	be
8	42	50	O	dispersed
9	52	53	O	in
10	55	59	O	water
11	60	60	O	,
12	62	67	O	orange
13	69	73	O	juice
14	74	74	O	,
15	76	77	O	or
16	79	83	O	apple
17	85	89	O	juice
NULL

Delavirdine	DDI-DrugBank.d251.s0	NO_SECTION	NO_SETID	27
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.
1	0	7	O	Antiacid
2	8	8	O	,
3	10	23	U-UNK	clarithromycin
4	24	24	O	,
5	26	35	U-UNK	Didanosine
6	36	36	O	,
7	38	48	U-UNK	Fluconazole
8	49	49	O	,
9	51	60	U-UNK	Fluoxetine
10	61	61	O	,
11	63	71	O	Indanavir
12	72	72	O	,
13	74	85	U-UNK	Ketoconazole
14	86	86	O	,
15	88	96	U-UNK	Phenytoin
16	97	97	O	,
17	99	111	O	Phenobarbitol
18	112	112	O	,
19	114	126	U-UNK	carbamazepine
20	127	127	O	,
21	129	137	U-UNK	Rifabutin
22	138	138	O	,
23	140	147	U-UNK	Rifampin
24	148	148	O	,
25	150	158	O	Ritanovir
26	159	159	O	,
27	161	170	U-UNK	Saquinavir
NULL

Demecarium bromide	DDI-DrugBank.d149.s0	NO_SECTION	NO_SETID	12
Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.
1	0	7	O	Possible
2	9	12	O	drug
3	14	25	O	interactions
4	27	28	O	of
5	30	37	O	XXXXXXXX
6	39	42	O	with
7	44	58	U-UNK	succinylcholine
8	60	61	O	or
9	63	66	O	with
10	68	72	O	other
11	74	91	B-UNK	anticholinesterase
12	93	98	L-UNK	agents
NULL

Demeclocycline	DDI-DrugBank.d409.s0	NO_SECTION	NO_SETID	26
Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
1	0	6	O	Because
2	8	10	O	the
3	12	24	U-UNK	tetracyclines
4	26	29	O	have
5	31	34	O	been
6	36	40	O	shown
7	42	43	O	to
8	45	51	O	depress
9	53	58	O	plasma
10	60	70	O	prothrombin
11	72	79	O	activity
12	80	80	O	,
13	82	89	O	patients
14	91	93	O	who
15	95	97	O	are
16	99	100	O	on
17	102	114	U-UNK	anticoagulant
18	116	122	O	therapy
19	124	126	O	may
20	128	134	O	require
21	136	143	O	downward
22	145	154	O	adjustment
23	156	157	O	of
24	159	163	O	their
25	165	177	U-UNK	anticoagulant
26	179	184	O	dosage
NULL

Demeclocycline	DDI-DrugBank.d409.s1	NO_SECTION	NO_SETID	30
Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.
1	0	4	O	Since
2	6	19	O	bacteriostatic
3	21	25	O	drugs
4	26	26	O	,
5	28	31	O	such
6	33	34	O	as
7	36	38	O	the
8	40	51	B-UNK	tetracycline
9	53	57	L-UNK	class
10	59	60	O	of
11	62	72	U-UNK	antibiotics
12	73	73	O	,
13	75	77	O	may
14	79	87	O	interfere
15	89	92	O	with
16	94	96	O	the
17	98	109	O	bactericidal
18	111	116	O	action
19	118	119	O	of
20	121	131	U-UNK	penicillins
21	132	132	O	,
22	134	135	O	it
23	137	138	O	is
24	140	142	O	not
25	144	152	O	advisable
26	154	155	O	to
27	157	166	O	administer
28	168	172	O	these
29	174	178	O	drugs
30	180	192	O	concomitantly
NULL

Demeclocycline	DDI-DrugBank.d409.s2	NO_SECTION	NO_SETID	13
Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	16	O	of
4	18	30	U-UNK	tetracyclines
5	32	35	O	with
6	37	40	O	oral
7	42	55	U-UNK	contraceptives
8	57	59	O	may
9	61	66	O	render
10	68	71	O	oral
11	73	86	U-UNK	contraceptives
12	88	91	O	less
13	93	101	O	effective
NULL

Demeclocycline	DDI-DrugBank.d409.s3	NO_SECTION	NO_SETID	5
Breakthrough bleeding has been reported
1	0	11	O	Breakthrough
2	13	20	O	bleeding
3	22	24	O	has
4	26	29	O	been
5	31	38	O	reported
NULL

Denileukin diftitox	DDI-DrugBank.d182.s0	NO_SECTION	NO_SETID	8
No clinical drug interaction studies have been conducted.
1	0	1	O	No
2	3	10	O	clinical
3	12	15	O	drug
4	17	27	O	interaction
5	29	35	O	studies
6	37	40	O	have
7	42	45	O	been
8	47	55	O	conducted
NULL

Denileukin diftitox	DDI-DrugBank.d182.s1	NO_SECTION	NO_SETID	16
However, in a single in vivo rodent study denileukin diftitox had no effect on P450 levels.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	12	O	a
5	14	19	O	single
6	21	22	O	in
7	24	27	O	vivo
8	29	34	O	rodent
9	36	40	O	study
10	42	60	O	XXXXXXXX
11	62	64	O	had
12	66	67	O	no
13	69	74	O	effect
14	76	77	O	on
15	79	82	O	P450
16	84	89	O	levels
NULL

Deserpidine	DDI-DrugBank.d311.s0	NO_SECTION	NO_SETID	34
Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.
1	0	5	O	Taking
2	7	7	O	a
3	9	17	B-UNK	rauwolfia
4	19	26	L-UNK	alkaloid
5	28	32	O	while
6	34	36	O	you
7	38	40	O	are
8	42	47	O	taking
9	49	50	O	or
10	52	57	O	within
11	59	59	O	2
12	61	65	O	weeks
13	67	68	O	of
14	70	75	O	taking
15	77	79	B-UNK	MAO
16	81	90	L-UNK	inhibitors
17	92	94	O	may
18	96	103	O	increase
19	105	107	O	the
20	109	112	O	risk
21	114	115	O	of
22	117	123	O	central
23	125	131	O	nervous
24	133	138	O	system
25	140	149	O	depression
26	151	152	O	or
27	154	156	O	may
28	158	162	O	cause
29	164	164	O	a
30	166	171	O	severe
31	173	176	O	high
32	178	182	O	blood
33	184	191	O	pressure
34	193	200	O	reaction
NULL

Desflurane	DDI-DrugBank.d363.s0	NO_SECTION	NO_SETID	31
No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (muscle relaxants, intravenous agents, and local anesthetic agents) were reported in clinical trials.
1	0	1	O	No
2	3	12	O	clinically
3	14	24	O	significant
4	26	32	O	adverse
5	34	45	O	interactions
6	47	50	O	with
7	52	59	O	commonly
8	61	64	O	used
9	66	78	O	preanesthetic
10	80	84	O	drugs
11	85	85	O	,
12	87	88	O	or
13	90	94	O	drugs
14	96	99	O	used
15	101	106	O	during
16	108	117	O	anesthesia
17	120	125	B-UNK	muscle
18	127	135	L-UNK	relaxants
19	136	136	O	,
20	138	148	O	intravenous
21	150	155	O	agents
22	156	156	O	,
23	158	160	O	and
24	162	166	O	local
25	168	177	B-UNK	anesthetic
26	179	184	L-UNK	agents
27	187	190	O	were
28	192	199	O	reported
29	201	202	O	in
30	204	211	O	clinical
31	213	218	O	trials
NULL

Desflurane	DDI-DrugBank.d363.s1	NO_SECTION	NO_SETID	14
The effect of desflurane on the disposition of other drugs has not been determined.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	26	O	on
6	28	30	O	the
7	32	42	O	disposition
8	44	45	O	of
9	47	51	O	other
10	53	57	O	drugs
11	59	61	O	has
12	63	65	O	not
13	67	70	O	been
14	72	81	O	determined
NULL

Desflurane	DDI-DrugBank.d363.s2	NO_SECTION	NO_SETID	20
Like isoflurane, desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine.
1	0	3	O	Like
2	5	14	U-UNK	isoflurane
3	15	15	O	,
4	17	26	O	XXXXXXXX
5	28	31	O	does
6	33	35	O	not
7	37	46	O	predispose
8	48	49	O	to
9	51	59	O	premature
10	61	71	O	ventricular
11	73	83	O	arrhythmias
12	85	86	O	in
13	88	90	O	the
14	92	99	O	presence
15	101	102	O	of
16	104	114	O	exogenously
17	116	122	O	infused
18	124	134	U-UNK	epinephrine
19	136	137	O	in
20	139	143	O	swine
NULL

Desipramine	DDI-DrugBank.d386.s1	NO_SECTION	NO_SETID	39
Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers);
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	24	O	P450
5	26	28	O	2D6
6	29	29	O	:
7	31	33	O	The
8	35	45	O	biochemical
9	47	54	O	activity
10	56	57	O	of
11	59	61	O	the
12	63	66	O	drug
13	68	79	O	metabolizing
14	81	87	O	isozyme
15	89	98	O	cytochrome
16	100	103	O	P450
17	105	107	O	2D6
18	110	120	O	debrisoquin
19	122	132	O	hydroxylase
20	135	136	O	is
21	138	144	O	reduced
22	146	147	O	in
23	149	149	O	a
24	151	156	O	subset
25	158	159	O	of
26	161	163	O	the
27	165	173	O	caucasian
28	175	184	O	population
29	187	191	O	about
30	193	193	O	7
31	195	196	O	to
32	198	200	O	10%
33	202	203	O	of
34	205	214	O	caucasians
35	216	218	O	are
36	220	221	O	so
37	223	228	O	called
38	230	233	O	poor
39	235	246	O	metabolizers
NULL

Desipramine	DDI-DrugBank.d386.s2	NO_SECTION	NO_SETID	22
reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
1	0	7	O	reliable
2	9	17	O	estimates
3	19	20	O	of
4	22	24	O	the
5	26	35	O	prevalence
6	37	38	O	of
7	40	46	O	reduced
8	48	51	O	P450
9	53	55	O	2D6
10	57	63	O	isozyme
11	65	72	O	activity
12	74	78	O	among
13	80	84	O	Asian
14	85	85	O	,
15	87	93	O	African
16	95	97	O	and
17	99	103	O	other
18	105	115	O	populations
19	117	119	O	are
20	121	123	O	not
21	125	127	O	yet
22	129	137	O	available
NULL

Desipramine	DDI-DrugBank.d386.s3	NO_SECTION	NO_SETID	16
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
1	0	3	O	Poor
2	5	16	O	metabolizers
3	18	21	O	have
4	23	28	O	higher
5	30	33	O	than
6	35	42	O	expected
7	44	49	O	plasma
8	51	64	O	concentrations
9	66	67	O	of
10	69	77	B-UNK	tricyclic
11	79	93	L-UNK	antidepressants
12	96	99	U-UNK	TCAs
13	102	105	O	when
14	107	111	O	given
15	113	117	O	usual
16	119	123	O	doses
NULL

Desipramine	DDI-DrugBank.d386.s4	NO_SECTION	NO_SETID	32
Depending on the traction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).
1	0	8	O	Depending
2	10	11	O	on
3	13	15	O	the
4	17	24	O	traction
5	26	27	O	of
6	29	32	O	drug
7	34	44	O	metabolized
8	46	47	O	by
9	49	52	O	P450
10	54	56	O	2D6
11	57	57	O	,
12	59	61	O	the
13	63	70	O	increase
14	72	73	O	in
15	75	80	O	plasma
16	82	94	O	concentration
17	96	98	O	may
18	100	101	O	be
19	103	107	O	small
20	108	108	O	,
21	110	111	O	or
22	113	117	O	quite
23	119	123	O	large
24	126	126	O	8
25	128	131	O	fold
26	133	140	O	increase
27	142	143	O	in
28	145	150	O	plasma
29	152	154	O	AUC
30	156	157	O	of
31	159	161	O	the
32	163	165	U-UNK	TCA
NULL

Desipramine	DDI-DrugBank.d386.s5	NO_SECTION	NO_SETID	17
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	certain
5	21	25	O	drugs
6	27	33	O	inhibit
7	35	37	O	the
8	39	46	O	activity
9	48	49	O	of
10	51	54	O	this
11	56	62	O	isozyme
12	64	66	O	and
13	68	71	O	make
14	73	78	O	normal
15	80	91	O	metabolizers
16	93	100	O	resemble
17	102	104	O	p.o
NULL

Desipramine	DDI-DrugBank.d386.s7	NO_SECTION	NO_SETID	25
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
1	0	1	O	An
2	3	12	O	individual
3	14	16	O	who
4	18	19	O	is
5	21	26	O	stable
6	28	29	O	on
7	31	31	O	a
8	33	37	O	given
9	39	42	O	dose
10	44	45	O	of
11	47	49	U-UNK	TCA
12	51	53	O	may
13	55	60	O	become
14	62	69	O	abruptly
15	71	75	O	toxic
16	77	80	O	when
17	82	86	O	given
18	88	90	O	one
19	92	93	O	of
20	95	99	O	these
21	101	110	O	inhibiting
22	112	116	O	drugs
23	118	119	O	as
24	121	131	O	concomitant
25	133	139	O	therapy
NULL

Desipramine	DDI-DrugBank.d386.s8	NO_SECTION	NO_SETID	17
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;
1	0	2	O	The
2	4	8	O	drugs
3	10	13	O	that
4	15	21	O	inhibit
5	23	32	O	cytochrome
6	34	37	O	P450
7	39	41	O	2D6
8	43	49	O	include
9	51	54	O	some
10	56	59	O	that
11	61	63	O	are
12	65	67	O	not
13	69	79	O	metabolized
14	81	82	O	by
15	84	86	O	the
16	88	93	O	enzyme
17	96	104	U-UNK	quinidine
NULL

Desipramine	DDI-DrugBank.d386.s9	NO_SECTION	NO_SETID	23
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythrnics propatenone and flecainide).
1	0	9	U-UNK	cimetidine
2	12	14	O	and
3	16	19	O	many
4	21	24	O	that
5	26	28	O	are
6	30	39	O	substrates
7	41	43	O	for
8	45	48	O	P450
9	50	52	O	2D6
10	55	58	O	many
11	60	64	O	other
12	66	80	U-UNK	antidepressants
13	81	81	O	,
14	83	96	U-UNK	phenothiazines
15	97	97	O	,
16	99	101	O	and
17	103	105	O	the
18	107	110	O	Type
19	112	113	O	1C
20	115	130	O	antiarrhythrnics
21	132	142	O	propatenone
22	144	146	O	and
23	148	157	U-UNK	flecainide
NULL

Desipramine	DDI-DrugBank.d386.s10	NO_SECTION	NO_SETID	30
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
1	0	4	O	While
2	6	8	O	all
3	10	12	O	the
4	14	22	B-UNK	selective
5	24	32	I-UNK	serotonin
6	34	41	I-UNK	reuptake
7	43	52	L-UNK	inhibitors
8	55	59	U-UNK	SSRIs
9	61	61	O	,
10	63	65	O	e.g
11	67	67	O	,
12	69	78	U-UNK	fluoxetine
13	79	79	O	,
14	81	90	O	seriraline
15	91	91	O	,
16	93	95	O	and
17	97	106	U-UNK	paroxetine
18	107	107	O	,
19	109	115	O	inhibit
20	117	120	O	P450
21	122	124	O	2D6
22	125	125	O	,
23	127	130	O	they
24	132	134	O	may
25	136	139	O	vary
26	141	142	O	in
27	144	146	O	the
28	148	153	O	extent
29	155	156	O	of
30	158	167	O	inhibition
NULL

Desipramine	DDI-DrugBank.d386.s11	NO_SECTION	NO_SETID	25
The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	to
4	14	18	O	which
5	20	23	U-UNK	SSRI
6	25	27	U-UNK	TCA
7	29	40	O	interactions
8	42	44	O	may
9	46	49	O	pose
10	51	58	O	clinical
11	60	67	O	problems
12	69	72	O	will
13	74	79	O	depend
14	81	82	O	on
15	84	86	O	the
16	88	93	O	degree
17	95	96	O	of
18	98	107	O	inhibition
19	109	111	O	and
20	113	115	O	the
21	117	132	O	pharmacokinetics
22	134	135	O	of
23	137	139	O	the
24	141	144	U-UNK	SSRI
25	146	153	O	involved
NULL

Desipramine	DDI-DrugBank.d386.s12	NO_SECTION	NO_SETID	26
Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	O	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	43	O	co
9	45	58	O	administration
10	60	61	O	of
11	63	65	U-UNK	T.A
12	68	71	O	with
13	73	75	O	any
14	77	78	O	of
15	80	82	O	the
16	84	88	U-UNK	SSRIs
17	90	92	O	and
18	94	97	O	also
19	99	100	O	in
20	102	110	O	switching
21	112	115	O	from
22	117	119	O	one
23	121	125	O	class
24	127	128	O	to
25	130	132	O	the
26	134	138	O	other
NULL

Desipramine	DDI-DrugBank.d386.s13	NO_SECTION	NO_SETID	38
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
1	0	1	O	Of
2	3	12	O	particular
3	14	23	O	importance
4	24	24	O	,
5	26	35	O	sufficient
6	37	40	O	time
7	42	45	O	must
8	47	52	O	elapse
9	54	59	O	before
10	61	70	O	initiating
11	72	74	O	TCA
12	76	84	O	treatment
13	86	87	O	in
14	89	89	O	a
15	91	97	O	patient
16	99	103	O	being
17	105	113	O	withdrawn
18	115	118	O	from
19	120	129	U-UNK	fluoxetine
20	130	130	O	,
21	132	136	O	given
22	138	140	O	the
23	142	145	O	long
24	147	150	O	half
25	152	155	O	life
26	157	158	O	of
27	160	162	O	the
28	164	169	O	parent
29	171	173	O	and
30	175	180	O	active
31	182	191	O	metabolite
32	194	195	O	at
33	197	201	O	least
34	203	203	O	5
35	205	209	O	weeks
36	211	213	O	may
37	215	216	O	be
38	218	226	O	necessary
NULL

Desipramine	DDI-DrugBank.d386.s14	NO_SECTION	NO_SETID	29
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	27	B-UNK	tricyclic
5	29	43	L-UNK	antidepressants
6	45	48	O	with
7	50	54	O	drugs
8	56	59	O	that
9	61	63	O	can
10	65	71	O	inhibit
11	73	82	O	cytochrome
12	84	87	O	P450
13	89	91	O	2D6
14	93	95	O	may
15	97	103	O	require
16	105	109	O	lower
17	111	115	O	doses
18	117	120	O	than
19	122	128	O	usually
20	130	139	O	prescribed
21	141	143	O	for
22	145	150	O	either
23	152	154	O	the
24	156	164	B-UNK	tricyclic
25	166	179	L-UNK	antidepressant
26	181	182	O	or
27	184	186	O	the
28	188	192	O	other
29	194	197	O	drug
NULL

Desipramine	DDI-DrugBank.d386.s15	NO_SECTION	NO_SETID	23
Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	20	O	whenever
4	22	24	O	one
5	26	27	O	of
6	29	33	O	these
7	35	39	O	other
8	41	45	O	drugs
9	47	48	O	is
10	50	58	O	withdrawn
11	60	63	O	from
12	65	66	O	co
13	68	74	O	therapy
14	75	75	O	,
15	77	78	O	an
16	80	88	O	increased
17	90	93	O	dose
18	95	96	O	of
19	98	106	B-UNK	tricyclic
20	108	121	L-UNK	antidepressant
21	123	125	O	may
22	127	128	O	be
23	130	137	O	required
NULL

Desipramine	DDI-DrugBank.d386.s16	NO_SECTION	NO_SETID	28
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	desirable
4	16	17	O	to
5	19	25	O	monitor
6	27	29	U-UNK	TCA
7	31	36	O	plasma
8	38	43	O	levels
9	45	52	O	whenever
10	54	54	O	a
11	56	58	U-UNK	TCA
12	60	61	O	is
13	63	67	O	going
14	69	70	O	to
15	72	73	O	be
16	75	76	O	co
17	78	89	O	administered
18	91	94	O	with
19	96	102	O	another
20	104	107	O	drug
21	109	113	O	known
22	115	116	O	to
23	118	119	O	be
24	121	122	O	an
25	124	132	O	inhibitor
26	134	135	O	of
27	137	140	O	P450
28	142	144	O	2D6
NULL

Desipramine	DDI-DrugBank.d386.s18	NO_SECTION	NO_SETID	20
Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs.
1	0	4	O	Close
2	6	16	O	supervision
3	18	20	O	and
4	22	28	O	careful
5	30	39	O	adjustment
6	41	42	O	of
7	44	49	O	dosage
8	51	53	O	are
9	55	62	O	required
10	64	67	O	when
11	69	72	O	this
12	74	77	O	drug
13	79	80	O	is
14	82	86	O	given
15	88	100	O	concomitantly
16	102	105	O	with
17	107	121	U-UNK	anticholinergic
18	123	124	O	or
19	126	140	B-UNK	sympathomimetic
20	142	146	L-UNK	drugs
NULL

Desipramine	DDI-DrugBank.d386.s20	NO_SECTION	NO_SETID	13
Clinical experience in the concurrent administration of ECT and antidepressant drugs is limited.
1	0	7	O	Clinical
2	9	18	O	experience
3	20	21	O	in
4	23	25	O	the
5	27	36	O	concurrent
6	38	51	O	administration
7	53	54	O	of
8	56	58	O	ECT
9	60	62	O	and
10	64	77	B-UNK	antidepressant
11	79	83	L-UNK	drugs
12	85	86	O	is
13	88	94	O	limited
NULL

Desipramine	DDI-DrugBank.d386.s21	NO_SECTION	NO_SETID	19
Thus, if such treatment is essential, the possibility of increased risk relative to benefits should be considered.
1	0	3	O	Thus
2	4	4	O	,
3	6	7	O	if
4	9	12	O	such
5	14	22	O	treatment
6	24	25	O	is
7	27	35	O	essential
8	36	36	O	,
9	38	40	O	the
10	42	52	O	possibility
11	54	55	O	of
12	57	65	O	increased
13	67	70	O	risk
14	72	79	O	relative
15	81	82	O	to
16	84	91	O	benefits
17	93	98	O	should
18	100	101	O	be
19	103	112	O	considered
NULL

Desipramine	DDI-DrugBank.d386.s23	NO_SECTION	NO_SETID	46
If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
1	0	1	O	If
2	3	13	O	XXXXXXXX
3	15	27	O	hydrochloride
4	29	30	O	is
5	32	33	O	to
6	35	36	O	be
7	38	45	O	combined
8	47	50	O	with
9	52	56	O	other
10	58	69	B-DYN	psychotropic
11	71	76	L-DYN	agents
12	78	81	O	such
13	83	84	O	as
14	86	98	U-DYN	tranquilizers
15	100	101	O	or
16	103	110	U-DYN	sedative
17	111	111	O	/
18	112	120	U-DYN	hypnotics
19	121	121	O	,
20	123	129	O	careful
21	131	143	O	consideration
22	145	150	O	should
23	152	153	O	be
24	155	159	O	given
25	161	162	O	to
26	164	166	O	the
27	168	179	O	pharmacology
28	181	182	O	of
29	184	186	O	the
30	188	193	O	agents
31	195	202	O	employed
32	204	208	O	since
33	210	212	O	the
34	214	221	O	sedative
35	223	229	O	effects
36	231	232	O	of
37	234	244	O	XXXXXXXX
38	246	248	O	and
39	250	264	U-DYN	benzodiazepines
40	267	269	O	e.g
41	271	271	O	,
42	273	288	U-DYN	chlordiazepoxide
43	290	291	O	or
44	293	300	U-DYN	diazepam
45	303	305	O	are
46	307	314	O	additive
NULL

Desipramine	DDI-DrugBank.d386.s24	NO_SECTION	NO_SETID	17
Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine.
1	0	3	O	Both
2	5	7	O	the
3	9	16	O	sedative
4	18	20	O	and
5	22	36	O	anticholinergic
6	38	44	O	effects
7	46	47	O	of
8	49	51	O	the
9	53	57	B-DYN	major
10	59	71	L-DYN	tranquilizers
11	73	75	O	are
12	77	80	O	also
13	82	89	O	additive
14	91	92	O	to
15	94	98	O	those
16	100	101	O	of
17	103	113	O	XXXXXXXX
NULL

Desipramine	DDI-DrugBank.d386.s26	NO_SECTION	NO_SETID	20
Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	38	U-UNK	cimetidine
5	40	42	O	and
6	44	52	B-UNK	tricyclic
7	54	68	L-UNK	antidepressants
8	70	72	O	can
9	74	80	O	produce
10	82	91	O	clinically
11	93	103	O	significant
12	105	113	O	increases
13	115	116	O	in
14	118	120	O	the
15	122	127	O	plasma
16	129	134	O	levels
17	136	137	O	of
18	139	141	O	the
19	143	151	B-UNK	tricyclic
20	153	167	L-UNK	antidepressants
NULL

Desipramine	DDI-DrugBank.d386.s27	NO_SECTION	NO_SETID	32
Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.
1	0	9	O	Conversely
2	10	10	O	,
3	12	20	O	decreases
4	22	23	O	in
5	25	30	O	plasma
6	32	37	O	levels
7	39	40	O	of
8	42	44	O	the
9	46	54	B-UNK	tricyclic
10	56	70	L-UNK	antidepressants
11	72	75	O	have
12	77	80	O	been
13	82	89	O	reported
14	91	94	O	upon
15	96	110	O	discontinuation
16	112	113	O	of
17	115	124	U-UNK	cimetidine
18	126	130	O	which
19	132	134	O	may
20	136	141	O	result
21	143	144	O	in
22	146	148	O	the
23	150	153	O	loss
24	155	156	O	of
25	158	160	O	the
26	162	172	O	therapeutic
27	174	181	O	efficacy
28	183	184	O	of
29	186	188	O	the
30	190	198	B-UNK	tricyclic
31	200	213	L-UNK	antidepressant
32	215	215	O	6
NULL

Desipramine	DDI-DrugBank.d386.s28	NO_SECTION	NO_SETID	26
There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	22	O	greater
5	24	27	O	than
6	29	31	O	two
7	33	36	O	fold
8	38	46	O	increases
9	48	49	O	of
10	51	60	O	previously
11	62	67	O	stable
12	69	74	O	plasma
13	76	81	O	levels
14	83	84	O	of
15	86	94	B-UNK	tricyclic
16	96	110	L-UNK	antidepressants
17	112	115	O	when
18	117	126	U-UNK	fluoxetine
19	128	130	O	has
20	132	135	O	been
21	137	148	O	administered
22	150	151	O	in
23	153	163	O	combination
24	165	168	O	with
25	170	174	O	these
26	176	181	O	agents
NULL

Desloratadine	DDI-DrugBank.d67.s0	NO_SECTION	NO_SETID	52
In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days.
1	0	1	O	In
2	3	5	O	two
3	7	16	O	controlled
4	18	26	O	crossover
5	28	35	O	clinical
6	37	48	O	pharmacology
7	50	56	O	studies
8	58	59	O	in
9	61	67	O	healthy
10	69	72	O	male
11	75	78	O	n=12
12	80	81	O	in
13	83	86	O	each
14	88	92	O	study
15	95	95	O	a
16	97	98	O	nd
17	100	105	O	female
18	108	111	O	n=12
19	113	114	O	in
20	116	119	O	each
21	121	125	O	study
22	128	137	O	volunteers
23	138	138	O	,
24	140	152	O	XXXXXXXX
25	154	156	O	7.5
26	158	159	O	mg
27	162	164	O	1.5
28	166	170	O	times
29	172	174	O	the
30	176	180	O	daily
31	182	185	O	dose
32	188	191	O	once
33	193	197	O	daily
34	199	201	O	was
35	203	216	O	coadministered
36	218	221	O	with
37	223	234	U-UNK	erythromycin
38	236	238	O	500
39	240	241	O	mg
40	243	247	O	every
41	249	249	O	8
42	251	255	O	hours
43	257	258	O	or
44	260	271	U-UNK	ketoconazole
45	273	275	O	200
46	277	278	O	mg
47	280	284	O	every
48	286	287	O	12
49	289	293	O	hours
50	295	297	O	for
51	299	300	O	10
52	302	305	O	days
NULL

Desloratadine	DDI-DrugBank.d67.s1	NO_SECTION	NO_SETID	78
In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.
1	0	1	O	In
2	3	7	O	three
3	9	16	O	separate
4	18	27	O	controlled
5	28	28	O	,
6	30	37	O	parallel
7	39	43	O	group
8	45	52	O	clinical
9	54	65	O	pharmacology
10	67	73	O	studies
11	74	74	O	,
12	76	88	O	XXXXXXXX
13	90	91	O	at
14	93	95	O	the
15	97	104	O	clinical
16	106	109	O	dose
17	111	112	O	of
18	114	114	O	5
19	116	117	O	mg
20	119	121	O	has
21	123	126	O	been
22	128	141	O	coadministered
23	143	146	O	with
24	148	159	U-UNK	azithromycin
25	161	163	O	500
26	165	166	O	mg
27	168	175	O	followed
28	177	178	O	by
29	180	182	O	250
30	184	185	O	mg
31	187	190	O	once
32	192	196	O	daily
33	198	200	O	for
34	202	202	O	4
35	204	207	O	days
36	210	213	O	n=18
37	216	217	O	or
38	219	222	O	with
39	224	233	U-UNK	fluoxetine
40	235	236	O	20
41	238	239	O	mg
42	241	244	O	once
43	246	250	O	daily
44	252	254	O	for
45	256	256	O	7
46	258	261	O	days
47	263	267	O	after
48	269	269	O	a
49	271	272	O	23
50	274	276	O	day
51	278	289	O	pretreatment
52	291	296	O	period
53	298	301	O	with
54	303	312	U-UNK	fluoxetine
55	315	318	O	n=18
56	321	322	O	or
57	324	327	O	with
58	329	338	U-UNK	cimetidine
59	340	342	O	600
60	344	345	O	mg
61	347	351	O	every
62	353	354	O	12
63	356	360	O	hours
64	362	364	O	for
65	366	367	O	14
66	369	372	O	days
67	375	378	O	n=18
68	381	385	O	under
69	387	392	O	steady
70	394	398	O	state
71	400	409	O	conditions
72	411	412	O	to
73	414	419	O	normal
74	421	427	O	healthy
75	429	432	O	male
76	434	436	O	and
77	438	443	O	female
78	445	454	O	volunteers
NULL

Desloratadine	DDI-DrugBank.d67.s2	NO_SECTION	NO_SETID	54
Although increased plasma concentrations (C max and AUC 0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.
1	0	7	O	Although
2	9	17	O	increased
3	19	24	O	plasma
4	26	39	O	concentrations
5	42	42	O	C
6	44	46	O	max
7	48	50	O	and
8	52	54	O	AUC
9	56	56	O	0
10	58	59	O	24
11	61	63	O	hrs
12	66	67	O	of
13	69	81	O	XXXXXXXX
14	83	85	O	and
15	87	87	O	3
16	89	95	O	hydroxy
17	96	108	O	XXXXXXXX
18	110	113	O	were
19	115	122	O	observed
20	124	124	O	,
21	126	130	O	there
22	132	135	O	were
23	137	138	O	no
24	140	149	O	clinically
25	151	158	O	relevant
26	160	166	O	changes
27	168	169	O	in
28	171	173	O	the
29	175	180	O	safety
30	182	188	O	profile
31	190	191	O	of
32	193	205	O	XXXXXXXX
33	206	206	O	,
34	208	209	O	as
35	211	218	O	assessed
36	220	221	O	by
37	223	242	O	electrocardiographic
38	244	253	O	parameters
39	256	264	O	including
40	266	268	O	the
41	270	278	O	corrected
42	280	281	O	QT
43	283	290	O	interval
44	292	292	O	,
45	294	301	O	clinical
46	303	312	O	laboratory
47	314	318	O	tests
48	319	319	O	,
49	321	325	O	vital
50	327	331	O	signs
51	332	332	O	,
52	334	336	O	and
53	338	344	O	adverse
54	346	351	O	events
NULL

Desloratadine	DDI-DrugBank.d67.s3	NO_SECTION	NO_SETID	16
Table 1 Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers
1	0	4	O	Table
2	6	6	O	1
3	8	14	O	Changes
4	16	17	O	in
5	19	31	O	XXXXXXXX
6	33	35	O	and
7	37	37	O	3
8	39	45	O	Hydroxy
9	46	58	O	XXXXXXXX
10	60	75	O	Pharmacokinetics
11	77	78	O	in
12	80	86	O	Healthy
13	88	91	O	Male
14	93	95	O	and
15	97	102	O	Female
16	104	113	O	Volunteers
NULL

Desloratadine	DDI-DrugBank.d67.s5	NO_SECTION	NO_SETID	4
Desloratadine 3-Hydroxydesloratadine
1	0	12	O	XXXXXXXX
2	14	14	O	3
3	16	22	O	Hydroxy
4	23	35	O	XXXXXXXX
NULL

Desloratadine	DDI-DrugBank.d67.s7	NO_SECTION	NO_SETID	12
C max AUC 0-24 hrs C max AUC 0-24 hrs
1	0	0	O	C
2	2	4	O	max
3	6	8	O	AUC
4	10	10	O	0
5	12	13	O	24
6	15	17	O	hrs
7	19	19	O	C
8	21	23	O	max
9	25	27	O	AUC
10	29	29	O	0
11	31	32	O	24
12	34	36	O	hrs
NULL

Desloratadine	DDI-DrugBank.d67.s15	NO_SECTION	NO_SETID	10
(500 mg day 1, 250 mg QD   4 days)
1	1	3	O	500
2	5	6	O	mg
3	8	10	O	day
4	12	12	O	1
5	13	13	O	,
6	15	17	O	250
7	19	20	O	mg
8	22	23	O	QD
9	27	27	O	4
10	29	32	O	days
NULL

Desmopressin	DDI-DrugBank.d348.s0	NO_SECTION	NO_SETID	32
Although the pressor activity of Desmopressin is very low compared to its antidiuretic activity, large doses of Desmopressin Tablets should be used with other pressor agents only with careful patient monitoring.
1	0	7	O	Although
2	9	11	O	the
3	13	19	O	pressor
4	21	28	O	activity
5	30	31	O	of
6	33	44	O	XXXXXXXX
7	46	47	O	is
8	49	52	O	very
9	54	56	O	low
10	58	65	O	compared
11	67	68	O	to
12	70	72	O	its
13	74	85	O	antidiuretic
14	87	94	O	activity
15	95	95	O	,
16	97	101	O	large
17	103	107	O	doses
18	109	110	O	of
19	112	123	O	XXXXXXXX
20	125	131	O	Tablets
21	133	138	O	should
22	140	141	O	be
23	143	146	O	used
24	148	151	O	with
25	153	157	O	other
26	159	165	O	pressor
27	167	172	O	agents
28	174	177	O	only
29	179	182	O	with
30	184	190	O	careful
31	192	198	O	patient
32	200	209	O	monitoring
NULL

Desogestrel	DDI-DrugBank.d285.s0	NO_SECTION	NO_SETID	19
Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin.
1	0	6	O	Reduced
2	8	15	O	efficacy
3	17	19	O	and
4	21	29	O	increased
5	31	39	O	incidence
6	41	42	O	of
7	44	55	O	breakthrough
8	57	64	O	bleeding
9	66	68	O	and
10	70	78	O	menstrual
11	80	93	O	irregularities
12	95	98	O	have
13	100	103	O	been
14	105	114	O	associated
15	116	119	O	with
16	121	131	O	concomitant
17	133	135	O	use
18	137	138	O	of
19	140	147	U-UNK	rifampin
NULL

Desogestrel	DDI-DrugBank.d285.s1	NO_SECTION	NO_SETID	31
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72)
1	0	0	O	A
2	2	8	O	similar
3	10	20	O	association
4	21	21	O	,
5	23	28	O	though
6	30	33	O	less
7	35	40	O	marked
8	41	41	O	,
9	43	45	O	has
10	47	50	O	been
11	52	60	O	suggested
12	62	65	O	with
13	67	78	U-UNK	barbiturates
14	79	79	O	,
15	81	86	O	phenyl
16	88	95	O	butazone
17	96	96	O	,
18	98	106	B-UNK	phenytoin
19	108	113	L-UNK	sodium
20	114	114	O	,
21	116	128	U-UNK	carbamazepine
22	130	132	O	and
23	134	141	O	possibly
24	143	146	O	with
25	148	159	U-UNK	griseofulvin
26	160	160	O	,
27	162	171	U-UNK	ampicillin
28	172	172	O	,
29	174	176	O	and
30	178	190	U-UNK	tetracyclines
31	193	194	O	72
NULL

Desoximetasone	DDI-DrugBank.d280.s0	NO_SECTION	NO_SETID	4
No specific information available
1	0	1	O	No
2	3	10	O	specific
3	12	22	O	information
4	24	32	O	available
NULL

Dexamethasone	DDI-DrugBank.d314.s0	NO_SECTION	NO_SETID	9
Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.
1	0	16	U-UNK	Aminoglutethimide
2	17	17	O	:
3	19	35	U-UNK	Aminoglutethimide
4	37	39	O	may
5	41	48	O	diminish
6	50	56	O	adrenal
7	58	68	O	suppression
8	70	71	O	by
9	73	87	U-UNK	corticosteroids
NULL

Dexamethasone	DDI-DrugBank.d314.s1	NO_SECTION	NO_SETID	33
Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.
1	0	11	B-UNK	Amphotericin
2	13	13	L-UNK	B
3	15	23	O	injection
4	25	27	O	and
5	29	37	O	potassium
6	39	47	O	depleting
7	49	54	O	agents
8	55	55	O	:
9	57	60	O	When
10	62	76	U-UNK	corticosteroids
11	78	80	O	are
12	82	93	O	administered
13	95	107	O	concomitantly
14	109	112	O	with
15	114	122	O	potassium
16	124	132	O	depleting
17	134	139	O	agents
18	142	144	O	e.g
19	146	146	O	,
20	148	159	B-UNK	amphotericin
21	161	161	L-UNK	B
22	162	162	O	,
23	164	172	U-UNK	diuretics
24	174	174	O	,
25	176	183	O	patients
26	185	190	O	should
27	192	193	O	be
28	195	202	O	observed
29	204	210	O	closely
30	212	214	O	for
31	216	226	O	development
32	228	229	O	of
33	231	241	O	hypokalemia
NULL

Dexamethasone	DDI-DrugBank.d314.s2	NO_SECTION	NO_SETID	26
In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	17	O	there
5	19	22	O	have
6	24	27	O	been
7	29	33	O	cases
8	35	42	O	reported
9	44	45	O	in
10	47	51	O	which
11	53	63	O	concomitant
12	65	67	O	use
13	69	70	O	of
14	72	83	B-UNK	amphotericin
15	85	85	L-UNK	B
16	87	89	O	and
17	91	104	U-UNK	hydrocortisone
18	106	108	O	was
19	110	117	O	followed
20	119	120	O	by
21	122	128	O	cardiac
22	130	140	O	enlargement
23	142	144	O	and
24	146	155	O	congestive
25	157	161	O	heart
26	163	169	O	failure
NULL

Dexamethasone	DDI-DrugBank.d314.s3	NO_SECTION	NO_SETID	15
Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.
1	0	10	U-UNK	Antibiotics
2	11	11	O	:
3	13	21	B-UNK	Macrolide
4	23	33	L-UNK	antibiotics
5	35	38	O	have
6	40	43	O	been
7	45	52	O	reported
8	54	55	O	to
9	57	61	O	cause
10	63	63	O	a
11	65	75	O	significant
12	77	84	O	decrease
13	86	87	O	in
14	89	102	U-UNK	corticosteroid
15	104	112	O	clearance
NULL

Dexamethasone	DDI-DrugBank.d314.s4	NO_SECTION	NO_SETID	18
Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.
1	0	18	U-UNK	Anticholinesterases
2	19	19	O	:
3	21	31	O	Concomitant
4	33	35	O	use
5	37	38	O	of
6	40	57	B-UNK	anticholinesterase
7	59	64	L-UNK	agents
8	66	68	O	and
9	70	84	U-UNK	corticosteroids
10	86	88	O	may
11	90	96	O	produce
12	98	103	O	severe
13	105	112	O	weakness
14	114	115	O	in
15	117	124	O	patients
16	126	129	O	with
17	131	140	O	myasthenia
18	142	147	O	gravis
NULL

Dexamethasone	DDI-DrugBank.d314.s5	NO_SECTION	NO_SETID	16
If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.
1	0	1	O	If
2	3	10	O	possible
3	11	11	O	,
4	13	30	B-UNK	anticholinesterase
5	32	37	L-UNK	agents
6	39	44	O	should
7	46	47	O	be
8	49	57	O	withdrawn
9	59	60	O	at
10	62	66	O	least
11	68	69	O	24
12	71	75	O	hours
13	77	82	O	before
14	84	93	O	initiating
15	95	108	U-UNK	corticosteroid
16	110	116	O	therapy
NULL

Dexamethasone	DDI-DrugBank.d314.s6	NO_SECTION	NO_SETID	26
Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.
1	0	13	U-UNK	Anticoagulants
2	14	14	O	,
3	16	19	O	oral
4	20	20	O	:
5	22	23	O	Co
6	25	38	O	administration
7	40	41	O	of
8	43	57	U-UNK	corticosteroids
9	59	61	O	and
10	63	70	U-UNK	warfarin
11	72	78	O	usually
12	80	86	O	results
13	88	89	O	in
14	91	100	O	inhibition
15	102	103	O	of
16	105	112	O	response
17	114	115	O	to
18	117	124	U-UNK	warfarin
19	125	125	O	,
20	127	134	O	although
21	136	140	O	there
22	142	145	O	have
23	147	150	O	been
24	152	155	O	some
25	157	167	O	conflicting
26	169	175	O	reports
NULL

Dexamethasone	DDI-DrugBank.d314.s7	NO_SECTION	NO_SETID	14
Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.
1	0	8	O	Therefore
2	9	9	O	,
3	11	21	O	coagulation
4	23	29	O	indices
5	31	36	O	should
6	38	39	O	be
7	41	49	O	monitored
8	51	60	O	frequently
9	62	63	O	to
10	65	72	O	maintain
11	74	76	O	the
12	78	84	O	desired
13	86	98	O	anticoagulant
14	100	105	O	effect
NULL

Dexamethasone	DDI-DrugBank.d314.s8	NO_SECTION	NO_SETID	18
Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.
1	0	12	U-UNK	Antidiabetics
2	13	13	O	:
3	15	21	O	Because
4	23	37	U-UNK	corticosteroids
5	39	41	O	may
6	43	50	O	increase
7	52	56	O	blood
8	58	64	O	glucose
9	66	79	O	concentrations
10	80	80	O	,
11	82	87	O	dosage
12	89	99	O	adjustments
13	101	102	O	of
14	104	115	B-UNK	antidiabetic
15	117	122	L-UNK	agents
16	124	126	O	may
17	128	129	O	be
18	131	138	O	required
NULL

Dexamethasone	DDI-DrugBank.d314.s9	NO_SECTION	NO_SETID	10
Antitubercular drugs: Serum concentrations of isoniazid may be decreased.
1	0	13	O	Antitubercular
2	15	19	O	drugs
3	20	20	O	:
4	22	26	O	Serum
5	28	41	O	concentrations
6	43	44	O	of
7	46	54	U-UNK	isoniazid
8	56	58	O	may
9	60	61	O	be
10	63	71	O	decreased
NULL

Dexamethasone	DDI-DrugBank.d314.s10	NO_SECTION	NO_SETID	9
Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.
1	0	13	U-UNK	Cholestyramine
2	14	14	O	:
3	16	29	U-UNK	Cholestyramine
4	31	33	O	may
5	35	42	O	increase
6	44	46	O	the
7	48	56	O	clearance
8	58	59	O	of
9	61	75	U-UNK	corticosteroids
NULL

Dexamethasone	DDI-DrugBank.d314.s11	NO_SECTION	NO_SETID	17
Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.
1	0	11	U-UNK	Cyclosporine
2	12	12	O	:
3	14	22	O	Increased
4	24	31	O	activity
5	33	34	O	of
6	36	39	O	both
7	41	52	U-UNK	cyclosporine
8	54	56	O	and
9	58	72	U-UNK	corticosteroids
10	74	76	O	may
11	78	82	O	occur
12	84	87	O	when
13	89	91	O	the
14	93	95	O	two
15	97	99	O	are
16	101	104	O	used
17	106	117	O	concurrently
NULL

Dexamethasone	DDI-DrugBank.d314.s12	NO_SECTION	NO_SETID	8
Convulsions have been reported with this concurrent use.
1	0	10	O	Convulsions
2	12	15	O	have
3	17	20	O	been
4	22	29	O	reported
5	31	34	O	with
6	36	39	O	this
7	41	50	O	concurrent
8	52	54	O	use
NULL

Dexamethasone	DDI-DrugBank.d314.s13	NO_SECTION	NO_SETID	23
Dexamethasone suppression test (DST): False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported.
1	0	12	O	XXXXXXXX
2	14	24	O	suppression
3	26	29	O	test
4	32	34	O	DST
5	36	36	O	:
6	38	42	O	False
7	44	51	O	negative
8	53	59	O	results
9	61	62	O	in
10	64	66	O	the
11	68	80	O	XXXXXXXX
12	82	92	O	suppression
13	94	97	O	test
14	100	102	O	DST
15	105	106	O	in
16	108	115	O	patients
17	117	121	O	being
18	123	129	O	treated
19	131	134	O	with
20	136	147	U-UNK	indomethacin
21	149	152	O	have
22	154	157	O	been
23	159	166	O	reported
NULL

Dexamethasone	DDI-DrugBank.d314.s14	NO_SECTION	NO_SETID	14
Thus, results of the DST should be interpreted with caution in these patients.
1	0	3	O	Thus
2	4	4	O	,
3	6	12	O	results
4	14	15	O	of
5	17	19	O	the
6	21	23	O	DST
7	25	30	O	should
8	32	33	O	be
9	35	45	O	interpreted
10	47	50	O	with
11	52	58	O	caution
12	60	61	O	in
13	63	67	O	these
14	69	76	O	patients
NULL

Dexamethasone	DDI-DrugBank.d314.s15	NO_SECTION	NO_SETID	17
Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.
1	0	8	B-UNK	Digitalis
2	10	19	L-UNK	glycosides
3	20	20	O	:
4	22	29	O	Patients
5	31	32	O	on
6	34	42	B-UNK	digitalis
7	44	53	L-UNK	glycosides
8	55	57	O	may
9	59	60	O	be
10	62	63	O	at
11	65	73	O	increased
12	75	78	O	risk
13	80	81	O	of
14	83	93	O	arrhythmias
15	95	97	O	due
16	99	100	O	to
17	102	112	O	hypokalemia
NULL

Dexamethasone	DDI-DrugBank.d314.s16	NO_SECTION	NO_SETID	28
Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.
1	0	8	U-UNK	Ephedrine
2	9	9	O	:
3	11	19	U-UNK	Ephedrine
4	21	23	O	may
5	25	31	O	enhance
6	33	35	O	the
7	37	45	O	metabolic
8	47	55	O	clearance
9	57	58	O	of
10	60	74	U-UNK	corticosteroids
11	75	75	O	,
12	77	85	O	resulting
13	87	88	O	in
14	90	98	O	decreased
15	100	104	O	blood
16	106	111	O	levels
17	113	115	O	and
18	117	124	O	lessened
19	126	136	O	physiologic
20	138	145	O	activity
21	146	146	O	,
22	148	151	O	thus
23	153	161	O	requiring
24	163	164	O	an
25	166	173	O	increase
26	175	176	O	in
27	178	191	U-UNK	corticosteroid
28	193	198	O	dosage
NULL

Dexamethasone	DDI-DrugBank.d314.s17	NO_SECTION	NO_SETID	20
Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.
1	0	8	U-UNK	Estrogens
2	9	9	O	,
3	11	19	O	including
4	21	24	O	oral
5	26	39	U-UNK	contraceptives
6	40	40	O	:
7	42	50	U-UNK	Estrogens
8	52	54	O	may
9	56	63	O	decrease
10	65	67	O	the
11	69	75	O	hepatic
12	77	86	O	metabolism
13	88	89	O	of
14	91	97	O	certain
15	99	113	U-UNK	corticosteroids
16	114	114	O	,
17	116	122	O	thereby
18	124	133	O	increasing
19	135	139	O	their
20	141	146	O	effect
NULL

Dexamethasone	DDI-DrugBank.d314.s18	NO_SECTION	NO_SETID	43
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
1	0	6	O	Hepatic
2	8	13	O	Enzyme
3	15	22	O	Inducers
4	23	23	O	,
5	25	34	O	Inhibitors
6	36	38	O	and
7	40	49	O	Substrates
8	50	50	O	:
9	52	56	O	Drugs
10	58	62	O	which
11	64	69	O	induce
12	71	80	O	cytochrome
13	82	85	O	P450
14	87	89	O	3A4
15	92	94	O	CYP
16	96	98	O	3A4
17	101	106	O	enzyme
18	108	115	O	activity
19	118	120	O	e.g
20	122	122	O	,
21	124	135	U-UNK	barbiturates
22	136	136	O	,
23	138	146	U-UNK	phenytoin
24	147	147	O	,
25	149	161	U-UNK	carbamazepine
26	162	162	O	,
27	164	171	U-UNK	rifampin
28	174	176	O	may
29	178	184	O	enhance
30	186	188	O	the
31	190	199	O	metabolism
32	201	202	O	of
33	204	218	U-UNK	corticosteroids
34	220	222	O	and
35	224	230	O	require
36	232	235	O	that
37	237	239	O	the
38	241	246	O	dosage
39	248	249	O	of
40	251	253	O	the
41	255	268	U-UNK	corticosteroid
42	270	271	O	be
43	273	281	O	increased
NULL

Dexamethasone	DDI-DrugBank.d314.s19	NO_SECTION	NO_SETID	25
Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.
1	0	4	O	Drugs
2	6	10	O	which
3	12	18	O	inhibit
4	20	22	O	CYP
5	24	26	O	3A4
6	29	31	O	e.g
7	33	33	O	,
8	35	46	U-UNK	ketoconazole
9	47	47	O	,
10	49	57	B-UNK	macrolide
11	59	69	L-UNK	antibiotics
12	71	74	O	such
13	76	77	O	as
14	79	90	U-UNK	erythromycin
15	93	96	O	have
16	98	100	O	the
17	102	110	O	potential
18	112	113	O	to
19	115	120	O	result
20	122	123	O	in
21	125	133	O	increased
22	135	140	O	plasma
23	142	155	O	concentrations
24	157	158	O	of
25	160	174	U-UNK	corticosteroids
NULL

Dexamethasone	DDI-DrugBank.d314.s20	NO_SECTION	NO_SETID	8
Dexamethasone is a moderate inducer of CYP 3A4.
1	0	12	O	XXXXXXXX
2	14	15	O	is
3	17	17	O	a
4	19	26	O	moderate
5	28	34	O	inducer
6	36	37	O	of
7	39	41	O	CYP
8	43	45	O	3A4
NULL

Dexamethasone	DDI-DrugBank.d314.s21	NO_SECTION	NO_SETID	26
Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration.
1	0	1	O	Co
2	3	16	O	administration
3	18	21	O	with
4	23	27	O	other
5	29	33	O	drugs
6	35	38	O	that
7	40	42	O	are
8	44	54	O	metabolized
9	56	57	O	by
10	59	61	O	CYP
11	63	65	O	3A4
12	68	70	O	e.g
13	72	72	O	,
14	74	82	U-UNK	indinavir
15	83	83	O	,
16	85	96	U-UNK	erythromycin
17	99	101	O	may
18	103	110	O	increase
19	112	116	O	their
20	118	126	O	clearance
21	127	127	O	,
22	129	137	O	resulting
23	139	140	O	in
24	142	150	O	decreased
25	152	157	O	plasma
26	159	171	O	concentration
NULL

Dexamethasone	DDI-DrugBank.d314.s22	NO_SECTION	NO_SETID	26
Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	25	U-UNK	Ketoconazole
4	27	29	O	has
5	31	34	O	been
6	36	43	O	reported
7	45	46	O	to
8	48	55	O	decrease
9	57	59	O	the
10	61	70	O	metabolism
11	72	73	O	of
12	75	81	O	certain
13	83	97	U-UNK	corticosteroids
14	99	100	O	by
15	102	103	O	up
16	105	106	O	to
17	108	110	O	60%
18	111	111	O	,
19	113	119	O	leading
20	121	122	O	to
21	124	132	O	increased
22	134	137	O	risk
23	139	140	O	of
24	142	155	U-UNK	corticosteroid
25	157	160	O	side
26	162	168	O	effects
NULL

Dexamethasone	DDI-DrugBank.d314.s23	NO_SECTION	NO_SETID	18
In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	24	U-UNK	ketoconazole
5	26	30	O	alone
6	32	34	O	can
7	36	42	O	inhibit
8	44	50	O	adrenal
9	52	65	U-UNK	corticosteroid
10	67	75	O	synthesis
11	77	79	O	and
12	81	83	O	may
13	85	89	O	cause
14	91	97	O	adrenal
15	99	111	O	insufficiency
16	113	118	O	during
17	120	133	O	corticosteroid
18	135	144	O	withdrawal
NULL

Dexamethasone	DDI-DrugBank.d314.s24	NO_SECTION	NO_SETID	24
Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.
1	0	11	B-UNK	Nonsteroidal
2	13	16	I-UNK	anti
3	18	29	I-UNK	inflammatory
4	31	36	L-UNK	agents
5	39	44	U-UNK	NSAIDS
6	46	46	O	:
7	48	58	O	Concomitant
8	60	62	O	use
9	64	65	O	of
10	67	73	O	XXXXXXXX
11	76	77	O	or
12	79	83	O	other
13	85	96	B-UNK	nonsteroidal
14	98	113	I-UNK	antiinflammatory
15	115	120	L-UNK	agents
16	123	125	O	and
17	127	141	U-DYN	corticosteroids
18	143	151	O	increases
19	153	155	O	the
20	157	160	O	risk
21	162	163	O	of
22	165	180	O	gastrointestinal
23	182	185	O	side
24	187	193	O	effects
NULL

Dexamethasone	DDI-DrugBank.d314.s25	NO_SECTION	NO_SETID	11
Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
1	0	6	O	XXXXXXXX
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	32	O	cautiously
6	34	35	O	in
7	37	47	O	conjunction
8	49	52	O	with
9	54	68	U-DYN	corticosteroids
10	70	71	O	in
11	73	91	O	hypoprothrombinemia
NULL

Dexamethasone	DDI-DrugBank.d314.s26	NO_SECTION	NO_SETID	12
The clearance of salicylates may be increased with concurrent use of corticosteroids.
1	0	2	O	The
2	4	12	O	clearance
3	14	15	O	of
4	17	27	U-UNK	salicylates
5	29	31	O	may
6	33	34	O	be
7	36	44	O	increased
8	46	49	O	with
9	51	60	O	concurrent
10	62	64	O	use
11	66	67	O	of
12	69	83	U-UNK	corticosteroids
NULL

Dexamethasone	DDI-DrugBank.d314.s27	NO_SECTION	NO_SETID	30
Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.
1	0	8	U-UNK	Phenytoin
2	9	9	O	:
3	11	12	O	In
4	14	17	O	post
5	19	27	O	marketing
6	29	38	O	experience
7	39	39	O	,
8	41	45	O	there
9	47	50	O	have
10	52	55	O	been
11	57	63	O	reports
12	65	66	O	of
13	68	71	O	both
14	73	81	O	increases
15	83	85	O	and
16	87	95	O	decreases
17	97	98	O	in
18	100	108	U-KIN	phenytoin
19	110	115	O	levels
20	117	120	O	with
21	122	134	O	XXXXXXXX
22	136	137	O	co
23	139	152	O	administration
24	153	153	O	,
25	155	161	O	leading
26	163	164	O	to
27	166	176	O	alterations
28	178	179	O	in
29	181	187	O	seizure
30	189	195	O	control
NULL

Dexamethasone	DDI-DrugBank.d314.s28	NO_SECTION	NO_SETID	10
Skin tests: Corticosteroids may suppress reactions to skin tests.
1	0	3	O	Skin
2	5	9	O	tests
3	10	10	O	:
4	12	26	U-UNK	Corticosteroids
5	28	30	O	may
6	32	39	O	suppress
7	41	49	O	reactions
8	51	52	O	to
9	54	57	O	skin
10	59	63	O	tests
NULL

Dexamethasone	DDI-DrugBank.d314.s29	NO_SECTION	NO_SETID	21
Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.
1	0	10	U-UNK	Thalidomide
2	11	11	O	:
3	13	14	O	Co
4	16	29	O	administration
5	31	34	O	with
6	36	46	U-UNK	thalidomide
7	48	53	O	should
8	55	56	O	be
9	58	65	O	employed
10	67	76	O	cautiously
11	77	77	O	,
12	79	80	O	as
13	82	86	O	toxic
14	88	96	O	epidermal
15	98	107	O	necrolysis
16	109	111	O	has
17	113	116	O	been
18	118	125	O	reported
19	127	130	O	with
20	132	142	O	concomitant
21	144	146	O	use
NULL

Dexamethasone	DDI-DrugBank.d314.s30	NO_SECTION	NO_SETID	24
Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.
1	0	7	U-UNK	Vaccines
2	8	8	O	:
3	10	17	O	Patients
4	19	20	O	on
5	22	35	U-UNK	corticosteroid
6	37	43	O	therapy
7	45	47	O	may
8	49	55	O	exhibit
9	57	57	O	a
10	59	68	O	diminished
11	70	77	O	response
12	79	80	O	to
13	82	88	O	toxoids
14	90	92	O	and
15	94	97	B-UNK	live
16	99	100	I-UNK	or
17	102	112	I-UNK	inactivated
18	114	121	L-UNK	vaccines
19	123	125	O	due
20	127	128	O	to
21	130	139	O	inhibition
22	141	142	O	of
23	144	151	O	antibody
24	153	160	O	response
NULL

Dexamethasone	DDI-DrugBank.d314.s31	NO_SECTION	NO_SETID	14
Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.
1	0	14	U-UNK	Corticosteroids
2	16	18	O	may
3	20	23	O	also
4	25	34	O	potentiate
5	36	38	O	the
6	40	50	O	replication
7	52	53	O	of
8	55	58	O	some
9	60	68	O	organisms
10	70	78	O	contained
11	80	81	O	in
12	83	86	B-UNK	live
13	88	97	I-UNK	attenuated
14	99	106	L-UNK	vaccines
NULL

Dexamethasone	DDI-DrugBank.d314.s32	NO_SECTION	NO_SETID	16
Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.
1	0	6	O	Routine
2	8	21	O	administration
3	23	24	O	of
4	26	33	U-UNK	vaccines
5	35	36	O	or
6	38	44	O	toxoids
7	46	51	O	should
8	53	54	O	be
9	56	63	O	deferred
10	65	69	O	until
11	71	84	U-UNK	corticosteroid
12	86	92	O	therapy
13	94	95	O	is
14	97	108	O	discontinued
15	110	111	O	if
16	113	120	O	possible
NULL

Dexbrompheniramine	DDI-DrugBank.d62.s0	NO_SECTION	NO_SETID	64
Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
1	0	17	O	XXXXXXXX
2	19	21	O	can
3	23	30	O	interact
4	32	35	O	with
5	37	43	U-UNK	alcohol
6	45	46	O	or
7	48	52	O	other
8	54	56	B-UNK	CNS
9	58	68	L-UNK	depressants
10	71	73	O	may
11	75	84	O	potentiate
12	86	88	O	the
13	90	92	O	CNS
14	94	103	O	depressant
15	105	111	O	effects
16	113	114	O	of
17	116	121	O	either
18	123	127	O	these
19	129	139	O	medications
20	141	142	O	or
21	144	157	U-UNK	antihistamines
22	159	159	O	,
23	161	176	U-UNK	anticholinergics
24	178	179	O	or
25	181	185	O	other
26	187	197	O	medications
27	199	202	O	with
28	204	218	O	anticholinergic
29	220	227	O	activity
30	230	244	O	anticholinergic
31	246	252	O	effects
32	254	256	O	may
33	258	259	O	be
34	261	271	O	potentiated
35	273	276	O	when
36	278	282	O	these
37	284	294	O	medications
38	296	298	O	are
39	300	303	O	used
40	305	316	O	concurrently
41	318	321	O	with
42	323	336	U-UNK	antihistamines
43	338	338	O	,
44	340	342	O	and
45	344	352	B-UNK	monoamine
46	354	360	I-UNK	oxidase
47	363	365	I-UNK	MAO
48	368	377	L-UNK	inhibitors
49	380	389	O	concurrent
50	391	393	O	use
51	395	398	O	with
52	400	413	U-UNK	antihistamines
53	415	417	O	may
54	419	425	O	prolong
55	427	429	O	and
56	431	439	O	intensify
57	441	443	O	the
58	445	459	O	anticholinergic
59	461	463	O	and
60	465	467	O	CNS
61	469	478	O	depressant
62	480	486	O	effects
63	488	489	O	of
64	491	504	U-UNK	antihistamines
NULL

Dexfenfluramine	DDI-DrugBank.d423.s0	NO_SECTION	NO_SETID	40
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
1	0	1	O	In
2	3	10	O	patients
3	12	20	O	receiving
4	22	33	O	nonselective
5	35	43	B-UNK	monoamine
6	45	51	I-UNK	oxidase
7	53	62	L-UNK	inhibitors
8	65	69	U-UNK	MAOIs
9	73	75	O	e.g
10	77	77	O	,
11	79	88	B-UNK	selegiline
12	90	102	L-UNK	hydrochloride
13	105	106	O	in
14	108	118	O	combination
15	120	123	O	with
16	125	138	B-UNK	serotoninergic
17	140	145	L-UNK	agents
18	148	150	O	e.g
19	152	152	O	,
20	154	163	U-UNK	fluoxetine
21	164	164	O	,
22	166	176	U-UNK	fluvoxamine
23	177	177	O	,
24	179	188	U-UNK	paroxetine
25	189	189	O	,
26	191	200	U-UNK	sertraline
27	201	201	O	,
28	203	213	U-UNK	venlafaxine
29	215	215	O	,
30	217	221	O	there
31	223	226	O	have
32	228	231	O	been
33	233	239	O	reports
34	241	242	O	of
35	244	250	O	serious
36	251	251	O	,
37	253	261	O	sometimes
38	263	267	O	fatal
39	268	268	O	,
40	270	278	O	reactions
NULL

Dexfenfluramine	DDI-DrugBank.d423.s1	NO_SECTION	NO_SETID	20
Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.
1	0	6	O	Because
2	8	22	O	XXXXXXXX
3	24	25	O	is
4	27	27	O	a
5	29	37	O	serotonin
6	39	46	O	releaser
7	48	50	O	and
8	52	59	O	reuptake
9	61	69	O	inhibitor
10	70	70	O	,
11	72	86	O	XXXXXXXX
12	88	93	O	should
13	95	97	O	not
14	99	100	O	be
15	102	105	O	used
16	107	119	O	concomitantly
17	121	124	O	with
18	126	126	O	a
19	128	130	B-DYN	MAO
20	132	140	L-DYN	inhibitor
NULL

Dexfenfluramine	DDI-DrugBank.d423.s2	NO_SECTION	NO_SETID	18
At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.
1	0	1	O	At
2	3	7	O	least
3	9	10	O	14
4	12	15	O	days
5	17	22	O	should
6	24	29	O	elapse
7	31	37	O	between
8	39	53	O	discontinuation
9	55	56	O	of
10	58	58	O	a
11	60	62	B-DYN	MAO
12	64	72	L-DYN	inhibitor
13	74	76	O	and
14	78	87	O	initiation
15	89	90	O	of
16	92	100	O	treatment
17	102	105	O	with
18	107	121	O	XXXXXXXX
NULL

Dexfenfluramine	DDI-DrugBank.d423.s3	NO_SECTION	NO_SETID	18
At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.
1	0	1	O	At
2	3	7	O	least
3	9	9	O	3
4	11	15	O	weeks
5	17	22	O	should
6	24	29	O	elapse
7	31	37	O	between
8	39	53	O	discontinuation
9	55	56	O	of
10	58	72	O	XXXXXXXX
11	74	76	O	and
12	78	87	O	initiation
13	89	90	O	of
14	92	100	O	treatment
15	102	105	O	with
16	107	107	O	a
17	109	111	B-DYN	MAO
18	113	121	L-DYN	inhibitor
NULL

Dexfenfluramine	DDI-DrugBank.d423.s4	NO_SECTION	NO_SETID	40
A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
1	0	0	O	A
2	2	5	O	rare
3	6	6	O	,
4	8	10	O	but
5	12	18	O	serious
6	19	19	O	,
7	21	33	O	constellation
8	35	36	O	of
9	38	45	O	symptoms
10	46	46	O	,
11	48	53	O	termed
12	55	63	O	serotonin
13	65	72	O	syndrome
14	73	73	O	,
15	75	77	O	has
16	79	82	O	been
17	84	91	O	reported
18	93	96	O	with
19	98	100	O	the
20	102	112	O	concomitant
21	114	116	O	use
22	118	119	O	of
23	121	129	B-DYN	selective
24	131	139	I-DYN	serotonin
25	141	148	I-DYN	reuptake
26	150	159	L-DYN	inhibitors
27	162	166	U-DYN	SSRIs
28	169	171	O	and
29	173	178	O	agents
30	180	182	O	for
31	184	191	O	migraine
32	193	199	O	therapy
33	200	200	O	,
34	202	205	O	such
35	207	208	O	as
36	210	216	O	XXXXXXXX
37	219	229	B-UNK	sumatriptan
38	231	239	L-UNK	succinate
39	242	244	O	and
40	246	262	U-UNK	dihydroergotamine
NULL

Dexfenfluramine	DDI-DrugBank.d423.s5	NO_SECTION	NO_SETID	65
The syndrome requires immediate medical attention and may include one or more of the following symptoms: excitement, hypomania, restlessness, loss of consciousness, confusion, disorientation, anxiety, agitation, motor weakness, myoclonus, tremor, hemiballismus, hyperreflexia, ataxia, dysarthria, incoordination, hyperthermia, shivering, pupillary dilation, diaphoresis, emesis, and tachycardia.
1	0	2	O	The
2	4	11	O	syndrome
3	13	20	O	requires
4	22	30	O	immediate
5	32	38	O	medical
6	40	48	O	attention
7	50	52	O	and
8	54	56	O	may
9	58	64	O	include
10	66	68	O	one
11	70	71	O	or
12	73	76	O	more
13	78	79	O	of
14	81	83	O	the
15	85	93	O	following
16	95	102	O	symptoms
17	103	103	O	:
18	105	114	O	excitement
19	115	115	O	,
20	117	125	O	hypomania
21	126	126	O	,
22	128	139	O	restlessness
23	140	140	O	,
24	142	145	O	loss
25	147	148	O	of
26	150	162	O	consciousness
27	163	163	O	,
28	165	173	O	confusion
29	174	174	O	,
30	176	189	O	disorientation
31	190	190	O	,
32	192	198	O	anxiety
33	199	199	O	,
34	201	209	O	agitation
35	210	210	O	,
36	212	216	O	motor
37	218	225	O	weakness
38	226	226	O	,
39	228	236	O	myoclonus
40	237	237	O	,
41	239	244	O	tremor
42	245	245	O	,
43	247	259	O	hemiballismus
44	260	260	O	,
45	262	274	O	hyperreflexia
46	275	275	O	,
47	277	282	O	ataxia
48	283	283	O	,
49	285	294	O	dysarthria
50	295	295	O	,
51	297	310	O	incoordination
52	311	311	O	,
53	313	324	O	hyperthermia
54	325	325	O	,
55	327	335	O	shivering
56	336	336	O	,
57	338	346	O	pupillary
58	348	355	O	dilation
59	356	356	O	,
60	358	368	O	diaphoresis
61	369	369	O	,
62	371	376	O	emesis
63	377	377	O	,
64	379	381	O	and
65	383	393	O	tachycardia
NULL

Dexfenfluramine	DDI-DrugBank.d423.s6	NO_SECTION	NO_SETID	9
Dexfenfluramine should not be administered with other serotoninergic agents.
1	0	14	O	XXXXXXXX
2	16	21	O	should
3	23	25	O	not
4	27	28	O	be
5	30	41	O	administered
6	43	46	O	with
7	48	52	O	other
8	54	67	B-DYN	serotoninergic
9	69	74	L-DYN	agents
NULL

Dexfenfluramine	DDI-DrugBank.d423.s7	NO_SECTION	NO_SETID	14
The appropriate interval between administration of these agents and dexfenfluramine has not been established.
1	0	2	O	The
2	4	14	O	appropriate
3	16	23	O	interval
4	25	31	O	between
5	33	46	O	administration
6	48	49	O	of
7	51	55	O	these
8	57	62	O	agents
9	64	66	O	and
10	68	82	O	XXXXXXXX
11	84	86	O	has
12	88	90	O	not
13	92	95	O	been
14	97	107	O	established
NULL

Dexfenfluramine	DDI-DrugBank.d423.s8	NO_SECTION	NO_SETID	14
The use of dexfenfluramine with other CNS-active drugs has not been systematically evaluated;
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	25	O	XXXXXXXX
5	27	30	O	with
6	32	36	O	other
7	38	40	O	CNS
8	42	47	O	active
9	49	53	O	drugs
10	55	57	O	has
11	59	61	O	not
12	63	66	O	been
13	68	81	O	systematically
14	83	91	O	evaluated
NULL

Dexfenfluramine	DDI-DrugBank.d423.s9	NO_SECTION	NO_SETID	13
consequently, caution is advised if dexfenfluramine and such drugs are prescribed concurrently.
1	0	11	O	consequently
2	12	12	O	,
3	14	20	O	caution
4	22	23	O	is
5	25	31	O	advised
6	33	34	O	if
7	36	50	O	XXXXXXXX
8	52	54	O	and
9	56	59	O	such
10	61	65	O	drugs
11	67	69	O	are
12	71	80	O	prescribed
13	82	93	O	concurrently
NULL

Dexmedetomidine	DDI-DrugBank.d197.s0	NO_SECTION	NO_SETID	25
General In vitro studies in human liver microsomes demonstrated no evidence of cytochrome P450-mediated drug interactions that are likely to be of clinical relevance.
1	0	6	O	General
2	8	9	O	In
3	11	15	O	vitro
4	17	23	O	studies
5	25	26	O	in
6	28	32	O	human
7	34	38	O	liver
8	40	49	O	microsomes
9	51	62	O	demonstrated
10	64	65	O	no
11	67	74	O	evidence
12	76	77	O	of
13	79	88	O	cytochrome
14	90	93	O	P450
15	95	102	O	mediated
16	104	107	O	drug
17	109	120	O	interactions
18	122	125	O	that
19	127	129	O	are
20	131	136	O	likely
21	138	139	O	to
22	141	142	O	be
23	144	145	O	of
24	147	154	O	clinical
25	156	164	O	relevance
NULL

Dexmedetomidine	DDI-DrugBank.d197.s1	NO_SECTION	NO_SETID	30
Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
1	0	10	U-UNK	Anesthetics
2	11	11	O	/
3	12	20	U-UNK	Sedatives
4	21	21	O	/
5	22	30	U-UNK	Hypnotics
6	31	31	O	/
7	32	38	U-UNK	Opioids
8	39	39	O	:
9	41	42	O	Co
10	44	57	O	administration
11	59	60	O	of
12	62	69	O	XXXXXXXX
13	71	74	O	with
14	76	86	U-DYN	anesthetics
15	87	87	O	,
16	89	97	U-DYN	sedatives
17	98	98	O	,
18	100	108	U-DYN	hypnotics
19	109	109	O	,
20	111	113	O	and
21	115	121	U-DYN	opioids
22	123	124	O	is
23	126	131	O	likely
24	133	134	O	to
25	136	139	O	lead
26	141	142	O	to
27	144	145	O	an
28	147	157	O	enhancement
29	159	160	O	of
30	162	168	O	effects
NULL

Dexmedetomidine	DDI-DrugBank.d197.s2	NO_SECTION	NO_SETID	17
Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.
1	0	7	O	Specific
2	9	15	O	studies
3	17	20	O	have
4	22	30	O	confirmed
5	32	36	O	these
6	38	44	O	effects
7	46	49	O	with
8	51	61	U-UNK	sevoflurane
9	62	62	O	,
10	64	73	U-UNK	isoflurane
11	74	74	O	,
12	76	83	U-UNK	propofol
13	84	84	O	,
14	86	95	U-UNK	alfentanil
15	96	96	O	,
16	98	100	O	and
17	102	110	U-UNK	midazolam
NULL

Dexmedetomidine	DDI-DrugBank.d197.s3	NO_SECTION	NO_SETID	17
No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam have been demonstrated.
1	0	1	O	No
2	3	17	O	pharmacokinetic
3	19	30	O	interactions
4	32	38	O	between
5	40	54	O	XXXXXXXX
6	56	58	O	and
7	60	69	U-UNK	isoflurane
8	70	70	O	,
9	72	79	U-UNK	propofol
10	80	80	O	,
11	82	91	U-UNK	alfentanil
12	92	92	O	,
13	94	96	O	and
14	98	106	U-UNK	midazolam
15	108	111	O	have
16	113	116	O	been
17	118	129	O	demonstrated
NULL

Dexmedetomidine	DDI-DrugBank.d197.s4	NO_SECTION	NO_SETID	33
However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	due
4	13	14	O	to
5	16	23	O	possible
6	25	39	O	pharmacodynamic
7	41	52	O	interactions
8	53	53	O	,
9	55	58	O	when
10	60	61	O	co
11	63	74	O	administered
12	76	79	O	with
13	81	88	O	XXXXXXXX
14	89	89	O	,
15	91	91	O	a
16	93	101	O	reduction
17	103	104	O	in
18	106	111	O	dosage
19	113	114	O	of
20	116	123	O	XXXXXXXX
21	125	126	O	on
22	128	130	O	the
23	132	142	O	concomitant
24	144	153	U-DYN	anesthetic
25	154	154	O	,
26	156	163	U-DYN	sedative
27	164	164	O	,
28	166	173	U-DYN	hypnotic
29	175	176	O	or
30	178	183	U-DYN	opioid
31	185	187	O	may
32	189	190	O	be
33	192	199	O	required
NULL

Dexmedetomidine	DDI-DrugBank.d197.s5	NO_SECTION	NO_SETID	43
Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.
1	0	12	B-UNK	Neuromuscular
2	14	21	L-UNK	Blockers
3	22	22	O	:
4	24	25	O	In
5	27	29	O	one
6	31	35	O	study
7	37	38	O	of
8	40	41	O	10
9	43	49	O	healthy
10	51	60	O	volunteers
11	61	61	O	,
12	63	76	O	administration
13	78	79	O	of
14	81	88	O	XXXXXXXX
15	90	92	O	for
16	94	95	O	45
17	97	103	O	minutes
18	105	106	O	at
19	108	108	O	a
20	110	115	O	plasma
21	117	129	O	concentration
22	131	132	O	of
23	134	134	O	1
24	137	139	O	one
25	142	143	O	ng
26	144	144	O	/
27	145	146	O	mL
28	148	155	O	resulted
29	157	158	O	in
30	160	161	O	no
31	163	172	O	clinically
32	174	183	O	meaningful
33	185	193	O	increases
34	195	196	O	in
35	198	200	O	the
36	202	210	O	magnitude
37	212	213	O	or
38	215	227	O	neuromuscular
39	229	236	O	blockade
40	238	247	O	associated
41	249	252	O	with
42	254	263	U-UNK	rocuronium
43	265	278	O	administration
NULL

Dexrazoxane	DDI-DrugBank.d38.s0	NO_SECTION	NO_SETID	8
ZINECARD does not influence the pharmacokinetics of doxorubicin.
1	0	7	O	XXXXXXXX
2	9	12	O	does
3	14	16	O	not
4	18	26	O	influence
5	28	30	O	the
6	32	47	O	pharmacokinetics
7	49	50	O	of
8	52	62	U-UNK	doxorubicin
NULL

Dexrazoxane	DDI-DrugBank.d38.s1	NO_SECTION	NO_SETID	20
Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term carcinogenicity studies have been carried out with dexrazoxane in animals.
1	0	13	O	Carcinogenesis
2	14	14	O	,
3	16	26	O	Mutagenesis
4	27	27	O	,
5	29	38	O	Impairment
6	40	41	O	of
7	43	51	O	Fertility
8	53	54	O	No
9	56	59	O	long
10	61	64	O	term
11	66	80	O	carcinogenicity
12	82	88	O	studies
13	90	93	O	have
14	95	98	O	been
15	100	106	O	carried
16	108	110	O	out
17	112	115	O	with
18	117	127	O	XXXXXXXX
19	129	130	O	in
20	132	138	O	animals
NULL

Dexrazoxane	DDI-DrugBank.d38.s2	NO_SECTION	NO_SETID	29
Dexrazoxane was not mutagenic in the Ames test but was found to be clastogenic to human lymphocytes in vitro and to mouse bone marrow erythrocytes in vivo (micronucleus test).
1	0	10	O	XXXXXXXX
2	12	14	O	was
3	16	18	O	not
4	20	28	O	mutagenic
5	30	31	O	in
6	33	35	O	the
7	37	40	O	Ames
8	42	45	O	test
9	47	49	O	but
10	51	53	O	was
11	55	59	O	found
12	61	62	O	to
13	64	65	O	be
14	67	77	O	clastogenic
15	79	80	O	to
16	82	86	O	human
17	88	98	O	lymphocytes
18	100	101	O	in
19	103	107	O	vitro
20	109	111	O	and
21	113	114	O	to
22	116	120	O	mouse
23	122	125	O	bone
24	127	132	O	marrow
25	134	145	O	erythrocytes
26	147	148	O	in
27	150	153	O	vivo
28	156	167	O	micronucleus
29	169	172	O	test
NULL

Dexrazoxane	DDI-DrugBank.d38.s3	NO_SECTION	NO_SETID	24
The possible adverse effects of ZINECARD on the fertility of humans and experimental animals, male or female, have not been adequately studied.
1	0	2	O	The
2	4	11	O	possible
3	13	19	O	adverse
4	21	27	O	effects
5	29	30	O	of
6	32	39	O	XXXXXXXX
7	41	42	O	on
8	44	46	O	the
9	48	56	O	fertility
10	58	59	O	of
11	61	66	O	humans
12	68	70	O	and
13	72	83	O	experimental
14	85	91	O	animals
15	92	92	O	,
16	94	97	O	male
17	99	100	O	or
18	102	107	O	female
19	108	108	O	,
20	110	113	O	have
21	115	117	O	not
22	119	122	O	been
23	124	133	O	adequately
24	135	141	O	studied
NULL

Dexrazoxane	DDI-DrugBank.d38.s4	NO_SECTION	NO_SETID	62
Testicular atrophy was seen with dexrazoxane administration at doses as low as 30 mg/kg weekly for 6 weeks in rats (1/3 the human dose on a mg/m 2 basis) and as low as 20 mg/kg weekly for 13 weeks in dogs (approximately equal to the human dose on a mg/m 2 basis).
1	0	9	O	Testicular
2	11	17	O	atrophy
3	19	21	O	was
4	23	26	O	seen
5	28	31	O	with
6	33	43	O	XXXXXXXX
7	45	58	O	administration
8	60	61	O	at
9	63	67	O	doses
10	69	70	O	as
11	72	74	O	low
12	76	77	O	as
13	79	80	O	30
14	82	83	O	mg
15	84	84	O	/
16	85	86	O	kg
17	88	93	O	weekly
18	95	97	O	for
19	99	99	O	6
20	101	105	O	weeks
21	107	108	O	in
22	110	113	O	rats
23	116	116	O	1
24	117	117	O	/
25	118	118	O	3
26	120	122	O	the
27	124	128	O	human
28	130	133	O	dose
29	135	136	O	on
30	138	138	O	a
31	140	141	O	mg
32	142	142	O	/
33	143	143	O	m
34	145	145	O	2
35	147	151	O	basis
36	154	156	O	and
37	158	159	O	as
38	161	163	O	low
39	165	166	O	as
40	168	169	O	20
41	171	172	O	mg
42	173	173	O	/
43	174	175	O	kg
44	177	182	O	weekly
45	184	186	O	for
46	188	189	O	13
47	191	195	O	weeks
48	197	198	O	in
49	200	203	O	dogs
50	206	218	O	approximately
51	220	224	O	equal
52	226	227	O	to
53	229	231	O	the
54	233	237	O	human
55	239	242	O	dose
56	244	245	O	on
57	247	247	O	a
58	249	250	O	mg
59	251	251	O	/
60	252	252	O	m
61	254	254	O	2
62	256	260	O	basis
NULL

Dextroamphetamine	DDI-DrugBank.d236.s0	NO_SECTION	NO_SETID	25
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.
1	0	9	B-UNK	Acidifying
2	11	16	L-UNK	agents
3	17	17	O	:
4	19	34	B-UNK	Gastrointestinal
5	36	45	I-UNK	acidifying
6	47	52	L-UNK	agents
7	55	66	U-UNK	guanethidine
8	67	67	O	,
9	69	77	U-UNK	reserpine
10	78	78	O	,
11	80	87	B-UNK	glutamic
12	89	92	I-UNK	acid
13	94	96	L-UNK	HCl
14	97	97	O	,
15	99	106	B-UNK	ascorbic
16	108	111	L-UNK	acid
17	112	112	O	,
18	114	118	O	fruit
19	120	125	O	juices
20	126	126	O	,
21	128	130	O	etc
22	134	138	O	lower
23	140	149	O	absorption
24	151	152	O	of
25	154	165	U-UNK	amphetamines
NULL

Dextroamphetamine	DDI-DrugBank.d236.s1	NO_SECTION	NO_SETID	27
Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
1	0	6	B-UNK	Urinary
2	8	17	I-UNK	acidifying
3	19	24	L-UNK	agents
4	27	34	B-UNK	ammonium
5	36	43	L-UNK	chloride
6	44	44	O	,
7	46	51	B-UNK	sodium
8	53	56	I-UNK	acid
9	58	66	L-UNK	phosphate
10	67	67	O	,
11	69	71	O	etc
12	75	82	O	increase
13	84	86	O	the
14	88	100	O	concentration
15	102	103	O	of
16	105	107	O	the
17	109	115	O	ionized
18	117	123	O	species
19	125	126	O	of
20	128	130	O	the
21	132	142	U-UNK	amphetamine
22	144	151	O	molecule
23	152	152	O	,
24	154	160	O	thereby
25	162	171	O	increasing
26	173	179	O	urinary
27	181	189	O	excretion
NULL

Dextroamphetamine	DDI-DrugBank.d236.s2	NO_SECTION	NO_SETID	11
Both groups of agents lower blood levels and efficacy of amphetamines.
1	0	3	O	Both
2	5	10	O	groups
3	12	13	O	of
4	15	20	O	agents
5	22	26	O	lower
6	28	32	O	blood
7	34	39	O	levels
8	41	43	O	and
9	45	52	O	efficacy
10	54	55	O	of
11	57	68	U-UNK	amphetamines
NULL

Dextroamphetamine	DDI-DrugBank.d236.s3	NO_SECTION	NO_SETID	9
Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.
1	0	9	B-UNK	Adrenergic
2	11	18	L-UNK	blockers
3	19	19	O	:
4	21	30	B-UNK	Adrenergic
5	32	39	L-UNK	blockers
6	41	43	O	are
7	45	53	O	inhibited
8	55	56	O	by
9	58	69	U-UNK	amphetamines
NULL

Dextroamphetamine	DDI-DrugBank.d236.s4	NO_SECTION	NO_SETID	14
Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.
1	0	11	O	Alkalinizing
2	13	18	O	agents
3	19	19	O	:
4	21	36	O	Gastrointestinal
5	38	49	O	alkalinizing
6	51	56	O	agents
7	59	64	B-UNK	sodium
8	66	76	L-UNK	bicarbonate
9	77	77	O	,
10	79	81	O	etc
11	85	92	O	increase
12	94	103	O	absorption
13	105	106	O	of
14	108	119	U-UNK	amphetamines
NULL

Dextroamphetamine	DDI-DrugBank.d236.s5	NO_SECTION	NO_SETID	24
Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.
1	0	6	O	Urinary
2	8	19	O	alkalinizing
3	21	26	O	agents
4	29	41	U-UNK	acetazolamide
5	42	42	O	,
6	44	47	O	some
7	49	57	U-UNK	thiazides
8	60	67	O	increase
9	69	71	O	the
10	73	85	O	concentration
11	87	88	O	of
12	90	92	O	the
13	94	96	O	non
14	98	104	O	ionized
15	106	112	O	species
16	114	115	O	of
17	117	119	O	the
18	121	131	U-UNK	amphetamine
19	133	140	O	molecule
20	141	141	O	,
21	143	149	O	thereby
22	151	160	O	decreasing
23	162	168	O	urinary
24	170	178	O	excretion
NULL

Dextroamphetamine	DDI-DrugBank.d236.s6	NO_SECTION	NO_SETID	14
Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines.
1	0	3	O	Both
2	5	10	O	groups
3	12	13	O	of
4	15	20	O	agents
5	22	29	O	increase
6	31	35	O	blood
7	37	42	O	levels
8	44	46	O	and
9	48	56	O	therefore
10	58	67	O	potentiate
11	69	71	O	the
12	73	79	O	actions
13	81	82	O	of
14	84	95	U-UNK	amphetamines
NULL

Dextroamphetamine	DDI-DrugBank.d236.s7	NO_SECTION	NO_SETID	14
Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;
1	0	14	U-UNK	Antidepressants
2	15	15	O	,
3	17	25	U-UNK	tricyclic
4	26	26	O	:
5	28	39	U-UNK	Amphetamines
6	41	43	O	may
7	45	51	O	enhance
8	53	55	O	the
9	57	64	O	activity
10	66	67	O	of
11	69	77	U-UNK	tricyclic
12	79	80	O	or
13	82	96	B-UNK	sympathomimetic
14	98	103	L-UNK	agents
NULL

Dextroamphetamine	DDI-DrugBank.d236.s8	NO_SECTION	NO_SETID	24
d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
1	0	0	B-UNK	d
2	2	12	L-UNK	amphetamine
3	14	17	O	with
4	19	29	U-UNK	desipramine
5	31	32	O	or
6	34	46	U-UNK	protriptyline
7	48	50	O	and
8	52	59	O	possibly
9	61	65	O	other
10	67	76	U-UNK	tricyclics
11	78	82	O	cause
12	84	91	O	striking
13	93	95	O	and
14	97	105	O	sustained
15	107	115	O	increases
16	117	118	O	in
17	120	122	O	the
18	124	136	O	concentration
19	138	139	O	of
20	141	141	B-UNK	d
21	143	153	L-UNK	amphetamine
22	155	156	O	in
23	158	160	O	the
24	162	166	O	brain
NULL

Dextroamphetamine	DDI-DrugBank.d236.s9	NO_SECTION	NO_SETID	5
cardiovascular effects can be potentiated.
1	0	13	O	cardiovascular
2	15	21	O	effects
3	23	25	O	can
4	27	28	O	be
5	30	40	O	potentiated
NULL

Dextroamphetamine	DDI-DrugBank.d236.s10	NO_SECTION	NO_SETID	17
MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
1	0	2	B-UNK	MAO
2	4	13	L-UNK	inhibitors
3	14	14	O	:
4	16	19	B-UNK	MAOI
5	21	35	L-UNK	antidepressants
6	36	36	O	,
7	38	39	O	as
8	41	44	O	well
9	46	47	O	as
10	49	49	O	a
11	51	60	O	metabolite
12	62	63	O	of
13	65	76	U-UNK	furazolidone
14	77	77	O	,
15	79	82	O	slow
16	84	94	U-UNK	amphetamine
17	96	105	O	metabolism
NULL

Dextroamphetamine	DDI-DrugBank.d236.s11	NO_SECTION	NO_SETID	20
This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings;
1	0	3	O	This
2	5	11	O	slowing
3	13	23	O	potentiates
4	25	36	U-UNK	amphetamines
5	37	37	O	,
6	39	48	O	increasing
7	50	54	O	their
8	56	61	O	effect
9	63	64	O	on
10	66	68	O	the
11	70	76	O	release
12	78	79	O	of
13	81	94	O	norepinephrine
14	96	98	O	and
15	100	104	O	other
16	106	115	O	monoamines
17	117	120	O	from
18	122	131	O	adrenergic
19	133	137	O	nerve
20	139	145	O	endings
NULL

Dextroamphetamine	DDI-DrugBank.d236.s12	NO_SECTION	NO_SETID	10
this can cause headaches and other signs of hypertensive crisis.
1	0	3	O	this
2	5	7	O	can
3	9	13	O	cause
4	15	23	O	headaches
5	25	27	O	and
6	29	33	O	other
7	35	39	O	signs
8	41	42	O	of
9	44	55	O	hypertensive
10	57	62	O	crisis
NULL

Dextroamphetamine	DDI-DrugBank.d236.s13	NO_SECTION	NO_SETID	16
A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results.
1	0	0	O	A
2	2	8	O	variety
3	10	11	O	of
4	13	24	O	neurological
5	26	30	O	toxic
6	32	38	O	effects
7	40	42	O	and
8	44	52	O	malignant
9	54	65	O	hyperpyrexia
10	67	69	O	can
11	71	75	O	occur
12	76	76	O	,
13	78	86	O	sometimes
14	88	91	O	with
15	93	97	O	fatal
16	99	105	O	results
NULL

Dextroamphetamine	DDI-DrugBank.d236.s14	NO_SECTION	NO_SETID	10
Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
1	0	13	U-UNK	Antihistamines
2	14	14	O	:
3	16	27	U-UNK	Amphetamines
4	29	31	O	may
5	33	42	O	counteract
6	44	46	O	the
7	48	55	O	sedative
8	57	62	O	effect
9	64	65	O	of
10	67	80	U-UNK	antihistamines
NULL

Dextroamphetamine	DDI-DrugBank.d236.s15	NO_SECTION	NO_SETID	10
Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
1	0	16	U-UNK	Antihypertensives
2	17	17	O	:
3	19	30	U-UNK	Amphetamines
4	32	34	O	may
5	36	45	O	antagonize
6	47	49	O	the
7	51	61	O	hypotensive
8	63	69	O	effects
9	71	72	O	of
10	74	90	U-UNK	antihypertensives
NULL

Dextroamphetamine	DDI-DrugBank.d236.s16	NO_SECTION	NO_SETID	26
Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.
1	0	13	U-UNK	Chlorpromazine
2	14	14	O	:
3	16	29	U-UNK	Chlorpromazine
4	31	36	O	blocks
5	38	45	O	dopamine
6	47	49	O	and
7	51	64	O	norepinephrine
8	66	73	O	reuptake
9	74	74	O	,
10	76	79	O	thus
11	81	90	O	inhibiting
12	92	94	O	the
13	96	102	O	central
14	104	112	O	stimulant
15	114	120	O	effects
16	122	123	O	of
17	125	136	U-UNK	amphetamines
18	137	137	O	,
19	139	141	O	and
20	143	145	O	can
21	147	148	O	be
22	150	153	O	used
23	155	156	O	to
24	158	162	O	treat
25	164	174	U-UNK	amphetamine
26	176	184	O	poisoning
NULL

Dextroamphetamine	DDI-DrugBank.d236.s17	NO_SECTION	NO_SETID	9
Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
1	0	11	U-UNK	Ethosuximide
2	12	12	O	:
3	14	25	U-UNK	Amphetamines
4	27	29	O	may
5	31	35	O	delay
6	37	46	O	intestinal
7	48	57	O	absorption
8	59	60	O	of
9	62	73	U-UNK	ethosuximide
NULL

Dextroamphetamine	DDI-DrugBank.d236.s18	NO_SECTION	NO_SETID	17
Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.
1	0	10	U-UNK	Haloperidol
2	11	11	O	:
3	13	23	U-UNK	Haloperidol
4	25	30	O	blocks
5	32	39	O	dopamine
6	41	43	O	and
7	45	58	O	norepinephrine
8	60	67	O	reuptake
9	68	68	O	,
10	70	73	O	thus
11	75	84	O	inhibiting
12	86	88	O	the
13	90	96	O	central
14	98	106	O	stimulant
15	108	114	O	effects
16	116	117	O	of
17	119	130	U-UNK	amphetamines
NULL

Dextroamphetamine	DDI-DrugBank.d236.s19	NO_SECTION	NO_SETID	14
Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.
1	0	6	B-UNK	Lithium
2	8	16	L-UNK	carbonate
3	17	17	O	:
4	19	21	O	The
5	23	33	O	stimulatory
6	35	41	O	effects
7	43	44	O	of
8	46	57	U-UNK	amphetamines
9	59	61	O	may
10	63	64	O	be
11	66	74	O	inhibited
12	76	77	O	by
13	79	85	B-UNK	lithium
14	87	95	L-UNK	carbonate
NULL

Dextroamphetamine	DDI-DrugBank.d236.s20	NO_SECTION	NO_SETID	9
Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
1	0	9	U-UNK	Meperidine
2	10	10	O	:
3	12	23	U-UNK	Amphetamines
4	25	34	O	potentiate
5	36	38	O	the
6	40	48	O	analgesic
7	50	55	O	effect
8	57	58	O	of
9	60	69	U-UNK	meperidine
NULL

Dextroamphetamine	DDI-DrugBank.d236.s21	NO_SECTION	NO_SETID	22
Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.
1	0	10	U-UNK	Methenamine
2	12	18	O	therapy
3	19	19	O	:
4	21	27	O	Urinary
5	29	37	O	excretion
6	39	40	O	of
7	42	53	U-UNK	amphetamines
8	55	56	O	is
9	58	66	O	increased
10	67	67	O	,
11	69	71	O	and
12	73	80	O	efficacy
13	82	83	O	is
14	85	91	O	reduced
15	92	92	O	,
16	94	95	O	by
17	97	106	B-UNK	acidifying
18	108	113	L-UNK	agents
19	115	118	O	used
20	120	121	O	in
21	123	133	U-UNK	methenamine
22	135	141	O	therapy
NULL

Dextroamphetamine	DDI-DrugBank.d236.s22	NO_SECTION	NO_SETID	9
Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
1	0	13	U-UNK	Norepinephrine
2	14	14	O	:
3	16	27	U-UNK	Amphetamines
4	29	35	O	enhance
5	37	39	O	the
6	41	50	O	adrenergic
7	52	57	O	effect
8	59	60	O	of
9	62	75	U-UNK	norepinephrine
NULL

Dextroamphetamine	DDI-DrugBank.d236.s23	NO_SECTION	NO_SETID	9
Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
1	0	12	U-UNK	Phenobarbital
2	13	13	O	:
3	15	26	U-UNK	Amphetamines
4	28	30	O	may
5	32	36	O	delay
6	38	47	O	intestinal
7	49	58	O	absorption
8	60	61	O	of
9	63	75	U-UNK	phenobarbital
NULL

Dextroamphetamine	DDI-DrugBank.d236.s24	NO_SECTION	NO_SETID	10
co-administration of phenobarbital may produce a synergistic anticonvulsant action.
1	0	1	O	co
2	3	16	O	administration
3	18	19	O	of
4	21	33	U-UNK	phenobarbital
5	35	37	O	may
6	39	45	O	produce
7	47	47	O	a
8	49	59	O	synergistic
9	61	74	O	anticonvulsant
10	76	81	O	action
NULL

Dextroamphetamine	DDI-DrugBank.d236.s25	NO_SECTION	NO_SETID	9
Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
1	0	8	U-UNK	Phenytoin
2	9	9	O	:
3	11	22	U-UNK	Amphetamines
4	24	26	O	may
5	28	32	O	delay
6	34	43	O	intestinal
7	45	54	O	absorption
8	56	57	O	of
9	59	67	U-UNK	phenytoin
NULL

Dextroamphetamine	DDI-DrugBank.d236.s26	NO_SECTION	NO_SETID	10
co-administration of phenytoin may produce a synergistic anticonvulsant action.
1	0	1	O	co
2	3	16	O	administration
3	18	19	O	of
4	21	29	U-UNK	phenytoin
5	31	33	O	may
6	35	41	O	produce
7	43	43	O	a
8	45	55	O	synergistic
9	57	70	O	anticonvulsant
10	72	77	O	action
NULL

Dextroamphetamine	DDI-DrugBank.d236.s27	NO_SECTION	NO_SETID	18
Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
1	0	11	U-UNK	Propoxyphene
2	12	12	O	:
3	14	15	O	In
4	17	21	O	cases
5	23	24	O	of
6	26	37	U-UNK	propoxyphene
7	39	48	O	overdosage
8	49	49	O	,
9	51	61	U-UNK	amphetamine
10	63	65	O	CNS
11	67	77	O	stimulation
12	79	80	O	is
13	82	92	O	potentiated
14	94	96	O	and
15	98	102	O	fatal
16	104	114	O	convulsions
17	116	118	O	can
18	120	124	O	occur
NULL

Dextroamphetamine	DDI-DrugBank.d236.s28	NO_SECTION	NO_SETID	11
Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
1	0	7	B-UNK	Veratrum
2	9	17	L-UNK	alkaloids
3	18	18	O	:
4	20	31	U-UNK	Amphetamines
5	33	39	O	inhibit
6	41	43	O	the
7	45	55	O	hypotensive
8	57	62	O	effect
9	64	65	O	of
10	67	74	B-UNK	veratrum
11	76	84	L-UNK	alkaloids
NULL

Dextroamphetamine	DDI-DrugBank.d236.s29	NO_SECTION	NO_SETID	16
Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	33	33	O	:
7	35	46	U-UNK	Amphetamines
8	48	50	O	can
9	52	56	O	cause
10	58	58	O	a
11	60	70	O	significant
12	72	80	O	elevation
13	82	83	O	in
14	85	90	O	plasma
15	92	105	U-UNK	corticosteroid
16	107	112	O	levels
NULL

Dextroamphetamine	DDI-DrugBank.d236.s30	NO_SECTION	NO_SETID	7
This increase is greatest in the evening.
1	0	3	O	This
2	5	12	O	increase
3	14	15	O	is
4	17	24	O	greatest
5	26	27	O	in
6	29	31	O	the
7	33	39	O	evening
NULL

Dextroamphetamine	DDI-DrugBank.d236.s31	NO_SECTION	NO_SETID	7
Amphetamines may interfere with urinary steroid determinations.
1	0	11	U-UNK	Amphetamines
2	13	15	O	may
3	17	25	O	interfere
4	27	30	O	with
5	32	38	O	urinary
6	40	46	O	steroid
7	48	61	O	determinations
NULL

Dezocine	DDI-DrugBank.d461.s0	NO_SECTION	NO_SETID	22
Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, hypnotics, alcohol, and other opiate analgesics.
1	0	7	O	Additive
2	9	18	O	depressant
3	20	25	O	effect
4	27	30	O	when
5	32	35	O	used
6	37	40	O	with
7	42	48	O	general
8	50	60	U-UNK	anesthetics
9	61	61	O	,
10	63	71	U-UNK	sedatives
11	72	72	O	,
12	74	84	B-UNK	antianxiety
13	86	90	L-UNK	drugs
14	91	91	O	,
15	93	101	U-UNK	hypnotics
16	102	102	O	,
17	104	110	U-UNK	alcohol
18	111	111	O	,
19	113	115	O	and
20	117	121	O	other
21	123	128	B-UNK	opiate
22	130	139	L-UNK	analgesics
NULL

Diatrizoate	DDI-DrugBank.d293.s0	NO_SECTION	NO_SETID	32
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).
1	0	2	O	May
2	4	11	O	interact
3	13	16	O	with
4	18	24	O	thyroid
5	26	35	O	medication
6	38	40	O	e.g
7	42	42	O	,
8	44	56	U-UNK	levothyroxine
9	58	58	O	,
10	60	65	U-UNK	iodine
11	67	76	O	containing
12	78	85	O	products
13	86	86	O	,
14	88	95	U-UNK	antacids
15	96	96	O	,
16	98	99	B-UNK	H2
17	101	111	L-UNK	antagonists
18	114	116	O	e.g
19	118	118	O	,
20	120	129	U-UNK	famotidine
21	130	130	O	,
22	132	141	U-UNK	ranitidine
23	143	143	O	,
24	145	147	O	and
25	149	154	B-UNK	proton
26	156	159	I-UNK	pump
27	161	170	L-UNK	inhibitors
28	173	175	O	e.g
29	177	177	O	,
30	179	190	U-UNK	lansoprazole
31	191	191	O	,
32	193	202	U-UNK	omeprazole
NULL

Diatrizoate	DDI-DrugBank.d293.s1	NO_SECTION	NO_SETID	10
This product can affect the results of certain lab tests.
1	0	3	O	This
2	5	11	O	product
3	13	15	O	can
4	17	22	O	affect
5	24	26	O	the
6	28	34	O	results
7	36	37	O	of
8	39	45	O	certain
9	47	49	O	lab
10	51	55	O	tests
NULL

Dichlorphenamide	DDI-DrugBank.d36.s0	NO_SECTION	NO_SETID	33
Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.
1	0	6	O	Caution
2	8	9	O	is
3	11	17	O	advised
4	19	20	O	in
5	22	29	O	patients
6	31	39	O	receiving
7	41	51	O	concomitant
8	53	56	O	high
9	58	61	O	dose
10	63	69	O	XXXXXXXX
11	71	73	O	and
12	75	82	B-DYN	carbonic
13	84	92	I-DYN	anhydrase
14	94	103	L-DYN	inhibitors
15	104	104	O	,
16	106	107	O	as
17	109	116	O	anorexia
18	117	117	O	,
19	119	127	O	tachypnea
20	128	128	O	,
21	130	137	O	lethargy
22	139	141	O	and
23	143	146	O	coma
24	148	151	O	have
25	153	156	O	been
26	158	163	O	rarely
27	165	172	O	reported
28	174	176	O	due
29	178	179	O	to
30	181	181	O	a
31	183	190	O	possible
32	192	195	O	drug
33	197	207	O	interaction
NULL

Diclofenac	DDI-DrugBank.d249.s0	NO_SECTION	NO_SETID	39
Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.
1	0	6	O	XXXXXXXX
2	7	7	O	:
3	9	19	O	Concomitant
4	21	34	O	administration
5	36	37	O	of
6	39	48	U-DYN	diclofenac
7	50	52	O	and
8	54	60	O	XXXXXXXX
9	62	63	O	is
10	65	67	O	not
11	69	79	O	recommended
12	81	87	O	because
13	89	98	U-KIN	diclofenac
14	100	101	O	is
15	103	111	O	displaced
16	113	116	O	from
17	118	120	O	its
18	122	128	O	binding
19	130	134	O	sites
20	136	141	O	during
21	143	145	O	the
22	147	157	O	concomitant
23	159	172	O	administration
24	174	175	O	of
25	177	183	O	XXXXXXXX
26	184	184	O	,
27	186	194	O	resulting
28	196	197	O	in
29	199	203	O	lower
30	205	210	O	plasma
31	212	225	O	concentrations
32	226	226	O	,
33	228	231	O	peak
34	233	238	O	plasma
35	240	245	O	levels
36	246	246	O	,
37	248	250	O	and
38	252	254	O	AUC
39	256	261	O	values
NULL

Diclofenac	DDI-DrugBank.d249.s1	NO_SECTION	NO_SETID	32
Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.
1	0	13	U-UNK	Anticoagulants
2	14	14	O	:
3	16	20	O	While
4	22	28	O	studies
5	30	33	O	have
6	35	37	O	not
7	39	43	O	shown
8	45	54	O	XXXXXXXX
9	56	57	O	to
10	59	66	O	interact
11	68	71	O	with
12	73	86	B-UNK	anticoagulants
13	88	89	I-UNK	of
14	91	93	I-UNK	the
15	95	102	I-UNK	warfarin
16	104	107	L-UNK	type
17	108	108	O	,
18	110	116	O	caution
19	118	123	O	should
20	125	126	O	be
21	128	136	O	exercised
22	137	137	O	,
23	139	149	O	nonetheless
24	150	150	O	,
25	152	156	O	since
26	158	169	O	interactions
27	171	174	O	have
28	176	179	O	been
29	181	184	O	seen
30	186	189	O	with
31	191	195	O	other
32	197	202	U-DYN	NSAIDs
NULL

Diclofenac	DDI-DrugBank.d249.s2	NO_SECTION	NO_SETID	45
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
1	0	6	O	Because
2	8	21	O	prostaglandins
3	23	26	O	play
4	28	29	O	an
5	31	39	O	important
6	41	44	O	role
7	46	47	O	in
8	49	58	O	hemostasis
9	59	59	O	,
10	61	63	O	and
11	65	70	U-UNK	NSAIDs
12	72	77	O	affect
13	79	86	O	platelet
14	88	95	O	function
15	97	98	O	as
16	100	103	O	well
17	104	104	O	,
18	106	115	O	concurrent
19	117	123	O	therapy
20	125	128	O	with
21	130	132	O	all
22	134	139	U-UNK	NSAIDs
23	140	140	O	,
24	142	150	O	including
25	152	161	O	XXXXXXXX
26	162	162	O	,
27	164	166	O	and
28	168	175	U-DYN	warfarin
29	177	184	O	requires
30	186	190	O	close
31	192	201	O	monitoring
32	203	204	O	of
33	206	213	O	patients
34	215	216	O	to
35	218	219	O	be
36	221	227	O	certain
37	229	232	O	that
38	234	235	O	no
39	237	242	O	change
40	244	245	O	in
41	247	251	O	their
42	253	265	U-UNK	anticoagulant
43	267	272	O	dosage
44	274	275	O	is
45	277	284	O	required
NULL

Diclofenac	DDI-DrugBank.d249.s3	NO_SECTION	NO_SETID	23
Digoxin, Methotrexate, Cyclosporine: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.
1	0	6	U-UNK	Digoxin
2	7	7	O	,
3	9	20	U-UNK	Methotrexate
4	21	21	O	,
5	23	34	U-UNK	Cyclosporine
6	35	35	O	:
7	37	46	O	XXXXXXXX
8	47	47	O	,
9	49	52	O	like
10	54	58	O	other
11	60	65	U-UNK	NSAIDs
12	66	66	O	,
13	68	70	O	may
14	72	77	O	affect
15	79	83	O	renal
16	85	98	O	prostaglandins
17	100	102	O	and
18	104	111	O	increase
19	113	115	O	the
20	117	124	O	toxicity
21	126	127	O	of
22	129	135	O	certain
23	137	141	O	drugs
NULL

Diclofenac	DDI-DrugBank.d249.s4	NO_SECTION	NO_SETID	16
Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.
1	0	8	O	Ingestion
2	10	11	O	of
3	13	22	O	XXXXXXXX
4	24	26	O	may
5	28	35	O	increase
6	37	41	O	serum
7	43	56	O	concentrations
8	58	59	O	of
9	61	67	U-KIN	digoxin
10	69	71	O	and
11	73	84	U-KIN	methotrexate
12	86	88	O	and
13	90	97	O	increase
14	99	110	U-DYN	cyclosporine
15	112	112	O	s
16	114	127	O	nephrotoxicity
NULL

Diclofenac	DDI-DrugBank.d249.s5	NO_SECTION	NO_SETID	30
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
1	0	7	O	Patients
2	9	11	O	who
3	13	17	O	begin
4	19	24	O	taking
5	26	35	O	XXXXXXXX
6	37	38	O	or
7	40	42	O	who
8	44	51	O	increase
9	53	57	O	their
10	59	68	O	XXXXXXXX
11	70	73	O	dose
12	75	76	O	or
13	78	80	O	any
14	82	86	O	other
15	88	92	U-UNK	NSAID
16	94	98	O	while
17	100	105	O	taking
18	107	113	U-DYN	digoxin
19	114	114	O	,
20	116	127	U-DYN	methotrexate
21	128	128	O	,
22	130	131	O	or
23	133	144	U-DYN	cyclosporine
24	146	148	O	may
25	150	156	O	develop
26	158	165	O	toxicity
27	167	181	O	characteristics
28	183	185	O	for
29	187	191	O	these
30	193	197	O	drugs
NULL

Diclofenac	DDI-DrugBank.d249.s6	NO_SECTION	NO_SETID	12
They should be observed closely, particularly if renal function is impaired.
1	0	3	O	They
2	5	10	O	should
3	12	13	O	be
4	15	22	O	observed
5	24	30	O	closely
6	31	31	O	,
7	33	44	O	particularly
8	46	47	O	if
9	49	53	O	renal
10	55	62	O	function
11	64	65	O	is
12	67	74	O	impaired
NULL

Diclofenac	DDI-DrugBank.d249.s7	NO_SECTION	NO_SETID	11
In the case of digoxin, serum levels should be monitored.
1	0	1	O	In
2	3	5	O	the
3	7	10	O	case
4	12	13	O	of
5	15	21	U-UNK	digoxin
6	22	22	O	,
7	24	28	O	serum
8	30	35	O	levels
9	37	42	O	should
10	44	45	O	be
11	47	55	O	monitored
NULL

Diclofenac	DDI-DrugBank.d249.s8	NO_SECTION	NO_SETID	12
Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	18	O	XXXXXXXX
4	20	28	O	decreases
5	30	36	U-KIN	lithium
6	38	42	O	renal
7	44	52	O	clearance
8	54	56	O	and
9	58	66	O	increases
10	68	74	U-KIN	lithium
11	76	81	O	plasma
12	83	88	O	levels
NULL

Diclofenac	DDI-DrugBank.d249.s9	NO_SECTION	NO_SETID	12
In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	28	O	XXXXXXXX
5	30	32	O	and
6	34	40	U-DYN	lithium
7	42	54	O	concomitantly
8	55	55	O	,
9	57	63	U-UNK	lithium
10	65	72	O	toxicity
11	74	76	O	may
12	78	84	O	develop
NULL

Diclofenac	DDI-DrugBank.d249.s10	NO_SECTION	NO_SETID	22
Oral Hypoglycemics: Diclofenac does not alter glucose metabolism in normal subjects nor does it alter the effects of oral hypoglycemic agents.
1	0	3	O	Oral
2	5	17	U-UNK	Hypoglycemics
3	18	18	O	:
4	20	29	O	XXXXXXXX
5	31	34	O	does
6	36	38	O	not
7	40	44	O	alter
8	46	52	O	glucose
9	54	63	O	metabolism
10	65	66	O	in
11	68	73	O	normal
12	75	82	O	subjects
13	84	86	O	nor
14	88	91	O	does
15	93	94	O	it
16	96	100	O	alter
17	102	104	O	the
18	106	112	O	effects
19	114	115	O	of
20	117	120	O	oral
21	122	133	B-UNK	hypoglycemic
22	135	140	L-UNK	agents
NULL

Diclofenac	DDI-DrugBank.d249.s11	NO_SECTION	NO_SETID	35
There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.
1	0	4	O	There
2	6	8	O	are
3	10	13	O	rare
4	15	21	O	reports
5	22	22	O	,
6	24	30	O	however
7	31	31	O	,
8	33	36	O	from
9	38	46	O	marketing
10	48	58	O	experiences
11	59	59	O	,
12	61	62	O	of
13	64	70	O	changes
14	72	73	O	in
15	75	81	O	effects
16	83	84	O	of
17	86	92	U-DYN	insulin
18	94	95	O	or
19	97	100	O	oral
20	102	113	B-DYN	hypoglycemic
21	115	120	L-DYN	agents
22	122	123	O	in
23	125	127	O	the
24	129	136	O	presence
25	138	139	O	of
26	141	150	O	XXXXXXXX
27	152	155	O	that
28	157	168	O	necessitated
29	170	176	O	changes
30	178	179	O	in
31	181	183	O	the
32	185	189	O	doses
33	191	192	O	of
34	194	197	O	such
35	199	204	O	agents
NULL

Diclofenac	DDI-DrugBank.d249.s12	NO_SECTION	NO_SETID	8
Both hypo- and hyperglycemic effects have been reported.
1	0	3	O	Both
2	5	8	O	hypo
3	11	13	O	and
4	15	27	O	hyperglycemic
5	29	35	O	effects
6	37	40	O	have
7	42	45	O	been
8	47	54	O	reported
NULL

Diclofenac	DDI-DrugBank.d249.s13	NO_SECTION	NO_SETID	30
A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.
1	0	0	O	A
2	2	7	O	direct
3	9	14	O	causal
4	16	27	O	relationship
5	29	31	O	has
6	33	35	O	not
7	37	40	O	been
8	42	52	O	established
9	53	53	O	,
10	55	57	O	but
11	59	68	O	physicians
12	70	75	O	should
13	77	84	O	consider
14	86	88	O	the
15	90	100	O	possibility
16	102	105	O	that
17	107	116	O	XXXXXXXX
18	118	120	O	may
19	122	126	O	alter
20	128	128	O	a
21	130	137	O	diabetic
22	139	145	O	patient
23	147	147	O	s
24	149	156	O	response
25	158	159	O	to
26	161	167	U-DYN	insulin
27	169	170	O	or
28	172	175	O	oral
29	177	188	B-DYN	hypoglycemic
30	190	195	L-DYN	agents
NULL

Diclofenac	DDI-DrugBank.d249.s14	NO_SECTION	NO_SETID	12
Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.
1	0	8	U-UNK	Diuretics
2	9	9	O	:
3	11	20	O	XXXXXXXX
4	22	24	O	and
5	26	30	O	other
6	32	37	U-UNK	NSAIDs
7	39	41	O	can
8	43	49	O	inhibit
9	51	53	O	the
10	55	62	O	activity
11	64	65	O	of
12	67	75	U-DYN	diuretics
NULL

Diclofenac	DDI-DrugBank.d249.s15	NO_SECTION	NO_SETID	14
Concomitant treatment with potassium-sparing diuretics may be associated with increased serum potassium levels.
1	0	10	O	Concomitant
2	12	20	O	treatment
3	22	25	O	with
4	27	35	B-UNK	potassium
5	37	43	I-UNK	sparing
6	45	53	L-UNK	diuretics
7	55	57	O	may
8	59	60	O	be
9	62	71	O	associated
10	73	76	O	with
11	78	86	O	increased
12	88	92	O	serum
13	94	102	O	potassium
14	104	109	O	levels
NULL

Diclofenac	DDI-DrugBank.d249.s16	NO_SECTION	NO_SETID	45
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.
1	0	4	O	Other
2	6	10	O	Drugs
3	11	11	O	:
4	13	14	O	In
5	16	20	O	small
6	22	27	O	groups
7	29	30	O	of
8	32	39	O	patients
9	42	42	O	7
10	44	45	O	10
11	46	46	O	/
12	47	57	O	interaction
13	59	63	O	study
14	65	65	O	,
15	67	69	O	the
16	71	81	O	concomitant
17	83	96	O	administration
18	98	99	O	of
19	101	112	U-UNK	azathioprine
20	113	113	O	,
21	115	118	U-UNK	gold
22	119	119	O	,
23	121	131	U-UNK	chloroquine
24	132	132	O	,
25	134	134	B-UNK	D
26	136	148	L-UNK	penicillamine
27	149	149	O	,
28	151	162	U-UNK	prednisolone
29	163	163	O	,
30	165	175	U-UNK	doxycycline
31	176	176	O	,
32	178	179	O	or
33	181	189	U-UNK	digitoxin
34	191	193	O	did
35	195	197	O	not
36	199	211	O	significantly
37	213	218	O	affect
38	220	222	O	the
39	224	227	O	peak
40	229	234	O	levels
41	236	238	O	and
42	240	242	O	AUC
43	244	249	O	values
44	251	252	O	of
45	254	263	O	XXXXXXXX
NULL

Diclofenac	DDI-DrugBank.d249.s17	NO_SECTION	NO_SETID	21
Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.
1	0	12	U-UNK	Phenobarbital
2	14	21	O	toxicity
3	23	25	O	has
4	27	30	O	been
5	32	39	O	reported
6	41	42	O	to
7	44	47	O	have
8	49	56	O	occurred
9	58	59	O	in
10	61	61	O	a
11	63	69	O	patient
12	71	72	O	on
13	74	80	O	chronic
14	82	94	U-DYN	phenobarbital
15	96	104	O	treatment
16	106	114	O	following
17	116	118	O	the
18	120	129	O	initiation
19	131	132	O	of
20	134	143	O	XXXXXXXX
21	145	151	O	therapy
NULL

Diclofenac	DDI-DrugBank.d249.s18	NO_SECTION	NO_SETID	34
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.
1	0	6	O	Protein
2	8	14	O	Binding
3	16	17	O	In
4	19	23	O	vitro
5	24	24	O	,
6	26	35	O	XXXXXXXX
7	37	46	O	interferes
8	48	56	O	minimally
9	58	59	O	or
10	61	63	O	not
11	65	66	O	at
12	68	70	O	all
13	72	75	O	with
14	77	79	O	the
15	81	87	O	protein
16	89	95	O	binding
17	97	98	O	of
18	100	108	B-KIN	salicylic
19	110	113	L-KIN	acid
20	116	118	O	20%
21	120	127	O	decrease
22	129	130	O	in
23	132	138	O	binding
24	140	140	O	,
25	142	152	U-KIN	tolbutamide
26	153	153	O	,
27	155	166	U-KIN	prednisolone
28	169	171	O	10%
29	173	180	O	decrease
30	182	183	O	in
31	185	191	O	binding
32	193	193	O	,
33	195	196	O	or
34	198	205	U-KIN	warfarin
NULL

Diclofenac	DDI-DrugBank.d249.s19	NO_SECTION	NO_SETID	30
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.
1	0	15	U-UNK	Benzylpenicillin
2	16	16	O	,
3	18	27	U-UNK	ampicillin
4	28	28	O	,
5	30	38	U-UNK	oxacillin
6	39	39	O	,
7	41	57	U-UNK	chlortetracycline
8	58	58	O	,
9	60	70	U-UNK	doxycycline
10	71	71	O	,
11	73	83	U-UNK	cephalothin
12	84	84	O	,
13	86	97	U-UNK	erythromycin
14	98	98	O	,
15	100	102	O	and
16	104	119	U-UNK	sulfamethoxazole
17	121	124	O	have
18	126	127	O	no
19	129	137	O	influence
20	139	140	O	in
21	142	146	O	vitro
22	148	149	O	on
23	151	153	O	the
24	155	161	O	protein
25	163	169	O	binding
26	171	172	O	of
27	174	183	O	XXXXXXXX
28	185	186	O	in
29	188	192	O	human
30	194	198	O	serum
NULL

Diclofenac	DDI-DrugBank.d249.s20	NO_SECTION	NO_SETID	37
Drug/Laboratory Test Interactions Effect on Blood Coagulation: Diclofenac increases platelet aggregation time but does not affect bleeding time, plasma thrombin clotting time, plasma fibrinogen, or factors V and VII to XII.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	39	O	Effect
7	41	42	O	on
8	44	48	O	Blood
9	50	60	O	Coagulation
10	61	61	O	:
11	63	72	O	XXXXXXXX
12	74	82	O	increases
13	84	91	O	platelet
14	93	103	O	aggregation
15	105	108	O	time
16	110	112	O	but
17	114	117	O	does
18	119	121	O	not
19	123	128	O	affect
20	130	137	O	bleeding
21	139	142	O	time
22	143	143	O	,
23	145	150	O	plasma
24	152	159	O	thrombin
25	161	168	O	clotting
26	170	173	O	time
27	174	174	O	,
28	176	181	O	plasma
29	183	192	O	fibrinogen
30	193	193	O	,
31	195	196	O	or
32	198	204	O	factors
33	206	206	O	V
34	208	210	O	and
35	212	214	O	VII
36	216	217	O	to
37	219	221	O	XII
NULL

Diclofenac	DDI-DrugBank.d249.s21	NO_SECTION	NO_SETID	15
Statistically significant changes in prothrombin and partial thromboplastin times have been reported in normal volunteers.
1	0	12	O	Statistically
2	14	24	O	significant
3	26	32	O	changes
4	34	35	O	in
5	37	47	O	prothrombin
6	49	51	O	and
7	53	59	O	partial
8	61	74	O	thromboplastin
9	76	80	O	times
10	82	85	O	have
11	87	90	O	been
12	92	99	O	reported
13	101	102	O	in
14	104	109	O	normal
15	111	120	O	volunteers
NULL

Diclofenac	DDI-DrugBank.d249.s22	NO_SECTION	NO_SETID	24
The mean changes were observed to be less than 1 second in both instances, however, and are unlikely to be clinically important.
1	0	2	O	The
2	4	7	O	mean
3	9	15	O	changes
4	17	20	O	were
5	22	29	O	observed
6	31	32	O	to
7	34	35	O	be
8	37	40	O	less
9	42	45	O	than
10	47	47	O	1
11	49	54	O	second
12	56	57	O	in
13	59	62	O	both
14	64	72	O	instances
15	73	73	O	,
16	75	81	O	however
17	82	82	O	,
18	84	86	O	and
19	88	90	O	are
20	92	99	O	unlikely
21	101	102	O	to
22	104	105	O	be
23	107	116	O	clinically
24	118	126	O	important
NULL

Diclofenac	DDI-DrugBank.d249.s23	NO_SECTION	NO_SETID	23
Diclofenac is a prostaglandin synthetase inhibitor, however, and all drugs that inhibit prostaglandin synthesis interfere with platelet function to some degree;
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	14	O	a
4	16	28	O	prostaglandin
5	30	39	O	synthetase
6	41	49	O	inhibitor
7	50	50	O	,
8	52	58	O	however
9	59	59	O	,
10	61	63	O	and
11	65	67	O	all
12	69	73	O	drugs
13	75	78	O	that
14	80	86	O	inhibit
15	88	100	O	prostaglandin
16	102	110	O	synthesis
17	112	120	O	interfere
18	122	125	O	with
19	127	134	O	platelet
20	136	143	O	function
21	145	146	O	to
22	148	151	O	some
23	153	158	O	degree
NULL

Diclofenac	DDI-DrugBank.d249.s24	NO_SECTION	NO_SETID	16
therefore, patients who may be adversely affected by such an action should be carefully observed.
1	0	8	O	therefore
2	9	9	O	,
3	11	18	O	patients
4	20	22	O	who
5	24	26	O	may
6	28	29	O	be
7	31	39	O	adversely
8	41	48	O	affected
9	50	51	O	by
10	53	56	O	such
11	58	59	O	an
12	61	66	O	action
13	68	73	O	should
14	75	76	O	be
15	78	86	O	carefully
16	88	95	O	observed
NULL

Dicloxacillin	DDI-DrugBank.d517.s0	NO_SECTION	NO_SETID	22
Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.
1	0	11	U-UNK	Tetracycline
2	12	12	O	,
3	14	14	O	a
4	16	29	B-UNK	bacteriostatic
5	31	40	L-UNK	antibiotic
6	41	41	O	,
7	43	45	O	may
8	47	56	O	antagonize
9	58	60	O	the
10	62	72	O	bactercidal
11	74	79	O	effect
12	81	82	O	of
13	84	93	U-UNK	penicillin
14	95	97	O	and
15	99	108	O	concurrent
16	110	112	O	use
17	114	115	O	of
18	117	121	O	these
19	123	127	O	drugs
20	129	134	O	should
21	136	137	O	be
22	139	145	O	avoided
NULL

Dicyclomine	DDI-DrugBank.d543.s0	NO_SECTION	NO_SETID	28
The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.
1	0	2	O	The
2	4	12	O	following
3	14	19	O	agents
4	21	23	O	may
5	25	32	O	increase
6	34	40	O	certain
7	42	48	O	actions
8	50	51	O	or
9	53	56	O	side
10	58	64	O	effects
11	66	67	O	of
12	69	83	B-UNK	anticholinergic
13	85	89	L-UNK	drugs
14	92	101	U-UNK	amantadine
15	103	116	B-UNK	antiarrhythmic
16	118	123	L-UNK	agents
17	125	126	O	of
18	128	132	O	class
19	135	137	O	e.g
20	140	148	U-UNK	quinidine
21	150	150	O	,
22	152	165	U-UNK	antihistamines
23	167	179	B-UNK	antipsychotic
24	181	186	L-UNK	agents
25	189	191	O	e.g
26	194	207	U-UNK	phenothiazines
27	209	209	O	,
28	211	225	U-UNK	benzodiazepines
NULL

Dicyclomine	DDI-DrugBank.d543.s1	NO_SECTION	NO_SETID	25
MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
1	0	2	B-UNK	MAO
2	4	13	L-UNK	inhibitors
3	14	14	O	,
4	16	23	B-UNK	narcotic
5	25	34	L-UNK	analgesics
6	37	39	O	e.g
7	41	41	O	,
8	43	52	U-UNK	meperidine
9	54	54	O	,
10	56	63	U-UNK	nitrates
11	65	67	O	and
12	69	76	U-UNK	nitrites
13	77	77	O	,
14	79	93	B-UNK	sympathomimetic
15	95	100	L-UNK	agents
16	101	101	O	,
17	103	111	B-UNK	tricyclic
18	113	127	L-UNK	antidepressants
19	128	128	O	,
20	130	132	O	and
21	134	138	O	other
22	140	144	O	drugs
23	146	151	O	having
24	153	167	O	anticholinergic
25	169	176	O	activity
NULL

Dicyclomine	DDI-DrugBank.d543.s2	NO_SECTION	NO_SETID	7
Anticholinergics antagonize the effects of antiglaucoma agents.
1	0	15	U-UNK	Anticholinergics
2	17	26	O	antagonize
3	28	30	O	the
4	32	38	O	effects
5	40	41	O	of
6	43	54	B-UNK	antiglaucoma
7	56	61	L-UNK	agents
NULL

Dicyclomine	DDI-DrugBank.d543.s3	NO_SECTION	NO_SETID	21
Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corti costeroids..
1	0	14	B-UNK	Anticholinergic
2	16	20	L-UNK	drugs
3	22	23	O	in
4	25	27	O	the
5	29	36	O	presence
6	38	39	O	of
7	41	49	O	increased
8	51	61	O	intraocular
9	63	70	O	pressure
10	72	74	O	may
11	76	77	O	be
12	79	87	O	hazardous
13	89	92	O	when
14	94	98	O	taken
15	100	111	O	concurrently
16	113	116	O	with
17	118	123	O	agents
18	125	128	O	such
19	130	131	O	as
20	133	137	O	corti
21	139	148	O	costeroids
NULL

Dicyclomine	DDI-DrugBank.d543.s4	NO_SECTION	NO_SETID	18
Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;
1	0	14	B-UNK	Anticholinergic
2	16	21	L-UNK	agents
3	23	25	O	may
4	27	32	O	affect
5	34	49	O	gastrointestinal
6	51	60	O	absorption
7	62	63	O	of
8	65	71	O	various
9	73	77	O	drugs
10	78	78	O	,
11	80	83	O	such
12	85	86	O	as
13	88	93	O	slowly
14	95	104	O	dissolving
15	106	111	O	dosage
16	113	117	O	forms
17	119	120	O	of
18	122	128	U-UNK	digoxin
NULL

Dicyclomine	DDI-DrugBank.d543.s5	NO_SECTION	NO_SETID	6
increased serum digoxin concentrations may result.
1	0	8	O	increased
2	10	14	O	serum
3	16	22	U-UNK	digoxin
4	24	37	O	concentrations
5	39	41	O	may
6	43	48	O	result
NULL

Dicyclomine	DDI-DrugBank.d543.s6	NO_SECTION	NO_SETID	17
Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.
1	0	14	B-UNK	Anticholinergic
2	16	20	L-UNK	drugs
3	22	24	O	may
4	26	35	O	antagonize
5	37	39	O	the
6	41	47	O	effects
7	49	50	O	of
8	52	54	O	the
9	56	60	O	drugs
10	62	65	O	that
11	67	71	O	alter
12	73	88	O	gastrointestinal
13	90	97	O	motility
14	98	98	O	,
15	100	103	O	such
16	105	106	O	as
17	108	121	U-UNK	metoclopramide
NULL

Dicyclomine	DDI-DrugBank.d543.s7	NO_SECTION	NO_SETID	19
Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.
1	0	6	O	Because
2	8	15	U-UNK	antacids
3	17	19	O	may
4	21	29	O	interfere
5	31	34	O	with
6	36	38	O	the
7	40	49	O	absorption
8	51	52	O	of
9	54	68	B-UNK	anticholinergic
10	70	75	L-UNK	agents
11	76	76	O	,
12	78	89	O	simultaneous
13	91	93	O	use
14	95	96	O	of
15	98	102	O	these
16	104	108	O	drugs
17	110	115	O	should
18	117	118	O	be
19	120	126	O	avoided
NULL

Dicyclomine	DDI-DrugBank.d543.s8	NO_SECTION	NO_SETID	26
The inhibiting effects of anticholinergic drugs on gastric hydrochloric acid secretion are antagonized by agents used to treat achlorhydria and those used to test gastric secretion.
1	0	2	O	The
2	4	13	O	inhibiting
3	15	21	O	effects
4	23	24	O	of
5	26	40	B-UNK	anticholinergic
6	42	46	L-UNK	drugs
7	48	49	O	on
8	51	57	O	gastric
9	59	70	O	hydrochloric
10	72	75	O	acid
11	77	85	O	secretion
12	87	89	O	are
13	91	101	O	antagonized
14	103	104	O	by
15	106	111	O	agents
16	113	116	O	used
17	118	119	O	to
18	121	125	O	treat
19	127	138	O	achlorhydria
20	140	142	O	and
21	144	148	O	those
22	150	153	O	used
23	155	156	O	to
24	158	161	O	test
25	163	169	O	gastric
26	171	179	O	secretion
NULL

Didanosine	DDI-DrugBank.d43.s0	NO_SECTION	NO_SETID	41
Coadministration of VIDEX with drugs that are known to cause pancreatitis may increase the risk of this toxicity (see WARNINGS) and should be done with extreme caution, only if other alternatives are not available, and only if clearly indicated.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	24	O	XXXXXXXX
4	26	29	O	with
5	31	35	O	drugs
6	37	40	O	that
7	42	44	O	are
8	46	50	O	known
9	52	53	O	to
10	55	59	O	cause
11	61	72	O	pancreatitis
12	74	76	O	may
13	78	85	O	increase
14	87	89	O	the
15	91	94	O	risk
16	96	97	O	of
17	99	102	O	this
18	104	111	O	toxicity
19	114	116	O	see
20	118	125	O	WARNINGS
21	128	130	O	and
22	132	137	O	should
23	139	140	O	be
24	142	145	O	done
25	147	150	O	with
26	152	158	O	extreme
27	160	166	O	caution
28	167	167	O	,
29	169	172	O	only
30	174	175	O	if
31	177	181	O	other
32	183	194	O	alternatives
33	196	198	O	are
34	200	202	O	not
35	204	212	O	available
36	213	213	O	,
37	215	217	O	and
38	219	222	O	only
39	224	225	O	if
40	227	233	O	clearly
41	235	243	O	indicated
NULL

Didanosine	DDI-DrugBank.d43.s1	NO_SECTION	NO_SETID	36
Neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy, including stavudine, and these patients may be at increased risk of neuropathy during VIDEX therapy (see ADVERSE REACTIONS).
1	0	9	O	Neuropathy
2	11	13	O	has
3	15	22	O	occurred
4	24	27	O	more
5	29	38	O	frequently
6	40	41	O	in
7	43	50	O	patients
8	52	55	O	with
9	57	57	O	a
10	59	65	O	history
11	67	68	O	of
12	70	79	O	neuropathy
13	81	82	O	or
14	84	93	O	neurotoxic
15	95	98	O	drug
16	100	106	O	therapy
17	107	107	O	,
18	109	117	O	including
19	119	127	U-UNK	stavudine
20	128	128	O	,
21	130	132	O	and
22	134	138	O	these
23	140	147	O	patients
24	149	151	O	may
25	153	154	O	be
26	156	157	O	at
27	159	167	O	increased
28	169	172	O	risk
29	174	175	O	of
30	177	186	O	neuropathy
31	188	193	O	during
32	195	199	O	XXXXXXXX
33	201	207	O	therapy
34	210	212	O	see
35	214	220	O	ADVERSE
36	222	230	O	REACTIONS
NULL

Didanosine	DDI-DrugBank.d43.s2	NO_SECTION	NO_SETID	40
Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).
1	0	10	U-UNK	Allopurinol
2	11	11	O	:
3	13	15	O	The
4	17	19	O	AUC
5	21	22	O	of
6	24	33	U-UNK	didanosine
7	35	37	O	was
8	39	47	O	increased
9	49	53	O	about
10	55	55	O	4
11	57	60	O	fold
12	62	65	O	when
13	67	77	U-KIN	allopurinol
14	79	80	O	at
15	82	84	O	300
16	86	87	O	mg
17	88	88	O	/
18	89	91	O	day
19	93	95	O	was
20	97	110	O	coadministered
21	112	115	O	with
22	117	117	O	a
23	119	124	O	single
24	126	128	O	200
25	130	131	O	mg
26	133	136	O	dose
27	138	139	O	of
28	141	145	O	XXXXXXXX
29	147	148	O	to
30	150	152	O	two
31	154	161	O	patients
32	163	166	O	with
33	168	172	O	renal
34	174	183	O	impairment
35	186	192	O	CLcr=15
36	194	196	O	and
37	198	199	O	18
38	201	202	O	mL
39	203	203	O	/
40	204	206	O	min
NULL

Didanosine	DDI-DrugBank.d43.s3	NO_SECTION	NO_SETID	16
The effects of allopurinol on didanosine pharmacokinetics in subjects with normal renal function are not known.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	25	U-UNK	allopurinol
5	27	28	O	on
6	30	39	O	XXXXXXXX
7	41	56	O	pharmacokinetics
8	58	59	O	in
9	61	68	O	subjects
10	70	73	O	with
11	75	80	O	normal
12	82	86	O	renal
13	88	95	O	function
14	97	99	O	are
15	101	103	O	not
16	105	109	O	known
NULL

Didanosine	DDI-DrugBank.d43.s4	NO_SECTION	NO_SETID	32
Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
1	0	7	U-UNK	Antacids
2	8	8	O	:
3	10	20	O	Concomitant
4	22	35	O	administration
5	37	38	O	of
6	40	47	U-DYN	antacids
7	49	58	O	containing
8	60	68	U-DYN	magnesium
9	70	71	O	or
10	73	80	U-DYN	aluminum
11	82	85	O	with
12	87	91	O	XXXXXXXX
13	93	100	O	Chewable
14	101	101	O	/
15	102	112	O	Dispersible
16	114	121	O	Buffered
17	123	129	O	Tablets
18	131	132	O	or
19	134	142	O	Pediatric
20	144	149	O	Powder
21	151	153	O	for
22	155	158	O	Oral
23	160	167	O	Solution
24	169	171	O	may
25	173	182	O	potentiate
26	184	190	O	adverse
27	192	197	O	events
28	199	208	O	associated
29	210	213	O	with
30	215	217	O	the
31	219	225	U-UNK	antacid
32	227	236	O	components
NULL

Didanosine	DDI-DrugBank.d43.s5	NO_SECTION	NO_SETID	33
Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.
1	0	4	O	Drugs
2	6	10	O	Whose
3	12	21	O	Absorption
4	23	25	O	Can
5	27	28	O	Be
6	30	37	O	Affected
7	39	40	O	by
8	42	44	O	the
9	46	50	O	Level
10	52	53	O	of
11	55	61	O	Acidity
12	63	64	O	in
13	66	68	O	the
14	70	76	O	Stomach
15	77	77	O	:
16	79	83	O	Drugs
17	85	88	O	such
18	90	91	O	as
19	93	104	U-DYN	ketoconazole
20	106	108	O	and
21	110	121	U-DYN	itraconazole
22	123	128	O	should
23	130	131	O	be
24	133	144	O	administered
25	146	147	O	at
26	149	153	O	least
27	155	155	O	2
28	157	161	O	hours
29	163	167	O	prior
30	169	170	O	to
31	172	177	O	dosing
32	179	182	O	with
33	184	188	O	XXXXXXXX
NULL

Didanosine	DDI-DrugBank.d43.s6	NO_SECTION	NO_SETID	31
Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).
1	0	10	U-UNK	Ganciclovir
2	11	11	O	:
3	13	26	O	Administration
4	28	29	O	of
5	31	35	O	XXXXXXXX
6	37	37	O	2
7	39	43	O	hours
8	45	49	O	prior
9	51	52	O	to
10	54	55	O	or
11	57	66	O	concurrent
12	68	71	O	with
13	73	76	O	oral
14	78	88	U-KIN	ganciclovir
15	90	92	O	was
16	94	103	O	associated
17	105	108	O	with
18	110	110	O	a
19	112	114	O	111
20	117	121	O	114)%
21	123	130	O	increase
22	132	133	O	in
23	135	137	O	the
24	139	144	O	steady
25	146	150	O	state
26	152	154	O	AUC
27	156	157	O	of
28	159	168	U-UNK	didanosine
29	171	171	O	n
30	173	173	O	=
31	175	176	O	12
NULL

Didanosine	DDI-DrugBank.d43.s7	NO_SECTION	NO_SETID	35
A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).
1	0	0	O	A
2	2	3	O	21
3	6	9	O	17)%
4	11	18	O	decrease
5	20	21	O	in
6	23	25	O	the
7	27	32	O	steady
8	34	38	O	state
9	40	42	O	AUC
10	44	45	O	of
11	47	57	U-UNK	ganciclovir
12	59	61	O	was
13	63	70	O	observed
14	72	75	O	when
15	77	81	O	XXXXXXXX
16	83	85	O	was
17	87	98	O	administered
18	100	100	O	2
19	102	106	O	hours
20	108	112	O	prior
21	114	115	O	to
22	117	127	U-KIN	ganciclovir
23	128	128	O	,
24	130	132	O	but
25	134	136	O	not
26	138	141	O	when
27	143	145	O	the
28	147	149	O	two
29	151	155	O	drugs
30	157	160	O	were
31	162	173	O	administered
32	175	188	O	simultaneously
33	191	191	O	n
34	193	193	O	=
35	195	196	O	12
NULL

Didanosine	DDI-DrugBank.d43.s8	NO_SECTION	NO_SETID	37
Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
1	0	8	U-UNK	Quinolone
2	10	20	O	Antibiotics
3	21	21	O	:
4	23	27	O	XXXXXXXX
5	29	34	O	should
6	36	37	O	be
7	39	50	O	administered
8	52	53	O	at
9	55	59	O	least
10	61	61	O	2
11	63	67	O	hours
12	69	73	O	after
13	75	76	O	or
14	78	78	O	6
15	80	84	O	hours
16	86	91	O	before
17	93	98	O	dosing
18	100	103	O	with
19	105	117	U-DYN	ciprofloxacin
20	119	125	O	because
21	127	132	O	plasma
22	134	147	O	concentrations
23	149	150	O	of
24	152	164	U-UNK	ciprofloxacin
25	166	168	O	are
26	170	178	O	decreased
27	180	183	O	when
28	185	196	O	administered
29	198	201	O	with
30	203	210	U-UNK	antacids
31	212	221	O	containing
32	223	231	U-UNK	magnesium
33	232	232	O	,
34	234	240	U-UNK	calcium
35	241	241	O	,
36	243	244	O	or
37	246	253	U-UNK	aluminum
NULL

Didanosine	DDI-DrugBank.d43.s9	NO_SECTION	NO_SETID	41
In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.
1	0	1	O	In
2	3	7	O	eight
3	9	11	O	HIV
4	13	20	O	infected
5	22	29	O	patients
6	30	30	O	,
7	32	34	O	the
8	36	41	O	steady
9	43	47	O	state
10	49	51	O	AUC
11	53	54	O	of
12	56	68	U-UNK	ciprofloxacin
13	70	72	O	was
14	74	82	O	decreased
15	84	85	O	an
16	87	93	O	average
17	95	96	O	of
18	98	100	O	26%
19	103	105	O	95%
20	107	108	O	CI
21	110	110	O	=
22	112	114	O	14%
23	115	115	O	,
24	117	119	O	37%
25	122	125	O	when
26	127	139	U-KIN	ciprofloxacin
27	141	143	O	was
28	145	156	O	administered
29	158	158	O	2
30	160	164	O	hours
31	166	170	O	prior
32	172	173	O	to
33	175	175	O	a
34	177	184	O	marketed
35	186	193	O	chewable
36	194	194	O	/
37	195	205	O	dispersible
38	207	212	O	tablet
39	214	224	O	formulation
40	226	227	O	of
41	229	233	O	XXXXXXXX
NULL

Didanosine	DDI-DrugBank.d43.s10	NO_SECTION	NO_SETID	22
The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.
1	0	2	O	The
2	4	6	O	AUC
3	8	9	O	of
4	11	23	U-UNK	ciprofloxacin
5	25	27	O	was
6	29	37	O	decreased
7	39	40	O	an
8	42	48	O	average
9	50	51	O	of
10	53	54	O	15
11	56	59	O	fold
12	61	62	O	in
13	64	65	O	12
14	67	73	O	healthy
15	75	82	O	subjects
16	84	88	O	given
17	90	102	U-KIN	ciprofloxacin
18	104	106	O	and
19	108	117	O	XXXXXXXX
20	119	125	O	placebo
21	127	133	O	tablets
22	135	146	O	concurrently
NULL

Didanosine	DDI-DrugBank.d43.s11	NO_SECTION	NO_SETID	31
In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	single
4	12	18	O	subject
5	20	24	O	given
6	26	28	O	one
7	30	33	O	dose
8	35	36	O	of
9	38	50	U-KIN	ciprofloxacin
10	52	52	O	2
11	54	58	O	hours
12	60	64	O	after
13	66	66	O	a
14	68	71	O	dose
15	73	74	O	of
16	76	85	O	XXXXXXXX
17	87	93	O	placebo
18	95	101	O	tablets
19	102	102	O	,
20	104	104	O	a
21	106	112	O	greater
22	114	117	O	than
23	119	121	O	50%
24	123	131	O	reduction
25	133	134	O	in
26	136	138	O	the
27	140	142	O	AUC
28	144	145	O	of
29	147	159	U-UNK	ciprofloxacin
30	161	163	O	was
31	165	172	O	observed
NULL

Didanosine	DDI-DrugBank.d43.s12	NO_SECTION	NO_SETID	18
Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.
1	0	5	O	Plasma
2	7	20	O	concentrations
3	22	23	O	of
4	25	33	B-UNK	quinolone
5	35	45	L-UNK	antibiotics
6	47	49	O	are
7	51	59	O	decreased
8	61	64	O	when
9	66	77	O	administered
10	79	82	O	with
11	84	91	U-UNK	antacids
12	93	102	O	containing
13	104	112	U-UNK	magnesium
14	113	113	O	,
15	115	121	U-UNK	calcium
16	122	122	O	,
17	124	125	O	or
18	127	134	U-UNK	aluminum
NULL

Didanosine	DDI-DrugBank.d43.s13	NO_SECTION	NO_SETID	18
The optimal dosing interval for coadministration with VIDEX should be determined by consulting the appropriate quinolone package insert.
1	0	2	O	The
2	4	10	O	optimal
3	12	17	O	dosing
4	19	26	O	interval
5	28	30	O	for
6	32	47	O	coadministration
7	49	52	O	with
8	54	58	O	XXXXXXXX
9	60	65	O	should
10	67	68	O	be
11	70	79	O	determined
12	81	82	O	by
13	84	93	O	consulting
14	95	97	O	the
15	99	109	O	appropriate
16	111	119	U-UNK	quinolone
17	121	127	O	package
18	129	134	O	insert
NULL

Didanosine	DDI-DrugBank.d43.s14	NO_SECTION	NO_SETID	26
Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.
1	0	11	O	Interactions
2	13	16	O	with
3	18	22	O	Other
4	24	37	B-UNK	Antiretroviral
5	39	43	L-UNK	Drugs
6	44	44	O	:
7	46	56	O	Significant
8	58	66	O	decreases
9	68	69	O	in
10	71	73	O	the
11	75	77	O	AUC
12	79	80	O	of
13	82	92	U-KIN	delavirdine
14	95	97	O	20%
15	100	102	O	and
16	104	112	U-KIN	indinavir
17	115	117	O	84%
18	120	127	O	occurred
19	129	137	O	following
20	139	150	O	simultaneous
21	152	165	O	administration
22	167	168	O	of
23	170	174	O	these
24	176	181	O	agents
25	183	186	O	with
26	188	192	O	XXXXXXXX
NULL

Didanosine	DDI-DrugBank.d43.s15	NO_SECTION	NO_SETID	18
To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.
1	0	1	O	To
2	3	7	O	avoid
3	9	12	O	this
4	14	24	O	interaction
5	25	25	O	,
6	27	37	U-DYN	delavirdine
7	39	40	O	or
8	42	50	U-DYN	indinavir
9	52	57	O	should
10	59	60	O	be
11	62	66	O	given
12	68	68	O	1
13	70	73	O	hour
14	75	79	O	prior
15	81	82	O	to
16	84	89	O	dosing
17	91	94	O	with
18	96	100	O	XXXXXXXX
NULL

Didanosine	DDI-DrugBank.d43.s16	NO_SECTION	NO_SETID	24
The pharmacokinetics of nelfinavir are not altered to a clinically significant degree when it is administered with a light meal 1 hour after VIDEX.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	33	U-UNK	nelfinavir
5	35	37	O	are
6	39	41	O	not
7	43	49	O	altered
8	51	52	O	to
9	54	54	O	a
10	56	65	O	clinically
11	67	77	O	significant
12	79	84	O	degree
13	86	89	O	when
14	91	92	O	it
15	94	95	O	is
16	97	108	O	administered
17	110	113	O	with
18	115	115	O	a
19	117	121	O	light
20	123	126	O	meal
21	128	128	O	1
22	130	133	O	hour
23	135	139	O	after
24	141	145	O	XXXXXXXX
NULL

Dienestrol	DDI-DrugBank.d570.s0	NO_SECTION	NO_SETID	19
Drug/ Laboratory Test Interactions Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.
1	0	3	O	Drug
2	4	4	O	/
3	6	15	O	Laboratory
4	17	20	O	Test
5	22	33	O	Interactions
6	35	41	O	Certain
7	43	51	O	endocrine
8	53	55	O	and
9	57	61	O	liver
10	63	70	O	function
11	72	76	O	tests
12	78	80	O	may
13	82	83	O	be
14	85	92	O	affected
15	94	95	O	by
16	97	104	U-UNK	estrogen
17	106	115	O	containing
18	117	120	O	oral
19	122	135	U-UNK	contraceptives
NULL

Dienestrol	DDI-DrugBank.d570.s1	NO_SECTION	NO_SETID	16
The following similar changes may be expected with larger doses of estrogen: - Increased sulfobromophthalein retention
1	0	2	O	The
2	4	12	O	following
3	14	20	O	similar
4	22	28	O	changes
5	30	32	O	may
6	34	35	O	be
7	37	44	O	expected
8	46	49	O	with
9	51	56	O	larger
10	58	62	O	doses
11	64	65	O	of
12	67	74	U-UNK	estrogen
13	75	75	O	:
14	79	87	O	Increased
15	89	107	O	sulfobromophthalein
16	109	117	O	retention
NULL

Dienestrol	DDI-DrugBank.d570.s3	NO_SECTION	NO_SETID	12
- Increased prothrombin and factors VII, VIII, IX, and X;
1	2	10	O	Increased
2	12	22	O	prothrombin
3	24	26	O	and
4	28	34	O	factors
5	36	38	O	VII
6	39	39	O	,
7	41	44	O	VIII
8	45	45	O	,
9	47	48	O	IX
10	49	49	O	,
11	51	53	O	and
12	55	55	O	XXXXXXXX
NULL

Dienestrol	DDI-DrugBank.d570.s4	NO_SECTION	NO_SETID	3
decreased antithrombin 3;
1	0	8	O	decreased
2	10	21	B-UNK	antithrombin
3	23	23	L-UNK	3
NULL

Dienestrol	DDI-DrugBank.d570.s5	NO_SECTION	NO_SETID	5
increased norepinephrine-induced platelet aggregability
1	0	8	O	increased
2	10	23	O	norepinephrine
3	25	31	O	induced
4	33	40	O	platelet
5	42	54	O	aggregability
NULL

Dienestrol	DDI-DrugBank.d570.s7	NO_SECTION	NO_SETID	13
- Increased thyroid-binding globulin (TBG) leading to in-creased circulating total thyroid hormone;
1	2	10	O	Increased
2	12	18	O	thyroid
3	20	26	O	binding
4	28	35	O	globulin
5	38	40	O	TBG
6	43	49	O	leading
7	51	52	O	to
8	54	55	O	in
9	57	63	O	creased
10	65	75	O	circulating
11	77	81	O	total
12	83	89	O	thyroid
13	91	97	O	hormone
NULL

Dienestrol	DDI-DrugBank.d570.s8	NO_SECTION	NO_SETID	13
as measured by PBI, T4 by column, or T4 by radioimmunoassay.
1	0	1	O	as
2	3	10	O	measured
3	12	13	O	by
4	15	17	O	PBI
5	18	18	O	,
6	20	21	O	T4
7	23	24	O	by
8	26	31	O	column
9	32	32	O	,
10	34	35	O	or
11	37	38	O	T4
12	40	41	O	by
13	43	58	O	radioimmunoassay
NULL

Dienestrol	DDI-DrugBank.d570.s9	NO_SECTION	NO_SETID	11
Free T3 resin uptake is decreased, reflecting the elevated TBG;
1	0	3	O	Free
2	5	6	O	T3
3	8	12	O	resin
4	14	19	O	uptake
5	21	22	O	is
6	24	32	O	decreased
7	33	33	O	,
8	35	44	O	reflecting
9	46	48	O	the
10	50	57	O	elevated
11	59	61	O	TBG
NULL

Dienestrol	DDI-DrugBank.d570.s10	NO_SECTION	NO_SETID	5
free T4 concentration is unaltered
1	0	3	O	free
2	5	6	O	T4
3	8	20	O	concentration
4	22	23	O	is
5	25	33	O	unaltered
NULL

Dienestrol	DDI-DrugBank.d570.s12	NO_SECTION	NO_SETID	3
- Impaired glucose tolerance
1	2	9	O	Impaired
2	11	17	O	glucose
3	19	27	O	tolerance
NULL

Dienestrol	DDI-DrugBank.d570.s14	NO_SECTION	NO_SETID	3
- Decreased pregnanediol excretion
1	2	10	O	Decreased
2	12	23	O	pregnanediol
3	25	33	O	excretion
NULL

Dienestrol	DDI-DrugBank.d570.s16	NO_SECTION	NO_SETID	5
- Reduced response to metyrapone test
1	2	8	O	Reduced
2	10	17	O	response
3	19	20	O	to
4	22	31	O	metyrapone
5	33	36	O	test
NULL

Dienestrol	DDI-DrugBank.d570.s18	NO_SECTION	NO_SETID	4
- Reduced serum folate concentration
1	2	8	O	Reduced
2	10	14	O	serum
3	16	21	O	folate
4	23	35	O	concentration
NULL

Dienestrol	DDI-DrugBank.d570.s20	NO_SECTION	NO_SETID	6
- Increased serum triglyceride and phospholipid concentration.
1	2	10	O	Increased
2	12	16	O	serum
3	18	29	O	triglyceride
4	31	33	O	and
5	35	46	O	phospholipid
6	48	60	O	concentration
NULL

Diethylpropion	DDI-DrugBank.d352.s0	NO_SECTION	NO_SETID	9
Antidiabetic drug requirements (i.e., insulin) may be altered.
1	0	11	B-UNK	Antidiabetic
2	13	16	L-UNK	drug
3	18	29	O	requirements
4	32	34	O	i.e
5	36	36	O	,
6	38	44	U-UNK	insulin
7	47	49	O	may
8	51	52	O	be
9	54	60	O	altered
NULL

Diethylpropion	DDI-DrugBank.d352.s1	NO_SECTION	NO_SETID	9
Concurrent use with general anesthetics may result in arrhythmias.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	18	O	with
4	20	26	O	general
5	28	38	U-UNK	anesthetics
6	40	42	O	may
7	44	49	O	result
8	51	52	O	in
9	54	64	O	arrhythmias
NULL

Diethylpropion	DDI-DrugBank.d352.s2	NO_SECTION	NO_SETID	19
The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly;
1	0	2	O	The
2	4	10	O	pressor
3	12	18	O	effects
4	20	21	O	of
5	23	36	O	XXXXXXXX
6	38	40	O	and
7	42	46	O	those
8	48	49	O	of
9	51	55	O	other
10	57	61	O	drugs
11	63	65	O	may
12	67	68	O	be
13	70	77	O	additive
14	79	82	O	when
15	84	86	O	the
16	88	92	O	drugs
17	94	96	O	are
18	98	101	O	used
19	103	115	O	concomitantly
NULL

Diethylpropion	DDI-DrugBank.d352.s3	NO_SECTION	NO_SETID	14
conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).
1	0	9	O	conversely
2	10	10	O	,
3	12	25	O	XXXXXXXX
4	27	29	O	may
5	31	39	O	interfere
6	41	44	O	with
7	46	61	B-UNK	antihypertensive
8	63	67	L-UNK	drugs
9	70	72	O	i.e
10	74	74	O	,
11	76	87	U-UNK	guanethidine
12	88	88	O	,
13	90	90	B-UNK	a
14	92	101	L-UNK	methyldopa
NULL

Diethylpropion	DDI-DrugBank.d352.s4	NO_SECTION	NO_SETID	11
Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	16	O	of
4	18	31	U-DYN	phenothiazines
5	33	35	O	may
6	37	46	O	antagonize
7	48	50	O	the
8	52	60	O	anorectic
9	62	67	O	effect
10	69	70	O	of
11	72	85	O	XXXXXXXX
NULL

Diethylstilbestrol	DDI-DrugBank.d248.s0	NO_SECTION	NO_SETID	30
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).
1	0	2	O	May
2	4	11	O	interact
3	13	26	U-UNK	anticoagulants
4	29	35	O	altered
5	37	40	O	hypo
6	42	56	O	prothrombinemic
7	58	63	O	effect
8	65	65	O	,
9	67	78	U-UNK	barbiturates
10	79	79	O	,
11	81	88	U-UNK	rifampin
12	90	92	O	and
13	94	98	O	other
14	100	107	O	inducers
15	109	110	O	of
16	112	118	O	hepatic
17	120	129	O	microsomal
18	131	136	O	enzyme
19	138	146	O	oxidation
20	148	153	O	system
21	156	164	O	decreased
22	166	171	O	effect
23	173	174	O	of
24	176	193	O	XXXXXXXX
25	195	195	O	,
26	197	211	U-UNK	corticosteroids
27	214	222	O	increased
28	224	229	O	effect
29	231	232	O	of
30	234	248	U-UNK	corticosteroids
NULL

Diflunisal	DDI-DrugBank.d132.s0	NO_SECTION	NO_SETID	26
Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.
1	0	3	O	Oral
2	5	18	U-UNK	Anticoagulants
3	19	19	O	:
4	21	22	O	In
5	24	27	O	some
6	29	34	O	normal
7	36	45	O	volunteers
8	46	46	O	,
9	48	50	O	the
10	52	62	O	concomitant
11	64	77	O	administration
12	79	80	O	of
13	82	91	O	XXXXXXXX
14	93	95	O	and
15	97	104	U-DYN	warfarin
16	105	105	O	,
17	107	119	U-DYN	acenocoumarol
18	120	120	O	,
19	122	123	O	or
20	125	137	U-DYN	phenprocoumon
21	139	146	O	resulted
22	148	149	O	in
23	151	162	O	prolongation
24	164	165	O	of
25	167	177	O	prothrombin
26	179	182	O	time
NULL

Diflunisal	DDI-DrugBank.d132.s1	NO_SECTION	NO_SETID	12
This may occur because diflunisal competitively displaces coumarins from protein binding sites.
1	0	3	O	This
2	5	7	O	may
3	9	13	O	occur
4	15	21	O	because
5	23	32	O	XXXXXXXX
6	34	46	O	competitively
7	48	56	O	displaces
8	58	66	U-KIN	coumarins
9	68	71	O	from
10	73	79	O	protein
11	81	87	O	binding
12	89	93	O	sites
NULL

Diflunisal	DDI-DrugBank.d132.s2	NO_SECTION	NO_SETID	26
Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.
1	0	10	O	Accordingly
2	11	11	O	,
3	13	16	O	when
4	18	27	O	XXXXXXXX
5	29	30	O	is
6	32	43	O	administered
7	45	48	O	with
8	50	53	O	oral
9	55	68	U-DYN	anticoagulants
10	69	69	O	,
11	71	73	O	the
12	75	85	O	prothrombin
13	87	90	O	time
14	92	97	O	should
15	99	100	O	be
16	102	108	O	closely
17	110	118	O	monitored
18	120	125	O	during
19	127	129	O	and
20	131	133	O	for
21	135	141	O	several
22	143	146	O	days
23	148	152	O	after
24	154	164	O	concomitant
25	166	169	O	drug
26	171	184	O	administration
NULL

Diflunisal	DDI-DrugBank.d132.s3	NO_SECTION	NO_SETID	9
Adjustment of dosage of oral anticoagulants may be required.
1	0	9	O	Adjustment
2	11	12	O	of
3	14	19	O	dosage
4	21	22	O	of
5	24	27	O	oral
6	29	42	U-UNK	anticoagulants
7	44	46	O	may
8	48	49	O	be
9	51	58	O	required
NULL

Diflunisal	DDI-DrugBank.d132.s4	NO_SECTION	NO_SETID	23
Tolbutamide: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.
1	0	10	U-UNK	Tolbutamide
2	11	11	O	:
3	13	14	O	In
4	16	23	O	diabetic
5	25	32	O	patients
6	34	42	O	receiving
7	44	53	O	XXXXXXXX
8	55	57	O	and
9	59	69	U-UNK	tolbutamide
10	70	70	O	,
11	72	73	O	no
12	75	85	O	significant
13	87	93	O	effects
14	95	98	O	were
15	100	103	O	seen
16	105	106	O	on
17	108	118	U-UNK	tolbutamide
18	120	125	O	plasma
19	127	132	O	levels
20	134	135	O	or
21	137	143	O	fasting
22	145	149	O	blood
23	151	157	O	glucose
NULL

Diflunisal	DDI-DrugBank.d132.s5	NO_SECTION	NO_SETID	20
Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.
1	0	18	U-UNK	Hydrochlorothiazide
2	19	19	O	:
3	21	22	O	In
4	24	29	O	normal
5	31	40	O	volunteers
6	41	41	O	,
7	43	53	O	concomitant
8	55	68	O	administration
9	70	71	O	of
10	73	82	O	XXXXXXXX
11	84	86	O	and
12	88	106	U-KIN	hydrochlorothiazide
13	108	115	O	resulted
14	117	118	O	in
15	120	132	O	significantly
16	134	142	O	increased
17	144	149	O	plasma
18	151	156	O	levels
19	158	159	O	of
20	161	179	U-UNK	hydrochlorothiazide
NULL

Diflunisal	DDI-DrugBank.d132.s6	NO_SECTION	NO_SETID	7
Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.
1	0	9	O	XXXXXXXX
2	11	19	O	decreased
3	21	23	O	the
4	25	37	O	hyperuricemic
5	39	44	O	effect
6	46	47	O	of
7	49	67	U-DYN	hydrochlorothiazide
NULL

Diflunisal	DDI-DrugBank.d132.s7	NO_SECTION	NO_SETID	22
Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.
1	0	9	U-UNK	Furosemide
2	10	10	O	:
3	12	13	O	In
4	15	20	O	normal
5	22	31	O	volunteers
6	32	32	O	,
7	34	36	O	the
8	38	48	O	concomitant
9	50	63	O	administration
10	65	66	O	of
11	68	77	O	XXXXXXXX
12	79	81	O	and
13	83	92	U-UNK	furosemide
14	94	96	O	had
15	98	99	O	no
16	101	106	O	effect
17	108	109	O	on
18	111	113	O	the
19	115	122	O	diuretic
20	124	131	O	activity
21	133	134	O	of
22	136	145	U-UNK	furosemide
NULL

Diflunisal	DDI-DrugBank.d132.s8	NO_SECTION	NO_SETID	7
Diflunisal decreased the hyperuricemic effect of furosemide.
1	0	9	O	XXXXXXXX
2	11	19	O	decreased
3	21	23	O	the
4	25	37	O	hyperuricemic
5	39	44	O	effect
6	46	47	O	of
7	49	58	U-DYN	furosemide
NULL

Diflunisal	DDI-DrugBank.d132.s9	NO_SECTION	NO_SETID	12
Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.
1	0	7	U-UNK	Antacids
2	8	8	O	:
3	10	20	O	Concomitant
4	22	35	O	administration
5	37	38	O	of
6	40	47	U-KIN	antacids
7	49	51	O	may
8	53	58	O	reduce
9	60	65	O	plasma
10	67	72	O	levels
11	74	75	O	of
12	77	86	O	XXXXXXXX
NULL

Diflunisal	DDI-DrugBank.d132.s10	NO_SECTION	NO_SETID	23
This effect is small with occasional doses of antacids, but may be clinically significant when antacids are used on a continuous schedule.
1	0	3	O	This
2	5	10	O	effect
3	12	13	O	is
4	15	19	O	small
5	21	24	O	with
6	26	35	O	occasional
7	37	41	O	doses
8	43	44	O	of
9	46	53	U-UNK	antacids
10	54	54	O	,
11	56	58	O	but
12	60	62	O	may
13	64	65	O	be
14	67	76	O	clinically
15	78	88	O	significant
16	90	93	O	when
17	95	102	U-UNK	antacids
18	104	106	O	are
19	108	111	O	used
20	113	114	O	on
21	116	116	O	a
22	118	127	O	continuous
23	129	136	O	schedule
NULL

Diflunisal	DDI-DrugBank.d132.s11	NO_SECTION	NO_SETID	23
Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.
1	0	12	U-UNK	Acetaminophen
2	13	13	O	:
3	15	16	O	In
4	18	23	O	normal
5	25	34	O	volunteers
6	35	35	O	,
7	37	47	O	concomitant
8	49	62	O	administration
9	64	65	O	of
10	67	76	O	XXXXXXXX
11	78	80	O	and
12	82	94	U-KIN	acetaminophen
13	96	103	O	resulted
14	105	106	O	in
15	108	109	O	an
16	111	121	O	approximate
17	123	125	O	50%
18	127	134	O	increase
19	136	137	O	in
20	139	144	O	plasma
21	146	151	O	levels
22	153	154	O	of
23	156	168	U-UNK	acetaminophen
NULL

Diflunisal	DDI-DrugBank.d132.s12	NO_SECTION	NO_SETID	9
Acetaminophen had no effect on plasma levels of diflunisal.
1	0	12	U-UNK	Acetaminophen
2	14	16	O	had
3	18	19	O	no
4	21	26	O	effect
5	28	29	O	on
6	31	36	O	plasma
7	38	43	O	levels
8	45	46	O	of
9	48	57	O	XXXXXXXX
NULL

Diflunisal	DDI-DrugBank.d132.s13	NO_SECTION	NO_SETID	27
Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.
1	0	4	O	Since
2	6	18	U-UNK	acetaminophen
3	20	21	O	in
4	23	26	O	high
5	28	32	O	doses
6	34	36	O	has
7	38	41	O	been
8	43	52	O	associated
9	54	57	O	with
10	59	72	O	hepatotoxicity
11	73	73	O	,
12	75	85	O	concomitant
13	87	100	O	administration
14	102	103	O	of
15	105	114	O	XXXXXXXX
16	116	118	O	and
17	120	132	U-DYN	acetaminophen
18	134	139	O	should
19	141	142	O	be
20	144	147	O	used
21	149	158	O	cautiously
22	159	159	O	,
23	161	164	O	with
24	166	172	O	careful
25	174	183	O	monitoring
26	185	186	O	of
27	188	195	O	patients
NULL

Diflunisal	DDI-DrugBank.d132.s14	NO_SECTION	NO_SETID	50
Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	39	O	XXXXXXXX
5	41	43	O	and
6	45	57	U-DYN	acetaminophen
7	59	60	O	in
8	62	65	O	dogs
9	66	66	O	,
10	68	70	O	but
11	72	74	O	not
12	76	77	O	in
13	79	82	O	rats
14	83	83	O	,
15	85	86	O	at
16	88	100	O	approximately
17	102	102	O	2
18	104	108	O	times
19	110	112	O	the
20	114	124	O	recommended
21	126	132	O	maximum
22	134	138	O	human
23	140	150	O	therapeutic
24	152	155	O	dose
25	157	158	O	of
26	160	163	O	each
27	166	167	O	40
28	169	170	O	to
29	172	173	O	52
30	175	176	O	mg
31	177	177	O	/
32	178	179	O	kg
33	180	180	O	/
34	181	183	O	day
35	185	186	O	of
36	188	197	O	XXXXXXXX
37	198	198	O	/
38	199	211	U-UNK	acetaminophen
39	214	221	O	resulted
40	223	224	O	in
41	226	232	O	greater
42	234	249	O	gastrointestinal
43	251	258	O	toxicity
44	260	263	O	than
45	265	268	O	when
46	270	275	O	either
47	277	280	O	drug
48	282	284	O	was
49	286	297	O	administered
50	299	303	O	alone
NULL

Diflunisal	DDI-DrugBank.d132.s15	NO_SECTION	NO_SETID	10
The clinical significance of these findings has not been established.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	33	O	these
6	35	42	O	findings
7	44	46	O	has
8	48	50	O	not
9	52	55	O	been
10	57	67	O	established
NULL

Diflunisal	DDI-DrugBank.d132.s16	NO_SECTION	NO_SETID	13
Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.
1	0	11	U-UNK	Methotrexate
2	12	12	O	:
3	14	20	O	Caution
4	22	27	O	should
5	29	30	O	be
6	32	35	O	used
7	37	38	O	if
8	40	49	O	XXXXXXXX
9	51	52	O	is
10	54	65	O	administered
11	67	79	O	concomitantly
12	81	84	O	with
13	86	97	U-DYN	methotrexate
NULL

Diflunisal	DDI-DrugBank.d132.s17	NO_SECTION	NO_SETID	19
Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
1	0	11	B-UNK	Nonsteroidal
2	13	16	I-UNK	anti
3	18	29	I-UNK	inflammatory
4	31	35	L-UNK	drugs
5	37	40	O	have
6	42	45	O	been
7	47	54	O	reported
8	56	57	O	to
9	59	66	O	decrease
10	68	70	O	the
11	72	78	O	tubular
12	80	88	O	secretion
13	90	91	O	of
14	93	104	U-UNK	methotrexate
15	106	108	O	and
16	110	111	O	to
17	113	122	O	potentiate
18	124	126	O	its
19	128	135	O	toxicity
NULL

Diflunisal	DDI-DrugBank.d132.s18	NO_SECTION	NO_SETID	30
Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
1	0	11	U-UNK	Cyclosporine
2	12	12	O	:
3	14	27	O	Administration
4	29	30	O	of
5	32	42	B-UNK	nonsteroial
6	44	47	I-UNK	anti
7	49	60	I-UNK	inflammatory
8	62	66	L-UNK	drugs
9	68	80	O	concomitantly
10	82	85	O	with
11	87	98	U-UNK	cyclosporine
12	100	102	O	has
13	104	107	O	been
14	109	118	O	associated
15	120	123	O	with
16	125	126	O	an
17	128	135	O	increase
18	137	138	O	in
19	140	151	U-UNK	cyclosporine
20	153	159	O	induced
21	161	168	O	toxicity
22	169	169	O	,
23	171	178	O	possibly
24	180	182	O	due
25	184	185	O	to
26	187	195	O	decreased
27	197	205	O	synthesis
28	207	208	O	of
29	210	214	O	renal
30	216	227	O	prostacyclin
NULL

Diflunisal	DDI-DrugBank.d132.s19	NO_SECTION	NO_SETID	18
NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
1	0	5	U-UNK	NSAIDs
2	7	12	O	should
3	14	15	O	be
4	17	20	O	used
5	22	25	O	with
6	27	33	O	caution
7	35	36	O	in
8	38	45	O	patients
9	47	52	O	taking
10	54	65	U-UNK	cyclosporine
11	66	66	O	,
12	68	70	O	and
13	72	76	O	renal
14	78	85	O	function
15	87	92	O	should
16	94	95	O	be
17	97	105	O	carefully
18	107	115	O	monitored
NULL

Diflunisal	DDI-DrugBank.d132.s20	NO_SECTION	NO_SETID	26
Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.
1	0	11	B-UNK	Nonsteroidal
2	13	16	I-UNK	Anti
3	18	29	I-UNK	Inflammatory
4	31	35	L-UNK	Drugs
5	36	36	O	:
6	38	40	O	The
7	42	55	O	administration
8	57	58	O	of
9	60	69	O	XXXXXXXX
10	71	72	O	to
11	74	79	O	normal
12	81	90	O	volunteers
13	92	100	O	receiving
14	102	113	U-KIN	indomethacin
15	115	123	O	decreased
16	125	127	O	the
17	129	133	O	renal
18	135	143	O	clearance
19	145	147	O	and
20	149	161	O	significantly
21	163	171	O	increased
22	173	175	O	the
23	177	182	O	plasma
24	184	189	O	levels
25	191	192	O	of
26	194	205	U-UNK	indomethacin
NULL

Diflunisal	DDI-DrugBank.d132.s21	NO_SECTION	NO_SETID	17
In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.
1	0	1	O	In
2	3	6	O	some
3	8	15	O	patients
4	17	19	O	the
5	21	28	O	combined
6	30	32	O	use
7	34	35	O	of
8	37	48	U-DYN	indomethacin
9	50	52	O	and
10	54	63	O	XXXXXXXX
11	65	67	O	has
12	69	72	O	been
13	74	83	O	associated
14	85	88	O	with
15	90	94	O	fatal
16	96	111	O	gastrointestinal
17	113	122	O	hemorrhage
NULL

Diflunisal	DDI-DrugBank.d132.s22	NO_SECTION	NO_SETID	10
Therefore, indomethacin and diflunisal should not be used concomitantly.
1	0	8	O	Therefore
2	9	9	O	,
3	11	22	U-DYN	indomethacin
4	24	26	O	and
5	28	37	O	XXXXXXXX
6	39	44	O	should
7	46	48	O	not
8	50	51	O	be
9	53	56	O	used
10	58	70	O	concomitantly
NULL

Diflunisal	DDI-DrugBank.d132.s23	NO_SECTION	NO_SETID	28
The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	32	O	XXXXXXXX
6	34	40	O	tablets
7	42	44	O	and
8	46	50	O	other
9	52	57	U-DYN	NSAIDs
10	59	60	O	is
11	62	64	O	not
12	66	76	O	recommended
13	78	80	O	due
14	82	83	O	to
15	85	87	O	the
16	89	97	O	increased
17	99	109	O	possibility
18	111	112	O	of
19	114	129	O	gastrointestinal
20	131	138	O	toxicity
21	139	139	O	,
22	141	144	O	with
23	146	151	O	little
24	153	154	O	or
25	156	157	O	no
26	159	166	O	increase
27	168	169	O	in
28	171	178	O	efficacy
NULL

Diflunisal	DDI-DrugBank.d132.s24	NO_SECTION	NO_SETID	10
The following information was obtained from studies in normal volunteers.
1	0	2	O	The
2	4	12	O	following
3	14	24	O	information
4	26	28	O	was
5	30	37	O	obtained
6	39	42	O	from
7	44	50	O	studies
8	52	53	O	in
9	55	60	O	normal
10	62	71	O	volunteers
NULL

Diflunisal	DDI-DrugBank.d132.s25	NO_SECTION	NO_SETID	24
Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.
1	0	6	O	XXXXXXXX
2	7	7	O	:
3	9	10	O	In
4	12	17	O	normal
5	19	28	O	volunteers
6	29	29	O	,
7	31	31	O	a
8	33	37	O	small
9	39	46	O	decrease
10	48	49	O	in
11	51	60	U-UNK	diflunisal
12	62	67	O	levels
13	69	71	O	was
14	73	80	O	observed
15	82	85	O	when
16	87	94	O	multiple
17	96	100	O	doses
18	102	103	O	of
19	105	114	U-KIN	diflunisal
20	116	118	O	and
21	120	126	O	XXXXXXXX
22	128	131	O	were
23	133	144	O	administered
24	146	158	O	concomitantly
NULL

Diflunisal	DDI-DrugBank.d132.s26	NO_SECTION	NO_SETID	29
Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.
1	0	7	U-UNK	Sulindac
2	8	8	O	:
3	10	12	O	The
4	14	24	O	concomitant
5	26	39	O	administration
6	41	42	O	of
7	44	53	O	XXXXXXXX
8	55	57	O	and
9	59	66	U-KIN	sulindac
10	68	69	O	in
11	71	76	O	normal
12	78	87	O	volunteers
13	89	96	O	resulted
14	98	99	O	in
15	101	108	O	lowering
16	110	111	O	of
17	113	115	O	the
18	117	122	O	plasma
19	124	129	O	levels
20	131	132	O	of
21	134	136	O	the
22	138	143	O	active
23	145	152	O	sulindac
24	154	160	O	sulfide
25	162	171	O	metabolite
26	173	174	O	by
27	176	188	O	approximately
28	190	192	O	one
29	194	198	O	third
NULL

Diflunisal	DDI-DrugBank.d132.s27	NO_SECTION	NO_SETID	34
Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.
1	0	7	U-UNK	Naproxen
2	8	8	O	:
3	10	12	O	The
4	14	24	O	concomitant
5	26	39	O	administration
6	41	42	O	of
7	44	53	O	XXXXXXXX
8	55	57	O	and
9	59	66	U-KIN	naproxen
10	68	69	O	in
11	71	76	O	normal
12	78	87	O	volunteers
13	89	91	O	had
14	93	94	O	no
15	96	101	O	effect
16	103	104	O	on
17	106	108	O	the
18	110	115	O	plasma
19	117	122	O	levels
20	124	125	O	of
21	127	134	U-UNK	naproxen
22	135	135	O	,
23	137	139	O	but
24	141	153	O	significantly
25	155	163	O	decreased
26	165	167	O	the
27	169	175	O	urinary
28	177	185	O	excretion
29	187	188	O	of
30	190	197	U-UNK	naproxen
31	199	201	O	and
32	203	205	O	its
33	207	217	O	glucuronide
34	219	228	O	metabolite
NULL

Diflunisal	DDI-DrugBank.d132.s28	NO_SECTION	NO_SETID	9
Naproxen had no effect on plasma levels of diflunisal.
1	0	7	U-UNK	Naproxen
2	9	11	O	had
3	13	14	O	no
4	16	21	O	effect
5	23	24	O	on
6	26	31	O	plasma
7	33	38	O	levels
8	40	41	O	of
9	43	52	O	XXXXXXXX
NULL

Diflunisal	DDI-DrugBank.d132.s29	NO_SECTION	NO_SETID	24
Drug laboratory Test Interactions Serum Salicylate Assays: Caution should be used in interpreting the results of serum salicylate assays when diflunisal is present.
1	0	3	O	Drug
2	5	14	O	laboratory
3	16	19	O	Test
4	21	32	O	Interactions
5	34	38	O	Serum
6	40	49	O	Salicylate
7	51	56	O	Assays
8	57	57	O	:
9	59	65	O	Caution
10	67	72	O	should
11	74	75	O	be
12	77	80	O	used
13	82	83	O	in
14	85	96	O	interpreting
15	98	100	O	the
16	102	108	O	results
17	110	111	O	of
18	113	117	O	serum
19	119	128	O	salicylate
20	130	135	O	assays
21	137	140	O	when
22	142	151	O	XXXXXXXX
23	153	154	O	is
24	156	162	O	present
NULL

Diflunisal	DDI-DrugBank.d132.s30	NO_SECTION	NO_SETID	13
Salicylate levels have been found to be falsely elevated with some assay methods.
1	0	9	U-UNK	Salicylate
2	11	16	O	levels
3	18	21	O	have
4	23	26	O	been
5	28	32	O	found
6	34	35	O	to
7	37	38	O	be
8	40	46	O	falsely
9	48	55	O	elevated
10	57	60	O	with
11	62	65	O	some
12	67	71	O	assay
13	73	79	O	methods
NULL

Digoxin	DDI-DrugBank.d450.s0	NO_SECTION	NO_SETID	11
Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.
1	0	8	B-UNK	Potassium
2	10	18	I-UNK	depleting
3	20	28	L-UNK	diuretics
4	30	32	O	are
5	34	34	O	a
6	36	40	O	major
7	42	53	O	contributing
8	55	60	O	factor
9	62	63	O	to
10	65	73	U-UNK	digitalis
11	75	82	O	toxicity
NULL

Digoxin	DDI-DrugBank.d450.s1	NO_SECTION	NO_SETID	18
Calcium, particularly if administered rapidly by the intravenous route, may produce serious arrhythmias in digitalized patients.
1	0	6	U-UNK	Calcium
2	7	7	O	,
3	9	20	O	particularly
4	22	23	O	if
5	25	36	O	administered
6	38	44	O	rapidly
7	46	47	O	by
8	49	51	O	the
9	53	63	O	intravenous
10	65	69	O	route
11	70	70	O	,
12	72	74	O	may
13	76	82	O	produce
14	84	90	O	serious
15	92	102	O	arrhythmias
16	104	105	O	in
17	107	117	O	digitalized
18	119	126	O	patients
NULL

Digoxin	DDI-DrugBank.d450.s2	NO_SECTION	NO_SETID	46
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
1	0	8	U-KIN	Quinidine
2	9	9	O	,
3	11	19	U-KIN	verapamil
4	20	20	O	,
5	22	31	U-KIN	amiodarone
6	32	32	O	,
7	34	44	U-KIN	propafenone
8	45	45	O	,
9	47	58	U-KIN	indomethacin
10	59	59	O	,
11	61	72	U-KIN	itraconazole
12	73	73	O	,
13	75	84	U-KIN	alprazolam
14	85	85	O	,
15	87	89	O	and
16	91	104	U-KIN	spironolactone
17	106	110	O	raise
18	112	114	O	the
19	116	120	O	serum
20	122	128	O	XXXXXXXX
21	130	142	O	concentration
22	144	146	O	due
23	148	149	O	to
24	151	151	O	a
25	153	161	O	reduction
26	163	164	O	in
27	166	174	O	clearance
28	176	178	O	and
29	179	179	O	/
30	180	181	O	or
31	183	184	O	in
32	186	191	O	volume
33	193	194	O	of
34	196	207	O	distribution
35	209	210	O	of
36	212	214	O	the
37	216	219	O	drug
38	220	220	O	,
39	222	225	O	with
40	227	229	O	the
41	231	241	O	implication
42	243	246	O	that
43	248	256	U-UNK	digitalis
44	258	269	O	intoxication
45	271	273	O	may
46	275	280	O	result
NULL

Digoxin	DDI-DrugBank.d450.s3	NO_SECTION	NO_SETID	33
Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
1	0	11	U-KIN	Erythromycin
2	13	15	O	and
3	17	30	U-KIN	clarithromycin
4	33	35	O	and
5	37	44	O	possibly
6	46	50	O	other
7	52	60	B-KIN	macrolide
8	62	72	L-KIN	antibiotics
9	75	77	O	and
10	79	90	U-KIN	tetracycline
11	92	94	O	may
12	96	103	O	increase
13	105	111	O	XXXXXXXX
14	113	122	O	absorption
15	124	125	O	in
16	127	134	O	patients
17	136	138	O	who
18	140	149	O	inactivate
19	151	157	O	XXXXXXXX
20	159	160	O	by
21	162	170	O	bacterial
22	172	181	O	metabolism
23	183	184	O	in
24	186	188	O	the
25	190	194	O	lower
26	196	204	O	intestine
27	205	205	O	,
28	207	208	O	so
29	210	213	O	that
30	215	223	U-UNK	digitalis
31	225	236	O	intoxication
32	238	240	O	may
33	242	247	O	result
NULL

Digoxin	DDI-DrugBank.d450.s4	NO_SECTION	NO_SETID	14
The risk of this interaction may be reduced if digoxin is given as capsules.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	15	O	this
5	17	27	O	interaction
6	29	31	O	may
7	33	34	O	be
8	36	42	O	reduced
9	44	45	O	if
10	47	53	O	XXXXXXXX
11	55	56	O	is
12	58	62	O	given
13	64	65	O	as
14	67	74	O	capsules
NULL

Digoxin	DDI-DrugBank.d450.s5	NO_SECTION	NO_SETID	13
Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.
1	0	12	U-KIN	Propantheline
2	14	16	O	and
3	18	30	U-KIN	diphenoxylate
4	31	31	O	,
5	33	34	O	by
6	36	45	O	decreasing
7	47	49	O	gut
8	51	58	O	motility
9	59	59	O	,
10	61	63	O	may
11	65	72	O	increase
12	74	80	O	XXXXXXXX
13	82	91	O	absorption
NULL

Digoxin	DDI-DrugBank.d450.s6	NO_SECTION	NO_SETID	30
Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.
1	0	7	U-KIN	Antacids
2	8	8	O	,
3	10	15	U-KIN	kaolin
4	17	22	O	pectin
5	23	23	O	,
6	25	37	U-KIN	sulfasalazine
7	38	38	O	,
8	40	47	U-KIN	neomycin
9	48	48	O	,
10	50	63	U-KIN	cholestyramine
11	64	64	O	,
12	66	72	O	certain
13	74	83	O	anticancer
14	85	89	O	drugs
15	90	90	O	,
16	92	94	O	and
17	96	109	U-KIN	metoclopramide
18	111	113	O	may
19	115	123	O	interfere
20	125	128	O	with
21	130	139	O	intestinal
22	141	147	O	XXXXXXXX
23	149	158	O	absorption
24	159	159	O	,
25	161	169	O	resulting
26	171	172	O	in
27	174	185	O	unexpectedly
28	187	189	O	low
29	191	195	O	serum
30	197	210	O	concentrations
NULL

Digoxin	DDI-DrugBank.d450.s7	NO_SECTION	NO_SETID	22
Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.
1	0	7	U-KIN	Rifampin
2	9	11	O	may
3	13	20	O	decrease
4	22	26	O	serum
5	28	34	O	XXXXXXXX
6	36	48	O	concentration
7	49	49	O	,
8	51	60	O	especially
9	62	63	O	in
10	65	72	O	patients
11	74	77	O	with
12	79	83	O	renal
13	85	95	O	dysfunction
14	96	96	O	,
15	98	99	O	by
16	101	110	O	increasing
17	112	114	O	the
18	116	118	O	non
19	120	124	O	renal
20	126	134	O	clearance
21	136	137	O	of
22	139	145	O	XXXXXXXX
NULL

Digoxin	DDI-DrugBank.d450.s8	NO_SECTION	NO_SETID	20
There have been inconsistent reports regarding the effects of other drugs (e.g., quinine, penicillamine) on serum digoxin concentration.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	27	O	inconsistent
5	29	35	O	reports
6	37	45	O	regarding
7	47	49	O	the
8	51	57	O	effects
9	59	60	O	of
10	62	66	O	other
11	68	72	O	drugs
12	75	77	O	e.g
13	79	79	O	,
14	81	87	U-UNK	quinine
15	88	88	O	,
16	90	102	U-UNK	penicillamine
17	105	106	O	on
18	108	112	O	serum
19	114	120	O	XXXXXXXX
20	122	134	O	concentration
NULL

Digoxin	DDI-DrugBank.d450.s9	NO_SECTION	NO_SETID	15
Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.
1	0	6	U-DYN	Thyroid
2	8	21	O	administration
3	23	24	O	to
4	26	26	O	a
5	28	38	O	digitalized
6	39	39	O	,
7	41	51	O	hypothyroid
8	53	59	O	patient
9	61	63	O	may
10	65	72	O	increase
11	74	76	O	the
12	78	81	O	dose
13	83	93	O	requirement
14	95	96	O	of
15	98	104	O	XXXXXXXX
NULL

Digoxin	DDI-DrugBank.d450.s10	NO_SECTION	NO_SETID	12
Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	25	O	XXXXXXXX
5	27	29	O	and
6	31	46	U-DYN	sympathomimetics
7	48	56	O	increases
8	58	60	O	the
9	62	65	O	risk
10	67	68	O	of
11	70	76	O	cardiac
12	78	88	O	arrhythmias
NULL

Digoxin	DDI-DrugBank.d450.s11	NO_SECTION	NO_SETID	20
Succinylcholine may cause a sudden extrusion of potassium from muscle cells, and may thereby cause arrhythmias in digitalized patients.
1	0	14	U-UNK	Succinylcholine
2	16	18	O	may
3	20	24	O	cause
4	26	26	O	a
5	28	33	O	sudden
6	35	43	O	extrusion
7	45	46	O	of
8	48	56	O	potassium
9	58	61	O	from
10	63	68	O	muscle
11	70	74	O	cells
12	75	75	O	,
13	77	79	O	and
14	81	83	O	may
15	85	91	O	thereby
16	93	97	O	cause
17	99	109	O	arrhythmias
18	111	112	O	in
19	114	124	O	digitalized
20	126	133	O	patients
NULL

Digoxin	DDI-DrugBank.d450.s12	NO_SECTION	NO_SETID	35
Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.
1	0	7	O	Although
2	9	12	B-DYN	beta
3	14	23	I-DYN	adrenergic
4	25	32	L-DYN	blockers
5	34	35	O	or
6	37	43	B-DYN	calcium
7	45	51	I-DYN	channel
8	53	60	L-DYN	blockers
9	62	64	O	and
10	66	72	O	XXXXXXXX
11	74	76	O	may
12	78	79	O	be
13	81	86	O	useful
14	88	89	O	in
15	91	101	O	combination
16	103	104	O	to
17	106	112	O	control
18	114	119	O	atrial
19	121	132	O	fibrillation
20	133	133	O	,
21	135	139	O	their
22	141	148	O	additive
23	150	156	O	effects
24	158	159	O	on
25	161	162	O	AV
26	164	167	O	node
27	169	178	O	conduction
28	180	182	O	can
29	184	189	O	result
30	191	192	O	in
31	194	201	O	advanced
32	203	204	O	or
33	206	213	O	complete
34	215	219	O	heart
35	221	225	O	block
NULL

Digoxin	DDI-DrugBank.d450.s13	NO_SECTION	NO_SETID	22
Due to the considerable variability of these interactions, the dosage of digoxin should be individualized when patients receive these medications concurrently.
1	0	2	O	Due
2	4	5	O	to
3	7	9	O	the
4	11	22	O	considerable
5	24	34	O	variability
6	36	37	O	of
7	39	43	O	these
8	45	56	O	interactions
9	57	57	O	,
10	59	61	O	the
11	63	68	O	dosage
12	70	71	O	of
13	73	79	O	XXXXXXXX
14	81	86	O	should
15	88	89	O	be
16	91	104	O	individualized
17	106	109	O	when
18	111	118	O	patients
19	120	126	O	receive
20	128	132	O	these
21	134	144	O	medications
22	146	157	O	concurrently
NULL

Digoxin	DDI-DrugBank.d450.s14	NO_SECTION	NO_SETID	37
Furthermore, caution should be exercised when combining digoxin with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of digoxin.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	19	O	caution
4	21	26	O	should
5	28	29	O	be
6	31	39	O	exercised
7	41	44	O	when
8	46	54	O	combining
9	56	62	O	XXXXXXXX
10	64	67	O	with
11	69	71	O	any
12	73	76	O	drug
13	78	81	O	that
14	83	85	O	may
15	87	91	O	cause
16	93	93	O	a
17	95	105	O	significant
18	107	119	O	deterioration
19	121	122	O	in
20	124	128	O	renal
21	130	137	O	function
22	138	138	O	,
23	140	144	O	since
24	146	146	O	a
25	148	154	O	decline
26	156	157	O	in
27	159	168	O	glomerular
28	170	179	O	filtration
29	181	182	O	or
30	184	190	O	tubular
31	192	200	O	secretion
32	202	204	O	may
33	206	211	O	impair
34	213	215	O	the
35	217	225	O	excretion
36	227	228	O	of
37	230	236	O	XXXXXXXX
NULL

Dihydroergotamine	DDI-DrugBank.d410.s0	NO_SECTION	NO_SETID	25
Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.
1	0	15	U-UNK	Vasoconstrictors
2	16	16	O	:
3	18	26	O	XXXXXXXX
4	30	46	B-UNK	dihydroergotamine
5	48	55	L-UNK	mesylate
6	58	66	O	Injection
7	67	67	O	,
8	69	71	O	USP
9	73	78	O	should
10	80	82	O	not
11	84	85	O	be
12	87	90	O	used
13	92	95	O	with
14	97	106	B-DYN	peripheral
15	108	123	L-DYN	vasoconstrictors
16	125	131	O	because
17	133	135	O	the
18	137	147	O	combination
19	149	151	O	may
20	153	157	O	cause
21	159	169	O	synergistic
22	171	179	O	elevation
23	181	182	O	of
24	184	188	O	blood
25	190	197	O	pressure
NULL

Dihydroergotamine	DDI-DrugBank.d410.s1	NO_SECTION	NO_SETID	25
Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.
1	0	10	U-UNK	Sumatriptan
2	11	11	O	:
3	13	23	U-DYN	Sumatriptan
4	25	27	O	has
5	29	32	O	been
6	34	41	O	reported
7	43	44	O	to
8	46	50	O	cause
9	52	59	O	coronary
10	61	66	O	artery
11	68	76	O	vasospasm
12	77	77	O	,
13	79	81	O	and
14	83	85	O	its
15	87	92	O	effect
16	94	98	O	could
17	100	101	O	be
18	103	110	O	additive
19	112	115	O	with
20	117	125	O	XXXXXXXX
21	129	145	B-UNK	dihydroergotamine
22	147	154	L-UNK	mesylate
23	157	165	O	Injection
24	166	166	O	,
25	168	170	O	USP
NULL

Dihydroergotamine	DDI-DrugBank.d410.s2	NO_SECTION	NO_SETID	18
Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..
1	0	10	U-DYN	Sumatriptan
2	12	14	O	and
3	16	24	O	XXXXXXXX
4	28	44	B-UNK	dihydroergotamine
5	46	53	L-UNK	mesylate
6	56	64	O	Injection
7	65	65	O	,
8	67	69	O	USP
9	71	76	O	should
10	78	80	O	not
11	82	83	O	be
12	85	89	O	taken
13	91	96	O	within
14	98	99	O	24
15	101	105	O	hours
16	107	108	O	of
17	110	113	O	each
18	115	119	O	other
NULL

Dihydroergotamine	DDI-DrugBank.d410.s3	NO_SECTION	NO_SETID	53
Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.
1	0	3	B-UNK	Beta
2	5	12	L-UNK	Blockers
3	13	13	O	:
4	15	22	O	Although
5	24	26	O	the
6	28	34	O	results
7	36	37	O	of
8	39	39	O	a
9	41	48	O	clinical
10	50	54	O	study
11	56	58	O	did
12	60	62	O	not
13	64	71	O	indicate
14	73	73	O	a
15	75	78	O	safe
16	80	86	O	problem
17	88	97	O	associated
18	99	102	O	with
19	104	106	O	the
20	108	121	O	administration
21	123	124	O	of
22	126	134	O	XXXXXXXX
23	138	154	B-UNK	dihydroergotamine
24	156	163	L-UNK	mesylate
25	166	174	O	Injection
26	175	175	O	,
27	177	179	O	USP
28	181	182	O	to
29	184	191	O	subjects
30	193	199	O	already
31	201	209	O	receiving
32	211	221	U-UNK	propranolol
33	222	222	O	,
34	224	228	O	there
35	230	233	O	have
36	235	238	O	been
37	240	246	O	reports
38	248	251	O	that
39	253	263	U-UNK	propranolol
40	265	267	O	may
41	269	278	O	potentiate
42	280	282	O	the
43	284	299	O	vasoconstrictive
44	301	306	O	action
45	308	309	O	of
46	311	320	U-UNK	ergotamine
47	322	323	O	by
48	325	332	O	blocking
49	334	336	O	the
50	338	349	O	vasodilating
51	351	358	O	property
52	360	361	O	of
53	363	373	O	epinephrine
NULL

Dihydroergotamine	DDI-DrugBank.d410.s4	NO_SECTION	NO_SETID	19
Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.
1	0	7	U-UNK	Nicotine
2	8	8	O	:
3	10	17	U-UNK	Nicotine
4	19	21	O	may
5	23	29	O	provoke
6	31	46	O	vasoconstriction
7	48	49	O	in
8	51	54	O	some
9	56	63	O	patients
10	64	64	O	,
11	66	77	O	predisposing
12	79	80	O	to
13	82	82	O	a
14	84	90	O	greater
15	92	99	O	ischemic
16	101	108	O	response
17	110	111	O	to
18	113	117	U-UNK	ergot
19	119	125	O	therapy
NULL

Dihydroergotamine	DDI-DrugBank.d410.s5	NO_SECTION	NO_SETID	50
Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.
1	0	8	B-UNK	Macrolide
2	10	20	L-UNK	Antibiotics
3	23	23	O	e
4	26	26	O	g
5	29	40	U-UNK	erythromycin
6	42	44	O	and
7	46	59	U-UNK	troleandomycin
8	61	61	O	:
9	63	68	O	Agents
10	70	71	O	of
11	73	75	O	the
12	77	81	B-UNK	ergot
13	83	90	I-UNK	alkaloid
14	92	96	L-UNK	class
15	97	97	O	,
16	99	100	O	of
17	102	106	O	which
18	108	116	O	XXXXXXXX
19	120	136	B-UNK	dihydroergotamine
20	138	145	L-UNK	mesylate
21	148	156	O	Injection
22	157	157	O	,
23	159	161	O	USP
24	163	164	O	is
25	166	166	O	a
26	168	173	O	member
27	174	174	O	,
28	176	179	O	have
29	181	184	O	been
30	186	190	O	shown
31	192	193	O	to
32	195	202	O	interact
33	204	207	O	with
34	209	219	U-UNK	antibiotics
35	221	222	O	of
36	224	226	O	the
37	228	236	B-KIN	macrolide
38	238	242	L-KIN	class
39	243	243	O	,
40	245	253	O	resulting
41	255	256	O	in
42	258	266	O	increased
43	268	273	O	plasma
44	275	280	O	levels
45	282	283	O	of
46	285	293	O	unchanged
47	295	303	O	alkaloids
48	305	307	O	and
49	309	318	O	peripheral
50	320	335	O	vasoconstriction
NULL

Dihydroergotamine	DDI-DrugBank.d410.s6	NO_SECTION	NO_SETID	18
Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.
1	0	10	O	Vasospastic
2	12	20	O	reactions
3	22	25	O	have
4	27	30	O	been
5	32	39	O	reported
6	41	44	O	with
7	46	56	O	therapeutic
8	58	62	O	doses
9	64	65	O	of
10	67	76	U-UNK	ergotamine
11	78	87	O	containing
12	89	93	O	drugs
13	95	98	O	when
14	100	101	O	co
15	103	114	O	administered
16	116	119	O	with
17	121	125	O	these
18	127	137	U-UNK	antibiotics
NULL

Dihydroergotamine	DDI-DrugBank.d410.s7	NO_SECTION	NO_SETID	23
SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.
1	0	4	U-UNK	SSRIs
2	5	5	O	:
3	7	14	O	Weakness
4	16	28	O	hyperreflexia
5	29	29	O	,
6	31	33	O	and
7	35	48	O	incoordination
8	50	53	O	have
9	55	58	O	been
10	60	67	O	reported
11	69	74	O	rarely
12	76	79	O	when
13	81	81	B-UNK	5
14	83	85	I-UNK	HT1
15	87	94	L-UNK	agonists
16	96	99	O	have
17	101	104	O	been
18	106	107	O	co
19	109	120	O	administered
20	122	125	O	with
21	127	131	U-UNK	SSRIs
22	134	134	O	e
23	137	137	O	g
NULL

Dihydroergotamine	DDI-DrugBank.d410.s8	NO_SECTION	NO_SETID	7
fluoxetine, fluvoxamine, paroxetine, sertraline).
1	0	9	U-UNK	fluoxetine
2	10	10	O	,
3	12	22	U-UNK	fluvoxamine
4	23	23	O	,
5	25	34	U-UNK	paroxetine
6	35	35	O	,
7	37	46	U-UNK	sertraline
NULL

Dihydroergotamine	DDI-DrugBank.d410.s9	NO_SECTION	NO_SETID	21
There have been no reported cases from spontaneous reports of drug interaction between SSRIs and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	17	O	no
5	19	26	O	reported
6	28	32	O	cases
7	34	37	O	from
8	39	49	O	spontaneous
9	51	57	O	reports
10	59	60	O	of
11	62	65	O	drug
12	67	77	O	interaction
13	79	85	O	between
14	87	91	U-UNK	SSRIs
15	93	95	O	and
16	97	105	O	XXXXXXXX
17	109	125	B-UNK	dihydroergotamine
18	127	134	L-UNK	mesylate
19	137	145	O	Injection
20	146	146	O	,
21	148	150	O	USP
NULL

Dihydroergotamine	DDI-DrugBank.d410.s10	NO_SECTION	NO_SETID	22
Oral Contraceptives: The effect of oral contraceptives on the pharmacokinetics of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP has not been studied.
1	0	3	O	Oral
2	5	18	U-UNK	Contraceptives
3	19	19	O	:
4	21	23	O	The
5	25	30	O	effect
6	32	33	O	of
7	35	38	O	oral
8	40	53	U-UNK	contraceptives
9	55	56	O	on
10	58	60	O	the
11	62	77	O	pharmacokinetics
12	79	80	O	of
13	82	90	O	XXXXXXXX
14	94	110	B-UNK	dihydroergotamine
15	112	119	L-UNK	mesylate
16	122	130	O	Injection
17	131	131	O	,
18	133	135	O	USP
19	137	139	O	has
20	141	143	O	not
21	145	148	O	been
22	150	156	O	studied
NULL

Dihydrotachysterol	DDI-DrugBank.d452.s0	NO_SECTION	NO_SETID	17
Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.
1	0	13	O	Administration
2	15	16	O	of
3	18	25	B-DYN	thiazide
4	27	35	L-DYN	diuretics
5	37	38	O	to
6	40	54	O	hypoparathyroid
7	56	63	O	patients
8	65	67	O	who
9	69	71	O	are
10	73	84	O	concurrently
11	86	90	O	being
12	92	98	O	treated
13	100	103	O	with
14	105	122	O	XXXXXXXX
15	124	126	O	may
16	128	132	O	cause
17	134	146	O	hypercalcemia
NULL

Diltiazem	DDI-DrugBank.d565.s0	NO_SECTION	NO_SETID	32
Due to the potential for additive effects, caution and careful titration are warranted in patients receiving diltiazem hydrochloride concomitantly with other agents known to affect cardiac contractility and/or conduction.
1	0	2	O	Due
2	4	5	O	to
3	7	9	O	the
4	11	19	O	potential
5	21	23	O	for
6	25	32	O	additive
7	34	40	O	effects
8	41	41	O	,
9	43	49	O	caution
10	51	53	O	and
11	55	61	O	careful
12	63	71	O	titration
13	73	75	O	are
14	77	85	O	warranted
15	87	88	O	in
16	90	97	O	patients
17	99	107	O	receiving
18	109	117	O	XXXXXXXX
19	119	131	O	hydrochloride
20	133	145	O	concomitantly
21	147	150	O	with
22	152	156	O	other
23	158	163	O	agents
24	165	169	O	known
25	171	172	O	to
26	174	179	O	affect
27	181	187	O	cardiac
28	189	201	O	contractility
29	203	205	O	and
30	206	206	O	/
31	207	208	O	or
32	210	219	O	conduction
NULL

Diltiazem	DDI-DrugBank.d565.s1	NO_SECTION	NO_SETID	22
Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.
1	0	12	O	Pharmacologic
2	14	20	O	studies
3	22	29	O	indicate
4	31	34	O	that
5	36	40	O	there
6	42	44	O	may
7	46	47	O	be
8	49	56	O	additive
9	58	64	O	effects
10	66	67	O	in
11	69	78	O	prolonging
12	80	81	O	AV
13	83	92	O	conduction
14	94	97	O	when
15	99	103	O	using
16	105	108	B-DYN	beta
17	110	117	L-DYN	blockers
18	119	120	O	or
19	122	130	U-DYN	digitalis
20	132	144	O	concomitantly
21	146	149	O	with
22	151	156	O	XXXXXXXX
NULL

Diltiazem	DDI-DrugBank.d565.s2	NO_SECTION	NO_SETID	15
As with all drugs, care should be exercised when treating patients with multiple medications.
1	0	1	O	As
2	3	6	O	with
3	8	10	O	all
4	12	16	O	drugs
5	17	17	O	,
6	19	22	O	care
7	24	29	O	should
8	31	32	O	be
9	34	42	O	exercised
10	44	47	O	when
11	49	56	O	treating
12	58	65	O	patients
13	67	70	O	with
14	72	79	O	multiple
15	81	91	O	medications
NULL

Diltiazem	DDI-DrugBank.d565.s3	NO_SECTION	NO_SETID	16
Diltiazem is both a substrate and an inhibitor of the cytochrome P-450 3A4 enzyme system.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	16	O	both
4	18	18	O	a
5	20	28	O	substrate
6	30	32	O	and
7	34	35	O	an
8	37	45	O	inhibitor
9	47	48	O	of
10	50	52	O	the
11	54	63	O	cytochrome
12	65	65	O	P
13	67	69	O	450
14	71	73	O	3A4
15	75	80	O	enzyme
16	82	87	O	system
NULL

Diltiazem	DDI-DrugBank.d565.s4	NO_SECTION	NO_SETID	29
Other drugs that are specific substrates, inhibitors, or inducers of the enzyme system may have a significant impact on the efficacy and side effect profile of diltiazem.
1	0	4	O	Other
2	6	10	O	drugs
3	12	15	O	that
4	17	19	O	are
5	21	28	O	specific
6	30	39	O	substrates
7	40	40	O	,
8	42	51	O	inhibitors
9	52	52	O	,
10	54	55	O	or
11	57	64	O	inducers
12	66	67	O	of
13	69	71	O	the
14	73	78	O	enzyme
15	80	85	O	system
16	87	89	O	may
17	91	94	O	have
18	96	96	O	a
19	98	108	O	significant
20	110	115	O	impact
21	117	118	O	on
22	120	122	O	the
23	124	131	O	efficacy
24	133	135	O	and
25	137	140	O	side
26	142	147	O	effect
27	149	155	O	profile
28	157	158	O	of
29	160	168	O	XXXXXXXX
NULL

Diltiazem	DDI-DrugBank.d565.s5	NO_SECTION	NO_SETID	40
Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to maintain optimum therapeutic blood levels.
1	0	7	O	Patients
2	9	14	O	taking
3	16	20	O	other
4	22	26	O	drugs
5	28	31	O	that
6	33	35	O	are
7	37	46	O	substrates
8	48	49	O	of
9	51	56	O	CYP450
10	58	60	O	3A4
11	61	61	O	,
12	63	72	O	especially
13	74	81	O	patients
14	83	86	O	with
15	88	92	O	renal
16	94	96	O	and
17	97	97	O	/
18	98	99	O	or
19	101	107	O	hepatic
20	109	118	O	impairment
21	119	119	O	,
22	121	123	O	may
23	125	131	O	require
24	133	138	O	dosage
25	140	149	O	adjustment
26	151	154	O	when
27	156	163	O	starting
28	165	166	O	or
29	168	175	O	stopping
30	177	189	O	concomitantly
31	191	202	O	administered
32	204	212	O	XXXXXXXX
33	214	215	O	in
34	217	221	O	order
35	223	224	O	to
36	226	233	O	maintain
37	235	241	O	optimum
38	243	253	O	therapeutic
39	255	259	O	blood
40	261	266	O	levels
NULL

Diltiazem	DDI-DrugBank.d565.s7	NO_SECTION	NO_SETID	43
Controlled and uncontrolled domestic studies suggest that concomitant use of diltiazem hydrochloride and beta-blockers is usually well tolerated, but available data are not sufficient to predict the effects of concomitant treatment in patients with left ventricular dysfunction or cardiac conduction abnormalities.
1	0	9	O	Controlled
2	11	13	O	and
3	15	26	O	uncontrolled
4	28	35	O	domestic
5	37	43	O	studies
6	45	51	O	suggest
7	53	56	O	that
8	58	68	O	concomitant
9	70	72	O	use
10	74	75	O	of
11	77	85	O	XXXXXXXX
12	87	99	O	hydrochloride
13	101	103	O	and
14	105	108	B-UNK	beta
15	110	117	L-UNK	blockers
16	119	120	O	is
17	122	128	O	usually
18	130	133	O	well
19	135	143	O	tolerated
20	144	144	O	,
21	146	148	O	but
22	150	158	O	available
23	160	163	O	data
24	165	167	O	are
25	169	171	O	not
26	173	182	O	sufficient
27	184	185	O	to
28	187	193	O	predict
29	195	197	O	the
30	199	205	O	effects
31	207	208	O	of
32	210	220	O	concomitant
33	222	230	O	treatment
34	232	233	O	in
35	235	242	O	patients
36	244	247	O	with
37	249	252	O	left
38	254	264	O	ventricular
39	266	276	O	dysfunction
40	278	279	O	or
41	281	287	O	cardiac
42	289	298	O	conduction
43	300	312	O	abnormalities
NULL

Diltiazem	DDI-DrugBank.d565.s8	NO_SECTION	NO_SETID	27
Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.
1	0	13	O	Administration
2	15	16	O	of
3	18	26	O	XXXXXXXX
4	28	40	O	hydrochloride
5	42	54	O	concomitantly
6	56	59	O	with
7	61	71	U-KIN	propranolol
8	73	74	O	in
9	76	79	O	five
10	81	86	O	normal
11	88	97	O	volunteers
12	99	106	O	resulted
13	108	109	O	in
14	111	119	O	increased
15	121	131	U-UNK	propranolol
16	133	138	O	levels
17	140	141	O	in
18	143	145	O	all
19	147	154	O	subjects
20	156	158	O	and
21	160	174	O	bioavailability
22	176	177	O	of
23	179	189	U-UNK	propranolol
24	191	193	O	was
25	195	203	O	increased
26	205	217	O	approximately
27	219	221	O	50%
NULL

Diltiazem	DDI-DrugBank.d565.s9	NO_SECTION	NO_SETID	14
In vitro, propranolol appears to be displaced from its binding sites by diltiazem.
1	0	1	O	In
2	3	7	O	vitro
3	8	8	O	,
4	10	20	U-KIN	propranolol
5	22	28	O	appears
6	30	31	O	to
7	33	34	O	be
8	36	44	O	displaced
9	46	49	O	from
10	51	53	O	its
11	55	61	O	binding
12	63	67	O	sites
13	69	70	O	by
14	72	80	O	XXXXXXXX
NULL

Diltiazem	DDI-DrugBank.d565.s10	NO_SECTION	NO_SETID	21
If combination therapy is initiated or withdrawn in conjunction with propranolol, an adjustment in the propranolol dose may be warranted.
1	0	1	O	If
2	3	13	O	combination
3	15	21	O	therapy
4	23	24	O	is
5	26	34	O	initiated
6	36	37	O	or
7	39	47	O	withdrawn
8	49	50	O	in
9	52	62	O	conjunction
10	64	67	O	with
11	69	79	U-UNK	propranolol
12	80	80	O	,
13	82	83	O	an
14	85	94	O	adjustment
15	96	97	O	in
16	99	101	O	the
17	103	113	U-UNK	propranolol
18	115	118	O	dose
19	120	122	O	may
20	124	125	O	be
21	127	135	O	warranted
NULL

Diltiazem	DDI-DrugBank.d565.s12	NO_SECTION	NO_SETID	38
A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.
1	0	0	O	A
2	2	6	O	study
3	8	9	O	in
4	11	13	O	six
5	15	21	O	healthy
6	23	32	O	volunteers
7	34	36	O	has
8	38	42	O	shown
9	44	44	O	a
10	46	56	O	significant
11	58	65	O	increase
12	67	68	O	in
13	70	73	O	peak
14	75	83	O	XXXXXXXX
15	85	90	O	plasma
16	92	97	O	levels
17	100	102	O	58%
18	105	107	O	and
19	109	111	O	AUC
20	114	116	O	53%
21	119	123	O	after
22	125	125	O	a
23	127	127	O	1
24	129	132	O	week
25	134	139	O	course
26	141	142	O	of
27	144	153	U-KIN	cimetidine
28	155	158	O	1200
29	160	161	O	mg
30	162	162	O	/
31	163	165	O	day
32	167	169	O	and
33	171	171	O	a
34	173	178	O	single
35	180	183	O	dose
36	185	186	O	of
37	188	196	O	XXXXXXXX
38	198	201	O	60mg
NULL

Diltiazem	DDI-DrugBank.d565.s13	NO_SECTION	NO_SETID	6
Ranitidine produced smaller, nonsignificant increases.
1	0	9	U-UNK	Ranitidine
2	11	18	O	produced
3	20	26	O	smaller
4	27	27	O	,
5	29	42	O	nonsignificant
6	44	52	O	increases
NULL

Diltiazem	DDI-DrugBank.d565.s14	NO_SECTION	NO_SETID	26
The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.
1	0	2	O	The
2	4	9	O	effect
3	11	13	O	may
4	15	16	O	be
5	18	25	O	mediated
6	27	28	O	by
7	30	40	O	cimetidines
8	42	46	O	known
9	48	57	O	inhibition
10	59	60	O	of
11	62	68	O	hepatic
12	70	79	O	cytochrome
13	81	81	O	P
14	83	85	O	450
15	86	86	O	,
16	88	90	O	the
17	92	97	O	enzyme
18	99	104	O	system
19	106	116	O	responsible
20	118	120	O	for
21	122	124	O	the
22	126	130	O	first
23	132	135	O	pass
24	137	146	O	metabolism
25	148	149	O	of
26	151	159	O	XXXXXXXX
NULL

Diltiazem	DDI-DrugBank.d565.s15	NO_SECTION	NO_SETID	22
Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.
1	0	7	O	Patients
2	9	17	O	currently
3	19	27	O	receiving
4	29	37	O	XXXXXXXX
5	39	45	O	therapy
6	47	52	O	should
7	54	55	O	be
8	57	65	O	carefully
9	67	75	O	monitored
10	77	79	O	for
11	81	81	O	a
12	83	88	O	change
13	90	91	O	in
14	93	107	O	pharmacological
15	109	114	O	effect
16	116	119	O	when
17	121	130	O	initiating
18	132	134	O	and
19	136	148	O	discontinuing
20	150	156	O	therapy
21	158	161	O	with
22	163	172	U-DYN	cimetidine
NULL

Diltiazem	DDI-DrugBank.d565.s16	NO_SECTION	NO_SETID	9
An adjustment in the diltiazem dose may be warranted.
1	0	1	O	An
2	3	12	O	adjustment
3	14	15	O	in
4	17	19	O	the
5	21	29	O	XXXXXXXX
6	31	34	O	dose
7	36	38	O	may
8	40	41	O	be
9	43	51	O	warranted
NULL

Diltiazem	DDI-DrugBank.d565.s18	NO_SECTION	NO_SETID	17
Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.
1	0	13	O	Administration
2	15	16	O	of
3	18	26	O	XXXXXXXX
4	28	40	O	hydrochloride
5	42	45	O	with
6	47	53	U-KIN	digoxin
7	55	56	O	in
8	58	59	O	24
9	61	67	O	healthy
10	69	72	O	male
11	74	81	O	subjects
12	83	91	O	increased
13	93	98	O	plasma
14	100	106	U-UNK	digoxin
15	108	121	O	concentrations
16	123	135	O	approximately
17	137	139	O	20%
NULL

Diltiazem	DDI-DrugBank.d565.s19	NO_SECTION	NO_SETID	15
Another investigator found no increase in digoxin levels in 12 patients with coronary artery disease.
1	0	6	O	Another
2	8	19	O	investigator
3	21	25	O	found
4	27	28	O	no
5	30	37	O	increase
6	39	40	O	in
7	42	48	U-UNK	digoxin
8	50	55	O	levels
9	57	58	O	in
10	60	61	O	12
11	63	70	O	patients
12	72	75	O	with
13	77	84	O	coronary
14	86	91	O	artery
15	93	99	O	disease
NULL

Diltiazem	DDI-DrugBank.d565.s20	NO_SECTION	NO_SETID	38
Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.
1	0	4	O	Since
2	6	10	O	there
3	12	15	O	have
4	17	20	O	been
5	22	32	O	conflicting
6	34	40	O	results
7	42	50	O	regarding
8	52	54	O	the
9	56	61	O	effect
10	63	64	O	of
11	66	72	U-UNK	digoxin
12	74	79	O	levels
13	80	80	O	,
14	82	83	O	it
15	85	86	O	is
16	88	98	O	recommended
17	100	103	O	that
18	105	111	U-DYN	digoxin
19	113	118	O	levels
20	120	121	O	be
21	123	131	O	monitored
22	133	136	O	when
23	138	147	O	initiating
24	148	148	O	,
25	150	158	O	adjusting
26	159	159	O	,
27	161	163	O	and
28	165	177	O	discontinuing
29	179	187	O	XXXXXXXX
30	189	201	O	hydrochloride
31	203	209	O	therapy
32	211	212	O	to
33	214	218	O	avoid
34	220	227	O	possible
35	229	232	O	over
36	235	236	O	or
37	238	242	O	under
38	244	257	O	digitalization
NULL

Diltiazem	DDI-DrugBank.d565.s22	NO_SECTION	NO_SETID	26
The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.
1	0	2	O	The
2	4	13	O	depression
3	15	16	O	of
4	18	24	O	cardiac
5	26	38	O	contractility
6	39	39	O	,
7	41	52	O	conductivity
8	53	53	O	,
9	55	57	O	and
10	59	70	O	automaticity
11	72	73	O	as
12	75	78	O	well
13	80	81	O	as
14	83	85	O	the
15	87	94	O	vascular
16	96	103	O	dilation
17	105	114	O	associated
18	116	119	O	with
19	121	131	U-UNK	anesthetics
20	133	135	O	may
21	137	138	O	be
22	140	150	O	potentiated
23	152	153	O	by
24	155	161	B-UNK	calcium
25	163	169	I-UNK	channel
26	171	178	L-UNK	blockers
NULL

Diltiazem	DDI-DrugBank.d565.s23	NO_SECTION	NO_SETID	13
When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.
1	0	3	O	When
2	5	8	O	used
3	10	22	O	concomitantly
4	23	23	O	,
5	25	35	U-UNK	anesthetics
6	37	39	O	and
7	41	47	B-UNK	calcium
8	49	55	I-UNK	channel
9	57	64	L-UNK	blockers
10	66	71	O	should
11	73	74	O	be
12	76	83	O	titrated
13	85	93	O	carefully
NULL

Diltiazem	DDI-DrugBank.d565.s25	NO_SECTION	NO_SETID	18
A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.
1	0	0	O	A
2	2	16	O	pharmacokinetic
3	18	28	O	interaction
4	30	36	O	between
5	38	46	O	XXXXXXXX
6	48	50	O	and
7	52	63	U-UNK	cyclosporine
8	65	67	O	has
9	69	72	O	been
10	74	81	O	observed
11	83	88	O	during
12	90	96	O	studies
13	98	106	O	involving
14	108	112	O	renal
15	114	116	O	and
16	118	124	O	cardiac
17	126	135	O	transplant
18	137	144	O	patients
NULL

Diltiazem	DDI-DrugBank.d565.s26	NO_SECTION	NO_SETID	34
In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.
1	0	1	O	In
2	3	7	O	renal
3	9	11	O	and
4	13	19	O	cardiac
5	21	30	O	transplant
6	32	41	O	recipients
7	42	42	O	,
8	44	44	O	a
9	46	54	O	reduction
10	56	57	O	of
11	59	70	U-KIN	cyclosporine
12	72	75	O	dose
13	77	83	O	ranging
14	85	88	O	from
15	90	92	O	15%
16	94	95	O	to
17	97	99	O	48%
18	101	103	O	was
19	105	113	O	necessary
20	115	116	O	to
21	118	125	O	maintain
22	127	138	U-UNK	cyclosporine
23	140	145	O	trough
24	147	160	O	concentrations
25	162	168	O	similar
26	170	171	O	to
27	173	177	O	those
28	179	182	O	seen
29	184	188	O	prior
30	190	191	O	to
31	193	195	O	the
32	197	204	O	addition
33	206	207	O	of
34	209	217	O	XXXXXXXX
NULL

Diltiazem	DDI-DrugBank.d565.s27	NO_SECTION	NO_SETID	26
If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.
1	0	1	O	If
2	3	7	O	these
3	9	14	O	agents
4	16	18	O	are
5	20	21	O	to
6	23	24	O	be
7	26	37	O	administered
8	39	50	O	concurrently
9	51	51	O	,
10	53	64	U-DYN	cyclosporine
11	66	79	O	concentrations
12	81	86	O	should
13	88	89	O	be
14	91	99	O	monitored
15	100	100	O	,
16	102	111	O	especially
17	113	116	O	when
18	118	126	O	XXXXXXXX
19	128	134	O	therapy
20	136	137	O	is
21	139	147	O	initiated
22	148	148	O	,
23	150	157	O	adjusted
24	158	158	O	,
25	160	161	O	or
26	163	174	O	discontinued
NULL

Diltiazem	DDI-DrugBank.d565.s28	NO_SECTION	NO_SETID	12
The effect of cyclosporine on diltiazem plasma concentrations has not been evaluated.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	25	U-UNK	cyclosporine
5	27	28	O	on
6	30	38	O	XXXXXXXX
7	40	45	O	plasma
8	47	60	O	concentrations
9	62	64	O	has
10	66	68	O	not
11	70	73	O	been
12	75	83	O	evaluated
NULL

Diltiazem	DDI-DrugBank.d565.s30	NO_SECTION	NO_SETID	28
Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	38	O	XXXXXXXX
5	40	43	O	with
6	45	57	U-KIN	carbamazepine
7	59	61	O	has
8	63	66	O	been
9	68	75	O	reported
10	77	78	O	to
11	80	85	O	result
12	87	88	O	in
13	90	97	O	elevated
14	99	103	O	serum
15	105	110	O	levels
16	112	113	O	of
17	115	127	U-UNK	carbamazepine
18	130	132	O	40%
19	134	135	O	to
20	137	139	O	72%
21	141	148	O	increase
22	150	150	O	,
23	152	160	O	resulting
24	162	163	O	in
25	165	172	O	toxicity
26	174	175	O	in
27	177	180	O	some
28	182	186	O	cases
NULL

Diltiazem	DDI-DrugBank.d565.s31	NO_SECTION	NO_SETID	13
Patients receiving these drugs concurrently should be monitored for a potential drug interaction.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	23	O	these
4	25	29	O	drugs
5	31	42	O	concurrently
6	44	49	O	should
7	51	52	O	be
8	54	62	O	monitored
9	64	66	O	for
10	68	68	O	a
11	70	78	O	potential
12	80	83	O	drug
13	85	95	O	interaction
NULL

Diltiazem	DDI-DrugBank.d565.s33	NO_SECTION	NO_SETID	25
Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.
1	0	6	O	Studies
2	8	13	O	showed
3	15	18	O	that
4	20	28	O	XXXXXXXX
5	30	38	O	increased
6	40	42	O	the
7	44	46	O	AUC
8	48	49	O	of
9	51	59	U-KIN	midazolam
10	61	63	O	and
11	65	73	U-KIN	triazolam
12	75	76	O	by
13	78	78	O	3
14	80	80	O	4
15	82	85	O	fold
16	87	89	O	and
17	91	93	O	the
18	95	98	O	Cmax
19	100	101	O	by
20	103	103	O	2
21	105	108	O	fold
22	109	109	O	,
23	111	118	O	compared
24	120	121	O	to
25	123	129	O	placebo
NULL

Diltiazem	DDI-DrugBank.d565.s34	NO_SECTION	NO_SETID	17
The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.
1	0	2	O	The
2	4	14	O	elimination
3	16	19	O	half
4	21	24	O	life
5	26	27	O	of
6	29	37	U-KIN	midazolam
7	39	41	O	and
8	43	51	U-KIN	triazolam
9	53	56	O	also
10	58	66	O	increased
11	69	71	O	1.5
12	73	75	O	2.5
13	77	80	O	fold
14	83	88	O	during
15	90	105	O	coadministration
16	107	110	O	with
17	112	120	O	XXXXXXXX
NULL

Diltiazem	DDI-DrugBank.d565.s35	NO_SECTION	NO_SETID	21
These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.
1	0	4	O	These
2	6	20	O	pharmacokinetic
3	22	28	O	effects
4	30	33	O	seen
5	35	40	O	during
6	42	50	O	XXXXXXXX
7	52	67	O	coadministration
8	69	71	O	can
9	73	78	O	result
10	80	81	O	in
11	83	91	O	increased
12	93	100	O	clinical
13	102	108	O	effects
14	111	113	O	e.g
15	115	115	O	,
16	117	125	O	prolonged
17	127	137	O	sodation)of
18	139	142	O	both
19	144	152	U-DYN	midazolam
20	154	156	O	and
21	158	166	U-DYN	triazolam
NULL

Diltiazem	DDI-DrugBank.d565.s37	NO_SECTION	NO_SETID	30
In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;
1	0	1	O	In
2	3	3	O	a
3	5	7	O	ten
4	9	15	O	subject
5	17	21	O	study
6	22	22	O	,
7	24	39	O	coadministration
8	41	42	O	of
9	44	52	O	XXXXXXXX
10	55	57	O	120
11	59	60	O	mg
12	62	64	O	bid
13	67	70	O	with
14	72	81	U-KIN	lovastatin
15	83	90	O	resulted
16	92	93	O	in
17	95	95	O	a
18	97	97	O	3
19	99	99	O	4
20	101	105	O	times
21	107	114	O	increase
22	116	117	O	in
23	119	122	O	mean
24	124	133	U-UNK	lovastatin
25	135	137	O	AUC
26	139	141	O	and
27	143	146	O	Cmax
28	148	149	O	vs
29	152	161	U-UNK	lovastatin
30	163	167	O	alone
NULL

Diltiazem	DDI-DrugBank.d565.s38	NO_SECTION	NO_SETID	12
no change in pravastatin AUC and Cmax was observed during diltiazem coadministration.
1	0	1	O	no
2	3	8	O	change
3	10	11	O	in
4	13	23	U-UNK	pravastatin
5	25	27	O	AUC
6	29	31	O	and
7	33	36	O	Cmax
8	38	40	O	was
9	42	49	O	observed
10	51	56	O	during
11	58	66	O	XXXXXXXX
12	68	83	O	coadministration
NULL

Diltiazem	DDI-DrugBank.d565.s39	NO_SECTION	NO_SETID	11
Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.
1	0	8	O	XXXXXXXX
2	10	15	O	plasma
3	17	22	O	levels
4	24	27	O	were
5	29	31	O	not
6	33	45	O	significantly
7	47	54	O	affected
8	56	57	O	by
9	59	68	U-UNK	lovastatin
10	70	71	O	or
11	73	83	U-UNK	pravastatin
NULL

Diltiazem	DDI-DrugBank.d565.s41	NO_SECTION	NO_SETID	13
Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	27	U-KIN	rifampin
4	29	32	O	with
5	34	42	O	XXXXXXXX
6	44	50	O	lowered
7	52	54	O	the
8	56	64	O	XXXXXXXX
9	66	71	O	plasma
10	73	86	O	concentrations
11	88	89	O	to
12	91	102	O	undetectable
13	104	109	O	levels
NULL

Diltiazem	DDI-DrugBank.d565.s42	NO_SECTION	NO_SETID	20
Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	28	O	XXXXXXXX
4	30	33	O	with
5	35	42	U-DYN	rifampin
6	44	45	O	or
7	47	49	O	any
8	51	55	O	known
9	57	62	O	CYP3A4
10	64	70	O	inducer
11	72	77	O	should
12	79	80	O	be
13	82	88	O	avoided
14	90	93	O	when
15	95	102	O	possible
16	103	103	O	,
17	105	107	O	and
18	109	119	O	alternative
19	121	127	O	therapy
20	129	138	O	considered
NULL

Dimenhydrinate	DDI-DrugBank.d96.s0	NO_SECTION	NO_SETID	7
Dimenhydrinate may decrease emetic response to apomorphine.
1	0	13	O	XXXXXXXX
2	15	17	O	may
3	19	26	O	decrease
4	28	33	U-UNK	emetic
5	35	42	O	response
6	44	45	O	to
7	47	57	U-DYN	apomorphine
NULL

Dinoprost Tromethamine	DDI-DrugBank.d181.s0	NO_SECTION	NO_SETID	30
Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;
1	0	7	U-UNK	Oxytocin
2	9	10	O	or
3	12	16	O	other
4	18	26	U-UNK	oxytocics
5	29	38	O	concurrent
6	40	42	O	use
7	44	47	O	with
8	49	57	U-UNK	dinoprost
9	59	61	O	may
10	63	68	O	result
11	70	71	O	in
12	73	79	O	uterine
13	81	90	O	hypertonus
14	91	91	O	,
15	93	100	O	possibly
16	102	108	O	causing
17	110	116	O	uterine
18	118	124	O	rupture
19	126	127	O	or
20	129	136	O	cervical
21	138	147	O	laceration
22	148	148	O	,
23	150	159	O	especially
24	161	162	O	in
25	164	166	O	the
26	168	174	O	absence
27	176	177	O	of
28	179	186	O	adequate
29	188	195	O	cervical
30	197	206	O	dilatation
NULL

Dinoprost Tromethamine	DDI-DrugBank.d181.s1	NO_SECTION	NO_SETID	18
although combinations are sometimes used for therapeutic advantage, when used concurrently, patient should be closely monitored.
1	0	7	O	although
2	9	20	O	combinations
3	22	24	O	are
4	26	34	O	sometimes
5	36	39	O	used
6	41	43	O	for
7	45	55	O	therapeutic
8	57	65	O	advantage
9	66	66	O	,
10	68	71	O	when
11	73	76	O	used
12	78	89	O	concurrently
13	90	90	O	,
14	92	98	O	patient
15	100	105	O	should
16	107	108	O	be
17	110	116	O	closely
18	118	126	O	monitored
NULL

Dinoprostone	DDI-DrugBank.d2.s0	NO_SECTION	NO_SETID	9
PROSTIN E2 may augment the activity of other oxytocic drugs.
1	0	9	O	XXXXXXXX
2	11	13	O	may
3	15	21	O	augment
4	23	25	O	the
5	27	34	O	activity
6	36	37	O	of
7	39	43	O	other
8	45	52	B-DYN	oxytocic
9	54	58	L-DYN	drugs
NULL

Dinoprostone	DDI-DrugBank.d2.s1	NO_SECTION	NO_SETID	9
Concomitant use with other oxytocic agents is not recommended.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	19	O	with
4	21	25	O	other
5	27	34	B-UNK	oxytocic
6	36	41	L-UNK	agents
7	43	44	O	is
8	46	48	O	not
9	50	60	O	recommended
NULL

Diphenhydramine	DDI-DrugBank.d296.s0	NO_SECTION	NO_SETID	18
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
1	0	14	O	XXXXXXXX
2	16	28	O	hydrochloride
3	30	32	O	has
4	34	41	O	additive
5	43	49	O	effects
6	51	54	O	with
7	56	62	U-DYN	alcohol
8	64	66	O	and
9	68	72	O	other
10	74	76	B-DYN	CNS
11	78	88	L-DYN	depressants
12	91	99	U-DYN	hypnotics
13	100	100	O	,
14	102	110	U-DYN	sedatives
15	111	111	O	,
16	113	125	U-DYN	tranquilizers
17	126	126	O	,
18	128	130	O	etc
NULL

Diphenhydramine	DDI-DrugBank.d296.s1	NO_SECTION	NO_SETID	11
MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.
1	0	2	B-UNK	MAO
2	4	13	L-UNK	inhibitors
3	15	21	O	prolong
4	23	25	O	and
5	27	35	O	intensify
6	37	39	O	the
7	41	55	O	anticholinergic
8	58	63	O	drying
9	66	72	O	effects
10	74	75	O	of
11	77	90	U-UNK	antihistamines
NULL

Diphenidol	DDI-DrugBank.d120.s0	NO_SECTION	NO_SETID	16
CNS depression producing medications - concurrent use may potentiate the effects of either these medications or diphenidol;
1	0	2	O	CNS
2	4	13	O	depression
3	15	23	O	producing
4	25	35	O	medications
5	39	48	O	concurrent
6	50	52	O	use
7	54	56	O	may
8	58	67	O	potentiate
9	69	71	O	the
10	73	79	O	effects
11	81	82	O	of
12	84	89	O	either
13	91	95	O	these
14	97	107	O	medications
15	109	110	O	or
16	112	121	O	XXXXXXXX
NULL

Diphenidol	DDI-DrugBank.d120.s1	NO_SECTION	NO_SETID	20
anticholinergics or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with diphenidol;
1	0	15	U-UNK	anticholinergics
2	17	18	O	or
3	20	24	O	other
4	26	36	O	medications
5	38	41	O	with
6	43	57	O	anticholinergic
7	59	66	O	activity
8	70	84	O	anticholinergic
9	86	92	O	effects
10	94	96	O	may
11	98	99	O	be
12	101	111	O	potentiated
13	113	116	O	when
14	118	122	O	these
15	124	134	O	medications
16	136	138	O	are
17	140	143	O	used
18	145	156	O	concurrently
19	158	161	O	with
20	163	172	O	XXXXXXXX
NULL

Diphenidol	DDI-DrugBank.d120.s2	NO_SECTION	NO_SETID	17
apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.
1	0	10	U-UNK	apomorphine
2	14	18	O	prior
3	20	28	O	ingestion
4	30	31	O	of
5	33	42	O	XXXXXXXX
6	44	46	O	may
7	48	55	O	decrease
8	57	59	O	the
9	61	66	U-UNK	emetic
10	68	75	O	response
11	77	78	O	to
12	80	90	U-DYN	apomorphine
13	92	93	O	in
14	95	97	O	the
15	99	107	O	treatment
16	109	110	O	of
17	112	120	O	poisoning
NULL

Diphenoxylate	DDI-DrugBank.d538.s0	NO_SECTION	NO_SETID	10
Known drug interactions include barbiturates, tranquilizers, and alcohol.
1	0	4	O	Known
2	6	9	O	drug
3	11	22	O	interactions
4	24	30	O	include
5	32	43	U-UNK	barbiturates
6	44	44	O	,
7	46	58	U-UNK	tranquilizers
8	59	59	O	,
9	61	63	O	and
10	65	71	U-UNK	alcohol
NULL

Diphenoxylate	DDI-DrugBank.d538.s1	NO_SECTION	NO_SETID	37
Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.
1	0	12	O	XXXXXXXX
2	14	16	O	HCl
3	18	20	O	and
4	22	29	B-UNK	atropine
5	31	37	L-UNK	sulfate
6	39	41	O	may
7	43	50	O	interact
8	52	55	O	with
9	57	59	B-UNK	MAO
10	61	70	L-UNK	inhibitors
11	72	73	O	In
12	75	81	O	studies
13	83	86	O	with
14	88	91	O	male
15	93	96	O	rats
16	97	97	O	,
17	99	111	O	XXXXXXXX
18	113	125	O	hydrochloride
19	127	129	O	was
20	131	135	O	found
21	137	138	O	to
22	140	146	O	inhibit
23	148	150	O	the
24	152	158	O	hepatic
25	160	169	O	microsomal
26	171	176	O	enzyme
27	178	183	O	system
28	185	186	O	at
29	188	188	O	a
30	190	193	O	dose
31	195	196	O	of
32	198	198	O	2
33	200	201	O	mg
34	202	202	O	/
35	203	204	O	kg
36	205	205	O	/
37	206	208	O	day
NULL

Diphenoxylate	DDI-DrugBank.d538.s2	NO_SECTION	NO_SETID	29
Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system.
1	0	8	O	Therefore
2	9	9	O	,
3	11	23	O	XXXXXXXX
4	25	27	O	has
5	29	31	O	the
6	33	41	O	potential
7	43	44	O	to
8	46	52	O	prolong
9	54	56	O	the
10	58	67	O	biological
11	69	72	O	half
12	74	78	O	lives
13	80	81	O	of
14	83	87	O	drugs
15	89	91	O	for
16	93	97	O	which
17	99	101	O	the
18	103	106	O	rate
19	108	109	O	of
20	111	121	O	elimination
21	123	124	O	is
22	126	134	O	dependent
23	136	137	O	on
24	139	141	O	the
25	143	152	O	microsomal
26	154	157	O	drug
27	159	170	O	metabolizing
28	172	177	O	enzyme
29	179	184	O	system
NULL

Diphenylpyraline	DDI-DrugBank.d168.s0	NO_SECTION	NO_SETID	65
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
1	0	3	O	This
2	5	8	O	drug
3	10	12	O	may
4	14	21	O	interact
5	23	26	O	with
6	28	34	U-UNK	alcohol
7	36	37	O	or
8	39	43	O	other
9	45	47	B-UNK	CNS
10	49	59	L-UNK	depressants
11	62	64	O	may
12	66	75	O	potentiate
13	77	79	O	the
14	81	83	O	CNS
15	85	94	O	depressant
16	96	102	O	effects
17	104	105	O	of
18	107	112	O	either
19	114	118	O	these
20	120	130	O	medications
21	132	133	O	or
22	135	148	U-UNK	antihistamines
23	150	150	O	,
24	152	167	U-UNK	anticholinergics
25	169	170	O	or
26	172	176	O	other
27	178	188	O	medications
28	190	193	O	with
29	195	209	O	anticholinergic
30	211	218	O	activity
31	221	235	O	anticholinergic
32	237	243	O	effects
33	245	247	O	may
34	249	250	O	be
35	252	262	O	potentiated
36	264	267	O	when
37	269	273	O	these
38	275	285	O	medications
39	287	289	O	are
40	291	294	O	used
41	296	307	O	concurrently
42	309	312	O	with
43	314	327	U-UNK	antihistamines
44	329	329	O	,
45	331	333	O	and
46	335	343	B-UNK	monoamine
47	345	351	I-UNK	oxidase
48	354	356	I-UNK	MAO
49	359	368	L-UNK	inhibitors
50	371	380	O	concurrent
51	382	384	O	use
52	386	389	O	with
53	391	404	U-UNK	antihistamines
54	406	408	O	may
55	410	416	O	prolong
56	418	420	O	and
57	422	430	O	intensify
58	432	434	O	the
59	436	450	O	anticholinergic
60	452	454	O	and
61	456	458	O	CNS
62	460	469	O	depressant
63	471	477	O	effects
64	479	480	O	of
65	482	495	U-UNK	antihistamines
NULL

Dipyridamole	DDI-DrugBank.d505.s0	NO_SECTION	NO_SETID	13
No pharmacokinetic drug-drug interaction studies were conducted with PERSANTINE  (dipyridamole USP) Tablets.
1	0	1	O	No
2	3	17	O	pharmacokinetic
3	19	22	O	drug
4	24	27	O	drug
5	29	39	O	interaction
6	41	47	O	studies
7	49	52	O	were
8	54	62	O	conducted
9	64	67	O	with
10	69	78	O	XXXXXXXX
11	82	93	U-UNK	dipyridamole
12	95	97	O	USP
13	100	106	O	Tablets
NULL

Dipyridamole	DDI-DrugBank.d505.s1	NO_SECTION	NO_SETID	8
The following information was obtained from the literature.
1	0	2	O	The
2	4	12	O	following
3	14	24	O	information
4	26	28	O	was
5	30	37	O	obtained
6	39	42	O	from
7	44	46	O	the
8	48	57	O	literature
NULL

Dipyridamole	DDI-DrugBank.d505.s2	NO_SECTION	NO_SETID	16
Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.
1	0	8	U-UNK	Adenosine
2	9	9	O	:
3	11	22	O	XXXXXXXX
4	24	26	O	has
5	28	31	O	been
6	33	40	O	reported
7	42	43	O	to
8	45	52	O	increase
9	54	56	O	the
10	58	63	O	plasma
11	65	70	O	levels
12	72	74	O	and
13	76	89	O	cardiovascular
14	91	97	O	effects
15	99	100	O	of
16	102	110	U-KIN	adenosine
NULL

Dipyridamole	DDI-DrugBank.d505.s3	NO_SECTION	NO_SETID	7
Adjustment of adenosine dosage may be necessary.
1	0	9	O	Adjustment
2	11	12	O	of
3	14	22	U-UNK	adenosine
4	24	29	O	dosage
5	31	33	O	may
6	35	36	O	be
7	38	46	O	necessary
NULL

Dipyridamole	DDI-DrugBank.d505.s4	NO_SECTION	NO_SETID	18
Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.
1	0	13	B-UNK	Cholinesterase
2	15	24	L-UNK	Inhibitors
3	25	25	O	:
4	27	38	O	XXXXXXXX
5	40	42	O	may
6	44	53	O	counteract
7	55	57	O	the
8	59	76	O	anticholinesterase
9	78	83	O	effect
10	85	86	O	of
11	88	101	B-DYN	cholinesterase
12	103	112	L-DYN	inhibitors
13	113	113	O	,
14	115	121	O	thereby
15	123	133	O	potentially
16	135	145	O	aggravating
17	147	156	O	myasthenia
18	158	163	O	gravis
NULL

Dirithromycin	DDI-DrugBank.d522.s0	NO_SECTION	NO_SETID	20
Terfenadine: In a prospective study involving six-healthy-male volunteers, dirithromycin did not affect the metabolism of terfenadine.
1	0	10	U-UNK	Terfenadine
2	11	11	O	:
3	13	14	O	In
4	16	16	O	a
5	18	28	O	prospective
6	30	34	O	study
7	36	44	O	involving
8	46	48	O	six
9	50	56	O	healthy
10	58	61	O	male
11	63	72	O	volunteers
12	73	73	O	,
13	75	87	O	XXXXXXXX
14	89	91	O	did
15	93	95	O	not
16	97	102	O	affect
17	104	106	O	the
18	108	117	O	metabolism
19	119	120	O	of
20	122	132	U-UNK	terfenadine
NULL

Dirithromycin	DDI-DrugBank.d522.s1	NO_SECTION	NO_SETID	28
These six volunteers received terfenadine alone (60 mg twice daily) for 8 days, followed by terfenadine in combination with dirithromycin (500 mg once daily) for 10 days.
1	0	4	O	These
2	6	8	O	six
3	10	19	O	volunteers
4	21	28	O	received
5	30	40	U-UNK	terfenadine
6	42	46	O	alone
7	49	50	O	60
8	52	53	O	mg
9	55	59	O	twice
10	61	65	O	daily
11	68	70	O	for
12	72	72	O	8
13	74	77	O	days
14	78	78	O	,
15	80	87	O	followed
16	89	90	O	by
17	92	102	U-UNK	terfenadine
18	104	105	O	in
19	107	117	O	combination
20	119	122	O	with
21	124	136	O	XXXXXXXX
22	139	141	O	500
23	143	144	O	mg
24	146	149	O	once
25	151	155	O	daily
26	158	160	O	for
27	162	163	O	10
28	165	168	O	days
NULL

Dirithromycin	DDI-DrugBank.d522.s2	NO_SECTION	NO_SETID	8
(Both drugs were thus dosed to steady state.)
1	1	4	O	Both
2	6	10	O	drugs
3	12	15	O	were
4	17	20	O	thus
5	22	26	O	dosed
6	28	29	O	to
7	31	36	O	steady
8	38	42	O	state
NULL

Dirithromycin	DDI-DrugBank.d522.s3	NO_SECTION	NO_SETID	29
The pharmacokinetics of terfenadine and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with terfenadine alone, and with terfenadine plus dirithromycin.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	34	U-UNK	terfenadine
5	36	38	O	and
6	40	42	O	its
7	44	47	O	acid
8	49	58	O	metabolite
9	60	62	O	and
10	64	66	O	the
11	68	87	O	electrocardiographic
12	89	90	O	QT
13	92	92	O	c
14	94	101	O	interval
15	103	106	O	were
16	108	115	O	measured
17	117	122	O	during
18	124	127	O	both
19	129	135	O	periods
20	136	136	O	:
21	138	141	O	with
22	143	153	U-UNK	terfenadine
23	155	159	O	alone
24	160	160	O	,
25	162	164	O	and
26	166	169	O	with
27	171	181	U-UNK	terfenadine
28	183	186	O	plus
29	188	200	O	XXXXXXXX
NULL

Dirithromycin	DDI-DrugBank.d522.s4	NO_SECTION	NO_SETID	15
In five men, terfenadine levels were undetectable ( 5 ng/mL) throughout the study;
1	0	1	O	In
2	3	6	O	five
3	8	10	O	men
4	11	11	O	,
5	13	23	U-UNK	terfenadine
6	25	30	O	levels
7	32	35	O	were
8	37	48	O	undetectable
9	52	52	O	5
10	54	55	O	ng
11	56	56	O	/
12	57	58	O	mL
13	61	70	O	throughout
14	72	74	O	the
15	76	80	O	study
NULL

Dirithromycin	DDI-DrugBank.d522.s5	NO_SECTION	NO_SETID	26
in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.
1	0	1	O	in
2	3	5	O	one
3	7	9	O	man
4	10	10	O	,
5	12	14	O	the
6	16	16	O	C
7	18	20	O	max
8	22	23	O	of
9	25	35	U-UNK	terfenadine
10	37	39	O	was
11	41	43	O	8.1
12	45	46	O	ng
13	47	47	O	/
14	48	49	O	mL
15	51	54	O	with
16	56	66	U-UNK	terfenadine
17	68	72	O	alone
18	74	76	O	and
19	78	80	O	7.2
20	82	83	O	ng
21	84	84	O	/
22	85	86	O	mL
23	88	91	O	with
24	93	103	U-KIN	terfenadine
25	105	108	O	plus
26	110	122	O	XXXXXXXX
NULL

Dirithromycin	DDI-DrugBank.d522.s6	NO_SECTION	NO_SETID	20
The mean C max , T max , and AUC of the acid metabolite of terfenadine were not significantly changed.
1	0	2	O	The
2	4	7	O	mean
3	9	9	O	C
4	11	13	O	max
5	15	15	O	,
6	17	17	O	T
7	19	21	O	max
8	23	23	O	,
9	25	27	O	and
10	29	31	O	AUC
11	33	34	O	of
12	36	38	O	the
13	40	43	O	acid
14	45	54	O	metabolite
15	56	57	O	of
16	59	69	U-UNK	terfenadine
17	71	74	O	were
18	76	78	O	not
19	80	92	O	significantly
20	94	100	O	changed
NULL

Dirithromycin	DDI-DrugBank.d522.s7	NO_SECTION	NO_SETID	17
The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.
1	0	2	O	The
2	4	7	O	mean
3	9	10	O	QT
4	12	12	O	c
5	14	21	O	interval
6	24	27	O	msec
7	30	32	O	was
8	34	36	O	369
9	38	41	O	with
10	43	53	U-UNK	terfenadine
11	55	59	O	alone
12	61	63	O	and
13	65	67	O	367
14	69	72	O	with
15	74	84	U-DYN	terfenadine
16	86	89	O	plus
17	91	103	O	XXXXXXXX
NULL

Dirithromycin	DDI-DrugBank.d522.s8	NO_SECTION	NO_SETID	14
Also, in vitro experiments demonstrated a lack of interaction between dirithromycin and terfenadine.
1	0	3	O	Also
2	4	4	O	,
3	6	7	O	in
4	9	13	O	vitro
5	15	25	O	experiments
6	27	38	O	demonstrated
7	40	40	O	a
8	42	45	O	lack
9	47	48	O	of
10	50	60	O	interaction
11	62	68	O	between
12	70	82	O	XXXXXXXX
13	84	86	O	and
14	88	98	U-UNK	terfenadine
NULL

Dirithromycin	DDI-DrugBank.d522.s9	NO_SECTION	NO_SETID	14
Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.
1	0	3	O	Thus
2	4	4	O	,
3	6	8	O	the
4	10	20	O	interaction
5	22	29	O	observed
6	31	37	O	between
7	39	50	U-UNK	erythromycin
8	52	54	O	and
9	56	66	U-UNK	terfenadine
10	68	69	O	is
11	71	73	O	not
12	75	82	O	expected
13	84	86	O	for
14	88	100	O	XXXXXXXX
NULL

Dirithromycin	DDI-DrugBank.d522.s10	NO_SECTION	NO_SETID	20
Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.
1	0	6	O	Serious
2	8	14	O	cardiac
3	16	27	O	dysrhythmias
4	28	28	O	,
5	30	33	O	some
6	35	43	O	resulting
7	45	46	O	in
8	48	52	O	death
9	53	53	O	,
10	55	58	O	have
11	60	67	O	occurred
12	69	70	O	in
13	72	79	O	patients
14	81	89	O	receiving
15	91	101	U-UNK	terfenadine
16	103	115	O	concomitantly
17	117	120	O	with
18	122	126	O	other
19	128	136	B-UNK	macrolide
20	138	148	L-UNK	antibiotics
NULL

Dirithromycin	DDI-DrugBank.d522.s11	NO_SECTION	NO_SETID	39
In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	16	O	most
5	18	27	U-UNK	macrolides
6	29	31	O	are
7	33	47	O	contraindicated
8	49	50	O	in
9	52	59	O	patients
10	61	69	O	receiving
11	71	81	U-UNK	terfenadine
12	83	89	O	therapy
13	91	93	O	who
14	95	98	O	have
15	100	102	O	pre
16	104	111	O	existing
17	113	119	O	cardiac
18	121	133	O	abnormalities
19	136	145	O	arrhythmia
20	146	146	O	,
21	148	158	O	bradycardia
22	159	159	O	,
23	161	162	O	QT
24	164	164	O	c
25	166	173	O	interval
26	175	186	O	prolongation
27	187	187	O	,
28	189	196	O	ischemic
29	198	202	O	heart
30	204	210	O	disease
31	211	211	O	,
32	213	222	O	congestive
33	224	228	O	heart
34	230	236	O	failure
35	237	237	O	,
36	239	241	O	etc
37	245	246	O	or
38	248	258	O	electrolyte
39	260	271	O	disturbances
NULL

Dirithromycin	DDI-DrugBank.d522.s12	NO_SECTION	NO_SETID	41
Theophylline: Following co-administration of two 250-mg dirithromycin tablets administered once daily with 200-mg theophylline tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.
1	0	11	U-UNK	Theophylline
2	12	12	O	:
3	14	22	O	Following
4	24	25	O	co
5	27	40	O	administration
6	42	43	O	of
7	45	47	O	two
8	49	51	O	250
9	53	54	O	mg
10	56	68	O	XXXXXXXX
11	70	76	O	tablets
12	78	89	O	administered
13	91	94	O	once
14	96	100	O	daily
15	102	105	O	with
16	107	109	O	200
17	111	112	O	mg
18	114	125	U-UNK	theophylline
19	127	133	O	tablets
20	135	146	O	administered
21	148	152	O	twice
22	154	158	O	daily
23	160	162	O	for
24	164	165	O	10
25	167	170	O	days
26	172	173	O	to
27	175	176	O	14
28	178	184	O	healthy
29	186	193	O	subjects
30	194	194	O	,
31	196	198	O	the
32	200	205	O	steady
33	207	211	O	state
34	213	218	O	plasma
35	220	232	O	concentration
36	234	235	O	of
37	237	248	U-UNK	theophylline
38	250	252	O	was
39	254	256	O	not
40	258	270	O	significantly
41	272	278	O	altered
NULL

Dirithromycin	DDI-DrugBank.d522.s13	NO_SECTION	NO_SETID	28
In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.
1	0	1	O	In
2	3	9	O	general
3	10	10	O	,
4	12	15	O	most
5	17	24	O	patients
6	26	32	O	treated
7	34	37	O	with
8	39	51	O	XXXXXXXX
9	53	55	O	who
10	57	59	O	are
11	61	69	O	receiving
12	71	81	O	concomitant
13	83	94	U-UNK	theophylline
14	96	102	O	therapy
15	104	106	O	may
16	108	110	O	not
17	112	118	O	require
18	120	126	O	empiric
19	128	137	O	adjustment
20	139	140	O	of
21	142	153	U-UNK	theophylline
22	155	160	O	dosage
23	162	163	O	or
24	165	174	O	monitoring
25	176	177	O	of
26	179	190	U-UNK	theophylline
27	192	197	O	plasma
28	199	212	O	concentrations
NULL

Dirithromycin	DDI-DrugBank.d522.s14	NO_SECTION	NO_SETID	45
However, theophylline plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given theophylline plasma concentration for optimal pulmonary function or in patients with theophylline concentrations at the higher end of the therapeutic range.
1	0	6	O	However
2	7	7	O	,
3	9	20	U-UNK	theophylline
4	22	27	O	plasma
5	29	42	O	concentrations
6	44	49	O	should
7	51	52	O	be
8	54	62	O	monitored
9	63	63	O	,
10	65	68	O	with
11	70	75	O	dosage
12	77	86	O	adjustment
13	88	89	O	as
14	91	101	O	appropriate
15	102	102	O	,
16	104	105	O	in
17	107	114	O	patients
18	116	120	O	whose
19	122	130	O	pulmonary
20	132	138	O	disease
21	140	147	O	requires
22	149	159	O	maintaining
23	161	161	O	a
24	163	167	O	given
25	169	180	U-UNK	theophylline
26	182	187	O	plasma
27	189	201	O	concentration
28	203	205	O	for
29	207	213	O	optimal
30	215	223	O	pulmonary
31	225	232	O	function
32	234	235	O	or
33	237	238	O	in
34	240	247	O	patients
35	249	252	O	with
36	254	265	U-UNK	theophylline
37	267	280	O	concentrations
38	282	283	O	at
39	285	287	O	the
40	289	294	O	higher
41	296	298	O	end
42	300	301	O	of
43	303	305	O	the
44	307	317	O	therapeutic
45	319	323	O	range
NULL

Dirithromycin	DDI-DrugBank.d522.s15	NO_SECTION	NO_SETID	27
Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.
1	0	7	U-UNK	Antacids
2	9	10	O	or
3	12	12	B-UNK	H
4	14	14	I-UNK	2
5	16	23	I-UNK	receptor
6	25	35	L-UNK	antagonists
7	36	36	O	:
8	38	41	O	When
9	43	55	O	XXXXXXXX
10	57	58	O	is
11	60	71	O	administered
12	73	83	O	immediately
13	85	93	O	following
14	95	102	U-KIN	antacids
15	104	105	O	or
16	107	107	B-KIN	H
17	109	109	I-KIN	2
18	112	119	I-KIN	receptor
19	121	131	L-KIN	antagonists
20	132	132	O	,
21	134	136	O	the
22	138	147	O	absorption
23	149	150	O	of
24	152	164	O	XXXXXXXX
25	166	167	O	is
26	169	176	O	slightly
27	178	185	O	enhanced
NULL

Dirithromycin	DDI-DrugBank.d522.s16	NO_SECTION	NO_SETID	10
The following drug interactions have been reported with erythromycin products.
1	0	2	O	The
2	4	12	O	following
3	14	17	O	drug
4	19	30	O	interactions
5	32	35	O	have
6	37	40	O	been
7	42	49	O	reported
8	51	54	O	with
9	56	67	U-UNK	erythromycin
10	69	76	O	products
NULL

Dirithromycin	DDI-DrugBank.d522.s17	NO_SECTION	NO_SETID	13
It is presently not known whether these same drug interactions occur with dirithromycin.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	presently
4	16	18	O	not
5	20	24	O	known
6	26	32	O	whether
7	34	38	O	these
8	40	43	O	same
9	45	48	O	drug
10	50	61	O	interactions
11	63	67	O	occur
12	69	72	O	with
13	74	86	O	XXXXXXXX
NULL

Dirithromycin	DDI-DrugBank.d522.s18	NO_SECTION	NO_SETID	21
Until further data are available regarding the potential interaction of dirithromycin with these compounds, caution should be used during coadministration.
1	0	4	O	Until
2	6	12	O	further
3	14	17	O	data
4	19	21	O	are
5	23	31	O	available
6	33	41	O	regarding
7	43	45	O	the
8	47	55	O	potential
9	57	67	O	interaction
10	69	70	O	of
11	72	84	O	XXXXXXXX
12	86	89	O	with
13	91	95	O	these
14	97	105	O	compounds
15	106	106	O	,
16	108	114	O	caution
17	116	121	O	should
18	123	124	O	be
19	126	129	O	used
20	131	136	O	during
21	138	153	O	coadministration
NULL

Dirithromycin	DDI-DrugBank.d522.s19	NO_SECTION	NO_SETID	23
Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.
1	0	8	U-UNK	Triazolam
2	9	9	O	:
3	11	22	U-UNK	Erythromycin
4	24	26	O	has
5	28	31	O	been
6	33	40	O	reported
7	42	43	O	to
8	45	52	O	decrease
9	54	56	O	the
10	58	66	O	clearance
11	68	69	O	of
12	71	79	U-UNK	triazolam
13	81	83	O	and
14	84	84	O	,
15	86	89	O	thus
16	90	90	O	,
17	92	94	O	may
18	96	103	O	increase
19	105	107	O	the
20	109	121	O	pharmacologic
21	123	128	O	effect
22	130	131	O	of
23	133	141	U-UNK	triazolam
NULL

Dirithromycin	DDI-DrugBank.d522.s20	NO_SECTION	NO_SETID	18
Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	19	O	Concomitant
4	21	34	O	administration
5	36	37	O	of
6	39	50	U-UNK	erythromycin
7	52	54	O	and
8	56	62	U-UNK	digoxin
9	64	66	O	has
10	68	71	O	been
11	73	80	O	reported
12	82	83	O	to
13	85	90	O	result
14	92	93	O	in
15	95	102	O	elevated
16	104	110	U-UNK	digoxin
17	112	116	O	serum
18	118	123	O	levels
NULL

Dirithromycin	DDI-DrugBank.d522.s21	NO_SECTION	NO_SETID	18
Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
1	0	13	U-UNK	Anticoagulants
2	14	14	O	:
3	16	20	O	There
4	22	25	O	have
5	27	30	O	been
6	32	38	O	reports
7	40	41	O	of
8	43	51	O	increased
9	53	65	O	anticoagulant
10	67	73	O	effects
11	75	78	O	when
12	80	91	U-UNK	erythromycin
13	93	95	O	and
14	97	100	O	oral
15	102	115	U-UNK	anticoagulants
16	117	120	O	were
17	122	125	O	used
18	127	139	O	concomitantly
NULL

Dirithromycin	DDI-DrugBank.d522.s22	NO_SECTION	NO_SETID	17
Increased anticoagulation effects due to a drug interaction with erythromycin may be more pronounced in the elderly.
1	0	8	O	Increased
2	10	24	O	anticoagulation
3	26	32	O	effects
4	34	36	O	due
5	38	39	O	to
6	41	41	O	a
7	43	46	O	drug
8	48	58	O	interaction
9	60	63	O	with
10	65	76	U-UNK	erythromycin
11	78	80	O	may
12	82	83	O	be
13	85	88	O	more
14	90	99	O	pronounced
15	101	102	O	in
16	104	106	O	the
17	108	114	O	elderly
NULL

Dirithromycin	DDI-DrugBank.d522.s23	NO_SECTION	NO_SETID	27
Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
1	0	9	U-UNK	Ergotamine
2	10	10	O	:
3	12	21	O	Concurrent
4	23	25	O	use
5	27	28	O	of
6	30	41	U-UNK	erythromycin
7	43	45	O	and
8	47	56	U-UNK	ergotamine
9	58	59	O	or
10	61	77	U-UNK	dihydroergotamine
11	79	81	O	has
12	83	86	O	been
13	88	97	O	associated
14	99	100	O	in
15	102	105	O	some
16	107	114	O	patients
17	116	119	O	with
18	121	125	O	acute
19	127	131	O	ergot
20	133	140	O	toxicity
21	142	154	O	characterized
22	156	157	O	by
23	159	164	O	severe
24	166	175	O	peripheral
25	177	185	O	vasospasm
26	187	189	O	and
27	191	201	O	dysesthesia
NULL

Dirithromycin	DDI-DrugBank.d522.s24	NO_SECTION	NO_SETID	37
Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
1	0	4	O	Other
2	6	10	O	drugs
3	12	15	O	Drug
4	17	28	O	interactions
5	30	33	O	have
6	35	38	O	been
7	40	47	O	reported
8	49	52	O	with
9	54	64	O	concomitant
10	66	79	O	administration
11	81	82	O	of
12	84	95	U-UNK	erythromycin
13	97	99	O	and
14	101	105	O	other
15	107	117	O	medications
16	118	118	O	,
17	120	128	O	including
18	130	141	U-UNK	cyclosporine
19	142	142	O	,
20	144	155	U-UNK	hexobarbital
21	156	156	O	,
22	158	170	U-UNK	carbamazepine
23	171	171	O	,
24	173	182	U-UNK	alfentanil
25	183	183	O	,
26	185	196	U-UNK	disopyramide
27	197	197	O	,
28	199	207	U-UNK	phenytoin
29	208	208	O	,
30	210	222	U-UNK	bromocriptine
31	223	223	O	,
32	225	233	U-UNK	valproate
33	234	234	O	,
34	236	245	U-UNK	astemizole
35	246	246	O	,
36	248	250	O	and
37	252	261	U-UNK	lovastatin
NULL

Disopyramide	DDI-DrugBank.d506.s0	NO_SECTION	NO_SETID	22
If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.
1	0	1	O	If
2	3	11	U-KIN	phenytoin
3	13	14	O	or
4	16	20	O	other
5	22	28	O	hepatic
6	30	35	O	enzyme
7	37	44	O	inducers
8	46	48	O	are
9	50	54	O	taken
10	56	67	O	concurrently
11	69	72	O	with
12	74	80	O	Norpace
13	82	83	O	or
14	85	94	O	XXXXXXXX
15	95	95	O	,
16	97	101	O	lower
17	103	108	O	plasma
18	110	115	O	levels
19	117	118	O	of
20	120	131	U-UNK	disopyramide
21	133	135	O	may
22	137	141	O	occur
NULL

Disopyramide	DDI-DrugBank.d506.s1	NO_SECTION	NO_SETID	15
Monitoring of disopyramide plasma levels is recommended in such concurrent use to avoid ineffective therapy.
1	0	9	O	Monitoring
2	11	12	O	of
3	14	25	O	XXXXXXXX
4	27	32	O	plasma
5	34	39	O	levels
6	41	42	O	is
7	44	54	O	recommended
8	56	57	O	in
9	59	62	O	such
10	64	73	O	concurrent
11	75	77	O	use
12	79	80	O	to
13	82	86	O	avoid
14	88	98	O	ineffective
15	100	106	O	therapy
NULL

Disopyramide	DDI-DrugBank.d506.s2	NO_SECTION	NO_SETID	19
Other antiarrhythmic drugs (eg, quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace.
1	0	4	O	Other
2	6	19	B-UNK	antiarrhythmic
3	21	25	L-UNK	drugs
4	28	29	O	eg
5	30	30	O	,
6	32	40	U-UNK	quinidine
7	41	41	O	,
8	43	54	U-UNK	procainamide
9	55	55	O	,
10	57	65	U-UNK	lidocaine
11	66	66	O	,
12	68	78	U-UNK	propranolol
13	81	84	O	have
14	86	97	O	occasionally
15	99	102	O	been
16	104	107	O	used
17	109	120	O	concurrently
18	122	125	O	with
19	127	133	O	XXXXXXXX
NULL

Disopyramide	DDI-DrugBank.d506.s3	NO_SECTION	NO_SETID	20
Excessive widening of the QRS complex and/or prolongation of the Q-T interval may occur in these situations.
1	0	8	O	Excessive
2	10	17	O	widening
3	19	20	O	of
4	22	24	O	the
5	26	28	O	QRS
6	30	36	O	complex
7	38	40	O	and
8	41	41	O	/
9	42	43	O	or
10	45	56	O	prolongation
11	58	59	O	of
12	61	63	O	the
13	65	65	O	Q
14	67	67	O	T
15	69	76	O	interval
16	78	80	O	may
17	82	86	O	occur
18	88	89	O	in
19	91	95	O	these
20	97	106	O	situations
NULL

Disopyramide	DDI-DrugBank.d506.s4	NO_SECTION	NO_SETID	20
In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either propranolol or diazepam.
1	0	1	O	In
2	3	9	O	healthy
3	11	18	O	subjects
4	19	19	O	,
5	21	22	O	no
6	24	34	O	significant
7	36	39	O	drug
8	41	44	O	drug
9	46	56	O	interaction
10	58	60	O	was
11	62	69	O	observed
12	71	74	O	when
13	76	82	O	XXXXXXXX
14	84	86	O	was
15	88	101	O	coadministered
16	103	106	O	with
17	108	113	O	either
18	115	125	U-UNK	propranolol
19	127	128	O	or
20	130	137	U-UNK	diazepam
NULL

Disopyramide	DDI-DrugBank.d506.s5	NO_SECTION	NO_SETID	21
Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	36	O	XXXXXXXX
5	38	40	O	and
6	42	50	U-KIN	quinidine
7	52	59	O	resulted
8	61	62	O	in
9	64	69	O	slight
10	71	79	O	increases
11	81	82	O	in
12	84	89	O	plasma
13	91	102	U-UNK	disopyramide
14	104	109	O	levels
15	111	113	O	and
16	115	120	O	slight
17	122	130	O	decreases
18	132	133	O	in
19	135	140	O	plasma
20	142	150	U-UNK	quinidine
21	152	157	O	levels
NULL

Disopyramide	DDI-DrugBank.d506.s6	NO_SECTION	NO_SETID	7
Norpace does not increase serum digoxin levels.
1	0	6	O	XXXXXXXX
2	8	11	O	does
3	13	15	O	not
4	17	24	O	increase
5	26	30	O	serum
6	32	38	U-UNK	digoxin
7	40	45	O	levels
NULL

Disopyramide	DDI-DrugBank.d506.s7	NO_SECTION	NO_SETID	31
Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.
1	0	7	O	Patients
2	9	14	O	taking
3	16	27	O	XXXXXXXX
4	29	37	O	phosphate
5	39	41	O	and
6	43	54	U-KIN	erythromycin
7	56	68	O	concomitantly
8	70	72	O	may
9	74	80	O	develop
10	82	90	O	increased
11	92	96	O	serum
12	98	111	O	concentrations
13	113	114	O	of
14	116	127	O	XXXXXXXX
15	129	137	O	resulting
16	139	140	O	in
17	142	150	O	excessive
18	152	159	O	widening
19	161	162	O	of
20	164	166	O	the
21	168	170	O	QRS
22	172	178	O	complex
23	180	182	O	and
24	183	183	O	/
25	184	185	O	or
26	187	198	O	prolongation
27	200	201	O	of
28	203	205	O	the
29	207	207	O	Q
30	209	209	O	T
31	211	218	O	interval
NULL

Disopyramide	DDI-DrugBank.d506.s8	NO_SECTION	NO_SETID	13
Patients taking disopyramide phosphate and hepatic enzyme inhibitors concomitantly should be closely monitored.
1	0	7	O	Patients
2	9	14	O	taking
3	16	27	O	XXXXXXXX
4	29	37	O	phosphate
5	39	41	O	and
6	43	49	O	hepatic
7	51	56	O	enzyme
8	58	67	O	inhibitors
9	69	81	O	concomitantly
10	83	88	O	should
11	90	91	O	be
12	93	99	O	closely
13	101	109	O	monitored
NULL

Disopyramide	DDI-DrugBank.d506.s9	NO_SECTION	NO_SETID	28
Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.
1	0	4	O	Until
2	6	9	O	data
3	11	12	O	on
4	14	21	O	possible
5	23	34	O	interactions
6	36	42	O	between
7	44	52	U-UNK	verapamil
8	54	56	O	and
9	58	69	O	XXXXXXXX
10	71	79	O	phosphate
11	81	83	O	are
12	85	92	O	obtained
13	93	93	O	,
14	95	106	O	XXXXXXXX
15	108	113	O	should
16	115	117	O	not
17	119	120	O	be
18	122	133	O	administered
19	135	140	O	within
20	142	143	O	48
21	145	149	O	hours
22	151	156	O	before
23	158	159	O	or
24	161	162	O	24
25	164	168	O	hours
26	170	174	O	after
27	176	184	U-DYN	verapamil
28	186	199	O	administration
NULL

Disulfiram	DDI-DrugBank.d19.s0	NO_SECTION	NO_SETID	29
Disulfiram appears to decrease the rate at which certain drugs are metabolized and therefore may increase the blood levels and the possibility of clinical toxicity of drugs given concomitantly.
1	0	9	O	XXXXXXXX
2	11	17	O	appears
3	19	20	O	to
4	22	29	O	decrease
5	31	33	O	the
6	35	38	O	rate
7	40	41	O	at
8	43	47	O	which
9	49	55	O	certain
10	57	61	O	drugs
11	63	65	O	are
12	67	77	O	metabolized
13	79	81	O	and
14	83	91	O	therefore
15	93	95	O	may
16	97	104	O	increase
17	106	108	O	the
18	110	114	O	blood
19	116	121	O	levels
20	123	125	O	and
21	127	129	O	the
22	131	141	O	possibility
23	143	144	O	of
24	146	153	O	clinical
25	155	162	O	toxicity
26	164	165	O	of
27	167	171	O	drugs
28	173	177	O	given
29	179	191	O	concomitantly
NULL

Disulfiram	DDI-DrugBank.d19.s1	NO_SECTION	NO_SETID	14
DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.
1	0	9	O	XXXXXXXX
2	11	16	O	SHOULD
3	18	19	O	BE
4	21	24	O	USED
5	26	29	O	WITH
6	31	37	O	CAUTION
7	39	40	O	IN
8	42	46	O	THOSE
9	48	55	O	PATIENTS
10	57	65	O	REVEIVING
11	67	75	U-DYN	PHENYTOIN
12	77	79	O	AND
13	81	83	O	ITS
14	85	93	O	CONGENERS
NULL

Disulfiram	DDI-DrugBank.d19.s2	NO_SECTION	NO_SETID	33
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.
1	0	4	O	SINCE
2	6	8	O	THE
3	10	20	O	CONCOMITANT
4	22	35	O	ADMINISTRATION
5	37	38	O	OF
6	40	44	O	THESE
7	46	48	O	TWO
8	50	54	O	DRUGS
9	56	58	O	CAN
10	60	63	O	LEAD
11	65	66	O	TO
12	68	76	U-UNK	PHENYTOIN
13	78	89	O	INTOXICATION
14	90	90	O	,
15	92	96	O	PRIOR
16	98	99	O	TO
17	101	113	O	ADMINISTERING
18	115	124	O	XXXXXXXX
19	126	127	O	TO
20	129	129	O	A
21	131	137	O	PATIENT
22	139	140	O	ON
23	142	150	U-DYN	PHENYTOIN
24	152	158	O	THERAPY
25	159	159	O	,
26	161	161	O	A
27	163	170	O	BASELINE
28	172	180	U-UNK	PHENYTOIN
29	182	186	O	SERUM
30	188	192	O	LEVEL
31	194	199	O	SHOULD
32	201	202	O	BE
33	204	211	O	OBTAINED
NULL

Disulfiram	DDI-DrugBank.d19.s3	NO_SECTION	NO_SETID	6
SUBSEQUENT TO INITIATION OF DISULFIRAM THERAPY.
1	0	9	O	SUBSEQUENT
2	11	12	O	TO
3	14	23	O	INITIATION
4	25	26	O	OF
5	28	37	O	XXXXXXXX
6	39	45	O	THERAPY
NULL

Disulfiram	DDI-DrugBank.d19.s4	NO_SECTION	NO_SETID	22
SERUM LEVELS OF PHENYTOIN SHOULD BE DETERMINED ON DIFFERENT DAYS FOR EVIDENCE OF AN INCREASE OR FOR A CONTINUING RISE IN LEVELS.
1	0	4	O	SERUM
2	6	11	O	LEVELS
3	13	14	O	OF
4	16	24	U-UNK	PHENYTOIN
5	26	31	O	SHOULD
6	33	34	O	BE
7	36	45	O	DETERMINED
8	47	48	O	ON
9	50	58	O	DIFFERENT
10	60	63	O	DAYS
11	65	67	O	FOR
12	69	76	O	EVIDENCE
13	78	79	O	OF
14	81	82	O	AN
15	84	91	O	INCREASE
16	93	94	O	OR
17	96	98	O	FOR
18	100	100	O	A
19	102	111	O	CONTINUING
20	113	116	O	RISE
21	118	119	O	IN
22	121	126	O	LEVELS
NULL

Disulfiram	DDI-DrugBank.d19.s5	NO_SECTION	NO_SETID	10
INCREASED PHENYTOIN LEVELS SHOULD BE TREATED WITH APPROPRIATE DOSAGE ADJUSTMENT.
1	0	8	O	INCREASED
2	10	18	U-UNK	PHENYTOIN
3	20	25	O	LEVELS
4	27	32	O	SHOULD
5	34	35	O	BE
6	37	43	O	TREATED
7	45	48	O	WITH
8	50	60	O	APPROPRIATE
9	62	67	O	DOSAGE
10	69	78	O	ADJUSTMENT
NULL

Disulfiram	DDI-DrugBank.d19.s6	NO_SECTION	NO_SETID	22
It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.
1	0	1	O	It
2	3	5	O	may
3	7	8	O	be
4	10	18	O	necessary
5	20	21	O	to
6	23	28	O	adjust
7	30	32	O	the
8	34	39	O	dosage
9	41	42	O	of
10	44	47	O	oral
11	49	62	U-DYN	anticoagulants
12	64	67	O	upon
13	69	77	O	beginning
14	79	80	O	or
15	82	89	O	stopping
16	91	100	O	XXXXXXXX
17	103	107	O	since
18	109	118	O	XXXXXXXX
19	120	122	O	may
20	124	130	O	prolong
21	132	142	O	prothrombin
22	144	147	O	time
NULL

Disulfiram	DDI-DrugBank.d19.s7	NO_SECTION	NO_SETID	22
Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;
1	0	7	O	Patients
2	9	14	O	taking
3	16	24	U-DYN	isoniazid
4	26	29	O	when
5	31	40	O	XXXXXXXX
6	42	43	O	is
7	45	49	O	given
8	51	56	O	should
9	58	59	O	be
10	61	68	O	observed
11	70	72	O	for
12	74	76	O	the
13	78	87	O	appearance
14	89	90	O	of
15	92	99	O	unsteady
16	101	104	O	gait
17	106	107	O	or
18	109	114	O	marked
19	116	122	O	changes
20	124	125	O	in
21	127	132	O	mental
22	134	139	O	status
NULL

Disulfiram	DDI-DrugBank.d19.s8	NO_SECTION	NO_SETID	9
the disulfiram should be discontinued if such signs appear.
1	0	2	O	the
2	4	13	O	XXXXXXXX
3	15	20	O	should
4	22	23	O	be
5	25	36	O	discontinued
6	38	39	O	if
7	41	44	O	such
8	46	50	O	signs
9	52	57	O	appear
NULL

Disulfiram	DDI-DrugBank.d19.s9	NO_SECTION	NO_SETID	45
In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.
1	0	1	O	In
2	3	6	O	rats
3	7	7	O	,
4	9	20	O	simultaneous
5	22	30	O	ingestion
6	32	33	O	of
7	35	44	O	XXXXXXXX
8	46	48	O	and
9	50	56	U-DYN	nitrite
10	58	59	O	in
11	61	63	O	the
12	65	68	O	diet
13	70	72	O	for
14	74	75	O	78
15	77	81	O	weeks
16	83	85	O	has
17	87	90	O	been
18	92	99	O	reported
19	101	102	O	to
20	104	108	O	cause
21	110	115	O	tumors
22	116	116	O	,
23	118	120	O	and
24	122	123	O	it
25	125	127	O	has
26	129	132	O	been
27	134	142	O	suggested
28	144	147	O	that
29	149	158	O	XXXXXXXX
30	160	162	O	may
31	164	168	O	react
32	170	173	O	with
33	175	182	U-DYN	nitrites
34	184	185	O	in
35	187	189	O	the
36	191	193	O	rat
37	195	201	O	stomach
38	203	204	O	to
39	206	209	O	form
40	211	211	O	a
41	213	223	O	nitrosamine
42	224	224	O	,
43	226	230	O	which
44	232	233	O	is
45	235	245	O	tumorigenic
NULL

Disulfiram	DDI-DrugBank.d19.s10	NO_SECTION	NO_SETID	13
Disulfiram alone in the rat s diet did not lead to such tumors.
1	0	9	O	XXXXXXXX
2	11	15	O	alone
3	17	18	O	in
4	20	22	O	the
5	24	26	O	rat
6	28	28	O	s
7	30	33	O	diet
8	35	37	O	did
9	39	41	O	not
10	43	46	O	lead
11	48	49	O	to
12	51	54	O	such
13	56	61	O	tumors
NULL

Disulfiram	DDI-DrugBank.d19.s11	NO_SECTION	NO_SETID	13
The relevance of this finding to humans is not known at this time.
1	0	2	O	The
2	4	12	O	relevance
3	14	15	O	of
4	17	20	O	this
5	22	28	O	finding
6	30	31	O	to
7	33	38	O	humans
8	40	41	O	is
9	43	45	O	not
10	47	51	O	known
11	53	54	O	at
12	56	59	O	this
13	61	64	O	time
NULL

Dobutamine	DDI-DrugBank.d274.s0	NO_SECTION	NO_SETID	18
Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.
1	0	5	O	Animal
2	7	13	O	studies
3	15	22	O	indicate
4	24	27	O	that
5	29	38	O	XXXXXXXX
6	40	42	O	may
7	44	45	O	be
8	47	57	O	ineffective
9	59	60	O	if
10	62	64	O	the
11	66	72	O	patient
12	74	76	O	has
13	78	85	O	recently
14	87	94	O	received
15	96	96	O	a
16	98	98	B-DYN	b
17	100	107	I-DYN	blocking
18	109	112	L-DYN	drug
NULL

Dobutamine	DDI-DrugBank.d274.s1	NO_SECTION	NO_SETID	11
In such a case, the peripheral vascular resistance may increase.
1	0	1	O	In
2	3	6	O	such
3	8	8	O	a
4	10	13	O	case
5	14	14	O	,
6	16	18	O	the
7	20	29	O	peripheral
8	31	38	O	vascular
9	40	49	O	resistance
10	51	53	O	may
11	55	62	O	increase
NULL

Dobutamine	DDI-DrugBank.d274.s2	NO_SECTION	NO_SETID	33
Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.
1	0	10	O	Preliminary
2	12	18	O	studies
3	20	27	O	indicate
4	29	32	O	that
5	34	36	O	the
6	38	48	O	concomitant
7	50	52	O	use
8	54	55	O	of
9	57	66	O	XXXXXXXX
10	68	70	O	and
11	72	84	U-DYN	nitroprusside
12	86	92	O	results
13	94	95	O	in
14	97	97	O	a
15	99	104	O	higher
16	106	112	O	cardiac
17	114	119	O	output
18	121	123	O	and
19	124	124	O	,
20	126	132	O	usually
21	133	133	O	,
22	135	135	O	a
23	137	141	O	lower
24	143	151	O	pulmonary
25	153	157	O	wedge
26	159	166	O	pressure
27	168	171	O	than
28	173	176	O	when
29	178	183	O	either
30	185	188	O	drug
31	190	191	O	is
32	193	196	O	used
33	198	202	O	alone
NULL

Dobutamine	DDI-DrugBank.d274.s3	NO_SECTION	NO_SETID	52
There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	20	O	evidence
5	22	23	O	of
6	25	28	O	drug
7	30	41	O	interactions
8	43	44	O	in
9	46	53	O	clinical
10	55	61	O	studies
11	63	64	O	in
12	66	70	O	which
13	72	81	O	XXXXXXXX
14	83	85	O	was
15	87	98	O	administered
16	100	111	O	concurrently
17	113	116	O	with
18	118	122	O	other
19	124	128	O	drugs
20	129	129	O	,
21	131	139	O	including
22	141	149	B-UNK	digitalis
23	151	162	L-UNK	preparations
24	163	163	O	,
25	165	174	U-UNK	furosemide
26	175	175	O	,
27	177	190	U-UNK	spironolactone
28	191	191	O	,
29	193	201	U-UNK	lidocaine
30	202	202	O	,
31	204	211	B-UNK	glyceryl
32	213	222	L-UNK	trinitrate
33	223	223	O	,
34	225	234	B-UNK	isosorbide
35	236	244	L-UNK	dinitrate
36	245	245	O	,
37	247	254	U-UNK	morphine
38	255	255	O	,
39	257	264	U-UNK	atropine
40	265	265	O	,
41	267	273	U-UNK	heparin
42	274	274	O	,
43	276	284	U-UNK	protamine
44	285	285	O	,
45	287	295	B-UNK	potassium
46	297	304	L-UNK	chloride
47	305	305	O	,
48	307	311	B-UNK	folic
49	313	316	L-UNK	acid
50	317	317	O	,
51	319	321	O	and
52	323	335	U-UNK	acetaminophen
NULL

Docetaxel	DDI-DrugBank.d371.s0	NO_SECTION	NO_SETID	17
There have been no formal clinical studies to evaluate the drug interactions of TAXOTERE with other medications.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	17	O	no
5	19	24	O	formal
6	26	33	O	clinical
7	35	41	O	studies
8	43	44	O	to
9	46	53	O	evaluate
10	55	57	O	the
11	59	62	O	drug
12	64	75	O	interactions
13	77	78	O	of
14	80	87	O	XXXXXXXX
15	89	92	O	with
16	94	98	O	other
17	100	110	O	medications
NULL

Docetaxel	DDI-DrugBank.d371.s1	NO_SECTION	NO_SETID	44
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	26	O	shown
6	28	31	O	that
7	33	35	O	the
8	37	46	O	metabolism
9	48	49	O	of
10	51	59	O	XXXXXXXX
11	61	63	O	may
12	65	66	O	be
13	68	75	O	modified
14	77	78	O	by
15	80	82	O	the
16	84	94	O	concomitant
17	96	109	O	administration
18	111	112	O	of
19	114	122	O	compounds
20	124	127	O	that
21	129	134	O	induce
22	135	135	O	,
23	137	143	O	inhibit
24	144	144	O	,
25	146	147	O	or
26	149	151	O	are
27	153	163	O	metabolized
28	165	166	O	by
29	168	177	O	cytochrome
30	179	182	O	P450
31	184	186	O	3A4
32	187	187	O	,
33	189	192	O	such
34	194	195	O	as
35	197	208	U-KIN	cyclosporine
36	209	209	O	,
37	211	221	U-KIN	terfenadine
38	222	222	O	,
39	224	235	U-KIN	ketoconazole
40	236	236	O	,
41	238	249	U-KIN	erythromycin
42	250	250	O	,
43	252	254	O	and
44	256	269	U-KIN	troleandomycin
NULL

Docetaxel	DDI-DrugBank.d371.s2	NO_SECTION	NO_SETID	21
Caution should be exercised with these drugs when treating patients receiving TAXOTERE as there is a potential for a significant interaction.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	with
6	33	37	O	these
7	39	43	O	drugs
8	45	48	O	when
9	50	57	O	treating
10	59	66	O	patients
11	68	76	O	receiving
12	78	85	O	XXXXXXXX
13	87	88	O	as
14	90	94	O	there
15	96	97	O	is
16	99	99	O	a
17	101	109	O	potential
18	111	113	O	for
19	115	115	O	a
20	117	127	O	significant
21	129	139	O	interaction
NULL

Dofetilide	DDI-DrugBank.d558.s0	NO_SECTION	NO_SETID	7
Drug/Laboratory Test Interactions None known.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	37	O	None
7	39	43	O	known
NULL

Dofetilide	DDI-DrugBank.d558.s1	NO_SECTION	NO_SETID	11
Drug-Drug Interactions Cimetidine: Concomitant use of cimetidine is contraindicated.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	21	O	Interactions
4	23	32	U-UNK	Cimetidine
5	33	33	O	:
6	35	45	O	Concomitant
7	47	49	O	use
8	51	52	O	of
9	54	63	U-UNK	cimetidine
10	65	66	O	is
11	68	82	O	contraindicated
NULL

Dofetilide	DDI-DrugBank.d558.s2	NO_SECTION	NO_SETID	29
Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.
1	0	9	U-KIN	Cimetidine
2	11	12	O	at
3	14	16	O	400
4	18	19	O	mg
5	21	23	O	BID
6	26	28	O	the
7	30	34	O	usual
8	36	47	O	prescription
9	49	52	O	dose
10	55	56	O	co
11	58	69	O	administered
12	71	74	O	with
13	76	82	O	XXXXXXXX
14	85	87	O	500
15	89	91	O	mcg
16	93	95	O	BID
17	98	100	O	for
18	102	102	O	7
19	104	107	O	days
20	109	111	O	has
21	113	116	O	been
22	118	122	O	shown
23	124	125	O	to
24	127	134	O	increase
25	136	145	U-UNK	dofetilide
26	147	152	O	plasma
27	154	159	O	levels
28	161	162	O	by
29	164	166	O	58%
NULL

Dofetilide	DDI-DrugBank.d558.s3	NO_SECTION	NO_SETID	22
Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).
1	0	9	U-KIN	Cimetidine
2	11	12	O	at
3	14	18	O	doses
4	20	21	O	of
5	23	25	O	100
6	27	28	O	mg
7	30	32	O	BID
8	35	37	O	OTC
9	39	42	O	dose
10	45	52	O	resulted
11	54	55	O	in
12	57	57	O	a
13	59	61	O	13%
14	63	70	O	increase
15	72	73	O	in
16	75	84	O	XXXXXXXX
17	86	91	O	plasma
18	93	98	O	levels
19	101	103	O	500
20	105	107	O	mcg
21	109	114	O	single
22	116	119	O	dose
NULL

Dofetilide	DDI-DrugBank.d558.s4	NO_SECTION	NO_SETID	10
No studies have been conducted at intermediate doses of cimetidine.
1	0	1	O	No
2	3	9	O	studies
3	11	14	O	have
4	16	19	O	been
5	21	29	O	conducted
6	31	32	O	at
7	34	45	O	intermediate
8	47	51	O	doses
9	53	54	O	of
10	56	65	U-UNK	cimetidine
NULL

Dofetilide	DDI-DrugBank.d558.s5	NO_SECTION	NO_SETID	43
If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
1	0	1	O	If
2	3	3	O	a
3	5	11	O	patient
4	13	20	O	requires
5	22	28	O	XXXXXXXX
6	30	32	O	and
7	34	37	B-UNK	anti
8	39	43	L-UNK	ulcer
9	45	51	O	therapy
10	52	52	O	,
11	54	55	O	it
12	57	58	O	is
13	60	68	O	suggested
14	70	73	O	that
15	75	84	U-UNK	omeprazole
16	85	85	O	,
17	87	96	U-UNK	ranitidine
18	97	97	O	,
19	99	100	O	or
20	102	109	U-UNK	antacids
21	112	119	B-UNK	aluminum
22	121	123	I-UNK	and
23	125	133	L-UNK	magnesium
24	135	144	O	hydroxides
25	147	148	O	be
26	150	153	O	used
27	155	156	O	as
28	158	169	O	alternatives
29	171	172	O	to
30	174	183	U-DYN	cimetidine
31	184	184	O	,
32	186	187	O	as
33	189	193	O	these
34	195	200	O	agents
35	202	205	O	have
36	207	208	O	no
37	210	215	O	effect
38	217	218	O	on
39	220	222	O	the
40	224	238	O	pharmacokinetic
41	240	246	O	profile
42	248	249	O	of
43	251	257	O	XXXXXXXX
NULL

Dofetilide	DDI-DrugBank.d558.s6	NO_SECTION	NO_SETID	8
Verapamil: Concomitant use of verapamil is contraindicated.
1	0	8	U-UNK	Verapamil
2	9	9	O	:
3	11	21	O	Concomitant
4	23	25	O	use
5	27	28	O	of
6	30	38	U-UNK	verapamil
7	40	41	O	is
8	43	57	O	contraindicated
NULL

Dofetilide	DDI-DrugBank.d558.s7	NO_SECTION	NO_SETID	26
Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	27	O	XXXXXXXX
5	29	32	O	with
6	34	42	U-KIN	verapamil
7	44	51	O	resulted
8	53	54	O	in
9	56	64	O	increases
10	66	67	O	in
11	69	78	U-UNK	dofetilide
12	80	83	O	peak
13	85	90	O	plasma
14	92	97	O	levels
15	99	100	O	of
16	102	104	O	42%
17	105	105	O	,
18	107	114	O	although
19	116	122	O	overall
20	124	131	O	exposure
21	133	134	O	to
22	136	145	U-UNK	dofetilide
23	147	149	O	was
24	151	153	O	not
25	155	167	O	significantly
26	169	177	O	increased
NULL

Dofetilide	DDI-DrugBank.d558.s8	NO_SECTION	NO_SETID	29
In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.
1	0	1	O	In
2	3	4	O	an
3	6	13	O	analysis
4	15	16	O	of
5	18	20	O	the
6	22	37	O	supraventricular
7	39	48	O	arrhythmia
8	50	52	O	and
9	54	60	O	DIAMOND
10	62	68	O	patient
11	70	80	O	populations
12	81	81	O	,
13	83	85	O	the
14	87	97	O	concomitant
15	99	112	O	administration
16	114	115	O	of
17	117	125	U-DYN	verapamil
18	127	130	O	with
19	132	141	O	XXXXXXXX
20	143	145	O	was
21	147	156	O	associated
22	158	161	O	with
23	163	163	O	a
24	165	170	O	higher
25	172	181	O	occurrence
26	183	184	O	of
27	186	192	O	torsade
28	194	195	O	de
29	197	203	O	pointes
NULL

Dofetilide	DDI-DrugBank.d558.s9	NO_SECTION	NO_SETID	8
Ketoconazole: Concomitant use of ketoconazole is contraindicated.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	24	O	Concomitant
4	26	28	O	use
5	30	31	O	of
6	33	44	U-UNK	ketoconazole
7	46	47	O	is
8	49	63	O	contraindicated
NULL

Dofetilide	DDI-DrugBank.d558.s10	NO_SECTION	NO_SETID	46
Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.
1	0	11	U-KIN	Ketoconazole
2	13	14	O	at
3	16	18	O	400
4	20	21	O	mg
5	23	27	O	daily
6	30	32	O	the
7	34	40	O	maximum
8	42	49	O	approved
9	51	62	O	prescription
10	64	67	O	dose
11	70	71	O	co
12	73	84	O	administered
13	86	89	O	with
14	91	97	O	XXXXXXXX
15	100	102	O	500
16	104	106	O	mcg
17	108	110	O	BID
18	113	115	O	for
19	117	117	O	7
20	119	122	O	days
21	124	126	O	has
22	128	131	O	been
23	133	137	O	shown
24	139	140	O	to
25	142	149	O	increase
26	151	160	U-UNK	dofetilide
27	162	165	O	Cmax
28	167	168	O	by
29	170	172	O	53%
30	174	175	O	in
31	177	181	O	males
32	183	185	O	and
33	187	189	O	97%
34	191	192	O	in
35	194	200	O	females
36	201	201	O	,
37	203	205	O	and
38	207	209	O	AUC
39	211	212	O	by
40	214	216	O	41%
41	218	219	O	in
42	221	225	O	males
43	227	229	O	and
44	231	233	O	69%
45	235	236	O	in
46	238	244	O	females
NULL

Dofetilide	DDI-DrugBank.d558.s11	NO_SECTION	NO_SETID	20
Trimethoprim Alone or in Combination with Sulfamethoxazole: Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.
1	0	11	U-UNK	Trimethoprim
2	13	17	O	Alone
3	19	20	O	or
4	22	23	O	in
5	25	35	O	Combination
6	37	40	O	with
7	42	57	U-UNK	Sulfamethoxazole
8	58	58	O	:
9	60	70	O	Concomitant
10	72	74	O	use
11	76	77	O	of
12	79	90	U-UNK	trimethoprim
13	92	96	O	alone
14	98	99	O	or
15	101	102	O	in
16	104	114	O	combination
17	116	119	O	with
18	121	136	U-UNK	sulfamethoxazole
19	138	139	O	is
20	141	155	O	contraindicated
NULL

Dofetilide	DDI-DrugBank.d558.s12	NO_SECTION	NO_SETID	21
Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.
1	0	18	U-UNK	Hydrochlorothiazide
2	21	24	U-UNK	HCTZ
3	27	31	O	Alone
4	33	34	O	or
5	36	37	O	in
6	39	49	O	Combination
7	51	54	O	with
8	56	66	U-UNK	Triamterene
9	67	67	O	:
10	69	79	O	Concomitant
11	81	83	O	use
12	85	86	O	of
13	88	91	U-UNK	HCTZ
14	93	97	O	alone
15	99	100	O	or
16	102	103	O	in
17	105	115	O	combination
18	117	120	O	with
19	122	132	U-UNK	triamterene
20	134	135	O	is
21	137	151	O	contraindicated
NULL

Dofetilide	DDI-DrugBank.d558.s13	NO_SECTION	NO_SETID	33
HCTZ 50 mg QD or HCTZ/triamterene 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose).
1	0	3	U-UNK	HCTZ
2	5	6	O	50
3	8	9	O	mg
4	11	12	O	QD
5	14	15	O	or
6	17	20	U-UNK	HCTZ
7	21	21	O	/
8	22	32	U-UNK	triamterene
9	34	35	O	50
10	36	36	O	/
11	37	39	O	100
12	41	42	O	mg
13	44	45	O	QD
14	47	49	O	was
15	51	52	O	co
16	54	65	O	administered
17	67	70	O	with
18	72	78	O	XXXXXXXX
19	81	83	O	500
20	85	87	O	mcg
21	89	91	O	BID
22	94	96	O	for
23	98	98	O	5
24	100	103	O	days
25	106	114	O	following
26	116	116	O	2
27	118	121	O	days
28	123	124	O	of
29	126	133	U-UNK	diuretic
30	135	137	O	use
31	139	140	O	at
32	142	145	O	half
33	147	150	O	dose
NULL

Dofetilide	DDI-DrugBank.d558.s14	NO_SECTION	NO_SETID	15
In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.
1	0	1	O	In
2	3	10	O	patients
3	12	20	O	receiving
4	22	25	U-KIN	HCTZ
5	27	31	O	alone
6	32	32	O	,
7	34	43	O	XXXXXXXX
8	45	47	O	AUC
9	49	57	O	increased
10	59	60	O	by
11	62	64	O	27%
12	66	68	O	and
13	70	73	O	Cmax
14	75	76	O	by
15	78	80	O	21%
NULL

Dofetilide	DDI-DrugBank.d558.s15	NO_SECTION	NO_SETID	18
However, the pharmacodynamic effect increased by 197% (QTc increase over time) and by 95% (maximum QTc increase).
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	27	O	pharmacodynamic
5	29	34	O	effect
6	36	44	O	increased
7	46	47	O	by
8	49	52	O	197%
9	55	57	O	QTc
10	59	66	O	increase
11	68	71	O	over
12	73	76	O	time
13	79	81	O	and
14	83	84	O	by
15	86	88	O	95%
16	91	97	O	maximum
17	99	101	O	QTc
18	103	110	O	increase
NULL

Dofetilide	DDI-DrugBank.d558.s16	NO_SECTION	NO_SETID	18
However, the pharmacodynamic effect increased by 190% (QTc increase over time) and by 84% (Maximum QTc increase).
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	27	O	pharmacodynamic
5	29	34	O	effect
6	36	44	O	increased
7	46	47	O	by
8	49	52	O	190%
9	55	57	O	QTc
10	59	66	O	increase
11	68	71	O	over
12	73	76	O	time
13	79	81	O	and
14	83	84	O	by
15	86	88	O	84%
16	91	97	O	Maximum
17	99	101	O	QTc
18	103	110	O	increase
NULL

Dofetilide	DDI-DrugBank.d558.s17	NO_SECTION	NO_SETID	21
The pharmacodynamic effects can be explained by a combination of the increase in dofetilide exposure and the reductions in serum potassium.
1	0	2	O	The
2	4	18	O	pharmacodynamic
3	20	26	O	effects
4	28	30	O	can
5	32	33	O	be
6	35	43	O	explained
7	45	46	O	by
8	48	48	O	a
9	50	60	O	combination
10	62	63	O	of
11	65	67	O	the
12	69	76	O	increase
13	78	79	O	in
14	81	90	O	XXXXXXXX
15	92	99	O	exposure
16	101	103	O	and
17	105	107	O	the
18	109	118	O	reductions
19	120	121	O	in
20	123	127	O	serum
21	129	137	O	potassium
NULL

Dofetilide	DDI-DrugBank.d558.s18	NO_SECTION	NO_SETID	30
In the DIAMOND trials, 1252 patients were treated with TIKOSYN and diuretics concomitantly of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics.
1	0	1	O	In
2	3	5	O	the
3	7	13	O	DIAMOND
4	15	20	O	trials
5	21	21	O	,
6	23	26	O	1252
7	28	35	O	patients
8	37	40	O	were
9	42	48	O	treated
10	50	53	O	with
11	55	61	O	XXXXXXXX
12	63	65	O	and
13	67	75	U-UNK	diuretics
14	77	89	O	concomitantly
15	91	92	O	of
16	94	97	O	whom
17	99	101	O	493
18	103	106	O	died
19	108	115	O	compared
20	117	118	O	to
21	120	122	O	508
22	124	129	O	deaths
23	131	135	O	among
24	137	139	O	the
25	141	144	O	1248
26	146	153	O	patients
27	155	163	O	receiving
28	165	171	O	placebo
29	173	175	O	and
30	177	185	U-UNK	diuretics
NULL

Dofetilide	DDI-DrugBank.d558.s19	NO_SECTION	NO_SETID	39
Of the 229 patients who had potassium depleting diuretics added to their concomitant medications in the DIAMOND trials, the patients on TIKOSYN had a non-significantly reduced relative risk for death of 0.68 (95% CI 0.376, 1.230).
1	0	1	O	Of
2	3	5	O	the
3	7	9	O	229
4	11	18	O	patients
5	20	22	O	who
6	24	26	O	had
7	28	36	B-UNK	potassium
8	38	46	I-UNK	depleting
9	48	56	L-UNK	diuretics
10	58	62	O	added
11	64	65	O	to
12	67	71	O	their
13	73	83	O	concomitant
14	85	95	O	medications
15	97	98	O	in
16	100	102	O	the
17	104	110	O	DIAMOND
18	112	117	O	trials
19	118	118	O	,
20	120	122	O	the
21	124	131	O	patients
22	133	134	O	on
23	136	142	O	XXXXXXXX
24	144	146	O	had
25	148	148	O	a
26	150	152	O	non
27	154	166	O	significantly
28	168	174	O	reduced
29	176	183	O	relative
30	185	188	O	risk
31	190	192	O	for
32	194	198	O	death
33	200	201	O	of
34	203	206	O	0.68
35	209	211	O	95%
36	213	214	O	CI
37	216	220	O	0.376
38	221	221	O	,
39	223	227	O	1.230
NULL

Dofetilide	DDI-DrugBank.d558.s20	NO_SECTION	NO_SETID	12
Potential Drug Interactions Dofetilide is eliminated in the kidney by cationic secretion.
1	0	8	O	Potential
2	10	13	O	Drug
3	15	26	O	Interactions
4	28	37	O	XXXXXXXX
5	39	40	O	is
6	42	51	O	eliminated
7	53	54	O	in
8	56	58	O	the
9	60	65	O	kidney
10	67	68	O	by
11	70	77	O	cationic
12	79	87	O	secretion
NULL

Dofetilide	DDI-DrugBank.d558.s21	NO_SECTION	NO_SETID	9
Inhibitors of renal cationic secretion are contraindicated with TIKOSYN.
1	0	9	O	Inhibitors
2	11	12	O	of
3	14	18	O	renal
4	20	27	O	cationic
5	29	37	O	secretion
6	39	41	O	are
7	43	57	O	contraindicated
8	59	62	O	with
9	64	70	O	XXXXXXXX
NULL

Dofetilide	DDI-DrugBank.d558.s22	NO_SECTION	NO_SETID	30
In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	17	O	drugs
5	19	22	O	that
6	24	26	O	are
7	28	35	O	actively
8	37	44	O	secreted
9	46	48	O	via
10	50	53	O	this
11	55	59	O	route
12	62	64	O	e.g
13	66	66	O	,
14	68	78	U-DYN	triamterene
15	79	79	O	,
16	81	89	U-DYN	metformin
17	91	93	O	and
18	95	103	U-DYN	amiloride
19	106	111	O	should
20	113	114	O	be
21	116	117	O	co
22	119	130	O	administered
23	132	135	O	with
24	137	140	O	care
25	142	143	O	as
26	145	148	O	they
27	150	154	O	might
28	156	163	O	increase
29	165	174	O	XXXXXXXX
30	176	181	O	levels
NULL

Dofetilide	DDI-DrugBank.d558.s23	NO_SECTION	NO_SETID	16
Dofetilide is metabolized to a small extent by the CYP3A4 isoenzyme of the cytochrome P450 system.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	metabolized
4	26	27	O	to
5	29	29	O	a
6	31	35	O	small
7	37	42	O	extent
8	44	45	O	by
9	47	49	O	the
10	51	56	O	CYP3A4
11	58	66	O	isoenzyme
12	68	69	O	of
13	71	73	O	the
14	75	84	O	cytochrome
15	86	89	O	P450
16	91	96	O	system
NULL

Dofetilide	DDI-DrugBank.d558.s24	NO_SECTION	NO_SETID	10
Inhibitors of the CYP3A4 isoenzyme could increase systemic dofetilide exposure.
1	0	9	O	Inhibitors
2	11	12	O	of
3	14	16	O	the
4	18	23	O	CYP3A4
5	25	33	O	isoenzyme
6	35	39	O	could
7	41	48	O	increase
8	50	57	O	systemic
9	59	68	O	XXXXXXXX
10	70	77	O	exposure
NULL

Dofetilide	DDI-DrugBank.d558.s25	NO_SECTION	NO_SETID	49
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
1	0	9	O	Inhibitors
2	11	12	O	of
3	14	17	O	this
4	19	27	O	isoenzyme
5	30	32	O	e.g
6	34	34	O	,
7	36	44	B-DYN	macrolide
8	46	56	L-DYN	antibiotics
9	57	57	O	,
10	59	63	B-DYN	azole
11	65	74	I-DYN	antifungal
12	76	81	L-DYN	agents
13	82	82	O	,
14	84	91	B-DYN	protease
15	93	102	L-DYN	inhibitors
16	103	103	O	,
17	105	113	B-DYN	serotonin
18	115	122	I-DYN	reuptake
19	124	133	L-DYN	inhibitors
20	134	134	O	,
21	136	145	U-DYN	amiodarone
22	146	146	O	,
23	148	159	U-DYN	cannabinoids
24	160	160	O	,
25	162	170	U-DYN	diltiazem
26	171	171	O	,
27	173	182	O	grapefruit
28	184	188	O	juice
29	189	189	O	,
30	191	200	U-DYN	nefazadone
31	201	201	O	,
32	203	213	U-DYN	norfloxacin
33	214	214	O	,
34	216	222	U-DYN	quinine
35	223	223	O	,
36	225	235	U-DYN	zafirlukast
37	238	243	O	should
38	245	246	O	be
39	248	257	O	cautiously
40	259	272	O	coadministered
41	274	277	O	with
42	279	285	O	XXXXXXXX
43	287	288	O	as
44	290	293	O	they
45	295	297	O	can
46	299	309	O	potentially
47	311	318	O	increase
48	320	329	U-UNK	dofetilide
49	331	336	O	levels
NULL

Dofetilide	DDI-DrugBank.d558.s26	NO_SECTION	NO_SETID	30
Dofetilide is not an inhibitor of CYP3A4 nor of other cytochrome P450 isoenzymes (e.g., CYP2C9, CYP2D6) and is not expected to increase levels of drugs metabolized by CYP3A4.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	16	O	not
4	18	19	O	an
5	21	29	O	inhibitor
6	31	32	O	of
7	34	39	O	CYP3A4
8	41	43	O	nor
9	45	46	O	of
10	48	52	O	other
11	54	63	O	cytochrome
12	65	68	O	P450
13	70	79	O	isoenzymes
14	82	84	O	e.g
15	86	86	O	,
16	88	93	O	CYP2C9
17	94	94	O	,
18	96	101	O	CYP2D6
19	104	106	O	and
20	108	109	O	is
21	111	113	O	not
22	115	122	O	expected
23	124	125	O	to
24	127	134	O	increase
25	136	141	O	levels
26	143	144	O	of
27	146	150	O	drugs
28	152	162	O	metabolized
29	164	165	O	by
30	167	172	O	CYP3A4
NULL

Dofetilide	DDI-DrugBank.d558.s27	NO_SECTION	NO_SETID	21
Other Drug Interaction Information Digoxin: Studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics of digoxin.
1	0	4	O	Other
2	6	9	O	Drug
3	11	21	O	Interaction
4	23	33	O	Information
5	35	41	U-UNK	Digoxin
6	42	42	O	:
7	44	50	O	Studies
8	52	53	O	in
9	55	61	O	healthy
10	63	72	O	volunteers
11	74	77	O	have
12	79	83	O	shown
13	85	88	O	that
14	90	96	O	XXXXXXXX
15	98	101	O	does
16	103	105	O	not
17	107	112	O	affect
18	114	116	O	the
19	118	133	O	pharmacokinetics
20	135	136	O	of
21	138	144	U-UNK	digoxin
NULL

Dofetilide	DDI-DrugBank.d558.s28	NO_SECTION	NO_SETID	20
In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.
1	0	1	O	In
2	3	10	O	patients
3	11	11	O	,
4	13	15	O	the
5	17	27	O	concomitant
6	29	42	O	administration
7	44	45	O	of
8	47	53	U-DYN	digoxin
9	55	58	O	with
10	60	69	O	XXXXXXXX
11	71	73	O	was
12	75	84	O	associated
13	86	89	O	with
14	91	91	O	a
15	93	98	O	higher
16	100	109	O	occurrence
17	111	112	O	of
18	114	120	O	torsade
19	122	123	O	de
20	125	131	O	pointes
NULL

Dofetilide	DDI-DrugBank.d558.s29	NO_SECTION	NO_SETID	24
It is not clear whether this represents an interaction with TIKOSYN or the presence of more severe structural heart disease in patients on digoxin;
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	clear
5	16	22	O	whether
6	24	27	O	this
7	29	38	O	represents
8	40	41	O	an
9	43	53	O	interaction
10	55	58	O	with
11	60	66	O	XXXXXXXX
12	68	69	O	or
13	71	73	O	the
14	75	82	O	presence
15	84	85	O	of
16	87	90	O	more
17	92	97	O	severe
18	99	108	O	structural
19	110	114	O	heart
20	116	122	O	disease
21	124	125	O	in
22	127	134	O	patients
23	136	137	O	on
24	139	145	U-UNK	digoxin
NULL

Dofetilide	DDI-DrugBank.d558.s30	NO_SECTION	NO_SETID	10
structural heart disease is a known risk factor for arrhythmia.
1	0	9	O	structural
2	11	15	O	heart
3	17	23	O	disease
4	25	26	O	is
5	28	28	O	a
6	30	34	O	known
7	36	39	O	risk
8	41	46	O	factor
9	48	50	O	for
10	52	61	O	arrhythmia
NULL

Dofetilide	DDI-DrugBank.d558.s31	NO_SECTION	NO_SETID	13
No increase in mortality was observed in patients taking digoxin as concomitant medication.
1	0	1	O	No
2	3	10	O	increase
3	12	13	O	in
4	15	23	O	mortality
5	25	27	O	was
6	29	36	O	observed
7	38	39	O	in
8	41	48	O	patients
9	50	55	O	taking
10	57	63	U-UNK	digoxin
11	65	66	O	as
12	68	78	O	concomitant
13	80	89	O	medication
NULL

Dofetilide	DDI-DrugBank.d558.s32	NO_SECTION	NO_SETID	42
Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
1	0	4	O	Other
2	6	10	O	Drugs
3	11	11	O	:
4	13	14	O	In
5	16	22	O	healthy
6	24	33	O	volunteers
7	34	34	O	,
8	36	45	U-UNK	amlodipine
9	46	46	O	,
10	48	56	U-UNK	phenytoin
11	57	57	O	,
12	59	67	U-UNK	glyburide
13	68	68	O	,
14	70	79	U-UNK	ranitidine
15	80	80	O	,
16	82	91	U-UNK	omeprazole
17	92	92	O	,
18	94	100	O	hormone
19	102	112	O	replacement
20	114	120	O	therapy
21	123	123	O	a
22	125	135	O	combination
23	137	138	O	of
24	140	149	O	conjugated
25	151	159	U-UNK	estrogens
26	161	163	O	and
27	165	183	U-UNK	medroxyprogesterone
28	185	185	O	,
29	187	193	U-UNK	antacid
30	196	203	B-UNK	aluminum
31	205	207	I-UNK	and
32	209	217	L-UNK	magnesium
33	219	228	O	hydroxides
34	231	233	O	and
35	235	246	U-UNK	theophylline
36	248	250	O	did
37	252	254	O	not
38	256	261	O	affect
39	263	265	O	the
40	267	282	O	pharmacokinetics
41	284	285	O	of
42	287	293	O	XXXXXXXX
NULL

Dofetilide	DDI-DrugBank.d558.s33	NO_SECTION	NO_SETID	38
In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	studies
5	21	22	O	in
6	24	30	O	healthy
7	32	41	O	volunteers
8	43	46	O	have
9	48	52	O	shown
10	54	57	O	that
11	59	65	O	XXXXXXXX
12	67	70	O	does
13	72	74	O	not
14	76	81	O	affect
15	83	85	O	the
16	87	102	O	pharmacokinetics
17	104	105	O	or
18	107	122	O	pharmacodynamics
19	124	125	O	of
20	127	134	U-UNK	warfarin
21	135	135	O	,
22	137	138	O	or
23	140	142	O	the
24	144	159	O	pharmacokinetics
25	161	162	O	of
26	164	174	U-UNK	propranolol
27	177	178	O	40
28	180	181	O	mg
29	183	187	O	twice
30	189	193	O	daily
31	195	195	O	,
32	197	205	U-UNK	phenytoin
33	206	206	O	,
34	208	219	U-UNK	theophylline
35	220	220	O	,
36	222	223	O	or
37	225	228	O	oral
38	230	243	U-UNK	contraceptives
NULL

Dofetilide	DDI-DrugBank.d558.s34	NO_SECTION	NO_SETID	30
Population pharmacokinetic analyses were conducted on plasma concentration data from 1445 patients in clinical trials to examine the effects of concomitant medications on clearance or volume of distribution of dofetilide.
1	0	9	O	Population
2	11	25	O	pharmacokinetic
3	27	34	O	analyses
4	36	39	O	were
5	41	49	O	conducted
6	51	52	O	on
7	54	59	O	plasma
8	61	73	O	concentration
9	75	78	O	data
10	80	83	O	from
11	85	88	O	1445
12	90	97	O	patients
13	99	100	O	in
14	102	109	O	clinical
15	111	116	O	trials
16	118	119	O	to
17	121	127	O	examine
18	129	131	O	the
19	133	139	O	effects
20	141	142	O	of
21	144	154	O	concomitant
22	156	166	O	medications
23	168	169	O	on
24	171	179	O	clearance
25	181	182	O	or
26	184	189	O	volume
27	191	192	O	of
28	194	205	O	distribution
29	207	208	O	of
30	210	219	O	XXXXXXXX
NULL

Dofetilide	DDI-DrugBank.d558.s35	NO_SECTION	NO_SETID	65
Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
1	0	10	O	Concomitant
2	12	22	O	medications
3	24	27	O	were
4	29	35	O	grouped
5	37	38	O	as
6	40	42	B-UNK	ACE
7	44	53	L-UNK	inhibitors
8	54	54	O	,
9	56	59	O	oral
10	61	74	U-UNK	anticoagulants
11	75	75	O	,
12	77	83	B-UNK	calcium
13	85	91	I-UNK	channel
14	93	100	L-UNK	blockers
15	101	101	O	,
16	103	106	B-UNK	beta
17	108	115	L-UNK	blockers
18	116	116	O	,
19	118	124	B-UNK	cardiac
20	126	135	L-UNK	glycosides
21	136	136	O	,
22	138	145	O	inducers
23	147	148	O	of
24	150	155	O	CYP3A4
25	156	156	O	,
26	158	167	O	substrates
27	169	171	O	and
28	173	182	O	inhibitors
29	184	185	O	of
30	187	192	O	CYP3A4
31	193	193	O	,
32	195	204	O	substrates
33	206	208	O	and
34	210	219	O	inhibitors
35	221	222	O	of
36	224	224	O	P
37	226	237	O	glycoprotein
38	238	238	O	,
39	240	247	U-UNK	nitrates
40	248	248	O	,
41	250	263	U-UNK	sulphonylureas
42	264	264	O	,
43	266	269	B-UNK	loop
44	271	279	L-UNK	diuretics
45	280	280	O	,
46	282	290	B-UNK	potassium
47	292	298	I-UNK	sparing
48	300	308	L-UNK	diuretics
49	309	309	O	,
50	311	318	B-UNK	thiazide
51	320	328	L-UNK	diuretics
52	329	329	O	,
53	331	340	O	substrates
54	342	344	O	and
55	346	355	O	inhibitors
56	357	358	O	of
57	360	366	O	tubular
58	368	374	O	organic
59	376	381	O	cation
60	383	391	O	transport
61	392	392	O	,
62	394	396	O	and
63	398	400	O	QTc
64	402	411	O	prolonging
65	413	417	O	drugs
NULL

Dofetilide	DDI-DrugBank.d558.s36	NO_SECTION	NO_SETID	23
Differences in clearance between patients on these medications (at any occasion in the study) and those off medications varied between -16% and +3%.
1	0	10	O	Differences
2	12	13	O	in
3	15	23	O	clearance
4	25	31	O	between
5	33	40	O	patients
6	42	43	O	on
7	45	49	O	these
8	51	61	O	medications
9	64	65	O	at
10	67	69	O	any
11	71	78	O	occasion
12	80	81	O	in
13	83	85	O	the
14	87	91	O	study
15	94	96	O	and
16	98	102	O	those
17	104	106	O	off
18	108	118	O	medications
19	120	125	O	varied
20	127	133	O	between
21	136	138	O	16%
22	140	142	O	and
23	144	146	O	+3%
NULL

Dofetilide	DDI-DrugBank.d558.s37	NO_SECTION	NO_SETID	24
The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.
1	0	2	O	The
2	4	7	O	mean
3	9	18	O	clearances
4	20	21	O	of
5	23	32	O	XXXXXXXX
6	34	37	O	were
7	39	41	O	16%
8	43	45	O	and
9	47	49	O	15%
10	51	55	O	lower
11	57	58	O	in
12	60	67	O	patients
13	69	70	O	on
14	72	79	B-KIN	thiazide
15	81	89	L-KIN	diuretics
16	91	93	O	and
17	95	104	O	inhibitors
18	106	107	O	of
19	109	115	O	tubular
20	117	123	O	organic
21	125	130	O	cation
22	132	140	O	transport
23	141	141	O	,
24	143	154	O	respectively
NULL

Dolasetron	DDI-DrugBank.d42.s0	NO_SECTION	NO_SETID	35
The potential for clinically significant drug-drug interactions posed by dolasetron and hydrodolasetron appears to be low for drugs commonly used in chemotherapy or surgery, because hydrodolasetron is eliminated by multiple routes.
1	0	2	O	The
2	4	12	O	potential
3	14	16	O	for
4	18	27	O	clinically
5	29	39	O	significant
6	41	44	O	drug
7	46	49	O	drug
8	51	62	O	interactions
9	64	68	O	posed
10	70	71	O	by
11	73	82	O	XXXXXXXX
12	84	86	O	and
13	88	92	O	hydro
14	93	102	O	XXXXXXXX
15	104	110	O	appears
16	112	113	O	to
17	115	116	O	be
18	118	120	O	low
19	122	124	O	for
20	126	130	O	drugs
21	132	139	O	commonly
22	141	144	O	used
23	146	147	O	in
24	149	160	O	chemotherapy
25	162	163	O	or
26	165	171	O	surgery
27	172	172	O	,
28	174	180	O	because
29	182	186	O	hydro
30	187	196	O	XXXXXXXX
31	198	199	O	is
32	201	210	O	eliminated
33	212	213	O	by
34	215	222	O	multiple
35	224	229	O	routes
NULL

Dolasetron	DDI-DrugBank.d42.s1	NO_SECTION	NO_SETID	39
Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.
1	0	4	O	Blood
2	6	11	O	levels
3	13	14	O	of
4	16	20	O	hydro
5	21	30	O	XXXXXXXX
6	32	40	O	increased
7	42	44	O	24%
8	46	49	O	when
9	51	60	O	XXXXXXXX
10	62	64	O	was
11	66	79	O	coadministered
12	81	84	O	with
13	86	95	U-KIN	cimetidine
14	98	109	O	nonselective
15	111	119	O	inhibitor
16	121	122	O	of
17	124	133	O	cytochrome
18	135	135	O	P
19	137	139	O	450
20	142	144	O	for
21	146	146	O	7
22	148	151	O	days
23	152	152	O	,
24	154	156	O	and
25	158	166	O	decreased
26	168	170	O	28%
27	172	175	O	with
28	177	192	O	coadministration
29	194	195	O	of
30	197	204	U-KIN	rifampin
31	207	212	O	potent
32	214	220	O	inducer
33	222	223	O	of
34	225	234	O	cytochrome
35	236	236	O	P
36	238	240	O	450
37	243	245	O	for
38	247	247	O	7
39	249	252	O	days
NULL

Dolasetron	DDI-DrugBank.d42.s2	NO_SECTION	NO_SETID	12
Dolasetron has been safely coadministered with drugs used in chemotherapy and surgery.
1	0	9	O	XXXXXXXX
2	11	13	O	has
3	15	18	O	been
4	20	25	O	safely
5	27	40	O	coadministered
6	42	45	O	with
7	47	51	O	drugs
8	53	56	O	used
9	58	59	O	in
10	61	72	O	chemotherapy
11	74	76	O	and
12	78	84	O	surgery
NULL

Dolasetron	DDI-DrugBank.d42.s3	NO_SECTION	NO_SETID	24
As with other agents which prolong ECG intervals, caution should be exercised in patients taking drugs which prolong ECG intervals, particularly QTc.
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	19	O	agents
5	21	25	O	which
6	27	33	O	prolong
7	35	37	O	ECG
8	39	47	O	intervals
9	48	48	O	,
10	50	56	O	caution
11	58	63	O	should
12	65	66	O	be
13	68	76	O	exercised
14	78	79	O	in
15	81	88	O	patients
16	90	95	O	taking
17	97	101	O	drugs
18	103	107	O	which
19	109	115	O	prolong
20	117	119	O	ECG
21	121	129	O	intervals
22	130	130	O	,
23	132	143	O	particularly
24	145	147	O	QTc
NULL

Dolasetron	DDI-DrugBank.d42.s4	NO_SECTION	NO_SETID	33
In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	28	U-UNK	furosemide
5	29	29	O	,
6	31	40	U-UNK	nifedipine
7	41	41	O	,
8	43	51	U-UNK	diltiazem
9	52	52	O	,
10	54	56	B-UNK	ACE
11	58	67	L-UNK	inhibitors
12	68	68	O	,
13	70	78	U-UNK	verapamil
14	79	79	O	,
15	81	89	U-UNK	glyburide
16	90	90	O	,
17	92	102	U-UNK	propranolol
18	103	103	O	,
19	105	107	O	and
20	109	115	O	various
21	117	128	O	chemotherapy
22	130	135	O	agents
23	136	136	O	,
24	138	139	O	no
25	141	146	O	effect
26	148	150	O	was
27	152	156	O	shown
28	158	159	O	on
29	161	163	O	the
30	165	173	O	clearance
31	175	176	O	of
32	178	182	O	hydro
33	183	192	O	XXXXXXXX
NULL

Dolasetron	DDI-DrugBank.d42.s5	NO_SECTION	NO_SETID	17
Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.
1	0	8	O	Clearance
2	10	11	O	of
3	13	17	O	hydro
4	18	27	O	XXXXXXXX
5	29	37	O	decreased
6	39	40	O	by
7	42	46	O	about
8	48	50	O	27%
9	52	55	O	when
10	57	66	O	XXXXXXXX
11	68	75	O	mesylate
12	77	79	O	was
13	81	92	O	administered
14	94	106	O	intravenously
15	108	120	O	concomitantly
16	122	125	O	with
17	127	134	U-KIN	atenolol
NULL

Dolasetron	DDI-DrugBank.d42.s6	NO_SECTION	NO_SETID	9
Dolasetron does not influence anesthesia recovery time in patients.
1	0	9	O	XXXXXXXX
2	11	14	O	does
3	16	18	O	not
4	20	28	O	influence
5	30	39	O	anesthesia
6	41	48	O	recovery
7	50	53	O	time
8	55	56	O	in
9	58	65	O	patients
NULL

Dolasetron	DDI-DrugBank.d42.s7	NO_SECTION	NO_SETID	24
Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.
1	0	9	O	XXXXXXXX
2	11	18	O	mesylate
3	20	22	O	did
4	24	26	O	not
5	28	34	O	inhibit
6	36	38	O	the
7	40	48	O	antitumor
8	50	57	O	activity
9	59	60	O	of
10	62	65	O	four
11	67	82	B-UNK	chemotherapeutic
12	84	89	L-UNK	agents
13	92	100	U-UNK	cisplatin
14	101	101	O	,
15	103	103	B-UNK	5
16	105	116	L-UNK	fluorouracil
17	117	117	O	,
18	119	129	U-UNK	doxorubicin
19	130	130	O	,
20	132	147	U-UNK	cyclophosphamide
21	150	151	O	in
22	153	156	O	four
23	158	163	O	murine
24	165	170	O	models
NULL

Donepezil	DDI-DrugBank.d319.s0	NO_SECTION	NO_SETID	16
Drugs that inhibit or Induce CYP 2D6 and CYP 3A4 may affect the concentration on Aricept.
1	0	4	O	Drugs
2	6	9	O	that
3	11	17	O	inhibit
4	19	20	O	or
5	22	27	O	Induce
6	29	31	O	CYP
7	33	35	O	2D6
8	37	39	O	and
9	41	43	O	CYP
10	45	47	O	3A4
11	49	51	O	may
12	53	58	O	affect
13	60	62	O	the
14	64	76	O	concentration
15	78	79	O	on
16	81	87	O	XXXXXXXX
NULL

Dopamine	DDI-DrugBank.d325.s0	NO_SECTION	NO_SETID	20
Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine.
1	0	6	O	Because
2	8	15	O	XXXXXXXX
3	17	18	O	is
4	20	30	O	metabolized
5	32	33	O	by
6	35	43	O	monoamine
7	45	51	O	oxidase
8	54	56	O	MAO
9	58	58	O	,
10	60	69	O	inhibition
11	71	72	O	of
12	74	77	O	this
13	79	84	O	enzyme
14	86	93	O	prolongs
15	95	97	O	and
16	99	109	O	potentiates
17	111	113	O	the
18	115	120	O	effect
19	122	123	O	of
20	125	132	O	XXXXXXXX
NULL

Dopamine	DDI-DrugBank.d325.s1	NO_SECTION	NO_SETID	39
Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.
1	0	7	O	Patients
2	9	11	O	who
3	13	16	O	have
4	18	21	O	been
5	23	29	O	treated
6	31	34	O	with
7	36	38	B-DYN	MAO
8	40	49	L-DYN	inhibitors
9	51	56	O	within
10	58	60	O	two
11	62	63	O	to
12	65	69	O	three
13	71	75	O	weeks
14	77	81	O	prior
15	83	84	O	to
16	86	88	O	the
17	90	103	O	administration
18	105	106	O	of
19	108	115	O	XXXXXXXX
20	117	119	O	HCl
21	121	126	O	should
22	128	134	O	receive
23	136	142	O	initial
24	144	148	O	doses
25	150	151	O	of
26	153	160	O	XXXXXXXX
27	162	164	O	HCl
28	166	167	O	no
29	169	175	O	greater
30	177	180	O	than
31	182	184	O	one
32	186	190	O	tenth
33	193	193	O	1
34	194	194	O	/
35	195	196	O	10
36	199	200	O	of
37	202	204	O	the
38	206	210	O	usual
39	212	215	O	dose
NULL

Dopamine	DDI-DrugBank.d325.s2	NO_SECTION	NO_SETID	20
Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	31	O	low
5	33	36	O	dose
6	38	45	O	XXXXXXXX
7	47	49	O	HCl
8	51	53	O	and
9	55	62	B-DYN	diuretic
10	64	69	L-DYN	agents
11	71	73	O	may
12	75	81	O	produce
13	83	84	O	an
14	86	93	O	additive
15	95	96	O	or
16	98	109	O	potentiating
17	111	116	O	effect
18	118	119	O	on
19	121	125	O	urine
20	127	130	O	flow
NULL

Dopamine	DDI-DrugBank.d325.s3	NO_SECTION	NO_SETID	10
Tricyclic antidepressants may potentiate the cardiovascular effects of adreneric agents.
1	0	8	B-UNK	Tricyclic
2	10	24	L-UNK	antidepressants
3	26	28	O	may
4	30	39	O	potentiate
5	41	43	O	the
6	45	58	O	cardiovascular
7	60	66	O	effects
8	68	69	O	of
9	71	79	O	adreneric
10	81	86	O	agents
NULL

Dopamine	DDI-DrugBank.d325.s4	NO_SECTION	NO_SETID	17
Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
1	0	6	O	Cardiac
2	8	14	O	effects
3	16	17	O	of
4	19	26	O	XXXXXXXX
5	28	30	O	are
6	32	42	O	antagonized
7	44	45	O	by
8	47	50	B-DYN	beta
9	52	61	I-DYN	adrenergic
10	63	70	I-DYN	blocking
11	72	77	L-DYN	agents
12	78	78	O	,
13	80	83	O	such
14	85	86	O	as
15	88	98	U-DYN	propranolol
16	100	102	O	and
17	104	113	U-DYN	metoprolol
NULL

Dopamine	DDI-DrugBank.d325.s5	NO_SECTION	NO_SETID	17
The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.
1	0	2	O	The
2	4	13	O	peripheral
3	15	30	O	vasoconstriction
4	32	37	O	caused
5	39	40	O	by
6	42	45	O	high
7	47	51	O	doses
8	53	54	O	of
9	56	63	O	XXXXXXXX
10	65	67	O	HCl
11	69	70	O	is
12	72	82	O	antagonized
13	84	85	O	by
14	87	91	B-DYN	alpha
15	93	102	I-DYN	adrenergic
16	104	111	I-DYN	blocking
17	113	118	L-DYN	agents
NULL

Dopamine	DDI-DrugBank.d325.s6	NO_SECTION	NO_SETID	17
Dopamine-induced renal and mesenteric vasodilation is not antagonized by either alpha- or beta-adrenergic blocking agents.
1	0	7	O	XXXXXXXX
2	9	15	O	induced
3	17	21	O	renal
4	23	25	O	and
5	27	36	O	mesenteric
6	38	49	O	vasodilation
7	51	52	O	is
8	54	56	O	not
9	58	68	O	antagonized
10	70	71	O	by
11	73	78	O	either
12	80	84	B-UNK	alpha
13	87	88	I-UNK	or
14	90	93	I-UNK	beta
15	95	104	I-UNK	adrenergic
16	106	113	I-UNK	blocking
17	115	120	L-UNK	agents
NULL

Dopamine	DDI-DrugBank.d325.s7	NO_SECTION	NO_SETID	21
Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
1	0	13	U-DYN	Butyrophenones
2	16	19	O	such
3	21	22	O	as
4	24	34	U-DYN	haloperidol
5	37	39	O	and
6	41	54	U-DYN	phenothiazines
7	56	58	O	can
8	60	67	O	suppress
9	69	71	O	the
10	73	80	O	XXXXXXXX
11	81	84	O	rgic
12	86	90	O	renal
13	92	94	O	and
14	96	105	O	mesenteric
15	107	118	O	vasodilation
16	120	126	O	induced
17	128	131	O	with
18	133	135	O	low
19	137	140	O	dose
20	142	149	O	XXXXXXXX
21	151	158	O	infusion
NULL

Dopamine	DDI-DrugBank.d325.s8	NO_SECTION	NO_SETID	26
Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
1	0	11	U-DYN	Cyclopropane
2	13	14	O	or
3	16	26	B-DYN	halogenated
4	28	38	I-DYN	hydrocarbon
5	40	50	L-DYN	anesthetics
6	52	59	O	increase
7	61	67	O	cardiac
8	69	77	O	autonomic
9	79	90	O	irritability
10	92	94	O	and
11	96	98	O	may
12	100	108	O	sensitize
13	110	112	O	the
14	114	123	O	myocardium
15	125	126	O	to
16	128	130	O	the
17	132	137	O	action
18	139	140	O	of
19	142	148	O	certain
20	150	162	O	intravenously
21	164	175	O	administered
22	177	190	U-UNK	catecholamines
23	191	191	O	,
24	193	196	O	such
25	198	199	O	as
26	201	208	O	XXXXXXXX
NULL

Dopamine	DDI-DrugBank.d325.s9	NO_SECTION	NO_SETID	26
This interaction appears to be related both to pressor activity and to beta-adrenergic stimulating properties of these catecholamines and may produce ventricular arrhythmias and hypertension.
1	0	3	O	This
2	5	15	O	interaction
3	17	23	O	appears
4	25	26	O	to
5	28	29	O	be
6	31	37	O	related
7	39	42	O	both
8	44	45	O	to
9	47	53	O	pressor
10	55	62	O	activity
11	64	66	O	and
12	68	69	O	to
13	71	74	O	beta
14	76	85	O	adrenergic
15	87	97	O	stimulating
16	99	108	O	properties
17	110	111	O	of
18	113	117	O	these
19	119	132	U-UNK	catecholamines
20	134	136	O	and
21	138	140	O	may
22	142	148	O	produce
23	150	160	O	ventricular
24	162	172	O	arrhythmias
25	174	176	O	and
26	178	189	O	hypertension
NULL

Dopamine	DDI-DrugBank.d325.s10	NO_SECTION	NO_SETID	19
Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	O	EXTREME
4	19	25	O	CAUTION
5	27	32	O	should
6	34	35	O	be
7	37	45	O	exercised
8	47	50	O	when
9	52	64	O	administering
10	66	73	O	XXXXXXXX
11	75	77	O	HCl
12	79	80	O	to
13	82	89	O	patients
14	91	99	O	receiving
15	101	112	U-DYN	cyclopropane
16	114	115	O	or
17	117	127	B-DYN	halogenated
18	129	139	I-DYN	hydrocarbon
19	141	151	L-DYN	anesthetics
NULL

Dopamine	DDI-DrugBank.d325.s11	NO_SECTION	NO_SETID	23
It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.
1	0	1	O	It
2	3	5	O	has
3	7	10	O	been
4	12	19	O	reported
5	21	24	O	that
6	26	32	O	results
7	34	35	O	of
8	37	43	O	studies
9	45	46	O	in
10	48	54	O	animals
11	56	63	O	indicate
12	65	68	O	that
13	70	77	O	XXXXXXXX
14	79	85	O	induced
15	87	97	O	ventricular
16	99	109	O	arrhythmias
17	111	116	O	during
18	118	127	O	anesthesia
19	129	131	O	can
20	133	134	O	be
21	136	143	O	reversed
22	145	146	O	by
23	148	158	U-DYN	propranolol
NULL

Dopamine	DDI-DrugBank.d325.s12	NO_SECTION	NO_SETID	20
The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	34	O	vasopressors
6	35	35	O	,
7	37	52	O	vasoconstricting
8	54	59	O	agents
9	62	65	O	such
10	67	68	O	as
11	70	79	U-UNK	ergonovine
12	82	84	O	and
13	86	89	O	some
14	91	98	B-UNK	oxytocic
15	100	104	L-UNK	drugs
16	106	108	O	may
17	110	115	O	result
18	117	118	O	in
19	120	125	O	severe
20	127	138	O	hypertension
NULL

Dopamine	DDI-DrugBank.d325.s13	NO_SECTION	NO_SETID	17
Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.
1	0	13	O	Administration
2	15	16	O	of
3	18	26	U-DYN	phenytoin
4	28	29	O	to
5	31	38	O	patients
6	40	48	O	receiving
7	50	57	O	XXXXXXXX
8	59	61	O	HCl
9	63	65	O	has
10	67	70	O	been
11	72	79	O	reported
12	81	82	O	to
13	84	87	O	lead
14	89	90	O	to
15	92	102	O	hypotension
16	104	106	O	and
17	108	118	O	bradycardia
NULL

Dopamine	DDI-DrugBank.d325.s14	NO_SECTION	NO_SETID	21
It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	suggested
4	16	19	O	that
5	21	22	O	in
6	24	31	O	patients
7	33	41	O	receiving
8	43	50	O	XXXXXXXX
9	52	54	O	HCl
10	55	55	O	,
11	57	68	O	alternatives
12	70	71	O	to
13	73	81	U-DYN	phenytoin
14	83	88	O	should
15	90	91	O	be
16	93	96	O	used
17	98	99	O	if
18	101	114	U-UNK	anticonvulsant
19	116	122	O	therapy
20	124	125	O	is
21	127	132	O	needed
NULL

Dornase Alfa	DDI-DrugBank.d93.s0	NO_SECTION	NO_SETID	43
Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.
1	0	7	O	Clinical
2	9	14	O	trials
3	16	19	O	have
4	21	29	O	indicated
5	31	34	O	that
6	36	44	O	XXXXXXXX
7	46	48	O	can
8	50	51	O	be
9	53	63	O	effectively
10	65	67	O	and
11	69	74	O	safely
12	76	79	O	used
13	81	82	O	in
14	84	94	O	conjunction
15	96	99	O	with
16	101	108	O	standard
17	110	115	O	cystic
18	117	124	O	fibrosis
19	126	134	O	therapies
20	136	144	O	including
21	146	149	O	oral
22	150	150	O	,
23	152	158	O	inhaled
24	160	162	O	and
25	163	163	O	/
26	164	165	O	or
27	167	176	O	parenteral
28	178	188	U-UNK	antibiotics
29	189	189	O	,
30	191	205	U-UNK	bronchodilators
31	206	206	O	,
32	208	213	O	enzyme
33	215	225	O	supplements
34	226	226	O	,
35	228	235	U-UNK	vitamins
36	236	236	O	,
37	238	241	O	oral
38	243	244	O	or
39	246	252	O	inhaled
40	254	268	U-UNK	corticosteroids
41	269	269	O	,
42	271	273	O	and
43	275	284	U-UNK	analgesics
NULL

Dornase Alfa	DDI-DrugBank.d93.s1	NO_SECTION	NO_SETID	8
No formal drug interaction studies have been performed.
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	25	O	interaction
5	27	33	O	studies
6	35	38	O	have
7	40	43	O	been
8	45	53	O	performed
NULL

Dorzolamide	DDI-DrugBank.d34.s0	NO_SECTION	NO_SETID	46
Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).
1	0	7	O	Although
2	9	12	O	acid
3	14	17	O	base
4	19	21	O	and
5	23	33	O	electrolyte
6	35	46	O	disturbances
7	48	51	O	were
8	53	55	O	not
9	57	64	O	reported
10	66	67	O	in
11	69	71	O	the
12	73	80	O	clinical
13	82	87	O	trials
14	89	92	O	with
15	94	104	O	XXXXXXXX
16	105	105	O	,
17	107	111	O	these
18	113	124	O	disturbances
19	126	129	O	have
20	131	134	O	been
21	136	143	O	reported
22	145	148	O	with
23	150	153	O	oral
24	155	162	B-DYN	carbonic
25	164	172	I-DYN	anhydrase
26	174	183	L-DYN	inhibitors
27	185	187	O	and
28	189	192	O	have
29	193	193	O	,
30	195	196	O	in
31	198	201	O	some
32	203	211	O	instances
33	212	212	O	,
34	214	221	O	resulted
35	223	224	O	in
36	226	229	O	drug
37	231	242	O	interactions
38	245	247	O	e.g
39	249	249	O	,
40	251	258	O	toxicity
41	260	269	O	associated
42	271	274	O	with
43	276	279	O	high
44	281	284	O	dose
45	286	295	U-UNK	salicylate
46	297	303	O	therapy
NULL

Dorzolamide	DDI-DrugBank.d34.s1	NO_SECTION	NO_SETID	15
Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	23	O	potential
5	25	27	O	for
6	29	32	O	such
7	34	37	O	drug
8	39	50	O	interactions
9	52	57	O	should
10	59	60	O	be
11	62	71	O	considered
12	73	74	O	in
13	76	83	O	patients
14	85	93	O	receiving
15	95	105	O	XXXXXXXX
NULL

Doxacurium chloride	DDI-DrugBank.d267.s0	NO_SECTION	NO_SETID	16
Prior administration of succinylcholine has no clinically important effect on the neuromuscular blocking action of NUROMAX.
1	0	4	O	Prior
2	6	19	O	administration
3	21	22	O	of
4	24	38	U-UNK	succinylcholine
5	40	42	O	has
6	44	45	O	no
7	47	56	O	clinically
8	58	66	O	important
9	68	73	O	effect
10	75	76	O	on
11	78	80	O	the
12	82	94	O	neuromuscular
13	96	103	O	blocking
14	105	110	O	action
15	112	113	O	of
16	115	121	O	XXXXXXXX
NULL

Doxacurium chloride	DDI-DrugBank.d267.s1	NO_SECTION	NO_SETID	19
The use of NUROMAX before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	17	O	XXXXXXXX
5	19	24	O	before
6	26	40	U-UNK	succinylcholine
7	42	43	O	to
8	45	53	O	attenuate
9	55	58	O	some
10	60	61	O	of
11	63	65	O	the
12	67	70	O	side
13	72	78	O	effects
14	80	81	O	of
15	83	97	U-UNK	succinylcholine
16	99	101	O	has
17	103	105	O	not
18	107	110	O	been
19	112	118	O	studied
NULL

Doxacurium chloride	DDI-DrugBank.d267.s2	NO_SECTION	NO_SETID	16
There are no clinical data on concomitant use of NUROMAX and other nondepolarizing neuromuscular blocking agents.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	20	O	clinical
5	22	25	O	data
6	27	28	O	on
7	30	40	O	concomitant
8	42	44	O	use
9	46	47	O	of
10	49	55	O	XXXXXXXX
11	57	59	O	and
12	61	65	O	other
13	67	81	O	nondepolarizing
14	83	95	B-UNK	neuromuscular
15	97	104	I-UNK	blocking
16	106	111	L-UNK	agents
NULL

Doxacurium chloride	DDI-DrugBank.d267.s3	NO_SECTION	NO_SETID	15
Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.
1	0	9	U-KIN	Isoflurane
2	10	10	O	,
3	12	20	U-KIN	enflurane
4	21	21	O	,
5	23	25	O	and
6	27	35	U-KIN	halothane
7	37	44	O	decrease
8	46	48	O	the
9	50	53	O	ED50
10	55	56	O	of
11	58	64	O	XXXXXXXX
12	66	67	O	by
13	69	71	O	30%
14	73	74	O	to
15	76	78	O	45%
NULL

Doxacurium chloride	DDI-DrugBank.d267.s4	NO_SECTION	NO_SETID	15
These agents may also prolong the clinically effective duration of action by up to 25%.
1	0	4	O	These
2	6	11	O	agents
3	13	15	O	may
4	17	20	O	also
5	22	28	O	prolong
6	30	32	O	the
7	34	43	O	clinically
8	45	53	O	effective
9	55	62	O	duration
10	64	65	O	of
11	67	72	O	action
12	74	75	O	by
13	77	78	O	up
14	80	81	O	to
15	83	85	O	25%
NULL

Doxacurium chloride	DDI-DrugBank.d267.s5	NO_SECTION	NO_SETID	51
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
1	0	4	O	Other
2	6	10	O	drugs
3	12	16	O	which
4	18	20	O	may
5	22	28	O	enhance
6	30	32	O	the
7	34	46	O	neuromuscular
8	48	55	O	blocking
9	57	62	O	action
10	64	65	O	of
11	67	81	O	nondepolarizing
12	83	88	O	agents
13	90	93	O	such
14	95	96	O	as
15	98	104	O	XXXXXXXX
16	106	112	O	include
17	114	120	O	certain
18	122	132	U-DYN	antibiotics
19	135	135	O	e
20	138	138	O	g
21	140	140	O	,
22	142	156	U-DYN	aminoglycosides
23	157	157	O	,
24	159	171	U-DYN	tetracyclines
25	172	172	O	,
26	174	183	U-DYN	bacitracin
27	184	184	O	,
28	186	195	U-DYN	polymyxins
29	196	196	O	,
30	198	207	U-DYN	lincomycin
31	208	208	O	,
32	210	220	U-DYN	clindamycin
33	221	221	O	,
34	223	230	U-DYN	colistin
35	231	231	O	,
36	233	235	O	and
37	237	242	B-DYN	sodium
38	244	257	L-DYN	colistimethate
39	259	259	O	,
40	261	269	U-DYN	magnesium
41	271	275	O	salts
42	276	276	O	,
43	278	284	U-DYN	lithium
44	285	285	O	,
45	287	291	O	local
46	293	303	U-DYN	anesthetics
47	304	304	O	,
48	306	317	U-DYN	procainamide
49	318	318	O	,
50	320	322	O	and
51	324	332	U-DYN	quinidine
NULL

Doxacurium chloride	DDI-DrugBank.d267.s6	NO_SECTION	NO_SETID	34
As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.
1	0	1	O	As
2	3	6	O	with
3	8	11	O	some
4	13	17	O	other
5	19	33	B-UNK	nondepolarizing
6	35	47	I-UNK	neuromuscular
7	49	56	I-UNK	blocking
8	58	63	L-UNK	agents
9	64	64	O	,
10	66	68	O	the
11	70	73	O	time
12	75	76	O	of
13	78	82	O	onset
14	84	85	O	of
15	87	99	O	neuromuscular
16	101	105	O	block
17	107	113	O	induced
18	115	116	O	by
19	118	124	O	XXXXXXXX
20	126	127	O	is
21	129	138	O	lengthened
22	140	142	O	and
23	144	146	O	the
24	148	155	O	duration
25	157	158	O	of
26	160	164	O	block
27	166	167	O	is
28	169	177	O	shortened
29	179	180	O	in
30	182	189	O	patients
31	191	199	O	receiving
32	201	209	U-DYN	phenytoin
33	211	212	O	or
34	214	226	U-DYN	carbamazepine
NULL

Doxapram	DDI-DrugBank.d332.s0	NO_SECTION	NO_SETID	21
Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .
1	0	13	O	Administration
2	15	16	O	of
3	18	25	O	XXXXXXXX
4	27	28	O	to
5	30	37	O	patients
6	39	41	O	who
7	43	45	O	are
8	47	55	O	receiving
9	57	71	U-DYN	sympathomimetic
10	73	74	O	or
11	76	84	B-DYN	monoamine
12	86	92	I-DYN	oxidase
13	94	103	I-DYN	inhibiting
14	105	109	L-DYN	drugs
15	111	113	O	may
16	115	120	O	result
17	122	123	O	in
18	125	126	O	an
19	128	135	O	additive
20	137	143	O	pressor
21	145	150	O	effect
NULL

Doxapram	DDI-DrugBank.d332.s1	NO_SECTION	NO_SETID	19
In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.
1	0	1	O	In
2	3	10	O	patients
3	12	14	O	who
4	16	19	O	have
5	21	28	O	received
6	30	35	B-UNK	muscle
7	37	45	L-UNK	relaxants
8	46	46	O	,
9	48	55	O	XXXXXXXX
10	57	59	O	may
11	61	71	O	temporarily
12	73	76	O	mask
13	78	80	O	the
14	82	89	O	residual
15	91	97	O	effects
16	99	100	O	of
17	102	107	B-DYN	muscle
18	109	116	I-DYN	relaxant
19	118	122	L-DYN	drugs
NULL

Doxapram	DDI-DrugBank.d332.s2	NO_SECTION	NO_SETID	47
In patients who have received general anesthesia utilizing a volatile agent known to sensitize the myocardium to catecholamines, administration of doxapram should be delayed until the volatile agent has been excreted in order to lessen the potential for arrhythmias, including ventricular tachycardia and ventricular fibrillation.
1	0	1	O	In
2	3	10	O	patients
3	12	14	O	who
4	16	19	O	have
5	21	28	O	received
6	30	36	O	general
7	38	47	O	anesthesia
8	49	57	O	utilizing
9	59	59	O	a
10	61	68	O	volatile
11	70	74	O	agent
12	76	80	O	known
13	82	83	O	to
14	85	93	O	sensitize
15	95	97	O	the
16	99	108	O	myocardium
17	110	111	O	to
18	113	126	O	catecholamines
19	127	127	O	,
20	129	142	O	administration
21	144	145	O	of
22	147	154	O	XXXXXXXX
23	156	161	O	should
24	163	164	O	be
25	166	172	O	delayed
26	174	178	O	until
27	180	182	O	the
28	184	191	O	volatile
29	193	197	O	agent
30	199	201	O	has
31	203	206	O	been
32	208	215	O	excreted
33	217	218	O	in
34	220	224	O	order
35	226	227	O	to
36	229	234	O	lessen
37	236	238	O	the
38	240	248	O	potential
39	250	252	O	for
40	254	264	O	arrhythmias
41	265	265	O	,
42	267	275	O	including
43	277	287	O	ventricular
44	289	299	O	tachycardia
45	301	303	O	and
46	305	315	O	ventricular
47	317	328	O	fibrillation
NULL

Doxazosin	DDI-DrugBank.d367.s0	NO_SECTION	NO_SETID	8
Most (98%) of plasma doxazosin is protein bound.
1	0	3	O	Most
2	6	8	O	98%
3	11	12	O	of
4	14	19	O	plasma
5	21	29	O	XXXXXXXX
6	31	32	O	is
7	34	40	O	protein
8	42	46	O	bound
NULL

Doxazosin	DDI-DrugBank.d367.s1	NO_SECTION	NO_SETID	24
In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin.
1	0	1	O	In
2	3	7	O	vitro
3	9	12	O	data
4	14	15	O	in
5	17	21	O	human
6	23	28	O	plasma
7	30	37	O	indicate
8	39	42	O	that
9	44	52	O	XXXXXXXX
10	54	61	O	mesylate
11	63	65	O	has
12	67	68	O	no
13	70	75	O	effect
14	77	78	O	on
15	80	86	O	protein
16	88	94	O	binding
17	96	97	O	of
18	99	105	U-UNK	digoxin
19	106	106	O	,
20	108	115	U-UNK	warfarin
21	116	116	O	,
22	118	126	U-UNK	phenytoin
23	128	129	O	or
24	131	142	U-UNK	indomethacin
NULL

Doxazosin	DDI-DrugBank.d367.s2	NO_SECTION	NO_SETID	17
There is no information on the effect of other highly plasma protein bound drugs on doxazosin binding.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	22	O	information
5	24	25	O	on
6	27	29	O	the
7	31	36	O	effect
8	38	39	O	of
9	41	45	O	other
10	47	52	O	highly
11	54	59	O	plasma
12	61	67	O	protein
13	69	73	O	bound
14	75	79	O	drugs
15	81	82	O	on
16	84	92	O	XXXXXXXX
17	94	100	O	binding
NULL

Doxazosin	DDI-DrugBank.d367.s3	NO_SECTION	NO_SETID	28
Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta-blocking agents, and nonsteroidal anti-inflammatory drugs.
1	0	8	O	XXXXXXXX
2	10	17	O	mesylate
3	19	21	O	has
4	23	26	O	been
5	28	39	O	administered
6	41	47	O	without
7	49	51	O	any
8	53	60	O	evidence
9	62	63	O	of
10	65	66	O	an
11	68	74	O	adverse
12	76	79	O	drug
13	81	91	O	interaction
14	93	94	O	to
15	96	103	O	patients
16	105	113	O	receiving
17	115	122	B-UNK	thiazide
18	124	132	L-UNK	diuretics
19	133	133	O	,
20	135	138	B-UNK	beta
21	140	147	L-UNK	blocking
22	149	154	O	agents
23	155	155	O	,
24	157	159	O	and
25	161	172	B-UNK	nonsteroidal
26	174	177	I-UNK	anti
27	179	190	I-UNK	inflammatory
28	192	196	L-UNK	drugs
NULL

Doxazosin	DDI-DrugBank.d367.s4	NO_SECTION	NO_SETID	63
In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.
1	0	1	O	In
2	3	3	O	a
3	5	11	O	placebo
4	13	22	O	controlled
5	24	28	O	trial
6	30	31	O	in
7	33	38	O	normal
8	40	49	O	volunteers
9	50	50	O	,
10	52	54	O	the
11	56	69	O	administration
12	71	72	O	of
13	74	74	O	a
14	76	81	O	single
15	83	83	O	1
16	85	86	O	mg
17	88	91	O	dose
18	93	94	O	of
19	96	104	O	XXXXXXXX
20	106	107	O	on
21	109	111	O	day
22	113	113	O	1
23	115	116	O	of
24	118	118	O	a
25	120	123	O	four
26	125	127	O	day
27	129	135	O	regimen
28	137	138	O	of
29	140	143	O	oral
30	145	154	U-KIN	cimetidine
31	157	159	O	400
32	161	162	O	mg
33	164	168	O	twice
34	170	174	O	daily
35	177	184	O	resulted
36	186	187	O	in
37	189	189	O	a
38	191	193	O	10%
39	195	202	O	increase
40	204	205	O	in
41	207	210	O	mean
42	212	214	O	AUC
43	216	217	O	of
44	219	227	O	XXXXXXXX
45	230	236	O	p=0.006
46	238	238	O	,
47	240	242	O	and
48	244	244	O	a
49	246	251	O	slight
50	253	255	O	but
51	257	259	O	not
52	261	273	O	statistically
53	275	285	O	significant
54	287	294	O	increase
55	296	297	O	in
56	299	302	O	mean
57	304	307	O	Cmax
58	309	311	O	and
59	313	316	O	mean
60	318	321	O	half
61	323	326	O	life
62	328	329	O	of
63	331	339	O	XXXXXXXX
NULL

Doxazosin	DDI-DrugBank.d367.s5	NO_SECTION	NO_SETID	11
The clinical significance of this increase in doxazosin AUC is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	41	O	increase
7	43	44	O	in
8	46	54	O	XXXXXXXX
9	56	58	O	AUC
10	60	61	O	is
11	63	69	O	unknown
NULL

Doxazosin	DDI-DrugBank.d367.s6	NO_SECTION	NO_SETID	18
In clinical trials, doxazosin mesylate tablets have been administered to patients on a variety of concomitant medications;
1	0	1	O	In
2	3	10	O	clinical
3	12	17	O	trials
4	18	18	O	,
5	20	28	O	XXXXXXXX
6	30	37	O	mesylate
7	39	45	O	tablets
8	47	50	O	have
9	52	55	O	been
10	57	68	O	administered
11	70	71	O	to
12	73	80	O	patients
13	82	83	O	on
14	85	85	O	a
15	87	93	O	variety
16	95	96	O	of
17	98	108	O	concomitant
18	110	120	O	medications
NULL

Doxazosin	DDI-DrugBank.d367.s7	NO_SECTION	NO_SETID	13
while no formal interaction studies have been conducted, no interactions were observed.
1	0	4	O	while
2	6	7	O	no
3	9	14	O	formal
4	16	26	O	interaction
5	28	34	O	studies
6	36	39	O	have
7	41	44	O	been
8	46	54	O	conducted
9	55	55	O	,
10	57	58	O	no
11	60	71	O	interactions
12	73	76	O	were
13	78	85	O	observed
NULL

Doxazosin	DDI-DrugBank.d367.s8	NO_SECTION	NO_SETID	15
Doxazosin mesylate tablets have been used with the following drugs or drug classes: 1.
1	0	8	O	XXXXXXXX
2	10	17	O	mesylate
3	19	25	O	tablets
4	27	30	O	have
5	32	35	O	been
6	37	40	O	used
7	42	45	O	with
8	47	49	O	the
9	51	59	O	following
10	61	65	O	drugs
11	67	68	O	or
12	70	73	O	drug
13	75	81	O	classes
14	82	82	O	:
15	84	84	O	1
NULL

Doxazosin	DDI-DrugBank.d367.s9	NO_SECTION	NO_SETID	18
Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin).
1	0	8	U-UNK	Analgesic
2	9	9	O	/
3	10	13	B-UNK	anti
4	15	26	L-UNK	inflammatory
5	29	31	O	e.g
6	33	33	O	,
7	35	47	U-UNK	acetaminophen
8	48	48	O	,
9	50	56	O	XXXXXXXX
10	57	57	O	,
11	59	65	U-UNK	codeine
12	67	69	O	and
13	71	77	U-UNK	codeine
14	79	90	O	combinations
15	91	91	O	,
16	93	101	U-UNK	ibuprofen
17	102	102	O	,
18	104	115	U-UNK	indomethacin
NULL

Doxazosin	DDI-DrugBank.d367.s11	NO_SECTION	NO_SETID	10
Antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin).
1	0	10	U-UNK	Antibiotics
2	13	15	O	e.g
3	17	17	O	,
4	19	30	U-UNK	erythromycin
5	31	31	O	,
6	33	44	U-UNK	trimethoprim
7	46	48	O	and
8	50	65	U-UNK	sulfamethoxazole
9	66	66	O	,
10	68	78	U-UNK	amoxicillin
NULL

Doxazosin	DDI-DrugBank.d367.s13	NO_SECTION	NO_SETID	4
Antihistamines (e.g., chlorpheniramine).
1	0	13	U-UNK	Antihistamines
2	16	18	O	e.g
3	20	20	O	,
4	22	37	U-UNK	chlorpheniramine
NULL

Doxazosin	DDI-DrugBank.d367.s15	NO_SECTION	NO_SETID	9
Cardiovascular agents (e.g., atenolol, hydrochlorothiazide, propranolol).
1	0	13	O	Cardiovascular
2	15	20	O	agents
3	23	25	O	e.g
4	27	27	O	,
5	29	36	U-UNK	atenolol
6	37	37	O	,
7	39	57	U-UNK	hydrochlorothiazide
8	58	58	O	,
9	60	70	U-UNK	propranolol
NULL

Doxazosin	DDI-DrugBank.d367.s19	NO_SECTION	NO_SETID	5
Gastrointestinal agents (e.g., antacids).
1	0	15	O	Gastrointestinal
2	17	22	O	agents
3	25	27	O	e.g
4	29	29	O	,
5	31	38	U-UNK	antacids
NULL

Doxazosin	DDI-DrugBank.d367.s21	NO_SECTION	NO_SETID	4
Hypoglycemics and endocrine drugs.
1	0	12	U-UNK	Hypoglycemics
2	14	16	O	and
3	18	26	O	endocrine
4	28	32	O	drugs
NULL

Doxazosin	DDI-DrugBank.d367.s23	NO_SECTION	NO_SETID	6
Sedatives and tranquilizers (e.g., diazepam).
1	0	8	U-UNK	Sedatives
2	10	12	O	and
3	14	26	U-UNK	tranquilizers
4	29	31	O	e.g
5	33	33	O	,
6	35	42	U-UNK	diazepam
NULL

Doxazosin	DDI-DrugBank.d367.s25	NO_SECTION	NO_SETID	4
Cold and flu remedies.
1	0	3	O	Cold
2	5	7	O	and
3	9	11	O	flu
4	13	20	O	remedies
NULL

Doxepin	DDI-DrugBank.d223.s0	NO_SECTION	NO_SETID	38
Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called poor metabolizers);
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	24	O	P450
5	26	28	O	2D6
6	29	29	O	:
7	31	33	O	The
8	35	45	O	biochemical
9	47	54	O	activity
10	56	57	O	of
11	59	61	O	the
12	63	66	O	drug
13	68	79	O	metabolizing
14	81	87	O	isozyme
15	89	98	O	cytochrome
16	100	103	O	P450
17	105	107	O	2D6
18	110	120	O	debrisoquin
19	122	132	O	hydroxylase
20	135	136	O	is
21	138	144	O	reduced
22	146	147	O	in
23	149	149	O	a
24	151	156	O	subset
25	158	159	O	of
26	161	163	O	the
27	165	173	O	Caucasian
28	175	184	O	population
29	187	191	O	about
30	193	193	O	7
31	195	197	O	10%
32	199	200	O	of
33	202	211	O	Caucasians
34	213	215	O	are
35	217	218	O	so
36	220	225	O	called
37	227	230	O	poor
38	232	243	O	metabolizers
NULL

Doxepin	DDI-DrugBank.d223.s1	NO_SECTION	NO_SETID	22
reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
1	0	7	O	reliable
2	9	17	O	estimates
3	19	20	O	of
4	22	24	O	the
5	26	35	O	prevalence
6	37	38	O	of
7	40	46	O	reduced
8	48	51	O	P450
9	53	55	O	2D6
10	57	63	O	isozyme
11	65	72	O	activity
12	74	78	O	among
13	80	84	O	Asian
14	85	85	O	,
15	87	93	O	African
16	95	97	O	and
17	99	103	O	other
18	105	115	O	populations
19	117	119	O	are
20	121	123	O	not
21	125	127	O	yet
22	129	137	O	available
NULL

Doxepin	DDI-DrugBank.d223.s2	NO_SECTION	NO_SETID	16
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
1	0	3	O	Poor
2	5	16	O	metabolizers
3	18	21	O	have
4	23	28	O	higher
5	30	33	O	than
6	35	42	O	expected
7	44	49	O	plasma
8	51	64	O	concentrations
9	66	67	O	of
10	69	77	B-UNK	tricyclic
11	79	93	L-UNK	antidepressants
12	96	99	U-UNK	TCAs
13	102	105	O	when
14	107	111	O	given
15	113	117	O	usual
16	119	123	O	doses
NULL

Doxepin	DDI-DrugBank.d223.s3	NO_SECTION	NO_SETID	32
Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).
1	0	8	O	Depending
2	10	11	O	on
3	13	15	O	the
4	17	24	O	fraction
5	26	27	O	of
6	29	32	O	drug
7	34	44	O	metabolized
8	46	47	O	by
9	49	52	O	P450
10	54	56	O	2D6
11	57	57	O	,
12	59	61	O	the
13	63	70	O	increase
14	72	73	O	in
15	75	80	O	plasma
16	82	94	O	concentration
17	96	98	O	may
18	100	101	O	be
19	103	107	O	small
20	108	108	O	,
21	110	111	O	or
22	113	117	O	quite
23	119	123	O	large
24	126	126	O	8
25	128	131	O	fold
26	133	140	O	increase
27	142	143	O	in
28	145	150	O	plasma
29	152	154	O	AUC
30	156	157	O	of
31	159	161	O	the
32	163	165	O	TCA
NULL

Doxepin	DDI-DrugBank.d223.s4	NO_SECTION	NO_SETID	18
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	certain
5	21	25	O	drugs
6	27	33	O	inhibit
7	35	37	O	the
8	39	46	O	activity
9	48	49	O	of
10	51	54	O	this
11	56	62	O	isozyme
12	64	66	O	and
13	68	71	O	make
14	73	78	O	normal
15	80	91	O	metabolizers
16	93	100	O	resemble
17	102	105	O	poor
18	107	118	O	metabolizers
NULL

Doxepin	DDI-DrugBank.d223.s5	NO_SECTION	NO_SETID	25
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
1	0	1	O	An
2	3	12	O	individual
3	14	16	O	who
4	18	19	O	is
5	21	26	O	stable
6	28	29	O	on
7	31	31	O	a
8	33	37	O	given
9	39	42	O	dose
10	44	45	O	of
11	47	49	U-UNK	TCA
12	51	53	O	may
13	55	60	O	become
14	62	69	O	abruptly
15	71	75	O	toxic
16	77	80	O	when
17	82	86	O	given
18	88	90	O	one
19	92	93	O	of
20	95	99	O	these
21	101	110	O	inhibiting
22	112	116	O	drugs
23	118	119	O	as
24	121	131	O	concomitant
25	133	139	O	therapy
NULL

Doxepin	DDI-DrugBank.d223.s6	NO_SECTION	NO_SETID	17
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;
1	0	2	O	The
2	4	8	O	drugs
3	10	13	O	that
4	15	21	O	inhibit
5	23	32	O	cytochrome
6	34	37	O	P450
7	39	41	O	2D6
8	43	49	O	include
9	51	54	O	some
10	56	59	O	that
11	61	63	O	are
12	65	67	O	not
13	69	79	O	metabolized
14	81	82	O	by
15	84	86	O	the
16	88	93	O	enzyme
17	96	104	U-UNK	quinidine
NULL

Doxepin	DDI-DrugBank.d223.s7	NO_SECTION	NO_SETID	23
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
1	0	9	U-UNK	cimetidine
2	12	14	O	and
3	16	19	O	many
4	21	24	O	that
5	26	28	O	are
6	30	39	O	substrates
7	41	43	O	for
8	45	48	O	P450
9	50	52	O	2D6
10	55	58	O	many
11	60	64	O	other
12	66	80	U-UNK	antidepressants
13	81	81	O	,
14	83	96	U-UNK	phenothiazines
15	97	97	O	,
16	99	101	O	and
17	103	105	O	the
18	107	110	B-UNK	Type
19	112	113	I-UNK	1C
20	115	129	L-UNK	antiarrhythmics
21	131	141	U-UNK	propafenone
22	143	145	O	and
23	147	156	U-UNK	flecainide
NULL

Doxepin	DDI-DrugBank.d223.s8	NO_SECTION	NO_SETID	34
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
1	0	4	O	While
2	6	8	O	all
3	10	12	O	the
4	14	22	B-UNK	selective
5	24	32	I-UNK	serotonin
6	34	41	I-UNK	reuptake
7	43	52	L-UNK	inhibitors
8	55	59	U-UNK	SSRIs
9	61	61	O	,
10	63	65	O	e.g
11	67	67	O	,
12	69	78	U-UNK	citalopram
13	79	79	O	,
14	81	92	U-UNK	escitalopram
15	93	93	O	,
16	95	104	U-UNK	fluoxetine
17	105	105	O	,
18	107	116	U-UNK	sertraline
19	117	117	O	,
20	119	121	O	and
21	123	132	U-UNK	paroxetine
22	133	133	O	,
23	135	141	O	inhibit
24	143	146	O	P450
25	148	150	O	2D6
26	151	151	O	,
27	153	156	O	they
28	158	160	O	may
29	162	165	O	vary
30	167	168	O	in
31	170	172	O	the
32	174	179	O	extent
33	181	182	O	of
34	184	193	O	inhibition
NULL

Doxepin	DDI-DrugBank.d223.s9	NO_SECTION	NO_SETID	25
The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	to
4	14	18	O	which
5	20	23	U-UNK	SSRI
6	25	27	U-UNK	TCA
7	29	40	O	interactions
8	42	44	O	may
9	46	49	O	pose
10	51	58	O	clinical
11	60	67	O	problems
12	69	72	O	will
13	74	79	O	depend
14	81	82	O	on
15	84	86	O	the
16	88	93	O	degree
17	95	96	O	of
18	98	107	O	inhibition
19	109	111	O	and
20	113	115	O	the
21	117	132	O	pharmacokinetics
22	134	135	O	of
23	137	139	O	the
24	141	144	U-UNK	SSRI
25	146	153	O	involved
NULL

Doxepin	DDI-DrugBank.d223.s10	NO_SECTION	NO_SETID	26
Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	O	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	43	O	co
9	45	58	O	administration
10	60	61	O	of
11	63	66	U-UNK	TCAs
12	68	71	O	with
13	73	75	O	any
14	77	78	O	of
15	80	82	O	the
16	84	88	U-UNK	SSRIs
17	90	92	O	and
18	94	97	O	also
19	99	100	O	in
20	102	110	O	switching
21	112	115	O	from
22	117	119	O	one
23	121	125	O	class
24	127	128	O	to
25	130	132	O	the
26	134	138	O	other
NULL

Doxepin	DDI-DrugBank.d223.s11	NO_SECTION	NO_SETID	38
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
1	0	1	O	Of
2	3	12	O	particular
3	14	23	O	importance
4	24	24	O	,
5	26	35	O	sufficient
6	37	40	O	time
7	42	45	O	must
8	47	52	O	elapse
9	54	59	O	before
10	61	70	O	initiating
11	72	74	O	TCA
12	76	84	O	treatment
13	86	87	O	in
14	89	89	O	a
15	91	97	O	patient
16	99	103	O	being
17	105	113	O	withdrawn
18	115	118	O	from
19	120	129	U-UNK	fluoxetine
20	130	130	O	,
21	132	136	O	given
22	138	140	O	the
23	142	145	O	long
24	147	150	O	half
25	152	155	O	life
26	157	158	O	of
27	160	162	O	the
28	164	169	O	parent
29	171	173	O	and
30	175	180	O	active
31	182	191	O	metabolite
32	194	195	O	at
33	197	201	O	least
34	203	203	O	5
35	205	209	O	weeks
36	211	213	O	may
37	215	216	O	be
38	218	226	O	necessary
NULL

Doxepin	DDI-DrugBank.d223.s12	NO_SECTION	NO_SETID	29
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	27	B-UNK	tricyclic
5	29	43	L-UNK	antidepressants
6	45	48	O	with
7	50	54	O	drugs
8	56	59	O	that
9	61	63	O	can
10	65	71	O	inhibit
11	73	82	O	cytochrome
12	84	87	O	P450
13	89	91	O	2D6
14	93	95	O	may
15	97	103	O	require
16	105	109	O	lower
17	111	115	O	doses
18	117	120	O	than
19	122	128	O	usually
20	130	139	O	prescribed
21	141	143	O	for
22	145	150	O	either
23	152	154	O	the
24	156	164	B-UNK	tricyclic
25	166	179	L-UNK	antidepressant
26	181	182	O	or
27	184	186	O	the
28	188	192	O	other
29	194	197	O	drug
NULL

Doxepin	DDI-DrugBank.d223.s13	NO_SECTION	NO_SETID	23
Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	20	O	whenever
4	22	24	O	one
5	26	27	O	of
6	29	33	O	these
7	35	39	O	other
8	41	45	O	drugs
9	47	48	O	is
10	50	58	O	withdrawn
11	60	63	O	from
12	65	66	O	co
13	68	74	O	therapy
14	75	75	O	,
15	77	78	O	an
16	80	88	O	increased
17	90	93	O	dose
18	95	96	O	of
19	98	106	B-UNK	tricyclic
20	108	121	L-UNK	antidepressant
21	123	125	O	may
22	127	128	O	be
23	130	137	O	required
NULL

Doxepin	DDI-DrugBank.d223.s14	NO_SECTION	NO_SETID	28
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	desirable
4	16	17	O	to
5	19	25	O	monitor
6	27	29	U-UNK	TCA
7	31	36	O	plasma
8	38	43	O	levels
9	45	52	O	whenever
10	54	54	O	a
11	56	58	U-UNK	TCA
12	60	61	O	is
13	63	67	O	going
14	69	70	O	to
15	72	73	O	be
16	75	76	O	co
17	78	89	O	administered
18	91	94	O	with
19	96	102	O	another
20	104	107	O	drug
21	109	113	O	known
22	115	116	O	to
23	118	119	O	be
24	121	122	O	an
25	124	132	O	inhibitor
26	134	135	O	of
27	137	140	O	P450
28	142	144	O	2D6
NULL

Doxepin	DDI-DrugBank.d223.s15	NO_SECTION	NO_SETID	13
Doxepin is primarily metabolized by CYP2D6 (with CYP1A2  and  CYP3A4 as minor pathways).
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	19	O	primarily
4	21	31	O	metabolized
5	33	34	O	by
6	36	41	O	CYP2D6
7	44	47	O	with
8	49	54	O	CYP1A2
9	57	59	O	and
10	62	67	O	CYP3A4
11	69	70	O	as
12	72	76	O	minor
13	78	85	O	pathways
NULL

Doxepin	DDI-DrugBank.d223.s16	NO_SECTION	NO_SETID	24
Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.
1	0	9	O	Inhibitors
2	11	12	O	or
3	14	23	O	substrates
4	25	26	O	of
5	28	33	O	CYP2D6
6	36	38	O	i.e
7	40	40	O	,
8	42	50	U-KIN	quinidine
9	51	51	O	,
10	53	61	B-KIN	selective
11	63	71	I-KIN	serotonin
12	73	80	I-KIN	reuptake
13	82	91	L-KIN	inhibitors
14	94	98	U-KIN	SSRIs
15	102	104	O	may
16	106	113	O	increase
17	115	117	O	the
18	119	124	O	plasma
19	126	138	O	concentration
20	140	141	O	of
21	143	149	O	XXXXXXXX
22	151	154	O	when
23	156	167	O	administered
24	169	181	O	concomitantly
NULL

Doxepin	DDI-DrugBank.d223.s17	NO_SECTION	NO_SETID	12
The extent of interaction depends on the variability of effect on CYP2D6.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	of
4	14	24	O	interaction
5	26	32	O	depends
6	34	35	O	on
7	37	39	O	the
8	41	51	O	variability
9	53	54	O	of
10	56	61	O	effect
11	63	64	O	on
12	66	71	O	CYP2D6
NULL

Doxepin	DDI-DrugBank.d223.s18	NO_SECTION	NO_SETID	13
The clinical significance of this interaction with doxepin has not been systematically evaluated.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	44	O	interaction
7	46	49	O	with
8	51	57	O	XXXXXXXX
9	59	61	O	has
10	63	65	O	not
11	67	70	O	been
12	72	85	O	systematically
13	87	95	O	evaluated
NULL

Doxepin	DDI-DrugBank.d223.s19	NO_SECTION	NO_SETID	22
MAO Inhibitors: Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors.
1	0	2	B-UNK	MAO
2	4	13	L-UNK	Inhibitors
3	14	14	O	:
4	16	22	O	Serious
5	24	27	O	side
6	29	35	O	effects
7	37	39	O	and
8	41	44	O	even
9	46	50	O	death
10	52	55	O	have
11	57	60	O	been
12	62	69	O	reported
13	71	79	O	following
14	81	83	O	the
15	85	95	O	concomitant
16	97	99	O	use
17	101	102	O	of
18	104	110	O	certain
19	112	116	O	drugs
20	118	121	O	with
21	123	125	B-UNK	MAO
22	127	136	L-UNK	inhibitors
NULL

Doxepin	DDI-DrugBank.d223.s20	NO_SECTION	NO_SETID	20
Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with SINEQUAN.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	B-DYN	MAO
4	15	24	L-DYN	inhibitors
5	26	31	O	should
6	33	34	O	be
7	36	47	O	discontinued
8	49	50	O	at
9	52	56	O	least
10	58	60	O	two
11	62	66	O	weeks
12	68	72	O	prior
13	74	75	O	to
14	77	79	O	the
15	81	88	O	cautious
16	90	99	O	initiation
17	101	102	O	of
18	104	110	O	therapy
19	112	115	O	with
20	117	124	O	XXXXXXXX
NULL

Doxepin	DDI-DrugBank.d223.s21	NO_SECTION	NO_SETID	31
The exact length of time may vary and is dependent upon the particular MAO inhibitor being used, the length of time it has been administered, and the dosage involved.
1	0	2	O	The
2	4	8	O	exact
3	10	15	O	length
4	17	18	O	of
5	20	23	O	time
6	25	27	O	may
7	29	32	O	vary
8	34	36	O	and
9	38	39	O	is
10	41	49	O	dependent
11	51	54	O	upon
12	56	58	O	the
13	60	69	O	particular
14	71	73	B-UNK	MAO
15	75	83	L-UNK	inhibitor
16	85	89	O	being
17	91	94	O	used
18	95	95	O	,
19	97	99	O	the
20	101	106	O	length
21	108	109	O	of
22	111	114	O	time
23	116	117	O	it
24	119	121	O	has
25	123	126	O	been
26	128	139	O	administered
27	140	140	O	,
28	142	144	O	and
29	146	148	O	the
30	150	155	O	dosage
31	157	164	O	involved
NULL

Doxepin	DDI-DrugBank.d223.s22	NO_SECTION	NO_SETID	20
Cimetidine: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.
1	0	9	U-UNK	Cimetidine
2	10	10	O	:
3	12	21	U-UNK	Cimetidine
4	23	25	O	has
5	27	30	O	been
6	32	39	O	reported
7	41	42	O	to
8	44	50	O	produce
9	52	61	O	clinically
10	63	73	O	significant
11	75	86	O	fluctuations
12	88	89	O	in
13	91	96	O	steady
14	98	102	O	state
15	104	108	O	serum
16	110	123	O	concentrations
17	125	126	O	of
18	128	134	O	various
19	136	144	B-UNK	tricyclic
20	146	160	L-UNK	antidepressants
NULL

Doxepin	DDI-DrugBank.d223.s23	NO_SECTION	NO_SETID	31
Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated.
1	0	6	O	Serious
2	8	22	O	anticholinergic
3	24	31	O	symptoms
4	34	36	O	i.e
5	38	38	O	,
6	40	45	O	severe
7	47	49	O	dry
8	51	55	O	mouth
9	56	56	O	,
10	58	64	O	urinary
11	66	74	O	retention
12	76	78	O	and
13	80	86	O	blurred
14	88	93	O	vision
15	96	99	O	have
16	101	104	O	been
17	106	115	O	associated
18	117	120	O	with
19	122	131	O	elevations
20	133	134	O	in
21	136	138	O	the
22	140	144	O	serum
23	146	151	O	levels
24	153	154	O	of
25	156	164	B-UNK	tricyclic
26	166	179	L-UNK	antidepressant
27	181	184	O	when
28	186	195	U-UNK	cimetidine
29	197	203	O	therapy
30	205	206	O	is
31	208	216	O	initiated
NULL

Doxepin	DDI-DrugBank.d223.s24	NO_SECTION	NO_SETID	20
Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine.
1	0	11	O	Additionally
2	12	12	O	,
3	14	19	O	higher
4	21	24	O	than
5	26	33	O	expected
6	35	43	B-UNK	tricyclic
7	45	58	L-UNK	antidepressant
8	60	65	O	levels
9	67	70	O	have
10	72	75	O	been
11	77	84	O	observed
12	86	89	O	when
13	91	94	O	they
14	96	98	O	are
15	100	104	O	begun
16	106	107	O	in
17	109	116	O	patients
18	118	124	O	already
19	126	131	O	taking
20	133	142	U-UNK	cimetidine
NULL

Doxepin	DDI-DrugBank.d223.s25	NO_SECTION	NO_SETID	38
In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.
1	0	1	O	In
2	3	10	O	patients
3	12	14	O	who
4	16	19	O	have
5	21	24	O	been
6	26	33	O	reported
7	35	36	O	to
8	38	39	O	be
9	41	44	O	well
10	46	55	O	controlled
11	57	58	O	on
12	60	68	B-UNK	tricyclic
13	70	84	L-UNK	antidepressants
14	86	94	O	receiving
15	96	105	O	concurrent
16	107	116	U-UNK	cimetidine
17	118	124	O	therapy
18	125	125	O	,
19	127	141	O	discontinuation
20	143	144	O	of
21	146	155	U-UNK	cimetidine
22	157	159	O	has
23	161	164	O	been
24	166	173	O	reported
25	175	176	O	to
26	178	185	O	decrease
27	187	197	O	established
28	199	204	O	steady
29	206	210	O	state
30	212	216	O	serum
31	218	226	B-UNK	tricyclic
32	228	241	L-UNK	antidepressant
33	243	248	O	levels
34	250	252	O	and
35	254	263	O	compromise
36	265	269	O	their
37	271	281	O	therapeutic
38	283	289	O	effects
NULL

Doxepin	DDI-DrugBank.d223.s26	NO_SECTION	NO_SETID	23
Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.
1	0	6	U-UNK	Alcohol
2	7	7	O	:
3	9	10	O	It
4	12	17	O	should
5	19	20	O	be
6	22	26	O	borne
7	28	29	O	in
8	31	34	O	mind
9	36	39	O	that
10	41	47	U-KIN	alcohol
11	49	57	O	ingestion
12	59	61	O	may
13	63	70	O	increase
14	72	74	O	the
15	76	81	O	danger
16	83	90	O	inherent
17	92	93	O	in
18	95	97	O	any
19	99	109	O	intentional
20	111	112	O	or
21	114	126	O	unintentional
22	128	135	O	XXXXXXXX
23	137	146	O	overdosage
NULL

Doxepin	DDI-DrugBank.d223.s27	NO_SECTION	NO_SETID	11
This is especially important in patients who may use alcohol excessively.
1	0	3	O	This
2	5	6	O	is
3	8	17	O	especially
4	19	27	O	important
5	29	30	O	in
6	32	39	O	patients
7	41	43	O	who
8	45	47	O	may
9	49	51	O	use
10	53	59	U-UNK	alcohol
11	61	71	O	excessively
NULL

Doxepin	DDI-DrugBank.d223.s28	NO_SECTION	NO_SETID	34
Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).
1	0	9	U-UNK	Tolazamide
2	10	10	O	:
3	12	12	O	A
4	14	17	O	case
5	19	20	O	of
6	22	27	O	severe
7	29	40	O	hypoglycemia
8	42	44	O	has
9	46	49	O	been
10	51	58	O	reported
11	60	61	O	in
12	63	63	O	a
13	65	68	O	type
14	70	71	O	II
15	73	80	O	diabetic
16	82	88	O	patient
17	90	99	O	maintained
18	101	102	O	on
19	104	113	U-DYN	tolazamide
20	116	116	O	1
21	118	119	O	gm
22	120	120	O	/
23	121	123	O	day
24	126	127	O	11
25	129	132	O	days
26	134	138	O	after
27	140	142	O	the
28	144	151	O	addition
29	153	154	O	of
30	156	162	O	XXXXXXXX
31	165	166	O	75
32	168	169	O	mg
33	170	170	O	/
34	171	173	O	day
NULL

Doxorubicin	DDI-DrugBank.d127.s0	NO_SECTION	NO_SETID	10
No formal drug interaction studies have been conducted with DOXIL  .
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	25	O	interaction
5	27	33	O	studies
6	35	38	O	have
7	40	43	O	been
8	45	53	O	conducted
9	55	58	O	with
10	60	64	O	XXXXXXXX
NULL

Doxorubicin	DDI-DrugBank.d127.s1	NO_SECTION	NO_SETID	18
Until specific compatibility data are available, it is not recommended that DOXIL  be mixed with other drugs.
1	0	4	O	Until
2	6	13	O	specific
3	15	27	O	compatibility
4	29	32	O	data
5	34	36	O	are
6	38	46	O	available
7	47	47	O	,
8	49	50	O	it
9	52	53	O	is
10	55	57	O	not
11	59	69	O	recommended
12	71	74	O	that
13	76	80	O	XXXXXXXX
14	83	84	O	be
15	86	90	O	mixed
16	92	95	O	with
17	97	101	O	other
18	103	107	O	drugs
NULL

Doxorubicin	DDI-DrugBank.d127.s2	NO_SECTION	NO_SETID	15
DOXIL  may interact with drugs known to interact with the conventional formulation of doxorubicin HCl.
1	0	4	O	XXXXXXXX
2	7	9	O	may
3	11	18	O	interact
4	20	23	O	with
5	25	29	O	drugs
6	31	35	O	known
7	37	38	O	to
8	40	47	O	interact
9	49	52	O	with
10	54	56	O	the
11	58	69	O	conventional
12	71	81	O	formulation
13	83	84	O	of
14	86	96	B-UNK	doxorubicin
15	98	100	L-UNK	HCl
NULL

Doxycycline	DDI-DrugBank.d500.s0	NO_SECTION	NO_SETID	25
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
1	0	6	O	Because
2	8	20	U-UNK	tetracyclines
3	22	25	O	have
4	27	30	O	been
5	32	36	O	shown
6	38	39	O	to
7	41	47	O	depress
8	49	54	O	plasma
9	56	66	O	prothrombin
10	68	75	O	activity
11	76	76	O	,
12	78	85	O	patients
13	87	89	O	who
14	91	93	O	are
15	95	96	O	on
16	98	110	U-UNK	anticoagulant
17	112	118	O	therapy
18	120	122	O	may
19	124	130	O	require
20	132	139	O	downward
21	141	150	O	adjustment
22	152	153	O	of
23	155	159	O	their
24	161	173	U-UNK	anticoagulant
25	175	180	O	dosage
NULL

Doxycycline	DDI-DrugBank.d500.s1	NO_SECTION	NO_SETID	23
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.
1	0	4	O	Since
2	6	19	O	bacteriostatic
3	21	25	O	drugs
4	27	29	O	may
5	31	39	O	interfere
6	41	44	O	with
7	46	48	O	the
8	50	61	O	bactericidal
9	63	68	O	action
10	70	71	O	of
11	73	82	U-UNK	penicillin
12	83	83	O	,
13	85	86	O	it
14	88	89	O	is
15	91	99	O	advisable
16	101	102	O	to
17	104	108	O	avoid
18	110	115	O	giving
19	117	129	U-UNK	tetracyclines
20	131	132	O	in
21	134	144	O	conjunction
22	146	149	O	with
23	151	160	U-UNK	penicillin
NULL

Doxycycline	DDI-DrugBank.d500.s2	NO_SECTION	NO_SETID	19
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
1	0	9	O	Absorption
2	11	12	O	of
3	14	26	U-UNK	tetracyclines
4	28	29	O	is
5	31	38	O	impaired
6	40	41	O	by
7	43	50	U-UNK	antacids
8	52	61	O	containing
9	63	70	U-UNK	aluminum
10	71	71	O	,
11	73	79	U-UNK	calcium
12	80	80	O	,
13	82	83	O	or
14	85	93	U-UNK	magnesium
15	94	94	O	,
16	96	98	O	and
17	100	103	U-UNK	iron
18	105	114	O	containing
19	116	127	O	preparations
NULL

Doxycycline	DDI-DrugBank.d500.s3	NO_SECTION	NO_SETID	8
Absorption of tetracycline is impaired by bismuth subsalicylate.
1	0	9	O	Absorption
2	11	12	O	of
3	14	25	U-UNK	tetracycline
4	27	28	O	is
5	30	37	O	impaired
6	39	40	O	by
7	42	48	B-UNK	bismuth
8	50	62	L-UNK	subsalicylate
NULL

Doxycycline	DDI-DrugBank.d500.s4	NO_SECTION	NO_SETID	12
Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
1	0	11	U-KIN	Barbiturates
2	12	12	O	,
3	14	26	U-KIN	carbamazepine
4	27	27	O	,
5	29	31	O	and
6	33	41	U-KIN	phenytoin
7	43	50	O	decrease
8	52	54	O	the
9	56	59	O	half
10	61	64	O	life
11	66	67	O	of
12	69	79	O	XXXXXXXX
NULL

Doxycycline	DDI-DrugBank.d500.s5	NO_SECTION	NO_SETID	17
The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.
1	0	2	O	The
2	4	13	O	concurrent
3	15	17	O	use
4	19	20	O	of
5	22	33	U-DYN	tetracycline
6	35	37	O	and
7	39	47	O	XXXXXXXX
8	50	63	U-UNK	methoxyflurane
9	66	68	O	has
10	70	73	O	been
11	75	82	O	reported
12	84	85	O	to
13	87	92	O	result
14	94	95	O	in
15	97	101	O	fatal
16	103	107	O	renal
17	109	116	O	toxicity
NULL

Doxycycline	DDI-DrugBank.d500.s6	NO_SECTION	NO_SETID	10
Concurrent use of tetracycline may render oral contraceptives less effective.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	16	O	of
4	18	29	U-UNK	tetracycline
5	31	33	O	may
6	35	40	O	render
7	42	45	O	oral
8	47	60	U-UNK	contraceptives
9	62	65	O	less
10	67	75	O	effective
NULL

Doxycycline	DDI-DrugBank.d500.s7	NO_SECTION	NO_SETID	20
Drug/Laboratory Test Interactions False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	38	O	False
7	40	49	O	elevations
8	51	52	O	of
9	54	60	O	urinary
10	62	74	O	catecholamine
11	76	81	O	levels
12	83	85	O	may
13	87	91	O	occur
14	93	95	O	due
15	97	98	O	to
16	100	111	O	interference
17	113	116	O	with
18	118	120	O	the
19	122	133	O	fluorescence
20	135	138	O	test
NULL

Doxylamine	DDI-DrugBank.d387.s0	NO_SECTION	NO_SETID	18
Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.
1	0	8	O	Potential
2	10	13	O	drug
3	15	26	O	interactions
4	28	30	O	for
5	32	41	O	XXXXXXXX
6	43	49	O	include
7	50	50	O	,
8	52	60	O	increased
9	62	69	O	sedation
10	71	72	O	if
11	74	83	O	XXXXXXXX
12	85	86	O	is
13	88	95	O	combined
14	97	100	O	with
15	102	106	O	other
16	108	110	B-DYN	CNS
17	112	121	I-DYN	depressant
18	123	127	L-DYN	drugs
NULL

Doxylamine	DDI-DrugBank.d387.s1	NO_SECTION	NO_SETID	11
Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.
1	0	13	U-UNK	Antihistamines
2	15	17	O	may
3	19	27	O	partially
4	29	38	O	counteract
5	40	42	O	the
6	44	58	O	anticoagulation
7	60	66	O	effects
8	68	69	O	of
9	71	77	U-UNK	heparin
10	79	80	O	or
11	82	89	U-UNK	warfarin
NULL

Doxylamine	DDI-DrugBank.d387.s2	NO_SECTION	NO_SETID	7
Doxylamine may enhance the effects of epinephrine.
1	0	9	O	XXXXXXXX
2	11	13	O	may
3	15	21	O	enhance
4	23	25	O	the
5	27	33	O	effects
6	35	36	O	of
7	38	48	U-DYN	epinephrine
NULL

Dromostanolone	DDI-DrugBank.d129.s0	NO_SECTION	NO_SETID	7
Androgens may increase sensitivity to oral anticoagulahts.
1	0	8	U-UNK	Androgens
2	10	12	O	may
3	14	21	O	increase
4	23	33	O	sensitivity
5	35	36	O	to
6	38	41	O	oral
7	43	56	O	anticoagulahts
NULL

Dromostanolone	DDI-DrugBank.d129.s1	NO_SECTION	NO_SETID	14
Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.
1	0	5	O	Dosage
2	7	8	O	of
3	10	12	O	the
4	14	26	U-UNK	anticoagulant
5	28	30	O	may
6	32	38	O	require
7	40	48	O	reduction
8	50	51	O	in
9	53	57	O	order
10	59	60	O	to
11	62	69	O	maintain
12	71	82	O	satisfactory
13	84	94	O	therapeutic
14	96	114	O	hypoprothrombinemia
NULL

Dromostanolone	DDI-DrugBank.d129.s2	NO_SECTION	NO_SETID	14
Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	43	U-UNK	oxyphenbutazone
5	45	47	O	and
6	49	57	U-UNK	androgens
7	59	61	O	may
8	63	68	O	result
9	70	71	O	in
10	73	80	O	elevated
11	82	86	O	serum
12	88	93	O	levels
13	95	96	O	of
14	98	112	U-UNK	oxyphenbutazone
NULL

Dromostanolone	DDI-DrugBank.d129.s3	NO_SECTION	NO_SETID	18
In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
1	0	1	O	In
2	3	10	O	diabetic
3	12	19	O	patients
4	20	20	O	,
5	22	24	O	the
6	26	34	O	metabolic
7	36	42	O	effects
8	44	45	O	of
9	47	55	U-UNK	androgens
10	57	59	O	may
11	61	68	O	decrease
12	70	74	O	blood
13	76	82	O	glucose
14	84	86	O	and
15	88	96	O	therefore
16	97	97	O	,
17	99	105	U-UNK	insulin
18	107	118	O	requirements
NULL

Droperidol	DDI-DrugBank.d254.s0	NO_SECTION	NO_SETID	20
Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.
1	0	4	O	Other
2	6	8	B-DYN	CNS
3	10	19	I-DYN	depressant
4	21	25	L-DYN	drugs
5	28	30	O	e.g
6	33	44	U-DYN	barbiturates
7	45	45	O	,
8	47	59	U-DYN	tranquilizers
9	60	60	O	,
10	62	68	U-DYN	opioids
11	70	72	O	and
12	74	80	O	general
13	82	92	U-DYN	anesthetics
14	95	98	O	have
15	100	107	O	additive
16	109	110	O	or
17	112	123	O	potentiating
18	125	131	O	effects
19	133	136	O	with
20	138	145	O	XXXXXXXX
NULL

Droperidol	DDI-DrugBank.d254.s1	NO_SECTION	NO_SETID	17
When patients have received such drugs, the dose of INAPSINE required will be less than usual.
1	0	3	O	When
2	5	12	O	patients
3	14	17	O	have
4	19	26	O	received
5	28	31	O	such
6	33	37	O	drugs
7	38	38	O	,
8	40	42	O	the
9	44	47	O	dose
10	49	50	O	of
11	52	59	O	XXXXXXXX
12	61	68	O	required
13	70	73	O	will
14	75	76	O	be
15	78	81	O	less
16	83	86	O	than
17	88	92	O	usual
NULL

Droperidol	DDI-DrugBank.d254.s2	NO_SECTION	NO_SETID	16
Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.
1	0	8	O	Following
2	10	12	O	the
3	14	27	O	administration
4	29	30	O	of
5	32	39	O	XXXXXXXX
6	40	40	O	,
7	42	44	O	the
8	46	49	O	dose
9	51	52	O	of
10	54	58	O	other
11	60	62	B-DYN	CNS
12	64	73	I-DYN	depressant
13	75	79	L-DYN	drugs
14	81	86	O	should
15	88	89	O	be
16	91	97	O	reduced
NULL

Drotrecogin alfa	DDI-DrugBank.d190.s0	NO_SECTION	NO_SETID	14
Drug interaction studies with Xigris have not been performed in patients with severe sepsis.
1	0	3	O	Drug
2	5	15	O	interaction
3	17	23	O	studies
4	25	28	O	with
5	30	35	O	XXXXXXXX
6	37	40	O	have
7	42	44	O	not
8	46	49	O	been
9	51	59	O	performed
10	61	62	O	in
11	64	71	O	patients
12	73	76	O	with
13	78	83	O	severe
14	85	90	O	sepsis
NULL

Drotrecogin alfa	DDI-DrugBank.d190.s1	NO_SECTION	NO_SETID	27
However, since there is an increased risk of bleeding with Xigris, caution should be employed when Xigris is used with other drugs that affect hemostasis.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	since
4	15	19	O	there
5	21	22	O	is
6	24	25	O	an
7	27	35	O	increased
8	37	40	O	risk
9	42	43	O	of
10	45	52	O	bleeding
11	54	57	O	with
12	59	64	O	XXXXXXXX
13	65	65	O	,
14	67	73	O	caution
15	75	80	O	should
16	82	83	O	be
17	85	92	O	employed
18	94	97	O	when
19	99	104	O	XXXXXXXX
20	106	107	O	is
21	109	112	O	used
22	114	117	O	with
23	119	123	O	other
24	125	129	O	drugs
25	131	134	O	that
26	136	141	O	affect
27	143	152	O	hemostasis
NULL

Drotrecogin alfa	DDI-DrugBank.d190.s2	NO_SECTION	NO_SETID	44
Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin (unfractionated heparin up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products.
1	0	12	O	Approximately
2	14	14	O	2
3	15	15	O	/
4	16	16	O	3
5	18	19	O	of
6	21	23	O	the
7	25	32	O	patients
8	34	35	O	in
9	37	39	O	the
10	41	45	O	Phase
11	47	47	O	3
12	49	53	O	study
13	55	62	O	received
14	64	69	O	either
15	71	82	O	prophylactic
16	84	86	O	low
17	88	91	O	dose
18	93	99	U-UNK	heparin
19	102	115	B-UNK	unfractionated
20	117	123	L-UNK	heparin
21	125	126	O	up
22	128	129	O	to
23	131	136	O	15,000
24	138	142	O	units
25	143	143	O	/
26	144	146	O	day
27	149	150	O	or
28	152	163	O	prophylactic
29	165	169	O	doses
30	171	172	O	of
31	174	176	B-UNK	low
32	178	186	I-UNK	molecular
33	188	193	I-UNK	weight
34	195	202	L-UNK	heparins
35	204	205	O	as
36	207	215	O	indicated
37	217	218	O	in
38	220	222	O	the
39	224	234	O	prescribing
40	236	246	O	information
41	248	250	O	for
42	252	254	O	the
43	256	263	O	specific
44	265	272	O	products
NULL

Drotrecogin alfa	DDI-DrugBank.d190.s3	NO_SECTION	NO_SETID	35
Concomitant use of prophylactic low dose heparin did not appear to affect safety, however, its effects on the efficacy of Xigris have not been evaluated in an adequate and well-controlled clinical trial.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	30	O	prophylactic
5	32	34	O	low
6	36	39	O	dose
7	41	47	U-UNK	heparin
8	49	51	O	did
9	53	55	O	not
10	57	62	O	appear
11	64	65	O	to
12	67	72	O	affect
13	74	79	O	safety
14	80	80	O	,
15	82	88	O	however
16	89	89	O	,
17	91	93	O	its
18	95	101	O	effects
19	103	104	O	on
20	106	108	O	the
21	110	117	O	efficacy
22	119	120	O	of
23	122	127	O	XXXXXXXX
24	129	132	O	have
25	134	136	O	not
26	138	141	O	been
27	143	151	O	evaluated
28	153	154	O	in
29	156	157	O	an
30	159	166	O	adequate
31	168	170	O	and
32	172	175	O	well
33	177	186	O	controlled
34	188	195	O	clinical
35	197	201	O	trial
NULL

Drotrecogin alfa	DDI-DrugBank.d190.s4	NO_SECTION	NO_SETID	39
Drug/Laboratory Test Interaction Because Xigris may affect the APTT assay, Xigris present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays).
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	31	O	Interaction
6	33	39	O	Because
7	41	46	O	XXXXXXXX
8	48	50	O	may
9	52	57	O	affect
10	59	61	O	the
11	63	66	O	APTT
12	68	72	O	assay
13	73	73	O	,
14	75	80	O	XXXXXXXX
15	82	88	O	present
16	90	91	O	in
17	93	98	O	plasma
18	100	106	O	samples
19	108	110	O	may
20	112	120	O	interfere
21	122	125	O	with
22	127	129	O	one
23	131	135	O	stage
24	137	147	O	coagulation
25	149	154	O	assays
26	156	160	O	based
27	162	163	O	on
28	165	167	O	the
29	169	172	O	APTT
30	175	178	O	such
31	180	181	O	as
32	183	188	O	factor
33	190	193	O	VIII
34	194	194	O	,
35	196	197	O	IX
36	198	198	O	,
37	200	202	O	and
38	204	205	O	XI
39	207	212	O	assays
NULL

Drotrecogin alfa	DDI-DrugBank.d190.s5	NO_SECTION	NO_SETID	16
This interference may result in an apparent factor concentration that is lower than the true concentration.
1	0	3	O	This
2	5	16	O	interference
3	18	20	O	may
4	22	27	O	result
5	29	30	O	in
6	32	33	O	an
7	35	42	O	apparent
8	44	49	O	factor
9	51	63	O	concentration
10	65	68	O	that
11	70	71	O	is
12	73	77	O	lower
13	79	82	O	than
14	84	86	O	the
15	88	91	O	true
16	93	105	O	concentration
NULL

Drotrecogin alfa	DDI-DrugBank.d190.s6	NO_SECTION	NO_SETID	29
Xigris present in plasma samples does not interfere with one-stage factor assays based on the PT (such as factor II, V, VII, and X assays).
1	0	5	O	XXXXXXXX
2	7	13	O	present
3	15	16	O	in
4	18	23	O	plasma
5	25	31	O	samples
6	33	36	O	does
7	38	40	O	not
8	42	50	O	interfere
9	52	55	O	with
10	57	59	O	one
11	61	65	O	stage
12	67	72	O	factor
13	74	79	O	assays
14	81	85	O	based
15	87	88	O	on
16	90	92	O	the
17	94	95	O	PT
18	98	101	O	such
19	103	104	O	as
20	106	111	O	factor
21	113	114	O	II
22	115	115	O	,
23	117	117	O	V
24	118	118	O	,
25	120	122	O	VII
26	123	123	O	,
27	125	127	O	and
28	129	129	O	XXXXXXXX
29	131	136	O	assays
NULL

Duloxetine	DDI-DrugBank.d548.s0	NO_SECTION	NO_SETID	17
Potential for Other Drugs to Affect Duloxetine: Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.
1	0	8	O	Potential
2	10	12	O	for
3	14	18	O	Other
4	20	24	O	Drugs
5	26	27	O	to
6	29	34	O	Affect
7	36	45	O	XXXXXXXX
8	46	46	O	:
9	48	51	O	Both
10	53	58	O	CYP1A2
11	60	62	O	and
12	64	69	O	CYP2D6
13	71	73	O	are
14	75	85	O	responsible
15	87	89	O	for
16	91	100	O	XXXXXXXX
17	102	111	O	metabolism
NULL

Duloxetine	DDI-DrugBank.d548.s1	NO_SECTION	NO_SETID	35
Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.
1	0	9	O	Inhibitors
2	11	12	O	of
3	14	19	O	CYP1A2
4	20	20	O	:
5	22	32	O	Concomitant
6	34	36	O	use
7	38	39	O	of
8	41	50	O	XXXXXXXX
9	52	55	O	with
10	57	67	U-KIN	fluvoxamine
11	68	68	O	,
12	70	71	O	an
13	73	81	O	inhibitor
14	83	84	O	of
15	86	91	O	CYP1A2
16	92	92	O	,
17	94	100	O	results
18	102	103	O	in
19	105	117	O	approximately
20	119	119	O	a
21	121	121	O	6
22	123	126	O	fold
23	128	135	O	increase
24	137	138	O	in
25	140	142	O	AUC
26	144	146	O	and
27	148	152	O	about
28	154	154	O	a
29	156	158	O	2.5
30	160	163	O	fold
31	165	172	O	increase
32	174	175	O	in
33	177	180	O	Cmax
34	182	183	O	of
35	185	194	O	XXXXXXXX
NULL

Duloxetine	DDI-DrugBank.d548.s2	NO_SECTION	NO_SETID	16
Some quinolone antibiotics would be expected to have similar effects and these combinations should be avoided.
1	0	3	O	Some
2	5	13	B-UNK	quinolone
3	15	25	L-UNK	antibiotics
4	27	31	O	would
5	33	34	O	be
6	36	43	O	expected
7	45	46	O	to
8	48	51	O	have
9	53	59	O	similar
10	61	67	O	effects
11	69	71	O	and
12	73	77	O	these
13	79	90	O	combinations
14	92	97	O	should
15	99	100	O	be
16	102	108	O	avoided
NULL

Duloxetine	DDI-DrugBank.d548.s3	NO_SECTION	NO_SETID	28
Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.
1	0	9	O	Inhibitors
2	11	12	O	of
3	14	19	O	CYP2D6
4	20	20	O	:
5	22	28	O	Because
6	30	35	O	CYP2D6
7	37	38	O	is
8	40	47	O	involved
9	49	50	O	in
10	52	61	O	XXXXXXXX
11	63	72	O	metabolism
12	73	73	O	,
13	75	85	O	concomitant
14	87	89	O	use
15	91	92	O	of
16	94	103	O	XXXXXXXX
17	105	108	O	with
18	110	115	O	potent
19	117	126	O	inhibitors
20	128	129	O	of
21	131	136	O	CYP2D6
22	138	140	O	may
23	142	147	O	result
24	149	150	O	in
25	152	157	O	higher
26	159	172	O	concentrations
27	174	175	O	of
28	177	186	O	XXXXXXXX
NULL

Duloxetine	DDI-DrugBank.d548.s4	NO_SECTION	NO_SETID	28
Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.
1	0	9	U-KIN	Paroxetine
2	12	13	O	20
3	15	16	O	mg
4	18	19	O	QD
5	22	30	O	increased
6	32	34	O	the
7	36	48	O	concentration
8	50	51	O	of
9	53	62	O	XXXXXXXX
10	65	66	O	40
11	68	69	O	mg
12	71	72	O	QD
13	75	76	O	by
14	78	82	O	about
15	84	86	O	60%
16	87	87	O	,
17	89	91	O	and
18	93	99	O	greater
19	101	107	O	degrees
20	109	110	O	of
21	112	121	O	inhibition
22	123	125	O	are
23	127	134	O	expected
24	136	139	O	with
25	141	146	O	higher
26	148	152	O	doses
27	154	155	O	of
28	157	166	U-UNK	paroxetine
NULL

Duloxetine	DDI-DrugBank.d548.s5	NO_SECTION	NO_SETID	15
Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine).
1	0	6	O	Similar
2	8	14	O	effects
3	16	20	O	would
4	22	23	O	be
5	25	32	O	expected
6	34	37	O	with
7	39	43	O	other
8	45	50	O	potent
9	52	57	O	CYP2D6
10	59	68	O	inhibitors
11	71	73	O	e.g
12	75	75	O	,
13	77	86	U-UNK	fluoxetine
14	87	87	O	,
15	89	97	U-UNK	quinidine
NULL

Duloxetine	DDI-DrugBank.d548.s6	NO_SECTION	NO_SETID	43
Potential for Duloxetine to Affect Other Drugs: Drugs Metabolized by CYP1A2: In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity, and it is unlikely to have a clinically significant effect on the metabolism of CYP1A2 substrates.
1	0	8	O	Potential
2	10	12	O	for
3	14	23	O	XXXXXXXX
4	25	26	O	to
5	28	33	O	Affect
6	35	39	O	Other
7	41	45	O	Drugs
8	46	46	O	:
9	48	52	O	Drugs
10	54	64	O	Metabolized
11	66	67	O	by
12	69	74	O	CYP1A2
13	75	75	O	:
14	77	78	O	In
15	80	84	O	vitro
16	86	89	O	drug
17	91	101	O	interaction
18	103	109	O	studies
19	111	121	O	demonstrate
20	123	126	O	that
21	128	137	O	XXXXXXXX
22	139	142	O	does
23	144	146	O	not
24	148	153	O	induce
25	155	160	O	CYP1A2
26	162	169	O	activity
27	170	170	O	,
28	172	174	O	and
29	176	177	O	it
30	179	180	O	is
31	182	189	O	unlikely
32	191	192	O	to
33	194	197	O	have
34	199	199	O	a
35	201	210	O	clinically
36	212	222	O	significant
37	224	229	O	effect
38	231	232	O	on
39	234	236	O	the
40	238	247	O	metabolism
41	249	250	O	of
42	252	257	O	CYP1A2
43	259	268	O	substrates
NULL

Duloxetine	DDI-DrugBank.d548.s7	NO_SECTION	NO_SETID	12
Drugs Metabolized by CYP2D6: Duloxetine is a moderate inhibitor of CYP2D6.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	26	O	CYP2D6
5	27	27	O	:
6	29	38	O	XXXXXXXX
7	40	41	O	is
8	43	43	O	a
9	45	52	O	moderate
10	54	62	O	inhibitor
11	64	65	O	of
12	67	72	O	CYP2D6
NULL

Duloxetine	DDI-DrugBank.d548.s8	NO_SECTION	NO_SETID	33
When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.
1	0	3	O	When
2	5	14	O	XXXXXXXX
3	16	18	O	was
4	20	31	O	administered
5	34	35	O	at
6	37	37	O	a
7	39	42	O	dose
8	44	45	O	of
9	47	48	O	60
10	50	51	O	mg
11	53	55	O	BID
12	58	59	O	in
13	61	71	O	conjunction
14	73	76	O	with
15	78	78	O	a
16	80	85	O	single
17	87	88	O	50
18	90	91	O	mg
19	93	96	O	dose
20	98	99	O	of
21	101	111	U-KIN	desipramine
22	112	112	O	,
23	114	114	O	a
24	116	121	O	CYP2D6
25	123	131	O	substrate
26	132	132	O	,
27	134	136	O	the
28	138	140	O	AUC
29	142	143	O	of
30	145	155	U-UNK	desipramine
31	157	165	O	increased
32	167	167	O	3
33	169	172	O	fold
NULL

Duloxetine	DDI-DrugBank.d548.s9	NO_SECTION	NO_SETID	56
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	co
4	14	27	O	administration
5	29	30	O	of
6	32	41	O	XXXXXXXX
7	43	46	O	with
8	48	52	O	other
9	54	58	O	drugs
10	60	63	O	that
11	65	67	O	are
12	69	79	O	extensively
13	81	91	O	metabolized
14	93	94	O	by
15	96	99	O	this
16	101	107	O	isozyme
17	109	111	O	and
18	113	117	O	which
19	119	122	O	have
20	124	124	O	a
21	126	131	O	narrow
22	133	143	O	therapeutic
23	145	149	O	index
24	150	150	O	,
25	152	160	O	including
26	162	168	O	certain
27	170	184	U-DYN	antidepressants
28	187	195	B-DYN	tricyclic
29	197	211	L-DYN	antidepressants
30	214	217	U-DYN	TCAs
31	219	219	O	,
32	221	224	O	such
33	226	227	O	as
34	229	241	U-DYN	nortriptyline
35	242	242	O	,
36	244	256	U-DYN	amitriptyline
37	257	257	O	,
38	259	261	O	and
39	263	272	U-DYN	imipramine
40	274	274	O	,
41	276	289	U-DYN	phenothiazines
42	291	293	O	and
43	295	298	B-DYN	Type
44	300	301	I-DYN	1C
45	303	317	L-DYN	antiarrhythmics
46	320	322	O	e.g
47	324	324	O	,
48	326	336	U-DYN	propafenone
49	337	337	O	,
50	339	348	U-DYN	flecainide
51	350	350	O	,
52	352	357	O	should
53	359	360	O	be
54	362	371	O	approached
55	373	376	O	with
56	378	384	O	caution
NULL

Duloxetine	DDI-DrugBank.d548.s10	NO_SECTION	NO_SETID	27
Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.
1	0	5	O	Plasma
2	7	9	U-UNK	TCA
3	11	24	O	concentrations
4	26	28	O	may
5	30	33	O	need
6	35	36	O	to
7	38	39	O	be
8	41	49	O	monitored
9	51	53	O	and
10	55	57	O	the
11	59	62	O	dose
12	64	65	O	of
13	67	69	O	the
14	71	73	U-UNK	TCA
15	75	77	O	may
16	79	82	O	need
17	84	85	O	to
18	87	88	O	be
19	90	96	O	reduced
20	98	99	O	if
21	101	101	O	a
22	103	105	U-DYN	TCA
23	107	108	O	is
24	110	111	O	co
25	113	124	O	administered
26	126	129	O	with
27	131	140	O	XXXXXXXX
NULL

Duloxetine	DDI-DrugBank.d548.s11	NO_SECTION	NO_SETID	28
Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	18	O	risk
5	20	21	O	of
6	23	29	O	serious
7	31	41	O	ventricular
8	43	53	O	arrhythmias
9	55	57	O	and
10	59	64	O	sudden
11	66	70	O	death
12	72	82	O	potentially
13	84	93	O	associated
14	95	98	O	with
15	100	107	O	elevated
16	109	114	O	plasma
17	116	121	O	levels
18	123	124	O	of
19	126	137	U-UNK	thioridazine
20	138	138	O	,
21	140	149	O	XXXXXXXX
22	151	153	O	and
23	155	166	U-DYN	thioridazine
24	168	173	O	should
25	175	177	O	not
26	179	180	O	be
27	182	183	O	co
28	185	196	O	administered
NULL

Duloxetine	DDI-DrugBank.d548.s12	NO_SECTION	NO_SETID	20
Drugs Metabolized by CYP3A: Results of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	25	O	CYP3A
5	26	26	O	:
6	28	34	O	Results
7	36	37	O	of
8	39	40	O	in
9	42	46	O	vitro
10	48	54	O	studies
11	56	66	O	demonstrate
12	68	71	O	that
13	73	82	O	XXXXXXXX
14	84	87	O	does
15	89	91	O	not
16	93	99	O	inhibit
17	101	102	O	or
18	104	109	O	induce
19	111	115	O	CYP3A
20	117	124	O	activity
NULL

Duloxetine	DDI-DrugBank.d548.s13	NO_SECTION	NO_SETID	47
Duloxetine May Have a Clinically Important Interaction with the Following Other Drugs: Alcohol: When Duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, Duloxetine did not increase the impairment of mental and motor skills caused by alcohol.
1	0	9	O	XXXXXXXX
2	11	13	O	May
3	15	18	O	Have
4	20	20	O	a
5	22	31	O	Clinically
6	33	41	O	Important
7	43	53	O	Interaction
8	55	58	O	with
9	60	62	O	the
10	64	72	O	Following
11	74	78	O	Other
12	80	84	O	Drugs
13	85	85	O	:
14	87	93	U-UNK	Alcohol
15	94	94	O	:
16	96	99	O	When
17	101	110	O	XXXXXXXX
18	112	114	O	and
19	116	122	U-UNK	ethanol
20	124	127	O	were
21	129	140	O	administered
22	142	148	O	several
23	150	154	O	hours
24	156	160	O	apart
25	162	163	O	so
26	165	168	O	that
27	170	173	O	peak
28	175	188	O	concentrations
29	190	191	O	of
30	193	196	O	each
31	198	202	O	would
32	204	211	O	coincide
33	212	212	O	,
34	214	223	O	XXXXXXXX
35	225	227	O	did
36	229	231	O	not
37	233	240	O	increase
38	242	244	O	the
39	246	255	O	impairment
40	257	258	O	of
41	260	265	O	mental
42	267	269	O	and
43	271	275	O	motor
44	277	282	O	skills
45	284	289	O	caused
46	291	292	O	by
47	294	300	U-UNK	alcohol
NULL

Duloxetine	DDI-DrugBank.d548.s14	NO_SECTION	NO_SETID	27
In the Duloxetine clinical trials database, three Duloxetine-treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction.
1	0	1	O	In
2	3	5	O	the
3	7	16	O	XXXXXXXX
4	18	25	O	clinical
5	27	32	O	trials
6	34	41	O	database
7	42	42	O	,
8	44	48	O	three
9	50	59	O	XXXXXXXX
10	61	67	O	treated
11	69	76	O	patients
12	78	80	O	had
13	82	86	O	liver
14	88	93	O	injury
15	95	96	O	as
16	98	107	O	manifested
17	109	110	O	by
18	112	114	O	ALT
19	116	118	O	and
20	120	124	O	total
21	126	134	O	bilirubin
22	136	145	O	elevations
23	146	146	O	,
24	148	151	O	with
25	153	160	O	evidence
26	162	163	O	of
27	165	175	O	obstruction
NULL

Duloxetine	DDI-DrugBank.d548.s15	NO_SECTION	NO_SETID	21
Substantial intercurrent ethanol use was present in each of these cases, and this may have contributed to the abnormalities seen.
1	0	10	O	Substantial
2	12	23	O	intercurrent
3	25	31	U-UNK	ethanol
4	33	35	O	use
5	37	39	O	was
6	41	47	O	present
7	49	50	O	in
8	52	55	O	each
9	57	58	O	of
10	60	64	O	these
11	66	70	O	cases
12	71	71	O	,
13	73	75	O	and
14	77	80	O	this
15	82	84	O	may
16	86	89	O	have
17	91	101	O	contributed
18	103	104	O	to
19	106	108	O	the
20	110	122	O	abnormalities
21	124	127	O	seen
NULL

Duloxetine	DDI-DrugBank.d548.s16	NO_SECTION	NO_SETID	41
CNS Acting Drugs: Given the primary CNS effects of Duloxetine, it should be used with caution when it is taken in combination with or substituted for other centrally acting drugs, including those with a similar mechanism of action.
1	0	2	O	CNS
2	4	9	O	Acting
3	11	15	O	Drugs
4	16	16	O	:
5	18	22	O	Given
6	24	26	O	the
7	28	34	O	primary
8	36	38	O	CNS
9	40	46	O	effects
10	48	49	O	of
11	51	60	O	XXXXXXXX
12	61	61	O	,
13	63	64	O	it
14	66	71	O	should
15	73	74	O	be
16	76	79	O	used
17	81	84	O	with
18	86	92	O	caution
19	94	97	O	when
20	99	100	O	it
21	102	103	O	is
22	105	109	O	taken
23	111	112	O	in
24	114	124	O	combination
25	126	129	O	with
26	131	132	O	or
27	134	144	O	substituted
28	146	148	O	for
29	150	154	O	other
30	156	164	O	centrally
31	166	171	O	acting
32	173	177	O	drugs
33	178	178	O	,
34	180	188	O	including
35	190	194	O	those
36	196	199	O	with
37	201	201	O	a
38	203	209	O	similar
39	211	219	O	mechanism
40	221	222	O	of
41	224	229	O	action
NULL

Duloxetine	DDI-DrugBank.d548.s17	NO_SECTION	NO_SETID	31
Potential for Interaction with Drugs that Affect Gastric Acidity: Duloxetine has an enteric coating that resists dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5.
1	0	8	O	Potential
2	10	12	O	for
3	14	24	O	Interaction
4	26	29	O	with
5	31	35	O	Drugs
6	37	40	O	that
7	42	47	O	Affect
8	49	55	O	Gastric
9	57	63	O	Acidity
10	64	64	O	:
11	66	75	O	XXXXXXXX
12	77	79	O	has
13	81	82	O	an
14	84	90	O	enteric
15	92	98	O	coating
16	100	103	O	that
17	105	111	O	resists
18	113	123	O	dissolution
19	125	129	O	until
20	131	138	O	reaching
21	140	140	O	a
22	142	148	O	segment
23	150	151	O	of
24	153	155	O	the
25	157	172	O	gastrointestinal
26	174	178	O	tract
27	180	184	O	where
28	186	188	O	the
29	190	191	O	pH
30	193	199	O	exceeds
31	201	203	O	5.5
NULL

Duloxetine	DDI-DrugBank.d548.s18	NO_SECTION	NO_SETID	19
In extremely acidic conditions, Duloxetine, unprotected by the enteric coating, may undergo hydrolysis to form naphthol.
1	0	1	O	In
2	3	11	O	extremely
3	13	18	O	acidic
4	20	29	O	conditions
5	30	30	O	,
6	32	41	O	XXXXXXXX
7	42	42	O	,
8	44	54	O	unprotected
9	56	57	O	by
10	59	61	O	the
11	63	69	O	enteric
12	71	77	O	coating
13	78	78	O	,
14	80	82	O	may
15	84	90	O	undergo
16	92	101	O	hydrolysis
17	103	104	O	to
18	106	109	O	form
19	111	118	O	naphthol
NULL

Duloxetine	DDI-DrugBank.d548.s19	NO_SECTION	NO_SETID	19
Caution is advised in using Duloxetine in patients with conditions that may slow gastric emptying (e.g., some diabetics).
1	0	6	O	Caution
2	8	9	O	is
3	11	17	O	advised
4	19	20	O	in
5	22	26	O	using
6	28	37	O	XXXXXXXX
7	39	40	O	in
8	42	49	O	patients
9	51	54	O	with
10	56	65	O	conditions
11	67	70	O	that
12	72	74	O	may
13	76	79	O	slow
14	81	87	O	gastric
15	89	96	O	emptying
16	99	101	O	e.g
17	103	103	O	,
18	105	108	O	some
19	110	118	O	diabetics
NULL

Duloxetine	DDI-DrugBank.d548.s20	NO_SECTION	NO_SETID	14
Drugs that raise the gastrointestinal pH may lead to an earlier release of duloxetine.
1	0	4	O	Drugs
2	6	9	O	that
3	11	15	O	raise
4	17	19	O	the
5	21	36	O	gastrointestinal
6	38	39	O	pH
7	41	43	O	may
8	45	48	O	lead
9	50	51	O	to
10	53	54	O	an
11	56	62	O	earlier
12	64	70	O	release
13	72	73	O	of
14	75	84	O	XXXXXXXX
NULL

Duloxetine	DDI-DrugBank.d548.s21	NO_SECTION	NO_SETID	39
However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	co
4	12	25	O	administration
5	27	28	O	of
6	30	39	O	XXXXXXXX
7	41	44	O	with
8	46	53	U-UNK	aluminum
9	56	58	O	and
10	60	68	U-UNK	magnesium
11	70	79	O	containing
12	81	88	U-UNK	antacids
13	91	92	O	51
14	94	96	O	mEq
15	99	100	O	or
16	102	111	O	XXXXXXXX
17	113	116	O	with
18	118	127	U-UNK	famotidine
19	128	128	O	,
20	130	132	O	had
21	134	135	O	no
22	137	147	O	significant
23	149	154	O	effect
24	156	157	O	on
25	159	161	O	the
26	163	166	O	rate
27	168	169	O	or
28	171	176	O	extent
29	178	179	O	of
30	181	190	O	XXXXXXXX
31	192	201	O	absorption
32	203	207	O	after
33	209	222	O	administration
34	224	225	O	of
35	227	227	O	a
36	229	230	O	40
37	232	233	O	mg
38	235	238	O	oral
39	240	243	O	dose
NULL

Duloxetine	DDI-DrugBank.d548.s22	NO_SECTION	NO_SETID	14
It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption.
1	0	1	O	It
2	3	4	O	is
3	6	12	O	unknown
4	14	20	O	whether
5	22	24	O	the
6	26	36	O	concomitant
7	38	51	O	administration
8	53	54	O	of
9	56	61	B-UNK	proton
10	63	66	I-UNK	pump
11	68	77	L-UNK	inhibitors
12	79	85	O	affects
13	87	96	O	XXXXXXXX
14	98	107	O	absorption
NULL

Dyphylline	DDI-DrugBank.d4.s0	NO_SECTION	NO_SETID	17
Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.
1	0	8	O	Synergism
2	10	16	O	between
3	18	25	B-UNK	xanthine
4	27	41	L-UNK	bronchodilators
5	44	46	O	e.g
6	48	48	O	,
7	50	61	U-UNK	theophylline
8	63	63	O	,
9	65	73	U-UNK	ephedrine
10	74	74	O	,
11	76	78	O	and
12	80	84	O	other
13	86	100	B-UNK	sympathomimetic
14	102	116	L-UNK	bronchodilators
15	118	120	O	has
16	122	125	O	been
17	127	134	O	reported
NULL

Dyphylline	DDI-DrugBank.d4.s1	NO_SECTION	NO_SETID	10
This should be considered whenever these agents are prescribed concomitantly.
1	0	3	O	This
2	5	10	O	should
3	12	13	O	be
4	15	24	O	considered
5	26	33	O	whenever
6	35	39	O	these
7	41	46	O	agents
8	48	50	O	are
9	52	61	O	prescribed
10	63	75	O	concomitantly
NULL

Dyphylline	DDI-DrugBank.d4.s2	NO_SECTION	NO_SETID	24
Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	38	O	XXXXXXXX
5	40	42	O	and
6	44	53	U-KIN	probenecid
7	54	54	O	,
8	56	60	O	which
9	62	69	O	competes
10	71	73	O	for
11	75	81	O	tubular
12	83	91	O	secretion
13	92	92	O	,
14	94	96	O	has
15	98	101	O	been
16	103	107	O	shown
17	109	110	O	to
18	112	119	O	increase
19	121	123	O	the
20	125	130	O	plasma
21	132	135	O	half
22	137	140	O	life
23	142	143	O	of
24	145	154	O	XXXXXXXX
NULL

Echothiophate Iodide	DDI-DrugBank.d377.s0	NO_SECTION	NO_SETID	14
Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.
1	0	10	B-UNK	Phospholine
2	12	17	L-UNK	Iodide
3	19	29	O	potentiates
4	31	35	O	other
5	37	50	B-UNK	cholinesterase
6	52	61	L-UNK	inhibitors
7	63	66	O	such
8	68	69	O	as
9	71	85	U-UNK	succinylcholine
10	87	88	O	or
11	90	104	B-UNK	organophosphate
12	106	108	I-UNK	and
13	110	118	L-UNK	carbamate
14	120	131	O	insecticides
NULL

Echothiophate Iodide	DDI-DrugBank.d377.s1	NO_SECTION	NO_SETID	16
Patients undergoing systemic anticholinesterase treatment should be warned of the possible additive effects of Phospholine Iodide.
1	0	7	O	Patients
2	9	18	O	undergoing
3	20	27	O	systemic
4	29	46	O	anticholinesterase
5	48	56	O	treatment
6	58	63	O	should
7	65	66	O	be
8	68	73	O	warned
9	75	76	O	of
10	78	80	O	the
11	82	89	O	possible
12	91	98	O	additive
13	100	106	O	effects
14	108	109	O	of
15	111	121	B-UNK	Phospholine
16	123	128	L-UNK	Iodide
NULL

Eculizumab	DDI-DrugBank.d49.s0	NO_SECTION	NO_SETID	9
Drug interaction studies have not been performed with Soliris.
1	0	3	O	Drug
2	5	15	O	interaction
3	17	23	O	studies
4	25	28	O	have
5	30	32	O	not
6	34	37	O	been
7	39	47	O	performed
8	49	52	O	with
9	54	60	O	XXXXXXXX
NULL

Edetic Acid	DDI-DrugBank.d191.s0	NO_SECTION	NO_SETID	11
There is no known drug interference with standard clinical laboratory tests.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	16	O	known
5	18	21	O	drug
6	23	34	O	interference
7	36	39	O	with
8	41	48	O	standard
9	50	57	O	clinical
10	59	68	O	laboratory
11	70	74	O	tests
NULL

Edetic Acid	DDI-DrugBank.d191.s1	NO_SECTION	NO_SETID	28
Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7
1	0	7	U-UNK	Steroids
2	9	15	O	enhance
3	17	19	O	the
4	21	25	O	renal
5	27	34	O	toxicity
6	36	37	O	of
7	39	45	B-UNK	edetate
8	47	53	I-UNK	calcium
9	55	62	L-UNK	disodium
10	64	65	O	in
11	67	73	O	animals
12	76	76	O	7
13	78	84	B-UNK	Edetate
14	86	92	I-UNK	calcium
15	94	101	L-UNK	disodium
16	103	112	O	interferes
17	114	117	O	with
18	119	121	O	the
19	123	128	O	action
20	130	131	O	of
21	133	136	B-UNK	zinc
22	138	144	L-UNK	insulin
23	146	157	O	preparations
24	159	160	O	by
25	162	170	O	chelating
26	172	174	O	the
27	176	179	U-UNK	zinc
28	182	182	O	7
NULL

Edrophonium	DDI-DrugBank.d292.s0	NO_SECTION	NO_SETID	21
Care should be given when administering this drug to patients with symptoms of myasthenic weakness who are also on anticholinesterase drugs.
1	0	3	O	Care
2	5	10	O	should
3	12	13	O	be
4	15	19	O	given
5	21	24	O	when
6	26	38	O	administering
7	40	43	O	this
8	45	48	O	drug
9	50	51	O	to
10	53	60	O	patients
11	62	65	O	with
12	67	74	O	symptoms
13	76	77	O	of
14	79	88	O	myasthenic
15	90	97	O	weakness
16	99	101	O	who
17	103	105	O	are
18	107	110	O	also
19	112	113	O	on
20	115	132	B-UNK	anticholinesterase
21	134	138	L-UNK	drugs
NULL

Edrophonium	DDI-DrugBank.d292.s1	NO_SECTION	NO_SETID	24
Since symptoms of anticholinesterase overdose (cholinergic crisis) may mimic underdosage (myasthenic weakness), their condition may be worsened by the use of this drug.
1	0	4	O	Since
2	6	13	O	symptoms
3	15	16	O	of
4	18	35	O	anticholinesterase
5	37	44	O	overdose
6	47	57	O	cholinergic
7	59	64	O	crisis
8	67	69	O	may
9	71	75	O	mimic
10	77	87	O	underdosage
11	90	99	O	myasthenic
12	101	108	O	weakness
13	110	110	O	,
14	112	116	O	their
15	118	126	O	condition
16	128	130	O	may
17	132	133	O	be
18	135	142	O	worsened
19	144	145	O	by
20	147	149	O	the
21	151	153	O	use
22	155	156	O	of
23	158	161	O	this
24	163	166	O	drug
NULL

Efalizumab	DDI-DrugBank.d44.s0	NO_SECTION	NO_SETID	10
No formal drug interaction studies have been performed with RAPTIVA.
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	25	O	interaction
5	27	33	O	studies
6	35	38	O	have
7	40	43	O	been
8	45	53	O	performed
9	55	58	O	with
10	60	66	O	XXXXXXXX
NULL

Efalizumab	DDI-DrugBank.d44.s1	NO_SECTION	NO_SETID	9
RAPTIVA should not be used with other immunosuppressive drugs.
1	0	6	O	XXXXXXXX
2	8	13	O	should
3	15	17	O	not
4	19	20	O	be
5	22	25	O	used
6	27	30	O	with
7	32	36	O	other
8	38	54	B-DYN	immunosuppressive
9	56	60	L-DYN	drugs
NULL

Efalizumab	DDI-DrugBank.d44.s2	NO_SECTION	NO_SETID	14
Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.
1	0	8	B-UNK	Acellular
2	9	9	I-UNK	,
3	11	14	I-UNK	live
4	16	18	I-UNK	and
5	20	23	I-UNK	live
6	25	34	I-UNK	attenuated
7	36	43	L-UNK	vaccines
8	45	50	O	should
9	52	54	O	not
10	56	57	O	be
11	59	70	O	administered
12	72	77	O	during
13	79	85	O	XXXXXXXX
14	87	95	O	treatment
NULL

Efalizumab	DDI-DrugBank.d44.s3	NO_SECTION	NO_SETID	22
Drug/Laboratory Test Interactions Increases in lymphocyte counts related to the pharmacologic mechanism of action are frequently observed during RAPTIVA treatment.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	42	O	Increases
7	44	45	O	in
8	47	56	O	lymphocyte
9	58	63	O	counts
10	65	71	O	related
11	73	74	O	to
12	76	78	O	the
13	80	92	O	pharmacologic
14	94	102	O	mechanism
15	104	105	O	of
16	107	112	O	action
17	114	116	O	are
18	118	127	O	frequently
19	129	136	O	observed
20	138	143	O	during
21	145	151	O	XXXXXXXX
22	153	161	O	treatment
NULL

Efavirenz	DDI-DrugBank.d531.s0	NO_SECTION	NO_SETID	9
Efavirenz has been shown in vivo to induce CYP3A4.
1	0	8	O	XXXXXXXX
2	10	12	O	has
3	14	17	O	been
4	19	23	O	shown
5	25	26	O	in
6	28	31	O	vivo
7	33	34	O	to
8	36	41	O	induce
9	43	48	O	CYP3A4
NULL

Efavirenz	DDI-DrugBank.d531.s1	NO_SECTION	NO_SETID	17
Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with SUSTIVA (efavirenz).
1	0	4	O	Other
2	6	14	O	compounds
3	16	19	O	that
4	21	23	O	are
5	25	34	O	substrates
6	36	37	O	of
7	39	44	O	CYP3A4
8	46	48	O	may
9	50	53	O	have
10	55	63	O	decreased
11	65	70	O	plasma
12	72	85	O	concentrations
13	87	90	O	when
14	92	105	O	coadministered
15	107	110	O	with
16	112	118	O	XXXXXXXX
17	121	129	U-UNK	efavirenz
NULL

Efavirenz	DDI-DrugBank.d531.s2	NO_SECTION	NO_SETID	23
In vitro studies have demonstrated that efavirenz inhibits 2C9, 2C19, and 3A4 isozymes in the range of observed efavirenz plasma concentrations.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	33	O	demonstrated
6	35	38	O	that
7	40	48	O	XXXXXXXX
8	50	57	O	inhibits
9	59	61	O	2C9
10	62	62	O	,
11	64	67	O	2C19
12	68	68	O	,
13	70	72	O	and
14	74	76	O	3A4
15	78	85	O	isozymes
16	87	88	O	in
17	90	92	O	the
18	94	98	O	range
19	100	101	O	of
20	103	110	O	observed
21	112	120	O	XXXXXXXX
22	122	127	O	plasma
23	129	142	O	concentrations
NULL

Efavirenz	DDI-DrugBank.d531.s3	NO_SECTION	NO_SETID	20
Coadministration of efavirenz with drugs primarily metabolized by these isozymes may result in altered plasma concentrations of the coadministered drug.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	28	O	XXXXXXXX
4	30	33	O	with
5	35	39	O	drugs
6	41	49	O	primarily
7	51	61	O	metabolized
8	63	64	O	by
9	66	70	O	these
10	72	79	O	isozymes
11	81	83	O	may
12	85	90	O	result
13	92	93	O	in
14	95	101	O	altered
15	103	108	O	plasma
16	110	123	O	concentrations
17	125	126	O	of
18	128	130	O	the
19	132	145	O	coadministered
20	147	150	O	drug
NULL

Efavirenz	DDI-DrugBank.d531.s4	NO_SECTION	NO_SETID	11
Therefore, appropriate dose adjustments may be necessary for these drugs.
1	0	8	O	Therefore
2	9	9	O	,
3	11	21	O	appropriate
4	23	26	O	dose
5	28	38	O	adjustments
6	40	42	O	may
7	44	45	O	be
8	47	55	O	necessary
9	57	59	O	for
10	61	65	O	these
11	67	71	O	drugs
NULL

Efavirenz	DDI-DrugBank.d531.s5	NO_SECTION	NO_SETID	26
Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
1	0	4	O	Drugs
2	6	10	O	which
3	12	17	O	induce
4	19	24	O	CYP3A4
5	26	33	O	activity
6	36	37	O	eg
7	38	38	O	,
8	40	52	U-KIN	phenobarbital
9	53	53	O	,
10	55	62	U-KIN	rifampin
11	63	63	O	,
12	65	73	U-KIN	rifabutin
13	76	80	O	would
14	82	83	O	be
15	85	92	O	expected
16	94	95	O	to
17	97	104	O	increase
18	106	108	O	the
19	110	118	O	clearance
20	120	121	O	of
21	123	131	O	XXXXXXXX
22	133	141	O	resulting
23	143	144	O	in
24	146	152	O	lowered
25	154	159	O	plasma
26	161	174	O	concentrations
NULL

Efavirenz	DDI-DrugBank.d531.s6	NO_SECTION	NO_SETID	9
Drug interactions with SUSTIVA are summarized in Table 5.
1	0	3	O	Drug
2	5	16	O	interactions
3	18	21	O	with
4	23	29	O	XXXXXXXX
5	31	33	O	are
6	35	44	O	summarized
7	46	47	O	in
8	49	53	O	Table
9	55	55	O	5
NULL

Efavirenz	DDI-DrugBank.d531.s7	NO_SECTION	NO_SETID	11
Table 5a: Drugs That Should Not Be Coadministered With SUSTIVA
1	0	4	O	Table
2	6	7	O	5a
3	8	8	O	:
4	10	14	O	Drugs
5	16	19	O	That
6	21	26	O	Should
7	28	30	O	Not
8	32	33	O	Be
9	35	48	O	Coadministered
10	50	53	O	With
11	55	61	O	XXXXXXXX
NULL

Efavirenz	DDI-DrugBank.d531.s9	NO_SECTION	NO_SETID	9
Drugs Within Class Not To Be Coadministered With SUSTIVA
1	0	4	O	Drugs
2	6	11	O	Within
3	13	17	O	Class
4	19	21	O	Not
5	23	24	O	To
6	26	27	O	Be
7	29	42	O	Coadministered
8	44	47	O	With
9	49	55	O	XXXXXXXX
NULL

Efavirenz	DDI-DrugBank.d531.s10	NO_SECTION	NO_SETID	9
Antihistamines: Benzodiazepines GI Motility Agents Anti-Migraine Antifungal
1	0	13	U-UNK	Antihistamines
2	14	14	O	:
3	16	30	U-UNK	Benzodiazepines
4	32	33	O	GI
5	35	42	O	Motility
6	44	49	O	Agents
7	51	54	B-UNK	Anti
8	56	63	L-UNK	Migraine
9	65	74	U-UNK	Antifungal
NULL

Efavirenz	DDI-DrugBank.d531.s11	NO_SECTION	NO_SETID	8
astemizole midazolam, triazolam cisapride ergot derivatives voriconazole
1	0	9	U-UNK	astemizole
2	11	19	U-UNK	midazolam
3	20	20	O	,
4	22	30	U-UNK	triazolam
5	32	40	U-UNK	cisapride
6	42	46	O	ergot
7	48	58	O	derivatives
8	60	71	U-UNK	voriconazole
NULL

Efavirenz	DDI-DrugBank.d531.s12	NO_SECTION	NO_SETID	3
Established Drug Interactions
1	0	10	O	Established
2	12	15	O	Drug
3	17	28	O	Interactions
NULL

Efavirenz	DDI-DrugBank.d531.s19	NO_SECTION	NO_SETID	28
When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).
1	0	3	O	When
2	5	18	O	coadministered
3	20	23	O	with
4	25	31	O	XXXXXXXX
5	33	34	O	in
6	36	44	O	treatment
7	46	50	O	naive
8	52	59	O	patients
9	60	60	O	,
10	62	64	O	the
11	66	76	O	recommended
12	78	81	O	dose
13	83	84	O	of
14	86	95	U-UNK	atazanavir
15	97	98	O	is
16	100	102	O	300
17	104	105	O	mg
18	107	110	O	with
19	112	120	U-UNK	ritonavir
20	122	124	O	100
21	126	127	O	mg
22	129	131	O	and
23	133	139	O	XXXXXXXX
24	141	143	O	600
25	145	146	O	mg
26	149	151	O	all
27	153	156	O	once
28	158	162	O	daily
NULL

Efavirenz	DDI-DrugBank.d531.s20	NO_SECTION	NO_SETID	14
Dosing recommendations for SUSTIVA and atazanavir in treatment-experienced patients have not been established.
1	0	5	O	Dosing
2	7	21	O	recommendations
3	23	25	O	for
4	27	33	O	XXXXXXXX
5	35	37	O	and
6	39	48	U-UNK	atazanavir
7	50	51	O	in
8	53	61	O	treatment
9	63	73	O	experienced
10	75	82	O	patients
11	84	87	O	have
12	89	91	O	not
13	93	96	O	been
14	98	108	O	established
NULL

Efavirenz	DDI-DrugBank.d531.s21	NO_SECTION	NO_SETID	4
Established Drug Interactions (continued)
1	0	10	O	Established
2	12	15	O	Drug
3	17	28	O	Interactions
4	31	39	O	continued
NULL

Efavirenz	DDI-DrugBank.d531.s26	NO_SECTION	NO_SETID	2
clarithromycin concentration
1	0	13	U-UNK	clarithromycin
2	15	27	O	concentration
NULL

Efavirenz	DDI-DrugBank.d531.s27	NO_SECTION	NO_SETID	5
Plasma concentrations decreased by SUSTIVA;
1	0	5	O	Plasma
2	7	20	O	concentrations
3	22	30	O	decreased
4	32	33	O	by
5	35	41	O	XXXXXXXX
NULL

Efavirenz	DDI-DrugBank.d531.s28	NO_SECTION	NO_SETID	3
clinical significance unknown.
1	0	7	O	clinical
2	9	20	O	significance
3	22	28	O	unknown
NULL

Efavirenz	DDI-DrugBank.d531.s29	NO_SECTION	NO_SETID	12
In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.
1	0	1	O	In
2	3	12	O	uninfected
3	14	23	O	volunteers
4	24	24	O	,
5	26	28	O	46%
6	30	38	O	developed
7	40	43	O	rash
8	45	49	O	while
9	51	59	O	receiving
10	61	67	O	XXXXXXXX
11	69	71	O	and
12	73	86	U-DYN	clarithromycin
NULL

Efavirenz	DDI-DrugBank.d531.s30	NO_SECTION	NO_SETID	11
No dose adjustment of SUSTIVA is recommended when given with clarithromycin.
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	of
5	22	28	O	XXXXXXXX
6	30	31	O	is
7	33	43	O	recommended
8	45	48	O	when
9	50	54	O	given
10	56	59	O	with
11	61	74	U-UNK	clarithromycin
NULL

Efavirenz	DDI-DrugBank.d531.s31	NO_SECTION	NO_SETID	11
Alternatives to clarithromycin, such as azithromycin, should be considered.
1	0	11	O	Alternatives
2	13	14	O	to
3	16	29	U-UNK	clarithromycin
4	30	30	O	,
5	32	35	O	such
6	37	38	O	as
7	40	51	U-UNK	azithromycin
8	52	52	O	,
9	54	59	O	should
10	61	62	O	be
11	64	73	O	considered
NULL

Efavirenz	DDI-DrugBank.d531.s32	NO_SECTION	NO_SETID	16
Other macrolide antibiotics, such as erythromycin, have not been studied in combination with SUSTIVA.
1	0	4	O	Other
2	6	14	B-UNK	macrolide
3	16	26	L-UNK	antibiotics
4	27	27	O	,
5	29	32	O	such
6	34	35	O	as
7	37	48	U-UNK	erythromycin
8	49	49	O	,
9	51	54	O	have
10	56	58	O	not
11	60	63	O	been
12	65	71	O	studied
13	73	74	O	in
14	76	86	O	combination
15	88	91	O	with
16	93	99	O	XXXXXXXX
NULL

Efavirenz	DDI-DrugBank.d531.s34	NO_SECTION	NO_SETID	4
14-OH metabolite concentration
1	0	1	O	14
2	3	4	O	OH
3	6	15	O	metabolite
4	17	29	O	concentration
NULL

Efavirenz	DDI-DrugBank.d531.s36	NO_SECTION	NO_SETID	2
indinavir concentration
1	0	8	U-UNK	indinavir
2	10	22	O	concentration
NULL

Efavirenz	DDI-DrugBank.d531.s37	NO_SECTION	NO_SETID	16
The optimal dose of indinavir, when given in combination with SUSTIVA, is not known.
1	0	2	O	The
2	4	10	O	optimal
3	12	15	O	dose
4	17	18	O	of
5	20	28	U-UNK	indinavir
6	29	29	O	,
7	31	34	O	when
8	36	40	O	given
9	42	43	O	in
10	45	55	O	combination
11	57	60	O	with
12	62	68	O	XXXXXXXX
13	69	69	O	,
14	71	72	O	is
15	74	76	O	not
16	78	82	O	known
NULL

Efavirenz	DDI-DrugBank.d531.s38	NO_SECTION	NO_SETID	21
Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.
1	0	9	O	Increasing
2	11	13	O	the
3	15	23	U-UNK	indinavir
4	25	28	O	dose
5	30	31	O	to
6	33	36	O	1000
7	38	39	O	mg
8	41	45	O	every
9	47	47	O	8
10	49	53	O	hours
11	55	58	O	does
12	60	62	O	not
13	64	73	O	compensate
14	75	77	O	for
15	79	81	O	the
16	83	91	O	increased
17	93	101	U-KIN	indinavir
18	103	112	O	metabolism
19	114	116	O	due
20	118	119	O	to
21	121	127	O	XXXXXXXX
NULL

Efavirenz	DDI-DrugBank.d531.s39	NO_SECTION	NO_SETID	50
When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.
1	0	3	O	When
2	5	13	U-KIN	indinavir
3	15	16	O	at
4	18	19	O	an
5	21	29	O	increased
6	31	34	O	dose
7	37	40	O	1000
8	42	43	O	mg
9	45	49	O	every
10	51	51	O	8
11	53	57	O	hours
12	60	62	O	was
13	64	68	O	given
14	70	73	O	with
15	75	81	O	XXXXXXXX
16	84	86	O	600
17	88	89	O	mg
18	91	94	O	once
19	96	100	O	daily
20	102	102	O	,
21	104	106	O	the
22	108	116	U-UNK	indinavir
23	118	120	O	AUC
24	122	124	O	and
25	126	129	O	Cmin
26	131	134	O	were
27	136	144	O	decreased
28	146	147	O	on
29	149	155	O	average
30	157	158	O	by
31	160	161	O	33
32	163	165	O	46%
33	167	169	O	and
34	171	172	O	39
35	174	176	O	57%
36	177	177	O	,
37	179	190	O	respectively
38	191	191	O	,
39	193	200	O	compared
40	202	203	O	to
41	205	208	O	when
42	210	218	U-UNK	indinavir
43	221	223	O	800
44	225	226	O	mg
45	228	232	O	every
46	234	234	O	8
47	236	240	O	hours
48	243	245	O	was
49	247	251	O	given
50	253	257	O	alone
NULL

Efavirenz	DDI-DrugBank.d531.s41	NO_SECTION	NO_SETID	2
lopinavir concentration
1	0	8	U-UNK	lopinavir
2	10	22	O	concentration
NULL

Efavirenz	DDI-DrugBank.d531.s42	NO_SECTION	NO_SETID	30
A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.
1	0	0	O	A
2	2	5	O	dose
3	7	14	O	increase
4	16	17	O	of
5	19	27	U-DYN	lopinavir
6	28	28	O	/
7	29	37	U-DYN	ritonavir
8	39	40	O	to
9	42	44	O	533
10	45	45	O	/
11	46	48	O	133
12	50	51	O	mg
13	54	54	O	4
14	56	63	O	capsules
15	65	66	O	or
16	68	70	O	6.5
17	72	73	O	mL
18	76	80	O	twice
19	82	86	O	daily
20	88	92	O	taken
21	94	97	O	with
22	99	102	O	food
23	104	105	O	is
24	107	117	O	recommended
25	119	122	O	when
26	124	127	O	used
27	129	130	O	in
28	132	142	O	combination
29	144	147	O	with
30	149	155	O	XXXXXXXX
NULL

Efavirenz	DDI-DrugBank.d531.s44	NO_SECTION	NO_SETID	2
methadone concentration
1	0	8	U-UNK	methadone
2	10	22	O	concentration
NULL

Efavirenz	DDI-DrugBank.d531.s45	NO_SECTION	NO_SETID	24
Coadministration in HIV-infected individuals with a history of injection drug use resulted in decreased plasma levels of methadone and signs of opiate withdrawal.
1	0	15	O	Coadministration
2	17	18	O	in
3	20	22	O	HIV
4	24	31	O	infected
5	33	43	O	individuals
6	45	48	O	with
7	50	50	O	a
8	52	58	O	history
9	60	61	O	of
10	63	71	O	injection
11	73	76	O	drug
12	78	80	O	use
13	82	89	O	resulted
14	91	92	O	in
15	94	102	O	decreased
16	104	109	O	plasma
17	111	116	O	levels
18	118	119	O	of
19	121	129	U-UNK	methadone
20	131	133	O	and
21	135	139	O	signs
22	141	142	O	of
23	144	149	U-UNK	opiate
24	151	160	O	withdrawal
NULL

Efavirenz	DDI-DrugBank.d531.s46	NO_SECTION	NO_SETID	13
Methadone dose was increased by a mean of 22% to alleviate withdrawal symptoms.
1	0	8	U-UNK	Methadone
2	10	13	O	dose
3	15	17	O	was
4	19	27	O	increased
5	29	30	O	by
6	32	32	O	a
7	34	37	O	mean
8	39	40	O	of
9	42	44	O	22%
10	46	47	O	to
11	49	57	O	alleviate
12	59	68	O	withdrawal
13	70	77	O	symptoms
NULL

Efavirenz	DDI-DrugBank.d531.s47	NO_SECTION	NO_SETID	19
Patients should be monitored for signs of withdrawal and their methadone dose increased as required to alleviate withdrawal symptoms.
1	0	7	O	Patients
2	9	14	O	should
3	16	17	O	be
4	19	27	O	monitored
5	29	31	O	for
6	33	37	O	signs
7	39	40	O	of
8	42	51	O	withdrawal
9	53	55	O	and
10	57	61	O	their
11	63	71	U-UNK	methadone
12	73	76	O	dose
13	78	86	O	increased
14	88	89	O	as
15	91	98	O	required
16	100	101	O	to
17	103	111	O	alleviate
18	113	122	O	withdrawal
19	124	131	O	symptoms
NULL

Efavirenz	DDI-DrugBank.d531.s49	NO_SECTION	NO_SETID	3
ethinyl estradiol concentration
1	0	6	B-UNK	ethinyl
2	8	16	L-UNK	estradiol
3	18	30	O	concentration
NULL

Efavirenz	DDI-DrugBank.d531.s50	NO_SECTION	NO_SETID	6
Plasma concentrations increased by SUSTIVA (efavirenz);
1	0	5	O	Plasma
2	7	20	O	concentrations
3	22	30	O	increased
4	32	33	O	by
5	35	41	O	XXXXXXXX
6	44	52	U-UNK	efavirenz
NULL

Efavirenz	DDI-DrugBank.d531.s51	NO_SECTION	NO_SETID	3
clinical significance unknown.
1	0	7	O	clinical
2	9	20	O	significance
3	22	28	O	unknown
NULL

Efavirenz	DDI-DrugBank.d531.s52	NO_SECTION	NO_SETID	29
Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.
1	0	6	O	Because
2	8	10	O	the
3	12	20	O	potential
4	22	32	O	interaction
5	34	35	O	of
6	37	45	O	XXXXXXXX
7	47	50	O	with
8	52	55	O	oral
9	57	70	U-DYN	contraceptives
10	72	74	O	has
11	76	78	O	not
12	80	83	O	been
13	85	89	O	fully
14	91	103	O	characterized
15	104	104	O	,
16	106	106	O	a
17	108	115	O	reliable
18	117	122	O	method
19	124	125	O	of
20	127	133	O	barrier
21	135	147	O	contraception
22	149	154	O	should
23	156	157	O	be
24	159	162	O	used
25	164	165	O	in
26	167	174	O	addition
27	176	177	O	to
28	179	182	O	oral
29	184	197	U-UNK	contraceptives
NULL

Efavirenz	DDI-DrugBank.d531.s54	NO_SECTION	NO_SETID	2
rifabutin concentration
1	0	8	U-UNK	rifabutin
2	10	22	O	concentration
NULL

Efavirenz	DDI-DrugBank.d531.s55	NO_SECTION	NO_SETID	7
Increase daily dose of rifabutin by 50%.
1	0	7	O	Increase
2	9	13	O	daily
3	15	18	O	dose
4	20	21	O	of
5	23	31	U-UNK	rifabutin
6	33	34	O	by
7	36	38	O	50%
NULL

Efavirenz	DDI-DrugBank.d531.s56	NO_SECTION	NO_SETID	17
Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week.
1	0	7	O	Consider
2	9	16	O	doubling
3	18	20	O	the
4	22	30	U-UNK	rifabutin
5	32	35	O	dose
6	37	38	O	in
7	40	47	O	regimens
8	49	53	O	where
9	55	63	U-UNK	rifabutin
10	65	66	O	is
11	68	72	O	given
12	74	74	O	2
13	76	77	O	or
14	79	79	O	3
15	81	85	O	times
16	87	87	O	a
17	89	92	O	week
NULL

Efavirenz	DDI-DrugBank.d531.s58	NO_SECTION	NO_SETID	2
efavirenz concentration
1	0	8	O	XXXXXXXX
2	10	22	O	concentration
NULL

Efavirenz	DDI-DrugBank.d531.s59	NO_SECTION	NO_SETID	7
Clinical significance of reduced efavirenz concentrations unknown.
1	0	7	O	Clinical
2	9	20	O	significance
3	22	23	O	of
4	25	31	O	reduced
5	33	41	O	XXXXXXXX
6	43	56	O	concentrations
7	58	64	O	unknown
NULL

Efavirenz	DDI-DrugBank.d531.s61	NO_SECTION	NO_SETID	2
ritonavir concentration
1	0	8	U-UNK	ritonavir
2	10	22	O	concentration
NULL

Efavirenz	DDI-DrugBank.d531.s62	NO_SECTION	NO_SETID	24
Combination was associated with a higher frequency of adverse clinical experiences (eg, dizziness, nausea, paresthesia) and laboratory abnormalities (elevated liver enzymes).
1	0	10	O	Combination
2	12	14	O	was
3	16	25	O	associated
4	27	30	O	with
5	32	32	O	a
6	34	39	O	higher
7	41	49	O	frequency
8	51	52	O	of
9	54	60	O	adverse
10	62	69	O	clinical
11	71	81	O	experiences
12	84	85	O	eg
13	86	86	O	,
14	88	96	O	dizziness
15	97	97	O	,
16	99	104	O	nausea
17	105	105	O	,
18	107	117	O	paresthesia
19	120	122	O	and
20	124	133	O	laboratory
21	135	147	O	abnormalities
22	150	157	O	elevated
23	159	163	O	liver
24	165	171	O	enzymes
NULL

Efavirenz	DDI-DrugBank.d531.s63	NO_SECTION	NO_SETID	14
Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.
1	0	9	O	Monitoring
2	11	12	O	of
3	14	18	O	liver
4	20	26	O	enzymes
5	28	29	O	is
6	31	41	O	recommended
7	43	46	O	when
8	48	54	O	XXXXXXXX
9	56	57	O	is
10	59	62	O	used
11	64	65	O	in
12	67	77	O	combination
13	79	82	O	with
14	84	92	U-DYN	ritonavir
NULL

Efavirenz	DDI-DrugBank.d531.s64	NO_SECTION	NO_SETID	2
efavirenz concentration
1	0	8	O	XXXXXXXX
2	10	22	O	concentration
NULL

Efavirenz	DDI-DrugBank.d531.s66	NO_SECTION	NO_SETID	2
saquinavir concentration
1	0	9	U-UNK	saquinavir
2	11	23	O	concentration
NULL

Efavirenz	DDI-DrugBank.d531.s67	NO_SECTION	NO_SETID	12
Should not be used as sole protease inhibitor in combination with SUSTIVA.
1	0	5	O	Should
2	7	9	O	not
3	11	12	O	be
4	14	17	O	used
5	19	20	O	as
6	22	25	O	sole
7	27	34	B-UNK	protease
8	36	44	L-UNK	inhibitor
9	46	47	O	in
10	49	59	O	combination
11	61	64	O	with
12	66	72	O	XXXXXXXX
NULL

Efavirenz	DDI-DrugBank.d531.s69	NO_SECTION	NO_SETID	2
sertraline concentration
1	0	9	U-UNK	sertraline
2	11	23	O	concentration
NULL

Efavirenz	DDI-DrugBank.d531.s70	NO_SECTION	NO_SETID	10
Increases in sertraline dose should be guided by clinical response.
1	0	8	O	Increases
2	10	11	O	in
3	13	22	U-UNK	sertraline
4	24	27	O	dose
5	29	34	O	should
6	36	37	O	be
7	39	44	O	guided
8	46	47	O	by
9	49	56	O	clinical
10	58	65	O	response
NULL

Efavirenz	DDI-DrugBank.d531.s71	NO_SECTION	NO_SETID	11
Other Potentially Clinically Significant Drug or Herbal Product Interactions With SUSTIVAb
1	0	4	O	Other
2	6	16	O	Potentially
3	18	27	O	Clinically
4	29	39	O	Significant
5	41	44	O	Drug
6	46	47	O	or
7	49	54	O	Herbal
8	56	62	O	Product
9	64	75	O	Interactions
10	77	80	O	With
11	82	89	O	SUSTIVAb
NULL

Efavirenz	DDI-DrugBank.d531.s72	NO_SECTION	NO_SETID	3
Anticoagulants: Warfarin
1	0	13	U-UNK	Anticoagulants
2	14	14	O	:
3	16	23	U-UNK	Warfarin
NULL

Efavirenz	DDI-DrugBank.d531.s73	NO_SECTION	NO_SETID	10
Plasma concentrations and effects potentially increased or decreased by SUSTIVA.
1	0	5	O	Plasma
2	7	20	O	concentrations
3	22	24	O	and
4	26	32	O	effects
5	34	44	O	potentially
6	46	54	O	increased
7	56	57	O	or
8	59	67	O	decreased
9	69	70	O	by
10	72	78	O	XXXXXXXX
NULL

Efavirenz	DDI-DrugBank.d531.s74	NO_SECTION	NO_SETID	5
Anticonvulsants: Phenytoin Phenobarbital Carbamazepine
1	0	14	U-UNK	Anticonvulsants
2	15	15	O	:
3	17	25	U-UNK	Phenytoin
4	27	39	U-UNK	Phenobarbital
5	41	53	U-UNK	Carbamazepine
NULL

Efavirenz	DDI-DrugBank.d531.s75	NO_SECTION	NO_SETID	11
Potential for reduction in anticonvulsant and/or efavirenz plasma levels;
1	0	8	O	Potential
2	10	12	O	for
3	14	22	O	reduction
4	24	25	O	in
5	27	40	U-KIN	anticonvulsant
6	42	44	O	and
7	45	45	O	/
8	46	47	O	or
9	49	57	O	XXXXXXXX
10	59	64	O	plasma
11	66	71	O	levels
NULL

Efavirenz	DDI-DrugBank.d531.s76	NO_SECTION	NO_SETID	9
periodic monitoring of anticonvulsant plasma levels should be conducted.
1	0	7	O	periodic
2	9	18	O	monitoring
3	20	21	O	of
4	23	36	U-UNK	anticonvulsant
5	38	43	O	plasma
6	45	50	O	levels
7	52	57	O	should
8	59	60	O	be
9	62	70	O	conducted
NULL

Efavirenz	DDI-DrugBank.d531.s77	NO_SECTION	NO_SETID	4
Antifungals: Itraconazole Ketoconazole
1	0	10	U-UNK	Antifungals
2	11	11	O	:
3	13	24	U-UNK	Itraconazole
4	26	37	U-UNK	Ketoconazole
NULL

Efavirenz	DDI-DrugBank.d531.s78	NO_SECTION	NO_SETID	15
Drug interaction studies with SUSTIVA and these imidazole and triazole antifungals have not been conducted.
1	0	3	O	Drug
2	5	15	O	interaction
3	17	23	O	studies
4	25	28	O	with
5	30	36	O	XXXXXXXX
6	38	40	O	and
7	42	46	O	these
8	48	56	B-UNK	imidazole
9	58	60	I-UNK	and
10	62	69	I-UNK	triazole
11	71	81	L-UNK	antifungals
12	83	86	O	have
13	88	90	O	not
14	92	95	O	been
15	97	105	O	conducted
NULL

Efavirenz	DDI-DrugBank.d531.s79	NO_SECTION	NO_SETID	12
SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.
1	0	6	O	XXXXXXXX
2	8	10	O	has
3	12	14	O	the
4	16	24	O	potential
5	26	27	O	to
6	29	36	O	decrease
7	38	43	O	plasma
8	45	58	O	concentrations
9	60	61	O	of
10	63	74	U-KIN	itraconazole
11	76	78	O	and
12	80	91	U-KIN	ketoconazole
NULL

Efavirenz	DDI-DrugBank.d531.s80	NO_SECTION	NO_SETID	9
Anti-HIV protease inhibitors: Saquinavir/ritonavir combination
1	0	3	B-UNK	Anti
2	5	7	I-UNK	HIV
3	9	16	I-UNK	protease
4	18	27	L-UNK	inhibitors
5	28	28	O	:
6	30	39	U-UNK	Saquinavir
7	40	40	O	/
8	41	49	U-UNK	ritonavir
9	51	61	O	combination
NULL

Efavirenz	DDI-DrugBank.d531.s81	NO_SECTION	NO_SETID	5
No pharmacokinetic data are available.
1	0	1	O	No
2	3	17	O	pharmacokinetic
3	19	22	O	data
4	24	26	O	are
5	28	36	O	available
NULL

Efavirenz	DDI-DrugBank.d531.s83	NO_SECTION	NO_SETID	9
SUSTIVAhas the potential to decrease serum concentrations of amprenavir.
1	0	9	O	SUSTIVAhas
2	11	13	O	the
3	15	23	O	potential
4	25	26	O	to
5	28	35	O	decrease
6	37	41	O	serum
7	43	56	O	concentrations
8	58	59	O	of
9	61	70	U-UNK	amprenavir
NULL

Efavirenz	DDI-DrugBank.d531.s84	NO_SECTION	NO_SETID	5
Non-nucleoside reverse transcriptase inhibitors
1	0	2	B-UNK	Non
2	4	13	I-UNK	nucleoside
3	15	21	I-UNK	reverse
4	23	35	I-UNK	transcriptase
5	37	46	L-UNK	inhibitors
NULL

Efavirenz	DDI-DrugBank.d531.s85	NO_SECTION	NO_SETID	8
No studies have been performed with other NNRTIs.
1	0	1	O	No
2	3	9	O	studies
3	11	14	O	have
4	16	19	O	been
5	21	29	O	performed
6	31	34	O	with
7	36	40	O	other
8	42	47	U-UNK	NNRTIs
NULL

Efavirenz	DDI-DrugBank.d531.s86	NO_SECTION	NO_SETID	6
St. John s wort (Hypericum perforatum)
1	0	1	O	St
2	4	7	O	John
3	9	9	O	s
4	11	14	O	wort
5	17	25	O	Hypericum
6	27	36	O	perforatum
NULL

Efavirenz	DDI-DrugBank.d531.s87	NO_SECTION	NO_SETID	15
Expected to substantially decrease plasma levels of efavirenz;has not been studied in combination with SUSTIVA.
1	0	7	O	Expected
2	9	10	O	to
3	12	24	O	substantially
4	26	33	O	decrease
5	35	40	O	plasma
6	42	47	O	levels
7	49	50	O	of
8	52	64	O	efavirenz;has
9	66	68	O	not
10	70	73	O	been
11	75	81	O	studied
12	83	84	O	in
13	86	96	O	combination
14	98	101	O	with
15	103	109	O	XXXXXXXX
NULL

Efavirenz	DDI-DrugBank.d531.s88	NO_SECTION	NO_SETID	6
a See Tables 1 and 2.
1	0	0	O	a
2	2	4	O	See
3	6	11	O	Tables
4	13	13	O	1
5	15	17	O	and
6	19	19	O	2
NULL

Efavirenz	DDI-DrugBank.d531.s89	NO_SECTION	NO_SETID	7
b This table is not all-inclusive.
1	0	0	O	b
2	2	5	O	This
3	7	11	O	table
4	13	14	O	is
5	16	18	O	not
6	20	22	O	all
7	24	32	O	inclusive
NULL

Efavirenz	DDI-DrugBank.d531.s90	NO_SECTION	NO_SETID	50
Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.
1	0	4	O	Other
2	6	10	O	Drugs
3	11	11	O	:
4	13	17	O	Based
5	19	20	O	on
6	22	24	O	the
7	26	32	O	results
8	34	35	O	of
9	37	40	O	drug
10	42	52	O	interaction
11	54	60	O	studies
12	61	61	O	,
13	63	64	O	no
14	66	71	O	dosage
15	73	82	O	adjustment
16	84	85	O	is
17	87	97	O	recommended
18	99	102	O	when
19	104	110	O	XXXXXXXX
20	113	121	U-UNK	efavirenz
21	124	125	O	is
22	127	131	O	given
23	133	136	O	with
24	138	140	O	the
25	142	150	O	following
26	151	151	O	:
27	153	160	B-UNK	aluminum
28	161	161	I-UNK	/
29	162	170	I-UNK	magnesium
30	172	180	I-UNK	hydroxide
31	182	189	L-UNK	antacids
32	190	190	O	,
33	192	203	U-UNK	azithromycin
34	204	204	O	,
35	206	215	U-UNK	cetirizine
36	216	216	O	,
37	218	227	U-UNK	famotidine
38	228	228	O	,
39	230	240	U-UNK	fluconazole
40	241	241	O	,
41	243	252	U-UNK	lamivudine
42	253	253	O	,
43	255	263	U-UNK	lorazepam
44	264	264	O	,
45	266	275	U-UNK	nelfinavir
46	276	276	O	,
47	278	287	U-UNK	paroxetine
48	288	288	O	,
49	290	292	O	and
50	294	303	U-UNK	zidovudine
NULL

Efavirenz	DDI-DrugBank.d531.s91	NO_SECTION	NO_SETID	17
Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine.
1	0	7	O	Specific
2	9	12	O	drug
3	14	24	O	interaction
4	26	32	O	studies
5	34	37	O	have
6	39	41	O	not
7	43	46	O	been
8	48	56	O	performed
9	58	61	O	with
10	63	69	O	XXXXXXXX
11	71	73	O	and
12	75	79	U-UNK	NRTIs
13	81	85	O	other
14	87	90	O	than
15	92	101	U-UNK	lamivudine
16	103	105	O	and
17	107	116	U-UNK	zidovudine
NULL

Efavirenz	DDI-DrugBank.d531.s92	NO_SECTION	NO_SETID	32
Clinically significant interactions would not be expected since the NRTIs are metabolized via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.
1	0	9	O	Clinically
2	11	21	O	significant
3	23	34	O	interactions
4	36	40	O	would
5	42	44	O	not
6	46	47	O	be
7	49	56	O	expected
8	58	62	O	since
9	64	66	O	the
10	68	72	U-UNK	NRTIs
11	74	76	O	are
12	78	88	O	metabolized
13	90	92	O	via
14	94	94	O	a
15	96	104	O	different
16	106	110	O	route
17	112	115	O	than
18	117	125	O	XXXXXXXX
19	127	129	O	and
20	131	135	O	would
21	137	138	O	be
22	140	147	O	unlikely
23	149	150	O	to
24	152	158	O	compete
25	160	162	O	for
26	164	166	O	the
27	168	171	O	same
28	173	181	O	metabolic
29	183	189	O	enzymes
30	191	193	O	and
31	195	205	O	elimination
32	207	214	O	pathways
NULL

Emtricitabine	DDI-DrugBank.d375.s0	NO_SECTION	NO_SETID	23
The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.
1	0	2	O	The
2	4	12	O	potential
3	14	16	O	for
4	18	21	O	drug
5	23	34	O	interactions
6	36	39	O	with
7	41	47	O	XXXXXXXX
8	49	51	O	has
9	53	56	O	been
10	58	64	O	studied
11	66	67	O	in
12	69	79	O	combination
13	81	84	O	with
14	86	94	U-UNK	indinavir
15	95	95	O	,
16	97	105	U-UNK	stavudine
17	106	106	O	,
18	108	118	U-UNK	famciclovir
19	119	119	O	,
20	121	123	O	and
21	125	133	B-UNK	tenofovir
22	135	144	I-UNK	disoproxil
23	146	153	L-UNK	fumarate
NULL

Emtricitabine	DDI-DrugBank.d375.s1	NO_SECTION	NO_SETID	12
There were no clinically significant drug interactions for any of these drugs
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	23	O	clinically
5	25	35	O	significant
6	37	40	O	drug
7	42	53	O	interactions
8	55	57	O	for
9	59	61	O	any
10	63	64	O	of
11	66	70	O	these
12	72	76	O	drugs
NULL

Enalapril	DDI-DrugBank.d107.s0	NO_SECTION	NO_SETID	39
Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.
1	0	10	O	Hypotension
2	11	11	O	:
3	13	20	O	Patients
4	22	23	O	on
5	25	32	O	Diuretic
6	34	40	O	Therapy
7	41	41	O	:
8	43	50	O	Patients
9	52	53	O	on
10	55	63	U-DYN	diuretics
11	65	67	O	and
12	69	78	O	especially
13	80	84	O	those
14	86	87	O	in
15	89	92	O	whom
16	94	101	O	diuretic
17	103	109	O	therapy
18	111	113	O	was
19	115	122	O	recently
20	124	133	O	instituted
21	134	134	O	,
22	136	138	O	may
23	140	151	O	occasionally
24	153	162	O	experience
25	164	165	O	an
26	167	175	O	excessive
27	177	185	O	reduction
28	187	188	O	of
29	190	194	O	blood
30	196	203	O	pressure
31	205	209	O	after
32	211	220	O	initiation
33	222	223	O	of
34	225	231	O	therapy
35	233	236	O	with
36	238	246	O	XXXXXXXX
37	248	249	O	or
38	251	259	O	XXXXXXXX
39	260	261	O	at
NULL

Enalapril	DDI-DrugBank.d107.s1	NO_SECTION	NO_SETID	33
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.
1	0	2	O	The
2	4	14	O	possibility
3	16	17	O	of
4	19	29	O	hypotensive
5	31	37	O	effects
6	39	42	O	with
7	44	52	O	XXXXXXXX
8	54	55	O	or
9	57	65	O	XXXXXXXX
10	66	67	O	at
11	69	71	O	can
12	73	74	O	be
13	76	84	O	minimized
14	86	87	O	by
15	89	94	O	either
16	96	108	O	discontinuing
17	110	112	O	the
18	114	121	U-DYN	diuretic
19	123	124	O	or
20	126	135	O	increasing
21	137	139	O	the
22	141	144	O	salt
23	146	151	O	intake
24	153	157	O	prior
25	159	160	O	to
26	162	171	O	initiation
27	173	174	O	of
28	176	184	O	treatment
29	186	189	O	with
30	191	199	O	XXXXXXXX
31	201	202	O	or
32	204	212	O	XXXXXXXX
33	213	214	O	at
NULL

Enalapril	DDI-DrugBank.d107.s2	NO_SECTION	NO_SETID	34
If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour..
1	0	1	O	If
2	3	4	O	it
3	6	7	O	is
4	9	17	O	necessary
5	19	20	O	to
6	22	29	O	continue
7	31	33	O	the
8	35	42	U-UNK	diuretic
9	43	43	O	,
10	45	51	O	provide
11	53	57	O	close
12	59	65	O	medical
13	67	77	O	supervision
14	79	83	O	after
15	85	87	O	the
16	89	95	O	initial
17	97	100	O	dose
18	102	104	O	for
19	106	107	O	at
20	109	113	O	least
21	115	117	O	two
22	119	123	O	hours
23	125	127	O	and
24	129	133	O	until
25	135	139	O	blood
26	141	148	O	pressure
27	150	152	O	has
28	154	163	O	stabilized
29	165	167	O	for
30	169	170	O	at
31	172	176	O	least
32	178	179	O	an
33	181	190	O	additional
34	192	195	O	hour
NULL

Enalapril	DDI-DrugBank.d107.s3	NO_SECTION	NO_SETID	25
Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
1	0	5	O	Agents
2	7	13	O	Causing
3	15	19	O	Renin
4	21	27	O	Release
5	28	28	O	:
6	30	32	O	The
7	34	49	O	antihypertensive
8	51	56	O	effect
9	58	59	O	of
10	61	69	O	XXXXXXXX
11	71	73	O	and
12	75	83	O	XXXXXXXX
13	85	86	O	IV
14	88	89	O	is
15	91	99	O	augmented
16	101	102	O	by
17	104	119	B-DYN	antihypertensive
18	121	126	L-DYN	agents
19	128	131	O	that
20	133	137	O	cause
21	139	143	O	renin
22	145	151	O	release
23	154	156	O	e.g
24	158	158	O	,
25	160	168	U-DYN	diuretics
NULL

Enalapril	DDI-DrugBank.d107.s4	NO_SECTION	NO_SETID	37
Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.
1	0	2	B-UNK	Non
2	4	12	I-UNK	steroidal
3	14	17	I-UNK	Anti
4	19	30	I-UNK	inflammatory
5	32	37	L-UNK	Agents
6	38	38	O	:
7	40	41	O	In
8	43	46	O	some
9	48	55	O	patients
10	57	60	O	with
11	62	72	O	compromised
12	74	78	O	renal
13	80	87	O	function
14	89	91	O	who
15	93	95	O	are
16	97	101	O	being
17	103	109	O	treated
18	111	114	O	with
19	116	127	B-DYN	nonsteroidal
20	129	132	I-DYN	anti
21	134	145	I-DYN	inflammatory
22	147	151	L-DYN	drugs
23	152	152	O	,
24	154	156	O	the
25	158	159	O	co
26	161	174	O	administration
27	176	177	O	of
28	179	187	O	XXXXXXXX
29	189	191	O	may
30	193	198	O	result
31	200	201	O	in
32	203	203	O	a
33	205	211	O	further
34	213	225	O	deterioration
35	227	228	O	of
36	230	234	O	renal
37	236	243	O	function
NULL

Enalapril	DDI-DrugBank.d107.s5	NO_SECTION	NO_SETID	5
These effects are usually reversible.
1	0	4	O	These
2	6	12	O	effects
3	14	16	O	are
4	18	24	O	usually
5	26	35	O	reversible
NULL

Enalapril	DDI-DrugBank.d107.s6	NO_SECTION	NO_SETID	16
In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	clinical
4	14	25	O	pharmacology
5	27	31	O	study
6	32	32	O	,
7	34	45	U-UNK	indomethacin
8	47	48	O	or
9	50	57	U-UNK	sulindac
10	59	61	O	was
11	63	74	O	administered
12	76	77	O	to
13	79	90	O	hypertensive
14	92	99	O	patients
15	101	109	O	receiving
16	111	117	O	XXXXXXXX
NULL

Enalapril	DDI-DrugBank.d107.s7	NO_SECTION	NO_SETID	16
In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC.
1	0	1	O	In
2	3	6	O	this
3	8	12	O	study
4	14	18	O	there
5	20	22	O	was
6	24	25	O	no
7	27	34	O	evidence
8	36	37	O	of
9	39	39	O	a
10	41	48	O	blunting
11	50	51	O	of
12	53	55	O	the
13	57	72	O	antihypertensive
14	74	79	O	action
15	81	82	O	of
16	84	90	O	XXXXXXXX
NULL

Enalapril	DDI-DrugBank.d107.s8	NO_SECTION	NO_SETID	14
However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	reports
4	17	23	O	suggest
5	25	28	O	that
6	30	35	U-UNK	NSAIDs
7	37	39	O	may
8	41	48	O	diminish
9	50	52	O	the
10	54	69	O	antihypertensive
11	71	76	O	effect
12	78	79	O	of
13	81	83	B-UNK	ACE
14	85	94	L-UNK	inhibitors
NULL

Enalapril	DDI-DrugBank.d107.s9	NO_SECTION	NO_SETID	14
This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
1	0	3	O	This
2	5	15	O	interaction
3	17	22	O	should
4	24	25	O	be
5	27	31	O	given
6	33	45	O	consideration
7	47	48	O	in
8	50	57	O	patients
9	59	64	O	taking
10	66	71	U-UNK	NSAIDs
11	73	85	O	concomitantly
12	87	90	O	with
13	92	94	B-UNK	ACE
14	96	105	L-UNK	inhibitors
NULL

Enalapril	DDI-DrugBank.d107.s10	NO_SECTION	NO_SETID	38
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
1	0	4	O	Other
2	6	19	O	Cardiovascular
3	21	26	O	Agents
4	27	27	O	:
5	29	37	O	XXXXXXXX
6	39	41	O	and
7	43	51	O	XXXXXXXX
8	53	54	O	IV
9	56	59	O	have
10	61	64	O	been
11	66	69	O	used
12	71	83	O	concomitantly
13	85	88	O	with
14	90	93	B-UNK	beta
15	95	104	I-UNK	adrenergic
16	106	113	I-UNK	blocking
17	115	120	L-UNK	agents
18	121	121	O	,
19	123	132	U-UNK	methyldopa
20	133	133	O	,
21	135	142	U-UNK	nitrates
22	143	143	O	,
23	145	151	B-UNK	calcium
24	153	160	I-UNK	blocking
25	162	167	L-UNK	agents
26	168	168	O	,
27	170	180	U-UNK	hydralazine
28	181	181	O	,
29	183	190	U-UNK	prazosin
30	192	194	O	and
31	196	202	U-UNK	digoxin
32	204	210	O	without
33	212	219	O	evidence
34	221	222	O	of
35	224	233	O	clinically
36	235	245	O	significant
37	247	253	O	adverse
38	255	266	O	interactions
NULL

Enalapril	DDI-DrugBank.d107.s11	NO_SECTION	NO_SETID	15
Enalapril IV has been used concomitantly with digitalis without evidence of clinically significant adverse reactions.
1	0	8	O	XXXXXXXX
2	10	11	O	IV
3	13	15	O	has
4	17	20	O	been
5	22	25	O	used
6	27	39	O	concomitantly
7	41	44	O	with
8	46	54	U-UNK	digitalis
9	56	62	O	without
10	64	71	O	evidence
11	73	74	O	of
12	76	85	O	clinically
13	87	97	O	significant
14	99	105	O	adverse
15	107	115	O	reactions
NULL

Enalapril	DDI-DrugBank.d107.s12	NO_SECTION	NO_SETID	17
Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.
1	0	5	O	Agents
2	7	16	O	Increasing
3	18	22	O	Serum
4	24	32	O	Potassium
5	33	33	O	:
6	35	43	O	XXXXXXXX
7	45	47	O	and
8	49	57	O	XXXXXXXX
9	59	60	O	IV
10	62	70	O	attenuate
11	72	80	O	potassium
12	82	85	O	loss
13	87	92	O	caused
14	94	95	O	by
15	97	104	B-DYN	thiazide
16	106	109	I-DYN	type
17	111	119	L-DYN	diuretics
NULL

Enalapril	DDI-DrugBank.d107.s13	NO_SECTION	NO_SETID	28
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
1	0	8	B-UNK	Potassium
2	10	16	I-UNK	sparing
3	18	26	L-UNK	diuretics
4	29	31	O	e.g
5	33	33	O	,
6	35	48	U-UNK	spironolactone
7	49	49	O	,
8	51	61	U-UNK	triamterene
9	62	62	O	,
10	64	65	O	or
11	67	75	U-UNK	amiloride
12	77	77	O	,
13	79	87	U-UNK	potassium
14	89	99	O	supplements
15	100	100	O	,
16	102	103	O	or
17	105	113	U-UNK	potassium
18	115	124	O	containing
19	126	129	O	salt
20	131	141	O	substitutes
21	143	145	O	may
22	147	150	O	lead
23	152	153	O	to
24	155	165	O	significant
25	167	175	O	increases
26	177	178	O	in
27	180	184	O	serum
28	186	194	O	potassium
NULL

Enalapril	DDI-DrugBank.d107.s14	NO_SECTION	NO_SETID	28
Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	if
4	14	24	O	concomitant
5	26	28	O	use
6	30	31	O	of
7	33	37	O	these
8	39	44	O	agents
9	46	47	O	is
10	49	57	O	indicated
11	59	65	O	because
12	67	68	O	of
13	70	81	O	demonstrated
14	83	93	O	hypokalemia
15	94	94	O	,
16	96	99	O	they
17	101	106	O	should
18	108	109	O	be
19	111	114	O	used
20	116	119	O	with
21	121	127	O	caution
22	129	131	O	and
23	133	136	O	with
24	138	145	O	frequent
25	147	156	O	monitoring
26	158	159	O	of
27	161	165	O	serum
28	167	175	O	potassium
NULL

Enalapril	DDI-DrugBank.d107.s15	NO_SECTION	NO_SETID	15
Potassium sparing agents should generally not be used in patients with heart failure receiving enalapril.
1	0	8	O	Potassium
2	10	16	O	sparing
3	18	23	O	agents
4	25	30	O	should
5	32	40	O	generally
6	42	44	O	not
7	46	47	O	be
8	49	52	O	used
9	54	55	O	in
10	57	64	O	patients
11	66	69	O	with
12	71	75	O	heart
13	77	83	O	failure
14	85	93	O	receiving
15	95	103	O	XXXXXXXX
NULL

Enalapril	DDI-DrugBank.d107.s16	NO_SECTION	NO_SETID	23
Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	15	U-UNK	Lithium
4	17	24	O	toxicity
5	26	28	O	has
6	30	33	O	been
7	35	42	O	reported
8	44	45	O	in
9	47	54	O	patients
10	56	64	O	receiving
11	66	72	U-UNK	lithium
12	74	86	O	concomitantly
13	88	91	O	with
14	93	97	O	drugs
15	99	103	O	which
16	105	109	O	cause
17	111	121	O	elimination
18	123	124	O	of
19	126	131	O	sodium
20	132	132	O	,
21	134	142	O	including
22	144	146	B-UNK	ACE
23	148	157	L-UNK	inhibitors
NULL

Enalapril	DDI-DrugBank.d107.s17	NO_SECTION	NO_SETID	17
It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	27	O	serum
6	29	35	U-UNK	lithium
7	37	42	O	levels
8	44	45	O	be
9	47	55	O	monitored
10	57	66	O	frequently
11	68	69	O	if
12	71	79	O	XXXXXXXX
13	81	82	O	is
14	84	95	O	administered
15	97	109	O	concomitantly
16	111	114	O	with
17	116	122	U-DYN	lithium
NULL

Enflurane	DDI-DrugBank.d6.s0	NO_SECTION	NO_SETID	9
The action of nondepolarizing relaxants is augmented by Enflurane.
1	0	2	O	The
2	4	9	O	action
3	11	12	O	of
4	14	28	O	nondepolarizing
5	30	38	O	relaxants
6	40	41	O	is
7	43	51	O	augmented
8	53	54	O	by
9	56	64	O	XXXXXXXX
NULL

Enflurane	DDI-DrugBank.d6.s1	NO_SECTION	NO_SETID	11
Less than the usual amounts of these medicines should be used.
1	0	3	O	Less
2	5	8	O	than
3	10	12	O	the
4	14	18	O	usual
5	20	26	O	amounts
6	28	29	O	of
7	31	35	O	these
8	37	45	O	medicines
9	47	52	O	should
10	54	55	O	be
11	57	60	O	used
NULL

Enflurane	DDI-DrugBank.d6.s2	NO_SECTION	NO_SETID	37
If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when halothane or nitrous oxide with a balanced technique are used.
1	0	1	O	If
2	3	5	O	the
3	7	11	O	usual
4	13	19	O	amounts
5	21	22	O	of
6	24	38	O	nondepolarizing
7	40	48	O	relaxants
8	50	52	O	are
9	54	58	O	given
10	59	59	O	,
11	61	63	O	the
12	65	68	O	time
13	70	72	O	for
14	74	81	O	recovery
15	83	86	O	from
16	88	100	O	neuromuscular
17	102	109	O	blockade
18	111	114	O	will
19	116	117	O	be
20	119	124	O	longer
21	126	127	O	in
22	129	131	O	the
23	133	140	O	presence
24	142	143	O	of
25	145	153	O	XXXXXXXX
26	155	158	O	than
27	160	163	O	when
28	165	173	U-UNK	halothane
29	175	176	O	or
30	178	184	B-UNK	nitrous
31	186	190	L-UNK	oxide
32	192	195	O	with
33	197	197	O	a
34	199	206	O	balanced
35	208	216	O	technique
36	218	220	O	are
37	222	225	O	used
NULL

Enfuvirtide	DDI-DrugBank.d535.s0	NO_SECTION	NO_SETID	29
CYP450 Metabolized Drugs Results from in vitro and in vivo studies suggest that enfuvirtide is unlikely to have significant drug interactions with concomitantly administered drugs metabolized by CYP450 enzymes.
1	0	5	O	CYP450
2	7	17	O	Metabolized
3	19	23	O	Drugs
4	25	31	O	Results
5	33	36	O	from
6	38	39	O	in
7	41	45	O	vitro
8	47	49	O	and
9	51	52	O	in
10	54	57	O	vivo
11	59	65	O	studies
12	67	73	O	suggest
13	75	78	O	that
14	80	90	O	XXXXXXXX
15	92	93	O	is
16	95	102	O	unlikely
17	104	105	O	to
18	107	110	O	have
19	112	122	O	significant
20	124	127	O	drug
21	129	140	O	interactions
22	142	145	O	with
23	147	159	O	concomitantly
24	161	172	O	administered
25	174	178	O	drugs
26	180	190	O	metabolized
27	192	193	O	by
28	195	200	O	CYP450
29	202	208	O	enzymes
NULL

Enfuvirtide	DDI-DrugBank.d535.s1	NO_SECTION	NO_SETID	30
Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.
1	0	13	B-UNK	Antiretroviral
2	15	20	L-UNK	Agents
3	21	21	O	:
4	23	24	O	No
5	26	29	O	drug
6	31	42	O	interactions
7	44	47	O	with
8	49	53	O	other
9	55	68	B-UNK	antiretroviral
10	70	80	L-UNK	medications
11	82	85	O	have
12	87	90	O	been
13	92	101	O	identified
14	103	106	O	that
15	108	112	O	would
16	114	120	O	warrant
17	122	131	O	alteration
18	133	134	O	of
19	136	141	O	either
20	143	145	O	the
21	147	157	O	XXXXXXXX
22	159	162	O	dose
23	164	165	O	or
24	167	169	O	the
25	171	174	O	dose
26	176	177	O	of
27	179	181	O	the
28	183	187	O	other
29	189	202	B-UNK	antiretroviral
30	204	213	L-UNK	medication
NULL

Enoxacin	DDI-DrugBank.d395.s0	NO_SECTION	NO_SETID	22
Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.
1	0	6	U-UNK	Bismuth
2	7	7	O	:
3	9	15	B-KIN	Bismuth
4	17	29	L-KIN	subsalicylate
5	30	30	O	,
6	32	36	O	given
7	38	50	O	concomitantly
8	52	55	O	with
9	57	64	O	XXXXXXXX
10	66	67	O	or
11	69	70	O	60
12	72	78	O	minutes
13	80	88	O	following
14	90	97	O	XXXXXXXX
15	99	112	O	administration
16	113	113	O	,
17	115	123	O	decreased
18	125	132	O	XXXXXXXX
19	134	148	O	bioavailability
20	150	151	O	by
21	153	165	O	approximately
22	167	169	O	25%
NULL

Enoxacin	DDI-DrugBank.d395.s1	NO_SECTION	NO_SETID	12
Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.
1	0	3	O	Thus
2	4	4	O	,
3	6	16	O	concomitant
4	18	31	O	administration
5	33	34	O	of
6	36	43	O	XXXXXXXX
7	45	47	O	and
8	49	55	B-DYN	bismuth
9	57	69	L-DYN	subsalicylate
10	71	76	O	should
11	78	79	O	be
12	81	87	O	avoided
NULL

Enoxacin	DDI-DrugBank.d395.s2	NO_SECTION	NO_SETID	19
Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
1	0	7	U-UNK	Caffeine
2	8	8	O	:
3	10	17	O	XXXXXXXX
4	19	20	O	is
5	22	22	O	a
6	24	29	O	potent
7	31	39	O	inhibitor
8	41	42	O	of
9	44	46	O	the
10	48	57	O	cytochrome
11	59	59	O	P
12	61	63	O	450
13	65	72	O	isozymes
14	74	84	O	responsible
15	86	88	O	for
16	90	92	O	the
17	94	103	O	metabolism
18	105	106	O	of
19	108	122	U-KIN	methylxanthines
NULL

Enoxacin	DDI-DrugBank.d395.s3	NO_SECTION	NO_SETID	47
In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	multiple
4	14	17	O	dose
5	19	23	O	study
6	24	24	O	,
7	26	33	O	XXXXXXXX
8	35	40	O	caused
9	42	42	O	a
10	44	47	O	dose
11	49	55	O	related
12	57	64	O	increase
13	66	67	O	in
14	69	71	O	the
15	73	76	O	mean
16	78	88	O	elimination
17	90	93	O	half
18	95	98	O	life
19	100	101	O	of
20	103	110	U-KIN	caffeine
21	111	111	O	,
22	113	119	O	thereby
23	121	130	O	decreasing
24	132	134	O	the
25	136	144	O	clearance
26	146	147	O	of
27	149	156	U-UNK	caffeine
28	158	159	O	by
29	161	162	O	up
30	164	165	O	to
31	167	169	O	80%
32	171	173	O	and
33	175	181	O	leading
34	183	184	O	to
35	186	186	O	a
36	188	191	O	five
37	193	196	O	fold
38	198	205	O	increase
39	207	208	O	in
40	210	212	O	the
41	214	216	O	AUC
42	218	220	O	and
43	222	224	O	the
44	226	229	O	half
45	231	234	O	life
46	236	237	O	of
47	239	246	U-UNK	caffeine
NULL

Enoxacin	DDI-DrugBank.d395.s4	NO_SECTION	NO_SETID	15
Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.
1	0	5	O	Trough
2	7	12	O	plasma
3	14	21	O	XXXXXXXX
4	23	28	O	levels
5	30	33	O	were
6	35	38	O	also
7	40	42	O	20%
8	44	49	O	higher
9	51	54	O	when
10	56	63	U-KIN	caffeine
11	65	67	O	and
12	69	76	O	XXXXXXXX
13	78	81	O	were
14	83	94	O	administered
15	96	108	O	concomitantly
NULL

Enoxacin	DDI-DrugBank.d395.s5	NO_SECTION	NO_SETID	15
Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.
1	0	7	U-UNK	Caffeine
2	9	15	O	related
3	17	23	O	adverse
4	25	31	O	effects
5	33	36	O	have
6	38	45	O	occurred
7	47	48	O	in
8	50	57	O	patients
9	59	67	O	consuming
10	69	76	U-DYN	caffeine
11	78	82	O	while
12	84	85	O	on
13	87	93	O	therapy
14	95	98	O	with
15	100	107	O	XXXXXXXX
NULL

Enoxacin	DDI-DrugBank.d395.s6	NO_SECTION	NO_SETID	22
Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
1	0	11	U-UNK	Cyclosporine
2	12	12	O	:
3	14	21	O	Elevated
4	23	27	O	serum
5	29	34	O	levels
6	36	37	O	of
7	39	50	U-UNK	cyclosporine
8	52	55	O	have
9	57	60	O	been
10	62	69	O	reported
11	71	74	O	with
12	76	86	O	concomitant
13	88	90	O	use
14	92	93	O	of
15	95	106	U-UNK	cyclosporine
16	108	111	O	with
17	113	117	O	other
18	119	125	O	members
19	127	128	O	of
20	130	132	O	the
21	134	142	B-UNK	quinolone
22	144	148	L-UNK	class
NULL

Enoxacin	DDI-DrugBank.d395.s7	NO_SECTION	NO_SETID	11
Digoxin: Enoxacin may raise serum digoxin levels in some individuals.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	16	O	XXXXXXXX
4	18	20	O	may
5	22	26	O	raise
6	28	32	O	serum
7	34	40	U-KIN	digoxin
8	42	47	O	levels
9	49	50	O	in
10	52	55	O	some
11	57	67	O	individuals
NULL

Enoxacin	DDI-DrugBank.d395.s8	NO_SECTION	NO_SETID	30
If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.
1	0	1	O	If
2	3	7	O	signs
3	9	11	O	and
4	13	20	O	symptoms
5	22	31	O	suggestive
6	33	34	O	of
7	36	42	U-UNK	digoxin
8	44	51	O	toxicity
9	53	57	O	occur
10	59	62	O	when
11	64	71	O	XXXXXXXX
12	73	75	O	and
13	77	83	U-DYN	digoxin
14	85	87	O	are
15	89	93	O	given
16	95	107	O	concomitantly
17	108	108	O	,
18	110	119	O	physicians
19	121	123	O	are
20	125	131	O	advised
21	133	134	O	to
22	136	141	O	obtain
23	143	147	O	serum
24	149	155	U-UNK	digoxin
25	157	162	O	levels
26	164	166	O	and
27	168	173	O	adjust
28	175	181	U-UNK	digoxin
29	183	187	O	doses
30	189	201	O	appropriately
NULL

Enoxacin	DDI-DrugBank.d395.s9	NO_SECTION	NO_SETID	22
Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.
1	0	2	B-UNK	Non
2	4	12	I-UNK	steroidal
3	14	17	I-UNK	anti
4	19	30	I-UNK	inflammatory
5	32	37	L-UNK	agents
6	38	38	O	:
7	40	47	O	Seizures
8	49	52	O	have
9	54	57	O	been
10	59	66	O	reported
11	68	69	O	in
12	71	78	O	patients
13	80	85	O	taking
14	87	94	O	XXXXXXXX
15	96	108	O	concomitantly
16	110	113	O	with
17	115	117	O	the
18	119	130	B-UNK	nonsteroidal
19	132	135	I-UNK	anti
20	137	148	I-UNK	inflammatory
21	150	153	L-UNK	drug
22	155	162	U-DYN	fenbufen
NULL

Enoxacin	DDI-DrugBank.d395.s10	NO_SECTION	NO_SETID	16
Animal studies also suggest an increased potential for seizures when these two drugs are given concomitantly.
1	0	5	O	Animal
2	7	13	O	studies
3	15	18	O	also
4	20	26	O	suggest
5	28	29	O	an
6	31	39	O	increased
7	41	49	O	potential
8	51	53	O	for
9	55	62	O	seizures
10	64	67	O	when
11	69	73	O	these
12	75	77	O	two
13	79	83	O	drugs
14	85	87	O	are
15	89	93	O	given
16	95	107	O	concomitantly
NULL

Enoxacin	DDI-DrugBank.d395.s11	NO_SECTION	NO_SETID	11
Fenbufen is not approved in the United States at this time.
1	0	7	U-UNK	Fenbufen
2	9	10	O	is
3	12	14	O	not
4	16	23	O	approved
5	25	26	O	in
6	28	30	O	the
7	32	37	O	United
8	39	44	O	States
9	46	47	O	at
10	49	52	O	this
11	54	57	O	time
NULL

Enoxacin	DDI-DrugBank.d395.s12	NO_SECTION	NO_SETID	10
Sucralfate and antacids: Quinolones form chelates with metal cations.
1	0	9	U-UNK	Sucralfate
2	11	13	O	and
3	15	22	U-UNK	antacids
4	23	23	O	:
5	25	34	U-UNK	Quinolones
6	36	39	O	form
7	41	48	O	chelates
8	50	53	O	with
9	55	59	O	metal
10	61	67	O	cations
NULL

Enoxacin	DDI-DrugBank.d395.s13	NO_SECTION	NO_SETID	14
Therefore, administration of quinolones with antacids containing calcium, magnesium, or aluminum;
1	0	8	O	Therefore
2	9	9	O	,
3	11	24	O	administration
4	26	27	O	of
5	29	38	U-UNK	quinolones
6	40	43	O	with
7	45	52	U-UNK	antacids
8	54	63	O	containing
9	65	71	U-UNK	calcium
10	72	72	O	,
11	74	82	U-UNK	magnesium
12	83	83	O	,
13	85	86	O	or
14	88	95	U-UNK	aluminum
NULL

Enoxacin	DDI-DrugBank.d395.s15	NO_SECTION	NO_SETID	8
with divalent or trivalent cations such as iron;
1	0	3	O	with
2	5	12	O	divalent
3	14	15	O	or
4	17	25	O	trivalent
5	27	33	O	cations
6	35	38	O	such
7	40	41	O	as
8	43	46	U-UNK	iron
NULL

Enoxacin	DDI-DrugBank.d395.s16	NO_SECTION	NO_SETID	20
or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.
1	0	1	O	or
2	3	6	O	with
3	8	20	U-UNK	multivitamins
4	22	31	O	containing
5	33	36	U-UNK	zinc
6	38	40	O	may
7	42	54	O	substantially
8	56	64	O	interfere
9	66	69	O	with
10	71	74	O	drug
11	76	85	O	absorption
12	87	89	O	and
13	91	96	O	result
14	98	99	O	in
15	101	112	O	insufficient
16	114	119	O	plasma
17	121	123	O	and
18	125	130	O	tissue
19	132	140	U-UNK	quinolone
20	142	155	O	concentrations
NULL

Enoxacin	DDI-DrugBank.d395.s17	NO_SECTION	NO_SETID	15
Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.
1	0	7	U-UNK	Antacids
2	9	18	O	containing
3	20	27	B-KIN	aluminum
4	29	37	L-KIN	hydroxide
5	39	41	O	and
6	43	51	B-KIN	magnesium
7	53	61	L-KIN	hydroxide
8	63	68	O	reduce
9	70	72	O	the
10	74	77	O	oral
11	79	88	O	absorption
12	90	91	O	of
13	93	100	O	XXXXXXXX
14	102	103	O	by
15	105	107	O	75%
NULL

Enoxacin	DDI-DrugBank.d395.s18	NO_SECTION	NO_SETID	13
The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.
1	0	2	O	The
2	4	7	O	oral
3	9	23	O	bioavailability
4	25	26	O	of
5	28	35	O	XXXXXXXX
6	37	38	O	is
7	40	46	O	reduced
8	48	49	O	by
9	51	53	O	60%
10	55	58	O	with
11	60	75	O	coadministration
12	77	78	O	of
13	80	89	U-KIN	ranitidine
NULL

Enoxacin	DDI-DrugBank.d395.s19	NO_SECTION	NO_SETID	17
These agents should not be taken for 8 hours before or for 2 hours after enoxacin administration.
1	0	4	O	These
2	6	11	O	agents
3	13	18	O	should
4	20	22	O	not
5	24	25	O	be
6	27	31	O	taken
7	33	35	O	for
8	37	37	O	8
9	39	43	O	hours
10	45	50	O	before
11	52	53	O	or
12	55	57	O	for
13	59	59	O	2
14	61	65	O	hours
15	67	71	O	after
16	73	80	O	XXXXXXXX
17	82	95	O	administration
NULL

Enoxacin	DDI-DrugBank.d395.s20	NO_SECTION	NO_SETID	19
Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.
1	0	11	U-UNK	Theophylline
2	12	12	O	:
3	14	21	O	XXXXXXXX
4	23	24	O	is
5	26	26	O	a
6	28	33	O	potent
7	35	43	O	inhibitor
8	45	46	O	of
9	48	50	O	the
10	52	61	O	cytochrome
11	63	63	O	P
12	65	67	O	450
13	69	76	O	isozymes
14	78	88	O	responsible
15	90	92	O	for
16	94	96	O	the
17	98	107	O	metabolism
18	109	110	O	of
19	112	126	U-KIN	methylxanthines
NULL

Enoxacin	DDI-DrugBank.d395.s21	NO_SECTION	NO_SETID	30
Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.
1	0	7	O	XXXXXXXX
2	9	18	O	interferes
3	20	23	O	with
4	25	27	O	the
5	29	38	O	metabolism
6	40	41	O	of
7	43	54	U-KIN	theophylline
8	56	64	O	resulting
9	66	67	O	in
10	69	69	O	a
11	71	73	O	42%
12	75	76	O	to
13	78	80	O	74%
14	82	85	O	dose
15	87	93	O	related
16	95	102	O	decrease
17	104	105	O	in
18	107	118	U-UNK	theophylline
19	120	128	O	clearance
20	130	132	O	and
21	134	134	O	a
22	136	145	O	subsequent
23	147	150	O	260%
24	152	153	O	to
25	155	158	O	350%
26	160	167	O	increase
27	169	170	O	in
28	172	176	O	serum
29	178	189	O	theophylline
30	191	196	O	levels
NULL

Enoxacin	DDI-DrugBank.d395.s22	NO_SECTION	NO_SETID	14
Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.
1	0	11	U-UNK	Theophylline
2	13	19	O	related
3	21	27	O	adverse
4	29	35	O	effects
5	37	40	O	have
6	42	49	O	occurred
7	51	52	O	in
8	54	61	O	patients
9	63	66	O	when
10	68	79	U-DYN	theophylline
11	81	83	O	and
12	85	92	O	XXXXXXXX
13	94	97	O	were
14	99	112	O	coadministered
NULL

Enoxacin	DDI-DrugBank.d395.s23	NO_SECTION	NO_SETID	21
Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	19	U-UNK	Quinolones
4	20	20	O	,
5	22	30	O	including
6	32	39	O	XXXXXXXX
7	40	40	O	,
8	42	49	O	decrease
9	51	53	O	the
10	55	63	O	clearance
11	65	66	O	of
12	68	68	B-KIN	R
13	70	77	L-KIN	warfarin
14	78	78	O	,
15	80	82	O	the
16	84	87	O	less
17	89	94	O	active
18	96	101	O	isomer
19	103	104	O	of
20	106	112	O	racemic
21	114	121	U-UNK	warfarin
NULL

Enoxacin	DDI-DrugBank.d395.s24	NO_SECTION	NO_SETID	27
Enoxacin does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when enoxacin and warfarin were coadministered.
1	0	7	O	XXXXXXXX
2	9	12	O	does
3	14	16	O	not
4	18	23	O	affect
5	25	27	O	the
6	29	37	O	clearance
7	39	40	O	of
8	42	44	O	the
9	46	51	O	active
10	53	53	O	S
11	55	60	O	isomer
12	61	61	O	,
13	63	65	O	and
14	67	73	O	changes
15	75	76	O	in
16	78	85	O	clotting
17	87	90	O	time
18	92	95	O	have
19	97	99	O	not
20	101	104	O	been
21	106	113	O	observed
22	115	118	O	when
23	120	127	O	XXXXXXXX
24	129	131	O	and
25	133	140	U-UNK	warfarin
26	142	145	O	were
27	147	160	O	coadministered
NULL

Enoxacin	DDI-DrugBank.d395.s25	NO_SECTION	NO_SETID	23
Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	16	O	the
4	18	28	O	prothrombin
5	30	33	O	time
6	35	36	O	or
7	38	42	O	other
8	44	51	O	suitable
9	53	63	O	coagulation
10	65	68	O	test
11	70	75	O	should
12	77	78	O	be
13	80	88	O	monitored
14	90	93	O	when
15	95	102	U-DYN	warfarin
16	104	105	O	or
17	107	109	O	its
18	111	121	O	derivatives
19	123	125	O	and
20	127	134	O	XXXXXXXX
21	136	138	O	are
22	140	144	O	given
23	146	158	O	concomitantly
NULL

Enoxaparin	DDI-DrugBank.d474.s0	NO_SECTION	NO_SETID	22
Unless really needed, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of Lovenox Injection therapy.
1	0	5	O	Unless
2	7	12	O	really
3	14	19	O	needed
4	20	20	O	,
5	22	27	O	agents
6	29	33	O	which
7	35	37	O	may
8	39	45	O	enhance
9	47	49	O	the
10	51	54	O	risk
11	56	57	O	of
12	59	68	O	hemorrhage
13	70	75	O	should
14	77	78	O	be
15	80	91	O	discontinued
16	93	97	O	prior
17	99	100	O	to
18	102	111	O	initiation
19	113	114	O	of
20	116	122	O	XXXXXXXX
21	124	132	O	Injection
22	134	140	O	therapy
NULL

Enoxaparin	DDI-DrugBank.d474.s1	NO_SECTION	NO_SETID	27
These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.
1	0	4	O	These
2	6	11	O	agents
3	13	19	O	include
4	21	31	O	medications
5	33	36	O	such
6	38	39	O	as
7	40	40	O	:
8	42	55	U-UNK	anticoagulants
9	56	56	O	,
10	58	65	B-UNK	platelet
11	67	76	L-UNK	inhibitors
12	78	86	O	including
13	88	102	B-UNK	acetylsalicylic
14	104	107	L-UNK	acid
15	108	108	O	,
16	110	113	O	sali
17	115	121	O	cylates
18	122	122	O	,
19	124	129	U-UNK	NSAIDs
20	132	140	O	including
21	142	150	B-UNK	ketorolac
22	152	163	L-UNK	tromethamine
23	165	165	O	,
24	167	178	U-UNK	dipyridamole
25	179	179	O	,
26	181	182	O	or
27	184	197	U-UNK	sulfinpyrazone
NULL

Enoxaparin	DDI-DrugBank.d474.s2	NO_SECTION	NO_SETID	12
If co-administration is essential, conduct close clinical and laboratory monitoring
1	0	1	O	If
2	3	4	O	co
3	6	19	O	administration
4	21	22	O	is
5	24	32	O	essential
6	33	33	O	,
7	35	41	O	conduct
8	43	47	O	close
9	49	56	O	clinical
10	58	60	O	and
11	62	71	O	laboratory
12	73	82	O	monitoring
NULL

Entacapone	DDI-DrugBank.d455.s0	NO_SECTION	NO_SETID	39
In vitro studies of human CYP enzymes showed that entacapone inhibited the CYP enzymes 1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A only at very high concentrations (IC50 from 200 to over 1000 uM;
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	18	O	of
5	20	24	O	human
6	26	28	O	CYP
7	30	36	O	enzymes
8	38	43	O	showed
9	45	48	O	that
10	50	59	O	XXXXXXXX
11	61	69	O	inhibited
12	71	73	O	the
13	75	77	O	CYP
14	79	85	O	enzymes
15	87	89	O	1A2
16	90	90	O	,
17	92	94	O	2A6
18	95	95	O	,
19	97	99	O	2C9
20	100	100	O	,
21	102	105	O	2C19
22	106	106	O	,
23	108	110	O	2D6
24	111	111	O	,
25	113	115	O	2E1
26	117	119	O	and
27	121	122	O	3A
28	124	127	O	only
29	129	130	O	at
30	132	135	O	very
31	137	140	O	high
32	142	155	O	concentrations
33	158	161	O	IC50
34	163	166	O	from
35	168	170	O	200
36	172	173	O	to
37	175	178	O	over
38	180	183	O	1000
39	185	186	O	uM
NULL

Entacapone	DDI-DrugBank.d455.s1	NO_SECTION	NO_SETID	15
an oral 200 mg dose achieves a highest level of approximately 5 uM in people);
1	0	1	O	an
2	3	6	O	oral
3	8	10	O	200
4	12	13	O	mg
5	15	18	O	dose
6	20	27	O	achieves
7	29	29	O	a
8	31	37	O	highest
9	39	43	O	level
10	45	46	O	of
11	48	60	O	approximately
12	62	62	O	5
13	64	65	O	uM
14	67	68	O	in
15	70	75	O	people
NULL

Entacapone	DDI-DrugBank.d455.s2	NO_SECTION	NO_SETID	13
these enzymes would therefore not be expected to be inhibited in clinical use.
1	0	4	O	these
2	6	12	O	enzymes
3	14	18	O	would
4	20	28	O	therefore
5	30	32	O	not
6	34	35	O	be
7	37	44	O	expected
8	46	47	O	to
9	49	50	O	be
10	52	60	O	inhibited
11	62	63	O	in
12	65	72	O	clinical
13	74	76	O	use
NULL

Entacapone	DDI-DrugBank.d455.s3	NO_SECTION	NO_SETID	9
Protein Binding: Entacapone is highly protein bound (98%).
1	0	6	O	Protein
2	8	14	O	Binding
3	15	15	O	:
4	17	26	O	XXXXXXXX
5	28	29	O	is
6	31	36	O	highly
7	38	44	O	protein
8	46	50	O	bound
9	53	55	O	98%
NULL

Entacapone	DDI-DrugBank.d455.s4	NO_SECTION	NO_SETID	27
In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	26	O	shown
6	28	29	O	no
7	31	37	O	binding
8	39	50	O	displacement
9	52	58	O	between
10	60	69	O	XXXXXXXX
11	71	73	O	and
12	75	79	O	other
13	81	86	O	highly
14	88	92	O	bound
15	94	98	O	drugs
16	99	99	O	,
17	101	104	O	such
18	106	107	O	as
19	109	116	U-UNK	warfarin
20	117	117	O	,
21	119	127	B-UNK	salicylic
22	129	132	L-UNK	acid
23	133	133	O	,
24	135	148	U-UNK	phenylbutazone
25	149	149	O	,
26	151	153	O	and
27	155	162	U-UNK	diazepam
NULL

Entacapone	DDI-DrugBank.d455.s5	NO_SECTION	NO_SETID	23
Drugs Metabolized by Catechol-O-methyltransferase (COMT): Hormone levels: Levodopa is known to depress prolactin secretion and increase growth hormone levels.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	28	O	Catechol
5	30	30	O	O
6	32	48	O	methyltransferase
7	51	54	O	COMT
8	56	56	O	:
9	58	64	O	Hormone
10	66	71	O	levels
11	72	72	O	:
12	74	81	U-UNK	Levodopa
13	83	84	O	is
14	86	90	O	known
15	92	93	O	to
16	95	101	O	depress
17	103	111	O	prolactin
18	113	121	O	secretion
19	123	125	O	and
20	127	134	O	increase
21	136	141	O	growth
22	143	149	O	hormone
23	151	156	O	levels
NULL

Entacapone	DDI-DrugBank.d455.s6	NO_SECTION	NO_SETID	15
Treatment with entacapone coadministered with levodopa/dopa decarboxylase inhibitor does not change these effects.
1	0	8	O	Treatment
2	10	13	O	with
3	15	24	O	XXXXXXXX
4	26	39	O	coadministered
5	41	44	O	with
6	46	53	U-UNK	levodopa
7	54	54	O	/
8	55	58	B-UNK	dopa
9	60	72	I-UNK	decarboxylase
10	74	82	L-UNK	inhibitor
11	84	87	O	does
12	89	91	O	not
13	93	98	O	change
14	100	104	O	these
15	106	112	O	effects
NULL

Entacapone	DDI-DrugBank.d455.s7	NO_SECTION	NO_SETID	28
No interaction was noted with the MAO-B inhibitor selegiline in two multiple-dose interaction studies when entacapone was coadministered with a levodopa/dopa decarboxylase inhibitor (n=29).
1	0	1	O	No
2	3	13	O	interaction
3	15	17	O	was
4	19	23	O	noted
5	25	28	O	with
6	30	32	O	the
7	34	36	B-UNK	MAO
8	38	38	I-UNK	B
9	40	48	L-UNK	inhibitor
10	50	59	U-UNK	selegiline
11	61	62	O	in
12	64	66	O	two
13	68	75	O	multiple
14	77	80	O	dose
15	82	92	O	interaction
16	94	100	O	studies
17	102	105	O	when
18	107	116	O	XXXXXXXX
19	118	120	O	was
20	122	135	O	coadministered
21	137	140	O	with
22	142	142	O	a
23	144	151	U-UNK	levodopa
24	152	152	O	/
25	153	156	B-UNK	dopa
26	158	170	I-UNK	decarboxylase
27	172	180	L-UNK	inhibitor
28	183	186	O	n=29
NULL

Entacapone	DDI-DrugBank.d455.s8	NO_SECTION	NO_SETID	22
More than 600 Parkinsons disease patients in clinical trials have used selegiline in combination with entacapone and levodopa/dopa decarboxylase inhibitor.
1	0	3	O	More
2	5	8	O	than
3	10	12	O	600
4	14	23	O	Parkinsons
5	25	31	O	disease
6	33	40	O	patients
7	42	43	O	in
8	45	52	O	clinical
9	54	59	O	trials
10	61	64	O	have
11	66	69	O	used
12	71	80	U-UNK	selegiline
13	82	83	O	in
14	85	95	O	combination
15	97	100	O	with
16	102	111	O	XXXXXXXX
17	113	115	O	and
18	117	124	U-UNK	levodopa
19	125	125	O	/
20	126	129	B-UNK	dopa
21	131	143	I-UNK	decarboxylase
22	145	153	L-UNK	inhibitor
NULL

Entacapone	DDI-DrugBank.d455.s9	NO_SECTION	NO_SETID	33
As most entacapone excretion is via the bile, caution should be exercised when drugs known to interfere with biliary excretion, glucuronidation, and intestinal beta-glucuronidase are given concurrently with entacapone.
1	0	1	O	As
2	3	6	O	most
3	8	17	O	XXXXXXXX
4	19	27	O	excretion
5	29	30	O	is
6	32	34	O	via
7	36	38	O	the
8	40	43	O	bile
9	44	44	O	,
10	46	52	O	caution
11	54	59	O	should
12	61	62	O	be
13	64	72	O	exercised
14	74	77	O	when
15	79	83	O	drugs
16	85	89	O	known
17	91	92	O	to
18	94	102	O	interfere
19	104	107	O	with
20	109	115	O	biliary
21	117	125	O	excretion
22	126	126	O	,
23	128	142	O	glucuronidation
24	143	143	O	,
25	145	147	O	and
26	149	158	O	intestinal
27	160	163	O	beta
28	165	177	O	glucuronidase
29	179	181	O	are
30	183	187	O	given
31	189	200	O	concurrently
32	202	205	O	with
33	207	216	O	XXXXXXXX
NULL

Entacapone	DDI-DrugBank.d455.s10	NO_SECTION	NO_SETID	17
These include probenecid, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).
1	0	4	O	These
2	6	12	O	include
3	14	23	U-UNK	probenecid
4	24	24	O	,
5	26	39	U-UNK	cholestyramine
6	40	40	O	,
7	42	44	O	and
8	46	49	O	some
9	51	61	U-UNK	antibiotics
10	64	66	O	e.g
11	69	80	U-UNK	erythromycin
12	81	81	O	,
13	83	93	O	rifamipicin
14	94	94	O	,
15	96	105	U-UNK	ampicillin
16	107	109	O	and
17	111	125	U-UNK	chloramphenicol
NULL

Entacapone	DDI-DrugBank.d455.s11	NO_SECTION	NO_SETID	23
No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.
1	0	1	O	No
2	3	13	O	interaction
3	15	18	O	with
4	20	22	O	the
5	24	32	B-UNK	tricyclic
6	34	47	L-UNK	antidepressant
7	49	58	U-UNK	imipramine
8	60	62	O	was
9	64	68	O	shown
10	70	71	O	in
11	73	73	O	a
12	75	80	O	single
13	82	85	O	dose
14	87	91	O	study
15	93	96	O	with
16	98	107	O	XXXXXXXX
17	109	115	O	without
18	117	130	O	coadministered
19	132	139	U-UNK	levodopa
20	140	140	O	/
21	141	144	B-UNK	dopa
22	146	158	I-UNK	decarboxylase
23	160	168	L-UNK	inhibitor
NULL

Entecavir	DDI-DrugBank.d295.s0	NO_SECTION	NO_SETID	35
Since entecavir is primarily eliminated by the kidneys, coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.
1	0	4	O	Since
2	6	14	U-UNK	entecavir
3	16	17	O	is
4	19	27	O	primarily
5	29	38	O	eliminated
6	40	41	O	by
7	43	45	O	the
8	47	53	O	kidneys
9	54	54	O	,
10	56	71	O	coadministration
11	73	74	O	of
12	76	84	O	XXXXXXXX
13	86	89	O	with
14	91	95	O	drugs
15	97	100	O	that
16	102	107	O	reduce
17	109	113	O	renal
18	115	122	O	function
19	124	125	O	or
20	127	133	O	compete
21	135	137	O	for
22	139	144	O	active
23	146	152	O	tubular
24	154	162	O	secretion
25	164	166	O	may
26	168	175	O	increase
27	177	181	O	serum
28	183	196	O	concentrations
29	198	199	O	of
30	201	206	O	either
31	208	216	U-UNK	entecavir
32	218	219	O	or
33	221	223	O	the
34	225	238	O	coadministered
35	240	243	O	drug
NULL

Entecavir	DDI-DrugBank.d295.s1	NO_SECTION	NO_SETID	18
Coadministration of entecavir with lamivudine, adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	28	O	XXXXXXXX
4	30	33	O	with
5	35	44	U-UNK	lamivudine
6	45	45	O	,
7	47	54	U-UNK	adefovir
8	56	67	O	dipivoxil,or
9	69	77	B-UNK	tenofovir
10	79	88	I-UNK	disoproxil
11	90	97	L-UNK	fumarate
12	99	101	O	did
13	103	105	O	not
14	107	112	O	result
15	114	115	O	in
16	117	127	O	significant
17	129	132	O	drug
18	134	145	O	interactions
NULL

Entecavir	DDI-DrugBank.d295.s2	NO_SECTION	NO_SETID	41
The effects of coadministration of BARACLUDE with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when BARACLUDE is coadministered with such drugs.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	30	O	coadministration
5	32	33	O	of
6	35	43	O	XXXXXXXX
7	45	48	O	with
8	50	54	O	other
9	56	60	O	drugs
10	62	65	O	that
11	67	69	O	are
12	71	77	O	renally
13	79	88	O	eliminated
14	90	91	O	or
15	93	95	O	are
16	97	101	O	known
17	103	104	O	to
18	106	111	O	affect
19	113	117	O	renal
20	119	126	O	function
21	128	131	O	have
22	133	135	O	not
23	137	140	O	been
24	142	150	O	evaluated
25	151	151	O	,
26	153	155	O	and
27	157	164	O	patients
28	166	171	O	should
29	173	174	O	be
30	176	184	O	monitored
31	186	192	O	closely
32	194	196	O	for
33	198	204	O	adverse
34	206	211	O	events
35	213	216	O	when
36	218	226	O	XXXXXXXX
37	228	229	O	is
38	231	244	O	coadministered
39	246	249	O	with
40	251	254	O	such
41	256	260	O	drugs
NULL

Epinephrine	DDI-DrugBank.d247.s0	NO_SECTION	NO_SETID	14
Epinephrine should be used cautiously in patients with hyperthyroidism, hypertension and cardiac arrhythmias.
1	0	10	O	XXXXXXXX
2	12	17	O	should
3	19	20	O	be
4	22	25	O	used
5	27	36	O	cautiously
6	38	39	O	in
7	41	48	O	patients
8	50	53	O	with
9	55	69	O	hyperthyroidism
10	70	70	O	,
11	72	83	O	hypertension
12	85	87	O	and
13	89	95	O	cardiac
14	97	107	O	arrhythmias
NULL

Epinephrine	DDI-DrugBank.d247.s1	NO_SECTION	NO_SETID	13
All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.
1	0	2	O	All
2	4	15	U-UNK	vasopressors
3	17	22	O	should
4	24	25	O	be
5	27	30	O	used
6	32	41	O	cautiously
7	43	44	O	in
8	46	53	O	patients
9	55	60	O	taking
10	62	70	B-UNK	monoamine
11	72	78	I-UNK	oxidase
12	81	83	I-UNK	MAO
13	86	95	L-UNK	inhibitors
NULL

Epinephrine	DDI-DrugBank.d247.s2	NO_SECTION	NO_SETID	21
Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.
1	0	10	O	XXXXXXXX
2	12	17	O	should
3	19	21	O	not
4	23	24	O	be
5	26	37	O	administered
6	39	51	O	concomitantly
7	53	56	O	with
8	58	62	O	other
9	64	78	B-DYN	sympathomimetic
10	80	84	L-DYN	drugs
11	87	90	O	such
12	92	93	O	as
13	95	107	U-DYN	isoproterenol
14	110	116	O	because
15	118	119	O	of
16	121	128	O	possible
17	130	137	O	additive
18	139	145	O	effects
19	147	149	O	and
20	151	159	O	increased
21	161	168	O	toxicity
NULL

Epinephrine	DDI-DrugBank.d247.s3	NO_SECTION	NO_SETID	7
Combined effects may induce serious cardiac arrhythmias.
1	0	7	O	Combined
2	9	15	O	effects
3	17	19	O	may
4	21	26	O	induce
5	28	34	O	serious
6	36	42	O	cardiac
7	44	54	O	arrhythmias
NULL

Epinephrine	DDI-DrugBank.d247.s4	NO_SECTION	NO_SETID	15
They may be administered alternately when the preceding effect of other such drug has subsided.
1	0	3	O	They
2	5	7	O	may
3	9	10	O	be
4	12	23	O	administered
5	25	35	O	alternately
6	37	40	O	when
7	42	44	O	the
8	46	54	O	preceding
9	56	61	O	effect
10	63	64	O	of
11	66	70	O	other
12	72	75	O	such
13	77	80	O	drug
14	82	84	O	has
15	86	93	O	subsided
NULL

Epinephrine	DDI-DrugBank.d247.s5	NO_SECTION	NO_SETID	24
Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
1	0	13	O	Administration
2	15	16	O	of
3	18	28	O	XXXXXXXX
4	30	31	O	to
5	33	40	O	patients
6	42	50	O	receiving
7	52	63	U-DYN	cyclopropane
8	65	66	O	or
9	68	78	B-DYN	halogenated
10	80	90	I-DYN	hydrocarbon
11	92	98	I-DYN	general
12	100	110	L-DYN	anesthetics
13	112	115	O	such
14	117	118	O	as
15	120	128	U-DYN	halothane
16	130	134	O	which
17	136	144	O	sensitize
18	146	148	O	the
19	150	159	O	myocardium
20	160	160	O	,
21	162	164	O	may
22	166	171	O	induce
23	173	179	O	cardiac
24	181	190	O	arrhythmia
NULL

Epinephrine	DDI-DrugBank.d247.s6	NO_SECTION	NO_SETID	15
When encountered, such arrhythmias may respond to administration of a beta-adrenergic blocking drug.
1	0	3	O	When
2	5	15	O	encountered
3	16	16	O	,
4	18	21	O	such
5	23	33	O	arrhythmias
6	35	37	O	may
7	39	45	O	respond
8	47	48	O	to
9	50	63	O	administration
10	65	66	O	of
11	68	68	O	a
12	70	73	B-UNK	beta
13	75	84	I-UNK	adrenergic
14	86	93	I-UNK	blocking
15	95	98	L-UNK	drug
NULL

Epinephrine	DDI-DrugBank.d247.s7	NO_SECTION	NO_SETID	24
Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.
1	0	10	O	XXXXXXXX
2	12	15	O	also
3	17	22	O	should
4	24	25	O	be
5	27	30	O	used
6	32	41	O	cautiously
7	43	46	O	with
8	48	52	O	other
9	54	58	O	drugs
10	61	63	O	e.g
11	65	65	O	,
12	67	75	U-DYN	digitalis
13	76	76	O	,
14	78	87	U-DYN	glycosides
15	90	93	O	that
16	95	103	O	sensitize
17	105	107	O	the
18	109	118	O	myocardium
19	120	121	O	to
20	123	125	O	the
21	127	133	O	actions
22	135	136	O	of
23	138	152	B-UNK	sympathomimetic
24	154	158	L-UNK	drugs
NULL

Epinephrine	DDI-DrugBank.d247.s8	NO_SECTION	NO_SETID	12
Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.
1	0	7	B-DYN	Diuretic
2	9	14	L-DYN	agents
3	16	18	O	may
4	20	27	O	decrease
5	29	36	O	vascular
6	38	45	O	response
7	47	48	O	to
8	50	56	O	pressor
9	58	62	O	drugs
10	64	67	O	such
11	69	70	O	as
12	72	82	O	XXXXXXXX
NULL

Epinephrine	DDI-DrugBank.d247.s9	NO_SECTION	NO_SETID	21
Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.
1	0	10	O	XXXXXXXX
2	12	14	O	may
3	16	25	O	antagonize
4	27	29	O	the
5	31	36	O	neuron
6	38	45	O	blockade
7	47	54	O	produced
8	56	57	O	by
9	59	70	U-DYN	guanethidine
10	72	80	O	resulting
11	82	83	O	in
12	85	93	O	decreased
13	95	110	O	antihypertensive
14	112	117	O	effect
15	119	121	O	and
16	123	131	O	requiring
17	133	141	O	increased
18	143	148	O	dosage
19	150	151	O	of
20	153	155	O	the
21	157	162	O	latter
NULL

Epirubicin	DDI-DrugBank.d428.s0	NO_SECTION	NO_SETID	21
ELLENCE when used in combination with other cytotoxic drugs may show on-treatment additive toxicity, especially hematologic and gastrointestinal effects.
1	0	6	O	XXXXXXXX
2	8	11	O	when
3	13	16	O	used
4	18	19	O	in
5	21	31	O	combination
6	33	36	O	with
7	38	42	O	other
8	44	52	O	cytotoxic
9	54	58	O	drugs
10	60	62	O	may
11	64	67	O	show
12	69	70	O	on
13	72	80	O	treatment
14	82	89	O	additive
15	91	98	O	toxicity
16	99	99	O	,
17	101	110	O	especially
18	112	122	O	hematologic
19	124	126	O	and
20	128	143	O	gastrointestinal
21	145	151	O	effects
NULL

Epirubicin	DDI-DrugBank.d428.s1	NO_SECTION	NO_SETID	27
Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	25	O	XXXXXXXX
5	27	30	O	with
6	32	36	O	other
7	38	49	O	cardioactive
8	51	59	O	compounds
9	61	64	O	that
10	66	70	O	could
11	72	76	O	cause
12	78	82	O	heart
13	84	90	O	failure
14	93	95	O	e.g
15	97	97	O	,
16	99	105	B-DYN	calcium
17	107	113	I-DYN	channel
18	115	122	L-DYN	blockers
19	124	124	O	,
20	126	133	O	requires
21	135	139	O	close
22	141	150	O	monitoring
23	152	153	O	of
24	155	161	O	cardiac
25	163	170	O	function
26	172	181	O	throughout
27	183	191	O	treatment
NULL

Epirubicin	DDI-DrugBank.d428.s2	NO_SECTION	NO_SETID	12
There are few data regarding the coadministration of radiation therapy and epirubicin.
1	0	4	O	There
2	6	8	O	are
3	10	12	O	few
4	14	17	O	data
5	19	27	O	regarding
6	29	31	O	the
7	33	48	O	coadministration
8	50	51	O	of
9	53	61	O	radiation
10	63	69	O	therapy
11	71	73	O	and
12	75	84	O	XXXXXXXX
NULL

Epirubicin	DDI-DrugBank.d428.s3	NO_SECTION	NO_SETID	22
In adjuvant trials of epirubicin-containing CEF-120 or FEC-100 chemotherapies, breast irradiation was delayed until after chemotherapy was completed.
1	0	1	O	In
2	3	10	O	adjuvant
3	12	17	O	trials
4	19	20	O	of
5	22	31	O	XXXXXXXX
6	33	42	O	containing
7	44	46	O	CEF
8	48	50	O	120
9	52	53	O	or
10	55	57	O	FEC
11	59	61	O	100
12	63	76	O	chemotherapies
13	77	77	O	,
14	79	84	O	breast
15	86	96	O	irradiation
16	98	100	O	was
17	102	108	O	delayed
18	110	114	O	until
19	116	120	O	after
20	122	133	O	chemotherapy
21	135	137	O	was
22	139	147	O	completed
NULL

Epirubicin	DDI-DrugBank.d428.s4	NO_SECTION	NO_SETID	19
This practice resulted in no apparent increase in local breast cancer recurrence relative to published accounts in the literature.
1	0	3	O	This
2	5	12	O	practice
3	14	21	O	resulted
4	23	24	O	in
5	26	27	O	no
6	29	36	O	apparent
7	38	45	O	increase
8	47	48	O	in
9	50	54	O	local
10	56	61	O	breast
11	63	68	O	cancer
12	70	79	O	recurrence
13	81	88	O	relative
14	90	91	O	to
15	93	101	O	published
16	103	110	O	accounts
17	112	113	O	in
18	115	117	O	the
19	119	128	O	literature
NULL

Epirubicin	DDI-DrugBank.d428.s5	NO_SECTION	NO_SETID	24
A small number of patients received epirubicin-based chemotherapy concomitantly with radiation therapy but had chemotherapy interrupted in order to avoid potential overlapping toxicities.
1	0	0	O	A
2	2	6	O	small
3	8	13	O	number
4	15	16	O	of
5	18	25	O	patients
6	27	34	O	received
7	36	45	O	XXXXXXXX
8	47	51	O	based
9	53	64	O	chemotherapy
10	66	78	O	concomitantly
11	80	83	O	with
12	85	93	O	radiation
13	95	101	O	therapy
14	103	105	O	but
15	107	109	O	had
16	111	122	O	chemotherapy
17	124	134	O	interrupted
18	136	137	O	in
19	139	143	O	order
20	145	146	O	to
21	148	152	O	avoid
22	154	162	O	potential
23	164	174	O	overlapping
24	176	185	O	toxicities
NULL

Epirubicin	DDI-DrugBank.d428.s6	NO_SECTION	NO_SETID	18
It is likely that use of epirubicin with radiotherapy may sensitize tissues to the cytotoxic actions of irradiation.
1	0	1	O	It
2	3	4	O	is
3	6	11	O	likely
4	13	16	O	that
5	18	20	O	use
6	22	23	O	of
7	25	34	O	XXXXXXXX
8	36	39	O	with
9	41	52	O	radiotherapy
10	54	56	O	may
11	58	66	O	sensitize
12	68	74	O	tissues
13	76	77	O	to
14	79	81	O	the
15	83	91	O	cytotoxic
16	93	99	O	actions
17	101	102	O	of
18	104	114	O	irradiation
NULL

Epirubicin	DDI-DrugBank.d428.s7	NO_SECTION	NO_SETID	19
Administration of ELLENCE after previous radiation therapy may induce an inflammatory recall reaction at the site of the irradiation.
1	0	13	O	Administration
2	15	16	O	of
3	18	24	O	XXXXXXXX
4	26	30	O	after
5	32	39	O	previous
6	41	49	O	radiation
7	51	57	O	therapy
8	59	61	O	may
9	63	68	O	induce
10	70	71	O	an
11	73	84	O	inflammatory
12	86	91	O	recall
13	93	100	O	reaction
14	102	103	O	at
15	105	107	O	the
16	109	112	O	site
17	114	115	O	of
18	117	119	O	the
19	121	131	O	irradiation
NULL

Epirubicin	DDI-DrugBank.d428.s8	NO_SECTION	NO_SETID	7
Epirubicin is extensively metabolized by the liver.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	extensively
4	26	36	O	metabolized
5	38	39	O	by
6	41	43	O	the
7	45	49	O	liver
NULL

Epirubicin	DDI-DrugBank.d428.s9	NO_SECTION	NO_SETID	22
Changes in hepatic function induced by concomitant therapies may affect epirubicin metabolism, pharmacokinetics, therapeutic efficacy, and/or toxicity.
1	0	6	O	Changes
2	8	9	O	in
3	11	17	O	hepatic
4	19	26	O	function
5	28	34	O	induced
6	36	37	O	by
7	39	49	O	concomitant
8	51	59	O	therapies
9	61	63	O	may
10	65	70	O	affect
11	72	81	O	XXXXXXXX
12	83	92	O	metabolism
13	93	93	O	,
14	95	110	O	pharmacokinetics
15	111	111	O	,
16	113	123	O	therapeutic
17	125	132	O	efficacy
18	133	133	O	,
19	135	137	O	and
20	138	138	O	/
21	139	140	O	or
22	142	149	O	toxicity
NULL

Epirubicin	DDI-DrugBank.d428.s10	NO_SECTION	NO_SETID	8
Cimetidine increased the AUC of epirubicin by 50%.
1	0	9	U-KIN	Cimetidine
2	11	19	O	increased
3	21	23	O	the
4	25	27	O	AUC
5	29	30	O	of
6	32	41	O	XXXXXXXX
7	43	44	O	by
8	46	48	O	50%
NULL

Epirubicin	DDI-DrugBank.d428.s11	NO_SECTION	NO_SETID	9
Cimetidine treatment should be stopped during treatment with ELLENCE.
1	0	9	U-DYN	Cimetidine
2	11	19	O	treatment
3	21	26	O	should
4	28	29	O	be
5	31	37	O	stopped
6	39	44	O	during
7	46	54	O	treatment
8	56	59	O	with
9	61	67	O	XXXXXXXX
NULL

Epirubicin	DDI-DrugBank.d428.s12	NO_SECTION	NO_SETID	14
Drug-Laboratory Test Interactions There are no known interactions between ELLENCE and laboratory tests.
1	0	3	O	Drug
2	5	14	O	Laboratory
3	16	19	O	Test
4	21	32	O	Interactions
5	34	38	O	There
6	40	42	O	are
7	44	45	O	no
8	47	51	O	known
9	53	64	O	interactions
10	66	72	O	between
11	74	80	O	XXXXXXXX
12	82	84	O	and
13	86	95	O	laboratory
14	97	101	O	tests
NULL

Eplerenone	DDI-DrugBank.d20.s0	NO_SECTION	NO_SETID	10
Inhibitors of CYP3A4-Eplerenone metabolism is predominantly mediated via CYP3A4.
1	0	9	O	Inhibitors
2	11	12	O	of
3	14	19	O	CYP3A4
4	21	30	O	XXXXXXXX
5	32	41	O	metabolism
6	43	44	O	is
7	46	58	O	predominantly
8	60	67	O	mediated
9	69	71	O	via
10	73	78	O	CYP3A4
NULL

Eplerenone	DDI-DrugBank.d20.s1	NO_SECTION	NO_SETID	46
A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.
1	0	0	O	A
2	2	16	O	pharmacokinetic
3	18	22	O	study
4	24	33	O	evaluating
5	35	37	O	the
6	39	52	O	administration
7	54	55	O	of
8	57	57	O	a
9	59	64	O	single
10	66	69	O	dose
11	71	72	O	of
12	74	79	O	XXXXXXXX
13	81	83	O	100
14	85	86	O	mg
15	88	91	O	with
16	93	104	U-KIN	ketoconazole
17	106	108	O	200
18	110	111	O	mg
19	113	115	O	BID
20	116	116	O	,
21	118	118	O	a
22	120	125	O	potent
23	127	135	O	inhibitor
24	137	138	O	of
25	140	142	O	the
26	144	149	O	CYP3A4
27	151	157	O	pathway
28	158	158	O	,
29	160	165	O	showed
30	167	167	O	a
31	169	171	O	1.7
32	173	176	O	fold
33	178	185	O	increase
34	187	188	O	in
35	190	193	O	Cmax
36	195	196	O	of
37	198	207	U-UNK	eplerenone
38	209	211	O	and
39	213	213	O	a
40	215	217	O	5.4
41	219	222	O	fold
42	224	231	O	increase
43	233	234	O	in
44	236	238	O	AUC
45	240	241	O	of
46	243	252	U-UNK	eplerenone
NULL

Eplerenone	DDI-DrugBank.d20.s2	NO_SECTION	NO_SETID	16
INSPRA should not be used with drugs described as strong inhibitors of CYP3A4 in their labeling.
1	0	5	O	XXXXXXXX
2	7	12	O	should
3	14	16	O	not
4	18	19	O	be
5	21	24	O	used
6	26	29	O	with
7	31	35	O	drugs
8	37	45	O	described
9	47	48	O	as
10	50	55	O	strong
11	57	66	O	inhibitors
12	68	69	O	of
13	71	76	O	CYP3A4
14	78	79	O	in
15	81	85	O	their
16	87	94	O	labeling
NULL

Eplerenone	DDI-DrugBank.d20.s3	NO_SECTION	NO_SETID	48
Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.
1	0	13	O	Administration
2	15	16	O	of
3	18	27	O	XXXXXXXX
4	29	32	O	with
5	34	38	O	other
6	40	45	O	CYP3A4
7	47	56	O	inhibitors
8	59	61	O	e.g
9	63	63	O	,
10	65	76	U-KIN	erythromycin
11	78	80	O	500
12	82	83	O	mg
13	85	87	O	BID
14	88	88	O	,
15	90	98	U-KIN	verapamil
16	100	102	O	240
17	104	105	O	mg
18	107	108	O	QD
19	109	109	O	,
20	111	120	U-KIN	saquinavir
21	122	125	O	1200
22	127	128	O	mg
23	130	132	O	TID
24	133	133	O	,
25	135	145	U-KIN	fluconazole
26	147	149	O	200
27	151	152	O	mg
28	154	155	O	QD
29	158	165	O	resulted
30	167	168	O	in
31	170	178	O	increases
32	180	181	O	in
33	183	186	O	Cmax
34	188	189	O	of
35	191	200	O	XXXXXXXX
36	202	208	O	ranging
37	210	213	O	from
38	215	217	O	1.4
39	220	221	O	to
40	223	225	O	1.6
41	228	231	O	fold
42	233	235	O	and
43	237	239	O	AUC
44	241	244	O	from
45	246	248	O	2.0
46	251	252	O	to
47	254	256	O	2.9
48	259	262	O	fold
NULL

Eplerenone	DDI-DrugBank.d20.s4	NO_SECTION	NO_SETID	37
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).
1	0	2	B-UNK	ACE
2	4	13	L-UNK	Inhibitors
3	15	17	O	and
4	19	29	B-UNK	Angiotensin
5	31	32	I-UNK	II
6	34	41	I-UNK	Receptor
7	43	53	L-UNK	Antagonists
8	56	65	O	Congestive
9	67	71	O	Heart
10	73	79	O	Failure
11	81	84	O	Post
12	86	95	O	Myocardial
13	97	106	O	Infarction
14	110	111	O	In
15	113	119	O	EPHESUS
16	120	120	O	,
17	122	125	O	3020
18	128	130	O	91%
19	133	140	O	patients
20	142	150	O	receiving
21	152	157	O	XXXXXXXX
22	159	160	O	25
23	162	163	O	to
24	165	166	O	50
25	168	169	O	mg
26	171	174	O	also
27	176	183	O	received
28	185	187	B-UNK	ACE
29	189	198	L-UNK	inhibitors
30	200	201	O	or
31	203	213	B-UNK	angiotensin
32	215	216	I-UNK	II
33	218	225	I-UNK	receptor
34	227	237	L-UNK	antagonists
35	240	243	U-UNK	ACEI
36	244	244	O	/
37	245	247	U-UNK	ARB
NULL

Eplerenone	DDI-DrugBank.d20.s5	NO_SECTION	NO_SETID	21
Rates of patients with maximum potassium levels  5.5 mEq/L were similar regardless of the use of ACEI/ARB.
1	0	4	O	Rates
2	6	7	O	of
3	9	16	O	patients
4	18	21	O	with
5	23	29	O	maximum
6	31	39	O	potassium
7	41	46	O	levels
8	49	51	O	5.5
9	53	55	O	mEq
10	56	56	O	/
11	57	57	O	L
12	59	62	O	were
13	64	70	O	similar
14	72	81	O	regardless
15	83	84	O	of
16	86	88	O	the
17	90	92	O	use
18	94	95	O	of
19	97	100	U-UNK	ACEI
20	101	101	O	/
21	102	104	U-UNK	ARB
NULL

Eplerenone	DDI-DrugBank.d20.s6	NO_SECTION	NO_SETID	43
ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).
1	0	2	B-UNK	ACE
2	4	13	L-UNK	Inhibitors
3	15	17	O	and
4	19	29	B-UNK	Angiotensin
5	31	32	I-UNK	II
6	34	41	I-UNK	Receptor
7	43	53	L-UNK	Antagonists
8	56	67	O	Hypertension
9	71	72	O	In
10	74	81	O	clinical
11	83	89	O	studies
12	91	92	O	of
13	94	101	O	patients
14	103	106	O	with
15	108	119	O	hypertension
16	120	120	O	,
17	122	124	O	the
18	126	133	O	addition
19	135	136	O	of
20	138	143	O	XXXXXXXX
21	145	146	O	50
22	148	149	O	to
23	151	153	O	100
24	155	156	O	mg
25	158	159	O	to
26	161	163	B-DYN	ACE
27	165	174	L-DYN	inhibitors
28	176	178	O	and
29	180	190	B-DYN	angiotensin
30	192	193	I-DYN	II
31	195	202	I-DYN	receptor
32	204	214	L-DYN	antagonists
33	216	224	O	increased
34	226	229	O	mean
35	231	235	O	serum
36	237	245	O	potassium
37	247	254	O	slightly
38	257	261	O	about
39	263	266	O	0.09
40	268	271	O	0.13
41	273	275	O	mEq
42	276	276	O	/
43	277	277	O	L
NULL

Eplerenone	DDI-DrugBank.d20.s7	NO_SECTION	NO_SETID	36
In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	in
5	14	22	O	diabetics
6	24	27	O	with
7	29	44	O	microalbuminuria
8	46	51	O	XXXXXXXX
9	53	55	O	200
10	57	58	O	mg
11	60	67	O	combined
12	69	72	O	with
13	74	76	O	the
14	78	80	B-UNK	ACE
15	82	90	L-UNK	inhibitor
16	92	100	U-DYN	enalapril
17	102	103	O	10
18	105	106	O	mg
19	108	116	O	increased
20	118	120	O	the
21	122	130	O	frequency
22	132	133	O	of
23	135	146	O	hyperkalemia
24	149	153	O	serum
25	155	163	O	potassium
26	166	168	O	5.5
27	170	172	O	mEq
28	173	173	O	/
29	174	174	O	L
30	177	180	O	from
31	182	184	O	17%
32	186	187	O	on
33	189	197	U-UNK	enalapril
34	199	203	O	alone
35	205	206	O	to
36	208	210	O	38%
NULL

Eplerenone	DDI-DrugBank.d20.s8	NO_SECTION	NO_SETID	13
Lithium-A drug interaction study of eplerenone with lithium has not been conducted.
1	0	6	U-UNK	Lithium
2	8	8	O	A
3	10	13	O	drug
4	15	25	O	interaction
5	27	31	O	study
6	33	34	O	of
7	36	45	O	XXXXXXXX
8	47	50	O	with
9	52	58	U-UNK	lithium
10	60	62	O	has
11	64	66	O	not
12	68	71	O	been
13	73	81	O	conducted
NULL

Eplerenone	DDI-DrugBank.d20.s9	NO_SECTION	NO_SETID	14
Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.
1	0	4	O	Serum
2	6	12	U-UNK	lithium
3	14	19	O	levels
4	21	26	O	should
5	28	29	O	be
6	31	39	O	monitored
7	41	50	O	frequently
8	52	53	O	if
9	55	60	O	XXXXXXXX
10	62	63	O	is
11	65	76	O	administered
12	78	90	O	concomitantly
13	92	95	O	with
14	97	103	U-DYN	lithium
NULL

Eplerenone	DDI-DrugBank.d20.s10	NO_SECTION	NO_SETID	18
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of eplerenone with an NSAID has not been conducted.
1	0	11	B-UNK	Nonsteroidal
2	13	16	I-UNK	Anti
3	18	29	I-UNK	Inflammatory
4	31	35	L-UNK	Drugs
5	38	43	U-UNK	NSAIDs
6	46	46	O	A
7	48	51	O	drug
8	53	63	O	interaction
9	65	69	O	study
10	71	72	O	of
11	74	83	O	XXXXXXXX
12	85	88	O	with
13	90	91	O	an
14	93	97	U-UNK	NSAID
15	99	101	O	has
16	103	105	O	not
17	107	110	O	been
18	112	120	O	conducted
NULL

Eplerenone	DDI-DrugBank.d20.s11	NO_SECTION	NO_SETID	31
The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.
1	0	2	O	The
2	4	17	O	administration
3	19	20	O	of
4	22	26	O	other
5	28	36	B-UNK	potassium
6	38	44	I-UNK	sparing
7	46	62	L-UNK	antihypertensives
8	64	67	O	with
9	69	74	U-UNK	NSAIDs
10	76	78	O	has
11	80	83	O	been
12	85	89	O	shown
13	91	92	O	to
14	94	99	O	reduce
15	101	103	O	the
16	105	120	O	antihypertensive
17	122	127	O	effect
18	129	130	O	in
19	132	135	O	some
20	137	144	O	patients
21	146	148	O	and
22	150	155	O	result
23	157	158	O	in
24	160	165	O	severe
25	167	178	O	hyperkalemia
26	180	181	O	in
27	183	190	O	patients
28	192	195	O	with
29	197	204	O	impaired
30	206	210	O	renal
31	212	219	O	function
NULL

Eplerenone	DDI-DrugBank.d20.s12	NO_SECTION	NO_SETID	25
Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	21	O	XXXXXXXX
5	23	25	O	and
6	27	32	U-DYN	NSAIDs
7	34	36	O	are
8	38	41	O	used
9	43	55	O	concomitantly
10	56	56	O	,
11	58	65	O	patients
12	67	72	O	should
13	74	75	O	be
14	77	84	O	observed
15	86	87	O	to
16	89	97	O	determine
17	99	105	O	whether
18	107	109	O	the
19	111	117	O	desired
20	119	124	O	effect
21	126	127	O	on
22	129	133	O	blood
23	135	142	O	pressure
24	144	145	O	is
25	147	154	O	obtained
NULL

Epoetin alfa	DDI-DrugBank.d496.s0	NO_SECTION	NO_SETID	17
No evidence of interaction of PROCRIT with other drugs was observed in the course of clinical trials.
1	0	1	O	No
2	3	10	O	evidence
3	12	13	O	of
4	15	25	O	interaction
5	27	28	O	of
6	30	36	O	XXXXXXXX
7	38	41	O	with
8	43	47	O	other
9	49	53	O	drugs
10	55	57	O	was
11	59	66	O	observed
12	68	69	O	in
13	71	73	O	the
14	75	80	O	course
15	82	83	O	of
16	85	92	O	clinical
17	94	99	O	trials
NULL

Epoprostenol	DDI-DrugBank.d241.s0	NO_SECTION	NO_SETID	20
Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.
1	0	9	O	Additional
2	11	20	O	reductions
3	22	23	O	in
4	25	29	O	blood
5	31	38	O	pressure
6	40	42	O	may
7	44	48	O	occur
8	50	53	O	when
9	55	60	O	XXXXXXXX
10	62	63	O	is
11	65	76	O	administered
12	78	81	O	with
13	83	91	U-DYN	diuretics
14	92	92	O	,
15	94	109	B-DYN	antihypertensive
16	111	116	L-DYN	agents
17	117	117	O	,
18	119	120	O	or
19	122	126	O	other
20	128	139	U-DYN	vasodilators
NULL

Epoprostenol	DDI-DrugBank.d241.s1	NO_SECTION	NO_SETID	22
When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.
1	0	3	O	When
2	5	9	O	other
3	11	22	B-DYN	antiplatelet
4	24	29	L-DYN	agents
5	31	32	O	or
6	34	47	U-DYN	anticoagulants
7	49	51	O	are
8	53	56	O	used
9	58	70	O	concomitantly
10	71	71	O	,
11	73	77	O	there
12	79	80	O	is
13	82	84	O	the
14	86	94	O	potential
15	96	98	O	for
16	100	105	O	XXXXXXXX
17	107	108	O	to
18	110	117	O	increase
19	119	121	O	the
20	123	126	O	risk
21	128	129	O	of
22	131	138	O	bleeding
NULL

Epoprostenol	DDI-DrugBank.d241.s2	NO_SECTION	NO_SETID	19
However, patients receiving infusions of FLOLAN in clinical trials were maintained on anticoagulants without evidence of increased bleeding.
1	0	6	O	However
2	7	7	O	,
3	9	16	O	patients
4	18	26	O	receiving
5	28	36	O	infusions
6	38	39	O	of
7	41	46	O	XXXXXXXX
8	48	49	O	in
9	51	58	O	clinical
10	60	65	O	trials
11	67	70	O	were
12	72	81	O	maintained
13	83	84	O	on
14	86	99	U-UNK	anticoagulants
15	101	107	O	without
16	109	116	O	evidence
17	118	119	O	of
18	121	129	O	increased
19	131	138	O	bleeding
NULL

Epoprostenol	DDI-DrugBank.d241.s3	NO_SECTION	NO_SETID	79
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.
1	0	1	O	In
2	3	10	O	clinical
3	12	17	O	trials
4	18	18	O	,
5	20	25	O	XXXXXXXX
6	27	29	O	was
7	31	34	O	used
8	36	39	O	with
9	41	47	U-UNK	digoxin
10	48	48	O	,
11	50	58	U-UNK	diuretics
12	59	59	O	,
13	61	74	U-UNK	anticoagulants
14	75	75	O	,
15	77	80	O	oral
16	82	93	U-UNK	vasodilators
17	94	94	O	,
18	96	98	O	and
19	100	111	O	supplemental
20	113	121	O	oxygen.In
21	123	123	O	a
22	125	139	O	pharmacokinetic
23	141	148	O	substudy
24	150	151	O	in
25	153	160	O	patients
26	162	165	O	with
27	167	176	O	congestive
28	178	182	O	heart
29	184	190	O	failure
30	192	200	O	receiving
31	202	211	U-KIN	furosemide
32	213	214	O	or
33	216	222	U-KIN	digoxin
34	224	225	O	in
35	227	230	O	whom
36	232	238	O	therapy
37	240	243	O	with
38	245	250	O	XXXXXXXX
39	252	254	O	was
40	256	264	O	initiated
41	265	265	O	,
42	267	274	O	apparent
43	276	279	O	oral
44	281	289	O	clearance
45	291	296	O	values
46	298	300	O	for
47	302	311	U-UNK	furosemide
48	314	314	O	n
49	316	316	O	=
50	318	319	O	23
51	322	324	O	and
52	326	332	U-UNK	digoxin
53	335	335	O	n
54	337	337	O	=
55	339	340	O	30
56	343	346	O	were
57	348	356	O	decreased
58	358	359	O	by
59	361	363	O	13%
60	365	367	O	and
61	369	371	O	15%
62	372	372	O	,
63	374	385	O	respectively
64	386	386	O	,
65	388	389	O	on
66	391	393	O	the
67	395	400	O	second
68	402	404	O	day
69	406	407	O	of
70	409	415	O	therapy
71	417	419	O	and
72	421	423	O	had
73	425	432	O	returned
74	434	435	O	to
75	437	444	O	baseline
76	446	451	O	values
77	453	454	O	by
78	456	458	O	day
79	460	461	O	87
NULL

Epoprostenol	DDI-DrugBank.d241.s4	NO_SECTION	NO_SETID	13
The change in furosemide clearance value is not likely to be clinically significant.
1	0	2	O	The
2	4	9	O	change
3	11	12	O	in
4	14	23	U-UNK	furosemide
5	25	33	O	clearance
6	35	39	O	value
7	41	42	O	is
8	44	46	O	not
9	48	53	O	likely
10	55	56	O	to
11	58	59	O	be
12	61	70	O	clinically
13	72	82	O	significant
NULL

Epoprostenol	DDI-DrugBank.d241.s5	NO_SECTION	NO_SETID	29
However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.
1	0	6	O	However
2	7	7	O	,
3	9	16	O	patients
4	18	19	O	on
5	21	27	U-KIN	digoxin
6	29	31	O	may
7	33	36	O	show
8	38	47	O	elevations
9	49	50	O	of
10	52	58	U-UNK	digoxin
11	60	73	O	concentrations
12	75	79	O	after
13	81	90	O	initiation
14	92	93	O	of
15	95	101	O	therapy
16	103	106	O	with
17	108	113	O	XXXXXXXX
18	114	114	O	,
19	116	120	O	which
20	122	124	O	may
21	126	127	O	be
22	129	138	O	clinically
23	140	150	O	significant
24	152	153	O	in
25	155	162	O	patients
26	164	168	O	prone
27	170	171	O	to
28	173	179	U-UNK	digoxin
29	181	188	O	toxicity
NULL

Eprosartan	DDI-DrugBank.d525.s0	NO_SECTION	NO_SETID	20
Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide.
1	0	9	O	XXXXXXXX
2	11	13	O	has
3	15	18	O	been
4	20	24	O	shown
5	26	27	O	to
6	29	32	O	have
7	34	35	O	no
8	37	42	O	effect
9	44	45	O	on
10	47	49	O	the
11	51	66	O	pharmacokinetics
12	68	69	O	of
13	71	77	U-UNK	digoxin
14	79	81	O	and
15	83	85	O	the
16	87	102	O	pharmacodynamics
17	104	105	O	of
18	107	114	U-UNK	warfarin
19	116	118	O	and
20	120	128	U-UNK	glyburide
NULL

Eprosartan	DDI-DrugBank.d525.s1	NO_SECTION	NO_SETID	12
Thus no dosing adjustments are necessary during concomitant use with these agents.
1	0	3	O	Thus
2	5	6	O	no
3	8	13	O	dosing
4	15	25	O	adjustments
5	27	29	O	are
6	31	39	O	necessary
7	41	46	O	during
8	48	58	O	concomitant
9	60	62	O	use
10	64	67	O	with
11	69	73	O	these
12	75	80	O	agents
NULL

Eprosartan	DDI-DrugBank.d525.s2	NO_SECTION	NO_SETID	48
Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.
1	0	6	O	Because
2	8	17	O	XXXXXXXX
3	19	20	O	is
4	22	24	O	not
5	26	36	O	metabolized
6	38	39	O	by
7	41	43	O	the
8	45	54	O	cytochrome
9	56	59	O	P450
10	61	66	O	system
11	67	67	O	,
12	69	78	O	inhibitors
13	80	81	O	of
14	83	88	O	CYP450
15	90	95	O	enzyme
16	97	101	O	would
17	103	105	O	not
18	107	108	O	be
19	110	117	O	expected
20	119	120	O	to
21	122	127	O	affect
22	129	131	O	its
23	133	142	O	metabolism
24	143	143	O	,
25	145	147	O	and
26	149	160	U-UNK	ketoconazole
27	162	164	O	and
28	166	176	U-UNK	fluconazole
29	177	177	O	,
30	179	184	O	potent
31	186	195	O	inhibitors
32	197	198	O	of
33	200	204	O	CYP3A
34	206	208	O	and
35	210	212	O	2C9
36	213	213	O	,
37	215	226	O	respectively
38	227	227	O	,
39	229	232	O	have
40	234	237	O	been
41	239	243	O	shown
42	245	246	O	to
43	248	251	O	have
44	253	254	O	no
45	256	261	O	effect
46	263	264	O	on
47	266	275	O	XXXXXXXX
48	277	292	O	pharmacokinetics
NULL

Eprosartan	DDI-DrugBank.d525.s3	NO_SECTION	NO_SETID	8
Ranitidine also has no effect on eprosartan pharmacokinetics.
1	0	9	U-UNK	Ranitidine
2	11	14	O	also
3	16	18	O	has
4	20	21	O	no
5	23	28	O	effect
6	30	31	O	on
7	33	42	O	XXXXXXXX
8	44	59	O	pharmacokinetics
NULL

Eprosartan	DDI-DrugBank.d525.s4	NO_SECTION	NO_SETID	21
Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide).
1	0	9	O	XXXXXXXX
2	12	13	O	up
3	15	16	O	to
4	18	20	O	400
5	22	23	O	mg
6	25	29	O	b.i.d
7	32	33	O	or
8	35	37	O	800
9	39	40	O	mg
10	42	44	O	q.d
11	48	52	O	doses
12	54	57	O	have
13	59	62	O	been
14	64	69	O	safely
15	71	74	O	used
16	76	88	O	concomitantly
17	90	93	O	with
18	95	95	O	a
19	97	104	B-UNK	thiazide
20	106	113	L-UNK	diuretic
21	116	134	U-UNK	hydrochlorothiazide
NULL

Eprosartan	DDI-DrugBank.d525.s5	NO_SECTION	NO_SETID	28
Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions.
1	0	9	O	XXXXXXXX
2	11	15	O	doses
3	17	18	O	of
4	20	21	O	up
5	23	24	O	to
6	26	28	O	300
7	30	31	O	mg
8	33	37	O	b.i.d
9	40	43	O	have
10	45	48	O	been
11	50	55	O	safely
12	57	60	O	used
13	62	74	O	concomitantly
14	76	79	O	with
15	81	89	O	sustained
16	91	97	O	release
17	99	105	B-UNK	calcium
18	107	113	I-UNK	channel
19	115	122	L-UNK	blockers
20	125	133	O	sustained
21	135	141	O	release
22	143	152	U-UNK	nifedipine
23	155	158	O	with
24	160	161	O	no
25	163	172	O	clinically
26	174	184	O	significant
27	186	192	O	adverse
28	194	205	O	interactions
NULL

Eptifibatide	DDI-DrugBank.d278.s0	NO_SECTION	NO_SETID	30
Enoxaparin dosed as a 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of eptifibatide or the level of platelet aggregation in healthy adults.
1	0	9	U-UNK	Enoxaparin
2	11	15	O	dosed
3	17	18	O	as
4	20	20	O	a
5	22	24	O	1.0
6	26	27	O	mg
7	28	28	O	/
8	29	30	O	kg
9	32	43	O	subcutaneous
10	45	53	O	injection
11	55	58	O	q12h
12	60	62	O	for
13	64	67	O	four
14	69	73	O	doses
15	75	77	O	did
16	79	81	O	not
17	83	87	O	alter
18	89	91	O	the
19	93	108	O	pharmacokinetics
20	110	111	O	of
21	113	124	O	XXXXXXXX
22	126	127	O	or
23	129	131	O	the
24	133	137	O	level
25	139	140	O	of
26	142	149	O	platelet
27	151	161	O	aggregation
28	163	164	O	in
29	166	172	O	healthy
30	174	179	O	adults
NULL

Ergocalciferol	DDI-DrugBank.d471.s0	NO_SECTION	NO_SETID	15
Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.
1	0	6	B-UNK	Mineral
2	8	10	L-UNK	oil
3	12	21	O	interferes
4	23	26	O	with
5	28	30	O	the
6	32	41	O	absorption
7	43	44	O	of
8	46	48	B-UNK	fat
9	50	56	I-UNK	soluble
10	58	65	L-UNK	vitamins
11	66	66	O	,
12	68	76	O	including
13	78	84	B-UNK	vitamin
14	86	86	I-UNK	D
15	88	99	L-UNK	preparations
NULL

Ergocalciferol	DDI-DrugBank.d471.s1	NO_SECTION	NO_SETID	17
Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.
1	0	13	O	Administration
2	15	16	O	of
3	18	25	B-DYN	thiazide
4	27	35	L-DYN	diuretics
5	37	38	O	to
6	40	54	O	hypoparathyroid
7	56	63	O	patients
8	65	67	O	who
9	69	71	O	are
10	73	84	O	concurrently
11	86	90	O	being
12	92	98	O	treated
13	100	103	O	with
14	105	118	O	XXXXXXXX
15	120	122	O	may
16	124	128	O	cause
17	130	142	O	hypercalcemia
NULL

Ergoloid mesylate	DDI-DrugBank.d201.s0	NO_SECTION	NO_SETID	3
No reported interactions.
1	0	1	O	No
2	3	10	O	reported
3	12	23	O	interactions
NULL

Ergotamine	DDI-DrugBank.d59.s0	NO_SECTION	NO_SETID	15
The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	21	O	XXXXXXXX
5	23	25	O	may
6	27	28	O	be
7	30	40	O	potentiated
8	42	43	O	by
9	45	65	U-KIN	triacetyloleandomycin
10	67	71	O	which
11	73	80	O	inhibits
12	82	84	O	the
13	86	95	O	metabolism
14	97	98	O	of
15	100	109	U-UNK	ergotamine
NULL

Ergotamine	DDI-DrugBank.d59.s1	NO_SECTION	NO_SETID	15
The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.
1	0	2	O	The
2	4	10	O	pressor
3	12	18	O	effects
4	20	21	O	of
5	23	29	O	XXXXXXXX
6	31	33	O	and
7	35	39	O	other
8	41	55	B-DYN	vasoconstrictor
9	57	61	L-DYN	drugs
10	63	65	O	can
11	67	73	O	combine
12	75	76	O	to
13	78	82	O	cause
14	84	92	O	dangerous
15	94	105	O	hypertension
NULL

Erlotinib	DDI-DrugBank.d456.s0	NO_SECTION	NO_SETID	15
Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.
1	0	1	O	Co
2	3	11	O	treatment
3	13	16	O	with
4	18	20	O	the
5	22	27	O	potent
6	29	34	O	CYP3A4
7	36	44	O	inhibitor
8	46	57	U-KIN	ketoconazole
9	59	67	O	increases
10	69	77	O	XXXXXXXX
11	79	81	O	AUC
12	83	84	O	by
13	86	86	O	2
14	87	87	O	/
15	88	88	O	3
NULL

Erlotinib	DDI-DrugBank.d456.s1	NO_SECTION	NO_SETID	47
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	26	O	when
6	28	40	O	administering
7	42	43	O	or
8	45	50	O	taking
9	52	58	O	XXXXXXXX
10	60	63	O	with
11	65	76	U-DYN	ketoconazole
12	78	80	O	and
13	82	86	O	other
14	88	93	O	strong
15	95	100	O	CYP3A4
16	102	111	O	inhibitors
17	113	116	O	such
18	118	119	O	as
19	120	120	O	,
20	122	124	O	but
21	126	128	O	not
22	130	136	O	limited
23	138	139	O	to
24	140	140	O	,
25	142	151	U-DYN	atazanavir
26	152	152	O	,
27	154	167	U-DYN	clarithromycin
28	168	168	O	,
29	170	178	U-DYN	indinavir
30	179	179	O	,
31	181	192	U-DYN	itraconazole
32	193	193	O	,
33	195	204	U-DYN	nefazodone
34	205	205	O	,
35	207	216	U-DYN	nelfinavir
36	217	217	O	,
37	219	227	U-DYN	ritonavir
38	228	228	O	,
39	230	239	U-DYN	saquinavir
40	240	240	O	,
41	242	254	U-DYN	telithromycin
42	255	255	O	,
43	257	270	U-DYN	troleandomycin
44	273	275	U-DYN	TAO
45	277	277	O	,
46	279	281	O	and
47	283	294	U-DYN	voriconazole
NULL

Erlotinib	DDI-DrugBank.d456.s2	NO_SECTION	NO_SETID	15
Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.
1	0	2	O	Pre
2	4	12	O	treatment
3	14	17	O	with
4	19	21	O	the
5	23	28	O	CYP3A4
6	30	36	O	inducer
7	38	47	U-KIN	rifampicin
8	49	57	O	decreased
9	59	67	O	XXXXXXXX
10	69	71	O	AUC
11	73	74	O	by
12	76	80	O	about
13	82	82	O	2
14	83	83	O	/
15	84	84	O	3
NULL

Erlotinib	DDI-DrugBank.d456.s3	NO_SECTION	NO_SETID	9
Alternate treatments lacking CYP3A4 inducing activity should be considered.
1	0	8	O	Alternate
2	10	19	O	treatments
3	21	27	O	lacking
4	29	34	O	CYP3A4
5	36	43	O	inducing
6	45	52	O	activity
7	54	59	O	should
8	61	62	O	be
9	64	73	O	considered
NULL

Erlotinib	DDI-DrugBank.d456.s4	NO_SECTION	NO_SETID	31
If an alternative treatment is unavailable, a TARCEVA dose greater than 150 mg should be considered for NSCLC patients, and greater than 100 mg considered for pancreatic cancer patients.
1	0	1	O	If
2	3	4	O	an
3	6	16	O	alternative
4	18	26	O	treatment
5	28	29	O	is
6	31	41	O	unavailable
7	42	42	O	,
8	44	44	O	a
9	46	52	O	XXXXXXXX
10	54	57	O	dose
11	59	65	O	greater
12	67	70	O	than
13	72	74	O	150
14	76	77	O	mg
15	79	84	O	should
16	86	87	O	be
17	89	98	O	considered
18	100	102	O	for
19	104	108	O	NSCLC
20	110	117	O	patients
21	118	118	O	,
22	120	122	O	and
23	124	130	O	greater
24	132	135	O	than
25	137	139	O	100
26	141	142	O	mg
27	144	153	O	considered
28	155	157	O	for
29	159	168	O	pancreatic
30	170	175	O	cancer
31	177	184	O	patients
NULL

Erlotinib	DDI-DrugBank.d456.s5	NO_SECTION	NO_SETID	22
If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.
1	0	1	O	If
2	3	5	O	the
3	7	13	O	XXXXXXXX
4	15	18	O	dose
5	20	21	O	is
6	23	30	O	adjusted
7	32	37	O	upward
8	38	38	O	,
9	40	42	O	the
10	44	47	O	dose
11	49	52	O	will
12	54	57	O	need
13	59	60	O	to
14	62	63	O	be
15	65	71	O	reduced
16	73	76	O	upon
17	78	92	O	discontinuation
18	94	95	O	of
19	97	106	U-DYN	rifampicin
20	108	109	O	or
21	111	115	O	other
22	117	124	O	inducers
NULL

Erlotinib	DDI-DrugBank.d456.s6	NO_SECTION	NO_SETID	24
Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital and St. Johns Wort.
1	0	4	O	Other
2	6	11	O	CYP3A4
3	13	20	O	inducers
4	22	28	O	include
5	29	29	O	,
6	31	33	O	but
7	35	37	O	are
8	39	41	O	not
9	43	49	O	limited
10	51	52	O	to
11	53	53	O	,
12	55	63	U-UNK	rifabutin
13	64	64	O	,
14	66	76	U-UNK	rifapentine
15	77	77	O	,
16	79	87	U-UNK	phenytoin
17	88	88	O	,
18	90	102	U-UNK	carbamazepine
19	103	103	O	,
20	105	117	U-UNK	phenobarbital
21	119	121	O	and
22	123	124	O	St
23	127	131	O	Johns
24	133	136	O	Wort
NULL

Erlotinib	DDI-DrugBank.d456.s7	NO_SECTION	NO_SETID	13
Hepatotoxicity Asymptomatic increases in liver transaminases have been observed in TARCEVA treated patients;
1	0	13	O	Hepatotoxicity
2	15	26	O	Asymptomatic
3	28	36	O	increases
4	38	39	O	in
5	41	45	O	liver
6	47	59	O	transaminases
7	61	64	O	have
8	66	69	O	been
9	71	78	O	observed
10	80	81	O	in
11	83	89	O	XXXXXXXX
12	91	97	O	treated
13	99	106	O	patients
NULL

Erlotinib	DDI-DrugBank.d456.s8	NO_SECTION	NO_SETID	16
therefore, periodic liver function testing (transaminases, bilirubin, and alkaline phosphatase) should be considered.
1	0	8	O	therefore
2	9	9	O	,
3	11	18	O	periodic
4	20	24	O	liver
5	26	33	O	function
6	35	41	O	testing
7	44	56	O	transaminases
8	57	57	O	,
9	59	67	O	bilirubin
10	68	68	O	,
11	70	72	O	and
12	74	81	O	alkaline
13	83	93	O	phosphatase
14	96	101	O	should
15	103	104	O	be
16	106	115	O	considered
NULL

Erlotinib	DDI-DrugBank.d456.s9	NO_SECTION	NO_SETID	16
Dose reduction or interruption of TARCEVA should be considered if changes in liver function are severe.
1	0	3	O	Dose
2	5	13	O	reduction
3	15	16	O	or
4	18	29	O	interruption
5	31	32	O	of
6	34	40	O	XXXXXXXX
7	42	47	O	should
8	49	50	O	be
9	52	61	O	considered
10	63	64	O	if
11	66	72	O	changes
12	74	75	O	in
13	77	81	O	liver
14	83	90	O	function
15	92	94	O	are
16	96	101	O	severe
NULL

Erlotinib	DDI-DrugBank.d456.s10	NO_SECTION	NO_SETID	19
Patients with Hepatic Impairment In vitro and in vivo evidence suggest that erlotinib is cleared primarily by the liver.
1	0	7	O	Patients
2	9	12	O	with
3	14	20	O	Hepatic
4	22	31	O	Impairment
5	33	34	O	In
6	36	40	O	vitro
7	42	44	O	and
8	46	47	O	in
9	49	52	O	vivo
10	54	61	O	evidence
11	63	69	O	suggest
12	71	74	O	that
13	76	84	O	XXXXXXXX
14	86	87	O	is
15	89	95	O	cleared
16	97	105	O	primarily
17	107	108	O	by
18	110	112	O	the
19	114	118	O	liver
NULL

Erlotinib	DDI-DrugBank.d456.s11	NO_SECTION	NO_SETID	12
Therefore, erlotinib exposure may be increased in patients with hepatic dysfunction.
1	0	8	O	Therefore
2	9	9	O	,
3	11	19	O	XXXXXXXX
4	21	28	O	exposure
5	30	32	O	may
6	34	35	O	be
7	37	45	O	increased
8	47	48	O	in
9	50	57	O	patients
10	59	62	O	with
11	64	70	O	hepatic
12	72	82	O	dysfunction
NULL

Erlotinib	DDI-DrugBank.d456.s12	NO_SECTION	NO_SETID	37
Elevated International Normalized Ratio and Potential Bleeding International Normalized Ratio (INR) elevations and infrequent reports of bleeding events including gastrointestinal and non-gastrointestinal bleedings have been reported in clinical studies, some associated with concomitant warfarin administration.
1	0	7	O	Elevated
2	9	21	O	International
3	23	32	O	Normalized
4	34	38	O	Ratio
5	40	42	O	and
6	44	52	O	Potential
7	54	61	O	Bleeding
8	63	75	O	International
9	77	86	O	Normalized
10	88	92	O	Ratio
11	95	97	O	INR
12	100	109	O	elevations
13	111	113	O	and
14	115	124	O	infrequent
15	126	132	O	reports
16	134	135	O	of
17	137	144	O	bleeding
18	146	151	O	events
19	153	161	O	including
20	163	178	O	gastrointestinal
21	180	182	O	and
22	184	186	O	non
23	188	203	O	gastrointestinal
24	205	213	O	bleedings
25	215	218	O	have
26	220	223	O	been
27	225	232	O	reported
28	234	235	O	in
29	237	244	O	clinical
30	246	252	O	studies
31	253	253	O	,
32	255	258	O	some
33	260	269	O	associated
34	271	274	O	with
35	276	286	O	concomitant
36	288	295	U-UNK	warfarin
37	297	310	O	administration
NULL

Erlotinib	DDI-DrugBank.d456.s13	NO_SECTION	NO_SETID	19
Patients taking warfarin or other coumarin-derivative anticoagulants should be monitored regularly for changes in prothrombin time or INR
1	0	7	O	Patients
2	9	14	O	taking
3	16	23	U-UNK	warfarin
4	25	26	O	or
5	28	32	O	other
6	34	41	B-UNK	coumarin
7	43	52	I-UNK	derivative
8	54	67	L-UNK	anticoagulants
9	69	74	O	should
10	76	77	O	be
11	79	87	O	monitored
12	89	97	O	regularly
13	99	101	O	for
14	103	109	O	changes
15	111	112	O	in
16	114	124	O	prothrombin
17	126	129	O	time
18	131	132	O	or
19	134	136	O	INR
NULL

Ertapenem	DDI-DrugBank.d329.s0	NO_SECTION	NO_SETID	27
When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.
1	0	3	O	When
2	5	13	O	XXXXXXXX
3	15	16	O	is
4	18	19	O	co
5	21	32	O	administered
6	34	37	O	with
7	39	48	U-UNK	probenecid
8	51	53	O	500
9	55	56	O	mg
10	58	60	O	p.o
11	63	67	O	every
12	69	69	O	6
13	71	75	O	hours
14	77	77	O	,
15	79	88	U-KIN	probenecid
16	90	97	O	competes
17	99	101	O	for
18	103	108	O	active
19	110	116	O	tubular
20	118	126	O	secretion
21	128	130	O	and
22	132	138	O	reduces
23	140	142	O	the
24	144	148	O	renal
25	150	158	O	clearance
26	160	161	O	of
27	163	171	O	XXXXXXXX
NULL

Ertapenem	DDI-DrugBank.d329.s1	NO_SECTION	NO_SETID	25
Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.
1	0	4	O	Based
2	6	7	O	on
3	9	13	O	total
4	15	23	O	XXXXXXXX
5	25	38	O	concentrations
6	39	39	O	,
7	41	50	U-KIN	probenecid
8	52	60	O	increased
9	62	64	O	the
10	66	68	O	AUC
11	70	71	O	by
12	73	75	O	25%
13	77	79	O	and
14	81	87	O	reduced
15	89	91	O	the
16	93	98	O	plasma
17	100	102	O	and
18	104	108	O	renal
19	110	119	O	clearances
20	121	122	O	by
21	124	126	O	20%
22	128	130	O	and
23	132	134	O	35%
24	135	135	O	,
25	137	148	O	respectively
NULL

Ertapenem	DDI-DrugBank.d329.s2	NO_SECTION	NO_SETID	9
The half-life increased from 4.0 to 4.8 hours.
1	0	2	O	The
2	4	7	O	half
3	9	12	O	life
4	14	22	O	increased
5	24	27	O	from
6	29	31	O	4.0
7	33	34	O	to
8	36	38	O	4.8
9	40	44	O	hours
NULL

Ertapenem	DDI-DrugBank.d329.s3	NO_SECTION	NO_SETID	23
Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	19	O	small
5	21	26	O	effect
6	28	29	O	on
7	31	34	O	half
8	36	39	O	life
9	40	40	O	,
10	42	44	O	the
11	46	61	O	coadministration
12	63	66	O	with
13	68	77	U-DYN	probenecid
14	79	80	O	to
15	82	87	O	extend
16	89	91	O	the
17	93	96	O	half
18	98	101	O	life
19	103	104	O	of
20	106	114	O	XXXXXXXX
21	116	117	O	is
22	119	121	O	not
23	123	133	O	recommended
NULL

Ertapenem	DDI-DrugBank.d329.s4	NO_SECTION	NO_SETID	29
In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	24	O	indicate
5	26	29	O	that
6	31	39	O	XXXXXXXX
7	41	44	O	does
8	46	48	O	not
9	50	56	O	inhibit
10	58	58	O	P
11	60	71	O	glycoprotein
12	73	80	O	mediated
13	82	90	O	transport
14	92	93	O	of
15	95	101	U-UNK	digoxin
16	103	104	O	or
17	106	116	U-UNK	vinblastine
18	118	120	O	and
19	122	125	O	that
20	127	135	O	XXXXXXXX
21	137	138	O	is
22	140	142	O	not
23	144	144	O	a
24	146	154	O	substrate
25	156	158	O	for
26	160	160	O	P
27	162	173	O	glycoprotein
28	175	182	O	mediated
29	184	192	O	transport
NULL

Ertapenem	DDI-DrugBank.d329.s5	NO_SECTION	NO_SETID	37
In vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the following six cytochrome p450 (CYP) isoforms: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	18	O	in
5	20	24	O	human
6	26	30	O	liver
7	32	41	O	microsomes
8	43	50	O	indicate
9	52	55	O	that
10	57	65	O	XXXXXXXX
11	67	70	O	does
12	72	74	O	not
13	76	82	O	inhibit
14	84	93	O	metabolism
15	95	102	O	mediated
16	104	105	O	by
17	107	109	O	any
18	111	112	O	of
19	114	116	O	the
20	118	126	O	following
21	128	130	O	six
22	132	141	O	cytochrome
23	143	146	O	p450
24	149	151	O	CYP
25	154	161	O	isoforms
26	162	162	O	:
27	164	166	O	1A2
28	167	167	O	,
29	169	171	O	2C9
30	172	172	O	,
31	174	177	O	2C19
32	178	178	O	,
33	180	182	O	2D6
34	183	183	O	,
35	185	187	O	2E1
36	189	191	O	and
37	193	195	O	3A4
NULL

Ertapenem	DDI-DrugBank.d329.s6	NO_SECTION	NO_SETID	22
Drug interactions caused by inhibition of P-glycoprotein-mediated drug clearance or CYP-mediated drug clearance with the listed isoforms are unlikely.
1	0	3	O	Drug
2	5	16	O	interactions
3	18	23	O	caused
4	25	26	O	by
5	28	37	O	inhibition
6	39	40	O	of
7	42	42	O	P
8	44	55	O	glycoprotein
9	57	64	O	mediated
10	66	69	O	drug
11	71	79	O	clearance
12	81	82	O	or
13	84	86	O	CYP
14	88	95	O	mediated
15	97	100	O	drug
16	102	110	O	clearance
17	112	115	O	with
18	117	119	O	the
19	121	126	O	listed
20	128	135	O	isoforms
21	137	139	O	are
22	141	148	O	unlikely
NULL

Ertapenem	DDI-DrugBank.d329.s7	NO_SECTION	NO_SETID	14
Other than with probenecid, no specific clinical drug interaction studies have been conducted
1	0	4	O	Other
2	6	9	O	than
3	11	14	O	with
4	16	25	U-UNK	probenecid
5	26	26	O	,
6	28	29	O	no
7	31	38	O	specific
8	40	47	O	clinical
9	49	52	O	drug
10	54	64	O	interaction
11	66	72	O	studies
12	74	77	O	have
13	79	82	O	been
14	84	92	O	conducted
NULL

Erythromycin	DDI-DrugBank.d397.s0	NO_SECTION	NO_SETID	25
Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.
1	0	11	O	XXXXXXXX
2	13	15	O	use
3	17	18	O	in
4	20	27	O	patients
5	29	31	O	who
6	33	35	O	are
7	37	45	O	receiving
8	47	50	O	high
9	52	56	O	doses
10	58	59	O	of
11	61	72	U-DYN	theophylline
12	74	76	O	may
13	78	79	O	be
14	81	90	O	associated
15	92	95	O	with
16	97	98	O	an
17	100	107	O	increase
18	109	110	O	in
19	112	116	O	serum
20	118	129	U-UNK	theophylline
21	131	136	O	levels
22	138	140	O	and
23	142	150	O	potential
24	152	163	U-UNK	theophylline
25	165	172	O	toxicity
NULL

Erythromycin	DDI-DrugBank.d397.s1	NO_SECTION	NO_SETID	28
In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.
1	0	1	O	In
2	3	6	O	case
3	8	9	O	of
4	11	22	U-UNK	theophylline
5	24	31	O	toxicity
6	33	35	O	and
7	36	36	O	/
8	37	38	O	or
9	40	47	O	elevated
10	49	53	O	serum
11	55	66	U-UNK	theophylline
12	68	73	O	levels
13	74	74	O	,
14	76	78	O	the
15	80	83	O	dose
16	85	86	O	of
17	88	99	U-DYN	theophylline
18	101	106	O	should
19	108	109	O	be
20	111	117	O	reduced
21	119	123	O	while
22	125	127	O	the
23	129	135	O	patient
24	137	138	O	is
25	140	148	O	receiving
26	150	160	O	concomitant
27	162	173	O	XXXXXXXX
28	175	181	O	therapy
NULL

Erythromycin	DDI-DrugBank.d397.s2	NO_SECTION	NO_SETID	16
Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	41	O	XXXXXXXX
5	43	45	O	and
6	47	53	U-KIN	digoxin
7	55	57	O	has
8	59	62	O	been
9	64	71	O	reported
10	73	74	O	to
11	76	81	O	result
12	83	84	O	in
13	86	93	O	elevated
14	95	101	U-UNK	digoxin
15	103	107	O	serum
16	109	114	O	levels
NULL

Erythromycin	DDI-DrugBank.d397.s3	NO_SECTION	NO_SETID	16
There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	22	O	reports
5	24	25	O	of
6	27	35	O	increased
7	37	49	O	anticoagulant
8	51	57	O	effects
9	59	62	O	when
10	64	75	O	XXXXXXXX
11	77	79	O	and
12	81	84	O	oral
13	86	99	U-DYN	anticoagulants
14	101	104	O	were
15	106	109	O	used
16	111	123	O	concomitantly
NULL

Erythromycin	DDI-DrugBank.d397.s4	NO_SECTION	NO_SETID	19
Increased anticoagulation effects due to interactions of erythromycin with various oral anticoagulents may be more pronounced in the elderly.
1	0	8	O	Increased
2	10	24	O	anticoagulation
3	26	32	O	effects
4	34	36	O	due
5	38	39	O	to
6	41	52	O	interactions
7	54	55	O	of
8	57	68	O	XXXXXXXX
9	70	73	O	with
10	75	81	O	various
11	83	86	O	oral
12	88	101	O	anticoagulents
13	103	105	O	may
14	107	108	O	be
15	110	113	O	more
16	115	124	O	pronounced
17	126	127	O	in
18	129	131	O	the
19	133	139	O	elderly
NULL

Erythromycin	DDI-DrugBank.d397.s5	NO_SECTION	NO_SETID	25
Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	16	O	of
4	18	29	O	XXXXXXXX
5	31	33	O	and
6	35	44	U-DYN	ergotamine
7	46	47	O	or
8	49	65	U-DYN	dihydroergotamine
9	67	69	O	has
10	71	74	O	been
11	76	85	O	associated
12	87	88	O	in
13	90	93	O	some
14	95	102	O	patients
15	104	107	O	with
16	109	113	O	acute
17	115	119	O	ergot
18	121	128	O	toxicity
19	130	142	O	characterized
20	144	145	O	by
21	147	152	O	severe
22	154	163	O	peripheral
23	165	173	O	vasospasm
24	175	177	O	and
25	179	189	O	dysesthesia
NULL

Erythromycin	DDI-DrugBank.d397.s6	NO_SECTION	NO_SETID	22
Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.
1	0	11	O	XXXXXXXX
2	13	15	O	has
3	17	20	O	been
4	22	29	O	reported
5	31	32	O	to
6	34	41	O	decrease
7	43	45	O	the
8	47	55	O	clearance
9	57	58	O	of
10	60	68	U-KIN	triazolam
11	70	72	O	and
12	74	82	U-KIN	midazolam
13	84	86	O	and
14	88	91	O	thus
15	93	95	O	may
16	97	104	O	increase
17	106	108	O	the
18	110	122	O	pharmacologic
19	124	129	O	effect
20	131	132	O	of
21	134	138	O	these
22	140	154	U-DYN	benzodiazepines
NULL

Erythromycin	DDI-DrugBank.d397.s7	NO_SECTION	NO_SETID	27
The use of erythromycin in patients concurrently taking drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these other drugs.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	22	O	XXXXXXXX
5	24	25	O	in
6	27	34	O	patients
7	36	47	O	concurrently
8	49	54	O	taking
9	56	60	O	drugs
10	62	72	O	metabolized
11	74	75	O	by
12	77	79	O	the
13	81	90	O	cytochrome
14	92	95	O	P450
15	97	102	O	system
16	104	106	O	may
17	108	109	O	be
18	111	120	O	associated
19	122	125	O	with
20	127	136	O	elevations
21	138	139	O	in
22	141	145	O	serum
23	147	152	O	levels
24	154	155	O	of
25	157	161	O	these
26	163	167	O	other
27	169	173	O	drugs
NULL

Erythromycin	DDI-DrugBank.d397.s8	NO_SECTION	NO_SETID	35
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	22	O	reports
5	24	25	O	of
6	27	38	O	interactions
7	40	41	O	of
8	43	54	O	XXXXXXXX
9	56	59	O	with
10	61	73	U-UNK	carbamazepine
11	74	74	O	,
12	76	87	U-UNK	cyclosporine
13	88	88	O	,
14	90	99	U-UNK	tacrolimus
15	100	100	O	,
16	102	113	U-UNK	hexobarbital
17	114	114	O	,
18	116	124	U-UNK	phenytoin
19	125	125	O	,
20	127	136	U-UNK	alfentanil
21	137	137	O	,
22	139	147	U-UNK	cisapride
23	148	148	O	,
24	150	161	U-UNK	disopyramide
25	162	162	O	,
26	164	173	U-UNK	lovastatin
27	174	174	O	,
28	176	188	U-UNK	bromocriptine
29	189	189	O	,
30	191	199	U-UNK	valproate
31	200	200	O	,
32	202	212	U-UNK	terfenadine
33	213	213	O	,
34	215	217	O	and
35	219	228	U-UNK	astemizole
NULL

Erythromycin	DDI-DrugBank.d397.s9	NO_SECTION	NO_SETID	19
Serum concentrations of drugs metabolized by the cytochrome P450 system should be monitored closely in patients concurrently receiving erythromycin.
1	0	4	O	Serum
2	6	19	O	concentrations
3	21	22	O	of
4	24	28	O	drugs
5	30	40	O	metabolized
6	42	43	O	by
7	45	47	O	the
8	49	58	O	cytochrome
9	60	63	O	P450
10	65	70	O	system
11	72	77	O	should
12	79	80	O	be
13	82	90	O	monitored
14	92	98	O	closely
15	100	101	O	in
16	103	110	O	patients
17	112	123	O	concurrently
18	125	133	O	receiving
19	135	146	O	XXXXXXXX
NULL

Erythromycin	DDI-DrugBank.d397.s10	NO_SECTION	NO_SETID	18
Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.
1	0	11	O	XXXXXXXX
2	13	15	O	has
3	17	20	O	been
4	22	29	O	reported
5	31	32	O	to
6	34	46	O	significantly
7	48	52	O	alter
8	54	56	O	the
9	58	67	O	metabolism
10	69	70	O	of
11	72	82	O	nonsedating
12	84	97	U-UNK	antihistamines
13	99	109	U-KIN	terfenadine
14	111	113	O	and
15	115	124	U-KIN	astemizole
16	126	129	O	when
17	131	135	O	taken
18	137	149	O	concomitantly
NULL

Erythromycin	DDI-DrugBank.d397.s11	NO_SECTION	NO_SETID	30
Rare cases of serious cardiovascular adverse events, including electrocardiographic QT/QTc interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias have been observed.
1	0	3	O	Rare
2	5	9	O	cases
3	11	12	O	of
4	14	20	O	serious
5	22	35	O	cardiovascular
6	37	43	O	adverse
7	45	50	O	events
8	51	51	O	,
9	53	61	O	including
10	63	82	O	electrocardiographic
11	84	85	O	QT
12	86	86	O	/
13	87	89	O	QTc
14	91	98	O	interval
15	100	111	O	prolongation
16	112	112	O	,
17	114	120	O	cardiac
18	122	127	O	arrest
19	128	128	O	,
20	130	137	O	torsades
21	139	140	O	de
22	142	148	O	pointes
23	149	149	O	,
24	151	153	O	and
25	155	159	O	other
26	161	171	O	ventricular
27	173	183	O	arrhythmias
28	185	188	O	have
29	190	193	O	been
30	195	202	O	observed
NULL

Erythromycin	DDI-DrugBank.d397.s12	NO_SECTION	NO_SETID	15
In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	18	O	deaths
5	20	23	O	have
6	25	28	O	been
7	30	37	O	reported
8	39	44	O	rarely
9	46	49	O	with
10	51	61	O	concomitant
11	63	76	O	administration
12	78	79	O	of
13	81	91	U-DYN	terfenadine
14	93	95	O	and
15	97	108	O	XXXXXXXX
NULL

Erythromycin	DDI-DrugBank.d397.s13	NO_SECTION	NO_SETID	46
There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	28	O	postmarketing
5	30	36	O	reports
6	38	39	O	of
7	41	44	O	drug
8	46	57	O	interactions
9	59	62	O	when
10	64	75	O	XXXXXXXX
11	77	78	O	is
12	80	93	O	coadministered
13	95	98	O	with
14	100	108	U-DYN	cisapride
15	109	109	O	,
16	111	119	O	resulting
17	121	122	O	in
18	124	125	O	QT
19	127	138	O	prolongation
20	139	139	O	,
21	141	147	O	cardiac
22	149	158	O	arrythmias
23	159	159	O	,
24	161	171	O	ventricular
25	173	183	O	tachycardia
26	184	184	O	,
27	186	196	O	ventricular
28	198	208	O	fibrulation
29	209	209	O	,
30	211	213	O	and
31	215	222	O	torsades
32	224	225	O	de
33	227	233	O	pointes
34	234	234	O	,
35	236	239	O	most
36	241	244	O	like
37	246	248	O	due
38	250	251	O	to
39	253	262	O	inhibition
40	264	265	O	of
41	267	273	O	hepatic
42	275	284	O	metabolism
43	286	287	O	of
44	289	297	U-KIN	cisapride
45	299	300	O	by
46	302	313	O	XXXXXXXX
NULL

Erythromycin	DDI-DrugBank.d397.s14	NO_SECTION	NO_SETID	4
Fatalities have been reported.
1	0	9	O	Fatalities
2	11	14	O	have
3	16	19	O	been
4	21	28	O	reported
NULL

Erythromycin	DDI-DrugBank.d397.s15	NO_SECTION	NO_SETID	10
Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;
1	0	7	O	Patients
2	9	17	O	receiving
3	19	29	O	concomitant
4	31	40	U-DYN	lovastatin
5	42	44	O	and
6	46	57	O	XXXXXXXX
7	59	64	O	should
8	66	67	O	be
9	69	77	O	carefully
10	79	87	O	monitored
NULL

Erythromycin	DDI-DrugBank.d397.s16	NO_SECTION	NO_SETID	10
cases of rhabdomyolysis have been reported in seriously ill patients.
1	0	4	O	cases
2	6	7	O	of
3	9	22	O	rhabdomyolysis
4	24	27	O	have
5	29	32	O	been
6	34	41	O	reported
7	43	44	O	in
8	46	54	O	seriously
9	56	58	O	ill
10	60	67	O	patients
NULL

Escitalopram	DDI-DrugBank.d568.s0	NO_SECTION	NO_SETID	25
CNS Drugs - Given the primary CNS effects of escitalopram, caution should be used when it is taken in combination with other centrally acting drugs.
1	0	2	O	CNS
2	4	8	O	Drugs
3	12	16	O	Given
4	18	20	O	the
5	22	28	O	primary
6	30	32	O	CNS
7	34	40	O	effects
8	42	43	O	of
9	45	56	O	XXXXXXXX
10	57	57	O	,
11	59	65	O	caution
12	67	72	O	should
13	74	75	O	be
14	77	80	O	used
15	82	85	O	when
16	87	88	O	it
17	90	91	O	is
18	93	97	O	taken
19	99	100	O	in
20	102	112	O	combination
21	114	117	O	with
22	119	123	O	other
23	125	133	O	centrally
24	135	140	O	acting
25	142	146	O	drugs
NULL

Escitalopram	DDI-DrugBank.d568.s1	NO_SECTION	NO_SETID	35
Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.
1	0	6	U-UNK	Alcohol
2	10	17	O	Although
3	19	25	O	XXXXXXXX
4	27	29	O	did
5	31	33	O	not
6	35	44	O	potentiate
7	46	48	O	the
8	50	58	O	cognitive
9	60	62	O	and
10	64	68	O	motor
11	70	76	O	effects
12	78	79	O	of
13	81	87	U-UNK	alcohol
14	89	90	O	in
15	92	92	O	a
16	94	101	O	clinical
17	103	107	O	trial
18	108	108	O	,
19	110	111	O	as
20	113	116	O	with
21	118	122	O	other
22	124	135	B-DYN	psychotropic
23	137	147	L-DYN	medications
24	148	148	O	,
25	150	152	O	the
26	154	156	O	use
27	158	159	O	of
28	161	167	U-DYN	alcohol
29	169	170	O	by
30	172	179	O	patients
31	181	186	O	taking
32	188	194	O	XXXXXXXX
33	196	197	O	is
34	199	201	O	not
35	203	213	O	recommended
NULL

Escitalopram	DDI-DrugBank.d568.s2	NO_SECTION	NO_SETID	4
Monoamine Oxidase Inhibitors (MAOIs)
1	0	8	B-UNK	Monoamine
2	10	16	I-UNK	Oxidase
3	18	27	L-UNK	Inhibitors
4	30	34	U-UNK	MAOIs
NULL

Escitalopram	DDI-DrugBank.d568.s3	NO_SECTION	NO_SETID	12
Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)
1	0	4	O	Drugs
2	6	9	O	That
3	11	19	O	Interfere
4	21	24	O	With
5	26	35	O	Hemostasis
6	38	43	U-UNK	NSAIDs
7	44	44	O	,
8	46	52	O	XXXXXXXX
9	53	53	O	,
10	55	62	U-UNK	Warfarin
11	63	63	O	,
12	65	67	O	etc
NULL

Escitalopram	DDI-DrugBank.d568.s4	NO_SECTION	NO_SETID	10
Serotonin release by platelets plays an important role in hemostasis.
1	0	8	O	Serotonin
2	10	16	O	release
3	18	19	O	by
4	21	29	O	platelets
5	31	35	O	plays
6	37	38	O	an
7	40	48	O	important
8	50	53	O	role
9	55	56	O	in
10	58	67	O	hemostasis
NULL

Escitalopram	DDI-DrugBank.d568.s5	NO_SECTION	NO_SETID	47
Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.
1	0	14	O	Epidemiological
2	16	22	O	studies
3	24	25	O	of
4	27	29	O	the
5	31	34	O	case
6	36	42	O	control
7	44	46	O	and
8	48	53	O	cohort
9	55	60	O	design
10	62	65	O	that
11	67	70	O	have
12	72	83	O	demonstrated
13	85	86	O	an
14	88	98	O	association
15	100	106	O	between
16	108	110	O	use
17	112	113	O	of
18	115	126	B-DYN	psychotropic
19	128	132	L-DYN	drugs
20	134	137	O	that
21	139	147	O	interfere
22	149	152	O	with
23	154	162	O	serotonin
24	164	171	O	reuptake
25	173	175	O	and
26	177	179	O	the
27	181	190	O	occurrence
28	192	193	O	of
29	195	199	O	upper
30	201	216	O	gastrointestinal
31	218	225	O	bleeding
32	227	230	O	have
33	232	235	O	also
34	237	241	O	shown
35	243	246	O	that
36	248	257	O	concurrent
37	259	261	O	use
38	263	264	O	of
39	266	267	O	an
40	269	273	U-UNK	NSAID
41	275	276	O	or
42	278	284	O	XXXXXXXX
43	286	296	O	potentiated
44	298	300	O	the
45	302	305	O	risk
46	307	308	O	of
47	310	317	O	bleeding
NULL

Escitalopram	DDI-DrugBank.d568.s6	NO_SECTION	NO_SETID	15
Thus, patients should be cautioned about the use of such drugs concurrently with LEXAPRO.
1	0	3	O	Thus
2	4	4	O	,
3	6	13	O	patients
4	15	20	O	should
5	22	23	O	be
6	25	33	O	cautioned
7	35	39	O	about
8	41	43	O	the
9	45	47	O	use
10	49	50	O	of
11	52	55	O	such
12	57	61	O	drugs
13	63	74	O	concurrently
14	76	79	O	with
15	81	87	O	XXXXXXXX
NULL

Escitalopram	DDI-DrugBank.d568.s7	NO_SECTION	NO_SETID	42
Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.
1	0	9	U-UNK	Cimetidine
2	13	14	O	In
3	16	23	O	subjects
4	25	27	O	who
5	29	31	O	had
6	33	40	O	received
7	42	43	O	21
8	45	48	O	days
9	50	51	O	of
10	53	54	O	40
11	56	57	O	mg
12	58	58	O	/
13	59	61	O	day
14	63	69	O	racemic
15	71	80	U-UNK	citalopram
16	81	81	O	,
17	83	90	O	combined
18	92	105	O	administration
19	107	108	O	of
20	110	112	O	400
21	114	115	O	mg
22	116	116	O	/
23	117	119	O	day
24	121	130	U-UNK	cimetidine
25	132	134	O	for
26	136	136	O	8
27	138	141	O	days
28	143	150	O	resulted
29	152	153	O	in
30	155	156	O	an
31	158	165	O	increase
32	167	168	O	in
33	170	179	U-UNK	citalopram
34	181	183	O	AUC
35	185	187	O	and
36	189	192	O	Cmax
37	194	195	O	of
38	197	199	O	43%
39	201	203	O	and
40	205	207	O	39%
41	208	208	O	,
42	210	221	O	respectively
NULL

Escitalopram	DDI-DrugBank.d568.s8	NO_SECTION	NO_SETID	8
The clinical significance of these findings is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	33	O	these
6	35	42	O	findings
7	44	45	O	is
8	47	53	O	unknown
NULL

Escitalopram	DDI-DrugBank.d568.s9	NO_SECTION	NO_SETID	38
Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.
1	0	6	U-UNK	Digoxin
2	10	11	O	In
3	13	20	O	subjects
4	22	24	O	who
5	26	28	O	had
6	30	37	O	received
7	39	40	O	21
8	42	45	O	days
9	47	48	O	of
10	50	51	O	40
11	53	54	O	mg
12	55	55	O	/
13	56	58	O	day
14	60	66	O	racemic
15	68	77	U-UNK	citalopram
16	78	78	O	,
17	80	87	O	combined
18	89	102	O	administration
19	104	105	O	of
20	107	116	U-UNK	citalopram
21	118	120	O	and
22	122	128	U-UNK	digoxin
23	131	136	O	single
24	138	141	O	dose
25	143	144	O	of
26	146	146	O	1
27	148	149	O	mg
28	152	154	O	did
29	156	158	O	not
30	160	172	O	significantly
31	174	179	O	affect
32	181	183	O	the
33	185	200	O	pharmacokinetics
34	202	203	O	of
35	205	210	O	either
36	212	221	U-UNK	citalopram
37	223	224	O	or
38	226	232	U-UNK	digoxin
NULL

Escitalopram	DDI-DrugBank.d568.s10	NO_SECTION	NO_SETID	32
Lithium - Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.
1	0	6	U-UNK	Lithium
2	10	25	O	Coadministration
3	27	28	O	of
4	30	36	O	racemic
5	38	47	U-UNK	citalopram
6	50	51	O	40
7	53	54	O	mg
8	55	55	O	/
9	56	58	O	day
10	60	62	O	for
11	64	65	O	10
12	67	70	O	days
13	73	75	O	and
14	77	83	U-UNK	lithium
15	86	87	O	30
16	89	92	O	mmol
17	93	93	O	/
18	94	96	O	day
19	98	100	O	for
20	102	102	O	5
21	104	107	O	days
22	110	112	O	had
23	114	115	O	no
24	117	127	O	significant
25	129	134	O	effect
26	136	137	O	on
27	139	141	O	the
28	143	158	O	pharmacokinetics
29	160	161	O	of
30	163	172	U-UNK	citalopram
31	174	175	O	or
32	177	183	U-UNK	lithium
NULL

Escitalopram	DDI-DrugBank.d568.s11	NO_SECTION	NO_SETID	21
Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	19	O	plasma
4	21	27	U-UNK	lithium
5	29	34	O	levels
6	36	41	O	should
7	43	44	O	be
8	46	54	O	monitored
9	56	59	O	with
10	61	71	O	appropriate
11	73	82	O	adjustment
12	84	85	O	to
13	87	89	O	the
14	91	97	U-UNK	lithium
15	99	102	O	dose
16	104	105	O	in
17	107	116	O	accordance
18	118	121	O	with
19	123	130	O	standard
20	132	139	O	clinical
21	141	148	O	practice
NULL

Escitalopram	DDI-DrugBank.d568.s12	NO_SECTION	NO_SETID	20
Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.
1	0	6	O	Because
2	8	14	U-UNK	lithium
3	16	18	O	may
4	20	26	O	enhance
5	28	30	O	the
6	32	43	O	serotonergic
7	45	51	O	effects
8	53	54	O	of
9	56	67	U-UNK	escitalopram
10	68	68	O	,
11	70	76	O	caution
12	78	83	O	should
13	85	86	O	be
14	88	96	O	exercised
15	98	101	O	when
16	103	109	O	XXXXXXXX
17	111	113	O	and
18	115	121	U-DYN	lithium
19	123	125	O	are
20	127	140	O	coadministered
NULL

Escitalopram	DDI-DrugBank.d568.s13	NO_SECTION	NO_SETID	46
Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.
1	0	7	U-UNK	Pimozide
2	9	11	O	and
3	13	18	O	XXXXXXXX
4	22	23	O	In
5	25	25	O	a
6	27	36	O	controlled
7	38	42	O	study
8	43	43	O	,
9	45	45	O	a
10	47	52	O	single
11	54	57	O	dose
12	59	60	O	of
13	62	69	U-UNK	pimozide
14	71	71	O	2
15	73	74	O	mg
16	76	77	O	co
17	79	90	O	administered
18	92	95	O	with
19	97	103	O	racemic
20	105	114	U-UNK	citalopram
21	116	117	O	40
22	119	120	O	mg
23	122	126	O	given
24	128	131	O	once
25	133	137	O	daily
26	139	141	O	for
27	143	144	O	11
28	146	149	O	days
29	151	153	O	was
30	155	164	O	associated
31	166	169	O	with
32	171	171	O	a
33	173	176	O	mean
34	178	185	O	increase
35	187	188	O	in
36	190	192	O	QTc
37	194	199	O	values
38	201	202	O	of
39	204	216	O	approximately
40	218	219	O	10
41	221	224	O	msec
42	226	233	O	compared
43	235	236	O	to
44	238	245	U-UNK	pimozide
45	247	251	O	given
46	253	257	O	alone
NULL

Escitalopram	DDI-DrugBank.d568.s14	NO_SECTION	NO_SETID	12
Racemic citalopram did not alter the mean AUC or Cmax of pimozide.
1	0	6	O	Racemic
2	8	17	U-UNK	citalopram
3	19	21	O	did
4	23	25	O	not
5	27	31	O	alter
6	33	35	O	the
7	37	40	O	mean
8	42	44	O	AUC
9	46	47	O	or
10	49	52	O	Cmax
11	54	55	O	of
12	57	64	U-UNK	pimozide
NULL

Escitalopram	DDI-DrugBank.d568.s15	NO_SECTION	NO_SETID	9
The mechanism of this pharmacodynamic interaction is not known.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	20	O	this
5	22	36	O	pharmacodynamic
6	38	48	O	interaction
7	50	51	O	is
8	53	55	O	not
9	57	61	O	known
NULL

Escitalopram	DDI-DrugBank.d568.s16	NO_SECTION	NO_SETID	28
Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
1	0	10	U-UNK	Sumatriptan
2	14	18	O	There
3	20	23	O	have
4	25	28	O	been
5	30	33	O	rare
6	35	47	O	postmarketing
7	49	55	O	reports
8	57	66	O	describing
9	68	75	O	patients
10	77	80	O	with
11	82	89	O	weakness
12	90	90	O	,
13	92	104	O	hyperreflexia
14	105	105	O	,
15	107	109	O	and
16	111	124	O	incoordination
17	126	134	O	following
18	136	138	O	the
19	140	142	O	use
20	144	145	O	of
21	147	147	O	a
22	149	157	B-UNK	selective
23	159	167	I-UNK	serotonin
24	169	176	I-UNK	reuptake
25	178	186	L-UNK	inhibitor
26	189	192	U-UNK	SSRI
27	195	197	O	and
28	199	209	U-UNK	sumatriptan
NULL

Escitalopram	DDI-DrugBank.d568.s17	NO_SECTION	NO_SETID	32
If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
1	0	1	O	If
2	3	13	O	concomitant
3	15	23	O	treatment
4	25	28	O	with
5	30	40	U-DYN	sumatriptan
6	42	44	O	and
7	46	47	O	an
8	49	52	U-UNK	SSRI
9	55	57	O	e.g
10	59	59	O	,
11	61	70	U-UNK	fluoxetine
12	71	71	O	,
13	73	83	U-UNK	fluvoxamine
14	84	84	O	,
15	86	95	U-UNK	paroxetine
16	96	96	O	,
17	98	107	U-UNK	sertraline
18	108	108	O	,
19	110	119	U-UNK	citalopram
20	120	120	O	,
21	122	133	O	XXXXXXXX
22	136	137	O	is
23	139	148	O	clinically
24	150	158	O	warranted
25	159	159	O	,
26	161	171	O	appropriate
27	173	183	O	observation
28	185	186	O	of
29	188	190	O	the
30	192	198	O	patient
31	200	201	O	is
32	203	209	O	advised
NULL

Escitalopram	DDI-DrugBank.d568.s18	NO_SECTION	NO_SETID	30
Theophylline - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.
1	0	11	U-UNK	Theophylline
2	15	22	O	Combined
3	24	37	O	administration
4	39	40	O	of
5	42	48	O	racemic
6	50	59	U-UNK	citalopram
7	62	63	O	40
8	65	66	O	mg
9	67	67	O	/
10	68	70	O	day
11	72	74	O	for
12	76	77	O	21
13	79	82	O	days
14	85	87	O	and
15	89	91	O	the
16	93	98	O	CYP1A2
17	100	108	O	substrate
18	110	121	U-UNK	theophylline
19	124	129	O	single
20	131	134	O	dose
21	136	137	O	of
22	139	141	O	300
23	143	144	O	mg
24	147	149	O	did
25	151	153	O	not
26	155	160	O	affect
27	162	164	O	the
28	166	181	O	pharmacokinetics
29	183	184	O	of
30	186	197	U-UNK	theophylline
NULL

Escitalopram	DDI-DrugBank.d568.s19	NO_SECTION	NO_SETID	12
The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	25	U-UNK	theophylline
5	27	28	O	on
6	30	32	O	the
7	34	49	O	pharmacokinetics
8	51	52	O	of
9	54	63	U-UNK	citalopram
10	65	67	O	was
11	69	71	O	not
12	73	81	O	evaluated
NULL

Escitalopram	DDI-DrugBank.d568.s20	NO_SECTION	NO_SETID	23
Warfarin - Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.
1	0	7	U-UNK	Warfarin
2	11	24	O	Administration
3	26	27	O	of
4	29	30	O	40
5	32	33	O	mg
6	34	34	O	/
7	35	37	O	day
8	39	45	O	racemic
9	47	56	U-UNK	citalopram
10	58	60	O	for
11	62	63	O	21
12	65	68	O	days
13	70	72	O	did
14	74	76	O	not
15	78	83	O	affect
16	85	87	O	the
17	89	104	O	pharmacokinetics
18	106	107	O	of
19	109	116	U-UNK	warfarin
20	117	117	O	,
21	119	119	O	a
22	121	126	O	CYP3A4
23	128	136	O	substrate
NULL

Escitalopram	DDI-DrugBank.d568.s21	NO_SECTION	NO_SETID	14
Prothrombin time was increased by 5%, the clinical significance of which is unknown.
1	0	10	O	Prothrombin
2	12	15	O	time
3	17	19	O	was
4	21	29	O	increased
5	31	32	O	by
6	34	35	O	5%
7	36	36	O	,
8	38	40	O	the
9	42	49	O	clinical
10	51	62	O	significance
11	64	65	O	of
12	67	71	O	which
13	73	74	O	is
14	76	82	O	unknown
NULL

Escitalopram	DDI-DrugBank.d568.s22	NO_SECTION	NO_SETID	36
Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.
1	0	12	U-UNK	Carbamazepine
2	16	23	O	Combined
3	25	38	O	administration
4	40	41	O	of
5	43	49	O	racemic
6	51	60	U-UNK	citalopram
7	63	64	O	40
8	66	67	O	mg
9	68	68	O	/
10	69	71	O	day
11	73	75	O	for
12	77	78	O	14
13	80	83	O	days
14	86	88	O	and
15	90	102	U-UNK	carbamazepine
16	105	112	O	titrated
17	114	115	O	to
18	117	119	O	400
19	121	122	O	mg
20	123	123	O	/
21	124	126	O	day
22	128	130	O	for
23	132	133	O	35
24	135	138	O	days
25	141	143	O	did
26	145	147	O	not
27	149	161	O	significantly
28	163	168	O	affect
29	170	172	O	the
30	174	189	O	pharmacokinetics
31	191	192	O	of
32	194	206	U-UNK	carbamazepine
33	207	207	O	,
34	209	209	O	a
35	211	216	O	CYP3A4
36	218	226	O	substrate
NULL

Escitalopram	DDI-DrugBank.d568.s23	NO_SECTION	NO_SETID	35
Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.
1	0	7	O	Although
2	9	14	O	trough
3	16	25	U-UNK	citalopram
4	27	32	O	plasma
5	34	39	O	levels
6	41	44	O	were
7	46	55	O	unaffected
8	56	56	O	,
9	58	62	O	given
10	64	66	O	the
11	68	73	O	enzyme
12	75	82	O	inducing
13	84	93	O	properties
14	95	96	O	of
15	98	110	U-UNK	carbamazepine
16	111	111	O	,
17	113	115	O	the
18	117	127	O	possibility
19	129	132	O	that
20	134	146	U-KIN	carbamazepine
21	148	152	O	might
22	154	161	O	increase
23	163	165	O	the
24	167	175	O	clearance
25	177	178	O	of
26	180	191	O	XXXXXXXX
27	193	198	O	should
28	200	201	O	be
29	203	212	O	considered
30	214	215	O	if
31	217	219	O	the
32	221	223	O	two
33	225	229	O	drugs
34	231	233	O	are
35	235	248	O	coadministered
NULL

Escitalopram	DDI-DrugBank.d568.s24	NO_SECTION	NO_SETID	36
Triazolam - Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.
1	0	8	U-UNK	Triazolam
2	12	19	O	Combined
3	21	34	O	administration
4	36	37	O	of
5	39	45	O	racemic
6	47	56	U-UNK	citalopram
7	59	66	O	titrated
8	68	69	O	to
9	71	72	O	40
10	74	75	O	mg
11	76	76	O	/
12	77	79	O	day
13	81	83	O	for
14	85	86	O	28
15	88	91	O	days
16	94	96	O	and
17	98	100	O	the
18	102	107	O	CYP3A4
19	109	117	O	substrate
20	119	127	U-UNK	triazolam
21	130	135	O	single
22	137	140	O	dose
23	142	143	O	of
24	145	148	O	0.25
25	150	151	O	mg
26	154	156	O	did
27	158	160	O	not
28	162	174	O	significantly
29	176	181	O	affect
30	183	185	O	the
31	187	202	O	pharmacokinetics
32	204	205	O	of
33	207	212	O	either
34	214	223	U-UNK	citalopram
35	225	226	O	or
36	228	236	U-UNK	triazolam
NULL

Escitalopram	DDI-DrugBank.d568.s25	NO_SECTION	NO_SETID	35
Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.
1	0	11	U-UNK	Ketoconazole
2	15	22	O	Combined
3	24	37	O	administration
4	39	40	O	of
5	42	48	O	racemic
6	50	59	U-UNK	citalopram
7	62	63	O	40
8	65	66	O	mg
9	69	71	O	and
10	73	84	U-UNK	ketoconazole
11	87	89	O	200
12	91	92	O	mg
13	95	103	O	decreased
14	105	107	O	the
15	109	112	O	Cmax
16	114	116	O	and
17	118	120	O	AUC
18	122	123	O	of
19	125	136	U-UNK	ketoconazole
20	138	139	O	by
21	141	143	O	21%
22	145	147	O	and
23	149	151	O	10%
24	152	152	O	,
25	154	165	O	respectively
26	166	166	O	,
27	168	170	O	and
28	172	174	O	did
29	176	178	O	not
30	180	192	O	significantly
31	194	199	O	affect
32	201	203	O	the
33	205	220	O	pharmacokinetics
34	222	223	O	of
35	225	234	U-UNK	citalopram
NULL

Escitalopram	DDI-DrugBank.d568.s26	NO_SECTION	NO_SETID	37
Ritonavir - Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram.
1	0	8	U-UNK	Ritonavir
2	12	19	O	Combined
3	21	34	O	administration
4	36	37	O	of
5	39	39	O	a
6	41	46	O	single
7	48	51	O	dose
8	53	54	O	of
9	56	64	U-UNK	ritonavir
10	67	69	O	600
11	71	72	O	mg
12	74	74	O	,
13	76	79	O	both
14	81	81	O	a
15	83	88	O	CYP3A4
16	90	98	O	substrate
17	100	102	O	and
18	104	104	O	a
19	106	111	O	potent
20	113	121	O	inhibitor
21	123	124	O	of
22	126	131	O	CYP3A4
23	132	132	O	,
24	134	136	O	and
25	138	149	O	XXXXXXXX
26	152	153	O	20
27	155	156	O	mg
28	159	161	O	did
29	163	165	O	not
30	167	172	O	affect
31	174	176	O	the
32	178	193	O	pharmacokinetics
33	195	196	O	of
34	198	203	O	either
35	205	213	U-UNK	ritonavir
36	215	216	O	or
37	218	229	O	XXXXXXXX
NULL

Escitalopram	DDI-DrugBank.d568.s27	NO_SECTION	NO_SETID	22
CYP3A4 and -2C19 Inhibitors - In vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram.
1	0	5	O	CYP3A4
2	7	9	O	and
3	12	15	O	2C19
4	17	26	O	Inhibitors
5	30	31	O	In
6	33	37	O	vitro
7	39	45	O	studies
8	47	55	O	indicated
9	57	60	O	that
10	62	67	O	CYP3A4
11	69	71	O	and
12	74	77	O	2C19
13	79	81	O	are
14	83	85	O	the
15	87	93	O	primary
16	95	101	O	enzymes
17	103	110	O	involved
18	112	113	O	in
19	115	117	O	the
20	119	128	O	metabolism
21	130	131	O	of
22	133	144	O	XXXXXXXX
NULL

Escitalopram	DDI-DrugBank.d568.s28	NO_SECTION	NO_SETID	26
However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram.
1	0	6	O	However
2	7	7	O	,
3	9	24	O	coadministration
4	26	27	O	of
5	29	40	O	XXXXXXXX
6	43	44	O	20
7	46	47	O	mg
8	50	52	O	and
9	54	62	U-UNK	ritonavir
10	65	67	O	600
11	69	70	O	mg
12	72	72	O	,
13	74	74	O	a
14	76	81	O	potent
15	83	91	O	inhibitor
16	93	94	O	of
17	96	101	O	CYP3A4
18	102	102	O	,
19	104	106	O	did
20	108	110	O	not
21	112	124	O	significantly
22	126	131	O	affect
23	133	135	O	the
24	137	152	O	pharmacokinetics
25	154	155	O	of
26	157	168	O	XXXXXXXX
NULL

Escitalopram	DDI-DrugBank.d568.s29	NO_SECTION	NO_SETID	20
Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.
1	0	6	O	Because
2	8	19	O	XXXXXXXX
3	21	22	O	is
4	24	34	O	metabolized
5	36	37	O	by
6	39	46	O	multiple
7	48	53	O	enzyme
8	55	61	O	systems
9	62	62	O	,
10	64	73	O	inhibition
11	75	76	O	of
12	78	78	O	a
13	80	85	O	single
14	87	92	O	enzyme
15	94	96	O	may
16	98	100	O	not
17	102	112	O	appreciably
18	114	121	O	decrease
19	123	134	O	XXXXXXXX
20	136	144	O	clearance
NULL

Escitalopram	DDI-DrugBank.d568.s30	NO_SECTION	NO_SETID	18
Drugs Metabolized by Cytochrome P4502D6 - In vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	30	O	Cytochrome
5	32	38	O	P4502D6
6	42	43	O	In
7	45	49	O	vitro
8	51	57	O	studies
9	59	61	O	did
10	63	65	O	not
11	67	72	O	reveal
12	74	75	O	an
13	77	86	O	inhibitory
14	88	93	O	effect
15	95	96	O	of
16	98	109	O	XXXXXXXX
17	111	112	O	on
18	114	119	O	CYP2D6
NULL

Escitalopram	DDI-DrugBank.d568.s31	NO_SECTION	NO_SETID	51
In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	18	O	steady
5	20	24	O	state
6	26	31	O	levels
7	33	34	O	of
8	36	42	O	racemic
9	44	53	U-UNK	citalopram
10	55	58	O	were
11	60	62	O	not
12	64	76	O	significantly
13	78	86	O	different
14	88	89	O	in
15	91	94	O	poor
16	96	107	O	metabolizers
17	109	111	O	and
18	113	121	O	extensive
19	123	128	O	CYP2D6
20	130	141	O	metabolizers
21	143	147	O	after
22	149	156	O	multiple
23	158	161	O	dose
24	163	176	O	administration
25	178	179	O	of
26	181	190	U-UNK	citalopram
27	191	191	O	,
28	193	202	O	suggesting
29	204	207	O	that
30	209	224	O	coadministration
31	225	225	O	,
32	227	230	O	with
33	232	243	O	XXXXXXXX
34	244	244	O	,
35	246	247	O	of
36	249	249	O	a
37	251	254	O	drug
38	256	259	O	that
39	261	268	O	inhibits
40	270	275	O	CYP2D6
41	276	276	O	,
42	278	279	O	is
43	281	288	O	unlikely
44	290	291	O	to
45	293	296	O	have
46	298	307	O	clinically
47	309	319	O	significant
48	321	327	O	effects
49	329	330	O	on
50	332	343	O	XXXXXXXX
51	345	354	O	metabolism
NULL

Escitalopram	DDI-DrugBank.d568.s32	NO_SECTION	NO_SETID	60
However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	there
4	15	17	O	are
5	19	25	O	limited
6	27	28	O	in
7	30	33	O	vivo
8	35	38	O	data
9	40	49	O	suggesting
10	51	51	O	a
11	53	58	O	modest
12	60	65	O	CYP2D6
13	67	76	O	inhibitory
14	78	83	O	effect
15	85	87	O	for
16	89	100	O	XXXXXXXX
17	101	101	O	,
18	103	105	O	i.e
19	107	107	O	,
20	109	124	O	coadministration
21	126	127	O	of
22	129	140	O	XXXXXXXX
23	143	144	O	20
24	146	147	O	mg
25	148	148	O	/
26	149	151	O	day
27	153	155	O	for
28	157	158	O	21
29	160	163	O	days
30	166	169	O	with
31	171	173	O	the
32	175	183	B-UNK	tricyclic
33	185	198	L-UNK	antidepressant
34	200	210	U-KIN	desipramine
35	213	218	O	single
36	220	223	O	dose
37	225	226	O	of
38	228	229	O	50
39	231	232	O	mg
40	234	234	O	,
41	236	236	O	a
42	238	246	O	substrate
43	248	250	O	for
44	252	257	O	CYP2D6
45	258	258	O	,
46	260	267	O	resulted
47	269	270	O	in
48	272	272	O	a
49	274	276	O	40%
50	278	285	O	increase
51	287	288	O	in
52	290	293	O	Cmax
53	295	297	O	and
54	299	299	O	a
55	301	304	O	100%
56	306	313	O	increase
57	315	316	O	in
58	318	320	O	AUC
59	322	323	O	of
60	325	335	U-UNK	desipramine
NULL

Escitalopram	DDI-DrugBank.d568.s33	NO_SECTION	NO_SETID	8
The clinical significance of this finding is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	40	O	finding
7	42	43	O	is
8	45	51	O	unknown
NULL

Escitalopram	DDI-DrugBank.d568.s34	NO_SECTION	NO_SETID	15
Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	O	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	57	O	coadministration
9	59	60	O	of
10	62	73	O	XXXXXXXX
11	75	77	O	and
12	79	83	O	drugs
13	85	95	O	metabolized
14	97	98	O	by
15	100	105	O	CYP2D6
NULL

Escitalopram	DDI-DrugBank.d568.s35	NO_SECTION	NO_SETID	40
Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).
1	0	9	U-UNK	Metoprolol
2	13	26	O	Administration
3	28	29	O	of
4	31	32	O	20
5	34	35	O	mg
6	36	36	O	/
7	37	39	O	day
8	41	47	O	XXXXXXXX
9	49	51	O	for
10	53	54	O	21
11	56	59	O	days
12	61	62	O	in
13	64	70	O	healthy
14	72	81	O	volunteers
15	83	90	O	resulted
16	92	93	O	in
17	95	95	O	a
18	97	99	O	50%
19	101	108	O	increase
20	110	111	O	in
21	113	116	O	Cmax
22	118	120	O	and
23	122	124	O	82%
24	126	133	O	increase
25	135	136	O	in
26	138	140	O	AUC
27	142	143	O	of
28	145	147	O	the
29	149	152	B-UNK	beta
30	154	163	I-UNK	adrenergic
31	165	171	L-UNK	blocker
32	173	182	U-KIN	metoprolol
33	185	189	O	given
34	191	192	O	in
35	194	194	O	a
36	196	201	O	single
37	203	206	O	dose
38	208	209	O	of
39	211	213	O	100
40	215	216	O	mg
NULL

Escitalopram	DDI-DrugBank.d568.s36	NO_SECTION	NO_SETID	10
Increased metoprolol plasma levels have been associated with decreased cardioselectivity.
1	0	8	O	Increased
2	10	19	U-UNK	metoprolol
3	21	26	O	plasma
4	28	33	O	levels
5	35	38	O	have
6	40	43	O	been
7	45	54	O	associated
8	56	59	O	with
9	61	69	O	decreased
10	71	87	O	cardioselectivity
NULL

Escitalopram	DDI-DrugBank.d568.s37	NO_SECTION	NO_SETID	16
Coadministration of LEXAPRO and metoprolol had no clinically significant effects on blood pressure or heart rate.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	26	O	XXXXXXXX
4	28	30	O	and
5	32	41	U-UNK	metoprolol
6	43	45	O	had
7	47	48	O	no
8	50	59	O	clinically
9	61	71	O	significant
10	73	79	O	effects
11	81	82	O	on
12	84	88	O	blood
13	90	97	O	pressure
14	99	100	O	or
15	102	106	O	heart
16	108	111	O	rate
NULL

Escitalopram	DDI-DrugBank.d568.s38	NO_SECTION	NO_SETID	16
Electroconvulsive Therapy (ECT) - There are no clinical studies of the combined use of ECT and escitalopram.
1	0	16	O	Electroconvulsive
2	18	24	O	Therapy
3	27	29	O	ECT
4	34	38	O	There
5	40	42	O	are
6	44	45	O	no
7	47	54	O	clinical
8	56	62	O	studies
9	64	65	O	of
10	67	69	O	the
11	71	78	O	combined
12	80	82	O	use
13	84	85	O	of
14	87	89	O	ECT
15	91	93	O	and
16	95	106	O	XXXXXXXX
NULL

Escitalopram	DDI-DrugBank.d568.s39	NO_SECTION	NO_SETID	24
Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.
1	0	10	O	Concomitant
2	12	25	O	Administration
3	27	30	O	with
4	32	38	O	Racemic
5	40	49	U-UNK	Citalopram
6	51	60	U-UNK	Citalopram
7	64	68	O	Since
8	70	81	U-DYN	escitalopram
9	83	84	O	is
10	86	88	O	the
11	90	95	O	active
12	97	102	O	isomer
13	104	105	O	of
14	107	113	O	racemic
15	115	124	U-UNK	citalopram
16	127	132	O	XXXXXXXX
17	134	134	O	,
18	136	138	O	the
19	140	142	O	two
20	144	149	O	agents
21	151	156	O	should
22	158	160	O	not
23	162	163	O	be
24	165	178	O	coadministered
NULL

Esmolol	DDI-DrugBank.d422.s0	NO_SECTION	NO_SETID	19
Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.
1	0	12	O	Catecholamine
2	14	22	O	depleting
3	24	28	O	drugs
4	29	29	O	,
5	31	33	O	e.g
6	35	35	O	,
7	37	45	U-UNK	reserpine
8	46	46	O	,
9	48	50	O	may
10	52	55	O	have
11	57	58	O	an
12	60	67	O	additive
13	69	74	O	effect
14	76	79	O	when
15	81	85	O	given
16	87	90	O	with
17	92	95	B-UNK	beta
18	97	104	I-UNK	blocking
19	106	111	L-UNK	agents
NULL

Esmolol	DDI-DrugBank.d422.s1	NO_SECTION	NO_SETID	35
Patients treated concurrently with BREVIBLOC (esmolol HCl) and a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.
1	0	7	O	Patients
2	9	15	O	treated
3	17	28	O	concurrently
4	30	33	O	with
5	35	43	O	XXXXXXXX
6	46	52	B-UNK	esmolol
7	54	56	L-UNK	HCl
8	59	61	O	and
9	63	63	O	a
10	65	77	O	catecholamine
11	79	86	O	depletor
12	88	93	O	should
13	95	103	O	therefore
14	105	106	O	be
15	108	114	O	closely
16	116	123	O	observed
17	125	127	O	for
18	129	136	O	evidence
19	138	139	O	of
20	141	151	O	hypotension
21	153	154	O	or
22	156	161	O	marked
23	163	173	O	bradycardia
24	174	174	O	,
25	176	180	O	which
26	182	184	O	may
27	186	191	O	result
28	193	194	O	in
29	196	202	O	vertigo
30	203	203	O	,
31	205	211	O	syncope
32	212	212	O	,
33	214	215	O	or
34	217	224	O	postural
35	226	236	O	hypotension
NULL

Esmolol	DDI-DrugBank.d422.s2	NO_SECTION	NO_SETID	22
A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.
1	0	0	O	A
2	2	6	O	study
3	8	9	O	of
4	11	21	O	interaction
5	23	29	O	between
6	31	39	O	XXXXXXXX
7	41	43	O	and
8	45	52	U-UNK	warfarin
9	54	59	O	showed
10	61	64	O	that
11	66	76	O	concomitant
12	78	91	O	administration
13	93	94	O	of
14	96	104	O	XXXXXXXX
15	106	108	O	and
16	110	117	U-UNK	warfarin
17	119	122	O	does
18	124	126	O	not
19	128	132	O	alter
20	134	141	U-UNK	warfarin
21	143	148	O	plasma
22	150	155	O	levels
NULL

Esmolol	DDI-DrugBank.d422.s3	NO_SECTION	NO_SETID	19
BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.
1	0	8	O	XXXXXXXX
2	10	23	O	concentrations
3	25	28	O	were
4	30	40	O	equivocally
5	42	47	O	higher
6	49	52	O	when
7	54	58	O	given
8	60	63	O	with
9	65	72	U-KIN	warfarin
10	73	73	O	,
11	75	77	O	but
12	79	82	O	this
13	84	85	O	is
14	87	89	O	not
15	91	96	O	likely
16	98	99	O	to
17	101	102	O	be
18	104	113	O	clinically
19	115	123	O	important
NULL

Esmolol	DDI-DrugBank.d422.s4	NO_SECTION	NO_SETID	26
When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.
1	0	3	O	When
2	5	11	U-KIN	digoxin
3	13	15	O	and
4	17	25	O	XXXXXXXX
5	27	30	O	were
6	32	44	O	concomitantly
7	46	57	O	administered
8	59	71	O	intravenously
9	73	74	O	to
10	76	81	O	normal
11	83	92	O	volunteers
12	93	93	O	,
13	95	99	O	there
14	101	103	O	was
15	105	105	O	a
16	107	108	O	10
17	110	112	O	20%
18	114	121	O	increase
19	123	124	O	in
20	126	132	U-UNK	digoxin
21	134	138	O	blood
22	140	145	O	levels
23	147	148	O	at
24	150	153	O	some
25	155	158	O	time
26	160	165	O	points
NULL

Esmolol	DDI-DrugBank.d422.s5	NO_SECTION	NO_SETID	6
Digoxin did not affect BREVIBLOC pharmacokinetics.
1	0	6	U-UNK	Digoxin
2	8	10	O	did
3	12	14	O	not
4	16	21	O	affect
5	23	31	O	XXXXXXXX
6	33	48	O	pharmacokinetics
NULL

Esmolol	DDI-DrugBank.d422.s6	NO_SECTION	NO_SETID	36
When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.
1	0	3	O	When
2	5	15	O	intravenous
3	17	24	U-UNK	morphine
4	26	28	O	and
5	30	38	O	XXXXXXXX
6	40	43	O	were
7	45	57	O	concomitantly
8	59	70	O	administered
9	72	73	O	in
10	75	80	O	normal
11	82	89	O	subjects
12	90	90	O	,
13	92	93	O	no
14	95	100	O	effect
15	102	103	O	on
16	105	112	U-UNK	morphine
17	114	118	O	blood
18	120	125	O	levels
19	127	129	O	was
20	131	134	O	seen
21	135	135	O	,
22	137	139	O	but
23	141	149	O	XXXXXXXX
24	151	156	O	steady
25	158	162	O	state
26	164	168	O	blood
27	170	175	O	levels
28	177	180	O	were
29	182	190	O	increased
30	192	193	O	by
31	195	197	O	46%
32	199	200	O	in
33	202	204	O	the
34	206	213	O	presence
35	215	216	O	of
36	218	225	U-KIN	morphine
NULL

Esmolol	DDI-DrugBank.d422.s7	NO_SECTION	NO_SETID	6
No other pharmacokinetic parameters were changed.
1	0	1	O	No
2	3	7	O	other
3	9	23	O	pharmacokinetic
4	25	34	O	parameters
5	36	39	O	were
6	41	47	O	changed
NULL

Esmolol	DDI-DrugBank.d422.s8	NO_SECTION	NO_SETID	18
The effect of BREVIBLOC on the duration of succinylcholine-induced neuromuscular blockade was studied in patients undergoing surgery.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	22	U-UNK	BREVIBLOC
5	24	25	O	on
6	27	29	O	the
7	31	38	O	duration
8	40	41	O	of
9	43	57	U-UNK	succinylcholine
10	59	65	O	induced
11	67	79	O	neuromuscular
12	81	88	O	blockade
13	90	92	O	was
14	94	100	O	studied
15	102	103	O	in
16	105	112	O	patients
17	114	123	O	undergoing
18	125	131	O	surgery
NULL

Esmolol	DDI-DrugBank.d422.s9	NO_SECTION	NO_SETID	26
The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.
1	0	2	O	The
2	4	8	O	onset
3	10	11	O	of
4	13	25	O	neuromuscular
5	27	34	O	blockade
6	36	37	O	by
7	39	53	U-DYN	succinylcholine
8	55	57	O	was
9	59	68	O	unaffected
10	70	71	O	by
11	73	81	O	XXXXXXXX
12	82	82	O	,
13	84	86	O	but
14	88	90	O	the
15	92	99	O	duration
16	101	102	O	of
17	104	116	O	neuromuscular
18	118	125	O	blockade
19	127	129	O	was
20	131	139	O	prolonged
21	141	144	O	from
22	146	146	O	5
23	148	154	O	minutes
24	156	157	O	to
25	159	159	O	8
26	161	167	O	minutes
NULL

Esmolol	DDI-DrugBank.d422.s10	NO_SECTION	NO_SETID	36
Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
1	0	7	O	Although
2	9	11	O	the
3	13	24	O	interactions
4	26	33	O	observed
5	35	36	O	in
6	38	42	O	these
7	44	50	O	studies
8	52	53	O	do
9	55	57	O	not
10	59	64	O	appear
11	66	67	O	to
12	69	70	O	be
13	72	73	O	of
14	75	79	O	major
15	81	88	O	clinical
16	90	99	O	importance
17	100	100	O	,
18	102	110	O	XXXXXXXX
19	112	117	O	should
20	119	120	O	be
21	122	129	O	titrated
22	131	134	O	with
23	136	142	O	caution
24	144	145	O	in
25	147	154	O	patients
26	156	160	O	being
27	162	168	O	treated
28	170	181	O	concurrently
29	183	186	O	with
30	188	194	U-DYN	digoxin
31	195	195	O	,
32	197	204	U-DYN	morphine
33	205	205	O	,
34	207	221	U-DYN	succinylcholine
35	223	224	O	or
36	226	233	U-DYN	warfarin
NULL

Esmolol	DDI-DrugBank.d422.s11	NO_SECTION	NO_SETID	33
While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.
1	0	4	O	While
2	6	11	O	taking
3	13	16	B-UNK	beta
4	18	25	L-UNK	blockers
5	26	26	O	,
6	28	35	O	patients
7	37	40	O	with
8	42	42	O	a
9	44	50	O	history
10	52	53	O	of
11	55	60	O	severe
12	62	73	O	anaphylactic
13	75	82	O	reaction
14	84	85	O	to
15	87	87	O	a
16	89	95	O	variety
17	97	98	O	of
18	100	108	O	allergens
19	110	112	O	may
20	114	115	O	be
21	117	120	O	more
22	122	129	O	reactive
23	131	132	O	to
24	134	141	O	repeated
25	143	151	O	challenge
26	152	152	O	,
27	154	159	O	either
28	161	170	O	accidental
29	171	171	O	,
30	173	182	O	diagnostic
31	183	183	O	,
32	185	186	O	or
33	188	198	O	therapeutic
NULL

Esmolol	DDI-DrugBank.d422.s12	NO_SECTION	NO_SETID	16
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
1	0	3	O	Such
2	5	12	O	patients
3	14	16	O	may
4	18	19	O	be
5	21	32	O	unresponsive
6	34	35	O	to
7	37	39	O	the
8	41	45	O	usual
9	47	51	O	doses
10	53	54	O	of
11	56	66	U-UNK	epinephrine
12	68	71	O	used
13	73	74	O	to
14	76	80	O	treat
15	82	89	O	allergic
16	91	98	O	reaction
NULL

Esmolol	DDI-DrugBank.d422.s13	NO_SECTION	NO_SETID	18
Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	43	O	considering
7	45	47	O	the
8	49	51	O	use
9	53	54	O	of
10	56	64	O	XXXXXXXX
11	66	68	O	and
12	70	78	U-DYN	verapamil
13	80	81	O	in
14	83	90	O	patients
15	92	95	O	with
16	97	105	O	depressed
17	107	116	O	myocardial
18	118	125	O	function
NULL

Esmolol	DDI-DrugBank.d422.s14	NO_SECTION	NO_SETID	10
Fatal cardiac arrests have occurred in patients receiving both drugs.
1	0	4	O	Fatal
2	6	12	O	cardiac
3	14	20	O	arrests
4	22	25	O	have
5	27	34	O	occurred
6	36	37	O	in
7	39	46	O	patients
8	48	56	O	receiving
9	58	61	O	both
10	63	67	O	drugs
NULL

Esmolol	DDI-DrugBank.d422.s15	NO_SECTION	NO_SETID	43
Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.
1	0	11	O	Additionally
2	12	12	O	,
3	14	22	O	XXXXXXXX
4	24	29	O	should
5	31	33	O	not
6	35	36	O	be
7	38	41	O	used
8	43	44	O	to
9	46	52	O	control
10	54	69	O	supraventricular
11	71	81	O	tachycardia
12	83	84	O	in
13	86	88	O	the
14	90	97	O	presence
15	99	100	O	of
16	102	107	O	agents
17	109	113	O	which
18	115	117	O	are
19	119	134	O	vasoconstrictive
20	136	138	O	and
21	140	148	O	inotropic
22	150	153	O	such
23	155	156	O	as
24	158	165	U-DYN	dopamine
25	166	166	O	,
26	168	178	U-DYN	epinephrine
27	179	179	O	,
28	181	183	O	and
29	185	198	U-DYN	norepinephrine
30	200	206	O	because
31	208	209	O	of
32	211	213	O	the
33	215	220	O	danger
34	222	223	O	of
35	225	232	O	blocking
36	234	240	O	cardiac
37	242	254	O	contractility
38	256	259	O	when
39	261	268	O	systemic
40	270	277	O	vascular
41	279	288	O	resistance
42	290	291	O	is
43	293	296	O	high
NULL

Esomeprazole	DDI-DrugBank.d29.s0	NO_SECTION	NO_SETID	11
Esomeprazole is extensively metabolized in the liver by CYP2C19 and CYP3A4.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	26	O	extensively
4	28	38	O	metabolized
5	40	41	O	in
6	43	45	O	the
7	47	51	O	liver
8	53	54	O	by
9	56	62	O	CYP2C19
10	64	66	O	and
11	68	73	O	CYP3A4
NULL

Esomeprazole	DDI-DrugBank.d29.s1	NO_SECTION	NO_SETID	27
In vitro and in vivo studies have shown that esomeprazole is not likely to inhibit CYPs 1A2, 2A6, 2C9, 2D6, 2E1 and 3A4.
1	0	1	O	In
2	3	7	O	vitro
3	9	11	O	and
4	13	14	O	in
5	16	19	O	vivo
6	21	27	O	studies
7	29	32	O	have
8	34	38	O	shown
9	40	43	O	that
10	45	56	O	XXXXXXXX
11	58	59	O	is
12	61	63	O	not
13	65	70	O	likely
14	72	73	O	to
15	75	81	O	inhibit
16	83	86	O	CYPs
17	88	90	O	1A2
18	91	91	O	,
19	93	95	O	2A6
20	96	96	O	,
21	98	100	O	2C9
22	101	101	O	,
23	103	105	O	2D6
24	106	106	O	,
25	108	110	O	2E1
26	112	114	O	and
27	116	118	O	3A4
NULL

Esomeprazole	DDI-DrugBank.d29.s2	NO_SECTION	NO_SETID	14
No clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected.
1	0	1	O	No
2	3	12	O	clinically
3	14	21	O	relevant
4	23	34	O	interactions
5	36	39	O	with
6	41	45	O	drugs
7	47	57	O	metabolized
8	59	60	O	by
9	62	66	O	these
10	68	70	O	CYP
11	72	78	O	enzymes
12	80	84	O	would
13	86	87	O	be
14	89	96	O	expected
NULL

Esomeprazole	DDI-DrugBank.d29.s3	NO_SECTION	NO_SETID	24
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin.
1	0	3	O	Drug
2	5	15	O	interaction
3	17	23	O	studies
4	25	28	O	have
5	30	34	O	shown
6	36	39	O	that
7	41	52	O	XXXXXXXX
8	54	57	O	does
9	59	61	O	not
10	63	66	O	have
11	68	70	O	any
12	72	81	O	clinically
13	83	93	O	significant
14	95	106	O	interactions
15	108	111	O	with
16	113	121	U-UNK	phenytoin
17	122	122	O	,
18	124	131	U-UNK	warfarin
19	132	132	O	,
20	134	142	U-UNK	quinidine
21	143	143	O	,
22	145	158	U-UNK	clarithromycin
23	160	161	O	or
24	163	173	U-UNK	amoxicillin
NULL

Esomeprazole	DDI-DrugBank.d29.s4	NO_SECTION	NO_SETID	19
Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant warfarin and esomeprazole therapy.
1	0	3	O	Post
2	5	13	O	marketing
3	15	21	O	reports
4	23	24	O	of
5	26	32	O	changes
6	34	35	O	in
7	37	47	O	prothrombin
8	49	56	O	measures
9	58	61	O	have
10	63	66	O	been
11	68	75	O	received
12	77	81	O	among
13	83	90	O	patients
14	92	93	O	on
15	95	105	O	concomitant
16	107	114	U-UNK	warfarin
17	116	118	O	and
18	120	131	U-DYN	XXXXXXXX
19	133	139	O	therapy
NULL

Esomeprazole	DDI-DrugBank.d29.s5	NO_SECTION	NO_SETID	14
Increases in INR and prothrombin time may lead to abnormal bleeding and even death.
1	0	8	O	Increases
2	10	11	O	in
3	13	15	O	INR
4	17	19	O	and
5	21	31	O	prothrombin
6	33	36	O	time
7	38	40	O	may
8	42	45	O	lead
9	47	48	O	to
10	50	57	O	abnormal
11	59	66	O	bleeding
12	68	70	O	and
13	72	75	O	even
14	77	81	O	death
NULL

Esomeprazole	DDI-DrugBank.d29.s6	NO_SECTION	NO_SETID	21
Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
1	0	7	O	Patients
2	9	15	O	treated
3	17	20	O	with
4	22	27	B-UNK	proton
5	29	32	I-UNK	pump
6	34	43	L-UNK	inhibitors
7	45	47	O	and
8	49	56	U-UNK	warfarin
9	58	70	O	concomitantly
10	72	74	O	may
11	76	79	O	need
12	81	82	O	to
13	84	85	O	be
14	87	95	O	monitored
15	97	99	O	for
16	101	109	O	increases
17	111	112	O	in
18	114	116	O	INR
19	118	120	O	and
20	122	132	O	prothrombin
21	134	137	O	time
NULL

Esomeprazole	DDI-DrugBank.d29.s7	NO_SECTION	NO_SETID	12
Esomeprazole may potentially interfere with CYP2C19, the major esomeprazole metabolizing enzyme.
1	0	11	O	XXXXXXXX
2	13	15	O	may
3	17	27	O	potentially
4	29	37	O	interfere
5	39	42	O	with
6	44	50	O	CYP2C19
7	51	51	O	,
8	53	55	O	the
9	57	61	O	major
10	63	74	O	XXXXXXXX
11	76	87	O	metabolizing
12	89	94	O	enzyme
NULL

Esomeprazole	DDI-DrugBank.d29.s8	NO_SECTION	NO_SETID	21
Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	31	O	XXXXXXXX
4	33	34	O	30
5	36	37	O	mg
6	39	41	O	and
7	43	50	U-KIN	diazepam
8	51	51	O	,
9	53	53	O	a
10	55	61	O	CYP2C19
11	63	71	O	substrate
12	72	72	O	,
13	74	81	O	resulted
14	83	84	O	in
15	86	86	O	a
16	88	90	O	45%
17	92	99	O	decrease
18	101	102	O	in
19	104	112	O	clearance
20	114	115	O	of
21	117	124	U-UNK	diazepam
NULL

Esomeprazole	DDI-DrugBank.d29.s9	NO_SECTION	NO_SETID	13
Increased plasma levels of diazepam were observed 12 hours after dosing and onwards.
1	0	8	O	Increased
2	10	15	O	plasma
3	17	22	O	levels
4	24	25	O	of
5	27	34	U-UNK	diazepam
6	36	39	O	were
7	41	48	O	observed
8	50	51	O	12
9	53	57	O	hours
10	59	63	O	after
11	65	70	O	dosing
12	72	74	O	and
13	76	82	O	onwards
NULL

Esomeprazole	DDI-DrugBank.d29.s10	NO_SECTION	NO_SETID	28
However, at that time, the plasma levels of diazepam were below the therapeutic interval, and thus this interaction is unlikely to be of clinical relevance.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	at
4	12	15	O	that
5	17	20	O	time
6	21	21	O	,
7	23	25	O	the
8	27	32	O	plasma
9	34	39	O	levels
10	41	42	O	of
11	44	51	U-UNK	diazepam
12	53	56	O	were
13	58	62	O	below
14	64	66	O	the
15	68	78	O	therapeutic
16	80	87	O	interval
17	88	88	O	,
18	90	92	O	and
19	94	97	O	thus
20	99	102	O	this
21	104	114	O	interaction
22	116	117	O	is
23	119	126	O	unlikely
24	128	129	O	to
25	131	132	O	be
26	134	135	O	of
27	137	144	O	clinical
28	146	154	O	relevance
NULL

Esomeprazole	DDI-DrugBank.d29.s11	NO_SECTION	NO_SETID	5
Esomeprazole inhibits gastric acid secretion.
1	0	11	O	XXXXXXXX
2	13	20	O	inhibits
3	22	28	O	gastric
4	30	33	O	acid
5	35	43	O	secretion
NULL

Esomeprazole	DDI-DrugBank.d29.s12	NO_SECTION	NO_SETID	27
Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
1	0	8	O	Therefore
2	9	9	O	,
3	11	22	O	XXXXXXXX
4	24	26	O	may
5	28	36	O	interfere
6	38	41	O	with
7	43	45	O	the
8	47	56	O	absorption
9	58	59	O	of
10	61	65	O	drugs
11	67	71	O	where
12	73	79	O	gastric
13	81	82	O	pH
14	84	85	O	is
15	87	88	O	an
16	90	98	O	important
17	100	110	O	determinant
18	112	113	O	of
19	115	129	O	bioavailability
20	132	133	O	eg
21	134	134	O	,
22	136	147	U-KIN	ketoconazole
23	148	148	O	,
24	150	153	U-KIN	iron
25	155	159	O	salts
26	161	163	O	and
27	165	171	U-KIN	digoxin
NULL

Esomeprazole	DDI-DrugBank.d29.s13	NO_SECTION	NO_SETID	21
Coadministration of oral contraceptives, diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	23	O	oral
4	25	38	U-UNK	contraceptives
5	39	39	O	,
6	41	48	U-UNK	diazepam
7	49	49	O	,
8	51	59	U-UNK	phenytoin
9	60	60	O	,
10	62	63	O	or
11	65	73	U-UNK	quinidine
12	75	77	O	did
13	79	81	O	not
14	83	86	O	seem
15	88	89	O	to
16	91	96	O	change
17	98	100	O	the
18	102	116	O	pharmacokinetic
19	118	124	O	profile
20	126	127	O	of
21	129	140	O	XXXXXXXX
NULL

Esomeprazole	DDI-DrugBank.d29.s14	NO_SECTION	NO_SETID	8
Concomitant administration of clarithromycin with pimozide is contraindicated.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	43	U-UNK	clarithromycin
5	45	48	O	with
6	50	57	U-UNK	pimozide
7	59	60	O	is
8	62	76	O	contraindicated
NULL

Estazolam	DDI-DrugBank.d338.s0	NO_SECTION	NO_SETID	26
If ProSom is given concomitantly with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of all agents.
1	0	1	O	If
2	3	8	O	XXXXXXXX
3	10	11	O	is
4	13	17	O	given
5	19	31	O	concomitantly
6	33	36	O	with
7	38	42	O	other
8	44	48	O	drugs
9	50	55	O	acting
10	57	58	O	on
11	60	62	O	the
12	64	70	O	central
13	72	78	O	nervous
14	80	85	O	system
15	86	86	O	,
16	88	94	O	careful
17	96	108	O	consideration
18	110	115	O	should
19	117	118	O	be
20	120	124	O	given
21	126	127	O	to
22	129	131	O	the
23	133	144	O	pharmacology
24	146	147	O	of
25	149	151	O	all
26	153	158	O	agents
NULL

Estazolam	DDI-DrugBank.d338.s1	NO_SECTION	NO_SETID	35
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
1	0	2	O	The
2	4	9	O	action
3	11	12	O	of
4	14	16	O	the
5	18	32	U-UNK	benzodiazepines
6	34	36	O	may
7	38	39	O	be
8	41	51	O	potentiated
9	53	54	O	by
10	56	70	U-UNK	anticonvulsants
11	71	71	O	,
12	73	86	U-UNK	antihistamines
13	87	87	O	,
14	89	95	U-UNK	alcohol
15	96	96	O	,
16	98	109	U-UNK	barbiturates
17	110	110	O	,
18	112	120	B-UNK	monoamine
19	122	128	I-UNK	oxidase
20	130	139	L-UNK	inhibitors
21	140	140	O	,
22	142	150	U-UNK	narcotics
23	151	151	O	,
24	153	166	U-UNK	phenothiazines
25	167	167	O	,
26	169	180	B-UNK	psychotropic
27	182	192	L-UNK	medications
28	193	193	O	,
29	195	196	O	or
30	198	202	O	other
31	204	208	O	drugs
32	210	213	O	that
33	215	221	O	produce
34	223	225	O	CNS
35	227	236	O	depression
NULL

Estazolam	DDI-DrugBank.d338.s2	NO_SECTION	NO_SETID	11
Smokers have an increased clearance of benzodiazepines as compared to nonsmokers;
1	0	6	O	Smokers
2	8	11	O	have
3	13	14	O	an
4	16	24	O	increased
5	26	34	O	clearance
6	36	37	O	of
7	39	53	U-UNK	benzodiazepines
8	55	56	O	as
9	58	65	O	compared
10	67	68	O	to
11	70	79	O	nonsmokers
NULL

Estazolam	DDI-DrugBank.d338.s3	NO_SECTION	NO_SETID	7
this was seen in studies with estazolam.
1	0	3	O	this
2	5	7	O	was
3	9	12	O	seen
4	14	15	O	in
5	17	23	O	studies
6	25	28	O	with
7	30	38	O	XXXXXXXX
NULL

Estazolam	DDI-DrugBank.d338.s4	NO_SECTION	NO_SETID	40
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
1	0	4	O	While
2	6	7	O	no
3	9	10	O	in
4	12	15	O	vivo
5	17	20	O	drug
6	22	25	O	drug
7	27	37	O	interaction
8	39	45	O	studies
9	47	50	O	were
10	52	60	O	conducted
11	62	68	O	between
12	70	78	O	XXXXXXXX
13	80	82	O	and
14	84	91	O	inducers
15	93	94	O	of
16	96	100	O	CYP3A
17	101	101	O	,
18	103	111	O	compounds
19	113	116	O	that
20	118	120	O	are
21	122	127	O	potent
22	129	133	O	CYP3A
23	135	142	O	inducers
24	145	148	O	such
25	150	151	O	as
26	153	165	U-KIN	carbamazepine
27	166	166	O	,
28	168	176	U-KIN	phenytoin
29	177	177	O	,
30	179	186	U-KIN	rifampin
31	187	187	O	,
32	189	191	O	and
33	193	204	U-KIN	barbiturates
34	207	211	O	would
35	213	214	O	be
36	216	223	O	expected
37	225	226	O	to
38	228	235	O	decrease
39	237	245	U-KIN	XXXXXXXX
40	247	260	O	concentrations
NULL

Estazolam	DDI-DrugBank.d338.s5	NO_SECTION	NO_SETID	36
Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.
1	0	8	O	XXXXXXXX
2	9	9	O	:
3	11	21	O	Interaction
4	23	26	O	with
5	28	32	O	Drugs
6	34	37	O	that
7	39	45	O	Inhibit
8	47	56	O	Metabolism
9	58	60	O	via
10	62	71	O	Cytochrome
11	73	76	O	P450
12	78	79	O	3A
13	82	86	O	CYP3A
14	88	88	O	:
15	90	92	O	The
16	94	103	O	metabolism
17	105	106	O	of
18	108	116	O	XXXXXXXX
19	118	119	O	to
20	121	123	O	the
21	125	129	O	major
22	131	141	O	circulating
23	143	152	O	metabolite
24	154	154	O	4
25	156	162	O	hydroxy
26	164	172	O	XXXXXXXX
27	174	176	O	and
28	178	180	O	the
29	182	191	O	metabolism
30	193	194	O	of
31	196	200	O	other
32	202	224	U-UNK	triazolobenzodiazepines
33	226	227	O	is
34	229	237	O	catalyzed
35	239	240	O	by
36	242	246	O	CYP3A
NULL

Estazolam	DDI-DrugBank.d338.s6	NO_SECTION	NO_SETID	20
Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
1	0	11	O	Consequently
2	12	12	O	,
3	14	22	O	XXXXXXXX
4	24	29	O	should
5	31	32	O	be
6	34	40	O	avoided
7	42	43	O	in
8	45	52	O	patients
9	54	62	O	receiving
10	64	75	U-DYN	ketoconazole
11	77	79	O	and
12	81	92	U-DYN	itraconazole
13	93	93	O	,
14	95	99	O	which
15	101	103	O	are
16	105	108	O	very
17	110	115	O	potent
18	117	126	O	inhibitors
19	128	129	O	of
20	131	135	O	CYP3A
NULL

Estazolam	DDI-DrugBank.d338.s7	NO_SECTION	NO_SETID	26
With drugs inhibiting CYP3A to a lesser, but still significant degree, estazolam should be used only with caution and consideration of appropriate dosage reduction.
1	0	3	O	With
2	5	9	O	drugs
3	11	20	O	inhibiting
4	22	26	O	CYP3A
5	28	29	O	to
6	31	31	O	a
7	33	38	O	lesser
8	39	39	O	,
9	41	43	O	but
10	45	49	O	still
11	51	61	O	significant
12	63	68	O	degree
13	69	69	O	,
14	71	79	O	XXXXXXXX
15	81	86	O	should
16	88	89	O	be
17	91	94	O	used
18	96	99	O	only
19	101	104	O	with
20	106	112	O	caution
21	114	116	O	and
22	118	130	O	consideration
23	132	133	O	of
24	135	145	O	appropriate
25	147	152	O	dosage
26	154	162	O	reduction
NULL

Estazolam	DDI-DrugBank.d338.s8	NO_SECTION	NO_SETID	36
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
1	0	2	O	The
2	4	12	O	following
3	14	16	O	are
4	18	25	O	examples
5	27	28	O	of
6	30	34	O	drugs
7	36	40	O	known
8	42	43	O	to
9	45	51	O	inhibit
10	53	55	O	the
11	57	66	O	metabolism
12	68	69	O	of
13	71	75	O	other
14	77	83	O	related
15	85	99	U-UNK	benzodiazepines
16	100	100	O	,
17	102	111	O	presumably
18	113	119	O	through
19	121	130	O	inhibition
20	132	133	O	of
21	135	139	O	CYP3A
22	140	140	O	:
23	142	151	U-UNK	nefazodone
24	152	152	O	,
25	154	164	U-UNK	fluvoxamine
26	165	165	O	,
27	167	176	U-UNK	cimetidine
28	177	177	O	,
29	179	187	U-UNK	diltiazem
30	188	188	O	,
31	190	199	U-UNK	isoniazide
32	200	200	O	,
33	202	204	O	and
34	206	209	O	some
35	211	219	B-UNK	macrolide
36	221	231	L-UNK	antibiotics
NULL

Estazolam	DDI-DrugBank.d338.s9	NO_SECTION	NO_SETID	31
Drug Interaction with Fluoxetine: A multiple-dose study was conducted to assess the effect of fluoxetine 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS after seven days.
1	0	3	O	Drug
2	5	15	O	Interaction
3	17	20	O	with
4	22	31	U-UNK	Fluoxetine
5	32	32	O	:
6	34	34	O	A
7	36	43	O	multiple
8	45	48	O	dose
9	50	54	O	study
10	56	58	O	was
11	60	68	O	conducted
12	70	71	O	to
13	73	78	O	assess
14	80	82	O	the
15	84	89	O	effect
16	91	92	O	of
17	94	103	U-UNK	fluoxetine
18	105	106	O	20
19	108	109	O	mg
20	111	113	O	BID
21	115	116	O	on
22	118	120	O	the
23	122	137	O	pharmacokinetics
24	139	140	O	of
25	142	150	O	XXXXXXXX
26	152	152	O	2
27	154	155	O	mg
28	157	159	O	QHS
29	161	165	O	after
30	167	171	O	seven
31	173	176	O	days
NULL

Estazolam	DDI-DrugBank.d338.s10	NO_SECTION	NO_SETID	21
The pharmacokinetics of estazolam (Cmax and AUC) were not affected during multiple-dose fluoxetine, suggesting no clinically significant pharmacokinetic interaction.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	32	O	XXXXXXXX
5	35	38	O	Cmax
6	40	42	O	and
7	44	46	O	AUC
8	49	52	O	were
9	54	56	O	not
10	58	65	O	affected
11	67	72	O	during
12	74	81	O	multiple
13	83	86	O	dose
14	88	97	U-UNK	fluoxetine
15	98	98	O	,
16	100	109	O	suggesting
17	111	112	O	no
18	114	123	O	clinically
19	125	135	O	significant
20	137	151	O	pharmacokinetic
21	153	163	O	interaction
NULL

Estazolam	DDI-DrugBank.d338.s11	NO_SECTION	NO_SETID	50
Estazolam: Interaction with Other Drugs that are Metabolized by Cytochrome P450 (CYP): At clinically relevant concentrations, in vitro studies indicate that estazolam (0.6 M) was not inhibitory towards the major cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A.
1	0	8	O	XXXXXXXX
2	9	9	O	:
3	11	21	O	Interaction
4	23	26	O	with
5	28	32	O	Other
6	34	38	O	Drugs
7	40	43	O	that
8	45	47	O	are
9	49	59	O	Metabolized
10	61	62	O	by
11	64	73	O	Cytochrome
12	75	78	O	P450
13	81	83	O	CYP
14	85	85	O	:
15	87	88	O	At
16	90	99	O	clinically
17	101	108	O	relevant
18	110	123	O	concentrations
19	124	124	O	,
20	126	127	O	in
21	129	133	O	vitro
22	135	141	O	studies
23	143	150	O	indicate
24	152	155	O	that
25	157	165	O	XXXXXXXX
26	168	170	O	0.6
27	172	172	O	M
28	175	177	O	was
29	179	181	O	not
30	183	192	O	inhibitory
31	194	200	O	towards
32	202	204	O	the
33	206	210	O	major
34	212	221	O	cytochrome
35	223	226	O	P450
36	228	235	O	isoforms
37	237	242	O	CYP1A2
38	243	243	O	,
39	245	250	O	CYP2A6
40	251	251	O	,
41	253	258	O	CYP2C9
42	259	259	O	,
43	261	267	O	CYP2C19
44	268	268	O	,
45	270	275	O	CYP2D6
46	276	276	O	,
47	278	283	O	CYP2E1
48	284	284	O	,
49	286	288	O	and
50	290	294	O	CYP3A
NULL

Estazolam	DDI-DrugBank.d338.s12	NO_SECTION	NO_SETID	25
Therefore, based on these in vitro data, estazolam is very unlikely to inhibit the biotransformation of other drugs metabolized by these CYP isoforms
1	0	8	O	Therefore
2	9	9	O	,
3	11	15	O	based
4	17	18	O	on
5	20	24	O	these
6	26	27	O	in
7	29	33	O	vitro
8	35	38	O	data
9	39	39	O	,
10	41	49	O	XXXXXXXX
11	51	52	O	is
12	54	57	O	very
13	59	66	O	unlikely
14	68	69	O	to
15	71	77	O	inhibit
16	79	81	O	the
17	83	99	O	biotransformation
18	101	102	O	of
19	104	108	O	other
20	110	114	O	drugs
21	116	126	O	metabolized
22	128	129	O	by
23	131	135	O	these
24	137	139	O	CYP
25	141	148	O	isoforms
NULL

Estradiol	DDI-DrugBank.d301.s1	NO_SECTION	NO_SETID	6
Drug and Laboratory Test Interactions 1.
1	0	3	O	Drug
2	5	7	O	and
3	9	18	O	Laboratory
4	20	23	O	Test
5	25	36	O	Interactions
6	38	38	O	1
NULL

Estradiol	DDI-DrugBank.d301.s2	NO_SECTION	NO_SETID	12
Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time;
1	0	10	O	Accelerated
2	12	22	O	prothrombin
3	24	27	O	time
4	28	28	O	,
5	30	36	O	partial
6	38	51	O	thromboplastin
7	53	56	O	time
8	57	57	O	,
9	59	61	O	and
10	63	70	O	platelet
11	72	82	O	aggregation
12	84	87	O	time
NULL

Estradiol	DDI-DrugBank.d301.s3	NO_SECTION	NO_SETID	3
increased platelet count;
1	0	8	O	increased
2	10	17	O	platelet
3	19	23	O	count
NULL

Estradiol	DDI-DrugBank.d301.s4	NO_SECTION	NO_SETID	32
increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin;
1	0	8	O	increased
2	10	16	O	factors
3	18	19	O	II
4	20	20	O	,
5	22	24	O	VII
6	26	32	O	antigen
7	33	33	O	,
8	35	38	O	VIII
9	40	46	O	antigen
10	47	47	O	,
11	49	52	O	VIII
12	54	62	O	coagulant
13	64	71	O	activity
14	72	72	O	,
15	74	75	O	IX
16	76	76	O	,
17	78	78	O	XXXXXXXX
18	79	79	O	,
19	81	83	O	XII
20	84	84	O	,
21	86	88	O	VII
22	90	90	O	XXXXXXXX
23	92	98	O	complex
24	99	99	O	,
25	101	102	O	II
26	104	106	O	VII
27	108	108	O	XXXXXXXX
28	110	116	O	complex
29	117	117	O	,
30	119	121	O	and
31	123	126	O	beta
32	128	142	O	thromboglobulin
NULL

Estradiol	DDI-DrugBank.d301.s5	NO_SECTION	NO_SETID	14
decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity;
1	0	8	O	decreased
2	10	15	O	levels
3	17	18	O	of
4	20	23	O	anti
5	25	30	O	factor
6	32	33	O	Xa
7	35	37	O	and
8	39	50	O	antithrombin
9	52	54	O	III
10	55	55	O	,
11	57	65	O	decreased
12	67	78	O	antithrombin
13	80	82	O	III
14	84	91	O	activity
NULL

Estradiol	DDI-DrugBank.d301.s6	NO_SECTION	NO_SETID	7
increased levels of fibrinogen and fibrinogen activity;
1	0	8	O	increased
2	10	15	O	levels
3	17	18	O	of
4	20	29	O	fibrinogen
5	31	33	O	and
6	35	44	O	fibrinogen
7	46	53	O	activity
NULL

Estradiol	DDI-DrugBank.d301.s7	NO_SECTION	NO_SETID	5
increased plasminogen antigen and activity.
1	0	8	O	increased
2	10	20	O	plasminogen
3	22	28	O	antigen
4	30	32	O	and
5	34	41	O	activity
NULL

Estradiol	DDI-DrugBank.d301.s9	NO_SECTION	NO_SETID	34
Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone levels, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay.
1	0	8	O	Increased
2	10	16	O	thyroid
3	18	24	O	binding
4	26	33	O	globulin
5	36	38	O	TBG
6	41	47	O	leading
7	49	50	O	to
8	52	60	O	increased
9	62	72	O	circulating
10	74	78	O	total
11	80	86	O	thyroid
12	88	94	O	hormone
13	96	101	O	levels
14	102	102	O	,
15	104	105	O	as
16	107	114	O	measured
17	116	117	O	by
18	119	125	O	protein
19	127	131	O	bound
20	133	138	O	iodine
21	141	143	O	PBI
22	145	145	O	,
23	147	148	O	T4
24	150	155	O	levels
25	158	159	O	by
26	161	166	O	column
27	168	169	O	or
28	171	172	O	by
29	174	189	O	radioimmunoassay
30	192	193	O	or
31	195	196	O	T3
32	198	203	O	levels
33	205	206	O	by
34	208	223	O	radioimmunoassay
NULL

Estradiol	DDI-DrugBank.d301.s10	NO_SECTION	NO_SETID	10
T3 resin uptake is decreased, reflecting the elevated TBG.
1	0	1	O	T3
2	3	7	O	resin
3	9	14	O	uptake
4	16	17	O	is
5	19	27	O	decreased
6	28	28	O	,
7	30	39	O	reflecting
8	41	43	O	the
9	45	52	O	elevated
10	54	56	O	TBG
NULL

Estradiol	DDI-DrugBank.d301.s11	NO_SECTION	NO_SETID	7
Free T4 and T3 concentrations are unaltered.
1	0	3	O	Free
2	5	6	O	T4
3	8	10	O	and
4	12	13	O	T3
5	15	28	O	concentrations
6	30	32	O	are
7	34	42	O	unaltered
NULL

Estradiol	DDI-DrugBank.d301.s12	NO_SECTION	NO_SETID	12
Patients on thyroid replacement therapy may require higher doses of thyroid hormone.
1	0	7	O	Patients
2	9	10	O	on
3	12	18	O	thyroid
4	20	30	O	replacement
5	32	38	O	therapy
6	40	42	O	may
7	44	50	O	require
8	52	57	O	higher
9	59	63	O	doses
10	65	66	O	of
11	68	74	B-UNK	thyroid
12	76	82	L-UNK	hormone
NULL

Estradiol	DDI-DrugBank.d301.s14	NO_SECTION	NO_SETID	33
Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively.
1	0	4	O	Other
2	6	12	O	binding
3	14	21	O	proteins
4	23	25	O	may
5	27	28	O	be
6	30	37	O	elevated
7	39	40	O	in
8	42	46	O	serum
9	47	47	O	,
10	49	51	O	i.e
11	53	53	O	,
12	55	68	O	corticosteroid
13	70	76	O	binding
14	78	85	O	globulin
15	88	90	O	CBG
16	92	92	O	,
17	94	96	O	sex
18	98	104	O	hormone
19	106	112	O	binding
20	114	121	O	globulin
21	124	127	O	SHBG
22	129	129	O	,
23	131	137	O	leading
24	139	140	O	to
25	142	150	O	increased
26	152	156	O	total
27	158	168	O	circulating
28	170	184	U-UNK	corticosteroids
29	186	188	O	and
30	190	192	B-UNK	sex
31	194	201	L-UNK	steroids
32	202	202	O	,
33	204	215	O	respectively
NULL

Estradiol	DDI-DrugBank.d301.s15	NO_SECTION	NO_SETID	6
Free hormone concentrations may be decreased.
1	0	3	O	Free
2	5	11	O	hormone
3	13	26	O	concentrations
4	28	30	O	may
5	32	33	O	be
6	35	43	O	decreased
NULL

Estradiol	DDI-DrugBank.d301.s16	NO_SECTION	NO_SETID	16
Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).
1	0	4	O	Other
2	6	11	O	plasma
3	13	20	O	proteins
4	22	24	O	may
5	26	27	O	be
6	29	37	O	increased
7	40	54	O	angiotensinogen
8	55	55	O	/
9	56	60	O	renin
10	62	70	O	substrate
11	71	71	O	,
12	73	77	O	alpha
13	79	79	O	1
14	81	91	O	antitrypsin
15	92	92	O	,
16	94	106	O	ceruloplasmin
NULL

Estradiol	DDI-DrugBank.d301.s18	NO_SECTION	NO_SETID	17
Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels.
1	0	8	O	Increased
2	10	15	O	plasma
3	17	19	O	HDL
4	21	23	O	and
5	25	28	O	HDL2
6	30	40	O	cholesterol
7	42	52	O	subfraction
8	54	67	O	concentrations
9	68	68	O	,
10	70	76	O	reduced
11	78	80	O	LDL
12	82	92	O	cholesterol
13	94	106	O	concentration
14	107	107	O	,
15	109	117	O	increased
16	119	130	O	triglyceride
17	132	137	O	levels
NULL

Estradiol	DDI-DrugBank.d301.s20	NO_SECTION	NO_SETID	3
Impaired glucose tolerance.
1	0	7	O	Impaired
2	9	15	O	glucose
3	17	25	O	tolerance
NULL

Estradiol	DDI-DrugBank.d301.s22	NO_SECTION	NO_SETID	5
Reduced response to metyrapone test.
1	0	6	O	Reduced
2	8	15	O	response
3	17	18	O	to
4	20	29	O	metyrapone
5	31	34	O	test
NULL

Estramustine	DDI-DrugBank.d481.s0	NO_SECTION	NO_SETID	17
Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.
1	0	3	O	Milk
2	4	4	O	,
3	6	9	O	milk
4	11	18	O	products
5	19	19	O	,
6	21	23	O	and
7	25	31	U-KIN	calcium
8	33	36	O	rich
9	38	42	O	foods
10	44	45	O	or
11	47	51	O	drugs
12	53	55	O	may
13	57	62	O	impair
14	64	66	O	the
15	68	77	O	absorption
16	79	80	O	of
17	82	86	O	XXXXXXXX
NULL

Eszopiclone	DDI-DrugBank.d216.s0	NO_SECTION	NO_SETID	30
CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
1	0	2	O	CNS
2	4	9	O	Active
3	11	15	O	Drugs
4	17	23	U-UNK	Ethanol
5	25	26	O	An
6	28	35	O	additive
7	37	42	O	effect
8	44	45	O	on
9	47	57	O	psychomotor
10	59	69	O	performance
11	71	73	O	was
12	75	78	O	seen
13	80	83	O	with
14	85	100	O	coadministration
15	102	103	O	of
16	105	115	O	XXXXXXXX
17	117	119	O	and
18	121	127	U-DYN	ethanol
19	129	132	O	0.70
20	134	134	O	g
21	135	135	O	/
22	136	137	O	kg
23	139	141	O	for
24	143	144	O	up
25	146	147	O	to
26	149	149	O	4
27	151	155	O	hours
28	157	161	O	after
29	163	169	U-UNK	ethanol
30	171	184	O	administration
NULL

Eszopiclone	DDI-DrugBank.d216.s1	NO_SECTION	NO_SETID	24
Paroxetine: Coadministration of single doses of eszopiclone 3 mg and paroxetine 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.
1	0	9	U-UNK	Paroxetine
2	10	10	O	:
3	12	27	O	Coadministration
4	29	30	O	of
5	32	37	O	single
6	39	43	O	doses
7	45	46	O	of
8	48	58	O	XXXXXXXX
9	60	60	O	3
10	62	63	O	mg
11	65	67	O	and
12	69	78	U-UNK	paroxetine
13	80	81	O	20
14	83	84	O	mg
15	86	90	O	daily
16	92	94	O	for
17	96	96	O	7
18	98	101	O	days
19	103	110	O	produced
20	112	113	O	no
21	115	129	O	pharmacokinetic
22	131	132	O	or
23	134	148	O	pharmacodynamic
24	150	160	O	interaction
NULL

Eszopiclone	DDI-DrugBank.d216.s2	NO_SECTION	NO_SETID	28
Lorazepam: Coadministration of single doses of eszopiclone 3 mg and lorazepam 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.
1	0	8	U-UNK	Lorazepam
2	9	9	O	:
3	11	26	O	Coadministration
4	28	29	O	of
5	31	36	O	single
6	38	42	O	doses
7	44	45	O	of
8	47	57	O	XXXXXXXX
9	59	59	O	3
10	61	62	O	mg
11	64	66	O	and
12	68	76	U-UNK	lorazepam
13	78	78	O	2
14	80	81	O	mg
15	83	85	O	did
16	87	89	O	not
17	91	94	O	have
18	96	105	O	clinically
19	107	114	O	relevant
20	116	122	O	effects
21	124	125	O	on
22	127	129	O	the
23	131	146	O	pharmacodynamics
24	148	149	O	or
25	151	166	O	pharmacokinetics
26	168	169	O	of
27	171	176	O	either
28	178	181	O	drug
NULL

Eszopiclone	DDI-DrugBank.d216.s3	NO_SECTION	NO_SETID	17
Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.
1	0	9	U-UNK	Olanzapine
2	10	10	O	:
3	12	27	O	Coadministration
4	29	30	O	of
5	32	42	O	XXXXXXXX
6	44	44	O	3
7	46	47	O	mg
8	49	51	O	and
9	53	62	U-DYN	olanzapine
10	64	65	O	10
11	67	68	O	mg
12	70	77	O	produced
13	79	79	O	a
14	81	88	O	decrease
15	90	91	O	in
16	93	96	O	DSST
17	98	103	O	scores
NULL

Eszopiclone	DDI-DrugBank.d216.s4	NO_SECTION	NO_SETID	4
The interaction was pharmacodynamic;
1	0	2	O	The
2	4	14	O	interaction
3	16	18	O	was
4	20	34	O	pharmacodynamic
NULL

Eszopiclone	DDI-DrugBank.d216.s5	NO_SECTION	NO_SETID	10
there was no alteration in the pharmacokinetics of either drug.
1	0	4	O	there
2	6	8	O	was
3	10	11	O	no
4	13	22	O	alteration
5	24	25	O	in
6	27	29	O	the
7	31	46	O	pharmacokinetics
8	48	49	O	of
9	51	56	O	either
10	58	61	O	drug
NULL

Eszopiclone	DDI-DrugBank.d216.s6	NO_SECTION	NO_SETID	15
Drugs That Inhibit CYP3A4 (Ketoconazole) CYP3A4 is a major metabolic pathway for elimination of eszopiclone.
1	0	4	O	Drugs
2	6	9	O	That
3	11	17	O	Inhibit
4	19	24	O	CYP3A4
5	27	38	U-UNK	Ketoconazole
6	41	46	O	CYP3A4
7	48	49	O	is
8	51	51	O	a
9	53	57	O	major
10	59	67	O	metabolic
11	69	75	O	pathway
12	77	79	O	for
13	81	91	O	elimination
14	93	94	O	of
15	96	106	O	XXXXXXXX
NULL

Eszopiclone	DDI-DrugBank.d216.s7	NO_SECTION	NO_SETID	25
The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.
1	0	2	O	The
2	4	6	O	AUC
3	8	9	O	of
4	11	21	O	XXXXXXXX
5	23	25	O	was
6	27	35	O	increased
7	37	39	O	2.2
8	41	44	O	fold
9	46	47	O	by
10	49	64	O	coadministration
11	66	67	O	of
12	69	80	U-KIN	ketoconazole
13	81	81	O	,
14	83	83	O	a
15	85	90	O	potent
16	92	100	O	inhibitor
17	102	103	O	of
18	105	110	O	CYP3A4
19	111	111	O	,
20	113	115	O	400
21	117	118	O	mg
22	120	124	O	daily
23	126	128	O	for
24	130	130	O	5
25	132	135	O	days
NULL

Eszopiclone	DDI-DrugBank.d216.s8	NO_SECTION	NO_SETID	14
Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respectively.
1	0	3	O	Cmax
2	5	7	O	and
3	9	10	O	t1
4	11	11	O	/
5	12	12	O	2
6	14	17	O	were
7	19	27	O	increased
8	29	31	O	1.4
9	33	36	O	fold
10	38	40	O	and
11	42	44	O	1.3
12	46	49	O	fold
13	50	50	O	,
14	52	63	O	respectively
NULL

Eszopiclone	DDI-DrugBank.d216.s9	NO_SECTION	NO_SETID	24
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.
1	0	4	O	Other
2	6	11	O	strong
3	13	22	O	inhibitors
4	24	25	O	of
5	27	32	O	CYP3A4
6	35	37	O	e.g
7	39	39	O	,
8	41	52	U-UNK	itraconazole
9	53	53	O	,
10	55	68	U-UNK	clarithromycin
11	69	69	O	,
12	71	80	U-UNK	nefazodone
13	81	81	O	,
14	83	96	U-UNK	troleandomycin
15	97	97	O	,
16	99	107	U-UNK	ritonavir
17	108	108	O	,
18	110	119	U-UNK	nelfinavir
19	122	126	O	would
20	128	129	O	be
21	131	138	O	expected
22	140	141	O	to
23	143	148	O	behave
24	150	158	O	similarly
NULL

Eszopiclone	DDI-DrugBank.d216.s10	NO_SECTION	NO_SETID	21
Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.
1	0	4	O	Drugs
2	6	9	O	That
3	11	16	O	Induce
4	18	23	O	CYP3A4
5	26	35	U-UNK	Rifampicin
6	38	44	O	Racemic
7	46	54	U-UNK	zopiclone
8	56	63	O	exposure
9	65	67	O	was
10	69	77	O	decreased
11	79	81	O	80%
12	83	84	O	by
13	86	96	O	concomitant
14	98	102	O	useof
15	104	113	U-UNK	rifampicin
16	114	114	O	,
17	116	116	O	a
18	118	123	O	potent
19	125	131	O	inducer
20	133	134	O	of
21	136	141	O	CYP3A4
NULL

Eszopiclone	DDI-DrugBank.d216.s11	NO_SECTION	NO_SETID	8
A similar effect would be expected with eszopiclone.
1	0	0	O	A
2	2	8	O	similar
3	10	15	O	effect
4	17	21	O	would
5	23	24	O	be
6	26	33	O	expected
7	35	38	O	with
8	40	50	O	XXXXXXXX
NULL

Eszopiclone	DDI-DrugBank.d216.s12	NO_SECTION	NO_SETID	17
Drugs Highly Bound To Plasma Protein Eszopiclone is not highly bound to plasma proteins (52-59% bound);
1	0	4	O	Drugs
2	6	11	O	Highly
3	13	17	O	Bound
4	19	20	O	To
5	22	27	O	Plasma
6	29	35	O	Protein
7	37	47	O	XXXXXXXX
8	49	50	O	is
9	52	54	O	not
10	56	61	O	highly
11	63	67	O	bound
12	69	70	O	to
13	72	77	O	plasma
14	79	86	O	proteins
15	89	90	O	52
16	92	94	O	59%
17	96	100	O	bound
NULL

Eszopiclone	DDI-DrugBank.d216.s13	NO_SECTION	NO_SETID	17
therefore, the disposition of eszopiclone is not expected to be sensitive to alterations in protein binding.
1	0	8	O	therefore
2	9	9	O	,
3	11	13	O	the
4	15	25	O	disposition
5	27	28	O	of
6	30	40	O	XXXXXXXX
7	42	43	O	is
8	45	47	O	not
9	49	56	O	expected
10	58	59	O	to
11	61	62	O	be
12	64	72	O	sensitive
13	74	75	O	to
14	77	87	O	alterations
15	89	90	O	in
16	92	98	O	protein
17	100	106	O	binding
NULL

Eszopiclone	DDI-DrugBank.d216.s14	NO_SECTION	NO_SETID	31
Administration of eszopiclone 3 mg to a patient taking another drug that is highly protein-bound would not be expected to cause an alteration in the free concentration of either drug.
1	0	13	O	Administration
2	15	16	O	of
3	18	28	O	XXXXXXXX
4	30	30	O	3
5	32	33	O	mg
6	35	36	O	to
7	38	38	O	a
8	40	46	O	patient
9	48	53	O	taking
10	55	61	O	another
11	63	66	O	drug
12	68	71	O	that
13	73	74	O	is
14	76	81	O	highly
15	83	89	O	protein
16	91	95	O	bound
17	97	101	O	would
18	103	105	O	not
19	107	108	O	be
20	110	117	O	expected
21	119	120	O	to
22	122	126	O	cause
23	128	129	O	an
24	131	140	O	alteration
25	142	143	O	in
26	145	147	O	the
27	149	152	O	free
28	154	166	O	concentration
29	168	169	O	of
30	171	176	O	either
31	178	181	O	drug
NULL

Eszopiclone	DDI-DrugBank.d216.s15	NO_SECTION	NO_SETID	44
Drugs With A Narrow Therapeutic Index Digoxin A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.
1	0	4	O	Drugs
2	6	9	O	With
3	11	11	O	A
4	13	18	O	Narrow
5	20	30	O	Therapeutic
6	32	36	O	Index
7	38	44	U-UNK	Digoxin
8	46	46	O	A
9	48	53	O	single
10	55	58	O	dose
11	60	61	O	of
12	63	73	O	XXXXXXXX
13	75	75	O	3
14	77	78	O	mg
15	80	82	O	did
16	84	86	O	not
17	88	93	O	affect
18	95	97	O	the
19	99	114	O	pharmacokinetics
20	116	117	O	of
21	119	125	U-UNK	digoxin
22	127	134	O	measured
23	136	137	O	at
24	139	144	O	steady
25	146	150	O	state
26	152	160	O	following
27	162	167	O	dosing
28	169	170	O	of
29	172	174	O	0.5
30	176	177	O	mg
31	179	183	O	twice
32	185	189	O	daily
33	191	193	O	for
34	195	197	O	one
35	199	201	O	day
36	203	205	O	and
37	207	210	O	0.25
38	212	213	O	mg
39	215	219	O	daily
40	221	223	O	for
41	225	227	O	the
42	229	232	O	next
43	234	234	O	6
44	236	239	O	days
NULL

Eszopiclone	DDI-DrugBank.d216.s16	NO_SECTION	NO_SETID	41
Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	20	O	XXXXXXXX
4	22	22	O	3
5	24	25	O	mg
6	27	38	O	administered
7	40	44	O	daily
8	46	48	O	for
9	50	50	O	5
10	52	55	O	days
11	57	59	O	did
12	61	63	O	not
13	65	70	O	affect
14	72	74	O	the
15	76	91	O	pharmacokinetics
16	93	94	O	of
17	97	97	B-UNK	R
18	101	102	I-UNK	or
19	105	105	L-UNK	S
20	108	115	U-UNK	warfarin
21	116	116	O	,
22	118	120	O	nor
23	122	125	O	were
24	127	131	O	there
25	133	135	O	any
26	137	143	O	changes
27	145	146	O	in
28	148	150	O	the
29	152	166	O	pharmacodynamic
30	168	174	O	profile
31	177	187	O	prothrombin
32	189	192	O	time
33	195	203	O	following
34	205	205	O	a
35	207	212	O	single
36	214	215	O	25
37	217	218	O	mg
38	220	223	O	oral
39	225	228	O	dose
40	230	231	O	of
41	233	240	U-UNK	warfarin
NULL

Etanercept	DDI-DrugBank.d341.s0	NO_SECTION	NO_SETID	10
Specific drug interaction studies have not been conducted with ENBREL .
1	0	7	O	Specific
2	9	12	O	drug
3	14	24	O	interaction
4	26	32	O	studies
5	34	37	O	have
6	39	41	O	not
7	43	46	O	been
8	48	56	O	conducted
9	58	61	O	with
10	63	68	O	XXXXXXXX
NULL

Etanercept	DDI-DrugBank.d341.s1	NO_SECTION	NO_SETID	19
However, it was observed that the pharmacokinetics of ENBREL  was unaltered by concomitant methotrexate in rheumatoid arthritis patients.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	it
4	12	14	O	was
5	16	23	O	observed
6	25	28	O	that
7	30	32	O	the
8	34	49	O	pharmacokinetics
9	51	52	O	of
10	54	59	O	XXXXXXXX
11	62	64	O	was
12	66	74	O	unaltered
13	76	77	O	by
14	79	89	O	concomitant
15	91	102	U-UNK	methotrexate
16	104	105	O	in
17	107	116	O	rheumatoid
18	118	126	O	arthritis
19	128	135	O	patients
NULL

Etanercept	DDI-DrugBank.d341.s2	NO_SECTION	NO_SETID	42
In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	in
5	14	18	O	which
6	20	27	O	patients
7	29	32	O	with
8	34	39	O	active
9	41	42	O	RA
10	44	47	O	were
11	49	55	O	treated
12	57	59	O	for
13	61	62	O	up
14	64	65	O	to
15	67	68	O	24
16	70	74	O	weeks
17	76	79	O	with
18	81	90	O	concurrent
19	92	97	O	XXXXXXXX
20	100	102	O	and
21	104	111	U-DYN	anakinra
22	113	119	O	therapy
23	120	120	O	,
24	122	122	O	a
25	124	125	O	7%
26	127	130	O	rate
27	132	133	O	of
28	135	141	O	serious
29	143	152	O	infections
30	154	156	O	was
31	158	165	O	observed
32	166	166	O	,
33	168	172	O	which
34	174	176	O	was
35	178	183	O	higher
36	185	188	O	than
37	190	193	O	that
38	195	202	O	observed
39	204	207	O	with
40	209	214	O	XXXXXXXX
41	217	221	O	alone
42	224	225	O	0%
NULL

Etanercept	DDI-DrugBank.d341.s3	NO_SECTION	NO_SETID	18
Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).
1	0	2	O	Two
2	4	10	O	percent
3	12	13	O	of
4	15	22	O	patients
5	24	30	O	treated
6	32	43	O	concurrently
7	45	48	O	with
8	50	55	O	XXXXXXXX
9	58	60	O	and
10	62	69	U-DYN	anakinra
11	71	79	O	developed
12	81	91	O	neutropenia
13	94	96	O	ANC
14	100	100	O	1
15	102	102	O	x
16	104	106	O	109
17	107	107	O	/
18	108	108	O	L
NULL

Etanercept	DDI-DrugBank.d341.s4	NO_SECTION	NO_SETID	42
Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.
1	0	7	O	Patients
2	9	10	O	in
3	12	12	O	a
4	14	21	O	clinical
5	23	27	O	study
6	29	31	O	who
7	33	36	O	were
8	38	39	O	on
9	41	51	O	established
10	53	59	O	therapy
11	61	64	O	with
12	66	78	U-DYN	sulfasalazine
13	79	79	O	,
14	81	82	O	to
15	84	88	O	which
16	90	95	O	XXXXXXXX
17	97	99	O	was
18	101	105	O	added
19	106	106	O	,
20	108	111	O	were
21	113	117	O	noted
22	119	120	O	to
23	122	128	O	develop
24	130	130	O	a
25	132	135	O	mild
26	137	144	O	decrease
27	146	147	O	in
28	149	152	O	mean
29	154	163	O	neutrophil
30	165	170	O	counts
31	172	173	O	in
32	175	184	O	comparison
33	186	187	O	to
34	189	194	O	groups
35	196	202	O	treated
36	204	207	O	with
37	209	214	O	either
38	216	221	O	XXXXXXXX
39	223	224	O	CI
40	226	227	O	or
41	229	241	U-UNK	sulfasalazine
42	243	247	O	alone
NULL

Etanercept	DDI-DrugBank.d341.s5	NO_SECTION	NO_SETID	8
The clinical significance of this observation is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	44	O	observation
7	46	47	O	is
8	49	55	O	unknown
NULL

Ethacrynic acid	DDI-DrugBank.d414.s0	NO_SECTION	NO_SETID	22
Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
1	0	6	U-UNK	Lithium
2	8	16	O	generally
3	18	23	O	should
4	25	27	O	not
5	29	30	O	be
6	32	36	O	given
7	38	41	O	with
8	43	51	U-UNK	diuretics
9	53	59	O	because
10	61	64	O	they
11	66	71	O	reduce
12	73	75	O	its
13	77	81	O	renal
14	83	91	O	clearance
15	93	95	O	and
16	97	99	O	add
17	101	101	O	a
18	103	106	O	high
19	108	111	O	risk
20	113	114	O	of
21	116	122	U-UNK	lithium
22	124	131	O	toxicity
NULL

Ethacrynic acid	DDI-DrugBank.d414.s1	NO_SECTION	NO_SETID	11
Read circulars for lithium preparations before use of such concomitant therapy.
1	0	3	O	Read
2	5	13	O	circulars
3	15	17	O	for
4	19	25	U-UNK	lithium
5	27	38	O	preparations
6	40	45	O	before
7	47	49	O	use
8	51	52	O	of
9	54	57	O	such
10	59	69	O	concomitant
11	71	77	O	therapy
NULL

Ethacrynic acid	DDI-DrugBank.d414.s2	NO_SECTION	NO_SETID	16
EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.
1	0	6	O	XXXXXXXX
2	8	10	O	may
3	12	19	O	increase
4	21	23	O	the
5	25	32	O	ototoxic
6	34	42	O	potential
7	44	45	O	of
8	47	51	O	other
9	53	57	O	drugs
10	59	62	O	such
11	64	65	O	as
12	67	80	U-DYN	aminoglycoside
13	82	84	O	and
14	86	89	O	some
15	91	103	B-DYN	cephalosporin
16	105	115	L-DYN	antibiotics
NULL

Ethacrynic acid	DDI-DrugBank.d414.s3	NO_SECTION	NO_SETID	6
Their concurrent use should be avoided.
1	0	4	O	Their
2	6	15	O	concurrent
3	17	19	O	use
4	21	26	O	should
5	28	29	O	be
6	31	37	O	avoided
NULL

Ethacrynic acid	DDI-DrugBank.d414.s4	NO_SECTION	NO_SETID	17
A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;
1	0	0	O	A
2	2	7	O	number
3	9	10	O	of
4	12	16	O	drugs
5	17	17	O	,
6	19	27	O	including
7	29	43	O	XXXXXXXX
8	44	44	O	,
9	46	49	O	have
10	51	54	O	been
11	56	60	O	shown
12	62	63	O	to
13	65	72	O	displace
14	74	81	U-KIN	warfarin
15	83	86	O	from
16	88	93	O	plasma
17	95	101	O	protein
NULL

Ethacrynic acid	DDI-DrugBank.d414.s5	NO_SECTION	NO_SETID	15
a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs.
1	0	0	O	a
2	2	10	O	reduction
3	12	13	O	in
4	15	17	O	the
5	19	23	O	usual
6	25	37	U-UNK	anticoagulant
7	39	44	O	dosage
8	46	48	O	may
9	50	51	O	be
10	53	60	O	required
11	62	63	O	in
12	65	72	O	patients
13	74	82	O	receiving
14	84	87	O	both
15	89	93	O	drugs
NULL

Ethacrynic acid	DDI-DrugBank.d414.s6	NO_SECTION	NO_SETID	30
In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.
1	0	1	O	In
2	3	6	O	some
3	8	15	O	patients
4	16	16	O	,
5	18	20	O	the
6	22	35	O	administration
7	37	38	O	of
8	40	40	O	a
9	42	44	B-UNK	non
10	47	55	I-UNK	steroidal
11	57	72	I-UNK	antiinflammatory
12	74	78	L-UNK	agent
13	80	82	O	can
14	84	89	O	reduce
15	91	93	O	the
16	95	102	O	diuretic
17	103	103	O	,
18	105	115	O	natriuretic
19	116	116	O	,
20	118	120	O	and
21	122	137	O	antihypertensive
22	139	145	O	effects
23	147	148	O	of
24	150	153	B-UNK	loop
25	154	154	I-UNK	,
26	156	164	I-UNK	potassium
27	167	173	I-UNK	sparing
28	175	177	I-UNK	and
29	179	186	I-UNK	thiazide
30	188	196	L-UNK	diuretics
NULL

Ethacrynic acid	DDI-DrugBank.d414.s7	NO_SECTION	NO_SETID	31
Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	22	O	XXXXXXXX
5	24	26	O	and
6	28	30	B-DYN	non
7	33	41	I-DYN	steroidal
8	43	46	I-DYN	anti
9	49	60	I-DYN	inflammatory
10	62	67	L-DYN	agents
11	69	71	O	are
12	73	76	O	used
13	78	90	O	concomitantly
14	91	91	O	,
15	93	95	O	the
16	97	103	O	patient
17	105	110	O	should
18	112	113	O	be
19	115	122	O	observed
20	124	130	O	closely
21	132	133	O	to
22	135	143	O	determine
23	145	146	O	if
24	148	150	O	the
25	152	158	O	desired
26	160	165	O	effect
27	167	168	O	of
28	170	172	O	the
29	174	181	U-UNK	diuretic
30	183	184	O	is
31	186	193	O	obtained
NULL

Ethambutol	DDI-DrugBank.d160.s0	NO_SECTION	NO_SETID	58
The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.
1	0	2	O	The
2	4	10	O	results
3	12	13	O	of
4	15	15	O	a
5	17	21	O	study
6	23	24	O	of
7	26	41	O	coadministration
8	43	44	O	of
9	46	55	O	XXXXXXXX
10	58	59	O	50
11	61	62	O	mg
12	63	63	O	/
13	64	65	O	kg
14	68	71	O	with
15	73	74	O	an
16	76	83	B-KIN	aluminum
17	85	93	L-KIN	hydroxide
18	95	104	O	containing
19	106	112	U-UNK	antacid
20	114	115	O	to
21	117	118	O	13
22	120	127	O	patients
23	129	132	O	with
24	134	145	O	tuberculosis
25	147	152	O	showed
26	154	154	O	a
27	156	164	O	reduction
28	166	167	O	of
29	169	172	O	mean
30	174	178	O	serum
31	180	193	O	concentrations
32	195	197	O	and
33	199	205	O	urinary
34	207	215	O	excretion
35	217	218	O	of
36	220	229	O	XXXXXXXX
37	231	232	O	of
38	234	246	O	approximately
39	248	250	O	20%
40	252	254	O	and
41	256	258	O	13%
42	259	259	O	,
43	261	272	O	respectively
44	273	273	O	,
45	275	284	O	suggesting
46	286	289	O	that
47	291	293	O	the
48	295	298	O	oral
49	300	309	O	absorption
50	311	312	O	of
51	314	323	O	XXXXXXXX
52	325	327	O	may
53	329	330	O	be
54	332	338	O	reduced
55	340	341	O	by
56	343	347	O	these
57	349	355	B-UNK	antacid
58	357	364	L-UNK	products
NULL

Ethambutol	DDI-DrugBank.d160.s1	NO_SECTION	NO_SETID	22
It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	19	O	to
5	21	25	O	avoid
6	27	36	O	concurrent
7	38	51	O	administration
8	53	54	O	of
9	56	65	O	XXXXXXXX
10	67	70	O	with
11	72	79	B-DYN	aluminum
12	81	89	L-DYN	hydroxide
13	91	100	O	containing
14	102	109	U-UNK	antacids
15	111	113	O	for
16	115	116	O	at
17	118	122	O	least
18	124	124	O	4
19	126	130	O	hours
20	132	140	O	following
21	142	151	O	XXXXXXXX
22	153	166	O	administration
NULL

Ethchlorvynol	DDI-DrugBank.d405.s0	NO_SECTION	NO_SETID	7
Dicumarol and warfarin may decrease hypoprothrombinemic effect.
1	0	8	U-UNK	Dicumarol
2	10	12	O	and
3	14	21	U-UNK	warfarin
4	23	25	O	may
5	27	34	O	decrease
6	36	54	O	hypoprothrombinemic
7	56	61	O	effect
NULL

Ethchlorvynol	DDI-DrugBank.d405.s1	NO_SECTION	NO_SETID	18
Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.
1	0	4	O	Other
2	6	17	O	depressasnts
3	19	22	O	such
4	24	25	O	as
5	27	33	U-DYN	alcohol
6	34	34	O	,
7	36	47	U-DYN	barbiturates
8	48	48	O	,
9	50	52	O	and
10	54	58	U-DYN	MAOIs
11	60	62	O	may
12	64	70	O	enhance
13	72	74	O	CNS
14	76	85	O	depression
15	87	90	O	when
16	92	103	O	administered
17	105	108	O	with
18	110	122	O	XXXXXXXX
NULL

Ethinamate	DDI-DrugBank.d376.s0	NO_SECTION	NO_SETID	45
May interact with addictive medications, especially central nervous system (CNS) depressants with habituating potential (prolonged concurrent use may increase the risk of habituation), alcohol or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or ethinamate).
1	0	2	O	May
2	4	11	O	interact
3	13	16	O	with
4	18	26	O	addictive
5	28	38	O	medications
6	39	39	O	,
7	41	50	O	especially
8	52	58	B-UNK	central
9	60	66	I-UNK	nervous
10	68	73	I-UNK	system
11	76	78	I-UNK	CNS
12	81	91	L-UNK	depressants
13	93	96	O	with
14	98	108	O	habituating
15	110	118	O	potential
16	121	129	O	prolonged
17	131	140	O	concurrent
18	142	144	O	use
19	146	148	O	may
20	150	157	O	increase
21	159	161	O	the
22	163	166	O	risk
23	168	169	O	of
24	171	181	O	habituation
25	183	183	O	,
26	185	191	U-UNK	alcohol
27	193	194	O	or
28	196	198	O	CNS
29	200	209	O	depression
30	211	219	O	producing
31	221	231	O	medications
32	234	243	O	concurrent
33	245	247	O	use
34	249	251	O	may
35	253	260	O	increase
36	262	264	O	the
37	266	268	O	CNS
38	270	279	O	depressant
39	281	287	O	effects
40	289	290	O	of
41	292	297	O	either
42	299	303	O	these
43	305	315	O	medications
44	317	318	O	or
45	320	329	O	XXXXXXXX
NULL

Ethinyl Estradiol	DDI-DrugBank.d152.s0	NO_SECTION	NO_SETID	14
Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.
1	0	6	O	Certain
2	8	16	O	endocrine
3	18	20	O	and
4	22	26	O	liver
5	28	35	O	function
6	37	41	O	tests
7	43	45	O	may
8	47	48	O	be
9	50	57	O	affected
10	59	60	O	by
11	62	69	U-UNK	estrogen
12	71	80	O	containing
13	82	85	O	oral
14	87	100	U-UNK	contraceptives
NULL

Ethinyl Estradiol	DDI-DrugBank.d152.s1	NO_SECTION	NO_SETID	16
The following similar changes may be expected with larger doses of estrogen: Increased sulfobromophthalein retention;
1	0	2	O	The
2	4	12	O	following
3	14	20	O	similar
4	22	28	O	changes
5	30	32	O	may
6	34	35	O	be
7	37	44	O	expected
8	46	49	O	with
9	51	56	O	larger
10	58	62	O	doses
11	64	65	O	of
12	67	74	U-UNK	estrogen
13	75	75	O	:
14	77	85	O	Increased
15	87	105	O	sulfobromophthalein
16	107	115	O	retention
NULL

Ethinyl Estradiol	DDI-DrugBank.d152.s2	NO_SECTION	NO_SETID	12
increased prothrombin and factors VII, VIII, IX, and X;
1	0	8	O	increased
2	10	20	O	prothrombin
3	22	24	O	and
4	26	32	O	factors
5	34	36	O	VII
6	37	37	O	,
7	39	42	O	VIII
8	43	43	O	,
9	45	46	O	IX
10	47	47	O	,
11	49	51	O	and
12	53	53	O	XXXXXXXX
NULL

Ethinyl Estradiol	DDI-DrugBank.d152.s3	NO_SECTION	NO_SETID	3
decreased antithrombin 3;
1	0	8	O	decreased
2	10	21	O	antithrombin
3	23	23	O	3
NULL

Ethinyl Estradiol	DDI-DrugBank.d152.s4	NO_SECTION	NO_SETID	6
increased norepinephrine-induced platel et aggregation;
1	0	8	O	increased
2	10	23	O	norepinephrine
3	25	31	O	induced
4	33	38	O	platel
5	40	41	O	et
6	43	53	O	aggregation
NULL

Ethinyl Estradiol	DDI-DrugBank.d152.s5	NO_SECTION	NO_SETID	26
increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by PBI, T4 by column, or T4 by radioimmunoassay.
1	0	8	O	increased
2	10	16	O	thyroid
3	18	24	O	binding
4	26	33	O	globulin
5	36	38	O	TBG
6	41	47	O	leading
7	49	50	O	to
8	52	60	O	increased
9	62	72	O	circulating
10	74	78	O	total
11	80	86	O	thyroid
12	88	94	O	hormone
13	95	95	O	,
14	97	98	O	as
15	100	107	O	measured
16	109	110	O	by
17	112	114	O	PBI
18	115	115	O	,
19	117	118	O	T4
20	120	121	O	by
21	123	128	O	column
22	129	129	O	,
23	131	132	O	or
24	134	135	O	T4
25	137	138	O	by
26	140	155	O	radioimmunoassay
NULL

Ethinyl Estradiol	DDI-DrugBank.d152.s6	NO_SECTION	NO_SETID	11
Free T3 resin uptake is decreased, reflecting the elevated TBG;
1	0	3	O	Free
2	5	6	O	T3
3	8	12	O	resin
4	14	19	O	uptake
5	21	22	O	is
6	24	32	O	decreased
7	33	33	O	,
8	35	44	O	reflecting
9	46	48	O	the
10	50	57	O	elevated
11	59	61	O	TBG
NULL

Ethinyl Estradiol	DDI-DrugBank.d152.s7	NO_SECTION	NO_SETID	9
free T4 concentration is unaltered: impaired glucose tolerance;
1	0	3	O	free
2	5	6	O	T4
3	8	20	O	concentration
4	22	23	O	is
5	25	33	O	unaltered
6	34	34	O	:
7	36	43	O	impaired
8	45	51	O	glucose
9	53	61	O	tolerance
NULL

Ethinyl Estradiol	DDI-DrugBank.d152.s8	NO_SECTION	NO_SETID	3
decreased pregnanediol excretion;
1	0	8	O	decreased
2	10	21	O	pregnanediol
3	23	31	O	excretion
NULL

Ethinyl Estradiol	DDI-DrugBank.d152.s9	NO_SECTION	NO_SETID	5
reduced response to metyrapone test;
1	0	6	O	reduced
2	8	15	O	response
3	17	18	O	to
4	20	29	O	metyrapone
5	31	34	O	test
NULL

Ethinyl Estradiol	DDI-DrugBank.d152.s10	NO_SECTION	NO_SETID	4
reduced serum folate concentration;
1	0	6	O	reduced
2	8	12	O	serum
3	14	19	O	folate
4	21	33	O	concentration
NULL

Ethinyl Estradiol	DDI-DrugBank.d152.s11	NO_SECTION	NO_SETID	6
increased serum triglyceride and phospholipid concentration.
1	0	8	O	increased
2	10	14	O	serum
3	16	27	O	triglyceride
4	29	31	O	and
5	33	44	O	phospholipid
6	46	58	O	concentration
NULL

Ethionamide	DDI-DrugBank.d166.s0	NO_SECTION	NO_SETID	11
Trecator has been found to temporarily raise serum concentrations of isoniazid.
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	16	O	been
4	18	22	O	found
5	24	25	O	to
6	27	37	O	temporarily
7	39	43	O	raise
8	45	49	O	serum
9	51	64	O	concentrations
10	66	67	O	of
11	69	77	U-KIN	isoniazid
NULL

Ethionamide	DDI-DrugBank.d166.s1	NO_SECTION	NO_SETID	12
Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.
1	0	7	O	XXXXXXXX
2	9	11	O	may
3	13	22	O	potentiate
4	24	26	O	the
5	28	34	O	adverse
6	36	42	O	effects
7	44	45	O	of
8	47	51	O	other
9	53	67	B-DYN	antituberculous
10	69	73	L-DYN	drugs
11	75	86	O	administered
12	88	100	O	concomitantly
NULL

Ethionamide	DDI-DrugBank.d166.s2	NO_SECTION	NO_SETID	28
In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.
1	0	1	O	In
2	3	12	O	particular
3	13	13	O	,
4	15	25	O	convulsions
5	27	30	O	have
6	32	35	O	been
7	37	44	O	reported
8	46	49	O	when
9	51	61	O	XXXXXXXX
10	63	64	O	is
11	66	77	O	administered
12	79	82	O	with
13	84	94	U-DYN	cycloserine
14	96	98	O	and
15	100	106	O	special
16	108	111	O	care
17	113	118	O	should
18	120	121	O	be
19	123	127	O	taken
20	129	132	O	when
21	134	136	O	the
22	138	146	O	treatment
23	148	154	O	regimen
24	156	163	O	includes
25	165	168	O	both
26	170	171	O	of
27	173	177	O	these
28	179	183	O	drugs
NULL

Ethionamide	DDI-DrugBank.d166.s3	NO_SECTION	NO_SETID	13
Excessive ethanol ingestion should be avoided because a psychotic reaction has been reported.
1	0	8	O	Excessive
2	10	16	U-UNK	ethanol
3	18	26	O	ingestion
4	28	33	O	should
5	35	36	O	be
6	38	44	O	avoided
7	46	52	O	because
8	54	54	O	a
9	56	64	O	psychotic
10	66	73	O	reaction
11	75	77	O	has
12	79	82	O	been
13	84	91	O	reported
NULL

Ethopropazine	DDI-DrugBank.d240.s0	NO_SECTION	NO_SETID	14
Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.
1	0	12	O	XXXXXXXX
2	14	16	O	may
3	18	25	O	interact
4	27	30	O	with
5	32	38	U-DYN	alcohol
6	40	41	O	or
7	43	47	O	other
8	49	51	B-DYN	CNS
9	53	63	L-DYN	depressants
10	64	64	O	,
11	66	72	O	causing
12	74	82	O	increased
13	84	91	O	sedative
14	93	99	O	effects
NULL

Ethopropazine	DDI-DrugBank.d240.s1	NO_SECTION	NO_SETID	19
It may also interact with amantadine or other anticholinergic drugs or MAOIs, which may intensify the anticholinergic action.
1	0	1	O	It
2	3	5	O	may
3	7	10	O	also
4	12	19	O	interact
5	21	24	O	with
6	26	35	U-UNK	amantadine
7	37	38	O	or
8	40	44	O	other
9	46	60	B-UNK	anticholinergic
10	62	66	L-UNK	drugs
11	68	69	O	or
12	71	75	U-UNK	MAOIs
13	76	76	O	,
14	78	82	O	which
15	84	86	O	may
16	88	96	O	intensify
17	98	100	O	the
18	102	116	O	anticholinergic
19	118	123	O	action
NULL

Ethopropazine	DDI-DrugBank.d240.s2	NO_SECTION	NO_SETID	11
Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.
1	0	12	O	XXXXXXXX
2	14	16	O	can
3	18	25	O	interact
4	27	30	O	with
5	32	45	U-KIN	chlorpromazine
6	46	46	O	,
7	48	57	O	increasing
8	59	61	O	the
9	63	72	O	metabolism
10	74	75	O	of
11	77	90	U-UNK	chlorpromazine
NULL

Ethosuximide	DDI-DrugBank.d205.s0	NO_SECTION	NO_SETID	42
Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
1	0	4	O	Since
2	6	13	O	XXXXXXXX
3	16	27	U-UNK	ethosuximide
4	30	32	O	may
5	34	41	O	interact
6	43	46	O	with
7	48	59	O	concurrently
8	61	72	O	administered
9	74	86	B-UNK	antiepileptic
10	88	92	L-UNK	drugs
11	93	93	O	,
12	95	102	O	periodic
13	104	108	O	serum
14	110	114	O	level
15	116	129	O	determinations
16	131	132	O	of
17	134	138	O	these
18	140	144	O	drugs
19	146	148	O	may
20	150	151	O	be
21	153	161	O	necessary
22	164	165	O	eg
23	166	166	O	,
24	168	179	U-UNK	ethosuximide
25	181	183	O	may
26	185	191	O	elevate
27	193	201	U-UNK	phenytoin
28	203	207	O	serum
29	209	214	O	levels
30	216	218	O	and
31	220	227	B-UNK	valproic
32	229	232	L-UNK	acid
33	234	236	O	has
34	238	241	O	been
35	243	250	O	reported
36	252	253	O	to
37	255	258	O	both
38	260	267	O	increase
39	269	271	O	and
40	273	280	O	decrease
41	282	293	U-UNK	ethosuximide
42	295	300	O	levels
NULL

Ethotoin	DDI-DrugBank.d359.s0	NO_SECTION	NO_SETID	19
PEGANONE used in combination with other drugs known to adversely affect the hematopoietic system should be avoided if possible.
1	0	7	O	XXXXXXXX
2	9	12	O	used
3	14	15	O	in
4	17	27	O	combination
5	29	32	O	with
6	34	38	O	other
7	40	44	O	drugs
8	46	50	O	known
9	52	53	O	to
10	55	63	O	adversely
11	65	70	O	affect
12	72	74	O	the
13	76	88	O	hematopoietic
14	90	95	O	system
15	97	102	O	should
16	104	105	O	be
17	107	113	O	avoided
18	115	116	O	if
19	118	125	O	possible
NULL

Ethotoin	DDI-DrugBank.d359.s1	NO_SECTION	NO_SETID	24
Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.
1	0	11	O	Considerable
2	13	19	O	caution
3	21	26	O	should
4	28	29	O	be
5	31	39	O	exercised
6	41	42	O	if
7	44	51	O	PEGANONE
8	53	54	O	is
9	56	67	O	administered
10	69	80	O	concurrently
11	82	85	O	with
12	87	95	U-DYN	XXXXXXXX
13	98	108	U-DYN	phenacemide
14	111	115	O	since
15	117	124	O	paranoid
16	126	133	O	symptoms
17	135	138	O	have
18	140	143	O	been
19	145	152	O	reported
20	154	159	O	during
21	161	167	O	therapy
22	169	172	O	with
23	174	177	O	this
24	179	189	O	combination
NULL

Ethotoin	DDI-DrugBank.d359.s2	NO_SECTION	NO_SETID	18
A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.
1	0	0	O	A
2	2	4	O	two
3	6	8	O	way
4	10	20	O	interaction
5	22	28	O	between
6	30	32	O	the
7	34	42	B-UNK	hydantoin
8	44	56	L-UNK	antiepileptic
9	57	57	O	,
10	59	67	U-UNK	phenytoin
11	68	68	O	,
12	70	72	O	and
13	74	76	O	the
14	78	85	U-UNK	coumarin
15	87	100	O	anticoagulants
16	102	104	O	has
17	106	109	O	been
18	111	119	O	suggested
NULL

Ethotoin	DDI-DrugBank.d359.s3	NO_SECTION	NO_SETID	28
Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.
1	0	9	O	Presumably
2	10	10	O	,
3	12	20	U-UNK	phenytoin
4	22	25	O	acts
5	27	28	O	as
6	30	30	O	a
7	32	41	O	stimulator
8	43	44	O	of
9	46	53	U-UNK	coumarin
10	55	64	O	metabolism
11	66	68	O	and
12	70	72	O	has
13	74	77	O	been
14	79	86	O	reported
15	88	89	O	to
16	91	95	O	cause
17	97	105	O	decreased
18	107	111	O	serum
19	113	118	O	levels
20	120	121	O	of
21	123	125	O	the
22	127	134	B-UNK	coumarin
23	136	149	L-UNK	anticoagulants
24	151	153	O	and
25	155	163	O	increased
26	165	175	O	prothrombin
27	177	188	O	proconvertin
28	190	203	O	concentrations
NULL

Ethotoin	DDI-DrugBank.d359.s4	NO_SECTION	NO_SETID	25
Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.
1	0	9	O	Conversely
2	10	10	O	,
3	12	14	O	the
4	16	23	B-UNK	coumarin
5	25	38	L-UNK	anticoagulants
6	40	43	O	have
7	45	48	O	been
8	50	57	O	reported
9	59	60	O	to
10	62	69	O	increase
11	71	73	O	the
12	75	79	O	serum
13	81	86	O	levels
14	88	90	O	and
15	92	98	O	prolong
16	100	102	O	the
17	104	108	O	serum
18	110	113	O	half
19	115	118	O	life
20	120	121	O	of
21	123	131	U-UNK	phenytoin
22	133	134	O	by
23	136	145	O	inhibiting
24	147	149	O	its
25	151	160	O	metabolism
NULL

Ethotoin	DDI-DrugBank.d359.s5	NO_SECTION	NO_SETID	19
Although there is no documentation of such, a similar interaction between ethotoin and the coumarin anticoagulants may occur.
1	0	7	O	Although
2	9	13	O	there
3	15	16	O	is
4	18	19	O	no
5	21	33	O	documentation
6	35	36	O	of
7	38	41	O	such
8	42	42	O	,
9	44	44	O	a
10	46	52	O	similar
11	54	64	O	interaction
12	66	72	O	between
13	74	81	O	XXXXXXXX
14	83	85	O	and
15	87	89	O	the
16	91	98	B-UNK	coumarin
17	100	113	L-UNK	anticoagulants
18	115	117	O	may
19	119	123	O	occur
NULL

Ethotoin	DDI-DrugBank.d359.s6	NO_SECTION	NO_SETID	12
Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.
1	0	6	O	Caution
2	8	9	O	is
3	11	19	O	therefore
4	21	27	O	advised
5	29	32	O	when
6	34	46	O	administering
7	48	55	O	XXXXXXXX
8	57	58	O	to
9	60	67	O	patients
10	69	77	O	receiving
11	79	86	B-DYN	coumarin
12	88	101	L-DYN	anticoagulants
NULL

Ethoxzolamide	DDI-DrugBank.d286.s0	NO_SECTION	NO_SETID	14
Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
1	0	12	O	XXXXXXXX
2	14	16	O	may
3	18	25	O	increase
4	27	29	O	the
5	31	36	O	action
6	38	39	O	of
7	41	50	U-DYN	tricyclics
8	51	51	O	,
9	53	64	U-DYN	amphetamines
10	65	65	O	,
11	67	78	U-DYN	procainamide
12	79	79	O	,
13	81	83	O	and
14	85	93	U-DYN	quinidine
NULL

Ethoxzolamide	DDI-DrugBank.d286.s1	NO_SECTION	NO_SETID	19
It may increase excretion of barbiturates, lithium, and ASA and may also increase the toxicity of salicylates.
1	0	1	O	It
2	3	5	O	may
3	7	14	O	increase
4	16	24	O	excretion
5	26	27	O	of
6	29	40	U-UNK	barbiturates
7	41	41	O	,
8	43	49	U-UNK	lithium
9	50	50	O	,
10	52	54	O	and
11	56	58	U-UNK	ASA
12	60	62	O	and
13	64	66	O	may
14	68	71	O	also
15	73	80	O	increase
16	82	84	O	the
17	86	93	O	toxicity
18	95	96	O	of
19	98	108	U-UNK	salicylates
NULL

Ethoxzolamide	DDI-DrugBank.d286.s2	NO_SECTION	NO_SETID	15
Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	32	O	XXXXXXXX
4	34	37	O	with
5	39	43	O	other
6	45	53	U-DYN	diuretics
7	54	54	O	,
8	56	67	B-DYN	amphotericin
9	69	69	L-DYN	B
10	70	70	O	,
11	72	74	O	and
12	76	90	U-DYN	corticosteroids
13	92	94	O	may
14	96	100	O	cause
15	102	112	O	hypokalemia
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s0	NO_SECTION	NO_SETID	11
Ethinyl estradiol: Substrate of CYP3A4 (major), 3A5-7 (minor);
1	0	6	B-UNK	Ethinyl
2	8	16	L-UNK	estradiol
3	17	17	O	:
4	19	27	O	Substrate
5	29	30	O	of
6	32	37	O	CYP3A4
7	40	44	O	major
8	46	46	O	,
9	48	50	O	3A5
10	52	52	O	7
11	55	59	O	minor
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s1	NO_SECTION	NO_SETID	12
Inhibits CYP1A2 (weak), 2B6 (weak), 2C19 (weak), 3A4 (weak).
1	0	7	O	Inhibits
2	9	14	O	CYP1A2
3	17	20	O	weak
4	22	22	O	,
5	24	26	O	2B6
6	29	32	O	weak
7	34	34	O	,
8	36	39	O	2C19
9	42	45	O	weak
10	47	47	O	,
11	49	51	O	3A4
12	54	57	O	weak
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s2	NO_SECTION	NO_SETID	14
Acetaminophen: May increase plasma concentration of synthetic estrogens, possibly by inhibiting conjugation.
1	0	12	U-UNK	Acetaminophen
2	13	13	O	:
3	15	17	O	May
4	19	26	O	increase
5	28	33	O	plasma
6	35	47	O	concentration
7	49	50	O	of
8	52	60	B-UNK	synthetic
9	62	70	L-UNK	estrogens
10	71	71	O	,
11	73	80	O	possibly
12	82	83	O	by
13	85	94	O	inhibiting
14	96	106	O	conjugation
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s3	NO_SECTION	NO_SETID	11
Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen.
1	0	10	O	Combination
2	12	19	B-UNK	hormonal
3	21	34	L-UNK	contraceptives
4	36	38	O	may
5	40	43	O	also
6	45	52	O	decrease
7	54	56	O	the
8	58	63	O	plasma
9	65	77	O	concentration
10	79	80	O	of
11	82	94	U-UNK	acetaminophen
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s4	NO_SECTION	NO_SETID	13
Acitretin: Interferes with the contraceptive effect of microdosed progestin-containing minipill preparations.
1	0	8	U-UNK	Acitretin
2	9	9	O	:
3	11	20	O	Interferes
4	22	25	O	with
5	27	29	O	the
6	31	43	O	contraceptive
7	45	50	O	effect
8	52	53	O	of
9	55	64	O	microdosed
10	66	74	U-UNK	progestin
11	76	85	O	containing
12	87	94	O	minipill
13	96	107	O	preparations
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s5	NO_SECTION	NO_SETID	13
The effect on other progestational contraceptives (eg, implants, injectables) is unknown.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	on
4	14	18	O	other
5	20	33	B-UNK	progestational
6	35	48	L-UNK	contraceptives
7	51	52	O	eg
8	53	53	O	,
9	55	62	O	implants
10	63	63	O	,
11	65	75	O	injectables
12	78	79	O	is
13	81	87	O	unknown
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s6	NO_SECTION	NO_SETID	15
Aminoglutethimide: May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.
1	0	16	U-UNK	Aminoglutethimide
2	17	17	O	:
3	19	21	O	May
4	23	30	O	increase
5	32	34	O	CYP
6	36	45	O	metabolism
7	47	48	O	of
8	50	59	U-UNK	progestins
9	61	67	O	leading
10	69	70	O	to
11	72	79	O	possible
12	81	88	O	decrease
13	90	91	O	in
14	93	105	O	contraceptive
15	107	119	O	effectiveness
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s7	NO_SECTION	NO_SETID	8
Use of a nonhormonal contraceptive product is recommended.
1	0	2	O	Use
2	4	5	O	of
3	7	7	O	a
4	9	19	B-UNK	nonhormonal
5	21	33	I-UNK	contraceptive
6	35	41	L-UNK	product
7	43	44	O	is
8	46	56	O	recommended
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s8	NO_SECTION	NO_SETID	31
Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.
1	0	10	U-UNK	Antibiotics
2	13	22	U-UNK	ampicillin
3	23	23	O	,
4	25	36	U-UNK	tetracycline
5	38	38	O	:
6	40	48	O	Pregnancy
7	50	52	O	has
8	54	57	O	been
9	59	66	O	reported
10	68	76	O	following
11	78	88	O	concomitant
12	90	92	O	use
13	93	93	O	,
14	95	101	O	however
15	102	102	O	,
16	104	118	O	pharmacokinetic
17	120	126	O	studies
18	128	131	O	have
19	133	135	O	not
20	137	141	O	shown
21	143	152	O	consistent
22	154	160	O	effects
23	162	165	O	with
24	167	171	O	these
25	173	183	U-UNK	antibiotics
26	185	186	O	on
27	188	193	O	plasma
28	195	208	O	concentrations
29	210	211	O	of
30	213	221	B-UNK	synthetic
31	223	230	L-UNK	steroids
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s9	NO_SECTION	NO_SETID	8
Use of a nonhormonal contraceptive product is recommended.
1	0	2	O	Use
2	4	5	O	of
3	7	7	O	a
4	9	19	B-UNK	nonhormonal
5	21	33	I-UNK	contraceptive
6	35	41	L-UNK	product
7	43	44	O	is
8	46	56	O	recommended
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s10	NO_SECTION	NO_SETID	14
Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.
1	0	13	U-UNK	Anticoagulants
2	14	14	O	:
3	16	26	O	Combination
4	28	35	B-UNK	hormonal
5	37	50	L-UNK	contraceptives
6	52	54	O	may
7	56	63	O	increase
8	65	66	O	or
9	68	75	O	decrease
10	77	79	O	the
11	81	87	O	effects
12	89	90	O	of
13	92	99	B-UNK	coumarin
14	101	111	L-UNK	derivatives
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s11	NO_SECTION	NO_SETID	10
Combination hormonal contraceptives may also increase risk of thromboembolic disorders.
1	0	10	O	Combination
2	12	19	B-UNK	hormonal
3	21	34	L-UNK	contraceptives
4	36	38	O	may
5	40	43	O	also
6	45	52	O	increase
7	54	57	O	risk
8	59	60	O	of
9	62	75	O	thromboembolic
10	77	85	O	disorders
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s12	NO_SECTION	NO_SETID	30
Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
1	0	14	U-UNK	Anticonvulsants
2	17	29	U-UNK	carbamazepine
3	30	30	O	,
4	32	40	U-UNK	felbamate
5	41	41	O	,
6	43	55	U-UNK	phenobarbital
7	56	56	O	,
8	58	66	U-UNK	phenytoin
9	67	67	O	,
10	69	78	U-UNK	topiramate
11	80	80	O	:
12	82	89	O	Increase
13	91	93	O	the
14	95	104	O	metabolism
15	106	107	O	of
16	109	115	B-UNK	ethinyl
17	117	125	L-UNK	estradiol
18	127	129	O	and
19	130	130	O	/
20	131	132	O	or
21	134	137	O	some
22	139	148	U-UNK	progestins
23	149	149	O	,
24	151	157	O	leading
25	159	160	O	to
26	162	169	O	possible
27	171	178	O	decrease
28	180	181	O	in
29	183	195	O	contraceptive
30	197	209	O	effectiveness
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s13	NO_SECTION	NO_SETID	8
Use of a nonhormonal contraceptive product is recommended.
1	0	2	O	Use
2	4	5	O	of
3	7	7	O	a
4	9	19	B-UNK	nonhormonal
5	21	33	I-UNK	contraceptive
6	35	41	L-UNK	product
7	43	44	O	is
8	46	56	O	recommended
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s14	NO_SECTION	NO_SETID	30
Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;
1	0	7	B-UNK	Ascorbic
2	9	12	L-UNK	acid
3	13	13	O	:
4	15	19	O	Doses
5	21	22	O	of
6	24	31	B-UNK	ascorbic
7	33	36	L-UNK	acid
8	39	45	B-UNK	vitamin
9	47	47	L-UNK	C
10	50	50	O	1
11	52	52	O	g
12	53	53	O	/
13	54	56	O	day
14	58	61	O	have
15	63	66	O	been
16	68	75	O	reported
17	77	78	O	to
18	80	87	O	increase
19	89	94	O	plasma
20	96	108	O	concentration
21	110	111	O	of
22	113	121	B-UNK	synthetic
23	123	131	L-UNK	estrogens
24	133	134	O	by
25	136	139	O	~47%
26	140	140	O	,
27	142	149	O	possibly
28	151	152	O	by
29	154	163	O	inhibiting
30	165	175	O	conjugation
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s15	NO_SECTION	NO_SETID	4
clinical implications are unclear.
1	0	7	O	clinical
2	9	20	O	implications
3	22	24	O	are
4	26	32	O	unclear
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s16	NO_SECTION	NO_SETID	11
Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.
1	0	11	U-UNK	Atorvastatin
2	12	12	O	:
3	14	25	U-UNK	Atorvastatin
4	27	35	O	increases
5	37	39	O	the
6	41	43	O	AUC
7	45	47	O	for
8	49	61	U-UNK	norethindrone
9	63	65	O	and
10	67	73	B-UNK	ethinyl
11	75	83	L-UNK	estradiol
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s17	NO_SECTION	NO_SETID	28
Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
1	0	14	U-UNK	Benzodiazepines
2	15	15	O	:
3	17	27	O	Combination
4	29	36	B-UNK	hormonal
5	38	51	L-UNK	contraceptives
6	53	55	O	may
7	57	64	O	decrease
8	66	68	O	the
9	70	78	O	clearance
10	80	81	O	of
11	83	86	O	some
12	88	102	U-UNK	benzodiazepines
13	105	114	U-UNK	alprazolam
14	115	115	O	,
15	117	132	U-UNK	chlordiazepoxide
16	133	133	O	,
17	135	142	U-UNK	diazepam
18	145	147	O	and
19	149	156	O	increase
20	158	160	O	the
21	162	170	O	clearance
22	172	173	O	of
23	175	180	O	others
24	183	191	U-UNK	lorazepam
25	192	192	O	,
26	194	201	U-UNK	oxazepam
27	202	202	O	,
28	204	212	U-UNK	temazepam
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s18	NO_SECTION	NO_SETID	13
Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.
1	0	8	B-UNK	Clofibric
2	10	13	L-UNK	acid
3	14	14	O	:
4	16	26	O	Combination
5	28	35	B-UNK	hormonal
6	37	50	L-UNK	contraceptives
7	52	54	O	may
8	56	63	O	increase
9	65	67	O	the
10	69	77	O	clearance
11	79	80	O	of
12	82	90	B-UNK	clofibric
13	92	95	L-UNK	acid
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s19	NO_SECTION	NO_SETID	17
Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;
1	0	11	U-UNK	Cyclosporine
2	12	12	O	:
3	14	24	O	Combination
4	26	33	B-UNK	hormonal
5	35	48	L-UNK	contraceptives
6	50	52	O	may
7	54	60	O	inhibit
8	62	64	O	the
9	66	75	O	metabolism
10	77	78	O	of
11	80	91	U-UNK	cyclosporine
12	92	92	O	,
13	94	100	O	leading
14	102	103	O	to
15	105	113	O	increased
16	115	120	O	plasma
17	122	135	O	concentrations
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s20	NO_SECTION	NO_SETID	3
monitor cyclosporine levels.
1	0	6	O	monitor
2	8	19	U-UNK	cyclosporine
3	21	26	O	levels
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s21	NO_SECTION	NO_SETID	14
CYP3A4 inducers: CYP3A4 inducers may decrease the levels/effects of ethinyl estradiol.
1	0	5	O	CYP3A4
2	7	14	O	inducers
3	15	15	O	:
4	17	22	O	CYP3A4
5	24	31	O	inducers
6	33	35	O	may
7	37	44	O	decrease
8	46	48	O	the
9	50	55	O	levels
10	56	56	O	/
11	57	63	O	effects
12	65	66	O	of
13	68	74	B-UNK	ethinyl
14	76	84	L-UNK	estradiol
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s22	NO_SECTION	NO_SETID	17
Example inducers include aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins.
1	0	6	O	Example
2	8	15	O	inducers
3	17	23	O	include
4	25	41	U-UNK	aminoglutethimide
5	42	42	O	,
6	44	56	U-UNK	carbamazepine
7	57	57	O	,
8	59	67	U-UNK	nafcillin
9	68	68	O	,
10	70	79	U-UNK	nevirapine
11	80	80	O	,
12	82	94	U-UNK	phenobarbital
13	95	95	O	,
14	97	105	U-UNK	phenytoin
15	106	106	O	,
16	108	110	O	and
17	112	121	U-UNK	rifamycins
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s23	NO_SECTION	NO_SETID	14
Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;
1	0	11	U-UNK	Griseofulvin
2	12	12	O	:
3	14	25	U-UNK	Griseofulvin
4	27	29	O	may
5	31	36	O	induce
6	38	40	O	the
7	42	51	O	metabolism
8	53	54	O	of
9	56	66	B-UNK	combination
10	68	75	I-UNK	hormonal
11	77	90	L-UNK	contraceptives
12	92	98	O	causing
13	100	108	O	menstrual
14	110	116	O	changes
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s24	NO_SECTION	NO_SETID	4
pregnancies have been reported.
1	0	10	O	pregnancies
2	12	15	O	have
3	17	20	O	been
4	22	29	O	reported
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s25	NO_SECTION	NO_SETID	12
Use of barrier form of contraception is suggested while on griseofulvin therapy.
1	0	2	O	Use
2	4	5	O	of
3	7	13	O	barrier
4	15	18	O	form
5	20	21	O	of
6	23	35	O	contraception
7	37	38	O	is
8	40	48	O	suggested
9	50	54	O	while
10	56	57	O	on
11	59	70	U-UNK	griseofulvin
12	72	78	O	therapy
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s26	NO_SECTION	NO_SETID	11
Morphine: Combination hormonal contraceptives may increase the clearance of morphine.
1	0	7	U-UNK	Morphine
2	8	8	O	:
3	10	20	O	Combination
4	22	29	B-UNK	hormonal
5	31	44	L-UNK	contraceptives
6	46	48	O	may
7	50	57	O	increase
8	59	61	O	the
9	63	71	O	clearance
10	73	74	O	of
11	76	83	U-UNK	morphine
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s27	NO_SECTION	NO_SETID	16
Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;
1	0	2	B-UNK	Non
2	4	13	I-UNK	nucleoside
3	15	21	I-UNK	reverse
4	23	35	I-UNK	transcriptase
5	37	46	L-UNK	inhibitors
6	49	54	U-UNK	NNRTIs
7	56	56	O	:
8	58	67	U-UNK	Nevirapine
9	69	71	O	may
10	73	80	O	decrease
11	82	87	O	plasma
12	89	94	O	levels
13	96	97	O	of
14	99	109	B-UNK	combination
15	111	118	I-UNK	hormonal
16	120	133	L-UNK	contraceptives
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s28	NO_SECTION	NO_SETID	8
use of a nonhormonal contraceptive product is recommended.
1	0	2	O	use
2	4	5	O	of
3	7	7	O	a
4	9	19	B-UNK	nonhormonal
5	21	33	I-UNK	contraceptive
6	35	41	L-UNK	product
7	43	44	O	is
8	46	56	O	recommended
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s29	NO_SECTION	NO_SETID	4
No data for delavirdine;
1	0	1	O	No
2	3	6	O	data
3	8	10	O	for
4	12	22	U-UNK	delavirdine
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s30	NO_SECTION	NO_SETID	4
incomplete data for efavirenz.
1	0	9	O	incomplete
2	11	14	O	data
3	16	18	O	for
4	20	28	U-UNK	efavirenz
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s31	NO_SECTION	NO_SETID	16
Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.
1	0	11	U-UNK	Prednisolone
2	12	12	O	:
3	14	20	B-UNK	Ethinyl
4	22	30	L-UNK	estradiol
5	32	34	O	may
6	36	42	O	inhibit
7	44	46	O	the
8	48	57	O	metabolism
9	59	60	O	of
10	62	73	U-UNK	prednisolone
11	74	74	O	,
12	76	82	O	leading
13	84	85	O	to
14	87	95	O	increased
15	97	102	O	plasma
16	104	117	O	concentrations
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s32	NO_SECTION	NO_SETID	22
Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
1	0	7	B-UNK	Protease
2	9	18	L-UNK	inhibitors
3	19	19	O	:
4	21	30	U-UNK	Amprenavir
5	31	31	O	,
6	33	41	U-UNK	lopinavir
7	42	42	O	,
8	44	53	U-UNK	nelfinavir
9	54	54	O	,
10	56	58	O	and
11	60	68	U-UNK	ritonavir
12	70	73	O	have
13	75	78	O	been
14	80	84	O	shown
15	86	87	O	to
16	89	96	O	decrease
17	98	103	O	plasma
18	105	110	O	levels
19	112	113	O	of
20	115	125	B-UNK	combination
21	127	134	I-UNK	hormonal
22	136	149	L-UNK	contraceptives
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s33	NO_SECTION	NO_SETID	8
use of a nonhormonal contraceptive product is recommended.
1	0	2	O	use
2	4	5	O	of
3	7	7	O	a
4	9	19	B-UNK	nonhormonal
5	21	33	I-UNK	contraceptive
6	35	41	L-UNK	product
7	43	44	O	is
8	46	56	O	recommended
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s34	NO_SECTION	NO_SETID	12
Indinavir has been shown to increase plasma levels of combination hormonal contraceptives.
1	0	8	U-UNK	Indinavir
2	10	12	O	has
3	14	17	O	been
4	19	23	O	shown
5	25	26	O	to
6	28	35	O	increase
7	37	42	O	plasma
8	44	49	O	levels
9	51	52	O	of
10	54	64	B-UNK	combination
11	66	73	I-UNK	hormonal
12	75	88	L-UNK	contraceptives
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s35	NO_SECTION	NO_SETID	4
No data for saquinavir.
1	0	1	O	No
2	3	6	O	data
3	8	10	O	for
4	12	21	U-UNK	saquinavir
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s36	NO_SECTION	NO_SETID	22
Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.
1	0	7	U-UNK	Rifampin
2	8	8	O	:
3	10	17	U-UNK	Rifampin
4	19	27	O	increases
5	29	31	O	the
6	33	42	O	metabolism
7	44	45	O	of
8	47	53	B-UNK	ethinyl
9	55	63	L-UNK	estradiol
10	65	67	O	and
11	69	72	O	some
12	74	83	U-UNK	progestins
13	86	98	U-UNK	norethindrone
14	101	109	O	resulting
15	111	112	O	in
16	114	122	O	decreased
17	124	136	O	contraceptive
18	138	150	O	effectiveness
19	152	154	O	and
20	156	164	O	increased
21	166	174	O	menstrual
22	176	189	O	irregularities
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s37	NO_SECTION	NO_SETID	8
Use of a nonhormonal contraceptive product is recommended.
1	0	2	O	Use
2	4	5	O	of
3	7	7	O	a
4	9	19	B-UNK	nonhormonal
5	21	33	I-UNK	contraceptive
6	35	41	L-UNK	product
7	43	44	O	is
8	46	56	O	recommended
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s38	NO_SECTION	NO_SETID	13
Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.
1	0	8	B-UNK	Salicylic
2	10	13	L-UNK	acid
3	14	14	O	:
4	16	26	O	Combination
5	28	35	B-UNK	hormonal
6	37	50	L-UNK	contraceptives
7	52	54	O	may
8	56	63	O	increase
9	65	67	O	the
10	69	77	O	clearance
11	79	80	O	of
12	82	90	B-UNK	salicylic
13	92	95	L-UNK	acid
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s39	NO_SECTION	NO_SETID	12
Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.
1	0	9	U-UNK	Selegiline
2	10	10	O	:
3	12	22	B-UNK	Combination
4	24	31	I-UNK	hormonal
5	33	46	L-UNK	contraceptives
6	48	50	O	may
7	52	59	O	increase
8	61	63	O	the
9	65	69	O	serum
10	71	83	O	concentration
11	85	86	O	of
12	88	97	U-UNK	selegiline
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s40	NO_SECTION	NO_SETID	16
Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.
1	0	11	U-UNK	Theophylline
2	12	12	O	:
3	14	20	B-UNK	Ethinyl
4	22	30	L-UNK	estradiol
5	32	34	O	may
6	36	42	O	inhibit
7	44	46	O	the
8	48	57	O	metabolism
9	59	60	O	of
10	62	73	U-UNK	theophylline
11	74	74	O	,
12	76	82	O	leading
13	84	85	O	to
14	87	95	O	increased
15	97	102	O	plasma
16	104	117	O	concentrations
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s41	NO_SECTION	NO_SETID	22
Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
1	0	8	B-UNK	Tricyclic
2	10	24	L-UNK	antidepressants
3	27	39	U-UNK	amitriptyline
4	40	40	O	,
5	42	51	U-UNK	imipramine
6	52	52	O	,
7	54	66	U-UNK	nortriptyline
8	68	68	O	:
9	70	79	O	Metabolism
10	81	83	O	may
11	85	86	O	be
12	88	96	O	inhibited
13	98	99	O	by
14	101	111	B-UNK	combination
15	113	120	I-UNK	hormonal
16	122	135	L-UNK	contraceptives
17	136	136	O	,
18	138	147	O	increasing
19	149	154	O	plasma
20	156	161	O	levels
21	163	164	O	of
22	166	179	U-UNK	antidepressant
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s43	NO_SECTION	NO_SETID	25
ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.
1	0	6	U-UNK	ETHANOL
2	8	8	O	/
3	10	18	O	NUTRITION
4	20	20	O	/
5	22	25	O	HERB
6	27	38	O	INTERACTIONS
7	39	39	O	:
8	41	44	O	Food
9	45	45	O	:
10	47	49	O	CNS
11	51	57	O	effects
12	59	60	O	of
13	62	69	U-UNK	caffeine
14	71	73	O	may
15	75	76	O	be
16	78	85	O	enhanced
17	87	88	O	if
18	90	100	B-UNK	combination
19	102	109	I-UNK	hormonal
20	111	124	L-UNK	contraceptives
21	126	128	O	are
22	130	133	O	used
23	135	146	O	concurrently
24	148	151	O	with
25	153	160	U-UNK	caffeine
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s44	NO_SECTION	NO_SETID	17
Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well;
1	0	9	O	Grapefruit
2	11	15	O	juice
3	17	25	O	increases
4	27	33	B-UNK	ethinyl
5	35	43	L-UNK	estradiol
6	45	58	O	concentrations
7	60	62	O	and
8	64	68	O	would
9	70	71	O	be
10	73	80	O	expected
11	82	83	O	to
12	85	92	O	increase
13	94	105	U-UNK	progesterone
14	107	111	O	serum
15	113	118	O	levels
16	120	121	O	as
17	123	126	O	well
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s45	NO_SECTION	NO_SETID	4
clinical implications are unclear.
1	0	7	O	clinical
2	9	20	O	implications
3	22	24	O	are
4	26	32	O	unclear
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s46	NO_SECTION	NO_SETID	19
Herb/Nutraceutical: St Johns wort may decrease the effectiveness of combination hormonal contraceptives by inducing hepatic enzymes.
1	0	3	O	Herb
2	4	4	O	/
3	5	17	O	Nutraceutical
4	18	18	O	:
5	20	21	O	St
6	23	27	O	Johns
7	29	32	O	wort
8	34	36	O	may
9	38	45	O	decrease
10	47	49	O	the
11	51	63	O	effectiveness
12	65	66	O	of
13	68	78	B-UNK	combination
14	80	87	I-UNK	hormonal
15	89	102	L-UNK	contraceptives
16	104	105	O	by
17	107	114	O	inducing
18	116	122	O	hepatic
19	124	130	O	enzymes
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s47	NO_SECTION	NO_SETID	9
Avoid dong quai and black cohosh (have estrogen activity).
1	0	4	O	Avoid
2	6	9	O	dong
3	11	14	O	quai
4	16	18	O	and
5	20	24	O	black
6	26	31	O	cohosh
7	34	37	O	have
8	39	46	O	estrogen
9	48	55	O	activity
NULL

Ethynodiol Diacetate	DDI-DrugBank.d485.s48	NO_SECTION	NO_SETID	8
Avoid saw palmetto, red clover, ginseng.
1	0	4	O	Avoid
2	6	8	O	saw
3	10	17	O	palmetto
4	18	18	O	,
5	20	22	O	red
6	24	29	O	clover
7	30	30	O	,
8	32	38	O	ginseng
NULL

Etidronic acid	DDI-DrugBank.d327.s0	NO_SECTION	NO_SETID	20
There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	23	O	isolated
5	25	31	O	reports
6	33	34	O	of
7	36	43	O	patients
8	45	56	O	experiencing
9	58	66	O	increases
10	68	69	O	in
11	71	75	O	their
12	77	87	O	prothrombin
13	89	93	O	times
14	95	98	O	when
15	100	109	U-UNK	etidronate
16	111	113	O	was
17	115	119	O	added
18	121	122	O	to
19	124	131	U-UNK	warfarin
20	133	139	O	therapy
NULL

Etidronic acid	DDI-DrugBank.d327.s1	NO_SECTION	NO_SETID	15
The majority of these reports concerned variable elevations in prothrombin times without clinically significant sequelae.
1	0	2	O	The
2	4	11	O	majority
3	13	14	O	of
4	16	20	O	these
5	22	28	O	reports
6	30	38	O	concerned
7	40	47	O	variable
8	49	58	O	elevations
9	60	61	O	in
10	63	73	O	prothrombin
11	75	79	O	times
12	81	87	O	without
13	89	98	O	clinically
14	100	110	O	significant
15	112	119	O	sequelae
NULL

Etidronic acid	DDI-DrugBank.d327.s2	NO_SECTION	NO_SETID	24
Although the relevance of these reports and any mechanism of coagulation alterations is unclear, patients on warfarin should have their prothrombin time monitored.
1	0	7	O	Although
2	9	11	O	the
3	13	21	O	relevance
4	23	24	O	of
5	26	30	O	these
6	32	38	O	reports
7	40	42	O	and
8	44	46	O	any
9	48	56	O	mechanism
10	58	59	O	of
11	61	71	O	coagulation
12	73	83	O	alterations
13	85	86	O	is
14	88	94	O	unclear
15	95	95	O	,
16	97	104	O	patients
17	106	107	O	on
18	109	116	U-UNK	warfarin
19	118	123	O	should
20	125	128	O	have
21	130	134	O	their
22	136	146	O	prothrombin
23	148	151	O	time
24	153	161	O	monitored
NULL

Etodolac	DDI-DrugBank.d219.s0	NO_SECTION	NO_SETID	14
ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
1	0	2	B-UNK	ACE
2	4	13	L-UNK	inhibitors
3	15	21	O	Reports
4	23	29	O	suggest
5	31	34	O	that
6	36	41	U-UNK	NSAIDs
7	43	45	O	may
8	47	54	O	diminish
9	56	58	O	the
10	60	75	O	antihypertensive
11	77	82	O	effect
12	84	85	O	of
13	87	89	B-UNK	ACE
14	91	100	L-UNK	inhibitors
NULL

Etodolac	DDI-DrugBank.d219.s1	NO_SECTION	NO_SETID	14
This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.
1	0	3	O	This
2	5	15	O	interaction
3	17	22	O	should
4	24	25	O	be
5	27	31	O	given
6	33	45	O	consideration
7	47	48	O	in
8	50	57	O	patients
9	59	64	O	taking
10	66	71	U-UNK	NSAIDs
11	73	85	O	concomitantly
12	87	90	O	with
13	92	94	B-UNK	ACE
14	96	105	L-UNK	inhibitors
NULL

Etodolac	DDI-DrugBank.d219.s2	NO_SECTION	NO_SETID	18
Antacids: The concomitant administration of antacids has no apparent effect on the extent of absorption of Lodine.
1	0	7	U-UNK	Antacids
2	8	8	O	:
3	10	12	O	The
4	14	24	O	concomitant
5	26	39	O	administration
6	41	42	O	of
7	44	51	U-UNK	antacids
8	53	55	O	has
9	57	58	O	no
10	60	67	O	apparent
11	69	74	O	effect
12	76	77	O	on
13	79	81	O	the
14	83	88	O	extent
15	90	91	O	of
16	93	102	O	absorption
17	104	105	O	of
18	107	112	O	XXXXXXXX
NULL

Etodolac	DDI-DrugBank.d219.s3	NO_SECTION	NO_SETID	23
However, antacids can decrease the peak concentration reached by 15% to 20% but have no detectable effect on the time-to-peak.
1	0	6	O	However
2	7	7	O	,
3	9	16	U-UNK	antacids
4	18	20	O	can
5	22	29	O	decrease
6	31	33	O	the
7	35	38	O	peak
8	40	52	O	concentration
9	54	60	O	reached
10	62	63	O	by
11	65	67	O	15%
12	69	70	O	to
13	72	74	O	20%
14	76	78	O	but
15	80	83	O	have
16	85	86	O	no
17	88	97	O	detectable
18	99	104	O	effect
19	106	107	O	on
20	109	111	O	the
21	113	116	O	time
22	118	119	O	to
23	121	124	O	peak
NULL

Etodolac	DDI-DrugBank.d219.s4	NO_SECTION	NO_SETID	24
Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.
1	0	6	O	XXXXXXXX
2	7	7	O	:
3	9	12	O	When
4	14	19	O	Lodine
5	21	22	O	is
6	24	35	O	administered
7	37	40	O	with
8	42	48	U-KIN	XXXXXXXX
9	49	49	O	,
10	51	53	O	its
11	55	61	O	protein
12	63	69	O	binding
13	71	72	O	is
14	74	80	O	reduced
15	81	81	O	,
16	83	90	O	although
17	92	94	O	the
18	96	104	O	clearance
19	106	107	O	of
20	109	112	O	free
21	114	121	U-UNK	etodolac
22	123	124	O	is
23	126	128	O	not
24	130	136	O	altered
NULL

Etodolac	DDI-DrugBank.d219.s5	NO_SECTION	NO_SETID	9
The clinical significance of this interaction is not known;
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	44	O	interaction
7	46	47	O	is
8	49	51	O	not
9	53	57	O	known
NULL

Etodolac	DDI-DrugBank.d219.s6	NO_SECTION	NO_SETID	25
however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.
1	0	6	O	however
2	7	7	O	,
3	9	10	O	as
4	12	15	O	with
5	17	21	O	other
6	23	28	U-UNK	NSAIDs
7	29	29	O	,
8	31	41	O	concomitant
9	43	56	O	administration
10	58	59	O	of
11	61	66	O	Lodine
12	68	70	O	and
13	72	78	U-DYN	XXXXXXXX
14	80	81	O	is
15	83	85	O	not
16	87	95	O	generally
17	97	107	O	recommended
18	109	115	O	because
19	117	118	O	of
20	120	122	O	the
21	124	132	O	potential
22	134	135	O	of
23	137	145	O	increased
24	147	153	O	adverse
25	155	161	O	effects
NULL

Etodolac	DDI-DrugBank.d219.s7	NO_SECTION	NO_SETID	41
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
1	0	11	O	Cyclosporine
2	12	12	O	,
3	14	20	O	Digoxin
4	21	21	O	,
5	23	34	O	Methotrexate
6	36	41	O	XXXXXXXX
7	42	42	O	,
8	44	47	O	like
9	49	53	O	other
10	55	60	U-UNK	NSAIDs
11	61	61	O	,
12	63	69	O	through
13	71	77	O	effects
14	79	80	O	on
15	82	86	O	renal
16	88	101	O	prostaglandins
17	102	102	O	,
18	104	106	O	may
19	108	112	O	cause
20	114	120	O	changes
21	122	123	O	in
22	125	127	O	the
23	129	139	O	elimination
24	141	142	O	of
25	144	148	O	these
26	150	154	O	drugs
27	156	162	O	leading
28	164	165	O	to
29	167	174	O	elevated
30	176	180	O	serum
31	182	187	O	levels
32	189	190	O	of
33	192	203	U-KIN	cyclosporine
34	204	204	O	,
35	206	212	U-KIN	digoxin
36	213	213	O	,
37	215	226	U-KIN	methotrexate
38	227	227	O	,
39	229	231	O	and
40	233	241	O	increased
41	243	250	O	toxicity
NULL

Etodolac	DDI-DrugBank.d219.s8	NO_SECTION	NO_SETID	8
Nephrotoxicity associated with cyclosporine may also be enhanced.
1	0	13	O	Nephrotoxicity
2	15	24	O	associated
3	26	29	O	with
4	31	42	U-UNK	cyclosporine
5	44	46	O	may
6	48	51	O	also
7	53	54	O	be
8	56	63	O	enhanced
NULL

Etodolac	DDI-DrugBank.d219.s9	NO_SECTION	NO_SETID	36
Patients receiving these drugs who are given Lodine, or any other NSAID, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	23	O	these
4	25	29	O	drugs
5	31	33	O	who
6	35	37	O	are
7	39	43	O	given
8	45	50	O	XXXXXXXX
9	51	51	O	,
10	53	54	O	or
11	56	58	O	any
12	60	64	O	other
13	66	70	U-UNK	NSAID
14	71	71	O	,
15	73	75	O	and
16	77	88	O	particularly
17	90	94	O	those
18	96	103	O	patients
19	105	108	O	with
20	110	116	O	altered
21	118	122	O	renal
22	124	131	O	function
23	132	132	O	,
24	134	139	O	should
25	141	142	O	be
26	144	151	O	observed
27	153	155	O	for
28	157	159	O	the
29	161	171	O	development
30	173	174	O	of
31	176	178	O	the
32	180	187	O	specific
33	189	198	O	toxicities
34	200	201	O	of
35	203	207	O	these
36	209	213	O	drugs
NULL

Etodolac	DDI-DrugBank.d219.s10	NO_SECTION	NO_SETID	14
Diuretics: Etodolac has no apparent pharmacokinetic interaction when administered with furosemide or hydrochlorothiazide.
1	0	8	U-UNK	Diuretics
2	9	9	O	:
3	11	18	O	XXXXXXXX
4	20	22	O	has
5	24	25	O	no
6	27	34	O	apparent
7	36	50	O	pharmacokinetic
8	52	62	O	interaction
9	64	67	O	when
10	69	80	O	administered
11	82	85	O	with
12	87	96	U-UNK	furosemide
13	98	99	O	or
14	101	119	U-UNK	hydrochlorothiazide
NULL

Etodolac	DDI-DrugBank.d219.s11	NO_SECTION	NO_SETID	26
Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	21	O	clinical
4	23	29	O	studies
5	30	30	O	,
6	32	33	O	as
7	35	38	O	well
8	40	41	O	as
9	43	55	O	postmarketing
10	57	68	O	observations
11	70	73	O	have
12	75	79	O	shown
13	81	84	O	that
14	86	91	O	XXXXXXXX
15	93	95	O	can
16	97	102	O	reduce
17	104	106	O	the
18	108	118	O	natriuretic
19	120	125	O	effect
20	127	128	O	of
21	130	139	U-DYN	furosemide
22	141	143	O	and
23	145	153	U-DYN	thiazides
24	155	156	O	in
25	158	161	O	some
26	163	170	O	patients
NULL

Etodolac	DDI-DrugBank.d219.s12	NO_SECTION	NO_SETID	11
This response has been attributed to inhibition of renal prostaglandin synthesis.
1	0	3	O	This
2	5	12	O	response
3	14	16	O	has
4	18	21	O	been
5	23	32	O	attributed
6	34	35	O	to
7	37	46	O	inhibition
8	48	49	O	of
9	51	55	O	renal
10	57	69	O	prostaglandin
11	71	79	O	synthesis
NULL

Etodolac	DDI-DrugBank.d219.s13	NO_SECTION	NO_SETID	25
During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
1	0	5	O	During
2	7	17	O	concomitant
3	19	25	O	therapy
4	27	30	O	with
5	32	37	U-UNK	NSAIDs
6	38	38	O	,
7	40	42	O	the
8	44	50	O	patient
9	52	57	O	should
10	59	60	O	be
11	62	69	O	observed
12	71	77	O	closely
13	79	81	O	for
14	83	87	O	signs
15	89	90	O	of
16	92	96	O	renal
17	98	104	O	failure
18	105	105	O	,
19	107	108	O	as
20	110	113	O	well
21	115	116	O	as
22	118	119	O	to
23	121	126	O	assure
24	128	135	O	diuretic
25	137	144	O	efficacy
NULL

Etodolac	DDI-DrugBank.d219.s14	NO_SECTION	NO_SETID	12
Glyburide: Etodolac has no apparent pharmacokinetic interaction when administered with glyburide.
1	0	8	U-UNK	Glyburide
2	9	9	O	:
3	11	18	O	XXXXXXXX
4	20	22	O	has
5	24	25	O	no
6	27	34	O	apparent
7	36	50	O	pharmacokinetic
8	52	62	O	interaction
9	64	67	O	when
10	69	80	O	administered
11	82	85	O	with
12	87	95	U-UNK	glyburide
NULL

Etodolac	DDI-DrugBank.d219.s15	NO_SECTION	NO_SETID	18
Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	14	U-UNK	NSAIDs
4	16	19	O	have
5	21	28	O	produced
6	30	31	O	an
7	33	41	O	elevation
8	43	44	O	of
9	46	51	O	plasma
10	53	59	U-UNK	lithium
11	61	66	O	levels
12	68	70	O	and
13	72	72	O	a
14	74	82	O	reduction
15	84	85	O	in
16	87	91	O	renal
17	93	99	U-UNK	lithium
18	101	109	O	clearance
NULL

Etodolac	DDI-DrugBank.d219.s16	NO_SECTION	NO_SETID	16
The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%.
1	0	2	O	The
2	4	7	O	mean
3	9	15	O	minimum
4	17	23	U-UNK	lithium
5	25	37	O	concentration
6	39	47	O	increased
7	49	51	O	15%
8	53	55	O	and
9	57	59	O	the
10	61	65	O	renal
11	67	75	O	clearance
12	77	79	O	was
13	81	89	O	decreased
14	91	92	O	by
15	94	106	O	approximately
16	108	110	O	20%
NULL

Etodolac	DDI-DrugBank.d219.s17	NO_SECTION	NO_SETID	14
These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID.
1	0	4	O	These
2	6	12	O	effects
3	14	17	O	have
4	19	22	O	been
5	24	33	O	attributed
6	35	36	O	to
7	38	47	O	inhibition
8	49	50	O	of
9	52	56	O	renal
10	58	70	O	prostaglandin
11	72	80	O	synthesis
12	82	83	O	by
13	85	87	O	the
14	89	93	U-UNK	NSAID
NULL

Etodolac	DDI-DrugBank.d219.s18	NO_SECTION	NO_SETID	20
Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
1	0	3	O	Thus
2	4	4	O	,
3	6	9	O	when
4	11	16	U-UNK	NSAIDs
5	18	20	O	and
6	22	28	U-UNK	lithium
7	30	32	O	are
8	34	45	O	administered
9	47	58	O	concurrently
10	59	59	O	,
11	61	68	O	subjects
12	70	75	O	should
13	77	78	O	be
14	80	87	O	observed
15	89	97	O	carefully
16	99	101	O	for
17	103	107	O	signs
18	109	110	O	of
19	112	118	U-UNK	lithium
20	120	127	O	toxicity
NULL

Etodolac	DDI-DrugBank.d219.s19	NO_SECTION	NO_SETID	14
Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.
1	0	13	U-UNK	Phenylbutazone
2	14	14	O	:
3	16	29	U-KIN	Phenylbutazone
4	31	36	O	causes
5	38	45	O	increase
6	48	49	O	by
7	51	55	O	about
8	57	59	O	80%
9	62	63	O	in
10	65	67	O	the
11	69	72	O	free
12	74	81	O	fraction
13	83	84	O	of
14	86	93	O	XXXXXXXX
NULL

Etodolac	DDI-DrugBank.d219.s20	NO_SECTION	NO_SETID	28
Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.
1	0	7	O	Although
2	9	10	O	in
3	12	15	O	vivo
4	17	23	O	studies
5	25	28	O	have
6	30	32	O	not
7	34	37	O	been
8	39	42	O	done
9	44	45	O	to
10	47	49	O	see
11	51	52	O	if
12	54	61	O	XXXXXXXX
13	63	71	O	clearance
14	73	74	O	is
15	76	82	O	changed
16	84	85	O	by
17	87	102	O	coadministration
18	104	105	O	of
19	107	120	U-DYN	phenylbutazone
20	121	121	O	,
21	123	124	O	it
22	126	127	O	is
23	129	131	O	not
24	133	143	O	recommended
25	145	148	O	that
26	150	153	O	they
27	155	156	O	be
28	158	171	O	coadministered
NULL

Etodolac	DDI-DrugBank.d219.s21	NO_SECTION	NO_SETID	12
Phenytoin: Etodolac has no apparent pharmacokinetic interaction when administered with phenytoin.
1	0	8	U-UNK	Phenytoin
2	9	9	O	:
3	11	18	O	XXXXXXXX
4	20	22	O	has
5	24	25	O	no
6	27	34	O	apparent
7	36	50	O	pharmacokinetic
8	52	62	O	interaction
9	64	67	O	when
10	69	80	O	administered
11	82	85	O	with
12	87	95	U-UNK	phenytoin
NULL

Etodolac	DDI-DrugBank.d219.s22	NO_SECTION	NO_SETID	37
Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	12	O	The
4	14	20	O	effects
5	22	23	O	of
6	25	32	U-UNK	warfarin
7	34	36	O	and
8	38	43	U-UNK	NSAIDs
9	45	46	O	on
10	48	49	O	GI
11	51	58	O	bleeding
12	60	62	O	are
13	64	74	O	synergistic
14	75	75	O	,
15	77	80	O	such
16	82	85	O	that
17	87	91	O	users
18	93	94	O	of
19	96	99	O	both
20	101	105	O	drugs
21	107	114	O	together
22	116	119	O	have
23	121	121	O	a
24	123	126	O	risk
25	128	129	O	of
26	131	137	O	serious
27	139	140	O	GI
28	142	149	O	bleeding
29	151	156	O	higher
30	158	161	O	than
31	163	166	O	that
32	168	169	O	of
33	171	175	O	users
34	177	178	O	of
35	180	185	O	either
36	187	190	O	drug
37	192	196	O	alone
NULL

Etodolac	DDI-DrugBank.d219.s23	NO_SECTION	NO_SETID	36
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.
1	0	4	O	Short
2	6	9	O	term
3	11	25	O	pharmacokinetic
4	27	33	O	studies
5	35	38	O	have
6	40	51	O	demonstrated
7	53	56	O	that
8	58	68	O	concomitant
9	70	83	O	administration
10	85	86	O	of
11	88	95	U-KIN	warfarin
12	97	99	O	and
13	101	106	O	XXXXXXXX
14	110	117	U-UNK	etodolac
15	119	126	O	capsules
16	128	130	O	and
17	132	138	O	tablets
18	141	147	O	results
19	149	150	O	in
20	152	158	O	reduced
21	160	166	O	protein
22	168	174	O	binding
23	176	177	O	of
24	179	186	U-UNK	warfarin
25	187	187	O	,
26	189	191	O	but
27	193	197	O	there
28	199	201	O	was
29	203	204	O	no
30	206	211	O	change
31	213	214	O	in
32	216	218	O	the
33	220	228	O	clearance
34	230	231	O	of
35	233	236	O	free
36	238	245	U-UNK	warfarin
NULL

Etodolac	DDI-DrugBank.d219.s24	NO_SECTION	NO_SETID	23
There was no significant difference in the pharmacodynamic effect of warfarin administered alone and warfarin administered with Lodine as measured by prothrombin time.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	23	O	significant
5	25	34	O	difference
6	36	37	O	in
7	39	41	O	the
8	43	57	O	pharmacodynamic
9	59	64	O	effect
10	66	67	O	of
11	69	76	U-UNK	warfarin
12	78	89	O	administered
13	91	95	O	alone
14	97	99	O	and
15	101	108	U-UNK	warfarin
16	110	121	O	administered
17	123	126	O	with
18	128	133	O	XXXXXXXX
19	135	136	O	as
20	138	145	O	measured
21	147	148	O	by
22	150	160	O	prothrombin
23	162	165	O	time
NULL

Etodolac	DDI-DrugBank.d219.s25	NO_SECTION	NO_SETID	16
Thus, concomitant therapy with warfarin and Lodine should not require dosage adjustment of either drug.
1	0	3	O	Thus
2	4	4	O	,
3	6	16	O	concomitant
4	18	24	O	therapy
5	26	29	O	with
6	31	38	U-UNK	warfarin
7	40	42	O	and
8	44	49	O	XXXXXXXX
9	51	56	O	should
10	58	60	O	not
11	62	68	O	require
12	70	75	O	dosage
13	77	86	O	adjustment
14	88	89	O	of
15	91	96	O	either
16	98	101	O	drug
NULL

Etodolac	DDI-DrugBank.d219.s26	NO_SECTION	NO_SETID	32
However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	caution
4	17	22	O	should
5	24	25	O	be
6	27	35	O	exercised
7	37	43	O	because
8	45	49	O	there
9	51	54	O	have
10	56	59	O	been
11	61	61	O	a
12	63	65	O	few
13	67	77	O	spontaneous
14	79	85	O	reports
15	87	88	O	of
16	90	98	O	prolonged
17	100	110	O	prothrombin
18	112	116	O	times
19	117	117	O	,
20	119	122	O	with
21	124	125	O	or
22	127	133	O	without
23	135	142	O	bleeding
24	143	143	O	,
25	145	146	O	in
26	148	155	O	XXXXXXXX
27	157	163	O	treated
28	165	172	O	patients
29	174	182	O	receiving
30	184	194	O	concomitant
31	196	203	U-DYN	warfarin
32	205	211	O	therapy
NULL

Etodolac	DDI-DrugBank.d219.s27	NO_SECTION	NO_SETID	31
Drug/Laboratory Test Interactions The urine of patients who take Lodine can give a false-positive reaction for urinary bilirubin (urobilin) due to the presence of phenolic metabolites of etodolac.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	36	O	The
7	38	42	O	urine
8	44	45	O	of
9	47	54	O	patients
10	56	58	O	who
11	60	63	O	take
12	65	70	O	XXXXXXXX
13	72	74	O	can
14	76	79	O	give
15	81	81	O	a
16	83	87	O	false
17	89	96	O	positive
18	98	105	O	reaction
19	107	109	O	for
20	111	117	O	urinary
21	119	127	O	bilirubin
22	130	137	O	urobilin
23	140	142	O	due
24	144	145	O	to
25	147	149	O	the
26	151	158	O	presence
27	160	161	O	of
28	163	170	O	phenolic
29	172	182	O	metabolites
30	184	185	O	of
31	187	194	U-UNK	etodolac
NULL

Etodolac	DDI-DrugBank.d219.s28	NO_SECTION	NO_SETID	25
Diagnostic dip-stick methodology, used to detect ketone bodies in urine, has resulted in false-positive findings in some patients treated with Lodine.
1	0	9	O	Diagnostic
2	11	13	O	dip
3	15	19	O	stick
4	21	31	O	methodology
5	32	32	O	,
6	34	37	O	used
7	39	40	O	to
8	42	47	O	detect
9	49	54	O	ketone
10	56	61	O	bodies
11	63	64	O	in
12	66	70	O	urine
13	71	71	O	,
14	73	75	O	has
15	77	84	O	resulted
16	86	87	O	in
17	89	93	O	false
18	95	102	O	positive
19	104	111	O	findings
20	113	114	O	in
21	116	119	O	some
22	121	128	O	patients
23	130	136	O	treated
24	138	141	O	with
25	143	148	O	XXXXXXXX
NULL

Etodolac	DDI-DrugBank.d219.s29	NO_SECTION	NO_SETID	13
Generally, this phenomenon has not been associated with other clinically significant events.
1	0	8	O	Generally
2	9	9	O	,
3	11	14	O	this
4	16	25	O	phenomenon
5	27	29	O	has
6	31	33	O	not
7	35	38	O	been
8	40	49	O	associated
9	51	54	O	with
10	56	60	O	other
11	62	71	O	clinically
12	73	83	O	significant
13	85	90	O	events
NULL

Etodolac	DDI-DrugBank.d219.s30	NO_SECTION	NO_SETID	6
No dose relationship has been observed.
1	0	1	O	No
2	3	6	O	dose
3	8	19	O	relationship
4	21	23	O	has
5	25	28	O	been
6	30	37	O	observed
NULL

Etodolac	DDI-DrugBank.d219.s31	NO_SECTION	NO_SETID	13
Lodine treatment is associated with a small decrease in serum uric acid levels.
1	0	5	O	XXXXXXXX
2	7	15	O	treatment
3	17	18	O	is
4	20	29	O	associated
5	31	34	O	with
6	36	36	O	a
7	38	42	O	small
8	44	51	O	decrease
9	53	54	O	in
10	56	60	O	serum
11	62	65	O	uric
12	67	70	O	acid
13	72	77	O	levels
NULL

Etodolac	DDI-DrugBank.d219.s32	NO_SECTION	NO_SETID	32
In clinical trials, mean decreases of 1 to 2 mg/dL were observed in arthritic patients receiving etodolac (600 mg to 1000 mg/day) after 4 weeks of therapy.
1	0	1	O	In
2	3	10	O	clinical
3	12	17	O	trials
4	18	18	O	,
5	20	23	O	mean
6	25	33	O	decreases
7	35	36	O	of
8	38	38	O	1
9	40	41	O	to
10	43	43	O	2
11	45	46	O	mg
12	47	47	O	/
13	48	49	O	dL
14	51	54	O	were
15	56	63	O	observed
16	65	66	O	in
17	68	76	O	arthritic
18	78	85	O	patients
19	87	95	O	receiving
20	97	104	O	XXXXXXXX
21	107	109	O	600
22	111	112	O	mg
23	114	115	O	to
24	117	120	O	1000
25	122	123	O	mg
26	124	124	O	/
27	125	127	O	day
28	130	134	O	after
29	136	136	O	4
30	138	142	O	weeks
31	144	145	O	of
32	147	153	O	therapy
NULL

Etodolac	DDI-DrugBank.d219.s33	NO_SECTION	NO_SETID	12
These levels then remained stable for up to 1 year of therapy.
1	0	4	O	These
2	6	11	O	levels
3	13	16	O	then
4	18	25	O	remained
5	27	32	O	stable
6	34	36	O	for
7	38	39	O	up
8	41	42	O	to
9	44	44	O	1
10	46	49	O	year
11	51	52	O	of
12	54	60	O	therapy
NULL

Etomidate	DDI-DrugBank.d119.s0	NO_SECTION	NO_SETID	9
The following drug interactions have been reported with etomidate.
1	0	2	O	The
2	4	12	O	following
3	14	17	O	drug
4	19	30	O	interactions
5	32	35	O	have
6	37	40	O	been
7	42	49	O	reported
8	51	54	O	with
9	56	64	O	XXXXXXXX
NULL

Etomidate	DDI-DrugBank.d119.s2	NO_SECTION	NO_SETID	5
Probenecid    Prolonged action of etomidate
1	0	9	U-UNK	Probenecid
2	14	22	O	Prolonged
3	24	29	O	action
4	31	32	O	of
5	34	42	O	XXXXXXXX
NULL

Etomidate	DDI-DrugBank.d119.s3	NO_SECTION	NO_SETID	2
Diazoxide    Hypotension
1	0	8	U-UNK	Diazoxide
2	13	23	O	Hypotension
NULL

Etomidate	DDI-DrugBank.d119.s4	NO_SECTION	NO_SETID	3
Zimelidine    etomidate antagonism
1	0	9	U-UNK	Zimelidine
2	14	22	O	XXXXXXXX
3	24	33	O	antagonism
NULL

Etomidate	DDI-DrugBank.d119.s5	NO_SECTION	NO_SETID	5
Opioid analgesics    Decreased antinociceptive action
1	0	5	B-UNK	Opioid
2	7	16	L-UNK	analgesics
3	21	29	O	Decreased
4	31	45	O	antinociceptive
5	47	52	O	action
NULL

Etomidate	DDI-DrugBank.d119.s6	NO_SECTION	NO_SETID	3
Aminophylline     Etomidate antagonism
1	0	12	U-UNK	Aminophylline
2	18	26	O	XXXXXXXX
3	28	37	O	antagonism
NULL

Etomidate	DDI-DrugBank.d119.s7	NO_SECTION	NO_SETID	2
Midazolam    Synergism
1	0	8	U-UNK	Midazolam
2	13	21	O	Synergism
NULL

Etonogestrel	DDI-DrugBank.d484.s0	NO_SECTION	NO_SETID	99
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
1	0	11	U-UNK	Etonogestrel
2	13	15	O	may
3	17	24	O	interact
4	26	29	O	with
5	31	33	O	the
6	35	43	O	following
7	45	55	O	medications
8	56	56	O	:
9	58	70	U-UNK	acetaminophen
10	73	79	O	Tylenol
11	81	81	O	,
12	83	93	U-UNK	antibiotics
13	95	98	O	such
14	100	101	O	as
15	103	112	U-UNK	ampicillin
16	114	116	O	and
17	118	129	U-UNK	tetracycline
18	130	130	O	,
19	132	146	U-UNK	anticonvulsants
20	149	156	O	Dilantin
21	157	157	O	,
22	159	171	U-UNK	Phenobarbital
23	172	172	O	,
24	174	181	O	Tegretol
25	182	182	O	,
26	184	192	O	Trileptal
27	193	193	O	,
28	195	201	O	Topamax
29	202	202	O	,
30	204	211	O	Felbatol
31	213	213	O	,
32	215	225	U-UNK	antifungals
33	228	231	O	Gris
34	233	235	O	PEG
35	236	236	O	,
36	238	244	O	Nizoral
37	245	245	O	,
38	247	254	O	Sporanox
39	256	256	O	,
40	258	269	U-UNK	atorvastatin
41	272	278	O	Lipitor
42	280	280	O	,
43	282	291	U-UNK	clofibrate
44	294	300	O	Atromid
45	302	302	O	S
46	304	304	O	,
47	306	317	U-UNK	cyclosporine
48	320	325	O	Neoral
49	326	326	O	,
50	328	337	O	Sandimmune
51	339	339	O	,
52	341	343	O	HIV
53	345	349	O	drugs
54	351	360	O	classified
55	362	363	O	as
56	365	372	B-UNK	protease
57	374	383	L-UNK	inhibitors
58	386	394	O	Agenerase
59	395	395	O	,
60	397	404	O	Crixivan
61	405	405	O	,
62	407	415	O	Fortovase
63	416	416	O	,
64	418	425	O	Invirase
65	426	426	O	,
66	428	434	O	Kaletra
67	435	435	O	,
68	437	442	O	Norvir
69	443	443	O	,
70	445	452	O	Viracept
71	454	454	O	,
72	456	463	U-UNK	morphine
73	466	475	O	Astramorph
74	476	476	O	,
75	478	483	O	Kadian
76	484	484	O	,
77	486	487	O	MS
78	489	494	O	Contin
79	496	496	O	,
80	498	511	U-UNK	phenylbutazone
81	512	512	O	,
82	514	525	U-UNK	prednisolone
83	528	534	O	Prelone
84	536	536	O	,
85	538	544	O	rifadin
86	547	554	U-UNK	rifampin
87	556	556	O	,
88	558	559	O	St
89	562	566	O	Johns
90	568	571	O	wort
91	572	572	O	,
92	574	582	U-UNK	temazepam
93	583	583	O	,
94	585	596	U-UNK	theophylline
95	599	606	O	XXXXXXXX
96	608	608	O	,
97	610	612	O	and
98	614	620	B-UNK	vitamin
99	622	622	L-UNK	C
NULL

Etoposide	DDI-DrugBank.d194.s0	NO_SECTION	NO_SETID	20
Caution should be exercised when administering ETOPOPHOS with drugs that are known to inhibit phosphatase activities (e.g., levamisole hydrochloride).
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	45	O	administering
7	47	55	O	XXXXXXXX
8	57	60	O	with
9	62	66	O	drugs
10	68	71	O	that
11	73	75	O	are
12	77	81	O	known
13	83	84	O	to
14	86	92	O	inhibit
15	94	104	O	phosphatase
16	106	115	O	activities
17	118	120	O	e.g
18	122	122	O	,
19	124	133	B-DYN	levamisole
20	135	147	L-DYN	hydrochloride
NULL

Etoposide	DDI-DrugBank.d194.s1	NO_SECTION	NO_SETID	39
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.
1	0	3	O	High
2	5	8	O	dose
3	10	20	B-KIN	cyclosporin
4	22	22	L-KIN	A
5	24	32	O	resulting
6	34	35	O	in
7	37	50	O	concentrations
8	52	56	O	above
9	58	61	O	2000
10	63	64	O	ng
11	65	65	O	/
12	66	67	O	mL
13	69	80	O	administered
14	82	85	O	with
15	87	90	O	oral
16	92	100	O	XXXXXXXX
17	102	104	O	has
18	106	108	O	led
19	110	111	O	to
20	113	114	O	an
21	116	118	O	80%
22	120	127	O	increase
23	129	130	O	in
24	132	140	O	XXXXXXXX
25	142	149	O	exposure
26	151	154	O	with
27	156	156	O	a
28	158	160	O	38%
29	162	169	O	decrease
30	171	172	O	in
31	174	178	O	total
32	180	183	O	body
33	185	193	O	clearance
34	195	196	O	of
35	198	206	O	XXXXXXXX
36	208	215	O	compared
37	217	218	O	to
38	220	228	O	XXXXXXXX
39	230	234	O	alone
NULL

Exemestane	DDI-DrugBank.d435.s0	NO_SECTION	NO_SETID	27
Exemestane is extensively metabolized by CYP 3A4, but coadministration of ketoconazole, a potent inhibitor of CYP 3A4, has no significant effect on exemestane pharmacokinetics.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	extensively
4	26	36	O	metabolized
5	38	39	O	by
6	41	43	O	CYP
7	45	47	O	3A4
8	48	48	O	,
9	50	52	O	but
10	54	69	O	coadministration
11	71	72	O	of
12	74	85	U-UNK	ketoconazole
13	86	86	O	,
14	88	88	O	a
15	90	95	O	potent
16	97	105	O	inhibitor
17	107	108	O	of
18	110	112	O	CYP
19	114	116	O	3A4
20	117	117	O	,
21	119	121	O	has
22	123	124	O	no
23	126	136	O	significant
24	138	143	O	effect
25	145	146	O	on
26	148	157	O	XXXXXXXX
27	159	174	O	pharmacokinetics
NULL

Exemestane	DDI-DrugBank.d435.s1	NO_SECTION	NO_SETID	12
Significant pharmacokinetic interactions mediated by inhibition of CYP isoenzymes therefore appear unlikely.
1	0	10	O	Significant
2	12	26	O	pharmacokinetic
3	28	39	O	interactions
4	41	48	O	mediated
5	50	51	O	by
6	53	62	O	inhibition
7	64	65	O	of
8	67	69	O	CYP
9	71	80	O	isoenzymes
10	82	90	O	therefore
11	92	97	O	appear
12	99	106	O	unlikely
NULL

Exemestane	DDI-DrugBank.d435.s2	NO_SECTION	NO_SETID	27
Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.
1	0	1	O	Co
2	3	13	O	medications
3	15	18	O	that
4	20	25	O	induce
5	27	29	O	CYP
6	31	33	O	3A4
7	36	38	O	e.g
8	40	40	O	,
9	42	51	U-KIN	rifampicin
10	52	52	O	,
11	54	62	U-KIN	phenytoin
12	63	63	O	,
13	65	77	U-KIN	carbamazepine
14	78	78	O	,
15	80	92	U-KIN	phenobarbital
16	93	93	O	,
17	95	96	O	or
18	98	99	O	St
19	102	105	O	John
20	107	107	O	s
21	109	112	O	wort
22	115	117	O	may
23	119	131	O	significantly
24	133	140	O	decrease
25	142	149	O	exposure
26	151	152	O	to
27	154	163	O	XXXXXXXX
NULL

Exemestane	DDI-DrugBank.d435.s3	NO_SECTION	NO_SETID	15
Dose modification is recommended for patients who are also receiving a potent CYP 3A4 inducer.
1	0	3	O	Dose
2	5	16	O	modification
3	18	19	O	is
4	21	31	O	recommended
5	33	35	O	for
6	37	44	O	patients
7	46	48	O	who
8	50	52	O	are
9	54	57	O	also
10	59	67	O	receiving
11	69	69	O	a
12	71	76	O	potent
13	78	80	O	CYP
14	82	84	O	3A4
15	86	92	O	inducer
NULL

Exemestane	DDI-DrugBank.d435.s4	NO_SECTION	NO_SETID	19
Drug/Laboratory Tests Interactions No clinically relevant changes in the results of clinical laboratory tests have been observed.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	20	O	Tests
5	22	33	O	Interactions
6	35	36	O	No
7	38	47	O	clinically
8	49	56	O	relevant
9	58	64	O	changes
10	66	67	O	in
11	69	71	O	the
12	73	79	O	results
13	81	82	O	of
14	84	91	O	clinical
15	93	102	O	laboratory
16	104	108	O	tests
17	110	113	O	have
18	115	118	O	been
19	120	127	O	observed
NULL

Famciclovir	DDI-DrugBank.d112.s0	NO_SECTION	NO_SETID	22
Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	18	O	with
4	20	29	U-UNK	probenecid
5	31	32	O	or
6	34	38	O	other
7	40	44	O	drugs
8	46	58	O	significantly
9	60	69	O	eliminated
10	71	72	O	by
11	74	79	O	active
12	81	85	O	renal
13	87	93	O	tubular
14	95	103	O	secretion
15	105	107	O	may
16	109	114	O	result
17	116	117	O	in
18	119	127	O	increased
19	129	134	O	plasma
20	136	149	O	concentrations
21	151	152	O	of
22	154	164	U-UNK	penciclovir
NULL

Famciclovir	DDI-DrugBank.d112.s1	NO_SECTION	NO_SETID	13
The conversion of 6-deoxy penciclovir to penciclovir is catalyzed by aldehyde oxidase.
1	0	2	O	The
2	4	13	O	conversion
3	15	16	O	of
4	18	18	B-UNK	6
5	20	24	I-UNK	deoxy
6	26	36	L-UNK	penciclovir
7	38	39	O	to
8	41	51	U-UNK	penciclovir
9	53	54	O	is
10	56	64	O	catalyzed
11	66	67	O	by
12	69	76	O	aldehyde
13	78	84	O	oxidase
NULL

Famciclovir	DDI-DrugBank.d112.s2	NO_SECTION	NO_SETID	11
Interactions with other drugs metabolized by this enzyme could potentially occur.
1	0	11	O	Interactions
2	13	16	O	with
3	18	22	O	other
4	24	28	O	drugs
5	30	40	O	metabolized
6	42	43	O	by
7	45	48	O	this
8	50	55	O	enzyme
9	57	61	O	could
10	63	73	O	potentially
11	75	79	O	occur
NULL

Famotidine	DDI-DrugBank.d203.s0	NO_SECTION	NO_SETID	6
No drug interactions have been identified.
1	0	1	O	No
2	3	6	O	drug
3	8	19	O	interactions
4	21	24	O	have
5	26	29	O	been
6	31	40	O	identified
NULL

Famotidine	DDI-DrugBank.d203.s1	NO_SECTION	NO_SETID	35
Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system.
1	0	6	O	Studies
2	8	11	O	with
3	13	22	O	XXXXXXXX
4	24	25	O	in
5	27	29	O	man
6	30	30	O	,
7	32	33	O	in
8	35	40	O	animal
9	42	47	O	models
10	48	48	O	,
11	50	52	O	and
12	54	55	O	in
13	57	61	O	vitro
14	63	66	O	have
15	68	72	O	shown
16	74	75	O	no
17	77	87	O	significant
18	89	100	O	interference
19	102	105	O	with
20	107	109	O	the
21	111	121	O	disposition
22	123	124	O	of
23	126	134	O	compounds
24	136	146	O	metabolized
25	148	149	O	by
26	151	153	O	the
27	155	161	O	hepatic
28	163	172	O	microsomal
29	174	180	O	enzymes
30	181	181	O	,
31	183	185	O	e.g
32	187	187	O	,
33	189	198	O	cytochrome
34	200	203	O	P450
35	205	210	O	system
NULL

Famotidine	DDI-DrugBank.d203.s2	NO_SECTION	NO_SETID	16
Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine.
1	0	8	O	Compounds
2	10	15	O	tested
3	17	18	O	in
4	20	22	O	man
5	24	30	O	include
6	32	39	U-UNK	warfarin
7	40	40	O	,
8	42	53	U-UNK	theophylline
9	54	54	O	,
10	56	64	U-UNK	phenytoin
11	65	65	O	,
12	67	74	U-UNK	diazepam
13	75	75	O	,
14	77	87	U-UNK	aminopyrine
15	89	91	O	and
16	93	102	U-UNK	antipyrine
NULL

Famotidine	DDI-DrugBank.d203.s3	NO_SECTION	NO_SETID	19
Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.
1	0	10	B-UNK	Indocyanine
2	12	16	L-UNK	green
3	18	19	O	as
4	21	22	O	an
5	24	28	O	index
6	30	31	O	of
7	33	39	O	hepatic
8	41	44	O	drug
9	46	55	O	extraction
10	57	59	O	has
11	61	64	O	been
12	66	71	O	tested
13	73	75	O	and
14	77	78	O	no
15	80	90	O	significant
16	92	98	O	effects
17	100	103	O	have
18	105	108	O	been
19	110	114	O	found
NULL

Felbamate	DDI-DrugBank.d434.s0	NO_SECTION	NO_SETID	22
The drug interaction data described in this section were obtained from controlled clinical trials and studies involving otherwise healthy adults with epilepsy.
1	0	2	O	The
2	4	7	O	drug
3	9	19	O	interaction
4	21	24	O	data
5	26	34	O	described
6	36	37	O	in
7	39	42	O	this
8	44	50	O	section
9	52	55	O	were
10	57	64	O	obtained
11	66	69	O	from
12	71	80	O	controlled
13	82	89	O	clinical
14	91	96	O	trials
15	98	100	O	and
16	102	108	O	studies
17	110	118	O	involving
18	120	128	O	otherwise
19	130	136	O	healthy
20	138	143	O	adults
21	145	148	O	with
22	150	157	O	epilepsy
NULL

Felbamate	DDI-DrugBank.d434.s1	NO_SECTION	NO_SETID	24
Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.
1	0	2	O	Use
2	4	5	O	in
3	7	17	O	Conjunction
4	19	22	O	with
5	24	28	O	Other
6	30	42	B-UNK	Antiepileptic
7	44	48	L-UNK	Drugs
8	49	49	O	:
9	51	53	O	The
10	55	62	O	addition
11	64	65	O	of
12	67	74	O	XXXXXXXX
13	77	78	O	to
14	80	92	B-KIN	antiepileptic
15	94	98	L-KIN	drugs
16	101	104	U-KIN	AEDs
17	107	113	O	affects
18	115	117	O	the
19	119	124	O	steady
20	126	130	O	state
21	132	137	O	plasma
22	139	152	O	concentrations
23	154	155	O	of
24	157	160	U-UNK	AEDs
NULL

Felbamate	DDI-DrugBank.d434.s2	NO_SECTION	NO_SETID	16
The net effect of these interactions is summarized in the following table: AED AED Felbatol
1	0	2	O	The
2	4	6	O	net
3	8	13	O	effect
4	15	16	O	of
5	18	22	O	these
6	24	35	O	interactions
7	37	38	O	is
8	40	49	O	summarized
9	51	52	O	in
10	54	56	O	the
11	58	66	O	following
12	68	72	O	table
13	73	73	O	:
14	75	77	U-UNK	AED
15	79	81	U-UNK	AED
16	83	90	O	XXXXXXXX
NULL

Felbamate	DDI-DrugBank.d434.s3	NO_SECTION	NO_SETID	3
Coadministered Concentration Concentration
1	0	13	O	Coadministered
2	15	27	O	Concentration
3	29	41	O	Concentration
NULL

Felbamate	DDI-DrugBank.d434.s9	NO_SECTION	NO_SETID	9
*Not administered, but an active metabolite of carbamazepine.
1	0	3	O	Not
2	5	16	O	administered
3	17	17	O	,
4	19	21	O	but
5	23	24	O	an
6	26	31	O	active
7	33	42	O	metabolite
8	44	45	O	of
9	47	59	U-UNK	carbamazepine
NULL

Felbamate	DDI-DrugBank.d434.s10	NO_SECTION	NO_SETID	3
**No significant effect.
1	0	3	O	No
2	5	15	O	significant
3	17	22	O	effect
NULL

Felbamate	DDI-DrugBank.d434.s11	NO_SECTION	NO_SETID	20
Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.
1	0	7	O	Specific
2	9	15	O	Effects
3	17	18	O	of
4	20	27	O	XXXXXXXX
5	30	31	O	on
6	33	37	O	Other
7	39	51	B-UNK	Antiepileptic
8	53	57	L-UNK	Drugs
9	59	67	U-UNK	Phenytoin
10	68	68	O	:
11	70	77	O	XXXXXXXX
12	80	85	O	causes
13	87	88	O	an
14	90	97	O	increase
15	99	100	O	in
16	102	107	O	steady
17	109	113	O	state
18	115	123	U-KIN	phenytoin
19	125	130	O	plasma
20	132	145	O	concentrations
NULL

Felbamate	DDI-DrugBank.d434.s12	NO_SECTION	NO_SETID	23
In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steadystate trough (Cmin) phenytoin plasma concentration was 17 5 micrograms/mL.
1	0	1	O	In
2	3	4	O	10
3	6	14	O	otherwise
4	16	22	O	healthy
5	24	31	O	subjects
6	33	36	O	with
7	38	45	O	epilepsy
8	47	55	O	ingesting
9	57	65	U-UNK	phenytoin
10	66	66	O	,
11	68	70	O	the
12	72	82	O	steadystate
13	84	89	O	trough
14	92	95	O	Cmin
15	98	106	U-UNK	phenytoin
16	108	113	O	plasma
17	115	127	O	concentration
18	129	131	O	was
19	133	134	O	17
20	136	136	O	5
21	138	147	O	micrograms
22	148	148	O	/
23	149	150	O	mL
NULL

Felbamate	DDI-DrugBank.d434.s13	NO_SECTION	NO_SETID	20
The steady-state Cmin increased to 21 5 micrograms/mL when 1200 mg/day of felbamate was coadministered.
1	0	2	O	The
2	4	9	O	steady
3	11	15	O	state
4	17	20	O	Cmin
5	22	30	O	increased
6	32	33	O	to
7	35	36	O	21
8	38	38	O	5
9	40	49	O	micrograms
10	50	50	O	/
11	51	52	O	mL
12	54	57	O	when
13	59	62	O	1200
14	64	65	O	mg
15	66	66	O	/
16	67	69	O	day
17	71	72	O	of
18	74	82	O	XXXXXXXX
19	84	86	O	was
20	88	101	O	coadministered
NULL

Felbamate	DDI-DrugBank.d434.s14	NO_SECTION	NO_SETID	26
Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.
1	0	9	O	Increasing
2	11	13	O	the
3	15	23	O	XXXXXXXX
4	25	28	O	dose
5	30	31	O	to
6	33	36	O	1800
7	38	39	O	mg
8	40	40	O	/
9	41	43	O	day
10	45	46	O	in
11	48	50	O	six
12	52	53	O	of
13	55	59	O	these
14	61	68	O	subjects
15	70	78	O	increased
16	80	82	O	the
17	84	89	O	steady
18	91	95	O	state
19	97	105	U-KIN	phenytoin
20	107	110	O	Cmin
21	112	113	O	to
22	115	116	O	25
23	118	118	O	7
24	120	129	O	micrograms
25	130	130	O	/
26	131	132	O	mL
NULL

Felbamate	DDI-DrugBank.d434.s15	NO_SECTION	NO_SETID	37
In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.
1	0	1	O	In
2	3	7	O	order
3	9	10	O	to
4	12	19	O	maintain
5	21	29	U-UNK	phenytoin
6	31	36	O	levels
7	37	37	O	,
8	39	43	O	limit
9	45	51	O	adverse
10	53	63	O	experiences
11	64	64	O	,
12	66	68	O	and
13	70	76	O	achieve
14	78	80	O	the
15	82	90	O	XXXXXXXX
16	92	95	O	dose
17	97	98	O	of
18	100	103	O	3600
19	105	106	O	mg
20	107	107	O	/
21	108	110	O	day
22	111	111	O	,
23	113	113	O	a
24	115	123	U-DYN	phenytoin
25	125	128	O	dose
26	130	138	O	reduction
27	140	141	O	of
28	143	155	O	approximately
29	157	159	O	40%
30	161	163	O	was
31	165	173	O	necessary
32	175	177	O	for
33	179	183	O	eight
34	185	186	O	of
35	188	192	O	these
36	194	195	O	10
37	197	204	O	subjects
NULL

Felbamate	DDI-DrugBank.d434.s16	NO_SECTION	NO_SETID	30
In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to Felbatol  administration.
1	0	1	O	In
2	3	3	O	a
3	5	14	O	controlled
4	16	23	O	clinical
5	25	29	O	trial
6	30	30	O	,
7	32	32	O	a
8	34	36	O	20%
9	38	46	O	reduction
10	48	49	O	of
11	51	53	O	the
12	55	63	U-UNK	phenytoin
13	65	68	O	dose
14	70	71	O	at
15	73	75	O	the
16	77	86	O	initiation
17	88	89	O	of
18	91	98	O	XXXXXXXX
19	101	107	O	therapy
20	109	116	O	resulted
21	118	119	O	in
22	121	129	U-UNK	phenytoin
23	131	136	O	levels
24	138	147	O	comparable
25	149	150	O	to
26	152	156	O	those
27	158	162	O	prior
28	164	165	O	to
29	167	174	O	XXXXXXXX
30	177	190	O	administration
NULL

Felbamate	DDI-DrugBank.d434.s17	NO_SECTION	NO_SETID	24
Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.
1	0	12	U-UNK	Carbamazepine
2	13	13	O	:
3	15	22	O	XXXXXXXX
4	25	30	O	causes
5	32	32	O	a
6	34	41	O	decrease
7	43	44	O	in
8	46	48	O	the
9	50	55	O	steady
10	57	61	O	state
11	63	75	U-KIN	carbamazepine
12	77	82	O	plasma
13	84	97	O	concentrations
14	99	101	O	and
15	103	104	O	an
16	106	113	O	increase
17	115	116	O	in
18	118	120	O	the
19	122	127	O	steady
20	129	133	O	state
21	135	147	B-UNK	carbamazepine
22	149	155	L-UNK	epoxide
23	157	162	O	plasma
24	164	176	O	concentration
NULL

Felbamate	DDI-DrugBank.d434.s18	NO_SECTION	NO_SETID	23
In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 8 2 micrograms/mL.
1	0	1	O	In
2	3	6	O	nine
3	8	16	O	otherwise
4	18	24	O	healthy
5	26	33	O	subjects
6	35	38	O	with
7	40	47	O	epilepsy
8	49	57	O	ingesting
9	59	71	U-UNK	carbamazepine
10	72	72	O	,
11	74	76	O	the
12	78	83	O	steady
13	85	89	O	state
14	91	96	O	trough
15	99	102	O	Cmin
16	105	117	U-UNK	carbamazepine
17	119	131	O	concentration
18	133	135	O	was
19	137	137	O	8
20	139	139	O	2
21	141	150	O	micrograms
22	151	151	O	/
23	152	153	O	mL
NULL

Felbamate	DDI-DrugBank.d434.s19	NO_SECTION	NO_SETID	26
The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.
1	0	2	O	The
2	4	16	U-KIN	carbamazepine
3	18	23	O	steady
4	25	29	O	state
5	31	34	O	Cmin
6	36	44	O	decreased
7	46	48	O	31%
8	50	51	O	to
9	53	53	O	5
10	55	55	O	1
11	57	66	O	micrograms
12	67	67	O	/
13	68	69	O	mL
14	71	74	O	when
15	76	84	O	XXXXXXXX
16	87	90	O	3000
17	92	93	O	mg
18	94	94	O	/
19	95	97	O	day
20	98	98	O	,
21	100	106	O	divided
22	108	111	O	into
23	113	117	O	three
24	119	123	O	doses
25	126	128	O	was
26	130	143	O	coadministered
NULL

Felbamate	DDI-DrugBank.d434.s20	NO_SECTION	NO_SETID	22
Carbamazepine epoxide steady-state Cmin concentrations increased 57% from 1.0 0.3 to 1.6 0.4 micrograms/mL with the addition of felbamate.
1	0	12	B-UNK	Carbamazepine
2	14	20	L-UNK	epoxide
3	22	27	O	steady
4	29	33	O	state
5	35	38	O	Cmin
6	40	53	O	concentrations
7	55	63	O	increased
8	65	67	O	57%
9	69	72	O	from
10	74	76	O	1.0
11	78	80	O	0.3
12	82	83	O	to
13	85	87	O	1.6
14	89	91	O	0.4
15	93	102	O	micrograms
16	103	103	O	/
17	104	105	O	mL
18	107	110	O	with
19	112	114	O	the
20	116	123	O	addition
21	125	126	O	of
22	128	136	O	XXXXXXXX
NULL

Felbamate	DDI-DrugBank.d434.s21	NO_SECTION	NO_SETID	13
In clinical trials, similar changes in carbamazepine and carbamazepine epoxide were seen.
1	0	1	O	In
2	3	10	O	clinical
3	12	17	O	trials
4	18	18	O	,
5	20	26	O	similar
6	28	34	O	changes
7	36	37	O	in
8	39	51	U-UNK	carbamazepine
9	53	55	O	and
10	57	69	B-UNK	carbamazepine
11	71	77	L-UNK	epoxide
12	79	82	O	were
13	84	87	O	seen
NULL

Felbamate	DDI-DrugBank.d434.s22	NO_SECTION	NO_SETID	11
Valproate: Felbatol  causes an increase in steady-state valproate concentrations.
1	0	8	U-UNK	Valproate
2	9	9	O	:
3	11	18	O	XXXXXXXX
4	21	26	O	causes
5	28	29	O	an
6	31	38	O	increase
7	40	41	O	in
8	43	48	O	steady
9	50	54	O	state
10	56	64	U-KIN	valproate
11	66	79	O	concentrations
NULL

Felbamate	DDI-DrugBank.d434.s23	NO_SECTION	NO_SETID	22
In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 63 16 micrograms/mL.
1	0	1	O	In
2	3	6	O	four
3	8	15	O	subjects
4	17	20	O	with
5	22	29	O	epilepsy
6	31	39	O	ingesting
7	41	49	U-UNK	valproate
8	50	50	O	,
9	52	54	O	the
10	56	61	O	steady
11	63	67	O	state
12	69	74	O	trough
13	77	80	O	Cmin
14	83	91	U-UNK	valproate
15	93	98	O	plasma
16	100	112	O	concentration
17	114	116	O	was
18	118	119	O	63
19	121	122	O	16
20	124	133	O	micrograms
21	134	134	O	/
22	135	136	O	mL
NULL

Felbamate	DDI-DrugBank.d434.s24	NO_SECTION	NO_SETID	20
The steady-state Cmin increased to 78 14 micrograms/mL when 1200 mg/day of felbamate was coadministered.
1	0	2	O	The
2	4	9	O	steady
3	11	15	O	state
4	17	20	O	Cmin
5	22	30	O	increased
6	32	33	O	to
7	35	36	O	78
8	38	39	O	14
9	41	50	O	micrograms
10	51	51	O	/
11	52	53	O	mL
12	55	58	O	when
13	60	63	O	1200
14	65	66	O	mg
15	67	67	O	/
16	68	70	O	day
17	72	73	O	of
18	75	83	O	XXXXXXXX
19	85	87	O	was
20	89	102	O	coadministered
NULL

Felbamate	DDI-DrugBank.d434.s25	NO_SECTION	NO_SETID	20
Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.
1	0	9	O	Increasing
2	11	13	O	the
3	15	23	O	XXXXXXXX
4	25	28	O	dose
5	30	31	O	to
6	33	36	O	2400
7	38	39	O	mg
8	40	40	O	/
9	41	43	O	day
10	45	53	O	increased
11	55	57	O	the
12	59	69	O	steadystate
13	71	79	U-KIN	valproate
14	81	84	O	Cmin
15	86	87	O	to
16	89	90	O	96
17	92	93	O	25
18	95	104	O	micrograms
19	105	105	O	/
20	106	107	O	mL
NULL

Felbamate	DDI-DrugBank.d434.s26	NO_SECTION	NO_SETID	33
Corresponding values for free valproate Cmin concentrations were 7 3, 9 4, and 11 6 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol , respectively.
1	0	12	O	Corresponding
2	14	19	O	values
3	21	23	O	for
4	25	28	O	free
5	30	38	U-UNK	valproate
6	40	43	O	Cmin
7	45	58	O	concentrations
8	60	63	O	were
9	65	65	O	7
10	67	67	O	3
11	68	68	O	,
12	70	70	O	9
13	72	72	O	4
14	73	73	O	,
15	75	77	O	and
16	79	80	O	11
17	82	82	O	6
18	84	93	O	micrograms
19	94	94	O	/
20	95	96	O	mL
21	98	100	O	for
22	102	102	O	0
23	103	103	O	,
24	105	108	O	1200
25	109	109	O	,
26	111	113	O	and
27	115	118	O	2400
28	120	121	O	mg
29	122	122	O	/
30	123	125	O	day
31	127	134	O	XXXXXXXX
32	136	136	O	,
33	138	149	O	respectively
NULL

Felbamate	DDI-DrugBank.d434.s27	NO_SECTION	NO_SETID	40
The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol , respectively.
1	0	2	O	The
2	4	9	O	ratios
3	11	12	O	of
4	14	16	O	the
5	18	21	O	AUCs
6	23	24	O	of
7	26	32	O	unbound
8	34	42	U-UNK	valproate
9	44	45	O	to
10	47	49	O	the
11	51	54	O	AUCs
12	56	57	O	of
13	59	61	O	the
14	63	67	O	total
15	69	77	U-UNK	valproate
16	79	82	O	were
17	84	87	O	11.1
18	89	89	O	%
19	90	90	O	,
20	92	96	O	13.0%
21	97	97	O	,
22	99	101	O	and
23	103	107	O	11.5%
24	108	108	O	,
25	110	113	O	with
26	115	130	O	coadministration
27	132	133	O	of
28	135	135	O	0
29	136	136	O	,
30	138	141	O	1200
31	142	142	O	,
32	144	146	O	and
33	148	151	O	2400
34	153	154	O	mg
35	155	155	O	/
36	156	158	O	day
37	160	161	O	of
38	163	170	O	XXXXXXXX
39	172	172	O	,
40	174	185	O	respectively
NULL

Felbamate	DDI-DrugBank.d434.s28	NO_SECTION	NO_SETID	36
Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
1	0	12	U-UNK	Phenobarbital
2	13	13	O	:
3	15	30	O	Coadministration
4	32	33	O	of
5	35	43	O	XXXXXXXX
6	45	48	O	with
7	50	62	U-KIN	phenobarbital
8	64	69	O	causes
9	71	72	O	an
10	74	81	O	increase
11	83	84	O	in
12	86	98	U-UNK	phenobarbital
13	100	105	O	plasma
14	107	120	O	concentrations
15	121	121	O	,
16	123	124	O	In
17	126	127	O	12
18	129	137	O	otherwise
19	139	145	O	healthy
20	147	150	O	male
21	152	161	O	volunteers
22	163	171	O	ingesting
23	173	185	U-UNK	phenobarbital
24	186	186	O	,
25	188	190	O	the
26	192	197	O	steady
27	199	203	O	state
28	205	210	O	trough
29	213	216	O	Cmin
30	219	231	U-UNK	phenobarbital
31	233	245	O	concentration
32	247	249	O	was
33	251	254	O	14.2
34	256	265	O	micrograms
35	266	266	O	/
36	267	268	O	mL
NULL

Felbamate	DDI-DrugBank.d434.s29	NO_SECTION	NO_SETID	23
The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week.
1	0	2	O	The
2	4	9	O	steady
3	11	15	O	state
4	17	20	O	Cmin
5	22	34	O	concentration
6	36	44	O	increased
7	46	47	O	to
8	49	52	O	17.8
9	54	63	O	micrograms
10	64	64	O	/
11	65	66	O	mL
12	68	71	O	when
13	73	76	O	2400
14	78	79	O	mg
15	80	80	O	/
16	81	83	O	day
17	85	86	O	of
18	88	96	O	XXXXXXXX
19	98	100	O	was
20	102	115	O	coadministered
21	117	119	O	for
22	121	123	O	one
23	125	128	O	week
NULL

Felbamate	DDI-DrugBank.d434.s30	NO_SECTION	NO_SETID	55
Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
1	0	6	O	Effects
2	8	9	O	of
3	11	15	O	Other
4	17	29	B-UNK	Antiepileptic
5	31	35	L-UNK	Drugs
6	37	38	O	on
7	40	47	O	XXXXXXXX
8	50	58	U-UNK	Phenytoin
9	59	59	O	:
10	61	69	U-KIN	Phenytoin
11	71	76	O	causes
12	78	79	O	an
13	81	91	O	approximate
14	93	100	O	doubling
15	102	103	O	of
16	105	107	O	the
17	109	117	O	clearance
18	119	120	O	of
19	122	129	O	XXXXXXXX
20	133	141	U-UNK	felbamate
21	144	145	O	at
22	147	152	O	steady
23	154	158	O	state
24	160	162	O	and
25	163	163	O	,
26	165	173	O	therefore
27	174	174	O	,
28	176	178	O	the
29	180	187	O	addition
30	189	190	O	of
31	192	200	U-KIN	phenytoin
32	202	207	O	causes
33	209	210	O	an
34	212	222	O	approximate
35	224	226	O	45%
36	228	235	O	decrease
37	237	238	O	in
38	240	242	O	the
39	244	249	O	steady
40	251	255	O	state
41	257	262	O	trough
42	264	277	O	concentrations
43	279	280	O	of
44	282	289	O	XXXXXXXX
45	292	293	O	as
46	295	302	O	compared
47	304	305	O	to
48	307	309	O	the
49	311	314	O	same
50	316	319	O	dose
51	321	322	O	of
52	324	331	O	XXXXXXXX
53	334	338	O	given
54	340	341	O	as
55	343	353	O	monotherapy
NULL

Felbamate	DDI-DrugBank.d434.s31	NO_SECTION	NO_SETID	49
Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.
1	0	12	U-UNK	Carbamazepine
2	13	13	O	:
3	15	27	U-KIN	Carbamazepine
4	29	34	O	causes
5	36	37	O	an
6	39	49	O	approximate
7	51	53	O	50%
8	55	62	O	increase
9	64	65	O	in
10	67	69	O	the
11	71	79	O	clearance
12	81	82	O	of
13	84	91	O	XXXXXXXX
14	94	95	O	at
15	97	102	O	steady
16	104	108	O	state
17	110	112	O	and
18	113	113	O	,
19	115	123	O	therefore
20	124	124	O	,
21	126	128	O	the
22	130	137	O	addition
23	139	140	O	of
24	142	154	U-KIN	carbamazepine
25	156	162	O	results
26	164	165	O	in
27	167	168	O	an
28	170	180	O	approximate
29	182	184	O	40%
30	186	193	O	decrease
31	195	196	O	in
32	198	200	O	the
33	202	207	O	steady
34	209	213	O	state
35	215	220	O	trough
36	222	235	O	concentrations
37	237	238	O	of
38	240	247	O	XXXXXXXX
39	250	251	O	as
40	253	260	O	compared
41	262	263	O	to
42	265	267	O	the
43	269	272	O	same
44	274	277	O	dose
45	279	280	O	of
46	282	289	O	XXXXXXXX
47	292	296	O	given
48	298	299	O	as
49	301	311	O	monotherapy
NULL

Felbamate	DDI-DrugBank.d434.s32	NO_SECTION	NO_SETID	42
Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.
1	0	8	U-UNK	Valproate
2	9	9	O	:
3	11	19	O	Available
4	21	24	O	data
5	26	32	O	suggest
6	34	37	O	that
7	39	43	O	there
8	45	46	O	is
9	48	49	O	no
10	51	61	O	significant
11	63	68	O	effect
12	70	71	O	of
13	73	81	U-UNK	valproate
14	83	84	O	on
15	86	88	O	the
16	90	98	O	clearance
17	100	101	O	of
18	103	110	O	XXXXXXXX
19	113	114	O	at
20	116	121	O	steady
21	123	127	O	state
22	128	128	O	,
23	130	138	O	Therefore
24	139	139	O	,
25	141	143	O	the
26	145	152	O	addition
27	154	155	O	of
28	157	165	U-UNK	valproate
29	167	168	O	is
30	170	172	O	not
31	174	181	O	expected
32	183	184	O	to
33	186	190	O	cause
34	192	192	O	a
35	194	203	O	clinically
36	205	213	O	important
37	215	220	O	effect
38	222	223	O	on
39	225	232	O	XXXXXXXX
40	236	244	U-UNK	felbamate
41	247	252	O	plasma
42	254	267	O	concentrations
NULL

Felbamate	DDI-DrugBank.d434.s33	NO_SECTION	NO_SETID	11
Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.
1	0	12	U-UNK	Phenobarbital
2	13	13	O	:
3	15	16	O	It
4	18	24	O	appears
5	26	29	O	that
6	31	43	U-KIN	phenobarbital
7	45	47	O	may
8	49	54	O	reduce
9	56	61	O	plasma
10	63	71	O	XXXXXXXX
11	73	86	O	concentrations
NULL

Felbamate	DDI-DrugBank.d434.s34	NO_SECTION	NO_SETID	32
Steady-state plasma felbamate concentrations were found to be 29% lower than the mean concentrations of a group of newly diagnosed subjects with epilepsy also receiving 2400 mg of felbamate a day.
1	0	5	O	Steady
2	7	11	O	state
3	13	18	O	plasma
4	20	28	O	XXXXXXXX
5	30	43	O	concentrations
6	45	48	O	were
7	50	54	O	found
8	56	57	O	to
9	59	60	O	be
10	62	64	O	29%
11	66	70	O	lower
12	72	75	O	than
13	77	79	O	the
14	81	84	O	mean
15	86	99	O	concentrations
16	101	102	O	of
17	104	104	O	a
18	106	110	O	group
19	112	113	O	of
20	115	119	O	newly
21	121	129	O	diagnosed
22	131	138	O	subjects
23	140	143	O	with
24	145	152	O	epilepsy
25	154	157	O	also
26	159	167	O	receiving
27	169	172	O	2400
28	174	175	O	mg
29	177	178	O	of
30	180	188	O	XXXXXXXX
31	190	190	O	a
32	192	194	O	day
NULL

Felbamate	DDI-DrugBank.d434.s35	NO_SECTION	NO_SETID	30
Effects of Antacids on Felbatol  The rate and extent of absorption of a 2400 mg dose of Felbatol  as monotherapy given as tablets was not affected when coadministered with antacids.
1	0	6	O	Effects
2	8	9	O	of
3	11	18	U-UNK	Antacids
4	20	21	O	on
5	23	30	O	XXXXXXXX
6	33	35	O	The
7	37	40	O	rate
8	42	44	O	and
9	46	51	O	extent
10	53	54	O	of
11	56	65	O	absorption
12	67	68	O	of
13	70	70	O	a
14	72	75	O	2400
15	77	78	O	mg
16	80	83	O	dose
17	85	86	O	of
18	88	95	O	XXXXXXXX
19	98	99	O	as
20	101	111	O	monotherapy
21	113	117	O	given
22	119	120	O	as
23	122	128	O	tablets
24	130	132	O	was
25	134	136	O	not
26	138	145	O	affected
27	147	150	O	when
28	152	165	O	coadministered
29	167	170	O	with
30	172	179	U-UNK	antacids
NULL

Felbamate	DDI-DrugBank.d434.s36	NO_SECTION	NO_SETID	52
Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.
1	0	6	O	Effects
2	8	9	O	of
3	11	22	U-UNK	Erythromycin
4	24	25	O	on
5	27	34	O	XXXXXXXX
6	37	39	O	The
7	41	56	O	coadministration
8	58	59	O	of
9	61	72	U-UNK	erythromycin
10	75	78	O	1000
11	80	81	O	mg
12	82	82	O	/
13	83	85	O	day
14	88	90	O	for
15	92	93	O	10
16	95	98	O	days
17	100	102	O	did
18	104	106	O	not
19	108	112	O	alter
20	114	116	O	the
21	118	132	O	pharmacokinetic
22	134	143	O	parameters
23	145	146	O	of
24	148	151	O	Cmax
25	152	152	O	,
26	154	157	O	Cmin
27	158	158	O	,
28	160	162	O	AUC
29	163	163	O	,
30	165	166	O	CI
31	167	167	O	/
32	168	169	O	kg
33	171	172	O	or
34	174	177	O	tmax
35	179	180	O	at
36	182	190	U-UNK	felbamate
37	192	196	O	daily
38	198	202	O	doses
39	204	205	O	of
40	207	210	O	3000
41	212	213	O	or
42	215	218	O	3600
43	220	221	O	mg
44	222	222	O	/
45	223	225	O	day
46	227	228	O	in
47	230	231	O	10
48	233	241	O	otherwise
49	243	249	O	healthy
50	251	258	O	subjects
51	260	263	O	with
52	265	272	O	epilepsy
NULL

Felbamate	DDI-DrugBank.d434.s37	NO_SECTION	NO_SETID	60
Effects of Felbatol  on Low-Dose Combination Oral Contraceptives A group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 mg ethinyl estradiol and 75 mg gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles.
1	0	6	O	Effects
2	8	9	O	of
3	11	18	O	XXXXXXXX
4	21	22	O	on
5	24	26	O	Low
6	28	31	O	Dose
7	33	43	B-UNK	Combination
8	45	48	I-UNK	Oral
9	50	63	L-UNK	Contraceptives
10	65	65	O	A
11	67	71	O	group
12	73	74	O	of
13	76	77	O	24
14	79	88	O	nonsmoking
15	89	89	O	,
16	91	97	O	healthy
17	99	103	O	white
18	105	110	O	female
19	112	121	O	volunteers
20	123	133	O	established
21	135	136	O	on
22	138	139	O	an
23	141	144	O	oral
24	146	158	U-UNK	contraceptive
25	160	166	O	regimen
26	168	177	O	containing
27	179	180	O	30
28	182	183	O	mg
29	185	191	B-UNK	ethinyl
30	193	201	L-UNK	estradiol
31	203	205	O	and
32	207	208	O	75
33	210	211	O	mg
34	213	221	U-UNK	gestodene
35	223	225	O	for
36	227	228	O	at
37	230	234	O	least
38	236	236	O	3
39	238	243	O	months
40	245	252	O	received
41	254	257	O	2400
42	259	260	O	mg
43	261	261	O	/
44	262	264	O	day
45	266	267	O	of
46	269	277	U-UNK	felbamate
47	279	282	O	from
48	284	291	O	midcycle
49	294	296	O	day
50	298	299	O	15
51	302	303	O	to
52	305	312	O	midcycle
53	315	317	O	day
54	319	320	O	14
55	323	324	O	of
56	326	328	O	two
57	330	340	O	consecutive
58	342	345	O	oral
59	347	359	U-UNK	contraceptive
60	361	366	O	cycles
NULL

Felbamate	DDI-DrugBank.d434.s38	NO_SECTION	NO_SETID	28
Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.
1	0	8	O	XXXXXXXX
2	10	18	O	treatment
3	20	27	O	resulted
4	29	30	O	in
5	32	32	O	a
6	34	36	O	42%
7	38	45	O	decrease
8	47	48	O	in
9	50	52	O	the
10	54	62	U-KIN	gestodene
11	64	66	O	AUC
12	68	68	O	0
13	70	71	O	24
14	72	72	O	,
15	74	76	O	but
16	78	79	O	no
17	81	90	O	clinically
18	92	99	O	relevant
19	101	106	O	effect
20	108	110	O	was
21	112	119	O	observed
22	121	122	O	on
23	124	126	O	the
24	128	142	O	pharmacokinetic
25	144	153	O	parameters
26	155	156	O	of
27	158	164	B-UNK	ethinyl
28	166	174	L-UNK	estradiol
NULL

Felbamate	DDI-DrugBank.d434.s39	NO_SECTION	NO_SETID	17
No volunteer showed hormonal evidence of ovulation, but one volunteer reported intermenstrual bleeding during felbamate treatment.
1	0	1	O	No
2	3	11	O	volunteer
3	13	18	O	showed
4	20	27	O	hormonal
5	29	36	O	evidence
6	38	39	O	of
7	41	49	O	ovulation
8	50	50	O	,
9	52	54	O	but
10	56	58	O	one
11	60	68	O	volunteer
12	70	77	O	reported
13	79	92	O	intermenstrual
14	94	101	O	bleeding
15	103	108	O	during
16	110	118	O	XXXXXXXX
17	120	128	O	treatment
NULL

Felodipine	DDI-DrugBank.d316.s0	NO_SECTION	NO_SETID	7
CYP3A4 Inhibitors Felodipine is metabolized by CYP3A4.
1	0	5	U-UNK	CYP3A4
2	7	16	O	Inhibitors
3	18	27	O	XXXXXXXX
4	29	30	O	is
5	32	42	O	metabolized
6	44	45	O	by
7	47	52	U-UNK	CYP3A4
NULL

Felodipine	DDI-DrugBank.d316.s1	NO_SECTION	NO_SETID	46
Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	26	O	CYP3A4
5	28	37	O	inhibitors
6	40	41	O	eg
7	42	42	O	,
8	44	55	U-UNK	ketoconazole
9	56	56	O	,
10	58	69	U-UNK	itraconazole
11	70	70	O	,
12	72	83	U-UNK	erythromycin
13	84	84	O	,
14	86	95	O	grapefruit
15	97	101	O	juice
16	102	102	O	,
17	104	113	U-UNK	cimetidine
18	116	119	O	with
19	121	130	O	XXXXXXXX
20	132	134	O	may
21	136	139	O	lead
22	141	142	O	to
23	144	150	O	several
24	153	156	O	fold
25	158	166	O	increases
26	168	169	O	in
27	171	173	O	the
28	175	180	O	plasma
29	182	187	O	levels
30	189	190	O	of
31	192	201	O	XXXXXXXX
32	202	202	O	,
33	204	209	O	either
34	211	213	O	due
35	215	216	O	to
36	218	219	O	an
37	221	228	O	increase
38	230	231	O	in
39	233	247	O	bioavailability
40	249	250	O	or
41	252	254	O	due
42	256	257	O	to
43	259	259	O	a
44	261	268	O	decrease
45	270	271	O	in
46	273	282	O	metabolism
NULL

Felodipine	DDI-DrugBank.d316.s2	NO_SECTION	NO_SETID	17
These increases in concentration may lead to increased effects, (lower blood pressure and increased heart rate).
1	0	4	O	These
2	6	14	O	increases
3	16	17	O	in
4	19	31	O	concentration
5	33	35	O	may
6	37	40	O	lead
7	42	43	O	to
8	45	53	O	increased
9	55	61	O	effects
10	62	62	O	,
11	65	69	O	lower
12	71	75	O	blood
13	77	84	O	pressure
14	86	88	O	and
15	90	98	O	increased
16	100	104	O	heart
17	106	109	O	rate
NULL

Felodipine	DDI-DrugBank.d316.s3	NO_SECTION	NO_SETID	14
These effects have been observed with co-administration of itraconazole (a potent CYP3A4 inhibitor).
1	0	4	O	These
2	6	12	O	effects
3	14	17	O	have
4	19	22	O	been
5	24	31	O	observed
6	33	36	O	with
7	38	39	O	co
8	41	54	O	administration
9	56	57	O	of
10	59	70	U-UNK	itraconazole
11	73	73	O	a
12	75	80	O	potent
13	82	87	U-UNK	CYP3A4
14	89	97	O	inhibitor
NULL

Felodipine	DDI-DrugBank.d316.s4	NO_SECTION	NO_SETID	12
Caution should be used when CYP3A4 inhibitors are co-administered with felodipine.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	26	O	when
6	28	33	U-UNK	CYP3A4
7	35	44	O	inhibitors
8	46	48	O	are
9	50	51	O	co
10	53	64	O	administered
11	66	69	O	with
12	71	80	O	XXXXXXXX
NULL

Felodipine	DDI-DrugBank.d316.s5	NO_SECTION	NO_SETID	9
A conservative approach to dosing felodipine should be taken.
1	0	0	O	A
2	2	13	O	conservative
3	15	22	O	approach
4	24	25	O	to
5	27	32	O	dosing
6	34	43	O	XXXXXXXX
7	45	50	O	should
8	52	53	O	be
9	55	59	O	taken
NULL

Felodipine	DDI-DrugBank.d316.s6	NO_SECTION	NO_SETID	49
The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of felodipine with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine.
1	0	2	O	The
2	4	12	O	following
3	14	21	O	specific
4	23	34	O	interactions
5	36	39	O	have
6	41	44	O	been
7	46	53	O	reported
8	54	54	O	:
9	56	67	O	Itraconazole
10	69	70	O	Co
11	72	85	O	administration
12	87	88	O	of
13	90	96	O	another
14	98	105	O	extended
15	107	113	O	release
16	115	125	O	formulation
17	127	128	O	of
18	130	139	O	XXXXXXXX
19	141	144	O	with
20	146	157	U-UNK	itraconazole
21	159	166	O	resulted
22	168	169	O	in
23	171	183	O	approximately
24	185	185	O	8
25	187	190	O	fold
26	192	199	O	increase
27	201	202	O	in
28	204	206	O	the
29	208	210	O	AUC
30	211	211	O	,
31	213	216	O	more
32	218	221	O	than
33	223	223	O	6
34	226	229	O	fold
35	231	238	O	increase
36	240	241	O	in
37	243	245	O	the
38	247	250	O	Cmax
39	251	251	O	,
40	253	255	O	and
41	257	257	O	2
42	259	262	O	fold
43	264	275	O	prolongation
44	277	278	O	in
45	280	282	O	the
46	284	287	O	half
47	290	293	O	life
48	295	296	O	of
49	298	307	O	XXXXXXXX
NULL

Felodipine	DDI-DrugBank.d316.s7	NO_SECTION	NO_SETID	31
Erythromycin Co-administration of felodipine (PLENDIL) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.
1	0	11	O	Erythromycin
2	13	14	O	Co
3	16	29	O	administration
4	31	32	O	of
5	34	43	O	XXXXXXXX
6	46	52	U-UNK	PLENDIL
7	55	58	O	with
8	60	71	U-UNK	erythromycin
9	73	80	O	resulted
10	82	83	O	in
11	85	97	O	approximately
12	99	101	O	2.5
13	104	107	O	fold
14	109	116	O	increase
15	118	119	O	in
16	121	123	O	the
17	125	127	O	AUC
18	129	131	O	and
19	133	136	O	Cmax
20	137	137	O	,
21	139	141	O	and
22	143	147	O	about
23	149	149	O	2
24	152	155	O	fold
25	157	168	O	prolongation
26	170	171	O	in
27	173	175	O	the
28	177	180	O	half
29	183	186	O	life
30	188	189	O	of
31	191	200	O	XXXXXXXX
NULL

Felodipine	DDI-DrugBank.d316.s8	NO_SECTION	NO_SETID	31
Grapefruit juice Co-administration of felodipine with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of felodipine.
1	0	9	O	Grapefruit
2	11	15	O	juice
3	17	18	O	Co
4	20	33	O	administration
5	35	36	O	of
6	38	47	O	XXXXXXXX
7	49	52	O	with
8	54	63	O	grapefruit
9	65	69	O	juice
10	71	78	O	resulted
11	80	81	O	in
12	83	86	O	more
13	88	91	O	than
14	93	93	O	2
15	95	98	O	fold
16	100	107	O	increase
17	109	110	O	in
18	112	114	O	the
19	116	118	O	AUC
20	120	122	O	and
21	124	127	O	Cmax
22	128	128	O	,
23	130	132	O	but
24	134	135	O	no
25	137	148	O	prolongation
26	150	151	O	in
27	153	155	O	the
28	157	160	O	half
29	163	166	O	life
30	168	169	O	of
31	171	180	O	XXXXXXXX
NULL

Felodipine	DDI-DrugBank.d316.s9	NO_SECTION	NO_SETID	29
Cimetidine Co-administration of felodipine with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine.
1	0	9	O	Cimetidine
2	11	12	O	Co
3	14	27	O	administration
4	29	30	O	of
5	32	41	O	XXXXXXXX
6	43	46	O	with
7	48	57	U-UNK	cimetidine
8	60	60	O	a
9	62	64	O	non
10	66	73	O	specific
11	75	77	O	CYP
12	79	81	O	450
13	83	91	O	inhibitor
14	94	101	O	resulted
15	103	104	O	in
16	106	107	O	an
17	109	116	O	increase
18	118	119	O	of
19	121	133	O	approximately
20	135	137	O	50%
21	139	140	O	in
22	142	144	O	the
23	146	148	O	AUC
24	150	152	O	and
25	154	156	O	the
26	158	161	O	Cmax
27	162	162	O	,
28	164	165	O	of
29	167	176	O	XXXXXXXX
NULL

Felodipine	DDI-DrugBank.d316.s10	NO_SECTION	NO_SETID	21
Beta-Blocking Agents  A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine.
1	0	3	O	Beta
2	5	12	O	Blocking
3	14	19	O	Agents
4	22	22	O	A
5	24	38	O	pharmacokinetic
6	40	44	O	study
7	46	47	O	of
8	49	58	O	XXXXXXXX
9	60	61	O	in
10	63	73	O	conjunction
11	75	78	O	with
12	80	89	U-UNK	metoprolol
13	91	102	O	demonstrated
14	104	105	O	no
15	107	117	O	significant
16	119	125	O	effects
17	127	128	O	on
18	130	132	O	the
19	134	149	O	pharmacokinetics
20	151	152	O	of
21	154	163	O	XXXXXXXX
NULL

Felodipine	DDI-DrugBank.d316.s11	NO_SECTION	NO_SETID	17
The AUC and Cmax of metoprolol, however, were increased approximately 31 and 38%, respectively.
1	0	2	O	The
2	4	6	O	AUC
3	8	10	O	and
4	12	15	O	Cmax
5	17	18	O	of
6	20	29	U-UNK	metoprolol
7	30	30	O	,
8	32	38	O	however
9	39	39	O	,
10	41	44	O	were
11	46	54	O	increased
12	56	68	O	approximately
13	70	71	O	31
14	73	75	O	and
15	77	79	O	38%
16	80	80	O	,
17	82	93	O	respectively
NULL

Felodipine	DDI-DrugBank.d316.s12	NO_SECTION	NO_SETID	20
In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated.
1	0	1	O	In
2	3	12	O	controlled
3	14	21	O	clinical
4	23	28	O	trials
5	29	29	O	,
6	31	37	O	however
7	38	38	O	,
8	40	43	B-UNK	beta
9	45	52	L-UNK	blockers
10	54	62	O	including
11	64	73	U-UNK	metoprolol
12	75	78	O	were
13	80	91	O	concurrently
14	93	104	O	administered
15	106	109	O	with
16	111	120	O	XXXXXXXX
17	122	124	O	and
18	126	129	O	were
19	131	134	O	well
20	136	144	O	tolerated
NULL

Felodipine	DDI-DrugBank.d316.s13	NO_SECTION	NO_SETID	19
Digoxin  When given concomitantly with PLENDIL the pharmacokinetics of digoxin in patients with heart failure were not significantly altered.
1	0	6	O	Digoxin
2	9	12	O	When
3	14	18	O	given
4	20	32	O	concomitantly
5	34	37	O	with
6	39	45	U-UNK	PLENDIL
7	47	49	O	the
8	51	66	O	pharmacokinetics
9	68	69	O	of
10	71	77	U-UNK	digoxin
11	79	80	O	in
12	82	89	O	patients
13	91	94	O	with
14	96	100	O	heart
15	102	108	O	failure
16	110	113	O	were
17	115	117	O	not
18	119	131	O	significantly
19	133	139	O	altered
NULL

Felodipine	DDI-DrugBank.d316.s14	NO_SECTION	NO_SETID	35
Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
1	0	14	U-UNK	Anticonvulsants
2	15	15	O	:
3	17	18	O	In
4	20	20	O	a
5	22	36	O	pharmacokinetic
6	38	42	O	study
7	43	43	O	,
8	45	51	O	maximum
9	53	58	O	plasma
10	60	73	O	concentrations
11	75	76	O	of
12	78	87	O	XXXXXXXX
13	89	92	O	were
14	94	105	O	considerably
15	107	111	O	lower
16	113	114	O	in
17	116	124	O	epileptic
18	126	133	O	patients
19	135	136	O	on
20	138	141	O	long
21	143	146	O	term
22	148	161	U-KIN	anticonvulsant
23	163	169	O	therapy
24	172	173	O	eg
25	174	174	O	,
26	176	184	U-KIN	phenytoin
27	185	185	O	,
28	187	199	U-KIN	carbamazepine
29	200	200	O	,
30	202	203	O	or
31	205	217	U-KIN	phenobarbital
32	220	223	O	than
33	225	226	O	in
34	228	234	O	healthy
35	236	245	O	volunteers
NULL

Felodipine	DDI-DrugBank.d316.s15	NO_SECTION	NO_SETID	26
In such patients, the mean area under the felodipine plasma concentration-time curve was also reduced to approximately 6% of that observed in healthy volunteers.
1	0	1	O	In
2	3	6	O	such
3	8	15	O	patients
4	16	16	O	,
5	18	20	O	the
6	22	25	O	mean
7	27	30	O	area
8	32	36	O	under
9	38	40	O	the
10	42	51	O	XXXXXXXX
11	53	58	O	plasma
12	60	72	O	concentration
13	74	77	O	time
14	79	83	O	curve
15	85	87	O	was
16	89	92	O	also
17	94	100	O	reduced
18	102	103	O	to
19	105	117	O	approximately
20	119	120	O	6%
21	122	123	O	of
22	125	128	O	that
23	130	137	O	observed
24	139	140	O	in
25	142	148	O	healthy
26	150	159	O	volunteers
NULL

Felodipine	DDI-DrugBank.d316.s16	NO_SECTION	NO_SETID	18
Since a clinically significant interaction may be anticipated, alternative antihypertensive therapy should be considered in these patients.
1	0	4	O	Since
2	6	6	O	a
3	8	17	O	clinically
4	19	29	O	significant
5	31	41	O	interaction
6	43	45	O	may
7	47	48	O	be
8	50	60	O	anticipated
9	61	61	O	,
10	63	73	O	alternative
11	75	90	U-UNK	antihypertensive
12	92	98	O	therapy
13	100	105	O	should
14	107	108	O	be
15	110	119	O	considered
16	121	122	O	in
17	124	128	O	these
18	130	137	O	patients
NULL

Felodipine	DDI-DrugBank.d316.s17	NO_SECTION	NO_SETID	9
Tacrolimus  Felodipine may increase the blood concentration of tacrolimus.
1	0	9	O	Tacrolimus
2	12	21	O	XXXXXXXX
3	23	25	O	may
4	27	34	O	increase
5	36	38	O	the
6	40	44	O	blood
7	46	58	O	concentration
8	60	61	O	of
9	63	72	U-UNK	tacrolimus
NULL

Felodipine	DDI-DrugBank.d316.s18	NO_SECTION	NO_SETID	22
When given concomitantly with felodipine, the tacrolimus blood concentration should be followed and the tacrolimus dose may need to be adjusted.
1	0	3	O	When
2	5	9	O	given
3	11	23	O	concomitantly
4	25	28	O	with
5	30	39	O	XXXXXXXX
6	40	40	O	,
7	42	44	O	the
8	46	55	U-UNK	tacrolimus
9	57	61	O	blood
10	63	75	O	concentration
11	77	82	O	should
12	84	85	O	be
13	87	94	O	followed
14	96	98	O	and
15	100	102	O	the
16	104	113	O	tacrolimus
17	115	118	O	dose
18	120	122	O	may
19	124	127	O	need
20	129	130	O	to
21	132	133	O	be
22	135	142	O	adjusted
NULL

Felodipine	DDI-DrugBank.d316.s19	NO_SECTION	NO_SETID	21
Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone.
1	0	4	O	Other
2	6	16	O	Concomitant
3	18	24	O	Therapy
4	27	28	O	In
5	30	36	O	healthy
6	38	45	O	subjects
7	47	51	O	there
8	53	56	O	were
9	58	59	O	no
10	61	70	O	clinically
11	72	82	O	significant
12	84	95	O	interactions
13	97	100	O	when
14	102	111	O	XXXXXXXX
15	113	115	O	was
16	117	121	O	given
17	123	135	O	concomitantly
18	137	140	O	with
19	142	153	U-UNK	indomethacin
20	155	156	O	or
21	158	171	U-UNK	spironolactone
NULL

Felodipine	DDI-DrugBank.d316.s20	NO_SECTION	NO_SETID	10
Interaction with Food  See CLINICAL PHARMACOLOGY, Pharmacokinetics and Metabolism.
1	0	10	O	Interaction
2	12	15	O	with
3	17	20	O	Food
4	23	25	O	See
5	27	34	O	CLINICAL
6	36	47	O	PHARMACOLOGY
7	48	48	O	,
8	50	65	O	Pharmacokinetics
9	67	69	O	and
10	71	80	O	Metabolism
NULL

Fenfluramine	DDI-DrugBank.d104.s0	NO_SECTION	NO_SETID	17
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.
1	0	11	O	XXXXXXXX
2	13	15	O	may
3	17	24	O	increase
4	26	33	O	slightly
5	35	37	O	the
6	39	44	O	effect
7	46	47	O	of
8	49	64	B-DYN	antihypertensive
9	66	70	L-DYN	drugs
10	71	71	O	,
11	73	75	O	e.g
12	77	77	O	,
13	79	90	U-DYN	guanethidine
14	91	91	O	,
15	93	102	U-DYN	methyldopa
16	103	103	O	,
17	105	113	U-DYN	reserpine
NULL

Fenfluramine	DDI-DrugBank.d104.s1	NO_SECTION	NO_SETID	20
Other CNS depressant drugs should be used with caution in patients taking fenfluramine, since the effects may be additive.
1	0	4	O	Other
2	6	8	B-DYN	CNS
3	10	19	I-DYN	depressant
4	21	25	L-DYN	drugs
5	27	32	O	should
6	34	35	O	be
7	37	40	O	used
8	42	45	O	with
9	47	53	O	caution
10	55	56	O	in
11	58	65	O	patients
12	67	72	O	taking
13	74	85	O	XXXXXXXX
14	86	86	O	,
15	88	92	O	since
16	94	96	O	the
17	98	104	O	effects
18	106	108	O	may
19	110	111	O	be
20	113	120	O	additive
NULL

Fenofibrate	DDI-DrugBank.d283.s0	NO_SECTION	NO_SETID	15
Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR.
1	0	3	O	Oral
2	5	18	U-UNK	Anticoagulants
3	20	26	O	CAUTION
4	28	33	O	SHOULD
5	35	36	O	BE
6	38	46	O	EXERCISED
7	48	51	O	WHEN
8	53	60	B-DYN	COUMARIN
9	62	75	L-DYN	ANTICOAGULANTS
10	77	79	O	ARE
11	81	85	O	GIVEN
12	87	88	O	IN
13	90	100	O	CONJUNCTION
14	102	105	O	WITH
15	107	112	O	XXXXXXXX
NULL

Fenofibrate	DDI-DrugBank.d283.s1	NO_SECTION	NO_SETID	23
THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS.
1	0	2	O	THE
2	4	9	O	DOSAGE
3	11	12	O	OF
4	14	16	O	THE
5	18	31	U-UNK	ANTICOAGULANTS
6	33	38	O	SHOULD
7	40	41	O	BE
8	43	49	O	REDUCED
9	51	52	O	TO
10	54	61	O	MAINTAIN
11	63	65	O	THE
12	67	77	O	PROTHROMBIN
13	79	82	O	TIME
14	83	83	O	/
15	84	86	O	INR
16	88	89	O	AT
17	91	93	O	THE
18	95	101	O	DESIRED
19	103	107	O	LEVEL
20	109	110	O	TO
21	112	118	O	PREVENT
22	120	127	O	BLEEDING
23	129	141	O	COMPLICATIONS
NULL

Fenofibrate	DDI-DrugBank.d283.s2	NO_SECTION	NO_SETID	22
FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED.
1	0	7	O	FREQUENT
2	9	19	O	PROTHROMBIN
3	21	24	O	TIME
4	25	25	O	/
5	26	28	O	INR
6	30	43	O	DETERMINATIONS
7	45	47	O	ARE
8	49	57	O	ADVISABLE
9	59	63	O	UNTIL
10	65	66	O	IT
11	68	70	O	HAS
12	72	75	O	BEEN
13	77	86	O	DEFINITELY
14	88	97	O	DETERMINED
15	99	102	O	THAT
16	104	106	O	THE
17	108	118	O	PROTHROMBIN
18	120	123	O	TIME
19	124	124	O	/
20	125	127	O	INR
21	129	131	O	HAS
22	133	142	O	STABILIZED
NULL

Fenofibrate	DDI-DrugBank.d283.s3	NO_SECTION	NO_SETID	38
HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.
1	0	2	B-UNK	HMG
2	4	6	I-UNK	CoA
3	8	16	I-UNK	reductase
4	18	27	L-UNK	inhibitors
5	28	28	O	:
6	30	32	O	The
7	34	41	O	combined
8	43	45	O	use
9	47	48	O	of
10	50	55	O	XXXXXXXX
11	57	59	O	and
12	61	63	B-DYN	HMG
13	65	67	I-DYN	CoA
14	69	77	I-DYN	reductase
15	79	88	L-DYN	inhibitors
16	90	95	O	should
17	97	98	O	be
18	100	106	O	avoided
19	108	113	O	unless
20	115	117	O	the
21	119	125	O	benefit
22	127	128	O	of
23	130	136	O	further
24	138	148	O	alterations
25	150	151	O	in
26	153	157	O	lipid
27	159	164	O	levels
28	166	167	O	is
29	169	174	O	likely
30	176	177	O	to
31	179	186	O	outweigh
32	188	190	O	the
33	192	200	O	increased
34	202	205	O	risk
35	207	208	O	of
36	210	213	O	this
37	215	218	O	drug
38	220	230	O	combination
NULL

Fenofibrate	DDI-DrugBank.d283.s4	NO_SECTION	NO_SETID	37
Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.
1	0	5	U-UNK	Resins
2	6	6	O	:
3	8	12	O	Since
4	14	17	B-UNK	bile
5	19	22	I-UNK	acid
6	24	35	L-UNK	sequestrants
7	37	39	O	may
8	41	44	O	bind
9	46	50	O	other
10	52	56	O	drugs
11	58	62	O	given
12	64	75	O	concurrently
13	76	76	O	,
14	78	85	O	patients
15	87	92	O	should
16	94	97	O	take
17	99	104	O	XXXXXXXX
18	106	107	O	at
19	109	113	O	least
20	115	115	O	1
21	117	120	O	hour
22	122	127	O	before
23	129	130	O	or
24	132	132	O	4
25	134	134	O	6
26	136	140	O	hours
27	142	146	O	after
28	148	148	O	a
29	150	153	B-KIN	bile
30	155	158	I-KIN	acid
31	160	166	I-KIN	binding
32	168	172	L-KIN	resin
33	174	175	O	to
34	177	181	O	avoid
35	183	190	O	impeding
36	192	194	O	its
37	196	205	O	absorption
NULL

Fenofibrate	DDI-DrugBank.d283.s5	NO_SECTION	NO_SETID	44
Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.
1	0	11	U-UNK	Cyclosporine
2	12	12	O	:
3	14	20	O	Because
4	22	33	U-DYN	cyclosporine
5	35	37	O	can
6	39	45	O	produce
7	47	60	O	nephrotoxicity
8	62	65	O	with
9	67	75	O	decreases
10	77	78	O	in
11	80	89	O	creatinine
12	91	99	O	clearance
13	101	103	O	and
14	105	109	O	rises
15	111	112	O	in
16	114	118	O	serum
17	120	129	O	creatinine
18	130	130	O	,
19	132	134	O	and
20	136	142	O	because
21	144	148	O	renal
22	150	158	O	excretion
23	160	161	O	is
24	163	165	O	the
25	167	173	O	primary
26	175	185	O	elimination
27	187	191	O	route
28	193	194	O	of
29	196	202	B-UNK	fibrate
30	204	208	L-UNK	drugs
31	210	218	O	including
32	220	225	O	XXXXXXXX
33	226	226	O	,
34	228	232	O	there
35	234	235	O	is
36	237	237	O	a
37	239	242	O	risk
38	244	247	O	that
39	249	250	O	an
40	252	262	O	interaction
41	264	267	O	will
42	269	272	O	lead
43	274	275	O	to
44	277	289	O	deterioration
NULL

Fenofibrate	DDI-DrugBank.d283.s6	NO_SECTION	NO_SETID	25
The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed
1	0	2	O	The
2	4	11	O	benefits
3	13	15	O	and
4	17	21	O	risks
5	23	24	O	of
6	26	30	O	using
7	32	37	O	XXXXXXXX
8	39	42	O	with
9	44	61	U-DYN	immunosuppressants
10	63	65	O	and
11	67	71	O	other
12	73	83	O	potentially
13	85	95	O	nephrotoxic
14	97	102	O	agents
15	104	109	O	should
16	111	112	O	be
17	114	122	O	carefully
18	124	133	O	considered
19	134	134	O	,
20	136	138	O	and
21	140	142	O	the
22	144	149	O	lowest
23	151	159	O	effective
24	161	164	O	dose
25	166	173	O	employed
NULL

Fenofibrate	DDI-DrugBank.d283.s8	NO_SECTION	NO_SETID	32
Drug-drug interactions In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.
1	0	3	O	Drug
2	5	8	O	drug
3	10	21	O	interactions
4	23	24	O	In
5	26	30	O	vitro
6	32	38	O	studies
7	40	44	O	using
8	46	50	O	human
9	52	56	O	liver
10	58	67	O	microsomes
11	69	76	O	indicate
12	78	81	O	that
13	83	93	O	XXXXXXXX
14	95	97	O	and
15	99	108	B-UNK	fenofibric
16	110	113	L-UNK	acid
17	115	117	O	are
18	119	121	O	not
19	123	132	O	inhibitors
20	134	135	O	of
21	137	146	O	cytochrome
22	149	151	O	CYP
23	154	157	O	P450
24	159	166	O	isoforms
25	168	173	O	CYP3A4
26	174	174	O	,
27	176	181	O	CYP2D6
28	182	182	O	,
29	184	189	O	CYP2E1
30	190	190	O	,
31	192	193	O	or
32	195	200	O	CYP1A2
NULL

Fenofibrate	DDI-DrugBank.d283.s9	NO_SECTION	NO_SETID	19
They are weak inhibitors of CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.
1	0	3	O	They
2	5	7	O	are
3	9	12	O	weak
4	14	23	O	inhibitors
5	25	26	O	of
6	28	34	O	CYP2C19
7	36	38	O	and
8	40	45	O	CYP2A6
9	46	46	O	,
10	48	50	O	and
11	52	55	O	mild
12	57	58	O	to
13	60	67	O	moderate
14	69	78	O	inhibitors
15	80	81	O	of
16	83	88	O	CYP2C9
17	90	91	O	at
18	93	103	O	therapeutic
19	105	118	O	concentrations
NULL

Fenofibrate	DDI-DrugBank.d283.s10	NO_SECTION	NO_SETID	16
Potentiation of coumarin-type anticoagulants has been observed with prolongation of the prothrombin time/INR.
1	0	11	O	Potentiation
2	13	14	O	of
3	16	23	B-UNK	coumarin
4	25	28	I-UNK	type
5	30	43	L-UNK	anticoagulants
6	45	47	O	has
7	49	52	O	been
8	54	61	O	observed
9	63	66	O	with
10	68	79	O	prolongation
11	81	82	O	of
12	84	86	O	the
13	88	98	O	prothrombin
14	100	103	O	time
15	104	104	O	/
16	105	107	O	INR
NULL

Fenofibrate	DDI-DrugBank.d283.s11	NO_SECTION	NO_SETID	12
Bile acid sequestrants have been shown to bind other drugs given concurrently.
1	0	3	B-UNK	Bile
2	5	8	I-UNK	acid
3	10	21	L-UNK	sequestrants
4	23	26	O	have
5	28	31	O	been
6	33	37	O	shown
7	39	40	O	to
8	42	45	O	bind
9	47	51	O	other
10	53	57	O	drugs
11	59	63	O	given
12	65	76	O	concurrently
NULL

Fenofibrate	DDI-DrugBank.d283.s12	NO_SECTION	NO_SETID	26
Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption .
1	0	8	O	Therefore
2	9	9	O	,
3	11	21	O	XXXXXXXX
4	23	28	O	should
5	30	31	O	be
6	33	37	O	taken
7	39	40	O	at
8	42	46	O	least
9	48	48	O	1
10	50	53	O	hour
11	55	60	O	before
12	62	63	O	or
13	65	65	O	4
14	67	67	O	6
15	69	73	O	hours
16	75	79	O	after
17	81	81	O	a
18	83	86	B-DYN	bile
19	88	91	I-DYN	acid
20	93	99	I-DYN	binding
21	101	105	L-DYN	resin
22	107	108	O	to
23	110	114	O	avoid
24	116	123	O	impeding
25	125	127	O	its
26	129	138	O	absorption
NULL

Fenofibrate	DDI-DrugBank.d283.s13	NO_SECTION	NO_SETID	81
Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	40	U-UNK	fenofibrate
5	43	52	O	equivalent
6	54	55	O	to
7	57	61	O	145mg
8	63	68	O	XXXXXXXX
9	71	74	O	with
10	76	86	U-KIN	pravastatin
11	89	90	O	40
12	92	93	O	mg
13	96	99	O	once
14	101	105	O	daily
15	107	109	O	for
16	111	112	O	10
17	114	117	O	days
18	119	121	O	has
19	123	126	O	been
20	128	132	O	shown
21	134	135	O	to
22	137	144	O	increase
23	146	148	O	the
24	150	153	O	mean
25	155	158	O	Cmax
26	160	162	O	and
27	164	166	O	AUC
28	168	173	O	values
29	175	177	O	for
30	179	189	U-UNK	pravastatin
31	191	192	O	by
32	194	196	O	36%
33	199	203	O	range
34	205	208	O	from
35	210	212	O	69%
36	214	221	O	decrease
37	223	224	O	to
38	226	229	O	321%
39	231	238	O	increase
40	241	243	O	and
41	245	247	O	28%
42	250	254	O	range
43	256	259	O	from
44	261	263	O	54%
45	265	272	O	decrease
46	274	275	O	to
47	277	280	O	128%
48	282	289	O	increase
49	291	291	O	,
50	293	304	O	respectively
51	305	305	O	,
52	307	309	O	and
53	311	313	O	for
54	315	315	O	3
55	318	324	O	hydroxy
56	326	328	O	iso
57	330	340	O	pravastatin
58	342	343	O	by
59	345	347	O	55%
60	350	354	O	range
61	356	359	O	from
62	361	363	O	32%
63	365	372	O	decrease
64	374	375	O	to
65	377	380	O	314%
66	382	389	O	increase
67	392	394	O	and
68	396	398	O	39%
69	401	405	O	range
70	407	410	O	from
71	412	414	O	24%
72	416	423	O	decrease
73	425	426	O	to
74	428	431	O	261%
75	433	440	O	increase
76	442	442	O	,
77	444	455	O	respectively
78	457	458	O	in
79	460	461	O	23
80	463	469	O	healthy
81	471	476	O	adults
NULL

Fenofibrate	DDI-DrugBank.d283.s14	NO_SECTION	NO_SETID	16
A single dose of pravastatin had no clinically important effect on the pharmacokinetics of fenofibric acid.
1	0	0	O	A
2	2	7	O	single
3	9	12	O	dose
4	14	15	O	of
5	17	27	U-UNK	pravastatin
6	29	31	O	had
7	33	34	O	no
8	36	45	O	clinically
9	47	55	O	important
10	57	62	O	effect
11	64	65	O	on
12	67	69	O	the
13	71	86	O	pharmacokinetics
14	88	89	O	of
15	91	100	B-UNK	fenofibric
16	102	105	L-UNK	acid
NULL

Fenofibrate	DDI-DrugBank.d283.s15	NO_SECTION	NO_SETID	38
Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	40	U-UNK	fenofibrate
5	43	52	O	equivalent
6	54	55	O	to
7	57	59	O	145
8	61	62	O	mg
9	64	69	O	XXXXXXXX
10	72	75	O	with
11	77	88	U-KIN	atorvastatin
12	91	92	O	20
13	94	95	O	mg
14	98	101	O	once
15	103	107	O	daily
16	109	111	O	for
17	113	114	O	10
18	116	119	O	days
19	121	128	O	resulted
20	130	131	O	in
21	133	145	O	approximately
22	147	149	O	17%
23	151	158	O	decrease
24	161	165	O	range
25	167	170	O	from
26	172	174	O	67%
27	176	183	O	decrease
28	185	186	O	to
29	188	190	O	44%
30	192	199	O	increase
31	202	203	O	in
32	205	216	U-UNK	atorvastatin
33	218	220	O	AUC
34	222	227	O	values
35	229	230	O	in
36	232	233	O	22
37	235	241	O	healthy
38	243	247	O	males
NULL

Fenofibrate	DDI-DrugBank.d283.s16	NO_SECTION	NO_SETID	10
The atorvastatin Cmax values were not significantly affected by fenofibrate.
1	0	2	O	The
2	4	15	U-UNK	atorvastatin
3	17	20	O	Cmax
4	22	27	O	values
5	29	32	O	were
6	34	36	O	not
7	38	50	O	significantly
8	52	59	O	affected
9	61	62	O	by
10	64	74	O	XXXXXXXX
NULL

Fenofibrate	DDI-DrugBank.d283.s17	NO_SECTION	NO_SETID	11
The pharmacokinetics of fenofibric acid were not significantly affected by atorvastatin
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	33	B-UNK	fenofibric
5	35	38	L-UNK	acid
6	40	43	O	were
7	45	47	O	not
8	49	61	O	significantly
9	63	70	O	affected
10	72	73	O	by
11	75	86	U-UNK	atorvastatin
NULL

Fenoldopam	DDI-DrugBank.d546.s0	NO_SECTION	NO_SETID	16
Drug Interactions with Beta-Blockers: Concomitant use of fenoldopam with beta-blockers should be avoided.
1	0	3	O	Drug
2	5	16	O	Interactions
3	18	21	O	with
4	23	26	B-UNK	Beta
5	28	35	L-UNK	Blockers
6	36	36	O	:
7	38	48	O	Concomitant
8	50	52	O	use
9	54	55	O	of
10	57	66	O	XXXXXXXX
11	68	71	O	with
12	73	76	B-DYN	beta
13	78	85	L-DYN	blockers
14	87	92	O	should
15	94	95	O	be
16	97	103	O	avoided
NULL

Fenoldopam	DDI-DrugBank.d546.s1	NO_SECTION	NO_SETID	27
If the drugs are used together, caution should be exercised because unexpected hypotension could result from beta-blocker inhibition of the sympathetic reflex response to fenoldopam.
1	0	1	O	If
2	3	5	O	the
3	7	11	O	drugs
4	13	15	O	are
5	17	20	O	used
6	22	29	O	together
7	30	30	O	,
8	32	38	O	caution
9	40	45	O	should
10	47	48	O	be
11	50	58	O	exercised
12	60	66	O	because
13	68	77	O	unexpected
14	79	89	O	hypotension
15	91	95	O	could
16	97	102	O	result
17	104	107	O	from
18	109	112	O	beta
19	114	120	O	blocker
20	122	131	O	inhibition
21	133	134	O	of
22	136	138	O	the
23	140	150	O	sympathetic
24	152	157	O	reflex
25	159	166	O	response
26	168	169	O	to
27	171	180	O	XXXXXXXX
NULL

Fenoldopam	DDI-DrugBank.d546.s2	NO_SECTION	NO_SETID	28
Drug Interactions, General: Although there have been no formal interaction studies, intravenous fenoldopam has been administered safely with drugs such as digitalis and sublingual nitroglycerin.
1	0	3	O	Drug
2	5	16	O	Interactions
3	17	17	O	,
4	19	25	O	General
5	26	26	O	:
6	28	35	O	Although
7	37	41	O	there
8	43	46	O	have
9	48	51	O	been
10	53	54	O	no
11	56	61	O	formal
12	63	73	O	interaction
13	75	81	O	studies
14	82	82	O	,
15	84	94	O	intravenous
16	96	105	O	XXXXXXXX
17	107	109	O	has
18	111	114	O	been
19	116	127	O	administered
20	129	134	O	safely
21	136	139	O	with
22	141	145	O	drugs
23	147	150	O	such
24	152	153	O	as
25	155	163	U-UNK	digitalis
26	165	167	O	and
27	169	178	O	sublingual
28	180	192	U-UNK	nitroglycerin
NULL

Fenoldopam	DDI-DrugBank.d546.s3	NO_SECTION	NO_SETID	27
There is limited experience with concomitant antihypertensive agents such as alpha-blockers, calcium channel-blockers, ACE inhibitors, and diuretics (both thiazide-like and loop).
1	0	4	O	There
2	6	7	O	is
3	9	15	O	limited
4	17	26	O	experience
5	28	31	O	with
6	33	43	O	concomitant
7	45	60	B-UNK	antihypertensive
8	62	67	L-UNK	agents
9	69	72	O	such
10	74	75	O	as
11	77	81	B-UNK	alpha
12	83	90	L-UNK	blockers
13	91	91	O	,
14	93	99	B-UNK	calcium
15	101	107	I-UNK	channel
16	109	116	L-UNK	blockers
17	117	117	O	,
18	119	121	B-UNK	ACE
19	123	132	L-UNK	inhibitors
20	133	133	O	,
21	135	137	O	and
22	139	147	U-UNK	diuretics
23	150	153	O	both
24	155	162	U-UNK	thiazide
25	164	167	O	like
26	169	171	O	and
27	173	176	O	loop
NULL

Fenoprofen	DDI-DrugBank.d154.s0	NO_SECTION	NO_SETID	30
The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.
1	0	2	O	The
2	4	19	O	coadministration
3	21	22	O	of
4	24	30	O	XXXXXXXX
5	32	40	O	decreases
6	42	44	O	the
7	46	53	O	biologic
8	55	58	O	half
9	60	63	O	life
10	65	66	O	of
11	68	77	U-KIN	fenoprofen
12	79	85	O	because
13	87	88	O	of
14	90	91	O	an
15	93	100	O	increase
16	102	103	O	in
17	105	113	O	metabolic
18	115	123	O	clearance
19	125	128	O	that
20	130	136	O	results
21	138	139	O	in
22	141	141	O	a
23	143	149	O	greater
24	151	156	O	amount
25	158	159	O	of
26	161	172	B-UNK	hydroxylated
27	174	183	L-UNK	fenoprofen
28	185	186	O	in
29	188	190	O	the
30	192	196	O	urine
NULL

Fenoprofen	DDI-DrugBank.d154.s1	NO_SECTION	NO_SETID	27
Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.
1	0	7	O	Although
2	9	11	O	the
3	13	21	O	mechanism
4	23	24	O	of
5	26	36	O	interaction
6	38	44	O	between
7	46	55	U-KIN	fenoprofen
8	57	59	O	and
9	61	67	O	XXXXXXXX
10	69	70	O	is
11	72	74	O	not
12	76	82	O	totally
13	84	88	O	known
14	89	89	O	,
15	91	96	O	enzyme
16	98	106	O	induction
17	108	110	O	and
18	112	123	O	displacement
19	125	126	O	of
20	128	137	U-UNK	fenoprofen
21	139	142	O	from
22	144	149	O	plasma
23	151	157	O	albumin
24	159	165	O	binding
25	167	171	O	sites
26	173	175	O	are
27	177	189	O	possibilities
NULL

Fenoprofen	DDI-DrugBank.d154.s2	NO_SECTION	NO_SETID	38
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.
1	0	6	O	Because
2	8	13	O	XXXXXXXX
3	15	17	O	has
4	19	21	O	not
5	23	26	O	been
6	28	32	O	shown
7	34	35	O	to
8	37	43	O	produce
9	45	47	O	any
10	49	58	O	additional
11	60	65	O	effect
12	67	72	O	beyond
13	74	77	O	that
14	79	86	O	obtained
15	88	91	O	with
16	93	99	O	aspirin
17	101	105	O	alone
18	107	109	O	and
19	111	117	O	because
20	119	125	O	aspirin
21	127	135	O	increases
22	137	139	O	the
23	141	144	O	rate
24	146	147	O	of
25	149	157	O	excretion
26	159	160	O	of
27	162	167	U-KIN	XXXXXXXX
28	168	168	O	,
29	170	172	O	the
30	174	184	O	concomitant
31	186	188	O	use
32	190	191	O	of
33	193	198	O	XXXXXXXX
34	200	202	O	and
35	204	214	U-DYN	salicylates
36	216	217	O	is
37	219	221	O	not
38	223	233	O	recommended
NULL

Fenoprofen	DDI-DrugBank.d154.s3	NO_SECTION	NO_SETID	23
Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.
1	0	6	O	Chronic
2	8	21	O	administration
3	23	24	O	of
4	26	38	U-KIN	phenobarbital
5	39	39	O	,
6	41	41	O	a
7	43	47	O	known
8	49	54	O	enzyme
9	56	62	O	inducer
10	63	63	O	,
11	65	67	O	may
12	69	70	O	be
13	72	81	O	associated
14	83	86	O	with
15	88	88	O	a
16	90	97	O	decrease
17	99	100	O	in
18	102	104	O	the
19	106	111	O	plasma
20	113	116	O	half
21	118	121	O	life
22	123	124	O	of
23	126	135	O	XXXXXXXX
NULL

Fenoprofen	DDI-DrugBank.d154.s4	NO_SECTION	NO_SETID	17
When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.
1	0	3	O	When
2	5	17	U-DYN	phenobarbital
3	19	20	O	is
4	22	26	O	added
5	28	29	O	to
6	31	32	O	or
7	34	42	O	withdrawn
8	44	47	O	from
9	49	57	O	treatment
10	58	58	O	,
11	60	65	O	dosage
12	67	76	O	adjustment
13	78	79	O	of
14	81	86	O	XXXXXXXX
15	88	90	O	may
16	92	93	O	be
17	95	102	O	required
NULL

Fenoprofen	DDI-DrugBank.d154.s5	NO_SECTION	NO_SETID	36
In vitro studies have shown that fenoprofen, because of its affinity for albumin, may displace from their binding sites other drugs that are also albumin bound, and this may lead to drug interaction.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	26	O	shown
6	28	31	O	that
7	33	42	O	XXXXXXXX
8	43	43	O	,
9	45	51	O	because
10	53	54	O	of
11	56	58	O	its
12	60	67	O	affinity
13	69	71	O	for
14	73	79	O	albumin
15	80	80	O	,
16	82	84	O	may
17	86	93	O	displace
18	95	98	O	from
19	100	104	O	their
20	106	112	O	binding
21	114	118	O	sites
22	120	124	O	other
23	126	130	O	drugs
24	132	135	O	that
25	137	139	O	are
26	141	144	O	also
27	146	152	O	albumin
28	154	158	O	bound
29	159	159	O	,
30	161	163	O	and
31	165	168	O	this
32	170	172	O	may
33	174	177	O	lead
34	179	180	O	to
35	182	185	O	drug
36	187	197	O	interaction
NULL

Fenoprofen	DDI-DrugBank.d154.s6	NO_SECTION	NO_SETID	7
Theoretically, fenoprofen could likewise be displaced.
1	0	12	O	Theoretically
2	13	13	O	,
3	15	24	O	XXXXXXXX
4	26	30	O	could
5	32	39	O	likewise
6	41	42	O	be
7	44	52	O	displaced
NULL

Fenoprofen	DDI-DrugBank.d154.s7	NO_SECTION	NO_SETID	27
Patients receiving hydantoins, sulfonamides, or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	28	U-UNK	hydantoins
4	29	29	O	,
5	31	42	U-UNK	sulfonamides
6	43	43	O	,
7	45	46	O	or
8	48	60	U-UNK	sulfonylureas
9	62	67	O	should
10	69	70	O	be
11	72	79	O	observed
12	81	83	O	for
13	85	93	O	increased
14	95	102	O	activity
15	104	105	O	of
16	107	111	O	these
17	113	117	O	drugs
18	119	121	O	and
19	122	122	O	,
20	124	132	O	therefore
21	133	133	O	,
22	135	139	O	signs
23	141	142	O	of
24	144	151	O	toxicity
25	153	156	O	from
26	158	162	O	these
27	164	168	O	drugs
NULL

Fenoprofen	DDI-DrugBank.d154.s8	NO_SECTION	NO_SETID	18
In patients receiving coumarin-type anticoagulants, the addition of Nalfon to therapy could prolong the prothrombin time.
1	0	1	O	In
2	3	10	O	patients
3	12	20	O	receiving
4	22	29	B-DYN	coumarin
5	31	34	I-DYN	type
6	36	49	L-DYN	anticoagulants
7	50	50	O	,
8	52	54	O	the
9	56	63	O	addition
10	65	66	O	of
11	68	73	O	XXXXXXXX
12	75	76	O	to
13	78	84	O	therapy
14	86	90	O	could
15	92	98	O	prolong
16	100	102	O	the
17	104	114	O	prothrombin
18	116	119	O	time
NULL

Fenoprofen	DDI-DrugBank.d154.s9	NO_SECTION	NO_SETID	9
Patients receiving both drugs should be under careful observation.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	22	O	both
4	24	28	O	drugs
5	30	35	O	should
6	37	38	O	be
7	40	44	O	under
8	46	52	O	careful
9	54	64	O	observation
NULL

Fenoprofen	DDI-DrugBank.d154.s10	NO_SECTION	NO_SETID	13
Patients treated with Nalfon may be resistant to the effects of loop diuretics.
1	0	7	O	Patients
2	9	15	O	treated
3	17	20	O	with
4	22	27	O	XXXXXXXX
5	29	31	O	may
6	33	34	O	be
7	36	44	O	resistant
8	46	47	O	to
9	49	51	O	the
10	53	59	O	effects
11	61	62	O	of
12	64	67	B-DYN	loop
13	69	77	L-DYN	diuretics
NULL

Fenoprofen	DDI-DrugBank.d154.s11	NO_SECTION	NO_SETID	28
In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.
1	0	1	O	In
2	3	10	O	patients
3	12	20	O	receiving
4	22	27	O	XXXXXXXX
5	29	31	O	and
6	33	33	O	a
7	35	41	U-DYN	steroid
8	43	55	O	concomitantly
9	56	56	O	,
10	58	60	O	any
11	62	70	O	reduction
12	72	73	O	in
13	75	81	U-UNK	steroid
14	83	88	O	dosage
15	90	95	O	should
16	97	98	O	be
17	100	106	O	gradual
18	108	109	O	in
19	111	115	O	order
20	117	118	O	to
21	120	124	O	avoid
22	126	128	O	the
23	130	137	O	possible
24	139	151	O	complications
25	153	154	O	of
26	156	161	O	sudden
27	163	169	U-UNK	steroid
28	171	180	O	withdrawal
NULL

Fentanyl	DDI-DrugBank.d170.s0	NO_SECTION	NO_SETID	37
Agents Affecting Cytochrome P450 3A4 Isoenzyme System Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when DURAGESIC  is given concurrently with agents that affect CYP3A4 activity.
1	0	5	O	Agents
2	7	15	O	Affecting
3	17	26	O	Cytochrome
4	28	31	O	P450
5	33	35	O	3A4
6	37	45	O	Isoenzyme
7	47	52	O	System
8	54	61	U-UNK	Fentanyl
9	63	64	O	is
10	66	76	O	metabolized
11	78	83	O	mainly
12	85	87	O	via
13	89	91	O	the
14	93	97	O	human
15	99	108	O	cytochrome
16	110	113	O	P450
17	115	117	O	3A4
18	119	127	O	isoenzyme
19	129	134	O	system
20	137	142	O	CYP3A4
21	144	144	O	,
22	146	154	O	therefore
23	156	164	O	potential
24	166	177	O	interactions
25	179	181	O	may
26	183	187	O	occur
27	189	192	O	when
28	194	202	O	XXXXXXXX
29	205	206	O	is
30	208	212	O	given
31	214	225	O	concurrently
32	227	230	O	with
33	232	237	O	agents
34	239	242	O	that
35	244	249	O	affect
36	251	256	O	CYP3A4
37	258	265	O	activity
NULL

Fentanyl	DDI-DrugBank.d170.s1	NO_SECTION	NO_SETID	13
Coadminstration with agents that induce 3A4 activity may reduce the efficacy of DURAGESIC .
1	0	14	O	Coadminstration
2	16	19	O	with
3	21	26	O	agents
4	28	31	O	that
5	33	38	O	induce
6	40	42	O	3A4
7	44	51	O	activity
8	53	55	O	may
9	57	62	O	reduce
10	64	66	O	the
11	68	75	O	efficacy
12	77	78	O	of
13	80	88	O	XXXXXXXX
NULL

Fentanyl	DDI-DrugBank.d170.s2	NO_SECTION	NO_SETID	36
The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	33	O	transdermal
6	35	42	O	XXXXXXXX
7	44	47	O	with
8	49	57	U-KIN	ritonavir
9	59	60	O	or
10	62	66	O	other
11	68	73	O	potent
12	75	77	O	3A4
13	79	88	O	inhibitors
14	90	93	O	such
15	95	96	O	as
16	98	109	U-KIN	ketoconazole
17	110	110	O	,
18	112	123	U-KIN	itraconazole
19	124	124	O	,
20	126	139	U-KIN	troleandomycin
21	140	140	O	,
22	142	155	U-KIN	clarithromycin
23	156	156	O	,
24	158	167	U-KIN	nelfinavir
25	168	168	O	,
26	170	172	O	and
27	174	183	O	nefazadone
28	185	187	O	may
29	189	194	O	result
30	196	197	O	in
31	199	200	O	an
32	202	209	O	increase
33	211	212	O	in
34	214	221	O	XXXXXXXX
35	223	228	O	plasma
36	230	243	O	concentrations
NULL

Fentanyl	DDI-DrugBank.d170.s3	NO_SECTION	NO_SETID	40
The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	27	O	other
6	29	34	O	CYP3A4
7	36	45	O	inhibitors
8	47	50	O	such
9	52	53	O	as
10	55	63	U-KIN	diltiazem
11	65	67	O	and
12	69	80	U-KIN	erythromycin
13	82	85	O	with
14	87	97	O	transdermal
15	99	106	O	XXXXXXXX
16	108	110	O	may
17	112	115	O	also
18	117	122	O	result
19	124	125	O	in
20	127	128	O	an
21	130	137	O	increase
22	139	140	O	in
23	142	149	O	XXXXXXXX
24	151	156	O	plasma
25	158	171	O	concentrations
26	172	172	O	,
27	174	178	O	which
28	180	184	O	could
29	186	193	O	increase
30	195	196	O	or
31	198	204	O	prolong
32	206	212	O	adverse
33	214	217	O	drug
34	219	225	O	effects
35	227	229	O	and
36	231	233	O	may
37	235	239	O	cause
38	241	247	O	serious
39	249	259	O	respiratory
40	261	270	O	depression
NULL

Fentanyl	DDI-DrugBank.d170.s4	NO_SECTION	NO_SETID	11
In this situation, special patient care and observation are appropriate.
1	0	1	O	In
2	3	6	O	this
3	8	16	O	situation
4	17	17	O	,
5	19	25	O	special
6	27	33	O	patient
7	35	38	O	care
8	40	42	O	and
9	44	54	O	observation
10	56	58	O	are
11	60	70	O	appropriate
NULL

Fentanyl	DDI-DrugBank.d170.s5	NO_SECTION	NO_SETID	67
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
1	0	6	B-UNK	Central
2	8	14	I-UNK	Nervous
3	16	21	I-UNK	System
4	23	33	L-UNK	Depressants
5	34	34	O	:
6	36	38	O	The
7	40	50	O	concomitant
8	52	54	O	use
9	56	57	O	of
10	59	67	O	XXXXXXXX
11	71	78	U-UNK	fentanyl
12	80	90	O	transdermal
13	92	97	O	system
14	100	103	O	with
15	105	109	O	other
16	111	117	B-DYN	central
17	119	125	I-DYN	nervous
18	127	132	I-DYN	system
19	134	144	L-DYN	depressants
20	145	145	O	,
21	147	155	O	including
22	157	159	O	but
23	161	163	O	not
24	165	171	O	limited
25	173	174	O	to
26	176	180	O	other
27	182	188	U-DYN	opioids
28	189	189	O	,
29	191	199	U-DYN	sedatives
30	200	200	O	,
31	202	210	U-DYN	hypnotics
32	211	211	O	,
33	213	225	U-DYN	tranquilizers
34	228	230	O	e.g
35	232	232	O	,
36	234	248	U-DYN	benzodiazepines
37	250	250	O	,
38	252	258	O	general
39	260	270	U-DYN	anesthetics
40	271	271	O	,
41	273	286	U-DYN	phenothiazines
42	287	287	O	,
43	289	296	B-DYN	skeletal
44	298	303	I-DYN	muscle
45	305	313	L-DYN	relaxants
46	314	314	O	,
47	316	318	O	and
48	320	326	U-DYN	alcohol
49	327	327	O	,
50	329	331	O	may
51	333	337	O	cause
52	339	349	O	respiratory
53	351	360	O	depression
54	361	361	O	,
55	363	373	O	hypotension
56	374	374	O	,
57	376	378	O	and
58	380	387	O	profound
59	389	396	O	sedation
60	397	397	O	,
61	399	400	O	or
62	402	412	O	potentially
63	414	419	O	result
64	421	422	O	in
65	424	427	O	coma
66	429	430	O	or
67	432	436	O	death
NULL

Fentanyl	DDI-DrugBank.d170.s6	NO_SECTION	NO_SETID	18
When such combined therapy is contemplated, the dose of one or both agents should be significantly reduced.
1	0	3	O	When
2	5	8	O	such
3	10	17	O	combined
4	19	25	O	therapy
5	27	28	O	is
6	30	41	O	contemplated
7	42	42	O	,
8	44	46	O	the
9	48	51	O	dose
10	53	54	O	of
11	56	58	O	one
12	60	61	O	or
13	63	66	O	both
14	68	73	O	agents
15	75	80	O	should
16	82	83	O	be
17	85	97	O	significantly
18	99	105	O	reduced
NULL

Fentanyl	DDI-DrugBank.d170.s7	NO_SECTION	NO_SETID	32
MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics
1	0	2	B-UNK	MAO
2	4	13	L-UNK	Inhibitors
3	14	14	O	:
4	16	24	O	XXXXXXXX
5	27	28	O	is
6	30	32	O	not
7	34	44	O	recommended
8	46	48	O	for
9	50	52	O	use
10	54	55	O	in
11	57	64	O	patients
12	66	68	O	who
13	70	73	O	have
14	75	82	O	received
15	84	87	U-DYN	MAOI
16	89	94	O	within
17	96	97	O	14
18	99	102	O	days
19	104	110	O	because
20	112	117	O	severe
21	119	121	O	and
22	123	135	O	unpredictable
23	137	148	O	potentiation
24	150	151	O	by
25	153	155	B-UNK	MAO
26	157	166	L-UNK	inhibitors
27	168	170	O	has
28	172	175	O	been
29	177	184	O	reported
30	186	189	O	with
31	191	196	B-UNK	opioid
32	198	207	L-UNK	analgesics
NULL

Fexofenadine	DDI-DrugBank.d466.s0	NO_SECTION	NO_SETID	16
Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.
1	0	3	O	Drug
2	5	15	O	Interaction
3	17	20	O	with
4	22	33	U-UNK	Erythromycin
5	35	37	O	and
6	39	50	U-UNK	Ketoconazole
7	52	63	O	XXXXXXXX
8	65	67	O	has
9	69	72	O	been
10	74	78	O	shown
11	80	81	O	to
12	83	89	O	exhibit
13	91	97	O	minimal
14	100	101	O	ca
15	104	105	O	5%
16	108	117	O	metabolism
NULL

Fexofenadine	DDI-DrugBank.d466.s1	NO_SECTION	NO_SETID	19
However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	co
4	13	26	O	administration
5	28	29	O	of
6	31	42	O	XXXXXXXX
7	44	56	O	hydrochloride
8	58	61	O	with
9	63	68	O	either
10	70	81	U-KIN	ketoconazole
11	83	84	O	or
12	86	97	U-KIN	erythromycin
13	99	101	O	led
14	103	104	O	to
15	106	114	O	increased
16	116	121	O	plasma
17	123	136	O	concentrations
18	138	139	O	of
19	141	152	O	XXXXXXXX
NULL

Fexofenadine	DDI-DrugBank.d466.s2	NO_SECTION	NO_SETID	12
Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.
1	0	11	O	XXXXXXXX
2	13	15	O	had
3	17	18	O	no
4	20	25	O	effect
5	27	28	O	on
6	30	32	O	the
7	34	49	O	pharmacokinetics
8	51	52	O	of
9	54	59	O	either
10	61	72	U-UNK	erythromycin
11	74	75	O	or
12	77	88	U-UNK	ketoconazole
NULL

Fexofenadine	DDI-DrugBank.d466.s3	NO_SECTION	NO_SETID	44
In 2 separate studies, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was co-administered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy volunteers (n=24, each study).
1	0	1	O	In
2	3	3	O	2
3	5	12	O	separate
4	14	20	O	studies
5	21	21	O	,
6	23	34	O	XXXXXXXX
7	36	48	O	hydrochloride
8	50	52	O	120
9	54	55	O	mg
10	57	61	O	twice
11	63	67	O	daily
12	70	72	O	240
13	74	75	O	mg
14	77	81	O	total
15	83	87	O	daily
16	89	92	O	dose
17	95	97	O	was
18	99	100	O	co
19	102	113	O	administered
20	115	118	O	with
21	120	125	O	either
22	127	138	U-UNK	erythromycin
23	140	142	O	500
24	144	145	O	mg
25	147	151	O	every
26	153	153	O	8
27	155	159	O	hours
28	161	162	O	or
29	164	175	U-UNK	ketoconazole
30	177	179	O	400
31	181	182	O	mg
32	184	187	O	once
33	189	193	O	daily
34	195	199	O	under
35	201	206	O	steady
36	208	212	O	state
37	214	223	O	conditions
38	225	226	O	to
39	228	234	O	healthy
40	236	245	O	volunteers
41	248	251	O	n=24
42	252	252	O	,
43	254	257	O	each
44	259	263	O	study
NULL

Fexofenadine	DDI-DrugBank.d466.s4	NO_SECTION	NO_SETID	25
No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.
1	0	1	O	No
2	3	13	O	differences
3	15	16	O	in
4	18	24	O	adverse
5	26	31	O	events
6	33	34	O	or
7	36	38	O	QTc
8	40	47	O	interval
9	49	52	O	were
10	54	61	O	observed
11	63	66	O	when
12	68	75	O	subjects
13	77	80	O	were
14	82	93	O	administered
15	95	106	O	XXXXXXXX
16	108	120	O	hydrochloride
17	122	126	O	alone
18	128	129	O	or
19	131	132	O	in
20	134	144	O	combination
21	146	149	O	with
22	151	156	O	either
23	158	169	U-UNK	erythromycin
24	171	172	O	or
25	174	185	U-UNK	ketoconazole
NULL

Fexofenadine	DDI-DrugBank.d466.s5	NO_SECTION	NO_SETID	43
The findings of these studies are summarized in the following table: Effects on steady-state fexofenadine pharmacokinetics after 7 days of co-administration with fexofenadine hydrochloride 120 mg every 12 hours (two times the recommended twice daily dose) in healthy volunteers (n=24)
1	0	2	O	The
2	4	11	O	findings
3	13	14	O	of
4	16	20	O	these
5	22	28	O	studies
6	30	32	O	are
7	34	43	O	summarized
8	45	46	O	in
9	48	50	O	the
10	52	60	O	following
11	62	66	O	table
12	67	67	O	:
13	69	75	O	Effects
14	77	78	O	on
15	80	85	O	steady
16	87	91	O	state
17	93	104	O	XXXXXXXX
18	106	121	O	pharmacokinetics
19	123	127	O	after
20	129	129	O	7
21	131	134	O	days
22	136	137	O	of
23	139	140	O	co
24	142	155	O	administration
25	157	160	O	with
26	162	173	O	XXXXXXXX
27	175	187	O	hydrochloride
28	189	191	O	120
29	193	194	O	mg
30	196	200	O	every
31	202	203	O	12
32	205	209	O	hours
33	212	214	O	two
34	216	220	O	times
35	222	224	O	the
36	226	236	O	recommended
37	238	242	O	twice
38	244	248	O	daily
39	250	253	O	dose
40	256	257	O	in
41	259	265	O	healthy
42	267	276	O	volunteers
43	279	282	O	n=24
NULL

Fexofenadine	DDI-DrugBank.d466.s7	NO_SECTION	NO_SETID	4
cmaxSS (Peak plasma concentration)
1	0	5	O	cmaxSS
2	8	11	O	Peak
3	13	18	O	plasma
4	20	32	O	concentration
NULL

Fexofenadine	DDI-DrugBank.d466.s8	NO_SECTION	NO_SETID	6
AUCss(0-12h) (Extent of systemic exposure)
1	0	6	O	AUCss(0
2	8	10	O	12h
3	14	19	O	Extent
4	21	22	O	of
5	24	31	O	systemic
6	33	40	O	exposure
NULL

Fexofenadine	DDI-DrugBank.d466.s9	NO_SECTION	NO_SETID	6
Erythromycin (500 mg every 8 hrs)
1	0	11	U-UNK	Erythromycin
2	14	16	O	500
3	18	19	O	mg
4	21	25	O	every
5	27	27	O	8
6	29	31	O	hrs
NULL

Fexofenadine	DDI-DrugBank.d466.s12	NO_SECTION	NO_SETID	5
Ketoconazole (400 mg once daily)
1	0	11	U-UNK	Ketoconazole
2	14	16	O	400
3	18	19	O	mg
4	21	24	O	once
5	26	30	O	daily
NULL

Fexofenadine	DDI-DrugBank.d466.s15	NO_SECTION	NO_SETID	20
The changes in plasma levels were within the range of plasma levels achieved in adequate and well-controlled clinical trials.
1	0	2	O	The
2	4	10	O	changes
3	12	13	O	in
4	15	20	O	plasma
5	22	27	O	levels
6	29	32	O	were
7	34	39	O	within
8	41	43	O	the
9	45	49	O	range
10	51	52	O	of
11	54	59	O	plasma
12	61	66	O	levels
13	68	75	O	achieved
14	77	78	O	in
15	80	87	O	adequate
16	89	91	O	and
17	93	96	O	well
18	98	107	O	controlled
19	109	116	O	clinical
20	118	123	O	trials
NULL

Fexofenadine	DDI-DrugBank.d466.s16	NO_SECTION	NO_SETID	20
The mechanism of these interactions has been evaluated in in vitro, in situ, and in vivo animal models.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	21	O	these
5	23	34	O	interactions
6	36	38	O	has
7	40	43	O	been
8	45	53	O	evaluated
9	55	56	O	in
10	58	59	O	in
11	61	65	O	vitro
12	66	66	O	,
13	68	69	O	in
14	71	74	O	situ
15	75	75	O	,
16	77	79	O	and
17	81	82	O	in
18	84	87	O	vivo
19	89	94	O	animal
20	96	101	O	models
NULL

Fexofenadine	DDI-DrugBank.d466.s17	NO_SECTION	NO_SETID	13
These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.
1	0	4	O	These
2	6	12	O	studies
3	14	21	O	indicate
4	23	26	O	that
5	28	39	U-KIN	ketoconazole
6	41	42	O	or
7	44	55	U-KIN	erythromycin
8	57	58	O	co
9	60	73	O	administration
10	75	82	O	enhances
11	84	95	O	XXXXXXXX
12	97	112	O	gastrointestinal
13	114	123	O	absorption
NULL

Fexofenadine	DDI-DrugBank.d466.s18	NO_SECTION	NO_SETID	46
This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.
1	0	3	O	This
2	5	12	O	observed
3	14	21	O	increase
4	23	24	O	in
5	26	28	O	the
6	30	44	O	bioavailability
7	46	47	O	of
8	49	60	O	XXXXXXXX
9	62	64	O	may
10	66	67	O	be
11	69	71	O	due
12	73	74	O	to
13	76	84	O	transport
14	86	92	O	related
15	94	100	O	effects
16	101	101	O	,
17	103	106	O	such
18	108	109	O	as
19	111	111	O	p
20	113	124	O	glycoprotein
21	127	128	O	in
22	130	133	O	vivo
23	135	140	O	animal
24	142	148	O	studies
25	150	153	O	also
26	155	161	O	suggest
27	163	166	O	that
28	168	169	O	in
29	171	178	O	addition
30	180	181	O	to
31	183	191	O	enhancing
32	193	202	O	absorption
33	203	203	O	,
34	205	216	U-KIN	ketoconazole
35	218	226	O	decreases
36	228	239	O	XXXXXXXX
37	241	256	O	gastrointestinal
38	258	266	O	secretion
39	267	267	O	,
40	269	273	O	while
41	275	286	U-UNK	erythromycin
42	288	290	O	may
43	292	295	O	also
44	297	304	O	decrease
45	306	312	O	biliary
46	314	322	O	excretion
NULL

Fexofenadine	DDI-DrugBank.d466.s19	NO_SECTION	NO_SETID	36
Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
1	0	3	O	Drug
2	5	16	O	Interactions
3	18	21	O	with
4	23	30	U-UNK	Antacids
5	32	45	O	Administration
6	47	48	O	of
7	50	52	O	120
8	54	55	O	mg
9	57	58	O	of
10	60	71	B-KIN	fexofenadine
11	73	85	L-KIN	hydrochloride
12	88	88	O	2
13	90	90	O	x
14	92	93	O	60
15	95	96	O	mg
16	98	104	O	capsule
17	107	112	O	within
18	114	115	O	15
19	117	123	O	minutes
20	125	126	O	of
21	128	129	O	an
22	131	138	U-UNK	aluminum
23	140	142	O	and
24	144	152	U-UNK	magnesium
25	154	163	O	containing
26	165	171	U-UNK	antacid
27	174	179	O	XXXXXXXX
28	183	191	O	decreased
29	193	204	U-UNK	fexofenadine
30	206	208	O	AUC
31	210	211	O	by
32	213	215	O	41%
33	217	219	O	and
34	221	224	O	cmax
35	226	227	O	by
36	229	231	O	43%
NULL

Fexofenadine	DDI-DrugBank.d466.s20	NO_SECTION	NO_SETID	14
ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.
1	0	6	O	XXXXXXXX
2	8	13	O	should
3	15	17	O	not
4	19	20	O	be
5	22	26	O	taken
6	28	34	O	closely
7	36	37	O	in
8	39	42	O	time
9	44	47	O	with
10	49	56	U-DYN	aluminum
11	58	60	O	and
12	62	70	U-DYN	magnesium
13	72	81	O	containing
14	83	90	U-UNK	antacids
NULL

Fexofenadine	DDI-DrugBank.d466.s21	NO_SECTION	NO_SETID	21
Interactions with Fruit Juices Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.
1	0	11	O	Interactions
2	13	16	O	with
3	18	22	O	Fruit
4	24	29	O	Juices
5	31	35	O	Fruit
6	37	42	O	juices
7	44	47	O	such
8	49	50	O	as
9	52	61	O	grapefruit
10	62	62	O	,
11	64	69	O	orange
12	71	73	O	and
13	75	79	O	apple
14	81	83	O	may
15	85	90	O	reduce
16	92	94	O	the
17	96	110	O	bioavailability
18	112	114	O	and
19	116	123	O	exposure
20	125	126	O	of
21	128	139	O	XXXXXXXX
NULL

Fexofenadine	DDI-DrugBank.d466.s22	NO_SECTION	NO_SETID	22
This is based on the results from 3 clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.
1	0	3	O	This
2	5	6	O	is
3	8	12	O	based
4	14	15	O	on
5	17	19	O	the
6	21	27	O	results
7	29	32	O	from
8	34	34	O	3
9	36	43	O	clinical
10	45	51	O	studies
11	53	57	O	using
12	59	67	U-UNK	histamine
13	69	75	O	induced
14	77	80	O	skin
15	82	87	O	wheals
16	89	91	O	and
17	93	98	O	flares
18	100	106	O	coupled
19	108	111	O	with
20	113	122	O	population
21	124	138	O	pharmacokinetic
22	140	147	O	analysis
NULL

Fexofenadine	DDI-DrugBank.d466.s23	NO_SECTION	NO_SETID	23
The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.
1	0	2	O	The
2	4	7	O	size
3	9	10	O	of
4	12	16	O	wheal
5	18	20	O	and
6	22	26	O	flare
7	28	31	O	were
8	33	45	O	significantly
9	47	52	O	larger
10	54	57	O	when
11	59	70	O	XXXXXXXX
12	72	84	O	hydrochloride
13	86	88	O	was
14	90	101	O	administered
15	103	106	O	with
16	108	113	O	either
17	115	124	O	grapefruit
18	126	127	O	or
19	129	134	O	orange
20	136	141	O	juices
21	143	150	O	compared
22	152	153	O	to
23	155	159	O	water
NULL

Fexofenadine	DDI-DrugBank.d466.s24	NO_SECTION	NO_SETID	20
Based on the literature reports, the same effects may be extrapolated to other fruit juices such as apple juice.
1	0	4	O	Based
2	6	7	O	on
3	9	11	O	the
4	13	22	O	literature
5	24	30	O	reports
6	31	31	O	,
7	33	35	O	the
8	37	40	O	same
9	42	48	O	effects
10	50	52	O	may
11	54	55	O	be
12	57	68	O	extrapolated
13	70	71	O	to
14	73	77	O	other
15	79	83	O	fruit
16	85	90	O	juices
17	92	95	O	such
18	97	98	O	as
19	100	104	O	apple
20	106	110	O	juice
NULL

Fexofenadine	DDI-DrugBank.d466.s25	NO_SECTION	NO_SETID	8
The clinical significance of these observations is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	33	O	these
6	35	46	O	observations
7	48	49	O	is
8	51	57	O	unknown
NULL

Fexofenadine	DDI-DrugBank.d466.s26	NO_SECTION	NO_SETID	35
In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	17	O	based
5	19	20	O	on
6	22	24	O	the
7	26	35	O	population
8	37	52	O	pharmacokinetics
9	54	61	O	analysis
10	63	64	O	of
11	66	68	O	the
12	70	77	O	combined
13	79	82	O	data
14	84	87	O	from
15	89	98	O	grapefruit
16	100	102	O	and
17	104	109	O	orange
18	111	116	O	juices
19	118	124	O	studies
20	126	129	O	with
21	131	133	O	the
22	135	138	O	data
23	140	143	O	from
24	145	145	O	a
25	147	160	O	bioequivalence
26	162	166	O	study
27	167	167	O	,
28	169	171	O	the
29	173	187	O	bioavailability
30	189	190	O	of
31	192	203	O	XXXXXXXX
32	205	207	O	was
33	209	215	O	reduced
34	217	218	O	by
35	220	222	O	36%
NULL

Fexofenadine	DDI-DrugBank.d466.s27	NO_SECTION	NO_SETID	19
Therefore, to maximize the effects of fexofenadine, it is recommended that ALLEGRA should be taken with water
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	to
4	14	21	O	maximize
5	23	25	O	the
6	27	33	O	effects
7	35	36	O	of
8	38	49	U-UNK	fexofenadine
9	50	50	O	,
10	52	53	O	it
11	55	56	O	is
12	58	68	O	recommended
13	70	73	O	that
14	75	81	O	XXXXXXXX
15	83	88	O	should
16	90	91	O	be
17	93	97	O	taken
18	99	102	O	with
19	104	108	O	water
NULL

Filgrastim	DDI-DrugBank.d1.s0	NO_SECTION	NO_SETID	12
Drug interactions between NEUPOGEN  and other drugs have not been fully evaluated.
1	0	3	O	Drug
2	5	16	O	interactions
3	18	24	O	between
4	26	33	O	XXXXXXXX
5	36	38	O	and
6	40	44	O	other
7	46	50	O	drugs
8	52	55	O	have
9	57	59	O	not
10	61	64	O	been
11	66	70	O	fully
12	72	80	O	evaluated
NULL

Filgrastim	DDI-DrugBank.d1.s1	NO_SECTION	NO_SETID	18
Drugs which may potentiate the release of neutrophils, such as lithium, should be used with caution.
1	0	4	O	Drugs
2	6	10	O	which
3	12	14	O	may
4	16	25	O	potentiate
5	27	29	O	the
6	31	37	O	release
7	39	40	O	of
8	42	52	O	neutrophils
9	53	53	O	,
10	55	58	O	such
11	60	61	O	as
12	63	69	U-UNK	lithium
13	70	70	O	,
14	72	77	O	should
15	79	80	O	be
16	82	85	O	used
17	87	90	O	with
18	92	98	O	caution
NULL

Finasteride	DDI-DrugBank.d209.s0	NO_SECTION	NO_SETID	9
No drug interactions of clinical importance have been identified.
1	0	1	O	No
2	3	6	O	drug
3	8	19	O	interactions
4	21	22	O	of
5	24	31	O	clinical
6	33	42	O	importance
7	44	47	O	have
8	49	52	O	been
9	54	63	O	identified
NULL

Finasteride	DDI-DrugBank.d209.s1	NO_SECTION	NO_SETID	14
Finasteride does not appear to affect the cytochrome P450-linked drug-metabolizing enzyme system.
1	0	10	O	XXXXXXXX
2	12	15	O	does
3	17	19	O	not
4	21	26	O	appear
5	28	29	O	to
6	31	36	O	affect
7	38	40	O	the
8	42	51	O	cytochrome
9	53	56	O	P450
10	58	63	O	linked
11	65	68	O	drug
12	70	81	O	metabolizing
13	83	88	O	enzyme
14	90	95	O	system
NULL

Finasteride	DDI-DrugBank.d209.s2	NO_SECTION	NO_SETID	25
Compounds that have been tested in man include antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found.
1	0	8	O	Compounds
2	10	13	O	that
3	15	18	O	have
4	20	23	O	been
5	25	30	O	tested
6	32	33	O	in
7	35	37	O	man
8	39	45	O	include
9	47	56	U-UNK	antipyrine
10	57	57	O	,
11	59	65	U-UNK	digoxin
12	66	66	O	,
13	68	78	U-UNK	propranolol
14	79	79	O	,
15	81	92	U-UNK	theophylline
16	93	93	O	,
17	95	97	O	and
18	99	106	U-UNK	warfarin
19	108	110	O	and
20	112	113	O	no
21	115	124	O	clinically
22	126	135	O	meaningful
23	137	148	O	interactions
24	150	153	O	were
25	155	159	O	found
NULL

Finasteride	DDI-DrugBank.d209.s3	NO_SECTION	NO_SETID	85
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
1	0	4	O	Other
2	6	16	O	concomitant
3	18	24	O	therapy
4	26	33	O	Although
5	35	42	O	specific
6	44	54	O	interaction
7	56	62	O	studies
8	64	67	O	were
9	69	71	O	not
10	73	81	O	performed
11	82	82	O	,
12	84	94	O	XXXXXXXX
13	96	100	O	doses
14	102	103	O	of
15	105	105	O	1
16	107	108	O	mg
17	110	111	O	or
18	113	116	O	more
19	118	121	O	were
20	123	135	O	concomitantly
21	137	140	O	used
22	142	143	O	in
23	145	152	O	clinical
24	154	160	O	studies
25	162	165	O	with
26	167	179	U-UNK	acetaminophen
27	180	180	O	,
28	182	196	B-UNK	acetylsalicylic
29	198	201	L-UNK	acid
30	202	202	O	,
31	204	204	O	a
32	206	213	O	blockers
33	214	214	O	,
34	216	225	U-UNK	analgesics
35	226	226	O	,
36	228	238	B-UNK	angiotensin
37	240	249	I-UNK	converting
38	251	256	I-UNK	enzyme
39	259	261	I-UNK	ACE
40	264	273	L-UNK	inhibitors
41	274	274	O	,
42	276	290	U-UNK	anticonvulsants
43	291	291	O	,
44	293	307	U-UNK	benzodiazepines
45	308	308	O	,
46	310	313	B-UNK	beta
47	315	322	L-UNK	blockers
48	323	323	O	,
49	325	331	B-UNK	calcium
50	333	339	I-UNK	channel
51	341	348	L-UNK	blockers
52	349	349	O	,
53	351	357	O	cardiac
54	359	366	U-UNK	nitrates
55	367	367	O	,
56	369	377	U-UNK	diuretics
57	378	378	O	,
58	380	381	B-UNK	H2
59	383	393	L-UNK	antagonists
60	394	394	O	,
61	396	398	B-UNK	HMG
62	400	402	I-UNK	CoA
63	404	412	I-UNK	reductase
64	414	423	L-UNK	inhibitors
65	424	424	O	,
66	426	438	B-UNK	prostaglandin
67	440	449	I-UNK	synthetase
68	451	460	L-UNK	inhibitors
69	463	466	O	also
70	468	475	O	referred
71	477	478	O	to
72	480	481	O	as
73	483	488	U-UNK	NSAIDs
74	490	490	O	,
75	492	494	O	and
76	496	504	B-UNK	quinolone
77	506	509	I-UNK	anti
78	511	520	L-UNK	infectives
79	522	528	O	without
80	530	537	O	evidence
81	539	540	O	of
82	542	551	O	clinically
83	553	563	O	significant
84	565	571	O	adverse
85	573	584	O	interactions
NULL

Finasteride	DDI-DrugBank.d209.s4	NO_SECTION	NO_SETID	48
Drug/Laboratory Test Interactions Finasteride had no effect on circulating levels of cortisol, thyroid-stimulating hormone, or thyroxine, nor did it affect the plasma lipid profile (e.g., total cholesterol, low-density lipoproteins, high-density lipoproteins and triglycerides) or bone mineral density.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	44	O	XXXXXXXX
7	46	48	O	had
8	50	51	O	no
9	53	58	O	effect
10	60	61	O	on
11	63	73	O	circulating
12	75	80	O	levels
13	82	83	O	of
14	85	92	O	cortisol
15	93	93	O	,
16	95	101	O	thyroid
17	103	113	O	stimulating
18	115	121	O	hormone
19	122	122	O	,
20	124	125	O	or
21	127	135	O	thyroxine
22	136	136	O	,
23	138	140	O	nor
24	142	144	O	did
25	146	147	O	it
26	149	154	O	affect
27	156	158	O	the
28	160	165	O	plasma
29	167	171	O	lipid
30	173	179	O	profile
31	182	184	O	e.g
32	186	186	O	,
33	188	192	O	total
34	194	204	O	cholesterol
35	205	205	O	,
36	207	209	O	low
37	211	217	O	density
38	219	230	O	lipoproteins
39	231	231	O	,
40	233	236	O	high
41	238	244	O	density
42	246	257	O	lipoproteins
43	259	261	O	and
44	263	275	O	triglycerides
45	278	279	O	or
46	281	284	O	bone
47	286	292	O	mineral
48	294	300	O	density
NULL

Finasteride	DDI-DrugBank.d209.s5	NO_SECTION	NO_SETID	22
In studies with finasteride, no clinically meaningful changes in luteinizing hormone (LH), follicle-stimulating hormone (FSH) or prolactin were detected.
1	0	1	O	In
2	3	9	O	studies
3	11	14	O	with
4	16	26	O	XXXXXXXX
5	27	27	O	,
6	29	30	O	no
7	32	41	O	clinically
8	43	52	O	meaningful
9	54	60	O	changes
10	62	63	O	in
11	65	75	O	luteinizing
12	77	83	O	hormone
13	86	87	O	LH
14	89	89	O	,
15	91	98	O	follicle
16	100	110	O	stimulating
17	112	118	O	hormone
18	121	123	O	FSH
19	126	127	O	or
20	129	137	O	prolactin
21	139	142	O	were
22	144	151	O	detected
NULL

Finasteride	DDI-DrugBank.d209.s6	NO_SECTION	NO_SETID	30
In healthy volunteers, treatment with finasteride did not alter the response of LH and FSH to gonadotropin-releasing hormone indicating that the hypothalamic-pituitary-testicular axis was not affected.
1	0	1	O	In
2	3	9	O	healthy
3	11	20	O	volunteers
4	21	21	O	,
5	23	31	O	treatment
6	33	36	O	with
7	38	48	O	XXXXXXXX
8	50	52	O	did
9	54	56	O	not
10	58	62	O	alter
11	64	66	O	the
12	68	75	O	response
13	77	78	O	of
14	80	81	O	LH
15	83	85	O	and
16	87	89	O	FSH
17	91	92	O	to
18	94	105	O	gonadotropin
19	107	115	O	releasing
20	117	123	O	hormone
21	125	134	O	indicating
22	136	139	O	that
23	141	143	O	the
24	145	156	O	hypothalamic
25	158	166	O	pituitary
26	168	177	O	testicular
27	179	182	O	axis
28	184	186	O	was
29	188	190	O	not
30	192	199	O	affected
NULL

Finasteride	DDI-DrugBank.d209.s7	NO_SECTION	NO_SETID	42
In clinical studies with PROPECIA (finasteride, 1 mg) in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12.
1	0	1	O	In
2	3	10	O	clinical
3	12	18	O	studies
4	20	23	O	with
5	25	32	O	XXXXXXXX
6	35	45	U-UNK	finasteride
7	46	46	O	,
8	48	48	O	1
9	50	51	O	mg
10	54	55	O	in
11	57	59	O	men
12	61	62	O	18
13	64	65	O	41
14	67	71	O	years
15	73	74	O	of
16	76	78	O	age
17	79	79	O	,
18	81	83	O	the
19	85	88	O	mean
20	90	94	O	value
21	96	97	O	of
22	99	103	O	serum
23	105	112	O	prostate
24	114	121	O	specific
25	123	129	O	antigen
26	132	134	O	PSA
27	137	145	O	decreased
28	147	150	O	from
29	152	154	O	0.7
30	156	157	O	ng
31	158	158	O	/
32	159	160	O	mL
33	162	163	O	at
34	165	172	O	baseline
35	174	175	O	to
36	177	179	O	0.5
37	181	182	O	ng
38	183	183	O	/
39	184	185	O	mL
40	187	188	O	at
41	190	194	O	Month
42	196	197	O	12
NULL

Finasteride	DDI-DrugBank.d209.s8	NO_SECTION	NO_SETID	30
Further, in clinical studies with PROSCAR (finasteride, 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%.
1	0	6	O	Further
2	7	7	O	,
3	9	10	O	in
4	12	19	O	clinical
5	21	27	O	studies
6	29	32	O	with
7	34	40	O	XXXXXXXX
8	43	53	U-UNK	finasteride
9	54	54	O	,
10	56	56	O	5
11	58	59	O	mg
12	62	65	O	when
13	67	70	O	used
14	72	73	O	in
15	75	79	O	older
16	81	83	O	men
17	85	87	O	who
18	89	92	O	have
19	94	99	O	benign
20	101	109	O	prostatic
21	111	121	O	hyperplasia
22	124	126	O	BPH
23	128	128	O	,
24	130	132	O	PSA
25	134	139	O	levels
26	141	143	O	are
27	145	153	O	decreased
28	155	156	O	by
29	158	170	O	approximately
30	172	174	O	50%
NULL

Finasteride	DDI-DrugBank.d209.s9	NO_SECTION	NO_SETID	19
These findings should be taken into account for proper interpretation of serum PSA when evaluating men treated with finasteride.
1	0	4	O	These
2	6	13	O	findings
3	15	20	O	should
4	22	23	O	be
5	25	29	O	taken
6	31	34	O	into
7	36	42	O	account
8	44	46	O	for
9	48	53	O	proper
10	55	68	O	interpretation
11	70	71	O	of
12	73	77	O	serum
13	79	81	O	PSA
14	83	86	O	when
15	88	97	O	evaluating
16	99	101	O	men
17	103	109	O	treated
18	111	114	O	with
19	116	126	O	XXXXXXXX
NULL

Flecainide	DDI-DrugBank.d87.s1	NO_SECTION	NO_SETID	17
TAMBOCOR has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects.
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	16	O	been
4	18	29	O	administered
5	31	32	O	to
6	34	41	O	patients
7	43	51	O	receiving
8	53	61	B-UNK	digitalis
9	63	74	L-UNK	preparations
10	76	77	O	or
11	79	82	B-UNK	beta
12	84	93	I-UNK	adrenergic
13	95	102	I-UNK	blocking
14	104	109	L-UNK	agents
15	111	117	O	without
16	119	125	O	adverse
17	127	133	O	effects
NULL

Flecainide	DDI-DrugBank.d87.s2	NO_SECTION	NO_SETID	32
During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.
1	0	5	O	During
2	7	20	O	administration
3	22	23	O	of
4	25	32	O	multiple
5	34	37	O	oral
6	39	43	O	doses
7	45	46	O	of
8	48	55	O	XXXXXXXX
9	57	58	O	to
10	60	66	O	healthy
11	68	75	O	subjects
12	77	86	O	stabilized
13	88	89	O	on
14	91	91	O	a
15	93	103	O	maintenance
16	105	108	O	dose
17	110	111	O	of
18	113	119	U-KIN	digoxin
19	120	120	O	,
20	122	122	O	a
21	124	126	O	13%
22	128	130	O	19%
23	132	139	O	increase
24	141	142	O	in
25	144	149	O	plasma
26	151	157	U-UNK	digoxin
27	159	164	O	levels
28	166	173	O	occurred
29	175	176	O	at
30	178	180	O	six
31	182	186	O	hours
32	188	195	O	postdose
NULL

Flecainide	DDI-DrugBank.d87.s3	NO_SECTION	NO_SETID	30
In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	19	O	involving
5	21	27	O	healthy
6	29	36	O	subjects
7	38	46	O	receiving
8	48	55	O	XXXXXXXX
9	57	59	O	and
10	61	71	U-KIN	propranolol
11	73	84	O	concurrently
12	85	85	O	,
13	87	92	O	plasma
14	94	103	U-UNK	flecainide
15	105	110	O	levels
16	112	115	O	were
17	117	125	O	increased
18	127	131	O	about
19	133	135	O	20%
20	137	139	O	and
21	141	151	U-UNK	propranolol
22	153	158	O	levels
23	160	163	O	were
24	165	173	O	increased
25	175	179	O	about
26	181	183	O	30%
27	185	192	O	compared
28	194	195	O	to
29	197	203	O	control
30	205	210	O	values
NULL

Flecainide	DDI-DrugBank.d87.s4	NO_SECTION	NO_SETID	17
In this formal interaction study, TAMBOCOR and propranolol were each found to have negative inotropic effects;
1	0	1	O	In
2	3	6	O	this
3	8	13	O	formal
4	15	25	O	interaction
5	27	31	O	study
6	32	32	O	,
7	34	41	O	XXXXXXXX
8	43	45	O	and
9	47	57	U-UNK	propranolol
10	59	62	O	were
11	64	67	O	each
12	69	73	O	found
13	75	76	O	to
14	78	81	O	have
15	83	90	O	negative
16	92	100	O	inotropic
17	102	108	O	effects
NULL

Flecainide	DDI-DrugBank.d87.s5	NO_SECTION	NO_SETID	11
when the drugs were administered together, the effects were additive.
1	0	3	O	when
2	5	7	O	the
3	9	13	O	drugs
4	15	18	O	were
5	20	31	O	administered
6	33	40	O	together
7	41	41	O	,
8	43	45	O	the
9	47	53	O	effects
10	55	58	O	were
11	60	67	O	additive
NULL

Flecainide	DDI-DrugBank.d87.s6	NO_SECTION	NO_SETID	17
The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	25	O	concomitant
5	27	40	O	administration
6	42	43	O	of
7	45	52	O	XXXXXXXX
8	54	56	O	and
9	58	68	U-DYN	propranolol
10	70	71	O	on
11	73	75	O	the
12	77	78	O	PR
13	80	87	O	interval
14	89	92	O	were
15	94	97	O	less
16	99	102	O	than
17	104	111	O	additive
NULL

Flecainide	DDI-DrugBank.d87.s7	NO_SECTION	NO_SETID	21
In TAMBOCOR clinical trials, patients who were receiving beta blockers concurrently did not experience an increased incidence of side effects.
1	0	1	O	In
2	3	10	O	XXXXXXXX
3	12	19	O	clinical
4	21	26	O	trials
5	27	27	O	,
6	29	36	O	patients
7	38	40	O	who
8	42	45	O	were
9	47	55	O	receiving
10	57	60	B-UNK	beta
11	62	69	L-UNK	blockers
12	71	82	O	concurrently
13	84	86	O	did
14	88	90	O	not
15	92	101	O	experience
16	103	104	O	an
17	106	114	O	increased
18	116	124	O	incidence
19	126	127	O	of
20	129	132	O	side
21	134	140	O	effects
NULL

Flecainide	DDI-DrugBank.d87.s8	NO_SECTION	NO_SETID	17
Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	16	O	the
4	18	28	O	possibility
5	30	31	O	of
6	33	40	O	additive
7	42	49	O	negative
8	51	59	O	inotropic
9	61	67	O	effects
10	69	70	O	of
11	72	75	B-DYN	beta
12	77	84	L-DYN	blockers
13	86	88	O	and
14	90	99	O	XXXXXXXX
15	101	106	O	should
16	108	109	O	be
17	111	120	O	recognized
NULL

Flecainide	DDI-DrugBank.d87.s9	NO_SECTION	NO_SETID	8
Flecainide is not extensively bound to plasma proteins.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	16	O	not
4	18	28	O	extensively
5	30	34	O	bound
6	36	37	O	to
7	39	44	O	plasma
8	46	53	O	proteins
NULL

Flecainide	DDI-DrugBank.d87.s10	NO_SECTION	NO_SETID	29
In vitro studies with several drugs which may be administered concomitantly showed that the extent of flecainide binding to human plasma proteins is either unchanged or only slightly less.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	with
5	22	28	O	several
6	30	34	O	drugs
7	36	40	O	which
8	42	44	O	may
9	46	47	O	be
10	49	60	O	administered
11	62	74	O	concomitantly
12	76	81	O	showed
13	83	86	O	that
14	88	90	O	the
15	92	97	O	extent
16	99	100	O	of
17	102	111	O	XXXXXXXX
18	113	119	O	binding
19	121	122	O	to
20	124	128	O	human
21	130	135	O	plasma
22	137	144	O	proteins
23	146	147	O	is
24	149	154	O	either
25	156	164	O	unchanged
26	166	167	O	or
27	169	172	O	only
28	174	181	O	slightly
29	183	186	O	less
NULL

Flecainide	DDI-DrugBank.d87.s11	NO_SECTION	NO_SETID	18
Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected.
1	0	11	O	Consequently
2	12	12	O	,
3	14	25	O	interactions
4	27	30	O	with
5	32	36	O	other
6	38	42	O	drugs
7	44	48	O	which
8	50	52	O	are
9	54	59	O	highly
10	61	67	O	protein
11	69	73	O	bound
12	76	78	O	e.g
13	80	80	O	,
14	82	95	U-UNK	anticoagulants
15	99	103	O	would
16	105	107	O	not
17	109	110	O	be
18	112	119	O	expected
NULL

Flecainide	DDI-DrugBank.d87.s12	NO_SECTION	NO_SETID	15
TAMBOCOR has been used in a large number of patients receiving diuretics without apparent interaction.
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	16	O	been
4	18	21	O	used
5	23	24	O	in
6	26	26	O	a
7	28	32	O	large
8	34	39	O	number
9	41	42	O	of
10	44	51	O	patients
11	53	61	O	receiving
12	63	71	U-UNK	diuretics
13	73	79	O	without
14	81	88	O	apparent
15	90	100	O	interaction
NULL

Flecainide	DDI-DrugBank.d87.s13	NO_SECTION	NO_SETID	24
Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
1	0	6	O	Limited
2	8	11	O	data
3	13	14	O	in
4	16	23	O	patients
5	25	33	O	receiving
6	35	39	O	known
7	41	46	O	enzyme
8	48	55	O	inducers
9	59	67	U-KIN	phenytoin
10	68	68	O	,
11	70	82	U-KIN	phenobarbital
12	83	83	O	,
13	85	97	U-KIN	carbamazepine
14	101	108	O	indicate
15	110	113	O	only
16	115	115	O	a
17	117	119	O	30%
18	121	128	O	increase
19	130	131	O	in
20	133	135	O	the
21	137	140	O	rate
22	142	143	O	of
23	145	154	O	XXXXXXXX
24	156	166	O	elimination
NULL

Flecainide	DDI-DrugBank.d87.s14	NO_SECTION	NO_SETID	26
In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.
1	0	1	O	In
2	3	9	O	healthy
3	11	18	O	subjects
4	20	28	O	receiving
5	30	39	U-KIN	cimetidine
6	42	42	O	1
7	44	45	O	gm
8	47	51	O	daily
9	54	56	O	for
10	58	60	O	one
11	62	65	O	week
12	66	66	O	,
13	68	73	O	plasma
14	75	84	O	XXXXXXXX
15	86	91	O	levels
16	93	101	O	increased
17	103	104	O	by
18	106	110	O	about
19	112	114	O	30%
20	116	118	O	and
21	120	123	O	half
22	125	128	O	life
23	130	138	O	increased
24	140	141	O	by
25	143	147	O	about
26	149	151	O	10%
NULL

Flecainide	DDI-DrugBank.d87.s15	NO_SECTION	NO_SETID	27
When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.
1	0	3	O	When
2	5	14	U-KIN	amiodarone
3	16	17	O	is
4	19	23	O	added
5	25	26	O	to
6	28	37	O	XXXXXXXX
7	39	45	O	therapy
8	46	46	O	,
9	48	53	O	plasma
10	55	64	O	XXXXXXXX
11	66	71	O	levels
12	73	75	O	may
13	77	84	O	increase
14	86	88	O	two
15	90	93	O	fold
16	95	96	O	or
17	98	101	O	more
18	103	104	O	in
19	106	109	O	some
20	111	118	O	patients
21	119	119	O	,
22	121	122	O	if
23	124	133	O	XXXXXXXX
24	135	140	O	dosage
25	142	143	O	is
26	145	147	O	not
27	149	155	O	reduced
NULL

Flecainide	DDI-DrugBank.d87.s16	NO_SECTION	NO_SETID	25
Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;
1	0	4	O	Drugs
2	6	9	O	that
3	11	17	O	inhibit
4	19	28	O	cytochrome
5	30	37	O	P450IID6
6	38	38	O	,
7	40	43	O	such
8	45	46	O	as
9	48	56	U-KIN	quinidine
10	58	58	O	,
11	60	64	O	might
12	66	73	O	increase
13	75	77	O	the
14	79	84	O	plasma
15	86	99	O	concentrations
16	101	102	O	of
17	104	113	O	XXXXXXXX
18	115	116	O	in
19	118	125	O	patients
20	127	130	O	that
21	132	134	O	are
22	136	137	O	on
23	139	145	O	chronic
24	147	156	O	XXXXXXXX
25	158	164	O	therapy
NULL

Flecainide	DDI-DrugBank.d87.s17	NO_SECTION	NO_SETID	7
especially if these patients are extensive metabolizers.
1	0	9	O	especially
2	11	12	O	if
3	14	18	O	these
4	20	27	O	patients
5	29	31	O	are
6	33	41	O	extensive
7	43	54	O	metabolizers
NULL

Flecainide	DDI-DrugBank.d87.s18	NO_SECTION	NO_SETID	15
There has been little experience with the coadministration of TAMBOCOR and either disopyramide or verapamil.
1	0	4	O	There
2	6	8	O	has
3	10	13	O	been
4	15	20	O	little
5	22	31	O	experience
6	33	36	O	with
7	38	40	O	the
8	42	57	O	coadministration
9	59	60	O	of
10	62	69	O	XXXXXXXX
11	71	73	O	and
12	75	80	O	either
13	82	93	U-UNK	disopyramide
14	95	96	O	or
15	98	106	U-UNK	verapamil
NULL

Flecainide	DDI-DrugBank.d87.s19	NO_SECTION	NO_SETID	46
Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.
1	0	6	O	Because
2	8	11	O	both
3	13	14	O	of
4	16	20	O	these
5	22	26	O	drugs
6	28	31	O	have
7	33	40	O	negative
8	42	50	O	inotropic
9	52	61	O	properties
10	63	65	O	and
11	67	69	O	the
12	71	77	O	effects
13	79	80	O	of
14	82	97	O	coadministration
15	99	102	O	with
16	104	111	O	XXXXXXXX
17	113	115	O	are
18	117	123	O	unknown
19	124	124	O	,
20	126	132	O	neither
21	134	145	U-DYN	disopyramide
22	147	149	O	nor
23	151	159	U-DYN	verapamil
24	161	166	O	should
25	168	169	O	be
26	171	182	O	administered
27	184	195	O	concurrently
28	197	200	O	with
29	202	209	O	XXXXXXXX
30	211	216	O	unless
31	217	217	O	,
32	219	220	O	in
33	222	224	O	the
34	226	233	O	judgment
35	235	236	O	of
36	238	240	O	the
37	242	250	O	physician
38	251	251	O	,
39	253	255	O	the
40	257	264	O	benefits
41	266	267	O	of
42	269	272	O	this
43	274	284	O	combination
44	286	293	O	outweigh
45	295	297	O	the
46	299	303	O	risks
NULL

Flecainide	DDI-DrugBank.d87.s20	NO_SECTION	NO_SETID	19
There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.
1	0	4	O	There
2	6	8	O	has
3	10	13	O	been
4	15	17	O	too
5	19	24	O	little
6	26	35	O	experience
7	37	40	O	with
8	42	44	O	the
9	46	61	O	coadministration
10	63	64	O	of
11	66	73	O	XXXXXXXX
12	75	78	O	with
13	80	89	U-UNK	nifedipine
14	91	92	O	or
15	94	102	U-UNK	diltiazem
16	104	105	O	to
17	107	115	O	recommend
18	117	127	O	concomitant
19	129	131	O	use
NULL

Floxuridine	DDI-DrugBank.d361.s0	NO_SECTION	NO_SETID	30
Combination Therapy: Any form of therapy which adds to the stress of the patient, interferes with nutrition or depresses bone marrow function will increase the toxicity of Floxuridine.
1	0	10	O	Combination
2	12	18	O	Therapy
3	19	19	O	:
4	21	23	O	Any
5	25	28	O	form
6	30	31	O	of
7	33	39	O	therapy
8	41	45	O	which
9	47	50	O	adds
10	52	53	O	to
11	55	57	O	the
12	59	64	O	stress
13	66	67	O	of
14	69	71	O	the
15	73	79	O	patient
16	80	80	O	,
17	82	91	O	interferes
18	93	96	O	with
19	98	106	O	nutrition
20	108	109	O	or
21	111	119	O	depresses
22	121	124	O	bone
23	126	131	O	marrow
24	133	140	O	function
25	142	145	O	will
26	147	154	O	increase
27	156	158	O	the
28	160	167	O	toxicity
29	169	170	O	of
30	172	182	O	XXXXXXXX
NULL

Flucytosine	DDI-DrugBank.d453.s0	NO_SECTION	NO_SETID	20
Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.
1	0	7	B-DYN	Cytosine
2	9	19	L-DYN	arabinoside
3	20	20	O	,
4	22	22	O	a
5	24	33	B-UNK	cytostatic
6	35	39	L-UNK	agent
7	40	40	O	,
8	42	44	O	has
9	46	49	O	been
10	51	58	O	reported
11	60	61	O	to
12	63	72	O	inactivate
13	74	76	O	the
14	78	87	O	antifungal
15	89	96	O	activity
16	98	99	O	of
17	101	111	O	XXXXXXXX
18	113	114	O	by
19	116	126	O	competitive
20	128	137	O	inhibition
NULL

Flucytosine	DDI-DrugBank.d453.s1	NO_SECTION	NO_SETID	13
Drugs which impair glomerular filtration may prolong the biological half-life of flucytosine.
1	0	4	O	Drugs
2	6	10	O	which
3	12	17	O	impair
4	19	28	O	glomerular
5	30	39	O	filtration
6	41	43	O	may
7	45	51	O	prolong
8	53	55	O	the
9	57	66	O	biological
10	68	71	O	half
11	73	76	O	life
12	78	79	O	of
13	81	91	O	XXXXXXXX
NULL

Flucytosine	DDI-DrugBank.d453.s2	NO_SECTION	NO_SETID	33
Drug/Laboratory Test Interactions: Measurement of serum creatinine levels should be determined by the Jaffe reaction, since Ancobon does not interfere with the determination of creatinine values by this method.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	33	33	O	:
7	35	45	O	Measurement
8	47	48	O	of
9	50	54	O	serum
10	56	65	O	creatinine
11	67	72	O	levels
12	74	79	O	should
13	81	82	O	be
14	84	93	O	determined
15	95	96	O	by
16	98	100	O	the
17	102	106	O	Jaffe
18	108	115	O	reaction
19	116	116	O	,
20	118	122	O	since
21	124	130	O	XXXXXXXX
22	132	135	O	does
23	137	139	O	not
24	141	149	O	interfere
25	151	154	O	with
26	156	158	O	the
27	160	172	O	determination
28	174	175	O	of
29	177	186	O	creatinine
30	188	193	O	values
31	195	196	O	by
32	198	201	O	this
33	203	208	O	method
NULL

Flucytosine	DDI-DrugBank.d453.s3	NO_SECTION	NO_SETID	13
Most automated equipment for measurement of creatinine makes use of the Jaffe reaction.
1	0	3	O	Most
2	5	13	O	automated
3	15	23	O	equipment
4	25	27	O	for
5	29	39	O	measurement
6	41	42	O	of
7	44	53	O	creatinine
8	55	59	O	makes
9	61	63	O	use
10	65	66	O	of
11	68	70	O	the
12	72	76	O	Jaffe
13	78	85	O	reaction
NULL

Fludarabine	DDI-DrugBank.d444.s0	NO_SECTION	NO_SETID	21
The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	17	O	XXXXXXXX
5	19	21	O	FOR
6	23	31	O	INJECTION
7	33	34	O	in
8	36	46	O	combination
9	48	51	O	with
10	53	63	U-DYN	pentostatin
11	65	66	O	is
12	68	70	O	not
13	72	82	O	recommended
14	84	86	O	due
15	88	89	O	to
16	91	93	O	the
17	95	98	O	risk
18	100	101	O	of
19	103	108	O	severe
20	110	118	O	pulmonary
21	120	127	O	toxicity
NULL

Fludrocortisone	DDI-DrugBank.d526.s0	NO_SECTION	NO_SETID	12
When administered concurrently, the following drugs may interact with adrenal corticosteroids.
1	0	3	O	When
2	5	16	O	administered
3	18	29	O	concurrently
4	30	30	O	,
5	32	34	O	the
6	36	44	O	following
7	46	50	O	drugs
8	52	54	O	may
9	56	63	O	interact
10	65	68	O	with
11	70	76	B-UNK	adrenal
12	78	92	L-UNK	corticosteroids
NULL

Fludrocortisone	DDI-DrugBank.d526.s1	NO_SECTION	NO_SETID	17
Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.
1	0	11	B-UNK	Amphotericin
2	13	13	L-UNK	B
3	15	16	O	or
4	18	26	B-UNK	potassium
5	28	36	I-UNK	depleting
6	38	46	L-UNK	diuretics
7	49	65	U-UNK	benzothiadiazines
8	67	69	O	and
9	71	77	O	related
10	79	83	O	drugs
11	84	84	O	,
12	86	95	B-UNK	ethacrynic
13	97	100	L-UNK	acid
14	102	104	O	and
15	106	115	U-UNK	furosemide
16	118	125	O	enhanced
17	127	137	O	hypokalemia
NULL

Fludrocortisone	DDI-DrugBank.d526.s2	NO_SECTION	NO_SETID	7
Check serum potassium levels at frequent intervals;
1	0	4	O	Check
2	6	10	O	serum
3	12	20	O	potassium
4	22	27	O	levels
5	29	30	O	at
6	32	39	O	frequent
7	41	49	O	intervals
NULL

Fludrocortisone	DDI-DrugBank.d526.s3	NO_SECTION	NO_SETID	5
use potassium supplements if necessary .
1	0	2	O	use
2	4	12	U-UNK	potassium
3	14	24	O	supplements
4	26	27	O	if
5	29	37	O	necessary
NULL

Fludrocortisone	DDI-DrugBank.d526.s4	NO_SECTION	NO_SETID	12
Digitalis glycosides enhanced possibility of arrhythmias or digitalis toxicity associated with hypokalemia.
1	0	8	B-UNK	Digitalis
2	10	19	L-UNK	glycosides
3	21	28	O	enhanced
4	30	40	O	possibility
5	42	43	O	of
6	45	55	O	arrhythmias
7	57	58	O	or
8	60	68	U-UNK	digitalis
9	70	77	O	toxicity
10	79	88	O	associated
11	90	93	O	with
12	95	105	O	hypokalemia
NULL

Fludrocortisone	DDI-DrugBank.d526.s5	NO_SECTION	NO_SETID	4
Monitor serum potassium levels;
1	0	6	O	Monitor
2	8	12	O	serum
3	14	22	O	potassium
4	24	29	O	levels
NULL

Fludrocortisone	DDI-DrugBank.d526.s6	NO_SECTION	NO_SETID	5
use potassium supplements if necessary.
1	0	2	O	use
2	4	12	U-UNK	potassium
3	14	24	O	supplements
4	26	27	O	if
5	29	37	O	necessary
NULL

Fludrocortisone	DDI-DrugBank.d526.s7	NO_SECTION	NO_SETID	6
Oral anticoagulants decreased prothrombin time response.
1	0	3	O	Oral
2	5	18	U-UNK	anticoagulants
3	20	28	O	decreased
4	30	40	O	prothrombin
5	42	45	O	time
6	47	54	O	response
NULL

Fludrocortisone	DDI-DrugBank.d526.s8	NO_SECTION	NO_SETID	8
Monitor prothrombin levels and adjust anticoagulant dosage accordingly.
1	0	6	O	Monitor
2	8	18	O	prothrombin
3	20	25	O	levels
4	27	29	O	and
5	31	36	O	adjust
6	38	50	U-UNK	anticoagulant
7	52	57	O	dosage
8	59	69	O	accordingly
NULL

Fludrocortisone	DDI-DrugBank.d526.s9	NO_SECTION	NO_SETID	9
Antidiabetic drugs (oral agents and insulin) diminished antidiabetic effect.
1	0	11	B-UNK	Antidiabetic
2	13	17	L-UNK	drugs
3	20	23	O	oral
4	25	30	O	agents
5	32	34	O	and
6	36	42	U-UNK	insulin
7	45	54	O	diminished
8	56	67	O	antidiabetic
9	69	74	O	effect
NULL

Fludrocortisone	DDI-DrugBank.d526.s10	NO_SECTION	NO_SETID	5
Monitor for symptoms of hyperglycemia;
1	0	6	O	Monitor
2	8	10	O	for
3	12	19	O	symptoms
4	21	22	O	of
5	24	36	O	hyperglycemia
NULL

Fludrocortisone	DDI-DrugBank.d526.s11	NO_SECTION	NO_SETID	8
adjust dosage of antidiabetic drug upward if necessary.
1	0	5	O	adjust
2	7	12	O	dosage
3	14	15	O	of
4	17	28	B-UNK	antidiabetic
5	30	33	L-UNK	drug
6	35	40	O	upward
7	42	43	O	if
8	45	53	O	necessary
NULL

Fludrocortisone	DDI-DrugBank.d526.s12	NO_SECTION	NO_SETID	4
Aspirin increased ulcerogenic effect;
1	0	6	O	XXXXXXXX
2	8	16	O	increased
3	18	28	O	ulcerogenic
4	30	35	O	effect
NULL

Fludrocortisone	DDI-DrugBank.d526.s13	NO_SECTION	NO_SETID	5
decreased pharmacologic effect of aspirin.
1	0	8	O	decreased
2	10	22	O	pharmacologic
3	24	29	O	effect
4	31	32	O	of
5	34	40	O	XXXXXXXX
NULL

Fludrocortisone	DDI-DrugBank.d526.s14	NO_SECTION	NO_SETID	16
Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.
1	0	5	O	Rarely
2	7	16	U-UNK	salicylate
3	18	25	O	toxicity
4	27	29	O	may
5	31	35	O	occur
6	37	38	O	in
7	40	47	O	patients
8	49	51	O	who
9	53	63	O	discontinue
10	65	72	U-DYN	steroids
11	74	78	O	after
12	80	89	O	concurrent
13	91	94	O	high
14	96	99	O	dose
15	101	107	O	XXXXXXXX
16	109	115	O	therapy
NULL

Fludrocortisone	DDI-DrugBank.d526.s15	NO_SECTION	NO_SETID	12
Monitor salicylate levels or the therapeutic effect for which aspirin is given;
1	0	6	O	Monitor
2	8	17	U-UNK	salicylate
3	19	24	O	levels
4	26	27	O	or
5	29	31	O	the
6	33	43	O	therapeutic
7	45	50	O	effect
8	52	54	O	for
9	56	60	O	which
10	62	68	O	XXXXXXXX
11	70	71	O	is
12	73	77	O	given
NULL

Fludrocortisone	DDI-DrugBank.d526.s16	NO_SECTION	NO_SETID	8
adjust salicylate dosage accordingly if effect is altered.
1	0	5	O	adjust
2	7	16	U-UNK	salicylate
3	18	23	O	dosage
4	25	35	O	accordingly
5	37	38	O	if
6	40	45	O	effect
7	47	48	O	is
8	50	56	O	altered
NULL

Fludrocortisone	DDI-DrugBank.d526.s17	NO_SECTION	NO_SETID	19
Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.
1	0	11	U-KIN	Barbiturates
2	12	12	O	,
3	14	22	U-KIN	phenytoin
4	23	23	O	,
5	25	26	O	or
6	28	35	U-KIN	rifampin
7	37	45	O	increased
8	47	55	O	metabolic
9	57	65	O	clearance
10	67	68	O	of
11	70	84	O	XXXXXXXX
12	86	92	O	acetate
13	94	100	O	because
14	102	103	O	of
15	105	107	O	the
16	109	117	O	induction
17	119	120	O	of
18	122	128	O	hepatic
19	130	136	O	enzymes
NULL

Fludrocortisone	DDI-DrugBank.d526.s18	NO_SECTION	NO_SETID	15
Observe the patient for possible diminished effect of steroid and increase the steroid dosage accordingly.
1	0	6	O	Observe
2	8	10	O	the
3	12	18	O	patient
4	20	22	O	for
5	24	31	O	possible
6	33	42	O	diminished
7	44	49	O	effect
8	51	52	O	of
9	54	60	U-UNK	steroid
10	62	64	O	and
11	66	73	O	increase
12	75	77	O	the
13	79	85	U-UNK	steroid
14	87	92	O	dosage
15	94	104	O	accordingly
NULL

Fludrocortisone	DDI-DrugBank.d526.s19	NO_SECTION	NO_SETID	22
Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.
1	0	7	B-UNK	Anabolic
2	9	16	L-UNK	steroids
3	19	30	O	particularly
4	32	32	O	C
5	34	35	O	17
6	37	45	O	alkylated
7	47	55	U-UNK	androgens
8	57	60	O	such
9	62	63	O	as
10	65	76	U-UNK	oxymetholone
11	77	77	O	,
12	79	96	U-UNK	methandrostenolone
13	97	97	O	,
14	99	113	U-UNK	norethandrolone
15	114	114	O	,
16	116	118	O	and
17	120	126	O	similar
18	128	136	O	compounds
19	139	146	O	enhanced
20	148	155	O	tendency
21	157	162	O	toward
22	164	168	O	edema
NULL

Fludrocortisone	DDI-DrugBank.d526.s20	NO_SECTION	NO_SETID	16
Use caution when giving these drugs together, especially in patients with hepatic or cardiac disease.
1	0	2	O	Use
2	4	10	O	caution
3	12	15	O	when
4	17	22	O	giving
5	24	28	O	these
6	30	34	O	drugs
7	36	43	O	together
8	44	44	O	,
9	46	55	O	especially
10	57	58	O	in
11	60	67	O	patients
12	69	72	O	with
13	74	80	O	hepatic
14	82	83	O	or
15	85	91	O	cardiac
16	93	99	O	disease
NULL

Fludrocortisone	DDI-DrugBank.d526.s21	NO_SECTION	NO_SETID	8
Vaccines neurological complications and lack of antibody response .
1	0	7	U-UNK	Vaccines
2	9	20	O	neurological
3	22	34	O	complications
4	36	38	O	and
5	40	43	O	lack
6	45	46	O	of
7	48	55	O	antibody
8	57	64	O	response
NULL

Fludrocortisone	DDI-DrugBank.d526.s22	NO_SECTION	NO_SETID	14
Estrogen increased levels of corticosteroid-binding globulin, thereby increasing the bound (inactive) fraction;
1	0	7	U-UNK	Estrogen
2	9	17	O	increased
3	19	24	O	levels
4	26	27	O	of
5	29	42	O	corticosteroid
6	44	50	O	binding
7	52	59	O	globulin
8	60	60	O	,
9	62	68	O	thereby
10	70	79	O	increasing
11	81	83	O	the
12	85	89	O	bound
13	92	99	O	inactive
14	102	109	O	fraction
NULL

Fludrocortisone	DDI-DrugBank.d526.s23	NO_SECTION	NO_SETID	11
this effect is at least balanced by decreased metabolism of corticosteroids.
1	0	3	O	this
2	5	10	O	effect
3	12	13	O	is
4	15	16	O	at
5	18	22	O	least
6	24	31	O	balanced
7	33	34	O	by
8	36	44	O	decreased
9	46	55	O	metabolism
10	57	58	O	of
11	60	74	U-UNK	corticosteroids
NULL

Fludrocortisone	DDI-DrugBank.d526.s24	NO_SECTION	NO_SETID	25
When estrogen therapy is initiated, a reduction in corticosteroid dosage may be required, and increased amounts may be required when estrogen is terminated.
1	0	3	O	When
2	5	12	U-UNK	estrogen
3	14	20	O	therapy
4	22	23	O	is
5	25	33	O	initiated
6	34	34	O	,
7	36	36	O	a
8	38	46	O	reduction
9	48	49	O	in
10	51	64	U-UNK	corticosteroid
11	66	71	O	dosage
12	73	75	O	may
13	77	78	O	be
14	80	87	O	required
15	88	88	O	,
16	90	92	O	and
17	94	102	O	increased
18	104	110	O	amounts
19	112	114	O	may
20	116	117	O	be
21	119	126	O	required
22	128	131	O	when
23	133	140	U-UNK	estrogen
24	142	143	O	is
25	145	154	O	terminated
NULL

Fludrocortisone	DDI-DrugBank.d526.s25	NO_SECTION	NO_SETID	19
Drug/Laboratory Test Interactions Corticosteroids may affect the nitrobluetetrazolium test for bacterial infection and produce false-negative results
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	48	U-UNK	Corticosteroids
7	50	52	O	may
8	54	59	O	affect
9	61	63	O	the
10	65	84	O	nitrobluetetrazolium
11	86	89	O	test
12	91	93	O	for
13	95	103	O	bacterial
14	105	113	O	infection
15	115	117	O	and
16	119	125	O	produce
17	127	131	O	false
18	133	140	O	negative
19	142	148	O	results
NULL

Flumazenil	DDI-DrugBank.d234.s0	NO_SECTION	NO_SETID	14
Interaction with central nervous system depressants other than benzodiazepines has not been specifically studied;
1	0	10	O	Interaction
2	12	15	O	with
3	17	23	B-UNK	central
4	25	31	I-UNK	nervous
5	33	38	I-UNK	system
6	40	50	L-UNK	depressants
7	52	56	O	other
8	58	61	O	than
9	63	77	U-UNK	benzodiazepines
10	79	81	O	has
11	83	85	O	not
12	87	90	O	been
13	92	103	O	specifically
14	105	111	O	studied
NULL

Flumazenil	DDI-DrugBank.d234.s1	NO_SECTION	NO_SETID	30
however, no deleterious interactions were seen when ROMAZICON was administered after narcotics, inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.
1	0	6	O	however
2	7	7	O	,
3	9	10	O	no
4	12	22	O	deleterious
5	24	35	O	interactions
6	37	40	O	were
7	42	45	O	seen
8	47	50	O	when
9	52	60	O	XXXXXXXX
10	62	64	O	was
11	66	77	O	administered
12	79	83	O	after
13	85	93	U-UNK	narcotics
14	94	94	O	,
15	96	107	O	inhalational
16	109	119	U-UNK	anesthetics
17	120	120	O	,
18	122	127	B-UNK	muscle
19	129	137	L-UNK	relaxants
20	139	141	O	and
21	143	148	O	muscle
22	150	157	O	relaxant
23	159	169	O	antagonists
24	171	182	O	administered
25	184	185	O	in
26	187	197	O	conjunction
27	199	202	O	with
28	204	211	O	sedation
29	213	214	O	or
30	216	225	O	anesthesia
NULL

Flumazenil	DDI-DrugBank.d234.s2	NO_SECTION	NO_SETID	43
Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.
1	0	9	O	Particular
2	11	17	O	caution
3	19	20	O	is
4	22	30	O	necessary
5	32	35	O	when
6	37	41	O	using
7	43	51	O	XXXXXXXX
8	53	54	O	in
9	56	60	O	cases
10	62	63	O	of
11	65	69	O	mixed
12	71	74	O	drug
13	76	85	O	overdosage
14	87	91	O	since
15	93	95	O	the
16	97	101	O	toxic
17	103	109	O	effects
18	112	115	O	such
19	117	118	O	as
20	120	130	O	convulsions
21	132	134	O	and
22	136	142	O	cardiac
23	144	155	O	dysrhythmias
24	158	159	O	of
25	161	165	O	other
26	167	171	O	drugs
27	173	177	O	taken
28	179	180	O	in
29	182	189	O	overdose
30	192	201	O	especially
31	203	208	B-DYN	cyclic
32	210	224	L-DYN	antidepressants
33	227	229	O	may
34	231	236	O	emerge
35	238	241	O	with
36	243	245	O	the
37	247	254	O	reversal
38	256	257	O	of
39	259	261	O	the
40	263	276	U-UNK	benzodiazepine
41	278	283	O	effect
42	285	286	O	by
43	288	297	U-UNK	flumazenil
NULL

Flumazenil	DDI-DrugBank.d234.s3	NO_SECTION	NO_SETID	20
The use of ROMAZICON is not recommended in epileptic patients who have been receiving benzodiazepine treatment for a prolonged period.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	19	O	XXXXXXXX
5	21	22	O	is
6	24	26	O	not
7	28	38	O	recommended
8	40	41	O	in
9	43	51	O	epileptic
10	53	60	O	patients
11	62	64	O	who
12	66	69	O	have
13	71	74	O	been
14	76	84	O	receiving
15	86	99	O	benzodiazepine
16	101	109	O	treatment
17	111	113	O	for
18	115	115	O	a
19	117	125	O	prolonged
20	127	132	O	period
NULL

Flumazenil	DDI-DrugBank.d234.s4	NO_SECTION	NO_SETID	28
Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.
1	0	7	O	Although
2	9	17	O	XXXXXXXX
3	19	24	O	exerts
4	26	26	O	a
5	28	33	O	slight
6	35	43	O	intrinsic
7	45	58	O	anticonvulsant
8	60	65	O	effect
9	66	66	O	,
10	68	70	O	its
11	72	77	O	abrupt
12	79	89	O	suppression
13	91	92	O	of
14	94	96	O	the
15	98	107	O	protective
16	109	114	O	effect
17	116	117	O	of
18	119	119	O	a
19	121	134	U-DYN	benzodiazepine
20	136	142	O	agonist
21	144	146	O	can
22	148	151	O	give
23	153	156	O	rise
24	158	159	O	to
25	161	171	O	convulsions
26	173	174	O	in
27	176	184	O	epileptic
28	186	193	O	patients
NULL

Flumazenil	DDI-DrugBank.d234.s5	NO_SECTION	NO_SETID	14
ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.
1	0	8	O	XXXXXXXX
2	10	15	O	blocks
3	17	19	O	the
4	21	27	O	central
5	29	35	O	effects
6	37	38	O	of
7	40	54	U-DYN	benzodiazepines
8	56	57	O	by
9	59	69	O	competitive
10	71	81	O	interaction
11	83	84	O	at
12	86	88	O	the
13	90	97	O	receptor
14	99	103	O	level
NULL

Flumazenil	DDI-DrugBank.d234.s6	NO_SECTION	NO_SETID	22
The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	31	O	nonbenzodiazepine
5	33	40	O	agonists
6	42	43	O	at
7	45	58	O	benzodiazepine
8	60	68	O	receptors
9	69	69	O	,
10	71	74	O	such
11	76	77	O	as
12	79	87	U-DYN	zopiclone
13	88	88	O	,
14	90	108	O	triazolopyridazines
15	110	112	O	and
16	114	119	O	others
17	120	120	O	,
18	122	124	O	are
19	126	129	O	also
20	131	137	O	blocked
21	139	140	O	by
22	142	150	O	XXXXXXXX
NULL

Flumazenil	DDI-DrugBank.d234.s7	NO_SECTION	NO_SETID	14
The pharmacokinetics of benzodiazepines are unaltered in the presence of flumazenil and vice versa.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	38	U-UNK	benzodiazepines
5	40	42	O	are
6	44	52	O	unaltered
7	54	55	O	in
8	57	59	O	the
9	61	68	O	presence
10	70	71	O	of
11	73	82	O	XXXXXXXX
12	84	86	O	and
13	88	91	O	vice
14	93	97	O	versa
NULL

Flumazenil	DDI-DrugBank.d234.s8	NO_SECTION	NO_SETID	9
There is no pharmacokinetic interaction between ethanol and flumazenil.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	26	O	pharmacokinetic
5	28	38	O	interaction
6	40	46	O	between
7	48	54	U-UNK	ethanol
8	56	58	O	and
9	60	69	O	XXXXXXXX
NULL

Flumazenil	DDI-DrugBank.d234.s9	NO_SECTION	NO_SETID	22
Use in Ambulatory Patients The effects of ROMAZICON may wear off before a long-acting benzodiazepine is completely cleared from the body.
1	0	2	O	Use
2	4	5	O	in
3	7	16	O	Ambulatory
4	18	25	O	Patients
5	27	29	O	The
6	31	37	O	effects
7	39	40	O	of
8	42	50	O	XXXXXXXX
9	52	54	O	may
10	56	59	O	wear
11	61	63	O	off
12	65	70	O	before
13	72	72	O	a
14	74	77	B-UNK	long
15	79	84	I-UNK	acting
16	86	99	L-UNK	benzodiazepine
17	101	102	O	is
18	104	113	O	completely
19	115	121	O	cleared
20	123	126	O	from
21	128	130	O	the
22	132	135	O	body
NULL

Flumazenil	DDI-DrugBank.d234.s10	NO_SECTION	NO_SETID	30
In general, if a patient shows no signs of sedation within 2 hours after a 1-mg dose of flumazenil, serious resedation at a later time is unlikely.
1	0	1	O	In
2	3	9	O	general
3	10	10	O	,
4	12	13	O	if
5	15	15	O	a
6	17	23	O	patient
7	25	29	O	shows
8	31	32	O	no
9	34	38	O	signs
10	40	41	O	of
11	43	50	O	sedation
12	52	57	O	within
13	59	59	O	2
14	61	65	O	hours
15	67	71	O	after
16	73	73	O	a
17	75	75	O	1
18	77	78	O	mg
19	80	83	O	dose
20	85	86	O	of
21	88	97	O	XXXXXXXX
22	98	98	O	,
23	100	106	O	serious
24	108	117	O	resedation
25	119	120	O	at
26	122	122	O	a
27	124	128	O	later
28	130	133	O	time
29	135	136	O	is
30	138	145	O	unlikely
NULL

Flumazenil	DDI-DrugBank.d234.s11	NO_SECTION	NO_SETID	36
An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as diazepam) or large doses of short-acting benzodiazepines (such as  10 mg of midazolam) have been used.
1	0	1	O	An
2	3	10	O	adequate
3	12	17	O	period
4	19	20	O	of
5	22	32	O	observation
6	34	37	O	must
7	39	40	O	be
8	42	49	O	provided
9	51	53	O	for
10	55	57	O	any
11	59	65	O	patient
12	67	68	O	in
13	70	73	O	whom
14	75	80	O	either
15	82	85	B-UNK	long
16	87	92	I-UNK	acting
17	94	108	L-UNK	benzodiazepines
18	111	114	O	such
19	116	117	O	as
20	119	126	U-UNK	diazepam
21	129	130	O	or
22	132	136	O	large
23	138	142	O	doses
24	144	145	O	of
25	147	151	B-UNK	short
26	153	158	I-UNK	acting
27	160	174	L-UNK	benzodiazepines
28	177	180	O	such
29	182	183	O	as
30	186	187	O	10
31	189	190	O	mg
32	192	193	O	of
33	195	203	U-UNK	midazolam
34	206	209	O	have
35	211	214	O	been
36	216	219	O	used
NULL

Flumazenil	DDI-DrugBank.d234.s12	NO_SECTION	NO_SETID	56
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	23	O	increased
5	25	28	O	risk
6	30	31	O	of
7	33	39	O	adverse
8	41	49	O	reactions
9	51	52	O	in
10	54	61	O	patients
11	63	65	O	who
12	67	70	O	have
13	72	75	O	been
14	77	82	O	taking
15	84	98	U-UNK	benzodiazepines
16	100	101	O	on
17	103	103	O	a
18	105	111	O	regular
19	113	117	O	basis
20	118	118	O	,
21	120	121	O	it
22	123	124	O	is
23	126	137	O	particularly
24	139	147	O	important
25	149	152	O	that
26	154	163	O	physicians
27	165	169	O	query
28	171	178	O	patients
29	180	181	O	or
30	183	187	O	their
31	189	197	O	guardians
32	199	207	O	carefully
33	209	213	O	about
34	215	228	U-UNK	benzodiazepine
35	229	229	O	,
36	231	237	U-UNK	alcohol
37	239	241	O	and
38	243	250	U-UNK	sedative
39	252	254	O	use
40	256	257	O	as
41	259	262	O	part
42	264	265	O	of
43	267	269	O	the
44	271	277	O	history
45	279	283	O	prior
46	285	286	O	to
47	288	290	O	any
48	292	300	O	procedure
49	302	303	O	in
50	305	309	O	which
51	311	313	O	the
52	315	317	O	use
53	319	320	O	of
54	322	330	O	XXXXXXXX
55	332	333	O	is
56	335	341	O	planned
NULL

Fluorouracil	DDI-DrugBank.d214.s0	NO_SECTION	NO_SETID	3
No information available.
1	0	1	O	No
2	3	13	O	information
3	15	23	O	available
NULL

Fluoxetine	DDI-DrugBank.d482.s0	NO_SECTION	NO_SETID	15
Do not take this medicine with thioridizine, or within 5 weeks of taking fluoxetine.
1	0	1	O	Do
2	3	5	O	not
3	7	10	O	take
4	12	15	O	this
5	17	24	O	medicine
6	26	29	O	with
7	31	42	O	thioridizine
8	43	43	O	,
9	45	46	O	or
10	48	53	O	within
11	55	55	O	5
12	57	61	O	weeks
13	63	64	O	of
14	66	71	O	taking
15	73	82	O	XXXXXXXX
NULL

Fluoxetine	DDI-DrugBank.d482.s1	NO_SECTION	NO_SETID	17
Talk to your doctor if you are taking certain antibiotics such as erythromycin, clarithromycin or azithromycin.
1	0	3	O	Talk
2	5	6	O	to
3	8	11	O	your
4	13	18	O	doctor
5	20	21	O	if
6	23	25	O	you
7	27	29	O	are
8	31	36	O	taking
9	38	44	O	certain
10	46	56	U-UNK	antibiotics
11	58	61	O	such
12	63	64	O	as
13	66	77	U-UNK	erythromycin
14	78	78	O	,
15	80	93	U-UNK	clarithromycin
16	95	96	O	or
17	98	109	U-UNK	azithromycin
NULL

Fluoxetine	DDI-DrugBank.d482.s2	NO_SECTION	NO_SETID	9
This medicine should not be taken with MAO inhibitors.
1	0	3	O	This
2	5	12	O	medicine
3	14	19	O	should
4	21	23	O	not
5	25	26	O	be
6	28	32	O	taken
7	34	37	O	with
8	39	41	B-UNK	MAO
9	43	52	L-UNK	inhibitors
NULL

Fluoxetine	DDI-DrugBank.d482.s3	NO_SECTION	NO_SETID	19
Caution should be exercised when taking this medicine certain antibiotics, such as erythromycin, clarithromycin, or azithromycin.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	38	O	taking
7	40	43	O	this
8	45	52	O	medicine
9	54	60	O	certain
10	62	72	U-UNK	antibiotics
11	73	73	O	,
12	75	78	O	such
13	80	81	O	as
14	83	94	U-UNK	erythromycin
15	95	95	O	,
16	97	110	U-UNK	clarithromycin
17	111	111	O	,
18	113	114	O	or
19	116	127	U-UNK	azithromycin
NULL

Fluoxetine	DDI-DrugBank.d482.s4	NO_SECTION	NO_SETID	9
This medicine should not be taken with MAO inhibitors.
1	0	3	O	This
2	5	12	O	medicine
3	14	19	O	should
4	21	23	O	not
5	25	26	O	be
6	28	32	O	taken
7	34	37	O	with
8	39	41	B-UNK	MAO
9	43	52	L-UNK	inhibitors
NULL

Fluoxetine	DDI-DrugBank.d482.s5	NO_SECTION	NO_SETID	15
If you think you are taking an MAO inhibitor talk to your doctor or pharmacist.
1	0	1	O	If
2	3	5	O	you
3	7	11	O	think
4	13	15	O	you
5	17	19	O	are
6	21	26	O	taking
7	28	29	O	an
8	31	33	B-UNK	MAO
9	35	43	L-UNK	inhibitor
10	45	48	O	talk
11	50	51	O	to
12	53	56	O	your
13	58	63	O	doctor
14	65	66	O	or
15	68	77	O	pharmacist
NULL

Fluoxetine	DDI-DrugBank.d482.s6	NO_SECTION	NO_SETID	16
Do not take this medicine with St. Johns Wort because of the additive effects of sertonin.
1	0	1	O	Do
2	3	5	O	not
3	7	10	O	take
4	12	15	O	this
5	17	24	O	medicine
6	26	29	O	with
7	31	32	O	St
8	35	39	O	Johns
9	41	44	O	Wort
10	46	52	O	because
11	54	55	O	of
12	57	59	O	the
13	61	68	O	additive
14	70	76	O	effects
15	78	79	O	of
16	81	88	O	sertonin
NULL

Fluoxetine	DDI-DrugBank.d482.s7	NO_SECTION	NO_SETID	9
This medication should not be taken with MAO inhibitors.
1	0	3	O	This
2	5	14	O	medication
3	16	21	O	should
4	23	25	O	not
5	27	28	O	be
6	30	34	O	taken
7	36	39	O	with
8	41	43	B-UNK	MAO
9	45	54	L-UNK	inhibitors
NULL

Fluoxetine	DDI-DrugBank.d482.s8	NO_SECTION	NO_SETID	12
Your doctor or pharmacist can give you more information on MAO inhibitors.
1	0	3	O	Your
2	5	10	O	doctor
3	12	13	O	or
4	15	24	O	pharmacist
5	26	28	O	can
6	30	33	O	give
7	35	37	O	you
8	39	42	O	more
9	44	54	O	information
10	56	57	O	on
11	59	61	B-UNK	MAO
12	63	72	L-UNK	inhibitors
NULL

Fluoxetine	DDI-DrugBank.d482.s9	NO_SECTION	NO_SETID	13
Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.
1	0	3	O	Wait
2	5	5	O	5
3	7	11	O	weeks
4	13	17	O	after
5	19	26	O	stopping
6	28	39	U-UNK	escitalopram
7	41	46	O	before
8	48	55	O	starting
9	57	57	O	a
10	59	61	B-UNK	non
11	63	71	I-UNK	selective
12	73	75	I-UNK	MAO
13	77	85	L-UNK	inhibitor
NULL

Fluoxetine	DDI-DrugBank.d482.s10	NO_SECTION	NO_SETID	11
Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.
1	0	3	O	Wait
2	5	5	O	2
3	7	11	O	weeks
4	13	17	O	after
5	19	26	O	stopping
6	28	29	O	an
7	31	33	B-UNK	MAO
8	35	43	L-UNK	inhibitor
9	45	50	O	before
10	52	59	O	starting
11	61	72	U-UNK	escitalopram
NULL

Fluoxetine	DDI-DrugBank.d482.s11	NO_SECTION	NO_SETID	19
If you are taking medications for migraines such as Imitrex, talk to your doctor before starting this medicine.
1	0	1	O	If
2	3	5	O	you
3	7	9	O	are
4	11	16	O	taking
5	18	28	O	medications
6	30	32	O	for
7	34	42	O	migraines
8	44	47	O	such
9	49	50	O	as
10	52	58	O	XXXXXXXX
11	59	59	O	,
12	61	64	O	talk
13	66	67	O	to
14	69	72	O	your
15	74	79	O	doctor
16	81	86	O	before
17	88	95	O	starting
18	97	100	O	this
19	102	109	O	medicine
NULL

Fluoxetine	DDI-DrugBank.d482.s12	NO_SECTION	NO_SETID	16
If you are taking a tricyclic antidepressant, talk to your doctor before taking this medicine.
1	0	1	O	If
2	3	5	O	you
3	7	9	O	are
4	11	16	O	taking
5	18	18	O	a
6	20	28	B-UNK	tricyclic
7	30	43	L-UNK	antidepressant
8	44	44	O	,
9	46	49	O	talk
10	51	52	O	to
11	54	57	O	your
12	59	64	O	doctor
13	66	71	O	before
14	73	78	O	taking
15	80	83	O	this
16	85	92	O	medicine
NULL

Fluoxetine	DDI-DrugBank.d482.s13	NO_SECTION	NO_SETID	18
St. John  s Wort should be avoided while taking this medicine due to the additive effects of serotonin.
1	0	1	O	St
2	4	7	O	John
3	10	10	O	s
4	12	15	O	Wort
5	17	22	O	should
6	24	25	O	be
7	27	33	O	avoided
8	35	39	O	while
9	41	46	O	taking
10	48	51	O	this
11	53	60	O	medicine
12	62	64	O	due
13	66	67	O	to
14	69	71	O	the
15	73	80	O	additive
16	82	88	O	effects
17	90	91	O	of
18	93	101	O	serotonin
NULL

Fluoxetine	DDI-DrugBank.d482.s14	NO_SECTION	NO_SETID	42
Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
1	0	3	O	Tell
2	5	8	O	your
3	10	15	O	doctor
4	17	18	O	if
5	20	22	O	you
6	24	26	O	are
7	28	33	O	taking
8	35	37	O	any
9	39	40	O	of
10	42	44	O	the
11	46	54	O	following
12	56	60	O	drugs
13	61	61	O	:
14	63	67	U-UNK	blood
15	69	76	O	thinners
16	79	86	O	Coumadin
17	89	93	O	other
18	95	109	U-UNK	antidepressants
19	111	120	U-UNK	metoprolol
20	122	135	U-UNK	antihistamines
21	137	149	U-UNK	carbamazepine
22	152	159	O	Tegretol
23	162	171	U-UNK	cimetidine
24	174	180	O	Tagamet
25	183	191	U-UNK	estrogens
26	193	202	U-UNK	fluoxetine
27	205	210	O	Prozac
28	213	225	O	intraconazole
29	228	235	O	Sporanox
30	238	249	U-UNK	ketoconazole
31	252	258	O	XXXXXXXX
32	261	268	U-UNK	levodopa
33	270	276	U-UNK	lithium
34	278	283	B-UNK	muscle
35	285	293	L-UNK	relaxants
36	295	299	O	birth
37	301	307	O	control
38	309	313	O	pills
39	315	322	O	sleeping
40	324	328	O	pills
41	330	336	O	thyroid
42	338	348	O	medications
NULL

Fluoxymesterone	DDI-DrugBank.d355.s0	NO_SECTION	NO_SETID	7
Androgens may increase sensitivity to oral anticoagulahts.
1	0	8	U-UNK	Androgens
2	10	12	O	may
3	14	21	O	increase
4	23	33	O	sensitivity
5	35	36	O	to
6	38	41	O	oral
7	43	56	O	anticoagulahts
NULL

Fluoxymesterone	DDI-DrugBank.d355.s1	NO_SECTION	NO_SETID	14
Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.
1	0	5	O	Dosage
2	7	8	O	of
3	10	12	O	the
4	14	26	U-UNK	anticoagulant
5	28	30	O	may
6	32	38	O	require
7	40	48	O	reduction
8	50	51	O	in
9	53	57	O	order
10	59	60	O	to
11	62	69	O	maintain
12	71	82	O	satisfactory
13	84	94	O	therapeutic
14	96	114	O	hypoprothrombinemia
NULL

Fluoxymesterone	DDI-DrugBank.d355.s2	NO_SECTION	NO_SETID	14
Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	43	U-UNK	oxyphenbutazone
5	45	47	O	and
6	49	57	U-UNK	androgens
7	59	61	O	may
8	63	68	O	result
9	70	71	O	in
10	73	80	O	elevated
11	82	86	O	serum
12	88	93	O	levels
13	95	96	O	of
14	98	112	U-UNK	oxyphenbutazone
NULL

Fluoxymesterone	DDI-DrugBank.d355.s3	NO_SECTION	NO_SETID	18
In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
1	0	1	O	In
2	3	10	O	diabetic
3	12	19	O	patients
4	20	20	O	,
5	22	24	O	the
6	26	34	O	metabolic
7	36	42	O	effects
8	44	45	O	of
9	47	55	U-UNK	androgens
10	57	59	O	may
11	61	68	O	decrease
12	70	74	O	blood
13	76	82	O	glucose
14	84	86	O	and
15	88	96	O	therefore
16	97	97	O	,
17	99	105	U-UNK	insulin
18	107	118	O	requirements
NULL

Flupenthixol	DDI-DrugBank.d13.s0	NO_SECTION	NO_SETID	43
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
1	0	3	O	Drug
2	5	16	O	Interactions
3	17	17	O	:
4	19	30	O	XXXXXXXX
5	32	34	O	may
6	36	43	O	interact
7	45	48	O	with
8	50	53	O	some
9	55	59	O	drugs
10	60	60	O	,
11	62	65	O	like
12	67	75	B-UNK	Monoamine
13	77	83	I-UNK	oxidase
14	85	94	L-UNK	inhibitors
15	97	100	U-UNK	MAOI
16	102	102	O	:
17	104	107	U-DYN	MAOI
18	109	113	O	could
19	115	127	O	theoretically
20	129	134	O	affect
21	136	147	O	XXXXXXXX
22	149	164	O	pharmacodynamics
23	168	176	U-UNK	Arecoline
24	180	190	O	Eproxindine
25	194	200	U-UNK	Ethanol
26	201	201	O	:
27	203	214	O	XXXXXXXX
28	216	218	O	and
29	220	226	U-DYN	Ethanol
30	228	232	O	cause
31	234	241	O	additive
32	243	245	O	CNS
33	247	256	O	depression
34	260	268	B-UNK	Tricyclic
35	270	284	L-UNK	antidepressants
36	285	285	O	:
37	287	298	O	XXXXXXXX
38	300	308	O	increases
39	310	312	O	the
40	314	319	O	effect
41	321	322	O	of
42	324	332	B-DYN	Tricyclic
43	334	348	L-DYN	antidepressants
NULL

Flurbiprofen	DDI-DrugBank.d529.s0	NO_SECTION	NO_SETID	25
Antacids: Administration of flurbiprofen to volunteers under fasting conditions, or with antacid suspension yielded similar serum flurbiprofen time profiles in young subjects (n=12).
1	0	7	U-UNK	Antacids
2	8	8	O	:
3	10	23	O	Administration
4	25	26	O	of
5	28	39	O	XXXXXXXX
6	41	42	O	to
7	44	53	O	volunteers
8	55	59	O	under
9	61	67	O	fasting
10	69	78	O	conditions
11	79	79	O	,
12	81	82	O	or
13	84	87	O	with
14	89	95	U-UNK	antacid
15	97	106	O	suspension
16	108	114	O	yielded
17	116	122	O	similar
18	124	128	O	serum
19	130	141	O	XXXXXXXX
20	143	146	O	time
21	148	155	O	profiles
22	157	158	O	in
23	160	164	O	young
24	166	173	O	subjects
25	176	179	O	n=12
NULL

Flurbiprofen	DDI-DrugBank.d529.s1	NO_SECTION	NO_SETID	18
In geriatric subjects (n=7) there was a reduction in the rate but not the extent of flurbiprofen absorption.
1	0	1	O	In
2	3	11	O	geriatric
3	13	20	O	subjects
4	23	25	O	n=7
5	28	32	O	there
6	34	36	O	was
7	38	38	O	a
8	40	48	O	reduction
9	50	51	O	in
10	53	55	O	the
11	57	60	O	rate
12	62	64	O	but
13	66	68	O	not
14	70	72	O	the
15	74	79	O	extent
16	81	82	O	of
17	84	95	O	XXXXXXXX
18	97	106	O	absorption
NULL

Flurbiprofen	DDI-DrugBank.d529.s2	NO_SECTION	NO_SETID	30
Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.
1	0	13	U-UNK	Anticoagulants
2	14	14	O	:
3	16	27	O	XXXXXXXX
4	29	32	O	like
5	34	38	O	other
6	40	51	B-UNK	nonsteroidal
7	53	56	I-UNK	anti
8	58	69	I-UNK	inflammatory
9	71	75	L-UNK	drugs
10	76	76	O	,
11	78	80	O	has
12	82	85	O	been
13	87	91	O	shown
14	93	94	O	to
15	96	101	O	affect
16	103	110	O	bleeding
17	112	121	O	parameters
18	123	124	O	in
19	126	133	O	patients
20	135	143	O	receiving
21	145	148	B-DYN	anti
22	150	159	L-DYN	coagulants
23	160	160	O	,
24	162	164	O	and
25	166	172	O	serious
26	174	181	O	clinical
27	183	190	O	bleeding
28	192	194	O	has
29	196	199	O	been
30	201	208	O	reported
NULL

Flurbiprofen	DDI-DrugBank.d529.s3	NO_SECTION	NO_SETID	12
The physician should be cautious when administering flurbiprofen to patients taking anticoagulants.
1	0	2	O	The
2	4	12	O	physician
3	14	19	O	should
4	21	22	O	be
5	24	31	O	cautious
6	33	36	O	when
7	38	50	O	administering
8	52	63	O	XXXXXXXX
9	65	66	O	to
10	68	75	O	patients
11	77	82	O	taking
12	84	97	U-DYN	anticoagulants
NULL

Flurbiprofen	DDI-DrugBank.d529.s4	NO_SECTION	NO_SETID	15
Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.
1	0	6	O	XXXXXXXX
2	7	7	O	:
3	9	18	O	Concurrent
4	20	33	O	administration
5	35	36	O	of
6	38	44	O	XXXXXXXX
7	46	48	O	and
8	50	61	U-KIN	flurbiprofen
9	63	70	O	resulted
10	72	73	O	in
11	75	77	O	50%
12	79	83	O	lower
13	85	89	O	serum
14	91	102	U-UNK	flurbiprofen
15	104	117	O	concentrations
NULL

Flurbiprofen	DDI-DrugBank.d529.s5	NO_SECTION	NO_SETID	35
This effect of aspirin (which also lowers serum concentrations of other nonsteroidal anti-inflammatory drugs given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16).
1	0	3	O	This
2	5	10	O	effect
3	12	13	O	of
4	15	21	O	XXXXXXXX
5	24	28	O	which
6	30	33	O	also
7	35	40	O	lowers
8	42	46	O	serum
9	48	61	O	concentrations
10	63	64	O	of
11	66	70	O	other
12	72	83	B-UNK	nonsteroidal
13	85	88	I-UNK	anti
14	90	101	I-UNK	inflammatory
15	103	107	L-UNK	drugs
16	109	113	O	given
17	115	118	O	with
18	120	121	O	it
19	124	126	O	has
20	128	131	O	been
21	133	144	O	demonstrated
22	146	147	O	in
23	149	156	O	patients
24	158	161	O	with
25	163	172	O	rheumatoid
26	174	182	O	arthritis
27	185	186	O	n=
28	188	189	O	15
29	192	193	O	as
30	195	198	O	well
31	200	201	O	as
32	203	208	O	normal
33	210	219	O	volunteers
34	222	223	O	n=
35	225	226	O	16
NULL

Flurbiprofen	DDI-DrugBank.d529.s6	NO_SECTION	NO_SETID	10
Concurrent use of flurbiprofen and aspirin is therefore not recommended.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	16	O	of
4	18	29	U-DYN	flurbiprofen
5	31	33	O	and
6	35	41	O	XXXXXXXX
7	43	44	O	is
8	46	54	O	therefore
9	56	58	O	not
10	60	70	O	recommended
NULL

Flurbiprofen	DDI-DrugBank.d529.s7	NO_SECTION	NO_SETID	28
Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).
1	0	3	B-UNK	Beta
2	5	14	I-UNK	adrenergic
3	16	23	I-UNK	Blocking
4	25	30	L-UNK	Agents
5	31	31	O	:
6	33	35	O	The
7	37	42	O	effect
8	44	45	O	of
9	47	58	O	XXXXXXXX
10	60	61	O	on
11	63	67	O	blood
12	69	76	O	pressure
13	78	85	O	response
14	87	88	O	to
15	90	100	U-UNK	propranolol
16	102	104	O	and
17	106	113	U-UNK	atenolol
18	115	117	O	was
19	119	127	O	evaluated
20	129	130	O	in
21	132	134	O	men
22	136	139	O	with
23	141	144	O	mild
24	146	158	O	uncomplicated
25	160	171	O	hypertension
26	174	174	O	n
27	176	176	O	=
28	178	179	O	10
NULL

Flurbiprofen	DDI-DrugBank.d529.s8	NO_SECTION	NO_SETID	15
Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol.
1	0	11	O	XXXXXXXX
2	13	24	O	pretreatment
3	26	35	O	attenuated
4	37	39	O	the
5	41	51	O	hypotensive
6	53	58	O	effect
7	60	61	O	of
8	63	63	O	a
9	65	70	O	single
10	72	75	O	dose
11	77	78	O	of
12	80	90	U-DYN	propranolol
13	92	94	O	but
14	96	98	O	not
15	100	107	U-UNK	atenolol
NULL

Flurbiprofen	DDI-DrugBank.d529.s9	NO_SECTION	NO_SETID	14
Flurbiprofen did not appear to affect the beta-blocker-mediated reduction in heart rate.
1	0	11	O	XXXXXXXX
2	13	15	O	did
3	17	19	O	not
4	21	26	O	appear
5	28	29	O	to
6	31	36	O	affect
7	38	40	O	the
8	42	45	O	beta
9	47	53	O	blocker
10	55	62	O	mediated
11	64	72	O	reduction
12	74	75	O	in
13	77	81	O	heart
14	83	86	O	rate
NULL

Flurbiprofen	DDI-DrugBank.d529.s10	NO_SECTION	NO_SETID	24
Flurbiprofen did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with propranolols hypotensive effect is unknown.
1	0	11	O	XXXXXXXX
2	13	15	O	did
3	17	19	O	not
4	21	26	O	affect
5	28	30	O	the
6	32	46	O	pharmacokinetic
7	48	54	O	profile
8	56	57	O	of
9	59	64	O	either
10	66	69	O	drug
11	70	70	O	,
12	72	74	O	and
13	76	78	O	the
14	80	88	O	mechanism
15	90	94	O	under
16	96	100	O	lying
17	102	104	O	the
18	106	117	O	interference
19	119	122	O	with
20	124	135	O	propranolols
21	137	147	O	hypotensive
22	149	154	O	effect
23	156	157	O	is
24	159	165	O	unknown
NULL

Flurbiprofen	DDI-DrugBank.d529.s11	NO_SECTION	NO_SETID	20
Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.
1	0	7	O	Patients
2	9	14	O	taking
3	16	19	O	both
4	21	32	O	XXXXXXXX
5	34	36	O	and
6	38	38	O	a
7	40	43	B-DYN	beta
8	45	51	L-DYN	blocker
9	53	58	O	should
10	60	61	O	be
11	63	71	O	monitored
12	73	74	O	to
13	76	81	O	ensure
14	83	86	O	that
15	88	88	O	a
16	90	101	O	satisfactory
17	103	113	O	hypotensive
18	115	120	O	effect
19	122	123	O	is
20	125	132	O	achieved
NULL

Flurbiprofen	DDI-DrugBank.d529.s12	NO_SECTION	NO_SETID	42
Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.
1	0	9	U-UNK	Cimetidine
2	10	10	O	,
3	12	21	U-UNK	Ranitidine
4	22	22	O	:
5	24	25	O	In
6	27	32	O	normal
7	34	43	O	volunteers
8	46	48	O	n=9
9	50	50	O	,
10	52	63	O	pretreatment
11	65	68	O	with
12	70	79	U-UNK	cimetidine
13	81	82	O	or
14	84	93	U-UNK	ranitidine
15	95	97	O	did
16	99	101	O	not
17	103	108	O	affect
18	110	121	O	XXXXXXXX
19	123	138	O	pharmacokinetics
20	140	145	O	except
21	147	150	O	that
22	152	152	O	a
23	154	158	O	small
24	161	162	O	13
25	164	164	O	%
26	167	169	O	but
27	171	183	O	statistically
28	185	195	O	significant
29	197	204	O	increase
30	206	207	O	in
31	209	211	O	the
32	213	216	O	area
33	218	222	O	under
34	224	226	O	the
35	228	232	O	serum
36	234	246	O	concentration
37	248	252	O	curve
38	254	255	O	of
39	257	268	O	XXXXXXXX
40	270	277	O	resulted
41	279	282	O	with
42	284	293	U-KIN	cimetidine
NULL

Flurbiprofen	DDI-DrugBank.d529.s13	NO_SECTION	NO_SETID	29
Digoxin: Studies of concomitant administration of flurbiprofen and digoxin to healthy men (n= 14) did not show a change in the steady state serum levels of either drug.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	15	O	Studies
4	17	18	O	of
5	20	30	O	concomitant
6	32	45	O	administration
7	47	48	O	of
8	50	61	O	XXXXXXXX
9	63	65	O	and
10	67	73	U-UNK	digoxin
11	75	76	O	to
12	78	84	O	healthy
13	86	88	O	men
14	91	92	O	n=
15	94	95	O	14
16	98	100	O	did
17	102	104	O	not
18	106	109	O	show
19	111	111	O	a
20	113	118	O	change
21	120	121	O	in
22	123	125	O	the
23	127	132	O	steady
24	134	138	O	state
25	140	144	O	serum
26	146	151	O	levels
27	153	154	O	of
28	156	161	O	either
29	163	166	O	drug
NULL

Flurbiprofen	DDI-DrugBank.d529.s14	NO_SECTION	NO_SETID	24
Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.
1	0	8	U-UNK	Diuretics
2	9	9	O	:
3	11	17	O	Studies
4	19	20	O	in
5	22	27	O	normal
6	29	38	O	volunteers
7	40	43	O	have
8	45	49	O	shown
9	51	54	O	that
10	56	67	O	XXXXXXXX
11	69	72	O	like
12	74	78	O	other
13	80	91	B-UNK	nonsteroidal
14	93	96	I-UNK	anti
15	98	109	I-UNK	inflammatory
16	111	115	L-UNK	drugs
17	116	116	O	,
18	118	120	O	can
19	122	130	O	interfere
20	132	135	O	with
21	137	139	O	the
22	141	147	O	effects
23	149	150	O	of
24	152	161	U-DYN	furosemide
NULL

Flurbiprofen	DDI-DrugBank.d529.s15	NO_SECTION	NO_SETID	22
Although results have varied from study to study, effects have been shown on furosemide-stimulated diuresis, natriuresis, and kaliuresis.
1	0	7	O	Although
2	9	15	O	results
3	17	20	O	have
4	22	27	O	varied
5	29	32	O	from
6	34	38	O	study
7	40	41	O	to
8	43	47	O	study
9	48	48	O	,
10	50	56	O	effects
11	58	61	O	have
12	63	66	O	been
13	68	72	O	shown
14	74	75	O	on
15	77	86	U-UNK	furosemide
16	88	97	O	stimulated
17	99	106	O	diuresis
18	107	107	O	,
19	109	119	O	natriuresis
20	120	120	O	,
21	122	124	O	and
22	126	135	O	kaliuresis
NULL

Flurbiprofen	DDI-DrugBank.d529.s16	NO_SECTION	NO_SETID	25
Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.
1	0	4	O	Other
2	6	17	B-UNK	nonsteroidal
3	19	22	I-UNK	anti
4	24	35	I-UNK	inflammatory
5	37	41	L-UNK	drugs
6	43	46	O	that
7	48	54	O	inhibit
8	56	68	O	prostaglandin
9	70	78	O	synthesis
10	80	83	O	have
11	85	88	O	been
12	90	94	O	shown
13	96	97	O	to
14	99	107	O	interfere
15	109	112	O	with
16	114	121	B-UNK	thiazide
17	123	131	L-UNK	diuretics
18	133	134	O	in
19	136	139	O	some
20	141	147	O	studies
21	149	151	O	and
22	153	156	O	with
23	158	166	B-UNK	potassium
24	168	174	I-UNK	sparing
25	176	184	L-UNK	diuretics
NULL

Flurbiprofen	DDI-DrugBank.d529.s17	NO_SECTION	NO_SETID	20
Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	30	O	XXXXXXXX
4	32	34	O	and
5	36	45	U-DYN	furosemide
6	47	48	O	or
7	50	54	O	other
8	56	64	U-DYN	diuretics
9	66	71	O	should
10	73	74	O	be
11	76	83	O	observed
12	85	91	O	closely
13	93	94	O	to
14	96	104	O	determine
15	106	107	O	if
16	109	111	O	the
17	113	119	O	desired
18	121	126	O	effect
19	128	129	O	is
20	131	138	O	obtained
NULL

Flurbiprofen	DDI-DrugBank.d529.s18	NO_SECTION	NO_SETID	33
Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).
1	0	3	O	Oral
2	5	16	B-UNK	Hypoglycemic
3	18	23	L-UNK	Agents
4	24	24	O	:
5	26	27	O	In
6	29	31	O	one
7	33	37	O	study
8	38	38	O	,
9	40	51	O	XXXXXXXX
10	53	55	O	was
11	57	61	O	given
12	63	64	O	to
13	66	70	O	adult
14	72	80	O	diabetics
15	82	84	O	who
16	86	89	O	were
17	91	97	O	already
18	99	107	O	receiving
19	109	117	U-UNK	glyburide
20	120	122	O	n=4
21	124	124	O	,
22	126	134	U-UNK	metformin
23	137	139	O	n=2
24	142	155	U-UNK	chlorpropamide
25	157	160	O	with
26	162	171	U-UNK	phenformin
27	174	175	O	n=
28	177	177	O	3
29	180	181	O	or
30	183	191	U-UNK	glyburide
31	193	196	O	with
32	198	207	U-UNK	phenformin
33	210	212	O	n=6
NULL

Flurbiprofen	DDI-DrugBank.d529.s19	NO_SECTION	NO_SETID	27
Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents, there were no signs or symptoms of hypoglycemia.
1	0	7	O	Although
2	9	13	O	there
3	15	17	O	was
4	19	19	O	a
5	21	26	O	slight
6	28	36	O	reduction
7	38	39	O	in
8	41	45	O	blood
9	47	51	O	sugar
10	53	66	O	concentrations
11	68	73	O	during
12	75	85	O	concomitant
13	87	100	O	administration
14	102	103	O	of
15	105	116	O	XXXXXXXX
16	118	120	O	and
17	122	133	B-DYN	hypoglycemic
18	135	140	L-DYN	agents
19	141	141	O	,
20	143	147	O	there
21	149	152	O	were
22	154	155	O	no
23	157	161	O	signs
24	163	164	O	or
25	166	173	O	symptoms
26	175	176	O	of
27	178	189	O	hypoglycemia
NULL

Flutamide	DDI-DrugBank.d442.s0	NO_SECTION	NO_SETID	18
Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.
1	0	8	O	Increases
2	10	11	O	in
3	13	23	O	prothrombin
4	25	28	O	time
5	30	33	O	have
6	35	38	O	been
7	40	44	O	noted
8	46	47	O	in
9	49	56	O	patients
10	58	66	O	receiving
11	68	71	O	long
12	74	77	O	term
13	79	86	U-DYN	warfarin
14	88	94	O	therapy
15	96	100	O	after
16	102	110	O	XXXXXXXX
17	112	114	O	was
18	116	124	O	initiated
NULL

Flutamide	DDI-DrugBank.d442.s1	NO_SECTION	NO_SETID	26
Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.
1	0	8	O	Therefore
2	9	9	O	,
3	11	15	O	close
4	17	26	O	monitoring
5	28	29	O	of
6	31	41	O	prothrombin
7	43	46	O	time
8	48	49	O	is
9	51	61	O	recommended
10	63	65	O	and
11	67	76	O	adjustment
12	78	79	O	of
13	81	83	O	the
14	85	97	U-UNK	anticoagulant
15	99	102	O	dose
16	104	106	O	may
17	108	109	O	be
18	111	119	O	necessary
19	121	124	O	when
20	126	132	O	XXXXXXXX
21	134	141	O	Capsules
22	143	145	O	are
23	147	158	O	administered
24	160	172	O	concomitantly
25	174	177	O	with
26	179	186	U-DYN	warfarin
NULL

Fluvoxamine	DDI-DrugBank.d76.s0	NO_SECTION	NO_SETID	7
Potential for Interaction with Monoamine Oxidase Inhibitors
1	0	8	O	Potential
2	10	12	O	for
3	14	24	O	Interaction
4	26	29	O	with
5	31	39	B-UNK	Monoamine
6	41	47	I-UNK	Oxidase
7	49	58	L-UNK	Inhibitors
NULL

Fluvoxamine	DDI-DrugBank.d76.s1	NO_SECTION	NO_SETID	57
In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.
1	0	1	O	In
2	3	10	O	patients
3	12	20	O	receiving
4	22	28	O	another
5	30	38	B-UNK	serotonin
6	40	47	I-UNK	reuptake
7	49	57	I-UNK	inhibitor
8	59	62	L-UNK	drug
9	64	65	O	in
10	67	77	O	combination
11	79	82	O	with
12	84	92	B-UNK	monoamine
13	94	100	I-UNK	oxidase
14	102	111	L-UNK	inhibitors
15	114	117	U-UNK	MAOI
16	119	119	O	,
17	121	125	O	there
18	127	130	O	have
19	132	135	O	been
20	137	143	O	reports
21	145	146	O	of
22	148	154	O	serious
23	155	155	O	,
24	157	165	O	sometimes
25	167	171	O	fatal
26	172	172	O	,
27	174	182	O	reactions
28	184	192	O	including
29	194	205	O	hyperthermia
30	206	206	O	,
31	208	215	O	rigidity
32	216	216	O	,
33	218	226	O	myoclonus
34	227	227	O	,
35	229	237	O	autonomic
36	239	249	O	instability
37	251	254	O	with
38	256	263	O	possible
39	265	269	O	rapid
40	271	282	O	fluctuations
41	284	285	O	of
42	287	291	O	vital
43	293	297	O	signs
44	298	298	O	,
45	300	302	O	and
46	304	309	O	mental
47	311	316	O	status
48	318	324	O	changes
49	326	329	O	that
50	331	337	O	include
51	339	345	O	extreme
52	347	355	O	agitation
53	357	367	O	progressing
54	369	370	O	to
55	372	379	O	delirium
56	381	383	O	and
57	385	388	O	coma
NULL

Fluvoxamine	DDI-DrugBank.d76.s2	NO_SECTION	NO_SETID	20
These reactions have also been reported in patients who have discontinued that drug and have been started on a MAOI.
1	0	4	O	These
2	6	14	O	reactions
3	16	19	O	have
4	21	24	O	also
5	26	29	O	been
6	31	38	O	reported
7	40	41	O	in
8	43	50	O	patients
9	52	54	O	who
10	56	59	O	have
11	61	72	O	discontinued
12	74	77	O	that
13	79	82	O	drug
14	84	86	O	and
15	88	91	O	have
16	93	96	O	been
17	98	104	O	started
18	106	107	O	on
19	109	109	O	a
20	111	114	U-UNK	MAOI
NULL

Fluvoxamine	DDI-DrugBank.d76.s3	NO_SECTION	NO_SETID	9
Some cases presented with features resembling neuroleptic malignant syndrome.
1	0	3	O	Some
2	5	9	O	cases
3	11	19	O	presented
4	21	24	O	with
5	26	33	O	features
6	35	44	O	resembling
7	46	56	O	neuroleptic
8	58	66	O	malignant
9	68	75	O	syndrome
NULL

Fluvoxamine	DDI-DrugBank.d76.s4	NO_SECTION	NO_SETID	26
Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	it
4	14	15	O	is
5	17	27	O	recommended
6	29	32	O	that
7	34	44	O	XXXXXXXX
8	46	52	O	Tablets
9	54	56	O	not
10	58	59	O	be
11	61	64	O	used
12	66	67	O	in
13	69	79	O	combination
14	81	84	O	with
15	86	90	U-DYN	MAOIs
16	91	91	O	,
17	93	94	O	or
18	96	101	O	within
19	103	104	O	14
20	106	109	O	days
21	111	112	O	of
22	114	126	O	discontinuing
23	128	136	O	treatment
24	138	141	O	with
25	143	143	O	a
26	145	148	U-DYN	MAOI
NULL

Fluvoxamine	DDI-DrugBank.d76.s5	NO_SECTION	NO_SETID	16
After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.
1	0	4	O	After
2	6	13	O	stopping
3	15	25	O	XXXXXXXX
4	27	33	O	Tablets
5	34	34	O	,
6	36	37	O	at
7	39	43	O	least
8	45	45	O	2
9	47	51	O	weeks
10	53	58	O	should
11	60	61	O	be
12	63	69	O	allowed
13	71	76	O	before
14	78	85	O	starting
15	87	87	O	a
16	89	92	U-DYN	MAOI
NULL

Fluvoxamine	DDI-DrugBank.d76.s6	NO_SECTION	NO_SETID	8
Potential Terfenadine, Astemizole, and Cisapride Interactions
1	0	8	O	Potential
2	10	20	U-UNK	Terfenadine
3	21	21	O	,
4	23	32	U-UNK	Astemizole
5	33	33	O	,
6	35	37	O	and
7	39	47	U-UNK	Cisapride
8	49	60	O	Interactions
NULL

Fluvoxamine	DDI-DrugBank.d76.s7	NO_SECTION	NO_SETID	43
Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.
1	0	10	U-UNK	Terfenadine
2	11	11	O	,
3	13	22	U-UNK	astemizole
4	24	26	O	and
5	28	36	U-UNK	cisapride
6	38	40	O	are
7	42	44	O	all
8	46	56	O	metabolized
9	58	59	O	by
10	61	63	O	the
11	65	74	O	cytochrome
12	76	84	O	P450IIIA4
13	86	92	O	isozyme
14	93	93	O	,
15	95	97	O	and
16	99	100	O	it
17	102	104	O	has
18	106	109	O	been
19	111	122	O	demonstrated
20	124	127	O	that
21	129	140	U-UNK	ketoconazole
22	141	141	O	,
23	143	143	O	a
24	145	150	O	potent
25	152	160	O	inhibitor
26	162	163	O	of
27	165	169	O	IIIA4
28	170	170	O	,
29	172	177	O	blocks
30	179	181	O	the
31	183	192	O	metabolism
32	194	195	O	of
33	197	201	O	these
34	203	207	O	drugs
35	208	208	O	,
36	210	218	O	resulting
37	220	221	O	in
38	223	231	O	increased
39	233	238	O	plasma
40	240	253	O	concentrations
41	255	256	O	of
42	258	263	O	parent
43	265	268	O	drug
NULL

Fluvoxamine	DDI-DrugBank.d76.s8	NO_SECTION	NO_SETID	27
Increased plasma concentrations of terfenadine, astemizole, and cisapride cause QT prolongation and have been associated with torsades de pointes-type ventricular tachycardia, sometimes fatal.
1	0	8	O	Increased
2	10	15	O	plasma
3	17	30	O	concentrations
4	32	33	O	of
5	35	45	U-UNK	terfenadine
6	46	46	O	,
7	48	57	U-UNK	astemizole
8	58	58	O	,
9	60	62	O	and
10	64	72	U-UNK	cisapride
11	74	78	O	cause
12	80	81	O	QT
13	83	94	O	prolongation
14	96	98	O	and
15	100	103	O	have
16	105	108	O	been
17	110	119	O	associated
18	121	124	O	with
19	126	133	O	torsades
20	135	136	O	de
21	138	144	O	pointes
22	146	149	O	type
23	151	161	O	ventricular
24	163	173	O	tachycardia
25	174	174	O	,
26	176	184	O	sometimes
27	186	190	O	fatal
NULL

Fluvoxamine	DDI-DrugBank.d76.s9	NO_SECTION	NO_SETID	25
As noted below, a sub- for fluvoxamine in combination with alprazolam, a drug that is known to be metabolized by the IIIA4 isozyme.
1	0	1	O	As
2	3	7	O	noted
3	9	13	O	below
4	14	14	O	,
5	16	16	O	a
6	18	20	O	sub
7	23	25	O	for
8	27	37	O	XXXXXXXX
9	39	40	O	in
10	42	52	O	combination
11	54	57	O	with
12	59	68	U-UNK	alprazolam
13	69	69	O	,
14	71	71	O	a
15	73	76	O	drug
16	78	81	O	that
17	83	84	O	is
18	86	90	O	known
19	92	93	O	to
20	95	96	O	be
21	98	108	O	metabolized
22	110	111	O	by
23	113	115	O	the
24	117	121	O	IIIA4
25	123	129	O	isozyme
NULL

Fluvoxamine	DDI-DrugBank.d76.s10	NO_SECTION	NO_SETID	29
Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.
1	0	7	O	Although
2	9	10	O	it
3	12	14	O	has
4	16	18	O	not
5	20	23	O	been
6	25	36	O	definitively
7	38	49	O	demonstrated
8	51	54	O	that
9	56	66	O	XXXXXXXX
10	68	69	O	is
11	71	71	O	a
12	73	78	O	potent
13	80	84	O	IIIA4
14	86	94	O	inhibitor
15	95	95	O	,
16	97	98	O	it
17	100	101	O	is
18	103	108	O	likely
19	110	111	O	to
20	113	114	O	be
21	115	115	O	,
22	117	121	O	given
23	123	125	O	the
24	127	137	O	substantial
25	139	149	O	interaction
26	151	152	O	of
27	154	164	O	XXXXXXXX
28	166	169	O	with
29	171	180	U-UNK	alprazolam
NULL

Fluvoxamine	DDI-DrugBank.d76.s11	NO_SECTION	NO_SETID	20
Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
1	0	11	O	Consequently
2	12	12	O	,
3	14	15	O	it
4	17	18	O	is
5	20	30	O	recommended
6	32	35	O	that
7	37	47	O	XXXXXXXX
8	49	51	O	not
9	53	54	O	be
10	56	59	O	used
11	61	62	O	in
12	64	74	O	combination
13	76	79	O	with
14	81	86	O	either
15	88	98	U-DYN	terbinafine
16	99	99	O	,
17	101	110	U-DYN	astemizole
18	111	111	O	,
19	113	114	O	or
20	116	124	U-DYN	cisapride
NULL

Fluvoxamine	DDI-DrugBank.d76.s12	NO_SECTION	NO_SETID	39
Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
1	0	4	O	Other
2	6	16	O	Potentially
3	18	26	O	Important
4	28	31	O	Drug
5	33	44	O	Interactions
6	45	45	O	:
7	47	61	U-UNK	Benzodiazepines
8	62	62	O	:
9	64	78	U-KIN	Benzodiazepines
10	80	90	O	metabolized
11	92	93	O	by
12	95	101	O	hepatic
13	103	111	O	oxidation
14	114	116	O	e.g
15	118	118	O	,
16	120	129	U-KIN	alprazolam
17	130	130	O	,
18	132	140	U-KIN	midazolam
19	141	141	O	,
20	143	151	U-KIN	triazolam
21	153	155	O	elc
22	159	164	O	should
23	166	167	O	be
24	169	172	O	used
25	174	177	O	with
26	179	185	O	caution
27	187	193	O	because
28	195	197	O	the
29	199	207	O	clearance
30	209	210	O	of
31	212	216	O	these
32	218	222	O	drugs
33	224	225	O	is
34	227	232	O	likely
35	234	235	O	to
36	237	238	O	be
37	240	246	O	reduced
38	248	249	O	by
39	251	261	O	XXXXXXXX
NULL

Fluvoxamine	DDI-DrugBank.d76.s13	NO_SECTION	NO_SETID	22
The clearance of benzodiazepines metabolized by glucuronidation (e. g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine.
1	0	2	O	The
2	4	12	O	clearance
3	14	15	O	of
4	17	31	U-UNK	benzodiazepines
5	33	43	O	metabolized
6	45	46	O	by
7	48	62	O	glucuronidation
8	65	65	O	e
9	68	68	O	g
10	70	70	O	,
11	72	80	U-UNK	lorazepam
12	81	81	O	,
13	83	90	U-UNK	oxazepam
14	91	91	O	,
15	93	101	U-UNK	temazepam
16	104	105	O	is
17	107	114	O	unlikely
18	116	117	O	to
19	119	120	O	be
20	122	129	O	affected
21	131	132	O	by
22	134	144	O	XXXXXXXX
NULL

Fluvoxamine	DDI-DrugBank.d76.s14	NO_SECTION	NO_SETID	45
Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;
1	0	9	U-UNK	Alprazolam
2	10	10	O	:
3	12	15	O	When
4	17	27	O	XXXXXXXX
5	29	35	O	maleate
6	38	40	O	100
7	42	43	O	mg
8	45	46	O	qd
9	49	51	O	and
10	53	62	U-KIN	alprazolam
11	65	65	O	1
12	67	68	O	mg
13	70	72	O	q.d
14	75	78	O	were
15	80	81	O	co
16	83	94	O	administered
17	96	97	O	to
18	99	104	O	steady
19	106	110	O	state
20	111	111	O	,
21	113	118	O	plasma
22	120	132	O	concentration
23	134	136	O	and
24	138	142	O	other
25	144	159	O	pharmacokinetics
26	161	170	O	parameters
27	173	175	O	AUC
28	176	176	O	,
29	178	181	O	Cmax
30	182	182	O	,
31	184	185	O	T1
32	186	186	O	/
33	187	188	O	2,
34	191	192	O	of
35	194	203	U-UNK	alprazolam
36	205	208	O	were
37	210	222	O	approximately
38	224	228	O	twice
39	230	234	O	those
40	236	243	O	observed
41	245	248	O	when
42	250	259	U-UNK	alprazolam
43	261	263	O	was
44	265	276	O	administered
45	278	282	O	alone
NULL

Fluvoxamine	DDI-DrugBank.d76.s15	NO_SECTION	NO_SETID	7
oral clearance was reduced by about 50%.
1	0	3	O	oral
2	5	13	O	clearance
3	15	17	O	was
4	19	25	O	reduced
5	27	28	O	by
6	30	34	O	about
7	36	38	O	50%
NULL

Fluvoxamine	DDI-DrugBank.d76.s16	NO_SECTION	NO_SETID	12
The elevated plasma alprazolam concentrations resulted in decreased psychomotor performance and memory.
1	0	2	O	The
2	4	11	O	elevated
3	13	18	O	plasma
4	20	29	U-UNK	alprazolam
5	31	44	O	concentrations
6	46	53	O	resulted
7	55	56	O	in
8	58	66	O	decreased
9	68	78	O	psychomotor
10	80	90	O	performance
11	92	94	O	and
12	96	101	O	memory
NULL

Fluvoxamine	DDI-DrugBank.d76.s17	NO_SECTION	NO_SETID	69
This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.
1	0	3	O	This
2	5	15	O	interaction
3	16	16	O	,
4	18	22	O	which
5	24	26	O	has
6	28	30	O	not
7	32	35	O	been
8	37	48	O	investigated
9	50	54	O	using
10	56	61	O	higher
11	63	67	O	doses
12	69	70	O	of
13	72	82	O	XXXXXXXX
14	83	83	O	,
15	85	87	O	may
16	89	90	O	be
17	92	95	O	more
18	97	106	O	pronounced
19	108	109	O	if
20	111	111	O	a
21	113	115	O	300
22	117	118	O	mg
23	120	124	O	daily
24	126	129	O	dose
25	131	132	O	is
26	134	135	O	co
27	137	148	O	administered
28	149	149	O	,
29	151	162	O	particularly
30	164	168	O	since
31	170	180	O	XXXXXXXX
32	182	189	O	exhibits
33	191	193	O	non
34	195	200	O	linear
35	202	217	O	pharmacokinetics
36	219	222	O	over
37	224	226	O	the
38	228	233	O	dosage
39	235	239	O	range
40	241	243	O	100
41	245	247	O	300
42	249	250	O	mg
43	253	254	O	If
44	256	265	U-DYN	alprazolam
45	267	268	O	is
46	270	271	O	co
47	273	284	O	administered
48	286	289	O	with
49	291	301	O	XXXXXXXX
50	303	309	O	Tablets
51	310	310	O	,
52	312	314	O	the
53	316	322	O	initial
54	324	333	U-UNK	alprazolam
55	335	340	O	dosage
56	342	347	O	should
57	349	350	O	be
58	352	353	O	at
59	355	359	O	least
60	361	366	O	halved
61	368	370	O	and
62	372	380	O	titration
63	382	383	O	to
64	385	387	O	the
65	389	394	O	lowest
66	396	404	O	effective
67	406	409	O	dose
68	411	412	O	is
69	414	424	O	recommended
NULL

Fluvoxamine	DDI-DrugBank.d76.s18	NO_SECTION	NO_SETID	8
No dosage adjustment is required for Fluvoxamine Tablets.
1	0	1	O	No
2	3	8	O	dosage
3	10	19	O	adjustment
4	21	22	O	is
5	24	31	O	required
6	33	35	O	for
7	37	47	O	XXXXXXXX
8	49	55	O	Tablets
NULL

Fluvoxamine	DDI-DrugBank.d76.s19	NO_SECTION	NO_SETID	14
Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.
1	0	7	U-UNK	Diazepam
2	8	8	O	:
3	10	12	O	The
4	14	15	O	co
5	17	30	O	administration
6	32	33	O	of
7	35	45	O	XXXXXXXX
8	47	53	O	Tablets
9	55	57	O	and
10	59	66	U-DYN	diazepam
11	68	69	O	is
12	71	79	O	generally
13	81	83	O	not
14	85	93	O	advisable
NULL

Fluvoxamine	DDI-DrugBank.d76.s20	NO_SECTION	NO_SETID	31
Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.
1	0	6	O	Because
2	8	18	O	XXXXXXXX
3	20	26	O	reduces
4	28	30	O	the
5	32	40	O	clearance
6	42	43	O	of
7	45	48	O	both
8	50	57	U-KIN	diazepam
9	59	61	O	and
10	63	65	O	its
11	67	72	O	active
12	74	83	O	metabolite
13	84	84	O	,
14	86	86	B-KIN	N
15	88	104	L-KIN	desmethyldiazepam
16	105	105	O	,
17	107	111	O	there
18	113	114	O	is
19	116	116	O	a
20	118	123	O	strong
21	125	134	O	likelihood
22	136	137	O	of
23	139	149	O	substantial
24	151	162	O	accumulation
25	164	165	O	of
26	167	170	O	both
27	172	178	O	species
28	180	185	O	during
29	187	193	O	chronic
30	195	196	O	co
31	198	211	O	administration
NULL

Fluvoxamine	DDI-DrugBank.d76.s21	NO_SECTION	NO_SETID	41
Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.
1	0	7	O	Evidence
2	9	18	O	supporting
3	20	22	O	the
4	24	33	O	conclusion
5	35	38	O	that
6	40	41	O	it
7	43	44	O	is
8	46	56	O	inadvisable
9	58	59	O	to
10	61	62	O	co
11	64	73	O	administer
12	75	85	O	XXXXXXXX
13	87	89	O	and
14	91	98	U-DYN	diazepam
15	100	101	O	is
16	103	109	O	derived
17	111	114	O	from
18	116	116	O	a
19	118	122	O	study
20	124	125	O	in
21	127	131	O	which
22	133	139	O	healthy
23	141	150	O	volunteers
24	152	157	O	taking
25	159	161	O	150
26	163	164	O	mg
27	165	165	O	/
28	166	168	O	day
29	170	171	O	of
30	173	183	O	XXXXXXXX
31	185	188	O	were
32	190	201	O	administered
33	203	203	O	a
34	205	210	O	single
35	212	215	O	oral
36	217	220	O	dose
37	222	223	O	of
38	225	226	O	10
39	228	229	O	mg
40	231	232	O	of
41	234	241	U-UNK	diazepam
NULL

Fluvoxamine	DDI-DrugBank.d76.s22	NO_SECTION	NO_SETID	37
In these subjects (R= B), the clearance of diazepam was reduced by 65% and that of N-desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study.
1	0	1	O	In
2	3	7	O	these
3	9	16	O	subjects
4	19	20	O	R=
5	22	22	O	B
6	24	24	O	,
7	26	28	O	the
8	30	38	O	clearance
9	40	41	O	of
10	43	50	U-UNK	diazepam
11	52	54	O	was
12	56	62	O	reduced
13	64	65	O	by
14	67	69	O	65%
15	71	73	O	and
16	75	78	O	that
17	80	81	O	of
18	83	83	B-UNK	N
19	85	101	L-UNK	desmethyldiazepam
20	103	104	O	to
21	106	106	O	a
22	108	112	O	level
23	114	117	O	that
24	119	121	O	was
25	123	125	O	too
26	127	129	O	low
27	131	132	O	to
28	134	140	O	measure
29	142	145	O	over
30	147	149	O	the
31	151	156	O	course
32	158	159	O	of
33	161	163	O	the
34	165	165	O	2
35	167	170	O	week
36	172	175	O	long
37	177	181	O	study
NULL

Fluvoxamine	DDI-DrugBank.d76.s23	NO_SECTION	NO_SETID	18
It is likely that experience significantly underestimates the degree of accumulation that might occur with repealed diazepam administration.
1	0	1	O	It
2	3	4	O	is
3	6	11	O	likely
4	13	16	O	that
5	18	27	O	experience
6	29	41	O	significantly
7	43	56	O	underestimates
8	58	60	O	the
9	62	67	O	degree
10	69	70	O	of
11	72	83	O	accumulation
12	85	88	O	that
13	90	94	O	might
14	96	100	O	occur
15	102	105	O	with
16	107	114	O	repealed
17	116	123	U-UNK	diazepam
18	125	138	O	administration
NULL

Fluvoxamine	DDI-DrugBank.d76.s24	NO_SECTION	NO_SETID	23
Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.
1	0	7	O	Moreover
2	8	8	O	,
3	10	11	O	as
4	13	17	O	noted
5	19	22	O	with
6	24	33	U-DYN	alprazolam
7	34	34	O	,
8	36	38	O	the
9	40	45	O	effect
10	47	48	O	of
11	50	60	O	XXXXXXXX
12	62	64	O	may
13	66	69	O	even
14	71	72	O	be
15	74	77	O	more
16	79	88	O	pronounced
17	90	93	O	when
18	95	96	O	it
19	98	99	O	is
20	101	112	O	administered
21	114	115	O	at
22	117	122	O	higher
23	124	128	O	doses
NULL

Fluvoxamine	DDI-DrugBank.d76.s25	NO_SECTION	NO_SETID	11
Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.
1	0	10	O	Accordingly
2	11	11	O	,
3	13	20	U-DYN	diazepam
4	22	24	O	and
5	26	36	O	XXXXXXXX
6	38	43	O	should
7	45	47	O	not
8	49	58	O	ordinarily
9	60	61	O	be
10	63	64	O	co
11	66	77	O	administered
NULL

Fluvoxamine	DDI-DrugBank.d76.s26	NO_SECTION	NO_SETID	36
Theophylline: The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.
1	0	11	U-UNK	Theophylline
2	12	12	O	:
3	14	16	O	The
4	18	23	O	effect
5	25	26	O	of
6	28	33	O	steady
7	35	39	O	state
8	41	51	O	XXXXXXXX
9	53	55	O	l50
10	57	58	O	mg
11	60	62	O	bid
12	64	65	O	on
13	67	69	O	the
14	71	86	O	pharmacokinetics
15	88	89	O	of
16	91	91	O	a
17	93	98	O	single
18	100	103	O	dose
19	105	106	O	of
20	108	119	U-UNK	Theophylline
21	122	124	O	375
22	126	127	O	mg
23	130	131	O	as
24	133	135	O	442
25	137	138	O	mg
26	140	152	U-UNK	aminophylline
27	154	156	O	was
28	158	166	O	evaluated
29	168	169	O	in
30	171	172	O	12
31	174	180	O	healthy
32	182	184	O	non
33	186	192	O	smoking
34	193	193	O	,
35	195	198	O	male
36	200	209	O	volunteers
NULL

Fluvoxamine	DDI-DrugBank.d76.s27	NO_SECTION	NO_SETID	9
The clearance of theophylline was decreased approximately 3-fold.
1	0	2	O	The
2	4	12	O	clearance
3	14	15	O	of
4	17	28	U-UNK	theophylline
5	30	32	O	was
6	34	42	O	decreased
7	44	56	O	approximately
8	58	58	O	3
9	60	63	O	fold
NULL

Fluvoxamine	DDI-DrugBank.d76.s28	NO_SECTION	NO_SETID	33
Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	if
4	14	25	U-DYN	theophylline
5	27	28	O	is
6	30	31	O	co
7	33	44	O	administered
8	46	49	O	with
9	51	61	O	XXXXXXXX
10	63	69	O	maleate
11	70	70	O	,
12	72	74	O	its
13	76	79	O	dose
14	81	86	O	should
15	88	89	O	be
16	91	97	O	reduced
17	99	100	O	to
18	102	104	O	one
19	106	110	O	third
20	112	113	O	of
21	115	117	O	the
22	119	123	O	usual
23	125	129	O	daily
24	131	141	O	maintenance
25	143	146	O	dose
26	148	150	O	and
27	152	157	O	plasma
28	159	172	O	concentrations
29	174	175	O	of
30	177	188	U-UNK	theophylline
31	190	195	O	should
32	197	198	O	to
33	200	208	O	monitored
NULL

Fluvoxamine	DDI-DrugBank.d76.s29	NO_SECTION	NO_SETID	8
No dosage adjustment is required for Fluvoxamine Tablets.
1	0	1	O	No
2	3	8	O	dosage
3	10	19	O	adjustment
4	21	22	O	is
5	24	31	O	required
6	33	35	O	for
7	37	47	O	XXXXXXXX
8	49	55	O	Tablets
NULL

Fluvoxamine	DDI-DrugBank.d76.s30	NO_SECTION	NO_SETID	28
Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	13	O	When
4	15	25	O	XXXXXXXX
5	27	33	O	maleate
6	36	37	O	50
7	39	40	O	mg
8	42	44	O	tid
9	47	49	O	was
10	51	62	O	administered
11	64	76	O	concomitantly
12	78	81	O	with
13	83	90	U-KIN	warfarin
14	92	94	O	for
15	96	98	O	two
16	100	104	O	weeks
17	105	105	O	,
18	107	114	U-UNK	warfarin
19	116	121	O	plasma
20	123	136	O	concentrations
21	138	146	O	increased
22	148	149	O	by
23	151	153	O	98%
24	155	157	O	and
25	159	169	O	prothrombin
26	171	175	O	times
27	177	180	O	were
28	182	190	O	prolonged
NULL

Fluvoxamine	DDI-DrugBank.d76.s31	NO_SECTION	NO_SETID	20
Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.
1	0	3	O	Thus
2	5	12	O	patients
3	14	22	O	receiving
4	24	27	O	oral
5	29	42	U-DYN	anticoagulants
6	44	46	O	and
7	48	58	O	XXXXXXXX
8	60	66	O	Tablets
9	68	73	O	should
10	75	78	O	have
11	80	84	O	their
12	86	96	O	prothrombin
13	98	101	O	time
14	103	111	O	monitored
15	113	115	O	and
16	117	121	O	their
17	123	135	U-UNK	anticoagulant
18	137	140	O	dose
19	142	149	O	adjusted
20	151	161	O	accordingly
NULL

Fluvoxamine	DDI-DrugBank.d76.s32	NO_SECTION	NO_SETID	8
No dosage adjustment is required for Fluvoxamine Tablets.
1	0	1	O	No
2	3	8	O	dosage
3	10	19	O	adjustment
4	21	22	O	is
5	24	31	O	required
6	33	35	O	for
7	37	47	O	XXXXXXXX
8	49	55	O	Tablets
NULL

Folic Acid	DDI-DrugBank.d425.s0	NO_SECTION	NO_SETID	18
Medications that interfere with your bodys ability to use folate may also increase the need for this vitamin.
1	0	10	O	Medications
2	12	15	O	that
3	17	25	O	interfere
4	27	30	O	with
5	32	35	O	your
6	37	41	O	bodys
7	43	49	O	ability
8	51	52	O	to
9	54	56	O	use
10	58	63	O	folate
11	65	67	O	may
12	69	72	O	also
13	74	81	O	increase
14	83	85	O	the
15	87	90	O	need
16	92	94	O	for
17	96	99	O	this
18	101	107	U-UNK	vitamin
NULL

Folic Acid	DDI-DrugBank.d425.s1	NO_SECTION	NO_SETID	56
Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
1	0	10	O	Medications
2	12	14	O	can
3	16	24	O	interfere
4	26	29	O	with
5	31	36	O	folate
6	38	48	O	utilization
7	49	49	O	,
8	51	59	O	including
9	60	60	O	:
10	62	75	B-UNK	anticonvulsant
11	77	87	L-UNK	medications
12	90	93	O	such
13	95	96	O	as
14	98	106	U-UNK	phenytoin
15	107	107	O	,
16	109	111	O	and
17	113	121	U-UNK	primidone
18	124	132	U-UNK	metformin
19	135	143	O	sometimes
20	145	154	O	prescribed
21	156	157	O	to
22	159	165	O	control
23	167	171	O	blood
24	173	177	O	sugar
25	179	180	O	in
26	182	185	O	type
27	187	187	O	2
28	189	196	O	diabetes
29	199	211	U-UNK	sulfasalazine
30	214	217	O	used
31	219	220	O	to
32	222	228	O	control
33	230	241	O	inflammation
34	243	252	O	associated
35	254	257	O	with
36	259	264	O	Crohns
37	266	272	O	disease
38	274	276	O	and
39	278	287	O	ulcerative
40	289	295	O	colitis
41	298	308	U-UNK	triamterene
42	311	311	O	a
43	313	320	U-UNK	diuretic
44	323	334	U-UNK	Methotrexate
45	336	340	O	There
46	342	344	O	has
47	346	349	O	been
48	351	357	O	concern
49	359	363	O	about
50	365	367	O	the
51	369	379	O	interaction
52	381	387	O	between
53	389	395	B-UNK	vitamin
54	397	399	L-UNK	B12
55	401	403	O	and
56	405	414	O	XXXXXXXX
NULL

Folic Acid	DDI-DrugBank.d425.s2	NO_SECTION	NO_SETID	11
Folic acid supplements can correct the anemia associated with vitamin B12 deficiency.
1	0	9	O	XXXXXXXX
2	11	21	O	supplements
3	23	25	O	can
4	27	33	O	correct
5	35	37	O	the
6	39	44	O	anemia
7	46	55	O	associated
8	57	60	O	with
9	62	68	O	vitamin
10	70	72	O	B12
11	74	83	O	deficiency
NULL

Folic Acid	DDI-DrugBank.d425.s3	NO_SECTION	NO_SETID	17
Unfortunately, folic acid will not correct changes in the nervous system that result from vitamin B12 deficiency.
1	0	12	O	Unfortunately
2	13	13	O	,
3	15	24	O	XXXXXXXX
4	26	29	O	will
5	31	33	O	not
6	35	41	O	correct
7	43	49	O	changes
8	51	52	O	in
9	54	56	O	the
10	58	64	O	nervous
11	66	71	O	system
12	73	76	O	that
13	78	83	O	result
14	85	88	O	from
15	90	96	O	vitamin
16	98	100	O	B12
17	102	111	O	deficiency
NULL

Folic Acid	DDI-DrugBank.d425.s4	NO_SECTION	NO_SETID	13
Permanent nerve damage could theoretically occur if vitamin B12 deficiency is not treated.
1	0	8	O	Permanent
2	10	14	O	nerve
3	16	21	O	damage
4	23	27	O	could
5	29	41	O	theoretically
6	43	47	O	occur
7	49	50	O	if
8	52	58	O	vitamin
9	60	62	O	B12
10	64	73	O	deficiency
11	75	76	O	is
12	78	80	O	not
13	82	88	O	treated
NULL

Folic Acid	DDI-DrugBank.d425.s5	NO_SECTION	NO_SETID	27
Therefore, intake of supplemental folic acid should not exceed 1000 micrograms ( g, sometimes mcg) per day to prevent folic acid from masking symptoms of vitamin B12 deficiency.
1	0	8	O	Therefore
2	9	9	O	,
3	11	16	O	intake
4	18	19	O	of
5	21	32	O	supplemental
6	34	43	O	XXXXXXXX
7	45	50	O	should
8	52	54	O	not
9	56	61	O	exceed
10	63	66	O	1000
11	68	77	O	micrograms
12	81	81	O	g
13	82	82	O	,
14	84	92	O	sometimes
15	94	96	O	mcg
16	99	101	O	per
17	103	105	O	day
18	107	108	O	to
19	110	116	O	prevent
20	118	127	O	XXXXXXXX
21	129	132	O	from
22	134	140	O	masking
23	142	149	O	symptoms
24	151	152	O	of
25	154	160	O	vitamin
26	162	164	O	B12
27	166	175	O	deficiency
NULL

Folic Acid	DDI-DrugBank.d425.s6	NO_SECTION	NO_SETID	29
It is important for older adults to be aware of the relationship between folic acid and vitamin B12 because they are at greater risk of having a vitamin B12 deficiency.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	important
4	16	18	O	for
5	20	24	O	older
6	26	31	O	adults
7	33	34	O	to
8	36	37	O	be
9	39	43	O	aware
10	45	46	O	of
11	48	50	O	the
12	52	63	O	relationship
13	65	71	O	between
14	73	82	O	XXXXXXXX
15	84	86	O	and
16	88	94	B-UNK	vitamin
17	96	98	L-UNK	B12
18	100	106	O	because
19	108	111	O	they
20	113	115	O	are
21	117	118	O	at
22	120	126	O	greater
23	128	131	O	risk
24	133	134	O	of
25	136	141	O	having
26	143	143	O	a
27	145	151	O	vitamin
28	153	155	O	B12
29	157	166	O	deficiency
NULL

Folic Acid	DDI-DrugBank.d425.s7	NO_SECTION	NO_SETID	26
If you are 50 years of age or older, ask your physician to check your B12 status before you take a supplement that contains folic acid.
1	0	1	O	If
2	3	5	O	you
3	7	9	O	are
4	11	12	O	50
5	14	18	O	years
6	20	21	O	of
7	23	25	O	age
8	27	28	O	or
9	30	34	O	older
10	35	35	O	,
11	37	39	O	ask
12	41	44	O	your
13	46	54	O	physician
14	56	57	O	to
15	59	63	O	check
16	65	68	O	your
17	70	72	O	B12
18	74	79	O	status
19	81	86	O	before
20	88	90	O	you
21	92	95	O	take
22	97	97	O	a
23	99	108	O	supplement
24	110	113	O	that
25	115	122	O	contains
26	124	133	O	XXXXXXXX
NULL

Follitropin beta	DDI-DrugBank.d402.s0	NO_SECTION	NO_SETID	9
No drug/drug interaction studies have been performed.
1	0	1	O	No
2	3	6	O	drug
3	7	7	O	/
4	8	11	O	drug
5	13	23	O	interaction
6	25	31	O	studies
7	33	36	O	have
8	38	41	O	been
9	43	51	O	performed
NULL

Fomepizole	DDI-DrugBank.d228.s0	NO_SECTION	NO_SETID	33
Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.
1	0	3	O	Oral
2	5	9	O	doses
3	11	12	O	of
4	14	20	O	XXXXXXXX
5	23	24	O	10
6	26	27	O	20
7	29	30	O	mg
8	31	31	O	/
9	32	33	O	kg
10	35	35	O	,
11	37	39	O	via
12	41	47	O	alcohol
13	49	61	O	dehydrogenase
14	63	72	O	inhibition
15	73	73	O	,
16	75	87	O	significantly
17	89	95	O	reduced
18	97	99	O	the
19	101	104	O	rate
20	106	107	O	of
21	109	119	O	elimination
22	121	122	O	of
23	124	130	U-KIN	ethanol
24	133	134	O	by
25	136	148	O	approximately
26	150	152	O	40%
27	155	159	O	given
28	161	162	O	to
29	164	170	O	healthy
30	172	181	O	volunteers
31	183	184	O	in
32	186	193	O	moderate
33	195	199	O	doses
NULL

Fomepizole	DDI-DrugBank.d228.s1	NO_SECTION	NO_SETID	17
Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.
1	0	8	O	Similarly
2	9	9	O	,
3	11	17	U-KIN	ethanol
4	19	27	O	decreased
5	29	31	O	the
6	33	36	O	rate
7	38	39	O	of
8	41	51	O	elimination
9	53	54	O	of
10	56	62	O	XXXXXXXX
11	65	66	O	by
12	68	80	O	approximately
13	82	84	O	50%
14	87	88	O	by
15	90	92	O	the
16	94	97	O	same
17	99	107	O	mechanism
NULL

Fomepizole	DDI-DrugBank.d228.s2	NO_SECTION	NO_SETID	35
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied
1	0	9	O	Reciprocal
2	11	22	O	interactions
3	24	26	O	may
4	28	32	O	occur
5	34	37	O	with
6	39	49	O	concomitant
7	51	53	O	use
8	55	56	O	of
9	58	64	O	XXXXXXXX
10	66	68	O	and
11	70	74	O	drugs
12	76	79	O	that
13	81	88	O	increase
14	90	91	O	or
15	93	99	O	inhibit
16	101	103	O	the
17	105	114	O	cytochrome
18	116	119	O	P450
19	121	126	O	system
20	129	131	O	e.g
21	133	133	O	,
22	135	143	U-KIN	phenytoin
23	144	144	O	,
24	146	158	U-KIN	carbamazepine
25	159	159	O	,
26	161	170	U-KIN	cimetidine
27	171	171	O	,
28	173	184	U-KIN	ketoconazole
29	186	186	O	,
30	188	193	O	though
31	195	198	O	this
32	200	202	O	has
33	204	206	O	not
34	208	211	O	been
35	213	219	O	studied
NULL

Fondaparinux sodium	DDI-DrugBank.d15.s0	NO_SECTION	NO_SETID	35
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
1	0	1	O	In
2	3	10	O	clinical
3	12	18	O	studies
4	20	28	O	performed
5	30	33	O	with
6	35	46	U-UNK	Fondaparinux
7	47	47	O	,
8	49	51	O	the
9	53	63	O	concomitant
10	65	67	O	use
11	69	70	O	of
12	72	75	O	oral
13	77	90	U-UNK	anticoagulants
14	93	100	U-UNK	warfarin
15	102	102	O	,
16	104	111	B-UNK	platelet
17	113	122	L-UNK	inhibitors
18	125	139	B-UNK	acetylsalicylic
19	141	144	L-UNK	acid
20	146	146	O	,
21	148	153	U-UNK	NSAIDs
22	156	164	U-UNK	piroxicam
23	166	166	O	,
24	168	170	O	and
25	172	178	U-UNK	digoxin
26	180	182	O	did
27	184	186	O	not
28	188	200	O	significantly
29	202	207	O	affect
30	209	211	O	the
31	213	228	O	pharmacokinetics
32	229	229	O	/
33	230	245	O	pharmacodynamics
34	247	248	O	of
35	250	268	O	XXXXXXXX
NULL

Fondaparinux sodium	DDI-DrugBank.d15.s1	NO_SECTION	NO_SETID	27
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	24	U-UNK	Fondaparinux
5	26	32	O	neither
6	34	43	O	influenced
7	45	47	O	the
8	49	64	O	pharmacodynamics
9	66	67	O	of
10	69	76	U-UNK	warfarin
11	77	77	O	,
12	79	93	B-UNK	acetylsalicylic
13	95	98	L-UNK	acid
14	99	99	O	,
15	101	109	U-UNK	piroxicam
16	110	110	O	,
17	112	114	O	and
18	116	122	U-UNK	digoxin
19	123	123	O	,
20	125	127	O	nor
21	129	131	O	the
22	133	148	O	pharmacokinetics
23	150	151	O	of
24	153	159	U-UNK	digoxin
25	161	162	O	at
26	164	169	O	steady
27	171	175	O	state
NULL

Fondaparinux sodium	DDI-DrugBank.d15.s2	NO_SECTION	NO_SETID	17
Agents that may enhance the risk of hemorrhage should be discontinued prior to initiation of Fondaparinux therapy.
1	0	5	O	Agents
2	7	10	O	that
3	12	14	O	may
4	16	22	O	enhance
5	24	26	O	the
6	28	31	O	risk
7	33	34	O	of
8	36	45	O	hemorrhage
9	47	52	O	should
10	54	55	O	be
11	57	68	O	discontinued
12	70	74	O	prior
13	76	77	O	to
14	79	88	O	initiation
15	90	91	O	of
16	93	104	U-UNK	Fondaparinux
17	106	112	O	therapy
NULL

Fondaparinux sodium	DDI-DrugBank.d15.s3	NO_SECTION	NO_SETID	11
If co-administration is essential, close monitoring may be appropriate.
1	0	1	O	If
2	3	4	O	co
3	6	19	O	administration
4	21	22	O	is
5	24	32	O	essential
6	33	33	O	,
7	35	39	O	close
8	41	50	O	monitoring
9	52	54	O	may
10	56	57	O	be
11	59	69	O	appropriate
NULL

Fondaparinux sodium	DDI-DrugBank.d15.s4	NO_SECTION	NO_SETID	31
In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 m m M i.e., 350 mg/L) was 17-28%.
1	0	1	O	In
2	3	4	O	an
3	6	7	O	in
4	9	13	O	vitro
5	15	19	O	study
6	21	22	O	in
7	24	28	O	human
8	30	34	O	liver
9	36	45	O	microsomes
10	46	46	O	,
11	48	57	O	inhibition
12	59	60	O	of
13	62	67	O	CYP2A6
14	69	81	O	hydroxylation
15	83	84	O	of
16	86	93	U-UNK	coumarin
17	95	96	O	by
18	98	109	U-UNK	fondaparinux
19	112	114	O	200
20	116	116	O	m
21	118	118	O	m
22	120	120	O	M
23	122	124	O	i.e
24	126	126	O	,
25	128	130	O	350
26	132	133	O	mg
27	134	134	O	/
28	135	135	O	L
29	138	140	O	was
30	142	143	O	17
31	145	147	O	28%
NULL

Fondaparinux sodium	DDI-DrugBank.d15.s5	NO_SECTION	NO_SETID	22
Inhibition of the other isozymes evaluated (CYPs 2A1, 2C9, 2C19, 2D6, 3A4, and 3E1) was 0-16%.
1	0	9	O	Inhibition
2	11	12	O	of
3	14	16	O	the
4	18	22	O	other
5	24	31	O	isozymes
6	33	41	O	evaluated
7	44	47	O	CYPs
8	49	51	O	2A1
9	52	52	O	,
10	54	56	O	2C9
11	57	57	O	,
12	59	62	O	2C19
13	63	63	O	,
14	65	67	O	2D6
15	68	68	O	,
16	70	72	O	3A4
17	73	73	O	,
18	75	77	O	and
19	79	81	O	3E1
20	84	86	O	was
21	88	88	O	0
22	90	92	O	16%
NULL

Fondaparinux sodium	DDI-DrugBank.d15.s6	NO_SECTION	NO_SETID	44
Since fondaparinux does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, fondaparinux sodium is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes.
1	0	4	O	Since
2	6	17	U-UNK	fondaparinux
3	19	22	O	does
4	24	26	O	not
5	28	35	O	markedly
6	37	43	O	inhibit
7	45	51	O	CYP450s
8	54	59	O	CYP1A2
9	60	60	O	,
10	62	67	O	CYP2A6
11	68	68	O	,
12	70	75	O	CYP2C9
13	76	76	O	,
14	78	84	O	CYP2C19
15	85	85	O	,
16	87	92	O	CYP2D6
17	93	93	O	,
18	95	100	O	CYP2E1
19	101	101	O	,
20	103	104	O	or
21	106	111	O	CYP3A4
22	114	115	O	in
23	117	121	O	vitro
24	122	122	O	,
25	124	142	O	XXXXXXXX
26	144	145	O	is
27	147	149	O	not
28	151	158	O	expected
29	160	161	O	to
30	163	175	O	significantly
31	177	184	O	interact
32	186	189	O	with
33	191	195	O	other
34	197	201	O	drugs
35	203	204	O	in
36	206	209	O	vivo
37	211	212	O	by
38	214	223	O	inhibition
39	225	226	O	of
40	228	237	O	metabolism
41	239	246	O	mediated
42	248	249	O	by
43	251	255	O	these
44	257	264	O	isozymes
NULL

Fondaparinux sodium	DDI-DrugBank.d15.s7	NO_SECTION	NO_SETID	22
Since fondaparinux sodium does not bind significantly to plasma proteins other than ATIII, no drug interactions by protein-binding displacement are expected.
1	0	4	O	Since
2	6	24	O	XXXXXXXX
3	26	29	O	does
4	31	33	O	not
5	35	38	O	bind
6	40	52	O	significantly
7	54	55	O	to
8	57	62	O	plasma
9	64	71	O	proteins
10	73	77	O	other
11	79	82	O	than
12	84	88	O	ATIII
13	89	89	O	,
14	91	92	O	no
15	94	97	O	drug
16	99	110	O	interactions
17	112	113	O	by
18	115	121	O	protein
19	123	129	O	binding
20	131	142	O	displacement
21	144	146	O	are
22	148	155	O	expected
NULL

Formoterol	DDI-DrugBank.d103.s0	NO_SECTION	NO_SETID	25
Short-Acting beta2-agonists: Aerosol bronchodilators of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using formoterol.
1	0	4	B-UNK	Short
2	6	11	I-UNK	Acting
3	13	17	I-UNK	beta2
4	19	26	L-UNK	agonists
5	27	27	O	:
6	29	35	O	Aerosol
7	37	51	U-UNK	bronchodilators
8	53	54	O	of
9	56	58	O	the
10	60	64	O	short
11	66	71	O	acting
12	73	82	O	adrenergic
13	84	92	O	stimulant
14	94	97	O	type
15	99	101	O	may
16	103	104	O	be
17	106	109	O	used
18	111	113	O	for
19	115	120	O	relief
20	122	123	O	of
21	125	136	O	breakthrough
22	138	145	O	symptoms
23	147	151	O	while
24	153	157	O	using
25	159	168	O	XXXXXXXX
NULL

Formoterol	DDI-DrugBank.d103.s1	NO_SECTION	NO_SETID	24
However, increasing use of such preparations to control symptoms indicates deterioration of asthma control and the need to reassess the patient s therapy.
1	0	6	O	However
2	7	7	O	,
3	9	18	O	increasing
4	20	22	O	use
5	24	25	O	of
6	27	30	O	such
7	32	43	O	preparations
8	45	46	O	to
9	48	54	O	control
10	56	63	O	symptoms
11	65	73	O	indicates
12	75	87	O	deterioration
13	89	90	O	of
14	92	97	O	asthma
15	99	105	O	control
16	107	109	O	and
17	111	113	O	the
18	115	118	O	need
19	120	121	O	to
20	123	130	O	reassess
21	132	134	O	the
22	136	142	O	patient
23	144	144	O	s
24	146	152	O	therapy
NULL

Formoterol	DDI-DrugBank.d103.s2	NO_SECTION	NO_SETID	13
Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	34	O	other
5	36	50	B-DYN	sympathomimetic
6	52	57	L-DYN	agents
7	59	61	O	may
8	63	72	O	potentiate
9	74	76	O	the
10	78	88	O	undesirable
11	90	96	O	effects
12	98	99	O	of
13	101	107	O	XXXXXXXX
NULL

Formoterol	DDI-DrugBank.d103.s3	NO_SECTION	NO_SETID	40
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.
1	0	8	B-UNK	Monoamine
2	10	16	I-UNK	Oxidase
3	18	27	L-UNK	Inhibitors
4	29	31	O	and
5	33	41	B-UNK	Tricyclic
6	43	57	L-UNK	Antidepressants
7	58	58	O	:
8	60	66	O	XXXXXXXX
9	68	73	O	should
10	75	76	O	be
11	78	89	O	administered
12	91	94	O	with
13	96	102	O	extreme
14	104	110	O	caution
15	112	113	O	in
16	115	122	O	patients
17	124	128	O	being
18	130	136	O	treated
19	138	141	O	with
20	143	151	B-DYN	monoamine
21	153	159	I-DYN	oxidase
22	161	170	L-DYN	inhibitors
23	172	173	O	or
24	175	183	B-DYN	tricyclic
25	185	199	L-DYN	antidepressants
26	201	207	O	because
27	209	211	O	the
28	213	218	O	action
29	220	221	O	of
30	223	232	U-UNK	formoterol
31	234	235	O	on
32	237	239	O	the
33	241	254	O	cardiovascular
34	256	261	O	system
35	263	265	O	may
36	267	268	O	be
37	270	280	O	potentiated
38	282	283	O	by
39	285	289	O	these
40	291	296	O	agents
NULL

Formoterol	DDI-DrugBank.d103.s4	NO_SECTION	NO_SETID	25
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.
1	0	14	U-UNK	Corticosteroids
2	15	15	O	,
3	17	31	U-UNK	Methylxanthines
4	33	35	O	and
5	37	45	U-UNK	Diuretics
6	46	46	O	:
7	48	58	O	Concomitant
8	60	68	O	treatment
9	70	73	O	with
10	75	82	B-UNK	xanthine
11	84	94	L-UNK	derivatives
12	95	95	O	,
13	97	104	U-UNK	steroids
14	105	105	O	,
15	107	108	O	or
16	110	118	U-UNK	diuretics
17	120	122	O	may
18	124	133	O	potentiate
19	135	135	O	a
20	137	144	O	possible
21	146	156	O	hypokalemic
22	158	163	O	effect
23	165	166	O	of
24	169	173	B-UNK	beta2
25	175	182	L-UNK	agonists
NULL

Formoterol	DDI-DrugBank.d103.s5	NO_SECTION	NO_SETID	12
Hypokalemia may increase susceptibility to cardiac arrhythmias in patients treated with digitalis.
1	0	10	O	Hypokalemia
2	12	14	O	may
3	16	23	O	increase
4	25	38	O	susceptibility
5	40	41	O	to
6	43	49	O	cardiac
7	51	61	O	arrhythmias
8	63	64	O	in
9	66	73	O	patients
10	75	81	O	treated
11	83	86	O	with
12	88	96	U-UNK	digitalis
NULL

Formoterol	DDI-DrugBank.d103.s6	NO_SECTION	NO_SETID	13
-adrenergic Blockers:  -adrenergic blockers may weaken or antagonise the effect of FORADIL.
1	1	10	O	adrenergic
2	12	19	O	Blockers
3	20	20	O	:
4	24	33	O	adrenergic
5	35	42	O	blockers
6	44	46	O	may
7	48	53	O	weaken
8	55	56	O	or
9	58	67	O	antagonise
10	69	71	O	the
11	73	78	O	effect
12	80	81	O	of
13	83	89	O	XXXXXXXX
NULL

Formoterol	DDI-DrugBank.d103.s7	NO_SECTION	NO_SETID	21
Therefore FORADIL should not be given together with  -adrenergic blockers (including eye drops) unless there are compelling reasons for their use.
1	0	8	O	Therefore
2	10	16	O	XXXXXXXX
3	18	23	O	should
4	25	27	O	not
5	29	30	O	be
6	32	36	O	given
7	38	45	O	together
8	47	50	O	with
9	54	63	O	adrenergic
10	65	72	O	blockers
11	75	83	O	including
12	85	87	O	eye
13	89	93	O	drops
14	96	101	O	unless
15	103	107	O	there
16	109	111	O	are
17	113	122	O	compelling
18	124	130	O	reasons
19	132	134	O	for
20	136	140	O	their
21	142	144	O	use
NULL

Formoterol	DDI-DrugBank.d103.s8	NO_SECTION	NO_SETID	31
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.
1	0	4	O	Other
2	6	16	O	Drugs:Drugs
3	18	21	O	such
4	23	24	O	as
5	26	34	U-UNK	quinidine
6	35	35	O	,
7	37	48	U-UNK	disopyramide
8	49	49	O	,
9	51	62	U-UNK	procainamide
10	63	63	O	,
11	65	78	U-UNK	phenothiazines
12	79	79	O	,
13	81	94	U-UNK	antihistamines
14	95	95	O	,
15	97	99	O	and
16	101	109	B-UNK	tricyclic
17	111	125	L-UNK	antidepressants
18	127	129	O	may
19	131	132	O	be
20	134	143	O	associated
21	145	148	O	with
22	150	151	O	QT
23	153	160	O	interval
24	162	173	O	prolongation
25	175	177	O	and
26	179	180	O	an
27	182	190	O	increased
28	192	195	O	risk
29	197	198	O	of
30	200	210	O	ventricular
31	212	221	O	arrhythmia
NULL

Formoterol	DDI-DrugBank.d103.s9	NO_SECTION	NO_SETID	18
INFORMATION TO BE PROVIDED TO THE PATIENT OR GUARDIAN See illustrated Information For The Patient or Guardian section.
1	0	10	O	INFORMATION
2	12	13	O	TO
3	15	16	O	BE
4	18	25	O	PROVIDED
5	27	28	O	TO
6	30	32	O	THE
7	34	40	O	PATIENT
8	42	43	O	OR
9	45	52	O	GUARDIAN
10	54	56	O	See
11	58	68	O	illustrated
12	70	80	O	Information
13	82	84	O	For
14	86	88	O	The
15	90	96	O	Patient
16	98	99	O	or
17	101	108	O	Guardian
18	110	116	O	section
NULL

Formoterol	DDI-DrugBank.d103.s10	NO_SECTION	NO_SETID	36
It is important that patients understand how to use FORADIL  (formoterol fumarate) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	important
4	16	19	O	that
5	21	28	O	patients
6	30	39	O	understand
7	41	43	O	how
8	45	46	O	to
9	48	50	O	use
10	52	58	O	XXXXXXXX
11	62	71	B-UNK	formoterol
12	73	80	L-UNK	fumarate
13	83	90	O	capsules
14	92	95	O	with
15	97	99	O	the
16	101	108	O	supplied
17	110	120	O	AerolizerTM
18	122	131	O	inhalation
19	133	138	O	device
20	140	142	O	and
21	144	146	O	how
22	148	149	O	it
23	151	156	O	should
24	158	159	O	be
25	161	164	O	used
26	166	167	O	in
27	169	176	O	relation
28	178	179	O	to
29	181	185	O	other
30	187	192	O	asthma
31	194	195	O	or
32	197	200	O	COPD
33	202	212	O	medications
34	214	217	O	they
35	219	221	O	are
36	223	228	O	taking
NULL

Formoterol	DDI-DrugBank.d103.s11	NO_SECTION	NO_SETID	11
Patients/Guardians should be given the following information: i.
1	0	7	O	Patients
2	8	8	O	/
3	9	17	O	Guardians
4	19	24	O	should
5	26	27	O	be
6	29	33	O	given
7	35	37	O	the
8	39	47	O	following
9	49	59	O	information
10	60	60	O	:
11	62	62	O	i
NULL

Formoterol	DDI-DrugBank.d103.s12	NO_SECTION	NO_SETID	17
The recommended dosage (one or two capsules twice daily, morning and evening) should not be exceeded.
1	0	2	O	The
2	4	14	O	recommended
3	16	21	O	dosage
4	24	26	O	one
5	28	29	O	or
6	31	33	O	two
7	35	42	O	capsules
8	44	48	O	twice
9	50	54	O	daily
10	55	55	O	,
11	57	63	O	morning
12	65	67	O	and
13	69	75	O	evening
14	78	83	O	should
15	85	87	O	not
16	89	90	O	be
17	92	99	O	exceeded
NULL

Formoterol	DDI-DrugBank.d103.s14	NO_SECTION	NO_SETID	21
FORADIL is not meant to relieve acute asthma or COPD symptoms and extra doses should not be used for that purpose.
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	13	O	not
4	15	19	O	meant
5	21	22	O	to
6	24	30	O	relieve
7	32	36	O	acute
8	38	43	O	asthma
9	45	46	O	or
10	48	51	O	COPD
11	53	60	O	symptoms
12	62	64	O	and
13	66	70	O	extra
14	72	76	O	doses
15	78	83	O	should
16	85	87	O	not
17	89	90	O	be
18	92	95	O	used
19	97	99	O	for
20	101	104	O	that
21	106	112	O	purpose
NULL

Formoterol	DDI-DrugBank.d103.s15	NO_SECTION	NO_SETID	35
Acute symptoms should be treated with a short-acting, inhaled  beta2-agonist such as salbutamol (the physician should provide the patient with such medication and instruct the patient in how it should be used).
1	0	4	O	Acute
2	6	13	O	symptoms
3	15	20	O	should
4	22	23	O	be
5	25	31	O	treated
6	33	36	O	with
7	38	38	O	a
8	40	44	O	short
9	46	51	O	acting
10	52	52	O	,
11	54	60	O	inhaled
12	63	67	B-UNK	beta2
13	69	75	L-UNK	agonist
14	77	80	O	such
15	82	83	O	as
16	85	94	U-UNK	salbutamol
17	97	99	O	the
18	101	109	O	physician
19	111	116	O	should
20	118	124	O	provide
21	126	128	O	the
22	130	136	O	patient
23	138	141	O	with
24	143	146	O	such
25	148	157	O	medication
26	159	161	O	and
27	163	170	O	instruct
28	172	174	O	the
29	176	182	O	patient
30	184	185	O	in
31	187	189	O	how
32	191	192	O	it
33	194	199	O	should
34	201	202	O	be
35	204	207	O	used
NULL

Formoterol	DDI-DrugBank.d103.s17	NO_SECTION	NO_SETID	33
The physician should be notified immediately if any of the following situations occur, which may be a sign of seriously worsening asthma:   Decreased effectiveness of short-acting, inhaled beta2-agonists;
1	0	2	O	The
2	4	12	O	physician
3	14	19	O	should
4	21	22	O	be
5	24	31	O	notified
6	33	43	O	immediately
7	45	46	O	if
8	48	50	O	any
9	52	53	O	of
10	55	57	O	the
11	59	67	O	following
12	69	78	O	situations
13	80	84	O	occur
14	85	85	O	,
15	87	91	O	which
16	93	95	O	may
17	97	98	O	be
18	100	100	O	a
19	102	105	O	sign
20	107	108	O	of
21	110	118	O	seriously
22	120	128	O	worsening
23	130	135	O	asthma
24	136	136	O	:
25	140	148	O	Decreased
26	150	162	O	effectiveness
27	164	165	O	of
28	167	171	B-UNK	short
29	173	178	I-UNK	acting
30	179	179	I-UNK	,
31	181	187	I-UNK	inhaled
32	189	193	I-UNK	beta2
33	195	202	L-UNK	agonists
NULL

Formoterol	DDI-DrugBank.d103.s18	NO_SECTION	NO_SETID	13
Need for more inhalations than usual of short-acting, inhaled beta2-agonists.
1	0	3	O	Need
2	5	7	O	for
3	9	12	O	more
4	14	24	O	inhalations
5	26	29	O	than
6	31	35	O	usual
7	37	38	O	of
8	40	44	B-UNK	short
9	46	51	I-UNK	acting
10	52	52	I-UNK	,
11	54	60	I-UNK	inhaled
12	62	66	I-UNK	beta2
13	68	75	L-UNK	agonists
NULL

Formoterol	DDI-DrugBank.d103.s20	NO_SECTION	NO_SETID	13
FORADIL should not be used as a substitute for oral or inhaled corticosteroids.
1	0	6	O	XXXXXXXX
2	8	13	O	should
3	15	17	O	not
4	19	20	O	be
5	22	25	O	used
6	27	28	O	as
7	30	30	O	a
8	32	41	O	substitute
9	43	45	O	for
10	47	50	O	oral
11	52	53	O	or
12	55	61	O	inhaled
13	63	77	U-UNK	corticosteroids
NULL

Formoterol	DDI-DrugBank.d103.s21	NO_SECTION	NO_SETID	31
The dosage of these medications should not be changed and they should not be stopped without consulting the physician, even if the patient feels better after initiating treatment with FORADIL.
1	0	2	O	The
2	4	9	O	dosage
3	11	12	O	of
4	14	18	O	these
5	20	30	O	medications
6	32	37	O	should
7	39	41	O	not
8	43	44	O	be
9	46	52	O	changed
10	54	56	O	and
11	58	61	O	they
12	63	68	O	should
13	70	72	O	not
14	74	75	O	be
15	77	83	O	stopped
16	85	91	O	without
17	93	102	O	consulting
18	104	106	O	the
19	108	116	O	physician
20	117	117	O	,
21	119	122	O	even
22	124	125	O	if
23	127	129	O	the
24	131	137	O	patient
25	139	143	O	feels
26	145	150	O	better
27	152	156	O	after
28	158	167	O	initiating
29	169	177	O	treatment
30	179	182	O	with
31	184	190	O	XXXXXXXX
NULL

Formoterol	DDI-DrugBank.d103.s22	NO_SECTION	NO_SETID	17
v. Patients should be cautioned regarding potential adverse cardiovascular effects, such as palpitations or chest pain.
1	0	0	O	v
2	3	10	O	Patients
3	12	17	O	should
4	19	20	O	be
5	22	30	O	cautioned
6	32	40	O	regarding
7	42	50	O	potential
8	52	58	O	adverse
9	60	73	O	cardiovascular
10	75	81	O	effects
11	82	82	O	,
12	84	87	O	such
13	89	90	O	as
14	92	103	O	palpitations
15	105	106	O	or
16	108	112	O	chest
17	114	117	O	pain
NULL

Formoterol	DDI-DrugBank.d103.s24	NO_SECTION	NO_SETID	17
In patients receiving FORADIL, other inhaled medications should be used only as directed by the physician.
1	0	1	O	In
2	3	10	O	patients
3	12	20	O	receiving
4	22	28	O	XXXXXXXX
5	29	29	O	,
6	31	35	O	other
7	37	43	O	inhaled
8	45	55	O	medications
9	57	62	O	should
10	64	65	O	be
11	67	70	O	used
12	72	75	O	only
13	77	78	O	as
14	80	87	O	directed
15	89	90	O	by
16	92	94	O	the
17	96	104	O	physician
NULL

Formoterol	DDI-DrugBank.d103.s26	NO_SECTION	NO_SETID	33
Guardians of children who have been prescribed FORADIL should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of short-acting  beta2-agonists.
1	0	8	O	Guardians
2	10	11	O	of
3	13	20	O	children
4	22	24	O	who
5	26	29	O	have
6	31	34	O	been
7	36	45	O	prescribed
8	47	53	O	XXXXXXXX
9	55	60	O	should
10	62	63	O	be
11	65	71	O	alerted
12	73	74	O	to
13	76	78	O	the
14	80	86	O	general
15	88	94	O	concern
16	96	104	O	regarding
17	106	111	O	asthma
18	113	119	O	therapy
19	121	130	O	compliance
20	131	131	O	,
21	133	142	O	especially
22	144	150	O	neglect
23	152	153	O	of
24	155	158	O	anti
25	160	171	O	inflammatory
26	173	179	O	therapy
27	181	183	O	and
28	185	191	O	overuse
29	193	194	O	of
30	196	200	B-UNK	short
31	202	207	I-UNK	acting
32	210	214	I-UNK	beta2
33	216	223	L-UNK	agonists
NULL

Foscarnet	DDI-DrugBank.d511.s0	NO_SECTION	NO_SETID	12
A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.
1	0	0	O	A
2	2	9	O	possible
3	11	14	O	drug
4	16	26	O	interaction
5	28	29	O	of
6	31	38	O	XXXXXXXX
7	40	42	O	and
8	44	54	O	intravenous
9	56	66	U-UNK	pentamidine
10	68	70	O	has
11	72	75	O	been
12	77	85	O	described
NULL

Foscarnet	DDI-DrugBank.d511.s1	NO_SECTION	NO_SETID	18
Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;
1	0	10	O	Concomitant
2	12	20	O	treatment
3	22	23	O	of
4	25	28	O	four
5	30	37	O	patients
6	39	40	O	in
7	42	44	O	the
8	46	51	O	United
9	53	59	O	Kingdom
10	61	64	O	with
11	66	73	O	XXXXXXXX
12	75	77	O	and
13	79	89	O	intravenous
14	91	101	U-DYN	pentamidine
15	103	105	O	may
16	107	110	O	have
17	112	117	O	caused
18	119	130	O	hypocalcemia
NULL

Foscarnet	DDI-DrugBank.d511.s2	NO_SECTION	NO_SETID	6
one patient died with severe hypocalcemia.
1	0	2	O	one
2	4	10	O	patient
3	12	15	O	died
4	17	20	O	with
5	22	27	O	severe
6	29	40	O	hypocalcemia
NULL

Foscarnet	DDI-DrugBank.d511.s3	NO_SECTION	NO_SETID	12
Toxicity associated with concomitant use of aerosolized pentamidine has not been reported.
1	0	7	O	Toxicity
2	9	18	O	associated
3	20	23	O	with
4	25	35	O	concomitant
5	37	39	O	use
6	41	42	O	of
7	44	54	O	aerosolized
8	56	66	U-UNK	pentamidine
9	68	70	O	has
10	72	74	O	not
11	76	79	O	been
12	81	88	O	reported
NULL

Foscarnet	DDI-DrugBank.d511.s4	NO_SECTION	NO_SETID	41
Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
1	0	6	O	Because
2	8	9	O	of
3	11	20	O	foscarnets
4	22	29	O	tendency
5	31	32	O	to
6	34	38	O	cause
7	40	44	O	renal
8	46	55	O	impairment
9	56	56	O	,
10	58	60	O	the
11	62	64	O	use
12	66	67	O	of
13	69	76	O	XXXXXXXX
14	78	83	O	should
15	85	86	O	be
16	88	94	O	avoided
17	96	97	O	in
18	99	109	O	combination
19	111	114	O	with
20	116	126	O	potentially
21	128	138	O	nephrotoxic
22	140	144	O	drugs
23	146	149	O	such
24	151	152	O	as
25	154	168	U-DYN	aminoglycosides
26	169	169	O	,
27	171	182	B-DYN	amphotericin
28	184	184	L-DYN	B
29	186	188	O	and
30	190	200	O	intravenous
31	202	212	U-DYN	pentamidine
32	214	219	O	unless
33	221	223	O	the
34	225	233	O	potential
35	235	242	O	benefits
36	244	251	O	outweigh
37	253	255	O	the
38	257	261	O	risks
39	263	264	O	to
40	266	268	O	the
41	270	276	O	patient
NULL

Foscarnet	DDI-DrugBank.d511.s5	NO_SECTION	NO_SETID	26
Since FOSCAVIR decreases serum concentrations of ionized calcium, concurrent treatment with other drugs known to influence serum calcium concentrations should be used with particular caution.
1	0	4	O	Since
2	6	13	O	XXXXXXXX
3	15	23	O	decreases
4	25	29	O	serum
5	31	44	O	concentrations
6	46	47	O	of
7	49	55	O	ionized
8	57	63	O	calcium
9	64	64	O	,
10	66	75	O	concurrent
11	77	85	O	treatment
12	87	90	O	with
13	92	96	O	other
14	98	102	O	drugs
15	104	108	O	known
16	110	111	O	to
17	113	121	O	influence
18	123	127	O	serum
19	129	135	O	calcium
20	137	150	O	concentrations
21	152	157	O	should
22	159	160	O	be
23	162	165	O	used
24	167	170	O	with
25	172	181	O	particular
26	183	189	O	caution
NULL

Foscarnet	DDI-DrugBank.d511.s6	NO_SECTION	NO_SETID	27
Ganciclovir: The pharmacokinetics of foscarnet and ganciclovir were not altered in 13 patients receiving either concomitant therapy or daily alternating therapy for maintenance of CMV disease.
1	0	10	U-UNK	Ganciclovir
2	11	11	O	:
3	13	15	O	The
4	17	32	O	pharmacokinetics
5	34	35	O	of
6	37	45	O	XXXXXXXX
7	47	49	O	and
8	51	61	U-UNK	ganciclovir
9	63	66	O	were
10	68	70	O	not
11	72	78	O	altered
12	80	81	O	in
13	83	84	O	13
14	86	93	O	patients
15	95	103	O	receiving
16	105	110	O	either
17	112	122	O	concomitant
18	124	130	O	therapy
19	132	133	O	or
20	135	139	O	daily
21	141	151	O	alternating
22	153	159	O	therapy
23	161	163	O	for
24	165	175	O	maintenance
25	177	178	O	of
26	180	182	O	CMV
27	184	190	O	disease
NULL

Fosfomycin	DDI-DrugBank.d199.s0	NO_SECTION	NO_SETID	25
Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.
1	0	13	U-UNK	Metoclopramide
2	14	14	O	:
3	16	19	O	When
4	21	34	O	coadministered
5	36	39	O	with
6	41	47	O	XXXXXXXX
7	48	48	O	,
8	50	63	U-KIN	metoclopramide
9	64	64	O	,
10	66	66	O	a
11	68	71	O	drug
12	73	77	O	which
13	79	87	O	increases
14	89	104	O	gastrointestinal
15	106	113	O	motility
16	114	114	O	,
17	116	121	O	lowers
18	123	125	O	the
19	127	131	O	serum
20	133	145	O	concentration
21	147	149	O	and
22	151	157	O	urinary
23	159	167	O	excretion
24	169	170	O	of
25	172	181	U-UNK	fosfomycin
NULL

Fosfomycin	DDI-DrugBank.d199.s1	NO_SECTION	NO_SETID	10
Other drugs that increase gastrointestinal motility may produce similar effects.
1	0	4	O	Other
2	6	10	O	drugs
3	12	15	O	that
4	17	24	O	increase
5	26	41	O	gastrointestinal
6	43	50	O	motility
7	52	54	O	may
8	56	62	O	produce
9	64	70	O	similar
10	72	78	O	effects
NULL

Fosfomycin	DDI-DrugBank.d199.s2	NO_SECTION	NO_SETID	14
Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.
1	0	9	U-UNK	Cimetidine
2	10	10	O	:
3	12	21	U-UNK	Cimetidine
4	23	26	O	does
5	28	30	O	not
6	32	37	O	affect
7	39	41	O	the
8	43	58	O	pharmacokinetics
9	60	61	O	of
10	63	72	U-UNK	fosfomycin
11	74	77	O	when
12	79	92	O	coadministered
13	94	97	O	with
14	99	105	O	XXXXXXXX
NULL

Fosinopril	DDI-DrugBank.d176.s0	NO_SECTION	NO_SETID	29
Diuretics: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.
1	0	8	U-UNK	Diuretics
2	9	9	O	:
3	11	18	O	Patients
4	20	21	O	on
5	23	31	U-DYN	diuretics
6	32	32	O	,
7	34	43	O	especially
8	45	49	O	those
9	51	54	O	with
10	56	68	O	intravascular
11	70	75	O	volume
12	77	85	O	depletion
13	86	86	O	,
14	88	90	O	may
15	92	103	O	occasionally
16	105	114	O	experience
17	116	117	O	an
18	119	127	O	excessive
19	129	137	O	reduction
20	139	140	O	of
21	142	146	O	blood
22	148	155	O	pressure
23	157	161	O	after
24	163	172	O	initiation
25	174	175	O	of
26	177	183	O	therapy
27	185	188	O	with
28	190	199	O	XXXXXXXX
29	201	206	O	sodium
NULL

Fosinopril	DDI-DrugBank.d176.s1	NO_SECTION	NO_SETID	25
The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium.
1	0	2	O	The
2	4	14	O	possibility
3	16	17	O	of
4	19	29	O	hypotensive
5	31	37	O	effects
6	39	41	O	can
7	43	44	O	be
8	46	54	O	minimized
9	56	57	O	by
10	59	64	O	either
11	66	78	O	discontinuing
12	80	82	O	the
13	84	91	U-DYN	diuretic
14	93	94	O	or
15	96	105	O	increasing
16	107	110	O	salt
17	112	117	O	intake
18	119	123	O	prior
19	125	126	O	to
20	128	137	O	initiation
21	139	140	O	of
22	142	150	O	treatment
23	152	155	O	with
24	157	166	O	XXXXXXXX
25	168	173	O	sodium
NULL

Fosinopril	DDI-DrugBank.d176.s2	NO_SECTION	NO_SETID	36
If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION.)
1	0	1	O	If
2	3	6	O	this
3	8	9	O	is
4	11	13	O	not
5	15	22	O	possible
6	23	23	O	,
7	25	27	O	the
8	29	36	O	starting
9	38	41	O	dose
10	43	48	O	should
11	50	51	O	be
12	53	59	O	reduced
13	61	63	O	and
14	65	67	O	the
15	69	75	O	patient
16	77	82	O	should
17	84	85	O	be
18	87	94	O	observed
19	96	102	O	closely
20	104	106	O	for
21	108	114	O	several
22	116	120	O	hours
23	122	130	O	following
24	132	133	O	an
25	135	141	O	initial
26	143	146	O	dose
27	148	150	O	and
28	152	156	O	until
29	158	162	O	blood
30	164	171	O	pressure
31	173	175	O	has
32	177	186	O	stabilized
33	189	191	O	see
34	193	198	O	DOSAGE
35	200	202	O	AND
36	204	217	O	ADMINISTRATION
NULL

Fosinopril	DDI-DrugBank.d176.s3	NO_SECTION	NO_SETID	17
Potassium Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.
1	0	8	U-UNK	Potassium
2	10	20	O	Supplements
3	22	24	O	and
4	26	34	B-UNK	Potassium
5	36	42	I-UNK	Sparing
6	44	52	L-UNK	Diuretics
7	53	53	O	:
8	55	64	O	XXXXXXXX
9	66	71	O	sodium
10	73	75	O	can
11	77	85	O	attenuate
12	87	95	O	potassium
13	97	100	O	loss
14	102	107	O	caused
15	109	110	O	by
16	112	119	B-DYN	thiazide
17	121	129	L-DYN	diuretics
NULL

Fosinopril	DDI-DrugBank.d176.s4	NO_SECTION	NO_SETID	18
Potassium-sparing diuretics (spironolactone, amiloride,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.
1	0	8	B-UNK	Potassium
2	10	16	I-UNK	sparing
3	18	26	L-UNK	diuretics
4	29	42	U-UNK	spironolactone
5	43	43	O	,
6	45	65	O	amiloride,triamterene
7	66	66	O	,
8	68	70	O	and
9	72	77	O	others
10	80	81	O	or
11	83	91	U-UNK	potassium
12	93	103	O	supplements
13	105	107	O	can
14	109	116	O	increase
15	118	120	O	the
16	122	125	O	risk
17	127	128	O	of
18	130	141	O	hyperkalemia
NULL

Fosinopril	DDI-DrugBank.d176.s5	NO_SECTION	NO_SETID	27
Therefore, if concomitant use of such agents is indicated, they should be given with caution, and the patients serum potassium should be monitored frequently.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	if
4	14	24	O	concomitant
5	26	28	O	use
6	30	31	O	of
7	33	36	O	such
8	38	43	O	agents
9	45	46	O	is
10	48	56	O	indicated
11	57	57	O	,
12	59	62	O	they
13	64	69	O	should
14	71	72	O	be
15	74	78	O	given
16	80	83	O	with
17	85	91	O	caution
18	92	92	O	,
19	94	96	O	and
20	98	100	O	the
21	102	109	O	patients
22	111	115	O	serum
23	117	125	O	potassium
24	127	132	O	should
25	134	135	O	be
26	137	145	O	monitored
27	147	156	O	frequently
NULL

Fosinopril	DDI-DrugBank.d176.s6	NO_SECTION	NO_SETID	23
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	17	O	Increased
4	19	23	O	serum
5	25	31	U-UNK	lithium
6	33	38	O	levels
7	40	42	O	and
8	44	51	O	symptoms
9	53	54	O	of
10	56	62	U-UNK	lithium
11	64	71	O	toxicity
12	73	76	O	have
13	78	81	O	been
14	83	90	O	reported
15	92	93	O	in
16	95	102	O	patients
17	104	112	O	receiving
18	114	116	B-UNK	ACE
19	118	127	L-UNK	inhibitors
20	129	134	O	during
21	136	142	O	therapy
22	144	147	O	with
23	149	155	U-UNK	lithium
NULL

Fosinopril	DDI-DrugBank.d176.s7	NO_SECTION	NO_SETID	17
These drugs should be coadministered with caution, and frequent monitoring of serum lithium levels is recommended.
1	0	4	O	These
2	6	10	O	drugs
3	12	17	O	should
4	19	20	O	be
5	22	35	O	coadministered
6	37	40	O	with
7	42	48	O	caution
8	49	49	O	,
9	51	53	O	and
10	55	62	O	frequent
11	64	73	O	monitoring
12	75	76	O	of
13	78	82	O	serum
14	84	90	U-UNK	lithium
15	92	97	O	levels
16	99	100	O	is
17	102	112	O	recommended
NULL

Fosinopril	DDI-DrugBank.d176.s8	NO_SECTION	NO_SETID	15
If a diuretic is also used, the risk of lithium toxicity may be increased.
1	0	1	O	If
2	3	3	O	a
3	5	12	U-UNK	diuretic
4	14	15	O	is
5	17	20	O	also
6	22	25	O	used
7	26	26	O	,
8	28	30	O	the
9	32	35	O	risk
10	37	38	O	of
11	40	46	O	lithium
12	48	55	O	toxicity
13	57	59	O	may
14	61	62	O	be
15	64	72	O	increased
NULL

Fosinopril	DDI-DrugBank.d176.s9	NO_SECTION	NO_SETID	46
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
1	0	7	U-UNK	Antacids
2	8	8	O	:
3	10	11	O	In
4	13	13	O	a
5	15	22	O	clinical
6	24	35	O	pharmacology
7	37	41	O	study
8	42	42	O	,
9	44	59	O	coadministration
10	61	62	O	of
11	64	65	O	an
12	67	73	U-KIN	antacid
13	76	83	B-KIN	aluminum
14	85	93	L-KIN	hydroxide
15	94	94	O	,
16	96	104	B-KIN	magnesium
17	106	114	L-KIN	hydroxide
18	115	115	O	,
19	117	119	O	and
20	121	131	U-KIN	simethicone
21	134	137	O	with
22	139	148	O	XXXXXXXX
23	150	156	O	reduced
24	158	162	O	serum
25	164	169	O	levels
26	171	173	O	and
27	175	181	O	urinary
28	183	191	O	excretion
29	193	194	O	of
30	196	205	O	XXXXXXXX
31	206	207	O	at
32	209	210	O	as
33	212	219	O	compared
34	221	224	O	with
35	226	235	O	XXXXXXXX
36	237	248	O	administered
37	250	254	O	alone
38	255	255	O	,
39	257	266	O	suggesting
40	268	271	O	that
41	273	280	U-KIN	antacids
42	282	284	O	may
43	286	291	O	impair
44	293	302	O	absorption
45	304	305	O	of
46	307	316	O	XXXXXXXX
NULL

Fosinopril	DDI-DrugBank.d176.s10	NO_SECTION	NO_SETID	18
Therefore, if concomitant administration of these agents is indicated, dosing should be separated by 2 hours.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	if
4	14	24	O	concomitant
5	26	39	O	administration
6	41	42	O	of
7	44	48	O	these
8	50	55	O	agents
9	57	58	O	is
10	60	68	O	indicated
11	69	69	O	,
12	71	76	O	dosing
13	78	83	O	should
14	85	86	O	be
15	88	96	O	separated
16	98	99	O	by
17	101	101	O	2
18	103	107	O	hours
NULL

Fosinopril	DDI-DrugBank.d176.s11	NO_SECTION	NO_SETID	15
Other: Neither fosinopril sodium nor its metabolites have been found to interact with food.
1	0	4	O	Other
2	5	5	O	:
3	7	13	O	Neither
4	15	24	O	XXXXXXXX
5	26	31	O	sodium
6	33	35	O	nor
7	37	39	O	its
8	41	51	O	metabolites
9	53	56	O	have
10	58	61	O	been
11	63	67	O	found
12	69	70	O	to
13	72	79	O	interact
14	81	84	O	with
15	86	89	O	food
NULL

Fosinopril	DDI-DrugBank.d176.s12	NO_SECTION	NO_SETID	47
In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.
1	0	1	O	In
2	3	10	O	separate
3	12	17	O	single
4	19	20	O	or
5	22	29	O	multiple
6	31	34	O	dose
7	36	50	O	pharmacokinetic
8	52	62	O	interaction
9	64	70	O	studies
10	72	75	O	with
11	77	90	U-UNK	chlorthalidone
12	91	91	O	,
13	93	102	U-UNK	nifedipine
14	103	103	O	,
15	105	114	U-UNK	propanolol
16	115	115	O	,
17	117	135	U-UNK	hydrochlorothiazide
18	136	136	O	,
19	138	147	U-UNK	cimetidine
20	148	148	O	,
21	150	163	U-UNK	metoclopramide
22	164	164	O	,
23	166	178	U-UNK	propantheline
24	179	179	O	,
25	181	187	U-UNK	digoxin
26	188	188	O	,
27	190	192	O	and
28	194	201	U-UNK	warfarin
29	202	202	O	,
30	204	206	O	the
31	208	222	O	bioavailability
32	224	225	O	of
33	227	236	O	XXXXXXXX
34	237	238	O	at
35	240	242	O	was
36	244	246	O	not
37	248	254	O	altered
38	256	257	O	by
39	259	274	O	coadministration
40	276	277	O	of
41	279	288	O	XXXXXXXX
42	290	293	O	with
43	295	297	O	any
44	299	301	O	one
45	303	304	O	of
46	306	310	O	these
47	312	316	O	drugs
NULL

Fosinopril	DDI-DrugBank.d176.s13	NO_SECTION	NO_SETID	20
In a study with concomitant administration of aspirin and fosinopril sodium, the bioavailability of unbound fosinoprilat was not altered.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	14	O	with
5	16	26	O	concomitant
6	28	41	O	administration
7	43	44	O	of
8	46	52	O	XXXXXXXX
9	54	56	O	and
10	58	67	B-UNK	fosinopril
11	69	74	L-UNK	sodium
12	75	75	O	,
13	77	79	O	the
14	81	95	O	bioavailability
15	97	98	O	of
16	100	106	O	unbound
17	108	119	U-UNK	fosinoprilat
18	121	123	O	was
19	125	127	O	not
20	129	135	O	altered
NULL

Fosinopril	DDI-DrugBank.d176.s14	NO_SECTION	NO_SETID	31
In a pharmacokinetic interaction study with warfarin, bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of warfarin were not significantly changed.
1	0	1	O	In
2	3	3	O	a
3	5	19	O	pharmacokinetic
4	21	31	O	interaction
5	33	37	O	study
6	39	42	O	with
7	44	51	U-UNK	warfarin
8	52	52	O	,
9	54	68	O	bioavailability
10	70	79	O	parameters
11	80	80	O	,
12	82	84	O	the
13	86	91	O	degree
14	93	94	O	of
15	96	102	O	protein
16	104	110	O	binding
17	111	111	O	,
18	113	115	O	and
19	117	119	O	the
20	121	133	O	anticoagulant
21	135	140	O	effect
22	143	150	O	measured
23	152	153	O	by
24	155	165	O	prothrombin
25	167	170	O	time
26	173	174	O	of
27	176	183	U-UNK	warfarin
28	185	188	O	were
29	190	192	O	not
30	194	206	O	significantly
31	208	214	O	changed
NULL

Fosinopril	DDI-DrugBank.d176.s15	NO_SECTION	NO_SETID	24
Drug/Laboratory Test Interaction Fosinopril may cause a false low measurement of serum digoxin levels with the Digi- Tab  RIA Kit for Digoxin.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	31	O	Interaction
6	33	42	O	XXXXXXXX
7	44	46	O	may
8	48	52	O	cause
9	54	54	O	a
10	56	60	O	false
11	62	64	O	low
12	66	76	O	measurement
13	78	79	O	of
14	81	85	O	serum
15	87	93	U-UNK	digoxin
16	95	100	O	levels
17	102	105	O	with
18	107	109	O	the
19	111	114	O	Digi
20	117	119	O	Tab
21	122	124	O	RIA
22	126	128	O	Kit
23	130	132	O	for
24	134	140	U-UNK	Digoxin
NULL

Fosinopril	DDI-DrugBank.d176.s16	NO_SECTION	NO_SETID	15
Other kits, such as the Coat-A-Count  RIA Kit, may be used.
1	0	4	O	Other
2	6	9	O	kits
3	10	10	O	,
4	12	15	O	such
5	17	18	O	as
6	20	22	O	the
7	24	27	O	Coat
8	29	29	O	A
9	31	35	O	Count
10	38	40	O	RIA
11	42	44	O	Kit
12	45	45	O	,
13	47	49	O	may
14	51	52	O	be
15	54	57	O	used
NULL

Fosphenytoin	DDI-DrugBank.d40.s0	NO_SECTION	NO_SETID	13
No drugs are known to interfere with the conversion of fosphenytoin to phenytoin.
1	0	1	O	No
2	3	7	O	drugs
3	9	11	O	are
4	13	17	O	known
5	19	20	O	to
6	22	30	O	interfere
7	32	35	O	with
8	37	39	O	the
9	41	50	O	conversion
10	52	53	O	of
11	55	66	O	XXXXXXXX
12	68	69	O	to
13	71	79	U-UNK	phenytoin
NULL

Fosphenytoin	DDI-DrugBank.d40.s1	NO_SECTION	NO_SETID	42
Conversion could be affected by alterations in the level of phosphatase activity, but given the abundance and wide distribution of phosphatases in the body it is unlikely that drugs would affect this activity enough to affect conversion of fosphenytoin to phenytoin.
1	0	9	O	Conversion
2	11	15	O	could
3	17	18	O	be
4	20	27	O	affected
5	29	30	O	by
6	32	42	O	alterations
7	44	45	O	in
8	47	49	O	the
9	51	55	O	level
10	57	58	O	of
11	60	70	O	phosphatase
12	72	79	O	activity
13	80	80	O	,
14	82	84	O	but
15	86	90	O	given
16	92	94	O	the
17	96	104	O	abundance
18	106	108	O	and
19	110	113	O	wide
20	115	126	O	distribution
21	128	129	O	of
22	131	142	O	phosphatases
23	144	145	O	in
24	147	149	O	the
25	151	154	O	body
26	156	157	O	it
27	159	160	O	is
28	162	169	O	unlikely
29	171	174	O	that
30	176	180	O	drugs
31	182	186	O	would
32	188	193	O	affect
33	195	198	O	this
34	200	207	O	activity
35	209	214	O	enough
36	216	217	O	to
37	219	224	O	affect
38	226	235	O	conversion
39	237	238	O	of
40	240	251	O	XXXXXXXX
41	253	254	O	to
42	256	264	U-UNK	phenytoin
NULL

Fosphenytoin	DDI-DrugBank.d40.s2	NO_SECTION	NO_SETID	12
Drugs highly bound to albumin could increase the unbound fraction of fosphenytoin.
1	0	4	O	Drugs
2	6	11	O	highly
3	13	17	O	bound
4	19	20	O	to
5	22	28	O	albumin
6	30	34	O	could
7	36	43	O	increase
8	45	47	O	the
9	49	55	O	unbound
10	57	64	O	fraction
11	66	67	O	of
12	69	80	O	XXXXXXXX
NULL

Fosphenytoin	DDI-DrugBank.d40.s3	NO_SECTION	NO_SETID	29
Although, it is unknown whether this could result in clinically significant effects, caution is advised when administering Cerebyx with other drugs that significantly bind to serum albumin.
1	0	7	O	Although
2	8	8	O	,
3	10	11	O	it
4	13	14	O	is
5	16	22	O	unknown
6	24	30	O	whether
7	32	35	O	this
8	37	41	O	could
9	43	48	O	result
10	50	51	O	in
11	53	62	O	clinically
12	64	74	O	significant
13	76	82	O	effects
14	83	83	O	,
15	85	91	O	caution
16	93	94	O	is
17	96	102	O	advised
18	104	107	O	when
19	109	121	O	administering
20	123	129	O	XXXXXXXX
21	131	134	O	with
22	136	140	O	other
23	142	146	O	drugs
24	148	151	O	that
25	153	165	O	significantly
26	167	170	O	bind
27	172	173	O	to
28	175	179	O	serum
29	181	187	O	albumin
NULL

Fosphenytoin	DDI-DrugBank.d40.s4	NO_SECTION	NO_SETID	26
The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	23	O	and
4	25	31	O	protein
5	33	39	O	binding
6	41	42	O	of
7	44	55	U-UNK	fosphenytoin
8	56	56	O	,
9	58	66	U-UNK	phenytoin
10	67	67	O	,
11	69	71	O	and
12	73	80	U-UNK	diazepam
13	82	85	O	were
14	87	89	O	not
15	91	97	O	altered
16	99	102	O	when
17	104	111	U-UNK	diazepam
18	113	115	O	and
19	117	123	O	XXXXXXXX
20	125	128	O	were
21	130	141	O	concurrently
22	143	154	O	administered
23	156	157	O	in
24	159	164	O	single
25	166	175	O	submaximal
26	177	181	O	doses
NULL

Fosphenytoin	DDI-DrugBank.d40.s5	NO_SECTION	NO_SETID	19
The most significant drug interactions following administration of Cerebyx are expected to occur with drugs that interact with phenytoin.
1	0	2	O	The
2	4	7	O	most
3	9	19	O	significant
4	21	24	O	drug
5	26	37	O	interactions
6	39	47	O	following
7	49	62	O	administration
8	64	65	O	of
9	67	73	O	XXXXXXXX
10	75	77	O	are
11	79	86	O	expected
12	88	89	O	to
13	91	95	O	occur
14	97	100	O	with
15	102	106	O	drugs
16	108	111	O	that
17	113	120	O	interact
18	122	125	O	with
19	127	135	U-UNK	phenytoin
NULL

Fosphenytoin	DDI-DrugBank.d40.s6	NO_SECTION	NO_SETID	14
Phenytoin is extensively bound to serum plasma proteins and is prone to competitive displacement.
1	0	8	U-UNK	Phenytoin
2	10	11	O	is
3	13	23	O	extensively
4	25	29	O	bound
5	31	32	O	to
6	34	38	O	serum
7	40	45	O	plasma
8	47	54	O	proteins
9	56	58	O	and
10	60	61	O	is
11	63	67	O	prone
12	69	70	O	to
13	72	82	O	competitive
14	84	95	O	displacement
NULL

Fosphenytoin	DDI-DrugBank.d40.s7	NO_SECTION	NO_SETID	23
Phenytoin is metabolized by hepatic cytochrome P450 enzymes and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism.
1	0	8	U-UNK	Phenytoin
2	10	11	O	is
3	13	23	O	metabolized
4	25	26	O	by
5	28	34	O	hepatic
6	36	45	O	cytochrome
7	47	50	O	P450
8	52	58	O	enzymes
9	60	62	O	and
10	64	65	O	is
11	67	78	O	particularly
12	80	90	O	susceptible
13	92	93	O	to
14	95	104	O	inhibitory
15	106	109	O	drug
16	111	122	O	interactions
17	124	130	O	because
18	132	133	O	it
19	135	136	O	is
20	138	144	O	subject
21	146	147	O	to
22	149	157	O	saturable
23	159	168	O	metabolism
NULL

Fosphenytoin	DDI-DrugBank.d40.s8	NO_SECTION	NO_SETID	18
Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity.
1	0	9	O	Inhibition
2	11	12	O	of
3	14	23	O	metabolism
4	25	27	O	may
5	29	35	O	produce
6	37	47	O	significant
7	49	57	O	increases
8	59	60	O	in
9	62	72	O	circulating
10	74	82	U-UNK	phenytoin
11	84	97	O	concentrations
12	99	101	O	and
13	103	109	O	enhance
14	111	113	O	the
15	115	118	O	risk
16	120	121	O	of
17	123	126	O	drug
18	128	135	O	toxicity
NULL

Fosphenytoin	DDI-DrugBank.d40.s9	NO_SECTION	NO_SETID	10
Phenytoin is a potent inducer of hepatic drug-metabolizing enzymes.
1	0	8	U-UNK	Phenytoin
2	10	11	O	is
3	13	13	O	a
4	15	20	O	potent
5	22	28	O	inducer
6	30	31	O	of
7	33	39	O	hepatic
8	41	44	O	drug
9	46	57	O	metabolizing
10	59	65	O	enzymes
NULL

Fosphenytoin	DDI-DrugBank.d40.s10	NO_SECTION	NO_SETID	65
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
1	0	2	O	The
2	4	7	O	most
3	9	16	O	commonly
4	18	26	O	occurring
5	28	31	O	drug
6	33	44	O	interactions
7	46	48	O	are
8	50	55	O	listed
9	57	61	O	below
10	62	62	O	:
11	66	70	O	Drugs
12	72	75	O	that
13	77	79	O	may
14	81	88	O	increase
15	90	95	O	plasma
16	97	105	U-UNK	phenytoin
17	107	120	O	concentrations
18	122	128	O	include
19	129	129	O	:
20	131	135	O	acute
21	137	143	U-UNK	alcohol
22	145	150	O	intake
23	151	151	O	,
24	153	162	U-UNK	amiodarone
25	163	163	O	,
26	165	179	O	chboramphenicol
27	180	180	O	,
28	182	197	U-UNK	chlordiazepoxide
29	198	198	O	,
30	200	209	U-UNK	cimetidine
31	210	210	O	,
32	212	219	U-UNK	diazepam
33	220	220	O	,
34	222	230	U-UNK	dicumarol
35	231	231	O	,
36	233	242	U-UNK	disulfiram
37	243	243	O	,
38	245	253	U-UNK	estrogens
39	254	254	O	,
40	256	267	U-UNK	ethosuximide
41	268	268	O	,
42	270	279	U-UNK	fluoxetine
43	280	280	O	,
44	282	283	B-UNK	H2
45	285	295	L-UNK	antagonists
46	296	296	O	,
47	298	306	U-UNK	halothane
48	307	307	O	,
49	309	317	U-UNK	isoniazid
50	318	318	O	,
51	320	334	U-UNK	methylphenidate
52	335	335	O	,
53	337	350	U-UNK	phenothiazines
54	351	351	O	,
55	353	366	U-UNK	phenylbutazone
56	367	367	O	,
57	369	379	U-UNK	salicylates
58	380	380	O	,
59	382	393	U-UNK	succinimides
60	394	394	O	,
61	396	407	U-UNK	sulfonamides
62	408	408	O	,
63	410	420	U-UNK	tolbutamide
64	421	421	O	,
65	423	431	U-UNK	trazodone
NULL

Fosphenytoin	DDI-DrugBank.d40.s12	NO_SECTION	NO_SETID	16
- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine
1	2	6	O	Drugs
2	8	11	O	that
3	13	15	O	may
4	17	24	O	decrease
5	26	31	O	plasma
6	33	41	U-UNK	phenytoin
7	43	56	O	concentrations
8	58	64	O	include
9	65	65	O	:
10	67	79	U-UNK	carbamazepine
11	80	80	O	,
12	82	88	O	chronic
13	90	96	U-UNK	alcohol
14	98	102	O	abuse
15	103	103	O	,
16	105	113	U-UNK	reserpine
NULL

Fosphenytoin	DDI-DrugBank.d40.s14	NO_SECTION	NO_SETID	20
- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.
1	2	6	O	Drugs
2	8	11	O	that
3	13	15	O	may
4	17	22	O	either
5	24	31	O	increase
6	33	34	O	or
7	36	43	O	decrease
8	45	50	O	plasma
9	52	60	U-UNK	phenytoin
10	62	75	O	concentrations
11	77	83	O	include
12	84	84	O	:
13	86	98	U-UNK	phenobarbital
14	99	99	O	,
15	101	108	O	vaiproic
16	110	113	O	acid
17	114	114	O	,
18	116	118	O	and
19	120	125	B-UNK	sodium
20	127	135	L-UNK	valproate
NULL

Fosphenytoin	DDI-DrugBank.d40.s15	NO_SECTION	NO_SETID	18
Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable
1	0	8	O	Similarly
2	9	9	O	,
3	11	13	O	the
4	15	21	O	effects
5	23	24	O	of
6	26	34	U-UNK	phenytoin
7	36	37	O	on
8	39	51	U-UNK	phenobarbital
9	52	52	O	,
10	54	61	B-UNK	valproic
11	63	66	L-UNK	acid
12	68	70	O	and
13	72	77	O	sodium
14	79	84	O	plasma
15	86	94	U-UNK	valproate
16	96	109	O	concentrations
17	111	113	O	are
18	115	127	O	unpredictable
NULL

Fosphenytoin	DDI-DrugBank.d40.s17	NO_SECTION	NO_SETID	23
- Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted
1	2	9	O	Although
2	11	13	O	not
3	15	15	O	a
4	17	20	O	true
5	22	25	O	drug
6	27	37	O	interaction
7	38	38	O	,
8	40	48	B-DYN	tricyclic
9	50	64	L-DYN	antidepressants
10	66	68	O	may
11	70	80	O	precipitate
12	82	89	O	seizures
13	91	92	O	in
14	94	104	O	susceptible
15	106	113	O	patients
16	115	117	O	and
17	119	125	O	XXXXXXXX
18	127	132	O	dosage
19	134	136	O	may
20	138	141	O	need
21	143	144	O	to
22	146	147	O	be
23	149	156	O	adjusted
NULL

Fosphenytoin	DDI-DrugBank.d40.s19	NO_SECTION	NO_SETID	34
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
1	2	6	O	Drugs
2	8	12	O	whose
3	14	21	O	efficacy
4	23	24	O	is
5	26	33	O	impaired
6	35	36	O	by
7	38	46	U-UNK	phenytoin
8	48	54	O	include
9	55	55	O	:
10	57	70	U-UNK	anticoagulants
11	71	71	O	,
12	73	87	U-UNK	corticosteroids
13	88	88	O	,
14	90	97	U-UNK	coumarin
15	98	98	O	,
16	100	108	U-UNK	digitoxin
17	109	109	O	,
18	111	121	U-UNK	doxycycline
19	122	122	O	,
20	124	132	U-UNK	estrogens
21	133	133	O	,
22	135	144	U-UNK	furosemide
23	145	145	O	,
24	147	150	O	oral
25	152	165	U-UNK	contraceptives
26	166	166	O	,
27	168	175	U-UNK	rifampin
28	176	176	O	,
29	178	186	U-UNK	quinidine
30	187	187	O	,
31	189	200	U-UNK	theophylline
32	201	201	O	,
33	203	209	B-UNK	vitamin
34	211	211	L-UNK	D
NULL

Fosphenytoin	DDI-DrugBank.d40.s20	NO_SECTION	NO_SETID	14
Monitoring of plasma phenytoin concentrations may be helpful when possible drug interactions are suspected.
1	0	9	O	Monitoring
2	11	12	O	of
3	14	19	O	plasma
4	21	29	U-UNK	phenytoin
5	31	44	O	concentrations
6	46	48	O	may
7	50	51	O	be
8	53	59	O	helpful
9	61	64	O	when
10	66	73	O	possible
11	75	78	O	drug
12	80	91	O	interactions
13	93	95	O	are
14	97	105	O	suspected
NULL

Fosphenytoin	DDI-DrugBank.d40.s21	NO_SECTION	NO_SETID	12
Drug/Laboratory Test Interactions Phenytoin may decrease serum concentrations of 14.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	42	U-UNK	Phenytoin
7	44	46	O	may
8	48	55	O	decrease
9	57	61	O	serum
10	63	76	O	concentrations
11	78	79	O	of
12	81	82	O	14
NULL

Fosphenytoin	DDI-DrugBank.d40.s22	NO_SECTION	NO_SETID	12
It may also produce artifactually low results in dexamethasone or metyrapone tests.
1	0	1	O	It
2	3	5	O	may
3	7	10	O	also
4	12	18	O	produce
5	20	32	O	artifactually
6	34	36	O	low
7	38	44	O	results
8	46	47	O	in
9	49	61	O	dexamethasone
10	63	64	O	or
11	66	75	O	metyrapone
12	77	81	O	tests
NULL

Fosphenytoin	DDI-DrugBank.d40.s23	NO_SECTION	NO_SETID	18
Phenytoin may also cause increased serum concentrations of glucose, alkaline phosphatase, and gamma glutamyl transpeptidase (GGT).
1	0	8	U-UNK	Phenytoin
2	10	12	O	may
3	14	17	O	also
4	19	23	O	cause
5	25	33	O	increased
6	35	39	O	serum
7	41	54	O	concentrations
8	56	57	O	of
9	59	65	O	glucose
10	66	66	O	,
11	68	75	O	alkaline
12	77	87	O	phosphatase
13	88	88	O	,
14	90	92	O	and
15	94	98	O	gamma
16	100	107	O	glutamyl
17	109	122	O	transpeptidase
18	125	127	O	GGT
NULL

Fosphenytoin	DDI-DrugBank.d40.s24	NO_SECTION	NO_SETID	16
Care should be taken when using immunoanalytical methods to measure plasma phenytoin concentrations following Cerebyx administration.
1	0	3	O	Care
2	5	10	O	should
3	12	13	O	be
4	15	19	O	taken
5	21	24	O	when
6	26	30	O	using
7	32	47	O	immunoanalytical
8	49	55	O	methods
9	57	58	O	to
10	60	66	O	measure
11	68	73	O	plasma
12	75	83	U-UNK	phenytoin
13	85	98	O	concentrations
14	100	108	O	following
15	110	116	O	XXXXXXXX
16	118	131	O	administration
NULL

Frovatriptan	DDI-DrugBank.d426.s0	NO_SECTION	NO_SETID	11
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions.
1	0	4	O	Ergot
2	6	15	O	containing
3	17	21	O	drugs
4	23	26	O	have
5	28	31	O	been
6	33	40	O	reported
7	42	43	O	to
8	45	49	O	cause
9	51	59	O	prolonged
10	61	71	O	vasospastic
11	73	81	O	reactions
NULL

Frovatriptan	DDI-DrugBank.d426.s1	NO_SECTION	NO_SETID	39
Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).
1	0	2	O	Due
2	4	5	O	to
3	7	7	O	a
4	9	19	O	theoretical
5	21	24	O	risk
6	26	27	O	of
7	29	29	O	a
8	31	45	O	pharmacodynamic
9	47	57	O	interaction
10	58	58	O	,
11	60	62	O	use
12	64	65	O	of
13	67	76	U-DYN	ergotamine
14	78	87	O	containing
15	89	90	O	or
16	92	96	B-DYN	ergot
17	98	101	I-DYN	type
18	103	113	L-DYN	medications
19	116	119	O	like
20	121	137	U-DYN	dihydroergotamine
21	139	140	O	or
22	142	153	U-DYN	methysergide
23	156	158	O	and
24	160	164	O	XXXXXXXX
25	166	171	O	within
26	173	174	O	24
27	176	180	O	hours
28	182	183	O	of
29	185	188	O	each
30	190	194	O	other
31	196	201	O	should
32	203	204	O	be
33	206	212	O	avoided
34	215	217	O	see
35	220	220	O	a
36	222	226	O	href=
37	228	232	O	XXXXXXXX
38	233	242	O	_od.htm#CI
39	244	260	O	CONTRAINDICATIONS
NULL

Frovatriptan	DDI-DrugBank.d426.s2	NO_SECTION	NO_SETID	18
Concomitant use of other 5-HT1B/1D agonists within 24 hours of FROVA treatment is not recommended.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	23	O	other
5	25	25	O	5
6	27	30	O	HT1B
7	31	31	O	/
8	32	33	O	1D
9	35	42	O	agonists
10	44	49	O	within
11	51	52	O	24
12	54	58	O	hours
13	60	61	O	of
14	63	67	O	XXXXXXXX
15	69	77	O	treatment
16	79	80	O	is
17	82	84	O	not
18	86	96	O	recommended
NULL

Frovatriptan	DDI-DrugBank.d426.s3	NO_SECTION	NO_SETID	34
Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
1	0	8	B-UNK	Selective
2	10	18	I-UNK	serotonin
3	20	27	I-UNK	reuptake
4	29	38	L-UNK	inhibitors
5	41	45	U-UNK	SSRIs
6	49	51	O	e.g
7	53	53	O	,
8	55	64	U-UNK	fluoxetine
9	65	65	O	,
10	67	77	U-UNK	fluvoxamine
11	78	78	O	,
12	80	89	U-UNK	paroxetine
13	90	90	O	,
14	92	101	U-UNK	sertraline
15	104	107	O	have
16	109	112	O	been
17	114	121	O	reported
18	122	122	O	,
19	124	129	O	rarely
20	130	130	O	,
21	132	133	O	to
22	135	139	O	cause
23	141	148	O	weakness
24	149	149	O	,
25	151	163	O	hyperreflexia
26	164	164	O	,
27	166	168	O	and
28	170	183	O	incoordination
29	185	188	O	when
30	190	203	O	coadministered
31	205	208	O	with
32	210	210	B-UNK	5
33	212	214	I-UNK	HT1
34	216	223	L-UNK	agonists
NULL

Frovatriptan	DDI-DrugBank.d426.s4	NO_SECTION	NO_SETID	19
If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
1	0	1	O	If
2	3	13	O	concomitant
3	15	23	O	treatment
4	25	28	O	with
5	30	41	O	XXXXXXXX
6	43	45	O	and
7	47	48	O	an
8	50	53	U-DYN	SSRI
9	55	56	O	is
10	58	67	O	clinically
11	69	77	O	warranted
12	78	78	O	,
13	80	90	O	appropriate
14	92	102	O	observation
15	104	105	O	of
16	107	109	O	the
17	111	117	O	patient
18	119	120	O	is
19	122	128	O	advised
NULL

Frovatriptan	DDI-DrugBank.d426.s5	NO_SECTION	NO_SETID	17
Drug/Laboratory Test Interactions FROVA is not known to interfere with commonly employed clinical laboratory tests.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	38	O	XXXXXXXX
7	40	41	O	is
8	43	45	O	not
9	47	51	O	known
10	53	54	O	to
11	56	64	O	interfere
12	66	69	O	with
13	71	78	O	commonly
14	80	87	O	employed
15	89	96	O	clinical
16	98	107	O	laboratory
17	109	113	O	tests
NULL

Fulvestrant	DDI-DrugBank.d70.s0	NO_SECTION	NO_SETID	8
Fulvestrant is metabolized by CYP 3A4 in vitro.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	25	O	metabolized
4	27	28	O	by
5	30	32	O	CYP
6	34	36	O	3A4
7	38	39	O	in
8	41	45	O	vitro
NULL

Fulvestrant	DDI-DrugBank.d70.s1	NO_SECTION	NO_SETID	19
Clinical studies of the effect of strong CYP 3A4 inhibitors on the pharmacokinetics of fulvestrant have not been performed.
1	0	7	O	Clinical
2	9	15	O	studies
3	17	18	O	of
4	20	22	O	the
5	24	29	O	effect
6	31	32	O	of
7	34	39	O	strong
8	41	43	O	CYP
9	45	47	O	3A4
10	49	58	O	inhibitors
11	60	61	O	on
12	63	65	O	the
13	67	82	O	pharmacokinetics
14	84	85	O	of
15	87	97	O	XXXXXXXX
16	99	102	O	have
17	104	106	O	not
18	108	111	O	been
19	113	121	O	performed
NULL

Fulvestrant	DDI-DrugBank.d70.s2	NO_SECTION	NO_SETID	47
Carcinogenesis, Mutagenesis and Impairment of Fertility A two-year carcinogenesis study was conducted in female and male rats, at intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days and 10 mg/rat/15 days.
1	0	13	O	Carcinogenesis
2	14	14	O	,
3	16	26	O	Mutagenesis
4	28	30	O	and
5	32	41	O	Impairment
6	43	44	O	of
7	46	54	O	Fertility
8	56	56	O	A
9	58	60	O	two
10	62	65	O	year
11	67	80	O	carcinogenesis
12	82	86	O	study
13	88	90	O	was
14	92	100	O	conducted
15	102	103	O	in
16	105	110	O	female
17	112	114	O	and
18	116	119	O	male
19	121	124	O	rats
20	125	125	O	,
21	127	128	O	at
22	130	142	O	intramuscular
23	144	148	O	doses
24	150	151	O	of
25	153	154	O	15
26	156	157	O	mg
27	158	158	O	/
28	159	160	O	kg
29	161	161	O	/
30	162	163	O	30
31	165	168	O	days
32	169	169	O	,
33	171	172	O	10
34	174	175	O	mg
35	176	176	O	/
36	177	179	O	rat
37	180	180	O	/
38	181	182	O	30
39	184	187	O	days
40	189	191	O	and
41	193	194	O	10
42	196	197	O	mg
43	198	198	O	/
44	199	201	O	rat
45	202	202	O	/
46	203	204	O	15
47	206	209	O	days
NULL

Fulvestrant	DDI-DrugBank.d70.s3	NO_SECTION	NO_SETID	42
These doses correspond to approximately 1-, 3-, and 5-fold (in females) and 1.3-, 1.3-, and 1.6-fold (in males) the systemic exposure [AUC0-30 days]] achieved in women receiving the recommended dose of 250 mg/month.
1	0	4	O	These
2	6	10	O	doses
3	12	21	O	correspond
4	23	24	O	to
5	26	38	O	approximately
6	40	40	O	1
7	42	42	O	,
8	44	44	O	3
9	46	46	O	,
10	48	50	O	and
11	52	52	O	5
12	54	57	O	fold
13	60	61	O	in
14	63	69	O	females
15	72	74	O	and
16	76	78	O	1.3
17	80	80	O	,
18	82	84	O	1.3
19	86	86	O	,
20	88	90	O	and
21	92	94	O	1.6
22	96	99	O	fold
23	102	103	O	in
24	105	109	O	males
25	112	114	O	the
26	116	123	O	systemic
27	125	132	O	exposure
28	135	138	O	AUC0
29	140	141	O	30
30	143	146	O	days
31	150	157	O	achieved
32	159	160	O	in
33	162	166	O	women
34	168	176	O	receiving
35	178	180	O	the
36	182	192	O	recommended
37	194	197	O	dose
38	199	200	O	of
39	202	204	O	250
40	206	207	O	mg
41	208	208	O	/
42	209	213	O	month
NULL

Fulvestrant	DDI-DrugBank.d70.s4	NO_SECTION	NO_SETID	41
An increased incidence of benign ovarian granulosa cell tumors and testicular Leydig cell tumors was evident, in females dosed at 10 mg/rat/15 days and males dosed at 15 mg/rat/30 days, respectively.
1	0	1	O	An
2	3	11	O	increased
3	13	21	O	incidence
4	23	24	O	of
5	26	31	O	benign
6	33	39	O	ovarian
7	41	49	O	granulosa
8	51	54	O	cell
9	56	61	O	tumors
10	63	65	O	and
11	67	76	O	testicular
12	78	83	O	Leydig
13	85	88	O	cell
14	90	95	O	tumors
15	97	99	O	was
16	101	107	O	evident
17	108	108	O	,
18	110	111	O	in
19	113	119	O	females
20	121	125	O	dosed
21	127	128	O	at
22	130	131	O	10
23	133	134	O	mg
24	135	135	O	/
25	136	138	O	rat
26	139	139	O	/
27	140	141	O	15
28	143	146	O	days
29	148	150	O	and
30	152	156	O	males
31	158	162	O	dosed
32	164	165	O	at
33	167	168	O	15
34	170	171	O	mg
35	172	172	O	/
36	173	175	O	rat
37	176	176	O	/
38	177	178	O	30
39	180	183	O	days
40	184	184	O	,
41	186	197	O	respectively
NULL

Fulvestrant	DDI-DrugBank.d70.s5	NO_SECTION	NO_SETID	20
Induction of such tumors is consistent with the pharmacology-related endocrine feedback alterations in gonadotropin levels caused by an antiestrogen.
1	0	8	O	Induction
2	10	11	O	of
3	13	16	O	such
4	18	23	O	tumors
5	25	26	O	is
6	28	37	O	consistent
7	39	42	O	with
8	44	46	O	the
9	48	59	O	pharmacology
10	61	67	O	related
11	69	77	O	endocrine
12	79	86	O	feedback
13	88	98	O	alterations
14	100	101	O	in
15	103	114	O	gonadotropin
16	116	121	O	levels
17	123	128	O	caused
18	130	131	O	by
19	133	134	O	an
20	136	147	U-UNK	antiestrogen
NULL

Fulvestrant	DDI-DrugBank.d70.s6	NO_SECTION	NO_SETID	58
Fulvestrant was not mutagenic or clastogenic in multiple in vitro tests with and without the addition of a mammalian liver metabolic activation factor (bacterial mutation assay in strains of Salmonella typhimurium and Escherichia coli, in vitro cytogenetics study in human lymphocytes, mammalian cell mutation assay in mouse lymphoma cells and in vivo micronucleus test in rat.
1	0	10	O	XXXXXXXX
2	12	14	O	was
3	16	18	O	not
4	20	28	O	mutagenic
5	30	31	O	or
6	33	43	O	clastogenic
7	45	46	O	in
8	48	55	O	multiple
9	57	58	O	in
10	60	64	O	vitro
11	66	70	O	tests
12	72	75	O	with
13	77	79	O	and
14	81	87	O	without
15	89	91	O	the
16	93	100	O	addition
17	102	103	O	of
18	105	105	O	a
19	107	115	O	mammalian
20	117	121	O	liver
21	123	131	O	metabolic
22	133	142	O	activation
23	144	149	O	factor
24	152	160	O	bacterial
25	162	169	O	mutation
26	171	175	O	assay
27	177	178	O	in
28	180	186	O	strains
29	188	189	O	of
30	191	200	O	Salmonella
31	202	212	O	typhimurium
32	214	216	O	and
33	218	228	O	Escherichia
34	230	233	O	coli
35	234	234	O	,
36	236	237	O	in
37	239	243	O	vitro
38	245	256	O	cytogenetics
39	258	262	O	study
40	264	265	O	in
41	267	271	O	human
42	273	283	O	lymphocytes
43	284	284	O	,
44	286	294	O	mammalian
45	296	299	O	cell
46	301	308	O	mutation
47	310	314	O	assay
48	316	317	O	in
49	319	323	O	mouse
50	325	332	O	lymphoma
51	334	338	O	cells
52	340	342	O	and
53	344	345	O	in
54	347	350	O	vivo
55	352	363	O	micronucleus
56	365	368	O	test
57	370	371	O	in
58	373	375	O	rat
NULL

Fulvestrant	DDI-DrugBank.d70.s7	NO_SECTION	NO_SETID	49
In female rats, fulvestrant administered at doses   0.01 mg/kg/day (approximately one-hundredth of the human recommended dose based on body surface area [BSA], for 2 weeks prior to and for 1 week following mating, caused a reduction in fertility and embryonic survival.
1	0	1	O	In
2	3	8	O	female
3	10	13	O	rats
4	14	14	O	,
5	16	26	O	XXXXXXXX
6	28	39	O	administered
7	41	42	O	at
8	44	48	O	doses
9	52	55	O	0.01
10	57	58	O	mg
11	59	59	O	/
12	60	61	O	kg
13	62	62	O	/
14	63	65	O	day
15	68	80	O	approximately
16	82	84	O	one
17	86	94	O	hundredth
18	96	97	O	of
19	99	101	O	the
20	103	107	O	human
21	109	119	O	recommended
22	121	124	O	dose
23	126	130	O	based
24	132	133	O	on
25	135	138	O	body
26	140	146	O	surface
27	148	151	O	area
28	154	156	O	BSA
29	158	158	O	,
30	160	162	O	for
31	164	164	O	2
32	166	170	O	weeks
33	172	176	O	prior
34	178	179	O	to
35	181	183	O	and
36	185	187	O	for
37	189	189	O	1
38	191	194	O	week
39	196	204	O	following
40	206	211	O	mating
41	212	212	O	,
42	214	219	O	caused
43	221	221	O	a
44	223	231	O	reduction
45	233	234	O	in
46	236	244	O	fertility
47	246	248	O	and
48	250	258	O	embryonic
49	260	267	O	survival
NULL

Fulvestrant	DDI-DrugBank.d70.s8	NO_SECTION	NO_SETID	32
No adverse effects on female fertility and embryonic survival were evident in female animals dosed at 0.001 mg/kg/day (approximately one-thousandth of the human dose based on BSA).
1	0	1	O	No
2	3	9	O	adverse
3	11	17	O	effects
4	19	20	O	on
5	22	27	O	female
6	29	37	O	fertility
7	39	41	O	and
8	43	51	O	embryonic
9	53	60	O	survival
10	62	65	O	were
11	67	73	O	evident
12	75	76	O	in
13	78	83	O	female
14	85	91	O	animals
15	93	97	O	dosed
16	99	100	O	at
17	102	106	O	0.001
18	108	109	O	mg
19	110	110	O	/
20	111	112	O	kg
21	113	113	O	/
22	114	116	O	day
23	119	131	O	approximately
24	133	135	O	one
25	137	146	O	thousandth
26	148	149	O	of
27	151	153	O	the
28	155	159	O	human
29	161	164	O	dose
30	166	170	O	based
31	172	173	O	on
32	175	177	O	BSA
NULL

Fulvestrant	DDI-DrugBank.d70.s9	NO_SECTION	NO_SETID	33
Restoration of female fertility to values similar to controls was evident following a 29-day withdrawal period after dosing at 2 mg/kg/day (twice the human dose based on BSA).
1	0	10	O	Restoration
2	12	13	O	of
3	15	20	O	female
4	22	30	O	fertility
5	32	33	O	to
6	35	40	O	values
7	42	48	O	similar
8	50	51	O	to
9	53	60	O	controls
10	62	64	O	was
11	66	72	O	evident
12	74	82	O	following
13	84	84	O	a
14	86	87	O	29
15	89	91	O	day
16	93	102	O	withdrawal
17	104	109	O	period
18	111	115	O	after
19	117	122	O	dosing
20	124	125	O	at
21	127	127	O	2
22	129	130	O	mg
23	131	131	O	/
24	132	133	O	kg
25	134	134	O	/
26	135	137	O	day
27	140	144	O	twice
28	146	148	O	the
29	150	154	O	human
30	156	159	O	dose
31	161	165	O	based
32	167	168	O	on
33	170	172	O	BSA
NULL

Fulvestrant	DDI-DrugBank.d70.s10	NO_SECTION	NO_SETID	19
The effects of fulvestrant on the fertility of female rats appear to be consistent with its anti-estrogenic activity.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	25	O	XXXXXXXX
5	27	28	O	on
6	30	32	O	the
7	34	42	O	fertility
8	44	45	O	of
9	47	52	O	female
10	54	57	O	rats
11	59	64	O	appear
12	66	67	O	to
13	69	70	O	be
14	72	81	O	consistent
15	83	86	O	with
16	88	90	O	its
17	92	95	O	anti
18	97	106	O	estrogenic
19	108	115	O	activity
NULL

Fulvestrant	DDI-DrugBank.d70.s11	NO_SECTION	NO_SETID	74
The potential effects of fulvestrant on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days fulvestrant showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides.
1	0	2	O	The
2	4	12	O	potential
3	14	20	O	effects
4	22	23	O	of
5	25	35	O	XXXXXXXX
6	37	38	O	on
7	40	42	O	the
8	44	52	O	fertility
9	54	55	O	of
10	57	60	O	male
11	62	68	O	animals
12	70	73	O	were
13	75	77	O	not
14	79	85	O	studied
15	87	89	O	but
16	91	92	O	in
17	94	94	O	a
18	96	96	O	6
19	98	102	O	month
20	104	113	O	toxicology
21	115	119	O	study
22	120	120	O	,
23	122	125	O	male
24	127	130	O	rats
25	132	138	O	treated
26	140	143	O	with
27	145	157	O	intramuscular
28	159	163	O	doses
29	165	166	O	of
30	168	169	O	15
31	171	172	O	mg
32	173	173	O	/
33	174	175	O	kg
34	176	176	O	/
35	177	178	O	30
36	180	183	O	days
37	184	184	O	,
38	186	187	O	10
39	189	190	O	mg
40	191	191	O	/
41	192	194	O	rat
42	195	195	O	/
43	196	197	O	30
44	199	202	O	days
45	203	203	O	,
46	205	206	O	or
47	208	209	O	10
48	211	212	O	mg
49	213	213	O	/
50	214	216	O	rat
51	217	217	O	/
52	218	219	O	15
53	221	224	O	days
54	226	236	O	XXXXXXXX
55	238	243	O	showed
56	245	245	O	a
57	247	250	O	loss
58	252	253	O	of
59	255	265	O	spermatozoa
60	267	270	O	from
61	272	274	O	the
62	276	287	O	seminiferous
63	289	295	O	tubules
64	296	296	O	,
65	298	309	O	seminiferous
66	311	317	O	tubular
67	319	325	O	atrophy
68	326	326	O	,
69	328	330	O	and
70	332	343	O	degenerative
71	345	351	O	changes
72	353	354	O	in
73	356	358	O	the
74	360	371	O	epididymides
NULL

Fulvestrant	DDI-DrugBank.d70.s12	NO_SECTION	NO_SETID	15
Changes in the testes and epididymides had not recovered 20 weeks after cessation of dosing.
1	0	6	O	Changes
2	8	9	O	in
3	11	13	O	the
4	15	20	O	testes
5	22	24	O	and
6	26	37	O	epididymides
7	39	41	O	had
8	43	45	O	not
9	47	55	O	recovered
10	57	58	O	20
11	60	64	O	weeks
12	66	70	O	after
13	72	80	O	cessation
14	82	83	O	of
15	85	90	O	dosing
NULL

Fulvestrant	DDI-DrugBank.d70.s13	NO_SECTION	NO_SETID	22
These fulvestrant doses correspond to approximately 2-, 3-, and 3-fold the systemic exposure [AUC0-30 days] achieved in women.
1	0	4	O	These
2	6	16	O	XXXXXXXX
3	18	22	O	doses
4	24	33	O	correspond
5	35	36	O	to
6	38	50	O	approximately
7	52	52	O	2
8	54	54	O	,
9	56	56	O	3
10	58	58	O	,
11	60	62	O	and
12	64	64	O	3
13	66	69	O	fold
14	71	73	O	the
15	75	82	O	systemic
16	84	91	O	exposure
17	94	97	O	AUC0
18	99	100	O	30
19	102	105	O	days
20	108	115	O	achieved
21	117	118	O	in
22	120	124	O	women
NULL

Fulvestrant	DDI-DrugBank.d70.s14	NO_SECTION	NO_SETID	5
Pregnancy Pregnancy Category D: .
1	0	8	O	Pregnancy
2	10	18	O	Pregnancy
3	20	27	O	Category
4	29	29	O	D
5	30	30	O	:
NULL

Fulvestrant	DDI-DrugBank.d70.s15	NO_SECTION	NO_SETID	14
In studies in female rats at doses   0.01 mg/kg/day (IM;
1	0	1	O	In
2	3	9	O	studies
3	11	12	O	in
4	14	19	O	female
5	21	24	O	rats
6	26	27	O	at
7	29	33	O	doses
8	37	40	O	0.01
9	42	43	O	mg
10	44	44	O	/
11	45	46	O	kg
12	47	47	O	/
13	48	50	O	day
14	53	54	O	IM
NULL

Fulvestrant	DDI-DrugBank.d70.s16	NO_SECTION	NO_SETID	39
approximately one-hundredth of the human recommended dose based on body surface area [BSA]), fulvestrant caused a reversible reduction in female fertility, as well as effects on embryo/fetal development consistent with its anti-estrogenic activity.
1	0	12	O	approximately
2	14	16	O	one
3	18	26	O	hundredth
4	28	29	O	of
5	31	33	O	the
6	35	39	O	human
7	41	51	O	recommended
8	53	56	O	dose
9	58	62	O	based
10	64	65	O	on
11	67	70	O	body
12	72	78	O	surface
13	80	83	O	area
14	86	88	O	BSA
15	91	91	O	,
16	93	103	O	XXXXXXXX
17	105	110	O	caused
18	112	112	O	a
19	114	123	O	reversible
20	125	133	O	reduction
21	135	136	O	in
22	138	143	O	female
23	145	153	O	fertility
24	154	154	O	,
25	156	157	O	as
26	159	162	O	well
27	164	165	O	as
28	167	173	O	effects
29	175	176	O	on
30	178	183	O	embryo
31	184	184	O	/
32	185	189	O	fetal
33	191	201	O	development
34	203	212	O	consistent
35	214	217	O	with
36	219	221	O	its
37	223	226	O	anti
38	228	237	O	estrogenic
39	239	246	O	activity
NULL

Fulvestrant	DDI-DrugBank.d70.s17	NO_SECTION	NO_SETID	24
Fulvestrant caused an increased incidence of fetal abnormalities in rats (tarsal flexure of the hind paw at 2 mg/kg/day IM;
1	0	10	O	XXXXXXXX
2	12	17	O	caused
3	19	20	O	an
4	22	30	O	increased
5	32	40	O	incidence
6	42	43	O	of
7	45	49	O	fetal
8	51	63	O	abnormalities
9	65	66	O	in
10	68	71	O	rats
11	74	79	O	tarsal
12	81	87	O	flexure
13	89	90	O	of
14	92	94	O	the
15	96	99	O	hind
16	101	103	O	paw
17	105	106	O	at
18	108	108	O	2
19	110	111	O	mg
20	112	112	O	/
21	113	114	O	kg
22	115	115	O	/
23	116	118	O	day
24	120	121	O	IM
NULL

Fulvestrant	DDI-DrugBank.d70.s18	NO_SECTION	NO_SETID	45
twice the human dose on BSA) and non-ossification of the odontoid and ventral tubercle of the first cervical vertebra at doses   0.1 mg/kg/day IM (approximately one-tenth of the human dose on BSA) when administered during the period of organogenesis.
1	0	4	O	twice
2	6	8	O	the
3	10	14	O	human
4	16	19	O	dose
5	21	22	O	on
6	24	26	O	BSA
7	29	31	O	and
8	33	35	O	non
9	37	48	O	ossification
10	50	51	O	of
11	53	55	O	the
12	57	64	O	odontoid
13	66	68	O	and
14	70	76	O	ventral
15	78	85	O	tubercle
16	87	88	O	of
17	90	92	O	the
18	94	98	O	first
19	100	107	O	cervical
20	109	116	O	vertebra
21	118	119	O	at
22	121	125	O	doses
23	129	131	O	0.1
24	133	134	O	mg
25	135	135	O	/
26	136	137	O	kg
27	138	138	O	/
28	139	141	O	day
29	143	144	O	IM
30	147	159	O	approximately
31	161	163	O	one
32	165	169	O	tenth
33	171	172	O	of
34	174	176	O	the
35	178	182	O	human
36	184	187	O	dose
37	189	190	O	on
38	192	194	O	BSA
39	197	200	O	when
40	202	213	O	administered
41	215	220	O	during
42	222	224	O	the
43	226	231	O	period
44	233	234	O	of
45	236	248	O	organogenesis
NULL

Fulvestrant	DDI-DrugBank.d70.s19	NO_SECTION	NO_SETID	27
Rabbits failed to maintain pregnancy when dosed with 1 mg/kg/day fulvestrant IM (twice the human dose on BSA) during the period of organogenesis.
1	0	6	O	Rabbits
2	8	13	O	failed
3	15	16	O	to
4	18	25	O	maintain
5	27	35	O	pregnancy
6	37	40	O	when
7	42	46	O	dosed
8	48	51	O	with
9	53	53	O	1
10	55	56	O	mg
11	57	57	O	/
12	58	59	O	kg
13	60	60	O	/
14	61	63	O	day
15	65	75	O	XXXXXXXX
16	77	78	O	IM
17	81	85	O	twice
18	87	89	O	the
19	91	95	O	human
20	97	100	O	dose
21	102	103	O	on
22	105	107	O	BSA
23	110	115	O	during
24	117	119	O	the
25	121	126	O	period
26	128	129	O	of
27	131	143	O	organogenesis
NULL

Fulvestrant	DDI-DrugBank.d70.s20	NO_SECTION	NO_SETID	41
Further, in rabbits dosed at 0.25 mg/kg/day (about one-half the human dose on BSA), increases in placental weight and post-implantation loss were observed but, there were no observed effects on fetal development.
1	0	6	O	Further
2	7	7	O	,
3	9	10	O	in
4	12	18	O	rabbits
5	20	24	O	dosed
6	26	27	O	at
7	29	32	O	0.25
8	34	35	O	mg
9	36	36	O	/
10	37	38	O	kg
11	39	39	O	/
12	40	42	O	day
13	45	49	O	about
14	51	53	O	one
15	55	58	O	half
16	60	62	O	the
17	64	68	O	human
18	70	73	O	dose
19	75	76	O	on
20	78	80	O	BSA
21	82	82	O	,
22	84	92	O	increases
23	94	95	O	in
24	97	105	O	placental
25	107	112	O	weight
26	114	116	O	and
27	118	121	O	post
28	123	134	O	implantation
29	136	139	O	loss
30	141	144	O	were
31	146	153	O	observed
32	155	157	O	but
33	158	158	O	,
34	160	164	O	there
35	166	169	O	were
36	171	172	O	no
37	174	181	O	observed
38	183	189	O	effects
39	191	192	O	on
40	194	198	O	fetal
41	200	210	O	development
NULL

Fulvestrant	DDI-DrugBank.d70.s21	NO_SECTION	NO_SETID	32
Fulvestrant was associated with an increased incidence of fetal variations in rabbits (backwards displacement of the pelvic girdle, and 27 pre-sacral vertebrae at 0.25 mg/kg/day IM;
1	0	10	O	XXXXXXXX
2	12	14	O	was
3	16	25	O	associated
4	27	30	O	with
5	32	33	O	an
6	35	43	O	increased
7	45	53	O	incidence
8	55	56	O	of
9	58	62	O	fetal
10	64	73	O	variations
11	75	76	O	in
12	78	84	O	rabbits
13	87	95	O	backwards
14	97	108	O	displacement
15	110	111	O	of
16	113	115	O	the
17	117	122	O	pelvic
18	124	129	O	girdle
19	130	130	O	,
20	132	134	O	and
21	136	137	O	27
22	139	141	O	pre
23	143	148	O	sacral
24	150	158	O	vertebrae
25	160	161	O	at
26	163	166	O	0.25
27	168	169	O	mg
28	170	170	O	/
29	171	172	O	kg
30	173	173	O	/
31	174	176	O	day
32	178	179	O	IM
NULL

Fulvestrant	DDI-DrugBank.d70.s22	NO_SECTION	NO_SETID	14
one-half the human dose on BSA) when administered during the period of organogenesis.
1	0	2	O	one
2	4	7	O	half
3	9	11	O	the
4	13	17	O	human
5	19	22	O	dose
6	24	25	O	on
7	27	29	O	BSA
8	32	35	O	when
9	37	48	O	administered
10	50	55	O	during
11	57	59	O	the
12	61	66	O	period
13	68	69	O	of
14	71	83	O	organogenesis
NULL

Fulvestrant	DDI-DrugBank.d70.s23	NO_SECTION	NO_SETID	41
Because pregnancy could not be maintained in the rabbit following doses of fulvestrant of 1 mg/kg/day and above, this study was inadequate to fully define the possible adverse effects on fetal development at clinically relevant exposures.
1	0	6	O	Because
2	8	16	O	pregnancy
3	18	22	O	could
4	24	26	O	not
5	28	29	O	be
6	31	40	O	maintained
7	42	43	O	in
8	45	47	O	the
9	49	54	O	rabbit
10	56	64	O	following
11	66	70	O	doses
12	72	73	O	of
13	75	85	O	XXXXXXXX
14	87	88	O	of
15	90	90	O	1
16	92	93	O	mg
17	94	94	O	/
18	95	96	O	kg
19	97	97	O	/
20	98	100	O	day
21	102	104	O	and
22	106	110	O	above
23	111	111	O	,
24	113	116	O	this
25	118	122	O	study
26	124	126	O	was
27	128	137	O	inadequate
28	139	140	O	to
29	142	146	O	fully
30	148	153	O	define
31	155	157	O	the
32	159	166	O	possible
33	168	174	O	adverse
34	176	182	O	effects
35	184	185	O	on
36	187	191	O	fetal
37	193	203	O	development
38	205	206	O	at
39	208	217	O	clinically
40	219	226	O	relevant
41	228	236	O	exposures
NULL

Fulvestrant	DDI-DrugBank.d70.s24	NO_SECTION	NO_SETID	24
Nursing Mothers Fulvestrant is found in rat milk at levels significantly higher (approximately 12-fold) than plasma after administration of 2 mg/kg.
1	0	6	O	Nursing
2	8	14	O	Mothers
3	16	26	O	XXXXXXXX
4	28	29	O	is
5	31	35	O	found
6	37	38	O	in
7	40	42	O	rat
8	44	47	O	milk
9	49	50	O	at
10	52	57	O	levels
11	59	71	O	significantly
12	73	78	O	higher
13	81	93	O	approximately
14	95	96	O	12
15	98	101	O	fold
16	104	107	O	than
17	109	114	O	plasma
18	116	120	O	after
19	122	135	O	administration
20	137	138	O	of
21	140	140	O	2
22	142	143	O	mg
23	144	144	O	/
24	145	146	O	kg
NULL

Fulvestrant	DDI-DrugBank.d70.s25	NO_SECTION	NO_SETID	18
Drug exposure in rodent pups from fulvestrant-treated lactating dams was estimated as 10% of the administered dose.
1	0	3	O	Drug
2	5	12	O	exposure
3	14	15	O	in
4	17	22	O	rodent
5	24	27	O	pups
6	29	32	O	from
7	34	44	O	XXXXXXXX
8	46	52	O	treated
9	54	62	O	lactating
10	64	67	O	dams
11	69	71	O	was
12	73	81	O	estimated
13	83	84	O	as
14	86	88	O	10%
15	90	91	O	of
16	93	95	O	the
17	97	108	O	administered
18	110	113	O	dose
NULL

Fulvestrant	DDI-DrugBank.d70.s26	NO_SECTION	NO_SETID	11
It is not known if fulvestrant is excreted in human milk.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	known
5	16	17	O	if
6	19	29	O	XXXXXXXX
7	31	32	O	is
8	34	41	O	excreted
9	43	44	O	in
10	46	50	O	human
11	52	55	O	milk
NULL

Fulvestrant	DDI-DrugBank.d70.s27	NO_SECTION	NO_SETID	49
Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions from FASLODEX in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother.
1	0	6	O	Because
2	8	11	O	many
3	13	17	O	drugs
4	19	21	O	are
5	23	30	O	excreted
6	32	33	O	in
7	35	39	O	human
8	41	44	O	milk
9	45	45	O	,
10	47	49	O	and
11	51	57	O	because
12	59	60	O	of
13	62	64	O	the
14	66	74	O	potential
15	76	78	O	for
16	80	86	O	serious
17	88	94	O	adverse
18	96	104	O	reactions
19	106	109	O	from
20	111	118	O	XXXXXXXX
21	120	121	O	in
22	123	129	O	nursing
23	131	137	O	infants
24	138	138	O	,
25	140	140	O	a
26	142	149	O	decision
27	151	156	O	should
28	158	159	O	be
29	161	164	O	made
30	166	172	O	whether
31	174	175	O	to
32	177	187	O	discontinue
33	189	195	O	nursing
34	197	198	O	or
35	200	201	O	to
36	203	213	O	discontinue
37	215	217	O	the
38	219	222	O	drug
39	224	229	O	taking
40	231	234	O	into
41	236	242	O	account
42	244	246	O	the
43	248	257	O	importance
44	259	260	O	of
45	262	264	O	the
46	266	269	O	drug
47	271	272	O	to
48	274	276	O	the
49	278	283	O	mother
NULL

Fulvestrant	DDI-DrugBank.d70.s28	NO_SECTION	NO_SETID	15
Pediatric Use The safety and efficacy of FASLODEX in pediatric patients have not been established.
1	0	8	O	Pediatric
2	10	12	O	Use
3	14	16	O	The
4	18	23	O	safety
5	25	27	O	and
6	29	36	O	efficacy
7	38	39	O	of
8	41	48	O	XXXXXXXX
9	50	51	O	in
10	53	61	O	pediatric
11	63	70	O	patients
12	72	75	O	have
13	77	79	O	not
14	81	84	O	been
15	86	96	O	established
NULL

Fulvestrant	DDI-DrugBank.d70.s29	NO_SECTION	NO_SETID	53
Geriatric Use When tumor response was considered by age, objective responses were seen in 24% and 22% of patients under 65 years of age and in 16% and 11% of patients 65 years of age and older, who were treated with FASLODEX in the European and North American trials, respectively.
1	0	8	O	Geriatric
2	10	12	O	Use
3	14	17	O	When
4	19	23	O	tumor
5	25	32	O	response
6	34	36	O	was
7	38	47	O	considered
8	49	50	O	by
9	52	54	O	age
10	55	55	O	,
11	57	65	O	objective
12	67	75	O	responses
13	77	80	O	were
14	82	85	O	seen
15	87	88	O	in
16	90	92	O	24%
17	94	96	O	and
18	98	100	O	22%
19	102	103	O	of
20	105	112	O	patients
21	114	118	O	under
22	120	121	O	65
23	123	127	O	years
24	129	130	O	of
25	132	134	O	age
26	136	138	O	and
27	140	141	O	in
28	143	145	O	16%
29	147	149	O	and
30	151	153	O	11%
31	155	156	O	of
32	158	165	O	patients
33	167	168	O	65
34	170	174	O	years
35	176	177	O	of
36	179	181	O	age
37	183	185	O	and
38	187	191	O	older
39	192	192	O	,
40	194	196	O	who
41	198	201	O	were
42	203	209	O	treated
43	211	214	O	with
44	216	223	O	XXXXXXXX
45	225	226	O	in
46	228	230	O	the
47	232	239	O	European
48	241	243	O	and
49	245	249	O	North
50	251	258	O	American
51	260	265	O	trials
52	266	266	O	,
53	268	279	O	respectively
NULL

Furosemide	DDI-DrugBank.d231.s0	NO_SECTION	NO_SETID	18
Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.
1	0	9	O	XXXXXXXX
2	11	13	O	may
3	15	22	O	increase
4	24	26	O	the
5	28	35	O	ototoxic
6	37	45	O	potential
7	47	48	O	of
8	50	63	B-DYN	aminoglycoside
9	65	75	L-DYN	antibiotics
10	76	76	O	,
11	78	87	O	especially
12	89	90	O	in
13	92	94	O	the
14	96	103	O	presence
15	105	106	O	of
16	108	115	O	impaired
17	117	121	O	renal
18	123	130	O	function
NULL

Furosemide	DDI-DrugBank.d231.s1	NO_SECTION	NO_SETID	9
Except in life-threatening situations, avoid this combination.
1	0	5	O	Except
2	7	8	O	in
3	10	13	O	life
4	15	25	O	threatening
5	27	36	O	situations
6	37	37	O	,
7	39	43	O	avoid
8	45	48	O	this
9	50	60	O	combination
NULL

Furosemide	DDI-DrugBank.d231.s2	NO_SECTION	NO_SETID	15
Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.
1	0	9	O	XXXXXXXX
2	11	16	O	should
3	18	20	O	not
4	22	23	O	be
5	25	28	O	used
6	30	42	O	concomitantly
7	44	47	O	with
8	49	58	B-DYN	ethacrynic
9	60	63	L-DYN	acid
10	65	71	O	because
11	73	74	O	of
12	76	78	O	the
13	80	90	O	possibility
14	92	93	O	of
15	95	105	O	ototoxicity
NULL

Furosemide	DDI-DrugBank.d231.s3	NO_SECTION	NO_SETID	28
Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	22	O	high
4	24	28	O	doses
5	30	31	O	of
6	33	43	U-DYN	salicylates
7	45	57	O	concomitantly
8	59	62	O	with
9	64	73	O	XXXXXXXX
10	74	74	O	,
11	76	77	O	as
12	79	80	O	in
13	82	90	O	rheumatic
14	92	98	O	disease
15	99	99	O	,
16	101	103	O	may
17	105	114	O	experience
18	116	125	U-UNK	salicylate
19	127	134	O	toxicity
20	136	137	O	at
21	139	143	O	lower
22	145	149	O	doses
23	151	157	O	because
24	159	160	O	of
25	162	172	O	competitive
26	174	178	O	renal
27	180	188	O	excretory
28	190	194	O	sites
NULL

Furosemide	DDI-DrugBank.d231.s4	NO_SECTION	NO_SETID	20
Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
1	0	9	O	XXXXXXXX
2	11	13	O	has
3	15	15	O	a
4	17	24	O	tendency
5	26	27	O	to
6	29	38	O	antagonize
7	40	42	O	the
8	44	51	O	skeletal
9	53	58	O	muscle
10	60	67	O	relaxing
11	69	74	O	effect
12	76	77	O	of
13	79	90	U-DYN	tubocurarine
14	92	94	O	and
15	96	98	O	may
16	100	109	O	potentiate
17	111	113	O	the
18	115	120	O	action
19	122	123	O	of
20	125	139	U-DYN	succinylcholine
NULL

Furosemide	DDI-DrugBank.d231.s5	NO_SECTION	NO_SETID	22
Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.
1	0	6	U-UNK	Lithium
2	8	16	O	generally
3	18	23	O	should
4	25	27	O	not
5	29	30	O	be
6	32	36	O	given
7	38	41	O	with
8	43	51	U-UNK	diuretics
9	53	59	O	because
10	61	64	O	they
11	66	71	O	reduce
12	73	80	O	lithiums
13	82	86	O	renal
14	88	96	O	clearance
15	98	100	O	and
16	102	104	O	add
17	106	106	O	a
18	108	111	O	high
19	113	116	O	risk
20	118	119	O	of
21	121	127	U-UNK	lithium
22	129	136	O	toxicity
NULL

Furosemide	DDI-DrugBank.d231.s6	NO_SECTION	NO_SETID	13
Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.
1	0	9	O	XXXXXXXX
2	11	13	O	may
3	15	17	O	add
4	19	20	O	to
5	22	23	O	or
6	25	34	O	potentiate
7	36	38	O	the
8	40	50	O	therapeutic
9	52	57	O	effect
10	59	60	O	of
11	62	66	O	other
12	68	83	B-DYN	antihypertensive
13	85	89	L-DYN	drugs
NULL

Furosemide	DDI-DrugBank.d231.s7	NO_SECTION	NO_SETID	9
Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.
1	0	11	O	Potentiation
2	13	18	O	occurs
3	20	23	O	with
4	25	34	B-UNK	ganglionic
5	36	37	I-UNK	or
6	39	48	I-UNK	peripheral
7	50	59	I-UNK	adrenergic
8	61	68	I-UNK	blocking
9	70	74	L-UNK	drugs
NULL

Furosemide	DDI-DrugBank.d231.s8	NO_SECTION	NO_SETID	7
Furosemide may decrease arterial responsiveness to norepinephrine.
1	0	9	O	XXXXXXXX
2	11	13	O	may
3	15	22	O	decrease
4	24	31	O	arterial
5	33	46	O	responsiveness
6	48	49	O	to
7	51	64	U-DYN	norepinephrine
NULL

Furosemide	DDI-DrugBank.d231.s9	NO_SECTION	NO_SETID	8
However, norepinephrine may still be used effectively.
1	0	6	O	However
2	7	7	O	,
3	9	22	U-UNK	norepinephrine
4	24	26	O	may
5	28	32	O	still
6	34	35	O	be
7	37	40	O	used
8	42	52	O	effectively
NULL

Furosemide	DDI-DrugBank.d231.s10	NO_SECTION	NO_SETID	17
Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.
1	0	6	O	Tablets
2	8	19	O	Simultaneous
3	21	34	O	administration
4	36	37	O	of
5	39	48	U-DYN	sucralfate
6	50	52	O	and
7	54	63	O	XXXXXXXX
8	65	71	O	tablets
9	73	75	O	may
10	77	82	O	reduce
11	84	86	O	the
12	88	98	O	natriuretic
13	100	102	O	and
14	104	119	O	antihypertensive
15	121	127	O	effects
16	129	130	O	of
17	132	141	O	XXXXXXXX
NULL

Furosemide	DDI-DrugBank.d231.s11	NO_SECTION	NO_SETID	23
Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	22	O	both
4	24	28	O	drugs
5	30	35	O	should
6	37	38	O	be
7	40	47	O	observed
8	49	55	O	closely
9	57	58	O	to
10	60	68	O	determine
11	70	71	O	if
12	73	75	O	the
13	77	83	O	desired
14	85	92	O	diuretic
15	94	96	O	and
16	97	97	O	/
17	98	99	O	or
18	101	116	O	antihypertensive
19	118	123	O	effect
20	125	126	O	of
21	128	137	O	XXXXXXXX
22	139	140	O	is
23	142	149	O	achieved
NULL

Furosemide	DDI-DrugBank.d231.s12	NO_SECTION	NO_SETID	14
The intake of furosemide and sucralfate should be separated by at least two hours.
1	0	2	O	The
2	4	9	O	intake
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	27	O	and
6	29	38	U-DYN	sucralfate
7	40	45	O	should
8	47	48	O	be
9	50	58	O	separated
10	60	61	O	by
11	63	64	O	at
12	66	70	O	least
13	72	74	O	two
14	76	80	O	hours
NULL

Furosemide	DDI-DrugBank.d231.s13	NO_SECTION	NO_SETID	31
Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.
1	0	6	O	Tablets
2	7	7	O	,
3	9	17	O	Injection
4	18	18	O	,
5	20	22	O	and
6	24	27	O	Oral
7	29	36	O	Solution
8	38	40	O	One
9	42	46	O	study
10	48	49	O	in
11	51	53	O	six
12	55	62	O	subjects
13	64	75	O	demonstrated
14	77	80	O	that
15	82	84	O	the
16	86	96	O	combination
17	98	99	O	of
18	101	110	O	XXXXXXXX
19	112	114	O	and
20	116	130	B-DYN	acetylsalicylic
21	132	135	L-DYN	acid
22	137	147	O	temporarily
23	149	155	O	reduced
24	157	166	O	creatinine
25	168	176	O	clearance
26	178	179	O	in
27	181	188	O	patients
28	190	193	O	with
29	195	201	O	chronic
30	203	207	O	renal
31	209	221	O	insufficiency
NULL

Furosemide	DDI-DrugBank.d231.s14	NO_SECTION	NO_SETID	29
There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.
1	0	4	O	There
2	6	8	O	are
3	10	13	O	case
4	15	21	O	reports
5	23	24	O	of
6	26	33	O	patients
7	35	37	O	who
8	39	47	O	developed
9	49	57	O	increased
10	59	61	O	BUN
11	62	62	O	,
12	64	68	O	serum
13	70	79	O	creatinine
14	81	83	O	and
15	85	89	O	serum
16	91	99	O	potassium
17	101	106	O	levels
18	107	107	O	,
19	109	111	O	and
20	113	118	O	weight
21	120	123	O	gain
22	125	128	O	when
23	130	139	O	XXXXXXXX
24	141	143	O	was
25	145	148	O	used
26	150	151	O	in
27	153	163	O	conjunction
28	165	168	O	with
29	170	175	U-DYN	NSAIDs
NULL

Furosemide	DDI-DrugBank.d231.s15	NO_SECTION	NO_SETID	23
Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.
1	0	9	O	Literature
2	11	17	O	reports
3	19	26	O	indicate
4	28	31	O	that
5	33	48	O	coadministration
6	50	51	O	of
7	53	64	U-DYN	indomethacin
8	66	68	O	may
9	70	75	O	reduce
10	77	79	O	the
11	81	91	O	natriuretic
12	93	95	O	and
13	97	112	O	antihypertensive
14	114	120	O	effects
15	122	123	O	of
16	125	134	O	XXXXXXXX
17	136	137	O	in
18	139	142	O	some
19	144	151	O	patients
20	153	154	O	by
21	156	165	O	inhibiting
22	167	179	O	prostaglandin
23	181	189	O	synthesis
NULL

Furosemide	DDI-DrugBank.d231.s16	NO_SECTION	NO_SETID	15
Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation.
1	0	11	U-UNK	Indomethacin
2	13	15	O	may
3	17	20	O	also
4	22	27	O	affect
5	29	34	O	plasma
6	36	40	O	renin
7	42	47	O	levels
8	48	48	O	,
9	50	60	O	aldosterone
10	62	70	O	excretion
11	71	71	O	,
12	73	75	O	and
13	77	81	O	renin
14	83	89	O	profile
15	91	100	O	evaluation
NULL

Furosemide	DDI-DrugBank.d231.s17	NO_SECTION	NO_SETID	25
Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	22	O	both
4	24	35	U-DYN	indomethacin
5	37	39	O	and
6	41	50	O	XXXXXXXX
7	52	57	O	should
8	59	60	O	be
9	62	69	O	observed
10	71	77	O	closely
11	79	80	O	to
12	82	90	O	determine
13	92	93	O	if
14	95	97	O	the
15	99	105	O	desired
16	107	114	O	diuretic
17	116	118	O	and
18	119	119	O	/
19	120	121	O	or
20	123	138	O	antihypertensive
21	140	145	O	effect
22	147	148	O	of
23	150	159	O	XXXXXXXX
24	161	162	O	is
25	164	171	O	achieved
NULL

Gabapentin	DDI-DrugBank.d438.s0	NO_SECTION	NO_SETID	48
In vitro studies were conducted to investigate the potential of gabapentin to inhibit the major cytochrome P450 enzymes (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) that mediate drug and xenobiotic metabolism using isoform selective marker substrates and human liver microsomal preparations.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	were
5	22	30	O	conducted
6	32	33	O	to
7	35	45	O	investigate
8	47	49	O	the
9	51	59	O	potential
10	61	62	O	of
11	64	73	O	XXXXXXXX
12	75	76	O	to
13	78	84	O	inhibit
14	86	88	O	the
15	90	94	O	major
16	96	105	O	cytochrome
17	107	110	O	P450
18	112	118	O	enzymes
19	121	126	O	CYP1A2
20	127	127	O	,
21	129	134	O	CYP2A6
22	135	135	O	,
23	137	142	O	CYP2C9
24	143	143	O	,
25	145	151	O	CYP2C19
26	152	152	O	,
27	154	159	O	CYP2D6
28	160	160	O	,
29	162	167	O	CYP2E1
30	168	168	O	,
31	170	172	O	and
32	174	179	O	CYP3A4
33	182	185	O	that
34	187	193	O	mediate
35	195	198	O	drug
36	200	202	O	and
37	204	213	O	xenobiotic
38	215	224	O	metabolism
39	226	230	O	using
40	232	238	O	isoform
41	240	248	O	selective
42	250	255	O	marker
43	257	266	O	substrates
44	268	270	O	and
45	272	276	O	human
46	278	282	O	liver
47	284	293	O	microsomal
48	295	306	O	preparations
NULL

Gabapentin	DDI-DrugBank.d438.s1	NO_SECTION	NO_SETID	7
Only at the highest concentration tested (171
1	0	3	O	Only
2	5	6	O	at
3	8	10	O	the
4	12	18	O	highest
5	20	32	O	concentration
6	34	39	O	tested
7	42	44	O	171
NULL

Gabapentin	DDI-DrugBank.d438.s3	NO_SECTION	NO_SETID	14
1 mM) was a slight degree of inhibition (14%-30%) of isoform CYP2A6 observed.
1	0	0	O	1
2	2	3	O	mM
3	6	8	O	was
4	10	10	O	a
5	12	17	O	slight
6	19	24	O	degree
7	26	27	O	of
8	29	38	O	inhibition
9	41	43	O	14%
10	45	47	O	30%
11	50	51	O	of
12	53	59	O	isoform
13	61	66	O	CYP2A6
14	68	75	O	observed
NULL

Gabapentin	DDI-DrugBank.d438.s4	NO_SECTION	NO_SETID	30
No inhibition of any of the other isoforms tested was observed at gabapentin concentrations up to 171 mg/mL (approximately 15 times the Cmax at 3600 mg/day).
1	0	1	O	No
2	3	12	O	inhibition
3	14	15	O	of
4	17	19	O	any
5	21	22	O	of
6	24	26	O	the
7	28	32	O	other
8	34	41	O	isoforms
9	43	48	O	tested
10	50	52	O	was
11	54	61	O	observed
12	63	64	O	at
13	66	75	O	XXXXXXXX
14	77	90	O	concentrations
15	92	93	O	up
16	95	96	O	to
17	98	100	O	171
18	102	103	O	mg
19	104	104	O	/
20	105	106	O	mL
21	109	121	O	approximately
22	123	124	O	15
23	126	130	O	times
24	132	134	O	the
25	136	139	O	Cmax
26	141	142	O	at
27	144	147	O	3600
28	149	150	O	mg
29	151	151	O	/
30	152	154	O	day
NULL

Gabapentin	DDI-DrugBank.d438.s5	NO_SECTION	NO_SETID	17
Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	16	O	not
4	18	28	O	appreciably
5	30	40	O	metabolized
6	42	44	O	nor
7	46	49	O	does
8	51	52	O	it
9	54	62	O	interfere
10	64	67	O	with
11	69	71	O	the
12	73	82	O	metabolism
13	84	85	O	of
14	87	94	O	commonly
15	96	109	O	coadministered
16	111	123	B-UNK	antiepileptic
17	125	129	L-UNK	drugs
NULL

Gabapentin	DDI-DrugBank.d438.s6	NO_SECTION	NO_SETID	20
The drug interaction data described in this section were obtained from studies involving healthy adults and adult patients with epilepsy.
1	0	2	O	The
2	4	7	O	drug
3	9	19	O	interaction
4	21	24	O	data
5	26	34	O	described
6	36	37	O	in
7	39	42	O	this
8	44	50	O	section
9	52	55	O	were
10	57	64	O	obtained
11	66	69	O	from
12	71	77	O	studies
13	79	87	O	involving
14	89	95	O	healthy
15	97	102	O	adults
16	104	106	O	and
17	108	112	O	adult
18	114	121	O	patients
19	123	126	O	with
20	128	135	O	epilepsy
NULL

Gabapentin	DDI-DrugBank.d438.s7	NO_SECTION	NO_SETID	51
Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.
1	0	8	U-UNK	Phenytoin
2	9	9	O	:
3	11	12	O	In
4	14	14	O	a
5	16	21	O	single
6	24	26	O	400
7	28	29	O	mg
8	32	34	O	and
9	36	43	O	multiple
10	45	48	O	dose
11	51	53	O	400
12	55	56	O	mg
13	58	60	O	TID
14	63	67	O	study
15	69	70	O	of
16	72	80	O	XXXXXXXX
17	82	83	O	in
18	85	93	O	epileptic
19	95	102	O	patients
20	105	107	O	N=8
21	110	119	O	maintained
22	121	122	O	on
23	124	132	U-UNK	phenytoin
24	134	144	O	monotherapy
25	146	148	O	for
26	150	151	O	at
27	153	157	O	least
28	159	159	O	2
29	161	166	O	months
30	167	167	O	,
31	169	178	U-UNK	gabapentin
32	180	182	O	had
33	184	185	O	no
34	187	192	O	effect
35	194	195	O	on
36	197	199	O	the
37	201	206	O	steady
38	208	212	O	state
39	214	219	O	trough
40	221	226	O	plasma
41	228	241	O	concentrations
42	243	244	O	of
43	246	254	U-UNK	phenytoin
44	256	258	O	and
45	260	268	U-UNK	phenytoin
46	270	272	O	had
47	274	275	O	no
48	277	282	O	effect
49	284	285	O	on
50	287	296	U-UNK	gabapentin
51	298	313	O	pharmacokinetics
NULL

Gabapentin	DDI-DrugBank.d438.s8	NO_SECTION	NO_SETID	23
Carbamazepine: Steady-state trough plasma carbamazepine and carbamazepine 10, 11 epoxide concentrations were not affected by concomitant gabapentin (400 mg TID;
1	0	12	U-UNK	Carbamazepine
2	13	13	O	:
3	15	20	O	Steady
4	22	26	O	state
5	28	33	O	trough
6	35	40	O	plasma
7	42	54	U-UNK	carbamazepine
8	56	58	O	and
9	60	72	B-UNK	carbamazepine
10	74	75	I-UNK	10
11	76	76	I-UNK	,
12	78	79	I-UNK	11
13	81	87	L-UNK	epoxide
14	89	102	O	concentrations
15	104	107	O	were
16	109	111	O	not
17	113	120	O	affected
18	122	123	O	by
19	125	135	O	concomitant
20	137	146	O	XXXXXXXX
21	149	151	O	400
22	153	154	O	mg
23	156	158	O	TID
NULL

Gabapentin	DDI-DrugBank.d438.s9	NO_SECTION	NO_SETID	2
N=12) administration.
1	0	3	O	N=12
2	6	19	O	administration
NULL

Gabapentin	DDI-DrugBank.d438.s10	NO_SECTION	NO_SETID	9
Likewise, gabapentin pharmacokinetics were unaltered by carbamazepine administration.
1	0	7	O	Likewise
2	8	8	O	,
3	10	19	O	XXXXXXXX
4	21	36	O	pharmacokinetics
5	38	41	O	were
6	43	51	O	unaltered
7	53	54	O	by
8	56	68	U-UNK	carbamazepine
9	70	83	O	administration
NULL

Gabapentin	DDI-DrugBank.d438.s11	NO_SECTION	NO_SETID	22
Valproic Acid: The mean steady-state trough serum valproic acid concentrations prior to and during concomitant gabapentin administration (400 mg TID;
1	0	7	B-UNK	Valproic
2	9	12	L-UNK	Acid
3	13	13	O	:
4	15	17	O	The
5	19	22	O	mean
6	24	29	O	steady
7	31	35	O	state
8	37	42	O	trough
9	44	48	O	serum
10	50	57	B-UNK	valproic
11	59	62	L-UNK	acid
12	64	77	O	concentrations
13	79	83	O	prior
14	85	86	O	to
15	88	90	O	and
16	92	97	O	during
17	99	109	O	concomitant
18	111	120	O	XXXXXXXX
19	122	135	O	administration
20	138	140	O	400
21	142	143	O	mg
22	145	147	O	TID
NULL

Gabapentin	DDI-DrugBank.d438.s12	NO_SECTION	NO_SETID	14
N=17) were not different and neither were gabapentin pharmacokinetic parameters affected by valproic acid.
1	0	3	O	N=17
2	6	9	O	were
3	11	13	O	not
4	15	23	O	different
5	25	27	O	and
6	29	35	O	neither
7	37	40	O	were
8	42	51	O	XXXXXXXX
9	53	67	O	pharmacokinetic
10	69	78	O	parameters
11	80	87	O	affected
12	89	90	O	by
13	92	99	B-UNK	valproic
14	101	104	L-UNK	acid
NULL

Gabapentin	DDI-DrugBank.d438.s13	NO_SECTION	NO_SETID	15
Phenobarbital: Estimates of steady-state pharmacokinetic parameters for phenobarbital or gabapentin (300 mg TID;
1	0	12	U-UNK	Phenobarbital
2	13	13	O	:
3	15	23	O	Estimates
4	25	26	O	of
5	28	33	O	steady
6	35	39	O	state
7	41	55	O	pharmacokinetic
8	57	66	O	parameters
9	68	70	O	for
10	72	84	U-UNK	phenobarbital
11	86	87	O	or
12	89	98	O	XXXXXXXX
13	101	103	O	300
14	105	106	O	mg
15	108	110	O	TID
NULL

Gabapentin	DDI-DrugBank.d438.s14	NO_SECTION	NO_SETID	11
N=12) are identical whether the drugs are administered alone or together.
1	0	3	O	N=12
2	6	8	O	are
3	10	18	O	identical
4	20	26	O	whether
5	28	30	O	the
6	32	36	O	drugs
7	38	40	O	are
8	42	53	O	administered
9	55	59	O	alone
10	61	62	O	or
11	64	71	O	together
NULL

Gabapentin	DDI-DrugBank.d438.s15	NO_SECTION	NO_SETID	26
Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.
1	0	7	U-UNK	Naproxen
2	8	8	O	:
3	10	25	O	Coadministration
4	28	31	O	N=18
5	34	35	O	of
6	37	44	B-KIN	naproxen
7	46	51	L-KIN	sodium
8	53	60	O	capsules
9	63	65	O	250
10	67	68	O	mg
11	71	74	O	with
12	76	84	O	XXXXXXXX
13	87	89	O	125
14	91	92	O	mg
15	95	101	O	appears
16	103	104	O	to
17	106	113	O	increase
18	115	117	O	the
19	119	124	O	amount
20	126	127	O	of
21	129	138	U-UNK	gabapentin
22	140	147	O	absorbed
23	149	150	O	by
24	152	154	O	12%
25	156	157	O	to
26	159	161	O	15%
NULL

Gabapentin	DDI-DrugBank.d438.s16	NO_SECTION	NO_SETID	8
Gabapentin had no effect on naproxen pharmacokinetic parameters.
1	0	9	O	XXXXXXXX
2	11	13	O	had
3	15	16	O	no
4	18	23	O	effect
5	25	26	O	on
6	28	35	U-UNK	naproxen
7	37	51	O	pharmacokinetic
8	53	62	O	parameters
NULL

Gabapentin	DDI-DrugBank.d438.s17	NO_SECTION	NO_SETID	11
These doses are lower than the therapeutic doses for both drugs.
1	0	4	O	These
2	6	10	O	doses
3	12	14	O	are
4	16	20	O	lower
5	22	25	O	than
6	27	29	O	the
7	31	41	O	therapeutic
8	43	47	O	doses
9	49	51	O	for
10	53	56	O	both
11	58	62	O	drugs
NULL

Gabapentin	DDI-DrugBank.d438.s18	NO_SECTION	NO_SETID	15
The magnitude of interaction within the recommended dose ranges of either drug is not known.
1	0	2	O	The
2	4	12	O	magnitude
3	14	15	O	of
4	17	27	O	interaction
5	29	34	O	within
6	36	38	O	the
7	40	50	O	recommended
8	52	55	O	dose
9	57	62	O	ranges
10	64	65	O	of
11	67	72	O	either
12	74	77	O	drug
13	79	80	O	is
14	82	84	O	not
15	86	90	O	known
NULL

Gabapentin	DDI-DrugBank.d438.s19	NO_SECTION	NO_SETID	9
Hydrocodone: Coadministration of Neurontin  (125 to 500 mg;
1	0	10	U-UNK	Hydrocodone
2	11	11	O	:
3	13	28	O	Coadministration
4	30	31	O	of
5	33	41	O	XXXXXXXX
6	45	47	O	125
7	49	50	O	to
8	52	54	O	500
9	56	57	O	mg
NULL

Gabapentin	DDI-DrugBank.d438.s20	NO_SECTION	NO_SETID	5
N=48) decreases hydrocodone (10 mg;
1	0	3	O	N=48
2	6	14	O	decreases
3	16	26	U-UNK	hydrocodone
4	29	30	O	10
5	32	33	O	mg
NULL

Gabapentin	DDI-DrugBank.d438.s21	NO_SECTION	NO_SETID	16
N=50) Cmax and AUC values in a dose-dependent manner relative to administration of hydrocodone alone;
1	0	3	O	N=50
2	6	9	O	Cmax
3	11	13	O	and
4	15	17	O	AUC
5	19	24	O	values
6	26	27	O	in
7	29	29	O	a
8	31	34	O	dose
9	36	44	O	dependent
10	46	51	O	manner
11	53	60	O	relative
12	62	63	O	to
13	65	78	O	administration
14	80	81	O	of
15	83	93	U-UNK	hydrocodone
16	95	99	O	alone
NULL

Gabapentin	DDI-DrugBank.d438.s22	NO_SECTION	NO_SETID	32
Cmax and AUC values are 3% to 4% lower, respectively, after administration of 125 mg Neurontin  and 21% to 22% lower, respectively, after administration of 500 mg Neurontin .
1	0	3	O	Cmax
2	5	7	O	and
3	9	11	O	AUC
4	13	18	O	values
5	20	22	O	are
6	24	25	O	3%
7	27	28	O	to
8	30	31	O	4%
9	33	37	O	lower
10	38	38	O	,
11	40	51	O	respectively
12	52	52	O	,
13	54	58	O	after
14	60	73	O	administration
15	75	76	O	of
16	78	80	O	125
17	82	83	O	mg
18	85	93	O	XXXXXXXX
19	96	98	O	and
20	100	102	O	21%
21	104	105	O	to
22	107	109	O	22%
23	111	115	O	lower
24	116	116	O	,
25	118	129	O	respectively
26	130	130	O	,
27	132	136	O	after
28	138	151	O	administration
29	153	154	O	of
30	156	158	O	500
31	160	161	O	mg
32	163	171	O	XXXXXXXX
NULL

Gabapentin	DDI-DrugBank.d438.s23	NO_SECTION	NO_SETID	7
The mechanism for this interaction is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	16	O	for
4	18	21	O	this
5	23	33	O	interaction
6	35	36	O	is
7	38	44	O	unknown
NULL

Gabapentin	DDI-DrugBank.d438.s24	NO_SECTION	NO_SETID	7
Hydrocodone increases gabapentin AUC values by 14%.
1	0	10	U-KIN	Hydrocodone
2	12	20	O	increases
3	22	31	O	XXXXXXXX
4	33	35	O	AUC
5	37	42	O	values
6	44	45	O	by
7	47	49	O	14%
NULL

Gabapentin	DDI-DrugBank.d438.s25	NO_SECTION	NO_SETID	10
The magnitude of interaction at other doses is not known.
1	0	2	O	The
2	4	12	O	magnitude
3	14	15	O	of
4	17	27	O	interaction
5	29	30	O	at
6	32	36	O	other
7	38	42	O	doses
8	44	45	O	is
9	47	49	O	not
10	51	55	O	known
NULL

Gabapentin	DDI-DrugBank.d438.s26	NO_SECTION	NO_SETID	40
Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.
1	0	7	U-UNK	Morphine
2	8	8	O	:
3	10	10	O	A
4	12	21	O	literature
5	23	29	O	article
6	31	38	O	reported
7	40	43	O	that
8	45	48	O	when
9	50	50	O	a
10	52	53	O	60
11	55	56	O	mg
12	58	67	O	controlled
13	69	75	O	release
14	77	84	U-KIN	morphine
15	86	92	O	capsule
16	94	96	O	was
17	98	109	O	administered
18	111	111	O	2
19	113	117	O	hours
20	119	123	O	prior
21	125	126	O	to
22	128	128	O	a
23	130	132	O	600
24	134	135	O	mg
25	137	145	O	XXXXXXXX
26	148	154	O	capsule
27	157	160	O	N=12
28	162	162	O	,
29	164	167	O	mean
30	169	178	U-UNK	gabapentin
31	180	182	O	AUC
32	184	192	O	increased
33	194	195	O	by
34	197	199	O	44%
35	201	208	O	compared
36	210	211	O	to
37	213	222	U-UNK	gabapentin
38	224	235	O	administered
39	237	243	O	without
40	245	252	U-UNK	morphine
NULL

Gabapentin	DDI-DrugBank.d438.s27	NO_SECTION	NO_SETID	15
Morphine pharmacokinetic parameter values were not affected by administration of Neurontin  2 hours after morphine.
1	0	7	U-UNK	Morphine
2	9	23	O	pharmacokinetic
3	25	33	O	parameter
4	35	40	O	values
5	42	45	O	were
6	47	49	O	not
7	51	58	O	affected
8	60	61	O	by
9	63	76	O	administration
10	78	79	O	of
11	81	89	O	XXXXXXXX
12	92	92	O	2
13	94	98	O	hours
14	100	104	O	after
15	106	113	U-UNK	morphine
NULL

Gabapentin	DDI-DrugBank.d438.s28	NO_SECTION	NO_SETID	10
The magnitude of interaction at other doses is not known.
1	0	2	O	The
2	4	12	O	magnitude
3	14	15	O	of
4	17	27	O	interaction
5	29	30	O	at
6	32	36	O	other
7	38	42	O	doses
8	44	45	O	is
9	47	49	O	not
10	51	55	O	known
NULL

Gabapentin	DDI-DrugBank.d438.s29	NO_SECTION	NO_SETID	28
Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.
1	0	9	U-UNK	Cimetidine
2	10	10	O	:
3	12	13	O	In
4	15	17	O	the
5	19	26	O	presence
6	28	29	O	of
7	31	40	U-KIN	cimetidine
8	42	43	O	at
9	45	47	O	300
10	49	50	O	mg
11	52	54	O	QID
12	57	60	O	N=12
13	63	65	O	the
14	67	70	O	mean
15	72	79	O	apparent
16	81	84	O	oral
17	86	94	O	clearance
18	96	97	O	of
19	99	108	O	XXXXXXXX
20	110	113	O	fell
21	115	116	O	by
22	118	120	O	14%
23	122	124	O	and
24	126	135	O	creatinine
25	137	145	O	clearance
26	147	150	O	fell
27	152	153	O	by
28	155	157	O	10%
NULL

Gabapentin	DDI-DrugBank.d438.s30	NO_SECTION	NO_SETID	20
Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.
1	0	3	O	Thus
2	5	14	U-KIN	cimetidine
3	16	23	O	appeared
4	25	26	O	to
5	28	32	O	alter
6	34	36	O	the
7	38	42	O	renal
8	44	52	O	excretion
9	54	55	O	of
10	57	60	O	both
11	62	71	O	XXXXXXXX
12	73	75	O	and
13	77	86	O	creatinine
14	87	87	O	,
15	89	90	O	an
16	92	101	O	endogenous
17	103	108	O	marker
18	110	111	O	of
19	113	117	O	renal
20	119	126	O	function
NULL

Gabapentin	DDI-DrugBank.d438.s31	NO_SECTION	NO_SETID	17
This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.
1	0	3	O	This
2	5	9	O	small
3	11	18	O	decrease
4	20	21	O	in
5	23	31	O	excretion
6	33	34	O	of
7	36	45	O	XXXXXXXX
8	47	48	O	by
9	50	59	U-KIN	cimetidine
10	61	62	O	is
11	64	66	O	not
12	68	75	O	expected
13	77	78	O	to
14	80	81	O	be
15	83	84	O	of
16	86	93	O	clinical
17	95	104	O	importance
NULL

Gabapentin	DDI-DrugBank.d438.s32	NO_SECTION	NO_SETID	9
The effect of gabapentin on cimetidine was not evaluated.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	26	O	on
6	28	37	U-UNK	cimetidine
7	39	41	O	was
8	43	45	O	not
9	47	55	O	evaluated
NULL

Gabapentin	DDI-DrugBank.d438.s33	NO_SECTION	NO_SETID	46
Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;
1	0	3	O	Oral
2	5	17	U-UNK	Contraceptive
3	18	18	O	:
4	20	24	O	Based
5	26	27	O	on
6	29	31	O	AUC
7	33	35	O	and
8	37	40	O	half
9	42	45	O	life
10	46	46	O	,
11	48	55	O	multiple
12	57	60	O	dose
13	62	76	O	pharmacokinetic
14	78	85	O	profiles
15	87	88	O	of
16	90	102	U-UNK	norethindrone
17	104	106	O	and
18	108	114	B-UNK	ethinyl
19	116	124	L-UNK	estradiol
20	126	134	O	following
21	136	149	O	administration
22	151	152	O	of
23	154	160	O	tablets
24	162	171	O	containing
25	173	175	O	2.5
26	177	178	O	mg
27	180	181	O	of
28	183	195	B-UNK	norethindrone
29	197	203	L-UNK	acetate
30	205	207	O	and
31	209	210	O	50
32	212	214	O	mcg
33	216	217	O	of
34	219	225	B-UNK	ethinyl
35	227	235	L-UNK	estradiol
36	237	240	O	were
37	242	248	O	similar
38	250	253	O	with
39	255	257	O	and
40	259	265	O	without
41	267	282	O	coadministration
42	284	285	O	of
43	287	296	O	XXXXXXXX
44	299	301	O	400
45	303	304	O	mg
46	306	308	O	TID
NULL

Gabapentin	DDI-DrugBank.d438.s35	NO_SECTION	NO_SETID	13
The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;
1	0	2	O	The
2	4	7	O	Cmax
3	9	10	O	of
4	12	24	U-KIN	norethindrone
5	26	28	O	was
6	30	32	O	13%
7	34	39	O	higher
8	41	44	O	when
9	46	47	O	it
10	49	51	O	was
11	53	66	O	coadministered
12	68	71	O	with
13	73	82	O	XXXXXXXX
NULL

Gabapentin	DDI-DrugBank.d438.s36	NO_SECTION	NO_SETID	10
this interaction is not expected to be of clinical importance.
1	0	3	O	this
2	5	15	O	interaction
3	17	18	O	is
4	20	22	O	not
5	24	31	O	expected
6	33	34	O	to
7	36	37	O	be
8	39	40	O	of
9	42	49	O	clinical
10	51	60	O	importance
NULL

Gabapentin	DDI-DrugBank.d438.s37	NO_SECTION	NO_SETID	13
Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.
1	0	6	U-UNK	Antacid
2	9	14	O	XXXXXXXX
3	17	17	O	:
4	19	24	O	XXXXXXXX
5	26	32	O	reduced
6	34	36	O	the
7	38	52	O	bioavailability
8	54	55	O	of
9	57	66	U-KIN	gabapentin
10	69	72	O	N=16
11	75	76	O	by
12	78	82	O	about
13	84	86	O	20%
NULL

Gabapentin	DDI-DrugBank.d438.s38	NO_SECTION	NO_SETID	15
This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox.
1	0	3	O	This
2	5	12	O	decrease
3	14	15	O	in
4	17	31	O	bioavailability
5	33	35	O	was
6	37	41	O	about
7	43	44	O	5%
8	46	49	O	when
9	51	60	U-KIN	gabapentin
10	62	64	O	was
11	66	77	O	administered
12	79	79	O	2
13	81	85	O	hours
14	87	91	O	after
15	93	98	O	XXXXXXXX
NULL

Gabapentin	DDI-DrugBank.d438.s39	NO_SECTION	NO_SETID	14
It is recommended that gabapentin be taken at least 2 hours following Maalox administration.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	32	U-DYN	gabapentin
6	34	35	O	be
7	37	41	O	taken
8	43	44	O	at
9	46	50	O	least
10	52	52	O	2
11	54	58	O	hours
12	60	68	O	following
13	70	75	O	XXXXXXXX
14	77	90	O	administration
NULL

Gabapentin	DDI-DrugBank.d438.s40	NO_SECTION	NO_SETID	12
Effect of Probenecid: Probenecid is a blocker of renal tubular secretion.
1	0	5	O	Effect
2	7	8	O	of
3	10	19	U-UNK	Probenecid
4	20	20	O	:
5	22	31	U-UNK	Probenecid
6	33	34	O	is
7	36	36	O	a
8	38	44	O	blocker
9	46	47	O	of
10	49	53	O	renal
11	55	61	O	tubular
12	63	71	O	secretion
NULL

Gabapentin	DDI-DrugBank.d438.s41	NO_SECTION	NO_SETID	9
Gabapentin pharmacokinetic parameters without and with probenecid were comparable.
1	0	9	O	XXXXXXXX
2	11	25	O	pharmacokinetic
3	27	36	O	parameters
4	38	44	O	without
5	46	48	O	and
6	50	53	O	with
7	55	64	U-UNK	probenecid
8	66	69	O	were
9	71	80	O	comparable
NULL

Gabapentin	DDI-DrugBank.d438.s42	NO_SECTION	NO_SETID	18
This indicates that gabapentin does not undergo renal tubular secretion by the pathway that is blocked by probenecid.
1	0	3	O	This
2	5	13	O	indicates
3	15	18	O	that
4	20	29	O	XXXXXXXX
5	31	34	O	does
6	36	38	O	not
7	40	46	O	undergo
8	48	52	O	renal
9	54	60	O	tubular
10	62	70	O	secretion
11	72	73	O	by
12	75	77	O	the
13	79	85	O	pathway
14	87	90	O	that
15	92	93	O	is
16	95	101	O	blocked
17	103	104	O	by
18	106	115	U-UNK	probenecid
NULL

Gabapentin	DDI-DrugBank.d438.s43	NO_SECTION	NO_SETID	47
Drug/Laboratory Tests Interactions Because false positive readings were reported with the Ames N-Multistix SG dipstick test for urinary protein when gabapentin was added to other antiepileptic drugs, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	20	O	Tests
5	22	33	O	Interactions
6	35	41	O	Because
7	43	47	O	false
8	49	56	O	positive
9	58	65	O	readings
10	67	70	O	were
11	72	79	O	reported
12	81	84	O	with
13	86	88	O	the
14	90	93	O	Ames
15	95	95	O	N
16	97	105	O	Multistix
17	107	108	O	SG
18	110	117	O	dipstick
19	119	122	O	test
20	124	126	O	for
21	128	134	O	urinary
22	136	142	O	protein
23	144	147	O	when
24	149	158	O	XXXXXXXX
25	160	162	O	was
26	164	168	O	added
27	170	171	O	to
28	173	177	O	other
29	179	191	B-UNK	antiepileptic
30	193	197	L-UNK	drugs
31	198	198	O	,
32	200	202	O	the
33	204	207	O	more
34	209	216	O	specific
35	218	231	O	sulfosalicylic
36	233	236	O	acid
37	238	250	O	precipitation
38	252	260	O	procedure
39	262	263	O	is
40	265	275	O	recommended
41	277	278	O	to
42	280	288	O	determine
43	290	292	O	the
44	294	301	O	presence
45	303	304	O	of
46	306	310	O	urine
47	312	318	O	protein
NULL

Gadodiamide	DDI-DrugBank.d230.s0	NO_SECTION	NO_SETID	13
LABORATORY TEST FINDINGS Asymptomatic, transitory changes in serum iron have been observed.
1	0	9	O	LABORATORY
2	11	14	O	TEST
3	16	23	O	FINDINGS
4	25	36	O	Asymptomatic
5	37	37	O	,
6	39	48	O	transitory
7	50	56	O	changes
8	58	59	O	in
9	61	65	O	serum
10	67	70	O	iron
11	72	75	O	have
12	77	80	O	been
13	82	89	O	observed
NULL

Gadodiamide	DDI-DrugBank.d230.s1	NO_SECTION	NO_SETID	5
The clinical significance is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	is
5	29	35	O	unknown
NULL

Gadodiamide	DDI-DrugBank.d230.s2	NO_SECTION	NO_SETID	26
Omniscan interferes with serum calcium measurements with some colorimetric (complexometric) methods commonly used in hospitals, resulting in serum calcium concentrations lower than the true values.
1	0	7	O	XXXXXXXX
2	9	18	O	interferes
3	20	23	O	with
4	25	29	O	serum
5	31	37	O	calcium
6	39	50	O	measurements
7	52	55	O	with
8	57	60	O	some
9	62	73	O	colorimetric
10	76	89	O	complexometric
11	92	98	O	methods
12	100	107	O	commonly
13	109	112	O	used
14	114	115	O	in
15	117	125	O	hospitals
16	126	126	O	,
17	128	136	O	resulting
18	138	139	O	in
19	141	145	O	serum
20	147	153	O	calcium
21	155	168	O	concentrations
22	170	174	O	lower
23	176	179	O	than
24	181	183	O	the
25	185	188	O	true
26	190	195	O	values
NULL

Gadodiamide	DDI-DrugBank.d230.s3	NO_SECTION	NO_SETID	18
Thus, it is recommended not to use such methods for 12-24 hours after administration of Omniscan.
1	0	3	O	Thus
2	4	4	O	,
3	6	7	O	it
4	9	10	O	is
5	12	22	O	recommended
6	24	26	O	not
7	28	29	O	to
8	31	33	O	use
9	35	38	O	such
10	40	46	O	methods
11	48	50	O	for
12	52	53	O	12
13	55	56	O	24
14	58	62	O	hours
15	64	68	O	after
16	70	83	O	administration
17	85	86	O	of
18	88	95	O	XXXXXXXX
NULL

Gadodiamide	DDI-DrugBank.d230.s4	NO_SECTION	NO_SETID	13
If such measurements are necessary, the use of other methods is recommended.
1	0	1	O	If
2	3	6	O	such
3	8	19	O	measurements
4	21	23	O	are
5	25	33	O	necessary
6	34	34	O	,
7	36	38	O	the
8	40	42	O	use
9	44	45	O	of
10	47	51	O	other
11	53	59	O	methods
12	61	62	O	is
13	64	74	O	recommended
NULL

Gadodiamide	DDI-DrugBank.d230.s5	NO_SECTION	NO_SETID	10
All patients in whom this effect was observed remained asymptomatic.
1	0	2	O	All
2	4	11	O	patients
3	13	14	O	in
4	16	19	O	whom
5	21	24	O	this
6	26	31	O	effect
7	33	35	O	was
8	37	44	O	observed
9	46	53	O	remained
10	55	66	O	asymptomatic
NULL

Galsulfase	DDI-DrugBank.d58.s0	NO_SECTION	NO_SETID	8
No formal drug interaction studies have been conducted.
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	25	O	interaction
5	27	33	O	studies
6	35	38	O	have
7	40	43	O	been
8	45	53	O	conducted
NULL

Ganciclovir	DDI-DrugBank.d159.s0	NO_SECTION	NO_SETID	10
No drug interactions have been observed with the Vitrasert Implant.
1	0	1	O	No
2	3	6	O	drug
3	8	19	O	interactions
4	21	24	O	have
5	26	29	O	been
6	31	38	O	observed
7	40	43	O	with
8	45	47	O	the
9	49	57	O	XXXXXXXX
10	59	65	O	Implant
NULL

Ganciclovir	DDI-DrugBank.d159.s1	NO_SECTION	NO_SETID	15
There is limited experience with use of retinal tamponades in conjunction with the Vitrasert Implant.
1	0	4	O	There
2	6	7	O	is
3	9	15	O	limited
4	17	26	O	experience
5	28	31	O	with
6	33	35	O	use
7	37	38	O	of
8	40	46	O	retinal
9	48	57	O	tamponades
10	59	60	O	in
11	62	72	O	conjunction
12	74	77	O	with
13	79	81	O	the
14	83	91	O	XXXXXXXX
15	93	99	O	Implant
NULL

Gefitinib	DDI-DrugBank.d207.s0	NO_SECTION	NO_SETID	17
Substances that are inducers of CYP3A4 activity increase the metabolism of gefitinib and decrease its plasma concentrations.
1	0	9	O	Substances
2	11	14	O	that
3	16	18	O	are
4	20	27	O	inducers
5	29	30	O	of
6	32	37	O	CYP3A4
7	39	46	O	activity
8	48	55	O	increase
9	57	59	O	the
10	61	70	O	metabolism
11	72	73	O	of
12	75	83	O	XXXXXXXX
13	85	87	O	and
14	89	96	O	decrease
15	98	100	O	its
16	102	107	O	plasma
17	109	122	O	concentrations
NULL

Gefitinib	DDI-DrugBank.d207.s1	NO_SECTION	NO_SETID	56
In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).
1	0	1	O	In
2	3	10	O	patients
3	12	20	O	receiving
4	22	22	O	a
5	24	29	O	potent
6	31	36	O	CYP3A4
7	38	44	O	inducer
8	46	49	O	such
9	51	52	O	as
10	54	63	U-UNK	rifampicin
11	65	66	O	or
12	68	76	U-UNK	phenytoin
13	77	77	O	,
14	79	79	O	a
15	81	84	O	dose
16	86	93	O	increase
17	95	96	O	to
18	98	100	O	500
19	102	103	O	mg
20	105	109	O	daily
21	111	116	O	should
22	118	119	O	be
23	121	130	O	considered
24	132	133	O	in
25	135	137	O	the
26	139	145	O	absence
27	147	148	O	of
28	150	155	O	severe
29	157	163	O	adverse
30	165	168	O	drug
31	170	177	O	reaction
32	178	178	O	,
33	180	182	O	and
34	184	191	O	clinical
35	193	200	O	response
36	202	204	O	and
37	206	212	O	adverse
38	214	219	O	events
39	221	226	O	should
40	228	229	O	be
41	231	239	O	carefully
42	241	249	O	monitored
43	252	254	O	see
44	256	263	O	CLINICAL
45	265	276	O	PHARMACOLOGY
46	278	293	O	Pharmacokinetics
47	295	298	O	Drug
48	300	303	O	Drug
49	305	316	O	Interactions
50	318	320	O	and
51	322	327	O	DOSAGE
52	329	331	O	AND
53	333	346	O	ADMINISTRATION
54	348	353	O	Dosage
55	355	364	O	Adjustment
56	366	373	O	sections
NULL

Gefitinib	DDI-DrugBank.d207.s2	NO_SECTION	NO_SETID	22
International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.
1	0	12	O	International
2	14	23	O	Normalized
3	25	29	O	Ratio
4	32	34	O	INR
5	37	46	O	elevations
6	48	50	O	and
7	51	51	O	/
8	52	53	O	or
9	55	62	O	bleeding
10	64	69	O	events
11	71	74	O	have
12	76	79	O	been
13	81	88	O	reported
14	90	91	O	in
15	93	96	O	some
16	98	105	O	patients
17	107	112	O	taking
18	114	121	U-DYN	warfarin
19	123	127	O	while
20	129	130	O	on
21	132	137	O	XXXXXXXX
22	139	145	O	therapy
NULL

Gefitinib	DDI-DrugBank.d207.s3	NO_SECTION	NO_SETID	14
Patients taking warfarin should be monitored regularly for changes in prothrombin time or INR.
1	0	7	O	Patients
2	9	14	O	taking
3	16	23	U-UNK	warfarin
4	25	30	O	should
5	32	33	O	be
6	35	43	O	monitored
7	45	53	O	regularly
8	55	57	O	for
9	59	65	O	changes
10	67	68	O	in
11	70	80	O	prothrombin
12	82	85	O	time
13	87	88	O	or
14	90	92	O	INR
NULL

Gefitinib	DDI-DrugBank.d207.s4	NO_SECTION	NO_SETID	21
Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.
1	0	9	O	Substances
2	11	14	O	that
3	16	18	O	are
4	20	25	O	potent
5	27	36	O	inhibitors
6	38	39	O	of
7	41	46	O	CYP3A4
8	48	55	O	activity
9	58	59	O	eg
10	60	60	O	,
11	62	73	U-KIN	ketoconazole
12	75	77	O	and
13	79	90	U-KIN	itraconazole
14	93	100	O	decrease
15	102	110	O	XXXXXXXX
16	112	121	O	metabolism
17	123	125	O	and
18	127	134	O	increase
19	136	144	O	XXXXXXXX
20	146	151	O	plasma
21	153	166	O	concentrations
NULL

Gefitinib	DDI-DrugBank.d207.s5	NO_SECTION	NO_SETID	15
This increase may be clinically relevant as adverse experiences are related to dose and exposure;
1	0	3	O	This
2	5	12	O	increase
3	14	16	O	may
4	18	19	O	be
5	21	30	O	clinically
6	32	39	O	relevant
7	41	42	O	as
8	44	50	O	adverse
9	52	62	O	experiences
10	64	66	O	are
11	68	74	O	related
12	76	77	O	to
13	79	82	O	dose
14	84	86	O	and
15	88	95	O	exposure
NULL

Gefitinib	DDI-DrugBank.d207.s6	NO_SECTION	NO_SETID	12
therefore, caution should be used when administering CYP3A4 inhibitors with IRESSA.
1	0	8	O	therefore
2	9	9	O	,
3	11	17	O	caution
4	19	24	O	should
5	26	27	O	be
6	29	32	O	used
7	34	37	O	when
8	39	51	O	administering
9	53	58	O	CYP3A4
10	60	69	O	inhibitors
11	71	74	O	with
12	76	81	O	XXXXXXXX
NULL

Gefitinib	DDI-DrugBank.d207.s7	NO_SECTION	NO_SETID	30
Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.
1	0	4	O	Drugs
2	6	9	O	that
3	11	15	O	cause
4	17	27	O	significant
5	29	37	O	sustained
6	39	47	O	elevation
7	49	50	O	in
8	52	58	O	gastric
9	60	61	O	pH
10	64	72	B-KIN	histamine
11	74	75	I-KIN	H2
12	77	84	I-KIN	receptor
13	86	96	L-KIN	antagonists
14	98	101	O	such
15	103	104	O	as
16	106	115	U-KIN	ranitidine
17	117	118	O	or
18	120	129	U-KIN	cimetidine
19	132	134	O	may
20	136	141	O	reduce
21	143	148	O	plasma
22	150	163	O	concentrations
23	165	166	O	of
24	168	173	O	XXXXXXXX
25	175	177	O	and
26	179	187	O	therefore
27	189	199	O	potentially
28	201	203	O	may
29	205	210	O	reduce
30	212	219	O	efficacy
NULL

Gefitinib	DDI-DrugBank.d207.s8	NO_SECTION	NO_SETID	25
Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.
1	0	4	O	Phase
2	6	7	O	II
3	9	16	O	clinical
4	18	22	O	trial
5	24	27	O	data
6	28	28	O	,
7	30	34	O	where
8	36	41	O	XXXXXXXX
9	43	45	O	and
10	47	57	U-UNK	vinorelbine
11	59	62	O	have
12	64	67	O	been
13	69	72	O	used
14	74	86	O	concomitantly
15	87	87	O	,
16	89	96	O	indicate
17	98	101	O	that
18	103	108	O	XXXXXXXX
19	110	112	O	may
20	114	123	O	exacerbate
21	125	127	O	the
22	129	139	O	neutropenic
23	141	146	O	effect
24	148	149	O	of
25	151	161	U-DYN	vinorelbine
NULL

Gemcitabine	DDI-DrugBank.d161.s0	NO_SECTION	NO_SETID	8
No specific drug interaction studies have been conducted.
1	0	1	O	No
2	3	10	O	specific
3	12	15	O	drug
4	17	27	O	interaction
5	29	35	O	studies
6	37	40	O	have
7	42	45	O	been
8	47	55	O	conducted
NULL

Gemcitabine	DDI-DrugBank.d161.s1	NO_SECTION	NO_SETID	19
For information on the pharmacokinetics of Gemzar and cisplatin in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.
1	0	2	O	For
2	4	14	O	information
3	16	17	O	on
4	19	21	O	the
5	23	38	O	pharmacokinetics
6	40	41	O	of
7	43	48	O	XXXXXXXX
8	50	52	O	and
9	54	62	U-UNK	cisplatin
10	64	65	O	in
11	67	77	O	combination
12	78	78	O	,
13	80	82	O	see
14	84	87	O	Drug
15	89	100	O	Interactions
16	102	106	O	under
17	108	115	O	CLINICAL
18	117	128	O	PHARMACOLOGY
19	130	136	O	section
NULL

Gemfibrozil	DDI-DrugBank.d490.s5	NO_SECTION	NO_SETID	2
positive antinuclear
1	0	7	O	positive
2	9	19	O	antinuclear
NULL

Gemfibrozil	DDI-DrugBank.d490.s34	NO_SECTION	NO_SETID	3
bone marrow hypoplasia
1	0	3	O	bone
2	5	10	O	marrow
3	12	21	O	hypoplasia
NULL

Gemfibrozil	DDI-DrugBank.d490.s49	NO_SECTION	NO_SETID	2
exfoliative dermatitis
1	0	10	O	exfoliative
2	12	21	O	dermatitis
NULL

Gemifloxacin	DDI-DrugBank.d347.s0	NO_SECTION	NO_SETID	29
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.
1	0	13	O	Administration
2	15	16	O	of
3	18	23	O	repeat
4	25	29	O	doses
5	31	32	O	of
6	34	40	O	XXXXXXXX
7	42	44	O	had
8	46	47	O	no
9	49	54	O	effect
10	56	57	O	on
11	59	61	O	the
12	63	68	O	repeat
13	70	73	O	dose
14	75	90	O	pharmacokinetics
15	92	93	O	of
16	95	106	U-UNK	theophylline
17	107	107	O	,
18	109	115	U-UNK	digoxin
19	117	118	O	or
20	120	121	O	an
21	123	138	U-UNK	ethinylestradiol
22	139	139	O	/
23	140	153	O	levonorgestrol
24	155	158	O	oral
25	160	172	B-UNK	contraceptive
26	174	180	L-UNK	product
27	182	183	O	in
28	185	191	O	healthy
29	193	200	O	subjects
NULL

Gemifloxacin	DDI-DrugBank.d347.s1	NO_SECTION	NO_SETID	36
Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	36	O	XXXXXXXX
5	38	40	O	and
6	42	48	B-KIN	calcium
7	50	58	L-KIN	carbonate
8	59	59	O	,
9	61	70	U-KIN	cimetidine
10	71	71	O	,
11	73	82	U-KIN	omeprazole
12	83	83	O	,
13	85	86	O	or
14	88	89	O	an
15	91	98	U-KIN	estrogen
16	99	99	O	/
17	100	111	U-KIN	progesterone
18	113	116	O	oral
19	118	130	U-KIN	contraceptive
20	132	139	O	produced
21	141	145	O	minor
22	147	153	O	changes
23	155	156	O	in
24	158	160	O	the
25	162	177	O	pharmacokinetics
26	179	180	O	of
27	182	193	U-UNK	gemifloxacin
28	194	194	O	,
29	196	200	O	which
30	202	205	O	were
31	207	216	O	considered
32	218	219	O	to
33	221	222	O	be
34	224	230	O	without
35	232	239	O	clinical
36	241	252	O	significance
NULL

Gemifloxacin	DDI-DrugBank.d347.s2	NO_SECTION	NO_SETID	16
Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	36	O	XXXXXXXX
5	38	41	O	with
6	43	52	U-KIN	probenecid
7	54	61	O	resulted
8	63	64	O	in
9	66	66	O	a
10	68	70	O	45%
11	72	79	O	increase
12	81	82	O	in
13	84	91	O	systemic
14	93	100	O	exposure
15	102	103	O	to
16	105	116	U-UNK	gemifloxacin
NULL

Gemifloxacin	DDI-DrugBank.d347.s3	NO_SECTION	NO_SETID	18
FACTIVE had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable warfarin therapy.
1	0	6	O	XXXXXXXX
2	8	10	O	had
3	12	13	O	no
4	15	25	O	significant
5	27	32	O	effect
6	34	35	O	on
7	37	39	O	the
8	41	53	O	anticoagulant
9	55	60	O	effect
10	62	63	O	of
11	65	72	U-UNK	warfarin
12	74	75	O	in
13	77	83	O	healthy
14	85	92	O	subjects
15	94	95	O	on
16	97	102	O	stable
17	104	111	U-UNK	warfarin
18	113	119	O	therapy
NULL

Gemifloxacin	DDI-DrugBank.d347.s4	NO_SECTION	NO_SETID	45
However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	because
4	17	20	O	some
5	22	31	U-UNK	quinolones
6	33	36	O	have
7	38	41	O	been
8	43	50	O	reported
9	52	53	O	to
10	55	61	O	enhance
11	63	65	O	the
12	67	79	O	anticoagulant
13	81	87	O	effects
14	89	90	O	of
15	92	99	U-UNK	warfarin
16	101	102	O	or
17	104	106	O	its
18	108	118	O	derivatives
19	120	121	O	in
20	123	130	O	patients
21	131	131	O	,
22	133	135	O	the
23	137	147	O	prothrombin
24	149	152	O	time
25	154	155	O	or
26	157	161	O	other
27	163	170	O	suitable
28	172	182	O	coagulation
29	184	187	O	test
30	189	194	O	should
31	196	197	O	be
32	199	205	O	closely
33	207	215	O	monitored
34	217	218	O	if
35	220	220	O	a
36	222	230	B-UNK	quinolone
37	232	244	L-UNK	antimicrobial
38	246	247	O	is
39	249	260	O	administered
40	262	274	O	concomitantly
41	276	279	O	with
42	281	288	U-UNK	warfarin
43	290	291	O	or
44	293	295	O	its
45	297	307	O	derivatives
NULL

Gemifloxacin	DDI-DrugBank.d347.s5	NO_SECTION	NO_SETID	9
Quinolones form chelates with alkaline earth and transition metals.
1	0	9	U-UNK	Quinolones
2	11	14	O	form
3	16	23	O	chelates
4	25	28	O	with
5	30	37	O	alkaline
6	39	43	O	earth
7	45	47	O	and
8	49	58	O	transition
9	60	65	O	metals
NULL

Gemifloxacin	DDI-DrugBank.d347.s6	NO_SECTION	NO_SETID	19
The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.
1	0	2	O	The
2	4	13	O	absorption
3	15	16	O	of
4	18	21	O	oral
5	23	34	O	XXXXXXXX
6	36	37	O	is
7	39	51	O	significantly
8	53	59	O	reduced
9	61	62	O	by
10	64	66	O	the
11	68	78	O	concomitant
12	80	93	O	administration
13	95	96	O	of
14	98	99	O	an
15	101	107	U-UNK	antacid
16	109	118	O	containing
17	120	127	U-KIN	aluminum
18	129	131	O	and
19	133	141	U-KIN	magnesium
NULL

Gemifloxacin	DDI-DrugBank.d347.s7	NO_SECTION	NO_SETID	50
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
1	0	8	U-DYN	Magnesium
2	11	13	O	and
3	14	14	O	/
4	15	16	O	or
5	18	25	U-DYN	aluminum
6	27	36	O	containing
7	38	45	U-UNK	antacids
8	46	46	O	,
9	48	55	O	products
10	57	66	O	containing
11	68	74	B-DYN	ferrous
12	76	82	L-DYN	sulfate
13	85	88	U-DYN	iron
14	90	90	O	,
15	92	103	B-DYN	multivitamin
16	105	116	L-DYN	preparations
17	118	127	O	containing
18	129	132	U-DYN	zinc
19	134	135	O	or
20	137	141	O	other
21	143	147	O	metal
22	149	155	O	cations
23	156	156	O	,
24	158	159	O	or
25	161	165	O	Videx
26	168	177	U-DYN	didanosine
27	180	187	O	chewable
28	188	188	O	/
29	189	196	O	buffered
30	198	204	O	tablets
31	206	207	O	or
32	209	211	O	the
33	213	221	O	pediatric
34	223	228	O	powder
35	230	232	O	for
36	234	237	O	oral
37	239	246	O	solution
38	248	253	O	should
39	255	257	O	not
40	259	260	O	be
41	262	266	O	taken
42	268	273	O	within
43	275	275	O	3
44	277	281	O	hours
45	283	288	O	before
46	290	291	O	or
47	293	293	O	2
48	295	299	O	hours
49	301	305	O	after
50	307	313	U-DYN	XXXXXXXX
NULL

Gemifloxacin	DDI-DrugBank.d347.s8	NO_SECTION	NO_SETID	10
Sucralfate should not be taken within 2 hours of FACTIVE.
1	0	9	U-DYN	Sucralfate
2	11	16	O	should
3	18	20	O	not
4	22	23	O	be
5	25	29	O	taken
6	31	36	O	within
7	38	38	O	2
8	40	44	O	hours
9	46	47	O	of
10	49	55	O	XXXXXXXX
NULL

Gemtuzumab ozogamicin	DDI-DrugBank.d403.s0	NO_SECTION	NO_SETID	11
There have been no formal drug-interaction studies performed with Mylotarg.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	17	O	no
5	19	24	O	formal
6	26	29	O	drug
7	31	41	O	interaction
8	43	49	O	studies
9	51	59	O	performed
10	61	64	O	with
11	66	73	O	XXXXXXXX
NULL

Gemtuzumab ozogamicin	DDI-DrugBank.d403.s1	NO_SECTION	NO_SETID	18
The potential for drug-drug interaction with drugs affected by cytochrome P450 enzymes may not be ruled out.
1	0	2	O	The
2	4	12	O	potential
3	14	16	O	for
4	18	21	O	drug
5	23	26	O	drug
6	28	38	O	interaction
7	40	43	O	with
8	45	49	O	drugs
9	51	58	O	affected
10	60	61	O	by
11	63	72	O	cytochrome
12	74	77	O	P450
13	79	85	O	enzymes
14	87	89	O	may
15	91	93	O	not
16	95	96	O	be
17	98	102	O	ruled
18	104	106	O	out
NULL

Gemtuzumab ozogamicin	DDI-DrugBank.d403.s2	NO_SECTION	NO_SETID	3
Laboratory Test Interactions
1	0	9	O	Laboratory
2	11	14	O	Test
3	16	27	O	Interactions
NULL

Gemtuzumab ozogamicin	DDI-DrugBank.d403.s3	NO_SECTION	NO_SETID	11
Mylotarg is not known to interfere with any routine diagnostic tests.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	14	O	not
4	16	20	O	known
5	22	23	O	to
6	25	33	O	interfere
7	35	38	O	with
8	40	42	O	any
9	44	50	O	routine
10	52	61	O	diagnostic
11	63	67	O	tests
NULL

Glatiramer Acetate	DDI-DrugBank.d28.s0	NO_SECTION	NO_SETID	11
Interactions between COPAXONE  and other drugs have not been fully evaluated.
1	0	11	O	Interactions
2	13	19	O	between
3	21	28	O	XXXXXXXX
4	31	33	O	and
5	35	39	O	other
6	41	45	O	drugs
7	47	50	O	have
8	52	54	O	not
9	56	59	O	been
10	61	65	O	fully
11	67	75	O	evaluated
NULL

Glatiramer Acetate	DDI-DrugBank.d28.s1	NO_SECTION	NO_SETID	31
Results from existing clinical trials suggest no significant interactions between COPAXONE  and other therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to 28 days.
1	0	6	O	Results
2	8	11	O	from
3	13	20	O	existing
4	22	29	O	clinical
5	31	36	O	trials
6	38	44	O	suggest
7	46	47	O	no
8	49	59	O	significant
9	61	72	O	interactions
10	74	80	O	between
11	82	89	O	XXXXXXXX
12	92	94	O	and
13	96	100	O	other
14	102	110	O	therapies
15	112	119	O	commonly
16	121	124	O	used
17	126	127	O	in
18	129	130	O	MS
19	132	139	O	patients
20	140	140	O	,
21	142	150	O	including
22	152	154	O	the
23	156	165	O	concurrent
24	167	169	O	use
25	171	172	O	of
26	174	188	U-UNK	corticosteroids
27	190	192	O	for
28	194	195	O	up
29	197	198	O	to
30	200	201	O	28
31	203	206	O	days
NULL

Glatiramer Acetate	DDI-DrugBank.d28.s2	NO_SECTION	NO_SETID	11
COPAXONE  has not been formally evaluated in combination with Interferon beta.
1	0	7	O	XXXXXXXX
2	10	12	O	has
3	14	16	O	not
4	18	21	O	been
5	23	30	O	formally
6	32	40	O	evaluated
7	42	43	O	in
8	45	55	O	combination
9	57	60	O	with
10	62	71	B-UNK	Interferon
11	73	76	L-UNK	beta
NULL

Glatiramer Acetate	DDI-DrugBank.d28.s3	NO_SECTION	NO_SETID	28
However, 10 patients who switched from therapy with Interferon beta to COPAXONE  did not report any serious and unexpected adverse reactions thought to be related to treatment.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	10
4	12	19	O	patients
5	21	23	O	who
6	25	32	O	switched
7	34	37	O	from
8	39	45	O	therapy
9	47	50	O	with
10	52	61	B-UNK	Interferon
11	63	66	L-UNK	beta
12	68	69	O	to
13	71	78	O	XXXXXXXX
14	81	83	O	did
15	85	87	O	not
16	89	94	O	report
17	96	98	O	any
18	100	106	O	serious
19	108	110	O	and
20	112	121	O	unexpected
21	123	129	O	adverse
22	131	139	O	reactions
23	141	147	O	thought
24	149	150	O	to
25	152	153	O	be
26	155	161	O	related
27	163	164	O	to
28	166	174	O	treatment
NULL

Glibenclamide	DDI-DrugBank.d178.s0	NO_SECTION	NO_SETID	44
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
1	0	2	O	The
2	4	15	O	hypoglycemic
3	17	22	O	action
4	24	25	O	of
5	27	39	U-UNK	sulfonylureas
6	41	43	O	may
7	45	46	O	be
8	48	58	O	potentiated
9	60	61	O	by
10	63	69	O	certain
11	71	75	O	drugs
12	77	85	O	including
13	87	98	B-UNK	nonsteroidal
14	100	103	I-UNK	anti
15	105	116	I-UNK	inflammatory
16	118	123	L-UNK	agents
17	125	127	O	and
18	129	133	O	other
19	135	139	O	drugs
20	141	144	O	that
21	146	148	O	are
22	150	155	O	highly
23	157	163	O	protein
24	165	169	O	bound
25	170	170	O	,
26	172	182	U-UNK	salicylates
27	183	183	O	,
28	185	196	U-UNK	sulfonamides
29	197	197	O	,
30	199	213	U-UNK	chloramphenicol
31	214	214	O	,
32	216	225	U-UNK	probenecid
33	226	226	O	,
34	228	236	U-UNK	coumarins
35	237	237	O	,
36	239	247	B-UNK	monoamine
37	249	255	I-UNK	oxidase
38	257	266	L-UNK	inhibitors
39	267	267	O	,
40	269	271	O	and
41	273	276	B-UNK	beta
42	278	287	I-UNK	adrenergic
43	289	296	I-UNK	blocking
44	298	303	L-UNK	agents
NULL

Glibenclamide	DDI-DrugBank.d178.s1	NO_SECTION	NO_SETID	19
When such drugs are administered to a patient receiving MICRONASE, the patient should be observed closely for hypoglycemia.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	31	O	administered
6	33	34	O	to
7	36	36	O	a
8	38	44	O	patient
9	46	54	O	receiving
10	56	64	O	XXXXXXXX
11	65	65	O	,
12	67	69	O	the
13	71	77	O	patient
14	79	84	O	should
15	86	87	O	be
16	89	96	O	observed
17	98	104	O	closely
18	106	108	O	for
19	110	121	O	hypoglycemia
NULL

Glibenclamide	DDI-DrugBank.d178.s2	NO_SECTION	NO_SETID	21
When such drugs are withdrawn from a patient receiving MICRONASE, the patient should be observed closely for loss of control.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	28	O	withdrawn
6	30	33	O	from
7	35	35	O	a
8	37	43	O	patient
9	45	53	O	receiving
10	55	63	O	XXXXXXXX
11	64	64	O	,
12	66	68	O	the
13	70	76	O	patient
14	78	83	O	should
15	85	86	O	be
16	88	95	O	observed
17	97	103	O	closely
18	105	107	O	for
19	109	112	O	loss
20	114	115	O	of
21	117	123	O	control
NULL

Glibenclamide	DDI-DrugBank.d178.s3	NO_SECTION	NO_SETID	13
Certain drugs tend to produce hyperglycemia and may lead to loss of control.
1	0	6	O	Certain
2	8	12	O	drugs
3	14	17	O	tend
4	19	20	O	to
5	22	28	O	produce
6	30	42	O	hyperglycemia
7	44	46	O	and
8	48	50	O	may
9	52	55	O	lead
10	57	58	O	to
11	60	63	O	loss
12	65	66	O	of
13	68	74	O	control
NULL

Glibenclamide	DDI-DrugBank.d178.s4	NO_SECTION	NO_SETID	37
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.
1	0	4	O	These
2	6	10	O	drugs
3	12	18	O	include
4	20	22	O	the
5	24	32	U-UNK	thiazides
6	34	36	O	and
7	38	42	O	other
8	44	52	U-UNK	diuretics
9	53	53	O	,
10	55	69	U-UNK	corticosteroids
11	70	70	O	,
12	72	74	O	phe
13	76	86	O	nothiazines
14	87	87	O	,
15	89	95	B-UNK	thyroid
16	97	104	L-UNK	products
17	105	105	O	,
18	107	115	U-UNK	estrogens
19	116	116	O	,
20	118	121	O	oral
21	123	136	U-UNK	contraceptives
22	137	137	O	,
23	139	147	U-UNK	phenytoin
24	148	148	O	,
25	150	158	B-UNK	nicotinic
26	160	163	L-UNK	acid
27	164	164	O	,
28	166	178	O	sympathomimet
29	180	182	O	ics
30	183	183	O	,
31	185	191	B-UNK	calcium
32	193	199	I-UNK	channel
33	201	208	I-UNK	blocking
34	210	214	L-UNK	drugs
35	215	215	O	,
36	217	219	O	and
37	221	229	U-UNK	isoniazid
NULL

Glibenclamide	DDI-DrugBank.d178.s5	NO_SECTION	NO_SETID	21
When such drugs are administered to a patient receiving MICRONASE, the patient should be closely observed for loss of control.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	31	O	administered
6	33	34	O	to
7	36	36	O	a
8	38	44	O	patient
9	46	54	O	receiving
10	56	64	O	XXXXXXXX
11	65	65	O	,
12	67	69	O	the
13	71	77	O	patient
14	79	84	O	should
15	86	87	O	be
16	89	95	O	closely
17	97	104	O	observed
18	106	108	O	for
19	110	113	O	loss
20	115	116	O	of
21	118	124	O	control
NULL

Glibenclamide	DDI-DrugBank.d178.s6	NO_SECTION	NO_SETID	19
When such drugs are withdrawn from a patient receiving MICRONASE, the patient should be observed closely for hypoglycemia.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	28	O	withdrawn
6	30	33	O	from
7	35	35	O	a
8	37	43	O	patient
9	45	53	O	receiving
10	55	63	O	XXXXXXXX
11	64	64	O	,
12	66	68	O	the
13	70	76	O	patient
14	78	83	O	should
15	85	86	O	be
16	88	95	O	observed
17	97	103	O	closely
18	105	107	O	for
19	109	120	O	hypoglycemia
NULL

Glibenclamide	DDI-DrugBank.d178.s7	NO_SECTION	NO_SETID	26
A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.
1	0	0	O	A
2	2	9	O	possible
3	11	21	O	interaction
4	23	29	O	between
5	31	39	U-UNK	glyburide
6	41	43	O	and
7	45	57	U-UNK	ciprofloxacin
8	58	58	O	,
9	60	60	O	a
10	62	76	B-UNK	fluoroquinolone
11	78	87	L-UNK	antibiotic
12	88	88	O	,
13	90	92	O	has
14	94	97	O	been
15	99	106	O	reported
16	107	107	O	,
17	109	117	O	resulting
18	119	120	O	in
19	122	122	O	a
20	124	135	O	potentiation
21	137	138	O	of
22	140	142	O	the
23	144	155	O	hypoglycemic
24	157	162	O	action
25	164	165	O	of
26	167	175	U-UNK	glyburide
NULL

Glibenclamide	DDI-DrugBank.d178.s8	NO_SECTION	NO_SETID	8
The mechanism for this interaction is not known.
1	0	2	O	The
2	4	12	O	mechanism
3	14	16	O	for
4	18	21	O	this
5	23	33	O	interaction
6	35	36	O	is
7	38	40	O	not
8	42	46	O	known
NULL

Glibenclamide	DDI-DrugBank.d178.s9	NO_SECTION	NO_SETID	17
A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
1	0	0	O	A
2	2	10	O	potential
3	12	22	O	interaction
4	24	30	O	between
5	32	35	O	oral
6	37	46	U-UNK	miconazole
7	48	50	O	and
8	52	55	O	oral
9	57	68	B-UNK	hypoglycemic
10	70	75	L-UNK	agents
11	77	83	O	leading
12	85	86	O	to
13	88	93	O	severe
14	95	106	O	hypoglycemia
15	108	110	O	has
16	112	115	O	been
17	117	124	O	reported
NULL

Glibenclamide	DDI-DrugBank.d178.s10	NO_SECTION	NO_SETID	18
Whether this interaction also occurs with the intravenous, topical or vaginal preparations of miconazole is not known.
1	0	6	O	Whether
2	8	11	O	this
3	13	23	O	interaction
4	25	28	O	also
5	30	35	O	occurs
6	37	40	O	with
7	42	44	O	the
8	46	56	O	intravenous
9	57	57	O	,
10	59	65	O	topical
11	67	68	O	or
12	70	76	O	vaginal
13	78	89	O	preparations
14	91	92	O	of
15	94	103	U-UNK	miconazole
16	105	106	O	is
17	108	110	O	not
18	112	116	O	known
NULL

Glibenclamide	DDI-DrugBank.d178.s11	NO_SECTION	NO_SETID	25
Metformin: In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and Cmax were observed, but were highly variable.
1	0	8	U-UNK	Metformin
2	9	9	O	:
3	11	12	O	In
4	14	14	O	a
5	16	21	O	single
6	23	26	O	dose
7	28	38	O	interaction
8	40	44	O	study
9	46	47	O	in
10	49	53	O	NIDDM
11	55	62	O	subjects
12	63	63	O	,
13	65	73	O	decreases
14	75	76	O	in
15	78	86	U-UNK	glyburide
16	88	90	O	AUC
17	92	94	O	and
18	96	99	O	Cmax
19	101	104	O	were
20	106	113	O	observed
21	114	114	O	,
22	116	118	O	but
23	120	123	O	were
24	125	130	O	highly
25	132	139	O	variable
NULL

Glibenclamide	DDI-DrugBank.d178.s12	NO_SECTION	NO_SETID	29
The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmaco-dynamic effects, makes the clinical significance of this interaction uncertain.
1	0	2	O	The
2	4	9	O	single
3	11	14	O	dose
4	16	21	O	nature
5	23	24	O	of
6	26	29	O	this
7	31	35	O	study
8	37	39	O	and
9	41	43	O	the
10	45	48	O	lack
11	50	51	O	of
12	53	63	O	correlation
13	65	71	O	between
14	73	81	U-UNK	glyburide
15	83	87	O	blood
16	89	94	O	levels
17	96	98	O	and
18	100	107	O	pharmaco
19	109	115	O	dynamic
20	117	123	O	effects
21	124	124	O	,
22	126	130	O	makes
23	132	134	O	the
24	136	143	O	clinical
25	145	156	O	significance
26	158	159	O	of
27	161	164	O	this
28	166	176	O	interaction
29	178	186	O	uncertain
NULL

Glibenclamide	DDI-DrugBank.d178.s13	NO_SECTION	NO_SETID	19
Coadministration of gly-buride and metformin did not result in any changes in either metformin pharmacokinetics or pharmaco-dynamics.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	22	O	gly
4	24	29	O	buride
5	31	33	O	and
6	35	43	U-UNK	metformin
7	45	47	O	did
8	49	51	O	not
9	53	58	O	result
10	60	61	O	in
11	63	65	O	any
12	67	73	O	changes
13	75	76	O	in
14	78	83	O	either
15	85	93	U-UNK	metformin
16	95	110	O	pharmacokinetics
17	112	113	O	or
18	115	122	O	pharmaco
19	124	131	O	dynamics
NULL

Glimepiride	DDI-DrugBank.d521.s0	NO_SECTION	NO_SETID	15
Many other medicines may increase or decrease the effects of glimepiride or affect your condition.
1	0	3	O	Many
2	5	9	O	other
3	11	19	O	medicines
4	21	23	O	may
5	25	32	O	increase
6	34	35	O	or
7	37	44	O	decrease
8	46	48	O	the
9	50	56	O	effects
10	58	59	O	of
11	61	71	O	XXXXXXXX
12	73	74	O	or
13	76	81	O	affect
14	83	86	O	your
15	88	96	O	condition
NULL

Glimepiride	DDI-DrugBank.d521.s1	NO_SECTION	NO_SETID	46
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
1	0	5	O	Before
2	7	12	O	taking
3	14	24	U-DYN	glimepiride
4	25	25	O	,
5	27	30	O	tell
6	32	35	O	your
7	37	42	O	doctor
8	44	45	O	if
9	47	49	O	you
10	51	53	O	are
11	55	60	O	taking
12	62	64	O	any
13	66	67	O	of
14	69	71	O	the
15	73	81	O	following
16	83	91	O	medicines
17	92	92	O	:
18	96	102	O	aspirin
19	104	105	O	or
20	107	113	O	another
21	115	124	U-UNK	salicylate
22	126	129	O	such
23	131	132	O	as
24	134	142	B-UNK	magnesium
25	143	143	I-UNK	/
26	144	150	I-UNK	choline
27	152	161	L-UNK	salicylate
28	164	172	O	Trilisate
29	174	174	O	,
30	176	184	U-UNK	salsalate
31	187	194	O	Disalcid
32	195	195	O	,
33	197	202	O	others
34	204	204	O	,
35	206	212	B-UNK	choline
36	214	223	L-UNK	salicylate
37	226	234	U-UNK	Arthropan
38	236	236	O	,
39	238	246	B-UNK	magnesium
40	248	257	L-UNK	salicylate
41	260	264	O	Magan
42	266	266	O	,
43	268	269	O	or
44	271	277	B-UNK	bismuth
45	279	291	L-UNK	subsalicylate
46	294	305	O	XXXXXXXX
NULL

Glimepiride	DDI-DrugBank.d521.s2	NO_SECTION	NO_SETID	49
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
1	2	2	O	a
2	4	15	B-UNK	nonsteroidal
3	17	20	I-UNK	anti
4	22	33	I-UNK	inflammatory
5	35	38	L-UNK	drug
6	41	45	U-UNK	NSAID
7	48	51	O	such
8	53	54	O	as
9	56	64	U-UNK	ibuprofen
10	67	72	O	Motrin
11	73	73	O	,
12	75	79	O	Advil
13	80	80	O	,
14	82	87	O	Nuprin
15	88	88	O	,
16	90	95	O	others
17	97	97	O	,
18	99	108	U-UNK	ketoprofen
19	111	116	O	Orudis
20	117	117	O	,
21	119	124	O	Orudis
22	126	127	O	KT
23	128	128	O	,
24	130	136	O	Oruvail
25	138	138	O	,
26	140	149	U-UNK	diclofenac
27	152	159	O	Voltaren
28	160	160	O	,
29	162	169	O	Cataflam
30	171	171	O	,
31	173	180	U-UNK	etodolac
32	183	188	O	Lodine
33	190	190	O	,
34	192	203	U-UNK	indomethacin
35	206	212	O	Indocin
36	214	214	O	,
37	216	225	U-UNK	nabumetone
38	228	234	O	Relafen
39	236	236	O	,
40	238	246	U-UNK	oxaprozin
41	249	254	O	Daypro
42	256	256	O	,
43	258	260	O	and
44	262	269	U-UNK	naproxen
45	272	278	O	Anaprox
46	279	279	O	,
47	281	288	O	Naprosyn
48	289	289	O	,
49	291	295	O	XXXXXXXX
NULL

Glimepiride	DDI-DrugBank.d521.s3	NO_SECTION	NO_SETID	18
- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);
1	2	2	O	a
2	4	8	O	sulfa
3	10	14	O	based
4	16	19	O	drug
5	21	24	O	such
6	26	27	O	as
7	29	44	U-UNK	sulfamethoxazole
8	46	57	U-UNK	trimethoprim
9	60	66	O	Bactrim
10	67	67	O	,
11	69	74	O	Septra
12	76	76	O	,
13	78	90	U-UNK	sulfisoxazole
14	93	101	O	Gantrisin
15	103	103	O	,
16	105	106	O	or
17	108	120	U-UNK	sulfasalazine
18	123	132	O	XXXXXXXX
NULL

Glimepiride	DDI-DrugBank.d521.s4	NO_SECTION	NO_SETID	16
- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);
1	2	2	O	a
2	4	12	B-UNK	monoamine
3	14	20	I-UNK	oxidase
4	22	30	L-UNK	inhibitor
5	33	36	U-UNK	MAOI
6	39	42	O	such
7	44	45	O	as
8	47	59	U-UNK	isocarboxazid
9	62	68	O	Marplan
10	70	70	O	,
11	72	86	U-UNK	tranylcypromine
12	89	95	O	Parnate
13	97	97	O	,
14	99	100	O	or
15	102	111	U-UNK	phenelzine
16	114	119	O	XXXXXXXX
NULL

Glimepiride	DDI-DrugBank.d521.s5	NO_SECTION	NO_SETID	19
- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;
1	2	2	O	a
2	4	7	B-UNK	beta
3	9	15	L-UNK	blocker
4	17	20	O	such
5	22	23	O	as
6	25	35	U-UNK	propranolol
7	38	44	O	Inderal
8	46	46	O	,
9	48	55	U-UNK	atenolol
10	58	65	O	Tenormin
11	67	67	O	,
12	69	78	U-UNK	acebutolol
13	81	87	O	Sectral
14	89	89	O	,
15	91	100	U-UNK	metoprolol
16	103	111	O	XXXXXXXX
17	113	113	O	,
18	115	117	O	and
19	119	124	O	others
NULL

Glimepiride	DDI-DrugBank.d521.s6	NO_SECTION	NO_SETID	17
- a diuretic (water pill) such as hydrochlorothiazide (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;
1	2	2	O	a
2	4	11	U-UNK	diuretic
3	14	18	O	water
4	20	23	O	pill
5	26	29	O	such
6	31	32	O	as
7	34	52	U-UNK	hydrochlorothiazide
8	55	58	U-UNK	HCTZ
9	59	59	O	,
10	61	65	O	Hydro
11	66	71	O	XXXXXXXX
12	73	73	O	,
13	75	88	U-UNK	chlorothiazide
14	91	96	O	XXXXXXXX
15	98	98	O	,
16	100	102	O	and
17	104	109	O	others
NULL

Glimepiride	DDI-DrugBank.d521.s7	NO_SECTION	NO_SETID	26
- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;
1	2	2	O	a
2	4	10	B-UNK	steroid
3	12	19	L-UNK	medicine
4	21	24	O	such
5	26	27	O	as
6	29	38	U-UNK	prednisone
7	41	49	O	Deltasone
8	50	50	O	,
9	52	58	O	Orasone
10	59	59	O	,
11	61	66	O	others
12	68	68	O	,
13	70	87	U-UNK	methylprednisolone
14	90	95	O	Medrol
15	96	96	O	,
16	98	103	O	others
17	105	105	O	,
18	107	118	U-UNK	prednisolone
19	121	127	O	Prelone
20	128	128	O	,
21	130	138	O	XXXXXXXX
22	139	139	O	,
23	141	146	O	others
24	148	148	O	,
25	150	152	O	and
26	154	159	O	others
NULL

Glimepiride	DDI-DrugBank.d521.s8	NO_SECTION	NO_SETID	20
- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;
1	2	2	O	a
2	4	16	U-UNK	phenothiazine
3	18	21	O	such
4	23	24	O	as
5	26	39	U-UNK	chlorpromazine
6	42	50	O	Thorazine
7	52	52	O	,
8	54	65	U-UNK	fluphenazine
9	68	75	O	Prolixin
10	76	76	O	,
11	78	85	O	Permitil
12	87	87	O	,
13	89	104	U-UNK	prochlorperazine
14	107	115	O	Compazine
15	117	117	O	,
16	119	130	U-UNK	promethazine
17	133	141	O	XXXXXXXX
18	143	143	O	,
19	145	147	O	and
20	149	154	O	others
NULL

Glimepiride	DDI-DrugBank.d521.s9	NO_SECTION	NO_SETID	2
- phenytoin (Dilantin);
1	2	10	U-UNK	phenytoin
2	13	20	O	XXXXXXXX
NULL

Glimepiride	DDI-DrugBank.d521.s10	NO_SECTION	NO_SETID	2
- isoniazid (Nydrazid);
1	2	10	U-UNK	isoniazid
2	13	20	O	XXXXXXXX
NULL

Glimepiride	DDI-DrugBank.d521.s11	NO_SECTION	NO_SETID	4
- rifampin (Rifadin, Rifamate);
1	2	9	U-UNK	rifampin
2	12	18	O	Rifadin
3	19	19	O	,
4	21	28	O	XXXXXXXX
NULL

Glimepiride	DDI-DrugBank.d521.s12	NO_SECTION	NO_SETID	14
or - over-the-counter cough, cold, allergy, or weight loss medications.
1	0	1	O	or
2	5	8	O	over
3	10	12	O	the
4	14	20	O	counter
5	22	26	O	cough
6	27	27	O	,
7	29	32	O	cold
8	33	33	O	,
9	35	41	O	allergy
10	42	42	O	,
11	44	45	O	or
12	47	52	O	weight
13	54	57	O	loss
14	59	69	O	medications
NULL

Glimepiride	DDI-DrugBank.d521.s13	NO_SECTION	NO_SETID	19
You may require a dosage adjustment or special monitoring if you are taking any of the medicines listed above.
1	0	2	O	You
2	4	6	O	may
3	8	14	O	require
4	16	16	O	a
5	18	23	O	dosage
6	25	34	O	adjustment
7	36	37	O	or
8	39	45	O	special
9	47	56	O	monitoring
10	58	59	O	if
11	61	63	O	you
12	65	67	O	are
13	69	74	O	taking
14	76	78	O	any
15	80	81	O	of
16	83	85	O	the
17	87	95	O	medicines
18	97	102	O	listed
19	104	108	O	above
NULL

Glimepiride	DDI-DrugBank.d521.s14	NO_SECTION	NO_SETID	15
Drugs other than those listed here may also interact with glimepiride or affect your condition.
1	0	4	O	Drugs
2	6	10	O	other
3	12	15	O	than
4	17	21	O	those
5	23	28	O	listed
6	30	33	O	here
7	35	37	O	may
8	39	42	O	also
9	44	51	O	interact
10	53	56	O	with
11	58	68	O	XXXXXXXX
12	70	71	O	or
13	73	78	O	affect
14	80	83	O	your
15	85	93	O	condition
NULL

Glimepiride	DDI-DrugBank.d521.s15	NO_SECTION	NO_SETID	19
Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including herbal products.
1	0	3	O	Talk
2	5	6	O	to
3	8	11	O	your
4	13	18	O	doctor
5	20	22	O	and
6	24	33	O	pharmacist
7	35	40	O	before
8	42	47	O	taking
9	49	51	O	any
10	53	64	O	prescription
11	66	67	O	or
12	69	72	O	over
13	74	76	O	the
14	78	84	O	counter
15	86	94	O	medicines
16	95	95	O	,
17	97	105	O	including
18	107	112	O	herbal
19	114	121	O	products
NULL

Glipizide	DDI-DrugBank.d225.s0	NO_SECTION	NO_SETID	52
Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
1	0	8	O	Immediate
2	10	12	O	and
3	14	21	O	Extended
4	23	29	O	Release
5	31	37	O	Tablets
6	39	41	O	The
7	43	54	O	hypoglycemic
8	56	61	O	action
9	63	64	O	of
10	66	78	U-UNK	sulfonylureas
11	80	82	O	may
12	84	85	O	be
13	87	97	O	potentiated
14	99	100	O	by
15	102	108	O	certain
16	110	114	O	drugs
17	116	124	O	including
18	126	137	B-UNK	nonsteroidal
19	139	142	I-UNK	anti
20	144	155	I-UNK	inflammatory
21	157	162	L-UNK	agents
22	163	163	O	,
23	165	168	O	some
24	170	175	U-UNK	azoles
25	177	179	O	and
26	181	185	O	other
27	187	191	O	drugs
28	193	196	O	that
29	198	200	O	are
30	202	207	O	highly
31	209	215	O	protein
32	217	221	O	bound
33	222	222	O	,
34	224	234	U-UNK	salicylates
35	235	235	O	,
36	237	248	U-UNK	sulfonamides
37	249	249	O	,
38	251	265	U-UNK	chloramphenicol
39	266	266	O	,
40	268	277	U-UNK	probenecid
41	278	278	O	,
42	280	288	U-UNK	coumarins
43	289	289	O	,
44	291	299	B-UNK	monoamine
45	301	307	I-UNK	oxidase
46	309	318	L-UNK	inhibitors
47	319	319	O	,
48	321	323	O	and
49	325	328	B-UNK	beta
50	330	339	I-UNK	adrenergic
51	341	348	I-UNK	blocking
52	350	355	L-UNK	agents
NULL

Glipizide	DDI-DrugBank.d225.s1	NO_SECTION	NO_SETID	19
When such drugs are administered to a patient receiving glipizide, the patient should be observed closely for hypoglycemia.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	31	O	administered
6	33	34	O	to
7	36	36	O	a
8	38	44	O	patient
9	46	54	O	receiving
10	56	64	O	XXXXXXXX
11	65	65	O	,
12	67	69	O	the
13	71	77	O	patient
14	79	84	O	should
15	86	87	O	be
16	89	96	O	observed
17	98	104	O	closely
18	106	108	O	for
19	110	121	O	hypoglycemia
NULL

Glipizide	DDI-DrugBank.d225.s2	NO_SECTION	NO_SETID	21
When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for loss of control.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	28	O	withdrawn
6	30	33	O	from
7	35	35	O	a
8	37	43	O	patient
9	45	53	O	receiving
10	55	63	O	XXXXXXXX
11	64	64	O	,
12	66	68	O	the
13	70	76	O	patient
14	78	83	O	should
15	85	86	O	be
16	88	95	O	observed
17	97	103	O	closely
18	105	107	O	for
19	109	112	O	loss
20	114	115	O	of
21	117	123	O	control
NULL

Glipizide	DDI-DrugBank.d225.s3	NO_SECTION	NO_SETID	23
In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with salicylate or dicumarol.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	binding
4	17	23	O	studies
5	25	28	O	with
6	30	34	O	human
7	36	40	O	serum
8	42	49	O	proteins
9	51	58	O	indicate
10	60	63	O	that
11	65	73	O	XXXXXXXX
12	75	79	O	binds
13	81	91	O	differently
14	93	96	O	than
15	98	108	U-UNK	tolbutamide
16	110	112	O	and
17	114	117	O	does
18	119	121	O	not
19	123	130	O	interact
20	132	135	O	with
21	137	146	U-UNK	salicylate
22	148	149	O	or
23	151	159	U-UNK	dicumarol
NULL

Glipizide	DDI-DrugBank.d225.s4	NO_SECTION	NO_SETID	23
However, caution must be exercised in extrapolating these findings to the clinical situation and in the use of glipizide with these drugs.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	caution
4	17	20	O	must
5	22	23	O	be
6	25	33	O	exercised
7	35	36	O	in
8	38	50	O	extrapolating
9	52	56	O	these
10	58	65	O	findings
11	67	68	O	to
12	70	72	O	the
13	74	81	O	clinical
14	83	91	O	situation
15	93	95	O	and
16	97	98	O	in
17	100	102	O	the
18	104	106	O	use
19	108	109	O	of
20	111	119	O	XXXXXXXX
21	121	124	O	with
22	126	130	O	these
23	132	136	O	drugs
NULL

Glipizide	DDI-DrugBank.d225.s5	NO_SECTION	NO_SETID	13
Certain drugs tend to produce hyperglycemia and may lead to loss of control.
1	0	6	O	Certain
2	8	12	O	drugs
3	14	17	O	tend
4	19	20	O	to
5	22	28	O	produce
6	30	42	O	hyperglycemia
7	44	46	O	and
8	48	50	O	may
9	52	55	O	lead
10	57	58	O	to
11	60	63	O	loss
12	65	66	O	of
13	68	74	O	control
NULL

Glipizide	DDI-DrugBank.d225.s6	NO_SECTION	NO_SETID	35
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
1	0	4	O	These
2	6	10	O	drugs
3	12	18	O	include
4	20	22	O	the
5	24	32	U-UNK	thiazides
6	34	36	O	and
7	38	42	O	other
8	44	52	U-UNK	diuretics
9	53	53	O	,
10	55	69	U-UNK	corticosteroids
11	70	70	O	,
12	72	85	U-UNK	phenothiazines
13	86	86	O	,
14	88	94	B-UNK	thyroid
15	96	103	L-UNK	products
16	104	104	O	,
17	106	114	U-UNK	estrogens
18	115	115	O	,
19	117	120	O	oral
20	122	135	U-UNK	contraceptives
21	136	136	O	,
22	138	146	U-UNK	phenytoin
23	147	147	O	,
24	149	157	B-UNK	nicotinic
25	159	162	L-UNK	acid
26	163	163	O	,
27	165	180	U-UNK	sympathomimetics
28	181	181	O	,
29	183	189	B-UNK	calcium
30	191	197	I-UNK	channel
31	199	206	I-UNK	blocking
32	208	212	L-UNK	drugs
33	213	213	O	,
34	215	217	O	and
35	219	227	U-UNK	isoniazid
NULL

Glipizide	DDI-DrugBank.d225.s7	NO_SECTION	NO_SETID	21
When such drugs are administered to a patient receiving glipizide, the patient should be closely observed for loss of control.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	31	O	administered
6	33	34	O	to
7	36	36	O	a
8	38	44	O	patient
9	46	54	O	receiving
10	56	64	O	XXXXXXXX
11	65	65	O	,
12	67	69	O	the
13	71	77	O	patient
14	79	84	O	should
15	86	87	O	be
16	89	95	O	closely
17	97	104	O	observed
18	106	108	O	for
19	110	113	O	loss
20	115	116	O	of
21	118	124	O	control
NULL

Glipizide	DDI-DrugBank.d225.s8	NO_SECTION	NO_SETID	19
When such drugs are withdrawn from a patient receiving glipizide, the patient should be observed closely for hypoglycemia.
1	0	3	O	When
2	5	8	O	such
3	10	14	O	drugs
4	16	18	O	are
5	20	28	O	withdrawn
6	30	33	O	from
7	35	35	O	a
8	37	43	O	patient
9	45	53	O	receiving
10	55	63	O	XXXXXXXX
11	64	64	O	,
12	66	68	O	the
13	70	76	O	patient
14	78	83	O	should
15	85	86	O	be
16	88	95	O	observed
17	97	103	O	closely
18	105	107	O	for
19	109	120	O	hypoglycemia
NULL

Glipizide	DDI-DrugBank.d225.s9	NO_SECTION	NO_SETID	17
A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.
1	0	0	O	A
2	2	10	O	potential
3	12	22	O	interaction
4	24	30	O	between
5	32	35	O	oral
6	37	46	U-UNK	miconazole
7	48	50	O	and
8	52	55	O	oral
9	57	68	B-UNK	hypoglycemic
10	70	75	L-UNK	agents
11	77	83	O	leading
12	85	86	O	to
13	88	93	O	severe
14	95	106	O	hypoglycemia
15	108	110	O	has
16	112	115	O	been
17	117	124	O	reported
NULL

Glipizide	DDI-DrugBank.d225.s10	NO_SECTION	NO_SETID	19
Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.
1	0	6	O	Whether
2	8	11	O	this
3	13	23	O	interaction
4	25	28	O	also
5	30	35	O	occurs
6	37	40	O	with
7	42	44	O	the
8	46	56	O	intravenous
9	57	57	O	,
10	59	65	O	topical
11	66	66	O	,
12	68	69	O	or
13	71	77	O	vaginal
14	79	90	O	preparations
15	92	93	O	of
16	95	104	U-UNK	miconazole
17	106	107	O	is
18	109	111	O	not
19	113	117	O	known
NULL

Glipizide	DDI-DrugBank.d225.s11	NO_SECTION	NO_SETID	21
The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	24	O	concomitant
5	26	39	O	administration
6	41	42	O	of
7	44	54	U-UNK	fluconazole
8	56	58	O	and
9	60	68	O	XXXXXXXX
10	70	72	O	has
11	74	77	O	been
12	79	90	O	demonstrated
13	92	93	O	in
14	95	95	O	a
15	97	103	O	placebo
16	105	114	O	controlled
17	116	124	O	crossover
18	126	130	O	study
19	132	133	O	in
20	135	140	O	normal
21	142	151	O	volunteers
NULL

Glipizide	DDI-DrugBank.d225.s12	NO_SECTION	NO_SETID	22
All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for seven days.
1	0	2	O	All
2	4	11	O	subjects
3	13	20	O	received
4	22	30	O	XXXXXXXX
5	32	36	O	alone
6	38	40	O	and
7	42	50	O	following
8	52	60	O	treatment
9	62	65	O	with
10	67	69	O	100
11	71	72	O	mg
12	74	75	O	of
13	77	87	U-UNK	fluconazole
14	89	90	O	as
15	92	92	O	a
16	94	99	O	single
17	101	105	O	daily
18	107	110	O	oral
19	112	115	O	dose
20	117	119	O	for
21	121	125	O	seven
22	127	130	O	days
NULL

Glipizide	DDI-DrugBank.d225.s13	NO_SECTION	NO_SETID	18
The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).
1	0	2	O	The
2	4	7	O	mean
3	9	18	O	percentage
4	20	27	O	increase
5	29	30	O	in
6	32	34	O	the
7	36	44	O	XXXXXXXX
8	46	48	O	AUC
9	50	54	O	after
10	56	66	U-KIN	fluconazole
11	68	81	O	administration
12	83	85	O	was
13	87	91	O	56.9%
14	94	98	O	range
15	99	99	O	:
16	101	102	O	35
17	104	105	O	to
18	107	108	O	81
NULL

Glycopyrrolate	DDI-DrugBank.d510.s0	NO_SECTION	NO_SETID	41
The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
1	0	2	O	The
2	4	13	O	concurrent
3	15	17	O	use
4	19	20	O	of
5	22	28	O	XXXXXXXX
6	30	38	O	Injection
7	40	43	O	with
8	45	49	O	other
9	51	66	U-DYN	anticholinergics
10	68	69	O	or
11	71	81	O	medications
12	83	86	O	with
13	88	102	O	anticholinergic
14	104	111	O	activity
15	112	112	O	,
16	114	117	O	such
17	119	120	O	as
18	122	135	U-DYN	phenothiazines
19	136	136	O	,
20	138	150	B-DYN	antiparkinson
21	152	156	L-DYN	drugs
22	157	157	O	,
23	159	160	O	or
24	162	170	B-DYN	tricyclic
25	172	186	L-DYN	antidepressants
26	187	187	O	,
27	189	191	O	may
28	193	201	O	intensify
29	203	205	O	the
30	207	220	O	antimuscarinic
31	222	228	O	effects
32	230	232	O	and
33	234	236	O	may
34	238	243	O	result
35	245	246	O	in
36	248	249	O	an
37	251	258	O	increase
38	260	261	O	in
39	263	277	O	anticholinergic
40	279	282	O	side
41	284	290	O	effects
NULL

Glycopyrrolate	DDI-DrugBank.d510.s1	NO_SECTION	NO_SETID	31
Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	36	O	XXXXXXXX
5	38	46	O	Injection
6	48	50	O	and
7	52	60	B-KIN	potassium
8	62	69	L-KIN	chloride
9	71	72	O	in
10	74	74	O	a
11	76	78	O	wax
12	80	85	O	matrix
13	87	89	O	may
14	91	98	O	increase
15	100	102	O	the
16	104	111	O	severity
17	113	114	O	of
18	116	124	O	potassium
19	126	133	O	chloride
20	135	141	O	induced
21	143	158	O	gastrointestinal
22	160	166	O	lesions
23	168	169	O	as
24	171	171	O	a
25	173	178	O	result
26	180	181	O	of
27	183	183	O	a
28	185	190	O	slower
29	192	207	O	gastrointestinal
30	209	215	O	transit
31	217	220	O	time
NULL

Gonadorelin	DDI-DrugBank.d369.s0	NO_SECTION	NO_SETID	21
The Factrel test should be conducted in the absence of other drugs which directly affect the pituitary secretion of the gonadotropins.
1	0	2	O	The
2	4	10	O	XXXXXXXX
3	12	15	O	test
4	17	22	O	should
5	24	25	O	be
6	27	35	O	conducted
7	37	38	O	in
8	40	42	O	the
9	44	50	O	absence
10	52	53	O	of
11	55	59	O	other
12	61	65	O	drugs
13	67	71	O	which
14	73	80	O	directly
15	82	87	O	affect
16	89	91	O	the
17	93	101	O	pituitary
18	103	111	O	secretion
19	113	114	O	of
20	116	118	O	the
21	120	132	O	gonadotropins
NULL

Gonadorelin	DDI-DrugBank.d369.s1	NO_SECTION	NO_SETID	17
These would include a variety of preparations which contain androgens, estrogens, progestins, or glucocorticoids.
1	0	4	O	These
2	6	10	O	would
3	12	18	O	include
4	20	20	O	a
5	22	28	O	variety
6	30	31	O	of
7	33	44	O	preparations
8	46	50	O	which
9	52	58	O	contain
10	60	68	U-UNK	androgens
11	69	69	O	,
12	71	79	U-UNK	estrogens
13	80	80	O	,
14	82	91	U-UNK	progestins
15	92	92	O	,
16	94	95	O	or
17	97	111	U-UNK	glucocorticoids
NULL

Gonadorelin	DDI-DrugBank.d369.s2	NO_SECTION	NO_SETID	22
The gonadotropin levels may be transiently elevated by spironolactone, minimally elevated by levodopa, and suppressed by oral contraceptives and digoxin.
1	0	2	O	The
2	4	15	O	gonadotropin
3	17	22	O	levels
4	24	26	O	may
5	28	29	O	be
6	31	41	O	transiently
7	43	50	O	elevated
8	52	53	O	by
9	55	68	U-UNK	spironolactone
10	69	69	O	,
11	71	79	O	minimally
12	81	88	O	elevated
13	90	91	O	by
14	93	100	U-UNK	levodopa
15	101	101	O	,
16	103	105	O	and
17	107	116	O	suppressed
18	118	119	O	by
19	121	124	O	oral
20	126	139	U-UNK	contraceptives
21	141	143	O	and
22	145	151	U-UNK	digoxin
NULL

Gonadorelin	DDI-DrugBank.d369.s3	NO_SECTION	NO_SETID	18
The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.
1	0	2	O	The
2	4	11	O	response
3	13	14	O	to
4	16	22	O	XXXXXXXX
5	24	26	O	may
6	28	29	O	be
7	31	37	O	blunted
8	39	40	O	by
9	42	55	U-DYN	phenothiazines
10	57	59	O	and
11	61	68	B-DYN	dopamine
12	70	80	L-DYN	antagonists
13	82	86	O	which
14	88	92	O	cause
15	94	94	O	a
16	96	99	O	rise
17	101	102	O	in
18	104	112	O	prolactin
NULL

Goserelin	DDI-DrugBank.d50.s0	NO_SECTION	NO_SETID	9
No formal drug-drug interaction studies have been performed.
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	18	O	drug
5	20	30	O	interaction
6	32	38	O	studies
7	40	43	O	have
8	45	48	O	been
9	50	58	O	performed
NULL

Goserelin	DDI-DrugBank.d50.s1	NO_SECTION	NO_SETID	11
No confirmed interactions have been reported between ZOLADEX and other drugs
1	0	1	O	No
2	3	11	O	confirmed
3	13	24	O	interactions
4	26	29	O	have
5	31	34	O	been
6	36	43	O	reported
7	45	51	O	between
8	53	59	O	XXXXXXXX
9	61	63	O	and
10	65	69	O	other
11	71	75	O	drugs
NULL

Grepafloxacin	DDI-DrugBank.d78.s0	NO_SECTION	NO_SETID	18
Antacids, Sucralfate, Metal Cations, Multivitamins Quinolones form chelates with alkaline earth and transition metal cations.
1	0	7	U-UNK	Antacids
2	8	8	O	,
3	10	19	U-UNK	Sucralfate
4	20	20	O	,
5	22	26	O	Metal
6	28	34	O	Cations
7	35	35	O	,
8	37	49	U-UNK	Multivitamins
9	51	60	U-UNK	Quinolones
10	62	65	O	form
11	67	74	O	chelates
12	76	79	O	with
13	81	88	O	alkaline
14	90	94	O	earth
15	96	98	O	and
16	100	109	O	transition
17	111	115	O	metal
18	117	123	O	cations
NULL

Grepafloxacin	DDI-DrugBank.d78.s1	NO_SECTION	NO_SETID	72
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
1	0	13	O	Administration
2	15	16	O	of
3	18	27	U-KIN	quinolones
4	29	32	O	with
5	34	41	U-UNK	antacids
6	43	52	O	containing
7	54	61	U-UNK	aluminum
8	62	62	O	,
9	64	72	U-UNK	magnesium
10	73	73	O	,
11	75	76	O	or
12	78	84	U-UNK	calcium
13	85	85	O	,
14	87	90	O	with
15	92	101	U-UNK	sucralfate
16	102	102	O	,
17	104	107	O	with
18	109	113	O	metal
19	115	121	O	cations
20	123	126	O	such
21	128	129	O	as
22	131	134	U-UNK	iron
23	135	135	O	,
24	137	138	O	or
25	140	143	O	with
26	145	157	U-UNK	multivitamins
27	159	168	O	containing
28	170	173	U-UNK	iron
29	175	176	O	or
30	178	181	U-UNK	zinc
31	182	182	O	,
32	184	185	O	or
33	187	190	O	with
34	192	203	O	formulations
35	205	214	O	containing
36	216	223	O	divalent
37	225	227	O	and
38	229	237	O	trivalent
39	239	245	O	cations
40	247	250	O	such
41	252	253	O	as
42	255	259	O	XXXXXXXX
43	262	271	U-UNK	didanosine
44	274	281	O	chewable
45	282	282	O	/
46	283	290	O	buffered
47	292	298	O	tablets
48	300	301	O	or
49	303	305	O	the
50	307	315	O	pediatric
51	317	322	O	powder
52	324	326	O	for
53	328	331	O	oral
54	333	340	O	solution
55	341	341	O	,
56	343	345	O	may
57	347	359	O	substantially
58	361	369	O	interfere
59	371	374	O	with
60	376	378	O	the
61	380	389	O	absorption
62	391	392	O	of
63	394	403	U-UNK	quinolones
64	404	404	O	,
65	406	414	O	resulting
66	416	417	O	in
67	419	426	O	systemic
68	428	441	O	concentrations
69	443	454	O	considerably
70	456	460	O	lower
71	462	465	O	than
72	467	473	O	desired
NULL

Grepafloxacin	DDI-DrugBank.d78.s2	NO_SECTION	NO_SETID	16
These agents should not be taken within 4 hours before or 4 hours after grepafloxacin administration.
1	0	4	O	These
2	6	11	O	agents
3	13	18	O	should
4	20	22	O	not
5	24	25	O	be
6	27	31	O	taken
7	33	38	O	within
8	40	40	O	4
9	42	46	O	hours
10	48	53	O	before
11	55	56	O	or
12	58	58	O	4
13	60	64	O	hours
14	66	70	O	after
15	72	84	O	XXXXXXXX
16	86	99	O	administration
NULL

Grepafloxacin	DDI-DrugBank.d78.s3	NO_SECTION	NO_SETID	16
Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.
1	0	7	U-UNK	Caffeine
2	9	19	U-UNK	Theobromine
3	21	33	O	XXXXXXXX
4	34	34	O	,
5	36	39	O	like
6	41	45	O	other
7	47	56	U-UNK	quinolones
8	57	57	O	,
9	59	61	O	may
10	63	69	O	inhibit
11	71	73	O	the
12	75	84	O	metabolism
13	86	87	O	of
14	89	96	U-KIN	caffeine
15	98	100	O	and
16	102	112	U-KIN	theobromine
NULL

Grepafloxacin	DDI-DrugBank.d78.s4	NO_SECTION	NO_SETID	11
These stimulants are commonly found in coffee and tea, respectively.
1	0	4	O	These
2	6	15	O	stimulants
3	17	19	O	are
4	21	28	O	commonly
5	30	34	O	found
6	36	37	O	in
7	39	44	O	coffee
8	46	48	O	and
9	50	52	O	tea
10	53	53	O	,
11	55	66	O	respectively
NULL

Grepafloxacin	DDI-DrugBank.d78.s5	NO_SECTION	NO_SETID	24
In some patients, this may lead to reduced clearance, prolongation of plasma half-life, and enhanced effects of caffeine and theobromine.
1	0	1	O	In
2	3	6	O	some
3	8	15	O	patients
4	16	16	O	,
5	18	21	O	this
6	23	25	O	may
7	27	30	O	lead
8	32	33	O	to
9	35	41	O	reduced
10	43	51	O	clearance
11	52	52	O	,
12	54	65	O	prolongation
13	67	68	O	of
14	70	75	O	plasma
15	77	80	O	half
16	82	85	O	life
17	86	86	O	,
18	88	90	O	and
19	92	99	O	enhanced
20	101	107	O	effects
21	109	110	O	of
22	112	119	U-UNK	caffeine
23	121	123	O	and
24	125	135	U-UNK	theobromine
NULL

Grepafloxacin	DDI-DrugBank.d78.s6	NO_SECTION	NO_SETID	12
Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.
1	0	11	U-UNK	Theophylline
2	12	12	O	:
3	14	26	O	XXXXXXXX
4	28	29	O	is
5	31	31	O	a
6	33	43	O	competitive
7	45	53	O	inhibitor
8	55	56	O	of
9	58	60	O	the
10	62	71	O	metabolism
11	73	74	O	of
12	76	87	U-KIN	theophylline
NULL

Grepafloxacin	DDI-DrugBank.d78.s7	NO_SECTION	NO_SETID	14
Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.
1	0	4	O	Serum
2	6	17	U-UNK	theophylline
3	19	32	O	concentrations
4	34	41	O	increase
5	43	46	O	when
6	48	60	O	XXXXXXXX
7	62	63	O	is
8	65	73	O	initiated
9	75	76	O	in
10	78	78	O	a
11	80	86	O	patient
12	88	97	O	maintained
13	99	100	O	on
14	102	113	U-KIN	theophylline
NULL

Grepafloxacin	DDI-DrugBank.d78.s8	NO_SECTION	NO_SETID	46
When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.
1	0	3	O	When
2	5	14	O	initiating
3	16	16	O	a
4	18	22	O	multi
5	24	26	O	day
6	28	33	O	course
7	35	36	O	of
8	38	50	O	XXXXXXXX
9	52	53	O	in
10	55	55	O	a
11	57	63	O	patient
12	65	74	O	maintained
13	76	77	O	on
14	79	90	U-UNK	theophylline
15	91	91	O	,
16	93	95	O	the
17	97	108	U-DYN	theophylline
18	110	120	O	maintenance
19	122	125	O	dose
20	127	132	O	should
21	134	135	O	be
22	137	142	O	halved
23	144	146	O	for
24	148	150	O	the
25	152	157	O	period
26	159	160	O	of
27	162	171	O	concurrent
28	173	175	O	use
29	177	178	O	of
30	180	192	O	XXXXXXXX
31	194	196	O	and
32	198	207	O	monitoring
33	209	210	O	of
34	212	216	O	serum
35	218	229	U-UNK	theophylline
36	231	244	O	concentrations
37	246	251	O	should
38	253	254	O	be
39	256	264	O	initiated
40	266	267	O	as
41	269	269	O	a
42	271	275	O	guide
43	277	278	O	to
44	280	286	O	further
45	288	293	O	dosage
46	295	305	O	adjustments
NULL

Grepafloxacin	DDI-DrugBank.d78.s9	NO_SECTION	NO_SETID	19
Warfarin: In subjects receiving warfarin, no significant change in clotting time was observed when grepafloxacin was coadministered.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	11	O	In
4	13	20	O	subjects
5	22	30	O	receiving
6	32	39	U-UNK	warfarin
7	40	40	O	,
8	42	43	O	no
9	45	55	O	significant
10	57	62	O	change
11	64	65	O	in
12	67	74	O	clotting
13	76	79	O	time
14	81	83	O	was
15	85	92	O	observed
16	94	97	O	when
17	99	111	O	XXXXXXXX
18	113	115	O	was
19	117	130	O	coadministered
NULL

Grepafloxacin	DDI-DrugBank.d78.s10	NO_SECTION	NO_SETID	40
However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	because
4	17	20	O	some
5	22	31	U-UNK	quinolones
6	33	36	O	have
7	38	41	O	been
8	43	50	O	reported
9	52	53	O	to
10	55	61	O	enhance
11	63	65	O	the
12	67	73	O	effects
13	75	76	O	of
14	78	85	U-UNK	warfarin
15	87	88	O	or
16	90	92	O	its
17	94	104	O	derivatives
18	105	105	O	,
19	107	117	O	prothrombin
20	119	122	O	time
21	124	125	O	or
22	127	131	O	other
23	133	140	O	suitable
24	142	156	O	anticoagulation
25	158	161	O	test
26	163	168	O	should
27	170	171	O	be
28	173	181	O	monitored
29	183	189	O	closely
30	191	192	O	if
31	194	194	O	a
32	196	204	B-UNK	quinolone
33	206	218	L-UNK	antimicrobial
34	220	221	O	is
35	223	234	O	administered
36	236	239	O	with
37	241	248	U-UNK	warfarin
38	250	251	O	or
39	253	255	O	its
40	257	267	O	derivatives
NULL

Grepafloxacin	DDI-DrugBank.d78.s11	NO_SECTION	NO_SETID	29
Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	30	O	Cytochrome
5	32	35	O	P450
6	37	43	O	Enzymes
7	45	47	O	The
8	49	52	O	drug
9	54	64	O	interaction
10	66	70	O	study
11	72	81	O	evaluating
12	83	85	O	the
13	87	92	O	effect
14	94	95	O	of
15	97	109	O	XXXXXXXX
16	111	112	O	on
17	114	125	U-UNK	theophylline
18	127	135	O	indicates
19	137	140	O	that
20	142	154	O	XXXXXXXX
21	156	163	O	inhibits
22	165	176	U-KIN	theophylline
23	178	187	O	metabolism
24	188	188	O	,
25	190	194	O	which
26	196	197	O	is
27	199	206	O	mediated
28	208	209	O	by
29	211	216	O	CYP1A2
NULL

Grepafloxacin	DDI-DrugBank.d78.s12	NO_SECTION	NO_SETID	18
While no clinical studies have been conducted to evaluate the effect of grepafloxacin on the metabolism of C.P.A.
1	0	4	O	While
2	6	7	O	no
3	9	16	O	clinical
4	18	24	O	studies
5	26	29	O	have
6	31	34	O	been
7	36	44	O	conducted
8	46	47	O	to
9	49	56	O	evaluate
10	58	60	O	the
11	62	67	O	effect
12	69	70	O	of
13	72	84	O	XXXXXXXX
14	86	87	O	on
15	89	91	O	the
16	93	102	O	metabolism
17	104	105	O	of
18	107	111	O	C.P.A
NULL

Grepafloxacin	DDI-DrugBank.d78.s13	NO_SECTION	NO_SETID	17
substrates, in vitro data suggest similar effects of grepafloxacin in CYP3A4 mediated metabolism and theophylline metabolism.
1	0	9	O	substrates
2	10	10	O	,
3	12	13	O	in
4	15	19	O	vitro
5	21	24	O	data
6	26	32	O	suggest
7	34	40	O	similar
8	42	48	O	effects
9	50	51	O	of
10	53	65	O	XXXXXXXX
11	67	68	O	in
12	70	75	O	CYP3A4
13	77	84	O	mediated
14	86	95	O	metabolism
15	97	99	O	and
16	101	112	U-UNK	theophylline
17	114	123	O	metabolism
NULL

Grepafloxacin	DDI-DrugBank.d78.s14	NO_SECTION	NO_SETID	16
In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	17	O	other
5	19	28	U-UNK	quinolones
6	30	33	O	have
7	35	38	O	been
8	40	47	O	reported
9	49	50	O	to
10	52	59	O	decrease
11	61	63	O	the
12	65	70	O	CYP3A4
13	72	79	O	mediated
14	81	90	O	metabolism
15	92	93	O	of
16	95	106	U-UNK	cyclosporine
NULL

Grepafloxacin	DDI-DrugBank.d78.s15	NO_SECTION	NO_SETID	5
Other drugs metabolized by C.P.A.
1	0	4	O	Other
2	6	10	O	drugs
3	12	22	O	metabolized
4	24	25	O	by
5	27	31	O	C.P.A
NULL

Grepafloxacin	DDI-DrugBank.d78.s16	NO_SECTION	NO_SETID	11
include terfenadine, astemizole, cisapride, midazolam, and triazolam.
1	0	6	O	include
2	8	18	U-UNK	terfenadine
3	19	19	O	,
4	21	30	U-UNK	astemizole
5	31	31	O	,
6	33	41	U-UNK	cisapride
7	42	42	O	,
8	44	52	U-UNK	midazolam
9	53	53	O	,
10	55	57	O	and
11	59	67	U-UNK	triazolam
NULL

Grepafloxacin	DDI-DrugBank.d78.s17	NO_SECTION	NO_SETID	18
The clinical relevance of the potential effect of grepafloxacin on the metabolism of C.P.A. substrates is not known.
1	0	2	O	The
2	4	11	O	clinical
3	13	21	O	relevance
4	23	24	O	of
5	26	28	O	the
6	30	38	O	potential
7	40	45	O	effect
8	47	48	O	of
9	50	62	O	XXXXXXXX
10	64	65	O	on
11	67	69	O	the
12	71	80	O	metabolism
13	82	83	O	of
14	85	89	O	C.P.A
15	92	101	O	substrates
16	103	104	O	is
17	106	108	O	not
18	110	114	O	known
NULL

Grepafloxacin	DDI-DrugBank.d78.s18	NO_SECTION	NO_SETID	16
Patients receiving concurrent administration of substrates of C.P.A. were not excluded from clinical trials of grepafloxacin.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	28	O	concurrent
4	30	43	O	administration
5	45	46	O	of
6	48	57	O	substrates
7	59	60	O	of
8	62	66	O	C.P.A
9	69	72	O	were
10	74	76	O	not
11	78	85	O	excluded
12	87	90	O	from
13	92	99	O	clinical
14	101	106	O	trials
15	108	109	O	of
16	111	123	O	XXXXXXXX
NULL

Grepafloxacin	DDI-DrugBank.d78.s19	NO_SECTION	NO_SETID	27
Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.
1	0	11	B-UNK	Nonsteroidal
2	13	16	I-UNK	Anti
3	18	29	I-UNK	inflammatory
4	31	35	L-UNK	Drugs
5	38	43	U-UNK	NSAIDs
6	45	45	O	:
7	47	49	O	The
8	51	61	O	concomitant
9	63	76	O	administration
10	78	79	O	of
11	81	81	O	a
12	83	94	B-UNK	nonsteroidal
13	96	99	I-UNK	anti
14	101	112	I-UNK	inflammatory
15	114	117	L-UNK	drug
16	119	122	O	with
17	124	124	O	a
18	126	134	U-UNK	quinolone
19	136	138	O	may
20	140	147	O	increase
21	149	151	O	the
22	153	157	O	risks
23	159	160	O	of
24	162	164	O	CNS
25	166	176	O	stimulation
26	178	180	O	and
27	182	192	O	convulsions
NULL

Grepafloxacin	DDI-DrugBank.d78.s20	NO_SECTION	NO_SETID	26
Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent.
1	0	11	B-UNK	Antidiabetic
2	13	18	L-UNK	Agents
3	19	19	O	:
4	21	32	O	Disturbances
5	34	35	O	of
6	37	41	O	blood
7	43	49	O	glucose
8	50	50	O	,
9	52	60	O	including
10	62	74	O	hyperglycemia
11	76	78	O	and
12	80	91	O	hypoglycemia
13	92	92	O	,
14	94	97	O	have
15	99	102	O	been
16	104	111	O	reported
17	113	114	O	in
18	116	123	O	patients
19	125	131	O	treated
20	133	145	O	concomitantly
21	147	150	O	with
22	152	161	U-UNK	quinolones
23	163	165	O	and
24	167	168	O	an
25	170	181	B-UNK	antidiabetic
26	183	187	L-UNK	agent
NULL

Grepafloxacin	DDI-DrugBank.d78.s21	NO_SECTION	NO_SETID	14
Therefore, careful monitoring of blood glucose is recommended when these agents are coadministered.
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	O	careful
4	19	28	O	monitoring
5	30	31	O	of
6	33	37	O	blood
7	39	45	O	glucose
8	47	48	O	is
9	50	60	O	recommended
10	62	65	O	when
11	67	71	O	these
12	73	78	O	agents
13	80	82	O	are
14	84	97	O	coadministered
NULL

Griseofulvin	DDI-DrugBank.d83.s0	NO_SECTION	NO_SETID	18
Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.
1	0	7	O	Patients
2	9	10	O	on
3	12	19	B-DYN	warfarin
4	21	24	I-DYN	type
5	26	38	L-DYN	anticoagulant
6	40	46	O	therapy
7	48	50	O	may
8	52	58	O	require
9	60	65	O	dosage
10	67	76	O	adjustment
11	78	79	O	of
12	81	83	O	the
13	85	97	O	anticoagulant
14	99	104	O	during
15	106	108	O	and
16	110	114	O	after
17	116	127	O	XXXXXXXX
18	129	135	O	therapy
NULL

Griseofulvin	DDI-DrugBank.d83.s1	NO_SECTION	NO_SETID	14
Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	30	U-DYN	barbiturates
5	32	38	O	usually
6	40	48	O	depresses
7	50	61	O	XXXXXXXX
8	63	70	O	activity
9	72	74	O	and
10	76	78	O	may
11	80	90	O	necessitate
12	92	98	O	raising
13	100	102	O	the
14	104	109	O	dosage
NULL

Griseofulvin	DDI-DrugBank.d83.s2	NO_SECTION	NO_SETID	23
The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.
1	0	2	O	The
2	4	14	O	concomitant
3	16	29	O	administration
4	31	32	O	of
5	34	45	O	XXXXXXXX
6	47	49	O	has
7	51	54	O	been
8	56	63	O	reported
9	65	66	O	to
10	68	73	O	reduce
11	75	77	O	the
12	79	86	O	efficacy
13	88	89	O	of
14	91	94	O	oral
15	96	109	U-DYN	contraceptives
16	111	113	O	and
17	115	116	O	to
18	118	125	O	increase
19	127	129	O	the
20	131	139	O	incidence
21	141	142	O	of
22	144	155	O	breakthrough
23	157	164	O	bleeding
NULL

Guaifenesin	DDI-DrugBank.d398.s0	NO_SECTION	NO_SETID	26
The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	17	U-UNK	codeine
5	19	21	O	may
6	23	28	O	result
7	30	31	O	in
8	33	40	O	additive
9	42	44	O	CNS
10	46	55	O	depressant
11	57	63	O	effects
12	65	68	O	when
13	70	83	O	coadministered
14	85	88	O	with
15	90	96	U-UNK	alcohol
16	97	97	O	,
17	99	112	U-UNK	antihistamines
18	113	113	O	,
19	115	127	U-UNK	psychotropics
20	129	130	O	or
21	132	136	O	other
22	138	142	O	drugs
23	144	147	O	that
24	149	155	O	produce
25	157	159	O	CNS
26	161	170	O	depression
NULL

Guaifenesin	DDI-DrugBank.d398.s1	NO_SECTION	NO_SETID	13
Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).
1	0	6	O	Serious
2	8	15	O	toxicity
3	17	19	O	may
4	21	26	O	result
5	28	29	O	if
6	31	46	U-UNK	dextromethorphan
7	48	49	O	is
8	51	64	O	coadministered
9	66	69	O	with
10	71	79	B-UNK	monoamine
11	81	87	I-UNK	oxidase
12	89	98	L-UNK	inhibitors
13	101	105	U-UNK	MAOIs
NULL

Guaifenesin	DDI-DrugBank.d398.s2	NO_SECTION	NO_SETID	27
The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	26	B-UNK	dextromethorphan
5	28	39	L-UNK	hydrobromide
6	41	43	O	may
7	45	50	O	result
8	52	53	O	in
9	55	62	O	additive
10	64	66	O	CNS
11	68	77	O	depressant
12	79	85	O	effects
13	87	90	O	when
14	92	105	O	coadministered
15	107	110	O	with
16	112	118	U-UNK	alcohol
17	119	119	O	,
18	121	134	U-UNK	antihistamines
19	135	135	O	,
20	137	149	U-UNK	psychotropics
21	151	152	O	or
22	154	158	O	other
23	160	164	O	drugs
24	166	169	O	that
25	171	177	O	produce
26	179	181	O	CNS
27	183	192	O	depression
NULL

Guanethidine	DDI-DrugBank.d302.s0	NO_SECTION	NO_SETID	12
http://www.rxlist.com/cgi/generic3/guanethidine_od.htm
1	0	3	O	http
2	4	4	O	:
3	5	5	O	/
4	6	6	O	/
5	7	20	O	www.rxlist.com
6	21	21	O	/
7	22	24	O	cgi
8	25	25	O	/
9	26	33	O	generic3
10	34	34	O	/
11	35	46	O	XXXXXXXX
12	47	53	O	_od.htm
NULL

Guanfacine	DDI-DrugBank.d507.s0	NO_SECTION	NO_SETID	17
The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.
1	0	2	O	The
2	4	12	O	potential
3	14	16	O	for
4	18	26	O	increased
5	28	35	O	sedation
6	37	40	O	when
7	42	51	O	XXXXXXXX
8	53	54	O	is
9	56	60	O	given
10	62	65	O	with
11	67	71	O	other
12	73	75	B-DYN	CNS
13	77	86	I-DYN	depressant
14	88	91	L-DYN	drug
15	93	98	O	should
16	100	101	O	be
17	103	113	O	appreciated
NULL

Guanfacine	DDI-DrugBank.d507.s1	NO_SECTION	NO_SETID	31
The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.
1	0	2	O	The
2	4	17	O	administration
3	19	20	O	of
4	22	31	O	XXXXXXXX
5	33	45	O	concomitantly
6	47	50	O	with
7	52	56	O	known
8	58	67	O	microsomal
9	69	74	O	enzyme
10	76	82	O	inducer
11	85	97	U-KIN	phenobarbital
12	99	100	O	or
13	102	110	U-KIN	phenytoin
14	113	114	O	to
15	116	118	O	two
16	120	127	O	patients
17	129	132	O	with
18	134	138	O	renal
19	140	149	O	impairment
20	151	160	O	reportedly
21	162	169	O	resulted
22	171	172	O	in
23	174	184	O	significant
24	186	195	O	reductions
25	197	198	O	in
26	200	210	O	elimination
27	212	215	O	half
28	217	220	O	life
29	222	224	O	and
30	226	231	O	plasma
31	233	245	O	concentration
NULL

Guanfacine	DDI-DrugBank.d507.s2	NO_SECTION	NO_SETID	20
In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response.
1	0	1	O	In
2	3	6	O	such
3	8	12	O	cases
4	13	13	O	,
5	15	23	O	therefore
6	24	24	O	,
7	26	29	O	more
8	31	38	O	frequent
9	40	45	O	dosing
10	47	49	O	may
11	51	52	O	be
12	54	61	O	required
13	63	64	O	to
14	66	72	O	achieve
15	74	75	O	or
16	77	84	O	maintain
17	86	88	O	the
18	90	96	O	desired
19	98	108	O	hypotensive
20	110	117	O	response
NULL

Guanfacine	DDI-DrugBank.d507.s3	NO_SECTION	NO_SETID	26
Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena.
1	0	6	O	Further
2	7	7	O	,
3	9	10	O	if
4	12	21	O	XXXXXXXX
5	23	24	O	is
6	26	27	O	to
7	29	30	O	be
8	32	43	O	discontinued
9	45	46	O	in
10	48	51	O	such
11	53	60	O	patients
12	61	61	O	,
13	63	69	O	careful
14	71	78	O	tapering
15	80	81	O	of
16	83	85	O	the
17	87	92	O	dosage
18	94	96	O	may
19	98	99	O	be
20	101	109	O	necessary
21	111	112	O	in
22	114	118	O	order
23	120	121	O	to
24	123	127	O	avoid
25	129	135	O	rebound
26	137	145	O	phenomena
NULL

Guanfacine	DDI-DrugBank.d507.s4	NO_SECTION	NO_SETID	7
TCAs decrease the hypotensive effect of guanfacine.
1	0	3	U-DYN	TCAs
2	5	12	O	decrease
3	14	16	O	the
4	18	28	O	hypotensive
5	30	35	O	effect
6	37	38	O	of
7	40	49	O	XXXXXXXX
NULL

Guanfacine	DDI-DrugBank.d507.s5	NO_SECTION	NO_SETID	12
Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.
1	0	17	B-DYN	Noncardioselective
2	19	22	I-DYN	beta
3	24	31	L-DYN	blockers
4	34	60	O	nadolol,porpranolol,timolol
5	63	65	O	may
6	67	76	O	exacerbate
7	78	84	O	rebound
8	86	97	O	hypertension
9	99	102	O	when
10	104	113	O	XXXXXXXX
11	115	116	O	is
12	118	126	O	withdrawn
NULL

Guanfacine	DDI-DrugBank.d507.s6	NO_SECTION	NO_SETID	7
The beta-blocker should be withdrawn first.
1	0	2	O	The
2	4	7	B-UNK	beta
3	9	15	L-UNK	blocker
4	17	22	O	should
5	24	25	O	be
6	27	35	O	withdrawn
7	37	41	O	first
NULL

Guanfacine	DDI-DrugBank.d507.s7	NO_SECTION	NO_SETID	13
The gradual withdrawal of guafacine or a cardioselective beta-blocker could be substituted.
1	0	2	O	The
2	4	10	O	gradual
3	12	21	O	withdrawal
4	23	24	O	of
5	26	34	U-UNK	guafacine
6	36	37	O	or
7	39	39	O	a
8	41	55	B-UNK	cardioselective
9	57	60	I-UNK	beta
10	62	68	L-UNK	blocker
11	70	74	O	could
12	76	77	O	be
13	79	89	O	substituted
NULL

Guanfacine	DDI-DrugBank.d507.s8	NO_SECTION	NO_SETID	23
Anticoagulants: Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks.
1	0	13	U-UNK	Anticoagulants
2	14	14	O	:
3	16	18	O	Ten
4	20	27	O	patients
5	29	31	O	who
6	33	36	O	were
7	38	47	O	stabilized
8	49	50	O	on
9	52	55	O	oral
10	57	70	U-UNK	anticoagulants
11	72	75	O	were
12	77	81	O	given
13	83	92	O	XXXXXXXX
14	93	93	O	,
15	95	95	O	1
16	97	97	O	2
17	99	100	O	mg
18	101	101	O	/
19	102	104	O	day
20	105	105	O	,
21	107	109	O	for
22	111	111	O	4
23	113	117	O	weeks
NULL

Guanfacine	DDI-DrugBank.d507.s9	NO_SECTION	NO_SETID	9
No changes were observed in the degree of anticoagulation.
1	0	1	O	No
2	3	9	O	changes
3	11	14	O	were
4	16	23	O	observed
5	25	26	O	in
6	28	30	O	the
7	32	37	O	degree
8	39	40	O	of
9	42	56	O	anticoagulation
NULL

Guanfacine	DDI-DrugBank.d507.s10	NO_SECTION	NO_SETID	17
In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported.
1	0	1	O	In
2	3	9	O	several
3	11	14	O	well
4	16	25	O	controlled
5	27	33	O	studies
6	34	34	O	,
7	36	45	O	XXXXXXXX
8	47	49	O	was
9	51	62	O	administered
10	64	71	O	together
11	73	76	O	with
12	78	86	U-UNK	diuretics
13	88	91	O	with
14	93	94	O	no
15	96	99	O	drug
16	101	112	O	interactions
17	114	121	O	reported
NULL

Guanfacine	DDI-DrugBank.d507.s11	NO_SECTION	NO_SETID	19
In the long-term safety studies, guanfacine was given concomitantly with many drugs without evidence of any interactions.
1	0	1	O	In
2	3	5	O	the
3	7	10	O	long
4	12	15	O	term
5	17	22	O	safety
6	24	30	O	studies
7	31	31	O	,
8	33	42	O	XXXXXXXX
9	44	46	O	was
10	48	52	O	given
11	54	66	O	concomitantly
12	68	71	O	with
13	73	76	O	many
14	78	82	O	drugs
15	84	90	O	without
16	92	99	O	evidence
17	101	102	O	of
18	104	106	O	any
19	108	119	O	interactions
NULL

Guanfacine	DDI-DrugBank.d507.s12	NO_SECTION	NO_SETID	58
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
1	0	2	O	The
2	4	12	O	principal
3	14	18	O	drugs
4	20	24	O	given
5	27	32	O	number
6	34	35	O	of
7	37	44	O	patients
8	46	47	O	in
9	49	59	O	parentheses
10	62	65	O	were
11	66	66	O	:
12	68	74	B-UNK	cardiac
13	76	85	L-UNK	glycosides
14	88	90	O	115
15	92	92	O	,
16	94	102	U-UNK	sedatives
17	104	106	O	and
18	108	116	U-UNK	hypnotics
19	119	121	O	103
20	123	123	O	,
21	125	132	B-UNK	coronary
22	134	145	L-UNK	vasodilators
23	148	149	O	52
24	151	151	O	,
25	153	156	O	oral
26	158	170	U-UNK	hypoglycemics
27	173	174	O	45
28	176	176	O	,
29	178	182	O	cough
30	184	186	O	and
31	188	191	O	cold
32	193	204	O	preparations
33	207	208	O	45
34	210	210	O	,
35	212	217	U-UNK	NSAIDs
36	220	221	O	38
37	223	223	O	,
38	225	243	U-UNK	antihyperlipidemics
39	246	247	O	29
40	249	249	O	,
41	251	258	B-UNK	antigout
42	260	264	L-UNK	drugs
43	267	268	O	24
44	270	270	O	,
45	272	275	O	oral
46	277	290	U-UNK	contraceptives
47	293	294	O	18
48	296	296	O	,
49	298	312	U-UNK	bronchodilators
50	315	316	O	13
51	318	318	O	,
52	320	326	U-UNK	insulin
53	329	330	O	10
54	332	332	O	,
55	334	336	O	and
56	338	341	B-UNK	beta
57	343	350	L-UNK	blockers
58	353	354	O	10
NULL

Guanfacine	DDI-DrugBank.d507.s13	NO_SECTION	NO_SETID	25
Laboratory Test In clinical trials, no clinically relevant laboratory test abnormalities were identified as causally related to drug during short-term treatment with guanfacine.
1	0	9	O	Laboratory
2	11	14	O	Test
3	16	17	O	In
4	19	26	O	clinical
5	28	33	O	trials
6	34	34	O	,
7	36	37	O	no
8	39	48	O	clinically
9	50	57	O	relevant
10	59	68	O	laboratory
11	70	73	O	test
12	75	87	O	abnormalities
13	89	92	O	were
14	94	103	O	identified
15	105	106	O	as
16	108	115	O	causally
17	117	123	O	related
18	125	126	O	to
19	128	131	O	drug
20	133	138	O	during
21	140	144	O	short
22	146	149	O	term
23	151	159	O	treatment
24	161	164	O	with
25	166	175	O	XXXXXXXX
NULL

Guanfacine	DDI-DrugBank.d507.s14	NO_SECTION	NO_SETID	18
Drug/Laboratory Test Interactions No laboratory test abnormalities related to the use of guanfacine have been identified.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	35	O	No
7	37	46	O	laboratory
8	48	51	O	test
9	53	65	O	abnormalities
10	67	73	O	related
11	75	76	O	to
12	78	80	O	the
13	82	84	O	use
14	86	87	O	of
15	89	98	O	XXXXXXXX
16	100	103	O	have
17	105	108	O	been
18	110	119	O	identified
NULL

Haloperidol	DDI-DrugBank.d186.s0	NO_SECTION	NO_SETID	44
An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.
1	0	1	O	An
2	3	17	O	encephalopathic
3	19	26	O	syndrome
4	29	41	O	characterized
5	43	44	O	by
6	46	53	O	weakness
7	54	54	O	,
8	56	63	O	lethargy
9	64	64	O	,
10	66	70	O	fever
11	71	71	O	,
12	73	85	O	tremulousness
13	87	89	O	and
14	91	99	O	confusion
15	100	100	O	,
16	102	115	O	extrapyramidal
17	117	124	O	symptoms
18	125	125	O	,
19	127	138	O	leukocytosis
20	139	139	O	,
21	141	148	O	elevated
22	150	154	O	serum
23	156	162	O	enzymes
24	163	163	O	,
25	165	167	O	BUN
26	168	168	O	,
27	170	172	O	and
28	174	176	O	FBS
29	179	186	O	followed
30	188	189	O	by
31	191	202	O	irreversible
32	204	208	O	brain
33	210	215	O	damage
34	217	219	O	has
35	221	228	O	occurred
36	230	231	O	in
37	233	233	O	a
38	235	237	O	few
39	239	246	O	patients
40	248	254	O	treated
41	256	259	O	with
42	261	267	U-DYN	lithium
43	269	272	O	plus
44	274	279	O	XXXXXXXX
NULL

Haloperidol	DDI-DrugBank.d186.s1	NO_SECTION	NO_SETID	18
A causal relationship between these events and the concomitant administration of lithium and HALDOL has not been established;
1	0	0	O	A
2	2	7	O	causal
3	9	20	O	relationship
4	22	28	O	between
5	30	34	O	these
6	36	41	O	events
7	43	45	O	and
8	47	49	O	the
9	51	61	O	concomitant
10	63	76	O	administration
11	78	79	O	of
12	81	87	U-UNK	lithium
13	89	91	O	and
14	93	98	O	XXXXXXXX
15	100	102	O	has
16	104	106	O	not
17	108	111	O	been
18	113	123	O	established
NULL

Haloperidol	DDI-DrugBank.d186.s2	NO_SECTION	NO_SETID	25
however, patients receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear.
1	0	6	O	however
2	7	7	O	,
3	9	16	O	patients
4	18	26	O	receiving
5	28	31	O	such
6	33	40	O	combined
7	42	48	O	therapy
8	50	55	O	should
9	57	58	O	be
10	60	68	O	monitored
11	70	76	O	closely
12	78	80	O	for
13	82	86	O	early
14	88	95	O	evidence
15	97	98	O	of
16	100	111	O	neurological
17	113	120	O	toxicity
18	122	124	O	and
19	126	134	O	treatment
20	136	147	O	discontinued
21	149	156	O	promptly
22	158	159	O	if
23	161	164	O	such
24	166	170	O	signs
25	172	177	O	appear
NULL

Haloperidol	DDI-DrugBank.d186.s3	NO_SECTION	NO_SETID	27
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	26	B-UNK	antipsychotic
5	28	33	L-UNK	agents
6	34	34	O	,
7	36	37	O	it
8	39	44	O	should
9	46	47	O	be
10	49	53	O	noted
11	55	58	O	that
12	60	65	O	XXXXXXXX
13	67	69	O	may
14	71	72	O	be
15	74	80	O	capable
16	82	83	O	of
17	85	96	O	potentiating
18	98	100	B-DYN	CNS
19	102	112	L-DYN	depressants
20	114	117	O	such
21	119	120	O	as
22	122	132	U-DYN	anesthetics
23	133	133	O	,
24	135	141	U-DYN	opiates
25	142	142	O	,
26	144	146	O	and
27	148	154	U-DYN	alcohol
NULL

Haloperidol	DDI-DrugBank.d186.s4	NO_SECTION	NO_SETID	36
In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	15	O	12
6	17	29	O	schizophrenic
7	31	38	O	patients
8	40	53	O	coadministered
9	55	58	O	oral
10	60	70	O	XXXXXXXX
11	72	74	O	and
12	76	83	U-KIN	rifampin
13	84	84	O	,
14	86	91	O	plasma
15	93	103	O	XXXXXXXX
16	105	110	O	levels
17	112	115	O	were
18	117	125	O	decreased
19	127	128	O	by
20	130	130	O	a
21	132	135	O	mean
22	137	138	O	of
23	140	142	O	70%
24	144	146	O	and
25	148	151	O	mean
26	153	158	O	scores
27	160	161	O	on
28	163	165	O	the
29	167	171	O	Brief
30	173	183	O	Psychiatric
31	185	190	O	Rating
32	192	196	O	Scale
33	198	201	O	were
34	203	211	O	increased
35	213	216	O	from
36	218	225	O	baseline
NULL

Haloperidol	DDI-DrugBank.d186.s5	NO_SECTION	NO_SETID	24
In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.
1	0	1	O	In
2	3	3	O	5
3	5	9	O	other
4	11	23	O	schizophrenic
5	25	32	O	patients
6	34	40	O	treated
7	42	45	O	with
8	47	50	O	oral
9	52	62	O	XXXXXXXX
10	64	66	O	and
11	68	75	U-UNK	rifampin
12	76	76	O	,
13	78	92	O	discontinuation
14	94	95	O	of
15	97	104	U-KIN	rifampin
16	106	113	O	produced
17	115	115	O	a
18	117	120	O	mean
19	122	124	O	3.3
20	126	129	O	fold
21	131	138	O	increase
22	140	141	O	in
23	143	153	O	XXXXXXXX
24	155	168	O	concentrations
NULL

Haloperidol	DDI-DrugBank.d186.s6	NO_SECTION	NO_SETID	19
Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.
1	0	3	O	Thus
2	4	4	O	,
3	6	12	O	careful
4	14	23	O	monitoring
5	25	26	O	of
6	28	35	O	clinical
7	37	42	O	status
8	44	45	O	is
9	47	55	O	warranted
10	57	60	O	when
11	62	69	U-DYN	rifampin
12	71	72	O	is
13	74	85	O	administered
14	87	88	O	or
15	90	101	O	discontinued
16	103	104	O	in
17	106	116	O	XXXXXXXX
18	118	124	O	treated
19	126	133	O	patients
NULL

Halothane	DDI-DrugBank.d74.s0	NO_SECTION	NO_SETID	16
FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.
1	0	8	O	XXXXXXXX
2	10	17	O	augments
3	19	21	O	the
4	23	28	O	action
5	30	31	O	of
6	33	35	B-DYN	non
7	37	48	I-DYN	depolarising
8	50	55	L-DYN	muscle
9	57	65	O	relaxants
10	67	69	O	and
11	71	73	O	the
12	75	80	O	muscle
13	82	89	O	relaxant
14	91	97	O	effects
15	99	100	O	of
16	102	116	U-DYN	aminoglycosides
NULL

Halothane	DDI-DrugBank.d74.s1	NO_SECTION	NO_SETID	13
FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.
1	0	8	O	XXXXXXXX
2	10	12	O	may
3	14	20	O	augment
4	22	24	O	the
5	26	36	O	hypotension
6	38	43	O	caused
7	45	46	O	by
8	48	50	O	the
9	52	61	O	ganglionic
10	63	70	O	blocking
11	72	77	O	effect
12	79	80	O	of
13	82	93	U-DYN	tubocurarine
NULL

Halothane	DDI-DrugBank.d74.s2	NO_SECTION	NO_SETID	19
Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	33	O	during
6	35	37	O	the
7	39	52	O	administration
8	54	55	O	of
9	57	66	U-DYN	adrenaline
10	68	69	O	to
11	71	78	O	patients
12	80	92	O	anaesthetised
13	94	97	O	with
14	99	107	O	XXXXXXXX
15	109	110	O	as
16	112	122	O	arrhythmias
17	124	126	O	may
18	128	129	O	be
19	131	142	O	precipitated
NULL

Halothane	DDI-DrugBank.d74.s3	NO_SECTION	NO_SETID	17
For this reason the dose of adrenaline should be restricted and an antiarrhythmic agent administered as appropriate.
1	0	2	O	For
2	4	7	O	this
3	9	14	O	reason
4	16	18	O	the
5	20	23	O	dose
6	25	26	O	of
7	28	37	U-UNK	adrenaline
8	39	44	O	should
9	46	47	O	be
10	49	58	O	restricted
11	60	62	O	and
12	64	65	O	an
13	67	80	B-UNK	antiarrhythmic
14	82	86	L-UNK	agent
15	88	99	O	administered
16	101	102	O	as
17	104	114	O	appropriate
NULL

Halothane	DDI-DrugBank.d74.s4	NO_SECTION	NO_SETID	23
Caution should also be applied for other sympathomimetics, and for aminophylline and theophylline and tricyclic antidepressants, which may also precipitate arrhythmias.
1	0	6	O	Caution
2	8	13	O	should
3	15	18	O	also
4	20	21	O	be
5	23	29	O	applied
6	31	33	O	for
7	35	39	O	other
8	41	56	U-UNK	sympathomimetics
9	57	57	O	,
10	59	61	O	and
11	63	65	O	for
12	67	79	U-UNK	aminophylline
13	81	83	O	and
14	85	96	U-UNK	theophylline
15	98	100	O	and
16	102	110	B-UNK	tricyclic
17	112	126	L-UNK	antidepressants
18	127	127	O	,
19	129	133	O	which
20	135	137	O	may
21	139	142	O	also
22	144	154	O	precipitate
23	156	166	O	arrhythmias
NULL

Heparin	DDI-DrugBank.d488.s0	NO_SECTION	NO_SETID	21
Drug Interactions: a. Drugs Enhancing Heparin Effect: Oral anticoagulants: Heparin sodium may prolong the one-stage prothrombin time.
1	0	3	O	Drug
2	5	16	O	Interactions
3	17	17	O	:
4	19	19	O	a
5	22	26	O	Drugs
6	28	36	O	Enhancing
7	38	44	O	XXXXXXXX
8	46	51	O	Effect
9	52	52	O	:
10	54	57	O	Oral
11	59	72	U-UNK	anticoagulants
12	73	73	O	:
13	75	81	O	XXXXXXXX
14	83	88	O	sodium
15	90	92	O	may
16	94	100	O	prolong
17	102	104	O	the
18	106	108	O	one
19	110	114	O	stage
20	116	126	O	prothrombin
21	128	131	O	time
NULL

Heparin	DDI-DrugBank.d488.s1	NO_SECTION	NO_SETID	48
Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	22	O	XXXXXXXX
5	24	29	O	sodium
6	31	32	O	is
7	34	38	O	given
8	40	43	O	with
9	45	53	U-DYN	dicumarol
10	55	56	O	or
11	58	65	B-DYN	warfarin
12	67	72	L-DYN	sodium
13	73	73	O	,
14	75	75	O	a
15	77	82	O	period
16	84	85	O	of
17	87	88	O	at
18	90	94	O	least
19	96	96	O	5
20	98	102	O	hours
21	104	108	O	after
22	110	112	O	the
23	114	117	O	last
24	119	129	O	intravenous
25	131	134	O	dose
26	136	137	O	or
27	139	140	O	24
28	142	146	O	hours
29	148	152	O	after
30	154	156	O	the
31	158	161	O	last
32	163	174	O	subcutaneous
33	176	179	O	dose
34	181	186	O	should
35	188	193	O	elapse
36	195	200	O	before
37	202	206	O	blood
38	208	209	O	is
39	211	215	O	drawn
40	217	218	O	if
41	220	220	O	a
42	222	226	O	valid
43	228	238	O	prothrombin
44	240	243	O	time
45	245	246	O	is
46	248	249	O	to
47	251	252	O	be
48	254	261	O	obtained
NULL

Heparin	DDI-DrugBank.d488.s2	NO_SECTION	NO_SETID	50
Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
1	0	7	B-UNK	Platelet
2	9	18	L-UNK	inhibitors
3	19	19	O	:
4	21	25	O	Drugs
5	27	30	O	such
6	32	33	O	as
7	35	49	B-DYN	acetylsalicylic
8	51	54	L-DYN	acid
9	55	55	O	,
10	57	63	U-DYN	dextran
11	64	64	O	,
12	66	79	U-DYN	phenylbutazone
13	80	80	O	,
14	82	90	U-DYN	ibuprofen
15	91	91	O	,
16	93	104	U-DYN	indomethacin
17	105	105	O	,
18	107	118	U-DYN	dipyridamole
19	119	119	O	,
20	121	138	U-DYN	hydroxychloroquine
21	140	142	O	and
22	144	149	O	others
23	151	154	O	that
24	156	164	O	interfere
25	166	169	O	with
26	171	178	O	platelet
27	180	190	O	aggregation
28	192	200	O	reactions
29	203	205	O	the
30	207	210	O	main
31	212	221	O	hemostatic
32	223	229	O	defense
33	231	232	O	of
34	234	240	O	XXXXXXXX
35	241	244	O	ized
36	246	253	O	patients
37	256	258	O	may
38	260	265	O	induce
39	267	274	O	bleeding
40	276	278	O	and
41	280	285	O	should
42	287	288	O	be
43	290	293	O	used
44	295	298	O	with
45	300	306	O	caution
46	308	309	O	in
47	311	318	O	patients
48	320	328	O	receiving
49	330	336	O	XXXXXXXX
50	338	343	O	sodium
NULL

Heparin	DDI-DrugBank.d488.s3	NO_SECTION	NO_SETID	21
The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.
1	0	2	O	The
2	4	16	O	anticoagulant
3	18	23	O	effect
4	25	26	O	of
5	28	34	O	XXXXXXXX
6	36	37	O	is
7	39	46	O	enhanced
8	48	49	O	by
9	51	60	O	concurrent
10	62	70	O	treatment
11	72	75	O	with
12	77	88	B-DYN	antithrombin
13	90	92	L-DYN	III
14	95	99	O	human
15	102	103	O	in
16	105	112	O	patients
17	114	117	O	with
18	119	128	O	hereditary
19	130	141	O	antithrombin
20	143	145	O	III
21	147	156	O	deficiency
NULL

Heparin	DDI-DrugBank.d488.s4	NO_SECTION	NO_SETID	19
Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).
1	0	3	O	Thus
2	5	6	O	in
3	8	12	O	order
4	14	15	O	to
5	17	21	O	avoid
6	23	30	O	bleeding
7	31	31	O	,
8	33	39	O	reduced
9	41	46	O	dosage
10	48	49	O	of
11	51	57	O	XXXXXXXX
12	59	60	O	is
13	62	72	O	recommended
14	74	79	O	during
15	81	89	O	treatment
16	91	94	O	with
17	96	107	B-DYN	antithrombin
18	109	111	L-DYN	III
19	114	118	O	human
NULL

Heparin	DDI-DrugBank.d488.s6	NO_SECTION	NO_SETID	22
Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
1	0	4	O	Drugs
2	6	15	O	Decreasing
3	17	23	O	XXXXXXXX
4	25	30	O	Effect
5	31	31	O	:
6	33	41	U-DYN	Digitalis
7	42	42	O	,
8	44	56	U-DYN	tetracyclines
9	57	57	O	,
10	59	66	U-DYN	nicotine
11	67	67	O	,
12	69	70	O	or
13	72	85	U-DYN	antihistamines
14	87	89	O	may
15	91	99	O	partially
16	101	110	O	counteract
17	112	114	O	the
18	116	128	O	anticoagulant
19	130	135	O	action
20	137	138	O	of
21	140	146	O	XXXXXXXX
22	148	153	O	sodium
NULL

Heparin	DDI-DrugBank.d488.s7	NO_SECTION	NO_SETID	34
Heparin Sodium Injection should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.
1	0	6	O	XXXXXXXX
2	8	13	O	Sodium
3	15	23	O	Injection
4	25	30	O	should
5	32	34	O	not
6	36	37	O	be
7	39	43	O	mixed
8	45	48	O	with
9	50	60	U-UNK	doxorubicin
10	61	61	O	,
11	63	72	U-UNK	droperidol
12	73	73	O	,
13	75	87	U-UNK	ciprofloxacin
14	88	88	O	,
15	90	91	O	or
16	93	104	U-UNK	mitoxantrone
17	105	105	O	,
18	107	111	O	since
19	113	114	O	it
20	116	118	O	has
21	120	123	O	been
22	125	132	O	reported
23	134	137	O	that
24	139	143	O	these
25	145	149	O	drugs
26	151	153	O	are
27	155	166	O	incompatible
28	168	171	O	with
29	173	179	O	XXXXXXXX
30	181	183	O	and
31	185	185	O	a
32	187	197	O	precipitate
33	199	201	O	may
34	203	206	O	form
NULL

Heparin	DDI-DrugBank.d488.s8	NO_SECTION	NO_SETID	35
Drug/ Laboratory Tests Interactions Hyperaminotransferasemia: Significant elevations of aminotransferase (SGOT [S-AST] and SGPT [S-ALT]) levels have occurred in a high percentage of patients (and healthy subjects) who have received heparin sodium.
1	0	3	O	Drug
2	4	4	O	/
3	6	15	O	Laboratory
4	17	21	O	Tests
5	23	34	O	Interactions
6	36	59	O	Hyperaminotransferasemia
7	60	60	O	:
8	62	72	O	Significant
9	74	83	O	elevations
10	85	86	O	of
11	88	103	O	aminotransferase
12	106	109	O	SGOT
13	112	112	O	S
14	114	116	O	AST
15	119	121	O	and
16	123	126	O	SGPT
17	129	129	O	S
18	131	133	O	ALT
19	137	142	O	levels
20	144	147	O	have
21	149	156	O	occurred
22	158	159	O	in
23	161	161	O	a
24	163	166	O	high
25	168	177	O	percentage
26	179	180	O	of
27	182	189	O	patients
28	192	194	O	and
29	196	202	O	healthy
30	204	211	O	subjects
31	214	216	O	who
32	218	221	O	have
33	223	230	O	received
34	232	238	O	XXXXXXXX
35	240	245	O	sodium
NULL

Heparin	DDI-DrugBank.d488.s9	NO_SECTION	NO_SETID	33
Since aminotransferase determinations are important in the differential diagnosis of myocardial infarction, liver disease and pulmonary emboli, rises that might be caused by drugs (heparin sodium) should be interpreted with caution.
1	0	4	O	Since
2	6	21	O	aminotransferase
3	23	36	O	determinations
4	38	40	O	are
5	42	50	O	important
6	52	53	O	in
7	55	57	O	the
8	59	70	O	differential
9	72	80	O	diagnosis
10	82	83	O	of
11	85	94	O	myocardial
12	96	105	O	infarction
13	106	106	O	,
14	108	112	O	liver
15	114	120	O	disease
16	122	124	O	and
17	126	134	O	pulmonary
18	136	141	O	emboli
19	142	142	O	,
20	144	148	O	rises
21	150	153	O	that
22	155	159	O	might
23	161	162	O	be
24	164	169	O	caused
25	171	172	O	by
26	174	178	O	drugs
27	181	187	O	XXXXXXXX
28	189	194	O	sodium
29	197	202	O	should
30	204	205	O	be
31	207	217	O	interpreted
32	219	222	O	with
33	224	230	O	caution
NULL

Heroin	DDI-DrugBank.d514.s0	NO_SECTION	NO_SETID	18
Opioids are strong central nervous system depressants, but regular users develop physiological tolerance allowing gradually increased dosages.
1	0	6	U-UNK	Opioids
2	8	10	O	are
3	12	17	O	strong
4	19	25	B-UNK	central
5	27	33	I-UNK	nervous
6	35	40	I-UNK	system
7	42	52	L-UNK	depressants
8	53	53	O	,
9	55	57	O	but
10	59	65	O	regular
11	67	71	O	users
12	73	79	O	develop
13	81	93	O	physiological
14	95	103	O	tolerance
15	105	112	O	allowing
16	114	122	O	gradually
17	124	132	O	increased
18	134	140	O	dosages
NULL

Heroin	DDI-DrugBank.d514.s1	NO_SECTION	NO_SETID	35
In combination with other central nervous system depressants, heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.
1	0	1	O	In
2	3	13	O	combination
3	15	18	O	with
4	20	24	O	other
5	26	32	B-DYN	central
6	34	40	I-DYN	nervous
7	42	47	I-DYN	system
8	49	59	L-DYN	depressants
9	60	60	O	,
10	62	67	O	XXXXXXXX
11	69	71	O	may
12	73	77	O	still
13	79	82	O	kill
14	84	87	O	even
15	89	99	O	experienced
16	101	105	O	users
17	106	106	O	,
18	108	119	O	particularly
19	121	122	O	if
20	124	128	O	their
21	130	138	O	tolerance
22	140	141	O	to
23	143	145	O	the
24	147	150	O	drug
25	152	154	O	has
26	156	162	O	reduced
27	164	165	O	or
28	167	169	O	the
29	171	178	O	strength
30	180	181	O	of
31	183	187	O	their
32	189	193	O	usual
33	195	198	O	dose
34	200	202	O	has
35	204	212	O	increased
NULL

Heroin	DDI-DrugBank.d514.s2	NO_SECTION	NO_SETID	33
Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
1	0	9	O	Toxicology
2	11	17	O	studies
3	19	20	O	of
4	22	27	U-DYN	heroin
5	29	35	O	related
6	37	42	O	deaths
7	44	49	O	reveal
8	51	58	O	frequent
9	60	70	O	involvement
10	72	73	O	of
11	75	79	O	other
12	81	87	B-UNK	central
13	89	95	I-UNK	nervous
14	97	102	I-UNK	system
15	104	114	L-UNK	depressants
16	115	115	O	,
17	117	125	O	including
18	127	133	U-UNK	alcohol
19	134	134	O	,
20	136	150	U-UNK	benzodiazepines
21	152	155	O	such
22	157	158	O	as
23	160	167	U-UNK	diazepam
24	170	175	O	XXXXXXXX
25	177	177	O	,
26	179	181	O	and
27	182	182	O	,
28	184	185	O	to
29	187	187	O	a
30	189	194	O	rising
31	196	201	O	degree
32	202	202	O	,
33	204	212	U-UNK	methadone
NULL

Heroin	DDI-DrugBank.d514.s3	NO_SECTION	NO_SETID	20
Ironically, benzodiazepines are often used in the treatment of heroin addiction while they cause much more severe withdrawal symptoms.
1	0	9	O	Ironically
2	10	10	O	,
3	12	26	U-UNK	benzodiazepines
4	28	30	O	are
5	32	36	O	often
6	38	41	O	used
7	43	44	O	in
8	46	48	O	the
9	50	58	O	treatment
10	60	61	O	of
11	63	68	O	XXXXXXXX
12	70	78	O	addiction
13	80	84	O	while
14	86	89	O	they
15	91	95	O	cause
16	97	100	O	much
17	102	105	O	more
18	107	112	O	severe
19	114	123	O	withdrawal
20	125	132	O	symptoms
NULL

Heroin	DDI-DrugBank.d514.s4	NO_SECTION	NO_SETID	12
Cocaine sometimes proves to be fatal when used in combination with heroin.
1	0	6	U-DYN	Cocaine
2	8	16	O	sometimes
3	18	23	O	proves
4	25	26	O	to
5	28	29	O	be
6	31	35	O	fatal
7	37	40	O	when
8	42	45	O	used
9	47	48	O	in
10	50	60	O	combination
11	62	65	O	with
12	67	72	O	XXXXXXXX
NULL

Hexachlorophene	DDI-DrugBank.d421.s0	NO_SECTION	NO_SETID	3
No information available.
1	0	1	O	No
2	3	13	O	information
3	15	23	O	available
NULL

Hexobarbital	DDI-DrugBank.d457.s0	NO_SECTION	NO_SETID	23
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
1	0	11	U-UNK	Barbiturates
2	13	15	O	may
3	17	24	O	decrease
4	26	28	O	the
5	30	42	O	effectiveness
6	44	45	O	of
7	47	50	O	oral
8	52	65	U-UNK	contraceptives
9	66	66	O	,
10	68	74	O	certain
11	76	86	U-UNK	antibiotics
12	87	87	O	,
13	89	97	U-UNK	quinidine
14	98	98	O	,
15	100	111	U-UNK	theophylline
16	112	112	O	,
17	114	128	U-UNK	corticosteroids
18	129	129	O	,
19	131	144	U-UNK	anticoagulants
20	145	145	O	,
21	147	149	O	and
22	151	154	B-UNK	beta
23	156	163	L-UNK	blockers
NULL

Hydralazine	DDI-DrugBank.d31.s0	NO_SECTION	NO_SETID	11
MAO inhibitors should be used with caution in patients receiving hydralazine.
1	0	2	B-DYN	MAO
2	4	13	L-DYN	inhibitors
3	15	20	O	should
4	22	23	O	be
5	25	28	O	used
6	30	33	O	with
7	35	41	O	caution
8	43	44	O	in
9	46	53	O	patients
10	55	63	O	receiving
11	65	75	O	XXXXXXXX
NULL

Hydralazine	DDI-DrugBank.d31.s1	NO_SECTION	NO_SETID	33
When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.
1	0	3	O	When
2	5	9	O	other
3	11	16	O	potent
4	18	25	O	parental
5	27	42	B-DYN	antihypertensive
6	44	48	L-DYN	drugs
7	49	49	O	,
8	51	54	O	such
9	56	57	O	as
10	59	67	U-UNK	diazoxide
11	68	68	O	,
12	70	72	O	are
13	74	77	O	used
14	79	80	O	in
15	82	92	O	combination
16	94	97	O	with
17	99	109	O	XXXXXXXX
18	110	110	O	,
19	112	119	O	patients
20	121	126	O	should
21	128	129	O	be
22	131	142	O	continuously
23	144	151	O	observed
24	153	155	O	for
25	157	163	O	several
26	165	169	O	hours
27	171	173	O	for
28	175	177	O	any
29	179	187	O	excessive
30	189	192	O	fall
31	194	195	O	in
32	197	201	O	blood
33	203	210	O	pressure
NULL

Hydralazine	DDI-DrugBank.d31.s2	NO_SECTION	NO_SETID	13
Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.
1	0	7	O	Profound
2	9	19	O	hypotensive
3	21	28	O	episodes
4	30	32	O	may
5	34	38	O	occur
6	40	43	O	when
7	45	53	U-DYN	diazoxide
8	55	63	O	infection
9	65	67	O	and
10	69	79	O	XXXXXXXX
11	81	83	O	are
12	85	88	O	used
13	90	102	O	concomitantly
NULL

Hydralazine	DDI-DrugBank.d31.s3	NO_SECTION	NO_SETID	13
Beta-blockers (metoprolol, propranolol) serum concentrations and pharmacologic effects may be increased.
1	0	3	B-UNK	Beta
2	5	12	L-UNK	blockers
3	15	24	U-UNK	metoprolol
4	25	25	O	,
5	27	37	U-UNK	propranolol
6	40	44	O	serum
7	46	59	O	concentrations
8	61	63	O	and
9	65	77	O	pharmacologic
10	79	85	O	effects
11	87	89	O	may
12	91	92	O	be
13	94	102	O	increased
NULL

Hydralazine	DDI-DrugBank.d31.s4	NO_SECTION	NO_SETID	3
Monitor cardiovascular status.
1	0	6	O	Monitor
2	8	21	O	cardiovascular
3	23	28	O	status
NULL

Hydralazine	DDI-DrugBank.d31.s5	NO_SECTION	NO_SETID	6
Propranolol increases hydralazines serum concentrations.
1	0	10	U-KIN	Propranolol
2	12	20	O	increases
3	22	32	O	XXXXXXXX
4	33	33	O	s
5	35	39	O	serum
6	41	54	O	concentrations
NULL

Hydralazine	DDI-DrugBank.d31.s6	NO_SECTION	NO_SETID	19
Acebutolol, atenolol, and nadolol (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.
1	0	9	U-UNK	Acebutolol
2	10	10	O	,
3	12	19	U-UNK	atenolol
4	20	20	O	,
5	22	24	O	and
6	26	32	U-UNK	nadolol
7	35	37	O	low
8	39	45	O	hepatic
9	47	55	O	clearance
10	57	58	O	or
11	60	61	O	no
12	63	67	O	first
13	69	72	O	pass
14	74	83	O	metabolism
15	86	88	O	are
16	90	97	O	unlikely
17	99	100	O	to
18	102	103	O	be
19	105	112	O	affected
NULL

Hydralazine	DDI-DrugBank.d31.s7	NO_SECTION	NO_SETID	8
NSAIDs may decrease the hemodynamic effects of hydralazine;
1	0	5	U-DYN	NSAIDs
2	7	9	O	may
3	11	18	O	decrease
4	20	22	O	the
5	24	34	O	hemodynamic
6	36	42	O	effects
7	44	45	O	of
8	47	57	O	XXXXXXXX
NULL

Hydralazine	DDI-DrugBank.d31.s8	NO_SECTION	NO_SETID	15
avoid use if possible or closely monitor cardiovascular status at the end of drug interactions
1	0	4	O	avoid
2	6	8	O	use
3	10	11	O	if
4	13	20	O	possible
5	22	23	O	or
6	25	31	O	closely
7	33	39	O	monitor
8	41	54	O	cardiovascular
9	56	61	O	status
10	63	64	O	at
11	66	68	O	the
12	70	72	O	end
13	74	75	O	of
14	77	80	O	drug
15	82	93	O	interactions
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s0	NO_SECTION	NO_SETID	11
When given concurrently the following drugs may interact with thiazide diuretics.
1	0	3	O	When
2	5	9	O	given
3	11	22	O	concurrently
4	24	26	O	the
5	28	36	O	following
6	38	42	O	drugs
7	44	46	O	may
8	48	55	O	interact
9	57	60	O	with
10	62	69	B-UNK	thiazide
11	71	79	L-UNK	diuretics
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s1	NO_SECTION	NO_SETID	13
Alcohol, barbiturates, or narcotics: potentiation of orthostatic hypotension may occur.
1	0	6	U-UNK	Alcohol
2	7	7	O	,
3	9	20	U-UNK	barbiturates
4	21	21	O	,
5	23	24	O	or
6	26	34	U-UNK	narcotics
7	35	35	O	:
8	37	48	O	potentiation
9	50	51	O	of
10	53	63	O	orthostatic
11	65	75	O	hypotension
12	77	79	O	may
13	81	85	O	occur
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s2	NO_SECTION	NO_SETID	16
Antidiabetic drugs: (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required.
1	0	11	B-UNK	Antidiabetic
2	13	17	L-UNK	drugs
3	18	18	O	:
4	21	24	O	oral
5	26	31	O	agents
6	33	35	O	and
7	37	43	U-UNK	insulin
8	48	53	O	dosage
9	55	64	O	adjustment
10	66	67	O	of
11	69	71	O	the
12	73	84	B-UNK	antidiabetic
13	86	89	L-UNK	drug
14	91	93	O	may
15	95	96	O	be
16	98	105	O	required
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s3	NO_SECTION	NO_SETID	8
Other antihypertensive drugs: additive effect or potentiation.
1	0	4	O	Other
2	6	21	B-UNK	antihypertensive
3	23	27	L-UNK	drugs
4	28	28	O	:
5	30	37	O	additive
6	39	44	O	effect
7	46	47	O	or
8	49	60	O	potentiation
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s4	NO_SECTION	NO_SETID	17
Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.
1	0	13	U-UNK	Cholestyramine
2	15	17	O	and
3	19	28	U-UNK	colestipol
4	30	35	U-UNK	resins
5	36	36	O	:
6	38	47	O	Absorption
7	49	50	O	of
8	52	70	O	XXXXXXXX
9	72	73	O	is
10	75	82	O	impaired
11	84	85	O	in
12	87	89	O	the
13	91	98	O	presence
14	100	101	O	of
15	103	109	B-KIN	anionic
16	111	118	I-KIN	exchange
17	120	125	L-KIN	resins
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s5	NO_SECTION	NO_SETID	28
Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
1	0	5	O	Single
2	7	11	O	doses
3	13	14	O	of
4	16	21	O	either
5	23	36	U-KIN	cholestyramine
6	38	39	O	or
7	41	50	U-KIN	colestipol
8	52	57	U-UNK	resins
9	59	62	O	bind
10	64	66	O	the
11	68	86	O	XXXXXXXX
12	88	90	O	and
13	92	97	O	reduce
14	99	101	O	its
15	103	112	O	absorption
16	114	117	O	from
17	119	121	O	the
18	123	138	O	gastrointestinal
19	140	144	O	tract
20	146	147	O	by
21	149	150	O	up
22	152	153	O	to
23	155	156	O	85
24	158	160	O	and
25	162	163	O	43
26	165	171	O	percent
27	172	172	O	,
28	174	185	O	respectively
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s6	NO_SECTION	NO_SETID	10
Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia.
1	0	14	U-UNK	Corticosteroids
2	15	15	O	,
3	17	20	U-UNK	ACTH
4	21	21	O	:
5	23	33	O	intensified
6	35	45	O	electrolyte
7	47	55	O	depletion
8	56	56	O	,
9	58	69	O	particularly
10	71	81	O	hypokalemia
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s7	NO_SECTION	NO_SETID	19
Pressor amines (e.g., norepinephrine): possible decreased response to pressor amines but not sufficient to preclude their use.
1	0	6	O	Pressor
2	8	13	O	amines
3	16	18	O	e.g
4	20	20	O	,
5	22	35	U-UNK	norepinephrine
6	37	37	O	:
7	39	46	O	possible
8	48	56	O	decreased
9	58	65	O	response
10	67	68	O	to
11	70	76	O	pressor
12	78	83	O	amines
13	85	87	O	but
14	89	91	O	not
15	93	102	O	sufficient
16	104	105	O	to
17	107	114	O	preclude
18	116	120	O	their
19	122	124	O	use
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s8	NO_SECTION	NO_SETID	16
Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): possible increased responsiveness to the muscle relaxant.
1	0	7	B-UNK	Skeletal
2	9	14	I-UNK	muscle
3	16	24	L-UNK	relaxants
4	25	25	O	,
5	27	41	O	nondepolarizing
6	44	46	O	e.g
7	48	48	O	,
8	50	61	U-UNK	tubocurarine
9	63	63	O	:
10	65	72	O	possible
11	74	82	O	increased
12	84	97	O	responsiveness
13	99	100	O	to
14	102	104	O	the
15	106	111	B-UNK	muscle
16	113	120	L-UNK	relaxant
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s9	NO_SECTION	NO_SETID	9
Lithium: generally should not be given with diuretics.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	17	O	generally
4	19	24	O	should
5	26	28	O	not
6	30	31	O	be
7	33	37	O	given
8	39	42	O	with
9	44	52	U-UNK	diuretics
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s10	NO_SECTION	NO_SETID	16
Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
1	0	7	B-UNK	Diuretic
2	9	14	L-UNK	agents
3	16	21	O	reduce
4	23	25	O	the
5	27	31	O	renal
6	33	41	O	clearance
7	43	44	O	of
8	46	52	U-UNK	lithium
9	54	56	O	and
10	58	60	O	add
11	62	62	O	a
12	64	67	O	high
13	69	72	O	risk
14	74	75	O	of
15	77	83	U-UNK	lithium
16	85	92	O	toxicity
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s11	NO_SECTION	NO_SETID	15
Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.
1	0	4	O	Refer
2	6	7	O	to
3	9	11	O	the
4	13	19	O	package
5	21	26	O	insert
6	28	30	O	for
7	32	38	U-DYN	lithium
8	40	51	O	preparations
9	53	58	O	before
10	60	62	O	use
11	64	65	O	of
12	67	70	O	such
13	72	83	O	preparations
14	85	88	O	with
15	90	108	O	XXXXXXXX
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s12	NO_SECTION	NO_SETID	37
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
1	0	2	B-UNK	Non
2	4	12	I-UNK	steroidal
3	14	17	I-UNK	Anti
4	19	30	I-UNK	inflammatory
5	32	36	L-UNK	Drugs
6	37	37	O	:
7	39	40	O	In
8	42	45	O	some
9	47	54	O	patients
10	55	55	O	,
11	57	59	O	the
12	61	74	O	administration
13	76	77	O	of
14	79	79	O	a
15	81	83	B-UNK	non
16	85	93	I-UNK	steroidal
17	95	98	I-UNK	anti
18	100	111	I-UNK	inflammatory
19	113	117	L-UNK	agent
20	119	121	O	can
21	123	128	O	reduce
22	130	132	O	the
23	134	141	O	diuretic
24	142	142	O	,
25	144	154	O	natriuretic
26	155	155	O	,
27	157	159	O	and
28	161	176	O	antihypertensive
29	178	184	O	effects
30	186	187	O	of
31	189	192	B-UNK	loop
32	193	193	I-UNK	,
33	195	203	I-UNK	potassium
34	205	211	I-UNK	sparing
35	213	215	I-UNK	and
36	217	224	I-UNK	thiazide
37	226	234	L-UNK	diuretics
NULL

Hydrochlorothiazide	DDI-DrugBank.d162.s13	NO_SECTION	NO_SETID	31
Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	34	O	XXXXXXXX
5	36	38	O	and
6	40	42	B-DYN	non
7	44	52	I-DYN	steroidal
8	54	57	I-DYN	anti
9	59	70	I-DYN	inflammatory
10	72	77	L-DYN	agents
11	79	81	O	are
12	83	86	O	used
13	88	100	O	concomitantly
14	101	101	O	,
15	103	105	O	the
16	107	113	O	patient
17	115	120	O	should
18	122	123	O	be
19	125	132	O	observed
20	134	140	O	closely
21	142	143	O	to
22	145	153	O	determine
23	155	156	O	if
24	158	160	O	the
25	162	168	O	desired
26	170	175	O	effect
27	177	178	O	of
28	180	182	O	the
29	184	191	U-UNK	diuretic
30	193	194	O	is
31	196	203	O	obtained
NULL

Hydrocodone	DDI-DrugBank.d396.s0	NO_SECTION	NO_SETID	29
Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	23	O	other
4	25	32	B-DYN	narcotic
5	34	43	L-DYN	analgesics
6	44	44	O	,
7	46	59	U-DYN	antipsychotics
8	60	60	O	,
9	62	72	B-DYN	antianxiety
10	74	79	L-DYN	agents
11	80	80	O	,
12	82	83	O	or
13	85	89	O	other
14	91	93	B-DYN	CNS
15	95	105	L-DYN	depressants
16	108	116	O	including
17	118	124	U-DYN	alcohol
18	127	139	O	concomitantly
19	141	144	O	with
20	146	156	O	XXXXXXXX
21	158	160	O	and
22	162	174	U-UNK	acetaminophen
23	176	182	O	tablets
24	184	186	O	may
25	188	194	O	exhibit
26	196	197	O	an
27	199	206	O	additive
28	208	210	O	CNS
29	212	221	O	depression
NULL

Hydrocodone	DDI-DrugBank.d396.s1	NO_SECTION	NO_SETID	16
When combined therapy is contemplated, the dose of one or both agents should be reduced.
1	0	3	O	When
2	5	12	O	combined
3	14	20	O	therapy
4	22	23	O	is
5	25	36	O	contemplated
6	37	37	O	,
7	39	41	O	the
8	43	46	O	dose
9	48	49	O	of
10	51	53	O	one
11	55	56	O	or
12	58	61	O	both
13	63	68	O	agents
14	70	75	O	should
15	77	78	O	be
16	80	86	O	reduced
NULL

Hydrocodone	DDI-DrugBank.d396.s2	NO_SECTION	NO_SETID	21
The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	13	B-DYN	MAO
5	15	24	L-DYN	inhibitors
6	26	27	O	or
7	29	37	B-DYN	tricyclic
8	39	53	L-DYN	antidepressants
9	55	58	O	with
10	60	70	O	XXXXXXXX
11	72	83	O	preparations
12	85	87	O	may
13	89	96	O	increase
14	98	100	O	the
15	102	107	O	effect
16	109	110	O	of
17	112	117	O	either
18	119	121	O	the
19	123	136	U-UNK	antidepressant
20	138	139	O	or
21	141	151	O	XXXXXXXX
NULL

Hydrocodone	DDI-DrugBank.d396.s3	NO_SECTION	NO_SETID	11
The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.
1	0	2	O	The
2	4	13	O	concurrent
3	15	17	O	use
4	19	20	O	of
5	22	37	U-DYN	anticholinergics
6	39	42	O	with
7	44	54	O	XXXXXXXX
8	56	58	O	may
9	60	66	O	produce
10	68	76	O	paralytic
11	78	82	O	ileus
NULL

Hydrocortisone	DDI-DrugBank.d155.s0	NO_SECTION	NO_SETID	3
No information available.
1	0	1	O	No
2	3	13	O	information
3	15	23	O	available
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s0	NO_SECTION	NO_SETID	3
Anticoagulants, oral
1	0	13	U-UNK	Anticoagulants
2	14	14	O	,
3	16	19	O	oral
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s1	NO_SECTION	NO_SETID	10
(Effects may be decreased when used concurrently with thiazide diuretics;
1	1	7	O	Effects
2	9	11	O	may
3	13	14	O	be
4	16	24	O	decreased
5	26	29	O	when
6	31	34	O	used
7	36	47	O	concurrently
8	49	52	O	with
9	54	61	B-UNK	thiazide
10	63	71	L-UNK	diuretics
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s2	NO_SECTION	NO_SETID	5
dosage adjustments may be necessary.)
1	0	5	O	dosage
2	7	17	O	adjustments
3	19	21	O	may
4	23	24	O	be
5	26	34	O	necessary
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s3	NO_SECTION	NO_SETID	2
Antigout medications
1	0	7	B-UNK	Antigout
2	9	19	L-UNK	medications
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s4	NO_SECTION	NO_SETID	10
(Thiazide diuretics may raise the level of blood uric acid;
1	1	8	B-UNK	Thiazide
2	10	18	L-UNK	diuretics
3	20	22	O	may
4	24	28	O	raise
5	30	32	O	the
6	34	38	O	level
7	40	41	O	of
8	43	47	O	blood
9	49	52	O	uric
10	54	57	O	acid
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s5	NO_SECTION	NO_SETID	13
dosage adjustment of antigout medications may be necessary to control hyperuricemia and gout.)
1	0	5	O	dosage
2	7	16	O	adjustment
3	18	19	O	of
4	21	28	B-UNK	antigout
5	30	40	L-UNK	medications
6	42	44	O	may
7	46	47	O	be
8	49	57	O	necessary
9	59	60	O	to
10	62	68	O	control
11	70	82	O	hyperuricemia
12	84	86	O	and
13	88	91	O	gout
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s6	NO_SECTION	NO_SETID	26
Antihypertensive medications, other, especially diazoxide, or preanesthetic and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery
1	0	15	B-UNK	Antihypertensive
2	17	27	L-UNK	medications
3	28	28	O	,
4	30	34	O	other
5	35	35	O	,
6	37	46	O	especially
7	48	56	U-UNK	diazoxide
8	57	57	O	,
9	59	60	O	or
10	62	74	O	preanesthetic
11	76	78	O	and
12	80	89	O	anesthetic
13	91	96	O	agents
14	98	101	O	used
15	103	104	O	in
16	106	112	O	surgery
17	114	115	O	or
18	117	124	B-UNK	skeletal
19	126	131	I-UNK	muscle
20	133	141	L-UNK	relaxants
21	142	142	O	,
22	144	158	O	nondepolarizing
23	159	159	O	,
24	161	164	O	used
25	166	167	O	in
26	169	175	O	surgery
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s7	NO_SECTION	NO_SETID	10
(Effects may be potentiated when used concurrently with thiazide diuretics;
1	1	7	O	Effects
2	9	11	O	may
3	13	14	O	be
4	16	26	O	potentiated
5	28	31	O	when
6	33	36	O	used
7	38	49	O	concurrently
8	51	54	O	with
9	56	63	B-UNK	thiazide
10	65	73	L-UNK	diuretics
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s8	NO_SECTION	NO_SETID	5
dosage adjustments may be necessary.)
1	0	5	O	dosage
2	7	17	O	adjustments
3	19	21	O	may
4	23	24	O	be
5	26	34	O	necessary
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s9	NO_SECTION	NO_SETID	7
Amphotericin B or Corticosteroids or Corticotropin (ACTH)
1	0	11	B-UNK	Amphotericin
2	13	13	L-UNK	B
3	15	16	O	or
4	18	32	U-UNK	Corticosteroids
5	34	35	O	or
6	37	49	U-UNK	Corticotropin
7	52	55	U-UNK	ACTH
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s10	NO_SECTION	NO_SETID	12
(Concurrent use with thiazide diuretics may intensify electrolyte imbalance, particularly hypokalemia.)
1	1	10	O	Concurrent
2	12	14	O	use
3	16	19	O	with
4	21	28	B-UNK	thiazide
5	30	38	L-UNK	diuretics
6	40	42	O	may
7	44	52	O	intensify
8	54	64	O	electrolyte
9	66	74	O	imbalance
10	75	75	O	,
11	77	88	O	particularly
12	90	100	O	hypokalemia
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s12	NO_SECTION	NO_SETID	15
(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.)
1	1	10	O	Concurrent
2	12	14	O	use
3	16	19	O	with
4	21	28	B-UNK	thiazide
5	30	38	L-UNK	diuretics
6	40	42	O	may
7	44	50	O	enhance
8	52	54	O	the
9	56	66	O	possibility
10	68	69	O	of
11	71	79	U-UNK	digitalis
12	81	88	O	toxicity
13	90	99	O	associated
14	101	104	O	with
15	106	116	O	hypokalemia
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s14	NO_SECTION	NO_SETID	8
(May inhibit gastrointestinal absorption of the thiazide diuretics;
1	1	3	O	May
2	5	11	O	inhibit
3	13	28	O	gastrointestinal
4	30	39	O	absorption
5	41	42	O	of
6	44	46	O	the
7	48	55	B-UNK	thiazide
8	57	65	L-UNK	diuretics
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s15	NO_SECTION	NO_SETID	11
administration 1 hour before or 4 hours after colestipol is recommended.)
1	0	13	O	administration
2	15	15	O	1
3	17	20	O	hour
4	22	27	O	before
5	29	30	O	or
6	32	32	O	4
7	34	38	O	hours
8	40	44	O	after
9	46	55	U-UNK	colestipol
10	57	58	O	is
11	60	70	O	recommended
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s17	NO_SECTION	NO_SETID	7
(Thiazide diuretics may raise blood glucose levels;
1	1	8	B-UNK	Thiazide
2	10	18	L-UNK	diuretics
3	20	22	O	may
4	24	28	O	raise
5	30	34	O	blood
6	36	42	O	glucose
7	44	49	O	levels
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s18	NO_SECTION	NO_SETID	19
for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;
1	0	2	O	for
2	4	8	O	adult
3	10	14	O	onset
4	16	24	O	diabetics
5	25	25	O	,
6	27	32	O	dosage
7	34	43	O	adjustment
8	45	46	O	of
9	48	59	B-UNK	hypoglycemic
10	61	71	L-UNK	medications
11	73	75	O	may
12	77	78	O	be
13	80	88	O	necessary
14	90	95	O	during
15	97	99	O	and
16	101	105	O	after
17	107	114	B-UNK	thiazide
18	116	123	L-UNK	diuretic
19	125	131	O	therapy
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s19	NO_SECTION	NO_SETID	10
insulin requirements may be increased, decreased, or unchanged.)
1	0	6	U-UNK	insulin
2	8	19	O	requirements
3	21	23	O	may
4	25	26	O	be
5	28	36	O	increased
6	37	37	O	,
7	39	47	O	decreased
8	48	48	O	,
9	50	51	O	or
10	53	61	O	unchanged
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s21	NO_SECTION	NO_SETID	20
(Concurrent use with thiazide diuretics is not recommended, as they may provoke lithium toxicity because of reduced renal clearance.)
1	1	10	O	Concurrent
2	12	14	O	use
3	16	19	O	with
4	21	28	B-UNK	thiazide
5	30	38	L-UNK	diuretics
6	40	41	O	is
7	43	45	O	not
8	47	57	O	recommended
9	58	58	O	,
10	60	61	O	as
11	63	66	O	they
12	68	70	O	may
13	72	78	O	provoke
14	80	86	U-UNK	lithium
15	88	95	O	toxicity
16	97	103	O	because
17	105	106	O	of
18	108	114	O	reduced
19	116	120	O	renal
20	122	130	O	clearance
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s23	NO_SECTION	NO_SETID	16
(Effectiveness may be decreased when used concurrently with thiazide diuretics because of alkalinization of the urine.)
1	1	13	O	Effectiveness
2	15	17	O	may
3	19	20	O	be
4	22	30	O	decreased
5	32	35	O	when
6	37	40	O	used
7	42	53	O	concurrently
8	55	58	O	with
9	60	67	B-UNK	thiazide
10	69	77	L-UNK	diuretics
11	79	85	O	because
12	87	88	O	of
13	90	103	O	alkalinization
14	105	106	O	of
15	108	110	O	the
16	112	116	O	urine
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s24	NO_SECTION	NO_SETID	4
Nonsteroidal anti-inflammatory agents
1	0	11	B-UNK	Nonsteroidal
2	13	16	I-UNK	anti
3	18	29	I-UNK	inflammatory
4	31	36	L-UNK	agents
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s25	NO_SECTION	NO_SETID	28
(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.
1	1	2	O	In
2	4	7	O	some
3	9	16	O	patients
4	17	17	O	,
5	19	21	O	the
6	23	31	B-UNK	steroidal
7	33	36	I-UNK	anti
8	38	49	I-UNK	inflammatory
9	51	55	L-UNK	agent
10	57	59	O	can
11	61	66	O	reduce
12	68	70	O	the
13	72	79	O	diuretic
14	80	80	O	,
15	82	92	O	natriuretic
16	93	93	O	,
17	95	97	O	and
18	99	114	O	antihypertensive
19	116	122	O	effects
20	124	125	O	of
21	127	130	B-UNK	loop
22	131	131	I-UNK	,
23	133	141	I-UNK	potassium
24	143	149	I-UNK	sparing
25	150	150	I-UNK	,
26	152	154	I-UNK	and
27	156	163	I-UNK	thiazide
28	165	173	L-UNK	diuretics
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s26	NO_SECTION	NO_SETID	30
Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	33	O	XXXXXXXX
5	35	37	O	and
6	39	50	B-DYN	nonsteroidal
7	52	55	I-DYN	anti
8	57	68	I-DYN	inflammatory
9	70	75	L-DYN	agents
10	77	79	O	are
11	81	84	O	used
12	86	98	O	concomitantly
13	99	99	O	,
14	101	103	O	the
15	105	111	O	patient
16	113	118	O	should
17	120	121	O	be
18	123	130	O	observed
19	132	138	O	closely
20	140	141	O	to
21	143	151	O	determine
22	153	154	O	if
23	156	158	O	the
24	160	166	O	desired
25	168	173	O	effect
26	175	176	O	of
27	178	180	O	the
28	182	189	U-UNK	diuretic
29	191	192	O	is
30	194	201	O	obtained
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s28	NO_SECTION	NO_SETID	7
(Thiazides may decrease arterial responsiveness to norepinephrine.
1	1	9	U-UNK	Thiazides
2	11	13	O	may
3	15	22	O	decrease
4	24	31	O	arterial
5	33	46	O	responsiveness
6	48	49	O	to
7	51	64	U-UNK	norepinephrine
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s29	NO_SECTION	NO_SETID	15
This diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.)
1	0	3	O	This
2	5	14	O	diminution
3	16	17	O	is
4	19	21	O	not
5	23	32	O	sufficient
6	34	35	O	to
7	37	44	O	preclude
8	46	58	O	effectiveness
9	60	61	O	of
10	63	65	O	the
11	67	73	O	pressor
12	75	79	O	agent
13	81	83	O	for
14	85	95	O	therapeutic
15	97	99	O	use
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s31	NO_SECTION	NO_SETID	8
(Thiazide drugs may increase the responsiveness to tubocurarine.)
1	1	8	B-UNK	Thiazide
2	10	14	L-UNK	drugs
3	16	18	O	may
4	20	27	O	increase
5	29	31	O	the
6	33	46	O	responsiveness
7	48	49	O	to
8	51	62	U-UNK	tubocurarine
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s32	NO_SECTION	NO_SETID	66
DIAGNOSTIC INTERFERENCE With expected physiologic effects: Blood and urine glucose levels (usually only in patients with a predisposition for glucose intolerance) and Serum bilirubin levels (by displacement from albumin binding) and Serum calcium levels (thiazide diuretics should be discontinued before parathyroid-function tests are carried out) and Serum uric acid levels (may be increased) Serum magnesium, potassium, and sodium levels (may be decreased;
1	0	9	O	DIAGNOSTIC
2	11	22	O	INTERFERENCE
3	24	27	O	With
4	29	36	O	expected
5	38	48	O	physiologic
6	50	56	O	effects
7	57	57	O	:
8	59	63	O	Blood
9	65	67	O	and
10	69	73	O	urine
11	75	81	O	glucose
12	83	88	O	levels
13	91	97	O	usually
14	99	102	O	only
15	104	105	O	in
16	107	114	O	patients
17	116	119	O	with
18	121	121	O	a
19	123	136	O	predisposition
20	138	140	O	for
21	142	148	O	glucose
22	150	160	O	intolerance
23	163	165	O	and
24	167	171	O	Serum
25	173	181	O	bilirubin
26	183	188	O	levels
27	191	192	O	by
28	194	205	O	displacement
29	207	210	O	from
30	212	218	O	albumin
31	220	226	O	binding
32	229	231	O	and
33	233	237	O	Serum
34	239	245	O	calcium
35	247	252	O	levels
36	255	262	B-UNK	thiazide
37	264	272	L-UNK	diuretics
38	274	279	O	should
39	281	282	O	be
40	284	295	O	discontinued
41	297	302	O	before
42	304	314	O	parathyroid
43	316	323	O	function
44	325	329	O	tests
45	331	333	O	are
46	335	341	O	carried
47	343	345	O	out
48	348	350	O	and
49	352	356	O	Serum
50	358	361	O	uric
51	363	366	O	acid
52	368	373	O	levels
53	376	378	O	may
54	380	381	O	be
55	383	391	O	increased
56	394	398	O	Serum
57	400	408	O	magnesium
58	409	409	O	,
59	411	419	O	potassium
60	420	420	O	,
61	422	424	O	and
62	426	431	O	sodium
63	433	438	O	levels
64	441	443	O	may
65	445	446	O	be
66	448	456	O	decreased
NULL

Hydroflumethiazide	DDI-DrugBank.d17.s33	NO_SECTION	NO_SETID	28
serum magnesium levels may increase in uremic patients) Serum protein-bound iodine (PBI) levels (may be decreased) Thiazides should be discontinued before carrying out tests for parathyroid function.
1	0	4	O	serum
2	6	14	O	magnesium
3	16	21	O	levels
4	23	25	O	may
5	27	34	O	increase
6	36	37	O	in
7	39	44	O	uremic
8	46	53	O	patients
9	56	60	O	Serum
10	62	68	O	protein
11	70	74	O	bound
12	76	81	O	iodine
13	84	86	O	PBI
14	89	94	O	levels
15	97	99	O	may
16	101	102	O	be
17	104	112	O	decreased
18	115	123	U-UNK	Thiazides
19	125	130	O	should
20	132	133	O	be
21	135	146	O	discontinued
22	148	153	O	before
23	155	162	O	carrying
24	164	166	O	out
25	168	172	O	tests
26	174	176	O	for
27	178	188	O	parathyroid
28	190	197	O	function
NULL

Hydromorphone	DDI-DrugBank.d26.s0	NO_SECTION	NO_SETID	33
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	23	O	other
4	25	32	U-DYN	narcotic
5	34	43	O	analgesics
6	44	44	O	,
7	46	52	O	general
8	54	64	U-DYN	anesthetics
9	65	65	O	,
10	67	80	U-DYN	phenothiazines
11	81	81	O	,
12	83	95	U-DYN	tranquilizers
13	96	96	O	,
14	98	105	B-DYN	sedative
15	107	115	L-DYN	hypnotics
16	116	116	O	,
17	118	126	B-DYN	tricyclic
18	128	142	L-DYN	antidepressants
19	144	145	O	or
20	147	151	O	other
21	153	155	B-DYN	CNS
22	157	167	L-DYN	depressants
23	170	178	O	including
24	180	186	U-DYN	alcohol
25	189	201	O	concomitantly
26	203	206	O	with
27	208	215	O	XXXXXXXX
28	217	219	O	may
29	221	227	O	exhibit
30	229	230	O	an
31	232	239	O	additive
32	241	243	O	CNS
33	245	254	O	depression
NULL

Hydromorphone	DDI-DrugBank.d26.s1	NO_SECTION	NO_SETID	17
When such combined therapy is contemplated, the dose of one or both agents should be reduced.
1	0	3	O	When
2	5	8	O	such
3	10	17	O	combined
4	19	25	O	therapy
5	27	28	O	is
6	30	41	O	contemplated
7	42	42	O	,
8	44	46	O	the
9	48	51	O	dose
10	53	54	O	of
11	56	58	O	one
12	60	61	O	or
13	63	66	O	both
14	68	73	O	agents
15	75	80	O	should
16	82	83	O	be
17	85	91	O	reduced
NULL

Hydroxocobalamin	DDI-DrugBank.d418.s0	NO_SECTION	NO_SETID	10
No formal drug interaction studies have been conducted with Cyanokit.
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	25	O	interaction
5	27	33	O	studies
6	35	38	O	have
7	40	43	O	been
8	45	53	O	conducted
9	55	58	O	with
10	60	67	O	XXXXXXXX
NULL

Hydroxyurea	DDI-DrugBank.d16.s0	NO_SECTION	NO_SETID	16
Prospective studies on the potential for hydroxyurea to interact with other drugs have not been performed.
1	0	10	O	Prospective
2	12	18	O	studies
3	20	21	O	on
4	23	25	O	the
5	27	35	O	potential
6	37	39	O	for
7	41	51	O	XXXXXXXX
8	53	54	O	to
9	56	63	O	interact
10	65	68	O	with
11	70	74	O	other
12	76	80	O	drugs
13	82	85	O	have
14	87	89	O	not
15	91	94	O	been
16	96	104	O	performed
NULL

Hydroxyurea	DDI-DrugBank.d16.s1	NO_SECTION	NO_SETID	23
Concurrent use of hydroxyurea and other myelosuppressive agents or radiation therapy may increase the likelihood of bone marrow depression or other adverse events.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	16	O	of
4	18	28	O	XXXXXXXX
5	30	32	O	and
6	34	38	O	other
7	40	55	O	myelosuppressive
8	57	62	O	agents
9	64	65	O	or
10	67	75	O	radiation
11	77	83	O	therapy
12	85	87	O	may
13	89	96	O	increase
14	98	100	O	the
15	102	111	O	likelihood
16	113	114	O	of
17	116	119	O	bone
18	121	126	O	marrow
19	128	137	O	depression
20	139	140	O	or
21	142	146	O	other
22	148	154	O	adverse
23	156	161	O	events
NULL

Hydroxyurea	DDI-DrugBank.d16.s2	NO_SECTION	NO_SETID	18
Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary
1	0	4	O	Since
2	6	16	O	XXXXXXXX
3	18	20	O	may
4	22	26	O	raise
5	28	30	O	the
6	32	36	O	serum
7	38	41	O	uric
8	43	46	O	acid
9	48	52	O	level
10	53	53	O	,
11	55	60	O	dosage
12	62	71	O	adjustment
13	73	74	O	of
14	76	85	B-DYN	uricosuric
15	87	96	L-DYN	medication
16	98	100	O	may
17	102	103	O	be
18	105	113	O	necessary
NULL

Hydroxyzine	DDI-DrugBank.d308.s0	NO_SECTION	NO_SETID	29
THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
1	0	2	O	THE
2	4	15	O	POTENTIATING
3	17	22	O	ACTION
4	24	25	O	OF
5	27	37	O	XXXXXXXX
6	39	42	O	MUST
7	44	45	O	BE
8	47	56	O	CONSIDERED
9	58	61	O	WHEN
10	63	65	O	THE
11	67	70	O	DRUG
12	72	73	O	IS
13	75	78	O	USED
14	80	81	O	IN
15	83	93	O	CONJUNCTION
16	95	98	O	WITH
17	100	106	B-DYN	CENTRAL
18	108	114	I-DYN	NERVOUS
19	116	121	I-DYN	SYSTEM
20	123	133	L-DYN	DEPRESSANTS
21	135	138	O	SUCH
22	140	141	O	AS
23	143	151	U-DYN	NARCOTICS
24	152	152	O	,
25	154	156	B-DYN	NON
26	158	165	I-DYN	NARCOTIC
27	167	176	L-DYN	ANALGESICS
28	178	180	O	AND
29	182	193	U-DYN	BARBITURATES
NULL

Hydroxyzine	DDI-DrugBank.d308.s1	NO_SECTION	NO_SETID	16
Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.
1	0	8	O	Therefore
2	10	13	O	when
3	15	21	B-DYN	central
4	23	29	I-DYN	nervous
5	31	36	I-DYN	system
6	38	48	L-DYN	depressants
7	50	52	O	are
8	54	65	O	administered
9	67	79	O	concomitantly
10	81	84	O	with
11	86	96	O	XXXXXXXX
12	98	102	O	their
13	104	109	O	dosage
14	111	116	O	should
15	118	119	O	be
16	121	127	O	reduced
NULL

Hydroxyzine	DDI-DrugBank.d308.s2	NO_SECTION	NO_SETID	30
Since drowsiness may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking Atarax.
1	0	4	O	Since
2	6	15	O	drowsiness
3	17	19	O	may
4	21	25	O	occur
5	27	30	O	with
6	32	34	O	use
7	36	37	O	of
8	39	42	O	this
9	44	47	O	drug
10	48	48	O	,
11	50	57	O	patients
12	59	64	O	should
13	66	67	O	be
14	69	74	O	warned
15	76	77	O	of
16	79	82	O	this
17	84	94	O	possibility
18	96	98	O	and
19	100	108	O	cautioned
20	110	116	O	against
21	118	124	O	driving
22	126	126	O	a
23	128	130	O	car
24	132	133	O	or
25	135	143	O	operating
26	145	153	O	dangerous
27	155	163	O	machinery
28	165	169	O	while
29	171	176	O	taking
30	178	183	O	XXXXXXXX
NULL

Hydroxyzine	DDI-DrugBank.d308.s3	NO_SECTION	NO_SETID	24
Patients should be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effect of alcohol may be increased.
1	0	7	O	Patients
2	9	14	O	should
3	16	17	O	be
4	19	25	O	advised
5	27	33	O	against
6	35	37	O	the
7	39	50	O	simultaneous
8	52	54	O	use
9	56	57	O	of
10	59	63	O	other
11	65	67	B-UNK	CNS
12	69	78	I-UNK	depressant
13	80	84	L-UNK	drugs
14	85	85	O	,
15	87	89	O	and
16	91	99	O	cautioned
17	101	104	O	that
18	106	108	O	the
19	110	115	O	effect
20	117	118	O	of
21	120	126	U-UNK	alcohol
22	128	130	O	may
23	132	133	O	be
24	135	143	O	increased
NULL

Hyoscyamine	DDI-DrugBank.d142.s0	NO_SECTION	NO_SETID	34
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
1	0	7	O	Additive
2	9	15	O	adverse
3	17	23	O	effects
4	25	33	O	resulting
5	35	38	O	from
6	40	50	O	cholinergic
7	52	59	O	blockade
8	61	63	O	may
9	65	69	O	occur
10	71	74	O	when
11	76	81	O	XXXXXXXX
12	83	84	O	is
13	86	97	O	administered
14	99	111	O	concomitantly
15	113	116	O	with
16	118	122	O	other
17	124	138	U-DYN	antimuscarinics
18	139	139	O	,
19	141	150	U-DYN	amantadine
20	151	151	O	,
21	153	163	U-DYN	haloperidol
22	164	164	O	,
23	166	179	U-DYN	phenothiazines
24	180	180	O	,
25	182	190	B-DYN	monoamine
26	192	198	I-DYN	oxidase
27	201	203	I-DYN	MAO
28	206	215	L-DYN	inhibitors
29	216	216	O	,
30	218	226	B-DYN	tricyclic
31	228	242	L-DYN	antidepressants
32	244	245	O	or
33	247	250	O	some
34	252	265	U-DYN	antihistamines
NULL

Hyoscyamine	DDI-DrugBank.d142.s1	NO_SECTION	NO_SETID	8
Antacids may interfere with the absorption of LEVSIN.
1	0	7	U-KIN	Antacids
2	9	11	O	may
3	13	21	O	interfere
4	23	26	O	with
5	28	30	O	the
6	32	41	O	absorption
7	43	44	O	of
8	46	51	O	XXXXXXXX
NULL

Hyoscyamine	DDI-DrugBank.d142.s2	NO_SECTION	NO_SETID	4
Administer LEVSIN before meals;
1	0	9	O	Administer
2	11	16	O	XXXXXXXX
3	18	23	O	before
4	25	29	O	meals
NULL

Hyoscyamine	DDI-DrugBank.d142.s3	NO_SECTION	NO_SETID	3
antacids after meals.
1	0	7	U-UNK	antacids
2	9	13	O	after
3	15	19	O	meals
NULL

Ibandronate	DDI-DrugBank.d440.s0	NO_SECTION	NO_SETID	4
Calcium Supplements/Antacids
1	0	6	U-UNK	Calcium
2	8	18	O	Supplements
3	19	19	O	/
4	20	27	U-UNK	Antacids
NULL

Ibandronate	DDI-DrugBank.d440.s1	NO_SECTION	NO_SETID	22
Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
1	0	7	O	Products
2	9	18	O	containing
3	20	26	U-KIN	calcium
4	28	30	O	and
5	32	36	O	other
6	38	48	O	multivalent
7	50	56	O	cations
8	59	62	O	such
9	64	65	O	as
10	67	74	U-KIN	aluminum
11	75	75	O	,
12	77	85	U-KIN	magnesium
13	86	86	O	,
14	88	91	U-KIN	iron
15	94	96	O	are
16	98	103	O	likely
17	105	106	O	to
18	108	116	O	interfere
19	118	121	O	with
20	123	132	O	absorption
21	134	135	O	of
22	137	147	O	XXXXXXXX
NULL

Ibandronate	DDI-DrugBank.d440.s2	NO_SECTION	NO_SETID	21
Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).
1	0	10	O	XXXXXXXX
2	12	17	O	should
3	19	20	O	be
4	22	26	O	taken
5	28	29	O	at
6	31	35	O	least
7	37	38	O	60
8	40	46	O	minutes
9	48	53	O	before
10	55	57	O	any
11	59	62	O	oral
12	64	74	O	medications
13	76	85	O	containing
14	87	97	O	multivalent
15	99	105	O	cations
16	108	116	O	including
17	118	125	U-DYN	antacids
18	126	126	O	,
19	128	138	O	supplements
20	140	141	O	or
21	143	150	U-DYN	vitamins
NULL

Ibandronate	DDI-DrugBank.d440.s3	NO_SECTION	NO_SETID	7
H2 Blockers and Proton Pump Inhibitors (PPIs)
1	0	1	B-UNK	H2
2	3	10	L-UNK	Blockers
3	12	14	O	and
4	16	21	B-UNK	Proton
5	23	26	I-UNK	Pump
6	28	37	L-UNK	Inhibitors
7	40	43	U-UNK	PPIs
NULL

Ibandronate	DDI-DrugBank.d440.s4	NO_SECTION	NO_SETID	24
Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and PPIs).
1	0	1	O	Of
2	3	6	O	over
3	8	11	O	3500
4	13	20	O	patients
5	22	29	O	enrolled
6	31	32	O	in
7	34	36	O	the
8	38	48	O	XXXXXXXX
9	50	61	O	osteoporosis
10	63	71	O	Treatment
11	73	75	O	and
12	77	86	O	Prevention
13	88	94	O	Studies
14	95	95	O	,
15	97	99	O	15%
16	101	104	O	used
17	106	109	O	anti
18	111	116	O	peptic
19	118	123	O	agents
20	126	134	O	primarily
21	136	137	B-UNK	H2
22	139	146	L-UNK	blockers
23	148	150	O	and
24	152	155	U-UNK	PPIs
NULL

Ibandronate	DDI-DrugBank.d440.s5	NO_SECTION	NO_SETID	25
Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate was similar to that in placebo-treated patients.
1	0	4	O	Among
2	6	10	O	these
3	12	19	O	patients
4	20	20	O	,
5	22	24	O	the
6	26	34	O	incidence
7	36	37	O	of
8	39	43	O	upper
9	45	60	O	gastrointestinal
10	62	68	O	adverse
11	70	80	O	experiences
12	82	83	O	in
13	85	87	O	the
14	89	96	O	patients
15	98	104	O	treated
16	106	109	O	with
17	111	121	O	XXXXXXXX
18	123	125	O	was
19	127	133	O	similar
20	135	136	O	to
21	138	141	O	that
22	143	144	O	in
23	146	152	O	placebo
24	154	160	O	treated
25	162	169	O	patients
NULL

Ibandronate	DDI-DrugBank.d440.s6	NO_SECTION	NO_SETID	27
Similarly, of over 1600 patients enrolled in a study comparing once-monthly with daily dosing regimens of ibandronate, 14% of patients used anti-peptic agents.
1	0	8	O	Similarly
2	9	9	O	,
3	11	12	O	of
4	14	17	O	over
5	19	22	O	1600
6	24	31	O	patients
7	33	40	O	enrolled
8	42	43	O	in
9	45	45	O	a
10	47	51	O	study
11	53	61	O	comparing
12	63	66	O	once
13	68	74	O	monthly
14	76	79	O	with
15	81	85	O	daily
16	87	92	O	dosing
17	94	101	O	regimens
18	103	104	O	of
19	106	116	O	XXXXXXXX
20	117	117	O	,
21	119	121	O	14%
22	123	124	O	of
23	126	133	O	patients
24	135	138	O	used
25	140	143	O	anti
26	145	150	O	peptic
27	152	157	O	agents
NULL

Ibandronate	DDI-DrugBank.d440.s7	NO_SECTION	NO_SETID	34
Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with Ibandronate 150 mg once monthly was similar to that in patients treated with Ibandronate 2.5 mg once daily.
1	0	4	O	Among
2	6	10	O	these
3	12	19	O	patients
4	20	20	O	,
5	22	24	O	the
6	26	34	O	incidence
7	36	37	O	of
8	39	43	O	upper
9	45	60	O	gastrointestinal
10	62	68	O	adverse
11	70	80	O	experiences
12	82	83	O	in
13	85	87	O	the
14	89	96	O	patients
15	98	104	O	treated
16	106	109	O	with
17	111	121	O	XXXXXXXX
18	123	125	O	150
19	127	128	O	mg
20	130	133	O	once
21	135	141	O	monthly
22	143	145	O	was
23	147	153	O	similar
24	155	156	O	to
25	158	161	O	that
26	163	164	O	in
27	166	173	O	patients
28	175	181	O	treated
29	183	186	O	with
30	188	198	O	XXXXXXXX
31	200	202	O	2.5
32	204	205	O	mg
33	207	210	O	once
34	212	216	O	daily
NULL

Ibandronate	DDI-DrugBank.d440.s8	NO_SECTION	NO_SETID	6
Aspirin/Nonsteroidal Antiinflammatory Drugs (NSAIDs)
1	0	6	O	XXXXXXXX
2	7	7	O	/
3	8	19	B-UNK	Nonsteroidal
4	21	36	L-UNK	Antiinflammatory
5	38	42	O	Drugs
6	45	50	U-UNK	NSAIDs
NULL

Ibandronate	DDI-DrugBank.d440.s9	NO_SECTION	NO_SETID	24
In the large, placebo-controlled osteoporosis Treatment Study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 62% of the 2946 patients.
1	0	1	O	In
2	3	5	O	the
3	7	11	O	large
4	12	12	O	,
5	14	20	O	placebo
6	22	31	O	controlled
7	33	44	O	osteoporosis
8	46	54	O	Treatment
9	56	60	O	Study
10	61	61	O	,
11	63	69	O	XXXXXXXX
12	71	73	O	and
13	75	86	B-UNK	nonsteroidal
14	88	91	I-UNK	anti
15	93	104	I-UNK	inflammatory
16	106	110	L-UNK	drugs
17	112	115	O	were
18	117	121	O	taken
19	123	124	O	by
20	126	128	O	62%
21	130	131	O	of
22	133	135	O	the
23	137	140	O	2946
24	142	149	O	patients
NULL

Ibandronate	DDI-DrugBank.d440.s10	NO_SECTION	NO_SETID	31
Among aspirin or NSAID users, the incidence of upper gastrointestinal adverse events in patients treated with ibandronate 2.5 mg daily (28.9%) was similar to that in placebo-treated patients (30.7%).
1	0	4	O	Among
2	6	12	O	XXXXXXXX
3	14	15	O	or
4	17	21	U-UNK	NSAID
5	23	27	O	users
6	28	28	O	,
7	30	32	O	the
8	34	42	O	incidence
9	44	45	O	of
10	47	51	O	upper
11	53	68	O	gastrointestinal
12	70	76	O	adverse
13	78	83	O	events
14	85	86	O	in
15	88	95	O	patients
16	97	103	O	treated
17	105	108	O	with
18	110	120	U-UNK	ibandronate
19	122	124	O	2.5
20	126	127	O	mg
21	129	133	O	daily
22	136	140	O	28.9%
23	143	145	O	was
24	147	153	O	similar
25	155	156	O	to
26	158	161	O	that
27	163	164	O	in
28	166	172	O	placebo
29	174	180	O	treated
30	182	189	O	patients
31	192	196	O	30.7%
NULL

Ibandronate	DDI-DrugBank.d440.s11	NO_SECTION	NO_SETID	24
Similarly, in the 1-year monthly comparison study, aspirin and nonsteroidal anti-inflammatory drugs were taken by 39% of the 1602 patients.
1	0	8	O	Similarly
2	9	9	O	,
3	11	12	O	in
4	14	16	O	the
5	18	18	O	1
6	20	23	O	year
7	25	31	O	monthly
8	33	42	O	comparison
9	44	48	O	study
10	49	49	O	,
11	51	57	O	XXXXXXXX
12	59	61	O	and
13	63	74	B-UNK	nonsteroidal
14	76	79	I-UNK	anti
15	81	92	I-UNK	inflammatory
16	94	98	L-UNK	drugs
17	100	103	O	were
18	105	109	O	taken
19	111	112	O	by
20	114	116	O	39%
21	118	119	O	of
22	121	123	O	the
23	125	128	O	1602
24	130	137	O	patients
NULL

Ibandronate	DDI-DrugBank.d440.s12	NO_SECTION	NO_SETID	29
The incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking ibandronate 2.5 mg daily (21.7%) and 150 mg once monthly (22.0%).
1	0	2	O	The
2	4	12	O	incidence
3	14	15	O	of
4	17	21	O	upper
5	23	38	O	gastrointestinal
6	40	45	O	events
7	47	48	O	in
8	50	57	O	patients
9	59	71	O	concomitantly
10	73	78	O	taking
11	80	86	O	XXXXXXXX
12	88	89	O	or
13	91	96	U-UNK	NSAIDs
14	98	100	O	was
15	102	108	O	similar
16	110	111	O	in
17	113	120	O	patients
18	122	127	O	taking
19	129	139	U-UNK	ibandronate
20	141	143	O	2.5
21	145	146	O	mg
22	148	152	O	daily
23	155	159	O	21.7%
24	162	164	O	and
25	166	168	O	150
26	170	171	O	mg
27	173	176	O	once
28	178	184	O	monthly
29	187	191	O	22.0%
NULL

Ibandronate	DDI-DrugBank.d440.s13	NO_SECTION	NO_SETID	30
However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	since
4	15	21	O	XXXXXXXX
5	22	22	O	,
6	24	29	U-UNK	NSAIDs
7	30	30	O	,
8	32	34	O	and
9	36	50	U-UNK	bisphosphonates
10	52	54	O	are
11	56	58	O	all
12	60	69	O	associated
13	71	74	O	with
14	76	91	O	gastrointestinal
15	93	102	O	irritation
16	103	103	O	,
17	105	111	O	caution
18	113	118	O	should
19	120	121	O	be
20	123	131	O	exercised
21	133	134	O	in
22	136	138	O	the
23	140	150	O	concomitant
24	152	154	O	use
25	156	157	O	of
26	159	165	O	XXXXXXXX
27	167	168	O	or
28	170	175	U-UNK	NSAIDs
29	177	180	O	with
30	182	192	U-DYN	Ibandronate
NULL

Ibandronate	DDI-DrugBank.d440.s14	NO_SECTION	NO_SETID	5
Drug/Laboratory Test Interactions
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
NULL

Ibandronate	DDI-DrugBank.d440.s15	NO_SECTION	NO_SETID	12
Bisphosphonates are known to interfere with the use of bone-imaging agents.
1	0	14	U-UNK	Bisphosphonates
2	16	18	O	are
3	20	24	O	known
4	26	27	O	to
5	29	37	O	interfere
6	39	42	O	with
7	44	46	O	the
8	48	50	O	use
9	52	53	O	of
10	55	58	O	bone
11	60	66	O	imaging
12	68	73	O	agents
NULL

Ibandronate	DDI-DrugBank.d440.s16	NO_SECTION	NO_SETID	8
Specific studies with ibandronate have not been performed.
1	0	7	O	Specific
2	9	15	O	studies
3	17	20	O	with
4	22	32	O	XXXXXXXX
5	34	37	O	have
6	39	41	O	not
7	43	46	O	been
8	48	56	O	performed
NULL

Ibritumomab	DDI-DrugBank.d408.s0	NO_SECTION	NO_SETID	10
No formal drug interaction studies have been performed with ZEVALIN.
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	25	O	interaction
5	27	33	O	studies
6	35	38	O	have
7	40	43	O	been
8	45	53	O	performed
9	55	58	O	with
10	60	66	O	XXXXXXXX
NULL

Ibritumomab	DDI-DrugBank.d408.s1	NO_SECTION	NO_SETID	37
Due to the frequent occurrence of severe and prolonged thrombocytopenia, the potential benefits of medications which interfere with platelet function and/or anticoagulation should be weighed against the potential increased risks of bleeding and hemorrhage.
1	0	2	O	Due
2	4	5	O	to
3	7	9	O	the
4	11	18	O	frequent
5	20	29	O	occurrence
6	31	32	O	of
7	34	39	O	severe
8	41	43	O	and
9	45	53	O	prolonged
10	55	70	O	thrombocytopenia
11	71	71	O	,
12	73	75	O	the
13	77	85	O	potential
14	87	94	O	benefits
15	96	97	O	of
16	99	109	O	medications
17	111	115	O	which
18	117	125	O	interfere
19	127	130	O	with
20	132	139	O	platelet
21	141	148	O	function
22	150	152	O	and
23	153	153	O	/
24	154	155	O	or
25	157	171	O	anticoagulation
26	173	178	O	should
27	180	181	O	be
28	183	189	O	weighed
29	191	197	O	against
30	199	201	O	the
31	203	211	O	potential
32	213	221	O	increased
33	223	227	O	risks
34	229	230	O	of
35	232	239	O	bleeding
36	241	243	O	and
37	245	254	O	hemorrhage
NULL

Ibritumomab	DDI-DrugBank.d408.s2	NO_SECTION	NO_SETID	18
Patients receiving medications that interfere with platelet function or coagulation should have more frequent laboratory monitoring for thrombocytopenia.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	29	O	medications
4	31	34	O	that
5	36	44	O	interfere
6	46	49	O	with
7	51	58	O	platelet
8	60	67	O	function
9	69	70	O	or
10	72	82	O	coagulation
11	84	89	O	should
12	91	94	O	have
13	96	99	O	more
14	101	108	O	frequent
15	110	119	O	laboratory
16	121	130	O	monitoring
17	132	134	O	for
18	136	151	O	thrombocytopenia
NULL

Ibritumomab	DDI-DrugBank.d408.s3	NO_SECTION	NO_SETID	20
In addition, the transfusion practices for such patients may need to be modified given the increased risk of bleeding.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	15	O	the
5	17	27	O	transfusion
6	29	37	O	practices
7	39	41	O	for
8	43	46	O	such
9	48	55	O	patients
10	57	59	O	may
11	61	64	O	need
12	66	67	O	to
13	69	70	O	be
14	72	79	O	modified
15	81	85	O	given
16	87	89	O	the
17	91	99	O	increased
18	101	104	O	risk
19	106	107	O	of
20	109	116	O	bleeding
NULL

Ibritumomab	DDI-DrugBank.d408.s4	NO_SECTION	NO_SETID	31
Patients in clinical studies were prohibited from receiving growth factor treatment for 2 weeks prior to the ZEVALIN therapeutic regimen as well as for 2 weeks following completion of the regimen.
1	0	7	O	Patients
2	9	10	O	in
3	12	19	O	clinical
4	21	27	O	studies
5	29	32	O	were
6	34	43	O	prohibited
7	45	48	O	from
8	50	58	O	receiving
9	60	65	O	growth
10	67	72	O	factor
11	74	82	O	treatment
12	84	86	O	for
13	88	88	O	2
14	90	94	O	weeks
15	96	100	O	prior
16	102	103	O	to
17	105	107	O	the
18	109	115	O	XXXXXXXX
19	117	127	O	therapeutic
20	129	135	O	regimen
21	137	138	O	as
22	140	143	O	well
23	145	146	O	as
24	148	150	O	for
25	152	152	O	2
26	154	158	O	weeks
27	160	168	O	following
28	170	179	O	completion
29	181	182	O	of
30	184	186	O	the
31	188	194	O	regimen
NULL

Ibuprofen	DDI-DrugBank.d415.s0	NO_SECTION	NO_SETID	33
Coumarin-Type Anticoagulants: Several short-term controlled studies failed to wshow that ibuprofen significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on coumarin-type anticoagulants.
1	0	7	B-UNK	Coumarin
2	9	12	I-UNK	Type
3	14	27	L-UNK	Anticoagulants
4	28	28	O	:
5	30	36	O	Several
6	38	42	O	short
7	44	47	O	term
8	49	58	O	controlled
9	60	66	O	studies
10	68	73	O	failed
11	75	76	O	to
12	78	82	O	wshow
13	84	87	O	that
14	89	97	O	XXXXXXXX
15	99	111	O	significantly
16	113	120	O	affected
17	122	132	O	prothrombin
18	134	138	O	times
19	140	141	O	or
20	143	143	O	a
21	145	151	O	variety
22	153	154	O	of
23	156	160	O	other
24	162	169	O	clotting
25	171	177	O	factors
26	179	182	O	when
27	184	195	O	administered
28	197	198	O	to
29	200	210	O	individuals
30	212	213	O	on
31	215	222	B-UNK	coumarin
32	224	227	I-UNK	type
33	229	242	L-UNK	anticoagulants
NULL

Ibuprofen	DDI-DrugBank.d415.s1	NO_SECTION	NO_SETID	37
However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	because
4	17	24	O	bleeding
5	26	28	O	has
6	30	33	O	been
7	35	42	O	reported
8	44	47	O	when
9	49	57	O	XXXXXXXX
10	59	61	O	and
11	63	67	O	other
12	69	80	B-UNK	nonsteroidal
13	82	85	I-UNK	anti
14	87	98	I-UNK	inflammatory
15	100	105	L-UNK	agents
16	107	110	O	have
17	112	115	O	been
18	117	128	O	administered
19	130	131	O	to
20	133	140	O	patients
21	142	143	O	on
22	145	152	B-DYN	coumarin
23	154	157	I-DYN	type
24	159	172	L-DYN	anticoagulants
25	173	173	O	,
26	175	177	O	the
27	179	187	O	physician
28	189	194	O	should
29	196	197	O	be
30	199	206	O	cautious
31	208	211	O	when
32	213	225	O	administering
33	227	235	O	XXXXXXXX
34	237	238	O	to
35	240	247	O	patients
36	249	250	O	on
37	252	265	U-DYN	anticoagulants
NULL

Ibuprofen	DDI-DrugBank.d415.s2	NO_SECTION	NO_SETID	34
Aspirin: Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.
1	0	6	O	XXXXXXXX
2	7	7	O	:
3	9	14	O	Animal
4	16	22	O	studies
5	24	28	O	wshow
6	30	33	O	that
7	35	41	O	XXXXXXXX
8	43	47	O	given
9	49	52	O	with
10	54	65	B-DYN	nonsteroidal
11	67	70	I-DYN	anti
12	72	83	I-DYN	inflammatory
13	85	90	L-DYN	agents
14	91	91	O	,
15	93	101	O	including
16	103	111	U-DYN	ibuprofen
17	112	112	O	,
18	114	119	O	yields
19	121	121	O	a
20	123	125	O	net
21	127	134	O	decrease
22	136	137	O	in
23	139	142	O	anti
24	144	155	O	inflammatory
25	157	164	O	activity
26	166	169	O	with
27	171	177	O	lowered
28	179	183	O	blood
29	185	190	O	levels
30	192	193	O	of
31	195	197	O	the
32	199	201	O	non
33	203	209	O	XXXXXXXX
34	211	214	O	drug
NULL

Ibuprofen	DDI-DrugBank.d415.s3	NO_SECTION	NO_SETID	19
Single dose bioavailability studies in normal volunteers have failed to wshow an effect of aspirin on ibuprofen blood levels.
1	0	5	O	Single
2	7	10	O	dose
3	12	26	O	bioavailability
4	28	34	O	studies
5	36	37	O	in
6	39	44	O	normal
7	46	55	O	volunteers
8	57	60	O	have
9	62	67	O	failed
10	69	70	O	to
11	72	76	O	wshow
12	78	79	O	an
13	81	86	O	effect
14	88	89	O	of
15	91	97	O	XXXXXXXX
16	99	100	O	on
17	102	110	U-UNK	ibuprofen
18	112	116	O	blood
19	118	123	O	levels
NULL

Ibuprofen	DDI-DrugBank.d415.s4	NO_SECTION	NO_SETID	7
Correlative clinical studies have not been performed.
1	0	10	O	Correlative
2	12	19	O	clinical
3	21	27	O	studies
4	29	32	O	have
5	34	36	O	not
6	38	41	O	been
7	43	51	O	performed
NULL

Ibuprofen	DDI-DrugBank.d415.s5	NO_SECTION	NO_SETID	29
Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
1	0	11	U-UNK	Methotrexate
2	12	12	O	:
3	14	22	O	XXXXXXXX
4	23	23	O	,
5	25	26	O	as
6	28	31	O	well
7	33	34	O	as
8	36	40	O	other
9	42	53	B-UNK	nonsteroidal
10	55	58	I-UNK	anti
11	60	71	I-UNK	inflammatory
12	73	77	L-UNK	drugs
13	78	78	O	,
14	80	87	O	probably
15	89	95	O	reduces
16	97	99	O	the
17	101	107	O	tubular
18	109	117	O	secretion
19	119	120	O	of
20	122	133	U-KIN	methotrexate
21	135	139	O	based
22	141	142	O	on
23	144	145	O	in
24	147	151	O	vitro
25	153	159	O	studies
26	161	162	O	in
27	164	169	O	rabbit
28	171	176	O	kidney
29	178	183	O	slices
NULL

Ibuprofen	DDI-DrugBank.d415.s6	NO_SECTION	NO_SETID	11
This may indicate that ibuprofen could enhance the toxicity of methotrexate.
1	0	3	O	This
2	5	7	O	may
3	9	16	O	indicate
4	18	21	O	that
5	23	31	O	XXXXXXXX
6	33	37	O	could
7	39	45	O	enhance
8	47	49	O	the
9	51	58	O	toxicity
10	60	61	O	of
11	63	74	U-DYN	methotrexate
NULL

Ibuprofen	DDI-DrugBank.d415.s7	NO_SECTION	NO_SETID	11
Caution should be used if ibuprofen is administered concomitantly with methotrexate.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	24	O	if
6	26	34	O	XXXXXXXX
7	36	37	O	is
8	39	50	O	administered
9	52	64	O	concomitantly
10	66	69	O	with
11	71	82	U-DYN	methotrexate
NULL

Ibuprofen	DDI-DrugBank.d415.s8	NO_SECTION	NO_SETID	26
H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.
1	0	0	O	H
2	2	2	O	2
3	4	14	O	Antagonists
4	15	15	O	:
5	17	18	O	In
6	20	26	O	studies
7	28	31	O	with
8	33	37	O	human
9	39	48	O	volunteers
10	49	49	O	,
11	51	52	O	co
12	54	67	O	administration
13	69	70	O	of
14	72	81	U-UNK	cimetidine
15	83	84	O	or
16	86	95	U-UNK	ranitidine
17	97	100	O	with
18	102	110	O	XXXXXXXX
19	112	114	O	had
20	116	117	O	no
21	119	129	O	substantive
22	131	136	O	effect
23	138	139	O	on
24	141	149	O	XXXXXXXX
25	151	155	O	serum
26	157	170	O	concentrations
NULL

Ibuprofen	DDI-DrugBank.d415.s9	NO_SECTION	NO_SETID	27
Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.
1	0	9	U-UNK	Furosemide
2	10	10	O	:
3	12	19	O	Clinical
4	21	27	O	studies
5	28	28	O	,
6	30	31	O	as
7	33	36	O	well
8	38	39	O	as
9	41	46	O	random
10	48	59	O	observations
11	60	60	O	,
12	62	65	O	have
13	67	71	O	shown
14	73	76	O	that
15	78	86	O	XXXXXXXX
16	88	90	O	can
17	92	97	O	reduce
18	99	101	O	the
19	103	113	O	natriuretic
20	115	120	O	effect
21	122	123	O	of
22	125	134	U-DYN	furosemide
23	136	138	O	and
24	140	148	U-DYN	thiazides
25	150	151	O	in
26	153	156	O	some
27	158	165	O	patients
NULL

Ibuprofen	DDI-DrugBank.d415.s10	NO_SECTION	NO_SETID	11
This response has been attributed to inhibition of renal prostaglandin synthesis.
1	0	3	O	This
2	5	12	O	response
3	14	16	O	has
4	18	21	O	been
5	23	32	O	attributed
6	34	35	O	to
7	37	46	O	inhibition
8	48	49	O	of
9	51	55	O	renal
10	57	69	O	prostaglandin
11	71	79	O	synthesis
NULL

Ibuprofen	DDI-DrugBank.d415.s11	NO_SECTION	NO_SETID	25
During concomitant therapy with ibuprofen, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
1	0	5	O	During
2	7	17	O	concomitant
3	19	25	O	therapy
4	27	30	O	with
5	32	40	O	XXXXXXXX
6	41	41	O	,
7	43	45	O	the
8	47	53	O	patient
9	55	60	O	should
10	62	63	O	be
11	65	72	O	observed
12	74	80	O	closely
13	82	84	O	for
14	86	90	O	signs
15	92	93	O	of
16	95	99	O	renal
17	101	107	O	failure
18	108	108	O	,
19	110	111	O	as
20	113	116	O	well
21	118	119	O	as
22	121	122	O	to
23	124	129	O	assure
24	131	138	U-UNK	diuretic
25	140	147	O	efficacy
NULL

Ibuprofen	DDI-DrugBank.d415.s12	NO_SECTION	NO_SETID	24
Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	17	O	XXXXXXXX
4	19	26	O	produced
5	28	29	O	an
6	31	39	O	elevation
7	41	42	O	of
8	44	49	O	plasma
9	51	57	U-KIN	lithium
10	59	64	O	levels
11	66	68	O	and
12	70	70	O	a
13	72	80	O	reduction
14	82	83	O	in
15	85	89	O	renal
16	91	97	U-UNK	lithium
17	99	107	O	clearance
18	109	110	O	in
19	112	112	O	a
20	114	118	O	study
21	120	121	O	of
22	123	128	O	eleven
23	130	135	O	normal
24	137	146	O	volunteers
NULL

Ibuprofen	DDI-DrugBank.d415.s13	NO_SECTION	NO_SETID	24
The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration.
1	0	2	O	The
2	4	7	O	mean
3	9	15	O	minimum
4	17	23	U-UNK	lithium
5	25	37	O	concentration
6	39	47	O	increased
7	49	51	O	15%
8	53	55	O	and
9	57	59	O	the
10	61	65	O	renal
11	67	75	O	clearance
12	77	78	O	of
13	80	86	U-UNK	lithium
14	88	90	O	was
15	92	100	O	decreased
16	102	103	O	by
17	105	107	O	19%
18	109	114	O	during
19	116	119	O	this
20	121	126	O	period
21	128	129	O	of
22	131	141	O	concomitant
23	143	146	O	drug
24	148	161	O	administration
NULL

Ibuprofen	DDI-DrugBank.d415.s14	NO_SECTION	NO_SETID	13
This effect has been attributed to inhibition of renal prostaglandin synthesis by ibuprofen.
1	0	3	O	This
2	5	10	O	effect
3	12	14	O	has
4	16	19	O	been
5	21	30	O	attributed
6	32	33	O	to
7	35	44	O	inhibition
8	46	47	O	of
9	49	53	O	renal
10	55	67	O	prostaglandin
11	69	77	O	synthesis
12	79	80	O	by
13	82	90	O	XXXXXXXX
NULL

Ibuprofen	DDI-DrugBank.d415.s15	NO_SECTION	NO_SETID	20
Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
1	0	3	O	Thus
2	4	4	O	,
3	6	9	O	when
4	11	19	O	XXXXXXXX
5	21	23	O	and
6	25	31	U-DYN	lithium
7	33	35	O	are
8	37	48	O	administered
9	50	61	O	concurrently
10	62	62	O	,
11	64	71	O	subjects
12	73	78	O	should
13	80	81	O	be
14	83	90	O	observed
15	92	100	O	carefully
16	102	104	O	for
17	106	110	O	signs
18	112	113	O	of
19	115	121	U-UNK	lithium
20	123	130	O	toxicity
NULL

Ibuprofen	DDI-DrugBank.d415.s16	NO_SECTION	NO_SETID	11
(Read circulars for lithium preparation before use of such concurrent therapy).
1	1	4	O	Read
2	6	14	O	circulars
3	16	18	O	for
4	20	26	U-UNK	lithium
5	28	38	O	preparation
6	40	45	O	before
7	47	49	O	use
8	51	52	O	of
9	54	57	O	such
10	59	68	O	concurrent
11	70	76	O	therapy
NULL

Ibutilide	DDI-DrugBank.d68.s0	NO_SECTION	NO_SETID	11
No specific pharmacokinetic or other formal drug interaction studies were conducted.
1	0	1	O	No
2	3	10	O	specific
3	12	26	O	pharmacokinetic
4	28	29	O	or
5	31	35	O	other
6	37	42	O	formal
7	44	47	O	drug
8	49	59	O	interaction
9	61	67	O	studies
10	69	72	O	were
11	74	82	O	conducted
NULL

Ibutilide	DDI-DrugBank.d68.s1	NO_SECTION	NO_SETID	13
Digoxin: Supraventricular arrhythmias may mask the cardiotoxicity associated with excessive digoxin levels.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	24	O	Supraventricular
4	26	36	O	arrhythmias
5	38	40	O	may
6	42	45	O	mask
7	47	49	O	the
8	51	64	O	cardiotoxicity
9	66	75	O	associated
10	77	80	O	with
11	82	90	O	excessive
12	92	98	U-UNK	digoxin
13	100	105	O	levels
NULL

Ibutilide	DDI-DrugBank.d68.s2	NO_SECTION	NO_SETID	26
Therefore, it is advisable to be particularly cautious in patients whose plasma digoxin levels are above or suspected to be above the usual therapeutic range.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	it
4	14	15	O	is
5	17	25	O	advisable
6	27	28	O	to
7	30	31	O	be
8	33	44	O	particularly
9	46	53	O	cautious
10	55	56	O	in
11	58	65	O	patients
12	67	71	O	whose
13	73	78	O	plasma
14	80	86	U-UNK	digoxin
15	88	93	O	levels
16	95	97	O	are
17	99	103	O	above
18	105	106	O	or
19	108	116	O	suspected
20	118	119	O	to
21	121	122	O	be
22	124	128	O	above
23	130	132	O	the
24	134	138	O	usual
25	140	150	O	therapeutic
26	152	156	O	range
NULL

Ibutilide	DDI-DrugBank.d68.s3	NO_SECTION	NO_SETID	19
Coadministration of digoxin did not have effects on either the safety or efficacy of ibutilide in the clinical trials.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	26	U-UNK	digoxin
4	28	30	O	did
5	32	34	O	not
6	36	39	O	have
7	41	47	O	effects
8	49	50	O	on
9	52	57	O	either
10	59	61	O	the
11	63	68	O	safety
12	70	71	O	or
13	73	80	O	efficacy
14	82	83	O	of
15	85	93	O	XXXXXXXX
16	95	96	O	in
17	98	100	O	the
18	102	109	O	clinical
19	111	116	O	trials
NULL

Ibutilide	DDI-DrugBank.d68.s4	NO_SECTION	NO_SETID	27
Calcium channel blocking agents: Coadministration of calcium channel blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.
1	0	6	B-UNK	Calcium
2	8	14	I-UNK	channel
3	16	23	I-UNK	blocking
4	25	30	L-UNK	agents
5	31	31	O	:
6	33	48	O	Coadministration
7	50	51	O	of
8	53	59	B-UNK	calcium
9	61	67	I-UNK	channel
10	69	76	L-UNK	blockers
11	78	80	O	did
12	82	84	O	not
13	86	89	O	have
14	91	93	O	any
15	95	100	O	effect
16	102	103	O	on
17	105	110	O	either
18	112	114	O	the
19	116	121	O	safety
20	123	124	O	or
21	126	133	O	efficacy
22	135	136	O	of
23	138	146	O	XXXXXXXX
24	148	149	O	in
25	151	153	O	the
26	155	162	O	clinical
27	164	169	O	trials
NULL

Ibutilide	DDI-DrugBank.d68.s5	NO_SECTION	NO_SETID	28
Beta-adrenergic blocking agents: Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.
1	0	3	B-UNK	Beta
2	5	14	I-UNK	adrenergic
3	16	23	I-UNK	blocking
4	25	30	L-UNK	agents
5	31	31	O	:
6	33	48	O	Coadministration
7	50	51	O	of
8	53	56	B-UNK	beta
9	58	67	I-UNK	adrenergic
10	69	76	I-UNK	blocking
11	78	83	L-UNK	agents
12	85	87	O	did
13	89	91	O	not
14	93	96	O	have
15	98	100	O	any
16	102	107	O	effect
17	109	110	O	on
18	112	117	O	either
19	119	121	O	the
20	123	128	O	safety
21	130	131	O	or
22	133	140	O	efficacy
23	142	143	O	of
24	145	153	O	XXXXXXXX
25	155	156	O	in
26	158	160	O	the
27	162	169	O	clinical
28	171	176	O	trials
NULL

Icodextrin	DDI-DrugBank.d501.s0	NO_SECTION	NO_SETID	8
General No clinical drug interaction studies were performed.
1	0	6	O	General
2	8	9	O	No
3	11	18	O	clinical
4	20	23	O	drug
5	25	35	O	interaction
6	37	43	O	studies
7	45	48	O	were
8	50	58	O	performed
NULL

Icodextrin	DDI-DrugBank.d501.s1	NO_SECTION	NO_SETID	13
No evaluation of EXTRANEALs effects on the cytochrome P450 system was conducted.
1	0	1	O	No
2	3	12	O	evaluation
3	14	15	O	of
4	17	25	O	XXXXXXXX
5	26	26	O	s
6	28	34	O	effects
7	36	37	O	on
8	39	41	O	the
9	43	52	O	cytochrome
10	54	57	O	P450
11	59	64	O	system
12	66	68	O	was
13	70	78	O	conducted
NULL

Icodextrin	DDI-DrugBank.d501.s2	NO_SECTION	NO_SETID	16
As with other dialysis solutions, blood concentrations of dialyzable drugs may be reduced by dialysis.
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	21	B-UNK	dialysis
5	23	31	L-UNK	solutions
6	32	32	O	,
7	34	38	O	blood
8	40	53	O	concentrations
9	55	56	O	of
10	58	67	O	dialyzable
11	69	73	O	drugs
12	75	77	O	may
13	79	80	O	be
14	82	88	O	reduced
15	90	91	O	by
16	93	100	O	dialysis
NULL

Icodextrin	DDI-DrugBank.d501.s3	NO_SECTION	NO_SETID	8
Dosage adjustment of concomitant medications may be necessary.
1	0	5	O	Dosage
2	7	16	O	adjustment
3	18	19	O	of
4	21	31	O	concomitant
5	33	43	O	medications
6	45	47	O	may
7	49	50	O	be
8	52	60	O	necessary
NULL

Icodextrin	DDI-DrugBank.d501.s4	NO_SECTION	NO_SETID	21
In patients using cardiac glycosides (digoxin and others), plasma levels of calcium, potassium and magnesium must be carefully monitored.
1	0	1	O	In
2	3	10	O	patients
3	12	16	O	using
4	18	24	B-UNK	cardiac
5	26	35	L-UNK	glycosides
6	38	44	U-UNK	digoxin
7	46	48	O	and
8	50	55	O	others
9	57	57	O	,
10	59	64	O	plasma
11	66	71	O	levels
12	73	74	O	of
13	76	82	O	calcium
14	83	83	O	,
15	85	93	O	potassium
16	95	97	O	and
17	99	107	O	magnesium
18	109	112	O	must
19	114	115	O	be
20	117	125	O	carefully
21	127	135	O	monitored
NULL

Icodextrin	DDI-DrugBank.d501.s5	NO_SECTION	NO_SETID	38
Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulins ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL.
1	0	6	U-UNK	Insulin
2	7	7	O	:
3	9	9	O	A
4	11	18	O	clinical
5	20	24	O	study
6	26	27	O	in
7	29	29	O	6
8	31	37	O	insulin
9	39	47	O	dependent
10	49	56	O	diabetic
11	58	65	O	patients
12	67	78	O	demonstrated
13	80	81	O	no
14	83	88	O	effect
15	90	91	O	of
16	93	101	O	XXXXXXXX
17	103	104	O	on
18	106	112	U-UNK	insulin
19	114	123	O	absorption
20	125	128	O	from
21	130	132	O	the
22	134	143	O	peritoneal
23	145	150	O	cavity
24	152	153	O	or
25	155	156	O	on
26	158	165	O	insulins
27	167	173	O	ability
28	175	176	O	to
29	178	184	O	control
30	186	190	O	blood
31	192	198	O	glucose
32	200	203	O	when
33	205	211	U-UNK	insulin
34	213	215	O	was
35	217	228	O	administered
36	230	246	O	intraperitoneally
37	248	251	O	with
38	253	261	O	XXXXXXXX
NULL

Icodextrin	DDI-DrugBank.d501.s6	NO_SECTION	NO_SETID	24
However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.
1	0	6	O	However
2	7	7	O	,
3	9	19	O	appropriate
4	21	30	O	monitoring
5	32	33	O	of
6	35	39	O	blood
7	41	47	O	glucose
8	49	54	O	should
9	56	57	O	be
10	59	67	O	performed
11	69	72	O	when
12	74	83	O	initiating
13	85	93	O	XXXXXXXX
14	95	96	O	in
15	98	105	O	diabetic
16	107	114	O	patients
17	116	118	O	and
18	120	126	U-DYN	insulin
19	128	133	O	dosage
20	135	140	O	should
21	142	143	O	be
22	145	152	O	adjusted
23	154	155	O	if
24	157	162	O	needed
NULL

Icodextrin	DDI-DrugBank.d501.s7	NO_SECTION	NO_SETID	11
Heparin: No human drug interaction studies with heparin were conducted.
1	0	6	U-UNK	Heparin
2	7	7	O	:
3	9	10	O	No
4	12	16	O	human
5	18	21	O	drug
6	23	33	O	interaction
7	35	41	O	studies
8	43	46	O	with
9	48	54	U-UNK	heparin
10	56	59	O	were
11	61	69	O	conducted
NULL

Icodextrin	DDI-DrugBank.d501.s8	NO_SECTION	NO_SETID	12
In vitro studies demonstrated no evidence of incompatibility of heparin with EXTRANEAL.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	28	O	demonstrated
5	30	31	O	no
6	33	40	O	evidence
7	42	43	O	of
8	45	59	O	incompatibility
9	61	62	O	of
10	64	70	U-UNK	heparin
11	72	75	O	with
12	77	85	O	XXXXXXXX
NULL

Icodextrin	DDI-DrugBank.d501.s9	NO_SECTION	NO_SETID	11
Antibiotics: No human drug interaction studies with antibiotics were conducted.
1	0	10	U-UNK	Antibiotics
2	11	11	O	:
3	13	14	O	No
4	16	20	O	human
5	22	25	O	drug
6	27	37	O	interaction
7	39	45	O	studies
8	47	50	O	with
9	52	62	U-UNK	antibiotics
10	64	67	O	were
11	69	77	O	conducted
NULL

Icodextrin	DDI-DrugBank.d501.s10	NO_SECTION	NO_SETID	36
In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	26	O	evaluating
5	28	30	O	the
6	32	38	O	minimum
7	40	49	O	inhibitory
8	51	63	O	concentration
9	66	68	O	MIC
10	71	72	O	of
11	74	83	U-UNK	vancomycin
12	84	84	O	,
13	86	94	U-UNK	cefazolin
14	95	95	O	,
15	97	106	U-UNK	ampicillin
16	107	107	O	,
17	109	118	U-UNK	ampicillin
18	119	119	O	/
19	120	132	O	flucoxacillin
20	133	133	O	,
21	135	145	U-UNK	ceftazidime
22	146	146	O	,
23	148	157	U-UNK	gentamicin
24	158	158	O	,
25	160	162	O	and
26	164	175	U-UNK	amphotericin
27	177	188	O	demonstrated
28	190	191	O	no
29	193	200	O	evidence
30	202	203	O	of
31	205	219	O	incompatibility
32	221	222	O	of
33	224	228	O	these
34	230	240	U-UNK	antibiotics
35	242	245	O	with
36	247	255	O	XXXXXXXX
NULL

Icodextrin	DDI-DrugBank.d501.s11	NO_SECTION	NO_SETID	25
Drug/Laboratory Test Interactions Blood Glucose Blood glucose measurement must be done with a glucose-specific method to prevent maltose interference with test results.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	38	O	Blood
7	40	46	O	Glucose
8	48	52	O	Blood
9	54	60	O	glucose
10	62	72	O	measurement
11	74	77	O	must
12	79	80	O	be
13	82	85	O	done
14	87	90	O	with
15	92	92	O	a
16	94	100	O	glucose
17	102	109	O	specific
18	111	116	O	method
19	118	119	O	to
20	121	127	O	prevent
21	129	135	O	maltose
22	137	148	O	interference
23	150	153	O	with
24	155	158	O	test
25	160	166	O	results
NULL

Icodextrin	DDI-DrugBank.d501.s12	NO_SECTION	NO_SETID	42
Since falsely elevated glucose levels have been observed with blood glucose monitoring devices and test strips that use glucose dehydrogenase pyrroloquinolinequinone (GDH PQQ)-based methods, GDH PQQ-based methods should not be used to measure glucose levels in patients administered EXTRANEAL..
1	0	4	O	Since
2	6	12	O	falsely
3	14	21	O	elevated
4	23	29	O	glucose
5	31	36	O	levels
6	38	41	O	have
7	43	46	O	been
8	48	55	O	observed
9	57	60	O	with
10	62	66	O	blood
11	68	74	O	glucose
12	76	85	O	monitoring
13	87	93	O	devices
14	95	97	O	and
15	99	102	O	test
16	104	109	O	strips
17	111	114	O	that
18	116	118	O	use
19	120	126	O	glucose
20	128	140	O	dehydrogenase
21	142	164	O	pyrroloquinolinequinone
22	167	169	O	GDH
23	171	173	O	PQQ
24	176	180	O	based
25	182	188	O	methods
26	189	189	O	,
27	191	193	O	GDH
28	195	197	O	PQQ
29	199	203	O	based
30	205	211	O	methods
31	213	218	O	should
32	220	222	O	not
33	224	225	O	be
34	227	230	O	used
35	232	233	O	to
36	235	241	O	measure
37	243	249	O	glucose
38	251	256	O	levels
39	258	259	O	in
40	261	268	O	patients
41	270	281	O	administered
42	283	291	O	XXXXXXXX
NULL

Icodextrin	DDI-DrugBank.d501.s13	NO_SECTION	NO_SETID	16
Serum Amylase An apparent decrease in serum amylase activity has been observed in patients administered EXTRANEAL.
1	0	4	O	Serum
2	6	12	O	Amylase
3	14	15	O	An
4	17	24	O	apparent
5	26	33	O	decrease
6	35	36	O	in
7	38	42	O	serum
8	44	50	O	amylase
9	52	59	O	activity
10	61	63	O	has
11	65	68	O	been
12	70	77	O	observed
13	79	80	O	in
14	82	89	O	patients
15	91	102	O	administered
16	104	112	O	XXXXXXXX
NULL

Icodextrin	DDI-DrugBank.d501.s14	NO_SECTION	NO_SETID	20
Preliminary investigations indicate that icodextrin and its metabolites interfere with enzymatic-based amylase assays, resulting in inaccurately low values.
1	0	10	O	Preliminary
2	12	25	O	investigations
3	27	34	O	indicate
4	36	39	O	that
5	41	50	O	XXXXXXXX
6	52	54	O	and
7	56	58	O	its
8	60	70	O	metabolites
9	72	80	O	interfere
10	82	85	O	with
11	87	95	O	enzymatic
12	97	101	O	based
13	103	109	O	amylase
14	111	116	O	assays
15	117	117	O	,
16	119	127	O	resulting
17	129	130	O	in
18	132	143	O	inaccurately
19	145	147	O	low
20	149	154	O	values
NULL

Icodextrin	DDI-DrugBank.d501.s15	NO_SECTION	NO_SETID	21
This should be taken into account when evaluating serum amylase levels for diagnosis or monitoring of pancreatitis in patients using EXTRANEAL.
1	0	3	O	This
2	5	10	O	should
3	12	13	O	be
4	15	19	O	taken
5	21	24	O	into
6	26	32	O	account
7	34	37	O	when
8	39	48	O	evaluating
9	50	54	O	serum
10	56	62	O	amylase
11	64	69	O	levels
12	71	73	O	for
13	75	83	O	diagnosis
14	85	86	O	or
15	88	97	O	monitoring
16	99	100	O	of
17	102	113	O	pancreatitis
18	115	116	O	in
19	118	125	O	patients
20	127	131	O	using
21	133	141	O	XXXXXXXX
NULL

Icosapent	DDI-DrugBank.d35.s0	NO_SECTION	NO_SETID	26
Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
1	0	11	O	Interactions
2	13	15	O	may
3	17	21	O	occur
4	23	29	O	between
5	31	33	U-UNK	EPA
6	35	45	O	supplements
7	47	49	O	and
8	51	57	O	XXXXXXXX
9	59	61	O	and
10	63	67	O	other
11	69	71	B-UNK	non
12	73	81	I-UNK	steroidal
13	83	86	I-UNK	anti
14	88	99	I-UNK	inflammatory
15	101	105	L-UNK	drugs
16	107	109	O	and
17	111	115	O	herbs
18	117	120	O	such
19	122	123	O	as
20	125	130	O	garlic
21	133	138	O	Allium
22	140	146	O	sativum
23	149	151	O	and
24	153	158	U-UNK	ginkgo
25	161	166	B-UNK	Ginkgo
26	168	173	L-UNK	biloba
NULL

Icosapent	DDI-DrugBank.d35.s1	NO_SECTION	NO_SETID	23
Such interactions might be manifested by increased susceptibility to bruising, nosebleeds, hemoptysis, hematemesis, hematuria and blood in the stool.
1	0	3	O	Such
2	5	16	O	interactions
3	18	22	O	might
4	24	25	O	be
5	27	36	O	manifested
6	38	39	O	by
7	41	49	O	increased
8	51	64	O	susceptibility
9	66	67	O	to
10	69	76	O	bruising
11	77	77	O	,
12	79	88	O	nosebleeds
13	89	89	O	,
14	91	100	O	hemoptysis
15	101	101	O	,
16	103	113	O	hematemesis
17	114	114	O	,
18	116	124	O	hematuria
19	126	128	O	and
20	130	134	O	blood
21	136	137	O	in
22	139	141	O	the
23	143	147	O	stool
NULL

Icosapent	DDI-DrugBank.d35.s2	NO_SECTION	NO_SETID	25
Most who take EPA supplements and the above drugs or herbs do not suffer from these problems and if they occur, they are rare.
1	0	3	O	Most
2	5	7	O	who
3	9	12	O	take
4	14	16	U-UNK	EPA
5	18	28	O	supplements
6	30	32	O	and
7	34	36	O	the
8	38	42	O	above
9	44	48	O	drugs
10	50	51	O	or
11	53	57	O	herbs
12	59	60	O	do
13	62	64	O	not
14	66	71	O	suffer
15	73	76	O	from
16	78	82	O	these
17	84	91	O	problems
18	93	95	O	and
19	97	98	O	if
20	100	103	O	they
21	105	109	O	occur
22	110	110	O	,
23	112	115	O	they
24	117	119	O	are
25	121	124	O	rare
NULL

Icosapent	DDI-DrugBank.d35.s3	NO_SECTION	NO_SETID	13
If they do occur, the EPA dose should be lowered or discontinued.
1	0	1	O	If
2	3	6	O	they
3	8	9	O	do
4	11	15	O	occur
5	16	16	O	,
6	18	20	O	the
7	22	24	U-UNK	EPA
8	26	29	O	dose
9	31	36	O	should
10	38	39	O	be
11	41	47	O	lowered
12	49	50	O	or
13	52	63	O	discontinued
NULL

Icosapent	DDI-DrugBank.d35.s4	NO_SECTION	NO_SETID	27
Conflicting results have been reported regarding the effects of EPA supplements on glycemic control in non-diabetics with glucose intolerance, and those with type 2 diabetes.
1	0	10	O	Conflicting
2	12	18	O	results
3	20	23	O	have
4	25	28	O	been
5	30	37	O	reported
6	39	47	O	regarding
7	49	51	O	the
8	53	59	O	effects
9	61	62	O	of
10	64	66	U-UNK	EPA
11	68	78	O	supplements
12	80	81	O	on
13	83	90	O	glycemic
14	92	98	O	control
15	100	101	O	in
16	103	105	O	non
17	107	115	O	diabetics
18	117	120	O	with
19	122	128	O	glucose
20	130	140	O	intolerance
21	141	141	O	,
22	143	145	O	and
23	147	151	O	those
24	153	156	O	with
25	158	161	O	type
26	163	163	O	2
27	165	172	O	diabetes
NULL

Icosapent	DDI-DrugBank.d35.s5	NO_SECTION	NO_SETID	14
Some early studies indicated that EPA supplements might have detrimental effects in those groups.
1	0	3	O	Some
2	5	9	O	early
3	11	17	O	studies
4	19	27	O	indicated
5	29	32	O	that
6	34	36	U-UNK	EPA
7	38	48	O	supplements
8	50	54	O	might
9	56	59	O	have
10	61	71	O	detrimental
11	73	79	O	effects
12	81	82	O	in
13	84	88	O	those
14	90	95	O	groups
NULL

Icosapent	DDI-DrugBank.d35.s6	NO_SECTION	NO_SETID	11
Recent, better designed studies have not reported these adverse effects.
1	0	5	O	Recent
2	6	6	O	,
3	8	13	O	better
4	15	22	O	designed
5	24	30	O	studies
6	32	35	O	have
7	37	39	O	not
8	41	48	O	reported
9	50	54	O	these
10	56	62	O	adverse
11	64	70	O	effects
NULL

Icosapent	DDI-DrugBank.d35.s7	NO_SECTION	NO_SETID	23
There is no evidence that EPA supplements have detrimental effects on glucose tolerance, insulin secretion or insulin resistance in non-diabetic subjects.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	19	O	evidence
5	21	24	O	that
6	26	28	U-UNK	EPA
7	30	40	O	supplements
8	42	45	O	have
9	47	57	O	detrimental
10	59	65	O	effects
11	67	68	O	on
12	70	76	O	glucose
13	78	86	O	tolerance
14	87	87	O	,
15	89	95	O	insulin
16	97	105	O	secretion
17	107	108	O	or
18	110	116	O	insulin
19	118	127	O	resistance
20	129	130	O	in
21	132	134	O	non
22	136	143	O	diabetic
23	145	152	O	subjects
NULL

Icosapent	DDI-DrugBank.d35.s8	NO_SECTION	NO_SETID	20
Diabetics should discuss the use of these supplements with their physicians and note if the supplements affect their glycemic control.
1	0	8	O	Diabetics
2	10	15	O	should
3	17	23	O	discuss
4	25	27	O	the
5	29	31	O	use
6	33	34	O	of
7	36	40	O	these
8	42	52	O	supplements
9	54	57	O	with
10	59	63	O	their
11	65	74	O	physicians
12	76	78	O	and
13	80	83	O	note
14	85	86	O	if
15	88	90	O	the
16	92	102	O	supplements
17	104	109	O	affect
18	111	115	O	their
19	117	124	O	glycemic
20	126	132	O	control
NULL

Icosapent	DDI-DrugBank.d35.s9	NO_SECTION	NO_SETID	11
Diabetics who take EPA supplements should be monitored by their physicians.
1	0	8	O	Diabetics
2	10	12	O	who
3	14	17	O	take
4	19	21	U-UNK	EPA
5	23	33	O	supplements
6	35	40	O	should
7	42	43	O	be
8	45	53	O	monitored
9	55	56	O	by
10	58	62	O	their
11	64	73	O	physicians
NULL

Idoxuridine	DDI-DrugBank.d91.s0	NO_SECTION	NO_SETID	29
Other medicines - Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur.
1	0	4	O	Other
2	6	14	O	medicines
3	18	25	O	Although
4	27	33	O	certain
5	35	43	O	medicines
6	45	50	O	should
7	52	54	O	not
8	56	57	O	be
9	59	62	O	used
10	64	71	O	together
11	73	74	O	at
12	76	78	O	all
13	79	79	O	,
14	81	82	O	in
15	84	88	O	other
16	90	94	O	cases
17	96	98	O	two
18	100	108	O	different
19	110	118	O	medicines
20	120	122	O	may
21	124	125	O	be
22	127	130	O	used
23	132	139	O	together
24	141	144	O	even
25	146	147	O	if
26	149	150	O	an
27	152	162	O	interaction
28	164	168	O	might
29	170	174	O	occur
NULL

Idoxuridine	DDI-DrugBank.d91.s1	NO_SECTION	NO_SETID	19
In these cases, your doctor may want to change the dose, or other precautions may be necessary.
1	0	1	O	In
2	3	7	O	these
3	9	13	O	cases
4	14	14	O	,
5	16	19	O	your
6	21	26	O	doctor
7	28	30	O	may
8	32	35	O	want
9	37	38	O	to
10	40	45	O	change
11	47	49	O	the
12	51	54	O	dose
13	55	55	O	,
14	57	58	O	or
15	60	64	O	other
16	66	76	O	precautions
17	78	80	O	may
18	82	83	O	be
19	85	93	O	necessary
NULL

Idoxuridine	DDI-DrugBank.d91.s2	NO_SECTION	NO_SETID	28
When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.
1	0	3	O	When
2	5	7	O	you
3	9	11	O	are
4	13	17	O	using
5	19	29	O	XXXXXXXX
6	30	30	O	,
7	32	33	O	it
8	35	36	O	is
9	38	47	O	especially
10	49	57	O	important
11	59	62	O	that
12	64	67	O	your
13	69	74	O	health
14	76	79	O	care
15	81	92	O	professional
16	94	97	O	know
17	99	100	O	if
18	102	104	O	you
19	106	108	O	are
20	110	114	O	using
21	116	118	O	the
22	120	128	O	following
23	129	129	O	:
24	131	133	O	Eye
25	135	141	O	product
26	143	152	O	containing
27	154	158	B-DYN	boric
28	160	163	L-DYN	acid
NULL

Idoxuridine	DDI-DrugBank.d91.s3	NO_SECTION	NO_SETID	31
Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.
1	0	4	B-KIN	Boric
2	6	9	L-KIN	acid
3	11	13	O	may
4	15	22	O	interact
5	24	27	O	with
6	29	31	O	the
7	33	43	O	XXXXXXXX
8	45	55	O	preparation
9	57	63	O	causing
10	65	65	O	a
11	67	72	O	gritty
12	74	82	O	substance
13	84	85	O	to
14	87	90	O	form
15	92	93	O	or
16	95	97	O	may
17	99	106	O	interact
18	108	111	O	with
19	113	115	O	the
20	117	128	O	preservative
21	130	131	O	in
22	133	135	O	the
23	137	147	O	XXXXXXXX
24	149	159	O	preparation
25	161	167	O	causing
26	169	169	O	a
27	171	175	O	toxic
28	177	182	O	effect
29	184	185	O	in
30	187	189	O	the
31	191	193	O	eye
NULL

Ifosfamide	DDI-DrugBank.d515.s0	NO_SECTION	NO_SETID	33
The physician should be alert for possible combined drug actions, desirable or undesirable, involving ifosfamide even though ifosfamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.
1	0	2	O	The
2	4	12	O	physician
3	14	19	O	should
4	21	22	O	be
5	24	28	O	alert
6	30	32	O	for
7	34	41	O	possible
8	43	50	O	combined
9	52	55	O	drug
10	57	63	O	actions
11	64	64	O	,
12	66	74	O	desirable
13	76	77	O	or
14	79	89	O	undesirable
15	90	90	O	,
16	92	100	O	involving
17	102	111	O	XXXXXXXX
18	113	116	O	even
19	118	123	O	though
20	125	134	O	XXXXXXXX
21	136	138	O	has
22	140	143	O	been
23	145	148	O	used
24	150	161	O	successfully
25	163	174	O	concurrently
26	176	179	O	with
27	181	185	O	other
28	187	191	O	drugs
29	192	192	O	,
30	194	202	O	including
31	204	208	O	other
32	210	218	O	cytotoxic
33	220	224	O	drugs
NULL

Iloprost	DDI-DrugBank.d549.s0	NO_SECTION	NO_SETID	22
In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous iloprost and either nifedipine, diltiazem, or captopril.
1	0	1	O	In
2	3	9	O	studies
3	11	12	O	in
4	14	19	O	normal
5	21	30	O	volunteers
6	31	31	O	,
7	33	37	O	there
8	39	41	O	was
9	43	44	O	no
10	46	60	O	pharmacodynamic
11	62	72	O	interaction
12	74	80	O	between
13	82	92	O	intravenous
14	94	101	O	XXXXXXXX
15	103	105	O	and
16	107	112	O	either
17	114	123	U-UNK	nifedipine
18	124	124	O	,
19	126	134	U-UNK	diltiazem
20	135	135	O	,
21	137	138	O	or
22	140	148	U-UNK	captopril
NULL

Iloprost	DDI-DrugBank.d549.s1	NO_SECTION	NO_SETID	16
However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.
1	0	6	O	However
2	7	7	O	,
3	9	16	O	XXXXXXXX
4	18	20	O	has
5	22	24	O	the
6	26	34	O	potential
7	36	37	O	to
8	39	46	O	increase
9	48	50	O	the
10	52	62	O	hypotensive
11	64	69	O	effect
12	71	72	O	of
13	74	85	U-DYN	vasodilators
14	87	89	O	and
15	91	106	B-DYN	antihypertensive
16	108	113	L-DYN	agents
NULL

Iloprost	DDI-DrugBank.d549.s2	NO_SECTION	NO_SETID	22
Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.
1	0	4	O	Since
2	6	13	O	XXXXXXXX
3	15	22	O	inhibits
4	24	31	O	platelet
5	33	40	O	function
6	41	41	O	,
7	43	47	O	there
8	49	50	O	is
9	52	52	O	a
10	54	62	O	potential
11	64	66	O	for
12	68	76	O	increased
13	78	81	O	risk
14	83	84	O	of
15	86	93	O	bleeding
16	94	94	O	,
17	96	107	O	particularly
18	109	110	O	in
19	112	119	O	patients
20	121	130	O	maintained
21	132	133	O	on
22	135	148	U-DYN	anticoagulants
NULL

Iloprost	DDI-DrugBank.d549.s3	NO_SECTION	NO_SETID	32
During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
1	0	5	O	During
2	7	14	O	clinical
3	16	21	O	trials
4	22	22	O	,
5	24	31	O	XXXXXXXX
6	33	35	O	was
7	37	40	O	used
8	42	53	O	concurrently
9	55	58	O	with
10	60	73	U-UNK	anticoagulants
11	74	74	O	,
12	76	84	U-UNK	diuretics
13	85	85	O	,
14	87	93	B-UNK	cardiac
15	95	104	L-UNK	glycosides
16	105	105	O	,
17	107	113	B-UNK	calcium
18	115	121	I-UNK	channel
19	123	130	L-UNK	blockers
20	131	131	O	,
21	133	142	U-UNK	analgesics
22	143	143	O	,
23	145	156	U-UNK	antipyretics
24	157	157	O	,
25	159	170	B-UNK	nonsteroidal
26	172	189	L-UNK	antiinflammatories
27	190	190	O	,
28	192	206	U-UNK	corticosteroids
29	207	207	O	,
30	209	211	O	and
31	213	217	O	other
32	219	229	O	medications
NULL

Iloprost	DDI-DrugBank.d549.s4	NO_SECTION	NO_SETID	12
Intravenous infusion of iloprost had no effect on the pharmacokinetics of digoxin.
1	0	10	O	Intravenous
2	12	19	O	infusion
3	21	22	O	of
4	24	31	O	XXXXXXXX
5	33	35	O	had
6	37	38	O	no
7	40	45	O	effect
8	47	48	O	on
9	50	52	O	the
10	54	69	O	pharmacokinetics
11	71	72	O	of
12	74	80	U-UNK	digoxin
NULL

Iloprost	DDI-DrugBank.d549.s5	NO_SECTION	NO_SETID	10
Acetylsalicylic acid did not alter the clearance (pharmacokinetics) of iloprost.
1	0	14	B-UNK	Acetylsalicylic
2	16	19	L-UNK	acid
3	21	23	O	did
4	25	27	O	not
5	29	33	O	alter
6	35	37	O	the
7	39	47	O	clearance
8	50	65	O	pharmacokinetics
9	68	69	O	of
10	71	78	O	XXXXXXXX
NULL

Iloprost	DDI-DrugBank.d549.s6	NO_SECTION	NO_SETID	26
Although clinical studies have not been conducted, in vitro studies of iloprost indicate that no relevant inhibition of cytochrome P450 drug metabolism would be expected.
1	0	7	O	Although
2	9	16	O	clinical
3	18	24	O	studies
4	26	29	O	have
5	31	33	O	not
6	35	38	O	been
7	40	48	O	conducted
8	49	49	O	,
9	51	52	O	in
10	54	58	O	vitro
11	60	66	O	studies
12	68	69	O	of
13	71	78	O	XXXXXXXX
14	80	87	O	indicate
15	89	92	O	that
16	94	95	O	no
17	97	104	O	relevant
18	106	115	O	inhibition
19	117	118	O	of
20	120	129	O	cytochrome
21	131	134	O	P450
22	136	139	O	drug
23	141	150	O	metabolism
24	152	156	O	would
25	158	159	O	be
26	161	168	O	expected
NULL

Imatinib	DDI-DrugBank.d115.s0	NO_SECTION	NO_SETID	36
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).
1	0	4	O	Drugs
2	6	9	O	that
3	11	13	O	may
4	15	19	O	alter
5	21	28	U-UNK	imatinib
6	30	35	O	plasma
7	37	50	O	concentrations
8	52	56	O	Drugs
9	58	61	O	that
10	63	65	O	may
11	67	74	O	increase
12	76	83	U-UNK	imatinib
13	85	90	O	plasma
14	92	105	O	concentrations
15	106	106	O	:
16	108	114	O	Caution
17	116	117	O	is
18	119	129	O	recommended
19	131	134	O	when
20	136	148	O	administering
21	150	156	O	XXXXXXXX
22	158	161	O	with
23	163	172	O	inhibitors
24	174	175	O	of
25	177	179	O	the
26	181	186	O	CYP3A4
27	188	193	O	family
28	196	198	O	e.g
29	200	200	O	,
30	202	213	U-DYN	ketoconazole
31	214	214	O	,
32	216	227	U-DYN	itraconazole
33	228	228	O	,
34	230	241	U-DYN	erythromycin
35	242	242	O	,
36	244	257	U-DYN	clarithromycin
NULL

Imatinib	DDI-DrugBank.d115.s1	NO_SECTION	NO_SETID	16
Substances that inhibit the cytochrome P450 isoenzyme (CYP3A4) activity may decrease metabolism and increase imatinib concentrations.
1	0	9	O	Substances
2	11	14	O	that
3	16	22	O	inhibit
4	24	26	O	the
5	28	37	O	cytochrome
6	39	42	O	P450
7	44	52	O	isoenzyme
8	55	60	O	CYP3A4
9	63	70	O	activity
10	72	74	O	may
11	76	83	O	decrease
12	85	94	O	metabolism
13	96	98	O	and
14	100	107	O	increase
15	109	116	O	XXXXXXXX
16	118	131	O	concentrations
NULL

Imatinib	DDI-DrugBank.d115.s2	NO_SECTION	NO_SETID	17
There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).
1	0	4	O	There
2	6	7	O	is
3	9	9	O	a
4	11	21	O	significant
5	23	30	O	increase
6	32	33	O	in
7	35	42	O	exposure
8	44	45	O	to
9	47	54	U-UNK	imatinib
10	56	59	O	when
11	61	67	O	XXXXXXXX
12	69	70	O	is
13	72	85	O	coadministered
14	87	90	O	with
15	92	103	U-KIN	ketoconazole
16	106	111	O	CYP3A4
17	113	121	O	inhibitor
NULL

Imatinib	DDI-DrugBank.d115.s3	NO_SECTION	NO_SETID	23
Drugs that may decrease imatinib plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease imatinib plasma concentrations.
1	0	4	O	Drugs
2	6	9	O	that
3	11	13	O	may
4	15	22	O	decrease
5	24	31	O	XXXXXXXX
6	33	38	O	plasma
7	40	53	O	concentrations
8	54	54	O	:
9	56	65	O	Substances
10	67	70	O	that
11	72	74	O	are
12	76	83	O	inducers
13	85	86	O	of
14	88	93	O	CYP3A4
15	95	102	O	activity
16	104	106	O	may
17	108	115	O	increase
18	117	126	O	metabolism
19	128	130	O	and
20	132	139	O	decrease
21	141	148	O	XXXXXXXX
22	150	155	O	plasma
23	157	170	O	concentrations
NULL

Imatinib	DDI-DrugBank.d115.s4	NO_SECTION	NO_SETID	18
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital or St.
1	0	1	O	Co
2	3	13	O	medications
3	15	18	O	that
4	20	25	O	induce
5	27	32	O	CYP3A4
6	35	37	O	e.g
7	39	39	O	,
8	41	53	U-UNK	dexamethasone
9	54	54	O	,
10	56	64	U-UNK	phenytoin
11	65	65	O	,
12	67	79	U-UNK	carbamazepine
13	80	80	O	,
14	82	89	U-UNK	rifampin
15	90	90	O	,
16	92	104	U-UNK	phenobarbital
17	106	107	O	or
18	109	110	O	St
NULL

Imatinib	DDI-DrugBank.d115.s5	NO_SECTION	NO_SETID	8
Johns Wort) may significantly reduce exposure to Gleevec.
1	0	4	O	Johns
2	6	9	O	Wort
3	12	14	O	may
4	16	28	O	significantly
5	30	35	O	reduce
6	37	44	O	exposure
7	46	47	O	to
8	49	55	O	XXXXXXXX
NULL

Imatinib	DDI-DrugBank.d115.s6	NO_SECTION	NO_SETID	36
Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).
1	0	11	O	Pretreatment
2	13	14	O	of
3	16	22	O	healthy
4	24	33	O	volunteers
5	35	38	O	with
6	40	47	O	multiple
7	49	53	O	doses
8	55	56	O	of
9	58	65	U-KIN	rifampin
10	67	74	O	followed
11	76	77	O	by
12	79	79	O	a
13	81	86	O	single
14	88	91	O	dose
15	93	94	O	of
16	96	102	O	XXXXXXXX
17	103	103	O	,
18	105	113	O	increased
19	115	121	O	XXXXXXXX
20	123	126	O	oral
21	128	131	O	dose
22	133	141	O	clearance
23	143	144	O	by
24	146	148	O	3.8
25	150	153	O	fold
26	154	154	O	,
27	156	160	O	which
28	162	174	O	significantly
29	177	177	O	p
30	179	182	O	0.05
31	185	193	O	decreased
32	195	198	O	mean
33	200	203	O	cmax
34	205	207	O	and
35	209	213	O	AUC(0
36	215	215	O	8
NULL

Imatinib	DDI-DrugBank.d115.s7	NO_SECTION	NO_SETID	22
In patients where rifampin or other CYP3A4 inducers are indicated, alternative therapeutic agents with less enzyme induction potential should be considered.
1	0	1	O	In
2	3	10	O	patients
3	12	16	O	where
4	18	25	U-UNK	rifampin
5	27	28	O	or
6	30	34	O	other
7	36	41	O	CYP3A4
8	43	50	O	inducers
9	52	54	O	are
10	56	64	O	indicated
11	65	65	O	,
12	67	77	O	alternative
13	79	89	O	therapeutic
14	91	96	O	agents
15	98	101	O	with
16	103	106	O	less
17	108	113	O	enzyme
18	115	123	O	induction
19	125	133	O	potential
20	135	140	O	should
21	142	143	O	be
22	145	154	O	considered
NULL

Imatinib	DDI-DrugBank.d115.s8	NO_SECTION	NO_SETID	36
Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.
1	0	4	O	Drugs
2	6	9	O	that
3	11	13	O	may
4	15	18	O	have
5	20	24	O	their
6	26	31	O	plasma
7	33	45	O	concentration
8	47	53	O	altered
9	55	56	O	by
10	58	64	O	XXXXXXXX
11	66	72	O	XXXXXXXX
12	74	82	O	increases
13	84	86	O	the
14	88	91	O	mean
15	93	96	O	cmax
16	98	100	O	and
17	102	104	O	AUC
18	106	107	O	of
19	109	119	U-KIN	simvastatin
20	122	127	O	CYP3A4
21	129	137	O	substrate
22	140	140	O	2
23	143	145	O	and
24	147	149	O	3.5
25	151	154	O	fold
26	155	155	O	,
27	157	168	O	respectively
28	169	169	O	,
29	171	180	O	suggesting
30	182	183	O	an
31	185	194	O	inhibition
32	196	197	O	of
33	199	201	O	the
34	203	208	O	CYP3A4
35	210	211	O	by
36	213	219	O	XXXXXXXX
NULL

Imatinib	DDI-DrugBank.d115.s9	NO_SECTION	NO_SETID	21
Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).
1	0	9	O	Particular
2	11	17	O	caution
3	19	20	O	is
4	22	32	O	recommended
5	34	37	O	when
6	39	51	O	administering
7	53	59	O	XXXXXXXX
8	61	64	O	with
9	66	71	O	CYP3A4
10	73	82	O	substrates
11	84	87	O	that
12	89	92	O	have
13	94	94	O	a
14	96	101	O	narrow
15	103	113	O	therapeutic
16	115	120	O	window
17	123	125	O	e.g
18	127	127	O	,
19	129	140	U-DYN	cyclosporine
20	142	143	O	or
21	145	152	U-DYN	pimozide
NULL

Imatinib	DDI-DrugBank.d115.s10	NO_SECTION	NO_SETID	26
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).
1	0	6	O	XXXXXXXX
2	8	11	O	will
3	13	20	O	increase
4	22	40	O	plasmaconcentration
5	42	43	O	of
6	45	49	O	other
7	51	56	O	CYP3A4
8	58	68	O	metabolized
9	70	74	O	drugs
10	77	79	O	e.g
11	81	81	O	,
12	83	90	O	triazolo
13	92	106	U-KIN	benzodiazepines
14	107	107	O	,
15	109	123	B-KIN	dihydropyridine
16	125	131	I-KIN	calcium
17	133	139	I-KIN	channel
18	141	148	L-KIN	blockers
19	149	149	O	,
20	151	157	O	certain
21	159	161	B-KIN	HMG
22	163	165	I-KIN	CoA
23	167	175	I-KIN	reductase
24	177	186	L-KIN	inhibitors
25	187	187	O	,
26	189	191	O	etc
NULL

Imatinib	DDI-DrugBank.d115.s11	NO_SECTION	NO_SETID	21
Because warfarin is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard heparin.
1	0	6	O	Because
2	8	15	U-UNK	warfarin
3	17	18	O	is
4	20	30	O	metabolized
5	32	33	O	by
6	35	40	O	CYP2C9
7	42	44	O	and
8	46	51	O	CYP3A4
9	52	52	O	,
10	54	61	O	patients
11	63	65	O	who
12	67	73	O	require
13	75	89	O	anticoagulation
14	91	96	O	should
15	98	104	O	receive
16	106	108	O	low
17	110	118	O	molecular
18	120	125	O	weight
19	127	128	O	or
20	130	137	O	standard
21	139	145	U-UNK	heparin
NULL

Imatinib	DDI-DrugBank.d115.s12	NO_SECTION	NO_SETID	18
in vitro, Gleevec inhibits the cytochrome P450 isoenzyme CYP2D6 activity at similar concentrations that affect CYP3A4 activity.
1	0	1	O	in
2	3	7	O	vitro
3	8	8	O	,
4	10	16	O	XXXXXXXX
5	18	25	O	inhibits
6	27	29	O	the
7	31	40	O	cytochrome
8	42	45	O	P450
9	47	55	O	isoenzyme
10	57	62	O	CYP2D6
11	64	71	O	activity
12	73	74	O	at
13	76	82	O	similar
14	84	97	O	concentrations
15	99	102	O	that
16	104	109	O	affect
17	111	116	O	CYP3A4
18	118	125	O	activity
NULL

Imatinib	DDI-DrugBank.d115.s13	NO_SECTION	NO_SETID	15
Systemic exposure to substrates of CYP2D6 is expected to be increased when coadministered with Gleevec.
1	0	7	O	Systemic
2	9	16	O	exposure
3	18	19	O	to
4	21	30	O	substrates
5	32	33	O	of
6	35	40	O	CYP2D6
7	42	43	O	is
8	45	52	O	expected
9	54	55	O	to
10	57	58	O	be
11	60	68	O	increased
12	70	73	O	when
13	75	88	O	coadministered
14	90	93	O	with
15	95	101	O	Gleevec
NULL

Imatinib	DDI-DrugBank.d115.s14	NO_SECTION	NO_SETID	10
No specific studies have been performed and caution is recommended.
1	0	1	O	No
2	3	10	O	specific
3	12	18	O	studies
4	20	23	O	have
5	25	28	O	been
6	30	38	O	performed
7	40	42	O	and
8	44	50	O	caution
9	52	53	O	is
10	55	65	O	recommended
NULL

Imatinib	DDI-DrugBank.d115.s15	NO_SECTION	NO_SETID	16
in vitro, Gleevec inhibits acetaminophen O-glucuronidation (Ki value of 58.5  M) at therapeutic levels.
1	0	1	O	in
2	3	7	O	vitro
3	8	8	O	,
4	10	16	O	XXXXXXXX
5	18	25	O	inhibits
6	27	39	O	acetaminophen
7	41	41	O	O
8	43	57	O	glucuronidation
9	60	61	O	Ki
10	63	67	O	value
11	69	70	O	of
12	72	75	O	58.5
13	78	78	O	M
14	81	82	O	at
15	84	94	O	therapeutic
16	96	101	O	levels
NULL

Imatinib	DDI-DrugBank.d115.s16	NO_SECTION	NO_SETID	13
Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.
1	0	7	O	Systemic
2	9	16	O	exposure
3	18	19	O	to
4	21	33	U-KIN	acetaminophen
5	35	36	O	is
6	38	45	O	expected
7	47	48	O	to
8	50	51	O	be
9	53	61	O	increased
10	63	66	O	when
11	68	81	O	coadministered
12	83	86	O	with
13	88	94	O	XXXXXXXX
NULL

Imatinib	DDI-DrugBank.d115.s17	NO_SECTION	NO_SETID	12
No specific studies in humans have been performed and caution is recommended.
1	0	1	O	No
2	3	10	O	specific
3	12	18	O	studies
4	20	21	O	in
5	23	28	O	humans
6	30	33	O	have
7	35	38	O	been
8	40	48	O	performed
9	50	52	O	and
10	54	60	O	caution
11	62	63	O	is
12	65	75	O	recommended
NULL

Imipramine	DDI-DrugBank.d77.s0	NO_SECTION	NO_SETID	28
In occasional susceptible patients or in those receiving anticholinergic drugs (including antiparkinsonism agents) in addition, the atropine-like effects may become more pronounced (e.g., paralytic ileus).
1	0	1	O	In
2	3	12	O	occasional
3	14	24	O	susceptible
4	26	33	O	patients
5	35	36	O	or
6	38	39	O	in
7	41	45	O	those
8	47	55	O	receiving
9	57	71	B-UNK	anticholinergic
10	73	77	L-UNK	drugs
11	80	88	O	including
12	90	105	O	antiparkinsonism
13	107	112	O	agents
14	115	116	O	in
15	118	125	O	addition
16	126	126	O	,
17	128	130	O	the
18	132	139	O	atropine
19	141	144	O	like
20	146	152	O	effects
21	154	156	O	may
22	158	163	O	become
23	165	168	O	more
24	170	179	O	pronounced
25	182	184	O	e.g
26	186	186	O	,
27	188	196	O	paralytic
28	198	202	O	ileus
NULL

Imipramine	DDI-DrugBank.d77.s1	NO_SECTION	NO_SETID	18
Close supervision and careful adjustment of dosage is required when this drug is administered concomitantly with anticholinergic drugs.
1	0	4	O	Close
2	6	16	O	supervision
3	18	20	O	and
4	22	28	O	careful
5	30	39	O	adjustment
6	41	42	O	of
7	44	49	O	dosage
8	51	52	O	is
9	54	61	O	required
10	63	66	O	when
11	68	71	O	this
12	73	76	O	drug
13	78	79	O	is
14	81	92	O	administered
15	94	106	O	concomitantly
16	108	111	O	with
17	113	127	B-UNK	anticholinergic
18	129	133	L-UNK	drugs
NULL

Imipramine	DDI-DrugBank.d77.s2	NO_SECTION	NO_SETID	36
Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
1	0	4	O	Avoid
2	6	8	O	the
3	10	12	O	use
4	14	15	O	of
5	17	28	O	preparations
6	30	33	O	such
7	35	36	O	as
8	38	50	U-UNK	decongestants
9	52	54	O	and
10	56	60	O	local
11	62	72	U-UNK	anesthetics
12	74	78	O	which
13	80	86	O	contain
14	88	90	O	any
15	92	106	B-UNK	sympathomimetic
16	108	112	L-UNK	amine
17	115	117	O	e.g
18	119	119	O	,
19	121	131	U-UNK	epinephrine
20	132	132	O	,
21	134	147	U-UNK	norepinephrine
22	149	149	O	,
23	151	155	O	since
24	157	158	O	it
25	160	162	O	has
26	164	167	O	been
27	169	176	O	reported
28	178	181	O	that
29	183	191	B-UNK	tricyclic
30	193	207	L-UNK	antidepressants
31	209	211	O	can
32	213	222	O	potentiate
33	224	226	O	the
34	228	234	O	effects
35	236	237	O	of
36	239	252	O	catecholamines
NULL

Imipramine	DDI-DrugBank.d77.s3	NO_SECTION	NO_SETID	15
Caution should be exercised when imipramine hydrochloride is used with agents that lower blood pressure.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	42	O	XXXXXXXX
7	44	56	O	hydrochloride
8	58	59	O	is
9	61	64	O	used
10	66	69	O	with
11	71	76	O	agents
12	78	81	O	that
13	83	87	O	lower
14	89	93	O	blood
15	95	102	O	pressure
NULL

Imipramine	DDI-DrugBank.d77.s4	NO_SECTION	NO_SETID	10
Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.
1	0	9	O	XXXXXXXX
2	11	23	O	hydrochloride
3	25	27	O	may
4	29	38	O	potentiate
5	40	42	O	the
6	44	50	O	effects
7	52	53	O	of
8	55	57	B-DYN	CNS
9	59	68	I-DYN	depressant
10	70	74	L-DYN	drugs
NULL

Imipramine	DDI-DrugBank.d77.s5	NO_SECTION	NO_SETID	48
The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
1	0	2	O	The
2	4	9	O	plasma
3	11	23	O	concentration
4	25	26	O	of
5	28	37	O	XXXXXXXX
6	39	41	O	may
7	43	50	O	increase
8	52	55	O	when
9	57	59	O	the
10	61	64	O	drug
11	66	67	O	is
12	69	73	O	given
13	75	87	O	concomitantly
14	89	92	O	with
15	94	100	O	hepatic
16	102	107	O	enzyme
17	109	118	O	inhibitors
18	121	123	O	e.g
19	125	125	O	,
20	127	136	U-KIN	cimetidine
21	137	137	O	,
22	139	148	U-KIN	fluoxetine
23	151	153	O	and
24	155	162	O	decrease
25	164	165	O	by
26	167	177	O	concomitant
27	179	192	O	administration
28	194	195	O	of
29	197	203	O	hepatic
30	205	210	O	enzyme
31	212	219	O	inducers
32	222	224	O	e.g
33	226	226	O	,
34	228	239	U-KIN	barbiturates
35	240	240	O	,
36	242	250	U-KIN	phenytoin
37	252	252	O	,
38	254	256	O	and
39	258	267	O	adjustment
40	269	270	O	of
41	272	274	O	the
42	276	281	O	dosage
43	283	284	O	of
44	286	295	O	XXXXXXXX
45	297	299	O	may
46	301	309	O	therefore
47	311	312	O	be
48	314	322	O	necessary
NULL

Imipramine	DDI-DrugBank.d77.s6	NO_SECTION	NO_SETID	38
Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers);
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	24	O	P450
5	26	28	O	2D6
6	30	32	O	The
7	34	44	O	biochemical
8	46	53	O	activity
9	55	56	O	of
10	58	60	O	the
11	62	65	O	drug
12	67	78	O	metabolizing
13	80	86	O	isozyme
14	88	97	O	cytochrome
15	99	102	O	P450
16	104	106	O	2D6
17	109	119	O	debrisoquin
18	121	131	O	hydroxylase
19	134	135	O	is
20	137	143	O	reduced
21	145	146	O	in
22	148	148	O	a
23	150	155	O	subset
24	157	158	O	of
25	160	162	O	the
26	164	172	O	caucasian
27	174	183	O	population
28	186	190	O	about
29	192	192	O	7
30	194	195	O	to
31	197	199	O	10%
32	201	202	O	of
33	204	213	O	caucasians
34	215	217	O	are
35	219	220	O	so
36	222	227	O	called
37	229	232	O	poor
38	234	245	O	metabolizers
NULL

Imipramine	DDI-DrugBank.d77.s7	NO_SECTION	NO_SETID	22
reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
1	0	7	O	reliable
2	9	17	O	estimates
3	19	20	O	of
4	22	24	O	the
5	26	35	O	prevalence
6	37	38	O	of
7	40	46	O	reduced
8	48	51	O	P450
9	53	55	O	2D6
10	57	63	O	isozyme
11	65	72	O	activity
12	74	78	O	among
13	80	84	O	Asian
14	85	85	O	,
15	87	93	O	African
16	95	97	O	and
17	99	103	O	other
18	105	115	O	populations
19	117	119	O	are
20	121	123	O	not
21	125	127	O	yet
22	129	137	O	available
NULL

Imipramine	DDI-DrugBank.d77.s8	NO_SECTION	NO_SETID	16
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
1	0	3	O	Poor
2	5	16	O	metabolizers
3	18	21	O	have
4	23	28	O	higher
5	30	33	O	than
6	35	42	O	expected
7	44	49	O	plasma
8	51	64	O	concentrations
9	66	67	O	of
10	69	77	B-UNK	tricyclic
11	79	93	L-UNK	antidepressants
12	96	99	U-UNK	TCAs
13	102	105	O	when
14	107	111	O	given
15	113	117	O	usual
16	119	123	O	doses
NULL

Imipramine	DDI-DrugBank.d77.s9	NO_SECTION	NO_SETID	32
Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).
1	0	8	O	Depending
2	10	11	O	on
3	13	15	O	the
4	17	24	O	fraction
5	26	27	O	of
6	29	32	O	drug
7	34	44	O	metabolized
8	46	47	O	by
9	49	52	O	P450
10	54	56	O	2D6
11	57	57	O	,
12	59	61	O	the
13	63	70	O	increase
14	72	73	O	in
15	75	80	O	plasma
16	82	94	O	concentration
17	96	98	O	may
18	100	101	O	be
19	103	107	O	small
20	108	108	O	,
21	110	111	O	or
22	113	117	O	quite
23	119	123	O	large
24	126	126	O	8
25	128	131	O	fold
26	133	140	O	increase
27	142	143	O	in
28	145	150	O	plasma
29	152	154	O	AUC
30	156	157	O	of
31	159	161	O	the
32	163	165	U-UNK	TCA
NULL

Imipramine	DDI-DrugBank.d77.s10	NO_SECTION	NO_SETID	17
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble p.o.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	certain
5	21	25	O	drugs
6	27	33	O	inhibit
7	35	37	O	the
8	39	46	O	activity
9	48	49	O	of
10	51	54	O	this
11	56	62	O	isozyme
12	64	66	O	and
13	68	71	O	make
14	73	78	O	normal
15	80	91	O	metabolizers
16	93	100	O	resemble
17	102	104	O	p.o
NULL

Imipramine	DDI-DrugBank.d77.s12	NO_SECTION	NO_SETID	25
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
1	0	1	O	An
2	3	12	O	individual
3	14	16	O	who
4	18	19	O	is
5	21	26	O	stable
6	28	29	O	on
7	31	31	O	a
8	33	37	O	given
9	39	42	O	dose
10	44	45	O	of
11	47	49	U-UNK	TCA
12	51	53	O	may
13	55	60	O	become
14	62	69	O	abruptly
15	71	75	O	toxic
16	77	80	O	when
17	82	86	O	given
18	88	90	O	one
19	92	93	O	of
20	95	99	O	these
21	101	110	O	inhibiting
22	112	116	O	drugs
23	118	119	O	as
24	121	131	O	concomitant
25	133	139	O	therapy
NULL

Imipramine	DDI-DrugBank.d77.s13	NO_SECTION	NO_SETID	17
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine;
1	0	2	O	The
2	4	8	O	drugs
3	10	13	O	that
4	15	21	O	inhibit
5	23	32	O	cytochrome
6	34	37	O	P450
7	39	41	O	2D6
8	43	49	O	include
9	51	54	O	some
10	56	59	O	that
11	61	63	O	are
12	65	67	O	not
13	69	79	O	metabolized
14	81	82	O	by
15	84	86	O	the
16	88	93	O	enzyme
17	96	104	U-UNK	quinidine
NULL

Imipramine	DDI-DrugBank.d77.s14	NO_SECTION	NO_SETID	23
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
1	0	9	U-UNK	cimetidine
2	12	14	O	and
3	16	19	O	many
4	21	24	O	that
5	26	28	O	are
6	30	39	O	substrates
7	41	43	O	for
8	45	48	O	P450
9	50	52	O	2D6
10	55	58	O	many
11	60	64	O	other
12	66	80	U-UNK	antidepressants
13	81	81	O	,
14	83	96	U-UNK	phenothiazines
15	97	97	O	,
16	99	101	O	and
17	103	105	O	the
18	107	110	B-UNK	Type
19	112	113	I-UNK	1C
20	115	129	L-UNK	antiarrhythmics
21	131	141	U-UNK	propafenone
22	143	145	O	and
23	147	156	U-UNK	flecainide
NULL

Imipramine	DDI-DrugBank.d77.s15	NO_SECTION	NO_SETID	31
While all the selective serotonin reuptake inhibitors (SSRIs), e. g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
1	0	4	O	While
2	6	8	O	all
3	10	12	O	the
4	14	22	B-UNK	selective
5	24	32	I-UNK	serotonin
6	34	41	I-UNK	reuptake
7	43	52	L-UNK	inhibitors
8	55	59	U-UNK	SSRIs
9	61	61	O	,
10	63	63	O	e
11	66	66	O	g
12	68	68	O	,
13	70	79	U-UNK	fluoxetine
14	80	80	O	,
15	82	91	U-UNK	sertraline
16	92	92	O	,
17	94	96	O	and
18	98	107	U-UNK	paroxetine
19	108	108	O	,
20	110	116	O	inhibit
21	118	121	O	P450
22	123	125	O	2D6
23	126	126	O	,
24	128	131	O	they
25	133	135	O	may
26	137	140	O	vary
27	142	143	O	in
28	145	147	O	the
29	149	154	O	extent
30	156	157	O	of
31	159	168	O	inhibition
NULL

Imipramine	DDI-DrugBank.d77.s16	NO_SECTION	NO_SETID	26
The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	to
4	14	18	O	which
5	20	23	U-UNK	SSRI
6	25	27	U-UNK	TCA
7	29	40	O	interactions
8	42	44	O	may
9	46	49	O	pose
10	51	58	O	clinical
11	60	67	O	problems
12	69	72	O	will
13	74	79	O	depend
14	81	82	O	on
15	84	86	O	the
16	88	93	O	degree
17	95	96	O	of
18	98	107	O	inhibition
19	108	108	O	,
20	110	112	O	and
21	114	116	O	the
22	118	133	O	pharmacokinetics
23	135	136	O	of
24	138	140	O	the
25	142	145	U-UNK	SSRI
26	147	154	O	involved
NULL

Imipramine	DDI-DrugBank.d77.s17	NO_SECTION	NO_SETID	26
Nevertheless, caution is indicated in the co-administration of TCA5 with any of the SSRIs and also in switching from one class to the other.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	O	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	43	O	co
9	45	58	O	administration
10	60	61	O	of
11	63	66	O	TCA5
12	68	71	O	with
13	73	75	O	any
14	77	78	O	of
15	80	82	O	the
16	84	88	U-UNK	SSRIs
17	90	92	O	and
18	94	97	O	also
19	99	100	O	in
20	102	110	O	switching
21	112	115	O	from
22	117	119	O	one
23	121	125	O	class
24	127	128	O	to
25	130	132	O	the
26	134	138	O	other
NULL

Imipramine	DDI-DrugBank.d77.s18	NO_SECTION	NO_SETID	38
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
1	0	1	O	Of
2	3	12	O	particular
3	14	23	O	importance
4	24	24	O	,
5	26	35	O	sufficient
6	37	40	O	time
7	42	45	O	must
8	47	52	O	elapse
9	54	59	O	before
10	61	70	O	initiating
11	72	74	O	TCA
12	76	84	O	treatment
13	86	87	O	in
14	89	89	O	a
15	91	97	O	patient
16	99	103	O	being
17	105	113	O	withdrawn
18	115	118	O	from
19	120	129	U-UNK	fluoxetine
20	130	130	O	,
21	132	136	O	given
22	138	140	O	the
23	142	145	O	long
24	147	150	O	half
25	152	155	O	life
26	157	158	O	of
27	160	162	O	the
28	164	169	O	parent
29	171	173	O	and
30	175	180	O	active
31	182	191	O	metabolite
32	194	195	O	at
33	197	201	O	least
34	203	203	O	5
35	205	209	O	weeks
36	211	213	O	may
37	215	216	O	be
38	218	226	O	necessary
NULL

Imipramine	DDI-DrugBank.d77.s19	NO_SECTION	NO_SETID	29
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	27	B-UNK	tricyclic
5	29	43	L-UNK	antidepressants
6	45	48	O	with
7	50	54	O	drugs
8	56	59	O	that
9	61	63	O	can
10	65	71	O	inhibit
11	73	82	O	cytochrome
12	84	87	O	P450
13	89	91	O	2D6
14	93	95	O	may
15	97	103	O	require
16	105	109	O	lower
17	111	115	O	doses
18	117	120	O	than
19	122	128	O	usually
20	130	139	O	prescribed
21	141	143	O	for
22	145	150	O	either
23	152	154	O	the
24	156	164	B-UNK	tricyclic
25	166	179	L-UNK	antidepressant
26	181	182	O	or
27	184	186	O	the
28	188	192	O	other
29	194	197	O	drug
NULL

Imipramine	DDI-DrugBank.d77.s20	NO_SECTION	NO_SETID	22
Furthermore, whenever one of these other drugs is withdrawn from cotherapy, an increased dose of tricyclic antidepressant may be required.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	20	O	whenever
4	22	24	O	one
5	26	27	O	of
6	29	33	O	these
7	35	39	O	other
8	41	45	O	drugs
9	47	48	O	is
10	50	58	O	withdrawn
11	60	63	O	from
12	65	73	O	cotherapy
13	74	74	O	,
14	76	77	O	an
15	79	87	O	increased
16	89	92	O	dose
17	94	95	O	of
18	97	105	B-UNK	tricyclic
19	107	120	L-UNK	antidepressant
20	122	124	O	may
21	126	127	O	be
22	129	136	O	required
NULL

Imipramine	DDI-DrugBank.d77.s21	NO_SECTION	NO_SETID	28
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	desirable
4	16	17	O	to
5	19	25	O	monitor
6	27	29	U-UNK	TCA
7	31	36	O	plasma
8	38	43	O	levels
9	45	52	O	whenever
10	54	54	O	a
11	56	58	U-UNK	TCA
12	60	61	O	is
13	63	67	O	going
14	69	70	O	to
15	72	73	O	be
16	75	76	O	co
17	78	89	O	administered
18	91	94	O	with
19	96	102	O	another
20	104	107	O	drug
21	109	113	O	known
22	115	116	O	to
23	118	119	O	be
24	121	122	O	an
25	124	132	O	inhibitor
26	134	135	O	of
27	137	140	O	P450
28	142	144	O	2D6
NULL

Imiquimod	DDI-DrugBank.d555.s0	NO_SECTION	NO_SETID	3
No information available
1	0	1	O	No
2	3	13	O	information
3	15	23	O	available
NULL

Indinavir	DDI-DrugBank.d97.s0	NO_SECTION	NO_SETID	10
Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	14	O	an
4	16	24	O	inhibitor
5	26	27	O	of
6	29	31	O	the
7	33	42	O	cytochrome
8	44	47	O	P450
9	49	55	O	isoform
10	57	62	O	CYP3A4
NULL

Indinavir	DDI-DrugBank.d97.s1	NO_SECTION	NO_SETID	30
Coadministration of CRIXIVAN and drugs primarily metabolized by CYP3A4 may result in increased plasma concentrations of the other drug, which could increase or prolong its therapeutic and adverse effects.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	27	O	XXXXXXXX
4	29	31	O	and
5	33	37	O	drugs
6	39	47	O	primarily
7	49	59	O	metabolized
8	61	62	O	by
9	64	69	O	CYP3A4
10	71	73	O	may
11	75	80	O	result
12	82	83	O	in
13	85	93	O	increased
14	95	100	O	plasma
15	102	115	O	concentrations
16	117	118	O	of
17	120	122	O	the
18	124	128	O	other
19	130	133	O	drug
20	134	134	O	,
21	136	140	O	which
22	142	146	O	could
23	148	155	O	increase
24	157	158	O	or
25	160	166	O	prolong
26	168	170	O	its
27	172	182	O	therapeutic
28	184	186	O	and
29	188	194	O	adverse
30	196	202	O	effects
NULL

Indinavir	DDI-DrugBank.d97.s2	NO_SECTION	NO_SETID	5
Indinavir is metabolized by CYP3A4.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	23	O	metabolized
4	25	26	O	by
5	28	33	O	CYP3A4
NULL

Indinavir	DDI-DrugBank.d97.s3	NO_SECTION	NO_SETID	22
Drugs that induce CYP3A4 activity would be expected to increase the clearance of indinavir, resulting in lowered plasma concentrations of indinavir.
1	0	4	O	Drugs
2	6	9	O	that
3	11	16	O	induce
4	18	23	O	CYP3A4
5	25	32	O	activity
6	34	38	O	would
7	40	41	O	be
8	43	50	O	expected
9	52	53	O	to
10	55	62	O	increase
11	64	66	O	the
12	68	76	O	clearance
13	78	79	O	of
14	81	89	O	XXXXXXXX
15	90	90	O	,
16	92	100	O	resulting
17	102	103	O	in
18	105	111	O	lowered
19	113	118	O	plasma
20	120	133	O	concentrations
21	135	136	O	of
22	138	146	O	XXXXXXXX
NULL

Indinavir	DDI-DrugBank.d97.s4	NO_SECTION	NO_SETID	24
Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	27	O	XXXXXXXX
4	29	31	O	and
5	33	37	O	other
6	39	43	O	drugs
7	45	48	O	that
8	50	56	O	inhibit
9	58	63	O	CYP3A4
10	65	67	O	may
11	69	76	O	decrease
12	78	80	O	the
13	82	90	O	clearance
14	92	93	O	of
15	95	103	U-UNK	indinavir
16	105	107	O	and
17	109	111	O	may
18	113	118	O	result
19	120	121	O	in
20	123	131	O	increased
21	133	138	O	plasma
22	140	153	O	concentrations
23	155	156	O	of
24	158	166	U-UNK	indinavir
NULL

Indinavir	DDI-DrugBank.d97.s6	NO_SECTION	NO_SETID	8
Drugs That Should Not Be Coadministered with CRIXIVAN
1	0	4	O	Drugs
2	6	9	O	That
3	11	16	O	Should
4	18	20	O	Not
5	22	23	O	Be
6	25	38	O	Coadministered
7	40	43	O	with
8	45	52	O	XXXXXXXX
NULL

Indinavir	DDI-DrugBank.d97.s7	NO_SECTION	NO_SETID	7
Drug Class: Drug Name Clinical Comment
1	0	3	O	Drug
2	5	9	O	Class
3	10	10	O	:
4	12	15	O	Drug
5	17	20	O	Name
6	22	29	O	Clinical
7	31	37	O	Comment
NULL

Indinavir	DDI-DrugBank.d97.s8	NO_SECTION	NO_SETID	3
Antiarrhythmics: amiodarone
1	0	14	U-UNK	Antiarrhythmics
2	15	15	O	:
3	17	26	U-UNK	amiodarone
NULL

Indinavir	DDI-DrugBank.d97.s9	NO_SECTION	NO_SETID	16
CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
1	0	14	O	CONTRAINDICATED
2	16	18	O	due
3	20	21	O	to
4	23	31	O	potential
5	33	35	O	for
6	37	43	O	serious
7	45	47	O	and
8	48	48	O	/
9	49	50	O	or
10	52	55	O	life
11	57	67	O	threatening
12	69	77	O	reactions
13	79	82	O	such
14	84	85	O	as
15	87	93	O	cardiac
16	95	105	O	arrhythmias
NULL

Indinavir	DDI-DrugBank.d97.s10	NO_SECTION	NO_SETID	10
Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine
1	0	4	O	Ergot
2	6	16	O	derivatives
3	17	17	O	:
4	19	35	U-UNK	dihydroergotamine
5	36	36	O	,
6	38	47	U-UNK	ergonovine
7	48	48	O	,
8	50	59	U-UNK	ergotamine
9	60	60	O	,
10	62	77	U-UNK	methylergonovine
NULL

Indinavir	DDI-DrugBank.d97.s11	NO_SECTION	NO_SETID	29
CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
1	0	14	O	CONTRAINDICATED
2	16	18	O	due
3	20	21	O	to
4	23	31	O	potential
5	33	35	O	for
6	37	43	O	serious
7	45	47	O	and
8	48	48	O	/
9	49	50	O	or
10	52	55	O	life
11	57	67	O	threatening
12	69	77	O	reactions
13	79	82	O	such
14	84	85	O	as
15	87	91	O	acute
16	93	97	O	ergot
17	99	106	O	toxicity
18	108	120	O	characterized
19	122	123	O	by
20	125	134	O	peripheral
21	136	144	O	vasospasm
22	146	148	O	and
23	150	157	O	ischemia
24	159	160	O	of
25	162	164	O	the
26	166	176	O	extremities
27	178	180	O	and
28	182	186	O	other
29	188	194	O	tissues
NULL

Indinavir	DDI-DrugBank.d97.s12	NO_SECTION	NO_SETID	7
Sedative/hypnotics: midazolam, triazolam
1	0	7	U-UNK	Sedative
2	8	8	O	/
3	9	17	U-UNK	hypnotics
4	18	18	O	:
5	20	28	U-UNK	midazolam
6	29	29	O	,
7	31	39	U-UNK	triazolam
NULL

Indinavir	DDI-DrugBank.d97.s13	NO_SECTION	NO_SETID	21
CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.
1	0	14	O	CONTRAINDICATED
2	16	18	O	due
3	20	21	O	to
4	23	31	O	potential
5	33	35	O	for
6	37	43	O	serious
7	45	47	O	and
8	48	48	O	/
9	49	50	O	or
10	52	55	O	life
11	57	67	O	threatening
12	69	77	O	reactions
13	79	82	O	such
14	84	85	O	as
15	87	95	O	prolonged
16	97	98	O	or
17	100	108	O	increased
18	110	117	O	sedation
19	119	120	O	or
20	122	132	O	respiratory
21	134	143	O	depression
NULL

Indinavir	DDI-DrugBank.d97.s14	NO_SECTION	NO_SETID	5
GI motility agents: cisapride
1	0	1	O	GI
2	3	10	O	motility
3	12	17	O	agents
4	18	18	O	:
5	20	28	U-UNK	cisapride
NULL

Indinavir	DDI-DrugBank.d97.s15	NO_SECTION	NO_SETID	16
CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
1	0	14	O	CONTRAINDICATED
2	16	18	O	due
3	20	21	O	to
4	23	31	O	potential
5	33	35	O	for
6	37	43	O	serious
7	45	47	O	and
8	48	48	O	/
9	49	50	O	or
10	52	55	O	life
11	57	67	O	threatening
12	69	77	O	reactions
13	79	82	O	such
14	84	85	O	as
15	87	93	O	cardiac
16	95	105	O	arrhythmias
NULL

Indinavir	DDI-DrugBank.d97.s16	NO_SECTION	NO_SETID	3
Neuroleptic: pimozide
1	0	10	U-UNK	Neuroleptic
2	11	11	O	:
3	13	20	U-UNK	pimozide
NULL

Indinavir	DDI-DrugBank.d97.s17	NO_SECTION	NO_SETID	16
CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
1	0	14	O	CONTRAINDICATED
2	16	18	O	due
3	20	21	O	to
4	23	31	O	potential
5	33	35	O	for
6	37	43	O	serious
7	45	47	O	and
8	48	48	O	/
9	49	50	O	or
10	52	55	O	life
11	57	67	O	threatening
12	69	77	O	reactions
13	79	82	O	such
14	84	85	O	as
15	87	93	O	cardiac
16	95	105	O	arrhythmias
NULL

Indinavir	DDI-DrugBank.d97.s18	NO_SECTION	NO_SETID	9
Herbal products: St. John s wort (Hypericum perforatum)
1	0	5	O	Herbal
2	7	14	O	products
3	15	15	O	:
4	17	18	O	St
5	21	24	O	John
6	26	26	O	s
7	28	31	O	wort
8	34	42	O	Hypericum
9	44	53	O	perforatum
NULL

Indinavir	DDI-DrugBank.d97.s19	NO_SECTION	NO_SETID	19
May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors.
1	0	2	O	May
2	4	7	O	lead
3	9	10	O	to
4	12	15	O	loss
5	17	18	O	of
6	20	28	O	virologic
7	30	37	O	response
8	39	41	O	and
9	43	50	O	possible
10	52	61	O	resistance
11	63	64	O	to
12	66	73	O	XXXXXXXX
13	75	76	O	or
14	78	79	O	to
15	81	83	O	the
16	85	89	O	class
17	91	92	O	of
18	94	101	B-UNK	protease
19	103	112	L-UNK	inhibitors
NULL

Indinavir	DDI-DrugBank.d97.s20	NO_SECTION	NO_SETID	3
Antimycobacterial: rifampin
1	0	16	U-UNK	Antimycobacterial
2	17	17	O	:
3	19	26	U-UNK	rifampin
NULL

Indinavir	DDI-DrugBank.d97.s21	NO_SECTION	NO_SETID	24
May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors or other coadministered antiretroviral agents.
1	0	2	O	May
2	4	7	O	lead
3	9	10	O	to
4	12	15	O	loss
5	17	18	O	of
6	20	28	O	virologic
7	30	37	O	response
8	39	41	O	and
9	43	50	O	possible
10	52	61	O	resistance
11	63	64	O	to
12	66	73	O	XXXXXXXX
13	75	76	O	or
14	78	79	O	to
15	81	83	O	the
16	85	89	O	class
17	91	92	O	of
18	94	101	B-UNK	protease
19	103	112	L-UNK	inhibitors
20	114	115	O	or
21	117	121	O	other
22	123	136	O	coadministered
23	138	151	B-UNK	antiretroviral
24	153	158	L-UNK	agents
NULL

Indinavir	DDI-DrugBank.d97.s22	NO_SECTION	NO_SETID	8
HMG-CoA Reductase inhibitors: lovastatin, simvastatin
1	0	2	B-UNK	HMG
2	4	6	I-UNK	CoA
3	8	16	I-UNK	Reductase
4	18	27	L-UNK	inhibitors
5	28	28	O	:
6	30	39	U-UNK	lovastatin
7	40	40	O	,
8	42	52	U-UNK	simvastatin
NULL

Indinavir	DDI-DrugBank.d97.s23	NO_SECTION	NO_SETID	11
Potential for serious reactions such as risk of myopathy including rhabdomyolysis.
1	0	8	O	Potential
2	10	12	O	for
3	14	20	O	serious
4	22	30	O	reactions
5	32	35	O	such
6	37	38	O	as
7	40	43	O	risk
8	45	46	O	of
9	48	55	O	myopathy
10	57	65	O	including
11	67	80	O	rhabdomyolysis
NULL

Indinavir	DDI-DrugBank.d97.s24	NO_SECTION	NO_SETID	4
Protease inhibitor: atazanavir
1	0	7	B-UNK	Protease
2	9	17	L-UNK	inhibitor
3	18	18	O	:
4	20	29	U-UNK	atazanavir
NULL

Indinavir	DDI-DrugBank.d97.s25	NO_SECTION	NO_SETID	10
Both CRIXIVAN and atazanavir are associated with indirect (unconjugated) hyperbilirubinemia.
1	0	3	O	Both
2	5	12	O	XXXXXXXX
3	14	16	O	and
4	18	27	U-UNK	atazanavir
5	29	31	O	are
6	33	42	O	associated
7	44	47	O	with
8	49	56	O	indirect
9	59	70	O	unconjugated
10	73	90	O	hyperbilirubinemia
NULL

Indinavir	DDI-DrugBank.d97.s26	NO_SECTION	NO_SETID	17
Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.
1	0	11	O	Combinations
2	13	14	O	of
3	16	20	O	these
4	22	26	O	drugs
5	28	31	O	have
6	33	35	O	not
7	37	40	O	been
8	42	48	O	studied
9	50	52	O	and
10	54	69	O	coadministration
11	71	72	O	of
12	74	81	O	XXXXXXXX
13	83	85	O	and
14	87	96	U-DYN	atazanavir
15	98	99	O	is
16	101	103	O	not
17	105	115	O	recommended
NULL

Indinavir	DDI-DrugBank.d97.s28	NO_SECTION	NO_SETID	24
Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction
1	0	10	O	Established
2	12	14	O	and
3	16	20	O	Other
4	22	32	O	Potentially
5	34	44	O	Significant
6	46	49	O	Drug
7	51	62	O	Interactions
8	63	63	O	:
9	65	74	O	Alteration
10	76	77	O	in
11	79	82	O	Dose
12	84	85	O	or
13	87	93	O	Regimen
14	95	97	O	May
15	99	100	O	Be
16	102	112	O	Recommended
17	114	118	O	Based
18	120	121	O	on
19	123	126	O	Drug
20	128	138	O	Interaction
21	140	146	O	Studies
22	148	149	O	or
23	151	159	O	Predicted
24	161	171	O	Interaction
NULL

Indinavir	DDI-DrugBank.d97.s32	NO_SECTION	NO_SETID	3
HIV Antiviral Agents
1	0	2	B-UNK	HIV
2	4	12	I-UNK	Antiviral
3	14	19	L-UNK	Agents
NULL

Indinavir	DDI-DrugBank.d97.s34	NO_SECTION	NO_SETID	2
indinavir concentration
1	0	8	O	XXXXXXXX
2	10	22	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s35	NO_SECTION	NO_SETID	22
Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.
1	0	3	O	Dose
2	5	13	O	reduction
3	15	16	O	of
4	18	25	O	XXXXXXXX
5	27	28	O	to
6	30	32	O	600
7	34	35	O	mg
8	37	41	O	every
9	43	43	O	8
10	45	49	O	hours
11	51	56	O	should
12	58	59	O	be
13	61	70	O	considered
14	72	75	O	when
15	77	82	O	taking
16	84	94	U-DYN	delavirdine
17	96	98	O	400
18	100	101	O	mg
19	103	107	O	three
20	109	113	O	times
21	115	115	O	a
22	117	119	O	day
NULL

Indinavir	DDI-DrugBank.d97.s37	NO_SECTION	NO_SETID	18
Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.
1	0	8	O	XXXXXXXX
2	10	12	O	and
3	14	23	U-DYN	didanosine
4	25	36	O	formulations
5	38	47	O	containing
6	49	54	O	buffer
7	56	61	O	should
8	63	64	O	be
9	66	77	O	administered
10	79	80	O	at
11	82	86	O	least
12	88	90	O	one
13	92	95	O	hour
14	97	101	O	apart
15	103	104	O	on
16	106	107	O	an
17	109	113	O	empty
18	115	121	O	stomach
NULL

Indinavir	DDI-DrugBank.d97.s39	NO_SECTION	NO_SETID	2
indinavir concentration
1	0	8	O	XXXXXXXX
2	10	22	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s40	NO_SECTION	NO_SETID	16
The optimal dose of indinavir, when given in combination with efavirenz, is not known.
1	0	2	O	The
2	4	10	O	optimal
3	12	15	O	dose
4	17	18	O	of
5	20	28	O	XXXXXXXX
6	29	29	O	,
7	31	34	O	when
8	36	40	O	given
9	42	43	O	in
10	45	55	O	combination
11	57	60	O	with
12	62	70	U-UNK	efavirenz
13	71	71	O	,
14	73	74	O	is
15	76	78	O	not
16	80	84	O	known
NULL

Indinavir	DDI-DrugBank.d97.s41	NO_SECTION	NO_SETID	21
Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.
1	0	9	O	Increasing
2	11	13	O	the
3	15	23	O	XXXXXXXX
4	25	28	O	dose
5	30	31	O	to
6	33	36	O	1000
7	38	39	O	mg
8	41	45	O	every
9	47	47	O	8
10	49	53	O	hours
11	55	58	O	does
12	60	62	O	not
13	64	73	O	compensate
14	75	77	O	for
15	79	81	O	the
16	83	91	O	increased
17	93	101	O	XXXXXXXX
18	103	112	O	metabolism
19	114	116	O	due
20	118	119	O	to
21	121	129	U-KIN	efavirenz
NULL

Indinavir	DDI-DrugBank.d97.s43	NO_SECTION	NO_SETID	2
indinavir concentration
1	0	8	O	XXXXXXXX
2	10	22	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s44	NO_SECTION	NO_SETID	18
The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
1	0	2	O	The
2	4	14	O	appropriate
3	16	20	O	doses
4	22	24	O	for
5	26	29	O	this
6	31	41	O	combination
7	42	42	O	,
8	44	47	O	with
9	49	55	O	respect
10	57	58	O	to
11	60	67	O	efficacy
12	69	71	O	and
13	73	78	O	safety
14	79	79	O	,
15	81	84	O	have
16	86	88	O	not
17	90	93	O	been
18	95	105	O	established
NULL

Indinavir	DDI-DrugBank.d97.s46	NO_SECTION	NO_SETID	2
indinavir concentration
1	0	8	O	XXXXXXXX
2	10	22	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s47	NO_SECTION	NO_SETID	10
Indinavir concentrations may be decreased in the presence of nevirapine.
1	0	8	O	XXXXXXXX
2	10	23	O	concentrations
3	25	27	O	may
4	29	30	O	be
5	32	40	O	decreased
6	42	43	O	in
7	45	47	O	the
8	49	56	O	presence
9	58	59	O	of
10	61	70	U-KIN	nevirapine
NULL

Indinavir	DDI-DrugBank.d97.s48	NO_SECTION	NO_SETID	18
The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
1	0	2	O	The
2	4	14	O	appropriate
3	16	20	O	doses
4	22	24	O	for
5	26	29	O	this
6	31	41	O	combination
7	42	42	O	,
8	44	47	O	with
9	49	55	O	respect
10	57	58	O	to
11	60	67	O	efficacy
12	69	71	O	and
13	73	78	O	safety
14	79	79	O	,
15	81	84	O	have
16	86	88	O	not
17	90	93	O	been
18	95	105	O	established
NULL

Indinavir	DDI-DrugBank.d97.s50	NO_SECTION	NO_SETID	4
indinavir concentration   ritonavir concentration
1	0	8	O	XXXXXXXX
2	10	22	O	concentration
3	26	34	U-UNK	ritonavir
4	36	48	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s51	NO_SECTION	NO_SETID	18
The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
1	0	2	O	The
2	4	14	O	appropriate
3	16	20	O	doses
4	22	24	O	for
5	26	29	O	this
6	31	41	O	combination
7	42	42	O	,
8	44	47	O	with
9	49	55	O	respect
10	57	58	O	to
11	60	67	O	efficacy
12	69	71	O	and
13	73	78	O	safety
14	79	79	O	,
15	81	84	O	have
16	86	88	O	not
17	90	93	O	been
18	95	105	O	established
NULL

Indinavir	DDI-DrugBank.d97.s52	NO_SECTION	NO_SETID	26
Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.
1	0	10	O	Preliminary
2	12	19	O	clinical
3	21	24	O	data
4	26	32	O	suggest
5	34	37	O	that
6	39	41	O	the
7	43	51	O	incidence
8	53	54	O	of
9	56	70	O	nephrolithiasis
10	72	73	O	is
11	75	80	O	higher
12	82	83	O	in
13	85	92	O	patients
14	94	102	O	receiving
15	104	112	U-UNK	indinavir
16	114	115	O	in
17	117	127	O	combination
18	129	132	O	with
19	134	142	U-UNK	ritonavir
20	144	147	O	than
21	149	153	O	those
22	155	163	O	receiving
23	165	172	O	XXXXXXXX
24	174	176	O	800
25	178	179	O	mg
26	181	183	O	q8h
NULL

Indinavir	DDI-DrugBank.d97.s54	NO_SECTION	NO_SETID	2
saquinavir concentration
1	0	9	U-UNK	saquinavir
2	11	23	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s55	NO_SECTION	NO_SETID	18
The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
1	0	2	O	The
2	4	14	O	appropriate
3	16	20	O	doses
4	22	24	O	for
5	26	29	O	this
6	31	41	O	combination
7	42	42	O	,
8	44	47	O	with
9	49	55	O	respect
10	57	58	O	to
11	60	67	O	efficacy
12	69	71	O	and
13	73	78	O	safety
14	79	79	O	,
15	81	84	O	have
16	86	88	O	not
17	90	93	O	been
18	95	105	O	established
NULL

Indinavir	DDI-DrugBank.d97.s57	NO_SECTION	NO_SETID	8
Antiarrhythmics: bepridil, lidocaine (systemic) and quinidine
1	0	14	U-UNK	Antiarrhythmics
2	15	15	O	:
3	17	24	U-UNK	bepridil
4	25	25	O	,
5	27	35	U-UNK	lidocaine
6	38	45	O	systemic
7	48	50	O	and
8	52	60	U-UNK	quinidine
NULL

Indinavir	DDI-DrugBank.d97.s58	NO_SECTION	NO_SETID	3
antiarrhythmic agents concentration
1	0	13	B-UNK	antiarrhythmic
2	15	20	L-UNK	agents
3	22	34	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s59	NO_SECTION	NO_SETID	15
Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.
1	0	6	O	Caution
2	8	9	O	is
3	11	19	O	warranted
4	21	23	O	and
5	25	35	O	therapeutic
6	37	49	O	concentration
7	51	60	O	monitoring
8	62	63	O	is
9	65	75	O	recommended
10	77	79	O	for
11	81	95	U-DYN	antiarrhythmics
12	97	100	O	when
13	102	115	O	coadministered
14	117	120	O	with
15	122	129	O	XXXXXXXX
NULL

Indinavir	DDI-DrugBank.d97.s60	NO_SECTION	NO_SETID	7
Anticonvulsants: carbamazepine, phenobarbital, phenytoin
1	0	14	U-UNK	Anticonvulsants
2	15	15	O	:
3	17	29	U-UNK	carbamazepine
4	30	30	O	,
5	32	44	U-UNK	phenobarbital
6	45	45	O	,
7	47	55	U-UNK	phenytoin
NULL

Indinavir	DDI-DrugBank.d97.s61	NO_SECTION	NO_SETID	2
indinavir concentration
1	0	8	O	XXXXXXXX
2	10	22	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s63	NO_SECTION	NO_SETID	16
CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.
1	0	7	O	XXXXXXXX
2	9	11	O	may
3	13	15	O	not
4	17	18	O	be
5	20	28	O	effective
6	30	32	O	due
7	34	35	O	to
8	37	45	O	decreased
9	47	55	U-DYN	indinavir
10	57	70	O	concentrations
11	72	73	O	in
12	75	82	O	patients
13	84	89	O	taking
14	91	95	O	these
15	97	102	O	agents
16	104	116	O	concomitantly
NULL

Indinavir	DDI-DrugBank.d97.s64	NO_SECTION	NO_SETID	13
Calcium Channel Blockers, Dihydropyridine: e.g., felodipine, nifedipine, nicardipine
1	0	6	B-UNK	Calcium
2	8	14	I-UNK	Channel
3	16	23	L-UNK	Blockers
4	24	24	O	,
5	26	40	U-UNK	Dihydropyridine
6	41	41	O	:
7	43	45	O	e.g
8	47	47	O	,
9	49	58	U-UNK	felodipine
10	59	59	O	,
11	61	70	U-UNK	nifedipine
12	71	71	O	,
13	73	83	U-UNK	nicardipine
NULL

Indinavir	DDI-DrugBank.d97.s65	NO_SECTION	NO_SETID	5
dihydropyridine calcium channel blockers concentration
1	0	14	B-UNK	dihydropyridine
2	16	22	I-UNK	calcium
3	24	30	I-UNK	channel
4	32	39	L-UNK	blockers
5	41	53	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s66	NO_SECTION	NO_SETID	10
Caution is warranted and clinical monitoring of patients is recommended.
1	0	6	O	Caution
2	8	9	O	is
3	11	19	O	warranted
4	21	23	O	and
5	25	32	O	clinical
6	34	43	O	monitoring
7	45	46	O	of
8	48	55	O	patients
9	57	58	O	is
10	60	70	O	recommended
NULL

Indinavir	DDI-DrugBank.d97.s68	NO_SECTION	NO_SETID	4
clarithromycin concentration   indinavir concentration
1	0	13	U-UNK	clarithromycin
2	15	27	O	concentration
3	31	39	O	XXXXXXXX
4	41	53	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s69	NO_SECTION	NO_SETID	18
The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
1	0	2	O	The
2	4	14	O	appropriate
3	16	20	O	doses
4	22	24	O	for
5	26	29	O	this
6	31	41	O	combination
7	42	42	O	,
8	44	47	O	with
9	49	55	O	respect
10	57	58	O	to
11	60	67	O	efficacy
12	69	71	O	and
13	73	78	O	safety
14	79	79	O	,
15	81	84	O	have
16	86	88	O	not
17	90	93	O	been
18	95	105	O	established
NULL

Indinavir	DDI-DrugBank.d97.s70	NO_SECTION	NO_SETID	6
HMG-CoA Reductase Inhibitor: atorvastatin
1	0	2	B-UNK	HMG
2	4	6	I-UNK	CoA
3	8	16	I-UNK	Reductase
4	18	26	L-UNK	Inhibitor
5	27	27	O	:
6	29	40	U-UNK	atorvastatin
NULL

Indinavir	DDI-DrugBank.d97.s71	NO_SECTION	NO_SETID	2
atorvastatin concentration
1	0	11	U-UNK	atorvastatin
2	13	25	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s72	NO_SECTION	NO_SETID	36
Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.
1	0	2	O	Use
2	4	9	O	lowest
3	11	18	O	possible
4	20	23	O	dose
5	25	26	O	of
6	28	39	U-DYN	atorvastatin
7	41	44	O	with
8	46	52	O	careful
9	54	63	O	monitoring
10	64	64	O	,
11	66	67	O	or
12	69	76	O	consider
13	78	80	B-DYN	HMG
14	82	84	I-DYN	CoA
15	86	94	I-DYN	reductase
16	96	105	L-DYN	inhibitors
17	107	110	O	that
18	112	114	O	are
19	116	118	O	not
20	120	128	O	primarily
21	130	140	O	metabolized
22	142	143	O	by
23	145	150	O	CYP3A4
24	151	151	O	,
25	153	156	O	such
26	158	159	O	as
27	161	171	U-UNK	pravastatin
28	172	172	O	,
29	174	184	U-UNK	fluvastatin
30	185	185	O	,
31	187	188	O	or
32	190	201	U-UNK	rosuvastatin
33	203	204	O	in
34	206	216	O	combination
35	218	221	O	with
36	223	230	O	XXXXXXXX
NULL

Indinavir	DDI-DrugBank.d97.s73	NO_SECTION	NO_SETID	7
Immunosuppressants: cyclosporine, tacrolimus, sirolimus
1	0	17	U-UNK	Immunosuppressants
2	18	18	O	:
3	20	31	U-UNK	cyclosporine
4	32	32	O	,
5	34	43	U-UNK	tacrolimus
6	44	44	O	,
7	46	54	U-UNK	sirolimus
NULL

Indinavir	DDI-DrugBank.d97.s74	NO_SECTION	NO_SETID	3
immunosuppressant agents concentration
1	0	16	B-UNK	immunosuppressant
2	18	23	L-UNK	agents
3	25	37	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s75	NO_SECTION	NO_SETID	7
Plasma concentrations may be increased by CRIXIVAN.
1	0	5	O	Plasma
2	7	20	O	concentrations
3	22	24	O	may
4	26	27	O	be
5	29	37	O	increased
6	39	40	O	by
7	42	49	O	XXXXXXXX
NULL

Indinavir	DDI-DrugBank.d97.s77	NO_SECTION	NO_SETID	2
indinavir concentration
1	0	8	O	XXXXXXXX
2	10	22	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s78	NO_SECTION	NO_SETID	16
Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.
1	0	3	O	Dose
2	5	13	O	reduction
3	15	16	O	of
4	18	25	O	XXXXXXXX
5	27	28	O	to
6	30	32	O	600
7	34	35	O	mg
8	37	41	O	every
9	43	43	O	8
10	45	49	O	hours
11	51	52	O	is
12	54	64	O	recommended
13	66	69	O	when
14	71	83	O	administering
15	85	96	U-DYN	itraconazole
16	98	109	O	concurrently
NULL

Indinavir	DDI-DrugBank.d97.s80	NO_SECTION	NO_SETID	2
indinavir concentration
1	0	8	O	XXXXXXXX
2	10	22	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s81	NO_SECTION	NO_SETID	13
Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered.
1	0	3	O	Dose
2	5	13	O	reduction
3	15	16	O	of
4	18	25	O	XXXXXXXX
5	27	28	O	to
6	30	32	O	600
7	34	35	O	mg
8	37	41	O	every
9	43	43	O	8
10	45	49	O	hours
11	51	56	O	should
12	58	59	O	be
13	61	70	O	considered
NULL

Indinavir	DDI-DrugBank.d97.s83	NO_SECTION	NO_SETID	4
indinavir concentration   rifabutin concentration
1	0	8	O	XXXXXXXX
2	10	22	O	concentration
3	26	34	U-UNK	rifabutin
4	36	48	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s84	NO_SECTION	NO_SETID	33
Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.
1	0	3	O	Dose
2	5	13	O	reduction
3	15	16	O	of
4	18	26	U-UNK	rifabutin
5	28	29	O	to
6	31	34	O	half
7	36	38	O	the
8	40	47	O	standard
9	49	52	O	dose
10	54	56	O	and
11	58	58	O	a
12	60	63	O	dose
13	65	72	O	increase
14	74	75	O	of
15	77	84	O	XXXXXXXX
16	86	87	O	to
17	89	92	O	1000
18	94	95	O	mg
19	98	102	O	three
20	104	106	O	333
21	108	109	O	mg
22	111	118	O	capsules
23	121	125	O	every
24	127	127	O	8
25	129	133	O	hours
26	135	137	O	are
27	139	149	O	recommended
28	151	154	O	when
29	156	164	U-DYN	rifabutin
30	166	168	O	and
31	170	177	O	XXXXXXXX
32	179	181	O	are
33	183	196	O	coadministered
NULL

Indinavir	DDI-DrugBank.d97.s86	NO_SECTION	NO_SETID	2
sildenafil concentration
1	0	9	U-UNK	sildenafil
2	11	23	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s87	NO_SECTION	NO_SETID	21
Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.
1	0	9	U-DYN	Sildenafil
2	11	14	O	dose
3	16	21	O	should
4	23	25	O	not
5	27	32	O	exceed
6	34	34	O	a
7	36	42	O	maximum
8	44	45	O	of
9	47	48	O	25
10	50	51	O	mg
11	53	54	O	in
12	56	56	O	a
13	58	59	O	48
14	62	65	O	hour
15	67	72	O	period
16	74	75	O	in
17	77	84	O	patients
18	86	94	O	receiving
19	96	106	O	concomitant
20	108	116	O	XXXXXXXX
21	118	124	O	therapy
NULL

Indinavir	DDI-DrugBank.d97.s89	NO_SECTION	NO_SETID	2
tadalafil concentration
1	0	8	U-UNK	tadalafil
2	10	22	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s90	NO_SECTION	NO_SETID	21
Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.
1	0	8	U-DYN	Tadalafil
2	10	13	O	dose
3	15	20	O	should
4	22	24	O	not
5	26	31	O	exceed
6	33	33	O	a
7	35	41	O	maximum
8	43	44	O	of
9	46	47	O	10
10	49	50	O	mg
11	52	53	O	in
12	55	55	O	a
13	57	58	O	72
14	61	64	O	hour
15	66	71	O	period
16	73	74	O	in
17	76	83	O	patients
18	85	93	O	receiving
19	95	105	O	concomitant
20	107	115	O	XXXXXXXX
21	117	123	O	therapy
NULL

Indinavir	DDI-DrugBank.d97.s92	NO_SECTION	NO_SETID	2
vardenafil concentration
1	0	9	U-UNK	vardenafil
2	11	23	O	concentration
NULL

Indinavir	DDI-DrugBank.d97.s93	NO_SECTION	NO_SETID	21
Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.
1	0	9	U-DYN	Vardenafil
2	11	14	O	dose
3	16	21	O	should
4	23	25	O	not
5	27	32	O	exceed
6	34	34	O	a
7	36	42	O	maximum
8	44	45	O	of
9	47	49	O	2.5
10	51	52	O	mg
11	54	55	O	in
12	57	57	O	a
13	59	60	O	24
14	62	65	O	hour
15	67	72	O	period
16	74	75	O	in
17	77	84	O	patients
18	86	94	O	receiving
19	96	106	O	concomitant
20	108	116	O	XXXXXXXX
21	118	124	O	therapy
NULL

Indomethacin	DDI-DrugBank.d82.s0	NO_SECTION	NO_SETID	22
In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.
1	0	1	O	In
2	3	8	O	normal
3	10	19	O	volunteers
4	21	29	O	receiving
5	31	42	O	XXXXXXXX
6	43	43	O	,
7	45	47	O	the
8	49	62	O	administration
9	64	65	O	of
10	67	76	U-KIN	diflunisal
11	78	86	O	decreased
12	88	90	O	the
13	92	96	O	renal
14	98	106	O	clearance
15	108	110	O	and
16	112	124	O	significantly
17	126	134	O	increased
18	136	138	O	the
19	140	145	O	plasma
20	147	152	O	levels
21	154	155	O	of
22	157	168	O	XXXXXXXX
NULL

Indomethacin	DDI-DrugBank.d82.s1	NO_SECTION	NO_SETID	17
In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.
1	0	1	O	In
2	3	6	O	some
3	8	15	O	patients
4	16	16	O	,
5	18	25	O	combined
6	27	29	O	use
7	31	32	O	of
8	34	40	O	XXXXXXXX
9	42	44	O	and
10	46	55	U-DYN	diflunisal
11	57	59	O	has
12	61	64	O	been
13	66	75	O	associated
14	77	80	O	with
15	82	86	O	fatal
16	88	103	O	gastrointestinal
17	105	114	O	hemorrhage
NULL

Indomethacin	DDI-DrugBank.d82.s2	NO_SECTION	NO_SETID	10
Therefore, diflunisal and INDOCIN should not be used concomitantly.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	U-DYN	diflunisal
4	22	24	O	and
5	26	32	O	XXXXXXXX
6	34	39	O	should
7	41	43	O	not
8	45	46	O	be
9	48	51	O	used
10	53	65	O	concomitantly
NULL

Indomethacin	DDI-DrugBank.d82.s3	NO_SECTION	NO_SETID	27
In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	in
5	14	19	O	normal
6	21	30	O	volunteers
7	31	31	O	,
8	33	34	O	it
9	36	38	O	was
10	40	44	O	found
11	46	49	O	that
12	51	57	O	chronic
13	59	68	O	concurrent
14	70	83	O	administration
15	85	86	O	of
16	88	90	O	3.6
17	92	92	O	g
18	94	95	O	of
19	97	103	O	XXXXXXXX
20	105	107	O	per
21	109	111	O	day
22	113	121	O	decreases
23	123	134	U-KIN	indomethacin
24	136	140	O	blood
25	142	147	O	levels
26	149	161	O	approximately
27	163	165	O	20%
NULL

Indomethacin	DDI-DrugBank.d82.s4	NO_SECTION	NO_SETID	27
The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	29	O	XXXXXXXX
6	31	34	O	with
7	36	40	O	other
8	42	47	U-DYN	NSAIDs
9	49	50	O	is
10	52	54	O	not
11	56	66	O	recommended
12	68	70	O	due
13	72	73	O	to
14	75	77	O	the
15	79	87	O	increased
16	89	99	O	possibility
17	101	102	O	of
18	104	119	O	gastrointestinal
19	121	128	O	toxicity
20	129	129	O	,
21	131	134	O	with
22	136	141	O	little
23	143	144	O	or
24	146	147	O	no
25	149	156	O	increase
26	158	159	O	in
27	161	168	O	efficacy
NULL

Indomethacin	DDI-DrugBank.d82.s5	NO_SECTION	NO_SETID	14
Clinical studies have shown that INDOCIN does not influence the hypoprothrombinemia produced by anticoagulants.
1	0	7	O	Clinical
2	9	15	O	studies
3	17	20	O	have
4	22	26	O	shown
5	28	31	O	that
6	33	39	O	XXXXXXXX
7	41	44	O	does
8	46	48	O	not
9	50	58	O	influence
10	60	62	O	the
11	64	82	O	hypoprothrombinemia
12	84	91	O	produced
13	93	94	O	by
14	96	109	U-UNK	anticoagulants
NULL

Indomethacin	DDI-DrugBank.d82.s6	NO_SECTION	NO_SETID	32
However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.
1	0	6	O	However
2	7	7	O	,
3	9	12	O	when
4	14	16	O	any
5	18	27	O	additional
6	29	32	O	drug
7	33	33	O	,
8	35	43	O	including
9	45	51	O	XXXXXXXX
10	52	52	O	,
11	54	55	O	is
12	57	61	O	added
13	63	64	O	to
14	66	68	O	the
15	70	78	O	treatment
16	80	81	O	of
17	83	90	O	patients
18	92	93	O	on
19	95	107	U-DYN	anticoagulant
20	109	115	O	therapy
21	116	116	O	,
22	118	120	O	the
23	122	129	O	patients
24	131	136	O	should
25	138	139	O	be
26	141	148	O	observed
27	150	152	O	for
28	154	164	O	alterations
29	166	167	O	of
30	169	171	O	the
31	173	183	O	prothrombin
32	185	188	O	time
NULL

Indomethacin	DDI-DrugBank.d82.s7	NO_SECTION	NO_SETID	18
In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.
1	0	1	O	In
2	3	6	O	post
3	8	16	O	marketing
4	18	27	O	experience
5	28	28	O	,
6	30	37	O	bleeding
7	39	41	O	has
8	43	46	O	been
9	48	55	O	reported
10	57	58	O	in
11	60	67	O	patients
12	69	70	O	on
13	72	82	O	concomitant
14	84	92	O	treatment
15	94	97	O	with
16	99	112	U-DYN	anticoagulants
17	114	116	O	and
18	118	124	O	XXXXXXXX
NULL

Indomethacin	DDI-DrugBank.d82.s8	NO_SECTION	NO_SETID	11
Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	39	O	XXXXXXXX
7	41	43	O	and
8	45	58	U-DYN	anticoagulants
9	60	62	O	are
10	64	75	O	administered
11	77	89	O	concomitantly
NULL

Indomethacin	DDI-DrugBank.d82.s9	NO_SECTION	NO_SETID	19
When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.
1	0	3	O	When
2	5	11	O	XXXXXXXX
3	13	14	O	is
4	16	20	O	given
5	22	23	O	to
6	25	32	O	patients
7	34	42	O	receiving
8	44	53	U-KIN	probenecid
9	54	54	O	,
10	56	58	O	the
11	60	65	O	plasma
12	67	72	O	levels
13	74	75	O	of
14	77	88	U-UNK	indomethacin
15	90	92	O	are
16	94	99	O	likely
17	101	102	O	to
18	104	105	O	be
19	107	115	O	increased
NULL

Indomethacin	DDI-DrugBank.d82.s10	NO_SECTION	NO_SETID	15
Therefore, a lower total daily dosage of INDOCIN may produce a satisfactory therapeutic effect.
1	0	8	O	Therefore
2	9	9	O	,
3	11	11	O	a
4	13	17	O	lower
5	19	23	O	total
6	25	29	O	daily
7	31	36	O	dosage
8	38	39	O	of
9	41	47	O	XXXXXXXX
10	49	51	O	may
11	53	59	O	produce
12	61	61	O	a
13	63	74	O	satisfactory
14	76	86	O	therapeutic
15	88	93	O	effect
NULL

Indomethacin	DDI-DrugBank.d82.s11	NO_SECTION	NO_SETID	19
When increases in the dose of INDOCIN are made, they should be made carefully and in small increments.
1	0	3	O	When
2	5	13	O	increases
3	15	16	O	in
4	18	20	O	the
5	22	25	O	dose
6	27	28	O	of
7	30	36	O	XXXXXXXX
8	38	40	O	are
9	42	45	O	made
10	46	46	O	,
11	48	51	O	they
12	53	58	O	should
13	60	61	O	be
14	63	66	O	made
15	68	76	O	carefully
16	78	80	O	and
17	82	83	O	in
18	85	89	O	small
19	91	100	O	increments
NULL

Indomethacin	DDI-DrugBank.d82.s12	NO_SECTION	NO_SETID	11
Caution should be used if INDOCIN is administered simultaneously with methotrexate.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	24	O	if
6	26	32	O	XXXXXXXX
7	34	35	O	is
8	37	48	O	administered
9	50	63	O	simultaneously
10	65	68	O	with
11	70	81	U-DYN	methotrexate
NULL

Indomethacin	DDI-DrugBank.d82.s13	NO_SECTION	NO_SETID	16
INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.
1	0	6	O	XXXXXXXX
2	8	10	O	has
3	12	15	O	been
4	17	24	O	reported
5	26	27	O	to
6	29	36	O	decrease
7	38	40	O	the
8	42	48	O	tubular
9	50	58	O	secretion
10	60	61	O	of
11	63	74	U-KIN	methotrexate
12	76	78	O	and
13	80	81	O	to
14	83	92	O	potentiate
15	94	96	O	its
16	98	105	O	toxicity
NULL

Indomethacin	DDI-DrugBank.d82.s14	NO_SECTION	NO_SETID	29
Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.
1	0	13	O	Administration
2	15	16	O	of
3	18	20	B-UNK	non
4	22	30	I-UNK	steroidal
5	32	35	I-UNK	anti
6	37	48	I-UNK	inflammatory
7	50	54	L-UNK	drugs
8	56	68	O	concomitantly
9	70	73	O	with
10	75	86	U-UNK	cyclosporine
11	88	90	O	has
12	92	95	O	been
13	97	106	O	associated
14	108	111	O	with
15	113	114	O	an
16	116	123	O	increase
17	125	126	O	in
18	128	139	U-UNK	cyclosporine
19	141	147	O	induced
20	149	156	O	toxicity
21	157	157	O	,
22	159	166	O	possibly
23	168	170	O	due
24	172	173	O	to
25	175	183	O	decreased
26	185	193	O	synthesis
27	195	196	O	of
28	198	202	O	renal
29	204	215	O	prostacyclin
NULL

Indomethacin	DDI-DrugBank.d82.s15	NO_SECTION	NO_SETID	18
NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.
1	0	5	U-UNK	NSAIDs
2	7	12	O	should
3	14	15	O	be
4	17	20	O	used
5	22	25	O	with
6	27	33	O	caution
7	35	36	O	in
8	38	45	O	patients
9	47	52	O	taking
10	54	65	U-UNK	cyclosporine
11	66	66	O	,
12	68	70	O	and
13	72	76	O	renal
14	78	85	O	function
15	87	92	O	should
16	94	95	O	be
17	97	105	O	carefully
18	107	115	O	monitored
NULL

Indomethacin	DDI-DrugBank.d82.s16	NO_SECTION	NO_SETID	31
Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.
1	0	7	O	Capsules
2	9	15	O	XXXXXXXX
3	17	18	O	50
4	20	21	O	mg
5	23	27	O	t.i.d
6	30	37	O	produced
7	39	39	O	a
8	41	50	O	clinically
9	52	59	O	relevant
10	61	69	O	elevation
11	71	72	O	of
12	74	79	O	plasma
13	81	87	U-KIN	lithium
14	89	91	O	and
15	93	101	O	reduction
16	103	104	O	in
17	106	110	O	renal
18	112	118	U-UNK	lithium
19	120	128	O	clearance
20	130	131	O	in
21	133	143	O	psychiatric
22	145	152	O	patients
23	154	156	O	and
24	158	163	O	normal
25	165	172	O	subjects
26	174	177	O	with
27	179	184	O	steady
28	186	190	O	state
29	192	197	O	plasma
30	199	205	U-UNK	lithium
31	207	220	O	concentrations
NULL

Indomethacin	DDI-DrugBank.d82.s17	NO_SECTION	NO_SETID	10
This effect has been attributed to inhibition of prostaglandin synthesis.
1	0	3	O	This
2	5	10	O	effect
3	12	14	O	has
4	16	19	O	been
5	21	30	O	attributed
6	32	33	O	to
7	35	44	O	inhibition
8	46	47	O	of
9	49	61	O	prostaglandin
10	63	71	O	synthesis
NULL

Indomethacin	DDI-DrugBank.d82.s18	NO_SECTION	NO_SETID	23
As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.
1	0	1	O	As
2	3	3	O	a
3	5	15	O	consequence
4	16	16	O	,
5	18	21	O	when
6	23	29	O	XXXXXXXX
7	31	33	O	and
8	35	41	U-DYN	lithium
9	43	45	O	are
10	47	51	O	given
11	53	65	O	concomitantly
12	66	66	O	,
13	68	70	O	the
14	72	78	O	patient
15	80	85	O	should
16	87	88	O	be
17	90	98	O	carefully
18	100	107	O	observed
19	109	111	O	for
20	113	117	O	signs
21	119	120	O	of
22	122	128	U-UNK	lithium
23	130	137	O	toxicity
NULL

Indomethacin	DDI-DrugBank.d82.s19	NO_SECTION	NO_SETID	11
(Read circulars for lithium preparations before use of such concomitant therapy.)
1	1	4	O	Read
2	6	14	O	circulars
3	16	18	O	for
4	20	26	U-UNK	lithium
5	28	39	O	preparations
6	41	46	O	before
7	48	50	O	use
8	52	53	O	of
9	55	58	O	such
10	60	70	O	concomitant
11	72	78	O	therapy
NULL

Indomethacin	DDI-DrugBank.d82.s20	NO_SECTION	NO_SETID	21
In addition, the frequency of monitoring serum lithium concentration should be increased at the outset of such combination drug treatment.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	15	O	the
5	17	25	O	frequency
6	27	28	O	of
7	30	39	O	monitoring
8	41	45	O	serum
9	47	53	U-UNK	lithium
10	55	67	O	concentration
11	69	74	O	should
12	76	77	O	be
13	79	87	O	increased
14	89	90	O	at
15	92	94	O	the
16	96	101	O	outset
17	103	104	O	of
18	106	109	O	such
19	111	121	O	combination
20	123	126	O	drug
21	128	136	O	treatment
NULL

Indomethacin	DDI-DrugBank.d82.s21	NO_SECTION	NO_SETID	20
INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.
1	0	6	O	XXXXXXXX
2	8	12	O	given
3	14	26	O	concomitantly
4	28	31	O	with
5	33	39	U-KIN	digoxin
6	41	43	O	has
7	45	48	O	been
8	50	57	O	reported
9	59	60	O	to
10	62	69	O	increase
11	71	73	O	the
12	75	79	O	serum
13	81	93	O	concentration
14	95	97	O	and
15	99	105	O	prolong
16	107	109	O	the
17	111	114	O	half
18	116	119	O	life
19	121	122	O	of
20	124	130	U-UNK	digoxin
NULL

Indomethacin	DDI-DrugBank.d82.s22	NO_SECTION	NO_SETID	17
Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	22	O	XXXXXXXX
5	24	26	O	and
6	28	34	U-DYN	digoxin
7	36	38	O	are
8	40	43	O	used
9	45	57	O	concomitantly
10	58	58	O	,
11	60	64	O	serum
12	66	72	U-UNK	digoxin
13	74	79	O	levels
14	81	86	O	should
15	88	89	O	be
16	91	97	O	closely
17	99	107	O	monitored
NULL

Indomethacin	DDI-DrugBank.d82.s23	NO_SECTION	NO_SETID	27
In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.
1	0	1	O	In
2	3	6	O	some
3	8	15	O	patients
4	16	16	O	,
5	18	20	O	the
6	22	35	O	administration
7	37	38	O	of
8	40	46	O	XXXXXXXX
9	48	50	O	can
10	52	57	O	reduce
11	59	61	O	the
12	63	70	O	diuretic
13	71	71	O	,
14	73	83	O	natriuretic
15	84	84	O	,
16	86	88	O	and
17	90	105	O	antihypertensive
18	107	113	O	effects
19	115	116	O	of
20	118	121	B-UNK	loop
21	122	122	I-UNK	,
22	124	132	I-UNK	potassium
23	134	140	I-UNK	sparing
24	141	141	I-UNK	,
25	143	145	I-UNK	and
26	147	154	I-UNK	thiazide
27	156	164	L-UNK	diuretics
NULL

Indomethacin	DDI-DrugBank.d82.s24	NO_SECTION	NO_SETID	6
Therefore, when INDOCIN and INDOCIN.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	22	O	XXXXXXXX
5	24	26	O	and
6	28	34	O	XXXXXXXX
NULL

Indomethacin	DDI-DrugBank.d82.s25	NO_SECTION	NO_SETID	23
(Indomethacin) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
1	1	12	O	XXXXXXXX
2	15	23	U-UNK	diuretics
3	25	27	O	are
4	29	32	O	used
5	34	46	O	concomitantly
6	47	47	O	,
7	49	51	O	the
8	53	59	O	patient
9	61	66	O	should
10	68	69	O	be
11	71	78	O	observed
12	80	86	O	closely
13	88	89	O	to
14	91	99	O	determine
15	101	102	O	if
16	104	106	O	the
17	108	114	O	desired
18	116	121	O	effect
19	123	124	O	of
20	126	128	O	the
21	130	137	U-UNK	diuretic
22	139	140	O	is
23	142	149	O	obtained
NULL

Indomethacin	DDI-DrugBank.d82.s26	NO_SECTION	NO_SETID	25
INDOCIN reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion.
1	0	6	O	XXXXXXXX
2	8	14	O	reduces
3	16	20	O	basal
4	22	27	O	plasma
5	29	33	O	renin
6	35	42	O	activity
7	45	47	O	PRA
8	49	49	O	,
9	51	52	O	as
10	54	57	O	well
11	59	60	O	as
12	62	66	O	those
13	68	77	O	elevations
14	79	80	O	of
15	82	84	O	PRA
16	86	92	O	induced
17	94	95	O	by
18	97	106	U-UNK	furosemide
19	108	121	O	administration
20	122	122	O	,
21	124	125	O	or
22	127	130	O	salt
23	132	133	O	or
24	135	140	O	volume
25	142	150	O	depletion
NULL

Indomethacin	DDI-DrugBank.d82.s27	NO_SECTION	NO_SETID	13
These facts should be considered when evaluating plasma renin activity in hypertensive patients.
1	0	4	O	These
2	6	10	O	facts
3	12	17	O	should
4	19	20	O	be
5	22	31	O	considered
6	33	36	O	when
7	38	47	O	evaluating
8	49	54	O	plasma
9	56	60	O	renin
10	62	69	O	activity
11	71	72	O	in
12	74	85	O	hypertensive
13	87	94	O	patients
NULL

Indomethacin	DDI-DrugBank.d82.s28	NO_SECTION	NO_SETID	27
It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.
1	0	1	O	It
2	3	5	O	has
3	7	10	O	been
4	12	19	O	reported
5	21	24	O	that
6	26	28	O	the
7	30	37	O	addition
8	39	40	O	of
9	42	52	U-DYN	triamterene
10	54	55	O	to
11	57	57	O	a
12	59	69	O	maintenance
13	71	78	O	schedule
14	80	81	O	of
15	83	89	O	XXXXXXXX
16	91	98	O	resulted
17	100	101	O	in
18	103	112	O	reversible
19	114	118	O	acute
20	120	124	O	renal
21	126	132	O	failure
22	134	135	O	in
23	137	139	O	two
24	141	142	O	of
25	144	147	O	four
26	149	155	O	healthy
27	157	166	O	volunteers
NULL

Indomethacin	DDI-DrugBank.d82.s29	NO_SECTION	NO_SETID	8
INDOCIN and triamterene should not be administered together.
1	0	6	O	XXXXXXXX
2	8	10	O	and
3	12	22	U-DYN	triamterene
4	24	29	O	should
5	31	33	O	not
6	35	36	O	be
7	38	49	O	administered
8	51	58	O	together
NULL

Indomethacin	DDI-DrugBank.d82.s30	NO_SECTION	NO_SETID	14
INDOCIN and potassium-sparing diuretics each may be associated with increased serum potassium levels.
1	0	6	O	XXXXXXXX
2	8	10	O	and
3	12	20	B-UNK	potassium
4	22	28	I-UNK	sparing
5	30	38	L-UNK	diuretics
6	40	43	O	each
7	45	47	O	may
8	49	50	O	be
9	52	61	O	associated
10	63	66	O	with
11	68	76	O	increased
12	78	82	O	serum
13	84	92	O	potassium
14	94	99	O	levels
NULL

Indomethacin	DDI-DrugBank.d82.s31	NO_SECTION	NO_SETID	24
The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.
1	0	2	O	The
2	4	12	O	potential
3	14	20	O	effects
4	22	23	O	of
5	25	31	O	XXXXXXXX
6	33	35	O	and
7	37	45	B-DYN	potassium
8	47	53	I-DYN	sparing
9	55	63	L-DYN	diuretics
10	65	66	O	on
11	68	76	O	potassium
12	78	85	O	kinetics
13	87	89	O	and
14	91	95	O	renal
15	97	104	O	function
16	106	111	O	should
17	113	114	O	be
18	116	125	O	considered
19	127	130	O	when
20	132	136	O	these
21	138	143	O	agents
22	145	147	O	are
23	149	160	O	administered
24	162	173	O	concurrently
NULL

Indomethacin	DDI-DrugBank.d82.s32	NO_SECTION	NO_SETID	25
Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.
1	0	3	O	Most
2	5	6	O	of
3	8	10	O	the
4	12	16	O	above
5	18	24	O	effects
6	26	35	O	concerning
7	37	45	U-DYN	diuretics
8	47	50	O	have
9	52	55	O	been
10	57	66	O	attributed
11	67	67	O	,
12	69	70	O	at
13	72	76	O	least
14	78	79	O	in
15	81	84	O	part
16	85	85	O	,
17	87	88	O	to
18	90	99	O	mechanisms
19	101	109	O	involving
20	111	120	O	inhibition
21	122	123	O	of
22	125	137	O	prostaglandin
23	139	147	O	synthesis
24	149	150	O	by
25	152	158	O	XXXXXXXX
NULL

Indomethacin	DDI-DrugBank.d82.s33	NO_SECTION	NO_SETID	20
Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.
1	0	7	O	Blunting
2	9	10	O	of
3	12	14	O	the
4	16	31	O	antihypertensive
5	33	38	O	effect
6	40	41	O	of
7	43	46	B-DYN	beta
8	48	59	I-DYN	adrenoceptor
9	61	68	I-DYN	blocking
10	70	75	L-DYN	agents
11	77	78	O	by
12	80	82	B-UNK	non
13	84	92	I-UNK	steroidal
14	94	109	I-UNK	antiinflammatory
15	111	115	L-UNK	drugs
16	117	125	O	including
17	127	133	O	XXXXXXXX
18	135	137	O	has
19	139	142	O	been
20	144	151	O	reported
NULL

Indomethacin	DDI-DrugBank.d82.s34	NO_SECTION	NO_SETID	28
Therefore, when using these blocking agents to treat hypertension, patients should be observed carefully in order to confirm that the desired therapeutic effect has been obtained.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	20	O	using
5	22	26	O	these
6	28	35	O	blocking
7	37	42	O	agents
8	44	45	O	to
9	47	51	O	treat
10	53	64	O	hypertension
11	65	65	O	,
12	67	74	O	patients
13	76	81	O	should
14	83	84	O	be
15	86	93	O	observed
16	95	103	O	carefully
17	105	106	O	in
18	108	112	O	order
19	114	115	O	to
20	117	123	O	confirm
21	125	128	O	that
22	130	132	O	the
23	134	140	O	desired
24	142	152	O	therapeutic
25	154	159	O	effect
26	161	163	O	has
27	165	168	O	been
28	170	177	O	obtained
NULL

Indomethacin	DDI-DrugBank.d82.s35	NO_SECTION	NO_SETID	10
INDOCIN can reduce the antihypertensive effects of captopril and losartan.
1	0	6	O	XXXXXXXX
2	8	10	O	can
3	12	17	O	reduce
4	19	21	O	the
5	23	38	O	antihypertensive
6	40	46	O	effects
7	48	49	O	of
8	51	59	U-DYN	captopril
9	61	63	O	and
10	65	72	U-DYN	losartan
NULL

Indomethacin	DDI-DrugBank.d82.s36	NO_SECTION	NO_SETID	18
False-negative results in the dexamethasone suppression test (DST) in patients being treated with INDOCIN have been reported.
1	0	4	O	False
2	6	13	O	negative
3	15	21	O	results
4	23	24	O	in
5	26	28	O	the
6	30	42	O	dexamethasone
7	44	54	O	suppression
8	56	59	O	test
9	62	64	O	DST
10	67	68	O	in
11	70	77	O	patients
12	79	83	O	being
13	85	91	O	treated
14	93	96	O	with
15	98	104	O	XXXXXXXX
16	106	109	O	have
17	111	114	O	been
18	116	123	O	reported
NULL

Indomethacin	DDI-DrugBank.d82.s37	NO_SECTION	NO_SETID	14
Thus, results of the DST should be interpreted with caution in these patients.
1	0	3	O	Thus
2	4	4	O	,
3	6	12	O	results
4	14	15	O	of
5	17	19	O	the
6	21	23	O	DST
7	25	30	O	should
8	32	33	O	be
9	35	45	O	interpreted
10	47	50	O	with
11	52	58	O	caution
12	60	61	O	in
13	63	67	O	these
14	69	76	O	patients
NULL

Infliximab	DDI-DrugBank.d45.s0	NO_SECTION	NO_SETID	40
Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	38	U-UNK	etanercept
5	41	47	O	another
6	49	51	O	TNF
7	54	61	O	blocking
8	63	67	O	agent
9	70	72	O	and
10	74	81	U-UNK	anakinra
11	84	85	O	an
12	87	97	B-UNK	interleukin
13	99	99	I-UNK	1
14	101	110	L-UNK	antagonist
15	113	115	O	has
16	117	120	O	been
17	122	131	O	associated
18	133	136	O	with
19	138	139	O	an
20	141	149	O	increased
21	151	154	O	risk
22	156	157	O	of
23	159	165	O	serious
24	167	176	O	infections
25	177	177	O	,
26	179	181	O	and
27	183	191	O	increased
28	193	196	O	risk
29	198	199	O	of
30	201	211	O	neutropenia
31	213	215	O	and
32	217	218	O	no
33	220	229	O	additional
34	231	237	O	benefit
35	239	246	O	compared
36	248	249	O	to
37	251	255	O	these
38	257	265	O	medicinal
39	267	274	O	products
40	276	280	O	alone
NULL

Infliximab	DDI-DrugBank.d45.s1	NO_SECTION	NO_SETID	17
Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.
1	0	4	O	Other
2	6	9	B-UNK	TNFa
3	11	18	I-UNK	blocking
4	20	25	L-UNK	agents
5	28	36	O	including
6	38	45	O	XXXXXXXX
7	48	51	O	used
8	53	54	O	in
9	56	66	O	combination
10	68	71	O	with
11	73	80	U-DYN	anakinra
12	82	84	O	may
13	86	89	O	also
14	91	96	O	result
15	98	99	O	in
16	101	107	O	similar
17	109	118	O	toxicities
NULL

Infliximab	DDI-DrugBank.d45.s2	NO_SECTION	NO_SETID	14
Specific drug interaction studies, including interactions with MTX, have not been conducted.
1	0	7	O	Specific
2	9	12	O	drug
3	14	24	O	interaction
4	26	32	O	studies
5	33	33	O	,
6	35	43	O	including
7	45	56	O	interactions
8	58	61	O	with
9	63	65	U-UNK	MTX
10	66	66	O	,
11	68	71	O	have
12	73	75	O	not
13	77	80	O	been
14	82	90	O	conducted
NULL

Infliximab	DDI-DrugBank.d45.s3	NO_SECTION	NO_SETID	19
The majority of patients in rheumatoid arthritis or Crohn s disease clinical studies received one or more concomitant medications.
1	0	2	O	The
2	4	11	O	majority
3	13	14	O	of
4	16	23	O	patients
5	25	26	O	in
6	28	37	O	rheumatoid
7	39	47	O	arthritis
8	49	50	O	or
9	52	56	O	Crohn
10	58	58	O	s
11	60	66	O	disease
12	68	75	O	clinical
13	77	83	O	studies
14	85	92	O	received
15	94	96	O	one
16	98	99	O	or
17	101	104	O	more
18	106	116	O	concomitant
19	118	128	O	medications
NULL

Infliximab	DDI-DrugBank.d45.s4	NO_SECTION	NO_SETID	22
In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or narcotics.
1	0	1	O	In
2	3	12	O	rheumatoid
3	14	22	O	arthritis
4	23	23	O	,
5	25	35	O	concomitant
6	37	47	O	medications
7	49	55	O	besides
8	57	59	U-UNK	MTX
9	61	64	O	were
10	66	77	B-UNK	nonsteroidal
11	79	82	I-UNK	anti
12	84	95	I-UNK	inflammatory
13	97	102	L-UNK	agents
14	103	103	O	,
15	105	109	B-UNK	folic
16	111	114	L-UNK	acid
17	115	115	O	,
18	117	131	U-UNK	corticosteroids
19	133	135	O	and
20	136	136	O	/
21	137	138	O	or
22	140	148	U-UNK	narcotics
NULL

Infliximab	DDI-DrugBank.d45.s5	NO_SECTION	NO_SETID	18
Concomitant Crohn s disease medications were antibiotics, antivirals, corticosteroids, 6-MP/AZA and aminosalicylates.
1	0	10	O	Concomitant
2	12	16	O	Crohn
3	18	18	O	s
4	20	26	O	disease
5	28	38	O	medications
6	40	43	O	were
7	45	55	U-UNK	antibiotics
8	56	56	O	,
9	58	67	U-UNK	antivirals
10	68	68	O	,
11	70	84	U-UNK	corticosteroids
12	85	85	O	,
13	87	87	B-UNK	6
14	89	90	L-UNK	MP
15	91	91	O	/
16	92	94	U-UNK	AZA
17	96	98	O	and
18	100	115	O	aminosalicylates
NULL

Infliximab	DDI-DrugBank.d45.s6	NO_SECTION	NO_SETID	28
In psoriatic arthritis clinical trials, concomitant medications included MTX in approximately half of the patients as well as nonsteroidal anti-inflammatory agents, folic acid and corticosteroids.
1	0	1	O	In
2	3	11	O	psoriatic
3	13	21	O	arthritis
4	23	30	O	clinical
5	32	37	O	trials
6	38	38	O	,
7	40	50	O	concomitant
8	52	62	O	medications
9	64	71	O	included
10	73	75	U-UNK	MTX
11	77	78	O	in
12	80	92	O	approximately
13	94	97	O	half
14	99	100	O	of
15	102	104	O	the
16	106	113	O	patients
17	115	116	O	as
18	118	121	O	well
19	123	124	O	as
20	126	137	B-UNK	nonsteroidal
21	139	142	I-UNK	anti
22	144	155	I-UNK	inflammatory
23	157	162	L-UNK	agents
24	163	163	O	,
25	165	169	B-UNK	folic
26	171	174	L-UNK	acid
27	176	178	O	and
28	180	194	U-UNK	corticosteroids
NULL

Infliximab	DDI-DrugBank.d45.s7	NO_SECTION	NO_SETID	20
Patients with Crohn s disease who received immunosuppressants tended to experience fewer infusion reactions compared to patients on no immunosuppressants.
1	0	7	O	Patients
2	9	12	O	with
3	14	18	O	Crohn
4	20	20	O	s
5	22	28	O	disease
6	30	32	O	who
7	34	41	O	received
8	43	60	U-UNK	immunosuppressants
9	62	67	O	tended
10	69	70	O	to
11	72	81	O	experience
12	83	87	O	fewer
13	89	96	O	infusion
14	98	106	O	reactions
15	108	115	O	compared
16	117	118	O	to
17	120	127	O	patients
18	129	130	O	on
19	132	133	O	no
20	135	152	U-UNK	immunosuppressants
NULL

Infliximab	DDI-DrugBank.d45.s8	NO_SECTION	NO_SETID	28
Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.
1	0	4	O	Serum
2	6	15	O	XXXXXXXX
3	17	30	O	concentrations
4	32	39	O	appeared
5	41	42	O	to
6	44	45	O	be
7	47	56	O	unaffected
8	58	59	O	by
9	61	68	O	baseline
10	70	72	O	use
11	74	75	O	of
12	77	87	O	medications
13	89	91	O	for
14	93	95	O	the
15	97	105	O	treatment
16	107	108	O	of
17	110	114	O	Crohn
18	116	116	O	s
19	118	124	O	disease
20	126	134	O	including
21	136	150	U-UNK	corticosteroids
22	151	151	O	,
23	153	163	U-UNK	antibiotics
24	166	178	U-UNK	metronidazole
25	180	181	O	or
26	183	195	U-UNK	ciprofloxacin
27	198	200	O	and
28	202	217	O	aminosalicylates
NULL

Insulin Glargine recombinant	DDI-DrugBank.d527.s0	NO_SECTION	NO_SETID	17
A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.
1	0	0	O	A
2	2	7	O	number
3	9	10	O	of
4	12	21	O	substances
5	23	28	O	affect
6	30	36	O	glucose
7	38	47	O	metabolism
8	49	51	O	and
9	53	55	O	may
10	57	63	O	require
11	65	71	U-UNK	insulin
12	73	76	O	dose
13	78	87	O	adjustment
14	89	91	O	and
15	93	104	O	particularly
16	106	110	O	close
17	112	121	O	monitoring
NULL

Insulin Glargine recombinant	DDI-DrugBank.d527.s1	NO_SECTION	NO_SETID	47
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
1	0	2	O	The
2	4	12	O	following
3	14	16	O	are
4	18	25	O	examples
5	27	28	O	of
6	30	39	O	substances
7	41	44	O	that
8	46	48	O	may
9	50	57	O	increase
10	59	61	O	the
11	63	67	O	blood
12	69	75	O	glucose
13	77	84	O	lowering
14	86	91	O	effect
15	93	95	O	and
16	97	110	O	susceptibility
17	112	113	O	to
18	115	126	O	hypoglycemia
19	127	127	O	:
20	129	132	O	oral
21	134	145	O	antidiabetes
22	147	154	O	products
23	155	155	O	,
24	157	159	B-UNK	ACE
25	161	170	L-UNK	inhibitors
26	171	171	O	,
27	173	184	U-UNK	disopyramide
28	185	185	O	,
29	187	194	U-UNK	fibrates
30	195	195	O	,
31	197	206	U-UNK	fluoxetine
32	207	207	O	,
33	209	211	B-UNK	MAO
34	213	222	L-UNK	inhibitors
35	223	223	O	,
36	225	236	U-UNK	propoxyphene
37	237	237	O	,
38	239	249	U-UNK	salicylates
39	250	250	O	,
40	252	263	B-UNK	somatostatin
41	265	270	L-UNK	analog
42	273	275	O	e.g
43	277	277	O	,
44	279	288	U-UNK	octreotide
45	290	290	O	,
46	292	302	B-UNK	sulfonamide
47	304	314	L-UNK	antibiotics
NULL

Insulin Glargine recombinant	DDI-DrugBank.d527.s2	NO_SECTION	NO_SETID	51
The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
1	0	2	O	The
2	4	12	O	following
3	14	16	O	are
4	18	25	O	examples
5	27	28	O	of
6	30	39	O	substances
7	41	44	O	that
8	46	48	O	may
9	50	55	O	reduce
10	57	59	O	the
11	61	65	O	blood
12	67	73	O	glucose
13	75	82	O	lowering
14	84	89	O	effect
15	91	92	O	of
16	94	100	U-UNK	insulin
17	101	101	O	:
18	103	117	U-UNK	corticosteroids
19	118	118	O	,
20	120	126	U-UNK	danazol
21	127	127	O	,
22	129	137	U-UNK	diuretics
23	138	138	O	,
24	140	154	B-UNK	sympathomimetic
25	156	161	L-UNK	agents
26	164	166	O	e.g
27	168	168	O	,
28	170	180	U-UNK	epinephrine
29	181	181	O	,
30	183	191	U-UNK	albuterol
31	192	192	O	,
32	194	204	U-UNK	terbutaline
33	206	206	O	,
34	208	216	U-UNK	isoniazid
35	217	217	O	,
36	219	231	B-UNK	phenothiazine
37	233	243	L-UNK	derivatives
38	244	244	O	,
39	246	255	U-UNK	somatropin
40	256	256	O	,
41	258	264	B-UNK	thyroid
42	266	273	L-UNK	hormones
43	274	274	O	,
44	276	284	U-UNK	estrogens
45	285	285	O	,
46	287	298	U-UNK	progestogens
47	301	303	O	e.g
48	305	305	O	,
49	307	308	O	in
50	310	313	O	oral
51	315	328	U-UNK	contraceptives
NULL

Insulin Glargine recombinant	DDI-DrugBank.d527.s3	NO_SECTION	NO_SETID	22
Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
1	0	3	B-UNK	Beta
2	5	12	L-UNK	blockers
3	13	13	O	,
4	15	23	U-UNK	clonidine
5	24	24	O	,
6	26	32	U-UNK	lithium
7	34	38	O	salts
8	39	39	O	,
9	41	43	O	and
10	45	51	U-UNK	alcohol
11	53	55	O	may
12	57	62	O	either
13	64	73	O	potentiate
14	75	76	O	or
15	78	83	O	weaken
16	85	87	O	the
17	89	93	O	blood
18	95	101	O	glucose
19	103	110	O	lowering
20	112	117	O	effect
21	119	120	O	of
22	122	128	U-UNK	insulin
NULL

Insulin Glargine recombinant	DDI-DrugBank.d527.s4	NO_SECTION	NO_SETID	12
Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.
1	0	10	U-UNK	Pentamidine
2	12	14	O	may
3	16	20	O	cause
4	22	33	O	hypoglycemia
5	34	34	O	,
6	36	40	O	which
7	42	44	O	may
8	46	54	O	sometimes
9	56	57	O	be
10	59	66	O	followed
11	68	69	O	by
12	71	83	O	hyperglycemia
NULL

Insulin Glargine recombinant	DDI-DrugBank.d527.s5	NO_SECTION	NO_SETID	31
In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	17	O	under
5	19	21	O	the
6	23	31	O	influence
7	33	34	O	of
8	36	48	O	sympatholytic
9	50	58	O	medicinal
10	60	67	O	products
11	69	72	O	such
12	74	75	O	as
13	77	80	B-UNK	beta
14	82	89	L-UNK	blockers
15	90	90	O	,
16	92	100	U-UNK	clonidine
17	101	101	O	,
18	103	114	U-UNK	guanethidine
19	115	115	O	,
20	117	119	O	and
21	121	129	U-UNK	reserpine
22	130	130	O	,
23	132	134	O	the
24	136	140	O	signs
25	142	143	O	of
26	145	156	O	hypoglycemia
27	158	160	O	may
28	162	163	O	be
29	165	171	O	reduced
30	173	174	O	or
31	176	181	O	absent
NULL

Insulin recombinant	DDI-DrugBank.d313.s0	NO_SECTION	NO_SETID	17
A number of substances affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.
1	0	0	O	A
2	2	7	O	number
3	9	10	O	of
4	12	21	O	substances
5	23	28	O	affect
6	30	36	O	glucose
7	38	47	O	metabolism
8	49	51	O	and
9	53	55	O	may
10	57	63	O	require
11	65	71	U-UNK	insulin
12	73	76	O	dose
13	78	87	O	adjustment
14	89	91	O	and
15	93	104	O	particularly
16	106	110	O	close
17	112	121	O	monitoring
NULL

Insulin recombinant	DDI-DrugBank.d313.s1	NO_SECTION	NO_SETID	49
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
1	0	2	O	The
2	4	12	O	following
3	14	16	O	are
4	18	25	O	examples
5	27	28	O	of
6	30	39	O	substances
7	41	44	O	that
8	46	48	O	may
9	50	57	O	increase
10	59	61	O	the
11	63	67	O	blood
12	69	75	O	glucose
13	77	84	O	lowering
14	86	91	O	effect
15	93	95	O	and
16	97	110	O	susceptibility
17	112	113	O	to
18	115	126	O	hypoglycemia
19	127	127	O	:
20	129	132	O	oral
21	134	145	B-UNK	antidiabetic
22	147	154	L-UNK	products
23	155	155	O	,
24	157	159	B-UNK	ACE
25	161	170	L-UNK	inhibitors
26	171	171	O	,
27	173	184	U-UNK	disopyramide
28	185	185	O	,
29	187	194	U-UNK	fibrates
30	195	195	O	,
31	197	206	U-UNK	fluoxetine
32	207	207	O	,
33	209	217	B-UNK	monoamine
34	219	225	I-UNK	oxidase
35	228	230	I-UNK	MAO
36	233	242	L-UNK	inhibitors
37	243	243	O	,
38	245	256	U-UNK	propoxyphene
39	257	257	O	,
40	259	269	U-UNK	salicylates
41	270	270	O	,
42	272	283	B-UNK	somatostatin
43	285	290	L-UNK	analog
44	293	295	O	e.g
45	297	297	O	,
46	299	308	U-UNK	octreotide
47	310	310	O	,
48	312	322	B-UNK	sulfonamide
49	324	334	L-UNK	antibiotics
NULL

Insulin recombinant	DDI-DrugBank.d313.s2	NO_SECTION	NO_SETID	51
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
1	0	2	O	The
2	4	12	O	following
3	14	16	O	are
4	18	25	O	examples
5	27	28	O	of
6	30	39	O	substances
7	41	44	O	that
8	46	48	O	may
9	50	55	O	reduce
10	57	59	O	the
11	61	65	O	blood
12	67	73	O	glucose
13	75	82	O	lowering
14	84	89	O	effect
15	90	90	O	:
16	92	106	U-UNK	corticosteroids
17	107	107	O	,
18	109	114	U-UNK	niacin
19	115	115	O	,
20	117	123	U-UNK	danazol
21	124	124	O	,
22	126	134	U-UNK	diuretics
23	135	135	O	,
24	137	151	B-UNK	sympathomimetic
25	153	158	L-UNK	agents
26	161	163	O	e.g
27	165	165	O	,
28	167	177	U-UNK	epinephrine
29	178	178	O	,
30	180	189	U-UNK	salbutamol
31	190	190	O	,
32	192	202	U-UNK	terbutaline
33	204	204	O	,
34	206	214	U-UNK	isoniazid
35	215	215	O	,
36	217	229	B-UNK	phenothiazine
37	231	241	L-UNK	derivatives
38	242	242	O	,
39	244	253	U-UNK	somatropin
40	254	254	O	,
41	256	262	B-UNK	thyroid
42	264	271	L-UNK	hormones
43	272	272	O	,
44	274	282	U-UNK	estrogens
45	283	283	O	,
46	285	296	U-UNK	progestogens
47	299	301	O	e.g
48	303	303	O	,
49	305	306	O	in
50	308	311	O	oral
51	313	326	U-UNK	contraceptives
NULL

Insulin recombinant	DDI-DrugBank.d313.s3	NO_SECTION	NO_SETID	22
Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
1	0	3	B-UNK	Beta
2	5	12	L-UNK	blockers
3	13	13	O	,
4	15	23	U-UNK	clonidine
5	24	24	O	,
6	26	32	U-UNK	lithium
7	34	38	O	salts
8	39	39	O	,
9	41	43	O	and
10	45	51	U-UNK	alcohol
11	53	55	O	may
12	57	62	O	either
13	64	73	O	potentiate
14	75	76	O	or
15	78	83	O	weaken
16	85	87	O	the
17	89	93	O	blood
18	95	101	O	glucose
19	103	110	O	lowering
20	112	117	O	effect
21	119	120	O	of
22	122	128	U-UNK	insulin
NULL

Insulin recombinant	DDI-DrugBank.d313.s4	NO_SECTION	NO_SETID	12
Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.
1	0	10	U-UNK	Pentamidine
2	12	14	O	may
3	16	20	O	cause
4	22	33	O	hypoglycemia
5	34	34	O	,
6	36	40	O	which
7	42	44	O	may
8	46	54	O	sometimes
9	56	57	O	be
10	59	66	O	followed
11	68	69	O	by
12	71	83	O	hyperglycemia
NULL

Insulin recombinant	DDI-DrugBank.d313.s5	NO_SECTION	NO_SETID	31
In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	17	O	under
5	19	21	O	the
6	23	31	O	influence
7	33	34	O	of
8	36	48	O	sympatholytic
9	50	58	O	medicinal
10	60	67	O	products
11	69	72	O	such
12	74	75	O	as
13	77	80	B-UNK	beta
14	82	89	L-UNK	blockers
15	90	90	O	,
16	92	100	U-UNK	clonidine
17	101	101	O	,
18	103	114	U-UNK	guanethidine
19	115	115	O	,
20	117	119	O	and
21	121	129	U-UNK	reserpine
22	130	130	O	,
23	132	134	O	the
24	136	140	O	signs
25	142	143	O	of
26	145	156	O	hypoglycemia
27	158	160	O	may
28	162	163	O	be
29	165	171	O	reduced
30	173	174	O	or
31	176	181	O	absent
NULL

Insulin recombinant	DDI-DrugBank.d313.s7	NO_SECTION	NO_SETID	45
A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH human insulin immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.
1	0	0	O	A
2	2	9	O	clinical
3	11	15	O	study
4	17	18	O	in
5	20	26	O	healthy
6	28	31	O	male
7	33	42	O	volunteers
8	45	48	O	n=24
9	51	62	O	demonstrated
10	64	67	O	that
11	69	74	O	mixing
12	76	82	O	XXXXXXXX
13	84	87	O	with
14	89	91	B-UNK	NPH
15	93	97	I-UNK	human
16	99	105	L-UNK	insulin
17	107	117	O	immediately
18	119	124	O	before
19	126	134	O	injection
20	136	143	O	produced
21	145	148	O	some
22	150	160	O	attenuation
23	162	163	O	in
24	165	167	O	the
25	169	172	O	peak
26	174	186	O	concentration
27	188	189	O	of
28	191	197	O	XXXXXXXX
29	198	198	O	,
30	200	202	O	but
31	204	207	O	that
32	209	211	O	the
33	213	216	O	time
34	218	219	O	to
35	221	224	O	peak
36	226	228	O	and
37	230	232	O	the
38	234	238	O	total
39	240	254	O	bioavailability
40	256	257	O	of
41	259	265	O	XXXXXXXX
42	267	270	O	were
43	272	274	O	not
44	276	288	O	significantly
45	290	297	O	affected
NULL

Insulin recombinant	DDI-DrugBank.d313.s8	NO_SECTION	NO_SETID	17
If NovoLog is mixed with NPH human insulin, NovoLog should be drawn into the syringe first.
1	0	1	O	If
2	3	9	O	XXXXXXXX
3	11	12	O	is
4	14	18	O	mixed
5	20	23	O	with
6	25	27	B-UNK	NPH
7	29	33	I-UNK	human
8	35	41	L-UNK	insulin
9	42	42	O	,
10	44	50	O	XXXXXXXX
11	52	57	O	should
12	59	60	O	be
13	62	66	O	drawn
14	68	71	O	into
15	73	75	O	the
16	77	83	O	syringe
17	85	89	O	first
NULL

Insulin recombinant	DDI-DrugBank.d313.s9	NO_SECTION	NO_SETID	8
The injection should be made immediately after mixing.
1	0	2	O	The
2	4	12	O	injection
3	14	19	O	should
4	21	22	O	be
5	24	27	O	made
6	29	39	O	immediately
7	41	45	O	after
8	47	52	O	mixing
NULL

Insulin recombinant	DDI-DrugBank.d313.s10	NO_SECTION	NO_SETID	24
Because there are no data on the compatibility of NovoLog and crystalline zinc insulin preparations, NovoLog should not be mixed with these preparations.
1	0	6	O	Because
2	8	12	O	there
3	14	16	O	are
4	18	19	O	no
5	21	24	O	data
6	26	27	O	on
7	29	31	O	the
8	33	45	O	compatibility
9	47	48	O	of
10	50	56	O	XXXXXXXX
11	58	60	O	and
12	62	72	O	crystalline
13	74	77	B-UNK	zinc
14	79	85	L-UNK	insulin
15	87	98	O	preparations
16	99	99	O	,
17	101	107	O	XXXXXXXX
18	109	114	O	should
19	116	118	O	not
20	120	121	O	be
21	123	127	O	mixed
22	129	132	O	with
23	134	138	O	these
24	140	151	O	preparations
NULL

Insulin recombinant	DDI-DrugBank.d313.s11	NO_SECTION	NO_SETID	21
The effects of mixing NovoLog with insulins of animal source or insulin preparations produced by other manufacturers have not been studied .
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	20	O	mixing
5	22	28	O	XXXXXXXX
6	30	33	O	with
7	35	42	U-UNK	insulins
8	44	45	O	of
9	47	52	O	animal
10	54	59	O	source
11	61	62	O	or
12	64	70	U-UNK	insulin
13	72	83	O	preparations
14	85	92	O	produced
15	94	95	O	by
16	97	101	O	other
17	103	115	O	manufacturers
18	117	120	O	have
19	122	124	O	not
20	126	129	O	been
21	131	137	O	studied
NULL

Insulin recombinant	DDI-DrugBank.d313.s12	NO_SECTION	NO_SETID	6
Mixtures should not be administered intravenously.
1	0	7	O	Mixtures
2	9	14	O	should
3	16	18	O	not
4	20	21	O	be
5	23	34	O	administered
6	36	48	O	intravenously
NULL

Insulin recombinant	DDI-DrugBank.d313.s13	NO_SECTION	NO_SETID	21
When used in external subcutaneous infusion pumps for insulin, NovoLog should not be mixed with any other insulins or diluent.
1	0	3	O	When
2	5	8	O	used
3	10	11	O	in
4	13	20	O	external
5	22	33	O	subcutaneous
6	35	42	O	infusion
7	44	48	O	pumps
8	50	52	O	for
9	54	60	U-UNK	insulin
10	61	61	O	,
11	63	69	O	XXXXXXXX
12	71	76	O	should
13	78	80	O	not
14	82	83	O	be
15	85	89	O	mixed
16	91	94	O	with
17	96	98	O	any
18	100	104	O	other
19	106	113	U-UNK	insulins
20	115	116	O	or
21	118	124	O	diluent
NULL

Interferon beta-1a	DDI-DrugBank.d433.s0	NO_SECTION	NO_SETID	10
No formal drug interaction studies have been conducted with Rebif .
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	25	O	interaction
5	27	33	O	studies
6	35	38	O	have
7	40	43	O	been
8	45	53	O	conducted
9	55	58	O	with
10	60	64	O	XXXXXXXX
NULL

Interferon beta-1a	DDI-DrugBank.d433.s1	NO_SECTION	NO_SETID	25
Due to its potential to cause neutropenia and lymphopenia, proper monitoring of patients is required if Rebif  is given in combination with myelosuppressive agents.
1	0	2	O	Due
2	4	5	O	to
3	7	9	O	its
4	11	19	O	potential
5	21	22	O	to
6	24	28	O	cause
7	30	40	O	neutropenia
8	42	44	O	and
9	46	56	O	lymphopenia
10	57	57	O	,
11	59	64	O	proper
12	66	75	O	monitoring
13	77	78	O	of
14	80	87	O	patients
15	89	90	O	is
16	92	99	O	required
17	101	102	O	if
18	104	108	O	XXXXXXXX
19	111	112	O	is
20	114	118	O	given
21	120	121	O	in
22	123	133	O	combination
23	135	138	O	with
24	140	155	O	myelosuppressive
25	157	162	O	agents
NULL

Interferon beta-1a	DDI-DrugBank.d433.s2	NO_SECTION	NO_SETID	38
Also, the potential for hepatic injury should be considered when Rebif  is used in combination with other products associated with hepatic injury, or when new agents are added to the regimen of patients already on Rebif .
1	0	3	O	Also
2	4	4	O	,
3	6	8	O	the
4	10	18	O	potential
5	20	22	O	for
6	24	30	O	hepatic
7	32	37	O	injury
8	39	44	O	should
9	46	47	O	be
10	49	58	O	considered
11	60	63	O	when
12	65	69	O	XXXXXXXX
13	72	73	O	is
14	75	78	O	used
15	80	81	O	in
16	83	93	O	combination
17	95	98	O	with
18	100	104	O	other
19	106	113	O	products
20	115	124	O	associated
21	126	129	O	with
22	131	137	O	hepatic
23	139	144	O	injury
24	145	145	O	,
25	147	148	O	or
26	150	153	O	when
27	155	157	O	new
28	159	164	O	agents
29	166	168	O	are
30	170	174	O	added
31	176	177	O	to
32	179	181	O	the
33	183	189	O	regimen
34	191	192	O	of
35	194	201	O	patients
36	203	209	O	already
37	211	212	O	on
38	214	218	O	XXXXXXXX
NULL

Interferon beta-1b	DDI-DrugBank.d10.s0	NO_SECTION	NO_SETID	11
Interactions between Betaseron and other drugs have not been fully evaluated.
1	0	11	O	Interactions
2	13	19	O	between
3	21	29	O	XXXXXXXX
4	31	33	O	and
5	35	39	O	other
6	41	45	O	drugs
7	47	50	O	have
8	52	54	O	not
9	56	59	O	been
10	61	65	O	fully
11	67	75	O	evaluated
NULL

Interferon beta-1b	DDI-DrugBank.d10.s1	NO_SECTION	NO_SETID	37
Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron.
1	0	7	O	Although
2	9	15	O	studies
3	17	24	O	designed
4	26	27	O	to
5	29	35	O	examine
6	37	40	O	drug
7	42	53	O	interactions
8	55	58	O	have
9	60	62	O	not
10	64	67	O	been
11	69	72	O	done
12	73	73	O	,
13	75	76	O	it
14	78	80	O	was
15	82	86	O	noted
16	88	91	O	that
17	93	106	U-UNK	corticosteroid
18	108	109	O	or
19	111	114	U-UNK	ACTH
20	116	124	O	treatment
21	126	127	O	of
22	129	136	O	relapses
23	138	140	O	for
24	142	148	O	periods
25	150	151	O	of
26	153	154	O	up
27	156	157	O	to
28	159	160	O	28
29	162	165	O	days
30	167	169	O	has
31	171	174	O	been
32	176	187	O	administered
33	189	190	O	to
34	192	199	O	patients
35	202	206	O	N=180
36	209	217	O	receiving
37	219	227	O	XXXXXXXX
NULL

Interferon beta-1b	DDI-DrugBank.d10.s2	NO_SECTION	NO_SETID	44
Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.
1	0	8	O	XXXXXXXX
2	10	23	O	administration
3	25	26	O	to
4	28	32	O	three
5	34	39	O	cancer
6	41	48	O	patients
7	50	53	O	over
8	55	55	O	a
9	57	60	O	dose
10	62	66	O	range
11	68	69	O	of
12	71	75	O	0.025
13	77	78	O	mg
14	80	81	O	to
15	83	85	O	2.2
16	87	88	O	mg
17	90	92	O	led
18	94	95	O	to
19	97	97	O	a
20	99	102	O	dose
21	104	112	O	dependent
22	114	123	O	inhibition
23	125	126	O	of
24	128	137	U-KIN	antipyrine
25	139	152	O	elimination.14
26	154	156	O	The
27	158	163	O	effect
28	165	166	O	of
29	168	176	O	alternate
30	178	180	O	day
31	182	195	O	administration
32	197	198	O	of
33	200	203	O	0.25
34	205	206	O	mg
35	208	209	O	of
36	211	219	O	XXXXXXXX
37	221	222	O	on
38	224	227	O	drug
39	229	238	O	metabolism
40	240	241	O	in
41	243	244	O	MS
42	246	253	O	patients
43	255	256	O	is
44	258	264	O	unknown
NULL

Ipratropium	DDI-DrugBank.d51.s0	NO_SECTION	NO_SETID	30
ATROVENT Inhalation Aerosol has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, and steroids, commonly used in the treatment of chronic obstructive pulmonary disease.
1	0	7	O	XXXXXXXX
2	9	18	O	Inhalation
3	20	26	O	Aerosol
4	28	30	O	has
5	32	35	O	been
6	37	40	O	used
7	42	54	O	concomitantly
8	56	59	O	with
9	61	65	O	other
10	67	71	O	drugs
11	72	72	O	,
12	74	82	O	including
13	84	98	B-UNK	sympathomimetic
14	100	114	L-UNK	bronchodilators
15	115	115	O	,
16	117	131	U-UNK	methylxanthines
17	132	132	O	,
18	134	136	O	and
19	138	145	U-UNK	steroids
20	146	146	O	,
21	148	155	O	commonly
22	157	160	O	used
23	162	163	O	in
24	165	167	O	the
25	169	177	O	treatment
26	179	180	O	of
27	182	188	O	chronic
28	190	200	O	obstructive
29	202	210	O	pulmonary
30	212	218	O	disease
NULL

Ipratropium	DDI-DrugBank.d51.s1	NO_SECTION	NO_SETID	27
With the exception of albuterol, there are no formal studies fully evaluating the interaction effects of ATROVENT Inhalation Aerosol and these drugs with respect to effectiveness.
1	0	3	O	With
2	5	7	O	the
3	9	17	O	exception
4	19	20	O	of
5	22	30	U-UNK	albuterol
6	31	31	O	,
7	33	37	O	there
8	39	41	O	are
9	43	44	O	no
10	46	51	O	formal
11	53	59	O	studies
12	61	65	O	fully
13	67	76	O	evaluating
14	78	80	O	the
15	82	92	O	interaction
16	94	100	O	effects
17	102	103	O	of
18	105	112	O	XXXXXXXX
19	114	123	O	Inhalation
20	125	131	O	Aerosol
21	133	135	O	and
22	137	141	O	these
23	143	147	O	drugs
24	149	152	O	with
25	154	160	O	respect
26	162	163	O	to
27	165	177	O	effectiveness
NULL

Ipratropium	DDI-DrugBank.d51.s2	NO_SECTION	NO_SETID	27
Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.
1	0	14	B-UNK	Anticholinergic
2	16	21	L-UNK	agents
3	22	22	O	:
4	24	31	O	Although
5	33	43	O	XXXXXXXX
6	45	51	O	bromide
7	53	54	O	is
8	56	64	O	minimally
9	66	73	O	absorbed
10	75	78	O	into
11	80	82	O	the
12	84	91	O	systemic
13	93	103	O	circulation
14	104	104	O	,
15	106	110	O	there
16	112	113	O	is
17	115	118	O	some
18	120	128	O	potential
19	130	132	O	for
20	134	135	O	an
21	137	144	O	additive
22	146	156	O	interaction
23	158	161	O	with
24	163	175	O	concomitantly
25	177	180	O	used
26	182	196	B-DYN	anticholinergic
27	198	208	L-DYN	medications
NULL

Ipratropium	DDI-DrugBank.d51.s3	NO_SECTION	NO_SETID	16
Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.
1	0	6	O	Caution
2	8	9	O	is
3	11	19	O	therefore
4	21	27	O	advised
5	29	30	O	in
6	32	34	O	the
7	36	51	O	coadministration
8	53	54	O	of
9	56	63	O	XXXXXXXX
10	65	74	O	Inhalation
11	76	82	O	Aerosol
12	84	87	O	with
13	89	93	O	other
14	95	109	U-DYN	anticholinergic
15	111	120	O	containing
16	122	126	O	drugs
NULL

Irbesartan	DDI-DrugBank.d27.s0	NO_SECTION	NO_SETID	23
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.
1	0	1	O	No
2	3	13	O	significant
3	15	18	O	drug
4	20	23	O	drug
5	25	39	O	pharmacokinetic
6	42	43	O	or
7	45	59	O	pharmacodynamic
8	62	73	O	interactions
9	75	78	O	have
10	80	83	O	been
11	85	89	O	found
12	91	92	O	in
13	94	104	O	interaction
14	106	112	O	studies
15	114	117	O	with
16	119	137	U-UNK	hydrochlorothiazide
17	138	138	O	,
18	140	146	U-UNK	digoxin
19	147	147	O	,
20	149	156	U-UNK	warfarin
21	157	157	O	,
22	159	161	O	and
23	163	172	U-UNK	nifedipine
NULL

Irbesartan	DDI-DrugBank.d27.s1	NO_SECTION	NO_SETID	27
In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	show
5	22	32	O	significant
6	34	43	O	inhibition
7	45	46	O	of
8	48	50	O	the
9	52	60	O	formation
10	62	63	O	of
11	65	72	O	oxidized
12	74	83	O	XXXXXXXX
13	85	95	O	metabolites
14	97	100	O	with
15	102	104	O	the
16	106	110	O	known
17	112	121	O	cytochrome
18	123	125	O	CYP
19	127	129	O	2C9
20	131	140	O	substrates
21	141	141	O	/
22	142	151	O	inhibitors
23	153	164	U-UNK	sulphenazole
24	165	165	O	,
25	167	177	U-UNK	tolbutamide
26	179	181	O	and
27	183	192	U-UNK	nifedipine
NULL

Irbesartan	DDI-DrugBank.d27.s2	NO_SECTION	NO_SETID	17
However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	19	O	clinical
5	21	27	O	studies
6	29	31	O	the
7	33	44	O	consequences
8	46	47	O	of
9	49	59	O	concomitant
10	61	70	O	XXXXXXXX
11	72	73	O	on
12	75	77	O	the
13	79	94	O	pharmacodynamics
14	96	97	O	of
15	99	106	U-UNK	warfarin
16	108	111	O	were
17	113	122	O	negligible
NULL

Irbesartan	DDI-DrugBank.d27.s3	NO_SECTION	NO_SETID	25
Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isozymes 1A1, 1A2,2A6,2B6,2D6,2E1,or 3A4.
1	0	4	O	Based
2	6	7	O	on
3	9	10	O	in
4	12	16	O	vitro
5	18	21	O	data
6	22	22	O	,
7	24	25	O	no
8	27	37	O	interaction
9	39	43	O	would
10	45	46	O	be
11	48	55	O	expected
12	57	60	O	with
13	62	66	O	drugs
14	68	72	O	whose
15	74	83	O	metabolism
16	85	86	O	is
17	88	96	O	dependent
18	98	101	O	upon
19	103	112	O	cytochrome
20	114	117	O	P450
21	119	126	O	isozymes
22	128	130	O	1A1
23	131	131	O	,
24	133	154	O	1A2,2A6,2B6,2D6,2E1,or
25	156	158	O	3A4
NULL

Irbesartan	DDI-DrugBank.d27.s4	NO_SECTION	NO_SETID	35
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.
1	0	1	O	In
2	3	10	O	separate
3	12	18	O	studies
4	20	21	O	of
5	23	30	O	patients
6	32	40	O	receiving
7	42	52	O	maintenance
8	54	58	O	doses
9	60	61	O	of
10	63	70	U-UNK	warfarin
11	71	71	O	,
12	73	91	U-UNK	hydrochlorothiazide
13	92	92	O	,
14	94	95	O	or
15	97	103	U-UNK	digoxin
16	104	104	O	,
17	106	115	O	XXXXXXXX
18	117	130	O	administration
19	132	134	O	for
20	136	136	O	7
21	138	141	O	days
22	143	145	O	had
23	147	148	O	no
24	150	155	O	effect
25	157	158	O	on
26	160	162	O	the
27	164	179	O	pharmacodynamics
28	181	182	O	of
29	184	191	U-UNK	warfarin
30	194	204	O	prothrombin
31	206	209	O	time
32	212	213	O	or
33	215	230	O	pharmacokinetics
34	232	233	O	of
35	235	241	U-UNK	digoxin
NULL

Irbesartan	DDI-DrugBank.d27.s5	NO_SECTION	NO_SETID	13
The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	33	O	XXXXXXXX
5	35	38	O	were
6	40	42	O	not
7	44	51	O	affected
8	53	54	O	by
9	56	71	O	coadministration
10	73	74	O	of
11	76	85	U-UNK	nifedipine
12	87	88	O	or
13	90	108	U-UNK	hydrochlorothiazide
NULL

Irinotecan	DDI-DrugBank.d279.s0	NO_SECTION	NO_SETID	26
The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.
1	0	2	O	The
2	4	10	O	adverse
3	12	18	O	effects
4	20	21	O	of
5	23	31	O	XXXXXXXX
6	32	32	O	,
7	34	37	O	such
8	39	40	O	as
9	42	57	O	myelosuppression
10	59	61	O	and
11	63	70	O	diarrhea
12	71	71	O	,
13	73	77	O	would
14	79	80	O	be
15	82	89	O	expected
16	91	92	O	to
17	94	95	O	be
18	97	107	O	exacerbated
19	109	110	O	by
20	112	116	O	other
21	118	131	B-DYN	antineoplastic
22	133	138	L-DYN	agents
23	140	145	O	having
24	147	153	O	similar
25	155	161	O	adverse
26	163	169	O	effects
NULL

Irinotecan	DDI-DrugBank.d279.s1	NO_SECTION	NO_SETID	21
Patients who have previously received pelvic/ abdominal irradiation are at increased risk of severe myelosuppression following the administration of CAMPTOSAR.
1	0	7	O	Patients
2	9	11	O	who
3	13	16	O	have
4	18	27	O	previously
5	29	36	O	received
6	38	43	O	pelvic
7	44	44	O	/
8	46	54	O	abdominal
9	56	66	O	irradiation
10	68	70	O	are
11	72	73	O	at
12	75	83	O	increased
13	85	88	O	risk
14	90	91	O	of
15	93	98	O	severe
16	100	115	O	myelosuppression
17	117	125	O	following
18	127	129	O	the
19	131	144	O	administration
20	146	147	O	of
21	149	157	O	XXXXXXXX
NULL

Irinotecan	DDI-DrugBank.d279.s2	NO_SECTION	NO_SETID	16
The concurrent administration of CAMPTOSAR with irradiation has not been adequately studied and is not recommended.
1	0	2	O	The
2	4	13	O	concurrent
3	15	28	O	administration
4	30	31	O	of
5	33	41	O	XXXXXXXX
6	43	46	O	with
7	48	58	O	irradiation
8	60	62	O	has
9	64	66	O	not
10	68	71	O	been
11	73	82	O	adequately
12	84	90	O	studied
13	92	94	O	and
14	96	97	O	is
15	99	101	O	not
16	103	113	O	recommended
NULL

Irinotecan	DDI-DrugBank.d279.s3	NO_SECTION	NO_SETID	29
Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.
1	0	14	O	Lymphocytopenia
2	16	18	O	has
3	20	23	O	been
4	25	32	O	reported
5	34	35	O	in
6	37	44	O	patients
7	46	54	O	receiving
8	56	64	O	XXXXXXXX
9	65	65	O	,
10	67	69	O	and
11	71	72	O	it
12	74	75	O	is
13	77	84	O	possible
14	86	89	O	that
15	91	93	O	the
16	95	108	O	administration
17	110	111	O	of
18	113	125	U-DYN	dexamethasone
19	127	128	O	as
20	130	139	O	antiemetic
21	141	151	O	prophylaxis
22	153	155	O	may
23	157	160	O	have
24	162	169	O	enhanced
25	171	173	O	the
26	175	184	O	likelihood
27	186	187	O	of
28	189	192	O	this
29	194	199	O	effect
NULL

Irinotecan	DDI-DrugBank.d279.s4	NO_SECTION	NO_SETID	19
However, serious opportunistic infections have not been observed, and no complications have specifically been attributed to lymphocytopenia.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	serious
4	17	29	O	opportunistic
5	31	40	O	infections
6	42	45	O	have
7	47	49	O	not
8	51	54	O	been
9	56	63	O	observed
10	64	64	O	,
11	66	68	O	and
12	70	71	O	no
13	73	85	O	complications
14	87	90	O	have
15	92	103	O	specifically
16	105	108	O	been
17	110	119	O	attributed
18	121	122	O	to
19	124	138	O	lymphocytopenia
NULL

Irinotecan	DDI-DrugBank.d279.s5	NO_SECTION	NO_SETID	9
Hyperglycemia has also been reported in patients receiving CAMPTOSAR.
1	0	12	O	Hyperglycemia
2	14	16	O	has
3	18	21	O	also
4	23	26	O	been
5	28	35	O	reported
6	37	38	O	in
7	40	47	O	patients
8	49	57	O	receiving
9	59	67	O	XXXXXXXX
NULL

Irinotecan	DDI-DrugBank.d279.s6	NO_SECTION	NO_SETID	24
Usually, this has been observed in patients with a history of diabetes mellitus or evidence of glucose intolerance prior to administration of CAMPTOSAR.
1	0	6	O	Usually
2	7	7	O	,
3	9	12	O	this
4	14	16	O	has
5	18	21	O	been
6	23	30	O	observed
7	32	33	O	in
8	35	42	O	patients
9	44	47	O	with
10	49	49	O	a
11	51	57	O	history
12	59	60	O	of
13	62	69	O	diabetes
14	71	78	O	mellitus
15	80	81	O	or
16	83	90	O	evidence
17	92	93	O	of
18	95	101	O	glucose
19	103	113	O	intolerance
20	115	119	O	prior
21	121	122	O	to
22	124	137	O	administration
23	139	140	O	of
24	142	150	O	XXXXXXXX
NULL

Irinotecan	DDI-DrugBank.d279.s7	NO_SECTION	NO_SETID	17
It is probable that dexamethasone, given as antiemetic prophylaxis, contributed to hyperglycemia in some patients.
1	0	1	O	It
2	3	4	O	is
3	6	13	O	probable
4	15	18	O	that
5	20	32	U-UNK	dexamethasone
6	33	33	O	,
7	35	39	O	given
8	41	42	O	as
9	44	53	O	antiemetic
10	55	65	O	prophylaxis
11	66	66	O	,
12	68	78	O	contributed
13	80	81	O	to
14	83	95	O	hyperglycemia
15	97	98	O	in
16	100	103	O	some
17	105	112	O	patients
NULL

Irinotecan	DDI-DrugBank.d279.s8	NO_SECTION	NO_SETID	45
The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).
1	0	2	O	The
2	4	12	O	incidence
3	14	15	O	of
4	17	25	O	akathisia
5	27	28	O	in
6	30	37	O	clinical
7	39	44	O	trials
8	46	47	O	of
9	49	51	O	the
10	53	58	O	weekly
11	60	65	O	dosage
12	67	74	O	schedule
13	76	78	O	was
14	80	86	O	greater
15	89	92	O	8.5%
16	93	93	O	,
17	95	95	O	4
18	96	96	O	/
19	97	98	O	47
20	100	107	O	patients
21	110	113	O	when
22	115	130	U-DYN	prochlorperazine
23	132	134	O	was
24	136	147	O	administered
25	149	150	O	on
26	152	154	O	the
27	156	159	O	same
28	161	163	O	day
29	165	166	O	as
30	168	176	O	XXXXXXXX
31	178	181	O	than
32	183	186	O	when
33	188	192	O	these
34	194	198	O	drugs
35	200	203	O	were
36	205	209	O	given
37	211	212	O	on
38	214	221	O	separate
39	223	226	O	days
40	229	232	O	1.3%
41	233	233	O	,
42	235	235	O	1
43	236	236	O	/
44	237	238	O	80
45	240	247	O	patients
NULL

Irinotecan	DDI-DrugBank.d279.s9	NO_SECTION	NO_SETID	25
The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as a premedication for other chemotherapies.
1	0	2	O	The
2	4	7	O	8.5%
3	9	17	O	incidence
4	19	20	O	of
5	22	30	O	akathisia
6	31	31	O	,
7	33	39	O	however
8	40	40	O	,
9	42	43	O	is
10	45	50	O	within
11	52	54	O	the
12	56	60	O	range
13	62	69	O	reported
14	71	73	O	for
15	75	77	O	use
16	79	80	O	of
17	82	97	U-UNK	prochlorperazine
18	99	102	O	when
19	104	108	O	given
20	110	111	O	as
21	113	113	O	a
22	115	127	O	premedication
23	129	131	O	for
24	133	137	O	other
25	139	152	O	chemotherapies
NULL

Irinotecan	DDI-DrugBank.d279.s10	NO_SECTION	NO_SETID	26
It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.
1	0	1	O	It
2	3	7	O	would
3	9	10	O	be
4	12	19	O	expected
5	21	24	O	that
6	26	33	U-DYN	laxative
7	35	37	O	use
8	39	44	O	during
9	46	52	O	therapy
10	54	57	O	with
11	59	67	O	XXXXXXXX
12	69	73	O	would
13	75	80	O	worsen
14	82	84	O	the
15	86	94	O	incidence
16	96	97	O	or
17	99	106	O	severity
18	108	109	O	of
19	111	118	O	diarrhea
20	119	119	O	,
21	121	123	O	but
22	125	128	O	this
23	130	132	O	has
24	134	136	O	not
25	138	141	O	been
26	143	149	O	studied
NULL

Irinotecan	DDI-DrugBank.d279.s11	NO_SECTION	NO_SETID	41
In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.
1	0	1	O	In
2	3	6	O	view
3	8	9	O	of
4	11	13	O	the
5	15	23	O	potential
6	25	28	O	risk
7	30	31	O	of
8	33	43	O	dehydration
9	45	53	O	secondary
10	55	56	O	to
11	58	65	O	vomiting
12	67	69	O	and
13	70	70	O	/
14	71	72	O	or
15	74	81	O	diarrhea
16	83	89	O	induced
17	91	92	O	by
18	94	102	O	XXXXXXXX
19	103	103	O	,
20	105	107	O	the
21	109	117	O	physician
22	119	121	O	may
23	123	126	O	wish
24	128	129	O	to
25	131	138	O	withhold
26	140	148	U-DYN	diuretics
27	150	155	O	during
28	157	162	O	dosing
29	164	167	O	with
30	169	177	O	XXXXXXXX
31	179	181	O	and
32	182	182	O	,
33	184	192	O	certainly
34	193	193	O	,
35	195	200	O	during
36	202	208	O	periods
37	210	211	O	of
38	213	218	O	active
39	220	227	O	vomiting
40	229	230	O	or
41	232	239	O	diarrhea
NULL

Irinotecan	DDI-DrugBank.d279.s12	NO_SECTION	NO_SETID	14
Drug-Laboratory Test Interactions There are no known interactions between CAMPTOSAR and laboratory tests.
1	0	3	O	Drug
2	5	14	O	Laboratory
3	16	19	O	Test
4	21	32	O	Interactions
5	34	38	O	There
6	40	42	O	are
7	44	45	O	no
8	47	51	O	known
9	53	64	O	interactions
10	66	72	O	between
11	74	82	O	XXXXXXXX
12	84	86	O	and
13	88	97	O	laboratory
14	99	103	O	tests
NULL

Isocarboxazid	DDI-DrugBank.d108.s0	NO_SECTION	NO_SETID	15
Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).
1	0	12	U-DYN	Isocarboxazid
2	14	19	O	should
3	21	22	O	be
4	24	35	O	administered
5	37	40	O	with
6	42	48	O	caution
7	50	51	O	to
8	53	60	O	patients
9	62	70	O	receiving
10	72	79	O	XXXXXXXX
11	82	91	U-UNK	disulfiram
12	92	92	O	,
13	94	98	O	Wyeth
14	100	105	O	Ayerst
15	107	118	O	Laboratories
NULL

Isocarboxazid	DDI-DrugBank.d108.s1	NO_SECTION	NO_SETID	24
In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	single
4	12	16	O	study
5	17	17	O	,
6	19	22	O	rats
7	24	28	O	given
8	30	33	O	high
9	35	49	O	intraperitoneal
10	51	55	O	doses
11	57	58	O	of
12	60	61	O	an
13	63	65	B-UNK	MAO
14	67	75	L-UNK	inhibitor
15	77	80	O	plus
16	82	91	U-UNK	disulfiram
17	93	103	O	experienced
18	105	110	O	severe
19	112	119	O	toxicity
20	120	120	O	,
21	122	130	O	including
22	132	142	O	convulsions
23	144	146	O	and
24	148	152	O	death
NULL

Isocarboxazid	DDI-DrugBank.d108.s2	NO_SECTION	NO_SETID	17
Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	31	O	XXXXXXXX
5	33	35	O	and
6	37	41	O	other
7	43	54	B-DYN	psychotropic
8	56	61	L-DYN	agents
9	63	64	O	is
10	66	74	O	generally
11	76	78	O	not
12	80	90	O	recommended
13	92	98	O	because
14	100	101	O	of
15	103	110	O	possible
16	112	123	O	potentiating
17	125	131	O	effects
NULL

Isocarboxazid	DDI-DrugBank.d108.s3	NO_SECTION	NO_SETID	15
This is especially true in patients who may subject themselves to an overdosage of drugs.
1	0	3	O	This
2	5	6	O	is
3	8	17	O	especially
4	19	22	O	true
5	24	25	O	in
6	27	34	O	patients
7	36	38	O	who
8	40	42	O	may
9	44	50	O	subject
10	52	61	O	themselves
11	63	64	O	to
12	66	67	O	an
13	69	78	O	overdosage
14	80	81	O	of
15	83	87	O	drugs
NULL

Isocarboxazid	DDI-DrugBank.d108.s4	NO_SECTION	NO_SETID	20
If combination therapy is needed, careful consideration should be given to the pharmacology of all agents to be used.
1	0	1	O	If
2	3	13	O	combination
3	15	21	O	therapy
4	23	24	O	is
5	26	31	O	needed
6	32	32	O	,
7	34	40	O	careful
8	42	54	O	consideration
9	56	61	O	should
10	63	64	O	be
11	66	70	O	given
12	72	73	O	to
13	75	77	O	the
14	79	90	O	pharmacology
15	92	93	O	of
16	95	97	O	all
17	99	104	O	agents
18	106	107	O	to
19	109	110	O	be
20	112	115	O	used
NULL

Isocarboxazid	DDI-DrugBank.d108.s5	NO_SECTION	NO_SETID	33
The monoamine oxidase inhibitory effects of Isocarboxazid may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following Isocarboxazid.
1	0	2	O	The
2	4	12	O	monoamine
3	14	20	O	oxidase
4	22	31	O	inhibitory
5	33	39	O	effects
6	41	42	O	of
7	44	56	O	XXXXXXXX
8	58	60	O	may
9	62	68	O	persist
10	70	72	O	for
11	74	74	O	a
12	76	86	O	substantial
13	88	93	O	period
14	95	99	O	after
15	101	115	O	discontinuation
16	117	118	O	of
17	120	122	O	the
18	124	127	O	drug
19	128	128	O	,
20	130	132	O	and
21	134	137	O	this
22	139	144	O	should
23	146	147	O	be
24	149	153	O	borne
25	155	156	O	in
26	158	161	O	mind
27	163	166	O	when
28	168	174	O	another
29	176	179	O	drug
30	181	182	O	is
31	184	193	O	prescribed
32	195	203	O	following
33	205	217	O	XXXXXXXX
NULL

Isocarboxazid	DDI-DrugBank.d108.s6	NO_SECTION	NO_SETID	26
To avoid potentiation, the physician wishing to terminate treatment with Isocarboxazid and begin therapy with another agent should allow for an interval of 10 days.
1	0	1	O	To
2	3	7	O	avoid
3	9	20	O	potentiation
4	21	21	O	,
5	23	25	O	the
6	27	35	O	physician
7	37	43	O	wishing
8	45	46	O	to
9	48	56	O	terminate
10	58	66	O	treatment
11	68	71	O	with
12	73	85	O	XXXXXXXX
13	87	89	O	and
14	91	95	O	begin
15	97	103	O	therapy
16	105	108	O	with
17	110	116	O	another
18	118	122	O	agent
19	124	129	O	should
20	131	135	O	allow
21	137	139	O	for
22	141	142	O	an
23	144	151	O	interval
24	153	154	O	of
25	156	157	O	10
26	159	162	O	days
NULL

Isoetharine	DDI-DrugBank.d541.s0	NO_SECTION	NO_SETID	43
May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide, quinidine, phenothiazines, and procainamide (these medicines may increase the risk of heart problems).
1	0	2	O	May
2	4	11	O	interact
3	13	16	O	with
4	18	20	O	the
5	22	30	O	following
6	31	31	O	:
7	33	36	B-UNK	beta
8	38	47	I-UNK	adrenergic
9	49	56	I-UNK	blocking
10	58	63	L-UNK	agents
11	66	70	O	these
12	72	80	O	medicines
13	82	84	O	may
14	86	89	O	make
15	91	94	O	your
16	96	104	O	condition
17	106	110	O	worse
18	112	114	O	and
19	116	122	O	prevent
20	124	126	O	the
21	128	137	B-UNK	adrenergic
22	139	153	L-UNK	bronchodilators
23	155	158	O	from
24	160	166	O	working
25	168	175	O	properly
26	178	180	O	and
27	182	193	U-UNK	disopyramide
28	194	194	O	,
29	196	204	U-UNK	quinidine
30	205	205	O	,
31	207	220	U-UNK	phenothiazines
32	221	221	O	,
33	223	225	O	and
34	227	238	U-UNK	procainamide
35	241	245	O	these
36	247	255	O	medicines
37	257	259	O	may
38	261	268	O	increase
39	270	272	O	the
40	274	277	O	risk
41	279	280	O	of
42	282	286	O	heart
43	288	295	O	problems
NULL

Isoflurane	DDI-DrugBank.d227.s0	NO_SECTION	NO_SETID	30
Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
1	0	9	O	XXXXXXXX
2	11	21	O	potentiates
3	23	25	O	the
4	27	32	O	muscle
5	34	41	O	relaxant
6	43	48	O	effect
7	50	51	O	of
8	53	55	O	all
9	57	62	B-DYN	muscle
10	64	72	L-DYN	relaxants
11	73	73	O	,
12	75	78	O	most
13	80	86	O	notably
14	88	102	B-DYN	nondepolarizing
15	104	109	I-DYN	muscle
16	111	119	L-DYN	relaxants
17	120	120	O	,
18	122	124	O	and
19	126	128	O	MAC
20	131	137	O	minimum
21	139	146	O	alveolar
22	148	160	O	concentration
23	163	164	O	is
24	166	172	O	reduced
25	174	175	O	by
26	177	187	O	concomitant
27	189	202	O	administration
28	204	205	O	of
29	207	207	O	N
30	209	210	O	2O
NULL

Isoflurane	DDI-DrugBank.d227.s1	NO_SECTION	NO_SETID	3
See CLINICAL PHARMACOLOGY.
1	0	2	O	See
2	4	11	O	CLINICAL
3	13	24	O	PHARMACOLOGY
NULL

Isoniazid	DDI-DrugBank.d187.s0	NO_SECTION	NO_SETID	9
Food: Isoniazid should not be administered with food.
1	0	3	O	Food
2	4	4	O	:
3	6	14	O	XXXXXXXX
4	16	21	O	should
5	23	25	O	not
6	27	28	O	be
7	30	41	O	administered
8	43	46	O	with
9	48	51	O	food
NULL

Isoniazid	DDI-DrugBank.d187.s1	NO_SECTION	NO_SETID	15
Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food.
1	0	6	O	Studies
2	8	11	O	have
3	13	17	O	shown
4	19	22	O	that
5	24	26	O	the
6	28	42	O	bioavailability
7	44	45	O	of
8	47	55	O	XXXXXXXX
9	57	58	O	is
10	60	66	O	reduced
11	68	80	O	significantly
12	82	85	O	when
13	87	98	O	administered
14	100	103	O	with
15	105	108	O	food
NULL

Isoniazid	DDI-DrugBank.d187.s2	NO_SECTION	NO_SETID	15
Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.
1	0	12	U-UNK	Acetaminophen
2	13	13	O	:
3	15	15	O	A
4	17	22	O	report
5	24	25	O	of
6	27	32	O	severe
7	34	46	U-DYN	acetaminophen
8	48	55	O	toxicity
9	57	59	O	was
10	61	68	O	reported
11	70	71	O	in
12	73	73	O	a
13	75	81	O	patient
14	83	91	O	receiving
15	93	101	O	XXXXXXXX
NULL

Isoniazid	DDI-DrugBank.d187.s3	NO_SECTION	NO_SETID	28
It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.
1	0	1	O	It
2	3	4	O	is
3	6	13	O	believed
4	15	18	O	that
5	20	22	O	the
6	24	31	O	toxicity
7	33	35	O	may
8	37	40	O	have
9	42	49	O	resulted
10	51	54	O	from
11	56	56	O	a
12	58	67	O	previously
13	69	80	O	unrecognized
14	82	92	O	interaction
15	94	100	O	between
16	102	110	O	XXXXXXXX
17	112	114	O	and
18	116	128	U-DYN	acetaminophen
19	130	132	O	and
20	134	134	O	a
21	136	144	O	molecular
22	146	150	O	basis
23	152	154	O	for
24	156	159	O	this
25	161	171	O	interaction
26	173	175	O	has
27	177	180	O	been
28	182	189	O	proposed
NULL

Isoniazid	DDI-DrugBank.d187.s4	NO_SECTION	NO_SETID	28
However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	current
4	17	24	O	evidence
5	26	33	O	suggests
6	35	38	O	that
7	40	48	O	XXXXXXXX
8	50	53	O	does
9	55	60	O	induce
10	62	62	O	P
11	64	70	O	450IIE1
12	71	71	O	,
13	73	73	O	a
14	75	79	O	mixed
15	81	88	O	function
16	90	96	O	oxidase
17	98	103	O	enzyme
18	105	108	O	that
19	110	116	O	appears
20	118	119	O	to
21	121	128	O	generate
22	130	132	O	the
23	134	138	O	toxic
24	140	150	O	metabolites
25	151	151	O	,
26	153	154	O	in
27	156	158	O	the
28	160	164	O	liver
NULL

Isoniazid	DDI-DrugBank.d187.s5	NO_SECTION	NO_SETID	37
Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.
1	0	10	O	Furthermore
2	12	13	O	it
3	15	17	O	has
4	19	22	O	been
5	24	31	O	proposed
6	33	36	O	that
7	38	46	O	XXXXXXXX
8	48	55	O	resulted
9	57	58	O	In
10	60	68	O	induction
11	70	71	O	of
12	73	73	O	P
13	75	81	O	450IIE1
14	83	84	O	in
15	86	88	O	the
16	90	97	O	patients
17	99	103	O	liver
18	105	109	O	which
19	110	110	O	,
20	112	113	O	in
21	115	118	O	turn
22	119	119	O	,
23	121	128	O	resulted
24	130	131	O	in
25	133	133	O	a
26	135	141	O	greater
27	143	152	O	proportion
28	154	155	O	of
29	157	159	O	the
30	161	168	O	ingested
31	170	182	U-KIN	acetaminophen
32	184	188	O	being
33	190	198	O	converted
34	200	201	O	to
35	203	205	O	the
36	207	211	O	toxic
37	213	223	O	metabolites
NULL

Isoniazid	DDI-DrugBank.d187.s6	NO_SECTION	NO_SETID	13
Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats.
1	0	6	O	Studies
2	8	11	O	have
3	13	24	O	demonstrated
4	26	29	O	that
5	31	42	O	pretreatment
6	44	47	O	with
7	49	57	O	XXXXXXXX
8	59	69	O	potentiates
9	71	71	O	a
10	73	84	O	cetaminophen
11	86	97	O	hepatoxicity
12	99	100	O	in
13	102	105	O	rats
NULL

Isoniazid	DDI-DrugBank.d187.s7	NO_SECTION	NO_SETID	49
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
1	0	12	U-UNK	Carbamazepine
2	13	13	O	:
3	15	23	O	XXXXXXXX
4	25	26	O	is
5	28	32	O	known
6	34	35	O	to
7	37	40	O	slow
8	42	44	O	the
9	46	55	O	metabolism
10	57	58	O	of
11	60	72	U-KIN	carbamazepine
12	74	76	O	and
13	78	85	O	increase
14	87	89	O	its
15	91	95	O	serum
16	97	102	O	levels
17	104	116	U-DYN	Carbamazepine
18	118	123	O	levels
19	125	130	O	should
20	132	133	O	be
21	135	144	O	determined
22	146	150	O	prior
23	152	153	O	to
24	155	164	O	concurrent
25	166	179	O	administration
26	181	184	O	with
27	186	194	O	XXXXXXXX
28	195	195	O	,
29	197	201	O	signs
30	203	205	O	and
31	207	214	O	symptoms
32	216	217	O	of
33	219	231	U-UNK	carbamazepine
34	233	240	O	toxicity
35	242	247	O	should
36	249	250	O	be
37	252	260	O	monitored
38	262	268	O	closely
39	269	269	O	,
40	271	273	O	and
41	275	285	O	appropriate
42	287	292	O	dosage
43	294	303	O	adjustment
44	305	306	O	of
45	308	310	O	the
46	312	325	U-UNK	anticonvulsant
47	327	332	O	should
48	334	335	O	be
49	337	340	O	made
NULL

Isoniazid	DDI-DrugBank.d187.s8	NO_SECTION	NO_SETID	10
Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	22	O	Potential
4	24	34	O	interaction
5	36	37	O	of
6	39	50	U-UNK	Ketoconazole
7	52	54	O	and
8	56	64	O	XXXXXXXX
9	66	68	O	may
10	70	74	O	exist
NULL

Isoniazid	DDI-DrugBank.d187.s9	NO_SECTION	NO_SETID	9
Phenytoin: Isoniazid may increase serum levels of phenytoin.
1	0	8	U-UNK	Phenytoin
2	9	9	O	:
3	11	19	O	XXXXXXXX
4	21	23	O	may
5	25	32	O	increase
6	34	38	O	serum
7	40	45	O	levels
8	47	48	O	of
9	50	58	U-KIN	phenytoin
NULL

Isoniazid	DDI-DrugBank.d187.s10	NO_SECTION	NO_SETID	13
To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made.
1	0	1	O	To
2	3	7	O	avoid
3	9	17	U-UNK	phenytoin
4	19	30	O	intoxication
5	31	31	O	,
6	33	43	O	appropriate
7	45	54	O	adjustment
8	56	57	O	of
9	59	61	O	the
10	63	76	U-UNK	anticonvulsant
11	78	83	O	should
12	85	86	O	be
13	88	91	O	made
NULL

Isoniazid	DDI-DrugBank.d187.s11	NO_SECTION	NO_SETID	34
Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.
1	0	12	O	Therophylline
2	13	13	O	:
3	15	15	O	A
4	17	22	O	recent
5	24	28	O	study
6	30	32	O	has
7	34	38	O	shown
8	40	43	O	that
9	45	54	O	concomitan
10	56	69	O	administration
11	71	72	O	of
12	74	82	O	XXXXXXXX
13	84	86	O	and
14	88	99	U-KIN	theophylline
15	101	103	O	may
16	105	109	O	cause
17	111	118	O	elevated
18	120	125	O	plasma
19	127	132	O	levels
20	134	135	O	of
21	137	148	U-UNK	theophylline
22	149	149	O	,
23	151	153	O	and
24	155	156	O	in
25	158	161	O	some
26	163	171	O	instances
27	173	173	O	a
28	175	180	O	slight
29	182	189	O	decrease
30	191	192	O	in
31	194	196	O	the
32	198	208	O	elimination
33	210	211	O	of
34	213	221	O	XXXXXXXX
NULL

Isoniazid	DDI-DrugBank.d187.s12	NO_SECTION	NO_SETID	25
Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.
1	0	4	O	Since
2	6	8	O	the
3	10	20	O	therapeutic
4	22	26	O	range
5	28	29	O	of
6	31	42	U-UNK	theophylline
7	44	45	O	is
8	47	52	O	narrow
9	54	65	U-UNK	theophylline
10	67	71	O	serum
11	73	78	O	levels
12	80	85	O	should
13	87	88	O	be
14	90	98	O	monitored
15	100	106	O	closely
16	107	107	O	,
17	109	111	O	and
18	113	123	O	appropriate
19	125	130	O	dosage
20	132	142	O	adjustments
21	144	145	O	of
22	147	158	U-UNK	theophylline
23	160	165	O	should
24	167	168	O	be
25	170	173	O	made
NULL

Isoniazid	DDI-DrugBank.d187.s13	NO_SECTION	NO_SETID	22
Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.
1	0	8	U-UNK	Valproate
2	9	9	O	:
3	11	11	O	A
4	13	18	O	recent
5	20	23	O	case
6	25	29	O	study
7	31	33	O	has
8	35	39	O	shown
9	41	41	O	a
10	43	50	O	possible
11	52	59	O	increase
12	61	62	O	in
13	64	66	O	the
14	68	73	O	plasma
15	75	79	O	level
16	81	82	O	of
17	84	92	U-KIN	valproate
18	94	97	O	when
19	99	100	O	co
20	102	113	O	administered
21	115	118	O	with
22	120	128	O	XXXXXXXX
NULL

Isoniazid	DDI-DrugBank.d187.s14	NO_SECTION	NO_SETID	23
Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.
1	0	5	O	Plasma
2	7	15	U-UNK	valproate
3	17	29	O	concentration
4	31	36	O	should
5	38	39	O	be
6	41	49	O	monitored
7	51	54	O	when
8	56	64	O	XXXXXXXX
9	66	68	O	and
10	70	78	U-DYN	valproate
11	80	82	O	are
12	84	85	O	co
13	87	98	O	administered
14	99	99	O	,
15	101	103	O	and
16	105	115	O	appropriate
17	117	122	O	dosage
18	124	134	O	adjustments
19	136	137	O	of
20	139	147	U-UNK	valproate
21	149	154	O	should
22	156	157	O	be
23	159	162	O	made
NULL

Isoproterenol	DDI-DrugBank.d55.s0	NO_SECTION	NO_SETID	25
Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.
1	0	12	O	XXXXXXXX
2	14	26	O	hydrochloride
3	28	36	O	injection
4	38	40	O	and
5	42	52	U-DYN	epinephrine
6	54	59	O	should
7	61	63	O	not
8	65	66	O	be
9	68	79	O	administered
10	81	94	O	simultaneously
11	96	102	O	because
12	104	107	O	both
13	109	113	O	drugs
14	115	117	O	are
15	119	124	O	direct
16	126	132	O	cardiac
17	134	143	O	stimulants
18	145	147	O	and
19	149	153	O	their
20	155	162	O	combined
21	164	170	O	effects
22	172	174	O	may
23	176	181	O	induce
24	183	189	O	serious
25	191	201	O	arrhythmias
NULL

Isoproterenol	DDI-DrugBank.d55.s1	NO_SECTION	NO_SETID	17
The drugs may, however, be administered alternately provided a proper interval has elapsed between doses.
1	0	2	O	The
2	4	8	O	drugs
3	10	12	O	may
4	13	13	O	,
5	15	21	O	however
6	22	22	O	,
7	24	25	O	be
8	27	38	O	administered
9	40	50	O	alternately
10	52	59	O	provided
11	61	61	O	a
12	63	68	O	proper
13	70	77	O	interval
14	79	81	O	has
15	83	89	O	elapsed
16	91	97	O	between
17	99	103	O	doses
NULL

Isoproterenol	DDI-DrugBank.d55.s2	NO_SECTION	NO_SETID	32
ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.
1	0	6	O	XXXXXXXX
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	26	O	with
6	28	34	O	caution
7	35	35	O	,
8	37	38	O	if
9	40	41	O	at
10	43	45	O	all
11	46	46	O	,
12	48	51	O	when
13	53	58	O	potent
14	60	71	O	inhalational
15	73	83	U-DYN	anesthetics
16	85	88	O	such
17	90	91	O	as
18	93	101	U-DYN	halothane
19	103	105	O	are
20	107	114	O	employed
21	116	122	O	because
22	124	125	O	of
23	127	135	O	potential
24	137	138	O	to
25	140	148	O	sensitize
26	150	152	O	the
27	154	163	O	myocardium
28	165	166	O	to
29	168	174	O	effects
30	176	177	O	of
31	179	193	B-UNK	sympathomimetic
32	195	200	L-UNK	amines
NULL

Isosorbide Dinitrate	DDI-DrugBank.d465.s0	NO_SECTION	NO_SETID	13
The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators.
1	0	2	O	The
2	4	15	O	vasodilating
3	17	23	O	effects
4	25	26	O	of
5	28	47	O	XXXXXXXX
6	49	51	O	may
7	53	54	O	be
8	56	63	O	additive
9	65	68	O	with
10	70	74	O	those
11	76	77	O	of
12	79	83	O	other
13	85	96	U-DYN	vasodilators
NULL

Isosorbide Dinitrate	DDI-DrugBank.d465.s1	NO_SECTION	NO_SETID	15
Alcohol, in particular, has been found to exhibit additive effects of this variety.
1	0	6	U-UNK	Alcohol
2	7	7	O	,
3	9	10	O	in
4	12	21	O	particular
5	22	22	O	,
6	24	26	O	has
7	28	31	O	been
8	33	37	O	found
9	39	40	O	to
10	42	48	O	exhibit
11	50	57	O	additive
12	59	65	O	effects
13	67	68	O	of
14	70	73	O	this
15	75	81	O	variety
NULL

Isosorbide Mononitrate	DDI-DrugBank.d479.s0	NO_SECTION	NO_SETID	13
The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators.
1	0	2	O	The
2	4	15	O	vasodilating
3	17	23	O	effects
4	25	26	O	of
5	28	49	O	XXXXXXXX
6	51	53	O	may
7	55	56	O	be
8	58	65	O	additive
9	67	70	O	with
10	72	76	O	those
11	78	79	O	of
12	81	85	O	other
13	87	98	U-DYN	vasodilators
NULL

Isosorbide Mononitrate	DDI-DrugBank.d479.s1	NO_SECTION	NO_SETID	15
Alcohol, in particular, has been found to exhibit additive effects of this variety.
1	0	6	U-UNK	Alcohol
2	7	7	O	,
3	9	10	O	in
4	12	21	O	particular
5	22	22	O	,
6	24	26	O	has
7	28	31	O	been
8	33	37	O	found
9	39	40	O	to
10	42	48	O	exhibit
11	50	57	O	additive
12	59	65	O	effects
13	67	68	O	of
14	70	73	O	this
15	75	81	O	variety
NULL

Isosorbide Mononitrate	DDI-DrugBank.d479.s2	NO_SECTION	NO_SETID	18
Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.
1	0	5	O	Marked
2	7	17	O	symptomatic
3	19	29	O	orthostatic
4	31	41	O	hypotension
5	43	45	O	has
6	47	50	O	been
7	52	59	O	reported
8	61	64	O	when
9	66	72	B-UNK	calcium
10	74	80	I-UNK	channel
11	82	89	L-UNK	blockers
12	91	93	O	and
13	95	101	B-UNK	organic
14	103	110	L-UNK	nitrates
15	112	115	O	were
16	117	120	O	used
17	122	123	O	in
18	125	135	O	combination
NULL

Isosorbide Mononitrate	DDI-DrugBank.d479.s3	NO_SECTION	NO_SETID	10
Dose adjustments of either class of agents may be necessary.
1	0	3	O	Dose
2	5	15	O	adjustments
3	17	18	O	of
4	20	25	O	either
5	27	31	O	class
6	33	34	O	of
7	36	41	O	agents
8	43	45	O	may
9	47	48	O	be
10	50	58	O	necessary
NULL

Isotretinoin	DDI-DrugBank.d163.s0	NO_SECTION	NO_SETID	29
Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects
1	0	6	B-UNK	Vitamin
2	8	8	L-UNK	A
3	9	9	O	:
4	11	17	O	Because
5	19	20	O	of
6	22	24	O	the
7	26	37	O	relationship
8	39	40	O	of
9	42	49	O	XXXXXXXX
10	51	52	O	to
11	54	60	B-DYN	vitamin
12	62	62	L-DYN	A
13	63	63	O	,
14	65	72	O	patients
15	74	79	O	should
16	81	82	O	be
17	84	90	O	advised
18	92	98	O	against
19	100	105	O	taking
20	107	113	B-UNK	vitamin
21	115	125	L-UNK	supplements
22	127	136	O	containing
23	138	144	B-UNK	vitamin
24	146	146	L-UNK	A
25	148	149	O	to
26	151	155	O	avoid
27	157	164	O	additive
28	166	170	O	toxic
29	172	178	O	effects
NULL

Isotretinoin	DDI-DrugBank.d163.s2	NO_SECTION	NO_SETID	37
Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines
1	0	12	U-UNK	Tetracyclines
2	13	13	O	:
3	15	25	O	Concomitant
4	27	35	O	treatment
5	37	40	O	with
6	42	49	O	XXXXXXXX
7	51	53	O	and
8	55	67	U-DYN	tetracyclines
9	69	74	O	should
10	76	77	O	be
11	79	85	O	avoided
12	87	93	O	because
13	95	102	O	XXXXXXXX
14	104	106	O	use
15	108	110	O	has
16	112	115	O	been
17	117	126	O	associated
18	128	131	O	with
19	133	133	O	a
20	135	140	O	number
21	142	143	O	of
22	145	149	O	cases
23	151	152	O	of
24	154	164	O	pseudotumor
25	166	172	O	cerebri
26	175	180	O	benign
27	182	193	O	intracranial
28	195	206	O	hypertension
29	208	208	O	,
30	210	213	O	some
31	215	216	O	of
32	218	222	O	which
33	224	231	O	involved
34	233	243	O	concomitant
35	245	247	O	use
36	249	250	O	of
37	252	264	U-DYN	tetracyclines
NULL

Isotretinoin	DDI-DrugBank.d163.s4	NO_SECTION	NO_SETID	26
Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.
1	0	4	O	Micro
2	6	10	O	dosed
3	12	23	U-UNK	Progesterone
4	25	36	O	Preparations
5	37	37	O	:
6	39	43	O	Micro
7	45	49	O	dosed
8	51	62	U-DYN	progesterone
9	64	75	O	preparations
10	78	86	O	minipills
11	88	91	O	that
12	93	94	O	do
13	96	98	O	not
14	100	106	O	contain
15	108	109	O	an
16	111	118	U-UNK	estrogen
17	121	123	O	may
18	125	126	O	be
19	128	129	O	an
20	131	140	O	inadequate
21	142	147	O	method
22	149	150	O	of
23	152	164	O	contraception
24	166	171	O	during
25	173	180	O	XXXXXXXX
26	182	188	O	therapy
NULL

Isotretinoin	DDI-DrugBank.d163.s5	NO_SECTION	NO_SETID	37
Although other hormonal contraceptives are highly effective, there have been reports of pregnancy from women who have used combined oral contraceptives, as well as topical/injectable/implantable/insertable hormonal birth control products.
1	0	7	O	Although
2	9	13	O	other
3	15	22	B-UNK	hormonal
4	24	37	L-UNK	contraceptives
5	39	41	O	are
6	43	48	O	highly
7	50	58	O	effective
8	59	59	O	,
9	61	65	O	there
10	67	70	O	have
11	72	75	O	been
12	77	83	O	reports
13	85	86	O	of
14	88	96	O	pregnancy
15	98	101	O	from
16	103	107	O	women
17	109	111	O	who
18	113	116	O	have
19	118	121	O	used
20	123	130	B-UNK	combined
21	132	135	I-UNK	oral
22	137	150	L-UNK	contraceptives
23	151	151	O	,
24	153	154	O	as
25	156	159	O	well
26	161	162	O	as
27	164	170	O	topical
28	171	171	O	/
29	172	181	O	injectable
30	182	182	O	/
31	183	193	O	implantable
32	194	194	O	/
33	195	204	O	insertable
34	206	213	O	hormonal
35	215	219	O	birth
36	221	227	O	control
37	229	236	O	products
NULL

Isotretinoin	DDI-DrugBank.d163.s6	NO_SECTION	NO_SETID	15
These reports are more frequent for women who use only a single method of contraception.
1	0	4	O	These
2	6	12	O	reports
3	14	16	O	are
4	18	21	O	more
5	23	30	O	frequent
6	32	34	O	for
7	36	40	O	women
8	42	44	O	who
9	46	48	O	use
10	50	53	O	only
11	55	55	O	a
12	57	62	O	single
13	64	69	O	method
14	71	72	O	of
15	74	86	O	contraception
NULL

Isotretinoin	DDI-DrugBank.d163.s7	NO_SECTION	NO_SETID	15
It is not known if hormonal contraceptives differ in their effectiveness when used with Accutane.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	known
5	16	17	O	if
6	19	26	B-UNK	hormonal
7	28	41	L-UNK	contraceptives
8	43	48	O	differ
9	50	51	O	in
10	53	57	O	their
11	59	71	O	effectiveness
12	73	76	O	when
13	78	81	O	used
14	83	86	O	with
15	88	95	O	XXXXXXXX
NULL

Isotretinoin	DDI-DrugBank.d163.s8	NO_SECTION	NO_SETID	50
Therefore, it is critically important for women of childbearing potential to select and commit to use 2 forms of effective contraception simultaneously, at least 1 of which must be a primary form, unless absolute abstinence is the chosen method, or the patient has undergone a hysterectomy
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	it
4	14	15	O	is
5	17	26	O	critically
6	28	36	O	important
7	38	40	O	for
8	42	46	O	women
9	48	49	O	of
10	51	62	O	childbearing
11	64	72	O	potential
12	74	75	O	to
13	77	82	O	select
14	84	86	O	and
15	88	93	O	commit
16	95	96	O	to
17	98	100	O	use
18	102	102	O	2
19	104	108	O	forms
20	110	111	O	of
21	113	121	O	effective
22	123	135	O	contraception
23	137	150	O	simultaneously
24	151	151	O	,
25	153	154	O	at
26	156	160	O	least
27	162	162	O	1
28	164	165	O	of
29	167	171	O	which
30	173	176	O	must
31	178	179	O	be
32	181	181	O	a
33	183	189	O	primary
34	191	194	O	form
35	195	195	O	,
36	197	202	O	unless
37	204	211	O	absolute
38	213	222	O	abstinence
39	224	225	O	is
40	227	229	O	the
41	231	236	O	chosen
42	238	243	O	method
43	244	244	O	,
44	246	247	O	or
45	249	251	O	the
46	253	259	O	patient
47	261	263	O	has
48	265	273	O	undergone
49	275	275	O	a
50	277	288	O	hysterectomy
NULL

Isotretinoin	DDI-DrugBank.d163.s10	NO_SECTION	NO_SETID	20
Phenytoin: Accutane has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers.
1	0	8	U-UNK	Phenytoin
2	9	9	O	:
3	11	18	O	XXXXXXXX
4	20	22	O	has
5	24	26	O	not
6	28	31	O	been
7	33	37	O	shown
8	39	40	O	to
9	42	46	O	alter
10	48	50	O	the
11	52	67	O	pharmacokinetics
12	69	70	O	of
13	72	80	U-UNK	phenytoin
14	82	83	O	in
15	85	85	O	a
16	87	91	O	study
17	93	94	O	in
18	96	100	O	seven
19	102	108	O	healthy
20	110	119	O	volunteers
NULL

Isotretinoin	DDI-DrugBank.d163.s11	NO_SECTION	NO_SETID	28
These results are consistent with the in vitro finding that neither isotretinoin nor its metabolites induce or inhibit the activity of the CYP 2C9 human hepatic P450 enzyme.
1	0	4	O	These
2	6	12	O	results
3	14	16	O	are
4	18	27	O	consistent
5	29	32	O	with
6	34	36	O	the
7	38	39	O	in
8	41	45	O	vitro
9	47	53	O	finding
10	55	58	O	that
11	60	66	O	neither
12	68	79	O	XXXXXXXX
13	81	83	O	nor
14	85	87	O	its
15	89	99	O	metabolites
16	101	106	O	induce
17	108	109	O	or
18	111	117	O	inhibit
19	119	121	O	the
20	123	130	O	activity
21	132	133	O	of
22	135	137	O	the
23	139	141	O	CYP
24	143	145	O	2C9
25	147	151	O	human
26	153	159	O	hepatic
27	161	164	O	P450
28	166	171	O	enzyme
NULL

Isotretinoin	DDI-DrugBank.d163.s12	NO_SECTION	NO_SETID	6
Phenytoin is known to cause osteomalacia.
1	0	8	U-UNK	Phenytoin
2	10	11	O	is
3	13	17	O	known
4	19	20	O	to
5	22	26	O	cause
6	28	39	O	osteomalacia
NULL

Isotretinoin	DDI-DrugBank.d163.s13	NO_SECTION	NO_SETID	22
No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between phenytoin and Accutane.
1	0	1	O	No
2	3	8	O	formal
3	10	17	O	clinical
4	19	25	O	studies
5	27	30	O	have
6	32	35	O	been
7	37	45	O	conducted
8	47	48	O	to
9	50	55	O	assess
10	57	58	O	if
11	60	64	O	there
12	66	67	O	is
13	69	70	O	an
14	72	82	O	interactive
15	84	89	O	effect
16	91	92	O	on
17	94	97	O	bone
18	99	102	O	loss
19	104	110	O	between
20	112	120	U-UNK	phenytoin
21	122	124	O	and
22	126	133	O	XXXXXXXX
NULL

Isotretinoin	DDI-DrugBank.d163.s14	NO_SECTION	NO_SETID	11
Therefore, caution should be exercised when using these drugs together
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	O	caution
4	19	24	O	should
5	26	27	O	be
6	29	37	O	exercised
7	39	42	O	when
8	44	48	O	using
9	50	54	O	these
10	56	60	O	drugs
11	62	69	O	together
NULL

Isotretinoin	DDI-DrugBank.d163.s16	NO_SECTION	NO_SETID	10
Systemic Corticosteroids: Systemic corticosteroids are known to cause osteoporosis.
1	0	7	B-UNK	Systemic
2	9	23	L-UNK	Corticosteroids
3	24	24	O	:
4	26	33	B-UNK	Systemic
5	35	49	L-UNK	corticosteroids
6	51	53	O	are
7	55	59	O	known
8	61	62	O	to
9	64	68	O	cause
10	70	81	O	osteoporosis
NULL

Isotretinoin	DDI-DrugBank.d163.s17	NO_SECTION	NO_SETID	23
No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between systemic corticosteroids and Accutane.
1	0	1	O	No
2	3	8	O	formal
3	10	17	O	clinical
4	19	25	O	studies
5	27	30	O	have
6	32	35	O	been
7	37	45	O	conducted
8	47	48	O	to
9	50	55	O	assess
10	57	58	O	if
11	60	64	O	there
12	66	67	O	is
13	69	70	O	an
14	72	82	O	interactive
15	84	89	O	effect
16	91	92	O	on
17	94	97	O	bone
18	99	102	O	loss
19	104	110	O	between
20	112	119	B-UNK	systemic
21	121	135	L-UNK	corticosteroids
22	137	139	O	and
23	141	148	O	XXXXXXXX
NULL

Isotretinoin	DDI-DrugBank.d163.s18	NO_SECTION	NO_SETID	11
Therefore, caution should be exercised when using these drugs together.
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	O	caution
4	19	24	O	should
5	26	27	O	be
6	29	37	O	exercised
7	39	42	O	when
8	44	48	O	using
9	50	54	O	these
10	56	60	O	drugs
11	62	69	O	together
NULL

Isotretinoin	DDI-DrugBank.d163.s19	NO_SECTION	NO_SETID	28
Prescribers are advised to consult the package insert of medication administered concomitantly with hormonal contraceptives, since some medications may decrease the effectiveness of these birth control products.
1	0	10	O	Prescribers
2	12	14	O	are
3	16	22	O	advised
4	24	25	O	to
5	27	33	O	consult
6	35	37	O	the
7	39	45	O	package
8	47	52	O	insert
9	54	55	O	of
10	57	66	O	medication
11	68	79	O	administered
12	81	93	O	concomitantly
13	95	98	O	with
14	100	107	B-UNK	hormonal
15	109	122	L-UNK	contraceptives
16	123	123	O	,
17	125	129	O	since
18	131	134	O	some
19	136	146	O	medications
20	148	150	O	may
21	152	159	O	decrease
22	161	163	O	the
23	165	177	O	effectiveness
24	179	180	O	of
25	182	186	O	these
26	188	192	O	birth
27	194	200	O	control
28	202	209	O	products
NULL

Isotretinoin	DDI-DrugBank.d163.s20	NO_SECTION	NO_SETID	9
Accutane use is associated with depression in some patients.
1	0	7	O	XXXXXXXX
2	9	11	O	use
3	13	14	O	is
4	16	25	O	associated
5	27	30	O	with
6	32	41	O	depression
7	43	44	O	in
8	46	49	O	some
9	51	58	O	patients
NULL

Isotretinoin	DDI-DrugBank.d163.s21	NO_SECTION	NO_SETID	19
Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. Johns Wort.
1	0	10	O	Pregnancies
2	12	15	O	have
3	17	20	O	been
4	22	29	O	reported
5	31	32	O	by
6	34	38	O	users
7	40	41	O	of
8	43	50	B-UNK	combined
9	52	59	I-UNK	hormonal
10	61	74	L-UNK	contraceptives
11	76	78	O	who
12	80	83	O	also
13	85	88	O	used
14	90	93	O	some
15	95	98	O	form
16	100	101	O	of
17	103	104	O	St
18	107	111	O	Johns
19	113	116	O	Wort
NULL

Isotretinoin	DDI-DrugBank.d163.s22	NO_SECTION	NO_SETID	36
Laboratory Tests Pregnancy Test Female patients of childbearing potential must have negative results from 2 urine or serum pregnancy tests with a sensitivity of at least 25 mIU/mL before receiving the initial Accutane prescription.
1	0	9	O	Laboratory
2	11	15	O	Tests
3	17	25	O	Pregnancy
4	27	30	O	Test
5	32	37	O	Female
6	39	46	O	patients
7	48	49	O	of
8	51	62	O	childbearing
9	64	72	O	potential
10	74	77	O	must
11	79	82	O	have
12	84	91	O	negative
13	93	99	O	results
14	101	104	O	from
15	106	106	O	2
16	108	112	O	urine
17	114	115	O	or
18	117	121	O	serum
19	123	131	O	pregnancy
20	133	137	O	tests
21	139	142	O	with
22	144	144	O	a
23	146	156	O	sensitivity
24	158	159	O	of
25	161	162	O	at
26	164	168	O	least
27	170	171	O	25
28	173	175	O	mIU
29	176	176	O	/
30	177	178	O	mL
31	180	185	O	before
32	187	195	O	receiving
33	197	199	O	the
34	201	207	O	initial
35	209	216	O	XXXXXXXX
36	218	229	O	prescription
NULL

Isotretinoin	DDI-DrugBank.d163.s23	NO_SECTION	NO_SETID	24
The first test is obtained by the prescriber when the decision is made to pursue qualification of the patient for Accutane (a screening test).
1	0	2	O	The
2	4	8	O	first
3	10	13	O	test
4	15	16	O	is
5	18	25	O	obtained
6	27	28	O	by
7	30	32	O	the
8	34	43	O	prescriber
9	45	48	O	when
10	50	52	O	the
11	54	61	O	decision
12	63	64	O	is
13	66	69	O	made
14	71	72	O	to
15	74	79	O	pursue
16	81	93	O	qualification
17	95	96	O	of
18	98	100	O	the
19	102	108	O	patient
20	110	112	O	for
21	114	121	O	XXXXXXXX
22	124	124	O	a
23	126	134	O	screening
24	136	139	O	test
NULL

Isotretinoin	DDI-DrugBank.d163.s24	NO_SECTION	NO_SETID	26
The second pregnancy test (a confirmation test) should be done during the first 5 days of the menstrual period immediately preceding the beginning of Accutane therapy.
1	0	2	O	The
2	4	9	O	second
3	11	19	O	pregnancy
4	21	24	O	test
5	27	27	O	a
6	29	40	O	confirmation
7	42	45	O	test
8	48	53	O	should
9	55	56	O	be
10	58	61	O	done
11	63	68	O	during
12	70	72	O	the
13	74	78	O	first
14	80	80	O	5
15	82	85	O	days
16	87	88	O	of
17	90	92	O	the
18	94	102	O	menstrual
19	104	109	O	period
20	111	121	O	immediately
21	123	131	O	preceding
22	133	135	O	the
23	137	145	O	beginning
24	147	148	O	of
25	150	157	O	XXXXXXXX
26	159	165	O	therapy
NULL

Isotretinoin	DDI-DrugBank.d163.s25	NO_SECTION	NO_SETID	30
For patients with amenorrhea, the second test should be done at least 11 days after the last act of unprotected sexual intercourse (without using 2 effective forms of contraception).
1	0	2	O	For
2	4	11	O	patients
3	13	16	O	with
4	18	27	O	amenorrhea
5	28	28	O	,
6	30	32	O	the
7	34	39	O	second
8	41	44	O	test
9	46	51	O	should
10	53	54	O	be
11	56	59	O	done
12	61	62	O	at
13	64	68	O	least
14	70	71	O	11
15	73	76	O	days
16	78	82	O	after
17	84	86	O	the
18	88	91	O	last
19	93	95	O	act
20	97	98	O	of
21	100	110	O	unprotected
22	112	117	O	sexual
23	119	129	O	intercourse
24	132	138	O	without
25	140	144	O	using
26	146	146	O	2
27	148	156	O	effective
28	158	162	O	forms
29	164	165	O	of
30	167	179	O	contraception
NULL

Isotretinoin	DDI-DrugBank.d163.s26	NO_SECTION	NO_SETID	19
Each month of therapy, the patient must have a negative result from a urine or serum pregnancy test.
1	0	3	O	Each
2	5	9	O	month
3	11	12	O	of
4	14	20	O	therapy
5	21	21	O	,
6	23	25	O	the
7	27	33	O	patient
8	35	38	O	must
9	40	43	O	have
10	45	45	O	a
11	47	54	O	negative
12	56	61	O	result
13	63	66	O	from
14	68	68	O	a
15	70	74	O	urine
16	76	77	O	or
17	79	83	O	serum
18	85	93	O	pregnancy
19	95	98	O	test
NULL

Isotretinoin	DDI-DrugBank.d163.s27	NO_SECTION	NO_SETID	16
A pregnancy test must be repeated each month prior to the female patient receiving each prescription
1	0	0	O	A
2	2	10	O	pregnancy
3	12	15	O	test
4	17	20	O	must
5	22	23	O	be
6	25	32	O	repeated
7	34	37	O	each
8	39	43	O	month
9	45	49	O	prior
10	51	52	O	to
11	54	56	O	the
12	58	63	O	female
13	65	71	O	patient
14	73	81	O	receiving
15	83	86	O	each
16	88	99	O	prescription
NULL

Isotretinoin	DDI-DrugBank.d163.s29	NO_SECTION	NO_SETID	14
Lipids: Pretreatment and follow-up blood lipids should be obtained under fasting conditions.
1	0	5	O	Lipids
2	6	6	O	:
3	8	19	O	Pretreatment
4	21	23	O	and
5	25	30	O	follow
6	32	33	O	up
7	35	39	O	blood
8	41	46	O	lipids
9	48	53	O	should
10	55	56	O	be
11	58	65	O	obtained
12	67	71	O	under
13	73	79	O	fasting
14	81	90	O	conditions
NULL

Isotretinoin	DDI-DrugBank.d163.s30	NO_SECTION	NO_SETID	16
After consumption of alcohol, at least 36 hours should elapse before these determinations are made.
1	0	4	O	After
2	6	16	O	consumption
3	18	19	O	of
4	21	27	U-UNK	alcohol
5	28	28	O	,
6	30	31	O	at
7	33	37	O	least
8	39	40	O	36
9	42	46	O	hours
10	48	53	O	should
11	55	60	O	elapse
12	62	67	O	before
13	69	73	O	these
14	75	88	O	determinations
15	90	92	O	are
16	94	97	O	made
NULL

Isotretinoin	DDI-DrugBank.d163.s31	NO_SECTION	NO_SETID	21
It is recommended that these tests be performed at weekly or biweekly intervals until the lipid response to Accutane is established.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	27	O	these
6	29	33	O	tests
7	35	36	O	be
8	38	46	O	performed
9	48	49	O	at
10	51	56	O	weekly
11	58	59	O	or
12	61	68	O	biweekly
13	70	78	O	intervals
14	80	84	O	until
15	86	88	O	the
16	90	94	O	lipid
17	96	103	O	response
18	105	106	O	to
19	108	115	O	XXXXXXXX
20	117	118	O	is
21	120	130	O	established
NULL

Isotretinoin	DDI-DrugBank.d163.s32	NO_SECTION	NO_SETID	12
The incidence of hypertriglyceridemia is 1 patient in 4 on Accutane therapy
1	0	2	O	The
2	4	12	O	incidence
3	14	15	O	of
4	17	36	O	hypertriglyceridemia
5	38	39	O	is
6	41	41	O	1
7	43	49	O	patient
8	51	52	O	in
9	54	54	O	4
10	56	57	O	on
11	59	66	O	XXXXXXXX
12	68	74	O	therapy
NULL

Isotretinoin	DDI-DrugBank.d163.s34	NO_SECTION	NO_SETID	45
Liver Function Tests: Since elevations of liver enzymes have been observed during clinical trials, and hepatitis has been reported, pretreatment and follow-up liver function tests should be performed at weekly or biweekly intervals until the response to Accutane has been established
1	0	4	O	Liver
2	6	13	O	Function
3	15	19	O	Tests
4	20	20	O	:
5	22	26	O	Since
6	28	37	O	elevations
7	39	40	O	of
8	42	46	O	liver
9	48	54	O	enzymes
10	56	59	O	have
11	61	64	O	been
12	66	73	O	observed
13	75	80	O	during
14	82	89	O	clinical
15	91	96	O	trials
16	97	97	O	,
17	99	101	O	and
18	103	111	O	hepatitis
19	113	115	O	has
20	117	120	O	been
21	122	129	O	reported
22	130	130	O	,
23	132	143	O	pretreatment
24	145	147	O	and
25	149	154	O	follow
26	156	157	O	up
27	159	163	O	liver
28	165	172	O	function
29	174	178	O	tests
30	180	185	O	should
31	187	188	O	be
32	190	198	O	performed
33	200	201	O	at
34	203	208	O	weekly
35	210	211	O	or
36	213	220	O	biweekly
37	222	230	O	intervals
38	232	236	O	until
39	238	240	O	the
40	242	249	O	response
41	251	252	O	to
42	254	261	O	XXXXXXXX
43	263	265	O	has
44	267	270	O	been
45	272	282	O	established
NULL

Isotretinoin	DDI-DrugBank.d163.s36	NO_SECTION	NO_SETID	16
Glucose: Some patients receiving Accutane have experienced problems in the control of their blood sugar.
1	0	6	O	Glucose
2	7	7	O	:
3	9	12	O	Some
4	14	21	O	patients
5	23	31	O	receiving
6	33	40	O	XXXXXXXX
7	42	45	O	have
8	47	57	O	experienced
9	59	66	O	problems
10	68	69	O	in
11	71	73	O	the
12	75	81	O	control
13	83	84	O	of
14	86	90	O	their
15	92	96	O	blood
16	98	102	O	sugar
NULL

Isotretinoin	DDI-DrugBank.d163.s37	NO_SECTION	NO_SETID	21
In addition, new cases of diabetes have been diagnosed during Accutane therapy, although no causal relationship has been established
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	15	O	new
5	17	21	O	cases
6	23	24	O	of
7	26	33	O	diabetes
8	35	38	O	have
9	40	43	O	been
10	45	53	O	diagnosed
11	55	60	O	during
12	62	69	O	XXXXXXXX
13	71	77	O	therapy
14	78	78	O	,
15	80	87	O	although
16	89	90	O	no
17	92	97	O	causal
18	99	110	O	relationship
19	112	114	O	has
20	116	119	O	been
21	121	131	O	established
NULL

Isotretinoin	DDI-DrugBank.d163.s39	NO_SECTION	NO_SETID	17
CPK: Some patients undergoing vigorous physical activity while on Accutane therapy have experienced elevated CPK levels;
1	0	2	O	CPK
2	3	3	O	:
3	5	8	O	Some
4	10	17	O	patients
5	19	28	O	undergoing
6	30	37	O	vigorous
7	39	46	O	physical
8	48	55	O	activity
9	57	61	O	while
10	63	64	O	on
11	66	73	O	XXXXXXXX
12	75	81	O	therapy
13	83	86	O	have
14	88	98	O	experienced
15	100	107	O	elevated
16	109	111	O	CPK
17	113	118	O	levels
NULL

Isotretinoin	DDI-DrugBank.d163.s40	NO_SECTION	NO_SETID	7
however, the clinical significance is unknown.
1	0	6	O	however
2	7	7	O	,
3	9	11	O	the
4	13	20	O	clinical
5	22	33	O	significance
6	35	36	O	is
7	38	44	O	unknown
NULL

Isotretinoin	DDI-DrugBank.d163.s41	NO_SECTION	NO_SETID	15
There have been rare postmarketing reports of rhabdomyolysis, some associated with strenuous physical activity.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	19	O	rare
5	21	33	O	postmarketing
6	35	41	O	reports
7	43	44	O	of
8	46	59	O	rhabdomyolysis
9	60	60	O	,
10	62	65	O	some
11	67	76	O	associated
12	78	81	O	with
13	83	91	O	strenuous
14	93	100	O	physical
15	102	109	O	activity
NULL

Isotretinoin	DDI-DrugBank.d163.s42	NO_SECTION	NO_SETID	55
In a clinical trial of 217 pediatric patients (12 to 17 years) with severe recalcitrant nodular acne, transient elevations in CPK were observed in 12% of patients, including those undergoing strenuous physical activity in association with reported musculoskeletal adverse events such as back pain, arthralgia, limb injury, or muscle sprain.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	clinical
4	14	18	O	trial
5	20	21	O	of
6	23	25	O	217
7	27	35	O	pediatric
8	37	44	O	patients
9	47	48	O	12
10	50	51	O	to
11	53	54	O	17
12	56	60	O	years
13	63	66	O	with
14	68	73	O	severe
15	75	86	O	recalcitrant
16	88	94	O	nodular
17	96	99	O	acne
18	100	100	O	,
19	102	110	O	transient
20	112	121	O	elevations
21	123	124	O	in
22	126	128	O	CPK
23	130	133	O	were
24	135	142	O	observed
25	144	145	O	in
26	147	149	O	12%
27	151	152	O	of
28	154	161	O	patients
29	162	162	O	,
30	164	172	O	including
31	174	178	O	those
32	180	189	O	undergoing
33	191	199	O	strenuous
34	201	208	O	physical
35	210	217	O	activity
36	219	220	O	in
37	222	232	O	association
38	234	237	O	with
39	239	246	O	reported
40	248	262	O	musculoskeletal
41	264	270	O	adverse
42	272	277	O	events
43	279	282	O	such
44	284	285	O	as
45	287	290	O	back
46	292	295	O	pain
47	296	296	O	,
48	298	307	O	arthralgia
49	308	308	O	,
50	310	313	O	limb
51	315	320	O	injury
52	321	321	O	,
53	323	324	O	or
54	326	331	O	muscle
55	333	338	O	sprain
NULL

Isotretinoin	DDI-DrugBank.d163.s43	NO_SECTION	NO_SETID	24
In these patients, approximately half of the CPK elevations returned to normal within 2 weeks and half returned to normal within 4 weeks.
1	0	1	O	In
2	3	7	O	these
3	9	16	O	patients
4	17	17	O	,
5	19	31	O	approximately
6	33	36	O	half
7	38	39	O	of
8	41	43	O	the
9	45	47	O	CPK
10	49	58	O	elevations
11	60	67	O	returned
12	69	70	O	to
13	72	77	O	normal
14	79	84	O	within
15	86	86	O	2
16	88	92	O	weeks
17	94	96	O	and
18	98	101	O	half
19	103	110	O	returned
20	112	113	O	to
21	115	120	O	normal
22	122	127	O	within
23	129	129	O	4
24	131	135	O	weeks
NULL

Isotretinoin	DDI-DrugBank.d163.s44	NO_SECTION	NO_SETID	9
No cases of rhabdomyolysis were reported in this trial.
1	0	1	O	No
2	3	7	O	cases
3	9	10	O	of
4	12	25	O	rhabdomyolysis
5	27	30	O	were
6	32	39	O	reported
7	41	42	O	in
8	44	47	O	this
9	49	53	O	trial
NULL

Isradipine	DDI-DrugBank.d81.s0	NO_SECTION	NO_SETID	10
Nitroglycerin: DynaCirc  (isradipine) has been safely coadministered with nitroglycerin.
1	0	12	U-UNK	Nitroglycerin
2	13	13	O	:
3	15	22	O	XXXXXXXX
4	26	35	U-UNK	isradipine
5	38	40	O	has
6	42	45	O	been
7	47	52	O	safely
8	54	67	O	coadministered
9	69	72	O	with
10	74	86	U-UNK	nitroglycerin
NULL

Isradipine	DDI-DrugBank.d81.s1	NO_SECTION	NO_SETID	27
Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  (isradipine) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.
1	0	18	U-UNK	Hydrochlorothiazide
2	19	19	O	:
3	21	21	O	A
4	23	27	O	study
5	29	30	O	in
6	32	37	O	normal
7	39	45	O	healthy
8	47	56	O	volunteers
9	58	60	O	has
10	62	66	O	shown
11	68	71	O	that
12	73	83	O	concomitant
13	85	98	O	administration
14	100	101	O	of
15	103	110	O	XXXXXXXX
16	114	123	U-UNK	isradipine
17	126	128	O	and
18	130	148	U-UNK	hydrochlorothiazide
19	150	153	O	does
20	155	157	O	not
21	159	164	O	result
22	166	167	O	in
23	169	175	O	altered
24	177	192	O	pharmacoktnetics
25	194	195	O	of
26	197	202	O	either
27	204	207	O	drug
NULL

Isradipine	DDI-DrugBank.d81.s2	NO_SECTION	NO_SETID	30
In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	in
5	14	25	O	hypertensive
6	27	34	O	patients
7	35	35	O	,
8	37	44	O	addition
9	46	47	O	of
10	49	58	O	XXXXXXXX
11	60	61	O	to
12	63	70	O	existing
13	72	90	U-UNK	hydrochlorothiazide
14	92	98	O	therapy
15	100	102	O	did
16	104	106	O	not
17	108	113	O	result
18	115	116	O	in
19	118	120	O	any
20	122	131	O	unexpected
21	133	139	O	adverse
22	141	147	O	effects
23	148	148	O	,
24	150	152	O	and
25	154	163	O	XXXXXXXX
26	165	167	O	had
27	169	170	O	an
28	172	181	O	additional
29	183	198	O	antihypertensive
30	200	205	O	effect
NULL

Isradipine	DDI-DrugBank.d81.s3	NO_SECTION	NO_SETID	30
Propranolol: In a single dose study in normal volunteers, coadministration of propranolol had a small effect on the rate but no effect on the extent of isradipine bioavailability.
1	0	10	U-UNK	Propranolol
2	11	11	O	:
3	13	14	O	In
4	16	16	O	a
5	18	23	O	single
6	25	28	O	dose
7	30	34	O	study
8	36	37	O	in
9	39	44	O	normal
10	46	55	O	volunteers
11	56	56	O	,
12	58	73	O	coadministration
13	75	76	O	of
14	78	88	U-UNK	propranolol
15	90	92	O	had
16	94	94	O	a
17	96	100	O	small
18	102	107	O	effect
19	109	110	O	on
20	112	114	O	the
21	116	119	O	rate
22	121	123	O	but
23	125	126	O	no
24	128	133	O	effect
25	135	136	O	on
26	138	140	O	the
27	142	147	O	extent
28	149	150	O	of
29	152	161	O	XXXXXXXX
30	163	177	O	bioavailability
NULL

Isradipine	DDI-DrugBank.d81.s4	NO_SECTION	NO_SETID	20
Significant increases In AUC (27%) and Cmax (58%) and decreases in tmax (23%) of propranolol were noted in this study.
1	0	10	O	Significant
2	12	20	O	increases
3	22	23	O	In
4	25	27	O	AUC
5	30	32	O	27%
6	35	37	O	and
7	39	42	O	Cmax
8	45	47	O	58%
9	50	52	O	and
10	54	62	O	decreases
11	64	65	O	in
12	67	70	O	tmax
13	73	75	O	23%
14	78	79	O	of
15	81	91	U-UNK	propranolol
16	93	96	O	were
17	98	102	O	noted
18	104	105	O	in
19	107	110	O	this
20	112	116	O	study
NULL

Isradipine	DDI-DrugBank.d81.s5	NO_SECTION	NO_SETID	13
However, concomitant administration of 5 mg b.i.d. isradipine and 40 mg b.i.d.
1	0	6	O	However
2	7	7	O	,
3	9	19	O	concomitant
4	21	34	O	administration
5	36	37	O	of
6	39	39	O	5
7	41	42	O	mg
8	44	48	O	b.i.d
9	51	60	O	XXXXXXXX
10	62	64	O	and
11	66	67	O	40
12	69	70	O	mg
13	72	76	O	b.i.d
NULL

Isradipine	DDI-DrugBank.d81.s6	NO_SECTION	NO_SETID	45
propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.
1	0	10	U-UNK	propranolol
2	12	13	O	to
3	15	21	O	healthy
4	23	32	O	volunteers
5	34	38	O	under
6	40	45	O	steady
7	47	51	O	state
8	53	62	O	conditions
9	64	66	O	had
10	68	69	O	no
11	71	78	O	relevant
12	80	85	O	effect
13	87	88	O	on
14	90	95	O	either
15	97	100	O	drug
16	102	102	O	s
17	104	118	O	bioavailability
18	119	119	O	,
19	121	123	O	AUC
20	125	127	O	and
21	129	132	O	Cmax
22	133	133	O	,
23	135	145	O	differences
24	147	150	O	were
25	153	155	O	20%
26	157	163	O	between
27	165	174	O	XXXXXXXX
28	176	180	O	given
29	182	187	O	singly
30	189	191	O	and
31	193	194	O	in
32	196	206	O	combination
33	208	211	O	with
34	213	223	U-UNK	propranolol
35	224	224	O	,
36	226	228	O	and
37	230	236	O	between
38	238	248	U-UNK	propranolol
39	250	254	O	given
40	256	261	O	singly
41	263	265	O	and
42	267	268	O	in
43	270	280	O	combination
44	282	285	O	with
45	287	296	O	XXXXXXXX
NULL

Isradipine	DDI-DrugBank.d81.s7	NO_SECTION	NO_SETID	50
Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).
1	0	9	U-UNK	Cimetidine
2	10	10	O	:
3	12	13	O	In
4	15	15	O	a
5	17	21	O	study
6	23	24	O	in
7	26	32	O	healthy
8	34	43	O	volunteers
9	44	44	O	,
10	46	46	O	a
11	48	50	O	one
12	52	55	O	week
13	57	62	O	course
14	64	65	O	of
15	67	76	U-KIN	cimetidine
16	78	79	O	at
17	81	83	O	400
18	85	86	O	mg
19	88	92	O	b.i.d
20	95	98	O	with
21	100	100	O	a
22	102	107	O	single
23	109	109	O	5
24	111	112	O	mg
25	114	117	O	dose
26	119	120	O	of
27	122	131	O	XXXXXXXX
28	133	134	O	on
29	136	138	O	the
30	140	144	O	sixth
31	146	148	O	day
32	150	155	O	showed
33	157	158	O	an
34	160	167	O	increase
35	169	170	O	in
36	172	181	O	XXXXXXXX
37	183	186	O	mean
38	188	191	O	peak
39	193	198	O	plasma
40	200	213	O	concentrations
41	216	218	O	36%
42	221	223	O	and
43	225	235	O	significant
44	237	244	O	increase
45	246	247	O	in
46	249	252	O	area
47	254	258	O	under
48	260	262	O	the
49	264	268	O	curve
50	271	273	O	50%
NULL

Isradipine	DDI-DrugBank.d81.s8	NO_SECTION	NO_SETID	25
If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.
1	0	1	O	If
2	3	12	O	XXXXXXXX
3	14	20	O	therapy
4	22	23	O	is
5	25	33	O	initiated
6	35	36	O	in
7	38	38	O	a
8	40	46	O	patient
9	48	56	O	currently
10	58	66	O	receiving
11	68	77	U-DYN	cimetidine
12	79	85	O	careful
13	87	96	O	monitoring
14	98	100	O	for
15	102	108	O	adverse
16	110	118	O	reactions
17	120	121	O	is
18	123	129	O	advised
19	131	133	O	and
20	135	142	O	downward
21	144	147	O	dose
22	149	158	O	adjustment
23	160	162	O	may
24	164	165	O	be
25	167	174	O	required
NULL

Isradipine	DDI-DrugBank.d81.s9	NO_SECTION	NO_SETID	40
Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.
1	0	9	U-UNK	Rifampicin
2	10	10	O	:
3	12	13	O	In
4	15	15	O	a
5	17	21	O	study
6	23	24	O	in
7	26	32	O	healthy
8	34	43	O	volunteers
9	44	44	O	,
10	46	46	O	a
11	48	50	O	six
12	52	54	O	day
13	56	61	O	course
14	63	64	O	of
15	66	75	U-KIN	rifampicin
16	77	78	O	at
17	80	82	O	600
18	84	85	O	mg
19	86	86	O	/
20	87	89	O	day
21	91	98	O	followed
22	100	101	O	by
23	103	103	O	a
24	105	110	O	single
25	112	112	O	5
26	114	115	O	mg
27	117	120	O	dose
28	122	123	O	of
29	125	134	O	XXXXXXXX
30	136	143	O	resulted
31	145	146	O	in
32	148	148	O	a
33	150	158	O	reduction
34	160	161	O	in
35	163	172	O	XXXXXXXX
36	174	179	O	levels
37	181	182	O	to
38	184	188	O	below
39	190	199	O	detectable
40	201	206	O	limits
NULL

Isradipine	DDI-DrugBank.d81.s10	NO_SECTION	NO_SETID	30
If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.
1	0	1	O	If
2	3	12	U-KIN	rifampicin
3	14	20	O	therapy
4	22	23	O	is
5	25	32	O	required
6	33	33	O	,
7	35	44	O	XXXXXXXX
8	46	59	O	concentrations
9	61	63	O	and
10	65	75	O	therapeutic
11	77	83	O	effects
12	85	87	O	are
13	89	94	O	likely
14	96	97	O	to
15	99	100	O	be
16	102	109	O	markedly
17	111	117	O	reduced
18	119	120	O	or
19	122	130	O	abolished
20	132	133	O	as
21	135	135	O	a
22	137	147	O	consequence
23	149	150	O	of
24	152	160	O	increased
25	162	171	O	metabolism
26	173	175	O	and
27	177	182	O	higher
28	184	192	O	clearance
29	194	195	O	of
30	197	206	O	XXXXXXXX
NULL

Isradipine	DDI-DrugBank.d81.s11	NO_SECTION	NO_SETID	49
Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between isradipine and racemic warfarin was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	11	O	In
4	13	13	O	a
5	15	19	O	study
6	21	22	O	in
7	24	30	O	healthy
8	32	41	O	volunteers
9	42	42	O	,
10	44	45	O	no
11	47	56	O	clinically
12	58	65	O	relevant
13	67	81	O	pharmacokinetic
14	83	84	O	or
15	86	100	O	pharmacodynamic
16	102	112	O	interaction
17	114	120	O	between
18	122	131	O	XXXXXXXX
19	133	135	O	and
20	137	143	O	racemic
21	145	152	U-UNK	warfarin
22	154	156	O	was
23	158	161	O	seen
24	163	166	O	when
25	168	170	O	two
26	172	177	O	single
27	179	182	O	oral
28	184	188	O	doses
29	190	191	O	of
30	193	200	U-UNK	warfarin
31	203	205	O	0.7
32	207	208	O	mg
33	209	209	O	/
34	210	211	O	kg
35	213	216	O	body
36	218	223	O	weight
37	226	229	O	were
38	231	242	O	administered
39	244	249	O	during
40	251	252	O	11
41	254	257	O	days
42	259	260	O	of
43	262	273	O	multipledose
44	275	283	O	treatment
45	285	288	O	with
46	290	290	O	5
47	292	293	O	mg
48	295	299	O	b.i.d
49	302	311	O	XXXXXXXX
NULL

Isradipine	DDI-DrugBank.d81.s12	NO_SECTION	NO_SETID	20
Neither racemic warfarin nor isradipine binding to plasma proteins in vitro was altered by the addition of the other drug.
1	0	6	O	Neither
2	8	14	O	racemic
3	16	23	U-UNK	warfarin
4	25	27	O	nor
5	29	38	O	XXXXXXXX
6	40	46	O	binding
7	48	49	O	to
8	51	56	O	plasma
9	58	65	O	proteins
10	67	68	O	in
11	70	74	O	vitro
12	76	78	O	was
13	80	86	O	altered
14	88	89	O	by
15	91	93	O	the
16	95	102	O	addition
17	104	105	O	of
18	107	109	O	the
19	111	115	O	other
20	117	120	O	drug
NULL

Isradipine	DDI-DrugBank.d81.s13	NO_SECTION	NO_SETID	28
Digoxin: The concomitant administration of DynaCirc  (isradipine) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of digoxin.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	11	O	The
4	13	23	O	concomitant
5	25	38	O	administration
6	40	41	O	of
7	43	50	O	XXXXXXXX
8	54	63	U-UNK	isradipine
9	66	68	O	and
10	70	76	U-UNK	digoxin
11	78	79	O	in
12	81	81	O	a
13	83	88	O	single
14	90	93	O	dose
15	95	109	O	pharmacokinetic
16	111	115	O	study
17	117	119	O	did
18	121	123	O	not
19	125	130	O	affect
20	132	136	O	renal
21	137	137	O	,
22	139	146	O	nonrenal
23	148	150	O	and
24	152	156	O	total
25	158	161	O	body
26	163	171	O	clearance
27	173	174	O	of
28	176	182	U-UNK	digoxin
NULL

Isradipine	DDI-DrugBank.d81.s14	NO_SECTION	NO_SETID	23
Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.
1	0	7	U-UNK	Fentanyl
2	9	18	O	Anesthesia
3	19	19	O	:
4	21	26	O	Severe
5	28	38	O	hypotension
6	40	42	O	has
7	44	47	O	been
8	49	56	O	reported
9	58	63	O	during
10	65	72	U-UNK	fentanyl
11	74	83	O	anesthesia
12	85	88	O	with
13	90	100	O	concomitant
14	102	104	O	use
15	106	107	O	of
16	109	109	O	a
17	111	114	B-UNK	beta
18	116	122	L-UNK	blocker
19	124	126	O	and
20	128	128	O	a
21	130	136	B-UNK	calcium
22	138	144	I-UNK	channel
23	146	152	L-UNK	blocker
NULL

Isradipine	DDI-DrugBank.d81.s15	NO_SECTION	NO_SETID	31
Even though such interactions have not been seen in clinical studies with DynaCirc  (isradipine), an increased volume of circulating fluids might be required if such an interaction were to occur.
1	0	3	O	Even
2	5	10	O	though
3	12	15	O	such
4	17	28	O	interactions
5	30	33	O	have
6	35	37	O	not
7	39	42	O	been
8	44	47	O	seen
9	49	50	O	in
10	52	59	O	clinical
11	61	67	O	studies
12	69	72	O	with
13	74	81	O	XXXXXXXX
14	85	94	U-UNK	isradipine
15	96	96	O	,
16	98	99	O	an
17	101	109	O	increased
18	111	116	O	volume
19	118	119	O	of
20	121	131	O	circulating
21	133	138	O	fluids
22	140	144	O	might
23	146	147	O	be
24	149	156	O	required
25	158	159	O	if
26	161	164	O	such
27	166	167	O	an
28	169	179	O	interaction
29	181	184	O	were
30	186	187	O	to
31	189	193	O	occur
NULL

Itraconazole	DDI-DrugBank.d165.s0	NO_SECTION	NO_SETID	19
Both itraconazole and its major metabolite, hydroxyitraconazole, are inhibitors of the cytochrome P450 3A4 enzyme system.
1	0	3	O	Both
2	5	16	O	XXXXXXXX
3	18	20	O	and
4	22	24	O	its
5	26	30	O	major
6	32	41	O	metabolite
7	42	42	O	,
8	44	50	O	hydroxy
9	51	62	O	XXXXXXXX
10	63	63	O	,
11	65	67	O	are
12	69	78	O	inhibitors
13	80	81	O	of
14	83	85	O	the
15	87	96	O	cytochrome
16	98	101	O	P450
17	103	105	O	3A4
18	107	112	O	enzyme
19	114	119	O	system
NULL

Itraconazole	DDI-DrugBank.d165.s1	NO_SECTION	NO_SETID	33
Coadministration of Itraconazole and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	31	O	XXXXXXXX
4	33	35	O	and
5	37	41	O	drugs
6	43	51	O	primarily
7	53	63	O	metabolized
8	65	66	O	by
9	68	70	O	the
10	72	81	O	cytochrome
11	83	86	O	P450
12	88	90	O	3A4
13	92	97	O	enzyme
14	99	104	O	system
15	106	108	O	may
16	110	115	O	result
17	117	118	O	in
18	120	128	O	increased
19	130	135	O	plasma
20	137	150	O	concentrations
21	152	153	O	of
22	155	157	O	the
23	159	163	O	drugs
24	165	168	O	that
25	170	174	O	could
26	176	183	O	increase
27	185	186	O	or
28	188	194	O	prolong
29	196	199	O	both
30	201	211	O	therapeutic
31	213	215	O	and
32	217	223	O	adverse
33	225	231	O	effects
NULL

Itraconazole	DDI-DrugBank.d165.s2	NO_SECTION	NO_SETID	12
Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary.
1	0	8	O	Therefore
2	9	9	O	,
3	11	16	O	unless
4	18	26	O	otherwise
5	28	36	O	specified
6	37	37	O	,
7	39	49	O	appropriate
8	51	56	O	dosage
9	58	68	O	adjustments
10	70	72	O	may
11	74	75	O	be
12	77	85	O	necessary
NULL

Itraconazole	DDI-DrugBank.d165.s3	NO_SECTION	NO_SETID	26
Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	30	U-KIN	terfenadine
4	32	35	O	with
5	37	48	O	XXXXXXXX
6	50	52	O	has
7	54	56	O	led
8	58	59	O	to
9	61	68	O	elevated
10	70	75	O	plasma
11	77	90	O	concentrations
12	92	93	O	of
13	95	105	U-UNK	terfenadine
14	106	106	O	,
15	108	116	O	resulting
16	118	119	O	in
17	121	124	O	rare
18	126	134	O	instances
19	136	137	O	of
20	139	142	O	life
21	145	155	O	threatening
22	157	163	O	cardiac
23	165	176	O	dysrhythmias
24	178	180	O	and
25	182	184	O	one
26	186	190	O	death
NULL

Itraconazole	DDI-DrugBank.d165.s4	NO_SECTION	NO_SETID	30
Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.
1	0	6	O	Another
2	8	11	O	oral
3	13	17	B-UNK	azole
4	19	28	L-UNK	antifungal
5	29	29	O	,
6	31	42	U-UNK	ketoconazole
7	43	43	O	,
8	45	52	O	inhibits
9	54	56	O	the
10	58	67	O	metabolism
11	69	70	O	of
12	72	81	U-UNK	astemizole
13	82	82	O	,
14	84	92	O	resulting
15	94	95	O	in
16	97	104	O	elevated
17	106	111	O	plasma
18	113	126	O	concentrations
19	128	129	O	of
20	131	140	U-UNK	astemizole
21	142	144	O	and
22	146	148	O	its
23	150	155	O	active
24	157	166	O	metabolite
25	168	187	U-UNK	desmethylastermizole
26	189	193	O	which
27	195	197	O	may
28	199	205	O	prolong
29	207	208	O	QT
30	210	218	O	intervals
NULL

Itraconazole	DDI-DrugBank.d165.s5	NO_SECTION	NO_SETID	27
In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.
1	0	1	O	In
2	3	7	O	vitro
3	9	12	O	data
4	14	20	O	suggest
5	22	25	O	that
6	27	38	O	XXXXXXXX
7	39	39	O	,
8	41	44	O	when
9	46	53	O	compared
10	55	56	O	to
11	58	69	U-UNK	ketoconazole
12	70	70	O	,
13	72	74	O	has
14	76	76	O	a
15	78	81	O	less
16	83	92	O	pronounced
17	94	99	O	effect
18	101	102	O	on
19	104	106	O	the
20	108	124	O	biotransformation
21	126	131	O	system
22	133	143	O	responsible
23	145	147	O	for
24	149	151	O	the
25	153	162	O	metabolism
26	164	165	O	of
27	167	176	U-KIN	astemizole
NULL

Itraconazole	DDI-DrugBank.d165.s6	NO_SECTION	NO_SETID	17
Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.
1	0	4	O	Based
2	6	7	O	on
3	9	11	O	the
4	13	20	O	chemical
5	22	32	O	resemblance
6	34	35	O	of
7	37	48	O	XXXXXXXX
8	50	52	O	and
9	54	65	U-UNK	ketoconazole
10	66	66	O	,
11	68	83	O	coadministration
12	85	86	O	of
13	88	97	U-DYN	astemizole
14	99	102	O	with
15	104	115	O	XXXXXXXX
16	117	118	O	is
17	120	134	O	contraindicated
NULL

Itraconazole	DDI-DrugBank.d165.s7	NO_SECTION	NO_SETID	25
Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.
1	0	4	O	Human
2	6	21	O	pharmacokinetics
3	23	26	O	data
4	28	35	O	indicate
5	37	40	O	that
6	42	45	O	oral
7	47	58	U-UNK	ketoconazole
8	60	67	O	potently
9	69	76	O	inhibits
10	78	80	O	the
11	82	91	O	metabolism
12	93	94	O	of
13	96	104	U-UNK	cisapride
14	106	114	O	resulting
15	116	117	O	in
16	119	120	O	an
17	122	126	O	eight
18	128	131	O	fold
19	133	140	O	increase
20	142	143	O	in
21	145	147	O	the
22	149	152	O	mean
23	154	156	O	AUC
24	158	159	O	of
25	161	169	U-UNK	cisapride
NULL

Itraconazole	DDI-DrugBank.d165.s8	NO_SECTION	NO_SETID	20
Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
1	0	3	O	Data
2	5	11	O	suggest
3	13	16	O	that
4	18	33	O	coadministration
5	35	36	O	of
6	38	41	O	oral
7	43	54	U-UNK	ketoconazole
8	56	58	O	and
9	60	68	U-UNK	cisapride
10	70	72	O	can
11	74	79	O	result
12	81	82	O	in
13	84	95	O	prolongation
14	97	98	O	of
15	100	102	O	the
16	104	105	O	QT
17	107	114	O	interval
18	116	117	O	on
19	119	121	O	the
20	123	125	O	ECG
NULL

Itraconazole	DDI-DrugBank.d165.s9	NO_SECTION	NO_SETID	19
In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;
1	0	1	O	In
2	3	7	O	vitro
3	9	12	O	data
4	14	20	O	suggest
5	22	25	O	that
6	27	38	O	XXXXXXXX
7	40	43	O	also
8	45	52	O	markedly
9	54	61	O	inhibits
10	63	65	O	the
11	67	83	O	biotransformation
12	85	90	O	system
13	92	97	O	mainly
14	99	109	O	responsible
15	111	113	O	for
16	115	117	O	the
17	119	128	O	metabolism
18	130	131	O	of
19	133	141	U-KIN	cisapride
NULL

Itraconazole	DDI-DrugBank.d165.s10	NO_SECTION	NO_SETID	9
therefore concomitant administration of Itraconazole with cisapride is contraindicated.
1	0	8	O	therefore
2	10	20	O	concomitant
3	22	35	O	administration
4	37	38	O	of
5	40	51	O	XXXXXXXX
6	53	56	O	with
7	58	66	U-DYN	cisapride
8	68	69	O	is
9	71	85	O	contraindicated
NULL

Itraconazole	DDI-DrugBank.d165.s11	NO_SECTION	NO_SETID	19
Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	31	O	XXXXXXXX
4	33	36	O	with
5	38	41	O	oral
6	43	51	U-KIN	midazolam
7	53	54	O	or
8	56	64	U-KIN	triazolam
9	66	68	O	has
10	70	77	O	resulted
11	79	80	O	in
12	82	89	O	elevated
13	91	96	O	plasma
14	98	111	O	concentrations
15	113	114	O	of
16	116	118	O	the
17	120	125	O	latter
18	127	129	O	two
19	131	135	O	drugs
NULL

Itraconazole	DDI-DrugBank.d165.s12	NO_SECTION	NO_SETID	9
This may potentiate and prolong hypnotic and sedative effects.
1	0	3	O	This
2	5	7	O	may
3	9	18	O	potentiate
4	20	22	O	and
5	24	30	O	prolong
6	32	39	O	hypnotic
7	41	43	O	and
8	45	52	O	sedative
9	54	60	O	effects
NULL

Itraconazole	DDI-DrugBank.d165.s13	NO_SECTION	NO_SETID	11
These agents should not be used in patients treated with Itraconazole.
1	0	4	O	These
2	6	11	O	agents
3	13	18	O	should
4	20	22	O	not
5	24	25	O	be
6	27	30	O	used
7	32	33	O	in
8	35	42	O	patients
9	44	50	O	treated
10	52	55	O	with
11	57	68	O	XXXXXXXX
NULL

Itraconazole	DDI-DrugBank.d165.s14	NO_SECTION	NO_SETID	17
If midazolam is administered parenterally, special precaution is required since the sedative effect may be prolonged.
1	0	1	O	If
2	3	11	U-UNK	midazolam
3	13	14	O	is
4	16	27	O	administered
5	29	40	O	parenterally
6	41	41	O	,
7	43	49	O	special
8	51	60	O	precaution
9	62	63	O	is
10	65	72	O	required
11	74	78	O	since
12	80	82	O	the
13	84	91	O	sedative
14	93	98	O	effect
15	100	102	O	may
16	104	105	O	be
17	107	115	O	prolonged
NULL

Itraconazole	DDI-DrugBank.d165.s15	NO_SECTION	NO_SETID	20
Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	31	O	XXXXXXXX
4	33	35	O	and
5	37	48	U-KIN	cyclosporine
6	49	49	O	,
7	51	60	U-KIN	tacrolimus
8	62	63	O	or
9	65	71	U-KIN	digoxin
10	73	75	O	has
11	77	79	O	led
12	81	82	O	to
13	84	92	O	increased
14	94	99	O	plasma
15	101	114	O	concentrations
16	116	117	O	of
17	119	121	O	the
18	123	128	O	latter
19	130	134	O	three
20	136	140	O	drugs
NULL

Itraconazole	DDI-DrugBank.d165.s16	NO_SECTION	NO_SETID	29
Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
1	0	11	U-DYN	Cyclosporine
2	12	12	O	,
3	14	23	U-DYN	tacrolimus
4	25	27	O	and
5	29	35	U-DYN	digoxin
6	37	50	O	concentrations
7	52	57	O	should
8	59	60	O	be
9	62	70	O	monitored
10	72	73	O	at
11	75	77	O	the
12	79	88	O	initiation
13	90	91	O	of
14	93	104	O	XXXXXXXX
15	106	112	O	therapy
16	114	116	O	and
17	118	127	O	frequently
18	129	138	O	thereafter
19	139	139	O	,
20	141	143	O	and
21	145	147	O	the
22	149	152	O	dose
23	154	155	O	of
24	157	161	O	these
25	163	167	O	three
26	169	172	O	drug
27	174	181	O	products
28	183	190	O	adjusted
29	192	204	O	appropriately
NULL

Itraconazole	DDI-DrugBank.d165.s17	NO_SECTION	NO_SETID	23
Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.
1	0	13	O	Rhabdomyolysis
2	15	17	O	has
3	19	22	O	been
4	24	31	O	observed
5	33	34	O	in
6	36	43	O	patients
7	45	53	O	receiving
8	55	57	B-UNK	HMG
9	59	61	I-UNK	CoA
10	63	71	I-UNK	reductase
11	73	82	L-UNK	inhibitors
12	84	95	O	administered
13	97	101	O	alone
14	104	105	O	at
15	107	117	O	recommended
16	119	125	O	dosages
17	128	129	O	or
18	131	143	O	concomitantly
19	145	148	O	with
20	150	166	B-UNK	immunosuppressive
21	168	172	L-UNK	drugs
22	174	182	O	including
23	184	195	U-UNK	cyclosporine
NULL

Itraconazole	DDI-DrugBank.d165.s18	NO_SECTION	NO_SETID	19
When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.
1	0	3	O	When
2	5	16	O	XXXXXXXX
3	18	20	O	was
4	22	35	O	coadministered
5	37	40	O	with
6	42	50	U-KIN	phenytoin
7	51	51	O	,
8	53	60	U-KIN	rifampin
9	61	61	O	,
10	63	64	O	or
11	66	78	O	H2antagonists
12	79	79	O	,
13	81	87	O	reduced
14	89	94	O	plasma
15	96	109	O	concentrations
16	111	112	O	of
17	114	125	O	XXXXXXXX
18	127	130	O	were
19	132	139	O	reported
NULL

Itraconazole	DDI-DrugBank.d165.s19	NO_SECTION	NO_SETID	29
The physician is advised to monitor the plasma concentrations of itraconazole when any of these drugs is taken concurrently, and to increase the dose of Itraconazole if necessary.
1	0	2	O	The
2	4	12	O	physician
3	14	15	O	is
4	17	23	O	advised
5	25	26	O	to
6	28	34	O	monitor
7	36	38	O	the
8	40	45	O	plasma
9	47	60	O	concentrations
10	62	63	O	of
11	65	76	O	XXXXXXXX
12	78	81	O	when
13	83	85	O	any
14	87	88	O	of
15	90	94	O	these
16	96	100	O	drugs
17	102	103	O	is
18	105	109	O	taken
19	111	122	O	concurrently
20	123	123	O	,
21	125	127	O	and
22	129	130	O	to
23	132	139	O	increase
24	141	143	O	the
25	145	148	O	dose
26	150	151	O	of
27	153	164	O	XXXXXXXX
28	166	167	O	if
29	169	177	O	necessary
NULL

Itraconazole	DDI-DrugBank.d165.s20	NO_SECTION	NO_SETID	19
Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;
1	0	7	O	Although
2	9	10	O	no
3	12	18	O	studies
4	20	23	O	have
5	25	28	O	been
6	30	38	O	conducted
7	39	39	O	,
8	41	51	O	concomitant
9	53	66	O	administration
10	68	69	O	of
11	71	82	O	XXXXXXXX
12	84	86	O	and
13	88	96	U-KIN	phenytoin
14	98	100	O	may
15	102	106	O	alter
16	108	110	O	the
17	112	121	O	metabolism
18	123	124	O	of
19	126	134	U-UNK	phenytoin
NULL

Itraconazole	DDI-DrugBank.d165.s21	NO_SECTION	NO_SETID	17
therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.
1	0	8	O	therefore
2	9	9	O	,
3	11	16	O	plasma
4	18	31	O	concentrations
5	33	34	O	of
6	36	44	U-DYN	phenytoin
7	46	51	O	should
8	53	56	O	also
9	58	59	O	be
10	61	69	O	monitored
11	71	74	O	when
12	76	77	O	it
13	79	80	O	is
14	82	86	O	given
15	88	99	O	concurrently
16	101	104	O	with
17	106	117	O	XXXXXXXX
NULL

Itraconazole	DDI-DrugBank.d165.s22	NO_SECTION	NO_SETID	14
It has been reported that Itraconazole enhances the anticoagulant effect of coumarin-like drugs.
1	0	1	O	It
2	3	5	O	has
3	7	10	O	been
4	12	19	O	reported
5	21	24	O	that
6	26	37	O	XXXXXXXX
7	39	46	O	enhances
8	48	50	O	the
9	52	64	O	anticoagulant
10	66	71	O	effect
11	73	74	O	of
12	76	83	U-DYN	coumarin
13	85	88	O	like
14	90	94	O	drugs
NULL

Itraconazole	DDI-DrugBank.d165.s23	NO_SECTION	NO_SETID	17
Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.
1	0	8	O	Therefore
2	9	9	O	,
3	11	21	O	prothrombin
4	23	26	O	time
5	28	33	O	should
6	35	36	O	be
7	38	46	O	carefully
8	48	56	O	monitored
9	58	59	O	in
10	61	68	O	patients
11	70	78	O	receiving
12	80	91	O	XXXXXXXX
13	93	95	O	and
14	97	104	U-DYN	coumarin
15	106	109	O	like
16	111	115	O	drugs
17	117	130	O	simultaneously
NULL

Itraconazole	DDI-DrugBank.d165.s24	NO_SECTION	NO_SETID	13
Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid.
1	0	5	O	Plasma
2	7	20	O	concentrations
3	22	23	O	of
4	25	29	B-UNK	azole
5	31	40	I-UNK	antifungal
6	42	47	L-UNK	agents
7	49	51	O	are
8	53	59	O	reduced
9	61	64	O	when
10	66	70	O	given
11	72	83	O	concurrently
12	85	88	O	with
13	90	98	U-UNK	isoniazid
NULL

Itraconazole	DDI-DrugBank.d165.s25	NO_SECTION	NO_SETID	12
Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.
1	0	11	O	XXXXXXXX
2	13	18	O	plasma
3	20	33	O	concentrations
4	35	40	O	should
5	42	43	O	be
6	45	53	O	monitored
7	55	58	O	when
8	60	71	O	XXXXXXXX
9	73	75	O	and
10	77	85	U-DYN	isoniazid
11	87	89	O	are
12	91	104	O	coadministered
NULL

Itraconazole	DDI-DrugBank.d165.s26	NO_SECTION	NO_SETID	16
Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents.
1	0	5	O	Severe
2	7	18	O	hypoglycemia
3	20	22	O	has
4	24	27	O	been
5	29	36	O	reported
6	38	39	O	in
7	41	48	O	patients
8	50	62	O	concomitantly
9	64	72	O	receiving
10	74	78	B-UNK	azole
11	80	89	I-UNK	antifungal
12	91	96	L-UNK	agents
13	98	100	O	and
14	102	105	O	oral
15	107	118	B-UNK	hypoglycemic
16	120	125	L-UNK	agents
NULL

Itraconazole	DDI-DrugBank.d165.s27	NO_SECTION	NO_SETID	15
Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.
1	0	4	O	Blood
2	6	12	O	glucose
3	14	27	O	concentrations
4	29	34	O	should
5	36	37	O	be
6	39	47	O	carefully
7	49	57	O	monitored
8	59	62	O	when
9	64	75	O	XXXXXXXX
10	77	79	O	and
11	81	84	O	oral
12	86	97	B-DYN	hypoglycemic
13	99	104	L-DYN	agents
14	106	108	O	are
15	110	123	O	coadministered
NULL

Itraconazole	DDI-DrugBank.d165.s28	NO_SECTION	NO_SETID	14
Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.
1	0	7	O	Tinnitus
2	9	11	O	and
3	13	21	O	decreased
4	23	29	O	hearing
5	31	34	O	have
6	36	39	O	been
7	41	48	O	reported
8	50	51	O	in
9	53	60	O	patients
10	62	74	O	concomitantly
11	76	84	O	receiving
12	86	97	O	XXXXXXXX
13	99	101	O	and
14	103	111	U-DYN	quinidine
NULL

Itraconazole	DDI-DrugBank.d165.s29	NO_SECTION	NO_SETID	14
Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.
1	0	4	O	Edema
2	6	8	O	has
3	10	13	O	been
4	15	22	O	reported
5	24	25	O	in
6	27	34	O	patients
7	36	48	O	concomitantly
8	50	58	O	receiving
9	60	71	O	XXXXXXXX
10	73	75	O	and
11	77	91	B-DYN	dihydropyridine
12	93	99	I-DYN	calcium
13	101	107	I-DYN	channel
14	109	116	L-DYN	blockers
NULL

Itraconazole	DDI-DrugBank.d165.s30	NO_SECTION	NO_SETID	6
Appropriate dosage adjustments may be necessary.
1	0	10	O	Appropriate
2	12	17	O	dosage
3	19	29	O	adjustments
4	31	33	O	may
5	35	36	O	be
6	38	46	O	necessary
NULL

Itraconazole	DDI-DrugBank.d165.s31	NO_SECTION	NO_SETID	44
The results from a study in which eight HIV-infected individuals were treated with zidovudine, 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of zidovudine were not affected during concomitant administration of Itraconazole, 100 mg b.i.d.
1	0	2	O	The
2	4	10	O	results
3	12	15	O	from
4	17	17	O	a
5	19	23	O	study
6	25	26	O	in
7	28	32	O	which
8	34	38	O	eight
9	40	42	O	HIV
10	44	51	O	infected
11	53	63	O	individuals
12	65	68	O	were
13	70	76	O	treated
14	78	81	O	with
15	83	92	U-UNK	zidovudine
16	93	93	O	,
17	95	95	O	8
18	97	97	O	+
19	98	98	O	/
20	101	103	O	0.4
21	105	106	O	mg
22	107	107	O	/
23	108	109	O	kg
24	110	110	O	/
25	111	113	O	day
26	114	114	O	,
27	116	121	O	showed
28	123	126	O	that
29	128	130	O	the
30	132	147	O	pharmacokinetics
31	149	150	O	of
32	152	161	U-UNK	zidovudine
33	163	166	O	were
34	168	170	O	not
35	172	179	O	affected
36	181	186	O	during
37	188	198	O	concomitant
38	200	213	O	administration
39	215	216	O	of
40	218	229	O	XXXXXXXX
41	230	230	O	,
42	232	234	O	100
43	236	237	O	mg
44	239	243	O	b.i.d
NULL

Kanamycin	DDI-DrugBank.d57.s0	NO_SECTION	NO_SETID	20
In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.
1	0	1	O	In
2	3	7	O	vitro
3	9	14	O	mixing
4	16	17	O	of
5	19	20	O	an
6	22	35	U-UNK	aminoglycoside
7	37	40	O	with
8	42	45	O	beta
9	47	56	O	lactamtype
10	58	68	U-UNK	antibiotics
11	71	81	U-UNK	penicillins
12	83	84	O	or
13	86	99	U-UNK	cephalosporins
14	102	104	O	may
15	106	111	O	result
16	113	114	O	in
17	116	116	O	a
18	118	128	O	significant
19	130	135	O	mutual
20	137	148	O	inactivation
NULL

Kanamycin	DDI-DrugBank.d57.s1	NO_SECTION	NO_SETID	43
Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.
1	0	3	O	Even
2	5	8	O	when
3	10	11	O	an
4	13	26	U-UNK	aminoglycoside
5	28	30	O	and
6	32	32	O	a
7	34	43	U-UNK	penicillin
8	45	48	O	type
9	50	53	O	drug
10	55	57	O	are
11	59	70	O	administered
12	72	81	O	separately
13	83	84	O	by
14	86	94	O	different
15	96	101	O	routes
16	102	102	O	,
17	104	104	O	a
18	106	114	O	reduction
19	116	117	O	in
20	119	132	U-UNK	aminoglycoside
21	134	138	O	serum
22	140	143	O	half
23	145	148	O	life
24	150	151	O	or
25	153	157	O	serum
26	159	164	O	levels
27	166	168	O	has
28	170	173	O	been
29	175	182	O	reported
30	184	185	O	in
31	187	194	O	patients
32	196	199	O	with
33	201	208	O	impaired
34	210	214	O	renal
35	216	223	O	function
36	225	227	O	and
37	229	230	O	in
38	232	235	O	some
39	237	244	O	patients
40	246	249	O	with
41	251	256	O	normal
42	258	262	O	renal
43	264	271	O	function
NULL

Kanamycin	DDI-DrugBank.d57.s2	NO_SECTION	NO_SETID	18
Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function..
1	0	6	O	Usually
2	7	7	O	,
3	9	12	O	such
4	14	25	O	inactivation
5	27	28	O	of
6	30	32	O	the
7	34	47	U-UNK	aminoglycoside
8	49	50	O	is
9	52	61	O	clinically
10	63	73	O	significant
11	75	78	O	only
12	80	81	O	in
13	83	90	O	patients
14	92	95	O	with
15	97	104	O	severely
16	106	113	O	impaired
17	115	119	O	renal
18	121	128	O	function
NULL

Ketamine	DDI-DrugBank.d518.s0	NO_SECTION	NO_SETID	16
Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine.
1	0	8	O	Prolonged
2	10	17	O	recovery
3	19	22	O	time
4	24	26	O	may
5	28	32	O	occur
6	34	35	O	if
7	37	48	U-DYN	barbiturates
8	50	52	O	and
9	53	53	O	/
10	54	55	O	or
11	57	65	U-DYN	narcotics
12	67	69	O	are
13	71	74	O	used
14	76	87	O	concurrently
15	89	92	O	with
16	94	101	O	XXXXXXXX
NULL

Ketamine	DDI-DrugBank.d518.s1	NO_SECTION	NO_SETID	20
Ketamine is clinically compatible with the commonly used general and local anesthetic agents when an adequate respiratory exchange is maintained.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	21	O	clinically
4	23	32	O	compatible
5	34	37	O	with
6	39	41	O	the
7	43	50	O	commonly
8	52	55	O	used
9	57	63	O	general
10	65	67	O	and
11	69	73	O	local
12	75	84	B-UNK	anesthetic
13	86	91	L-UNK	agents
14	93	96	O	when
15	98	99	O	an
16	101	108	O	adequate
17	110	120	O	respiratory
18	122	129	O	exchange
19	131	132	O	is
20	134	143	O	maintained
NULL

Ketoconazole	DDI-DrugBank.d458.s0	NO_SECTION	NO_SETID	12
Ketoconazole is a potent inhibitor of the cytochrome P450 3A4 enzyme system.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	16	O	a
4	18	23	O	potent
5	25	33	O	inhibitor
6	35	36	O	of
7	38	40	O	the
8	42	51	O	cytochrome
9	53	56	O	P450
10	58	60	O	3A4
11	62	67	O	enzyme
12	69	74	O	system
NULL

Ketoconazole	DDI-DrugBank.d458.s1	NO_SECTION	NO_SETID	34
Coadministration of NIZORAL  Tablets and drugs primarily metabolized by the cytochrome P450 3A4 enzyme system may result in increased plasma concentrations of the drugs that could increase or prolong both therapeutic and adverse effects.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	26	O	XXXXXXXX
4	29	35	O	Tablets
5	37	39	O	and
6	41	45	O	drugs
7	47	55	O	primarily
8	57	67	O	metabolized
9	69	70	O	by
10	72	74	O	the
11	76	85	O	cytochrome
12	87	90	O	P450
13	92	94	O	3A4
14	96	101	O	enzyme
15	103	108	O	system
16	110	112	O	may
17	114	119	O	result
18	121	122	O	in
19	124	132	O	increased
20	134	139	O	plasma
21	141	154	O	concentrations
22	156	157	O	of
23	159	161	O	the
24	163	167	O	drugs
25	169	172	O	that
26	174	178	O	could
27	180	187	O	increase
28	189	190	O	or
29	192	198	O	prolong
30	200	203	O	both
31	205	215	O	therapeutic
32	217	219	O	and
33	221	227	O	adverse
34	229	235	O	effects
NULL

Ketoconazole	DDI-DrugBank.d458.s2	NO_SECTION	NO_SETID	12
Therefore, unless otherwise specified, appropriate dosage adjustments may be necessary.
1	0	8	O	Therefore
2	9	9	O	,
3	11	16	O	unless
4	18	26	O	otherwise
5	28	36	O	specified
6	37	37	O	,
7	39	49	O	appropriate
8	51	56	O	dosage
9	58	68	O	adjustments
10	70	72	O	may
11	74	75	O	be
12	77	85	O	necessary
NULL

Ketoconazole	DDI-DrugBank.d458.s3	NO_SECTION	NO_SETID	48
The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.
1	0	2	O	The
2	4	12	O	following
3	14	17	O	drug
4	19	30	O	interactions
5	32	35	O	have
6	37	40	O	been
7	42	51	O	identified
8	53	61	O	involving
9	63	69	O	XXXXXXXX
10	71	77	O	Tablets
11	79	81	O	and
12	83	87	O	other
13	89	93	O	drugs
14	95	105	O	metabolized
15	107	108	O	by
16	110	112	O	the
17	114	123	O	cytochrome
18	125	128	O	P450
19	130	132	O	3A4
20	134	139	O	enzyme
21	141	146	O	system
22	147	147	O	:
23	149	160	U-UNK	Ketoconazole
24	162	168	O	tablets
25	170	176	O	inhibit
26	178	180	O	the
27	182	191	O	metabolism
28	193	194	O	of
29	196	206	U-UNK	terfenadine
30	207	207	O	,
31	209	217	O	resulting
32	219	220	O	in
33	222	223	O	an
34	225	233	O	increased
35	235	240	O	plasma
36	242	254	O	concentration
37	256	257	O	of
38	259	269	U-UNK	terfenadine
39	271	273	O	and
40	275	275	O	a
41	277	281	O	delay
42	283	284	O	in
43	286	288	O	the
44	290	300	O	elimination
45	302	303	O	of
46	305	307	O	its
47	309	312	O	acid
48	314	323	O	metabolite
NULL

Ketoconazole	DDI-DrugBank.d458.s4	NO_SECTION	NO_SETID	15
The increased plasma concentration of terfenadine or its metabolite may result in prolonged QT intervals.
1	0	2	O	The
2	4	12	O	increased
3	14	19	O	plasma
4	21	33	O	concentration
5	35	36	O	of
6	38	48	U-UNK	terfenadine
7	50	51	O	or
8	53	55	O	its
9	57	66	O	metabolite
10	68	70	O	may
11	72	77	O	result
12	79	80	O	in
13	82	90	O	prolonged
14	92	93	O	QT
15	95	103	O	intervals
NULL

Ketoconazole	DDI-DrugBank.d458.s5	NO_SECTION	NO_SETID	29
Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.
1	0	14	O	Pharmacokinetic
2	16	19	O	data
3	21	28	O	indicate
4	30	33	O	that
5	35	38	O	oral
6	40	51	O	XXXXXXXX
7	53	60	O	inhibits
8	62	64	O	the
9	66	75	O	metabolism
10	77	78	O	of
11	80	89	U-DYN	astemizole
12	90	90	O	,
13	92	100	O	resulting
14	102	103	O	in
15	105	112	O	elevated
16	114	119	O	plasma
17	121	126	O	levels
18	128	129	O	of
19	131	140	U-UNK	astemizole
20	142	144	O	and
21	146	148	O	its
22	150	155	O	active
23	157	166	O	metabolite
24	168	186	U-UNK	desmethylastemizole
25	188	192	O	which
26	194	196	O	may
27	198	204	O	prolong
28	206	207	O	QT
29	209	217	O	intervals
NULL

Ketoconazole	DDI-DrugBank.d458.s6	NO_SECTION	NO_SETID	9
Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	U-DYN	astemizole
4	31	34	O	with
5	36	47	O	XXXXXXXX
6	49	55	O	tablets
7	57	58	O	is
8	60	68	O	therefore
9	70	84	O	contraindicated
NULL

Ketoconazole	DDI-DrugBank.d458.s7	NO_SECTION	NO_SETID	24
Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.
1	0	4	O	Human
2	6	21	O	pharmacokinetics
3	23	26	O	data
4	28	35	O	indicate
5	37	40	O	that
6	42	45	O	oral
7	47	58	O	XXXXXXXX
8	60	67	O	potently
9	69	76	O	inhibits
10	78	80	O	the
11	82	91	O	metabolism
12	93	94	O	of
13	96	104	U-KIN	cisapride
14	106	114	O	resulting
15	116	117	O	in
16	119	119	O	a
17	121	124	O	mean
18	126	130	O	eight
19	132	135	O	fold
20	137	144	O	increase
21	146	147	O	in
22	149	151	O	AUC
23	153	154	O	of
24	156	164	U-UNK	cisapride
NULL

Ketoconazole	DDI-DrugBank.d458.s8	NO_SECTION	NO_SETID	20
Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.
1	0	3	O	Data
2	5	11	O	suggest
3	13	16	O	that
4	18	33	O	coadministration
5	35	36	O	of
6	38	41	O	oral
7	43	54	O	XXXXXXXX
8	56	58	O	and
9	60	68	U-DYN	cisapride
10	70	72	O	can
11	74	79	O	result
12	81	82	O	in
13	84	95	O	prolongation
14	97	98	O	of
15	100	102	O	the
16	104	105	O	QT
17	107	114	O	interval
18	116	117	O	on
19	119	121	O	the
20	123	125	O	ECG
NULL

Ketoconazole	DDI-DrugBank.d458.s9	NO_SECTION	NO_SETID	10
Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.
1	0	8	O	Therefore
2	10	20	O	concomitant
3	22	35	O	administration
4	37	38	O	of
5	40	51	O	XXXXXXXX
6	53	59	O	tablets
7	61	64	O	with
8	66	74	U-DYN	cisapride
9	76	77	O	is
10	79	93	O	contraindicated
NULL

Ketoconazole	DDI-DrugBank.d458.s10	NO_SECTION	NO_SETID	23
Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.
1	0	11	O	XXXXXXXX
2	13	19	O	tablets
3	21	23	O	may
4	25	29	O	alter
5	31	33	O	the
6	35	44	O	metabolism
7	46	47	O	of
8	49	60	U-KIN	cyclosporine
9	61	61	O	,
10	63	72	U-KIN	tacrolimus
11	73	73	O	,
12	75	77	O	and
13	79	96	U-KIN	methylprednisolone
14	97	97	O	,
15	99	107	O	resulting
16	109	110	O	in
17	112	119	O	elevated
18	121	126	O	plasma
19	128	141	O	concentrations
20	143	144	O	of
21	146	148	O	the
22	150	155	O	latter
23	157	161	O	drugs
NULL

Ketoconazole	DDI-DrugBank.d458.s11	NO_SECTION	NO_SETID	18
Dosage adjustment may be required if cyclosporine, tacrolimus, or methylprednisolone are given concomitantly with NIZORAL  Tablets.
1	0	5	O	Dosage
2	7	16	O	adjustment
3	18	20	O	may
4	22	23	O	be
5	25	32	O	required
6	34	35	O	if
7	37	48	U-UNK	cyclosporine
8	49	49	O	,
9	51	60	U-UNK	tacrolimus
10	61	61	O	,
11	63	64	O	or
12	66	83	U-UNK	methylprednisolone
13	85	87	O	are
14	89	93	O	given
15	95	107	O	concomitantly
16	109	112	O	with
17	114	120	O	XXXXXXXX
18	123	129	O	Tablets
NULL

Ketoconazole	DDI-DrugBank.d458.s12	NO_SECTION	NO_SETID	19
Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	26	O	XXXXXXXX
4	29	35	O	Tablets
5	37	40	O	with
6	42	50	U-KIN	midazolam
7	52	53	O	or
8	55	63	U-KIN	triazolam
9	65	67	O	has
10	69	76	O	resulted
11	78	79	O	in
12	81	88	O	elevated
13	90	95	O	plasma
14	97	110	O	concentrations
15	112	113	O	of
16	115	117	O	the
17	119	124	O	latter
18	126	128	O	two
19	130	134	O	drugs
NULL

Ketoconazole	DDI-DrugBank.d458.s13	NO_SECTION	NO_SETID	20
This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents.
1	0	3	O	This
2	5	7	O	may
3	9	18	O	potentiate
4	20	22	O	and
5	24	30	O	prolong
6	32	39	O	hypnotic
7	41	43	O	and
8	45	52	O	sedative
9	54	60	O	effects
10	61	61	O	,
11	63	72	O	especially
12	74	77	O	with
13	79	86	O	repeated
14	88	93	O	dosing
15	95	96	O	or
16	98	104	O	chronic
17	106	119	O	administration
18	121	122	O	of
19	124	128	O	these
20	130	135	O	agents
NULL

Ketoconazole	DDI-DrugBank.d458.s14	NO_SECTION	NO_SETID	12
These agents should not be used in patients treated with NIZORAL  Tablets.
1	0	4	O	These
2	6	11	O	agents
3	13	18	O	should
4	20	22	O	not
5	24	25	O	be
6	27	30	O	used
7	32	33	O	in
8	35	42	O	patients
9	44	50	O	treated
10	52	55	O	with
11	57	63	O	XXXXXXXX
12	66	72	O	Tablets
NULL

Ketoconazole	DDI-DrugBank.d458.s15	NO_SECTION	NO_SETID	17
If midazolam is administered parenterally, special precaution is required since the sedative effect may be prolonged.
1	0	1	O	If
2	3	11	U-UNK	midazolam
3	13	14	O	is
4	16	27	O	administered
5	29	40	O	parenterally
6	41	41	O	,
7	43	49	O	special
8	51	60	O	precaution
9	62	63	O	is
10	65	72	O	required
11	74	78	O	since
12	80	82	O	the
13	84	91	O	sedative
14	93	98	O	effect
15	100	102	O	may
16	104	105	O	be
17	107	115	O	prolonged
NULL

Ketoconazole	DDI-DrugBank.d458.s16	NO_SECTION	NO_SETID	11
Rare cases of elevated plasma concentrations of digoxin have been reported.
1	0	3	O	Rare
2	5	9	O	cases
3	11	12	O	of
4	14	21	O	elevated
5	23	28	O	plasma
6	30	43	O	concentrations
7	45	46	O	of
8	48	54	U-UNK	digoxin
9	56	59	O	have
10	61	64	O	been
11	66	73	O	reported
NULL

Ketoconazole	DDI-DrugBank.d458.s17	NO_SECTION	NO_SETID	13
It is not clear whether this was due to the combination of therapy.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	clear
5	16	22	O	whether
6	24	27	O	this
7	29	31	O	was
8	33	35	O	due
9	37	38	O	to
10	40	42	O	the
11	44	54	O	combination
12	56	57	O	of
13	59	65	O	therapy
NULL

Ketoconazole	DDI-DrugBank.d458.s18	NO_SECTION	NO_SETID	14
It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.
1	0	1	O	It
2	3	4	O	is
3	5	5	O	,
4	7	15	O	therefore
5	16	16	O	,
6	18	26	O	advisable
7	28	29	O	to
8	31	37	O	monitor
9	39	45	U-DYN	digoxin
10	47	60	O	concentrations
11	62	63	O	in
12	65	72	O	patients
13	74	82	O	receiving
14	84	95	O	XXXXXXXX
NULL

Ketoconazole	DDI-DrugBank.d458.s19	NO_SECTION	NO_SETID	17
When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.
1	0	3	O	When
2	5	9	O	taken
3	11	16	O	orally
4	18	18	O	,
5	20	28	B-UNK	imidazole
6	30	38	L-UNK	compounds
7	40	43	O	like
8	45	56	O	XXXXXXXX
9	58	60	O	may
10	62	68	O	enhance
11	70	72	O	the
12	74	86	O	anticoagulant
13	88	93	O	effect
14	95	96	O	of
15	98	105	U-DYN	coumarin
16	107	110	O	like
17	112	116	O	drugs
NULL

Ketoconazole	DDI-DrugBank.d458.s20	NO_SECTION	NO_SETID	19
In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.
1	0	1	O	In
2	3	14	O	simultaneous
3	16	24	O	treatment
4	26	29	O	with
5	31	39	B-UNK	imidazole
6	41	45	L-UNK	drugs
7	47	49	O	and
8	51	58	B-UNK	coumarin
9	60	64	L-UNK	drugs
10	65	65	O	,
11	67	69	O	the
12	71	83	O	anticoagulant
13	85	90	O	effect
14	92	97	O	should
15	99	100	O	be
16	102	110	O	carefully
17	112	119	O	titrated
18	121	123	O	and
19	125	133	O	monitored
NULL

Ketoconazole	DDI-DrugBank.d458.s21	NO_SECTION	NO_SETID	40
Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.
1	0	6	O	Because
2	8	13	O	severe
3	15	26	O	hypoglycemia
4	28	30	O	has
5	32	35	O	been
6	37	44	O	reported
7	46	47	O	in
8	49	56	O	patients
9	58	70	O	concomitantly
10	72	80	O	receiving
11	82	85	O	oral
12	87	96	U-UNK	miconazole
13	99	100	O	an
14	102	110	U-UNK	imidazole
15	113	115	O	and
16	117	120	O	oral
17	122	133	B-UNK	hypoglycemic
18	135	140	L-UNK	agents
19	141	141	O	,
20	143	146	O	such
21	148	148	O	a
22	150	158	O	potential
23	160	170	O	interaction
24	172	180	O	involving
25	182	184	O	the
26	186	191	O	latter
27	193	198	O	agents
28	200	203	O	when
29	205	208	O	used
30	210	222	O	concomitantly
31	224	227	O	with
32	229	240	O	XXXXXXXX
33	242	248	O	tablets
34	251	252	O	an
35	254	262	U-UNK	imidazole
36	265	267	O	can
37	269	271	O	not
38	273	274	O	be
39	276	280	O	ruled
40	282	284	O	out
NULL

Ketoconazole	DDI-DrugBank.d458.s22	NO_SECTION	NO_SETID	18
Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	41	O	XXXXXXXX
5	43	49	O	tablets
6	51	54	O	with
7	56	64	U-KIN	phenytoin
8	66	68	O	may
9	70	74	O	alter
10	76	78	O	the
11	80	89	O	metabolism
12	91	92	O	of
13	94	96	O	one
14	98	99	O	or
15	101	104	O	both
16	106	107	O	of
17	109	111	O	the
18	113	117	O	drugs
NULL

Ketoconazole	DDI-DrugBank.d458.s23	NO_SECTION	NO_SETID	9
It is suggested to monitor both ketoconazole and phenytoin.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	suggested
4	16	17	O	to
5	19	25	O	monitor
6	27	30	O	both
7	32	43	O	XXXXXXXX
8	45	47	O	and
9	49	57	U-DYN	phenytoin
NULL

Ketoconazole	DDI-DrugBank.d458.s24	NO_SECTION	NO_SETID	14
Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	37	U-KIN	rifampin
5	39	42	O	with
6	44	55	O	XXXXXXXX
7	57	63	O	tablets
8	65	71	O	reduces
9	73	75	O	the
10	77	81	O	blood
11	83	88	O	levels
12	90	91	O	of
13	93	95	O	the
14	97	102	O	latter
NULL

Ketoconazole	DDI-DrugBank.d458.s25	NO_SECTION	NO_SETID	10
INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.
1	0	2	U-KIN	INH
2	5	13	U-KIN	Isoniazid
3	16	17	O	is
4	19	22	O	also
5	24	31	O	reported
6	33	34	O	to
7	36	41	O	affect
8	43	54	O	XXXXXXXX
9	56	69	O	concentrations
10	71	79	O	adversely
NULL

Ketoconazole	DDI-DrugBank.d458.s26	NO_SECTION	NO_SETID	7
These drugs should not be given concomitantly.
1	0	4	O	These
2	6	10	O	drugs
3	12	17	O	should
4	19	21	O	not
5	23	24	O	be
6	26	30	O	given
7	32	44	O	concomitantly
NULL

Ketoconazole	DDI-DrugBank.d458.s27	NO_SECTION	NO_SETID	46
After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.
1	0	4	O	After
2	6	8	O	the
3	10	25	O	coadministration
4	27	28	O	of
5	30	32	O	200
6	34	35	O	mg
7	37	40	O	oral
8	42	53	O	XXXXXXXX
9	55	59	O	twice
10	61	65	O	daily
11	67	69	O	and
12	71	73	O	one
13	75	76	O	20
14	78	79	O	mg
15	81	84	O	dose
16	86	87	O	of
17	89	98	U-KIN	loratadine
18	100	101	O	to
19	103	104	O	11
20	106	113	O	subjects
21	114	114	O	,
22	116	118	O	the
23	120	122	O	AUC
24	124	126	O	and
25	128	131	O	Cmax
26	133	134	O	of
27	136	145	U-UNK	loratadine
28	147	154	O	averaged
29	156	159	O	302%
30	164	166	O	142
31	168	170	O	S.D
32	174	176	O	and
33	178	181	O	251%
34	186	187	O	68
35	189	191	O	S.D
36	194	194	O	,
37	196	207	O	respectively
38	208	208	O	,
39	210	211	O	of
40	213	217	O	those
41	219	226	O	obtained
42	228	232	O	after
43	234	235	O	co
44	237	245	O	treatment
45	247	250	O	with
46	252	258	O	placebo
NULL

Ketoconazole	DDI-DrugBank.d458.s28	NO_SECTION	NO_SETID	21
The AUC and Cmax of descarboethoxyloratadine, an active metabolite, averaged 155% (  27 S.D.) and 141% (  35 S.D.), respectively.
1	0	2	O	The
2	4	6	O	AUC
3	8	10	O	and
4	12	15	O	Cmax
5	17	18	O	of
6	20	43	U-UNK	descarboethoxyloratadine
7	44	44	O	,
8	46	47	O	an
9	49	54	O	active
10	56	65	O	metabolite
11	66	66	O	,
12	68	75	O	averaged
13	77	80	O	155%
14	85	86	O	27
15	88	90	O	S.D
16	94	96	O	and
17	98	101	O	141%
18	106	107	O	35
19	109	111	O	S.D
20	114	114	O	,
21	116	127	O	respectively
NULL

Ketoconazole	DDI-DrugBank.d458.s29	NO_SECTION	NO_SETID	24
However, no related changes were noted in the QT0 on ECG taken at 2, 6, and 24 hours after the coadministration.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	no
4	12	18	O	related
5	20	26	O	changes
6	28	31	O	were
7	33	37	O	noted
8	39	40	O	in
9	42	44	O	the
10	46	48	O	QT0
11	50	51	O	on
12	53	55	O	ECG
13	57	61	O	taken
14	63	64	O	at
15	66	66	O	2
16	67	67	O	,
17	69	69	O	6
18	70	70	O	,
19	72	74	O	and
20	76	77	O	24
21	79	83	O	hours
22	85	89	O	after
23	91	93	O	the
24	95	110	O	coadministration
NULL

Ketoconazole	DDI-DrugBank.d458.s30	NO_SECTION	NO_SETID	19
Also, there were no clinically significant differences in adverse events when loratadine was administered with or without ketoconazole.
1	0	3	O	Also
2	4	4	O	,
3	6	10	O	there
4	12	15	O	were
5	17	18	O	no
6	20	29	O	clinically
7	31	41	O	significant
8	43	53	O	differences
9	55	56	O	in
10	58	64	O	adverse
11	66	71	O	events
12	73	76	O	when
13	78	87	U-UNK	loratadine
14	89	91	O	was
15	93	104	O	administered
16	106	109	O	with
17	111	112	O	or
18	114	120	O	without
19	122	133	O	XXXXXXXX
NULL

Ketoconazole	DDI-DrugBank.d458.s31	NO_SECTION	NO_SETID	12
Rare cases of a disulfiram-like reaction to alcohol have been reported.
1	0	3	O	Rare
2	5	9	O	cases
3	11	12	O	of
4	14	14	O	a
5	16	25	O	disulfiram
6	27	30	O	like
7	32	39	O	reaction
8	41	42	O	to
9	44	50	U-UNK	alcohol
10	52	55	O	have
11	57	60	O	been
12	62	69	O	reported
NULL

Ketoconazole	DDI-DrugBank.d458.s32	NO_SECTION	NO_SETID	17
These experiences have been characterized by flushing, rash, peripheral edema, nausea, and headache.
1	0	4	O	These
2	6	16	O	experiences
3	18	21	O	have
4	23	26	O	been
5	28	40	O	characterized
6	42	43	O	by
7	45	52	O	flushing
8	53	53	O	,
9	55	58	O	rash
10	59	59	O	,
11	61	70	O	peripheral
12	72	76	O	edema
13	77	77	O	,
14	79	84	O	nausea
15	85	85	O	,
16	87	89	O	and
17	91	98	O	headache
NULL

Ketoconazole	DDI-DrugBank.d458.s33	NO_SECTION	NO_SETID	6
Symptoms resolved within a few hours.
1	0	7	O	Symptoms
2	9	16	O	resolved
3	18	23	O	within
4	25	25	O	a
5	27	29	O	few
6	31	35	O	hours
NULL

Ketoprofen	DDI-DrugBank.d499.s0	NO_SECTION	NO_SETID	14
The following drug interactions were studied with ketoprofen doses of 200 mg/day.
1	0	2	O	The
2	4	12	O	following
3	14	17	O	drug
4	19	30	O	interactions
5	32	35	O	were
6	37	43	O	studied
7	45	48	O	with
8	50	59	O	XXXXXXXX
9	61	65	O	doses
10	67	68	O	of
11	70	72	O	200
12	74	75	O	mg
13	76	76	O	/
14	77	79	O	day
NULL

Ketoprofen	DDI-DrugBank.d499.s1	NO_SECTION	NO_SETID	35
The possibility of increased interaction should be kept in mind when Orudis doses greater than 50 mg as a single dose or 200 mg of ketoprofen per day are used concomitantly with highly bound drugs.
1	0	2	O	The
2	4	14	O	possibility
3	16	17	O	of
4	19	27	O	increased
5	29	39	O	interaction
6	41	46	O	should
7	48	49	O	be
8	51	54	O	kept
9	56	57	O	in
10	59	62	O	mind
11	64	67	O	when
12	69	74	O	XXXXXXXX
13	76	80	O	doses
14	82	88	O	greater
15	90	93	O	than
16	95	96	O	50
17	98	99	O	mg
18	101	102	O	as
19	104	104	O	a
20	106	111	O	single
21	113	116	O	dose
22	118	119	O	or
23	121	123	O	200
24	125	126	O	mg
25	128	129	O	of
26	131	140	U-UNK	ketoprofen
27	142	144	O	per
28	146	148	O	day
29	150	152	O	are
30	154	157	O	used
31	159	171	O	concomitantly
32	173	176	O	with
33	178	183	O	highly
34	185	189	O	bound
35	191	195	O	drugs
NULL

Ketoprofen	DDI-DrugBank.d499.s3	NO_SECTION	NO_SETID	26
Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.
1	0	7	U-UNK	Antacids
2	8	8	O	:
3	10	20	O	Concomitant
4	22	35	O	administration
5	37	38	O	of
6	40	48	B-UNK	magnesium
7	50	58	L-UNK	hydroxide
8	60	62	O	and
9	64	71	B-UNK	aluminum
10	73	81	L-UNK	hydroxide
11	83	86	O	does
12	88	90	O	not
13	92	100	O	interfere
14	102	105	O	with
15	107	109	O	the
16	111	114	O	rate
17	116	117	O	or
18	119	124	O	extent
19	126	127	O	of
20	129	131	O	the
21	133	142	O	absorption
22	144	145	O	of
23	147	156	U-UNK	ketoprofen
24	158	169	O	administered
25	171	172	O	as
26	174	179	O	XXXXXXXX
NULL

Ketoprofen	DDI-DrugBank.d499.s5	NO_SECTION	NO_SETID	8
Aspirin: Ketoprofen does not alter aspirin absorption;
1	0	6	O	XXXXXXXX
2	7	7	O	:
3	9	18	U-UNK	Ketoprofen
4	20	23	O	does
5	25	27	O	not
6	29	33	O	alter
7	35	41	O	XXXXXXXX
8	43	52	O	absorption
NULL

Ketoprofen	DDI-DrugBank.d499.s6	NO_SECTION	NO_SETID	41
however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.
1	0	6	O	however
2	7	7	O	,
3	9	10	O	in
4	12	12	O	a
5	14	18	O	study
6	20	21	O	of
7	23	24	O	12
8	26	31	O	normal
9	33	40	O	subjects
10	41	41	O	,
11	43	52	O	concurrent
12	54	67	O	administration
13	69	70	O	of
14	72	78	O	XXXXXXXX
15	80	88	O	decreased
16	90	99	U-KIN	ketoprofen
17	101	107	O	protein
18	109	115	O	binding
19	117	119	O	and
20	121	129	O	increased
21	131	140	U-KIN	ketoprofen
22	142	147	O	plasma
23	149	157	O	clearance
24	159	162	O	from
25	164	167	O	0.07
26	169	169	O	L
27	170	170	O	/
28	171	172	O	kg
29	173	173	O	/
30	174	174	O	h
31	176	182	O	without
32	184	190	O	XXXXXXXX
33	192	193	O	to
34	195	198	O	0.11
35	200	200	O	L
36	201	201	O	/
37	202	203	O	kg
38	204	204	O	/
39	205	205	O	h
40	207	210	O	with
41	212	218	O	XXXXXXXX
NULL

Ketoprofen	DDI-DrugBank.d499.s7	NO_SECTION	NO_SETID	11
The clinical significance of these changes has not been adequately studied.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	33	O	these
6	35	41	O	changes
7	43	45	O	has
8	47	49	O	not
9	51	54	O	been
10	56	65	O	adequately
11	67	73	O	studied
NULL

Ketoprofen	DDI-DrugBank.d499.s8	NO_SECTION	NO_SETID	11
Therefore, concurrent use of aspirin and ketoprofen is not recommended.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	concurrent
4	22	24	O	use
5	26	27	O	of
6	29	35	O	XXXXXXXX
7	37	39	O	and
8	41	50	U-DYN	ketoprofen
9	52	53	O	is
10	55	57	O	not
11	59	69	O	recommended
NULL

Ketoprofen	DDI-DrugBank.d499.s10	NO_SECTION	NO_SETID	22
Diuretic: Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.
1	0	7	U-UNK	Diuretic
2	8	8	O	:
3	10	28	U-DYN	Hydrochlorothiazide
4	29	29	O	,
5	31	35	O	given
6	37	49	O	concomitantly
7	51	54	O	with
8	56	65	O	XXXXXXXX
9	66	66	O	,
10	68	75	O	produces
11	77	77	O	a
12	79	87	O	reduction
13	89	90	O	in
14	92	98	O	urinary
15	100	108	O	potassium
16	110	112	O	and
17	114	121	O	chloride
18	123	131	O	excretion
19	133	140	O	compared
20	142	143	O	to
21	145	163	U-UNK	hydrochlorothiazide
22	165	169	O	alone
NULL

Ketoprofen	DDI-DrugBank.d499.s11	NO_SECTION	NO_SETID	24
Patients taking diuretics are at a greater risk of developing renal failure secondary to a decrease in renal blood flow caused by prostaglandin inhibition.
1	0	7	O	Patients
2	9	14	O	taking
3	16	24	U-UNK	diuretics
4	26	28	O	are
5	30	31	O	at
6	33	33	O	a
7	35	41	O	greater
8	43	46	O	risk
9	48	49	O	of
10	51	60	O	developing
11	62	66	O	renal
12	68	74	O	failure
13	76	84	O	secondary
14	86	87	O	to
15	89	89	O	a
16	91	98	O	decrease
17	100	101	O	in
18	103	107	O	renal
19	109	113	O	blood
20	115	118	O	flow
21	120	125	O	caused
22	127	128	O	by
23	130	142	O	prostaglandin
24	144	153	O	inhibition
NULL

Ketoprofen	DDI-DrugBank.d499.s13	NO_SECTION	NO_SETID	29
Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	10	O	In
4	12	12	O	a
5	14	18	O	study
6	20	21	O	in
7	23	24	O	12
8	26	33	O	patients
9	35	38	O	with
10	40	49	O	congestive
11	51	55	O	heart
12	57	63	O	failure
13	65	69	O	where
14	71	80	O	XXXXXXXX
15	82	84	O	and
16	86	92	U-UNK	digoxin
17	94	97	O	were
18	99	111	O	concomitantly
19	113	124	O	administered
20	125	125	O	,
21	127	136	O	XXXXXXXX
22	138	140	O	did
23	142	144	O	not
24	146	150	O	alter
25	152	154	O	the
26	156	160	O	serum
27	162	167	O	levels
28	169	170	O	of
29	172	178	U-UNK	digoxin
NULL

Ketoprofen	DDI-DrugBank.d499.s15	NO_SECTION	NO_SETID	26
Warfarin: In a short-term controlled study in 14 normal volunteers, ketoprofen did not significantly interfere with the effect of warfarin on prothrombin time.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	11	O	In
4	13	13	O	a
5	15	19	O	short
6	21	24	O	term
7	26	35	O	controlled
8	37	41	O	study
9	43	44	O	in
10	46	47	O	14
11	49	54	O	normal
12	56	65	O	volunteers
13	66	66	O	,
14	68	77	O	XXXXXXXX
15	79	81	O	did
16	83	85	O	not
17	87	99	O	significantly
18	101	109	O	interfere
19	111	114	O	with
20	116	118	O	the
21	120	125	O	effect
22	127	128	O	of
23	130	137	U-UNK	warfarin
24	139	140	O	on
25	142	152	O	prothrombin
26	154	157	O	time
NULL

Ketoprofen	DDI-DrugBank.d499.s16	NO_SECTION	NO_SETID	21
Bleeding from a number of sites may be a complication of warfarin treatment and GI bleeding a complication of ketoprofen treatment.
1	0	7	O	Bleeding
2	9	12	O	from
3	14	14	O	a
4	16	21	O	number
5	23	24	O	of
6	26	30	O	sites
7	32	34	O	may
8	36	37	O	be
9	39	39	O	a
10	41	52	O	complication
11	54	55	O	of
12	57	64	U-UNK	warfarin
13	66	74	O	treatment
14	76	78	O	and
15	80	81	O	GI
16	83	90	O	bleeding
17	92	92	O	a
18	94	105	O	complication
19	107	108	O	of
20	110	119	O	XXXXXXXX
21	121	129	O	treatment
NULL

Ketoprofen	DDI-DrugBank.d499.s17	NO_SECTION	NO_SETID	33
Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs.
1	0	6	O	Because
2	8	21	O	prostaglandina
3	23	26	O	play
4	28	29	O	an
5	31	39	O	important
6	41	44	O	role
7	46	47	O	in
8	49	58	O	hemostasis
9	60	62	O	and
10	64	73	O	XXXXXXXX
11	75	77	O	has
12	79	80	O	an
13	82	87	O	effect
14	89	90	O	on
15	92	99	O	platelet
16	101	108	O	function
17	110	111	O	as
18	113	116	O	well
19	117	117	O	,
20	119	127	O	concurent
21	129	135	O	therapy
22	137	140	O	with
23	142	151	O	XXXXXXXX
24	153	155	O	and
25	157	164	U-DYN	warfarin
26	166	173	O	requires
27	175	179	O	close
28	181	190	O	monitoring
29	192	193	O	of
30	195	202	O	patients
31	204	205	O	on
32	207	210	O	both
33	212	216	O	drugs
NULL

Ketoprofen	DDI-DrugBank.d499.s19	NO_SECTION	NO_SETID	28
Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.
1	0	9	U-UNK	Probenecid
2	10	10	O	:
3	12	21	U-KIN	Probenecid
4	23	31	O	increases
5	33	36	O	both
6	38	41	O	free
7	43	45	O	and
8	47	51	O	bound
9	53	62	O	XXXXXXXX
10	64	65	O	by
11	67	74	O	reducing
12	76	78	O	the
13	80	85	O	plasma
14	87	95	O	clearance
15	97	98	O	of
16	100	109	O	XXXXXXXX
17	111	112	O	to
18	114	118	O	about
19	120	122	O	one
20	124	128	O	third
21	129	129	O	,
22	131	132	O	as
23	134	137	O	well
24	139	140	O	as
25	142	151	O	decreasing
26	153	155	O	its
27	157	163	O	protein
28	165	171	O	binding
NULL

Ketoprofen	DDI-DrugBank.d499.s20	NO_SECTION	NO_SETID	11
Therefore, the combination of ketoprofen and probenecid is not recommended.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	25	O	combination
5	27	28	O	of
6	30	39	O	XXXXXXXX
7	41	43	O	and
8	45	54	U-DYN	probenecid
9	56	57	O	is
10	59	61	O	not
11	63	73	O	recommended
NULL

Ketoprofen	DDI-DrugBank.d499.s22	NO_SECTION	NO_SETID	27
Methotrexate: Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.
1	0	11	U-UNK	Methotrexate
2	12	12	O	:
3	14	23	O	XXXXXXXX
4	24	24	O	,
5	26	29	O	like
6	31	35	O	other
7	37	42	U-UNK	NSAIDs
8	43	43	O	,
9	45	47	O	may
10	49	53	O	cause
11	55	61	O	changes
12	63	64	O	in
13	66	68	O	the
14	70	80	O	elimination
15	82	83	O	of
16	85	96	U-KIN	methotrexate
17	98	104	O	leading
18	106	107	O	to
19	109	116	O	elevated
20	118	122	O	serum
21	124	129	O	levels
22	131	132	O	of
23	134	136	O	the
24	138	141	O	drug
25	143	145	O	and
26	147	155	O	increased
27	157	164	O	toxicity
NULL

Ketoprofen	DDI-DrugBank.d499.s24	NO_SECTION	NO_SETID	15
Lithium: Nonsteroidal anti-inflammatory agents have been reported to increase steadystate plasma lithium levels.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	20	B-UNK	Nonsteroidal
4	22	25	I-UNK	anti
5	27	38	I-UNK	inflammatory
6	40	45	L-UNK	agents
7	47	50	O	have
8	52	55	O	been
9	57	64	O	reported
10	66	67	O	to
11	69	76	O	increase
12	78	88	O	steadystate
13	90	95	O	plasma
14	97	103	U-UNK	lithium
15	105	110	O	levels
NULL

Ketoprofen	DDI-DrugBank.d499.s25	NO_SECTION	NO_SETID	15
It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	28	O	plasma
6	30	36	U-UNK	lithium
7	38	43	O	levels
8	45	46	O	be
9	48	56	O	monitored
10	58	61	O	when
11	63	72	O	XXXXXXXX
12	74	75	O	is
13	77	90	O	coadministered
14	92	95	O	with
15	97	103	U-DYN	lithium
NULL

Ketoprofen	DDI-DrugBank.d499.s26	NO_SECTION	NO_SETID	16
DRUG/LABORATORY TEST INTERACTIONS: EFFECT ON BLOOD COAGULATION Ketoprofen decreases platelet adhesion and aggregation.
1	0	3	O	DRUG
2	4	4	O	/
3	5	14	O	LABORATORY
4	16	19	O	TEST
5	21	32	O	INTERACTIONS
6	33	33	O	:
7	35	40	O	EFFECT
8	42	43	O	ON
9	45	49	O	BLOOD
10	51	61	O	COAGULATION
11	63	72	O	XXXXXXXX
12	74	82	O	decreases
13	84	91	O	platelet
14	93	100	O	adhesion
15	102	104	O	and
16	106	116	O	aggregation
NULL

Ketoprofen	DDI-DrugBank.d499.s27	NO_SECTION	NO_SETID	16
Therefore, it can prolong bleeding time by approximately 3 to 4 minutes from baseline values.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	it
4	14	16	O	can
5	18	24	O	prolong
6	26	33	O	bleeding
7	35	38	O	time
8	40	41	O	by
9	43	55	O	approximately
10	57	57	O	3
11	59	60	O	to
12	62	62	O	4
13	64	70	O	minutes
14	72	75	O	from
15	77	84	O	baseline
16	86	91	O	values
NULL

Ketoprofen	DDI-DrugBank.d499.s28	NO_SECTION	NO_SETID	19
There is no significant change in platelet count, prothrombin time, partial thromboplastin time, or thrombin time.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	22	O	significant
5	24	29	O	change
6	31	32	O	in
7	34	41	O	platelet
8	43	47	O	count
9	48	48	O	,
10	50	60	O	prothrombin
11	62	65	O	time
12	66	66	O	,
13	68	74	O	partial
14	76	89	O	thromboplastin
15	91	94	O	time
16	95	95	O	,
17	97	98	O	or
18	100	107	O	thrombin
19	109	112	O	time
NULL

Ketorolac	DDI-DrugBank.d3.s0	NO_SECTION	NO_SETID	10
Ketorolac is highly bound to human plasma protein (mean 99.2%).
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	18	O	highly
4	20	24	O	bound
5	26	27	O	to
6	29	33	O	human
7	35	40	O	plasma
8	42	48	O	protein
9	51	54	O	mean
10	56	60	O	99.2%
NULL

Ketorolac	DDI-DrugBank.d3.s1	NO_SECTION	NO_SETID	39
Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.
1	0	7	U-UNK	Warfarin
2	8	8	O	,
3	10	16	U-UNK	Digoxin
4	17	17	O	,
5	19	28	U-UNK	Salicylate
6	29	29	O	,
7	31	33	O	and
8	35	41	U-UNK	Heparin
9	43	45	O	The
10	47	48	O	in
11	50	54	O	vitro
12	56	62	O	binding
13	64	65	O	of
14	67	74	U-KIN	warfarin
15	76	77	O	to
16	79	84	O	plasma
17	86	93	O	proteins
18	95	96	O	is
19	98	101	O	only
20	103	110	O	slightly
21	112	118	O	reduced
22	120	121	O	by
23	123	131	O	XXXXXXXX
24	133	144	O	tromethamine
25	147	151	O	99.5%
26	153	159	O	control
27	161	162	O	vs
28	164	168	O	99.3%
29	171	174	O	when
30	176	184	O	XXXXXXXX
31	186	191	O	plasma
32	193	206	O	concentrations
33	208	212	O	reach
34	214	214	O	5
35	216	219	O	to10
36	221	221	O	m
37	223	223	O	g
38	224	224	O	/
39	225	226	O	mL
NULL

Ketorolac	DDI-DrugBank.d3.s2	NO_SECTION	NO_SETID	7
Ketorolac does not alter digoxin protein binding.
1	0	8	O	XXXXXXXX
2	10	13	O	does
3	15	17	O	not
4	19	23	O	alter
5	25	31	U-UNK	digoxin
6	33	39	O	protein
7	41	47	O	binding
NULL

Ketorolac	DDI-DrugBank.d3.s3	NO_SECTION	NO_SETID	39
In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	24	O	indicate
5	26	29	O	that
6	30	30	O	,
7	32	33	O	at
8	35	45	O	therapeutic
9	47	60	O	concentrations
10	62	63	O	of
11	65	74	U-KIN	salicylate
12	77	79	O	300
13	81	81	O	m
14	83	83	O	g
15	84	84	O	/
16	85	86	O	mL
17	88	88	O	,
18	90	92	O	the
19	94	100	O	binding
20	102	103	O	of
21	105	113	O	XXXXXXXX
22	115	117	O	was
23	119	125	O	reduced
24	127	130	O	from
25	132	144	O	approximately
26	146	150	O	99.2%
27	152	153	O	to
28	155	159	O	97.5%
29	160	160	O	,
30	162	173	O	representing
31	175	175	O	a
32	177	185	O	potential
33	187	193	O	twofold
34	195	202	O	increase
35	204	205	O	in
36	207	213	O	unbound
37	215	223	O	XXXXXXXX
38	225	230	O	plasma
39	232	237	O	levels
NULL

Ketorolac	DDI-DrugBank.d3.s4	NO_SECTION	NO_SETID	24
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.
1	0	10	O	Therapeutic
2	12	25	O	concentrations
3	27	28	O	of
4	30	36	U-UNK	digoxin
5	37	37	O	,
6	39	46	U-UNK	warfarin
7	47	47	O	,
8	49	57	U-UNK	ibuprofen
9	58	58	O	,
10	60	67	U-UNK	naproxen
11	68	68	O	,
12	70	78	U-UNK	piroxicam
13	79	79	O	,
14	81	93	U-UNK	acetaminophen
15	94	94	O	,
16	96	104	U-UNK	phenytoin
17	106	119	O	andtolbutamide
18	121	123	O	did
19	125	127	O	not
20	129	133	O	alter
21	135	143	O	XXXXXXXX
22	145	156	O	tromethamine
23	158	164	O	protein
24	166	172	O	binding
NULL

Ketorolac	DDI-DrugBank.d3.s5	NO_SECTION	NO_SETID	30
In a study involving 12 adult volunteers, TORADOLORAL was coadministered with a single dose of 25 mg warfarin, causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	19	O	involving
5	21	22	O	12
6	24	28	O	adult
7	30	39	O	volunteers
8	40	40	O	,
9	42	52	O	TORADOLORAL
10	54	56	O	was
11	58	71	O	coadministered
12	73	76	O	with
13	78	78	O	a
14	80	85	O	single
15	87	90	O	dose
16	92	93	O	of
17	95	96	O	25
18	98	99	O	mg
19	101	108	U-UNK	warfarin
20	109	109	O	,
21	111	117	O	causing
22	119	120	O	no
23	122	132	O	significant
24	134	140	O	changes
25	142	143	O	in
26	145	160	O	pharmacokinetics
27	162	163	O	or
28	165	180	O	pharmacodynamics
29	182	183	O	of
30	185	192	U-UNK	warfarin
NULL

Ketorolac	DDI-DrugBank.d3.s6	NO_SECTION	NO_SETID	59
In another study, TORADOLIV/IM was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo.
1	0	1	O	In
2	3	9	O	another
3	11	15	O	study
4	16	16	O	,
5	18	26	O	TORADOLIV
6	27	27	O	/
7	28	29	O	IM
8	31	33	O	was
9	35	39	O	given
10	41	44	O	with
11	46	48	O	two
12	50	54	O	doses
13	56	57	O	of
14	59	62	O	5000
15	64	64	O	U
16	66	67	O	of
17	69	75	U-UNK	heparin
18	77	78	O	to
19	80	81	O	11
20	83	89	O	healthy
21	91	100	O	volunteers
22	101	101	O	,
23	103	111	O	resulting
24	113	114	O	in
25	116	116	O	a
26	118	121	O	mean
27	123	130	O	template
28	132	139	O	bleeding
29	141	144	O	time
30	146	147	O	of
31	149	151	O	6.4
32	153	159	O	minutes
33	162	164	O	3.2
34	166	167	O	to
35	169	172	O	11.4
36	174	176	O	min
37	179	186	O	compared
38	188	189	O	to
39	191	191	O	a
40	193	196	O	mean
41	198	199	O	of
42	201	203	O	6.0
43	205	211	O	minutes
44	214	216	O	3.4
45	218	219	O	to
46	221	223	O	7.5
47	225	227	O	min
48	230	232	O	for
49	234	240	U-UNK	heparin
50	242	246	O	alone
51	248	250	O	and
52	252	254	O	5.1
53	256	262	O	minutes
54	265	267	O	3.5
55	269	270	O	to
56	272	274	O	8.5
57	276	278	O	min
58	281	283	O	for
59	285	291	O	placebo
NULL

Ketorolac	DDI-DrugBank.d3.s7	NO_SECTION	NO_SETID	36
Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.
1	0	7	O	Although
2	9	13	O	these
3	15	21	O	results
4	23	24	O	do
5	26	28	O	not
6	30	37	O	indicate
7	39	39	O	a
8	41	51	O	significant
9	53	63	O	interaction
10	65	71	O	between
11	73	79	O	XXXXXXXX
12	81	83	O	and
13	85	92	U-UNK	warfarin
14	94	95	O	or
15	97	103	U-UNK	heparin
16	104	104	O	,
17	106	108	O	the
18	110	123	O	administration
19	125	126	O	of
20	128	134	O	XXXXXXXX
21	136	137	O	to
22	139	146	O	patients
23	148	153	O	taking
24	155	168	U-DYN	anticoagulants
25	170	175	O	should
26	177	178	O	be
27	180	183	O	done
28	185	193	O	extremely
29	195	204	O	cautiously
30	205	205	O	,
31	207	209	O	and
32	211	218	O	patients
33	220	225	O	should
34	227	228	O	be
35	230	236	O	closely
36	238	246	O	monitored
NULL

Ketorolac	DDI-DrugBank.d3.s8	NO_SECTION	NO_SETID	26
Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
1	0	9	U-UNK	Furosemide
2	10	10	O	:
3	12	18	O	XXXXXXXX
4	20	21	O	IV
5	22	22	O	/
6	23	24	O	IM
7	26	32	O	reduced
8	34	36	O	the
9	38	45	U-UNK	diuretic
10	47	54	O	response
11	56	57	O	to
12	59	68	U-DYN	furosemide
13	70	71	O	in
14	73	84	O	normovolemic
15	86	92	O	healthy
16	94	101	O	subjects
17	103	104	O	by
18	106	118	O	approximately
19	120	122	O	20%
20	125	128	O	mean
21	130	135	O	sodium
22	137	139	O	and
23	141	147	O	urinary
24	149	154	O	output
25	156	164	O	decreased
26	166	168	O	17%
NULL

Ketorolac	DDI-DrugBank.d3.s9	NO_SECTION	NO_SETID	49
Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.
1	0	9	U-UNK	Probenecid
2	10	10	O	:
3	12	22	O	Concomitant
4	24	37	O	administration
5	39	40	O	of
6	42	48	O	XXXXXXXX
7	50	53	O	ORAL
8	55	57	O	and
9	59	68	U-KIN	probenecid
10	70	77	O	resulted
11	79	80	O	in
12	82	90	O	decreased
13	92	100	O	clearance
14	102	103	O	of
15	105	113	U-UNK	ketorolac
16	115	117	O	and
17	119	129	O	significant
18	131	139	O	increases
19	141	142	O	in
20	144	152	U-UNK	ketorolac
21	154	159	O	plasma
22	161	166	O	levels
23	169	173	O	total
24	175	177	O	AUC
25	179	187	O	increased
26	189	201	O	approximately
27	203	211	O	threefold
28	213	216	O	from
29	218	220	O	5.4
30	222	223	O	to
31	225	228	O	17.8
32	230	230	O	m
33	232	232	O	g
34	233	233	O	/
35	234	234	O	h
36	235	235	O	/
37	236	237	O	mL
38	240	242	O	and
39	244	251	O	terminal
40	253	256	O	half
41	258	261	O	life
42	263	271	O	increased
43	273	285	O	approximately
44	287	293	O	twofold
45	295	298	O	from
46	300	302	O	6.6
47	304	305	O	to
48	307	310	O	15.1
49	312	316	O	hours
NULL

Ketorolac	DDI-DrugBank.d3.s10	NO_SECTION	NO_SETID	10
Therefore, concomitant use of TORADOL and probenecid is contraindicated.
1	0	8	O	Therefore
2	9	9	O	,
3	11	21	O	concomitant
4	23	25	O	use
5	27	28	O	of
6	30	36	O	XXXXXXXX
7	38	40	O	and
8	42	51	U-DYN	probenecid
9	53	54	O	is
10	56	70	O	contraindicated
NULL

Ketorolac	DDI-DrugBank.d3.s11	NO_SECTION	NO_SETID	26
Lithium: Inhibition of renal lithium clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	18	O	Inhibition
4	20	21	O	of
5	23	27	O	renal
6	29	35	U-UNK	lithium
7	37	45	O	clearance
8	46	46	O	,
9	48	54	O	leading
10	56	57	O	to
11	59	60	O	an
12	62	69	O	increase
13	71	72	O	in
14	74	79	O	plasma
15	81	87	U-UNK	lithium
16	89	101	O	concentration
17	102	102	O	,
18	104	106	O	has
19	108	111	O	been
20	113	120	O	reported
21	122	125	O	with
22	127	130	O	some
23	132	144	O	prostaglandin
24	146	154	O	synthesis
25	156	165	O	inhibiting
26	167	171	O	drugs
NULL

Ketorolac	DDI-DrugBank.d3.s12	NO_SECTION	NO_SETID	25
The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	20	O	XXXXXXXX
5	22	23	O	on
6	25	30	O	plasma
7	32	38	U-UNK	lithium
8	40	42	O	has
9	44	46	O	not
10	48	51	O	been
11	53	59	O	studied
12	60	60	O	,
13	62	64	O	but
14	66	70	O	cases
15	72	73	O	of
16	75	83	O	increased
17	85	91	U-KIN	lithium
18	93	98	O	plasma
19	100	105	O	levels
20	107	112	O	during
21	114	120	O	XXXXXXXX
22	122	128	O	therapy
23	130	133	O	have
24	135	138	O	been
25	140	147	O	reported
NULL

Ketorolac	DDI-DrugBank.d3.s13	NO_SECTION	NO_SETID	24
Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.
1	0	11	U-UNK	Methotrexate
2	12	12	O	:
3	14	24	O	Concomitant
4	26	39	O	administration
5	41	42	O	of
6	44	55	U-UNK	methotrexate
7	57	59	O	and
8	61	64	O	some
9	66	71	U-UNK	NSAIDs
10	73	75	O	has
11	77	80	O	been
12	82	89	O	reported
13	91	92	O	to
14	94	99	O	reduce
15	101	103	O	the
16	105	113	O	clearance
17	115	116	O	of
18	118	129	U-UNK	methotrexate
19	130	130	O	,
20	132	140	O	enhancing
21	142	144	O	the
22	146	153	O	toxicity
23	155	156	O	of
24	158	169	U-UNK	methotrexate
NULL

Ketorolac	DDI-DrugBank.d3.s14	NO_SECTION	NO_SETID	11
The effect of TORADOL on methotrexate clearance has not been studied.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	20	O	XXXXXXXX
5	22	23	O	on
6	25	36	U-UNK	methotrexate
7	38	46	O	clearance
8	48	50	O	has
9	52	54	O	not
10	56	59	O	been
11	61	67	O	studied
NULL

Ketorolac	DDI-DrugBank.d3.s15	NO_SECTION	NO_SETID	27
Nondepolarizing Muscle Relaxants: In postmarketing experience there have been reports of a possible interaction between TORADOLIV/IM and nondepolarizing muscle relaxants that resulted in apnea.
1	0	14	B-UNK	Nondepolarizing
2	16	21	I-UNK	Muscle
3	23	31	L-UNK	Relaxants
4	32	32	O	:
5	34	35	O	In
6	37	49	O	postmarketing
7	51	60	O	experience
8	62	66	O	there
9	68	71	O	have
10	73	76	O	been
11	78	84	O	reports
12	86	87	O	of
13	89	89	O	a
14	91	98	O	possible
15	100	110	O	interaction
16	112	118	O	between
17	120	128	O	TORADOLIV
18	129	129	O	/
19	130	131	O	IM
20	133	135	O	and
21	137	151	B-UNK	nondepolarizing
22	153	158	I-UNK	muscle
23	160	168	L-UNK	relaxants
24	170	173	O	that
25	175	182	O	resulted
26	184	185	O	in
27	187	191	O	apnea
NULL

Ketorolac	DDI-DrugBank.d3.s16	NO_SECTION	NO_SETID	13
The concurrent use of TORADOL with muscle relaxants has not been formally studied.
1	0	2	O	The
2	4	13	O	concurrent
3	15	17	O	use
4	19	20	O	of
5	22	28	O	XXXXXXXX
6	30	33	O	with
7	35	40	B-UNK	muscle
8	42	50	L-UNK	relaxants
9	52	54	O	has
10	56	58	O	not
11	60	63	O	been
12	65	72	O	formally
13	74	80	O	studied
NULL

Ketorolac	DDI-DrugBank.d3.s17	NO_SECTION	NO_SETID	21
ACE Inhibitors: Concomitant use of ACE inhibitors may increase the risk of renal impairment, particularly in volume-depleted patients.
1	0	2	B-UNK	ACE
2	4	13	L-UNK	Inhibitors
3	14	14	O	:
4	16	26	O	Concomitant
5	28	30	O	use
6	32	33	O	of
7	35	37	B-UNK	ACE
8	39	48	L-UNK	inhibitors
9	50	52	O	may
10	54	61	O	increase
11	63	65	O	the
12	67	70	O	risk
13	72	73	O	of
14	75	79	O	renal
15	81	90	O	impairment
16	91	91	O	,
17	93	104	O	particularly
18	106	107	O	in
19	109	114	O	volume
20	116	123	O	depleted
21	125	132	O	patients
NULL

Ketorolac	DDI-DrugBank.d3.s18	NO_SECTION	NO_SETID	21
Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).
1	0	12	B-UNK	Antiepileptic
2	14	18	L-UNK	Drugs
3	19	19	O	:
4	21	28	O	Sporadic
5	30	34	O	cases
6	36	37	O	of
7	39	46	O	seizures
8	48	51	O	have
9	53	56	O	been
10	58	65	O	reported
11	67	72	O	during
12	74	84	O	concomitant
13	86	88	O	use
14	90	91	O	of
15	93	99	O	XXXXXXXX
16	101	103	O	and
17	105	117	B-DYN	antiepileptic
18	119	123	L-DYN	drugs
19	126	134	U-DYN	phenytoin
20	135	135	O	,
21	137	149	U-DYN	carbamazepine
NULL

Ketorolac	DDI-DrugBank.d3.s19	NO_SECTION	NO_SETID	21
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).
1	0	11	B-UNK	Psychoactive
2	13	17	L-UNK	Drugs
3	18	18	O	:
4	20	33	O	Hallucinations
5	35	38	O	have
6	40	43	O	been
7	45	52	O	reported
8	54	57	O	when
9	59	65	O	XXXXXXXX
10	67	69	O	was
11	71	74	O	used
12	76	77	O	in
13	79	86	O	patients
14	88	93	O	taking
15	95	106	B-DYN	psychoactive
16	108	112	L-DYN	drugs
17	115	124	U-DYN	fluoxetine
18	125	125	O	,
19	127	137	U-DYN	thiothixene
20	138	138	O	,
21	140	149	U-DYN	alprazolam
NULL

Ketorolac	DDI-DrugBank.d3.s20	NO_SECTION	NO_SETID	23
Morphine: TORADOLIV/IM has been administered concurrently with morphine in several clinical trials of postoperative pain without evidence of adverse interactions.
1	0	7	U-UNK	Morphine
2	8	8	O	:
3	10	18	O	TORADOLIV
4	19	19	O	/
5	20	21	O	IM
6	23	25	O	has
7	27	30	O	been
8	32	43	O	administered
9	45	56	O	concurrently
10	58	61	O	with
11	63	70	U-UNK	morphine
12	72	73	O	in
13	75	81	O	several
14	83	90	O	clinical
15	92	97	O	trials
16	99	100	O	of
17	102	114	O	postoperative
18	116	119	O	pain
19	121	127	O	without
20	129	136	O	evidence
21	138	139	O	of
22	141	147	O	adverse
23	149	160	O	interactions
NULL

Ketorolac	DDI-DrugBank.d3.s21	NO_SECTION	NO_SETID	10
Do not mix TORADOL and morphine in the same syringe.
1	0	1	O	Do
2	3	5	O	not
3	7	9	O	mix
4	11	17	O	XXXXXXXX
5	19	21	O	and
6	23	30	U-UNK	morphine
7	32	33	O	in
8	35	37	O	the
9	39	42	O	same
10	44	50	O	syringe
NULL

Ketorolac	DDI-DrugBank.d3.s22	NO_SECTION	NO_SETID	23
There is no evidence in animal or human studies that TORADOL induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	19	O	evidence
5	21	22	O	in
6	24	29	O	animal
7	31	32	O	or
8	34	38	O	human
9	40	46	O	studies
10	48	51	O	that
11	53	59	O	XXXXXXXX
12	61	67	O	induces
13	69	70	O	or
14	72	79	O	inhibits
15	81	87	O	hepatic
16	89	95	O	enzymes
17	97	103	O	capable
18	105	106	O	of
19	108	119	O	metabolizing
20	121	126	O	itself
21	128	129	O	or
22	131	135	O	other
23	137	141	O	drugs
NULL

L-Arginine	DDI-DrugBank.d95.s0	NO_SECTION	NO_SETID	9
Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.
1	0	11	U-UNK	Cyclosporine
2	15	24	O	XXXXXXXX
3	26	28	O	may
4	30	39	O	counteract
5	41	43	O	the
6	45	57	O	antinaturetic
7	59	64	O	effect
8	66	67	O	of
9	69	79	U-DYN	cyclosporin
NULL

L-Arginine	DDI-DrugBank.d95.s1	NO_SECTION	NO_SETID	11
Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.
1	0	8	U-UNK	Ibuprofen
2	12	21	O	XXXXXXXX
3	23	25	O	may
4	27	34	O	increase
5	36	38	O	the
6	40	49	O	absorption
7	51	52	O	of
8	54	62	U-KIN	ibuprofen
9	64	65	O	if
10	67	71	O	taken
11	73	85	O	concomitantly
NULL

L-Arginine	DDI-DrugBank.d95.s2	NO_SECTION	NO_SETID	15
Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.
1	0	6	O	Organic
2	8	15	U-UNK	nitrates
3	19	28	O	XXXXXXXX
4	30	40	O	supplements
5	42	54	O	theoretically
6	56	58	O	may
7	60	69	O	potentiate
8	71	73	O	the
9	75	81	O	effects
10	83	84	O	of
11	86	92	O	organic
12	94	101	U-DYN	nitrates
13	103	104	O	if
14	106	110	O	taken
15	112	124	O	concomitantly
NULL

L-Arginine	DDI-DrugBank.d95.s3	NO_SECTION	NO_SETID	19
Sildenafil citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.
1	0	9	B-UNK	Sildenafil
2	11	17	L-UNK	citrate
3	21	33	O	Theoretically
4	34	34	O	,
5	36	45	O	XXXXXXXX
6	47	57	O	supplements
7	59	63	O	taken
8	65	77	O	concomitantly
9	79	82	O	with
10	84	93	B-DYN	sildenafil
11	95	101	L-DYN	citrate
12	102	102	O	,
13	104	106	O	may
14	108	117	O	potentiate
15	119	121	O	the
16	123	129	O	effects
17	131	132	O	of
18	134	136	O	the
19	138	141	O	drug
NULL

L-Aspartic Acid	DDI-DrugBank.d243.s0	NO_SECTION	NO_SETID	12
No drug, nutritional supplement, food or herb interactions are known.
1	0	1	O	No
2	3	6	O	drug
3	7	7	O	,
4	9	19	O	nutritional
5	21	30	O	supplement
6	31	31	O	,
7	33	36	O	food
8	38	39	O	or
9	41	44	O	herb
10	46	57	O	interactions
11	59	61	O	are
12	63	67	O	known
NULL

L-Carnitine	DDI-DrugBank.d539.s0	NO_SECTION	NO_SETID	4
Interacts with valproic acid
1	0	8	O	Interacts
2	10	13	O	with
3	15	22	B-UNK	valproic
4	24	27	L-UNK	acid
NULL

L-Glutamic Acid	DDI-DrugBank.d92.s0	NO_SECTION	NO_SETID	8
No well-known drug interactions with glutamic acid
1	0	1	O	No
2	3	6	O	well
3	8	12	O	known
4	14	17	O	drug
5	19	30	O	interactions
6	32	35	O	with
7	37	44	B-UNK	glutamic
8	46	49	L-UNK	acid
NULL

L-Glutamine	DDI-DrugBank.d66.s0	NO_SECTION	NO_SETID	22
Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.
1	0	4	B-UNK	Human
2	6	11	I-UNK	growth
3	13	19	L-UNK	hormone
4	23	33	O	Concomitant
5	35	37	O	use
6	39	40	O	of
7	42	52	O	XXXXXXXX
8	54	56	O	and
9	58	62	B-KIN	human
10	64	69	I-KIN	growth
11	71	77	L-KIN	hormone
12	79	81	O	may
13	83	89	O	enhance
14	91	98	O	nutrient
15	100	109	O	absorption
16	111	112	O	in
17	114	118	O	those
18	120	123	O	with
19	125	130	O	severe
20	132	136	O	short
21	138	142	O	bowel
22	144	151	O	syndrome
NULL

L-Glutamine	DDI-DrugBank.d66.s1	NO_SECTION	NO_SETID	8
L-glutamine has orphan drug status for this indication.
1	0	10	O	XXXXXXXX
2	12	14	O	has
3	16	21	O	orphan
4	23	26	O	drug
5	28	33	O	status
6	35	37	O	for
7	39	42	O	this
8	44	53	O	indication
NULL

L-Glutamine	DDI-DrugBank.d66.s2	NO_SECTION	NO_SETID	15
Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.
1	0	11	U-UNK	Indomethacin
2	15	25	O	Concomitant
3	27	29	O	use
4	31	32	O	of
5	34	44	O	XXXXXXXX
6	46	48	O	and
7	50	61	U-DYN	indomethacin
8	63	65	O	may
9	67	76	O	ameliorate
10	78	86	O	increased
11	88	97	O	intestinal
12	99	110	O	permeability
13	112	117	O	caused
14	119	120	O	by
15	122	133	U-UNK	indomethacin
NULL

L-Glutamine	DDI-DrugBank.d66.s3	NO_SECTION	NO_SETID	18
The reported dose used for L-glutamine was 21 grams daily taken in divided doses three times a day.
1	0	2	O	The
2	4	11	O	reported
3	13	16	O	dose
4	18	21	O	used
5	23	25	O	for
6	27	37	O	XXXXXXXX
7	39	41	O	was
8	43	44	O	21
9	46	50	O	grams
10	52	56	O	daily
11	58	62	O	taken
12	64	65	O	in
13	67	73	O	divided
14	75	79	O	doses
15	81	85	O	three
16	87	91	O	times
17	93	93	O	a
18	95	97	O	day
NULL

L-Glutamine	DDI-DrugBank.d66.s4	NO_SECTION	NO_SETID	17
Further, misoprostol is reported to have a synergistic effect with this combination in ameliorating intestinal permeability.
1	0	6	O	Further
2	7	7	O	,
3	9	19	U-UNK	misoprostol
4	21	22	O	is
5	24	31	O	reported
6	33	34	O	to
7	36	39	O	have
8	41	41	O	a
9	43	53	O	synergistic
10	55	60	O	effect
11	62	65	O	with
12	67	70	O	this
13	72	82	O	combination
14	84	85	O	in
15	87	98	O	ameliorating
16	100	109	O	intestinal
17	111	122	O	permeability
NULL

L-Glutamine	DDI-DrugBank.d66.s5	NO_SECTION	NO_SETID	19
Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.
1	0	11	U-UNK	Methotrexate
2	15	19	O	There
3	21	22	O	is
4	24	26	O	one
5	28	33	O	report
6	35	38	O	that
7	40	51	U-DYN	methotrexate
8	53	55	O	may
9	57	64	O	decrease
10	66	68	O	the
11	70	77	O	possible
12	79	91	O	effectiveness
13	93	94	O	of
14	96	107	O	supplemental
15	109	119	O	XXXXXXXX
16	121	123	O	for
17	125	136	O	chemotherapy
18	138	144	O	induced
19	146	154	O	mucositis
NULL

L-Glutamine	DDI-DrugBank.d66.s6	NO_SECTION	NO_SETID	33
In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.
1	0	1	O	In
2	3	9	O	another
3	11	16	O	report
4	17	17	O	,
5	19	22	O	nine
6	24	31	O	patients
7	33	36	O	with
8	38	43	O	breast
9	45	50	O	cancer
10	52	55	O	were
11	57	64	O	reported
12	66	67	O	to
13	69	72	O	have
14	74	82	O	decreased
15	84	91	O	symptoms
16	93	94	O	of
17	96	107	U-DYN	methotrexate
18	109	115	O	related
19	117	124	O	toxicity
20	126	129	O	when
21	131	135	O	given
22	137	148	O	supplemental
23	150	160	O	XXXXXXXX
24	162	163	O	at
25	165	165	O	a
26	167	170	O	dose
27	172	173	O	of
28	175	177	O	0.5
29	179	182	O	gram
30	183	183	O	/
31	184	191	O	kilogram
32	192	192	O	/
33	193	195	O	day
NULL

L-Glutamine	DDI-DrugBank.d66.s7	NO_SECTION	NO_SETID	37
Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.
1	0	9	U-UNK	Paclitaxel
2	13	14	O	In
3	16	18	O	one
4	20	25	O	report
5	26	26	O	,
6	28	38	O	XXXXXXXX
7	40	41	O	at
8	43	43	O	a
9	45	48	O	dose
10	50	51	O	of
11	53	54	O	10
12	56	60	O	grams
13	62	66	O	three
14	68	72	O	times
15	74	78	O	daily
16	79	79	O	,
17	81	85	O	given
18	87	88	O	24
19	90	94	O	hours
20	96	100	O	after
21	102	110	O	receiving
22	112	121	U-DYN	paclitaxel
23	122	122	O	,
24	124	131	O	appeared
25	133	134	O	to
26	136	142	O	prevent
27	144	146	O	the
28	148	158	O	development
29	160	161	O	of
30	163	169	O	myalgia
31	171	173	O	and
32	175	184	O	arthralgia
33	185	185	O	,
34	187	193	O	adverse
35	195	203	O	reactions
36	205	206	O	of
37	208	217	U-UNK	paclitaxel
NULL

L-Histidine	DDI-DrugBank.d365.s0	NO_SECTION	NO_SETID	30
Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.
1	0	18	B-UNK	Medroxyprogesterone
2	20	26	L-UNK	Acetate
3	30	40	O	XXXXXXXX
4	42	44	O	was
5	46	53	O	observed
6	55	56	O	to
7	58	64	O	enhance
8	67	68	O	in
9	70	75	O	tissue
10	77	83	O	culture
11	86	88	O	the
12	90	95	O	effect
13	97	98	O	of
14	100	118	B-DYN	medroxyprogesterone
15	120	126	L-DYN	acetate
16	128	129	O	in
17	131	138	O	reducing
18	140	142	O	the
19	144	149	O	number
20	151	152	O	of
21	154	158	O	human
22	160	165	O	breast
23	167	172	O	cancer
24	174	178	O	cells
25	180	183	O	that
26	185	188	O	were
27	190	191	O	in
28	193	195	O	the
29	197	197	O	S
30	199	203	O	phase
NULL

L-Histidine	DDI-DrugBank.d365.s1	NO_SECTION	NO_SETID	25
H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.
1	0	1	B-UNK	H1
2	3	5	I-UNK	and
3	7	8	I-UNK	H2
4	10	17	L-UNK	Blockers
5	21	28	O	Although
6	30	32	O	not
7	34	41	O	reported
8	42	42	O	,
9	44	54	O	XXXXXXXX
10	55	55	O	,
11	57	59	O	via
12	61	63	O	its
13	65	74	O	metabolism
14	76	77	O	to
15	79	87	O	histamine
16	88	88	O	,
17	90	94	O	might
18	96	103	O	decrease
19	105	107	O	the
20	109	116	O	efficacy
21	118	119	O	of
22	121	122	B-UNK	H1
23	124	126	I-UNK	and
24	128	129	I-UNK	H2
25	131	138	L-UNK	blockers
NULL

L-Lysine	DDI-DrugBank.d344.s0	NO_SECTION	NO_SETID	11
Concomitant use of calcium supplements and L-lysine may increase calcium absorption
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	25	U-KIN	calcium
5	27	37	O	supplements
6	39	41	O	and
7	43	50	O	XXXXXXXX
8	52	54	O	may
9	56	63	O	increase
10	65	71	U-UNK	calcium
11	73	82	O	absorption
NULL

L-Methionine	DDI-DrugBank.d528.s0	NO_SECTION	NO_SETID	18
Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.
1	0	12	U-UNK	Acetaminophen
2	14	16	O	and
3	18	29	U-UNK	methotrexate
4	33	44	O	XXXXXXXX
5	46	48	O	may
6	50	57	O	decrease
7	59	65	O	hepatic
8	67	74	O	toxicity
9	76	77	O	in
10	79	83	O	those
11	85	88	O	with
12	90	102	U-DYN	acetaminophen
13	104	113	O	overdosage
14	115	116	O	or
15	118	119	O	in
16	121	125	O	those
17	127	132	O	taking
18	134	145	U-DYN	methotrexate
NULL

L-Methionine	DDI-DrugBank.d528.s1	NO_SECTION	NO_SETID	18
Theoretically, it may decrease hepatic toxicity in the case of other potential hepatotoxic drugs, as well.
1	0	12	O	Theoretically
2	13	13	O	,
3	15	16	O	it
4	18	20	O	may
5	22	29	O	decrease
6	31	37	O	hepatic
7	39	46	O	toxicity
8	48	49	O	in
9	51	53	O	the
10	55	58	O	case
11	60	61	O	of
12	63	67	O	other
13	69	77	O	potential
14	79	89	O	hepatotoxic
15	91	95	O	drugs
16	96	96	O	,
17	98	99	O	as
18	101	104	O	well
NULL

L-Methionine	DDI-DrugBank.d528.s2	NO_SECTION	NO_SETID	10
Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.
1	0	9	U-UNK	Gentamicin
2	13	22	U-UNK	Methionine
3	24	26	O	may
4	28	34	O	protect
5	36	42	O	against
6	44	46	O	the
7	48	55	O	ototoxic
8	57	63	O	effects
9	65	66	O	of
10	68	77	U-UNK	gentamicin
NULL

L-Phenylalanine	DDI-DrugBank.d530.s0	NO_SECTION	NO_SETID	15
Non-selective monoamine oxidase (MAO) inhibitors - including phenelzine sulfate, tranylcypromine sulfate and pargyline HC1.
1	0	2	B-UNK	Non
2	4	12	I-UNK	selective
3	14	22	I-UNK	monoamine
4	24	30	I-UNK	oxidase
5	33	35	I-UNK	MAO
6	38	47	L-UNK	inhibitors
7	51	59	O	including
8	61	70	B-UNK	phenelzine
9	72	78	L-UNK	sulfate
10	79	79	O	,
11	81	95	B-UNK	tranylcypromine
12	97	103	L-UNK	sulfate
13	105	107	O	and
14	109	117	U-UNK	pargyline
15	119	121	O	HC1
NULL

L-Phenylalanine	DDI-DrugBank.d530.s1	NO_SECTION	NO_SETID	12
Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	33	O	XXXXXXXX
5	35	37	O	and
6	39	41	B-DYN	non
7	43	51	I-DYN	selective
8	53	55	I-DYN	MAO
9	57	66	L-DYN	inhibitors
10	68	70	O	may
11	72	76	O	cause
12	78	89	O	hypertension
NULL

L-Phenylalanine	DDI-DrugBank.d530.s2	NO_SECTION	NO_SETID	16
Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.
1	0	9	U-UNK	Selegiline
2	13	27	O	XXXXXXXX
3	29	31	O	and
4	33	35	O	the
5	37	45	B-UNK	selective
6	47	49	I-UNK	MAO
7	51	59	L-UNK	inhibitor
8	61	70	U-DYN	selegiline
9	72	74	O	may
10	76	79	O	have
11	81	91	O	synergistic
12	93	106	O	antidepressant
13	108	115	O	activity
14	117	118	O	if
15	120	123	O	used
16	125	137	O	concomitantly
NULL

L-Phenylalanine	DDI-DrugBank.d530.s3	NO_SECTION	NO_SETID	18
Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.
1	0	10	B-DYN	Neuroleptic
2	12	16	L-DYN	Drugs
3	20	34	O	XXXXXXXX
4	36	38	O	may
5	40	49	O	potentiate
6	51	53	O	the
7	55	61	O	tardive
8	63	72	O	dyskinesia
9	74	77	O	side
10	79	87	O	reactions
11	89	90	O	of
12	92	102	B-UNK	neuroleptic
13	104	108	L-UNK	drugs
14	110	111	O	if
15	113	116	O	used
16	118	130	O	concomitantly
17	132	135	O	with
18	137	140	O	them
NULL

L-Tryptophan	DDI-DrugBank.d63.s0	NO_SECTION	NO_SETID	45
Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
1	0	8	B-UNK	Monoamine
2	10	16	I-UNK	oxidase
3	19	21	I-UNK	MAO
4	24	33	L-UNK	inhibitors
5	35	38	O	such
6	40	41	O	as
7	43	55	U-UNK	isocarboxazid
8	58	60	O	e.g
9	62	62	O	,
10	64	70	O	Marplan
11	72	72	O	,
12	74	83	U-UNK	phenelzine
13	86	88	O	e.g
14	90	90	O	,
15	92	97	O	Nardil
16	99	99	O	,
17	101	112	U-UNK	procarbazine
18	115	117	O	e.g
19	119	119	O	,
20	121	128	O	Matulane
21	130	130	O	,
22	132	141	U-UNK	selegiline
23	144	146	O	e.g
24	148	148	O	,
25	150	157	O	Eldepryl
26	159	159	O	,
27	161	163	O	and
28	165	179	U-UNK	tranylcypromine
29	182	184	O	e.g
30	186	186	O	,
31	188	194	O	XXXXXXXX
32	196	196	O	:
33	198	202	O	Using
34	204	208	O	these
35	210	218	O	medicines
36	220	223	O	with
37	225	225	B-UNK	L
38	227	236	L-UNK	tryptophan
39	238	240	O	may
40	242	249	O	increase
41	251	253	O	the
42	255	260	O	chance
43	262	263	O	of
44	265	268	O	side
45	270	276	O	effects
NULL

L-Tyrosine	DDI-DrugBank.d111.s0	NO_SECTION	NO_SETID	27
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.
1	0	2	B-UNK	Non
2	4	12	I-UNK	selective
3	14	16	I-UNK	MAO
4	18	27	L-UNK	inhibitors
5	29	37	O	including
6	39	53	B-UNK	tranylcypromine
7	55	61	L-UNK	sulfate
8	62	62	O	,
9	64	73	B-UNK	phenelzine
10	75	81	L-UNK	sulfate
11	82	82	O	,
12	84	86	O	and
13	88	96	U-UNK	pargyline
14	98	100	O	HC1
15	101	101	O	:
16	103	113	O	Concomitant
17	115	117	O	use
18	119	120	O	of
19	122	131	O	XXXXXXXX
20	133	135	O	and
21	137	139	O	non
22	141	149	O	selective
23	151	153	B-DYN	MAO
24	155	164	L-DYN	inhibitors
25	166	168	O	may
26	170	174	O	cause
27	176	187	O	hypertension
NULL

Labetalol	DDI-DrugBank.d412.s0	NO_SECTION	NO_SETID	29
In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.
1	0	1	O	In
2	3	5	O	one
3	7	12	O	survey
4	13	13	O	,
5	15	18	O	2.3%
6	20	21	O	of
7	23	30	O	patients
8	32	37	O	taking
9	39	47	O	XXXXXXXX
10	49	51	O	HCl
11	53	54	O	in
12	56	66	O	combination
13	68	71	O	with
14	73	81	B-DYN	tricyclic
15	83	97	L-DYN	antidepressants
16	99	109	O	experienced
17	111	116	O	tremor
18	117	117	O	,
19	119	120	O	as
20	122	129	O	compared
21	131	132	O	to
22	134	137	O	0.7%
23	139	146	O	reported
24	148	149	O	to
25	151	155	O	occur
26	157	160	O	with
27	162	170	O	XXXXXXXX
28	172	174	O	HCl
29	176	180	O	alone
NULL

Labetalol	DDI-DrugBank.d412.s1	NO_SECTION	NO_SETID	23
The contribution of each of the treatments to this adverse reaction is unknown but the possibility of a drug interaction cannot be excluded.
1	0	2	O	The
2	4	15	O	contribution
3	17	18	O	of
4	20	23	O	each
5	25	26	O	of
6	28	30	O	the
7	32	41	O	treatments
8	43	44	O	to
9	46	49	O	this
10	51	57	O	adverse
11	59	66	O	reaction
12	68	69	O	is
13	71	77	O	unknown
14	79	81	O	but
15	83	85	O	the
16	87	97	O	possibility
17	99	100	O	of
18	102	102	O	a
19	104	107	O	drug
20	109	119	O	interaction
21	121	126	O	cannot
22	128	129	O	be
23	131	138	O	excluded
NULL

Labetalol	DDI-DrugBank.d412.s2	NO_SECTION	NO_SETID	19
Drugs possessing beta-blocking properties can blunt the bronchodilator effect of beta-receptor agonist drugs in patients with bronchospasm;
1	0	4	O	Drugs
2	6	15	O	possessing
3	17	20	O	beta
4	22	29	O	blocking
5	31	40	O	properties
6	42	44	O	can
7	46	50	O	blunt
8	52	54	O	the
9	56	69	O	bronchodilator
10	71	76	O	effect
11	78	79	O	of
12	81	84	B-UNK	beta
13	86	93	I-UNK	receptor
14	95	101	I-UNK	agonist
15	103	107	L-UNK	drugs
16	109	110	O	in
17	112	119	O	patients
18	121	124	O	with
19	126	137	O	bronchospasm
NULL

Labetalol	DDI-DrugBank.d412.s3	NO_SECTION	NO_SETID	17
therefore, doses greater than the normal antiasthmatic dose of beta-agonist bronchodilator drugs may be required.
1	0	8	O	therefore
2	9	9	O	,
3	11	15	O	doses
4	17	23	O	greater
5	25	28	O	than
6	30	32	O	the
7	34	39	O	normal
8	41	53	O	antiasthmatic
9	55	58	O	dose
10	60	61	O	of
11	63	66	B-UNK	beta
12	68	74	I-UNK	agonist
13	76	89	I-UNK	bronchodilator
14	91	95	L-UNK	drugs
15	97	99	O	may
16	101	102	O	be
17	104	111	O	required
NULL

Labetalol	DDI-DrugBank.d412.s4	NO_SECTION	NO_SETID	11
Cimetidine has been shown to increase the bioavailability of labetalol HCl.
1	0	9	U-KIN	Cimetidine
2	11	13	O	has
3	15	18	O	been
4	20	24	O	shown
5	26	27	O	to
6	29	36	O	increase
7	38	40	O	the
8	42	56	O	bioavailability
9	58	59	O	of
10	61	69	O	XXXXXXXX
11	71	73	O	HCl
NULL

Labetalol	DDI-DrugBank.d412.s5	NO_SECTION	NO_SETID	37
Since this could be explained either by enhanced absorption or by an alteration of hepatic metabolism of labetalol HCl, special care should be used in establishing the dose required for blood pressure control in such patients.
1	0	4	O	Since
2	6	9	O	this
3	11	15	O	could
4	17	18	O	be
5	20	28	O	explained
6	30	35	O	either
7	37	38	O	by
8	40	47	O	enhanced
9	49	58	O	absorption
10	60	61	O	or
11	63	64	O	by
12	66	67	O	an
13	69	78	O	alteration
14	80	81	O	of
15	83	89	O	hepatic
16	91	100	O	metabolism
17	102	103	O	of
18	105	113	O	XXXXXXXX
19	115	117	O	HCl
20	118	118	O	,
21	120	126	O	special
22	128	131	O	care
23	133	138	O	should
24	140	141	O	be
25	143	146	O	used
26	148	149	O	in
27	151	162	O	establishing
28	164	166	O	the
29	168	171	O	dose
30	173	180	O	required
31	182	184	O	for
32	186	190	O	blood
33	192	199	O	pressure
34	201	207	O	control
35	209	210	O	in
36	212	215	O	such
37	217	224	O	patients
NULL

Labetalol	DDI-DrugBank.d412.s6	NO_SECTION	NO_SETID	12
Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl.
1	0	8	O	Synergism
2	10	12	O	has
3	14	17	O	been
4	19	23	O	shown
5	25	31	O	between
6	33	41	U-DYN	halothane
7	43	52	O	anesthesia
8	54	56	O	and
9	58	70	O	intravenously
10	72	83	O	administered
11	85	93	O	XXXXXXXX
12	95	97	O	HCl
NULL

Labetalol	DDI-DrugBank.d412.s7	NO_SECTION	NO_SETID	50
During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.
1	0	5	O	During
2	7	16	O	controlled
3	18	28	O	hypotensive
4	30	39	O	anesthesia
5	41	45	O	using
6	47	55	O	XXXXXXXX
7	57	59	O	HCl
8	61	62	O	in
9	64	74	O	association
10	76	79	O	with
11	81	89	U-DYN	halothane
12	90	90	O	,
13	92	95	O	high
14	97	110	O	concentrations
15	113	114	O	3%
16	116	117	O	or
17	119	123	O	above
18	126	127	O	of
19	129	137	U-UNK	halothane
20	139	144	O	should
21	146	148	O	not
22	150	151	O	be
23	153	156	O	used
24	158	164	O	because
25	166	168	O	the
26	170	175	O	degree
27	177	178	O	of
28	180	190	O	hypotension
29	192	195	O	will
30	197	198	O	be
31	200	208	O	increased
32	210	212	O	and
33	214	220	O	because
34	222	223	O	of
35	225	227	O	the
36	229	239	O	possibility
37	241	242	O	of
38	244	244	O	a
39	246	250	O	large
40	252	260	O	reduction
41	262	263	O	in
42	265	271	O	cardiac
43	273	278	O	output
44	280	282	O	and
45	284	285	O	an
46	287	294	O	increase
47	296	297	O	in
48	299	305	O	central
49	307	312	O	venous
50	314	321	O	pressure
NULL

Labetalol	DDI-DrugBank.d412.s8	NO_SECTION	NO_SETID	12
The anesthesiologist should be informed when a patient is receiving labetalol HCl.
1	0	2	O	The
2	4	19	O	anesthesiologist
3	21	26	O	should
4	28	29	O	be
5	31	38	O	informed
6	40	43	O	when
7	45	45	O	a
8	47	53	O	patient
9	55	56	O	is
10	58	66	O	receiving
11	68	76	O	XXXXXXXX
12	78	80	O	HCl
NULL

Labetalol	DDI-DrugBank.d412.s9	NO_SECTION	NO_SETID	14
Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.
1	0	8	O	XXXXXXXX
2	10	12	O	HCl
3	14	19	O	blunts
4	21	23	O	the
5	25	30	O	reflex
6	32	42	O	tachycardia
7	44	51	O	produced
8	53	54	O	by
9	56	68	U-DYN	nitroglycerin
10	70	76	O	without
11	78	87	O	preventing
12	89	91	O	its
13	93	103	O	hypotensive
14	105	110	O	effect
NULL

Labetalol	DDI-DrugBank.d412.s10	NO_SECTION	NO_SETID	18
If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.
1	0	1	O	If
2	3	11	O	XXXXXXXX
3	13	15	O	HCl
4	17	18	O	is
5	20	23	O	used
6	25	28	O	with
7	30	42	U-DYN	nitroglycerin
8	44	45	O	in
9	47	54	O	patients
10	56	59	O	with
11	61	66	O	angina
12	68	75	O	pectoris
13	76	76	O	,
14	78	87	O	additional
15	89	104	O	antihypertensive
16	106	112	O	effects
17	114	116	O	may
18	118	122	O	occur
NULL

Labetalol	DDI-DrugBank.d412.s11	NO_SECTION	NO_SETID	16
Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.
1	0	3	O	Care
2	5	10	O	should
3	12	13	O	be
4	15	19	O	taken
5	21	22	O	if
6	24	32	O	XXXXXXXX
7	34	35	O	is
8	37	40	O	used
9	42	54	O	concomitantly
10	56	59	O	with
11	61	67	U-DYN	calcium
12	69	79	O	antagonists
13	81	82	O	of
14	84	86	O	the
15	88	96	U-UNK	verapamil
16	98	101	O	type
NULL

Labetalol	DDI-DrugBank.d412.s12	NO_SECTION	NO_SETID	37
Risk of Anaphylactic Reaction While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.
1	0	3	O	Risk
2	5	6	O	of
3	8	19	O	Anaphylactic
4	21	28	O	Reaction
5	30	34	O	While
6	36	41	O	taking
7	43	46	B-UNK	beta
8	48	55	L-UNK	blockers
9	56	56	O	,
10	58	65	O	patients
11	67	70	O	with
12	72	72	O	a
13	74	80	O	history
14	82	83	O	of
15	85	90	O	severe
16	92	103	O	anaphylactic
17	105	112	O	reaction
18	114	115	O	to
19	117	117	O	a
20	119	125	O	variety
21	127	128	O	of
22	130	138	O	allergens
23	140	142	O	may
24	144	145	O	be
25	147	150	O	more
26	152	159	O	reactive
27	161	162	O	to
28	164	171	O	repeated
29	173	181	O	challenge
30	182	182	O	,
31	184	189	O	either
32	191	200	O	accidental
33	201	201	O	,
34	203	212	O	diagnostic
35	213	213	O	,
36	215	216	O	or
37	218	228	O	therapeutic
NULL

Labetalol	DDI-DrugBank.d412.s13	NO_SECTION	NO_SETID	16
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
1	0	3	O	Such
2	5	12	O	patients
3	14	16	O	may
4	18	19	O	be
5	21	32	O	unresponsive
6	34	35	O	to
7	37	39	O	the
8	41	45	O	usual
9	47	51	O	doses
10	53	54	O	of
11	56	66	U-UNK	epinephrine
12	68	71	O	used
13	73	74	O	to
14	76	80	O	treat
15	82	89	O	allergic
16	91	98	O	reaction
NULL

Labetalol	DDI-DrugBank.d412.s14	NO_SECTION	NO_SETID	36
Drug/Laboratory Test Interactions The presence of labetalol metabolites in the urine may result in falsely elevated levels of urinary catecholamines, metanephrine, normetanephrine and vanillylmandelic acid when measured by fluorimetric or photometric methods.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	36	O	The
7	38	45	O	presence
8	47	48	O	of
9	50	58	O	XXXXXXXX
10	60	70	O	metabolites
11	72	73	O	in
12	75	77	O	the
13	79	83	O	urine
14	85	87	O	may
15	89	94	O	result
16	96	97	O	in
17	99	105	O	falsely
18	107	114	O	elevated
19	116	121	O	levels
20	123	124	O	of
21	126	132	O	urinary
22	134	147	O	catecholamines
23	148	148	O	,
24	150	161	O	metanephrine
25	162	162	O	,
26	164	178	O	normetanephrine
27	180	182	O	and
28	184	199	O	vanillylmandelic
29	201	204	O	acid
30	206	209	O	when
31	211	218	O	measured
32	220	221	O	by
33	223	234	O	fluorimetric
34	236	237	O	or
35	239	249	O	photometric
36	251	257	O	methods
NULL

Labetalol	DDI-DrugBank.d412.s15	NO_SECTION	NO_SETID	44
In screening patients suspected of having a pheochromocytoma and being treated with labetalol HCl, a specific method, such as a high performance liquid chromatographic assay with solid phase extraction (e.g., J Chromatogr 385:241,1987) should be employed in determining levels of catecholamines.
1	0	1	O	In
2	3	11	O	screening
3	13	20	O	patients
4	22	30	O	suspected
5	32	33	O	of
6	35	40	O	having
7	42	42	O	a
8	44	59	O	pheochromocytoma
9	61	63	O	and
10	65	69	O	being
11	71	77	O	treated
12	79	82	O	with
13	84	92	O	XXXXXXXX
14	94	96	O	HCl
15	97	97	O	,
16	99	99	O	a
17	101	108	O	specific
18	110	115	O	method
19	116	116	O	,
20	118	121	O	such
21	123	124	O	as
22	126	126	O	a
23	128	131	O	high
24	133	143	O	performance
25	145	150	O	liquid
26	152	166	O	chromatographic
27	168	172	O	assay
28	174	177	O	with
29	179	183	O	solid
30	185	189	O	phase
31	191	200	O	extraction
32	203	205	O	e.g
33	207	207	O	,
34	209	209	O	J
35	211	220	O	Chromatogr
36	222	233	O	385:241,1987
37	236	241	O	should
38	243	244	O	be
39	246	253	O	employed
40	255	256	O	in
41	258	268	O	determining
42	270	275	O	levels
43	277	278	O	of
44	280	293	O	catecholamines
NULL

Labetalol	DDI-DrugBank.d412.s16	NO_SECTION	NO_SETID	40
Labetalol HCl has also been reported to produce a false positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods Toxi-Lab A  (thin-layer chromatographic assay) and Emit-d.a.u.  (radioenzymatic assay).
1	0	8	O	XXXXXXXX
2	10	12	O	HCl
3	14	16	O	has
4	18	21	O	also
5	23	26	O	been
6	28	35	O	reported
7	37	38	O	to
8	40	46	O	produce
9	48	48	O	a
10	50	54	O	false
11	56	63	O	positive
12	65	68	O	test
13	70	72	O	for
14	74	84	U-UNK	amphetamine
15	86	89	O	when
16	91	99	O	screening
17	101	105	O	urine
18	107	109	O	for
19	111	113	O	the
20	115	122	O	presence
21	124	125	O	of
22	127	131	O	drugs
23	133	137	O	using
24	139	141	O	the
25	143	154	O	commercially
26	156	164	O	available
27	166	170	O	assay
28	172	178	O	methods
29	180	183	O	Toxi
30	185	187	O	Lab
31	189	189	O	A
32	193	196	O	thin
33	198	202	O	layer
34	204	218	O	chromatographic
35	220	224	O	assay
36	227	229	O	and
37	231	234	O	Emit
38	236	240	O	d.a.u
39	245	258	O	radioenzymatic
40	260	264	O	assay
NULL

Labetalol	DDI-DrugBank.d412.s17	NO_SECTION	NO_SETID	33
When patients being treated with labetalol have a positive urine test for amphetamine using these techniques confirmation should be made by using more specific methods such as a gas chromatographic-mass spectrometer technique.
1	0	3	O	When
2	5	12	O	patients
3	14	18	O	being
4	20	26	O	treated
5	28	31	O	with
6	33	41	O	XXXXXXXX
7	43	46	O	have
8	48	48	O	a
9	50	57	O	positive
10	59	63	O	urine
11	65	68	O	test
12	70	72	O	for
13	74	84	U-UNK	amphetamine
14	86	90	O	using
15	92	96	O	these
16	98	107	O	techniques
17	109	120	O	confirmation
18	122	127	O	should
19	129	130	O	be
20	132	135	O	made
21	137	138	O	by
22	140	144	O	using
23	146	149	O	more
24	151	158	O	specific
25	160	166	O	methods
26	168	171	O	such
27	173	174	O	as
28	176	176	O	a
29	178	180	O	gas
30	182	196	O	chromatographic
31	198	201	O	mass
32	203	214	O	spectrometer
33	216	224	O	technique
NULL

Lactulose	DDI-DrugBank.d206.s0	NO_SECTION	NO_SETID	26
Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.
1	0	6	O	Results
2	8	9	O	of
3	11	21	O	preliminary
4	23	29	O	studies
5	31	32	O	in
6	34	39	O	humans
7	41	43	O	and
8	45	48	O	rats
9	50	56	O	suggest
10	58	61	O	that
11	63	75	O	nonabsorbable
12	77	84	U-KIN	antacids
13	86	90	O	given
14	92	103	O	concurrently
15	105	108	O	with
16	110	118	O	XXXXXXXX
17	120	122	O	may
18	124	130	O	inhibit
19	132	134	O	the
20	136	142	O	desired
21	144	152	O	XXXXXXXX
22	154	160	O	induced
23	162	165	O	drop
24	167	168	O	in
25	170	176	O	colonic
26	178	179	O	pH
NULL

Lactulose	DDI-DrugBank.d206.s1	NO_SECTION	NO_SETID	23
Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose.
1	0	8	O	Therefore
2	9	9	O	,
3	11	11	O	a
4	13	20	O	possible
5	22	25	O	lack
6	27	28	O	of
7	30	36	O	desired
8	38	43	O	effect
9	45	46	O	of
10	48	56	O	treatment
11	58	63	O	should
12	65	66	O	be
13	68	72	O	taken
14	74	77	O	into
15	79	91	O	consideration
16	93	98	O	before
17	100	103	O	such
18	105	109	O	drugs
19	111	113	O	are
20	115	119	O	given
21	121	133	O	concomitantly
22	135	138	O	with
23	140	148	O	XXXXXXXX
NULL

Lamivudine	DDI-DrugBank.d71.s0	NO_SECTION	NO_SETID	12
Lamivudine is predominantly eliminated in the urine by active organic cationic secretion.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	26	O	predominantly
4	28	37	O	eliminated
5	39	40	O	in
6	42	44	O	the
7	46	50	O	urine
8	52	53	O	by
9	55	60	O	active
10	62	68	O	organic
11	70	77	O	cationic
12	79	87	O	secretion
NULL

Lamivudine	DDI-DrugBank.d71.s1	NO_SECTION	NO_SETID	33
The possibility of interactions with other drugs administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system (e.g., trimethoprim).
1	0	2	O	The
2	4	14	O	possibility
3	16	17	O	of
4	19	30	O	interactions
5	32	35	O	with
6	37	41	O	other
7	43	47	O	drugs
8	49	60	O	administered
9	62	73	O	concurrently
10	75	80	O	should
11	82	83	O	be
12	85	94	O	considered
13	95	95	O	,
14	97	108	O	particularly
15	110	113	O	when
16	115	119	O	their
17	121	124	O	main
18	126	130	O	route
19	132	133	O	of
20	135	145	O	elimination
21	147	148	O	is
22	150	155	O	active
23	157	161	O	renal
24	163	171	O	secretion
25	173	175	O	via
26	177	179	O	the
27	181	187	O	organic
28	189	196	O	cationic
29	198	206	O	transport
30	208	213	O	system
31	216	218	O	e.g
32	220	220	O	,
33	222	233	U-UNK	trimethoprim
NULL

Lamivudine	DDI-DrugBank.d71.s2	NO_SECTION	NO_SETID	9
No change in dose of either drug is recommended.
1	0	1	O	No
2	3	8	O	change
3	10	11	O	in
4	13	16	O	dose
5	18	19	O	of
6	21	26	O	either
7	28	31	O	drug
8	33	34	O	is
9	36	46	O	recommended
NULL

Lamivudine	DDI-DrugBank.d71.s3	NO_SECTION	NO_SETID	26
There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat Pneumocystis carinii pneumonia.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	22	O	information
5	24	32	O	regarding
6	34	36	O	the
7	38	43	O	effect
8	45	46	O	on
9	48	57	O	XXXXXXXX
10	59	74	O	pharmacokinetics
11	76	77	O	of
12	79	84	O	higher
13	86	90	O	doses
14	92	93	O	of
15	95	97	U-UNK	TMP
16	98	98	O	/
17	99	101	U-UNK	SMX
18	103	106	O	such
19	108	109	O	as
20	111	115	O	those
21	117	120	O	used
22	122	123	O	to
23	125	129	O	treat
24	131	142	O	Pneumocystis
25	144	150	O	carinii
26	152	160	O	pneumonia
NULL

Lamivudine	DDI-DrugBank.d71.s4	NO_SECTION	NO_SETID	19
No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.
1	0	1	O	No
2	3	6	O	data
3	8	10	O	are
4	12	20	O	available
5	22	30	O	regarding
6	32	43	O	interactions
7	45	48	O	with
8	50	54	O	other
9	56	60	O	drugs
10	62	65	O	that
11	67	70	O	have
12	72	76	O	renal
13	78	86	O	clearance
14	88	97	O	mechanisms
15	99	105	O	similar
16	107	108	O	to
17	110	113	O	that
18	115	116	O	of
19	118	127	O	XXXXXXXX
NULL

Lamivudine	DDI-DrugBank.d71.s5	NO_SECTION	NO_SETID	11
Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.
1	0	9	O	XXXXXXXX
2	11	13	O	and
3	15	25	U-DYN	zalcitabine
4	27	29	O	may
5	31	37	O	inhibit
6	39	41	O	the
7	43	55	O	intracellular
8	57	71	O	phosphorylation
9	73	74	O	of
10	76	78	O	one
11	80	86	O	another
NULL

Lamivudine	DDI-DrugBank.d71.s6	NO_SECTION	NO_SETID	12
Therefore, use of lamivudine in combination with zalcitabine is not recommended
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	use
4	15	16	O	of
5	18	27	O	XXXXXXXX
6	29	30	O	in
7	32	42	O	combination
8	44	47	O	with
9	49	59	U-DYN	zalcitabine
10	61	62	O	is
11	64	66	O	not
12	68	78	O	recommended
NULL

Lansoprazole	DDI-DrugBank.d431.s0	NO_SECTION	NO_SETID	16
Lansoprazole is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	26	O	metabolized
4	28	34	O	through
5	36	38	O	the
6	40	49	O	cytochrome
7	51	54	O	P450
8	56	61	O	system
9	62	62	O	,
10	64	75	O	specifically
11	77	83	O	through
12	85	87	O	the
13	89	93	O	CYP3A
14	95	97	O	and
15	99	105	O	CYP2C19
16	107	114	O	isozymes
NULL

Lansoprazole	DDI-DrugBank.d431.s1	NO_SECTION	NO_SETID	46
Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
1	0	6	O	Studies
2	8	11	O	have
3	13	17	O	shown
4	19	22	O	that
5	24	35	O	XXXXXXXX
6	37	40	O	does
7	42	44	O	not
8	46	49	O	have
9	51	60	O	clinically
10	62	72	O	significant
11	74	85	O	interactions
12	87	90	O	with
13	92	96	O	other
14	98	102	O	drugs
15	104	114	O	metabolized
16	116	117	O	by
17	119	121	O	the
18	123	132	O	cytochrome
19	134	137	O	P450
20	139	144	O	system
21	145	145	O	,
22	147	150	O	such
23	152	153	O	as
24	155	162	U-UNK	warfarin
25	163	163	O	,
26	165	174	U-UNK	antipyrine
27	175	175	O	,
28	177	188	U-UNK	indomethacin
29	189	189	O	,
30	191	199	U-UNK	ibuprofen
31	200	200	O	,
32	202	210	U-UNK	phenytoin
33	211	211	O	,
34	213	223	U-UNK	propranolol
35	224	224	O	,
36	226	235	U-UNK	prednisone
37	236	236	O	,
38	238	245	U-UNK	diazepam
39	246	246	O	,
40	248	261	U-UNK	clarithromycin
41	262	262	O	,
42	264	265	O	or
43	267	277	U-UNK	terfenadine
44	279	280	O	in
45	282	288	O	healthy
46	290	297	O	subjects
NULL

Lansoprazole	DDI-DrugBank.d431.s2	NO_SECTION	NO_SETID	20
These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A.
1	0	4	O	These
2	6	14	O	compounds
3	16	18	O	are
4	20	30	O	metabolized
5	32	38	O	through
6	40	46	O	various
7	48	57	O	cytochrome
8	59	62	O	P450
9	64	71	O	isozymes
10	73	81	O	including
11	83	88	O	CYP1A2
12	89	89	O	,
13	91	96	O	CYP2C9
14	97	97	O	,
15	99	105	O	CYP2C19
16	106	106	O	,
17	108	113	O	CYP2D6
18	114	114	O	,
19	116	118	O	and
20	120	124	O	CYP3A
NULL

Lansoprazole	DDI-DrugBank.d431.s3	NO_SECTION	NO_SETID	22
When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.
1	0	3	O	When
2	5	16	O	XXXXXXXX
3	18	20	O	was
4	22	33	O	administered
5	35	47	O	concomitantly
6	49	52	O	with
7	54	65	U-KIN	theophylline
8	68	73	O	CYP1A2
9	74	74	O	,
10	76	80	O	CYP3A
11	82	82	O	,
12	84	84	O	a
13	86	90	O	minor
14	92	99	O	increase
15	102	104	O	10%
16	107	108	O	in
17	110	112	O	the
18	114	122	O	clearance
19	124	125	O	of
20	127	138	U-UNK	theophylline
21	140	142	O	was
22	144	147	O	seen
NULL

Lansoprazole	DDI-DrugBank.d431.s4	NO_SECTION	NO_SETID	22
Because the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be clinical concern.
1	0	6	O	Because
2	8	10	O	the
3	12	16	O	small
4	18	26	O	magnitude
5	28	30	O	and
6	32	34	O	the
7	36	44	O	direction
8	46	47	O	of
9	49	51	O	the
10	53	58	O	effect
11	60	61	O	on
12	63	74	U-UNK	theophylline
13	76	84	O	clearance
14	85	85	O	,
15	87	90	O	this
16	92	102	O	interaction
17	104	105	O	is
18	107	114	O	unlikely
19	116	117	O	to
20	119	120	O	be
21	122	129	O	clinical
22	131	137	O	concern
NULL

Lansoprazole	DDI-DrugBank.d431.s5	NO_SECTION	NO_SETID	24
Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.
1	0	10	O	Nonetheless
2	11	11	O	,
3	13	22	O	individual
4	24	31	O	patients
5	33	35	O	may
6	37	43	O	require
7	45	54	O	additional
8	56	64	O	titration
9	66	67	O	of
10	69	73	O	their
11	75	86	U-DYN	theophylline
12	88	93	O	dosage
13	95	98	O	when
14	100	111	O	XXXXXXXX
15	113	114	O	is
16	116	122	O	started
17	124	125	O	or
18	127	133	O	stopped
19	135	136	O	to
20	138	143	O	ensure
21	145	154	O	clinically
22	156	164	O	effective
23	166	170	O	blood
24	172	177	O	levels
NULL

Lansoprazole	DDI-DrugBank.d431.s6	NO_SECTION	NO_SETID	13
Lansoprazole has also been shown to have no clinically significant interaction with amoxicillin.
1	0	11	O	XXXXXXXX
2	13	15	O	has
3	17	20	O	also
4	22	25	O	been
5	27	31	O	shown
6	33	34	O	to
7	36	39	O	have
8	41	42	O	no
9	44	53	O	clinically
10	55	65	O	significant
11	67	77	O	interaction
12	79	82	O	with
13	84	94	U-UNK	amoxicillin
NULL

Lansoprazole	DDI-DrugBank.d431.s7	NO_SECTION	NO_SETID	49
In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	single
4	12	15	O	dose
5	17	25	O	crossover
6	27	31	O	study
7	33	41	O	examining
8	43	54	O	XXXXXXXX
9	56	57	O	30
10	59	60	O	mg
11	62	64	O	and
12	66	75	U-UNK	omeprazole
13	77	78	O	20
14	80	81	O	mg
15	83	86	O	each
16	88	99	O	administered
17	101	105	O	alone
18	107	109	O	and
19	111	123	O	concomitantly
20	125	128	O	with
21	130	139	U-UNK	sucralfate
22	141	141	O	1
23	143	146	O	gram
24	147	147	O	,
25	149	158	O	absorption
26	160	161	O	of
27	163	165	O	the
28	167	172	B-UNK	proton
29	174	177	I-UNK	pump
30	179	188	L-UNK	inhibitors
31	190	192	O	was
32	194	200	O	delayed
33	202	204	O	and
34	206	210	O	their
35	212	226	O	bioavailability
36	228	230	O	was
37	232	238	O	reduced
38	240	241	O	by
39	243	245	O	17%
40	247	249	O	and
41	251	253	O	16%
42	254	254	O	,
43	256	267	O	respectively
44	268	268	O	,
45	270	273	O	when
46	275	286	O	administered
47	288	300	O	concomitantly
48	302	305	O	with
49	307	316	U-UNK	sucralfate
NULL

Lansoprazole	DDI-DrugBank.d431.s8	NO_SECTION	NO_SETID	15
Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.
1	0	8	O	Therefore
2	9	9	O	,
3	11	16	B-UNK	proton
4	18	21	I-UNK	pump
5	23	32	L-UNK	inhibitors
6	34	39	O	should
7	41	42	O	be
8	44	48	O	taken
9	50	51	O	at
10	53	57	O	least
11	59	60	O	30
12	62	68	O	minutes
13	70	74	O	prior
14	76	77	O	to
15	79	88	U-UNK	sucralfate
NULL

Lansoprazole	DDI-DrugBank.d431.s9	NO_SECTION	NO_SETID	13
In clinical trials, antacids were administered concomitantly with lansoprazole delayed-release capsules;
1	0	1	O	In
2	3	10	O	clinical
3	12	17	O	trials
4	18	18	O	,
5	20	27	U-UNK	antacids
6	29	32	O	were
7	34	45	O	administered
8	47	59	O	concomitantly
9	61	64	O	with
10	66	77	O	XXXXXXXX
11	79	85	O	delayed
12	87	93	O	release
13	95	102	O	capsules
NULL

Lansoprazole	DDI-DrugBank.d431.s10	NO_SECTION	NO_SETID	7
this did not interfere with its effect.
1	0	3	O	this
2	5	7	O	did
3	9	11	O	not
4	13	21	O	interfere
5	23	26	O	with
6	28	30	O	its
7	32	37	O	effect
NULL

Lansoprazole	DDI-DrugBank.d431.s11	NO_SECTION	NO_SETID	12
Lansoprazole causes a profound and long lasting inhibition of gastric acid secretion;
1	0	11	O	XXXXXXXX
2	13	18	O	causes
3	20	20	O	a
4	22	29	O	profound
5	31	33	O	and
6	35	38	O	long
7	40	46	O	lasting
8	48	57	O	inhibition
9	59	60	O	of
10	62	68	O	gastric
11	70	73	O	acid
12	75	83	O	secretion
NULL

Lansoprazole	DDI-DrugBank.d431.s12	NO_SECTION	NO_SETID	34
therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
1	0	8	O	therefore
2	9	9	O	,
3	11	12	O	it
4	14	15	O	is
5	17	29	O	theoretically
6	31	38	O	possible
7	40	43	O	that
8	45	56	O	XXXXXXXX
9	58	60	O	may
10	62	70	O	interfere
11	72	75	O	with
12	77	79	O	the
13	81	90	O	absorption
14	92	93	O	of
15	95	99	O	drugs
16	101	105	O	where
17	107	113	O	gastric
18	115	116	O	pH
19	118	119	O	is
20	121	122	O	an
21	124	132	O	important
22	134	144	O	determinant
23	146	147	O	of
24	149	163	O	bioavailability
25	166	168	O	e.g
26	171	182	U-KIN	ketoconazole
27	183	183	O	,
28	185	194	U-KIN	ampicillin
29	196	201	O	esters
30	202	202	O	,
31	204	207	U-KIN	iron
32	209	213	O	salts
33	214	214	O	,
34	216	222	U-KIN	digoxin
NULL

Lapatinib	DDI-DrugBank.d135.s0	NO_SECTION	NO_SETID	22
Effects of Lapatinib on Drug Metabolizing Enzymes and Drug Transport Systems Lapatinib inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.
1	0	6	O	Effects
2	8	9	O	of
3	11	19	O	XXXXXXXX
4	21	22	O	on
5	24	27	O	Drug
6	29	40	O	Metabolizing
7	42	48	O	Enzymes
8	50	52	O	and
9	54	57	O	Drug
10	59	67	O	Transport
11	69	75	O	Systems
12	77	85	O	XXXXXXXX
13	87	94	O	inhibits
14	96	101	O	CYP3A4
15	103	105	O	and
16	107	112	O	CYP2C8
17	114	115	O	in
18	117	121	O	vitro
19	123	124	O	at
20	126	135	O	clinically
21	137	144	O	relevant
22	146	159	O	concentrations
NULL

Lapatinib	DDI-DrugBank.d135.s1	NO_SECTION	NO_SETID	32
Caution should be exercised and dose reduction of the concomitant substrate drug should be considered when dosing lapatinib concurrently with medications with narrow therapeutic windows that are substrates of CYP3A4 or CYP2C8.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	30	O	and
6	32	35	O	dose
7	37	45	O	reduction
8	47	48	O	of
9	50	52	O	the
10	54	64	O	concomitant
11	66	74	O	substrate
12	76	79	O	drug
13	81	86	O	should
14	88	89	O	be
15	91	100	O	considered
16	102	105	O	when
17	107	112	O	dosing
18	114	122	O	XXXXXXXX
19	124	135	O	concurrently
20	137	140	O	with
21	142	152	O	medications
22	154	157	O	with
23	159	164	O	narrow
24	166	176	O	therapeutic
25	178	184	O	windows
26	186	189	O	that
27	191	193	O	are
28	195	204	O	substrates
29	206	207	O	of
30	209	214	O	CYP3A4
31	216	217	O	or
32	219	224	O	CYP2C8
NULL

Lapatinib	DDI-DrugBank.d135.s2	NO_SECTION	NO_SETID	34
Lapatinib did not significantly inhibit the following enzymes in human liver microsomes: CYP1A2, CYP2C9, CYP2C19, and CYP2D6 or UGT enzymes in vitro, however, the clinical significance is unknown.
1	0	8	O	XXXXXXXX
2	10	12	O	did
3	14	16	O	not
4	18	30	O	significantly
5	32	38	O	inhibit
6	40	42	O	the
7	44	52	O	following
8	54	60	O	enzymes
9	62	63	O	in
10	65	69	O	human
11	71	75	O	liver
12	77	86	O	microsomes
13	87	87	O	:
14	89	94	O	CYP1A2
15	95	95	O	,
16	97	102	O	CYP2C9
17	103	103	O	,
18	105	111	O	CYP2C19
19	112	112	O	,
20	114	116	O	and
21	118	123	O	CYP2D6
22	125	126	O	or
23	128	130	O	UGT
24	132	138	O	enzymes
25	140	141	O	in
26	143	147	O	vitro
27	148	148	O	,
28	150	156	O	however
29	157	157	O	,
30	159	161	O	the
31	163	170	O	clinical
32	172	183	O	significance
33	185	186	O	is
34	188	194	O	unknown
NULL

Lapatinib	DDI-DrugBank.d135.s3	NO_SECTION	NO_SETID	5
Lapatinib inhibits human P-glycoprotein.
1	0	8	O	XXXXXXXX
2	10	17	O	inhibits
3	19	23	O	human
4	25	25	O	P
5	27	38	O	glycoprotein
NULL

Lapatinib	DDI-DrugBank.d135.s4	NO_SECTION	NO_SETID	26
If TYKERB is administered with drugs that are substrates of Pgp, increased concentrations of the substrate drug are likely, and caution should be exercised.
1	0	1	O	If
2	3	8	O	XXXXXXXX
3	10	11	O	is
4	13	24	O	administered
5	26	29	O	with
6	31	35	O	drugs
7	37	40	O	that
8	42	44	O	are
9	46	55	O	substrates
10	57	58	O	of
11	60	62	O	Pgp
12	63	63	O	,
13	65	73	O	increased
14	75	88	O	concentrations
15	90	91	O	of
16	93	95	O	the
17	97	105	O	substrate
18	107	110	O	drug
19	112	114	O	are
20	116	121	O	likely
21	122	122	O	,
22	124	126	O	and
23	128	134	O	caution
24	136	141	O	should
25	143	144	O	be
26	146	154	O	exercised
NULL

Lapatinib	DDI-DrugBank.d135.s5	NO_SECTION	NO_SETID	30
Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes Lapatinib undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter lapatinib concentrations significantly.
1	0	4	O	Drugs
2	6	9	O	that
3	11	17	O	Inhibit
4	19	20	O	or
5	22	27	O	Induce
6	29	38	O	Cytochrome
7	40	43	O	P450
8	45	47	O	3A4
9	49	55	O	Enzymes
10	57	65	O	XXXXXXXX
11	67	75	O	undergoes
12	77	85	O	extensive
13	87	96	O	metabolism
14	98	99	O	by
15	101	106	O	CYP3A4
16	107	107	O	,
17	109	111	O	and
18	113	123	O	concomitant
19	125	138	O	administration
20	140	141	O	of
21	143	148	O	strong
22	150	159	O	inhibitors
23	161	162	O	or
24	164	171	O	inducers
25	173	174	O	of
26	176	181	O	CYP3A4
27	183	187	O	alter
28	189	197	O	XXXXXXXX
29	199	212	O	concentrations
30	214	226	O	significantly
NULL

Lapatinib	DDI-DrugBank.d135.s6	NO_SECTION	NO_SETID	22
Dose adjustment of lapatinib should be considered for patients who must receive concomitant strong inhibitors or concomitant strong inducers of CYP3A4 enzymes.
1	0	3	O	Dose
2	5	14	O	adjustment
3	16	17	O	of
4	19	27	O	XXXXXXXX
5	29	34	O	should
6	36	37	O	be
7	39	48	O	considered
8	50	52	O	for
9	54	61	O	patients
10	63	65	O	who
11	67	70	O	must
12	72	78	O	receive
13	80	90	O	concomitant
14	92	97	O	strong
15	99	108	O	inhibitors
16	110	111	O	or
17	113	123	O	concomitant
18	125	130	O	strong
19	132	139	O	inducers
20	141	142	O	of
21	144	149	O	CYP3A4
22	151	157	O	enzymes
NULL

Lapatinib	DDI-DrugBank.d135.s7	NO_SECTION	NO_SETID	43
Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	15	O	In
4	17	23	O	healthy
5	25	32	O	subjects
6	34	42	O	receiving
7	44	55	U-KIN	ketoconazole
8	56	56	O	,
9	58	58	O	a
10	60	65	O	CYP3A4
11	67	75	O	inhibitor
12	76	76	O	,
13	78	79	O	at
14	81	83	O	200
15	85	86	O	mg
16	88	92	O	twice
17	94	98	O	daily
18	100	102	O	for
19	104	104	O	7
20	106	109	O	days
21	110	110	O	,
22	112	119	O	systemic
23	121	128	O	exposure
24	131	133	O	AUC
25	136	137	O	to
26	139	147	O	XXXXXXXX
27	149	151	O	was
28	153	161	O	increased
29	163	164	O	to
30	166	178	O	approximately
31	180	182	O	3.6
32	184	187	O	fold
33	189	190	O	of
34	192	198	O	control
35	200	202	O	and
36	204	207	O	half
37	209	212	O	life
38	214	222	O	increased
39	224	225	O	to
40	227	229	O	1.7
41	231	234	O	fold
42	236	237	O	of
43	239	245	O	control
NULL

Lapatinib	DDI-DrugBank.d135.s8	NO_SECTION	NO_SETID	38
Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.
1	0	12	U-UNK	Carbamazepine
2	13	13	O	:
3	15	16	O	In
4	18	24	O	healthy
5	26	33	O	subjects
6	35	43	O	receiving
7	45	47	O	the
8	49	54	O	CYP3A4
9	56	62	O	inducer
10	63	63	O	,
11	65	77	U-KIN	carbamazepine
12	78	78	O	,
13	80	81	O	at
14	83	85	O	100
15	87	88	O	mg
16	90	94	O	twice
17	96	100	O	daily
18	102	104	O	for
19	106	106	O	3
20	108	111	O	days
21	113	115	O	and
22	117	119	O	200
23	121	122	O	mg
24	124	128	O	twice
25	130	134	O	daily
26	136	138	O	for
27	140	141	O	17
28	143	146	O	days
29	147	147	O	,
30	149	156	O	systemic
31	158	165	O	exposure
32	168	170	O	AUC
33	173	174	O	to
34	176	184	O	XXXXXXXX
35	186	188	O	was
36	190	198	O	decreased
37	200	212	O	approximately
38	214	216	O	72%
NULL

Lapatinib	DDI-DrugBank.d135.s9	NO_SECTION	NO_SETID	19
Drugs that Inhibit Drug Transport Systems Lapatinib is a substrate of the efflux transporter P-glycoprotein (Pgp, ABCB1).
1	0	4	O	Drugs
2	6	9	O	that
3	11	17	O	Inhibit
4	19	22	O	Drug
5	24	32	O	Transport
6	34	40	O	Systems
7	42	50	O	XXXXXXXX
8	52	53	O	is
9	55	55	O	a
10	57	65	O	substrate
11	67	68	O	of
12	70	72	O	the
13	74	79	O	efflux
14	81	91	O	transporter
15	93	93	O	P
16	95	106	O	glycoprotein
17	109	111	O	Pgp
18	112	112	O	,
19	114	118	O	ABCB1
NULL

Lapatinib	DDI-DrugBank.d135.s10	NO_SECTION	NO_SETID	22
If TYKERB is administered with drugs that inhibit Pgp, increased concentrations of lapatinib are likely, and caution should be exercised.
1	0	1	O	If
2	3	8	O	XXXXXXXX
3	10	11	O	is
4	13	24	O	administered
5	26	29	O	with
6	31	35	O	drugs
7	37	40	O	that
8	42	48	O	inhibit
9	50	52	O	Pgp
10	53	53	O	,
11	55	63	O	increased
12	65	78	O	concentrations
13	80	81	O	of
14	83	91	U-UNK	lapatinib
15	93	95	O	are
16	97	102	O	likely
17	103	103	O	,
18	105	107	O	and
19	109	115	O	caution
20	117	122	O	should
21	124	125	O	be
22	127	135	O	exercised
NULL

Lapatinib	DDI-DrugBank.d135.s11	NO_SECTION	NO_SETID	28
Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).
1	0	4	O	Other
2	6	17	O	Chemotherapy
3	19	24	O	Agents
4	26	27	O	In
5	29	29	O	a
6	31	38	O	separate
7	40	44	O	study
8	45	45	O	,
9	47	57	O	concomitant
10	59	72	O	administration
11	74	75	O	of
12	77	85	O	XXXXXXXX
13	87	90	O	with
14	92	103	U-UNK	capecitabine
15	105	107	O	did
16	109	111	O	not
17	113	124	O	meaningfully
18	126	130	O	alter
19	132	134	O	the
20	136	151	O	pharmacokinetics
21	153	154	O	of
22	156	161	O	either
23	163	167	O	agent
24	170	171	O	or
25	173	175	O	the
26	177	187	O	metabolites
27	189	190	O	of
28	192	203	U-UNK	capecitabine
NULL

Laronidase	DDI-DrugBank.d300.s0	NO_SECTION	NO_SETID	8
No formal drug interaction studies have been conducted.
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	25	O	interaction
5	27	33	O	studies
6	35	38	O	have
7	40	43	O	been
8	45	53	O	conducted
NULL

Latanoprost	DDI-DrugBank.d118.s0	NO_SECTION	NO_SETID	17
In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	26	O	shown
6	28	31	O	that
7	33	45	O	precipitation
8	47	52	O	occurs
9	54	57	O	when
10	59	61	O	eye
11	63	67	O	drops
12	69	78	O	containing
13	80	89	U-UNK	thimerosal
14	91	93	O	are
15	95	99	O	mixed
16	101	104	O	with
17	106	116	O	XXXXXXXX
NULL

Latanoprost	DDI-DrugBank.d118.s1	NO_SECTION	NO_SETID	19
If such drugs are used they should be administered with an interval of at least 5 minutes between applications.
1	0	1	O	If
2	3	6	O	such
3	8	12	O	drugs
4	14	16	O	are
5	18	21	O	used
6	23	26	O	they
7	28	33	O	should
8	35	36	O	be
9	38	49	O	administered
10	51	54	O	with
11	56	57	O	an
12	59	66	O	interval
13	68	69	O	of
14	71	72	O	at
15	74	78	O	least
16	80	80	O	5
17	82	88	O	minutes
18	90	96	O	between
19	98	109	O	applications
NULL

Leflunomide	DDI-DrugBank.d41.s0	NO_SECTION	NO_SETID	31
Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .
1	0	13	U-UNK	Cholestyramine
2	15	17	O	and
3	19	26	U-UNK	Charcoal
4	28	41	O	Administration
5	43	44	O	of
6	46	59	U-KIN	cholestyramine
7	61	62	O	or
8	64	72	B-KIN	activated
9	74	81	L-KIN	charcoal
10	83	84	O	in
11	86	93	O	patients
12	96	99	O	n=13
13	102	104	O	and
14	106	115	O	volunteers
15	118	121	O	n=96
16	124	131	O	resulted
17	133	134	O	in
18	136	136	O	a
19	138	142	O	rapid
20	144	146	O	and
21	148	158	O	significant
22	160	167	O	decrease
23	169	170	O	in
24	172	177	O	plasma
25	179	180	O	M1
26	183	185	O	the
27	187	192	O	active
28	194	203	O	metabolite
29	205	206	O	of
30	208	218	O	XXXXXXXX
31	221	233	O	concentration
NULL

Leflunomide	DDI-DrugBank.d41.s1	NO_SECTION	NO_SETID	15
Hepatotoxic Drugs Increased side effects may occur when leflunomide is given concomitantly with hepatotoxic substances.
1	0	10	O	Hepatotoxic
2	12	16	O	Drugs
3	18	26	O	Increased
4	28	31	O	side
5	33	39	O	effects
6	41	43	O	may
7	45	49	O	occur
8	51	54	O	when
9	56	66	O	XXXXXXXX
10	68	69	O	is
11	71	75	O	given
12	77	89	O	concomitantly
13	91	94	O	with
14	96	106	O	hepatotoxic
15	108	117	O	substances
NULL

Leflunomide	DDI-DrugBank.d41.s2	NO_SECTION	NO_SETID	19
This is also to be considered when leflunomide treatment is followed by such drugs without a drug elimination procedure.
1	0	3	O	This
2	5	6	O	is
3	8	11	O	also
4	13	14	O	to
5	16	17	O	be
6	19	28	O	considered
7	30	33	O	when
8	35	45	O	XXXXXXXX
9	47	55	O	treatment
10	57	58	O	is
11	60	67	O	followed
12	69	70	O	by
13	72	75	O	such
14	77	81	O	drugs
15	83	89	O	without
16	91	91	O	a
17	93	96	O	drug
18	98	108	O	elimination
19	110	118	O	procedure
NULL

Leflunomide	DDI-DrugBank.d41.s3	NO_SECTION	NO_SETID	27
In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	small
4	12	15	O	n=30
5	18	28	O	combination
6	30	34	O	study
7	36	37	O	of
8	39	43	O	XXXXXXXX
9	45	48	O	with
10	50	61	U-DYN	methotrexate
11	62	62	O	,
12	64	64	O	a
13	66	66	O	2
14	69	70	O	to
15	72	72	O	3
16	74	77	O	fold
17	79	87	O	elevation
18	89	90	O	in
19	92	96	O	liver
20	98	104	O	enzymes
21	106	108	O	was
22	110	113	O	seen
23	115	116	O	in
24	118	118	O	5
25	120	121	O	of
26	123	124	O	30
27	126	133	O	patients
NULL

Leflunomide	DDI-DrugBank.d41.s4	NO_SECTION	NO_SETID	16
All elevations resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide.
1	0	2	O	All
2	4	13	O	elevations
3	15	22	O	resolved
4	23	23	O	,
5	25	25	O	2
6	27	30	O	with
7	32	43	O	continuation
8	45	46	O	of
9	48	51	O	both
10	53	57	O	drugs
11	59	61	O	and
12	63	63	O	3
13	65	69	O	after
14	71	85	O	discontinuation
15	87	88	O	of
16	90	100	O	XXXXXXXX
NULL

Leflunomide	DDI-DrugBank.d41.s5	NO_SECTION	NO_SETID	10
A  3-fold increase was seen in another 5 patients.
1	0	0	O	A
2	3	3	O	3
3	5	8	O	fold
4	10	17	O	increase
5	19	21	O	was
6	23	26	O	seen
7	28	29	O	in
8	31	37	O	another
9	39	39	O	5
10	41	48	O	patients
NULL

Leflunomide	DDI-DrugBank.d41.s6	NO_SECTION	NO_SETID	18
All of these also resolved, 2 with continuation of both drugs and 3 after discontinuation of leflunomide.
1	0	2	O	All
2	4	5	O	of
3	7	11	O	these
4	13	16	O	also
5	18	25	O	resolved
6	26	26	O	,
7	28	28	O	2
8	30	33	O	with
9	35	46	O	continuation
10	48	49	O	of
11	51	54	O	both
12	56	60	O	drugs
13	62	64	O	and
14	66	66	O	3
15	68	72	O	after
16	74	88	O	discontinuation
17	90	91	O	of
18	93	103	O	XXXXXXXX
NULL

Leflunomide	DDI-DrugBank.d41.s7	NO_SECTION	NO_SETID	19
Three patients met ACR criteria for liver biopsy (1: Roegnik Grade I, 2: Roegnik Grade IIIa).
1	0	4	O	Three
2	6	13	O	patients
3	15	17	O	met
4	19	21	O	ACR
5	23	30	O	criteria
6	32	34	O	for
7	36	40	O	liver
8	42	47	O	biopsy
9	50	50	O	1
10	51	51	O	:
11	53	59	O	Roegnik
12	61	65	O	Grade
13	67	67	O	I
14	68	68	O	,
15	70	70	O	2
16	71	71	O	:
17	73	79	O	Roegnik
18	81	85	O	Grade
19	87	90	O	IIIa
NULL

Leflunomide	DDI-DrugBank.d41.s8	NO_SECTION	NO_SETID	5
No pharmacokinetic interaction was identified.
1	0	1	O	No
2	3	17	O	pharmacokinetic
3	19	29	O	interaction
4	31	33	O	was
5	35	44	O	identified
NULL

Leflunomide	DDI-DrugBank.d41.s9	NO_SECTION	NO_SETID	31
NSAIDs: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range.
1	0	5	U-UNK	NSAIDs
2	6	6	O	:
3	8	9	O	In
4	11	12	O	in
5	14	18	O	vitro
6	20	26	O	studies
7	27	27	O	,
8	29	30	O	M1
9	32	34	O	was
10	36	40	O	shown
11	42	43	O	to
12	45	49	O	cause
13	51	59	O	increases
14	61	67	O	ranging
15	69	72	O	from
16	74	75	O	13
17	79	81	O	50%
18	83	84	O	in
19	86	88	O	the
20	90	93	O	free
21	95	102	O	fraction
22	104	105	O	of
23	107	116	U-UNK	diclofenac
24	118	120	O	and
25	122	130	U-UNK	ibuprofen
26	132	133	O	at
27	135	148	O	concentrations
28	150	151	O	in
29	153	155	O	the
30	157	164	O	clinical
31	166	170	O	range
NULL

Leflunomide	DDI-DrugBank.d41.s10	NO_SECTION	NO_SETID	8
The clinical significance of this finding is unknown;
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	40	O	finding
7	42	43	O	is
8	45	51	O	unknown
NULL

Leflunomide	DDI-DrugBank.d41.s11	NO_SECTION	NO_SETID	18
however, there was extensive concomitant use of NSAIDs in clinical studies and no differential effect was observed.
1	0	6	O	however
2	7	7	O	,
3	9	13	O	there
4	15	17	O	was
5	19	27	O	extensive
6	29	39	O	concomitant
7	41	43	O	use
8	45	46	O	of
9	48	53	U-UNK	NSAIDs
10	55	56	O	in
11	58	65	O	clinical
12	67	73	O	studies
13	75	77	O	and
14	79	80	O	no
15	82	93	O	differential
16	95	100	O	effect
17	102	104	O	was
18	106	113	O	observed
NULL

Leflunomide	DDI-DrugBank.d41.s12	NO_SECTION	NO_SETID	29
Tolbutamide: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of tolbutamide at concentrations in the clinical range.
1	0	10	U-UNK	Tolbutamide
2	11	11	O	:
3	13	14	O	In
4	16	17	O	in
5	19	23	O	vitro
6	25	31	O	studies
7	32	32	O	,
8	34	35	O	M1
9	37	39	O	was
10	41	45	O	shown
11	47	48	O	to
12	50	54	O	cause
13	56	64	O	increases
14	66	72	O	ranging
15	74	77	O	from
16	79	80	O	13
17	84	86	O	50%
18	88	89	O	in
19	91	93	O	the
20	95	98	O	free
21	100	107	O	fraction
22	109	110	O	of
23	112	122	U-UNK	tolbutamide
24	124	125	O	at
25	127	140	O	concentrations
26	142	143	O	in
27	145	147	O	the
28	149	156	O	clinical
29	158	162	O	range
NULL

Leflunomide	DDI-DrugBank.d41.s13	NO_SECTION	NO_SETID	8
The clinical significance of this finding is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	40	O	finding
7	42	43	O	is
8	45	51	O	unknown
NULL

Leflunomide	DDI-DrugBank.d41.s14	NO_SECTION	NO_SETID	33
Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.
1	0	7	U-UNK	Rifampin
2	8	8	O	:
3	10	18	O	Following
4	20	30	O	concomitant
5	32	45	O	administration
6	47	48	O	of
7	50	50	O	a
8	52	57	O	single
9	59	62	O	dose
10	64	65	O	of
11	67	71	O	XXXXXXXX
12	73	74	O	to
13	76	83	O	subjects
14	85	93	O	receiving
15	95	102	O	multiple
16	104	108	O	doses
17	110	111	O	of
18	113	120	U-KIN	rifampin
19	121	121	O	,
20	123	124	O	M1
21	126	129	O	peak
22	131	136	O	levels
23	138	141	O	were
24	143	151	O	increased
25	154	157	O	~40%
26	160	163	O	over
27	165	169	O	those
28	171	174	O	seen
29	176	179	O	when
30	181	185	O	XXXXXXXX
31	187	189	O	was
32	191	195	O	given
33	197	201	O	alone
NULL

Leflunomide	DDI-DrugBank.d41.s15	NO_SECTION	NO_SETID	29
Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	23	O	potential
5	25	27	O	for
6	29	33	O	XXXXXXXX
7	35	40	O	levels
8	42	43	O	to
9	45	52	O	continue
10	54	55	O	to
11	57	64	O	increase
12	66	69	O	with
13	71	78	O	multiple
14	80	85	O	dosing
15	86	86	O	,
16	88	94	O	caution
17	96	101	O	should
18	103	104	O	be
19	106	109	O	used
20	111	112	O	if
21	114	121	O	patients
22	123	125	O	are
23	127	128	O	to
24	130	131	O	be
25	133	141	O	receiving
26	143	146	O	both
27	148	152	O	XXXXXXXX
28	154	156	O	and
29	158	165	U-DYN	rifampin
NULL

Leflunomide	DDI-DrugBank.d41.s16	NO_SECTION	NO_SETID	18
Warfarin: Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	18	O	Increased
4	20	22	O	INR
5	25	37	O	International
6	39	48	O	Normalized
7	50	54	O	Ratio
8	57	60	O	when
9	62	66	O	XXXXXXXX
10	68	70	O	and
11	72	79	U-DYN	warfarin
12	81	84	O	were
13	86	87	O	co
14	89	100	O	administered
15	102	104	O	has
16	106	109	O	been
17	111	116	O	rarely
18	118	125	O	reported
NULL

Lenalidomide	DDI-DrugBank.d169.s0	NO_SECTION	NO_SETID	45
Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID  (lenalidomide) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450-based metabolic drug interactions in man.
1	0	6	O	Results
2	8	11	O	from
3	13	17	O	human
4	19	20	O	in
5	22	26	O	vitro
6	28	37	O	metabolism
7	39	45	O	studies
8	47	49	O	and
9	51	61	O	nonclinical
10	63	69	O	studies
11	71	74	O	show
12	76	79	O	that
13	81	88	O	XXXXXXXX
14	92	103	U-UNK	lenalidomide
15	106	107	O	is
16	109	115	O	neither
17	117	127	O	metabolized
18	129	130	O	by
19	132	134	O	nor
20	136	143	O	inhibits
21	145	146	O	or
22	148	154	O	induces
23	156	158	O	the
24	160	169	O	cytochrome
25	171	174	O	P450
26	176	182	O	pathway
27	184	193	O	suggesting
28	195	198	O	that
29	200	211	U-UNK	lenalidomide
30	213	214	O	is
31	216	218	O	not
32	220	225	O	likely
33	227	228	O	to
34	230	234	O	cause
35	236	237	O	or
36	239	240	O	be
37	242	248	O	subject
38	250	251	O	to
39	253	256	O	P450
40	258	262	O	based
41	264	272	O	metabolic
42	274	277	O	drug
43	279	290	O	interactions
44	292	293	O	in
45	295	297	O	man
NULL

Lenalidomide	DDI-DrugBank.d169.s1	NO_SECTION	NO_SETID	23
Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of R- and S- warfarin.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	28	O	multiple
5	30	34	O	doses
6	36	37	O	of
7	39	40	O	10
8	42	43	O	mg
9	45	46	O	of
10	48	59	O	XXXXXXXX
11	61	63	O	had
12	65	66	O	no
13	68	73	O	effect
14	75	76	O	on
15	78	80	O	the
16	82	87	O	single
17	89	92	O	dose
18	94	109	O	pharmacokinetics
19	111	112	O	of
20	114	114	B-UNK	R
21	117	119	I-UNK	and
22	121	121	I-UNK	S
23	124	131	L-UNK	warfarin
NULL

Lenalidomide	DDI-DrugBank.d169.s2	NO_SECTION	NO_SETID	17
Co-administration of single 25-mg dose warfarin had no effect on the pharmacokinetics of total lenalidomide.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	26	O	single
5	28	29	O	25
6	31	32	O	mg
7	34	37	O	dose
8	39	46	U-UNK	warfarin
9	48	50	O	had
10	52	53	O	no
11	55	60	O	effect
12	62	63	O	on
13	65	67	O	the
14	69	84	O	pharmacokinetics
15	86	87	O	of
16	89	93	O	total
17	95	106	O	XXXXXXXX
NULL

Lenalidomide	DDI-DrugBank.d169.s3	NO_SECTION	NO_SETID	25
Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant lenalidomide administration.
1	0	7	O	Expected
2	9	15	O	changes
3	17	18	O	in
4	20	29	O	laboratory
5	31	41	O	assessments
6	43	44	O	of
7	46	47	O	PT
8	49	51	O	and
9	53	55	O	INR
10	57	60	O	were
11	62	69	O	observed
12	71	75	O	after
13	77	84	U-UNK	warfarin
14	86	99	O	administration
15	100	100	O	,
16	102	104	O	but
17	106	110	O	these
18	112	118	O	changes
19	120	123	O	were
20	125	127	O	not
21	129	136	O	affected
22	138	139	O	by
23	141	151	O	concomitant
24	153	164	O	XXXXXXXX
25	166	179	O	administration
NULL

Lepirudin	DDI-DrugBank.d52.s0	NO_SECTION	NO_SETID	27
Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation
1	0	10	O	Concomitant
2	12	20	O	treatment
3	22	25	O	with
4	27	39	U-UNK	thrombolytics
5	42	43	O	eg
6	44	44	O	,
7	46	47	O	rt
8	49	50	O	PA
9	52	53	O	or
10	55	67	U-UNK	streptokinase
11	70	72	O	may
12	73	73	O	:
13	77	84	O	increase
14	86	88	O	the
15	90	93	O	risk
16	95	96	O	of
17	98	105	O	bleeding
18	107	119	O	complications
19	123	134	O	considerably
20	136	142	O	enhance
21	144	146	O	the
22	148	153	O	effect
23	155	156	O	of
24	158	165	O	XXXXXXXX
25	167	168	O	on
26	170	173	O	aPTT
27	175	186	O	prolongation
NULL

Lepirudin	DDI-DrugBank.d52.s1	NO_SECTION	NO_SETID	21
Concomitant treatment with coumarin derivatives (vitamin K antagonists) and drugs that affect platelet function may also increase the risk of bleeding.
1	0	10	O	Concomitant
2	12	20	O	treatment
3	22	25	O	with
4	27	34	B-UNK	coumarin
5	36	46	L-UNK	derivatives
6	49	55	B-UNK	vitamin
7	57	57	I-UNK	K
8	59	69	L-UNK	antagonists
9	72	74	O	and
10	76	80	O	drugs
11	82	85	O	that
12	87	92	O	affect
13	94	101	O	platelet
14	103	110	O	function
15	112	114	O	may
16	116	119	O	also
17	121	128	O	increase
18	130	132	O	the
19	134	137	O	risk
20	139	140	O	of
21	142	149	O	bleeding
NULL

Letrozole	DDI-DrugBank.d157.s0	NO_SECTION	NO_SETID	24
Clinical interaction studies with cimetidine and warfarin indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.
1	0	7	O	Clinical
2	9	19	O	interaction
3	21	27	O	studies
4	29	32	O	with
5	34	43	U-UNK	cimetidine
6	45	47	O	and
7	49	56	U-UNK	warfarin
8	58	66	O	indicated
9	68	71	O	that
10	73	75	O	the
11	77	92	O	coadministration
12	94	95	O	of
13	97	102	O	XXXXXXXX
14	104	107	O	with
15	109	113	O	these
16	115	119	O	drugs
17	121	124	O	does
18	126	128	O	not
19	130	135	O	result
20	137	138	O	in
21	140	149	O	clinically
22	152	162	O	significant
23	164	167	O	drug
24	169	180	O	interactions
NULL

Letrozole	DDI-DrugBank.d157.s1	NO_SECTION	NO_SETID	23
(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.
1	1	3	O	See
2	5	12	O	CLINICAL
3	14	25	O	PHARMACOLOGY
4	28	43	O	Coadministration
5	45	46	O	of
6	48	53	O	XXXXXXXX
7	55	57	O	and
8	59	67	U-KIN	tamoxifen
9	69	70	O	20
10	72	73	O	mg
11	75	79	O	daily
12	81	88	O	resulted
13	90	91	O	in
14	93	93	O	a
15	95	103	O	reduction
16	105	106	O	of
17	108	116	U-UNK	letrozole
18	118	123	O	plasma
19	125	130	O	levels
20	132	133	O	by
21	135	137	O	38%
22	139	140	O	on
23	142	148	O	average
NULL

Letrozole	DDI-DrugBank.d157.s2	NO_SECTION	NO_SETID	18
There is no clinical experience to date on the use of Femara in combination with other anticancer agents.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	19	O	clinical
5	21	30	O	experience
6	32	33	O	to
7	35	38	O	date
8	40	41	O	on
9	43	45	O	the
10	47	49	O	use
11	51	52	O	of
12	54	59	O	XXXXXXXX
13	61	62	O	in
14	64	74	O	combination
15	76	79	O	with
16	81	85	O	other
17	87	96	O	anticancer
18	98	103	O	agents
NULL

Letrozole	DDI-DrugBank.d157.s3	NO_SECTION	NO_SETID	7
Drug/Laboratory Test-Interactions None observed.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	37	O	None
7	39	46	O	observed
NULL

Leucovorin	DDI-DrugBank.d151.s0	NO_SECTION	NO_SETID	27
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.
1	0	4	B-UNK	Folic
2	6	9	L-UNK	acid
3	11	12	O	in
4	14	18	O	large
5	20	26	O	amounts
6	28	30	O	may
7	32	41	O	counteract
8	43	45	O	the
9	47	59	O	antiepileptic
10	61	66	O	effect
11	68	69	O	of
12	71	83	U-UNK	phenobarbital
13	84	84	O	,
14	86	94	U-UNK	phenytoin
15	96	98	O	and
16	100	108	U-UNK	primidone
17	109	109	O	,
18	111	113	O	and
19	115	122	O	increase
20	124	126	O	the
21	128	136	O	frequency
22	138	139	O	of
23	141	148	O	seizures
24	150	151	O	in
25	153	163	O	susceptible
26	165	173	O	pediatric
27	175	182	O	patients
NULL

Leucovorin	DDI-DrugBank.d151.s1	NO_SECTION	NO_SETID	43
Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.
1	0	10	O	Preliminary
2	12	17	O	animal
3	19	21	O	and
4	23	27	O	human
5	29	35	O	studies
6	37	40	O	have
7	42	46	O	shown
8	48	51	O	that
9	53	57	O	small
10	59	68	O	quantities
11	70	71	O	of
12	73	84	O	systemically
13	86	97	O	administered
14	99	108	O	XXXXXXXX
15	110	114	O	enter
16	116	118	O	the
17	120	122	O	CSF
18	124	132	O	primarily
19	134	135	O	as
20	137	137	O	5
21	139	154	O	methyltetrahydro
22	156	161	O	folate
23	163	165	O	and
24	166	166	O	,
25	168	169	O	in
26	171	176	O	humans
27	177	177	O	,
28	179	184	O	remain
29	186	186	O	1
30	188	189	O	to
31	191	191	O	3
32	193	198	O	orders
33	200	201	O	of
34	203	211	O	magnitude
35	213	217	O	lower
36	219	222	O	than
37	224	226	O	the
38	228	232	O	usual
39	234	245	U-UNK	methotrexate
40	247	260	O	concentrations
41	262	270	O	following
42	272	282	O	intrathecal
43	284	297	O	administration
NULL

Leucovorin	DDI-DrugBank.d151.s2	NO_SECTION	NO_SETID	14
However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.
1	0	6	O	However
2	7	7	O	,
3	9	12	O	high
4	14	18	O	doses
5	20	21	O	of
6	23	32	O	XXXXXXXX
7	34	36	O	may
8	38	43	O	reduce
9	45	47	O	the
10	49	56	O	efficacy
11	58	59	O	of
12	61	73	O	intrathecally
13	75	86	O	administered
14	88	99	U-DYN	methotrexate
NULL

Leucovorin	DDI-DrugBank.d151.s3	NO_SECTION	NO_SETID	8
Leucovorin may enhance the toxicity of 5-fluorouracil.
1	0	9	O	XXXXXXXX
2	11	13	O	may
3	15	21	O	enhance
4	23	25	O	the
5	27	34	O	toxicity
6	36	37	O	of
7	39	39	B-DYN	5
8	41	52	L-DYN	fluorouracil
NULL

Levamisole	DDI-DrugBank.d381.s0	NO_SECTION	NO_SETID	17
ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.
1	0	8	O	XXXXXXXX
2	12	21	B-UNK	levamisole
3	23	35	L-UNK	hydrochloride
4	38	40	O	has
5	42	45	O	been
6	47	54	O	reported
7	56	57	O	to
8	59	65	O	produce
9	67	74	O	ANTABUSE
10	76	79	O	like
11	81	84	O	side
12	86	92	O	effects
13	94	97	O	when
14	99	103	O	given
15	105	117	O	concomitantly
16	119	122	O	with
17	124	130	U-DYN	alcohol
NULL

Levamisole	DDI-DrugBank.d381.s1	NO_SECTION	NO_SETID	17
The physician is advised to monitor plasma levels of phenytoin and to decrease the dose if necessary.
1	0	2	O	The
2	4	12	O	physician
3	14	15	O	is
4	17	23	O	advised
5	25	26	O	to
6	28	34	O	monitor
7	36	41	O	plasma
8	43	48	O	levels
9	50	51	O	of
10	53	61	U-UNK	phenytoin
11	63	65	O	and
12	67	68	O	to
13	70	77	O	decrease
14	79	81	O	the
15	83	86	O	dose
16	88	89	O	if
17	91	99	O	necessary
NULL

Levamisole	DDI-DrugBank.d381.s2	NO_SECTION	NO_SETID	54
Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.
1	0	6	O	Because
2	8	9	O	of
3	11	17	O	reports
4	19	20	O	of
5	22	33	O	prolongation
6	35	36	O	of
7	38	40	O	the
8	42	52	O	prothrombin
9	54	57	O	time
10	59	64	O	beyond
11	66	68	O	the
12	70	80	O	therapeutic
13	82	86	O	range
14	88	89	O	in
15	91	98	O	patients
16	100	105	O	taking
17	107	116	O	concurrent
18	118	127	O	XXXXXXXX
19	129	131	O	and
20	133	140	B-DYN	warfarin
21	142	147	L-DYN	sodium
22	148	148	O	,
23	150	151	O	it
24	153	154	O	is
25	156	164	O	suggested
26	166	169	O	that
27	171	173	O	the
28	175	185	O	prothrombin
29	187	190	O	time
30	192	193	O	be
31	195	203	O	monitored
32	205	213	O	carefully
33	214	214	O	,
34	216	218	O	and
35	220	222	O	the
36	224	227	O	dose
37	229	230	O	of
38	232	239	B-UNK	warfarin
39	241	246	L-UNK	sodium
40	248	249	O	or
41	251	255	O	other
42	257	264	U-UNK	coumarin
43	266	269	O	like
44	271	275	O	drugs
45	277	282	O	should
46	284	285	O	be
47	287	294	O	adjusted
48	296	306	O	accordingly
49	307	307	O	,
50	309	310	O	in
51	312	319	O	patients
52	321	326	O	taking
53	328	331	O	both
54	333	337	O	drugs
NULL

Levetiracetam	DDI-DrugBank.d212.s0	NO_SECTION	NO_SETID	21
in vitro data on metabolic interactions indicate that Keppra  is unlikely to produce, or be subject to, pharmacokinetic interactions.
1	0	1	O	in
2	3	7	O	vitro
3	9	12	O	data
4	14	15	O	on
5	17	25	O	metabolic
6	27	38	O	interactions
7	40	47	O	indicate
8	49	52	O	that
9	54	59	O	XXXXXXXX
10	62	63	O	is
11	65	72	O	unlikely
12	74	75	O	to
13	77	83	O	produce
14	84	84	O	,
15	86	87	O	or
16	89	90	O	be
17	92	98	O	subject
18	100	101	O	to
19	102	102	O	,
20	104	118	O	pharmacokinetic
21	120	131	O	interactions
NULL

Levetiracetam	DDI-DrugBank.d212.s1	NO_SECTION	NO_SETID	40
Levetiracetam and its major metabolite, at concentrations well above cmax levels achieved within the therapeutic dose range, are neither inhibitors of nor high affinity substrates for human liver cytochrome P450 isoforms, epoxide hydrolase or UDP-glucuronidation enzymes.
1	0	12	O	XXXXXXXX
2	14	16	O	and
3	18	20	O	its
4	22	26	O	major
5	28	37	O	metabolite
6	38	38	O	,
7	40	41	O	at
8	43	56	O	concentrations
9	58	61	O	well
10	63	67	O	above
11	69	72	O	cmax
12	74	79	O	levels
13	81	88	O	achieved
14	90	95	O	within
15	97	99	O	the
16	101	111	O	therapeutic
17	113	116	O	dose
18	118	122	O	range
19	123	123	O	,
20	125	127	O	are
21	129	135	O	neither
22	137	146	O	inhibitors
23	148	149	O	of
24	151	153	O	nor
25	155	158	O	high
26	160	167	O	affinity
27	169	178	O	substrates
28	180	182	O	for
29	184	188	O	human
30	190	194	O	liver
31	196	205	O	cytochrome
32	207	210	O	P450
33	212	219	O	isoforms
34	220	220	O	,
35	222	228	O	epoxide
36	230	238	O	hydrolase
37	240	241	O	or
38	243	245	O	UDP
39	247	261	O	glucuronidation
40	263	269	O	enzymes
NULL

Levetiracetam	DDI-DrugBank.d212.s2	NO_SECTION	NO_SETID	14
In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	25	O	XXXXXXXX
5	27	30	O	does
6	32	34	O	not
7	36	41	O	affect
8	43	45	O	the
9	47	48	O	in
10	50	54	O	vitro
11	56	70	O	glucuronidation
12	72	73	O	of
13	75	82	B-UNK	valproic
14	84	87	L-UNK	acid
NULL

Levetiracetam	DDI-DrugBank.d212.s3	NO_SECTION	NO_SETID	9
Levetiracetam circulates largely unbound ( 10% bound) to plasma proteins;
1	0	12	O	XXXXXXXX
2	14	23	O	circulates
3	25	31	O	largely
4	33	39	O	unbound
5	43	45	O	10%
6	47	51	O	bound
7	54	55	O	to
8	57	62	O	plasma
9	64	71	O	proteins
NULL

Levetiracetam	DDI-DrugBank.d212.s4	NO_SECTION	NO_SETID	15
clinically significant interactions with other drugs through competition for protein binding sites are therefore unlikely.
1	0	9	O	clinically
2	11	21	O	significant
3	23	34	O	interactions
4	36	39	O	with
5	41	45	O	other
6	47	51	O	drugs
7	53	59	O	through
8	61	71	O	competition
9	73	75	O	for
10	77	83	O	protein
11	85	91	O	binding
12	93	97	O	sites
13	99	101	O	are
14	103	111	O	therefore
15	113	120	O	unlikely
NULL

Levetiracetam	DDI-DrugBank.d212.s5	NO_SECTION	NO_SETID	34
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.
1	0	8	O	Potential
2	10	24	O	pharmacokinetic
3	26	37	O	interactions
4	39	42	O	were
5	44	51	O	assessed
6	53	54	O	in
7	56	63	O	clinical
8	65	79	O	pharmacokinetic
9	81	87	O	studies
10	90	98	U-UNK	phenytoin
11	99	99	O	,
12	101	109	U-UNK	valproate
13	110	110	O	,
14	112	115	O	oral
15	117	129	U-UNK	contraceptive
16	130	130	O	,
17	132	138	U-UNK	digoxin
18	139	139	O	,
19	141	148	U-UNK	warfarin
20	149	149	O	,
21	151	160	U-UNK	probenecid
22	163	165	O	and
23	167	173	O	through
24	175	189	O	pharmacokinetic
25	191	199	O	screening
26	201	202	O	in
27	204	206	O	the
28	208	214	O	placebo
29	216	225	O	controlled
30	227	234	O	clinical
31	236	242	O	studies
32	244	245	O	in
33	247	254	O	epilepsy
34	256	263	O	patients
NULL

Levetiracetam	DDI-DrugBank.d212.s6	NO_SECTION	NO_SETID	29
Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	21	O	Interactions
4	23	29	O	Between
5	31	36	O	XXXXXXXX
6	39	41	O	And
7	43	47	O	Other
8	49	61	B-UNK	Antiepileptic
9	63	67	L-UNK	Drugs
10	70	73	U-UNK	AEDs
11	76	84	U-UNK	Phenytoin
12	86	91	O	XXXXXXXX
13	95	98	O	3000
14	100	101	O	mg
15	103	107	O	daily
16	110	112	O	had
17	114	115	O	no
18	117	122	O	effect
19	124	125	O	on
20	127	129	O	the
21	131	145	O	pharmacokinetic
22	147	157	O	disposition
23	159	160	O	of
24	162	170	U-UNK	phenytoin
25	172	173	O	in
26	175	182	O	patients
27	184	187	O	with
28	189	198	O	refractory
29	200	207	O	epilepsy
NULL

Levetiracetam	DDI-DrugBank.d212.s7	NO_SECTION	NO_SETID	9
Pharmacokinetics of levetiracetam were also not affected by phenytoin.
1	0	15	O	Pharmacokinetics
2	17	18	O	of
3	20	32	O	XXXXXXXX
4	34	37	O	were
5	39	42	O	also
6	44	46	O	not
7	48	55	O	affected
8	57	58	O	by
9	60	68	U-UNK	phenytoin
NULL

Levetiracetam	DDI-DrugBank.d212.s8	NO_SECTION	NO_SETID	16
Valproate Keppra  (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers.
1	0	8	U-UNK	Valproate
2	10	15	O	XXXXXXXX
3	19	22	O	1500
4	24	25	O	mg
5	27	31	O	twice
6	33	37	O	daily
7	40	42	O	did
8	44	46	O	not
9	48	52	O	alter
10	54	56	O	the
11	58	73	O	pharmacokinetics
12	75	76	O	of
13	78	86	U-UNK	valproate
14	88	89	O	in
15	91	97	O	healthy
16	99	108	O	volunteers
NULL

Levetiracetam	DDI-DrugBank.d212.s9	NO_SECTION	NO_SETID	22
Valproate 500 mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion.
1	0	8	U-UNK	Valproate
2	10	12	O	500
3	14	15	O	mg
4	17	21	O	twice
5	23	27	O	daily
6	29	31	O	did
7	33	35	O	not
8	37	42	O	modify
9	44	46	O	the
10	48	51	O	rate
11	53	54	O	or
12	56	61	O	extent
13	63	64	O	of
14	66	78	O	XXXXXXXX
15	80	89	O	absorption
16	91	92	O	or
17	94	96	O	its
18	98	103	O	plasma
19	105	113	O	clearance
20	115	116	O	or
21	118	124	O	urinary
22	126	134	O	excretion
NULL

Levetiracetam	DDI-DrugBank.d212.s10	NO_SECTION	NO_SETID	18
There also was no effect on exposure to and the excretion of the primary metabolite, ucb L057.
1	0	4	O	There
2	6	9	O	also
3	11	13	O	was
4	15	16	O	no
5	18	23	O	effect
6	25	26	O	on
7	28	35	O	exposure
8	37	38	O	to
9	40	42	O	and
10	44	46	O	the
11	48	56	O	excretion
12	58	59	O	of
13	61	63	O	the
14	65	71	O	primary
15	73	82	O	metabolite
16	83	83	O	,
17	85	87	O	ucb
18	89	92	O	L057
NULL

Levetiracetam	DDI-DrugBank.d212.s11	NO_SECTION	NO_SETID	39
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
1	0	8	O	Potential
2	10	13	O	drug
3	15	26	O	interactions
4	28	34	O	between
5	36	41	O	XXXXXXXX
6	44	46	O	and
7	48	52	O	other
8	54	57	U-UNK	AEDs
9	60	72	U-UNK	carbamazepine
10	73	73	O	,
11	75	84	U-UNK	gabapentin
12	85	85	O	,
13	87	97	U-UNK	lamotrigine
14	98	98	O	,
15	100	112	U-UNK	phenobarbital
16	113	113	O	,
17	115	123	U-UNK	phenytoin
18	124	124	O	,
19	126	134	U-UNK	primidone
20	136	138	O	and
21	140	148	U-UNK	valproate
22	151	154	O	were
23	156	159	O	also
24	161	168	O	assessed
25	170	171	O	by
26	173	182	O	evaluating
27	184	186	O	the
28	188	192	O	serum
29	194	207	O	concentrations
30	209	210	O	of
31	212	224	U-UNK	levetiracetam
32	226	228	O	and
33	230	234	O	these
34	236	239	U-UNK	AEDs
35	241	246	O	during
36	248	254	O	placebo
37	256	265	O	controlled
38	267	274	O	clinical
39	276	282	O	studies
NULL

Levetiracetam	DDI-DrugBank.d212.s12	NO_SECTION	NO_SETID	25
These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.
1	0	4	O	These
2	6	9	O	data
3	11	18	O	indicate
4	20	23	O	that
5	25	37	O	XXXXXXXX
6	39	42	O	does
7	44	46	O	not
8	48	56	O	influence
9	58	60	O	the
10	62	67	O	plasma
11	69	81	O	concentration
12	83	84	O	of
13	86	90	O	other
14	92	95	U-UNK	AEDs
15	97	99	O	and
16	101	104	O	that
17	106	110	O	these
18	112	115	U-UNK	AEDs
19	117	118	O	do
20	120	122	O	not
21	124	132	O	influence
22	134	136	O	the
23	138	153	O	pharmacokinetics
24	155	156	O	of
25	158	170	O	XXXXXXXX
NULL

Levetiracetam	DDI-DrugBank.d212.s13	NO_SECTION	NO_SETID	28
Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.
1	0	5	O	Effect
2	7	8	O	of
3	10	13	U-UNK	AEDs
4	15	16	O	in
5	18	26	O	Pediatric
6	28	35	O	Patients
7	37	41	O	There
8	43	45	O	was
9	47	51	O	about
10	53	53	O	a
11	55	57	O	22%
12	59	66	O	increase
13	68	69	O	of
14	71	78	O	apparent
15	80	84	O	total
16	86	89	O	body
17	91	99	O	clearance
18	101	102	O	of
19	104	116	O	XXXXXXXX
20	118	121	O	when
21	123	124	O	it
22	126	128	O	was
23	130	131	O	co
24	133	144	O	administered
25	146	149	O	with
26	151	156	O	enzyme
27	158	165	O	inducing
28	167	170	U-KIN	AEDs
NULL

Levetiracetam	DDI-DrugBank.d212.s14	NO_SECTION	NO_SETID	21
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine.
1	0	3	O	Dose
2	5	14	O	adjustment
3	16	17	O	is
4	19	21	O	not
5	23	33	O	recommended
6	35	47	O	XXXXXXXX
7	49	51	O	had
8	53	54	O	no
9	56	61	O	effect
10	63	64	O	on
11	66	71	O	plasma
12	73	86	O	concentrations
13	88	89	O	of
14	91	103	U-UNK	carbamazepine
15	104	104	O	,
16	106	114	U-UNK	valproate
17	115	115	O	,
18	117	126	U-UNK	topiramate
19	127	127	O	,
20	129	130	O	or
21	132	142	U-UNK	lamotrigine
NULL

Levetiracetam	DDI-DrugBank.d212.s15	NO_SECTION	NO_SETID	46
Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.
1	0	4	O	Other
2	6	9	O	Drug
3	11	22	O	Interactions
4	24	27	O	Oral
5	29	42	U-UNK	Contraceptives
6	44	49	O	XXXXXXXX
7	53	55	O	500
8	57	58	O	mg
9	60	64	O	twice
10	66	70	O	daily
11	73	75	O	did
12	77	79	O	not
13	81	89	O	influence
14	91	93	O	the
15	95	110	O	pharmacokinetics
16	112	113	O	of
17	115	116	O	an
18	118	121	O	oral
19	123	135	U-UNK	contraceptive
20	137	146	O	containing
21	148	151	O	0.03
22	153	154	O	mg
23	156	162	B-UNK	ethinyl
24	164	172	L-UNK	estradiol
25	174	176	O	and
26	178	181	O	0.15
27	183	184	O	mg
28	186	199	U-UNK	levonorgestrel
29	200	200	O	,
30	202	203	O	or
31	205	206	O	of
32	208	210	O	the
33	212	222	O	luteinizing
34	224	230	O	hormone
35	232	234	O	and
36	236	247	O	progesterone
37	249	254	O	levels
38	255	255	O	,
39	257	266	O	indicating
40	268	271	O	that
41	273	282	O	impairment
42	284	285	O	of
43	287	299	O	contraceptive
44	301	308	O	efficacy
45	310	311	O	is
46	313	320	O	unlikely
NULL

Levetiracetam	DDI-DrugBank.d212.s16	NO_SECTION	NO_SETID	12
Coadministration of this oral contraceptive did not influence the pharmacokinetics of levetiracetam.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	23	O	this
4	25	28	O	oral
5	30	42	U-UNK	contraceptive
6	44	46	O	did
7	48	50	O	not
8	52	60	O	influence
9	62	64	O	the
10	66	81	O	pharmacokinetics
11	83	84	O	of
12	86	98	O	XXXXXXXX
NULL

Levetiracetam	DDI-DrugBank.d212.s17	NO_SECTION	NO_SETID	24
Digoxin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day.
1	0	6	U-UNK	Digoxin
2	8	13	O	XXXXXXXX
3	17	20	O	1000
4	22	23	O	mg
5	25	29	O	twice
6	31	35	O	daily
7	38	40	O	did
8	42	44	O	not
9	46	54	O	influence
10	56	58	O	the
11	60	75	O	pharmacokinetics
12	77	79	O	and
13	81	96	O	pharmacodynamics
14	99	101	O	ECG
15	104	105	O	of
16	107	113	U-UNK	digoxin
17	115	119	O	given
18	121	122	O	as
19	124	124	O	a
20	126	129	O	0.25
21	131	132	O	mg
22	134	137	O	dose
23	139	143	O	every
24	145	147	O	day
NULL

Levetiracetam	DDI-DrugBank.d212.s18	NO_SECTION	NO_SETID	10
Coadministration of digoxin did not influence the pharmacokinetics of levetiracetam.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	26	U-UNK	digoxin
4	28	30	O	did
5	32	34	O	not
6	36	44	O	influence
7	46	48	O	the
8	50	65	O	pharmacokinetics
9	67	68	O	of
10	70	82	O	XXXXXXXX
NULL

Levetiracetam	DDI-DrugBank.d212.s19	NO_SECTION	NO_SETID	16
Warfarin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin.
1	0	7	U-UNK	Warfarin
2	9	14	O	XXXXXXXX
3	18	21	O	1000
4	23	24	O	mg
5	26	30	O	twice
6	32	36	O	daily
7	39	41	O	did
8	43	45	O	not
9	47	55	O	influence
10	57	59	O	the
11	61	76	O	pharmacokinetics
12	78	79	O	of
13	81	81	B-UNK	R
14	83	85	I-UNK	and
15	87	87	I-UNK	S
16	89	96	L-UNK	warfarin
NULL

Levetiracetam	DDI-DrugBank.d212.s20	NO_SECTION	NO_SETID	7
Prothrombin time was not affected by levetiracetam.
1	0	10	O	Prothrombin
2	12	15	O	time
3	17	19	O	was
4	21	23	O	not
5	25	32	O	affected
6	34	35	O	by
7	37	49	O	XXXXXXXX
NULL

Levetiracetam	DDI-DrugBank.d212.s21	NO_SECTION	NO_SETID	10
Coadministration of warfarin did not affect the pharmacokinetics of levetiracetam.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	27	U-UNK	warfarin
4	29	31	O	did
5	33	35	O	not
6	37	42	O	affect
7	44	46	O	the
8	48	63	O	pharmacokinetics
9	65	66	O	of
10	68	80	O	XXXXXXXX
NULL

Levetiracetam	DDI-DrugBank.d212.s22	NO_SECTION	NO_SETID	34
Probenecid: Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1000 mg twice daily.
1	0	9	U-UNK	Probenecid
2	10	10	O	:
3	12	21	U-UNK	Probenecid
4	22	22	O	,
5	24	24	O	a
6	26	30	O	renal
7	32	38	O	tubular
8	40	48	O	secretion
9	50	57	O	blocking
10	59	63	O	agent
11	64	64	O	,
12	66	77	O	administered
13	79	80	O	at
14	82	82	O	a
15	84	87	O	dose
16	89	90	O	of
17	92	94	O	500
18	96	97	O	mg
19	99	102	O	four
20	104	108	O	times
21	110	110	O	a
22	112	114	O	day
23	115	115	O	,
24	117	119	O	did
25	121	123	O	not
26	125	130	O	change
27	132	134	O	the
28	136	151	O	pharmacokinetics
29	153	154	O	of
30	156	168	O	XXXXXXXX
31	170	173	O	1000
32	175	176	O	mg
33	178	182	O	twice
34	184	188	O	daily
NULL

Levetiracetam	DDI-DrugBank.d212.s23	NO_SECTION	NO_SETID	29
Cssmax of the metabolite, ucb L057, was approximately doubled in the presence of probenecid while the fraction of drug excreted unchanged in the urine remained the same.
1	0	5	O	Cssmax
2	7	8	O	of
3	10	12	O	the
4	14	23	O	metabolite
5	24	24	O	,
6	26	28	O	ucb
7	30	33	O	L057
8	34	34	O	,
9	36	38	O	was
10	40	52	O	approximately
11	54	60	O	doubled
12	62	63	O	in
13	65	67	O	the
14	69	76	O	presence
15	78	79	O	of
16	81	90	U-UNK	probenecid
17	92	96	O	while
18	98	100	O	the
19	102	109	O	fraction
20	111	112	O	of
21	114	117	O	drug
22	119	126	O	excreted
23	128	136	O	unchanged
24	138	139	O	in
25	141	143	O	the
26	145	149	O	urine
27	151	158	O	remained
28	160	162	O	the
29	164	167	O	same
NULL

Levetiracetam	DDI-DrugBank.d212.s24	NO_SECTION	NO_SETID	24
Renal clearance of ucb L057 in the presence of probenecid decreased 60%, probably related to competitive inhibition of tubular secretion of ucb L057.
1	0	4	O	Renal
2	6	14	O	clearance
3	16	17	O	of
4	19	21	O	ucb
5	23	26	O	L057
6	28	29	O	in
7	31	33	O	the
8	35	42	O	presence
9	44	45	O	of
10	47	56	U-UNK	probenecid
11	58	66	O	decreased
12	68	70	O	60%
13	71	71	O	,
14	73	80	O	probably
15	82	88	O	related
16	90	91	O	to
17	93	103	O	competitive
18	105	114	O	inhibition
19	116	117	O	of
20	119	125	O	tubular
21	127	135	O	secretion
22	137	138	O	of
23	140	142	O	ucb
24	144	147	O	L057
NULL

Levetiracetam	DDI-DrugBank.d212.s25	NO_SECTION	NO_SETID	9
The effect of Keppra  on probenecid was not studied.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	19	O	XXXXXXXX
5	22	23	O	on
6	25	34	U-UNK	probenecid
7	36	38	O	was
8	40	42	O	not
9	44	50	O	studied
NULL

Levobunolol	DDI-DrugBank.d252.s0	NO_SECTION	NO_SETID	24
Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.
1	0	7	O	Although
2	9	15	O	XXXXXXXX
3	17	20	O	used
4	22	26	O	alone
5	28	30	O	has
6	32	37	O	little
7	39	40	O	or
8	42	43	O	no
9	45	50	O	effect
10	52	53	O	on
11	55	59	O	pupil
12	61	64	O	size
13	65	65	O	,
14	67	75	O	mydriasis
15	77	85	O	resulting
16	87	90	O	from
17	92	102	O	concomitant
18	104	110	O	therapy
19	112	115	O	with
20	117	123	O	XXXXXXXX
21	125	127	O	and
22	129	139	U-DYN	epinephrine
23	141	143	O	may
24	145	149	O	occur
NULL

Levobunolol	DDI-DrugBank.d252.s1	NO_SECTION	NO_SETID	48
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.
1	0	4	O	Close
2	6	16	O	observation
3	18	19	O	of
4	21	23	O	the
5	25	31	O	patient
6	33	34	O	is
7	36	46	O	recommended
8	48	51	O	when
9	53	53	O	a
10	55	58	B-UNK	beta
11	60	66	L-UNK	blocker
12	68	69	O	is
13	71	82	O	administered
14	84	85	O	to
15	87	94	O	patients
16	96	104	O	receiving
17	106	118	O	catecholamine
18	120	128	O	depleting
19	130	134	O	drugs
20	136	139	O	such
21	141	142	O	as
22	144	152	U-UNK	reserpine
23	153	153	O	,
24	155	161	O	because
25	163	164	O	of
26	166	173	O	possible
27	175	182	O	additive
28	184	190	O	effects
29	192	194	O	and
30	196	198	O	the
31	200	209	O	production
32	211	212	O	of
33	214	224	O	hypotension
34	226	228	O	and
35	229	229	O	/
36	230	231	O	or
37	233	238	O	marked
38	240	250	O	bradycardia
39	251	251	O	,
40	253	257	O	which
41	259	261	O	may
42	263	269	O	produce
43	271	277	O	vertigo
44	278	278	O	,
45	280	286	O	syncope
46	288	289	O	or
47	291	298	O	postural
48	300	310	O	hypotension
NULL

Levobunolol	DDI-DrugBank.d252.s2	NO_SECTION	NO_SETID	28
Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	22	B-UNK	beta
4	24	33	I-UNK	adrenergic
5	35	42	I-UNK	blocking
6	44	49	L-UNK	agents
7	51	55	O	along
8	57	60	O	with
9	62	67	O	either
10	69	72	O	oral
11	74	75	O	or
12	77	87	O	intravenous
13	89	95	B-UNK	calcium
14	97	107	L-UNK	antagonists
15	109	114	O	should
16	116	117	O	be
17	119	127	O	monitored
18	129	131	O	for
19	133	140	O	possible
20	142	157	O	atrioventricular
21	159	168	O	conduction
22	170	181	O	disturbances
23	182	182	O	,
24	184	187	O	left
25	189	199	O	ventricular
26	201	207	O	failure
27	209	211	O	and
28	213	223	O	hypotension
NULL

Levobunolol	DDI-DrugBank.d252.s3	NO_SECTION	NO_SETID	13
In patients with impaired cardiac function, simultaneous use should be avoided altogether.
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	24	O	impaired
5	26	32	O	cardiac
6	34	41	O	function
7	42	42	O	,
8	44	55	O	simultaneous
9	57	59	O	use
10	61	66	O	should
11	68	69	O	be
12	71	77	O	avoided
13	79	88	O	altogether
NULL

Levobunolol	DDI-DrugBank.d252.s4	NO_SECTION	NO_SETID	22
The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	26	B-UNK	beta
6	28	37	I-UNK	adrenergic
7	39	46	I-UNK	blocking
8	48	53	L-UNK	agents
9	55	58	O	with
10	60	68	U-UNK	digitalis
11	70	72	O	and
12	74	80	U-UNK	calcium
13	82	92	O	antagonists
14	94	96	O	may
15	98	101	O	have
16	103	110	O	additive
17	112	118	O	effects
18	120	121	O	on
19	123	132	O	prolonging
20	134	149	O	atrioventricular
21	151	160	O	conduction
22	162	165	O	time
NULL

Levobunolol	DDI-DrugBank.d252.s5	NO_SECTION	NO_SETID	22
Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other s metabolism.
1	0	12	B-UNK	Phenothiazine
2	14	20	I-UNK	related
3	22	30	L-UNK	compounds
4	32	34	O	and
5	36	39	B-UNK	beta
6	41	50	I-UNK	adrenergic
7	52	59	I-UNK	blocking
8	61	66	L-UNK	agents
9	68	70	O	may
10	72	75	O	have
11	77	84	O	additive
12	86	96	O	hypotensite
13	98	104	O	effects
14	106	108	O	due
15	110	111	O	to
16	113	115	O	the
17	117	126	O	inhibition
18	128	129	O	of
19	131	134	O	each
20	136	140	O	other
21	142	142	O	s
22	144	153	O	metabolism
NULL

Levobupivacaine	DDI-DrugBank.d320.s0	NO_SECTION	NO_SETID	31
Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.
1	0	9	O	XXXXXXXX
2	13	18	O	should
3	20	21	O	be
4	23	26	O	used
5	28	31	O	with
6	33	39	O	caution
7	41	42	O	in
8	44	51	O	patients
9	53	61	O	receiving
10	63	67	O	other
11	69	73	O	local
12	75	85	U-DYN	anesthetics
13	87	88	O	or
14	90	95	O	agents
15	97	108	O	structurally
16	110	116	O	related
17	118	119	O	to
18	121	125	O	amide
19	127	130	O	type
20	132	136	O	local
21	138	148	O	anesthetics
22	150	154	O	since
23	156	158	O	the
24	160	164	O	toxic
25	166	172	O	effects
26	174	175	O	of
27	177	181	O	these
28	183	187	O	drugs
29	189	193	O	could
30	195	196	O	be
31	198	205	O	additive
NULL

Levobupivacaine	DDI-DrugBank.d320.s1	NO_SECTION	NO_SETID	23
In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to desbutyl levobupivacaine and 3-hydroxy levobupivacaine, respectively.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	24	O	indicate
5	26	31	O	CYP3A4
6	33	39	O	isoform
7	41	43	O	and
8	45	50	O	CYP1A2
9	52	58	O	isoform
10	60	66	O	mediate
11	68	70	O	the
12	72	81	O	metabolism
13	83	84	O	of
14	86	100	O	XXXXXXXX
15	102	103	O	to
16	105	112	O	desbutyl
17	114	128	O	XXXXXXXX
18	130	132	O	and
19	134	134	O	3
20	136	142	O	hydroxy
21	144	158	O	XXXXXXXX
22	159	159	O	,
23	161	172	O	respectively
NULL

Levobupivacaine	DDI-DrugBank.d320.s2	NO_SECTION	NO_SETID	21
Thus agents likely to be concomitantly administered with Chirocaine that are metabolized by this isoenzyme family may potentially interact with Chirocaine.
1	0	3	O	Thus
2	5	10	O	agents
3	12	17	O	likely
4	19	20	O	to
5	22	23	O	be
6	25	37	O	concomitantly
7	39	50	O	administered
8	52	55	O	with
9	57	66	O	XXXXXXXX
10	68	71	O	that
11	73	75	O	are
12	77	87	O	metabolized
13	89	90	O	by
14	92	95	O	this
15	97	105	O	isoenzyme
16	107	112	O	family
17	114	116	O	may
18	118	128	O	potentially
19	130	137	O	interact
20	139	142	O	with
21	144	153	O	XXXXXXXX
NULL

Levobupivacaine	DDI-DrugBank.d320.s3	NO_SECTION	NO_SETID	39
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
1	0	7	O	Although
2	9	10	O	no
3	12	19	O	clinical
4	21	27	O	studies
5	29	32	O	have
6	34	37	O	been
7	39	47	O	conducted
8	48	48	O	,
9	50	51	O	it
10	53	54	O	is
11	56	61	O	likely
12	63	66	O	that
13	68	70	O	the
14	72	81	O	metabolism
15	83	84	O	of
16	86	100	O	XXXXXXXX
17	102	104	O	may
18	106	107	O	be
19	109	116	O	affected
20	118	119	O	by
21	121	123	O	the
22	125	129	O	known
23	131	136	O	CYP3A4
24	138	145	O	inducers
25	148	151	O	such
26	153	154	O	as
27	156	164	U-KIN	phenytoin
28	165	165	O	,
29	167	179	U-KIN	phenobarbital
30	180	180	O	,
31	182	189	U-KIN	rifampin
32	191	191	O	,
33	193	198	O	CYP3A4
34	200	209	O	inhibitors
35	212	216	O	azole
36	218	229	O	antimycotics
37	231	233	O	e.g
38	235	235	O	,
39	237	248	U-KIN	ketoconazole
NULL

Levobupivacaine	DDI-DrugBank.d320.s4	NO_SECTION	NO_SETID	6
certain protease inhibitors e.g., ritanovir;
1	0	6	O	certain
2	8	15	B-UNK	protease
3	17	26	L-UNK	inhibitors
4	28	30	O	e.g
5	32	32	O	,
6	34	42	O	ritanovir
NULL

Levobupivacaine	DDI-DrugBank.d320.s5	NO_SECTION	NO_SETID	5
macrolide antibiotics e.g., erythromycin;
1	0	8	B-UNK	macrolide
2	10	20	L-UNK	antibiotics
3	22	24	O	e.g
4	26	26	O	,
5	28	39	U-UNK	erythromycin
NULL

Levobupivacaine	DDI-DrugBank.d320.s6	NO_SECTION	NO_SETID	17
and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).
1	0	2	O	and
2	4	10	B-UNK	calcium
3	12	18	I-UNK	channel
4	20	30	L-UNK	antagonists
5	32	34	O	e.g
6	36	36	O	,
7	38	46	U-UNK	verapamil
8	48	48	O	,
9	50	55	O	CYP1A2
10	57	64	O	inducers
11	67	76	U-UNK	omeprazole
12	79	81	O	and
13	83	88	O	CYP1A2
14	90	99	O	inhibitors
15	102	112	U-UNK	furafylline
16	114	116	O	and
17	118	131	U-UNK	clarithromycin
NULL

Levobupivacaine	DDI-DrugBank.d320.s7	NO_SECTION	NO_SETID	25
Dosage adjustment may be warranted when levobupivacaine is concurrently administered with CYP3A4 inhibitors and CYP1A2 inhibitors as systemic levobupivacaine levels may rise resulting in toxicity.
1	0	5	O	Dosage
2	7	16	O	adjustment
3	18	20	O	may
4	22	23	O	be
5	25	33	O	warranted
6	35	38	O	when
7	40	54	O	XXXXXXXX
8	56	57	O	is
9	59	70	O	concurrently
10	72	83	O	administered
11	85	88	O	with
12	90	95	O	CYP3A4
13	97	106	O	inhibitors
14	108	110	O	and
15	112	117	O	CYP1A2
16	119	128	O	inhibitors
17	130	131	O	as
18	133	140	O	systemic
19	142	156	O	XXXXXXXX
20	158	163	O	levels
21	165	167	O	may
22	169	172	O	rise
23	174	182	O	resulting
24	184	185	O	in
25	187	194	O	toxicity
NULL

Levofloxacin	DDI-DrugBank.d242.s0	NO_SECTION	NO_SETID	10
Specific drug interaction studies have not been conducted with Levofloxacin.
1	0	7	O	Specific
2	9	12	O	drug
3	14	24	O	interaction
4	26	32	O	studies
5	34	37	O	have
6	39	41	O	not
7	43	46	O	been
8	48	56	O	conducted
9	58	61	O	with
10	63	74	O	XXXXXXXX
NULL

Levofloxacin	DDI-DrugBank.d242.s1	NO_SECTION	NO_SETID	54
However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	20	O	systemic
5	22	35	O	administration
6	37	38	O	of
7	40	43	O	some
8	45	54	U-UNK	quinolones
9	56	58	O	has
10	60	63	O	been
11	65	69	O	shown
12	71	72	O	to
13	74	80	O	elevate
14	82	87	O	plasma
15	89	102	O	concentrations
16	104	105	O	of
17	107	118	U-UNK	theophylline
18	119	119	O	,
19	121	129	O	interfere
20	131	134	O	with
21	136	138	O	the
22	140	149	O	metabolism
23	151	152	O	of
24	154	161	U-UNK	caffeine
25	162	162	O	,
26	164	166	O	and
27	168	174	O	enhance
28	176	178	O	the
29	180	186	O	effects
30	188	189	O	of
31	191	193	O	the
32	195	198	O	oral
33	200	212	U-UNK	anticoagulant
34	214	221	U-UNK	warfarin
35	223	225	O	and
36	227	229	O	its
37	231	241	O	derivatives
38	242	242	O	,
39	244	246	O	and
40	248	250	O	has
41	252	255	O	been
42	257	266	O	associated
43	268	271	O	with
44	273	281	O	transient
45	283	292	O	elevations
46	294	295	O	in
47	297	301	O	serum
48	303	312	O	creatinine
49	314	315	O	in
50	317	324	O	patients
51	326	334	O	receiving
52	336	343	O	systemic
53	345	356	U-UNK	cyclosporine
54	358	370	O	concomitantly
NULL

Levorphanol	DDI-DrugBank.d257.s0	NO_SECTION	NO_SETID	53
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
1	0	11	O	Interactions
2	13	16	O	with
3	18	22	O	Other
4	24	26	O	CNS
5	28	33	O	Agents
6	34	34	O	:
7	36	45	O	Concurrent
8	47	49	O	use
9	51	52	O	of
10	54	66	O	XXXXXXXX
11	68	71	O	with
12	73	75	O	all
13	77	83	B-DYN	central
14	85	91	I-DYN	nervous
15	93	98	I-DYN	system
16	100	110	L-DYN	depressants
17	113	114	O	eg
18	115	115	O	,
19	117	123	U-DYN	alcohol
20	124	124	O	,
21	126	134	U-DYN	sedatives
22	135	135	O	,
23	137	145	U-DYN	hypnotics
24	146	146	O	,
25	148	152	O	other
26	154	160	U-DYN	opioids
27	161	161	O	,
28	163	169	O	general
29	171	181	U-DYN	anesthetics
30	182	182	O	,
31	184	195	U-DYN	barbiturates
32	196	196	O	,
33	198	206	B-DYN	tricyclic
34	208	222	L-DYN	antidepressants
35	223	223	O	,
36	225	238	U-DYN	phenothiazines
37	239	239	O	,
38	241	253	U-DYN	tranquilizers
39	254	254	O	,
40	256	263	B-DYN	skeletal
41	265	270	I-DYN	muscle
42	272	280	L-DYN	relaxants
43	282	284	O	and
44	286	299	U-DYN	antihistamines
45	302	304	O	may
46	306	311	O	result
47	313	314	O	in
48	316	323	O	additive
49	325	331	O	central
50	333	339	O	nervous
51	341	346	O	system
52	348	357	O	depressant
53	359	365	O	effects
NULL

Levorphanol	DDI-DrugBank.d257.s1	NO_SECTION	NO_SETID	12
Respiratory depression, hypotension, and profound sedation or coma may occur.
1	0	10	O	Respiratory
2	12	21	O	depression
3	22	22	O	,
4	24	34	O	hypotension
5	35	35	O	,
6	37	39	O	and
7	41	48	O	profound
8	50	57	O	sedation
9	59	60	O	or
10	62	65	O	coma
11	67	69	O	may
12	71	75	O	occur
NULL

Levorphanol	DDI-DrugBank.d257.s2	NO_SECTION	NO_SETID	17
When such combined therapy is contemplated, the dose of one or both agents should be reduced.
1	0	3	O	When
2	5	8	O	such
3	10	17	O	combined
4	19	25	O	therapy
5	27	28	O	is
6	30	41	O	contemplated
7	42	42	O	,
8	44	46	O	the
9	48	51	O	dose
10	53	54	O	of
11	56	58	O	one
12	60	61	O	or
13	63	66	O	both
14	68	73	O	agents
15	75	80	O	should
16	82	83	O	be
17	85	91	O	reduced
NULL

Levorphanol	DDI-DrugBank.d257.s3	NO_SECTION	NO_SETID	21
Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.
1	0	7	O	Although
2	9	10	O	no
3	12	22	O	interaction
4	24	30	O	between
5	32	34	B-UNK	MAO
6	36	45	L-UNK	inhibitors
7	47	49	O	and
8	51	63	O	XXXXXXXX
9	65	67	O	has
10	69	72	O	been
11	74	81	O	observed
12	82	82	O	,
13	84	85	O	it
14	87	88	O	is
15	90	92	O	not
16	94	104	O	recommended
17	106	108	O	for
18	110	112	O	use
19	114	117	O	with
20	119	121	B-DYN	MAO
21	123	132	L-DYN	inhibitors
NULL

Levorphanol	DDI-DrugBank.d257.s4	NO_SECTION	NO_SETID	49
Most cases of serious or fatal adverse events involving Levo-Dromoran reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of levorphanol with other drugs affecting respiration.
1	0	3	O	Most
2	5	9	O	cases
3	11	12	O	of
4	14	20	O	serious
5	22	23	O	or
6	25	29	O	fatal
7	31	37	O	adverse
8	39	44	O	events
9	46	54	O	involving
10	56	68	O	XXXXXXXX
11	70	77	O	reported
12	79	80	O	to
13	82	84	O	the
14	86	97	O	manufacturer
15	99	100	O	or
16	102	104	O	the
17	106	108	O	FDA
18	110	113	O	have
19	115	122	O	involved
20	124	129	O	either
21	131	133	O	the
22	135	148	O	administration
23	150	151	O	of
24	153	157	O	large
25	159	165	O	initial
26	167	171	O	doses
27	173	174	O	or
28	176	178	O	too
29	180	187	O	frequent
30	189	193	O	doses
31	195	196	O	of
32	198	200	O	the
33	202	205	O	drug
34	207	208	O	to
35	210	218	O	nonopioid
36	220	227	O	tolerant
37	229	236	O	patients
38	237	237	O	,
39	239	240	O	or
40	242	244	O	the
41	246	257	O	simultaneous
42	259	272	O	administration
43	274	275	O	of
44	277	287	U-UNK	levorphanol
45	289	292	O	with
46	294	298	O	other
47	300	304	O	drugs
48	306	314	O	affecting
49	316	326	O	respiration
NULL

Levorphanol	DDI-DrugBank.d257.s5	NO_SECTION	NO_SETID	25
The initial dose of levorphanol should be reduced by approximately 50% or more when it is given to patients along with another drug affecting respiration.
1	0	2	O	The
2	4	10	O	initial
3	12	15	O	dose
4	17	18	O	of
5	20	30	O	XXXXXXXX
6	32	37	O	should
7	39	40	O	be
8	42	48	O	reduced
9	50	51	O	by
10	53	65	O	approximately
11	67	69	O	50%
12	71	72	O	or
13	74	77	O	more
14	79	82	O	when
15	84	85	O	it
16	87	88	O	is
17	90	94	O	given
18	96	97	O	to
19	99	106	O	patients
20	108	112	O	along
21	114	117	O	with
22	119	125	O	another
23	127	130	O	drug
24	132	140	O	affecting
25	142	152	O	respiration
NULL

Levorphanol	DDI-DrugBank.d257.s6	NO_SECTION	NO_SETID	50
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.
1	0	11	O	Interactions
2	13	16	O	with
3	18	22	B-UNK	Mixed
4	24	30	I-UNK	Agonist
5	31	31	I-UNK	/
6	32	41	I-UNK	Antagonist
7	43	48	I-UNK	Opioid
8	50	59	L-UNK	Analgesics
9	60	60	O	:
10	62	68	B-DYN	Agonist
11	69	69	I-DYN	/
12	70	79	I-DYN	antagonist
13	81	90	L-DYN	analgesics
14	93	94	O	eg
15	95	95	O	,
16	97	107	U-DYN	pentazocine
17	108	108	O	,
18	110	119	U-DYN	nalbuphine
19	120	120	O	,
20	122	132	U-DYN	butorphanol
21	133	133	O	,
22	135	142	U-DYN	dezocine
23	144	146	O	and
24	148	160	U-DYN	buprenorphine
25	163	168	O	should
26	170	172	O	NOT
27	174	175	O	be
28	177	188	O	administered
29	190	191	O	to
30	193	193	O	a
31	195	201	O	patient
32	203	205	O	who
33	207	209	O	has
34	211	218	O	received
35	220	221	O	or
36	223	224	O	is
37	226	234	O	receiving
38	236	236	O	a
39	238	243	O	course
40	245	246	O	of
41	248	254	O	therapy
42	256	259	O	with
43	261	261	O	a
44	263	266	B-DYN	pure
45	268	274	I-DYN	agonist
46	276	281	I-DYN	opioid
47	283	291	L-DYN	analgesic
48	293	296	O	such
49	298	299	O	as
50	301	313	O	XXXXXXXX
NULL

Levorphanol	DDI-DrugBank.d257.s7	NO_SECTION	NO_SETID	14
In opioid-dependent patients, mixed agonist/antagonist analgesics may precipitate withdrawal symptoms.
1	0	1	O	In
2	3	8	U-UNK	opioid
3	10	18	O	dependent
4	20	27	O	patients
5	28	28	O	,
6	30	34	B-UNK	mixed
7	36	42	I-UNK	agonist
8	43	43	I-UNK	/
9	44	53	I-UNK	antagonist
10	55	64	L-UNK	analgesics
11	66	68	O	may
12	70	80	O	precipitate
13	82	91	O	withdrawal
14	93	100	O	symptoms
NULL

Levosimendan	DDI-DrugBank.d189.s0	NO_SECTION	NO_SETID	33
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.
1	0	1	O	No
2	3	11	O	Important
3	13	24	O	Interactions
4	26	27	O	To
5	29	32	O	Date
6	34	45	O	XXXXXXXX
7	47	50	O	does
8	52	54	O	not
9	56	59	O	have
10	61	70	O	clinically
11	72	80	O	important
12	82	96	O	pharmacokinetic
13	98	109	O	interactions
14	111	114	O	with
15	116	124	U-UNK	captopril
16	125	125	O	,
17	127	130	B-UNK	beta
18	132	139	L-UNK	blockers
19	140	140	O	,
20	142	151	U-UNK	felodipine
21	152	152	O	,
22	154	160	U-UNK	digoxin
23	161	161	O	,
24	163	170	U-UNK	warfarin
25	171	171	O	,
26	173	182	B-UNK	isosorbide
27	184	194	L-UNK	mononitrate
28	195	195	O	,
29	197	206	U-UNK	carvedilol
30	207	207	O	,
31	209	215	U-UNK	ethanol
32	217	218	O	or
33	220	231	U-UNK	itraconazole
NULL

Levothyroxine	DDI-DrugBank.d411.s0	NO_SECTION	NO_SETID	46
The magnitude and relative importance of the effects noted below are likely to be patient specific and may vary by such factors as age, gender, race, intercurrent illnesses, dose of either agent, additional concomitant medications, and timing of drug administration.
1	0	2	O	The
2	4	12	O	magnitude
3	14	16	O	and
4	18	25	O	relative
5	27	36	O	importance
6	38	39	O	of
7	41	43	O	the
8	45	51	O	effects
9	53	57	O	noted
10	59	63	O	below
11	65	67	O	are
12	69	74	O	likely
13	76	77	O	to
14	79	80	O	be
15	82	88	O	patient
16	90	97	O	specific
17	99	101	O	and
18	103	105	O	may
19	107	110	O	vary
20	112	113	O	by
21	115	118	O	such
22	120	126	O	factors
23	128	129	O	as
24	131	133	O	age
25	134	134	O	,
26	136	141	O	gender
27	142	142	O	,
28	144	147	O	race
29	148	148	O	,
30	150	161	O	intercurrent
31	163	171	O	illnesses
32	172	172	O	,
33	174	177	O	dose
34	179	180	O	of
35	182	187	O	either
36	189	193	O	agent
37	194	194	O	,
38	196	205	O	additional
39	207	217	O	concomitant
40	219	229	O	medications
41	230	230	O	,
42	232	234	O	and
43	236	241	O	timing
44	243	244	O	of
45	246	249	O	drug
46	251	264	O	administration
NULL

Levothyroxine	DDI-DrugBank.d411.s1	NO_SECTION	NO_SETID	30
Any agent that alters thyroid hormone synthesis, secretion, distribution, effect on target tissues, metabolism, or elimination may alter the optimal therapeutic dose of levothyroxine sodium.
1	0	2	O	Any
2	4	8	O	agent
3	10	13	O	that
4	15	20	O	alters
5	22	28	O	thyroid
6	30	36	O	hormone
7	38	46	O	synthesis
8	47	47	O	,
9	49	57	O	secretion
10	58	58	O	,
11	60	71	O	distribution
12	72	72	O	,
13	74	79	O	effect
14	81	82	O	on
15	84	89	O	target
16	91	97	O	tissues
17	98	98	O	,
18	100	109	O	metabolism
19	110	110	O	,
20	112	113	O	or
21	115	125	O	elimination
22	127	129	O	may
23	131	135	O	alter
24	137	139	O	the
25	141	147	O	optimal
26	149	159	O	therapeutic
27	161	164	O	dose
28	166	167	O	of
29	169	181	O	XXXXXXXX
30	183	188	O	sodium
NULL

Levothyroxine	DDI-DrugBank.d411.s2	NO_SECTION	NO_SETID	44
Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
1	0	12	O	XXXXXXXX
2	14	19	O	Sodium
3	21	30	O	Absorption
4	31	31	O	:
5	33	35	O	The
6	37	45	O	following
7	47	52	O	agents
8	54	56	O	may
9	58	61	O	bind
10	63	65	O	and
11	67	74	O	decrease
12	76	85	O	absorption
13	87	88	O	of
14	90	102	O	XXXXXXXX
15	104	109	O	sodium
16	111	114	O	from
17	116	118	O	the
18	120	135	O	gastrointestinal
19	137	141	O	tract
20	142	142	O	:
21	144	151	B-KIN	aluminum
22	153	160	L-KIN	hydoxide
23	161	161	O	,
24	163	176	U-KIN	cholestyramine
25	178	182	O	resin
26	183	183	O	,
27	185	194	B-KIN	colestipol
28	196	208	L-KIN	hydrochloride
29	209	209	O	,
30	211	217	B-KIN	ferrous
31	219	225	L-KIN	sulfate
32	226	226	O	,
33	228	233	B-KIN	sodium
34	235	245	I-KIN	polystyrene
35	247	255	L-KIN	sulfonate
36	256	256	O	,
37	258	264	O	soybean
38	266	270	O	flour
39	273	275	O	e.g
40	277	277	O	,
41	279	284	O	infant
42	286	292	O	formula
43	294	294	O	,
44	296	305	U-KIN	sucralfate
NULL

Levothyroxine	DDI-DrugBank.d411.s3	NO_SECTION	NO_SETID	66
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
1	0	6	O	Binding
2	8	9	O	to
3	11	15	O	Serum
4	17	24	O	Proteins
5	25	25	O	:
6	27	29	O	The
7	31	39	O	following
8	41	46	O	agents
9	48	50	O	may
10	52	57	O	either
11	59	65	O	inhibit
12	67	79	O	XXXXXXXX
13	81	86	O	sodium
14	88	94	O	binding
15	96	97	O	to
16	99	103	O	serum
17	105	112	O	proteins
18	114	115	O	or
19	117	121	O	alter
20	123	125	O	the
21	127	140	O	concentrations
22	142	143	O	of
23	145	149	O	serum
24	151	157	O	binding
25	159	166	O	proteins
26	167	167	O	:
27	169	177	U-KIN	androgens
28	179	181	O	and
29	183	189	O	related
30	191	198	B-KIN	anabolic
31	200	207	L-KIN	hormones
32	208	208	O	,
33	210	221	U-KIN	asparaginase
34	222	222	O	,
35	224	233	U-KIN	clofibrate
36	234	234	O	,
37	236	244	U-KIN	estrogens
38	246	248	O	and
39	250	257	B-KIN	estrogen
40	259	268	I-KIN	containing
41	270	278	L-KIN	compounds
42	279	279	O	,
43	281	281	B-KIN	5
44	283	294	L-KIN	fluorouracil
45	295	295	O	,
46	297	306	U-KIN	furosemide
47	307	307	O	,
48	309	323	U-KIN	glucocorticoids
49	324	324	O	,
50	326	337	B-KIN	meclofenamic
51	339	342	L-KIN	acid
52	343	343	O	,
53	345	353	B-KIN	mefenamic
54	355	358	L-KIN	acid
55	359	359	O	,
56	361	369	U-KIN	methadone
57	370	370	O	,
58	372	383	U-KIN	perphenazine
59	384	384	O	,
60	386	399	U-KIN	phenylbutazone
61	400	400	O	,
62	402	410	U-KIN	phenytoin
63	411	411	O	,
64	413	423	U-KIN	salicylates
65	424	424	O	,
66	426	434	U-KIN	tamoxifen
NULL

Levothyroxine	DDI-DrugBank.d411.s4	NO_SECTION	NO_SETID	133
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
1	0	6	O	Thyroid
2	8	17	O	Physiology
3	18	18	O	:
4	20	22	O	The
5	24	32	O	following
6	34	39	O	agents
7	41	43	O	may
8	45	49	O	alter
9	51	57	O	thyroid
10	59	65	O	hormone
11	67	68	O	or
12	70	72	O	TSH
13	74	79	O	levels
14	80	80	O	,
15	82	90	O	generally
16	92	93	O	by
17	95	101	O	effects
18	103	104	O	on
19	106	112	O	thyroid
20	114	120	O	hormone
21	122	130	O	synthesis
22	131	131	O	,
23	133	141	O	secretion
24	142	142	O	,
25	144	155	O	distribution
26	156	156	O	,
27	158	167	O	metabolism
28	168	168	O	,
29	170	176	O	hormone
30	178	183	O	action
31	184	184	O	,
32	186	187	O	or
33	189	199	O	elimination
34	200	200	O	,
35	202	203	O	or
36	205	211	O	altered
37	213	215	O	TSH
38	217	225	O	secretion
39	226	226	O	:
40	228	244	U-UNK	aminoglutethimide
41	245	245	O	,
42	247	247	B-UNK	p
43	249	262	I-UNK	aminosalicylic
44	264	267	L-UNK	acid
45	268	268	O	,
46	270	279	U-UNK	amiodarone
47	280	280	O	,
48	282	290	U-UNK	androgens
49	292	294	O	and
50	296	302	O	related
51	304	311	O	anabolic
52	313	320	O	hormones
53	321	321	O	,
54	323	329	O	complex
55	331	336	O	anions
56	339	349	U-UNK	thiocyanate
57	350	350	O	,
58	352	362	U-UNK	perchlorate
59	363	363	O	,
60	365	377	U-UNK	pertechnetate
61	379	379	O	,
62	381	391	B-UNK	antithyroid
63	393	397	L-UNK	drugs
64	398	398	O	,
65	400	400	B-UNK	b
66	402	411	I-UNK	adrenergic
67	413	420	I-UNK	blocking
68	422	427	L-UNK	agents
69	428	428	O	,
70	430	442	U-UNK	carbamazepine
71	443	443	O	,
72	445	451	B-UNK	chloral
73	453	459	L-UNK	hydrate
74	460	460	O	,
75	462	469	U-UNK	diazepam
76	470	470	O	,
77	472	479	U-UNK	dopamine
78	481	483	O	and
79	485	492	B-UNK	dopamine
80	494	501	L-UNK	agonists
81	502	502	O	,
82	504	514	U-UNK	ethionamide
83	515	515	O	,
84	517	531	U-UNK	glucocorticoids
85	532	532	O	,
86	534	540	U-UNK	heparin
87	541	541	O	,
88	543	549	O	hepatic
89	551	556	O	enzyme
90	558	565	O	inducers
91	566	566	O	,
92	568	574	U-UNK	insulin
93	575	575	O	,
94	577	585	O	iodinated
95	587	601	O	cholestographic
96	603	608	O	agents
97	609	609	O	,
98	611	616	B-UNK	iodine
99	618	627	I-UNK	containing
100	629	637	L-UNK	compounds
101	638	638	O	,
102	640	647	U-UNK	levodopa
103	648	648	O	,
104	650	659	U-UNK	lovastatin
105	660	660	O	,
106	662	668	U-UNK	lithium
107	669	669	O	,
108	671	671	B-UNK	6
109	673	686	L-UNK	mercaptopurine
110	687	687	O	,
111	689	702	U-UNK	metoclopramide
112	703	703	O	,
113	705	712	U-UNK	mitotane
114	713	713	O	,
115	715	727	U-UNK	nitroprusside
116	728	728	O	,
117	730	742	U-UNK	phenobarbital
118	743	743	O	,
119	745	753	U-UNK	phenytoin
120	754	754	O	,
121	756	765	U-UNK	resorcinol
122	766	766	O	,
123	768	775	U-UNK	rifampin
124	776	776	O	,
125	778	789	B-UNK	somatostatin
126	791	797	L-UNK	analogs
127	798	798	O	,
128	800	811	U-UNK	sulfonamides
129	812	812	O	,
130	814	826	U-UNK	sulfonylureas
131	827	827	O	,
132	829	836	B-UNK	thiazide
133	838	846	L-UNK	diuretics
NULL

Levothyroxine	DDI-DrugBank.d411.s5	NO_SECTION	NO_SETID	25
Adrenocorticoids: Metabolic clearance of adrenocorticoids is decreased in hypothyroid patients and increased in hyperthyroid patients, and may therefore change with changing thyroid status.
1	0	15	O	Adrenocorticoids
2	16	16	O	:
3	18	26	O	Metabolic
4	28	36	O	clearance
5	38	39	O	of
6	41	56	O	adrenocorticoids
7	58	59	O	is
8	61	69	O	decreased
9	71	72	O	in
10	74	84	O	hypothyroid
11	86	93	O	patients
12	95	97	O	and
13	99	107	O	increased
14	109	110	O	in
15	112	123	O	hyperthyroid
16	125	132	O	patients
17	133	133	O	,
18	135	137	O	and
19	139	141	O	may
20	143	151	O	therefore
21	153	158	O	change
22	160	163	O	with
23	165	172	O	changing
24	174	180	O	thyroid
25	182	187	O	status
NULL

Levothyroxine	DDI-DrugBank.d411.s6	NO_SECTION	NO_SETID	10
Amiodarone: Amiodarone therapy alone can cause hypothyroidism or hyperthyroidism.
1	0	9	U-UNK	Amiodarone
2	10	10	O	:
3	12	21	U-UNK	Amiodarone
4	23	29	O	therapy
5	31	35	O	alone
6	37	39	O	can
7	41	45	O	cause
8	47	60	O	hypothyroidism
9	62	63	O	or
10	65	79	O	hyperthyroidism
NULL

Levothyroxine	DDI-DrugBank.d411.s7	NO_SECTION	NO_SETID	22
Anticoagulants (Oral): The hypoprothrombinemic effect of anticoagulants may be potentiated, apparently by increased catabloism of vitamin K-dependent clotting factors.
1	0	13	U-UNK	Anticoagulants
2	16	19	O	Oral
3	21	21	O	:
4	23	25	O	The
5	27	45	O	hypoprothrombinemic
6	47	52	O	effect
7	54	55	O	of
8	57	70	U-UNK	anticoagulants
9	72	74	O	may
10	76	77	O	be
11	79	89	O	potentiated
12	90	90	O	,
13	92	101	O	apparently
14	103	104	O	by
15	106	114	O	increased
16	116	125	O	catabloism
17	127	128	O	of
18	130	136	O	vitamin
19	138	138	O	K
20	140	148	O	dependent
21	150	157	O	clotting
22	159	165	O	factors
NULL

Levothyroxine	DDI-DrugBank.d411.s8	NO_SECTION	NO_SETID	34
Antidiabetic Agents (Insulin, Sulfonylureas): Requirements for insulin or oral antidiabetic agents may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy.
1	0	11	B-UNK	Antidiabetic
2	13	18	L-UNK	Agents
3	21	27	U-UNK	Insulin
4	28	28	O	,
5	30	42	U-UNK	Sulfonylureas
6	44	44	O	:
7	46	57	O	Requirements
8	59	61	O	for
9	63	69	U-UNK	insulin
10	71	72	O	or
11	74	77	O	oral
12	79	90	B-UNK	antidiabetic
13	92	97	L-UNK	agents
14	99	101	O	may
15	103	104	O	be
16	106	112	O	reduced
17	114	115	O	in
18	117	127	O	hypothyroid
19	129	136	O	patients
20	138	141	O	with
21	143	150	O	diabetes
22	152	159	O	mellitus
23	161	163	O	and
24	165	167	O	may
25	169	180	O	subsequently
26	182	189	O	increase
27	191	194	O	with
28	196	198	O	the
29	200	209	O	initiation
30	211	212	O	of
31	214	220	O	thyroid
32	222	228	O	hormone
33	230	240	O	replacement
34	242	248	O	therapy
NULL

Levothyroxine	DDI-DrugBank.d411.s9	NO_SECTION	NO_SETID	20
b-Adrenergic Blocking Agents: Actions of some of beta-blocking agents may be impaired when hypothyroid patients become euthyroid.
1	0	0	B-UNK	b
2	2	11	I-UNK	Adrenergic
3	13	20	I-UNK	Blocking
4	22	27	L-UNK	Agents
5	28	28	O	:
6	30	36	O	Actions
7	38	39	O	of
8	41	44	O	some
9	46	47	O	of
10	49	52	B-UNK	beta
11	54	61	I-UNK	blocking
12	63	68	L-UNK	agents
13	70	72	O	may
14	74	75	O	be
15	77	84	O	impaired
16	86	89	O	when
17	91	101	O	hypothyroid
18	103	110	O	patients
19	112	117	O	become
20	119	127	O	euthyroid
NULL

Levothyroxine	DDI-DrugBank.d411.s10	NO_SECTION	NO_SETID	15
Cytokines (interferon, interleukin): Cytokines have been reported to induce both hyperthyroidism and hypothyroidism.
1	0	8	U-UNK	Cytokines
2	11	20	U-UNK	interferon
3	21	21	O	,
4	23	33	U-UNK	interleukin
5	35	35	O	:
6	37	45	U-UNK	Cytokines
7	47	50	O	have
8	52	55	O	been
9	57	64	O	reported
10	66	67	O	to
11	69	74	O	induce
12	76	79	O	both
13	81	95	O	hyperthyroidism
14	97	99	O	and
15	101	114	O	hypothyroidism
NULL

Levothyroxine	DDI-DrugBank.d411.s11	NO_SECTION	NO_SETID	11
Digitalis Glycosides: Therapeutic effects of digitalis glycosides may be reduced.
1	0	8	B-UNK	Digitalis
2	10	19	L-UNK	Glycosides
3	20	20	O	:
4	22	32	O	Therapeutic
5	34	40	O	effects
6	42	43	O	of
7	45	53	B-UNK	digitalis
8	55	64	L-UNK	glycosides
9	66	68	O	may
10	70	71	O	be
11	73	79	O	reduced
NULL

Levothyroxine	DDI-DrugBank.d411.s12	NO_SECTION	NO_SETID	15
Serum digitalis levels may be decreased in hyperthyroidism or when a hypothyroid patient becomes euthyroid.
1	0	4	O	Serum
2	6	14	U-UNK	digitalis
3	16	21	O	levels
4	23	25	O	may
5	27	28	O	be
6	30	38	O	decreased
7	40	41	O	in
8	43	57	O	hyperthyroidism
9	59	60	O	or
10	62	65	O	when
11	67	67	O	a
12	69	79	O	hypothyroid
13	81	87	O	patient
14	89	95	O	becomes
15	97	105	O	euthyroid
NULL

Levothyroxine	DDI-DrugBank.d411.s13	NO_SECTION	NO_SETID	19
Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine sodium and ketamine.
1	0	7	U-UNK	Ketamine
2	8	8	O	:
3	10	15	O	Marked
4	17	28	O	hypertension
5	30	32	O	and
6	34	44	O	tachycardia
7	46	49	O	have
8	51	54	O	been
9	56	63	O	reported
10	65	66	O	in
11	68	78	O	association
12	80	83	O	with
13	85	95	O	concomitant
14	97	110	O	administration
15	112	113	O	of
16	115	127	O	XXXXXXXX
17	129	134	O	sodium
18	136	138	O	and
19	140	147	U-DYN	ketamine
NULL

Levothyroxine	DDI-DrugBank.d411.s14	NO_SECTION	NO_SETID	8
Maprotiline: Risk of cardiac arrhythmias may increase.
1	0	10	U-UNK	Maprotiline
2	11	11	O	:
3	13	16	O	Risk
4	18	19	O	of
5	21	27	O	cardiac
6	29	39	O	arrhythmias
7	41	43	O	may
8	45	52	O	increase
NULL

Levothyroxine	DDI-DrugBank.d411.s15	NO_SECTION	NO_SETID	17
Sodium Iodide (123I and 131I), Sodium Pertechnetate Tc99m: Uptake of radiolabeled ions may be decreased.
1	0	5	B-UNK	Sodium
2	7	12	L-UNK	Iodide
3	15	18	O	123I
4	20	22	O	and
5	24	27	O	131I
6	29	29	O	,
7	31	36	B-UNK	Sodium
8	38	50	I-UNK	Pertechnetate
9	52	56	L-UNK	Tc99m
10	57	57	O	:
11	59	64	O	Uptake
12	66	67	O	of
13	69	80	O	radiolabeled
14	82	85	O	ions
15	87	89	O	may
16	91	92	O	be
17	94	102	O	decreased
NULL

Levothyroxine	DDI-DrugBank.d411.s16	NO_SECTION	NO_SETID	14
Somatrem/Somatropin: Excessive concurrent use of thyroid hormone may accelerate epiphyseal closure.
1	0	7	U-UNK	Somatrem
2	8	8	O	/
3	9	18	U-UNK	Somatropin
4	19	19	O	:
5	21	29	O	Excessive
6	31	40	O	concurrent
7	42	44	O	use
8	46	47	O	of
9	49	55	B-UNK	thyroid
10	57	63	L-UNK	hormone
11	65	67	O	may
12	69	78	O	accelerate
13	80	89	O	epiphyseal
14	91	97	O	closure
NULL

Levothyroxine	DDI-DrugBank.d411.s17	NO_SECTION	NO_SETID	12
Untreated hypothyroidism may interfere with the growth response to somatrem or somatropin.
1	0	8	O	Untreated
2	10	23	O	hypothyroidism
3	25	27	O	may
4	29	37	O	interfere
5	39	42	O	with
6	44	46	O	the
7	48	53	O	growth
8	55	62	O	response
9	64	65	O	to
10	67	74	U-UNK	somatrem
11	76	77	O	or
12	79	88	U-UNK	somatropin
NULL

Levothyroxine	DDI-DrugBank.d411.s18	NO_SECTION	NO_SETID	19
Theophylline: Theophylline clearance may decrease in hypothyroid patients and return toward normal when a euthyroid state is achieved.
1	0	11	U-UNK	Theophylline
2	12	12	O	:
3	14	25	U-UNK	Theophylline
4	27	35	O	clearance
5	37	39	O	may
6	41	48	O	decrease
7	50	51	O	in
8	53	63	O	hypothyroid
9	65	72	O	patients
10	74	76	O	and
11	78	83	O	return
12	85	90	O	toward
13	92	97	O	normal
14	99	102	O	when
15	104	104	O	a
16	106	114	O	euthyroid
17	116	120	O	state
18	122	123	O	is
19	125	132	O	achieved
NULL

Levothyroxine	DDI-DrugBank.d411.s19	NO_SECTION	NO_SETID	22
Tricyclic Antidepressants: Concurrent use may increase the therapeutic and toxic effects of both drugs, possibly due to increased catecholamine sensitivity.
1	0	8	B-UNK	Tricyclic
2	10	24	L-UNK	Antidepressants
3	25	25	O	:
4	27	36	O	Concurrent
5	38	40	O	use
6	42	44	O	may
7	46	53	O	increase
8	55	57	O	the
9	59	69	O	therapeutic
10	71	73	O	and
11	75	79	O	toxic
12	81	87	O	effects
13	89	90	O	of
14	92	95	O	both
15	97	101	O	drugs
16	102	102	O	,
17	104	111	O	possibly
18	113	115	O	due
19	117	118	O	to
20	120	128	O	increased
21	130	142	O	catecholamine
22	144	154	O	sensitivity
NULL

Levothyroxine	DDI-DrugBank.d411.s20	NO_SECTION	NO_SETID	8
Onset of action of tricyclics may be accelerated.
1	0	4	O	Onset
2	6	7	O	of
3	9	14	O	action
4	16	17	O	of
5	19	28	U-UNK	tricyclics
6	30	32	O	may
7	34	35	O	be
8	37	47	O	accelerated
NULL

Levothyroxine	DDI-DrugBank.d411.s21	NO_SECTION	NO_SETID	15
Sympathomimetic Agents: Possible increased risk of coronary insufficiency in patients with coronary artery disease.
1	0	14	B-UNK	Sympathomimetic
2	16	21	L-UNK	Agents
3	22	22	O	:
4	24	31	O	Possible
5	33	41	O	increased
6	43	46	O	risk
7	48	49	O	of
8	51	58	O	coronary
9	60	72	O	insufficiency
10	74	75	O	in
11	77	84	O	patients
12	86	89	O	with
13	91	98	O	coronary
14	100	105	O	artery
15	107	113	O	disease
NULL

Lidocaine	DDI-DrugBank.d564.s0	NO_SECTION	NO_SETID	25
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.
1	0	2	O	The
2	4	17	O	administration
3	19	20	O	of
4	22	26	O	local
5	28	37	B-UNK	anesthetic
6	39	47	L-UNK	solutions
7	49	58	O	containing
8	60	70	U-UNK	epinephrine
9	72	73	O	or
10	75	88	U-UNK	norepinephrine
11	90	91	O	to
12	93	100	O	patients
13	102	110	O	receiving
14	112	120	B-UNK	monoamine
15	122	128	I-UNK	oxidase
16	130	139	L-UNK	inhibitors
17	141	142	O	or
18	144	152	B-UNK	tricyclic
19	154	168	L-UNK	antidepressants
20	170	172	O	may
21	174	180	O	produce
22	182	187	O	severe
23	188	188	O	,
24	190	198	O	prolonged
25	200	211	O	hypertension
NULL

Lidocaine	DDI-DrugBank.d564.s1	NO_SECTION	NO_SETID	12
Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
1	0	13	U-UNK	Phenothiazines
2	15	17	O	and
3	19	32	U-UNK	butyrophenones
4	34	36	O	may
5	38	43	O	reduce
6	45	46	O	or
7	48	54	O	reverse
8	56	58	O	the
9	60	66	O	pressor
10	68	73	O	effect
11	75	76	O	of
12	78	88	U-UNK	epinephrine
NULL

Lidocaine	DDI-DrugBank.d564.s2	NO_SECTION	NO_SETID	9
Concurrent use of these agents should generally be avoided.
1	0	9	O	Concurrent
2	11	13	O	use
3	15	16	O	of
4	18	22	O	these
5	24	29	O	agents
6	31	36	O	should
7	38	46	O	generally
8	48	49	O	be
9	51	57	O	avoided
NULL

Lidocaine	DDI-DrugBank.d564.s3	NO_SECTION	NO_SETID	13
In situations when concurrent therapy is necessary, careful patient monitoring is essential.
1	0	1	O	In
2	3	12	O	situations
3	14	17	O	when
4	19	28	O	concurrent
5	30	36	O	therapy
6	38	39	O	is
7	41	49	O	necessary
8	50	50	O	,
9	52	58	O	careful
10	60	66	O	patient
11	68	77	O	monitoring
12	79	80	O	is
13	82	90	O	essential
NULL

Lidocaine	DDI-DrugBank.d564.s4	NO_SECTION	NO_SETID	28
Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	39	B-UNK	vasopressor
5	41	45	L-UNK	drugs
6	48	50	O	for
7	52	54	O	the
8	56	64	O	treatment
9	66	67	O	of
10	69	79	O	hypotension
11	81	87	O	related
12	89	90	O	to
13	92	100	O	obstetric
14	102	107	O	blocks
15	110	112	O	and
16	114	118	B-UNK	ergot
17	120	123	I-UNK	type
18	125	132	I-UNK	oxytocic
19	134	138	L-UNK	drugs
20	140	142	O	may
21	144	148	O	cause
22	150	155	O	severe
23	156	156	O	,
24	158	167	O	persistent
25	169	180	O	hypertension
26	182	183	O	or
27	185	199	O	cerebrovascular
28	201	209	O	accidents
NULL

Lincomycin	DDI-DrugBank.d130.s0	NO_SECTION	NO_SETID	19
Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.
1	0	9	O	XXXXXXXX
2	11	13	O	has
3	15	18	O	been
4	20	24	O	shown
5	26	27	O	to
6	29	32	O	have
7	34	46	O	neuromuscular
8	48	55	O	blocking
9	57	66	O	properties
10	68	71	O	that
11	73	75	O	may
12	77	83	O	enhance
13	85	87	O	the
14	89	94	O	action
15	96	97	O	of
16	99	103	O	other
17	105	117	B-DYN	neuromuscular
18	119	126	I-DYN	blocking
19	128	133	L-DYN	agents
NULL

Lincomycin	DDI-DrugBank.d130.s1	NO_SECTION	NO_SETID	13
Therefore, it should be used in caution in patients receiving such agents.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	it
4	14	19	O	should
5	21	22	O	be
6	24	27	O	used
7	29	30	O	in
8	32	38	O	caution
9	40	41	O	in
10	43	50	O	patients
11	52	60	O	receiving
12	62	65	O	such
13	67	72	O	agents
NULL

Lincomycin	DDI-DrugBank.d130.s2	NO_SECTION	NO_SETID	10
Antagonism between lincomycin and erythromycin in vitro has been demonstrated.
1	0	9	O	Antagonism
2	11	17	O	between
3	19	28	O	XXXXXXXX
4	30	32	O	and
5	34	45	U-DYN	erythromycin
6	47	48	O	in
7	50	54	O	vitro
8	56	58	O	has
9	60	63	O	been
10	65	76	O	demonstrated
NULL

Lincomycin	DDI-DrugBank.d130.s3	NO_SECTION	NO_SETID	14
Because of possible clinical significance, the two drugs should not be administered concurrently.
1	0	6	O	Because
2	8	9	O	of
3	11	18	O	possible
4	20	27	O	clinical
5	29	40	O	significance
6	41	41	O	,
7	43	45	O	the
8	47	49	O	two
9	51	55	O	drugs
10	57	62	O	should
11	64	66	O	not
12	68	69	O	be
13	71	82	O	administered
14	84	95	O	concurrently
NULL

Lindane	DDI-DrugBank.d268.s0	NO_SECTION	NO_SETID	4
Oils may enhance absorption.
1	0	3	O	Oils
2	5	7	O	may
3	9	15	O	enhance
4	17	26	O	absorption
NULL

Lindane	DDI-DrugBank.d268.s1	NO_SECTION	NO_SETID	13
Therefore, simultaneous use of creams, ointments or oils should be avoided.
1	0	8	O	Therefore
2	9	9	O	,
3	11	22	O	simultaneous
4	24	26	O	use
5	28	29	O	of
6	31	36	O	creams
7	37	37	O	,
8	39	47	O	ointments
9	49	50	O	or
10	52	55	O	oils
11	57	62	O	should
12	64	65	O	be
13	67	73	O	avoided
NULL

Linezolid	DDI-DrugBank.d441.s0	NO_SECTION	NO_SETID	14
Monoamine Oxidase Inhibition: Linezolid is a reversible, nonselective inhibitor of monoamine oxidase.
1	0	8	O	Monoamine
2	10	16	O	Oxidase
3	18	27	O	Inhibition
4	28	28	O	:
5	30	38	O	XXXXXXXX
6	40	41	O	is
7	43	43	O	a
8	45	54	O	reversible
9	55	55	O	,
10	57	68	O	nonselective
11	70	78	O	inhibitor
12	80	81	O	of
13	83	91	O	monoamine
14	93	99	O	oxidase
NULL

Linezolid	DDI-DrugBank.d441.s1	NO_SECTION	NO_SETID	13
Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.
1	0	8	O	Therefore
2	9	9	O	,
3	11	19	O	XXXXXXXX
4	21	23	O	has
5	25	27	O	the
6	29	37	O	potential
7	39	41	O	for
8	43	53	O	interaction
9	55	58	O	with
10	60	69	U-UNK	adrenergic
11	71	73	O	and
12	75	86	B-UNK	serotonergic
13	88	93	L-UNK	agents
NULL

Linezolid	DDI-DrugBank.d441.s2	NO_SECTION	NO_SETID	24
Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.
1	0	9	U-UNK	Adrenergic
2	11	21	O	Agents:Some
3	23	33	O	individuals
4	35	43	O	receiving
5	45	49	O	XXXXXXXX
6	51	53	O	may
7	55	64	O	experience
8	66	66	O	a
9	68	77	O	reversible
10	79	89	O	enhancement
11	91	92	O	of
12	94	96	O	the
13	98	104	O	pressor
14	106	113	O	response
15	115	116	O	to
16	118	125	O	indirect
17	127	132	O	acting
18	134	148	B-DYN	sympathomimetic
19	150	155	L-DYN	agents
20	156	156	O	,
21	158	168	U-DYN	vasopressor
22	170	171	O	or
23	173	184	B-DYN	dopaminergic
24	186	191	L-DYN	agents
NULL

Linezolid	DDI-DrugBank.d441.s3	NO_SECTION	NO_SETID	12
Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied.
1	0	7	O	Commonly
2	9	12	O	used
3	14	18	O	drugs
4	20	23	O	such
5	25	26	O	as
6	28	46	U-UNK	phenylpropanolamine
7	48	50	O	and
8	52	66	U-UNK	pseudoephedrine
9	68	71	O	have
10	73	76	O	been
11	78	89	O	specifically
12	91	97	O	studied
NULL

Linezolid	DDI-DrugBank.d441.s4	NO_SECTION	NO_SETID	22
Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response.
1	0	6	O	Initial
2	8	12	O	doses
3	14	15	O	of
4	17	26	B-UNK	adrenergic
5	28	33	L-UNK	agents
6	34	34	O	,
7	36	39	O	such
8	41	42	O	as
9	44	51	U-UNK	dopamine
10	53	54	O	or
11	56	66	U-UNK	epinephrine
12	67	67	O	,
13	69	74	O	should
14	76	77	O	be
15	79	85	O	reduced
16	87	89	O	and
17	91	98	O	titrated
18	100	101	O	to
19	103	109	O	achieve
20	111	113	O	the
21	115	121	O	desired
22	123	130	O	response
NULL

Linezolid	DDI-DrugBank.d441.s5	NO_SECTION	NO_SETID	24
Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.
1	0	11	B-UNK	Serotonergic
2	13	18	L-UNK	Agents
3	19	19	O	:
4	21	22	O	Co
5	24	37	O	administration
6	39	40	O	of
7	42	50	O	XXXXXXXX
8	52	54	O	and
9	56	67	B-UNK	serotonergic
10	69	74	L-UNK	agents
11	76	78	O	was
12	80	82	O	not
13	84	93	O	associated
14	95	98	O	with
15	100	108	O	serotonin
16	110	117	O	syndrome
17	119	120	O	in
18	122	126	O	Phase
19	128	128	O	1
20	129	129	O	,
21	131	131	O	2
22	133	134	O	or
23	136	136	O	3
24	138	144	O	studies
NULL

Linezolid	DDI-DrugBank.d441.s6	NO_SECTION	NO_SETID	28
Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.
1	0	10	O	Spontaneous
2	12	18	O	reports
3	20	21	O	of
4	23	31	O	serotonin
5	33	40	O	syndrome
6	42	51	O	associated
7	53	56	O	with
8	58	59	O	co
9	61	74	O	administration
10	76	77	O	of
11	79	83	O	XXXXXXXX
12	85	87	O	and
13	89	100	B-DYN	serotonergic
14	102	107	L-DYN	agents
15	108	108	O	,
16	110	118	O	including
17	120	134	U-DYN	antidepressants
18	136	139	O	such
19	141	142	O	as
20	144	152	B-DYN	selective
21	154	162	I-DYN	serotonin
22	164	171	I-DYN	reuptake
23	173	182	L-DYN	inhibitors
24	185	189	U-DYN	SSRIs
25	191	191	O	,
26	193	196	O	have
27	198	201	O	been
28	203	210	O	reported
NULL

Linezolid	DDI-DrugBank.d441.s7	NO_SECTION	NO_SETID	31
Patients who are treated with ZYVOX and concomitant serotonergic agents should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).
1	0	7	O	Patients
2	9	11	O	who
3	13	15	O	are
4	17	23	O	treated
5	25	28	O	with
6	30	34	O	XXXXXXXX
7	36	38	O	and
8	40	50	O	concomitant
9	52	63	B-DYN	serotonergic
10	65	70	L-DYN	agents
11	72	77	O	should
12	79	80	O	be
13	82	88	O	closely
14	90	97	O	observed
15	99	101	O	for
16	103	107	O	signs
17	109	111	O	and
18	113	120	O	symptoms
19	122	123	O	of
20	125	133	O	serotonin
21	135	142	O	syndrome
22	145	147	O	e.g
23	149	149	O	,
24	151	159	O	cognitive
25	161	171	O	dysfunction
26	172	172	O	,
27	174	185	O	hyperpyrexia
28	186	186	O	,
29	188	200	O	hyperreflexia
30	201	201	O	,
31	203	216	O	incoordination
NULL

Linezolid	DDI-DrugBank.d441.s8	NO_SECTION	NO_SETID	21
If any signs or symptoms occur physicians should consider discontinuation of either one or both agents (ZYVOX or concomitant serotonergic agents).
1	0	1	O	If
2	3	5	O	any
3	7	11	O	signs
4	13	14	O	or
5	16	23	O	symptoms
6	25	29	O	occur
7	31	40	O	physicians
8	42	47	O	should
9	49	56	O	consider
10	58	72	O	discontinuation
11	74	75	O	of
12	77	82	O	either
13	84	86	O	one
14	88	89	O	or
15	91	94	O	both
16	96	101	O	agents
17	104	108	O	XXXXXXXX
18	110	111	O	or
19	113	123	O	concomitant
20	125	136	B-DYN	serotonergic
21	138	143	L-DYN	agents
NULL

Linezolid	DDI-DrugBank.d441.s9	NO_SECTION	NO_SETID	12
Drug-Laboratory Test Interactions There are no reported drug-laboratory test interactions.
1	0	3	O	Drug
2	5	14	O	Laboratory
3	16	19	O	Test
4	21	32	O	Interactions
5	34	38	O	There
6	40	42	O	are
7	44	45	O	no
8	47	54	O	reported
9	56	59	O	drug
10	61	70	O	laboratory
11	72	75	O	test
12	77	88	O	interactions
NULL

Liothyronine	DDI-DrugBank.d54.s0	NO_SECTION	NO_SETID	15
Oral Anticoagulants: Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors.
1	0	3	O	Oral
2	5	18	U-UNK	Anticoagulants
3	19	19	O	:
4	21	27	B-UNK	Thyroid
5	29	36	L-UNK	hormones
6	38	43	O	appear
7	45	46	O	to
8	48	55	O	increase
9	57	66	O	catabolism
10	68	69	O	of
11	71	77	O	vitamin
12	79	79	O	K
13	81	89	O	dependent
14	91	98	O	clotting
15	100	106	O	factors
NULL

Liothyronine	DDI-DrugBank.d54.s1	NO_SECTION	NO_SETID	16
If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired.
1	0	1	O	If
2	3	6	O	oral
3	8	21	U-UNK	anticoagulants
4	23	25	O	are
5	27	30	O	also
6	32	36	O	being
7	38	42	O	given
8	43	43	O	,
9	45	56	O	compensatory
10	58	66	O	increases
11	68	69	O	in
12	71	78	O	clotting
13	80	85	O	factor
14	87	95	O	synthesis
15	97	99	O	are
16	101	108	O	impaired
NULL

Liothyronine	DDI-DrugBank.d54.s2	NO_SECTION	NO_SETID	22
Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.
1	0	7	O	Patients
2	9	18	O	stabilized
3	20	21	O	on
4	23	26	O	oral
5	28	41	U-UNK	anticoagulants
6	43	45	O	who
7	47	49	O	are
8	51	55	O	found
9	57	58	O	to
10	60	66	O	require
11	68	74	U-UNK	thyroid
12	76	86	O	replacement
13	88	94	O	therapy
14	96	101	O	should
15	103	104	O	be
16	106	112	O	watched
17	114	117	O	very
18	119	125	O	closely
19	127	130	O	when
20	132	138	O	thyroid
21	140	141	O	is
22	143	149	O	started
NULL

Liothyronine	DDI-DrugBank.d54.s3	NO_SECTION	NO_SETID	19
If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required.
1	0	1	O	If
2	3	3	O	a
3	5	11	O	patient
4	13	14	O	is
5	16	20	O	truly
6	22	32	O	hypothyroid
7	33	33	O	,
8	35	36	O	it
9	38	39	O	is
10	41	46	O	likely
11	48	51	O	that
12	53	53	O	a
13	55	63	O	reduction
14	65	66	O	in
15	68	80	U-UNK	anticoagulant
16	82	87	O	dosage
17	89	92	O	will
18	94	95	O	be
19	97	104	O	required
NULL

Liothyronine	DDI-DrugBank.d54.s4	NO_SECTION	NO_SETID	23
No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy.
1	0	1	O	No
2	3	9	O	special
3	11	21	O	precautions
4	23	28	O	appear
5	30	31	O	to
6	33	34	O	be
7	36	44	O	necessary
8	46	49	O	when
9	51	54	O	oral
10	56	68	O	anticoagulant
11	70	76	O	therapy
12	78	79	O	is
13	81	85	O	begun
14	87	88	O	in
15	90	90	O	a
16	92	98	O	patient
17	100	106	O	already
18	108	117	O	stabilized
19	119	120	O	on
20	122	132	O	maintenance
21	134	140	O	thyroid
22	142	152	O	replacement
23	154	160	O	therapy
NULL

Liothyronine	DDI-DrugBank.d54.s5	NO_SECTION	NO_SETID	18
Insulin or Oral Hypoglycemics: Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements.
1	0	6	U-UNK	Insulin
2	8	9	O	or
3	11	14	O	Oral
4	16	28	U-UNK	Hypoglycemics
5	29	29	O	:
6	31	40	O	Initiating
7	42	48	O	thyroid
8	50	60	O	replacement
9	62	68	O	therapy
10	70	72	O	may
11	74	78	O	cause
12	80	88	O	increases
13	90	91	O	in
14	93	99	U-UNK	insulin
15	101	102	O	or
16	104	107	O	oral
17	109	120	U-UNK	hypoglycemic
18	122	133	O	requirements
NULL

Liothyronine	DDI-DrugBank.d54.s6	NO_SECTION	NO_SETID	27
The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient.
1	0	2	O	The
2	4	10	O	effects
3	12	15	O	seen
4	17	19	O	are
5	21	26	O	poorly
6	28	37	O	understood
7	39	41	O	and
8	43	48	O	depend
9	50	53	O	upon
10	55	55	O	a
11	57	63	O	variety
12	65	66	O	of
13	68	74	O	factors
14	76	79	O	such
15	81	82	O	as
16	84	87	O	dose
17	89	91	O	and
18	93	96	O	type
19	98	99	O	of
20	101	107	B-UNK	thyroid
21	109	120	L-UNK	preparations
22	122	124	O	and
23	126	134	O	endocrine
24	136	141	O	status
25	143	144	O	of
26	146	148	O	the
27	150	156	O	patient
NULL

Liothyronine	DDI-DrugBank.d54.s7	NO_SECTION	NO_SETID	16
Patients receiving insulin or oral hypoglycemics should be closely watched during initiation of thyroid replacement therapy.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	25	U-UNK	insulin
4	27	28	O	or
5	30	33	O	oral
6	35	47	U-UNK	hypoglycemics
7	49	54	O	should
8	56	57	O	be
9	59	65	O	closely
10	67	73	O	watched
11	75	80	O	during
12	82	91	O	initiation
13	93	94	O	of
14	96	102	O	thyroid
15	104	114	O	replacement
16	116	122	O	therapy
NULL

Liothyronine	DDI-DrugBank.d54.s8	NO_SECTION	NO_SETID	19
Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.
1	0	13	U-UNK	Cholestyramine
2	14	14	O	:
3	16	29	U-UNK	Cholestyramine
4	31	35	O	binds
5	37	40	O	both
6	42	43	U-UNK	T4
7	45	47	O	and
8	49	50	U-UNK	T3
9	52	53	O	in
10	55	57	O	the
11	59	67	O	intestine
12	68	68	O	,
13	70	73	O	thus
14	75	83	O	impairing
15	85	94	O	absorption
16	96	97	O	of
17	99	103	O	these
18	105	111	B-UNK	thyroid
19	113	120	L-UNK	hormones
NULL

Liothyronine	DDI-DrugBank.d54.s9	NO_SECTION	NO_SETID	11
In vitro studies indicate that the binding is not easily removed.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	24	O	indicate
5	26	29	O	that
6	31	33	O	the
7	35	41	O	binding
8	43	44	O	is
9	46	48	O	not
10	50	55	O	easily
11	57	63	O	removed
NULL

Liothyronine	DDI-DrugBank.d54.s10	NO_SECTION	NO_SETID	15
Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.
1	0	8	O	Therefore
2	9	9	O	,
3	11	11	O	4
4	13	14	O	to
5	16	16	O	5
6	18	22	O	hours
7	24	29	O	should
8	31	36	O	elapse
9	38	44	O	between
10	46	59	O	administration
11	61	62	O	of
12	64	77	U-UNK	cholestyramine
13	79	81	O	and
14	83	89	B-UNK	thyroid
15	91	98	L-UNK	hormones
NULL

Liothyronine	DDI-DrugBank.d54.s11	NO_SECTION	NO_SETID	14
Estrogen, Oral Contraceptives: Estrogens tend to increase serum thyroxine-binding globulin (TBg).
1	0	7	U-UNK	Estrogen
2	8	8	O	,
3	10	13	O	Oral
4	15	28	U-UNK	Contraceptives
5	29	29	O	:
6	31	39	U-UNK	Estrogens
7	41	44	O	tend
8	46	47	O	to
9	49	56	O	increase
10	58	62	O	serum
11	64	72	O	thyroxine
12	74	80	O	binding
13	82	89	O	globulin
14	92	94	O	TBg
NULL

Liothyronine	DDI-DrugBank.d54.s12	NO_SECTION	NO_SETID	28
In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.
1	0	1	O	In
2	3	3	O	a
3	5	11	O	patient
4	13	16	O	with
5	18	18	O	a
6	20	33	O	nonfunctioning
7	35	41	O	thyroid
8	43	47	O	gland
9	49	51	O	who
10	53	54	O	is
11	56	64	O	receiving
12	66	72	O	thyroid
13	74	84	O	replacement
14	86	92	O	therapy
15	93	93	O	,
16	95	98	O	free
17	100	112	U-UNK	levothyroxine
18	114	116	O	may
19	118	119	O	be
20	121	129	O	decreased
21	131	134	O	when
22	136	144	U-UNK	estrogens
23	146	148	O	are
24	150	156	O	started
25	158	161	O	thus
26	163	172	O	increasing
27	174	180	U-UNK	thyroid
28	182	193	O	requirements
NULL

Liothyronine	DDI-DrugBank.d54.s13	NO_SECTION	NO_SETID	27
However, if the patients thyroid gland has sufficient function, the decreased free thyroxine will result in a compensatory increase in thyroxine output by the thyroid.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	if
4	12	14	O	the
5	16	23	O	patients
6	25	31	O	thyroid
7	33	37	O	gland
8	39	41	O	has
9	43	52	O	sufficient
10	54	61	O	function
11	62	62	O	,
12	64	66	O	the
13	68	76	O	decreased
14	78	81	O	free
15	83	91	O	thyroxine
16	93	96	O	will
17	98	103	O	result
18	105	106	O	in
19	108	108	O	a
20	110	121	O	compensatory
21	123	130	O	increase
22	132	133	O	in
23	135	143	O	thyroxine
24	145	150	O	output
25	152	153	O	by
26	155	157	O	the
27	159	165	O	thyroid
NULL

Liothyronine	DDI-DrugBank.d54.s14	NO_SECTION	NO_SETID	30
Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	O	patients
4	20	26	O	without
5	28	28	O	a
6	30	40	O	functioning
7	42	48	U-UNK	thyroid
8	50	54	O	gland
9	56	58	O	who
10	60	62	O	are
11	64	65	O	on
12	67	73	O	thyroid
13	75	85	O	replacement
14	87	93	O	therapy
15	95	97	O	may
16	99	102	O	need
17	104	105	O	to
18	107	114	O	increase
19	116	120	O	their
20	122	128	O	thyroid
21	130	133	O	dose
22	135	136	O	if
23	138	146	U-UNK	estrogens
24	148	149	O	or
25	151	158	U-UNK	estrogen
26	160	169	O	containing
27	171	174	O	oral
28	176	189	U-UNK	contraceptives
29	191	193	O	are
30	195	199	O	given
NULL

Liothyronine	DDI-DrugBank.d54.s15	NO_SECTION	NO_SETID	27
Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
1	0	8	B-UNK	Tricyclic
2	10	24	L-UNK	Antidepressants
3	25	25	O	:
4	27	29	O	Use
5	31	32	O	of
6	34	40	B-UNK	thyroid
7	42	49	L-UNK	products
8	51	54	O	with
9	56	65	U-UNK	imipramine
10	67	69	O	and
11	71	75	O	other
12	77	85	B-UNK	tricyclic
13	87	101	L-UNK	antidepressants
14	103	105	O	may
15	107	114	O	increase
16	116	123	O	receptor
17	125	135	O	sensitivity
18	137	139	O	and
19	141	147	O	enhance
20	149	162	O	antidepressant
21	164	171	O	activity
22	173	181	O	transient
23	183	189	O	cardiac
24	191	201	O	arrhythmias
25	203	206	O	have
26	208	211	O	been
27	213	220	O	observed
NULL

Liothyronine	DDI-DrugBank.d54.s16	NO_SECTION	NO_SETID	7
Thyroid hormone activity may also be enhanced.
1	0	6	B-UNK	Thyroid
2	8	14	L-UNK	hormone
3	16	23	O	activity
4	25	27	O	may
5	29	32	O	also
6	34	35	O	be
7	37	44	O	enhanced
NULL

Liothyronine	DDI-DrugBank.d54.s17	NO_SECTION	NO_SETID	11
Digitalis: Thyroid preparations may potentiate the toxic effects of digitalis.
1	0	8	U-UNK	Digitalis
2	9	9	O	:
3	11	17	B-UNK	Thyroid
4	19	30	L-UNK	preparations
5	32	34	O	may
6	36	45	O	potentiate
7	47	49	O	the
8	51	55	O	toxic
9	57	63	O	effects
10	65	66	O	of
11	68	76	U-UNK	digitalis
NULL

Liothyronine	DDI-DrugBank.d54.s18	NO_SECTION	NO_SETID	14
Thyroid hormonal replacement increases metabolic rate, which requires an increase in digitalis dosage.
1	0	6	O	Thyroid
2	8	15	O	hormonal
3	17	27	O	replacement
4	29	37	O	increases
5	39	47	O	metabolic
6	49	52	O	rate
7	53	53	O	,
8	55	59	O	which
9	61	68	O	requires
10	70	71	O	an
11	73	80	O	increase
12	82	83	O	in
13	85	93	U-UNK	digitalis
14	95	100	O	dosage
NULL

Liothyronine	DDI-DrugBank.d54.s19	NO_SECTION	NO_SETID	19
Ketamine: When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia.
1	0	7	U-UNK	Ketamine
2	8	8	O	:
3	10	13	O	When
4	15	26	O	administered
5	28	29	O	to
6	31	38	O	patients
7	40	41	O	on
8	43	43	O	a
9	45	51	B-UNK	thyroid
10	53	63	L-UNK	preparation
11	64	64	O	,
12	66	69	O	this
13	71	80	O	parenteral
14	82	91	U-UNK	anesthetic
15	93	95	O	may
16	97	101	O	cause
17	103	114	O	hypertension
18	116	118	O	and
19	120	130	O	tachycardia
NULL

Liothyronine	DDI-DrugBank.d54.s20	NO_SECTION	NO_SETID	12
Use with caution and be prepared to treat hypertension, if necessary.
1	0	2	O	Use
2	4	7	O	with
3	9	15	O	caution
4	17	19	O	and
5	21	22	O	be
6	24	31	O	prepared
7	33	34	O	to
8	36	40	O	treat
9	42	53	O	hypertension
10	54	54	O	,
11	56	57	O	if
12	59	67	O	necessary
NULL

Liothyronine	DDI-DrugBank.d54.s21	NO_SECTION	NO_SETID	14
Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.
1	0	11	O	Vasopressors
2	12	12	O	:
3	14	22	U-UNK	Thyroxine
4	24	32	O	increases
5	34	36	O	the
6	38	47	O	adrenergic
7	49	54	O	effect
8	56	57	O	of
9	59	72	O	catecholamines
10	74	77	O	such
11	79	80	O	as
12	82	92	U-UNK	epinephrine
13	94	96	O	and
14	98	111	U-UNK	norepinephrine
NULL

Liothyronine	DDI-DrugBank.d54.s22	NO_SECTION	NO_SETID	25
Therefore, injection of these agents into patients receiving thyroid preparations increases the risk of precipitating coronary insufficiency especially in patients with coronary artery disease.
1	0	8	O	Therefore
2	9	9	O	,
3	11	19	O	injection
4	21	22	O	of
5	24	28	O	these
6	30	35	O	agents
7	37	40	O	into
8	42	49	O	patients
9	51	59	O	receiving
10	61	67	B-UNK	thyroid
11	69	80	L-UNK	preparations
12	82	90	O	increases
13	92	94	O	the
14	96	99	O	risk
15	101	102	O	of
16	104	116	O	precipitating
17	118	125	O	coronary
18	127	139	O	insufficiency
19	141	150	O	especially
20	152	153	O	in
21	155	162	O	patients
22	164	167	O	with
23	169	176	O	coronary
24	178	183	O	artery
25	185	191	O	disease
NULL

Liothyronine	DDI-DrugBank.d54.s23	NO_SECTION	NO_SETID	4
Careful observation is required.
1	0	6	O	Careful
2	8	18	O	observation
3	20	21	O	is
4	23	30	O	required
NULL

Liothyronine	DDI-DrugBank.d54.s24	NO_SECTION	NO_SETID	45
Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	36	O	The
7	38	46	O	following
8	48	52	O	drugs
9	54	55	O	or
10	57	64	O	moieties
11	66	68	O	are
12	70	74	O	known
13	76	77	O	to
14	79	87	O	interfere
15	89	92	O	with
16	94	103	O	laboratory
17	105	109	O	tests
18	111	119	O	performed
19	121	122	O	in
20	124	131	O	patients
21	133	134	O	on
22	136	142	B-UNK	thyroid
23	144	150	L-UNK	hormone
24	152	158	O	therapy
25	159	159	O	:
26	161	169	U-UNK	androgens
27	170	170	O	,
28	172	186	U-UNK	corticosteroids
29	187	187	O	,
30	189	197	U-UNK	estrogens
31	198	198	O	,
32	200	203	O	oral
33	205	218	U-UNK	contraceptives
34	220	229	O	containing
35	231	239	U-UNK	estrogens
36	240	240	O	,
37	242	247	U-UNK	iodine
38	249	258	O	containing
39	260	271	O	preparations
40	273	275	O	and
41	277	279	O	the
42	281	288	O	numerous
43	290	301	O	preparations
44	303	312	O	containing
45	314	324	U-UNK	salicylates
NULL

Liothyronine	DDI-DrugBank.d54.s25	NO_SECTION	NO_SETID	17
- Changes in TBg concentration should be taken into consideration in the interpretation of T4 and T3 values.
1	2	8	O	Changes
2	10	11	O	in
3	13	15	O	TBg
4	17	29	O	concentration
5	31	36	O	should
6	38	39	O	be
7	41	45	O	taken
8	47	50	O	into
9	52	64	O	consideration
10	66	67	O	in
11	69	71	O	the
12	73	86	O	interpretation
13	88	89	O	of
14	91	92	O	T4
15	94	96	O	and
16	98	99	O	T3
17	101	106	O	values
NULL

Liothyronine	DDI-DrugBank.d54.s26	NO_SECTION	NO_SETID	11
In such cases, the unbound (free) hormone should be measured.
1	0	1	O	In
2	3	6	O	such
3	8	12	O	cases
4	13	13	O	,
5	15	17	O	the
6	19	25	O	unbound
7	28	31	O	free
8	34	40	O	hormone
9	42	47	O	should
10	49	50	O	be
11	52	59	O	measured
NULL

Liothyronine	DDI-DrugBank.d54.s27	NO_SECTION	NO_SETID	10
Pregnancy estrogens and estrogen-containing oral contraceptives increase TBg concentrations.
1	0	8	O	Pregnancy
2	10	18	U-UNK	estrogens
3	20	22	O	and
4	24	31	U-UNK	estrogen
5	33	42	O	containing
6	44	47	O	oral
7	49	62	U-UNK	contraceptives
8	64	71	O	increase
9	73	75	O	TBg
10	77	90	O	concentrations
NULL

Liothyronine	DDI-DrugBank.d54.s28	NO_SECTION	NO_SETID	8
TBg may also be increased during infectious hepatitis.
1	0	2	O	TBg
2	4	6	O	may
3	8	11	O	also
4	13	14	O	be
5	16	24	O	increased
6	26	31	O	during
7	33	42	O	infectious
8	44	52	O	hepatitis
NULL

Liothyronine	DDI-DrugBank.d54.s29	NO_SECTION	NO_SETID	16
Decreases in TBg concentrations are observed in nephrosis, acromegaly and after androgen or corticosteroid therapy.
1	0	8	O	Decreases
2	10	11	O	in
3	13	15	O	TBg
4	17	30	O	concentrations
5	32	34	O	are
6	36	43	O	observed
7	45	46	O	in
8	48	56	O	nephrosis
9	57	57	O	,
10	59	68	O	acromegaly
11	70	72	O	and
12	74	78	O	after
13	80	87	U-UNK	androgen
14	89	90	O	or
15	92	105	U-UNK	corticosteroid
16	107	113	O	therapy
NULL

Liothyronine	DDI-DrugBank.d54.s30	NO_SECTION	NO_SETID	10
Familial hyper- or hypo-thyroxine-binding-globulinemias have been described.
1	0	7	O	Familial
2	9	13	O	hyper
3	16	17	O	or
4	19	22	O	hypo
5	24	32	O	thyroxine
6	34	40	O	binding
7	42	54	O	globulinemias
8	56	59	O	have
9	61	64	O	been
10	66	74	O	described
NULL

Liothyronine	DDI-DrugBank.d54.s31	NO_SECTION	NO_SETID	9
The incidence of TBg deficiency approximates 1 in 9000.
1	0	2	O	The
2	4	12	O	incidence
3	14	15	O	of
4	17	19	O	TBg
5	21	30	O	deficiency
6	32	43	O	approximates
7	45	45	O	1
8	47	48	O	in
9	50	53	O	9000
NULL

Liothyronine	DDI-DrugBank.d54.s32	NO_SECTION	NO_SETID	13
The binding of thyroxine by thyroxine-binding prealbumin (TBPA) is inhibited by salicylates
1	0	2	O	The
2	4	10	O	binding
3	12	13	O	of
4	15	23	O	thyroxine
5	25	26	O	by
6	28	36	O	thyroxine
7	38	44	O	binding
8	46	55	O	prealbumin
9	58	61	O	TBPA
10	64	65	O	is
11	67	75	O	inhibited
12	77	78	O	by
13	80	90	U-UNK	salicylates
NULL

Liothyronine	DDI-DrugBank.d54.s34	NO_SECTION	NO_SETID	29
- Medicinal or dietary iodine interferes with all in vivo tests of radio-iodine uptake producing low uptakes which may not be reflective of a true decrease in hormone synthesis
1	2	10	O	Medicinal
2	12	13	O	or
3	15	21	O	dietary
4	23	28	U-UNK	iodine
5	30	39	O	interferes
6	41	44	O	with
7	46	48	O	all
8	50	51	O	in
9	53	56	O	vivo
10	58	62	O	tests
11	64	65	O	of
12	67	71	O	radio
13	73	78	O	iodine
14	80	85	O	uptake
15	87	95	O	producing
16	97	99	O	low
17	101	107	O	uptakes
18	109	113	O	which
19	115	117	O	may
20	119	121	O	not
21	123	124	O	be
22	126	135	O	reflective
23	137	138	O	of
24	140	140	O	a
25	142	145	O	true
26	147	154	O	decrease
27	156	157	O	in
28	159	165	O	hormone
29	167	175	O	synthesis
NULL

Liothyronine	DDI-DrugBank.d54.s36	NO_SECTION	NO_SETID	33
- The persistence of clinical and laboratory evidence of hypothyroidism in spite of adequate dosage replacement indicates either poor patient compliance, poor absorption, excessive fecal loss, or inactivity of the preparation.
1	2	4	O	The
2	6	16	O	persistence
3	18	19	O	of
4	21	28	O	clinical
5	30	32	O	and
6	34	43	O	laboratory
7	45	52	O	evidence
8	54	55	O	of
9	57	70	O	hypothyroidism
10	72	73	O	in
11	75	79	O	spite
12	81	82	O	of
13	84	91	O	adequate
14	93	98	O	dosage
15	100	110	O	replacement
16	112	120	O	indicates
17	122	127	O	either
18	129	132	O	poor
19	134	140	O	patient
20	142	151	O	compliance
21	152	152	O	,
22	154	157	O	poor
23	159	168	O	absorption
24	169	169	O	,
25	171	179	O	excessive
26	181	185	O	fecal
27	187	190	O	loss
28	191	191	O	,
29	193	194	O	or
30	196	205	O	inactivity
31	207	208	O	of
32	210	212	O	the
33	214	224	O	preparation
NULL

Liothyronine	DDI-DrugBank.d54.s37	NO_SECTION	NO_SETID	8
Intracellular resistance to thyroid hormone is quite rare.
1	0	12	O	Intracellular
2	14	23	O	resistance
3	25	26	O	to
4	28	34	B-UNK	thyroid
5	36	42	L-UNK	hormone
6	44	45	O	is
7	47	51	O	quite
8	53	56	O	rare
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s0	NO_SECTION	NO_SETID	29
Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
1	0	6	O	Urinary
2	8	17	O	acidifying
3	19	24	O	agents
4	26	30	O	These
5	32	37	O	agents
6	40	47	B-UNK	ammonium
7	49	56	L-UNK	chloride
8	57	57	O	,
9	59	64	B-UNK	sodium
10	66	69	I-UNK	acid
11	71	79	L-UNK	phosphate
12	80	80	O	,
13	82	84	O	etc
14	88	95	O	increase
15	97	99	O	the
16	101	113	O	concentration
17	115	116	O	of
18	118	120	O	the
19	122	128	O	ionized
20	130	136	O	species
21	138	139	O	of
22	141	143	O	the
23	145	155	U-UNK	amphetamine
24	157	164	O	molecule
25	165	165	O	,
26	167	173	O	thereby
27	175	184	O	increasing
28	186	192	O	urinary
29	194	202	O	excretion
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s1	NO_SECTION	NO_SETID	11
Both groups of agents lower blood levels and efficacy of amphetamines.
1	0	3	O	Both
2	5	10	O	groups
3	12	13	O	of
4	15	20	O	agents
5	22	26	O	lower
6	28	32	O	blood
7	34	39	O	levels
8	41	43	O	and
9	45	52	O	efficacy
10	54	55	O	of
11	57	68	U-UNK	amphetamines
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s2	NO_SECTION	NO_SETID	8
Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.
1	0	9	B-UNK	Adrenergic
2	11	18	L-UNK	blockers
3	20	29	B-UNK	Adrenergic
4	31	38	L-UNK	blockers
5	40	42	O	are
6	44	52	O	inhibited
7	54	55	O	by
8	57	68	U-UNK	amphetamines
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s3	NO_SECTION	NO_SETID	14
Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;
1	0	14	U-UNK	Antidepressants
2	15	15	O	,
3	17	25	U-UNK	tricyclic
4	27	38	U-UNK	Amphetamines
5	40	42	O	may
6	44	50	O	enhance
7	52	54	O	the
8	56	63	O	activity
9	65	66	O	of
10	68	76	B-UNK	tricyclic
11	78	92	L-UNK	antidepressants
12	94	95	O	or
13	97	111	B-UNK	sympathomimetic
14	113	118	L-UNK	agents
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s4	NO_SECTION	NO_SETID	24
d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
1	0	0	B-UNK	d
2	2	12	L-UNK	amphetamine
3	14	17	O	with
4	19	29	U-UNK	desipramine
5	31	32	O	or
6	34	46	U-UNK	protriptyline
7	48	50	O	and
8	52	59	O	possibly
9	61	65	O	other
10	67	76	U-UNK	tricyclics
11	78	82	O	cause
12	84	91	O	striking
13	93	95	O	and
14	97	105	O	sustained
15	107	115	O	increases
16	117	118	O	in
17	120	122	O	the
18	124	136	O	concentration
19	138	139	O	of
20	141	141	B-UNK	d
21	143	153	L-UNK	amphetamine
22	155	156	O	in
23	158	160	O	the
24	162	166	O	brain
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s5	NO_SECTION	NO_SETID	5
cardiovascular effects can be potentiated.
1	0	13	O	cardiovascular
2	15	21	O	effects
3	23	25	O	can
4	27	28	O	be
5	30	40	O	potentiated
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s6	NO_SECTION	NO_SETID	16
MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
1	0	2	B-UNK	MAO
2	4	13	L-UNK	inhibitors
3	15	18	B-UNK	MAOI
4	20	34	L-UNK	antidepressants
5	35	35	O	,
6	37	38	O	as
7	40	43	O	well
8	45	46	O	as
9	48	48	O	a
10	50	59	O	metabolite
11	61	62	O	of
12	64	75	U-UNK	furazolidone
13	76	76	O	,
14	78	81	O	slow
15	83	93	U-UNK	amphetamine
16	95	104	O	metabolism
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s7	NO_SECTION	NO_SETID	20
This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings;
1	0	3	O	This
2	5	11	O	slowing
3	13	23	O	potentiates
4	25	36	U-UNK	amphetamines
5	37	37	O	,
6	39	48	O	increasing
7	50	54	O	their
8	56	61	O	effect
9	63	64	O	on
10	66	68	O	the
11	70	76	O	release
12	78	79	O	of
13	81	94	O	norepinephrine
14	96	98	O	and
15	100	104	O	other
16	106	115	O	monoamines
17	117	120	O	from
18	122	131	O	adrenergic
19	133	137	O	nerve
20	139	145	O	endings
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s8	NO_SECTION	NO_SETID	10
this can cause headaches and other signs of hypertensive crisis.
1	0	3	O	this
2	5	7	O	can
3	9	13	O	cause
4	15	23	O	headaches
5	25	27	O	and
6	29	33	O	other
7	35	39	O	signs
8	41	42	O	of
9	44	55	O	hypertensive
10	57	62	O	crisis
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s9	NO_SECTION	NO_SETID	16
A variety of toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results.
1	0	0	O	A
2	2	8	O	variety
3	10	11	O	of
4	13	17	O	toxic
5	19	30	O	neurological
6	32	38	O	effects
7	40	42	O	and
8	44	52	O	malignant
9	54	65	O	hyperpyrexia
10	67	69	O	can
11	71	75	O	occur
12	76	76	O	,
13	78	86	O	sometimes
14	88	91	O	with
15	93	97	O	fatal
16	99	105	O	results
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s10	NO_SECTION	NO_SETID	10
Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.
1	0	13	U-UNK	Antihistamines
2	14	14	O	:
3	16	27	U-UNK	Amphetamines
4	29	31	O	may
5	33	42	O	counteract
6	44	46	O	the
7	48	55	O	sedative
8	57	62	O	effect
9	64	65	O	of
10	67	80	U-UNK	antihistamines
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s11	NO_SECTION	NO_SETID	10
Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.
1	0	16	U-UNK	Antihypertensives
2	17	17	O	:
3	19	30	U-UNK	Amphetamines
4	32	34	O	may
5	36	45	O	antagonize
6	47	49	O	the
7	51	61	O	hypotensive
8	63	69	O	effects
9	71	72	O	of
10	74	90	U-UNK	antihypertensives
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s12	NO_SECTION	NO_SETID	25
Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.
1	0	13	U-UNK	Chlorpromazine
2	14	14	O	:
3	16	29	U-UNK	Chlorpromazine
4	31	36	O	blocks
5	38	45	O	dopamine
6	47	49	O	and
7	51	64	O	norepinephrine
8	66	74	O	receptors
9	75	75	O	,
10	77	80	O	thus
11	82	91	O	inhibiting
12	93	95	O	the
13	97	103	O	central
14	105	113	O	stimulant
15	115	121	O	effects
16	123	124	O	of
17	126	137	U-UNK	amphetamines
18	139	141	O	and
19	143	145	O	can
20	147	148	O	be
21	150	153	O	used
22	155	156	O	to
23	158	162	O	treat
24	164	174	U-UNK	amphetamine
25	176	184	O	poisoning
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s13	NO_SECTION	NO_SETID	9
Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.
1	0	11	U-UNK	Ethosuximide
2	12	12	O	:
3	14	25	U-UNK	Amphetamines
4	27	29	O	may
5	31	35	O	delay
6	37	46	O	intestinal
7	48	57	O	absorption
8	59	60	O	of
9	62	73	U-UNK	ethosuximide
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s14	NO_SECTION	NO_SETID	15
Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.
1	0	10	U-UNK	Haloperidol
2	11	11	O	:
3	13	23	U-UNK	Haloperidol
4	25	30	O	blocks
5	32	39	O	dopamine
6	41	49	O	receptors
7	50	50	O	,
8	52	55	O	thus
9	57	66	O	inhibiting
10	68	70	O	the
11	72	78	O	central
12	80	88	O	stimulant
13	90	96	O	effects
14	98	99	O	of
15	101	112	U-UNK	amphetamines
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s15	NO_SECTION	NO_SETID	16
Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.
1	0	6	B-UNK	Lithium
2	8	16	L-UNK	carbonate
3	17	17	O	:
4	19	21	O	The
5	23	31	O	anorectic
6	33	35	O	and
7	37	47	O	stimulatory
8	49	55	O	effects
9	57	58	O	of
10	60	71	U-UNK	amphetamines
11	73	75	O	may
12	77	78	O	be
13	80	88	O	inhibited
14	90	91	O	by
15	93	99	B-UNK	lithium
16	101	109	L-UNK	carbonate
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s16	NO_SECTION	NO_SETID	9
Meperidine: Amphetamines potentiate the analgesic effect of meperidine.
1	0	9	U-UNK	Meperidine
2	10	10	O	:
3	12	23	U-UNK	Amphetamines
4	25	34	O	potentiate
5	36	38	O	the
6	40	48	O	analgesic
7	50	55	O	effect
8	57	58	O	of
9	60	69	U-UNK	meperidine
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s17	NO_SECTION	NO_SETID	20
Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.
1	0	10	U-UNK	Methenamine
2	12	18	O	therapy
3	20	26	O	Urinary
4	28	36	O	excretion
5	38	39	O	of
6	41	52	U-UNK	amphetamines
7	54	55	O	is
8	57	65	O	increased
9	66	66	O	,
10	68	70	O	and
11	72	79	O	efficacy
12	81	82	O	is
13	84	90	O	reduced
14	92	93	O	by
15	95	104	O	acidifying
16	106	111	O	agents
17	113	116	O	used
18	118	119	O	in
19	121	131	U-UNK	methenamine
20	133	139	O	therapy
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s18	NO_SECTION	NO_SETID	9
Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.
1	0	13	U-UNK	Norepinephrine
2	14	14	O	:
3	16	27	U-UNK	Amphetamines
4	29	35	O	enhance
5	37	39	O	the
6	41	50	O	adrenergic
7	52	57	O	effect
8	59	60	O	of
9	62	75	U-UNK	norepinephrine
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s19	NO_SECTION	NO_SETID	9
Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;
1	0	12	U-UNK	Phenobarbital
2	13	13	O	:
3	15	26	U-UNK	Amphetamines
4	28	30	O	may
5	32	36	O	delay
6	38	47	O	intestinal
7	49	58	O	absorption
8	60	61	O	of
9	63	75	U-UNK	phenobarbital
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s20	NO_SECTION	NO_SETID	10
co-administration of phenobarbital may produce a synergistic anticonvulsant action.
1	0	1	O	co
2	3	16	O	administration
3	18	19	O	of
4	21	33	U-UNK	phenobarbital
5	35	37	O	may
6	39	45	O	produce
7	47	47	O	a
8	49	59	O	synergistic
9	61	74	O	anticonvulsant
10	76	81	O	action
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s21	NO_SECTION	NO_SETID	9
Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
1	0	8	U-UNK	Phenytoin
2	9	9	O	:
3	11	22	U-UNK	Amphetamines
4	24	26	O	may
5	28	32	O	delay
6	34	43	O	intestinal
7	45	54	O	absorption
8	56	57	O	of
9	59	67	U-UNK	phenytoin
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s22	NO_SECTION	NO_SETID	10
co-administration of phenytoin may produce a synergistic anticonvulsant action.
1	0	1	O	co
2	3	16	O	administration
3	18	19	O	of
4	21	29	U-UNK	phenytoin
5	31	33	O	may
6	35	41	O	produce
7	43	43	O	a
8	45	55	O	synergistic
9	57	70	O	anticonvulsant
10	72	77	O	action
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s23	NO_SECTION	NO_SETID	18
Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
1	0	11	U-UNK	Propoxyphene
2	12	12	O	:
3	14	15	O	In
4	17	21	O	cases
5	23	24	O	of
6	26	37	U-UNK	propoxyphene
7	39	48	O	overdosage
8	49	49	O	,
9	51	61	U-UNK	amphetamine
10	63	65	O	CNS
11	67	77	O	stimulation
12	79	80	O	is
13	82	92	O	potentiated
14	94	96	O	and
15	98	102	O	fatal
16	104	114	O	convulsions
17	116	118	O	can
18	120	124	O	occur
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s24	NO_SECTION	NO_SETID	11
Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
1	0	7	B-UNK	Veratrum
2	9	17	L-UNK	alkaloids
3	18	18	O	:
4	20	31	U-UNK	Amphetamines
5	33	39	O	inhibit
6	41	43	O	the
7	45	55	O	hypotensive
8	57	62	O	effect
9	64	65	O	of
10	67	74	B-UNK	veratrum
11	76	84	L-UNK	alkaloids
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s25	NO_SECTION	NO_SETID	16
Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	33	33	O	:
7	35	46	U-UNK	Amphetamines
8	48	50	O	can
9	52	56	O	cause
10	58	58	O	a
11	60	70	O	significant
12	72	80	O	elevation
13	82	83	O	in
14	85	90	O	plasma
15	92	105	O	corticosteroid
16	107	112	O	levels
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s26	NO_SECTION	NO_SETID	7
This increase is greatest in the evening.
1	0	3	O	This
2	5	12	O	increase
3	14	15	O	is
4	17	24	O	greatest
5	26	27	O	in
6	29	31	O	the
7	33	39	O	evening
NULL

Lisdexamfetamine	DDI-DrugBank.d158.s27	NO_SECTION	NO_SETID	7
Amphetamines may interfere with urinary steroid determinations.
1	0	11	U-UNK	Amphetamines
2	13	15	O	may
3	17	25	O	interfere
4	27	30	O	with
5	32	38	O	urinary
6	40	46	O	steroid
7	48	61	O	determinations
NULL

Lisinopril	DDI-DrugBank.d334.s0	NO_SECTION	NO_SETID	36
Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL.
1	0	10	O	Hypotension
2	14	21	O	Patients
3	23	24	O	on
4	26	33	O	Diuretic
5	35	41	O	Therapy
6	42	42	O	:
7	44	51	O	Patients
8	53	54	O	on
9	56	64	U-DYN	diuretics
10	65	65	O	,
11	67	69	O	and
12	71	80	O	especially
13	82	86	O	those
14	88	89	O	in
15	91	94	O	whom
16	96	103	O	diuretic
17	105	111	O	therapy
18	113	115	O	was
19	117	124	O	recently
20	126	135	O	instituted
21	136	136	O	,
22	138	140	O	may
23	142	153	O	occasionally
24	155	164	O	experience
25	166	167	O	an
26	169	177	O	excessive
27	179	187	O	reduction
28	189	190	O	of
29	192	196	O	blood
30	198	205	O	pressure
31	207	211	O	after
32	213	222	O	initiation
33	224	225	O	of
34	227	233	O	therapy
35	235	238	O	with
36	240	247	O	XXXXXXXX
NULL

Lisinopril	DDI-DrugBank.d334.s1	NO_SECTION	NO_SETID	27
The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.
1	0	2	O	The
2	4	14	O	possibility
3	16	17	O	of
4	19	29	O	hypotensive
5	31	37	O	effects
6	39	42	O	with
7	44	51	O	XXXXXXXX
8	53	55	O	can
9	57	58	O	be
10	60	68	O	minimized
11	70	71	O	by
12	73	78	O	either
13	80	92	O	discontinuing
14	94	96	O	the
15	98	105	U-DYN	diuretic
16	107	108	O	or
17	110	119	O	increasing
18	121	123	O	the
19	125	128	O	salt
20	130	135	O	intake
21	137	141	O	prior
22	143	144	O	to
23	146	155	O	initiation
24	157	158	O	of
25	160	168	O	treatment
26	170	173	O	with
27	175	182	O	XXXXXXXX
NULL

Lisinopril	DDI-DrugBank.d334.s2	NO_SECTION	NO_SETID	35
If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.
1	0	1	O	If
2	3	4	O	it
3	6	7	O	is
4	9	17	O	necessary
5	19	20	O	to
6	22	29	O	continue
7	31	33	O	the
8	35	42	U-DYN	diuretic
9	43	43	O	,
10	45	52	O	initiate
11	54	60	O	therapy
12	62	65	O	with
13	67	74	O	XXXXXXXX
14	76	77	O	at
15	79	79	O	a
16	81	84	O	dose
17	86	87	O	of
18	89	89	O	5
19	91	92	O	mg
20	94	98	O	daily
21	99	99	O	,
22	101	103	O	and
23	105	111	O	provide
24	113	117	O	close
25	119	125	O	medical
26	127	137	O	supervision
27	139	143	O	after
28	145	147	O	the
29	149	155	O	initial
30	157	160	O	dose
31	162	166	O	until
32	168	172	O	blood
33	174	181	O	pressure
34	183	185	O	has
35	187	196	O	stabilized
NULL

Lisinopril	DDI-DrugBank.d334.s3	NO_SECTION	NO_SETID	21
When a diuretic is added to the therapy of a patient receiving PRINIVIL, an additional antihypertensive effect is usually observed.
1	0	3	O	When
2	5	5	O	a
3	7	14	U-DYN	diuretic
4	16	17	O	is
5	19	23	O	added
6	25	26	O	to
7	28	30	O	the
8	32	38	O	therapy
9	40	41	O	of
10	43	43	O	a
11	45	51	O	patient
12	53	61	O	receiving
13	63	70	O	XXXXXXXX
14	71	71	O	,
15	73	74	O	an
16	76	85	O	additional
17	87	102	O	antihypertensive
18	104	109	O	effect
19	111	112	O	is
20	114	120	O	usually
21	122	129	O	observed
NULL

Lisinopril	DDI-DrugBank.d334.s4	NO_SECTION	NO_SETID	26
Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.
1	0	6	O	Studies
2	8	11	O	with
3	13	15	B-UNK	ACE
4	17	26	L-UNK	inhibitors
5	28	29	O	in
6	31	41	O	combination
7	43	46	O	with
8	48	56	U-UNK	diuretics
9	58	65	O	indicate
10	67	70	O	that
11	72	74	O	the
12	76	79	O	dose
13	81	82	O	of
14	84	86	O	the
15	88	90	B-UNK	ACE
16	92	100	L-UNK	inhibitor
17	102	104	O	can
18	106	107	O	be
19	109	115	O	reduced
20	117	120	O	when
21	122	123	O	it
22	125	126	O	is
23	128	132	O	given
24	134	137	O	with
25	139	139	O	a
26	141	148	U-UNK	diuretic
NULL

Lisinopril	DDI-DrugBank.d334.s5	NO_SECTION	NO_SETID	38
Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function.
1	0	2	B-UNK	Non
2	4	12	I-UNK	steroidal
3	14	17	I-UNK	Anti
4	19	30	I-UNK	inflammatory
5	32	37	L-UNK	Agents
6	38	38	O	:
7	40	41	O	In
8	43	46	O	some
9	48	55	O	patients
10	57	60	O	with
11	62	72	O	compromised
12	74	78	O	renal
13	80	87	O	function
14	89	91	O	who
15	93	95	O	are
16	97	101	O	being
17	103	109	O	treated
18	111	114	O	with
19	116	118	B-DYN	non
20	120	128	I-DYN	steroidal
21	130	133	I-DYN	anti
22	135	146	I-DYN	inflammatory
23	148	152	L-DYN	drugs
24	153	153	O	,
25	155	157	O	the
26	159	160	O	co
27	162	175	O	administration
28	177	178	O	of
29	180	189	O	XXXXXXXX
30	191	193	O	may
31	195	200	O	result
32	202	203	O	in
33	205	205	O	a
34	207	213	O	further
35	215	227	O	deterioration
36	229	230	O	of
37	232	236	O	renal
38	238	245	O	function
NULL

Lisinopril	DDI-DrugBank.d334.s6	NO_SECTION	NO_SETID	5
These effects are usually reversible.
1	0	4	O	These
2	6	12	O	effects
3	14	16	O	are
4	18	24	O	usually
5	26	35	O	reversible
NULL

Lisinopril	DDI-DrugBank.d334.s7	NO_SECTION	NO_SETID	15
Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.
1	0	6	O	Reports
2	8	14	O	suggest
3	16	19	O	that
4	21	26	U-DYN	NSAIDs
5	28	30	O	may
6	32	39	O	diminish
7	41	43	O	the
8	45	60	O	antihypertensive
9	62	67	O	effect
10	69	70	O	of
11	72	74	B-UNK	ACE
12	76	85	L-UNK	inhibitors
13	86	86	O	,
14	88	96	O	including
15	98	107	O	XXXXXXXX
NULL

Lisinopril	DDI-DrugBank.d334.s8	NO_SECTION	NO_SETID	14
This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
1	0	3	O	This
2	5	15	O	interaction
3	17	22	O	should
4	24	25	O	be
5	27	31	O	given
6	33	45	O	consideration
7	47	48	O	in
8	50	57	O	patients
9	59	64	O	taking
10	66	71	U-UNK	NSAIDs
11	73	85	O	concomitantly
12	87	90	O	with
13	92	94	B-UNK	ACE
14	96	105	L-UNK	inhibitors
NULL

Lisinopril	DDI-DrugBank.d334.s9	NO_SECTION	NO_SETID	49
In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	in
5	14	15	O	36
6	17	24	O	patients
7	26	29	O	with
8	31	34	O	mild
9	36	37	O	to
10	39	46	O	moderate
11	48	59	O	hypertension
12	61	65	O	where
13	67	69	O	the
14	71	86	O	antihypertensive
15	88	94	O	effects
16	96	97	O	of
17	99	106	O	XXXXXXXX
18	108	112	O	alone
19	114	117	O	were
20	119	126	O	compared
21	128	129	O	to
22	131	138	O	XXXXXXXX
23	140	144	O	given
24	146	158	O	concomitantly
25	160	163	O	with
26	165	176	U-UNK	indomethacin
27	177	177	O	,
28	179	181	O	the
29	183	185	O	use
30	187	188	O	of
31	190	201	U-UNK	indomethacin
32	203	205	O	was
33	207	216	O	associated
34	218	221	O	with
35	223	223	O	a
36	225	231	O	reduced
37	233	248	O	antihypertensive
38	250	255	O	effect
39	256	256	O	,
40	258	265	O	although
41	267	269	O	the
42	271	280	O	difference
43	282	288	O	between
44	290	292	O	the
45	294	296	O	two
46	298	305	O	regimens
47	307	309	O	was
48	311	313	O	not
49	315	325	O	significant
NULL

Lisinopril	DDI-DrugBank.d334.s10	NO_SECTION	NO_SETID	21
Other Agents: PRINIVIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions.
1	0	4	O	Other
2	6	11	O	Agents
3	12	12	O	:
4	14	21	O	XXXXXXXX
5	23	25	O	has
6	27	30	O	been
7	32	35	O	used
8	37	49	O	concomitantly
9	51	54	O	with
10	56	63	U-UNK	nitrates
11	65	67	O	and
12	68	68	O	/
13	69	70	O	or
14	72	78	U-UNK	digoxin
15	80	86	O	without
16	88	95	O	evidence
17	97	98	O	of
18	100	109	O	clinically
19	111	121	O	significant
20	123	129	O	adverse
21	131	142	O	interactions
NULL

Lisinopril	DDI-DrugBank.d334.s11	NO_SECTION	NO_SETID	13
This included post myocardial infarction patients who were receiving intravenous or transdermal nitroglycerin.
1	0	3	O	This
2	5	12	O	included
3	14	17	O	post
4	19	28	O	myocardial
5	30	39	O	infarction
6	41	48	O	patients
7	50	52	O	who
8	54	57	O	were
9	59	67	O	receiving
10	69	79	O	intravenous
11	81	82	O	or
12	84	94	O	transdermal
13	96	108	U-UNK	nitroglycerin
NULL

Lisinopril	DDI-DrugBank.d334.s12	NO_SECTION	NO_SETID	15
No clinically important pharmacokinetic interactions occurred when PRINIVIL was used concomitantly with propranolol or hydrochlorothiazide.
1	0	1	O	No
2	3	12	O	clinically
3	14	22	O	important
4	24	38	O	pharmacokinetic
5	40	51	O	interactions
6	53	60	O	occurred
7	62	65	O	when
8	67	74	O	XXXXXXXX
9	76	78	O	was
10	80	83	O	used
11	85	97	O	concomitantly
12	99	102	O	with
13	104	114	U-UNK	propranolol
14	116	117	O	or
15	119	137	U-UNK	hydrochlorothiazide
NULL

Lisinopril	DDI-DrugBank.d334.s13	NO_SECTION	NO_SETID	14
The presence of food in the stomach does not alter the bioavailability of PRINIVIL.
1	0	2	O	The
2	4	11	O	presence
3	13	14	O	of
4	16	19	O	food
5	21	22	O	in
6	24	26	O	the
7	28	34	O	stomach
8	36	39	O	does
9	41	43	O	not
10	45	49	O	alter
11	51	53	O	the
12	55	69	O	bioavailability
13	71	72	O	of
14	74	81	O	XXXXXXXX
NULL

Lisinopril	DDI-DrugBank.d334.s14	NO_SECTION	NO_SETID	14
Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics.
1	0	5	O	Agents
2	7	16	O	Increasing
3	18	22	O	Serum
4	24	32	O	Potassium
5	33	33	O	:
6	35	42	O	XXXXXXXX
7	44	53	O	attenuates
8	55	63	O	potassium
9	65	68	O	loss
10	70	75	O	caused
11	77	78	O	by
12	80	87	B-DYN	thiazide
13	89	92	I-DYN	type
14	94	102	L-DYN	diuretics
NULL

Lisinopril	DDI-DrugBank.d334.s15	NO_SECTION	NO_SETID	32
Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
1	0	2	O	Use
2	4	5	O	of
3	7	14	O	XXXXXXXX
4	16	19	O	with
5	21	29	B-DYN	potassium
6	31	37	I-DYN	sparing
7	39	47	L-DYN	diuretics
8	50	52	O	e.g
9	54	54	O	,
10	56	69	U-DYN	spironolactone
11	70	70	O	,
12	72	82	U-DYN	triamterene
13	83	83	O	,
14	85	86	O	or
15	88	96	U-DYN	amiloride
16	98	98	O	,
17	100	108	U-DYN	potassium
18	110	120	O	supplements
19	121	121	O	,
20	123	124	O	or
21	126	134	O	potassium
22	136	145	O	containing
23	147	150	O	salt
24	152	162	O	substitutes
25	164	166	O	may
26	168	171	O	lead
27	173	174	O	to
28	176	186	O	significant
29	188	196	O	increases
30	198	199	O	in
31	201	205	O	serum
32	207	215	O	potassium
NULL

Lisinopril	DDI-DrugBank.d334.s16	NO_SECTION	NO_SETID	28
Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	if
4	14	24	O	concomitant
5	26	28	O	use
6	30	31	O	of
7	33	37	O	these
8	39	44	O	agents
9	46	47	O	is
10	49	57	O	indicated
11	59	65	O	because
12	67	68	O	of
13	70	81	O	demonstrated
14	83	93	O	hypokalemia
15	94	94	O	,
16	96	99	O	they
17	101	106	O	should
18	108	109	O	be
19	111	114	O	used
20	116	119	O	with
21	121	127	O	caution
22	129	131	O	and
23	133	136	O	with
24	138	145	O	frequent
25	147	156	O	monitoring
26	158	159	O	of
27	161	165	O	serum
28	167	175	O	potassium
NULL

Lisinopril	DDI-DrugBank.d334.s17	NO_SECTION	NO_SETID	17
Potassium sparing agents should generally not be used in patients with heart failure who are receiving PRINIVIL.
1	0	8	O	Potassium
2	10	16	O	sparing
3	18	23	O	agents
4	25	30	O	should
5	32	40	O	generally
6	42	44	O	not
7	46	47	O	be
8	49	52	O	used
9	54	55	O	in
10	57	64	O	patients
11	66	69	O	with
12	71	75	O	heart
13	77	83	O	failure
14	85	87	O	who
15	89	91	O	are
16	93	101	O	receiving
17	103	110	O	XXXXXXXX
NULL

Lisinopril	DDI-DrugBank.d334.s18	NO_SECTION	NO_SETID	23
Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	15	U-UNK	Lithium
4	17	24	O	toxicity
5	26	28	O	has
6	30	33	O	been
7	35	42	O	reported
8	44	45	O	in
9	47	54	O	patients
10	56	64	O	receiving
11	66	72	U-UNK	lithium
12	74	86	O	concomitantly
13	88	91	O	with
14	93	97	O	drugs
15	99	103	O	which
16	105	109	O	cause
17	111	121	O	elimination
18	123	124	O	of
19	126	131	O	sodium
20	132	132	O	,
21	134	142	O	including
22	144	146	B-UNK	ACE
23	148	157	L-UNK	inhibitors
NULL

Lisinopril	DDI-DrugBank.d334.s19	NO_SECTION	NO_SETID	13
Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor.
1	0	6	U-UNK	Lithium
2	8	15	O	toxicity
3	17	19	O	was
4	21	27	O	usually
5	29	38	O	reversible
6	40	43	O	upon
7	45	59	O	discontinuation
8	61	62	O	of
9	64	70	U-UNK	lithium
10	72	74	O	and
11	76	78	O	the
12	80	82	B-UNK	ACE
13	84	92	L-UNK	inhibitor
NULL

Lisinopril	DDI-DrugBank.d334.s20	NO_SECTION	NO_SETID	17
It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	27	O	serum
6	29	35	U-UNK	lithium
7	37	42	O	levels
8	44	45	O	be
9	47	55	O	monitored
10	57	66	O	frequently
11	68	69	O	if
12	71	78	O	XXXXXXXX
13	80	81	O	is
14	83	94	O	administered
15	96	108	O	concomitantly
16	110	113	O	with
17	115	121	U-DYN	lithium
NULL

Lofexidine	DDI-DrugBank.d454.s0	NO_SECTION	NO_SETID	14
- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives
1	2	11	O	XXXXXXXX
2	13	15	O	may
3	17	23	O	enhance
4	25	27	O	the
5	29	31	O	CNS
6	33	42	O	depressive
7	44	50	O	effects
8	52	53	O	of
9	55	61	U-DYN	alcohol
10	62	62	O	,
11	64	75	U-DYN	barbiturates
12	77	79	O	and
13	81	85	O	other
14	87	95	U-DYN	sedatives
NULL

Lofexidine	DDI-DrugBank.d454.s2	NO_SECTION	NO_SETID	10
- Lofexidine may enhance the effects of anti-hypertensive drug therapy
1	2	11	O	XXXXXXXX
2	13	15	O	may
3	17	23	O	enhance
4	25	27	O	the
5	29	35	O	effects
6	37	38	O	of
7	40	43	B-DYN	anti
8	45	56	I-DYN	hypertensive
9	58	61	L-DYN	drug
10	63	69	O	therapy
NULL

Lofexidine	DDI-DrugBank.d454.s4	NO_SECTION	NO_SETID	11
- Concomitant use of tricyclic antidepressants may reduce the efficacy of lofexidine.
1	2	12	O	Concomitant
2	14	16	O	use
3	18	19	O	of
4	21	29	B-DYN	tricyclic
5	31	45	L-DYN	antidepressants
6	47	49	O	may
7	51	56	O	reduce
8	58	60	O	the
9	62	69	O	efficacy
10	71	72	O	of
11	74	83	O	XXXXXXXX
NULL

Lomefloxacin	DDI-DrugBank.d516.s0	NO_SECTION	NO_SETID	26
Theophylline: In three pharmacokinetic studies including 46 normal, healthy subjects, theophylline clearance and concentration were not significantly altered by the addition of lomefloxacin.
1	0	11	U-UNK	Theophylline
2	12	12	O	:
3	14	15	O	In
4	17	21	O	three
5	23	37	O	pharmacokinetic
6	39	45	O	studies
7	47	55	O	including
8	57	58	O	46
9	60	65	O	normal
10	66	66	O	,
11	68	74	O	healthy
12	76	83	O	subjects
13	84	84	O	,
14	86	97	U-UNK	theophylline
15	99	107	O	clearance
16	109	111	O	and
17	113	125	O	concentration
18	127	130	O	were
19	132	134	O	not
20	136	148	O	significantly
21	150	156	O	altered
22	158	159	O	by
23	161	163	O	the
24	165	172	O	addition
25	174	175	O	of
26	177	188	O	XXXXXXXX
NULL

Lomefloxacin	DDI-DrugBank.d516.s1	NO_SECTION	NO_SETID	30
In clinical studies where patients were on chronic theophylline therapy, lomefloxacin had no measurable effect on the mean distribution of theophylline concentrations or the mean estimates of theophylline clearance.
1	0	1	O	In
2	3	10	O	clinical
3	12	18	O	studies
4	20	24	O	where
5	26	33	O	patients
6	35	38	O	were
7	40	41	O	on
8	43	49	O	chronic
9	51	62	U-UNK	theophylline
10	64	70	O	therapy
11	71	71	O	,
12	73	84	O	XXXXXXXX
13	86	88	O	had
14	90	91	O	no
15	93	102	O	measurable
16	104	109	O	effect
17	111	112	O	on
18	114	116	O	the
19	118	121	O	mean
20	123	134	O	distribution
21	136	137	O	of
22	139	150	U-UNK	theophylline
23	152	165	O	concentrations
24	167	168	O	or
25	170	172	O	the
26	174	177	O	mean
27	179	187	O	estimates
28	189	190	O	of
29	192	203	U-UNK	theophylline
30	205	213	O	clearance
NULL

Lomefloxacin	DDI-DrugBank.d516.s2	NO_SECTION	NO_SETID	16
Though individual theophylline levels fluctuated, there were no clinically significant symptoms of drug inter-action.
1	0	5	O	Though
2	7	16	O	individual
3	18	29	U-UNK	theophylline
4	31	36	O	levels
5	38	47	O	fluctuated
6	48	48	O	,
7	50	54	O	there
8	56	59	O	were
9	61	62	O	no
10	64	73	O	clinically
11	75	85	O	significant
12	87	94	O	symptoms
13	96	97	O	of
14	99	102	O	drug
15	104	108	O	inter
16	110	115	O	action
NULL

Lomefloxacin	DDI-DrugBank.d516.s3	NO_SECTION	NO_SETID	48
Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
1	0	7	U-UNK	Antacids
2	9	11	O	and
3	13	22	U-UNK	sucralfate
4	23	23	O	:
5	25	34	U-UNK	Sucralfate
6	36	38	O	and
7	40	47	U-UNK	antacids
8	49	58	O	containing
9	60	68	U-UNK	magnesium
10	70	71	O	or
11	73	80	U-UNK	aluminum
12	81	81	O	,
13	83	84	O	as
14	86	89	O	well
15	91	92	O	as
16	94	105	O	formulations
17	107	116	O	containing
18	118	125	O	divalent
19	127	129	O	and
20	131	139	O	trivalent
21	141	147	O	cations
22	149	152	O	such
23	154	155	O	as
24	157	161	O	XXXXXXXX
25	165	174	U-UNK	didanosine
26	176	176	O	,
27	178	185	O	chewable
28	186	186	O	/
29	187	194	O	buffered
30	196	202	O	tablets
31	204	205	O	or
32	207	209	O	the
33	211	219	O	pediatric
34	221	226	O	powder
35	228	230	O	for
36	232	235	O	oral
37	237	244	O	solution
38	246	248	O	can
39	250	253	O	form
40	255	263	O	chelation
41	265	273	O	complexes
42	275	278	O	with
43	280	291	U-KIN	lomefloxacin
44	293	295	O	and
45	297	305	O	interfere
46	307	310	O	with
47	312	314	O	its
48	316	330	O	bioavailability
NULL

Lomefloxacin	DDI-DrugBank.d516.s4	NO_SECTION	NO_SETID	37
Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).
1	0	9	U-KIN	Sucralfate
2	11	22	O	administered
3	24	24	O	2
4	26	30	O	hours
5	32	37	O	before
6	39	50	O	XXXXXXXX
7	52	59	O	resulted
8	61	62	O	in
9	64	64	O	a
10	66	71	O	slower
11	73	82	O	absorption
12	85	88	O	mean
13	90	90	O	C
14	92	94	O	max
15	96	104	O	decreased
16	106	107	O	by
17	109	111	O	30%
18	113	115	O	and
19	117	120	O	mean
20	122	122	O	T
21	124	126	O	max
22	128	136	O	increased
23	138	139	O	by
24	141	141	O	1
25	143	146	O	hour
26	149	151	O	and
27	153	153	O	a
28	155	160	O	lesser
29	162	167	O	extent
30	169	170	O	of
31	172	181	O	absorption
32	184	187	O	mean
33	189	191	O	AUC
34	193	201	O	decreased
35	203	204	O	by
36	206	218	O	approximately
37	220	222	O	25%
NULL

Lomefloxacin	DDI-DrugBank.d516.s5	NO_SECTION	NO_SETID	18
Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
1	0	8	U-KIN	Magnesium
2	11	13	O	and
3	15	22	U-KIN	aluminum
4	24	33	O	containing
5	35	42	U-KIN	antacids
6	43	43	O	,
7	45	56	O	administered
8	58	70	O	concomitantly
9	72	75	O	with
10	77	88	O	XXXXXXXX
11	89	89	O	,
12	91	103	O	significantly
13	105	113	O	decreased
14	115	117	O	the
15	119	133	O	bioavailability
16	136	138	O	48%
17	141	142	O	of
18	144	155	O	XXXXXXXX
NULL

Lomefloxacin	DDI-DrugBank.d516.s6	NO_SECTION	NO_SETID	12
Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;
1	0	9	O	Separating
2	11	13	O	the
3	15	19	O	doses
4	21	22	O	of
5	24	30	U-KIN	antacid
6	32	34	O	and
7	36	47	O	XXXXXXXX
8	49	57	O	minimizes
9	59	62	O	this
10	64	71	O	decrease
11	73	74	O	in
12	76	90	O	bioavailability
NULL

Lomefloxacin	DDI-DrugBank.d516.s7	NO_SECTION	NO_SETID	22
therefore, administration of these agents should precede lomefloxacin dosing by 4 hours or follow lomefloxacin dosing by at least 2 hours.
1	0	8	O	therefore
2	9	9	O	,
3	11	24	O	administration
4	26	27	O	of
5	29	33	O	these
6	35	40	O	agents
7	42	47	O	should
8	49	55	O	precede
9	57	68	O	XXXXXXXX
10	70	75	O	dosing
11	77	78	O	by
12	80	80	O	4
13	82	86	O	hours
14	88	89	O	or
15	91	96	O	follow
16	98	109	O	XXXXXXXX
17	111	116	O	dosing
18	118	119	O	by
19	121	122	O	at
20	124	128	O	least
21	130	130	O	2
22	132	136	O	hours
NULL

Lomefloxacin	DDI-DrugBank.d516.s8	NO_SECTION	NO_SETID	40
Caffeine: Two hundred mg of caffeine (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of lomefloxacin after being dosed at 400 mg qd.
1	0	7	U-UNK	Caffeine
2	8	8	O	:
3	10	12	O	Two
4	14	20	O	hundred
5	22	23	O	mg
6	25	26	O	of
7	28	35	U-UNK	caffeine
8	38	47	O	equivalent
9	49	50	O	to
10	52	52	O	1
11	54	55	O	to
12	57	57	O	3
13	59	62	O	cups
14	64	65	O	of
15	67	74	O	American
16	76	81	O	coffee
17	84	86	O	was
18	88	99	O	administered
19	101	102	O	to
20	104	105	O	16
21	107	112	O	normal
22	113	113	O	,
23	115	121	O	healthy
24	123	132	O	volunteers
25	134	136	O	who
26	138	140	O	had
27	142	149	O	achieved
28	151	156	O	steady
29	158	162	O	state
30	164	168	O	blood
31	170	183	O	concentrations
32	185	186	O	of
33	188	199	O	XXXXXXXX
34	201	205	O	after
35	207	211	O	being
36	213	217	O	dosed
37	219	220	O	at
38	222	224	O	400
39	226	227	O	mg
40	229	230	O	qd
NULL

Lomefloxacin	DDI-DrugBank.d516.s9	NO_SECTION	NO_SETID	24
This did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either caffeine or its major metabolite, paraxanthine.
1	0	3	O	This
2	5	7	O	did
3	9	11	O	not
4	13	18	O	result
5	20	21	O	in
6	23	25	O	any
7	27	39	O	statistically
8	41	42	O	or
9	44	53	O	clinically
10	55	62	O	relevant
11	64	70	O	changes
12	72	73	O	in
13	75	77	O	the
14	79	93	O	pharmacokinetic
15	95	104	O	parameters
16	106	107	O	of
17	109	114	O	either
18	116	123	U-UNK	caffeine
19	125	126	O	or
20	128	130	O	its
21	132	136	O	major
22	138	147	O	metabolite
23	148	148	O	,
24	150	161	U-UNK	paraxanthine
NULL

Lomefloxacin	DDI-DrugBank.d516.s10	NO_SECTION	NO_SETID	47
No data are available on potential interactions in individuals who consume greater than 200 mg of caffeine per day or in those, such as the geriatric population, who are generally believed to be more susceptible to the development of drug-induced CNS-related adverse effects.
1	0	1	O	No
2	3	6	O	data
3	8	10	O	are
4	12	20	O	available
5	22	23	O	on
6	25	33	O	potential
7	35	46	O	interactions
8	48	49	O	in
9	51	61	O	individuals
10	63	65	O	who
11	67	73	O	consume
12	75	81	O	greater
13	83	86	O	than
14	88	90	O	200
15	92	93	O	mg
16	95	96	O	of
17	98	105	U-UNK	caffeine
18	107	109	O	per
19	111	113	O	day
20	115	116	O	or
21	118	119	O	in
22	121	125	O	those
23	126	126	O	,
24	128	131	O	such
25	133	134	O	as
26	136	138	O	the
27	140	148	O	geriatric
28	150	159	O	population
29	160	160	O	,
30	162	164	O	who
31	166	168	O	are
32	170	178	O	generally
33	180	187	O	believed
34	189	190	O	to
35	192	193	O	be
36	195	198	O	more
37	200	210	O	susceptible
38	212	213	O	to
39	215	217	O	the
40	219	229	O	development
41	231	232	O	of
42	234	237	O	drug
43	239	245	O	induced
44	247	249	O	CNS
45	251	257	O	related
46	259	265	O	adverse
47	267	273	O	effects
NULL

Lomefloxacin	DDI-DrugBank.d516.s11	NO_SECTION	NO_SETID	38
Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.
1	0	4	O	Other
2	6	15	U-UNK	quinolones
3	17	20	O	have
4	22	33	O	demonstrated
5	35	42	O	moderate
6	44	45	O	to
7	47	52	O	marked
8	54	65	O	interference
9	67	70	O	with
10	72	74	O	the
11	76	85	O	metabolism
12	87	88	O	of
13	90	97	U-UNK	caffeine
14	98	98	O	,
15	100	108	O	resulting
16	110	111	O	in
17	113	113	O	a
18	115	121	O	reduced
19	123	131	O	clearance
20	132	132	O	,
21	134	134	O	a
22	136	147	O	prolongation
23	149	150	O	of
24	152	157	O	plasma
25	159	162	O	half
26	164	167	O	life
27	168	168	O	,
28	170	172	O	and
29	174	175	O	an
30	177	184	O	increase
31	186	187	O	in
32	189	196	O	symptoms
33	198	201	O	that
34	203	211	O	accompany
35	213	216	O	high
36	218	223	O	levels
37	225	226	O	of
38	228	235	U-UNK	caffeine
NULL

Lomefloxacin	DDI-DrugBank.d516.s12	NO_SECTION	NO_SETID	14
Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones.
1	0	9	U-UNK	Cimetidine
2	10	10	O	:
3	12	21	U-UNK	Cimetidine
4	23	25	O	has
5	27	30	O	been
6	32	43	O	demonstrated
7	45	46	O	to
8	48	56	O	interfere
9	58	61	O	with
10	63	65	O	the
11	67	77	O	elimination
12	79	80	O	of
13	82	86	O	other
14	88	97	U-UNK	quinolones
NULL

Lomefloxacin	DDI-DrugBank.d516.s13	NO_SECTION	NO_SETID	12
This interference has resulted in significant increases in half-life and AUC.
1	0	3	O	This
2	5	16	O	interference
3	18	20	O	has
4	22	29	O	resulted
5	31	32	O	in
6	34	44	O	significant
7	46	54	O	increases
8	56	57	O	in
9	59	62	O	half
10	64	67	O	life
11	69	71	O	and
12	73	75	O	AUC
NULL

Lomefloxacin	DDI-DrugBank.d516.s14	NO_SECTION	NO_SETID	10
The interaction between lomefloxacin and cimetidine has not been studied.
1	0	2	O	The
2	4	14	O	interaction
3	16	22	O	between
4	24	35	O	XXXXXXXX
5	37	39	O	and
6	41	50	U-UNK	cimetidine
7	52	54	O	has
8	56	58	O	not
9	60	63	O	been
10	65	71	O	studied
NULL

Lomefloxacin	DDI-DrugBank.d516.s15	NO_SECTION	NO_SETID	22
Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
1	0	11	U-UNK	Cyclosporine
2	12	12	O	:
3	14	21	O	Elevated
4	23	27	O	serum
5	29	34	O	levels
6	36	37	O	of
7	39	50	U-UNK	cyclosporine
8	52	55	O	have
9	57	60	O	been
10	62	69	O	reported
11	71	74	O	with
12	76	86	O	concomitant
13	88	90	O	use
14	92	93	O	of
15	95	106	U-UNK	cyclosporine
16	108	111	O	with
17	113	117	O	other
18	119	125	O	members
19	127	128	O	of
20	130	132	O	the
21	134	142	B-UNK	quinolone
22	144	148	L-UNK	class
NULL

Lomefloxacin	DDI-DrugBank.d516.s16	NO_SECTION	NO_SETID	9
Interaction between lomefloxacin and cyclosporine has not been studied.
1	0	10	O	Interaction
2	12	18	O	between
3	20	31	O	XXXXXXXX
4	33	35	O	and
5	37	48	U-UNK	cyclosporine
6	50	52	O	has
7	54	56	O	not
8	58	61	O	been
9	63	69	O	studied
NULL

Lomefloxacin	DDI-DrugBank.d516.s17	NO_SECTION	NO_SETID	41
Omeprazole: No clinically significant changes in lomefloxacin pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of lomefloxacin 400 mg was given after multiple doses of omeprazole (20 mg qd) in 13 healthy volunteers.
1	0	9	U-UNK	Omeprazole
2	10	10	O	:
3	12	13	O	No
4	15	24	O	clinically
5	26	36	O	significant
6	38	44	O	changes
7	46	47	O	in
8	49	60	O	XXXXXXXX
9	62	77	O	pharmacokinetics
10	80	82	O	AUC
11	83	83	O	,
12	85	85	O	C
13	87	89	O	max
14	91	91	O	,
15	93	94	O	or
16	96	96	O	T
17	98	100	O	max
18	104	107	O	were
19	109	116	O	observed
20	118	121	O	when
21	123	123	O	a
22	125	130	O	single
23	132	135	O	dose
24	137	138	O	of
25	140	151	O	XXXXXXXX
26	153	155	O	400
27	157	158	O	mg
28	160	162	O	was
29	164	168	O	given
30	170	174	O	after
31	176	183	O	multiple
32	185	189	O	doses
33	191	192	O	of
34	194	203	U-UNK	omeprazole
35	206	207	O	20
36	209	210	O	mg
37	212	213	O	qd
38	216	217	O	in
39	219	220	O	13
40	222	228	O	healthy
41	230	239	O	volunteers
NULL

Lomefloxacin	DDI-DrugBank.d516.s18	NO_SECTION	NO_SETID	7
Changes in omeprazole pharmacokinetics were not studied.
1	0	6	O	Changes
2	8	9	O	in
3	11	20	U-UNK	omeprazole
4	22	37	O	pharmacokinetics
5	39	42	O	were
6	44	46	O	not
7	48	54	O	studied
NULL

Lomefloxacin	DDI-DrugBank.d516.s19	NO_SECTION	NO_SETID	48
Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.
1	0	8	U-UNK	Phenytoin
2	9	9	O	:
3	11	12	O	No
4	14	24	O	significant
5	26	36	O	differences
6	38	41	O	were
7	43	50	O	observed
8	52	53	O	in
9	55	58	O	mean
10	60	68	U-UNK	phenytoin
11	70	72	O	AUC
12	73	73	O	,
13	75	75	O	C
14	77	79	O	max
15	81	81	O	,
16	83	83	O	C
17	85	87	O	min
18	89	90	O	or
19	92	92	O	T
20	94	96	O	max
21	99	106	O	although
22	108	108	O	C
23	110	112	O	max
24	114	122	O	increased
25	124	125	O	by
26	127	129	O	11%
27	132	135	O	when
28	137	144	O	extended
29	146	154	B-UNK	phenytoin
30	156	161	L-UNK	sodium
31	163	170	O	capsules
32	173	175	O	100
33	177	178	O	mg
34	180	182	O	tid
35	185	188	O	were
36	190	203	O	coadministered
37	205	208	O	with
38	210	221	O	XXXXXXXX
39	224	226	O	400
40	228	229	O	mg
41	231	232	O	qd
42	235	237	O	for
43	239	242	O	five
44	244	247	O	days
45	249	250	O	in
46	252	253	O	15
47	255	261	O	healthy
48	263	267	O	males
NULL

Lomefloxacin	DDI-DrugBank.d516.s20	NO_SECTION	NO_SETID	11
Lomefloxacin is unlikely to have a significant effect on phenytoin metabolism.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	23	O	unlikely
4	25	26	O	to
5	28	31	O	have
6	33	33	O	a
7	35	45	O	significant
8	47	52	O	effect
9	54	55	O	on
10	57	65	U-UNK	phenytoin
11	67	76	O	metabolism
NULL

Lomefloxacin	DDI-DrugBank.d516.s21	NO_SECTION	NO_SETID	10
Probenecid: Probenecid slows the renal elimination of lome-floxacin.
1	0	9	U-UNK	Probenecid
2	10	10	O	:
3	12	21	U-UNK	Probenecid
4	23	27	O	slows
5	29	31	O	the
6	33	37	O	renal
7	39	49	O	elimination
8	51	52	O	of
9	54	57	O	lome
10	59	66	O	floxacin
NULL

Lomefloxacin	DDI-DrugBank.d516.s22	NO_SECTION	NO_SETID	34
An increase of 63% in the mean AUC and increases of 50% and 4%, respectively, in the mean T max and mean C max were noted in 1 study of 6 individuals.
1	0	1	O	An
2	3	10	O	increase
3	12	13	O	of
4	15	17	O	63%
5	19	20	O	in
6	22	24	O	the
7	26	29	O	mean
8	31	33	O	AUC
9	35	37	O	and
10	39	47	O	increases
11	49	50	O	of
12	52	54	O	50%
13	56	58	O	and
14	60	61	O	4%
15	62	62	O	,
16	64	75	O	respectively
17	76	76	O	,
18	78	79	O	in
19	81	83	O	the
20	85	88	O	mean
21	90	90	O	T
22	92	94	O	max
23	96	98	O	and
24	100	103	O	mean
25	105	105	O	C
26	107	109	O	max
27	111	114	O	were
28	116	120	O	noted
29	122	123	O	in
30	125	125	O	1
31	127	131	O	study
32	133	134	O	of
33	136	136	O	6
34	138	148	O	individuals
NULL

Lomefloxacin	DDI-DrugBank.d516.s23	NO_SECTION	NO_SETID	37
Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.
1	0	10	U-UNK	Terfenadine
2	11	11	O	:
3	13	14	O	No
4	16	25	O	clinically
5	27	37	O	significant
6	39	45	O	changes
7	47	54	O	occurred
8	56	57	O	in
9	59	63	O	heart
10	65	68	O	rate
11	70	71	O	or
12	73	81	O	corrected
13	83	84	O	QT
14	86	94	O	intervals
15	95	95	O	,
16	97	98	O	or
17	100	101	O	in
18	103	113	U-UNK	terfenadine
19	115	124	O	metabolite
20	126	127	O	or
21	129	140	O	XXXXXXXX
22	142	157	O	pharmacokinetics
23	158	158	O	,
24	160	165	O	during
25	167	176	O	concurrent
26	178	191	O	administration
27	193	194	O	of
28	196	207	O	XXXXXXXX
29	209	211	O	and
30	213	223	U-UNK	terfenadine
31	225	226	O	at
32	228	233	O	steady
33	235	239	O	state
34	241	242	O	in
35	244	245	O	28
36	247	253	O	healthy
37	255	259	O	males
NULL

Lomefloxacin	DDI-DrugBank.d516.s24	NO_SECTION	NO_SETID	17
Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	19	U-UNK	Quinolones
4	21	23	O	may
5	25	31	O	enhance
6	33	35	O	the
7	37	43	O	effects
8	45	46	O	of
9	48	50	O	the
10	52	55	O	oral
11	57	69	U-UNK	anticoagulant
12	70	70	O	,
13	72	79	U-UNK	warfarin
14	80	80	O	,
15	82	83	O	or
16	85	87	O	its
17	89	99	O	derivatives
NULL

Lomefloxacin	DDI-DrugBank.d516.s25	NO_SECTION	NO_SETID	17
When these products are administered concomitantly, prothrombin or other suitable coagulation tests should be monitored closely.
1	0	3	O	When
2	5	9	O	these
3	11	18	O	products
4	20	22	O	are
5	24	35	O	administered
6	37	49	O	concomitantly
7	50	50	O	,
8	52	62	O	prothrombin
9	64	65	O	or
10	67	71	O	other
11	73	80	O	suitable
12	82	92	O	coagulation
13	94	98	O	tests
14	100	105	O	should
15	107	108	O	be
16	110	118	O	monitored
17	120	126	O	closely
NULL

Lomefloxacin	DDI-DrugBank.d516.s26	NO_SECTION	NO_SETID	36
However, no clinically or statistically significant differences in prothrombin time ratio or warfarin enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both warfarin and lomefloxacin under steady-state conditions.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	no
4	12	21	O	clinically
5	23	24	O	or
6	26	38	O	statistically
7	40	50	O	significant
8	52	62	O	differences
9	64	65	O	in
10	67	77	O	prothrombin
11	79	82	O	time
12	84	88	O	ratio
13	90	91	O	or
14	93	100	U-UNK	warfarin
15	102	111	O	enantiomer
16	113	128	O	pharmacokinetics
17	130	133	O	were
18	135	142	O	observed
19	144	145	O	in
20	147	147	O	a
21	149	153	O	small
22	155	159	O	study
23	161	162	O	of
24	164	164	O	7
25	166	172	O	healthy
26	174	178	O	males
27	180	182	O	who
28	184	191	O	received
29	193	196	O	both
30	198	205	U-UNK	warfarin
31	207	209	O	and
32	211	222	O	XXXXXXXX
33	224	228	O	under
34	230	235	O	steady
35	237	241	O	state
36	243	252	O	conditions
NULL

Loperamide	DDI-DrugBank.d125.s0	NO_SECTION	NO_SETID	13
There was no evidence in clinical trials of drug interactions with concurrent medications.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	20	O	evidence
5	22	23	O	in
6	25	32	O	clinical
7	34	39	O	trials
8	41	42	O	of
9	44	47	O	drug
10	49	60	O	interactions
11	62	65	O	with
12	67	76	O	concurrent
13	78	88	O	medications
NULL

Loracarbef	DDI-DrugBank.d351.s0	NO_SECTION	NO_SETID	29
Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.
1	0	9	U-UNK	Probenecid
2	10	10	O	:
3	12	13	O	As
4	15	18	O	with
5	20	24	O	other
6	26	26	B-UNK	b
7	28	33	I-UNK	lactam
8	35	45	L-UNK	antibiotics
9	46	46	O	,
10	48	52	O	renal
11	54	62	O	excretion
12	64	65	O	of
13	67	76	O	XXXXXXXX
14	78	79	O	is
15	81	89	O	inhibited
16	91	92	O	by
17	94	103	U-KIN	probenecid
18	105	107	O	and
19	109	116	O	resulted
20	118	119	O	in
21	121	122	O	an
22	124	134	O	approximate
23	136	138	O	80%
24	140	147	O	increase
25	149	150	O	in
26	152	154	O	the
27	156	158	O	AUC
28	160	162	O	for
29	164	173	O	XXXXXXXX
NULL

Loratadine	DDI-DrugBank.d258.s0	NO_SECTION	NO_SETID	26
Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.
1	0	9	O	XXXXXXXX
2	12	13	O	10
3	15	16	O	mg
4	18	21	O	once
5	23	27	O	daily
6	30	32	O	has
7	34	37	O	been
8	39	52	O	coadministered
9	54	57	O	with
10	59	69	O	therapeutic
11	71	75	O	doses
12	77	78	O	of
13	80	91	U-UNK	erythromycin
14	92	92	O	,
15	94	103	U-UNK	cimetidine
16	104	104	O	,
17	106	108	O	and
18	110	121	U-UNK	ketoconazole
19	123	124	O	in
20	126	135	O	controlled
21	137	144	O	clinical
22	146	157	O	pharmacology
23	159	165	O	studies
24	167	168	O	in
25	170	174	O	adult
26	176	185	O	volunteers
NULL

Loratadine	DDI-DrugBank.d258.s1	NO_SECTION	NO_SETID	65
Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.
1	0	7	O	Although
2	9	17	O	increased
3	19	24	O	plasma
4	26	39	O	concentrations
5	42	44	O	AUC
6	46	46	O	0
7	48	49	O	24
8	51	53	O	hrs
9	56	57	O	of
10	59	68	O	XXXXXXXX
11	70	72	O	and
12	73	73	O	/
13	74	75	O	or
14	77	90	O	descarboethoxy
15	91	100	O	XXXXXXXX
16	102	105	O	were
17	107	114	O	observed
18	116	124	O	following
19	126	141	O	coadministration
20	143	144	O	of
21	146	155	O	XXXXXXXX
22	157	160	O	with
23	162	165	O	each
24	167	168	O	of
25	170	174	O	these
26	176	180	O	drugs
27	182	183	O	in
28	185	190	O	normal
29	192	201	O	volunteers
30	204	204	O	n
31	206	206	O	=
32	208	209	O	24
33	211	212	O	in
34	214	217	O	each
35	219	223	O	study
36	225	225	O	,
37	227	231	O	there
38	233	236	O	were
39	238	239	O	no
40	241	250	O	clinically
41	252	259	O	relevant
42	261	267	O	changes
43	269	270	O	in
44	272	274	O	the
45	276	281	O	safety
46	283	289	O	profile
47	291	292	O	of
48	294	303	O	XXXXXXXX
49	304	304	O	,
50	306	307	O	as
51	309	316	O	assessed
52	318	319	O	by
53	321	340	O	electrocardiographic
54	342	351	O	parameters
55	352	352	O	,
56	354	361	O	clinical
57	363	372	O	laboratory
58	374	378	O	tests
59	379	379	O	,
60	381	385	O	vital
61	387	391	O	signs
62	392	392	O	,
63	394	396	O	and
64	398	404	O	adverse
65	406	411	O	events
NULL

Loratadine	DDI-DrugBank.d258.s2	NO_SECTION	NO_SETID	16
There were no significant effects on QTc intervals, and no reports of sedation or syncope.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	24	O	significant
5	26	32	O	effects
6	34	35	O	on
7	37	39	O	QTc
8	41	49	O	intervals
9	50	50	O	,
10	52	54	O	and
11	56	57	O	no
12	59	65	O	reports
13	67	68	O	of
14	70	77	O	sedation
15	79	80	O	or
16	82	88	O	syncope
NULL

Loratadine	DDI-DrugBank.d258.s3	NO_SECTION	NO_SETID	11
No effects on plasma concentrations of cimetidine or ketoconazole were observed.
1	0	1	O	No
2	3	9	O	effects
3	11	12	O	on
4	14	19	O	plasma
5	21	34	O	concentrations
6	36	37	O	of
7	39	48	U-UNK	cimetidine
8	50	51	O	or
9	53	64	U-UNK	ketoconazole
10	66	69	O	were
11	71	78	O	observed
NULL

Loratadine	DDI-DrugBank.d258.s4	NO_SECTION	NO_SETID	21
Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.
1	0	5	O	Plasma
2	7	20	O	concentrations
3	23	25	O	AUC
4	27	27	O	0
5	29	30	O	24
6	32	34	O	hrs
7	37	38	O	of
8	40	51	U-KIN	erythromycin
9	53	61	O	decreased
10	63	65	O	15%
11	67	70	O	with
12	72	87	O	coadministration
13	89	90	O	of
14	92	101	O	XXXXXXXX
15	103	110	O	relative
16	112	113	O	to
17	115	118	O	that
18	120	127	O	observed
19	129	132	O	with
20	134	145	U-UNK	erythromycin
21	147	151	O	alone
NULL

Loratadine	DDI-DrugBank.d258.s5	NO_SECTION	NO_SETID	8
The clinical relevance of this difference is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	21	O	relevance
4	23	24	O	of
5	26	29	O	this
6	31	40	O	difference
7	42	43	O	is
8	45	51	O	unknown
NULL

Loratadine	DDI-DrugBank.d258.s6	NO_SECTION	NO_SETID	8
These above findings are summarized in TABLE 1.
1	0	4	O	These
2	6	10	O	above
3	12	19	O	findings
4	21	23	O	are
5	25	34	O	summarized
6	36	37	O	in
7	39	43	O	TABLE
8	45	45	O	1
NULL

Loratadine	DDI-DrugBank.d258.s7	NO_SECTION	NO_SETID	26
TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of Loratadine and Descarboethoxyloratadine After 10 Days of Coadministration (Loratadine 10 mg) in Normal Volunteers
1	0	4	O	TABLE
2	6	6	O	1
3	8	14	O	Effects
4	16	17	O	on
5	19	24	O	Plasma
6	26	39	O	Concentrations
7	42	44	O	AUC
8	46	46	O	0
9	48	49	O	24
10	51	53	O	hrs
11	56	57	O	of
12	59	68	O	XXXXXXXX
13	70	72	O	and
14	74	87	O	Descarboethoxy
15	88	97	O	XXXXXXXX
16	99	103	O	After
17	105	106	O	10
18	108	111	O	Days
19	113	114	O	of
20	116	131	O	Coadministration
21	134	143	O	XXXXXXXX
22	145	146	O	10
23	148	149	O	mg
24	152	153	O	in
25	155	160	O	Normal
26	162	171	O	Volunteers
NULL

Loratadine	DDI-DrugBank.d258.s8	NO_SECTION	NO_SETID	3
Loratadine Descarboethoxyloratadine
1	0	9	O	XXXXXXXX
2	11	24	O	Descarboethoxy
3	25	34	O	XXXXXXXX
NULL

Loratadine	DDI-DrugBank.d258.s9	NO_SECTION	NO_SETID	7
Erythromycin (500 mg q8h) + 40% +46%
1	0	11	U-UNK	Erythromycin
2	14	16	O	500
3	18	19	O	mg
4	21	23	O	q8h
5	26	26	O	+
6	28	30	O	40%
7	32	35	O	+46%
NULL

Loratadine	DDI-DrugBank.d258.s10	NO_SECTION	NO_SETID	7
Cimetidine (300 mg qid) +103% + 6%
1	0	9	U-UNK	Cimetidine
2	12	14	O	300
3	16	17	O	mg
4	19	21	O	qid
5	24	28	O	+103%
6	30	30	O	+
7	32	33	O	6%
NULL

Loratadine	DDI-DrugBank.d258.s11	NO_SECTION	NO_SETID	6
Ketoconazole (200 mg q12h) +307% +73%
1	0	11	U-UNK	Ketoconazole
2	14	16	O	200
3	18	19	O	mg
4	21	24	O	q12h
5	27	31	O	+307%
6	33	36	O	+73%
NULL

Loratadine	DDI-DrugBank.d258.s12	NO_SECTION	NO_SETID	19
There does not appear to be an increase in adverse events in subjects who received oral contraceptives and loratadine.
1	0	4	O	There
2	6	9	O	does
3	11	13	O	not
4	15	20	O	appear
5	22	23	O	to
6	25	26	O	be
7	28	29	O	an
8	31	38	O	increase
9	40	41	O	in
10	43	49	O	adverse
11	51	56	O	events
12	58	59	O	in
13	61	68	O	subjects
14	70	72	O	who
15	74	81	O	received
16	83	86	O	oral
17	88	101	U-UNK	contraceptives
18	103	105	O	and
19	107	116	O	XXXXXXXX
NULL

Lorazepam	DDI-DrugBank.d18.s0	NO_SECTION	NO_SETID	21
Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.
1	0	6	O	Tablets
2	7	7	O	:
3	9	11	O	The
4	13	27	U-UNK	benzodiazepines
5	28	28	O	,
6	30	38	O	including
7	40	48	O	XXXXXXXX
8	49	49	O	,
9	51	57	O	produce
10	59	61	O	CNS
11	63	72	O	depressant
12	74	80	O	effects
13	82	85	O	when
14	87	98	O	administered
15	100	103	O	with
16	105	108	O	such
17	110	120	O	medications
18	122	123	O	as
19	125	136	U-DYN	barbiturates
20	138	139	O	or
21	141	147	U-DYN	alcohol
NULL

Lorazepam	DDI-DrugBank.d18.s1	NO_SECTION	NO_SETID	55
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
1	0	8	O	Injection
2	9	9	O	:
3	11	19	O	XXXXXXXX
4	21	29	O	injection
5	30	30	O	,
6	32	35	O	like
7	37	41	O	other
8	43	52	O	injectable
9	54	68	U-UNK	benzodiazepines
10	69	69	O	,
11	71	78	O	produces
12	80	89	O	depression
13	91	92	O	of
14	94	96	O	the
15	98	104	O	central
16	106	112	O	nervous
17	114	119	O	system
18	121	124	O	when
19	126	137	O	administered
20	139	142	O	with
21	144	148	B-DYN	ethyl
22	150	156	L-DYN	alcohol
23	157	157	O	,
24	159	172	U-DYN	phenothiazines
25	173	173	O	,
26	175	186	U-DYN	barbiturates
27	187	187	O	,
28	189	191	B-DYN	MAO
29	193	202	L-DYN	inhibitors
30	203	203	O	,
31	205	207	O	and
32	209	213	O	other
33	215	234	O	antidepressants.When
34	236	246	U-DYN	scopolamine
35	248	249	O	is
36	251	254	O	used
37	256	268	O	concomitantly
38	270	273	O	with
39	275	284	O	injectable
40	286	294	O	XXXXXXXX
41	295	295	O	,
42	297	298	O	an
43	300	308	O	increased
44	310	318	O	incidence
45	320	321	O	of
46	323	330	O	sedation
47	331	331	O	,
48	333	346	O	hallucinations
49	347	347	O	,
50	349	351	O	and
51	353	362	O	irrational
52	364	371	O	behavior
53	373	375	O	has
54	377	380	O	been
55	382	389	O	observed
NULL

Losartan	DDI-DrugBank.d30.s0	NO_SECTION	NO_SETID	22
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.
1	0	1	O	No
2	3	13	O	significant
3	15	18	O	drug
4	20	23	O	drug
5	25	39	O	pharmacokinetic
6	41	52	O	interactions
7	54	57	O	have
8	59	62	O	been
9	64	68	O	found
10	70	71	O	in
11	73	83	O	interaction
12	85	91	O	studies
13	93	96	O	with
14	98	116	U-UNK	hydrochlorothiazide
15	117	117	O	,
16	119	125	U-UNK	digoxin
17	126	126	O	,
18	128	135	U-UNK	warfarin
19	136	136	O	,
20	138	147	U-UNK	cimetidine
21	149	151	O	and
22	153	165	U-UNK	phenobarbital
NULL

Losartan	DDI-DrugBank.d30.s1	NO_SECTION	NO_SETID	17
Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.
1	0	7	U-KIN	Rifampin
2	8	8	O	,
3	10	11	O	an
4	13	19	O	inducer
5	21	22	O	of
6	24	27	O	drug
7	29	38	O	metabolism
8	39	39	O	,
9	41	49	O	decreased
10	51	53	O	the
11	55	68	O	concentrations
12	70	71	O	of
13	73	80	O	XXXXXXXX
14	82	84	O	and
15	86	88	O	its
16	90	95	O	active
17	97	106	O	metabolite
NULL

Losartan	DDI-DrugBank.d30.s2	NO_SECTION	NO_SETID	11
In humans, two inhibitors of P450 3A4 have been studied.
1	0	1	O	In
2	3	8	O	humans
3	9	9	O	,
4	11	13	O	two
5	15	24	O	inhibitors
6	26	27	O	of
7	29	32	O	P450
8	34	36	O	3A4
9	38	41	O	have
10	43	46	O	been
11	48	54	O	studied
NULL

Losartan	DDI-DrugBank.d30.s3	NO_SECTION	NO_SETID	28
Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.
1	0	11	U-UNK	Ketoconazole
2	13	15	O	did
3	17	19	O	not
4	21	26	O	affect
5	28	30	O	the
6	32	41	O	conversion
7	43	44	O	of
8	46	53	O	XXXXXXXX
9	55	56	O	to
10	58	60	O	the
11	62	67	O	active
12	69	78	O	metabolite
13	80	84	O	after
14	86	96	O	intravenous
15	98	111	O	administration
16	113	114	O	of
17	116	123	O	XXXXXXXX
18	124	124	O	,
19	126	128	O	and
20	130	141	U-UNK	erythromycin
21	143	145	O	had
22	147	148	O	no
23	150	159	O	clinically
24	161	171	O	significant
25	173	178	O	effect
26	180	184	O	after
27	186	189	O	oral
28	191	204	O	administration
NULL

Losartan	DDI-DrugBank.d30.s4	NO_SECTION	NO_SETID	16
Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.
1	0	10	U-KIN	Fluconazole
2	11	11	O	,
3	13	14	O	an
4	16	24	O	inhibitor
5	26	27	O	of
6	29	32	O	P450
7	34	36	O	2C9
8	37	37	O	,
9	39	47	O	decreased
10	49	54	O	active
11	56	65	O	metabolite
12	67	79	O	concentration
13	81	83	O	and
14	85	93	O	increased
15	95	102	O	XXXXXXXX
16	104	116	O	concentration
NULL

Losartan	DDI-DrugBank.d30.s5	NO_SECTION	NO_SETID	17
The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined.
1	0	2	O	The
2	4	18	O	pharmacodynamic
3	20	31	O	consequences
4	33	34	O	of
5	36	46	O	concomitant
6	48	50	O	use
7	52	53	O	of
8	55	62	O	XXXXXXXX
9	64	66	O	and
10	68	77	O	inhibitors
11	79	80	O	of
12	82	85	O	P450
13	87	89	O	2C9
14	91	94	O	have
15	96	98	O	not
16	100	103	O	been
17	105	112	O	examined
NULL

Losartan	DDI-DrugBank.d30.s6	NO_SECTION	NO_SETID	23
Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9.
1	0	7	O	Subjects
2	9	11	O	who
3	13	14	O	do
4	16	18	O	not
5	20	29	O	metabolize
6	31	38	O	XXXXXXXX
7	40	41	O	to
8	43	48	O	active
9	50	59	O	metabolite
10	61	64	O	have
11	66	69	O	been
12	71	75	O	shown
13	77	78	O	to
14	80	83	O	have
15	85	85	O	a
16	87	94	O	specific
17	95	95	O	,
18	97	100	O	rare
19	102	107	O	defect
20	109	110	O	in
21	112	121	O	cytochrome
22	123	126	O	P450
23	128	130	O	2C9
NULL

Losartan	DDI-DrugBank.d30.s7	NO_SECTION	NO_SETID	22
These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4.
1	0	4	O	These
2	6	9	O	data
3	11	17	O	suggest
4	19	22	O	that
5	24	26	O	the
6	28	37	O	conversion
7	39	40	O	of
8	42	49	O	XXXXXXXX
9	51	52	O	to
10	54	56	O	its
11	58	63	O	active
12	65	74	O	metabolite
13	76	77	O	is
14	79	86	O	mediated
15	88	96	O	primarily
16	98	99	O	by
17	101	104	O	P450
18	106	108	O	2C9
19	110	112	O	and
20	114	116	O	not
21	118	121	O	P450
22	123	125	O	3A4
NULL

Losartan	DDI-DrugBank.d30.s8	NO_SECTION	NO_SETID	41
As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	18	O	drugs
5	20	23	O	that
6	25	29	O	block
7	31	41	O	angiotensin
8	43	44	O	II
9	46	47	O	or
10	49	51	O	its
11	53	59	O	effects
12	60	60	O	,
13	62	72	O	concomitant
14	74	76	O	use
15	78	79	O	of
16	81	89	B-UNK	potassium
17	91	97	I-UNK	sparing
18	99	107	L-UNK	diuretics
19	110	112	O	e.g
20	114	114	O	,
21	116	129	U-UNK	spironolactone
22	130	130	O	,
23	132	142	U-UNK	triamterene
24	143	143	O	,
25	145	153	U-UNK	amiloride
26	155	155	O	,
27	157	165	U-UNK	potassium
28	167	177	O	supplements
29	178	178	O	,
30	180	181	O	or
31	183	186	O	salt
32	188	198	O	substitutes
33	200	209	O	containing
34	211	219	O	potassium
35	221	223	O	may
36	225	228	O	lead
37	230	231	O	to
38	233	241	O	increases
39	243	244	O	in
40	246	250	O	serum
41	252	260	O	potassium
NULL

Losartan	DDI-DrugBank.d30.s9	NO_SECTION	NO_SETID	22
As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	29	B-UNK	antihypertensive
5	31	36	L-UNK	agents
6	37	37	O	,
7	39	41	O	the
8	43	58	O	antihypertensive
9	60	65	O	effect
10	67	68	O	of
11	70	77	O	XXXXXXXX
12	79	81	O	may
13	83	84	O	be
14	86	92	O	blunted
15	94	95	O	by
16	97	99	O	the
17	101	103	B-UNK	non
18	105	113	I-UNK	steroidal
19	115	118	I-UNK	anti
20	120	131	I-UNK	inflammatory
21	133	136	L-UNK	drug
22	138	149	U-DYN	indomethacin
NULL

Lovastatin	DDI-DrugBank.d567.s1	NO_SECTION	NO_SETID	11
Lovastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity;
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	metabolized
4	26	27	O	by
5	29	34	O	CYP3A4
6	36	38	O	but
7	40	42	O	has
8	44	45	O	no
9	47	52	O	CYP3A4
10	54	63	O	inhibitory
11	65	72	O	activity
NULL

Lovastatin	DDI-DrugBank.d567.s2	NO_SECTION	NO_SETID	16
therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.
1	0	8	O	therefore
2	10	11	O	it
3	13	14	O	is
4	16	18	O	not
5	20	27	O	expected
6	29	30	O	to
7	32	37	O	affect
8	39	41	O	the
9	43	48	O	plasma
10	50	63	O	concentrations
11	65	66	O	of
12	68	72	O	other
13	74	78	O	drugs
14	80	90	O	metabolized
15	92	93	O	by
16	95	100	O	CYP3A4
NULL

Lovastatin	DDI-DrugBank.d567.s3	NO_SECTION	NO_SETID	16
Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of lovastatin.
1	0	5	O	Potent
2	7	16	O	inhibitors
3	18	19	O	of
4	21	26	O	CYP3A4
5	29	33	O	below
6	36	43	O	increase
7	45	47	O	the
8	49	52	O	risk
9	54	55	O	of
10	57	64	O	myopathy
11	66	67	O	by
12	69	76	O	reducing
13	78	80	O	the
14	82	92	O	elimination
15	94	95	O	of
16	97	106	O	XXXXXXXX
NULL

Lovastatin	DDI-DrugBank.d567.s5	NO_SECTION	NO_SETID	18
Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
1	0	11	U-UNK	Itraconazole
2	13	24	U-UNK	Ketoconazole
3	26	37	U-UNK	Erythromycin
4	39	52	U-UNK	Clarithromycin
5	54	66	U-UNK	Telithromycin
6	68	70	B-UNK	HIV
7	72	79	I-UNK	protease
8	81	90	L-UNK	inhibitors
9	92	101	U-UNK	Nefazodone
10	103	114	U-UNK	Cyclosporine
11	116	120	O	Large
12	122	131	O	quantities
13	133	134	O	of
14	136	145	O	grapefruit
15	147	151	O	juice
16	155	155	O	1
17	157	161	O	quart
18	163	167	O	daily
NULL

Lovastatin	DDI-DrugBank.d567.s6	NO_SECTION	NO_SETID	12
Interactions with lipid-lowering drugs that can cause myopathy when given alone.
1	0	11	O	Interactions
2	13	16	O	with
3	18	22	O	lipid
4	24	31	O	lowering
5	33	37	O	drugs
6	39	42	O	that
7	44	46	O	can
8	48	52	O	cause
9	54	61	O	myopathy
10	63	66	O	when
11	68	72	O	given
12	74	78	O	alone
NULL

Lovastatin	DDI-DrugBank.d567.s7	NO_SECTION	NO_SETID	28
The risk of myopathy is also increased by the following lipid-lowering drugs that are not potent CYP3A4 inhibitors, but which can cause myopathy when given alone.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	O	myopathy
5	21	22	O	is
6	24	27	O	also
7	29	37	O	increased
8	39	40	O	by
9	42	44	O	the
10	46	54	O	following
11	56	60	O	lipid
12	62	69	O	lowering
13	71	75	O	drugs
14	77	80	O	that
15	82	84	O	are
16	86	88	O	not
17	90	95	O	potent
18	97	102	O	CYP3A4
19	104	113	O	inhibitors
20	114	114	O	,
21	116	118	O	but
22	120	124	O	which
23	126	128	O	can
24	130	134	O	cause
25	136	143	O	myopathy
26	145	148	O	when
27	150	154	O	given
28	156	160	O	alone
NULL

Lovastatin	DDI-DrugBank.d567.s8	NO_SECTION	NO_SETID	6
See WARNINGS, Myopathy/Rhabdomyolysis.
1	0	2	O	See
2	4	11	O	WARNINGS
3	12	12	O	,
4	14	21	O	Myopathy
5	22	22	O	/
6	23	36	O	Rhabdomyolysis
NULL

Lovastatin	DDI-DrugBank.d567.s9	NO_SECTION	NO_SETID	10
Gemfibrozil Other fibrates Niacin (nicotinic acid) (=1 g/day)
1	0	10	U-UNK	Gemfibrozil
2	12	16	O	Other
3	18	25	U-UNK	fibrates
4	27	32	U-UNK	Niacin
5	35	43	B-UNK	nicotinic
6	45	48	L-UNK	acid
7	52	53	O	=1
8	55	55	O	g
9	56	56	O	/
10	57	59	O	day
NULL

Lovastatin	DDI-DrugBank.d567.s10	NO_SECTION	NO_SETID	3
Other drug interactions
1	0	4	O	Other
2	6	9	O	drug
3	11	22	O	interactions
NULL

Lovastatin	DDI-DrugBank.d567.s11	NO_SECTION	NO_SETID	27
Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).
1	0	6	U-UNK	Danazol
2	7	7	O	:
3	9	11	O	The
4	13	16	O	risk
5	18	19	O	of
6	21	28	O	myopathy
7	29	29	O	/
8	30	43	O	rhabdomyolysis
9	45	46	O	is
10	48	56	O	increased
11	58	59	O	by
12	61	71	O	concomitant
13	73	86	O	administration
14	88	89	O	of
15	91	97	U-DYN	danazol
16	99	110	O	particularly
17	112	115	O	with
18	117	122	O	higher
19	124	128	O	doses
20	130	131	O	of
21	133	142	O	XXXXXXXX
22	145	147	O	see
23	149	156	O	WARNINGS
24	157	157	O	,
25	159	166	O	Myopathy
26	167	167	O	/
27	168	181	O	Rhabdomyolysis
NULL

Lovastatin	DDI-DrugBank.d567.s12	NO_SECTION	NO_SETID	38
Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).
1	0	9	U-UNK	Amiodarone
2	11	12	O	or
3	14	22	U-UNK	Verapamil
4	23	23	O	:
5	25	27	O	The
6	29	32	O	risk
7	34	35	O	of
8	37	44	O	myopathy
9	45	45	O	/
10	46	59	O	rhabdomyolysis
11	61	62	O	is
12	64	72	O	increased
13	74	77	O	when
14	79	84	O	either
15	86	95	U-UNK	amiodarone
16	97	98	O	or
17	100	108	U-UNK	verapamil
18	110	111	O	is
19	113	116	O	used
20	118	130	O	concomitantly
21	132	135	O	with
22	137	137	O	a
23	139	145	O	closely
24	147	153	O	related
25	155	160	O	member
26	162	163	O	of
27	165	167	O	the
28	169	171	B-UNK	HMG
29	173	175	I-UNK	CoA
30	177	185	I-UNK	reductase
31	187	195	I-UNK	inhibitor
32	197	201	L-UNK	class
33	204	206	O	see
34	208	215	O	WARNINGS
35	216	216	O	,
36	218	225	O	Myopathy
37	226	226	O	/
38	227	240	O	Rhabdomyolysis
NULL

Lovastatin	DDI-DrugBank.d567.s13	NO_SECTION	NO_SETID	25
Coumarin Anticoagulants: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected.
1	0	7	U-UNK	Coumarin
2	9	22	O	Anticoagulants
3	23	23	O	:
4	25	26	O	In
5	28	28	O	a
6	30	34	O	small
7	36	43	O	clinical
8	45	49	O	trial
9	51	52	O	in
10	54	58	O	which
11	60	69	O	XXXXXXXX
12	71	73	O	was
13	75	86	O	administered
14	88	89	O	to
15	91	98	U-UNK	warfarin
16	100	106	O	treated
17	108	115	O	patients
18	116	116	O	,
19	118	119	O	no
20	121	126	O	effect
21	128	129	O	on
22	131	141	O	prothrombin
23	143	146	O	time
24	148	150	O	was
25	152	159	O	detected
NULL

Lovastatin	DDI-DrugBank.d567.s14	NO_SECTION	NO_SETID	29
However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	another
4	17	19	B-UNK	HMG
5	21	23	I-UNK	CoA
6	25	33	I-UNK	reductase
7	35	43	L-UNK	inhibitor
8	45	47	O	has
9	49	52	O	been
10	54	58	O	found
11	60	61	O	to
12	63	69	O	produce
13	71	71	O	a
14	73	76	O	less
15	78	81	O	than
16	83	85	O	two
17	87	92	O	second
18	94	101	O	increase
19	103	104	O	in
20	106	116	O	prothrombin
21	118	121	O	time
22	123	124	O	in
23	126	132	O	healthy
24	134	143	O	volunteers
25	145	153	O	receiving
26	155	157	O	low
27	159	163	O	doses
28	165	166	O	of
29	168	175	U-UNK	warfarin
NULL

Lovastatin	DDI-DrugBank.d567.s15	NO_SECTION	NO_SETID	22
Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.
1	0	3	O	Also
2	4	4	O	,
3	6	13	O	bleeding
4	15	17	O	and
5	18	18	O	/
6	19	20	O	or
7	22	30	O	increased
8	32	42	O	prothrombin
9	44	47	O	time
10	49	52	O	have
11	54	57	O	been
12	59	66	O	reported
13	68	69	O	in
14	71	71	O	a
15	73	75	O	few
16	77	84	O	patients
17	86	91	O	taking
18	93	100	U-DYN	coumarin
19	102	115	O	anticoagulants
20	117	129	O	concomitantly
21	131	134	O	with
22	136	145	O	XXXXXXXX
NULL

Lovastatin	DDI-DrugBank.d567.s16	NO_SECTION	NO_SETID	32
It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	24	O	in
6	26	33	O	patients
7	35	40	O	taking
8	42	55	U-DYN	anticoagulants
9	56	56	O	,
10	58	68	O	prothrombin
11	70	73	O	time
12	75	76	O	be
13	78	87	O	determined
14	89	94	O	before
15	96	103	O	starting
16	105	114	O	XXXXXXXX
17	116	118	O	and
18	120	129	O	frequently
19	131	136	O	enough
20	138	143	O	during
21	145	149	O	early
22	151	157	O	therapy
23	159	160	O	to
24	162	167	O	insure
25	169	172	O	that
26	174	175	O	no
27	177	187	O	significant
28	189	198	O	alteration
29	200	201	O	of
30	203	213	O	prothrombin
31	215	218	O	time
32	220	225	O	occurs
NULL

Lovastatin	DDI-DrugBank.d567.s17	NO_SECTION	NO_SETID	24
Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.
1	0	3	O	Once
2	5	5	O	a
3	7	12	O	stable
4	14	24	O	prothrombin
5	26	29	O	time
6	31	33	O	has
7	35	38	O	been
8	40	49	O	documented
9	50	50	O	,
10	52	62	O	prothrombin
11	64	68	O	times
12	70	72	O	can
13	74	75	O	be
14	77	85	O	monitored
15	87	88	O	at
16	90	92	O	the
17	94	102	O	intervals
18	104	110	O	usually
19	112	122	O	recommended
20	124	126	O	for
21	128	135	O	patients
22	137	138	O	on
23	140	147	B-UNK	coumarin
24	149	162	L-UNK	anticoagulants
NULL

Lovastatin	DDI-DrugBank.d567.s18	NO_SECTION	NO_SETID	14
If the dose of lovastatin is changed, the same procedure should be repeated.
1	0	1	O	If
2	3	5	O	the
3	7	10	O	dose
4	12	13	O	of
5	15	24	O	XXXXXXXX
6	26	27	O	is
7	29	35	O	changed
8	36	36	O	,
9	38	40	O	the
10	42	45	O	same
11	47	55	O	procedure
12	57	62	O	should
13	64	65	O	be
14	67	74	O	repeated
NULL

Lovastatin	DDI-DrugBank.d567.s19	NO_SECTION	NO_SETID	19
Lovastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.
1	0	9	O	XXXXXXXX
2	11	17	O	therapy
3	19	21	O	has
4	23	25	O	not
5	27	30	O	been
6	32	41	O	associated
7	43	46	O	with
8	48	55	O	bleeding
9	57	58	O	or
10	60	63	O	with
11	65	71	O	changes
12	73	74	O	in
13	76	86	O	prothrombin
14	88	91	O	time
15	93	94	O	in
16	96	103	O	patients
17	105	107	O	not
18	109	114	O	taking
19	116	129	U-UNK	anticoagulants
NULL

Lovastatin	DDI-DrugBank.d567.s20	NO_SECTION	NO_SETID	25
Propranolol: In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and propranolol.
1	0	10	U-UNK	Propranolol
2	11	11	O	:
3	13	14	O	In
4	16	21	O	normal
5	23	32	O	volunteers
6	33	33	O	,
7	35	39	O	there
8	41	43	O	was
9	45	46	O	no
10	48	57	O	clinically
11	59	69	O	significant
12	71	85	O	pharmacokinetic
13	87	88	O	or
14	90	104	O	pharmacodynamic
15	106	116	O	interaction
16	118	121	O	with
17	123	133	O	concomitant
18	135	148	O	administration
19	150	151	O	of
20	153	158	O	single
21	160	164	O	doses
22	166	167	O	of
23	169	178	O	XXXXXXXX
24	180	182	O	and
25	184	194	U-UNK	propranolol
NULL

Lovastatin	DDI-DrugBank.d567.s21	NO_SECTION	NO_SETID	21
Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	10	O	In
4	12	19	O	patients
5	21	24	O	with
6	26	45	O	hypercholesterolemia
7	46	46	O	,
8	48	58	O	concomitant
9	60	73	O	administration
10	75	76	O	of
11	78	87	O	XXXXXXXX
12	89	91	O	and
13	93	99	U-UNK	digoxin
14	101	108	O	resulted
15	110	111	O	in
16	113	114	O	no
17	116	121	O	effect
18	123	124	O	on
19	126	132	U-UNK	digoxin
20	134	139	O	plasma
21	141	154	O	concentrations
NULL

Lovastatin	DDI-DrugBank.d567.s22	NO_SECTION	NO_SETID	26
Oral Hypoglycemic Agents: In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide
1	0	3	O	Oral
2	5	16	B-UNK	Hypoglycemic
3	18	23	L-UNK	Agents
4	24	24	O	:
5	26	27	O	In
6	29	43	O	pharmacokinetic
7	45	51	O	studies
8	53	54	O	of
9	56	62	O	XXXXXXXX
10	64	65	O	in
11	67	86	O	hypercholesterolemic
12	88	97	O	noninsulin
13	99	107	O	dependent
14	109	116	O	diabetic
15	118	125	O	patients
16	126	126	O	,
17	128	132	O	there
18	134	136	O	was
19	138	139	O	no
20	141	144	O	drug
21	146	156	O	interaction
22	158	161	O	with
23	163	171	U-UNK	glipizide
24	173	174	O	or
25	176	179	O	with
26	181	194	U-UNK	chlorpropamide
NULL

Loxapine	DDI-DrugBank.d504.s0	NO_SECTION	NO_SETID	23
There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	19	O	rare
5	21	27	O	reports
6	29	30	O	of
7	32	42	O	significant
8	44	54	O	respiratory
9	56	65	O	depression
10	66	66	O	,
11	68	73	O	stupor
12	75	77	O	and
13	78	78	O	/
14	79	80	O	or
15	82	92	O	hypotension
16	94	97	O	with
17	99	101	O	the
18	103	113	O	concomitant
19	115	117	O	use
20	119	120	O	of
21	122	129	O	XXXXXXXX
22	131	133	O	and
23	135	143	U-DYN	lorazepam
NULL

Loxapine	DDI-DrugBank.d504.s1	NO_SECTION	NO_SETID	16
The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	16	O	using
5	18	25	O	XXXXXXXX
6	27	28	O	in
7	30	40	O	combination
8	42	45	O	with
9	47	49	O	CNS
10	51	56	O	active
11	58	62	O	drugs
12	64	66	O	has
13	68	70	O	not
14	72	75	O	been
15	77	90	O	systematically
16	92	100	O	evaluated
NULL

Loxapine	DDI-DrugBank.d504.s2	NO_SECTION	NO_SETID	17
Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required.
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	O	caution
4	19	20	O	is
5	22	28	O	advised
6	30	31	O	if
7	33	35	O	the
8	37	47	O	concomitant
9	49	62	O	administration
10	64	65	O	of
11	67	74	O	XXXXXXXX
12	76	78	O	and
13	80	82	O	CNS
14	84	89	O	active
15	91	95	O	drugs
16	97	98	O	is
17	100	107	O	required
NULL

Lymecycline	DDI-DrugBank.d79.s0	NO_SECTION	NO_SETID	19
The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.
1	0	2	O	The
2	4	13	O	absorption
3	15	16	O	of
4	18	28	O	XXXXXXXX
5	30	32	O	may
6	34	35	O	be
7	37	44	O	affected
8	46	47	O	by
9	49	51	O	the
10	53	64	O	simultaneous
11	66	79	O	administration
12	81	82	O	of
13	84	94	O	indigestion
14	96	103	O	remedies
15	104	104	O	,
16	106	109	U-KIN	iron
17	111	112	O	or
18	114	117	U-KIN	zinc
19	119	129	O	supplements
NULL

Lymecycline	DDI-DrugBank.d79.s1	NO_SECTION	NO_SETID	11
Oral contraceptives may be less effective while you are taking lymecycline.
1	0	3	O	Oral
2	5	18	U-DYN	contraceptives
3	20	22	O	may
4	24	25	O	be
5	27	30	O	less
6	32	40	O	effective
7	42	46	O	while
8	48	50	O	you
9	52	54	O	are
10	56	61	O	taking
11	63	73	O	XXXXXXXX
NULL

Meclofenamic acid	DDI-DrugBank.d113.s0	NO_SECTION	NO_SETID	9
Warfarin: Meclofenamate sodium enhances the effect of warfarin.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	22	B-UNK	Meclofenamate
4	24	29	L-UNK	sodium
5	31	38	O	enhances
6	40	42	O	the
7	44	49	O	effect
8	51	52	O	of
9	54	61	U-UNK	warfarin
NULL

Meclofenamic acid	DDI-DrugBank.d113.s1	NO_SECTION	NO_SETID	28
Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	28	B-UNK	meclofenamate
5	30	35	L-UNK	sodium
6	37	38	O	is
7	40	44	O	given
8	46	47	O	to
9	49	49	O	a
10	51	57	O	patient
11	59	67	O	receiving
12	69	76	U-UNK	warfarin
13	77	77	O	,
14	79	81	O	the
15	83	88	O	dosage
16	90	91	O	of
17	93	100	U-UNK	warfarin
18	102	107	O	should
19	109	110	O	be
20	112	118	O	reduced
21	120	121	O	to
22	123	129	O	prevent
23	131	139	O	excessive
24	141	152	O	prolongation
25	154	155	O	of
26	157	159	O	the
27	161	171	O	prothrombin
28	173	176	O	time
NULL

Meclofenamic acid	DDI-DrugBank.d113.s2	NO_SECTION	NO_SETID	20
Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.
1	0	6	O	XXXXXXXX
2	7	7	O	:
3	9	18	O	Concurrent
4	20	33	O	administration
5	35	36	O	of
6	38	44	O	XXXXXXXX
7	46	48	O	may
8	50	54	O	lower
9	56	68	B-KIN	meclofenamate
10	70	75	L-KIN	sodium
11	77	82	O	plasma
12	84	89	O	levels
13	90	90	O	,
14	92	99	O	possibly
15	101	102	O	by
16	104	112	O	competing
17	114	116	O	for
18	118	124	O	protein
19	126	132	O	binding
20	134	138	O	sites
NULL

Meclofenamic acid	DDI-DrugBank.d113.s3	NO_SECTION	NO_SETID	18
The urinary excretion of meclofenamate sodium is unaffected by aspirin, indicating no change in meclofenamate sodium absorption.
1	0	2	O	The
2	4	10	O	urinary
3	12	20	O	excretion
4	22	23	O	of
5	25	37	B-UNK	meclofenamate
6	39	44	L-UNK	sodium
7	46	47	O	is
8	49	58	O	unaffected
9	60	61	O	by
10	63	69	O	XXXXXXXX
11	70	70	O	,
12	72	81	O	indicating
13	83	84	O	no
14	86	91	O	change
15	93	94	O	in
16	96	108	B-UNK	meclofenamate
17	110	115	L-UNK	sodium
18	117	126	O	absorption
NULL

Meclofenamic acid	DDI-DrugBank.d113.s4	NO_SECTION	NO_SETID	8
Meclofenamate sodium does not affect serum salicylate levels.
1	0	12	B-UNK	Meclofenamate
2	14	19	L-UNK	sodium
3	21	24	O	does
4	26	28	O	not
5	30	35	O	affect
6	37	41	O	serum
7	43	52	U-UNK	salicylate
8	54	59	O	levels
NULL

Meclofenamic acid	DDI-DrugBank.d113.s5	NO_SECTION	NO_SETID	16
Greater fecal blood loss results from concomitant administration of both drugs than from either drug alone.
1	0	6	O	Greater
2	8	12	O	fecal
3	14	18	O	blood
4	20	23	O	loss
5	25	31	O	results
6	33	36	O	from
7	38	48	O	concomitant
8	50	63	O	administration
9	65	66	O	of
10	68	71	O	both
11	73	77	O	drugs
12	79	82	O	than
13	84	87	O	from
14	89	94	O	either
15	96	99	O	drug
16	101	105	O	alone
NULL

Meclofenamic acid	DDI-DrugBank.d113.s6	NO_SECTION	NO_SETID	16
Propoxyphene: The concurrent administration of propoxyphene hydrochloride does not affect the bioavailability of meclofenamate sodium.
1	0	11	U-UNK	Propoxyphene
2	12	12	O	:
3	14	16	O	The
4	18	27	O	concurrent
5	29	42	O	administration
6	44	45	O	of
7	47	58	B-UNK	propoxyphene
8	60	72	L-UNK	hydrochloride
9	74	77	O	does
10	79	81	O	not
11	83	88	O	affect
12	90	92	O	the
13	94	108	O	bioavailability
14	110	111	O	of
15	113	125	B-UNK	meclofenamate
16	127	132	L-UNK	sodium
NULL

Meclofenamic acid	DDI-DrugBank.d113.s7	NO_SECTION	NO_SETID	17
Antacids: Concomitant administration of aluminum and magnesium hydroxides does not interfere with absorption of meclofenamate sodium.
1	0	7	U-UNK	Antacids
2	8	8	O	:
3	10	20	O	Concomitant
4	22	35	O	administration
5	37	38	O	of
6	40	47	B-UNK	aluminum
7	49	51	I-UNK	and
8	53	61	L-UNK	magnesium
9	63	72	O	hydroxides
10	74	77	O	does
11	79	81	O	not
12	83	91	O	interfere
13	93	96	O	with
14	98	107	O	absorption
15	109	110	O	of
16	112	124	B-UNK	meclofenamate
17	126	131	L-UNK	sodium
NULL

Mefenamic acid	DDI-DrugBank.d400.s0	NO_SECTION	NO_SETID	25
Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.
1	0	6	O	XXXXXXXX
2	7	7	O	:
3	9	10	O	As
4	12	15	O	with
5	17	21	O	other
6	23	28	U-DYN	NSAIDs
7	29	29	O	,
8	31	41	O	concomitant
9	43	56	O	administration
10	58	59	O	of
11	61	67	O	Ponstel
12	69	71	O	and
13	73	79	U-DYN	XXXXXXXX
14	81	82	O	is
15	84	86	O	not
16	88	96	O	generally
17	98	108	O	recommended
18	110	116	O	because
19	118	119	O	of
20	121	123	O	the
21	125	133	O	potential
22	135	136	O	of
23	138	146	O	increased
24	148	154	O	adverse
25	156	162	O	effects
NULL

Mefenamic acid	DDI-DrugBank.d400.s1	NO_SECTION	NO_SETID	15
Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.
1	0	11	U-UNK	Methotrexate
2	12	12	O	:
3	14	19	U-UNK	NSAIDs
4	21	24	O	have
5	26	29	O	been
6	31	38	O	reported
7	40	41	O	to
8	43	55	O	competitively
9	57	63	O	inhibit
10	65	76	U-UNK	methotrexate
11	78	89	O	accumulation
12	91	92	O	in
13	94	99	O	rabbit
14	101	106	O	kidney
15	108	113	O	slices
NULL

Mefenamic acid	DDI-DrugBank.d400.s2	NO_SECTION	NO_SETID	11
This may indicate that they could enhance the toxicity of methotrexate.
1	0	3	O	This
2	5	7	O	may
3	9	16	O	indicate
4	18	21	O	that
5	23	26	O	they
6	28	32	O	could
7	34	40	O	enhance
8	42	44	O	the
9	46	53	O	toxicity
10	55	56	O	of
11	58	69	U-UNK	methotrexate
NULL

Mefenamic acid	DDI-DrugBank.d400.s3	NO_SECTION	NO_SETID	11
Caution should be used when NSAIDs are administered concomitantly with methotrexate.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	26	O	when
6	28	33	U-UNK	NSAIDs
7	35	37	O	are
8	39	50	O	administered
9	52	64	O	concomitantly
10	66	69	O	with
11	71	82	U-UNK	methotrexate
NULL

Mefenamic acid	DDI-DrugBank.d400.s4	NO_SECTION	NO_SETID	15
ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
1	0	2	B-UNK	ACE
2	4	13	L-UNK	inhibitors
3	14	14	O	:
4	16	22	O	Reports
5	24	30	O	suggest
6	32	35	O	that
7	37	42	U-UNK	NSAIDs
8	44	46	O	may
9	48	55	O	diminish
10	57	59	O	the
11	61	76	O	antihypertensive
12	78	83	O	effect
13	85	86	O	of
14	88	90	B-UNK	ACE
15	92	101	L-UNK	inhibitors
NULL

Mefenamic acid	DDI-DrugBank.d400.s5	NO_SECTION	NO_SETID	14
This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
1	0	3	O	This
2	5	15	O	interaction
3	17	22	O	should
4	24	25	O	be
5	27	31	O	given
6	33	45	O	consideration
7	47	48	O	in
8	50	57	O	patients
9	59	64	O	taking
10	66	71	U-UNK	NSAIDs
11	73	85	O	concomitantly
12	87	90	O	with
13	92	94	B-UNK	ACE
14	96	105	L-UNK	inhibitors
NULL

Mefenamic acid	DDI-DrugBank.d400.s6	NO_SECTION	NO_SETID	28
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
1	0	9	U-UNK	Furosemide
2	10	10	O	:
3	12	19	O	Clinical
4	21	27	O	studies
5	28	28	O	,
6	30	31	O	as
7	33	36	O	well
8	38	39	O	as
9	41	44	O	post
10	46	54	O	marketing
11	56	67	O	observations
12	68	68	O	,
13	70	73	O	have
14	75	79	O	shown
15	81	84	O	that
16	86	91	U-UNK	NSAIDs
17	93	95	O	can
18	97	102	O	reduce
19	104	106	O	the
20	108	118	O	natriuretic
21	120	125	O	effect
22	127	128	O	of
23	130	139	U-UNK	furosemide
24	141	143	O	and
25	145	153	U-UNK	thiazides
26	155	156	O	in
27	158	161	O	some
28	163	170	O	patients
NULL

Mefenamic acid	DDI-DrugBank.d400.s7	NO_SECTION	NO_SETID	11
This response has been attributed to inhibition of renal prostaglandin synthesis.
1	0	3	O	This
2	5	12	O	response
3	14	16	O	has
4	18	21	O	been
5	23	32	O	attributed
6	34	35	O	to
7	37	46	O	inhibition
8	48	49	O	of
9	51	55	O	renal
10	57	69	O	prostaglandin
11	71	79	O	synthesis
NULL

Mefenamic acid	DDI-DrugBank.d400.s8	NO_SECTION	NO_SETID	27
During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
1	0	5	O	During
2	7	17	O	concomitant
3	19	25	O	therapy
4	27	28	O	of
5	30	36	O	XXXXXXXX
6	38	41	O	with
7	43	52	U-DYN	furosemide
8	53	53	O	,
9	55	57	O	the
10	59	65	O	patient
11	67	72	O	should
12	74	75	O	be
13	77	84	O	observed
14	86	92	O	closely
15	94	96	O	for
16	98	102	O	signs
17	104	105	O	of
18	107	111	O	renal
19	113	119	O	failure
20	120	120	O	,
21	122	123	O	as
22	125	128	O	well
23	130	131	O	as
24	133	134	O	to
25	136	141	O	assure
26	143	150	O	diuretic
27	152	159	O	efficacy
NULL

Mefenamic acid	DDI-DrugBank.d400.s9	NO_SECTION	NO_SETID	18
Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	14	U-UNK	NSAIDs
4	16	19	O	have
5	21	28	O	produced
6	30	31	O	an
7	33	41	O	elevation
8	43	44	O	of
9	46	51	O	plasma
10	53	59	U-UNK	lithium
11	61	66	O	levels
12	68	70	O	and
13	72	72	O	a
14	74	82	O	reduction
15	84	85	O	in
16	87	91	O	renal
17	93	99	U-UNK	lithium
18	101	109	O	clearance
NULL

Mefenamic acid	DDI-DrugBank.d400.s10	NO_SECTION	NO_SETID	16
The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%.
1	0	2	O	The
2	4	7	O	mean
3	9	15	O	minimum
4	17	23	U-UNK	lithium
5	25	37	O	concentration
6	39	47	O	increased
7	49	51	O	15%
8	53	55	O	and
9	57	59	O	the
10	61	65	O	renal
11	67	75	O	clearance
12	77	79	O	was
13	81	89	O	decreased
14	91	92	O	by
15	94	106	O	approximately
16	108	110	O	20%
NULL

Mefenamic acid	DDI-DrugBank.d400.s11	NO_SECTION	NO_SETID	14
These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID.
1	0	4	O	These
2	6	12	O	effects
3	14	17	O	have
4	19	22	O	been
5	24	33	O	attributed
6	35	36	O	to
7	38	47	O	inhibition
8	49	50	O	of
9	52	56	O	renal
10	58	70	O	prostaglandin
11	72	80	O	synthesis
12	82	83	O	by
13	85	87	O	the
14	89	93	U-UNK	NSAID
NULL

Mefenamic acid	DDI-DrugBank.d400.s12	NO_SECTION	NO_SETID	20
Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
1	0	3	O	Thus
2	4	4	O	,
3	6	9	O	when
4	11	16	U-UNK	NSAIDs
5	18	20	O	and
6	22	28	U-UNK	lithium
7	30	32	O	are
8	34	45	O	administered
9	47	58	O	concurrently
10	59	59	O	,
11	61	68	O	subjects
12	70	75	O	should
13	77	78	O	be
14	80	87	O	observed
15	89	97	O	carefully
16	99	101	O	for
17	103	107	O	signs
18	109	110	O	of
19	112	118	U-UNK	lithium
20	120	127	O	toxicity
NULL

Mefenamic acid	DDI-DrugBank.d400.s13	NO_SECTION	NO_SETID	35
Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	12	O	The
4	14	20	O	effects
5	22	23	O	of
6	25	32	U-UNK	warfarin
7	34	36	O	and
8	38	43	U-UNK	NSAIDs
9	45	46	O	on
10	48	49	O	GI
11	51	58	O	bleeding
12	60	62	O	are
13	64	74	O	synergistic
14	75	75	O	,
15	77	80	O	such
16	82	85	O	that
17	87	91	O	users
18	93	94	O	of
19	96	99	O	both
20	101	105	O	drugs
21	107	114	O	together
22	116	119	O	have
23	121	121	O	a
24	123	126	O	risk
25	128	129	O	of
26	131	137	O	serious
27	139	140	O	GI
28	142	149	O	bleeding
29	151	156	O	higher
30	158	161	O	than
31	163	167	O	users
32	169	170	O	of
33	172	177	O	either
34	179	182	O	drug
35	184	188	O	alone
NULL

Mefenamic acid	DDI-DrugBank.d400.s14	NO_SECTION	NO_SETID	51
Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.
1	0	7	U-UNK	Antacids
2	8	8	O	:
3	10	11	O	In
4	13	13	O	a
5	15	20	O	single
6	22	25	O	dose
7	27	31	O	study
8	34	36	O	n=6
9	38	38	O	,
10	40	48	O	ingestion
11	50	51	O	of
12	53	54	O	an
13	56	62	U-UNK	antacid
14	64	73	O	containing
15	75	77	O	1.7
16	79	82	O	gram
17	84	85	O	of
18	87	95	B-KIN	magnesium
19	97	105	L-KIN	hydroxide
20	107	110	O	with
21	112	114	O	500
22	116	117	O	mg
23	119	120	O	of
24	122	135	O	XXXXXXXX
25	137	145	O	increased
26	147	149	O	the
27	151	154	O	Cmax
28	156	158	O	and
29	160	162	O	AUC
30	164	165	O	of
31	167	180	O	XXXXXXXX
32	182	183	O	by
33	185	188	O	125%
34	190	192	O	and
35	194	196	O	36%
36	197	197	O	,
37	199	210	O	respectively
38	214	214	O	A
39	216	221	O	number
40	223	224	O	of
41	226	234	O	compounds
42	236	238	O	are
43	240	249	O	inhibitors
44	251	252	O	of
45	254	259	O	CYP2C9
46	261	269	O	including
47	271	281	U-UNK	fluconazole
48	282	282	O	,
49	284	293	U-UNK	lovastatin
50	295	297	O	and
51	299	310	U-UNK	trimethoprim
NULL

Mefenamic acid	DDI-DrugBank.d400.s15	NO_SECTION	NO_SETID	12
Drug interaction studies of mefenamic acid and these compounds have not been conducted.
1	0	3	O	Drug
2	5	15	O	interaction
3	17	23	O	studies
4	25	26	O	of
5	28	41	O	XXXXXXXX
6	43	45	O	and
7	47	51	O	these
8	53	61	O	compounds
9	63	66	O	have
10	68	70	O	not
11	72	75	O	been
12	77	85	O	conducted
NULL

Mefenamic acid	DDI-DrugBank.d400.s16	NO_SECTION	NO_SETID	18
The possibility of altered safety and efficacy should be considered when Ponstel is used concomitantly with these drugs.
1	0	2	O	The
2	4	14	O	possibility
3	16	17	O	of
4	19	25	O	altered
5	27	32	O	safety
6	34	36	O	and
7	38	45	O	efficacy
8	47	52	O	should
9	54	55	O	be
10	57	66	O	considered
11	68	71	O	when
12	73	79	O	XXXXXXXX
13	81	82	O	is
14	84	87	O	used
15	89	101	O	concomitantly
16	103	106	O	with
17	108	112	O	these
18	114	118	O	drugs
NULL

Mefloquine	DDI-DrugBank.d220.s0	NO_SECTION	NO_SETID	11
Drug-drug interactions with Mefloquine have not been explored in detail.
1	0	3	O	Drug
2	5	8	O	drug
3	10	21	O	interactions
4	23	26	O	with
5	28	37	O	XXXXXXXX
6	39	42	O	have
7	44	46	O	not
8	48	51	O	been
9	53	60	O	explored
10	62	63	O	in
11	65	70	O	detail
NULL

Mefloquine	DDI-DrugBank.d220.s1	NO_SECTION	NO_SETID	22
There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol).
1	0	4	O	There
2	6	7	O	is
3	9	11	O	one
4	13	18	O	report
5	20	21	O	of
6	23	37	O	cardiopulmonary
7	39	44	O	arrest
8	45	45	O	,
9	47	50	O	with
10	52	55	O	full
11	57	64	O	recovery
12	65	65	O	,
13	67	68	O	in
14	70	70	O	a
15	72	78	O	patient
16	80	82	O	who
17	84	86	O	was
18	88	93	O	taking
19	95	95	O	a
20	97	100	B-UNK	beta
21	102	108	L-UNK	blocker
22	111	121	U-UNK	propranolol
NULL

Mefloquine	DDI-DrugBank.d220.s2	NO_SECTION	NO_SETID	14
The effects of Mefloquineuine on the compromised cardiovascular system have not been evaluated.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	24	O	XXXXXXXX
5	25	28	O	uine
6	30	31	O	on
7	33	35	O	the
8	37	47	O	compromised
9	49	62	O	cardiovascular
10	64	69	O	system
11	71	74	O	have
12	76	78	O	not
13	80	83	O	been
14	85	93	O	evaluated
NULL

Mefloquine	DDI-DrugBank.d220.s3	NO_SECTION	NO_SETID	19
The benefits of Mefloquine therapy should be weighed against the possibility of adverse effects in patients with cardiac disease.
1	0	2	O	The
2	4	11	O	benefits
3	13	14	O	of
4	16	25	O	XXXXXXXX
5	27	33	O	therapy
6	35	40	O	should
7	42	43	O	be
8	45	51	O	weighed
9	53	59	O	against
10	61	63	O	the
11	65	75	O	possibility
12	77	78	O	of
13	80	86	O	adverse
14	88	94	O	effects
15	96	97	O	in
16	99	106	O	patients
17	108	111	O	with
18	113	119	O	cardiac
19	121	127	O	disease
NULL

Mefloquine	DDI-DrugBank.d220.s4	NO_SECTION	NO_SETID	25
Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	20	O	danger
5	22	23	O	of
6	25	25	O	a
7	27	37	O	potentially
8	39	43	O	fatal
9	45	56	O	prolongation
10	58	59	O	of
11	61	63	O	the
12	65	67	O	QTc
13	69	76	O	interval
14	77	77	O	,
15	79	90	U-DYN	halofantrine
16	92	95	O	must
17	97	99	O	not
18	101	102	O	be
19	104	108	O	given
20	110	123	O	simultaneously
21	125	128	O	with
22	130	131	O	or
23	133	142	O	subsequent
24	144	145	O	to
25	147	156	O	XXXXXXXX
NULL

Mefloquine	DDI-DrugBank.d220.s5	NO_SECTION	NO_SETID	25
Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	39	O	XXXXXXXX
5	41	43	O	and
6	45	49	O	other
7	51	57	O	related
8	59	67	O	compounds
9	70	71	O	eg
10	72	72	O	,
11	74	80	U-DYN	quinine
12	81	81	O	,
13	83	91	U-DYN	quinidine
14	93	95	O	and
15	97	107	U-DYN	chloroquine
16	110	112	O	may
17	114	120	O	produce
18	122	141	O	electrocardiographic
19	143	155	O	abnormalities
20	157	159	O	and
21	161	168	O	increase
22	170	172	O	the
23	174	177	O	risk
24	179	180	O	of
25	182	192	O	convulsions
NULL

Mefloquine	DDI-DrugBank.d220.s6	NO_SECTION	NO_SETID	28
If these drugs are to be used in the initial treatment of severe malaria, Mefloquine administration should be delayed at least 12 hours after the last dose.
1	0	1	O	If
2	3	7	O	these
3	9	13	O	drugs
4	15	17	O	are
5	19	20	O	to
6	22	23	O	be
7	25	28	O	used
8	30	31	O	in
9	33	35	O	the
10	37	43	O	initial
11	45	53	O	treatment
12	55	56	O	of
13	58	63	O	severe
14	65	71	O	malaria
15	72	72	O	,
16	74	83	O	XXXXXXXX
17	85	98	O	administration
18	100	105	O	should
19	107	108	O	be
20	110	116	O	delayed
21	118	119	O	at
22	121	125	O	least
23	127	128	O	12
24	130	134	O	hours
25	136	140	O	after
26	142	144	O	the
27	146	149	O	last
28	151	154	O	dose
NULL

Mefloquine	DDI-DrugBank.d220.s7	NO_SECTION	NO_SETID	19
There is evidence that the use of halofantrine after Mefloquineuine causes a significant lengthening of the QTc interval.
1	0	4	O	There
2	6	7	O	is
3	9	16	O	evidence
4	18	21	O	that
5	23	25	O	the
6	27	29	O	use
7	31	32	O	of
8	34	45	U-UNK	halofantrine
9	47	51	O	after
10	53	62	O	XXXXXXXX
11	63	66	O	uine
12	68	73	O	causes
13	75	75	O	a
14	77	87	O	significant
15	89	99	O	lengthening
16	101	102	O	of
17	104	106	O	the
18	108	110	O	QTc
19	112	119	O	interval
NULL

Mefloquine	DDI-DrugBank.d220.s8	NO_SECTION	NO_SETID	12
Clinically significant QTc prolongation has not been found with Mefloquineuine alone.
1	0	9	O	Clinically
2	11	21	O	significant
3	23	25	O	QTc
4	27	38	O	prolongation
5	40	42	O	has
6	44	46	O	not
7	48	51	O	been
8	53	57	O	found
9	59	62	O	with
10	64	73	O	XXXXXXXX
11	74	77	O	uine
12	79	83	O	alone
NULL

Mefloquine	DDI-DrugBank.d220.s9	NO_SECTION	NO_SETID	61
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
1	0	3	O	This
2	5	11	O	appears
3	13	14	O	to
4	16	17	O	be
5	19	21	O	the
6	23	26	O	only
7	28	37	O	clinically
8	39	46	O	relevant
9	48	58	O	interaction
10	60	61	O	of
11	63	66	O	this
12	68	71	O	kind
13	73	76	O	with
14	78	87	O	XXXXXXXX
15	88	88	O	,
16	90	97	O	although
17	99	111	O	theoretically
18	112	112	O	,
19	114	129	O	coadministration
20	131	132	O	of
21	134	138	O	other
22	140	144	O	drugs
23	146	150	O	known
24	152	153	O	to
25	155	159	O	alter
26	161	167	O	cardiac
27	169	178	O	conduction
28	181	182	O	eg
29	183	183	O	,
30	185	188	B-DYN	anti
31	190	199	L-DYN	arrhythmic
32	201	202	O	or
33	204	207	B-DYN	beta
34	209	218	I-DYN	adrenergic
35	220	227	I-DYN	blocking
36	229	234	L-DYN	agents
37	235	235	O	,
38	237	243	B-DYN	calcium
39	245	251	I-DYN	channel
40	253	260	L-DYN	blockers
41	261	261	O	,
42	263	276	U-DYN	antihistamines
43	278	279	O	or
44	281	282	B-DYN	H1
45	284	291	I-DYN	blocking
46	293	298	L-DYN	agents
47	299	299	O	,
48	301	309	B-DYN	tricyclic
49	311	325	L-DYN	antidepressants
50	327	329	O	and
51	331	344	U-DYN	phenothiazines
52	347	351	O	might
53	353	356	O	also
54	358	367	O	contribute
55	369	370	O	to
56	372	372	O	a
57	374	385	O	prolongation
58	387	388	O	of
59	390	392	O	the
60	394	396	O	QTc
61	398	405	O	interval
NULL

Mefloquine	DDI-DrugBank.d220.s10	NO_SECTION	NO_SETID	25
There are no data that conclusively establish whether the concomitant administration of Mefloquineuine and the above listed agents has an effect on cardiac function.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	16	O	data
5	18	21	O	that
6	23	34	O	conclusively
7	36	44	O	establish
8	46	52	O	whether
9	54	56	O	the
10	58	68	O	concomitant
11	70	83	O	administration
12	85	86	O	of
13	88	97	O	XXXXXXXX
14	98	101	O	uine
15	103	105	O	and
16	107	109	O	the
17	111	115	O	above
18	117	122	O	listed
19	124	129	O	agents
20	131	133	O	has
21	135	136	O	an
22	138	143	O	effect
23	145	146	O	on
24	148	154	O	cardiac
25	156	163	O	function
NULL

Mefloquine	DDI-DrugBank.d220.s11	NO_SECTION	NO_SETID	33
In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	20	O	an
5	22	35	U-DYN	anticonvulsant
6	38	39	O	eg
7	40	40	O	,
8	42	49	B-DYN	valproic
9	51	54	L-DYN	acid
10	55	55	O	,
11	57	69	U-DYN	carbamazepine
12	70	70	O	,
13	72	84	U-DYN	phenobarbital
14	86	87	O	or
15	89	97	U-DYN	phenytoin
16	99	99	O	,
17	101	103	O	the
18	105	115	O	concomitant
19	117	119	O	use
20	121	122	O	of
21	124	133	O	XXXXXXXX
22	135	137	O	may
23	139	144	O	reduce
24	146	152	O	seizure
25	154	160	O	control
26	162	163	O	by
27	165	172	O	lowering
28	174	176	O	the
29	178	183	O	plasma
30	185	190	O	levels
31	192	193	O	of
32	195	197	O	the
33	199	212	U-UNK	anticonvulsant
NULL

Mefloquine	DDI-DrugBank.d220.s12	NO_SECTION	NO_SETID	24
Therefore, patients concurrently taking antiseizure medication and Mefloquine should have the blood level of their antiseizure medication monitored and the dosage adjusted appropriately.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	O	patients
4	20	31	O	concurrently
5	33	38	O	taking
6	40	50	O	antiseizure
7	52	61	O	medication
8	63	65	O	and
9	67	76	O	XXXXXXXX
10	78	83	O	should
11	85	88	O	have
12	90	92	O	the
13	94	98	O	blood
14	100	104	O	level
15	106	107	O	of
16	109	113	O	their
17	115	125	O	antiseizure
18	127	136	O	medication
19	138	146	O	monitored
20	148	150	O	and
21	152	154	O	the
22	156	161	O	dosage
23	163	170	O	adjusted
24	172	184	O	appropriately
NULL

Mefloquine	DDI-DrugBank.d220.s13	NO_SECTION	NO_SETID	17
When Mefloquine is taken concurrently with oral live typhoid vaccines, attenuation of immunization cannot be excluded.
1	0	3	O	When
2	5	14	O	XXXXXXXX
3	16	17	O	is
4	19	23	O	taken
5	25	36	O	concurrently
6	38	41	O	with
7	43	46	O	oral
8	48	51	B-DYN	live
9	53	59	I-DYN	typhoid
10	61	68	L-DYN	vaccines
11	69	69	O	,
12	71	81	O	attenuation
13	83	84	O	of
14	86	97	O	immunization
15	99	104	O	cannot
16	106	107	O	be
17	109	116	O	excluded
NULL

Mefloquine	DDI-DrugBank.d220.s14	NO_SECTION	NO_SETID	19
Vaccinations with attenuated live bacteria should therefore be completed at least 3 days before the first dose of Mefloquine.
1	0	11	O	Vaccinations
2	13	16	O	with
3	18	27	O	attenuated
4	29	32	O	live
5	34	41	O	bacteria
6	43	48	O	should
7	50	58	O	therefore
8	60	61	O	be
9	63	71	O	completed
10	73	74	O	at
11	76	80	O	least
12	82	82	O	3
13	84	87	O	days
14	89	94	O	before
15	96	98	O	the
16	100	104	O	first
17	106	109	O	dose
18	111	112	O	of
19	114	123	O	XXXXXXXX
NULL

Mefloquine	DDI-DrugBank.d220.s15	NO_SECTION	NO_SETID	6
No other drug interactions are known.
1	0	1	O	No
2	3	7	O	other
3	9	12	O	drug
4	14	25	O	interactions
5	27	29	O	are
6	31	35	O	known
NULL

Mefloquine	DDI-DrugBank.d220.s16	NO_SECTION	NO_SETID	23
Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	16	O	the
4	18	24	O	effects
5	26	27	O	of
6	29	38	O	XXXXXXXX
7	40	41	O	on
8	43	51	O	travelers
9	53	61	O	receiving
10	63	74	O	comedication
11	75	75	O	,
12	77	88	O	particularly
13	90	98	O	diabetics
14	100	101	O	or
15	103	110	O	patients
16	112	116	O	using
17	118	131	U-DYN	anticoagulants
18	132	132	O	,
19	134	139	O	should
20	141	142	O	be
21	144	150	O	checked
22	152	157	O	before
23	159	167	O	departure
NULL

Mefloquine	DDI-DrugBank.d220.s17	NO_SECTION	NO_SETID	18
In clinical trials, the concomitant administration of sulfadoxine and pyrimethamine did not alter the adverse reaction profile.
1	0	1	O	In
2	3	10	O	clinical
3	12	17	O	trials
4	18	18	O	,
5	20	22	O	the
6	24	34	O	concomitant
7	36	49	O	administration
8	51	52	O	of
9	54	64	U-UNK	sulfadoxine
10	66	68	O	and
11	70	82	U-UNK	pyrimethamine
12	84	86	O	did
13	88	90	O	not
14	92	96	O	alter
15	98	100	O	the
16	102	108	O	adverse
17	110	117	O	reaction
18	119	125	O	profile
NULL

Menadione	DDI-DrugBank.d139.s0	NO_SECTION	NO_SETID	23
Broad-Spectrum Antibiotics-Broad-spectrum antibiotics may sterilize the bowel and decrease the vitamin K contribution to the body by the intestinal microflora.
1	0	4	B-UNK	Broad
2	6	13	I-UNK	Spectrum
3	15	25	L-UNK	Antibiotics
4	27	31	B-UNK	Broad
5	33	40	I-UNK	spectrum
6	42	52	L-UNK	antibiotics
7	54	56	O	may
8	58	66	O	sterilize
9	68	70	O	the
10	72	76	O	bowel
11	78	80	O	and
12	82	89	O	decrease
13	91	93	O	the
14	95	101	B-UNK	vitamin
15	103	103	L-UNK	K
16	105	116	O	contribution
17	118	119	O	to
18	121	123	O	the
19	125	128	O	body
20	130	131	O	by
21	133	135	O	the
22	137	146	O	intestinal
23	148	157	O	microflora
NULL

Menadione	DDI-DrugBank.d139.s1	NO_SECTION	NO_SETID	27
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.
1	0	13	U-UNK	Cephalosporins
2	15	28	U-UNK	Cephalosporins
3	30	39	O	containing
4	41	44	O	side
5	46	51	O	chains
6	53	54	O	of
7	56	56	O	N
8	58	76	O	methylthiotetrazole
9	79	89	U-UNK	cefmenoxime
10	90	90	O	,
11	92	103	U-UNK	cefoperazone
12	104	104	O	,
13	106	114	U-UNK	cefotetan
14	115	115	O	,
15	117	127	U-UNK	cefamandole
16	128	128	O	,
17	130	138	U-UNK	latamoxef
18	141	142	O	or
19	144	160	O	methylthiadiazole
20	163	171	U-UNK	cefazolin
21	174	176	O	can
22	178	182	O	cause
23	184	190	O	vitamin
24	192	192	O	K
25	194	203	O	deficiency
26	205	207	O	and
27	209	227	O	hypoprothrombinemia
NULL

Menadione	DDI-DrugBank.d139.s2	NO_SECTION	NO_SETID	10
These cephalosporins are inhibitors of hepatic vitamin K epoxide reductase.
1	0	4	O	These
2	6	19	U-UNK	cephalosporins
3	21	23	O	are
4	25	34	O	inhibitors
5	36	37	O	of
6	39	45	O	hepatic
7	47	53	O	vitamin
8	55	55	O	K
9	57	63	O	epoxide
10	65	73	O	reductase
NULL

Menadione	DDI-DrugBank.d139.s3	NO_SECTION	NO_SETID	15
Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.
1	0	13	U-UNK	Cholestyramine
2	15	25	O	Concomitant
3	27	32	O	intake
4	34	35	O	of
5	37	50	U-UNK	cholestyramine
6	52	54	O	and
7	56	62	B-UNK	vitamin
8	64	64	L-UNK	K
9	66	68	O	may
10	70	75	O	reduce
11	77	79	O	the
12	81	90	O	absorption
13	92	93	O	of
14	95	101	B-UNK	vitamin
15	103	103	L-UNK	K
NULL

Menadione	DDI-DrugBank.d139.s4	NO_SECTION	NO_SETID	15
Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.
1	0	9	U-UNK	Colestipol
2	11	21	O	Concomitant
3	23	28	O	intake
4	30	31	O	of
5	33	42	U-UNK	colestipol
6	44	46	O	and
7	48	54	B-UNK	vitamin
8	56	56	L-UNK	K
9	58	60	O	may
10	62	67	O	reduce
11	69	71	O	the
12	73	82	O	absorption
13	84	85	O	of
14	87	93	B-UNK	vitamin
15	95	95	L-UNK	K
NULL

Menadione	DDI-DrugBank.d139.s5	NO_SECTION	NO_SETID	17
Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.
1	0	6	B-UNK	Mineral
2	8	10	L-UNK	Oil
3	12	22	O	Concomitant
4	24	29	O	intake
5	31	32	O	of
6	34	40	B-UNK	mineral
7	42	44	L-UNK	oil
8	46	48	O	and
9	50	56	B-UNK	vitamin
10	58	58	L-UNK	K
11	60	62	O	may
12	64	69	O	reduce
13	71	73	O	the
14	75	84	O	absorption
15	86	87	O	of
16	89	95	B-UNK	vitamin
17	97	97	L-UNK	K
NULL

Menadione	DDI-DrugBank.d139.s6	NO_SECTION	NO_SETID	9
Orlistat-Orlistat may decrease the absorption of vitamin K.
1	0	7	U-UNK	Orlistat
2	9	16	U-UNK	Orlistat
3	18	20	O	may
4	22	29	O	decrease
5	31	33	O	the
6	35	44	O	absorption
7	46	47	O	of
8	49	55	B-UNK	vitamin
9	57	57	L-UNK	K
NULL

Menadione	DDI-DrugBank.d139.s7	NO_SECTION	NO_SETID	16
Salicylates-Salicylates in large doses may inhibit vitamin K epoxide reductase resulting in vitamin K deficiency.
1	0	10	U-UNK	Salicylates
2	12	22	U-UNK	Salicylates
3	24	25	O	in
4	27	31	O	large
5	33	37	O	doses
6	39	41	O	may
7	43	49	O	inhibit
8	51	57	O	vitamin
9	59	59	O	K
10	61	67	O	epoxide
11	69	77	O	reductase
12	79	87	O	resulting
13	89	90	O	in
14	92	98	O	vitamin
15	100	100	O	K
16	102	111	O	deficiency
NULL

Menadione	DDI-DrugBank.d139.s8	NO_SECTION	NO_SETID	9
Warfarin-Vitamin K can antagonize the effect of warfarin
1	0	7	U-UNK	Warfarin
2	9	15	B-UNK	Vitamin
3	17	17	L-UNK	K
4	19	21	O	can
5	23	32	O	antagonize
6	34	36	O	the
7	38	43	O	effect
8	45	46	O	of
9	48	55	U-UNK	warfarin
NULL

Nabilone	DDI-DrugBank.d552.s0	NO_SECTION	NO_SETID	41
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
1	0	7	O	XXXXXXXX
2	9	14	O	should
3	16	17	O	be
4	19	30	O	administered
5	32	35	O	with
6	37	43	O	caution
7	45	46	O	to
8	48	55	O	patients
9	57	59	O	who
10	61	63	O	are
11	65	70	O	taking
12	72	76	O	other
13	78	89	B-DYN	psychoactive
14	91	95	L-DYN	drugs
15	97	98	O	or
16	100	102	B-DYN	CNS
17	104	114	L-DYN	depressants
18	115	115	O	,
19	117	125	O	including
20	127	133	U-DYN	alcohol
21	134	134	O	,
22	136	147	U-DYN	barbiturates
23	149	151	O	and
24	153	160	B-DYN	narcotic
25	162	171	L-DYN	analgesics
26	172	172	O	,
27	174	175	O	or
28	177	178	O	to
29	180	184	O	those
30	186	189	O	with
31	191	191	O	a
32	193	199	O	history
33	201	202	O	of
34	204	214	O	psychiatric
35	216	223	O	disorder
36	226	234	O	including
37	236	240	O	manic
38	242	251	O	depressive
39	253	259	O	illness
40	261	263	O	and
41	265	277	O	schizophrenia
NULL

Nabilone	DDI-DrugBank.d552.s1	NO_SECTION	NO_SETID	22
Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
1	0	7	U-DYN	Nabilone
2	9	11	O	has
3	13	16	O	been
4	18	22	O	shown
5	24	25	O	to
6	27	30	O	have
7	32	33	O	an
8	35	42	O	additive
9	44	46	O	CNS
10	48	57	O	depressant
11	59	64	O	effect
12	66	69	O	when
13	71	75	O	given
14	77	80	O	with
15	82	87	O	either
16	89	96	U-UNK	diazepam
17	97	97	O	,
18	99	118	O	XXXXXXXX
19	119	119	O	,
20	121	127	U-UNK	alcohol
21	129	130	O	or
22	132	138	U-UNK	codeine
NULL

Nabumetone	DDI-DrugBank.d174.s0	NO_SECTION	NO_SETID	25
In vitro studies have shown that, because of its affinity for protein, 6MNA may displace other protein-bound drugs from their binding site.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	26	O	shown
6	28	31	O	that
7	32	32	O	,
8	34	40	O	because
9	42	43	O	of
10	45	47	O	its
11	49	56	O	affinity
12	58	60	O	for
13	62	68	O	protein
14	69	69	O	,
15	71	74	U-UNK	6MNA
16	76	78	O	may
17	80	87	O	displace
18	89	93	O	other
19	95	101	O	protein
20	103	107	O	bound
21	109	113	O	drugs
22	115	118	O	from
23	120	124	O	their
24	126	132	O	binding
25	134	137	O	site
NULL

Nabumetone	DDI-DrugBank.d174.s1	NO_SECTION	NO_SETID	17
Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	45	O	administering
7	47	56	O	XXXXXXXX
8	58	61	O	with
9	63	70	U-DYN	warfarin
10	72	76	O	since
11	78	89	O	interactions
12	91	94	O	have
13	96	99	O	been
14	101	104	O	seen
15	106	109	O	with
16	111	115	O	other
17	117	122	U-UNK	NSAIDs
NULL

Nabumetone	DDI-DrugBank.d174.s2	NO_SECTION	NO_SETID	16
Concomitant administration of an aluminum-containing antacid had no significant effect in the bioavailability of 6MNA.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	31	O	an
5	33	40	U-UNK	aluminum
6	42	51	O	containing
7	53	59	U-UNK	antacid
8	61	63	O	had
9	65	66	O	no
10	68	78	O	significant
11	80	85	O	effect
12	87	88	O	in
13	90	92	O	the
14	94	108	O	bioavailability
15	110	111	O	of
16	113	116	U-UNK	6MNA
NULL

Nabumetone	DDI-DrugBank.d174.s3	NO_SECTION	NO_SETID	12
When administered with food or milk, there is more rapid absorption;
1	0	3	O	When
2	5	16	O	administered
3	18	21	O	with
4	23	26	O	food
5	28	29	O	or
6	31	34	O	milk
7	35	35	O	,
8	37	41	O	there
9	43	44	O	is
10	46	49	O	more
11	51	55	O	rapid
12	57	66	O	absorption
NULL

Nabumetone	DDI-DrugBank.d174.s4	NO_SECTION	NO_SETID	12
however, the total amount of 6MNA in the plasma is unchanged .
1	0	6	O	however
2	7	7	O	,
3	9	11	O	the
4	13	17	O	total
5	19	24	O	amount
6	26	27	O	of
7	29	32	U-UNK	6MNA
8	34	35	O	in
9	37	39	O	the
10	41	46	O	plasma
11	48	49	O	is
12	51	59	O	unchanged
NULL

Nadolol	DDI-DrugBank.d204.s0	NO_SECTION	NO_SETID	28
When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.
1	0	3	O	When
2	5	16	O	administered
3	18	29	O	concurrently
4	30	30	O	,
5	32	34	O	the
6	36	44	O	following
7	46	50	O	drugs
8	52	54	O	may
9	56	63	O	interact
10	65	68	O	with
11	70	73	B-UNK	beta
12	75	84	I-UNK	adrenergic
13	86	93	I-UNK	receptor
14	95	102	I-UNK	blocking
15	104	109	L-UNK	agents
16	110	110	O	:
17	112	122	U-UNK	Anesthetics
18	123	123	O	,
19	125	131	O	general
20	132	132	O	:
21	134	145	O	exaggeration
22	147	148	O	of
23	150	152	O	the
24	154	164	O	hypotension
25	166	172	O	induced
26	174	175	O	by
27	177	183	O	general
28	185	195	U-UNK	anesthetics
NULL

Nadolol	DDI-DrugBank.d204.s1	NO_SECTION	NO_SETID	10
Antidiabetic drugs (oral agents and insulin): hypoglycemia or hyperglycemia;
1	0	11	B-UNK	Antidiabetic
2	13	17	L-UNK	drugs
3	20	23	O	oral
4	25	30	O	agents
5	32	34	O	and
6	36	42	U-UNK	insulin
7	44	44	O	:
8	46	57	O	hypoglycemia
9	59	60	O	or
10	62	74	O	hyperglycemia
NULL

Nadolol	DDI-DrugBank.d204.s2	NO_SECTION	NO_SETID	6
adjust dosage of antidiabetic drug accordingly.
1	0	5	O	adjust
2	7	12	O	dosage
3	14	15	O	of
4	17	28	B-UNK	antidiabetic
5	30	33	L-UNK	drug
6	35	45	O	accordingly
NULL

Nadolol	DDI-DrugBank.d204.s3	NO_SECTION	NO_SETID	9
Catecholamine-depleting drugs (e.g., reserpine): additive effect;
1	0	12	O	Catecholamine
2	14	22	O	depleting
3	24	28	O	drugs
4	31	33	O	e.g
5	35	35	O	,
6	37	45	U-UNK	reserpine
7	47	47	O	:
8	49	56	O	additive
9	58	63	O	effect
NULL

Nadolol	DDI-DrugBank.d204.s4	NO_SECTION	NO_SETID	19
monitor closely for evidence of hypotension and/or excessive bradycardia (e.g., vertigo, syncope, postural hypotension).
1	0	6	O	monitor
2	8	14	O	closely
3	16	18	O	for
4	20	27	O	evidence
5	29	30	O	of
6	32	42	O	hypotension
7	44	46	O	and
8	47	47	O	/
9	48	49	O	or
10	51	59	O	excessive
11	61	71	O	bradycardia
12	74	76	O	e.g
13	78	78	O	,
14	80	86	O	vertigo
15	87	87	O	,
16	89	95	O	syncope
17	96	96	O	,
18	98	105	O	postural
19	107	117	O	hypotension
NULL

Nadolol	DDI-DrugBank.d204.s5	NO_SECTION	NO_SETID	40
Response to Treatment for Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.
1	0	7	O	Response
2	9	10	O	to
3	12	20	O	Treatment
4	22	24	O	for
5	26	37	O	Anaphylactic
6	39	46	O	Reaction
7	47	47	O	:
8	49	53	O	While
9	55	60	O	taking
10	62	65	B-UNK	beta
11	67	74	L-UNK	blockers
12	75	75	O	,
13	77	84	O	patients
14	86	89	O	with
15	91	91	O	a
16	93	99	O	history
17	101	102	O	of
18	104	109	O	severe
19	111	122	O	anaphylactic
20	124	131	O	reaction
21	133	134	O	to
22	136	136	O	a
23	138	144	O	variety
24	146	147	O	of
25	149	157	O	allergens
26	159	161	O	may
27	163	164	O	be
28	166	169	O	more
29	171	178	O	reactive
30	180	181	O	to
31	183	190	O	repeated
32	192	200	O	challenge
33	201	201	O	,
34	203	208	O	either
35	210	219	O	accidental
36	220	220	O	,
37	222	231	O	diagnostic
38	232	232	O	,
39	234	235	O	or
40	237	247	O	therapeutic
NULL

Nadolol	DDI-DrugBank.d204.s6	NO_SECTION	NO_SETID	16
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
1	0	3	O	Such
2	5	12	O	patients
3	14	16	O	may
4	18	19	O	be
5	21	32	O	unresponsive
6	34	35	O	to
7	37	39	O	the
8	41	45	O	usual
9	47	51	O	doses
10	53	54	O	of
11	56	66	U-UNK	epinephrine
12	68	71	O	used
13	73	74	O	to
14	76	80	O	treat
15	82	89	O	allergic
16	91	98	O	reaction
NULL

Nafarelin	DDI-DrugBank.d218.s0	NO_SECTION	NO_SETID	12
No pharmacokinetic-based drug-drug interaction studies have been conducted with SYNAREL.
1	0	1	O	No
2	3	17	O	pharmacokinetic
3	19	23	O	based
4	25	28	O	drug
5	30	33	O	drug
6	35	45	O	interaction
7	47	53	O	studies
8	55	58	O	have
9	60	63	O	been
10	65	73	O	conducted
11	75	78	O	with
12	80	86	O	XXXXXXXX
NULL

Nafarelin	DDI-DrugBank.d218.s1	NO_SECTION	NO_SETID	45
However, because nafarelin acetate is a peptide that is primarily degraded by peptidase and not by cytochrome P-450 enzymes, and the drug is only about 80% bound to plasma proteins at 4 C, drug interactions would not be expected to occur.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	because
4	17	25	O	XXXXXXXX
5	27	33	O	acetate
6	35	36	O	is
7	38	38	O	a
8	40	46	O	peptide
9	48	51	O	that
10	53	54	O	is
11	56	64	O	primarily
12	66	73	O	degraded
13	75	76	O	by
14	78	86	O	peptidase
15	88	90	O	and
16	92	94	O	not
17	96	97	O	by
18	99	108	O	cytochrome
19	110	110	O	P
20	112	114	O	450
21	116	122	O	enzymes
22	123	123	O	,
23	125	127	O	and
24	129	131	O	the
25	133	136	O	drug
26	138	139	O	is
27	141	144	O	only
28	146	150	O	about
29	152	154	O	80%
30	156	160	O	bound
31	162	163	O	to
32	165	170	O	plasma
33	172	179	O	proteins
34	181	182	O	at
35	184	184	O	4
36	186	186	O	C
37	187	187	O	,
38	189	192	O	drug
39	194	205	O	interactions
40	207	211	O	would
41	213	215	O	not
42	217	218	O	be
43	220	227	O	expected
44	229	230	O	to
45	232	236	O	occur
NULL

Nafcillin	DDI-DrugBank.d261.s0	NO_SECTION	NO_SETID	22
Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
1	0	11	U-UNK	Tetracycline
2	12	12	O	,
3	14	14	O	a
4	16	29	B-UNK	bacteriostatic
5	31	40	L-UNK	antibiotic
6	41	41	O	,
7	43	45	O	may
8	47	56	O	antagonize
9	58	60	O	the
10	62	73	O	bactericidal
11	75	80	O	effect
12	82	83	O	of
13	85	94	U-UNK	penicillin
14	96	98	O	and
15	100	109	O	concurrent
16	111	113	O	use
17	115	116	O	of
18	118	122	O	these
19	124	128	O	drugs
20	130	135	O	should
21	137	138	O	be
22	140	146	O	avoided
NULL

Nalbuphine	DDI-DrugBank.d37.s0	NO_SECTION	NO_SETID	4
No specific information available
1	0	1	O	No
2	3	10	O	specific
3	12	22	O	information
4	24	32	O	available
NULL

Nalidixic Acid	DDI-DrugBank.d427.s0	NO_SECTION	NO_SETID	12
Elevated plasma levels of theophylline have been reported with concomitant quinolone use.
1	0	7	O	Elevated
2	9	14	O	plasma
3	16	21	O	levels
4	23	24	O	of
5	26	37	U-UNK	theophylline
6	39	42	O	have
7	44	47	O	been
8	49	56	O	reported
9	58	61	O	with
10	63	73	O	concomitant
11	75	83	U-UNK	quinolone
12	85	87	O	use
NULL

Nalidixic Acid	DDI-DrugBank.d427.s1	NO_SECTION	NO_SETID	18
There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	22	O	reports
5	24	25	O	of
6	27	38	U-UNK	theophylline
7	40	46	O	related
8	48	51	O	side
9	53	59	O	effects
10	61	62	O	in
11	64	71	O	patients
12	73	74	O	on
13	76	86	O	concomitant
14	88	94	O	therapy
15	96	99	O	with
16	101	110	U-UNK	quinolones
17	112	114	O	and
18	116	127	U-UNK	theophylline
NULL

Nalidixic Acid	DDI-DrugBank.d427.s2	NO_SECTION	NO_SETID	18
Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted, as required.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	monitoring
4	22	23	O	of
5	25	36	U-UNK	theophylline
6	38	43	O	plasma
7	45	50	O	levels
8	52	57	O	should
9	59	60	O	be
10	62	71	O	considered
11	73	75	O	and
12	77	82	O	dosage
13	84	85	O	of
14	87	98	U-UNK	theophylline
15	100	107	O	adjusted
16	108	108	O	,
17	110	111	O	as
18	113	120	O	required
NULL

Nalidixic Acid	DDI-DrugBank.d427.s3	NO_SECTION	NO_SETID	11
Quinolones have been shown to interfere with the metabolism of caffeine.
1	0	9	U-UNK	Quinolones
2	11	14	O	have
3	16	19	O	been
4	21	25	O	shown
5	27	28	O	to
6	30	38	O	interfere
7	40	43	O	with
8	45	47	O	the
9	49	58	O	metabolism
10	60	61	O	of
11	63	70	U-UNK	caffeine
NULL

Nalidixic Acid	DDI-DrugBank.d427.s4	NO_SECTION	NO_SETID	16
This may lead to reduced clearance of caffeine and the prolongation of its plasma half-life.
1	0	3	O	This
2	5	7	O	may
3	9	12	O	lead
4	14	15	O	to
5	17	23	O	reduced
6	25	33	O	clearance
7	35	36	O	of
8	38	45	U-UNK	caffeine
9	47	49	O	and
10	51	53	O	the
11	55	66	O	prolongation
12	68	69	O	of
13	71	73	O	its
14	75	80	O	plasma
15	82	85	O	half
16	87	90	O	life
NULL

Nalidixic Acid	DDI-DrugBank.d427.s5	NO_SECTION	NO_SETID	17
Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.
1	0	9	U-UNK	Quinolones
2	10	10	O	,
3	12	20	O	including
4	22	35	O	XXXXXXXX
5	36	36	O	,
6	38	40	O	may
7	42	48	O	enhance
8	50	52	O	the
9	54	60	O	effects
10	62	63	O	of
11	65	67	O	the
12	69	72	O	oral
13	74	86	U-UNK	anticoagulant
14	88	95	U-DYN	warfarin
15	97	98	O	or
16	100	102	O	its
17	104	114	O	derivatives
NULL

Nalidixic Acid	DDI-DrugBank.d427.s6	NO_SECTION	NO_SETID	18
When these products are administered concomitantly, prothrombin time or other suitable coagulation test should be closely monitored.
1	0	3	O	When
2	5	9	O	these
3	11	18	O	products
4	20	22	O	are
5	24	35	O	administered
6	37	49	O	concomitantly
7	50	50	O	,
8	52	62	O	prothrombin
9	64	67	O	time
10	69	70	O	or
11	72	76	O	other
12	78	85	O	suitable
13	87	97	O	coagulation
14	99	102	O	test
15	104	109	O	should
16	111	112	O	be
17	114	120	O	closely
18	122	130	O	monitored
NULL

Nalidixic Acid	DDI-DrugBank.d427.s7	NO_SECTION	NO_SETID	8
Nitrofurantoin interferes with the therapeutic action of nalidixic acid.
1	0	13	U-DYN	Nitrofurantoin
2	15	24	O	interferes
3	26	29	O	with
4	31	33	O	the
5	35	45	O	therapeutic
6	47	52	O	action
7	54	55	O	of
8	57	70	O	XXXXXXXX
NULL

Nalidixic Acid	DDI-DrugBank.d427.s8	NO_SECTION	NO_SETID	8
Antacids containing magnesium, aluminum, or calcium;
1	0	7	U-UNK	Antacids
2	9	18	O	containing
3	20	28	U-UNK	magnesium
4	29	29	O	,
5	31	38	U-UNK	aluminum
6	39	39	O	,
7	41	42	O	or
8	44	50	U-UNK	calcium
NULL

Nalidixic Acid	DDI-DrugBank.d427.s9	NO_SECTION	NO_SETID	9
sucralfate or divalent or trivalent cations such as iron;
1	0	9	U-UNK	sucralfate
2	11	12	O	or
3	14	21	O	divalent
4	23	24	O	or
5	26	34	O	trivalent
6	36	42	O	cations
7	44	47	O	such
8	49	50	O	as
9	52	55	U-UNK	iron
NULL

Nalidixic Acid	DDI-DrugBank.d427.s10	NO_SECTION	NO_SETID	3
multivitamins containing zinc;
1	0	12	U-UNK	multivitamins
2	14	23	O	containing
3	25	28	U-UNK	zinc
NULL

Nalidixic Acid	DDI-DrugBank.d427.s11	NO_SECTION	NO_SETID	33
and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.
1	0	2	O	and
2	4	8	O	XXXXXXXX
3	10	10	O	,
4	13	22	U-UNK	Didanosine
5	24	24	O	,
6	26	33	O	chewable
7	34	34	O	/
8	35	42	O	buffered
9	44	50	O	tablets
10	52	53	O	or
11	55	57	O	the
12	59	67	O	pediatric
13	69	74	O	powder
14	76	78	O	for
15	80	83	O	oral
16	85	92	O	solution
17	94	96	O	may
18	98	110	O	substantially
19	112	120	O	interfere
20	122	125	O	with
21	127	129	O	the
22	131	140	O	absorption
23	142	143	O	of
24	145	154	U-KIN	quinolones
25	155	155	O	,
26	157	165	O	resulting
27	167	168	O	in
28	170	177	O	systemic
29	179	184	O	levels
30	186	197	O	considerably
31	199	203	O	lower
32	205	208	O	than
33	210	216	O	desired
NULL

Nalidixic Acid	DDI-DrugBank.d427.s12	NO_SECTION	NO_SETID	21
These agents should not be taken within the two hour period before or within the two-hour period after nalidixic acid administration.
1	0	4	O	These
2	6	11	O	agents
3	13	18	O	should
4	20	22	O	not
5	24	25	O	be
6	27	31	O	taken
7	33	38	O	within
8	40	42	O	the
9	44	46	O	two
10	48	51	O	hour
11	53	58	O	period
12	60	65	O	before
13	67	68	O	or
14	70	75	O	within
15	77	79	O	the
16	81	83	O	two
17	85	88	O	hour
18	90	95	O	period
19	97	101	O	after
20	103	116	O	XXXXXXXX
21	118	131	O	administration
NULL

Nalidixic Acid	DDI-DrugBank.d427.s13	NO_SECTION	NO_SETID	17
Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.
1	0	7	O	Elevated
2	9	13	O	serum
3	15	20	O	levels
4	22	23	O	of
5	25	36	U-UNK	cyclosporine
6	38	41	O	have
7	43	46	O	been
8	48	55	O	reported
9	57	60	O	with
10	62	64	O	the
11	66	76	O	concomitant
12	78	80	O	use
13	82	83	O	of
14	85	88	O	some
15	90	99	U-UNK	quinolones
16	101	103	O	and
17	105	116	U-UNK	cyclosporine
NULL

Nalidixic Acid	DDI-DrugBank.d427.s14	NO_SECTION	NO_SETID	20
Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.
1	0	8	O	Therefore
2	9	9	O	,
3	11	22	U-UNK	cyclosporine
4	24	28	O	serum
5	30	35	O	levels
6	37	42	O	should
7	44	45	O	be
8	47	55	O	monitored
9	57	59	O	and
10	61	71	O	appropriate
11	73	84	U-UNK	cyclosporine
12	86	91	O	dosage
13	93	103	O	adjustments
14	105	108	O	made
15	110	113	O	when
16	115	119	O	these
17	121	125	O	drugs
18	127	129	O	are
19	131	134	O	used
20	136	148	O	concomitantly
NULL

Naltrexone	DDI-DrugBank.d346.s0	NO_SECTION	NO_SETID	16
Studies to evaluate possible interactions between REVIA and drugs other than opiates have not been performed.
1	0	6	O	Studies
2	8	9	O	to
3	11	18	O	evaluate
4	20	27	O	possible
5	29	40	O	interactions
6	42	48	O	between
7	50	54	O	XXXXXXXX
8	56	58	O	and
9	60	64	O	drugs
10	66	70	O	other
11	72	75	O	than
12	77	83	U-UNK	opiates
13	85	88	O	have
14	90	92	O	not
15	94	97	O	been
16	99	107	O	performed
NULL

Naltrexone	DDI-DrugBank.d346.s1	NO_SECTION	NO_SETID	16
Consequently, caution is advised if the concomitant administration of REVIA and other drugs is required.
1	0	11	O	Consequently
2	12	12	O	,
3	14	20	O	caution
4	22	23	O	is
5	25	31	O	advised
6	33	34	O	if
7	36	38	O	the
8	40	50	O	concomitant
9	52	65	O	administration
10	67	68	O	of
11	70	74	O	XXXXXXXX
12	76	78	O	and
13	80	84	O	other
14	86	90	O	drugs
15	92	93	O	is
16	95	102	O	required
NULL

Naltrexone	DDI-DrugBank.d346.s2	NO_SECTION	NO_SETID	35
The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.
1	0	2	O	The
2	4	9	O	safety
3	11	13	O	and
4	15	22	O	efficacy
5	24	25	O	of
6	27	37	O	concomitant
7	39	41	O	use
8	43	44	O	of
9	46	50	O	XXXXXXXX
10	52	54	O	and
11	56	65	U-DYN	disulfiram
12	67	68	O	is
13	70	76	O	unknown
14	77	77	O	,
15	79	81	O	and
16	83	85	O	the
17	87	97	O	concomitant
18	99	101	O	use
19	103	104	O	of
20	106	108	O	two
21	110	120	O	potentially
22	122	132	O	hepatotoxic
23	134	144	O	medications
24	146	147	O	is
25	149	151	O	not
26	153	162	O	ordinarily
27	164	174	O	recommended
28	176	181	O	unless
29	183	185	O	the
30	187	194	O	probable
31	196	203	O	benefits
32	205	212	O	outweigh
33	214	216	O	the
34	218	222	O	known
35	224	228	O	risks
NULL

Naltrexone	DDI-DrugBank.d346.s3	NO_SECTION	NO_SETID	12
Lethargy and somnolence have been reported following doses of REVIA and thioridazine.
1	0	7	O	Lethargy
2	9	11	O	and
3	13	22	O	somnolence
4	24	27	O	have
5	29	32	O	been
6	34	41	O	reported
7	43	51	O	following
8	53	57	O	doses
9	59	60	O	of
10	62	66	O	XXXXXXXX
11	68	70	O	and
12	72	83	U-DYN	thioridazine
NULL

Naltrexone	DDI-DrugBank.d346.s4	NO_SECTION	NO_SETID	24
Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.
1	0	7	O	Patients
2	9	14	O	taking
3	16	20	O	XXXXXXXX
4	22	24	O	may
5	26	28	O	not
6	30	36	O	benefit
7	38	41	O	from
8	43	48	U-DYN	opioid
9	50	59	O	containing
10	61	69	O	medicines
11	70	70	O	,
12	72	75	O	such
13	77	78	O	as
14	80	84	O	cough
15	86	88	O	and
16	90	93	O	cold
17	95	106	O	preparations
18	107	107	O	,
19	109	121	O	antidiarrheal
20	123	134	O	preparations
21	135	135	O	,
22	137	139	O	and
23	141	146	B-DYN	opioid
24	148	157	L-DYN	analgesics
NULL

Naltrexone	DDI-DrugBank.d346.s5	NO_SECTION	NO_SETID	38
In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.
1	0	1	O	In
2	3	4	O	an
3	6	14	O	emergency
4	16	24	O	situation
5	26	29	O	when
6	31	36	O	opioid
7	38	46	O	analgesia
8	48	51	O	must
9	53	54	O	be
10	56	67	O	administered
11	69	70	O	to
12	72	72	O	a
13	74	80	O	patient
14	82	90	O	receiving
15	92	96	O	XXXXXXXX
16	97	97	O	,
17	99	101	O	the
18	103	108	O	amount
19	110	111	O	of
20	113	118	U-DYN	opioid
21	120	127	O	required
22	129	131	O	may
23	133	134	O	be
24	136	142	O	greater
25	144	147	O	than
26	149	153	O	usual
27	154	154	O	,
28	156	158	O	and
29	160	162	O	the
30	164	172	O	resulting
31	174	184	O	respiratory
32	186	195	O	depression
33	197	199	O	may
34	201	202	O	be
35	204	209	O	deeper
36	211	213	O	and
37	215	218	O	more
38	220	228	O	prolonged
NULL

Naproxen	DDI-DrugBank.d85.s0	NO_SECTION	NO_SETID	16
The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	16	U-UNK	NSAIDs
5	18	19	O	in
6	21	28	O	patients
7	30	32	O	who
8	34	36	O	are
9	38	46	O	receiving
10	48	50	B-UNK	ACE
11	52	61	L-UNK	inhibitors
12	63	65	O	may
13	67	76	O	potentiate
14	78	82	O	renal
15	84	90	O	disease
16	92	97	O	states
NULL

Naproxen	DDI-DrugBank.d85.s1	NO_SECTION	NO_SETID	29
In vitro studies have shown that naproxen anion, because of its affinity for protein, may displace from their binding sites other drugs which are also albumin-bound .
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	26	O	shown
6	28	31	O	that
7	33	40	O	XXXXXXXX
8	42	46	O	anion
9	47	47	O	,
10	49	55	O	because
11	57	58	O	of
12	60	62	O	its
13	64	71	O	affinity
14	73	75	O	for
15	77	83	O	protein
16	84	84	O	,
17	86	88	O	may
18	90	97	O	displace
19	99	102	O	from
20	104	108	O	their
21	110	116	O	binding
22	118	122	O	sites
23	124	128	O	other
24	130	134	O	drugs
25	136	140	O	which
26	142	144	O	are
27	146	149	O	also
28	151	157	O	albumin
29	159	163	O	bound
NULL

Naproxen	DDI-DrugBank.d85.s2	NO_SECTION	NO_SETID	10
Theoretically, the naproxen anion itself could likewise be displaced.
1	0	12	O	Theoretically
2	13	13	O	,
3	15	17	O	the
4	19	26	O	XXXXXXXX
5	28	32	O	anion
6	34	39	O	itself
7	41	45	O	could
8	47	54	O	likewise
9	56	57	O	be
10	59	67	O	displaced
NULL

Naproxen	DDI-DrugBank.d85.s3	NO_SECTION	NO_SETID	23
Short-term controlled studies failed to show that taking the drug significantly affects prothrombin times when administered to individuals on coumarin-type anticoagulants.
1	0	4	O	Short
2	6	9	O	term
3	11	20	O	controlled
4	22	28	O	studies
5	30	35	O	failed
6	37	38	O	to
7	40	43	O	show
8	45	48	O	that
9	50	55	O	taking
10	57	59	O	the
11	61	64	O	drug
12	66	78	O	significantly
13	80	86	O	affects
14	88	98	O	prothrombin
15	100	104	O	times
16	106	109	O	when
17	111	122	O	administered
18	124	125	O	to
19	127	137	O	individuals
20	139	140	O	on
21	142	149	B-UNK	coumarin
22	151	154	I-UNK	type
23	156	169	L-UNK	anticoagulants
NULL

Naproxen	DDI-DrugBank.d85.s4	NO_SECTION	NO_SETID	17
Caution is advised nonetheless, since interactions have been seen with other nonsteroidal agents of this class.
1	0	6	O	Caution
2	8	9	O	is
3	11	17	O	advised
4	19	29	O	nonetheless
5	30	30	O	,
6	32	36	O	since
7	38	49	O	interactions
8	51	54	O	have
9	56	59	O	been
10	61	64	O	seen
11	66	69	O	with
12	71	75	O	other
13	77	88	O	nonsteroidal
14	90	95	O	agents
15	97	98	O	of
16	100	103	O	this
17	105	109	O	class
NULL

Naproxen	DDI-DrugBank.d85.s5	NO_SECTION	NO_SETID	23
Similarly, patients receiving the drug and a hydantoin, sulfonamide or sulfonylurea should be observed for signs of toxicity to these drugs.
1	0	8	O	Similarly
2	9	9	O	,
3	11	18	O	patients
4	20	28	O	receiving
5	30	32	O	the
6	34	37	O	drug
7	39	41	O	and
8	43	43	O	a
9	45	53	U-UNK	hydantoin
10	54	54	O	,
11	56	66	U-UNK	sulfonamide
12	68	69	O	or
13	71	82	U-UNK	sulfonylurea
14	84	89	O	should
15	91	92	O	be
16	94	101	O	observed
17	103	105	O	for
18	107	111	O	signs
19	113	114	O	of
20	116	123	O	toxicity
21	125	126	O	to
22	128	132	O	these
23	134	138	O	drugs
NULL

Naproxen	DDI-DrugBank.d85.s6	NO_SECTION	NO_SETID	33
Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	37	U-DYN	naproxen
5	39	41	O	and
6	43	49	O	XXXXXXXX
7	51	52	O	is
8	54	56	O	not
9	58	68	O	recommended
10	70	76	O	because
11	78	85	U-DYN	naproxen
12	87	88	O	is
13	90	98	O	displaced
14	100	103	O	from
15	105	107	O	its
16	109	115	O	binding
17	117	121	O	sites
18	123	128	O	during
19	130	132	O	the
20	134	144	O	concomitant
21	146	159	O	administration
22	161	162	O	of
23	164	170	O	XXXXXXXX
24	171	171	O	,
25	173	181	O	resulting
26	183	184	O	in
27	186	190	O	lower
28	192	197	O	plasma
29	199	212	O	concentrations
30	214	216	O	and
31	218	221	O	peak
32	223	228	O	plasma
33	230	235	O	levels
NULL

Naproxen	DDI-DrugBank.d85.s7	NO_SECTION	NO_SETID	17
The natriuretic effect of furosemide has been reported to be inhibited by some drugs of this class.
1	0	2	O	The
2	4	14	O	natriuretic
3	16	21	O	effect
4	23	24	O	of
5	26	35	U-UNK	furosemide
6	37	39	O	has
7	41	44	O	been
8	46	53	O	reported
9	55	56	O	to
10	58	59	O	be
11	61	69	O	inhibited
12	71	72	O	by
13	74	77	O	some
14	79	83	O	drugs
15	85	86	O	of
16	88	91	O	this
17	93	97	O	class
NULL

Naproxen	DDI-DrugBank.d85.s8	NO_SECTION	NO_SETID	16
Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.
1	0	9	O	Inhibition
2	11	12	O	of
3	14	18	O	renal
4	20	26	U-UNK	lithium
5	28	36	O	clearance
6	38	44	O	leading
7	46	47	O	to
8	49	57	O	increases
9	59	60	O	in
10	62	67	O	plasma
11	69	75	U-UNK	lithium
12	77	90	O	concentrations
13	92	94	O	has
14	96	99	O	also
15	101	104	O	been
16	106	113	O	reported
NULL

Naproxen	DDI-DrugBank.d85.s9	NO_SECTION	NO_SETID	15
Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
1	0	7	O	XXXXXXXX
2	9	11	O	and
3	13	17	O	other
4	19	24	U-UNK	NSAIDs
5	26	28	O	can
6	30	35	O	reduce
7	37	39	O	the
8	41	56	O	antihypertensive
9	58	63	O	effect
10	65	66	O	of
11	68	78	U-DYN	propranolol
12	80	82	O	and
13	84	88	O	other
14	90	93	B-DYN	beta
15	95	102	L-DYN	blockers
NULL

Naproxen	DDI-DrugBank.d85.s10	NO_SECTION	NO_SETID	15
Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.
1	0	9	U-KIN	Probenecid
2	11	15	O	given
3	17	28	O	concurrently
4	30	38	O	increases
5	40	47	O	XXXXXXXX
6	49	53	O	anion
7	55	60	O	plasma
8	62	67	O	levels
9	69	71	O	and
10	73	79	O	extends
11	81	83	O	its
12	85	90	O	plasma
13	92	95	O	half
14	97	100	O	life
15	102	114	O	significantly
NULL

Naproxen	DDI-DrugBank.d85.s11	NO_SECTION	NO_SETID	11
Caution should be used if naproxen is administered concomitantly with methotrexate.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	24	O	if
6	26	33	O	XXXXXXXX
7	35	36	O	is
8	38	49	O	administered
9	51	63	O	concomitantly
10	65	68	O	with
11	70	81	U-DYN	methotrexate
NULL

Naproxen	DDI-DrugBank.d85.s12	NO_SECTION	NO_SETID	28
Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
1	0	7	O	XXXXXXXX
2	8	8	O	,
3	10	17	O	XXXXXXXX
4	19	24	O	sodium
5	26	28	O	and
6	30	34	O	other
7	36	41	U-UNK	NSAIDs
8	43	46	O	have
9	48	51	O	been
10	53	60	O	reported
11	62	63	O	to
12	65	70	O	reduce
13	72	74	O	the
14	76	82	O	tubular
15	84	92	O	secretion
16	94	95	O	of
17	97	108	U-KIN	methotrexate
18	110	111	O	in
19	113	114	O	an
20	116	121	O	animal
21	123	127	O	model
22	128	128	O	,
23	130	137	O	possibly
24	139	148	O	increasing
25	150	152	O	the
26	154	161	O	toxicity
27	163	164	O	of
28	166	177	U-UNK	methotrexate
NULL

Naproxen	DDI-DrugBank.d85.s13	NO_SECTION	NO_SETID	14
Drug/Laboratory Test Interactions Naproxen may decrease platelet aggregation and prolong bleeding time.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	41	O	XXXXXXXX
7	43	45	O	may
8	47	54	O	decrease
9	56	63	O	platelet
10	65	75	O	aggregation
11	77	79	O	and
12	81	87	O	prolong
13	89	96	O	bleeding
14	98	101	O	time
NULL

Naproxen	DDI-DrugBank.d85.s14	NO_SECTION	NO_SETID	12
This effect should be kept in mind when bleeding times are determined.
1	0	3	O	This
2	5	10	O	effect
3	12	17	O	should
4	19	20	O	be
5	22	25	O	kept
6	27	28	O	in
7	30	33	O	mind
8	35	38	O	when
9	40	47	O	bleeding
10	49	53	O	times
11	55	57	O	are
12	59	68	O	determined
NULL

Naproxen	DDI-DrugBank.d85.s15	NO_SECTION	NO_SETID	33
The administration of naproxen may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-dinitrobenzene used in this assay.
1	0	2	O	The
2	4	17	O	administration
3	19	20	O	of
4	22	29	O	XXXXXXXX
5	31	33	O	may
6	35	40	O	result
7	42	43	O	in
8	45	53	O	increased
9	55	61	O	urinary
10	63	68	O	values
11	70	72	O	for
12	74	75	O	17
13	77	85	O	ketogenic
14	87	94	O	steroids
15	96	102	O	because
16	104	105	O	of
17	107	108	O	an
18	110	120	O	interaction
19	122	128	O	between
20	130	132	O	the
21	134	137	O	drug
22	139	141	O	and
23	142	142	O	/
24	143	144	O	or
25	146	148	O	its
26	150	160	O	metabolites
27	162	165	O	with
28	167	167	O	m
29	169	182	O	dinitrobenzene
30	184	187	O	used
31	189	190	O	in
32	192	195	O	this
33	197	201	O	assay
NULL

Naproxen	DDI-DrugBank.d85.s16	NO_SECTION	NO_SETID	43
Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with naproxen be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used.
1	0	7	O	Although
2	9	10	O	17
3	12	18	O	hydroxy
4	20	33	O	corticosteroid
5	35	46	O	measurements
6	49	54	O	Porter
7	56	61	O	Silber
8	63	66	O	test
9	69	70	O	do
10	72	74	O	not
11	76	81	O	appear
12	83	84	O	to
13	86	87	O	be
14	89	101	O	artifactually
15	103	109	O	altered
16	110	110	O	,
17	112	113	O	it
18	115	116	O	is
19	118	126	O	suggested
20	128	131	O	that
21	133	139	O	therapy
22	141	144	O	with
23	146	153	O	XXXXXXXX
24	155	156	O	be
25	158	168	O	temporarily
26	170	181	O	discontinued
27	183	184	O	72
28	186	190	O	hours
29	192	197	O	before
30	199	205	O	adrenal
31	207	214	O	function
32	216	220	O	tests
33	222	224	O	are
34	226	234	O	performed
35	236	237	O	if
36	239	241	O	the
37	243	248	O	Porter
38	250	255	O	Silber
39	257	260	O	test
40	262	263	O	is
41	265	266	O	to
42	268	269	O	be
43	271	274	O	used
NULL

Naproxen	DDI-DrugBank.d85.s17	NO_SECTION	NO_SETID	13
Naproxen may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA).
1	0	7	O	XXXXXXXX
2	9	11	O	may
3	13	21	O	interfere
4	23	26	O	with
5	28	31	O	some
6	33	39	O	urinary
7	41	46	O	assays
8	48	49	O	of
9	51	51	O	5
10	53	59	O	hydroxy
11	61	72	O	indoleacetic
12	74	77	O	acid
13	80	84	O	5HIAA
NULL

Naratriptan	DDI-DrugBank.d478.s0	NO_SECTION	NO_SETID	11
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions.
1	0	4	U-UNK	Ergot
2	6	15	O	containing
3	17	21	O	drugs
4	23	26	O	have
5	28	31	O	been
6	33	40	O	reported
7	42	43	O	to
8	45	49	O	cause
9	51	59	O	prolonged
10	61	71	O	vasospastic
11	73	81	O	reactions
NULL

Naratriptan	DDI-DrugBank.d478.s1	NO_SECTION	NO_SETID	32
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.
1	0	6	O	Because
2	8	12	O	there
3	14	15	O	is
4	17	17	O	a
5	19	29	O	theoretical
6	31	35	O	basis
7	37	40	O	that
8	42	46	O	these
9	48	54	O	effects
10	56	58	O	may
11	60	61	O	be
12	63	70	O	additive
13	71	71	O	,
14	73	75	O	use
15	77	78	O	of
16	80	89	U-DYN	ergotamine
17	91	100	O	containing
18	102	103	O	or
19	105	109	B-DYN	ergot
20	111	114	I-DYN	type
21	116	126	L-DYN	medications
22	129	132	O	like
23	134	150	U-DYN	dihydroergotamine
24	152	153	O	or
25	155	166	U-DYN	methysergide
26	169	171	O	and
27	173	183	O	XXXXXXXX
28	185	190	O	within
29	192	193	O	24
30	195	199	O	hours
31	201	202	O	is
32	204	218	O	contraindicated
NULL

Naratriptan	DDI-DrugBank.d478.s2	NO_SECTION	NO_SETID	16
The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients.
1	0	2	O	The
2	4	17	O	administration
3	19	20	O	of
4	22	32	O	XXXXXXXX
5	34	37	O	with
6	39	43	O	other
7	45	45	B-UNK	5
8	47	49	I-UNK	HT1
9	51	58	L-UNK	agonists
10	60	62	O	has
11	64	66	O	not
12	68	71	O	been
13	73	81	O	evaluated
14	83	84	O	in
15	86	93	O	migraine
16	95	102	O	patients
NULL

Naratriptan	DDI-DrugBank.d478.s3	NO_SECTION	NO_SETID	25
Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.
1	0	6	O	Because
2	8	12	O	their
3	14	24	O	vasospastic
4	26	32	O	effects
5	34	36	O	may
6	38	39	O	be
7	41	48	O	additive
8	49	49	O	,
9	51	66	O	coadministration
10	68	69	O	of
11	71	81	O	XXXXXXXX
12	83	85	O	and
13	87	91	O	other
14	93	93	B-DYN	5
15	95	97	I-DYN	HT1
16	99	106	L-DYN	agonists
17	108	113	O	within
18	115	116	O	24
19	118	122	O	hours
20	124	125	O	of
21	127	130	O	each
22	132	136	O	other
23	138	139	O	is
24	141	143	O	not
25	145	155	O	recommended
NULL

Naratriptan	DDI-DrugBank.d478.s4	NO_SECTION	NO_SETID	34
Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.
1	0	8	B-UNK	Selective
2	10	18	I-UNK	serotonin
3	20	27	I-UNK	reuptake
4	29	38	L-UNK	inhibitors
5	41	45	U-UNK	SSRIs
6	49	51	O	e.g
7	53	53	O	,
8	55	64	U-UNK	fluoxetine
9	65	65	O	,
10	67	77	U-UNK	fluvoxamine
11	78	78	O	,
12	80	89	U-UNK	paroxetine
13	90	90	O	,
14	92	101	U-UNK	sertraline
15	104	107	O	have
16	109	112	O	been
17	114	121	O	reported
18	122	122	O	,
19	124	129	O	rarely
20	130	130	O	,
21	132	133	O	to
22	135	139	O	cause
23	141	148	O	weakness
24	149	149	O	,
25	151	163	O	hyperreflexia
26	164	164	O	,
27	166	168	O	and
28	170	183	O	incoordination
29	185	188	O	when
30	190	203	O	coadministered
31	205	208	O	with
32	210	210	O	5
33	212	214	O	HTv
34	216	223	O	agonists
NULL

Naratriptan	DDI-DrugBank.d478.s5	NO_SECTION	NO_SETID	19
If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
1	0	1	O	If
2	3	13	O	concomitant
3	15	23	O	treatment
4	25	28	O	with
5	30	40	O	XXXXXXXX
6	42	44	O	and
7	46	47	O	an
8	49	52	U-DYN	SSRI
9	54	55	O	is
10	57	66	O	clinically
11	68	76	O	warranted
12	77	77	O	,
13	79	89	O	appropriate
14	91	101	O	observation
15	103	104	O	of
16	106	108	O	the
17	110	116	O	patient
18	118	119	O	is
19	121	127	O	advised
NULL

Naratriptan	DDI-DrugBank.d478.s6	NO_SECTION	NO_SETID	18
Drug/ Laboratory Test Interactions AMERGE Tablets are not known to interfere with commonly employed clinical laboratory tests.
1	0	3	O	Drug
2	4	4	O	/
3	6	15	O	Laboratory
4	17	20	O	Test
5	22	33	O	Interactions
6	35	40	O	XXXXXXXX
7	42	48	O	Tablets
8	50	52	O	are
9	54	56	O	not
10	58	62	O	known
11	64	65	O	to
12	67	75	O	interfere
13	77	80	O	with
14	82	89	O	commonly
15	91	98	O	employed
16	100	107	O	clinical
17	109	118	O	laboratory
18	120	124	O	tests
NULL

Natalizumab	DDI-DrugBank.d232.s0	NO_SECTION	NO_SETID	19
After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.
1	0	4	O	After
2	6	13	O	multiple
3	15	20	O	dosing
4	21	21	O	,
5	23	32	B-KIN	interferon
6	34	37	I-KIN	beta
7	39	40	L-KIN	1a
8	43	48	O	AVONEX
9	51	52	O	30
10	54	56	O	mcg
11	58	59	O	IM
12	61	64	O	once
13	66	71	O	weekly
14	74	80	O	reduced
15	82	88	U-KIN	XXXXXXXX
16	91	99	O	clearance
17	101	102	O	by
18	104	116	O	approximately
19	118	120	O	30%
NULL

Natalizumab	DDI-DrugBank.d232.s1	NO_SECTION	NO_SETID	42
The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).
1	0	2	O	The
2	4	13	O	similarity
3	15	16	O	of
4	18	20	O	the
5	22	28	O	XXXXXXXX
6	31	40	O	associated
7	42	48	O	adverse
8	50	54	O	event
9	56	62	O	profile
10	64	70	O	between
11	72	76	O	Study
12	78	78	O	1
13	81	87	O	without
14	89	90	O	co
15	92	103	O	administered
16	105	110	O	AVONEX
17	114	116	O	and
18	118	122	O	Study
19	124	124	O	2
20	127	130	O	with
21	132	133	O	co
22	135	146	O	administered
23	148	153	O	AVONEX
24	157	165	O	indicates
25	167	170	O	that
26	172	175	O	this
27	177	186	O	alteration
28	188	189	O	in
29	191	199	O	clearance
30	201	204	O	does
31	206	208	O	not
32	210	220	O	necessitate
33	222	230	O	reduction
34	232	233	O	of
35	235	237	O	the
36	239	245	O	XXXXXXXX
37	248	251	O	dose
38	253	254	O	to
39	256	263	O	maintain
40	265	270	O	safety
41	271	271	O	,
42	273	279	O	General
NULL

Natalizumab	DDI-DrugBank.d232.s2	NO_SECTION	NO_SETID	40
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.
1	0	6	O	Results
2	8	9	O	of
3	11	17	O	studies
4	19	20	O	in
5	22	29	O	multiple
6	31	39	O	sclerosis
7	41	48	O	patients
8	50	55	O	taking
9	57	63	O	TYSABRI
10	66	68	O	and
11	70	80	O	concomitant
12	82	91	B-UNK	interferon
13	93	96	I-UNK	beta
14	98	99	L-UNK	1a
15	102	107	O	XXXXXXXX
16	110	111	O	30
17	113	115	O	mcg
18	117	118	O	IM
19	120	123	O	once
20	125	130	O	weekly
21	133	134	O	or
22	136	145	B-UNK	glatiramer
23	147	153	L-UNK	acetate
24	155	158	O	were
25	160	171	O	inconclusive
26	173	176	O	with
27	178	183	O	regard
28	185	186	O	to
29	188	190	O	the
30	192	195	O	need
31	197	199	O	for
32	201	204	O	dose
33	206	215	O	adjustment
34	217	218	O	of
35	220	222	O	the
36	224	227	B-UNK	beta
37	229	238	L-UNK	interferon
38	240	241	O	or
39	243	252	B-UNK	glatiramer
40	254	260	L-UNK	acetate
NULL

Nateglinide	DDI-DrugBank.d460.s0	NO_SECTION	NO_SETID	25
In vitro drug metabolism studies indicate that Starlix is predominantly metabolized by the cytochrome P450 isozyme CYP2C9 (70%) and to a lesser extent CYP3A4 (30%).
1	0	1	O	In
2	3	7	O	vitro
3	9	12	O	drug
4	14	23	O	metabolism
5	25	31	O	studies
6	33	40	O	indicate
7	42	45	O	that
8	47	53	O	XXXXXXXX
9	55	56	O	is
10	58	70	O	predominantly
11	72	82	O	metabolized
12	84	85	O	by
13	87	89	O	the
14	91	100	O	cytochrome
15	102	105	O	P450
16	107	113	O	isozyme
17	115	120	O	CYP2C9
18	123	125	O	70%
19	128	130	O	and
20	132	133	O	to
21	135	135	O	a
22	137	142	O	lesser
23	144	149	O	extent
24	151	156	O	CYP3A4
25	159	161	O	30%
NULL

Nateglinide	DDI-DrugBank.d460.s1	NO_SECTION	NO_SETID	24
Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	11	O	a
4	13	21	O	potential
5	23	31	O	inhibitor
6	33	34	O	of
7	36	38	O	the
8	40	45	O	CYP2C9
9	47	55	O	isoenzyme
10	57	58	O	in
11	60	63	O	vivo
12	65	66	O	as
13	68	76	O	indicated
14	78	79	O	by
15	81	83	O	its
16	85	91	O	ability
17	93	94	O	to
18	96	102	O	inhibit
19	104	106	O	the
20	108	109	O	in
21	111	115	O	vitro
22	117	126	O	metabolism
23	128	129	O	of
24	131	141	U-KIN	tolbutamide
NULL

Nateglinide	DDI-DrugBank.d460.s2	NO_SECTION	NO_SETID	12
Inhibition of CYP3A4 metabolic reactions was not detected in in vitro experiments.
1	0	9	O	Inhibition
2	11	12	O	of
3	14	19	O	CYP3A4
4	21	29	O	metabolic
5	31	39	O	reactions
6	41	43	O	was
7	45	47	O	not
8	49	56	O	detected
9	58	59	O	in
10	61	62	O	in
11	64	68	O	vitro
12	70	80	O	experiments
NULL

Nateglinide	DDI-DrugBank.d460.s3	NO_SECTION	NO_SETID	37
Glyburide: In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg Starlix three times a day before meals for 1 day in combination with glyburide 10 mg daily.
1	0	8	U-UNK	Glyburide
2	9	9	O	:
3	11	12	O	In
4	14	14	O	a
5	16	25	O	randomized
6	26	26	O	,
7	28	35	O	multiple
8	37	40	O	dose
9	42	50	O	crossover
10	52	56	O	study
11	57	57	O	,
12	59	66	O	patients
13	68	71	O	with
14	73	76	O	Type
15	78	78	O	2
16	80	87	O	diabetes
17	89	92	O	were
18	94	105	O	administered
19	107	109	O	120
20	111	112	O	mg
21	114	120	O	XXXXXXXX
22	122	126	O	three
23	128	132	O	times
24	134	134	O	a
25	136	138	O	day
26	140	145	O	before
27	147	151	O	meals
28	153	155	O	for
29	157	157	O	1
30	159	161	O	day
31	163	164	O	in
32	166	176	O	combination
33	178	181	O	with
34	183	191	U-UNK	glyburide
35	193	194	O	10
36	196	197	O	mg
37	199	203	O	daily
NULL

Nateglinide	DDI-DrugBank.d460.s4	NO_SECTION	NO_SETID	12
There were no clinically relevant alterations in the pharmacokinetics of either agent.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	23	O	clinically
5	25	32	O	relevant
6	34	44	O	alterations
7	46	47	O	in
8	49	51	O	the
9	53	68	O	pharmacokinetics
10	70	71	O	of
11	73	78	O	either
12	80	84	O	agent
NULL

Nateglinide	DDI-DrugBank.d460.s5	NO_SECTION	NO_SETID	41
Metformin: When Starlix 120 mg three times daily before meals was administered in combination with metformin 500 mg three times daily to patients with Type 2 diabetes, there were no clinically relevant changes in the pharmacokinetics of either agent.
1	0	8	U-UNK	Metformin
2	9	9	O	:
3	11	14	O	When
4	16	22	O	XXXXXXXX
5	24	26	O	120
6	28	29	O	mg
7	31	35	O	three
8	37	41	O	times
9	43	47	O	daily
10	49	54	O	before
11	56	60	O	meals
12	62	64	O	was
13	66	77	O	administered
14	79	80	O	in
15	82	92	O	combination
16	94	97	O	with
17	99	107	U-UNK	metformin
18	109	111	O	500
19	113	114	O	mg
20	116	120	O	three
21	122	126	O	times
22	128	132	O	daily
23	134	135	O	to
24	137	144	O	patients
25	146	149	O	with
26	151	154	O	Type
27	156	156	O	2
28	158	165	O	diabetes
29	166	166	O	,
30	168	172	O	there
31	174	177	O	were
32	179	180	O	no
33	182	191	O	clinically
34	193	200	O	relevant
35	202	208	O	changes
36	210	211	O	in
37	213	215	O	the
38	217	232	O	pharmacokinetics
39	234	235	O	of
40	237	242	O	either
41	244	248	O	agent
NULL

Nateglinide	DDI-DrugBank.d460.s6	NO_SECTION	NO_SETID	36
Digoxin: When Starlix 120 mg before meals was administered in combination with a single 1-mg dose of digoxin to healthy volunteers, there were no clinically relevant changes in the pharmacokinetics of either agent.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	12	O	When
4	14	20	O	XXXXXXXX
5	22	24	O	120
6	26	27	O	mg
7	29	34	O	before
8	36	40	O	meals
9	42	44	O	was
10	46	57	O	administered
11	59	60	O	in
12	62	72	O	combination
13	74	77	O	with
14	79	79	O	a
15	81	86	O	single
16	88	88	O	1
17	90	91	O	mg
18	93	96	O	dose
19	98	99	O	of
20	101	107	U-UNK	digoxin
21	109	110	O	to
22	112	118	O	healthy
23	120	129	O	volunteers
24	130	130	O	,
25	132	136	O	there
26	138	141	O	were
27	143	144	O	no
28	146	155	O	clinically
29	157	164	O	relevant
30	166	172	O	changes
31	174	175	O	in
32	177	179	O	the
33	181	196	O	pharmacokinetics
34	198	199	O	of
35	201	206	O	either
36	208	212	O	agent
NULL

Nateglinide	DDI-DrugBank.d460.s7	NO_SECTION	NO_SETID	42
Warfarin: When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	13	O	When
4	15	21	O	healthy
5	23	30	O	subjects
6	32	35	O	were
7	37	48	O	administered
8	50	56	O	XXXXXXXX
9	58	60	O	120
10	62	63	O	mg
11	65	69	O	three
12	71	75	O	times
13	77	81	O	daily
14	83	88	O	before
15	90	94	O	meals
16	96	98	O	for
17	100	103	O	four
18	105	108	O	days
19	110	111	O	in
20	113	123	O	combination
21	125	128	O	with
22	130	130	O	a
23	132	137	O	single
24	139	142	O	dose
25	144	145	O	of
26	147	154	U-UNK	warfarin
27	156	157	O	30
28	159	160	O	mg
29	162	163	O	on
30	165	167	O	day
31	169	169	O	2
32	170	170	O	,
33	172	176	O	there
34	178	181	O	were
35	183	184	O	no
36	186	196	O	alterations
37	198	199	O	in
38	201	203	O	the
39	205	220	O	pharmacokinetics
40	222	223	O	of
41	225	230	O	either
42	232	236	O	agent
NULL

Nateglinide	DDI-DrugBank.d460.s8	NO_SECTION	NO_SETID	5
Prothrombin time was not affected.
1	0	10	O	Prothrombin
2	12	15	O	time
3	17	19	O	was
4	21	23	O	not
5	25	32	O	affected
NULL

Nateglinide	DDI-DrugBank.d460.s9	NO_SECTION	NO_SETID	36
Diclofenac: Administration of morning and lunch doses of Starlix 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.
1	0	9	U-UNK	Diclofenac
2	10	10	O	:
3	12	25	O	Administration
4	27	28	O	of
5	30	36	O	morning
6	38	40	O	and
7	42	46	O	lunch
8	48	52	O	doses
9	54	55	O	of
10	57	63	O	XXXXXXXX
11	65	67	O	120
12	69	70	O	mg
13	72	73	O	in
14	75	85	O	combination
15	87	90	O	with
16	92	92	O	a
17	94	99	O	single
18	101	102	O	75
19	104	105	O	mg
20	107	110	O	dose
21	112	113	O	of
22	115	124	U-UNK	diclofenac
23	126	127	O	in
24	129	135	O	healthy
25	137	146	O	volunteers
26	148	155	O	resulted
27	157	158	O	in
28	160	161	O	no
29	163	173	O	significant
30	175	181	O	changes
31	183	184	O	to
32	186	188	O	the
33	190	205	O	pharmacokinetics
34	207	208	O	of
35	210	215	O	either
36	217	221	O	agent
NULL

Nateglinide	DDI-DrugBank.d460.s10	NO_SECTION	NO_SETID	11
Nateglinide is highly bound to plasma proteins (98%), mainly albumin.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	20	O	highly
4	22	26	O	bound
5	28	29	O	to
6	31	36	O	plasma
7	38	45	O	proteins
8	48	50	O	98%
9	52	52	O	,
10	54	59	O	mainly
11	61	67	O	albumin
NULL

Nateglinide	DDI-DrugBank.d460.s11	NO_SECTION	NO_SETID	44
In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
1	0	1	O	In
2	3	7	O	vitro
3	9	20	O	displacement
4	22	28	O	studies
5	30	33	O	with
6	35	40	O	highly
7	42	48	O	protein
8	50	54	O	bound
9	56	60	O	drugs
10	62	65	O	such
11	67	68	O	as
12	70	79	U-UNK	furosemide
13	80	80	O	,
14	82	92	U-UNK	propranolol
15	93	93	O	,
16	95	103	U-UNK	captopril
17	104	104	O	,
18	106	116	U-UNK	nicardipine
19	117	117	O	,
20	119	129	U-UNK	pravastatin
21	130	130	O	,
22	132	140	U-UNK	glyburide
23	141	141	O	,
24	143	150	U-UNK	warfarin
25	151	151	O	,
26	153	161	U-UNK	phenytoin
27	162	162	O	,
28	164	178	B-UNK	acetylsalicylic
29	180	183	L-UNK	acid
30	184	184	O	,
31	186	196	U-UNK	tolbutamide
32	197	197	O	,
33	199	201	O	and
34	203	211	U-UNK	metformin
35	213	218	O	showed
36	220	221	O	no
37	223	231	O	influence
38	233	234	O	on
39	236	238	O	the
40	240	245	O	extent
41	247	248	O	of
42	250	260	O	XXXXXXXX
43	262	268	O	protein
44	270	276	O	binding
NULL

Nateglinide	DDI-DrugBank.d460.s12	NO_SECTION	NO_SETID	29
Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .
1	0	8	O	Similarly
2	9	9	O	,
3	11	21	O	XXXXXXXX
4	23	25	O	had
5	27	28	O	no
6	30	38	O	influence
7	40	41	O	on
8	43	45	O	the
9	47	51	O	serum
10	53	59	O	protein
11	61	67	O	binding
12	69	70	O	of
13	72	82	U-UNK	propranolol
14	83	83	O	,
15	85	93	U-UNK	glyburide
16	94	94	O	,
17	96	106	U-UNK	nicardipine
18	107	107	O	,
19	109	116	U-UNK	warfarin
20	117	117	O	,
21	119	127	U-UNK	phenytoin
22	128	128	O	,
23	130	144	B-UNK	acetylsalicylic
24	146	149	L-UNK	acid
25	150	150	O	,
26	152	154	O	and
27	156	166	U-UNK	tolbutamide
28	168	169	O	in
29	171	175	O	vitro
NULL

Nateglinide	DDI-DrugBank.d460.s13	NO_SECTION	NO_SETID	13
However, prudent evaluation of individual cases is warranted in the clinical setting.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	prudent
4	17	26	O	evaluation
5	28	29	O	of
6	31	40	O	individual
7	42	46	O	cases
8	48	49	O	is
9	51	59	O	warranted
10	61	62	O	in
11	64	66	O	the
12	68	75	O	clinical
13	77	83	O	setting
NULL

Nateglinide	DDI-DrugBank.d460.s14	NO_SECTION	NO_SETID	35
Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
1	0	6	O	Certain
2	8	12	O	drugs
3	13	13	O	,
4	15	23	O	including
5	25	36	B-DYN	nonsteroidal
6	38	41	I-DYN	anti
7	43	54	I-DYN	inflammatory
8	56	61	L-DYN	agents
9	64	69	U-DYN	NSAIDs
10	71	71	O	,
11	73	83	U-DYN	salicylates
12	84	84	O	,
13	86	94	B-DYN	monoamine
14	96	102	I-DYN	oxidase
15	104	113	L-DYN	inhibitors
16	114	114	O	,
17	116	118	O	and
18	120	122	B-DYN	non
19	124	132	I-DYN	selective
20	134	137	I-DYN	beta
21	139	148	I-DYN	adrenergic
22	150	157	I-DYN	blocking
23	159	164	L-DYN	agents
24	166	168	O	may
25	170	179	O	potentiate
26	181	183	O	the
27	185	196	O	hypoglycemic
28	198	203	O	action
29	205	206	O	of
30	208	214	O	XXXXXXXX
31	216	218	O	and
32	220	224	O	other
33	226	229	O	oral
34	231	242	B-UNK	antidiabetic
35	244	248	L-UNK	drugs
NULL

Nateglinide	DDI-DrugBank.d460.s15	NO_SECTION	NO_SETID	24
Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
1	0	6	O	Certain
2	8	12	O	drugs
3	14	22	O	including
4	24	32	U-DYN	thiazides
5	33	33	O	,
6	35	49	U-DYN	corticosteroids
7	50	50	O	,
8	52	58	B-DYN	thyroid
9	60	67	L-DYN	products
10	68	68	O	,
11	70	72	O	and
12	74	89	U-DYN	sympathomimetics
13	91	93	O	may
14	95	100	O	reduce
15	102	104	O	the
16	106	117	O	hypoglycemic
17	119	124	O	action
18	126	127	O	of
19	129	135	O	XXXXXXXX
20	137	139	O	and
21	141	145	O	other
22	147	150	O	oral
23	152	163	B-UNK	antidiabetic
24	165	169	L-UNK	drugs
NULL

Nateglinide	DDI-DrugBank.d460.s16	NO_SECTION	NO_SETID	24
When these drugs are administered to or withdrawn from patients receiving Starlix, the patient should be observed closely for changes in glycemic control.
1	0	3	O	When
2	5	9	O	these
3	11	15	O	drugs
4	17	19	O	are
5	21	32	O	administered
6	34	35	O	to
7	37	38	O	or
8	40	48	O	withdrawn
9	50	53	O	from
10	55	62	O	patients
11	64	72	O	receiving
12	74	80	O	XXXXXXXX
13	81	81	O	,
14	83	85	O	the
15	87	93	O	patient
16	95	100	O	should
17	102	103	O	be
18	105	112	O	observed
19	114	120	O	closely
20	122	124	O	for
21	126	132	O	changes
22	134	135	O	in
23	137	144	O	glycemic
24	146	152	O	control
NULL

Nedocromil	DDI-DrugBank.d61.s0	NO_SECTION	NO_SETID	37
In clinical studies, Tilade has been co-administered with other anti-asthma medications, including inhaled and oral bronchodilators, and inhaled corticosteroids, with no evidence of increased frequency of adverse events or laboratory abnormalities.
1	0	1	O	In
2	3	10	O	clinical
3	12	18	O	studies
4	19	19	O	,
5	21	26	O	XXXXXXXX
6	28	30	O	has
7	32	35	O	been
8	37	38	O	co
9	40	51	O	administered
10	53	56	O	with
11	58	62	O	other
12	64	67	O	anti
13	69	74	O	asthma
14	76	86	O	medications
15	87	87	O	,
16	89	97	O	including
17	99	105	O	inhaled
18	107	109	O	and
19	111	114	O	oral
20	116	130	U-UNK	bronchodilators
21	131	131	O	,
22	133	135	O	and
23	137	143	O	inhaled
24	145	159	U-UNK	corticosteroids
25	160	160	O	,
26	162	165	O	with
27	167	168	O	no
28	170	177	O	evidence
29	179	180	O	of
30	182	190	O	increased
31	192	200	O	frequency
32	202	203	O	of
33	205	211	O	adverse
34	213	218	O	events
35	220	221	O	or
36	223	232	O	laboratory
37	234	246	O	abnormalities
NULL

Nedocromil	DDI-DrugBank.d61.s1	NO_SECTION	NO_SETID	12
No formal drug-drug interaction studies, however, have been conducted.
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	18	O	drug
5	20	30	O	interaction
6	32	38	O	studies
7	39	39	O	,
8	41	47	O	however
9	48	48	O	,
10	50	53	O	have
11	55	58	O	been
12	60	68	O	conducted
NULL

Nelfinavir	DDI-DrugBank.d340.s0	NO_SECTION	NO_SETID	9
Nelfinavir is an inhibitor of CYP3A (cytochrome P450 3A).
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	15	O	an
4	17	25	O	inhibitor
5	27	28	O	of
6	30	34	O	CYP3A
7	37	46	O	cytochrome
8	48	51	O	P450
9	53	54	O	3A
NULL

Nelfinavir	DDI-DrugBank.d340.s1	NO_SECTION	NO_SETID	36
Coadministration of VIRACEPT and drugs primarily metabolized by CYP3A (e.g., dihydropyridine calcium channel blockers) may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	27	O	XXXXXXXX
4	29	31	O	and
5	33	37	O	drugs
6	39	47	O	primarily
7	49	59	O	metabolized
8	61	62	O	by
9	64	68	O	CYP3A
10	71	73	O	e.g
11	75	75	O	,
12	77	91	B-UNK	dihydropyridine
13	93	99	I-UNK	calcium
14	101	107	I-UNK	channel
15	109	116	L-UNK	blockers
16	119	121	O	may
17	123	128	O	result
18	130	131	O	in
19	133	141	O	increased
20	143	148	O	plasma
21	150	163	O	concentrations
22	165	166	O	of
23	168	170	O	the
24	172	176	O	other
25	178	181	O	drug
26	183	186	O	that
27	188	192	O	could
28	194	201	O	increase
29	203	204	O	or
30	206	212	O	prolong
31	214	217	O	both
32	219	221	O	its
33	223	233	O	therapeutic
34	235	237	O	and
35	239	245	O	adverse
36	247	253	O	effects
NULL

Nelfinavir	DDI-DrugBank.d340.s2	NO_SECTION	NO_SETID	7
Nelfinavir is metabolized in proof by C.P.A.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	metabolized
4	26	27	O	in
5	29	33	O	proof
6	35	36	O	by
7	38	42	O	C.P.A
NULL

Nelfinavir	DDI-DrugBank.d340.s3	NO_SECTION	NO_SETID	18
Coadministration of VIRACEPT and drugs that induce CYP3A may decrease nelfinavir plasma concentrations and reduce its therapeutic effect.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	27	O	XXXXXXXX
4	29	31	O	and
5	33	37	O	drugs
6	39	42	O	that
7	44	49	O	induce
8	51	55	O	CYP3A
9	57	59	O	may
10	61	68	O	decrease
11	70	79	U-UNK	nelfinavir
12	81	86	O	plasma
13	88	101	O	concentrations
14	103	105	O	and
15	107	112	O	reduce
16	114	116	O	its
17	118	128	O	therapeutic
18	130	135	O	effect
NULL

Nelfinavir	DDI-DrugBank.d340.s4	NO_SECTION	NO_SETID	13
Coadministration of VIRACEPT and drugs that inhibit CYP3A may increase nelfinavir plasma concentrations.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	27	O	XXXXXXXX
4	29	31	O	and
5	33	37	O	drugs
6	39	42	O	that
7	44	50	O	inhibit
8	52	56	O	CYP3A
9	58	60	O	may
10	62	69	O	increase
11	71	80	U-UNK	nelfinavir
12	82	87	O	plasma
13	89	102	O	concentrations
NULL

Nelfinavir	DDI-DrugBank.d340.s5	NO_SECTION	NO_SETID	29
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.
1	0	4	O	Based
2	6	7	O	on
3	9	13	O	known
4	15	23	O	metabolic
5	25	32	O	profiles
6	33	33	O	,
7	35	44	O	clinically
8	46	56	O	significant
9	58	61	O	drug
10	63	74	O	interactions
11	76	78	O	are
12	80	82	O	not
13	84	91	O	expected
14	93	99	O	between
15	101	108	O	XXXXXXXX
16	110	112	O	and
17	114	120	U-UNK	dapsone
18	121	121	O	,
19	123	134	U-UNK	trimethoprim
20	135	135	O	/
21	136	151	U-UNK	sulfamethoxazole
22	152	152	O	,
23	154	167	U-UNK	clarithromycin
24	168	168	O	,
25	170	181	U-UNK	erythromycin
26	182	182	O	,
27	184	195	U-UNK	itraconazole
28	197	198	O	or
29	200	210	U-UNK	fluconazole
NULL

Nelfinavir	DDI-DrugBank.d340.s6	NO_SECTION	NO_SETID	35
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
1	0	4	O	Drugs
2	6	9	O	That
3	11	16	O	Should
4	18	20	O	Not
5	22	23	O	Be
6	25	38	O	Coadministered
7	40	43	O	With
8	45	52	O	XXXXXXXX
9	54	68	U-DYN	Antiarrhythmics
10	69	69	O	:
11	71	80	U-DYN	amiodarone
12	81	81	O	,
13	83	91	U-DYN	quinidine
14	93	106	U-DYN	Antihistamines
15	107	107	O	:
16	109	118	U-DYN	astemizole
17	119	119	O	,
18	121	131	U-DYN	terfenadine
19	133	144	O	Antimigraine
20	145	145	O	:
21	147	151	B-DYN	ergot
22	153	163	L-DYN	derivatives
23	165	181	B-DYN	Antimycobacterial
24	183	188	L-DYN	agents
25	189	189	O	:
26	191	198	U-DYN	rifampin
27	200	214	U-DYN	Benzodiazepines
28	216	224	U-DYN	midazolam
29	225	225	O	,
30	227	235	U-DYN	triazolam
31	237	238	O	GI
32	240	247	O	motility
33	249	254	O	agents
34	255	255	O	:
35	257	265	U-DYN	cisapride
NULL

Nelfinavir	DDI-DrugBank.d340.s7	NO_SECTION	NO_SETID	14
Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin
1	0	4	O	Drugs
2	6	10	O	Which
3	12	18	O	Require
4	20	20	O	a
5	22	25	O	Dose
6	27	35	O	Reduction
7	37	40	O	When
8	42	54	O	Coadminstered
9	56	59	O	With
10	61	68	O	XXXXXXXX
11	70	86	B-DYN	Antimycobacterial
12	88	93	L-DYN	agents
13	94	94	O	:
14	96	104	U-DYN	rifabutin
NULL

Nelfinavir	DDI-DrugBank.d340.s8	NO_SECTION	NO_SETID	25
* This table is not all inclusive ** VIRACEPT may not be effective due to decreased nelfinavir plasma concentrations in patients taking these agents concomitantly
1	0	0	O	*
2	2	5	O	This
3	7	11	O	table
4	13	14	O	is
5	16	18	O	not
6	20	22	O	all
7	24	32	O	inclusive
8	34	35	O	**
9	37	44	O	XXXXXXXX
10	46	48	O	may
11	50	52	O	not
12	54	55	O	be
13	57	65	O	effective
14	67	69	O	due
15	71	72	O	to
16	74	82	O	decreased
17	84	93	U-UNK	nelfinavir
18	95	100	O	plasma
19	102	115	O	concentrations
20	117	118	O	in
21	120	127	O	patients
22	129	134	O	taking
23	136	140	O	these
24	142	147	O	agents
25	149	161	O	concomitantly
NULL

Nelfinavir	DDI-DrugBank.d340.s10	NO_SECTION	NO_SETID	16
Terfenadine: Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;
1	0	10	U-UNK	Terfenadine
2	11	11	O	:
3	13	26	O	Administration
4	28	29	O	of
5	31	41	U-UNK	terfenadine
6	43	46	O	with
7	48	55	O	XXXXXXXX
8	57	64	O	resulted
9	66	67	O	in
10	69	71	O	the
11	73	82	O	appearance
12	84	85	O	of
13	87	95	O	unchanged
14	97	107	U-UNK	terfenadine
15	109	110	O	in
16	112	117	O	plasma
NULL

Nelfinavir	DDI-DrugBank.d340.s11	NO_SECTION	NO_SETID	23
therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.
1	0	8	O	therefore
2	9	9	O	,
3	11	18	O	XXXXXXXX
4	20	25	O	should
5	27	29	O	not
6	31	32	O	be
7	34	45	O	administered
8	47	58	O	concurrently
9	60	63	O	with
10	65	75	U-DYN	terfenadine
11	77	83	O	because
12	85	86	O	of
13	88	90	O	the
14	92	100	O	potential
15	102	104	O	for
16	106	112	O	serious
17	114	116	O	and
18	117	117	O	/
19	118	119	O	or
20	121	124	O	life
21	126	136	O	threatening
22	138	144	O	cardiac
23	146	156	O	arrhythmias
NULL

Nelfinavir	DDI-DrugBank.d340.s12	NO_SECTION	NO_SETID	16
Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.
1	0	6	O	Because
2	8	8	O	a
3	10	16	O	similar
4	18	28	O	interaction
5	30	31	O	is
6	33	38	O	likely
7	39	39	O	,
8	41	48	O	XXXXXXXX
9	50	55	O	should
10	57	60	O	also
11	62	64	O	not
12	66	67	O	be
13	69	80	O	administered
14	82	93	O	concurrently
15	95	98	O	with
16	100	109	U-DYN	astemizole
NULL

Nelfinavir	DDI-DrugBank.d340.s13	NO_SECTION	NO_SETID	4
Anti-HIV Protease Inhibitors
1	0	3	B-UNK	Anti
2	5	7	I-UNK	HIV
3	9	16	I-UNK	Protease
4	18	27	L-UNK	Inhibitors
NULL

Nelfinavir	DDI-DrugBank.d340.s14	NO_SECTION	NO_SETID	24
Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.
1	0	8	U-UNK	Indinavir
2	9	9	O	:
3	11	26	O	Coadministration
4	28	29	O	of
5	31	39	U-KIN	indinavir
6	41	44	O	with
7	46	53	O	XXXXXXXX
8	55	62	O	resulted
9	64	65	O	in
10	67	68	O	an
11	70	72	O	83%
12	74	81	O	increase
13	83	84	O	in
14	86	95	U-UNK	nelfinavir
15	97	102	O	plasma
16	104	106	O	AUC
17	108	110	O	and
18	112	112	O	a
19	114	116	O	51%
20	118	125	O	increase
21	127	128	O	in
22	130	138	U-UNK	indinavir
23	140	145	O	plasma
24	147	149	O	A.C
NULL

Nelfinavir	DDI-DrugBank.d340.s15	NO_SECTION	NO_SETID	16
Currently, there are no safety and efficacy data available from the use of this combination.
1	0	8	O	Currently
2	9	9	O	,
3	11	15	O	there
4	17	19	O	are
5	21	22	O	no
6	24	29	O	safety
7	31	33	O	and
8	35	42	O	efficacy
9	44	47	O	data
10	49	57	O	available
11	59	62	O	from
12	64	66	O	the
13	68	70	O	use
14	72	73	O	of
15	75	78	O	this
16	80	90	O	combination
NULL

Nelfinavir	DDI-DrugBank.d340.s16	NO_SECTION	NO_SETID	24
Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.
1	0	8	U-UNK	Ritonavir
2	9	9	O	:
3	11	26	O	Coadministration
4	28	29	O	of
5	31	39	U-KIN	ritonavir
6	41	44	O	with
7	46	53	O	XXXXXXXX
8	55	62	O	resulted
9	64	65	O	in
10	67	67	O	a
11	69	72	O	152%
12	74	81	O	increase
13	83	84	O	in
14	86	95	U-UNK	nelfinavir
15	97	102	O	plasma
16	104	106	O	AUC
17	108	110	O	and
18	112	115	O	very
19	117	122	O	little
20	124	129	O	change
21	131	132	O	in
22	134	142	U-UNK	ritonavir
23	144	149	O	plasma
24	151	153	O	A.C
NULL

Nelfinavir	DDI-DrugBank.d340.s17	NO_SECTION	NO_SETID	16
Currently, there are no safety and efficacy data available from the use of this combination.
1	0	8	O	Currently
2	9	9	O	,
3	11	15	O	there
4	17	19	O	are
5	21	22	O	no
6	24	29	O	safety
7	31	33	O	and
8	35	42	O	efficacy
9	44	47	O	data
10	49	57	O	available
11	59	62	O	from
12	64	66	O	the
13	68	70	O	use
14	72	73	O	of
15	75	78	O	this
16	80	90	O	combination
NULL

Nelfinavir	DDI-DrugBank.d340.s18	NO_SECTION	NO_SETID	35
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.
1	0	9	U-UNK	Saquinavir
2	10	10	O	:
3	12	27	O	Coadministration
4	29	30	O	of
5	32	41	U-KIN	saquinavir
6	44	48	O	using
7	50	51	O	an
8	53	64	O	experimental
9	66	69	O	soft
10	71	77	O	gelatin
11	79	85	O	capsule
12	87	97	O	formulation
13	99	100	O	of
14	102	111	U-UNK	saquinavir
15	113	118	O	1200mg
16	121	124	O	with
17	126	133	O	XXXXXXXX
18	135	142	O	resulted
19	144	145	O	in
20	147	148	O	an
21	150	152	O	18%
22	154	161	O	increase
23	163	164	O	in
24	166	175	U-UNK	nelfinavir
25	177	182	O	plasma
26	184	186	O	AUC
27	188	190	O	and
28	192	192	O	a
29	194	194	O	4
30	196	199	O	fold
31	201	208	O	increase
32	210	211	O	in
33	213	222	U-UNK	saquinavir
34	224	229	O	plasma
35	231	233	O	A.C
NULL

Nelfinavir	DDI-DrugBank.d340.s19	NO_SECTION	NO_SETID	23
If used in combination with saquinavir hard gelatin capsules at the recommended dose of 600 mg tid, no dose adjustments are needed.
1	0	1	O	If
2	3	6	O	used
3	8	9	O	in
4	11	21	O	combination
5	23	26	O	with
6	28	37	U-UNK	saquinavir
7	39	42	O	hard
8	44	50	O	gelatin
9	52	59	O	capsules
10	61	62	O	at
11	64	66	O	the
12	68	78	O	recommended
13	80	83	O	dose
14	85	86	O	of
15	88	90	O	600
16	92	93	O	mg
17	95	97	O	tid
18	98	98	O	,
19	100	101	O	no
20	103	106	O	dose
21	108	118	O	adjustments
22	120	122	O	are
23	124	129	O	needed
NULL

Nelfinavir	DDI-DrugBank.d340.s20	NO_SECTION	NO_SETID	16
Currently, there are no safety and efficacy data available from the use of this combination.
1	0	8	O	Currently
2	9	9	O	,
3	11	15	O	there
4	17	19	O	are
5	21	22	O	no
6	24	29	O	safety
7	31	33	O	and
8	35	42	O	efficacy
9	44	47	O	data
10	49	57	O	available
11	59	62	O	from
12	64	66	O	the
13	68	70	O	use
14	72	73	O	of
15	75	78	O	this
16	80	90	O	combination
NULL

Nelfinavir	DDI-DrugBank.d340.s22	NO_SECTION	NO_SETID	16
Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	29	O	Coadministration
4	31	32	O	of
5	34	45	U-KIN	ketoconazole
6	47	50	O	with
7	52	59	O	XXXXXXXX
8	61	68	O	resulted
9	70	71	O	in
10	73	73	O	a
11	75	77	O	35%
12	79	86	O	increase
13	88	89	O	in
14	91	100	U-UNK	nelfinavir
15	102	107	O	plasma
16	109	111	O	A.C
NULL

Nelfinavir	DDI-DrugBank.d340.s23	NO_SECTION	NO_SETID	19
This change was not considered clinically significant and no dose adjustment is needed when ketoconazole and VIRACEPT are coadministered.
1	0	3	O	This
2	5	10	O	change
3	12	14	O	was
4	16	18	O	not
5	20	29	O	considered
6	31	40	O	clinically
7	42	52	O	significant
8	54	56	O	and
9	58	59	O	no
10	61	64	O	dose
11	66	75	O	adjustment
12	77	78	O	is
13	80	85	O	needed
14	87	90	O	when
15	92	103	U-UNK	ketoconazole
16	105	107	O	and
17	109	116	O	XXXXXXXX
18	118	120	O	are
19	122	135	O	coadministered
NULL

Nelfinavir	DDI-DrugBank.d340.s24	NO_SECTION	NO_SETID	5
Anti-HIV Reverse Transcriptase Inhibitors
1	0	3	B-UNK	Anti
2	5	7	I-UNK	HIV
3	9	15	I-UNK	Reverse
4	17	29	I-UNK	Transcriptase
5	31	40	L-UNK	Inhibitors
NULL

Nelfinavir	DDI-DrugBank.d340.s25	NO_SECTION	NO_SETID	13
Didanosine: It is recommended that didanosine be administered on an empty stomach;
1	0	9	U-UNK	Didanosine
2	10	10	O	:
3	12	13	O	It
4	15	16	O	is
5	18	28	O	recommended
6	30	33	O	that
7	35	44	U-UNK	didanosine
8	46	47	O	be
9	49	60	O	administered
10	62	63	O	on
11	65	66	O	an
12	68	72	O	empty
13	74	80	O	stomach
NULL

Nelfinavir	DDI-DrugBank.d340.s26	NO_SECTION	NO_SETID	18
therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.
1	0	8	O	therefore
2	9	9	O	,
3	11	20	O	XXXXXXXX
4	22	27	O	should
5	29	30	O	be
6	32	43	O	administered
7	46	49	O	with
8	51	54	O	food
9	57	59	O	one
10	61	64	O	hour
11	66	70	O	after
12	72	73	O	or
13	75	78	O	more
14	80	83	O	than
15	85	87	O	two
16	89	93	O	hours
17	95	100	O	before
18	102	111	U-DYN	didanosine
NULL

Nelfinavir	DDI-DrugBank.d340.s27	NO_SECTION	NO_SETID	12
A dose adjustment is not needed when zidovudine is administered with VIRACEPT.
1	0	0	O	A
2	2	5	O	dose
3	7	16	O	adjustment
4	18	19	O	is
5	21	23	O	not
6	25	30	O	needed
7	32	35	O	when
8	37	46	U-DYN	zidovudine
9	48	49	O	is
10	51	62	O	administered
11	64	67	O	with
12	69	76	O	XXXXXXXX
NULL

Nelfinavir	DDI-DrugBank.d340.s28	NO_SECTION	NO_SETID	20
Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with lamivudine or stavudine.
1	0	5	O	Little
2	7	8	O	or
3	10	11	O	no
4	13	18	O	change
5	20	21	O	in
6	23	25	O	the
7	27	42	O	pharmacokinetics
8	44	45	O	of
9	47	52	O	either
10	54	57	O	drug
11	59	61	O	was
12	63	70	O	observed
13	72	75	O	when
14	77	84	O	XXXXXXXX
15	86	88	O	was
16	90	103	O	coadministered
17	105	108	O	with
18	110	119	U-UNK	lamivudine
19	121	122	O	or
20	124	132	U-UNK	stavudine
NULL

Nelfinavir	DDI-DrugBank.d340.s29	NO_SECTION	NO_SETID	2
Antimycobacterial Agents
1	0	16	B-UNK	Antimycobacterial
2	18	23	L-UNK	Agents
NULL

Nelfinavir	DDI-DrugBank.d340.s30	NO_SECTION	NO_SETID	24
Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.
1	0	8	U-UNK	Rifabutin
2	9	9	O	:
3	11	26	O	Coadministration
4	28	29	O	of
5	31	39	U-KIN	rifabutin
6	41	43	O	and
7	45	52	O	XXXXXXXX
8	54	61	O	resulted
9	63	64	O	in
10	66	66	O	a
11	68	70	O	32%
12	72	79	O	decrease
13	81	82	O	in
14	84	93	U-UNK	nelfinavir
15	95	100	O	plasma
16	102	104	O	AUC
17	106	108	O	and
18	110	110	O	a
19	112	115	O	207%
20	117	124	O	increase
21	126	127	O	in
22	129	137	U-UNK	rifabutin
23	139	144	O	plasma
24	146	148	O	A.C
NULL

Nelfinavir	DDI-DrugBank.d340.s31	NO_SECTION	NO_SETID	20
It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	25	O	the
6	27	30	O	dose
7	32	33	O	of
8	35	43	U-DYN	rifabutin
9	45	46	O	be
10	48	54	O	reduced
11	56	57	O	to
12	59	61	O	one
13	63	66	O	half
14	68	70	O	the
15	72	76	O	usual
16	78	81	O	dose
17	83	86	O	when
18	88	99	O	administered
19	101	104	O	with
20	106	113	O	XXXXXXXX
NULL

Nelfinavir	DDI-DrugBank.d340.s32	NO_SECTION	NO_SETID	16
Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.
1	0	7	U-UNK	Rifampin
2	8	8	O	:
3	10	25	O	Coadministration
4	27	28	O	of
5	30	37	U-KIN	rifampin
6	39	41	O	and
7	43	50	O	XXXXXXXX
8	52	59	O	resulted
9	61	62	O	in
10	64	65	O	an
11	67	69	O	82%
12	71	78	O	decrease
13	80	81	O	in
14	83	92	U-UNK	nelfinavir
15	94	99	O	plasma
16	101	103	O	A.C
NULL

Nelfinavir	DDI-DrugBank.d340.s33	NO_SECTION	NO_SETID	7
VIRACEPT and rifampin should not be coadministered.
1	0	7	O	XXXXXXXX
2	9	11	O	and
3	13	20	U-DYN	rifampin
4	22	27	O	should
5	29	31	O	not
6	33	34	O	be
7	36	49	O	coadministered
NULL

Nelfinavir	DDI-DrugBank.d340.s35	NO_SECTION	NO_SETID	26
Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.
1	0	6	B-UNK	Ethinyl
2	8	16	L-UNK	Estradiol
3	18	20	O	and
4	22	34	U-UNK	Norethindrone
5	35	35	O	:
6	37	52	O	Coadministration
7	54	55	O	of
8	57	64	O	VIRACEPT
9	66	69	O	with
10	71	78	U-KIN	XXXXXXXX
11	80	87	O	resulted
12	89	90	O	in
13	92	92	O	a
14	94	96	O	47%
15	98	105	O	decrease
16	107	108	O	in
17	110	116	B-UNK	ethinyl
18	118	126	L-UNK	estradiol
19	128	130	O	and
20	132	133	O	an
21	135	137	O	18%
22	139	146	O	decrease
23	148	149	O	in
24	151	163	U-UNK	norethindrone
25	165	170	O	plasma
26	172	185	O	concentrations
NULL

Nelfinavir	DDI-DrugBank.d340.s36	NO_SECTION	NO_SETID	12
Alternate or additional contraceptive measures should be used during therapy with VIRACEPT
1	0	8	O	Alternate
2	10	11	O	or
3	13	22	O	additional
4	24	36	O	contraceptive
5	38	45	O	measures
6	47	52	O	should
7	54	55	O	be
8	57	60	O	used
9	62	67	O	during
10	69	75	O	therapy
11	77	80	O	with
12	82	89	O	XXXXXXXX
NULL

Neomycin	DDI-DrugBank.d330.s0	NO_SECTION	NO_SETID	30
Caution should be taken in concurrent or serial use of other neurotoxic and/ or nephrotoxic drugs because of possible enhancement of the nephrotoxicity and/or ototoxicity of neomycin.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	22	O	taken
5	24	25	O	in
6	27	36	O	concurrent
7	38	39	O	or
8	41	46	O	serial
9	48	50	O	use
10	52	53	O	of
11	55	59	O	other
12	61	70	O	neurotoxic
13	72	74	O	and
14	75	75	O	/
15	77	78	O	or
16	80	90	O	nephrotoxic
17	92	96	O	drugs
18	98	104	O	because
19	106	107	O	of
20	109	116	O	possible
21	118	128	O	enhancement
22	130	131	O	of
23	133	135	O	the
24	137	150	O	nephrotoxicity
25	152	154	O	and
26	155	155	O	/
27	156	157	O	or
28	159	169	O	ototoxicity
29	171	172	O	of
30	174	181	O	XXXXXXXX
NULL

Neomycin	DDI-DrugBank.d330.s1	NO_SECTION	NO_SETID	33
Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.
1	0	6	O	Caution
2	8	13	O	should
3	15	18	O	also
4	20	21	O	be
5	23	27	O	taken
6	29	30	O	in
7	32	41	O	concurrent
8	43	44	O	or
9	46	51	O	serial
10	53	55	O	use
11	57	58	O	of
12	60	64	O	other
13	66	80	U-UNK	aminoglycosides
14	82	84	O	and
15	86	95	U-UNK	polymyxins
16	97	103	O	because
17	105	108	O	they
18	110	112	O	may
19	114	120	O	enhance
20	122	129	O	XXXXXXXX
21	131	131	O	s
22	133	146	O	nephrotoxicity
23	148	150	O	and
24	151	151	O	/
25	152	153	O	or
26	155	165	O	ototoxicity
27	167	169	O	and
28	171	180	O	potentiate
29	182	189	O	XXXXXXXX
30	191	197	O	sulfate
31	199	211	O	neuromuscular
32	213	220	O	blocking
33	222	228	O	effects
NULL

Neomycin	DDI-DrugBank.d330.s2	NO_SECTION	NO_SETID	19
Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
1	0	3	O	Oral
2	5	12	O	XXXXXXXX
3	14	21	O	inhibits
4	23	25	O	the
5	27	42	O	gastrointestinal
6	44	53	O	absorption
7	55	56	O	of
8	58	67	B-KIN	penicillin
9	69	69	L-KIN	V
10	70	70	O	,
11	72	75	O	oral
12	77	83	B-KIN	vitamin
13	85	85	I-KIN	B
14	87	88	L-KIN	12
15	89	89	O	,
16	91	102	U-KIN	methotrexate
17	104	106	O	and
18	108	108	B-KIN	5
19	110	121	L-KIN	fluorouracil
NULL

Neomycin	DDI-DrugBank.d330.s3	NO_SECTION	NO_SETID	10
The gastrointestinal absorption of digoxin also appears to be inhibited.
1	0	2	O	The
2	4	19	O	gastrointestinal
3	21	30	O	absorption
4	32	33	O	of
5	35	41	U-UNK	digoxin
6	43	46	O	also
7	48	54	O	appears
8	56	57	O	to
9	59	60	O	be
10	62	70	O	inhibited
NULL

Neomycin	DDI-DrugBank.d330.s4	NO_SECTION	NO_SETID	8
Therefore, digoxin serum levels should be monitored.
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	U-UNK	digoxin
4	19	23	O	serum
5	25	30	O	levels
6	32	37	O	should
7	39	40	O	be
8	42	50	O	monitored
NULL

Neomycin	DDI-DrugBank.d330.s5	NO_SECTION	NO_SETID	16
Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.
1	0	3	O	Oral
2	5	12	O	XXXXXXXX
3	14	20	O	sulfate
4	22	24	O	may
5	26	32	O	enhance
6	34	36	O	the
7	38	43	O	effect
8	45	46	O	of
9	48	55	U-DYN	coumarin
10	57	58	O	in
11	60	73	U-DYN	anticoagulants
12	75	76	O	by
13	78	87	O	decreasing
14	89	95	O	vitamin
15	97	97	O	K
16	99	110	O	availability
NULL

Neostigmine	DDI-DrugBank.d498.s0	NO_SECTION	NO_SETID	23
Certain antibiotics, especially neomycin, streptomycin and kanamycin, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.
1	0	6	O	Certain
2	8	18	U-UNK	antibiotics
3	19	19	O	,
4	21	30	O	especially
5	32	39	U-UNK	neomycin
6	40	40	O	,
7	42	53	U-UNK	streptomycin
8	55	57	O	and
9	59	67	U-UNK	kanamycin
10	68	68	O	,
11	70	73	O	have
12	75	75	O	a
13	77	80	O	mild
14	82	84	O	but
15	86	93	O	definite
16	95	109	O	nondepolarizing
17	111	118	O	blocking
18	120	125	O	action
19	127	131	O	which
20	133	135	O	may
21	137	146	O	accentuate
22	148	160	O	neuromuscular
23	162	166	O	block
NULL

Neostigmine	DDI-DrugBank.d498.s1	NO_SECTION	NO_SETID	25
These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.
1	0	4	O	These
2	6	16	U-UNK	antibiotics
3	18	23	O	should
4	25	26	O	be
5	28	31	O	used
6	33	34	O	in
7	36	38	O	the
8	40	49	O	myasthenic
9	51	57	O	patient
10	59	62	O	only
11	64	68	O	where
12	70	79	O	definitely
13	81	89	O	indicated
14	90	90	O	,
15	92	94	O	and
16	96	99	O	then
17	101	107	O	careful
18	109	118	O	adjustment
19	120	125	O	should
20	127	128	O	be
21	130	133	O	made
22	135	136	O	of
23	138	147	O	adjunctive
24	149	166	U-UNK	anticholinesterase
25	168	173	O	dosage
NULL

Neostigmine	DDI-DrugBank.d498.s2	NO_SECTION	NO_SETID	30
Local and some general anesthetics, antiarrhythmic agents and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all, in patients with myasthenia gravis;
1	0	4	O	Local
2	6	8	O	and
3	10	13	O	some
4	15	21	O	general
5	23	33	U-UNK	anesthetics
6	34	34	O	,
7	36	49	B-UNK	antiarrhythmic
8	51	56	L-UNK	agents
9	58	60	O	and
10	62	66	O	other
11	68	72	O	drugs
12	74	77	O	that
13	79	87	O	interfere
14	89	92	O	with
15	94	106	O	neuromuscular
16	108	119	O	transmission
17	121	126	O	should
18	128	129	O	be
19	131	134	O	used
20	136	145	O	cautiously
21	146	146	O	,
22	148	149	O	if
23	151	152	O	at
24	154	156	O	all
25	157	157	O	,
26	159	160	O	in
27	162	169	O	patients
28	171	174	O	with
29	176	185	O	myasthenia
30	187	192	O	gravis
NULL

Neostigmine	DDI-DrugBank.d498.s3	NO_SECTION	NO_SETID	10
the dose of Prostigmin may have to be increased accordingly.
1	0	2	O	the
2	4	7	O	dose
3	9	10	O	of
4	12	21	O	XXXXXXXX
5	23	25	O	may
6	27	30	O	have
7	32	33	O	to
8	35	36	O	be
9	38	46	O	increased
10	48	58	O	accordingly
NULL

Nesiritide	DDI-DrugBank.d239.s0	NO_SECTION	NO_SETID	21
No trials specifically examining potential drug interactions with Natrecor were conducted, although many concomitant drugs were used in clinical trials.
1	0	1	O	No
2	3	8	O	trials
3	10	21	O	specifically
4	23	31	O	examining
5	33	41	O	potential
6	43	46	O	drug
7	48	59	O	interactions
8	61	64	O	with
9	66	73	O	XXXXXXXX
10	75	78	O	were
11	80	88	O	conducted
12	89	89	O	,
13	91	98	O	although
14	100	103	O	many
15	105	115	O	concomitant
16	117	121	O	drugs
17	123	126	O	were
18	128	131	O	used
19	133	134	O	in
20	136	143	O	clinical
21	145	150	O	trials
NULL

Nesiritide	DDI-DrugBank.d239.s1	NO_SECTION	NO_SETID	18
No drug interactions were detected except for an increase in symptomatic hypotension in patients receiving oral ACE inhibitors.
1	0	1	O	No
2	3	6	O	drug
3	8	19	O	interactions
4	21	24	O	were
5	26	33	O	detected
6	35	40	O	except
7	42	44	O	for
8	46	47	O	an
9	49	56	O	increase
10	58	59	O	in
11	61	71	O	symptomatic
12	73	83	O	hypotension
13	85	86	O	in
14	88	95	O	patients
15	97	105	O	receiving
16	107	110	O	oral
17	112	114	B-UNK	ACE
18	116	125	L-UNK	inhibitors
NULL

Nesiritide	DDI-DrugBank.d239.s2	NO_SECTION	NO_SETID	35
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).
1	0	2	O	The
2	4	5	O	co
3	7	20	O	administration
4	22	23	O	of
5	25	32	O	XXXXXXXX
6	34	37	O	with
7	39	40	O	IV
8	42	53	U-UNK	vasodilators
9	55	58	O	such
10	60	61	O	as
11	63	75	U-UNK	nitroglycerin
12	76	76	O	,
13	78	90	U-UNK	nitroprusside
14	91	91	O	,
15	93	101	U-UNK	milrinone
16	102	102	O	,
17	104	105	O	or
18	107	108	O	IV
19	110	112	B-UNK	ACE
20	114	123	L-UNK	inhibitors
21	125	127	O	has
22	129	131	O	not
23	133	136	O	been
24	138	146	O	evaluated
25	149	153	O	these
26	155	159	O	drugs
27	161	164	O	were
28	166	168	O	not
29	170	171	O	co
30	173	184	O	administered
31	186	189	O	with
32	191	198	O	XXXXXXXX
33	200	201	O	in
34	203	210	O	clinical
35	212	217	O	trials
NULL

Netilmicin	DDI-DrugBank.d417.s0	NO_SECTION	NO_SETID	26
Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.
1	0	9	O	XXXXXXXX
2	11	16	O	should
3	18	20	O	not
4	22	23	O	be
5	25	36	O	administered
6	38	50	O	concomitantly
7	52	55	O	with
8	57	62	O	potent
9	64	67	B-DYN	loop
10	69	77	L-DYN	diuretics
11	79	82	O	such
12	84	85	O	as
13	87	96	U-DYN	furosemide
14	98	100	O	and
15	102	111	B-DYN	ethacrynic
16	113	116	L-DYN	acid
17	118	119	O	as
18	121	123	O	the
19	125	133	O	potential
20	135	137	O	for
21	139	149	O	ototoxicity
22	151	152	O	is
23	154	161	O	enhanced
24	163	164	O	by
25	166	168	O	the
26	170	180	O	combination
NULL

Nevirapine	DDI-DrugBank.d270.s0	NO_SECTION	NO_SETID	16
Nevirapine is principally metabolized by the liver via the cytochrome P450 isoenzymes, 3A4 and 2B6.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	principally
4	26	36	O	metabolized
5	38	39	O	by
6	41	43	O	the
7	45	49	O	liver
8	51	53	O	via
9	55	57	O	the
10	59	68	O	cytochrome
11	70	73	O	P450
12	75	84	O	isoenzymes
13	85	85	O	,
14	87	89	O	3A4
15	91	93	O	and
16	95	97	O	2B6
NULL

Nevirapine	DDI-DrugBank.d270.s1	NO_SECTION	NO_SETID	10
Nevirapine is known to be an inducer of these enzymes.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	18	O	known
4	20	21	O	to
5	23	24	O	be
6	26	27	O	an
7	29	35	O	inducer
8	37	38	O	of
9	40	44	O	these
10	46	52	O	enzymes
NULL

Nevirapine	DDI-DrugBank.d270.s2	NO_SECTION	NO_SETID	23
As a result, drugs that are metabolized by these enzyme systems may have lower than expected plasma levels when coadministered with nevirapine.
1	0	1	O	As
2	3	3	O	a
3	5	10	O	result
4	11	11	O	,
5	13	17	O	drugs
6	19	22	O	that
7	24	26	O	are
8	28	38	O	metabolized
9	40	41	O	by
10	43	47	O	these
11	49	54	O	enzyme
12	56	62	O	systems
13	64	66	O	may
14	68	71	O	have
15	73	77	O	lower
16	79	82	O	than
17	84	91	O	expected
18	93	98	O	plasma
19	100	105	O	levels
20	107	110	O	when
21	112	125	O	coadministered
22	127	130	O	with
23	132	141	O	XXXXXXXX
NULL

Nevirapine	DDI-DrugBank.d270.s3	NO_SECTION	NO_SETID	22
The specific pharmacokinetic changes that occur with co-administration of nevirapine and other drugs are listed in CLINICAL PHARMACOLOGY, Table 1.
1	0	2	O	The
2	4	11	O	specific
3	13	27	O	pharmacokinetic
4	29	35	O	changes
5	37	40	O	that
6	42	46	O	occur
7	48	51	O	with
8	53	54	O	co
9	56	69	O	administration
10	71	72	O	of
11	74	83	O	XXXXXXXX
12	85	87	O	and
13	89	93	O	other
14	95	99	O	drugs
15	101	103	O	are
16	105	110	O	listed
17	112	113	O	in
18	115	122	O	CLINICAL
19	124	135	O	PHARMACOLOGY
20	136	136	O	,
21	138	142	O	Table
22	144	144	O	1
NULL

Nevirapine	DDI-DrugBank.d270.s4	NO_SECTION	NO_SETID	16
Clinical comments about possible dosage modifications based on these pharmacokinetic changes are listed in Table 3.
1	0	7	O	Clinical
2	9	16	O	comments
3	18	22	O	about
4	24	31	O	possible
5	33	38	O	dosage
6	40	52	O	modifications
7	54	58	O	based
8	60	61	O	on
9	63	67	O	these
10	69	83	O	pharmacokinetic
11	85	91	O	changes
12	93	95	O	are
13	97	102	O	listed
14	104	105	O	in
15	107	111	O	Table
16	113	113	O	3
NULL

Nevirapine	DDI-DrugBank.d270.s5	NO_SECTION	NO_SETID	24
The data inTables 1 and 3 are based on the results of drug interaction studies conducted in HIV-1 seropositive subjects unless otherwise indicated.
1	0	2	O	The
2	4	7	O	data
3	9	16	O	inTables
4	18	18	O	1
5	20	22	O	and
6	24	24	O	3
7	26	28	O	are
8	30	34	O	based
9	36	37	O	on
10	39	41	O	the
11	43	49	O	results
12	51	52	O	of
13	54	57	O	drug
14	59	69	O	interaction
15	71	77	O	studies
16	79	87	O	conducted
17	89	90	O	in
18	92	94	O	HIV
19	96	96	O	1
20	98	109	O	seropositive
21	111	118	O	subjects
22	120	125	O	unless
23	127	135	O	otherwise
24	137	145	O	indicated
NULL

Nevirapine	DDI-DrugBank.d270.s6	NO_SECTION	NO_SETID	27
In addition to established drug interactions, there may be potential pharmacokinetic interactions between nevirapine and other drug classes that are metabolized by the cytochrome P450 system.
1	0	1	O	In
2	3	10	O	addition
3	12	13	O	to
4	15	25	O	established
5	27	30	O	drug
6	32	43	O	interactions
7	44	44	O	,
8	46	50	O	there
9	52	54	O	may
10	56	57	O	be
11	59	67	O	potential
12	69	83	O	pharmacokinetic
13	85	96	O	interactions
14	98	104	O	between
15	106	115	O	XXXXXXXX
16	117	119	O	and
17	121	125	O	other
18	127	130	O	drug
19	132	138	O	classes
20	140	143	O	that
21	145	147	O	are
22	149	159	O	metabolized
23	161	162	O	by
24	164	166	O	the
25	168	177	O	cytochrome
26	179	182	O	P450
27	184	189	O	system
NULL

Nevirapine	DDI-DrugBank.d270.s7	NO_SECTION	NO_SETID	9
These potential drug interactions are listed in Table 4.
1	0	4	O	These
2	6	14	O	potential
3	16	19	O	drug
4	21	32	O	interactions
5	34	36	O	are
6	38	43	O	listed
7	45	46	O	in
8	48	52	O	Table
9	54	54	O	4
NULL

Nevirapine	DDI-DrugBank.d270.s8	NO_SECTION	NO_SETID	35
Although specific drug interaction studies in HIV-1 seropositive subjects have not been conducted for the classes of drugs listed in Table 4, additional clinical monitoring may be warranted when co-administering these drugs.
1	0	7	O	Although
2	9	16	O	specific
3	18	21	O	drug
4	23	33	O	interaction
5	35	41	O	studies
6	43	44	O	in
7	46	48	O	HIV
8	50	50	O	1
9	52	63	O	seropositive
10	65	72	O	subjects
11	74	77	O	have
12	79	81	O	not
13	83	86	O	been
14	88	96	O	conducted
15	98	100	O	for
16	102	104	O	the
17	106	112	O	classes
18	114	115	O	of
19	117	121	O	drugs
20	123	128	O	listed
21	130	131	O	in
22	133	137	O	Table
23	139	139	O	4
24	140	140	O	,
25	142	151	O	additional
26	153	160	O	clinical
27	162	171	O	monitoring
28	173	175	O	may
29	177	178	O	be
30	180	188	O	warranted
31	190	193	O	when
32	195	196	O	co
33	198	210	O	administering
34	212	216	O	these
35	218	222	O	drugs
NULL

Nevirapine	DDI-DrugBank.d270.s9	NO_SECTION	NO_SETID	13
The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.
1	0	2	O	The
2	4	5	O	in
3	7	11	O	vitro
4	13	23	O	interaction
5	25	31	O	between
6	33	42	O	XXXXXXXX
7	44	46	O	and
8	48	50	O	the
9	52	65	B-UNK	antithrombotic
10	67	71	L-UNK	agent
11	73	80	U-UNK	warfarin
12	82	83	O	is
13	85	91	O	complex
NULL

Nevirapine	DDI-DrugBank.d270.s10	NO_SECTION	NO_SETID	23
As a result, when giving these drugs concomitantly, plasma warfarin levels may change with the potential for increases in coagulation time.
1	0	1	O	As
2	3	3	O	a
3	5	10	O	result
4	11	11	O	,
5	13	16	O	when
6	18	23	O	giving
7	25	29	O	these
8	31	35	O	drugs
9	37	49	O	concomitantly
10	50	50	O	,
11	52	57	O	plasma
12	59	66	U-UNK	warfarin
13	68	73	O	levels
14	75	77	O	may
15	79	84	O	change
16	86	89	O	with
17	91	93	O	the
18	95	103	O	potential
19	105	107	O	for
20	109	117	O	increases
21	119	120	O	in
22	122	132	O	coagulation
23	134	137	O	time
NULL

Nevirapine	DDI-DrugBank.d270.s11	NO_SECTION	NO_SETID	14
When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.
1	0	3	O	When
2	5	12	U-DYN	warfarin
3	14	15	O	is
4	17	18	O	co
5	20	31	O	administered
6	33	36	O	with
7	38	47	O	XXXXXXXX
8	48	48	O	,
9	50	64	O	anticoagulation
10	66	71	O	levels
11	73	78	O	should
12	80	81	O	be
13	83	91	O	monitored
14	93	102	O	frequently
NULL

Nevirapine	DDI-DrugBank.d270.s12	NO_SECTION	NO_SETID	19
Table 3 Established Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies
1	0	4	O	Table
2	6	6	O	3
3	8	18	O	Established
4	20	23	O	Drug
5	25	36	O	Interactions
6	37	37	O	:
7	39	48	O	Alteration
8	50	51	O	in
9	53	56	O	Dose
10	58	59	O	or
11	61	67	O	Regimen
12	69	71	O	May
13	73	74	O	Be
14	76	86	O	Recommended
15	88	92	O	Based
16	94	95	O	on
17	97	100	O	Drug
18	102	112	O	Interaction
19	114	120	O	Studies
NULL

Nevirapine	DDI-DrugBank.d270.s14	NO_SECTION	NO_SETID	8
Effect on Concentration of Nevirapine or Concomitant Drug
1	0	5	O	Effect
2	7	8	O	on
3	10	22	O	Concentration
4	24	25	O	of
5	27	36	O	XXXXXXXX
6	38	39	O	or
7	41	51	O	Concomitant
8	53	56	O	Drug
NULL

Nevirapine	DDI-DrugBank.d270.s17	NO_SECTION	NO_SETID	3
Clarithromycin  14OH- clarithromycin
1	0	13	U-UNK	Clarithromycin
2	16	19	O	14OH
3	22	35	O	clarithromycin
NULL

Nevirapine	DDI-DrugBank.d270.s18	NO_SECTION	NO_SETID	7
Clarithromycin exposure was significantly decreased by nevirapine;
1	0	13	U-KIN	Clarithromycin
2	15	22	O	exposure
3	24	26	O	was
4	28	40	O	significantly
5	42	50	O	decreased
6	52	53	O	by
7	55	64	O	XXXXXXXX
NULL

Nevirapine	DDI-DrugBank.d270.s19	NO_SECTION	NO_SETID	25
however, 14-OH metabolite concentrations were increased.Because clarithromycin active metabolite has reduced activity against Mycobacteriumavium-intracellulare complex, overallactivity against this pathogen may bealtered.
1	0	6	O	however
2	7	7	O	,
3	9	10	O	14
4	12	13	O	OH
5	15	24	O	metabolite
6	26	39	O	concentrations
7	41	44	O	were
8	46	62	O	increased.Because
9	64	77	U-UNK	clarithromycin
10	79	84	O	active
11	86	95	O	metabolite
12	97	99	O	has
13	101	107	O	reduced
14	109	116	O	activity
15	118	124	O	against
16	126	143	O	Mycobacteriumavium
17	145	158	O	intracellulare
18	160	166	O	complex
19	167	167	O	,
20	169	183	O	overallactivity
21	185	191	O	against
22	193	196	O	this
23	198	205	O	pathogen
24	207	209	O	may
25	211	219	O	bealtered
NULL

Nevirapine	DDI-DrugBank.d270.s20	NO_SECTION	NO_SETID	9
Alternatives to clarithromycin,such as azithromycin, should be considered.
1	0	11	O	Alternatives
2	13	14	O	to
3	16	34	O	clarithromycin,such
4	36	37	O	as
5	39	50	U-UNK	azithromycin
6	51	51	O	,
7	53	58	O	should
8	60	61	O	be
9	63	72	O	considered
NULL

Nevirapine	DDI-DrugBank.d270.s23	NO_SECTION	NO_SETID	8
Appropriate doses for this combination are not established.
1	0	10	O	Appropriate
2	12	16	O	doses
3	18	20	O	for
4	22	25	O	this
5	27	37	O	combination
6	39	41	O	are
7	43	45	O	not
8	47	57	O	established
NULL

Nevirapine	DDI-DrugBank.d270.s24	NO_SECTION	NO_SETID	4
Ethinyl estradiol and Norethindrone
1	0	6	B-UNK	Ethinyl
2	8	16	L-UNK	estradiol
3	18	20	O	and
4	22	34	U-UNK	Norethindrone
NULL

Nevirapine	DDI-DrugBank.d270.s25	NO_SECTION	NO_SETID	3
Ethinyl estradiol Norethindrone
1	0	6	B-UNK	Ethinyl
2	8	16	L-UNK	estradiol
3	18	30	U-UNK	Norethindrone
NULL

Nevirapine	DDI-DrugBank.d270.s26	NO_SECTION	NO_SETID	30
Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.
1	0	3	O	Oral
2	5	18	U-DYN	contraceptives
3	20	22	O	and
4	24	28	O	other
5	30	44	O	hormonalmethods
6	46	47	O	of
7	49	53	O	birth
8	55	61	O	control
9	63	68	O	should
10	70	72	O	not
11	74	75	O	be
12	77	82	O	usedas
13	84	86	O	the
14	88	91	O	sole
15	93	98	O	method
16	100	101	O	of
17	103	115	O	contraception
18	117	123	O	inwomen
19	125	130	O	taking
20	132	141	O	XXXXXXXX
21	142	142	O	,
22	144	148	O	since
23	150	159	O	XXXXXXXX
24	160	162	O	may
25	164	168	O	lower
26	170	172	O	the
27	174	179	O	plasma
28	181	186	O	levels
29	188	189	O	of
30	191	206	O	thesemedications
NULL

Nevirapine	DDI-DrugBank.d270.s27	NO_SECTION	NO_SETID	9
An alternative or additional method of contraception is recommended.
1	0	1	O	An
2	3	13	O	alternative
3	15	16	O	or
4	18	27	O	additional
5	29	34	O	method
6	36	37	O	of
7	39	51	O	contraception
8	53	54	O	is
9	56	66	O	recommended
NULL

Nevirapine	DDI-DrugBank.d270.s30	NO_SECTION	NO_SETID	28
Because of the risk of increased exposure tonevirapine, caution should be used inconcomitant administration, and patients should be monitored closely for nevirapine-associated adverse events.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	18	O	risk
5	20	21	O	of
6	23	31	O	increased
7	33	40	O	exposure
8	42	43	O	to
9	44	53	O	XXXXXXXX
10	54	54	O	,
11	56	62	O	caution
12	64	69	O	should
13	71	72	O	be
14	74	77	O	used
15	79	91	O	inconcomitant
16	93	106	O	administration
17	107	107	O	,
18	109	111	O	and
19	113	120	O	patients
20	122	127	O	should
21	129	130	O	be
22	132	140	O	monitored
23	142	148	O	closely
24	150	152	O	for
25	154	163	O	XXXXXXXX
26	165	174	O	associated
27	176	182	O	adverse
28	184	189	O	events
NULL

Nevirapine	DDI-DrugBank.d270.s33	NO_SECTION	NO_SETID	18
Appropriate doses for this combination arenot established, but an increase in thedosage of indinavir may be required.
1	0	10	O	Appropriate
2	12	16	O	doses
3	18	20	O	for
4	22	25	O	this
5	27	37	O	combination
6	39	44	O	arenot
7	46	56	O	established
8	57	57	O	,
9	59	61	O	but
10	63	64	O	an
11	66	73	O	increase
12	75	76	O	in
13	78	86	O	thedosage
14	88	89	O	of
15	91	99	U-UNK	indinavir
16	101	103	O	may
17	105	106	O	be
18	108	115	O	required
NULL

Nevirapine	DDI-DrugBank.d270.s36	NO_SECTION	NO_SETID	18
Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.
1	0	9	O	XXXXXXXX
2	11	13	O	and
3	15	26	U-DYN	ketoconazole
4	28	33	O	should
5	35	37	O	not
6	39	52	O	beadministered
7	54	66	O	concomitantly
8	68	83	O	becausedecreases
9	85	86	O	in
10	88	99	U-UNK	ketoconazole
11	101	120	O	plasmaconcentrations
12	122	124	O	may
13	126	131	O	reduce
14	133	135	O	the
15	137	144	O	efficacy
16	146	147	O	of
17	149	151	O	the
18	153	156	O	drug
NULL

Nevirapine	DDI-DrugBank.d270.s39	NO_SECTION	NO_SETID	21
A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.
1	0	0	O	A
2	2	5	O	dose
3	7	14	O	increase
4	16	17	O	of
5	19	27	U-DYN	lopinavir
6	28	28	O	/
7	29	37	U-DYN	ritonavir
8	39	40	O	to
9	42	44	O	533
10	45	45	O	/
11	46	48	O	133
12	50	51	O	mg
13	53	57	O	twice
14	59	63	O	daily
15	65	68	O	with
16	70	73	O	food
17	75	87	O	isrecommended
18	89	90	O	in
19	92	102	O	combination
20	104	107	O	with
21	109	118	O	XXXXXXXX
NULL

Nevirapine	DDI-DrugBank.d270.s42	NO_SECTION	NO_SETID	35
Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.
1	0	8	U-UNK	Methadone
2	10	15	O	levels
3	17	19	O	may
4	21	22	O	be
5	24	32	O	decreased
6	35	43	O	increased
7	45	51	O	dosages
8	53	55	O	may
9	57	58	O	be
10	60	67	O	required
11	69	70	O	to
12	72	78	O	prevent
13	80	87	O	symptoms
14	89	90	O	of
15	92	97	U-UNK	opiate
16	99	108	O	withdrawal
17	111	119	U-DYN	Methadone
18	121	130	O	maintained
19	132	139	O	patients
20	141	149	O	beginning
21	151	160	O	XXXXXXXX
22	162	168	O	therapy
23	170	175	O	should
24	177	178	O	be
25	180	188	O	monitored
26	190	200	O	forevidence
27	202	203	O	of
28	205	214	O	withdrawal
29	216	218	O	and
30	220	228	U-UNK	methadone
31	230	233	O	dose
32	235	240	O	should
33	242	243	O	be
34	245	252	O	adjusted
35	254	264	O	accordingly
NULL

Nevirapine	DDI-DrugBank.d270.s45	NO_SECTION	NO_SETID	19
The appropriate dose for nelfinavir incombination with nevirapine, with respectto safety and efficacy, has not been established.
1	0	2	O	The
2	4	14	O	appropriate
3	16	19	O	dose
4	21	23	O	for
5	25	34	U-UNK	nelfinavir
6	36	48	O	incombination
7	50	53	O	with
8	55	64	O	XXXXXXXX
9	65	65	O	,
10	67	70	O	with
11	72	80	O	respectto
12	82	87	O	safety
13	89	91	O	and
14	93	100	O	efficacy
15	101	101	O	,
16	103	105	O	has
17	107	109	O	not
18	111	114	O	been
19	116	126	O	established
NULL

Nevirapine	DDI-DrugBank.d270.s48	NO_SECTION	NO_SETID	7
Rifabutin and its metabolite concentrationswere moderately increased.
1	0	8	U-UNK	Rifabutin
2	10	12	O	and
3	14	16	O	its
4	18	27	O	metabolite
5	29	46	O	concentrationswere
6	48	57	O	moderately
7	59	67	O	increased
NULL

Nevirapine	DDI-DrugBank.d270.s49	NO_SECTION	NO_SETID	22
Due to highintersubject variability, however, somepatients may experience large increases inrifabutin exposure and may be at higher riskfor rifabutin toxicity.
1	0	2	O	Due
2	4	5	O	to
3	7	22	O	highintersubject
4	24	34	O	variability
5	35	35	O	,
6	37	43	O	however
7	44	44	O	,
8	46	57	O	somepatients
9	59	61	O	may
10	63	72	O	experience
11	74	78	O	large
12	80	88	O	increases
13	90	100	O	inrifabutin
14	102	109	O	exposure
15	111	113	O	and
16	115	117	O	may
17	119	120	O	be
18	122	123	O	at
19	125	130	O	higher
20	132	138	O	riskfor
21	140	148	O	rifabutin
22	150	157	O	toxicity
NULL

Nevirapine	DDI-DrugBank.d270.s50	NO_SECTION	NO_SETID	9
Therefore, caution should be used in concomitant administration.
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	O	caution
4	19	24	O	should
5	26	27	O	be
6	29	32	O	used
7	34	35	O	in
8	37	47	O	concomitant
9	49	62	O	administration
NULL

Nevirapine	DDI-DrugBank.d270.s53	NO_SECTION	NO_SETID	17
Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.
1	0	9	O	XXXXXXXX
2	11	13	O	and
3	15	22	U-DYN	rifampin
4	24	29	O	should
5	31	33	O	not
6	35	48	O	beadministered
7	50	62	O	concomitantly
8	64	79	O	becausedecreases
9	81	82	O	in
10	84	93	O	XXXXXXXX
11	95	114	O	plasmaconcentrations
12	116	118	O	may
13	120	125	O	reduce
14	127	129	O	the
15	131	138	O	efficacy
16	140	144	O	ofthe
17	146	149	O	drug
NULL

Nevirapine	DDI-DrugBank.d270.s54	NO_SECTION	NO_SETID	16
Physicians needing to treatpatients co-infected with tuberculosis andusing a nevirapine containing regimen mayuse rifabutin instead.
1	0	9	O	Physicians
2	11	17	O	needing
3	19	20	O	to
4	22	34	O	treatpatients
5	36	37	O	co
6	39	46	O	infected
7	48	51	O	with
8	53	64	O	tuberculosis
9	66	73	O	andusing
10	75	75	O	a
11	77	86	O	XXXXXXXX
12	88	97	O	containing
13	99	105	O	regimen
14	107	112	O	mayuse
15	114	122	U-UNK	rifabutin
16	124	130	O	instead
NULL

Nevirapine	DDI-DrugBank.d270.s57	NO_SECTION	NO_SETID	18
Appropriate doses for this combination arenot established, but an increase in thedosage of saquinavir may be required.
1	0	10	O	Appropriate
2	12	16	O	doses
3	18	20	O	for
4	22	25	O	this
5	27	37	O	combination
6	39	44	O	arenot
7	46	56	O	established
8	57	57	O	,
9	59	61	O	but
10	63	64	O	an
11	66	73	O	increase
12	75	76	O	in
13	78	86	O	thedosage
14	88	89	O	of
15	91	100	U-UNK	saquinavir
16	102	104	O	may
17	106	107	O	be
18	109	116	O	required
NULL

Nevirapine	DDI-DrugBank.d270.s58	NO_SECTION	NO_SETID	24
aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.
1	0	5	O	aBased
2	7	8	O	on
3	10	16	O	reports
4	18	19	O	of
5	21	28	O	narcotic
6	30	39	O	withdrawal
7	41	48	O	syndrome
8	50	51	O	in
9	53	60	O	patients
10	62	68	O	treated
11	70	73	O	with
12	75	84	O	XXXXXXXX
13	86	88	O	and
14	90	98	U-DYN	methadone
15	100	111	O	concurrently
16	112	112	O	,
17	114	116	O	and
18	118	125	O	evidence
19	127	128	O	of
20	130	138	O	decreased
21	140	145	O	plasma
22	147	160	O	concentrations
23	162	163	O	of
24	165	173	U-UNK	methadone
NULL

Nevirapine	DDI-DrugBank.d270.s59	NO_SECTION	NO_SETID	24
Table 4        Potential Drug Interactions:Use With Caution, Dose Adjustment of Co-administered Drug May Be Needed due to Possible Decrease in Clinical Effect
1	0	4	O	Table
2	6	6	O	4
3	15	23	O	Potential
4	25	28	O	Drug
5	30	45	O	Interactions:Use
6	47	50	O	With
7	52	58	O	Caution
8	59	59	O	,
9	61	64	O	Dose
10	66	75	O	Adjustment
11	77	78	O	of
12	80	81	O	Co
13	83	94	O	administered
14	96	99	O	Drug
15	101	103	O	May
16	105	106	O	Be
17	108	113	O	Needed
18	115	117	O	due
19	119	120	O	to
20	122	129	O	Possible
21	131	138	O	Decrease
22	140	141	O	in
23	143	150	O	Clinical
24	152	157	O	Effect
NULL

Nevirapine	DDI-DrugBank.d270.s60	NO_SECTION	NO_SETID	15
Examples of Drugs in Which Plasma Concentrations May Be Decreased By Co-administration With Nevirapine
1	0	7	O	Examples
2	9	10	O	of
3	12	16	O	Drugs
4	18	19	O	in
5	21	25	O	Which
6	27	32	O	Plasma
7	34	47	O	Concentrations
8	49	51	O	May
9	53	54	O	Be
10	56	64	O	Decreased
11	66	67	O	By
12	69	70	O	Co
13	72	85	O	administration
14	87	90	O	With
15	92	101	O	XXXXXXXX
NULL

Nevirapine	DDI-DrugBank.d270.s61	NO_SECTION	NO_SETID	5
Drug Class Examples of Drugs
1	0	3	O	Drug
2	5	9	O	Class
3	11	18	O	Examples
4	20	21	O	of
5	23	27	O	Drugs
NULL

Nevirapine	DDI-DrugBank.d270.s63	NO_SECTION	NO_SETID	5
Amiodarone, disopyramide, lidocaine
1	0	9	U-UNK	Amiodarone
2	10	10	O	,
3	12	23	U-UNK	disopyramide
4	24	24	O	,
5	26	34	U-UNK	lidocaine
NULL

Nevirapine	DDI-DrugBank.d270.s65	NO_SECTION	NO_SETID	5
Carbamazepine, clonazepam, ethosuximide
1	0	12	U-UNK	Carbamazepine
2	13	13	O	,
3	15	24	U-UNK	clonazepam
4	25	25	O	,
5	27	38	U-UNK	ethosuximide
NULL

Nevirapine	DDI-DrugBank.d270.s68	NO_SECTION	NO_SETID	3
Calcium channel blockers
1	0	6	B-UNK	Calcium
2	8	14	I-UNK	channel
3	16	23	L-UNK	blockers
NULL

Nevirapine	DDI-DrugBank.d270.s69	NO_SECTION	NO_SETID	5
Diltiazem, nifedipine, verapamil
1	0	8	U-UNK	Diltiazem
2	9	9	O	,
3	11	20	U-UNK	nifedipine
4	21	21	O	,
5	23	31	U-UNK	verapamil
NULL

Nevirapine	DDI-DrugBank.d270.s75	NO_SECTION	NO_SETID	5
Cyclosporin, tacrolimus, sirolimus
1	0	10	U-UNK	Cyclosporin
2	11	11	O	,
3	13	22	U-UNK	tacrolimus
4	23	23	O	,
5	25	33	U-UNK	sirolimus
NULL

Nevirapine	DDI-DrugBank.d270.s80	NO_SECTION	NO_SETID	15
Examples of Drugs in Which Plasma Concentrations May Be Increased By Co-administration With Nevirapine
1	0	7	O	Examples
2	9	10	O	of
3	12	16	O	Drugs
4	18	19	O	in
5	21	25	O	Which
6	27	32	O	Plasma
7	34	47	O	Concentrations
8	49	51	O	May
9	53	54	O	Be
10	56	64	O	Increased
11	66	67	O	By
12	69	70	O	Co
13	72	85	O	administration
14	87	90	O	With
15	92	101	O	XXXXXXXX
NULL

Nevirapine	DDI-DrugBank.d270.s83	NO_SECTION	NO_SETID	4
Potential effect on anticoagulation.
1	0	8	O	Potential
2	10	15	O	effect
3	17	18	O	on
4	20	34	O	anticoagulation
NULL

Nevirapine	DDI-DrugBank.d270.s84	NO_SECTION	NO_SETID	6
Monitoring of anticoagulation levels is recommended.
1	0	9	O	Monitoring
2	11	12	O	of
3	14	28	O	anticoagulation
4	30	35	O	levels
5	37	38	O	is
6	40	50	O	recommended
NULL

Nevirapine	DDI-DrugBank.d270.s85	NO_SECTION	NO_SETID	39
Fat redistribution: Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and cushingoid appearance have been observed in patients receiving antiretroviral therapy.
1	0	2	O	Fat
2	4	17	O	redistribution
3	18	18	O	:
4	20	33	O	Redistribution
5	34	34	O	/
6	35	46	O	accumulation
7	48	49	O	of
8	51	54	O	body
9	56	58	O	fat
10	60	68	O	including
11	70	76	O	central
12	78	84	O	obesity
13	85	85	O	,
14	87	99	O	dorsocervical
15	101	103	O	fat
16	105	115	O	enlargement
17	118	124	O	buffalo
18	126	129	O	hump
19	131	131	O	,
20	133	142	O	peripheral
21	144	150	O	wasting
22	151	151	O	,
23	153	158	O	facial
24	160	166	O	wasting
25	167	167	O	,
26	169	174	O	breast
27	176	186	O	enlargement
28	187	187	O	,
29	189	191	O	and
30	193	202	O	cushingoid
31	204	213	O	appearance
32	215	218	O	have
33	220	223	O	been
34	225	232	O	observed
35	234	235	O	in
36	237	244	O	patients
37	246	254	O	receiving
38	256	269	U-UNK	antiretroviral
39	271	277	O	therapy
NULL

Nevirapine	DDI-DrugBank.d270.s86	NO_SECTION	NO_SETID	12
The mechanism and long-term consequences of these events are currently unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	16	O	and
4	18	21	O	long
5	23	26	O	term
6	28	39	O	consequences
7	41	42	O	of
8	44	48	O	these
9	50	55	O	events
10	57	59	O	are
11	61	69	O	currently
12	71	77	O	unknown
NULL

Nevirapine	DDI-DrugBank.d270.s87	NO_SECTION	NO_SETID	7
A causal relationship has not been established
1	0	0	O	A
2	2	7	O	causal
3	9	20	O	relationship
4	22	24	O	has
5	26	28	O	not
6	30	33	O	been
7	35	45	O	established
NULL

Niacin	DDI-DrugBank.d542.s0	NO_SECTION	NO_SETID	26
Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.
1	0	11	O	Interactions
2	13	15	O	for
3	17	23	B-UNK	Vitamin
4	25	26	L-UNK	B3
5	29	34	O	XXXXXXXX
6	36	36	O	:
7	38	53	U-UNK	Antihypertensive
8	55	61	O	Therapy
9	62	62	O	:
10	64	72	B-UNK	Nicotinic
11	74	77	L-UNK	acid
12	79	81	O	may
13	83	92	O	potentiate
14	94	96	O	the
15	98	104	O	effects
16	106	107	O	of
17	109	118	B-UNK	ganglionic
18	120	127	I-UNK	blocking
19	129	134	L-UNK	agents
20	136	138	O	and
21	140	149	O	vasoactive
22	151	155	O	drugs
23	157	165	O	resulting
24	167	168	O	in
25	170	177	O	postural
26	179	189	O	hypotension
NULL

Niacin	DDI-DrugBank.d542.s1	NO_SECTION	NO_SETID	12
Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.
1	0	6	O	XXXXXXXX
2	7	7	O	:
3	9	19	O	Concomitant
4	21	27	O	XXXXXXXX
5	29	31	O	may
6	33	40	O	decrease
7	42	44	O	the
8	46	54	O	metabolic
9	56	64	O	clearance
10	66	67	O	of
11	69	77	B-KIN	nicotinic
12	79	82	L-KIN	acid
NULL

Niacin	DDI-DrugBank.d542.s2	NO_SECTION	NO_SETID	8
The clinical relevance of this finding is unclear.
1	0	2	O	The
2	4	11	O	clinical
3	13	21	O	relevance
4	23	24	O	of
5	26	29	O	this
6	31	37	O	finding
7	39	40	O	is
8	42	48	O	unclear
NULL

Niacin	DDI-DrugBank.d542.s3	NO_SECTION	NO_SETID	26
Other: Concomitant alcohol or hot drinks may increase the side effects of flushing and pruritus and should be avoided at the time of drug ingestion.
1	0	4	O	Other
2	5	5	O	:
3	7	17	O	Concomitant
4	19	25	U-UNK	alcohol
5	27	28	O	or
6	30	32	O	hot
7	34	39	O	drinks
8	41	43	O	may
9	45	52	O	increase
10	54	56	O	the
11	58	61	O	side
12	63	69	O	effects
13	71	72	O	of
14	74	81	O	flushing
15	83	85	O	and
16	87	94	O	pruritus
17	96	98	O	and
18	100	105	O	should
19	107	108	O	be
20	110	116	O	avoided
21	118	119	O	at
22	121	123	O	the
23	125	128	O	time
24	130	131	O	of
25	133	136	O	drug
26	138	146	O	ingestion
NULL

Nicardipine	DDI-DrugBank.d468.s0	NO_SECTION	NO_SETID	20
Beta-Blockers: In controlled clinical studies, adrenergic beta-receptor blockers have been frequently administered concomitantly with nicardipine HCl.
1	0	3	B-UNK	Beta
2	5	12	L-UNK	Blockers
3	13	13	O	:
4	15	16	O	In
5	18	27	O	controlled
6	29	36	O	clinical
7	38	44	O	studies
8	45	45	O	,
9	47	56	B-UNK	adrenergic
10	58	61	I-UNK	beta
11	63	70	I-UNK	receptor
12	72	79	L-UNK	blockers
13	81	84	O	have
14	86	89	O	been
15	91	100	O	frequently
16	102	113	O	administered
17	115	127	O	concomitantly
18	129	132	O	with
19	134	144	O	XXXXXXXX
20	146	148	O	HCl
NULL

Nicardipine	DDI-DrugBank.d468.s1	NO_SECTION	NO_SETID	5
The combination is well tolerated.
1	0	2	O	The
2	4	14	O	combination
3	16	17	O	is
4	19	22	O	well
5	24	32	O	tolerated
NULL

Nicardipine	DDI-DrugBank.d468.s2	NO_SECTION	NO_SETID	8
Cimetidine: Cimetidine increases nicardipine HCl plasma levels.
1	0	9	U-UNK	Cimetidine
2	10	10	O	:
3	12	21	U-KIN	Cimetidine
4	23	31	O	increases
5	33	43	O	XXXXXXXX
6	45	47	O	HCl
7	49	54	O	plasma
8	56	61	O	levels
NULL

Nicardipine	DDI-DrugBank.d468.s3	NO_SECTION	NO_SETID	10
Patients receiving the two drugs concomitantly should be carefully monitored.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	21	O	the
4	23	25	O	two
5	27	31	O	drugs
6	33	45	O	concomitantly
7	47	52	O	should
8	54	55	O	be
9	57	65	O	carefully
10	67	75	O	monitored
NULL

Nicardipine	DDI-DrugBank.d468.s4	NO_SECTION	NO_SETID	15
Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	12	O	Some
4	14	20	B-UNK	calcium
5	22	29	L-UNK	blockers
6	31	33	O	may
7	35	42	O	increase
8	44	46	O	the
9	48	60	O	concentration
10	62	63	O	of
11	65	73	B-UNK	digitalis
12	75	86	L-UNK	preparations
13	88	89	O	in
14	91	93	O	the
15	95	99	O	blood
NULL

Nicardipine	DDI-DrugBank.d468.s5	NO_SECTION	NO_SETID	28
Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.
1	0	10	O	XXXXXXXX
2	12	14	O	HCl
3	16	22	O	usually
4	24	27	O	does
5	29	31	O	not
6	33	37	O	alter
7	39	41	O	the
8	43	48	O	plasma
9	50	55	O	levels
10	57	58	O	of
11	60	66	U-UNK	digoxin
12	67	67	O	,
13	69	75	O	however
14	76	76	O	,
15	78	82	O	serum
16	84	90	U-DYN	digoxin
17	92	97	O	levels
18	99	104	O	should
19	106	107	O	be
20	109	117	O	evaluated
21	119	123	O	after
22	125	135	O	concomitant
23	137	143	O	therapy
24	145	148	O	with
25	150	160	O	XXXXXXXX
26	162	164	O	HCl
27	166	167	O	is
28	169	177	O	initiated
NULL

Nicardipine	DDI-DrugBank.d468.s6	NO_SECTION	NO_SETID	12
Maalox * Coadministration of Maalox TC had no effect on nicardipine HCl absorption.
1	0	5	O	Maalox
2	7	7	O	*
3	9	24	O	Coadministration
4	26	27	O	of
5	29	37	O	XXXXXXXX
6	39	41	O	had
7	43	44	O	no
8	46	51	O	effect
9	53	54	O	on
10	56	66	B-UNK	nicardipine
11	68	70	L-UNK	HCl
12	72	81	O	absorption
NULL

Nicardipine	DDI-DrugBank.d468.s7	NO_SECTION	NO_SETID	30
Even though such interactions were not seen during clinical studies with nicardipine HCl, an increased volume of circulating fluids might be required if such an interaction were to occur.
1	0	3	O	Even
2	5	10	O	though
3	12	15	O	such
4	17	28	O	interactions
5	30	33	O	were
6	35	37	O	not
7	39	42	O	seen
8	44	49	O	during
9	51	58	O	clinical
10	60	66	O	studies
11	68	71	O	with
12	73	83	O	XXXXXXXX
13	85	87	O	HCl
14	88	88	O	,
15	90	91	O	an
16	93	101	O	increased
17	103	108	O	volume
18	110	111	O	of
19	113	123	O	circulating
20	125	130	O	fluids
21	132	136	O	might
22	138	139	O	be
23	141	148	O	required
24	150	151	O	if
25	153	156	O	such
26	158	159	O	an
27	161	171	O	interaction
28	173	176	O	were
29	178	179	O	to
30	181	185	O	occur
NULL

Nicardipine	DDI-DrugBank.d468.s8	NO_SECTION	NO_SETID	9
Cyclosporine: Concomitant administration of nicardipine and cyclosporine levels.
1	0	11	U-UNK	Cyclosporine
2	12	12	O	:
3	14	24	O	Concomitant
4	26	39	O	administration
5	41	42	O	of
6	44	54	O	XXXXXXXX
7	56	58	O	and
8	60	71	U-UNK	cyclosporine
9	73	78	O	levels
NULL

Nicardipine	DDI-DrugBank.d468.s9	NO_SECTION	NO_SETID	21
Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.
1	0	5	O	Plasma
2	7	20	O	concentrations
3	22	23	O	of
4	25	36	U-DYN	cyclosporine
5	38	43	O	should
6	45	53	O	therefore
7	55	56	O	be
8	58	64	O	closely
9	66	74	O	monitored
10	75	75	O	,
11	77	79	O	and
12	81	83	O	its
13	85	90	O	dosage
14	92	98	O	reduced
15	100	110	O	accordingly
16	111	111	O	,
17	113	114	O	in
18	116	123	O	patients
19	125	131	O	treated
20	133	136	O	with
21	138	148	O	XXXXXXXX
NULL

Nicardipine	DDI-DrugBank.d468.s10	NO_SECTION	NO_SETID	34
When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
1	0	3	O	When
2	5	15	O	therapeutic
3	17	30	O	concentrations
4	32	33	O	of
5	35	44	U-UNK	furosemide
6	45	45	O	,
7	47	57	U-UNK	propranolol
8	58	58	O	,
9	60	71	U-UNK	dipyridamole
10	72	72	O	,
11	74	81	U-UNK	warfarin
12	82	82	O	,
13	84	92	U-UNK	quinidine
14	93	93	O	,
15	95	96	O	or
16	98	105	U-UNK	naproxen
17	107	110	O	were
18	112	116	O	added
19	118	119	O	to
20	121	125	O	human
21	127	132	O	plasma
22	135	136	O	in
23	138	142	O	vitro
24	144	144	O	,
25	146	148	O	the
26	150	155	O	plasma
27	157	163	O	protein
28	165	171	O	binding
29	173	174	O	of
30	176	186	O	XXXXXXXX
31	188	190	O	HCl
32	192	194	O	was
33	196	198	O	not
34	200	206	O	altered
NULL

Nicotine	DDI-DrugBank.d271.s0	NO_SECTION	NO_SETID	28
Physiological changes resulting from smoking cessation, with or without nicotine replacement, may alter the pharmacokinetics of certain concomitant medications, such as tricyclic antidepressants and theophylline.
1	0	12	O	Physiological
2	14	20	O	changes
3	22	30	O	resulting
4	32	35	O	from
5	37	43	O	smoking
6	45	53	O	cessation
7	54	54	O	,
8	56	59	O	with
9	61	62	O	or
10	64	70	O	without
11	72	79	O	XXXXXXXX
12	81	91	O	replacement
13	92	92	O	,
14	94	96	O	may
15	98	102	O	alter
16	104	106	O	the
17	108	123	O	pharmacokinetics
18	125	126	O	of
19	128	134	O	certain
20	136	146	O	concomitant
21	148	158	O	medications
22	159	159	O	,
23	161	164	O	such
24	166	167	O	as
25	169	177	B-UNK	tricyclic
26	179	193	L-UNK	antidepressants
27	195	197	O	and
28	199	210	U-UNK	theophylline
NULL

Nicotine	DDI-DrugBank.d271.s1	NO_SECTION	NO_SETID	18
Doses of these and perhaps other medications may need to be adjusted in patients who successfully quit smoking.
1	0	4	O	Doses
2	6	7	O	of
3	9	13	O	these
4	15	17	O	and
5	19	25	O	perhaps
6	27	31	O	other
7	33	43	O	medications
8	45	47	O	may
9	49	52	O	need
10	54	55	O	to
11	57	58	O	be
12	60	67	O	adjusted
13	69	70	O	in
14	72	79	O	patients
15	81	83	O	who
16	85	96	O	successfully
17	98	101	O	quit
18	103	109	O	smoking
NULL

Nifedipine	DDI-DrugBank.d373.s0	NO_SECTION	NO_SETID	58
Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.
1	0	3	B-UNK	Beta
2	5	14	I-UNK	adrenergic
3	16	23	I-UNK	Blocking
4	25	30	L-UNK	Agents
5	31	31	O	:
6	33	42	O	Experience
7	44	45	O	in
8	47	50	O	over
9	52	55	O	1400
10	57	64	O	patients
11	66	67	O	in
12	69	69	O	a
13	71	73	O	non
14	75	85	O	comparative
15	87	94	O	clinical
16	96	100	O	trial
17	102	104	O	has
18	106	110	O	shown
19	112	115	O	that
20	117	127	O	concomitant
21	129	142	O	administration
22	144	145	O	of
23	147	156	O	XXXXXXXX
24	158	160	O	and
25	162	165	B-DYN	beta
26	167	174	I-DYN	blocking
27	176	181	L-DYN	agents
28	183	184	O	is
29	186	192	O	usually
30	194	197	O	well
31	199	207	O	tolerated
32	208	208	O	,
33	210	212	O	but
34	214	218	O	there
35	220	223	O	have
36	225	228	O	been
37	230	239	O	occasional
38	241	250	O	literature
39	252	258	O	reports
40	260	269	O	suggesting
41	271	274	O	that
42	276	278	O	the
43	280	290	O	combination
44	292	294	O	may
45	296	303	O	increase
46	305	307	O	the
47	309	318	O	likelihood
48	320	321	O	of
49	323	332	O	congestive
50	334	338	O	heart
51	340	346	O	failure
52	347	347	O	,
53	349	354	O	severe
54	356	366	O	hypotension
55	368	369	O	or
56	371	382	O	exacerbation
57	384	385	O	of
58	387	392	O	angina
NULL

Nifedipine	DDI-DrugBank.d373.s1	NO_SECTION	NO_SETID	28
Long Acting Nitrates: Nifedipine may be safely co-administered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.
1	0	3	O	Long
2	5	10	O	Acting
3	12	19	U-UNK	Nitrates
4	20	20	O	:
5	22	31	O	XXXXXXXX
6	33	35	O	may
7	37	38	O	be
8	40	45	O	safely
9	47	48	O	co
10	50	61	O	administered
11	63	66	O	with
12	68	75	U-UNK	nitrates
13	76	76	O	,
14	78	80	O	but
15	82	86	O	there
16	88	91	O	have
17	93	96	O	been
18	98	99	O	no
19	101	110	O	controlled
20	112	118	O	studies
21	120	121	O	to
22	123	130	O	evaluate
23	132	134	O	the
24	136	146	O	antianginal
25	148	160	O	effectiveness
26	162	163	O	of
27	165	168	O	this
28	170	180	O	combination
NULL

Nifedipine	DDI-DrugBank.d373.s2	NO_SECTION	NO_SETID	53
Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
1	0	8	U-UNK	Digitalis
2	9	9	O	:
3	11	19	O	Immediate
4	21	27	O	Release
5	29	36	O	Capsules
6	37	37	O	:
7	39	43	O	Since
8	45	49	O	there
9	51	54	O	have
10	56	59	O	been
11	61	68	O	isolated
12	70	76	O	reports
13	78	79	O	of
14	81	88	O	patients
15	90	93	O	with
16	95	102	O	elevated
17	104	110	U-UNK	digoxin
18	112	117	O	levels
19	118	118	O	,
20	120	122	O	and
21	124	128	O	there
22	130	131	O	is
23	133	133	O	a
24	135	142	O	possible
25	144	154	O	interaction
26	156	162	O	between
27	164	170	U-UNK	digoxin
28	172	174	O	and
29	176	185	O	XXXXXXXX
30	186	186	O	,
31	188	189	O	it
32	191	192	O	is
33	194	204	O	recommended
34	206	209	O	that
35	211	217	U-DYN	digoxin
36	219	224	O	levels
37	226	227	O	be
38	229	237	O	monitored
39	239	242	O	when
40	244	253	O	initiating
41	254	254	O	,
42	256	264	O	adjusting
43	265	265	O	,
44	267	269	O	and
45	271	283	O	discontinuing
46	285	294	O	XXXXXXXX
47	296	297	O	to
48	299	303	O	avoid
49	305	312	O	possible
50	314	317	O	over
51	320	321	O	or
52	323	327	O	under
53	329	342	O	digitalization
NULL

Nifedipine	DDI-DrugBank.d373.s3	NO_SECTION	NO_SETID	18
Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.
1	0	7	O	Extended
2	9	15	O	Release
3	17	23	O	Tablets
4	24	24	O	:
5	26	39	O	Administration
6	41	42	O	of
7	44	53	O	XXXXXXXX
8	55	58	O	with
9	60	66	U-UNK	digoxin
10	68	76	O	increased
11	78	84	U-UNK	digoxin
12	86	91	O	levels
13	93	94	O	in
14	96	96	O	9
15	98	99	O	of
16	101	102	O	12
17	104	109	O	normal
18	111	120	O	volunteers
NULL

Nifedipine	DDI-DrugBank.d373.s4	NO_SECTION	NO_SETID	5
The average increase was 45%.
1	0	2	O	The
2	4	10	O	average
3	12	19	O	increase
4	21	23	O	was
5	25	27	O	45%
NULL

Nifedipine	DDI-DrugBank.d373.s5	NO_SECTION	NO_SETID	15
Another investigator found no increase in digoxin levels in 13 patients with coronary artery disease.
1	0	6	O	Another
2	8	19	O	investigator
3	21	25	O	found
4	27	28	O	no
5	30	37	O	increase
6	39	40	O	in
7	42	48	U-UNK	digoxin
8	50	55	O	levels
9	57	58	O	in
10	60	61	O	13
11	63	70	O	patients
12	72	75	O	with
13	77	84	O	coronary
14	86	91	O	artery
15	93	99	O	disease
NULL

Nifedipine	DDI-DrugBank.d373.s6	NO_SECTION	NO_SETID	26
In an uncontrolled study of over 200 patients with congestive heart failure during which digoxin blood levels were not measured, digitalis toxicity was not observed.
1	0	1	O	In
2	3	4	O	an
3	6	17	O	uncontrolled
4	19	23	O	study
5	25	26	O	of
6	28	31	O	over
7	33	35	O	200
8	37	44	O	patients
9	46	49	O	with
10	51	60	O	congestive
11	62	66	O	heart
12	68	74	O	failure
13	76	81	O	during
14	83	87	O	which
15	89	95	U-UNK	digoxin
16	97	101	O	blood
17	103	108	O	levels
18	110	113	O	were
19	115	117	O	not
20	119	126	O	measured
21	127	127	O	,
22	129	137	O	digitalis
23	139	146	O	toxicity
24	148	150	O	was
25	152	154	O	not
26	156	163	O	observed
NULL

Nifedipine	DDI-DrugBank.d373.s7	NO_SECTION	NO_SETID	36
Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
1	0	4	O	Since
2	6	10	O	there
3	12	15	O	have
4	17	20	O	been
5	22	29	O	isolated
6	31	37	O	reports
7	39	40	O	of
8	42	49	O	patients
9	51	54	O	with
10	56	63	O	elevated
11	65	71	U-UNK	digoxin
12	73	78	O	levels
13	79	79	O	,
14	81	82	O	it
15	84	85	O	is
16	87	97	O	recommended
17	99	102	O	that
18	104	110	U-DYN	digoxin
19	112	117	O	levels
20	119	120	O	be
21	122	130	O	monitored
22	132	135	O	when
23	137	146	O	initiating
24	147	147	O	,
25	149	157	O	adjusting
26	158	158	O	,
27	160	162	O	and
28	164	176	O	discontinuing
29	178	187	O	XXXXXXXX
30	189	190	O	to
31	192	196	O	avoid
32	198	205	O	possible
33	207	210	O	over
34	213	214	O	or
35	216	220	O	under
36	222	235	O	digitalization
NULL

Nifedipine	DDI-DrugBank.d373.s8	NO_SECTION	NO_SETID	25
Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).
1	0	8	U-UNK	Quinidine
2	9	9	O	:
3	11	19	O	Immediate
4	21	27	O	Release
5	29	36	O	Capsules
6	37	37	O	:
7	39	43	O	There
8	45	48	O	have
9	50	53	O	been
10	55	58	O	rare
11	60	66	O	reports
12	68	69	O	of
13	71	72	O	an
14	74	84	O	interaction
15	86	92	O	between
16	94	102	U-KIN	quinidine
17	104	106	O	and
18	108	117	O	XXXXXXXX
19	120	123	O	with
20	125	125	O	a
21	127	135	O	decreased
22	137	142	O	plasma
23	144	148	O	level
24	150	151	O	of
25	153	161	U-UNK	quinidine
NULL

Nifedipine	DDI-DrugBank.d373.s9	NO_SECTION	NO_SETID	22
Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.
1	0	7	B-UNK	Coumarin
2	9	22	L-UNK	Anticoagulants
3	23	23	O	:
4	25	29	O	There
5	31	34	O	have
6	36	39	O	been
7	41	44	O	rare
8	46	52	O	reports
9	54	55	O	of
10	57	65	O	increased
11	67	77	O	prothrombin
12	79	82	O	time
13	84	85	O	in
14	87	94	O	patients
15	96	101	O	taking
16	103	110	B-DYN	coumarin
17	112	125	L-DYN	anticoagulants
18	127	128	O	to
19	130	133	O	whom
20	135	144	O	XXXXXXXX
21	146	148	O	was
22	150	161	O	administered
NULL

Nifedipine	DDI-DrugBank.d373.s10	NO_SECTION	NO_SETID	9
However, the relationship to nifedipine therapy is uncertain.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	24	O	relationship
5	26	27	O	to
6	29	38	O	XXXXXXXX
7	40	46	O	therapy
8	48	49	O	is
9	51	59	O	uncertain
NULL

Nifedipine	DDI-DrugBank.d373.s11	NO_SECTION	NO_SETID	44
Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.
1	0	9	U-UNK	Cimetidine
2	10	10	O	:
3	12	12	O	A
4	14	18	O	study
5	20	21	O	in
6	23	23	O	6
7	25	31	O	healthy
8	33	42	O	volunteers
9	44	46	O	has
10	48	52	O	shown
11	54	54	O	a
12	56	66	O	significant
13	68	75	O	increase
14	77	78	O	in
15	80	83	O	peak
16	85	94	O	XXXXXXXX
17	96	101	O	plasma
18	103	108	O	levels
19	111	113	O	80%
20	116	118	O	and
21	120	123	O	area
22	125	129	O	under
23	131	133	O	the
24	135	139	O	curve
25	142	144	O	74%
26	147	151	O	after
27	153	153	O	a
28	155	155	O	1
29	157	160	O	week
30	162	167	O	course
31	169	170	O	of
32	172	181	U-KIN	cimetidine
33	183	184	O	at
34	186	189	O	1000
35	191	192	O	mg
36	194	196	O	per
37	198	200	O	day
38	202	204	O	and
39	206	215	O	XXXXXXXX
40	217	218	O	at
41	220	221	O	40
42	223	224	O	mg
43	226	228	O	per
44	230	232	O	day
NULL

Nifedipine	DDI-DrugBank.d373.s12	NO_SECTION	NO_SETID	7
Ranitidine produced smaller, non-significant increases.
1	0	9	U-UNK	Ranitidine
2	11	18	O	produced
3	20	26	O	smaller
4	27	27	O	,
5	29	31	O	non
6	33	43	O	significant
7	45	53	O	increases
NULL

Nifedipine	DDI-DrugBank.d373.s13	NO_SECTION	NO_SETID	29
The effect may be mediated by the known inhibition of cimetidine on hepatic cytochrome P-450, the enzyme system probably responsible for the first-pass metabolism of nifedipine.
1	0	2	O	The
2	4	9	O	effect
3	11	13	O	may
4	15	16	O	be
5	18	25	O	mediated
6	27	28	O	by
7	30	32	O	the
8	34	38	O	known
9	40	49	O	inhibition
10	51	52	O	of
11	54	63	U-UNK	cimetidine
12	65	66	O	on
13	68	74	O	hepatic
14	76	85	O	cytochrome
15	87	87	O	P
16	89	91	O	450
17	92	92	O	,
18	94	96	O	the
19	98	103	O	enzyme
20	105	110	O	system
21	112	119	O	probably
22	121	131	O	responsible
23	133	135	O	for
24	137	139	O	the
25	141	145	O	first
26	147	150	O	pass
27	152	161	O	metabolism
28	163	164	O	of
29	166	175	O	XXXXXXXX
NULL

Nifedipine	DDI-DrugBank.d373.s14	NO_SECTION	NO_SETID	16
If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.
1	0	1	O	If
2	3	12	O	XXXXXXXX
3	14	20	O	therapy
4	22	23	O	is
5	25	33	O	initiated
6	35	36	O	in
7	38	38	O	a
8	40	46	O	patient
9	48	56	O	currently
10	58	66	O	receiving
11	68	77	U-DYN	cimetidine
12	78	78	O	,
13	80	87	O	cautious
14	89	97	O	titration
15	99	100	O	is
16	102	108	O	advised
NULL

Nilutamide	DDI-DrugBank.d177.s0	NO_SECTION	NO_SETID	29
In vitro, nilutamide has been shown to inhibit the activity of liver cytochrome P-450 isoenzymes and therefore, may reduce the metabolism of compounds requiring these systems.
1	0	1	O	In
2	3	7	O	vitro
3	8	8	O	,
4	10	19	O	XXXXXXXX
5	21	23	O	has
6	25	28	O	been
7	30	34	O	shown
8	36	37	O	to
9	39	45	O	inhibit
10	47	49	O	the
11	51	58	O	activity
12	60	61	O	of
13	63	67	O	liver
14	69	78	O	cytochrome
15	80	80	O	P
16	82	84	O	450
17	86	95	O	isoenzymes
18	97	99	O	and
19	101	109	O	therefore
20	110	110	O	,
21	112	114	O	may
22	116	121	O	reduce
23	123	125	O	the
24	127	136	O	metabolism
25	138	139	O	of
26	141	149	O	compounds
27	151	159	O	requiring
28	161	165	O	these
29	167	173	O	systems
NULL

Nilutamide	DDI-DrugBank.d177.s1	NO_SECTION	NO_SETID	37
Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, phenytoin, and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level.
1	0	11	O	Consequently
2	12	12	O	,
3	14	18	O	drugs
4	20	23	O	with
5	25	25	O	a
6	27	29	O	low
7	31	41	O	therapeutic
8	43	48	O	margin
9	49	49	O	,
10	51	54	O	such
11	56	57	O	as
12	59	65	B-UNK	vitamin
13	67	67	I-UNK	K
14	69	79	L-UNK	antagonists
15	80	80	O	,
16	82	90	U-UNK	phenytoin
17	91	91	O	,
18	93	95	O	and
19	97	108	U-UNK	theophylline
20	109	109	O	,
21	111	115	O	could
22	117	120	O	have
23	122	122	O	a
24	124	130	O	delayed
25	132	142	O	elimination
26	144	146	O	and
27	148	156	O	increases
28	158	159	O	in
29	161	165	O	their
30	167	171	O	serum
31	173	176	O	half
32	178	181	O	life
33	183	189	O	leading
34	191	192	O	to
35	194	194	O	a
36	196	200	O	toxic
37	202	206	O	level
NULL

Nilutamide	DDI-DrugBank.d177.s2	NO_SECTION	NO_SETID	23
The dosage of these drugs or others with a similar metabolism may need to be modified if they are administered concomitantly with nilutamide.
1	0	2	O	The
2	4	9	O	dosage
3	11	12	O	of
4	14	18	O	these
5	20	24	O	drugs
6	26	27	O	or
7	29	34	O	others
8	36	39	O	with
9	41	41	O	a
10	43	49	O	similar
11	51	60	O	metabolism
12	62	64	O	may
13	66	69	O	need
14	71	72	O	to
15	74	75	O	be
16	77	84	O	modified
17	86	87	O	if
18	89	92	O	they
19	94	96	O	are
20	98	109	O	administered
21	111	123	O	concomitantly
22	125	128	O	with
23	130	139	O	XXXXXXXX
NULL

Nilutamide	DDI-DrugBank.d177.s3	NO_SECTION	NO_SETID	32
For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.
1	0	2	O	For
2	4	10	O	example
3	11	11	O	,
4	13	16	O	when
5	18	24	B-DYN	vitamin
6	26	26	I-DYN	K
7	28	38	L-DYN	antagonists
8	40	42	O	are
9	44	55	O	administered
10	57	69	O	concomitantly
11	71	74	O	with
12	76	85	O	XXXXXXXX
13	86	86	O	,
14	88	98	O	prothrombin
15	100	103	O	time
16	105	110	O	should
17	112	113	O	be
18	115	123	O	carefully
19	125	133	O	monitored
20	135	137	O	and
21	139	140	O	if
22	142	150	O	necessary
23	151	151	O	,
24	153	155	O	the
25	157	162	O	dosage
26	164	165	O	of
27	167	173	B-UNK	vitamin
28	175	175	I-UNK	K
29	177	187	L-UNK	antagonists
30	189	194	O	should
31	196	197	O	be
32	199	205	O	reduced
NULL

Nimodipine	DDI-DrugBank.d310.s0	NO_SECTION	NO_SETID	20
It is possible that the cardiovascular action of other calcium channel blockers could be enhanced by the addition of Nimotop .
1	0	1	O	It
2	3	4	O	is
3	6	13	O	possible
4	15	18	O	that
5	20	22	O	the
6	24	37	O	cardiovascular
7	39	44	O	action
8	46	47	O	of
9	49	53	O	other
10	55	61	B-DYN	calcium
11	63	69	I-DYN	channel
12	71	78	L-DYN	blockers
13	80	84	O	could
14	86	87	O	be
15	89	96	O	enhanced
16	98	99	O	by
17	101	103	O	the
18	105	112	O	addition
19	114	115	O	of
20	117	123	O	XXXXXXXX
NULL

Nimodipine	DDI-DrugBank.d310.s1	NO_SECTION	NO_SETID	21
In Europe, Nimotop  was observed to occasionally intensify the effect of antihypertensive compounds taken concomitantly by patients suffering from hypertension;
1	0	1	O	In
2	3	8	O	Europe
3	9	9	O	,
4	11	17	O	XXXXXXXX
5	20	22	O	was
6	24	31	O	observed
7	33	34	O	to
8	36	47	O	occasionally
9	49	57	O	intensify
10	59	61	O	the
11	63	68	O	effect
12	70	71	O	of
13	73	88	B-DYN	antihypertensive
14	90	98	L-DYN	compounds
15	100	104	O	taken
16	106	118	O	concomitantly
17	120	121	O	by
18	123	130	O	patients
19	132	140	O	suffering
20	142	145	O	from
21	147	158	O	hypertension
NULL

Nimodipine	DDI-DrugBank.d310.s2	NO_SECTION	NO_SETID	10
this phenomenon was not observed in North American clinical trials.
1	0	3	O	this
2	5	14	O	phenomenon
3	16	18	O	was
4	20	22	O	not
5	24	31	O	observed
6	33	34	O	in
7	36	40	O	North
8	42	49	O	American
9	51	58	O	clinical
10	60	65	O	trials
NULL

Nimodipine	DDI-DrugBank.d310.s3	NO_SECTION	NO_SETID	47
A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.
1	0	0	O	A
2	2	6	O	study
3	8	9	O	in
4	11	15	O	eight
5	17	23	O	healthy
6	25	34	O	volunteers
7	36	38	O	has
8	40	44	O	shown
9	46	46	O	a
10	48	50	O	50%
11	52	59	O	increase
12	61	62	O	in
13	64	67	O	mean
14	69	72	O	peak
15	74	83	O	XXXXXXXX
16	85	90	O	plasma
17	92	105	O	concentrations
18	107	109	O	and
19	111	111	O	a
20	113	115	O	90%
21	117	124	O	increase
22	126	127	O	in
23	129	132	O	mean
24	134	137	O	area
25	139	143	O	under
26	145	147	O	the
27	149	153	O	curve
28	154	154	O	,
29	156	160	O	after
30	162	162	O	a
31	164	166	O	one
32	168	171	O	week
33	173	178	O	course
34	180	181	O	of
35	183	192	U-KIN	cimetidine
36	194	195	O	at
37	197	201	O	1,000
38	203	204	O	mg
39	205	205	O	/
40	206	208	O	day
41	210	212	O	and
42	214	223	O	XXXXXXXX
43	225	226	O	at
44	228	229	O	90
45	231	232	O	mg
46	233	233	O	/
47	234	236	O	day
NULL

Nimodipine	DDI-DrugBank.d310.s4	NO_SECTION	NO_SETID	25
This effect may be mediated by the known inhibition of hepatic cytochrome P- 450 by cimetidine, which could decrease first pass metabolism of nimodipine.
1	0	3	O	This
2	5	10	O	effect
3	12	14	O	may
4	16	17	O	be
5	19	26	O	mediated
6	28	29	O	by
7	31	33	O	the
8	35	39	O	known
9	41	50	O	inhibition
10	52	53	O	of
11	55	61	O	hepatic
12	63	72	O	cytochrome
13	74	74	O	P
14	77	79	O	450
15	81	82	O	by
16	84	93	U-UNK	cimetidine
17	94	94	O	,
18	96	100	O	which
19	102	106	O	could
20	108	115	O	decrease
21	117	121	O	first
22	123	126	O	pass
23	128	137	O	metabolism
24	139	140	O	of
25	142	151	U-KIN	XXXXXXXX
NULL

Nisoldipine	DDI-DrugBank.d106.s0	NO_SECTION	NO_SETID	22
A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.
1	0	0	O	A
2	2	3	O	30
3	5	6	O	to
4	8	10	O	45%
5	12	19	O	increase
6	21	22	O	in
7	24	26	O	AUC
8	28	30	O	and
9	32	35	O	Cmax
10	37	38	O	of
11	40	50	O	XXXXXXXX
12	52	54	O	was
13	56	63	O	observed
14	65	68	O	with
15	70	80	O	concomitant
16	82	95	O	administration
17	97	98	O	of
18	100	109	B-KIN	cimetidine
19	111	113	I-KIN	400
20	115	116	L-KIN	mg
21	118	122	O	twice
22	124	128	O	daily
NULL

Nisoldipine	DDI-DrugBank.d106.s1	NO_SECTION	NO_SETID	18
Ranitidine 150 mg twice daily did not interact significantly with nisoldipine (AUC was decreased by 15-20 %).
1	0	9	U-UNK	Ranitidine
2	11	13	O	150
3	15	16	O	mg
4	18	22	O	twice
5	24	28	O	daily
6	30	32	O	did
7	34	36	O	not
8	38	45	O	interact
9	47	59	O	significantly
10	61	64	O	with
11	66	76	O	XXXXXXXX
12	79	81	O	AUC
13	83	85	O	was
14	87	95	O	decreased
15	97	98	O	by
16	100	101	O	15
17	103	104	O	20
18	106	106	O	%
NULL

Nisoldipine	DDI-DrugBank.d106.s2	NO_SECTION	NO_SETID	11
No pharmacodynamic effects of either histamine H2 receptor antagonist were observed.
1	0	1	O	No
2	3	17	O	pharmacodynamic
3	19	25	O	effects
4	27	28	O	of
5	30	35	O	either
6	37	45	B-UNK	histamine
7	47	48	I-UNK	H2
8	50	57	I-UNK	receptor
9	59	68	L-UNK	antagonist
10	70	73	O	were
11	75	82	O	observed
NULL

Nisoldipine	DDI-DrugBank.d106.s3	NO_SECTION	NO_SETID	19
Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	28	U-KIN	phenytoin
4	30	33	O	with
5	35	36	O	40
6	38	39	O	mg
7	41	45	O	XXXXXXXX
8	47	53	O	tablets
9	55	56	O	in
10	58	66	O	epileptic
11	68	75	O	patients
12	77	83	O	lowered
13	85	87	O	the
14	89	99	U-UNK	nisoldipine
15	101	106	O	plasma
16	108	121	O	concentrations
17	123	124	O	to
18	126	137	O	undetectable
19	139	144	O	levels
NULL

Nisoldipine	DDI-DrugBank.d106.s4	NO_SECTION	NO_SETID	20
Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	24	O	XXXXXXXX
4	26	29	O	with
5	31	39	U-DYN	phenytoin
6	41	42	O	or
7	44	46	O	any
8	48	52	O	known
9	54	59	O	CYP3A4
10	61	67	O	inducer
11	69	74	O	should
12	76	77	O	be
13	79	85	O	avoided
14	87	89	O	and
15	91	101	O	alternative
16	103	118	U-UNK	antihypertensive
17	120	126	O	therapy
18	128	133	O	should
19	135	136	O	be
20	138	147	O	considered
NULL

Nisoldipine	DDI-DrugBank.d106.s5	NO_SECTION	NO_SETID	15
Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant.
1	0	14	O	Pharmacokinetic
2	16	27	O	interactions
3	29	35	O	between
4	37	47	O	XXXXXXXX
5	49	51	O	and
6	53	56	B-UNK	beta
7	58	65	L-UNK	blockers
8	68	75	U-UNK	atenolol
9	76	76	O	,
10	78	88	U-UNK	propranolol
11	91	94	O	were
12	96	103	O	variable
13	105	107	O	and
14	109	111	O	not
15	113	123	O	significant
NULL

Nisoldipine	DDI-DrugBank.d106.s6	NO_SECTION	NO_SETID	12
Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.
1	0	10	U-DYN	Propranolol
2	12	21	O	attenuated
3	23	25	O	the
4	27	31	O	heart
5	33	36	O	rate
6	38	45	O	increase
7	47	55	O	following
8	57	70	O	administration
9	72	73	O	of
10	75	83	O	immediate
11	85	91	O	release
12	93	103	O	XXXXXXXX
NULL

Nisoldipine	DDI-DrugBank.d106.s7	NO_SECTION	NO_SETID	22
The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.
1	0	2	O	The
2	4	8	O	blood
3	10	17	O	pressure
4	19	24	O	effect
5	26	27	O	of
6	29	33	O	XXXXXXXX
7	35	40	O	tended
8	42	43	O	to
9	45	46	O	be
10	48	54	O	greater
11	56	57	O	in
12	59	66	O	patients
13	68	69	O	on
14	71	78	U-DYN	atenolol
15	80	83	O	than
16	85	86	O	in
17	88	95	O	patients
18	97	98	O	on
19	100	101	O	no
20	103	107	O	other
21	109	124	U-UNK	antihypertensive
22	126	132	O	therapy
NULL

Nisoldipine	DDI-DrugBank.d106.s8	NO_SECTION	NO_SETID	19
Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.
1	0	8	U-KIN	Quinidine
2	10	11	O	at
3	13	15	O	648
4	17	18	O	mg
5	20	22	O	bid
6	24	32	O	decreased
7	34	36	O	the
8	38	52	O	bioavailability
9	55	57	O	AUC
10	60	61	O	of
11	63	73	O	XXXXXXXX
12	75	76	O	by
13	78	80	O	26%
14	81	81	O	,
15	83	85	O	but
16	87	89	O	not
17	91	93	O	the
18	95	98	O	peak
19	100	112	O	concentration
NULL

Nisoldipine	DDI-DrugBank.d106.s9	NO_SECTION	NO_SETID	19
The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.
1	0	2	O	The
2	4	12	O	immediate
3	14	20	O	release
4	21	21	O	,
5	23	25	O	but
6	27	29	O	not
7	31	33	O	the
8	35	38	O	coat
9	40	43	O	core
10	45	55	O	formulation
11	57	58	O	of
12	60	70	O	XXXXXXXX
13	72	80	O	increased
14	82	87	O	plasma
15	89	97	U-KIN	quinidine
16	99	112	O	concentrations
17	114	115	O	by
18	117	121	O	about
19	123	125	O	20%
NULL

Nisoldipine	DDI-DrugBank.d106.s10	NO_SECTION	NO_SETID	15
This interaction was not accompanied by ECG changes and its clinical significance is not known.
1	0	3	O	This
2	5	15	O	interaction
3	17	19	O	was
4	21	23	O	not
5	25	35	O	accompanied
6	37	38	O	by
7	40	42	O	ECG
8	44	50	O	changes
9	52	54	O	and
10	56	58	O	its
11	60	67	O	clinical
12	69	80	O	significance
13	82	83	O	is
14	85	87	O	not
15	89	93	O	known
NULL

Nisoldipine	DDI-DrugBank.d106.s11	NO_SECTION	NO_SETID	11
No significant interactions were found between nisoldipine and warfarin or digoxin.
1	0	1	O	No
2	3	13	O	significant
3	15	26	O	interactions
4	28	31	O	were
5	33	37	O	found
6	39	45	O	between
7	47	57	O	XXXXXXXX
8	59	61	O	and
9	63	70	U-UNK	warfarin
10	72	73	O	or
11	75	81	U-UNK	digoxin
NULL

Nitazoxanide	DDI-DrugBank.d354.s0	NO_SECTION	NO_SETID	8
Tizoxanide is highly bound to plasma protein ( 99.9%).
1	0	9	U-UNK	Tizoxanide
2	11	12	O	is
3	14	19	O	highly
4	21	25	O	bound
5	27	28	O	to
6	30	35	O	plasma
7	37	43	O	protein
8	47	51	O	99.9%
NULL

Nitazoxanide	DDI-DrugBank.d354.s1	NO_SECTION	NO_SETID	32
Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	O	caution
4	19	24	O	should
5	26	27	O	be
6	29	32	O	used
7	34	37	O	when
8	39	51	O	administering
9	53	64	O	XXXXXXXX
10	66	77	O	concurrently
11	79	82	O	with
12	84	88	O	other
13	90	95	O	highly
14	97	102	O	plasma
15	104	110	O	protein
16	112	116	O	bound
17	118	122	O	drugs
18	124	127	O	with
19	129	134	O	narrow
20	136	146	O	therapeutic
21	148	154	O	indices
22	155	155	O	,
23	157	158	O	as
24	160	170	O	competition
25	172	174	O	for
26	176	182	O	binding
27	184	188	O	sites
28	190	192	O	may
29	194	198	O	occur
30	201	203	O	e.g
31	205	205	O	,
32	207	214	U-KIN	warfarin
NULL

Nitazoxanide	DDI-DrugBank.d354.s2	NO_SECTION	NO_SETID	17
In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes.
1	0	1	O	In
2	3	7	O	vitro
3	9	18	O	metabolism
4	20	26	O	studies
5	28	31	O	have
6	33	44	O	demonstrated
7	46	49	O	that
8	51	60	U-UNK	tizoxanide
9	62	64	O	has
10	66	67	O	no
11	69	79	O	significant
12	81	90	O	inhibitory
13	92	97	O	effect
14	99	100	O	on
15	102	111	O	cytochrome
16	113	116	O	P450
17	118	124	O	enzymes
NULL

Nitazoxanide	DDI-DrugBank.d354.s3	NO_SECTION	NO_SETID	38
Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.
1	0	7	O	Although
2	9	10	O	no
3	12	15	O	drug
4	17	20	O	drug
5	22	32	O	interaction
6	34	40	O	studies
7	42	45	O	have
8	47	50	O	been
9	52	60	O	conducted
10	62	63	O	in
11	65	68	O	vivo
12	69	69	O	,
13	71	72	O	it
14	74	75	O	is
15	77	84	O	expected
16	86	89	O	that
17	91	92	O	no
18	94	104	O	significant
19	106	116	O	interaction
20	118	122	O	would
21	124	128	O	occur
22	130	133	O	when
23	135	146	O	XXXXXXXX
24	148	149	O	is
25	151	152	O	co
26	154	165	O	administered
27	167	170	O	with
28	172	176	O	drugs
29	178	181	O	that
30	183	188	O	either
31	190	192	O	are
32	194	204	O	metabolized
33	206	207	O	by
34	209	210	O	or
35	212	218	O	inhibit
36	220	229	O	cytochrome
37	231	234	O	P450
38	236	242	O	enzymes
NULL

Nitric Oxide	DDI-DrugBank.d183.s0	NO_SECTION	NO_SETID	33
No formal drug-interaction studies have been performed, and a clinically significant interaction with other medications used in the treatment of hypoxic respiratory failure cannot be excluded based on the available data.
1	0	1	O	No
2	3	8	O	formal
3	10	13	O	drug
4	15	25	O	interaction
5	27	33	O	studies
6	35	38	O	have
7	40	43	O	been
8	45	53	O	performed
9	54	54	O	,
10	56	58	O	and
11	60	60	O	a
12	62	71	O	clinically
13	73	83	O	significant
14	85	95	O	interaction
15	97	100	O	with
16	102	106	O	other
17	108	118	O	medications
18	120	123	O	used
19	125	126	O	in
20	128	130	O	the
21	132	140	O	treatment
22	142	143	O	of
23	145	151	O	hypoxic
24	153	163	O	respiratory
25	165	171	O	failure
26	173	178	O	cannot
27	180	181	O	be
28	183	190	O	excluded
29	192	196	O	based
30	198	199	O	on
31	201	203	O	the
32	205	213	O	available
33	215	218	O	data
NULL

Nitric Oxide	DDI-DrugBank.d183.s1	NO_SECTION	NO_SETID	19
INOmax has been administered with tolazoline, dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation.
1	0	5	O	XXXXXXXX
2	7	9	O	has
3	11	14	O	been
4	16	27	O	administered
5	29	32	O	with
6	34	43	U-UNK	tolazoline
7	44	44	O	,
8	46	53	U-UNK	dopamine
9	54	54	O	,
10	56	65	U-UNK	dobutamine
11	66	66	O	,
12	68	75	U-UNK	steroids
13	76	76	O	,
14	78	87	U-UNK	surfactant
15	88	88	O	,
16	90	92	O	and
17	94	97	O	high
18	99	107	O	frequency
19	109	119	O	ventilation
NULL

Nitric Oxide	DDI-DrugBank.d183.s2	NO_SECTION	NO_SETID	35
Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
1	0	7	O	Although
2	9	13	O	there
3	15	17	O	are
4	19	20	O	no
5	22	26	O	study
6	28	31	O	data
7	33	34	O	to
8	36	43	O	evaluate
9	45	47	O	the
10	49	59	O	possibility
11	60	60	O	,
12	62	67	B-DYN	nitric
13	69	73	I-DYN	oxide
14	75	79	I-DYN	donor
15	81	89	L-DYN	compounds
16	90	90	O	,
17	92	100	O	including
18	102	107	B-DYN	sodium
19	109	121	L-DYN	nitroprusside
20	123	125	O	and
21	127	139	U-DYN	nitroglycerin
22	140	140	O	,
23	142	144	O	may
24	146	149	O	have
25	151	152	O	an
26	154	161	O	additive
27	163	168	O	effect
28	170	173	O	with
29	175	180	O	XXXXXXXX
30	182	183	O	on
31	185	187	O	the
32	189	192	O	risk
33	194	195	O	of
34	197	206	O	developing
35	208	224	O	methemoglobinemia
NULL

Nitric Oxide	DDI-DrugBank.d183.s3	NO_SECTION	NO_SETID	24
An association between prilocaine and an increased risk of methaemoglobinaemia, particularly in infants, has specifically been described in a literature case report.
1	0	1	O	An
2	3	13	O	association
3	15	21	O	between
4	23	32	U-UNK	prilocaine
5	34	36	O	and
6	38	39	O	an
7	41	49	O	increased
8	51	54	O	risk
9	56	57	O	of
10	59	77	O	methaemoglobinaemia
11	78	78	O	,
12	80	91	O	particularly
13	93	94	O	in
14	96	102	O	infants
15	103	103	O	,
16	105	107	O	has
17	109	120	O	specifically
18	122	125	O	been
19	127	135	O	described
20	137	138	O	in
21	140	140	O	a
22	142	151	O	literature
23	153	156	O	case
24	158	163	O	report
NULL

Nitric Oxide	DDI-DrugBank.d183.s4	NO_SECTION	NO_SETID	17
This risk is present whether the drugs are administered as oral, parenteral, or topical formulations.
1	0	3	O	This
2	5	8	O	risk
3	10	11	O	is
4	13	19	O	present
5	21	27	O	whether
6	29	31	O	the
7	33	37	O	drugs
8	39	41	O	are
9	43	54	O	administered
10	56	57	O	as
11	59	62	O	oral
12	63	63	O	,
13	65	74	O	parenteral
14	75	75	O	,
15	77	78	O	or
16	80	86	O	topical
17	88	99	O	formulations
NULL

Nitrofurantoin	DDI-DrugBank.d276.s0	NO_SECTION	NO_SETID	19
Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.
1	0	7	U-UNK	Antacids
2	9	18	O	containing
3	20	28	B-KIN	magnesium
4	30	40	L-KIN	trisilicate
5	41	41	O	,
6	43	46	O	when
7	48	59	O	administered
8	61	73	O	concomitantly
9	75	78	O	with
10	80	93	O	XXXXXXXX
11	94	94	O	,
12	96	101	O	reduce
13	103	106	O	both
14	108	110	O	the
15	112	115	O	rate
16	117	119	O	and
17	121	126	O	extent
18	128	129	O	of
19	131	140	O	absorption
NULL

Nitrofurantoin	DDI-DrugBank.d276.s1	NO_SECTION	NO_SETID	16
The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.
1	0	2	O	The
2	4	12	O	mechanism
3	14	16	O	for
4	18	21	O	this
5	23	33	O	interaction
6	35	42	O	probably
7	44	45	O	is
8	47	56	O	adsorption
9	58	59	O	of
10	61	74	O	XXXXXXXX
11	76	79	O	onto
12	81	83	O	the
13	85	91	O	surface
14	93	94	O	of
15	96	104	B-KIN	magnesium
16	106	116	L-KIN	trisilicate
NULL

Nitrofurantoin	DDI-DrugBank.d276.s2	NO_SECTION	NO_SETID	16
Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
1	0	9	B-KIN	Uricosuric
2	11	15	L-KIN	drugs
3	16	16	O	,
4	18	21	O	such
5	23	24	O	as
6	26	35	U-KIN	probenecid
7	37	39	O	and
8	41	54	U-KIN	sulfinpyrazone
9	55	55	O	,
10	57	59	O	can
11	61	67	O	inhibit
12	69	73	O	renal
13	75	81	O	tubular
14	83	91	O	secretion
15	93	94	O	of
16	96	109	O	XXXXXXXX
NULL

Nitrofurantoin	DDI-DrugBank.d276.s3	NO_SECTION	NO_SETID	25
The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.
1	0	2	O	The
2	4	12	O	resulting
3	14	21	O	increase
4	23	24	O	in
5	26	39	O	XXXXXXXX
6	41	45	O	serum
7	47	52	O	levels
8	54	56	O	may
9	58	65	O	increase
10	67	74	O	toxicity
11	75	75	O	,
12	77	79	O	and
13	81	83	O	the
14	85	93	O	decreased
15	95	101	O	urinary
16	103	108	O	levels
17	110	114	O	could
18	116	121	O	lessen
19	123	125	O	its
20	127	134	O	efficacy
21	136	137	O	as
22	139	139	O	a
23	141	147	O	urinary
24	149	153	O	tract
25	155	167	U-UNK	antibacterial
NULL

Nitrofurantoin	DDI-DrugBank.d276.s4	NO_SECTION	NO_SETID	25
Drug/Laboratory Test Interactions As a result of the presence of nitrofurantoin, a false-positive reaction for glucose in the urine may occur.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	35	O	As
7	37	37	O	a
8	39	44	O	result
9	46	47	O	of
10	49	51	O	the
11	53	60	O	presence
12	62	63	O	of
13	65	78	O	XXXXXXXX
14	79	79	O	,
15	81	81	O	a
16	83	87	O	false
17	89	96	O	positive
18	98	105	O	reaction
19	107	109	O	for
20	111	117	O	glucose
21	119	120	O	in
22	122	124	O	the
23	126	130	O	urine
24	132	134	O	may
25	136	140	O	occur
NULL

Nitrofurantoin	DDI-DrugBank.d276.s5	NO_SECTION	NO_SETID	18
This has been observed with Benedict s and Fehling s solutions but not with the glucose enzymatic test.
1	0	3	O	This
2	5	7	O	has
3	9	12	O	been
4	14	21	O	observed
5	23	26	O	with
6	28	35	O	Benedict
7	37	37	O	s
8	39	41	O	and
9	43	49	O	Fehling
10	51	51	O	s
11	53	61	O	solutions
12	63	65	O	but
13	67	69	O	not
14	71	74	O	with
15	76	78	O	the
16	80	86	O	glucose
17	88	96	O	enzymatic
18	98	101	O	test
NULL

Nitroglycerin	DDI-DrugBank.d14.s0	NO_SECTION	NO_SETID	13
The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.
1	0	2	O	The
2	4	15	O	vasodilating
3	17	23	O	effects
4	25	26	O	of
5	28	40	O	XXXXXXXX
6	42	44	O	may
7	46	47	O	be
8	49	56	O	additive
9	58	61	O	with
10	63	67	O	those
11	69	70	O	of
12	72	76	O	other
13	78	89	U-DYN	vasodilators
NULL

Nitroglycerin	DDI-DrugBank.d14.s1	NO_SECTION	NO_SETID	15
Alcohol, in particular, has been found to exhibit additive effects of this variety.
1	0	6	U-UNK	Alcohol
2	7	7	O	,
3	9	10	O	in
4	12	21	O	particular
5	22	22	O	,
6	24	26	O	has
7	28	31	O	been
8	33	37	O	found
9	39	40	O	to
10	42	48	O	exhibit
11	50	57	O	additive
12	59	65	O	effects
13	67	68	O	of
14	70	73	O	this
15	75	81	O	variety
NULL

Nitroglycerin	DDI-DrugBank.d14.s2	NO_SECTION	NO_SETID	18
Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.
1	0	5	O	Marked
2	7	17	O	symptomatic
3	19	29	O	orthostatic
4	31	41	O	hypotension
5	43	45	O	has
6	47	50	O	been
7	52	59	O	reported
8	61	64	O	when
9	66	72	B-UNK	calcium
10	74	80	I-UNK	channel
11	82	89	L-UNK	blockers
12	91	93	O	and
13	95	101	O	organic
14	103	110	U-UNK	nitrates
15	112	115	O	were
16	117	120	O	used
17	122	123	O	in
18	125	135	O	combination
NULL

Nitroglycerin	DDI-DrugBank.d14.s3	NO_SECTION	NO_SETID	10
Dose adjustments of either class of agents may be necessary.
1	0	3	O	Dose
2	5	15	O	adjustments
3	17	18	O	of
4	20	25	O	either
5	27	31	O	class
6	33	34	O	of
7	36	41	O	agents
8	43	45	O	may
9	47	48	O	be
10	50	58	O	necessary
NULL

Nitroprusside	DDI-DrugBank.d394.s0	NO_SECTION	NO_SETID	28
The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.
1	0	2	O	The
2	4	14	O	hypotensive
3	16	21	O	effect
4	23	24	O	of
5	26	31	O	sodium
6	33	45	O	XXXXXXXX
7	47	48	O	is
8	50	58	O	augmented
9	60	61	O	by
10	63	66	O	that
11	68	69	O	of
12	71	74	O	most
13	76	80	O	other
14	82	92	B-DYN	hypotensive
15	94	98	L-DYN	drugs
16	99	99	O	,
17	101	109	O	including
18	111	120	B-DYN	ganglionic
19	122	129	I-DYN	blocking
20	131	136	L-DYN	agents
21	137	137	O	,
22	139	146	O	negative
23	148	156	O	inotropic
24	158	163	O	agents
25	164	164	O	,
26	166	168	O	and
27	170	176	O	inhaled
28	178	188	U-DYN	anesthetics
NULL

Nizatidine	DDI-DrugBank.d475.s0	NO_SECTION	NO_SETID	20
No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin.
1	0	1	O	No
2	3	14	O	interactions
3	16	19	O	have
4	21	24	O	been
5	26	33	O	observed
6	35	41	O	between
7	43	52	O	XXXXXXXX
8	54	56	O	and
9	58	69	U-UNK	theophylline
10	70	70	O	,
11	72	87	U-UNK	chlordiazepoxide
12	88	88	O	,
13	90	98	U-UNK	lorazepam
14	99	99	O	,
15	101	109	U-UNK	lidocaine
16	110	110	O	,
17	112	120	U-UNK	phenytoin
18	121	121	O	,
19	123	125	O	and
20	127	134	U-UNK	warfarin
NULL

Nizatidine	DDI-DrugBank.d475.s1	NO_SECTION	NO_SETID	13
Nizatidine does not inhibit the cytochrome P-450-linked drug-metabolizing enzyme system;
1	0	9	O	XXXXXXXX
2	11	14	O	does
3	16	18	O	not
4	20	26	O	inhibit
5	28	30	O	the
6	32	41	O	cytochrome
7	43	43	O	P
8	45	47	O	450
9	49	54	O	linked
10	56	59	O	drug
11	61	72	O	metabolizing
12	74	79	O	enzyme
13	81	86	O	system
NULL

Nizatidine	DDI-DrugBank.d475.s2	NO_SECTION	NO_SETID	15
therefore, drug interactions mediated by inhibition of hepatic metabolism are not expected to occur.
1	0	8	O	therefore
2	9	9	O	,
3	11	14	O	drug
4	16	27	O	interactions
5	29	36	O	mediated
6	38	39	O	by
7	41	50	O	inhibition
8	52	53	O	of
9	55	61	O	hepatic
10	63	72	O	metabolism
11	74	76	O	are
12	78	80	O	not
13	82	89	O	expected
14	91	92	O	to
15	94	98	O	occur
NULL

Nizatidine	DDI-DrugBank.d475.s3	NO_SECTION	NO_SETID	29
In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.
1	0	1	O	In
2	3	10	O	patients
3	12	16	O	given
4	18	21	O	very
5	23	26	O	high
6	28	32	O	doses
7	35	38	O	3900
8	40	41	O	mg
9	44	45	O	of
10	47	53	O	XXXXXXXX
11	55	59	O	daily
12	60	60	O	,
13	62	70	O	increases
14	72	73	O	in
15	75	79	O	serum
16	81	90	U-UNK	salicylate
17	92	97	O	levels
18	99	102	O	were
19	104	107	O	seen
20	109	112	O	when
21	114	123	U-KIN	nizatidine
22	124	124	O	,
23	126	128	O	150
24	130	131	O	mg
25	133	137	O	b.i.d
26	139	139	O	,
27	141	143	O	was
28	145	156	O	administered
29	158	169	O	concurrently
NULL

Norethindrone	DDI-DrugBank.d306.s0	NO_SECTION	NO_SETID	29
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.
1	0	2	O	The
2	4	16	O	effectiveness
3	18	19	O	of
4	21	29	U-UNK	progestin
5	31	34	O	only
6	36	40	O	pills
7	42	43	O	is
8	45	51	O	reduced
9	53	54	O	by
10	56	62	O	hepatic
11	64	69	O	enzyme
12	71	78	O	inducing
13	80	84	O	drugs
14	86	89	O	such
15	91	92	O	as
16	94	96	O	the
17	98	112	U-UNK	anticonvulsants
18	114	122	U-UNK	phenytoin
19	123	123	O	,
20	125	137	U-UNK	carbamazepine
21	138	138	O	,
22	140	142	O	and
23	144	155	U-UNK	barbiturates
24	156	156	O	,
25	158	160	O	and
26	162	164	O	the
27	166	181	B-UNK	antituberculosis
28	183	186	L-UNK	drug
29	188	195	U-UNK	rifampin
NULL

Norethindrone	DDI-DrugBank.d306.s1	NO_SECTION	NO_SETID	10
No significant interaction has been found with broad-spectrum antibiotics.
1	0	1	O	No
2	3	13	O	significant
3	15	25	O	interaction
4	27	29	O	has
5	31	34	O	been
6	36	40	O	found
7	42	45	O	with
8	47	51	O	broad
9	53	60	O	spectrum
10	62	72	U-UNK	antibiotics
NULL

Norfloxacin	DDI-DrugBank.d217.s0	NO_SECTION	NO_SETID	12
Elevated plasma levels of theophylline have been reported with concomitant quinolone use.
1	0	7	O	Elevated
2	9	14	O	plasma
3	16	21	O	levels
4	23	24	O	of
5	26	37	U-UNK	theophylline
6	39	42	O	have
7	44	47	O	been
8	49	56	O	reported
9	58	61	O	with
10	63	73	O	concomitant
11	75	83	U-UNK	quinolone
12	85	87	O	use
NULL

Norfloxacin	DDI-DrugBank.d217.s1	NO_SECTION	NO_SETID	18
There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	22	O	reports
5	24	25	O	of
6	27	38	U-UNK	theophylline
7	40	46	O	related
8	48	51	O	side
9	53	59	O	effects
10	61	62	O	in
11	64	71	O	patients
12	73	74	O	on
13	76	86	O	concomitant
14	88	94	O	therapy
15	96	99	O	with
16	101	111	O	XXXXXXXX
17	113	115	O	and
18	117	128	U-DYN	theophylline
NULL

Norfloxacin	DDI-DrugBank.d217.s2	NO_SECTION	NO_SETID	17
Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	monitoring
4	22	23	O	of
5	25	36	U-UNK	theophylline
6	38	43	O	plasma
7	45	50	O	levels
8	52	57	O	should
9	59	60	O	be
10	62	71	O	considered
11	73	75	O	and
12	77	82	O	dosage
13	84	85	O	of
14	87	98	U-UNK	theophylline
15	100	107	O	adjusted
16	109	110	O	as
17	112	119	O	required
NULL

Norfloxacin	DDI-DrugBank.d217.s3	NO_SECTION	NO_SETID	15
Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.
1	0	7	O	Elevated
2	9	13	O	serum
3	15	20	O	levels
4	22	23	O	of
5	25	36	U-UNK	cyclosporine
6	38	41	O	have
7	43	46	O	been
8	48	55	O	reported
9	57	60	O	with
10	62	72	O	concomitant
11	74	76	O	use
12	78	79	O	of
13	81	92	U-KIN	cyclosporine
14	94	97	O	with
15	99	109	O	XXXXXXXX
NULL

Norfloxacin	DDI-DrugBank.d217.s4	NO_SECTION	NO_SETID	20
Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.
1	0	8	O	Therefore
2	9	9	O	,
3	11	22	U-UNK	cyclosporine
4	24	28	O	serum
5	30	35	O	levels
6	37	42	O	should
7	44	45	O	be
8	47	55	O	monitored
9	57	59	O	and
10	61	71	O	appropriate
11	73	84	U-UNK	cyclosporine
12	86	91	O	dosage
13	93	103	O	adjustments
14	105	108	O	made
15	110	113	O	when
16	115	119	O	these
17	121	125	O	drugs
18	127	129	O	are
19	131	134	O	used
20	136	148	O	concomitantly
NULL

Norfloxacin	DDI-DrugBank.d217.s5	NO_SECTION	NO_SETID	21
Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
1	0	9	U-UNK	Quinolones
2	10	10	O	,
3	12	20	O	including
4	22	32	O	XXXXXXXX
5	33	33	O	,
6	35	37	O	may
7	39	45	O	enhance
8	47	49	O	the
9	51	57	O	effects
10	59	60	O	of
11	62	65	O	oral
12	67	80	U-DYN	anticoagulants
13	81	81	O	,
14	83	91	O	including
15	93	100	U-DYN	warfarin
16	102	103	O	or
17	105	107	O	its
18	109	119	O	derivatives
19	121	122	O	or
20	124	130	O	similar
21	132	137	O	agents
NULL

Norfloxacin	DDI-DrugBank.d217.s6	NO_SECTION	NO_SETID	18
When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be closely monitored.
1	0	3	O	When
2	5	9	O	these
3	11	18	O	products
4	20	22	O	are
5	24	35	O	administered
6	37	49	O	concomitantly
7	50	50	O	,
8	52	62	O	prothrombin
9	64	67	O	time
10	69	70	O	or
11	72	76	O	other
12	78	85	O	suitable
13	87	97	O	coagulation
14	99	103	O	tests
15	105	110	O	should
16	112	113	O	be
17	115	121	O	closely
18	123	131	O	monitored
NULL

Norfloxacin	DDI-DrugBank.d217.s7	NO_SECTION	NO_SETID	22
The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.
1	0	2	O	The
2	4	14	O	concomitant
3	16	29	O	administration
4	31	32	O	of
5	34	43	U-UNK	quinolones
6	45	53	O	including
7	55	65	O	XXXXXXXX
8	67	70	O	with
9	72	80	U-DYN	glyburide
10	83	83	O	a
11	85	96	B-UNK	sulfonylurea
12	98	102	L-UNK	agent
13	105	107	O	has
14	108	108	O	,
15	110	111	O	on
16	113	116	O	rare
17	118	126	O	occasions
18	127	127	O	,
19	129	136	O	resulted
20	138	139	O	in
21	141	146	O	severe
22	148	159	O	hypoglycemia
NULL

Norfloxacin	DDI-DrugBank.d217.s8	NO_SECTION	NO_SETID	14
Therefore, monitoring of blood glucose is recommended when these agents are co-administered.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	monitoring
4	22	23	O	of
5	25	29	O	blood
6	31	37	O	glucose
7	39	40	O	is
8	42	52	O	recommended
9	54	57	O	when
10	59	63	O	these
11	65	70	O	agents
12	72	74	O	are
13	76	77	O	co
14	79	90	O	administered
NULL

Norfloxacin	DDI-DrugBank.d217.s9	NO_SECTION	NO_SETID	16
Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.
1	0	9	O	Diminished
2	11	17	O	urinary
3	19	27	O	excretion
4	29	30	O	of
5	32	42	O	XXXXXXXX
6	44	46	O	has
7	48	51	O	been
8	53	60	O	reported
9	62	67	O	during
10	69	71	O	the
11	73	83	O	concomitant
12	85	98	O	administration
13	100	101	O	of
14	103	112	U-KIN	probenecid
15	114	116	O	and
16	118	128	O	XXXXXXXX
NULL

Norfloxacin	DDI-DrugBank.d217.s10	NO_SECTION	NO_SETID	21
The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	36	U-UNK	nitrofurantoin
6	38	39	O	is
7	41	43	O	not
8	45	55	O	recommended
9	57	61	O	since
10	63	76	U-DYN	nitrofurantoin
11	78	80	O	may
12	82	91	O	antagonize
13	93	95	O	the
14	97	109	O	antibacterial
15	111	116	O	effect
16	118	119	O	of
17	121	131	O	XXXXXXXX
18	133	134	O	in
19	136	138	O	the
20	140	146	O	urinary
21	148	152	O	tract
NULL

Norfloxacin	DDI-DrugBank.d217.s11	NO_SECTION	NO_SETID	46
Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
1	0	12	U-DYN	Multivitamins
2	13	13	O	,
3	15	16	O	or
4	18	22	O	other
5	24	31	O	products
6	33	42	O	containing
7	44	47	U-DYN	iron
8	49	50	O	or
9	52	55	U-DYN	zinc
10	56	56	O	,
11	58	65	U-DYN	antacids
12	67	68	O	or
13	70	79	U-DYN	sucralfate
14	81	86	O	should
15	88	90	O	not
16	92	93	O	be
17	95	106	O	administered
18	108	120	O	concomitantly
19	122	125	O	with
20	126	126	O	,
21	128	129	O	or
22	131	136	O	within
23	138	138	O	2
24	140	144	O	hours
25	146	147	O	of
26	148	148	O	,
27	150	152	O	the
28	154	167	O	administration
29	169	170	O	of
30	172	182	O	XXXXXXXX
31	183	183	O	,
32	185	191	O	because
33	193	196	O	they
34	198	200	O	may
35	202	210	O	interfere
36	212	215	O	with
37	217	226	O	absorption
38	228	236	O	resulting
39	238	239	O	in
40	241	245	O	lower
41	247	251	O	serum
42	253	255	O	and
43	257	261	O	urine
44	263	268	O	levels
45	270	271	O	of
46	273	283	O	XXXXXXXX
NULL

Norfloxacin	DDI-DrugBank.d217.s12	NO_SECTION	NO_SETID	47
Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
1	0	4	O	XXXXXXXX
2	7	16	U-UNK	Didanosine
3	19	26	O	chewable
4	27	27	O	/
5	28	35	O	buffered
6	37	43	O	tablets
7	45	46	O	or
8	48	50	O	the
9	52	60	O	pediatric
10	62	67	O	powder
11	69	71	O	for
12	73	76	O	oral
13	78	85	O	solution
14	87	92	O	should
15	94	96	O	not
16	98	99	O	be
17	101	112	O	administered
18	114	126	O	concomitantly
19	128	131	O	with
20	132	132	O	,
21	134	135	O	or
22	137	142	O	within
23	144	144	O	2
24	146	150	O	hours
25	152	153	O	of
26	154	154	O	,
27	156	158	O	the
28	160	173	O	administration
29	175	176	O	of
30	178	188	U-DYN	norfloxacin
31	189	189	O	,
32	191	197	O	because
33	199	203	O	these
34	205	212	O	products
35	214	216	O	may
36	218	226	O	interfere
37	228	231	O	with
38	233	242	O	absorption
39	244	252	O	resulting
40	254	255	O	in
41	257	261	O	lower
42	263	267	O	serum
43	269	271	O	and
44	273	277	O	urine
45	279	284	O	levels
46	286	287	O	of
47	289	299	U-UNK	norfloxacin
NULL

Norfloxacin	DDI-DrugBank.d217.s13	NO_SECTION	NO_SETID	13
Some quinolones have also been shown to interfere with the metabolism of caffeine.
1	0	3	O	Some
2	5	14	U-UNK	quinolones
3	16	19	O	have
4	21	24	O	also
5	26	29	O	been
6	31	35	O	shown
7	37	38	O	to
8	40	48	O	interfere
9	50	53	O	with
10	55	57	O	the
11	59	68	O	metabolism
12	70	71	O	of
13	73	80	U-UNK	caffeine
NULL

Norfloxacin	DDI-DrugBank.d217.s14	NO_SECTION	NO_SETID	16
This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life.
1	0	3	O	This
2	5	7	O	may
3	9	12	O	lead
4	14	15	O	to
5	17	23	O	reduced
6	25	33	O	clearance
7	35	36	O	of
8	38	45	U-UNK	caffeine
9	47	49	O	and
10	51	51	O	a
11	53	64	O	prolongation
12	66	67	O	of
13	69	71	O	its
14	73	78	O	plasma
15	80	83	O	half
16	85	88	O	life
NULL

Norgestimate	DDI-DrugBank.d360.s0	NO_SECTION	NO_SETID	19
Reduced efficacy and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin.
1	0	6	O	Reduced
2	8	15	O	efficacy
3	17	19	O	and
4	21	29	O	increased
5	31	39	O	incidence
6	41	42	O	of
7	44	55	O	breakthrough
8	57	64	O	bleeding
9	66	68	O	and
10	70	78	O	menstrual
11	80	93	O	irregularities
12	95	98	O	have
13	100	103	O	been
14	105	114	O	associated
15	116	119	O	with
16	121	131	O	concomitant
17	133	135	O	use
18	137	138	O	of
19	140	147	U-UNK	rifampin
NULL

Norgestimate	DDI-DrugBank.d360.s1	NO_SECTION	NO_SETID	32
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.
1	0	0	O	A
2	2	8	O	similar
3	10	20	O	association
4	21	21	O	,
5	23	28	O	though
6	30	33	O	less
7	35	40	O	marked
8	41	41	O	,
9	43	45	O	has
10	47	50	O	been
11	52	60	O	suggested
12	62	65	O	with
13	67	78	U-UNK	barbiturates
14	79	79	O	,
15	81	94	U-UNK	phenylbutazone
16	95	95	O	,
17	97	105	B-UNK	phenytoin
18	107	112	L-UNK	sodium
19	113	113	O	,
20	115	127	U-UNK	carbamazepine
21	128	128	O	,
22	130	141	U-UNK	griseofulvin
23	142	142	O	,
24	144	153	U-UNK	topiramate
25	154	154	O	,
26	156	158	O	and
27	160	167	O	possibly
28	169	172	O	with
29	174	183	U-UNK	ampicillin
30	185	187	O	and
31	189	201	U-UNK	tetracyclines
32	203	204	O	72
NULL

Norgestimate	DDI-DrugBank.d360.s2	NO_SECTION	NO_SETID	33
A possible interaction has been suggested with hormonal contraceptives and the herbal supplement St. Johns Wort based on some reports of oral contraceptive users experiencing breakthrough bleeding shortly after starting St. Johns Wort.
1	0	0	O	A
2	2	9	O	possible
3	11	21	O	interaction
4	23	25	O	has
5	27	30	O	been
6	32	40	O	suggested
7	42	45	O	with
8	47	54	B-UNK	hormonal
9	56	69	L-UNK	contraceptives
10	71	73	O	and
11	75	77	O	the
12	79	84	O	herbal
13	86	95	O	supplement
14	97	98	O	St
15	101	105	O	Johns
16	107	110	O	Wort
17	112	116	O	based
18	118	119	O	on
19	121	124	O	some
20	126	132	O	reports
21	134	135	O	of
22	137	140	O	oral
23	142	154	U-UNK	contraceptive
24	156	160	O	users
25	162	173	O	experiencing
26	175	186	O	breakthrough
27	188	195	O	bleeding
28	197	203	O	shortly
29	205	209	O	after
30	211	218	O	starting
31	220	221	O	St
32	224	228	O	Johns
33	230	233	O	Wort
NULL

Norgestimate	DDI-DrugBank.d360.s3	NO_SECTION	NO_SETID	19
Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. Johns Wort.
1	0	10	O	Pregnancies
2	12	15	O	have
3	17	20	O	been
4	22	29	O	reported
5	31	32	O	by
6	34	38	O	users
7	40	41	O	of
8	43	50	B-UNK	combined
9	52	59	I-UNK	hormonal
10	61	74	L-UNK	contraceptives
11	76	78	O	who
12	80	83	O	also
13	85	88	O	used
14	90	93	O	some
15	95	98	O	form
16	100	101	O	of
17	103	104	O	St
18	107	111	O	Johns
19	113	116	O	Wort
NULL

Norgestimate	DDI-DrugBank.d360.s4	NO_SECTION	NO_SETID	16
Healthcare prescribers are advised to consult the package inserts of medication administered concomitantly with oral contraceptives.
1	0	9	O	Healthcare
2	11	21	O	prescribers
3	23	25	O	are
4	27	33	O	advised
5	35	36	O	to
6	38	44	O	consult
7	46	48	O	the
8	50	56	O	package
9	58	64	O	inserts
10	66	67	O	of
11	69	78	O	medication
12	80	91	O	administered
13	93	105	O	concomitantly
14	107	110	O	with
15	112	115	O	oral
16	117	130	U-UNK	contraceptives
NULL

Nortriptyline	DDI-DrugBank.d202.s0	NO_SECTION	NO_SETID	23
Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.
1	0	5	O	Steady
2	7	11	O	state
3	13	17	O	serum
4	19	32	O	concentrations
5	34	35	O	of
6	37	45	B-UNK	tricyclic
7	47	61	L-UNK	antidepressants
8	63	65	O	are
9	67	74	O	reported
10	76	77	O	to
11	79	87	O	fluctuate
12	89	101	O	significantly
13	103	106	O	when
14	108	117	U-UNK	cimetidine
15	119	120	O	is
16	122	127	O	either
17	129	133	O	added
18	135	136	O	or
19	138	144	O	deleted
20	146	149	O	from
21	151	153	O	the
22	155	158	O	drug
23	160	166	O	regimen
NULL

Nortriptyline	DDI-DrugBank.d202.s1	NO_SECTION	NO_SETID	32
Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.
1	0	6	O	Serious
2	8	22	O	anticholinergic
3	24	31	O	symptoms
4	34	39	O	severe
5	41	43	O	dry
6	45	49	O	mouth
7	50	50	O	,
8	52	58	O	urinary
9	60	68	O	retention
10	69	69	O	,
11	71	77	O	blurred
12	79	84	O	vision
13	87	90	O	have
14	92	95	O	been
15	97	106	O	associated
16	108	111	O	with
17	113	122	O	elevations
18	124	125	O	in
19	127	129	O	the
20	131	135	O	serum
21	137	142	O	levels
22	144	145	O	of
23	147	155	B-UNK	tricyclic
24	157	171	L-UNK	antidepressants
25	173	176	O	when
26	178	187	U-UNK	cimetidine
27	189	190	O	is
28	192	196	O	added
29	198	199	O	to
30	201	203	O	the
31	205	208	O	drug
32	210	216	O	regimen
NULL

Nortriptyline	DDI-DrugBank.d202.s2	NO_SECTION	NO_SETID	25
In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	18	O	higher
5	20	23	O	than
6	25	32	O	expected
7	34	39	O	steady
8	41	45	O	state
9	47	51	O	serum
10	53	66	O	concentrations
11	68	69	O	of
12	71	79	B-UNK	tricyclic
13	81	95	L-UNK	antidepressants
14	97	100	O	have
15	102	105	O	been
16	107	114	O	observed
17	116	119	O	when
18	121	127	O	therapy
19	129	130	O	is
20	132	140	O	initiated
21	142	143	O	in
22	145	152	O	patients
23	154	160	O	already
24	162	167	O	taking
25	169	178	U-UNK	cimetidine
NULL

Nortriptyline	DDI-DrugBank.d202.s3	NO_SECTION	NO_SETID	29
In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.
1	0	1	O	In
2	3	6	O	well
3	8	17	O	controlled
4	19	26	O	patients
5	28	37	O	undergoing
6	39	48	O	concurrent
7	50	56	O	therapy
8	58	61	O	with
9	63	72	U-UNK	cimetidine
10	73	73	O	,
11	75	75	O	a
12	77	84	O	decrease
13	86	87	O	in
14	89	91	O	the
15	93	98	O	steady
16	100	104	O	state
17	106	110	O	serum
18	112	125	O	concentrations
19	127	128	O	of
20	130	138	B-UNK	tricyclic
21	140	154	L-UNK	antidepressants
22	156	158	O	may
23	160	164	O	occur
24	166	169	O	when
25	171	174	O	cime
26	176	181	O	tidine
27	183	189	O	therapy
28	191	192	O	is
29	194	205	O	discontinued
NULL

Nortriptyline	DDI-DrugBank.d202.s4	NO_SECTION	NO_SETID	16
The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.
1	0	2	O	The
2	4	14	O	therapeutic
3	16	23	O	efficacy
4	25	26	O	of
5	28	36	B-UNK	tricyclic
6	38	52	L-UNK	antidepressants
7	54	56	O	may
8	58	59	O	be
9	61	71	O	compromised
10	73	74	O	in
11	76	80	O	these
12	82	89	O	patients
13	91	94	O	when
14	96	105	U-UNK	cimetidine
15	107	108	O	is
16	110	121	O	discontinued
NULL

Nortriptyline	DDI-DrugBank.d202.s5	NO_SECTION	NO_SETID	11
Several of the tricyclic antidepressants have been cited in these reports.
1	0	6	O	Several
2	8	9	O	of
3	11	13	O	the
4	15	23	B-UNK	tricyclic
5	25	39	L-UNK	antidepressants
6	41	44	O	have
7	46	49	O	been
8	51	55	O	cited
9	57	58	O	in
10	60	64	O	these
11	66	72	O	reports
NULL

Nortriptyline	DDI-DrugBank.d202.s6	NO_SECTION	NO_SETID	31
There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	22	O	greater
5	24	27	O	than
6	29	29	O	2
7	31	34	O	fold
8	36	44	O	increases
9	46	47	O	in
10	49	58	O	previously
11	60	65	O	stable
12	67	72	O	plasma
13	74	79	O	levels
14	81	82	O	of
15	84	88	O	other
16	90	104	U-UNK	antidepressants
17	105	105	O	,
18	107	115	O	including
19	117	129	O	XXXXXXXX
20	130	130	O	,
21	132	135	O	when
22	137	146	B-KIN	fluoxetine
23	148	160	L-KIN	hydrochloride
24	162	164	O	has
25	166	169	O	been
26	171	182	O	administered
27	184	185	O	in
28	187	197	O	combination
29	199	202	O	with
30	204	208	O	these
31	210	215	O	agents
NULL

Nortriptyline	DDI-DrugBank.d202.s7	NO_SECTION	NO_SETID	32
Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other.
1	0	9	U-UNK	Fluoxetine
2	11	13	O	and
3	15	17	O	its
4	19	24	O	active
5	26	35	O	metabolite
6	36	36	O	,
7	38	46	O	norfluoxe
8	48	51	O	tine
9	52	52	O	,
10	54	57	O	have
11	59	62	O	long
12	64	67	O	half
13	69	73	O	lives
14	76	76	O	4
15	78	79	O	to
16	81	82	O	16
17	84	87	O	days
18	89	91	O	for
19	93	105	U-UNK	norfluoxetine
20	107	107	O	,
21	109	112	O	that
22	114	116	O	may
23	118	123	O	affect
24	125	134	O	strategies
25	136	141	O	during
26	143	152	O	conversion
27	154	157	O	from
28	159	161	O	one
29	163	166	O	drug
30	168	169	O	to
31	171	173	O	the
32	175	179	O	other
NULL

Nortriptyline	DDI-DrugBank.d202.s8	NO_SECTION	NO_SETID	21
Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a  stimulating  effect in some depressed patients.
1	0	13	O	Administration
2	15	16	O	of
3	18	26	U-UNK	reserpine
4	28	33	O	during
5	35	41	O	therapy
6	43	46	O	with
7	48	48	O	a
8	50	58	B-UNK	tricyclic
9	60	73	L-UNK	antidepressant
10	75	77	O	has
11	79	82	O	been
12	84	88	O	shown
13	90	91	O	to
14	93	99	O	produce
15	101	101	O	a
16	104	114	O	stimulating
17	117	122	O	effect
18	124	125	O	in
19	127	130	O	some
20	132	140	O	depressed
21	142	149	O	patients
NULL

Nortriptyline	DDI-DrugBank.d202.s9	NO_SECTION	NO_SETID	22
Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.
1	0	4	O	Close
2	6	16	O	supervision
3	18	20	O	and
4	22	28	O	careful
5	30	39	O	adjustment
6	41	42	O	of
7	44	46	O	the
8	48	53	O	dosage
9	55	57	O	are
10	59	66	O	required
11	68	71	O	when
12	73	85	O	XXXXXXXX
13	87	99	O	hydrochloride
14	101	102	O	is
15	104	107	O	used
16	109	112	O	with
17	114	118	O	other
18	120	134	B-DYN	anticholinergic
19	136	140	L-DYN	drugs
20	142	143	O	or
21	145	159	B-DYN	sympathomimetic
22	161	165	L-DYN	drugs
NULL

Nortriptyline	DDI-DrugBank.d202.s10	NO_SECTION	NO_SETID	13
The patient should be informed that the response to alcohol may be exaggerated.
1	0	2	O	The
2	4	10	O	patient
3	12	17	O	should
4	19	20	O	be
5	22	29	O	informed
6	31	34	O	that
7	36	38	O	the
8	40	47	O	response
9	49	50	O	to
10	52	58	U-UNK	alcohol
11	60	62	O	may
12	64	65	O	be
13	67	77	O	exaggerated
NULL

Nortriptyline	DDI-DrugBank.d202.s11	NO_SECTION	NO_SETID	27
Drugs Metabolized by P450IID6  A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	28	O	P450IID6
5	31	31	O	A
6	33	38	O	subset
7	41	42	O	3%
8	44	45	O	to
9	47	49	O	10%
10	52	53	O	of
11	55	57	O	the
12	59	68	O	population
13	70	72	O	has
14	74	80	O	reduced
15	82	89	O	activity
16	91	92	O	of
17	94	100	O	certain
18	102	105	O	drug
19	107	118	O	metabolizing
20	120	126	O	enzymes
21	128	131	O	such
22	133	134	O	as
23	136	138	O	the
24	140	149	O	cytochrome
25	151	154	O	P450
26	156	164	O	isoenzyme
27	166	173	O	P450IID6
NULL

Nortriptyline	DDI-DrugBank.d202.s12	NO_SECTION	NO_SETID	20
Such individuals are referred to as  poor metabolizers  of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants.
1	0	3	O	Such
2	5	15	O	individuals
3	17	19	O	are
4	21	28	O	referred
5	30	31	O	to
6	33	34	O	as
7	37	40	O	poor
8	42	53	O	metabolizers
9	56	57	O	of
10	59	63	O	drugs
11	65	68	O	such
12	70	71	O	as
13	73	83	U-UNK	debrisoquin
14	84	84	O	,
15	86	101	U-UNK	dextromethorphan
16	102	102	O	,
17	104	106	O	and
18	108	110	O	the
19	112	120	B-UNK	tricyclic
20	122	136	L-UNK	antidepressants
NULL

Nortriptyline	DDI-DrugBank.d202.s13	NO_SECTION	NO_SETID	16
These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses.
1	0	4	O	These
2	6	16	O	individuals
3	18	20	O	may
4	22	25	O	have
5	27	32	O	higher
6	34	37	O	than
7	39	46	O	expected
8	48	53	O	plasma
9	55	68	O	concentrations
10	70	71	O	of
11	73	81	B-UNK	tricyclic
12	83	97	L-UNK	antidepressants
13	99	102	O	when
14	104	108	O	given
15	110	114	O	usual
16	116	120	O	doses
NULL

Nortriptyline	DDI-DrugBank.d202.s14	NO_SECTION	NO_SETID	62
In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	certain
5	21	25	O	drugs
6	27	30	O	that
7	32	34	O	are
8	36	46	O	metabolized
9	48	49	O	by
10	51	54	O	this
11	56	64	O	isoenzyme
12	65	65	O	,
13	67	75	O	including
14	77	80	O	many
15	82	96	U-UNK	antidepressants
16	99	107	B-UNK	tricyclic
17	109	123	L-UNK	antidepressants
18	124	124	O	,
19	126	134	B-UNK	selective
20	136	144	I-UNK	serotonin
21	146	153	I-UNK	reuptake
22	155	164	L-UNK	inhibitors
23	165	165	O	,
24	167	169	O	and
25	171	176	O	others
26	178	178	O	,
27	180	182	O	may
28	184	190	O	inhibit
29	192	194	O	the
30	196	203	O	activity
31	205	206	O	of
32	208	211	O	this
33	213	221	O	isoenzyme
34	222	222	O	,
35	224	226	O	and
36	228	231	O	thus
37	233	235	O	may
38	237	240	O	make
39	242	247	O	normal
40	249	253	O	metab
41	255	261	O	olizers
42	263	270	O	resemble
43	272	275	O	poor
44	277	288	O	metabolizers
45	290	293	O	with
46	295	300	O	regard
47	302	303	O	to
48	305	315	O	concomitant
49	317	323	O	therapy
50	325	328	O	with
51	330	334	O	other
52	336	340	O	drugs
53	342	352	O	metabolized
54	354	355	O	by
55	357	360	O	this
56	362	367	O	enzyme
57	369	374	O	system
58	375	375	O	,
59	377	383	O	leading
60	385	386	O	to
61	388	391	O	drug
62	393	404	O	interactions
NULL

Nortriptyline	DDI-DrugBank.d202.s15	NO_SECTION	NO_SETID	28
Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	27	B-UNK	tricyclic
5	29	43	L-UNK	antidepressants
6	45	48	O	with
7	50	54	O	other
8	56	60	O	drugs
9	62	72	O	metabolized
10	74	75	O	by
11	77	86	O	cytochrome
12	88	95	O	P450IID6
13	97	99	O	may
14	101	107	O	require
15	109	113	O	lower
16	115	119	O	doses
17	121	124	O	than
18	126	132	O	usually
19	134	143	O	prescribed
20	145	147	O	for
21	149	154	O	either
22	156	158	O	the
23	160	168	B-UNK	tricyclic
24	170	183	L-UNK	antidepressant
25	185	186	O	or
26	188	190	O	the
27	192	196	O	other
28	198	201	O	drug
NULL

Nortriptyline	DDI-DrugBank.d202.s16	NO_SECTION	NO_SETID	52
Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	co
4	14	27	O	administration
5	29	30	O	of
6	32	40	B-UNK	tricyclic
7	42	56	L-UNK	antidepressants
8	58	61	O	with
9	63	67	O	other
10	69	73	O	drugs
11	75	78	O	that
12	80	82	O	are
13	84	94	O	metabolized
14	96	97	O	by
15	99	102	O	this
16	104	112	O	isoenzyme
17	113	113	O	,
18	115	123	O	including
19	125	129	O	other
20	131	145	U-UNK	antidepressants
21	146	146	O	,
22	148	161	U-UNK	phenothiazines
23	162	162	O	,
24	164	176	U-UNK	carbamazepine
25	177	177	O	,
26	179	181	O	and
27	183	186	B-UNK	Type
28	188	189	I-UNK	1C
29	191	205	L-UNK	antiarrhythmics
30	208	209	O	eg
31	210	210	O	,
32	212	222	U-UNK	propafenone
33	223	223	O	,
34	225	234	U-UNK	flecainide
35	235	235	O	,
36	237	239	O	and
37	241	249	U-UNK	encainide
38	251	251	O	,
39	253	254	O	or
40	256	259	O	that
41	261	267	O	inhibit
42	269	272	O	this
43	274	279	O	enzyme
44	282	283	O	eg
45	284	284	O	,
46	286	294	U-UNK	quinidine
47	296	296	O	,
48	298	303	O	should
49	305	306	O	be
50	308	317	O	approached
51	319	322	O	with
52	324	330	O	caution
NULL

Oxcarbazepine	DDI-DrugBank.d307.s0	NO_SECTION	NO_SETID	19
Oxcarbazepine can inhibit CYP2C19 and induce CYP3A4/5 with potentially important effects on plasma concentrations of other drugs.
1	0	12	O	XXXXXXXX
2	14	16	O	can
3	18	24	O	inhibit
4	26	32	O	CYP2C19
5	34	36	O	and
6	38	43	O	induce
7	45	50	O	CYP3A4
8	51	51	O	/
9	52	52	O	5
10	54	57	O	with
11	59	69	O	potentially
12	71	79	O	important
13	81	87	O	effects
14	89	90	O	on
15	92	97	O	plasma
16	99	112	O	concentrations
17	114	115	O	of
18	117	121	O	other
19	123	127	O	drugs
NULL

Oxcarbazepine	DDI-DrugBank.d307.s1	NO_SECTION	NO_SETID	19
In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	several
5	21	23	U-KIN	AED
6	25	25	O	s
7	27	30	O	that
8	32	34	O	are
9	36	45	O	cytochrome
10	47	50	O	P450
11	52	59	O	inducers
12	61	63	O	can
13	65	72	O	decrease
14	74	79	O	plasma
15	81	94	O	concentrations
16	96	97	O	of
17	99	111	O	XXXXXXXX
18	113	115	O	and
19	117	119	U-UNK	MHD
NULL

Oxcarbazepine	DDI-DrugBank.d307.s2	NO_SECTION	NO_SETID	25
Oxcarbazepine was evaluated in human liver microsomes to determine its capacity to inhibit the major cytochrome P450 enzymes responsible for the metabolism of other drugs.
1	0	12	O	XXXXXXXX
2	14	16	O	was
3	18	26	O	evaluated
4	28	29	O	in
5	31	35	O	human
6	37	41	O	liver
7	43	52	O	microsomes
8	54	55	O	to
9	57	65	O	determine
10	67	69	O	its
11	71	78	O	capacity
12	80	81	O	to
13	83	89	O	inhibit
14	91	93	O	the
15	95	99	O	major
16	101	110	O	cytochrome
17	112	115	O	P450
18	117	123	O	enzymes
19	125	135	O	responsible
20	137	139	O	for
21	141	143	O	the
22	145	154	O	metabolism
23	156	157	O	of
24	159	163	O	other
25	165	169	O	drugs
NULL

Oxcarbazepine	DDI-DrugBank.d307.s3	NO_SECTION	NO_SETID	52
Results demonstrate that oxcarbazepine and its pharmacologically active 10-monohydroxy metabolite (MHD) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated (CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP4A9 and CYP4A11) with the exception of CYP2C19 and CYP3A4/5.
1	0	6	O	Results
2	8	18	O	demonstrate
3	20	23	O	that
4	25	37	O	XXXXXXXX
5	39	41	O	and
6	43	45	O	its
7	47	63	O	pharmacologically
8	65	70	O	active
9	72	73	O	10
10	75	85	O	monohydroxy
11	87	96	O	metabolite
12	99	101	U-UNK	MHD
13	104	107	O	have
14	109	114	O	little
15	116	117	O	or
16	119	120	O	no
17	122	129	O	capacity
18	131	132	O	to
19	134	141	O	function
20	143	144	O	as
21	146	155	O	inhibitors
22	157	159	O	for
23	161	164	O	most
24	166	167	O	of
25	169	171	O	the
26	173	177	O	human
27	179	188	O	cytochrome
28	190	193	O	P450
29	195	201	O	enzymes
30	203	211	O	evaluated
31	214	219	O	CYP1A2
32	220	220	O	,
33	222	227	O	CYP2A6
34	228	228	O	,
35	230	235	O	CYP2C9
36	236	236	O	,
37	238	243	O	CYP2D6
38	244	244	O	,
39	246	251	O	CYP2E1
40	252	252	O	,
41	254	259	O	CYP4A9
42	261	263	O	and
43	265	271	O	CYP4A11
44	274	277	O	with
45	279	281	O	the
46	283	291	O	exception
47	293	294	O	of
48	296	302	O	CYP2C19
49	304	306	O	and
50	308	313	O	CYP3A4
51	314	314	O	/
52	315	315	O	5
NULL

Oxcarbazepine	DDI-DrugBank.d307.s4	NO_SECTION	NO_SETID	26
Although inhibition of CYP 3A4/5 by OXC and MHD did occur at high concentrations, it is not likely to be of clinical significance.
1	0	7	O	Although
2	9	18	O	inhibition
3	20	21	O	of
4	23	25	O	CYP
5	27	29	O	3A4
6	30	30	O	/
7	31	31	O	5
8	33	34	O	by
9	36	38	U-UNK	OXC
10	40	42	O	and
11	44	46	U-UNK	MHD
12	48	50	O	did
13	52	56	O	occur
14	58	59	O	at
15	61	64	O	high
16	66	79	O	concentrations
17	80	80	O	,
18	82	83	O	it
19	85	86	O	is
20	88	90	O	not
21	92	97	O	likely
22	99	100	O	to
23	102	103	O	be
24	105	106	O	of
25	108	115	O	clinical
26	117	128	O	significance
NULL

Oxcarbazepine	DDI-DrugBank.d307.s5	NO_SECTION	NO_SETID	15
The inhibition of CYP-2C19 by OXC and MHD, however, is clinically relevant.
1	0	2	O	The
2	4	13	O	inhibition
3	15	16	O	of
4	18	20	O	CYP
5	22	25	O	2C19
6	27	28	O	by
7	30	32	U-UNK	OXC
8	34	36	O	and
9	38	40	U-UNK	MHD
10	41	41	O	,
11	43	49	O	however
12	50	50	O	,
13	52	53	O	is
14	55	64	O	clinically
15	66	73	O	relevant
NULL

Oxcarbazepine	DDI-DrugBank.d307.s6	NO_SECTION	NO_SETID	16
In vitro, the UDP-glucuronyl transferase level was increased, indicating induction of this enzyme.
1	0	1	O	In
2	3	7	O	vitro
3	8	8	O	,
4	10	12	O	the
5	14	16	O	UDP
6	18	27	O	glucuronyl
7	29	39	O	transferase
8	41	45	O	level
9	47	49	O	was
10	51	59	O	increased
11	60	60	O	,
12	62	71	O	indicating
13	73	81	O	induction
14	83	84	O	of
15	86	89	O	this
16	91	96	O	enzyme
NULL

Oxcarbazepine	DDI-DrugBank.d307.s7	NO_SECTION	NO_SETID	11
Increases of 22% with MHD and 47% with oxcarbazepine were observed.
1	0	8	O	Increases
2	10	11	O	of
3	13	15	O	22%
4	17	20	O	with
5	22	24	U-UNK	MHD
6	26	28	O	and
7	30	32	O	47%
8	34	37	O	with
9	39	51	O	XXXXXXXX
10	53	56	O	were
11	58	65	O	observed
NULL

Oxcarbazepine	DDI-DrugBank.d307.s8	NO_SECTION	NO_SETID	43
As MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., valproic acid, lamotrigine).
1	0	1	O	As
2	3	5	U-UNK	MHD
3	6	6	O	,
4	8	10	O	the
5	12	22	O	predominant
6	24	29	O	plasma
7	31	39	O	substrate
8	40	40	O	,
9	42	43	O	is
10	45	48	O	only
11	50	50	O	a
12	52	55	O	weak
13	57	63	O	inducer
14	65	66	O	of
15	68	70	O	UDP
16	72	81	O	glucuronyl
17	83	93	O	transferase
18	94	94	O	,
19	96	97	O	it
20	99	100	O	is
21	102	109	O	unlikely
22	111	112	O	to
23	114	117	O	have
24	119	120	O	an
25	122	127	O	effect
26	129	130	O	on
27	132	136	O	drugs
28	138	141	O	that
29	143	145	O	are
30	147	152	O	mainly
31	154	163	O	eliminated
32	165	166	O	by
33	168	178	O	conjugation
34	180	186	O	through
35	188	190	O	UDP
36	192	201	O	glucuronyl
37	203	213	O	transferase
38	216	218	O	e.g
39	220	220	O	,
40	222	229	B-UNK	valproic
41	231	234	L-UNK	acid
42	235	235	O	,
43	237	247	U-UNK	lamotrigine
NULL

Oxcarbazepine	DDI-DrugBank.d307.s9	NO_SECTION	NO_SETID	39
In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	25	O	XXXXXXXX
5	27	29	O	and
6	31	33	U-UNK	MHD
7	35	40	O	induce
8	42	42	O	a
9	44	51	O	subgroup
10	53	54	O	of
11	56	58	O	the
12	60	69	O	cytochrome
13	71	74	O	P450
14	76	77	O	3A
15	79	84	O	family
16	87	92	O	CYP3A4
17	94	96	O	and
18	98	103	O	CYP3A5
19	106	116	O	responsible
20	118	120	O	for
21	122	124	O	the
22	126	135	O	metabolism
23	137	138	O	of
24	140	154	B-UNK	dihydropyridine
25	156	162	I-UNK	calcium
26	164	174	L-UNK	antagonists
27	176	178	O	and
28	180	183	O	oral
29	185	198	U-UNK	contraceptives
30	199	199	O	,
31	201	209	O	resulting
32	211	212	O	in
33	214	214	O	a
34	216	220	O	lower
35	222	227	O	plasma
36	229	241	O	concentration
37	243	244	O	of
38	246	250	O	these
39	252	256	O	drugs
NULL

Oxcarbazepine	DDI-DrugBank.d307.s10	NO_SECTION	NO_SETID	25
As binding of MHD to plasma proteins is low (40%), clinically significant interactions with other drugs through competition for protein binding sites are unlikely.
1	0	1	O	As
2	3	9	O	binding
3	11	12	O	of
4	14	16	U-UNK	MHD
5	18	19	O	to
6	21	26	O	plasma
7	28	35	O	proteins
8	37	38	O	is
9	40	42	O	low
10	45	47	O	40%
11	49	49	O	,
12	51	60	O	clinically
13	62	72	O	significant
14	74	85	O	interactions
15	87	90	O	with
16	92	96	O	other
17	98	102	O	drugs
18	104	110	O	through
19	112	122	O	competition
20	124	126	O	for
21	128	134	O	protein
22	136	142	O	binding
23	144	148	O	sites
24	150	152	O	are
25	154	161	O	unlikely
NULL

Oxcarbazepine	DDI-DrugBank.d307.s11	NO_SECTION	NO_SETID	15
Antiepileptic drugs: Potential interactions between Trileptal and other AEDs were assessed in clinical studies.
1	0	12	B-UNK	Antiepileptic
2	14	18	L-UNK	drugs
3	19	19	O	:
4	21	29	O	Potential
5	31	42	O	interactions
6	44	50	O	between
7	52	60	O	XXXXXXXX
8	62	64	O	and
9	66	70	O	other
10	72	75	U-UNK	AEDs
11	77	80	O	were
12	82	89	O	assessed
13	91	92	O	in
14	94	101	O	clinical
15	103	109	O	studies
NULL

Oxcarbazepine	DDI-DrugBank.d307.s12	NO_SECTION	NO_SETID	25
The effect of these interactions on mean AUCs and Cmin are summarized in Table 2: Table 2: Summary of AED interactions with Trileptal
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	18	O	these
5	20	31	O	interactions
6	33	34	O	on
7	36	39	O	mean
8	41	44	O	AUCs
9	46	48	O	and
10	50	53	O	Cmin
11	55	57	O	are
12	59	68	O	summarized
13	70	71	O	in
14	73	77	O	Table
15	79	79	O	2
16	80	80	O	:
17	82	86	O	Table
18	88	88	O	2
19	89	89	O	:
20	91	97	O	Summary
21	99	100	O	of
22	102	104	O	AED
23	106	117	O	interactions
24	119	122	O	with
25	124	132	O	XXXXXXXX
NULL

Oxcarbazepine	DDI-DrugBank.d307.s14	NO_SECTION	NO_SETID	6
Dose of AED (mg/day)
1	0	3	O	Dose
2	5	6	O	of
3	8	10	U-UNK	AED
4	13	14	O	mg
5	15	15	O	/
6	16	18	O	day
NULL

Oxcarbazepine	DDI-DrugBank.d307.s15	NO_SECTION	NO_SETID	5
Trileptal dose (mg/day)
1	0	8	O	XXXXXXXX
2	10	13	O	dose
3	16	17	O	mg
4	18	18	O	/
5	19	21	O	day
NULL

Oxcarbazepine	DDI-DrugBank.d307.s16	NO_SECTION	NO_SETID	12
Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval)
1	0	8	O	Influence
2	10	11	O	of
3	13	21	O	XXXXXXXX
4	23	24	O	on
5	26	28	U-UNK	AED
6	30	42	O	Concentration
7	45	48	O	Mean
8	50	55	O	change
9	56	56	O	,
10	58	60	O	90%
11	62	71	O	Confidence
12	73	80	O	Interval
NULL

Oxcarbazepine	DDI-DrugBank.d307.s17	NO_SECTION	NO_SETID	12
Influence of AED On MHD Concentration (Mean change, 90% Confidence Interval)
1	0	8	O	Influence
2	10	11	O	of
3	13	15	U-UNK	AED
4	17	18	O	On
5	20	22	U-UNK	MHD
6	24	36	O	Concentration
7	39	42	O	Mean
8	44	49	O	change
9	50	50	O	,
10	52	54	O	90%
11	56	65	O	Confidence
12	67	74	O	Interval
NULL

Oxcarbazepine	DDI-DrugBank.d307.s21	NO_SECTION	NO_SETID	10
nc1 40% decrease [CI: 17% decrease, 57% decrease]
1	0	2	O	nc1
2	4	6	O	40%
3	8	15	O	decrease
4	18	19	O	CI
5	20	20	O	:
6	22	24	O	17%
7	26	33	O	decrease
8	34	34	O	,
9	36	38	O	57%
10	40	47	O	decrease
NULL

Oxcarbazepine	DDI-DrugBank.d307.s25	NO_SECTION	NO_SETID	18
14% increase [CI: 2% increase, 24% increase] 25% decrease [CI: 12% decrease, 51% decrease]
1	0	2	O	14%
2	4	11	O	increase
3	14	15	O	CI
4	16	16	O	:
5	18	19	O	2%
6	21	28	O	increase
7	29	29	O	,
8	31	33	O	24%
9	35	42	O	increase
10	45	47	O	25%
11	49	56	O	decrease
12	59	60	O	CI
13	61	61	O	:
14	63	65	O	12%
15	67	74	O	decrease
16	75	75	O	,
17	77	79	O	51%
18	81	88	O	decrease
NULL

Oxcarbazepine	DDI-DrugBank.d307.s29	NO_SECTION	NO_SETID	11
nc1,2 30% decrease [CI: 3% decrease, 48 % decrease]
1	0	4	O	nc1,2
2	6	8	O	30%
3	10	17	O	decrease
4	20	21	O	CI
5	22	22	O	:
6	24	25	O	3%
7	27	34	O	decrease
8	35	35	O	,
9	37	38	O	48
10	40	40	O	%
11	42	49	O	decrease
NULL

Oxcarbazepine	DDI-DrugBank.d307.s30	NO_SECTION	NO_SETID	14
1200-2400 up to 40% increase3 [CI: 12% increase, 60 % increase]
1	0	3	O	1200
2	5	8	O	2400
3	10	11	O	up
4	13	14	O	to
5	16	18	O	40%
6	20	28	O	increase3
7	31	32	O	CI
8	33	33	O	:
9	35	37	O	12%
10	39	46	O	increase
11	47	47	O	,
12	49	50	O	60
13	52	52	O	%
14	54	61	O	increase
NULL

Oxcarbazepine	DDI-DrugBank.d307.s34	NO_SECTION	NO_SETID	11
nc1 18% decrease [CI: 13% decrease, 40 % decrease]
1	0	2	O	nc1
2	4	6	O	18%
3	8	15	O	decrease
4	18	19	O	CI
5	20	20	O	:
6	22	24	O	13%
7	26	33	O	decrease
8	34	34	O	,
9	36	37	O	40
10	39	39	O	%
11	41	48	O	decrease
NULL

Oxcarbazepine	DDI-DrugBank.d307.s35	NO_SECTION	NO_SETID	46
1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.
1	0	0	O	1
2	3	4	O	nc
3	6	12	O	denotes
4	14	14	O	a
5	16	19	O	mean
6	21	26	O	change
7	28	29	O	of
8	31	34	O	less
9	36	39	O	than
10	41	43	O	10%
11	45	45	O	2
12	48	57	O	Pediatrics
13	59	59	O	3
14	62	65	O	Mean
15	67	74	O	increase
16	76	77	O	in
17	79	84	O	adults
18	86	87	O	at
19	89	92	O	high
20	94	102	O	XXXXXXXX
21	104	108	O	doses
22	110	111	O	In
23	113	116	O	vivo
24	117	117	O	,
25	119	121	O	the
26	123	128	O	plasma
27	130	135	O	levels
28	137	138	O	of
29	140	148	U-KIN	phenytoin
30	150	158	O	increased
31	160	161	O	by
32	163	164	O	up
33	166	167	O	to
34	169	171	O	40%
35	172	172	O	,
36	174	177	O	when
37	179	187	O	XXXXXXXX
38	189	191	O	was
39	193	197	O	given
40	199	200	O	at
41	202	206	O	doses
42	208	212	O	above
43	214	217	O	1200
44	219	220	O	mg
45	221	221	O	/
46	222	224	O	day
NULL

Oxcarbazepine	DDI-DrugBank.d307.s36	NO_SECTION	NO_SETID	27
Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	20	O	using
5	22	26	O	doses
6	28	29	O	of
7	31	39	O	XXXXXXXX
8	41	47	O	greater
9	49	52	O	than
10	54	57	O	1200
11	59	60	O	mg
12	61	61	O	/
13	62	64	O	day
14	66	71	O	during
15	73	82	O	adjunctive
16	84	90	O	therapy
17	91	91	O	,
18	93	93	O	a
19	95	102	O	decrease
20	104	105	O	in
21	107	109	O	the
22	111	114	O	dose
23	116	117	O	of
24	119	127	U-DYN	phenytoin
25	129	131	O	may
26	133	134	O	be
27	136	143	O	required
NULL

Oxcarbazepine	DDI-DrugBank.d307.s37	NO_SECTION	NO_SETID	15
The increase of phenobarbital level, however, is small (15%) when given with Trileptal.
1	0	2	O	The
2	4	11	O	increase
3	13	14	O	of
4	16	28	U-KIN	phenobarbital
5	30	34	O	level
6	35	35	O	,
7	37	43	O	however
8	44	44	O	,
9	46	47	O	is
10	49	53	O	small
11	56	58	O	15%
12	61	64	O	when
13	66	70	O	given
14	72	75	O	with
15	77	85	O	XXXXXXXX
NULL

Oxcarbazepine	DDI-DrugBank.d307.s38	NO_SECTION	NO_SETID	24
Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, phenytoin and phenobarbital) have been shown to decrease the plasma levels of MHD (29-40%).
1	0	5	O	Strong
2	7	14	O	inducers
3	16	17	O	of
4	19	28	O	cytochrome
5	30	33	O	P450
6	35	41	O	enzymes
7	44	46	O	i.e
8	49	61	U-UNK	carbamazepine
9	62	62	O	,
10	64	72	U-UNK	phenytoin
11	74	76	O	and
12	78	90	U-UNK	phenobarbital
13	93	96	O	have
14	98	101	O	been
15	103	107	O	shown
16	109	110	O	to
17	112	119	O	decrease
18	121	123	O	the
19	125	130	O	plasma
20	132	137	O	levels
21	139	140	O	of
22	142	144	U-UNK	MHD
23	147	148	O	29
24	150	152	O	40%
NULL

Oxcarbazepine	DDI-DrugBank.d307.s39	NO_SECTION	NO_SETID	7
No autoinduction has been observed with Trileptal.
1	0	1	O	No
2	3	15	O	autoinduction
3	17	19	O	has
4	21	24	O	been
5	26	33	O	observed
6	35	38	O	with
7	40	48	O	XXXXXXXX
NULL

Oxcarbazepine	DDI-DrugBank.d307.s40	NO_SECTION	NO_SETID	29
Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).
1	0	7	O	Hormonal
2	9	22	U-UNK	contraceptives
3	24	25	O	Co
4	27	40	O	administration
5	42	43	O	of
6	45	53	O	XXXXXXXX
7	55	58	O	with
8	60	61	O	an
9	63	66	O	oral
10	68	80	U-KIN	contraceptive
11	82	84	O	has
12	86	89	O	been
13	91	95	O	shown
14	97	98	O	to
15	100	108	O	influence
16	110	112	O	the
17	114	119	O	plasma
18	121	134	O	concentrations
19	136	137	O	of
20	139	141	O	the
21	143	145	O	two
22	147	154	O	hormonal
23	156	165	O	components
24	166	166	O	,
25	168	183	U-UNK	ethinylestradiol
26	186	187	O	EE
27	190	192	O	and
28	194	207	U-UNK	levonorgestrel
29	210	212	O	LNG
NULL

Oxcarbazepine	DDI-DrugBank.d307.s41	NO_SECTION	NO_SETID	29
The mean AUC values of EE were decreased by 48% [90% CI: 22-65] in one study and 52% [90% CI: 38-52] in another study [1,2].
1	0	2	O	The
2	4	7	O	mean
3	9	11	O	AUC
4	13	18	O	values
5	20	21	O	of
6	23	24	O	EE
7	26	29	O	were
8	31	39	O	decreased
9	41	42	O	by
10	44	46	O	48%
11	49	51	O	90%
12	53	54	O	CI
13	55	55	O	:
14	57	58	O	22
15	60	61	O	65
16	64	65	O	in
17	67	69	O	one
18	71	75	O	study
19	77	79	O	and
20	81	83	O	52%
21	86	88	O	90%
22	90	91	O	CI
23	92	92	O	:
24	94	95	O	38
25	97	98	O	52
26	101	102	O	in
27	104	110	O	another
28	112	116	O	study
29	119	121	O	1,2
NULL

Oxcarbazepine	DDI-DrugBank.d307.s42	NO_SECTION	NO_SETID	28
The mean AUC values of LNG were decreased by 32% [90% CI: 20-45] in one study and 52% [90% CI: 42-52] in another study.
1	0	2	O	The
2	4	7	O	mean
3	9	11	O	AUC
4	13	18	O	values
5	20	21	O	of
6	23	25	O	LNG
7	27	30	O	were
8	32	40	O	decreased
9	42	43	O	by
10	45	47	O	32%
11	50	52	O	90%
12	54	55	O	CI
13	56	56	O	:
14	58	59	O	20
15	61	62	O	45
16	65	66	O	in
17	68	70	O	one
18	72	76	O	study
19	78	80	O	and
20	82	84	O	52%
21	87	89	O	90%
22	91	92	O	CI
23	93	93	O	:
24	95	96	O	42
25	98	99	O	52
26	102	103	O	in
27	105	111	O	another
28	113	117	O	study
NULL

Oxcarbazepine	DDI-DrugBank.d307.s43	NO_SECTION	NO_SETID	15
Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	concurrent
4	22	24	O	use
5	26	27	O	of
6	29	37	O	XXXXXXXX
7	39	42	O	with
8	44	51	B-DYN	hormonal
9	53	66	L-DYN	contraceptives
10	68	70	O	may
11	72	77	O	render
12	79	83	O	these
13	85	98	U-UNK	contraceptives
14	100	103	O	less
15	105	113	O	effective
NULL

Oxcarbazepine	DDI-DrugBank.d307.s44	NO_SECTION	NO_SETID	11
Studies with other oral or implant contraceptives have not been conducted.
1	0	6	O	Studies
2	8	11	O	with
3	13	17	O	other
4	19	22	O	oral
5	24	25	O	or
6	27	33	O	implant
7	35	48	U-UNK	contraceptives
8	50	53	O	have
9	55	57	O	not
10	59	62	O	been
11	64	72	O	conducted
NULL

Oxcarbazepine	DDI-DrugBank.d307.s45	NO_SECTION	NO_SETID	23
Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].
1	0	6	U-UNK	Calcium
2	8	18	O	Antagonists
3	19	19	O	:
4	21	25	O	After
5	27	34	O	repeated
6	36	37	O	co
7	39	52	O	administration
8	54	55	O	of
9	57	65	O	XXXXXXXX
10	66	66	O	,
11	68	70	O	the
12	72	74	O	AUC
13	76	77	O	of
14	79	88	U-KIN	felodipine
15	90	92	O	was
16	94	100	O	lowered
17	102	103	O	by
18	105	107	O	28%
19	110	112	O	90%
20	114	115	O	CI
21	116	116	O	:
22	118	119	O	20
23	121	122	O	33
NULL

Oxcarbazepine	DDI-DrugBank.d307.s46	NO_SECTION	NO_SETID	17
Verapamil produced a decrease of 20% [90% CI: 18-27] of the plasma levels of MHD.
1	0	8	U-UNK	Verapamil
2	10	17	O	produced
3	19	19	O	a
4	21	28	O	decrease
5	30	31	O	of
6	33	35	O	20%
7	38	40	O	90%
8	42	43	O	CI
9	44	44	O	:
10	46	47	O	18
11	49	50	O	27
12	53	54	O	of
13	56	58	O	the
14	60	65	O	plasma
15	67	72	O	levels
16	74	75	O	of
17	77	79	U-UNK	MHD
NULL

Oxcarbazepine	DDI-DrugBank.d307.s47	NO_SECTION	NO_SETID	16
Other drug interactions Cimetidine, erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of MHD.
1	0	4	O	Other
2	6	9	O	drug
3	11	22	O	interactions
4	24	33	U-UNK	Cimetidine
5	34	34	O	,
6	36	47	U-UNK	erythromycin
7	49	51	O	and
8	53	70	U-UNK	dextropropoxyphene
9	72	74	O	had
10	76	77	O	no
11	79	84	O	effect
12	86	87	O	on
13	89	91	O	the
14	93	108	O	pharmacokinetics
15	110	111	O	of
16	113	115	U-UNK	MHD
NULL

Oxcarbazepine	DDI-DrugBank.d307.s48	NO_SECTION	NO_SETID	16
Results with warfarin wshow no evidence of interaction with either single or repeated doses of Trileptal.
1	0	6	O	Results
2	8	11	O	with
3	13	20	U-UNK	warfarin
4	22	26	O	wshow
5	28	29	O	no
6	31	38	O	evidence
7	40	41	O	of
8	43	53	O	interaction
9	55	58	O	with
10	60	65	O	either
11	67	72	O	single
12	74	75	O	or
13	77	84	O	repeated
14	86	90	O	doses
15	92	93	O	of
16	95	103	O	XXXXXXXX
NULL

Paclitaxel	DDI-DrugBank.d288.s0	NO_SECTION	NO_SETID	48
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).
1	0	1	O	In
2	3	3	O	a
3	5	9	O	Phase
4	11	11	O	I
5	13	17	O	trial
6	19	23	O	using
7	25	34	O	escalating
8	36	40	O	doses
9	42	43	O	of
10	45	49	O	XXXXXXXX
11	52	54	O	110
12	56	58	O	200
13	60	61	O	mg
14	62	62	O	/
15	63	64	O	m2
16	67	69	O	and
17	71	79	U-UNK	cisplatin
18	82	83	O	50
19	85	86	O	or
20	88	89	O	75
21	91	92	O	mg
22	93	93	O	/
23	94	95	O	m2
24	98	102	O	given
25	104	105	O	as
26	107	116	O	sequential
27	118	126	O	infusions
28	127	127	O	,
29	129	144	O	myelosuppression
30	146	148	O	was
31	150	153	O	more
32	155	162	O	profound
33	164	167	O	when
34	169	173	O	XXXXXXXX
35	175	177	O	was
36	179	183	O	given
37	185	189	O	after
38	191	199	U-DYN	cisplatin
39	201	204	O	than
40	206	209	O	with
41	211	213	O	the
42	215	223	O	alternate
43	225	232	O	sequence
44	235	236	O	ie
45	237	237	O	,
46	239	243	O	XXXXXXXX
47	245	250	O	before
48	252	260	U-UNK	cisplatin
NULL

Paclitaxel	DDI-DrugBank.d288.s1	NO_SECTION	NO_SETID	20
Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.
1	0	14	O	Pharmacokinetic
2	16	19	O	data
3	21	24	O	from
4	26	30	O	these
5	32	39	O	patients
6	41	52	O	demonstrated
7	54	54	O	a
8	56	63	O	decrease
9	65	66	O	in
10	68	77	U-UNK	paclitaxel
11	79	87	O	clearance
12	89	90	O	of
13	92	104	O	approximately
14	106	108	O	33%
15	110	113	O	when
16	115	119	O	XXXXXXXX
17	121	123	O	was
18	125	136	O	administered
19	138	146	O	following
20	148	156	U-KIN	cisplatin
NULL

Paclitaxel	DDI-DrugBank.d288.s2	NO_SECTION	NO_SETID	14
The metabolism of TAXOL is catalyzed by cytochrome P450 isoen-zymes CYP2C8 and CYP3A4.
1	0	2	O	The
2	4	13	O	metabolism
3	15	16	O	of
4	18	22	O	XXXXXXXX
5	24	25	O	is
6	27	35	O	catalyzed
7	37	38	O	by
8	40	49	O	cytochrome
9	51	54	O	P450
10	56	60	O	isoen
11	62	66	O	zymes
12	68	73	O	CYP2C8
13	75	77	O	and
14	79	84	O	CYP3A4
NULL

Paclitaxel	DDI-DrugBank.d288.s3	NO_SECTION	NO_SETID	31
In the absence of formal clinical drug interaction studies, caution should be exercised when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4.
1	0	1	O	In
2	3	5	O	the
3	7	13	O	absence
4	15	16	O	of
5	18	23	O	formal
6	25	32	O	clinical
7	34	37	O	drug
8	39	49	O	interaction
9	51	57	O	studies
10	58	58	O	,
11	60	66	O	caution
12	68	73	O	should
13	75	76	O	be
14	78	86	O	exercised
15	88	91	O	when
16	93	105	O	administering
17	107	111	O	XXXXXXXX
18	113	125	O	concomitantly
19	127	130	O	with
20	132	136	O	known
21	138	147	O	substrates
22	149	150	O	or
23	152	161	O	inhibitors
24	163	164	O	of
25	166	168	O	the
26	170	179	O	cytochrome
27	181	184	O	P450
28	186	195	O	isoenzymes
29	197	202	O	CYP2C8
30	204	206	O	and
31	208	213	O	CYP3A4
NULL

Paclitaxel	DDI-DrugBank.d288.s4	NO_SECTION	NO_SETID	39
Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.
1	0	8	O	Potential
2	10	21	O	interactions
3	23	29	O	between
4	31	35	O	XXXXXXXX
5	36	36	O	,
6	38	38	O	a
7	40	48	O	substrate
8	50	51	O	of
9	53	58	O	CYP3A4
10	59	59	O	,
11	61	63	O	and
12	65	72	B-UNK	protease
13	74	83	L-UNK	inhibitors
14	86	94	U-UNK	ritonavir
15	95	95	O	,
16	97	106	U-UNK	saquinavir
17	107	107	O	,
18	109	117	U-UNK	indinavir
19	118	118	O	,
20	120	122	O	and
21	124	133	U-UNK	nelfinavir
22	135	135	O	,
23	137	141	O	which
24	143	145	O	are
25	147	156	O	substrates
26	158	160	O	and
27	161	161	O	/
28	162	163	O	or
29	165	174	O	inhibitors
30	176	177	O	of
31	179	184	O	CYP3A4
32	185	185	O	,
33	187	190	O	have
34	192	194	O	not
35	196	199	O	been
36	201	209	O	evaluated
37	211	212	O	in
38	214	221	O	clinical
39	223	228	O	trials
NULL

Paclitaxel	DDI-DrugBank.d288.s5	NO_SECTION	NO_SETID	26
Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.
1	0	6	O	Reports
2	8	9	O	in
3	11	13	O	the
4	15	24	O	literature
5	26	32	O	suggest
6	34	37	O	that
7	39	44	O	plasma
8	46	51	O	levels
9	53	54	O	of
10	56	66	U-UNK	doxorubicin
11	69	71	O	and
12	73	75	O	its
13	77	82	O	active
14	84	93	O	metabolite
15	95	107	U-UNK	doxorubicinol
16	110	112	O	may
17	114	115	O	be
18	117	125	O	increased
19	127	130	O	when
20	132	141	O	XXXXXXXX
21	143	145	O	and
22	147	157	U-KIN	doxorubicin
23	159	161	O	are
24	163	166	O	used
25	168	169	O	in
26	171	181	O	combination
NULL

Paclitaxel	DDI-DrugBank.d288.s6	NO_SECTION	NO_SETID	21
Hematology: TAXOL therapy should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3.
1	0	9	O	Hematology
2	10	10	O	:
3	12	16	O	XXXXXXXX
4	18	24	O	therapy
5	26	31	O	should
6	33	35	O	not
7	37	38	O	be
8	40	51	O	administered
9	53	54	O	to
10	56	63	O	patients
11	65	68	O	with
12	70	77	O	baseline
13	79	88	O	neutrophil
14	90	95	O	counts
15	97	98	O	of
16	100	103	O	less
17	105	108	O	than
18	110	114	O	1,500
19	116	120	O	cells
20	121	121	O	/
21	122	124	O	mm3
NULL

Paclitaxel	DDI-DrugBank.d288.s7	NO_SECTION	NO_SETID	25
In order to monitor the occurrence of myelotoxicity, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving TAXOL.
1	0	1	O	In
2	3	7	O	order
3	9	10	O	to
4	12	18	O	monitor
5	20	22	O	the
6	24	33	O	occurrence
7	35	36	O	of
8	38	50	O	myelotoxicity
9	51	51	O	,
10	53	54	O	it
11	56	57	O	is
12	59	69	O	recommended
13	71	74	O	that
14	76	83	O	frequent
15	85	94	O	peripheral
16	96	100	O	blood
17	102	105	O	cell
18	107	112	O	counts
19	114	115	O	be
20	117	125	O	performed
21	127	128	O	on
22	130	132	O	all
23	134	141	O	patients
24	143	151	O	receiving
25	153	157	O	XXXXXXXX
NULL

Paclitaxel	DDI-DrugBank.d288.s8	NO_SECTION	NO_SETID	31
Patients should not be re-treated with subsequent cycles of TAXOL until neutrophils recover to a level  1500 cells/mm3 and platelets recover to a level  100,000 cells/mm3.
1	0	7	O	Patients
2	9	14	O	should
3	16	18	O	not
4	20	21	O	be
5	23	24	O	re
6	26	32	O	treated
7	34	37	O	with
8	39	48	O	subsequent
9	50	55	O	cycles
10	57	58	O	of
11	60	64	O	XXXXXXXX
12	66	70	O	until
13	72	82	O	neutrophils
14	84	90	O	recover
15	92	93	O	to
16	95	95	O	a
17	97	101	O	level
18	104	107	O	1500
19	109	113	O	cells
20	114	114	O	/
21	115	117	O	mm3
22	119	121	O	and
23	123	131	O	platelets
24	133	139	O	recover
25	141	142	O	to
26	144	144	O	a
27	146	150	O	level
28	153	159	O	100,000
29	161	165	O	cells
30	166	166	O	/
31	167	169	O	mm3
NULL

Paclitaxel	DDI-DrugBank.d288.s9	NO_SECTION	NO_SETID	34
In the case of severe neutropenia ( 500 cells/mm3 for seven days or more) during a course of TAXOL therapy, a 20% reduction in dose for subsequent courses of therapy is recommended.
1	0	1	O	In
2	3	5	O	the
3	7	10	O	case
4	12	13	O	of
5	15	20	O	severe
6	22	32	O	neutropenia
7	36	38	O	500
8	40	44	O	cells
9	45	45	O	/
10	46	48	O	mm3
11	50	52	O	for
12	54	58	O	seven
13	60	63	O	days
14	65	66	O	or
15	68	71	O	more
16	74	79	O	during
17	81	81	O	a
18	83	88	O	course
19	90	91	O	of
20	93	97	O	XXXXXXXX
21	99	105	O	therapy
22	106	106	O	,
23	108	108	O	a
24	110	112	O	20%
25	114	122	O	reduction
26	124	125	O	in
27	127	130	O	dose
28	132	134	O	for
29	136	145	O	subsequent
30	147	153	O	courses
31	155	156	O	of
32	158	164	O	therapy
33	166	167	O	is
34	169	179	O	recommended
NULL

Paclitaxel	DDI-DrugBank.d288.s10	NO_SECTION	NO_SETID	41
For patients with advanced HIV disease and poor-risk AIDS-related Kaposi s sarcoma, TAXOL, at the recommended dose for this disease, can be initiated and repeated if the neutrophil count is at least 1000 cells/mm3.
1	0	2	O	For
2	4	11	O	patients
3	13	16	O	with
4	18	25	O	advanced
5	27	29	O	HIV
6	31	37	O	disease
7	39	41	O	and
8	43	46	O	poor
9	48	51	O	risk
10	53	56	O	AIDS
11	58	64	O	related
12	66	71	O	Kaposi
13	73	73	O	s
14	75	81	O	sarcoma
15	82	82	O	,
16	84	88	O	XXXXXXXX
17	89	89	O	,
18	91	92	O	at
19	94	96	O	the
20	98	108	O	recommended
21	110	113	O	dose
22	115	117	O	for
23	119	122	O	this
24	124	130	O	disease
25	131	131	O	,
26	133	135	O	can
27	137	138	O	be
28	140	148	O	initiated
29	150	152	O	and
30	154	161	O	repeated
31	163	164	O	if
32	166	168	O	the
33	170	179	O	neutrophil
34	181	185	O	count
35	187	188	O	is
36	190	191	O	at
37	193	197	O	least
38	199	202	O	1000
39	204	208	O	cells
40	209	209	O	/
41	210	212	O	mm3
NULL

Paclitaxel	DDI-DrugBank.d288.s11	NO_SECTION	NO_SETID	33
Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.
1	0	15	O	Hypersensitivity
2	17	25	O	Reactions
3	26	26	O	:
4	28	35	O	Patients
5	37	40	O	with
6	42	42	O	a
7	44	50	O	history
8	52	53	O	of
9	55	60	O	severe
10	62	77	O	hypersensitivity
11	79	87	O	reactions
12	89	90	O	to
13	92	99	O	products
14	101	110	O	containing
15	112	120	O	Cremophor
16	123	124	O	EL
17	127	128	O	eg
18	129	129	O	,
19	131	141	U-DYN	cyclosporin
20	143	145	O	for
21	147	155	O	injection
22	157	167	O	concentrate
23	169	171	O	and
24	173	182	U-DYN	teniposide
25	184	186	O	for
26	188	196	O	injection
27	198	208	O	concentrate
28	211	216	O	should
29	218	220	O	not
30	222	223	O	be
31	225	231	O	treated
32	233	236	O	with
33	238	242	O	XXXXXXXX
NULL

Paclitaxel	DDI-DrugBank.d288.s12	NO_SECTION	NO_SETID	35
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).
1	0	1	O	In
2	3	7	O	order
3	9	10	O	to
4	12	16	O	avoid
5	18	20	O	the
6	22	31	O	occurrence
7	33	34	O	of
8	36	41	O	severe
9	43	58	O	hypersensitivity
10	60	68	O	reactions
11	69	69	O	,
12	71	73	O	all
13	75	82	O	patients
14	84	90	O	treated
15	92	95	O	with
16	97	101	O	XXXXXXXX
17	103	108	O	should
18	110	111	O	be
19	113	124	O	premedicated
20	126	129	O	with
21	131	145	U-UNK	corticosteroids
22	148	151	O	such
23	153	154	O	as
24	156	168	U-UNK	dexamethasone
25	170	170	O	,
26	172	177	O	diphen
27	179	187	O	hydramine
28	189	191	O	and
29	193	194	B-UNK	H2
30	196	206	L-UNK	antagonists
31	209	212	O	such
32	214	215	O	as
33	217	226	U-UNK	cimetidine
34	228	229	O	or
35	231	240	U-UNK	ranitidine
NULL

Paclitaxel	DDI-DrugBank.d288.s13	NO_SECTION	NO_SETID	21
Minor symptoms such as flushing, skin reactions, dyspnea, hypotension, or tachycardia do not require interruption of therapy.
1	0	4	O	Minor
2	6	13	O	symptoms
3	15	18	O	such
4	20	21	O	as
5	23	30	O	flushing
6	31	31	O	,
7	33	36	O	skin
8	38	46	O	reactions
9	47	47	O	,
10	49	55	O	dyspnea
11	56	56	O	,
12	58	68	O	hypotension
13	69	69	O	,
14	71	72	O	or
15	74	84	O	tachycardia
16	86	87	O	do
17	89	91	O	not
18	93	99	O	require
19	101	112	O	interruption
20	114	115	O	of
21	117	123	O	therapy
NULL

Paclitaxel	DDI-DrugBank.d288.s14	NO_SECTION	NO_SETID	29
However, severe reactions, such as hypotension requiring treatment, dyspnea requiring bronchodilators, angioedema, or generalized urticaria require immediate discontinuation of TAXOL and aggressive symptomatic therapy.
1	0	6	O	However
2	7	7	O	,
3	9	14	O	severe
4	16	24	O	reactions
5	25	25	O	,
6	27	30	O	such
7	32	33	O	as
8	35	45	O	hypotension
9	47	55	O	requiring
10	57	65	O	treatment
11	66	66	O	,
12	68	74	O	dyspnea
13	76	84	O	requiring
14	86	100	U-UNK	bronchodilators
15	101	101	O	,
16	103	112	O	angioedema
17	113	113	O	,
18	115	116	O	or
19	118	128	O	generalized
20	130	138	O	urticaria
21	140	146	O	require
22	148	156	O	immediate
23	158	172	O	discontinuation
24	174	175	O	of
25	177	181	O	XXXXXXXX
26	183	185	O	and
27	187	196	O	aggressive
28	198	208	O	symptomatic
29	210	216	O	therapy
NULL

Paclitaxel	DDI-DrugBank.d288.s15	NO_SECTION	NO_SETID	13
Patients who have developed severe hypersensitivity reactions should not be rechallenged with TAXOL.
1	0	7	O	Patients
2	9	11	O	who
3	13	16	O	have
4	18	26	O	developed
5	28	33	O	severe
6	35	50	O	hypersensitivity
7	52	60	O	reactions
8	62	67	O	should
9	69	71	O	not
10	73	74	O	be
11	76	87	O	rechallenged
12	89	92	O	with
13	94	98	O	XXXXXXXX
NULL

Paclitaxel	DDI-DrugBank.d288.s16	NO_SECTION	NO_SETID	22
Cardiovascular: Hypotension, bradycardia, and hypertension have been observed during administration of TAXOL, but generally do not require treatment.
1	0	13	O	Cardiovascular
2	14	14	O	:
3	16	26	O	Hypotension
4	27	27	O	,
5	29	39	O	bradycardia
6	40	40	O	,
7	42	44	O	and
8	46	57	O	hypertension
9	59	62	O	have
10	64	67	O	been
11	69	76	O	observed
12	78	83	O	during
13	85	98	O	administration
14	100	101	O	of
15	103	107	O	XXXXXXXX
16	108	108	O	,
17	110	112	O	but
18	114	122	O	generally
19	124	125	O	do
20	127	129	O	not
21	131	137	O	require
22	139	147	O	treatment
NULL

Paclitaxel	DDI-DrugBank.d288.s17	NO_SECTION	NO_SETID	14
Occasionally TAXOL infusions must be interrupted or discontinued because of initial or recurrent hypertension.
1	0	11	O	Occasionally
2	13	17	O	XXXXXXXX
3	19	27	O	infusions
4	29	32	O	must
5	34	35	O	be
6	37	47	O	interrupted
7	49	50	O	or
8	52	63	O	discontinued
9	65	71	O	because
10	73	74	O	of
11	76	82	O	initial
12	84	85	O	or
13	87	95	O	recurrent
14	97	108	O	hypertension
NULL

Paclitaxel	DDI-DrugBank.d288.s18	NO_SECTION	NO_SETID	16
Frequent vital sign monitoring, particularly during the first hour of TAXOL infusion, is recommended.
1	0	7	O	Frequent
2	9	13	O	vital
3	15	18	O	sign
4	20	29	O	monitoring
5	30	30	O	,
6	32	43	O	particularly
7	45	50	O	during
8	52	54	O	the
9	56	60	O	first
10	62	65	O	hour
11	67	68	O	of
12	70	74	O	XXXXXXXX
13	76	83	O	infusion
14	84	84	O	,
15	86	87	O	is
16	89	99	O	recommended
NULL

Paclitaxel	DDI-DrugBank.d288.s19	NO_SECTION	NO_SETID	13
Continuous cardiac monitoring is not required except for patients with serious conduction abnormalities.
1	0	9	O	Continuous
2	11	17	O	cardiac
3	19	28	O	monitoring
4	30	31	O	is
5	33	35	O	not
6	37	44	O	required
7	46	51	O	except
8	53	55	O	for
9	57	64	O	patients
10	66	69	O	with
11	71	77	O	serious
12	79	88	O	conduction
13	90	102	O	abnormalities
NULL

Paclitaxel	DDI-DrugBank.d288.s20	NO_SECTION	NO_SETID	31
Nervous System: Although the occurrence of peripheral neuropathy is frequent, the development of severe symptomatology is unusual and requires a dose reduction of 20% for all subsequentcourses of TAXOL.
1	0	6	O	Nervous
2	8	13	O	System
3	14	14	O	:
4	16	23	O	Although
5	25	27	O	the
6	29	38	O	occurrence
7	40	41	O	of
8	43	52	O	peripheral
9	54	63	O	neuropathy
10	65	66	O	is
11	68	75	O	frequent
12	76	76	O	,
13	78	80	O	the
14	82	92	O	development
15	94	95	O	of
16	97	102	O	severe
17	104	117	O	symptomatology
18	119	120	O	is
19	122	128	O	unusual
20	130	132	O	and
21	134	141	O	requires
22	143	143	O	a
23	145	148	O	dose
24	150	158	O	reduction
25	160	161	O	of
26	163	165	O	20%
27	167	169	O	for
28	171	173	O	all
29	175	191	O	subsequentcourses
30	193	194	O	of
31	196	200	O	XXXXXXXX
NULL

Paclitaxel	DDI-DrugBank.d288.s21	NO_SECTION	NO_SETID	10
TAXOL contains dehydrated alcohol USP, 396 mg/mL;
1	0	4	O	XXXXXXXX
2	6	13	O	contains
3	15	24	O	dehydrated
4	26	32	O	alcohol
5	34	36	O	USP
6	37	37	O	,
7	39	41	O	396
8	43	44	O	mg
9	45	45	O	/
10	46	47	O	mL
NULL

Paclitaxel	DDI-DrugBank.d288.s22	NO_SECTION	NO_SETID	12
consideration should be given to possible CNS and other effects of alcohol.
1	0	12	O	consideration
2	14	19	O	should
3	21	22	O	be
4	24	28	O	given
5	30	31	O	to
6	33	40	O	possible
7	42	44	O	CNS
8	46	48	O	and
9	50	54	O	other
10	56	62	O	effects
11	64	65	O	of
12	67	73	U-UNK	alcohol
NULL

Paclitaxel	DDI-DrugBank.d288.s23	NO_SECTION	NO_SETID	23
Hepatic: There is limited evidence that the myelotoxicity of TAXOL may be exacerbated in patients with serum total bilirubin  2 times ULN.
1	0	6	O	Hepatic
2	7	7	O	:
3	9	13	O	There
4	15	16	O	is
5	18	24	O	limited
6	26	33	O	evidence
7	35	38	O	that
8	40	42	O	the
9	44	56	O	myelotoxicity
10	58	59	O	of
11	61	65	O	XXXXXXXX
12	67	69	O	may
13	71	72	O	be
14	74	84	O	exacerbated
15	86	87	O	in
16	89	96	O	patients
17	98	101	O	with
18	103	107	O	serum
19	109	113	O	total
20	115	123	O	bilirubin
21	126	126	O	2
22	128	132	O	times
23	134	136	O	ULN
NULL

Paclitaxel	DDI-DrugBank.d288.s24	NO_SECTION	NO_SETID	24
Extreme caution should be exercised when administering TAXOL to such patients, with dose reduction as recommended in DOSAGE AND ADMINISTRATION, Table 17.
1	0	6	O	Extreme
2	8	14	O	caution
3	16	21	O	should
4	23	24	O	be
5	26	34	O	exercised
6	36	39	O	when
7	41	53	O	administering
8	55	59	O	XXXXXXXX
9	61	62	O	to
10	64	67	O	such
11	69	76	O	patients
12	77	77	O	,
13	79	82	O	with
14	84	87	O	dose
15	89	97	O	reduction
16	99	100	O	as
17	102	112	O	recommended
18	114	115	O	in
19	117	122	O	DOSAGE
20	124	126	O	AND
21	128	141	O	ADMINISTRATION
22	142	142	O	,
23	144	148	O	Table
24	150	151	O	17
NULL

Paclitaxel	DDI-DrugBank.d288.s25	NO_SECTION	NO_SETID	32
InjectionSite Reaction: Injection site reactions, including reactions secondary to extravasation, were usually mild and consisted of erythema, tenderness, skin discoloration, or swelling at the injection site.
1	0	12	O	InjectionSite
2	14	21	O	Reaction
3	22	22	O	:
4	24	32	O	Injection
5	34	37	O	site
6	39	47	O	reactions
7	48	48	O	,
8	50	58	O	including
9	60	68	O	reactions
10	70	78	O	secondary
11	80	81	O	to
12	83	95	O	extravasation
13	96	96	O	,
14	98	101	O	were
15	103	109	O	usually
16	111	114	O	mild
17	116	118	O	and
18	120	128	O	consisted
19	130	131	O	of
20	133	140	O	erythema
21	141	141	O	,
22	143	152	O	tenderness
23	153	153	O	,
24	155	158	O	skin
25	160	172	O	discoloration
26	173	173	O	,
27	175	176	O	or
28	178	185	O	swelling
29	187	188	O	at
30	190	192	O	the
31	194	202	O	injection
32	204	207	O	site
NULL

Paclitaxel	DDI-DrugBank.d288.s26	NO_SECTION	NO_SETID	18
These reactions have been observed more frequently with the 24-hour infusion than with the 3-hour infusion.
1	0	4	O	These
2	6	14	O	reactions
3	16	19	O	have
4	21	24	O	been
5	26	33	O	observed
6	35	38	O	more
7	40	49	O	frequently
8	51	54	O	with
9	56	58	O	the
10	60	61	O	24
11	63	66	O	hour
12	68	75	O	infusion
13	77	80	O	than
14	82	85	O	with
15	87	89	O	the
16	91	91	O	3
17	93	96	O	hour
18	98	105	O	infusion
NULL

Paclitaxel	DDI-DrugBank.d288.s27	NO_SECTION	NO_SETID	27
Recurrence of skin reactions at a site of previous extravasation following administration of TAXOL at a different site, ie, recall, has been reported rarely.
1	0	9	O	Recurrence
2	11	12	O	of
3	14	17	O	skin
4	19	27	O	reactions
5	29	30	O	at
6	32	32	O	a
7	34	37	O	site
8	39	40	O	of
9	42	49	O	previous
10	51	63	O	extravasation
11	65	73	O	following
12	75	88	O	administration
13	90	91	O	of
14	93	97	O	XXXXXXXX
15	99	100	O	at
16	102	102	O	a
17	104	112	O	different
18	114	117	O	site
19	118	118	O	,
20	120	121	O	ie
21	122	122	O	,
22	124	129	O	recall
23	130	130	O	,
24	132	134	O	has
25	136	139	O	been
26	141	148	O	reported
27	150	155	O	rarely
NULL

Paclitaxel	DDI-DrugBank.d288.s28	NO_SECTION	NO_SETID	33
Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis, and fibrosis have been received as part of the continuing surveillance of TAXOL safety.
1	0	3	O	Rare
2	5	11	O	reports
3	13	14	O	of
4	16	19	O	more
5	21	26	O	severe
6	28	33	O	events
7	35	38	O	such
8	40	41	O	as
9	43	51	O	phlebitis
10	52	52	O	,
11	54	63	O	cellulitis
12	64	64	O	,
13	66	75	O	induration
14	76	76	O	,
15	78	81	O	skin
16	83	93	O	exfoliation
17	94	94	O	,
18	96	103	O	necrosis
19	104	104	O	,
20	106	108	O	and
21	110	117	O	fibrosis
22	119	122	O	have
23	124	127	O	been
24	129	136	O	received
25	138	139	O	as
26	141	144	O	part
27	146	147	O	of
28	149	151	O	the
29	153	162	O	continuing
30	164	175	O	surveillance
31	177	178	O	of
32	180	184	O	XXXXXXXX
33	186	191	O	safety
NULL

Paclitaxel	DDI-DrugBank.d288.s29	NO_SECTION	NO_SETID	25
In some cases the onset of the injection site reaction either occurred during a prolonged infusion or was delayed by a week to ten days.
1	0	1	O	In
2	3	6	O	some
3	8	12	O	cases
4	14	16	O	the
5	18	22	O	onset
6	24	25	O	of
7	27	29	O	the
8	31	39	O	injection
9	41	44	O	site
10	46	53	O	reaction
11	55	60	O	either
12	62	69	O	occurred
13	71	76	O	during
14	78	78	O	a
15	80	88	O	prolonged
16	90	97	O	infusion
17	99	100	O	or
18	102	104	O	was
19	106	112	O	delayed
20	114	115	O	by
21	117	117	O	a
22	119	122	O	week
23	124	125	O	to
24	127	129	O	ten
25	131	134	O	days
NULL

Paclitaxel	DDI-DrugBank.d288.s30	NO_SECTION	NO_SETID	11
A specific treatment for extravasation reactions is unknown at this time.
1	0	0	O	A
2	2	9	O	specific
3	11	19	O	treatment
4	21	23	O	for
5	25	37	O	extravasation
6	39	47	O	reactions
7	49	50	O	is
8	52	58	O	unknown
9	60	61	O	at
10	63	66	O	this
11	68	71	O	time
NULL

Paclitaxel	DDI-DrugBank.d288.s31	NO_SECTION	NO_SETID	21
Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration.
1	0	4	O	Given
2	6	8	O	the
3	10	20	O	possibility
4	22	23	O	of
5	25	37	O	extravasation
6	38	38	O	,
7	40	41	O	it
8	43	44	O	is
9	46	54	O	advisable
10	56	57	O	to
11	59	65	O	closely
12	67	73	O	monitor
13	75	77	O	the
14	79	86	O	infusion
15	88	91	O	site
16	93	95	O	for
17	97	104	O	possible
18	106	117	O	infiltration
19	119	124	O	during
20	126	129	O	drug
21	131	144	O	administration
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s0	NO_SECTION	NO_SETID	26
Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.
1	0	8	O	Treatment
2	10	13	O	with
3	15	21	O	XXXXXXXX
4	23	26	O	once
5	28	33	O	weekly
6	35	37	O	for
7	39	39	O	4
8	41	45	O	weeks
9	47	48	O	in
10	50	56	O	healthy
11	58	65	O	subjects
12	67	69	O	was
13	71	80	O	associated
14	82	85	O	with
15	87	88	O	an
16	90	99	O	inhibition
17	101	102	O	of
18	104	107	O	P450
19	109	111	O	1A2
20	113	115	O	and
21	117	117	O	a
22	119	121	O	25%
23	123	130	O	increase
24	132	133	O	in
25	135	146	U-KIN	theophylline
26	148	150	O	AUC
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s1	NO_SECTION	NO_SETID	18
Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.
1	0	11	U-UNK	Theophylline
2	13	17	O	serum
3	19	24	O	levels
4	26	31	O	should
5	33	34	O	be
6	36	44	O	monitored
7	46	48	O	and
8	50	60	O	appropriate
9	62	65	O	dose
10	67	77	O	adjustments
11	79	88	O	considered
12	90	92	O	for
13	94	101	O	patients
14	103	107	O	given
15	109	112	O	both
16	114	125	U-DYN	theophylline
17	127	129	O	and
18	131	137	O	XXXXXXXX
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s2	NO_SECTION	NO_SETID	23
There was no effect on the pharmacokinetics of representative drugs metabolized by CYP 2C9, CYP 2C19, CYP 2D6 or CYP 3A4.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	18	O	effect
5	20	21	O	on
6	23	25	O	the
7	27	42	O	pharmacokinetics
8	44	45	O	of
9	47	60	O	representative
10	62	66	O	drugs
11	68	78	O	metabolized
12	80	81	O	by
13	83	85	O	CYP
14	87	89	O	2C9
15	90	90	O	,
16	92	94	O	CYP
17	96	99	O	2C19
18	100	100	O	,
19	102	104	O	CYP
20	106	108	O	2D6
21	110	111	O	or
22	113	115	O	CYP
23	117	119	O	3A4
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s3	NO_SECTION	NO_SETID	23
In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS, PEGASYS treatment did not affect ribavirin distribution or clearance.
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	23	O	chronic
5	25	33	O	hepatitis
6	35	35	O	C
7	37	43	O	treated
8	45	48	O	with
9	50	56	O	XXXXXXXX
10	58	59	O	in
11	61	71	O	combination
12	73	76	O	with
13	78	84	O	COPEGUS
14	85	85	O	,
15	87	93	O	XXXXXXXX
16	95	103	O	treatment
17	105	107	O	did
18	109	111	O	not
19	113	118	O	affect
20	120	128	U-UNK	ribavirin
21	130	141	O	distribution
22	143	144	O	or
23	146	154	O	clearance
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s4	NO_SECTION	NO_SETID	12
Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.
1	0	9	O	Nucleoside
2	11	19	O	Analogues
3	21	30	U-UNK	Didanosine
4	32	33	O	Co
5	35	48	O	administration
6	50	51	O	of
7	53	59	O	XXXXXXXX
8	61	63	O	and
9	65	74	U-DYN	didanosine
10	76	77	O	is
11	79	81	O	not
12	83	93	O	recommended
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s5	NO_SECTION	NO_SETID	26
Reports of fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in clinical trials.
1	0	6	O	Reports
2	8	9	O	of
3	11	15	O	fatal
4	17	23	O	hepatic
5	25	31	O	failure
6	32	32	O	,
7	34	35	O	as
8	37	40	O	well
9	42	43	O	as
10	45	54	O	peripheral
11	56	65	O	neuropathy
12	66	66	O	,
13	68	79	O	pancreatitis
14	80	80	O	,
15	82	84	O	and
16	86	96	O	symptomatic
17	98	112	O	hyperlactatemia
18	113	113	O	/
19	114	119	O	lactic
20	121	128	O	acidosis
21	130	133	O	have
22	135	138	O	been
23	140	147	O	reported
24	149	150	O	in
25	152	159	O	clinical
26	161	166	O	trials
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s6	NO_SECTION	NO_SETID	17
Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.
1	0	8	U-UNK	Stavudine
2	10	12	O	and
3	14	23	U-UNK	Zidovudine
4	25	33	U-UNK	Ribavirin
5	35	37	O	can
6	39	48	O	antagonize
7	50	52	O	the
8	54	55	O	in
9	57	61	O	vitro
10	63	71	O	antiviral
11	73	80	O	activity
12	82	83	O	of
13	85	93	U-UNK	stavudine
14	95	97	O	and
15	99	108	U-UNK	zidovudine
16	110	116	O	against
17	118	120	O	HIV
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s7	NO_SECTION	NO_SETID	14
Therefore, concomitant use of ribavirin with either of these drugs should be avoided.
1	0	8	O	Therefore
2	9	9	O	,
3	11	21	O	concomitant
4	23	25	O	use
5	27	28	O	of
6	30	38	U-UNK	ribavirin
7	40	43	O	with
8	45	50	O	either
9	52	53	O	of
10	55	59	O	these
11	61	65	O	drugs
12	67	72	O	should
13	74	75	O	be
14	77	83	O	avoided
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s8	NO_SECTION	NO_SETID	17
Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis PEGASYS has not been tested for its carcinogenic potential.
1	0	13	O	Carcinogenesis
2	14	14	O	,
3	16	26	O	Mutagenesis
4	27	27	O	,
5	29	38	O	Impairment
6	40	41	O	of
7	43	51	O	Fertility
8	53	66	O	Carcinogenesis
9	68	74	O	XXXXXXXX
10	76	78	O	has
11	80	82	O	not
12	84	87	O	been
13	89	94	O	tested
14	96	98	O	for
15	100	102	O	its
16	104	115	O	carcinogenic
17	117	125	O	potential
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s9	NO_SECTION	NO_SETID	36
Mutagenesis PEGASYS did not cause DNA damage when tested in the Ames bacterial mutagenicity assay and in the in vitro chromosomal aberration assay in human lymphocytes, either in the presence or absence of metabolic activation.
1	0	10	O	Mutagenesis
2	12	18	O	XXXXXXXX
3	20	22	O	did
4	24	26	O	not
5	28	32	O	cause
6	34	36	O	DNA
7	38	43	O	damage
8	45	48	O	when
9	50	55	O	tested
10	57	58	O	in
11	60	62	O	the
12	64	67	O	Ames
13	69	77	O	bacterial
14	79	90	O	mutagenicity
15	92	96	O	assay
16	98	100	O	and
17	102	103	O	in
18	105	107	O	the
19	109	110	O	in
20	112	116	O	vitro
21	118	128	O	chromosomal
22	130	139	O	aberration
23	141	145	O	assay
24	147	148	O	in
25	150	154	O	human
26	156	166	O	lymphocytes
27	167	167	O	,
28	169	174	O	either
29	176	177	O	in
30	179	181	O	the
31	183	190	O	presence
32	192	193	O	or
33	195	201	O	absence
34	203	204	O	of
35	206	214	O	metabolic
36	216	225	O	activation
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s10	NO_SECTION	NO_SETID	8
Use With Ribavirin Ribavirin is genotoxic and mutagenic.
1	0	2	O	Use
2	4	7	O	With
3	9	17	U-UNK	Ribavirin
4	19	27	U-UNK	Ribavirin
5	29	30	O	is
6	32	40	O	genotoxic
7	42	44	O	and
8	46	54	O	mutagenic
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s11	NO_SECTION	NO_SETID	10
The carcinogenic potential of ribavirin has not been fully determined.
1	0	2	O	The
2	4	15	O	carcinogenic
3	17	25	O	potential
4	27	28	O	of
5	30	38	U-UNK	ribavirin
6	40	42	O	has
7	44	46	O	not
8	48	51	O	been
9	53	57	O	fully
10	59	68	O	determined
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s12	NO_SECTION	NO_SETID	27
In a p53 (+/-) mouse carcinogenicity study at doses up to the maximum tolerated dose of 100 mg/kg/day ribavirin was not oncogenic.
1	0	1	O	In
2	3	3	O	a
3	5	7	O	p53
4	10	10	O	+
5	11	11	O	/
6	15	19	O	mouse
7	21	35	O	carcinogenicity
8	37	41	O	study
9	43	44	O	at
10	46	50	O	doses
11	52	53	O	up
12	55	56	O	to
13	58	60	O	the
14	62	68	O	maximum
15	70	78	O	tolerated
16	80	83	O	dose
17	85	86	O	of
18	88	90	O	100
19	92	93	O	mg
20	94	94	O	/
21	95	96	O	kg
22	97	97	O	/
23	98	100	O	day
24	102	110	U-UNK	ribavirin
25	112	114	O	was
26	116	118	O	not
27	120	128	O	oncogenic
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s13	NO_SECTION	NO_SETID	22
However, on a body surface area basis, this dose was 0.5 times maximum recommended human 24-hour dose of ribavirin.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	on
4	12	12	O	a
5	14	17	O	body
6	19	25	O	surface
7	27	30	O	area
8	32	36	O	basis
9	37	37	O	,
10	39	42	O	this
11	44	47	O	dose
12	49	51	O	was
13	53	55	O	0.5
14	57	61	O	times
15	63	69	O	maximum
16	71	81	O	recommended
17	83	87	O	human
18	89	90	O	24
19	92	95	O	hour
20	97	100	O	dose
21	102	103	O	of
22	105	113	U-UNK	ribavirin
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s14	NO_SECTION	NO_SETID	13
A study in rats to assess the carcinogenic potential of ribavirin is ongoing.
1	0	0	O	A
2	2	6	O	study
3	8	9	O	in
4	11	14	O	rats
5	16	17	O	to
6	19	24	O	assess
7	26	28	O	the
8	30	41	O	carcinogenic
9	43	51	O	potential
10	53	54	O	of
11	56	64	U-UNK	ribavirin
12	66	67	O	is
13	69	75	O	ongoing
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s15	NO_SECTION	NO_SETID	10
Mutagenesis Impairment of Fertility PEGASYS may impair fertility in women.
1	0	10	O	Mutagenesis
2	12	21	O	Impairment
3	23	24	O	of
4	26	34	O	Fertility
5	36	42	O	XXXXXXXX
6	44	46	O	may
7	48	53	O	impair
8	55	63	O	fertility
9	65	66	O	in
10	68	72	O	women
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s16	NO_SECTION	NO_SETID	59
Prolonged menstrual cycles and/or amenorrhea were observed in female cynomolgus monkeys given sc injections of 600 m g/kg/dose (7200 m g/m2/dose) of PEGASYS every other day for one month, at approximately 180 times the recommended weekly human dose for a 60 kg person (based on body surface area).
1	0	8	O	Prolonged
2	10	18	O	menstrual
3	20	25	O	cycles
4	27	29	O	and
5	30	30	O	/
6	31	32	O	or
7	34	43	O	amenorrhea
8	45	48	O	were
9	50	57	O	observed
10	59	60	O	in
11	62	67	O	female
12	69	78	O	cynomolgus
13	80	86	O	monkeys
14	88	92	O	given
15	94	95	O	sc
16	97	106	O	injections
17	108	109	O	of
18	111	113	O	600
19	115	115	O	m
20	117	117	O	g
21	118	118	O	/
22	119	120	O	kg
23	121	121	O	/
24	122	125	O	dose
25	128	131	O	7200
26	133	133	O	m
27	135	135	O	g
28	136	136	O	/
29	137	138	O	m2
30	139	139	O	/
31	140	143	O	dose
32	146	147	O	of
33	149	155	O	XXXXXXXX
34	157	161	O	every
35	163	167	O	other
36	169	171	O	day
37	173	175	O	for
38	177	179	O	one
39	181	185	O	month
40	186	186	O	,
41	188	189	O	at
42	191	203	O	approximately
43	205	207	O	180
44	209	213	O	times
45	215	217	O	the
46	219	229	O	recommended
47	231	236	O	weekly
48	238	242	O	human
49	244	247	O	dose
50	249	251	O	for
51	253	253	O	a
52	255	256	O	60
53	258	259	O	kg
54	261	266	O	person
55	269	273	O	based
56	275	276	O	on
57	278	281	O	body
58	283	289	O	surface
59	291	294	O	area
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s17	NO_SECTION	NO_SETID	26
Menstrual cycle irregularities were accompanied by both a decrease and delay in the peak 17b -estradiol and progesterone levels following administration of PEGASYS to female monkeys.
1	0	8	O	Menstrual
2	10	14	O	cycle
3	16	29	O	irregularities
4	31	34	O	were
5	36	46	O	accompanied
6	48	49	O	by
7	51	54	O	both
8	56	56	O	a
9	58	65	O	decrease
10	67	69	O	and
11	71	75	O	delay
12	77	78	O	in
13	80	82	O	the
14	84	87	O	peak
15	89	91	O	17b
16	94	102	O	estradiol
17	104	106	O	and
18	108	119	O	progesterone
19	121	126	O	levels
20	128	136	O	following
21	138	151	O	administration
22	153	154	O	of
23	156	162	O	XXXXXXXX
24	164	165	O	to
25	167	172	O	female
26	174	180	O	monkeys
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s18	NO_SECTION	NO_SETID	10
A return to normal menstrual rhythm followed cessation of treatment.
1	0	0	O	A
2	2	7	O	return
3	9	10	O	to
4	12	17	O	normal
5	19	27	O	menstrual
6	29	34	O	rhythm
7	36	43	O	followed
8	45	53	O	cessation
9	55	56	O	of
10	58	66	O	treatment
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s19	NO_SECTION	NO_SETID	33
Every other day dosing with 100m g/kg (1200m g/m2) PEGASYS (equivalent to approximately 30 times the recommended human dose) had no effects on cycle duration or reproductive hormone status.
1	0	4	O	Every
2	6	10	O	other
3	12	14	O	day
4	16	21	O	dosing
5	23	26	O	with
6	28	31	O	100m
7	33	33	O	g
8	34	34	O	/
9	35	36	O	kg
10	39	43	O	1200m
11	45	45	O	g
12	46	46	O	/
13	47	48	O	m2
14	51	57	O	XXXXXXXX
15	60	69	O	equivalent
16	71	72	O	to
17	74	86	O	approximately
18	88	89	O	30
19	91	95	O	times
20	97	99	O	the
21	101	111	O	recommended
22	113	117	O	human
23	119	122	O	dose
24	125	127	O	had
25	129	130	O	no
26	132	138	O	effects
27	140	141	O	on
28	143	147	O	cycle
29	149	156	O	duration
30	158	159	O	or
31	161	172	O	reproductive
32	174	180	O	hormone
33	182	187	O	status
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s20	NO_SECTION	NO_SETID	11
The effects of PEGASYS on male fertility have not been studied.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	21	O	XXXXXXXX
5	23	24	O	on
6	26	29	O	male
7	31	39	O	fertility
8	41	44	O	have
9	46	48	O	not
10	50	53	O	been
11	55	61	O	studied
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s21	NO_SECTION	NO_SETID	35
However, no adverse effects on fertility were observed in male Rhesus monkeys treated with non-pegylated interferon alfa-2a for 5 months at doses up to 25 x 106 IU/kg/day.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	no
4	12	18	O	adverse
5	20	26	O	effects
6	28	29	O	on
7	31	39	O	fertility
8	41	44	O	were
9	46	53	O	observed
10	55	56	O	in
11	58	61	O	male
12	63	68	O	Rhesus
13	70	76	O	monkeys
14	78	84	O	treated
15	86	89	O	with
16	91	93	O	non
17	95	103	B-UNK	pegylated
18	105	114	I-UNK	interferon
19	116	119	I-UNK	alfa
20	121	122	L-UNK	2a
21	124	126	O	for
22	128	128	O	5
23	130	135	O	months
24	137	138	O	at
25	140	144	O	doses
26	146	147	O	up
27	149	150	O	to
28	152	153	O	25
29	155	155	O	x
30	157	159	O	106
31	161	162	O	IU
32	163	163	O	/
33	164	165	O	kg
34	166	166	O	/
35	167	169	O	day
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s22	NO_SECTION	NO_SETID	14
Pregnancy Pregnancy: Category C PEGASYS has not been studied for its teratogenic effect.
1	0	8	O	Pregnancy
2	10	18	O	Pregnancy
3	19	19	O	:
4	21	28	O	Category
5	30	30	O	C
6	32	38	O	XXXXXXXX
7	40	42	O	has
8	44	46	O	not
9	48	51	O	been
10	53	59	O	studied
11	61	63	O	for
12	65	67	O	its
13	69	79	O	teratogenic
14	81	86	O	effect
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s23	NO_SECTION	NO_SETID	28
Non-pegylated interferon alfa-2a treatment of pregnant Rhesus monkeys at approximately 20 to 500 times the human weekly dose resulted in a statistically significant increase in abortions.
1	0	2	B-UNK	Non
2	4	12	I-UNK	pegylated
3	14	23	I-UNK	interferon
4	25	28	I-UNK	alfa
5	30	31	L-UNK	2a
6	33	41	O	treatment
7	43	44	O	of
8	46	53	O	pregnant
9	55	60	O	Rhesus
10	62	68	O	monkeys
11	70	71	O	at
12	73	85	O	approximately
13	87	88	O	20
14	90	91	O	to
15	93	95	O	500
16	97	101	O	times
17	103	105	O	the
18	107	111	O	human
19	113	118	O	weekly
20	120	123	O	dose
21	125	132	O	resulted
22	134	135	O	in
23	137	137	O	a
24	139	151	O	statistically
25	153	163	O	significant
26	165	172	O	increase
27	174	175	O	in
28	177	185	O	abortions
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s24	NO_SECTION	NO_SETID	11
No teratogenic effects were seen in the offspring delivered at term.
1	0	1	O	No
2	3	13	O	teratogenic
3	15	21	O	effects
4	23	26	O	were
5	28	31	O	seen
6	33	34	O	in
7	36	38	O	the
8	40	48	O	offspring
9	50	58	O	delivered
10	60	61	O	at
11	63	66	O	term
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s25	NO_SECTION	NO_SETID	8
PEGASYS should be assumed to have abortifacient potential.
1	0	6	O	XXXXXXXX
2	8	13	O	should
3	15	16	O	be
4	18	24	O	assumed
5	26	27	O	to
6	29	32	O	have
7	34	46	O	abortifacient
8	48	56	O	potential
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s26	NO_SECTION	NO_SETID	13
There are no adequate and well-controlled studies of PEGASYS in pregnant women.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	20	O	adequate
5	22	24	O	and
6	26	29	O	well
7	31	40	O	controlled
8	42	48	O	studies
9	50	51	O	of
10	53	59	O	XXXXXXXX
11	61	62	O	in
12	64	71	O	pregnant
13	73	77	O	women
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s27	NO_SECTION	NO_SETID	19
PEGASYS is to be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	12	O	to
4	14	15	O	be
5	17	20	O	used
6	22	27	O	during
7	29	37	O	pregnancy
8	39	42	O	only
9	44	45	O	if
10	47	49	O	the
11	51	59	O	potential
12	61	67	O	benefit
13	69	77	O	justifies
14	79	81	O	the
15	83	91	O	potential
16	93	96	O	risk
17	98	99	O	to
18	101	103	O	the
19	105	109	O	fetus
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s28	NO_SECTION	NO_SETID	19
PEGASYS is recommended for use in women of childbearing potential only when they are using effective contraception during therapy.
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	21	O	recommended
4	23	25	O	for
5	27	29	O	use
6	31	32	O	in
7	34	38	O	women
8	40	41	O	of
9	43	54	O	childbearing
10	56	64	O	potential
11	66	69	O	only
12	71	74	O	when
13	76	79	O	they
14	81	83	O	are
15	85	89	O	using
16	91	99	O	effective
17	101	113	O	contraception
18	115	120	O	during
19	122	128	O	therapy
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s29	NO_SECTION	NO_SETID	27
Pregnancy: Category X: Use With Ribavirin (see CONTRAINDICATIONS) Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin.
1	0	8	O	Pregnancy
2	9	9	O	:
3	11	18	O	Category
4	20	20	O	XXXXXXXX
5	21	21	O	:
6	23	25	O	Use
7	27	30	O	With
8	32	40	U-UNK	Ribavirin
9	43	45	O	see
10	47	63	O	CONTRAINDICATIONS
11	66	76	O	Significant
12	78	88	O	teratogenic
13	90	92	O	and
14	93	93	O	/
15	94	95	O	or
16	97	107	O	embryocidal
17	109	115	O	effects
18	117	120	O	have
19	122	125	O	been
20	127	138	O	demonstrated
21	140	141	O	in
22	143	145	O	all
23	147	152	O	animal
24	154	160	O	species
25	162	168	O	exposed
26	170	171	O	to
27	173	181	U-UNK	ribavirin
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s30	NO_SECTION	NO_SETID	19
COPEGUS therapy is contraindicated in women who are pregnant and in the male partners of women who are pregnant .
1	0	6	O	XXXXXXXX
2	8	14	O	therapy
3	16	17	O	is
4	19	33	O	contraindicated
5	35	36	O	in
6	38	42	O	women
7	44	46	O	who
8	48	50	O	are
9	52	59	O	pregnant
10	61	63	O	and
11	65	66	O	in
12	68	70	O	the
13	72	75	O	male
14	77	84	O	partners
15	86	87	O	of
16	89	93	O	women
17	95	97	O	who
18	99	101	O	are
19	103	110	O	pregnant
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s31	NO_SECTION	NO_SETID	37
If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment cessation, such cases should be reported to the COPEGUS Pregnancy Registry at 1-800-526-6367.
1	0	1	O	If
2	3	11	O	pregnancy
3	13	18	O	occurs
4	20	21	O	in
5	23	23	O	a
6	25	31	O	patient
7	33	34	O	or
8	36	42	O	partner
9	44	45	O	of
10	47	47	O	a
11	49	55	O	patient
12	57	62	O	during
13	64	72	O	treatment
14	74	75	O	or
15	77	82	O	during
16	84	86	O	the
17	88	88	O	6
18	90	95	O	months
19	97	101	O	after
20	103	111	O	treatment
21	113	121	O	cessation
22	122	122	O	,
23	124	127	O	such
24	129	133	O	cases
25	135	140	O	should
26	142	143	O	be
27	145	152	O	reported
28	154	155	O	to
29	157	159	O	the
30	161	167	O	XXXXXXXX
31	169	177	O	Pregnancy
32	179	186	O	Registry
33	188	189	O	at
34	191	191	O	1
35	193	195	O	800
36	197	199	O	526
37	201	204	O	6367
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s32	NO_SECTION	NO_SETID	18
Nursing Mothers It is not known whether peginterferon or ribavirin or its components are excreted in human milk.
1	0	6	O	Nursing
2	8	14	O	Mothers
3	16	17	O	It
4	19	20	O	is
5	22	24	O	not
6	26	30	O	known
7	32	38	O	whether
8	40	52	U-UNK	peginterferon
9	54	55	O	or
10	57	65	U-UNK	ribavirin
11	67	68	O	or
12	70	72	O	its
13	74	83	O	components
14	85	87	O	are
15	89	96	O	excreted
16	98	99	O	in
17	101	105	O	human
18	107	110	O	milk
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s33	NO_SECTION	NO_SETID	19
The effect of orally ingested peginterferon or ribavirin from breast milk on the nursing infant has not been evaluated.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	19	O	orally
5	21	28	O	ingested
6	30	42	U-UNK	peginterferon
7	44	45	O	or
8	47	55	U-UNK	ribavirin
9	57	60	O	from
10	62	67	O	breast
11	69	72	O	milk
12	74	75	O	on
13	77	79	O	the
14	81	87	O	nursing
15	89	94	O	infant
16	96	98	O	has
17	100	102	O	not
18	104	107	O	been
19	109	117	O	evaluated
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s34	NO_SECTION	NO_SETID	29
Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue PEGASYS and COPEGUS treatment.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	23	O	potential
5	25	27	O	for
6	29	35	O	adverse
7	37	45	O	reactions
8	47	50	O	from
9	52	54	O	the
10	56	60	O	drugs
11	62	63	O	in
12	65	71	O	nursing
13	73	79	O	infants
14	80	80	O	,
15	82	82	O	a
16	84	91	O	decision
17	93	96	O	must
18	98	99	O	be
19	101	104	O	made
20	106	112	O	whether
21	114	115	O	to
22	117	127	O	discontinue
23	129	135	O	nursing
24	137	138	O	or
25	140	150	O	discontinue
26	152	158	O	PEGASYS
27	160	162	O	and
28	164	170	O	XXXXXXXX
29	172	180	O	treatment
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s35	NO_SECTION	NO_SETID	27
Pediatric Use The safety and effectiveness of PEGASYS, alone or in combination with COPEGUS in patients below the age of 18 years have not been established.
1	0	8	O	Pediatric
2	10	12	O	Use
3	14	16	O	The
4	18	23	O	safety
5	25	27	O	and
6	29	41	O	effectiveness
7	43	44	O	of
8	46	52	O	PEGASYS
9	53	53	O	,
10	55	59	O	alone
11	61	62	O	or
12	64	65	O	in
13	67	77	O	combination
14	79	82	O	with
15	84	90	O	XXXXXXXX
16	92	93	O	in
17	95	102	O	patients
18	104	108	O	below
19	110	112	O	the
20	114	116	O	age
21	118	119	O	of
22	121	122	O	18
23	124	128	O	years
24	130	133	O	have
25	135	137	O	not
26	139	142	O	been
27	144	154	O	established
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s36	NO_SECTION	NO_SETID	4
PEGASYS contains benzyl alcohol.
1	0	6	O	XXXXXXXX
2	8	15	O	contains
3	17	22	B-UNK	benzyl
4	24	30	L-UNK	alcohol
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s37	NO_SECTION	NO_SETID	26
Benzyl alcohol has been reported to be associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal.
1	0	5	B-UNK	Benzyl
2	7	13	L-UNK	alcohol
3	15	17	O	has
4	19	22	O	been
5	24	31	O	reported
6	33	34	O	to
7	36	37	O	be
8	39	48	O	associated
9	50	53	O	with
10	55	56	O	an
11	58	66	O	increased
12	68	76	O	incidence
13	78	79	O	of
14	81	92	O	neurological
15	94	96	O	and
16	98	102	O	other
17	104	116	O	complications
18	118	119	O	in
19	121	128	O	neonates
20	130	132	O	and
21	134	140	O	infants
22	141	141	O	,
23	143	147	O	which
24	149	151	O	are
25	153	161	O	sometimes
26	163	167	O	fatal
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s38	NO_SECTION	NO_SETID	12
Geriatric Use Younger patients have higher virologic response rates than older patients.
1	0	8	O	Geriatric
2	10	12	O	Use
3	14	20	O	Younger
4	22	29	O	patients
5	31	34	O	have
6	36	41	O	higher
7	43	51	O	virologic
8	53	60	O	response
9	62	66	O	rates
10	68	71	O	than
11	73	77	O	older
12	79	86	O	patients
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s39	NO_SECTION	NO_SETID	30
Clinical studies of PEGASYS alone or in combination with COPEGUS did not include sufficient numbers of subjects aged 65 or over to determine whether they respond differently from younger subjects.
1	0	7	O	Clinical
2	9	15	O	studies
3	17	18	O	of
4	20	26	O	PEGASYS
5	28	32	O	alone
6	34	35	O	or
7	37	38	O	in
8	40	50	O	combination
9	52	55	O	with
10	57	63	O	XXXXXXXX
11	65	67	O	did
12	69	71	O	not
13	73	79	O	include
14	81	90	O	sufficient
15	92	98	O	numbers
16	100	101	O	of
17	103	110	O	subjects
18	112	115	O	aged
19	117	118	O	65
20	120	121	O	or
21	123	126	O	over
22	128	129	O	to
23	131	139	O	determine
24	141	147	O	whether
25	149	152	O	they
26	154	160	O	respond
27	162	172	O	differently
28	174	177	O	from
29	179	185	O	younger
30	187	194	O	subjects
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s40	NO_SECTION	NO_SETID	40
Adverse reactions related to alpha interferons, such as CNS, cardiac, and systemic (eg, flu-like) effects may be more severe in the elderly and caution should be exercised in the use of PEGASYS in this population.
1	0	6	O	Adverse
2	8	16	O	reactions
3	18	24	O	related
4	26	27	O	to
5	29	33	U-UNK	alpha
6	35	45	O	interferons
7	46	46	O	,
8	48	51	O	such
9	53	54	O	as
10	56	58	O	CNS
11	59	59	O	,
12	61	67	O	cardiac
13	68	68	O	,
14	70	72	O	and
15	74	81	O	systemic
16	84	85	O	eg
17	86	86	O	,
18	88	90	O	flu
19	92	95	O	like
20	98	104	O	effects
21	106	108	O	may
22	110	111	O	be
23	113	116	O	more
24	118	123	O	severe
25	125	126	O	in
26	128	130	O	the
27	132	138	O	elderly
28	140	142	O	and
29	144	150	O	caution
30	152	157	O	should
31	159	160	O	be
32	162	170	O	exercised
33	172	173	O	in
34	175	177	O	the
35	179	181	O	use
36	183	184	O	of
37	186	192	O	XXXXXXXX
38	194	195	O	in
39	197	200	O	this
40	202	211	O	population
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s41	NO_SECTION	NO_SETID	27
PEGASYS and COPEGUS are excreted by the kidney, and the risk of toxic reactions to this therapy may be greater in patients with impaired renal function.
1	0	6	O	PEGASYS
2	8	10	O	and
3	12	18	O	XXXXXXXX
4	20	22	O	are
5	24	31	O	excreted
6	33	34	O	by
7	36	38	O	the
8	40	45	O	kidney
9	46	46	O	,
10	48	50	O	and
11	52	54	O	the
12	56	59	O	risk
13	61	62	O	of
14	64	68	O	toxic
15	70	78	O	reactions
16	80	81	O	to
17	83	86	O	this
18	88	94	O	therapy
19	96	98	O	may
20	100	101	O	be
21	103	109	O	greater
22	111	112	O	in
23	114	121	O	patients
24	123	126	O	with
25	128	135	O	impaired
26	137	141	O	renal
27	143	150	O	function
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s42	NO_SECTION	NO_SETID	28
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.
1	0	6	O	Because
2	8	14	O	elderly
3	16	23	O	patients
4	25	27	O	are
5	29	32	O	more
6	34	39	O	likely
7	41	42	O	to
8	44	47	O	have
9	49	57	O	decreased
10	59	63	O	renal
11	65	72	O	function
12	73	73	O	,
13	75	78	O	care
14	80	85	O	should
15	87	88	O	be
16	90	94	O	taken
17	96	97	O	in
18	99	102	O	dose
19	104	112	O	selection
20	114	116	O	and
21	118	119	O	it
22	121	123	O	may
23	125	126	O	be
24	128	133	O	useful
25	135	136	O	to
26	138	144	O	monitor
27	146	150	O	renal
28	152	159	O	function
NULL

Peginterferon alfa-2a	DDI-DrugBank.d196.s43	NO_SECTION	NO_SETID	30
PEGASYS should be used with caution in patients with creatinine clearance  50 mL/min and COPEGUS should not be administered to patients with creatinine clearance  50 mL/min
1	0	6	O	PEGASYS
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	26	O	with
6	28	34	O	caution
7	36	37	O	in
8	39	46	O	patients
9	48	51	O	with
10	53	62	O	creatinine
11	64	72	O	clearance
12	75	76	O	50
13	78	79	O	mL
14	80	80	O	/
15	81	83	O	min
16	85	87	O	and
17	89	95	O	XXXXXXXX
18	97	102	O	should
19	104	106	O	not
20	108	109	O	be
21	111	122	O	administered
22	124	125	O	to
23	127	134	O	patients
24	136	139	O	with
25	141	150	O	creatinine
26	152	160	O	clearance
27	163	164	O	50
28	166	167	O	mL
29	168	168	O	/
30	169	171	O	min
NULL

Piperacillin	DDI-DrugBank.d462.s0	NO_SECTION	NO_SETID	19
Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.
1	0	14	U-UNK	Aminoglycosides
2	15	15	O	:
3	17	19	O	The
4	21	26	O	mixing
5	28	29	O	of
6	31	42	O	XXXXXXXX
7	44	47	O	with
8	49	50	O	an
9	52	65	U-DYN	aminoglycoside
10	67	68	O	in
11	70	74	O	vitro
12	76	78	O	can
13	80	85	O	result
14	87	88	O	in
15	90	100	O	substantial
16	102	113	O	inactivation
17	115	116	O	of
18	118	120	O	the
19	122	135	U-UNK	aminoglycoside
NULL

Piperacillin	DDI-DrugBank.d462.s1	NO_SECTION	NO_SETID	22
Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.
1	0	9	U-UNK	Vecuronium
2	10	10	O	:
3	12	15	O	When
4	17	20	O	used
5	22	23	O	in
6	25	27	O	the
7	29	41	O	perioperative
8	43	48	O	period
9	49	49	O	,
10	51	62	O	XXXXXXXX
11	64	66	O	has
12	68	71	O	been
13	73	82	O	implicated
14	84	85	O	in
15	87	89	O	the
16	91	102	O	prolongation
17	104	105	O	of
18	107	109	O	the
19	111	123	O	neuromuscular
20	125	132	O	blockade
21	134	135	O	of
22	137	146	U-DYN	vecuronium
NULL

Piperacillin	DDI-DrugBank.d462.s2	NO_SECTION	NO_SETID	8
Caution is indicated when piperacillin is used perioperatively.
1	0	6	O	Caution
2	8	9	O	is
3	11	19	O	indicated
4	21	24	O	when
5	26	37	O	XXXXXXXX
6	39	40	O	is
7	42	45	O	used
8	47	61	O	perioperatively
NULL

Piperacillin	DDI-DrugBank.d462.s3	NO_SECTION	NO_SETID	20
In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.
1	0	1	O	In
2	3	5	O	one
3	7	16	O	controlled
4	18	25	O	clinical
5	27	31	O	study
6	32	32	O	,
7	34	36	O	the
8	38	54	O	ureidopenicillins
9	55	55	O	,
10	57	65	O	including
11	67	78	O	XXXXXXXX
12	79	79	O	,
13	81	84	O	were
14	86	93	O	reported
15	95	96	O	to
16	98	104	O	prolong
17	106	108	O	the
18	110	115	O	action
19	117	118	O	of
20	120	129	U-DYN	vecuronium
NULL

Piperacillin	DDI-DrugBank.d462.s4	NO_SECTION	NO_SETID	32
Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.
1	0	2	O	Due
2	4	5	O	to
3	7	11	O	their
4	13	19	O	similar
5	21	29	O	mechanism
6	31	32	O	of
7	34	39	O	action
8	40	40	O	,
9	42	43	O	it
10	45	46	O	is
11	48	55	O	expected
12	57	60	O	that
13	62	64	O	the
14	66	78	O	neuromuscular
15	80	87	O	blockade
16	89	96	O	produced
17	98	99	O	by
18	101	103	O	any
19	105	106	O	of
20	108	110	O	the
21	112	114	B-DYN	non
22	116	127	I-DYN	depolarizing
23	129	134	I-DYN	muscle
24	136	144	L-DYN	relaxants
25	146	150	O	could
26	152	153	O	be
27	155	163	O	prolonged
28	165	166	O	in
29	168	170	O	the
30	172	179	O	presence
31	181	182	O	of
32	184	195	O	XXXXXXXX
NULL

Piperacillin	DDI-DrugBank.d462.s5	NO_SECTION	NO_SETID	23
Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.
1	0	9	U-UNK	Probenecid
2	10	10	O	:
3	12	14	O	The
4	16	19	O	oral
5	21	31	O	combination
6	33	34	O	of
7	36	45	U-KIN	probenecid
8	47	52	O	before
9	54	66	O	intramuscular
10	68	76	O	injection
11	78	79	O	of
12	81	88	O	XXXXXXXX
13	90	97	O	produces
14	99	100	O	an
15	102	109	O	increase
16	111	112	O	in
17	114	125	U-UNK	piperacillin
18	127	130	O	peak
19	132	136	O	serum
20	138	142	O	level
21	144	145	O	of
22	147	151	O	about
23	153	155	O	30%
NULL

Piperacillin	DDI-DrugBank.d462.s6	NO_SECTION	NO_SETID	38
Anticoagulants: Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin, oral anticoagulants, or other drugs that may affect the blood coagulation system or the thrombocyte function.
1	0	13	U-UNK	Anticoagulants
2	14	14	O	:
3	16	26	O	Coagulation
4	28	37	O	parameters
5	39	44	O	should
6	46	47	O	be
7	49	54	O	tested
8	56	59	O	more
9	61	70	O	frequently
10	72	74	O	and
11	76	84	O	monitored
12	86	94	O	regularly
13	96	101	O	during
14	103	114	O	simultaneous
15	116	129	O	administration
16	131	132	O	of
17	134	137	O	high
18	139	143	O	doses
19	145	146	O	of
20	148	154	U-UNK	heparin
21	155	155	O	,
22	157	160	O	oral
23	162	175	U-UNK	anticoagulants
24	176	176	O	,
25	178	179	O	or
26	181	185	O	other
27	187	191	O	drugs
28	193	196	O	that
29	198	200	O	may
30	202	207	O	affect
31	209	211	O	the
32	213	217	O	blood
33	219	229	O	coagulation
34	231	236	O	system
35	238	239	O	or
36	241	243	O	the
37	245	255	O	thrombocyte
38	257	264	O	function
NULL

Piperacillin	DDI-DrugBank.d462.s7	NO_SECTION	NO_SETID	10
Methotrexate: Piperacillin sodium may reduce the excretion of methotrexate.
1	0	11	U-UNK	Methotrexate
2	12	12	O	:
3	14	25	O	XXXXXXXX
4	27	32	O	sodium
5	34	36	O	may
6	38	43	O	reduce
7	45	47	O	the
8	49	57	O	excretion
9	59	60	O	of
10	62	73	U-KIN	methotrexate
NULL

Piperacillin	DDI-DrugBank.d462.s8	NO_SECTION	NO_SETID	15
Therefore, serum levels of methotrexate should be monitored in patients to avoid drug toxicity.
1	0	8	O	Therefore
2	9	9	O	,
3	11	15	O	serum
4	17	22	O	levels
5	24	25	O	of
6	27	38	U-UNK	methotrexate
7	40	45	O	should
8	47	48	O	be
9	50	58	O	monitored
10	60	61	O	in
11	63	70	O	patients
12	72	73	O	to
13	75	79	O	avoid
14	81	84	O	drug
15	86	93	O	toxicity
NULL

Piperacillin	DDI-DrugBank.d462.s9	NO_SECTION	NO_SETID	31
Drug/Laboratory Test Interactions As with other penicillins, the administration of PIPRACIL may result in a false-positive reaction for glucose in the urine using a copper-reduction method.
1	0	3	O	Drug
2	4	4	O	/
3	5	14	O	Laboratory
4	16	19	O	Test
5	21	32	O	Interactions
6	34	35	O	As
7	37	40	O	with
8	42	46	O	other
9	48	58	U-UNK	penicillins
10	59	59	O	,
11	61	63	O	the
12	65	78	O	administration
13	80	81	O	of
14	83	90	O	XXXXXXXX
15	92	94	O	may
16	96	101	O	result
17	103	104	O	in
18	106	106	O	a
19	108	112	O	false
20	114	121	O	positive
21	123	130	O	reaction
22	132	134	O	for
23	136	142	O	glucose
24	144	145	O	in
25	147	149	O	the
26	151	155	O	urine
27	157	161	O	using
28	163	163	O	a
29	165	170	O	copper
30	172	180	O	reduction
31	182	187	O	method
NULL

Piperacillin	DDI-DrugBank.d462.s10	NO_SECTION	NO_SETID	14
It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	29	O	glucose
6	31	35	O	tests
7	37	41	O	based
8	43	44	O	on
9	46	54	O	enzymatic
10	56	62	O	glucose
11	64	70	O	oxidase
12	72	80	O	reactions
13	82	83	O	be
14	85	88	O	used
NULL

Piperacillin	DDI-DrugBank.d462.s11	NO_SECTION	NO_SETID	34
There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of Aspergillus infection.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	22	O	reports
5	24	25	O	of
6	27	34	O	positive
7	36	39	O	test
8	41	47	O	results
9	49	53	O	using
10	55	57	O	the
11	59	61	O	Bio
12	63	65	O	Rad
13	67	78	O	Laboratories
14	80	87	O	Platelia
15	89	99	O	Aspergillus
16	101	103	O	EIA
17	105	108	O	test
18	110	111	O	in
19	113	120	O	patients
20	122	130	O	receiving
21	132	143	O	XXXXXXXX
22	144	144	O	/
23	145	154	U-UNK	tazobactam
24	156	164	O	injection
25	166	168	O	who
26	170	173	O	were
27	175	186	O	subsequently
28	188	192	O	found
29	194	195	O	to
30	197	198	O	be
31	200	203	O	free
32	205	206	O	of
33	208	218	O	Aspergillus
34	220	228	O	infection
NULL

Piperacillin	DDI-DrugBank.d462.s12	NO_SECTION	NO_SETID	20
Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported.
1	0	4	O	Cross
2	6	14	O	reactions
3	16	19	O	with
4	21	23	O	non
5	25	35	O	Aspergillus
6	37	51	O	polysaccharides
7	53	55	O	and
8	57	69	O	polyfuranoses
9	71	74	O	with
10	76	78	O	the
11	80	82	O	Bio
12	84	86	O	Rad
13	88	99	O	Laboratories
14	101	108	O	Platelia
15	110	120	O	Aspergillus
16	122	124	O	EIA
17	126	129	O	test
18	131	134	O	have
19	136	139	O	been
20	141	148	O	reported
NULL

Piperacillin	DDI-DrugBank.d462.s13	NO_SECTION	NO_SETID	19
Therefore, positive test results in patients receiving piperacillin should be interpreted cautiously and confirmed by other diagnostic methods.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	O	positive
4	20	23	O	test
5	25	31	O	results
6	33	34	O	in
7	36	43	O	patients
8	45	53	O	receiving
9	55	66	O	XXXXXXXX
10	68	73	O	should
11	75	76	O	be
12	78	88	O	interpreted
13	90	99	O	cautiously
14	101	103	O	and
15	105	113	O	confirmed
16	115	116	O	by
17	118	122	O	other
18	124	133	O	diagnostic
19	135	141	O	methods
NULL

Piperazine	DDI-DrugBank.d326.s0	NO_SECTION	NO_SETID	14
Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).
1	0	13	U-UNK	Phenothiazines
2	17	22	O	Taking
3	24	33	O	XXXXXXXX
4	35	37	O	and
5	39	39	O	a
6	41	53	U-DYN	phenothiazine
7	55	62	O	together
8	64	66	O	may
9	68	75	O	increase
10	77	79	O	the
11	81	84	O	risk
12	86	87	O	of
13	89	99	O	convulsions
14	102	109	O	seizures
NULL

Piperazine	DDI-DrugBank.d326.s1	NO_SECTION	NO_SETID	15
Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.
1	0	7	U-UNK	Pyrantel
2	10	12	O	e.g
3	14	14	O	,
4	16	24	U-UNK	Antiminth
5	29	34	O	Taking
6	36	45	O	XXXXXXXX
7	47	49	O	and
8	51	58	U-DYN	pyrantel
9	60	67	O	together
10	69	71	O	may
11	73	80	O	decrease
12	82	84	O	the
13	86	92	O	effects
14	94	95	O	of
15	97	106	O	XXXXXXXX
NULL

Rofecoxib	DDI-DrugBank.d210.s0	NO_SECTION	NO_SETID	18
ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.
1	0	2	B-UNK	ACE
2	4	13	L-UNK	inhibitors
3	14	14	O	:
4	16	22	O	Reports
5	24	30	O	suggest
6	32	35	O	that
7	37	42	U-UNK	NSAIDs
8	44	46	O	may
9	48	55	O	diminish
10	57	59	O	the
11	61	76	O	antihypertensive
12	78	83	O	effect
13	85	86	O	of
14	88	98	B-UNK	Angiotensin
15	100	109	I-UNK	Converting
16	111	116	I-UNK	Enzyme
17	119	121	I-UNK	ACE
18	124	133	L-UNK	inhibitors
NULL

Rofecoxib	DDI-DrugBank.d210.s1	NO_SECTION	NO_SETID	49
In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	20	O	mild
5	22	23	O	to
6	25	32	O	moderate
7	34	45	O	hypertension
8	46	46	O	,
9	48	61	O	administration
10	63	64	O	of
11	66	67	O	25
12	69	70	O	mg
13	72	76	O	daily
14	78	79	O	of
15	81	85	O	XXXXXXXX
16	87	90	O	with
17	92	94	O	the
18	96	98	B-UNK	ACE
19	100	108	L-UNK	inhibitor
20	110	119	U-DYN	benazepril
21	120	120	O	,
22	122	123	O	10
23	125	126	O	to
24	128	129	O	40
25	131	132	O	mg
26	134	136	O	for
27	138	138	O	4
28	140	144	O	weeks
29	145	145	O	,
30	147	149	O	was
31	151	160	O	associated
32	162	165	O	with
33	167	168	O	an
34	170	176	O	average
35	178	185	O	increase
36	187	188	O	in
37	190	193	O	mean
38	195	202	O	arterial
39	204	211	O	pressure
40	213	214	O	of
41	216	220	O	about
42	222	222	O	3
43	224	225	O	mm
44	227	228	O	Hg
45	230	237	O	compared
46	239	240	O	to
47	242	244	B-UNK	ACE
48	246	254	L-UNK	inhibitor
49	256	260	O	alone
NULL

Rofecoxib	DDI-DrugBank.d210.s2	NO_SECTION	NO_SETID	14
This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.
1	0	3	O	This
2	5	15	O	interaction
3	17	22	O	should
4	24	25	O	be
5	27	31	O	given
6	33	45	O	consideration
7	47	48	O	in
8	50	57	O	patients
9	59	64	O	taking
10	66	70	O	XXXXXXXX
11	72	84	O	concomitantly
12	86	89	O	with
13	91	93	B-DYN	ACE
14	95	104	L-DYN	inhibitors
NULL

Rofecoxib	DDI-DrugBank.d210.s3	NO_SECTION	NO_SETID	29
Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.
1	0	6	O	Aspirin
2	7	7	O	:
3	9	19	O	Concomitant
4	21	34	O	administration
5	36	37	O	of
6	39	41	O	low
7	43	46	O	dose
8	48	54	O	aspirin
9	56	59	O	with
10	61	65	U-DYN	XXXXXXXX
11	67	69	O	may
12	71	76	O	result
13	78	79	O	in
14	81	82	O	an
15	84	92	O	increased
16	94	97	O	rate
17	99	100	O	of
18	102	103	O	GI
19	105	114	O	ulceration
20	116	117	O	or
21	119	123	O	other
22	125	137	O	complications
23	138	138	O	,
24	140	147	O	compared
25	149	150	O	to
26	152	154	O	use
27	156	157	O	of
28	159	163	O	XXXXXXXX
29	165	169	O	alone
NULL

Rofecoxib	DDI-DrugBank.d210.s4	NO_SECTION	NO_SETID	48
In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus VIOXX 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone.
1	0	1	O	In
2	3	3	O	a
3	5	6	O	12
4	8	11	O	week
5	13	21	O	endoscopy
6	23	27	O	study
7	29	37	O	conducted
8	39	40	O	in
9	42	43	O	OA
10	45	52	O	patients
11	54	58	O	there
12	60	62	O	was
13	64	65	O	no
14	67	76	O	difference
15	78	79	O	in
16	81	83	O	the
17	85	94	O	cumulative
18	96	104	O	incidence
19	106	107	O	of
20	109	118	O	endoscopic
21	120	133	O	gastroduodenal
22	135	140	O	ulcers
23	142	143	O	in
24	145	152	O	patients
25	154	159	O	taking
26	161	163	O	low
27	165	168	O	dose
28	171	172	O	81
29	174	175	O	mg
30	178	184	O	enteric
31	186	191	O	coated
32	193	199	O	aspirin
33	201	204	O	plus
34	206	210	O	XXXXXXXX
35	212	213	O	25
36	215	216	O	mg
37	218	222	O	daily
38	223	223	O	,
39	225	226	O	as
40	228	235	O	compared
41	237	238	O	to
42	240	244	O	those
43	246	251	O	taking
44	253	261	U-UNK	ibuprofen
45	263	266	O	2400
46	268	269	O	mg
47	271	275	O	daily
48	277	281	O	alone
NULL

Rofecoxib	DDI-DrugBank.d210.s5	NO_SECTION	NO_SETID	10
Patients taking low-dose aspirin plus ibuprofen were not studied.
1	0	7	O	Patients
2	9	14	O	taking
3	16	18	O	low
4	20	23	O	dose
5	25	31	O	XXXXXXXX
6	33	36	O	plus
7	38	46	U-UNK	ibuprofen
8	48	51	O	were
9	53	55	O	not
10	57	63	O	studied
NULL

Rofecoxib	DDI-DrugBank.d210.s6	NO_SECTION	NO_SETID	40
At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood.
1	0	1	O	At
2	3	8	O	steady
3	10	14	O	state
4	15	15	O	,
5	17	21	O	VIOXX
6	23	24	O	50
7	26	27	O	mg
8	29	32	O	once
9	34	38	O	daily
10	40	42	O	had
11	44	45	O	no
12	47	52	O	effect
13	54	55	O	on
14	57	59	O	the
15	61	64	O	anti
16	66	73	O	platelet
17	75	82	O	activity
18	84	85	O	of
19	87	89	O	low
20	91	94	O	dose
21	97	98	O	81
22	100	101	O	mg
23	103	106	O	once
24	108	112	O	daily
25	115	121	O	XXXXXXXX
26	122	122	O	,
27	124	125	O	as
28	127	134	O	assessed
29	136	137	O	by
30	139	140	O	ex
31	142	145	O	vivo
32	147	154	O	platelet
33	156	166	O	aggregation
34	168	170	O	and
35	172	176	O	serum
36	178	181	O	TXB2
37	183	192	O	generation
38	194	195	O	in
39	197	204	O	clotting
40	206	210	O	blood
NULL

Rofecoxib	DDI-DrugBank.d210.s7	NO_SECTION	NO_SETID	18
Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	its
4	15	18	O	lack
5	20	21	O	of
6	23	30	O	platelet
7	32	38	O	effects
8	39	39	O	,
9	41	45	O	VIOXX
10	47	48	O	is
11	50	52	O	not
12	54	54	O	a
13	56	65	O	substitute
14	67	69	O	for
15	71	77	O	XXXXXXXX
16	79	81	O	for
17	83	96	O	cardiovascular
18	98	108	O	prophylaxis
NULL

Rofecoxib	DDI-DrugBank.d210.s8	NO_SECTION	NO_SETID	25
Therefore, in patients taking VIOXX, antiplatelet therapies should not be discontinued and should be considered in patients with an indication for cardiovascular prophylaxis.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	in
4	14	21	O	patients
5	23	28	O	taking
6	30	34	O	XXXXXXXX
7	35	35	O	,
8	37	48	O	antiplatelet
9	50	58	O	therapies
10	60	65	O	should
11	67	69	O	not
12	71	72	O	be
13	74	85	O	discontinued
14	87	89	O	and
15	91	96	O	should
16	98	99	O	be
17	101	110	O	considered
18	112	113	O	in
19	115	122	O	patients
20	124	127	O	with
21	129	130	O	an
22	132	141	O	indication
23	143	145	O	for
24	147	160	O	cardiovascular
25	162	172	O	prophylaxis
NULL

Rofecoxib	DDI-DrugBank.d210.s9	NO_SECTION	NO_SETID	16
Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted.
1	0	10	O	Prospective
2	11	11	O	,
3	13	16	O	long
4	18	21	O	term
5	23	29	O	studies
6	31	32	O	on
7	34	44	O	concomitant
8	46	59	O	administration
9	61	62	O	of
10	64	68	O	VIOXX
11	70	72	O	and
12	74	80	O	XXXXXXXX
13	82	85	O	have
14	87	89	O	not
15	91	94	O	been
16	96	104	O	conducted
NULL

Rofecoxib	DDI-DrugBank.d210.s10	NO_SECTION	NO_SETID	33
Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.
1	0	9	U-UNK	Cimetidine
2	10	10	O	:
3	12	13	O	Co
4	15	28	O	administration
5	30	33	O	with
6	35	38	O	high
7	40	44	O	doses
8	46	47	O	of
9	49	58	U-KIN	cimetidine
10	61	63	O	800
11	65	66	O	mg
12	68	72	O	twice
13	74	78	O	daily
14	81	89	O	increased
15	91	93	O	the
16	95	98	O	Cmax
17	100	101	O	of
18	103	111	O	XXXXXXXX
19	113	114	O	by
20	116	118	O	21%
21	119	119	O	,
22	121	123	O	the
23	125	128	O	AUC0
24	130	134	O	120hr
25	136	137	O	by
26	139	141	O	23%
27	143	145	O	and
28	147	149	O	the
29	151	152	O	t1
30	153	153	O	/
31	154	154	O	2
32	156	157	O	by
33	159	161	O	15%
NULL

Rofecoxib	DDI-DrugBank.d210.s11	NO_SECTION	NO_SETID	13
These small changes are not clinically significant and no dose adjustment is necessary.
1	0	4	O	These
2	6	10	O	small
3	12	18	O	changes
4	20	22	O	are
5	24	26	O	not
6	28	37	O	clinically
7	39	49	O	significant
8	51	53	O	and
9	55	56	O	no
10	58	61	O	dose
11	63	72	O	adjustment
12	74	75	O	is
13	77	85	O	necessary
NULL

Rofecoxib	DDI-DrugBank.d210.s12	NO_SECTION	NO_SETID	29
Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	17	O	XXXXXXXX
4	19	20	O	75
5	22	23	O	mg
6	25	28	O	once
7	30	34	O	daily
8	36	38	O	for
9	40	41	O	11
10	43	46	O	days
11	48	51	O	does
12	53	55	O	not
13	57	61	O	alter
14	63	65	O	the
15	67	72	O	plasma
16	74	86	O	concentration
17	88	94	O	profile
18	96	97	O	or
19	99	103	O	renal
20	105	115	O	elimination
21	117	118	O	of
22	120	126	U-UNK	digoxin
23	128	132	O	after
24	134	134	O	a
25	136	141	O	single
26	143	145	O	0.5
27	147	148	O	mg
28	150	153	O	oral
29	155	158	O	dose
NULL

Rofecoxib	DDI-DrugBank.d210.s13	NO_SECTION	NO_SETID	28
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
1	0	9	U-UNK	Furosemide
2	10	10	O	:
3	12	19	O	Clinical
4	21	27	O	studies
5	28	28	O	,
6	30	31	O	as
7	33	36	O	well
8	38	39	O	as
9	41	44	O	post
10	46	54	O	marketing
11	56	67	O	observations
12	68	68	O	,
13	70	73	O	have
14	75	79	O	shown
15	81	84	O	that
16	86	91	U-UNK	NSAIDs
17	93	95	O	can
18	97	102	O	reduce
19	104	106	O	the
20	108	118	O	natriuretic
21	120	125	O	effect
22	127	128	O	of
23	130	139	U-UNK	furosemide
24	141	143	O	and
25	145	153	U-UNK	thiazides
26	155	156	O	in
27	158	161	O	some
28	163	170	O	patients
NULL

Rofecoxib	DDI-DrugBank.d210.s14	NO_SECTION	NO_SETID	11
This response has been attributed to inhibition of renal prostaglandin synthesis.
1	0	3	O	This
2	5	12	O	response
3	14	16	O	has
4	18	21	O	been
5	23	32	O	attributed
6	34	35	O	to
7	37	46	O	inhibition
8	48	49	O	of
9	51	55	O	renal
10	57	69	O	prostaglandin
11	71	79	O	synthesis
NULL

Rofecoxib	DDI-DrugBank.d210.s15	NO_SECTION	NO_SETID	18
Ketoconazole: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib.
1	0	11	U-UNK	Ketoconazole
2	12	12	O	:
3	14	25	U-UNK	Ketoconazole
4	27	29	O	400
5	31	32	O	mg
6	34	38	O	daily
7	40	42	O	did
8	44	46	O	not
9	48	51	O	have
10	53	55	O	any
11	57	66	O	clinically
12	68	76	O	important
13	78	83	O	effect
14	85	86	O	on
15	88	90	O	the
16	92	107	O	pharmacokinetics
17	109	110	O	of
18	112	120	O	XXXXXXXX
NULL

Rofecoxib	DDI-DrugBank.d210.s16	NO_SECTION	NO_SETID	18
Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	14	U-UNK	NSAIDs
4	16	19	O	have
5	21	28	O	produced
6	30	31	O	an
7	33	41	O	elevation
8	43	44	O	of
9	46	51	O	plasma
10	53	59	U-UNK	lithium
11	61	66	O	levels
12	68	70	O	and
13	72	72	O	a
14	74	82	O	reduction
15	84	85	O	in
16	87	91	O	renal
17	93	99	U-UNK	lithium
18	101	109	O	clearance
NULL

Rofecoxib	DDI-DrugBank.d210.s17	NO_SECTION	NO_SETID	14
In post-marketing experience there have been reports of increases in plasma lithium levels.
1	0	1	O	In
2	3	6	O	post
3	8	16	O	marketing
4	18	27	O	experience
5	29	33	O	there
6	35	38	O	have
7	40	43	O	been
8	45	51	O	reports
9	53	54	O	of
10	56	64	O	increases
11	66	67	O	in
12	69	74	O	plasma
13	76	82	U-UNK	lithium
14	84	89	O	levels
NULL

Rofecoxib	DDI-DrugBank.d210.s18	NO_SECTION	NO_SETID	20
Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
1	0	3	O	Thus
2	4	4	O	,
3	6	9	O	when
4	11	15	O	XXXXXXXX
5	17	19	O	and
6	21	27	U-DYN	lithium
7	29	31	O	are
8	33	44	O	administered
9	46	57	O	concurrently
10	58	58	O	,
11	60	67	O	subjects
12	69	74	O	should
13	76	77	O	be
14	79	86	O	observed
15	88	96	O	carefully
16	98	100	O	for
17	102	106	O	signs
18	108	109	O	of
19	111	117	U-UNK	lithium
20	119	126	O	toxicity
NULL

Rofecoxib	DDI-DrugBank.d210.s19	NO_SECTION	NO_SETID	48
Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.
1	0	11	U-UNK	Methotrexate
2	13	17	O	XXXXXXXX
3	19	22	O	12.5
4	23	23	O	,
5	25	26	O	25
6	27	27	O	,
7	29	31	O	and
8	33	34	O	50
9	36	37	O	mg
10	38	38	O	,
11	40	43	O	each
12	45	48	O	dose
13	50	61	O	administered
14	63	66	O	once
15	68	72	O	daily
16	74	76	O	for
17	78	78	O	7
18	80	83	O	days
19	84	84	O	,
20	86	88	O	had
21	90	91	O	no
22	93	98	O	effect
23	100	101	O	on
24	103	105	O	the
25	107	112	O	plasma
26	114	126	O	concentration
27	128	129	O	of
28	131	142	U-UNK	methotrexate
29	144	145	O	as
30	147	154	O	measured
31	156	157	O	by
32	159	162	O	AUC0
33	164	167	O	24hr
34	169	170	O	in
35	172	179	O	patients
36	181	189	O	receiving
37	191	196	O	single
38	198	203	O	weekly
39	205	216	U-UNK	methotrexate
40	218	222	O	doses
41	224	225	O	of
42	227	229	O	7.5
43	231	232	O	to
44	234	235	O	20
45	237	238	O	mg
46	240	242	O	for
47	244	253	O	rheumatoid
48	255	263	O	arthritis
NULL

Rofecoxib	DDI-DrugBank.d210.s20	NO_SECTION	NO_SETID	38
At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.
1	0	1	O	At
2	3	8	O	higher
3	10	13	O	than
4	15	25	O	recommended
5	27	31	O	doses
6	32	32	O	,
7	34	38	O	XXXXXXXX
8	40	41	O	75
9	43	44	O	mg
10	46	57	O	administered
11	59	62	O	once
12	64	68	O	daily
13	70	72	O	for
14	74	75	O	10
15	77	80	O	days
16	82	90	O	increased
17	92	97	O	plasma
18	99	112	O	concentrations
19	114	115	O	by
20	117	119	O	23%
21	121	122	O	as
22	124	131	O	measured
23	133	134	O	by
24	136	139	O	AUC0
25	141	144	O	24hr
26	146	147	O	in
27	149	156	O	patients
28	158	166	O	receiving
29	168	179	U-KIN	methotrexate
30	181	183	O	7.5
31	185	186	O	to
32	188	189	O	15
33	191	192	O	mg
34	193	193	O	/
35	194	197	O	week
36	199	201	O	for
37	203	212	O	rheumatoid
38	214	222	O	arthritis
NULL

Rofecoxib	DDI-DrugBank.d210.s21	NO_SECTION	NO_SETID	40
At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).
1	0	1	O	At
2	3	4	O	24
3	6	10	O	hours
4	12	19	O	postdose
5	20	20	O	,
6	22	22	O	a
7	24	30	O	similar
8	32	41	O	proportion
9	43	44	O	of
10	46	53	O	patients
11	55	61	O	treated
12	63	66	O	with
13	68	79	U-UNK	methotrexate
14	81	85	O	alone
15	88	90	O	94%
16	93	95	O	and
17	97	108	O	subsequently
18	110	116	O	treated
19	118	121	O	with
20	123	134	U-KIN	methotrexate
21	136	137	O	co
22	139	150	O	administered
23	152	155	O	with
24	157	158	O	75
25	160	161	O	mg
26	163	164	O	of
27	166	174	O	XXXXXXXX
28	177	179	O	88%
29	182	184	O	had
30	186	197	U-UNK	methotrexate
31	199	204	O	plasma
32	206	219	O	concentrations
33	221	225	O	below
34	227	229	O	the
35	231	240	O	measurable
36	242	246	O	limit
37	249	249	O	5
38	251	252	O	ng
39	253	253	O	/
40	254	255	O	mL
NULL

Rofecoxib	DDI-DrugBank.d210.s22	NO_SECTION	NO_SETID	16
Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.
1	0	7	O	Standard
2	9	18	O	monitoring
3	20	21	O	of
4	23	34	U-UNK	methotrexate
5	36	42	O	related
6	44	51	O	toxicity
7	53	58	O	should
8	60	61	O	be
9	63	71	O	continued
10	73	74	O	if
11	76	80	O	XXXXXXXX
12	82	84	O	and
13	86	97	U-DYN	methotrexate
14	99	101	O	are
15	103	114	O	administered
16	116	128	O	concomitantly
NULL

Rofecoxib	DDI-DrugBank.d210.s23	NO_SECTION	NO_SETID	18
Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone.
1	0	3	O	Oral
2	5	18	U-UNK	Contraceptives
3	20	28	O	XXXXXXXX
4	30	32	O	did
5	34	36	O	not
6	38	41	O	have
7	43	45	O	any
8	47	56	O	clinically
9	58	66	O	important
10	68	73	O	effect
11	75	76	O	on
12	78	80	O	the
13	82	97	O	pharmacokinetics
14	99	100	O	of
15	102	108	B-UNK	ethinyl
16	110	118	L-UNK	estradiol
17	120	122	O	and
18	124	136	U-UNK	norethindrone
NULL

Rofecoxib	DDI-DrugBank.d210.s24	NO_SECTION	NO_SETID	19
Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.
1	0	9	U-UNK	Prednisone
2	10	10	O	/
3	11	22	U-UNK	prednisolone
4	23	23	O	:
5	25	33	O	XXXXXXXX
6	35	37	O	did
7	39	41	O	not
8	43	46	O	have
9	48	50	O	any
10	52	61	O	clinically
11	63	71	O	important
12	73	78	O	effect
13	80	81	O	on
14	83	85	O	the
15	87	102	O	pharmacokinetics
16	104	105	O	of
17	107	118	U-UNK	prednisolone
18	120	121	O	or
19	123	132	U-UNK	prednisone
NULL

Rofecoxib	DDI-DrugBank.d210.s25	NO_SECTION	NO_SETID	28
Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.
1	0	7	U-UNK	Rifampin
2	8	8	O	:
3	10	11	O	Co
4	13	26	O	administration
5	28	29	O	of
6	31	35	O	XXXXXXXX
7	37	40	O	with
8	42	49	U-KIN	rifampin
9	51	53	O	600
10	55	56	O	mg
11	58	62	O	daily
12	63	63	O	,
13	65	65	O	a
14	67	72	O	potent
15	74	80	O	inducer
16	82	83	O	of
17	85	91	O	hepatic
18	93	102	O	metabolism
19	103	103	O	,
20	105	112	O	produced
21	114	115	O	an
22	117	127	O	approximate
23	129	131	O	50%
24	133	140	O	decrease
25	142	143	O	in
26	145	153	U-UNK	rofecoxib
27	155	160	O	plasma
28	162	175	O	concentrations
NULL

Rofecoxib	DDI-DrugBank.d210.s26	NO_SECTION	NO_SETID	30
Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism.
1	0	8	O	Therefore
2	9	9	O	,
3	11	11	O	a
4	13	20	O	starting
5	22	26	O	daily
6	28	31	O	dose
7	33	34	O	of
8	36	37	O	25
9	39	40	O	mg
10	42	43	O	of
11	45	49	O	XXXXXXXX
12	51	56	O	should
13	58	59	O	be
14	61	70	O	considered
15	72	74	O	for
16	76	78	O	the
17	80	88	O	treatment
18	90	91	O	of
19	93	106	O	osteoarthritis
20	108	111	O	when
21	113	117	O	XXXXXXXX
22	119	120	O	is
23	122	123	O	co
24	125	136	O	administered
25	138	141	O	with
26	143	148	O	potent
27	150	157	O	inducers
28	159	160	O	of
29	162	168	O	hepatic
30	170	179	O	metabolism
NULL

Rofecoxib	DDI-DrugBank.d210.s27	NO_SECTION	NO_SETID	35
Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.
1	0	11	U-UNK	Theophylline
2	13	17	O	XXXXXXXX
3	19	22	O	12.5
4	23	23	O	,
5	25	26	O	25
6	27	27	O	,
7	29	31	O	and
8	33	34	O	50
9	36	37	O	mg
10	39	50	O	administered
11	52	55	O	once
12	57	61	O	daily
13	63	65	O	for
14	67	67	O	7
15	69	72	O	days
16	74	82	O	increased
17	84	89	O	plasma
18	91	102	U-KIN	theophylline
19	104	117	O	concentrations
20	120	124	O	AUC(0
21	130	131	O	by
22	133	134	O	38
23	136	137	O	to
24	139	141	O	60%
25	143	144	O	in
26	146	152	O	healthy
27	154	161	O	subjects
28	163	174	O	administered
29	176	176	O	a
30	178	183	O	single
31	185	187	O	300
32	189	190	O	mg
33	192	195	O	dose
34	197	198	O	of
35	200	211	U-UNK	theophylline
NULL

Rofecoxib	DDI-DrugBank.d210.s28	NO_SECTION	NO_SETID	21
Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.
1	0	7	O	Adequate
2	9	18	O	monitoring
3	20	21	O	of
4	23	34	U-UNK	theophylline
5	36	41	O	plasma
6	43	56	O	concentrations
7	58	63	O	should
8	65	66	O	be
9	68	77	O	considered
10	79	82	O	when
11	84	90	O	therapy
12	92	95	O	with
13	97	101	O	XXXXXXXX
14	103	104	O	is
15	106	114	O	initiated
16	116	117	O	or
17	119	125	O	changed
18	127	128	O	in
19	130	137	O	patients
20	139	147	O	receiving
21	149	160	U-DYN	theophylline
NULL

Rofecoxib	DDI-DrugBank.d210.s29	NO_SECTION	NO_SETID	15
These data suggest that rofecoxib may produce a modest inhibition of cytochrome P450 (CYP) 1A2.
1	0	4	O	These
2	6	9	O	data
3	11	17	O	suggest
4	19	22	O	that
5	24	32	O	XXXXXXXX
6	34	36	O	may
7	38	44	O	produce
8	46	46	O	a
9	48	53	O	modest
10	55	64	O	inhibition
11	66	67	O	of
12	69	78	O	cytochrome
13	80	83	O	P450
14	86	88	O	CYP
15	91	93	O	1A2
NULL

Rofecoxib	DDI-DrugBank.d210.s30	NO_SECTION	NO_SETID	26
Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, tacrine, and zileuton).
1	0	8	O	Therefore
2	9	9	O	,
3	11	15	O	there
4	17	18	O	is
5	20	20	O	a
6	22	30	O	potential
7	32	34	O	for
8	36	37	O	an
9	39	49	O	interaction
10	51	54	O	with
11	56	60	O	other
12	62	66	O	drugs
13	68	71	O	that
14	73	75	O	are
15	77	87	O	metabolized
16	89	90	O	by
17	92	94	O	CYP
18	96	98	O	1A2
19	101	103	O	e.g
20	105	105	O	,
21	107	119	U-UNK	amitriptyline
22	120	120	O	,
23	122	128	U-UNK	tacrine
24	129	129	O	,
25	131	133	O	and
26	135	142	U-UNK	zileuton
NULL

Rofecoxib	DDI-DrugBank.d210.s31	NO_SECTION	NO_SETID	39
Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	22	O	Anticoagulant
4	24	31	O	activity
5	33	38	O	should
6	40	41	O	be
7	43	51	O	monitored
8	52	52	O	,
9	54	65	O	particularly
10	67	68	O	in
11	70	72	O	the
12	74	78	O	first
13	80	82	O	few
14	84	87	O	days
15	89	93	O	after
16	95	104	O	initiating
17	106	107	O	or
18	109	116	O	changing
19	118	122	O	XXXXXXXX
20	124	130	O	therapy
21	132	133	O	in
22	135	142	O	patients
23	144	152	O	receiving
24	154	161	U-DYN	warfarin
25	163	164	O	or
26	166	172	O	similar
27	174	179	O	agents
28	180	180	O	,
29	182	186	O	since
30	188	192	O	these
31	194	201	O	patients
32	203	205	O	are
33	207	208	O	at
34	210	211	O	an
35	213	221	O	increased
36	223	226	O	risk
37	228	229	O	of
38	231	238	O	bleeding
39	240	252	O	complications
NULL

Rofecoxib	DDI-DrugBank.d210.s32	NO_SECTION	NO_SETID	27
In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.
1	0	1	O	In
2	3	8	O	single
3	10	12	O	and
4	14	21	O	multiple
5	23	26	O	dose
6	28	34	O	studies
7	36	37	O	in
8	39	45	O	healthy
9	47	54	O	subjects
10	56	64	O	receiving
11	66	69	O	both
12	71	78	U-DYN	warfarin
13	80	82	O	and
14	84	92	O	XXXXXXXX
15	93	93	O	,
16	95	105	O	prothrombin
17	107	110	O	time
18	113	120	O	measured
19	122	123	O	as
20	125	127	O	INR
21	130	132	O	was
22	134	142	O	increased
23	144	145	O	by
24	147	159	O	approximately
25	161	162	O	8%
26	164	165	O	to
27	167	169	O	11%
NULL

Rofecoxib	DDI-DrugBank.d210.s33	NO_SECTION	NO_SETID	30
In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.
1	0	1	O	In
2	3	6	O	post
3	8	16	O	marketing
4	18	27	O	experience
5	28	28	O	,
6	30	37	O	bleeding
7	39	44	O	events
8	46	49	O	have
9	51	54	O	been
10	56	63	O	reported
11	64	64	O	,
12	66	78	O	predominantly
13	80	81	O	in
14	83	85	O	the
15	87	93	O	elderly
16	94	94	O	,
17	96	97	O	in
18	99	109	O	association
19	111	114	O	with
20	116	124	O	increases
21	126	127	O	in
22	129	139	O	prothrombin
23	141	144	O	time
24	146	147	O	in
25	149	156	O	patients
26	158	166	O	receiving
27	168	172	O	XXXXXXXX
28	174	185	O	concurrently
29	187	190	O	with
30	192	199	U-DYN	warfarin
NULL

Saquinavir	DDI-DrugBank.d124.s1	NO_SECTION	NO_SETID	12
Several drug interaction studies have been completed with both INVIRASE and FORTOVASE.
1	0	6	O	Several
2	8	11	O	drug
3	13	23	O	interaction
4	25	31	O	studies
5	33	36	O	have
6	38	41	O	been
7	43	51	O	completed
8	53	56	O	with
9	58	61	O	both
10	63	70	O	INVIRASE
11	72	74	O	and
12	76	84	O	XXXXXXXX
NULL

Saquinavir	DDI-DrugBank.d124.s2	NO_SECTION	NO_SETID	13
Observations from drug interaction studies with FORTOVASE may not be predictive for INVIRASE.
1	0	11	O	Observations
2	13	16	O	from
3	18	21	O	drug
4	23	33	O	interaction
5	35	41	O	studies
6	43	46	O	with
7	48	56	O	FORTOVASE
8	58	60	O	may
9	62	64	O	not
10	66	67	O	be
11	69	78	O	predictive
12	80	82	O	for
13	84	91	O	XXXXXXXX
NULL

Saquinavir	DDI-DrugBank.d124.s3	NO_SECTION	NO_SETID	22
Because ritonavir is coadministered, prescribers should also refer to the prescribing information for ritonavir regarding drug interactions associated with this agent.
1	0	6	O	Because
2	8	16	U-UNK	ritonavir
3	18	19	O	is
4	21	34	O	coadministered
5	35	35	O	,
6	37	47	O	prescribers
7	49	54	O	should
8	56	59	O	also
9	61	65	O	refer
10	67	68	O	to
11	70	72	O	the
12	74	84	O	prescribing
13	86	96	O	information
14	98	100	O	for
15	102	110	U-UNK	ritonavir
16	112	120	O	regarding
17	122	125	O	drug
18	127	138	O	interactions
19	140	149	O	associated
20	151	154	O	with
21	156	159	O	this
22	161	165	O	agent
NULL

Saquinavir	DDI-DrugBank.d124.s4	NO_SECTION	NO_SETID	22
The metabolism of saquinavir is mediated by cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90% of the hepatic metabolism.
1	0	2	O	The
2	4	13	O	metabolism
3	15	16	O	of
4	18	27	O	XXXXXXXX
5	29	30	O	is
6	32	39	O	mediated
7	41	42	O	by
8	44	53	O	cytochrome
9	55	58	O	P450
10	59	59	O	,
11	61	64	O	with
12	66	68	O	the
13	70	77	O	specific
14	79	87	O	isoenzyme
15	89	94	O	CYP3A4
16	96	106	O	responsible
17	108	110	O	for
18	112	114	O	90%
19	116	117	O	of
20	119	121	O	the
21	123	129	O	hepatic
22	131	140	O	metabolism
NULL

Saquinavir	DDI-DrugBank.d124.s5	NO_SECTION	NO_SETID	10
Additionally, saquinavir is a substrate for P-Glycoprotein (Pgp).
1	0	11	O	Additionally
2	12	12	O	,
3	14	23	O	XXXXXXXX
4	25	26	O	is
5	28	28	O	a
6	30	38	O	substrate
7	40	42	O	for
8	44	44	O	P
9	46	57	O	Glycoprotein
10	60	62	O	Pgp
NULL

Saquinavir	DDI-DrugBank.d124.s6	NO_SECTION	NO_SETID	17
Therefore, drugs that affect CYP3A4 and/or Pgp, may modify the pharmacokinetics of saquinavir.
1	0	8	O	Therefore
2	9	9	O	,
3	11	15	O	drugs
4	17	20	O	that
5	22	27	O	affect
6	29	34	O	CYP3A4
7	36	38	O	and
8	39	39	O	/
9	40	41	O	or
10	43	45	O	Pgp
11	46	46	O	,
12	48	50	O	may
13	52	57	O	modify
14	59	61	O	the
15	63	78	O	pharmacokinetics
16	80	81	O	of
17	83	92	O	XXXXXXXX
NULL

Saquinavir	DDI-DrugBank.d124.s7	NO_SECTION	NO_SETID	18
Similarly, saquinavir might also modify the pharmacokinetics of other drugs that are substrates for CYP3A4 or Pgp.
1	0	8	O	Similarly
2	9	9	O	,
3	11	20	O	XXXXXXXX
4	22	26	O	might
5	28	31	O	also
6	33	38	O	modify
7	40	42	O	the
8	44	59	O	pharmacokinetics
9	61	62	O	of
10	64	68	O	other
11	70	74	O	drugs
12	76	79	O	that
13	81	83	O	are
14	85	94	O	substrates
15	96	98	O	for
16	100	105	O	CYP3A4
17	107	108	O	or
18	110	112	O	Pgp
NULL

Saquinavir	DDI-DrugBank.d124.s8	NO_SECTION	NO_SETID	21
Drugs that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed CONTRAINDICATIONS.
1	0	4	O	Drugs
2	6	9	O	that
3	11	13	O	are
4	15	29	O	contraindicated
5	31	42	O	specifically
6	44	46	O	due
7	48	49	O	to
8	51	53	O	the
9	55	62	O	expected
10	64	72	O	magnitude
11	74	75	O	of
12	77	87	O	interaction
13	89	91	O	and
14	93	101	O	potential
15	103	105	O	for
16	107	113	O	serious
17	115	121	O	adverse
18	123	128	O	events
19	130	132	O	are
20	134	139	O	listed
21	141	157	O	CONTRAINDICATIONS
NULL

Saquinavir	DDI-DrugBank.d124.s9	NO_SECTION	NO_SETID	15
Additional drugs that are not recommended for coadministration with INVIRASE and ritonavir are included below.
1	0	9	O	Additional
2	11	15	O	drugs
3	17	20	O	that
4	22	24	O	are
5	26	28	O	not
6	30	40	O	recommended
7	42	44	O	for
8	46	61	O	coadministration
9	63	66	O	with
10	68	75	O	XXXXXXXX
11	77	79	O	and
12	81	89	U-UNK	ritonavir
13	91	93	O	are
14	95	102	O	included
15	104	108	O	below
NULL

Saquinavir	DDI-DrugBank.d124.s10	NO_SECTION	NO_SETID	28
These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy.
1	0	4	O	These
2	6	20	O	recommendations
3	22	24	O	are
4	26	30	O	based
5	32	33	O	on
6	35	40	O	either
7	42	45	O	drug
8	47	57	O	interaction
9	59	65	O	studies
10	67	68	O	or
11	70	78	O	predicted
12	80	91	O	interactions
13	93	95	O	due
14	97	98	O	to
15	100	102	O	the
16	104	111	O	expected
17	113	121	O	magnitude
18	123	124	O	of
19	126	136	O	interaction
20	138	140	O	and
21	142	150	O	potential
22	152	154	O	for
23	156	162	O	serious
24	164	169	O	events
25	171	172	O	or
26	174	177	O	loss
27	179	180	O	of
28	182	189	O	efficacy
NULL

Saquinavir	DDI-DrugBank.d124.s11	NO_SECTION	NO_SETID	14
With some agents, the metabolism may be induced, resulting in decreased concentrations.
1	0	3	O	With
2	5	8	O	some
3	10	15	O	agents
4	16	16	O	,
5	18	20	O	the
6	22	31	O	metabolism
7	33	35	O	may
8	37	38	O	be
9	40	46	O	induced
10	47	47	O	,
11	49	57	O	resulting
12	59	60	O	in
13	62	70	O	decreased
14	72	85	O	concentrations
NULL

Saquinavir	DDI-DrugBank.d124.s12	NO_SECTION	NO_SETID	10
Drugs That Should Not Be Coadministered With INVIRASE/Ritonavir
1	0	4	O	Drugs
2	6	9	O	That
3	11	16	O	Should
4	18	20	O	Not
5	22	23	O	Be
6	25	38	O	Coadministered
7	40	43	O	With
8	45	52	O	XXXXXXXX
9	53	53	O	/
10	54	62	U-UNK	Ritonavir
NULL

Saquinavir	DDI-DrugBank.d124.s13	NO_SECTION	NO_SETID	7
Drug Class: Drug Name Clinical Comment
1	0	3	O	Drug
2	5	9	O	Class
3	10	10	O	:
4	12	15	O	Drug
5	17	20	O	Name
6	22	29	O	Clinical
7	31	37	O	Comment
NULL

Saquinavir	DDI-DrugBank.d124.s14	NO_SECTION	NO_SETID	23
Antiarrhythmics: Amiodarone, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.
1	0	14	U-UNK	Antiarrhythmics
2	15	15	O	:
3	17	26	U-UNK	Amiodarone
4	27	27	O	,
5	29	36	U-UNK	bepridil
6	37	37	O	,
7	39	48	U-UNK	flecainide
8	49	49	O	,
9	51	61	U-UNK	propafenone
10	62	62	O	,
11	64	72	U-UNK	quinidine
12	74	88	O	CONTRAINDICATED
13	90	92	O	due
14	94	95	O	to
15	97	105	O	potential
16	107	109	O	for
17	111	117	O	serious
18	119	121	O	and
19	122	122	O	/
20	123	124	O	or
21	126	129	O	life
22	131	141	O	threatening
23	143	151	O	reactions
NULL

Saquinavir	DDI-DrugBank.d124.s15	NO_SECTION	NO_SETID	18
Antihistamines: astemizole*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.
1	0	13	U-UNK	Antihistamines
2	14	14	O	:
3	16	26	O	astemizole*
4	27	27	O	,
5	29	40	O	terfenadine*
6	42	56	O	CONTRAINDICATED
7	58	60	O	due
8	62	63	O	to
9	65	73	O	potential
10	75	77	O	for
11	79	85	O	serious
12	87	89	O	and
13	90	90	O	/
14	91	92	O	or
15	94	97	O	life
16	99	109	O	threatening
17	111	117	O	cardiac
18	119	129	O	arrhythmias
NULL

Saquinavir	DDI-DrugBank.d124.s16	NO_SECTION	NO_SETID	37
Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
1	0	4	B-UNK	Ergot
2	6	16	L-UNK	Derivatives
3	17	17	O	:
4	19	35	U-UNK	Dihydroergotamine
5	36	36	O	,
6	38	47	U-UNK	ergonovine
7	48	48	O	,
8	50	59	U-UNK	ergotamine
9	60	60	O	,
10	62	77	U-UNK	methylergonovine
11	79	93	O	CONTRAINDICATED
12	95	97	O	due
13	99	100	O	to
14	102	110	O	potential
15	112	114	O	for
16	116	122	O	serious
17	124	126	O	and
18	128	131	O	life
19	133	143	O	threatening
20	145	153	O	reactions
21	155	158	O	such
22	160	161	O	as
23	163	167	O	acute
24	169	173	U-UNK	ergot
25	175	182	O	toxicity
26	184	196	O	characterized
27	198	199	O	by
28	201	210	O	peripheral
29	212	220	O	vasospasm
30	222	224	O	and
31	226	233	O	ischemia
32	235	236	O	of
33	238	240	O	the
34	242	252	O	extremities
35	254	256	O	and
36	258	262	O	other
37	264	270	O	tissues
NULL

Saquinavir	DDI-DrugBank.d124.s17	NO_SECTION	NO_SETID	23
Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.
1	0	16	B-UNK	Antimycobacterial
2	18	23	L-UNK	Agents
3	24	24	O	:
4	26	33	U-UNK	rifampin
5	35	49	O	CONTRAINDICATED
6	51	55	O	since
7	57	59	O	the
8	61	76	O	coadministration
9	78	79	O	of
10	81	84	O	this
11	86	92	O	product
12	94	97	O	with
13	99	108	O	XXXXXXXX
14	110	111	O	in
15	113	114	O	an
16	116	129	U-UNK	antiretroviral
17	131	137	O	regimen
18	139	145	O	reduces
19	147	149	O	the
20	151	156	O	plasma
21	158	171	O	concentrations
22	173	174	O	of
23	176	185	O	XXXXXXXX
NULL

Saquinavir	DDI-DrugBank.d124.s18	NO_SECTION	NO_SETID	26
Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.
1	0	5	O	Garlic
2	7	14	O	Capsules
3	16	21	O	Garlic
4	23	30	O	capsules
5	32	37	O	should
6	39	41	O	not
7	43	44	O	be
8	46	49	O	used
9	51	55	O	while
10	57	62	O	taking
11	64	73	U-UNK	saquinavir
12	76	84	O	XXXXXXXX
13	87	88	O	as
14	90	92	O	the
15	94	97	O	sole
16	99	106	B-UNK	protease
17	108	116	L-UNK	inhibitor
18	118	120	O	due
19	122	123	O	to
20	125	127	O	the
21	129	132	O	risk
22	134	135	O	of
23	137	145	O	decreased
24	147	156	U-UNK	saquinavir
25	158	163	O	plasma
26	165	178	O	concentrations
NULL

Saquinavir	DDI-DrugBank.d124.s19	NO_SECTION	NO_SETID	18
No data are available for the coadministration of INVIRASE/ritonavir or FORTOVASE/ritonavir and garlic capsules.
1	0	1	O	No
2	3	6	O	data
3	8	10	O	are
4	12	20	O	available
5	22	24	O	for
6	26	28	O	the
7	30	45	O	coadministration
8	47	48	O	of
9	50	57	O	INVIRASE
10	58	58	O	/
11	59	67	U-UNK	ritonavir
12	69	70	O	or
13	72	80	O	XXXXXXXX
14	81	81	O	/
15	82	90	U-UNK	ritonavir
16	92	94	O	and
17	96	101	O	garlic
18	103	110	O	capsules
NULL

Saquinavir	DDI-DrugBank.d124.s20	NO_SECTION	NO_SETID	21
GI Motility Agent: cisapride* CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
1	0	1	O	GI
2	3	10	O	Motility
3	12	16	O	Agent
4	17	17	O	:
5	19	28	O	cisapride*
6	30	44	O	CONTRAINDICATED
7	46	48	O	due
8	50	51	O	to
9	53	61	O	potential
10	63	65	O	for
11	67	73	O	serious
12	75	77	O	and
13	78	78	O	/
14	79	80	O	or
15	82	85	O	life
16	87	97	O	threatening
17	99	107	O	reactions
18	109	112	O	such
19	114	115	O	as
20	117	123	O	cardiac
21	125	135	O	arrhythmias
NULL

Saquinavir	DDI-DrugBank.d124.s21	NO_SECTION	NO_SETID	30
Herbal Products: St. John s wort (hypericum perforatum) WARNING coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors.
1	0	5	O	Herbal
2	7	14	O	Products
3	15	15	O	:
4	17	18	O	St
5	21	24	O	John
6	26	26	O	s
7	28	31	O	wort
8	34	42	O	hypericum
9	44	53	O	perforatum
10	56	62	O	WARNING
11	64	79	O	coadministration
12	81	83	O	may
13	85	88	O	lead
14	90	91	O	to
15	93	96	O	loss
16	98	99	O	of
17	101	109	O	virologic
18	111	118	O	response
19	120	122	O	and
20	124	131	O	possible
21	133	142	O	resistance
22	144	145	O	to
23	147	154	O	XXXXXXXX
24	156	157	O	or
25	159	160	O	to
26	162	164	O	the
27	166	170	O	class
28	172	173	O	of
29	175	182	O	protease
30	184	193	O	inhibitors
NULL

Saquinavir	DDI-DrugBank.d124.s22	NO_SECTION	NO_SETID	20
HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.
1	0	2	B-UNK	HMG
2	4	6	I-UNK	CoA
3	8	16	I-UNK	Reductase
4	18	27	L-UNK	Inhibitors
5	28	28	O	:
6	30	39	U-UNK	lovastatin
7	40	40	O	,
8	42	52	U-UNK	simvastatin
9	54	60	O	WARNING
10	62	70	O	potential
11	72	74	O	for
12	76	82	O	serious
13	84	92	O	reactions
14	94	97	O	such
15	99	100	O	as
16	102	105	O	risk
17	107	108	O	of
18	110	117	O	myopathy
19	119	127	O	including
20	129	142	O	rhabdomyolysis
NULL

Saquinavir	DDI-DrugBank.d124.s23	NO_SECTION	NO_SETID	28
Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.
1	0	8	U-UNK	Sedatives
2	9	9	O	/
3	10	18	U-UNK	Hypnotics
4	19	19	O	:
5	21	29	U-UNK	triazolam
6	30	30	O	,
7	32	40	U-UNK	midazolam
8	42	56	O	CONTRAINDICATED
9	58	60	O	due
10	62	63	O	to
11	65	73	O	potential
12	75	77	O	for
13	79	85	O	serious
14	87	89	O	and
15	90	90	O	/
16	91	92	O	or
17	94	97	O	life
18	99	109	O	threatening
19	111	119	O	reactions
20	121	124	O	such
21	126	127	O	as
22	129	137	O	prolonged
23	139	140	O	or
24	142	150	O	increased
25	152	159	O	sedation
26	161	162	O	or
27	164	174	O	respiratory
28	176	185	O	depression
NULL

Saquinavir	DDI-DrugBank.d124.s24	NO_SECTION	NO_SETID	7
* No longer marketed in the US.
1	0	0	O	*
2	2	3	O	No
3	5	10	O	longer
4	12	19	O	marketed
5	21	22	O	in
6	24	26	O	the
7	28	29	O	US
NULL

Saquinavir	DDI-DrugBank.d124.s25	NO_SECTION	NO_SETID	7
Drugs That Are Mainly Metabolized by CYP3A4
1	0	4	O	Drugs
2	6	9	O	That
3	11	13	O	Are
4	15	20	O	Mainly
5	22	32	O	Metabolized
6	34	35	O	by
7	37	42	O	CYP3A4
NULL

Saquinavir	DDI-DrugBank.d124.s26	NO_SECTION	NO_SETID	63
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
1	0	7	O	Although
2	9	16	O	specific
3	18	24	O	studies
4	26	29	O	have
5	31	33	O	not
6	35	38	O	been
7	40	48	O	performed
8	49	49	O	,
9	51	66	O	coadministration
10	68	71	O	with
11	73	77	O	drugs
12	79	82	O	that
13	84	86	O	are
14	88	93	O	mainly
15	95	105	O	metabolized
16	107	108	O	by
17	110	115	O	CYP3A4
18	118	119	O	eg
19	120	120	O	,
20	122	128	B-KIN	calcium
21	130	136	I-KIN	channel
22	138	145	L-KIN	blockers
23	146	146	O	,
24	148	154	U-KIN	dapsone
25	155	155	O	,
26	157	168	U-KIN	disopyramide
27	169	169	O	,
28	171	177	U-KIN	quinine
29	178	178	O	,
30	180	189	U-KIN	amiodarone
31	190	190	O	,
32	192	200	U-KIN	quinidine
33	201	201	O	,
34	203	210	U-KIN	warfarin
35	211	211	O	,
36	213	222	U-KIN	tacrolimus
37	223	223	O	,
38	225	236	U-KIN	cyclosporine
39	237	237	O	,
40	239	243	B-KIN	ergot
41	245	255	L-KIN	derivatives
42	256	256	O	,
43	258	265	U-KIN	pimozide
44	266	266	O	,
45	268	280	U-KIN	carbamazepine
46	281	281	O	,
47	283	290	U-KIN	fentanyl
48	291	291	O	,
49	293	302	U-KIN	alfentanyl
50	303	303	O	,
51	305	314	U-KIN	alprazolam
52	315	315	O	,
53	317	319	O	and
54	321	329	U-KIN	triazolam
55	332	334	O	may
56	336	339	O	have
57	341	348	O	elevated
58	350	355	O	plasma
59	357	370	O	concentrations
60	372	375	O	when
61	377	390	O	coadministered
62	392	395	O	with
63	397	406	O	XXXXXXXX
NULL

Saquinavir	DDI-DrugBank.d124.s27	NO_SECTION	NO_SETID	9
therefore, these combinations should be used with caution.
1	0	8	O	therefore
2	9	9	O	,
3	11	15	O	these
4	17	28	O	combinations
5	30	35	O	should
6	37	38	O	be
7	40	43	O	used
8	45	48	O	with
9	50	56	O	caution
NULL

Saquinavir	DDI-DrugBank.d124.s28	NO_SECTION	NO_SETID	21
Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.
1	0	4	O	Since
2	6	13	O	XXXXXXXX
3	15	16	O	is
4	18	31	O	coadministered
5	33	36	O	with
6	38	46	U-DYN	ritonavir
7	47	47	O	,
8	49	51	O	the
9	53	61	U-UNK	ritonavir
10	63	67	O	label
11	69	74	O	should
12	76	77	O	be
13	79	86	O	reviewed
14	88	90	O	for
15	92	101	O	additional
16	103	107	O	drugs
17	109	112	O	that
18	114	119	O	should
19	121	123	O	not
20	125	126	O	be
21	128	141	O	coadministered
NULL

Saquinavir	DDI-DrugBank.d124.s30	NO_SECTION	NO_SETID	26
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.
1	0	15	O	Coadministration
2	17	20	O	with
3	22	30	O	compounds
4	32	35	O	that
5	37	39	O	are
6	41	46	O	potent
7	48	55	O	inducers
8	57	58	O	of
9	60	65	O	CYP3A4
10	68	69	O	eg
11	70	70	O	,
12	72	84	U-KIN	phenobarbital
13	85	85	O	,
14	87	95	U-KIN	phenytoin
15	96	96	O	,
16	98	110	U-KIN	dexamethasone
17	111	111	O	,
18	113	125	U-KIN	carbamazepine
19	128	130	O	may
20	132	137	O	result
21	139	140	O	in
22	142	150	O	decreased
23	152	157	O	plasma
24	159	164	O	levels
25	166	167	O	of
26	169	178	O	XXXXXXXX
NULL

Sulfacetamide	DDI-DrugBank.d65.s0	NO_SECTION	NO_SETID	7
Sulfacetamide preparations are incompatible with silver preparations.
1	0	12	O	XXXXXXXX
2	14	25	O	preparations
3	27	29	O	are
4	31	42	O	incompatible
5	44	47	O	with
6	49	54	U-UNK	silver
7	56	67	O	preparations
NULL

Sulfapyridine	DDI-DrugBank.d179.s1	NO_SECTION	NO_SETID	21
Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or
1	0	12	U-UNK	Sulfapyridine
2	14	16	O	may
3	18	25	O	interact
4	27	30	O	with
5	32	34	O	any
6	36	37	O	of
7	39	41	O	the
8	43	51	O	following
9	52	52	O	:
10	56	68	U-UNK	Acetaminophen
11	71	73	O	e.g
12	75	75	O	,
13	77	83	O	XXXXXXXX
14	87	90	O	with
15	92	95	O	long
16	97	100	O	term
17	101	101	O	,
18	103	106	O	high
19	108	111	O	dose
20	113	115	O	use
21	118	119	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s2	NO_SECTION	NO_SETID	5
- Amiodarone (e.g., Cordarone) or
1	2	11	U-UNK	Amiodarone
2	14	16	O	e.g
3	18	18	O	,
4	20	28	O	XXXXXXXX
5	31	32	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s3	NO_SECTION	NO_SETID	22
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or
1	2	9	B-UNK	Anabolic
2	11	18	L-UNK	steroids
3	21	30	U-UNK	nandrolone
4	33	35	O	e.g
5	37	37	O	,
6	39	46	O	Anabolin
7	48	48	O	,
8	50	60	U-UNK	oxandrolone
9	63	65	O	e.g
10	67	67	O	,
11	69	74	O	Anavar
12	76	76	O	,
13	78	89	U-UNK	oxymetholone
14	92	94	O	e.g
15	96	96	O	,
16	98	104	O	Anadrol
17	106	106	O	,
18	108	117	U-UNK	stanozolol
19	120	122	O	e.g
20	124	124	O	,
21	126	133	O	XXXXXXXX
22	137	138	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s4	NO_SECTION	NO_SETID	4
- Androgens (male hormones) or
1	2	10	U-UNK	Androgens
2	13	16	O	male
3	18	25	O	hormones
4	28	29	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s5	NO_SECTION	NO_SETID	7
- Antithyroid agents (medicine for overactive thyroid) or
1	2	12	B-UNK	Antithyroid
2	14	19	L-UNK	agents
3	22	29	O	medicine
4	31	33	O	for
5	35	44	O	overactive
6	46	52	O	thyroid
7	55	56	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s6	NO_SECTION	NO_SETID	5
- Carbamazepine (e.g., Tegretol) or
1	2	14	U-UNK	Carbamazepine
2	17	19	O	e.g
3	21	21	O	,
4	23	30	O	XXXXXXXX
5	33	34	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s7	NO_SECTION	NO_SETID	5
- Carmustine (e.g., BiCNU) or
1	2	11	U-UNK	Carmustine
2	14	16	O	e.g
3	18	18	O	,
4	20	24	O	XXXXXXXX
5	27	28	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s8	NO_SECTION	NO_SETID	5
- Chloroquine (e.g., Aralen) or
1	2	12	U-UNK	Chloroquine
2	15	17	O	e.g
3	19	19	O	,
4	21	26	O	XXXXXXXX
5	29	30	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s9	NO_SECTION	NO_SETID	5
- Dantrolene (e.g., Dantrium) or
1	2	11	U-UNK	Dantrolene
2	14	16	O	e.g
3	18	18	O	,
4	20	27	O	XXXXXXXX
5	30	31	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s10	NO_SECTION	NO_SETID	5
- Daunorubicin (e.g., Cerubidine) or
1	2	13	U-UNK	Daunorubicin
2	16	18	O	e.g
3	20	20	O	,
4	22	31	O	XXXXXXXX
5	34	35	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s11	NO_SECTION	NO_SETID	5
- Disulfiram (e.g., Antabuse) or
1	2	11	U-UNK	Disulfiram
2	14	16	O	e.g
3	18	18	O	,
4	20	27	O	XXXXXXXX
5	30	31	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s12	NO_SECTION	NO_SETID	5
- Divalproex (e.g., Depakote) or
1	2	11	U-UNK	Divalproex
2	14	16	O	e.g
3	18	18	O	,
4	20	27	O	XXXXXXXX
5	30	31	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s13	NO_SECTION	NO_SETID	4
- Estrogens (female hormones) or
1	2	10	U-UNK	Estrogens
2	13	18	O	female
3	20	27	O	hormones
4	30	31	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s14	NO_SECTION	NO_SETID	5
- Etretinate (e.g., Tegison) or
1	2	11	U-UNK	Etretinate
2	14	16	O	e.g
3	18	18	O	,
4	20	26	O	XXXXXXXX
5	29	30	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s15	NO_SECTION	NO_SETID	6
- Gold salts (medicine for arthritis) or
1	2	5	U-UNK	Gold
2	7	11	O	salts
3	14	21	O	medicine
4	23	25	O	for
5	27	35	O	arthritis
6	38	39	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s16	NO_SECTION	NO_SETID	5
- Hydroxychloroquine (e.g., Plaquenil) or
1	2	19	U-UNK	Hydroxychloroquine
2	22	24	O	e.g
3	26	26	O	,
4	28	36	O	XXXXXXXX
5	39	40	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s17	NO_SECTION	NO_SETID	5
- Mercaptopurine (e.g., Purinethol) or
1	2	15	U-UNK	Mercaptopurine
2	18	20	O	e.g
3	22	22	O	,
4	24	33	O	XXXXXXXX
5	36	37	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s18	NO_SECTION	NO_SETID	12
- Naltrexone (e.g., Trexan) (with long-term, high-dose use) or
1	2	11	U-UNK	Naltrexone
2	14	16	O	e.g
3	18	18	O	,
4	20	25	O	XXXXXXXX
5	29	32	O	with
6	34	37	O	long
7	39	42	O	term
8	43	43	O	,
9	45	48	O	high
10	50	53	O	dose
11	55	57	O	use
12	60	61	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s19	NO_SECTION	NO_SETID	8
- Oral contraceptives (birth control pills) containing estrogen or
1	2	5	O	Oral
2	7	20	U-UNK	contraceptives
3	23	27	O	birth
4	29	35	O	control
5	37	41	O	pills
6	44	53	O	containing
7	55	62	U-UNK	estrogen
8	64	65	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s20	NO_SECTION	NO_SETID	12
- Other anti-infectives by mouth or by injection (medicine for infection) or
1	2	6	O	Other
2	8	11	B-UNK	anti
3	13	22	L-UNK	infectives
4	24	25	O	by
5	27	31	O	mouth
6	33	34	O	or
7	36	37	O	by
8	39	47	O	injection
9	50	57	O	medicine
10	59	61	O	for
11	63	71	O	infection
12	74	75	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s21	NO_SECTION	NO_SETID	61
- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or
1	2	15	U-UNK	Phenothiazines
2	18	31	U-UNK	acetophenazine
3	34	36	O	e.g
4	38	38	O	,
5	40	45	O	Tindal
6	47	47	O	,
7	49	62	U-UNK	chlorpromazine
8	65	67	O	e.g
9	69	69	O	,
10	71	79	O	Thorazine
11	81	81	O	,
12	83	94	U-UNK	fluphenazine
13	97	99	O	e.g
14	101	101	O	,
15	103	110	O	Prolixin
16	112	112	O	,
17	114	125	O	mesoridazine
18	128	130	O	e.g
19	132	132	O	,
20	134	141	O	Serentil
21	143	143	O	,
22	145	156	U-UNK	perphenazine
23	159	161	O	e.g
24	163	163	O	,
25	165	172	O	Trilafon
26	174	174	O	,
27	176	191	U-UNK	prochlorperazine
28	194	196	O	e.g
29	198	198	O	,
30	200	208	O	Compazine
31	210	210	O	,
32	212	220	U-UNK	promazine
33	223	225	O	e.g
34	227	227	O	,
35	229	235	O	Sparine
36	237	237	O	,
37	239	250	U-UNK	promethazine
38	253	255	O	e.g
39	257	257	O	,
40	259	267	O	Phenergan
41	269	269	O	,
42	271	282	U-UNK	thioridazine
43	285	287	O	e.g
44	289	289	O	,
45	291	298	O	Mellaril
46	300	300	O	,
47	302	316	U-UNK	trifluoperazine
48	319	321	O	e.g
49	323	323	O	,
50	325	333	O	Stelazine
51	335	335	O	,
52	337	351	U-UNK	triflupromazine
53	354	356	O	e.g
54	358	358	O	,
55	360	366	O	Vesprin
56	368	368	O	,
57	370	381	U-UNK	trimeprazine
58	384	386	O	e.g
59	388	388	O	,
60	390	396	O	XXXXXXXX
61	400	401	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s22	NO_SECTION	NO_SETID	5
- Plicamycin (e.g., Mithracin) or
1	2	11	U-UNK	Plicamycin
2	14	16	O	e.g
3	18	18	O	,
4	20	28	O	XXXXXXXX
5	31	32	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s23	NO_SECTION	NO_SETID	21
- Valproic acid (e.g., Depakene) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the liver
1	2	9	B-UNK	Valproic
2	11	14	L-UNK	acid
3	17	19	O	e.g
4	21	21	O	,
5	23	30	O	XXXXXXXX
6	33	35	O	Use
7	37	38	O	of
8	40	52	U-UNK	sulfapyridine
9	54	57	O	with
10	59	63	O	these
11	65	73	O	medicines
12	75	77	O	may
13	79	86	O	increase
14	88	90	O	the
15	92	97	O	chance
16	99	100	O	of
17	102	105	O	side
18	107	113	O	effects
19	115	123	O	affecting
20	125	127	O	the
21	129	133	O	liver
NULL

Sulfapyridine	DDI-DrugBank.d179.s24	NO_SECTION	NO_SETID	6
- Acetohydroxamic acid (e.g., Lithostat) or
1	2	16	B-UNK	Acetohydroxamic
2	18	21	L-UNK	acid
3	24	26	O	e.g
4	28	28	O	,
5	30	38	O	XXXXXXXX
6	41	42	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s26	NO_SECTION	NO_SETID	5
- Furazolidone (e.g., Furoxone) or
1	2	13	U-UNK	Furazolidone
2	16	18	O	e.g
3	20	20	O	,
4	22	29	O	XXXXXXXX
5	32	33	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s27	NO_SECTION	NO_SETID	5
- Nitrofurantoin (e.g., Furadantin) or
1	2	15	U-UNK	Nitrofurantoin
2	18	20	O	e.g
3	22	22	O	,
4	24	33	O	XXXXXXXX
5	36	37	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s29	NO_SECTION	NO_SETID	5
- Procainamide (e.g., Pronestyl) or
1	2	13	U-UNK	Procainamide
2	16	18	O	e.g
3	20	20	O	,
4	22	30	O	XXXXXXXX
5	33	34	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s30	NO_SECTION	NO_SETID	5
- Quinidine (e.g., Quinidex) or
1	2	10	U-UNK	Quinidine
2	13	15	O	e.g
3	17	17	O	,
4	19	26	O	XXXXXXXX
5	29	30	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s31	NO_SECTION	NO_SETID	5
- Quinine (e.g., Quinamm) or
1	2	8	U-UNK	Quinine
2	11	13	O	e.g
3	15	15	O	,
4	17	23	O	XXXXXXXX
5	26	27	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s32	NO_SECTION	NO_SETID	5
- Sulfoxone (e.g., Diasone) or
1	2	10	U-UNK	Sulfoxone
2	13	15	O	e.g
3	17	17	O	,
4	19	25	O	XXXXXXXX
5	28	29	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s33	NO_SECTION	NO_SETID	23
- Vitamin K (e.g., AquaMEPHYTON, Synkayvite) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood
1	2	8	B-UNK	Vitamin
2	10	10	L-UNK	K
3	13	15	O	e.g
4	17	17	O	,
5	19	30	O	AquaMEPHYTON
6	31	31	O	,
7	33	42	O	XXXXXXXX
8	45	47	O	Use
9	49	50	O	of
10	52	64	U-UNK	sulfapyridine
11	66	69	O	with
12	71	75	O	these
13	77	85	O	medicines
14	87	89	O	may
15	91	98	O	increase
16	100	102	O	the
17	104	109	O	chance
18	111	112	O	of
19	114	117	O	side
20	119	125	O	effects
21	127	135	O	affecting
22	137	139	O	the
23	141	145	O	blood
NULL

Sulfapyridine	DDI-DrugBank.d179.s34	NO_SECTION	NO_SETID	4
- Anticoagulants (blood thinners) or
1	2	15	U-UNK	Anticoagulants
2	18	22	U-UNK	blood
3	24	31	O	thinners
4	34	35	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s35	NO_SECTION	NO_SETID	5
- Ethotoin (e.g., Peganone) or
1	2	9	U-UNK	Ethotoin
2	12	14	O	e.g
3	16	16	O	,
4	18	25	O	XXXXXXXX
5	28	29	O	or
NULL

Sulfapyridine	DDI-DrugBank.d179.s36	NO_SECTION	NO_SETID	20
- Mephenytoin (e.g., Mesantoin) Use of sulfapyridine with these medicines may increase the chance of side effects of these medicines
1	2	12	U-UNK	Mephenytoin
2	15	17	O	e.g
3	19	19	O	,
4	21	29	O	XXXXXXXX
5	32	34	O	Use
6	36	37	O	of
7	39	51	U-UNK	sulfapyridine
8	53	56	O	with
9	58	62	O	these
10	64	72	O	medicines
11	74	76	O	may
12	78	85	O	increase
13	87	89	O	the
14	91	96	O	chance
15	98	99	O	of
16	101	104	O	side
17	106	112	O	effects
18	114	115	O	of
19	117	121	O	these
20	123	131	O	medicines
NULL

Sulfapyridine	DDI-DrugBank.d179.s37	NO_SECTION	NO_SETID	34
- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics
1	2	14	U-UNK	Antidiabetics
2	15	15	O	,
3	17	20	O	oral
4	23	30	O	diabetes
5	32	39	O	medicine
6	41	43	O	you
7	45	48	O	take
8	50	51	O	by
9	53	57	O	mouth
10	60	62	O	Use
11	64	65	O	of
12	67	70	O	oral
13	72	84	U-DYN	antidiabetics
14	86	89	O	with
15	91	103	O	XXXXXXXX
16	105	107	O	may
17	109	116	O	increase
18	118	120	O	the
19	122	127	O	chance
20	129	130	O	of
21	132	135	O	side
22	137	143	O	effects
23	145	153	O	affecting
24	155	157	O	the
25	159	163	O	blood
26	165	167	O	and
27	168	168	O	/
28	169	170	O	or
29	172	174	O	the
30	176	179	O	side
31	181	187	O	effects
32	189	190	O	or
33	192	195	O	oral
34	197	209	U-UNK	antidiabetics
NULL

Sulfapyridine	DDI-DrugBank.d179.s38	NO_SECTION	NO_SETID	27
- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate
1	2	13	U-UNK	Methotrexate
2	16	18	O	e.g
3	20	20	O	,
4	22	27	O	XXXXXXXX
5	30	32	O	Use
6	34	35	O	of
7	37	48	U-UNK	methotrexate
8	50	53	O	with
9	55	67	U-UNK	sulfapyridine
10	69	71	O	may
11	73	80	O	increase
12	82	84	O	the
13	86	91	O	chance
14	93	94	O	of
15	96	99	O	side
16	101	107	O	effects
17	109	117	O	affecting
18	119	121	O	the
19	123	127	O	liver
20	129	131	O	and
21	132	132	O	/
22	133	134	O	or
23	136	138	O	the
24	140	143	O	side
25	145	151	O	effects
26	153	154	O	of
27	156	167	U-UNK	methotrexate
NULL

Sulfapyridine	DDI-DrugBank.d179.s39	NO_SECTION	NO_SETID	24
- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood
1	2	11	U-UNK	Methyldopa
2	14	16	O	e.g
3	18	18	O	,
4	20	26	O	XXXXXXXX
5	29	31	O	Use
6	33	34	O	of
7	36	45	U-UNK	methyldopa
8	47	50	O	with
9	52	64	U-UNK	sulfapyridine
10	66	68	O	may
11	70	77	O	increase
12	79	81	O	the
13	83	88	O	chance
14	90	91	O	of
15	93	96	O	side
16	98	104	O	effects
17	106	114	O	affecting
18	116	118	O	the
19	120	124	O	liver
20	126	128	O	and
21	129	129	O	/
22	130	131	O	or
23	133	135	O	the
24	137	141	O	blood
NULL

Sulfapyridine	DDI-DrugBank.d179.s40	NO_SECTION	NO_SETID	27
- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin
1	2	10	U-UNK	Phenytoin
2	13	15	O	e.g
3	17	17	O	,
4	19	26	O	XXXXXXXX
5	29	31	O	Use
6	33	34	O	of
7	36	44	U-UNK	phenytoin
8	46	49	O	with
9	51	63	U-UNK	sulfapyridine
10	65	67	O	may
11	69	76	O	increase
12	78	80	O	the
13	82	87	O	chance
14	89	90	O	of
15	92	95	O	side
16	97	103	O	effects
17	105	113	O	affecting
18	115	117	O	the
19	119	123	O	liver
20	125	127	O	and
21	128	128	O	/
22	129	130	O	or
23	132	134	O	the
24	136	139	O	side
25	141	147	O	effects
26	149	150	O	of
27	152	160	U-UNK	phenytoin
NULL

Tiagabine	DDI-DrugBank.d277.s0	NO_SECTION	NO_SETID	29
In evaluating the potential for interactions among co-administered antiepilepsy drugs (AEDs), whether or not an AED induces or does not induce metabolic enzymes is an important consideration.
1	0	1	O	In
2	3	12	O	evaluating
3	14	16	O	the
4	18	26	O	potential
5	28	30	O	for
6	32	43	O	interactions
7	45	49	O	among
8	51	52	O	co
9	54	65	O	administered
10	67	78	O	antiepilepsy
11	80	84	O	drugs
12	87	90	U-UNK	AEDs
13	92	92	O	,
14	94	100	O	whether
15	102	103	O	or
16	105	107	O	not
17	109	110	O	an
18	112	114	U-UNK	AED
19	116	122	O	induces
20	124	125	O	or
21	127	130	O	does
22	132	134	O	not
23	136	141	O	induce
24	143	151	O	metabolic
25	153	159	O	enzymes
26	161	162	O	is
27	164	165	O	an
28	167	175	O	important
29	177	189	O	consideration
NULL

Tiagabine	DDI-DrugBank.d277.s1	NO_SECTION	NO_SETID	12
Phenytoin, phenobarbital and carbamazepine are ge nerally classified as enzyme inducers;
1	0	8	U-UNK	Phenytoin
2	9	9	O	,
3	11	23	U-UNK	phenobarbital
4	25	27	O	and
5	29	41	U-UNK	carbamazepine
6	43	45	O	are
7	47	48	O	ge
8	50	56	O	nerally
9	58	67	O	classified
10	69	70	O	as
11	72	77	O	enzyme
12	79	86	O	inducers
NULL

Tiagabine	DDI-DrugBank.d277.s2	NO_SECTION	NO_SETID	5
valproate and gabapentin are not.
1	0	8	U-UNK	valproate
2	10	12	O	and
3	14	23	U-UNK	gabapentin
4	25	27	O	are
5	29	31	O	not
NULL

Tiagabine	DDI-DrugBank.d277.s3	NO_SECTION	NO_SETID	10
GABITRIL is considered to be a non-enzyme inducing AED.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	21	O	considered
4	23	24	O	to
5	26	27	O	be
6	29	29	O	a
7	31	33	O	non
8	35	40	O	enzyme
9	42	49	O	inducing
10	51	53	U-UNK	AED
NULL

Tiagabine	DDI-DrugBank.d277.s4	NO_SECTION	NO_SETID	20
The drug interaction data described in this section were obtained from studies involving either healthy subjects or patients with epilepsy.
1	0	2	O	The
2	4	7	O	drug
3	9	19	O	interaction
4	21	24	O	data
5	26	34	O	described
6	36	37	O	in
7	39	42	O	this
8	44	50	O	section
9	52	55	O	were
10	57	64	O	obtained
11	66	69	O	from
12	71	77	O	studies
13	79	87	O	involving
14	89	94	O	either
15	96	102	O	healthy
16	104	111	O	subjects
17	113	114	O	or
18	116	123	O	patients
19	125	128	O	with
20	130	137	O	epilepsy
NULL

Tiagabine	DDI-DrugBank.d277.s5	NO_SECTION	NO_SETID	27
Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.
1	0	6	O	Effects
2	8	9	O	of
3	11	18	O	XXXXXXXX
4	20	21	O	on
5	23	27	O	other
6	29	40	O	Antiepilepsy
7	42	46	O	Drugs
8	49	52	U-UNK	AEDs
9	55	55	O	:
10	57	65	U-UNK	Phenytoin
11	66	66	O	:
12	68	76	U-UNK	Tiagabine
13	78	80	O	had
14	82	83	O	no
15	85	90	O	effect
16	92	93	O	on
17	95	97	O	the
18	99	104	O	steady
19	106	110	O	state
20	112	117	O	plasma
21	119	132	O	concentrations
22	134	135	O	of
23	137	145	U-UNK	phenytoin
24	147	148	O	in
25	150	157	O	patients
26	159	162	O	with
27	164	171	O	epilepsy
NULL

Tiagabine	DDI-DrugBank.d277.s6	NO_SECTION	NO_SETID	22
Carbamazepine: Tiagabine had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy.
1	0	12	U-UNK	Carbamazepine
2	13	13	O	:
3	15	23	O	XXXXXXXX
4	25	27	O	had
5	29	30	O	no
6	32	37	O	effect
7	39	40	O	on
8	42	44	O	the
9	46	51	O	steady
10	53	57	O	state
11	59	64	O	plasma
12	66	79	O	concentrations
13	81	82	O	of
14	84	96	U-UNK	carbamazepine
15	98	99	O	or
16	101	103	O	its
17	105	111	O	epoxide
18	113	122	O	metabolite
19	124	125	O	in
20	127	134	O	patients
21	136	139	O	with
22	141	148	O	epilepsy
NULL

Tiagabine	DDI-DrugBank.d277.s7	NO_SECTION	NO_SETID	14
Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.
1	0	8	U-UNK	Valproate
2	9	9	O	:
3	11	19	O	XXXXXXXX
4	21	26	O	causes
5	28	28	O	a
6	30	35	O	slight
7	37	44	O	decrease
8	47	51	O	about
9	53	55	O	10%
10	58	59	O	in
11	61	66	O	steady
12	68	72	O	state
13	74	82	U-KIN	valproate
14	84	97	O	concentrations
NULL

Tiagabine	DDI-DrugBank.d277.s8	NO_SECTION	NO_SETID	22
Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone.
1	0	12	U-UNK	Phenobarbital
2	14	15	O	or
3	17	25	U-UNK	Primidone
4	27	27	O	:
5	29	30	O	No
6	32	37	O	formal
7	39	53	O	pharmacokinetic
8	55	61	O	studies
9	63	66	O	have
10	68	71	O	been
11	73	81	O	performed
12	83	91	O	examining
13	93	95	O	the
14	97	104	O	addition
15	106	107	O	of
16	109	117	O	XXXXXXXX
17	119	120	O	to
18	122	129	O	regimens
19	131	140	O	containing
20	142	154	U-UNK	phenobarbital
21	156	157	O	or
22	159	167	U-UNK	primidone
NULL

Tiagabine	DDI-DrugBank.d277.s9	NO_SECTION	NO_SETID	28
The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or primidone concentrations when compared to placebo.
1	0	2	O	The
2	4	11	O	addition
3	13	14	O	of
4	16	24	O	XXXXXXXX
5	26	27	O	in
6	29	29	O	a
7	31	37	O	limited
8	39	44	O	number
9	46	47	O	of
10	49	56	O	patients
11	58	59	O	in
12	61	65	O	three
13	67	70	O	well
14	72	81	O	controlled
15	83	89	O	studies
16	91	96	O	caused
17	98	99	O	no
18	101	110	O	systematic
19	112	118	O	changes
20	120	121	O	in
21	123	135	U-UNK	phenobarbital
22	137	138	O	or
23	140	148	U-UNK	primidone
24	150	163	O	concentrations
25	165	168	O	when
26	170	177	O	compared
27	179	180	O	to
28	182	188	O	placebo
NULL

Tiagabine	DDI-DrugBank.d277.s10	NO_SECTION	NO_SETID	32
Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.
1	0	6	O	Effects
2	8	9	O	of
3	11	15	O	other
4	17	28	O	Antiepilepsy
5	30	34	O	Drugs
6	37	40	U-UNK	AEDs
7	43	44	O	on
8	46	53	O	XXXXXXXX
9	55	55	O	:
10	57	69	U-UNK	Carbamazepine
11	70	70	O	:
12	72	81	O	Population
13	83	97	O	pharmacokinetic
14	99	106	O	analyses
15	108	115	O	indicate
16	117	120	O	that
17	122	130	U-UNK	tiagabine
18	132	140	O	clearance
19	142	143	O	is
20	145	147	O	60%
21	149	155	O	greater
22	157	158	O	in
23	160	167	O	patients
24	169	174	O	taking
25	176	188	U-UNK	carbamazepine
26	190	193	O	with
27	195	196	O	or
28	198	204	O	without
29	206	210	O	other
30	212	217	O	enzyme
31	220	227	O	inducing
32	229	232	U-UNK	AEDs
NULL

Tiagabine	DDI-DrugBank.d277.s11	NO_SECTION	NO_SETID	23
Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.
1	0	8	U-UNK	Phenytoin
2	9	9	O	:
3	11	20	O	Population
4	22	36	O	pharmacokinetic
5	38	45	O	analyses
6	47	54	O	indicate
7	56	59	O	that
8	61	69	O	XXXXXXXX
9	71	79	O	clearance
10	81	82	O	is
11	84	86	O	60%
12	88	94	O	greater
13	96	97	O	in
14	99	106	O	patients
15	108	113	O	taking
16	115	123	U-KIN	phenytoin
17	125	128	O	with
18	130	131	O	or
19	133	139	O	without
20	141	145	O	other
21	147	152	O	enzyme
22	155	162	O	inducing
23	164	167	U-UNK	AEDs
NULL

Tiagabine	DDI-DrugBank.d277.s12	NO_SECTION	NO_SETID	25
Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
1	0	12	U-UNK	Phenobarbital
2	15	23	U-UNK	Primidone
3	25	25	O	:
4	27	36	O	Population
5	38	52	O	pharmacokinetic
6	54	61	O	analyses
7	63	70	O	indicate
8	72	75	O	that
9	77	85	O	XXXXXXXX
10	87	95	O	clearance
11	97	98	O	is
12	100	102	O	60%
13	104	110	O	greater
14	112	113	O	in
15	115	122	O	patients
16	124	129	O	taking
17	131	143	U-KIN	phenobarbital
18	146	154	U-KIN	primidone
19	157	160	O	with
20	162	163	O	or
21	165	171	O	without
22	173	177	O	other
23	179	184	O	enzyme
24	186	193	O	inducing
25	195	198	U-UNK	AEDs
NULL

Tiagabine	DDI-DrugBank.d277.s13	NO_SECTION	NO_SETID	44
Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.
1	0	8	U-UNK	Valproate
2	9	9	O	:
3	11	13	O	The
4	15	22	O	addition
5	24	25	O	of
6	27	35	O	XXXXXXXX
7	37	38	O	to
8	40	47	O	patients
9	49	54	O	taking
10	56	64	U-UNK	valproate
11	66	76	O	chronically
12	78	80	O	had
13	82	83	O	no
14	85	90	O	effect
15	92	93	O	on
16	95	103	O	XXXXXXXX
17	105	120	O	pharmacokinetics
18	121	121	O	,
19	123	125	O	but
20	127	135	U-KIN	valproate
21	137	149	O	significantly
22	151	159	O	decreased
23	161	169	O	XXXXXXXX
24	171	177	O	binding
25	179	180	O	in
26	182	186	O	vitro
27	188	191	O	from
28	193	196	O	96.3
29	198	199	O	to
30	201	205	O	94.8%
31	206	206	O	,
32	208	212	O	which
33	214	221	O	resulted
34	223	224	O	in
35	226	227	O	an
36	229	236	O	increase
37	238	239	O	of
38	241	253	O	approximately
39	255	257	O	40%
40	259	260	O	in
41	262	264	O	the
42	266	269	O	free
43	271	279	O	XXXXXXXX
44	281	293	O	concentration
NULL

Tiagabine	DDI-DrugBank.d277.s14	NO_SECTION	NO_SETID	10
The clinical relevance of this in vitro finding is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	21	O	relevance
4	23	24	O	of
5	26	29	O	this
6	31	32	O	in
7	34	38	O	vitro
8	40	46	O	finding
9	48	49	O	is
10	51	57	O	unknown
NULL

Tiagabine	DDI-DrugBank.d277.s15	NO_SECTION	NO_SETID	28
Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.
1	0	10	O	Interaction
2	12	13	O	of
3	15	22	O	XXXXXXXX
4	24	27	O	with
5	29	33	O	Other
6	35	39	O	Drugs
7	41	41	O	:
8	43	52	U-UNK	Cimetidine
9	54	54	O	:
10	56	57	O	Co
11	59	72	O	administration
12	74	75	O	of
13	77	86	U-UNK	cimetidine
14	89	91	O	800
15	93	94	O	mg
16	95	95	O	/
17	96	98	O	day
18	101	102	O	to
19	104	111	O	patients
20	113	118	O	taking
21	120	128	U-UNK	tiagabine
22	130	140	O	chronically
23	142	144	O	had
24	146	147	O	no
25	149	154	O	effect
26	156	157	O	on
27	159	167	U-UNK	tiagabine
28	169	184	O	pharmacokinetics
NULL

Tiagabine	DDI-DrugBank.d277.s16	NO_SECTION	NO_SETID	19
Theophylline: A single 10 mg dose of tiagabine did not affect the pharmacokinetics of theophylline at steady state.
1	0	11	U-UNK	Theophylline
2	12	12	O	:
3	14	14	O	A
4	16	21	O	single
5	23	24	O	10
6	26	27	O	mg
7	29	32	O	dose
8	34	35	O	of
9	37	45	O	XXXXXXXX
10	47	49	O	did
11	51	53	O	not
12	55	60	O	affect
13	62	64	O	the
14	66	81	O	pharmacokinetics
15	83	84	O	of
16	86	97	U-UNK	theophylline
17	99	100	O	at
18	102	107	O	steady
19	109	113	O	state
NULL

Tiagabine	DDI-DrugBank.d277.s17	NO_SECTION	NO_SETID	28
Warfarin: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of tiagabine given as a single dose.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	11	O	No
4	13	23	O	significant
5	25	35	O	differences
6	37	40	O	were
7	42	49	O	observed
8	51	52	O	in
9	54	56	O	the
10	58	63	O	steady
11	65	69	O	state
12	71	86	O	pharmacokinetics
13	88	89	O	of
14	91	91	B-UNK	R
15	93	100	L-UNK	warfarin
16	102	103	O	or
17	105	105	B-UNK	S
18	107	114	L-UNK	warfarin
19	116	119	O	with
20	121	123	O	the
21	125	132	O	addition
22	134	135	O	of
23	137	145	O	XXXXXXXX
24	147	151	O	given
25	153	154	O	as
26	156	156	O	a
27	158	163	O	single
28	165	168	O	dose
NULL

Tiagabine	DDI-DrugBank.d277.s18	NO_SECTION	NO_SETID	7
Prothrombin times were not affected by tiagabine.
1	0	10	O	Prothrombin
2	12	16	O	times
3	18	21	O	were
4	23	25	O	not
5	27	34	O	affected
6	36	37	O	by
7	39	47	O	XXXXXXXX
NULL

Tiagabine	DDI-DrugBank.d277.s19	NO_SECTION	NO_SETID	24
Digoxin: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	19	O	Concomitant
4	21	34	O	administration
5	36	37	O	of
6	39	47	O	XXXXXXXX
7	49	51	O	did
8	53	55	O	not
9	57	62	O	affect
10	64	66	O	the
11	68	73	O	steady
12	75	79	O	state
13	81	96	O	pharmacokinetics
14	98	99	O	of
15	101	107	U-UNK	digoxin
16	109	110	O	or
17	112	114	O	the
18	116	119	O	mean
19	121	125	O	daily
20	127	132	O	trough
21	134	138	O	serum
22	140	144	O	level
23	146	147	O	of
24	149	155	U-UNK	digoxin
NULL

Tiagabine	DDI-DrugBank.d277.s20	NO_SECTION	NO_SETID	27
Ethanol or Triazolam: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and tiagabine (10 mg) when given together as a single dose.
1	0	6	U-UNK	Ethanol
2	8	9	O	or
3	11	19	U-UNK	Triazolam
4	20	20	O	:
5	22	23	O	No
6	25	35	O	significant
7	37	47	O	differences
8	49	52	O	were
9	54	61	O	observed
10	63	64	O	in
11	66	68	O	the
12	70	85	O	pharmacokinetics
13	87	88	O	of
14	90	98	U-UNK	triazolam
15	101	105	O	0.125
16	107	108	O	mg
17	111	113	O	and
18	115	123	O	XXXXXXXX
19	126	127	O	10
20	129	130	O	mg
21	133	136	O	when
22	138	142	O	given
23	144	151	O	together
24	153	154	O	as
25	156	156	O	a
26	158	163	O	single
27	165	168	O	dose
NULL

Tiagabine	DDI-DrugBank.d277.s21	NO_SECTION	NO_SETID	13
The pharmacokinetics of ethanol were not affected by multiple-dose administration of tiagabine.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	30	U-UNK	ethanol
5	32	35	O	were
6	37	39	O	not
7	41	48	O	affected
8	50	51	O	by
9	53	60	O	multiple
10	62	65	O	dose
11	67	80	O	administration
12	82	83	O	of
13	85	93	O	XXXXXXXX
NULL

Tiagabine	DDI-DrugBank.d277.s22	NO_SECTION	NO_SETID	16
Tiagabine has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or alcohol.
1	0	8	O	XXXXXXXX
2	10	12	O	has
3	14	18	O	shown
4	20	21	O	no
5	23	32	O	clinically
6	34	42	O	important
7	44	55	O	potentiation
8	57	58	O	of
9	60	62	O	the
10	64	78	O	pharmacodynamic
11	80	86	O	effects
12	88	89	O	of
13	91	96	O	triazo
14	98	100	O	lam
15	102	103	O	or
16	105	111	U-UNK	alcohol
NULL

Tiagabine	DDI-DrugBank.d277.s23	NO_SECTION	NO_SETID	26
Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	22	O	possible
5	24	31	O	additive
6	33	39	O	effects
7	41	42	O	of
8	44	48	O	drugs
9	50	53	O	that
10	55	57	O	may
11	59	65	O	depress
12	67	69	O	the
13	71	77	O	nervous
14	79	84	O	system
15	85	85	O	,
16	87	93	U-DYN	ethanol
17	95	96	O	or
18	98	106	U-DYN	triazolam
19	108	113	O	should
20	115	116	O	be
21	118	121	O	used
22	123	132	O	cautiously
23	134	135	O	in
24	137	147	O	combination
25	149	152	O	with
26	154	162	O	XXXXXXXX
NULL

Tiagabine	DDI-DrugBank.d277.s24	NO_SECTION	NO_SETID	27
Oral Contraceptives: Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.
1	0	3	O	Oral
2	5	18	U-UNK	Contraceptives
3	19	19	O	:
4	21	28	O	Multiple
5	30	33	O	dose
6	35	48	O	administration
7	50	51	O	of
8	53	61	O	XXXXXXXX
9	64	64	O	8
10	66	67	O	mg
11	68	68	O	/
12	69	71	O	day
13	73	83	O	monotherapy
14	86	88	O	did
15	90	92	O	not
16	94	98	O	alter
17	100	102	O	the
18	104	119	O	pharmacokinetics
19	121	122	O	of
20	124	127	O	oral
21	129	142	U-UNK	contraceptives
22	144	145	O	in
23	147	153	O	healthy
24	155	159	O	women
25	161	162	O	of
26	164	175	O	childbearing
27	177	179	O	age
NULL

Tiagabine	DDI-DrugBank.d277.s25	NO_SECTION	NO_SETID	15
Antipyrine : Antipyrine pharmacokinetics were not significantly different before and after tiagabine multiple-dose regimens.
1	0	9	U-UNK	Antipyrine
2	11	11	O	:
3	13	22	U-UNK	Antipyrine
4	24	39	O	pharmacokinetics
5	41	44	O	were
6	46	48	O	not
7	50	62	O	significantly
8	64	72	O	different
9	74	79	O	before
10	81	83	O	and
11	85	89	O	after
12	91	99	O	XXXXXXXX
13	101	108	O	multiple
14	110	113	O	dose
15	115	122	O	regimens
NULL

Tiagabine	DDI-DrugBank.d277.s26	NO_SECTION	NO_SETID	22
This indicates that tiagabine does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of antipyrine.
1	0	3	O	This
2	5	13	O	indicates
3	15	18	O	that
4	20	28	O	XXXXXXXX
5	30	33	O	does
6	35	37	O	not
7	39	43	O	cause
8	45	53	O	induction
9	55	56	O	or
10	58	67	O	inhibition
11	69	70	O	of
12	72	74	O	the
13	76	82	O	hepatic
14	84	93	O	microsomal
15	95	100	O	enzyme
16	102	108	O	systems
17	110	120	O	responsible
18	122	124	O	for
19	126	128	O	the
20	130	139	O	metabolism
21	141	142	O	of
22	144	153	U-UNK	antipyrine
NULL

Tiagabine	DDI-DrugBank.d277.s27	NO_SECTION	NO_SETID	35
Interaction of GABITRIL with Highly Protein Bound Drugs: In vitro data showed that tiagabine is 96% bound to human plasma protein and therefore has the potential to interact with other highly protein bound compounds.
1	0	10	O	Interaction
2	12	13	O	of
3	15	22	O	XXXXXXXX
4	24	27	O	with
5	29	34	O	Highly
6	36	42	O	Protein
7	44	48	O	Bound
8	50	54	O	Drugs
9	55	55	O	:
10	57	58	O	In
11	60	64	O	vitro
12	66	69	O	data
13	71	76	O	showed
14	78	81	O	that
15	83	91	U-UNK	tiagabine
16	93	94	O	is
17	96	98	O	96%
18	100	104	O	bound
19	106	107	O	to
20	109	113	O	human
21	115	120	O	plasma
22	122	128	O	protein
23	130	132	O	and
24	134	142	O	therefore
25	144	146	O	has
26	148	150	O	the
27	152	160	O	potential
28	162	163	O	to
29	165	172	O	interact
30	174	177	O	with
31	179	183	O	other
32	185	190	O	highly
33	192	198	O	protein
34	200	204	O	bound
35	206	214	O	compounds
NULL

Tiagabine	DDI-DrugBank.d277.s28	NO_SECTION	NO_SETID	17
Such an interaction can potentially lead to higher free fractions of either tiagabine or the competing drug.
1	0	3	O	Such
2	5	6	O	an
3	8	18	O	interaction
4	20	22	O	can
5	24	34	O	potentially
6	36	39	O	lead
7	41	42	O	to
8	44	49	O	higher
9	51	54	O	free
10	56	64	O	fractions
11	66	67	O	of
12	69	74	O	either
13	76	84	O	XXXXXXXX
14	86	87	O	or
15	89	91	O	the
16	93	101	O	competing
17	103	106	O	drug
NULL

Valdecoxib	DDI-DrugBank.d328.s0	NO_SECTION	NO_SETID	18
The drug interaction studies with valdecoxib were performed both with valdecoxib and a rapidly hydrolyzed intravenous prodrug form.
1	0	2	O	The
2	4	7	O	drug
3	9	19	O	interaction
4	21	27	O	studies
5	29	32	O	with
6	34	43	O	XXXXXXXX
7	45	48	O	were
8	50	58	O	performed
9	60	63	O	both
10	65	68	O	with
11	70	79	O	XXXXXXXX
12	81	83	O	and
13	85	85	O	a
14	87	93	O	rapidly
15	95	104	O	hydrolyzed
16	106	116	O	intravenous
17	118	124	O	prodrug
18	126	129	O	form
NULL

Valdecoxib	DDI-DrugBank.d328.s1	NO_SECTION	NO_SETID	24
The results from trials using the intravenous prodrug are reported in this section as they relate to the role of valdecoxib in drug interactions.
1	0	2	O	The
2	4	10	O	results
3	12	15	O	from
4	17	22	O	trials
5	24	28	O	using
6	30	32	O	the
7	34	44	O	intravenous
8	46	52	O	prodrug
9	54	56	O	are
10	58	65	O	reported
11	67	68	O	in
12	70	73	O	this
13	75	81	O	section
14	83	84	O	as
15	86	89	O	they
16	91	96	O	relate
17	98	99	O	to
18	101	103	O	the
19	105	108	O	role
20	110	111	O	of
21	113	122	O	XXXXXXXX
22	124	125	O	in
23	127	130	O	drug
24	132	143	O	interactions
NULL

Valdecoxib	DDI-DrugBank.d328.s2	NO_SECTION	NO_SETID	24
General: In humans, valdecoxib metabolism is predominantly mediated via CYP 3A4 and 2C9 with glucuronidation being a further (20%) route of metabolism.
1	0	6	O	General
2	7	7	O	:
3	9	10	O	In
4	12	17	O	humans
5	18	18	O	,
6	20	29	O	XXXXXXXX
7	31	40	O	metabolism
8	42	43	O	is
9	45	57	O	predominantly
10	59	66	O	mediated
11	68	70	O	via
12	72	74	O	CYP
13	76	78	O	3A4
14	80	82	O	and
15	84	86	O	2C9
16	88	91	O	with
17	93	107	O	glucuronidation
18	109	113	O	being
19	115	115	O	a
20	117	123	O	further
21	126	128	O	20%
22	131	135	O	route
23	137	138	O	of
24	140	149	O	metabolism
NULL

Valdecoxib	DDI-DrugBank.d328.s3	NO_SECTION	NO_SETID	61
In vitro studies indicate that valdecoxib is a moderate inhibitor of CYP 2C19 (IC50 = 6  g/mL or 19  M) and 2C9 (IC50 = 13  g/mL or 41  M), and a weak inhibitor of CYP 2D6 (IC50 = 31  g/mL or 100  M) and 3A4 (IC50 = 44  g/mL or 141  M )..
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	24	O	indicate
5	26	29	O	that
6	31	40	O	XXXXXXXX
7	42	43	O	is
8	45	45	O	a
9	47	54	O	moderate
10	56	64	O	inhibitor
11	66	67	O	of
12	69	71	O	CYP
13	73	76	O	2C19
14	79	82	O	IC50
15	84	84	O	=
16	86	86	O	6
17	89	89	O	g
18	90	90	O	/
19	91	92	O	mL
20	94	95	O	or
21	97	98	O	19
22	101	101	O	M
23	104	106	O	and
24	108	110	O	2C9
25	113	116	O	IC50
26	118	118	O	=
27	120	121	O	13
28	124	124	O	g
29	125	125	O	/
30	126	127	O	mL
31	129	130	O	or
32	132	133	O	41
33	136	136	O	M
34	138	138	O	,
35	140	142	O	and
36	144	144	O	a
37	146	149	O	weak
38	151	159	O	inhibitor
39	161	162	O	of
40	164	166	O	CYP
41	168	170	O	2D6
42	173	176	O	IC50
43	178	178	O	=
44	180	181	O	31
45	184	184	O	g
46	185	185	O	/
47	186	187	O	mL
48	189	190	O	or
49	192	194	O	100
50	197	197	O	M
51	200	202	O	and
52	204	206	O	3A4
53	209	212	O	IC50
54	214	214	O	=
55	216	217	O	44
56	220	220	O	g
57	221	221	O	/
58	222	223	O	mL
59	225	226	O	or
60	228	230	O	141
61	233	233	O	M
NULL

Valdecoxib	DDI-DrugBank.d328.s4	NO_SECTION	NO_SETID	23
Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.
1	0	6	O	XXXXXXXX
2	7	7	O	:
3	9	19	O	Concomitant
4	21	34	O	administration
5	36	37	O	of
6	39	45	O	XXXXXXXX
7	47	50	O	with
8	52	61	U-DYN	valdecoxib
9	63	65	O	may
10	67	72	O	result
11	74	75	O	in
12	77	78	O	an
13	80	88	O	increased
14	90	93	O	risk
15	95	96	O	of
16	98	99	O	GI
17	101	110	O	ulceration
18	112	114	O	and
19	116	128	O	complications
20	130	137	O	compared
21	139	140	O	to
22	142	151	U-UNK	valdecoxib
23	153	157	O	alone
NULL

Valdecoxib	DDI-DrugBank.d328.s5	NO_SECTION	NO_SETID	18
Because of its lack of anti-platelet effect valdecoxib is not a substitute for aspirin for cardiovascular prophylaxis.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	its
4	15	18	O	lack
5	20	21	O	of
6	23	26	O	anti
7	28	35	O	platelet
8	37	42	O	effect
9	44	53	U-UNK	valdecoxib
10	55	56	O	is
11	58	60	O	not
12	62	62	O	a
13	64	73	O	substitute
14	75	77	O	for
15	79	85	O	XXXXXXXX
16	87	89	O	for
17	91	104	O	cardiovascular
18	106	116	O	prophylaxis
NULL

Valdecoxib	DDI-DrugBank.d328.s6	NO_SECTION	NO_SETID	40
In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9), valdecoxib had no effect on in vitro aspirin-mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	parallel
4	14	18	O	group
5	20	23	O	drug
6	25	35	O	interaction
7	37	41	O	study
8	43	51	O	comparing
9	53	55	O	the
10	57	67	O	intravenous
11	69	75	O	prodrug
12	77	80	O	form
13	82	83	O	of
14	85	94	U-UNK	valdecoxib
15	96	97	O	at
16	99	100	O	40
17	102	103	O	mg
18	105	107	O	BID
19	110	113	O	n=10
20	116	117	O	vs
21	119	125	O	placebo
22	128	130	O	n=9
23	132	132	O	,
24	134	143	U-UNK	valdecoxib
25	145	147	O	had
26	149	150	O	no
27	152	157	O	effect
28	159	160	O	on
29	162	163	O	in
30	165	169	O	vitro
31	171	177	O	XXXXXXXX
32	179	186	O	mediated
33	188	197	O	inhibition
34	199	200	O	of
35	202	213	O	arachidonate
36	216	217	O	or
37	219	226	O	collagen
38	228	237	O	stimulated
39	239	246	O	platelet
40	248	258	O	aggregation
NULL

Valdecoxib	DDI-DrugBank.d328.s7	NO_SECTION	NO_SETID	21
Methotrexate: Valdecoxib 10 mg BID did not show a significant effect on the plasma exposure or renal clearance of methotrexate.
1	0	11	U-UNK	Methotrexate
2	12	12	O	:
3	14	23	O	XXXXXXXX
4	25	26	O	10
5	28	29	O	mg
6	31	33	O	BID
7	35	37	O	did
8	39	41	O	not
9	43	46	O	show
10	48	48	O	a
11	50	60	O	significant
12	62	67	O	effect
13	69	70	O	on
14	72	74	O	the
15	76	81	O	plasma
16	83	90	O	exposure
17	92	93	O	or
18	95	99	O	renal
19	101	109	O	clearance
20	111	112	O	of
21	114	125	U-UNK	methotrexate
NULL

Valdecoxib	DDI-DrugBank.d328.s8	NO_SECTION	NO_SETID	13
ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.
1	0	2	U-UNK	ACE
2	4	21	O	inhibitors:Reports
3	23	29	O	suggest
4	31	34	O	that
5	36	41	U-UNK	NSAIDs
6	43	45	O	may
7	47	54	O	diminish
8	56	58	O	the
9	60	75	O	antihypertensive
10	77	82	O	effect
11	84	85	O	of
12	87	89	B-UNK	ACE
13	91	100	L-UNK	inhibitors
NULL

Valdecoxib	DDI-DrugBank.d328.s9	NO_SECTION	NO_SETID	14
This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.
1	0	3	O	This
2	5	15	O	interaction
3	17	22	O	should
4	24	25	O	be
5	27	31	O	given
6	33	45	O	consideration
7	47	48	O	in
8	50	57	O	patients
9	59	64	O	taking
10	66	71	O	XXXXXXXX
11	73	85	O	concomitantly
12	87	90	O	with
13	92	94	B-DYN	ACE
14	96	105	L-DYN	inhibitors
NULL

Valdecoxib	DDI-DrugBank.d328.s10	NO_SECTION	NO_SETID	28
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
1	0	9	U-UNK	Furosemide
2	10	10	O	:
3	12	19	O	Clinical
4	21	27	O	studies
5	28	28	O	,
6	30	31	O	as
7	33	36	O	well
8	38	39	O	as
9	41	44	O	post
10	46	54	O	marketing
11	56	67	O	observations
12	68	68	O	,
13	70	73	O	have
14	75	79	O	shown
15	81	84	O	that
16	86	91	U-UNK	NSAIDs
17	93	95	O	can
18	97	102	O	reduce
19	104	106	O	the
20	108	118	O	natriuretic
21	120	125	O	effect
22	127	128	O	of
23	130	139	U-UNK	furosemide
24	141	143	O	and
25	145	153	U-UNK	thiazides
26	155	156	O	in
27	158	161	O	some
28	163	170	O	patients
NULL

Valdecoxib	DDI-DrugBank.d328.s11	NO_SECTION	NO_SETID	11
This response has been attributed to inhibition of renal prostaglandin synthesis.
1	0	3	O	This
2	5	12	O	response
3	14	16	O	has
4	18	21	O	been
5	23	32	O	attributed
6	34	35	O	to
7	37	46	O	inhibition
8	48	49	O	of
9	51	55	O	renal
10	57	69	O	prostaglandin
11	71	79	O	synthesis
NULL

Valdecoxib	DDI-DrugBank.d328.s12	NO_SECTION	NO_SETID	38
Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).
1	0	14	U-UNK	Anticonvulsants
2	17	25	U-UNK	Phenytoin
3	27	27	O	:
4	29	34	O	Steady
5	36	40	O	state
6	42	47	O	plasma
7	49	56	O	exposure
8	59	61	O	AUC
9	64	65	O	of
10	67	76	O	XXXXXXXX
11	79	80	O	40
12	82	83	O	mg
13	85	87	O	BID
14	89	91	O	for
15	93	94	O	12
16	96	99	O	days
17	102	104	O	was
18	106	114	O	decreased
19	116	117	O	by
20	119	121	O	27%
21	123	126	O	when
22	128	129	O	co
23	131	142	O	administered
24	144	147	O	with
25	149	156	O	multiple
26	158	162	O	doses
27	165	167	O	300
28	169	170	O	mg
29	172	173	O	QD
30	175	177	O	for
31	179	180	O	12
32	182	185	O	days
33	188	189	O	of
34	191	199	U-KIN	phenytoin
35	202	202	O	a
36	204	206	O	CYP
37	208	210	O	3A4
38	212	218	O	inducer
NULL

Valdecoxib	DDI-DrugBank.d328.s13	NO_SECTION	NO_SETID	17
Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.
1	0	7	O	Patients
2	9	15	O	already
3	17	26	O	stabilized
4	28	29	O	on
5	31	40	O	XXXXXXXX
6	42	47	O	should
7	49	50	O	be
8	52	58	O	closely
9	60	68	O	monitored
10	70	72	O	for
11	74	77	O	loss
12	79	80	O	of
13	82	88	O	symptom
14	90	96	O	control
15	98	101	O	with
16	103	111	U-DYN	phenytoin
17	113	128	O	coadministration
NULL

Valdecoxib	DDI-DrugBank.d328.s14	NO_SECTION	NO_SETID	20
Valdecoxib did not have a statistically significant effect on the pharmacokinetics of phenytoin (a CYP 2C9 and CYP 2C19 substrate).
1	0	9	O	XXXXXXXX
2	11	13	O	did
3	15	17	O	not
4	19	22	O	have
5	24	24	O	a
6	26	38	O	statistically
7	40	50	O	significant
8	52	57	O	effect
9	59	60	O	on
10	62	64	O	the
11	66	81	O	pharmacokinetics
12	83	84	O	of
13	86	94	U-UNK	phenytoin
14	97	97	O	a
15	99	101	O	CYP
16	103	105	O	2C9
17	107	109	O	and
18	111	113	O	CYP
19	115	118	O	2C19
20	120	128	O	substrate
NULL

Valdecoxib	DDI-DrugBank.d328.s15	NO_SECTION	NO_SETID	10
Drug interaction studies with other anticonvulsants have not been conducted.
1	0	3	O	Drug
2	5	15	O	interaction
3	17	23	O	studies
4	25	28	O	with
5	30	34	O	other
6	36	50	U-UNK	anticonvulsants
7	52	55	O	have
8	57	59	O	not
9	61	64	O	been
10	66	74	O	conducted
NULL

Valdecoxib	DDI-DrugBank.d328.s16	NO_SECTION	NO_SETID	19
Routine monitoring should be performed when therapy with BEXTRA is either initiated or discontinued in patients on anticonvulsant therapy.
1	0	6	O	Routine
2	8	17	O	monitoring
3	19	24	O	should
4	26	27	O	be
5	29	37	O	performed
6	39	42	O	when
7	44	50	O	therapy
8	52	55	O	with
9	57	62	O	XXXXXXXX
10	64	65	O	is
11	67	72	O	either
12	74	82	O	initiated
13	84	85	O	or
14	87	98	O	discontinued
15	100	101	O	in
16	103	110	O	patients
17	112	113	O	on
18	115	128	O	anticonvulsant
19	130	136	O	therapy
NULL

Valdecoxib	DDI-DrugBank.d328.s17	NO_SECTION	NO_SETID	16
Dextromethorphan: Dextromethorphan is primarily metabolized by CYP 2D6 and to a lesser extent by 3A4.
1	0	15	U-UNK	Dextromethorphan
2	16	16	O	:
3	18	33	U-UNK	Dextromethorphan
4	35	36	O	is
5	38	46	O	primarily
6	48	58	O	metabolized
7	60	61	O	by
8	63	65	O	CYP
9	67	69	O	2D6
10	71	73	O	and
11	75	76	O	to
12	78	78	O	a
13	80	85	O	lesser
14	87	92	O	extent
15	94	95	O	by
16	97	99	O	3A4
NULL

Valdecoxib	DDI-DrugBank.d328.s18	NO_SECTION	NO_SETID	32
Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.
1	0	15	O	Coadministration
2	17	20	O	with
3	22	31	O	XXXXXXXX
4	34	35	O	40
5	37	38	O	mg
6	40	42	O	BID
7	44	46	O	for
8	48	48	O	7
9	50	53	O	days
10	56	63	O	resulted
11	65	66	O	in
12	68	68	O	a
13	70	80	O	significant
14	82	89	O	increase
15	91	92	O	in
16	94	109	U-KIN	dextromethorphan
17	111	116	O	plasma
18	118	123	O	levels
19	125	134	O	suggesting
20	136	139	O	that
21	140	140	O	,
22	142	143	O	at
23	145	149	O	these
24	151	155	O	doses
25	156	156	O	,
26	158	167	O	XXXXXXXX
27	169	170	O	is
28	172	172	O	a
29	174	177	O	weak
30	179	187	O	inhibitor
31	189	190	O	of
32	192	194	O	2D6
NULL

Valdecoxib	DDI-DrugBank.d328.s19	NO_SECTION	NO_SETID	33
Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.
1	0	3	O	Even
2	5	6	O	so
3	8	23	U-KIN	dextromethorphan
4	25	30	O	plasma
5	32	45	O	concentrations
6	47	48	O	in
7	50	52	O	the
8	54	61	O	presence
9	63	64	O	of
10	66	69	O	high
11	71	75	O	doses
12	77	78	O	of
13	80	89	O	XXXXXXXX
14	91	94	O	were
15	96	101	O	almost
16	103	103	O	5
17	105	108	O	fold
18	110	114	O	lower
19	116	119	O	than
20	121	125	O	those
21	127	130	O	seen
22	132	133	O	in
23	135	137	O	CYP
24	139	141	O	2D6
25	143	146	O	poor
26	148	159	O	metabolizers
27	161	170	O	suggesting
28	172	175	O	that
29	177	180	O	dose
30	182	191	O	adjustment
31	193	194	O	is
32	196	198	O	not
33	200	208	O	necessary
NULL

Valdecoxib	DDI-DrugBank.d328.s20	NO_SECTION	NO_SETID	31
Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
1	0	6	U-UNK	Lithium
2	7	7	O	:
3	9	18	O	XXXXXXXX
4	20	21	O	40
5	23	24	O	mg
6	26	28	O	BID
7	30	32	O	for
8	34	34	O	7
9	36	39	O	days
10	41	48	O	produced
11	50	60	O	significant
12	62	70	O	decreases
13	72	73	O	in
14	75	81	U-KIN	lithium
15	83	87	O	serum
16	89	97	O	clearance
17	100	102	O	25%
18	105	107	O	and
19	109	113	O	renal
20	115	123	O	clearance
21	126	128	O	30%
22	131	134	O	with
23	136	136	O	a
24	138	140	O	34%
25	142	147	O	higher
26	149	153	O	serum
27	155	162	O	exposure
28	164	171	O	compared
29	173	174	O	to
30	176	182	U-UNK	lithium
31	184	188	O	alone
NULL

Valdecoxib	DDI-DrugBank.d328.s21	NO_SECTION	NO_SETID	18
Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.
1	0	6	U-UNK	Lithium
2	8	12	O	serum
3	14	27	O	concentrations
4	29	34	O	should
5	36	37	O	be
6	39	47	O	monitored
7	49	55	O	closely
8	57	60	O	when
9	62	71	O	initiating
10	73	74	O	or
11	76	83	O	changing
12	85	91	O	therapy
13	93	96	O	with
14	98	103	O	XXXXXXXX
15	105	106	O	in
16	108	115	O	patients
17	117	125	O	receiving
18	127	133	U-DYN	lithium
NULL

Valdecoxib	DDI-DrugBank.d328.s22	NO_SECTION	NO_SETID	14
Lithium carbonate (450 mg BID for 7 days) had no effect on valdecoxib pharmacokinetics.
1	0	6	B-UNK	Lithium
2	8	16	L-UNK	carbonate
3	19	21	O	450
4	23	24	O	mg
5	26	28	O	BID
6	30	32	O	for
7	34	34	O	7
8	36	39	O	days
9	42	44	O	had
10	46	47	O	no
11	49	54	O	effect
12	56	57	O	on
13	59	68	O	XXXXXXXX
14	70	85	O	pharmacokinetics
NULL

Valdecoxib	DDI-DrugBank.d328.s23	NO_SECTION	NO_SETID	32
Warfarin: The effect of valdecoxib on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	12	O	The
4	14	19	O	effect
5	21	22	O	of
6	24	33	U-UNK	valdecoxib
7	35	36	O	on
8	38	40	O	the
9	42	54	O	anticoagulant
10	56	61	O	effect
11	63	64	O	of
12	66	73	U-UNK	warfarin
13	76	76	O	1
14	80	80	O	8
15	82	83	O	mg
16	84	84	O	/
17	85	87	O	day
18	90	92	O	was
19	94	100	O	studied
20	102	103	O	in
21	105	111	O	healthy
22	113	120	O	subjects
23	122	123	O	by
24	125	140	O	coadministration
25	142	143	O	of
26	145	150	O	XXXXXXXX
27	152	153	O	40
28	155	156	O	mg
29	158	160	O	BID
30	162	164	O	for
31	166	166	O	7
32	168	171	O	days
NULL

Valdecoxib	DDI-DrugBank.d328.s24	NO_SECTION	NO_SETID	34
Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
1	0	9	O	XXXXXXXX
2	11	16	O	caused
3	18	18	O	a
4	20	32	O	statistically
5	34	44	O	significant
6	46	53	O	increase
7	55	56	O	in
8	58	63	O	plasma
9	65	73	O	exposures
10	75	76	O	of
11	78	78	B-KIN	R
12	80	87	L-KIN	warfarin
13	89	91	O	and
14	93	93	B-KIN	S
15	95	102	L-KIN	warfarin
16	105	107	O	12%
17	109	111	O	and
18	113	115	O	15%
19	116	116	O	,
20	118	129	O	respectively
21	131	131	O	,
22	133	135	O	and
23	137	138	O	in
24	140	142	O	the
25	144	158	O	pharmacodynamic
26	160	166	O	effects
27	169	179	O	prothrombin
28	181	184	O	time
29	185	185	O	,
30	187	194	O	measured
31	196	197	O	as
32	199	201	O	INR
33	204	205	O	of
34	207	214	U-DYN	warfarin
NULL

Valdecoxib	DDI-DrugBank.d328.s25	NO_SECTION	NO_SETID	24
While mean INR values were only slightly increased with coadministration of valdecoxib, the day-to-day variability in individual INR values was increased.
1	0	4	O	While
2	6	9	O	mean
3	11	13	O	INR
4	15	20	O	values
5	22	25	O	were
6	27	30	O	only
7	32	39	O	slightly
8	41	49	O	increased
9	51	54	O	with
10	56	71	O	coadministration
11	73	74	O	of
12	76	85	O	XXXXXXXX
13	86	86	O	,
14	88	90	O	the
15	92	94	O	day
16	96	97	O	to
17	99	101	O	day
18	103	113	O	variability
19	115	116	O	in
20	118	127	O	individual
21	129	131	O	INR
22	133	138	O	values
23	140	142	O	was
24	144	152	O	increased
NULL

Valdecoxib	DDI-DrugBank.d328.s26	NO_SECTION	NO_SETID	25
Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.
1	0	12	O	Anticoagulant
2	14	20	O	therapy
3	22	27	O	should
4	29	30	O	be
5	32	40	O	monitored
6	41	41	O	,
7	43	54	O	particularly
8	56	61	O	during
9	63	65	O	the
10	67	71	O	first
11	73	75	O	few
12	77	81	O	weeks
13	82	82	O	,
14	84	88	O	after
15	90	99	O	initiating
16	101	107	O	therapy
17	109	112	O	with
18	114	119	O	XXXXXXXX
19	121	122	O	in
20	124	131	O	patients
21	133	141	O	receiving
22	143	150	U-DYN	warfarin
23	152	153	O	or
24	155	161	O	similar
25	163	168	O	agents
NULL

Valdecoxib	DDI-DrugBank.d328.s27	NO_SECTION	NO_SETID	16
Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.
1	0	10	U-UNK	Fluconazole
2	12	14	O	and
3	16	27	U-UNK	Ketoconazole
4	28	28	O	:
5	30	41	U-UNK	Ketoconazole
6	43	45	O	and
7	47	57	U-UNK	fluconazole
8	59	61	O	are
9	63	75	O	predominantly
10	77	79	O	CYP
11	81	83	O	3A4
12	85	87	O	and
13	89	91	O	2C9
14	93	102	O	inhibitors
15	103	103	O	,
16	105	116	O	respectively
NULL

Valdecoxib	DDI-DrugBank.d328.s28	NO_SECTION	NO_SETID	23
Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.
1	0	10	O	Concomitant
2	12	17	O	single
3	19	22	O	dose
4	24	37	O	administration
5	39	40	O	of
6	42	51	O	XXXXXXXX
7	53	54	O	20
8	56	57	O	mg
9	59	62	O	with
10	64	71	O	multiple
11	73	77	O	doses
12	79	80	O	of
13	82	93	U-KIN	ketoconazole
14	95	97	O	and
15	99	109	U-KIN	fluconazole
16	111	118	O	produced
17	120	120	O	a
18	122	132	O	significant
19	134	141	O	increase
20	143	144	O	in
21	146	153	O	exposure
22	155	156	O	of
23	158	167	O	XXXXXXXX
NULL

Valdecoxib	DDI-DrugBank.d328.s29	NO_SECTION	NO_SETID	18
Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.
1	0	5	O	Plasma
2	7	14	O	exposure
3	17	19	O	AUC
4	22	23	O	to
5	25	34	O	XXXXXXXX
6	36	38	O	was
7	40	48	O	increased
8	50	52	O	62%
9	54	57	O	when
10	59	72	O	coadministered
11	74	77	O	with
12	79	89	U-KIN	fluconazole
13	91	93	O	and
14	95	97	O	38%
15	99	102	O	when
16	104	117	O	coadministered
17	119	122	O	with
18	124	135	U-KIN	ketoconazole
NULL

Valdecoxib	DDI-DrugBank.d328.s30	NO_SECTION	NO_SETID	8
Glyburide: Glyburide is a CYP 2C9 substrate.
1	0	8	U-UNK	Glyburide
2	9	9	O	:
3	11	19	U-UNK	Glyburide
4	21	22	O	is
5	24	24	O	a
6	26	28	O	CYP
7	30	32	O	2C9
8	34	42	O	substrate
NULL

Valdecoxib	DDI-DrugBank.d328.s31	NO_SECTION	NO_SETID	26
Coadministration of valdecoxib (10 mg BID for 7 days) with glyburide (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of glyburide.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	O	XXXXXXXX
4	32	33	O	10
5	35	36	O	mg
6	38	40	O	BID
7	42	44	O	for
8	46	46	O	7
9	48	51	O	days
10	54	57	O	with
11	59	67	U-UNK	glyburide
12	70	70	O	5
13	72	73	O	mg
14	75	76	O	QD
15	78	79	O	or
16	81	82	O	10
17	84	85	O	mg
18	87	89	O	BID
19	92	94	O	did
20	96	98	O	not
21	100	105	O	affect
22	107	109	O	the
23	111	126	O	pharmacokinetics
24	129	136	O	exposure
25	139	140	O	of
26	142	150	U-UNK	glyburide
NULL

Valdecoxib	DDI-DrugBank.d328.s32	NO_SECTION	NO_SETID	37
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	O	XXXXXXXX
4	32	33	O	40
5	35	36	O	mg
6	38	40	O	BID
7	43	45	O	day
8	47	47	O	1
9	50	52	O	and
10	54	55	O	40
11	57	58	O	mg
12	60	61	O	QD
13	64	67	O	days
14	69	69	O	2
15	71	71	O	7
16	75	78	O	with
17	80	88	U-UNK	glyburide
18	91	91	O	5
19	93	94	O	mg
20	96	97	O	QD
21	100	102	O	did
22	104	106	O	not
23	108	113	O	affect
24	115	120	O	either
25	122	124	O	the
26	126	141	O	pharmacokinetics
27	144	151	O	exposure
28	154	155	O	or
29	157	159	O	the
30	161	176	O	pharmacodynamics
31	179	183	O	blood
32	185	191	O	glucose
33	193	195	O	and
34	197	203	O	insulin
35	205	210	O	levels
36	213	214	O	of
37	216	224	U-UNK	glyburide
NULL

Valdecoxib	DDI-DrugBank.d328.s33	NO_SECTION	NO_SETID	45
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	O	XXXXXXXX
4	32	33	O	40
5	35	36	O	mg
6	38	40	O	BID
7	43	45	O	day
8	47	47	O	1
9	50	52	O	and
10	54	55	O	40
11	57	58	O	mg
12	60	61	O	QD
13	64	67	O	days
14	69	69	O	2
15	71	71	O	7
16	75	78	O	with
17	80	88	U-KIN	glyburide
18	91	92	O	10
19	94	95	O	mg
20	97	105	U-UNK	glyburide
21	107	109	O	BID
22	112	119	O	resulted
23	121	122	O	in
24	124	126	O	21%
25	128	135	O	increase
26	137	138	O	in
27	140	148	U-UNK	glyburide
28	150	153	O	AUC0
29	155	156	O	12
30	158	160	O	and
31	162	162	O	a
32	164	166	O	16%
33	168	175	O	increase
34	177	178	O	in
35	180	188	U-UNK	glyburide
36	190	193	O	Cmax
37	195	201	O	leading
38	203	204	O	to
39	206	206	O	a
40	208	210	O	16%
41	212	219	O	decrease
42	221	222	O	in
43	224	230	O	glucose
44	232	235	O	AUC0
45	237	238	O	24
NULL

Valdecoxib	DDI-DrugBank.d328.s34	NO_SECTION	NO_SETID	5
Insulin parameters were not affected.
1	0	6	O	Insulin
2	8	17	O	parameters
3	19	22	O	were
4	24	26	O	not
5	28	35	O	affected
NULL

Valdecoxib	DDI-DrugBank.d328.s35	NO_SECTION	NO_SETID	48
Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.
1	0	6	O	Because
2	8	14	O	changes
3	16	17	O	in
4	19	25	O	glucose
5	27	40	O	concentrations
6	42	45	O	with
7	47	56	O	XXXXXXXX
8	58	73	O	coadministration
9	75	78	O	were
10	80	85	O	within
11	87	89	O	the
12	91	96	O	normal
13	98	108	O	variability
14	110	112	O	and
15	114	123	O	individual
16	125	131	O	glucose
17	133	146	O	concentrations
18	148	151	O	were
19	153	157	O	above
20	159	160	O	or
21	162	165	O	near
22	167	168	O	70
23	170	171	O	mg
24	172	172	O	/
25	173	174	O	dL
26	175	175	O	,
27	177	180	O	dose
28	182	191	O	adjustment
29	193	195	O	for
30	197	205	U-DYN	glyburide
31	208	208	O	5
32	210	211	O	mg
33	213	214	O	QD
34	216	218	O	and
35	220	221	O	10
36	223	224	O	mg
37	226	228	O	BID
38	231	234	O	with
39	236	245	O	XXXXXXXX
40	247	262	O	coadministration
41	265	266	O	up
42	268	269	O	to
43	271	272	O	40
44	274	275	O	mg
45	277	278	O	QD
46	281	282	O	is
47	284	286	O	not
48	288	296	O	indicated
NULL

Valdecoxib	DDI-DrugBank.d328.s36	NO_SECTION	NO_SETID	19
Coadministration of glyburide with doses higher than 40 mg valdecoxib (e.g., 40 mg BID) have not been studied.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	28	U-UNK	glyburide
4	30	33	O	with
5	35	39	O	doses
6	41	46	O	higher
7	48	51	O	than
8	53	54	O	40
9	56	57	O	mg
10	59	68	O	XXXXXXXX
11	71	73	O	e.g
12	75	75	O	,
13	77	78	O	40
14	80	81	O	mg
15	83	85	O	BID
16	88	91	O	have
17	93	95	O	not
18	97	100	O	been
19	102	108	O	studied
NULL

Valdecoxib	DDI-DrugBank.d328.s37	NO_SECTION	NO_SETID	14
Omeprazole: Omeprazole is a CYP 3A4 substrate and CYP 2C19 substrate and inhibitor.
1	0	9	U-UNK	Omeprazole
2	10	10	O	:
3	12	21	U-UNK	Omeprazole
4	23	24	O	is
5	26	26	O	a
6	28	30	O	CYP
7	32	34	O	3A4
8	36	44	O	substrate
9	46	48	O	and
10	50	52	O	CYP
11	54	57	O	2C19
12	59	67	O	substrate
13	69	71	O	and
14	73	81	O	inhibitor
NULL

Valdecoxib	DDI-DrugBank.d328.s38	NO_SECTION	NO_SETID	20
Valdecoxib steady state plasma concentrations (40 mg BID) were not affected significantly with multiple doses of omeprazole (40 mg QD).
1	0	9	O	XXXXXXXX
2	11	16	O	steady
3	18	22	O	state
4	24	29	O	plasma
5	31	44	O	concentrations
6	47	48	O	40
7	50	51	O	mg
8	53	55	O	BID
9	58	61	O	were
10	63	65	O	not
11	67	74	O	affected
12	76	88	O	significantly
13	90	93	O	with
14	95	102	O	multiple
15	104	108	O	doses
16	110	111	O	of
17	113	122	U-UNK	omeprazole
18	125	126	O	40
19	128	129	O	mg
20	131	132	O	QD
NULL

Valdecoxib	DDI-DrugBank.d328.s39	NO_SECTION	NO_SETID	10
Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.
1	0	15	O	Coadministration
2	17	20	O	with
3	22	31	O	XXXXXXXX
4	33	41	O	increased
5	43	50	O	exposure
6	52	53	O	of
7	55	64	U-KIN	omeprazole
8	67	69	O	AUC
9	72	73	O	by
10	75	77	O	46%
NULL

Valdecoxib	DDI-DrugBank.d328.s40	NO_SECTION	NO_SETID	18
Drugs whose absorption is sensitive to pH may be negatively impacted by concomitant administration of omeprazole and valdecoxib.
1	0	4	O	Drugs
2	6	10	O	whose
3	12	21	O	absorption
4	23	24	O	is
5	26	34	O	sensitive
6	36	37	O	to
7	39	40	O	pH
8	42	44	O	may
9	46	47	O	be
10	49	58	O	negatively
11	60	67	O	impacted
12	69	70	O	by
13	72	82	O	concomitant
14	84	97	O	administration
15	99	100	O	of
16	102	111	U-UNK	omeprazole
17	113	115	O	and
18	117	126	O	XXXXXXXX
NULL

Valdecoxib	DDI-DrugBank.d328.s41	NO_SECTION	NO_SETID	30
However, because higher doses (up to 360 mg QD) of omeprazole are tolerated in Zollinger-Ellison (ZE) patients, no dose adjustment for omeprazole is recommended at current doses.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	because
4	17	22	O	higher
5	24	28	O	doses
6	31	32	O	up
7	34	35	O	to
8	37	39	O	360
9	41	42	O	mg
10	44	45	O	QD
11	48	49	O	of
12	51	60	U-UNK	omeprazole
13	62	64	O	are
14	66	74	O	tolerated
15	76	77	O	in
16	79	87	O	Zollinger
17	89	95	O	Ellison
18	98	99	O	ZE
19	102	109	O	patients
20	110	110	O	,
21	112	113	O	no
22	115	118	O	dose
23	120	129	O	adjustment
24	131	133	O	for
25	135	144	U-UNK	omeprazole
26	146	147	O	is
27	149	159	O	recommended
28	161	162	O	at
29	164	170	O	current
30	172	176	O	doses
NULL

Valdecoxib	DDI-DrugBank.d328.s42	NO_SECTION	NO_SETID	15
Coadministration of valdecoxib with doses higher than 40 mg QD omeprazole has not been studied.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	O	XXXXXXXX
4	31	34	O	with
5	36	40	O	doses
6	42	47	O	higher
7	49	52	O	than
8	54	55	O	40
9	57	58	O	mg
10	60	61	O	QD
11	63	72	U-UNK	omeprazole
12	74	76	O	has
13	78	80	O	not
14	82	85	O	been
15	87	93	O	studied
NULL

Valdecoxib	DDI-DrugBank.d328.s43	NO_SECTION	NO_SETID	32
Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).
1	0	3	O	Oral
2	5	18	U-UNK	Contraceptives
3	19	19	O	:
4	21	30	U-UNK	Valdecoxib
5	33	34	O	40
6	36	37	O	mg
7	39	41	O	BID
8	44	46	O	did
9	48	50	O	not
10	52	57	O	induce
11	59	61	O	the
12	63	72	O	metabolism
13	74	75	O	of
14	77	79	O	the
15	81	91	O	combination
16	93	96	O	oral
17	98	110	U-UNK	contraceptive
18	112	124	U-UNK	norethindrone
19	125	125	O	/
20	126	132	B-UNK	ethinyl
21	134	142	L-UNK	estradiol
22	145	145	O	1
23	147	148	O	mg
24	150	150	O	/
25	151	152	O	35
26	154	156	O	mcg
27	158	168	O	combination
28	169	169	O	,
29	171	181	O	XXXXXXXX
30	183	183	O	1
31	184	184	O	/
32	185	186	O	35
NULL

Valdecoxib	DDI-DrugBank.d328.s44	NO_SECTION	NO_SETID	22
Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	U-KIN	valdecoxib
4	31	33	O	and
5	35	45	O	XXXXXXXX
6	47	47	O	1
7	48	48	O	/
8	49	50	O	35
9	53	61	O	increased
10	63	65	O	the
11	67	74	O	exposure
12	76	77	O	of
13	79	91	U-UNK	norethindrone
14	93	95	O	and
15	97	103	B-UNK	ethinyl
16	105	113	L-UNK	estradiol
17	115	116	O	by
18	118	120	O	20%
19	122	124	O	and
20	126	128	O	34%
21	129	129	O	,
22	131	142	O	respectively
NULL

Valdecoxib	DDI-DrugBank.d328.s45	NO_SECTION	NO_SETID	25
Although there is little risk for loss of contraceptive efficacy, the clinical significance of these increased exposures in terms of safety is not known.
1	0	7	O	Although
2	9	13	O	there
3	15	16	O	is
4	18	23	O	little
5	25	28	O	risk
6	30	32	O	for
7	34	37	O	loss
8	39	40	O	of
9	42	54	O	contraceptive
10	56	63	O	efficacy
11	64	64	O	,
12	66	68	O	the
13	70	77	O	clinical
14	79	90	O	significance
15	92	93	O	of
16	95	99	O	these
17	101	109	O	increased
18	111	119	O	exposures
19	121	122	O	in
20	124	128	O	terms
21	130	131	O	of
22	133	138	O	safety
23	140	141	O	is
24	143	145	O	not
25	147	151	O	known
NULL

Valdecoxib	DDI-DrugBank.d328.s46	NO_SECTION	NO_SETID	22
These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.
1	0	4	O	These
2	6	14	O	increased
3	16	24	O	exposures
4	26	27	O	of
5	29	41	U-UNK	norethindrone
6	43	45	O	and
7	47	53	B-UNK	ethinyl
8	55	63	L-UNK	estradiol
9	65	70	O	should
10	72	73	O	be
11	75	79	O	taken
12	81	84	O	into
13	86	98	O	consideration
14	100	103	O	when
15	105	113	O	selecting
16	115	116	O	an
17	118	121	O	oral
18	123	135	U-DYN	contraceptive
19	137	139	O	for
20	141	145	O	women
21	147	152	O	taking
22	154	163	O	XXXXXXXX
NULL

Valdecoxib	DDI-DrugBank.d328.s47	NO_SECTION	NO_SETID	12
Diazepam: Diazepam (Valium) is a CYP 3A4 and CYP 2C19 substrate.
1	0	7	U-UNK	Diazepam
2	8	8	O	:
3	10	17	U-UNK	Diazepam
4	20	25	O	XXXXXXXX
5	28	29	O	is
6	31	31	O	a
7	33	35	O	CYP
8	37	39	O	3A4
9	41	43	O	and
10	45	47	O	CYP
11	49	52	O	2C19
12	54	62	O	substrate
NULL

Valdecoxib	DDI-DrugBank.d328.s48	NO_SECTION	NO_SETID	44
Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.
1	0	5	O	Plasma
2	7	14	O	exposure
3	16	17	O	of
4	19	26	U-KIN	diazepam
5	29	30	O	10
6	32	33	O	mg
7	35	37	O	BID
8	40	42	O	was
9	44	52	O	increased
10	54	55	O	by
11	57	59	O	28%
12	61	69	O	following
13	71	84	O	administration
14	86	87	O	of
15	89	98	O	XXXXXXXX
16	101	102	O	40
17	104	105	O	mg
18	107	109	O	BID
19	112	114	O	for
20	116	117	O	12
21	119	122	O	days
22	123	123	O	,
23	125	129	O	while
24	131	136	O	plasma
25	138	145	O	exposure
26	147	148	O	of
27	150	159	O	XXXXXXXX
28	162	163	O	40
29	165	166	O	mg
30	168	170	O	BID
31	173	175	O	was
32	177	179	O	not
33	181	193	O	substantially
34	195	203	O	increased
35	205	213	O	following
36	215	228	O	administration
37	230	231	O	of
38	233	240	U-UNK	diazepam
39	243	244	O	10
40	246	247	O	mg
41	249	251	O	BID
42	254	256	O	for
43	258	259	O	12
44	261	264	O	days
NULL

Valdecoxib	DDI-DrugBank.d328.s49	NO_SECTION	NO_SETID	37
Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.
1	0	7	O	Although
2	9	11	O	the
3	13	21	O	magnitude
4	23	24	O	of
5	26	32	O	changes
6	34	35	O	in
7	37	44	U-UNK	diazepam
8	46	51	O	plasma
9	53	60	O	exposure
10	62	65	O	when
11	67	80	O	coadministered
12	82	85	O	with
13	87	96	O	XXXXXXXX
14	98	101	O	were
15	103	105	O	not
16	107	116	O	sufficient
17	118	119	O	to
18	121	127	O	warrant
19	129	134	O	dosage
20	136	146	O	adjustments
21	147	147	O	,
22	149	156	O	patients
23	158	160	O	may
24	162	171	O	experience
25	173	180	O	enhanced
26	182	189	O	sedative
27	191	194	O	side
28	196	202	O	effects
29	204	209	O	caused
30	211	212	O	by
31	214	222	O	increased
32	224	231	O	exposure
33	233	234	O	of
34	236	243	U-DYN	diazepam
35	245	249	O	under
36	251	254	O	this
37	256	267	O	circumstance
NULL

Valdecoxib	DDI-DrugBank.d328.s50	NO_SECTION	NO_SETID	22
Patients should be cautioned against engaging in hazardous activities requiring complete mental alertness such as operating machinery or driving a motor vehicle.
1	0	7	O	Patients
2	9	14	O	should
3	16	17	O	be
4	19	27	O	cautioned
5	29	35	O	against
6	37	44	O	engaging
7	46	47	O	in
8	49	57	O	hazardous
9	59	68	O	activities
10	70	78	O	requiring
11	80	87	O	complete
12	89	94	O	mental
13	96	104	O	alertness
14	106	109	O	such
15	111	112	O	as
16	114	122	O	operating
17	124	132	O	machinery
18	134	135	O	or
19	137	143	O	driving
20	145	145	O	a
21	147	151	O	motor
22	153	159	O	vehicle
NULL

Vardenafil	DDI-DrugBank.d198.s0	NO_SECTION	NO_SETID	6
Effect of other drugs on Vardenafil
1	0	5	O	Effect
2	7	8	O	of
3	10	14	O	other
4	16	20	O	drugs
5	22	23	O	on
6	25	34	O	XXXXXXXX
NULL

Vardenafil	DDI-DrugBank.d198.s1	NO_SECTION	NO_SETID	31
In vitro studies: Studies in human liver microsomes showed that vardenafil is metabolized primarily by cytochrome P450 (CYP) isoforms 3A4/5, and to a lesser degree by CYP2C9.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	16	16	O	:
5	18	24	O	Studies
6	26	27	O	in
7	29	33	O	human
8	35	39	O	liver
9	41	50	O	microsomes
10	52	57	O	showed
11	59	62	O	that
12	64	73	O	XXXXXXXX
13	75	76	O	is
14	78	88	O	metabolized
15	90	98	O	primarily
16	100	101	O	by
17	103	112	O	cytochrome
18	114	117	O	P450
19	120	122	O	CYP
20	125	132	O	isoforms
21	134	136	O	3A4
22	137	137	O	/
23	138	138	O	5
24	139	139	O	,
25	141	143	O	and
26	145	146	O	to
27	148	148	O	a
28	150	155	O	lesser
29	157	162	O	degree
30	164	165	O	by
31	167	172	O	CYP2C9
NULL

Vardenafil	DDI-DrugBank.d198.s2	NO_SECTION	NO_SETID	12
Therefore, inhibitors of these enzymes are expected to reduce vardenafil clearance.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	inhibitors
4	22	23	O	of
5	25	29	O	these
6	31	37	O	enzymes
7	39	41	O	are
8	43	50	O	expected
9	52	53	O	to
10	55	60	O	reduce
11	62	71	O	XXXXXXXX
12	73	81	O	clearance
NULL

Vardenafil	DDI-DrugBank.d198.s3	NO_SECTION	NO_SETID	7
In vivo studies: Cytochrome P450 Inhibitors
1	0	1	O	In
2	3	6	O	vivo
3	8	14	O	studies
4	15	15	O	:
5	17	26	O	Cytochrome
6	28	31	O	P450
7	33	42	O	Inhibitors
NULL

Vardenafil	DDI-DrugBank.d198.s4	NO_SECTION	NO_SETID	27
Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.
1	0	9	U-UNK	Cimetidine
2	12	14	O	400
3	16	17	O	mg
4	19	23	O	b.i.d
5	27	29	O	had
6	31	32	O	no
7	34	39	O	effect
8	41	42	O	on
9	44	53	O	XXXXXXXX
10	55	69	O	bioavailability
11	72	74	O	AUC
12	77	79	O	and
13	81	87	O	maximum
14	89	101	O	concentration
15	104	107	O	Cmax
16	110	111	O	of
17	113	122	O	XXXXXXXX
18	124	127	O	when
19	129	130	O	co
20	132	143	O	administered
21	145	148	O	with
22	150	151	O	20
23	153	154	O	mg
24	156	165	O	XXXXXXXX
25	167	168	O	in
26	170	176	O	healthy
27	178	187	O	volunteers
NULL

Vardenafil	DDI-DrugBank.d198.s5	NO_SECTION	NO_SETID	29
Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.
1	0	11	U-KIN	Erythromycin
2	14	16	O	500
3	18	19	O	mg
4	21	25	O	t.i.d
5	28	35	O	produced
6	37	37	O	a
7	39	39	O	4
8	41	44	O	fold
9	46	53	O	increase
10	55	56	O	in
11	58	67	O	XXXXXXXX
12	69	71	O	AUC
13	73	75	O	and
14	77	77	O	a
15	79	79	O	3
16	81	84	O	fold
17	86	93	O	increase
18	95	96	O	in
19	98	101	O	Cmax
20	103	106	O	when
21	108	109	O	co
22	111	122	O	administered
23	124	127	O	with
24	129	138	O	XXXXXXXX
25	140	140	O	5
26	142	143	O	mg
27	145	146	O	in
28	148	154	O	healthy
29	156	165	O	volunteers
NULL

Vardenafil	DDI-DrugBank.d198.s6	NO_SECTION	NO_SETID	24
It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	20	O	not
5	22	23	O	to
6	25	30	O	exceed
7	32	32	O	a
8	34	39	O	single
9	41	41	O	5
10	43	44	O	mg
11	46	49	O	dose
12	51	52	O	of
13	54	63	O	XXXXXXXX
14	65	66	O	in
15	68	68	O	a
16	70	71	O	24
17	73	76	O	hour
18	78	83	O	period
19	85	88	O	when
20	90	93	O	used
21	95	96	O	in
22	98	108	O	combination
23	110	113	O	with
24	115	126	U-DYN	erythromycin
NULL

Vardenafil	DDI-DrugBank.d198.s7	NO_SECTION	NO_SETID	30
Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.
1	0	11	U-KIN	Ketoconazole
2	14	16	O	200
3	18	19	O	mg
4	21	24	O	once
5	26	30	O	daily
6	33	40	O	produced
7	42	42	O	a
8	44	45	O	10
9	47	50	O	fold
10	52	59	O	increase
11	61	62	O	in
12	64	73	O	XXXXXXXX
13	75	77	O	AUC
14	79	81	O	and
15	83	83	O	a
16	85	85	O	4
17	87	90	O	fold
18	92	99	O	increase
19	101	102	O	in
20	104	107	O	Cmax
21	109	112	O	when
22	114	115	O	co
23	117	128	O	administered
24	130	133	O	with
25	135	144	O	XXXXXXXX
26	147	147	O	5
27	149	150	O	mg
28	153	154	O	in
29	156	162	O	healthy
30	164	173	O	volunteers
NULL

Vardenafil	DDI-DrugBank.d198.s8	NO_SECTION	NO_SETID	19
A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.
1	0	0	O	A
2	2	2	O	5
3	4	5	O	mg
4	7	16	O	XXXXXXXX
5	18	21	O	dose
6	23	28	O	should
7	30	32	O	not
8	34	35	O	be
9	37	44	O	exceeded
10	46	49	O	when
11	51	54	O	used
12	56	57	O	in
13	59	69	O	combination
14	71	74	O	with
15	76	78	O	200
16	80	81	O	mg
17	83	86	O	once
18	88	92	O	daily
19	94	105	U-DYN	ketoconazole
NULL

Vardenafil	DDI-DrugBank.d198.s9	NO_SECTION	NO_SETID	43
Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.
1	0	4	O	Since
2	6	11	O	higher
3	13	17	O	doses
4	19	20	O	of
5	22	33	U-UNK	ketoconazole
6	36	38	O	400
7	40	41	O	mg
8	43	47	O	daily
9	50	52	O	may
10	54	59	O	result
11	61	62	O	in
12	64	69	O	higher
13	71	79	O	increases
14	81	82	O	in
15	84	87	O	Cmax
16	89	91	O	and
17	93	95	O	AUC
18	96	96	O	,
19	98	98	O	a
20	100	105	O	single
21	107	109	O	2.5
22	111	112	O	mg
23	114	117	O	dose
24	119	120	O	of
25	122	131	O	XXXXXXXX
26	133	138	O	should
27	140	142	O	not
28	144	145	O	be
29	147	154	O	exceeded
30	156	157	O	in
31	159	159	O	a
32	161	162	O	24
33	164	167	O	hour
34	169	174	O	period
35	176	179	O	when
36	181	184	O	used
37	186	187	O	in
38	189	199	O	combination
39	201	204	O	with
40	206	217	U-DYN	ketoconazole
41	219	221	O	400
42	223	224	O	mg
43	226	230	O	daily
NULL

Vardenafil	DDI-DrugBank.d198.s10	NO_SECTION	NO_SETID	40
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.
1	0	2	B-UNK	HIV
2	4	11	I-UNK	Protease
3	13	22	L-UNK	Inhibitors
4	23	23	O	:
5	25	33	U-KIN	Indinavir
6	36	38	O	800
7	40	41	O	mg
8	43	47	O	t.i.d
9	51	52	O	co
10	54	65	O	administered
11	67	70	O	with
12	72	81	O	XXXXXXXX
13	83	84	O	10
14	86	87	O	mg
15	89	96	O	resulted
16	98	99	O	in
17	101	101	O	a
18	103	104	O	16
19	106	109	O	fold
20	111	118	O	increase
21	120	121	O	in
22	123	132	O	XXXXXXXX
23	134	136	O	AUC
24	137	137	O	,
25	139	139	O	a
26	141	141	O	7
27	143	146	O	fold
28	148	155	O	increase
29	157	158	O	in
30	160	169	O	XXXXXXXX
31	171	174	O	Cmax
32	176	178	O	and
33	180	180	O	a
34	182	182	O	2
35	184	187	O	fold
36	189	196	O	increase
37	198	199	O	in
38	201	210	O	XXXXXXXX
39	212	215	O	half
40	217	220	O	life
NULL

Vardenafil	DDI-DrugBank.d198.s11	NO_SECTION	NO_SETID	23
It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	20	O	not
5	22	23	O	to
6	25	30	O	exceed
7	32	32	O	a
8	34	39	O	single
9	41	43	O	2.5
10	45	46	O	mg
11	48	57	O	XXXXXXXX
12	59	62	O	dose
13	64	65	O	in
14	67	67	O	a
15	69	70	O	24
16	72	75	O	hour
17	77	82	O	period
18	84	87	O	when
19	89	92	O	used
20	94	95	O	in
21	97	107	O	combination
22	109	112	O	with
23	114	122	U-DYN	indinavir
NULL

Vardenafil	DDI-DrugBank.d198.s12	NO_SECTION	NO_SETID	27
Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.
1	0	8	U-KIN	Ritonavir
2	11	13	O	600
3	15	16	O	mg
4	18	22	O	b.i.d
5	26	27	O	co
6	29	40	O	administered
7	42	45	O	with
8	47	56	O	XXXXXXXX
9	58	58	O	5
10	60	61	O	mg
11	63	70	O	resulted
12	72	73	O	in
13	75	75	O	a
14	77	78	O	49
15	80	83	O	fold
16	85	92	O	increase
17	94	95	O	in
18	97	106	O	XXXXXXXX
19	108	110	O	AUC
20	112	114	O	and
21	116	116	O	a
22	118	119	O	13
23	121	124	O	fold
24	126	133	O	increase
25	135	136	O	in
26	138	147	O	XXXXXXXX
27	149	152	O	Cmax
NULL

Vardenafil	DDI-DrugBank.d198.s13	NO_SECTION	NO_SETID	24
The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.
1	0	2	O	The
2	4	14	O	interaction
3	16	17	O	is
4	19	19	O	a
5	21	31	O	consequence
6	33	34	O	of
7	36	43	O	blocking
8	45	51	O	hepatic
9	53	62	O	metabolism
10	64	65	O	of
11	67	76	O	XXXXXXXX
12	78	79	O	by
13	81	89	U-KIN	ritonavir
14	90	90	O	,
15	92	92	O	a
16	94	99	O	highly
17	101	106	O	potent
18	108	113	O	CYP3A4
19	115	123	O	inhibitor
20	124	124	O	,
21	126	130	O	which
22	132	135	O	also
23	137	144	O	inhibits
24	146	151	O	CYP2C9
NULL

Vardenafil	DDI-DrugBank.d198.s14	NO_SECTION	NO_SETID	11
Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.
1	0	8	U-KIN	Ritonavir
2	10	22	O	significantly
3	24	32	O	prolonged
4	34	36	O	the
5	38	41	O	half
6	43	46	O	life
7	48	49	O	of
8	51	60	O	XXXXXXXX
9	62	63	O	to
10	65	66	O	26
11	68	72	O	hours
NULL

Vardenafil	DDI-DrugBank.d198.s15	NO_SECTION	NO_SETID	25
Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.
1	0	11	O	Consequently
2	12	12	O	,
3	14	15	O	it
4	17	18	O	is
5	20	30	O	recommended
6	32	34	O	not
7	36	37	O	to
8	39	44	O	exceed
9	46	46	O	a
10	48	53	O	single
11	55	57	O	2.5
12	59	60	O	mg
13	62	71	O	XXXXXXXX
14	73	76	O	dose
15	78	79	O	in
16	81	81	O	a
17	83	84	O	72
18	86	89	O	hour
19	91	96	O	period
20	98	101	O	when
21	103	106	O	used
22	108	109	O	in
23	111	121	O	combination
24	123	126	O	with
25	128	136	U-DYN	ritonavir
NULL

Vardenafil	DDI-DrugBank.d198.s16	NO_SECTION	NO_SETID	26
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, Maalox, and ranitidine.
1	0	4	O	Other
2	6	9	O	Drug
3	11	22	O	Interactions
4	23	23	O	:
5	25	26	O	No
6	28	42	O	pharmacokinetic
7	44	55	O	interactions
8	57	60	O	were
9	62	69	O	observed
10	71	77	O	between
11	79	88	U-UNK	vardenafil
12	90	92	O	and
13	94	96	O	the
14	98	106	O	following
15	108	112	O	drugs
16	113	113	O	:
17	115	123	U-UNK	glyburide
18	124	124	O	,
19	126	133	U-UNK	warfarin
20	134	134	O	,
21	136	142	U-UNK	digoxin
22	143	143	O	,
23	145	150	O	XXXXXXXX
24	151	151	O	,
25	153	155	O	and
26	157	166	U-UNK	ranitidine
NULL

Vardenafil	DDI-DrugBank.d198.s17	NO_SECTION	NO_SETID	17
In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.
1	0	1	O	In
2	3	5	O	the
3	7	14	U-UNK	warfarin
4	16	20	O	study
5	21	21	O	,
6	23	32	O	XXXXXXXX
7	34	36	O	had
8	38	39	O	no
9	41	46	O	effect
10	48	49	O	on
11	51	53	O	the
12	55	65	O	prothrombin
13	67	70	O	time
14	72	73	O	or
15	75	79	O	other
16	81	95	O	pharmacodynamic
17	97	106	O	parameters
NULL

Vardenafil	DDI-DrugBank.d198.s18	NO_SECTION	NO_SETID	6
Effects of Vardenafil on other drugs
1	0	6	O	Effects
2	8	9	O	of
3	11	20	O	XXXXXXXX
4	22	23	O	on
5	25	29	O	other
6	31	35	O	drugs
NULL

Vardenafil	DDI-DrugBank.d198.s19	NO_SECTION	NO_SETID	20
In vitro studies: Vardenafil and its metabolites had no effect on CYP1A2, 2A6, and 2E1 (Ki   100uM).
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	16	16	O	:
5	18	27	O	XXXXXXXX
6	29	31	O	and
7	33	35	O	its
8	37	47	O	metabolites
9	49	51	O	had
10	53	54	O	no
11	56	61	O	effect
12	63	64	O	on
13	66	71	O	CYP1A2
14	72	72	O	,
15	74	76	O	2A6
16	77	77	O	,
17	79	81	O	and
18	83	85	O	2E1
19	88	89	O	Ki
20	93	97	O	100uM
NULL

Vardenafil	DDI-DrugBank.d198.s20	NO_SECTION	NO_SETID	30
Weak inhibitory effects toward other isoforms (CYP2C8, 2C9, 2C19, 2D6, 3A4) were found, but Ki values were in excess of plasma concentrations achieved following dosing.
1	0	3	O	Weak
2	5	14	O	inhibitory
3	16	22	O	effects
4	24	29	O	toward
5	31	35	O	other
6	37	44	O	isoforms
7	47	52	O	CYP2C8
8	53	53	O	,
9	55	57	O	2C9
10	58	58	O	,
11	60	63	O	2C19
12	64	64	O	,
13	66	68	O	2D6
14	69	69	O	,
15	71	73	O	3A4
16	76	79	O	were
17	81	85	O	found
18	86	86	O	,
19	88	90	O	but
20	92	93	O	Ki
21	95	100	O	values
22	102	105	O	were
23	107	108	O	in
24	110	115	O	excess
25	117	118	O	of
26	120	125	O	plasma
27	127	140	O	concentrations
28	142	149	O	achieved
29	151	159	O	following
30	161	166	O	dosing
NULL

Vardenafil	DDI-DrugBank.d198.s21	NO_SECTION	NO_SETID	39
The most potent inhibitory activity was observed for vardenafil metabolite M1, which had a Ki of 1.4 uM toward CYP3A4, which is about 20 times higher than the M1 Cmax values after an 80 mg Vardenafil dose.
1	0	2	O	The
2	4	7	O	most
3	9	14	O	potent
4	16	25	O	inhibitory
5	27	34	O	activity
6	36	38	O	was
7	40	47	O	observed
8	49	51	O	for
9	53	62	O	XXXXXXXX
10	64	73	O	metabolite
11	75	76	O	M1
12	77	77	O	,
13	79	83	O	which
14	85	87	O	had
15	89	89	O	a
16	91	92	O	Ki
17	94	95	O	of
18	97	99	O	1.4
19	101	102	O	uM
20	104	109	O	toward
21	111	116	O	CYP3A4
22	117	117	O	,
23	119	123	O	which
24	125	126	O	is
25	128	132	O	about
26	134	135	O	20
27	137	141	O	times
28	143	148	O	higher
29	150	153	O	than
30	155	157	O	the
31	159	160	O	M1
32	162	165	O	Cmax
33	167	172	O	values
34	174	178	O	after
35	180	181	O	an
36	183	184	O	80
37	186	187	O	mg
38	189	198	O	XXXXXXXX
39	200	203	O	dose
NULL

Vardenafil	DDI-DrugBank.d198.s22	NO_SECTION	NO_SETID	51
In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.
1	0	1	O	In
2	3	6	O	vivo
3	8	14	O	studies
4	15	15	O	:
5	17	24	U-UNK	Nitrates
6	25	25	O	:
7	27	29	O	The
8	31	35	O	blood
9	37	44	O	pressure
10	46	53	O	lowering
11	55	61	O	effects
12	63	64	O	of
13	66	75	O	sublingual
14	77	84	U-KIN	nitrates
15	87	89	O	0.4
16	91	92	O	mg
17	95	99	O	taken
18	101	101	O	1
19	103	105	O	and
20	107	107	O	4
21	109	113	O	hours
22	115	119	O	after
23	121	130	O	XXXXXXXX
24	132	134	O	and
25	136	144	O	increases
26	146	147	O	in
27	149	153	O	heart
28	155	158	O	rate
29	160	163	O	when
30	165	169	O	taken
31	171	172	O	at
32	174	174	O	1
33	175	175	O	,
34	177	177	O	4
35	179	181	O	and
36	183	183	O	8
37	185	189	O	hours
38	191	194	O	were
39	196	206	O	potentiated
40	208	209	O	by
41	211	211	O	a
42	213	214	O	20
43	216	217	O	mg
44	219	222	O	dose
45	224	225	O	of
46	227	236	O	XXXXXXXX
47	238	239	O	in
48	241	247	O	healthy
49	249	254	O	middle
50	256	259	O	aged
51	261	268	O	subjects
NULL

Vardenafil	DDI-DrugBank.d198.s23	NO_SECTION	NO_SETID	16
These effects were not observed when Vardenafil 20 mg was taken 24 hours before the NTG.
1	0	4	O	These
2	6	12	O	effects
3	14	17	O	were
4	19	21	O	not
5	23	30	O	observed
6	32	35	O	when
7	37	46	O	XXXXXXXX
8	48	49	O	20
9	51	52	O	mg
10	54	56	O	was
11	58	62	O	taken
12	64	65	O	24
13	67	71	O	hours
14	73	78	O	before
15	80	82	O	the
16	84	86	U-UNK	NTG
NULL

Vardenafil	DDI-DrugBank.d198.s24	NO_SECTION	NO_SETID	27
Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.
1	0	11	O	Potentiation
2	13	14	O	of
3	16	18	O	the
4	20	30	O	hypotensive
5	32	38	O	effects
6	40	41	O	of
7	43	50	U-UNK	nitrates
8	52	54	O	for
9	56	63	O	patients
10	65	68	O	with
11	70	77	O	ischemic
12	79	83	O	heart
13	85	91	O	disease
14	93	95	O	has
15	97	99	O	not
16	101	104	O	been
17	106	114	O	evaluated
18	115	115	O	,
19	117	119	O	and
20	121	131	O	concomitant
21	133	135	O	use
22	137	138	O	of
23	140	149	O	XXXXXXXX
24	151	153	O	and
25	155	162	U-DYN	nitrates
26	164	165	O	is
27	167	181	O	contraindicated
NULL

Vardenafil	DDI-DrugBank.d198.s25	NO_SECTION	NO_SETID	42
Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.
1	0	9	U-UNK	Nifedipine
2	10	10	O	:
3	12	21	O	XXXXXXXX
4	23	24	O	20
5	26	27	O	mg
6	28	28	O	,
7	30	33	O	when
8	35	36	O	co
9	38	49	O	administered
10	51	54	O	with
11	56	59	O	slow
12	61	67	O	release
13	69	78	U-UNK	nifedipine
14	80	81	O	30
15	83	84	O	mg
16	86	87	O	or
17	89	90	O	60
18	92	93	O	mg
19	95	98	O	once
20	100	104	O	daily
21	105	105	O	,
22	107	109	O	did
23	111	113	O	not
24	115	120	O	affect
25	122	124	O	the
26	126	133	O	relative
27	135	149	O	bioavailability
28	152	154	O	AUC
29	157	158	O	or
30	160	166	O	maximum
31	168	180	O	concentration
32	183	186	O	Cmax
33	189	190	O	of
34	192	201	U-UNK	nifedipine
35	202	202	O	,
36	204	204	O	a
37	206	209	O	drug
38	211	214	O	that
39	216	217	O	is
40	219	229	O	metabolized
41	231	233	O	via
42	235	240	O	CYP3A4
NULL

Vardenafil	DDI-DrugBank.d198.s26	NO_SECTION	NO_SETID	13
Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.
1	0	9	U-UNK	Nifedipine
2	11	13	O	did
3	15	17	O	not
4	19	23	O	alter
5	25	27	O	the
6	29	34	O	plasma
7	36	41	O	levels
8	43	44	O	of
9	46	55	O	XXXXXXXX
10	57	60	O	when
11	62	66	O	taken
12	68	69	O	in
13	71	81	O	combination
NULL

Vardenafil	DDI-DrugBank.d198.s27	NO_SECTION	NO_SETID	32
In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.
1	0	1	O	In
2	3	7	O	these
3	9	16	O	patients
4	18	22	O	whose
5	24	35	O	hypertension
6	37	39	O	was
7	41	50	O	controlled
8	52	55	O	with
9	57	66	U-DYN	nifedipine
10	67	67	O	,
11	69	78	O	XXXXXXXX
12	80	81	O	20
13	83	84	O	mg
14	86	93	O	produced
15	95	98	O	mean
16	100	109	O	additional
17	111	116	O	supine
18	118	125	O	systolic
19	126	126	O	/
20	127	135	O	diastolic
21	137	141	O	blood
22	143	150	O	pressure
23	152	161	O	reductions
24	163	164	O	of
25	166	166	O	6
26	167	167	O	/
27	168	168	O	5
28	170	171	O	mm
29	173	174	O	Hg
30	176	183	O	compared
31	185	186	O	to
32	188	194	O	placebo
NULL

Vardenafil	DDI-DrugBank.d198.s28	NO_SECTION	NO_SETID	36
Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.
1	0	4	B-UNK	Alpha
2	6	13	L-UNK	blockers
3	14	14	O	:
4	16	19	O	When
5	21	30	O	XXXXXXXX
6	32	33	O	10
7	35	36	O	or
8	38	39	O	20
9	41	42	O	mg
10	44	46	O	was
11	48	52	O	given
12	54	55	O	to
13	57	63	O	healthy
14	65	74	O	volunteers
15	76	81	O	either
16	83	96	O	simultaneously
17	98	99	O	or
18	101	101	O	6
19	103	107	O	hours
20	109	113	O	after
21	115	115	O	a
22	117	118	O	10
23	120	121	O	mg
24	123	126	O	dose
25	128	129	O	of
26	131	139	U-DYN	terazosin
27	140	140	O	,
28	142	152	O	significant
29	154	164	O	hypotension
30	166	174	O	developed
31	176	177	O	in
32	179	179	O	a
33	181	191	O	substantial
34	193	198	O	number
35	200	201	O	of
36	203	210	O	subjects
NULL

Vardenafil	DDI-DrugBank.d198.s29	NO_SECTION	NO_SETID	28
With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
1	0	3	O	With
2	5	16	O	simultaneous
3	18	23	O	dosing
4	25	26	O	of
5	28	37	O	XXXXXXXX
6	39	40	O	10
7	42	43	O	mg
8	45	47	O	and
9	49	57	U-DYN	terazosin
10	59	60	O	10
11	62	63	O	mg
12	64	64	O	,
13	66	66	O	6
14	68	69	O	of
15	71	71	O	8
16	73	80	O	subjects
17	82	92	O	experienced
18	94	94	O	a
19	96	103	O	standing
20	105	112	O	systolic
21	114	118	O	blood
22	120	127	O	pressure
23	129	130	O	of
24	132	135	O	less
25	137	140	O	than
26	142	143	O	85
27	145	146	O	mm
28	148	149	O	Hg
NULL

Vardenafil	DDI-DrugBank.d198.s30	NO_SECTION	NO_SETID	28
With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.
1	0	3	O	With
2	5	16	O	simultaneous
3	18	23	O	dosing
4	25	26	O	of
5	28	37	O	XXXXXXXX
6	39	40	O	20
7	42	43	O	mg
8	45	47	O	and
9	49	57	U-DYN	terazosin
10	59	60	O	10
11	62	63	O	mg
12	64	64	O	,
13	66	66	O	2
14	68	69	O	of
15	71	71	O	9
16	73	80	O	subjects
17	82	92	O	experienced
18	94	94	O	a
19	96	103	O	standing
20	105	112	O	systolic
21	114	118	O	blood
22	120	127	O	pressure
23	129	130	O	of
24	132	135	O	less
25	137	140	O	than
26	142	143	O	85
27	145	146	O	mm
28	148	149	O	Hg
NULL

Vardenafil	DDI-DrugBank.d198.s31	NO_SECTION	NO_SETID	35
When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.
1	0	3	O	When
2	5	14	O	XXXXXXXX
3	16	21	O	dosing
4	23	25	O	was
5	27	35	O	separated
6	37	40	O	from
7	42	50	U-DYN	terazosin
8	52	53	O	10
9	55	56	O	mg
10	58	59	O	by
11	61	61	O	6
12	63	67	O	hours
13	68	68	O	,
14	70	70	O	7
15	72	73	O	of
16	75	76	O	28
17	78	85	O	subjects
18	87	89	O	who
19	91	98	O	received
20	100	101	O	20
21	103	104	O	mg
22	106	107	O	of
23	109	118	O	XXXXXXXX
24	120	130	O	experienced
25	132	132	O	a
26	134	141	O	decrease
27	143	144	O	in
28	146	153	O	standing
29	155	162	O	systolic
30	164	168	O	blood
31	170	177	O	pressure
32	179	183	O	below
33	185	186	O	85
34	188	189	O	mm
35	191	192	O	Hg
NULL

Vardenafil	DDI-DrugBank.d198.s32	NO_SECTION	NO_SETID	37
In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.
1	0	1	O	In
2	3	3	O	a
3	5	11	O	similar
4	13	17	O	study
5	19	22	O	with
6	24	33	U-UNK	tamsulosin
7	35	36	O	in
8	38	44	O	healthy
9	46	55	O	volunteers
10	56	56	O	,
11	58	58	O	1
12	60	61	O	of
13	63	64	O	24
14	66	73	O	subjects
15	75	79	O	dosed
16	81	84	O	with
17	86	95	O	XXXXXXXX
18	97	98	O	20
19	100	101	O	mg
20	103	105	O	and
21	107	116	U-DYN	tamsulosin
22	118	120	O	0.4
23	122	123	O	mg
24	125	133	O	separated
25	135	136	O	by
26	138	138	O	6
27	140	144	O	hours
28	146	156	O	experienced
29	158	158	O	a
30	160	167	O	standing
31	169	176	O	systolic
32	178	182	O	blood
33	184	191	O	pressure
34	193	197	O	below
35	199	200	O	85
36	202	203	O	mm
37	205	206	O	Hg
NULL

Vardenafil	DDI-DrugBank.d198.s33	NO_SECTION	NO_SETID	24
Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.
1	0	2	O	Two
2	4	5	O	of
3	7	8	O	16
4	10	17	O	subjects
5	19	23	O	dosed
6	25	38	O	simultaneously
7	40	43	O	with
8	45	54	O	XXXXXXXX
9	56	57	O	10
10	59	60	O	mg
11	62	64	O	and
12	66	75	U-DYN	tamsulosin
13	77	79	O	0.4
14	81	82	O	mg
15	84	94	O	experienced
16	96	96	O	a
17	98	105	O	standing
18	107	114	O	systolic
19	116	120	O	blood
20	122	129	O	pressure
21	131	135	O	below
22	137	138	O	85
23	140	141	O	mm
24	143	144	O	Hg
NULL

Vardenafil	DDI-DrugBank.d198.s34	NO_SECTION	NO_SETID	24
The administration of lower doses of Vardenafil with alpha-blockers has not been completely evaluated to determine if they can be safely administered together.
1	0	2	O	The
2	4	17	O	administration
3	19	20	O	of
4	22	26	O	lower
5	28	32	O	doses
6	34	35	O	of
7	37	46	O	XXXXXXXX
8	48	51	O	with
9	53	57	B-UNK	alpha
10	59	66	L-UNK	blockers
11	68	70	O	has
12	72	74	O	not
13	76	79	O	been
14	81	90	O	completely
15	92	100	O	evaluated
16	102	103	O	to
17	105	113	O	determine
18	115	116	O	if
19	118	121	O	they
20	123	125	O	can
21	127	128	O	be
22	130	135	O	safely
23	137	148	O	administered
24	150	157	O	together
NULL

Vardenafil	DDI-DrugBank.d198.s35	NO_SECTION	NO_SETID	16
Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.
1	0	4	O	Based
2	6	7	O	on
3	9	13	O	these
4	15	18	O	data
5	19	19	O	,
6	21	30	O	XXXXXXXX
7	32	37	O	should
8	39	41	O	not
9	43	44	O	be
10	46	49	O	used
11	51	52	O	in
12	54	61	O	patients
13	63	64	O	on
14	66	70	B-DYN	alpha
15	72	78	L-DYN	blocker
16	80	86	O	therapy
NULL

Vardenafil	DDI-DrugBank.d198.s36	NO_SECTION	NO_SETID	29
Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.
1	0	8	U-UNK	Ritonavir
2	10	12	O	and
3	14	22	U-UNK	indinavir
4	23	23	O	:
5	25	28	O	Upon
6	30	40	O	concomitant
7	42	55	O	administration
8	57	58	O	of
9	60	60	O	5
10	62	63	O	mg
11	65	66	O	of
12	68	77	O	XXXXXXXX
13	79	82	O	with
14	84	86	O	600
15	88	89	O	mg
16	91	93	O	BID
17	95	103	U-KIN	ritonavir
18	104	104	O	,
19	106	108	O	the
20	110	113	O	Cmax
21	115	117	O	and
22	119	121	O	AUC
23	123	124	O	of
24	126	134	U-UNK	ritonavir
25	136	139	O	were
26	141	147	O	reduced
27	149	150	O	by
28	152	164	O	approximately
29	166	168	O	20%
NULL

Vardenafil	DDI-DrugBank.d198.s37	NO_SECTION	NO_SETID	27
Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.
1	0	3	O	Upon
2	5	18	O	administration
3	20	21	O	of
4	23	24	O	10
5	26	27	O	mg
6	29	30	O	of
7	32	41	O	XXXXXXXX
8	43	46	O	with
9	48	50	O	800
10	52	53	O	mg
11	55	57	O	TID
12	59	67	U-KIN	indinavir
13	68	68	O	,
14	70	72	O	the
15	74	77	O	Cmax
16	79	81	O	and
17	83	85	O	AUC
18	87	88	O	of
19	90	98	U-UNK	indinavir
20	100	103	O	were
21	105	111	O	reduced
22	113	114	O	by
23	116	118	O	40%
24	120	122	O	and
25	124	126	O	30%
26	127	127	O	,
27	129	140	O	respectively
NULL

Vardenafil	DDI-DrugBank.d198.s38	NO_SECTION	NO_SETID	31
Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.
1	0	6	U-UNK	Alcohol
2	7	7	O	:
3	9	15	U-UNK	Alcohol
4	18	20	O	0.5
5	22	22	O	g
6	23	23	O	/
7	24	25	O	kg
8	27	30	O	body
9	32	37	O	weight
10	38	38	O	:
11	40	52	O	approximately
12	54	55	O	40
13	57	58	O	mL
14	60	61	O	of
15	63	70	O	absolute
16	72	78	O	alcohol
17	80	81	O	in
18	83	83	O	a
19	85	86	O	70
20	88	89	O	kg
21	91	96	O	person
22	99	101	O	and
23	103	112	O	XXXXXXXX
24	114	119	O	plasma
25	121	126	O	levels
26	128	131	O	were
27	133	135	O	not
28	137	143	O	altered
29	145	148	O	when
30	150	154	O	dosed
31	156	169	O	simultaneously
NULL

Vardenafil	DDI-DrugBank.d198.s39	NO_SECTION	NO_SETID	30
Vardenafil (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).
1	0	9	O	XXXXXXXX
2	12	13	O	20
3	15	16	O	mg
4	19	21	O	did
5	23	25	O	not
6	27	36	O	potentiate
7	38	40	O	the
8	42	52	O	hypotensive
9	54	60	O	effects
10	62	63	O	of
11	65	71	U-UNK	alcohol
12	73	78	O	during
13	80	82	O	the
14	84	84	O	4
15	86	89	O	hour
16	91	101	O	observation
17	103	108	O	period
18	110	111	O	in
19	113	119	O	healthy
20	121	130	O	volunteers
21	132	135	O	when
22	137	148	O	administered
23	150	153	O	with
24	155	161	U-UNK	alcohol
25	164	166	O	0.5
26	168	168	O	g
27	169	169	O	/
28	170	171	O	kg
29	173	176	O	body
30	178	183	O	weight
NULL

Vardenafil	DDI-DrugBank.d198.s40	NO_SECTION	NO_SETID	23
Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).
1	0	6	O	XXXXXXXX
2	7	7	O	:
3	9	18	U-UNK	Vardenafil
4	21	22	O	10
5	24	25	O	mg
6	27	29	O	and
7	31	32	O	20
8	34	35	O	mg
9	38	40	O	did
10	42	44	O	not
11	46	55	O	potentiate
12	57	59	O	the
13	61	68	O	increase
14	70	71	O	in
15	73	80	O	bleeding
16	82	85	O	time
17	87	92	O	caused
18	94	95	O	by
19	97	103	O	XXXXXXXX
20	106	108	O	two
21	110	111	O	81
22	113	114	O	mg
23	116	122	O	tablets
NULL

Vardenafil	DDI-DrugBank.d198.s41	NO_SECTION	NO_SETID	24
Other interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).
1	0	4	O	Other
2	6	17	O	interactions
3	18	18	O	:
4	20	29	O	XXXXXXXX
5	31	33	O	had
6	35	36	O	no
7	38	43	O	effect
8	45	46	O	on
9	48	50	O	the
10	52	67	O	pharmacodynamics
11	69	70	O	of
12	72	80	U-UNK	glyburide
13	83	89	O	glucose
14	91	93	O	and
15	95	101	O	insulin
16	103	116	O	concentrations
17	119	121	O	and
18	123	130	U-UNK	warfarin
19	133	143	O	prothrombin
20	145	148	O	time
21	150	151	O	or
22	153	157	O	other
23	159	173	O	pharmacodynamic
24	175	184	O	parameters
NULL

Zalcitabine	DDI-DrugBank.d263.s0	NO_SECTION	NO_SETID	17
Zidovudine: There is no significant pharmacokinetic interaction between ZDV and zalcitabine which has been confirmed clinically.
1	0	9	U-UNK	Zidovudine
2	10	10	O	:
3	12	16	O	There
4	18	19	O	is
5	21	22	O	no
6	24	34	O	significant
7	36	50	O	pharmacokinetic
8	52	62	O	interaction
9	64	70	O	between
10	72	74	U-UNK	ZDV
11	76	78	O	and
12	80	90	O	XXXXXXXX
13	92	96	O	which
14	98	100	O	has
15	102	105	O	been
16	107	115	O	confirmed
17	117	126	O	clinically
NULL

Zalcitabine	DDI-DrugBank.d263.s1	NO_SECTION	NO_SETID	32
Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).
1	0	10	O	XXXXXXXX
2	12	15	O	also
3	17	19	O	has
4	21	22	O	no
5	24	34	O	significant
6	36	41	O	effect
7	43	44	O	on
8	46	48	O	the
9	50	62	O	intracellular
10	64	78	O	phosphorylation
11	80	81	O	of
12	83	85	U-DYN	ZDV
13	86	86	O	,
14	88	89	O	as
15	91	95	O	shown
16	97	98	O	in
17	100	104	O	vitro
18	106	107	O	in
19	109	118	O	peripheral
20	120	124	O	blood
21	126	136	O	mononuclear
22	138	142	O	cells
23	144	145	O	or
24	147	148	O	in
25	150	152	O	two
26	154	158	O	other
27	160	163	O	cell
28	165	169	O	lines
29	172	175	O	U937
30	177	179	O	and
31	181	184	O	Molt
32	186	186	O	4
NULL

Zalcitabine	DDI-DrugBank.d263.s2	NO_SECTION	NO_SETID	26
In the same study it was shown that didanosine and stavudine had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.
1	0	1	O	In
2	3	5	O	the
3	7	10	O	same
4	12	16	O	study
5	18	19	O	it
6	21	23	O	was
7	25	29	O	shown
8	31	34	O	that
9	36	45	U-UNK	didanosine
10	47	49	O	and
11	51	59	U-UNK	stavudine
12	61	63	O	had
13	65	66	O	no
14	68	78	O	significant
15	80	85	O	effect
16	87	88	O	on
17	90	92	O	the
18	94	106	O	intracellular
19	108	122	O	phosphorylation
20	124	125	O	of
21	127	137	O	XXXXXXXX
22	139	140	O	in
23	142	151	O	peripheral
24	153	157	O	blood
25	159	169	O	mononuclear
26	171	175	O	cells
NULL

Zalcitabine	DDI-DrugBank.d263.s3	NO_SECTION	NO_SETID	28
Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.
1	0	9	U-UNK	Lamivudine
2	10	10	O	:
3	12	13	O	In
4	15	19	O	vitro
5	21	27	O	studies
6	29	30	O	in
7	32	41	O	peripheral
8	43	47	O	blood
9	49	59	O	mononuclear
10	61	65	O	cells
11	66	66	O	,
12	68	71	O	U937
13	73	75	O	and
14	77	80	O	Molt
15	82	82	O	4
16	84	88	O	cells
17	90	97	O	revealed
18	99	102	O	that
19	104	113	U-DYN	lamivudine
20	115	127	O	significantly
21	129	137	O	inhibited
22	139	149	O	XXXXXXXX
23	151	165	O	phosphorylation
24	167	168	O	in
25	170	170	O	a
26	172	175	O	dose
27	177	185	O	dependent
28	187	192	O	manner
NULL

Zalcitabine	DDI-DrugBank.d263.s4	NO_SECTION	NO_SETID	33
Effects were already seen with doses corresponding to relevant plasma levels in humans, and the intracellular phosphorylation of zalcitabine to its three metabolites (including the active zalcitabine triphosphate metabolite) was significantly inhibited.
1	0	6	O	Effects
2	8	11	O	were
3	13	19	O	already
4	21	24	O	seen
5	26	29	O	with
6	31	35	O	doses
7	37	49	O	corresponding
8	51	52	O	to
9	54	61	O	relevant
10	63	68	O	plasma
11	70	75	O	levels
12	77	78	O	in
13	80	85	O	humans
14	86	86	O	,
15	88	90	O	and
16	92	94	O	the
17	96	108	O	intracellular
18	110	124	O	phosphorylation
19	126	127	O	of
20	129	139	O	XXXXXXXX
21	141	142	O	to
22	144	146	O	its
23	148	152	O	three
24	154	164	O	metabolites
25	167	175	O	including
26	177	179	O	the
27	181	186	O	active
28	188	198	O	XXXXXXXX
29	200	211	O	triphosphate
30	213	222	O	metabolite
31	225	227	O	was
32	229	241	O	significantly
33	243	251	O	inhibited
NULL

Zalcitabine	DDI-DrugBank.d263.s5	NO_SECTION	NO_SETID	11
Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);
1	0	10	O	XXXXXXXX
2	12	20	O	inhibited
3	22	31	U-DYN	lamivudine
4	33	47	O	phosphorylation
5	49	50	O	at
6	52	55	O	high
7	57	69	O	concentration
8	71	76	O	ratios
9	79	80	O	10
10	82	84	O	and
11	86	88	O	100
NULL

Zalcitabine	DDI-DrugBank.d263.s6	NO_SECTION	NO_SETID	32
however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than zalcitabine.
1	0	6	O	however
2	7	7	O	,
3	9	10	O	it
4	12	13	O	is
5	15	24	O	considered
6	26	27	O	to
7	29	30	O	be
8	32	39	O	unlikely
9	41	44	O	that
10	46	49	O	this
11	51	58	O	decrease
12	60	61	O	of
13	63	76	O	phosphorylated
14	78	87	U-UNK	lamivudine
15	89	101	O	concentration
16	103	104	O	is
17	106	107	O	of
18	109	116	O	clinical
19	118	129	O	significance
20	130	130	O	,
21	132	133	O	as
22	135	144	U-UNK	lamivudine
23	146	147	O	is
24	149	149	O	a
25	151	154	O	more
26	156	164	O	efficient
27	166	174	O	substrate
28	176	178	O	for
29	180	192	O	deoxycytidine
30	194	199	O	kinase
31	201	204	O	than
32	206	216	O	XXXXXXXX
NULL

Zalcitabine	DDI-DrugBank.d263.s7	NO_SECTION	NO_SETID	35
These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.
1	0	4	O	These
2	6	7	O	in
3	9	13	O	vitro
4	15	21	O	studies
5	23	29	O	suggest
6	31	34	O	that
7	36	46	O	concomitant
8	48	61	O	administration
9	63	64	O	of
10	66	76	O	XXXXXXXX
11	78	80	O	and
12	82	91	U-DYN	lamivudine
13	93	94	O	in
14	96	101	O	humans
15	103	105	O	may
16	107	112	O	result
17	114	115	O	in
18	117	119	O	sub
19	121	131	O	therapeutic
20	133	146	O	concentrations
21	148	149	O	of
22	151	156	O	active
23	158	171	O	phosphorylated
24	173	183	O	XXXXXXXX
25	184	184	O	,
26	186	190	O	which
27	192	194	O	may
28	196	199	O	lead
29	201	202	O	to
30	204	204	O	a
31	206	214	O	decreased
32	216	229	U-UNK	antiretroviral
33	231	236	O	effect
34	238	239	O	of
35	241	251	O	XXXXXXXX
NULL

Zalcitabine	DDI-DrugBank.d263.s8	NO_SECTION	NO_SETID	16
It is unknown how the effect seen in these in vitro studies translates into clinical consequences.
1	0	1	O	It
2	3	4	O	is
3	6	12	O	unknown
4	14	16	O	how
5	18	20	O	the
6	22	27	O	effect
7	29	32	O	seen
8	34	35	O	in
9	37	41	O	these
10	43	44	O	in
11	46	50	O	vitro
12	52	58	O	studies
13	60	69	O	translates
14	71	74	O	into
15	76	83	O	clinical
16	85	96	O	consequences
NULL

Zalcitabine	DDI-DrugBank.d263.s9	NO_SECTION	NO_SETID	9
Concomitant use of zalcitabine and lamivudine is not recommended.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	29	O	XXXXXXXX
5	31	33	O	and
6	35	44	U-DYN	lamivudine
7	46	47	O	is
8	49	51	O	not
9	53	63	O	recommended
NULL

Zalcitabine	DDI-DrugBank.d263.s10	NO_SECTION	NO_SETID	19
Saquinavir: The combination of HIVID, saquinavir, and ZDV has been studied (as triple combination) in adults.
1	0	9	U-UNK	Saquinavir
2	10	10	O	:
3	12	14	O	The
4	16	26	O	combination
5	28	29	O	of
6	31	35	U-UNK	HIVID
7	36	36	O	,
8	38	47	U-UNK	saquinavir
9	48	48	O	,
10	50	52	O	and
11	54	56	U-UNK	ZDV
12	58	60	O	has
13	62	65	O	been
14	67	73	O	studied
15	76	77	O	as
16	79	84	O	triple
17	86	96	O	combination
18	99	100	O	in
19	102	107	O	adults
NULL

Zalcitabine	DDI-DrugBank.d263.s11	NO_SECTION	NO_SETID	22
Pharmacokinetic data suggest that absorption, metabolism, and elimination of each of these drugs are unchanged when they are used together.
1	0	14	O	Pharmacokinetic
2	16	19	O	data
3	21	27	O	suggest
4	29	32	O	that
5	34	43	O	absorption
6	44	44	O	,
7	46	55	O	metabolism
8	56	56	O	,
9	58	60	O	and
10	62	72	O	elimination
11	74	75	O	of
12	77	80	O	each
13	82	83	O	of
14	85	89	O	these
15	91	95	O	drugs
16	97	99	O	are
17	101	109	O	unchanged
18	111	114	O	when
19	116	119	O	they
20	121	123	O	are
21	125	128	O	used
22	130	137	O	together
NULL

Zalcitabine	DDI-DrugBank.d263.s12	NO_SECTION	NO_SETID	26
Drugs Associated With Peripheral Neuropathy: The concomitant use of HIVID with drugs that have the potential to cause peripheral neuropathy should be avoided where possible.
1	0	4	O	Drugs
2	6	15	O	Associated
3	17	20	O	With
4	22	31	O	Peripheral
5	33	42	O	Neuropathy
6	43	43	O	:
7	45	47	O	The
8	49	59	O	concomitant
9	61	63	O	use
10	65	66	O	of
11	68	72	U-UNK	HIVID
12	74	77	O	with
13	79	83	O	drugs
14	85	88	O	that
15	90	93	O	have
16	95	97	O	the
17	99	107	O	potential
18	109	110	O	to
19	112	116	O	cause
20	118	127	O	peripheral
21	129	138	O	neuropathy
22	140	145	O	should
23	147	148	O	be
24	150	156	O	avoided
25	158	162	O	where
26	164	171	O	possible
NULL

Zalcitabine	DDI-DrugBank.d263.s13	NO_SECTION	NO_SETID	43
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
1	0	4	O	Drugs
2	6	9	O	that
3	11	14	O	have
4	16	19	O	been
5	21	30	O	associated
6	32	35	O	with
7	37	46	O	peripheral
8	48	57	O	neuropathy
9	59	65	O	include
10	67	80	B-UNK	antiretroviral
11	82	91	I-UNK	nucleoside
12	93	101	L-UNK	analogues
13	102	102	O	,
14	104	118	U-UNK	chloramphenicol
15	119	119	O	,
16	121	129	U-UNK	cisplatin
17	130	130	O	,
18	132	138	U-UNK	dapsone
19	139	139	O	,
20	141	150	U-UNK	disulfiram
21	151	151	O	,
22	153	163	U-UNK	ethionamide
23	164	164	O	,
24	166	177	U-UNK	glutethimide
25	178	178	O	,
26	180	183	U-UNK	gold
27	184	184	O	,
28	186	196	U-UNK	hydralazine
29	197	197	O	,
30	199	208	U-UNK	iodoquinol
31	209	209	O	,
32	211	219	U-UNK	isoniazid
33	220	220	O	,
34	222	234	U-UNK	metronidazole
35	235	235	O	,
36	237	250	U-UNK	nitrofurantoin
37	251	251	O	,
38	253	261	U-UNK	phenytoin
39	262	262	O	,
40	264	272	U-UNK	ribavirin
41	273	273	O	,
42	275	277	O	and
43	279	289	U-UNK	vincristine
NULL

Zalcitabine	DDI-DrugBank.d263.s14	NO_SECTION	NO_SETID	9
Concomitant use of HIVID with didanosine is not recommended.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	23	U-UNK	HIVID
5	25	28	O	with
6	30	39	U-UNK	didanosine
7	41	42	O	is
8	44	46	O	not
9	48	58	O	recommended
NULL

Zalcitabine	DDI-DrugBank.d263.s15	NO_SECTION	NO_SETID	24
Intravenous Pentamidine: Treatment with HIVID should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.
1	0	10	O	Intravenous
2	12	22	U-UNK	Pentamidine
3	23	23	O	:
4	25	33	O	Treatment
5	35	38	O	with
6	40	44	U-UNK	HIVID
7	46	51	O	should
8	53	54	O	be
9	56	66	O	interrupted
10	68	71	O	when
11	73	75	O	the
12	77	79	O	use
13	81	82	O	of
14	84	84	O	a
15	86	89	O	drug
16	91	94	O	that
17	96	98	O	has
18	100	102	O	the
19	104	112	O	potential
20	114	115	O	to
21	117	121	O	cause
22	123	134	O	pancreatitis
23	136	137	O	is
24	139	146	O	required
NULL

Zalcitabine	DDI-DrugBank.d263.s16	NO_SECTION	NO_SETID	15
Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.
1	0	4	O	Death
2	6	8	O	due
3	10	11	O	to
4	13	21	O	fulminant
5	23	34	O	pancreatitis
6	36	43	O	possibly
7	45	51	O	related
8	53	54	O	to
9	56	66	O	intravenous
10	68	78	U-UNK	pentamidine
11	80	82	O	and
12	84	88	U-UNK	HIVID
13	90	92	O	has
14	94	97	O	been
15	99	106	O	reported
NULL

Zalcitabine	DDI-DrugBank.d263.s17	NO_SECTION	NO_SETID	17
If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.
1	0	1	O	If
2	3	13	O	intravenous
3	15	25	U-UNK	pentamidine
4	27	28	O	is
5	30	37	O	required
6	39	40	O	to
7	42	46	O	treat
8	48	59	O	Pneumocystis
9	61	67	O	carinii
10	69	77	O	pneumonia
11	78	78	O	,
12	80	88	O	treatment
13	90	93	O	with
14	95	99	U-UNK	HIVID
15	101	106	O	should
16	108	109	O	be
17	111	121	O	interrupted
NULL

Zalcitabine	DDI-DrugBank.d263.s18	NO_SECTION	NO_SETID	42
Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).
1	0	11	U-UNK	Amphotericin
2	12	12	O	,
3	14	22	U-UNK	Foscarnet
4	23	23	O	,
5	25	27	O	and
6	29	43	U-UNK	Aminoglycosides
7	44	44	O	:
8	46	50	O	Drugs
9	52	55	O	such
10	57	58	O	as
11	60	71	U-KIN	amphotericin
12	72	72	O	,
13	74	82	U-KIN	foscarnet
14	83	83	O	,
15	85	87	O	and
16	89	103	U-KIN	aminoglycosides
17	105	107	O	may
18	109	116	O	increase
19	118	120	O	the
20	122	125	O	risk
21	127	128	O	of
22	130	139	O	developing
23	141	150	O	peripheral
24	152	161	O	neuropathy
25	163	164	O	or
26	166	170	O	other
27	172	176	U-UNK	HIVID
28	178	187	O	associated
29	189	195	O	adverse
30	197	202	O	events
31	204	205	O	by
32	207	217	O	interfering
33	219	222	O	with
34	224	226	O	the
35	228	232	O	renal
36	234	242	O	clearance
37	244	245	O	of
38	247	257	O	XXXXXXXX
39	260	266	O	thereby
40	268	274	O	raising
41	276	283	O	systemic
42	285	292	O	exposure
NULL

Zalcitabine	DDI-DrugBank.d263.s19	NO_SECTION	NO_SETID	29
Patients who require the use of one of these drugs with HIVID should have frequent clinical and laboratory monitoring with dosage adjustment for any significant change in renal function.
1	0	7	O	Patients
2	9	11	O	who
3	13	19	O	require
4	21	23	O	the
5	25	27	O	use
6	29	30	O	of
7	32	34	O	one
8	36	37	O	of
9	39	43	O	these
10	45	49	O	drugs
11	51	54	O	with
12	56	60	U-UNK	HIVID
13	62	67	O	should
14	69	72	O	have
15	74	81	O	frequent
16	83	90	O	clinical
17	92	94	O	and
18	96	105	O	laboratory
19	107	116	O	monitoring
20	118	121	O	with
21	123	128	O	dosage
22	130	139	O	adjustment
23	141	143	O	for
24	145	147	O	any
25	149	159	O	significant
26	161	166	O	change
27	168	169	O	in
28	171	175	O	renal
29	177	184	O	function
NULL

Zalcitabine	DDI-DrugBank.d263.s20	NO_SECTION	NO_SETID	26
Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
1	0	9	U-UNK	Probenecid
2	11	12	O	or
3	14	23	U-UNK	Cimetidine
4	24	24	O	:
5	26	36	O	Concomitant
6	38	51	O	administration
7	53	54	O	of
8	56	65	U-KIN	probenecid
9	67	68	O	or
10	70	79	U-KIN	cimetidine
11	81	89	O	decreases
12	91	93	O	the
13	95	105	O	elimination
14	107	108	O	of
15	110	120	O	XXXXXXXX
16	121	121	O	,
17	123	126	O	most
18	128	133	O	likely
19	135	136	O	by
20	138	147	O	inhibition
21	149	150	O	of
22	152	156	O	renal
23	158	164	O	tubular
24	166	174	O	secretion
25	176	177	O	of
26	179	189	O	XXXXXXXX
NULL

Zalcitabine	DDI-DrugBank.d263.s21	NO_SECTION	NO_SETID	23
Patients receiving these drugs in combination with zalcitabine should be monitored for signs of toxicity and the dose of zalcitabine reduced if warranted.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	23	O	these
4	25	29	O	drugs
5	31	32	O	in
6	34	44	O	combination
7	46	49	O	with
8	51	61	O	XXXXXXXX
9	63	68	O	should
10	70	71	O	be
11	73	81	O	monitored
12	83	85	O	for
13	87	91	O	signs
14	93	94	O	of
15	96	103	O	toxicity
16	105	107	O	and
17	109	111	O	the
18	113	116	O	dose
19	118	119	O	of
20	121	131	O	XXXXXXXX
21	133	139	O	reduced
22	141	142	O	if
23	144	152	O	warranted
NULL

Zalcitabine	DDI-DrugBank.d263.s22	NO_SECTION	NO_SETID	24
Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.
1	0	8	U-UNK	Magnesium
2	9	9	O	/
3	10	17	U-UNK	Aluminum
4	19	28	O	containing
5	30	36	B-UNK	Antacid
6	38	45	L-UNK	Products
7	46	46	O	:
8	48	57	O	Absorption
9	59	60	O	of
10	62	72	O	XXXXXXXX
11	74	75	O	is
12	77	86	O	moderately
13	88	94	O	reduced
14	97	109	O	approximately
15	111	113	O	25%
16	116	119	O	when
17	121	134	O	coadministered
18	136	139	O	with
19	141	149	U-UNK	magnesium
20	150	150	O	/
21	151	158	U-UNK	aluminum
22	160	169	O	containing
23	171	177	B-UNK	antacid
24	179	186	L-UNK	products
NULL

Zalcitabine	DDI-DrugBank.d263.s23	NO_SECTION	NO_SETID	25
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	42	O	reduction
7	44	45	O	is
8	47	49	O	not
9	51	55	O	known
10	56	56	O	,
11	58	62	O	hence
12	64	74	O	XXXXXXXX
13	76	77	O	is
14	79	81	O	not
15	83	93	O	recommended
16	95	96	O	to
17	98	99	O	be
18	101	108	O	ingested
19	110	123	O	simultaneously
20	125	128	O	with
21	130	138	U-DYN	magnesium
22	139	139	O	/
23	140	147	U-DYN	aluminum
24	149	158	O	containing
25	160	167	U-DYN	antacids
NULL

Zalcitabine	DDI-DrugBank.d263.s24	NO_SECTION	NO_SETID	14
Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.
1	0	13	U-UNK	Metoclopramide
2	14	14	O	:
3	16	30	O	Bioavailability
4	32	33	O	is
5	35	40	O	mildly
6	42	48	O	reduced
7	51	63	O	approximately
8	65	67	O	10%
9	70	73	O	when
10	75	85	O	XXXXXXXX
11	87	89	O	and
12	91	104	U-KIN	metoclopramide
13	106	108	O	are
14	110	123	O	coadministered
NULL

Zalcitabine	DDI-DrugBank.d263.s25	NO_SECTION	NO_SETID	21
Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.
1	0	10	U-UNK	Doxorubicin
2	11	11	O	:
3	13	23	U-DYN	Doxorubicin
4	25	30	O	caused
5	32	32	O	a
6	34	41	O	decrease
7	43	44	O	in
8	46	56	O	XXXXXXXX
9	58	72	O	phosphorylation
10	76	78	O	50%
11	80	89	O	inhibition
12	91	92	O	of
13	94	98	O	total
14	100	108	O	phosphate
15	110	118	O	formation
16	121	122	O	in
17	124	127	O	U937
18	128	128	O	/
19	129	132	O	Molt
20	134	134	O	4
21	136	140	O	cells
NULL

Zalcitabine	DDI-DrugBank.d263.s26	NO_SECTION	NO_SETID	25
Although there may be decreased zalcitabine activity because of lessened active metabolite formation, the clinical relevance of these in vitro results are not known.
1	0	7	O	Although
2	9	13	O	there
3	15	17	O	may
4	19	20	O	be
5	22	30	O	decreased
6	32	42	O	XXXXXXXX
7	44	51	O	activity
8	53	59	O	because
9	61	62	O	of
10	64	71	O	lessened
11	73	78	O	active
12	80	89	O	metabolite
13	91	99	O	formation
14	100	100	O	,
15	102	104	O	the
16	106	113	O	clinical
17	115	123	O	relevance
18	125	126	O	of
19	128	132	O	these
20	134	135	O	in
21	137	141	O	vitro
22	143	149	O	results
23	151	153	O	are
24	155	157	O	not
25	159	163	O	known
NULL

Zaleplon	DDI-DrugBank.d324.s0	NO_SECTION	NO_SETID	18
As with all drugs, the potential exists for interaction with other drugs by a variety of mechanisms.
1	0	1	O	As
2	3	6	O	with
3	8	10	O	all
4	12	16	O	drugs
5	17	17	O	,
6	19	21	O	the
7	23	31	O	potential
8	33	38	O	exists
9	40	42	O	for
10	44	54	O	interaction
11	56	59	O	with
12	61	65	O	other
13	67	71	O	drugs
14	73	74	O	by
15	76	76	O	a
16	78	84	O	variety
17	86	87	O	of
18	89	98	O	mechanisms
NULL

Zaleplon	DDI-DrugBank.d324.s1	NO_SECTION	NO_SETID	59
CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.
1	0	2	O	CNS
2	4	9	O	Active
3	11	15	O	Drugs
4	17	23	U-UNK	Ethanol
5	24	24	O	:
6	26	31	O	XXXXXXXX
7	33	34	O	10
8	36	37	O	mg
9	39	49	O	potentiated
10	51	53	O	the
11	55	57	O	CNS
12	59	67	O	impairing
13	69	75	O	effects
14	77	78	O	of
15	80	86	U-DYN	ethanol
16	88	91	O	0.75
17	93	93	O	g
18	94	94	O	/
19	95	96	O	kg
20	98	99	O	on
21	101	107	O	balance
22	109	115	O	testing
23	117	119	O	and
24	121	128	O	reaction
25	130	133	O	time
26	135	137	O	for
27	139	139	O	1
28	141	144	O	hour
29	146	150	O	after
30	152	158	U-UNK	ethanol
31	160	173	O	administration
32	175	177	O	and
33	179	180	O	on
34	182	184	O	the
35	186	190	O	digit
36	192	197	O	symbol
37	199	210	O	substitution
38	212	215	O	test
39	218	221	O	DSST
40	223	223	O	,
41	225	230	O	symbol
42	232	238	O	copying
43	240	243	O	test
44	244	244	O	,
45	246	248	O	and
46	250	252	O	the
47	254	264	O	variability
48	266	274	O	component
49	276	277	O	of
50	279	281	O	the
51	283	289	O	divided
52	291	299	O	attention
53	301	304	O	test
54	306	308	O	for
55	310	312	O	2.5
56	314	318	O	hours
57	320	324	O	after
58	326	332	U-UNK	ethanol
59	334	347	O	administration
NULL

Zaleplon	DDI-DrugBank.d324.s2	NO_SECTION	NO_SETID	8
The potentiation resulted from a CNS pharmacodynamic interaction;
1	0	2	O	The
2	4	15	O	potentiation
3	17	24	O	resulted
4	26	29	O	from
5	31	31	O	a
6	33	35	O	CNS
7	37	51	O	pharmacodynamic
8	53	63	O	interaction
NULL

Zaleplon	DDI-DrugBank.d324.s3	NO_SECTION	NO_SETID	8
zaleplon did not affect the pharmacokinetics of ethanol.
1	0	7	O	XXXXXXXX
2	9	11	O	did
3	13	15	O	not
4	17	22	O	affect
5	24	26	O	the
6	28	43	O	pharmacokinetics
7	45	46	O	of
8	48	54	U-UNK	ethanol
NULL

Zaleplon	DDI-DrugBank.d324.s4	NO_SECTION	NO_SETID	31
Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
1	0	9	U-UNK	Imipramine
2	10	10	O	:
3	12	27	O	Coadministration
4	29	30	O	of
5	32	37	O	single
6	39	43	O	doses
7	45	46	O	of
8	48	53	O	XXXXXXXX
9	55	56	O	20
10	58	59	O	mg
11	61	63	O	and
12	65	74	U-DYN	imipramine
13	76	77	O	75
14	79	80	O	mg
15	82	89	O	produced
16	91	98	O	additive
17	100	106	O	effects
18	108	109	O	on
19	111	119	O	decreased
20	121	129	O	alertness
21	131	133	O	and
22	135	142	O	impaired
23	144	154	O	psychomotor
24	156	166	O	performance
25	168	170	O	for
26	172	172	O	2
27	174	175	O	to
28	177	177	O	4
29	179	183	O	hours
30	185	189	O	after
31	191	204	O	administration
NULL

Zaleplon	DDI-DrugBank.d324.s5	NO_SECTION	NO_SETID	13
The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug.
1	0	2	O	The
2	4	14	O	interaction
3	16	18	O	was
4	20	34	O	pharmacodynamic
5	36	39	O	with
6	41	42	O	no
7	44	53	O	alteration
8	55	56	O	of
9	58	60	O	the
10	62	77	O	pharmacokinetics
11	79	80	O	of
12	82	87	O	either
13	89	92	O	drug
NULL

Zaleplon	DDI-DrugBank.d324.s6	NO_SECTION	NO_SETID	27
Paroxetine: Coadministration of a single dose of Sonata 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.
1	0	9	U-UNK	Paroxetine
2	10	10	O	:
3	12	27	O	Coadministration
4	29	30	O	of
5	32	32	O	a
6	34	39	O	single
7	41	44	O	dose
8	46	47	O	of
9	49	54	O	XXXXXXXX
10	56	57	O	20
11	59	60	O	mg
12	62	64	O	and
13	66	75	U-UNK	paroxetine
14	77	78	O	20
15	80	81	O	mg
16	83	87	O	daily
17	89	91	O	for
18	93	93	O	7
19	95	98	O	days
20	100	102	O	did
21	104	106	O	not
22	108	114	O	produce
23	116	118	O	any
24	120	130	O	interaction
25	132	133	O	on
26	135	145	O	psychomotor
27	147	157	O	performance
NULL

Zaleplon	DDI-DrugBank.d324.s7	NO_SECTION	NO_SETID	23
Additionally, paroxetine did not alter the pharmacokinetics of Sonata, reflecting the absence of a role of CYP2D6 in zaleplon s metabolism.
1	0	11	O	Additionally
2	12	12	O	,
3	14	23	U-UNK	paroxetine
4	25	27	O	did
5	29	31	O	not
6	33	37	O	alter
7	39	41	O	the
8	43	58	O	pharmacokinetics
9	60	61	O	of
10	63	68	O	XXXXXXXX
11	69	69	O	,
12	71	80	O	reflecting
13	82	84	O	the
14	86	92	O	absence
15	94	95	O	of
16	97	97	O	a
17	99	102	O	role
18	104	105	O	of
19	107	112	O	CYP2D6
20	114	115	O	in
21	117	124	U-UNK	zaleplon
22	126	126	O	s
23	128	137	O	metabolism
NULL

Zaleplon	DDI-DrugBank.d324.s8	NO_SECTION	NO_SETID	31
Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
1	0	11	U-UNK	Thioridazine
2	12	12	O	:
3	14	29	O	Coadministration
4	31	32	O	of
5	34	39	O	single
6	41	45	O	doses
7	47	48	O	of
8	50	55	O	XXXXXXXX
9	57	58	O	20
10	60	61	O	mg
11	63	65	O	and
12	67	78	U-DYN	thioridazine
13	80	81	O	50
14	83	84	O	mg
15	86	93	O	produced
16	95	102	O	additive
17	104	110	O	effects
18	112	113	O	on
19	115	123	O	decreased
20	125	133	O	alertness
21	135	137	O	and
22	139	146	O	impaired
23	148	158	O	psychomotor
24	160	170	O	performance
25	172	174	O	for
26	176	176	O	2
27	178	179	O	to
28	181	181	O	4
29	183	187	O	hours
30	189	193	O	after
31	195	208	O	administration
NULL

Zaleplon	DDI-DrugBank.d324.s9	NO_SECTION	NO_SETID	13
The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug.
1	0	2	O	The
2	4	14	O	interaction
3	16	18	O	was
4	20	34	O	pharmacodynamic
5	36	39	O	with
6	41	42	O	no
7	44	53	O	alteration
8	55	56	O	of
9	58	60	O	the
10	62	77	O	pharmacokinetics
11	79	80	O	of
12	82	87	O	either
13	89	92	O	drug
NULL

Zaleplon	DDI-DrugBank.d324.s10	NO_SECTION	NO_SETID	36
Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.
1	0	10	U-UNK	Venlafaxine
2	11	11	O	:
3	13	28	O	Coadministration
4	30	31	O	of
5	33	33	O	a
6	35	40	O	single
7	42	45	O	dose
8	47	48	O	of
9	50	57	O	XXXXXXXX
10	59	60	O	10
11	62	63	O	mg
12	65	67	O	and
13	69	76	O	multiple
14	78	82	O	doses
15	84	85	O	of
16	87	97	U-UNK	venlafaxine
17	99	100	O	ER
18	103	110	O	extended
19	112	118	O	release
20	121	123	O	150
21	125	126	O	mg
22	128	130	O	did
23	132	134	O	not
24	136	141	O	result
25	143	144	O	in
26	146	148	O	any
27	150	160	O	significant
28	162	168	O	changes
29	170	171	O	in
30	173	175	O	the
31	177	192	O	pharmacokinetics
32	194	195	O	of
33	197	202	O	either
34	204	211	O	XXXXXXXX
35	213	214	O	or
36	216	226	U-UNK	venlafaxine
NULL

Zaleplon	DDI-DrugBank.d324.s11	NO_SECTION	NO_SETID	18
In addition, there was no pharmacodynamic interaction as a result of coadministration of zaleplon and venlafaxine ER.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	17	O	there
5	19	21	O	was
6	23	24	O	no
7	26	40	O	pharmacodynamic
8	42	52	O	interaction
9	54	55	O	as
10	57	57	O	a
11	59	64	O	result
12	66	67	O	of
13	69	84	O	coadministration
14	86	87	O	of
15	89	96	O	XXXXXXXX
16	98	100	O	and
17	102	112	U-UNK	venlafaxine
18	114	115	O	ER
NULL

Zaleplon	DDI-DrugBank.d324.s12	NO_SECTION	NO_SETID	41
Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.
1	0	11	U-UNK	Promethazine
2	12	12	O	:
3	14	29	O	Coadministration
4	31	32	O	of
5	34	34	O	a
6	36	41	O	single
7	43	46	O	dose
8	48	49	O	of
9	51	58	O	XXXXXXXX
10	60	62	O	and
11	64	75	U-KIN	promethazine
12	78	79	O	10
13	81	83	O	and
14	85	86	O	25
15	88	89	O	mg
16	90	90	O	,
17	92	103	O	respectively
18	106	113	O	resulted
19	115	116	O	in
20	118	118	O	a
21	120	122	O	15%
22	124	131	O	decrease
23	133	134	O	in
24	136	142	O	maximal
25	144	149	O	plasma
26	151	164	O	concentrations
27	166	167	O	of
28	169	176	O	XXXXXXXX
29	177	177	O	,
30	179	181	O	but
31	183	184	O	no
32	186	191	O	change
33	193	194	O	in
34	196	198	O	the
35	200	203	O	area
36	205	209	O	under
37	211	213	O	the
38	215	220	O	plasma
39	222	234	O	concentration
40	236	239	O	time
41	241	245	O	curve
NULL

Zaleplon	DDI-DrugBank.d324.s13	NO_SECTION	NO_SETID	14
However, the pharmacodynamics of coadministration of zaleplon and promethazine have not been evaluated.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	28	O	pharmacodynamics
5	30	31	O	of
6	33	48	O	coadministration
7	50	51	O	of
8	53	60	O	XXXXXXXX
9	62	64	O	and
10	66	77	U-UNK	promethazine
11	79	82	O	have
12	84	86	O	not
13	88	91	O	been
14	93	101	O	evaluated
NULL

Zaleplon	DDI-DrugBank.d324.s14	NO_SECTION	NO_SETID	10
Caution should be exercised when these 2 agents are coadministered.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	37	O	these
7	39	39	O	2
8	41	46	O	agents
9	48	50	O	are
10	52	65	O	coadministered
NULL

Zaleplon	DDI-DrugBank.d324.s15	NO_SECTION	NO_SETID	15
Drugs That Induce CYP3A4 Rifampin: CYP3A4 is ordinarily a minor metabolizing enzyme of zaleplon.
1	0	4	O	Drugs
2	6	9	O	That
3	11	16	O	Induce
4	18	23	O	CYP3A4
5	25	32	U-UNK	Rifampin
6	33	33	O	:
7	35	40	O	CYP3A4
8	42	43	O	is
9	45	54	O	ordinarily
10	56	56	O	a
11	58	62	O	minor
12	64	75	O	metabolizing
13	77	82	O	enzyme
14	84	85	O	of
15	87	94	O	XXXXXXXX
NULL

Zaleplon	DDI-DrugBank.d324.s16	NO_SECTION	NO_SETID	31
Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.
1	0	7	O	Multiple
2	9	12	O	dose
3	14	27	O	administration
4	29	30	O	of
5	32	34	O	the
6	36	41	O	potent
7	43	48	O	CYP3A4
8	50	56	O	inducer
9	58	65	U-KIN	rifampin
10	68	70	O	600
11	72	73	O	mg
12	75	79	O	every
13	81	82	O	24
14	84	88	O	hours
15	89	89	O	,
16	91	94	O	q24h
17	95	95	O	,
18	97	99	O	for
19	101	102	O	14
20	104	107	O	days
21	109	109	O	,
22	111	117	O	however
23	118	118	O	,
24	120	126	O	reduced
25	128	135	O	XXXXXXXX
26	137	140	O	Cmax
27	142	144	O	and
28	146	148	O	AUC
29	150	151	O	by
30	153	165	O	approximately
31	167	169	O	80%
NULL

Zaleplon	DDI-DrugBank.d324.s17	NO_SECTION	NO_SETID	23
The coadministration of a potent CYP3A4 enzyme inducer, although not posing a safety concern, thus could lead to ineffectiveness of zaleplon.
1	0	2	O	The
2	4	19	O	coadministration
3	21	22	O	of
4	24	24	O	a
5	26	31	O	potent
6	33	38	O	CYP3A4
7	40	45	O	enzyme
8	47	53	O	inducer
9	54	54	O	,
10	56	63	O	although
11	65	67	O	not
12	69	74	O	posing
13	76	76	O	a
14	78	83	O	safety
15	85	91	O	concern
16	92	92	O	,
17	94	97	O	thus
18	99	103	O	could
19	105	108	O	lead
20	110	111	O	to
21	113	127	O	ineffectiveness
22	129	130	O	of
23	132	139	O	XXXXXXXX
NULL

Zaleplon	DDI-DrugBank.d324.s18	NO_SECTION	NO_SETID	25
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, carbamazepine, and phenobarbital.
1	0	1	O	An
2	3	13	O	alternative
3	15	17	O	non
4	19	24	O	CYP3A4
5	26	34	O	substrate
6	36	43	B-UNK	hypnotic
7	45	49	L-UNK	agent
8	51	53	O	may
9	55	56	O	be
10	58	67	O	considered
11	69	70	O	in
12	72	79	O	patients
13	81	86	O	taking
14	88	93	O	CYP3A4
15	95	102	O	inducers
16	104	107	O	such
17	109	110	O	as
18	112	119	U-UNK	rifampin
19	120	120	O	,
20	122	130	U-UNK	phenytoin
21	131	131	O	,
22	133	145	U-UNK	carbamazepine
23	146	146	O	,
24	148	150	O	and
25	152	164	U-UNK	phenobarbital
NULL

Zaleplon	DDI-DrugBank.d324.s19	NO_SECTION	NO_SETID	53
Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose.
1	0	4	O	Drugs
2	6	9	O	That
3	11	17	O	Inhibit
4	19	24	O	CYP3A4
5	26	31	O	CYP3A4
6	33	34	O	is
7	36	36	O	a
8	38	42	O	minor
9	44	52	O	metabolic
10	54	60	O	pathway
11	62	64	O	for
12	66	68	O	the
13	70	80	O	elimination
14	82	83	O	of
15	85	92	O	XXXXXXXX
16	94	100	O	because
17	102	104	O	the
18	106	108	O	sum
19	110	111	O	of
20	113	120	O	desethyl
21	121	128	O	XXXXXXXX
22	131	136	O	formed
23	138	140	O	via
24	142	147	O	CYP3A4
25	149	150	O	in
26	152	156	O	vitro
27	159	161	O	and
28	163	165	O	its
29	167	177	O	metabolites
30	178	178	O	,
31	180	180	O	5
32	182	184	O	oxo
33	186	193	O	desethyl
34	194	201	O	XXXXXXXX
35	203	205	O	and
36	207	207	O	5
37	209	211	O	oxo
38	213	220	O	desethyl
39	221	228	O	XXXXXXXX
40	230	240	O	glucuronide
41	241	241	O	,
42	243	249	O	account
43	251	253	O	for
44	255	258	O	only
45	260	261	O	9%
46	263	264	O	of
47	266	268	O	the
48	270	276	O	urinary
49	278	285	O	recovery
50	287	288	O	of
51	290	290	O	a
52	292	299	O	XXXXXXXX
53	301	304	O	dose
NULL

Zaleplon	DDI-DrugBank.d324.s20	NO_SECTION	NO_SETID	47
Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	25	O	single
4	26	26	O	,
5	28	31	O	oral
6	33	37	O	doses
7	39	40	O	of
8	42	49	O	XXXXXXXX
9	51	54	O	with
10	56	67	U-KIN	erythromycin
11	70	71	O	10
12	73	74	O	mg
13	76	78	O	and
14	80	82	O	800
15	84	85	O	mg
16	86	86	O	,
17	88	99	O	respectively
18	101	101	O	,
19	103	103	O	a
20	105	110	O	strong
21	111	111	O	,
22	113	121	O	selective
23	123	128	O	CYP3A4
24	130	138	O	inhibitor
25	140	147	O	produced
26	149	149	O	a
27	151	153	O	34%
28	155	162	O	increase
29	164	165	O	in
30	167	174	O	XXXXXXXX
31	175	175	O	s
32	177	183	O	maximal
33	185	190	O	plasma
34	192	205	O	concentrations
35	207	209	O	and
36	211	211	O	a
37	213	215	O	20%
38	217	224	O	increase
39	226	227	O	in
40	229	231	O	the
41	233	236	O	area
42	238	242	O	under
43	244	246	O	the
44	248	253	O	plasma
45	255	267	O	concentration
46	269	272	O	time
47	274	278	O	curve
NULL

Zaleplon	DDI-DrugBank.d324.s21	NO_SECTION	NO_SETID	11
The magnitude of interaction with multiple doses of erythromycin is unknown.
1	0	2	O	The
2	4	12	O	magnitude
3	14	15	O	of
4	17	27	O	interaction
5	29	32	O	with
6	34	41	O	multiple
7	43	47	O	doses
8	49	50	O	of
9	52	63	U-UNK	erythromycin
10	65	66	O	is
11	68	74	O	unknown
NULL

Zaleplon	DDI-DrugBank.d324.s22	NO_SECTION	NO_SETID	18
Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.
1	0	4	O	Other
2	6	11	O	strong
3	13	21	O	selective
4	23	28	O	CYP3A4
5	30	39	O	inhibitors
6	41	44	O	such
7	46	47	O	as
8	49	60	U-KIN	ketoconazole
9	62	64	O	can
10	66	69	O	also
11	71	72	O	be
12	74	81	O	expected
13	83	84	O	to
14	86	93	O	increase
15	95	97	O	the
16	99	106	O	exposure
17	108	109	O	of
18	111	118	O	XXXXXXXX
NULL

Zaleplon	DDI-DrugBank.d324.s23	NO_SECTION	NO_SETID	10
A routine dosage adjustment of zaleplon is not considered necessary.
1	0	0	O	A
2	2	8	O	routine
3	10	15	O	dosage
4	17	26	O	adjustment
5	28	29	O	of
6	31	38	O	XXXXXXXX
7	40	41	O	is
8	43	45	O	not
9	47	56	O	considered
10	58	66	O	necessary
NULL

Zaleplon	DDI-DrugBank.d324.s24	NO_SECTION	NO_SETID	20
Drugs That Inhibit Aldehyde Oxidase The aldehyde oxidase enzyme system is less well studied than the cytochrome P450 enzyme system.
1	0	4	O	Drugs
2	6	9	O	That
3	11	17	O	Inhibit
4	19	26	O	Aldehyde
5	28	34	O	Oxidase
6	36	38	O	The
7	40	47	O	aldehyde
8	49	55	O	oxidase
9	57	62	O	enzyme
10	64	69	O	system
11	71	72	O	is
12	74	77	O	less
13	79	82	O	well
14	84	90	O	studied
15	92	95	O	than
16	97	99	O	the
17	101	110	O	cytochrome
18	112	115	O	P450
19	117	122	O	enzyme
20	124	129	O	system
NULL

Zaleplon	DDI-DrugBank.d324.s25	NO_SECTION	NO_SETID	27
Diphenhydramine: Diphenhydramine is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known.
1	0	14	U-UNK	Diphenhydramine
2	15	15	O	:
3	17	31	U-UNK	Diphenhydramine
4	33	34	O	is
5	36	43	O	reported
6	45	46	O	to
7	48	49	O	be
8	51	51	O	a
9	53	56	O	weak
10	58	66	O	inhibitor
11	68	69	O	of
12	71	78	O	aldehyde
13	80	86	O	oxidase
14	88	89	O	in
15	91	93	O	rat
16	95	99	O	liver
17	100	100	O	,
18	102	104	O	but
19	106	108	O	its
20	110	119	O	inhibitory
21	121	127	O	effects
22	129	130	O	in
23	132	136	O	human
24	138	142	O	liver
25	144	146	O	are
26	148	150	O	not
27	152	156	O	known
NULL

Zaleplon	DDI-DrugBank.d324.s26	NO_SECTION	NO_SETID	26
There is no pharmacokinetic interaction between zaleplon and diphenhydramine following the administration of a single dose (10 mg and 50 mg, respectively) of each drug.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	26	O	pharmacokinetic
5	28	38	O	interaction
6	40	46	O	between
7	48	55	O	XXXXXXXX
8	57	59	O	and
9	61	75	U-UNK	diphenhydramine
10	77	85	O	following
11	87	89	O	the
12	91	104	O	administration
13	106	107	O	of
14	109	109	O	a
15	111	116	O	single
16	118	121	O	dose
17	124	125	O	10
18	127	128	O	mg
19	130	132	O	and
20	134	135	O	50
21	137	138	O	mg
22	139	139	O	,
23	141	152	O	respectively
24	155	156	O	of
25	158	161	O	each
26	163	166	O	drug
NULL

Zaleplon	DDI-DrugBank.d324.s27	NO_SECTION	NO_SETID	17
However, because both of these compounds have CNS effects, an additive pharmacodynamic effect is possible.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	because
4	17	20	O	both
5	22	23	O	of
6	25	29	O	these
7	31	39	O	compounds
8	41	44	O	have
9	46	48	O	CNS
10	50	56	O	effects
11	57	57	O	,
12	59	60	O	an
13	62	69	O	additive
14	71	85	O	pharmacodynamic
15	87	92	O	effect
16	94	95	O	is
17	97	104	O	possible
NULL

Zaleplon	DDI-DrugBank.d324.s28	NO_SECTION	NO_SETID	37
Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.
1	0	4	O	Drugs
2	6	9	O	That
3	11	17	O	Inhibit
4	19	22	O	Both
5	24	31	O	Aldehyde
6	33	39	O	Oxidase
7	41	43	O	and
8	45	50	O	CYP3A4
9	52	61	U-UNK	Cimetidine
10	62	62	O	:
11	64	73	U-KIN	Cimetidine
12	75	82	O	inhibits
13	84	87	O	both
14	89	96	O	aldehyde
15	98	104	O	oxidase
16	107	108	O	in
17	110	114	O	vitro
18	117	119	O	and
19	121	126	O	CYP3A4
20	129	130	O	in
21	132	136	O	vitro
22	138	140	O	and
23	142	143	O	in
24	145	148	O	vivo
25	150	150	O	,
26	152	154	O	the
27	156	162	O	primary
28	164	166	O	and
29	168	176	O	secondary
30	178	184	O	enzymes
31	185	185	O	,
32	187	198	O	respectively
33	199	199	O	,
34	201	211	O	responsible
35	213	215	O	for
36	217	224	O	XXXXXXXX
37	226	235	O	metabolism
NULL

Zaleplon	DDI-DrugBank.d324.s29	NO_SECTION	NO_SETID	22
Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	35	O	XXXXXXXX
5	38	39	O	10
6	41	42	O	mg
7	45	47	O	and
8	49	58	U-KIN	cimetidine
9	61	63	O	800
10	65	66	O	mg
11	69	76	O	produced
12	78	79	O	an
13	81	83	O	85%
14	85	92	O	increase
15	94	95	O	in
16	97	99	O	the
17	101	104	O	mean
18	106	109	O	Cmax
19	111	113	O	and
20	115	117	O	AUC
21	119	120	O	of
22	122	129	U-UNK	zaleplon
NULL

Zaleplon	DDI-DrugBank.d324.s30	NO_SECTION	NO_SETID	18
An initial dose of 5 mg should be given to patients who are concomitantly being treated with cimetidine.
1	0	1	O	An
2	3	9	O	initial
3	11	14	O	dose
4	16	17	O	of
5	19	19	O	5
6	21	22	O	mg
7	24	29	O	should
8	31	32	O	be
9	34	38	O	given
10	40	41	O	to
11	43	50	O	patients
12	52	54	O	who
13	56	58	O	are
14	60	72	O	concomitantly
15	74	78	O	being
16	80	86	O	treated
17	88	91	O	with
18	93	102	U-UNK	cimetidine
NULL

Zaleplon	DDI-DrugBank.d324.s31	NO_SECTION	NO_SETID	18
Drugs Highly Bound to Plasma Protein Zaleplon is not highly bound to plasma proteins (fraction bound 60% 15%);
1	0	4	O	Drugs
2	6	11	O	Highly
3	13	17	O	Bound
4	19	20	O	to
5	22	27	O	Plasma
6	29	35	O	Protein
7	37	44	O	XXXXXXXX
8	46	47	O	is
9	49	51	O	not
10	53	58	O	highly
11	60	64	O	bound
12	66	67	O	to
13	69	74	O	plasma
14	76	83	O	proteins
15	86	93	O	fraction
16	95	99	O	bound
17	101	103	O	60%
18	105	107	O	15%
NULL

Zaleplon	DDI-DrugBank.d324.s32	NO_SECTION	NO_SETID	17
therefore, the disposition of zaleplon is not expected to be sensitive to alterations in protein binding.
1	0	8	O	therefore
2	9	9	O	,
3	11	13	O	the
4	15	25	O	disposition
5	27	28	O	of
6	30	37	O	XXXXXXXX
7	39	40	O	is
8	42	44	O	not
9	46	53	O	expected
10	55	56	O	to
11	58	59	O	be
12	61	69	O	sensitive
13	71	72	O	to
14	74	84	O	alterations
15	86	87	O	in
16	89	95	O	protein
17	97	103	O	binding
NULL

Zaleplon	DDI-DrugBank.d324.s33	NO_SECTION	NO_SETID	29
In addition, administration of Sonata to a patient taking another drug that is highly protein bound should not cause transient increase in free concentrations of the other drug.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	26	O	administration
5	28	29	O	of
6	31	36	O	XXXXXXXX
7	38	39	O	to
8	41	41	O	a
9	43	49	O	patient
10	51	56	O	taking
11	58	64	O	another
12	66	69	O	drug
13	71	74	O	that
14	76	77	O	is
15	79	84	O	highly
16	86	92	O	protein
17	94	98	O	bound
18	100	105	O	should
19	107	109	O	not
20	111	115	O	cause
21	117	125	O	transient
22	127	134	O	increase
23	136	137	O	in
24	139	142	O	free
25	144	157	O	concentrations
26	159	160	O	of
27	162	164	O	the
28	166	170	O	other
29	172	175	O	drug
NULL

Zaleplon	DDI-DrugBank.d324.s34	NO_SECTION	NO_SETID	27
Drugs with a Narrow Therapeutic Index Digoxin: Sonata (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days).
1	0	4	O	Drugs
2	6	9	O	with
3	11	11	O	a
4	13	18	O	Narrow
5	20	30	O	Therapeutic
6	32	36	O	Index
7	38	44	U-UNK	Digoxin
8	45	45	O	:
9	47	52	O	XXXXXXXX
10	55	56	O	10
11	58	59	O	mg
12	62	64	O	did
13	66	68	O	not
14	70	75	O	affect
15	77	79	O	the
16	81	95	O	pharmacokinetic
17	97	98	O	or
18	100	114	O	pharmacodynamic
19	116	122	O	profile
20	124	125	O	of
21	127	133	U-UNK	digoxin
22	136	140	O	0.375
23	142	143	O	mg
24	145	148	O	q24h
25	150	152	O	for
26	154	154	O	8
27	156	159	O	days
NULL

Zaleplon	DDI-DrugBank.d324.s35	NO_SECTION	NO_SETID	38
Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.
1	0	7	U-UNK	Warfarin
2	8	8	O	:
3	10	17	O	Multiple
4	19	22	O	oral
5	24	28	O	doses
6	30	31	O	of
7	33	38	O	XXXXXXXX
8	41	42	O	20
9	44	45	O	mg
10	47	50	O	q24h
11	52	54	O	for
12	56	57	O	13
13	59	62	O	days
14	65	67	O	did
15	69	71	O	not
16	73	78	O	affect
17	80	82	O	the
18	84	99	O	pharmacokinetics
19	101	102	O	of
20	104	111	U-UNK	warfarin
21	114	115	O	R+
22	119	120	O	or
23	123	123	O	S
24	127	137	O	enantiomers
25	139	140	O	or
26	142	144	O	the
27	146	161	O	pharmacodynamics
28	164	174	O	prothrombin
29	176	179	O	time
30	182	190	O	following
31	192	192	O	a
32	194	199	O	single
33	201	202	O	25
34	204	205	O	mg
35	207	210	O	oral
36	212	215	O	dose
37	217	218	O	of
38	220	227	U-UNK	warfarin
NULL

Zaleplon	DDI-DrugBank.d324.s36	NO_SECTION	NO_SETID	25
Drugs That Alter Renal Excretion Ibuprofen: Ibuprofen is known to affect renal function and, consequently, alter the renal excretion of other drugs.
1	0	4	O	Drugs
2	6	9	O	That
3	11	15	O	Alter
4	17	21	O	Renal
5	23	31	O	Excretion
6	33	41	U-UNK	Ibuprofen
7	42	42	O	:
8	44	52	U-UNK	Ibuprofen
9	54	55	O	is
10	57	61	O	known
11	63	64	O	to
12	66	71	O	affect
13	73	77	O	renal
14	79	86	O	function
15	88	90	O	and
16	91	91	O	,
17	93	104	O	consequently
18	105	105	O	,
19	107	111	O	alter
20	113	115	O	the
21	117	121	O	renal
22	123	131	O	excretion
23	133	134	O	of
24	136	140	O	other
25	142	146	O	drugs
NULL

Zaleplon	DDI-DrugBank.d324.s37	NO_SECTION	NO_SETID	24
There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	20	O	apparent
5	22	36	O	pharmacokinetic
6	38	48	O	interaction
7	50	56	O	between
8	58	65	O	XXXXXXXX
9	67	69	O	and
10	71	79	U-UNK	ibuprofen
11	81	89	O	following
12	91	96	O	single
13	98	101	O	dose
14	103	116	O	administration
15	119	120	O	10
16	122	123	O	mg
17	125	127	O	and
18	129	131	O	600
19	133	134	O	mg
20	135	135	O	,
21	137	148	O	respectively
22	151	152	O	of
23	154	157	O	each
24	159	162	O	drug
NULL

Zaleplon	DDI-DrugBank.d324.s38	NO_SECTION	NO_SETID	23
This was expected because zaleplon is primarily metabolized and renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose.
1	0	3	O	This
2	5	7	O	was
3	9	16	O	expected
4	18	24	O	because
5	26	33	O	XXXXXXXX
6	35	36	O	is
7	38	46	O	primarily
8	48	58	O	metabolized
9	60	62	O	and
10	64	68	O	renal
11	70	78	O	excretion
12	80	81	O	of
13	83	91	O	unchanged
14	93	100	O	XXXXXXXX
15	102	109	O	accounts
16	111	113	O	for
17	115	118	O	less
18	120	123	O	than
19	125	126	O	1%
20	128	129	O	of
21	131	133	O	the
22	135	146	O	administered
23	148	151	O	dose
NULL

